Paradoxically	O
,	O
loop	O
3i	O
from	O
the	O
M1Ach	B
-	I
muscarinic	I
receptor	I
also	O
maximally	O
inhibited	O
GnRH	B
agonist	O
-	O
stimulated	O
cAMP	O
accumulation	O
and	O
PRL	B
release	O
by	O
40	O
%	O
(	O
both	O
effects	O
mediated	O
through	O
activation	O
of	O
the	O
Gs	B
protein	I
)	O
.	O

Oligomers	O
corresponding	O
to	O
the	O
region	O
of	O
the	O
mlc-1	B
/	I
3	I
enhancer	I
,	O
which	O
encompasses	O
this	O
conserved	O
sequence	O
,	O
bound	O
MEF-2	B
and	O
competed	O
for	O
its	O
binding	O
to	O
the	O
mck	B
enhancer	O
.	O

Overall	O
graft	O
and	O
patient	O
survival	O
after	O
HAT	O
were	O
33.3	O
%	O
and	O
75	O
%	O
,	O
respectively	O
.	O

E2A	B
-	O
HLF	B
-	O
mediated	O
cell	O
transformation	O
requires	O
both	O
the	O
trans	O
-	O
activation	O
domains	O
of	O
E2A	B
and	O
the	O
leucine	O
zipper	O
dimerization	O
domain	O
of	O
HLF	B
.	O

One	O
patient	O
exhibited	O
a	O
non	O
-	O
sense	O
mutation	O
(	O
codon	O
388	O
)	O
,	O
which	O
changed	O
a	O
glutamine	O
codon	O
(	O
CAG	O
)	O
to	O
a	O
stop	O
codon	O
(	O
TAG	O
)	O
.	O

Comparison	O
of	O
the	O
encoded	O
ERCC3Dm	B
protein	I
with	O
the	O
homologous	O
proteins	O
of	O
mouse	O
and	O
man	O
shows	O
a	O
strong	O
amino	O
acid	O
conservation	O
(	O
71	O
%	O
identity	O
)	O
,	O
especially	O
in	O
the	O
postulated	O
DNA	O
binding	O
region	O
and	O
seven	O
'	B
helicase	I
'	I
domains	I
.	O

Previous	O
data	O
suggested	O
a	O
subtle	O
increase	O
in	O
serum	O
P	O
at	O
the	O
time	O
of	O
hCG	B
injection	O
without	O
LH	B
surge	O
reduces	O
the	O
PR	O
of	O
women	O
having	O
oocyte	O
retrievals	O
for	O
IVF	O
;	O
this	O
study	O
compared	O
PRs	O
of	O
recipients	O
in	O
a	O
shared	O
oocyte	O
program	O
according	O
to	O
the	O
donors	O
'	O
pre	B
-	I
hCG	I
P	O
level	O
.	O

Scleraxis	B
overexpression	O
enhanced	O
expression	O
of	O
the	O
aggrecan	B
gene	I
,	O
which	O
is	O
not	O
normally	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
osteoblastic	O
cells	O
.	O

A	O
29.425	O
kb	O
segment	O
on	O
the	O
left	O
arm	O
of	O
yeast	O
chromosome	O
XV	O
contains	O
more	O
than	O
twice	O
as	O
many	O
unknown	O
as	O
known	O
open	O
reading	O
frames	O
.	O

Ultimobranchial	O
body	O
and	O
parathyroid	O
glands	O
of	O
the	O
freshwater	O
snake	O
Natrix	O
piscator	O
in	O
response	O
to	O
vitamin	O
D3	O
administration	O
.	O

Given	O
a	O
rapid	O
induction	O
of	O
Egr-1	B
on	O
stimulation	O
with	O
growth	O
factors	O
or	O
injury	O
,	O
these	O
findings	O
may	O
represent	O
at	O
least	O
one	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
phenotypic	O
modulation	O
of	O
smooth	O
muscles	O
after	O
vascular	O
injury	O
.	O

Soluble	O
recombinant	O
RI	B
and	O
soluble	O
recombinant	O
C	B
alpha	I
can	O
associate	O
in	O
vitro	O
and	O
be	O
activated	O
by	O
cyclic	O
AMP	O
.	O

A	O
31-year	O
-	O
old	O
man	O
with	O
primary	O
myelofibrosis	O
initially	O
received	O
low	O
dose	O
Ara	O
C.	O

The	O
factors	O
defective	O
in	O
groups	O
A	O
(	O
CIITA	B
)	O
,	O
C	O
(	O
RFX5	B
)	O
and	O
D	O
(	O
RFXAP	B
)	O
have	O
been	O
identified	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
TCOF1	B
mutations	I
leading	O
to	O
the	O
Treacher	O
Collins	O
syndrome	O
phenotype	O
.	O

Acute	O
spontaneous	O
subdural	O
haematoma	O
.	O

Ultra	O
-	O
energy	O
(	O
UHE	O
)	O
imaging	O
is	O
usually	O
performed	O
in	O
simultaneous	O
F-18	O
FDG	O
/	O
Tc-99	O
m	O
MIBI	O
studies	O
.	O

The	O
effect	O
of	O
betamethasone	O
on	O
duodenal	O
calcium	O
absorption	O
and	O
1,25-dihydroxy	O
vitamin	O
D3	O
production	O
in	O
the	O
chick	O
.	O

Fluctuations	O
of	O
the	O
measured	O
ECF	O
energy	O
-	O
related	O
substances	O
corresponded	O
to	O
various	O
clinical	O
events	O
presumably	O
involving	O
hypoxia	O
/	O
ischemia	O
.	O

We	O
have	O
demonstrated	O
that	O
a	O
putative	O
HOX	B
cofactor	I
,	O
PBX1A	B
,	O
participates	O
in	O
cooperative	O
DNA	O
binding	O
with	O
HOXA-1	B
and	O
the	O
Deformed	B
group	O
protein	O
HOXD-4	B
.	O

The	O
effect	O
of	O
iron	O
on	O
the	O
toxigenicity	O
of	O
Vibrio	O
cholerae	O
.	O

Although	O
there	O
is	O
evidence	O
that	O
cone	O
ratios	O
do	O
determine	O
colour	O
appearance	O
under	O
many	O
conditions	O
,	O
the	O
site	O
or	O
sites	O
of	O
their	O
computation	O
is	O
unknown	O
.	O

In	O
an	O
effort	O
to	O
identify	O
factors	O
involved	O
in	O
the	O
expression	O
of	O
this	O
important	O
erythroid	O
-	O
specific	O
regulatory	O
protein	O
,	O
we	O
have	O
isolated	O
the	O
mouse	B
EKLF	I
gene	I
and	O
systematically	O
analyzed	O
the	O
promoter	O
region	O
.	O

RESULTS	O
:	O
All	O
primary	O
tumors	O
were	O
positive	O
for	O
CAM5.2	B
.	O

Moreover	O
,	O
since	O
the	O
integrated	O
transforming	O
DNA	O
was	O
not	O
altered	O
or	O
lost	O
expression	O
of	O
the	O
RbcS2::aadA::RbcS2	B
gene	B
(	I
s	I
)	I
appears	O
to	O
be	O
repressed	O
.	O

In	O
one	O
trial	O
,	O
116	O
subjects	O
with	O
transfusion	O
-	O
related	O
chronic	O
hepatitis	O
C	O
were	O
treated	O
with	O
lymphoblastoid	B
interferon	I
(	O
5	O
MU	O
/	O
m2	O
three	O
times	O
a	O
week	O
for	O
2	O
mo	O
,	O
then	O
3	O
MU	O
/	O
m2	O
three	O
times	O
a	O
week	O
for	O
4	O
or	O
10	O
mo	O
)	O
.	O

Instead	O
,	O
the	O
large	O
difference	O
in	O
ssDNA	O
-	O
binding	O
affinities	O
reflects	O
the	O
loss	O
of	O
hexamerization	O
ability	O
by	O
uvsY	B
,	O
suggesting	O
that	O
a	O
form	O
of	O
intrahexamer	O
synergism	O
or	O
cooperativity	O
between	O
binding	O
sites	O
within	O
the	O
uvsY	B
hexamer	I
leads	O
to	O
its	O
high	O
observed	O
affinity	O
for	O
ssDNA	O
.	O

Sox8	B
maps	O
to	O
the	O
t	B
complex	I
on	O
mouse	O
chromosome	O
17	O
and	O
to	O
human	O
chromosome	O
16p13.3	O
,	O
a	O
region	O
associated	O
with	O
the	O
microphthalmia	O
-	O
cataract	O
syndrome	O
CATM	O
and	O
the	O
alpha	O
-	O
thalassemia	O
/	O
mental	O
retardation	O
syndrome	O
ATR-16	O
.	O

Evaluation	O
of	O
the	O
effects	O
of	O
chelation	O
therapy	O
with	O
time	O
following	O
strontium	O
exposure	O
to	O
mice	O
.	O

To	O
better	O
understand	O
the	O
relationship	O
between	O
expression	O
of	O
an	O
oncogene	O
and	O
genetic	O
instability	O
,	O
we	O
have	O
studied	O
a	O
cell	O
line	O
expressing	O
an	O
activated	B
human	I
Ha	I
-	I
ras	I
under	O
the	O
control	O
of	O
bacterial	B
lactose	I
operon	I
regulatory	I
elements	I
for	O
changes	O
in	O
methotrexate	O
resistance	O
and	O
dihydrofolate	B
reductase	I
(	O
dhfr	B
)	O
gene	O
amplification	O
following	O
mutant	B
Ha	I
-	I
ras	I
induction	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
organize	O
chemical	O
data	O
in	O
a	O
client	O
-	O
server	O
environment	O
using	O
Database	O
Management	O
System	O
and	O
Web	O
fashion	O
for	O
the	O
client	O
interface	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
exhibits	O
95.3	O
and	O
76.1	O
%	O
identity	O
with	O
the	O
CAD	B
sequences	I
of	I
hamster	I
and	I
Squalus	I
acanthias	I
.	O

The	O
sulfur	O
species	O
could	O
be	O
separated	O
within	O
less	O
than	O
4	O
min	O
by	O
CZE	O
with	O
a	O
pyromellitic	O
acid	O
electrolyte	O
at	O
pH	O
3.5	O
to	O
5.0	O
.	O

Because	O
of	O
the	O
structural	O
similarities	O
the	O
new	O
gene	O
will	O
be	O
termed	O
scERV2	B
from	O
now	O
on	O
.	O

Analysis	O
of	O
the	O
DNA	O
sequence	O
upstream	O
of	O
the	O
narQ	B
gene	I
,	O
which	O
encodes	O
the	O
second	O
nitrate	O
-	O
responsive	O
sensor	O
-	O
transmitter	O
protein	O
in	O
Escherichia	O
coli	O
,	O
revealed	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
product	O
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
a	O
number	O
of	O
iron	B
-	I
sulfur	I
proteins	I
as	O
well	O
as	O
to	O
the	O
beta	O
subunit	O
of	O
glutamate	B
synthase	I
(	O
gltD	B
)	O
of	O
E.	O
coli	O
.	O

In	O
CYP7A1	B
transgenic	O
mice	O
,	O
livers	O
contained	O
approximately	O
3-fold	O
more	O
sterol	B
response	I
element	I
-	I
binding	I
protein-2	I
mRNA	I
.	O

A	O
total	O
of	O
10,763	O
men	O
and	O
3,118	O
women	O
has	O
been	O
studied	O
,	O
of	O
whom	O
97	O
%	O
and	O
89	O
%	O
,	O
respectively	O
,	O
have	O
been	O
traced	O
and	O
36	O
%	O
and	O
16	O
%	O
have	O
died	O
.	O

One	O
of	O
them	O
is	O
its	O
limited	O
sensitivity	O
to	O
weak	O
interactions	O
,	O
which	O
are	O
common	O
in	O
the	O
mammalian	O
cerebral	O
cortex	O
.	O

Cefminox	O
shows	O
greater	O
in	O
vivo	O
activity	O
than	O
that	O
expected	O
for	O
the	O
MICs	O
,	O
excellent	O
efficacy	O
and	O
safety	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
pyrene	O
in	O
diesel	O
-	O
exhaust	O
particles	O
(	O
DEP	O
)	O
has	O
an	O
adjuvant	O
activity	O
on	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
antibody	O
production	O
in	O
mice	O
immunized	O
with	O
Japanese	O
cedar	O
pollen	O
allergen	O
(	O
JCPA	O
)	O
or	O
ovalbumin	B
(	O
OA	B
)	O
intraperitoneally	O
.	O

The	O
corresponding	O
tetrapeptide	O
sequences	O
SSPD	O
and	O
SATD	O
for	O
human	B
and	I
mouse	I
PKC	I
-	I
epsilon	I
,	O
respectively	O
,	O
are	O
unusual	O
for	O
caspase-3	B
.	O

A	O
poly	O
(	O
ortho	O
ester	O
)	O
designed	O
for	O
combined	O
ocular	O
delivery	O
of	O
dexamethasone	O
sodium	O
phosphate	O
and	O
5-fluorouracil	O
:	O
subconjunctival	O
tolerance	O
and	O
in	O
vitro	O
release	O
.	O

Regardless	O
of	O
muscle	O
tensioning	O
or	O
marination	O
treatments	O
,	O
aging	O
of	O
the	O
carcass	O
for	O
24	O
h	O
(	O
T1	O
,	O
T2	O
,	O
and	O
T3	O
)	O
produced	O
meats	O
with	O
lower	O
shear	O
values	O
than	O
those	O
from	O
hot	O
-	O
boned	O
carcasses	O
(	O
T4	O
and	O
T5	O
)	O
.	O

This	O
effect	O
was	O
stronger	O
after	O
multiple	O
predoses	O
of	O
sertraline	O
,	O
when	O
imipramine	O
Cmax	O
and	O
AUC	O
(	O
0-infinity	O
)	O
were	O
increased	O
by	O
39	O
%	O
and	O
68	O
%	O
,	O
respectively	O
.	O

It	O
is	O
pathogenetically	O
proved	O
to	O
use	O
antithrombin	B
III	I
concentrate	O
preparations	O
with	O
anti-	O
and	O
dysaggregatory	O
properties	O
,	O
fibronectin	B
preparations	O
,	O
trasylol	O
or	O
its	O
analogs	O
during	O
complex	O
preoperative	O
preparation	O
of	O
patients	O
.	O

LV	O
compliance	O
was	O
determined	O
from	O
the	O
slope	O
of	O
the	O
LV	O
end	O
-	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
vs.	O

The	O
ARE	O
is	O
loosely	O
defined	O
as	O
the	O
five	O
-	O
nucleotide	O
sequence	O
AUUUA	O
embedded	O
in	O
a	O
uracil	O
-	O
rich	O
region	O
.	O

A	O
regulatory	O
element	O
of	O
the	O
empty	B
spiracles	I
homeobox	O
gene	O
is	O
composed	O
of	O
three	O
distinct	O
conserved	O
regions	O
that	O
bind	O
regulatory	O
proteins	O
.	O

Together	O
with	O
previous	O
work	O
our	O
results	O
suggest	O
that	O
C	B
/	I
EBP	I
may	O
be	O
a	O
general	O
cooperation	O
partner	O
for	O
v	B
-	I
Myb	I
in	O
myelomonocytic	O
cells	O
.	O

This	O
bud	O
morphology	O
results	O
at	O
least	O
in	O
part	O
from	O
a	O
cell	O
cycle	O
delay	O
imposed	O
by	O
the	O
Cdc28p	B
-	O
inhibitory	O
kinase	O
Swe1p	B
.	O

Nonlethal	O
sec71	B
-	I
1	I
and	O
sec72	B
-	I
1	I
mutations	I
eliminate	O
proteins	O
associated	O
with	O
the	O
Sec63p	B
-	O
BiP	B
complex	O
from	O
S.	O
cerevisiae	O
.	O

Analytical	O
scanning	O
isoelectrofocusing	O
.	O

In	O
the	O
future	O
,	O
transoesophageal	O
echocardiography	O
may	O
be	O
used	O
to	O
measure	O
variations	O
in	O
wall	O
thickness	O
which	O
change	O
the	O
global	O
loading	O
conditions	O
in	O
the	O
basal	O
midwall	O
compartments	O
of	O
the	O
left	O
ventricle	O
.	O

Thus	O
,	O
d	O
-	O
delta3-carene	O
was	O
about	O
four	O
times	O
more	O
potent	O
as	O
a	O
sensory	O
irritant	O
than	O
I	O
-	O
beta	O
-	O
pinene	O
,	O
whereas	O
the	O
difference	O
with	O
I	O
-	O
alpha	O
-	O
pinene	O
was	O
more	O
marked	O
;	O
as	O
a	O
sensory	O
irritant	O
,	O
I	O
-	O
alpha	O
-	O
pinene	O
is	O
almost	O
inactive	O
.	O

Sodium	O
dodecylsulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
showed	O
two	O
bands	O
of	O
about	O
the	O
same	O
intensity	O
with	O
apparent	O
molecular	O
masses	O
of	O
24.5	O
and	O
22.5	O
kDa	O
.	O

However	O
,	O
at	O
the	O
time	O
of	O
salvage	O
treatment	O
,	O
the	O
mean	O
serum	B
PSA	I
levels	O
were	O
9.1	O
and	O
1.1	O
ng	O
/	O
mL	O
for	O
the	O
salvage	O
RP	O
and	O
salvage	O
RT	O
groups	O
,	O
respectively	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

Uncoupling	O
gene	O
activity	O
from	O
chromatin	O
structure	O
:	O
promoter	O
mutations	O
can	O
inactivate	O
transcription	O
of	O
the	O
yeast	B
HSP82	I
gene	I
without	O
eliminating	O
nucleosome	O
-	O
free	O
regions	O
.	O

Maximal	O
exercise	O
duration	O
and	O
peak	O
oxygen	O
consumption	O
were	O
not	O
changed	O
.	O

Real	O
-	O
time	O
two	O
-	O
dimensional	O
echocardiographic	O
studies	O
of	O
the	O
mitral	O
valve	O
in	O
short	O
-	O
axis	O
view	O
were	O
obtained	O
from	O
10	O
normal	O
subjects	O
.	O

More	O
important	O
,	O
ligand	O
-	O
activated	O
insulin	B
and	O
IGF	B
-	I
I	I
receptors	I
phosphorylate	O
SHC	B
proteins	I
in	O
vitro	O
,	O
indicating	O
that	O
SHC	B
proteins	I
could	O
be	O
direct	O
substrates	O
for	O
insulin	B
and	O
IGF	B
-	I
I	I
receptors	I
.	O

To	O
test	O
for	O
progesterone	B
receptor	I
-	O
mediated	O
activation	O
of	O
transcription	O
in	O
yeast	O
,	O
reporter	O
plasmids	O
were	O
constructed	O
to	O
transform	O
yeast	O
cells	O
expressing	O
PRB	B
or	O
C1C2	B
receptors	I
.	O

TAF-1	B
activates	O
transcription	O
constitutively	O
and	O
was	O
mapped	O
to	O
the	O
first	O
32	O
amino	O
acids	O
of	O
the	O
A	O
-	O
region	O
.	O

We	O
have	O
used	O
the	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
reporter	O
gene	O
system	O
to	O
study	O
the	O
effect	O
of	O
T	B
on	O
the	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
of	O
a	O
large	O
family	O
of	O
human	O
endogenous	O
retrovirus	O
-	O
like	O
sequences	O
,	O
RTVL	O
-	O
H.	O

They	O
contain	O
a	O
large	O
(	O
0.9	O
X	O
10	O
(	O
3	O
)	O
to	O
1.88	O
X	O
10	O
(	O
3	O
)	O
base	O
-	O
pairs	O
)	O
intron	O
in	O
the	O
middle	O
of	O
the	O
gene	O
and	O
are	O
further	O
interrupted	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

Primer	O
extension	O
experiments	O
using	O
dbcAMP	O
-	O
differentiated	O
U937	O
RNA	O
indicated	O
a	O
single	O
transcriptional	O
initiation	O
site	O
.	O

On	O
a	O
variety	O
of	O
fronts	O
,	O
chronic	O
bacterial	O
infection	O
is	O
being	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
atherosclerosis	O
and	O
the	O
clinical	O
complications	O
of	O
unstable	O
angina	O
,	O
myocardial	O
infarction	O
,	O
and	O
stroke	O
.	O

025	O
)	O
.	O

Although	O
the	O
energy	O
-	O
based	O
DFT	O
was	O
not	O
affected	O
by	O
isoproterenol	O
(	O
from	O
6.1	O
+	O
/-	O

1.5	O
to	O
6.0	O
+	O
/-	O

1.7	O
J	O
)	O
,	O
it	O
was	O
decreased	O
to	O
3.7	O
+	O
/-	O

1.6	O
J	O
in	O
the	O
third	O
stage	O
by	O
infusion	O
of	O
E4031	O
and	O
isoproterenol	O
(	O
p	O
<	O
0.01	O
vs.	O
baseline	O
and	O
vs.	O
isoproterenol	O
)	O
.	O

In	O
cases	O
of	O
intracapsular	O
prostatic	O
cancer	O
the	O
level	O
of	O
prostatic	B
acid	I
phosphatase	I
(	O
PAP	B
)	O
measured	O
by	O
radioimmunoassay	O
was	O
1.4	O
+	O
/-	O

0.8	O
micrograms	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O
The	O
number	O
of	O
Spanish	O
articles	O
published	O
in	O
Anesthesiology	O
,	O
BJA	O
,	O
and	O
Anesth	O
Analg	O
is	O
low	O
,	O
although	O
the	O
comparison	O
of	O
our	O
productivity	O
with	O
that	O
of	O
other	O
EU	O
countries	O
in	O
function	O
of	O
GNPpc	O
places	O
us	O
in	O
an	O
intermediate	O
position	O
.	O

Neonatal	O
hyperthyroidism	O

Serum	O
prolactin	B
rapidly	O
decreased	O
after	O
institution	O
of	O
treatment	O
,	O
with	O
actual	O
normalization	O
(	O
less	O
than	O
20	O
ng	O
/	O
ml	O
)	O
by	O
the	O
3rd	O
month	O
.	O

Three	O
high	O
-	O
amylose	O
rice	O
varieties	O
,	O
IR42	O
,	O
IR36	O
,	O
and	O
IR62	O
,	O
with	O
similar	O
chemical	O
composition	O
including	O
amylose	O
content	O
(	O
26.7	O
-	O
27.0	O
%	O
)	O
,	O
were	O
cooked	O
under	O
the	O
same	O
conditions	O
and	O
tested	O
for	O
in	O
vitro	O
digestibility	O
as	O
well	O
as	O
blood	O
glucose	O
and	O
insulin	B
responses	O
in	O
healthy	O
human	O
volunteers	O
.	O

This	O
indicates	O
changes	O
in	O
postvaccination	O
allergy	O
to	O
BCG	O
.	O

Between	O
the	O
RNA	O
initiation	O
site	O
and	O
the	O
coding	O
region	O
is	O
a	O
GC	O
-	O
rich	O
hairpin	O
structure	O
followed	O
by	O
8	O
T	O
residues	O
that	O
looks	O
like	O
a	O
rho	B
-	I
independent	I
transcription	I
terminator	I
.	O

The	O
term	O
Kartagener	O
syndrome	O
applies	O
to	O
this	O
syndrome	O
when	O
accompanied	O
by	O
infertility	O
and	O
dextrocardia	O
or	O
situs	O
inversus	O
.	O

The	O
ferric	B
uptake	I
regulation	I
(	O
fur	B
)	O
gene	O
product	O
participates	O
in	O
regulating	O
expression	O
of	O
the	O
manganese-	O
and	O
iron	O
-	O
containing	O
superoxide	B
dismutase	I
genes	I
of	I
Escherichia	I
coli	I
.	O

On	O
average	O
these	O
maximum	O
potency	O
estimates	O
were	O
within	O
one	O
order	O
of	O
magnitude	O
of	O
the	O
inverse	O
maximum	O
dose	O
tested	O
.	O

Furthermore	O
,	O
CL100	B
suppresses	O
the	O
[	O
val12	O
]	O
ras	B
-	O
induced	O
activation	O
of	O
MAP	B
kinase	I
in	O
a	O
cell	O
-	O
free	O
system	O
from	O
Xenopus	O
oocytes	O
.	O

Static	O
and	O
dynamic	O
MRI	O
of	O
the	O
normal	O
and	O
pathological	O
female	O
pelvic	O
floor	O

Mutation	O
of	O
K14	O
in	O
H3	B
,	O
which	O
serves	O
as	O
the	O
major	O
target	O
of	O
recombinant	B
Gcn5p	I
acetylation	O
in	O
vitro	O
,	O
confers	O
a	O
strong	O
,	O
synthetic	O
growth	O
defect	O
in	O
gcn5	B
cells	O
.	O

Medical	O
management	O
of	O
early	O
-	O
stage	O
breast	O
cancer	O
.	O

Upon	O
incubation	O
of	O
the	O
most	O
highly	O
purified	O
fractions	O
with	O
Mn	O
-	O
ATP	O
or	O
Mg	O
-	O
ATP	O
,	O
p40	B
was	O
the	O
only	O
protein	O
phosphorylated	O
on	O
tyrosine	O
.	O

CLINICAL	O
FEATURES	O
:	O
This	O
30-yr	O
-	O
old	O
gravida	O
V	O
para	O
0	O
woman	O
presented	O
to	O
the	O
anaesthesia	O
consultation	O
clinic	O
at	O
37-wk	O
gestation	O
to	O
discuss	O
pain	O
relief	O
options	O
for	O
labour	O
and	O
delivery	O
.	O

Judge	O
Christian	O
Byk	O
renders	O
service	O
to	O
the	O
Steering	O
Committee	O
on	O
Bioethics	O
of	O
the	O
Council	O
of	O
Europe	O
(	O
CDBI	O
)	O
by	O
proposing	O
a	O
draft	O
of	O
the	O
protocol	O
destined	O
to	O
fill	O
in	O
a	O
gap	O
in	O
international	O
law	O
on	O
the	O
status	O
of	O
the	O
human	O
embryo	O
.	O

The	O
human	O
protein	O
is	O
encoded	O
by	O
a	O
900-base	O
pair	O
-	O
long	O
mRNA	O
that	O
is	O
expressed	O
in	O
the	O
glandular	O
epithelial	O
cells	O
of	O
the	O
endometrium	O
in	O
a	O
cyclic	O
manner	O
;	O
in	O
addition	O
,	O
it	O
is	O
found	O
in	O
the	O
mucosal	O
epithelial	O
cells	O
of	O
the	O
fallopian	O
tubes	O
.	O

We	O
conclude	O
that	O
a	O
0.25	O
mg	O
dose	O
of	O
triazolam	O
does	O
not	O
effectively	O
counteract	O
a	O
posture	O
-	O
induced	O
sleep	O
disturbance	O
,	O
but	O
induces	O
changes	O
in	O
the	O
EEG	O
spectra	O
which	O
are	O
typical	O
for	O
benzodiazepine	B
receptor	I
agonists	O
.	O

Northern	O
blot	O
analysis	O
of	O
liver	O
,	O
muscle	O
,	O
fat	O
,	O
and	O
pituitary	O
RNA	O
from	O
normal	O
(	O
DwDw	O
)	O
chickens	O
shows	O
a	O
major	O
transcript	O
of	O
4.3	O
kilobases	O
(	O
kb	O
)	O
and	O
three	O
minor	O
transcripts	O
(	O
0.8	O
,	O
1.7	O
,	O
and	O
3.2	O
kb	O
)	O
,	O
which	O
correspond	O
to	O
the	O
cGHR	B
.	O

The	O
procedure	O
was	O
technically	O
successful	O
in	O
12	O
of	O
14	O
(	O
86	O
%	O
)	O
stenoses	O
in	O
the	O
fibromuscular	O
dysplasia	O
subgroup	O
but	O
in	O
only	O
one	O
of	O
five	O
(	O
20	O
%	O
)	O
lesions	O
in	O
the	O
neurofibromatosis	O
subgroup	O
.	O

Amplitude	O
of	O
late	O
surface	O
(	O
P2	O
and	O
N2	O
)	O
and	O
depth	O
(	O
B	O
and	O
C	O
)	O
components	O
significantly	O
decreased	O
when	O
patients	O
shifted	O
from	O
SWS	O
IV	O
to	O
PS	O
and	O
increased	O
from	O
PS	O
to	O
W2	O
.	O

We	O
then	O
supplemented	O
these	O
spliceosomes	O
with	O
purified	O
proteins	O
or	O
yeast	O
extract	O
fractions	O
as	O
a	O
functional	O
assay	O
for	O
second	O
-	O
step	O
splicing	O
factors	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
DNA	O
-	O
protein	O
interactions	O
at	O
homologous	O
nucleotide	O
sequences	O
like	O
those	O
identified	O
in	O
PII	O
are	O
part	O
of	O
a	O
regulatory	O
gene	O
cascade	O
that	O
participates	O
in	O
timing	O
fla	B
gene	I
expression	O
in	O
the	O
C.	O
crescentus	O
cell	O
cycle	O
.	O

Nramp2	B
contains	O
a	O
classical	O
iron	O
responsive	O
element	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
that	O
confers	O
iron	O
dependent	O
mRNA	O
stabilization	O
.	O

When	O
a	O
longer	O
-714	O
to	O
+	O
78	O
fragment	O
of	O
the	O
PBGD	B
promoter	I
is	O
used	O
,	O
the	O
-70	O
GATA	O
mutant	O
still	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
is	O
cis	O
-	O
activated	O
by	O
the	O
5'HS-2	B
enhancer	I
,	O
while	O
the	O
-100	O
CCACC	O
mutant	O
is	O
completely	O
inactive	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
the	O
5'HS-2	B
enhancer	I
.	O

The	O
Robert	O
Wood	O
Johnson	O
Foundation	O
:	O
billion	O
dollar	O
force	O
for	O
health	O
-	O
care	O
change	O
.	O

Constant	O
slowing	O
of	O
median	O
MNCV	O
and	O
SNCV	O
and	O
ulnar	O
SNCV	O
without	O
changes	O
in	O
morphology	O
,	O
amplitude	O
and	O
duration	O
of	O
MAP	O
and	O
SAP	O
have	O
been	O
observed	O
in	O
92	O
patients	O
,	O
with	O
persistent	O
abnormalities	O
in	O
64	O
cases	O
after	O
six	O
months	O
.	O

Studies	O
with	O
and	O
without	O
attenuating	O
media	O
were	O
performed	O
,	O
and	O
myocardium	O
-	O
to	O
-	O
defect	O
count	O
ratios	O
and	O
defect	O
sizes	O
from	O
dual	O
-	O
isotope	O
SPECT	O
images	O
were	O
compared	O
to	O
myocardium	O
-	O
to	O
-	O
defect	O
count	O
ratios	O
and	O
defect	O
sizes	O
from	O
single	O
-	O
isotope	O
(	O
201Tl	O
and	O
99mTc	O
)	O
SPECT	O
images	O
.	O

The	O
N1-P2	O
amplitudes	O
of	O
the	O
AEP	O
decreased	O
with	O
increasing	O
strength	O
of	O
muscular	O
innervation	O
.	O

Measurements	O
in	O
rats	O
given	O
a	O
dose	O
of	O
propranolol	O
that	O
partially	O
inhibited	O
the	O
NA	O
-	O
induced	O
increase	O
in	O
Q	O
to	O
IBAT	O
indicated	O
that	O
the	O
decline	O
in	O
ENAIBAT	O
was	O
attributable	O
primarily	O
to	O
the	O
increase	O
in	O
Q	O
rather	O
than	O
to	O
increasing	O
saturation	O
of	O
uptake	O
mechanisms	O
.	O

The	O
role	O
of	O
NUT1	B
and	O
regulation	O
of	O
nitrogen	O
metabolism	O
in	O
the	O
disease	O
process	O
was	O
evaluated	O
by	O
pathogenicity	O
assays	O
.	O

This	O
study	O
tests	O
the	O
hypothesis	O
that	O
O2	O
is	O
a	O
critical	O
component	O
in	O
myocardial	O
protection	O
afforded	O
by	O
BCP	O
.	O

An	O
ICU	O
length	O
of	O
stay	O
shorter	O
than	O
24	O
h	O
was	O
not	O
related	O
to	O
the	O
frequency	O
of	O
group	O
C	O
errors	O
.	O

Injection	O
of	O
horseradish	B
peroxidase	I
(	O
HRP	B
)	O
into	O
the	O
cerebellar	O
flocculus	O
of	O
the	O
rat	O
was	O
employed	O
to	O
identify	O
neurons	O
in	O
the	O
abducens	O
nucleus	O
that	O
project	O
to	O
the	O
flocculus	O
.	O

The	O
enzyme	O
encoded	O
by	O
the	O
cloned	O
fragment	O
is	O
equally	O
active	O
on	O
pyruvate	O
and	O
hydroxypyruvate	O
,	O
indicating	O
that	O
the	O
enzyme	O
has	O
both	O
D	B
-	I
lactate	I
and	I
D	I
-	I
glycerate	I
dehydrogenase	I
activities	O
.	O

In	O
a	O
subsequent	O
phase	O
-	O
II	O
clinical	O
trial	O
safety	O
and	O
efficacy	O
of	O
transrectal	O
HIFU	O
as	O
a	O
novel	O
minimally	O
invasive	O
treatment	O
modality	O
for	O
patients	O
with	O
symptomatic	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
;	O
n	O
=	O
102	O
)	O
was	O
determined	O
.	O

Taking	O
into	O
account	O
certain	O
well	O
defined	O
conditions	O
(	O
frequent	O
feedings	O
,	O
no	O
supplementary	O
feeding	O
before	O
4	O
-	O
6	O
months	O
,	O
method	O
only	O
to	O
be	O
used	O
in	O
the	O
absence	O
of	O
menstruation	O
)	O
,	O
LAM	O
can	O
be	O
relied	O
on	O
for	O
contraceptive	O
protection	O
for	O
up	O
to	O
1	O
year	O
post	O
partum	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
ZF	B
-	I
HD	I
class	O
of	O
homeodomain	B
proteins	I
may	O
be	O
involved	O
in	O
the	O
establishment	O
of	O
the	O
characteristic	O
expression	O
pattern	O
of	O
the	O
C4	B
PEPCase	I
gene	I
.	O

Although	O
the	O
only	O
authoritative	O
way	O
to	O
determine	O
the	O
effect	O
of	O
diet	O
on	O
urinary	O
pH	O
is	O
a	O
feeding	O
trial	O
,	O
there	O
is	O
no	O
universally	O
accepted	O
protocol	O
for	O
measuring	O
urinary	O
pH.	O

In	O
stage	O
I	O
,	O
histochemistry	O
for	O
copper	O
was	O
positive	O
in	O
11	O
out	O
of	O
21	O
cases	O
:	O
6	O
cases	O
were	O
T+	O
;	O
1	O
case	O
R+	O
and	O
2	O
cases	O
O+	O
;	O
2	O
cases	O
were	O
T+	O
,	O
R+	O
,	O
O+	O
.	O

A	O
24-year	O
-	O
old	O
pregnant	O
woman	O
started	O
to	O
have	O
hyperemesis	O
gravidarum	O
6	O
weeks	O
before	O
admission	O
.	O

Biopsy	O
of	O
the	O
lesion	O
revealed	O
granulomatous	O
inflammation	O
and	O
numerous	O
septate	O
hyphae	O
.	O

Mating	O
response	O
,	O
ovulation	O
rate	O
,	O
follicle	O
and	O
corpus	O
luteum	O
size	O
,	O
gestation	O
length	O
,	O
pregnancy	O
rate	O
,	O
lambing	O
rate	O
,	O
and	O
lamb	O
birth	O
weight	O
were	O
recorded	O
.	O

A	O
biopsy	O
specimen	O
taken	O
from	O
the	O
frontal	O
branch	O
of	O
the	O
right	O
superficial	O
artery	O
revealed	O
segmental	O
intimal	O
thickening	O
consistent	O
with	O
intimal	O
fibroplasia	O
type	O
FMD	O
upon	O
histological	O
examination	O
.	O

Reduced	O
risk	O
of	O
upper	O
gastrointestinal	O
ulcer	O
complications	O
with	O
celecoxib	O
,	O
a	O
novel	O
COX-2	B
inhibitor	O
.	O

The	O
DW	O
directions	O
uniformly	O
sampled	O
the	O
diffusion	O
ellipsoid	O
surface	O
.	O

Recent	O
,	O
highly	O
visible	O
reviews	O
on	O
the	O
subject	O
have	O
clearly	O
pointed	O
out	O
that	O
little	O
is	O
known	O
about	O
the	O
cellular	O
mechanisms	O
through	O
which	O
inhaled	O
asbestos	O
fibers	O
cause	O
the	O
well	O
known	O
,	O
debilitating	O
lung	O
disease	O
-	O
asbestosis	O
(	O
i.e.	O
interstitial	O
pulmonary	O
fibrosis	O
)	O
.	O

The	O
Rep78	B
protein	I
of	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
contains	O
amino	O
acid	O
sequence	O
motifs	O
common	O
to	O
rolling	B
-	I
circle	I
replication	I
(	I
RCR	I
)	I
initiator	I
proteins	I
.	O

METHODS	O
:	O
Two	O
patients	O
developed	O
cervical	O
myelopathy	O
or	O
radiculopathy	O
after	O
spinal	O
manipulation	O
therapy	O
,	O
and	O
magnetic	O
resonance	O
imaging	O
showed	O
herniated	O
cervical	O
discs	O
at	O
C4-C5	O
and	O
C6-C7	O
,	O
respectively	O
.	O

Isolates	O
of	O
B.	O
burgdorferi	O
from	O
humans	O
,	O
rodents	O
,	O
and	O
I.	O
dammini	O
are	O
usually	O
indistinguishable	O
,	O
but	O
strains	O
of	O
B.	O
burgdorferi	O
with	O
different	O
major	O
proteins	O
have	O
been	O
identified	O
.	O

In	O
a	O
pilot	O
study	O
in	O
which	O
two	O
dogs	O
were	O
given	O
parenteral	O
rifampin	O
before	O
and	O
after	O
operation	O
and	O
grafts	O
were	O
preclotted	O
with	O
blood	O
that	O
contained	O
rifampin	O
,	O
it	O
was	O
suggested	O
that	O
there	O
was	O
a	O
slight	O
increase	O
in	O
inhibition	O
at	O
24	O
hours	O
(	O
93	O
%	O
)	O
.	O

To	O
study	O
the	O
mechanisms	O
and	O
the	O
signaling	O
pathways	O
involved	O
,	O
IGF-1R	B
promoter	I
reporter	I
constructs	I
were	O
transiently	O
transfected	O
in	O
CHO	O
-	O
AT1	O
cells	O
that	O
overexpress	O
angiotensin	B
AT1	I
receptors	I
.	O

Gel	O
shift	O
analysis	O
of	O
protein	O
binding	O
from	O
nuclear	O
extracts	O
to	O
these	O
caveolin	B
promoter	I
DNA	I
sequences	I
,	O
together	O
with	O
DNase	B
I	I
footprinting	O
,	O
confirmed	O
nucleoprotein	O
binding	O
to	O
the	O
SRE	O
-	O
like	O
elements	O
as	O
part	O
of	O
the	O
transcriptional	O
response	O
to	O
LDL	B
-	I
FC	I
.	O

Early	O
attempts	O
for	O
modifying	O
growth	O
functions	O
to	O
annual	O
variations	O
dating	O
back	O
up	O
to	O
2	O
decades	O
are	O
recalled	O
together	O
with	O
examples	O
for	O
their	O
application	O
showing	O
rather	O
different	O
degrees	O
of	O
approximation	O
.	O

Indications	O
for	O
therapy	O
using	O
MAO	B
inhibitors	O

Through	O
effective	O
use	O
of	O
laboratory	O
testing	O
database	O
,	O
it	O
will	O
be	O
possible	O
to	O
shift	O
away	O
our	O
vague	O
management	O
of	O
pre	O
-	O
analytic	O
phase	O
of	O
quality	O
control	O
so	O
far	O
to	O
its	O
established	O
system	O
based	O
on	O
objective	O
evaluation	O
.	O

The	O
melanoma	B
growth	I
stimulatory	I
activity	I
/	I
growth	I
-	I
regulated	I
protein	I
,	O
CXCL1	B
,	O
is	O
constitutively	O
expressed	O
at	O
high	O
levels	O
during	O
inflammation	O
and	O
progression	O
of	O
melanocytes	O
into	O
malignant	O
melanoma	O
.	O

The	O
activated	O
glucocorticoid	B
receptor	I
forms	O
a	O
complex	O
with	O
Stat5	B
and	O
enhances	O
Stat5-mediated	B
transcriptional	O
induction	O
.	O

The	O
median	O
levels	O
of	O
t	B
-	I
PA	I
Ag	I
and	O
PAI	B
in	O
plasma	O
were	O
respectively	O
10.7	O
ng	O
/	O
ml	O
(	O
interquartile	O
range	O
8.6	O
ng	O
/	O
ml	O
)	O
and	O
15.7	O
IU	O
/	O
ml	O
(	O
interquartile	O
range	O
12.2	O
IU	O
/	O
ml	O
)	O
.	O

The	O
rice	O
gene	O
consists	O
of	O
four	O
exons	O
.	O

One	O
of	O
the	O
ORFs	O
in	O
the	O
Methanococcus	O
jannaschii	O
genome	O
possesses	O
high	O
similarity	O
to	O
the	O
M.	B
aeolicus	I
ilvB	I
,	O
indicating	O
that	O
it	O
is	O
an	O
authentic	O
AHAS	B
.	O

It	O
differed	O
from	O
cued	O
recall	O
only	O
in	O
the	O
instructions	O
,	O
which	O
directed	O
subjects	O
away	O
from	O
the	O
memory	O
aspects	O
of	O
the	O
test	O
and	O
asked	O
them	O
to	O
complete	O
each	O
three	O
-	O
letter	O
cue	O
with	O
the	O
first	O
word	O
that	O
came	O
to	O
mind	O
.	O

Samarium-153	O
for	O
intravascular	O
irradiation	O
therapy	O
with	O
liquid	O
-	O
filled	O
balloons	O
to	O
prevent	O
restenosis	O
:	O
acute	O
and	O
long	O
-	O
term	O
results	O
in	O
a	O
hypercholesterolemic	O
rabbit	O
restenosis	O
model	O
.	O

We	O
determined	O
that	O
Hop	B
(	I
T42	I
)	I
contains	O
a	O
glutamic	O
acid	O
-	O
to	O
-	O
lysine	O
substitution	O
at	O
amino	O
acid	O
residue	O
695	O
(	O
E695	O
K	O
)	O
.	O

It	O
is	O
suggested	O
that	O
on	O
presentation	O
of	O
tail	O
tip	O
necrosis	O
in	O
kittens	O
a	O
diagnosis	O
of	O
neonatal	O
isoerythrolysis	O
or	O
isoagglutination	O
should	O
be	O
considered	O
.	O

The	O
effects	O
of	O
cefazolin	O
,	O
given	O
into	O
the	O
III	O
cerebral	O
ventricle	O
at	O
different	O
doses	O
were	O
studied	O
on	O
GABA	O
content	O
,	O
GAD	O
and	O
GABA	O
-	O
T	O
in	O
the	O
brain	O
-	O
stem	O
of	O
young	O
chickens	O
(	O
Gallus	O
domesticus	O
)	O
.	O

The	O
amino	B
-	I
terminal	I
gag	I
-	I
encoded	I
region	I
of	O
P140gag	B
-	O
fps	B
contains	O
a	O
phosphotyrosine	O
residue	O
in	O
addition	O
to	O
normal	O
gag	B
phosphorylation	O
sites	O
.	O

The	O
subjects	O
'	O
lungs	O
were	O
ventilated	O
with	O
N2O	O
in	O
O2	O
(	O
FIO2	O
0.3	O
)	O
to	O
the	O
end	O
-	O
tidal	O
CO2	O
present	O
before	O
anesthesia	O
,	O
and	O
then	O
CBF	O
was	O
measured	O
using	O
intravenous	O
133Xe	O
and	O
ten	O
scintillation	O
counters	O
,	O
five	O
over	O
each	O
cerebral	O
hemisphere	O
.	O

Six	O
patients	O
(	O
24	O
%	O
)	O
developed	O
sepsis	O
and	O
only	O
one	O
survived	O
.	O

Diabetic	O
osteopenia	O
,	O
a	O
known	O
chronic	O
complication	O
of	O
diabetes	O
,	O
has	O
been	O
demonstrated	O
with	O
alterations	O
in	O
the	O
calcium	O
-	O
vitamin	O
D	O
endocrine	O
system	O
.	O

In	O
this	O
reconstituted	O
system	O
,	O
RNAP	B
IIA	I
,	O
but	O
not	O
RNAP	B
IIB	I
,	O
can	O
transcribe	O
from	O
the	O
DHFR	B
promoter	I
.	O

Furthermore	O
,	O
the	O
data	O
suggest	O
an	O
immunological	O
non	O
-	O
responsiveness	O
to	O
enterotoxin	B
A	I
in	O
a	O
considerable	O
portion	O
of	O
the	O
patients	O
.	O

In	O
addition	O
,	O
the	O
authors	O
found	O
one	O
an3	B
allele	I
(	O
an3-W138A	B
)	O
in	O
which	O
a	O
dTph1	B
element	I
had	O
inserted	O
30	O
bp	O
upstream	O
the	O
translation	O
start	O
,	O
without	O
inactivating	O
the	O
gene	O
.	O

The	O
right	O
cornea	O
of	O
rats	O
was	O
cauterized	O
by	O
drops	O
of	O
1.5	O
N	O
HC1	O
over	O
30	O
s	O
;	O
the	O
left	O
one	O
served	O
as	O
a	O
control	O
.	O

Secretion	O
of	O
cuticle	O
over	O
and	O
between	O
the	O
domed	O
apical	O
surfaces	O
of	O
these	O
cells	O
leads	O
to	O
a	O
honeycomb	O
-	O
like	O
structure	O
and	O
gives	O
the	O
superficial	O
wart	O
-	O
like	O
phenotype	O
of	O
mitotic	O
clones	O
on	O
the	O
adult	O
.	O

The	O
sequences	O
of	O
two	O
previously	O
known	O
tail	B
genes	I
,	O
R	B
and	O
S	B
,	O
of	O
the	O
temperate	O
bacteriophage	O
P2	O
and	O
the	O
sequence	O
of	O
an	O
additional	O
open	O
reading	O
frame	O
(	O
orf-30	O
)	O
located	O
between	O
S	B
and	O
V	B
,	O
were	O
determined	O
.	O

After	O
a	O
shift	O
to	O
37	O
degrees	O
C	O
,	O
the	O
mutant	O
Rat7	B
-	I
1p	I
/	O
Nup159	B
-	I
1p	I
is	O
lost	O
from	O
the	O
nuclear	O
rim	O
of	O
rat7	O
-	O
1	O
cells	O
and	O
NPCs	O
,	O
which	O
are	O
clustered	O
together	O
in	O
these	O
cells	O
grown	O
under	O
permissive	O
conditions	O
become	O
substantially	O
less	O
clustered	O
.	O

This	O
paper	O
describes	O
a	O
course	O
of	O
therapy	O
with	O
an	O
agoraphobic	O
female	O
patient	O
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
-	O
dependent	O
reporter	O
gene	O
transcription	O
by	O
E1A	B
was	O
potently	O
suppressed	O
upon	O
coexpression	O
of	O
the	O
E1B	B
19-kDa	I
protein	I
(	I
19	I
K	I
)	I
.	O

We	O
conclude	O
that	O
transcription	O
of	O
both	O
SCD1	B
and	O
SCD2	B
genes	I
is	O
responsive	O
to	O
cellular	O
sterol	O
levels	O
and	O
to	O
the	O
levels	O
of	O
nuclear	O
SREBP	B
/	O
ADD1	B
and	O
that	O
transcriptional	O
induction	O
requires	O
three	O
spatially	O
conserved	O
cis	O
elements	O
,	O
that	O
bind	O
SREBP	B
and	O
NF	B
-	I
Y.	I

BACKGROUND	O
:	O
Recent	O
iterative	O
methods	O
for	O
sequence	O
alignment	O
have	O
indicated	O
that	O
the	O
380	O
kDa	O
motor	O
unit	O
of	O
dynein	B
belongs	O
to	O
the	O
AAA	B
class	I
of	O
chaperone	B
-	I
like	I
ATPases	I
.	O

The	O
vertebrate	B
transcription	I
factors	I
TCF	I
(	O
T	B
cell	I
factor	I
)	O
and	O
LEF	B
(	O
lymphocyte	B
enhancer	I
binding	I
factor	I
)	O
interact	O
with	O
beta	B
-	I
catenin	I
and	O
are	O
hypothesized	O
to	O
mediate	O
Wingless	B
/	O
Wnt	B
signaling	O
.	O

DESIGN	O
:	O
Activating	B
protein-1	I
(	O
AP-1	B
)	O
and	O
Tat	B
-	O
induced	O
transcription	O
were	O
assessed	O
using	O
Jun	B
and	O
hybrid	O
Tat	B
/	O
Jun	B
-	O
expression	O
plasmids	O
and	O
reporter	O
gene	O
constructs	O
which	O
contained	O
AP-1	B
binding	I
sites	I
upstream	O
of	O
the	O
rat	B
prolactin	I
TATAA	I
element	I
or	O
an	O
HIV-1	B
LTR	I
construct	I
in	O
which	O
AP-1	B
binding	I
sites	I
replaced	O
the	O
TAR	O
element	O
.	O

According	O
to	O
the	O
penetration	O
of	O
Ca-45	O
,	O
the	O
microleakage	O
level	O
was	O
scored	O
for	O
each	O
section	O
.	O

KatA	B
,	O
AhpCF	B
,	O
heme	O
biosynthesis	O
enzymes	O
,	O
and	O
MrgA	B
are	O
also	O
induced	O
upon	O
entry	O
into	O
stationary	O
phase	O
under	O
conditions	O
of	O
iron	O
and	O
manganese	O
limitation	O
.	O

Healthy	O
preterm	O
infants	O
of	O
gestational	O
age	O
26	O
-	O
29	O
weeks	O
showed	O
a	O
'	O
mature	O
'	O
pattern	O
of	O
permeability	O
at	O
birth	O
,	O
followed	O
by	O
a	O
temporary	O
period	O
of	O
enhanced	O
permeability	O
after	O
3	O
-	O
4	O
weeks	O
of	O
life	O
.	O

Reproduction	O
and	O
maternal	O
response	O
of	O
the	O
rat	O
when	O
thiamine	O
intake	O
is	O
limited	O
.	O

The	O
formation	O
of	O
tumorlike	O
lesions	O
in	O
the	O
cockroach	O
leucophaea	O
maderae	O
after	O
anal	O
blockage	O
.	O

Promoter	O
,	O
spliced	O
leader	O
,	O
and	O
coding	O
sequence	O
for	O
BICP4	B
,	O
the	O
largest	O
of	O
the	O
immediate	B
-	I
early	I
proteins	I
of	I
bovine	I
herpesvirus	I
1	I
.	O

Effects	O
of	O
prolonged	O
inhibition	O
of	O
labour	O
pains	O
with	O
Th	O
1165a	O
and	O
Isoptin	O
on	O
the	O
heart	O
,	O
circulation	O
,	O
organ-	O
and	O
metabolic	O
parameters	O
of	O
the	O
mother	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
whether	O
these	O
findings	O
are	O
idiosyncratic	O
,	O
coincidental	O
,	O
or	O
a	O
more	O
general	O
phenomenon	O
.	O

RESULTS	O
:	O
In	O
men	O
,	O
weight	O
/	O
height2	O
met	O
the	O
criteria	O
for	O
a	O
satisfactory	O
index	O
in	O
that	O
there	O
was	O
a	O
very	O
strong	O
correlation	O
with	O
triceps	O
skinfold	O
,	O
and	O
a	O
negligible	O
correlation	O
with	O
height	O
.	O

Identification	O
of	O
an	O
osteocalcin	B
gene	I
promoter	I
sequence	I
that	O
binds	O
AP1	B
.	O

Sexual	O
adventurism	O
,	O
high	O
-	O
risk	O
behavior	O
,	O
and	O
human	O
immunodeficiency	O
virus-1	O
seroconversion	O
among	O
the	O
Chicago	O
MACS	O
-	O
CCS	O
cohort	O
,	O
1984	O
to	O
1992	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
etiology	O
of	O
HITT	O
because	O
of	O
its	O
devastating	O
clinical	O
consequences	O
.	O

New	O
concepts	O
of	O
condyloma	O
acuminata	O
in	O
children	O
.	O

The	O
effect	O
of	O
lung	O
edema	O
on	O
pulmonary	O
vasoactivity	O
of	O
furosemide	O
.	O

Only	O
the	O
native	O
structure	O
of	O
phosphorylated	O
ERK	B
was	O
recognized	O
by	O
VHR	B
and	O
was	O
inactivated	O
with	O
a	O
second	O
-	O
order	O
rate	O
constant	O
of	O
40,000	O
M-1	O
s-1	O
.	O

The	O
Xenopus	B
homeobox	I
gene	I
twin	I
mediates	O
Wnt	B
induction	O
of	O
goosecoid	B
in	O
establishment	O
of	O
Spemann	O
's	O
organizer	O
.	O

Bovine	O
anaplasmosis	O
:	O
susceptibility	O
of	O
seronegative	O
cows	O
from	O
an	O
infected	O
herd	O
to	O
experimental	O
infection	O
with	O
Anaplasma	O
marginale	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
TGFbeta1	B
expression	O
is	O
upregulated	O
in	O
mouse	O
keratinocytes	O
infected	O
with	O
a	O
v	B
-	I
rasHa	I
retrovirus	O
,	O
although	O
the	O
functional	O
significance	O
of	O
this	O
has	O
not	O
been	O
clear	O
.	O

As	O
a	O
member	O
of	O
the	O
uncoupling	B
protein	I
family	I
,	O
UCP2	B
is	O
ubiquitously	O
expressed	O
in	O
rodents	O
and	O
humans	O
,	O
implicating	O
a	O
major	O
role	O
in	O
thermogenesis	O
.	O

In	O
situ	O
localization	O
of	O
PCP	B
-	I
A1	I
transcripts	I
revealed	O
that	O
they	O
accumulate	O
specifically	O
in	O
pollen	O
at	O
the	O
late	O
binucleate	O
/	O
trinucleate	O
stage	O
of	O
development	O
rather	O
than	O
in	O
the	O
tapetum	O
,	O
which	O
previously	O
was	O
taken	O
to	O
be	O
the	O
principal	O
source	O
of	O
the	O
pollen	O
coat	O
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
major	O
and	O
novel	O
Shc	B
tyrosine	O
phosphorylation	O
sites	O
,	O
Y239	O
and	O
Y240	O
.	O

Based	O
on	O
our	O
sequence	O
data	O
,	O
ORF2	O
from	O
most	O
isolates	O
excluding	O
G1	O
encode	O
truncated	O
49	O
aa	O
(	O
pORF2a	O
)	O
because	O
of	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
,	O
although	O
ORF2s	O
from	O
most	O
G1	O
isolates	O
encode	O
202	O
aa	O
(	O
pORF2ab	O
)	O
.	O

Fusions	O
between	O
the	O
GAL	B
DNA	I
binding	I
domain	I
and	O
full	B
-	I
length	I
mSin3	I
were	O
also	O
capable	O
of	O
repression	O
.	O

The	O
method	O
was	O
tested	O
on	O
7	O
rats	O
with	O
48-hr	O
-	O
old	O
myocardial	O
infarction	O
and	O
4	O
sham	O
-	O
operated	O
controls	O
.	O

Disruption	O
and	O
reconstruction	O
:	O
narrative	O
insights	O
into	O
the	O
experience	O
of	O
family	O
members	O
caring	O
for	O
a	O
relative	O
diagnosed	O
with	O
serious	O
mental	O
illness	O
.	O

Thus	O
,	O
an	O
increase	O
in	O
lactate	O
concentration	O
of	O
the	O
magnitude	O
observed	O
during	O
alkali	O
therapy	O
need	O
not	O
indicate	O
a	O
worsening	O
of	O
the	O
metabolic	O
picture	O
in	O
lactic	O
acidosis	O
.	O

A	O
wound	O
model	O
for	O
decubitus	O
and	O
leg	O
ulcers	O
consisting	O
of	O
human	O
dermal	O
fibroblasts	O
in	O
type	B
I	I
collagen	I
dermal	O
""""	O
equivalent	O
""""	O
matrix	O
(	O
DEM	O
)	O
was	O
exposed	O
in	O
vitro	O
to	O
electric	O
fields	O
similar	O
to	O
postulated	O
endogenous	O
fields	O
in	O
wounds	O
.	O

Lastly	O
,	O
several	O
restriction	O
length	O
polymorphisms	O
were	O
identified	O
and	O
mapped	O
within	O
a	O
1	O
kb	O
region	O
located	O
immediately	O
upstream	O
from	O
the	O
JH	B
cluster	I
.	O

Y1	B
,	O
Y2	B
,	O
and	O
Y4	B
/	O
PP1	B
.	O

A	O
case	O
comparison	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
in	O
homosexual	O
males	O
with	O
spindle	O
-	O
endothelial	O
cell	O
abnormalities	O
and	O
with	O
recrudescent	O
melioidosis	O
.	O

The	O
significance	O
of	O
these	O
changes	O
in	O
relation	O
to	O
the	O
control	O
of	O
phosphorus	O
balance	O
in	O
ruminants	O
is	O
discussed	O
.	O

UPR	O
elements	O
present	O
in	O
other	O
ER	O
chaperone	O
genes	O
,	O
such	O
as	O
yeast	B
KAR2	I
(	O
BiP	B
)	O
,	O
mammalian	B
GRP78	I
(	O
BiP	B
)	O
,	O
and	O
GRP94	B
,	O
function	O
in	O
an	O
analogous	O
manner	O
to	O
that	O
in	O
FKB2	B
.	O

Acceptability	O
of	O
home	O
monitoring	O
as	O
an	O
aid	O
to	O
conception	O
.	O

The	O
5-HT3	B
antagonist	O
ondansetron	O
reduced	O
alcohol	O
intake	O
in	O
both	O
the	O
medium	O
and	O
high	O
alcohol	O
preferring	O
rats	O
at	O
doses	O
between	O
0.01	O
and	O
0.16	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
we	O
mapped	O
a	O
putative	O
hnRNP	B
A1	I
binding	I
site	I
in	O
U5	B
RNA	I
and	O
demonstrated	O
that	O
p40CRS	B
(	O
hnRNP	B
A1	I
)	O
binding	O
to	O
that	O
site	O
correlates	O
with	O
CRS	B
function	O
.	O

The	O
gene	O
responsible	O
for	O
multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	B
)	O
,	O
a	O
heritable	O
predisposition	O
to	O
endocrine	O
tumours	O
in	O
man	O
,	O
has	O
recently	O
been	O
identified	O
.	O

trans	O
-	O
activation	O
of	O
the	O
HIV-1	B
LTR	I
by	O
the	O
HIV-1	B
Tat	I
and	O
HTLV	B
-	I
I	I
Tax	I
proteins	I
is	O
mediated	O
by	O
different	O
cis	O
-	O
acting	O
sequences	O
.	O

Using	O
green	B
fluorescent	I
protein	I
fusions	O
we	O
demonstrate	O
that	O
the	O
SYT	B
,	O
SSX	B
and	O
the	O
SYT	B
-	O
SSX	B
proteins	O
are	O
nuclear	O
proteins	O
.	O

Similarly	O
,	O
antisense	B
TGF	I
-	I
beta	I
type	I
II	I
receptor	I
oligodeoxynucleotides	I
(	I
40	I
microM	I
)	I
resulted	O
in	O
a	O
58	O
%	O
increase	O
in	O
branching	O
,	O
compared	O
to	O
scrambled	O
and	O
mismatched	O
sequence	O
controls	O
,	O
while	O
TGF	B
-	I
beta	I
,	I
type	I
II	I
receptor	I
mRNA	I
and	O
its	O
protein	O
expression	O
levels	O
were	O
suppressed	O
by	O
95	O
and	O
84	O
%	O
,	O
respectively	O
.	O

This	O
action	O
could	O
be	O
antagonized	O
by	O
aminophylline	O
,	O
a	O
competitive	O
antagonist	O
on	O
P1	B
purinoceptors	I
.	O

A	O
definition	O
of	O
bias	O
founded	O
on	O
the	O
concept	O
of	O
the	O
study	O
base	O
.	O

The	O
use	O
of	O
the	O
two	O
pharmacokinetic	O
parameters	O
,	O
t1	O
/	O
2	O
and	O
Cltp	O
,	O
as	O
indices	O
of	O
drug	O
elimination	O
ability	O
are	O
discussed	O
.	O

In	O
group	O
1	O
,	O
mean	O
z	O
-	O
score	O
for	O
GFR	O
was	O
-0.27	O
(	O
94.6	O
%	O
of	O
normal	O
)	O
and	O
in	O
group	O
2	O
mean	O
z	O
-	O
score	O
was	O
-1.51	O
(	O
72.7	O
%	O
of	O
normal	O
for	O
two	O
kidneys	O
)	O
(	O
P	O
=	O
0.022	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O

The	O
apparent	O
binding	O
constant	O
of	O
6	O
to	O
calf	O
thymus	O
DNA	O
is	O
1.68	O
X	O
10	O
(	O
5	O
)	O
M-1	O
whereas	O
netropsin	B
under	O
similar	O
conditions	O
gives	O
a	O
value	O
of	O
1.85	O
X	O
10	O
(	O
7	O
)	O
M-1	O
.	O

Neonatal	O
masculinization	O
affects	O
maternal	O
behavior	O
sensitivity	O
in	O
female	O
rats	O
.	O

However	O
,	O
there	O
are	O
some	O
cows	O
that	O
fail	O
to	O
produce	O
adequate	O
1,25-dihydroxyvitamin	O
D	O
at	O
the	O
onset	O
of	O
lactation	O
.	O

We	O
examined	O
the	O
mechanisms	O
by	O
which	O
two	O
different	O
types	O
of	O
photonic	O
radiation	O
,	O
short	O
wavelength	O
UV	O
(	O
UV	O
-	O
C	O
)	O
and	O
gamma	O
radiation	O
,	O
activate	O
transcription	O
factor	O
NF	B
-	I
kappaB.	I

Prenatal	O
diagnosis	O
of	O
genetic	O
diseases	O
.	O

M.	O
,	O
Apps	O
,	O
D.	O

The	O
three	O
OAS	B
genes	I
are	O
flanked	O
by	O
markers	B
WI-10614	I
(	O
cen	B
)	O
and	O
D12S2293	B
(	O
tel	B
)	O
and	O
are	O
contained	O
within	O
three	O
sets	O
of	O
overlapping	O
cosmid	O
clones	O
.	O

5'-Deletion	O
of	O
the	O
Stat	B
-	I
binding	I
sites	I
abolished	O
all	O
promoter	O
-	O
reporter	O
activity	O
in	O
response	O
to	O
PRL	B
.	O

The	O
main	O
new	O
features	O
of	O
this	O
version	O
are	O
that	O
end	O
-	O
tidal	O
PO2	O
instead	O
of	O
inspiratory	O
PO2	O
can	O
be	O
kept	O
constant	O
,	O
and	O
that	O
the	O
correcting	O
activity	O
of	O
both	O
controllers	O
(	O
capnostat	O
and	O
oxystat	O
)	O
is	O
proportional	O
to	O
the	O
magnitude	O
of	O
the	O
difference	O
between	O
the	O
actual	O
and	O
the	O
adjusted	O
end	O
-	O
tidal	O
PCO2	O
or	O
PO2	O
.	O

The	O
MAP	B
kinase	I
kinase	I
kinase	I
MLK2	B
co	O
-	O
localizes	O
with	O
activated	O
JNK	B
along	O
microtubules	O
and	O
associates	O
with	O
kinesin	B
superfamily	I
motor	O
KIF3	B
.	O

Materials	O
are	O
presented	O
of	O
a	O
comparative	O
study	O
of	O
morphological	O
and	O
cultural	O
properties	O
and	O
virulence	O
of	O
liophylized	O
cultures	O
of	O
Leishmania	O
tropica	O
major	O
after	O
their	O
rehydration	O
or	O
after	O
a	O
long	O
passage	O
on	O
the	O
NNN	O
medium	O
.	O

CrkII	B
and	O
CrkL	B
constitutively	O
formed	O
complex	O
with	O
the	O
guanine	B
nucleotide	I
exchange	I
factor	I
C3	B
G	I
,	O
in	O
unstimulated	O
as	O
well	O
as	O
PDGF	B
-	O
stimulated	O
cells	O
.	O

DSIP	O
was	O
found	O
to	O
significantly	O
increase	O
slow	O
-	O
waves	O
(	O
delta	O
sleep	O
)	O
in	O
the	O
sleep	O
EEG	O
.	O

Two	O
courses	O
of	O
chemotherapy	O
(	O
CBCDA	O
+	O
VDS	O
)	O
failed	O
to	O
gain	O
any	O
improvement	O
,	O
and	O
the	O
pain	O
resulting	O
from	O
recurrent	O
bone	O
metastases	O
was	O
managed	O
mainly	O
by	O
the	O
administration	O
of	O
the	O
best	O
supportive	O
care	O
.	O

Thus	O
,	O
the	O
search	O
for	O
genetic	O
and	O
acquired	O
susceptibility	O
to	O
nontuberculous	O
mycobacteria	O
is	O
also	O
a	O
search	O
for	O
susceptibility	O
factors	O
for	O
MTB	O
as	O
well	O
as	O
an	O
opportunity	O
to	O
recognize	O
endogenous	O
pathways	O
that	O
can	O
be	O
exploited	O
therapeutically	O
.	O

This	O
gene	O
is	O
divided	O
into	O
six	O
exons	O
spanning	O
about	O
3	O
kb	O
,	O
and	O
encodes	O
a	O
175	O
amino	O
acid	O
protein	O
with	O
40	O
-	O
52	O
%	O
identity	O
with	O
the	O
other	O
five	O
mouse	B
Reg	I
(	O
regenerating	B
gene	I
product	I
)	O
proteins	O
.	O

Interconversions	O
between	O
haloperidol	O
and	O
reduced	O
haloperidol	O
in	O
schizophrenic	O
patients	O
and	O
guinea	O
pigs	O
:	O
a	O
steady	O
-	O
state	O
study	O
.	O

Bilirubin	O
and	O
red	O
cell	O
metabolism	O
in	O
relation	O
to	O
neonatal	O
jaundice	O
.	O

Minute	B
virus	I
of	I
mice	I
NS1	I
,	O
an	O
83-kDa	O
mainly	O
nuclear	O
phosphoprotein	O
,	O
is	O
the	O
only	O
viral	O
nonstructural	O
protein	O
required	O
in	O
all	O
cell	O
types	O
and	O
it	O
is	O
involved	O
in	O
multiple	O
processes	O
necessary	O
for	O
virus	O
propagation	O
.	O

Pediatric	O
patients	O
--	O
handle	O
with	O
care	O
.	O

K.	O

Protection	O
levels	O
of	O
33.3	O
%	O
,	O
36.6	O
%	O
and	O
37.0	O
%	O
were	O
achieved	O
in	O
groups	O
which	O
had	O
received	O
,	O
respectively	O
,	O
1000	O
20-krad	O
cercariae	O
,	O
1000	O
10-krad	O
cercariae	O
,	O
2000	O
40-krad	O
cercariae	O
and	O
2000	O
60-krad	O
cercariae	O
.	O

Interferon	B
-	I
alpha	I
inducibility	O
of	O
IFI16	B
may	O
be	O
regulated	O
by	O
an	O
interferon	B
-	I
alpha	I
/	I
beta	I
-	O
stimulated	O
response	O
consensus	O
element	O
in	O
the	O
5	O
'	O
UT	O
exon	O
,	O
as	O
a	O
similar	O
motif	O
is	O
conserved	O
in	O
the	O
corresponding	O
position	O
in	O
the	O
related	O
myeloid	B
cell	I
nuclear	I
differentiation	I
antigen	I
gene.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

For	O
the	O
population	O
of	O
patients	O
with	O
melanoma	O
levels	O
III	O
and	O
IV	O
significant	O
differences	O
in	O
survival	O
rate	O
were	O
associated	O
with	O
thickness	O
(	O
less	O
than	O
2	O
mm	O
or	O
greater	O
than	O
or	O
equal	O
to	O
2	O
mm	O
;	O
p	O
less	O
than	O
0,001	O
)	O
,	O
though	O
not	O
with	O
level	O
.	O

However	O
,	O
the	O
in	O
vivo	O
attachment	O
strength	O
of	O
the	O
CSTi-2	O
coating	O
was	O
comparable	O
both	O
to	O
CSTi-1	O
and	O
to	O
an	O
HA	O
-	O
coated	O
control	O
after	O
8	O
weeks	O
.	O

Effects	O
of	O
negative	O
pi	O
mesons	O
on	O
mouse	O
bone	O
marrow	O
cells	O
.	O

The	O
(	O
0	O
0	O
2	O
)	O
diffraction	O
of	O
the	O
synthesized	O
HAp	O
crystals	O
on	O
a	O
Col	O
fiber	O
showed	O
an	O
around	O
60	O
arching	O
angle	O
,	O
while	O
that	O
on	O
a	O
ChS	O
fiber	O
showed	O
just	O
around	O
10	O
degrees	O
.	O

Mutations	O
of	O
SIN4	B
,	O
ROX3	B
,	O
SRB8	B
,	O
SRB9	B
,	O
SRB10	B
,	O
SRB11	B
,	O
and	O
two	O
novel	O
genes	O
,	O
NUT1	B
and	O
NUT2	B
,	O
relieve	O
the	O
requirement	O
of	O
Swi4p	B
for	O
expression	O
of	O
this	O
reporter	O
.	O

In	O
the	O
case	O
of	O
the	O
pT181	O
plasmid	O
,	O
inactivation	O
of	O
the	O
initiator	B
RepC	I
protein	I
occurs	O
by	O
the	O
attachment	O
of	O
an	O
oligonucleotide	O
to	O
its	O
active	O
tyrosine	O
residue	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
release	O
of	O
a	O
single	O
pulley	O
after	O
repair	O
of	O
the	O
tendons	O
in	O
this	O
area	O
improved	O
gliding	O
excursions	O
of	O
the	O
tendons	O
and	O
reduced	O
resistance	O
to	O
motion	O
of	O
the	O
repaired	O
tendons	O
,	O
and	O
provide	O
support	O
for	O
partial	O
A2	O
pulley	O
incision	O
after	O
repair	O
of	O
the	O
tendons	O
in	O
the	O
area	O
of	O
the	O
pulley	O
.	O

Differential	O
transcription	O
of	O
plastome	O
-	O
encoded	O
genes	O
in	O
the	O
mesophyll	O
and	O
bundle	O
-	O
sheath	O
chloroplasts	O
of	O
the	O
monocotyledonous	O
NADP	O
-	O
malic	B
enzyme	I
-	O
type	O
C4	O
plants	O
maize	O
and	O
Sorghum	O
.	O

RESULTS	O
--	O
The	O
maximal	O
early	O
asthmatic	O
response	O
after	O
allergen	O
with	O
placebo	O
treatment	O
was	O
18.4	O
%	O
(	O
SE	O
4.4	O
%	O
)	O
and	O
with	O
WEB	O
2086	O
18.9	O
%	O
(	O
4.4	O
%	O
)	O
.	O

A	O
total	O
of	O
64	O
uncomplicated	O
Type-2	O
diabetic	O
individuals	O
of	O
higher	O
middle	O
class	O
to	O
rich	O
socio	O
-	O
economic	O
status	O
were	O
studied	O
.	O

To	O
investigate	O
the	O
role	O
of	O
this	O
domain	O
in	O
the	O
incorporation	O
of	O
the	O
SIV	B
Env	I
into	O
virions	O
,	O
we	O
generated	O
a	O
series	O
of	O
SIV	B
Env	I
mutants	I
carrying	O
small	O
in	O
-	O
frame	O
deletions	O
within	O
the	O
cytoplasmic	O
domain	O
.	O

Ozone	O
uptake	O
was	O
assessed	O
in	O
awake	O
,	O
spontaneously	O
breathing	O
Fischer-344	O
Sprague	O
-	O
Dawley	O
,	O
and	O
Long	O
-	O
Evans	O
rats	O
and	O
Hartley	O
guinea	O
pigs	O
to	O
provide	O
data	O
on	O
the	O
dosimetry	O
of	O
O3	O
in	O
small	O
laboratory	O
animals	O
.	O

On	O
the	O
3rd	O
day	O
after	O
ischemia	O
of	O
the	O
remained	O
kidney	O
for	O
30	O
min	O
,	O
structural	O
components	O
of	O
the	O
walls	O
of	O
the	O
glomerular	O
arterioles	O
and	O
those	O
of	O
the	O
filtration	O
-	O
reabsorption	O
barrier	O
undergo	O
certain	O
ultrastructural	O
changes	O
,	O
that	O
with	O
time	O
elapsed	O
(	O
7	O
,	O
14	O
days	O
)	O
gradually	O
pass	O
away	O
,	O
and	O
amount	O
of	O
cells	O
with	O
hypertrophic	O
processes	O
increases	O
.	O

Patients	O
with	O
Eales	O
'	O
disease	O
,	O
chorioretinitis	O
,	O
central	O
serous	O
retinopathy	O
,	O
or	O
malignant	O
choroidal	O
melanoma	O
were	O
tested	O
for	O
HLA	B
antigen	O
deviation	O
.	O

Of	O
all	O
YASR	O
syndromes	O
,	O
the	O
highest	O
stability	O
was	O
for	O
the	O
Anxious	O
/	O
Depressed	O
scale	O
.	O

Significant	O
differences	O
were	O
observed	O
in	O
the	O
composition	O
of	O
nuclear	O
transcription	O
factors	O
bound	O
to	O
cis	O
-	O
elements	O
within	O
the	O
LDH	B
/	I
C	I
proximal	I
promoter	I
region	I
in	O
somatic	O
versus	O
germ	O
cells	O
.	O

We	O
conclude	O
that	O
although	O
the	O
G3	O
sequence	O
contains	O
two	O
protein	O
-	O
binding	O
motifs	O
,	O
the	O
organization	O
of	O
the	O
G3	O
enhancer	O
-	O
like	O
element	O
is	O
not	O
bipartite	O
.	O

A	O
preterm	O
formula	O
with	O
a	O
traditional	O
corn	O
oil	O
/	O
MCT	O
blend	O
containing	O
38	O
%	O
MCTs	O
(	O
MCT	O
group	O
)	O
was	O
compared	O
to	O
a	O
new	O
fat	O
blend	O
,	O
designed	O
to	O
resemble	O
human	O
milk	O
more	O
,	O
containing	O
6	O
%	O
MCTs	O
(	O
LCT	O
group	O
)	O
.	O

The	O
existence	O
of	O
a	O
TFIIIB	B
assembly	O
pathway	O
leading	O
to	O
the	O
faithful	O
transcription	O
of	O
natural	O
eukaryotic	O
tRNA	O
genes	O
in	O
the	O
absence	O
of	O
TFIIIC	B
provides	O
novel	O
insights	O
into	O
the	O
functional	O
flexibility	O
of	O
the	O
eukaryotic	O
tRNA	O
gene	O
transcription	O
machinery	O
and	O
on	O
its	O
evolution	O
from	O
an	O
ancestral	O
RNA	B
polymerase	I
III	I
system	O
relying	O
on	O
upstream	O
,	O
TATA-	O
centered	O
control	O
elements	O
.	O

Reasons	O
are	O
presented	O
to	O
support	O
the	O
contention	O
that	O
this	O
increase	O
is	O
in	O
part	O
real	O
.	O

Hypocalcemia	O
is	O
usually	O
due	O
to	O
either	O
a	O
disturbance	O
in	O
the	O
parathyroid	B
hormone	I
-	O
adenylate	B
cyclase	I
system	O
or	O
a	O
disturbance	O
in	O
vitamin	O
D	O
metabolism	O
.	O

Northern	O
blot	O
analysis	O
with	O
GPR37	B
probes	O
revealed	O
a	O
main	O
3.8-kb	O
mRNA	O
and	O
a	O
less	O
abundant	O
8-kb	O
mRNA	O
,	O
both	O
expressed	O
in	O
human	O
brain	O
tissues	O
,	O
particularly	O
in	O
corpus	O
callosum	O
,	O
medulla	O
,	O
putamen	O
,	O
and	O
caudate	O
nucleus	O
.	O

TNF	B
-	I
alpha	I
effect	O
was	O
eliminated	O
by	O
a	O
2-bp	O
substitution	O
mutation	O
in	O
the	O
NF	B
-	I
kappa	I
B1	I
binding	I
half	I
site	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
cis	I
element	I
.	O

The	O
tam	B
A	I
gene	I
of	I
Aspergillus	I
nidulans	I
encodes	O
a	O
739-amino	O
acid	O
protein	O
with	O
similarity	O
to	O
Uga35p	B
/	O
Dal81p	B
/	O
DurLp	B
of	O
Saccharomyces	O
cerevisiae	O
.	O

Glutathione	B
reductase	I
(	O
GR	B
)	O
was	O
purified	O
from	O
the	O
cyanobacterium	O
Anabaena	O
PCC	O
7120	O
.	O

The	O
effects	O
of	O
inoculum	O
size	O
,	O
medium	O
,	O
temperature	O
,	O
and	O
duration	O
of	O
growth	O
on	O
the	O
in	O
vitro	O
susceptibility	O
testing	O
of	O
Aspergillus	O
fumigatus	O
were	O
investigated	O
using	O
broth	O
micro-	O
and	O
macro	O
-	O
dilution	O
techniques	O
.	O

This	O
dynamic	O
nature	O
may	O
be	O
relevant	O
to	O
the	O
ability	O
of	O
E47	B
both	O
to	O
homodimerize	O
and	O
to	O
heterodimerize	O
with	O
MyoD	B
,	O
I	B
d	I
,	O
and	O
Tal1	B
.	O

In	O
spite	O
of	O
the	O
variability	O
of	O
DD95	O
with	O
regard	O
to	O
body	O
weight	O
,	O
the	O
recovery	O
of	O
neuromuscular	O
transmission	O
in	O
the	O
patients	O
of	O
the	O
three	O
groups	O
is	O
comparable	O
.	O

Kerstin	O
takes	O
the	O
abbreviated	O
medical	O
education	O
.	O

An	O
atypical	O
form	O
of	O
juvenile	O
myasthenia	O
gravis	O
associated	O
with	O
severe	O
emaciation	O
,	O
muscle	O
atrophy	O
,	O
ophthalmoplegia	O
,	O
bulbar	O
signs	O
and	O
joint	O
contracture	O

Autophosphorylation	O
on	O
the	O
major	O
phosphorylation	O
site	O
Y1235	O
upregulates	O
the	O
kinase	O
activity	O
of	O
the	O
receptor	O
,	O
increasing	O
the	O
Vmax	O
of	O
the	O
phosphotransfer	O
reaction	O
.	O

Two	O
pharmacokinetic	O
models	O
were	O
compared	O
.	O

The	O
cats	O
with	O
stage-2	O
lymphomas	O
that	O
were	O
FeLV	O
-	O
test	O
negative	O
had	O
the	O
best	O
response	O
to	O
treatment	O
.	O

Reality	O
and	O
clinical	O
application	O
of	O
immunoglobulin	B
preparations	O

Our	O
case	O
,	O
however	O
,	O
had	O
no	O
histologic	O
evidence	O
of	O
malignancy	O
,	O
no	O
serum	B
alpha	I
fetoprotein	I
at	O
7	O
months	O
of	O
age	O
,	O
and	O
no	O
recurrence	O
at	O
1	O
years	O
.	O

We	O
evaluated	O
99mTc	O
-	O
ECD	O
SPECT	O
comparing	O
with	O
rCBF	O
images	O
obtained	O
by	O
PET	O
in	O
12	O
patients	O
with	O
spinocerebellar	O
degeneration	O
(	O
SCD	O
)	O
.	O

Outlook	O
in	O
oral	O
and	O
cutaneous	O
Kaposi	O
's	O
sarcoma	O
.	O

The	O
concepts	O
were	O
developed	O
by	O
Mines	O
and	O
Garrey	O
during	O
the	O
next	O
10	O
years	O
.	O

Maximum	O
overexpression	O
of	O
holoenzyme	O
activity	O
was	O
achieved	O
by	O
the	O
inclusion	O
in	O
such	O
plasmids	O
of	O
Salmonella	O
typhimurium	O
cysG	O
,	O
which	O
encodes	O
a	O
uroporphyrinogen	B
III	I
methyltransferase	I
required	O
for	O
the	O
synthesis	O
of	O
siroheme	O
,	O
a	O
cofactor	O
for	O
the	O
hemoprotein	O
.	O

METHODS	O
:	O
Precision	O
and	O
accuracy	O
were	O
measured	O
using	O
controls	O
and	O
method	O
comparison	O
studies	O
.	O

Residues	O
crucial	O
for	O
Ras	B
interaction	O
with	O
GDP	B
-	I
GTP	I
exchangers	I
.	O

Expression	O
of	O
human	B
complement	I
receptor	I
type	I
2	I
(	O
CR2	B
/	O
CD21	B
)	O
is	O
primarily	O
restricted	O
to	O
mature	O
B	O
cells	O
and	O
follicular	O
dendritic	O
cells	O
.	O

The	O
AtNMT1	B
expression	O
profile	O
indicated	O
ubiquity	O
in	O
roots	O
,	O
stem	O
,	O
leaves	O
,	O
flowers	O
,	O
and	O
siliques	O
(	O
approximately	O
1.7	O
kb	O
transcript	O
and	O
approximately	O
50	O
kDa	O
immunoreactive	O
polypeptide	O
)	O
but	O
a	O
greater	O
level	O
in	O
the	O
younger	O
tissue	O
,	O
which	O
are	O
developmentally	O
very	O
active	O
.	O

Studies	O
in	O
26	O
patients	O
.	O

In	O
addition	O
,	O
mutations	O
within	O
the	O
Ubx	B
unit	I
exons	I
are	O
known	O
and	O
most	O
of	O
these	O
behave	O
as	O
null	O
alleles	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
specific	O
cis-	O
and	O
trans	O
-	O
acting	O
factors	O
control	O
activity	O
of	O
the	O
prodynorphin	B
promoter	I
are	O
not	O
as	O
clearly	O
defined	O
.	O

Sesame	O
seed	O
should	O
also	O
be	O
considered	O
a	O
cause	O
of	O
allergic	O
reactions	O
to	O
drug	O
products	O
and	O
cosmetics	O
.	O

In	O
absence	O
of	O
i.m	O
.	O

medication	O
,	O
levels	O
over	O
1,000	O
U	O
must	O
be	O
carefully	O
screened	O
in	O
order	O
to	O
rule	O
out	O
SNM	O
or	O
organic	O
pathology	O
associated	O
.	O

This	O
latter	O
complex	O
reacts	O
with	O
an	O
antibody	O
to	O
serum	B
response	I
factor	I
(	O
SRF	B
)	O
and	O
exhibits	O
the	O
same	O
binding	O
characteristics	O
as	O
purified	O
SRF	B
.	O

After	O
cumulative	O
occlusions	O
of	O
15	O
,	O
30	O
,	O
45	O
,	O
and	O
90	O
min	O
,	O
transmural	O
needle	O
biopsies	O
were	O
taken	O
from	O
the	O
ischemic	O
area	O
to	O
be	O
analyzed	O
for	O
adenine	O
nucleotides	O
,	O
nucleosides	O
,	O
creatine	O
phosphate	O
,	O
and	O
ultrastructural	O
changes	O
.	O

Although	O
indomethacin	O
is	O
useful	O
for	O
examining	O
the	O
role	O
of	O
cyclooxygenase	B
products	I
in	O
asthmatic	O
responses	O
,	O
it	O
should	O
not	O
be	O
considered	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Therapeutic	O
iodine	O
125	O
for	O
hyperthyroidism	O
:	O
evidence	O
for	O
a	O
special	O
radiobiological	O
effect	O
on	O
the	O
follicular	O
cell	O
.	O

The	O
biological	O
activity	O
of	O
these	O
mutants	O
was	O
tested	O
by	O
determining	O
their	O
capacity	O
to	O
(	O
i	O
)	O
reconstitute	O
RNA	B
polymerase	I
activity	O
in	O
vivo	O
by	O
cotransfection	O
with	O
proteins	O
NP	B
,	O
PB1	B
,	O
and	O
PA	B
and	O
a	O
virion	O
-	O
like	O
RNA	O
encoding	O
the	O
cat	B
gene	O
into	O
vaccinia	O
virus	O
T7-infected	O
COS-1	O
cells	O
and	O
(	O
ii	O
)	O
complete	O
with	O
the	O
wild	B
-	I
type	I
PB2	I
activity	O
.	O

Menstrual	O
and	O
lunar	O
cycles	O
.	O

A	O
nationwide	O
record	O
linkage	O
of	O
the	O
Finnish	O
Twin	O
Cohort	O
Study	O
(	O
FTCS	O
)	O
with	O
the	O
Hospital	O
Discharge	O
Registry	O
and	O
the	O
Registry	O
of	O
Rights	O
for	O
Free	O
medication	O
is	O
presented	O
.	O

Western	O
blot	O
experiments	O
detected	O
SMBP	B
as	O
a	O
70	O
kDa	O
protein	O
that	O
may	O
be	O
further	O
cleaved	O
into	O
an	O
active	O
34	O
kDa	O
N	O
-	O
terminal	O
polypeptide	O
.	O

On	O
Western	O
blots	O
,	O
the	O
same	O
antibodies	O
recognized	O
the	O
recombinant	O
protein	O
migrating	O
slightly	O
slower	O
on	O
SDS	O
/	O
PAGE	O
than	O
chicken	B
axonin-1	I
.	O

Denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
with	O
sequence	O
analysis	O
showed	O
that	O
PGCL4	B
is	O
a	O
major	O
member	O
in	O
the	O
female	O
mammary	O
gland	O
,	O
and	O
in	O
the	O
submaxillary	O
and	O
lachrymal	O
glands	O
of	O
both	O
sexes	O
,	O
while	O
the	O
counterpart	O
in	O
male	O
liver	O
and	O
the	O
coagulate	O
glands	O
was	O
found	O
to	O
be	O
PGCL1	B
.	O

ATF	O
is	O
formulated	O
from	O
the	O
prothrombin	B
time	O
(	O
PT	O
)	O
,	O
fibrinogen	B
transformation	O
rate	O
(	O
FTR	O
)	O
(	O
a	O
representation	O
of	O
thrombin	B
activity	O
)	O
,	O
and	O
a	O
consideration	O
of	O
the	O
fibrinogen	B
(	O
FBG	B
)	O
content	O
of	O
blood	O
plasma	O
.	O

Protein	O
binding	O
to	O
UAS1MLS1	B
was	O
observed	O
with	O
extracts	O
from	O
derepressed	O
but	O
not	O
from	O
repressed	O
cells	O
,	O
and	O
could	O
be	O
competed	O
for	O
by	O
an	O
excess	O
of	O
the	O
unlabelled	O
CSRE	O
(	O
ICL1	B
)	O
sequence	O
.	O

Recently	O
we	O
have	O
performed	O
a	O
detailed	O
analysis	O
of	O
specific	O
neuronal	O
populations	O
affected	O
by	O
the	O
mutation	O
which	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
Krox-20	B
in	O
the	O
segmentation	O
and	O
on	O
the	O
physiological	O
consequences	O
of	O
its	O
inactivation	O
.	O

Further	O
comparative	O
analysis	O
identified	O
an	O
ADNP	B
paralog	O
(	O
33	O
%	O
identity	O
and	O
46	O
%	O
similarity	O
)	O
,	O
indicating	O
that	O
these	O
genes	O
belong	O
to	O
a	O
novel	O
protein	O
family	O
with	O
a	O
nine	O
-	O
zinc	O
finger	O
motif	O
followed	O
by	O
a	O
homeobox	O
domain	O
.	O

Nature	O
and	O
incidence	O
of	O
conditioned	O
responses	O
in	O
a	O
methadone	O
population	O
:	O
a	O
comparison	O
of	O
laboratory	O
,	O
clinic	O
,	O
and	O
naturalistic	O
settings	O
.	O

Fourteen	O
Centers	O
participated	O
in	O
this	O
trial	O
.	O

Northern	O
blot	O
analysis	O
identified	O
retina	O
-	O
specific	O
transcripts	O
of	O
3.0	O
kb	O
for	O
rod	B
G	I
alpha	I
t	I
and	O
2.6	O
kb	O
for	O
cone	B
G	I
alpha	I
t.	I

This	O
interesting	O
exon	O
junction	O
resulted	O
in	O
novel	O
deduced	O
amino	O
terminal	O
open	O
reading	O
frames	O
,	O
which	O
are	O
completely	O
in	O
-	O
frame	O
with	O
sequences	O
located	O
further	O
downstream	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
evolution	O
of	O
bronchial	O
albumin	B
,	O
IgA	B
,	O
and	O
IgG	B
levels	O
in	O
ventilated	O
ICU	O
patients	O
in	O
relation	O
to	O
nosocomial	O
pneumonia	O
.	O

Membrane	O
depolarization	O
is	O
a	O
critical	O
element	O
of	O
neuronal	O
signaling	O
.	O

Humoral	O
immunity	O
is	O
altered	O
with	O
the	O
drop	O
in	O
IgG	B
levels	O
.	O

(	O
control	O
hearts	O
)	O
.	O

Although	O
several	O
other	O
signal	O
transduction	O
molecules	O
also	O
contain	O
tandemly	O
occurring	O
SH3	B
and	O
SH2	B
domains	I
,	O
the	O
function	O
of	O
these	O
closely	O
spaced	O
domains	O
is	O
not	O
well	O
understood	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
conducted	O
split	O
-	O
visual	O
-	O
field	O
studies	O
in	O
which	O
we	O
manipulated	O
stimulus	O
sets	O
,	O
recognition	O
task	O
,	O
and	O
exposure	O
duration	O
.	O

These	O
results	O
indicate	O
that	O
the	O
changes	O
in	O
the	O
patient	O
's	O
thyroid	O
scan	O
and	O
RAIU	O
were	O
attributable	O
to	O
the	O
presence	O
of	O
TSAb	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
Hv	B
-	I
p68	I
belongs	O
to	O
the	O
large	O
family	O
of	O
FAD	B
-	I
dependent	I
glucose	I
methanol	I
choline	I
oxidoreductases	I
and	O
that	O
it	O
shares	O
significant	O
sequence	O
identity	O
(	O
>	O
67	O
%	O
)	O
with	O
the	O
alcohol	B
oxidases	I
of	O
the	O
methylotrophic	O
yeasts	O
.	O

Coronatine	B
(	O
COR	B
)	O
is	O
a	O
plasmid	O
-	O
encoded	O
phytotoxin	O
synthesized	O
by	O
several	O
pathovars	O
of	O
phytopathogenic	O
Pseudomonas	O
syringae	O
.	O

Radioactively	O
labeled	O
microspheres	O
were	O
used	O
to	O
determine	O
and	O
compare	O
the	O
hemodynamic	O
effects	O
of	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
,	O
nitroglycerin	O
(	O
NTG	O
)	O
,	O
and	O
deep	O
enflurane	O
anesthesia	O
on	O
oral	O
tissues	O
during	O
controlled	O
hypotension	O
when	O
compared	O
with	O
controls	O
.	O

However	O
,	O
no	O
consensus	O
on	O
indications	O
exists	O
and	O
,	O
according	O
to	O
the	O
literature	O
,	O
results	O
are	O
contradictory	O
.	O

However	O
,	O
studies	O
using	O
the	O
A20	B
promoter	I
demonstrated	O
that	O
LMP1	B
transcriptionally	O
activates	O
the	O
A20	B
gene	I
through	O
cis	O
-	O
acting	O
kappa	B
B	I
sites	I
.	O

Finally	O
,	O
we	O
tested	O
whether	O
activation	O
by	O
either	O
of	O
these	O
factors	O
is	O
dependent	O
on	O
components	O
of	O
the	O
SAGA	B
complex	I
.	O

Recombinant	O
propeptides	O
containing	O
mutations	O
of	O
one	O
of	O
the	O
three	O
tryptophan	O
residues	O
were	O
three	O
orders	O
of	O
magnitude	O
less	O
effective	O
as	O
inhibitors	O
of	O
mature	B
cathepsin	I
S	I
than	O
the	O
wild	O
-	O
type	O
propeptide	O
.	O

AU	O
-	O
rich	O
elements	O
in	O
the	O
3'-untranslated	O
region	O
of	O
a	O
new	O
mucin	B
-	I
type	I
gene	I
family	O
of	O
Trypanosoma	O
cruzi	O
confers	O
mRNA	O
instability	O
and	O
modulates	O
translation	O
efficiency	O
.	O

The	O
repeats	O
are	O
highly	O
conserved	O
both	O
within	O
a	O
given	O
element	O
as	O
well	O
as	O
between	O
different	O
members	O
of	O
the	O
family	O
(	O
less	O
than	O
10	O
%	O
divergence	O
)	O
.	O

The	O
Polycomb	B
group	I
proteins	I
are	O
involved	O
in	O
maintenance	O
of	O
the	O
silenced	O
state	O
of	O
several	O
developmentally	O
regulated	O
genes	O
.	O

Alterations	O
in	O
TCR	B
-	O
MHC	B
contacts	O
subsequent	O
to	O
cross	O
-	O
recognition	O
of	O
class	B
I	I
MHC	I
and	O
singly	O
substituted	O
peptide	O
variants	O
.	O

We	O
also	O
show	O
that	O
the	O
products	O
of	O
both	O
the	O
GIY	B
-	I
YIG	I
ORF	O
and	O
the	O
non	O
-	O
canonical	O
LAGLI	B
-	I
DADG	I
-	I
GIY	I
-	I
YIG	I
ORF	O
,	O
which	O
is	O
generated	O
by	O
its	O
integration	O
,	O
have	O
endonuclease	O
activities	O
which	O
recognize	O
and	O
cut	O
the	O
insertion	O
site	O
of	O
the	O
optional	O
sequence	O
.	O

The	O
pharmacokinetics	O
were	O
best	O
described	O
by	O
a	O
two	O
-	O
compartment	O
open	O
model	O
giving	O
distribution	O
half	O
-	O
lives	O
of	O
0.31	O
h	O
and	O
1.53	O
h	O
,	O
and	O
elimination	O
half	O
-	O
lives	O
of	O
69.7	O
h	O
and	O
60.3	O
h	O
for	O
oxolinic	O
acid	O
and	O
oxytetracycline	O
,	O
respectively	O
.	O

Inhibitory	O
receptors	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
characteristic	O
sequence	O
known	O
as	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
(	O
ITIM	O
)	O
in	O
their	O
cytoplasmic	O
tail	O
.	O

Our	O
data	O
suggest	O
that	O
some	O
defects	O
observed	O
in	O
BS	O
,	O
WS	O
or	O
RTS	O
are	O
the	O
consequence	O
of	O
unrestrained	O
recombination	O
.	O

Alternative	O
splicing	O
of	O
the	O
human	B
serotonin	I
transporter	I
gene	I
.	O

Nuclear	O
proteins	O
bound	O
the	O
cad	B
+	I
55	I
/	I
+75	I
element	I
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
in	O
electromobility	O
shift	O
assays	O
;	O
antibodies	O
specific	O
to	O
USF	B
and	O
Max	B
blocked	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
different	O
growth	O
-	O
regulated	O
protein	O
-	O
DNA	O
complexes	O
.	O

The	O
carboxy	O
-	O
proximal	O
regions	O
of	O
the	O
VP1	B
,	O
which	O
contain	O
very	O
low	O
amino	O
acid	O
homology	O
,	O
displayed	O
evidence	O
of	O
conservation	O
in	O
structural	O
features	O
such	O
as	O
a	O
hydrophilic	O
,	O
highly	O
basic	O
domain	O
.	O

Here	O
we	O
show	O
that	O
inhibition	O
occurs	O
with	O
a	O
NS1-Rev	B
chimera	O
in	O
which	O
the	O
78	O
amino	O
-	O
terminal	O
amino	O
acids	O
of	O
the	O
NS1A	B
protein	I
comprising	O
its	O
entire	O
RNA	O
-	O
binding	O
domain	O
is	O
deleted	O
,	O
thereby	O
establishing	O
that	O
this	O
carboxyl	O
portion	O
of	O
the	O
NS1A	B
protein	I
can	O
function	O
as	O
an	O
independent	O
effector	O
domain	O
.	O

Thus	O
integration	B
host	I
factor	I
is	O
required	O
for	O
normal	O
type	B
1	I
fimbriae	I
phase	O
variation	O
in	O
E.	O
coli	O
.	O

Salts	O
of	O
these	O
four	O
metal	O
ions	O
may	O
be	O
added	O
to	O
the	O
growth	O
medium	O
to	O
facilitate	O
selective	O
isolation	O
of	O
Acinetobacter	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
on	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
catalytic	O
subunit	O
of	O
glucose-6-phosphatase	B
(	O
G6Pase	B
)	O
,	O
G6Pase	B
-	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
fusion	O
genes	O
were	O
transiently	O
transfected	O
into	O
either	O
the	O
liver	O
-	O
derived	O
HepG2	O
or	O
kidney	O
-	O
derived	O
LLC	O
-	O
PK	O
cell	O
line	O
.	O

Two	O
plasmids	O
,	O
one	O
containing	O
the	O
amino	O
terminus	O
of	O
P	O
fused	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
,	O
GAL4	B
,	O
and	O
the	O
other	O
containing	O
the	O
amino	O
terminus	O
of	O
NP	B
fused	O
to	O
the	O
herpesvirus	O
transactivator	O
,	O
VP16	B
,	O
were	O
transfected	O
in	O
COS-1	O
cells	O
along	O
with	O
a	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
reporter	O
plasmid	O
containing	O
GAL4	B
DNA	O
-	O
binding	O
sites	O
.	O

Ultrastructure	O
and	O
toxin	O
formation	O
of	O
Cor	O
.	O

diphtheriae	O
PW-8	O
cultured	O
in	O
the	O
presence	O
of	O
penicillin	O

Ras	B
involvement	O
in	O
signal	O
transduction	O
by	O
the	O
serotonin	B
5-HT2B	I
receptor	I
.	O

The	O
nine	O
subjects	O
were	O
treated	O
in	O
random	O
sequence	O
with	O
cimetidine	O
0	O
-	O
8	O
-	O
1	O
-	O
0	O
g	O
on	O
one	O
day	O
and	O
placebo	O
capsules	O
on	O
the	O
other	O
.	O

The	O
detection	O
limits	O
obtained	O
by	O
using	O
the	O
mixed	O
eluent	O
were	O
0.05	O
-	O
0.13	O
mg	O
/	O
L	O
,	O
several	O
times	O
lower	O
than	O
those	O
obtained	O
by	O
using	O
single	O
KHPh	O
eluent	O
.	O

The	O
effect	O
of	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
and	O
disulfiram	O
(	O
DSF	O
)	O
on	O
the	O
urotoxicity	O
induced	O
by	O
cyclophosphamide	O
(	O
CPA	O
)	O
was	O
examined	O
in	O
mice	O
.	O

One	O
of	O
these	O
clones	O
encodes	O
Xenopus	B
N	I
-	I
ras	I
.	O

Psoriasis	O
on	O
tumor	O
.	O

Flicker	O
thresholds	O
were	O
measured	O
from	O
1	O
to	O
40	O
Hz	O
with	O
a	O
vertical	O
-	O
line	O
target	O
used	O
for	O
the	O
asynchrony	O
thresholds	O
.	O

Buserelin	O
offers	O
an	O
effective	O
alternative	O
medical	O
treatment	O
of	O
carcinoma	O
of	O
the	O
prostate	O
and	O
,	O
apart	O
from	O
impotence	O
,	O
does	O
not	O
have	O
the	O
side	O
effects	O
of	O
oestrogens	O
.	O

Cell	O
sloughing	O
with	O
proparacaine	O
.	O

One	O
hundred	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
8	O
RTKs	B
were	O
identified	O
,	O
as	O
well	O
as	O
12	O
non	O
-	O
RTKs	B
and	O
2	O
serine	B
/	I
threonine	I
kinases	I
.	O

A	O
model	O
for	O
oligomerization	O
-	O
dependent	O
subunit	O
folding	O
.	O

The	O
reporter	O
gene	O
with	O
two	O
copies	O
of	O
the	O
wild	O
-	O
type	O
Repeat	O
2	O
+	O
3	O
sequence	O
was	O
transcribed	O
actively	O
in	O
sterol	O
-	O
deprived	O
cells	O
and	O
was	O
repressed	O
by	O
more	O
than	O
80	O
%	O
when	O
sterols	O
were	O
present	O
.	O

This	O
review	O
chronicles	O
the	O
characteristics	O
of	O
deliberate	O
and	O
accidental	O
mass	O
poisonings	O
that	O
occurred	O
in	O
World	O
Wars	O
I	O
and	O
II	O
,	O
in	O
Bhopal	O
,	O
and	O
in	O
other	O
historical	O
cases	O
up	O
to	O
and	O
including	O
modern	O
wars	O
.	O

Similar	O
to	O
what	O
was	O
observed	O
for	O
P.	O
putida	O
,	O
a	O
psrA	B
null	O
mutant	O
of	O
P.	O
aeruginosa	O
also	O
showed	O
a	O
90	O
%	O
reduction	O
in	O
rpoS	B
promoter	I
activity	O
;	O
both	O
mutants	O
could	O
be	O
complemented	O
for	O
rpoS	B
promoter	I
activity	O
when	O
the	O
psrA	B
gene	I
was	O
provided	O
in	O
trans	O
.	O

psrA	B
mutants	I
of	O
both	O
Pseudomonas	O
species	O
lost	O
the	O
ability	O
to	O
induce	O
rpoS	B
expression	O
at	O
stationary	O
phase	O
,	O
but	O
they	O
retained	O
the	O
ability	O
to	O
produce	O
quorum	O
-	O
sensing	O
autoinducer	O
molecules	O
.	O

Extracellular	B
protein	I
kinase	I
A	I
as	O
a	O
cancer	O
biomarker	O
:	O
its	O
expression	O
by	O
tumor	O
cells	O
and	O
reversal	O
by	O
a	O
myristate	O
-	O
lacking	O
Calpha	O
and	O
RIIbeta	O
subunit	O
overexpression	O
.	O

The	O
KEMAR	O
measurements	O
show	O
that	O
the	O
two	O
models	O
give	O
an	O
improvement	O
of	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
approximately	O
7.5	O
dB	O
in	O
a	O
diffuse	O
sound	O
field	O
.	O

Mutations	O
that	O
extend	O
the	O
specificity	O
of	O
the	O
endonuclease	O
activity	O
of	O
lambda	B
terminase	I
.	O

It	O
is	O
concluded	O
that	O
the	O
new	O
class	O
of	O
competitive	O
NMDA	B
receptor	I
antagonists	O
,	O
exemplified	O
by	O
CGP	O
37849	O
,	O
is	O
the	O
most	O
promising	O
candidate	O
for	O
clinical	O
trials	O
in	O
anxiety	O
disorders	O
.	O

In	O
the	O
fungus	O
Neurospora	O
crassa	O
,	O
nit-2	B
,	O
the	O
major	O
nitrogen	O
regulatory	O
gene	O
,	O
activates	O
the	O
expression	O
of	O
unlinked	O
structural	O
genes	O
that	O
specify	O
nitrogen	O
-	O
catabolic	O
enzymes	O
during	O
conditions	O
of	O
nitrogen	O
limitation	O
.	O

Tetrazepam	O
:	O
a	O
benzodiazepine	O
which	O
dissociates	O
sedation	O
from	O
other	O
benzodiazepine	O
activities	O
.	O

An	O
hcr1	B
null	O
mutant	O
was	O
viable	O
,	O
but	O
showed	O
slight	O
reduction	O
of	O
growth	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
strain	O
.	O

The	O
women	O
in	O
the	O
intermediate	O
calcium	O
group	O
had	O
approximately	O
the	O
same	O
mean	O
BMD	O
values	O
as	O
those	O
in	O
the	O
low	O
calcium	O
group	O
.	O

Serum	B
amyloid	I
A	I
(	O
SAA	B
)	O
is	O
a	O
plasma	O
protein	O
which	O
has	O
been	O
associated	O
with	O
several	O
diseases	O
,	O
including	O
amyloidosis	O
,	O
arthritis	O
,	O
and	O
atherosclerosis	O
,	O
and	O
its	O
abnormal	O
expression	O
,	O
particularly	O
in	O
nonhepatic	O
cells	O
,	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O

Convergence	O
of	O
trigeminal	O
input	O
with	O
visceral	O
and	O
phrenic	O
inputs	O
on	O
primate	O
C1-C2	O
spinothalamic	O
tract	O
neurons	O
.	O

A	O
Frank	O
vectorcardiogram	O
was	O
recorded	O
before	O
and	O
every	O
15	O
-	O
30	O
minutes	O
for	O
10	O
hours	O
after	O
the	O
occlusion	O
.	O

When	O
O-2A	O
/	O
c	B
-	I
myc	I
cells	O
underwent	O
terminal	O
differentiation	O
APprog	B
complexes	I
were	O
lost	O
and	O
conventional	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
became	O
evident	O
,	O
particularly	O
in	O
astrocytes	O
.	O

(	O
i	O
)	O
The	O
chimeric	O
gene	O
consisting	O
of	O
the	O
coding	O
and	O
5	O
'	O
nontranslated	O
leader	O
regions	O
of	O
the	O
TK	B
gene	I
fused	O
to	O
portions	O
of	O
the	O
domain	O
of	O
alpha	B
gene	I
0	I
extending	O
largely	O
upstream	O
from	O
the	O
site	O
of	O
initiation	O
of	O
transcription	O
of	O
alpha	B
gene	I
0	I
was	O
regulated	O
in	O
the	O
same	O
fashion	O
as	O
the	O
alpha	B
4-	I
and	I
alpha	I
27-TK	I
chimeras	O
.	O

Torsion	O
of	O
the	O
contralateral	O
testis	O
5	O
years	O
after	O
orchiopexy	O
.	O

Legionella	B
antibodies	I
in	O
domestic	O
animals	O

When	O
transfected	O
into	O
HepG2	O
cells	O
,	O
which	O
lack	O
C	B
/	I
EBP	I
alpha	I
,	O
the	O
mouse	B
ob	I
promoter	I
was	O
only	O
weakly	O
active	O
.	O

When	O
translated	O
in	O
-	O
frame	O
with	O
PKC	B
zeta	I
,	O
a	O
stop	O
codon	O
is	O
located	O
28	O
amino	O
acids	O
towards	O
the	O
N	O
-	O
terminus	O
of	O
the	O
divergence	O
point	O
and	O
the	O
intervening	O
sequence	O
lacks	O
an	O
expected	O
initiating	O
methionine	O
.	O

psi	B
PKC	I
zeta	I
is	O
non	O
-	O
functional	O
in	O
terms	O
of	O
protein	O
synthesis	O
since	O
Western	O
blotting	O
with	O
an	O
antibody	O
directed	O
against	O
the	O
C	O
-	O
terminus	O
of	O
PKC	B
zeta	I
failed	O
to	O
reveal	O
a	O
protein	O
smaller	O
than	O
PKC	B
zeta	I
,	O
and	O
synthetic	O
psi	B
PKC	I
zeta	I
RNA	I
failed	O
to	O
support	O
protein	O
synthesis	O
in	O
a	O
translation	O
system	O
in	O
vitro	O
.	O

Comparative	O
ultrafiltration	O
(	O
UF	O
)	O
studies	O
with	O
BiGG	O
and	O
standard	O
lactate	O
(	O
La	O
)	O
solutions	O
in	O
rabbits	O
showed	O
that	O
net	O
UF	O
with	O
La	O
solution	O
peaked	O
at	O
2	O
h	O
and	O
decreased	O
significantly	O
at	O
4	O
h	O
and	O
6	O
h.	O

JCAHO	O
moves	O
to	O
rewrite	O
many	O
rules	O
to	O
lessen	O
hospitals	O
'	O
regulatory	O
burden	O
.	O

However	O
,	O
it	O
is	O
not	O
easy	O
to	O
establish	O
the	O
diagnosis	O
of	O
thoracic	O
MFH	O
.	O

IGF	B
-	I
I	I
levels	O
were	O
measured	O
in	O
the	O
CSF	O
of	O
11	O
children	O
with	O
autism	O
(	O
4	O
females	O
,	O
7	O
males	O
;	O
mean	O
age	O
3.8	O
years	O
,	O
SD	O
1.1	O
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
method	O
and	O
compared	O
with	O
levels	O
in	O
11	O
control	O
participants	O
(	O
6	O
females	O
,	O
5	O
males	O
;	O
mean	O
age	O
3.8	O
years	O
)	O
.	O

Forty	O
-	O
five	O
patients	O
with	O
recent	O
-	O
onset	O
hyperthyroidism	O
(	O
<	O
12	O
weeks	O
)	O
were	O
sex	O
and	O
menopause	O
stratified	O
and	O
randomly	O
allocated	O
to	O
treatment	O
with	O
carbimazole	O
(	O
Neotomizol	O
)	O
,	O
carbimazole	O
plus	O
low	O
dose	O
CT	O
(	O
Calsynar	O
;	O
100	O
IU	O
/	O
day	O
,	O
2	O
days	O
/	O
week	O
)	O
,	O
or	O
carbimazole	O
plus	O
high	O
dose	O
CT	O
(	O
Calsynar	O
;	O
100	O
IU	O
/	O
day	O
,	O
14	O
days	O
/	O
month	O
)	O
.	O

We	O
also	O
show	O
that	O
psbH	B
and	O
psbT	B
are	O
transcribed	O
from	O
the	O
upstream	O
psbB	B
gene	I
promoter	I
,	O
and	O
that	O
the	O
psbH	B
mRNA	I
has	O
its	O
own	O
target	O
sequence	O
for	O
Mbb1	B
function	O
.	O

CONCLUSION	O
:	O
Men	O
presenting	O
with	O
urethritis	O
and	O
women	O
presenting	O
with	O
PID	O
both	O
have	O
significantly	O
greater	O
peripheral	O
blood	O
mononuclear	O
cell	O
proliferative	O
responses	O
to	O
the	O
DK20	O
strain	O
of	O
C	O
trachomatis	O
than	O
controls	O
.	O

Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
differential	O
splicing	O
in	O
the	O
extracellular	O
region	O
of	O
a	O
receptor	O
gene	O
generates	O
receptor	O
variants	O
with	O
different	O
ligand	O
-	O
binding	O
specificities	O
.	O

Intrathecal	O
injections	O
of	O
small	O
volumes	O
of	O
the	O
alpha	B
2-adrenoceptor	I
agonists	O
,	O
xylazine	O
and	O
clonidine	O
,	O
into	O
the	O
cervical	O
region	O
of	O
the	O
spinal	O
cord	O
of	O
conscious	O
unrestrained	O
sheep	O
produced	O
a	O
dose	O
-	O
dependent	O
analgesia	O
of	O
the	O
forelimbs	O
as	O
measured	O
using	O
a	O
mechanical	O
pressure	O
device	O
.	O

Estrogen	O
has	O
positive	O
effects	O
on	O
mood	O
,	O
sexual	O
function	O
,	O
target	O
end	O
organs	O
and	O
cognitive	O
function	O
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
Alzheimer	O
's	O
Disease	O
by	O
acting	O
to	O
prevent	O
amyloid	O
plaque	O
formation	O
,	O
oxidative	O
stress	O
,	O
or	O
deterioration	O
of	O
the	O
cholinergic	O
neurotransmitter	O
system	O
.	O

Effect	O
of	O
gentamycin	O
on	O
the	O
kidney	O
functional	O
state	O
in	O
experimental	O
pyelonephritis	O

Nucleocapsid	O
structure	O
and	O
thermostability	O
of	O
the	O
virion	O
,	O
nucleocapsid	O
and	O
polymerase	O
complex	O
.	O

Studies	O
on	O
recurrences	O
in	O
gingival	O
hyperplasia	O

Measurement	O
of	O
protein	O
in	O
natural	O
rubber	O
latex	O
.	O

Maximum	O
likelihood	O
estimation	O
in	O
covariance	O
structure	O
analysis	O
with	O
truncated	O
data	O
.	O

The	O
arterial	O
blood	O
pressure	O
was	O
measured	O
by	O
using	O
bloody	O
method	O
in	O
anesthizied	O
animals	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
location	O
,	O
domain	O
structure	O
,	O
and	O
biochemical	O
function	O
of	O
metaxin	B
were	O
investigated	O
.	O

There	O
is	O
,	O
however	O
,	O
uncertainty	O
as	O
to	O
how	O
results	O
obtained	O
in	O
recent	O
experiments	O
scale	O
up	O
to	O
landscape	O
and	O
regional	O
levels	O
and	O
generalize	O
across	O
ecosystem	O
types	O
and	O
processes	O
.	O

Chest	O
X	O
-	O
P	O
revealed	O
an	O
abnormal	O
shadow	O
in	O
the	O
left	O
upper	O
lobe	O
.	O

Changes	O
in	O
the	O
size	O
and	O
organisation	O
of	O
the	O
brain	O
in	O
man	O
and	O
his	O
ancestors	O
.	O

K562	O
erythroleukemia	O
cells	O
stably	O
transfected	O
with	O
constructs	O
containing	O
the	O
human	B
Agamma	I
-	I
globin	I
promoter	I
linked	O
to	O
an	O
enhanced	B
green	I
fluorescent	I
protein	I
(	O
EGFP	B
)	O
reporter	O
,	O
with	O
or	O
without	O
HS2	O
,	O
were	O
analyzed	O
for	O
EGFP	B
expression	O
by	O
flow	O
cytometry	O
.	O

Some	O
may	O
affect	O
the	O
folding	O
pathway	O
or	O
the	O
affinity	O
for	O
chaperonins	B
.	O

VBP	B
and	O
a1	B
/	I
EBP	I
could	O
mediate	O
the	O
high	O
rates	O
of	O
ALV	O
and	O
RSV	B
LTR	I
-	O
enhanced	O
transcription	O
in	O
bursal	O
lymphoma	O
cells	O
and	O
many	O
other	O
cell	O
types	O
.	O

The	O
BCL-6	B
POZ	O
domain	O
and	O
other	O
POZ	O
domains	O
interact	O
with	O
the	O
co	O
-	O
repressors	O
N	B
-	I
CoR	I
and	O
SMRT	B
.	O

The	O
traW	B
gene	I
of	I
the	I
Escherichia	I
coli	I
K-12	I
sex	I
factor	I
,	O
F	O
,	O
encodes	O
one	O
of	O
the	O
numerous	O
proteins	O
required	O
for	O
conjugative	O
transfer	O
of	O
this	O
plasmid	O
.	O

Expression	O
of	O
these	O
chemokines	O
is	O
similar	O
in	O
that	O
both	O
require	O
the	O
NF	B
-	I
kappa	I
B	I
element	I
and	O
additional	O
regions	O
such	O
as	O
the	O
CAAT	B
/	I
enhancer	I
binding	I
protein	I
(	O
C	B
/	I
EBP	I
)	O
element	O
of	O
the	O
IL-8	B
promoter	I
.	O

The	O
toxicity	O
of	O
copper	O
to	O
the	O
collembolan	O
Folsomia	O
fimetaria	O
L.	O
was	O
studied	O
in	O
soil	O
incubated	O
with	O
copper	O
sulfate	O
for	O
different	O
periods	O
before	O
the	O
introduction	O
of	O
collembolans	O
,	O
to	O
assess	O
the	O
effect	O
of	O
aging	O
of	O
contamination	O
on	O
the	O
toxicity	O
of	O
copper	O
.	O

Using	O
probes	O
containing	O
C	B
/	I
EBP	I
-	I
binding	I
sites	I
from	O
the	O
iNOS	B
gene	I
revealed	O
further	O
binding	O
of	O
different	O
complexes	O
,	O
all	O
of	O
which	O
were	O
strongly	O
inducible	O
by	O
cAMP	O
and	O
to	O
a	O
lower	O
extent	O
also	O
by	O
IL-1beta	B
.	O

The	O
duration	O
of	O
PGE2	O
and	O
PGF2	O
alpha	O
elevations	O
as	O
well	O
as	O
the	O
peak	O
values	O
were	O
influenced	O
by	O
day	O
of	O
the	O
cycle	O
.	O

RESULTS	O
:	O
Lateral	O
PF	O
OA	O
was	O
more	O
common	O
than	O
medial	O
PF	O
OA	O
(	O
P<0.0001	O
)	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
GATA-1	B
and	O
Sp1	B
synergize	O
from	O
a	O
distance	O
in	O
constructs	O
designed	O
to	O
mimic	O
the	O
architecture	O
of	O
globin	B
locus	I
control	I
regions	I
and	O
downstream	O
globin	B
promoters	I
.	O

The	O
effects	O
of	O
space	O
radiation	O
are	O
partially	O
known	O
on	O
astronauts	O
,	O
but	O
much	O
remains	O
to	O
be	O
discovered	O
.	O

First	O
,	O
the	O
amino	O
-	O
terminal	O
regulatory	O
arm	O
of	O
the	O
GDI	B
binds	O
to	O
the	O
switch	O
I	O
and	O
II	O
domains	O
of	O
Cdc42	B
leading	O
to	O
the	O
inhibition	O
of	O
both	O
GDP	O
dissociation	O
and	O
GTP	O
hydrolysis	O
.	O

In	O
the	O
virus	O
-	O
infected	O
cells	O
,	O
translation	O
of	O
the	O
M1	B
protein	I
was	O
reduced	O
to	O
10	O
to	O
20	O
%	O
of	O
that	O
of	O
the	O
wild	O
-	O
type	O
virus	O
;	O
however	O
,	O
the	O
translation	O
of	O
neither	O
the	O
nucleoprotein	O
nor	O
NS1	B
was	O
significantly	O
interfered	O
with	O
,	O
indicating	O
the	O
important	O
role	O
of	O
NS1	B
in	O
translational	O
stimulation	O
of	O
the	O
M1	B
protein	I
.	O

The	O
results	O
show	O
that	O
while	O
a	O
larger	O
polypeptide	O
substrate	O
carrying	O
the	O
HD1	B
/	I
3C	I
site	I
was	O
processed	O
more	O
efficiently	O
than	O
a	O
polypeptide	O
substrate	O
carrying	O
the	O
POL	B
/	I
Zn	I
site	I
,	O
cleavage	O
of	O
the	O
synthetic	O
peptide	O
substrates	O
containing	O
these	O
two	O
cleavage	O
sites	O
occurred	O
at	O
similar	O
efficiencies	O
.	O

The	O
GST	B
-	O
CBL	B
-	O
LZIP	B
fusion	O
protein	O
contains	O
a	O
binding	O
site	O
for	O
the	O
SH2	B
domain	I
of	O
the	O
p85	B
subunit	I
of	O
phosphatidylinositol	B
3-kinase	I
,	O
which	O
mapped	O
to	O
Tyr731	O
,	O
which	O
is	O
present	O
in	O
the	O
sequence	O
YEAM	O
.	O

The	O
level	O
of	O
transcription	O
generated	O
by	O
all	O
of	O
these	O
activators	O
is	O
greater	O
than	O
the	O
sum	O
of	O
the	O
levels	O
generated	O
by	O
individual	O
factors	O
,	O
a	O
phenomenon	O
designated	O
transcriptional	O
synergy	O
.	O

Growth	B
hormone	I
exerts	O
its	O
effects	O
on	O
the	O
ovarian	O
follicular	O
cycle	O
directly	O
or	O
by	O
local	O
production	O
of	O
insulin	B
-	I
like	I
growth	I
factor	I
1	I
(	O
IGF-1	B
)	O
.	O

The	O
results	O
suggest	O
that	O
the	O
posterior	O
wall	O
is	O
more	O
compliant	O
than	O
the	O
anterior	O
wall	O
(	O
that	O
is	O
,	O
for	O
a	O
given	O
difference	O
in	O
transmural	O
pressure	O
,	O
the	O
local	O
segment	O
length	O
change	O
of	O
the	O
posterior	O
wall	O
was	O
greater	O
)	O
.	O

No	O
consensus	O
binding	O
sequence	O
could	O
be	O
discerned	O
in	O
these	O
fragments	O
and	O
bound	O
factor	O
is	O
in	O
rapid	O
equilibrium	O
with	O
unbound	O
.	O

Sixteen	O
patients	O
(	O
25.4	O
%	O
)	O
encountered	O
rejection	O
while	O
weaning	O
at	O
median	O
period	O
of	O
9.5	O
months	O
(	O
range	O
,	O
1	O
-	O
63	O
months	O
)	O
from	O
the	O
start	O
of	O
weaning	O
.	O

The	O
results	O
in	O
the	O
untreated	O
patients	O
demonstrate	O
the	O
primary	O
importance	O
of	O
bulk	O
reduction	O
at	O
initial	O
laparotomy	O
.	O

Vertebrate	O
U6	B
small	I
nuclear	I
RNA	I
(	O
snRNA	O
)	O
loci	O
exemplify	O
a	O
novel	O
class	O
of	O
polymerase	B
III	I
-	O
transcribed	O
genes	O
that	O
lack	O
an	O
intragenic	O
control	O
region	O
(	O
ICR	O
)	O
.	O

This	O
article	O
focuses	O
on	O
a	O
general	O
approach	O
to	O
the	O
use	O
of	O
ARV	O
agents	O
.	O

Finally	O
,	O
there	O
is	O
now	O
appropriate	O
recognition	O
of	O
the	O
pivotal	O
role	O
of	O
BP	O
reduction	O
in	O
forestalling	O
pressure	O
-	O
related	O
cardiovascular	O
complications	O
,	O
even	O
among	O
high	O
-	O
risk	O
persons	O
with	O
diabetes	O
mellitus	O
and	O
renal	O
insufficiency	O
.	O

Most	O
other	O
differences	O
between	O
these	O
two	O
Leporipoxviruses	O
are	O
located	O
in	O
the	O
telomeres	O
.	O

The	O
Tat	B
protein	I
coded	O
by	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
a	O
strong	O
activator	O
of	O
viral	O
gene	O
expression	O
from	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Type	O
C	O
units	O
summate	O
the	O
responses	O
to	O
the	O
two	O
-	O
tone	O
stimulus	O
,	O
and	O
show	O
little	O
or	O
no	O
inhibitory	O
influences	O
.	O

19	O
,	O
4967	O
-	O
4973	O
)	O
.	O

Using	O
gel	O
retardation	O
analysis	O
,	O
four	O
binding	O
sites	O
for	O
Rap1p	B
have	O
been	O
identified	O
within	O
the	O
promoter	O
of	O
the	O
RAP1	B
gene	I
.	O

Unlike	O
CSK	B
,	O
the	O
SH3	B
domain	I
of	O
HYL	B
was	O
unique	O
since	O
the	O
ALYDY	O
motif	O
was	O
absent	O
.	O

RESULTS	O
:	O
Although	O
low	O
levels	O
of	O
vIRF-2	B
mRNAs	I
can	O
be	O
detected	O
in	O
the	O
HHV-8-positive	O
BCBL-1	O
tumor	O
cell	O
line	O
,	O
12	O
-	O
0-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
treatment	O
does	O
not	O
stimulate	O
expression	O
of	O
vIRF-2	B
gene	I
together	O
with	O
primary	O
lytic	O
cycle	O
genes	O
.	O

As	O
anticipated	O
,	O
both	O
intracellular	O
p54-SAPKbeta	B
activation	O
and	O
Bcl-2	B
phosphorylation	O
are	O
blocked	O
by	O
co	O
-	O
transfection	O
with	O
the	O
MAP	B
kinase	I
specific	O
phosphatase	O
MKP3	B
/	O
PYST1	B
.	O

RESULTS	O
:	O
In	O
76	O
trials	O
,	O
5,351	O
patients	O
received	O
24	O
different	O
regimens	O
of	O
droperidol	O
.	O

One	O
new	O
ORF	O
,	O
YBR0224	B
,	O
was	O
detected	O
,	O
coding	O
for	O
a	O
protein	O
with	O
918	O
amino	O
acids	O
.	O

This	O
suggests	O
that	O
the	O
duration	O
of	O
varicocele	O
per	O
se	O
could	O
affect	O
DHT	O
seminal	O
plasma	O
levels	O
.	O

Thus	O
,	O
the	O
cognitive	O
performance	O
of	O
elderly	O
subjects	O
could	O
be	O
trained	O
to	O
a	O
large	O
extent	O
.	O

Two	O
genes	O
from	O
the	O
family	O
encoding	O
mouse	B
ribosomal	I
protein	I
S16	I
were	O
cloned	O
,	O
sequenced	O
,	O
and	O
analyzed	O
.	O

Replacement	O
of	O
a	O
valine	O
(	O
V68	O
)	O
in	O
the	O
ETS	B
domain	O
of	O
SAP1a	B
by	O
aspartic	O
acid	O
(	O
as	O
found	O
in	O
c	B
-	I
Ets-1	I
,	O
Elk-1	B
,	O
and	O
Net	B
)	O
enhanced	O
ternary	O
complex	O
formation	O
by	O
more	O
than	O
60-fold	O
.	O

Tissue	O
-	O
specific	O
gene	O
regulation	O
of	O
eukaryotic	O
organisms	O
is	O
to	O
a	O
large	O
extent	O
mediated	O
by	O
transcription	O
factors	O
that	O
interact	O
with	O
genomic	O
DNA	O
sequences	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

As	O
exogenously	O
expressed	O
PKR	B
can	O
form	O
heterodimers	O
with	O
endogenous	B
PKR	I
,	O
the	O
results	O
obtained	O
on	O
the	O
functional	O
characterization	O
of	O
mutant	O
forms	O
of	O
PKR	B
have	O
been	O
taken	O
with	O
caution	O
.	O

Experimental	O
exposure	O
of	O
poults	O
with	O
each	O
of	O
two	O
strains	O
representing	O
the	O
rarely	O
reported	O
capsular	O
group	O
B	O
indicated	O
that	O
both	O
were	O
virulent	O
.	O

Studies	O
on	O
the	O
reaction	O
of	O
cytochrome	B
c	I
with	O
corticosteroids	O
.	O

The	O
results	O
can	O
be	O
summarized	O
as	O
follows	O
.	O

The	O
level	O
of	O
expression	O
of	O
the	O
PDE	B
protein	I
was	O
monitored	O
by	O
immunoblot	O
analysis	O
using	O
two	O
specific	O
cAMP	B
-	I
PDE	I
polyclonal	I
antibodies	I
and	O
by	O
measuring	O
the	O
PDE	B
activity	O
.	O

In	O
response	O
to	O
phosphorus	O
limitation	O
,	O
the	O
fungus	O
Neurospora	O
crassa	O
synthesizes	O
a	O
number	O
of	O
enzymes	O
that	O
function	O
to	O
bring	O
more	O
phosphate	O
into	O
the	O
cell	O
.	O

The	O
Cryotherapy	O
for	O
Retinopathy	O
of	O
Prematurity	O
Study	O
has	O
shown	O
that	O
this	O
number	O
can	O
be	O
halved	O
with	O
treatment	O
.	O

Many	O
of	O
the	O
metabolic	O
effects	O
induced	O
by	O
thiazide	O
diuretics	O
,	O
however	O
,	O
can	O
be	O
limited	O
by	O
the	O
use	O
of	O
low	O
doses	O
.	O

This	O
paper	O
describes	O
a	O
longitudinal	O
study	O
in	O
which	O
clinical	O
parameters	O
and	O
aspartate	B
aminotransferase	I
(	O
AST	B
)	O
in	O
gingival	O
crevicular	O
fluid	O
(	O
GCF	O
)	O
were	O
monitored	O
bimonthly	O
over	O
a	O
6	O
-	O
12	O
months	O
period	O
in	O
970	O
sites	O
from	O
7	O
treated	O
periodontitis	O
patients	O
.	O

Penicillamine	O
-	O
induced	O
myasthenia	O
gravis	O
associated	O
with	O
antibodies	O
to	O
acetylcholine	B
receptor	I
.	O

A	O
mutated	B
ABF1	I
site	I
that	O
displays	O
a	O
very	O
low	O
affinity	O
for	O
ABF1	B
does	O
not	O
functionally	O
replace	O
the	O
ILV1	B
REB1	B
site	I
.	O

1.23	O
)	O
as	O
a	O
PPARalpha	B
-	I
interacting	I
protein	I
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
prospective	O
study	O
was	O
conducted	O
with	O
44	O
cycles	O
for	O
34	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
1	O
)	O
and	O
47	O
cycles	O
for	O
40	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
2	O
)	O
with	O
a	O
long	O
IVF	O
protocol	O
;	O
68	O
cycles	O
for	O
46	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
3	O
)	O
and	O
56	O
cycles	O
for	O
39	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
4	O
)	O
with	O
a	O
short	O
IVF	O
protocol	O
;	O
39	O
cycles	O
for	O
32	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
5	O
)	O
and	O
50	O
cycles	O
for	O
30	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
6	O
)	O
with	O
a	O
long	O
ICSI	O
protocol	O
;	O
and	O
87	O
cycles	O
for	O
60	O
couples	O
with	O
nafarelin	O
acetate	O
(	O
group	O
7	O
)	O
and	O
81	O
cycles	O
for	O
61	O
couples	O
with	O
buserelin	O
acetate	O
(	O
group	O
8)	O
with	O
a	O
short	O
ICSI	O
protocol	O
.	O

They	O
are	O
both	O
insensitive	O
to	O
inhibitors	O
of	O
serine	B
and	I
aspartyl	I
proteinases	I
but	O
are	O
sensitive	O
to	O
sulfhydryl	O
reagents	O
and	O
0.5	O
mM	O
ZnCl2	O
.	O

Association	O
between	O
diaphragm	O
use	O
and	O
asymptomatic	O
bacteriuria	O
.	O

We	O
compared	O
these	O
responses	O
for	O
six	O
hatchling	O
and	O
eight	O
adult	O
Chrysemys	O
picta	O
from	O
an	O
Ohio	O
population	O
.	O

INTERNET	O
is	O
literally	O
a	O
world	O
of	O
data	O
,	O
dialogue	O
,	O
and	O
discourse	O
on	O
any	O
topic	O
imaginable	O
,	O
right	O
at	O
your	O
fingertips	O
.	O

We	O
established	O
that	O
,	O
in	O
unstimulated	O
lymphocytes	O
,	O
the	O
Src	B
homology	I
2	I
(	O
SH2	B
)	O
and	O
SH3	B
domain	I
-	I
containing	I
protein	I
Grb2	B
and	O
the	O
p85	B
subunit	O
of	O
phosphatidylinositol	B
3-kinase	I
,	O
associate	O
constitutively	O
with	O
Cbl	B
via	O
their	O
SH3	B
domains	I
.	O

Indirect	O
determination	O
of	O
maximal	O
O2	O
consumption	O
in	O
man	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
ICSBP	B
and	O
PU.1	B
are	O
critical	O
elements	O
for	O
IL-18	B
gene	I
expression	O
.	O

Sequence	O
divergence	O
of	O
approximately	O
16	O
%	O
reduced	O
transformation	O
frequencies	O
by	O
at	O
least	O
10-fold	O
.	O

During	O
subsequent	O
CS	O
-	O
alone	O
trials	O
,	O
the	O
responses	O
of	O
(	O
+	O
)	O
MK-801-injected	O
mice	O
were	O
extinguished	O
as	O
easily	O
as	O
those	O
of	O
saline	O
-	O
injected	O
mice	O
.	O

The	O
kinetics	O
of	O
[	O
14C	O
]	O
NG	O
in	O
the	O
blood	O
of	O
the	O
dosed	O
animals	O
was	O
followed	O
.	O

The	O
data	O
show	O
that	O
processing	O
time	O
as	O
a	O
function	O
of	O
intensity	O
is	O
modified	O
not	O
only	O
at	O
the	O
retina	O
but	O
also	O
at	O
later	O
processing	O
sites	O
.	O

Salt	O
wars	O
.	O

Analysis	O
of	O
domain	O
deletion	O
mutants	O
demonstrated	O
strong	O
synergy	O
between	O
the	O
RRM	O
and	O
a	O
central	O
degenerate	O
RRM	O
repeat	O
in	O
binding	O
to	O
RNA	O
.	O

We	O
used	O
an	O
immobilized	O
template	O
-	O
based	O
assay	O
to	O
examine	O
transcription	O
termination	O
by	O
VA1	B
,	O
7SL	B
,	O
and	O
Alu	B
class	I
III	I
templates	O
and	O
the	O
role	O
of	O
transcript	O
release	O
in	O
the	O
pol	B
III	I
terminator	O
-	O
dependent	O
inhibition	O
of	O
processing	O
of	O
B1-Alu	B
transcripts	O
.	O

Conservation	O
of	O
this	O
zinc	O
finger	O
motif	O
from	O
yeast	O
to	O
mouse	O
and	O
human	O
implies	O
functional	O
importance	O
.	O

The	O
terminal	O
a	O
sequence	O
of	O
the	O
herpes	O
simplex	O
virus	O
genome	O
contains	O
the	O
promoter	O
of	O
a	O
gene	O
located	O
in	O
the	O
repeat	O
sequences	O
of	O
the	O
L	O
component	O
.	O

A	O
simple	O
algorithm	O
fitting	O
the	O
data	O
for	O
the	O
moving	O
192Ir	O
source	O
is	O
proposed	O
.	O

Preventing	O
the	O
heterosexual	O
spread	O
of	O
HIV	O
into	O
this	O
vulnerable	O
population	O
is	O
a	O
formidable	O
public	O
health	O
challenge	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
the	O
corticotropin	B
-	I
releasing	I
factor	I
test	O
(	O
CRF	B
)	O
is	O
useful	O
for	O
the	O
aetiological	O
diagnosis	O
of	O
Cushing	O
's	O
syndrome	O
:	O
in	O
Cushing	O
's	O
disease	O
,	O
as	O
opposed	O
to	O
ectopic	O
ACTH	B
secretion	O
syndrome	O
,	O
the	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
can	O
still	O
be	O
stimulated	O
by	O
CRF	B
.	O

The	O
psi	B
zeta	I
gene	I
has	O
a	O
nonsense	O
mutation	O
in	O
exon	O
1	O
but	O
has	O
identical	O
promoter	O
sequence	O
and	O
RNA	O
processing	O
sites	O
to	O
the	O
zeta	B
gene	I
,	O
raising	O
the	O
possibility	O
that	O
both	O
psi	B
zeta	I
and	O
zeta	B
are	O
transcriptionally	O
active	O
.	O

Tax	B
and	O
the	O
active	O
Tax	B
mutants	I
were	O
able	O
to	O
abrogate	O
the	O
G1	O
arrest	O
and	O
apoptosis	O
induced	O
by	O
p53	B
,	O
and	O
this	O
effect	O
does	O
not	O
correlate	O
with	O
an	O
altered	O
localization	O
of	O
nuclear	B
p53	I
or	O
with	O
the	O
disruption	O
of	O
p53-DNA	B
complexes	I
.	O

Chronic	O
,	O
recurrent	O
multifocal	O
osteomyelitis	O
.	O

BACKGROUND	O
:	O
The	O
extract	O
of	O
medicinal	O
plants	O
containing	O
curcumin	O
is	O
traditionally	O
believed	O
to	O
have	O
a	O
positive	O
contraction	O
effect	O
on	O
the	O
human	O
gall	O
-	O
bladder	O
.	O

Moreover	O
,	O
the	O
formation	O
of	O
the	O
complex	O
between	O
IclR	B
and	O
the	O
operator	O
/	O
promoter	O
region	O
has	O
been	O
found	O
to	O
be	O
impaired	O
by	O
phosphoenol	O
pyruvate	O
but	O
insensitive	O
to	O
acetate	O
,	O
acetyl	O
-	O
CoA	O
,	O
pyruvate	O
,	O
and	O
oxaloacetate	O
.	O

Also	O
,	O
the	O
RVW	O
hypertrophy	O
,	O
the	O
IVS	O
hypertrophy	O
,	O
and	O
the	O
RV	O
high	O
pressure	O
load	O
to	O
the	O
LV	O
through	O
the	O
IVS	O
may	O
be	O
related	O
to	O
the	O
small	O
LV	O
,	O
high	O
EF	O
,	O
and	O
abnormal	O
two	O
chamber	O
inflow	O
in	O
the	O
PS	O
group	O
before	O
BV	O
.	O

OBJECTIVE	O
:	O
Respiratory	O
-	O
related	O
electromyographic	O
(	O
EMG	O
)	O
activity	O
of	O
the	O
superior	O
pharyngeal	O
constrictor	O
(	O
SPC	O
)	O
muscle	O
was	O
analyzed	O
during	O
the	O
early	O
stage	O
of	O
forced	O
breathing	O
.	O

Expression	O
,	O
characterization	O
,	O
and	O
genomic	O
structure	O
of	O
carp	B
JAK1	I
kinase	I
gene	I
.	O

Cough	O
-	O
CPR	O
,	O
a	O
deep	O
rhythmic	O
forceful	O
cough	O
repeated	O
30	O
-	O
60	O
times	O
per	O
minute	O
,	O
can	O
be	O
an	O
effective	O
resuscitative	O
technique	O
during	O
emergencies	O
occurring	O
in	O
the	O
cardiac	O
catheterization	O
laboratory	O
.	O

The	O
cause	O
for	O
the	O
increase	O
in	O
plasma	B
ANP	I
levels	O
in	O
the	O
active	O
phase	O
remains	O
to	O
be	O
determined	O
.	O

Further	O
interventions	O
were	O
:	O
nephrectomy	O
(	O
2x	O
)	O
,	O
resection	O
and	O
ligation	O
of	O
the	O
inferior	O
vena	O
cava	O
(	O
1x	O
)	O
,	O
resection	O
and	O
replacement	O
of	O
the	O
left	O
renal	O
vein	O
(	O
1x	O
)	O
.	O

These	O
clones	O
contain	O
most	O
of	O
the	O
exon	O
of	O
cyclin	B
D2	I
except	O
exon	O
5	O
.	O

The	O
odds	O
of	O
atopy	O
(	O
defined	O
as	O
a	O
positive	O
test	O
for	O
at	O
least	O
one	O
of	O
the	O
antigens	O
)	O
were	O
5	O
times	O
higher	O
(	O
odds	O
ratio	O
=	O
7.0	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1.6	O
-	O
31.1	O
%	O
;	O
p	O
=	O
0.01	O
)	O
in	O
the	O
uninfected	O
group	O
,	O
after	O
taking	O
into	O
account	O
the	O
potential	O
influence	O
of	O
gender	O
and	O
age	O
.	O

Similar	O
immunological	O
disturbances	O
were	O
observed	O
in	O
SCI	O
but	O
not	O
in	O
the	O
PC2	O
subgroup	O
,	O
i.e.	O
patients	O
examined	O
later	O
than	O
6	O
months	O
after	O
injury	O
.	O

In	O
the	O
remaining	O
91	O
patients	O
(	O
group	O
2	O
)	O
,	O
Pseudomonas	O
(	O
18	O
)	O
,	O
coagulase	B
-	O
negative	O
Staphylococci	O
(	O
15	O
)	O
,	O
Staphylococcus	O
epidermidis	O
(	O
23	O
)	O
,	O
Staphylococcus	O
aureus	O
(	O
16	O
)	O
,	O
Corynebacterium	O
species	O
(	O
12	O
)	O
,	O
and	O
others	O
(	O
seven	O
)	O
were	O
isolated	O
.	O

Serum	O
concentrations	O
of	O
hormones	O
in	O
patients	O
classified	O
as	O
C	O
were	O
characteristically	O
and	O
inclined	O
to	O
be	O
hypergonadotropic	O
and	O
hypoestrogenic	O
.	O

We	O
generated	O
""""	O
signature	O
""""	O
oligonucleotides	O
from	O
these	O
CDR3s	B
and	O
probed	O
PCR	O
amplified	O
V	B
kappa	I
products	I
from	O
the	O
synovium	O
and	O
PBLs	O
of	O
the	O
same	O
patient	O
,	O
and	O
from	O
PBLs	O
and	O
spleen	O
of	O
individuals	O
without	O
rheumatic	O
disease	O
.	O

Structure	O
and	O
regulation	O
of	O
KGD2	B
,	O
the	O
structural	O
gene	O
for	O
yeast	B
dihydrolipoyl	I
transsuccinylase	I
.	O

Above	O
this	O
transition	O
temperature	O
the	O
calcium	O
antagonist	O
lowers	O
fm	O
more	O
pronouncedly	O
than	O
below	O
.	O

Solution	O
of	O
the	O
Boltzmann	O
equation	O
in	O
a	O
random	O
magnetic	O
field	O
.	O

These	O
include	O
the	O
genes	O
,	O
undefined	B
1	I
(	O
UD1	B
)	O
,	O
UD2	B
,	O
and	O
UD3	B
,	O
each	O
coding	O
for	O
proteins	O
of	O
unknown	O
function	O
,	O
the	O
ken	B
gene	I
encoding	O
a	O
new	O
Kruppel	B
-	I
like	I
putative	I
transcription	I
factor	I
,	O
the	O
fly	O
homologues	O
of	O
the	O
mammalian	B
mitochondrial	I
trifunctional	I
enzyme	I
(	O
thiolase	B
)	O
,	O
and	O
the	O
TAR	B
DNA	I
-	I
binding	I
protein-43	I
(	O
TBPH	B
)	O
,	O
the	O
first	O
nonvertebrate	O
member	O
of	O
the	O
transmembrane	B
4	I
superfamily	I
(	O
TM4SF	B
)	O
gene	O
,	O
a	O
new	O
homeodomain	B
gene	I
,	O
and	O
a	O
gene	O
coding	O
for	O
a	O
putative	O
nuclear	O
binding	O
protein	O
(	O
PNBP	O
)	O
that	O
is	O
homologous	O
to	O
maleless	B
,	O
and	O
a	O
Copia	B
-	I
like	I
element	I
.	O

We	O
recently	O
described	O
the	O
isolation	O
and	O
characterization	O
of	O
nontoxic	O
PAP	B
mutants	I
,	O
NT123	O
-	O
2	O
,	O
which	O
has	O
a	O
point	O
mutation	O
(	O
E176V	O
)	O
in	O
the	O
active	O
site	O
that	O
abolishes	O
enzymatic	O
activity	O
,	O
and	O
NT124	O
-	O
3	O
,	O
which	O
has	O
a	O
nonsense	O
mutation	O
that	O
results	O
in	O
deletion	O
of	O
the	O
C	O
-	O
terminal	O
25	O
aa	O
(	O
W237Stop	O
)	O
.	O

This	O
ligand	O
-	O
independent	O
pathway	O
can	O
function	O
through	O
another	O
androgen	O
-	O
regulated	O
promoter	O
as	O
shown	O
by	O
the	O
use	O
of	O
the	O
mouse	B
mammary	I
tumor	I
virus	I
MMTV	I
-	I
CAT	I
reporter	I
.	O

Studies	O
on	O
low	O
-	O
dose	O
oral	O
contraceptives	O
:	O
cervical	O
mucus	O
and	O
plasma	O
hormone	O
changes	O
in	O
relation	O
to	O
circulating	O
D	O
-	O
norgestrel	O
and	O
17alpha	O
ethynyl	O
-	O
estradiol	O
concentrations	O
.	O

On	O
the	O
pharmacology	O
of	O
9,10-dihydro-10-	O
(	O
1-methyl-4-piperidylidene	O
)	O
-9-anthrol	O
(	O
WA	O
335	O
)	O
,	O
a	O
histamine	O
and	O
serotonin	O
antagonist	O

This	O
incompatibility	O
phenotype	O
requires	O
the	O
global	O
transcriptional	O
repressor	O
,	O
KorB	B
,	O
and	O
the	O
target	O
for	O
incC	B
-	O
mediated	O
incompatibility	O
is	O
a	O
KorB	B
-	I
binding	I
site	I
(	I
O	I
(	I
B	I
)	I
)	I
.	O

A	O
mean	O
value	O
for	O
HbA1	B
greater	O
than	O
10	O
%	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
progression	O
of	O
retinopathy	O
and	O
a	O
mean	O
value	O
less	O
than	O
8.7	O
%	O
was	O
associated	O
with	O
a	O
diminished	O
risk	O
.	O

Threefold	O
risks	O
were	O
observed	O
for	O
men	O
with	O
the	O
highest	O
level	O
of	O
intensity	O
and	O
for	O
those	O
with	O
the	O
highest	O
probability	O
of	O
EMF	O
exposure	O
,	O
although	O
women	O
with	O
heavy	O
EMF	O
exposure	O
did	O
not	O
experience	O
increased	O
risk	O
.	O

Early	O
complement	O
components	O
,	O
C1q	B
and	O
C4	B
,	O
and	O
IgA	B
secretory	O
piece	O
were	O
absent	O
.	O

Erdheim	O
-	O
Chester	O
disease	O
:	O
a	O
distinct	O
lipoidosis	O
or	O
part	O
of	O
the	O
spectrum	O
of	O
histiocytosis	O
?	O

Erdheim	O
-	O
Chester	O
disease	O
has	O
always	O
been	O
considered	O
a	O
distinct	O
lipoidosis	O
based	O
on	O
clinical	O
and	O
radiographic	O
criteria	O
.	O

The	O
leader	O
peptide	O
was	O
hypothesized	O
to	O
inhibit	O
ribosome	O
release	O
at	O
the	O
tnaC	B
stop	I
codon	I
,	O
thereby	O
blocking	O
Rho	B
's	O
access	O
to	O
the	O
transcript	O
.	O

In	O
the	O
presence	O
of	O
high	O
concentrations	O
(	O
propofol	O
100	O
microg	O
mL-1	O
,	O
thiopental	O
50	O
microg	O
mL-1	O
)	O
marked	O
relaxation	O
was	O
observed	O
(	O
propofol	O
-32	O
%	O
up	O
to	O
-49	O
%	O
,	O
P	O
<	O
0,05	O
;	O
thiopental	O
-23	O
%	O
up	O
to	O
-67	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Specifically	O
,	O
we	O
demonstrate	O
that	O
this	O
25-base	O
pair	O
region	O
mediates	O
the	O
up	O
-	O
regulatory	O
effect	O
of	O
TGF	B
-	I
beta	I
on	O
COL1A2	B
promoter	I
activity	O
and	O
allows	O
antagonistic	O
activity	O
of	O
TNF	B
-	I
alpha	I
on	O
the	O
TGF	B
-	I
beta	I
effect	O
.	O

The	O
mouse	O
lactoferrin	B
gene	O
promoter	O
was	O
active	O
in	O
human	O
endometrium	O
carcinoma	O
RL	O
95	O
-	O
2	O
cells	O
and	O
in	O
rat	O
glioma	O
C6	O
cells	O
.	O

Computer	O
analysis	O
revealed	O
that	O
the	O
human	B
protein	I
P1	I
sequence	I
corresponding	O
to	O
amino	O
acid	O
residues	O
within	O
the	O
N	O
-	O
terminal	O
RNA	O
binding	O
domain	O
displays	O
high	O
homology	O
(	O
greater	O
than	O
54	O
%	O
identity	O
;	O
61	O
to	O
94	O
%	O
similarity	O
)	O
with	O
two	O
animal	O
virus	O
proteins	O
which	O
possess	O
RNA	O
binding	O
activity	O
(	O
vaccinia	B
virus	I
E3L	I
;	O
rotavirus	B
VP2	I
)	O
and	O
two	O
proteins	O
of	O
unknown	O
function	O
(	O
murine	B
TIK	I
;	O
rotavirus	B
NS34	I
)	O
,	O
but	O
which	O
are	O
likely	O
RNA	O
binding	O
proteins	O
.	O

Conversely	O
the	O
rate	O
of	O
bioavailability	O
was	O
significantly	O
different	O
,	O
because	O
from	O
the	O
Reference	O
patch	O
the	O
release	O
rate	O
is	O
fast	O
in	O
the	O
first	O
24	O
h	O
,	O
leading	O
to	O
an	O
E2	O
peak	O
at	O
8	O
h	O
and	O
to	O
a	O
Cmax	O
in	O
average	O
at	O
23	O
h.	O

A	O
silica	O
-	O
based	O
,	O
fluoride	O
-	O
free	O
placebo	O
containing	O
NaTPP	O
,	O
and	O
a	O
NaF	O
-	O
containing	O
silica	O
-	O
based	O
USP	O
reference	O
standard	O
toothpaste	O
were	O
used	O
as	O
negative	O
and	O
positive	O
control	O
toothpastes	O
,	O
respectively	O
.	O

The	O
cost	O
and	O
effectiveness	O
of	O
nurse	O
education--1	O
.	O

No	O
significant	O
difference	O
in	O
plasma	O
ET	B
levels	O
was	O
found	O
between	O
cardiac	O
and	O
peripheral	O
sampling	O
sites	O
(	O
pulmonary	O
artery	O
;	O
1.07	O
+	O
/-	O

0.28	O
,	O
right	O
atrium	O
;	O
1.02	O
+	O
/-	O

0.28	O
,	O
peripheral	O
artery	O
;	O
1.12	O
+	O
/-	O

0.23	O
,	O
peripheral	O
vein	O
;	O
1.14	O
+	O
/-	O

0.38	O
fmol	O
/	O
ml	O
:	O
N.S.	O
)	O
,	O
or	O
among	O
patients	O
with	O
uncomplicated	O
MI	O
,	O
unstable	O
angina	O
(	O
1.00	O
+	O
/-	O

0.32	O
fmol	O
/	O
ml	O
)	O
,	O
and	O
healthy	O
subjects	O
(	O
1.01	O
+	O
/-	O

0.29	O
fmol	O
/	O
ml	O
)	O
.	O

Transfer	O
of	O
health	O
care	O
to	O
natives	O
holds	O
much	O
promise	O
,	O
lecturers	O
say	O
.	O

S.	O
aureus	O
leakage	O
into	O
the	O
totally	O
submerged	O
test	O
specimens	O
was	O
detected	O
in	O
1	O
of	O
5	O
samples	O
incubated	O
for	O
4	O
weeks	O
,	O
while	O
no	O
leakage	O
was	O
detected	O
in	O
specimens	O
incubated	O
for	O
3	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
and	O
8	O
weeks	O
.	O

The	O
Prompt	O
and	O
Praise	O
condition	O
was	O
superior	O
to	O
the	O
other	O
two	O
conditions	O
in	O
encouraging	O
participation	O
in	O
low	O
-	O
interest	O
recreational	O
activities	O
.	O

In	O
the	O
promoters	O
of	O
many	O
immediate	B
early	I
genes	I
,	O
including	O
c	B
-	I
fos	I
,	O
CArG	O
DNA	O
regulatory	O
elements	O
mediate	O
basal	O
constituitive	O
expression	O
and	O
rapid	O
and	O
transient	O
serum	O
induction	O
.	O

Strains	O
lacking	O
a	O
functional	B
RPL16A	I
gene	I
grow	O
as	O
rapidly	O
as	O
wild	O
type	O
,	O
whereas	O
those	O
containing	O
a	O
null	O
allele	O
of	O
RPL16B	B
grow	O
more	O
slowly	O
than	O
wild	O
type	O
.	O

DIC	O
and	O
low	O
grade	O
fibrinolysis	O
may	O
account	O
for	O
the	O
coagulation	O
abnormalities	O
of	O
the	O
syndrome	O
.	O

Overexpression	O
of	O
wild	O
type	O
and	O
SeCys	O
/	O
Cys	O
mutant	O
of	O
human	B
thioredoxin	I
reductase	I
in	O
E.	O
coli	O
:	O
the	O
role	O
of	O
selenocysteine	O
in	O
the	O
catalytic	O
activity	O
.	O

A	O
Meis1	B
cDNA	I
clone	O
that	O
encoded	O
a	O
novel	O
member	O
of	O
the	O
homeobox	B
gene	I
family	I
was	O
identified	O
.	O

Cellular	O
lysates	O
were	O
analyzed	O
for	O
luciferase	B
and	O
beta	B
-	I
galactosidase	I
activities	O
.	O

The	O
protein	O
contains	O
a	O
SHAQKYF	O
amino	O
acid	O
signature	O
motif	O
in	O
the	O
second	O
myb	B
-	I
like	I
repeat	I
,	O
which	O
is	O
highly	O
conserved	O
in	O
a	O
number	O
of	O
recently	O
identified	O
plant	B
myb	I
-	I
related	I
genes	I
,	O
thus	O
defining	O
a	O
new	O
class	O
of	O
plant	O
DNA	O
-	O
binding	O
proteins	O
.	O

The	O
use	O
of	O
aluminum	O
hydroxide	O
was	O
associated	O
with	O
an	O
increase	O
in	O
fecal	O
fluoride	O
excretion	O
and	O
a	O
decrease	O
in	O
net	O
absorption	O
of	O
fluoride	O
regardless	O
of	O
the	O
intake	O
fluoride	O
,	O
calcium	O
,	O
phosphorus	O
,	O
or	O
magnesium	O
.	O

First	O
aid	O
.	O

We	O
have	O
isolated	O
and	O
determined	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
another	O
operon	O
,	O
cpeCD	B
,	O
that	O
encodes	O
the	O
linker	O
proteins	O
associated	O
with	O
phycoerythrin	B
hexamers	I
in	O
the	O
phycobilisome	B
.	O

Here	O
,	O
we	O
describe	O
the	O
results	O
of	O
a	O
detailed	O
study	O
aimed	O
at	O
identifying	O
the	O
gene	O
or	O
genes	O
responsible	O
for	O
the	O
rapid	O
growth	O
-	O
arrest	O
response	O
obtained	O
with	O
human	O
chromosome-9	O
.	O

A	O
novel	O
Cdc42Hs	B
mutant	I
induces	O
cellular	O
transformation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
mechanism	O
of	O
ribosomal	O
frameshifting	O
at	O
the	O
PVM	O
signal	O
is	O
different	O
from	O
the	O
one	O
described	O
by	O
the	O
'	O
simultaneous	O
slippage	O
'	O
model	O
in	O
that	O
only	O
the	O
string	O
of	O
four	O
adenosine	O
nucleotides	O
represents	O
the	O
slippery	O
sequence	O
involved	O
in	O
a	O
-1	O
P	O
-	O
site	O
slippage	O
.	O

Kluyveromyces	O
lactis	O
,	O
a	O
budding	O
yeast	O
related	O
to	O
Saccharomyces	O
cerevisiae	O
,	O
can	O
grow	O
on	O
a	O
wider	O
variety	O
of	O
substrates	O
and	O
shows	O
less	O
sensitivity	O
to	O
glucose	O
repression	O
than	O
does	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
human	B
Fc	I
gamma	I
receptor	I
gene	I
Fc	B
gamma	I
RIIA	I
is	O
expressed	O
in	O
platelets	O
,	O
neutrophils	O
,	O
monocytes	O
and	O
macrophages	O
.	O

Hence	O
,	O
it	O
is	O
perhaps	O
not	O
necessary	O
to	O
perform	O
spinal	O
puncture	O
if	O
the	O
only	O
purpose	O
is	O
to	O
determine	O
the	O
CSF	O
/	O
serum	O
ratio	O
.	O

Interestingly	O
,	O
VDR	B
was	O
able	O
to	O
bind	O
to	O
VDREs	O
with	O
high	O
affinity	O
and	O
to	O
fully	O
activate	O
transcription	O
in	O
intact	O
yeast	O
cells	O
in	O
the	O
presence	O
of	O
the	O
retinoid	B
X	I
receptor	I
(	O
RXR	B
)	O
.	O

In	O
contrast	O
,	O
the	O
sequences	O
essential	O
for	O
the	O
transcription	O
of	O
EFT1	B
were	O
localized	O
to	O
the	O
region	O
between	O
the	O
start	O
ATG	O
and	O
the	O
stop	O
codon	O
of	O
the	O
VPS17	B
gene	I
that	O
terminates	O
267	O
nt	O
upstream	O
on	O
the	O
same	O
strand	O
.	O

Foreign	O
DNA	O
inserts	O
contained	O
within	O
the	O
fowlpox	O
virus	O
sequence	O
were	O
transferred	O
to	O
the	O
viral	O
genome	O
by	O
homologous	O
recombination	O
occurring	O
in	O
cells	O
infected	O
with	O
a	O
fowlpox	O
virus	O
temperature	O
-	O
sensitive	O
mutant	O
and	O
transfected	O
with	O
both	O
wild	O
-	O
type	O
viral	O
DNA	O
and	O
plasmid	O
DNA	O
.	O

The	O
LT	B
-	I
beta	I
gene	I
is	O
expressed	O
in	O
lymphoid	O
cells	O
and	O
organs	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
inducible	O
regulation	O
.	O

Genomic	O
organization	O
of	O
the	O
human	B
multidrug	I
resistance	I
(	I
MDR1	I
)	I
gene	I
and	O
origin	O
of	O
P	B
-	I
glycoproteins	I
.	O

Yet	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
production	O
are	O
independently	O
regulated	O
,	O
as	O
demonstrated	O
by	O
their	O
differential	O
expression	O
in	O
certain	O
T	O
cell	O
subsets	O
,	O
suggesting	O
that	O
the	O
regulatory	O
elements	O
in	O
these	O
two	O
genes	O
must	O
differ	O
.	O

Using	O
beta	B
1-AR	I
-	O
luciferase	B
reporter	O
recombinants	O
,	O
we	O
have	O
previously	O
determined	O
that	O
important	O
beta	B
1-AR	I
genetic	O
elements	O
controlling	O
expression	O
within	O
the	O
C6	O
glioma	O
cell	O
line	O
are	O
contained	O
within	O
the	O
region	O
-396	O
to	O
-299	O
,	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O

The	O
gene	O
is	O
predicted	O
to	O
encode	O
an	O
880-amino	O
-	O
acid	O
protein	O
which	O
contains	O
two	O
C2H2	O
zinc	O
fingers	O
,	O
a	O
nuclear	O
localization	O
sequence	O
and	O
two	O
transcriptional	O
activation	O
domains	O
.	O

Pathogenesis	O
of	O
fever	O
.	O

In	O
many	O
other	O
contractile	O
protein	O
gene	O
families	O
,	O
genes	O
encoding	O
cardiac	O
isoforms	O
are	O
expressed	O
early	O
in	O
skeletal	O
muscle	O
development	O
and	O
are	O
later	O
repressed	O
.	O

This	O
is	O
the	O
first	O
clinical	O
case	O
report	O
of	O
NIHF	O
due	O
to	O
fetal	O
Kasabach	O
-	O
Merritt	O
syndrome	O
that	O
was	O
prenatally	O
diagnosed	O
by	O
sonography	O
,	O
computerized	O
tomography	O
,	O
and	O
percutaneous	O
umbilical	O
blood	O
sampling	O
.	O

Growth	O
factors	O
promote	O
cell	O
survival	O
through	O
phosphorylation	O
of	O
Bad	B
,	O
resulting	O
in	O
its	O
dissociation	O
from	O
Bcl-2	B
and	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
and	O
its	O
association	O
with	O
14	B
-	I
3	I
-	I
3tau	I
.	O

Developmental	O
regulation	O
of	O
expression	O
of	O
the	O
malate	B
synthase	I
gene	I
in	O
transgenic	O
plants	O
.	O

Of	O
3841	O
serum	O
samples	O
from	O
sows	O
received	O
from	O
the	O
Tennessee	O
State	O
Diagnostic	O
Laboratory	O
in	O
1991	O
-	O
1992	O
,	O
1130	O
were	O
positive	O
for	O
Toxoplasma	B
gondii	I
antibody	I
.	O

An	O
insertion	O
sequence	O
element	O
(	O
IS1170	O
)	O
was	O
identified	O
upstream	O
of	O
the	O
nimC	B
gene	I
.	O

We	O
show	O
that	O
the	O
upstream	O
region	O
of	O
the	O
beta	B
-MyHC	I
gene	I
(	O
-5518	O
to	O
-2490	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
)	O
directed	O
high	O
levels	O
of	O
transcriptional	O
activity	O
only	O
when	O
stably	O
integrated	O
,	O
but	O
not	O
when	O
expressed	O
extrachromosomally	O
in	O
transient	O
assays	O
.	O

Similarly	O
,	O
TAM-67	B
reverted	O
the	O
morphology	O
of	O
the	O
AdoMetDC	B
-	I
antisense	I
expressors	I
.	O

Immune	O
and	O
clinical	O
impact	O
of	O
Lactobacillus	O
acidophilus	O
on	O
asthma	O
.	O

To	O
examine	O
the	O
functional	O
relationship	O
between	O
distinct	O
cis	O
-	O
active	O
elements	O
within	O
the	O
distal	O
enhancer	O
region	O
of	O
the	O
rat	B
PRL	I
gene	I
,	O
we	O
have	O
used	O
deletional	O
and	O
mutational	O
analysis	O
of	O
that	O
region	O
in	O
transient	O
transfection	O
studies	O
in	O
GH3	O
pituitary	O
tumor	O
cells	O
.	O

While	O
there	O
is	O
growing	O
evidence	O
that	O
perception	O
and	O
imagery	O
share	O
common	O
neural	O
substrates	O
,	O
the	O
fact	O
that	O
D.F.	O
shows	O
intact	O
visual	O
imagery	O
in	O
the	O
face	O
of	O
a	O
massive	O
perceptual	O
deficit	O
in	O
form	O
vision	O
challenges	O
recent	O
suggestions	O
that	O
these	O
two	O
psychological	O
processes	O
share	O
common	O
input	O
pathways	O
in	O
early	O
vision	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
conserved	O
cysteine	O
residue	O
(	O
tom1C3235A	B
)	O
in	O
the	O
hect	B
-	I
domain	I
,	O
supposed	O
to	O
be	O
necessary	O
for	O
thioester	O
-	O
bond	O
formation	O
with	O
ubiquitin	B
,	O
abolished	O
the	O
gene	O
function	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
encoded	O
by	O
MSK1	B
is	O
homologous	O
to	O
yeast	B
cytoplasmic	I
lysyl	I
-	I
tRNA	I
synthetase	I
and	O
to	O
the	O
product	O
of	O
the	O
herC	B
gene	I
,	O
which	O
has	O
recently	O
been	O
suggested	O
to	O
code	O
for	O
the	O
Escherichia	O
coli	O
enzyme	O
.	O

Joint	O
ultrasonography	O
demonstrating	O
thickening	O
of	O
synoviae	O
and	O
tendons	O
has	O
become	O
a	O
useful	O
non	O
-	O
invasive	O
diagnostic	O
tool	O
,	O
although	O
it	O
is	O
not	O
specific	O
for	O
beta	B
2-M	I
amyloidosis	O
,	O
and	O
results	O
depend	O
on	O
observer	O
experience	O
.	O

Videoanalysis	O
confirms	O
the	O
ballistic	O
character	O
of	O
the	O
initial	O
phase	O
of	O
the	O
reaching	O
movement	O
.	O

Toward	O
this	O
end	O
,	O
we	O
used	O
two	O
cultured	O
colon	O
cancer	O
cell	O
lines	O
;	O
one	O
(	O
RKO	O
)	O
has	O
a	O
transcriptionally	O
activated	O
u	B
-	I
PAR	I
gene	I
,	O
and	O
the	O
other	O
(	O
GEO	O
)	O
overexpresses	O
the	O
receptor	O
only	O
after	O
phorbol	O
ester	O
treatment	O
.	O

Mortality	O
among	O
patients	O
with	O
CAVB	O
is	O
still	O
high	O
and	O
has	O
not	O
declined	O
within	O
the	O
last	O
decade	O
.	O

Serum	O
triglycerides	O
also	O
showed	O
an	O
increase	O
from	O
birth	O
to	O
6	O
months	O
of	O
age	O
,	O
but	O
a	O
decrease	O
from	O
6	O
months	O
to	O
1	O
years	O
of	O
age	O
.	O

In	O
contrast	O
SF	B
,	O
but	O
not	O
GM	B
-	I
CSF	I
or	O
IL-3	B
,	O
induced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	B
C	I
-	I
gamma	I
(	O
PLC	B
-	I
gamma	I
)	O
.	O

The	O
effects	O
of	O
oxalate	O
-	O
containing	O
products	O
on	O
the	O
exposed	O
dentine	O
surface	O
:	O
an	O
SEM	O
investigation	O
.	O

Up	O
to	O
1988	O
,	O
145	O
cases	O
had	O
been	O
reported	O
in	O
literature	O
and	O
32	O
cases	O
in	O
our	O
country	O
.	O

Disorganization	O
scores	O
of	O
the	O
hypertrophy	O
zone	O
and	O
trabecular	O
bone	O
were	O
low	O
,	O
approaching	O
normal	O
(	O
P	O
<	O
0.05	O
)	O
,	O
for	O
turkey	O
poults	O
fed	O
on	O
diets	O
with	O
phytase	B
supplementation	O
,	O
and	O
tibial	O
abnormality	O
scores	O
were	O
linearly	O
decreased	O
(	O
P	O
<	O
0.001	O
)	O
as	O
nP	O
levels	O
increased	O
(	O
zero	O
score	O
is	O
considered	O
normal	O
)	O
.	O

These	O
results	O
suggest	O
that	O
1a	B
,	O
which	O
also	O
interacts	O
independently	O
with	O
the	O
ER	O
and	O
viral	O
RNA	O
,	O
is	O
a	O
key	O
organizer	O
of	O
RNA	O
replication	O
complex	O
assembly	O
.	O

Here	O
we	O
examine	O
the	O
population	O
of	O
gammaS	B
transcripts	I
in	O
adult	O
human	O
lens	O
and	O
the	O
structure	O
of	O
the	O
human	B
CRYGS	I
genes	I
.	O

Functional	O
importance	O
of	O
a	O
properly	O
folded	O
surface	O
loop	O
covering	O
the	O
catalytic	O
center	O
.	O

This	O
mechanism	O
seems	O
to	O
be	O
involved	O
in	O
VIP	B
-	O
induced	O
PRL	B
gene	I
regulation	O
.	O

A	O
Brassica	O
cDNA	O
clone	O
encoding	O
a	O
bifunctional	O
hydroxymethylpyrimidine	B
kinase	I
/	O
thiamin	B
-	I
phosphate	I
pyrophosphorylase	I
involved	O
in	O
thiamin	O
biosynthesis	O
.	O

When	O
CSF	O
[	O
HCO3-	O
]	O
is	O
shown	O
as	O
a	O
function	O
of	O
CSF	O
PCO2	O
the	O
data	O
of	O
K	O
-	O
depleted	O
rats	O
are	O
no	O
longer	O
displaced	O
when	O
compared	O
to	O
controls	O
but	O
still	O
have	O
a	O
significantly	O
greater	O
slope	O
(	O
1.21	O
+	O
/-	O

0.23	O
vs.	O

In	O
the	O
matched	O
control	O
group	O
the	O
acquisition	O
-	O
rate	O
of	O
both	O
symptomatic	O
and	O
asymptomatic	O
0acteriuria	O
was	O
over	O
12	O
%	O
,	O
a	O
figure	O
similar	O
to	O
the	O
percentage	O
of	O
women	O
present	O
in	O
the	O
practice	O
population	O
during	O
one	O
year	O
with	O
transient	O
,	O
symptomatic	O
,	O
and	O
persistent	O
A.B.	O

In	O
2	O
subjects	O
the	O
phytomitogen	O
reactivity	O
of	O
the	O
lymphocytes	O
was	O
improved	O
after	O
treatment	O
.	O

The	O
maintenance	O
of	O
increased	O
myocardial	O
capillary	O
density	O
required	O
a	O
similar	O
amount	O
of	O
exercise	O
,	O
and	O
at	O
least	O
1	O
h	O
of	O
exercise	O
once	O
a	O
week	O
was	O
necessary	O
to	O
maintain	O
the	O
enlargement	O
of	O
ECA.20	O

These	O
observations	O
have	O
led	O
us	O
to	O
conclude	O
that	O
an	O
elevated	O
VIII	O
-	O
ratio	O
is	O
a	O
very	O
sensitive	O
indicator	O
of	O
intravascular	O
coagulation	O
.	O

The	O
inner	O
ears	O
were	O
exposed	O
by	O
microdissection	O
,	O
and	O
the	O
vestibular	O
sensory	O
regions	O
were	O
either	O
sectioned	O
and	O
studied	O
with	O
light	O
or	O
electron	O
microscopy	O
,	O
or	O
prepared	O
and	O
studied	O
with	O
the	O
surface	O
specimen	O
technique	O
.	O

The	O
matrix	O
surrounding	O
the	O
clusters	O
either	O
showed	O
a	O
normal	O
morphology	O
or	O
a	O
homogeneous	O
appearance	O
,	O
within	O
which	O
faint	O
cross	O
striations	O
but	O
no	O
distinctly	O
fibrillar	O
outlines	O
could	O
be	O
identified	O
.	O

The	O
incidence	O
of	O
DNCB	O
reactions	O
was	O
78	O
per	O
cent	O
for	O
Stage	O
I	O
and	O
II	O
cancers	O
(	O
37	O
patinets	O
)	O
,	O
73	O
per	O
cent	O
for	O
resectable	O
Stage	O
III	O
cancer	O
(	O
22	O
patients	O
)	O
,	O
and	O
66	O
per	O
cent	O
in	O
patients	O
with	O
unresectable	O
or	O
inoperable	O
Stage	O
III	O
cancer	O
.	O

Workers	O
with	O
""""	O
sensitivity	O
""""	O
to	O
toluene	O
diisocyanate	O
(	O
TDI	O
)	O
studied	O
in	O
depth	O
in	O
an	O
attempt	O
to	O
determine	O
mechanisms	O
of	O
bronchial	O
hyperreactivity	O
.	O

Bertioga	O
(	O
Guama	O
group	O
)	O
and	O
Anhembi	O
(	O
Bunyamwera	O
group	O
)	O
,	O
two	O
new	O
arboviruses	O
isolated	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

The	O
'	O
field	O
of	O
stress	O
'	O
of	O
the	O
supervisory	O
nurse	O

Williams	O
,	O
2	O
August	O
1977	O
.	O

Disrupted	O
vaccines	O
and	O
whole	O
-	O
virus	O
vaccines	O
containing	O
type	B
B	I
antigen	I
only	O
did	O
not	O
cause	O
significant	O
reactivity	O
.	O

255	O
-	O
61	O
.	O

The	O
maximum	O
period	O
of	O
treatment	O
was	O
73	O
(	O
oral	O
)	O
,	O
73	O
(	O
intraperitoneal	O
)	O
or	O
75	O
(	O
dermal	O
)	O
weeks	O
.	O

Bone	O
marrow	O
transplantation-1979	O
.	O

Inherent	O
hematology	O
of	O
old	O
age	O

Immunologic	O
mechanisms	O
in	O
chronic	O
brucellosis	O
in	O
humans	O
.	O

This	O
expression	O
assumes	O
:	O
(	O
1	O
)	O
a	O
laminar	O
flow	O
regimen	O
during	O
expiration	O
,	O
and	O
(	O
2	O
)	O
a	O
constant	O
CT	O
value	O
over	O
the	O
range	O
of	O
VT	O
.	O

In	O
addition	O
a	O
significant	O
Treatment	O
X	O
Strain	O
interaction	O
was	O
due	O
to	O
the	O
larger	O
defecation	O
numbers	O
displayed	O
by	O
the	O
taurine	O
-	O
injected	O
MR	O
rats	O
relative	O
to	O
the	O
saline	O
-	O
injected	O
MR	O
rats	O
.	O

It	O
has	O
come	O
out	O
that	O
CAEC	O
is	O
between	O
CC	O
and	O
CIEC	O
and	O
that	O
attacks	O
of	O
biliary	O
fever	O
and	O
high	O
levels	O
of	O
alkaline	B
phosphatase	I
and	O
transaminases	O
in	O
the	O
serum	O
are	O
the	O
helpful	O
findings	O
for	O
preoperative	O
diagnosis	O
.	O

The	O
present	O
study	O
examined	O
the	O
dependence	O
of	O
difference	O
tone	O
level	O
[	O
L	O
(	O
f2-f1	O
)	O
]	O
on	O
the	O
following	O
parameters	O
of	O
the	O
two	O
-	O
tone	O
input	O
:	O
f1	O
,	O
f2	O
/	O
f1	O
(	O
f2	O
greater	O
than	O
f1	O
)	O
,	O
L1	O
,	O
L2	O
,	O
and	O
L1	O
=	O
L2	O
.	O

All	O
13	O
patients	O
showed	O
endoscopic	O
evidence	O
of	O
oesophagitis	O
,	O
moderate	O
in	O
4	O
and	O
severe	O
in	O
9	O
.	O

Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol-17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B
sulphatase	I
deficiency	O
.	O

When	O
two	O
determinations	O
were	O
performed	O
on	O
12	O
samples	O
of	O
plasma	O
taken	O
from	O
normal	O
adults	O
in	O
October	O
,	O
the	O
values	O
were	O
22.6	O
+	O
/-	O

4.8	O
and	O
21.0	O
+	O
/-	O

3.6	O
(	O
mean	O
+	O
/-	O

SD	O
)	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

None	O
of	O
the	O
cystometrograms	O
showed	O
uninhibited	O
detrusor	O
contractions	O
.	O

Treatment	O
of	O
Graves	O
'	O
disease	O
.	O

A	O
highly	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
fibrinolytic	O
degradation	O
products	O
(	O
FDP	O
)	O
and	O
the	O
incidence	O
of	O
nephropathy	O
and	O
renal	O
insufficiency	O
,	O
as	O
well	O
as	O
between	O
the	O
presence	O
of	O
fibrin	B
monomers	I
(	O
Godal	O
's	O
ethanol	O
-	O
gelification	O
test	O
)	O
and	O
the	O
evolutive	O
signs	O
of	O
the	O
primary	O
disease	O
(	O
fever	O
,	O
accelerated	O
ESR	O
)	O
.	O

2	O
cases	O
of	O
toxic	O
lymphomononucleosis	O

A	O
one	O
-	O
week	O
ulcer	O
therapy	O
with	O
atropine	O
and	O
Vikalin	O
(	O
Roter	O
)	O
led	O
to	O
a	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
reduction	O
of	O
the	O
nocturnal	O
proteolytic	O
activity	O
.	O

Action	O
of	O
strontium-90	O
and	O
metaphos	O
on	O
Cyprinus	O
carpio	O

Escherichia	O
of	O
a	O
single	O
sero	O
-	O
anzymatic	O
type	O
(	O
06a6b	O
:	O
K13	O
:	O
H1	O
)	O
were	O
isolated	O
in	O
a	O
group	O
affection	O
.	O

A	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
performed	O
separately	O
for	O
men	O
and	O
women	O
for	O
differences	O
among	O
the	O
three	O
phobic	O
groups	O
on	O
field	O
dependence	O
,	O
showed	O
significance	O
(	O
rho	O
less	O
than	O
.05	O
)	O
for	O
the	O
females	O
,	O
with	O
the	O
famale	O
agoraphobic	O
being	O
more	O
field	O
dependent	O
than	O
the	O
female	O
simple	O
phobic	O
groups	O
,	O
but	O
not	O
for	O
the	O
males	O
.	O

The	O
results	O
of	O
a	O
quantitative	O
study	O
of	O
vasculosyncytial	O
membranes	O
in	O
123	O
placentas	O
are	O
presented	O
.	O

Platelet	O
serotonin	O
(	O
5-HT	O
)	O
and	O
5-HT	B
releasing	I
factor	I
in	O
plasma	O
of	O
migrainous	O
patients	O
.	O

The	O
vigilance	O
task	O
and	O
the	O
measurement	O
of	O
attentional	O
deficits	O
.	O

Absorption	O
varied	O
between	O
65	O
and	O
95	O
per	O
cent	O
,	O
with	O
a	O
mean	O
absorption	O
of	O
80	O
per	O
cent	O
,	O
in	O
both	O
pregnant	O
and	O
non	O
-	O
pregnant	O
subjects	O
.	O

A	O
diagnosis	O
of	O
MS	O
was	O
made	O
based	O
on	O
subtle	O
neurologic	O
signs	O
,	O
spinal	O
fluid	O
gamma	B
globulin	I
elevations	O
,	O
and	O
abnormalities	O
in	O
neuropsychological	O
testing	O
.	O

The	O
elevated	O
Viso	O
V	O
in	O
the	O
RDS	O
group	O
suggests	O
an	O
increase	O
in	O
small	O
airway	O
resistance	O
secondary	O
to	O
the	O
disease	O
or	O
to	O
its	O
therapy	O
.	O

The	O
psychological	O
tests	O
consisted	O
of	O
a	O
free	O
-	O
recall	O
task	O
,	O
a	O
test	O
for	O
visuomotor	O
coordination	O
and	O
a	O
recognition	O
task	O
.	O

Eleven	O
strains	O
of	O
Fusarium	O
poae	O
and	O
F.	O
sporotrichioides	O
from	O
the	O
U.S.S.R.	O
and	O
7	O
strains	O
of	O
these	O
species	O
and	O
one	O
of	O
F.	O
sporotrichioides	O
var	O
.	O

tricinctum	O
from	O
U.S.A.	O
and	O
France	O
have	O
been	O
compared	O
as	O
to	O
their	O
capacity	O
to	O
yield	O
T-2	B
toxin	I
.	O

Amikacin	O
was	O
used	O
in	O
the	O
treatment	O
of	O
56	O
serious	O
gram	O
-	O
negative	O
infections	O
in	O
54	O
patients	O
of	O
whom	O
47	O
survived	O
.	O

Evaluation	O
of	O
the	O
new	O
Gravigard	O
IUCD	O
inserter	O
.	O

Well	O
-	O
visualised	O
arteriograms	O
of	O
the	O
limbs	O
can	O
be	O
obtained	O
by	O
xeroradiography	O
after	O
rapid	O
manual	O
injection	O
of	O
contrast	O
-	O
medium	O
into	O
an	O
arm	O
vein	O
,	O
as	O
demonstrated	O
in	O
28	O
patients	O
.	O

Possibility	O
of	O
a	O
TSH	B
-	O
Screening	O
method	O
for	O
detection	O
of	O
hypothyroidism	O
in	O
the	O
newborn	O

Thus	O
analysis	O
indicated	O
no	O
reliable	O
evidence	O
that	O
conscious	O
presleep	O
suggestions	O
become	O
incorporated	O
into	O
dream	O
content	O
.	O

Batch	O
cultures	O
of	O
S.	O
mutans	O
serotype	O
a	O
demonstrated	O
no	O
growth	O
on	O
MSB	O
agar	O
.	O

Pregnant	O
women	O
at	O
term	O
had	O
the	O
lowest	O
levels	O
of	O
antithrombin	B
III	I
.	O

The	O
recovered	O
calves	O
were	O
tested	O
for	O
immunity	O
to	O
homologous	O
severe	O
challenge	O
,	O
50	O
or	O
73	O
days	O
after	O
the	O
first	O
infection	O
.	O

Preflight	O
,	O
inflight	O
,	O
and	O
postflight	O
exercise	O
response	O
tests	O
were	O
conducted	O
on	O
the	O
astronauts	O
of	O
the	O
second	O
Skylab	O
mission	O
(	O
Skylab	O
3	O
)	O
as	O
part	O
of	O
an	O
evaluation	O
of	O
physiological	O
adaptation	O
to	O
long	O
-	O
term	O
weightlessness	O
.	O

E	O
50	O
,	O
843	O
(	O
1994	O
)	O
]	O
.	O

With	O
the	O
help	O
of	O
a	O
nomogram	O
one	O
can	O
read	O
off	O
the	O
refraction	O
,	O
when	O
axis	O
length	O
and	O
corneal	O
curvature	O
are	O
known	O
.	O

Potscoital	O
test	O

Since	O
1968	O
,	O
a	O
steep	O
decrease	O
in	O
the	O
number	O
of	O
strains	O
resistant	O
to	O
three	O
or	O
more	O
antibiotics	O
(	O
multiple	O
-	O
resistant	O
)	O
and	O
in	O
strains	O
of	O
the	O
83A	O
complex	O
was	O
noticed	O
.	O

Alpha-1	B
antitrypsin	I
and	O
Indian	O
childhood	O
cirrhosis	O
.	O

Two	O
patients	O
were	O
treated	O
with	O
both	O
regimens	O
.	O

IgG	B
levels	O
of	O
1	O
/	O
100	O
were	O
present	O
in	O
only	O
four	O
out	O
of	O
ten	O
samples	O
obtained	O
150	O
days	O
after	O
the	O
clinical	O
onset	O
.	O

Letter	O
:	O
Perspectives	O
in	O
bone	O
marrow	O
transplantation	O
.	O

A	O
clinically	O
useful	O
diagnostic	O
method	O
has	O
been	O
developed	O
for	O
detecting	O
and	O
quantitating	O
periods	O
of	O
apnea	O
in	O
pediatric	O
patients	O
.	O

Before	O
this	O
date	O
,	O
the	O
drug	O
directly	O
inhibits	O
fetal	O
weight	O
gain	O
,	O
whereas	O
the	O
sensitivity	O
of	O
the	O
placenta	O
is	O
only	O
transient	O
at	O
day	O
16	O
resulting	O
in	O
maximum	O
weight	O
decrease	O
of	O
this	O
organ	O
24	O
h	O
later	O
.	O

The	O
interpretation	O
of	O
antibiotic	O
disc	O
sensitivities	O
.	O

Her	O
serum	O
FT3	O
concentration	O
was	O
,	O
however	O
,	O
much	O
higher	O
than	O
the	O
ranges	O
in	O
normal	O
pregnancy	O
or	O
in	O
GTD	O
patients	O
without	O
clinical	O
hyperthyroidism	O
.	O

Hypertonic	O
glucose	O
administered	O
intrajejunally	O
in	O
Heidenhain	O
pouch	O
dogs	O
resulted	O
in	O
an	O
equal	O
inhibition	O
of	O
pentagastrin	O
-	O
induced	O
acid	O
secretion	O
from	O
the	O
pouch	O
and	O
the	O
main	O
stomach	O
,	O
whereas	O
hypertonic	O
saline	O
had	O
no	O
effect	O
.	O

The	O
study	O
of	O
calcium	O
metabolism	O
in	O
ten	O
thalassaemic	O
children	O
comperatively	O
with	O
controls	O
after	O
oral	O
administration	O
of	O
47Ca	O
has	O
shown	O
diminished	O
intestinal	O
absorption	O
.	O

In	O
contrast	O
,	O
the	O
insulin	B
response	O
had	O
returned	O
to	O
the	O
non	O
-	O
pregnant	O
value	O
by	O
the	O
second	O
day	O
of	O
the	O
puerperium	O
.	O

The	O
apparent	O
Kd	O
of	O
the	O
MetRS	B
/	I
CAU	I
operator	I
complex	I
is	O
one	O
order	O
magnitude	O
higher	O
than	O
that	O
of	O
the	O
ThrRS	B
/	I
CGU	I
operator	I
complex	I
.	O

Characterization	O
of	O
the	O
human	B
gene	I
encoding	I
cytokeratin	I
17	I
and	O
its	O
expression	O
pattern	O
.	O

For	O
the	O
first	O
group	O
,	O
the	O
maximal	O
decrease	O
in	O
plasma	O
potassium	O
elicited	O
by	O
salbutamol	O
was	O
0.80	O
+	O
/-	O

0.19	O
,	O
0.48	O
+	O
/-	O

0.22	O
,	O
and	O
0.78	O
+	O
/-	O

0.46	O
mmol	O
/	O
l	O
,	O
and	O
for	O
the	O
second	O
group	O
,	O
maximal	O
decrement	O
was	O
1.31	O
+	O
/-	O

0.37	O
,	O
0.70	O
+	O
/-	O

0.24	O
,	O
and	O
0.84	O
+	O
/-	O

0.17	O
mmol	O
/	O
l	O
for	O
the	O
iv	O
,	O
po	O
,	O
and	O
it	O
routes	O
,	O
respectively	O
.	O

The	O
two	O
drugs	O
increase	O
the	O
rate	O
of	O
early	O
diastolic	O
filling	O
.	O

100	O
years	O
of	O
dentistry	O
at	O
the	O
Friedrich	O
Schiller	O
University	O
in	O
Jena	O

These	O
studies	O
show	O
that	O
UCRBP	B
binds	O
to	O
various	O
target	O
motifs	O
that	O
are	O
distinct	O
from	O
the	O
UCR	O
motif	O
:	O
the	O
adeno	B
-	I
associated	I
virus	I
P5	I
promoter	I
and	O
elements	O
in	O
the	O
immunoglobulin	B
light-	I
and	I
heavy	I
-	I
chain	I
genes	O
,	O
as	O
well	O
as	O
elements	O
in	O
ribosomal	B
protein	I
genes	I
.	O

The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B
serine	I
/	I
threonine	I
kinase	I
domain	I
.	O

In	O
contrast	O
,	O
gel	O
mobility	O
shift	O
experiments	O
have	O
failed	O
to	O
reveal	O
that	O
HAP2	B
or	O
HAP3	B
binds	O
to	O
domain	O
1	O
or	O
that	O
hap3	B
mutations	O
affect	O
the	O
complexes	O
bound	O
to	O
it	O
.	O

Two	O
points	O
are	O
indicated	O
:	O
first	O
,	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
interrelated	O
to	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2-	O
.	O

.OH	O
and	O
YHPD-	O
.	O
)	O
;	O
second	O
,	O
although	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
stronger	O
than	O
that	O
of	O
BHPD	O
,	O
yet	O
the	O
photosensitized	O
damage	O
is	O
negatively	O
correlated	O
to	O
the	O
yield	O
of	O
1O2	O
but	O
positively	O
correlated	O
to	O
those	O
of	O
O2-	O
.	O

and	O
OH	O
.	O

Fructokinase	B
activity	O
is	O
elevated	O
up	O
to	O
twofold	O
when	O
Z.	O
mobilis	O
was	O
grown	O
on	O
fructose	O
instead	O
of	O
glucose	O
,	O
and	O
there	O
was	O
a	O
parallel	O
increase	O
in	O
frk	B
mRNA	I
levels	O
.	O

METHODS	O
:	O
IgG	B
antibodies	I
vs	O
HHV-6	O
(	O
anti	B
-	I
HHV-6-IgG	I
)	O
were	O
determined	O
by	O
indirect	O
immunofluorescence	O
in	O
100	O
IVDA	O
(	O
29	O
seronegative	O
and	O
71	O
seropositive	O
for	O
HIV-1	O
of	O
which	O
45	O
were	O
in	O
stage	O
II	O
and	O
26	O
in	O
IV	O
-	O
C1	O
of	O
CDC	O
)	O
as	O
well	O
as	O
in	O
100	O
healthy	O
subjects	O
of	O
a	O
similar	O
age	O
(	O
control	O
group	O
)	O
.	O

Possible	O
roles	O
of	O
RAD5	B
putative	O
ATPase	B
/	O
DNA	B
helicase	I
activity	O
in	O
DNA	O
repair	O
and	O
in	O
the	O
maintenance	O
of	O
wild	O
-	O
type	O
rates	O
of	O
instability	O
of	O
simple	O
repetitive	O
sequences	O
are	O
discussed	O
.	O

Replication	O
of	O
bovine	O
papillomavirus-1	O
(	O
BPV-1	O
)	O
DNA	O
requires	O
two	O
viral	O
gene	O
products	O
,	O
the	O
E1	B
protein	I
and	O
the	O
full	B
-	I
length	I
E2	I
protein	I
.	O

Insertional	O
inactivation	O
of	O
sms	B
led	O
to	O
increased	O
sensitivity	O
to	O
the	O
alkylating	O
agent	O
methylmethane	O
sulfonate	O
,	O
but	O
not	O
to	O
a	O
requirement	O
for	O
serine	O
or	O
other	O
metabolites	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
MAP	B
kinase	I
activator	I
/	O
MAP	B
kinase	I
system	O
may	O
be	O
the	O
downstream	O
components	O
of	O
ras	B
signal	O
transduction	O
pathways	O
.	O

T	B
-	I
cell	I
receptor	I
beta	I
(	O
TCR	B
beta	I
)	O
gene	O
rearrangements	O
occur	O
in	O
a	O
third	O
of	O
early	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
RII	B
beta	I
gene	I
was	O
composed	O
of	O
two	O
adjacent	O
functional	O
elements	O
.	O

Here	O
we	O
show	O
that	O
epidermal	B
growth	I
factor	I
or	O
platelet	B
-	I
derived	I
growth	I
factor	I
stimulation	O
of	O
intact	O
human	O
or	O
murine	O
cells	O
leads	O
to	O
phosphorylation	O
of	O
Nck	B
protein	I
on	O
tyrosine	O
,	O
serine	O
,	O
and	O
threonine	O
residues	O
.	O

Structure	O
and	O
expression	O
of	O
a	O
gene	O
from	O
Arabidopsis	O
thaliana	O
encoding	O
a	O
protein	O
related	O
to	O
SNF1	B
protein	O
kinase	O
.	O

Effects	O
of	O
dioxins	O
on	O
thyroid	O
function	O
in	O
newborn	O
babies	O
.	O

cDNA	O
clones	O
encoding	O
Arabidopsis	O
thaliana	O
and	O
Zea	B
mays	I
mitochondrial	I
chaperonin	I
HSP60	B
and	O
gene	O
expression	O
during	O
seed	O
germination	O
and	O
heat	O
shock	O
.	O

Gestational	O
trophoblastic	O
diseases	O
:	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
cytogenetics	O
,	O
histopathology	O
,	O
and	O
natural	O
history	O
.	O

These	O
sites	O
are	O
also	O
potential	O
keratan	O
sulfate	O
attachment	O
sites	O
.	O

In	O
addition	O
,	O
the	O
hGCSFR	B
gene	I
was	O
chromosomally	O
localized	O
by	O
Southern	O
blot	O
analysis	O
of	O
its	O
segregation	O
pattern	O
in	O
a	O
panel	O
of	O
rodent	O
-	O
human	O
hybrid	O
DNAs	O
using	O
the	O
radiolabeled	O
cDNA	O
probe	O
.	O

Thus	O
,	O
cibenzoline	O
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
with	O
a	O
favourable	O
pharmacokinetic	O
profile	O
that	O
may	O
be	O
considered	O
with	O
other	O
class	O
I	O
drugs	O
in	O
patients	O
requiring	O
therapy	O
for	O
high	O
risk	O
arrhythmias	O
.	O

T	B
antigen	I
contains	O
four	O
H-2Db	O
-	O
restricted	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
recognition	O
epitopes	O
that	O
are	O
targets	O
for	O
CTL	O
clones	O
Y-1	O
,	O
Y-2	O
,	O
Y-3	O
,	O
and	O
Y-5	O
.	O

The	O
treatment	O
group	O
also	O
showed	O
in	O
vivo	O
T	O
-	O
cell	O
activation	O
with	O
an	O
initial	O
lymphopenia	O
followed	O
by	O
a	O
rebound	O
lymphocytosis	O
and	O
upregulation	O
of	O
the	O
subset	O
markers	O
CD25	B
(	O
interleukin	B
2	I
receptor	I
)	O
and	O
CD45RO	B
(	O
T	O
-	O
memory	O
cells	O
)	O
.	O

In	O
contrast	O
,	O
the	O
lumenal	O
domains	O
of	O
Sec12p	B
,	O
Stl1p	B
and	O
Stl2p	B
are	O
very	O
different	O
in	O
size	O
and	O
do	O
not	O
show	O
any	O
appreciable	O
homology	O
.	O

The	O
promoter	O
was	O
stimulated	O
8	O
-	O
20-fold	O
by	O
phorbol	O
esters	O
accounting	O
for	O
the	O
previously	O
observed	O
transcriptional	O
activation	O
of	O
protein	B
kinase	I
C	I
beta	I
.	O

PaO2	O
threshold	O
was	O
determined	O
through	O
an	O
indwelling	O
O2	O
sensor	O
catheter	O
.	O

We	O
found	O
that	O
both	O
the	O
E26	O
virus	O
-	O
encoded	O
v	B
-	I
ets	I
and	O
the	O
myeloid	B
/	I
B	I
-	I
cell	I
-	I
specific	I
factor	I
PU.1	I
bind	O
efficiently	O
to	O
this	O
site	O
in	O
vitro	O
.	O

The	O
IgG	B
subclass	O
profile	O
of	O
untreated	O
coeliac	O
disease	O
was	O
found	O
to	O
be	O
the	O
same	O
as	O
in	O
healthy	O
controls	O
(	O
IgG1	B
approximately	O
IgG2	B
>	O
IgG3	B
>	O
IgG4	B
)	O
,	O
with	O
only	O
the	O
magnitude	O
of	O
the	O
individual	O
subclass	O
responses	O
being	O
increased	O
in	O
coeliac	O
patients	O
.	O

Subcutaneous	O
administration	O
of	O
the	O
somatostatin	B
analogue	O
,	O
octreotide	O
,	O
100	O
micrograms	O
thrice	O
daily	O
,	O
resulted	O
in	O
a	O
sustained	O
improvement	O
in	O
diarrhoea	O
and	O
disappearance	O
of	O
faecal	O
incontinence	O
without	O
reducing	O
calcitonin	B
levels	O
.	O

GAL4-VP16-mediated	B
antirepression	O
required	O
an	O
auxiliary	O
factor	O
,	O
denoted	O
as	O
a	O
co	O
-	O
antirepressor	O
,	O
which	O
was	O
partially	O
purified	O
from	O
Drosophila	O
embryos	O
.	O

One	O
phage	O
clone	O
contains	O
a	O
junction	O
between	O
alpha	O
satellite	O
DNA	O
and	O
a	O
novel	O
low	O
-	O
copy	O
repeated	O
sequence	O
.	O

Dopamine	O
neurons	O
in	O
subjects	O
that	O
received	O
6-OHDA	O
were	O
protected	O
by	O
pre	O
-	O
treatment	O
with	O
GBR-12909	O
.	O

The	O
mean	O
blood	O
flow	O
in	O
the	O
penile	O
foreskin	O
was	O
estimated	O
to	O
be	O
15	O
ml	O
/	O
min	O
/	O
100	O
g	O
and	O
it	O
increased	O
to	O
150	O
-	O
200	O
%	O
after	O
the	O
induction	O
of	O
anesthesia	O
,	O
and	O
then	O
decreased	O
to	O
72	O
%	O
at	O
the	O
tip	O
of	O
the	O
created	O
parameatal	O
foreskin	O
flap	O
.	O

On	O
the	O
other	O
hand	O
,	O
neither	O
phosphate	O
buffered	O
saline	O
injection	O
into	O
the	O
ES	O
nor	O
primary	O
KLH	B
challenges	O
of	O
the	O
ES	O
were	O
capable	O
of	O
elevating	O
the	O
threshold	O
level	O
and	O
changing	O
the	O
latency	O
.	O

Model	O
predictions	O
were	O
in	O
accord	O
with	O
the	O
nine	O
-	O
year	O
survival	O
experience	O
of	O
women	O
in	O
the	O
HIP	O
trial	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
women	O
40	O
-	O
44	O
years	O
old	O
,	O
with	O
HIP	O
data	O
on	O
18-year	O
survival	O
.	O

Exon	O
-	O
intron	O
junctions	O
in	O
the	O
human	O
and	O
rat	B
AdoMet	I
decarboxylase	I
genes	I
were	O
in	O
identical	O
positions	O
except	O
that	O
exons	O
6	O
and	O
7	O
of	O
the	O
human	O
gene	O
formed	O
a	O
single	O
exon	O
in	O
the	O
rat	O
gene	O
.	O

The	O
gene	O
encoding	O
TRP-2	B
maps	O
to	O
mouse	O
chromosome	O
14	O
,	O
in	O
the	O
region	O
of	O
the	O
coat	B
colour	I
mutation	I
slaty	I
.	O

Comparison	O
of	O
the	O
genomic	O
DNA	O
sequence	O
with	O
that	O
of	O
the	O
four	O
different	O
mRNAs	O
indicates	O
that	O
these	O
transcripts	O
are	O
produced	O
by	O
alternative	O
splicing	O
of	O
the	O
murine	O
pre	O
-	O
mRNA	O
according	O
to	O
a	O
cassette	O
model	O
.	O

Probable	O
progressive	O
multifocal	O
leukoencephalopathy	O
(	O
PML	O
)	O
was	O
diagnosed	O
on	O
the	O
basis	O
of	O
clinical	O
picture	O
and	O
magnetic	O
resonance	O
imaging	O
in	O
a	O
63-year	O
-	O
old	O
man	O
with	O
a	O
complete	O
remission	O
of	O
a	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
.	O

Marker	O
rescue	O
analysis	O
has	O
localized	O
ts8	B
to	O
a	O
910-bp	O
internal	O
segment	O
of	O
rpoB	B
that	O
encodes	O
the	O
Rif	B
domain	I
.	O

Competition	O
analysis	O
by	O
gel	O
mobility	O
shift	O
electrophoresis	O
indicates	O
that	O
this	O
DNA	O
-	O
protein	O
interaction	O
is	O
novel	O
and	O
not	O
related	O
to	O
many	O
transcription	O
factors	O
previously	O
reported	O
.	O

The	O
1.7	O
kb	O
cloned	O
fragment	O
was	O
sequenced	O
and	O
shown	O
to	O
contain	O
the	O
entire	O
fliA	B
gene	I
.	O

The	O
SEN1	B
gene	I
corresponds	O
to	O
a	O
6,336-bp	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
2,112-amino	O
-	O
acid	O
protein	O
(	O
molecular	O
mass	O
,	O
239	O
kDa	O
)	O
.	O

At	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
is	O
a	O
domain	O
that	O
contains	O
sequences	O
very	O
similar	O
to	O
those	O
found	O
in	O
the	O
breakpoint	O
cluster	O
region	O
gene	O
product	O
,	O
n	B
-	I
chimerin	I
,	O
and	O
rho	B
GAP	I
,	O
all	O
of	O
which	O
have	O
been	O
shown	O
to	O
possess	O
intrinsic	O
GAP	B
activity	O
on	O
small	B
GTPases	I
.	O

Neural	O
-	O
specific	O
expression	O
,	O
genomic	O
structure	O
,	O
and	O
chromosomal	O
localization	O
of	O
the	O
gene	O
encoding	O
the	O
zinc	B
-	I
finger	I
transcription	I
factor	I
NGFI	I
-	I
C.	I

These	O
results	O
support	O
the	O
diagnostic	O
validity	O
of	O
NFPD	O
in	O
CP	O
/	O
NCA	O
patients	O
,	O
because	O
such	O
patients	O
had	O
a	O
family	O
history	O
of	O
panic	O
disorder	O
similar	O
to	O
patients	O
with	O
a	O
more	O
classical	O
panic	O
disorder	O
presentation	O
.	O

Furthermore	O
,	O
no	O
transcripts	O
of	O
the	O
same	O
size	O
and	O
having	O
the	O
same	O
developmental	O
profile	O
as	O
those	O
generated	O
by	O
the	O
wild	B
-	I
type	I
E10	I
fragment	I
were	O
identified	O
by	O
probes	O
covering	O
the	O
remainder	O
of	O
the	O
cloned	O
region	O
.	O

Both	O
parents	O
are	O
clinically	O
normal	O
and	O
unrelated	O
.	O

The	O
sequence	O
-	O
specific	O
interaction	O
of	O
nuclear	B
factor	I
HiNF	I
-	I
D	I
with	O
this	O
key	O
proximal	O
promoter	O
element	O
of	O
the	O
H4-FO108	B
gene	I
is	O
cell	O
cycle	O
regulated	O
in	O
normal	O
diploid	O
cells	O
(	O
J.	O

While	O
blood	O
pressure	O
and	O
noradrenergic	O
activity	O
,	O
assessed	O
as	O
changes	O
in	O
the	O
plasma	O
levels	O
and	O
urinary	O
excretion	O
of	O
norepinephrine	O
,	O
remained	O
unaffected	O
in	O
the	O
Pl	O
group	O
,	O
a	O
significant	O
drop	O
in	O
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
,	O
as	O
well	O
as	O
in	O
the	O
resting	O
venous	O
norepinephrine	O
level	O
and	O
in	O
urinary	O
norepinephrine	O
excretion	O
was	O
found	O
after	O
the	O
first	O
month	O
of	O
dF	O
administration	O
.	O

The	O
homologies	O
between	O
RAD16	B
,	O
RAD54	B
and	O
SNF2	B
are	O
also	O
shared	O
by	O
several	O
additional	O
,	O
recently	O
isolated	O
yeast	O
and	O
Drosophila	O
genes	O
.	O

Two	O
cDNAs	O
encoding	O
casein	B
kinase-1	I
have	O
been	O
isolated	O
from	O
a	O
yeast	O
cDNA	O
library	O
and	O
termed	O
CKI1	B
and	O
CKI2	B
.	O

The	O
observed	O
sequence	O
variation	O
disrupts	O
the	O
first	O
ORF	O
in	O
many	O
Y	B
's	O
while	O
most	O
of	O
the	O
second	O
ORF	O
including	O
the	O
putative	O
helicase	B
region	I
is	O
unaffected	O
.	O

The	O
final	O
screening	O
yielded	O
a	O
clone	O
containing	O
a	O
2	O
kilobase	O
(	O
kb	O
)	O
insert	O
.	O

Lesions	O
were	O
made	O
by	O
pressure	O
injection	O
of	O
kainic	O
acid	O
into	O
the	O
SOC	O
through	O
a	O
stereotaxically	O
positioned	O
glass	O
micropipette	O
.	O

Cardiovascular	O
risk	O
factors	O
were	O
measured	O
by	O
standardized	O
techniques	O
.	O

The	O
results	O
indicate	O
that	O
the	O
carbon	O
-	O
perfused	O
areas	O
and	O
MBF	O
in	O
the	O
liver	O
,	O
renal	O
cortex	O
,	O
spleen	O
,	O
and	O
small	O
intestinal	O
serosa	O
(	O
only	O
MBF	O
)	O
increased	O
significantly	O
5	O
h	O
after	O
CLP	O
.	O

Lewis	O
,	O
N.	O

This	O
accurate	O
and	O
rapid	O
method	O
makes	O
the	O
MLPA	O
test	O
logistically	O
feasible	O
for	O
large	O
-	O
scale	O
screening	O
.	O

The	O
modalities	O
for	O
using	O
reference	O
values	O
for	O
individual	O
subjects	O
as	O
well	O
as	O
for	O
groups	O
are	O
then	O
discussed	O
and	O
the	O
main	O
points	O
of	O
research	O
which	O
must	O
be	O
faced	O
in	O
the	O
near	O
future	O
regarding	O
reference	O
values	O
are	O
highlighted	O
.	O

In	O
addition	O
to	O
the	O
previously	O
identified	O
and	O
characterized	O
attenuator	B
1	I
situated	O
93	O
nucleotides	O
downstream	O
from	O
the	O
major	O
late	O
transcription	O
start	O
site	O
,	O
a	O
second	O
attenuator	O
,	O
attenuator	B
2	I
,	O
situated	O
55	O
nucleotides	O
downstream	O
from	O
it	O
,	O
has	O
been	O
identified	O
.	O

These	O
experiments	O
delineate	O
a	O
186-bp	O
,	O
EBNA-2-responsive	B
cell	O
DNA	O
fragment	O
and	O
provide	O
firm	O
evidence	O
that	O
EBNA-2	B
transactivates	O
transcription	O
of	O
cell	O
genes	O
.	O

This	O
repression	O
was	O
mediated	O
through	O
binding	O
to	O
the	O
E2	B
DNA	I
-	I
binding	I
site	I
immediately	O
upstream	O
of	O
the	O
P105	B
promoter	O
TATA	O
box	O
and	O
could	O
be	O
abrogated	O
by	O
preincubation	O
of	O
the	O
HPV-18	B
P105	I
promoter	I
template	O
with	O
the	O
nuclear	O
extract	O
allowing	O
the	O
formation	O
of	O
the	O
preinitiation	O
complex	O
.	O

We	O
have	O
determined	O
that	O
the	O
mutants	O
define	O
two	O
complementation	O
groups	O
,	O
designated	O
cgs1	B
+	I
and	O
cgs2	B
+	I
(	O
continues	O
to	O
grow	O
in	O
stationary	O
)	O
.	O

The	O
strategy	O
has	O
been	O
used	O
to	O
determine	O
2.6	O
kilobases	O
of	O
nucleotide	O
sequence	O
in	O
the	O
Saccharomyces	B
cerevisiae	I
ADE	I
1	I
locus	I
.	O

Its	O
neuromuscular	O
effects	O
are	O
similar	O
to	O
a	O
single	O
ED90	O
dose	O
of	O
vecuronium	O
.	O

Wnt-1	B
(	O
int-1	B
)	O
is	O
a	O
cellular	O
oncogene	O
often	O
activated	O
by	O
insertion	O
of	O
proviral	O
DNA	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
.	O

We	O
speculate	O
that	O
these	O
tumors	O
may	O
represent	O
congenital	O
hamartomatous	O
growths	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
promoter	O
for	O
the	O
cytotactin	B
gene	I
.	O

2:121	O
-	O
133	O
,	O
1988	O
)	O
.	O

Although	O
the	O
N13-N20	O
interpeak	O
interval	O
remained	O
stable	O
because	O
of	O
the	O
parallel	O
shift	O
of	O
the	O
2	O
peaks	O
,	O
the	O
central	O
conduction	O
time	O
measured	O
from	O
onset	O
latencies	O
of	O
N11	O
and	O
N20	O
significantly	O
increased	O
.	O

The	O
murine	B
mutation	I
dominant	I
white	I
spotting	I
(	O
W	B
)	O
is	O
in	O
the	O
proto	O
-	O
oncogene	O
,	O
c	B
-	I
kit	I
.	O

A	O
full	B
-	I
length	I
human	I
pim-1	I
cDNA	I
was	O
subcloned	O
into	O
the	O
bacterial	O
vector	O
pGEX-2	O
T	O
and	O
the	O
Pim-1	B
protein	I
expressed	O
as	O
a	O
fusion	O
product	O
with	O
bacterial	B
glutathione	I
S	I
-	I
transferase	I
(	O
GST	B
)	O
.	O

We	O
characterized	O
cDNA	O
clones	O
specific	O
for	O
the	O
extracellular	O
matrix	O
glycoprotein	O
undulin	B
.	O

Regulation	O
of	O
the	O
alpha	B
inhibin	I
gene	I
by	O
cyclic	O
adenosine	O
3',5'-monophosphate	O
after	O
transfection	O
into	O
rat	O
granulosa	O
cells	O
.	O

E.	O
,	O
Hession	O
,	O
C.	O
,	O
Goff	O
,	O
D.	O
,	O
Griffiths	O
,	O
B.	O
,	O
Tizard	O
,	O
R.	O
,	O
Newman	O
,	O
B.	O
,	O
Chi	O
-	O
Rosso	O
,	O
G.	O
,	O
and	O
Lobb	O
,	O
R.	O
,	O
(	O
1990	O
)	O
Cell	O
63	O
,	O
1349	O
-	O
1356	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
certain	O
angiotensin	B
converting	I
enzyme	I
inhibitors	O
can	O
potentiate	O
their	O
effect	O
on	O
the	O
endogenous	O
nitrovasodilator	O
EDRF	B
.	O

They	O
were	O
checked	O
for	O
anti	B
-	I
HCV	I
(	O
anti	B
-	I
C100	I
-	I
3	I
)	O
with	O
HCV	O
EIA	O
kit	O
(	O
Abbott	O
Lab	O
.	O

,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Diltiazem	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
epicardial	O
diameter	O
(	O
+	O
10	O
%	O
;	O
p	O
=	O
0.001	O
)	O
and	O
in	O
coronary	O
blood	O
flow	O
(	O
CBF	O
)	O
(	O
+	O
30	O
%	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

These	O
risk	O
factors	O
can	O
be	O
divided	O
into	O
2	O
groups	O
:	O
local	O
vessel	O
wall	O
-	O
related	O
factors	O
,	O
and	O
local	O
(	O
focal	O
action	O
)	O
systemic	O
factors	O
.	O

Vaccinia	O
virus	O
(	O
VV	O
)	O
is	O
a	O
potent	O
immunogen	O
,	O
but	O
the	O
nature	O
of	O
VV	O
proteins	O
involved	O
in	O
the	O
activation	O
of	O
the	O
immune	O
response	O
of	O
the	O
host	O
is	O
not	O
yet	O
known	O
.	O

The	O
tissue	O
specificity	O
of	O
gene	O
expression	O
was	O
identical	O
to	O
that	O
described	O
previously	O
for	O
the	O
CaMV	B
35S	I
domain	I
B	I
enhancer	I
element	I
.	O

The	O
size	O
of	O
the	O
mutant	O
molecule	O
corresponds	O
to	O
the	O
unprocessed	O
cytoplasmic	O
precursor	O
(	O
pre	B
-	I
super	I
-	I
pro	I
-	I
PrB	I
)	O
,	O
as	O
detected	O
in	O
sec61	B
mutants	I
,	O
when	O
translocation	O
into	O
the	O
endoplasmic	O
reticulum	O
is	O
blocked	O
.	O

Thus	O
,	O
the	O
active	O
-	O
site	O
mutation	O
prevents	O
the	O
wild	O
-	O
type	O
processing	O
of	O
the	O
N	O
-	O
glycosylated	O
73-kDa	O
precursor	O
of	O
PrB	B
to	O
the	O
41.5	B
kDa	I
pro	I
-	I
PrB	I
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Bone	O
and	O
bones	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
overexpressed	O
Kex2p	B
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
.	O

J.	O

The	O
major	B
49-kDa	I
core	I
protein	I
in	O
the	O
liver	O
HSPG	B
preparation	O
was	O
found	O
to	O
be	O
reactive	O
to	O
an	O
antibody	O
that	O
specifically	O
recognizes	O
the	O
cytoplasmic	O
domain	O
of	O
fibroglycan	B
.	O

We	O
have	O
isolated	O
cDNAs	O
for	O
a	O
gene	O
coding	O
for	O
a	O
G	B
protein	I
alpha	I
subunit	I
from	I
tomato	I
(	O
Lycopersicon	O
esculentum	O
,	O
cv	O
.	O

Substituting	O
a	O
Ser	O
for	O
Gly69	O
or	O
a	O
Glu	O
for	O
Lys	O
71	O
in	O
the	O
conserved	O
TGEK	B
tetrapeptide	I
in	O
finger	O
II	O
of	O
TFIIIA	B
resulted	O
in	O
the	O
loss	O
of	O
DNA	O
binding	O
.	O

The	O
model	O
is	O
able	O
to	O
anticipate	O
why	O
the	O
effect	O
of	O
water	O
fluoridation	O
on	O
caries	O
prevalence	O
is	O
most	O
pronounced	O
when	O
caries	O
is	O
diagnosed	O
at	O
cavity	O
level	O
.	O

Auditory	O
threshold	O
shifts	O
,	O
as	O
measured	O
by	O
the	O
auditory	O
evoked	O
brainstem	O
response	O
,	O
were	O
measured	O
at	O
2,4,8,12,16	O
,	O
20	O
and	O
24	O
kHz	O
.	O

Fundamental	O
and	O
clinical	O
evaluation	O
of	O
equilibrium	O
dialysis	O
--	O
radioimmunoassay	O
system	O
for	O
measurement	O
of	O
serum	O
free	O
thyroxine	O

We	O
conclude	O
that	O
TA	O
caused	O
a	O
specific	O
decrease	O
in	O
AGD	O
on	O
GD	O
20	O
that	O
was	O
largely	O
reversed	O
by	O
PCD	O
23	O
.	O

When	O
examined	O
as	O
adults	O
(	O
8	O
weeks	O
old	O
)	O
,	O
the	O
external	O
genitalia	O
of	O
TA	O
-	O
exposed	O
offspring	O
were	O
normal	O
.	O

A	O
330-kb	O
YAC	O
,	O
A148A7	O
,	O
spanned	O
from	O
the	O
HLA	B
-	O
DQA1	B
locus	O
through	O
the	O
Y3	B
/	O
Ring	B
4	I
locus	O
and	O
extended	O
at	O
least	O
130	O
kb	O
centromeric	O
of	O
YAC	O
B1D12	O
.	O

We	O
examined	O
behavioral	O
alterations	O
in	O
the	O
brown	O
cockroach	O
,	O
Periplaneta	O
brunnea	O
,	O
infected	O
with	O
the	O
acanthocephalan	O
,	O
Moniliformis	O
moniliformis	O
.	O

The	O
existence	O
of	O
threshold	O
concentrations	O
,	O
above	O
which	O
certain	O
phenomena	O
may	O
occur	O
,	O
strengthens	O
the	O
role	O
of	O
sentinels	O
.	O

These	O
changes	O
were	O
n't	O
so	O
significant	O
in	O
the	O
group	O
of	O
obese	O
children	O
who	O
did	O
n't	O
lose	O
weight	O
.	O

Magnetotherapy	O
of	O
hepatitis	O
A	O
and	O
B	O
in	O
children	O

The	O
presence	O
of	O
local	O
abnormalities	O
in	O
both	O
patients	O
can	O
support	O
the	O
hypothesis	O
that	O
the	O
cortex	O
,	O
especially	O
of	O
the	O
temporal	O
anterior	O
lobe	O
,	O
is	O
involved	O
in	O
the	O
origin	O
of	O
the	O
laughing	O
seizures	O
.	O

TPTA	O
produced	O
brain	O
congestion	O
,	O
and	O
hepatic	O
and	O
pulmonary	O
petechial	O
and	O
generalized	O
hemorrhages	O
.	O

Resolution	O
of	O
thermographic	O
asymmetry	O
and/or	O
decrease	O
in	O
Delta	O
T	O
was	O
demonstrated	O
in	O
approximately	O
81	O
%	O
of	O
the	O
post	O
-	O
treatment	O
population	O
.	O

The	O
ED30	O
values	O
were	O
2.4	O
and	O
2.2	O
mg	O
/	O
kg	O
and	O
similar	O
to	O
the	O
respective	O
values	O
of	O
nifedipine	O
(	O
ED	O
30:2.4,2.1	O
mg	O
/	O
kg	O
)	O
.	O

The	O
abundance	O
of	O
transcripts	O
from	O
several	O
unrelated	O
genes	O
is	O
decreased	O
in	O
cdc68	B
-	I
1	I
mutant	I
cells	O
after	O
transfer	O
to	O
the	O
restrictive	O
temperature	O
,	O
while	O
at	O
least	O
one	O
transcript	O
,	O
from	O
the	O
HSP82	B
gene	I
,	O
persists	O
in	O
an	O
aberrant	O
fashion	O
.	O

The	O
spectrum	O
of	O
histologically	O
diagnosed	O
malignant	O
neoplasms	O
in	O
Sabah	O
,	O
1983	O
-	O
1988	O
.	O

When	O
transfected	O
into	O
Drosophila	O
SL-2	O
cells	O
,	O
pCAT	O
plasmid	O
containing	O
2,090	O
bp	O
of	O
5'-flanking	O
region	O
shows	O
a	O
3.0-	O
to	O
3.5-fold	O
increase	O
in	O
chloramphenicol	B
acetyltransferase	I
activity	O
after	O
induction	O
with	O
retinoic	O
acid	O
and/or	O
8-bromo	O
-	O
cAMP	O
.	O

The	O
N	O
-	O
terminus	O
of	O
another	O
open	O
reading	O
frame	O
was	O
found	O
3	O
'	O
from	O
nifA	B
and	O
tentatively	O
identified	O
as	O
nifB	B
by	O
amino	O
acid	O
sequence	O
comparison	O
.	O

A	O
novel	O
cDNA	O
clone	O
termed	O
R2	O
was	O
isolated	O
by	O
subtractive	O
hybridization	O
of	O
a	O
cDNA	O
library	O
of	O
phytohemagglutinin	B
(	O
PHA	B
)	O
/	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
Jurkat	O
cells	O
and	O
by	O
rescreening	O
a	O
cDNA	O
library	O
of	O
PHA	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocytes	O
.	O

Suggestive	O
evidence	O
was	O
obtained	O
that	O
cstA	B
is	O
involved	O
in	O
peptide	O
utilization	O
.	O

Identification	O
and	O
nucleotide	O
sequence	O
of	O
Rhizobium	B
meliloti	I
insertion	I
sequence	I
ISRm3	I
:	O
similarity	O
between	O
the	O
putative	O
transposase	B
encoded	O
by	O
ISRm3	B
and	O
those	O
encoded	O
by	O
Staphylococcus	B
aureus	I
IS256	I
and	O
Thiobacillus	B
ferrooxidans	I
IST2	I
.	O

To	O
determine	O
the	O
relationship	O
of	O
these	O
viruses	O
,	O
the	O
complete	O
DNA	O
sequence	O
of	O
KV	O
consisting	O
of	O
4754	O
bp	O
was	O
determined	O
.	O

Heterodimers	O
of	O
myogenin	B
and	O
E12	B
(	O
or	O
MyoD	B
and	O
E12	B
)	O
specifically	O
bound	O
a	O
restriction	O
fragment	O
extending	O
from	O
-200	O
to	O
-103	O
relative	O
to	O
the	O
start	O
of	O
cardiac	B
alpha	I
-	I
actin	I
transcription	O
.	O

The	O
Italian	O
Lung	O
Cancer	O
Task	O
Force	O
(	O
FONICAP	O
)	O
.	O

The	O
5	O
'	O
region	O
shows	O
strong	O
sequence	O
similarity	O
to	O
Escherichia	O
coli	O
consensus	O
promoters	O
and	O
ribosome	O
-	O
binding	O
sequences	O
and	O
allows	O
high	O
levels	O
of	O
expression	O
in	O
E.	O
coli	O
.	O

Young	O
CD-1	O
mice	O
,	O
4	O
days	O
old	O
,	O
exposed	O
to	O
0.1	O
%	O
nicotine	O
sulfate	O
on	O
gestational	O
days	O
6	O
-	O
20	O
were	O
compared	O
with	O
untreated	O
pups	O
of	O
the	O
same	O
age	O
to	O
determine	O
its	O
effect	O
on	O
the	O
development	O
of	O
mandibular	O
first	O
molars	O
.	O

USF	B
synthesized	O
in	O
an	O
in	O
vitro	O
transcription	O
and	O
translation	O
system	O
also	O
binds	O
to	O
the	O
ADH	B
promoter	I
as	O
well	O
as	O
to	O
the	O
MLP	O
.	O

Arterial	O
radioactivity	O
content	O
after	O
the	O
intravenous	O
administration	O
of	O
HMPAO	O
in	O
seven	O
human	O
subjects	O
was	O
analyzed	O
.	O

Experimentally	O
in	O
green	O
monkeys	O
,	O
Syrian	O
hamsters	O
and	O
white	O
mice	O
the	O
authors	O
studied	O
the	O
pathogenic	O
properties	O
of	O
a	O
new	O
virus	O
Issyk	O
-	O
Kul	O
.	O

Limits	O
of	O
energy	O
turnover	O
in	O
relation	O
to	O
physical	O
performance	O
were	O
addressed	O
in	O
terms	O
of	O
upper	O
and	O
lower	O
limit	O
,	O
changes	O
during	O
a	O
training	O
programme	O
and	O
how	O
to	O
regulate	O
energy	O
balance	O
at	O
a	O
changing	O
energy	O
turnover	O
.	O

The	O
smaller	O
uptake	O
rate	O
and	O
faster	O
clearance	O
rate	O
resulted	O
in	O
the	O
lower	O
BCF	O
for	O
SWA	O
killifish	O
.	O

Determinants	O
of	O
recurrent	O
ischaemia	O
and	O
revascularisation	O
procedures	O
after	O
thrombolysis	O
with	O
recombinant	O
tissue	B
plasminogen	I
activator	I
in	O
primary	O
coronary	O
occlusion	O
.	O

Bronchial	O
mucosa	O
tattooing	O
in	O
persons	O
exposed	O
to	O
different	O
industrial	O
aerosols	O
did	O
not	O
depend	O
on	O
the	O
forms	O
of	O
PC	O
,	O
DB	O
and	O
the	O
diseases	O
'	O
stages	O
.	O

Lipoprotein	B
lipase	I
(	O
LPL	B
)	O
,	O
a	O
key	O
enzyme	O
in	O
normal	O
lipoprotein	O
metabolism	O
,	O
has	O
a	O
complex	O
pattern	O
of	O
regulation	O
and	O
tissue	O
-	O
specific	O
expression	O
.	O

Comparison	O
of	O
the	O
cDNA	O
-	O
predicted	O
avian	B
TnIcardiac	I
amino	I
acid	I
sequences	I
with	O
known	O
TnI	B
sequences	I
indicated	O
1	O
)	O
that	O
the	O
presence	O
of	O
an	O
N	O
-	O
terminal	O
extension	O
sequence	O
carrying	O
a	O
dual	O
protein	B
kinase	I
A	I
phosphorylation	O
target	O
site	O
and	O
an	O
adjacent	O
proline	O
-	O
rich	O
segment	O
is	O
an	O
ancient	O
cardiac	O
-	O
specific	O
feature	O
of	O
TnI	B
which	O
has	O
been	O
conserved	O
since	O
the	O
bird	O
/	O
mammal	O
divergence	O
,	O
2	O
)	O
that	O
features	O
of	O
the	O
near	O
-	O
N	O
-	O
terminal	O
troponin	B
C	I
(	O
TnC	B
)	O
-binding	O
site	O
sequence	O
suggest	O
isoform	O
-	O
specific	O
adaptation	O
of	O
TnI	B
and	O
TnC	B
,	O
and	O
3	O
)	O
that	O
the	O
avian	O
TnIcardiac	B
internal	O
actin	B
/	I
TnC	I
-	I
binding	I
,	I
actomyosin	I
-	I
inhibitory	I
,	I
domain	I
shows	O
significant	O
sequence	O
divergence	O
from	O
mammalian	B
TnIcardiac	I
sequences	I
,	O
including	O
the	O
absence	O
of	O
a	O
protein	B
kinase	I
C	I
target	O
site	O
which	O
is	O
a	O
cardiac	O
-	O
specific	O
feature	O
of	O
TnI	B
in	O
mammals	O
.	O

It	O
was	O
found	O
that	O
the	O
ROSP	O
undergoes	O
a	O
number	O
of	O
fluctuations	O
in	O
the	O
negative	O
and	O
positive	O
directions	O
with	O
a	O
gradually	O
decreasing	O
amplitude	O
in	O
the	O
course	O
of	O
5	O
-	O
25	O
days	O
following	O
the	O
operation	O
,	O
after	O
which	O
relatively	O
stable	O
negative	O
values	O
of	O
the	O
ROSP	O
are	O
established	O
on	O
the	O
average	O
in	O
electrodes	O
implanted	O
to	O
the	O
level	O
of	O
the	O
dura	O
mater	O
,	O
and	O
positive	O
values	O
in	O
electrodes	O
implanted	O
to	O
the	O
level	O
of	O
the	O
pia	O
mater	O
.	O

Blood	O
flow	O
velocity	O
waveforms	O
were	O
recorded	O
by	O
pulsed	O
Doppler	O
examination	O
of	O
the	O
fetal	O
internal	O
carotid	O
and	O
middle	O
cerebral	O
arteries	O
using	O
the	O
established	O
transabdominal	O
route	O
as	O
well	O
as	O
a	O
new	O
transvaginal	O
approach	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
the	O
animals	O
were	O
randomized	O
to	O
subretinal	O
treatment	O
with	O
2.5	O
micrograms	O
of	O
tissue	B
plasminogen	I
activator	I
or	O
a	O
similar	O
volume	O
of	O
physiologic	O
saline	O
.	O

Evaluation	O
of	O
antiepileptic	O
drug	O
effect	O
on	O
membrane	O
fluidity	O
.	O

We	O
conclude	O
that	O
solidification	O
could	O
occur	O
in	O
all	O
feeds	O
containing	O
casein	B
and	O
that	O
alternative	O
feeds	O
should	O
be	O
considered	O
in	O
patients	O
with	O
increased	O
gastric	O
acidity	O
.	O

Determination	O
of	O
an	O
RNA	O
structure	O
involved	O
in	O
splicing	O
inhibition	O
of	O
a	O
muscle	O
-	O
specific	O
exon	O
.	O

The	O
antihypertensive	O
effect	O
of	O
Estulic	O
has	O
been	O
examined	O
over	O
a	O
12-month	O
period	O
in	O
101	O
hypertensive	O
patients	O
.	O

Monitoring	O
patients	O
with	O
acute	O
leukemia	O
for	O
IL-1	B
and	O
TNF	B
levels	O
throughout	O
the	O
clinical	O
course	O
of	O
disease	O
may	O
help	O
clarify	O
the	O
causes	O
of	O
febrile	O
episodes	O
.	O

The	O
1489-base	O
pair	O
EFIA	B
cDNA	O
encodes	O
a	O
322-amino	O
acid	O
protein	O
which	O
is	O
nearly	O
identical	O
to	O
two	O
previously	O
described	O
human	O
DNA	O
binding	O
proteins	O
.	O

Translational	O
fusions	O
of	O
the	O
aroF	B
regulatory	I
regions	I
to	O
lacZ	B
were	O
constructed	O
and	O
then	O
introduced	O
in	O
single	O
copy	O
into	O
the	O
E.	O
coli	O
chromosome	O
.	O

beta	B
-	I
Galactosidase	I
assays	O
for	O
tyrR	O
-	O
mediated	O
regulation	O
of	O
aroF	B
-	O
lacZ	B
expression	O
revealed	O
that	O
the	O
E.	B
coli	I
TyrR	I
repressor	I
apparently	O
recognizes	O
the	O
operators	O
of	O
both	O
organisms	O
with	O
about	O
equal	O
efficiency	O
.	O

We	O
reviewed	O
the	O
records	O
of	O
151	O
patients	O
with	O
optic	O
neuritis	O
examined	O
over	O
an	O
eight	O
-	O
year	O
period	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
contains	O
three	O
binding	O
sites	O
for	O
the	O
transcriptional	O
factor	O
Sp1	B
.	O

Differences	O
in	O
the	O
clinical	O
presentation	O
and	O
the	O
gross	O
appearance	O
of	O
the	O
two	O
cases	O
are	O
described	O
,	O
and	O
similarities	O
in	O
the	O
microscopic	O
features	O
are	O
discussed	O
.	O

Using	O
an	O
ELISA	O
,	O
we	O
found	O
that	O
surfactant	B
protein	I
A	I
(	O
SP	B
-	I
A	I
)	O
was	O
markedly	O
elevated	O
in	O
the	O
pneumonia	O
patients	O
.	O

The	O
prevalence	O
of	O
opportunistic	O
infection	O
among	O
surviving	O
AIDS	O
patients	O
and	O
the	O
probability	O
of	O
being	O
in	O
tumour	O
response	O
following	O
cancer	O
therapy	O
conditional	O
on	O
being	O
alive	O
are	O
two	O
examples	O
of	O
such	O
functions	O
.	O

To	O
test	O
promotor	O
function	O
,	O
chimeric	O
genes	O
were	O
constructed	O
linking	O
fragments	O
of	O
chicken	O
IGF	B
-	I
I	I
5'-flanking	O
DNA	O
to	O
a	O
promoterless	O
reporter	O
plasmid	O
.	O

The	O
alpha	B
4	I
gene	I
5	O
'	O
flanking	O
region	O
acted	O
as	O
a	O
promoter	O
in	O
transfection	O
assays	O
.	O

Characterization	O
of	O
the	O
alpha	B
4	I
integrin	I
gene	I
promoter	I
.	O

In	O
contrast	O
,	O
similar	O
rates	O
of	O
B.	O
sphaericus	O
products	O
,	O
ABG-6184	O
technical	O
powder	O
and	O
BSP-2	O
flowable	O
concentrate	O
,	O
produced	O
no	O
significant	O
reduction	O
.	O

Some	O
of	O
the	O
PCR	O
products	O
contained	O
mutations	O
in	O
ATG1	B
and/or	O
ATG2	B
.	O

An	O
RME1-independent	B
pathway	O
for	O
sporulation	O
control	O
in	O
Saccharomyces	O
cerevisiae	O
acts	O
through	O
IME1	B
transcript	I
accumulation	O
.	O

Its	O
application	O
in	O
Madagascar	O
:	O
advantages	O
and	O
disadvantages	O

ARPIA	O
has	O
been	O
implemented	O
by	O
using	O
a	O
relational	O
DBMS	O
,	O
very	O
cheap	O
and	O
highly	O
diffused	O
on	O
personal	O
computers	O
.	O

Immuno	O
-	O
cytochemistry	O
,	O
using	O
antisera	O
against	O
Campylobacter	O
jejuni	O
,	O
showed	O
that	O
the	O
positive	O
staining	O
in	O
altered	O
epithelial	O
cells	O
were	O
restricted	O
to	O
intracellular	O
organisms	O
having	O
a	O
structure	O
resembling	O
Campylobacter	O
spp	O
.	O

We	O
also	O
discovered	O
a	O
V	B
lambda	I
pseudogene	I
,	O
called	O
psi	B
V	I
lambda	I
1	I
,	O
3	O
kb	O
upstream	O
of	O
the	O
U266	B
lambda	I
gene	I
.	O

Like	O
other	O
members	O
of	O
this	O
family	O
,	O
the	O
AP-4	B
HLH	O
motif	O
and	O
the	O
adjacent	O
basic	O
domain	O
are	O
necessary	O
and	O
sufficient	O
to	O
confer	O
site	O
-	O
specific	O
DNA	O
binding	O
.	O

A	O
bacteriological	O
relapse	O
requiring	O
treatment	O
occurred	O
by	O
5	O
years	O
in	O
16.8	O
%	O
of	O
113	O
R3	O
,	O
5.2	O
%	O
of	O
97	O
R5	O
,	O
and	O
20.0	O
%	O
of	O
115	O
Z5	O
patients	O
with	O
organisms	O
sensitive	O
to	O
streptomycin	O
and	O
isoniazid	O
initially	O
.	O

Northern	O
blot	O
analysis	O
indicates	O
that	O
AHA2	B
mRNA	I
relative	O
to	O
total	O
cellular	O
RNA	O
is	O
expressed	O
at	O
significantly	O
higher	O
levels	O
in	O
root	O
tissue	O
as	O
compared	O
with	O
shoot	O
tissue	O
.	O

A	O
4.8-kilobase	O
BamHI	B
-	O
HindIII	B
fragment	O
encoding	O
the	O
entire	B
Neurospora	I
crassa	I
CuZn	I
superoxide	I
dismutase	I
gene	I
(	O
herein	O
designated	O
sod-1	B
)	O
was	O
isolated	O
from	O
a	O
genomic	O
library	O
using	O
two	O
60-base	O
deoxyoligonucleotide	O
probes	O
corresponding	O
to	O
the	O
published	O
N.	O
crassa	O
amino	O
acid	O
sequence	O
.	O

The	O
nmr	B
gene	I
is	O
the	O
major	O
negative	O
regulatory	O
gene	O
in	O
the	O
nitrogen	O
control	O
circuit	O
of	O
Neurospora	O
crassa	O
,	O
which	O
,	O
together	O
with	O
positive	O
regulatory	O
genes	O
,	O
governs	O
the	O
expression	O
of	O
multiple	O
unlinked	O
structural	O
genes	O
of	O
the	O
circuit	O
.	O

This	O
result	O
indicates	O
that	O
separate	O
complexes	O
exist	O
containing	O
ankyrin	B
and	O
fodrin	B
with	O
either	O
uvomorulin	B
or	O
Na+,K+-ATPase	B
.	O

It	O
is	O
the	O
human	O
homolog	O
of	O
the	O
mouse	B
Mx	I
protein	I
involved	O
in	O
resistance	O
to	O
influenza	O
virus	O
.	O

Summers	O
,	O
Virology	O
89:517	O
-	O
527	O
,	O
1978	O
)	O
.	O

Various	O
mutant	B
HN	I
genes	I
were	O
constructed	O
to	O
examine	O
the	O
role	O
of	O
residues	O
flanking	O
the	O
signal	O
-	O
anchor	O
domain	O
,	O
including	O
the	O
cytoplasmic	O
tail	O
,	O
on	O
assembly	O
and	O
intracellular	O
transport	O
of	O
the	O
HN	B
glycoprotein	I
.	O

A	O
DNA	O
motif	O
related	O
to	O
the	O
cAMP	O
-	O
responsive	O
element	O
and	O
an	O
exon	B
-	I
located	I
activator	I
protein-2	I
binding	I
site	I
in	O
the	O
human	B
tissue	I
-	I
type	I
plasminogen	I
activator	I
gene	I
promoter	I
cooperate	O
in	O
basal	O
expression	O
and	O
convey	O
activation	O
by	O
phorbol	O
ester	O
and	O
cAMP	O
.	O

The	O
recombinant	O
contains	O
the	O
normal	O
beta	B
A	I
-	I
globin	I
gene	I
,	O
the	O
mutant	O
gene	O
and	O
Ylp	O
vector	O
sequences	O
between	O
the	O
two	O
copies	O
.	O

Some	O
of	O
the	O
mutations	O
obtained	O
do	O
not	O
contain	O
a	O
copy	O
of	O
the	O
Ulysses	B
element	I
at	O
the	O
mutant	O
locus	O
,	O
suggesting	O
that	O
a	O
different	O
transposable	O
element	O
may	O
be	O
responsible	O
for	O
the	O
mutation	O
.	O

Kinetic	O
experiments	O
revealed	O
that	O
within	O
10	O
min	O
this	O
radiolabeled	O
precursor	O
protein	O
was	O
converted	O
in	O
HL-60	O
cells	O
into	O
an	O
Mr	O
approximately	O
150,000	O
chondroitin	O
sulfate	O
proteoglycan	O
intermediate	O
.	O

The	O
Saccharomyces	B
cerevisiae	I
14DM	I
gene	I
,	O
encoding	O
cytochrome	B
P450	I
lanosterol	I
14	I
alpha	I
-	I
demethylase	I
(	O
14DM	B
)	O
,	O
was	O
overexpressed	O
in	O
various	O
S.	O
cerevisiae	O
strains	O
under	O
the	O
control	O
of	O
three	O
strong	O
heterologous	O
yeast	O
transcription	O
promoters	O
(	O
pADC1	B
,	O
pGPD	B
,	O
pPHO5	B
)	O
and	O
under	O
the	O
control	O
of	O
its	O
own	O
promoter	O
.	O

Serum	B
beta	I
2-microglobulin	I
levels	O
(	O
beta-2-M	B
)	O
were	O
studied	O
in	O
150	O
drug	O
addicts	O
,	O
50	O
of	O
them	O
asymptomatic	O
carriers	O
of	O
anti	B
HIV-1	I
antibodies	I
,	O
50	O
symptomatic	O
carriers	O
with	O
persistent	O
generalized	O
lymphadenopathy	O
(	O
P.G.L.	O
)	O
and	O
50	O
serum	O
negative	O
patients	O
who	O
had	O
been	O
living	O
in	O
a	O
closed	O
community	O
for	O
at	O
least	O
2	O
years	O
.	O

This	O
emancipation	O
of	O
the	O
ability	O
to	O
copulate	O
from	O
hormonal	O
influence	O
makes	O
female	O
sexual	O
motivation	O
the	O
primary	O
regulator	O
of	O
mating	O
in	O
primates	O
.	O

Analysis	O
of	O
various	O
deletion	O
mutants	O
indicates	O
that	O
the	O
sequence	O
requirements	O
for	O
binding	O
by	O
QBP	B
in	O
vitro	O
are	O
indistinguishable	O
from	O
those	O
necessary	O
for	O
Q	O
activity	O
in	O
vivo	O
,	O
strongly	O
suggesting	O
that	O
QBP	B
is	O
required	O
for	O
the	O
function	O
of	O
this	O
TATA	O
-	O
independent	O
promoter	O
.	O

The	O
two	O
larger	O
peptides	O
,	O
one	O
containing	O
amino	O
acids	O
1	O
-	O
228	O
and	O
the	O
other	O
containing	O
amino	O
acids	O
85	O
-	O
228	O
,	O
formed	O
dimers	O
in	O
solution	O
and	O
bound	O
DNA	O
specifically	O
as	O
a	O
dimer	O
.	O

In	O
vitro	O
transcription	O
extracts	O
from	O
ret1	B
-	I
1	I
cells	O
terminate	O
less	O
efficiently	O
at	O
weak	O
transcription	O
termination	O
signals	O
than	O
those	O
from	O
RET1	B
cells	O
,	O
using	O
a	O
variety	O
of	O
tRNA	O
templates	O
.	O

These	O
latter	O
results	O
showed	O
that	O
the	O
ABFI	B
protein	I
,	O
like	O
the	O
RAP1	B
protein	I
,	O
bound	O
sequences	O
required	O
for	O
positive	O
as	O
well	O
as	O
negative	O
regulation	O
of	O
gene	O
expression	O
.	O

Homozygous	O
protein	B
C	I
(	O
PC	B
)	O
deficiency	O
is	O
reported	O
in	O
two	O
siblings	O
(	O
girl	O
and	O
boy	O
)	O
who	O
received	O
their	O
proper	O
diagnoses	O
at	O
the	O
ages	O
of	O
7	O
4	O
/	O
12	O
and	O
1	O
3	O
/	O
12	O
years	O
respectively	O
.	O

Horseradish	B
peroxidase	I
as	O
a	O
permeability	O
marker	O
in	O
injured	O
rat	O
caudal	O
and	O
iliac	O
arteries	O
.	O

The	O
effects	O
of	O
coenzyme	O
Q10	O
(	O
CoQ	O
)	O
and	O
captopril	O
on	O
functional	O
capacity	O
,	O
hemodynamics	O
and	O
survival	O
were	O
studied	O
in	O
154	O
rats	O
that	O
recovered	O
after	O
experimental	O
myocardial	O
infarction	O
.	O

Some	O
mutations	O
affected	O
Dhfr	B
in	O
a	O
qualitative	O
manner	O
,	O
such	O
as	O
by	O
changing	O
the	O
startpoint	O
of	O
one	O
of	O
the	O
major	O
Dhfr	B
transcripts	I
or	O
changing	O
the	O
relative	O
abundance	O
of	O
the	O
two	O
major	O
Dhfr	B
transcripts	I
.	O

Modification	O
by	O
this	O
latter	O
compound	O
was	O
so	O
extensive	O
that	O
the	O
amount	O
of	O
membrane	O
-	O
associated	O
N	O
-	O
myristoylated	O
protein	O
was	O
decreased	O
.	O

Expression	O
of	O
the	O
human	O
T	B
cell	I
receptor	I
(	I
TCR	I
)	I
alpha	I
gene	I
is	O
regulated	O
by	O
a	O
T	O
cell	O
-	O
specific	O
transcriptional	O
enhancer	O
that	O
is	O
located	O
4.5	O
kilobases	O
(	O
kb	O
)	O
3	O
'	O
to	O
the	O
C	B
alpha	I
gene	I
segment	I
.	O

Cerebral	O
flow	O
and	O
resistance	O
showed	O
minor	O
reductions	O
with	O
HD	O
.	O

Auditory	O
-	O
visual	O
interaction	O
in	O
the	O
generation	O
of	O
saccades	O
in	O
man	O
.	O

The	O
upstream	O
promoter	O
is	O
located	O
within	O
the	O
coding	O
sequence	O
of	O
a	O
divergent	O
gene	O
expressing	O
a	O
protein	O
of	O
Mr	O
39	O
kDa	O
of	O
unknown	O
function	O
.	O

Coenzyme	O
Q10	O
:	O
blood	O
levels	O
and	O
metabolic	O
demand	O
.	O

Serum	O
Fibrin	B
Degradation	I
Products	I
(	O
FDP	B
)	O
were	O
determined	O
in	O
50	O
oral	O
cancer	O
patients	O
and	O
50	O
normal	O
individuals	O
prior	O
to	O
any	O
kind	O
of	O
treatment	O
.	O

Staining	O
with	O
IF	O
MoAB	O
alone	O
of	O
BAL	O
fluid	O
only	O
seemed	O
to	O
be	O
even	O
more	O
sensitive	O
than	O
silver	O
methenamine	O
staining	O
of	O
BAL	O
,	O
TBB	O
and	O
brushing	O
material	O
.	O

By	O
introducing	O
a	O
series	O
of	O
deletions	O
in	O
the	O
vimentin	B
promoter	O
,	O
we	O
further	O
restrict	O
these	O
sequences	O
to	O
30	O
base	O
pairs	O
,	O
located	O
between	O
241	O
and	O
210	O
base	O
pairs	O
upstream	O
of	O
the	O
mRNA	O
cap	O
site	O
.	O

The	O
beta	O
chain	O
contains	O
five	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
and	O
endoglycosidase	B
digestion	O
suggested	O
that	O
the	O
beta	O
chain	O
contained	O
multiple	O
complex	O
carbohydrate	O
side	O
chains	O
.	O

Thyrotropin	B
-	O
induced	O
expression	O
of	O
a	O
gene	O
for	O
a	O
ribosomal	B
protein	I
related	O
to	O
the	O
trk	B
oncogene	I
.	O

The	O
BAL	O
-	O
to	O
-	O
plasma	O
specific	O
activity	O
of	O
urea	O
was	O
about	O
twice	O
that	O
of	O
Na+	O
,	O
indicating	O
that	O
urea	O
diffused	O
into	O
the	O
ELF	O
more	O
rapidly	O
than	O
Na+	O
during	O
the	O
70	O
s	O
that	O
elapsed	O
between	O
the	O
time	O
the	O
radioactive	O
urea	O
and	O
Na+	O
were	O
injected	O
into	O
the	O
circulation	O
and	O
the	O
time	O
when	O
lavage	O
was	O
complete	O
.	O

Intron	O
1	O
is	O
6.5	O
kb	O
long	O
,	O
and	O
the	O
minimal	O
sizes	O
of	O
introns	O
2	O
and	O
3	O
are	O
estimated	O
to	O
be	O
32	O
kb	O
each	O
.	O

Approximately	O
65	O
%	O
of	O
the	O
total	O
cAMP	B
-	I
dependent	I
phosphotransferase	I
activity	O
is	O
recovered	O
in	O
particulate	O
fractions	O
of	O
homogenates	O
prepared	O
from	O
asynchronous	O
populations	O
of	O
C.	O
elegans	O
.	O

High	O
levels	O
of	O
C	B
subunits	I
are	O
observed	O
in	O
several	O
subsequent	O
larval	O
and	O
adult	O
stages	O
of	O
development	O
.	O

French	O
,	O
M.	O

There	O
was	O
a	O
gradual	O
increase	O
in	O
the	O
myocyte	O
diameter	O
according	O
to	O
age	O
in	O
the	O
biopsy	O
and	O
autopsy	O
specimens	O
.	O

Despite	O
the	O
absence	O
of	O
exercise	O
-	O
induced	O
asthma	O
(	O
EIA	O
)	O
while	O
breathing	O
WH	O
air	O
,	O
asthmatic	O
patients	O
still	O
had	O
significantly	O
higher	O
mean	O
GH	O
increments	O
than	O
normal	O
subjects	O
(	O
9.2	O
vs	O
2.3	O
ng	O
/	O
ml	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Sequence	O
analysis	O
of	O
these	O
genes	O
and	O
their	O
surrounding	O
sequences	O
are	O
presented	O
and	O
compared	O
with	O
other	O
known	O
tRNA	O
genes	O
from	O
plant	O
mitochondria	O
.	O

Basing	O
on	O
experimental	O
toxicity	O
research	O
it	O
was	O
established	O
that	O
,	O
out	O
of	O
50	O
atmosphere	O
metal	O
corrosion	O
inhibitors	O
,	O
some	O
14	O
per	O
cent	O
were	O
found	O
extremely	O
hazardous	O
,	O
42	O
per	O
cent	O
--	O
of	O
high	O
level	O
hazardous	O
,	O
33	O
percent	O
--	O
of	O
moderate	O
and	O
11	O
per	O
cent	O
--	O
of	O
low	O
hazardous	O
.	O

Changes	O
in	O
prognosis	O
of	O
twin	O
births	O
over	O
20	O
years	O
.	O

In	O
contrast	O
,	O
2,397	O
(	O
74	O
%	O
)	O
had	O
one	O
or	O
more	O
risk	O
factors	O
(	O
not	O
low	O
risk	O
)	O
;	O
of	O
these	O
,	O
5.3	O
%	O
died	O
in	O
6	O
weeks	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
6	O
of	O
24	O
infants	O
studied	O
(	O
27th-40th	O
weeks	O
of	O
gestation	O
)	O
,	O
acquired	O
and	O
congenital	O
structural	O
anomalies	O
of	O
the	O
airways	O
were	O
detected	O
with	O
an	O
ultrathin	O
flexible	O
fiberscope	O
(	O
Olympus	O
PF18	O
S	O
,	O
1.8	O
mm	O
)	O
.	O

Sprague	O
-	O
Dawley	O
newborn	O
rats	O
(	O
n	O
=	O
85	O
)	O
breathed	O
100	O
%	O
oxygen	O
(	O
O2	O
)	O
or	O
room	O
air	O
(	O
RA	O
)	O
during	O
the	O
first	O
8	O
days	O
of	O
life	O
,	O
and	O
then	O
RA	O
.	O

The	O
Lm	O
increased	O
and	O
the	O
alveoli	O
/	O
mm2	O
and	O
elastic	O
recoil	O
pressure	O
decreased	O
.	O

Thus	O
,	O
this	O
reading	O
frame	O
was	O
concluded	O
to	O
encode	O
the	O
precursor	O
of	O
mitochondrial	B
fumarase	I
.	O

Role	O
of	O
superoxide	B
dismutase	I
in	O
cellular	O
oxidative	O
processes	O
and	O
method	O
of	O
its	O
determination	O
in	O
biological	O
materials	O

A.	O

The	O
levels	O
of	O
both	O
MAP1-specific	B
and	I
MAP2-specific	I
mRNAs	I
decline	O
in	O
the	O
postnatal	O
developing	O
brain	O
;	O
the	O
level	O
of	O
MAP1-specific	B
mRNA	I
also	O
increases	O
slightly	O
in	O
rat	O
PC12	O
cells	O
upon	O
exposure	O
to	O
nerve	B
growth	I
factor	I
.	O

Prognosis	O
of	O
asymptomatic	O
multiple	O
myeloma	O
.	O

The	O
size	O
discrepancy	O
is	O
not	O
due	O
to	O
glycosylation	O
or	O
phosphorylation	O
of	O
Ag35	B
but	O
may	O
result	O
from	O
a	O
proline	O
-	O
rich	O
sequence	O
which	O
occurs	O
in	O
this	O
polypeptide	O
.	O

Serum	O
prostatic	B
acid	I
phosphatase	I
levels	O
showed	O
a	O
significantly	O
weaker	O
correlation	O
with	O
cancer	O
volume	O
(	O
r	O
equals	O
0.51	O
)	O
and	O
every	O
other	O
pathological	O
parameter	O
.	O

Their	O
studies	O
have	O
revealed	O
a	O
considerable	O
increase	O
of	O
CSF	B
AP	I
activity	O
in	O
purulent	O
meningitides	O
whereas	O
in	O
serous	O
meningitides	O
it	O
grows	O
negligibly	O
.	O

Dopamine	O
caused	O
a	O
prominent	O
potassium	O
efflux	O
measured	O
as	O
86Rb+	O
efflux	O
from	O
control	O
glands	O
,	O
but	O
was	O
without	O
effect	O
in	O
denervated	O
glands	O
.	O

The	O
ratio	O
of	O
radioactivity	O
in	O
tumour	O
compared	O
with	O
normal	O
tissue	O
(	O
T	O
:	O
N	O
ratio	O
)	O
was	O
determined	O
after	O
simultaneously	O
injecting	O
microspheres	O
into	O
the	O
portal	O
and	O
arterial	O
circulation	O
of	O
each	O
animal	O
.	O

The	O
mRNA	O
was	O
converted	O
to	O
cDNA	O
and	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
.	O

Cotransfection	O
of	O
either	O
construct	O
with	O
plasmids	O
encoding	O
PKI	B
(	I
1	I
-	I
31	I
)	I
inhibits	O
cAMP	O
-	O
stimulated	O
but	O
not	O
basal-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
expression	O
.	O

Structural	O
organization	O
and	O
expression	O
of	O
the	O
mouse	B
estrogen	I
receptor	I
.	O

Muscle	O
action	O
potential	O
and	O
masticatory	O
rhythm	O
of	O
anterior	O
temporal	O
and	O
masseter	O
muscles	O
in	O
children	O
and	O
adults	O

Growth	O
of	O
tracheal	O
anastomoses	O
in	O
growing	O
animals	O

The	O
other	O
patients	O
continued	O
the	O
trial	O
with	O
single	O
daily	O
doses	O
of	O
monotherapy	O
.	O

Using	O
mutated	B
IL2R	I
alpha	I
promoter	I
constructs	I
in	O
transient	O
transfection	O
and	O
DNA	O
binding	O
assays	O
,	O
we	O
now	O
demonstrate	O
that	O
sequences	O
located	O
immediately	O
upstream	O
and	O
downstream	O
of	O
the	O
kappa	B
B	I
enhancer	I
also	O
contribute	O
to	O
the	O
regulation	O
of	O
IL2R	B
alpha	I
gene	I
expression	O
.	O

The	O
overall	O
prevalence	O
of	O
HBV	O
markers	O
was	O
higher	O
among	O
staff	O
members	O
than	O
in	O
the	O
blood	O
donors	O
of	O
our	O
area	O
.	O

Plasma	O
concentrations	O
of	O
ANF	B
(	O
pANF	B
)	O
,	O
aldosterone	O
(	O
PAC	O
)	O
and	O
renin	B
(	O
PRC	B
)	O
were	O
measured	O
daily	O
,	O
as	O
were	O
hemodynamic	O
parameters	O
.	O

Administration	O
of	O
dexamethasone	O
was	O
associated	O
with	O
progressive	O
rises	O
in	O
plasma	O
17	O
alpha	O
OH	O
progesterone	O
,	O
11	O
beta	O
-	O
desoxycortisol	O
,	O
DHEA	O
sulphate	O
,	O
androstenedione	O
and	O
testosterone	O
,	O
together	O
with	O
increased	O
urinary	O
excretion	O
of	O
androsterone	O
,	O
11	O
beta	O
OH	O
androsterone	O
,	O
etiocholanolone	O
,	O
DHEA	O
,	O
and	O
16	O
alpha	O
OH	O
DHEA	O
.	O

In	O
HeLa	O
cells	O
,	O
it	O
activated	O
transcription	O
from	O
the	O
herpes	B
simplex	I
virus	I
type	I
1	I
thymidine	I
kinase	I
promoter	I
linked	O
to	O
the	O
chloramphenicol	B
acetyltransferase	I
gene	I
when	O
located	O
in	O
inverted	O
orientation	O
upstream	O
of	O
the	O
thymidine	B
kinase	I
promoter	I
or	O
downstream	O
of	O
the	O
chloramphenicol	B
acetyltransferase	I
gene	I
coding	I
sequence	I
.	O

The	O
mustard	B
chloroplast	I
gene	I
rps16	I
is	O
split	O
by	O
an	O
887	O
bp	O
group	O
II	O
(	O
or	O
III	O
)	O
intron	O
.	O

A	O
brief	O
account	O
of	O
the	O
1988	O
seminar	O
in	O
Shanghai	O
on	O
viral	O
hepatitis	O
A	O

Restriction	O
maps	O
of	O
the	O
cloned	O
plasmids	O
revealed	O
that	O
their	O
chromosomal	O
inserts	O
consisted	O
of	O
overlapping	O
fragments	O
.	O

Insert2	O
contains	O
repetitive	O
non	O
-	O
Ig	B
-	O
related	O
sequences	O
and	O
a	O
small	B
Ig	I
-	I
related	I
sequence	I
.	O

In	O
patients	O
resistant	O
to	O
VAD	O
,	O
high	O
-	O
dose	O
therapies	O
with	O
intravenous	O
melphalan	O
,	O
a	O
CBV	O
combination	O
(	O
cyclophosphamide	O
-	O
BCNU	O
-	O
VP-16	O
)	O
or	O
an	O
EDAP	O
regimen	O
(	O
VP-16	O
-platinum	O
)	O
produced	O
responses	O
in	O
about	O
40	O
%	O
of	O
patients	O
.	O

Most	O
of	O
them	O
were	O
situated	O
at	O
Sylvius	O
fissure	O
(	O
13	O
cases	O
)	O
.	O

Specifically	O
,	O
they	O
were	O
performed	O
to	O
determine	O
whether	O
detection	O
of	O
envelope	O
phase	O
disparity	O
was	O
consistent	O
with	O
processing	O
within	O
a	O
single	O
channel	O
in	O
which	O
the	O
AM	O
tones	O
were	O
simply	O
added	O
.	O

Gel	O
retardation	O
assays	O
combined	O
with	O
DNase	B
I	I
footprinting	O
and	O
diethyl	O
pyrocarbonate	O
interference	O
showed	O
that	O
a	O
nuclear	O
factor	O
from	O
differentiated	O
C2	O
myotubes	O
and	O
BC3H1	O
myocytes	O
recognized	O
a	O
conserved	O
A	O
+	O
T	O
-	O
rich	O
sequence	O
within	O
the	O
peripheral	O
activating	O
region	O
.	O

No	O
changes	O
were	O
evident	O
in	O
the	O
FR	O
-	O
task	O
performance	O
of	O
controls	O
that	O
received	O
daily	O
saline	O
injections	O
.	O

Collaborative	O
study	O
of	O
Japanese	O
Pharmacopoeia	O
Heparin	O
Sodium	O
Reference	O
Standard	O

In	O
Rat-1a	O
cells	O
the	O
expression	O
of	O
human	B
c	I
-	I
jun	I
mRNA	I
was	O
associated	O
with	O
the	O
ability	O
to	O
clone	O
in	O
soft	O
agarose	O
and	O
form	O
tumors	O
in	O
nude	O
mice	O
.	O

Furthermore	O
,	O
formation	O
of	O
foci	O
of	O
transformed	O
RECs	O
by	O
the	O
c	B
-	I
jun	I
/	O
ras	B
combination	O
was	O
augmented	O
3-fold	O
by	O
the	O
tumor	O
promoter	O
phorbol	O
12-tetradecanoate	O
13-acetate	O
.	O

US	O
-	O
Doppler	O
has	O
recently	O
gained	O
attention	O
as	O
a	O
noninvasive	O
method	O
for	O
the	O
functional	O
evaluation	O
of	O
arteriovenous	O
fistulas	O
(	O
FAV	O
)	O
.	O

Doppler	O
echo	O
in	O
evaluating	O
arteriovenous	O
fistulae	O
for	O
dialysis	O

Improved	O
cosmesis	O
,	O
extension	O
of	O
the	O
scope	O
of	O
the	O
problems	O
that	O
can	O
be	O
addressed	O
with	O
this	O
repair	O
(	O
including	O
treatment	O
of	O
a	O
distal	O
urethrocutaneous	O
fistula	O
)	O
and	O
the	O
ease	O
with	O
which	O
the	O
Arap	O
procedure	O
can	O
be	O
performed	O
are	O
the	O
advantages	O
that	O
this	O
operation	O
has	O
over	O
other	O
1-stage	O
distal	O
hypospadias	O
repairs	O
.	O

Following	O
the	O
patients	O
during	O
a	O
course	O
of	O
therapy	O
with	O
a	O
selective	O
vasodilator	O
calcium	O
antagonist	O
,	O
the	O
beta	O
-	O
adrenergic	O
reflex	O
vasodilation	O
became	O
substantially	O
attenuated	O
but	O
was	O
preserved	O
during	O
a	O
placebo	O
course	O
of	O
therapy	O
.	O

Psychiatry	O
and	O
the	O
skin	O
.	O

The	O
present	O
data	O
also	O
suggest	O
that	O
when	O
compared	O
to	O
the	O
systemic	O
vascular	O
bed	O
,	O
the	O
pulmonary	O
vascular	O
bed	O
is	O
less	O
responsive	O
to	O
bolus	O
administration	O
of	O
ET-1	B
.	O

A	O
significant	O
relationship	O
existed	O
during	O
the	O
evolution	O
of	O
the	O
disease	O
between	O
CRS	O
/	O
BW	O
and	O
gas	O
exchange	O
parameters	O
(	O
FIO2	O
and	O
a	O
/	O
AO2	O
ratio	O
)	O
(	O
P	O
less	O
than	O
0.01	O
)	O
,	O
but	O
gas	O
exchange	O
improved	O
earlier	O
than	O
lung	O
mechanics	O
.	O

The	O
predicted	O
molecular	O
weight	O
of	O
the	O
polyprotein	O
encoded	O
by	O
ORF1	O
is	O
33	O
kilodaltons	O
(	O
kDa	O
)	O
.	O

Allelic	O
variation	O
in	O
HLA	B
-	I
B	I
and	O
HLA	B
-	I
C	I
sequences	I
and	O
the	O
evolution	O
of	O
the	O
HLA	B
-	I
B	I
alleles	I
.	O

Similarly	O
,	O
the	O
sequence	O
of	O
the	O
U2	B
RNA	I
region	I
shown	O
to	O
be	O
involved	O
in	O
pre	O
-	O
mRNA	O
branchpoint	O
recognition	O
in	O
yeast	O
,	O
and	O
exactly	O
conserved	O
in	O
metazoan	B
U2	I
RNAs	I
,	O
was	O
totally	O
divergent	O
in	O
trypanosomes	O
.	O

A	O
raised	O
amplitude	O
of	O
the	O
aggregation	O
of	O
plates	O
and	O
a	O
decrease	O
in	O
the	O
threshold	O
of	O
their	O
sensitivity	O
to	O
ADP	O
were	O
established	O
in	O
the	O
persons	O
with	O
types	O
IIa	O
and	O
IIb	O
HLP	O
and	O
in	O
CHD	O
without	O
HLP	O
.	O

Significant	O
intergroup	O
differences	O
are	O
highlighted	O
for	O
both	O
selected	O
dentoskeletal	O
and	O
soft	O
tissue	O
profile	O
variables	O
.	O

Molecular	O
cloning	O
and	O
characterisation	O
of	O
the	O
two	O
homologous	O
genes	O
coding	O
for	O
nitrate	B
reductase	I
in	I
tobacco	I
.	O

COUP	B
transcription	I
factor	I
is	O
a	O
member	O
of	O
the	O
steroid	B
receptor	I
superfamily	I
.	O

Qualitatively	O
,	O
the	O
results	O
are	O
similar	O
for	O
the	O
two	O
species	O
:	O
Both	O
rhesus	O
monkey	O
and	O
man	O
have	O
photopic	O
and	O
scotopic	O
branches	O
,	O
which	O
cross	O
at	O
approximately	O
the	O
same	O
time	O
in	O
the	O
dark	O
and	O
at	O
approximately	O
the	O
same	O
background	O
luminance	O
.	O

Endometrial	O
biopsies	O
and	O
plasma	O
oestradiol	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
P4	O
)	O
levels	O
in	O
23	O
patients	O
were	O
evaluated	O
during	O
26	O
replacement	O
therapy	O
cycles	O
for	O
premature	O
ovarian	O
failure	O
.	O

Behaviorally	O
,	O
a	O
pain	O
-	O
tolerant	O
group	O
(	O
PT	O
=	O
29	O
Ss	O
)	O
tolerated	O
the	O
entire	O
3-min	O
test	O
(	O
means	O
=	O
180	O
+	O
/-	O

0	O
sec	O
)	O
,	O
while	O
a	O
pain	O
-	O
sensitive	O
group	O
(	O
PS	O
=	O
13	O
Ss	O
)	O
averaged	O
only	O
50.31	O
+	O
/-	O

20.81	O
sec	O
of	O
the	O
cold	O
-	O
pressor	O
test	O
(	O
t	O
=	O
16.75	O
,	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
replicating	O
our	O
earlier	O
studies	O
.	O

Initial	O
experience	O
with	O
a	O
microprocessor	O
controlled	O
current	O
based	O
defibrillator	O
.	O

The	O
values	O
were	O
consistently	O
lower	O
(	O
P	O
less	O
than	O
0.01	O
)	O
during	O
summer	O
(	O
3.79	O
+	O
/-	O

0.13	O
micrograms	O
/	O
100	O
ml	O
)	O
,	O
as	O
compared	O
to	O
winter	O
(	O
5.06	O
+	O
/-	O
0.27	O
)	O
.	O

Changes	O
in	O
xanthine	B
oxidase	I
activity	O
in	O
patients	O
with	O
circulatory	O
failure	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
preferentially	O
infects	O
CD4	B
+	I
T	O
lymphocytes	O
and	O
may	O
exist	O
as	O
a	O
latent	O
provirus	O
within	O
these	O
cells	O
for	O
extended	O
periods	O
.	O

The	O
subepicardial	O
lymphatic	O
capillaries	O
were	O
ramified	O
and	O
anastomosed	O
with	O
each	O
other	O
to	O
form	O
a	O
relatively	O
dense	O
network	O
which	O
extended	O
over	O
the	O
entire	O
surface	O
of	O
both	O
ventricles	O
.	O

During	O
sub	O
-	O
maximal	O
exercise	O
,	O
DCR	O
in	O
the	O
UT	O
dogs	O
decreased	O
from	O
a	O
resting	O
value	O
of	O
4.08	O
+	O
/-	O

0.18	O
mm	O
Hg	O
X	O
ml-1	O
X	O
min-1	O
to	O
1.91	O
+	O
/-	O

0.17	O
mm	O
Hg	O
X	O
ml-1	O
X	O
min-1	O
at	O
a	O
workload	O
of	O
6.4	O
kph	O
(	O
speed	O
)	O
/	O
16	O
%	O
(	O
grade	O
)	O
.	O

An	O
analysis	O
of	O
the	O
steady	O
state	O
RNA	O
levels	O
in	O
T	O
-	O
lymphoid	O
cell	O
lines	O
showed	O
that	O
at	O
least	O
three	O
different	O
incomplete	O
proviral	O
transcripts	O
and	O
their	O
spliced	O
products	O
made	O
up	O
the	O
majority	O
of	O
expressed	O
RD-114	B
mRNA	I
,	O
and	O
further	O
demonstrated	O
that	O
partially	O
deleted	O
proviral	O
loci	O
have	O
the	O
potential	O
to	O
be	O
transcriptionally	O
vigorous	O
in	O
certain	O
feline	O
cell	O
types	O
.	O

Sodium	O
dodecyl	O
sulphate	O
-	O
induced	O
cleavage	O
by	O
eukaryotic	B
topoisomerase	I
I	I
is	O
known	O
to	O
yield	O
enzyme	O
covalently	O
attached	O
to	O
the	O
3	O
'	O
cut	O
end	O
of	O
the	O
DNA	O
.	O

RVEF	O
and	O
LVEF	O
both	O
increased	O
by	O
about	O
14	O
%	O
(	O
p	O
less	O
than	O
0.05	O
and	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Quantitative	O
assays	O
in	O
which	O
the	O
activity	O
of	O
the	O
synthetic	B
alpha	I
s-1	I
was	O
compared	O
to	O
that	O
of	O
native	O
purified	O
human	B
erythrocyte	I
type-1	I
Gs	I
,	O
indicated	O
that	O
the	O
two	O
products	O
are	O
equipotent	O
within	O
a	O
2-fold	O
margin	O
of	O
error	O
.	O

Most	O
patients	O
with	O
high	O
blood	O
pressure	O
(	O
BP	O
)	O
can	O
be	O
managed	O
by	O
using	O
one	O
of	O
4	O
classes	O
of	O
compounds	O
:	O
a	O
diuretic	O
,	O
beta	O
blocker	O
,	O
converting	O
enzyme	O
inhibitor	O
or	O
calcium	O
antagonist	O
.	O

Seventy	O
-	O
one	O
supplementary	O
doses	O
of	O
vecuronium	O
were	O
used	O
for	O
muscle	O
relaxation	O
during	O
a	O
22-h	O
-	O
long	O
NLA	O
II	O
anaesthesia	O
.	O

The	O
East	O
African	O
dik	O
-	O
dik	O
antelope	O
represents	O
a	O
miniature	O
model	O
ruminant	O
for	O
comparative	O
studies	O
.	O

2	O
cases	O
of	O
type	O
II	O
tyrosinosis	O
(	O
Richner	O
-	O
Hanhart	O
syndrome	O
)	O

Effects	O
of	O
aging	O
and	O
beta	O
-	O
adrenergic	O
-	O
blockade	O
on	O
standing	O
-	O
induced	O
QT	O
/	O
QS2	O
changes	O
.	O

Hemodynamic	O
assessment	O
was	O
obtained	O
before	O
and	O
following	O
administration	O
of	O
digoxin	O
10	O
micrograms	O
/	O
kg	O
IV	O
or	O
dopamine	O
,	O
5	O
to	O
12	O
micrograms	O
/	O
kg	O
/	O
min	O
IV	O
.	O

For	O
the	O
present	O
work	O
we	O
used	O
water	O
saturated	O
with	O
a	O
50	O
/	O
50	O
mixture	O
of	O
H2	O
and	O
O2	O
gases	O
,	O
for	O
which	O
the	O
heat	O
defect	O
is	O
calculated	O
to	O
be	O
-2.1	O
%	O
.	O

During	O
flexion	O
whiplash	O
,	O
the	O
torque	O
at	O
the	O
occipital	O
condyle	O
reverses	O
its	O
direction	O
at	O
about	O
25	O
ms	O
after	O
impact	O
.	O

Functional	O
flow	O
was	O
evaluated	O
using	O
laser	O
Doppler	O
flowmetry	O
(	O
LDF	O
)	O
,	O
for	O
which	O
the	O
output	O
signal	O
,	O
blood	O
cell	O
flux	O
(	O
BCF	O
)	O
,	O
is	O
expressed	O
in	O
terms	O
of	O
volts	O
.	O

The	O
clinical	O
picture	O
and	O
laboratory	O
parameters	O
were	O
consistent	O
with	O
a	O
serum	O
sickness	O
reaction	O
.	O

The	O
seco	O
-	O
steroid	O
hormone	O
1,25-dihydroxyvitamin	O
D3	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
a	O
calcium	O
binding	O
protein	O
termed	O
calbindin	B
-	I
D28	I
K	I
in	O
a	O
variety	O
of	O
target	O
tissues	O
.	O

In	O
addition	O
,	O
the	O
calbindin	B
-	I
D28	I
K	I
promoter	I
is	O
composed	O
of	O
a	O
variety	O
of	O
simple	O
repeated	O
sequences	O
,	O
some	O
of	O
which	O
are	O
components	O
of	O
putative	O
regulatory	O
signals	O
.	O

Organ	O
transplantation	O
in	O
Denmark	O
.	O

Those	O
dosages	O
that	O
inhibited	O
mean	O
NTE	B
activity	O
in	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
72	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
66	O
%	O
of	O
control	O
values	O
within	O
44	O
hr	O
postexposure	O
produced	O
marked	O
spinal	O
cord	O
pathology	O
14	O
days	O
postexposure	O
in	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
of	O
similarly	O
dosed	O
animals	O
.	O

Thirty	O
of	O
the	O
clones	O
contained	O
a	O
complete	O
340	O
base	O
-	O
pair	O
dimer	O
unit	O
of	O
the	O
repeat	O
.	O

Cattaneo	O
,	O
and	O
J.	O

Next	O
,	O
with	O
carcinoma	O
presenting	O
a	O
leather	O
bottle	O
(	O
linitis	O
plastica	O
type	O
)	O
of	O
the	O
stomach	O
itself	O
,	O
the	O
II	O
c	O
portion	O
of	O
the	O
stomach	O
consisted	O
of	O
fundic	O
glands	O
(	O
undifferentiated	O
carcinoma	O
)	O
shall	O
become	O
the	O
primary	O
focus	O
supporting	O
Nakamura	O
's	O
theory	O
.	O

In	O
the	O
DNAs	O
of	O
all	O
Ph1-positive	O
chronic	O
myelocytic	O
leukemia	O
patients	O
studied	O
to	O
date	O
,	O
a	O
breakpoint	O
on	O
chromosome	O
22	O
(	O
the	O
Ph1	O
chromosome	O
)	O
can	O
be	O
demonstrated	O
with	O
a	O
probe	O
from	O
the	O
bcr	B
(	O
breakpoint	B
cluster	I
region	I
)	O
.	O

The	O
5'-nontranslated	O
sequences	O
and	O
parts	O
of	O
the	O
coding	O
sequences	O
of	O
various	O
yeast	O
genes	O
have	O
been	O
cloned	O
into	O
representative	O
lacZ	B
fusion	O
vectors	O
.	O

It	O
is	O
concluded	O
that	O
suppression	O
of	O
elevated	O
prolactin	B
levels	O
in	O
progressive	O
metastatic	O
breast	O
cancer	O
patients	O
is	O
not	O
effective	O
in	O
restoring	O
tumor	O
sensitivity	O
to	O
chemotherapy	O
.	O

We	O
also	O
found	O
an	O
eIF-4A	B
intronless	O
retroposon	O
which	O
,	O
when	O
compared	O
to	O
the	O
cDNA	O
,	O
contains	O
a	O
single	O
nucleotide	O
difference	O
.	O

In	O
view	O
of	O
these	O
results	O
,	O
simultaneous	O
pancreas	O
-	O
kidney	O
transplantation	O
appears	O
to	O
be	O
the	O
treatment	O
of	O
choice	O
for	O
Type	O
I	O
diabetic	O
patients	O
.	O

Factors	O
influencing	O
the	O
bond	O
strength	O
between	O
glass	O
polyalkenoate	O
(	O
ionomer	O
)	O
cements	O
and	O
dentine	O
.	O

Research	O
on	O
ethylene	O
glycol	O
and	O
diethylene	O
glycol	O
for	O
carcinogenic	O
effects	O

Isolation	O
and	O
characterization	O
of	O
a	O
vinculin	B
cDNA	I
from	I
chick	I
-	I
embryo	I
fibroblasts	I
.	O

A	O
complementary	O
study	O
,	O
showing	O
a	O
good	O
agreement	O
between	O
surface	O
and	O
oesophageal	O
EMGd	O
seems	O
to	O
confirm	O
that	O
surface	O
EMGd	O
is	O
a	O
useful	O
and	O
promising	O
tool	O
for	O
clinical	O
investigation	O
.	O

No	O
differences	O
in	O
fixation	O
quality	O
were	O
observed	O
between	O
cochleas	O
fixed	O
by	O
intravascular	O
perfusion	O
and	O
cochleas	O
fixed	O
by	O
intralabyrinthine	O
perfusion	O
.	O

The	O
requirement	O
of	O
different	O
essential	O
fatty	O
acids	O
in	O
patients	O
with	O
total	O
parenteral	O
nutrition	O
after	O
heavy	O
injury	O
is	O
of	O
special	O
interest	O
with	O
respect	O
to	O
the	O
development	O
and	O
prognosis	O
of	O
shock	O
,	O
sepsis	O
or	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
protein	O
mixtures	O
of	O
sesame	O
flour	O
and	O
soybean	O
flour	O
were	O
well	O
accepted	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
coding	O
region	O
was	O
located	O
precisely	O
by	O
comparing	O
the	O
deduced	O
amino	O
acid	O
sequence	O
to	O
the	O
actual	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
IHF	B
.	O

Conservative	O
treatment	O
of	O
bladder	O
carcinoma	O
by	O
partial	O
cystectomy	O
and	O
interstitial	O
iridium	O
192	O
.	O

Existence	O
and	O
uniqueness	O
of	O
solutions	O
of	O
the	O
appropriate	O
boundary	O
value	O
problems	O
are	O
established	O
,	O
in	O
the	O
case	O
of	O
small	O
permeability	O
coefficients	O
and	O
transport	O
rates	O
,	O
or	O
large	O
diffusion	O
coefficients	O
and	O
small	O
resistance	O
to	O
flow	O
constants	O
.	O

Neuromyelitis	O
optica	O
(	O
Devic	O
's	O
syndrome	O
)	O
:	O
not	O
always	O
multiple	O
sclerosis	O
.	O

None	O
had	O
a	O
past	O
history	O
of	O
opportunistic	O
infections	O
;	O
neither	O
did	O
any	O
have	O
lymphopenia	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
ribosomal	B
protein	I
gene	I
expression	O
during	O
development	O
in	O
Dictyostelium	O
discoideum	O
.	O

The	O
temporal	O
and	O
static	O
plasma	O
concentration	O
-	O
effect	O
relationships	O
were	O
evaluated	O
by	O
pharmacodynamic	O
modeling	O
and	O
linear	O
regression	O
.	O

Many	O
children	O
with	O
BGC	O
are	O
delayed	O
in	O
their	O
development	O
,	O
but	O
calcifications	O
are	O
not	O
directly	O
related	O
to	O
specific	O
forms	O
of	O
neurologic	O
dysfunction	O
.	O

R	O
-	O
wave	O
voltage	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
anthracycline	O
cardiomyopathy	O
:	O
a	O
clinical	O
study	O
.	O

Secretory	O
function	O
of	O
the	O
prostate	O
gland	O
.	O

Minor	O
differences	O
were	O
noted	O
with	O
latamoxef	O
producing	O
mild	O
persistant	O
elevation	O
of	O
prothrombin	B
time	O
(	O
0.7	O
second	O
)	O
associated	O
with	O
depression	O
of	O
factor	B
II	I
and	O
factor	B
VII	I
.	O

The	O
size	O
of	O
the	O
group	O
allocated	O
to	O
the	O
good	O
compliance	O
category	O
by	O
the	O
use	O
of	O
the	O
digoxin	O
marker	O
was	O
equivalent	O
in	O
size	O
to	O
a	O
group	O
of	O
patients	O
who	O
had	O
returned	O
less	O
than	O
15	O
%	O
of	O
their	O
prescribed	O
dose	O
or	O
reported	O
a	O
deviation	O
of	O
less	O
than	O
6	O
%	O
from	O
their	O
prescription	O
.	O

Bullous	O
keratopathy	O
was	O
usually	O
aphakic	O
in	O
origin	O
in	O
1982	O
,	O
but	O
after	O
1983	O
pseudophakic	O
bullous	O
keratopathy	O
(	O
PBK	O
)	O
was	O
the	O
most	O
common	O
cause	O
of	O
bullous	O
keratopathy	O
.	O

The	O
epidermal	B
growth	I
factor	I
(	I
EGF	I
)	I
receptor	I
,	O
which	O
exhibits	O
intrinsic	O
protein	B
tyrosine	I
kinase	I
activity	O
,	O
undergoes	O
a	O
rapid	O
,	O
intramolecular	O
self	O
-	O
phosphorylation	O
reaction	O
following	O
EGF	B
activation	O
.	O

The	O
glomerular	O
filtration	O
rate	O
and	O
effective	O
renal	O
plasma	O
flow	O
were	O
determined	O
by	O
a	O
standard	O
clearance	O
method	O
,	O
employing	O
continuous	O
infusion	O
of	O
inulin	O
and	O
para	O
-	O
aminohippuric	O
acid	O
.	O

In	O
contrast	O
,	O
the	O
MAN	O
showed	O
a	O
unimodal	O
,	O
skewed	O
distribution	O
,	O
with	O
a	O
range	O
from	O
approximately	O
1	O
to	O
14	O
micron	O
and	O
a	O
maximum	O
at	O
3	O
-	O
4	O
micron	O
.	O

Abnormal	O
technetium	O
Tc	O
99	O
m	O
medronate	O
scans	O
in	O
patients	O
with	O
previously	O
undiagnosed	O
polyarthralgias	O
suggested	O
inflammatory	O
arthropathy	O
and	O
influenced	O
management	O
decisions	O
with	O
favorable	O
therapeutic	O
outcomes	O
.	O

The	O
state	O
of	O
the	O
liver	O
in	O
generalized	O
forms	O
of	O
meningococcal	O
infection	O

The	O
actuarial	O
local	O
control	O
rates	O
at	O
10	O
years	O
for	O
the	O
three	O
treatment	O
groups	O
were	O
as	O
follows	O
:	O
subtotal	O
excision	O
alone	O
,	O
18	O
%	O
;	O
subtotal	O
excision	O
plus	O
postoperative	O
radiation	O
therapy	O
,	O
82	O
%	O
;	O
and	O
total	O
excision	O
alone	O
,	O
77	O
%	O
.	O

Ischemic	O
heart	O
disease	O
,	O
age	O
of	O
more	O
than	O
75	O
years	O
,	O
and	O
the	O
fact	O
that	O
the	O
patient	O
was	O
a	O
woman	O
were	O
independent	O
predictors	O
of	O
poor	O
cardiac	O
function	O
.	O

These	O
findings	O
indicate	O
that	O
autophosphorylation	O
of	O
Thr286	O
(	O
alpha	O
subunit	O
)	O
and	O
Thr287	O
(	O
beta	O
subunit	O
)	O
is	O
responsible	O
for	O
transition	O
of	O
CaM	B
-	I
kinase	I
II	I
to	O
the	O
Ca2	O
+	O
-independent	O
form	O
.	O

This	O
rapid	O
and	O
extensive	O
penetration	O
of	O
intrathecally	O
administered	O
chemotherapy	O
may	O
offer	O
insight	O
into	O
the	O
myelopathy	O
observed	O
with	O
these	O
treatments	O
.	O

Moreover	O
,	O
unlike	O
control	O
rats	O
operated	O
animals	O
did	O
not	O
show	O
aversion	O
to	O
the	O
highest	O
concentrations	O
of	O
saccharin	O
solutions	O
.	O

Two	O
scintigraphic	O
methods	O
,	O
resting	O
dipyridamole	O
and	O
exercise	O
thallium-201	O
myocardial	O
perfusion	O
imaging	O
,	O
to	O
detect	O
and	O
localize	O
coronary	O
artery	O
stenosis	O
were	O
compared	O
in	O
32	O
patients	O
suffering	O
from	O
coronary	O
artery	O
disease	O
.	O

X2	O
test	O
,	O
with	O
Yates	O
correction	O
if	O
need	O
,	O
was	O
used	O
as	O
statistical	O
.	O

method	O
.	O

Mean	O
fluorosis	O
scores	O
,	O
however	O
,	O
were	O
similar	O
.	O

Pharmacologic	O
properties	O
of	O
serotonergic	O
agents	O
and	O
antidepressant	O
drugs	O
.	O

The	O
incidence	O
of	O
second	O
malignant	O
neoplasms	O
was	O
lower	O
(	O
1.3	O
%	O
)	O
in	O
the	O
group	O
treated	O
with	O
5-fluorouracil	O
,	O
doxorubicin	O
,	O
and	O
cyclophosphamide	O
than	O
in	O
the	O
historical	O
control	O
group	O
(	O
4.8	O
%	O
)	O
.	O

Based	O
on	O
our	O
observations	O
,	O
we	O
propose	O
a	O
model	O
whereby	O
inactive	O
precursor	O
molecules	O
produced	O
from	O
the	O
PEP4	B
gene	I
self	O
-	O
activate	O
within	O
the	O
yeast	O
vacuole	O
and	O
subsequently	O
activate	O
other	O
vacuolar	B
hydrolases	I
.	O

Several	O
new	O
techniques	O
are	O
available	O
for	O
monitoring	O
control	O
of	O
diabetes	O
.	O

Postglucose	O
serum	B
insulin	I
levels	O
showed	O
no	O
significant	O
correlations	O
with	O
systolic	O
or	O
diastolic	O
blood	O
pressure	O
levels	O
in	O
men	O
,	O
but	O
in	O
female	O
diabetic	O
and	O
non	O
-	O
diabetic	O
subjects	O
significant	O
correlations	O
were	O
found	O
in	O
particular	O
with	O
systolic	O
blood	O
pressure	O
level	O
.	O

We	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
to	O
alter	O
a	O
site	O
in	O
MucA	B
homologous	O
to	O
the	O
Ala	O
-	O
Gly	O
cleavage	O
site	O
of	O
LexA.	B

The	O
latter	O
was	O
determined	O
as	O
follows	O
:	O
Type	O
I	O
-	O
solid	O
tumor	O
tissue	O
without	O
significant	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
II	O
-	O
solid	O
tumor	O
tissue	O
associated	O
with	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
III	O
-	O
isolated	O
tumor	O
cells	O
only	O
.	O

Rabbits	O
developed	O
profound	O
hypocalcemia	O
,	O
with	O
levels	O
falling	O
from	O
15.5	O
+	O
/-	O

0.2	O
to	O
7.6	O
+	O
/-	O

0.4	O
mg	O
/	O
dl	O
under	O
the	O
influence	O
of	O
TSST-1	B
.	O

Dorsal	O
foot	O
TcpO2	O
was	O
measured	O
by	O
using	O
oxygen	O
-	O
sensing	O
electrodes	O
with	O
surface	O
temperatures	O
of	O
42	O
degrees	O
C	O
and	O
45	O
degrees	O
C	O
;	O
in	O
theory	O
,	O
changes	O
in	O
sympathetic	O
activity	O
should	O
affect	O
vasomotor	O
tone	O
and	O
TcpO2	O
in	O
skin	O
beneath	O
an	O
electrode	O
at	O
42	O
degrees	O
C	O
(	O
submaximal	O
vasodilation	O
)	O
,	O
but	O
not	O
at	O
45	O
degrees	O
C	O
(	O
maximal	O
vasodilation	O
)	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
human	B
and	I
murine	I
ornithine	I
decarboxylase	I
mRNAs	I
share	O
an	O
85	O
%	O
homology	O
,	O
even	O
in	O
their	O
3'-noncoding	O
regions	O
.	O

In	O
cases	O
of	O
1	O
degrees	O
HPT	O
,	O
the	O
plasma	O
1,25-	O
(	O
OH	O
)	O
2D	O
level	O
rose	O
significantly	O
in	O
all	O
cases	O
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
although	O
the	O
pattern	O
of	O
the	O
increase	O
was	O
not	O
uniform	O
.	O

Data	O
from	O
119	O
men	O
and	O
40	O
women	O
undergoing	O
coronary	O
angiography	O
provide	O
an	O
opportunity	O
to	O
compare	O
these	O
associations	O
in	O
relation	O
to	O
a	O
direct	O
and	O
continuous	O
measure	O
of	O
atherosclerosis	O
while	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
income	O
,	O
hypertension	O
,	O
serum	O
cholesterol	O
,	O
smoking	O
,	O
angina	O
,	O
diabetes	O
,	O
family	O
history	O
of	O
heart	O
disease	O
,	O
Type	O
A	O
behavior	O
pattern	O
,	O
and	O
hostility	O
.	O

Immobilization	O
of	O
the	O
fracture	O
in	O
a	O
collar	O
and	O
cuff	O
sling	O
was	O
as	O
effective	O
as	O
more	O
elaborate	O
methods	O
.	O

Comparison	O
of	O
patients	O
receiving	O
phenytoin	O
and	O
those	O
who	O
were	O
not	O
showed	O
significantly	O
lower	O
serum	O
folate	O
in	O
the	O
sub	O
-	O
group	O
receiving	O
phenytoin	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
sub	O
-	O
groups	O
with	O
respect	O
to	O
vitamin	O
B12	O
or	O
behaviour	O
problem	O
rating	O
.	O

Effects	O
of	O
a	O
low	O
-	O
energy	O
laser	O
beam	O
on	O
the	O
cells	O
of	O
the	O
newt	O
embryo	O

Separate	O
experiments	O
measured	O
AIB	O
and	O
86RbCl	O
uptake	O
in	O
36B-10	O
cells	O
in	O
vitro	O
1	O
and	O
2	O
days	O
following	O
20	O
Gy	O
irradiation	O
to	O
assess	O
whether	O
this	O
radiation	O
dose	O
reduced	O
the	O
capacity	O
of	O
tumor	O
cells	O
to	O
trap	O
AIB	O
or	O
Rb+	O
.	O

Hyperthyroidism	O

These	O
changes	O
at	O
the	O
site	O
of	O
injection	O
consist	O
of	O
a	O
focal	O
abnormality	O
characterized	O
by	O
a	O
slight	O
increase	O
in	O
signal	O
intensity	O
on	O
T1	O
weighted	O
images	O
and	O
markedly	O
increased	O
signal	O
intensity	O
on	O
T2	O
weighted	O
images	O
.	O

References	O
for	O
occupational	O
fitness	O
of	O
adolescents	O
with	O
diseases	O
of	O
the	O
respiratory	O
tract	O
and	O
lungs	O

Salzburg	O
,	O
9	O
-	O
12	O
September	O
1987	O
.	O

The	O
selenium	O
level	O
and	O
glutathione	B
peroxidase	I
activity	O
in	O
the	O
blood	O
,	O
liver	O
,	O
and	O
stomach	O
mucosa	O
were	O
significantly	O
higher	O
in	O
the	O
high	O
-	O
selenium	O
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
selenium	O
diet	O
group	O
.	O

Oxygen	O
delivery	O
and	O
consumption	O
and	O
P50	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

It	O
was	O
found	O
that	O
the	O
primary	O
visual	O
cortex	O
of	O
the	O
rat	O
is	O
asymmetrical	O
in	O
volume	O
,	O
and	O
that	O
the	O
asymmetry	O
reflects	O
side	O
differences	O
in	O
the	O
number	O
of	O
neurons	O
.	O

Estimated	O
nucleic	O
acid	O
N	O
absorption	O
is	O
7	O
-	O
8	O
%	O
of	O
N	O
intake	O
.	O

However	O
,	O
further	O
analyses	O
of	O
the	O
data	O
indicate	O
that	O
increasing	O
VO2	O
AT	O
(	O
r	O
=	O
-0.63	O
,	O
P	O
less	O
than	O
0.05	O
)	O
rather	O
than	O
VO2max	O
(	O
r	O
=	O
-0.15	O
)	O
could	O
result	O
in	O
improving	O
the	O
10,000	O
m	O
race	O
performance	O
to	O
a	O
larger	O
extent	O
,	O
and	O
that	O
the	O
absolute	O
amount	O
of	O
change	O
(	O
delta	O
)	O
in	O
the	O
10,000	O
m	O
run	O
time	O
is	O
best	O
accounted	O
for	O
by	O
a	O
combination	O
of	O
delta	O
VO2	O
AT	O
and	O
delta	O
5,000	O
m	O
run	O
time	O
.	O

Liver	O
TG	O
and	O
serum	O
NEFA	O
concentrations	O
were	O
positively	O
correlated	O
.	O

Pharmacological	O
action	O
of	O
eptazocine	O
(	O
l-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benz	O
azonine	O
)	O
.	O

Failures	O
of	O
colorimetric	O
additivity	O
under	O
these	O
experimental	O
conditions	O
are	O
discussed	O
.	O

Further	O
investigations	O
are	O
necessary	O
to	O
elucidate	O
the	O
biochemical	O
and	O
physiological	O
properties	O
of	O
DLIS	O
.	O

Renal	O
clearance	O
fell	O
from	O
19.0	O
+	O
/-	O

4.9	O
ml	O
/	O
min	O
/	O
1.73	O
m2	O
(	O
group	O
I	O
)	O
to	O
1.0	O
+	O
/-	O

0.4	O
ml	O
/	O
min	O
/	O
1.73	O
m2	O
(	O
group	O
IV	O
)	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
explored	O
in	O
some	O
detail	O
,	O
specifically	O
as	O
it	O
relates	O
to	O
reticuloendothelial	O
system	O
(	O
RES	O
)	O
Fc	B
receptor	I
blockade	O
and	O
suppression	O
of	O
antiplatelet	O
antibody	O
synthesis	O
.	O

We	O
analyzed	O
data	O
from	O
56	O
patients	O
with	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
in	O
whom	O
renal	O
biopsies	O
were	O
done	O
systematically	O
.	O

The	O
possibility	O
of	O
a	O
hereditary	O
disorder	O
leading	O
to	O
a	O
minor	O
defect	O
in	O
elastic	O
fibre	O
structure	O
which	O
could	O
be	O
responsible	O
for	O
the	O
spontaneous	O
lesions	O
is	O
discussed	O
.	O

Seventeen	O
of	O
them	O
were	O
on	O
treatment	O
with	O
systemic	O
steroids	O
.	O

This	O
lack	O
of	O
correlation	O
may	O
be	O
due	O
to	O
variations	O
in	O
the	O
metabolic	O
activity	O
of	O
the	O
endometriotic	O
implants	O
present	O
at	O
different	O
stages	O
of	O
the	O
disease	O
.	O

Human	O
and	O
Chinese	B
hamster	I
S14	I
protein	I
sequences	I
deduced	O
from	O
the	O
cDNAs	O
are	O
identical	O
.	O

These	O
fusion	O
proteins	O
also	O
allowed	O
the	O
localization	O
of	O
the	O
transcriptional	O
activation	O
and	O
DNA	O
binding	O
domains	O
of	O
the	O
ToxR	B
protein	I
to	O
its	O
cytoplasmically	O
located	O
N	O
-	O
terminal	O
portion	O
.	O

The	O
risk	O
for	O
these	O
complications	O
is	O
increased	O
by	O
the	O
following	O
factors	O
:	O
multiple	O
gestation	O
,	O
the	O
combination	O
of	O
magnesium	O
sulfate	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
,	O
and	O
the	O
use	O
of	O
adrenocortico	O
-	O
steroids	O
to	O
hasten	O
fetal	O
pulmonary	O
maturity	O
.	O

II	O
.	O

In	O
19	O
patients	O
vagotomy	O
not	O
only	O
curbed	O
the	O
bleeding	O
but	O
provided	O
definitive	O
therapy	O
(	O
Visick	O
I	O
-	O
II	O
)	O
;	O
4	O
patients	O
died	O
(	O
mortality	O
rate	O
16	O
%	O
)	O
.	O

A	O
retrospective	O
study	O
of	O
banked	O
sera	O
from	O
19	O
cats	O
with	O
the	O
eosinophilic	O
granuloma	O
complex	O
revealed	O
that	O
68	O
%	O
of	O
affected	O
cats	O
had	O
circulating	O
antibodies	O
to	O
components	O
of	O
normal	O
cat	O
epithelium	O
.	O

In	O
memory	O
of	O
Magdelaine	O
Comtesse	O

All	O
patients	O
had	O
elevated	O
levels	O
of	O
serum	B
IgE	I
antibodies	I
to	O
the	O
crude	O
soybean	O
extract	O
;	O
binding	O
values	O
ranged	O
from	O
2.3	O
to	O
28.1	O
times	O
that	O
of	O
a	O
negative	O
control	O
serum	O
.	O

Dual	O
radionuclide	O
subtraction	O
imaging	O
of	O
the	O
spleen	O
using	O
67Ga	O
citrate	O
and	O
99mTc	O
is	O
useful	O
in	O
further	O
delineating	O
lesions	O
that	O
are	O
identified	O
on	O
either	O
a	O
routine	O
radiogallium	O
survey	O
or	O
on	O
a	O
conventional	O
sulfur	O
colloid	O
liver	O
-	O
spleen	O
image	O
.	O

The	O
volume	O
of	O
blood	O
to	O
the	O
flap	O
ranges	O
from	O
1	O
to	O
2	O
ml	O
/	O
min	O
,	O
collateral	O
circulation	O
to	O
the	O
flap	O
exists	O
,	O
but	O
is	O
negligible	O
,	O
and	O
there	O
is	O
little	O
change	O
in	O
the	O
capillary	O
blood	O
flow	O
as	O
the	O
flap	O
ages	O
.	O

Laboratory	O
pyrolyses	O
have	O
indeed	O
shown	O
that	O
PCBs	O
give	O
significant	O
yields	O
of	O
PCDFs	O
,	O
and	O
chlorobenzenes	O
give	O
both	O
PCDFs	O
and	O
PCDDs	O
.	O

No	O
consistent	O
correlation	O
between	O
blood	O
pressure	O
change	O
and	O
SCR	O
-	O
change	O
was	O
seen	O
.	O

Piroxicam	O
produced	O
a	O
lower	O
incidence	O
of	O
gastric	O
ulcers	O
than	O
equivalent	O
doses	O
of	O
indomethacin	O
.	O

Since	O
1970	O
the	O
frequency	O
of	O
potassium	O
-	O
induced	O
ulceration	O
has	O
been	O
low--3	O
cases	O
per	O
100	O
000	O
patient	O
-	O
years	O
of	O
slow	O
-	O
release	O
tablet	O
use	O
.	O

Ultrastructure	O
of	O
the	O
heart	O
muscle	O
in	O
experimental	O
myocardial	O
infarct	O
following	O
physical	O
training	O

Pharmacological	O
desympathization	O
leads	O
to	O
the	O
development	O
of	O
hyper	O
-	O
reactivity	O
of	O
the	O
true	O
pacemakers	O
to	O
noradrenaline	O
and	O
dopamine	O
and	O
triggers	O
off	O
changes	O
in	O
the	O
regulation	O
of	O
the	O
electric	O
activity	O
of	O
these	O
cells	O
by	O
catecholamines	O
.	O

Vitiligo	O
in	O
diabetes	O
mellitus	O
.	O

The	O
pharmacokinetics	O
of	O
each	O
tetracycline	O
in	O
serum	O
and	O
dermal	O
,	O
suction	O
blister	O
fluid	O
were	O
determined	O
after	O
oral	O
doses	O
of	O
300	O
mg	O
lymecycline	O
or	O
100	O
mg	O
doxycycline	O
on	O
the	O
3rd	O
day	O
.	O

Either	O
a	O
UV	O
detector	O
set	O
at	O
268	O
nm	O
or	O
an	O
electrochemical	O
(	O
EC	O
)	O
detector	O
set	O
at	O
a	O
potential	O
of	O
+	O
0.9	O
V	O
(	O
versus	O
Ag	O
/	O
AgCl	O
/	O
3	O
M	O
NaCl	O
)	O
was	O
used	O
to	O
monitor	O
the	O
drug	O
.	O

The	O
mean	O
transfer	O
ratios	O
of	O
the	O
drug	O
into	O
the	O
genital	O
tissues	O
to	O
the	O
concentration	O
in	O
the	O
uterine	O
arterial	O
blood	O
were	O
such	O
that	O
the	O
transfer	O
ratio	O
into	O
the	O
portio	O
vaginalis	O
was	O
the	O
highest	O
,	O
followed	O
by	O
the	O
uterine	O
cervix	O
and	O
the	O
myometrium	O
,	O
and	O
that	O
into	O
the	O
oviduct	O
was	O
the	O
lowest	O
with	O
about	O
1	O
/	O
2	O
that	O
into	O
the	O
portio	O
vaginalis	O
.	O

Lower	O
extremity	O
weight	O
bearing	O
under	O
various	O
standing	O
conditions	O
in	O
independently	O
ambulatory	O
patients	O
with	O
hemiparesis	O
.	O

On	O
d	O
112	O
,	O
progesterone	O
was	O
higher	O
(	O
P	O
less	O
than	O
.05	O
)	O
in	O
hysterectomized	O
heifers	O
than	O
in	O
other	O
treatment	O
groups	O
.	O

Supraventricular	O
arrhythmias	O
--	O
digoxin	O
and	O
quinidine	O
revisited	O
.	O

Visidex	O
I	O
is	O
unsuitable	O
for	O
storage	O
and	O
re	O
-	O
reading	O
.	O

The	O
transit	O
time	O
was	O
significantly	O
shortened	O
.	O

Relations	O
between	O
cellular	O
electrical	O
activity	O
and	O
cardiac	O
mechanical	O
activity	O
in	O
man	O
,	O
the	O
dog	O
and	O
the	O
rabbit	O

Ultraviolet	O
light	O
-	O
induced	O
kinin	B
formation	O
in	O
human	O
skin	O
.	O

Prevention	O
of	O
maternal	O
Rh	O
sensitization	O
:	O
anti	B
-	I
Rh	I
immune	I
globulin	I
.	O

Enzyme	O
histochemical	O
findings	O
in	O
the	O
ultimobranchial	O
body	O
of	O
the	O
horse	O

Pre	B
-	I
beta-1	I
lipoprotein	I
and	O
early	O
detection	O
of	O
risk	O
factors	O
for	O
coronary	O
heart	O
disease	O
.	O

Absence	O
of	O
action	O
potentials	O
in	O
frog	O
slow	O
muscle	O
fibres	O
paralysed	O
by	O
botulinum	B
toxin	I
.	O

I.	O

Particles	O
resembling	O
microbodies	O
in	O
normal	O
and	O
neoplastic	O
perianal	O
glands	O
of	O
dogs	O
.	O

Problems	O
common	O
to	O
pediatrics	O
and	O
anesthesiology	O

Junctions	O
between	O
cells	O
of	O
the	O
human	O
enamel	O
organ	O
.	O

Taxonomically	O
significant	O
colour	O
changes	O
in	O
Brevibacterium	O
linens	O
probably	O
associated	O
with	O
a	O
carotenoid	O
-	O
like	O
pigment	O
.	O

A	O
short	O
history	O
of	O
dermatology	O
in	O
Lagos	O
,	O
Nigeria	O
.	O

Glucose	O
disappearance	O
rate	O
and	O
changes	O
in	O
plasma	O
nutrients	O
after	O
intravenouly	O
injected	O
glucose	O
in	O
normoglycaemic	O
and	O
hypoglycaemic	O
underweight	O
newborns	O
.	O

Normal	O
values	O
for	O
the	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
of	O
the	O
grey	O
(	O
Armenian	O
)	O
hamster	O

Methyl	O
mercury	O
intoxication	O
in	O
rat	O
kidneys	O
.	O

Suppression	O
of	O
food	O
intake	O
in	O
the	O
rat	O
by	O
tung	O
oil	O
.	O

Change	O
in	O
the	O
makeup	O
of	O
the	O
blood	O
following	O
a	O
short	O
-	O
term	O
local	O
action	O
of	O
a	O
permanent	O
magnetic	O
field	O
on	O
the	O
human	O
body	O

Observations	O
on	O
saccules	O
of	O
rats	O
exposed	O
to	O
long	O
-	O
term	O
hypergravity	O
.	O

The	O
levels	O
of	O
galactosyltransferase	B
activity	O
in	O
sera	O
from	O
normal	O
children	O
and	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

Effects	O
of	O
ionizing	O
radiation	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
oropharynx	O
:	O
results	O
of	O
a	O
survey	O
.	O

Isolation	O
of	O
Proteus	O
vulgaris	O
MC-63	O
from	O
carcinoma	O
63	O
and	O
its	O
antitumor	O
effect	O
on	O
Crocker	O
sarcoma	O
180	O
and	O
Ehrlich	O
carcinoma	O
.	O

Heterogeneity	O
of	O
human	B
serum	I
albumin	I
.	O

Reactivities	O
to	O
horse	B
anti	I
-	I
lymphocyte	I
globulin	I
.	O

Relation	O
between	O
mixing	O
ratio	O
of	O
raw	O
materials	O
and	O
composition	O
of	O
products	O
in	O
the	O
synthesis	O
of	O
aluminosilicates	O

Sinusoidal	O
oscillations	O
of	O
a	O
gas	O
dilution	O
indicator	O

Studies	O
on	O
the	O
hereditary	O
nature	O
of	O
sole	O
prints	O
--	O
with	O
special	O
reference	O
to	O
interdigital	O
and	O
triradii	O

Successive	O
abdominal	O
scintillation	O
with	O
131-I	O
-	O
tagged	O
BSP	O
--	O
description	O
of	O
the	O
thyroid	O
gland	O
,	O
kidney	O
and	O
spleen	O
(	O
comparison	O
with	O
131-I	O
-	O
RB	O
)	O

Osteosarcoma	O
caused	O
by	O
3,4-benzopyrene	O

The	O
content	O
of	O
glucosamine	O
and	O
galactosamine	O
in	O
tartar	O

Relapse	O
of	O
leukemia	O
after	O
prolonged	O
remission	O
.	O

Influence	O
of	O
cigarette	O
smoking	O
on	O
some	O
blood	O
coagulation	O
tests	O
.	O

SAM	O
-	O
TR-68	O
-	O
54	O
.	O

Spinal	O
cord	O
representation	O
of	O
the	O
micturition	O
reflex	O
.	O

Pitfalls	O
in	O
the	O
use	O
of	O
chromosome	O
aberration	O
analysis	O
for	O
biological	O
radiation	O
dosimetry	O
.	O

Midge	O
control	O
in	O
flood	O
channels	O
.	O

The	O
effects	O
of	O
taloximine	O
and	O
aminophylline	O
on	O
isolated	O
human	O
smooth	O
muscle	O
.	O

The	O
exploratory	O
behaviour	O
in	O
normal	O
and	O
aggressive	O
mice	O
.	O

18F	O
and	O
85Sr	O
scintimetry	O
in	O
the	O
study	O
of	O
primary	O
arthropathies	O
.	O

Endocardial	O
fibro	O
-	O
elastosis	O
,	O
mitral	O
incompetence	O
,	O
and	O
coarctation	O
of	O
abdominal	O
aorta	O
.	O

The	O
significance	O
of	O
structural	O
integrity	O
of	O
lymphoid	O
tissue	O
for	O
antibody	O
production	O
in	O
culture	O
in	O
vivo	O

Hemodynamics	O
changes	O
in	O
man	O
during	O
flight	O

Automatic	O
view	O
box	O
.	O

I.	O

Experience	O
with	O
the	O
restoration	O
of	O
agglutination	O
properties	O
of	O
non	O
-	O
agglutinating	O
dysenterial	O
cultures	O
with	O
the	O
use	O
of	O
Rzhaninov	O
's	O
method	O

Study	O
on	O
the	O
evagination	O
of	O
Cysticercus	O
pisiformis	O
.	O

Compensatory	O
renal	O
hypertrophy	O
in	O
parabiotic	O
rats	O
.	O

In	O
vitro	O
evaluation	O
of	O
the	O
mucolytic	O
action	O
of	O
urea	O
.	O

Histogenetic	O
aspects	O
of	O
mesoblastic	O
nephroma	O
.	O

Upstream	O
activation	O
sites	O
of	O
the	O
CYC1	B
gene	I
of	O
Saccharomyces	O
cerevisiae	O
are	O
active	O
when	O
inverted	O
but	O
not	O
when	O
placed	O
downstream	O
of	O
the	O
""""	O
TATA	O
box	O
""""	O
.	O

Cardiac	O
taurine	O
levels	O
and	O
sarcolemmal	O
calcium	O
binding	O
activity	O
in	O
furazolidone	O
-	O
induced	O
cardiomyopathy	O
.	O

Separation	O
of	O
malaria	O
-	O
infected	O
erythrocytes	O
from	O
whole	O
blood	O
:	O
use	O
of	O
a	O
selective	O
high	O
-	O
gradient	O
magnetic	O
separation	O
technique	O
.	O

Brief	O
report	O
.	O

In	O
several	O
cases	O
of	O
definite	O
SjS	O
,	O
labial	O
salivary	O
gland	O
examinations	O
after	O
more	O
than	O
a	O
one	O
year	O
interval	O
were	O
performed	O
on	O
two	O
occasions	O
,	O
and	O
the	O
clinical	O
and	O
histopathological	O
changes	O
were	O
investigated	O
.	O

In	O
most	O
cases	O
of	O
acute	O
transmural	O
infarction	O
,	O
the	O
reciprocal	O
ST	O
segment	O
depressions	O
observed	O
in	O
contralateral	O
leads	O
are	O
less	O
marked	O
than	O
the	O
primary	O
ST	O
segment	O
elevations	O
.	O

No	O
direct	O
repeats	O
flank	O
the	O
pseudogene	O
in	O
the	O
U2	B
/	I
4	I
locus	I
.	O

Radioimmunoassay	O
of	O
serum	O
creatine	B
kinase	I
B	I
isoenzyme	I
in	O
the	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
.	O

Selective	O
macrophage	O
inhibition	O
abolishes	O
warfarin	O
-	O
induced	O
reduction	O
of	O
metastasis	O
.	O

A	O
haemolytic	O
enterotoxigenic	O
strain	O
of	O
E.	O
coli	O
(	O
O149	O
:	O
K88	O
:	O
H10	O
)	O
was	O
regularly	O
recovered	O
from	O
piglets	O
with	O
PWD	O
while	O
rotavirus	O
was	O
demonstrated	O
on	O
a	O
number	O
of	O
occasions	O
.	O

Restoration	O
of	O
impaired	O
immune	O
functions	O
in	O
aging	O
animals	O
.	O

Another	O
sequence	O
,	O
GGGXGGAG	O
,	O
which	O
is	O
repeated	O
several	O
times	O
in	O
many	O
polyomaviruses	O
and	O
adenoviruses	O
,	O
and	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
DNA	O
replication	O
and/or	O
transcription	O
,	O
is	O
not	O
found	O
in	O
the	O
JCV	O
sequence	O
presented	O
.	O

I.	O

USA	O
80	O
,	O
802	O
-	O
806	O
]	O
was	O
used	O
to	O
isolate	O
a	O
genomic	O
clone	O
lambda	O
PGK-1	B
containing	O
a	O
portion	O
of	O
an	O
autosomal	O
locus	O
for	O
phosphoglycerate	B
kinase	I
(	O
PGK	B
)	O
.	O

A.	O

Frog	O
type	O
I	O
(	O
Ft	O
I	O
)	O
and	O
frog	O
type	O
II	O
(	O
Ft	O
II	O
)	O
slowly	O
adapting	O
(	O
SA	O
)	O
units	O
produced	O
spikes	O
only	O
at	O
the	O
indentation	O
phase	O
,	O
and	O
the	O
threshold	O
response	O
phase	O
(	O
TRP	O
)	O
,	O
i.e	O
..	O
the	O
phase	O
of	O
the	O
first	O
spike	O
was	O
for	O
ca	O
.	O

The	O
clinical	O
efficacy	O
rates	O
evaluated	O
in	O
151	O
cases	O
(	O
KS	O
-	O
R1	O
group	O
in	O
77	O
cases	O
,	O
oral	O
group	O
in	O
74	O
cases	O
)	O
on	O
standard	O
criteria	O
of	O
committee	O
members	O
were	O
88.3	O
%	O
for	O
the	O
KS	O
-	O
R1	O
group	O
and	O
86.5	O
%	O
for	O
the	O
oral	O
group	O
,	O
respectively	O
.	O

Martin	O
Luther	O
and	O
his	O
physicians	O
.	O

Renal	O
response	O
to	O
captopril	O
in	O
severe	O
heart	O
failure	O
:	O
role	O
of	O
furosemide	O
in	O
natriuresis	O
and	O
reversal	O
of	O
hyponatremia	O
.	O

EGV	O
had	O
no	O
detectable	O
effect	O
on	O
PP	B
secretion	O
under	O
basal	O
or	O
stimulated	O
conditions	O
.	O

Lung	O
prostacyclin	O
production	O
may	O
be	O
related	O
to	O
flow	O
.	O

For	O
the	O
first	O
30	O
min	O
following	O
insulin	B
administration	O
,	O
the	O
rate	O
of	O
change	O
in	O
glucose	O
levels	O
was	O
significantly	O
less	O
among	O
the	O
patients	O
with	O
major	O
depressive	O
disorder	O
than	O
among	O
either	O
the	O
patients	O
with	O
dysthymic	O
disorder	O
or	O
the	O
normal	O
control	O
subjects	O
.	O

Urease	B
activity	O
of	O
97	O
%	O
of	O
these	O
organisms	O
became	O
evident	O
within	O
30	O
min	O
.	O

Regional	O
CBF	O
was	O
determined	O
by	O
clearance	O
of	O
xenon	O
133	O
in	O
67	O
patients	O
undergoing	O
coronary	O
bypass	O
grafting	O
procedures	O
.	O

Cardiovascular	O
and	O
adrenal	O
medullo	O
-	O
sympathetic	O
reactions	O
to	O
acute	O
tobacco	O
poisoning	O

Exposure	O
of	O
endothelium	O
to	O
pulsatile	O
shear	O
stresses	O
that	O
followed	O
a	O
tape	O
recording	O
of	O
physiological	O
flow	O
waveforms	O
(	O
electromagnetic	O
flowmeter	O
)	O
did	O
not	O
cause	O
gross	O
injury	O
or	O
denudation	O
even	O
when	O
peak	O
shear	O
exceeded	O
1500	O
dyne	O
/	O
cm2	O
.	O

Hydrocortisone	O
seems	O
to	O
be	O
unable	O
to	O
hinder	O
the	O
postdenervation	O
changes	O
in	O
the	O
muscle	O
membrane	O
whereas	O
high	O
doses	O
of	O
the	O
hormone	O
are	O
able	O
to	O
induce	O
changes	O
in	O
the	O
muscle	O
membrane	O
.	O

Salivary	O
estradiol	O
17	O
beta	O
(	O
E2	O
-	O
17	O
beta	O
)	O
and	O
progesterone	O
(	O
P	O
)	O
were	O
determined	O
by	O
using	O
radioimmunoassay	O
techniques	O
in	O
30	O
pregnant	O
females	O
in	O
the	O
first	O
,	O
second	O
and	O
third	O
trimesters	O
as	O
well	O
as	O
in	O
10	O
non	O
-	O
pregnant	O
controls	O
during	O
the	O
luteal	O
phase	O
of	O
the	O
menstrual	O
cycle	O
.	O

Variable	O
FHR	O
decelerations	O
or	O
bradycardias	O
were	O
encountered	O
on	O
95	O
nonstress	O
tests	O
(	O
18.8	O
%	O
)	O
in	O
80	O
(	O
33.5	O
%	O
)	O
postdate	O
patients	O
.	O

The	O
response	O
chain	O
in	O
each	O
component	O
was	O
maintained	O
by	O
food	O
presentation	O
under	O
a	O
fixed	O
-	O
ratio	O
schedule	O
.	O

This	O
machine	O
drift	O
,	O
which	O
was	O
not	O
associated	O
with	O
a	O
rise	O
in	O
water	O
phantom	O
temperature	O
and	O
did	O
not	O
consistently	O
correlate	O
with	O
estimated	O
x	O
-	O
ray	O
tube	O
heat	O
,	O
could	O
result	O
in	O
a	O
significant	O
overestimation	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
for	O
a	O
xenon	O
/	O
CT	O
rCBF	O
protocol	O
involving	O
5	O
-	O
7	O
sequential	O
scans	O
obtained	O
at	O
1-min	O
interscan	O
intervals	O
.	O

Reaction	O
of	O
human	O
organism	O
to	O
exercise	O
.	O

HA	O
resulted	O
in	O
decreased	O
(	O
p	O
less	O
than	O
0.05	O
)	O
Tre	O
(	O
0.4	O
degrees	O
C	O
)	O
and	O
HR	O
(	O
17	O
b	O
X	O
min-1	O
)	O
,	O
and	O
increased	O
(	O
p	O
less	O
than	O
0.05	O
)	O
Msw	O
(	O
16	O
g	O
X	O
m-2	O
X	O
h-1	O
)	O
during	O
the	O
saline	O
experiments	O
.	O

We	O
conclude	O
that	O
administration	O
of	O
the	O
calcium	O
antagonist	O
Verapamil	O
is	O
of	O
no	O
additional	O
value	O
in	O
tocolytic	O
treatment	O
with	O
beta	O
-	O
mimetics	O
.	O

During	O
a	O
single	O
LAD	O
occlusion	O
lasting	O
35	O
minutes	O
(	O
series	O
I	O
,	O
n	O
=	O
10	O
)	O
9	O
microns	O
TMs	O
were	O
infused	O
immediately	O
and	O
30	O
minutes	O
after	O
ligation	O
,	O
15	O
microns	O
TMs	O
being	O
infused	O
after	O
15	O
-	O
20	O
minutes	O
.	O

Brain	O
pH	O
following	O
3	O
h	O
of	O
cerebral	O
focal	O
ischemia	O
changed	O
from	O
a	O
normal	O
value	O
of	O
7.0	O
to	O
6.5	O
and	O
6.2	O
in	O
animals	O
studied	O
under	O
barbiturate	O
and	O
halothane	O
anesthesia	O
,	O
respectively	O
.	O

After	O
clofelin	O
administration	O
the	O
autoregulation	O
borders	O
shifted	O
to	O
the	O
right	O
i.	O
e.	O
towards	O
higher	O
AP	O
levels	O
.	O

Angionephroscintigraphy	O
in	O
the	O
diagnosis	O
of	O
diseases	O
of	O
the	O
kidney	O

Serum	O
lipids	O
and	O
lipoproteins	O
of	O
29	O
insulin	B
dependent	O
diabetic	O
children	O
have	O
been	O
determined	O
and	O
related	O
to	O
the	O
metabolic	O
status	O
of	O
the	O
patients	O
.	O

Out	O
of	O
these	O
families	O
74,3	O
%	O
planned	O
next	O
pregnancy	O
(	O
table	O
IX	O
)	O
,	O
57,6	O
%	O
wanted	O
to	O
have	O
prenatal	O
diagnosis	O
(	O
table	O
VI	O
)	O
.	O

Dipetalonema	O
(	O
Alafilaria	O
)	O
hydrochoerus	O
subgen	O
.	O

et	O
sp.	O
n.	O

Despite	O
total	O
tumor	O
resection	O
,	O
multiple	O
intraperitoneal	O
tumor	O
nodules	O
of	O
varying	O
sizes	O
were	O
found	O
and	O
resected	O
six	O
months	O
and	O
one	O
year	O
later	O
.	O

Additionally	O
,	O
observations	O
that	O
patients	O
with	O
mitral	O
versus	O
aortic	O
regurgitation	O
respond	O
differently	O
to	O
valve	O
replacement	O
suggest	O
that	O
differences	O
exist	O
preoperatively	O
between	O
these	O
two	O
types	O
of	O
volume	O
overload	O
.	O

Is	O
nisoldipine	O
capable	O
of	O
reducing	O
left	O
ventricular	O
preload	O
?	O

In	O
ten	O
anesthetized	O
pigs	O
,	O
nisoldipine	O
(	O
2	O
-	O
4	O
micrograms	O
X	O
kg-1	O
X	O
min-1	O
)	O
,	O
a	O
calcium	O
channel	O
blocker	O
structurally	O
related	O
to	O
nifedipine	O
,	O
reduced	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
40	O
%	O
)	O
and	O
systemic	O
vascular	O
resistance	O
(	O
35	O
%	O
)	O
,	O
whereas	O
maxLVdP	O
/	O
dt	O
decreased	O
by	O
20	O
%	O
and	O
cardiac	O
output	O
was	O
unchanged	O
.	O

The	O
importance	O
of	O
selective	O
renal	O
vein	O
phlebography	O
in	O
the	O
evaluation	O
of	O
unexplained	O
hematuria	O
and	O
filing	O
defects	O
in	O
the	O
excretory	O
urogram	O
is	O
illustrated	O
.	O

The	O
pyramidal	O
tract	O
and	O
Mesencephalic	O
Reticular	O
Formation	O
(	O
MRF	O
)	O
were	O
stimulated	O
before	O
and	O
after	O
the	O
transection	O
.	O

There	O
is	O
now	O
a	O
significative	O
difference	O
between	O
age	O
group	O
1	O
-	O
5	O
and	O
the	O
others	O
(	O
p	O
Less	O
Than	O
0,02	O
)	O
.	O

The	O
sympathetic	O
neuroeffector	O
influence	O
on	O
the	O
myocardium	O
with	O
ATCI	O
depends	O
to	O
a	O
large	O
measure	O
on	O
the	O
intensity	O
of	O
the	O
neurotransmitter	O
biosynthesis	O
and	O
function	O
of	O
cardiomyocyte	O
adrenoreceptors	O
.	O

In	O
silicosis	O
,	O
significant	O
relationships	O
between	O
patients	O
and	O
sons	O
were	O
not	O
seen	O
with	O
respect	O
to	O
arterial	O
blood	O
gas	O
determinations	O
and	O
ventilatory	O
responses	O
except	O
for	O
Paco2	O
of	O
patients	O
and	O
hypercapnic	O
ventilatory	O
responses	O
of	O
sons	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
and	O
compare	O
the	O
ability	O
of	O
three	O
different	O
forms	O
of	O
DSG	O
to	O
block	O
EIB	O
.	O

Many	O
of	O
these	O
landfill	O
operations	O
were	O
undertaken	O
in	O
the	O
early	O
1950s	O
and	O
1960s	O
,	O
when	O
knowledge	O
regarding	O
the	O
safe	O
and	O
prolonged	O
containment	O
of	O
the	O
waste	O
buried	O
was	O
nonexistent	O
or	O
minimal	O
at	O
best	O
.	O

Acute	O
type	O
A	O
hepatitis	O
in	O
three	O
patients	O
with	O
chronic	O
HBV	O
infection	O
.	O

Echosismography	O
enables	O
to	O
improve	O
the	O
diagnosis	O
when	O
compared	O
with	O
classical	O
sonography	O
in	O
about	O
20	O
%	O
of	O
cases	O
.	O

A	O
reassessment	O
of	O
the	O
prevalence	O
data	O
was	O
carried	O
out	O
in	O
the	O
southern	O
province	O
of	O
Uusimaa	O
and	O
in	O
the	O
western	O
province	O
of	O
Vaasa	O
,	O
the	O
prevalence	O
day	O
being	O
January	O
1	O
,	O
1979	O
.	O

In	O
visible	O
tumours	O
the	O
best	O
results	O
were	O
obtained	O
with	O
FB	O
(	O
85	O
%	O
)	O
while	O
TBN	O
was	O
positive	O
in	O
65	O
%	O
.	O

Alveolar	O
growth	O
,	O
contemporary	O
with	O
dental	O
eruption	O
,	O
is	O
sufficient	O
to	O
compensate	O
possible	O
hypotrophy	O
of	O
maxillary	O
bone	O
bases	O
.	O

Correlation	O
between	O
intraocular	O
involvement	O
and	O
systemic	O
outcome	O
was	O
poor	O
.	O

At	O
necropsy	O
28	O
days	O
post	O
-	O
inoculation	O
,	O
F344	O
rats	O
had	O
no	O
gross	O
lung	O
lesions	O
,	O
even	O
those	O
given	O
the	O
maximum	O
dose	O
of	O
1.4	O
X	O
10	O
(	O
9	O
)	O
colony	O
-	O
forming	O
units	O
of	O
M.	O
pulmonis	O
.	O

Aneurysmectomy	O
and	O
the	O
performance	O
of	O
CABG	O
were	O
not	O
significantly	O
associated	O
with	O
postoperative	O
ECG	O
changes	O
,	O
but	O
more	O
bypass	O
grafts	O
per	O
patient	O
grafted	O
appeared	O
in	O
the	O
group	O
with	O
postoperative	O
ECG	O
changes	O
,	O
suggesting	O
that	O
coronary	O
artery	O
disease	O
may	O
be	O
more	O
severe	O
in	O
that	O
group	O
.	O

Contractile	O
responses	O
to	O
norepinephrine	O
,	O
serotonin	O
and	O
potassium	O
(	O
K+	O
)	O
and	O
relaxant	O
responses	O
to	O
isoproterenol	O
and	O
papaverine	O
were	O
studied	O
in	O
vitro	O
with	O
spirally	O
cut	O
thoracic	O
aortic	O
strips	O
from	O
aortic	O
coarcted	O
hypertensive	O
rats	O
(	O
AHR	O
)	O
2	O
,	O
6	O
,	O
14	O
and	O
28	O
days	O
postoperatively	O
and	O
compared	O
to	O
time	O
-	O
matched	O
,	O
sham	O
-	O
operated	O
normotensive	O
controls	O
.	O

In	O
the	O
diabetics	O
,	O
Ca2	O
+	O
infusions	O
induced	O
a	O
rise	O
of	O
plasma	O
Ca2	O
+	O
up	O
to	O
3.2	O
+	O
/-	O

0.1	O
mmol	O
/	O
1	O
and	O
a	O
fall	O
of	O
circulating	O
glucagon	B
(	O
-26.4	O
+	O
/-	O

5.7	O
%	O
;	O
p	O
less	O
than	O
0.001	O
)	O
and	O
glucose	O
(	O
-23.3	O
+	O
/-	O

3.6	O
%	O
;	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Rats	O
underwent	O
either	O
a	O
90	O
-	O
95	O
%	O
JIB	O
or	O
a	O
sham	O
operation	O
.	O

Large	O
and	O
small	O
medullary	O
lesions	O
inhibited	O
the	O
occurrence	O
of	O
target	O
fibres	O
in	O
the	O
tenotomized	O
muscles	O
,	O
the	O
smallest	O
one	O
being	O
neurolysis	O
of	O
the	O
dorsal	O
roots	O
.	O

Selenium	O
status	O
of	O
thoroughbreds	O
in	O
the	O
United	O
Kingdom	O
.	O

These	O
results	O
suggested	O
the	O
possibility	O
that	O
the	O
fetus	O
played	O
some	O
role	O
in	O
the	O
production	O
of	O
E3	O
-	O
16-G	O
in	O
early	O
pregnancy	O
.	O

This	O
study	O
demonstrates	O
secretion	O
of	O
bicarbonate	O
by	O
the	O
human	O
stomach	O
in	O
vivo	O
at	O
a	O
rate	O
equivalent	O
to	O
10	O
-	O
-20	O
%	O
of	O
basal	O
acid	O
secretion	O
.	O

The	O
tetraphasic	O
action	O
of	O
lidocaine	O
on	O
CNS	O
electrical	O
activity	O
and	O
behavior	O
in	O
cats	O
.	O

The	O
favourable	O
effect	O
of	O
thymic	O
shielding	O
was	O
also	O
reflected	O
in	O
a	O
significant	O
increase	O
of	O
LD50	O
/	O
30	O
,	O
and	O
the	O
dose	O
reduction	O
factor	O
was	O
equal	O
to	O
2	O
.	O

Mastocytosis	O
.	O

TCZ	O
provides	O
quick	O
,	O
inexpensive	O
,	O
noninvasive	O
indication	O
of	O
tissue	O
necrosis	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
intracranial	O
hemorrhage	O
,	O
and	O
delayed	O
brain	O
maturation	O
.	O

Adverse	O
reaction	O
of	O
the	O
apparently	O
healthy	O
partner	O
in	O
response	O
to	O
improvement	O
in	O
the	O
overtly	O
dysfunctional	O
partner	O
.	O

Since	O
only	O
58	O
%	O
of	O
our	O
sample	O
could	O
be	O
adequately	O
classified	O
with	O
one	O
diagnosis	O
,	O
we	O
expect	O
that	O
the	O
ASDC	O
nosology	O
will	O
need	O
to	O
evolve	O
further	O
.	O

Static	O
lung	O
function	O
in	O
puppies	O
after	O
pneumonectomy	O
.	O

Current	O
status	O
of	O
chemotherapy	O
for	O
Hodgkin	O
's	O
disease	O

In	O
Group	O
V	O
,	O
the	O
salvaged	O
tissue	O
was	O
primarily	O
subepicardial	O
with	O
virtually	O
no	O
lateral	O
zone	O
of	O
salvaged	O
tissue	O
(	O
ratio	O
of	O
salvaged	O
subepicardium	O
to	O
salvaged	O
subendocardium	O
14.8	O
+	O
/-	O

1.9	O
to	O
1	O
)	O
.	O

Responses	O
to	O
brainstem	O
of	O
nuclei	O
medialis	O
dorsalis	O
,	O
lateralis	O
posterior	O
were	O
of	O
considerably	O
longer	O
latency	O
.	O

A	O
simplified	O
thin	O
-	O
layer	O
chromatographic	O
determination	O
of	O
hippuric	O
acid	O
and	O
methylhippuric	O
acids	O
.	O

MSMS	O
Council	O
hears	O
new	O
public	O
health	O
director	O
.	O

Twenty	O
patients	O
aged	O
45	O
or	O
older	O
with	O
the	O
diagnosis	O
of	O
endogenous	O
depression	O
were	O
evaluated	O
in	O
terms	O
of	O
safety	O
and	O
efficacy	O
in	O
their	O
response	O
to	O
multiple	O
monitored	O
electroconvulsive	O
therapy	O
(	O
MMECT	O
)	O
versus	O
single	O
electroconvulsive	O
therapy	O
(	O
SECT	O
)	O
.	O

Tests	O
of	O
the	O
method	O
indicate	O
(	O
1	O
)	O
the	O
Mossbauer	O
source	O
can	O
be	O
placed	O
on	O
the	O
basilar	O
membrane	O
without	O
altering	O
the	O
signal	O
-	O
transmission	O
properties	O
of	O
the	O
cochlea	O
,	O
and	O
(	O
2	O
)	O
the	O
source	O
adheres	O
to	O
the	O
basilar	O
membrane	O
.	O

Importance	O
of	O
determining	O
the	O
blood	O
sulfhydryl	O
groups	O
in	O
fractures	O
of	O
the	O
long	O
tubular	O
bones	O
complicated	O
by	O
infection	O

The	O
ability	O
of	O
sodium	O
phenobarbital	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
sodium	O
barbital	O
(	O
80	O
mg	O
/	O
kg	O
)	O
to	O
produce	O
a	O
taste	O
aversion	O
in	O
23	O
hr	O
fluid	O
deprived	O
rats	O
was	O
examined	O
using	O
a	O
discrimination	O
or	O
two	O
bottle	O
taste	O
aversion	O
task	O
(	O
0.125	O
%	O
sodium	O
saccharin	O
solution	O
or	O
water	O
)	O
.	O

In	O
spite	O
of	O
this	O
and	O
other	O
complications	O
of	O
corticosteroids	O
,	O
she	O
made	O
a	O
full	O
recovery	O
from	O
the	O
fungal	O
infection	O
following	O
treatment	O
with	O
amphotericin	O
B	O
and	O
surgical	O
excision	O
of	O
the	O
lung	O
abscess	O
.	O

Marked	O
sedative	O
activity	O
was	O
observed	O
with	O
9-methoxy-5-phenylpyrrolo	O
[	O
2,1-d	O
]	O
[	O
1,5	O
]	O
benzothiazepin-6,6-dioxide	O
(	O
NF19	O
)	O
and	O
9-chloro-5-p	O
-	O
nitrophenylpyrrolo	O
[	O
2,1-d	O
]	O
[	O
1,5	O
]	O
benzothiazepin-6,6-dioxide	O
(	O
NF20	O
)	O
.	O

The	O
potentially	O
SLE	O
-	O
inducing	O
drugs	O
are	O
reviewed	O
.	O

EUK-8	O
is	O
a	O
novel	O
,	O
synthetic	O
,	O
low	O
-	O
molecular	O
-	O
weight	O
salen	O
-	O
manganese	O
complex	O
that	O
exhibits	O
both	O
superoxide	B
dismutase	I
and	O
catalase	B
activities	O
in	O
vitro	O
.	O

Patients	O
with	O
psychotropic	O
drugs	O
showed	O
significantly	O
higher	O
PRL	B
levels	O
.	O

BSE	O
and	O
farmworkers	O
.	O

Considerably	O
high	O
levels	O
of	O
IgE	B
antibodies	I
was	O
also	O
established	O
while	O
other	O
pollens	O
did	O
not	O
show	O
such	O
correspondence	O
.	O

This	O
is	O
particularly	O
intriguing	O
because	O
SKUT-1B-20	O
cells	O
lack	O
the	O
transcription	O
factor	O
Pit-1	B
.	O

The	O
number	O
of	O
lactotropes	O
,	O
somatotropes	O
,	O
thyrotropes	O
,	O
and	O
gonadotropes	O
was	O
not	O
altered	O
compared	O
with	O
controls	O
,	O
indicating	O
that	O
in	O
the	O
adult	O
pituitary	O
,	O
POMC	B
products	I
are	O
not	O
required	O
to	O
maintain	O
the	O
distribution	O
of	O
cell	O
types	O
.	O

Correlation	O
coefficients	O
between	O
the	O
reference	O
methods	O
and	O
NIT	O
were	O
>	O
or	O
=	O
0.95	O
for	O
water	O
,	O
fat	O
,	O
crude	O
protein	O
and	O
connective	O
-	O
tissue	O
-	O
protein	O
frei	O
meat	O
protein	O
,	O
and	O
>	O
or	O
=	O
0.86	O
for	O
connective	O
-	O
tissue	O
-	O
protein	O
.	O

Histopathologic	O
observations	O
showed	O
that	O
both	O
somatostatin	B
and	O
triamcinolone	O
acetonide	O
reduced	O
the	O
inflammatory	O
signs	O
in	O
the	O
joint	O
structures	O
,	O
although	O
triamcinolone	O
acetonide	O
appeared	O
to	O
be	O
more	O
effective	O
.	O

Preferential	O
heterodimeric	O
parallel	O
coiled	O
-	O
coil	O
formation	O
by	O
synthetic	B
Max	I
and	O
c	B
-	I
Myc	I
leucine	I
zippers	I
:	O
a	O
description	O
of	O
putative	O
electrostatic	O
interactions	O
responsible	O
for	O
the	O
specificity	O
of	O
heterodimerization	O
.	O

These	O
results	O
demonstrate	O
that	O
tip	B
acts	O
at	O
an	O
early	O
stage	O
of	O
the	O
T	O
-	O
cell	O
signal	O
transduction	O
cascade	O
by	O
associating	O
with	O
Lck	B
and	O
downregulating	O
Lck	O
-	O
mediated	O
activation	O
.	O

As	O
hGM	B
-	I
CSF	I
receptor	I
(	O
hGMR	B
)	O
does	O
not	O
contain	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
PI	B
3-kinase	I
,	O
hGMR	B
must	O
use	O
a	O
distinct	O
mechanism	O
for	O
its	O
association	O
with	O
and	O
activation	O
of	O
PI	B
3-kinase	I
.	O

Therefore	O
,	O
we	O
studied	O
ninety	O
coagulopathic	O
patients	O
with	O
the	O
aim	O
of	O
determining	O
the	O
prevalence	O
of	O
hepatitis	B
C	I
virus	I
(	I
HCV	I
)	I
antibodies	I
using	O
the	O
ELISA	O
and	O
RIBA	O
methods	O
.	O

Hepatitis	B
B	I
surface	I
antigen	I
was	O
detected	O
in	O
2	O
patients	O
,	O
with	O
negative	O
hepatitis	B
C	I
virus	I
antibody	I
.	O

Liver	O
transplantation	O
in	O
one	O
patient	O
resolved	O
metabolic	O
complications	O
but	O
did	O
not	O
improve	O
PMN	O
count	O
or	O
the	O
infectious	O
status	O
,	O
while	O
neutropenia	O
was	O
corrected	O
by	O
G	B
-	I
CSF	I
.	O

Activation	O
of	O
the	O
SH2-containing	B
protein	I
tyrosine	I
phosphatase	I
,	O
SH	B
-	I
PTP2	I
,	O
by	O
phosphotyrosine	O
-	O
containing	O
peptides	O
derived	O
from	O
insulin	B
receptor	I
substrate-1	I
.	O

Tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
is	O
the	O
earliest	O
identifiable	O
event	O
following	O
T	B
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
stimulation	O
and	O
is	O
essential	O
for	O
activating	O
downstream	O
signaling	O
machinery	O
.	O

Microvessels	O
were	O
counted	O
in	O
a	O
x200	O
field	O
(	O
0.754	O
mm2	O
)	O
in	O
the	O
area	O
of	O
maximal	O
angiogenesis	O
.	O

Pharmacological	O
and	O
pharmacokinetic	O
characteristics	O
of	O
the	O
non	O
-	O
ionic	O
monomeric	O
X	O
-	O
ray	O
contrast	O
agent	O
iopromide	O
(	O
Ultravist	O
,	O
CAS	O
73334	O
-	O
07	O
-	O
3	O
)	O
were	O
evaluated	O
in	O
preclinical	O
studies	O
.	O

In	O
this	O
paper	O
we	O
report	O
that	O
ligand	O
binding	O
induced	O
tyrosine	O
phosphorylation	O
in	O
BaF3	O
cells	O
engineered	O
to	O
express	O
the	O
murine	B
Mpl	I
receptor	I
(	O
BaF3	O
/	O
mMpl	B
)	O
.	O

To	O
identify	O
critical	O
regions	O
mediating	O
growth	O
signal	O
transduction	O
by	O
hG	B
-	I
CSFR	I
,	O
deletions	O
or	O
site	O
-	O
directed	O
amino	O
acid	O
substitutions	O
were	O
introduced	O
into	O
the	O
cytoplasmic	O
domain	O
of	O
hG	B
-	I
CSFR	I
,	O
and	O
the	O
mutant	O
cDNAs	O
were	O
transfected	O
into	O
the	O
murine	B
interleukin-3	I
(	O
IL-3	B
)	O
-dependent	O
Ba	O
/	O
F3	O
and	O
FDCP	O
cell	O
lines	O
.	O

The	O
fusion	O
proteins	O
were	O
tested	O
by	O
ELISA	O
for	O
reactivity	O
with	O
a	O
panel	O
of	O
human	B
anti	I
-	I
La	I
sera	I
in	O
order	O
to	O
define	O
the	O
nature	O
of	O
the	O
epitopes	O
.	O

Our	O
results	O
suggest	O
that	O
protein	O
binding	O
to	O
the	O
E2F	B
-	I
like	I
sequences	I
may	O
act	O
to	O
reduce	O
expression	O
.	O

The	O
optimal	O
care	O
of	O
CHF	O
patient	O
includes	O
the	O
recognition	O
and	O
management	O
of	O
these	O
electrolyte	O
disturbances	O
.	O

METHODS	O
:	O
rHb1.1	B
or	O
human	B
serum	I
albumin	I
was	O
administered	O
intravenously	O
to	O
fasting	O
male	O
volunteers	O
.	O

Several	O
different	O
oncogenes	O
and	O
growth	O
factors	O
promote	O
G1	O
phase	O
progression	O
.	O

The	O
chloramphenicol	B
-	I
resistance	I
transposon	I
Tn4451	B
undergoes	O
precise	O
conjugative	O
deletion	O
from	O
its	O
parent	O
plasmid	O
plP401	O
in	O
Clostridium	O
perfringens	O
and	O
precise	O
spontaneous	O
excision	O
from	O
multicopy	O
plasmids	O
in	O
Escherichia	O
coli	O
.	O

Deletions	O
were	O
examined	O
in	O
the	O
LYS2	B
gene	I
,	O
using	O
a	O
set	O
of	O
31-	O
to	O
156-bp	O
inserts	O
that	O
included	O
inserts	O
with	O
no	O
apparent	O
potential	O
for	O
secondary	O
structure	O
as	O
well	O
as	O
two	O
quasipalindromes	O
.	O

The	O
hydropathy	O
plot	O
revealed	O
a	O
rather	O
hydrophilic	O
N	O
-	O
terminal	O
region	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
signal	O
peptide	O
.	O

All	O
carcasses	O
resulted	O
in	O
contamination	O
with	O
aerobic	O
mesophilic	O
bacteria	O
in	O
the	O
range	O
from	O
6	O
x	O
10	O
(	O
3	O
)	O
to	O
1.2	O
x	O
10	O
(	O
6	O
)	O
CFU	O
/	O
ml	O
liquid	O
washed	O
,	O
and	O
94	O
%	O
them	O
with	O
sporulate	O
bacteria	O
,	O
the	O
threshold	O
being	O
under	O
100	O
CFU	O
/	O
ml	O
(	O
Figure	O
1	O
)	O
.	O

The	O
debate	O
over	O
electives--1899	O
.	O

The	O
effects	O
of	O
Codonopsis	O
pilosula	O
oral	O
liquor	O
(	O
CPOL	O
)	O
on	O
tissue	B
-	I
type	I
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
and	O
plasminogen	B
activator	I
inhibitor	I
(	O
PAI	B
)	O
in	O
the	O
plasma	O
of	O
25	O
patients	O
of	O
coronary	O
heart	O
disease	O
with	O
blood	O
stasis	O
were	O
studied	O
.	O

We	O
also	O
isolated	O
two	O
alternatively	O
spliced	O
forms	O
of	O
human	B
CD6	I
cDNA	I
lacking	O
sequences	O
encoding	O
membrane	O
-	O
proximal	O
regions	O
of	O
the	O
cytoplasmic	O
domain	O
which	O
maintain	O
the	O
same	O
reading	O
frame	O
as	O
CD6-PB1	B
.	O

The	O
average	O
values	O
were	O
199	O
and	O
424	O
revertants	O
/	O
g	O
for	O
the	O
hamburgers	O
and	O
hot	O
dogs	O
,	O
respectively	O
.	O

Another	O
common	O
mutation	O
involved	O
amino	O
acids	O
that	O
are	O
thought	O
to	O
make	O
specific	O
contacts	O
with	O
DNA	O
.	O

Altogether	O
our	O
data	O
indicate	O
that	O
PEDF	B
belongs	O
to	O
the	O
subgroup	O
of	O
noninhibitory	O
serpins	B
and	O
that	O
its	O
N	O
-	O
terminal	O
region	O
confers	O
a	O
neurite	O
-	O
promoting	O
activity	O
to	O
the	O
protein	O
.	O

We	O
conclude	O
that	O
this	O
new	O
measurement	O
technique	O
provides	O
an	O
easy	O
and	O
accurate	O
P0.1	O
measurement	O
using	O
standard	O
respiratory	O
equipment	O
when	O
tested	O
in	O
a	O
lung	O
model	O
.	O

After	O
cells	O
were	O
stably	O
transfected	O
with	O
CIITA	B
,	O
endogenous	O
MHC	B
class	I
II	I
genes	I
were	O
constitutively	O
expressed	O
,	O
and	O
MHC	B
class	I
II	I
promoters	I
,	O
delivered	O
by	O
transfection	O
,	O
were	O
actively	O
transcribed	O
in	O
CIITA	B
-	O
expressing	O
cells	O
.	O

Mean	O
growth	O
changes	O
in	O
this	O
Class	O
II	O
sample	O
were	O
comparable	O
to	O
those	O
previously	O
reported	O
for	O
male	O
subjects	O
with	O
Class	O
I	O
malocclusions	O
over	O
the	O
same	O
age	O
period	O
,	O
suggesting	O
a	O
similarity	O
in	O
postpubertal	O
development	O
between	O
these	O
two	O
groups	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
two	O
early	O
class	B
II	I
flagellar	I
genes	I
contained	O
in	O
the	O
orfX	O
-	O
fliP	B
locus	O
.	O

To	O
discern	O
whether	O
these	O
disorders	O
of	O
GnRH	B
deficiency	O
are	O
associated	O
with	O
altered	O
melatonin	O
secretion	O
profiles	O
,	O
we	O
compared	O
untreated	O
young	O
males	O
IGD	O
(	O
n	O
=	O
7	O
)	O
and	O
DP	O
(	O
n	O
=	O
7	O
)	O
to	O
normal	O
pubertal	O
male	O
controls	O
(	O
n	O
=	O
6	O
)	O
.	O

Oncological	O
,	O
clinical	O
and	O
psychological	O
aspects	O
are	O
evaluated	O
according	O
to	O
experience	O
accumulated	O
in	O
recent	O
years	O
,	O
with	O
immediate	O
and	O
delayed	O
reconstruction	O
,	O
carried	O
out	O
in	O
the	O
most	O
diverse	O
specialized	O
centers	O
.	O

Basal	O
promoter	O
activity	O
is	O
enhanced	O
by	O
a	O
functional	O
M1	O
domain	O
in	O
LHR	B
-	O
expressing	O
mouse	O
Leydig	O
tumor	O
cells	O
(	O
MLTC	O
)	O
but	O
not	O
in	O
non	O
-	O
expressing	O
CHO	O
cells	O
.	O

CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
isoforms	I
beta	I
and	I
delta	I
are	O
expressed	O
in	O
mammary	O
epithelial	O
cells	O
and	O
bind	O
to	O
multiple	O
sites	O
in	O
the	O
beta	B
-	I
casein	I
gene	I
promoter	I
.	O

To	O
explore	O
the	O
mechanism	O
of	O
RSK	B
activation	O
,	O
a	O
cloned	O
human	O
RSK	B
cDNA	O
(	O
RSK3	B
)	O
was	O
used	O
to	O
generate	O
and	O
characterize	O
several	O
site	O
-	O
directed	O
RSK	B
mutants	I
;	O
K91A	O
(	O
N	O
-	O
Lys	O
,	O
NH2-terminal	O
ATP	O
-	O
binding	O
mutant	O
)	O
,	O
K444A	O
(	O
C	O
-	O
Lys	O
,	O
COOH	O
-	O
terminal	O
ATP	O
-	O
binding	O
mutant	O
)	O
,	O
N	O
/	O
C	O
-	O
Lys	O
(	O
double	O
ATP	O
-	O
binding	O
mutant	O
)	O
T570A	O
(	O
C	O
-	O
Thr	O
,	O
mutant	O
of	O
the	O
putative	O
MAPK	B
phosphorylation	O
site	O
in	O
subdomain	O
VIII	O
of	O
the	O
C	O
-	O
domain	O
)	O
,	O
S218A	O
(	O
N	O
-	O
Ser	O
,	O
mutant	O
of	O
the	O
corresponding	O
NH2-terminal	O
residue	O
)	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
dominant	O
negative	O
forms	O
of	O
Rac	B
and	O
Cdc42	B
or	O
of	O
the	O
Rho	B
inhibitor	O
C3	B
transferase	I
blocked	O
serum	O
-	O
induced	O
DNA	O
synthesis	O
.	O

The	O
yeast	O
enzyme	O
was	O
6-fold	O
slower	O
than	O
the	O
mammalian	O
enzymes	O
,	O
which	O
made	O
it	O
amenable	O
to	O
pre	O
-	O
steady	O
-	O
state	O
stopped	O
-	O
flow	O
spectroscopic	O
kinetic	O
analysis	O
at	O
30	O
degrees	O
C	O
and	O
pH	O
6.0	O
.	O

The	O
CVA16.4	B
proteolipid	I
transcript	I
is	O
the	O
most	O
prevalent	O
of	O
the	O
two	O
proteolipid	O
messages	O
in	O
expanding	O
ovules	O
harvested	O
10	O
d	O
post	O
-	O
anthesis	O
.	O

IgE	B
levels	O
showed	O
higher	O
values	O
compared	O
to	O
normal	O
individuals	O
and	O
IgE	B
levels	O
were	O
higher	O
in	O
children	O
groups	O
than	O
in	O
adults	O
regardless	O
of	O
the	O
intensity	O
of	O
infection	O
.	O

In	O
one	O
glioblastoma	O
cell	O
line	O
,	O
a	O
Shc	B
-	O
associated	O
p190	B
was	O
identified	O
as	O
the	O
activated	O
PDGFR	B
.	O

Using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
Whipple	O
-	O
specific	O
DNA	O
fragments	O
of	O
284	O
base	O
pairs	O
from	O
the	O
genome	O
of	O
the	O
Whipple	O
bacterium	O
(	O
Tropheryma	O
whippelii	O
)	O
were	O
demonstrated	O
.	O

The	O
immunosuppressant	O
FK506	O
inhibits	O
amino	O
acid	O
import	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

This	O
300	O
bp	O
5'-upstream	O
sequence	O
of	O
K3	B
keratin	I
gene	I
,	O
which	O
can	O
function	O
in	O
vitro	O
as	O
a	O
keratinocyte	O
-	O
specific	O
promoter	O
,	O
contains	O
two	O
clusters	O
of	O
partially	O
overlapping	O
motifs	O
,	O
one	O
with	O
an	O
NFkB	B
consensus	O
sequence	O
and	O
another	O
with	O
a	O
GC	O
box	O
.	O

Here	O
the	O
cloning	O
and	O
molecular	O
analysis	O
of	O
the	O
Zm	B
-	I
ERabp1	I
,	O
Zm	B
-	I
ERabp4	I
,	O
and	O
Zm	B
-	I
ERabp5	I
genes	I
is	O
presented	O
.	O

The	O
presence	O
of	O
the	O
RV	O
5'	O
(	O
+	O
)	O
SL	O
sequence	O
had	O
the	O
primary	O
enhancing	O
effect	O
on	O
translation	O
.	O

Solitary	O
thyroid	O
nodule	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
in	O
the	O
region	O
of	O
the	O
specificity	O
pocket	O
is	O
similar	O
to	O
that	O
of	O
S.	B
griseus	I
proteases	I
A	I
,	I
B	I
,	I
and	I
C.	I

Binding	O
of	O
meAda	B
is	O
necessary	O
to	O
activate	O
transcription	O
of	O
the	O
adaptive	O
response	O
genes	O
;	O
accordingly	O
,	O
in	O
vitro	O
transcription	O
of	O
aidB	B
is	O
dependent	O
on	O
the	O
presence	O
of	O
meAda	B
.	O

Vascular	O
endothelial	O
cells	O
undergo	O
profound	O
changes	O
upon	O
cellular	O
activation	O
including	O
expression	O
of	O
a	O
spectrum	O
of	O
cell	O
activation	O
-	O
associated	O
genes	O
.	O

The	O
MPS1	B
open	I
reading	I
frame	I
has	O
been	O
fused	O
to	O
those	O
that	O
encode	O
the	O
LexA	B
protein	I
or	O
the	O
GST	B
protein	I
and	O
both	O
of	O
these	O
constructs	O
function	O
in	O
yeast	O
.	O

Restriction	O
mapping	O
analysis	O
localized	O
this	O
cDNA	O
to	O
the	O
HHV-6A	B
(	I
U1102	I
)	I
genomic	I
BamHI	I
G	I
fragment	I
,	O
at	O
the	O
right	O
end	O
of	O
the	O
unique	O
long	O
segment	O
of	O
the	O
genome	O
and	O
to	O
the	O
SalI	B
L	I
and	O
SalI	B
O	I
fragments	I
within	O
the	O
left	O
and	O
right	O
terminal	O
direct	O
repeat	O
regions	O
,	O
respectively	O
.	O

Sequence	O
comparisons	O
of	O
prokaryotic	B
RCR	I
initiators	I
has	O
revealed	O
a	O
set	O
of	O
three	O
common	O
motifs	O
,	O
two	O
of	O
which	O
,	O
a	O
putative	O
metal	O
coordination	O
site	O
and	O
a	O
downstream	O
active	O
-	O
site	O
tyrosine	O
motif	O
,	O
could	O
be	O
tentatively	O
identified	O
in	O
parvoviral	B
replicator	I
proteins	I
.	O

The	O
2	O
kb	O
of	O
5'-flanking	O
region	O
and	O
the	O
1.1	O
kb	O
of	O
the	O
entire	O
sGTH	B
alpha	I
subunit	I
coding	O
region	O
were	O
sequenced	O
from	O
the	O
genomic	O
clone	O
,	O
sGTH	B
alpha	I
-	I
G1	I
.	O

His	O
carnitine	B
palmitoyltransferase	I
(	I
CPT	I
)	I
I	I
and	I
II	I
activities	O
were	O
0.06	O
and	O
0.12	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
as	O
compared	O
with	O
a	O
mean	O
value	O
of	O
0.22	O
+	O
/-	O

0.14	O
and	O
0.27	O
+	O
/-	O

0.07	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
,	O
in	O
control	O
subjects	O
.	O

We	O
used	O
two	O
approaches	O
to	O
ascertain	O
whether	O
CDP	B
/	O
cut	B
serves	O
as	O
a	O
repressor	O
of	O
gp91-phox	B
gene	O
expression	O
.	O

Despite	O
the	O
activation	O
of	O
these	O
intracellular	O
signaling	O
molecules	O
,	O
PDGF	B
beta	I
receptor	I
activation	O
elicited	O
no	O
detectable	O
effect	O
on	O
cell	O
proliferation	O
or	O
differentiation	O
.	O

Furthermore	O
,	O
45Ca	O
-	O
binding	O
assays	O
revealed	O
that	O
CCaMK	B
directly	O
binds	O
Ca2	O
+	O
.	O

Primer	O
extension	O
experiments	O
revealed	O
a	O
strong	O
transcription	O
initiation	O
site	O
102	O
bp	O
upstream	O
of	O
the	O
translational	O
start	O
site	O
.	O

The	O
bHLH	B
proteins	I
function	O
as	O
potent	O
transcriptional	O
activators	O
of	O
tissue	O
-	O
specific	O
genes	O
by	O
forming	O
heterodimers	O
between	O
ubiquitous	O
and	O
cell	O
-	O
restricted	O
family	O
members	O
.	O

The	O
other	O
two	O
clones	O
,	O
Ash	B
-	I
m	I
and	I
-s	I
,	O
had	O
nucleotide	O
sequences	O
identical	O
with	O
Ash	B
-	I
l	I
cDNA	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
-DEDDDL	O
sequence	O
stabilizes	O
GDP	O
binding	O
to	O
Ran	B
,	O
and	O
that	O
the	O
domain	O
is	O
required	O
for	O
high	O
affinity	O
interaction	O
with	O
a	O
Ran	B
-	I
binding	I
protein	I
,	O
HTF9A	B
/	O
RanBP1	B
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
incidence	O
and	O
presentation	O
of	O
acute	O
pernicious	O
or	O
fulminating	O
beriberi	O
in	O
a	O
general	O
district	O
hospital	O
.	O

CPT-11	O
was	O
administered	O
as	O
a	O
30-minute	O
i.v	O
.	O

infusion	O
at	O
a	O
dose	O
of	O
350	O
mg	O
/	O
m2	O
diluted	O
in	O
250	O
ml	O
normal	O
saline	O
every	O
3	O
weeks	O
.	O

Moreover	O
,	O
Western	O
blots	O
demonstrated	O
at	O
least	O
six	O
types	O
of	O
Ypt	B
in	O
both	O
Cr	O
and	O
Vc	O
,	O
suggesting	O
that	O
these	O
Ypt	B
are	O
used	O
for	O
household	O
functions	O
responsible	O
for	O
vesicle	O
transport	O
rather	O
than	O
for	O
cellular	O
differentiation	O
.	O

There	O
is	O
a	O
national	O
effort	O
to	O
begin	O
to	O
ask	O
all	O
female	O
patients	O
about	O
family	O
violence	O
.	O

SRY	B
-	I
related	I
cDNA	I
encoding	O
a	O
protein	O
with	O
a	O
high	B
-	I
mobility	I
-	I
group	I
(	O
HMG	B
)	O
box	O
and	O
a	O
leucine	O
zipper	O
motif	O
,	O
which	O
was	O
designated	O
SOX	B
-	I
LZ	I
,	O
was	O
isolated	O
from	O
a	O
rainbow	O
trout	O
testis	O
cDNA	O
library	O
.	O

We	O
compared	O
the	O
inhibitory	O
effect	O
of	O
naturally	O
occurring	O
mutant	B
hTR	I
beta	I
1	I
,	O
artificially	O
created	O
hTR	B
alpha	I
1	I
mutants	I
,	O
c	B
-	I
erbA	I
alpha	I
2	I
and	O
the	O
human	B
peroxisome	I
proliferator	I
-	I
activated	I
receptor	I
(	O
hPPAR	B
)	O
on	O
three	O
prototypic	O
T3-response	O
elements	O
(	O
TREs	O
)	O
,	O
TRE	O
-	O
PAL	O
,	O
DR	O
+	O
4	O
and	O
TRE	O
-	O
LAP	O
.	O

The	O
27-base	O
element	O
interacts	O
with	O
a	O
PDGF	B
-	O
activated	O
serine	O
/	O
threonine	O
phosphoprotein	O
that	O
is	O
detected	O
only	O
within	O
the	O
nucleus	O
of	O
PDGF	O
-	O
treated	O
3T3	O
cells	O
.	O

Characterization	O
of	O
the	O
promoter	O
for	O
the	O
human	B
85	I
kDa	I
cytosolic	I
phospholipase	I
A2	I
gene	I
.	O

Characterization	O
of	O
FIII	B
/	O
YY1	B
,	O
a	O
Xenopus	B
laevis	I
conserved	I
zinc	I
-	I
finger	I
protein	I
binding	O
to	O
the	O
first	O
exon	O
of	O
L1	B
and	O
L14	B
ribosomal	I
protein	I
genes	I
.	O

This	O
structure	O
of	O
cucumisin	B
suggests	O
that	O
it	O
is	O
probably	O
synthesized	O
as	O
an	O
inactive	O
precursor	O
.	O

A	O
unique	O
leucine	O
-	O
proline	O
repeat	O
element	O
found	O
N	O
-	O
terminal	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
EmBP-1	B
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
DNA	O
-	O
binding	O
or	O
dimerization	O
.	O

Deletion	O
of	O
both	O
prfA	B
and	O
ponA	B
resulted	O
in	O
extremely	O
slow	O
growth	O
and	O
a	O
reduction	O
in	O
sporulation	O
efficiency	O
.	O

In	O
broken	O
L	O
-	O
cell	O
membranes	O
expressing	O
wild	O
type	O
or	O
mutant	B
M6P	I
/	I
IGF	I
II	I
receptors	I
,	O
30	O
nM	O
IGF	B
II	I
also	O
failed	O
to	O
affect	O
the	O
pertussis	B
toxin	I
substrate	O
activity	O
.	O

For	O
the	O
first	O
time	O
we	O
describe	O
deletion	O
and	O
point	O
mutations	O
within	O
the	O
plasma	B
membrane	I
family	I
of	I
guanylyl	I
cyclase	I
receptors	I
that	O
result	O
in	O
the	O
formation	O
of	O
effective	O
dominant	O
negative	O
proteins	O
.	O

Similarly	O
approximately	O
300	O
bp	O
of	O
sequence	O
downstream	O
of	O
the	O
translation	O
terminator	O
TGA	O
of	O
the	O
beta	B
-	I
tubulin	I
2	I
(	O
BTU2	B
)	O
gene	O
could	O
substitute	O
for	O
the	O
3	O
'	O
region	O
of	O
the	O
H4-I	B
gene	I
.	O

The	O
introduction	O
of	O
an	O
acidic	O
residue	O
at	O
the	O
second	O
site	O
was	O
essential	O
for	O
suppression	O
of	O
the	O
Asn-285	O
mutation	O
because	O
Lys-220	O
and	O
Gln-220	O
second	O
-	O
site	O
mutants	O
of	O
the	O
Asn-285	O
mutant	O
showed	O
very	O
low	O
tetracycline	O
resistance.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

One	O
complex	O
appears	O
to	O
be	O
ubiquitous	O
but	O
enriched	O
in	O
lymphoid	O
cells	O
and	O
represents	O
the	O
binding	O
of	O
a	O
potentially	O
novel	O
factor	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
approximately	O
50	O
kDa	O
.	O

Each	O
type	O
was	O
divided	O
into	O
two	O
subgroups	O
on	O
the	O
basis	O
of	O
whether	O
the	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
showed	O
intense	O
fatty	O
replacement	O
(	O
type	O
a	O
=	O
negative	O
for	O
intense	O
fatty	O
replacement	O
,	O
type	O
b	O
=	O
positive	O
for	O
intense	O
fatty	O
replacement	O
)	O
.	O

Between	O
the	O
subgroups	O
of	O
dementia	O
disorders	O
there	O
were	O
no	O
significant	O
differences	O
in	O
basal	O
cortisol	O
levels	O
.	O

The	O
region	O
between	O
DXS52	B
and	O
Factor	B
VIII	I
gene	I
in	O
the	O
human	O
Xq28	O
chromosomal	O
band	O
contains	O
a	O
G+C	O
-	O
rich	O
isochore	O
to	O
which	O
many	O
genes	O
have	O
been	O
mapped	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
DNA	B
polymerase	I
gene	I
of	I
Bombyx	I
mori	I
nuclear	I
polyhedrosis	I
virus	I
.	O

A	O
comparison	O
of	O
the	O
Flavobacterium	O
glycosylasparaginase	B
with	O
a	O
mammalian	O
glycosylasparaginase	B
revealed	O
30	O
%	O
structural	O
identity	O
and	O
60	O
%	O
overall	O
similarity	O
between	O
the	O
prokaryotic	O
and	O
eukaryotic	O
forms	O
of	O
the	O
enzyme	O
.	O

To	O
understand	O
the	O
function	O
of	O
receptor	B
-	I
linked	I
tyrosine	I
phosphatases	I
in	O
neural	O
development	O
,	O
we	O
sought	O
to	O
identify	O
LAR	B
isoforms	I
preferentially	O
expressed	O
in	O
the	O
nervous	O
system	O
and	O
cellular	O
processes	O
regulating	O
LAR	B
alternative	O
splicing	O
.	O

135	O
students	O
had	O
a	O
count	O
of	O
less	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O

urine	O
and	O
56	O
had	O
more	O
than	O
50	O
eggs	O
/	O
10ml	O
.	O

Physical	O
analysis	O
maps	O
SAL6	B
to	O
chromosome	O
XVI	O
between	O
TPK2	B
and	O
spt14	B
.	O

Rho	B
GDP	I
/	I
GTP	I
exchange	I
inhibitor	I
,	O
Rho	B
GDI	I
,	O
comigrated	O
with	O
Rac2	B
and	O
RhoA	B
,	O
but	O
not	O
Rac1	B
.	O

Schnell	O
,	O
J.	O

The	O
expression	O
of	O
this	O
clone	O
in	O
a	O
wee1	B
/	O
mik1-deficient	B
mutant	O
causes	O
an	O
elongated	O
cell	O
phenotype	O
under	O
non	O
-	O
permissive	O
growth	O
conditions	O
.	O

The	O
mean	O
jitter	O
and	O
the	O
fiber	O
density	O
did	O
not	O
change	O
significantly	O
from	O
day	O
0	O
(	O
30.1	O
+	O
/-	O

3.6	O
microseconds	O
;	O
1.4	O
+	O
/-	O

0.07	O
)	O
to	O
day	O
30	O
(	O
34.5	O
+	O
/-	O

2.7	O
microseconds	O
;	O
1.6	O
+	O
/-	O

0.13	O
)	O
.	O

One	O
member	O
of	O
this	O
family	O
,	O
RFX1	B
,	O
is	O
a	O
transcription	O
factor	O
for	O
a	O
variety	O
of	O
viral	O
and	O
cellular	O
genes	O
.	O

During	O
ISO+AT	O
infusion	O
,	O
abdominal	O
fat	O
blood	O
flow	O
was	O
still	O
significantly	O
increased	O
as	O
compared	O
with	O
control	O
values	O
in	O
lean	O
and	O
obese	O
subjects	O
.	O

The	O
first	O
open	O
reading	O
frame	O
of	O
the	O
blueberry	O
scorch	O
carlavirus	O
(	O
BBScV	O
)	O
genome	O
encodes	O
a	O
putative	O
replication	O
-	O
associated	O
protein	O
of	O
223	O
kDa	O
(	O
p223	B
)	O
.	O

From	O
sequence	O
alignments	O
with	O
phylogenetically	O
related	O
viruses	O
,	O
including	O
tymoviruses	O
,	O
we	O
predicted	O
that	O
p223	B
contained	O
a	O
papain	B
-	I
like	I
proteinase	I
domain	I
with	O
a	O
putative	O
catalytic	O
cysteine994	O
and	O
histidine1075	O
.	O

The	O
regions	O
of	O
the	O
tooth	O
fracture	O
are	O
determined	O
.	O

Like	O
humans	O
,	O
the	O
PITSLRE	B
PK	I
genes	I
in	I
chickens	I
must	O
be	O
closely	O
linked	O
,	O
based	O
on	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
localization	O
of	O
these	O
genes	O
to	O
a	O
single	O
chicken	O
microchromosome	O
.	O

Mutation	O
of	O
the	O
P450BM-3	B
Barbie	I
box	I
significantly	O
increased	O
the	O
expression	O
of	O
both	O
P450BM-3	B
and	O
Bm3P1	B
(	O
another	O
small	O
gene	O
located	O
upstream	O
of	O
the	O
P450BM-3	B
gene	I
that	O
encodes	O
a	O
second	O
putative	O
regulatory	O
protein	O
)	O
in	O
response	O
to	O
pentobarbital	O
induction	O
but	O
left	O
the	O
basal	O
levels	O
unaffected	O
.	O

When	O
combined	O
with	O
serum	O
ferritin	B
and	O
hemoglobin	B
determinations	O
,	O
the	O
serum	O
transferrin	B
receptor	I
assay	O
is	O
a	O
valuable	O
addition	O
in	O
epidemiologic	O
surveys	O
because	O
it	O
provides	O
a	O
quantitative	O
measure	O
of	O
functional	O
iron	O
deficiency	O
and	O
it	O
distinguishes	O
true	O
IDA	O
from	O
the	O
anemia	O
of	O
chronic	O
disease	O
.	O

We	O
have	O
screened	O
the	O
mouse	O
cDNA	O
library	O
of	O
an	O
MIN6	O
cell	O
line	O
,	O
derived	O
from	O
pancreatic	O
beta	O
cells	O
,	O
for	O
its	O
novel	O
isoform	O
and	O
have	O
identified	O
a	O
cDNA	O
encoding	O
a	O
593-amino	O
acid	O
protein	O
having	O
63	O
,	O
53	O
,	O
and	O
30	O
%	O
identity	O
with	O
munc-18	B
/	I
n	I
-	I
Sec1	I
/	I
rbSec1	I
,	O
Caenorhabditis	B
elegans	I
unc18	I
,	O
and	O
Saccharomyces	B
cerevisiae	I
Sec1p	I
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
hypoxia	O
-	O
induced	O
expression	O
of	O
the	O
endogenous	O
Epo	B
gene	I
was	O
significantly	O
inhibited	O
in	O
Hep3B	O
cells	O
stably	O
transfected	O
with	O
HNF-4	B
delta	I
C.	I

Small	B
Maf	I
proteins	I
heterodimerize	O
with	O
Fos	B
and	O
may	O
act	O
as	O
competitive	O
repressors	O
of	O
the	O
NF	B
-	I
E2	I
transcription	I
factor	I
.	O

Glomerular	O
hemodynamics	O
during	O
abortion	O
induced	O
by	O
RU	O
486	O
and	O
sepsis	O
in	O
rats	O
.	O

Alternatively	O
processed	O
isoforms	O
of	O
cellular	B
nucleic	I
acid	I
-	I
binding	I
protein	I
interact	O
with	O
a	O
suppressor	O
region	O
of	O
the	O
human	B
beta	I
-	I
myosin	I
heavy	I
chain	I
gene	I
.	O

Erythrocyte	B
delta	I
-	I
aminolevulinic	I
acid	I
dehydratase	I
(	O
ALAD	B
)	O
activity	O
,	O
erythrocyte	O
zinc	O
protoporphyrin	O
(	O
ZPP	O
)	O
/	O
heme	O
ratio	O
,	O
and	O
urinary	O
coproporphyrin	O
(	O
UC	O
)	O
concentration	O
have	O
been	O
employed	O
as	O
biological	O
indicators	O
of	O
moderate	O
-	O
to	O
high	O
-	O
level	O
lead	O
exposure	O
,	O
corresponding	O
to	O
blood	O
levels	O
in	O
excess	O
of	O
50	O
micrograms	O
/	O
dl	O
,	O
in	O
human	O
subjects	O
.	O

Analysis	O
of	O
disassociation	O
rates	O
indicates	O
that	O
the	O
Grf10-Swi5-DNA	B
complex	O
has	O
a	O
longer	O
half	O
-	O
life	O
than	O
protein	O
-	O
DNA	O
complexes	O
that	O
contain	O
only	O
Swi5	B
or	O
Grf10	B
.	O

Results	O
from	O
in	O
vitro	O
transcription	O
-	O
translation	O
analysis	O
and	O
maxicell	O
experiments	O
suggested	O
that	O
the	O
447-bp	O
ORF	O
was	O
the	O
one	O
being	O
actively	O
expressed	O
.	O

The	O
use	O
of	O
specific	O
antibodies	O
allowed	O
the	O
identification	O
of	O
at	O
least	O
RAR	B
beta	I
in	O
some	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
,	O
although	O
the	O
four	O
sequences	O
bind	O
single	O
RARs	B
transfected	O
in	O
COS	O
cells	O
much	O
less	O
efficiently	O
,	O
or	O
not	O
at	O
all	O
,	O
when	O
compared	O
to	O
a	O
canonical	O
RAR	B
responsive	I
element	I
.	O

A	O
decanucleotide	O
promoter	O
sequence	O
homologous	O
to	O
those	O
found	O
in	O
humans	O
and	O
mice	O
was	O
located	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
one	O
horse	O
gene	O
.	O

BACKGROUND	O
:	O
We	O
conducted	O
a	O
phase	O
I	O
study	O
with	O
MDL	O
73,147EF	O
,	O
a	O
new	O
5	B
hydroxytryptamine	I
3	I
(	I
5-HT3	I
)	I
receptor	I
antagonist	O
,	O
in	O
25	O
patients	O
requiring	O
emetogenic	O
chemotherapy	O
.	O

The	O
DNA	O
sequence	O
adjacent	O
to	O
the	O
lacZ	B
gene	I
has	O
been	O
determined	O
for	O
91	O
vegetative	O
fusion	O
genes	O
whose	O
products	O
have	O
been	O
localized	O
and	O
for	O
43	O
meiotically	O
induced	O
fusions	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	O
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

We	O
previously	O
showed	O
that	O
v	B
-	I
Rel	I
,	O
the	O
oncoprotein	O
of	O
the	O
avian	O
retrovirus	O
Rev	O
-	O
T	O
,	O
can	O
increase	O
expression	O
from	O
promoters	O
containing	O
binding	O
sites	O
for	O
the	O
cellular	O
transcription	O
factor	O
Sp1	B
in	O
chicken	O
embryo	O
fibroblasts	O
(	O
S.	O

Treatment	O
with	O
amphotericin	O
B	O
and	O
flucytosine	O
led	O
to	O
improvement	O
of	O
the	O
symptoms	O
but	O
did	O
not	O
eradicate	O
the	O
micro	O
-	O
organisms	O
from	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

Consequently	O
functional	O
mRNAs	O
can	O
be	O
produced	O
by	O
endogenous	B
RNA	I
polymerase	I
I.	O

Univariate	O
statistical	O
analysis	O
based	O
on	O
Kaplan	O
-	O
Meier	O
-	O
estimates	O
and	O
Log	O
-	O
Rank	O
-	O
Test	O
showed	O
the	O
following	O
prognostically	O
beneficial	O
factors	O
:	O
Limited	O
disease	O
stage	O
(	O
p	O
=	O
0.009	O
)	O
,	O
NSE	B
serum	O
level	O
less	O
than	O
25	O
micrograms	O
/	O
l	O
(	O
p	O
=	O
0.016	O
)	O
,	O
serum	O
alkaline	B
phosphatase	I
less	O
than	O
200	O
U	O
/	O
l	O
(	O
p	O
=	O
0.035	O
)	O
,	O
normal	O
serum	O
albumin	B
(	O
p	O
=	O
0.003	O
)	O
and	O
activity	O
index	O
of	O
minimum	O
of	O
70	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Of	O
419	O
persons	O
surveyed	O
,	O
207	O
(	O
49.4	O
%	O
)	O
were	O
antigen	O
-	O
positive	O
with	O
the	O
Og4C3	B
assay	O
.	O

Ten	O
volunteers	O
were	O
tested	O
at	O
18,000	O
ft	O
(	O
5,486	O
m	O
)	O
,	O
and	O
through	O
12,000	O
,	O
8,000	O
,	O
and	O
5,000	O
ft	O
(	O
3,657	O
,	O
2,438	O
,	O
and	O
1,524	O
m	O
)	O
with	O
directional	O
sounds	O
recorded	O
via	O
a	O
dummy	O
head	O
microphone	O
and	O
presented	O
binaurally	O
.	O

Upon	O
differentiation	O
with	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
transcription	O
of	O
the	O
Rex-1	B
gene	I
decreases	O
rapidly	O
.	O

Rat	B
kidney	I
carboxylesterase	I
.	O

Infect	O
.	O

The	O
Nur77	B
protein	I
can	O
act	O
as	O
a	O
potent	O
transcription	O
activator	O
and	O
may	O
function	O
to	O
regulate	O
the	O
expression	O
of	O
downstream	O
genes	O
in	O
response	O
to	O
extracellular	O
stimuli	O
.	O

KRN2391	O
and	O
cromakalim	O
produced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
aortic	O
and	O
coronary	O
blood	O
flow	O
.	O

Basal	O
plasma	O
AVP	B
levels	O
and	O
AVP	B
release	O
after	O
postural	O
change	O
were	O
assessed	O
,	O
and	O
plasma	O
NPY	B
levels	O
were	O
measured	O
in	O
the	O
same	O
samples	O
.	O

Surprisingly	O
,	O
nuclear	O
forms	O
of	O
IE110	B
were	O
found	O
to	O
move	O
a	O
cytoplasmic	O
form	O
of	O
IE175	B
into	O
nuclear	O
punctate	O
structures	O
,	O
and	O
a	O
cytoplasmic	O
form	O
of	O
IE110	B
was	O
able	O
to	O
retain	O
nuclear	O
forms	O
of	O
IE175	B
in	O
cytoplasmic	O
punctate	O
structures	O
.	O

The	O
inflation	O
hub	O
of	O
the	O
probe	O
is	O
recreated	O
by	O
modifying	O
a	O
standard	O
USCI	O
Tuohy	O
-	O
Borst	O
Y	O
adaptor	O
and	O
attaching	O
this	O
to	O
the	O
transected	O
probe	O
hypotube	O
.	O

Mutational	O
analysis	O
of	O
yeast	B
CEG1	I
demonstrated	O
that	O
four	O
of	O
the	O
five	O
conserved	O
motifs	O
are	O
essential	O
for	O
capping	B
enzyme	I
function	O
in	O
vivo	O
.	O

A	O
sequence	O
representing	O
about	O
50	O
%	O
of	O
the	O
expected	O
complete	O
sequence	O
was	O
obtained	O
by	O
translation	O
of	O
the	O
two	O
open	O
reading	O
frames	O
present	O
on	O
a	O
1.6	O
kb	O
DNA	O
genomic	O
fragment	O
.	O

METHODS--16	O
volunteered	O
for	O
spirometry	O
with	O
methacholine	O
provocation	O
test	O
including	O
a	O
test	O
for	O
small	O
airways	O
function	O
by	O
volume	O
of	O
trapped	O
gas	O
(	O
VTG	O
)	O
.	O

Relationship	O
of	O
CDK	B
-	I
activating	I
kinase	I
and	O
RNA	B
polymerase	I
II	I
CTD	O
kinase	O
TFIIH	B
/	O
TFIIK	B
.	O

The	O
effects	O
of	O
social	O
isolation	O
on	O
morphine	O
-	O
induced	O
locomotor	O
activity	O
were	O
compared	O
in	O
:	O
(	O
i	O
)	O
animals	O
with	O
an	O
intact	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
;	O
(	O
ii	O
)	O
animals	O
in	O
which	O
stress	O
-	O
induced	O
corticosterone	O
secretion	O
was	O
blocked	O
by	O
adrenalectomy	O
.	O

Standard	O
curve	O
correlation	O
coefficients	O
of	O
0.995	O
or	O
greater	O
were	O
obtained	O
during	O
validation	O
experiments	O
and	O
analysis	O
of	O
study	O
samples	O
.	O

There	O
was	O
no	O
difference	O
in	O
plasma	O
concentrations	O
of	O
PGI2	O
(	O
figure	O
4	O
)	O
and	O
TxA2	O
in	O
patients	O
with	O
normal	O
blood	O
pressure	O
,	O
mild	O
preeclampsia	O
and	O
hypotension	O
,	O
whereas	O
in	O
severe	O
preeclampsia	O
,	O
the	O
plasma	O
concentration	O
of	O
PGI2	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.001	O
)	O
and	O
of	O
TxA2	O
significantly	O
higher	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Under	O
resting	O
conditions	O
,	O
activity	O
levels	O
of	O
cardiac	O
vagal	O
and	O
sympathetic	O
outflows	O
are	O
not	O
related	O
across	O
young	O
,	O
healthy	O
human	O
subjects	O
and	O
peripheral	O
interaction	O
is	O
not	O
manifest	O
between	O
the	O
autonomic	O
divisions	O
.	O

Both	O
proprioceptive	O
and	O
electroreceptive	O
units	O
showed	O
a	O
progression	O
of	O
receptive	O
fields	O
from	O
anterior	O
to	O
posterior	O
body	O
in	O
the	O
rostral	O
to	O
caudal	O
direction	O
along	O
the	O
length	O
of	O
DGR	O
.	O

Granisetron	O
,	O
but	O
not	O
saline	O
,	O
abolished	O
vomiting	O
and	O
nausea	O
when	O
given	O
as	O
intervention	O
after	O
this	O
combined	O
emetic	O
regimen	O
.	O

This	O
was	O
obtained	O
with	O
the	O
thermal	O
neutron	O
fluency	O
2.0	O
x	O
10	O
(	O
10	O
)	O
n	O
/	O
cm2	O
.	O

Endotoxemia	O
induced	O
by	O
gram	O
-	O
negative	O
bacteria	O
leads	O
to	O
endotoxic	O
shock	O
pathogenetically	O
stemming	O
from	O
the	O
integral	O
component	O
of	O
the	O
bacterial	O
wall	O
--	O
lipid	O
A.	O

The	O
study	O
made	O
to	O
define	O
the	O
ability	O
of	O
lipid	B
A	I
monoclonal	I
antibodies	I
to	O
correct	O
hemodynamic	O
disturbances	O
due	O
to	O
endotoxemia	O
in	O
dog	O
experiments	O
showed	O
the	O
efficacy	O
of	O
the	O
antibodies	O
administration	O
.	O

This	O
sequenced	O
region	O
of	O
the	O
V	O
beta	O
locus	O
contains	O
an	O
average	O
number	O
of	O
repetitive	O
DNA	O
elements	O
(	O
21	O
Alu	B
,	O
three	O
L1	B
,	O
three	O
MER	O
,	O
and	O
three	O
retrovirus	O
-	O
related	O
elements	O
.	O

In	O
an	O
in	O
vitro	O
study	O
,	O
10	O
/	O
0	O
nylon	O
was	O
found	O
to	O
require	O
a	O
significantly	O
lower	O
laser	O
energy	O
density	O
to	O
produce	O
suture	O
lysis	O
following	O
a	O
single	O
shot	O
than	O
either	O
10	O
/	O
0	O
Dacron	O
or	O
10	O
/	O
0	O
prolene	O
.	O

We	O
report	O
here	O
that	O
microinjection	O
of	O
an	O
anti	B
-	I
CBP	I
antiserum	I
into	O
fibroblasts	O
can	O
inhibit	O
transcription	O
from	O
a	O
cAMP	O
responsive	O
promoter	O
.	O

Ketamine	O
in	O
the	O
treatment	O
of	O
bronchospasm	O
during	O
mechanical	O
ventilation	O
.	O

In	O
conclusion	O
,	O
the	O
disposition	O
of	O
venlafaxine	O
and	O
O	O
-	O
desmethylvenlafaxine	O
is	O
markedly	O
altered	O
in	O
renal	O
disease	O
;	O
therefore	O
dosage	O
adjustment	O
is	O
warranted	O
for	O
patients	O
with	O
creatinine	O
clearance	O
values	O
below	O
30	O
ml	O
/	O
min	O
.	O

M.	O
,	O
and	O
D.	O

At	O
least	O
some	O
of	O
the	O
difference	O
in	O
stability	O
of	O
the	O
two	O
kinds	O
of	O
complexes	O
was	O
due	O
to	O
the	O
fact	O
that	O
the	O
dissociation	O
rate	O
of	O
the	O
A	O
stem	O
substrate	O
from	O
the	O
protein	O
-	O
DNA	O
complexes	O
was	O
approximately	O
fourfold	O
faster	O
than	O
that	O
of	O
the	O
complete	O
TR	B
.	O

Number	O
and	O
size	O
of	O
silver	O
-	O
stained	O
nucleoli	O
(	O
Ag	O
-	O
NOR	O
clusters	O
)	O
in	O
canine	O
seminomas	O
:	O
correlation	O
with	O
histological	O
features	O
and	O
tumour	O
behaviour	O
.	O

The	O
tumor	O
suppressor	O
and	O
transcriptional	O
factor	O
p53	B
is	O
a	O
phosphorylated	O
protein	O
.	O

The	O
acfD	B
gene	I
encompasses	O
254	O
nt	O
that	O
are	O
predicted	O
to	O
encode	O
an	O
88-amino	O
-	O
acid	O
(	O
aa	O
)	O
protein	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
KRAB	B
domain	I
present	O
in	O
the	O
non	O
-	O
finger	O
region	O
of	O
many	O
ZFP	B
genes	I
quenches	O
transcription	O
possibly	O
due	O
to	O
specific	O
protein	O
-	O
protein	O
interactions	O
between	O
the	O
KRAB	B
-	I
A	I
domain	I
and	O
components	O
of	O
the	O
proximal	O
transcriptional	O
apparatus	O
.	O

The	O
newly	O
recognised	O
skeletogenital	O
syndrome	O
.	O

The	O
immune	O
response	O
of	O
past	O
-	O
infection	O
of	O
cytomegalovirus	O
in	O
the	O
patients	O
of	O
RTID	O
is	O
rather	O
remarkable	O
.	O

Reduced	O
NK	O
activity	O
correlates	O
with	O
active	O
disease	O
in	O
HIV-	O
patients	O
with	O
multidrug	O
-	O
resistant	O
pulmonary	O
tuberculosis	O
.	O

These	O
results	O
suggest	O
that	O
leader	O
-	O
mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA	O
-	O
RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

Comparison	O
with	O
the	O
bovine	O
gene	O
showed	O
that	O
the	O
5'-flanking	O
region	O
of	O
the	O
hATP1	B
gene	I
has	O
an	O
unconserved	O
guanine	O
-	O
cytosine	O
(	O
GC	O
)	O
rich	O
region	O
,	O
including	O
several	O
binding	O
motifs	O
of	O
transcriptional	O
factors	O
,	O
such	O
as	O
Sp1	B
,	O
AP-2	B
,	O
and	O
GCF	B
.	O

Here	O
,	O
we	O
present	O
genetic	O
evidence	O
in	O
Saccharomyces	O
cerevisiae	O
for	O
a	O
functional	O
interaction	O
between	O
the	O
DEAH	B
protein	I
Prp16	B
,	O
and	O
the	O
U6	B
and	O
U2	B
spliceosomal	I
snRNAs	I
.	O

These	O
mutants	O
had	O
deletions	O
of	O
the	O
extreme	O
amino	O
-	O
terminal	O
residues	O
as	O
far	O
as	O
amino	O
acid	O
residue	O
30	O
.	O

Through	O
a	O
stretch	O
of	O
56	O
amino	O
acids	O
,	O
constituting	O
the	O
MADS	B
domain	I
,	O
the	O
two	O
proteins	O
are	O
identical	O
except	O
for	O
two	O
conservative	O
amino	O
acid	O
substitutions	O
.	O

Clinical	O
aspects	O
of	O
early	O
increase	O
in	O
serum	O
gamma	B
-	I
glutamyl	I
transferase	I
in	O
cerebral	O
infarction	O
.	O

The	O
indoor	O
radon	O
concentration	O
in	O
the	O
summer	O
(	O
1990	O
)	O
period	O
ranged	O
between	O
8	O
and	O
81	O
Bq	O
m-3	O
,	O
while	O
in	O
the	O
winter	O
(	O
1989	O
-	O
1990	O
)	O
it	O
ranged	O
between	O
20	O
and	O
143	O
Bq	O
m-3	O
for	O
the	O
first	O
year	O
of	O
measurements	O
or	O
between	O
8	O
and	O
92	O
Bq	O
m-3	O
in	O
the	O
summer	O
(	O
1991	O
)	O
period	O
and	O
between	O
12	O
and	O
119	O
Bq	O
m-3	O
in	O
the	O
winter	O
(	O
1990	O
-	O
1991	O
)	O
for	O
the	O
second	O
year	O
of	O
measurements	O
.	O

The	O
results	O
indicate	O
that	O
hrpRS	B
and	O
hrpL	B
are	O
part	O
of	O
a	O
regulatory	O
cascade	O
in	O
which	O
HrpR	B
and	O
HrpS	B
activate	O
expression	O
of	O
hrpL	B
and	O
HrpL	B
,	O
a	O
putative	O
sigma	B
factor	I
,	O
induces	O
expression	O
of	O
HrpL	B
-	I
responsive	I
genes	I
.	O

DtxR	B
is	O
an	O
iron	O
-	O
dependent	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
that	O
binds	O
to	O
the	O
tox	B
operator	I
,	O
an	O
inverted	O
-	O
repeat	O
nucleotide	O
sequence	O
located	O
upstream	O
from	O
the	O
diphtheria	B
toxin	I
gene	I
.	O

We	O
have	O
previously	O
shown	O
that	O
LBP-1	B
represses	O
HIV-1	O
transcription	O
by	O
inhibiting	O
the	O
binding	O
of	O
TFIID	B
to	O
the	O
TATA	O
box	O
.	O

Sodium	O
-	O
taurocholate	O
-	O
induced	O
acute	O
necrotizing	O
pancreatitis	O
does	O
not	O
affect	O
jejunal	O
oxygenation	O
in	O
pigs	O
.	O

The	O
epidemic	O
occurred	O
in	O
a	O
group	O
of	O
26	O
community	O
members	O
(	O
23	O
men	O
and	O
3	O
women	O
,	O
mean	O
age	O
,	O
28.9	O
-	O
-3	O
years	O
)	O
living	O
and	O
working	O
together	O
,	O
who	O
underwent	O
acute	O
and	O
convalescent	O
serologic	O
tests	O
for	O
Mycoplasma	O
pneumoniae	O
,	O
Legionella	O
pneumophila	O
,	O
cytomegalovirus	O
,	O
adenovirus	O
,	O
Coxiella	O
burnetii	O
,	O
and	O
Chlamydia	O
pneumoniae	O
.	O

Genomic	O
DNA	O
clones	O
containing	O
the	O
T	B
-	I
cell	I
-	I
specific	I
human	I
MAL	I
gene	I
were	O
isolated	O
.	O

Expression	O
of	O
the	O
dibasic	O
proprotein	O
processing	O
enzyme	O
furin	B
is	O
directed	O
by	O
multiple	O
promoters	O
.	O

Genetic	O
and	O
phenotypic	O
analysis	O
indicates	O
that	O
NHP6A	B
and	O
NHP6B	B
function	O
downstream	O
of	O
SLT2	B
.	O

Rather	O
,	O
complete	O
skipping	O
of	O
exon	O
V	O
and	O
subsequent	O
joining	O
of	O
exon	O
IV	O
to	O
exon	O
VI	O
caused	O
a	O
shift	O
in	O
the	O
open	O
reading	O
frame	O
,	O
which	O
remodeled	O
GPHe	B
(	I
P2	I
)	I
with	O
an	O
elongated	O
new	O
hydrophobic	O
sequence	O
for	O
membrane	O
anchoring	O
.	O

The	O
presence	O
of	O
the	O
foreign	O
gene	O
was	O
confirmed	O
by	O
Southern	O
analysis	O
.	O

Functional	O
postnatal	O
development	O
of	O
the	O
rat	O
primary	O
visual	O
cortex	O
and	O
the	O
role	O
of	O
visual	O
experience	O
:	O
dark	O
rearing	O
and	O
monocular	O
deprivation	O
.	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
Ypt51p	B
,	O
Ypt52p	B
,	O
and	O
Ypt53p	B
are	O
required	O
for	O
transport	O
in	O
the	O
endocytic	O
pathway	O
and	O
for	O
correct	O
sorting	O
of	O
vacuolar	B
hydrolases	I
suggesting	O
a	O
possible	O
intersection	O
of	O
the	O
endocytic	O
with	O
the	O
vacuolar	O
sorting	O
pathway	O
.	O

The	O
variable	O
regions	O
of	O
vertebrate	O
striated	O
TnT	B
isoforms	I
reflect	O
the	O
subsequent	O
addition	O
and	O
modification	O
of	O
genomic	O
sequences	O
to	O
give	O
rise	O
to	O
members	O
of	O
the	O
TnT	B
multigene	I
family	I
.	O

These	O
viruses	O
depend	O
on	O
the	O
host	O
cell	O
machinery	O
for	O
their	O
existence	O
,	O
and	O
interference	O
with	O
these	O
processes	O
typically	O
interferes	O
with	O
other	O
important	O
host	O
physiology	O
.	O

The	O
experiment	O
included	O
6	O
male	O
and	O
4	O
female	O
healthy	O
subjects	O
who	O
,	O
during	O
a	O
24-hour	O
stay	O
in	O
the	O
respiration	O
chambers	O
,	O
performed	O
,	O
in	O
the	O
morning	O
and	O
afternoon	O
,	O
15	O
min	O
cycling	O
with	O
the	O
total	O
work	O
of	O
6,750	O
kg	O
m.	O

Using	O
the	O
sequence	O
data	O
obtained	O
from	O
the	O
human	O
TCRAC	B
/	O
TCRDC	B
region	O
,	O
we	O
have	O
extended	O
a	O
polymerase	O
chain	O
reaction	O
-	O
based	O
assay	O
to	O
test	O
for	O
the	O
expression	O
of	O
the	O
individual	O
TCRAJ	B
gene	I
segments	I
.	O

The	O
baroreflex	O
latency	O
(	O
from	O
the	O
ECG	O
R	O
-	O
wave	O
to	O
the	O
integrated	O
MSNA	O
burst	O
peak	O
)	O
was	O
constant	O
at	O
approximately	O
1.20	O
s	O
during	O
sleep	O
,	O
suggesting	O
that	O
pulse	O
-	O
synchronicity	O
was	O
maintained	O
.	O

Furthermore	O
,	O
unlike	O
the	O
case	O
for	O
HIS3	B
where	O
only	O
a	O
limited	O
subset	O
of	O
TATA	O
-	O
like	O
sequences	O
can	O
activate	O
transcription	O
in	O
conjunction	O
with	O
GCN4p	B
,	O
many	O
divergent	O
TATA	O
-	O
like	O
sequences	O
allowed	O
GCN4p	B
activation	O
of	O
TRP3	B
.	O

This	O
strategy	O
was	O
used	O
to	O
place	O
both	O
the	O
Tn903	B
neo	I
gene	I
and	O
the	O
Rhodosporidium	B
toruloides	I
phenylalanine	I
ammonia	I
lyase	I
(	O
PAL	B
)	O
-encoding	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
pPGK::REP2	B
.	O

A-69-year	O
-	O
old	O
patient	O
with	O
postoperative	O
small	O
-	O
bowel	O
obstruction	O
underwent	O
laparotomy	O
three	O
times	O
.	O

VP-16	O
,	O
ifosfamide	O
and	O
cisplatin	O
(	O
VIP	O
)	O
for	O
extensive	O
small	O
cell	O
lung	O
cancer	O
.	O

To	O
identify	O
the	O
precise	O
location	O
of	O
the	O
phosphorylation	O
site	O
on	O
the	O
64-kDa	O
protein	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
mutagenesis	O
procedures	O
was	O
followed	O
.	O

Measurement	O
of	O
SaO2	O
at	O
moderate	O
altitude	O
can	O
be	O
helpful	O
in	O
the	O
care	O
of	O
both	O
healthy	O
and	O
ill	O
newborns	O
or	O
infants	O
.	O

TATA	O
and	O
CCAAT	O
boxes	O
are	O
located	O
34-bp	O
and	O
68-bp	O
,	O
respectively	O
,	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
the	O
5'-untranslated	O
leader	O
is	O
78	O
nucleotides	O
long	O
,	O
and	O
the	O
intronless	O
gene	O
has	O
at	O
least	O
two	O
different	O
polyadenylation	O
sites	O
.	O

GGS1	B
is	O
the	O
same	O
gene	O
as	O
TPS1	B
which	O
was	O
identified	O
as	O
encoding	O
a	O
subunit	O
of	O
the	O
trehalose-6-phosphate	B
synthase	I
/	I
phosphatase	I
complex	I
and	O
it	O
is	O
allelic	O
to	O
the	O
fdp1	B
,	O
byp1	B
,	O
glc6	B
and	O
cif1	O
mutations	O
.	O

CONCLUSION	O
:	O
The	O
study	O
demonstrates	O
that	O
transvaginal	O
ultrasonography	O
has	O
an	O
efficiency	O
of	O
88	O
%	O
in	O
differentiating	O
endometriomas	O
from	O
other	O
ovarian	O
masses	O
with	O
a	O
specificity	O
of	O
90	O
%	O
.	O

A	O
series	O
of	O
5'-deletions	O
revealed	O
that	O
the	O
fragment	O
-218	O
to	O
+	O
4	O
from	O
the	O
TSS	O
had	O
the	O
highest	O
promoter	O
activity	O
,	O
nearly	O
1000-fold	O
greater	O
than	O
the	O
promoterless	O
chloramphenicol	B
acetyltransferase	I
construct	I
.	O

The	O
bioavailability	O
of	O
etodolac	O
from	O
capsules	O
exposed	O
to	O
stressed	O
conditions	O
was	O
compared	O
in	O
both	O
dogs	O
and	O
humans	O
to	O
capsules	O
stored	O
at	O
RT	O
conditions	O
.	O

Four	O
forms	O
of	O
salmonellosis	O
were	O
recognised	O
in	O
feedlots	O
and	O
during	O
transport	O
by	O
sea	O
:	O
septicaemic	O
,	O
and	O
acute	O
,	O
subacute	O
and	O
chronic	O
enteric	O
.	O

In	O
addition	O
to	O
the	O
protein	B
-	I
tyrosine	I
kinase	I
domain	I
,	O
p56lck	B
possesses	O
Src	B
homology	I
2	I
and	I
3	I
(	O
SH2	B
and	O
SH3	B
)	O
domains	O
as	O
well	O
as	O
a	O
unique	O
N	O
-	O
terminal	O
region	O
.	O

The	O
fourth	O
dose	O
produced	O
favorable	O
results	O
(	O
66.7	O
%	O
)	O
in	O
individuals	O
with	O
HB	B
antibodies	I
between	O
10	O
and	O
100	O
IU	O
/	O
ml	O
and	O
unfavorable	O
ones	O
(	O
3.8	O
%	O
)	O
where	O
the	O
HB	B
antibodies	I
were	O
below	O
10	O
IU	O
/	O
ml	O
.	O

Similarly	O
,	O
the	O
N	O
-	O
terminal	O
cytoplasmic	O
domain	O
of	O
the	O
latent	B
membrane	I
protein	I
2A	I
(	O
LMP2A	B
)	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
contains	O
a	O
single	O
copy	O
of	O
the	O
Tyr	O
-	O
X	O
-	O
X	O
-	O
Leu	O
/	O
Ile	O
-	O
containing	O
motif	O
which	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
transformation	O
.	O

The	O
cloning	O
of	O
PTR2	B
represents	O
the	O
first	O
example	O
of	O
the	O
molecular	O
genetic	O
characterization	O
of	O
a	O
eucaryotic	O
peptide	O
transport	O
gene	O
.	O

TGF	B
beta	I
1	I
expression	O
is	O
largely	O
governed	O
by	O
three	O
AP-1	B
binding	I
sites	I
located	O
in	O
two	O
different	O
promoters	O
of	O
this	O
gene	O
.	O

Strategic	O
change	O
in	O
the	O
NHS	O
.	O

A	O
favourable	O
response	O
was	O
achieved	O
with	O
a	O
combination	O
of	O
amphotericin	O
B	O
and	O
cotrimoxazole	O
.	O

RESULTS	O
:	O
At	O
the	O
beginning	O
of	O
the	O
QA	O
/	O
QI	O
process	O
,	O
monitoring	O
of	O
blood	O
administration	O
practices	O
revealed	O
that	O
a	O
variance	O
from	O
institutional	O
blood	O
administration	O
policy	O
occurred	O
during	O
50	O
percent	O
of	O
blood	O
and	O
component	O
transfusions	O
.	O

The	O
predicted	O
Pay4p	B
sequence	I
contains	O
two	O
putative	O
ATP	O
-	O
binding	O
domains	O
and	O
shows	O
structural	O
relationships	O
to	O
other	O
potential	O
ATP	B
-	I
binding	I
proteins	I
involved	O
in	O
biological	O
processes	O
as	O
diverse	O
as	O
peroxisome	O
biogenesis	O
,	O
vesicle	O
-	O
mediated	O
protein	O
transport	O
,	O
cell	O
cycle	O
control	O
,	O
and	O
transcriptional	O
regulation	O
.	O

Peripheral	O
vitreochorioretinal	O
dystrophies	O
in	O
myopia	O
patients	O

Thomas	O
'	O
Hospital	O
solution	O
(	O
with	O
95	O
%	O
O2:5	O
%	O
CO2	O
)	O
can	O
meet	O
the	O
metabolic	O
demand	O
of	O
the	O
ischaemic	O
myocardium	O
and	O
thus	O
increase	O
the	O
safe	O
duration	O
of	O
cardiac	O
arrest	O
.	O

Animal	O
age	O
and	O
sex	O
had	O
no	O
significant	O
effects	O
on	O
CSF	O
composition	O
,	O
but	O
serum	O
IgG	B
concentration	O
increased	O
with	O
age	O
.	O

A	O
randomized	O
,	O
multicenter	O
study	O
comparing	O
the	O
efficacy	O
and	O
tolerability	O
of	O
tropisetron	O
,	O
a	O
new	O
5-HT3	B
receptor	I
antagonist	O
,	O
with	O
a	O
metoclopramide	O
-	O
containing	O
antiemetic	O
cocktail	O
in	O
the	O
prevention	O
of	O
cisplatin	O
-	O
induced	O
emesis	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
SAP-1	B
cDNA	I
showed	O
that	O
mature	B
SAP-1	I
consisted	O
of	O
1093	O
amino	O
acids	O
and	O
a	O
transmembrane	B
-	I
type	I
PTP	I
,	O
which	O
possessed	O
a	O
single	O
PTP	B
-	I
conserved	I
domain	I
in	O
the	O
cytoplasmic	O
region	O
.	O

Several	O
features	O
of	O
10.24.6	O
cells	O
suggest	O
that	O
the	O
mutation	O
disrupts	O
normal	O
intracellular	O
formation	O
of	O
peptide	B
/	I
DR	I
complexes	I
.	O

One	O
of	O
these	O
elements	O
,	O
the	O
homeodomain	B
-	I
binding	I
element	I
,	O
was	O
identified	O
to	O
mediate	O
negative	O
regulation	O
.	O

Twenty	O
-	O
three	O
sequence	O
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
were	O
mapped	O
within	O
the	O
contig	O
,	O
a	O
density	O
of	O
approximately	O
1	O
per	O
200	O
kb	O
.	O

These	O
results	O
demonstrate	O
that	O
dopamine	B
receptor	I
stimulation	O
by	O
different	O
dopamine	O
agonists	O
produces	O
a	O
different	O
pattern	O
of	O
effects	O
on	O
the	O
characteristics	O
of	O
the	O
reaction	O
time	O
response	O
.	O

The	O
first	O
group	O
of	O
sequential	O
BMB	O
showed	O
a	O
significant	O
progress	O
to	O
myelofibrosis	O
in	O
so	O
-	O
called	O
""""	O
Chronic	O
Megakaryocytic	O
-	O
Granulocytic	O
Myelosis	O
"""--"	O
CMGM-	O
,	O
which	O
corresponds	O
to	O
Agnogenic	O
Myeloid	O
Metaplasia	O
-	O
AMM	O
-	O
in	O
72.4	O
%	O
(	O
21	O
/	O
29	O
patients	O
)	O
,	O
as	O
well	O
as	O
in	O
CML	O
with	O
megakaryocytic	O
increase	O
-	O
CML.MI	O
-	O
in	O
39.2	O
%	O
(	O
20	O
/	O
51	O
)	O
.	O

Chicken	O
sterol	B
carrier	I
protein	I
2	I
/	O
sterol	B
carrier	I
protein	I
x	I
:	O
cDNA	O
cloning	O
reveals	O
evolutionary	O
conservation	O
of	O
structure	O
and	O
regulated	O
expression	O
.	O

A	O
single	O
five	O
minute	O
period	O
of	O
rapid	O
atrial	O
pacing	O
fails	O
to	O
limit	O
infarct	O
size	O
in	O
the	O
in	O
situ	O
rabbit	O
heart	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
20S	B
proteasome	I
is	O
a	O
catalytic	O
core	O
of	O
the	O
26S	B
proteolytic	I
complex	I
that	O
possesses	O
a	O
latent	O
multicatalytic	O
proteinase	O
activity	O
and	O
catalyzes	O
an	O
ATP	O
-	O
dependent	O
,	O
selective	O
breakdown	O
of	O
proteins	O
ligated	O
to	O
ubiquitin	B
.	O

The	O
phosphorylation	O
efficiency	O
is	O
improved	O
by	O
increasing	O
the	O
number	O
of	O
N	O
-	O
terminal	O
arginine	O
residues	O
and	O
by	O
moving	O
the	O
arginyl	O
cluster	O
one	O
residue	O
further	O
away	O
from	O
the	O
serine	O
,	O
the	O
nonapeptide	O
(	O
Arg	O
)	O
4-Ala	O
-	O
Ala	O
-	O
Ser	O
-	O
Val	O
-	O
Ala	O
being	O
the	O
best	O
substrate	O
among	O
all	O
the	O
short	O
peptides	O
tested	O
(	O
Km	O
=	O
15	O
microM	O
)	O
.	O

The	O
UV	O
induction	O
of	O
c	B
-	I
jun	I
is	O
mediated	O
by	O
two	O
UV	O
response	O
elements	O
consisting	O
of	O
AP-1-like	B
sequences	I
within	O
its	O
5	O
'	O
control	O
region	O
.	O

When	O
comparing	O
the	O
barley	B
PSI	I
-	I
K	I
and	O
PSI	B
-	I
G	I
with	O
the	O
reported	O
PSI	B
-	I
K	I
sequence	I
from	I
Synechococcus	I
vulcanus	I
,	O
the	O
degree	O
of	O
similarity	O
is	O
equal	O
,	O
suggesting	O
that	O
an	O
ancestral	O
gene	O
has	O
been	O
duplicated	O
in	O
a	O
chloroplast	O
progenitor	O
but	O
not	O
in	O
a	O
cyanobacterial	O
.	O

The	O
simultaneous	O
recording	O
of	O
electrical	O
activity	O
from	O
the	O
surface	O
electrocardiogram	O
,	O
right	O
ventricular	O
apex	O
,	O
His	O
bundle	O
,	O
high	O
right	O
atrium	O
,	O
coronary	O
sinus	O
,	O
with	O
or	O
without	O
a	O
roving	O
mapping	O
catheter	O
,	O
enables	O
us	O
to	O
precisely	O
map	O
the	O
electrical	O
activation	O
sequence	O
in	O
the	O
heart	O
.	O

Differences	O
in	O
profiles	O
of	O
viscosity	O
variables	O
between	O
subgroups	O
of	O
EAD	O
in	O
RA	O
patients	O
were	O
observed	O
.	O

Since	O
the	O
-172	O
/	O
-148	O
element	O
also	O
conferred	O
estrogen	O
and	O
thyroid	O
hormone	O
responsiveness	O
,	O
it	O
can	O
be	O
considered	O
a	O
composite	O
hormone	O
response	O
element	O
.	O

Together	O
with	O
a	O
considerably	O
shortened	O
and	O
interrupted	O
aromatic	O
aa	O
stretch	O
in	O
this	O
region	O
,	O
these	O
differences	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
peculiar	O
affinity	O
of	O
cyanobacterial	B
cytochrome	I
oxidases	I
for	O
acidic	O
c	B
-	I
type	I
cytochromes	I
.	O

Mutation	O
of	O
the	O
presumptive	O
phosphorylated	O
tyrosine	O
and	O
threonine	O
residues	O
of	O
Mpk1p	B
individually	O
to	O
phenylalanine	O
and	O
alanine	O
,	O
respectively	O
,	O
severely	O
impaired	O
Mpk1p	B
function	O
.	O

16	O
,	O
99	O
-	O
104	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
focus	O
on	O
the	O
genetics	O
of	O
the	O
region	O
of	O
the	O
17	B
hep	I
syn	I
gB	I
gene	I
that	O
conferred	O
both	O
the	O
syncytial	O
and	O
pathogenic	O
phenotypes	O
to	O
17	B
syn+	I
.	O

Drugs	O
suppressed	O
>	O
or	O
=	O
75	O
%	O
of	O
the	O
total	O
premature	O
ventricular	O
contractions	O
in	O
all	O
patients	O
who	O
had	O
both	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
and	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
,	O
in	O
79	O
%	O
of	O
patients	O
with	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
alone	O
,	O
in	O
70	O
%	O
with	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
alone	O
,	O
and	O
in	O
11	O
%	O
with	O
neither	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
nor	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
.	O

Genetic	O
interactions	O
between	O
BCK2	B
and	O
other	O
pathway	O
components	O
suggested	O
that	O
BCK2	B
functions	O
on	O
a	O
common	O
pathway	O
branch	O
with	O
PPZ1	B
and	O
PPZ2	B
.	O

These	O
experiments	O
confirm	O
that	O
the	O
6-S	O
liganded	O
form	O
of	O
the	O
receptor	O
identified	O
in	O
nuclear	O
extracts	O
of	O
cells	O
treated	O
with	O
2,3,7,8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
contains	O
the	O
Ah	B
receptor	I
protein	I
and	O
ARNT	B
but	O
not	O
the	O
90-kDa	B
heat	I
shock	I
protein	I
.	O

Regulated	O
activity	O
of	O
the	O
distal	O
promoter	O
-	O
like	O
element	O
of	O
the	O
human	B
corticotropin	I
-	I
releasing	I
hormone	I
gene	I
and	O
secondary	O
structural	O
features	O
of	O
its	O
corresponding	O
transcripts	O
.	O

We	O
linked	O
hypersensitivity	O
site	O
2	O
(	O
HS2	O
)	O
from	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
to	O
a	O
A	B
gamma	I
-	I
globin	I
gene	O
(	O
A	B
gamma	I
*	I
)	O
mutationally	O
marked	O
to	O
allow	O
its	O
transcript	O
to	O
be	O
distinguished	O
from	O
endogenous	O
gamma	B
-	I
globin	I
mRNA	O
.	O

Skin	O
and	O
bowel	O
TPO2	O
varied	O
with	O
DO2	O
and	O
each	O
other	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Transgenic	O
mice	O
harboring	O
the	O
rat	O
TnI	B
-	O
CAT	B
fusion	O
gene	O
expressed	O
the	O
reporter	O
specifically	O
in	O
the	O
skeletal	O
muscle	O
.	O

METHODS	O
:	O
Fifty	O
-	O
one	O
healthy	O
eyes	O
,	O
169	O
ocular	O
hypertensive	O
eyes	O
with	O
normal	O
visual	O
fields	O
,	O
and	O
132	O
glaucomatous	O
eyes	O
with	O
early	O
visual	O
field	O
defects	O
were	O
evaluated	O
with	O
qualitative	O
and	O
quantitative	O
measures	O
of	O
structural	O
damage	O
to	O
the	O
optic	O
nerve	O
and	O
nerve	O
fiber	O
layer	O
.	O

To	O
identify	O
factors	O
that	O
may	O
modify	O
the	O
heterosexual	O
transmission	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
534	O
married	O
couples	O
enrolled	O
in	O
the	O
Miyazaki	O
Cohort	O
Study	O
between	O
November	O
1984	O
and	O
April	O
1989	O
were	O
studied	O
:	O
95	O
husband	O
HTLV	O
-	O
I	O
-	O
seropositive	O
(	O
H+	O
)	O
/	O
wife	O
seropositive	O
(	O
W+	O
)	O
,	O
33	O
H+	O
/	O
W-	O
,	O
64	O
H-	O
/	O
W+	O
,	O
and	O
342	O
H-	O
/	O
W-	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
gene	O
predicts	O
a	O
polypeptide	O
of	O
215	O
amino	O
acids	O
(	O
25.2	O
kDa	O
)	O
with	O
two	O
putative	O
membrane	O
-	O
spanning	O
domains	O
.	O

An	O
extensive	O
inverted	O
repeat	O
is	O
present	O
3	O
'	O
of	O
rpeA	B
;	O
inverted	O
repeats	O
are	O
found	O
downstream	O
of	O
all	O
PE	B
operons	I
sequenced	O
to	O
date	O
,	O
although	O
the	O
sequence	O
is	O
not	O
conserved	O
.	O

Localization	O
of	O
the	O
intronless	O
gene	O
coding	O
for	O
calmodulin	B
-	I
like	I
protein	I
CLP	B
to	O
human	O
chromosome	O
10p13-ter	O
.	O

In	O
wandering	O
stage	O
larvae	O
,	O
the	O
OBP	B
transcript	I
appeared	O
to	O
be	O
at	O
least	O
250-fold	O
less	O
abundant	O
than	O
ribosomal	O
RNA	O
.	O

However	O
,	O
L	B
-	I
plastin	I
has	O
been	O
found	O
in	O
many	O
types	O
of	O
malignant	O
human	O
cells	O
of	O
non	O
-	O
hemopoietic	O
origin	O
suggesting	O
that	O
its	O
expression	O
is	O
induced	O
accompanying	O
tumorigenesis	O
in	O
solid	O
tissues	O
.	O

The	O
DNase	B
I	I
footprint	O
extended	O
5	O
'	O
in	O
the	O
silencer	O
region	O
to	O
include	O
an	O
inverted	O
repeat	O
of	O
a	O
six	O
-	O
nucleotide	O
motif	O
(	O
epsilon	O
-267	O
to	O
-278	O
bp	O
)	O
which	O
shares	O
5	O
of	O
6	O
bases	O
with	O
the	O
GATA-1	B
consensus	I
sequence	I
.	O

This	O
report	O
describes	O
the	O
identification	O
of	O
a	O
gene	O
of	O
related	O
function	O
,	O
SMD1	B
,	O
located	O
immediately	O
3	O
'	O
to	O
PRP38	B
.	O

This	O
short	O
communication	O
compares	O
a	O
novel	O
fluorimetric	O
microplate	O
enzyme	O
immunoassay	O
(	O
FEIA	O
)	O
with	O
a	O
commercial	O
time	O
-	O
resolved	O
fluoroimmunoassay	O
for	O
the	O
determination	O
of	O
thyrotropin	B
in	O
dried	O
blood	O
spots	O
.	O

Constructs	O
containing	O
the	O
full	B
-	I
length	I
PfCPK	I
cDNA	I
have	O
been	O
expressed	O
in	O
Escherichia	O
coli	O
at	O
a	O
high	O
level	O
to	O
generate	O
a	O
60-kDa	O
recombinant	O
protein	O
.	O

Endosonography	O
accurately	O
assessed	O
tumor	O
extension	O
in	O
two	O
T2	O
tumors	O
,	O
14	O
T3	O
tumors	O
,	O
and	O
seven	O
T4	O
tumors	O
.	O

Analysis	O
of	O
cell	O
cycle	O
regulation	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
shown	O
that	O
a	O
central	O
regulatory	O
protein	O
kinase	O
,	O
Cdc28	B
,	O
undergoes	O
changes	O
in	O
activity	O
through	O
the	O
cell	O
cycle	O
by	O
associating	O
with	O
distinct	O
groups	O
of	O
cyclins	B
that	O
accumulate	O
at	O
different	O
times	O
.	O

Ig	B
-	I
alpha	I
and	O
Ig	B
-	I
beta	I
contain	O
extended	O
cytoplasmic	O
structure	O
(	O
61	O
and	O
48	O
amino	O
acids	O
,	O
respectively	O
)	O
and	O
associate	O
with	O
cytoplasmic	O
effectors	O
indicating	O
that	O
they	O
are	O
directly	O
involved	O
in	O
signal	O
transduction	O
.	O

Internal	O
amino	O
acid	O
sequence	O
has	O
now	O
been	O
obtained	O
from	O
this	O
protein	O
which	O
shares	O
50	O
-	O
100	O
%	O
sequence	O
identity	O
with	O
sequences	O
encoded	O
by	O
mammalian	B
G	I
alpha	I
11	I
and	O
G	B
alpha	I
q	I
cDNAs	I
.	O

Nitric	O
oxide	O
inhalation	O
selectively	O
reduces	O
pulmonary	O
hypertension	O
in	O
porcine	O
endotoxin	O
shock	O
and	O
improves	O
arterial	O
oxygenation	O
and	O
pH	O
with	O
a	O
marked	O
attenuation	O
of	O
sympathetic	O
activation	O
.	O

The	O
fission	B
yeast	I
dsk1	I
+	I
gene	I
,	O
a	O
multicopy	O
suppressor	O
for	O
cold	O
-	O
sensitive	O
dis1	B
mutants	I
,	O
encodes	O
a	O
novel	O
61-kd	O
protein	O
kinase	O
.	O

The	O
strategies	O
by	O
which	O
hepatitis	O
B	O
and	O
hepatitis	O
D	O
can	O
be	O
diminished	O
and	O
eventually	O
eliminated	O
are	O
:	O
immunization	O
,	O
measures	O
to	O
prevent	O
exposure	O
to	O
infective	O
blood	O
or	O
blood	O
derivatives	O
and	O
education	O
(	O
in	O
particular	O
awareness	O
that	O
hepatitis	O
B	O
is	O
a	O
sexually	O
transmitted	O
disease	O
)	O
.	O

The	O
gene	O
encoding	O
the	O
receptor	O
for	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
1	I
(	O
CSF-1	B
)	O
,	O
the	O
c	B
-	I
fms	I
protooncogene	I
,	O
is	O
selectively	O
expressed	O
in	O
immature	O
and	O
mature	O
mononuclear	O
phagocytes	O
and	O
trophoblasts	O
.	O

This	O
sequence	O
similarity	O
raises	O
the	O
possibility	O
that	O
GCN1	B
interacts	O
with	O
ribosomes	O
or	O
tRNA	O
molecules	O
and	O
functions	O
in	O
conjunction	O
with	O
GCN2	B
in	O
monitoring	O
uncharged	O
tRNA	O
levels	O
during	O
the	O
process	O
of	O
translation	O
elongation	O
.	O

However	O
,	O
study	O
of	O
the	O
productive	O
gamma	O
gene	O
showed	O
that	O
the	O
skipped	O
variable	O
exon	O
was	O
bounded	O
by	O
normal	O
splicing	O
signals	O
and	O
that	O
the	O
adjacent	O
intron	O
organization	O
was	O
not	O
altered	O
.	O

Patient	O
characteristics	O
associated	O
with	O
deep	O
wounds	O
as	O
well	O
as	O
patient	O
and	O
wound	O
characteristics	O
predictive	O
of	O
the	O
extent	O
of	O
healing	O
and	O
time	O
required	O
for	O
healing	O
were	O
identified	O
.	O

The	O
remaining	O
RAD+	B
cells	O
progressed	O
to	O
form	O
microcolonies	O
(	O
<	O
30	O
cells	O
)	O
containing	O
aberrantly	O
shaped	O
inviable	O
cells	O
.	O

The	O
human	B
gp39	I
promoter	I
.	O

There	O
is	O
no	O
TATA	O
box	O
around	O
the	O
transcriptional	O
start	O
points	O
(	O
tsp	O
)	O
,	O
as	O
determined	O
by	O
primer	O
extension	O
analysis	O
.	O

In	O
summary	O
,	O
the	O
efficacies	O
of	O
adjuvant	O
carboplatin	O
and	O
of	O
abdominal	O
radiotherapy	O
seem	O
to	O
be	O
identical	O
.	O

Thus	O
,	O
SPECT	O
was	O
not	O
as	O
sensitive	O
as	O
PET	O
in	O
this	O
activation	O
task	O
.	O

Transcriptional	O
activation	O
of	O
the	O
chicken	B
lysozyme	I
gene	I
by	O
NF	B
-	I
kappa	I
Bp65	I
(	O
RelA	B
)	O
and	O
c	B
-	I
Rel	I
,	O
but	O
not	O
by	O
NF	B
-	I
kappa	I
Bp50	I
.	O

Consistent	O
with	O
a	O
possible	O
role	O
in	O
transcription	O
,	O
Paf1p	B
is	O
localized	O
to	O
the	O
nucleus	O
.	O

Hb	B
levels	O
remained	O
adequate	O
(	O
Hb	B
=	O
10.68	O
+	O
/-	O

0.77	O
g	O
/	O
dl	O
)	O
after	O
14.6	O
+	O
/-	O

7.64	O
months	O
.	O

SBF	B
binds	O
to	O
the	O
promoter	O
prior	O
to	O
the	O
activation	O
of	O
transcription	O
in	O
late	O
G1	O
,	O
suggesting	O
that	O
Cln	B
/	O
Cdc28	B
kinase	O
regulates	O
the	O
ability	O
of	O
previously	O
bound	O
SBF	B
to	O
activate	O
transcription	O
.	O

This	O
analysis	O
revealed	O
that	O
SAP	B
145	I
,	O
together	O
with	O
four	O
other	O
SF3a	B
/	O
SF3b	B
subunits	O
,	O
UV	O
cross	O
-	O
links	O
to	O
pre	O
-	O
mRNA	O
in	O
a	O
20-nucleotide	O
region	O
upstream	O
of	O
the	O
BPS	O
.	O

Molecular	O
cloning	O
,	O
expression	O
pattern	O
,	O
and	O
chromosomal	O
localization	O
of	O
human	O
CDKN2D	B
/	O
INK4d	B
,	O
an	O
inhibitor	O
of	O
cyclin	B
D	I
-	I
dependent	I
kinases	I
.	O

The	O
IL-8	B
receptor	I
is	O
a	O
seven	O
-	O
transmembrane	O
spanning	O
receptor	O
coupled	O
to	O
specific	O
heterotrimeric	B
G	I
proteins	I
including	O
Gi	B
and	O
G16	B
.	O

During	O
the	O
following	O
pregnancy	O
ultrasonographic	O
studies	O
of	O
the	O
male	O
fetus	O
in	O
the	O
16th	O
week	O
of	O
gestation	O
revealed	O
severe	O
micrognathia	O
,	O
short	O
and	O
wide	O
thumbs	O
,	O
and	O
big	O
toes	O
,	O
and	O
bowed	O
tibiae	O
.	O

The	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31.8	O
+	O
/-	O

6.3	O
kg	O
/	O
m2	O
and	O
28.5	O
+	O
/-	O

6.3	O
kg	O
/	O
m2	O
in	O
women	O
and	O
men	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
RPF-1	B
is	O
likely	O
to	O
be	O
involved	O
in	O
early	O
steps	O
in	O
the	O
differentiation	O
of	O
amacrine	O
and	O
ganglion	O
cells	O
.	O

In	O
the	O
point	O
mutant	O
we	O
observed	O
normal	O
repair	O
of	O
endonuclease	B
III	I
site	I
(	O
i.e.	O
as	O
wild	O
type	O
)	O
,	O
but	O
no	O
removal	O
of	O
CPDs	O
at	O
the	O
MAT	B
alpha	I
and	O
HML	B
alpha	I
loci	I
.	O

Carboxy	O
-	O
terminal	O
Spc110p	B
truncations	O
lacking	O
the	O
calmodulin	B
binding	O
site	O
can	O
support	O
growth	O
and	O
are	O
also	O
phosphorylated	O
in	O
a	O
cell	O
cycle	O
-	O
specific	O
manner	O
.	O

Ongoing	O
and	O
future	O
investigations	O
may	O
better	O
define	O
the	O
optimal	O
approach	O
for	O
local	O
control	O
,	O
the	O
optimal	O
duration	O
of	O
maintenance	O
chemotherapy	O
,	O
and	O
the	O
possible	O
role	O
of	O
biologic	O
response	O
modifiers	O
and	O
growth	O
factors	O
in	O
further	O
improving	O
the	O
outcome	O
for	O
patients	O
with	O
this	O
disease	O
.	O

SUMMARY	O
OF	O
REVIEW	O
:	O
We	O
discuss	O
the	O
criteria	O
that	O
make	O
such	O
studies	O
comparable	O
,	O
drawing	O
on	O
the	O
experiences	O
of	O
recent	O
studies	O
performed	O
around	O
the	O
world	O
.	O

Left	O
atrial	O
volumes	O
were	O
greater	O
in	O
old	O
compared	O
with	O
young	O
subjects	O
(	O
maximal	O
:	O
31	O
+	O
/-	O

10	O
cm3	O
/	O
m2	O
vs	O
24	O
+	O
/-	O

8	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0.02	O
;	O
at	O
onset	O
of	O
atrial	O
systole	O
:	O
23	O
+	O
/-	O

8	O
cm3	O
/	O
m2	O
vs	O
15	O
+	O
/-	O

5	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0.0002	O
;	O
minimal	O
:	O
13	O
+	O
/-	O

5	O
cm3	O
/	O
m2	O
vs	O
9	O
+	O
/-	O

4	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0.001	O
)	O
.	O

We	O
observed	O
abundant	O
levels	O
of	O
Rev	B
-	O
erbA	B
alpha	I
mRNA	O
in	O
dividing	O
C2C12	O
myoblasts	O
,	O
which	O
were	O
suppressed	O
when	O
the	O
cells	O
differentiated	O
into	O
postmitotic	O
multinucleated	O
myotubes	O
.	O

As	O
expected	O
,	O
glycosylation	O
of	O
Env	B
produced	O
from	O
mutants	O
was	O
affected	O
but	O
,	O
irrespective	O
of	O
the	O
glycosylation	O
phenotype	O
,	O
(	O
i	O
)	O
similar	O
quantities	O
of	O
Env	B
were	O
synthesized	O
,	O
(	O
ii	O
)	O
the	O
immunoreactivity	O
of	O
V3	B
was	O
similar	O
,	O
(	O
iii	O
)	O
gp160	B
was	O
efficiently	O
cleaved	O
into	O
gp120	B
and	O
gp41	B
,	O
(	O
vi	O
)	O
Env	B
was	O
exposed	O
at	O
the	O
cell	O
membrane	O
,	O
(	O
v	O
)	O
secreted	O
gp120	B
bound	O
CD4	B
,	O
and	O
(	O
vi	O
)	O
membrane	O
gp41	B
was	O
able	O
to	O
induce	O
membrane	O
fusion	O
with	O
CD4	B
+	I
cells	O
.	O

On	O
the	O
trail	O
of	O
Dr.	O

Analysis	O
of	O
RAR	B
alpha	I
mutants	I
in	O
transfection	O
studies	O
reveals	O
that	O
the	O
DNA	O
binding	O
domain	O
is	O
sufficient	O
for	O
inhibition	O
of	O
BZLF1	B
activity	O
.	O

We	O
measured	O
serum	B
hepatocyte	I
growth	I
factor	I
(	O
HGF	B
)	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
other	O
heart	O
diseases	O
.	O

No	O
significant	O
differences	O
existed	O
between	O
the	O
two	O
age	O
groups	O
in	O
baseline	O
characteristics	O
,	O
including	O
treatment	O
protocol	O
,	O
performance	O
status	O
,	O
and	O
serum	B
lactate	I
dehydrogenase	I
(	O
LDH	B
)	O
level	O
.	O

In	O
agreement	O
with	O
previous	O
in	O
vitro	O
data	O
,	O
we	O
have	O
shown	O
that	O
UmuD	B
and	O
UmuD	B
'	I
are	O
able	O
to	O
form	O
both	O
homodimers	O
(	O
UmuD	B
-	O
UmuD	B
and	O
UmuD'-UmuD	B
'	B
)	O
and	O
a	O
heterodimer	O
(	O
UmuD	B
-	O
UmuD	B
'	I
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
crude	O
extracts	O
from	O
FREJ4	O
cells	O
revealed	O
the	O
binding	O
of	O
a	O
member	O
(	O
s	O
)	O
of	O
the	O
Ets	B
family	I
of	I
transcription	I
factors	I
to	O
the	O
P4	B
EBS	I
,	O
as	O
well	O
as	O
the	O
interaction	O
of	O
two	O
members	O
of	O
the	O
Sp1	B
family	I
,	O
Sp1	B
and	O
Sp3	B
,	O
with	O
the	O
adjacent	O
GC	O
box	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
thrombin	B
-	O
stimulated	O
vascular	O
smooth	O
muscle	O
proliferation	O
is	O
delayed	O
and	O
requires	O
the	O
de	O
novo	O
expression	O
of	O
one	O
or	O
more	O
autocrine	O
mitogens	O
.	O

Adduction	O
of	O
the	O
human	B
N	I
-	I
ras	I
codon	I
61	I
sequence	I
with	O
(	O
-	O
)	O
-	O
(	O
7S,8R,9R,10S	O
)	O
-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo	O
[	O
a	O
]	O
pyrene	O
:	O
structural	O
refinement	O
of	O
the	O
intercalated	O
SRSR	O
(	O
61,2	O
)	O
(	O
-	O
)	O
-	O
(	O
7S,8R,9S,10R	O
)	O
-N6-	O
[	O
10-	O
(	O
7,8,9,10-	O
tetrahydrobenzo	O
[	O
a	O
]	O
pyrenyl	O
)	O
]	O
-2'-deoxyadenosyl	O
adduct	O
from	O
1H	O
NMR	O
.	O

Menstrual	O
-	O
cycle	O
phase	O
did	O
not	O
significantly	O
affect	O
personality	O
variables	O
in	O
either	O
group	O
.	O

Ca2	O
+	O
decreased	O
Zn2	O
+	O
binding	O
in	O
S100	B
beta	I
but	O
it	O
did	O
not	O
influence	O
binding	O
to	O
MRP14	B
,	O
suggesting	O
that	O
the	O
Zn2	O
+	O
binding	O
site	O
was	O
distinct	O
from	O
and	O
independent	O
of	O
the	O
two	O
Ca2	O
+	O
binding	O
domains	O
.	O

A	O
direct	O
role	O
for	O
sterol	B
regulatory	I
element	I
binding	I
protein	I
in	O
activation	O
of	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
reductase	I
gene	I
.	O

An	O
inactive	O
analog	O
of	O
wortmannin	O
,	O
WM12	O
,	O
did	O
not	O
affect	O
TCR	B
/	O
CD3-induced	B
Erk2	B
activation	O
,	O
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
Erk2	B
when	O
added	O
directly	O
to	O
the	O
in	O
vitro	O
assays	O
.	O

The	O
transcription	O
start	O
point	O
of	O
the	O
proximal	O
promoter	O
aligns	O
to	O
that	O
of	O
mouse	O
promoter	O
P3	O
and	O
lies	O
within	O
a	O
conserved	O
region	O
of	O
sequence	O
.	O

To	O
determine	O
the	O
signal	B
recognition	I
particle	I
(	O
SRP	B
)	O
-SRP	O
receptor	B
(	O
Srb	B
)	O
system	O
in	O
Bacillus	O
subtilis	O
(	O
Bs	O
)	O
,	O
we	O
cloned	O
the	O
Bs	B
srb	I
gene	I
,	O
which	O
encodes	O
a	O
homologue	O
of	O
the	O
mammalian	B
SRP	I
receptor	I
alpha	I
-	I
subunit	I
[	O
Oguro	O
et	O
al.	O
,	O
DNA	O
Res	O
.	O

An	O
apparent	O
ufo	B
mRNA	I
overexpression	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
positive	O
leukemia	O
cell	O
lines	O
,	O
but	O
was	O
identified	O
in	O
the	O
drug	O
-	O
resistant	O
subclones	O
of	O
the	O
cervix	O
carcinoma	O
cell	O
line	O
HeLa	O
.	O

Reproducing	O
populations	O
of	O
this	O
aphid	O
were	O
first	O
detected	O
in	O
Puerto	O
Rico	O
in	O
April	O
1992	O
.	O

At	O
cuticular	O
positions	O
exhibiting	O
the	O
Brd	B
bristle	I
loss	I
phenotype	I
,	O
we	O
have	O
found	O
that	O
the	O
progeny	O
of	O
the	O
multiplied	O
SOPs	O
develop	O
aberrantly	O
,	O
in	O
that	O
neurons	O
and	O
thecogen	O
(	O
sheath	O
)	O
cells	O
appear	O
but	O
not	O
trichogen	O
(	O
shaft	O
)	O
and	O
tormogen	O
(	O
socket	O
)	O
cells	O
.	O

Transcriptional	O
blockade	O
was	O
reversed	O
by	O
co	O
-	O
transfections	O
of	O
a	O
wild	B
-	I
type	I
SRF	I
expression	O
vector	O
,	O
but	O
was	O
not	O
rescued	O
by	O
the	O
expression	O
of	O
other	O
myogenic	O
factors	O
,	O
such	O
as	O
MyoD	B
and	O
Mef-2C	B
.	O

The	O
mMIWC1	B
promoter	I
was	O
identified	O
and	O
contained	O
TATA	O
,	O
CAAT	O
,	O
GATA	O
,	O
and	O
AP-2	B
elements	I
;	O
primer	O
extension	O
revealed	O
mMIWC	B
transcription	O
initiation	O
at	O
621	O
bp	O
upstream	O
from	O
the	O
mMIWC1	B
translational	O
initiation	O
site	O
.	O

We	O
have	O
obtained	O
the	O
human	B
EP4	I
receptor	I
gene	I
sequence	I
and	O
determined	O
its	O
structure	O
relative	O
to	O
EP4R	B
cDNA	I
synthesized	O
from	O
peripheral	O
blood	O
lymphocytes	O
.	O

Specifically	O
,	O
the	O
deduced	O
FR-19	B
amino	I
acid	I
sequence	I
has	O
approximately89	O
,	O
77	O
,	O
and	O
68	O
%	O
overall	O
identity	O
to	O
chicken	B
TEF-1A	I
,	O
mouse	B
TEF-1	I
,	O
and	O
mouse	B
embryonic	I
TEA	I
domain	I
-	I
containing	I
factor	I
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
the	O
human	B
DSG3	I
gene	I
and	O
examined	O
the	O
transcriptional	O
regulation	O
of	O
its	O
expression	O
.	O

ZIOS	O
was	O
significantly	O
more	O
sensitive	O
than	O
all	O
subsequent	O
methods	O
,	O
and	O
Ptc	O
,	O
O2	O
was	O
significantly	O
more	O
sensitive	O
than	O
FEV1	O
.	O

Vacuolar	O
membrane	O
vesicles	O
from	O
hum1	B
mutants	I
lack	O
all	O
Ca2+	O
/	O
H+	O
antiport	O
activity	O
,	O
demonstrating	O
that	O
Hum1p	B
catalyzes	O
the	O
exchange	O
of	O
Ca2	O
+	O
for	O
H+	O
across	O
the	O
yeast	O
vacuolar	O
membrane	O
.	O

However	O
,	O
one	O
3	O
'	O
splice	O
site	O
,	O
located	O
at	O
nucleotide	O
(	O
nt	O
)	O
3225	O
,	O
is	O
used	O
for	O
the	O
processing	O
of	O
most	O
BPV-1	O
pre	O
-	O
mRNAs	O
in	O
BPV-1-transformed	O
C127	O
cells	O
and	O
at	O
early	O
to	O
intermediate	O
times	O
in	O
productively	O
infected	O
warts	O
.	O

HS	O
inducibility	O
required	O
the	O
HSE	O
which	O
was	O
bound	O
by	O
HS	B
transcription	I
factor-1	I
(	O
HSF-1	B
)	O
present	O
in	O
extracts	O
prepared	O
from	O
cells	O
exposed	O
to	O
HS	O
.	O

The	O
logistic	O
regression	O
analysis	O
of	O
the	O
manual	O
method	O
(	O
percentage	O
normal	O
morphology	O
)	O
and	O
IVOS	O
indicated	O
that	O
both	O
were	O
predictors	O
of	O
fertilization	O
.	O

There	O
was	O
a	O
general	O
broadening	O
of	O
proton	O
resonances	O
for	O
a	O
three	O
-	O
nucleotide	O
segment	O
centered	O
about	O
the	O
lesion	O
site	O
which	O
resulted	O
in	O
a	O
tentative	O
assignment	O
for	O
the	O
sugar	O
protons	O
of	O
the	O
C7	O
residue	O
in	O
the	O
spectrum	O
of	O
the	O
adduct	O
duplex	O
.	O

Cbl	B
constitutively	O
interacts	O
with	O
the	O
SH3	B
domains	I
of	O
Grb2	B
,	O
with	O
a	O
preference	O
for	O
the	O
amino	O
-	O
terminal	O
domain	O
,	O
and	O
is	O
in	O
this	O
way	O
recruited	O
to	O
Shc	B
upon	O
BCR	B
stimulation	O
.	O

Activation	O
mediated	O
by	O
Cat8p	B
was	O
no	O
longer	O
detectable	O
in	O
a	O
cat1	B
mutant	I
.	O

METHODS	O
:	O
DSF	O
was	O
instilled	O
in	O
one	O
eye	O
chosen	O
at	O
random	O
and	O
CF	O
in	O
the	O
fellow	O
eye	O
of	O
13	O
normal	O
subjects	O
and	O
in	O
13	O
patients	O
with	O
KCS	O
.	O

In	O
addition	O
,	O
they	O
display	O
common	O
features	O
that	O
make	O
them	O
strikingly	O
related	O
to	O
snoRNA	B
U14	I
.	O

The	O
relative	O
tumor	O
FDG	O
-	O
uptake	O
(	O
Q	O
-	O
MRGlu	O
)	O
(	O
tumor	O
/	O
contralateral	O
cortex	O
)	O
of	O
all	O
meningiomas	O
was	O
calculated	O
with	O
0.73	O
+	O
/-	O

0.37	O
(	O
0.24	O
-	O
1.79	O
)	O
.	O

The	O
most	O
frequent	O
causes	O
of	O
the	O
meningitis	O
was	O
the	O
external	O
ventricular	O
drainage	O
(	O
14.8	O
%	O
)	O
,	O
post	O
-	O
neurosurgical	O
(	O
0.8	O
%	O
)	O
and	O
head	O
injury	O
(	O
0.0007	O
%	O
)	O
.	O

Fifty	O
-	O
one	O
patients	O
with	O
primary	O
refractory	O
or	O
relapsed	O
malignant	O
lymphoma	O
(	O
47	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
and	O
four	O
Hodgkin	O
's	O
disease	O
)	O
were	O
treated	O
with	O
a	O
new	O
chemotherapeutic	O
regimen	O
(	O
cisplatinum	O
,	O
methyl	O
GAG	O
,	O
bleomocyin	O
,	O
methyl	O
prednisolon	O
)	O
.	O

In	O
3	O
treatments	O
the	O
diet	O
was	O
supplemented	O
with	O
0	O
,	O
100	O
and	O
150	O
mg	O
probiotic	O
/	O
kg	O
food	O
.	O

This	O
caused	O
severe	O
cortical	O
damage	O
and	O
neuronal	O
loss	O
in	O
hippocampus	O
subfields	O
CA1	O
,	O
CA3	O
,	O
and	O
hilus	O
.	O

Thus	O
,	O
the	O
characterization	O
of	O
the	O
promoter	O
region	O
should	O
help	O
to	O
define	O
regulatory	O
elements	O
that	O
control	O
neuron	O
-	O
specific	O
and	O
developmental	O
expression	O
of	O
the	O
MAP1B	B
gene	I
.	O

Mutants	O
lacking	O
the	O
3	O
'	O
stem	O
-	O
loop	O
exhibited	O
a	O
75	O
%	O
reduction	O
in	O
the	O
level	O
of	O
psaB	B
mRNA	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
was	O
highly	O
conserved	O
across	O
the	O
wide	O
range	O
of	O
eukaryotes	O
(	O
vertebrates	O
,	O
invertebrates	O
,	O
fungi	O
,	O
plants	O
and	O
protozoa	O
)	O
in	O
which	O
this	O
gene	O
has	O
now	O
been	O
identified	O
.	O

Semidominant	O
mutations	O
in	O
the	O
yeast	B
Rad51	I
protein	I
and	O
their	O
relationships	O
with	O
the	O
Srs2	B
helicase	I
.	O

The	O
cDNA	O
clone	O
was	O
used	O
as	O
a	O
homologous	O
probe	O
to	O
isolate	O
a	O
truncated	O
genomic	O
clone	O
encoding	O
H2A1	B
.	O

Subsequent	O
to	O
their	O
secretion	O
,	O
the	O
IGF	B
-	I
II	I
in	O
xz97	O
and	O
G11	O
cells	O
accumulated	O
in	O
the	O
conditioned	O
medium	O
mostly	O
as	O
two	O
partially	O
processed	O
species	O
with	O
appMr	O
,	O
of	O
17	O
K	O
and	O
14	O
K	O
,	O
respectively	O
.	O

Stably	O
transfected	O
human	O
kidney	O
293	O
cells	O
expressing	O
the	O
wild	B
type	I
rat	I
LH	I
/	I
CG	I
receptor	I
(	O
rLHR	B
)	O
or	O
receptors	O
with	O
C	O
-	O
terminal	O
tails	O
truncated	O
at	O
residues	O
653	O
,	O
631	O
,	O
or	O
628	O
(	O
designated	O
rLHR	B
-	I
t653	I
,	O
rLHR	B
-	I
t631	I
,	O
and	O
rLHR	B
-	I
t628	I
)	O
were	O
used	O
to	O
probe	O
the	O
importance	O
of	O
this	O
region	O
on	O
the	O
regulation	O
of	O
hormonal	O
responsiveness	O
.	O

Sleep	O
was	O
determined	O
again	O
for	O
an	O
additional	O
3	O
days	O
and	O
6	O
hours	O
.	O

A	O
neuropsychological	O
test	O
battery	O
was	O
used	O
that	O
contained	O
the	O
Wisconsin	O
card	O
sorting	O
test	O
,	O
Street	O
completion	O
test	O
,	O
Stroop	O
test	O
,	O
a	O
dichotic	O
memory	O
listening	O
test	O
,	O
and	O
a	O
facial	O
recognition	O
test	O
.	O

We	O
conclude	O
that	O
CPET	O
is	O
a	O
useful	O
investigation	O
in	O
the	O
management	O
of	O
patients	O
with	O
cardiopulmonary	O
disease	O
and	O
complements	O
the	O
various	O
other	O
investigations	O
offered	O
by	O
a	O
pulmonary	O
function	O
laboratory	O
.	O

Update	O
:	O
diphtheria	O
epidemic	O
in	O
the	O
newly	O
independent	O
states	O
of	O
the	O
former	O
USSR	O
,	O
January	O
1995-March	O
1996	O
.	O

A	O
novel	O
phosphotyrosine	O
-	O
binding	O
domain	O
in	O
the	O
N	O
-	O
terminal	O
transforming	O
region	O
of	O
Cbl	B
interacts	O
directly	O
and	O
selectively	O
with	O
ZAP-70	B
in	O
T	O
cells	O
.	O

Myelomatous	O
pleural	O
effusion	O
as	O
presentation	O
form	O
of	O
multiple	O
myeloma	O

METHODS	O
AND	O
RESULTS	O
:	O
A	O
64-year	O
-	O
old	O
woman	O
with	O
confirmed	O
AV	O
nodal	O
reentrant	O
tachycardia	O
underwent	O
a	O
successful	O
""""	O
slow	O
pathway	O
""""	O
AV	O
modification	O
with	O
a	O
single	O
radiofrequency	O
application	O
.	O

Mutations	O
in	O
three	O
loci	O
(	O
SIC1	B
,	O
SWI5	B
,	O
and	O
RIC3	B
)	O
were	O
identified	O
.	O

Almost	O
complete	O
sequence	O
identity	O
was	O
found	O
between	O
the	O
3	O
'	O
end	O
of	O
the	O
DXS6673E	B
gene	I
and	O
two	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
and	O
between	O
the	O
5	O
'	O
end	O
of	O
the	O
DXS6673E	B
gene	I
and	O
a	O
third	O
EST	O
.	O

Sequencing	O
of	O
the	O
16p	O
11.1	O
/	O
Xq28	O
duplication	O
breakpoints	O
has	O
revealed	O
the	O
presence	O
of	O
repetitive	O
immunoglobulin	B
-	I
like	I
CAGGG	I
pentamer	I
sequences	I
at	O
or	O
near	O
the	O
paralogy	O
boundaries	O
.	O

Chernoff	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

Neither	O
CES1	B
nor	O
CES4	B
is	O
essential	O
for	O
cell	O
growth	O
,	O
and	O
a	O
double	O
deletion	O
mutant	O
is	O
viable	O
.	O

Constitutive	O
phosphorylation	O
of	O
the	O
CD30v	B
protein	I
was	O
demonstrated	O
by	O
in	O
vitro	O
labeling	O
with	O
[	O
32P	O
]	O
.	O

A	O
system	O
is	O
described	O
in	O
which	O
the	O
volume	O
flow	O
rate	O
of	O
blood	O
in	O
a	O
vessel	O
is	O
determined	O
using	O
transverse	O
colour	O
Doppler	O
ultrasound	O
imaging	O
.	O

This	O
paper	O
gives	O
an	O
overview	O
of	O
the	O
global	O
pattern	O
of	O
casualties	O
in	O
earthquakes	O
which	O
occurred	O
during	O
the	O
30-month	O
period	O
from	O
1	O
September	O
1993	O
to	O
29	O
February	O
1996	O
.	O

Transcription	O
factor	O
recognition	O
surface	O
on	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	I
is	O
involved	O
in	O
contact	O
with	O
the	O
DNA	O
enhancer	O
element	O
.	O

Moreover	O
,	O
it	O
also	O
discusses	O
the	O
effects	O
of	O
antihypertensive	O
drugs	O
currently	O
regarded	O
as	O
first	O
-	O
choice	O
agents	O
,	O
i.e.	O
calcium	O
antagonists	O
and	O
the	O
angiotensin	B
converting	I
enzyme	I
inhibitors	O
,	O
on	O
intrarenal	O
hemodynamics	O
.	O

B	B
cell	I
antigen	I
receptor	I
(	O
BCR	B
)	O
-induced	O
apoptosis	O
in	O
the	O
WEHI-231	O
B	O
lymphoma	O
cell	O
line	O
can	O
be	O
prevented	O
by	O
engaging	O
CD40	B
.	O

An	O
InlC	B
deletion	I
mutant	I
shows	O
reduced	O
virulence	O
when	O
tested	O
in	O
an	O
intravenous	O
mouse	O
model	O
,	O
but	O
intracellular	O
replication	O
of	O
the	O
mutant	O
in	O
Caco-2	O
and	O
J774	O
cells	O
appears	O
to	O
be	O
comparable	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Mutations	O
at	O
two	O
neighboring	O
sites	O
,	O
serine	O
242	O
and	O
threonine	O
255	O
,	O
exacerbated	O
the	O
effect	O
.	O

In	O
both	O
settings	O
,	O
it	O
can	O
be	O
phosphorylated	O
by	O
cyclin	B
D	I
-	I
dependent	I
kinases	I
,	O
suggesting	O
that	O
its	O
transcriptional	O
activity	O
may	O
normally	O
be	O
regulated	O
through	O
such	O
mechanisms	O
.	O

Individuals	O
attending	O
the	O
GUM	O
Department	O
in	O
the	O
Royal	O
Infirmary	O
of	O
Edinburgh	O
between	O
1990	O
and	O
1994	O
with	O
the	O
diagnosis	O
of	O
HIV	O
infection	O
,	O
genital	O
warts	O
,	O
genital	O
herpes	O
,	O
non	O
-	O
specific	O
genital	O
infection	O
(	O
NSGI	O
)	O
,	O
gonorrhoea	O
and	O
syphilis	O
were	O
included	O
in	O
the	O
study	O
.	O

Rss1p	B
encodes	O
a	O
novel	O
essential	O
protein	O
of	O
538	O
amino	O
acids	O
,	O
which	O
contains	O
an	O
extended	O
predicted	O
coiled	O
-	O
coil	O
domain	O
and	O
is	O
located	O
both	O
at	O
nuclear	O
pore	O
complexes	O
(	O
NPCs	O
)	O
and	O
in	O
the	O
cytoplasm	O
.	O

In	O
spite	O
of	O
much	O
effort	O
,	O
no	O
one	O
has	O
succeeded	O
in	O
isolating	O
and	O
characterizing	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
synthesis	O
of	O
cellulose	O
,	O
the	O
major	O
cell	O
wall	O
polymer	O
of	O
plants	O
.	O

Factor	O
V	O
Leiden	O
is	O
a	O
genetic	O
disorder	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
.	O

In	O
vitro	O
DNase	B
I	I
footprinting	O
showed	O
that	O
OxyR	B
-	I
C199S	I
protected	O
Pmom	B
from	O
-104	O
to	O
-46	O
on	O
the	O
top	O
strand	O
and	O
produced	O
a	O
protection	O
pattern	O
characteristic	O
of	O
reduced	B
wild	I
-	I
type	I
OxyR.	I

These	O
data	O
provide	O
strong	O
evidence	O
that	O
E2F	B
or	O
an	O
E2F	B
-	I
related	I
transcription	I
factor	I
is	O
involved	O
in	O
the	O
regulation	O
of	O
nonmuscle	B
myosin	I
expression	O
.	O

The	O
nucleotide	O
sequence	O
alignment	O
between	O
mouse	O
and	O
human	B
CA	I
IV	I
shows	O
69	O
%	O
identity	O
in	O
the	O
coding	O
region	O
and	O
all	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
are	O
conserved	O
,	O
as	O
are	O
the	O
sizes	O
of	O
the	O
introns	O
.	O

These	O
findings	O
suggest	O
that	O
fodrin	B
proteolysis	O
in	O
vivo	O
may	O
reflect	O
the	O
activity	O
of	O
multiple	O
ICE	B
/	O
Ced-3	B
proteases	O
whose	O
partial	O
sensitivity	O
to	O
DEVD	O
-	O
CHO	O
reflects	O
a	O
limited	O
contribution	O
from	O
CPP32	B
,	O
or	O
an	O
ICE	B
/	O
Ced-3	B
protease	O
less	O
sensitive	O
than	O
CPP32	B
to	O
DEVD	O
-	O
CHO	O
inhibition	O
.	O

Recurrent	O
G	O
-	O
to	O
-	O
A	O
substitution	O
in	O
a	O
single	O
codon	O
of	O
SREBP	B
cleavage	I
-	I
activating	I
protein	I
causes	O
sterol	O
resistance	O
in	O
three	O
mutant	O
Chinese	O
hamster	O
ovary	O
cell	O
lines	O
.	O

The	O
Escherichia	B
coli	I
tet	I
-	I
repressor	I
(	O
TetR	B
)	O
operator	O
system	O
was	O
used	O
to	O
develop	O
a	O
variation	O
of	O
the	O
yeast	O
two	O
-	O
hybrid	O
assay	O
in	O
which	O
disruptions	O
of	O
protein	O
-	O
protein	O
interactions	O
can	O
be	O
identified	O
by	O
a	O
positive	O
selection	O
.	O

FK506	O
is	O
10-	O
to	O
100-fold	O
more	O
potent	O
than	O
cyclosporin	O
A	O
in	O
preventing	O
organ	O
rejection	O
and	O
in	O
toxicity	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
promoter	O
and	O
enhancer	O
regions	O
identified	O
here	O
are	O
essential	O
for	O
maintaining	O
the	O
efficient	O
promoter	O
activity	O
of	O
the	O
human	B
activin	I
betaA	I
subunit	I
gene	I
.	O

Northern	O
(	O
RNA	O
)	O
blot	O
analyses	O
indicated	O
that	O
the	O
cdh	B
genes	I
encoding	O
the	O
five	O
subunits	O
and	O
an	O
open	O
reading	O
frame	O
(	O
ORF1	O
)	O
with	O
unknown	O
function	O
are	O
cotranscribed	O
during	O
growth	O
on	O
acetate	O
.	O

Damage	O
to	O
the	O
BBB	O
was	O
judged	O
by	O
extravasation	O
of	O
Evans	O
Blue	O
(	O
EB	O
)	O
dye	O
,	O
which	O
was	O
administered	O
either	O
2	O
,	O
3	O
,	O
24	O
or	O
48	O
h	O
after	O
onset	O
of	O
MCAo	O
.	O

The	O
determination	O
of	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
antibodies	O
by	O
one	O
of	O
several	O
laboratory	O
tests	O
,	O
by	O
skin	O
-	O
prick	O
tests	O
or	O
by	O
appropriate	O
challenge	O
procedures	O
is	O
useful	O
either	O
to	O
identify	O
atopic	O
individuals	O
or	O
as	O
outcome	O
predictors	O
in	O
wheezy	O
children	O
.	O

In	O
contrast	O
,	O
extracts	O
of	O
the	O
mutant	O
virions	O
catalyze	O
the	O
wild	O
-	O
type	O
level	O
of	O
transcription	O
from	O
an	O
exogenous	O
template	O
containing	O
an	O
early	O
promoter	O
.	O

In	O
Group	O
IV	O
dogs	O
that	O
received	O
alpha	B
-	I
MSH	I
only	O
during	O
reperfusion	O
,	O
BAEPs	O
were	O
increased	O
approximately	O
10	O
to	O
14	O
%	O
more	O
than	O
in	O
Group	O
II	O
during	O
the	O
late	O
reperfusion	O
period	O
.	O

Complementary	O
DNAs	O
encompassing	O
the	O
coat	B
protein	I
coding	O
and	O
adjacent	O
regions	O
of	O
Agropyron	O
mosaic	O
virus	O
(	O
AgMV	O
)	O
and	O
Hordeum	O
mosaic	O
virus	O
(	O
HoMV	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

In	O
some	O
cases	O
,	O
factor	O
-	O
induced	O
Rac	B
activation	O
results	O
in	O
Rho	B
activation	O
,	O
and	O
factor	O
-	O
induced	O
Cdc42	B
activation	O
leads	O
to	O
Rac	B
activation	O
,	O
as	O
determined	O
by	O
specific	O
morphological	O
changes	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
a	O
correlation	O
between	O
serum	O
and	O
seminal	B
plasma	I
PSA	I
levels	O
.	O

This	O
establishes	O
Rad3	B
/	O
Mec1	B
as	O
the	O
only	O
conserved	O
protein	O
which	O
is	O
required	O
for	O
all	O
the	O
DNA	O
structure	O
checkpoints	O
in	O
both	O
yeast	O
model	O
systems	O
.	O

The	O
P13	O
and	O
N22	O
of	O
ppSEPs	O
had	O
phase	O
reversal	O
relationship	O
with	O
the	O
P2	O
and	O
N2	O
recorded	O
from	O
the	O
PES	O
,	O
respectively	O
.	O

The	O
promoter	O
region	O
(	O
P1	O
)	O
corresponding	O
to	O
the	O
main	O
group	O
of	O
transcription	O
initiation	O
sites	O
is	O
devoid	O
of	O
TATA	O
and	O
CAAT	O
boxes	O
but	O
has	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	B
factor	I
SP1	I
and	O
is	O
embedded	O
in	O
a	O
large	O
G	O
+	O
C	O
-	O
rich	O
domain	O
of	O
a	O
CpG	O
island	O
,	O
features	O
shared	O
by	O
the	O
promoters	O
of	O
constitutively	O
expressed	O
housekeeping	O
genes	O
.	O

Children	O
born	O
from	O
chronic	O
alcoholic	O
mothers	O
have	O
shown	O
behavioral	O
teratogenic	O
effects	O
more	O
frequently	O
than	O
morphological	O
malformations	O
.	O

Here	O
we	O
report	O
that	O
expression	O
of	O
the	O
I	B
-	I
POU	I
/	O
tI	B
-	I
POU	I
message	O
is	O
maximal	O
late	O
in	O
the	O
embryonic	O
phase	O
of	O
Drosophila	O
development	O
,	O
and	O
I	B
-	I
POU	I
is	O
the	O
preferred	O
splice	O
variant	O
.	O

Although	O
p48	B
gene	I
induction	O
is	O
dependent	O
on	O
STAT1	B
and	O
JAK1	B
,	O
activated	O
STAT1	B
does	O
not	O
bind	O
to	O
GATE	B
.	O

Differential	O
signaling	O
and	O
immediate	B
-	I
early	I
gene	I
activation	O
by	O
four	O
splice	O
variants	O
of	O
the	O
human	B
pituitary	I
adenylate	I
cyclase	I
-	I
activating	I
polypeptide	I
receptor	I
(	O
hPACAP	B
-	I
R	I
)	O
.	O

Fourth	O
,	O
the	O
3'-region	O
splice	O
junctions	O
of	O
the	O
MSRs	B
during	O
latent	O
and	O
productive	O
infection	O
were	O
determined	O
by	O
sequencing	O
RNA	O
-	O
PCR	O
products	O
generated	O
with	O
primers	O
that	O
flank	O
the	O
3	O
'	O
splice	O
region	O
.	O

In	O
all	O
cases	O
the	O
antigenemia	O
was	O
transient	O
and	O
cleared	O
by	O
28th	O
day	O
post	O
-	O
vaccination	O
.	O

However	O
,	O
five	O
new	O
mutation	O
sites	O
(	O
S61	B
,	O
SL1	B
,	O
S29	B
,	O
SL11	B
,	O
SL196	B
and	O
SL126	B
)	O
are	O
unique	O
to	O
the	O
nrdB	B
intron	O
and	O
disrupt	O
self	O
-	O
splicing	O
.	O

Serotonin	O
concentration	O
in	O
the	O
blood	O
of	O
patients	O
with	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O

CONCLUSION	O
:	O
Some	O
Gulf	O
War	O
veterans	O
may	O
have	O
delayed	O
,	O
chronic	O
neurotoxic	O
syndromes	O
from	O
wartime	O
exposure	O
to	O
combinations	O
of	O
chemicals	O
that	O
inhibit	O
butyrylcholinesterase	B
and	O
neuropathy	B
target	I
esterase	I
.	O

No	O
correlation	O
between	O
the	O
age	O
of	O
the	O
horses	O
and	O
the	O
antibody	O
level	O
could	O
be	O
found	O
.	O

The	O
Y	O
-	O
type	O
structural	O
motif	O
is	O
also	O
conserved	O
among	O
a	O
number	O
of	O
divergent	O
BiP	B
mRNAs	I
.	O

SIM1	B
and	O
SIM2	B
do	O
not	O
form	O
homodimers	O
,	O
and	O
they	O
do	O
not	O
interact	O
with	O
AHR	B
.	O

A	O
heterologous	O
promoter	O
construct	O
containing	O
three	O
repeats	O
of	O
a	O
consensus	O
Sp1	B
site	I
,	O
cloned	O
upstream	O
of	O
a	O
single	O
copy	O
of	O
the	O
ZII	B
(	O
CREB	B
/	I
AP1	I
)	O
element	O
from	O
the	O
BZLF1	B
promoter	I
linked	O
to	O
the	O
beta	B
-	I
globin	I
TATA	O
box	O
,	O
exhibited	O
phorbol	O
ester	O
inducibility	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
cAMP	O
-	O
dependent	O
control	O
of	O
the	O
amounts	O
of	O
the	O
activator	O
SF-1	B
vs.	O
the	O
repressor	O
COUP	B
-	I
TF	I
could	O
influence	O
CRS2-dependent	O
transcription	O
.	O

Interaction	O
of	O
Ets-1	B
and	O
the	O
POU	B
-	I
homeodomain	I
protein	I
GHF-1	B
/	O
Pit-1	B
reconstitutes	O
pituitary	O
-	O
specific	O
gene	O
expression	O
.	O

Enhanced	O
period	O
-	O
peak	O
analysis	O
of	O
electro	O
-	O
encephalograms	O
using	O
a	O
fast	O
sinc	O
function	O
.	O

We	O
have	O
measured	O
the	O
MBF	O
on	O
incisors	O
and	O
its	O
direction	O
in	O
three	O
dimensions	O
for	O
different	O
jaw	O
openings	O
in	O
ten	O
subjects	O
.	O

The	O
neuroprotective	O
efficacy	O
of	O
the	O
selective	O
N	O
-	O
type	O
voltage	O
-	O
sensitive	O
calcium	O
channel	O
blocker	O
,	O
SNX-111	O
,	O
was	O
evaluated	O
in	O
spontaneously	O
hypertensive	O
rats	O
subjected	O
to	O
60	O
min	O
of	O
focal	O
cerebral	O
ischemia	O
by	O
permanent	O
ligation	O
of	O
the	O
right	O
common	O
carotid	O
artery	O
and	O
temporary	O
occlusion	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
.	O

The	O
HBP	B
gene	I
is	O
composed	O
of	O
eight	O
exons	O
covering	O
19.5	O
kb	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
4	O
.	O

The	O
intensity	O
of	O
the	O
SSTEs	O
is	O
an	O
order	O
of	O
magnitude	O
larger	O
than	O
that	O
of	O
the	O
MSEs	O
and	O
determines	O
the	O
signal	O
contrast	O
if	O
both	O
effects	O
are	O
selected	O
simultaneously	O
.	O

In	O
eukaryotic	O
cells	O
,	O
premature	O
termination	O
of	O
translation	O
at	O
nonsense	O
codons	O
has	O
been	O
implicated	O
as	O
the	O
cause	O
of	O
a	O
variety	O
of	O
posttranscriptional	O
events	O
,	O
including	O
rapid	O
mRNA	O
decay	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
altered	O
splice	O
site	O
selection	O
,	O
and	O
exon	O
skipping	O
.	O

A	O
miracle	O
cure	O
and	O
its	O
solution	O

Ume6p	B
,	O
which	O
also	O
controls	O
the	O
expression	O
of	O
early	O
meiotic	O
genes	O
,	O
represses	O
CAR1	B
expression	O
through	O
a	O
sequence	O
called	O
URS	O
,	O
as	O
a	O
function	O
of	O
nitrogen	O
availability	O
.	O

None	O
of	O
these	O
organic	O
manifestations	O
was	O
discovered	O
by	O
scintigraphic	O
means	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
U1	B
snRNP	I
is	O
recruited	O
to	O
the	O
5	O
'	O
splice	O
site	O
by	O
protein	O
/	O
protein	O
interactions	O
involving	O
the	O
SR	B
domains	O
of	O
the	O
U1	B
-	I
70	I
K	I
protein	I
and	O
SF2	B
/	O
ASF	B
.	O

An	O
aromatic	O
stacking	O
interaction	O
between	O
subunits	O
helps	O
mediate	O
DNA	O
sequence	O
specificity	O
:	O
operator	O
site	O
discrimination	O
by	O
phage	B
lambda	I
cI	I
repressor	I
.	O

Here	O
we	O
report	O
the	O
purification	O
of	O
this	O
larger	O
form	O
as	O
an	O
approximately	O
320-kDa	O
particle	O
that	O
contains	O
mRNP3	B
+	I
4	I
and	O
nine	O
additional	O
polypeptides	O
,	O
including	O
mRNA	O
-	O
binding	O
polypeptides	O
of	O
34	O
and	O
36	O
kDa	O
and	O
a	O
doublet	O
of	O
110	O
/	O
105	O
kDa	O
that	O
proved	O
to	O
be	O
nucleolin	B
.	O

The	O
perioperative	O
mortality	O
of	O
all	O
patients	O
was	O
1.9	O
%	O
,	O
the	O
mortality	O
of	O
patients	O
older	O
than	O
70	O
years	O
was	O
4.3	O
%	O
.	O

Having	O
an	O
LRR	B
domain	I
and	O
an	O
SH3-binding	B
domain	I
,	O
Acan125	B
and	O
the	O
C.	O
elegans	O
homologue	O
define	O
a	O
novel	O
family	O
of	O
bifunctional	O
binding	O
proteins	O
.	O

The	O
capacity	O
to	O
repair	O
8-OxoG	O
has	O
been	O
measured	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
wild	O
-	O
type	O
and	O
ogg1	B
strains	O
using	O
a	O
34mer	O
DNA	O
fragment	O
containing	O
a	O
single	O
8-OxoG	O
residue	O
paired	O
with	O
a	O
cytosine	O
(	O
8-OxoG	O
/	O
C	O
)	O
as	O
a	O
substrate	O
.	O

The	O
likelihood	O
that	O
a	O
common	O
region	O
of	O
deletions	O
would	O
contain	O
a	O
tumor	O
suppressor	O
is	O
strongly	O
enhanced	O
by	O
coincidence	O
of	O
that	O
region	O
with	O
a	O
chromosome	O
fragment	O
suppressing	O
tumorigenicity	O
upon	O
introduction	O
in	O
tumor	O
cells	O
.	O

However	O
,	O
in	O
some	O
of	O
them	O
either	O
pattern	O
may	O
predominate	O
or	O
be	O
exclusively	O
present	O
.	O

The	O
carboxyl	O
-	O
terminal	O
CCCC	O
module	O
is	O
structurally	O
related	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	I
.	O

A	O
polypeptide	O
encoded	O
by	O
the	O
NTS	O
16	O
open	O
reading	O
frame	O
has	O
sequence	O
similarity	O
to	O
the	O
catalytic	O
domain	O
of	O
several	O
receptor	B
protein	I
kinases	I
from	I
plants	I
including	O
the	O
S	B
-	I
receptor	I
kinases	I
implicated	O
in	O
the	O
rejection	O
of	O
self	O
-	O
pollen	O
in	O
Brassica	O
species	O
and	O
the	O
Pto	B
gene	I
product	I
of	I
tomato	I
which	O
confers	O
resistance	O
to	O
a	O
bacterial	O
pathogen	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
factors	O
present	O
in	O
nuclear	O
extracts	O
derived	O
from	O
differentiated	O
osteoblast	O
bound	O
to	O
oligonucleotide	O
probes	O
containing	O
the	O
E	O
-	O
box	O
1	O
and	O
E	O
-	O
box	O
2	O
elements	O
.	O

RESULTS	O
:	O
Surprisingly	O
,	O
PAF	B
blockade	O
increased	O
mortality	O
after	O
trauma	O
(	O
5	O
of	O
11	O
WEB-2086	O
animals	O
versus	O
1	O
of	O
9	O
vehicle	O
animals	O
;	O
p	O
=	O
0.15	O
)	O
and	O
depressed	O
cardiac	O
index	O
and	O
O2	O
delivery	O
at	O
72	O
hours	O
(	O
p	O
<	O
0.05	O
)	O
.	O

We	O
thus	O
conclude	O
that	O
the	O
NFAT	B
RIR	I
plays	O
an	O
essential	O
dual	O
role	O
in	O
DNA	O
recognition	O
and	O
cooperative	O
binding	O
to	O
AP-1	B
family	I
transcription	I
factors	I
.	O

Thus	O
,	O
the	O
association	O
of	O
PS1	B
fragments	I
may	O
be	O
maintained	O
during	O
cycles	O
of	O
phosphorylation	O
/	O
dephosphorylation	O
of	O
the	O
PS1	B
CTF	I
.	O

A	O
patient	O
of	O
Group	O
B	O
had	O
severe	O
athetoid	O
CP	O
with	O
spasticity	O
,	O
being	O
unable	O
to	O
right	O
his	O
trunk	O
and	O
neck	O
.	O

Thus	O
,	O
our	O
studies	O
suggest	O
that	O
pV	O
-	O
mediated	O
activation	O
of	O
HIV-1	B
LTR	I
activity	O
is	O
controlled	O
by	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
,	O
which	O
is	O
mediated	O
by	O
IkappaBalpha	B
serine	O
phosphorylation	O
and	O
degradation	O
,	O
but	O
also	O
by	O
a	O
still	O
undefined	O
NF	B
-	I
kappaB	I
-	O
independent	O
pathway	O
.	O

We	O
also	O
review	O
the	O
role	O
of	O
grains	O
in	O
the	O
formation	O
of	O
complex	O
molecules	O
in	O
interstellar	O
molecular	O
clouds	O
.	O

Like	O
the	O
elicitors	O
of	O
the	O
hypersensitive	O
reaction	O
(	O
HR	O
)	O
produced	O
by	O
E.	O
chrysanthemi	O
(	O
HarpinEch	O
)	O
and	O
E.	O
amylovora	O
(	O
HarpinEa	O
)	O
,	O
the	O
deduced	O
36-kDa	O
protein	O
does	O
not	O
possess	O
a	O
typical	O
signal	O
sequence	O
,	O
but	O
it	O
contains	O
a	O
putative	O
membrane	O
-	O
spanning	O
domain	O
.	O

Rep	B
-	O
Rep	B
protein	O
interaction	O
was	O
confirmed	O
in	O
vitro	O
through	O
coimmunoprecipitation	O
experiments	O
with	O
a	O
bacterially	O
expressed	O
maltose	B
-	I
binding	I
protein	I
-	O
Rep78	B
fusion	O
protein	O
in	O
combination	O
with	O
[	O
35S	O
]	O
methionine	O
-	O
labeled	O
Rep78	B
synthesized	O
in	O
a	O
coupled	O
in	O
vitro	O
transcription	O
-	O
translation	O
system	O
.	O

Fourteen	O
patients	O
with	O
New	O
York	O
Heart	O
Association	O
class	O
II	O
congestive	O
heart	O
failure	O
were	O
enrolled	O
in	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
.	O

The	O
main	O
advantages	O
of	O
Multi	O
-	O
MUP	O
analysis	O
are	O
:	O
(	O
1	O
)	O
quick	O
acquisition	O
of	O
many	O
MUPs	O
;	O
(	O
2	O
)	O
simultaneous	O
collection	O
of	O
several	O
MUPs	O
at	O
one	O
recording	O
site	O
;	O
(	O
3	O
)	O
possibility	O
to	O
analyze	O
not	O
only	O
low	O
threshold	O
MUPs	O
;	O
(	O
4	O
)	O
less	O
bias	O
in	O
the	O
selection	O
of	O
MUPs	O
and	O
(	O
5	O
)	O
the	O
reproducibility	O
of	O
the	O
results	O
that	O
allow	O
the	O
same	O
reference	O
values	O
to	O
be	O
used	O
in	O
different	O
laboratories	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
a	O
hamster	O
cell	O
line	O
(	O
ts13	O
)	O
with	O
a	O
point	O
mutation	O
in	O
the	O
TAF	B
(	I
II	I
)	I
250	I
/	O
CCG1	B
(	O
TAF	B
(	I
II	I
)	I
250	I
)	O
gene	O
shows	O
temperature	O
-	O
sensitive	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
and	O
arrests	O
in	O
late	O
G1	O
at	O
39.5	O
degrees	O
C.	O

METHODS	O
:	O
The	O
responses	O
of	O
a	O
31-year	O
-	O
old	O
woman	O
with	O
complex	O
regional	O
pain	O
syndrome	O
type	O
I	O
(	O
reflex	O
sympathetic	O
dystrophy	O
)	O
to	O
a	O
thermal	O
grill	O
were	O
evaluated	O
before	O
and	O
after	O
stellate	O
ganglion	O
block	O
.	O

More	O
recently	O
,	O
however	O
,	O
a	O
number	O
of	O
developments	O
such	O
as	O
the	O
successful	O
use	O
of	O
the	O
inhaled	O
steroid	O
budesonide	O
and	O
oral	O
dexamethasone	O
have	O
reinforced	O
the	O
argument	O
for	O
using	O
steroids	O
.	O

In	O
ciliates	O
,	O
both	O
mechanisms	O
are	O
readily	O
observed	O
.	O

Based	O
on	O
the	O
occurrence	O
of	O
several	O
transcription	O
signals	O
in	O
the	O
Thermus	B
pyr	I
promoter	I
region	I
and	O
strong	O
amino	O
acid	O
sequence	O
identities	O
(	O
about	O
60	O
%	O
)	O
between	O
Thermus	B
PyrR	I
and	O
the	O
PyrR	B
attenuation	I
proteins	I
of	O
two	O
Bacillus	O
sp.	O
,	O
we	O
propose	O
a	O
regulatory	O
mechanism	O
involving	O
transcriptional	O
attenuation	O
to	O
control	O
pyr	B
gene	I
expression	O
in	O
Thermus	O
.	O

Thus	O
,	O
the	O
B	O
-	O
S	O
mutant	O
does	O
not	O
mimic	O
efficiently	O
the	O
chloroplastic	B
GAPDHs	I
,	O
and	O
long	O
-	O
range	O
and/or	O
second	O
-	O
layer	O
effects	O
,	O
not	O
easily	O
predictable	O
from	O
visual	O
inspection	O
of	O
three	O
-	O
dimensional	O
structures	O
,	O
need	O
to	O
be	O
taken	O
into	O
account	O
for	O
designing	O
a	O
true	O
""""	O
chloroplastic	O
-	O
like	O
""""	O
mutant	O
of	O
cytosolic	B
GAPDH	I
.	O

Evaluation	O
of	O
myocardial	O
perfusion	O
by	O
99mTc	O
-	O
tetrofosmin	O
SPECT	O
before	O
and	O
after	O
emergent	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
for	O
acute	O
myocardial	O
infarction	O

The	O
1.1-	O
and	O
1.3-kb	O
mRNA	O
species	O
were	O
found	O
only	O
in	O
the	O
heart	O
,	O
and	O
the	O
2.6-kb	O
species	O
was	O
found	O
in	O
the	O
heart	O
,	O
kidney	O
and	O
brain	O
,	O
but	O
not	O
in	O
skeletal	O
muscle	O
or	O
liver	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
whether	O
consuming	O
several	O
small	O
feedings	O
of	O
preexercise	O
carbohydrate	O
(	O
CHO	O
)	O
,	O
rather	O
than	O
a	O
single	O
bolus	O
,	O
would	O
affect	O
blood	O
glucose	O
and	O
insulin	B
responses	O
during	O
rest	O
and	O
exercise	O
.	O

Whereas	O
the	O
mutant	O
enzymes	O
terminate	O
normally	O
at	O
the	O
late	O
terminator	O
in	O
T7	O
DNA	O
(	O
T	O
(	O
phi	O
)	O
)	O
and	O
rrnB	B
T2	O
,	O
they	O
fail	O
to	O
terminate	O
at	O
one	O
of	O
the	O
termination	O
sites	O
of	O
rrnB	B
T1	O
,	O
and	O
also	O
fail	O
to	O
recognize	O
the	O
PTH	B
and	O
CJ	O
signals	O
.	O

Cytological	O
data	O
suggest	O
that	O
the	O
transgenes	O
associate	O
with	O
a	O
nucleolus	O
.	O

Strikingly	O
,	O
stoichiometric	O
association	O
of	O
p107	B
or	O
p130	B
with	O
either	O
cyclin	B
E	I
-	O
cdk2	B
or	O
cyclin	B
A	I
-	O
cdk2	B
negated	O
the	O
activities	O
of	O
these	O
kinases	O
.	O

Clinical	O
and	O
haematological	O
signs	O
are	O
not	O
specific	O
in	O
this	O
setting	O
,	O
and	O
the	O
diagnosis	O
relies	O
on	O
histological	O
features	O
,	O
mainly	O
bone	O
marrow	O
examination	O
.	O

A	O
striking	O
feature	O
of	O
the	O
recombinant	B
H19	I
allele	I
is	O
the	O
occurrence	O
of	O
a	O
parental	O
imprint	O
set	O
on	O
the	O
neo	B
replacement	I
cassette	I
.	O

Identification	O
of	O
five	O
new	O
genes	O
,	O
closely	O
related	O
to	O
the	O
interleukin-1beta	B
converting	I
enzyme	I
gene	I
,	O
that	O
do	O
not	O
encode	O
functional	O
proteases	O
.	O

However	O
,	O
we	O
could	O
not	O
find	O
the	O
homologous	O
regions	O
with	O
guanine	B
nucleotide	I
exchange	I
factors	I
or	O
GTPase	B
-	I
activating	I
proteins	I
in	O
the	O
c	B
-	I
cbl	I
gene	I
.	O

Serum	B
response	I
factor	I
(	O
SRF	B
)	O
,	O
a	O
member	O
of	O
an	O
ancient	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
,	O
is	O
generally	O
assumed	O
to	O
be	O
a	O
ubiquitous	O
transcription	O
factor	O
involved	O
in	O
regulating	O
growth	O
factor	O
-	O
responsive	O
genes	O
.	O

Activity	O
of	O
palgD	B
in	O
the	O
cysB	B
mutant	I
,	O
in	O
CHA	O
and	O
in	O
the	O
non	O
-	O
mucoid	O
strain	O
PAO	O
was	O
assessed	O
by	O
the	O
use	O
of	O
a	O
transcriptional	O
algD	B
-	O
xylE	B
fusion	O
.	O

The	O
Man9-mannosidase	B
specificity	O
of	O
the	O
cDNA	O
construct	O
was	O
verified	O
by	O
the	O
observation	O
that	O
all	O
peptide	O
sequences	O
derived	O
from	O
a	O
previously	O
purified	O
,	O
catalytically	O
active	O
49-kDa	O
fragment	O
were	O
found	O
within	O
the	O
coding	O
region	O
.	O

ORF	O
M1	O
has	O
striking	O
homology	O
to	O
poxvirus	O
serpins	B
,	O
while	O
ORF	O
M11	O
encodes	O
a	O
potential	O
homolog	O
of	O
Bcl-2-like	B
molecules	I
encoded	O
by	O
other	O
gammaherpesviruses	O
(	O
gene	B
16	I
of	O
HVS	O
and	O
KSHV	O
and	O
the	O
BHRF1	B
gene	I
of	O
EBV	O
)	O
.	O

Stereotactic	O
radiofrequency	O
lesioning	O
of	O
the	O
hamartoma	O
resulted	O
in	O
seizure	O
remission	O
without	O
complications	O
20	O
months	O
after	O
surgery	O
.	O

However	O
,	O
mean	O
food	O
intake	O
in	O
the	O
40	O
%	O
group	O
was	O
half	O
that	O
of	O
the	O
ACT	O
group	O
(	O
p	O
<	O
0.001	O
)	O
and	O
significantly	O
less	O
(	O
p	O
<	O
0.01	O
)	O
than	O
the	O
SEP	O
group	O
,	O
which	O
consumed	O
amounts	O
equivalent	O
to	O
65	O
%	O
of	O
daily	O
requirement	O
.	O

The	O
following	O
technique	O
describes	O
a	O
modification	O
to	O
a	O
bar	O
superstructure	O
that	O
provided	O
the	O
advantages	O
of	O
convenience	O
,	O
security	O
,	O
and	O
consistent	O
positioning	O
even	O
though	O
one	O
implant	O
was	O
lost	O
and	O
the	O
angulation	O
of	O
implants	O
limited	O
accuracy	O
.	O

Its	O
potential	O
as	O
a	O
diagnostic	O
tool	O
for	O
epidemiological	O
surveillance	O
was	O
assessed	O
in	O
comparison	O
with	O
three	O
other	O
diagnostic	O
tests	O
:	O
stool	O
examination	O
,	O
ELISA	O
with	O
soluble	B
egg	I
antigen	I
(	O
SEA	B
)	O
and	O
the	O
circumoval	O
precipitin	B
test	O
(	O
COPT	O
)	O
.	O

Human	B
thymine	I
-	I
DNA	I
glycosylase	I
maps	O
at	O
chromosome	O
12q22-q24.1	O
:	O
a	O
region	O
of	O
high	O
loss	O
of	O
heterozygosity	O
in	O
gastric	O
cancer	O
.	O

FOG	B
is	O
coexpressed	O
with	O
GATA-1	B
during	O
embryonic	O
development	O
and	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O

Autoimmune	O
neutropenia	O
(	O
AIN	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
chronic	O
neutropenia	O
especially	O
in	O
youngest	O
children	O
.	O

Here	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
the	O
short	O
transcripts	O
,	O
or	O
proteins	O
translated	O
from	O
the	O
short	O
transcripts	O
,	O
are	O
also	O
required	O
for	O
respiration	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
this	O
notion	O
by	O
using	O
ligation	O
-	O
mediated	O
PCR	O
to	O
assess	O
the	O
formation	O
of	O
recombination	B
-	I
activating	I
gene	I
(	O
RAG	B
)	O
-dependent	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
at	O
RSSs	O
3	O
'	O
of	O
Ddelta3	B
and	O
5	O
'	O
of	O
Jdelta1	B
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
Cbl	B
,	O
the	O
120-kDa	O
protein	O
product	O
of	O
the	O
c	B
-	I
cbl	I
proto	I
-	I
oncogene	I
,	O
serves	O
as	O
a	O
substrate	O
of	O
a	O
number	O
of	O
receptor	B
-	I
coupled	I
tyrosine	I
kinases	I
and	O
forms	O
complexes	O
with	O
SH3	B
and	O
SH2	B
domain	O
-	O
containing	O
proteins	O
,	O
pointing	O
to	O
its	O
role	O
in	O
signal	O
transduction	O
.	O

Volunteers	O
were	O
irradiated	O
on	O
their	O
backs	O
with	O
suberythemal	O
UV	O
daily	O
for	O
5	O
d	O
after	O
application	O
of	O
the	O
sunscreens	O
and	O
their	O
base	O
lotion	O
to	O
different	O
sites	O
.	O

It	O
is	O
thus	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
triiodothyronine	O
-	O
mediated	O
control	O
of	O
growth	O
,	O
differentiation	O
and	O
basal	O
metabolism	O
in	O
vertebrates	O
.	O

Patients	O
received	O
either	O
diltiazem	O
CD	O
180	O
mg	O
or	O
placebo	O
once	O
/	O
day	O
in	O
combination	O
with	O
existing	O
antianginal	O
therapy	O
.	O

Induction	O
of	O
B	O
cell	O
apoptosis	O
by	O
co	O
-	O
cross	O
-	O
linking	O
CD23	B
and	O
sIg	B
involves	O
aberrant	O
regulation	O
of	O
c	B
-	I
myc	I
and	O
is	O
inhibited	O
by	O
bcl-2	B
.	O

Because	O
the	O
biosynthetic	O
pathway	O
to	O
the	O
vacuole	O
intersects	O
with	O
the	O
endocytic	O
pathway	O
,	O
internalization	O
of	O
a	O
bulk	O
membrane	O
endocytic	O
marker	O
FM	O
4	O
-	O
64	O
was	O
assayed	O
in	O
the	O
sop	B
mutants	I
.	O

Genes	O
belonging	O
to	O
the	O
ras	B
superfamily	I
encode	O
low	B
-	I
molecular	I
-	I
weight	I
GTP	I
/	I
GDP	I
-	I
binding	I
proteins	I
that	O
are	O
highly	O
conserved	O
in	O
wide	O
variety	O
of	O
organisms	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
and	O
characterize	O
two	O
overlapping	O
ELL	B
functional	I
domains	I
that	O
govern	O
its	O
interaction	O
with	O
RNA	B
polymerase	I
II	I
and	O
the	O
ternary	O
elongation	O
complex	O
.	O

The	O
position	O
,	O
transcription	O
orientation	O
,	O
and	O
imprinted	O
status	O
of	O
the	O
genes	O
immediately	O
flanking	O
Igf2r	B
have	O
been	O
assessed	O
.	O

The	O
MCAD	B
nuclear	I
receptor	I
response	I
element	I
1	I
(	O
NRRE-1	B
)	O
interacts	O
in	O
vitro	O
with	O
ERR	B
alpha	I
expressed	O
in	O
COS-7	O
cells	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
gene	O
also	O
revealed	O
the	O
presence	O
of	O
multiple	O
TATA	O
and	O
CAAT	O
sequences	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
competition	O
experiments	O
showed	O
that	O
site	O
A	O
is	O
recognized	O
by	O
an	O
NF1	B
protein	I
.	O

A	O
specific	O
distal	O
promoter	O
controls	O
gamma	B
-	I
glutamyl	I
transpeptidase	I
gene	I
expression	O
in	O
undifferentiated	O
rat	O
transformed	O
liver	O
cells	O
.	O

Proteasomes	O
are	O
the	O
multisubunit	O
protease	O
involved	O
in	O
the	O
generation	O
of	O
peptides	O
presented	O
by	O
MHC	B
class	I
I	I
molecules	I
.	O

These	O
discoloration	O
's	O
can	O
be	O
treated	O
in	O
several	O
ways	O
but	O
up	O
to	O
lately	O
tooth	O
structure	O
had	O
to	O
be	O
removed	O
in	O
an	O
irreversible	O
manner	O
in	O
order	O
to	O
provide	O
sufficient	O
bulk	O
for	O
the	O
new	O
restorative	O
material	O
.	O

We	O
report	O
the	O
preliminary	O
biochemical	O
characterization	O
of	O
the	O
T	B
antigens	I
encoded	O
by	O
three	O
SV40	O
mutants	O
,	O
5030	O
,	O
5031	O
,	O
and	O
5061	O
,	O
each	O
of	O
which	O
have	O
altered	O
residues	O
within	O
or	O
near	O
the	O
ATP	O
binding	O
pocket	O
.	O

Interestingly	O
,	O
the	O
RXRalphaF318A	B
constitutive	O
activity	O
generated	O
within	O
heterodimers	O
in	O
the	O
presence	O
of	O
BMS614	O
requires	O
the	O
integrity	O
of	O
both	O
RXR	B
and	O
RAR	B
AF-2	O
domains	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
Src	B
homology-2	I
(	O
SH2	B
)	O
domain	O
-	O
containing	O
protein	B
-	I
tyrosine	I
phosphatase	I
,	O
SHP-2	B
,	O
associates	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
PECAM-1	B
as	O
it	O
becomes	O
tyrosine	O
-	O
phosphorylated	O
during	O
platelet	O
aggregation	O
:	O
a	O
process	O
that	O
can	O
be	O
mimicked	O
in	O
part	O
by	O
small	O
synthetic	O
phosphopeptides	O
corresponding	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
PECAM-1	B
encompassing	O
tyrosine	O
residues	O
Tyr-663	O
or	O
Tyr-686	O
.	O

We	O
found	O
that	O
multiple	O
tumor	O
suppressor	O
genes	O
(	O
e.g.	O
,	O
p53	B
,	O
DCC	B
,	O
APC	B
,	O
MCC	B
,	O
BRCA1	B
,	O
and	O
WAF1	B
/	O
CIP1	B
)	O
were	O
inactivated	O
at	O
different	O
frequencies	O
via	O
various	O
mechanisms	O
[	O
e.g.	O
,	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
,	O
loss	O
of	O
expression	O
(	O
LOE	O
)	O
,	O
mutation	O
,	O
and	O
inactivation	O
by	O
cellular	O
binding	O
protein	O
]	O
.	O

Because	O
the	O
deletion	O
included	O
the	O
TK	B
gene	I
,	O
selection	O
with	O
gancyclovir	O
against	O
cells	O
not	O
having	O
undergone	O
recombination	O
was	O
possible	O
.	O

Fermentation	O
process	O
after	O
supplementation	O
of	O
nitrate	O
,	O
nitrite	O
,	O
lactic	O
acid	O
bacteria	O
and	O
formic	O
acid	O

The	O
Trx	B
-	O
CT	B
fusion	O
protein	O
was	O
produced	O
less	O
efficiently	O
(	O
20	O
%	O
of	O
total	O
soluble	O
cellular	O
protein	O
)	O
.	O

U4	B
/	O
U6	B
snRNP	O
is	O
one	O
of	O
four	O
essential	O
small	O
nuclear	O
ribonucleoprotein	O
(	O
snRNP	O
)	O
particles	O
(	O
U1	B
,	O
U2	B
,	O
U5	B
and	O
U4	B
/	O
U6	B
)	O
present	O
in	O
the	O
spliceosome	O
.	O

We	O
cloned	O
a	O
complete	O
cDNA	O
(	O
2.9	O
kb	O
)	O
for	O
HET	B
from	O
an	O
MCF-7	O
cDNA	O
library	O
.	O

Thus	O
,	O
ZNF74	B
sublocalization	O
in	O
nuclear	O
domains	O
enriched	O
in	O
pre	O
-	O
mRNA	O
maturating	O
factors	O
,	O
its	O
RNA	O
binding	O
activity	O
,	O
and	O
its	O
direct	O
phosphodependent	O
interaction	O
with	O
the	O
pol	B
IIo	I
,	O
a	O
form	O
of	O
the	O
RNA	B
polymerase	I
functionally	O
associated	O
with	O
pre-	O
mRNA	O
processing	O
,	O
suggest	O
a	O
role	O
for	O
this	O
member	O
of	O
the	O
KRAB	B
multifinger	I
protein	I
family	I
in	O
RNA	O
processing	O
.	O

Modulation	O
of	O
AUUUA	O
response	O
element	O
binding	O
by	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
A1	I
in	O
human	O
T	O
lymphocytes	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
the	O
Sp1	B
site	I
also	O
significantly	O
reduced	O
promoter	O
activity	O
.	O

These	O
residues	O
,	O
Ile244	O
at	O
the	O
extracellular	O
end	O
of	O
transmembrane	O
helix	O
3	O
,	O
and	O
Tyr318	O
at	O
the	O
COOH	O
-	O
terminal	O
portion	O
of	O
extracellular	O
loop	O
2	O
,	O
are	O
replaced	O
by	O
Leu	O
and	O
Ile	O
in	O
the	O
PTH-1	B
receptor	I
,	O
respectively	O
.	O

Together	O
,	O
our	O
results	O
show	O
that	O
tinman	B
is	O
controlled	O
by	O
an	O
array	O
of	O
discrete	O
enhancer	O
elements	O
that	O
are	O
activated	O
successively	O
by	O
differential	O
genetic	O
inputs	O
,	O
as	O
well	O
as	O
by	O
closely	O
linked	O
activator	O
and	O
repressor	O
binding	O
sites	O
within	O
an	O
early	O
-	O
acting	O
enhancer	O
,	O
which	O
restrict	O
twist	B
activity	O
to	O
specific	O
areas	O
within	O
the	O
twist	B
expression	I
domain	I
.	O

The	O
Fis	B
protein	I
regulates	O
site	O
-	O
specific	O
DNA	O
inversion	O
catalyzed	O
by	O
a	O
family	O
of	O
DNA	B
invertases	I
when	O
bound	O
to	O
a	O
cis	O
-	O
acting	O
recombinational	O
enhancer	O
.	O

These	O
studies	O
serve	O
as	O
the	O
basis	O
for	O
the	O
further	O
characterization	O
of	O
the	O
regulatory	O
mechanism	O
of	O
aromatase	B
expression	O
in	O
human	O
breast	O
cancer	O
and	O
ASCs	O
.	O

A	O
second	O
aim	O
was	O
to	O
determine	O
whether	O
the	O
decrease	O
in	O
muscle	O
-	O
tendon	O
unit	O
rest	O
length	O
produced	O
by	O
prolonged	O
immobilisation	O
in	O
a	O
shortened	O
position	O
is	O
mediated	O
primarily	O
by	O
adaptations	O
of	O
the	O
muscle	O
or	O
tendon	O
.	O

The	O
lysozyme	B
FEF	B
site	O
is	O
immediately	O
5	O
'	O
to	O
a	O
PU	B
.	O

Expression	O
of	O
thiamin	O
biosynthetic	O
genes	O
(	O
thiCOGE	B
)	O
and	O
production	O
of	O
symbiotic	B
terminal	I
oxidase	I
cbb3	I
in	O
Rhizobium	O
etli	O
.	O

Chimeras	O
containing	O
IE1	B
peptides	I
dramatically	O
activated	O
transcription	O
of	O
the	O
basal	O
promoter	O
only	O
when	O
lac	B
operator	I
sequences	I
were	O
present	O
.	O

Transfection	O
of	O
HepG2	O
and	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
with	O
constructs	O
deleted	O
of	O
additional	O
5'-flanking	O
fragments	O
permitted	O
the	O
definition	O
of	O
a	O
minimal	O
200	O
bp	O
promoter	O
fragment	O
containing	O
the	O
pseudo	O
-	O
TATA	O
box	O
and	O
two	O
putative	O
SP1-binding	B
sites	I
.	O

Epitopes	O
of	O
adhesion	O
-	O
perturbing	O
monoclonal	O
antibodies	O
map	O
within	O
a	O
predicted	O
alpha	O
-	O
helical	O
domain	O
of	O
the	O
integrin	B
beta	I
1	I
subunit	I
.	O

Radiation	O
decreased	O
the	O
levels	O
of	O
T4	O
and	O
T3	O
6	O
h	O
and	O
72	O
h	O
in	O
group	O
C	O
,	O
in	O
group	O
A	O
at	O
72	O
h	O
,	O
in	O
group	O
B	O
at	O
24	O
h	O
postexposure	O
.	O

Furthermore	O
,	O
DNA	O
-	O
bound	O
LAZ3	B
/	O
BCL6	B
recruits	O
SMRT	B
in	O
vivo	O
,	O
and	O
both	O
overexpressed	O
proteins	O
completely	O
colocalize	O
in	O
nuclear	O
dots	O
.	O

All	O
pigs	O
had	O
significant	O
regional	O
LV	O
dysfunction	O
and	O
reduced	O
LV	O
ejection	O
fraction	O
(	O
41+	O
/	O
-11	O
%	O
)	O
.	O

4	O
)	O
PU	B
and	O
PD	B
lacked	O
the	O
canonical	O
TATA	O
or	O
CAAT	O
motifs	O
,	O
and	O
are	O
AT	O
-	O
rich	O
.	O

The	O
prescription	O
for	O
apoplexy	O
includes	O
C1	O
-	O
7	O
,	O
T1	O
-	O
9	O
and	O
L2	O
-	O
4	O
.	O

Interleukin-1	B
levels	O
remained	O
low	O
throughout	O
the	O
course	O
.	O

Sequences	O
required	O
for	O
interaction	O
of	O
mu2	B
and	O
CTLA-4	B
were	O
localized	O
to	O
residues	O
,	O
161TTGVY	O
in	O
CTLA-4	B
;	O
this	O
sequence	O
is	O
N	O
-	O
terminal	O
to	O
,	O
but	O
overlaps	O
with	O
,	O
a	O
previously	O
identified	O
SH2	B
binding	I
motif	I
,	O
165YVKM	O
,	O
involved	O
in	O
CTLA-4	B
signaling	O
.	O

During	O
the	O
conditioning	O
procedure	O
,	O
the	O
C	O
-	O
fiber	O
reflex	O
was	O
facilitated	O
(	O
wind	O
-	O
up	O
)	O
in	O
a	O
stimulus	O
-	O
dependent	O
fashion	O
in	O
intact	O
,	O
anesthetized	O
animals	O
during	O
the	O
application	O
of	O
the	O
first	O
seven	O
conditioning	O
stimuli	O
;	O
thereafter	O
,	O
the	O
magnitude	O
of	O
the	O
responses	O
reached	O
a	O
plateau	O
and	O
then	O
decreased	O
.	O

Multiple	O
regression	O
analyses	O
revealed	O
that	O
WAIS	O
-	O
R	O
factor	O
scores	O
Verbal	O
Comprehension	O
and	O
Freedom	O
from	O
Distractibility	O
accounted	O
for	O
up	O
to	O
42	O
%	O
of	O
the	O
variance	O
in	O
WMS	O
-	O
R	O
and	O
CVLT	O
indices	O
.	O

In	O
ICU	O
patients	O
,	O
the	O
LIS	O
related	O
to	O
the	O
postoperative	O
rise	O
in	O
IL-6	B
level	O
only	O
,	O
even	O
though	O
the	O
rise	O
in	O
plasma	O
concentrations	O
of	O
cytokines	O
interrelated	O
.	O

The	O
SR	B
protein	I
family	I
is	O
involved	O
in	O
constitutive	O
and	O
regulated	O
pre	O
-	O
mRNA	O
splicing	O
and	O
has	O
been	O
found	O
to	O
be	O
evolutionarily	O
conserved	O
in	O
metazoan	O
organisms	O
.	O

Holliday	B
junction	I
resolvase	I
in	O
Schizosaccharomyces	O
pombe	O
has	O
identical	O
endonuclease	O
activity	O
to	O
the	O
CCE1	B
homologue	O
YDC2	B
.	O

In	O
Xenopus	O
embryos	O
,	O
the	O
engineered	B
PDGF	I
receptor	I
protein	I
induced	O
the	O
formation	O
of	O
mesoderm	O
from	O
animal	O
-	O
pole	O
explants	O
in	O
an	O
FK1012-dependent	O
manner	O
.	O

A	O
genomic	O
clone	O
was	O
isolated	O
that	O
contained	O
12.5	O
kb	O
of	O
the	O
5'-flanking	O
region	O
and	O
the	O
first	O
exon	O
of	O
the	O
p69	B
/	I
71	I
2	I
-	I
5A	I
synthetase	I
gene	I
.	O

In	O
the	O
clinical	O
study	O
,	O
the	O
defect	O
size	O
shown	O
by	O
BMIPP	O
imaging	O
was	O
greater	O
in	O
anterior	O
than	O
in	O
inferior	O
infarcts	O
(	O
p	O
<	O
0.001	O
)	O
and	O
correlated	O
well	O
with	O
the	O
risk	O
area	O
revealed	O
by	O
contrast	O
ventriculography	O
(	O
r	O
=	O
0.80	O
,	O
p	O
<	O
0.0001	O
)	O
CONCLUSION	O
:	O
The	O
above	O
preliminary	O
data	O
,	O
admittedly	O
from	O
a	O
small	O
group	O
of	O
patients	O
,	O
suggest	O
that	O
tomographic	O
BMIPP	O
imaging	O
provides	O
an	O
accurate	O
quantification	O
of	O
defect	O
size	O
by	O
means	O
of	O
a	O
simple	O
threshold	O
technique	O
and	O
,	O
in	O
the	O
subacute	O
phase	O
,	O
permits	O
determination	O
of	O
the	O
amount	O
of	O
myocardium	O
at	O
risk	O
after	O
acute	O
myocardial	O
infarction	O
.	O

This	O
information	O
,	O
together	O
with	O
estimation	O
of	O
the	O
size	O
of	O
the	O
deglycosylated	O
A	O
subunit	O
relative	O
to	O
a	O
series	O
of	O
C	B
-	I
terminal	I
truncated	I
TSHR	I
ectodomain	I
variants	I
,	O
places	O
cleavage	O
Site	O
1	O
in	O
the	O
vicinity	O
of	O
,	O
or	O
closely	O
upstream	O
to	O
,	O
residue	O
317	O
.	O

Here	O
we	O
report	O
that	O
in	O
cultured	O
cells	O
from	O
Drosophila	O
melanogaster	O
human	B
Sp1	I
efficiently	O
activates	O
transcription	O
from	O
synthetic	O
promoters	O
containing	O
TATA	O
boxes	O
,	O
but	O
not	O
from	O
promoters	O
that	O
contain	O
an	O
initiator	O
instead	O
of	O
a	O
TATA	O
box	O
.	O

No	O
apparent	O
clinical	O
signs	O
indicative	O
of	O
systemic	O
toxicity	O
were	O
observed	O
in	O
the	O
F0	O
and	O
F1	O
animals	O
of	O
either	O
sex	O
.	O

Such	O
mutations	O
are	O
thought	O
to	O
exert	O
their	O
dominant	O
phenotype	O
by	O
sequestration	O
of	O
the	O
guanine	B
nucleotide	I
exchange	I
factor	I
(	O
GNEF	B
)	O
.	O

Upon	O
analysis	O
of	O
various	O
deletion	O
and	O
point	O
-	O
mutated	O
variants	O
of	O
the	O
human	B
IL-6	I
gene	I
promoter	I
coupled	O
to	O
a	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
possible	O
cooperating	O
transcription	O
factors	O
.	O

Our	O
purpose	O
was	O
to	O
determine	O
if	O
intact	O
perianal	O
(	O
S4	O
-	O
5	O
)	O
pin	O
sensation	O
(	O
PPS	O
)	O
and	O
bulbocavernosus	O
(	O
S2	O
-	O
4	O
)	O
reflex	O
(	O
BCR	O
)	O
shortly	O
after	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
are	O
predictive	O
of	O
bladder	O
function	O
recovery	O
.	O

Platelet	O
aggregation	O
in	O
response	O
to	O
10	O
micrograms	O
collagen	B
/	O
ml	O
was	O
decreased	O
in	O
parallel	O
after	O
treatment	O
with	O
ASA	O
.	O

The	O
inhibition	O
of	O
focus	O
formation	O
observed	O
in	O
the	O
presence	O
of	O
C3	B
G	I
was	O
not	O
due	O
to	O
toxic	O
effects	O
on	O
cell	O
viability	O
,	O
since	O
transfected	O
C3	B
G	I
cells	O
exhibited	O
the	O
same	O
survival	O
and	O
growth	O
rates	O
as	O
untransfected	O
NIH3T3	O
cells	O
or	O
cells	O
transfected	O
with	O
plasmid	O
vector	O
alone	O
.	O

Furthermore	O
,	O
direct	O
association	O
with	O
D3	O
phosphatidylinositides	O
seems	O
to	O
be	O
essential	O
for	O
activation	O
of	O
PKB	B
/	O
Akt	B
.	O

The	O
FMN	O
moiety	O
but	O
not	O
the	O
[	O
3Fe-4S	O
]	O
cluster	O
of	O
the	O
subunit	O
appears	O
to	O
participate	O
in	O
this	O
reaction	O
.	O

However	O
,	O
laparoscopy	O
failed	O
to	O
establish	O
inoperability	O
in	O
any	O
cases	O
of	O
carcinoma	O
spread	O
to	O
areas	O
not	O
accessible	O
to	O
laparoscopic	O
visualization	O
.	O

Molecular	O
characterization	O
of	O
the	O
50-	O
and	O
57-kDa	O
subunits	O
of	O
the	O
bovine	B
vacuolar	I
proton	I
pump	I
.	O

In	O
C.	O
albicans	O
,	O
HST6	B
is	O
expressed	O
constitutively	O
at	O
high	O
levels	O
in	O
the	O
different	O
cell	O
types	O
analysed	O
(	O
yeast	O
,	O
hyphae	O
,	O
white	O
and	O
opaque	O
)	O
,	O
demonstrating	O
that	O
HST6	B
transcription	O
is	O
not	O
repressed	O
in	O
this	O
diploid	O
yeast	O
,	O
unlike	O
in	O
diploid	O
S.	O
cerevisiae	O
,	O
and	O
suggesting	O
a	O
basic	O
biological	O
function	O
for	O
the	O
Hst6p	B
transporter	O
in	O
C.	O
albicans	O
.	O

No	O
TATA	O
box	O
was	O
found	O
in	O
the	O
putative	O
promoter	O
region	O
,	O
but	O
multiple	O
GC	O
boxes	O
were	O
found	O
around	O
the	O
cap	O
sites	O
,	O
supporting	O
the	O
previously	O
inferred	O
housekeeping	O
nature	O
of	O
CYP51	B
gene	I
and	O
the	O
existence	O
of	O
the	O
multiple	O
transcription	O
initiation	O
sites	O
.	O

Cis	O
-	O
regulation	O
downstream	O
of	O
cell	O
type	O
specification	O
:	O
a	O
single	O
compact	O
element	O
controls	O
the	O
complex	O
expression	O
of	O
the	O
CyIIa	B
gene	I
in	O
sea	O
urchin	O
embryos	O
.	O

Randomised	O
comparison	O
of	O
addition	O
of	O
autologous	O
bone	O
-	O
marrow	O
transplantation	O
to	O
intensive	O
chemotherapy	O
for	O
acute	O
myeloid	O
leukaemia	O
in	O
first	O
remission	O
:	O
results	O
of	O
MRC	O
AML	O
10	O
trial	O
.	O

In	O
ferrets	O
naturally	O
infected	O
with	O
H.	O
mustelae	O
,	O
a	O
single	O
dose	O
(	O
50	O
mg	O
/	O
kg	O
,	O
per	O
os	O
)	O
of	O
fluorofamide	O
completely	O
inhibited	O
bacterial	B
urease	I
.	O

The	O
risk	O
factors	O
for	O
hematuria	O
in	O
patients	O
with	O
renal	O
hypouricemia	O
are	O
the	O
elevation	O
of	O
urinary	O
urate	O
concentration	O
and	O
the	O
subtypes	O
of	O
Post	O
and	O
Secretion	O
.	O

RESULTS	O
:	O
Using	O
information	O
in	O
the	O
dbEST	O
database	O
of	O
expressed	O
sequence	O
tags	O
,	O
we	O
isolated	O
an	O
Arabidopsis	O
thaliana	O
gene	O
(	O
GCR1	B
)	O
that	O
encodes	O
a	O
protein	O
with	O
seven	O
predicted	O
membrane	O
-	O
spanning	O
domains	O
and	O
other	O
features	O
characteristic	O
of	O
7TM	B
receptors	I
.	O

Purification	O
of	O
MvaT	B
enriched	O
for	O
two	O
polypeptides	O
of	O
approximate	O
molecular	O
mass	O
15	O
kDa	O
and	O
16	O
kDa	O
,	O
designated	O
P15	B
and	O
P16	B
.	O

BACKGROUND	O
:	O
Defensins	B
,	O
also	O
known	O
as	O
human	B
neutrophil	I
peptides	I
,	O
are	O
antimicrobial	O
peptides	O
present	O
in	O
the	O
azurophil	O
granules	O
of	O
neutrophils	O
.	O

The	O
PDH	B
complex	I
-	I
encoding	I
genes	I
were	O
identified	O
by	O
hybridization	O
experiments	O
and	O
sequence	O
analysis	O
in	O
two	O
separate	O
gene	O
regions	O
in	O
the	O
genome	O
of	O
Z.	O
mobilis	O
.	O

Cervicovaginal	O
foetal	B
fibronectin	I
in	O
the	O
prediction	O
of	O
preterm	O
labour	O
in	O
a	O
low	O
-	O
risk	O
population	O
.	O

The	O
RAS	B
-	O
cyclic	B
AMP	I
-	I
dependent	I
protein	I
kinase	I
cAPK	B
pathway	O
prevents	O
the	O
UAS	O
activity	O
of	O
IREu	B
in	O
the	O
presence	O
of	O
glucose	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
while	O
the	O
transcriptional	O
activators	O
Msn2p	B
and	O
Msn4p	B
promote	O
the	O
UAS	O
activity	O
of	O
this	O
repeat	O
in	O
the	O
presence	O
of	O
acetate	O
.	O

Cytochrome	B
b	I
in	O
human	B
complex	I
II	I
(	O
succinate	B
-	I
ubiquinone	I
oxidoreductase	I
)	O
:	O
cDNA	O
cloning	O
of	O
the	O
components	O
in	O
liver	O
mitochondria	O
and	O
chromosome	O
assignment	O
of	O
the	O
genes	O
for	O
the	O
large	O
(	O
SDHC	B
)	O
and	O
small	O
(	O
SDHD	B
)	O
subunits	O
to	O
1q21	O
and	O
11q23	O
.	O

Analysis	O
of	O
promoter	O
and	O
androgen	O
regulatory	O
sequences	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
rat	O
androgen	B
-	I
binding	I
protein	I
gene	O
.	O

Thus	O
,	O
Sir	B
proteins	I
from	O
K.	O
lactis	O
have	O
roles	O
in	O
both	O
silencing	O
and	O
telomere	O
length	O
maintenance	O
,	O
reflecting	O
conserved	O
functional	O
themes	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B
hnRNP	I
methyltransferase	I
(	O
HMT1	B
)	O
.	O

Serum	O
levels	O
of	O
testosterone	O
also	O
showed	O
no	O
significant	O
changes	O
by	O
exposure	O
to	O
p	O
,	O
p'-DDE	O
under	O
the	O
conditions	O
of	O
this	O
study	O
.	O

Based	O
on	O
the	O
current	O
literature	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
toxicity	O
of	O
OA	B
indicate	O
three	O
major	O
effects	O
:	O
(	O
1	O
)	O
inhibition	O
of	O
mitochondrial	O
respiration	O
correlated	O
with	O
a	O
depletion	O
of	O
ATP	O
;	O
(	O
2	O
)	O
inhibition	O
of	O
tRNA	B
-	I
synthetase	I
accompanied	O
by	O
a	O
reduced	O
protein	O
synthesis	O
;	O
and	O
(	O
3	O
)	O
enhanced	O
lipid	O
peroxidation	O
.	O

In	O
addition	O
to	O
restoring	O
checkpoint	O
control	O
,	O
overexpression	O
of	O
sum1	B
+	I
inhibits	O
the	O
normal	O
cell	O
cycle	O
response	O
to	O
osmotic	O
stress	O
.	O

Decreased	O
levels	O
of	O
alpha2-antiplasmin	B
were	O
also	O
observed	O
in	O
the	O
mediastinum	O
(	O
0.50	O
versus	O
0.61	O
U	O
/	O
mL	O
;	O
p	O
<	O
0.05	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
acute	O
administration	O
of	O
various	O
doses	O
of	O
malathion	O
via	O
oral	O
and	O
dermal	O
routes	O
to	O
mice	O
and	O
rats	O
on	O
serum	O
levels	O
of	O
histamine	O
was	O
evaluated	O
.	O

Using	O
Southern	O
blot	O
analysis	O
and	O
restriction	O
mapping	O
of	O
genomic	O
YAC	O
(	O
yeast	O
artificial	O
chromosome	O
)	O
and	O
cosmid	O
clones	O
,	O
we	O
located	O
the	O
human	B
RIL	I
gene	I
240	O
-	O
260	O
kb	O
telomeric	O
to	O
the	O
IRF1	B
gene	I
and	O
characterized	O
its	O
genomic	O
structure	O
.	O

However	O
,	O
mandibular	O
position	O
(	O
S	O
-	O
N	O
-	O
B	O
and	O
S	O
-	O
N	O
-	O
Pog	O
)	O
was	O
found	O
to	O
be	O
significantly	O
more	O
retrusive	O
in	O
Class	O
II	O
when	O
compared	O
with	O
Class	O
I	O
subjects	O
.	O

Echinostomiasis	O
is	O
aggravated	O
by	O
socioeconomic	O
factors	O
such	O
as	O
poverty	O
,	O
malnutrition	O
,	O
an	O
explosively	O
growing	O
free	O
-	O
food	O
market	O
,	O
a	O
lack	O
of	O
supervised	O
food	O
inspection	O
,	O
poor	O
or	O
insufficient	O
sanitation	O
,	O
other	O
helminthiases	O
,	O
and	O
declining	O
economic	O
conditions	O
.	O

To	O
clarify	O
whether	O
seizure	O
-	O
offset	O
patterns	O
are	O
reliable	O
in	O
predicting	O
seizure	O
outcome	O
,	O
we	O
studied	O
SEEG	O
/	O
ECoG	O
in	O
a	O
similar	O
group	O
of	O
patients	O
with	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
.	O

These	O
modifications	O
may	O
improve	O
the	O
interlaboratory	O
reproducibility	O
of	O
CD34	B
determinations	O
due	O
to	O
the	O
reduction	O
in	O
sample	O
handling	O
and	O
calculation	O
of	O
results	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
is	O
78.0	O
%	O
identical	O
to	O
the	O
cytoplasmic	B
dynein	I
heavy	I
chain	I
of	I
Neurospora	I
crassa	I
,	O
70.2	O
%	O
identical	O
to	O
that	O
of	O
Aspergillus	O
nidulans	O
and	O
24.8	O
%	O
identical	O
to	O
that	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
5'-flanking	O
region	O
,	O
from	O
nucleotide	O
-837	O
to	O
-336	O
,	O
contains	O
TATA	O
and	O
inverted	O
CAAT	O
boxes	O
as	O
well	O
as	O
GATA-1	B
/	O
SP1	B
erythroid	O
-	O
specific	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O

RESULTS	O
:	O
Horses	O
with	O
colic	O
had	O
significantly	O
higher	O
fibrinogen	B
concentration	O
,	O
greater	O
alpha	B
2AP	I
and	O
protein	B
C	I
activities	O
,	O
and	O
longer	O
PT	O
and	O
APTT	O
than	O
did	O
healthy	O
horses	O
.	O

The	O
same	O
IL-4-inducible	B
reporter	O
gene	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
endogenous	B
Stat6	I
and	O
NF	B
-	I
kappaB	I
proteins	I
in	O
IL-4-stimulated	B
I.29mu	O
B	O
lymphoma	O
cells	O
.	O

Convulsive	O
seizure	O
during	O
a	O
treatment	O
with	O
interferon	B
alpha	I
for	O
chronic	O
viral	O
hepatitis	O
C	O

A	O
stratified	O
random	O
sample	O
of	O
20	O
active	O
employees	O
from	O
a	O
cohort	O
of	O
phenoxy	O
herbicide	O
workers	O
was	O
selected	O
in	O
1995	O
for	O
determining	O
PCDD	O
and	O
PCDF	O
congeners	O
in	O
blood	O
lipids	O
to	O
assess	O
the	O
extent	O
of	O
past	O
PCDD	O
and	O
PCDF	O
exposure	O
in	O
this	O
cohort	O
and	O
whether	O
that	O
exposure	O
might	O
explain	O
site	O
-	O
specific	O
cancer	O
findings	O
in	O
the	O
total	O
cohort	O
.	O

We	O
specially	O
devised	O
3	O
types	O
of	O
turbo	O
pumps	O
,	O
a	O
centrifugal	O
pump	O
(	O
CFP	O
)	O
,	O
a	O
mixed	O
flow	O
pump	O
(	O
MFP	O
)	O
,	O
and	O
an	O
axial	O
flow	O
pump	O
(	O
AFP	O
)	O
,	O
and	O
analyzed	O
their	O
in	O
vitro	O
performance	O
.	O

Two	O
members	O
of	O
the	O
Cbl	B
family	I
have	O
since	O
been	O
defined	O
in	O
mammals	O
(	O
c	B
-	I
Cbl	I
and	O
Cbl	B
-	I
b	I
)	O
,	O
one	O
in	O
C.	O
elegans	O
(	O
Sli-1	B
)	O
and	O
one	O
in	O
Drosophila	O
(	O
D	B
-	I
Cbl	I
)	O
.	O

The	O
therapeutic	O
use	O
of	O
botulinum	B
toxin	I
(	O
Botox	B
)	O
is	O
increasing	O
in	O
popularity	O
.	O

The	O
viral	B
oncoprotein	I
E1A	I
inhibits	O
NFAT	B
-	O
dependent	O
transactivation	O
in	O
a	O
p300-dependent	B
manner	O
.	O

The	O
pre	O
-	O
mRNA	O
splicing	O
factor	O
U2AF	B
(	O
U2	B
small	I
nuclear	I
ribonucleoprotein	I
particle	I
[	I
snRNP	I
]	I
auxiliary	I
factor	I
)	O
plays	O
a	O
critical	O
role	O
in	O
3	O
'	O
splice	O
site	O
selection	O
.	O

The	O
second	O
patient	O
had	O
received	O
pituitary	B
-	I
derived	I
growth	I
hormone	I
for	O
treatment	O
of	O
growth	B
hormone	I
deficiency	O
,	O
secondary	O
to	O
a	O
third	O
ventricle	O
teratoma	O
,	O
exised	O
13	O
yr	O
earlier	O
.	O

Osteoadherin	B
is	O
a	O
recently	O
described	O
bone	O
proteoglycan	O
containing	O
keratan	O
sulfate	O
.	O

Intron	O
8	O
harbored	O
a	O
strong	O
erythroid	O
-	O
specific	O
enhancer	O
activity	O
which	O
was	O
orientation	O
-	O
dependent	O
.	O

The	O
intron	O
8	O
enhancer	O
region	O
was	O
not	O
activated	O
by	O
GATA-1	B
together	O
with	O
Sp1	B
in	O
transactivation	O
experiments	O
in	O
COS-1	O
cells	O
indicating	O
the	O
involvement	O
of	O
a	O
related	O
Sp1	B
protein	I
or	O
of	O
another	O
unidentified	O
erythroid	O
factor	O
.	O

Moreover	O
,	O
the	O
mass	O
estimated	O
with	O
the	O
QCM	O
response	O
through	O
the	O
Sauerbrey	O
equation	O
and	O
the	O
mass	O
which	O
can	O
be	O
measured	O
thanks	O
to	O
other	O
analytical	O
techniques	O
,	O
in	O
our	O
case	O
an	O
enzymatic	O
assay	O
,	O
are	O
different	O
:	O
the	O
deposited	O
mass	O
is	O
generally	O
overestimated	O
by	O
the	O
QCM	O
.	O

Human	O
isoforms	O
,	O
designated	O
1	O
to	O
4	O
,	O
differ	O
from	O
each	O
other	O
by	O
the	O
start	O
codon	O
used	O
.	O

He	O
was	O
administered	O
recombinant	B
IFN	I
alpha-2b	I
under	O
the	O
diagnosis	O
of	O
chronic	O
hepatitis	O
C.	O

We	O
then	O
studied	O
four	O
unrelated	O
Japanese	O
families	O
with	O
GSD	O
-	O
Ib	O
,	O
and	O
found	O
three	O
novel	O
mutations	O
:	O
a	O
four	O
-	O
base	O
deletion	O
/	O
two	O
-	O
base	O
insertion	O
,	O
a	O
point	O
mutation	O
within	O
a	O
consensus	O
splicing	O
donor	O
site	O
,	O
and	O
a	O
missense	O
mutation	O
(	O
W118R	O
)	O
.	O

Downregulation	O
of	O
FUS	B
expression	O
in	O
BCR	B
/	O
ABL	B
-	O
expressing	O
32Dcl3	O
cells	O
was	O
associated	O
with	O
suppression	O
of	O
growth	O
factor	O
-	O
independent	O
colony	O
formation	O
,	O
restoration	O
of	O
G	B
-	I
CSF	I
-	O
induced	O
granulocytic	O
differentiation	O
and	O
reduced	O
tumorigenic	O
potential	O
in	O
vivo	O
.	O

These	O
results	O
with	O
clozapine	O
illustrate	O
that	O
LI	O
is	O
sensitive	O
to	O
antipsychotics	O
which	O
differ	O
in	O
their	O
mode	O
of	O
action	O
and	O
furthermore	O
emphasize	O
the	O
value	O
of	O
LI	O
as	O
a	O
test	O
model	O
for	O
detecting	O
the	O
antipsychotic	O
potential	O
of	O
novel	O
drugs	O
.	O

The	O
complement	B
C3a	I
anaphylatoxin	I
receptor	I
(	O
C3aR	B
)	O
is	O
a	O
seven	B
-	I
transmembrane	I
G	I
-	I
protein	I
coupled	I
chemoattractant	I
receptor	I
that	O
on	O
binding	O
the	O
C3a	B
peptide	I
ligand	I
mediates	O
numerous	O
cellular	O
responses	O
,	O
including	O
histamine	O
release	O
from	O
mast	O
cells	O
.	O

smooth	O
muscle	O
contraction	O
,	O
and	O
the	O
directed	O
migration	O
of	O
eosinophils	O
.	O

The	O
heterogeneous	O
nuclear	B
ribonucleoprotein	I
C	I
protein	I
tetramer	I
binds	O
U1	B
,	O
U2	B
,	O
and	O
U6	B
snRNAs	I
through	O
its	O
high	O
affinity	O
RNA	O
binding	O
domain	O
(	O
the	O
bZIP	O
-	O
like	O
motif	O
)	O
.	O

Acute	O
idiopathic	O
thrombocytopenic	O
purpura	O
presenting	O
a	O
high	O
serum	O
level	O
of	O
immunoglobulin	B
E	I
and	O
eosinophilia	O
in	O
an	O
elderly	O
patient	O
.	O

Anesthesia	O
with	O
M	O
/	O
K	O
was	O
reversed	O
after	O
41.6	O
min	O
of	O
immobilization	O
with	O
atipamezole	O
.	O

MK-801	O
administration	O
resulted	O
in	O
a	O
biphasic	O
response	O
in	O
seizure	O
latency	O
.	O

The	O
binding	O
of	O
NF	B
-	I
ATp	I
,	O
although	O
not	O
NF	B
-	I
AT4	I
,	O
to	O
this	O
enhancer	O
also	O
occurs	O
along	O
with	O
HTLV	O
-	O
I	O
-	O
mediated	O
infection	O
of	O
human	O
peripheral	O
blood	O
T	O
-	O
cells	O
.	O

Peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPAR	B
)	O
modulate	O
transcription	O
by	O
binding	O
to	O
specific	O
peroxisome	O
proliferator	O
-	O
response	O
elements	O
(	O
PPRE	O
)	O
through	O
heterodimerization	O
with	O
the	O
9-cis	B
retinoic	I
acid	I
receptor	I
(	O
RXR	B
)	O
.	O

Co	O
-	O
transfection	O
of	O
the	O
Sp1	B
expression	O
plasmid	O
and	O
the	O
-58	O
promoter	O
construct	O
into	O
Drosophila	O
Schneider	O
cells	O
revealed	O
that	O
Sp1	B
contributed	O
to	O
the	O
kinase	O
basal	O
promoter	O
activity	O
by	O
binding	O
to	O
the	O
non	O
-	O
consensus	O
site	O
in	O
the	O
-58	O
region	O
.	O

Likewise	O
,	O
at	O
150	O
degrees	O
C	O
with	O
2	O
%	O
APS	O
the	O
surface	O
density	O
of	O
NH2	O
groups	O
reached	O
a	O
maximum	O
at	O
24	O
hr	O
and	O
remained	O
relatively	O
constant	O
up	O
to	O
96	O
hr	O
.	O

Studies	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
also	O
did	O
not	O
provide	O
evidence	O
for	O
the	O
formation	O
of	O
a	O
VDR	B
-	O
TR	B
protein	O
-	O
protein	O
interaction	O
.	O

Mutation	O
of	O
either	O
the	O
AP-1	B
or	O
the	O
ets	B
component	O
of	O
this	O
site	O
also	O
prevented	O
promoter	O
activity	O
in	O
SMCs	O
.	O

Surprisingly	O
,	O
double	O
mutants	O
of	O
the	O
shy2	B
-	I
1D	I
mutant	I
with	O
the	O
phytochrome	B
-	O
deficient	O
mutants	O
hy2	B
,	O
hy3	B
(	O
phyB-1	B
)	O
and	O
fre1	B
-	I
1	I
(	O
phyA-201	B
)	O
showed	O
reduced	O
photomorphogenic	O
response	O
in	O
darkness	O
with	O
a	O
longer	O
hypocotyl	O
,	O
a	O
longer	O
inflorescence	O
stem	O
,	O
and	O
a	O
lower	O
level	O
expression	O
of	O
the	O
CAB	B
gene	I
than	O
the	O
shy2	B
-	I
1D	I
single	I
mutant	I
.	O

Wild	O
-	O
type	O
and	O
mutant	O
MyoD	B
were	O
introduced	O
into	O
cells	O
using	O
an	O
E1	B
,	O
E3-deleted	B
adenoviral	O
vector	O
.	O

Endoscopic	O
examinations	O
,	O
peripheral	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
,	O
and	O
assays	O
of	O
myeloperoxidase	B
activity	O
(	O
MPO	B
)	O
in	O
homogenates	O
of	O
colon	O
mucosa	O
were	O
performed	O
after	O
one	O
week	O
(	O
4	O
%	O
DSS	O
model	O
)	O
and	O
eight	O
weeks	O
(	O
1	O
%	O
DSS	O
model	O
)	O
.	O

The	O
human	O
T	O
cell	O
lymphotropic	O
retrovirus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
trans	O
-	O
activator	O
,	O
Tax	B
,	O
interacts	O
specifically	O
with	O
the	O
basic	B
-	I
domain	I
/	I
leucine	I
-	I
zipper	I
(	I
bZip	I
)	I
protein	I
,	O
cAMP	B
response	I
element	I
binding	I
protein	I
(	O
CREB	B
)	O
,	O
bound	O
to	O
the	O
viral	B
Tax	I
-	I
responsive	I
element	I
consisting	O
of	O
three	O
imperfect	O
21-base	O
pair	O
repeats	O
,	O
each	O
with	O
a	O
cAMP	O
response	O
element	O
core	O
flanked	O
by	O
G	O
/	O
C	O
-	O
rich	O
sequences	O
.	O

However	O
,	O
changing	O
the	O
half	O
-	O
site	O
to	O
the	O
consensus	O
sequence	O
AGGTCA	O
(	O
IRper-1	O
)	O
increased	O
binding	O
of	O
AaEcR.AaUSP	B
10-fold	O
over	O
IRhsp-1	O
and	O
,	O
at	O
the	O
same	O
time	O
,	O
reduced	O
the	O
stringency	O
of	O
the	O
spacer	O
length	O
requirement	O
,	O
with	O
IRper-0	O
to	O
IRper-5	O
showing	O
detectable	O
binding	O
.	O

Sequence	O
comparisons	O
strongly	O
suggest	O
that	O
the	O
S27a	B
and	O
the	O
ubiquitin	B
coding	O
sequences	O
found	O
in	O
the	O
genome	O
of	O
CP	O
Rit	O
were	O
both	O
derived	O
from	O
a	O
bovine	O
mRNA	O
encoding	O
a	O
hybrid	O
protein	O
with	O
the	O
structure	O
NH2-ubiquitin	O
-	O
S27a	B
-	O
COOH	O
.	O

J.	O

EGFR	B
levels	O
were	O
found	O
to	O
be	O
elevated	O
5-	O
,	O
3	O
.	O

T.	O
,	O
Mahasneh	O
,	O
A.	O
,	O
and	O
Cote	O
,	O
G.	O

A	O
simple	O
analytical	O
method	O
for	O
l	O
-	O
menthol	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
with	O
a	O
polarized	O
photometric	O
detector	O
was	O
established	O
.	O

Although	O
E2FBP1	B
lacks	O
the	O
transactivation	O
domain	O
,	O
it	O
stimulates	O
E2F	B
site	O
-	O
dependent	O
transcription	O
in	O
cooperation	O
with	O
E2F-1	B
.	O

Analysis	O
of	O
chromosomal	O
DNA	O
sequence	O
immediately	O
downstream	O
of	O
the	O
transposon	O
insertion	O
identified	O
two	O
open	O
reading	O
frames	O
,	O
designated	O
csrR	B
and	O
csrS	B
,	O
which	O
exhibited	O
sequence	O
similarity	O
to	O
bacterial	O
two	O
-	O
component	O
regulatory	O
systems	O
.	O

We	O
previously	O
delineated	O
a	O
region	O
in	O
the	O
fatty	B
-	I
acid	I
synthase	I
promoter	I
,	O
which	O
was	O
responsible	O
for	O
obesity	O
-	O
related	O
overexpression	O
of	O
the	O
fatty	B
-	I
acid	I
synthase	I
(	O
FAS	B
)	O
gene	O
,	O
by	O
negatively	O
regulating	O
the	O
activity	O
of	O
the	O
downstream	O
promoter	O
in	O
lean	O
but	O
not	O
obese	O
rat	O
fat	O
cells	O
.	O

J.	O

RESULTS	O
:	O
We	O
identified	O
a	O
full	O
-	O
length	O
cDNA	O
with	O
an	O
open	O
reading	O
frame	O
of	O
2883	O
bp	O
corresponding	O
to	O
a	O
predicted	O
protein	O
of	O
961	O
amino	O
acids	O
that	O
shares	O
greater	O
than	O
95	O
%	O
homology	O
with	O
the	O
rat	B
gamma	I
-	I
aminobutyric	I
acid	I
B	I
(	I
GABAB	I
)	I
receptor	I
.	O

Another	O
tentative	O
hotspot	O
mutation	O
in	O
the	O
third	O
patient	O
,	O
a	O
frame	O
shift	O
caused	O
by	O
a	O
G	O
nucleotide	O
insertion	O
in	O
a	O
monotonous	O
repeat	O
of	O
six	O
Gs	O
in	O
HPRT	B
exon	I
3	I
,	O
has	O
been	O
reported	O
previously	O
in	O
three	O
other	O
LN	O
patients	O
.	O

One	O
of	O
these	O
fragments	O
shows	O
the	O
highest	O
amino	O
acid	O
sequence	O
homology	O
to	O
the	O
insect	O
ecdysone	O
inducible	O
gene	B
E75	I
.	O

Based	O
on	O
sequence	O
homology	O
,	O
the	O
genes	O
were	O
identified	O
as	O
TEF	B
,	O
encoding	O
translation	B
elongation	I
factor-1	I
alpha	I
and	O
RPS7	B
,	O
encoding	O
ribosomal	O
protein	O
S7	B
.	O

Fatal	O
apneusis	O
was	O
observed	O
under	O
following	O
conditions	O
:	O
(	O
1	O
)	O
Persistent	O
apnea	O
was	O
produced	O
after	O
a	O
single	O
KA	O
microinjection	O
in	O
one	O
side	O
of	O
the	O
VRG	O
-	O
Apa	O
(	O
5	O
animals	O
)	O
.	O

Competition	O
EMSA	O
established	O
that	O
constitutively	O
expressed	O
nuclear	O
proteins	O
bound	O
the	O
KCS	B
element	I
selectively	O
;	O
KCS	B
protein	I
binding	O
activity	O
correlated	O
with	O
promoter	O
activity	O
in	O
the	O
transient	O
transfection	O
reporter	O
assay	O
.	O

Paralemmin	B
is	O
also	O
phosphorylated	O
,	O
and	O
its	O
mRNA	O
is	O
differentially	O
spliced	O
in	O
a	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
manner	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
mechanism	O
of	O
activation	O
of	O
HIF-1alpha	B
is	O
a	O
multi	O
-	O
step	O
process	O
which	O
includes	O
hypoxia	O
-	O
dependent	O
nuclear	O
import	O
and	O
activation	O
(	O
derepression	O
)	O
of	O
the	O
transactivation	O
domain	O
,	O
resulting	O
in	O
recruitment	O
of	O
the	O
CREB	B
-	I
binding	I
protein	I
(	O
CBP	B
)	O
/	O
p300	B
coactivator	I
.	O

It	O
is	O
now	O
well	O
established	O
that	O
progression	O
through	O
the	O
eukaryotic	O
cell	O
cycle	O
is	O
controlled	O
by	O
oscillations	O
in	O
the	O
activity	O
of	O
cyclin-	B
dependent	I
kinases	I
(	O
CDKs	B
)	O
.	O

The	O
hematopoietic	B
colony	I
-	I
stimulating	I
factors	I
(	O
CSF	B
)	O
have	O
been	O
introduced	O
into	O
clinical	O
practice	O
as	O
additional	O
supportive	O
measures	O
that	O
can	O
reduce	O
the	O
incidence	O
of	O
infectious	O
complications	O
in	O
patients	O
with	O
cancer	O
and	O
neutropenia	O
.	O

This	O
model	O
is	O
supported	O
by	O
experiments	O
showing	O
that	O
Cdr2	B
associates	O
with	O
the	O
N	B
-	I
terminal	I
regulatory	I
domain	I
of	I
Wee1	I
in	O
cell	O
lysates	O
and	O
phosphorylates	O
Wee1	B
in	O
vitro	O
.	O

Mean	O
intake	O
of	O
vitamin	O
A	O
amounted	O
to	O
1.1	O
and	O
0.9	O
mg	O
RE	O
/	O
day	O
for	O
men	O
and	O
women	O
,	O
respectively	O
;	O
the	O
contributions	O
of	O
meat	O
,	O
fats	O
and	O
oils	O
,	O
vegetables	O
and	O
dairy	O
products	O
to	O
total	O
intake	O
were	O
35	O
%	O
,	O
24	O
%	O
,	O
16	O
%	O
,	O
and	O
16	O
%	O
,	O
respectively	O
.	O

The	O
Mig1	B
repressor	I
is	O
a	O
zinc	B
finger	I
protein	I
that	O
mediates	O
glucose	O
repression	O
in	O
yeast	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
FCR1	B
gene	I
behaves	O
as	O
a	O
negative	O
regulator	O
of	O
drug	O
resistance	O
in	O
C.	O
albicans	O
and	O
constitute	O
the	O
first	O
evidence	O
that	O
FCZ	O
resistance	O
can	O
result	O
from	O
the	O
inactivation	O
of	O
a	O
regulatory	O
factor	O
such	O
as	O
Fcr1p	B
.	O

These	O
findings	O
suggest	O
that	O
late	O
MYO	O
/	O
M	O
is	O
more	O
useful	O
than	O
washout	O
rate	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
on	O
heart	O
failure	O
due	O
to	O
DCM	O
.	O

With	O
regard	O
to	O
the	O
optimal	O
threshold	O
values	O
,	O
sensitivity	O
and	O
specificity	O
were	O
100%	O
/	O
97	O
%	O
and	O
95%	O
/	O
95	O
%	O
with	O
FDG	O
PET	O
,	O
compared	O
to	O
86%	O
/	O
92	O
%	O
and	O
77%	O
/	O
82	O
%	O
with	O
IS	O
,	O
respectively	O
.	O

Lead	O
fixation	O
in	O
dogs	O
achieved	O
with	O
RF	O
energy	O
.	O

The	O
percutaneous	O
absorption	O
of	O
clindamycin	O
was	O
studied	O
in	O
healthy	O
male	O
volunteers	O
,	O
comparing	O
two	O
investigative	O
clindamycin	O
(	O
%	O
w	O
/	O
v	O
)	O
/	O
tretinoin	O
(	O
0.025	O
%	O
w	O
/	O
v	O
)	O
gels	O
,	O
containing	O
clindamycin	O
phosphate	O
ester	O
and	O
clindamycin	O
HCl	O
,	O
respectively	O
,	O
relative	O
to	O
a	O
clindamycin	O
phosphate	O
lotion	O
(	O
1	O
%	O
clindamycin	O
;	O
Dalacin	O
T	O
)	O
.	O

The	O
orbitofrontal	O
,	O
cingulate	O
,	O
and	O
anteromedial	O
part	O
of	O
the	O
dorsal	O
premotor	O
areas	O
were	O
preferentially	O
activated	O
by	O
the	O
self	O
-	O
initiated	O
hand	O
movement	O
task	O
(	O
SELF	O
)	O
.	O

The	O
active	O
site	O
includes	O
the	O
acidic	O
triad	O
Asp53	O
(	O
the	O
site	O
of	O
phosphorylation	O
)	O
,	O
Asp10	O
and	O
Glu9	O
.	O

Epstein	B
-	I
Barr	I
virus	I
-	I
encoded	I
latent	I
membrane	I
protein	I
1	I
activates	O
the	O
JNK	B
pathway	O
through	O
its	O
extreme	O
C	O
terminus	O
via	O
a	O
mechanism	O
involving	O
TRADD	B
and	O
TRAF2	B
.	O

Furthermore	O
,	O
using	O
transgenic	O
mouse	O
technology	O
we	O
localized	O
independent	O
cis	O
-	O
regulatory	O
elements	O
controlling	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
Pax6	B
.	O

Interferon	B
-	I
alpha	I
treatment	O
of	O
posttransplant	O
lymphoproliferative	O
disorder	O
in	O
recipients	O
of	O
solid	O
organ	O
transplants	O
.	O

We	O
show	O
that	O
the	O
Sm	B
-	I
binding	I
site	I
and	O
stem	O
-	O
loop	O
III	O
structures	O
are	O
necessary	O
for	O
correct	O
3'-end	O
formation	O
.	O

Further	O
experiments	O
will	O
be	O
required	O
to	O
highlight	O
the	O
in	O
vivo	O
role	O
of	O
ELE1	B
in	O
nuclear	O
receptor	O
functioning	O
.	O

A	O
gapped	O
search	O
with	O
the	O
C	O
-	O
terminal	O
region	O
of	O
CDED	B
/	O
LIOR	B
revealed	O
a	O
36	O
-	O
41	O
%	O
similarity	O
to	O
several	O
proteins	O
related	O
to	O
signal	O
transduction	O
and	O
cell	O
replication	O
,	O
such	O
as	O
ORC1	B
and	O
KSR	B
.	O

Unitary	O
-	O
group	O
approach	O
to	O
spin	O
-	O
dependent	O
operators	O
.	O

C3	B
toxin	I
completely	O
inhibited	O
RhoA	B
function	O
,	O
partially	O
inhibited	O
SRE	O
:	O
Luc	B
activity	O
,	O
but	O
had	O
no	O
effect	O
on	O
LPA	O
-	O
stimulated	O
c	B
-	I
Fos	I
expression	O
.	O

Trinipatch	O
is	O
a	O
small	O
,	O
transparent	O
,	O
matricial	O
,	O
monolayer	O
patch	O
with	O
an	O
absorption	O
promoter	O
,	O
marketed	O
in	O
two	O
dose	O
-	O
strengths	O
(	O
5	O
mg	O
/	O
24	O
h	O
and	O
10	O
mg	O
/	O
24	O
h	O
)	O
by	O
Laboratoires	O
Synthelabo	O
.	O

The	O
starting	O
point	O
is	O
the	O
consideration	O
that	O
the	O
conceptions	O
underlying	O
the	O
ICIDH	O
are	O
not	O
suitable	O
to	O
serve	O
as	O
a	O
mainstay	O
of	O
a	O
model	O
for	O
diagnostics	O
in	O
rehabilitation	O
because	O
they	O
do	O
not	O
reflect	O
essential	O
characteristics	O
of	O
the	O
diagnostic	O
process	O
which	O
is	O
the	O
basis	O
for	O
intervention	O
.	O

Envelope	O
-	O
function	O
matching	O
conditions	O
for	O
GaAs	O
/	O
(	O
Al	O
,	O
Ga	O
)	O
As	O
heterojunctions	O
.	O

NMR	O
of	O
diffusing	O
atoms	O
in	O
a	O
periodic	O
porous	O
medium	O
in	O
the	O
presence	O
of	O
a	O
nonuniform	O
magnetic	O
field	O
.	O

Microstructure	O
and	O
conductivity	O
of	O
hierarchical	O
laminate	O
composites	O
.	O

Erratum	O
:	O
Absence	O
of	O
precursor	O
effects	O
above	O
the	O
martensitic	O
transformation	O
in	O
a	O
virgin	O
crystal	O
of	O
Li	O
metal	O

However	O
,	O
after	O
PRK	O
at	O
5	O
weeks	O
of	O
age	O
,	O
partial	O
retreatment	O
may	O
be	O
necessary	O
due	O
to	O
regression	O
of	O
the	O
PRK	O
effect	O
.	O

BACKGROUND	O
:	O
In	O
the	O
ubiquitin	B
-	O
dependent	O
proteolysis	O
pathway	O
,	O
a	O
ubiquitin	B
ligase	I
(	O
E3	B
)	O
is	O
responsible	O
for	O
substrate	O
selectivity	O
and	O
timing	O
of	O
degradation	O
.	O

Quantum	O
-	O
statistical	O
theory	O
of	O
high	O
-	O
field	O
transport	O
phenomena	O
.	O

NH3	O
and	O
NO	O
interaction	O
with	O
Si	O
(	O
100	O
)	O
-	O
(	O
2	O
x	O
1	O
)	O
surfaces	O
.	O

Temperature	O
dependence	O
of	O
the	O
sublattice	O
spontaneous	O
magnetization	O
of	O
YBa2Cu3O6	O
.	O

Depth	O
-	O
controlled	O
grazing	O
-	O
incidence	O
diffraction	O
of	O
synchrotron	O
x	O
radiation	O
.	O

Large	O
scale	O
electronic	O
structure	O
calculations	O
.	O

Band	O
structure	O
effects	O
of	O
transport	O
properties	O
in	O
icosahedral	O
quasicrystals	O
.	O

Nipponbare	O
as	O
well	O
as	O
O.	O
australiensis	O
.	O

KEY	O
WORDS	O
:	O

Melaleuca	O
;	O
Lake	O
Okeechobee	O
;	O
Littoral	O
zone	O
;	O
Water	O
level	O
;	O
Regulation	O
schedule	O

These	O
observations	O
of	O
elevated	O
serum	B
lipase	I
and	O
serum	O
CA	B
19	I
-	I
9	I
in	O
Sjogren	O
's	O
syndrome	O
without	O
evidence	O
of	O
malignancy	O
may	O
reflect	O
pancreatic	O
involvement	O
in	O
this	O
disorder	O
.	O

Calcinosis	O
cutis	O
following	O
intravenous	O
infusion	O
of	O
calcium	O
gluconate	O
.	O

Medicare	O
SNF	O
benefits	O
revised	O
--	O
again	O
.	O

BACKGROUND	O
:	O
The	O
MAZE	O
-	O
III	O
is	O
the	O
surgical	O
treatment	O
of	O
choice	O
for	O
medically	O
refractory	O
atrial	O
fibrillation	O
.	O

This	O
scFv	O
was	O
therefore	O
used	O
as	O
control	O
in	O
experiments	O
where	O
another	O
anti	B
-	I
Ras	I
scFv	I
(	O
Y259	B
scFv	I
,	O
derived	O
from	O
the	O
neutralizing	O
anti	B
-	I
Ras	I
mAb	I
Y13	I
-	I
259	I
)	O
blocked	O
the	O
Ras	B
pathway	O
in	O
vitro	O
and	O
led	O
to	O
tumor	O
regression	O
in	O
a	O
nude	O
mouse	O
model	O
[	O
Cochet	O
,	O
O.	O
,	O
Kenigsberg	O
,	O
M.	O
,	O
Delumeau	O
,	O
I.	O
,	O
Virone	O
-	O
Oddos	O
,	O
A.	O
,	O
Multon	O
,	O
M.C.	O
,	O
Fridman	O
,	O
W.H.	O
,	O
Schweighoffer	O
,	O
F.	O
,	O
Teillaud	O
,	O
J.L.	O
,	O
Tocque	O
,	O
B.	O
,	O
1998	O
.	O

The	O
responsive	O
region	O
of	O
the	O
alpha	B
2	I
(	I
V	I
)	I
collagen	I
gene	I
was	O
localized	O
to	O
a	O
fragment	O
including	O
100	O
bp	O
of	O
basal	O
promoter	O
and	O
150	O
bp	O
of	O
exon	O
1	O
sequences	O
,	O
which	O
contained	O
two	O
CRE	O
-	O
like	O
elements	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
administration	O
of	O
misoprostol	O
prevents	O
gastric	O
hemorrhage	O
in	O
healthy	O
dogs	O
treated	O
with	O
high	O
doses	O
of	O
methylprednisolone	O
sodium	O
succinate	O
(	O
MPSS	O
)	O
.	O

(	O
i	O
)	O
Complete	O
Grb10	B
expression	O
from	O
cDNA	O
with	O
an	O
ecdysone	O
-	O
regulated	O
transient	O
expression	O
system	O
stimulated	O
PDGF	B
-	I
BB-	I
,	O
IGF	B
-	I
I	I
,	O
and	O
insulin-	B
but	O
not	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
-induced	O
DNA	O
synthesis	O
in	O
an	O
ecdysone	O
dose	O
-	O
responsive	O
fashion	O
.	O

CONCLUSIONS	O
:	O
In	O
healthy	O
individuals	O
,	O
whole	O
body	O
insulin	B
sensitivity	O
is	O
related	O
,	O
or	O
""""	O
coupled	O
,	O
""""	O
to	O
the	O
anaerobic	O
threshold	O
.	O

The	O
intron	O
RNA	O
consists	O
of	O
2492	O
nucleotides	O
which	O
can	O
be	O
folded	O
into	O
a	O
secondary	O
structure	O
with	O
all	O
the	O
expected	O
sequence	O
motifs	O
of	O
subgroup	O
-	O
IIA1	O
introns	O
(	O
Michel	O
et	O
al.	O

272	O
,	O
1904	O
]	O
.	O

OBJECTIVE	O
:	O
1998	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
data	O
estimate	O
an	O
83.1	O
%	O
5-year	O
survival	O
rate	O
for	O
corpus	O
uteri	O
adenocarcinoma	O
FIGO	O
stage	O
II	O
.	O

Treatment	O
of	O
unstable	O
angina	O
:	O
role	O
of	O
antithrombotic	O
therapy	O
.	O

J.	O

Duch	O
,	O
and	O
F.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
IENF	O
and	O
sural	O
nerve	O
unmyelinated	O
fiber	O
densities	O
(	O
r	O
=	O
0.32	O
,	O
p	O
=	O
0.054	O
)	O
.	O

In	O
addition	O
,	O
all	O
three	O
Opa	B
proteins	I
of	O
C751	O
bind	O
equally	O
well	O
to	O
HeLa	O
cells	O
transfected	O
with	O
cDNA	O
encoding	O
the	O
carcinoembryonic	B
antigen	I
[	O
CEA	B
(	O
CD66e	B
)	O
]	O
subgroup	O
of	O
the	O
CD66	B
family	I
,	O
but	O
show	O
distinct	O
tropism	O
for	O
CGM1-	B
(	O
CD66d	B
)	O
and	O
NCA	B
(	O
CD66c	B
)	O
-expressing	O
cells	O
.	O

The	O
proliferation	O
-	O
specific	O
HNF-3	B
/	O
fork	B
head	I
homolog-11B	I
protein	O
(	O
HFH-11B	B
;	O
also	O
known	O
as	O
Trident	B
and	O
Win	B
)	O
is	O
a	O
family	O
member	O
of	O
the	O
winged	B
helix	I
/	O
fork	B
head	I
transcription	O
factors	O
and	O
in	O
regenerating	O
liver	O
its	O
expression	O
is	O
reactivated	O
prior	O
to	O
hepatocyte	O
entry	O
into	O
DNA	O
replication	O
(	O
S	O
phase	O
)	O
.	O

The	O
role	O
of	O
transport	O
by	O
sea	O
ice	O
from	O
the	O
Kara	O
Sea	O
into	O
the	O
Arctic	O
Ocean	O
was	O
assessed	O
by	O
a	O
small	O
subgroup	O
at	O
GEOMAR	O
.	O

Results	O
confirmed	O
that	O
stress	O
produced	O
CA3	O
dendritic	O
atrophy	O
and	O
tianeptine	O
prevented	O
it	O
.	O

Studies	O
have	O
substantiated	O
the	O
involvement	O
of	O
numerous	O
loci	O
on	O
certain	O
chromosomes	O
;	O
in	O
excess	O
of	O
10	O
chromosomes	O
are	O
thought	O
to	O
be	O
involved	O
.	O

Analysis	O
of	O
its	O
genomic	O
region	O
revealed	O
that	O
the	O
13-kb	O
Cdc6	B
gene	I
is	O
divided	O
into	O
12	O
exons	O
by	O
11	O
introns	O
.	O

The	O
availability	O
of	O
potent	O
regulatory	O
DNA	O
cassettes	O
harboring	O
the	O
murine	B
D1A	I
gene	I
promoter	I
could	O
aid	O
testing	O
the	O
neuronal	O
-	O
specific	O
expression	O
of	O
transgenes	O
in	O
vivo	O
.	O

Of	O
these	O
patients	O
,	O
46,164	O
were	O
placed	O
on	O
a	O
waiting	O
list	O
for	O
transplantation	O
,	O
23,275	O
of	O
whom	O
received	O
a	O
first	O
cadaveric	O
transplant	O
between	O
1991	O
and	O
1997	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
,	O
this	O
GLUT4	B
repressor	I
element	I
(	O
G4RE	B
)	O
generated	O
specific	O
bands	O
with	O
nuclear	O
extracts	O
from	O
preadipocytes	O
,	O
but	O
not	O
from	O
adipocytes	O
.	O

We	O
show	O
here	O
that	O
the	O
third	O
SH3	B
domain	I
binds	O
to	O
Sos	B
,	O
a	O
guanine	B
nucleotide	I
exchange	I
factor	I
for	O
Ras	B
and	O
Rac	B
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

They	O
are	O
subdivided	O
into	O
two	O
types	O
that	O
activate	O
transduction	O
pathways	O
via	O
different	O
cell	O
surface	O
receptors	O
.	O

Demyelinating	O
diseases	O
involving	O
the	O
grey	O
matter	O
were	O
very	O
rare	O
,	O
but	O
we	O
must	O
consider	O
the	O
presence	O
of	O
symmetrical	O
thalamic	O
involvement	O
in	O
patients	O
with	O
ADEM	O
.	O

In	O
part	O
as	O
a	O
result	O
of	O
its	O
inability	O
to	O
sustain	O
radiative	O
loses	O
,	O
the	O
BB	O
resonator	O
has	O
extremely	O
low	O
RF	O
power	O
requirements	O
.	O

In	O
addition	O
to	O
the	O
bZIP	B
protein	I
Opaque2	I
(	O
O2	B
)	O
,	O
there	O
are	O
other	O
maize	O
endosperm	O
nuclear	O
proteins	O
that	O
recognize	O
the	O
O2	B
box	I
in	O
22	O
kDa	O
zein	B
gene	O
promoters	O
.	O

The	O
signalling	O
molecules	O
Wnt1	B
and	O
Sonic	B
hedgehog	I
,	O
implicated	O
in	O
the	O
activation	O
of	O
Myf5	B
in	O
myogenic	O
progenitor	O
cells	O
in	O
the	O
somite	O
,	O
are	O
also	O
produced	O
in	O
the	O
viscinity	O
of	O
the	O
Myf5	B
expression	I
domain	I
in	O
the	O
mesencephalon	O
.	O

Overexpression	O
of	O
CDP	B
/	O
cut	B
in	O
ROS	O
17	O
/	O
2.8	O
osteosarcoma	O
cells	O
results	O
in	O
repression	O
of	O
OC	B
promoter	I
activity	O
;	O
this	O
repression	O
is	O
abrogated	O
by	O
mutating	O
OC	B
box	I
I.	I

Sequence	O
analysis	O
of	O
the	O
promoter	O
region	O
showed	O
no	O
TATA	O
box	O
but	O
identified	O
consensus	O
binding	O
motifs	O
for	O
Sp1	B
,	O
CREB	B
,	O
and	O
half	O
sites	O
of	O
the	O
estrogen	B
receptor	I
binding	I
site	I
.	O

Sak	B
kinase	I
gene	O
structure	O
and	O
transcriptional	O
regulation	O
.	O

These	O
data	O
indicate	O
that	O
the	O
interaction	O
of	O
eIF4A	B
with	O
the	O
middle	O
region	O
of	O
eIF4GI	B
is	O
necessary	O
for	O
translation	O
,	O
whereas	O
the	O
interaction	O
of	O
eIF4A	B
with	O
the	O
C	O
-	O
terminal	O
region	O
plays	O
a	O
modulatory	O
role	O
.	O

Northern	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
analyses	O
of	O
human	O
mRNA	O
samples	O
demonstrate	O
that	O
RNR	B
is	O
expressed	O
exclusively	O
in	O
the	O
retina	O
,	O
with	O
transcripts	O
of	O
approximately	O
7.5	O
kb	O
,	O
approximately	O
3.0	O
kb	O
,	O
and	O
approximately	O
2.3	O
kb	O
by	O
Northern	O
blot	O
analysis	O
.	O

Maximum	O
induction	O
of	O
AP-1	B
was	O
reached	O
at	O
a	O
concentration	O
of	O
250	O
nmol	O
/	O
L	O
of	O
CalC.	O

CONCLUSION	O
:	O
In	O
Cdks	B
functioning	O
throughout	O
the	O
cell	O
cycle	O
,	O
tyrosine	O
phosphorylation	O
is	O
inhibitory	O
to	O
the	O
activation	O
of	O
kinase	O
,	O
whereas	O
the	O
phosphorylation	O
of	O
threonine	O
in	O
the	O
T	O
-	O
loop	O
is	O
essential	O
for	O
activation	O
.	O

We	O
also	O
report	O
that	O
AHR	B
interacts	O
with	O
COUP	B
-	I
TF	I
in	O
transfected	O
CV-1	O
cells	O
.	O

The	O
single	O
strandedness	O
is	O
manifested	O
as	O
a	O
terminal	O
extension	O
of	O
the	O
G	O
-	O
rich	O
strand	O
(	O
G	O
tails	O
)	O
that	O
can	O
occur	O
independently	O
of	O
telomerase	B
,	O
suggesting	O
that	O
cdc17	B
/	O
pol1	B
mutants	O
exhibit	O
defects	O
in	O
telomeric	O
lagging	O
-	O
strand	O
synthesis	O
.	O

An	O
ASIC	O
-	O
chip	O
for	O
stereoscopic	O
depth	O
analysis	O
in	O
video	O
-	O
real	O
-	O
time	O
based	O
on	O
visual	O
cortical	O
cell	O
behavior	O
.	O

The	O
concomitant	O
interaction	O
of	O
mSTI1	B
with	O
hsp70	B
and	O
hsp90	B
at	O
its	O
N-	O
and	O
C	O
-	O
termini	O
respectively	O
is	O
mediated	O
by	O
the	O
tetratricopeptide	O
repeat	O
(	O
TPR	O
)	O
motifs	O
in	O
these	O
regions	O
.	O

Characterization	O
of	O
a	O
human	B
alternatively	I
spliced	I
truncated	I
reduced	I
folate	I
carrier	I
increasing	O
folate	O
accumulation	O
in	O
parental	O
leukemia	O
cells	O
.	O

Desmethylferrochloroquine	O
1a	O
and	O
didesmethylferrochloroquine	O
2	O
would	O
be	O
more	O
potent	O
against	O
schizontocides	O
than	O
CQ	O
in	O
vitro	O
against	O
two	O
strains	O
(	O
HB3	O
and	O
Dd2	O
)	O
of	O
Plasmodium	O
falciparum	O
.	O

Zebrafish	O
cyclops	B
(	O
cyc	B
)	O
encodes	O
a	O
Transforming	B
Growth	I
Factor	I
beta	I
(	O
TGFbeta	B
)	O
signaling	O
factor	O
closely	O
related	O
to	O
mouse	O
Nodal	B
.	O

CONCLUSION	O
:	O
Presence	O
of	O
APOE	B
epsilon4	I
/	I
*	I
seems	O
to	O
increase	O
the	O
risk	O
for	O
dementia	O
and	O
AD	O
independently	O
of	O
its	O
effect	O
on	O
dyslipidemia	O
and	O
atherogenesis	O
.	O

There	O
was	O
a	O
2.4-fold	O
difference	O
in	O
CAT	B
produced	O
from	O
these	O
transcripts	O
in	O
HeLa	O
cells	O
,	O
which	O
contain	O
a	O
greater	O
natural	O
abundance	O
of	O
PTB	B
.	O

Multiple	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signaling	O
pathways	O
connect	O
the	O
cot	B
oncoprotein	I
to	O
the	O
c	B
-	I
jun	I
promoter	I
and	O
to	O
cellular	O
transformation	O
.	O

Protein	O
sequence	O
analysis	O
reveals	O
that	O
MAN1	B
shares	O
a	O
conserved	O
globular	O
domain	O
of	O
approximately	O
40	O
amino	O
acids	O
,	O
which	O
we	O
term	O
the	O
LEM	B
module	I
,	O
with	O
inner	O
nuclear	O
membrane	O
proteins	O
lamina	B
-	I
associated	I
polypeptide	I
2	I
and	O
emerin	B
.	O

In	O
vitro	O
expression	O
of	O
four	O
different	O
naturally	O
occurring	O
nonsense	O
and	O
missense	O
mutations	O
revealed	O
a	O
dramatically	O
altered	O
subcellular	O
location	O
of	O
the	O
protein	O
in	O
cultured	O
cells	O
.	O

As	O
no	O
complete	O
PPARgamma	B
antagonists	O
have	O
been	O
described	O
hitherto	O
,	O
we	O
have	O
constructed	O
a	O
dominant	O
-	O
negative	O
mutant	O
receptor	O
to	O
inhibit	O
wild	O
-	O
type	O
PPARgamma	B
action	O
.	O

EMSA	O
showed	O
that	O
nuclear	O
proteins	O
from	O
PC12	O
but	O
not	O
C6	O
or	O
Rat2	O
cells	O
bind	O
the	O
CRE	O
as	O
a	O
complex	O
containing	O
activating	B
transcription	I
factor	I
(	I
ATF	I
)	I
-4	I
and	O
CCAAT	B
enhancer	I
-	I
binding	I
protein	I
beta	I
,	O
while	O
both	O
PC12	O
and	O
C6	O
cell	O
nuclear	O
extracts	O
were	O
recruited	O
by	O
the	O
CCAAT	O
-	O
box	O
as	O
a	O
complex	O
containing	O
nuclear	B
factor	I
Y.	I

National	O
abortion	O
laws	O
usually	O
do	O
not	O
allow	O
abortion	O
when	O
a	O
foetus	O
is	O
independently	O
viable	O
,	O
i.e.	O
from	O
a	O
gestational	O
age	O
of	O
about	O
24	O
weeks	O
.	O

The	O
variations	O
were	O
caused	O
by	O
opposite	O
shifts	O
in	O
TSH	B
frequency	O
distribution	O
in	O
mothers	O
and	O
neonates	O
.	O

Antipyretic	O
therapy	O
:	O
physiologic	O
rationale	O
,	O
diagnostic	O
implications	O
,	O
and	O
clinical	O
consequences	O
.	O

Cross	O
-	O
reaction	O
between	O
a	O
monoclonal	O
antibody	O
and	O
two	O
alpha	B
beta	I
T	I
cell	I
receptors	I
.	O

Thus	O
,	O
patients	O
with	O
metastatic	O
melanoma	O
are	O
not	O
tolerant	O
to	O
gp100	B
Ag	I
based	O
on	O
the	O
detection	O
of	O
CD8	B
+	I
T	O
cells	O
specific	O
for	O
multiple	O
HLA	B
-	I
A*0201-restricted	I
,	O
gp100-derived	B
epitopes	O
.	O

Following	O
the	O
observation	O
that	O
non	O
-	O
organ	O
-	O
specific	O
antibodies	O
are	O
related	O
with	O
pregnancy	O
loss	O
and	O
preeclampsia	O
,	O
the	O
role	O
of	O
organ	O
-	O
specific	O
antibodies	O
is	O
currently	O
being	O
extensively	O
investigated	O
.	O

As	O
assessed	O
by	O
a	O
genetic	O
assay	O
that	O
measures	O
AAI	O
-	O
dependent	O
DNA	O
binding	O
,	O
TraM	B
inhibited	O
TraR	B
function	O
before	O
and	O
after	O
the	O
transcription	O
factor	O
had	O
bound	O
to	O
its	O
DNA	O
recognition	O
site	O
.	O

Gene	O
silencing	O
associated	O
with	O
repeated	O
DNA	O
sequences	O
has	O
been	O
reported	O
for	O
many	O
eukaryotes	O
,	O
including	O
plants	O
.	O

Thus	O
,	O
while	O
the	O
genomic	O
organization	O
of	O
mHuA	B
is	O
similar	O
to	O
the	O
neural	O
-	O
restricted	O
members	O
of	O
the	O
Elav	B
family	I
,	O
the	O
promoter	O
element	O
differs	O
substantially	O
both	O
by	O
sequence	O
analysis	O
and	O
transcriptional	O
activity	O
in	O
non	O
-	O
neural	O
cell	O
types	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	B
Elavl1	I
(	O
mHuA	B
)	O
gene	O
reveals	O
a	O
transcriptional	O
regulatory	O
element	O
and	O
evidence	O
for	O
conserved	O
genomic	O
organization	O
.	O

mHuA	B
(	O
Elavl1	B
)	O
belongs	O
to	O
a	O
highly	O
conserved	O
family	O
of	O
genes	O
encoding	O
RNA	O
-	O
binding	O
proteins	O
and	O
has	O
been	O
linked	O
to	O
cell	O
growth	O
and	O
proliferation	O
through	O
its	O
regulation	O
of	O
mRNA	O
stability	O
.	O

Here	O
we	O
review	O
progress	O
to	O
date	O
in	O
this	O
area	O
.	O

Therefore	O
the	O
binding	O
sites	O
for	O
liver	O
-	O
enriched	O
factors	O
,	O
present	O
in	O
the	O
hamster	B
CYP7A1	I
proximal	I
promoter	I
in	O
close	O
vicinity	O
and	O
conserved	O
between	O
species	O
,	O
constitute	O
a	O
regulatory	O
unit	O
important	O
for	O
basal	O
hepatic	O
expression	O
and	O
tissue	O
restriction	O
of	O
the	O
action	O
of	O
hormones	O
such	O
as	O
insulin	B
.	O

Molecule	O
(	O
s	O
)	O
secreted	O
by	O
neuronal	O
cultures	O
contribute	O
to	O
this	O
induction	O
of	O
GLT-1	B
,	O
but	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
mediating	O
this	O
regulation	O
.	O

In	O
the	O
icosahaedral	O
MVMi	O
capsid	O
,	O
this	O
sequence	O
forms	O
the	O
carboxy	O
end	O
of	O
the	O
amphipathic	O
beta	O
-	O
strand	O
I	O
(	O
betaI	O
)	O
,	O
and	O
all	O
its	O
basic	O
residues	O
are	O
contiguously	O
positioned	O
at	O
the	O
face	O
that	O
in	O
the	O
unassembled	O
subunit	O
would	O
be	O
exposed	O
to	O
solvent	O
.	O

Advanced	O
adenoma	O
was	O
defined	O
as	O
an	O
adenoma	O
larger	O
than	O
10	O
mm	O
or	O
an	O
adenoma	O
of	O
any	O
size	O
with	O
villous	O
component	O
,	O
high	O
-	O
grade	O
dysplasia	O
or	O
invasive	O
carcinoma	O
.	O

In	O
transient	O
assays	O
,	O
using	O
rice	O
suspension	O
-	O
cultured	O
cells	O
transformed	O
by	O
particle	O
bombardment	O
,	O
we	O
showed	O
previously	O
that	O
Oshox1	B
can	O
transcriptionally	O
repress	O
the	O
activity	O
of	O
reporter	O
gene	O
constructs	O
with	O
upstream	O
HD	B
-	I
Zip	I
binding	O
sites	O
.	O

Electrophile	O
Response	O
Elements	O
(	O
EpREs	O
)	O
,	O
located	O
in	O
5'-flanking	O
sequences	O
of	O
both	O
the	O
GCSh	B
and	O
GCSl	B
subunit	I
genes	I
,	O
are	O
hypothesized	O
to	O
at	O
least	O
partially	O
mediate	O
gene	O
induction	O
following	O
xenobiotic	O
exposure	O
.	O

TbRAB31	B
behaviour	O
was	O
also	O
studied	O
during	O
the	O
cell	O
cycle	O
;	O
TbRAB31	B
always	O
localised	O
to	O
a	O
discrete	O
structure	O
that	O
duplicated	O
very	O
early	O
in	O
mitosis	O
and	O
relocated	O
to	O
daughter	O
cells	O
in	O
a	O
coordinate	O
manner	O
with	O
the	O
basal	O
body	O
and	O
kinetoplast	O
,	O
suggesting	O
the	O
involvement	O
of	O
microtubules	O
.	O

The	O
human	B
T	I
cell	I
leukemia	I
/	I
lymphotropic	I
virus	I
type	I
1	I
Tax	I
protein	I
represses	O
MyoD	B
-	O
dependent	O
transcription	O
by	O
inhibiting	O
MyoD	B
-	O
binding	O
to	O
the	O
KIX	B
domain	I
of	O
p300	B
.	O

Inhibitor-1	B
(	O
I-1	B
)	O
and	O
inhibitor-2	B
(	O
I-2	B
)	O
selectively	O
inhibit	O
type	B
1	I
protein	I
serine	I
/	I
threonine	I
phosphatases	I
(	O
PP1	B
)	O
.	O

A	O
variety	O
of	O
professional	O
and	O
self	O
-	O
applied	O
fluoride	O
products	O
are	O
available	O
and	O
new	O
fluoride	O
delivery	O
systems	O
have	O
recently	O
entered	O
the	O
market	O
.	O

CONCLUSION	O
:	O
More	O
than	O
50	O
%	O
of	O
patients	O
with	O
perennial	O
rhinitis	O
and	O
CRS	O
do	O
not	O
improve	O
after	O
surgery	O
,	O
a	O
response	O
that	O
may	O
be	O
predicted	O
by	O
more	O
cells	O
expressing	O
IL-5	B
mRNA	I
in	O
the	O
ethmoid	O
sinuses	O
.	O

Here	O
we	O
report	O
on	O
the	O
isolation	O
of	O
ICK2	B
,	O
and	O
show	O
that	O
it	O
interacts	O
with	O
Cdc2aAt	B
,	O
but	O
not	O
with	O
a	O
second	O
CDK	B
from	I
Arabidopsis	I
,	O
Cdc2bAt	B
.	O

Recombination	O
,	O
replication	O
,	O
repair	O
:	O
from	O
complexity	O
to	O
harmony	O
.	O

The	O
C	B
-	I
terminal	I
Cdk2	I
truncations	O
,	O
however	O
,	O
were	O
non	O
-	O
functional	O
in	O
these	O
strains	O
and	O
thus	O
dependent	O
for	O
activity	O
on	O
the	O
pho85	B
coding	I
region	I
which	O
remained	O
in	O
the	O
mutant	B
pho85::HIS3	I
chromosomal	B
locus	I
.	O

Antibodies	O
raised	O
against	O
a	O
C	O
-	O
terminal	O
portion	O
of	O
Sec31A	B
co	O
-	O
precipitate	O
Sec13	B
and	O
inhibit	O
ER	O
-	O
Golgi	O
transport	O
of	O
temperature	O
-	O
arrested	O
vesicular	O
stomatitis	B
G	I
protein	I
in	O
a	O
semi	O
-	O
intact	O
cell	O
assay	O
.	O

This	O
tendency	O
is	O
likely	O
due	O
to	O
the	O
biased	O
nucleotide	O
composition	O
of	O
the	O
asparagus	O
genome	O
,	O
rather	O
than	O
to	O
the	O
translational	O
selection	O
for	O
specific	O
codons	O
.	O

Regulation	O
of	O
pituitary	O
vasopressin	B
V1b	I
receptors	I
plays	O
a	O
critical	O
role	O
in	O
regulating	O
pituitary	B
adrenocorticotropic	I
hormone	I
(	O
ACTH	B
)	O
secretion	O
during	O
adaptation	O
to	O
stress	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
trials	O
comparing	O
children	O
undergoing	O
systematic	O
therapy	O
focusing	O
on	O
the	O
family	O
in	O
conjunction	O
with	O
asthma	O
medication	O
,	O
with	O
children	O
taking	O
asthma	O
medication	O
only	O
.	O

The	O
models	O
were	O
tested	O
by	O
studying	O
their	O
response	O
to	O
disturbances	O
of	O
the	O
afferent	O
signal	O
from	O
the	O
bladder	O
.	O

Our	O
data	O
show	O
also	O
that	O
phagocytic	O
killing	O
of	O
meningococci	O
is	O
probably	O
a	O
more	O
consistent	O
assay	O
than	O
antibody	O
titer	O
levels	O
for	O
antimeningococcal	O
immunity	O
,	O
especially	O
in	O
LCC	O
-	O
deficient	O
patients	O
.	O

Vancomycin	O
data	O
were	O
analyzed	O
according	O
to	O
a	O
one	O
-	O
compartment	O
open	O
model	O
with	O
use	O
of	O
NONMEM	O
population	O
pharmacokinetic	O
software	O
.	O

Interestingly	O
,	O
a	O
decreased	O
transcription	O
from	O
the	O
endogenous	O
c	B
-	I
Myb	I
promoter	I
was	O
observed	O
in	O
several	O
HTLV	O
-	O
I	O
transformed	O
T	O
-	O
cell	O
lines	O
.	O

H19	B
and	O
Igf2	B
monoallelic	O
expression	O
is	O
regulated	O
in	O
two	O
distinct	O
ways	O
by	O
a	O
shared	O
cis	O
acting	O
regulatory	O
region	O
upstream	O
of	O
H19	B
.	O

The	O
gene	O
amplification	O
model	O
of	O
Coquelle	O
et	O
al.	O

Up	O
to	O
95	O
%	O
of	O
the	O
total	O
UV	O
exposure	O
received	O
is	O
in	O
the	O
UV	O
-	O
A	O
waveband	O
(	O
320	O
-	O
400	O
nm	O
)	O
.	O

Among	O
genes	O
induced	O
by	O
added	O
pMesogenin1	B
is	O
Xwnt-8	B
,	O
a	O
signaling	O
factor	O
that	O
induces	O
a	O
similar	O
repertoire	O
of	O
marker	O
genes	O
and	O
a	O
similar	O
cellular	O
phenotype	O
.	O

Accordingly	O
,	O
no	O
Ha	B
-	I
ras	I
codon	I
12	I
mutations	O
are	O
found	O
in	O
the	O
EtNU	O
-	O
induced	O
mammary	O
tumors	O
.	O

The	O
cellular	O
part	O
of	O
the	O
third	O
chimeric	O
clone	O
shows	O
significant	O
homology	O
to	O
an	O
exon	O
of	O
the	O
human	B
tyrosine	I
phosphatase	I
1	I
gene	I
,	O
although	O
oriented	O
in	O
the	O
antisense	O
direction	O
compared	O
to	O
the	O
adjacent	O
LTR	O
.	O

Phosphorylation	O
of	O
tyrosine	O
residues	O
in	O
the	O
kinase	O
domain	O
and	O
juxtamembrane	O
region	O
regulates	O
the	O
biological	O
and	O
catalytic	O
activities	O
of	O
Eph	B
receptors	I
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
MAP	B
kinase	I
stimulates	O
the	O
hPL	B
-	I
B	I
enhancer	I
by	O
an	O
NF	B
-	I
IL-6-dependent	I
pathway	O
.	O

The	O
effect	O
of	O
acute	O
,	O
mid	O
-	O
cervical	O
spinal	O
cord	O
lesions	O
on	O
neuronal	O
and	O
reflex	O
activity	O
evoked	O
by	O
the	O
noxious	O
visceral	O
stimulus	O
,	O
colorectal	O
distension	O
(	O
CRD	O
;	O
80	O
mmHg	O
,	O
20	O
s	O
)	O
,	O
was	O
determined	O
in	O
halothane	O
-	O
anesthetized	O
rats	O
.	O

The	O
administration	O
of	O
the	O
GnRH	B
agonist	O
reduced	O
the	O
bone	O
mineral	O
density	O
in	O
the	O
whole	O
femur	O
to	O
91.0	O
%	O
of	O
that	O
in	O
the	O
control	O
group	O
.	O

When	O
the	O
LCx	O
was	O
partially	O
occluded	O
,	O
mild	O
PM	O
-	O
induced	O
tachycardia	O
resulted	O
in	O
decreased	O
AoP	O
(	O
P=0.045	O
)	O
as	O
well	O
as	O
in	O
decreased	O
SV	O
(	O
P=0.048	O
)	O
;	O
the	O
LVEDP	O
remained	O
high	O
(	O
P=0.002	O
)	O
.	O

GAP	O
JUNCTIONS	O
IN	O
THE	O
BRAIN	O
:	O
PREFACE	O
.	O

In	O
hemodialyzed	O
patients	O
(	O
Epo	B
and	O
Non	O
-	O
Epo	B
group	O
)	O
leptin	B
levels	O
were	O
significantly	O
higher	O
when	O
compared	O
to	O
CAPD	O
patients	O
(	O
Epo	B
and	O
Non	O
-	O
Epo	B
group	O
,	O
respectively	O
)	O
.	O

Screening	O
,	O
counseling	O
,	O
and	O
treatment	O
for	O
alcohol	O
and	O
illicit	O
drug	O
use	O
should	O
be	O
essential	O
components	O
in	O
comprehensive	O
HBP	O
care	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
eukaryotic	O
transcription	O
factor	O
complex	O
containing	O
both	O
a	O
MADS	B
-	I
box	I
and	O
a	O
forkhead	B
protein	I
,	O
and	O
it	O
has	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
mammalian	O
gene	O
expression	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
AMP	O
CT	O
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
on	O
urogenital	O
specimens	O
taken	O
from	O
symptomatic	O
patients	O
and	O
on	O
first	O
void	O
urine	O
(	O
FVU	O
)	O
specimens	O
from	O
asymptomatic	O
patients	O
.	O

The	O
repetitive	O
ETn	B
(	O
early	B
transposon	I
)	O
family	O
of	O
sequences	O
represents	O
an	O
active	O
""""	O
mobile	O
mutagen	O
""""	O
in	O
the	O
mouse	O
genome	O
.	O

The	O
two	O
main	O
experimental	O
variables	O
were	O
the	O
attended	O
hemifield	O
(	O
left	O
or	O
right	O
)	O
and	O
the	O
proportion	O
of	O
trials	O
requiring	O
a	O
shift	O
within	O
that	O
hemifield	O
(	O
20	O
%	O
or	O
80	O
%	O
)	O
.	O

Pharmacoeconomic	O
assessment	O
of	O
HMG	B
-	I
CoA	I
reductase	I
inhibitor	O
therapy	O
:	O
an	O
analysis	O
based	O
on	O
the	O
CURVES	O
study	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
controlled	O
trials	O
where	O
adults	O
with	O
schizophrenia	O
or	O
similar	O
illnesses	O
were	O
randomised	O
to	O
quetiapine	O
,	O
placebo	O
or	O
other	O
neuroleptic	O
drugs	O
and	O
where	O
clinically	O
relevant	O
outcomes	O
were	O
reported	O
.	O

Twenty	O
eligible	O
patients	O
with	O
cirrhosis	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
10	O
patients	O
treated	O
with	O
6	O
million	O
units	O
of	O
natural	O
IFN	B
-	I
beta	I
twice	O
a	O
week	O
for	O
36	O
months	O
and	O
10	O
patients	O
without	O
IFN	B
therapy	O
.	O

VaI	O
and	O
VaII	O
co	O
-	O
immunoprecipitated	O
with	O
ErbB2	B
,	O
but	O
not	O
with	O
ErbB1	B
,	O
ErbB3	B
,	O
or	O
ErbB4	B
.	O

In	O
contrast	O
to	O
full	B
-	I
length	I
E2F-3	I
,	O
which	O
is	O
expressed	O
only	O
at	O
the	O
G1	O
/	O
S	O
boundary	O
,	O
E2F-3B	B
is	O
detected	O
throughout	O
the	O
cell	O
cycle	O
with	O
peak	O
levels	O
in	O
GO	O
where	O
it	O
is	O
associated	O
with	O
Rb	B
.	O

Five	O
of	O
the	O
PDP1	B
isoforms	I
differ	O
by	O
the	O
substitution	O
or	O
insertion	O
of	O
amino	O
acids	O
at	O
or	O
near	O
the	O
N	O
-	O
terminal	O
of	O
the	O
protein	O
.	O

To	O
analyze	O
the	O
regulatory	O
activity	O
of	O
Gtx	B
,	O
we	O
first	O
identified	O
the	O
optimal	O
Gtx	B
-	I
binding	I
sequence	I
using	O
an	O
in	O
vitro	O
DNA	O
-	O
binding	O
assay	O
.	O

The	O
loss	O
of	O
avirulence	O
activity	O
because	O
of	O
mutations	O
in	O
the	O
acidic	O
transcriptional	O
activation	O
domain	O
was	O
restored	O
by	O
addition	O
of	O
the	O
activation	O
domain	O
from	O
the	O
herpes	B
simplex	I
viral	I
protein	I
VP16	I
.	O

Although	O
there	O
is	O
little	O
evidence	O
that	O
diet	O
composition	O
plays	O
a	O
clinically	O
important	O
role	O
in	O
the	O
absorption	O
or	O
expenditure	O
of	O
energy	O
,	O
it	O
does	O
appear	O
to	O
play	O
a	O
role	O
in	O
food	O
intake	O
.	O

DATA	O
SYNTHESIS	O
:	O
Intracoronary	O
ultrasound	O
has	O
been	O
shown	O
to	O
improve	O
upon	O
demonstrated	O
weaknesses	O
of	O
coronary	O
angiography	O
.	O

TB	O
bone	O
area	O
(	O
p	O
<	O
0.001	O
)	O
,	O
height	O
(	O
p	O
<	O
0.01	O
)	O
,	O
years	O
in	O
present	O
colony	O
(	O
p	O
=	O
0.03	O
)	O
,	O
and	O
menses	O
(	O
p	O
<	O
0.01	O
)	O
predicted	O
TB	O
BMC	O
.	O

Viruses	O
were	O
isolated	O
from	O
9	O
lungs	O
:	O
7	O
with	O
PI-3V	O
,	O
1	O
with	O
NCP	O
BVDV	O
type	O
1	O
,	O
and	O
1	O
with	O
both	O
BVHV-1	O
and	O
BVDV	O
.	O

In	O
addition	O
,	O
the	O
ketamine	O
-	O
treated	O
rats	O
had	O
more	O
neurons	O
and	O
glial	O
cells	O
surrounding	O
the	O
ventricles	O
.	O

The	O
differences	O
were	O
as	O
follows	O
:	O
for	O
overall	O
response	O
rate	O
p	O
=	O
0.004	O
;	O
power	O
(	O
for	O
p	O
=	O
0.05	O
)	O
85	O
%	O
;	O
for	O
survival	O
p	O
=	O
0.09	O
;	O
for	O
grade	O
IV	O
granulocytopenia	O
p	O
=	O
0.3	O
;	O
and	O
for	O
febrile	O
neutropenia	O
p	O
=	O
0.61	O
.	O

These	O
regions	O
may	O
be	O
differentially	O
involved	O
in	O
tissue	O
-	O
specificity	O
,	O
and/or	O
circadian	O
regulation	O
,	O
of	O
the	O
human	B
hPer1	I
gene	I
transcription	O
.	O

Genomic	O
and	O
functional	O
characterization	O
of	O
the	O
oas	B
gene	I
family	I
encoding	O
O	B
-	I
acetylserine	I
(	I
thiol	I
)	I
lyases	I
,	O
enzymes	O
catalyzing	O
the	O
final	O
step	O
in	O
cysteine	O
biosynthesis	O
in	O
Arabidopsis	O
thaliana	O
.	O

Further	O
characterization	O
of	O
these	O
putative	O
Hoxa-1	B
target	I
genes	I
will	O
aid	O
in	O
delineating	O
the	O
functions	O
of	O
the	O
Hoxa-1	B
protein	I
in	O
the	O
differentiation	O
processes	O
which	O
occur	O
during	O
embryogenesis	O
.	O

The	O
ability	O
of	O
U6-U57	B
mutants	O
to	O
influence	O
the	O
fidelity	O
of	O
both	O
branch	O
site	O
and	O
3	O
'	O
splice	O
site	O
recognition	O
suggests	O
that	O
this	O
nucleotide	O
may	O
participate	O
in	O
the	O
formation	O
of	O
the	O
active	O
site	O
(	O
s	O
)	O
of	O
the	O
spliceosome	O
.	O

Only	O
two	O
of	O
27	O
participants	O
(	O
7.4	O
%	O
)	O
with	O
definite	O
POAG	O
had	O
been	O
previously	O
diagnosed	O
and	O
treated	O
,	O
and	O
66.7	O
%	O
of	O
the	O
previously	O
undiagnosed	O
had	O
IOP	O
less	O
than	O
22	O
mmHg	O
.	O

Because	O
GH	B
-	O
induced	O
Akt	B
activation	O
was	O
completely	O
inhibited	O
in	O
both	O
cells	O
by	O
the	O
same	O
concentration	O
of	O
LY294002	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
wortmannin	O
sensitivity	O
of	O
both	O
the	O
IRS-1-independent	B
and	O
-dependent	O
GH	B
-	O
induced	O
MAP	B
kinase	I
activation	O
may	O
reflect	O
the	O
activity	O
of	O
another	O
wortmannin	O
-	O
sensitive	O
target	O
(	O
s	O
)	O
in	O
addition	O
to	O
PI3	B
K	I
in	O
mediation	O
of	O
GH	B
-	O
induced	O
MAP	B
kinase	I
activation	O
in	O
these	O
cells	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
p53	B
protein	I
contributes	O
to	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
through	O
recombinational	O
repair	O
.	O

Mutating	O
the	O
Fcp1p	B
-	O
binding	O
motif	O
KEFGK	O
in	O
the	O
RAP74	B
(	O
Tfg1p	B
)	O
subunit	O
of	O
TFIIF	B
to	O
EEFGE	O
led	O
to	O
both	O
synthetic	O
phenotypes	O
in	O
certain	O
fcp1	B
tfg1	B
double	O
mutants	O
and	O
a	O
reduced	O
ability	O
of	O
Fcp1p	B
to	O
activate	O
transcription	O
when	O
it	O
is	O
artificially	O
tethered	O
to	O
a	O
promoter	O
.	O

Recombinant	O
AROM	B
-	O
p64	B
displayed	O
high	O
binding	O
to	O
single	O
-	O
stranded	O
DNA	O
and	O
poly	O
(	O
A	O
)	O
homopolymers	O
suggesting	O
that	O
this	O
protein	O
could	O
play	O
a	O
role	O
in	O
mRNA	O
maturation	O
/	O
metabolism	O
.	O

It	O
is	O
now	O
estimated	O
that	O
inactivation	O
mutants	O
of	O
PTEN	B
exist	O
in	O
60	O
%	O
of	O
all	O
forms	O
of	O
solid	O
tumors	O
.	O

Src	B
activation	O
induced	O
by	O
FGF1	B
was	O
blocked	O
by	O
the	O
SH2	B
domain	I
of	O
Src	B
and	O
PP2	B
,	O
a	O
specific	O
inhibitor	O
of	O
Src	B
.	O

The	O
use	O
of	O
the	O
PLCgamma	B
inhibitory	I
peptide	I
,	O
neomycin	O
and	O
the	O
calcium	O
chelator	O
BAPTA	O
-	O
AM	O
on	O
oocytes	O
expressing	O
FGFR1	B
or	O
the	O
stimulation	O
by	O
PDGF	B
-	I
BB	I
of	O
oocytes	O
expressing	O
PDGFR	B
-	O
FGFR1	B
mutated	O
on	O
the	O
PLCgamma	B
binding	I
site	I
,	O
prevented	O
GVBD	O
and	O
ERK2	B
phosphorylation	O
.	O

HYPOTHESIS	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
oxidative	O
susceptibility	O
of	O
apolipoprotein	B
B	I
-	I
containing	I
lipoproteins	I
and	O
antioxidant	O
status	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
and	O
chronic	O
stable	O
angina	O
pectoris	O
.	O

We	O
cloned	O
a	O
DNA	O
fragment	O
encoding	O
the	O
N	O
-	O
terminal	O
part	O
of	O
a	O
protein	O
with	O
significant	O
similarity	O
to	O
members	O
of	O
the	O
LysR	B
family	I
of	I
transcriptional	I
regulators	I
(	O
LTTRs	B
)	O
.	O

Expression	O
of	O
a	O
dominant	B
negative	I
Smad2	I
significantly	O
reduces	O
the	O
level	O
of	O
luciferase	B
reporter	I
activity	O
induced	O
by	O
nodal	O
treatment	O
.	O

The	O
Drosophila	B
melanogaster	I
suppressor	I
of	I
sable	I
gene	I
,	O
su	B
(	I
s	I
)	I
,	O
encodes	O
a	O
novel	O
,	O
150-kDa	O
nuclear	O
RNA	O
binding	O
protein	O
,	O
SU	B
(	I
S	I
)	I
,	O
that	O
negatively	O
regulates	O
RNA	O
accumulation	O
from	O
mutant	O
alleles	O
of	O
other	O
genes	O
that	O
have	O
transposon	O
insertions	O
in	O
the	O
5	O
'	O
transcribed	O
region	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
defined	O
two	O
arginine	O
-	O
rich	O
motifs	O
(	O
ARM1	O
and	O
ARM2	O
)	O
that	O
mediate	O
the	O
RNA	O
binding	O
activity	O
of	O
SU	B
(	I
S	I
)	I
.	O

This	O
interaction	O
inhibits	O
the	O
histone	B
acetyltransferase	I
activity	O
of	O
p300	B
,	O
resulting	O
in	O
drastic	O
reduction	O
of	O
nucleosomal	O
histone	B
acetylation	O
and	O
alteration	O
of	O
chromatin	O
structure	O
.	O

Both	O
the	O
Cmax	O
and	O
AUC	O
values	O
were	O
almost	O
doubled	O
with	O
doubling	O
the	O
dose	O
.	O

Diary	O
.	O

In	O
transient	O
analysis	O
using	O
particle	O
bombardment	O
of	O
tobacco	O
leaf	O
sections	O
,	O
a	O
tetramer	O
of	O
the	O
distB	O
ABRE	O
(	O
abscisic	O
acid	O
-	O
responsive	O
element	O
)	O
mediated	O
transactivation	O
by	O
ABI3	B
and	O
ABI3-dependent	B
response	O
to	O
ABA	O
,	O
whereas	O
a	O
tetramer	O
of	O
the	O
composite	O
RY	O
/	O
G	O
complex	O
,	O
containing	O
RY	O
repeats	O
and	O
a	O
G	O
-	O
box	O
,	O
mediated	O
only	O
ABA	O
-	O
independent	O
transactivation	O
by	O
ABI3	B
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Studies	O
were	O
undertaken	O
in	O
9	O
isolated	O
guinea	O
pig	O
hearts	O
,	O
which	O
demonstrated	O
reverse	O
use	O
-	O
dependent	O
prolongation	O
of	O
cardiac	O
repolarization	O
by	O
100	O
nmol	O
/	O
L	O
domperidone	O
.	O

CONCLUSIONS	O
:	O
LSCC	O
malformation	O
,	O
like	O
other	O
inner	O
ear	O
malformations	O
such	O
as	O
large	O
vestibular	O
aqueduct	O
and	O
X	O
-	O
linked	O
mixed	O
deafness	O
with	O
perilymph	O
gusher	O
,	O
can	O
be	O
associated	O
with	O
CHL	O
,	O
SNHL	O
,	O
or	O
normal	O
hearing	O
.	O

Thus	O
,	O
methylation	O
of	O
Pph21p	B
is	O
important	O
for	O
formation	O
of	O
PP2A	B
trimeric	I
and	I
dimeric	I
complexes	I
,	O
and	O
consequently	O
,	O
for	O
PP2A	B
function	O
.	O

Thus	O
,	O
diamide	O
treatment	O
of	O
nuclear	O
extracts	O
strongly	O
reduces	O
the	O
binding	O
of	O
NFI	B
proteins	I
,	O
and	O
the	O
addition	O
of	O
higher	O
concentrations	O
of	O
dithiothreitol	O
to	O
nuclear	O
extracts	O
from	O
TG	B
-	O
treated	O
cells	O
restores	O
NFI	B
-	I
DNA	I
binding	O
to	O
levels	O
in	O
extracts	O
from	O
untreated	O
cells	O
.	O

Further	O
,	O
Tax	B
-	O
mediated	O
apoptosis	O
was	O
effectively	O
prevented	O
by	O
ectopic	O
expression	O
of	O
the	O
p300	B
coactivator	I
.	O

There	O
were	O
no	O
instances	O
of	O
major	O
flap	O
necrosis	O
although	O
two	O
flaps	O
showed	O
tip	O
ischaemia	O
.	O

One	O
of	O
these	O
factors	O
,	O
IRF-2	B
,	O
was	O
initially	O
cloned	O
as	O
an	O
antagonistic	O
counterpart	O
to	O
IRF-1	B
with	O
oncogenic	O
potential	O
.	O

Exon	O
A	O
is	O
located	O
approximately	O
7	O
kb	O
5	O
'	O
to	O
the	O
HSL	B
translation	I
start	I
site	I
.	O

Cardiovascular	O
risk	O
factors	O
and	O
antihypertensive	O
treatment	O
.	O

These	O
two	O
mAbs	O
used	O
the	O
same	O
V	O
(	O
H	O
)	O
and	O
J	O
(	O
H	O
)	O
gene	O
segments	O
,	O
but	O
different	O
D	O
,	O
Vkappa	O
,	O
and	O
Jkappa	O
genes	O
.	O

Patients	O
had	O
to	O
have	O
adequate	O
liver	O
,	O
renal	O
,	O
and	O
marrow	O
functions	O
.	O

In	O
15	O
ventilator	O
-	O
dependent	O
,	O
SB	O
,	O
and	O
actively	O
expiring	O
patients	O
,	O
we	O
found	O
that	O
the	O
difference	O
PEEP	O
(	O
i	O
)	O
,dyn	O
-	O
Pga	O
,	O
total	O
decay	O
(	O
mean	O
+	O
/-	O

SD	O
,	O
5.7	O
+	O
/-	O

1.9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
was	O
quite	O
similar	O
to	O
PEEP	O
(	O
i	O
)	O
,dyn	O
ref	O
(	O
5.3	O
+	O
/-	O

1.9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
.	O

Of	O
208	O
eligible	O
subjects	O
,	O
82	O
received	O
supervised	O
IPT	O
at	O
a	O
dose	O
of	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
A	O
)	O
,	O
73	O
received	O
unsupervised	O
IPT	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
B	O
)	O
,	O
and	O
53	O
received	O
unsupervised	O
IPT	O
300	O
mg	O
daily	O
for	O
6	O
mo	O
(	O
Regimen	O
C	O
)	O
.	O

This	O
dynamic	O
response	O
strongly	O
suggests	O
that	O
the	O
p53	B
and	O
Rb	B
tumor	O
suppressor	O
pathways	O
are	O
intact	O
in	O
HeLa	O
cells	O
and	O
that	O
repression	O
of	O
HPV	B
E6	I
and	O
E7	B
mobilizes	O
these	O
pathways	O
in	O
an	O
orderly	O
fashion	O
to	O
deliver	O
growth	O
inhibitory	O
signals	O
to	O
the	O
cells	O
.	O

Thus	O
,	O
blocks	O
in	O
the	O
RARalpha	B
-	O
specific	O
pathway	O
of	O
retinoid	O
-	O
induced	O
differentiation	O
may	O
be	O
bypassed	O
during	O
retinoid	O
induction	O
of	O
FR	B
-	I
beta	I
expression	O
.	O

To	O
test	O
whether	O
or	O
not	O
SOCS-3	B
also	O
binds	O
to	O
the	O
IGFIR	B
,	O
we	O
cloned	O
human	B
SOCS-3	I
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
from	O
human	O
skeletal	O
muscle	O
mRNA	O
.	O

Interestingly	O
,	O
this	O
mutant	O
cell	O
line	O
lacks	O
expression	O
of	O
the	O
IKK	B
regulatory	I
protein	I
,	O
IKKgamma	B
.	O

RESULTS	O
:	O
The	O
main	O
effect	O
of	O
muscle	O
pain	O
,	O
compared	O
to	O
non	O
-	O
painful	O
stimulation	O
,	O
was	O
a	O
significant	O
and	O
long	O
-	O
lasting	O
increase	O
of	O
delta	O
(	O
1	O
-	O
3	O
Hz	O
)	O
power	O
and	O
an	O
alpha-1	O
(	O
9	O
-	O
11	O
Hz	O
)	O
power	O
increase	O
over	O
the	O
contralateral	O
parietal	O
locus	O
.	O

This	O
transcriptional	O
regulation	O
occurs	O
through	O
modulation	O
of	O
the	O
forkhead	B
transcription	I
factor	I
FKHR	B
-	I
L1	I
,	O
and	O
IL-3	B
inhibited	O
FKHR	B
-	I
L1	I
activity	O
in	O
a	O
PI3K	B
-	O
dependent	O
manner	O
.	O

Unlike	O
the	O
mammalian	O
proteins	O
,	O
XFGF3	B
is	O
efficiently	O
secreted	O
as	O
a	O
Mr	O
31,000	O
glycoprotein	O
,	O
gp31	B
,	O
which	O
undergoes	O
proteolytic	O
cleavage	O
to	O
produce	O
an	O
NH2-terminally	O
truncated	O
product	O
,	O
gp27	B
.	O

Characterization	O
of	O
the	O
microtubule	O
binding	O
domain	O
of	O
microtubule	B
actin	I
crosslinking	I
factor	I
(	O
MACF	B
)	O
:	O
identification	O
of	O
a	O
novel	O
group	O
of	O
microtubule	B
associated	I
proteins	I
.	O

Four	O
cases	O
of	O
synovial	O
chondromatosis	O
are	O
presented	O
.	O

These	O
cells	O
produced	O
P2Y	B
(	I
11	I
)	I
mRNA	I
during	O
culture	O
.	O

Coexpression	O
studies	O
indicate	O
that	O
insulin	B
and	O
PKB	B
suppress	O
transactivation	O
by	O
C	B
/	I
EBPbeta	I
,	O
but	O
not	O
C	B
/	I
EBPalpha	I
,	O
and	O
that	O
N	O
-	O
terminal	O
transactivation	O
domains	O
in	O
C	B
/	I
EBPbeta	I
are	O
required	O
.	O

Therefore	O
,	O
in	O
our	O
in	O
vitro	O
model	O
,	O
the	O
localization	O
of	O
the	O
mutation	O
in	O
the	O
K	B
-	I
ras	I
gene	I
predisposes	O
to	O
a	O
different	O
level	O
of	O
aggressiveness	O
in	O
the	O
transforming	O
phenotype	O
.	O

One	O
of	O
the	O
sequelae	O
of	O
the	O
antiphospholipid	O
-	O
antibodies	O
is	O
an	O
impaired	O
uteroplacental	O
circulation	O
.	O

PM	O
12	O
or	O
18	O
mg	O
/	O
kg	O
daily	O
plus	O
a	O
standard	O
dose	O
of	O
SB	O
for	O
21	O
days	O
was	O
statistically	O
more	O
effective	O
than	O
SB	O
in	O
producing	O
a	O
final	O
cure	O
for	O
patients	O
with	O
VL	O
in	O
Bihar	O
,	O
India	O
.	O

In	O
whole	O
sardine	O
,	O
domoic	O
acid	O
was	O
detected	O
in	O
levels	O
exceeding	O
sometimes	O
the	O
regulatory	O
limit	O
.	O

We	O
demonstrate	O
that	O
the	O
protein	O
is	O
a	O
murine	B
homologue	I
of	I
SAF	I
-	I
A	I
which	O
has	O
been	O
shown	O
to	O
bind	O
selectively	O
to	O
MARs	O
and	O
is	O
responsible	O
for	O
the	O
satMa	B
-	O
binding	O
activity	O
in	O
the	O
chromatographic	O
fractions	O
.	O

The	O
molecular	O
associations	O
dictating	O
INCENP	B
behavior	O
during	O
mitosis	O
are	O
currently	O
unknown	O
.	O

Termination	O
of	O
induced	O
VT	O
on	O
the	O
first	O
attempt	O
was	O
comparable	O
with	O
BV	O
pacing	O
(	O
87.4	O
%	O
)	O
versus	O
RV	O
pacing	O
(	O
89.6	O
%	O
)	O
.	O

Perfusion	O
technique	O
for	O
perfusion	O
-	O
assisted	O
direct	O
coronary	O
artery	O
bypass	O
(	O
PADCAB	O
)	O
.	O

To	O
account	O
for	O
this	O
observation	O
,	O
other	O
possible	O
causes	O
include	O
increased	O
CSF	O
pulsation	O
in	O
children	O
creating	O
motion	O
artifact	O
,	O
changes	O
in	O
arterial	O
oxygen	O
concentration	O
intrinsic	O
to	O
propofol	O
or	O
related	O
to	O
the	O
supplemental	O
oxygen	O
normally	O
administered	O
,	O
or	O
changes	O
in	O
CSF	O
protein	O
levels	O
related	O
to	O
propofol	O
binding	O
to	O
proteins	O
for	O
uptake	O
into	O
CSF	O
.	O

In	O
three	O
cases	O
(	O
21.4	O
%	O
)	O
,	O
the	O
MR	O
imaging	O
was	O
interpreted	O
as	O
negative	O
,	O
but	O
microscopic	O
tumor	O
was	O
shown	O
around	O
seroma	O
on	O
reexcision	O
.	O

This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C	B
/	I
EBP	I
dimer	I
binding	O
to	O
a	O
strong	O
C	B
/	I
EBP	I
site	I
leads	O
to	O
enhanced	O
CREB-1	B
recruitment	O
to	O
ATF	B
/	O
CREB	B
sites	O
that	O
are	O
weakly	O
bound	O
by	O
CREB	B
.	O

Quantitative	O
PCR	O
studies	O
indicated	O
that	O
synthesis	O
and	O
transport	O
of	O
vector	O
DNA	O
into	O
the	O
nucleus	O
were	O
similar	O
for	O
macrophages	O
infected	O
with	O
the	O
clone	O
239	O
and	O
316	O
pseudotypes	O
,	O
suggesting	O
that	O
the	O
restriction	O
for	O
SIVmac239	O
infection	O
is	O
after	O
reverse	O
transcription	O
and	O
nuclear	O
import	O
of	O
viral	O
DNA	O
.	O

Interestingly	O
,	O
the	O
similarities	O
with	O
the	O
endophilin	B
proteins	I
cover	O
the	O
entire	O
sequence	O
of	O
the	O
SH3GLB	B
family	I
,	O
suggesting	O
a	O
common	O
fold	O
and	O
presumably	O
a	O
common	O
mode	O
of	O
action	O
.	O

To	O
study	O
the	O
in	O
vivo	O
role	O
of	O
p16.7	B
,	O
a	O
phi29	O
mutant	O
containing	O
a	O
suppressible	O
mutation	O
in	O
gene	B
16.7	I
was	O
constructed	O
.	O

In	O
contrast	O
,	O
we	O
did	O
not	O
detect	O
a	O
significant	O
correlation	O
between	O
plasma	B
TNFalpha	I
and	O
radiation	O
pneumonitis	O
.	O

METHODS	O
:	O
Sixteen	O
pigs	O
were	O
assigned	O
randomly	O
to	O
control	O
and	O
shock	O
groups	O
.	O

Serial	O
US	O
images	O
were	O
obtained	O
before	O
and	O
20	O
,	O
30	O
,	O
40	O
,	O
50	O
,	O
60	O
,	O
90	O
,	O
120	O
,	O
150	O
,	O
180	O
,	O
240	O
,	O
and	O
300	O
s	O
after	O
intravenous	O
injection	O
of	O
2	O
g	O
of	O
contrast	O
agent	O
using	O
conventional	O
and	O
harmonic	O
PD	O
US	O
.	O

This	O
supports	O
previous	O
arguments	O
for	O
the	O
improbability	O
of	O
biological	O
effects	O
at	O
UHF	O
frequencies	O
unless	O
a	O
mechanism	O
can	O
be	O
found	O
for	O
accumulating	O
energy	O
over	O
time	O
and	O
space	O
and	O
focussing	O
it	O
.	O

To	O
assess	O
the	O
maximum	O
oxygen	O
uptake	O
(	O
V'O2	O
max	O
)	O
of	O
Hong	O
Kong	O
Chinese	O
children	O
and	O
to	O
explore	O
its	O
association	O
with	O
respiratory	O
illnesses	O
,	O
we	O
conducted	O
the	O
Multistage	O
Fitness	O
Test	O
(	O
MFT	O
)	O
,	O
a	O
20-m	O
shuttle	O
run	O
test	O
,	O
in	O
1,427	O
schoolchildren	O
aged	O
between	O
8	O
-	O
12	O
years	O
.	O

The	O
corresponding	O
genotype	O
was	O
determined	O
with	O
a	O
restriction	O
enzyme	O
-	O
based	O
assay	O
.	O

The	O
regulation	O
of	O
PGHS-2	B
mRNA	I
and	O
protein	O
was	O
studied	O
in	O
primary	O
cultures	O
of	O
bovine	O
uterine	O
stromal	O
cells	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
;	O
100	O
nM	O
)	O
.	O

Functional	O
analysis	O
of	O
various	O
PTP	B
-	O
deficient	O
DT40	O
B	O
cell	O
lines	O
stably	O
expressing	O
wild	O
-	O
type	O
chimeric	O
Fc	B
gamma	I
RIIB1-PECAM-1	I
receptor	I
indicated	O
that	O
cytoplasmic	B
Src	I
homology	I
2-domain	I
-	I
containing	I
phosphatases	I
,	O
SHP-1	B
and	O
SHP-2	B
,	O
were	O
both	O
necessary	O
and	O
sufficient	O
to	O
deliver	O
inhibitory	O
negative	O
regulation	O
upon	O
coligation	O
of	O
BCR	B
complex	I
with	O
inhibitory	O
receptor	O
.	O

In	O
contrast	O
,	O
the	O
failure	O
of	O
the	O
QKTT	O
motif	O
and	O
TGN46	O
cytoplasmic	O
tail	O
to	O
induce	O
steady	O
-	O
state	O
ER	O
localization	O
of	O
vesicular	B
stomatitis	I
virus	I
glycoprotein	I
(	O
VSVG	B
)	O
chimeras	O
in	O
HeLa	O
and	O
NRK	O
cells	O
indicates	O
that	O
significant	O
differences	O
in	O
early	O
secretory	O
trafficking	O
also	O
exist	O
.	O

Consistent	O
with	O
the	O
specificity	O
observed	O
for	O
the	O
interaction	O
of	O
DmCKIIalpha	B
with	O
these	O
bHLH	B
proteins	I
,	O
sequence	O
alignment	O
suggests	O
that	O
only	O
m5	B
,	O
m7	B
,	O
and	O
m8	B
contain	O
a	O
consensus	O
site	O
for	O
phosphorylation	O
by	O
CKII	B
within	O
a	O
subdomain	O
unique	O
to	O
these	O
three	O
proteins	O
.	O

Sevelamer	O
hydrochloride	O
(	O
Renagel	O
)	O
is	O
a	O
nonabsorbed	O
phosphate	O
-	O
binding	O
polymer	O
marketed	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
in	O
adult	O
patients	O
receiving	O
hemodialysis	O
.	O

The	O
Genescan	O
program	O
predicted	O
an	O
open	O
reading	O
frame	O
of	O
a	O
novel	O
,	O
intron	O
-	O
less	O
gene	O
adjacent	O
to	O
the	O
B236	O
spot	O
that	O
encodes	O
a	O
putative	O
493-amino	O
acid	O
protein	O
containing	O
the	O
SNAG	O
repressor	O
motif	O
in	O
the	O
NH2-terminal	O
region	O
and	O
five	O
C2H2-type	O
zinc	O
finger	O
motifs	O
in	O
the	O
COOH	O
-	O
terminal	O
half	O
.	O

The	O
BFA	O
System	O
reads	O
a	O
text	O
file	O
with	O
flows	O
,	O
measured	O
with	O
fluorescent	O
microsphere	O
technique	O
,	O
and	O
constructs	O
the	O
lung	O
anatomy	O
with	O
volumetric	O
pixels	O
showing	O
the	O
flows	O
with	O
a	O
color	O
schema	O
.	O

Managing	O
HIV	O
.	O

Cells	O
containing	O
alpha	O
subunits	O
that	O
lacked	O
a	O
distal	O
domain	O
(	O
term-3	O
)	O
or	O
had	O
the	O
alternatively	O
spliced	O
alpha-2	O
distal	O
domain	O
showed	O
markedly	O
decreased	O
ability	O
to	O
support	O
tyrosine	O
phosphorylation	O
of	O
Jak-2	B
and	O
its	O
substrates	O
or	O
to	O
up	O
-	O
regulate	O
CD86	B
.	O

For	O
this	O
purpose	O
,	O
the	O
immediate	O
and	O
the	O
final	O
(	O
after	O
swelling	O
)	O
fixation	O
strengths	O
of	O
two	O
variations	O
of	O
the	O
swellable	O
bone	O
anchor	O
designs	O
(	O
a	O
smooth	O
anchor	O
and	O
a	O
screw	O
anchor	O
)	O
were	O
measured	O
in	O
two	O
different	O
foams	O
(	O
used	O
to	O
simulate	O
bone	O
)	O
with	O
different	O
densities	O
.	O

RESULTS	O
:	O
Within	O
7	O
days	O
,	O
all	O
groups	O
re	O
-	O
acquired	O
responding	O
for	O
heroin	O
under	O
CRF	O
at	O
rates	O
similar	O
to	O
their	O
pre	O
-	O
lesion	O
performance	O
.	O

A	O
novel	O
growth	O
-	O
related	O
nuclear	O
protein	O
binds	O
and	O
inhibits	O
rat	O
aldolase	B
B	I
gene	I
promoter	O
.	O

Mechanism	O
in	O
the	O
sequential	O
control	O
of	O
cell	O
morphology	O
and	O
S	O
phase	O
entry	O
by	O
epidermal	B
growth	I
factor	I
involves	O
distinct	O
MEK	B
/	O
ERK	B
activations	O
.	O

3D	O
image	O
-	O
processing	O
permits	O
to	O
analyse	O
ultrasound	O
data	O
interactively	O
in	O
three	O
orthogonal	O
planes	O
(	O
section	O
mode	O
)	O
or	O
in	O
realistic	O
3D	O
views	O
(	O
rendering	O
mode	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
significant	O
differences	O
between	O
the	O
5	O
'	O
region	O
of	O
the	O
beta	O
subunit	O
gene	O
and	O
the	O
corresponding	O
regions	O
of	O
the	O
homologous	B
GlyR	I
alpha	I
subunit	I
genes	I
;	O
it	O
also	O
identified	O
a	O
novel	O
exon	O
(	O
exon	O
0	O
)	O
that	O
encodes	O
most	O
of	O
the	O
5'-untranslated	O
portion	O
of	O
the	O
GlyR	B
beta	I
mRNA	I
.	O

Forskolin	O
treatment	O
(	O
10	O
microM	O
)	O
of	O
the	O
transfected	O
cells	O
for	O
3	O
-	O
-6	O
h	O
maximally	O
induced	O
luciferase	B
threefold	O
.	O

B	B
-	I
myb	I
is	O
essential	O
for	O
G1	O
/	O
S	O
transition	O
and	O
has	O
been	O
shown	O
to	O
be	O
phosphorylated	O
by	O
the	O
cyclin	B
A2	I
/	O
cdk2	B
complex	O
.	O

The	O
flux	O
rates	O
of	O
p	O
-	O
toluidine	O
decreased	O
as	O
the	O
pH	O
value	O
in	O
the	O
donor	O
solution	O
increased	O
.	O

The	O
438	B
bp	I
EcoRI	I
fragment	I
,	O
which	O
was	O
detected	O
by	O
Southern	O
hybridization	O
,	O
reveals	O
an	O
open	O
reading	O
frame	O
which	O
encodes	O
a	O
protein	O
of	O
103	O
amino	O
acids	O
.	O

Nrf2	B
regulates	O
expression	O
of	O
genes	O
encoding	O
enzymes	O
with	O
antioxidant	O
(	O
e.g.	O
heme	B
oxygenase-1	I
(	O
HO-1	B
)	O
)	O
or	O
xenobiotic	O
detoxification	O
(	O
e.g.	O

These	O
results	O
indicate	O
that	O
ATF4	B
regulates	O
basal	O
and	O
CdCl	O
(	O
2	O
)	O
-induced	O
expression	O
of	O
the	O
ho-1	B
gene	I
in	O
a	O
cell	O
-	O
specific	O
manner	O
and	O
possibly	O
in	O
a	O
complex	O
with	O
Nrf2	B
.	O

This	O
effect	O
was	O
observed	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
independent	O
of	O
histone	B
deacetylase	I
activity	O
.	O

Corticosteroid	O
-	O
mediated	O
transcriptional	O
inhibition	O
was	O
greater	O
for	O
MR	B
/	O
GR	B
in	O
combination	O
than	O
for	O
MR	B
or	O
GR	B
alone	O
.	O

SV1	B
has	O
a	O
33-amino	O
acid	O
insert	O
in	O
the	O
S1	O
transmembrane	O
domain	O
that	O
does	O
not	O
alter	O
S1	O
overall	O
hydrophobicity	O
,	O
but	O
makes	O
the	O
S0-S1	O
linker	O
longer	O
.	O

Deterministic	O
effects	O
.	O

No	O
preferential	O
VH	B
/	O
VL	B
-	O
chains	O
correlated	O
with	O
any	O
of	O
the	O
12	O
different	O
antigen	O
reactivities	O
,	O
even	O
for	O
mAbs	O
with	O
nearly	O
identical	O
cross	O
-	O
reactivities	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
purified	O
RAG1	B
/	I
2	I
proteins	I
can	O
cleave	O
DNA	O
hairpins	O
in	O
vitro	O
,	O
but	O
the	O
same	O
activity	O
was	O
also	O
described	O
for	O
a	O
protein	O
complex	O
of	O
the	O
DNA	O
repair	O
proteins	O
Nbs1	B
/	O
Mre11	B
/	O
Rad50	B
.	O

Instead	O
,	O
TRPS1	B
potently	O
and	O
specifically	O
represses	O
transcriptional	O
activation	O
mediated	O
by	O
other	O
GATA	B
factors	I
.	O

PABP	B
is	O
a	O
modular	O
protein	O
,	O
with	O
four	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domains	O
and	O
an	O
extensive	O
C	O
terminus	O
.	O

METHODS	O
:	O
126	O
patients	O
with	O
histologically	O
confirmed	O
MFH	O
were	O
analyzed	O
.	O

Their	O
numbers	O
have	O
regularly	O
increased	O
since	O
the	O
mid-1970s	O
.	O

In	O
contrast	O
,	O
the	O
ubiquitous	O
expression	O
of	O
p19	B
(	O
INK4d	B
)	O
has	O
not	O
been	O
previously	O
described	O
in	O
human	O
or	O
murine	O
B	O
-	O
lineage	O
cells	O
.	O

Cross	O
-	O
linking	O
FcalphaR	B
on	O
wt	B
-	I
ITAM	I
or	O
IIA	B
-	I
ITAM	I
cells	O
triggered	O
equivalent	O
PI	B
3-kinase	I
-	O
dependent	O
activation	O
of	O
PKBalpha	B
.	O

The	O
UBA	B
domains	I
of	O
RAD23	B
and	O
DDI1	B
are	O
required	O
for	O
these	O
interactions	O
.	O

Through	O
two	O
novel	O
mechanisms	O
,	O
Arf	B
inhibits	O
the	O
oncoprotein	B
Hdm2	I
,	O
a	O
negative	O
regulator	O
of	O
p53	B
.	O

Srb10	B
is	O
a	O
physiological	O
regulator	O
of	O
Gcn4	B
stability	O
because	O
both	O
phosphorylation	O
and	O
turnover	O
of	O
Gcn4	B
are	O
diminished	O
in	O
srb10	B
mutants	I
.	O

A	O
log	O
-	O
linear	O
dose	O
-	O
response	O
was	O
obtained	O
for	O
the	O
average	O
increase	O
in	O
FEV1	O
up	O
to	O
6	O
h	O
(	O
AUC0	O
-	O
6	O
h	O
)	O
and	O
peak	O
FEV1	O
across	O
the	O
dose	O
range	O
administered	O
by	O
Respimat	O
.	O

The	O
COD	O
and	O
color	O
removals	O
were	O
both	O
more	O
than	O
90	O
%	O
when	O
FeCl3	O
was	O
used	O
as	O
the	O
coagulation	O
(	O
dosages	O
of	O
two	O
-	O
step	O
coagulation	O
were	O
0.031	O
and	O
0.012	O
mol	O
/	O
L	O
respectively	O
)	O
after	O
a	O
ferrous	O
hydrogen	O
peroxide	O
oxidation	O
pretreatment	O
at	O
a	O
H2O2	O
dosage	O
of	O
0.06	O
mol	O
/	O
L.	O

It	O
is	O
useful	O
as	O
an	O
adjunct	O
to	O
mammography	O
in	O
those	O
patients	O
with	O
radiographically	O
dense	O
breasts	O
for	O
the	O
characterization	O
of	O
palpable	O
masses	O
.	O

Changes	O
of	O
the	O
DB	O
sequence	O
without	O
affecting	O
the	O
postulated	O
stem	O
structure	O
led	O
to	O
drastic	O
losses	O
of	O
translation	O
efficiency	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
forkhead	B
homologue	I
in	I
rhabdomyosarcoma	I
(	O
FKHR	B
)	O
,	O
a	O
recently	O
described	O
member	O
of	O
the	O
hepatocyte	B
nuclear	I
factor	I
3	I
/	O
forkhead	B
homeotic	B
gene	I
family	I
,	O
as	O
a	O
nuclear	B
hormone	I
receptor	I
(	O
NR	B
)	O
intermediary	O
protein	O
.	O

Saccharomyces	O
cerevisiae	O
activates	O
a	O
regulatory	O
network	O
called	O
""""	O
general	O
control	O
""""	O
that	O
provides	O
the	O
cell	O
with	O
sufficient	O
amounts	O
of	O
protein	O
precursors	O
during	O
amino	O
acid	O
starvation	O
.	O

Mutation	O
analyses	O
identified	O
the	O
cobalt	O
-	O
responsive	O
sequences	O
as	O
the	O
stress	O
-	O
response	O
elements	O
(	O
StREs	O
)	O
.	O

During	O
most	O
of	O
the	O
cell	O
cycle	O
,	O
separase	B
is	O
kept	O
inactive	O
by	O
binding	O
to	O
an	O
inhibitory	O
protein	O
called	O
securin	B
.	O

Mechanical	O
ventilation	O
in	O
control	O
lungs	O
produced	O
a	O
47	O
%	O
decrease	O
in	O
chord	O
compliance	O
,	O
an	O
increase	O
in	O
lung	O
lavage	O
levels	O
of	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
(	O
722	O
+	O
/-	O

306	O
pg	O
/	O
ml	O
)	O
,	O
interleukin	B
(	I
IL	I
)	I
-1beta	I
(	O
902	O
+	O
/-	O

322	O
pg	O
/	O
ml	O
)	O
,	O
and	O
macrophage	B
inflammatory	I
protein-2	I
(	O
MIP-2	B
)	O
(	O
363	O
+	O
/-	O

104	O
pg	O
/	O
ml	O
)	O
as	O
compared	O
with	O
low	O
levels	O
of	O
cytokines	O
detected	O
in	O
preventilation	O
data	O
,	O
and	O
no	O
change	O
in	O
percentage	O
of	O
surfactant	O
large	O
aggregates	O
(	O
LA	O
)	O
.	O

In	O
conclusion	O
,	O
USPIO	O
-	O
enhanced	O
MRI	O
data	O
were	O
capable	O
to	O
characterize	O
tumor	O
microvessel	O
properties	O
in	O
this	O
breast	O
cancer	O
model	O
:	O
microvascular	O
permeability	O
(	O
determined	O
using	O
USPIO	O
)	O
correlated	O
significantly	O
with	O
tumor	O
grade	O
.	O

Inhibition	O
of	O
constitutive	O
NF	B
-	I
kappaB	I
activity	O
results	O
in	O
cell	O
death	O
of	O
TT	O
cells	O
and	O
blocks	O
focus	O
formation	O
induced	O
by	O
oncogenic	O
forms	O
of	O
RET	B
in	O
NIH	O
3T3	O
cells	O
.	O

The	O
described	O
results	O
show	O
that	O
DTD	O
is	O
fast	O
,	O
simple	O
,	O
and	O
easy	O
to	O
automate	O
;	O
requires	O
only	O
a	O
small	O
amount	O
of	O
sample	O
(	O
approximately	O
50	O
mg	O
)	O
;	O
and	O
affords	O
quantitative	O
information	O
about	O
the	O
main	O
groups	O
of	O
compounds	O
present	O
in	O
cheeses	O
.	O

Newcastle	B
disease	I
antibody	I
titre	O
is	O
dependent	O
on	O
serum	O
calcium	O
concentration	O
.	O

10.0	O
+	O
/-	O

2.0	O
pmol	O
/	O
24	O
h	O
,	O
P	O
<	O
0.01	O
)	O
and	O
remained	O
elevated	O
.	O

CONCLUSIONS	O
:	O
Ketamine	O
-	O
induced	O
dissociative	O
anesthesia	O
produces	O
persistently	O
elevated	O
BIS	O
index	O
which	O
is	O
different	O
from	O
thiamylal	O
and	O
those	O
reported	O
with	O
other	O
conventional	O
anesthetic	O
agents	O
.	O

Positive	O
and	O
significant	O
correlations	O
were	O
found	O
between	O
the	O
weeks	O
of	O
pregnancy	O
and	O
Se	O
levels	O
in	O
kidney	O
(	O
r=0.433	O
,	O
P=0.023	O
)	O
and	O
heart	O
(	O
r=0.313	O
,	O
P=0.030	O
)	O
.	O

STAT5A	B
mutations	O
in	O
the	O
Src	B
homology	I
2	I
(	O
SH2	B
)	O
and	O
SH3	B
domains	I
did	O
not	O
alter	O
the	O
BTK	B
-	O
mediated	O
tyrosine	O
phosphorylation	O
.	O

Among	O
individuals	O
,	O
however	O
,	O
changes	O
were	O
strongly	O
correlated	O
with	O
ACR	O
levels	O
at	O
baseline	O
.	O

The	O
other	O
inhibitor	O
was	O
a	O
single	O
TAR	B
decoy	O
,	O
driven	O
by	O
the	O
U6	B
small	I
nuclear	I
RNA	I
promoter	I
(	O
U6-P	B
)	O
.	O

In	O
contrast	O
to	O
MPc3	B
,	O
data	O
indicate	O
that	O
the	O
Pc	B
protein	I
M33	B
does	O
not	O
interact	O
with	O
AF9	B
.	O

The	O
amount	O
of	O
drained	O
effusion	O
was	O
measured	O
,	O
and	O
fluid	O
was	O
sent	O
for	O
diagnostic	O
assessment	O
.	O

A	O
rare	O
case	O
of	O
primary	O
group	O
A	O
streptococcal	O
peritonitis	O
.	O

Statistical	O
Analysis	O
included	O
ANOVA	O
,	O
the	O
Pearson	O
Product	O
Moment	O
Correlation	O
Coefficient	O
,	O
Principal	O
Components	O
Analysis	O
and	O
Discriminant	O
Function	O
Analysis	O
and	O
the	O
calculation	O
of	O
Cronbach	O
's	O
alpha	O
(	O
alpha	O
)	O
RESULTS	O
:	O
Both	O
Sensitivity	O
and	O
specificity	O
exceed	O
90.00	O
at	O
23	O
/	O
24	O
,	O
Chronbach	O
's	O
alpha	O
for	O
the	O
total	O
scale	O
was	O
equal	O
to	O
0.95	O
.	O

The	O
telomerase	B
RNA	I
-	I
protein	I
complex	I
responsible	O
for	O
maintenance	O
of	O
telomeric	O
DNA	O
at	O
chromosome	O
ends	O
,	O
is	O
usually	O
inactive	O
in	O
most	O
primary	O
somatic	O
human	O
cells	O
,	O
but	O
is	O
specifically	O
activated	O
with	O
in	O
vitro	O
immortalization	O
and	O
during	O
tumorigenesis	O
.	O

Altogether	O
,	O
we	O
confirm	O
that	O
all	O
genes	O
of	O
the	O
Rad52	B
recombinational	O
repair	O
pathway	O
are	O
required	O
for	O
the	O
survival	O
of	O
rad27	B
Delta	I
strains	O
at	O
both	O
permissive	O
(	O
23	O
degrees	O
C	O
)	O
and	O
semipermissive	O
(	O
30	O
degrees	O
C	O
)	O
temperatures	O
for	O
growth	O
.	O

We	O
report	O
the	O
results	O
of	O
a	O
detailed	O
policy	O
analysis	O
comparing	O
2	O
CJD	O
-	O
related	O
decisions	O
:	O
a	O
1995	O
recall	O
of	O
blood	O
from	O
a	O
donor	O
with	O
classic	O
CJD	O
and	O
the	O
1999	O
decision	O
to	O
defer	O
donations	O
from	O
individuals	O
with	O
a	O
6-month	O
travel	O
history	O
to	O
the	O
UK	O
between	O
1980	O
and	O
1996	O
due	O
to	O
concerns	O
related	O
to	O
variant	O
CJD	O
.	O

The	O
novel	O
approach	O
to	O
insulin	B
administration	O
known	O
as	O
chronic	O
intermittent	O
intravenous	O
insulin	B
therapy	O
(	O
CIIIT	O
)	O
delivers	O
insulin	B
in	O
a	O
pulsatile	O
fashion	O
and	O
achieves	O
physiological	O
insulin	B
concentration	O
in	O
the	O
portal	O
vein	O
.	O

Breast	O
cancer	O
risk	O
assessment	O
:	O

Who	O
holds	O
the	O
magic	O
crystal	O
ball	O
?	O

In	O
addition	O
,	O
these	O
patients	O
show	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
in	O
their	O
infectious	O
microbiological	O
spectrum	O
,	O
mainly	O
in	O
clean	O
-	O
contaminated	O
,	O
contaminated	O
and	O
dirty	O
surgical	O
procedures	O
.	O

RESULTS	O
:	O
In	O
vivo	O
,	O
there	O
was	O
a	O
wide	O
distribution	O
with	O
the	O
coefficient	O
of	O
variation	O
(	O
SD	O
/	O
mean	O
x	O
100	O
%	O
)	O
for	O
different	O
valve	O
sizes	O
ranging	O
from	O
21	O
%	O
to	O
39	O
%	O
in	O
the	O
St	O
Jude	O
Medical	O
valve	O
and	O
from	O
25	O
%	O
to	O
33	O
%	O
in	O
the	O
Omnicarbon	O
valve	O
.	O

Even	O
if	O
the	O
electrocardiographic	O
signs	O
are	O
subdued	O
,	O
the	O
underlying	O
blockade	O
of	O
I	O
(	O
Kr	O
)	O
current	O
may	O
precipitate	O
the	O
occurrence	O
of	O
arrhythmia	O
.	O

The	O
production	O
of	O
ceramide	O
is	O
emerging	O
as	O
a	O
fixture	O
of	O
programmed	O
cell	O
death	O
.	O

In	O
the	O
further	O
development	O
of	O
bladder	O
neck	O
suspension	O
according	O
to	O
Stamey	O
-	O
Pereyra	O
,	O
the	O
use	O
of	O
miniature	O
bone	O
anchors	O
received	O
considerable	O
support	O
.	O

Moreover	O
,	O
elderly	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
below	O
the	O
median	O
[	O
40	O
pmol	O
/	O
liter	O
(	O
11	O
pg	O
/	O
ml	O
)	O
]	O
had	O
significantly	O
higher	O
rates	O
of	O
bone	O
loss	O
and	O
levels	O
of	O
bone	O
resorption	O
markers	O
than	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
above	O
40	O
pmol	O
/	O
liter	O
.	O

Forced	O
expression	O
of	O
BZAP45	B
strongly	O
stimulates	O
H4	B
promoter	I
(	O
nt	O
-215	O
to	O
-1	O
)	O
/	O
CAT	B
reporter	O
gene	O
activity	O
.	O

No	O
mutation	O
of	O
the	O
NRL	B
gene	I
was	O
found	O
in	O
any	O
of	O
the	O
two	O
families	O
.	O

The	O
deubiquitinating	O
enzyme	O
DUB-2	B
is	O
induced	O
in	O
response	O
to	O
IL-2	B
but	O
as	O
yet	O
its	O
function	O
has	O
not	O
been	O
determined	O
.	O

Cardiac	O
output	O
at	O
anaerobic	O
threshold	O
(	O
COAT	O
)	O
<	O
or	O
=	O
7.3	O
L	O
/	O
min	O
was	O
the	O
best	O
cutoff	O
value	O
for	O
identifying	O
multivessel	O
coronary	O
artery	O
disease	O
(	O
relative	O
risk	O
,	O
3.1	O
)	O
.	O

In	O
conclusion	O
,	O
NF	B
-	I
Y	I
and	O
Sp1	B
binding	O
sites	O
play	O
a	O
decisive	O
role	O
in	O
the	O
basal	O
expression	O
of	O
the	O
rat	B
mrp2	I
gene	I
,	O
while	O
the	O
human	B
MRP2	I
gene	I
is	O
regulated	O
differently	O
.	O

NB-506	O
completely	O
inhibits	O
the	O
capacity	O
of	O
topoisomerase	B
I	I
to	O
phosphorylate	O
,	O
in	O
vitro	O
,	O
the	O
human	B
splicing	I
factor	I
2	I
/	O
alternative	B
splicing	I
factor	I
(	O
SF2	B
/	O
ASF	B
)	O
.	O

A	O
split	O
motor	O
domain	O
in	O
a	O
cytoplasmic	B
dynein	I
.	O

In	O
hypertensive	O
nephrosclerosis	O
,	O
therapy	O
containing	O
an	O
ACEI	O
alone	O
or	O
in	O
combination	O
significantly	O
reduces	O
the	O
incidence	O
of	O
renal	O
events	O
.	O

Body	O
weight	O
reduction	O
increases	O
insulin	B
sensitivity	O
and	O
improves	O
both	O
blood	O
glucose	O
and	O
blood	O
pressure	O
control	O
.	O

The	O
best	O
regression	O
model	O
for	O
predicting	O
changes	O
in	O
the	O
WCXR	O
included	O
time	O
to	O
first	O
positive	O
culture	O
and	O
antibody	O
titer	O
for	O
Pa	B
elastase	I
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
an	O
initial	O
study	O
on	O
the	O
application	O
of	O
linear	O
solvation	O
energy	O
relationships	O
(	O
LSERs	O
)	O
to	O
the	O
prediction	O
of	O
internal	O
standard	O
compounds	O
in	O
reversed	O
-	O
phase	O
liquid	O
chromatographic	O
(	O
RPLC	O
)	O
method	O
development	O
.	O

In	O
the	O
TVD	O
-	O
patients	O
decreases	O
in	O
skin	O
blood	O
flow	O
were	O
similar	O
compared	O
with	O
the	O
healthy	O
controls	O
.	O

In	O
Exp	O
.	O

Several	O
distinct	O
apoptotic	O
stimuli	O
induce	O
the	O
expression	O
and	O
caspase	B
-	O
dependent	O
cleavage	O
of	O
hTAF	B
(	I
II	I
)	I
80	I
delta	I
.	O

hTAF	B
(	I
II	I
)	I
80	I
delta	I
,	O
unlike	O
hTAF	B
(	I
II	I
)	I
80	I
,	O
forms	O
a	O
TFIID	B
-	I
like	I
complex	I
lacking	O
hTAF	B
(	I
II	I
)	I
31	I
.	O

Paul	O
Monagle	O
addresses	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
outside	O
of	O
the	O
central	O
nervous	O
system	O
in	O
both	O
arterial	O
and	O
venous	O
locations	O
,	O
and	O
those	O
that	O
occur	O
in	O
utero	O
.	O

Saunders	O
Company	O
.	O

Effects	O
of	O
activating	O
blood	O
circulation	O
to	O
remove	O
blood	O
stasis	O
on	O
barrier	O
action	O
of	O
gastric	O
wall	O
in	O
chronic	O
atrophic	O
gastritis	O

Schistosoma	O
mansoni	O
schistosomiasis	O
]	O

Schistosomosis	O
are	O
parasitic	O
diseases	O
caused	O
by	O
blood	O
flukes	O
of	O
the	O
Schistosoma	O
genus	O
.	O

Since	O
functional	O
characteristics	O
for	O
profilin	B
II	I
are	O
lacking	O
,	O
we	O
assayed	O
the	O
actin	B
,	O
the	O
phosphatidylinositol	O
4,5-bisphosphate	O
and	O
the	O
poly	O
(	O
L	O
-	O
proline	O
)	O
binding	O
properties	O
of	O
this	B
isoform	I
.	O

Since	O
our	O
earlier	O
studies	O
of	O
Acanthamoeba	O
profilins	B
suggested	O
the	O
importance	O
of	O
PIP2	O
binding	O
for	O
suppression	O
,	O
we	O
conclude	O
that	O
both	O
activities	O
are	O
implicated	O
and	O
that	O
an	O
interplay	O
between	O
PIP2	O
binding	O
and	O
actin	B
binding	O
may	O
be	O
important	O
for	O
profilin	B
function	O
.	O

Since	O
the	O
NH2	O
terminus	O
of	O
profilin	B
is	O
blocked	O
,	O
Edman	O
degradation	O
gave	O
only	O
the	O
sequence	O
of	O
the	O
conjugated	O
actin	B
CNBr	O
fragment	O
beginning	O
with	O
Trp-356	O
.	O

Single	O
-	O
headed	O
myosin	O
,	O
which	O
consists	O
of	O
a	O
full	O
length	O
myosin	B
heavy	I
chain	I
and	O
a	O
tagged	O
tail	O
,	O
was	O
isolated	O
on	O
the	O
basis	O
of	O
the	O
affinities	O
for	O
Nickel	O
agarose	O
and	O
actin	B
.	O

Smooth	B
muscle	I
alpha	I
actin	I
and	O
myosin	B
heavy	I
chain	I
expression	O
in	O
the	O
vascular	O
smooth	O
muscle	O
cells	O
surrounding	O
human	O
endometrial	O
arterioles	O
.	O

Smooth	B
muscle	I
talin	I
prepared	O
from	O
chicken	O
gizzard	O
binds	O
to	O
skeletal	B
muscle	I
actin	I
in	O
vitro	O
.	O

So	O
far	O
,	O
three	O
ligands	O
for	O
profilin	B
have	O
been	O
well	O
-	O
characterized	O
in	O
vitro	O
:	O
actin	B
monomers	I
,	O
membrane	O
polyphosphoinositides	O
and	O
poly	O
-	O
L	O
-	O
proline	O
.	O

Specific	O
antibodies	O
to	O
myosin	B
heavy	I
chain	I
isoforms	B
(	O
SM1	B
,	O
SM2	B
,	O
SMemb	B
)	O
,	O
caldesmon	B
,	O
and	O
alpha	B
-	I
smooth	I
muscle	I
actin	I
and	O
cDNAs	O
for	O
SMemb	B
were	O
used	O
.	O

Specific	O
interaction	O
between	O
the	O
nucleocapsid	B
protein	I
(	O
N	B
)	O
and	O
the	O
phosphoprotein	B
(	O
P	B
)	O
of	B
vesicular	I
stomatitis	I
virus	I
(	O
VSV	O
)	O
,	O
an	O
important	O
step	O
in	O
the	O
life	O
-	O
cycle	O
of	O
the	O
virus	O
,	O
was	O
studied	O
by	O
using	O
a	O
two	O
-	O
hybrid	O
system	O
.	O

Specific	O
interactions	O
between	O
the	O
nucleocapsid	B
protein	I
(	O
N	B
)	O
and	O
the	O
phosphoprotein	B
(	O
P	B
)	O
of	B
bovine	I
respiratory	I
syncytial	I
virus	I
(	O
BRSV	O
)	O
have	O
been	O
investigated	O
using	O
a	O
yeast	O
-	O
based	O
two	O
-	O
hybrid	O
system	O
.	O

Specific	O
interactions	O
between	O
the	O
human	B
RAD51	I
and	O
RAD52	B
proteins	B
.	O

Spontaneous	O
and	O
mitomycin	O
C	O
-	O
induced	O
SCE	O
levels	O
were	O
significantly	O
reduced	O
for	O
chicken	O
DT40	O
B	O
cells	O
lacking	O
the	O
key	O
HR	O
genes	O
RAD51	B
and	O
RAD54	B
but	O
not	O
for	O
nonhomologous	O
DNA	O
end	O
-	O
joining	O
(	O
NHEJ	O
)	O
-defective	O
KU70	O
(	O
-	O
/	O
-	O
)	O
cells	O
.	O

Stable	O
transfection	O
of	O
mutant	O
plakoglobin	B
molecules	B
showed	O
that	O
deletion	O
of	O
the	O
N	B
-	I
cadherin	I
binding	O
domain	O
,	O
but	O
not	O
the	O
alpha	B
-	I
catenin	I
binding	O
domain	O
,	O
abolished	O
beta	B
-	I
catenin	I
downregulation	O
.	O

Stimulus	O
-	O
dependent	O
disorganization	O
of	O
actin	B
filaments	O
induced	O
by	O
overexpression	O
of	O
cofilin	B
in	O
C2	O
myoblasts	O
.	O

Structural	O
studies	O
on	O
the	O
ribbon	O
-	O
to	O
-	O
helix	O
transition	O
in	O
profilin	B
:	O
actin	B
crystals	O
.	O

Studies	O
on	O
cultured	O
cells	O
have	O
suggested	O
that	O
both	O
alpha	B
-	I
catenin	I
and	O
plakoglobin	B
are	O
important	O
for	O
the	O
adhesive	O
function	O
of	O
cadherins	O
.	O

Studies	O
on	O
the	O
interaction	O
between	O
actin	B
and	O
cofilin	B
purified	O
by	O
a	O
new	O
method	O
.	O

Study	O
of	O
mutated	O
yeast	O
profilins	B
and	O
profilins	B
from	O
Acanthamoeba	O
suggests	O
that	O
the	O
ability	O
of	O
profilin	B
to	O
suppress	O
cap-	B
cells	O
is	O
dependent	O
upon	O
a	O
property	O
other	O
than	O
,	O
or	O
in	O
addition	O
to	O
,	O
its	B
ability	O
to	O
bind	O
actin	B
.	O

Such	O
motifs	O
are	O
known	O
to	O
bind	O
to	O
profilins	O
(	O
PFNs	O
)	O
,	O
small	O
proteins	O
engaged	O
in	O
the	O
control	O
of	O
actin	B
dynamics	O
.	O

Suppression	O
of	O
cell	O
transformation	O
by	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p57KIP2	B
requires	O
binding	O
to	O
proliferating	B
cell	I
nuclear	I
antigen	I
.	O

Surprisingly	O
,	O
although	O
maintained	O
in	O
mitogen	O
-	O
rich	O
medium	O
,	O
this	O
ectopic	O
expression	O
was	O
associated	O
with	O
a	O
transactivation	O
of	O
the	O
endogenous	O
myogenin	B
and	O
myosin	B
light	I
chain	I
2	I
gene	O
but	O
not	O
the	O
endogenous	O
MyoD1	B
,	O
MRF4	B
,	O
Myf5	B
,	O
the	O
skeletal	B
muscle	I
actin	I
,	O
or	O
the	O
myosin	B
heavy	I
chain	I
genes	O
.	O

Targeting	O
by	O
antisense	O
3'UTI	O
significantly	O
increased	O
motility	O
compared	O
with	O
the	O
corresponding	O
sense	O
ODN	O
.	O

alpha	B
-	I
Sm	I
actin	I
inhibition	O
also	O
led	O
to	O
the	O
formation	O
of	O
less	O
prominent	O
focal	O
adhesions	O
as	O
revealed	O
by	O
immunofluorescence	O
staining	O
against	O
vinculin	B
,	O
talin	B
,	O
and	O
beta1-integrin	B
.	O

Testicular	B
protein	I
kinase	I
1	I
(	O
TESK1	B
)	O
is	O
a	O
serine	O
/	O
threonine	O
kinase	O
highly	O
expressed	O
in	O
testicular	O
germ	O
cells	O
and	O
has	O
the	O
potential	O
to	O
phosphorylate	O
cofilin	B
and	O
induce	O
actin	B
cytoskeletal	O
reorganization	O
.	O

The	O
16236	O
nt	O
genome	O
encodes	O
eight	O
proteins	O
,	O
nucleocapsid	B
protein	I
(	O
NP	B
)	O
,	O
phosphoprotein	B
(	O
P	B
)	O
,	O
V	B
protein	I
,	O
matrix	B
protein	I
(	O
M	B
)	O
,	O
fusion	B
protein	I
(	O
F	B
)	O
,	O
small	B
hydrophobic	I
(	O
SH	B
)	O
protein	B
,	O
haemagglutinin	B
-	I
neuraminidase	I
(	O
HN	B
)	O
protein	B
and	O
large	B
(	O
L	B
)	O
protein	B
,	O
which	O
are	O
flanked	O
by	O
a	O
55	O
nt	O
leader	O
sequence	O
and	O
a	O
54	O
nt	O
trailer	O
sequence	O
.	O

The	O
actin	O
-	O
binding	O
protein	O
profilin	B
binds	O
to	O
PIP2	O
and	O
inhibits	O
its	O
hydrolysis	O
by	O
phospholipase	B
C	I
.	O

The	O
actin	O
-	O
binding	O
protein	O
profilin	B
was	O
isolated	O
from	O
Tetrahymena	O
thermophila	O
by	O
affinity	O
chromatography	O
,	O
and	O
the	O
peptide	O
sequence	O
was	O
determined	O
for	O
part	O
of	O
the	O
protein	O
.	O

act1	B
-	I
157	I
,	O
an	O
actin	B
mutant	O
with	O
an	O
increased	O
intrinsic	O
rate	O
of	O
nucleotide	O
exchange	O
,	O
suppressed	O
defects	O
in	O
actin	B
organization	O
,	O
cell	O
growth	O
,	O
and	O
fluid	O
-	O
phase	O
endocytosis	O
of	O
pfy1	B
-	I
4	I
,	O
a	O
profilin	B
mutant	O
defective	O
in	O
actin	B
binding	O
.	O

The	O
actin	B
bundle	O
formation	O
induced	O
by	O
overexpression	O
of	O
cofilin	B
is	O
accompanied	O
with	O
an	O
increase	O
in	O
cell	O
motility	O
of	O
Dictyostelium	O
cells	O
.	O

4	O
.	O

The	O
actin	B
cytoskeleton	O
-	O
associated	O
protein	B
talin	I
binds	O
to	O
integrins	B
,	O
vinculin	B
,	O
and	O
actin	B
.	O

The	O
actin	B
monomer	B
-	I
binding	I
protein	O
,	O
profilin	B
,	O
influences	O
the	O
dynamics	O
of	O
actin	B
filaments	O
in	O
vitro	O
by	O
suppressing	O
nucleation	O
,	O
enhancing	O
nucleotide	O
exchange	O
on	O
actin	B
,	O
and	O
promoting	O
barbed	O
-	O
end	O
assembly	O
.	O

The	O
actin	B
-	I
sequestering	I
activity	O
of	O
both	O
maize	B
profilin	I
classes	O
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
concentration	O
of	O
free	O
calcium	O
.	O

The	O
alpha	B
-	I
catenin	I
molecule	B
links	O
E	B
-	I
cadherin	I
/	O
beta	B
-	I
catenin	I
or	O
E	B
-	I
cadherin	I
/	I
plakoglobin	I
complexes	O
to	O
the	O
actin	B
cytoskeleton	O
.	O

The	O
ability	O
of	O
these	O
three	O
mutant	O
UL5	B
proteins	B
to	O
form	O
specific	O
interactions	O
with	O
other	O
members	O
of	O
the	O
helicase	O
-	O
primase	O
complex	O
,	O
UL8	B
and	O
UL52	B
,	O
indicates	O
that	O
the	O
functional	O
domains	O
required	O
for	O
replication	O
activity	O
of	O
UL5	B
are	O
separable	O
from	O
domains	O
responsible	O
for	O
protein	O
-	O
protein	O
interactions	O
.	O

The	O
ability	O
of	O
WIP	B
to	O
replace	O
verprolin	B
is	O
dependent	O
on	O
its	B
WH2	O
actin	B
binding	O
domain	O
and	O
a	O
putative	O
profilin	B
binding	O
domain	O
.	O

The	O
cellular	O
tumor	O
antigen	B
p53	I
is	O
bound	O
to	O
the	O
simian	B
virus	I
40	I
(	O
SV40	O
)	O
large	B
T	I
-	I
antigen	I
in	O
SV40-infected	O
and	O
-transformed	O
cells	O
.	O

The	O
CREB	B
binding	O
domain	O
of	O
CBP	B
is	O
sufficient	O
to	O
contact	O
to	O
c	B
-	I
Jun	I
in	O
vitro	O
.	O

The	O
activation	O
of	O
the	O
c	B
-	I
Raf-1-BxB	I
-	I
ER	I
protein	O
leads	O
to	O
an	O
accumulation	O
of	O
high	O
levels	O
of	O
cyclin	B
D1	I
protein	B
and	O
a	O
repression	O
of	O
the	O
p27Kip1	B
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
under	O
all	O
culture	O
conditions	O
tested	O
.	O

The	O
adventitial	O
tissue	O
underlying	O
PTCA	O
-	O
induced	O
lesions	O
temporarily	O
expressed	O
alpha	B
-	I
SM	I
actin	I
,	O
desmin	B
,	O
and	O
SM	B
myosin	I
heavy	I
chain	I
isoforms	O
,	O
but	O
not	O
smoothelin	B
.	O

The	O
affinity	O
of	O
yeast	B
profilin	I
for	O
rabbit	B
actin	I
(	O
2.9	O
microM	O
)	O
is	O
approximately	O
30-fold	O
weaker	O
than	O
the	O
affinity	O
of	O
human	B
platelet	I
profilin	I
for	O
rabbit	B
actin	I
(	O
0.1	O
microM	O
)	O
,	O
and	O
the	O
relative	O
contributions	O
of	O
entropic	O
and	O
enthalpic	O
terms	O
to	O
the	O
overall	O
free	O
energy	O
of	O
binding	O
are	O
different	O
for	O
the	O
two	O
profilins	B
.	O

The	O
affinity	O
of	O
ZmPRO4	B
for	O
monomeric	O
actin	B
,	O
which	O
was	O
measured	O
by	O
two	O
independent	O
methods	O
,	O
is	O
similar	O
to	O
that	O
of	O
the	O
three	O
profilin	B
isoforms	I
previously	O
identified	O
in	O
pollen	O
.	O

The	O
aim	O
of	O
our	O
study	O
on	O
human	O
seminiferous	O
tubules	O
of	O
adolescent	O
testes	O
was	O
to	O
study	O
the	O
localization	O
of	O
two	O
actin	B
-	I
associated	I
proteins	O
of	O
the	O
adherens	O
junctions	O
,	O
such	O
as	O
vinculin	B
and	O
talin	B
,	O
and	O
to	O
verify	O
if	O
there	O
were	O
modifications	O
in	O
their	O
pattern	O
in	O
varicocele	O
,	O
a	O
frequent	O
disease	O
of	O
the	O
testis	O
in	O
adolescent	O
age	O
.	O

The	O
amino	O
acid	O
composition	O
of	O
the	O
15-kDa	O
protein	O
was	O
similar	O
to	O
that	O
of	O
mammalian	O
profilin	B
and	O
it	O
inhibited	O
the	O
salt	O
-	O
induced	O
polymerization	O
of	O
rabbit	O
skeletal	B
muscle	I
actin	I
.	O

The	O
amount	O
of	O
unassembled	O
actin	B
(	O
12	O
microM	O
)	O
is	O
accounted	O
for	O
by	O
the	O
sequestering	O
functions	O
of	O
T	B
beta	I
4Xen	I
(	O
20	O
microM	O
)	O
and	O
profilin	B
(	O
5	O
microM	O
)	O
,	O
the	O
barbed	O
ends	O
being	O
capped	O
.	O

The	O
analysis	O
of	O
the	O
viral	O
proteins	O
by	O
electrophoresis	O
indicates	O
molecular	O
weight	O
differences	O
between	O
CDV	O
and	O
PDV	O
in	O
the	O
fusion	B
(	O
F	B
)	O
,	O
phosphoprotein	B
(	O
P	B
)	O
,	O
H	B
,	O
nucleocapsid	B
(	O
N	B
)	O
and	O
matrix	B
(	O
M	B
)	O
proteins	B
.	O

The	O
APC	B
binding	O
site	O
on	O
beta	B
-	I
catenin	I
may	O
be	O
discontinuous	O
since	O
neither	O
the	O
carboxyl-	O
nor	O
amino	O
-	O
terminal	O
halves	O
of	O
beta	B
-	I
catenin	I
will	O
independently	O
associate	O
with	O
APC	B
,	O
although	O
the	O
amino	O
-	O
terminal	O
half	O
independently	O
binds	O
alpha	B
-	I
catenin	I
.	O

The	O
APC	B
protein	B
and	O
E	B
-	I
cadherin	I
form	O
similar	O
but	O
independent	O
complexes	O
with	O
alpha	B
-	I
catenin	I
,	O
beta	B
-	I
catenin	I
,	O
and	O
plakoglobin	B
.	O

The	O
apparent	O
critical	O
concentration	O
for	O
polymerization	O
of	O
actin	B
is	O
increased	O
by	O
the	O
addition	O
of	O
profilin	B
.	O

The	O
PRT1	B
,	O
TIF34	B
,	O
GCD10	B
,	O
and	O
SUI1	B
proteins	O
of	O
Saccharomyces	O
cerevisiae	O
were	O
found	O
previously	O
to	O
copurify	O
with	O
eukaryotic	B
translation	I
initiation	I
factor	I
3	I
(	O
eIF3	B
)	O
activity	O
.	O

The	O
RAD51-interacting	B
region	O
(	O
amino	O
acids	O
291	O
-	O
330	O
)	O
of	O
the	O
human	B
RAD52	I
protein	I
shows	O
no	O
homology	O
with	O
the	O
yeast	B
RAD52	I
protein	I
,	O
indicating	O
that	O
the	O
interaction	O
between	O
RAD51	B
and	O
RAD52	B
is	O
species	O
-	O
specific	O
.	O

The	O
Arp2	B
/	I
3	I
complex	O
,	O
first	O
isolated	O
from	O
Acanthamoeba	O
castellani	O
by	O
affinity	O
chromatography	O
on	O
profilin	B
,	O
consists	O
of	O
seven	O
polypeptides	O
;	O
two	O
actin	B
-	I
related	I
proteins	O
,	O
Arp2	B
and	O
Arp3	B
;	O
and	O
five	O
apparently	O
novel	O
proteins	O
,	O
p40	B
,	O
p35	B
,	O
p19	B
,	O
p18	B
,	O
and	O
p14	B
(	O
Machesky	O
et	O
al.	O
,	O
1994	O
)	O
.	O

The	O
Arp2	B
/	I
3	I
complex	O
with	O
full	O
-	O
length	O
Scar	B
,	O
Scar	B
containing	O
P	O
,	O
W	O
,	O
and	O
A	O
domains	O
,	O
or	O
Scar	B
containing	O
W	O
and	O
A	O
domains	O
overcomes	O
inhibition	O
of	O
nucleation	O
by	O
the	O
actin	B
monomer	I
-	I
binding	I
protein	B
profilin	I
,	O
giving	O
active	O
nucleation	O
over	O
a	O
low	O
background	O
of	O
spontaneous	O
nucleation	O
.	O

The	O
assay	O
detects	O
the	O
high	O
-	O
affinity	O
binding	O
of	O
actin	B
to	O
actin	B
-	I
binding	I
proteins	I
(	O
ABPs	B
)	O
,	O
cofilin	B
or	O
DNase	B
I	I
.	O

The	O
assembly	O
of	O
complete	O
HSV	O
replication	O
compartments	O
and	O
incorporation	O
of	O
BrdU	O
were	O
both	O
abolished	O
by	O
treatment	O
with	O
phosphonoacetic	O
acid	O
(	O
PAA	O
)	O
and	O
by	O
omission	O
of	O
any	O
one	O
of	O
the	O
seven	O
viral	O
replication	O
proteins	O
,	O
UL5	B
,	O
UL8	B
,	O
UL9	B
,	O
UL42	B
,	O
UL52	B
,	O
SSB	B
,	O
and	O
Pol	B
,	O
that	O
are	O
essential	O
for	O
viral	O
DNA	O
replication	O
.	O

The	O
UL8	B
component	O
of	O
the	O
herpes	O
simplex	O
virus	O
helicase	O
-	O
primase	O
complex	O
stimulates	O
primer	O
synthesis	O
by	O
a	O
subassembly	O
of	O
the	O
UL5	B
and	O
UL52	B
components	B
.	O

The	O
AV	O
nodal	O
effects	O
of	O
draflazine	O
,	O
ITU	O
,	O
EHNA	O
,	O
and	O
PD81,723	O
were	O
reversed	O
by	O
the	O
A1	B
adenosine	I
receptor	I
antagonist	O
8-cyclopentyltheophylline	O
and	O
adenosine	B
deaminase	I
,	O
implicating	O
endogenous	O
adenosine	O
acting	O
at	O
the	O
A1	B
adenosine	I
receptor	I
.	O

The	O
adenosine	B
deaminase	I
-	I
binding	I
region	O
is	O
distinct	O
from	O
major	O
anti	B
-	I
CD26	I
mAb	O
epitopes	O
on	O
the	O
human	B
dipeptidyl	I
peptidase	I
IV	I
(	I
CD26	I
)	I
molecule	I
.	O

cDNA	O
cloning	O
,	O
heterologous	O
expression	O
,	O
and	O
actin	B
-	I
binding	I
properties	O
.	O

The	O
cofilin	B
homology	O
sequence	O
is	O
critical	O
for	O
stimulating	O
actin	B
nucleation	O
with	O
the	O
Arp2	B
/	I
3	I
complex	O
in	O
vitro	O
,	O
and	O
is	O
essential	O
for	O
actin	B
polymerization	O
and	O
motility	O
in	O
cells	O
.	O

The	O
binding	O
constants	O
of	O
Acanthamoeba	B
profilin	I
to	O
fluorescein	O
-	O
labeled	O
actin	B
from	B
Acanthamoeba	I
and	O
from	B
rabbit	I
skeletal	I
muscle	I
have	O
been	O
determined	O
by	O
measuring	O
the	O
reduction	O
in	O
the	O
actin	B
tracer	O
diffusion	O
coefficients	O
,	O
determined	O
by	O
fluorescence	O
photobleaching	O
recovery	O
,	O
as	O
a	O
function	O
of	O
added	O
profilin	B
concentration	O
.	O

The	O
binding	O
of	O
125I	O
-	O
labeled	O
recombinant	O
birch	B
pollen	I
profilin	I
to	O
plant	B
and	O
animal	B
actins	I
can	O
be	O
blocked	O
by	O
profilin	B
-	I
specific	I
antibodies	O
that	O
react	O
with	O
different	O
epitopes	O
of	O
birch	B
profilin	I
.	O

The	O
binding	O
surfaces	O
for	O
segment	O
1	O
and	O
profilin	B
are	O
different	O
,	O
although	O
they	O
peripherally	O
overlap	O
on	O
actin	B
.	O

The	O
myosin	B
heavy	I
chain	I
(	O
MHC	B
)	O
contains	O
the	O
actin-	B
and	O
ATP	O
-	O
binding	O
sites	O
and	O
represents	O
the	O
molecular	O
motor	O
of	O
muscle	O
contraction	O
.	O

The	O
phosphoprotein	B
(	O
P	B
)	O
of	B
vesicular	I
stomatitis	I
virus	I
(	O
VSV	O
)	O
serotypes	B
New	B
Jersey	I
[	O
P	B
(	I
NJ	I
)	I
]	O
and	O
Indiana	B
[	O
P	B
(	I
I	I
)	I
]	O
contains	O
a	O
highly	O
conserved	O
carboxy	O
-	O
terminal	O
domain	O
which	O
is	O
required	O
for	O
binding	O
to	O
the	O
cognate	O
N	O
-	O
RNA	O
template	O
as	O
well	O
as	O
to	O
form	O
a	O
soluble	O
complex	O
with	O
the	O
nucleocapsid	O
protein	O
N	B
in	O
vivo	O
.	O

The	O
RAD54	B
and	O
RAD51	B
genes	O
are	O
involved	O
in	O
genetic	O
recombination	O
and	O
double	O
-	O
strand	O
break	O
repair	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
talin	B
dimer	O
,	O
which	O
is	O
crucial	O
for	O
actin	B
and	O
lipid	O
binding	O
,	O
is	O
built	O
of	O
a	O
backbone	O
containing	O
the	O
200	O
kDa	O
rod	O
portions	O
,	O
at	O
both	O
ends	O
of	O
which	O
a	O
47	O
kDa	O
globular	O
domain	O
is	O
attached	O
.	O

The	O
verprolin	B
-	I
like	I
central	O
(	O
vc	O
)	O
region	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	I
induces	O
Arp2	B
/	I
3	I
complex	O
-	O
dependent	O
actin	B
nucleation	O
.	O

The	O
C374S	O
mutation	O
had	O
the	O
most	O
pronounced	O
effect	O
;	O
it	O
reduced	O
the	O
polymerizability	O
of	O
the	O
actin	B
,	O
abolished	O
its	B
binding	O
to	O
profilin	B
,	O
and	O
filaments	O
containing	O
this	O
mutation	O
moved	O
at	O
reduced	O
rates	O
in	O
the	O
in	O
vitro	O
motility	O
assay	O
.	O

The	O
cadherin	B
-	I
associated	I
proteins	O
,	O
alpha	B
-	I
catenin	I
and	O
beta	B
-	I
catenin	I
,	O
were	O
present	O
in	O
both	O
mesotheliomas	O
and	O
adenocarcinomas	O
.	O

The	O
cardiac	B
myosin	I
heavy	I
chain	I
Arg-403	O
--	O
>	O
Gln	O
mutation	O
that	O
causes	O
hypertrophic	O
cardiomyopathy	O
does	O
not	O
affect	O
the	O
actin-	B
or	O
ATP	O
-	O
binding	O
capacities	O
of	O
two	O
size	O
-	O
limited	O
recombinant	O
myosin	B
heavy	I
chain	I
fragments	O
.	O

The	O
cardiac	B
ventricular	I
myosin	I
heavy	I
chain	I
phenotype	O
is	O
developmentally	O
and	O
hormonally	O
regulated	O
,	O
but	O
less	O
is	O
known	O
concerning	O
the	O
actin	B
phenotype	O
.	O

The	O
cellular	O
concentrations	O
and	O
binding	O
characteristics	O
of	O
these	O
molecules	O
are	O
consistent	O
with	O
profilin	B
being	O
a	O
negative	O
regulator	O
of	O
the	O
phosphoinositide	O
signaling	O
pathway	O
in	O
addition	O
to	O
its	B
established	O
function	O
as	O
an	O
inhibitor	O
of	O
actin	B
polymerization	O
.	O

The	O
cellular	O
morphological	O
changes	O
were	O
analyzed	O
and	O
correlated	O
with	O
the	O
distribution	O
of	O
cell	O
-	O
substratum	O
contacts	O
viewed	O
by	O
confocal	O
images	O
obtained	O
after	O
immunostaining	O
with	O
antibodies	O
raised	O
against	O
the	O
fibronectin	B
receptor	I
,	O
talin	B
,	O
vinculin	B
and	O
actin	B
.	O

The	O
cellular	O
transcription	O
co	B
-	I
activators	I
p300	B
and	O
the	O
CREB	O
-	O
binding	O
protein	O
CBP	B
are	O
cellular	O
targets	O
for	O
transformation	O
by	O
the	O
E1A	B
proteins	I
of	O
non	O
-	O
oncogenic	O
adenovirus	O
5	O
(	O
Ad5	O
)	O
.	O

The	O
centrifugation	O
assay	O
and	O
the	O
DNase	B
I	I
inhibition	O
assay	O
demonstrate	O
that	O
cofilin	B
binds	O
to	O
actin	B
filaments	O
in	O
a	O
1:1	O
molar	O
ratio	O
of	O
cofilin	B
to	O
actin	B
monomer	O
in	O
the	O
filament	O
and	O
that	O
cofilin	B
increases	O
the	O
monomeric	O
actin	B
to	O
a	O
limited	O
extent	O
(	O
up	O
to	O
1.1	O
-	O
1.5	O
microM	O
monomer	O
)	O
in	O
the	O
presence	O
of	O
physiological	O
concentrations	O
of	O
Mg2	O
+	O
and	O
KCl	O
.	O

The	O
characteristics	O
of	O
the	O
vitamin	B
D	I
-	I
binding	I
protein	I
and	O
profilin	B
interactions	O
with	O
actin	B
are	O
similar	O
.	O

The	O
clone	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
139	O
amino	O
acid	O
residues	O
which	O
shows	O
greater	O
than	O
40	O
%	O
sequence	O
identity	O
in	O
a	O
91	O
amino	O
acid	O
overlap	O
to	O
animal	O
actin	B
-	I
depolymerizing	I
factors	I
(	O
ADF	B
)	O
,	O
cofilin	B
and	O
destrin	B
.	O

The	O
colocalization	O
of	O
gelsolin	B
and	O
profilin	B
in	O
motile	O
,	O
microfilament	O
-	O
rich	O
areas	O
supports	O
the	O
hypothesis	O
that	O
they	B
synergistically	O
regulate	O
the	O
actin	B
dynamics	O
that	O
underlie	O
neurite	O
growth	O
.	O

The	O
common	O
denominator	O
is	O
impaired	O
beta	B
-	I
catenin	I
association	O
with	O
either	O
E	B
-	I
cadherin	I
(	O
PaTuII	O
)	O
or	O
alpha	B
-	I
catenin	I
(	O
BxPc3	O
and	O
T3M4	O
)	O
.	O

The	O
comparison	O
of	O
E	B
-	I
CD	I
proteins	B
synthesized	O
by	O
E62	O
and	O
E24	O
cell	O
lines	O
revealed	O
no	O
structural	O
or	O
functional	O
differences	O
because	O
both	B
localized	O
at	O
cell	O
-	O
cell	O
contacts	O
and	O
associated	O
with	O
alpha	B
-	I
catenin	I
,	O
beta	B
-	I
catenin	I
,	O
and	O
plakoglobin	B
.	O

The	O
concentration	O
of	O
beta	B
-	I
catenin	I
was	O
constant	O
during	O
the	O
follicular	O
phase	O
,	O
whereas	O
the	O
content	O
of	O
alpha	B
-	I
catenin	I
decreased	O
in	O
granulosa	O
cells	O
after	O
treatment	O
with	O
diethylstilboestrol	O
or	O
hCG	O
.	O

The	O
contents	O
of	O
myosin	B
heavy	I
chain	I
,	O
myosin	B
light	I
chain	I
2	I
,	O
actin	B
,	O
troponin	B
-	I
I	I
in	O
125-week	O
-	O
old	O
rats	O
decreased	O
compared	O
with	O
those	O
of	O
12-week	O
-	O
old	O
rats	O
.	O

The	O
core	O
histones	B
from	B
Physarum	I
,	O
histones	B
H2A	B
,	O
H2B	B
,	O
H3	B
,	O
and	O
H4	B
,	O
are	O
rapidly	O
acetylated	O
;	O
histone	O
H4	B
shows	O
five	O
subfractions	O
,	O
analogous	O
to	O
the	O
five	O
subfractions	O
of	O
mammalian	O
histone	O
H4	B
(	O
containing	O
zero	O
to	O
four	O
acetyllysine	O
residues	O
per	O
molecule	O
)	O
;	O
histone	O
H3	B
has	O
a	O
more	O
complex	O
pattern	O
that	O
we	O
interpret	O
as	O
zero	O
to	O
four	O
acetyllysine	O
residues	O
on	O
each	O
of	O
two	O
sequence	O
variants	O
of	O
histone	O
H3	B
;	O
histones	B
H2A	B
and	O
H2B	B
show	O
less	O
heterogeneity	O
.	O

The	O
core	O
,	O
isolated	O
in	O
the	O
absence	O
of	O
free	O
Ca2	O
+	O
,	O
contains	O
five	O
major	O
proteins	O
:	O
the	O
actin	B
(	O
Mr	O
43	O
000	O
)	O
that	O
makes	O
up	O
the	O
filaments	O
,	O
the	O
villin	B
(	O
Mr	O
95	O
000	O
)	O
and	O
fimbrin	B
(	O
Mr	O
68	O
000	O
)	O
that	O
cross	O
-	O
link	O
the	O
filaments	O
together	O
,	O
and	O
the	O
110	O
000	O
Mr	O
polypeptide	B
-	I
calmodulin	I
complex	O
that	O
makes	O
up	O
cross	O
-	O
filaments	O
which	O
project	O
laterally	O
from	O
the	O
core	O
and	O
link	O
it	O
to	O
the	O
inner	O
surface	O
of	O
the	O
microvillus	O
membrane	O
.	O

The	O
C	O
-	O
terminal	O
of	O
TRADD	B
comprises	O
the	O
death	O
domain	O
that	O
is	O
responsible	O
for	O
association	O
of	O
TNFR1	B
and	O
other	O
death	O
domain	O
-	O
containing	O
proteins	O
such	O
as	O
FADD	B
and	O
RIP	B
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
ORC3	B
was	O
,	O
however	O
,	O
necessary	O
to	O
bring	O
ORC4	B
and	O
ORC5	B
into	O
the	O
core	O
complex	O
.	O

The	O
current	O
view	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
Acanthamoeba	B
profilin	I
is	O
that	O
it	B
binds	O
to	O
actin	B
monomers	I
,	O
forming	O
a	O
complex	O
that	O
can	O
not	O
polymerize	O
[	O
Tobacman	O
,	O
L.	O
S.	O
,	O
&	O
Korn	O
,	O
E.	O
D.	O
(	O
1982	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O

257	O
,	O
4166	O
-	O
4170	O
;	O
Tseng	O
,	O
P.	O
,	O
&	O
Pollard	O
,	O
T.	O
D.	O
(	O
1982	O
)	O
J.	O
Cell	O
Biol	O
.	O

94	O
,	O
213	O
-	O
218	O
;	O
Tobacman	O
,	O
L.	O
S.	O
,	O
Brenner	O
,	O
S.	O
L.	O
,	O
&	O
Korn	O
,	O
E.	O
D.	O
(	O
1983	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
258	O
,	O
8806	O
-	O
8812	O
]	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
E	B
-	I
cadherin	I
can	O
not	O
directly	O
associate	O
with	O
alpha	B
-	I
catenin	I
but	O
interacts	O
with	O
high	O
affinity	O
with	O
beta	B
-	I
catenin	I
,	O
whereas	O
the	O
binding	O
of	O
gamma	B
-	I
catenin	I
(	O
plakoglobin	B
)	O
to	O
E	B
-	I
cadherin	I
is	O
less	O
efficient	O
.	O

alpha-	B
and	O
beta	B
-	I
catenin	I
assemble	O
into	O
a	O
1:1	O
heterodimeric	O
complex	O
.	O

The	O
data	O
suggest	O
that	O
profilin	B
binding	O
to	O
actin	B
weakens	O
nucleotide	O
binding	O
to	O
actin	B
by	O
disrupting	O
Mg	O
(	O
2	O
+	O
)	O
coordination	O
in	O
the	O
actin	B
central	O
cleft	O
.	O

The	O
deduced	O
peptide	O
sequence	O
contained	O
a	O
nuclear	O
localization	O
signal	O
and	O
a	O
putative	O
actin	B
-	I
binding	I
sequence	O
as	O
reported	O
in	O
NM	B
-	I
type	I
cofilin	I
.	O

The	O
differential	O
localization	O
of	O
the	O
three	O
actin	B
monomer	B
-	I
binding	I
proteins	B
suggests	O
that	O
they	B
have	O
different	O
biologic	O
functions	O
in	O
Acanthamoeba	O
and	O
is	O
consistent	O
with	O
the	O
hypotheses	O
that	O
(	O
1	O
)	O
profilin	B
I	I
functions	O
predominantly	O
as	O
an	O
actin	B
monomer	B
-	I
binding	I
protein	O
;	O
(	O
2	O
)	O
profilin	B
II	I
regulates	O
,	O
or	O
is	O
regulated	O
by	O
,	O
PIP2	O
;	O
and	O
(	O
3	O
)	O
actobindin	B
inhibits	O
nucleation	O
of	O
new	O
filaments	O
and	O
facilitates	O
elongation	O
of	O
existing	O
polarized	O
filaments	O
in	O
actively	O
motile	O
regions	O
.	O

The	O
distribution	O
of	O
actin	B
filaments	O
is	O
altered	O
by	O
profilin	B
overexpression	O
.	O

The	O
domain	O
consists	O
of	O
a	O
mixed	O
alpha	O
-	O
helical	O
/	O
beta	O
-	O
sheet	O
fold	O
that	O
resembles	O
a	O
circular	O
permutation	O
of	O
the	O
actin	B
/	I
poly	I
-	I
proline	I
binding	O
protein	O
,	O
profilin	B
,	O
and	O
the	O
GAF	B
/	I
PAS	I
family	O
of	O
regulatory	O
modules	O
.	O

The	O
domains	O
in	O
CBP	B
that	O
are	O
involved	O
in	O
CREB	B
binding	O
and	O
transcriptional	O
activation	O
are	O
highly	O
related	O
to	O
the	O
adenoviral	B
E1A	I
-	I
associated	I
cellular	O
protein	B
p300	I
(	O
refs	O
2	O
,	O
3	O
)	O
,	O
and	O
to	O
two	O
hypothetical	O
proteins	O
from	O
Caenorhabditis	O
elegans	O
,	O
R10E11.1	B
and	O
K03H1.10	B
(	O
refs	O
4	O
and	O
5	O
,	O
respectively	O
)	O
,	O
whose	O
functions	O
are	O
unknown	O
.	O

The	O
drastic	O
effects	O
of	O
the	O
exogenous	O
cofilin	B
on	O
actin	B
assembly	O
were	O
suppressed	O
by	O
phosphatidylinositol	O
4,5-bisphosphate	O
(	O
PIP2	O
)	O
.	O

The	O
E	B
-	I
cadherin	I
-	I
associated	I
proteins	B
alpha	B
-	I
catenin	I
and	O
beta	B
-	I
catenin	I
were	O
not	O
significantly	O
affected	O
by	O
treatment	O
with	O
TPA	B
.	O

The	O
effects	O
of	O
two	O
adhesion	O
substrates	O
(	O
serum	O
and	O
laminin	B
)	O
and	O
time	O
in	O
culture	O
on	O
the	O
expression	O
of	O
genes	B
encoding	I
myosin	B
heavy	I
chain	I
(	O
MHC	B
)	O
isoforms	B
and	O
alpha	B
-	I
skeletal	I
actin	I
were	O
analysed	O
in	O
myocytes	O
isolated	O
from	O
adult	O
rat	O
heart	O
and	O
maintained	O
in	O
serum	O
-	O
free	O
culture	O
.	O

The	O
enzyme	O
showed	O
hardly	O
any	O
activity	O
below	O
50	O
degrees	O
C	O
but	O
considerable	O
activity	O
at	O
around	O
60	O
degrees	O
C	O
against	O
myofibrils	O
,	O
digesting	O
myosin	B
heavy	I
chain	I
,	O
actin	B
and	O
tropomyosin	B
.	O

The	O
essential	O
role	O
of	O
profilin	B
in	O
the	O
assembly	O
of	O
actin	B
for	O
microspike	O
formation	O
.	O

The	O
existence	O
of	O
this	O
pathway	O
helps	O
to	O
explain	O
some	O
of	O
the	O
effects	O
of	O
LIM	B
kinase	I
and	O
cofilin	B
in	O
the	O
control	O
of	O
actin	B
dynamics	O
.	O

The	O
exogeneous	O
cofilin	B
,	O
but	O
not	O
ADF	B
,	O
caused	O
quick	O
disassembly	O
of	O
actin	B
filaments	O
and	O
accumulated	O
in	O
furrow	O
region	O
of	O
dividing	O
cells	O
.	O

alpha-	B
and	O
beta	B
-	I
catenin	I
were	O
present	O
in	O
most	O
ovarian	O
cells	O
at	O
all	O
stages	O
of	O
folliculogenesis	O
.	O

The	O
expression	O
of	O
APC	B
,	O
alpha	B
-	I
catenin	I
and	O
beta	B
-	I
catenin	I
also	O
was	O
decreased	O
in	O
HT29	O
cells	O
,	O
with	O
a	O
translocation	O
of	O
APC	B
into	O
the	O
nucleus	O
.	O

The	O
findings	O
suggest	O
that	O
M1	B
muscarinic	O
receptors	O
are	O
involved	O
in	O
muscarinic	B
receptor	I
-	I
mediated	I
enhancement	O
of	O
IL-2	B
production	O
in	O
Jurkat	O
cells	O
and	O
that	O
the	O
transcription	O
factor	B
AP-1	I
and	O
pathways	O
via	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	B
MAPK	I
)	I
/	I
extracellular	I
signal	B
regulated	I
protein	I
kinase	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
but	O
not	O
via	O
p38	B
MAPK	O
,	O
may	O
be	O
involved	O
in	O
the	O
muscarinic	B
receptor	I
-	I
mediated	I
enhancement	O
of	O
IL-2	B
production	O
.	O

The	O
gel	O
point	O
assay	O
using	O
an	O
actin	B
cross	O
-	O
linking	O
protein	O
and	O
the	O
nucleation	O
assay	O
also	O
suggested	O
that	O
cofilin	B
shortens	O
the	O
actin	B
filaments	O
and	O
hence	O
increases	O
the	O
filament	O
number	O
.	O

The	O
gene	O
RVS167	B
therefore	O
could	O
be	O
implicated	O
in	O
cytoskeletal	O
reorganization	O
in	O
response	O
to	O
environmental	O
stresses	O
and	O
could	O
act	O
in	O
the	O
budding	O
site	O
selection	O
mechanism	O
.	O

The	O
gene	O
for	O
the	O
human	O
CREB	B
binding	I
protein	I
,	O
the	O
transcriptional	O
coactivator	O
CBP	B
,	O
is	O
included	O
in	O
the	O
RT1	O
cosmid	O
,	O
and	O
mutations	O
in	O
CBP	B
have	O
recently	O
been	O
identified	O
in	O
nondeleted	O
RTS	O
patients	O
.	O

The	O
genes	O
considered	O
are	O
those	O
for	O
5S	B
,	O
5.8S	B
and	O
18S	B
rRNA	I
,	O
actin	B
I	I
,	O
profilins	B
Ia	B
/	I
b	I
and	O
II	B
,	O
myosins	B
IB	B
,	O
IC	B
and	O
II	B
,	O
and	O
calmodulin	B
.	O

The	O
head	O
domain	O
of	O
talin	B
thus	O
binds	O
to	O
integrins	B
to	O
form	O
a	O
link	O
to	O
the	O
actin	B
cytoskeleton	O
and	O
can	O
thus	O
regulate	O
integrin	B
function	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
and	O
neural	O
progenitor	O
(	O
NP	O
)	O
cells	O
are	O
excellent	O
models	O
for	O
recapitulating	O
early	O
neuronal	O
development	O
in	O
vitro	O
,	O
and	O
are	O
key	O
to	O
establishing	O
strategies	O
for	O
the	O
treatment	O
of	O
degenerative	O
disorders	O
.	O

While	O
much	O
effort	O
had	O
been	O
undertaken	O
to	O
analyze	O
transcriptional	O
and	O
epigenetic	O
differences	O
during	O
the	O
transition	O
of	O
hESC	O
to	O
NP	O
,	O
very	O
little	O
work	O
has	O
been	O
performed	O
to	O
understand	O
post	O
-	O
transcriptional	O
changes	O
during	O
neuronal	O
differentiation	O
.	O

Alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
a	O
major	O
form	O
of	O
post	O
-	O
transcriptional	O
gene	O
regulation	O
,	O
is	O
important	O
in	O
mammalian	O
development	O
and	O
neuronal	O
function	O
.	O

Human	O
ESC	O
,	O
hESC	O
-	O
derived	O
NP	O
,	O
and	O
human	O
central	O
nervous	O
system	O
stem	O
cells	O
were	O
compared	O
using	O
Affymetrix	O
exon	O
arrays	O
.	O

We	O
introduced	O
an	O
outlier	O
detection	O
approach	O
,	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
to	O
identify	O
1,737	O
internal	O
exons	O
that	O
are	O
predicted	O
to	O
undergo	O
AS	O
in	O
NP	O
compared	O
to	O
hESC	O
.	O

Experimental	O
validation	O
of	O
REAP	O
-	O
predicted	O
AS	O
events	O
indicated	O
a	O
threshold	O
-	O
dependent	O
sensitivity	O
ranging	O
from	O
56	O
%	O
to	O
69	O
%	O
,	O
at	O
a	O
specificity	O
of	O
77	O
%	O
to	O
96	O
%	O
.	O

REAP	O
predictions	O
significantly	O
overlapped	O
sets	O
of	O
alternative	O
events	O
identified	O
using	O
expressed	O
sequence	O
tags	O
and	O
evolutionarily	O
conserved	O
AS	O
events	O
.	O

Our	O
results	O
also	O
reveal	O
that	O
focusing	O
on	O
differentially	O
expressed	O
genes	O
between	O
hESC	O
and	O
NP	O
will	O
overlook	O
14	O
%	O
of	O
potential	O
AS	O
genes	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
REAP	O
predictions	O
are	O
enriched	O
in	O
genes	O
encoding	O
serine	B
/	I
threonine	I
kinase	I
and	O
helicase	B
activities	O
.	O

An	O
example	O
is	O
a	O
REAP	O
-	O
predicted	O
alternative	O
exon	O
in	O
the	O
SLK	B
(	O
serine	B
/	I
threonine	I
kinase	I
2	I
)	O
gene	O
that	O
is	O
differentially	O
included	O
in	O
hESC	O
,	O
but	O
skipped	O
in	O
NP	O
as	O
well	O
as	O
in	O
other	O
differentiated	O
tissues	O
.	O

Lastly	O
,	O
comparative	O
sequence	O
analysis	O
revealed	O
conserved	O
intronic	O
cis	O
-	O
regulatory	O
elements	O
such	O
as	O
the	O
FOX1	B
/	I
2	I
binding	O
site	O
GCAUG	O
as	O
being	O
proximal	O
to	O
candidate	O
AS	O
exons	O
,	O
suggesting	O
that	O
FOX1	B
/	I
2	I
may	O
participate	O
in	O
the	O
regulation	O
of	O
AS	O
in	O
NP	O
and	O
hESC	O
.	O

In	O
summary	O
,	O
a	O
new	O
methodology	O
for	O
exon	O
array	O
analysis	O
was	O
introduced	O
,	O
leading	O
to	O
new	O
insights	O
into	O
the	O
complexity	O
of	O
AS	O
in	O
human	O
embryonic	O
stem	O
cells	O
and	O
their	O
transition	O
to	O
neural	O
stem	O
cells	O
.	O

Author	O
SummaryDeriving	O
neural	O
progenitors	O
(	O
NP	O
)	O
from	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESC	O
)	O
is	O
the	O
first	O
step	O
in	O
creating	O
homogeneous	O
populations	O
of	O
cells	O
that	O
will	O
differentiate	O
into	O
myriad	O
neuronal	O
subtypes	O
necessary	O
to	O
form	O
a	O
human	O
brain	O
.	O

During	O
alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
noncoding	O
sequences	O
(	O
introns	O
)	O
in	O
a	O
pre	O
-	O
mRNA	O
are	O
differentially	O
removed	O
in	O
different	O
cell	O
types	O
and	O
tissues	O
,	O
and	O
the	O
remaining	O
sequences	O
(	O
exons	O
)	O
are	O
joined	O
to	O
form	O
multiple	O
forms	O
of	O
mature	O
RNA	O
,	O
playing	O
an	O
important	O
role	O
in	O
cellular	O
diversity	O
.	O

The	O
authors	O
utilized	O
Affymetrix	O
exon	O
arrays	O
with	O
probes	O
targeting	O
hundreds	O
of	O
thousands	O
of	O
exons	O
to	O
study	O
AS	O
comparing	O
human	O
ES	O
to	O
NP	O
.	O

To	O
accomplish	O
this	O
,	O
a	O
novel	O
computational	O
method	O
,	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
is	O
introduced	O
to	O
analyze	O
the	O
exon	O
array	O
data	O
.	O

The	O
authors	O
showed	O
that	O
REAP	O
candidates	O
are	O
consistent	O
with	O
other	O
types	O
of	O
methods	O
for	O
discovering	O
alternative	O
exons	O
.	O

In	O
addition	O
,	O
REAP	O
candidate	O
alternative	O
exons	O
are	O
enriched	O
in	O
genes	O
encoding	O
serine	B
/	I
theronine	I
kinases	I
and	O
helicase	B
activities	O
.	O

An	O
example	O
is	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	B
(	O
serine	B
/	I
threonine	I
kinase	I
2	I
)	O
gene	O
that	O
is	O
included	O
in	O
hESC	O
,	O
but	O
excluded	O
in	O
NP	O
as	O
well	O
as	O
in	O
other	O
differentiated	O
tissues	O
.	O

Finally	O
,	O
by	O
comparing	O
genomic	O
sequences	O
across	O
multiple	O
mammals	O
,	O
the	O
authors	O
identified	O
dozens	O
of	O
conserved	O
candidate	O
binding	O
sites	O
that	O
were	O
enriched	O
proximal	O
to	O
REAP	O
candidate	O
exons	O
.	O

The	O
human	O
central	O
nervous	O
system	O
is	O
composed	O
of	O
thousands	O
of	O
neuronal	O
subtypes	O
originating	O
from	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
that	O
migrate	O
from	O
the	O
developing	O
neural	O
tube	O
.	O

Such	O
neuronal	O
complexity	O
is	O
generated	O
by	O
a	O
vast	O
repertoire	O
of	O
molecular	O
,	O
genetic	O
,	O
and	O
epigenetic	O
mechanisms	O
,	O
such	O
as	O
the	O
active	O
retrotransposition	O
of	O
transposable	O
elements	O
[	O
1	O
]	O
,	O
alternative	O
promoter	O
usage	O
,	O
alternative	O
RNA	O
splicing	O
(	O
AS	O
)	O
,	O
alternative	O
polyadenylation	O
,	O
RNA	O
editing	O
,	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
epigenetic	O
modulation	O
[	O
2	O
]	O
.	O

Understanding	O
the	O
processes	O
that	O
generate	O
neuronal	O
diversity	O
is	O
key	O
to	O
gaining	O
insights	O
into	O
neuronal	O
development	O
and	O
paving	O
new	O
avenues	O
for	O
biomedical	O
research	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
pluripotent	O
cells	O
that	O
propagate	O
perpetually	O
in	O
culture	O
as	O
undifferentiated	O
cells	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
a	O
multitude	O
of	O
cell	O
types	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
3	O
]	O
.	O

As	O
hESCs	O
can	O
theoretically	O
generate	O
all	O
cell	O
types	O
that	O
make	O
up	O
an	O
organism	O
,	O
they	O
serve	O
as	O
an	O
important	O
model	O
for	O
understanding	O
early	O
human	O
embryonic	O
development	O
.	O

In	O
addition	O
,	O
the	O
hESCs	O
are	O
a	O
nearly	O
infinite	O
source	O
for	O
generating	O
specialized	O
cells	O
such	O
as	O
neurons	O
and	O
glia	O
for	O
potential	O
therapeutic	O
purposes	O
[	O
4,5	O
]	O
.	O

In	O
recent	O
years	O
,	O
methods	O
have	O
been	O
introduced	O
to	O
induce	O
hESCs	O
to	O
differentiate	O
into	O
neural	O
progenitors	O
(	O
NPs	O
)	O
[	O
6,7	O
]	O
and	O
neuronal	O
and	O
glial	O
subtypes	O
[	O
8–12	O
]	O
.	O

The	O
therapeutic	O
interest	O
in	O
understanding	O
the	O
molecular	O
basis	O
of	O
pluripotency	O
and	O
differentiation	O
has	O
led	O
to	O
many	O
studies	O
comparing	O
transcriptional	O
profiles	O
in	O
different	O
hESC	O
lines	O
and	O
the	O
study	O
of	O
expression	O
changes	O
during	O
the	O
differentiation	O
of	O
hESCs	O
to	O
various	O
lineages	O
[	O
13–17	O
]	O
.	O

NSCs	O
and	O
progenitor	O
cells	O
(	O
NPs	O
)	O
are	O
present	O
throughout	O
development	O
and	O
persist	O
into	O
adulthood	O
[	O
18–20	O
]	O
.	O

They	O
are	O
critical	O
for	O
both	O
basic	O
research	O
and	O
developing	O
approaches	O
to	O
treat	O
neurological	O
disorders	O
,	O
such	O
as	O
Parkinson	O
disease	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
and	O
stroke	O
or	O
head	O
injuries	O
[	O
21,22	O
]	O
.	O

NSCs	O
and	O
NPCs	O
can	O
be	O
isolated	O
from	O
human	O
fetal	O
brain	O
tissue	O
[	O
23–26	O
]	O
,	O
as	O
well	O
as	O
from	O
several	O
regions	O
of	O
the	O
adult	O
human	O
brain	O
,	O
such	O
as	O
the	O
cortex	O
,	O
hippocampus	O
,	O
and	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
of	O
the	O
lateral	O
ventricles	O
[	O
26–35	O
]	O
.	O

Several	O
studies	O
have	O
explored	O
expression	O
patterns	O
of	O
NPCs	O
.	O

For	O
example	O
,	O
Wright	O
et	O
al.	O
identified	O
""""	O
expressed	O
""""	O
and	O
""""	O
not	O
expressed	O
""""	O
genes	O
in	O
NPCs	O
isolated	O
from	O
the	O
human	O
embryonic	O
cortex	O
[	O
24	O
]	O
;	O
Cai	O
et	O
al.	O
used	O
the	O
massively	O
parallel	O
signature	O
sequencing	O
profiling	O
(	O
MPSS	O
)	O
technique	O
to	O
analyze	O
expression	O
of	O
fetal	O
NPCs	O
in	O
comparison	O
to	O
hESCs	O
and	O
astrocyte	O
precursors	O
[	O
27	O
]	O
;	O
Maisel	O
et	O
al.	O
used	O
Affymetrix	O
Gene	O
Chip	O
arrays	O
to	O
compare	O
adult	O
and	O
fetal	O
NPCs	O
propagated	O
in	O
neurospheres	O
[	O
35	O
]	O
.	O

However	O
,	O
as	O
with	O
hESCs	O
,	O
the	O
focus	O
thus	O
far	O
has	O
been	O
primarily	O
on	O
transcriptional	O
differences	O
,	O
which	O
ignores	O
differential	O
RNA	O
processing	O
such	O
as	O
AS	O
,	O
polyadenylation	O
,	O
degradation	O
,	O
or	O
promoter	O
usage	O
.	O

AS	O
is	O
frequently	O
used	O
to	O
regulate	O
gene	O
expression	O
and	O
to	O
generate	O
tissue	O
-	O
specific	O
mRNA	O
and	O
protein	O
isoforms	O
[	O
36–39	O
]	O
.	O

Recent	O
studies	O
using	O
splicing	O
-	O
sensitive	O
microarrays	O
suggested	O
that	O
up	O
to	O
75	O
%	O
of	O
human	O
genes	O
undergo	O
AS	O
,	O
where	O
multiple	O
isoforms	O
are	O
derived	O
from	O
the	O
same	O
genetic	O
loci	O
[	O
40	O
]	O
.	O

This	O
functional	O
complexity	O
underscores	O
the	O
challenge	O
and	O
importance	O
of	O
elucidating	O
AS	O
regulation	O
.	O

AS	O
appears	O
to	O
play	O
a	O
dominant	O
role	O
in	O
regulating	O
neuronal	O
gene	O
expression	O
and	O
function	O
[	O
41,42	O
]	O
.	O

Examples	O
of	O
splicing	O
regulators	O
that	O
are	O
enriched	O
and	O
function	O
specifically	O
in	O
neuronal	O
cells	O
include	O
the	O
brain	B
-	I
specific	I
splicing	I
factor	I
Nova	I
[	O
43,44	O
]	O
and	O
neural	B
-	I
specific	I
polypyrimidine	I
tract	I
binding	I
protein	I
(	O
nPTB	B
)	O
,	O
which	O
antagonizes	O
its	O
paralogous	O
PTB	O
to	O
regulate	O
exon	O
exclusion	O
in	O
neuronal	O
cells	O
[	O
45–47	O
]	O
.	O

Finally	O
,	O
an	O
early	O
report	O
estimating	O
that	O
15	O
%	O
of	O
point	O
mutations	O
disrupt	O
splicing	O
underscores	O
the	O
importance	O
of	O
splicing	O
in	O
human	O
disease	O
[	O
48	O
]	O
.	O

Indeed	O
,	O
the	O
disruption	O
of	O
specific	O
AS	O
events	O
has	O
been	O
implicated	O
in	O
several	O
human	O
genetic	O
diseases	O
,	O
such	O
as	O
frontotemporal	O
dementia	O
and	O
parkinsonism	O
,	O
Frasier	O
syndrome	O
,	O
and	O
atypical	O
cystic	O
fibrosis	O
[	O
49	O
]	O
.	O

While	O
insights	O
into	O
the	O
regulation	O
of	O
AS	O
have	O
come	O
predominantly	O
from	O
the	O
molecular	O
dissection	O
of	O
individual	O
genes	O
[	O
36,49	O
]	O
,	O
it	O
is	O
becoming	O
clear	O
that	O
molecular	O
rules	O
can	O
be	O
identified	O
from	O
large	O
-	O
scale	O
studies	O
of	O
both	O
constitutive	O
splicing	O
and	O
AS	O
[	O
40	O
]	O
.	O

Most	O
systematic	O
global	O
analyses	O
on	O
AS	O
have	O
focused	O
on	O
comparisons	O
across	O
differentiated	O
human	O
tissues	O
[	O
50–52	O
]	O
.	O

Only	O
one	O
study	O
,	O
utilizing	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
collections	O
from	O
stem	O
cells	O
,	O
has	O
attempted	O
to	O
find	O
AS	O
differences	O
between	O
embryonic	O
and	O
hematopoietic	O
stem	O
cells	O
[	O
53	O
]	O
.	O

However	O
,	O
utilizing	O
ESTs	O
to	O
identify	O
AS	O
has	O
intrinsic	O
problems	O
,	O
as	O
ESTs	O
tend	O
to	O
be	O
biased	O
for	O
the	O
3′	O
ends	O
of	O
genes	O
,	O
and	O
full	O
coverage	O
of	O
the	O
genome	O
by	O
ESTs	O
is	O
severely	O
limited	O
by	O
sequencing	O
costs	O
.	O

The	O
commercial	O
availability	O
of	O
Affymetrix	O
exon	O
arrays	O
provides	O
an	O
alternative	O
approach	O
to	O
interrogate	O
the	O
expression	O
of	O
every	O
known	O
and	O
predicted	O
exon	O
in	O
the	O
human	O
genome	O
.	O

The	O
Affymetrix	O
GeneChip	O
Human	O
Exon	O
1.0	O
ST	O
array	O
contains	O
∼5.4	O
million	O
features	O
used	O
to	O
interrogate	O
∼1	O
million	O
exon	O
clusters	O
(	O
collections	O
of	O
overlapping	O
)	O
of	O
known	O
and	O
predicted	O
exons	O
with	O
more	O
than	O
1.4	O
million	O
probesets	O
,	O
with	O
an	O
average	O
of	O
four	O
probes	O
per	O
exon	O
.	O

Our	O
goal	O
was	O
to	O
identify	O
and	O
characterize	O
AS	O
events	O
that	O
distinguish	O
pluripotent	O
hESCs	O
from	O
multipotent	O
NPs	O
,	O
paving	O
the	O
way	O
for	O
future	O
candidate	O
gene	O
approaches	O
to	O
study	O
the	O
impact	O
of	O
AS	O
in	O
hESCs	O
and	O
NPs	O
.	O

However	O
,	O
as	O
different	O
hESC	O
lines	O
were	O
established	O
under	O
different	O
culture	O
conditions	O
from	O
embryos	O
with	O
unique	O
genetic	O
backgrounds	O
,	O
we	O
expected	O
that	O
hESCs	O
and	O
their	O
derived	O
NPs	O
might	O
have	O
distinct	O
epigenetic	O
and	O
molecular	O
signatures	O
[	O
54	O
]	O
.	O

As	O
both	O
common	O
and	O
cell	O
-	O
line	O
specific	O
alternatively	O
spliced	O
exons	O
are	O
likely	O
to	O
be	O
important	O
in	O
regenerative	O
research	O
,	O
in	O
our	O
study	O
two	O
separate	O
hESC	O
lines	O
were	O
used	O
,	O
with	O
independent	O
protocols	O
for	O
differentiating	O
the	O
hESCs	O
into	O
NPs	O
positive	O
for	O
Sox1	B
,	O
an	O
early	O
neuroectodermal	O
marker	O
.	O

As	O
an	O
endogenously	O
occurring	O
population	O
of	O
NPs	O
,	O
human	O
central	O
nervous	O
system	O
stem	O
cells	O
grown	O
as	O
neurospheres	O
(	O
hCNS	O
-	O
SCns	O
)	O
were	O
utilized	O
as	O
a	O
natural	O
benchmark	O
for	O
derived	O
NPs	O
.	O

We	O
developed	O
an	O
approach	O
called	O
REAP	O
(	O
Regression	O
-	O
based	O
Exon	O
Array	O
Protocol	O
)	O
,	O
which	O
is	O
based	O
on	O
robust	O
regression	O
that	O
analyzed	O
signal	O
estimates	O
from	O
Affymetrix	O
exon	O
array	O
data	O
to	O
identify	O
AS	O
exons	O
.	O

Experimental	O
validation	O
revealed	O
alternative	O
exons	O
that	O
distinguish	O
hESCs	O
from	O
NPs	O
;	O
some	O
of	O
them	O
also	O
distinguish	O
hESCs	O
from	O
a	O
variety	O
of	O
differentiated	O
tissues	O
.	O

A	O
comparison	O
of	O
REAP	O
-	O
predicted	O
alternative	O
events	O
with	O
independent	O
methods	O
,	O
such	O
as	O
using	O
publicly	O
available	O
transcripts	O
(	O
ESTs	O
and	O
mRNAs	O
)	O
and	O
computational	O
predictions	O
based	O
on	O
genomic	O
sequence	O
information	O
alone	O
[	O
55	O
]	O
,	O
showed	O
a	O
strong	O
concordance	O
of	O
REAP	O
-	O
identified	O
AS	O
exons	O
with	O
AS	O
events	O
identified	O
from	O
these	O
orthogonal	O
methods	O
.	O

Finally	O
,	O
using	O
analysis	O
of	O
the	O
sequences	O
flanking	O
REAP	O
-	O
identified	O
alternative	O
exons	O
,	O
we	O
were	O
able	O
to	O
discover	O
known	O
and	O
novel	O
cis	O
-	O
regulatory	O
elements	O
that	O
potentially	O
regulate	O
these	O
AS	O
events	O
.	O

Derivation	O
of	O
Neural	O
Progenitors	O
from	O
Embryonic	O
Stem	O
CellsNPs	O
were	O
independently	O
derived	O
from	O
two	O
hESC	O
lines	O
,	O
and	O
RNA	O
extracted	O
from	O
the	O
cell	O
lines	O
was	O
processed	O
and	O
hybridized	O
onto	O
Affymetrix	O
Human	O
1.0	O
ST	O
exon	O
arrays	O
.	O

Immunohistochemical	O
and	O
reverse	O
-	O
transcriptase	B
polymerase	B
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
demonstrated	O
that	O
the	O
hESCs	O
expressed	O
pluripotent	O
marker	O
genes	O
,	O
and	O
the	O
derived	O
NPs	O
expressed	O
multipotent	O
and	O
neurogenic	O
markers	O
similar	O
to	O
hCNS	O
-	O
SCns	O
.	O

Undifferentiated	O
Cythera	O
(	O
Cyt	O
-	O
ES	O
)	O
and	O
HUES6	O
(	O
HUES6-ES	O
)	O
hESC	O
lines	O
were	O
maintained	O
in	O
culture	O
as	O
previously	O
described	O
[	O
12,23,56	O
]	O
.	O

Utilizing	O
specific	O
antibodies	O
,	O
we	O
observed	O
that	O
undifferentiated	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
cells	O
were	O
positive	O
for	O
the	O
pluripotent	O
markers	O
Oct4	B
,	O
SSEA-4	B
,	O
and	O
Tra-1–80	B
(	O
unpublished	O
data	O
)	O
.	O

NPs	O
were	O
derived	O
from	O
the	O
hESC	O
cell	O
lines	O
using	O
protocols	O
optimized	O
for	O
each	O
line	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Greater	O
than	O
90	O
%	O
of	O
derived	O
NP	O
cells	O
(	O
Cyt	O
-	O
NP	O
from	O
Cyt	O
-	O
ES	O
and	O
HUES6-NP	O
from	O
HUES6-ES	O
)	O
were	O
positive	O
for	O
Sox1	B
,	O
an	O
early	O
neuroectodermal	O
marker	O
,	O
and	O
Nestin	B
(	O
Figure	O
1A	O
)	O
,	O
and	O
negative	O
for	O
Oct4	B
(	O
unpublished	O
data	O
)	O
.	O

As	O
a	O
natural	O
benchmark	O
for	O
the	O
derived	O
NPs	O
,	O
we	O
utilized	O
hCNS	O
-	O
SCns	O
,	O
which	O
were	O
previously	O
isolated	O
from	O
fresh	O
human	O
fetal	O
brain	O
tissues	O
using	O
antibodies	O
to	O
cell	O
-	O
surface	O
markers	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorting	O
[	O
12,23	O
]	O
.	O

The	O
hCNS	O
-	O
SCns	O
form	O
neurospheres	O
in	O
culture	O
which	O
are	O
greater	O
than	O
90	O
%	O
Nestin	B
and	O
Sox1	B
positive	O
,	O
and	O
differentiate	O
into	O
both	O
neurons	O
and	O
glial	O
cells	O
in	O
vitro	O
[	O
12,23	O
]	O
.	O

Immunohistochemical	O
analysis	O
confirmed	O
that	O
hCNS	O
-	O
SCns	O
were	O
negative	O
for	O
Oct4	B
(	O
unpublished	O
data	O
)	O
and	O
positive	O
for	O
Sox1	B
and	O
Nestin	B
(	O
Figure	O
1A	O
)	O
.Figure	O
1Molecular	O
Characterization	O
of	O
Human	O
Embryonic	O
Stem	O
Cell	O
Lines	O
and	O
Neuronal	O
Progenitors	O
(	O
A	O
)	O
Immunohistochemical	O
analysis	O
of	O
markers	O
in	O
NPs	O
derived	O
from	O
the	O
hESC	O
lines	O
(	O
Cyt	O
-	O
NP	O
from	O
Cyt	O
-	O
ES	O
;	O
and	O
HUES6-NP	O
from	O
HUES6-ES	O
)	O
and	O
in	O
hCNS	O
-	O
SCns	O
.	O

Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
cells	O
were	O
Nestin	B
and	O
Sox1	B
positive	O
.	O

Nuclei	O
stained	O
positive	O
for	O
Dapi	O
.	O

White	O
horizontal	O
bar	O
indicated	O
15	O
μm.	O
(	O
B	O
)	O
Gene	O
-	O
level	O
signal	O
estimates	O
of	O
marker	O
genes	O
(	O
GAPDH	B
,	O
Oct4	B
,	O
Nanog	B
,	O
Nestin	B
,	O
Notch1	B
,	O
DNER	B
,	O
and	O
Sox1	B
)	O
from	O
Affymetrix	O
exon	O
array	O
analysis	O
.	O

Vertical	O
bars	O
indicated	O
average	O
log2	O
normalized	O
signal	O
estimates	O
,	O
and	O
error	O
bars	O
represented	O
standard	O
deviations	O
from	O
three	O
independent	O
replicate	O
experiments	O
per	O
cell	O
type.	O
(	O
C	O
)	O
RT	O
-	O
PCR	O
of	O
marker	O
genes	O
(	O
GAPDH	B
,	O
Oct4	B
,	O
Nanog	B
,	O
Nestin	B
,	O
Notch1	B
,	O
DNER	B
,	O
and	O
Sox1	B
)	O
.Here	O
,	O
known	O
molecular	O
markers	O
were	O
subjected	O
to	O
RT	O
-	O
PCR	O
measurements	O
,	O
which	O
were	O
compared	O
to	O
gene	O
-	O
level	O
signal	O
estimates	O
generated	O
from	O
the	O
exon	O
array	O
data	O
.	O

Total	O
RNA	O
was	O
extracted	O
,	O
and	O
labeled	O
cDNA	O
targets	O
were	O
generated	O
from	O
three	O
independent	O
preparations	O
of	O
each	O
cell	O
type	O
,	O
namely	O
Cyt	O
-	O
ES	O
,	O
HUES6-ES	O
,	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
.	O

To	O
facilitate	O
downstream	O
analyses	O
,	O
instead	O
of	O
utilizing	O
the	O
meta	O
-	O
gene	O
sets	O
available	O
from	O
the	O
manufacturers	O
,	O
we	O
generated	O
our	O
own	O
gene	O
models	O
by	O
clustering	O
alignments	O
of	O
ESTs	O
and	O
mRNAs	O
to	O
annotated	O
known	O
genes	O
from	O
the	O
University	O
of	O
California	O
Santa	O
Cruz	O
(	O
UCSC	O
)	O
Genome	O
Browser	O
Database	O
.	O

After	O
hybridization	O
,	O
scanning	O
,	O
and	O
extraction	O
of	O
signal	O
estimates	O
for	O
each	O
probeset	O
on	O
the	O
exon	O
arrays	O
,	O
gene	O
-	O
level	O
estimates	O
were	O
computed	O
based	O
on	O
our	O
gene	O
models	O
using	O
available	O
normalization	O
and	O
signal	O
estimation	O
software	O
from	O
Affymetrix	O
.	O

For	O
every	O
gene	O
,	O
a	O
t	O
-	O
statistic	O
and	O
corresponding	O
p	O
-	O
value	O
were	O
computed	O
representing	O
the	O
relative	O
enrichment	O
of	O
the	O
expression	O
of	O
the	O
gene	O
in	O
hESC	O
versus	O
NP	O
,	O
such	O
as	O
in	O
Cyt	O
-	O
ES	O
versus	O
Cyt	O
-	O
NP	O
.	O

After	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
method	O
,	O
a	O
p	O
-	O
value	O
cutoff	O
of	O
0.01	O
was	O
used	O
to	O
identify	O
enriched	O
genes	O
.	O

Close	O
inspection	O
of	O
all	O
pairs	O
of	O
hESC	O
-	O
NP	O
comparisons	O
revealed	O
a	O
generally	O
significant	O
overlap	O
from	O
31	O
%	O
to	O
85	O
%	O
of	O
the	O
smaller	O
of	O
two	O
compared	O
sets	O
of	O
enriched	O
genes	O
(	O
see	O
Figure	O
S1	O
)	O
.	O

Thus	O
for	O
the	O
purpose	O
of	O
identifying	O
overall	O
pluripotent	O
and	O
neural	O
lineage	O
-	O
specific	O
genes	O
,	O
the	O
collective	O
set	O
of	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
was	O
compared	O
to	O
the	O
collective	O
set	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
.Oct4	O
and	O
Nanog	B
,	O
which	O
are	O
important	O
in	O
maintaining	O
the	O
pluripotent	O
state	O
of	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
were	O
highly	O
expressed	O
in	O
hESCs	O
but	O
were	O
significantly	O
lower	O
in	O
NPs	O
(	O
Figure	O
1B	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
Oct4	B
and	O
Nanog	B
mRNA	O
levels	O
accurately	O
reflected	O
the	O
signal	O
estimates	O
from	O
the	O
array	O
(	O
Figure	O
1C	O
)	O
.	O

Interestingly	O
,	O
Nestin	B
was	O
not	O
significantly	O
higher	O
in	O
NPs	O
as	O
compared	O
to	O
the	O
hESC	O
from	O
the	O
gene	O
-	O
level	O
estimates	O
(	O
p	O
-	O
value	O
0.065	O
)	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
1C	O
)	O
.	O

Notch	B
was	O
recently	O
identified	O
to	O
be	O
important	O
in	O
promoting	O
the	O
neural	O
lineage	O
entry	O
in	O
mouse	O
ESCs	O
[	O
57	O
]	O
and	O
was	O
shown	O
to	O
regulate	O
stem	O
cell	O
proliferation	O
in	O
somatic	O
mouse	O
and	O
hESC	O
[	O
58	O
]	O
.	O

Gene	O
-	O
level	O
signal	O
estimates	O
suggested	O
that	O
Notch	B
was	O
significantly	O
higher	O
in	O
hCNS	O
-	O
SCns	O
relative	O
to	O
hESCs	O
,	O
but	O
levels	O
of	O
Notch	B
were	O
not	O
significantly	O
different	O
in	O
the	O
derived	O
NPs	O
compared	O
to	O
hESCs	O
.	O

Delta	B
/	I
Notch	I
-	I
like	I
EGF	I
-	I
related	I
receptor	I
(	O
DNER	B
)	O
,	O
a	O
neuron	O
-	O
specific	O
transmembrane	O
protein	O
,	O
was	O
recently	O
shown	O
to	O
bind	O
to	O
Notch	B
at	O
cell	O
–	O
cell	O
contacts	O
and	O
activates	O
Notch	B
signaling	O
in	O
vitro	O
[	O
59	O
]	O
.	O

RT	O
-	O
PCR	O
validation	O
of	O
DNER	B
confirmed	O
array	O
-	O
derived	O
signal	O
estimates	O
,	O
indicating	O
an	O
enrichment	O
of	O
DNER	B
in	O
NPs	O
relative	O
to	O
hESCs	O
(	O
Figure	O
1C	O
)	O
.	O

Finally	O
,	O
Sox1	B
,	O
a	O
HMG	B
-	I
box	I
protein	I
related	O
to	O
SRY	B
,	O
was	O
shown	O
to	O
be	O
one	O
of	O
the	O
earliest	O
transcription	O
factors	O
expressed	O
in	O
cells	O
committed	O
to	O
the	O
neural	O
fate	O
[	O
60	O
]	O
.	O

Here	O
the	O
gene	O
-	O
level	O
estimates	O
indicated	O
that	O
Sox1	B
was	O
expressed	O
significantly	O
higher	O
in	O
NPs	O
relative	O
to	O
hESCs	O
(	O
p	O
-	O
value	O
0.00013	O
,	O
Figure	O
1B	O
)	O
,	O
a	O
finding	O
that	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
1C	O
)	O
.From	O
these	O
examples	O
,	O
we	O
concluded	O
that	O
RT	O
-	O
PCR	O
validation	O
correlated	O
well	O
with	O
gene	O
-	O
level	O
estimates	O
from	O
the	O
exon	O
array	O
.	O

In	O
addition	O
,	O
the	O
derived	O
NPs	O
had	O
decreased	O
levels	O
of	O
pluripotent	O
markers	O
Oct4	B
and	O
Nanog	B
but	O
had	O
levels	O
of	O
Sox1	B
that	O
were	O
comparable	O
to	O
hCNS	O
-	O
SCns	O
.	O

This	O
finding	O
confirmed	O
that	O
the	O
derived	O
NPs	O
were	O
committed	O
to	O
a	O
neural	O
fate	O
and	O
validated	O
the	O
use	O
of	O
hCNS	O
-	O
SCns	O
as	O
a	O
benchmark	O
for	O
NPs	O
.	O

Next	O
we	O
asked	O
whether	O
the	O
highest	O
enriched	O
genes	O
in	O
hESCs	O
relative	O
to	O
NPs	O
reflected	O
our	O
existing	O
knowledge	O
in	O
the	O
literature	O
.	O

Using	O
the	O
above	O
-	O
mentioned	O
groupings	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
,	O
HUES6-ES	O
)	O
and	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
,	O
2,945	O
genes	O
were	O
enriched	O
in	O
hESCs	O
relative	O
to	O
NPs	O
;	O
and	O
552	O
genes	O
were	O
enriched	O
in	O
the	O
NPs	O
relative	O
to	O
hESCs	O
,	O
at	O
a	O
p	O
-	O
value	O
significance	O
cutoff	O
of	O
0.01	O
(	O
correcting	O
for	O
multiple	O
hypothesis	O
testing	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
method	O
)	O
.	O

The	O
15	O
most	O
enriched	O
genes	O
in	O
hESCs	O
included	O
genes	O
such	O
as	O
teratocarcinoma	B
-	I
derived	I
growth	I
factor	I
1	I
(	O
TDGF1	B
/	B
cripto	I
;	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
zinc	B
finger	I
protein	I
42	I
(	O
Zfp42	B
/	O
Rex1	B
;	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
Oct4	B
(	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
Nanog	B
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
lin-28	B
homolog	I
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
cadherin	B
1	I
preprotein	I
(	O
p	O
-	O
value	O
<	O
10−10	O
)	O
,	O
claudin	B
6	I
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
,	O
ephrin	O
receptor	O
EphA1	B
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
,	O
and	O
erbB3	B
(	O
p	O
-	O
value	O
<	O
10−9	O
)	O
.	O

TDGF1	B
/	B
cripto	I
was	O
first	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
of	O
both	O
undifferentiated	O
and	O
differentiated	O
embryonic	O
carcinoma	O
cells	O
[	O
61	O
]	O
and	O
was	O
later	O
shown	O
to	O
be	O
important	O
for	O
cardiomyocyte	O
formation	O
from	O
mouse	O
ESC	O
[	O
62	O
]	O
.	O

Oct4	B
,	O
reviewed	O
in	O
[	O
63	O
]	O
,	O
and	O
Nanog	B
[	O
64	O
]	O
are	O
crucial	O
for	O
the	O
pluripotency	O
of	O
hESCs	O
.	O

Recently	O
,	O
knockdown	O
of	O
Zfp42	B
/	O
Rex-1	B
in	O
mouse	O
ESC	O
caused	O
the	O
cells	O
to	O
differentiate	O
[	O
65	O
]	O
.	O

Our	O
gene	O
-	O
level	O
exon	O
array	O
analysis	O
confirmed	O
that	O
the	O
hESCs	O
and	O
NPs	O
were	O
molecularly	O
distinct	O
.	O

To	O
reveal	O
global	O
functional	O
differences	O
between	O
the	O
enriched	O
genes	O
in	O
hESCs	O
or	O
NPs	O
,	O
the	O
enriched	O
genes	O
were	O
subjected	O
to	O
a	O
Gene	O
Ontology	O
(	O
GO	O
,	O
http://www.geneontology.org	O
)	O
analysis	O
as	O
described	O
previously	O
[	O
55	O
]	O
.	O

Enriched	O
genes	O
in	O
hESCs	O
were	O
more	O
likely	O
to	O
be	O
in	O
molecular	O
function	O
categories	O
,	O
such	O
as	O
""""	O
RNA	O
binding	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−12	O
)	O
,	O
""""	O
structural	O
constituent	O
of	O
ribosome	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−51	O
)	O
,	O
""""	O
exonuclease	O
activity	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
""""	O
cytochrome	O
-	O
c	O
oxidase	O
activity	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−5	O
)	O
,	O
and	O
""""	O
ATP	O
binding	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
and	O
in	O
biological	O
processes	O
involved	O
with	O
""""	O
tRNA	O
processing	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
and	O
""""	O
protein	O
biosynthesis	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−48	O
)	O
,	O
consistent	O
with	O
our	O
knowledge	O
of	O
hESCs	O
as	O
a	O
rapidly	O
proliferating	O
population	O
of	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

Similar	O
analysis	O
of	O
the	O
enriched	O
genes	O
in	O
NPs	O
revealed	O
an	O
overrepresentation	O
in	O
molecular	O
functional	O
categories	O
,	O
such	O
as	O
""""	O
calcium	O
ion	O
binding	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−8	O
)	O
and	O
""""	O
structural	O
molecule	O
activity	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−5	O
)	O
,	O
and	O
in	O
biological	O
processes	O
involved	O
with	O
""""	O
neurogenesis	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−38	O
)	O
,	O
""""	O
cell	O
adhesion	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−13	O
)	O
,	O
""""	O
cell	O
motility	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
,	O
""""	O
development	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−6	O
)	O
,	O
""""	O
neuropeptide	O
signaling	O
pathway	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
,	O
and	O
""""	O
endocytosis	O
""""	O
(	O
p	O
-	O
value	O
<	O
10−4	O
)	O
(	O
Figure	O
2B	O
)	O
.	O

Considering	O
that	O
these	O
were	O
the	O
only	O
categories	O
that	O
were	O
significantly	O
enriched	O
out	O
of	O
more	O
than	O
18,000	O
GO	O
terms	O
,	O
and	O
that	O
randomly	O
selected	O
sets	O
of	O
similar	O
numbers	O
of	O
genes	O
did	O
not	O
reveal	O
statistical	O
differences	O
in	O
GO	O
categories	O
,	O
our	O
results	O
confirmed	O
that	O
the	O
global	O
molecular	O
profiles	O
derived	O
from	O
exon	O
array	O
analysis	O
were	O
consistent	O
with	O
known	O
differences	O
between	O
hESCs	O
and	O
NPs	O
.	O

Figure	O
2Gene	O
Ontology	O
AnalysisDifferential	O
gene	O
expression	O
of	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
and	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
was	O
computed	O
from	O
gene	O
-	O
level	O
signal	O
estimates	O
.	O

Statistical	O
significance	O
for	O
differential	O
gene	O
expression	O
was	O
determined	O
by	O
using	O
t	O
-	O
statistics	O
with	O
Benjamini	O
-	O
Hochberg	O
correction	O
for	O
false	O
discovery	O
rate	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Gene	O
Ontology	O
""""	O
molecular	O
function	O
,	O
""""	O
""""	O
cellular	O
component	O
,	O
""""	O
and	O
""""	O
biological	O
process	O
""""	O
categories	O
,	O
which	O
differed	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
representation	O
between	O
significantly	O
enriched	O
genes	O
(	O
black	O
bars	O
)	O
and	O
all	O
other	O
genes	O
(	O
white	O
bars	O
)	O
,	O
were	O
shown	O
.	O

Statistical	O
significance	O
for	O
GO	O
analysis	O
was	O
assessed	O
by	O
using	O
χ2	O
statistics	O
with	O
Bonferroni	O
correction	O
for	O
multiple	O
hypothesis	O
testing	O
.	O

GO	O
categories	O
are	O
ordered	O
from	O
top	O
to	O
bottom	O
in	O
order	O
of	O
decreasingly	O
significant	O
bias	O
toward	O
enriched	O
genes.	O
(	O
A	O
)	O
GO	O
analysis	O
of	O
enriched	O
genes	O
in	O
hESCs.	O
(	O
B	O
)	O
GO	O
analysis	O
of	O
enriched	O
genes	O
in	O
NPs	O
.	O

To	O
summarize	O
,	O
firstly	O
immunohistochemical	O
and	O
RT	O
-	O
PCR	O
evidence	O
validated	O
that	O
the	O
cells	O
exhibited	O
expected	O
characteristics	O
;	O
secondly	O
,	O
stage	O
-	O
specific	O
marker	O
gene	O
differences	O
by	O
RT	O
-	O
PCR	O
were	O
reflected	O
accurately	O
by	O
gene	O
-	O
level	O
estimates	O
from	O
the	O
exon	O
arrays	O
;	O
thirdly	O
,	O
the	O
hESC	O
-	O
enriched	O
genes	O
were	O
coherent	O
with	O
known	O
genes	O
that	O
controlled	O
pluripotency	O
and	O
self	O
-	O
renewal	O
;	O
and	O
lastly	O
,	O
the	O
global	O
functional	O
profiles	O
exemplified	O
expected	O
biological	O
differences	O
between	O
hESC	O
and	O
NP	O
cells	O
.	O

Description	O
of	O
the	O
Regression	O
-	O
Based	O
Exon	O
Array	O
ProtocolConvinced	O
that	O
the	O
signal	O
estimates	O
from	O
the	O
exon	O
arrays	O
reflected	O
expected	O
molecular	O
and	O
biological	O
differences	O
between	O
hESCs	O
and	O
NPs	O
,	O
we	O
sought	O
to	O
identify	O
AS	O
events	O
.	O

We	O
compared	O
Cyt	O
-	O
ES	O
to	O
hCNS	O
-	O
SCns	O
to	O
illustrate	O
our	O
approach	O
.	O

First	O
we	O
normalized	O
the	O
data	O
and	O
generated	O
signal	O
estimates	O
with	O
Robust	O
Multichip	O
Analysis	O
(	O
RMA	O
)	O
and	O
estimated	O
the	O
probability	O
that	O
each	O
probeset	O
was	O
detected	O
above	O
background	O
(	O
DABG	O
)	O
using	O
publicly	O
available	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
.	O

We	O
analyzed	O
probesets	O
that	O
(	O
i	O
)	O
comprised	O
three	O
or	O
more	O
individual	O
probes	O
;	O
(	O
ii	O
)	O
were	O
localized	O
within	O
the	O
exons	O
of	O
our	O
gene	O
models	O
with	O
evidence	O
from	O
at	O
least	O
three	O
sources	O
(	O
mRNA	O
,	O
EST	O
,	O
or	O
full	O
-	O
length	O
cDNA	O
)	O
;	O
and	O
(	O
iii	O
)	O
were	O
detected	O
above	O
background	O
in	O
at	O
least	O
one	O
of	O
the	O
cell	O
lines	O
.	O

In	O
total	O
,	O
17,430	O
gene	O
models	O
were	O
represented	O
by	O
probesets	O
that	O
satisfied	O
these	O
criteria	O
.	O

Next	O
we	O
asked	O
whether	O
the	O
probeset	O
expression	O
within	O
each	O
gene	O
model	O
was	O
positively	O
correlated	O
for	O
any	O
two	O
cell	O
lines	O
.	O

To	O
do	O
this	O
we	O
calculated	O
the	O
Pearson	O
correlation	O
coefficient	O
between	O
the	O
vectors	O
of	O
median	O
signal	O
estimates	O
across	O
replicates	O
in	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

The	O
vast	O
majority	O
of	O
genes	O
(	O
>	O
80	O
%	O
)	O
was	O
found	O
to	O
have	O
probeset	O
-	O
level	O
Pearson	O
correlation	O
coefficients	O
of	O
greater	O
than	O
0.8	O
(	O
Figure	O
3A	O
)	O
.	O

Next	O
we	O
randomly	O
permuted	O
the	O
association	O
between	O
the	O
median	O
signal	O
estimates	O
and	O
the	O
probesets	O
for	O
each	O
gene	O
in	O
hESCs	O
(	O
or	O
hCNS	O
-	O
SCns	O
)	O
and	O
observed	O
that	O
the	O
distribution	O
of	O
Pearson	O
correlation	O
coefficients	O
for	O
the	O
permuted	O
sets	O
was	O
centered	O
at	O
zero	O
,	O
as	O
expected	O
(	O
Figure	O
3A	O
)	O
.	O

This	O
indicated	O
that	O
the	O
signal	O
estimates	O
for	O
probesets	O
between	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
were	O
highly	O
correlated	O
and	O
suggested	O
that	O
a	O
scatter	O
plot	O
of	O
probeset	O
signal	O
estimates	O
between	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
would	O
reveal	O
a	O
linear	O
relationship	O
for	O
the	O
majority	O
of	O
genes	O
.	O

We	O
hypothesized	O
that	O
a	O
linear	O
regression	O
to	O
determine	O
if	O
some	O
probesets	O
behaved	O
unexpectedly	O
in	O
one	O
cell	O
type	O
compared	O
to	O
the	O
other	O
might	O
be	O
a	O
reasonable	O
approach	O
to	O
identify	O
AS	O
exons	O
.	O

Figure	O
3Description	O
of	O
the	O
REAP	O
Algorithm	O
Comparing	O
Exon	O
Array	O
Signal	O
Estimates	O
from	O
hCNS	O
-	O
SCns	O
and	O
Cyt	O
-	O
ES	O
(	O
A	O
)	O
Histogram	O
of	O
Pearson	O
correlation	O
coefficients	O
computed	O
from	O
median	O
signal	O
estimates	O
for	O
probesets	O
between	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
for	O
genes	O
(	O
blue	O
bars	O
)	O
.	O

Genes	O
were	O
required	O
to	O
have	O
more	O
than	O
five	O
probesets	O
localized	O
within	O
the	O
exons	O
in	O
the	O
gene	O
.	O

Red	O
bars	O
represented	O
Pearson	O
correlation	O
coefficients	O
computed	O
from	O
exons	O
with	O
shuffled	O
signal	O
estimates.	O
(	O
B	O
)	O

Each	O
probeset	O
contained	O
probeset	O
-	O
level	O
estimates	O
from	O
three	O
replicates	O
each	O
,	O
(	O
a	O
,	O
b	O
,	O
c	O
)	O
in	O
Cyt	O
-	O
ES	O
and	O
(	O
d	O
,	O
e	O
,	O
f	O
)	O
in	O
hCNS	O
-	O
SCns	O
.	O

The	O
five	O
points	O
summarizing	O
the	O
log2	O
probeset	O
-	O
level	O
estimates	O
are	O
indicated	O
by	O
black	O
filled	O
circles.	O
(	O
C	O
)	O

Each	O
probeset	O
was	O
summarized	O
by	O
five	O
points	O
.	O

Scatter	O
plots	O
of	O
signal	O
estimates	O
for	O
probesets	O
that	O
were	O
present	O
in	O
at	O
least	O
one	O
cell	O
type	O
(	O
Cyt	O
-	O
ES	O
or	O
hCNS	O
-	O
SCns	O
)	O
for	O
the	O
EHBP1	B
gene	O
.	O

Probesets	O
were	O
considered	O
present	O
if	O
the	O
DABG	O
p	O
-	O
value	O
was	O
<	O
0.05	O
for	O
all	O
three	O
replicates	O
in	O
the	O
cell	O
type	O
.	O

A	O
regression	O
line	O
derived	O
from	O
robust	O
linear	O
regression	O
with	O
MM	O
estimation	O
is	O
indicated	O
.	O

Points	O
above	O
the	O
line	O
represent	O
probesets	O
within	O
exons	O
that	O
were	O
enriched	O
in	O
Cyt	O
-	O
ES	O
and	O
points	O
below	O
represent	O
exons	O
that	O
were	O
enriched	O
in	O
hCNS	O
-	O
SCns	O
.	O

Points	O
close	O
to	O
the	O
regression	O
line	O
are	O
not	O
significantly	O
different	O
in	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

Boxed	O
points	O
represented	O
the	O
five	O
-	O
point	O
summary	O
of	O
a	O
probeset	O
that	O
was	O
significantly	O
enriched	O
in	O
Cyt	O
-	O
ES	O
but	O
was	O
skipped	O
in	O
hCNS	O
-	O
SCns.	O
(	O
D	O
)	O
Histogram	O
of	O
studentized	O
residuals	O
for	O
points	O
from	O
the	O
scatter	O
plot	O
in	O
(	O
C	O
)	O
in	O
EHBP1.	B
(	O
E	O
)	O
The	O
histogram	O
of	O
studentized	O
residuals	O
for	O
all	O
points	O
for	O
all	O
analyzed	O
probesets	O
(	O
100	O
bins	O
)	O
.	O
(	O
F	O
)	O

The	O
scatter	O
plot	O
of	O
studentized	O
residuals	O
generated	O
from	O
comparing	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
and	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
of	O
5,000	O
randomly	O
chosen	O
probesets	O
.	O

Here	O
,	O
a	O
possible	O
representation	O
of	O
the	O
data	O
was	O
explored	O
.	O

If	O
we	O
had	O
N	O
replicates	O
in	O
one	O
condition	O
and	O
M	O
replicates	O
in	O
the	O
other	O
,	O
we	O
could	O
consider	O
N*M	O
points	O
if	O
we	O
analyzed	O
every	O
possible	O
pairing	O
.	O

For	O
instance	O
,	O
three	O
replicate	O
signal	O
estimates	O
for	O
every	O
probeset	O
per	O
cell	O
line	O
,	O
such	O
as	O
signal	O
estimates	O
a	O
,	O
b	O
,	O
and	O
c	O
in	O
hESCs	O
and	O
d	O
,	O
e	O
,	O
and	O
f	O
in	O
hCNS	O
-	O
SCns	O
,	O
would	O
translate	O
to	O
pairing	O
every	O
signal	O
(	O
d	O
,	O
a	O
)	O
,	O
(	O
d	O
,	O
b	O
)	O
,	O
(	O
d	O
,	O
c	O
)	O
…	O
(	O
f	O
,	O
a	O
)	O
,	O
(	O
f	O
,	O
b	O
)	O
,	O
(	O
f	O
,	O
c	O
)	O
for	O
linear	O
regression	O
(	O
Figure	O
3B	O
)	O
.	O

Instead	O
,	O
pairing	O
the	O
signal	O
estimates	O
of	O
all	O
replicates	O
in	O
one	O
condition	O
to	O
the	O
median	O
of	O
the	O
other	O
would	O
only	O
require	O
N	O
+	O
M	O
−	O
1	O
points	O
and	O
would	O
capture	O
the	O
variation	O
of	O
the	O
signal	O
estimates	O
of	O
each	O
probeset	O
.	O

For	O
example	O
,	O
we	O
considered	O
(	O
d	O
,	O
b	O
)	O
,	O
(	O
e	O
,	O
a	O
)	O
,	O
(	O
e	O
,	O
b	O
)	O
,	O
(	O
e	O
,	O
c	O
)	O
,	O
and	O
(	O
f	O
,	O
b	O
)	O
points	O
where	O
b	O
and	O
d	O
were	O
the	O
median	O
intensities	O
for	O
the	O
replicates	O
in	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
,	O
respectively	O
(	O
Figure	O
3B	O
)	O
.	O

A	O
scatter	O
plot	O
of	O
all	O
probesets	O
of	O
the	O
EHBP1	B
(	O
EH	B
domain	I
binding	I
protein	I
,	O
RefSeq	O
identifier	O
NM_015252	O
)	O
is	O
shown	O
in	O
Figure	O
3C	O
in	O
the	O
format	O
described	O
.	O

Each	O
probeset	O
was	O
represented	O
by	O
5	O
points	O
of	O
log	O
-	O
transformed	O
(	O
base	O
2	O
)	O
values	O
;	O
and	O
each	O
point	O
on	O
the	O
scatter	O
plot	O
reflected	O
the	O
extent	O
of	O
inclusion	O
of	O
an	O
exon	O
in	O
hESCs	O
and	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
3C	O
)	O
.A	O
classical	O
linear	O
regression	O
model	O
could	O
be	O
proposed	O
to	O
fit	O
the	O
response	O
variable	O
yij	O
,	O
the	O
log2	O
expression	O
of	O
probeset	O
i	O
in	O
cell	O
-	O
type	O
j	O
(	O
for	O
example	O
,	O
j	O
is	O
Cyt	O
-	O
ESC	O
)	O
to	O
explanatory	O
variables	O
xik	O
,	O
and	O
the	O
log2	O
expression	O
of	O
probeset	O
i	O
in	O
cell	O
type	O
k	O
(	O
for	O
example	O
,	O
k	O
is	O
hCNS	O
-	O
SCns	O
)	O
.	O

However	O
,	O
classical	O
linear	O
regression	O
by	O
least	O
-	O
squares	O
estimation	O
is	O
biased	O
because	O
the	O
least	O
squares	O
predictions	O
are	O
strongly	O
influenced	O
by	O
the	O
outliers	O
,	O
leading	O
to	O
completely	O
incorrect	O
regression	O
line	O
estimates	O
,	O
masking	O
of	O
the	O
outliers	O
,	O
and	O
incorrect	O
predictions	O
of	O
outliers	O
.	O

Therefore	O
,	O
we	O
applied	O
M	O
-	O
estimation	O
robust	O
regression	O
to	O
estimate	O
the	O
line	O
,	O
which	O
is	O
less	O
sensitive	O
to	O
outliers	O
.	O

Fitting	O
was	O
performed	O
using	O
an	O
iterated	O
,	O
re	O
-	O
weighted	O
least	O
squares	O
analysis	O
.	O

Our	O
assumption	O
was	O
that	O
most	O
of	O
the	O
points	O
were	O
""""	O
correct	O
,	O
""""	O
i.e.	O
,	O
that	O
most	O
of	O
the	O
exons	O
were	O
constitutively	O
spliced	O
.	O

Thus	O
,	O
robust	O
regression	O
would	O
find	O
the	O
line	O
that	O
was	O
least	O
dependent	O
on	O
outliers	O
,	O
which	O
would	O
be	O
potential	O
AS	O
exons	O
.	O

This	O
assumption	O
was	O
substantiated	O
by	O
our	O
observation	O
that	O
,	O
using	O
publicly	O
available	O
ESTs	O
and	O
mRNAs	O
,	O
a	O
minority	O
of	O
human	O
exons	O
(	O
7	O
%	O
)	O
have	O
evidence	O
for	O
exon	O
-	O
skipping	O
,	O
the	O
most	O
common	O
form	O
of	O
AS	O
.	O

Using	O
robust	O
regression	O
,	O
the	O
regression	O
line	O
for	O
Cyt	O
-	O
ESC	O
versus	O
hCNS	O
-	O
SCns	O
in	O
the	O
EHBP1	B
gene	O
is	O
illustrated	O
in	O
Figure	O
3C	O
.	O

The	O
boxed	O
points	O
belonged	O
to	O
a	O
probeset	O
that	O
was	O
enriched	O
in	O
hESCs	O
but	O
depleted	O
in	O
hCNS	O
-	O
SCns	O
,	O
which	O
was	O
suspected	O
to	O
be	O
due	O
to	O
AS	O
.	O

The	O
difference	O
between	O
the	O
actual	O
and	O
regression	O
-	O
based	O
predicted	O
value	O
,	O
normalized	O
by	O
the	O
estimate	O
of	O
its	O
standard	O
deviation	O
,	O
is	O
called	O
the	O
studentized	O
residuals	O
.	O

Studentized	O
residuals	O
were	O
computed	O
for	O
all	O
probeset	O
pairs	O
in	O
EHBP1	B
,	O
and	O
the	O
histogram	O
depicting	O
their	O
distribution	O
is	O
illustrated	O
in	O
Figure	O
3D	O
.	O

As	O
expected	O
,	O
the	O
mean	O
of	O
the	O
distribution	O
was	O
close	O
to	O
zero	O
,	O
and	O
the	O
distribution	O
was	O
approximated	O
by	O
a	O
t	O
-	O
distribution	O
with	O
n	O
-	O
p-1	O
degrees	O
of	O
freedom	O
,	O
where	O
n	O
was	O
the	O
number	O
of	O
points	O
on	O
the	O
scatter	O
plot	O
,	O
and	O
the	O
number	O
of	O
parameters	O
p	O
was	O
2	O
.	O

The	O
boxed	O
points	O
had	O
studentized	O
residuals	O
of	O
1.829	O
,	O
3.104	O
,	O
2.634	O
,	O
3.012	O
,	O
and	O
2.125	O
with	O
p	O
-	O
values	O
of	O
0.034	O
,	O
0.00119	O
,	O
0.00477	O
,	O
0.00158	O
,	O
and	O
0.01780	O
,	O
respectively	O
,	O
computed	O
based	O
on	O
the	O
t	O
-	O
distribution	O
(	O
Figure	O
3C	O
)	O
.	O

At	O
a	O
stringent	O
p	O
-	O
value	O
cutoff	O
of	O
0.01	O
,	O
four	O
of	O
the	O
five	O
studentized	O
residuals	O
were	O
designated	O
as	O
significant	O
""""	O
outliers	O
,	O
""""	O
indicating	O
that	O
the	O
probeset	O
was	O
""""	O
unusual	O
.	O
""""	O
RT	O
-	O
PCR	O
confirmed	O
that	O
the	O
exon	O
,	O
represented	O
by	O
the	O
probeset	O
,	O
was	O
indeed	O
differentially	O
included	O
in	O
hESCs	O
and	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7B	O
)	O
.	O

Applying	O
this	O
approach	O
to	O
all	O
gene	O
models	O
revealed	O
that	O
,	O
as	O
expected	O
,	O
the	O
majority	O
of	O
studentized	O
residuals	O
are	O
centered	O
at	O
zero	O
(	O
Figure	O
3E	O
)	O
.	O

Thus	O
far	O
in	O
the	O
example	O
,	O
our	O
analysis	O
was	O
based	O
on	O
regression	O
of	O
hESCs	O
(	O
y	O
-	O
axis	O
)	O
versus	O
hCNS	O
-	O
SCns	O
(	O
x	O
-	O
axis	O
)	O
(	O
Figure	O
3B–3D	O
)	O
.	O

However	O
,	O
robust	O
regression	O
as	O
described	O
was	O
not	O
symmetrical	O
,	O
i.e.	O
,	O
parameter	O
estimation	O
of	O
y	O
as	O
a	O
function	O
of	O
x	O
was	O
not	O
the	O
same	O
as	O
that	O
of	O
x	O
as	O
a	O
function	O
of	O
y.	O
The	O
negative	O
slope	O
revealed	O
that	O
probesets	O
enriched	O
in	O
hESCs	O
versus	O
hCNS	O
-	O
SCns	O
(	O
positive	O
valued	O
)	O
,	O
were	O
expectedly	O
depleted	O
when	O
hCNS	O
-	O
SCns	O
was	O
compared	O
to	O
hESCs	O
(	O
negative	O
valued	O
;	O
Figure	O
3F	O
)	O
.	O

As	O
our	O
method	O
for	O
predicting	O
candidate	O
alternative	O
exons	O
was	O
based	O
on	O
identification	O
of	O
outliers	O
using	O
robust	O
regression	O
,	O
we	O
named	O
the	O
method	O
REAP	O
.	O

Identification	O
and	O
Removal	O
of	O
False	O
PositivesIn	O
the	O
process	O
of	O
experimentally	O
validating	O
our	O
predictions	O
,	O
we	O
encountered	O
three	O
main	O
sources	O
of	O
false	O
positives	O
(	O
FP	O
)	O
from	O
robust	O
regression	O
.	O

First	O
,	O
we	O
identified	O
genes	O
with	O
probeset	O
signal	O
estimates	O
that	O
were	O
poorly	O
correlated	O
and	O
were	O
not	O
amenable	O
to	O
our	O
method	O
.	O

As	O
an	O
example	O
,	O
the	O
median	O
probeset	O
signal	O
estimates	O
in	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
of	O
the	O
FIP1L1	B
gene	O
(	O
gene	O
identifiers	O
BC011543	O
,	O
AL136910	O
)	O
had	O
a	O
Pearson	O
correlation	O
coefficient	O
of	O
0.38	O
,	O
and	O
the	O
distribution	O
of	O
points	O
was	O
not	O
amenable	O
to	O
robust	O
regression	O
(	O
Figure	O
4A	O
)	O
.	O

To	O
avoid	O
inappropriate	O
application	O
of	O
REAP	O
and	O
generating	O
false	O
predictions	O
,	O
we	O
empirically	O
determined	O
that	O
a	O
gene	O
had	O
to	O
have	O
a	O
Pearson	O
correlation	O
coefficient	O
cutoff	O
of	O
0.6	O
before	O
being	O
amenable	O
to	O
REAP	O
analysis	O
.	O

Next	O
,	O
we	O
managed	O
two	O
additional	O
sources	O
of	O
FPs	O
,	O
namely	O
""""	O
high	O
-	O
leverage	O
""""	O
and	O
""""	O
high	O
-	O
influence	O
""""	O
points	O
,	O
which	O
we	O
were	O
able	O
to	O
identify	O
by	O
computing	O
the	O
following	O
metrics	O
.	O

For	O
every	O
point	O
,	O
we	O
computed	O
(	O
i	O
)	O
the	O
studentized	O
residual	O
(	O
as	O
described	O
above	O
)	O
,	O
(	O
ii	O
)	O
the	O
influence	O
,	O
and	O
(	O
iii	O
)	O
the	O
leverage	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
more	O
details	O
)	O
.	O

Leverage	O
assessed	O
how	O
far	O
away	O
a	O
value	O
of	O
the	O
independent	O
variable	O
was	O
from	O
the	O
mean	O
value	O
;	O
the	O
farther	O
away	O
the	O
observation	O
the	O
more	O
leverage	O
it	O
had	O
.	O

The	O
influence	O
of	O
a	O
point	O
was	O
related	O
to	O
its	O
covariance	O
ratio	O
:	O
a	O
covariance	O
ratio	O
larger	O
(	O
or	O
smaller	O
)	O
than	O
1	O
implied	O
that	O
the	O
point	O
was	O
closer	O
(	O
or	O
farther	O
)	O
than	O
was	O
typical	O
to	O
the	O
regression	O
line	O
,	O
so	O
removing	O
it	O
would	O
hurt	O
(	O
or	O
help	O
)	O
the	O
accuracy	O
of	O
the	O
line	O
and	O
would	O
increase	O
(	O
or	O
decrease	O
)	O
the	O
error	O
term	O
variance	O
.	O

Influence	O
was	O
computed	O
as	O
the	O
absolute	O
difference	O
between	O
the	O
covariance	O
ratio	O
and	O
unity	O
.	O

To	O
illustrate	O
further	O
,	O
a	O
point	O
was	O
classified	O
as	O
an	O
""""	O
outlier	O
""""	O
if	O
it	O
had	O
a	O
large	O
studentized	O
residual	O
(	O
p	O
<	O
0.01	O
)	O
and	O
low	O
leverage	O
(	O
boxed	O
point	O
""""	O
a	O
""""	O
)	O
;	O
as	O
a	O
""""	O
high	O
-	O
leverage	O
""""	O
point	O
if	O
it	O
had	O
a	O
low	O
studentized	O
residual	O
and	O
high	O
leverage	O
(	O
boxed	O
point	O
""""	O
b	O
""""	O
)	O
;	O
and	O
as	O
a	O
""""	O
high	O
-	O
influence	O
""""	O
point	O
if	O
it	O
had	O
a	O
high	O
studentized	O
residual	O
,	O
high	O
leverage	O
,	O
and	O
high	O
influence	O
(	O
boxed	O
point	O
""""	O
c	O
""""	O
;	O
Figure	O
4B	O
)	O
.	O

Points	O
that	O
resembled	O
boxed	O
point	O
""""	O
a	O
""""	O
were	O
designated	O
as	O
potential	O
AS	O
events	O
.	O

For	O
example	O
,	O
four	O
of	O
the	O
five	O
boxed	O
points	O
in	O
Figure	O
3C	O
were	O
""""	O
outliers	O
,	O
""""	O
and	O
RT	O
-	O
PCR	O
validation	O
indicated	O
that	O
the	O
exon	O
represented	O
by	O
the	O
probeset	O
was	O
indeed	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
(	O
EHBP1	O
,	O
Figure	O
7B	O
)	O
.	O

Points	O
that	O
were	O
""""	O
high	O
-	O
leverage	O
,	O
""""	O
such	O
as	O
the	O
five	O
points	O
in	O
the	O
CLCN2	B
gene	O
,	O
were	O
experimentally	O
verified	O
to	O
be	O
a	O
FP	O
(	O
Figure	O
4C	O
;	O
unpublished	O
data	O
)	O
.	O

Points	O
that	O
were	O
""""	O
high	O
-	O
influence	O
,	O
""""	O
such	O
as	O
the	O
four	O
of	O
five	O
boxed	O
points	O
in	O
the	O
ABCA3	B
gene	O
were	O
also	O
experimentally	O
verified	O
to	O
be	O
a	O
FP	O
(	O
Figure	O
4D	O
;	O
unpublished	O
data	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
order	O
to	O
reduce	O
the	O
FP	O
rate	O
,	O
all	O
points	O
were	O
evaluated	O
according	O
to	O
the	O
metrics	O
described	O
,	O
and	O
points	O
that	O
were	O
significant	O
""""	O
outliers	O
""""	O
were	O
considered	O
putative	O
AS	O
events	O
.	O

Figure	O
4Sources	O
of	O
False	O
Positives	O
(	O
A	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
FIP1L1	B
gene	O
and	O
the	O
line	O
representing	O
the	O
robust	O
regression	O
estimate.	O
(	O
B	O
)	O

Boxed	O
point	O
""""	O
a	O
""""	O
represents	O
a	O
significant	O
""""	O
outlier	O
""""	O
(	O
with	O
a	O
significantly	O
different	O
studentized	O
residual	O
and	O
low	O
leverage	O
)	O
.	O

Boxed	O
point	O
""""	O
b	O
""""	O
represents	O
a	O
""""	O
high	O
leverage	O
""""	O
point	O
(	O
low	O
studentized	O
residual	O
and	O
a	O
high	O
leverage	O
)	O
.	O

Boxed	O
point	O
""""	O
c	O
""""	O
represents	O
a	O
""""	O
high	O
influence	O
""""	O
point	O
(	O
high	O
studentized	O
residual	O
,	O
high	O
leverage	O
,	O
and	O
high	O
influence	O
)	O
.	O
(	O
C	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
CLCN2	B
gene	O
.	O

Boxed	O
points	O
represent	O
""""	O
high	O
leverage	O
""""	O
points.	O
(	O
D	O
)	O
Scatter	O
plot	O
of	O
points	O
for	O
the	O
ABCA3	B
gene	O
.	O

Boxed	O
points	O
represent	O
""""	O
high	O
influence	O
""""	O
points	O
.	O

Global	O
Identification	O
and	O
Characterization	O
of	O
REAP	O
[	O
+	O
]	O
ExonsREAP	O
was	O
applied	O
to	O
identify	O
AS	O
events	O
in	O
NPs	O
compared	O
to	O
hESCs	O
:	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
;	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
.	O

After	O
removing	O
potential	O
FPs	O
,	O
11,348	O
genes	O
containing	O
158,657	O
probesets	O
were	O
scored	O
by	O
REAP.As	O
described	O
above	O
,	O
for	O
each	O
pair	O
of	O
cell	O
lines	O
compared	O
,	O
each	O
probset	O
was	O
represented	O
by	O
five	O
points	O
,	O
where	O
each	O
point	O
was	O
defined	O
a	O
significant	O
outlier	O
if	O
it	O
had	O
a	O
high	O
residual	O
(	O
p	O
<	O
0.01	O
)	O
,	O
low	O
influence	O
,	O
and	O
high	O
leverage	O
.	O

Points	O
per	O
probeset	O
should	O
be	O
correlated	O
;	O
in	O
other	O
words	O
,	O
if	O
one	O
point	O
was	O
a	O
significant	O
outlier	O
,	O
the	O
other	O
points	O
were	O
expected	O
to	O
be	O
outliers	O
as	O
well	O
.	O

To	O
ensure	O
that	O
this	O
was	O
the	O
case	O
,	O
we	O
counted	O
the	O
number	O
of	O
probesets	O
with	O
N	O
significant	O
outliers	O
,	O
where	O
N	O
was	O
varied	O
from	O
0	O
to	O
5	O
.	O

Next	O
,	O
the	O
identity	O
of	O
the	O
probesets	O
and	O
points	O
derived	O
from	O
them	O
were	O
exchanged	O
with	O
other	O
probesets	O
,	O
keeping	O
constant	O
the	O
total	O
number	O
of	O
points	O
that	O
were	O
considered	O
significant	O
outliers	O
.	O

At	O
N	O
=	O
0	O
,	O
we	O
observed	O
approximately	O
equal	O
numbers	O
of	O
probesets	O
in	O
the	O
actual	O
versus	O
shuffled	O
controls	O
.	O

In	O
contrast	O
,	O
we	O
observed	O
that	O
there	O
were	O
1.5	O
times	O
more	O
probesets	O
with	O
N	O
=	O
2	O
significant	O
outliers	O
relative	O
to	O
shuffled	O
controls	O
;	O
12–31	O
times	O
more	O
probesets	O
with	O
N	O
=	O
3	O
;	O
and	O
17–612	O
times	O
more	O
probesets	O
that	O
had	O
N	O
=	O
4	O
significant	O
outliers	O
(	O
Figure	O
5A	O
;	O
see	O
Table	O
S1	O
)	O
.	O

For	O
example	O
,	O
in	O
hCNS	O
-	O
SCns	O
compared	O
to	O
Cyt	O
-	O
ES	O
,	O
approximately	O
0.39	O
%	O
(	O
490	O
of	O
124,604	O
)	O
of	O
probesets	O
had	O
three	O
significant	O
outliers	O
and	O
0.25	O
%	O
(	O
308	O
probesets	O
)	O
had	O
four	O
significant	O
outliers	O
,	O
relative	O
to	O
0.02	O
%	O
and	O
0	O
%	O
of	O
shuffled	O
controls	O
,	O
respectively	O
.	O

Figure	O
5Correlation	O
between	O
""""	O
"Outliers"""	O
(	O
A	O
)	O
The	O
number	O
of	O
probesets	O
with	O
N	O
significant	O
""""	O
outliers	O
""""	O
was	O
determined	O
for	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
,	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
,	O
Cyt	O
-	O
NPs	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
HUES6-NPs	O
versus	O
HUES6-ES	O
(	O
N	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
)	O
.	O

For	O
comparison	O
,	O
points	O
to	O
probeset	O
relationships	O
were	O
randomly	O
permuted	O
,	O
retaining	O
the	O
same	O
number	O
of	O
""""	O
outliers	O
.	O
""""	O

Vertical	O
bars	O
represent	O
the	O
ratio	O
between	O
the	O
number	O
of	O
actual	O
points	O
and	O
the	O
randomly	O
permutated	O
sets.	O
(	O
B	O
)	O
Similar	O
to	O
(	O
A	O
)	O
,	O
except	O
points	O
were	O
counted	O
as	O
""""	O
outliers	O
""""	O
only	O
if	O
they	O
were	O
""""	O
outliers	O
""""	O
in	O
both	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
(	O
combined	O
hCNS	O
-	O
SCns	O
versus	O
hESC	O
;	O
blue	O
bars	O
)	O
;	O
in	O
both	O
HUES6-NP	O
versus	O
HUES6-ES	O
and	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
(	O
combined	O
derived	O
NP	O
versus	O
hESC	O
;	O
red	O
bars	O
)	O
;	O
and	O
in	O
all	O
four	O
comparisons	O
(	O
combined	O
NP	O
versus	O
hESC	O
;	O
yellow	O
bar	O
)	O
.Next	O
we	O
asked	O
whether	O
the	O
overlap	O
between	O
related	O
comparisons	O
was	O
higher	O
than	O
expected	O
.	O

Comparing	O
the	O
significant	O
probesets	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
revealed	O
672	O
significant	O
probesets	O
(	O
N	O
≥	O
2	O
)	O
,	O
whereas	O
if	O
we	O
shuffled	O
the	O
associations	O
between	O
probeset	O
identity	O
and	O
significant	O
outliers	O
,	O
only	O
four	O
significant	O
probesets	O
(	O
N	O
≥	O
2	O
)	O
were	O
identified	O
—	O
a	O
168-fold	O
enrichment	O
(	O
Figure	O
5B	O
,	O
Table	O
S1	O
)	O
.	O

A	O
total	O
of	O
236	O
significant	O
probesets	O
overlapped	O
when	O
we	O
compared	O
the	O
derived	O
NPs	O
to	O
hESCs	O
(	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
and	O
HUES6-NP	O
versus	O
HUES6-ES	O
)	O
,	O
relative	O
to	O
seven	O
significant	O
probesets	O
(	O
34-fold	O
enrichment	O
)	O
.At	O
a	O
cutoff	O
of	O
two	O
significant	O
outliers	O
,	O
1,737	O
probesets	O
contained	O
in	O
internal	O
exons	O
were	O
defined	O
as	O
positive	O
REAP	O
predictions	O
(	O
hereafter	O
called	O
REAP	O
[	O
+	O
]	O
)	O
exons	O
—	O
candidate	O
AS	O
events	O
that	O
distinguished	O
NP	O
from	O
hESC	O
.	O

Surprisingly	O
,	O
we	O
observed	O
that	O
the	O
majority	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
specific	O
to	O
the	O
pair	O
of	O
hESC	O
and	O
NP	O
that	O
was	O
compared	O
,	O
likely	O
reflecting	O
differences	O
in	O
genetic	O
origins	O
and/or	O
culturing	O
and	O
differentiation	O
conditions	O
of	O
the	O
cell	O
lines	O
:	O
614	O
REAP	O
[	O
+	O
]	O
events	O
were	O
unique	O
to	O
hCNS	O
-	O
SCns	O
versus	O
HUE6-ES	O
;	O
220	O
were	O
unique	O
to	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
;	O
439	O
were	O
unique	O
to	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
and	O
250	O
were	O
unique	O
to	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
.	O

The	O
shared	O
events	O
between	O
pairs	O
of	O
comparisons	O
made	O
up	O
a	O
minority	O
of	O
the	O
total	O
number	O
identified	O
:	O
102	O
REAP	O
[	O
+	O
]	O
events	O
were	O
found	O
to	O
be	O
in	O
common	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
;	O
48	O
between	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
HUES6-NP	O
versus	O
HUES6-ES	O
;	O
and	O
only	O
17	O
between	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
ES	O
and	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
(	O
Table	O
S2	O
)	O
.	O

Comparison	O
of	O
REAP	O
to	O
EST	O
-	O
Based	O
Method	O
and	O
ACEScanTraditionally	O
,	O
AS	O
exons	O
were	O
discovered	O
by	O
using	O
EST	O
alignments	O
to	O
genomic	O
loci	O
,	O
and	O
also	O
more	O
recently	O
by	O
computational	O
algorithms	O
that	O
used	O
sequence	O
information	O
extracted	O
from	O
multiple	O
genomes	O
.	O

Here	O
,	O
we	O
compared	O
REAP	O
predictions	O
to	O
both	O
approaches	O
.	O

In	O
the	O
first	O
comparison	O
,	O
publicly	O
available	O
ESTs	O
and	O
mRNA	O
transcripts	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
sequence	O
.	O

13,934	O
exons	O
with	O
evidence	O
for	O
exon	O
-	O
skipping	O
and/or	O
inclusion	O
(	O
EST	O
-	O
SE	O
for	O
EST	O
-	O
verified	O
skipped	O
exons	O
)	O
were	O
generated	O
,	O
comprising	O
∼7	O
%	O
of	O
all	O
internal	O
exons	O
.	O

First	O
we	O
analyzed	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

If	O
we	O
required	O
that	O
none	O
of	O
the	O
points	O
per	O
probeset	O
(	O
exon	O
)	O
was	O
significant	O
,	O
6	O
%	O
(	O
4,402	O
of	O
71,731	O
)	O
of	O
exons	O
(	O
after	O
probeset	O
mapping	O
)	O
had	O
evidence	O
for	O
EST	O
-	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

Shuffling	O
the	O
mapping	O
between	O
these	O
probesets	O
and	O
exons	O
resulted	O
in	O
8	O
%	O
(	O
5,777	O
of	O
71,731	O
)	O
of	O
exons	O
with	O
evidence	O
for	O
EST	O
-	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

These	O
percentages	O
were	O
not	O
significantly	O
different	O
from	O
the	O
7	O
%	O
of	O
exons	O
with	O
EST	O
evidence	O
for	O
AS	O
observed	O
from	O
using	O
all	O
exons	O
.	O

By	O
raising	O
the	O
requirement	O
that	O
probesets	O
had	O
to	O
contain	O
at	O
least	O
one	O
significant	O
point	O
to	O
five	O
significant	O
points	O
,	O
the	O
percentage	O
of	O
EST	O
-	O
SE	O
increased	O
dramatically	O
from	O
11	O
%	O
(	O
531	O
of	O
4,898	O
exons	O
)	O
to	O
26	O
%	O
(	O
33	O
of	O
126	O
)	O
.	O

In	O
comparison	O
,	O
the	O
shuffled	O
probesets	O
at	O
the	O
same	O
requirements	O
remained	O
at	O
∼8	O
%	O
,	O
rising	O
slightly	O
to	O
11	O
%	O
at	O
five	O
points	O
,	O
due	O
to	O
small	O
sample	O
sizes	O
.	O

Similar	O
trends	O
were	O
observed	O
with	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
the	O
derived	O
NPs	O
versus	O
hESCs	O
(	O
Figure	O
6A	O
)	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
enriched	O
for	O
AS	O
events	O
independently	O
identified	O
by	O
a	O
transcript	O
-	O
based	O
approach	O
.	O

Figure	O
6Comparison	O
of	O
REAP	O
Predictions	O
for	O
hCNS	O
-	O
SCns	O
versus	O
Cyt	O
-	O
hES	O
,	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
,	O
Cyt	O
-	O
NP	O
versus	O
Cyt	O
-	O
ES	O
,	O
and	O
HUES6-NPs	O
versus	O
HUES6-ES	O
with	O
Alternative	O
Exons	O
Identified	O
by	O
an	O
EST	O
-	O
Based	O
Method	O
and	O
ACEScan	O
(	O
A	O
)	O
Black	O
-	O
filled	O
squares	O
represented	O
the	O
fraction	O
of	O
exons	O
containing	O
probesets	O
with	O
N	O
significant	O
points	O
that	O
had	O
EST	O
evidence	O
for	O
exon	O
inclusion	O
or	O
exclusion	O
(	O
N	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
)	O
.	O

White	O
-	O
filled	O
triangles	O
represented	O
similarly	O
computed	O
fractions	O
with	O
permuted	O
probeset	O
to	O
exon	O
mappings.	O
(	O
B	O
)	O
Black	O
-	O
filled	O
squares	O
represented	O
the	O
fraction	O
of	O
exons	O
containing	O
probesets	O
with	O
N	O
significant	O
points	O
that	O
had	O
ACEScan	O
positive	O
scores	O
,	O
indicative	O
of	O
evolutionarily	O
conserved	O
alternative	O
exons	O
.	O

White	O
-	O
filled	O
triangles	O
represented	O
similarly	O
computed	O
fractions	O
with	O
permuted	O
probeset	O
to	O
exon	O
mappings	O
.	O

Next	O
,	O
we	O
compared	O
REAP	O
predictions	O
to	O
a	O
computational	O
approach	O
of	O
identifying	O
exons	O
with	O
AS	O
conserved	O
in	O
human	O
and	O
mouse	O
,	O
ACEScan	O
[	O
55	O
]	O
.	O

ACEScan	O
receives	O
as	O
input	O
orthologous	O
human	O
–	O
mouse	O
exon	O
pairs	O
and	O
flanking	O
intronic	O
regions	O
and	O
computes	O
sequence	O
features	O
and	O
integrates	O
the	O
features	O
into	O
a	O
machine	O
-	O
learning	O
algorithm	O
to	O
assign	O
a	O
real	O
-	O
valued	O
score	O
to	O
the	O
exon	O
.	O

A	O
positive	O
score	O
indicated	O
a	O
higher	O
likelihood	O
of	O
being	O
AS	O
in	O
both	O
human	O
and	O
mouse	O
.	O

ACEScan	O
was	O
updated	O
in	O
the	O
following	O
ways	O
.	O

Firstly	O
,	O
instead	O
of	O
relying	O
on	O
orthology	O
information	O
by	O
Ensembl	O
,	O
and	O
then	O
aligning	O
flanking	O
introns	O
in	O
""""	O
orthologous	O
""""	O
exons	O
,	O
conserved	O
exonic	O
and	O
intronic	O
regions	O
in	O
human	O
and	O
mouse	O
from	O
genome	O
-	O
wide	O
multiple	O
alignments	O
were	O
extracted	O
.	O

Secondly	O
,	O
whereas	O
in	O
our	O
previous	O
analysis	O
exons	O
from	O
the	O
longest	O
transcript	O
in	O
Ensembl	O
were	O
utilized	O
,	O
now	O
we	O
collapsed	O
all	O
the	O
transcripts	O
available	O
at	O
the	O
UCSC	O
genome	O
browser	O
and	O
analyzed	O
all	O
exons	O
in	O
the	O
entire	O
gene	O
loci	O
.	O

ACEScan	O
was	O
utilized	O
to	O
assign	O
ACEScan	O
scores	O
to	O
all	O
∼162,000	O
internal	O
exons	O
in	O
our	O
genes	O
.	O

Exons	O
annotated	O
as	O
first	O
or	O
last	O
exons	O
in	O
Refseq	O
mRNAs	O
were	O
excluded	O
from	O
our	O
analysis	O
,	O
resulting	O
in	O
4,487	O
positive	O
-	O
scoring	O
exons	O
,	O
2-fold	O
more	O
exons	O
than	O
originally	O
published	O
.	O

Here	O
we	O
repeated	O
our	O
analysis	O
with	O
exons	O
with	O
positive	O
ACEScan	O
scores	O
(	O
ACE	O
[	O
+	O
]	O
)	O
instead	O
of	O
EST	O
-	O
SEs	O
.	O

If	O
we	O
required	O
that	O
none	O
of	O
the	O
points	O
per	O
probeset	O
(	O
exon	O
)	O
was	O
significant	O
,	O
2	O
%	O
(	O
1,645	O
of	O
71,731	O
)	O
of	O
exons	O
(	O
after	O
probeset	O
mapping	O
)	O
were	O
ACE	O
[	O
+	O
]	O
(	O
Figure	O
6B	O
)	O
.	O

Shuffling	O
the	O
mapping	O
between	O
these	O
probesets	O
and	O
exons	O
resulted	O
in	O
3	O
%	O
(	O
2,044	O
of	O
71,731	O
)	O
of	O
exons	O
being	O
ACE	O
[	O
+	O
]	O
(	O
Figure	O
6B	O
)	O
.	O

These	O
percentages	O
were	O
not	O
significantly	O
different	O
from	O
the	O
2.7	O
%	O
observed	O
from	O
all	O
exons	O
(	O
4,487	O
of	O
the	O
162,000	O
exons	O
that	O
were	O
scored	O
by	O
ACEScan	O
)	O
.	O

By	O
raising	O
the	O
requirement	O
that	O
probesets	O
had	O
to	O
contain	O
five	O
significant	O
points	O
,	O
the	O
percentage	O
of	O
ACE	O
[	O
+	O
]	O
exons	O
increased	O
from	O
4	O
%	O
to	O
11	O
%	O
.	O

However	O
,	O
the	O
sample	O
sizes	O
were	O
small	O
.	O

In	O
comparison	O
,	O
the	O
shuffled	O
probesets	O
at	O
the	O
same	O
requirements	O
remained	O
at	O
∼4	O
%	O
.	O

Similar	O
overall	O
trends	O
were	O
observed	O
with	O
hCNS	O
-	O
SCns	O
versus	O
HUES6-ES	O
and	O
the	O
derived	O
NPs	O
versus	O
hESCs	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
total	O
,	O
7.5	O
%	O
(	O
131	O
of	O
1,737	O
)	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
designated	O
as	O
ACEScan	O
[	O
+	O
]	O
compared	O
to	O
2.4	O
%	O
(	O
2,328	O
of	O
97,437	O
)	O
of	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

This	O
result	O
suggested	O
that	O
a	O
small	O
but	O
significantly	O
enriched	O
fraction	O
of	O
AS	O
events	O
in	O
hESCs	O
versus	O
NPs	O
was	O
likely	O
to	O
be	O
evolutionarily	O
conserved	O
in	O
human	O
and	O
mouse	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggested	O
that	O
REAP	O
predictions	O
were	O
congruent	O
with	O
predictions	O
from	O
two	O
independent	O
,	O
orthogonal	O
methods	O
.	O

Experimental	O
Validation	O
of	O
Alternative	O
ExonsThe	O
sensitivity	O
and	O
specificity	O
of	O
REAP	O
in	O
the	O
identification	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
was	O
tested	O
by	O
RT	O
-	O
PCR	O
.	O

To	O
validate	O
REAP	O
[	O
+	O
]	O
alternative	O
exons	O
,	O
RT	O
-	O
PCR	O
primers	O
were	O
designed	O
in	O
the	O
flanking	O
exons	O
to	O
amplify	O
both	O
isoforms	O
.	O

To	O
be	O
a	O
positively	O
validated	O
candidate	O
,	O
the	O
PCR	O
products	O
on	O
a	O
gel	O
had	O
to	O
satisfy	O
all	O
of	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
at	O
least	O
one	O
isoform	O
with	O
the	O
expected	O
size	O
must	O
be	O
visible	O
in	O
each	O
cell	O
type	O
;	O
(	O
ii	O
)	O
the	O
relative	O
abundance	O
of	O
the	O
two	O
isoforms	O
must	O
be	O
altered	O
between	O
two	O
cell	O
types	O
and	O
the	O
direction	O
of	O
change	O
have	O
to	O
be	O
consistent	O
with	O
the	O
REAP	O
studentized	O
residuals	O
:	O
in	O
our	O
study	O
positive	O
residuals	O
implied	O
inclusion	O
in	O
hESCs	O
and	O
skipping	O
in	O
NPs	O
,	O
and	O
negative	O
residuals	O
implied	O
inclusion	O
in	O
NP	O
and	O
skipping	O
in	O
hESCs	O
;	O
and	O
(	O
iii	O
)	O
the	O
results	O
were	O
replicable	O
in	O
at	O
least	O
two	O
experiments	O
.	O

For	O
simplicity	O
of	O
design	O
,	O
we	O
tested	O
candidates	O
predicted	O
from	O
Cyt	O
-	O
ES	O
versus	O
hCNS	O
-	O
SCns	O
.	O

Fifteen	O
REAP	O
[	O
+	O
]	O
exons	O
with	O
at	O
least	O
two	O
significant	O
outliers	O
(	O
out	O
of	O
five	O
)	O
were	O
randomly	O
chosen	O
as	O
predicted	O
alternative	O
events	O
and	O
thirty	O
-	O
five	O
exons	O
with	O
less	O
than	O
two	O
significant	O
outliers	O
were	O
randomly	O
chosen	O
as	O
constitutive	O
events	O
(	O
Table	O
S3	O
)	O
.	O

Nine	O
of	O
the	O
fifteen	O
exons	O
(	O
60	O
%	O
)	O
were	O
validated	O
as	O
AS	O
events	O
by	O
our	O
criteria	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
algorithm	O
at	O
the	O
cutoff	O
of	O
two	O
is	O
69	O
%	O
and	O
77	O
%	O
.	O

Increasing	O
the	O
cutoff	O
to	O
three	O
increased	O
the	O
specificity	O
to	O
85	O
%	O
,	O
with	O
a	O
slight	O
decrease	O
in	O
sensitivity	O
to	O
67	O
%	O
(	O
Figure	O
7A	O
)	O
.	O

The	O
patterns	O
of	O
AS	O
in	O
hESCs	O
were	O
similar	O
in	O
both	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
for	O
all	O
AS	O
events	O
validated	O
,	O
but	O
the	O
NPs	O
(	O
Cyt	O
-	O
NP	O
,	O
HUES6-NP	O
,	O
and	O
hCNS	O
-	O
SCns	O
)	O
had	O
more	O
varied	O
AS	O
.	O

The	O
pattern	O
of	O
AS	O
in	O
the	O
REAP	O
[	O
+	O
]	O
exons	O
in	O
the	O
SLK	B
(	O
serine	B
/	I
threonine	I
kinase	I
2	I
)	O
and	O
POT1	B
(	O
protection	B
of	I
telomeres	I
1	I
)	O
genes	O
showed	O
remarkable	O
agreement	O
within	O
derived	O
NPs	O
and	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7B	O
)	O
.	O

The	O
AS	O
exon	O
in	O
SLK	B
was	O
observed	O
to	O
be	O
included	O
in	O
hESCs	O
and	O
completely	O
excluded	O
in	O
NPs	O
;	O
the	O
AS	O
exon	O
in	O
the	O
POT1	B
gene	O
was	O
included	O
more	O
in	O
hESCs	O
and	O
a	O
smaller	O
isoform	O
persisted	O
in	O
NPs	O
.	O

The	O
AS	O
patterns	O
of	O
the	O
other	O
verified	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
consistently	O
similar	O
in	O
hESCs	O
but	O
were	O
more	O
varied	O
in	O
the	O
NP	O
.	O

Interestingly	O
,	O
the	O
patterns	O
of	O
AS	O
in	O
the	O
derived	O
NPs	O
(	O
Cyt	O
-	O
NP	O
and	O
HUES6-NP	O
)	O
were	O
not	O
always	O
identical	O
to	O
those	O
of	O
hCNS	O
-	O
SCns	O
.	O

For	O
example	O
,	O
the	O
AS	O
exon	O
in	O
the	O
EHBP1	B
(	O
EH	B
domain	I
binding	I
protein	I
1	I
)	O
gene	O
was	O
included	O
in	O
hESCs	O
but	O
skipped	O
in	O
hCNS	O
-	O
SCns	O
,	O
and	O
both	O
isoforms	O
were	O
present	O
in	O
the	O
derived	O
NPs	O
(	O
Figure	O
7B	O
)	O
.	O

As	O
another	O
example	O
,	O
the	O
AS	O
exon	O
in	O
the	O
SORBS1	B
(	O
sorbin	B
and	I
SH3	I
domain	I
containing	I
1	I
)	O
gene	O
was	O
skipped	O
in	O
hESCs	O
and	O
included	O
in	O
hCNS	O
-	O
SCns	O
,	O
but	O
exhibited	O
an	O
intermediate	O
pattern	O
in	O
the	O
derived	O
NPs	O
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
the	O
AS	O
patterns	O
in	O
the	O
derived	O
NPs	O
were	O
different	O
from	O
both	O
hESCs	O
and	O
hCNS	O
-	O
SCns	O
(	O
such	O
as	O
in	O
the	O
AS	O
exon	O
in	O
UNC84A	B
,	O
SIRT1	B
,	O
and	O
MLLT10	B
)	O
.Figure	O
7RT	O
-	O
PCR	O
Validation	O
of	O
REAP	O
-	O
Predicted	O
Alternative	O
Exons	O
(	O
A	O
)	O
Probesets	O
(	O
exons	O
)	O
were	O
considered	O
REAP	O
[	O
+	O
]	O
candidates	O
if	O
they	O
contained	O
at	O
least	O
N	O
=	O
2	O
(	O
white	O
bars	O
)	O
,	O
3	O
(	O
gray	O
bars	O
)	O
,	O
or	O
4	O
(	O
black	O
bars	O
)	O
significant	O
outliers	O
.	O

True	O
positive	O
(	O
TP	O
)	O
,	O
true	O
negative	O
(	O
TN	O
)	O
,	O
false	O
positive	O
(	O
FP	O
)	O
,	O
and	O
false	O
negative	O
(	O
FN	O
)	O
rates	O
were	O
calculated	O
from	O
RT	O
-	O
PCR	O
-	O
validated	O
REAP	O
[	O
+	O
]	O
exons	O
at	O
the	O
different	O
cutoffs	O
(	O
N	O
=	O
2	O
,	O
3	O
,	O
4	O
)	O
.	O
(	O
B	O
)	O
Nine	O
RT	O
-	O
PCR	O
validated	O
REAP	O
[	O
+	O
]	O
AS	O
events	O
in	O
hESCs	O
(	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
)	O
,	O
derived	O
NPs	O
(	O
Cyt	O
-	O
NP	O
and	O
HUES6-NP	O
)	O
,	O
and	O
hCNS	O
-	O
SCns	O
.	O

Arrows	O
indicate	O
the	O
larger	O
(	O
exon	O
-	O
included	O
)	O
isoforms	O
and	O
smaller	O
(	O
exon	O
-	O
skipped	O
)	O
isoforms.	O
(	O
C	O
)	O
RT	O
-	O
PCR	O
of	O
REAP	O
[	O
+	O
]	O
alternative	O
exons	O
from	O
EHBP1	B
,	O
SLK	B
,	O
and	O
RAI14	B
across	O
a	O
panel	O
of	O
human	O
tissues	O
.	O

Arrows	O
indicate	O
the	O
larger	O
(	O
exon	O
-	O
included	O
)	O
isoforms	O
and	O
smaller	O
(	O
exon	O
-	O
skipped	O
)	O
isoforms	O
.	O

First	O
,	O
given	O
three	O
independent	O
samples	O
each	O
from	O
two	O
conditions	O
,	O
we	O
concluded	O
that	O
REAP	O
was	O
able	O
to	O
identify	O
AS	O
events	O
with	O
high	O
specificity	O
but	O
with	O
moderate	O
sensitivity	O
.	O

Second	O
,	O
AS	O
events	O
in	O
hESCs	O
were	O
more	O
similar	O
,	O
whereas	O
the	O
AS	O
events	O
in	O
derived	O
NPs	O
were	O
consistent	O
with	O
or	O
intermediate	O
to	O
the	O
benchmark	O
hCNS	O
-	O
SCns	O
,	O
likely	O
reflecting	O
differences	O
in	O
the	O
cell	O
lines	O
and/or	O
differentiation	O
protocols	O
.	O

In	O
addition	O
,	O
we	O
tested	O
the	O
AS	O
patterns	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
from	O
EHBP1	B
,	O
SLK	B
,	O
and	O
RAI14	B
in	O
a	O
panel	O
of	O
differentiated	O
human	O
tissues	O
(	O
Figure	O
7C	O
)	O
.	O

The	O
REAP	O
[	O
+	O
]	O
alternative	O
exon	O
in	O
the	O
RAI14	B
(	O
retinoic	B
acid	I
induced	I
14	I
)	O
gene	O
was	O
observed	O
to	O
have	O
the	O
same	O
AS	O
pattern	O
in	O
NPs	O
as	O
in	O
frontal	O
and	O
temporal	O
cortex	O
and	O
in	O
several	O
other	O
,	O
non	O
-	O
brain	O
adult	O
tissues	O
,	O
such	O
as	O
heart	O
and	O
spleen	O
.	O

The	O
AS	O
pattern	O
of	O
the	O
REAP	O
[	O
+	O
]	O
exon	O
in	O
the	O
SLK	B
gene	O
in	O
NPs	O
was	O
similar	O
to	O
most	O
differentiated	O
tissues	O
;	O
however	O
,	O
the	O
relatively	O
strong	O
inclusion	O
of	O
the	O
exon	O
in	O
hESCs	O
was	O
unique	O
.	O

Even	O
in	O
esophagus	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
prostate	O
,	O
both	O
isoforms	O
were	O
present	O
.	O

The	O
relative	O
ratio	O
of	O
the	O
exon	O
-	O
included	O
to	O
exon	O
-	O
skipped	O
isoforms	O
in	O
SLK	B
likely	O
represents	O
an	O
ESC	O
-	O
specific	O
AS	O
signature	O
.	O

The	O
alternative	O
exon	O
in	O
the	O
EHBP1	B
gene	O
was	O
unusual	O
.	O

The	O
exon	O
was	O
included	O
in	O
hESCs	O
but	O
also	O
in	O
frontal	O
cortex	O
and	O
temporal	O
cortex	O
,	O
a	O
finding	O
that	O
was	O
unexpected	O
given	O
the	O
exclusion	O
of	O
the	O
exon	O
in	O
hCNS	O
-	O
SCns	O
(	O
Figure	O
7C	O
)	O
.	O

The	O
AS	O
pattern	O
in	O
hCNS	O
-	O
SCns	O
may	O
represent	O
a	O
transient	O
,	O
early	O
neuronal	O
molecular	O
change	O
.	O

Functional	O
and	O
Expression	O
Characteristics	O
of	O
REAP	O
[	O
+	O
]	O
GenesIn	O
total	O
,	O
1,500	O
genes	O
were	O
identified	O
that	O
contained	O
1,737	O
REAP	O
[	O
+	O
]	O
exons	O
,	O
68	O
%	O
of	O
which	O
lacked	O
prior	O
transcript	O
(	O
EST	O
/	O
cDNA	O
)	O
evidence	O
for	O
AS	O
.	O

To	O
determine	O
whether	O
genes	O
that	O
contained	O
REAP	O
[	O
+	O
]	O
exons	O
,	O
which	O
we	O
refer	O
to	O
as	O
REAP	O
[	O
+	O
]	O
genes	O
,	O
are	O
biased	O
toward	O
particular	O
biological	O
activities	O
,	O
REAP	O
[	O
+	O
]	O
genes	O
were	O
compared	O
to	O
a	O
set	O
of	O
REAP	O
analyzed	O
genes	O
not	O
found	O
to	O
have	O
REAP	O
[	O
+	O
]	O
exons	O
(	O
REAP	O
[	O
−	O
]	O
genes	O
)	O
.	O

A	O
Gene	O
Ontology	O
analysis	O
revealed	O
that	O
REAP	O
[	O
+	O
]	O
genes	O
are	O
enriched	O
for	O
GO	O
molecular	O
function	O
categories	O
""""	O
ATP	O
binding	O
,	O
""""	O
""""	O
helicase	B
activity	O
,	O
""""	O
""""	O
protein	O
serine	O
/	O
theronine	O
kinase	O
activity	O
,	O
""""	O
""""	O
small	B
GTPase	I
regulatory	I
/	I
interacting	I
protein	I
activity	O
,	O
""""	O
and	O
""""	O
thyroid	B
hormone	I
receptor	I
binding	O
""""	O
(	O
Table	O
1	O
)	O
.	O

In	O
terms	O
of	O
GO	O
biological	O
process	O
categories	O
,	O
REAP	O
[	O
+	O
]	O
genes	O
were	O
more	O
frequently	O
involved	O
in	O
""""	O
ubiquitin	B
cycle	O
.	O
""""	O

Similar	O
results	O
were	O
obtained	O
when	O
we	O
compared	O
REAP	O
[	O
+	O
]	O
genes	O
to	O
all	O
human	O
genes	O
that	O
did	O
not	O
contain	O
REAP	O
[	O
+	O
]	O
exons	O
(	O
Table	O
1	O
)	O
[	O
55	O
]	O
.Table	O
1Significantly	O
Enriched	O
Gene	O
Ontology	O
Terms	O
in	O
REAP	O
[	O
+	O
]	O
Genes	O
(	O
Cutoff	O
of	O
Two	O
Significant	O
""""	O
Outliers	O
""""	O
per	O
Probeset	O
)	O
Next	O
we	O
asked	O
if	O
REAP	O
[	O
+	O
]	O
genes	O
are	O
differentially	O
expressed	O
in	O
hESCs	O
compared	O
to	O
NPs	O
and	O
vice	O
versa	O
.	O

For	O
this	O
analysis	O
,	O
the	O
t	O
-	O
statistics	O
computed	O
above	O
measuring	O
the	O
enrichment	O
of	O
a	O
gene	O
in	O
hESCs	O
relative	O
to	O
NPs	O
was	O
utilized	O
for	O
only	O
REAP	O
-	O
analyzed	O
genes	O
.	O

At	O
a	O
defined	O
absolute	O
-	O
valued	O
cutoff	O
,	O
genes	O
were	O
divided	O
into	O
three	O
categories	O
:	O
""""	O
enriched	O
in	O
hESCs	O
,	O
""""	O
""""	O
enriched	O
in	O
NP	O
,	O
""""	O
or	O
""""	O
unchanged	O
""""	O
(	O
Figure	O
8A	O
)	O
.	O

Increasing	O
the	O
t	O
-	O
statistic	O
cutoff	O
from	O
one	O
to	O
five	O
,	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
genes	O
relative	O
to	O
REAP	O
-	O
analyzed	O
genes	O
remained	O
constant	O
in	O
the	O
""""	O
unchanged	O
""""	O
categories	O
(	O
Figure	O
8B	O
)	O
.	O

However	O
,	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
decreased	O
significantly	O
in	O
""""	O
enriched	O
in	O
hESCs	O
""""	O
and	O
""""	O
enriched	O
in	O
NPs	O
""""	O
categories	O
.	O

If	O
we	O
increased	O
the	O
cutoffs	O
on	O
genes	O
that	O
were	O
randomly	O
assigned	O
as	O
REAP	O
[	O
+	O
]	O
and	O
REAP	O
[	O
−	O
]	O
,	O
controlling	O
for	O
the	O
same	O
number	O
of	O
genes	O
in	O
each	O
category	O
,	O
we	O
observed	O
that	O
the	O
fraction	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
remained	O
unchanged	O
for	O
all	O
three	O
categories	O
(	O
Figure	O
8C	O
)	O
.	O

To	O
illustrate	O
,	O
at	O
a	O
cutoff	O
of	O
five	O
,	O
10	O
%	O
(	O
29	O
of	O
267	O
)	O
of	O
enriched	O
NP	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
genes	O
and	O
8.8	O
%	O
(	O
102	O
of	O
1,162	O
)	O
of	O
enriched	O
hESC	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
,	O
significantly	O
different	O
(	O
p	O
<	O
0.000005	O
)	O
from	O
the	O
random	O
control	O
where	O
∼14	O
%	O
of	O
enriched	O
NP	O
and	O
enriched	O
hESC	O
genes	O
were	O
REAP	O
[	O
+	O
]	O
.	O

At	O
a	O
cutoff	O
of	O
five	O
,	O
14	O
%	O
(	O
1,368	O
of	O
9,636	O
)	O
of	O
genes	O
that	O
were	O
expressed	O
at	O
similar	O
levels	O
between	O
hESCs	O
and	O
NPs	O
were	O
REAP	O
[	O
+	O
]	O
.	O

Our	O
results	O
suggested	O
that	O
a	O
strategy	O
of	O
focusing	O
on	O
differentially	O
expressed	O
genes	O
would	O
miss	O
at	O
least	O
14	O
%	O
of	O
transcriptionally	O
unchanged	O
genes	O
that	O
may	O
nevertheless	O
have	O
functional	O
AS	O
differences	O
between	O
hESCs	O
and	O
NPs	O
.	O

Figure	O
8Analysis	O
of	O
REAP	O
[	O
+	O
]	O
Genes	O
Relative	O
to	O
Transcriptional	O
Differences	O
(	O
A	O
)	O
Histogam	O
of	O
t	O
-	O
statistics	O
computed	O
from	O
gene	O
-	O
level	O
signal	O
estimates	O
measuring	O
the	O
enrichment	O
of	O
genes	O
in	O
hESC	O
and	O
in	O
NP	O
.	O

Genes	O
on	O
the	O
right	O
of	O
the	O
vertical	O
line	O
at	O
5	O
were	O
designated	O
enriched	O
in	O
hESC	O
and	O
genes	O
on	O
the	O
left	O
of	O
the	O
vertical	O
line	O
at	O
−5	O
were	O
designated	O
enriched	O
in	O
NP	O
;	O
genes	O
in	O
between	O
−5	O
and	O
5	O
were	O
designated	O
as	O
""""	O
unchanged	O
""""	O
or	O
expressed	O
similarly	O
in	O
hESC	O
and	O
NP.	O
(	O
B	O
)	O
Vertical	O
bars	O
representing	O
the	O
percentage	O
of	O
REAP	O
[	O
+	O
]	O
genes	O
out	O
of	O
all	O
genes	O
in	O
the	O
different	O
classifications	O
(	O
dashed	O
bar	O
:	O
""""	O
enriched	O
in	O
hESC	O
""""	O
;	O
black	O
filled	O
bar	O
:	O
""""	O
unchanged	O
""""	O
;	O
white	O
filled	O
bar	O
:	O
""""	O
enriched	O
in	O
NP	O
""""	O
)	O
,	O
at	O
different	O
cutoffs	O
of	O
1	O
to	O
5.	O
(	O
C	O
)	O
Set	O
of	O
genes	O
where	O
REAP	O
[	O
+	O
]	O
designation	O
was	O
randomly	O
chosen	O
.	O

Similar	O
representation	O
as	O
in	O
(	O
B	O
)	O
.	O

Conserved	O
Intronic	O
Splicing	O
Regulatory	O
Elements	O
Proximal	O
to	O
REAP	O
[	O
+	O
]	O
hESC	O
and	O
NP	O
ExonsMany	O
,	O
if	O
not	O
most	O
,	O
alternative	O
exons	O
undergo	O
cell	O
type	O
–	O
specific	O
regulation	O
by	O
the	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
splicing	O
regulatory	O
cis	O
-	O
elements	O
located	O
proximal	O
to	O
or	O
within	O
the	O
exons	O
.	O

As	O
many	O
tissue	O
-	O
specific	O
splicing	O
cis	O
-	O
regulatory	O
elements	O
were	O
localized	O
in	O
intronic	O
regions	O
of	O
AS	O
exons	O
,	O
we	O
focused	O
on	O
the	O
identification	O
of	O
intronic	O
splicing	O
regulatory	O
elements	O
(	O
ISREs	O
)	O
proximal	O
to	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

In	O
addition	O
,	O
we	O
wanted	O
to	O
identify	O
both	O
common	O
and	O
cell	O
type	O
–	O
specific	O
ISREs	O
.	O

Three	O
sets	O
of	O
exons	O
were	O
generated	O
:	O
(	O
i	O
)	O
REAP	O
[	O
+	O
]	O
exons	O
that	O
were	O
predicted	O
to	O
be	O
included	O
in	O
NPs	O
and	O
skipped	O
in	O
hESCs	O
(	O
REAP	O
[	O
+	O
]	O
NP	O
)	O
;	O
(	O
ii	O
)	O
REAP	O
[	O
+	O
]	O
exons	O
that	O
were	O
predicted	O
to	O
be	O
included	O
in	O
hESCs	O
and	O
skipped	O
in	O
NPs	O
(	O
REAP	O
[	O
+	O
]	O
hESC	O
)	O
;	O
and	O
(	O
iii	O
)	O
all	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

Regions	O
of	O
400	O
base	O
pairs	O
flanking	O
the	O
exons	O
were	O
targeted	O
for	O
search	O
.	O

Initially	O
,	O
5-mers	O
that	O
were	O
significantly	O
enriched	O
between	O
the	O
upstream	O
and	O
downstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
relative	O
to	O
REAP	O
[	O
−	O
]	O
exons	O
were	O
enumerated	O
.	O

We	O
were	O
not	O
able	O
to	O
identify	O
5-mers	O
that	O
were	O
statistically	O
significantly	O
different	O
.	O

Next	O
,	O
we	O
focused	O
on	O
splicing	O
signals	O
that	O
were	O
conserved	O
across	O
mammalian	O
genomes	O
as	O
a	O
way	O
of	O
enhancing	O
the	O
signal	O
of	O
detecting	O
functional	O
splicing	O
regulatory	O
sequences	O
[	O
66	O
]	O
.	O

Exons	O
that	O
were	O
orthologous	O
across	O
human	O
,	O
dog	O
,	O
rat	O
,	O
and	O
mouse	O
were	O
obtained	O
and	O
the	O
flanking	O
intronic	O
regions	O
were	O
aligned	O
(	O
400	O
bases	O
upstream	O
and	O
downstream	O
separately	O
;	O
Figure	O
9A	O
)	O
.	O

We	O
enumerated	O
k	O
-	O
mers	O
that	O
were	O
perfectly	O
conserved	O
across	O
all	O
four	O
genomes	O
in	O
the	O
upstream	O
(	O
and	O
downstream	O
)	O
intronic	O
regions	O
.	O

Each	O
conserved	O
k	O
-	O
mer	O
was	O
attributed	O
a	O
χ	O
score	O
representing	O
its	O
enrichment	O
in	O
a	O
set	O
of	O
exons	O
relative	O
to	O
another	O
set	O
of	O
exons	O
.	O

The	O
higher	O
the	O
score	O
,	O
the	O
more	O
frequent	O
the	O
conserved	O
k	O
-	O
mer	O
was	O
in	O
the	O
first	O
set	O
relative	O
to	O
the	O
second	O
set	O
.	O

As	O
a	O
negative	O
control	O
,	O
the	O
associations	O
between	O
REAP	O
scores	O
and	O
exons	O
were	O
shuffled	O
.	O

The	O
enrichment	O
scores	O
for	O
all	O
downstream	O
intronic	O
5-mers	O
for	O
shuffled	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
set	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
for	O
shuffled	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
were	O
displayed	O
(	O
Figure	O
9B	O
)	O
.	O

At	O
a	O
χ	O
cutoff	O
of	O
three	O
,	O
which	O
corresponded	O
to	O
a	O
p	O
-	O
value	O
of	O
0.0015	O
,	O
the	O
majority	O
of	O
5-mers	O
were	O
not	O
significantly	O
enriched	O
in	O
either	O
shuffled	O
set	O
.	O

Confident	O
that	O
no	O
association	O
of	O
k	O
-	O
mers	O
with	O
shuffled	O
REAP	O
exons	O
were	O
found	O
;	O
we	O
repeated	O
the	O
analyses	O
for	O
upstream	O
and	O
downstream	O
intronic	O
5-mers	O
for	O
the	O
original	O
unshuffled	O
sets	O
.	O

We	O
identified	O
68	O
conserved	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
;	O
and	O
34	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
(	O
Figure	O
9C	O
;	O
Table	O
S4	O
)	O
.	O

Of	O
the	O
5-mers	O
that	O
were	O
significantly	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
,	O
we	O
identified	O
a	O
U	O
-	O
rich	O
motif	O
(	O
UUUUU	O
)	O
,	O
a	O
GU	O
-	O
rich	O
motif	O
(	O
GUGUG	O
)	O
,	O
and	O
a	O
CU	O
-	O
rich	O
motif	O
(	O
CCUCU	O
,	O
CUCUC	O
,	O
UCUCU	O
,	O
GCUCU	O
)	O
.	O

It	O
is	O
known	O
that	O
the	O
heterogeneous	B
ribonucleoprotein	I
C	I
(	O
hnRNP	B
C	I
)	O
binding	O
site	O
obtained	O
by	O
SELEX	O
is	O
five	O
""""	O
"U""s"	O
[	O
67	O
]	O
.	O

GU	O
-	O
rich	O
sequences	O
in	O
flanking	O
intronic	O
regions	O
were	O
shown	O
to	O
bind	O
to	O
splicing	O
factor	O
ETR-3	B
to	O
regulate	O
AS	O
[	O
68	O
]	O
.	O

CU	O
-	O
rich	O
sequences	O
were	O
shown	O
to	O
bind	O
the	O
splicing	B
factor	I
PTB	I
[	O
69	O
]	O
.	O

Of	O
the	O
5-mers	O
enriched	O
upstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
we	O
observed	O
CUAAC	O
,	O
which	O
resembled	O
the	O
splicing	O
branch	O
-	O
signal	O
.	O

Of	O
the	O
six	O
5-mers	O
that	O
were	O
enriched	O
upstream	O
of	O
both	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
we	O
identified	O
GCAUG	O
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
an	O
intronic	O
splicing	O
cis	O
-	O
element	O
for	O
the	O
mammalian	O
fibronectin	B
and	O
calcitonin	B
/	O
CGRP	B
genes	O
[	O
70–72	O
]	O
.	O

More	O
recently	O
,	O
both	O
mammalian	O
Fox1	B
and	I
2	I
have	O
been	O
demonstrated	O
to	O
regulate	O
alternatively	O
spliced	O
exons	O
via	O
UGCAUG	O
binding	O
sites	O
in	O
neighboring	O
introns	O
in	O
neuronal	O
cell	O
cultures	O
[	O
73	O
]	O
.Figure	O
9Conserved	O
Intronic	O
cis	O
-	O
Elements	O
Enriched	O
Proximal	O
to	O
REAP	O
[	O
+	O
]	O
Alternative	O
Exons	O
(	O
A	O
)	O
Schematic	O
describing	O
the	O
enumeration	O
of	O
intronic	O
elements	O
across	O
400	O
bases	O
of	O
flanking	O
mammalian	O
introns	O
(	O
human	O
,	O
dog	O
,	O
rat	O
,	O
and	O
mouse	O
)	O
.	O

Red	O
and	O
green	O
horizontal	O
bars	O
represent	O
conserved	O
intronic	O
elements	O
and	O
nonconserved	O
elements	O
,	O
respectively	O
.	O

Internal	O
exons	O
were	O
divided	O
into	O
REAP	O
[	O
+	O
]	O
NP	O
,	O
REAP	O
[	O
+	O
]	O
ES	O
,	O
and	O
REAP	O
[	O
−	O
]	O
exons	O
.	O

The	O
χ	O
statistic	O
was	O
computed	O
to	O
represent	O
the	O
enrichment	O
of	O
conserved	O
elements	O
in	O
intronic	O
regions	O
flanking	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
.	O

The	O
sign	O
represented	O
the	O
direction	O
of	O
change	O
,	O
i.e.	O
,	O
positive	O
if	O
enriched	O
in	O
introns	O
flanking	O
REAP	O
[	O
+	O
]	O
versus	O
REAP	O
[	O
−	O
]	O
exon	O
.	O

Each	O
conserved	O
5-mer	O
was	O
associated	O
with	O
two	O
numbers	O
:	O
the	O
enrichment	O
in	O
introns	O
proximal	O
to	O
REAP	O
[	O
+	O
]	O
NP	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
x	O
-	O
axis	O
)	O
,	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
versus	O
REAP	O
[	O
−	O
]	O
exons	O
(	O
y	O
-	O
axis	O
)	O
.	O
(	O
B	O
)	O
Downstream	O
intronic	O
regions	O
,	O
where	O
the	O
association	O
between	O
REAP	O
[	O
+	O
]	O
designation	O
and	O
the	O
exons	O
was	O
shuffled.	O
(	O
C	O
)	O
Upstream	O
intronic	O
regions	O
.	O

Circled	O
5-mers	O
in	O
the	O
upper	O
right	O
quadrant	O
represent	O
conserved	O
5-mers	O
enriched	O
in	O
the	O
upstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons.	O
(	O
D	O
)	O

Downstream	O
intronic	O
regions	O
.	O

Circled	O
5-mers	O
in	O
the	O
upper	O
right	O
quadrant	O
represent	O
conserved	O
5-mers	O
enriched	O
in	O
the	O
downstream	O
intronic	O
regions	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
.	O

Eighteen	O
conserved	O
5-mers	O
were	O
significantly	O
enriched	O
in	O
the	O
downstream	O
introns	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
;	O
and	O
76	O
5-mers	O
were	O
enriched	O
downstream	O
of	O
REAP	O
[	O
+	O
]	O
NP	O
exons	O
(	O
Table	O
S4	O
,	O
Figure	O
9D	O
)	O
.	O

We	O
identified	O
a	O
motif	O
CUCAU	O
resembling	O
the	O
Nova	B
binding	O
site	O
YCAY	O
[	O
74	O
]	O
,	O
and	O
a	O
G	O
-	O
rich	O
motif	O
(	O
AGGGG	O
,	O
GGGGA	O
,	O
GGGGC	O
,	O
GGGGG	O
,	O
GGGGU	O
)	O
enriched	O
in	O
the	O
introns	O
downstream	O
of	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
.	O

G	O
-	O
rich	O
motifs	O
had	O
previously	O
been	O
shown	O
to	O
be	O
part	O
of	O
a	O
bipartite	O
signal	O
that	O
silences	O
AS	O
exons	O
[	O
75	O
]	O
.	O

Of	O
the	O
five	O
5-mers	O
that	O
were	O
enriched	O
downstream	O
of	O
both	O
REAP	O
[	O
+	O
]	O
NP	O
and	O
REAP	O
[	O
+	O
]	O
ES	O
exons	O
,	O
GCAUG	O
and	O
a	O
U	O
-	O
rich	O
motif	O
(	O
UUUUU	O
)	O
were	O
identified	O
.	O

We	O
concluded	O
that	O
potential	O
ISREs	O
were	O
enriched	O
proximal	O
to	O
a	O
subset	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
;	O
in	O
particular	O
,	O
the	O
Fox1	B
/	I
2	I
binding	O
site	O
GCUAG	O
may	O
play	O
a	O
regulatory	O
role	O
in	O
controlling	O
AS	O
events	O
in	O
hESCs	O
and	O
NPs	O
.	O

The	O
ability	O
of	O
ESCs	O
to	O
generate	O
all	O
three	O
embryonic	O
germ	O
layers	O
has	O
raised	O
the	O
exciting	O
possibility	O
that	O
hESCs	O
may	O
become	O
an	O
unlimited	O
source	O
of	O
cells	O
for	O
transplantation	O
therapies	O
involving	O
organs	O
or	O
tissues	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
blood	O
,	O
and	O
nervous	O
system	O
,	O
and	O
become	O
tools	O
to	O
explore	O
the	O
molecular	O
mechanisms	O
of	O
human	O
development	O
.	O

Despite	O
such	O
interests	O
,	O
relatively	O
little	O
is	O
understood	O
about	O
the	O
molecular	O
mechanisms	O
defining	O
their	O
pluripotency	O
and	O
the	O
molecular	O
changes	O
important	O
for	O
hESCs	O
to	O
differentiate	O
into	O
specific	O
cell	O
types	O
.	O

To	O
understand	O
these	O
events	O
,	O
protocols	O
are	O
still	O
being	O
developed	O
to	O
differentiate	O
ESCs	O
into	O
a	O
variety	O
of	O
lineages	O
.	O

Of	O
particular	O
biomedical	O
interest	O
is	O
in	O
the	O
capacity	O
of	O
hESCs	O
to	O
be	O
differentiated	O
into	O
a	O
self	O
-	O
renewing	O
population	O
of	O
NPs	O
that	O
can	O
be	O
then	O
further	O
coaxed	O
into	O
a	O
variety	O
of	O
neuronal	O
subtypes	O
,	O
such	O
as	O
dopaminergic	O
neurons	O
that	O
are	O
important	O
in	O
the	O
treatment	O
of	O
Parkinson	O
disease	O
or	O
cholinergic	O
neurons	O
for	O
ALS	O
(	O
amyotrophic	O
lateral	O
sclerosis	O
)	O
.	O

While	O
many	O
microarray	O
studies	O
have	O
explored	O
molecular	O
differences	O
between	O
hESCs	O
and	O
derived	O
NPs	O
,	O
most	O
,	O
if	O
not	O
all	O
,	O
have	O
focused	O
on	O
transcriptional	O
changes	O
.	O

These	O
studies	O
have	O
largely	O
ignored	O
intermediate	O
RNA	O
processing	O
events	O
prior	O
to	O
and	O
during	O
translation	O
.	O

In	O
recent	O
years	O
,	O
AS	O
has	O
gained	O
momentum	O
as	O
being	O
important	O
in	O
development	O
,	O
apoptosis	O
,	O
and	O
cancer	O
.	O

REAP	O
,	O
a	O
regression	O
-	O
based	O
method	O
for	O
analyzing	O
exon	O
array	O
data	O
was	O
introduced	O
,	O
and	O
was	O
applied	O
to	O
discover	O
AS	O
events	O
in	O
hESCs	O
,	O
their	O
derived	O
NPs	O
,	O
and	O
in	O
hCNS	O
-	O
SCns	O
.	O

REAP	O
was	O
based	O
on	O
the	O
assumptions	O
that	O
most	O
exons	O
in	O
the	O
gene	O
of	O
interest	O
and	O
in	O
the	O
genome	O
are	O
constitutively	O
spliced	O
and	O
that	O
outliers	O
in	O
a	O
linear	O
pairwise	O
comparison	O
of	O
the	O
signal	O
estimates	O
for	O
probesets	O
in	O
a	O
gene	O
could	O
be	O
detected	O
using	O
a	O
robust	O
regression	O
-	O
based	O
approach	O
.	O

REAP	O
predictions	O
were	O
found	O
to	O
correlate	O
well	O
with	O
transcript	O
-	O
based	O
methods	O
for	O
identifying	O
alternative	O
exons	O
,	O
which	O
interestingly	O
suggested	O
that	O
current	O
databases	O
of	O
transcript	O
information	O
,	O
albeit	O
not	O
specifically	O
enriched	O
for	O
hESC	O
or	O
NPs	O
,	O
in	O
aggregate	O
are	O
nevertheless	O
predictive	O
of	O
AS	O
events	O
in	O
hESC	O
and	O
NP	O
.	O

In	O
addition	O
,	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
also	O
enriched	O
for	O
ACEScan	O
-	O
predicted	O
evolutionarily	O
conserved	O
exons	O
[	O
55	O
]	O
.	O

As	O
ACEScan	O
utilized	O
a	O
different	O
set	O
of	O
information	O
from	O
REAP	O
,	O
the	O
agreement	O
between	O
both	O
algorithms	O
served	O
to	O
further	O
validate	O
the	O
predicted	O
alternative	O
exons	O
.	O

Additional	O
studies	O
in	O
mouse	O
ESCs	O
and	O
neural	O
derivatives	O
will	O
be	O
necessary	O
to	O
determine	O
if	O
these	O
AS	O
events	O
are	O
indeed	O
preserved	O
in	O
these	O
analogous	O
and	O
orthologous	O
cell	O
types	O
.	O

Our	O
finding	O
that	O
only	O
a	O
minority	O
of	O
AS	O
events	O
was	O
common	O
between	O
various	O
hESC	O
to	O
NP	O
comparisons	O
is	O
intriguing	O
.	O

A	O
possible	O
explanation	O
is	O
that	O
the	O
cell	O
lines	O
were	O
not	O
only	O
genetically	O
different	O
,	O
but	O
were	O
also	O
exposed	O
to	O
different	O
isolation	O
and	O
culture	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
different	O
differentiation	O
protocols	O
established	O
as	O
optimal	O
for	O
generating	O
Nestin	B
and	O
Sox1	B
positive	O
neural	O
precursors	O
may	O
lead	O
to	O
vastly	O
different	O
molecular	O
changes	O
.	O

It	O
is	O
likely	O
that	O
post	O
-	O
transcriptional	O
changes	O
such	O
as	O
AS	O
may	O
be	O
more	O
variable	O
despite	O
the	O
cells	O
being	O
at	O
acknowledged	O
""""	O
end	O
-	O
points	O
""""	O
defined	O
by	O
a	O
limited	O
set	O
of	O
immunohistochemical	O
markers	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
a	O
recent	O
study	O
that	O
showed	O
that	O
while	O
two	O
well	O
-	O
established	O
hESC	O
lines	O
differentiate	O
into	O
functional	O
neurons	O
,	O
the	O
two	O
lines	O
exhibited	O
distinct	O
differentiation	O
potentials	O
,	O
suggesting	O
that	O
some	O
preprogramming	O
had	O
occurred	O
[	O
76	O
]	O
.	O

In	O
particular	O
,	O
microRNA	O
profiling	O
revealed	O
significant	O
expression	O
differences	O
between	O
the	O
two	O
hESC	O
lines	O
,	O
suggesting	O
that	O
microRNAs	O
,	O
known	O
post	O
-	O
transcriptional	O
regulators	O
,	O
may	O
sway	O
the	O
differentiation	O
properties	O
of	O
the	O
cell	O
lines	O
[	O
76	O
]	O
.	O

We	O
postulated	O
that	O
AS	O
events	O
may	O
serve	O
also	O
to	O
bias	O
the	O
differentiation	O
spectrum	O
of	O
the	O
cells	O
,	O
an	O
important	O
avenue	O
for	O
future	O
work	O
.	O

Experimental	O
validation	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
suggested	O
a	O
high	O
specificity	O
at	O
the	O
expense	O
of	O
relatively	O
moderate	O
sensitivity	O
.	O

We	O
believe	O
that	O
the	O
high	O
FP	O
rates	O
may	O
arise	O
from	O
cross	O
-	O
hybridization	O
effects	O
that	O
remained	O
unaccounted	O
for	O
.	O

However	O
,	O
our	O
specificity	O
of	O
77	O
%	O
at	O
the	O
cutoff	O
of	O
two	O
significant	O
outliers	O
per	O
probeset	O
allowed	O
us	O
to	O
estimate	O
that	O
at	O
least	O
1,336	O
of	O
1,737	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
true	O
AS	O
events	O
that	O
changed	O
during	O
neuronal	O
differentiation	O
of	O
hESC	O
cells	O
,	O
and/or	O
were	O
different	O
between	O
endogeneous	O
NPs	O
and	O
hESC	O
.	O

On	O
average	O
,	O
7	O
%	O
of	O
all	O
human	O
exons	O
have	O
been	O
estimated	O
by	O
transcript	O
data	O
to	O
undergo	O
AS	O
;	O
thus	O
REAP	O
's	O
validation	O
rate	O
of	O
60	O
%	O
at	O
the	O
cutoff	O
of	O
two	O
is	O
73-fold	O
(	O
60	O
/	O
7	O
)	O
higher	O
than	O
expected	O
.	O

In	O
addition	O
,	O
we	O
validated	O
nine	O
novel	O
AS	O
events	O
that	O
distinguish	O
hESCs	O
and	O
NPs	O
.	O

Consistent	O
with	O
our	O
computational	O
results	O
,	O
we	O
observed	O
that	O
the	O
AS	O
patterns	O
in	O
hCNS	O
-	O
SCns	O
were	O
not	O
always	O
similar	O
to	O
those	O
of	O
the	O
derived	O
NPs	O
.	O

It	O
was	O
important	O
to	O
point	O
out	O
that	O
while	O
transcriptional	O
expression	O
of	O
these	O
genes	O
did	O
not	O
distinguish	O
these	O
cells	O
from	O
one	O
another	O
,	O
in	O
several	O
instances	O
the	O
REAP	O
-	O
predicted	O
AS	O
event	O
was	O
able	O
to	O
separate	O
derived	O
NPs	O
and	O
hCNS	O
-	O
SCns	O
.	O

A	O
notable	O
exception	O
was	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	B
gene	O
,	O
encoding	O
a	O
serine	B
/	I
threonine	I
kinase	I
protein	O
,	O
which	O
was	O
commonly	O
included	O
in	O
both	O
hESCs	O
,	O
i.e.	O
,	O
the	O
exon	O
-	O
excluded	O
isoform	O
was	O
not	O
present	O
in	O
hESCs	O
compared	O
to	O
NPs	O
,	O
as	O
well	O
as	O
in	O
a	O
variety	O
of	O
differentiated	O
tissues	O
.	O

Closer	O
inspection	O
of	O
the	O
REAP	O
[	O
+	O
]	O
-validated	O
AS	O
exon	O
in	O
the	O
SLK	B
gene	O
revealed	O
strong	O
conservation	O
in	O
the	O
intronic	O
region	O
flanking	O
the	O
exon	O
,	O
a	O
hallmark	O
feature	O
of	O
evolutionarily	O
conserved	O
AS	O
exons	O
[	O
55,77,78	O
]	O
.	O

A	O
study	O
analyzing	O
the	O
expression	O
patterns	O
of	O
the	O
SLK	B
gene	O
suggested	O
a	O
potential	O
functional	O
role	O
during	O
embryonic	O
development	O
and	O
in	O
the	O
adult	O
central	O
nervous	O
system	O
[	O
79	O
]	O
;	O
however	O
,	O
to	O
our	O
knowledge	O
,	O
our	O
identification	O
of	O
the	O
SLK	B
alternative	O
exon	O
is	O
the	O
first	O
report	O
of	O
a	O
hESC	O
-	O
biased	O
AS	O
pattern	O
during	O
neuronal	O
differentiation	O
and	O
across	O
a	O
myriad	O
of	O
differentiated	O
tissues	O
.	O

In	O
agreement	O
,	O
GO	O
analysis	O
suggested	O
that	O
genes	O
containing	O
REAP	O
[	O
+	O
]	O
exons	O
were	O
enriched	O
in	O
serine	B
/	I
threonine	I
kinase	I
activity	O
,	O
of	O
which	O
SLK	B
is	O
a	O
family	O
member	O
.	O

Future	O
work	O
will	O
be	O
required	O
to	O
study	O
the	O
impact	O
of	O
AS	O
in	O
these	O
genes	O
in	O
hESCs	O
and	O
NPs	O
.	O

We	O
predict	O
it	O
is	O
unlikely	O
that	O
the	O
alternative	O
exon	O
in	O
the	O
SLK	B
gene	O
is	O
the	O
only	O
case	O
common	O
across	O
hESC	O
and	O
different	O
from	O
differentiated	O
tissues	O
,	O
but	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
identify	O
other	O
hESC	O
-	O
specific	O
exons	O
.	O

REAP	O
[	O
+	O
]	O
exons	O
were	O
underrepresented	O
in	O
genes	O
that	O
were	O
differentially	O
transcriptionally	O
regulated	O
in	O
hESCs	O
and	O
NPs	O
.	O

Our	O
results	O
act	O
as	O
a	O
reminder	O
that	O
focusing	O
only	O
on	O
genes	O
that	O
are	O
differentially	O
expressed	O
will	O
overlook	O
RNA	O
processing	O
events	O
that	O
may	O
be	O
biologically	O
relevant	O
to	O
the	O
system	O
of	O
interest	O
.	O

Finally	O
,	O
we	O
identified	O
potential	O
cis	O
-	O
regulatory	O
intronic	O
elements	O
conserved	O
and	O
enriched	O
proximal	O
to	O
the	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

In	O
particular	O
,	O
the	O
FOX1	B
/	I
2	I
binding	O
site	O
,	O
GCUAG	O
,	O
was	O
conserved	O
and	O
enriched	O
in	O
the	O
flanking	O
introns	O
of	O
a	O
subset	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
explore	O
the	O
importance	O
of	O
FOX1	B
family	O
members	O
in	O
early	O
neuronal	O
differentiation	O
.	O

In	O
conclusion	O
,	O
our	O
introduction	O
of	O
REAP	O
and	O
its	O
application	O
to	O
identifying	O
AS	O
events	O
has	O
revealed	O
new	O
and	O
unanticipated	O
insights	O
into	O
hESC	O
biology	O
and	O
their	O
transition	O
to	O
NP	O
cells	O
.	O

Collectively	O
,	O
these	O
exons	O
represent	O
a	O
set	O
of	O
molecular	O
changes	O
that	O
are	O
likely	O
to	O
be	O
important	O
for	O
studying	O
human	O
neural	O
differentiation	O
with	O
applications	O
in	O
neuronal	O
regenerative	O
medicine	O
.	O

Maintenance	O
and	O
differentiation	O
of	O
hESCs	O
and	O
hCNS	O
-	O
SCns.hESC	O
line	O
Cy203	O
(	O
Cythera	O
)	O
was	O
cultured	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

To	O
differentiate	O
into	O
neuroepithelial	O
precursor	O
cells	O
,	O
colonies	O
were	O
manually	O
isolated	O
from	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
cut	O
in	O
small	O
pieces	O
.	O

These	O
pieces	O
were	O
transferred	O
to	O
a	O
T75	O
flask	O
with	O
hESCs	O
differentiation	O
media	O
(	O
same	O
hESC	O
medium	O
but	O
10	O
%	O
KSR	B
and	O
no	O
FGF-2	B
)	O
.	O

Medium	O
was	O
changed	O
the	O
next	O
day	O
by	O
transferring	O
the	O
floating	O
hESC	O
aggregates	O
to	O
a	O
new	O
flask	O
.	O

After	O
culturing	O
for	O
a	O
week	O
,	O
the	O
hESC	O
cell	O
aggregates	O
formed	O
mature	O
embroid	O
bodies	O
(	O
EBs	O
;	O
∼10	O
um	O
round	O
clusters	O
with	O
dark	O
centers	O
)	O
.	O

EBs	O
were	O
plated	O
on	O
a	O
coated	O
10-cm	O
dish	O
in	O
hESC	O
differentiation	O
media	O
.	O

The	O
next	O
day	O
,	O
the	O
medium	O
was	O
changed	O
to	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
ITS	B
and	O
fibronectin	B
.	O

Medium	O
was	O
changed	O
every	O
other	O
day	O
for	O
a	O
week	O
or	O
until	O
the	O
cells	O
formed	O
rosette	O
-	O
like	O
columnar	O
structures	O
that	O
were	O
isolated	O
manually	O
.	O

These	O
structures	O
were	O
then	O
transferred	O
to	O
coated	O
dishes	O
in	O
neural	O
induction	O
medium	O
(	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
FGF-2	B
)	O
for	O
a	O
week	O
.	O

Elongated	O
single	O
cells	O
were	O
separated	O
from	O
leftover	O
aggregates	O
using	O
non	O
-	O
enzymatic	O
dissociation	O
.	O

After	O
one	O
to	O
two	O
passages	O
,	O
the	O
cells	O
formed	O
a	O
monolayer	O
of	O
homogeneous	O
NPs	O
(	O
negative	O
for	O
Sox1	B
immunostaining	O
)	O
.	O

Upon	O
confluence	O
,	O
cells	O
will	O
form	O
neurospheres	O
that	O
can	O
also	O
be	O
isolated	O
from	O
the	O
neuroepithelial	O
precursor	O
cells	O
(	O
positive	O
for	O
Sox1	B
immunostaining	O
)	O
.	O

At	O
any	O
of	O
these	O
two	O
stages	O
,	O
pan	O
-	O
neuronal	O
differentiation	O
can	O
be	O
achieved	O
after	O
three	O
to	O
four	O
weeks	O
.	O

hESC	O
line	O
HUES6	O
was	O
cultured	O
on	O
MEF	O
feeders	O
as	O
previously	O
described	O
(	O
http://www.mcb.harvard.edu/melton/hues/	O
)	O
or	O
on	O
GFR	O
matrigel	O
coated	O
plates	O
.	O

Cells	O
grown	O
on	O
matrigel	O
were	O
grown	O
in	O
MEF	O
-	O
conditioned	O
medium	O
and	O
FGF-2	B
was	O
used	O
at	O
20	O
ng	O
/	O
mL	O
instead	O
of	O
10	O
ng	O
/	O
mL	O
for	O
cells	O
grown	O
on	O
MEFs	O
.	O

To	O
differentiate	O
neuroepithelial	O
precursors	O
,	O
colonies	O
were	O
removed	O
by	O
treatment	O
with	O
collagenase	B
IV	I
(	O
Sigma	O
)	O
and	O
washed	O
three	O
times	O
in	O
growth	O
media	O
.	O

The	O
pieces	O
of	O
colonies	O
were	O
resuspended	O
in	O
HUES	O
growth	O
media	O
without	O
FGF2	B
in	O
an	O
uncoated	O
bacterial	O
Petri	O
dish	O
to	O
form	O
EBs	O
.	O

After	O
one	O
week	O
,	O
EBs	O
were	O
plated	O
on	O
polyornathine	O
/	O
laminin	B
coated	O
plates	O
in	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
FGF2	B
.	O

Rosette	O
structures	O
were	O
manually	O
collected	O
and	O
enzymatically	O
dissociated	O
with	O
TryPLE	O
(	O
Invitrogen	O
)	O
,	O
plated	O
on	O
polyornathine	O
/	O
laminin	O
coated	O
plates	O
,	O
and	O
grown	O
in	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
N2	O
and	O
B27-RA	B
and	O
20	O
ng	O
/	O
mL	O
FGF-2	B
.	O

Cells	O
could	O
be	O
grown	O
as	O
a	O
monolayer	O
for	O
up	O
to	O
at	O
least	O
ten	O
passages	O
.	O

Cells	O
were	O
Sox1	B
and	O
nestin	B
positive	O
and	O
readily	O
differentiated	O
into	O
neurons	O
upon	O
withdrawal	O
of	O
FGF-2	B
.	O

Human	O
central	O
nervous	O
system	O
stem	O
cell	O
line	O
FBR1664	O
(	O
StemCells	O
)	O
which	O
is	O
referred	O
to	O
as	O
hCNS	O
-	O
SCns	O
in	O
the	O
main	O
text	O
was	O
cultured	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
medium	O
consisting	O
of	O
Ex	O
Vivo	O
15	O
(	O
BioWhittaker	O
)	O
medium	O
with	O
N2	O
supplement	O
(	O
GIBCO	O
)	O
,	O
FGF2	B
(	O
20	O
ng	O
/	O
mL	O
)	O
,	O
epidermal	B
growth	I
factor	I
(	O
20	O
ng	O
/	O
mL	O
)	O
,	O
lymphocyte	B
inhibitory	I
factor	I
(	O
10	O
ng	O
/	O
mL	O
)	O
,	O
0.2	O
mg	O
/	O
ml	O
heparin	O
,	O
and	O
60	O
ug	O
/	O
mL	O
N	O
-	O
acetylcysteine	O
.	O

Cultures	O
were	O
fed	O
weekly	O
and	O
passaged	O
at	O
∼two	O
to	O
three	O
weeks	O
using	O
collagenases	B
(	O
Roche	O
)	O
.	O

The	O
following	O
antibodies	O
and	O
corresponding	O
dilutions	O
were	O
utilized	O
for	O
the	O
immunohistochemical	O
analysis	O
of	O
marker	O
genes	O
in	O
Cyt	O
-	O
ES	O
and	O
HUES6-ES	O
:	O
Sox2	B
(	O
Chemicon	O
,	O
1:500	O
)	O
,	O
Oct4	B
(	O
Santa	O
Cruz	O
,	O
1:500	O
)	O
,	O
Sox1	B
(	O
Chemicon	O
,	O
1:500	O
)	O
,	O
Nestin	B
(	O
Pharmingen	O
,	O
1:250	O
)	O
;	O
hCNS	O
-	O
SCns	O
:	O
Sox2	B
(	O
Chemicon	O
,	O
1:200	O
)	O
,	O
Nestin	B
(	O
Chemicon	O
,	O
1:200	O
)	O
.	O

RNA	O
preparation	O
and	O
array	O
hybridization	O
.	O

Total	O
RNA	O
from	O
cells	O
was	O
processed	O
as	O
follows	O
.	O

Cells	O
were	O
lysed	O
in	O
1	O
mL	O
of	O
RNA	O
-	O
bee	O
(	O
Teltest	O
)	O
.	O

The	O
RNA	O
was	O
isolated	O
by	O
chloroform	O
extraction	O
of	O
the	O
aqueous	O
phase	O
,	O
followed	O
by	O
isopropanol	O
precipitation	O
as	O
per	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
precipitated	O
RNA	O
was	O
washed	O
in	O
75	O
%	O
ethanol	O
and	O
eluted	O
with	O
DEPC	O
-	O
treated	O
water	O
.	O

Five	O
ug	O
of	O
RNA	O
was	O
treated	O
with	O
RQ1	O
DNAase	B
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

One	O
ug	O
of	O
total	O
RNA	O
for	O
each	O
sample	O
was	O
processed	O
using	O
the	O
Affymetrix	O
GeneChip	O
Whole	O
Transcript	O
Sense	O
Target	O
Labeling	O
Assay	O
(	O
Affymetrix	O
)	O
.	O

Ribosomal	O
RNA	O
was	O
reduced	O
with	O
the	O
RiboMinus	O
Kit	O
(	O
Invitrogen	O
)	O
.	O

Target	O
material	O
was	O
prepared	O
using	O
commercially	O
available	O
Affymetrix	O
GeneChip	O
WT	O
cDNA	O
Synthesis	O
Kit	O
,	O
WT	O
cDNA	O
Amplification	O
Kit	O
,	O
and	O
WT	O
Terminal	O
Labeling	O
Kit	O
(	O
Affymetrix	O
)	O
as	O
per	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
cocktails	O
containing	O
∼5	O
ug	O
of	O
fragmented	O
and	O
labeled	O
DNA	O
target	O
were	O
prepared	O
and	O
applied	O
to	O
GeneChip	O
Human	O
Exon	O
1.0	O
ST	O
arrays	O
.	O

Hybridization	O
was	O
performed	O
for	O
16	O
hours	O
using	O
the	O
Fluidics	O
450	O
station	O
.	O

Arrays	O
were	O
scanned	O
using	O
the	O
Affymetrix	O
3000	O
7	O
G	O
scanner	O
and	O
GeneChip	O
Operating	O
Software	O
version	O
1.4	O
to	O
produce	O
.CEL	O
intensity	O
files	O
.	O

Detection	O
of	O
AS	O
by	O
RT	O
-	O
PCR.cDNAs	O
were	O
generated	O
from	O
total	O
RNA	O
with	O
Superscript	O
III	O
reverse	B
transcriptase	I
(	O
Invitrogen	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
primer	O
pairs	O
designed	O
for	O
AS	O
targets	O
(	O
annealing	O
at	O
58	O
°	O
C	O
and	O
amplification	O
for	O
30	O
or	O
35	O
cycles	O
)	O
.	O

PCR	O
products	O
were	O
resolved	O
on	O
either	O
1.5	O
%	O
or	O
3	O
%	O
agarose	O
gel	O
in	O
TBE	O
.	O

The	O
Ethidium	O
Bromide	O
-	O
stained	O
gels	O
were	O
scanned	O
with	O
Typhoon	O
8600	O
scanner	O
(	O
Molecular	O
Dynamics	O
)	O
for	O
quantification	O
.	O

The	O
number	O
of	O
true	O
positives	O
(	O
TP	O
;	O
false	O
negatives	O
,	O
FN	O
)	O
was	O
computed	O
as	O
the	O
number	O
of	O
REAP	O
[	O
+	O
]	O
(	O
REAP	O
[	O
−	O
]	O
)	O
exons	O
that	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
as	O
AS	O
.	O

The	O
number	O
of	O
true	O
negatives	O
(	O
TN	O
;	O
or	O
FPs	O
)	O
was	O
computed	O
as	O
the	O
number	O
of	O
REAP	O
[	O
−	O
]	O
(	O
REAP	O
[	O
+	O
]	O
)	O
exons	O
that	O
were	O
validated	O
by	O
RT	O
-	O
PCR	O
as	O
constitutively	O
spliced	O
.	O

The	O
true	O
(	O
false	O
)	O
positive	O
rate	O
was	O
computed	O
as	O
TP	O
(	O
FP	O
)	O
divided	O
by	O
the	O
total	O
number	O
of	O
REAP	O
[	O
+	O
]	O
exons	O
in	O
the	O
experimentally	O
validated	O
set	O
.	O

The	O
true	O
(	O
false	O
)	O
negative	O
rate	O
was	O
computed	O
as	O
the	O
TN	O
(	O
FN	O
)	O
divided	O
by	O
the	O
total	O
number	O
of	O
REAP	O
[	O
−	O
]	O
exons	O
in	O
the	O
experimentally	O
validated	O
set	O
.	O

Sensitivity	O
was	O
computed	O
as	O
TP	O
/	O
(	O
TP+FN	O
)	O
and	O
specificity	O
was	O
computed	O
as	O
TN	O
/	O
(	O
FP+TN	O
)	O
.	O

Sequence	O
databases	O
.	O

Genome	O
sequences	O
of	O
human	O
(	O
hg17	O
)	O
,	O
dog	O
(	O
canFam1	O
)	O
,	O
rat	O
(	O
rn3	O
)	O
,	O
and	O
mouse	O
(	O
mm5	O
)	O
were	O
obtained	O
from	O
UCSC	O
,	O
as	O
were	O
the	O
whole	O
-	O
genome	O
MULTIZ	O
alignments	O
[	O
80	O
]	O
.	O

The	O
lists	O
of	O
known	O
human	O
genes	O
(	O
knownGene	O
containing	O
43,401	O
entries	O
)	O
and	O
known	O
isoforms	O
(	O
knownIsoforms	O
containing	O
43,286	O
entries	O
in	O
21,397	O
unique	O
isoform	O
clusters	O
)	O
with	O
annotated	O
exon	O
alignments	O
to	O
human	O
hg17	O
genomic	O
sequence	O
were	O
processed	O
as	O
follows	O
.	O

Known	O
genes	O
that	O
were	O
mapped	O
to	O
different	O
isoform	O
clusters	O
were	O
discarded	O
.	O

All	O
mRNAs	O
aligned	O
to	O
hg17	O
that	O
were	O
greater	O
than	O
300	O
bases	O
long	O
were	O
clustered	O
together	O
with	O
the	O
known	O
isoforms	O
.	O

Genes	O
containing	O
less	O
than	O
three	O
exons	O
were	O
removed	O
from	O
further	O
consideration	O
.	O

A	O
total	O
of	O
2.7	O
million	O
spliced	O
ESTs	O
were	O
mapped	O
onto	O
the	O
17,478	O
high	O
-	O
quality	O
genes	O
to	O
infer	O
AS	O
.	O

Exons	O
with	O
canonical	O
splice	O
signals	O
(	O
GT	O
-	O
AG	O
,	O
AT	O
-	O
AC	O
,	O
GC	O
-	O
AG	O
)	O
were	O
retained	O
,	O
resulting	O
in	O
a	O
total	O
of	O
213,736	O
exons	O
.	O

Of	O
these	O
,	O
197,262	O
(	O
92	O
%	O
of	O
all	O
exons	O
)	O
were	O
constitutive	O
exons	O
,	O
13,934	O
exons	O
(	O
7	O
%	O
)	O
had	O
evidence	O
of	O
exon	O
-	O
skipping	O
,	O
1,615	O
(	O
1	O
%	O
)	O
exons	O
were	O
mutually	O
exclusive	O
alternative	O
events	O
,	O
5,930	O
(	O
3	O
%	O
)	O
exons	O
had	O
alternative	O
3′	O
splice	O
sites	O
,	O
5,181	O
(	O
2	O
%	O
)	O
exons	O
had	O
alternative	O
5′	O
splice	O
sites	O
,	O
and	O
175	O
(	O
<	O
1	O
%	O
)	O
exons	O
overlapped	O
another	O
exon	O
,	O
but	O
did	O
not	O
fall	O
into	O
the	O
above	O
classifications	O
.	O

A	O
total	O
of	O
324,139	O
probesets	O
from	O
the	O
Affymetrix	O
Human	O
Exon	O
1.0	O
ST	O
array	O
were	O
mapped	O
to	O
208,422	O
human	O
exons	O
,	O
representing	O
17,431	O
genes	O
.	O

These	O
probesets	O
were	O
used	O
to	O
derive	O
gene	O
and	O
exon	O
-	O
level	O
signal	O
estimates	O
from	O
the	O
CEL	O
files	O
.	O

The	O
four	O
-	O
way	O
mammalian	O
(	O
four	O
-	O
mammal	O
)	O
whole	O
-	O
genome	O
alignment	O
(	O
hg17	O
,	O
canFam1	O
,	O
mm5	O
,	O
rn3	O
)	O
was	O
extracted	O
from	O
the	O
eight	O
-	O
way	O
vertebrate	O
MULTIZ	O
alignments	O
(	O
hg17	O
,	O
panTrol1	O
,	O
mm5	O
,	O
rn3	O
,	O
canFam1	O
,	O
galGal2	O
,	O
fr1	O
,	O
danRer1	O
)	O
obtained	O
from	O
the	O
UCSC	O
Genome	O
Browser	O
.	O

Four	O
-	O
way	O
mammal	O
alignments	O
were	O
extracted	O
for	O
all	O
internal	O
exons	O
,	O
and	O
400	O
bases	O
of	O
flanking	O
intronic	O
sequence	O
,	O
resulting	O
in	O
a	O
total	O
of	O
161,731	O
conserved	O
internal	O
exons	O
.	O

A	O
total	O
of	O
145,613	O
(	O
90	O
%	O
of	O
total	O
)	O
conserved	O
internal	O
exons	O
were	O
constitutive	O
exons	O
,	O
13,653	O
exons	O
(	O
8	O
%	O
)	O
had	O
evidence	O
of	O
exon	O
-	O
skipping	O
,	O
1,576	O
exons	O
were	O
mutually	O
exclusive	O
alternative	O
events	O
,	O
5,818	O
exons	O
had	O
alternative	O
3′	O
splice	O
sites	O
,	O
5,046	O
exons	O
had	O
alternative	O
5′	O
splice	O
sites	O
,	O
and	O
168	O
exons	O
overlapped	O
another	O
exon	O
.	O

Exon	O
array	O
analysis	O
.	O

The	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
suite	O
of	O
programs	O
was	O
obtained	O
from	O
http://www.affymetrix.com/support/developer/powertools/index.affx	O
.	O

Exon	O
(	O
probeset	O
)	O
and	O
gene	O
-	O
level	O
signal	O
estimates	O
were	O
derived	O
from	O
the	O
CEL	O
files	O
by	O
RMA	O
–	O
sketch	O
normalization	O
as	O
a	O
method	O
in	O
the	O
apt	O
-	O
probeset	O
-	O
summarize	O
program	O
.	O

To	O
determine	O
if	O
the	O
signal	O
intensity	O
for	O
a	O
given	O
probeset	O
is	O
above	O
the	O
expected	O
level	O
of	O
background	O
noise	O
,	O
we	O
utilized	O
the	O
DABG	O
(	O
detection	O
above	O
background	O
)	O
quantification	O
method	O
available	O
in	O
the	O
apt	O
-	O
probeset	O
-	O
summarize	O
program	O
as	O
part	O
of	O
Affymetrix	O
Power	O
Tools	O
(	O
APT	O
)	O
.	O

Briefly	O
,	O
DABG	O
compared	O
the	O
signal	O
for	O
each	O
probe	O
to	O
a	O
background	O
distribution	O
of	O
signals	O
from	O
anti	O
-	O
genomic	O
probes	O
with	O
the	O
same	O
GC	O
content	O
.	O

The	O
DABG	O
algorithm	O
generated	O
a	O
p	O
-	O
value	O
representing	O
the	O
probability	O
that	O
the	O
signal	O
intensity	O
of	O
a	O
given	O
probe	O
was	O
part	O
of	O
the	O
background	O
distribution	O
.	O

We	O
considered	O
a	O
probeset	O
with	O
a	O
DABG	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
as	O
detected	O
above	O
background	O
.	O

The	O
statistic	O
thCNS	O
-	O
SCns	O
,	O
ESC	O
=	O
(	O
μhCNS	O
-	O
SCns	O
−	O
μESC	O
)	O
/	O
sqrt	O
(	O
(	O
(	O
nhCNS	O
-	O
SCns	O
−	O
1	O
)	O
σ2hCNS	O
-	O
SCns	O
+	O
(	O
nESC	O
−	O
1	O
)	O
σ2ESC	O
)	O
(	O
nhCNS	O
-	O
SCns	O
+	O
nESC	O
)	O
)	O
/	O
(	O
(	O
nhCNS	O
-	O
SCnsnESC	O
)	O
(	O
nhCNS	O
-	O
SCns	O
+	O
nESC	O
−	O
2	O
)	O
)	O
)	O
,	O
where	O
nhCNS	O
-	O
SCns	O
and	O
nESC	O
were	O
the	O
number	O
of	O
replicates	O
,	O
μhCNS	O
-	O
SCns	O
and	O
μESC	O
were	O
the	O
mean	O
,	O
and	O
σ2hCNS	O
-	O
SCns	O
and	O
σ2ESC	O
were	O
the	O
variances	O
of	O
the	O
expression	O
values	O
for	O
the	O
two	O
datasets	O
used	O
to	O
represent	O
the	O
differential	O
enrichment	O
of	O
a	O
gene	O
using	O
gene	O
-	O
level	O
estimates	O
in	O
hCNS	O
-	O
SCns	O
relative	O
to	O
hESCs	O
.	O

Multiple	O
hypothesis	O
testing	O
was	O
corrected	O
by	O
controlling	O
for	O
the	O
false	O
discovery	O
rate	O
(	O
Benjamini	O
-	O
Hochberg	O
)	O
.	O

AS	O
detection	O
by	O
REAP.The	O
log2	O
signal	O
estimate	O
xij	O
for	O
probeset	O
i	O
in	O
cell	O
-	O
type	O
j	O
had	O
to	O
satisfy	O
two	O
conditions	O
,	O
otherwise	O
the	O
probeset	O
was	O
discarded	O
:	O
(	O
i	O
)	O
2	O
<	O
xij	O
<	O
10,000	O
for	O
all	O
conditions	O
/	O
cell	O
-	O
types	O
j	O
;	O
and	O
(	O
ii	O
)	O
DABG	O
p	O
-	O
value	O
<	O
0.05	O
for	O
all	O
replicates	O
in	O
at	O
least	O
one	O
condition	O
/	O
cell	O
-	O
type	O
j.	O
A	O
gene	O
had	O
to	O
have	O
five	O
probesets	O
that	O
satisfied	O
the	O
two	O
conditions	O
above	O
in	O
order	O
to	O
be	O
considered	O
for	O
robust	O
regression	O
analysis	O
.	O

After	O
generating	O
the	O
points	O
(	O
as	O
described	O
in	O
the	O
Results	O
section	O
)	O
,	O
we	O
utilized	O
the	O
robust	O
regression	O
method	O
rlm	O
in	O
R	O
-	O
package	O
""""	O
MASS	O
""""	O
(	O
version	O
6.1–2	O
)	O
with	O
M	O
-	O
estimation	O
and	O
a	O
maximum	O
iteration	O
setting	O
of	O
30	O
to	O
estimate	O
the	O
linear	O
function	O
yi	O
=	O
αxi	O
+	O
β	O
.	O

For	O
each	O
probeset	O
,	O
we	O
computed	O
the	O
error	O
term	O
ei	O
,	O
,	O
which	O
was	O
the	O
difference	O
between	O
the	O
actual	O
value	O
yi	O
and	O
the	O
estimated	O
value	O
ξi	O
,	O
from	O
the	O
estimated	O
function	O
ξi	O
=	O
Axi	O
+	O
B	O
,	O
where	O
A	O
and	O
B	O
were	O
estimates	O
of	O
α	O
and	O
β	O
.	O

The	O
error	O
term	O
variance	O
was	O
estimated	O
by	O
se2	O
=	O
Σei2	O
/	O
(	O
n	O
−	O
p	O
)	O
,	O
which	O
was	O
used	O
to	O
estimate	O
the	O
variance	O
of	O
the	O
predicted	O
value	O
,	O
sξi2	O
=	O
se2	O
(	O
n−1	O
+	O
(	O
xi	O
−	O
μx	O
)	O
2	O
/	O
sx2	O
(	O
n	O
−	O
1	O
)	O
)	O
.	O

Here	O
,	O
n	O
referred	O
to	O
the	O
number	O
of	O
points	O
(	O
generated	O
for	O
each	O
gene	O
)	O
,	O
and	O
p	O
referred	O
to	O
the	O
number	O
of	O
independent	O
variables	O
(	O
p	O
=	O
2	O
in	O
our	O
method	O
)	O
;	O
and	O
μx	O
=	O
Σxi2	O
/	O
n	O
;	O
sx2	O
=	O
n−1	O
Σ	O
(	O
xi	O
−	O
μx	O
)	O
2	O
.	O

Following	O
Belsley	O
et	O
al.	O
[	O
81	O
]	O
,	O
we	O
defined	O
the	O
leverage	O
hi	O
of	O
the	O
ith	O
point	O
as	O
hi	O
=	O
n−1	O
+	O
(	O
xi	O
−	O
μx	O
)	O
2	O
/	O
sx2	O
(	O
n	O
−	O
1	O
)	O
.	O

Here	O
we	O
considered	O
a	O
point	O
to	O
have	O
high	O
leverage	O
if	O
hi	O
>	O
3p	O
/	O
n	O
.	O

Next	O
,	O
we	O
calculated	O
the	O
covariance	O
ratio	O
,	O
covi	O
=	O
(	O
si2	O
/	O
sr2	O
)	O
p	O
/	O
(	O
1	O
−	O
hi	O
)	O
,	O
which	O
is	O
the	O
ratio	O
of	O
the	O
determinant	O
of	O
the	O
covariance	O
matrix	O
after	O
deleting	O
the	O
ith	O
observation	O
to	O
the	O
determinant	O
of	O
the	O
covariance	O
matrix	O
with	O
the	O
entire	O
sample	O
.	O

We	O
considered	O
a	O
point	O
to	O
have	O
high	O
influence	O
if	O
|covi	O
−	O
1|	O
>	O
3p	O
/	O
n	O
.	O

Lastly	O
,	O
we	O
computed	O
the	O
studentized	O
residuals	O
,	O
rstudenti	O
=	O
ei	O
/	O
(	O
s	O
(	O
i	O
)	O
2	O
(	O
1	O
−	O
hi	O
)	O
0.5	O
)	O
,	O
where	O
s	O
(	O
i	O
)	O
2	O
=	O
(	O
n	O
-	O
p	O
)	O
se2	O
/	O
(	O
n	O
-	O
p-1	O
)	O
–	O
ei2	O
/	O
(	O
n	O
-	O
p-1	O
)	O
(	O
1	O
−	O
hi	O
)	O
,	O
the	O
error	O
term	O
variance	O
after	O
deleting	O
the	O
ith	O
point	O
.	O

As	O
rstudenti	O
was	O
distributed	O
as	O
Student	O
's	O
t	O
-	O
distribution	O
with	O
n	O
-	O
p-1	O
degrees	O
of	O
freedom	O
,	O
each	O
rstudenti	O
value	O
was	O
associated	O
with	O
a	O
p	O
-	O
value	O
.	O

We	O
considered	O
a	O
point	O
to	O
be	O
an	O
""""	O
outlier	O
""""	O
if	O
p	O
<	O
0.01	O
.	O

Identification	O
of	O
motifs	O
.	O

The	O
enrichment	O
score	O
of	O
a	O
sequence	O
element	O
of	O
length	O
k	O
(	O
k	O
-	O
mer	O
)	O
in	O
one	O
set	O
of	O
sequences	O
(	O
set	O
1	O
)	O
versus	O
another	O
set	O
of	O
sequences	O
(	O
set	O
2	O
)	O
was	O
represented	O
by	O
the	O
nonparametric	O
χ2	O
statistic	O
with	O
Yates	O
correction	O
,	O
computed	O
from	O
the	O
two	O
by	O
two	O
contingency	O
table	O
,	O
T	O
(	O
T11	O
:	O
number	O
of	O
occurrences	O
of	O
the	O
element	O
in	O
set	O
1	O
;	O
T12	O
:	O
number	O
of	O
occurrences	O
of	O
all	O
other	O
elements	O
of	O
similar	O
length	O
in	O
set	O
1	O
;	O
T21	O
:	O
number	O
of	O
occurrences	O
of	O
element	O
in	O
set	O
2	O
;	O
T22	O
:	O
number	O
of	O
occurrences	O
of	O
all	O
other	O
elements	O
of	O
similar	O
length	O
in	O
set	O
2	O
.	O

All	O
elements	O
had	O
to	O
be	O
greater	O
than	O
5	O
.	O

To	O
correct	O
for	O
multiple	O
hypothesis	O
testing	O
,	O
p	O
-	O
values	O
were	O
multiplied	O
by	O
the	O
total	O
number	O
of	O
comparisons	O
.	O

Extracts	O
of	O
the	O
creosote	O
bush	O
(	O
Larrea	O
tridentata	O
,	O
family	O
Zygophyllaceae	O
)	O
have	O
long	O
been	O
used	O
as	O
a	O
folk	O
remedy	O
for	O
Type	O
II	O
(	O
non	O
-	O
insulin	B
-	O
dependent	O
)	O
diabetes	O
by	O
native	O
Americans	O
in	O
southwestern	O
North	O
America	O
.	O

In	O
this	O
study	O
we	O
have	O
evaluated	O
the	O
metabolic	O
effects	O
of	O
masoprocol	O
,	O
a	O
pure	O
compound	O
isolated	O
from	O
the	O
creosote	O
bush	O
,	O
in	O
a	O
rat	O
model	O
of	O
Type	O
II	O
diabetes	O
.	O

Animals	O
were	O
fed	O
a	O
20	O
%	O
fat	O
(	O
by	O
weight	O
)	O
diet	O
for	O
2	O
weeks	O
prior	O
to	O
intravenous	O
injection	O
with	O
streptozotocin	O
(	O
STZ	O
,	O
0.19	O
mmol	O
/	O
kg	O
)	O
.	O

Diabetic	O
animals	O
(	O
glucose	O
16	O
-	O
33	O
mmol	O
/	O
l	O
)	O
were	O
treated	O
with	O
vehicle	O
,	O
metformin	O
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
or	O
masoprocol	O
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
a	O
day	O
for	O
4	O
days	O
.	O

Masoprocol	O
treatment	O
lowered	O
glucose	O
concentrations	O
an	O
average	O
of	O
35	O
%	O
compared	O
with	O
vehicle	O
(	O
14.2+	O
/	O
-1.1	O
vs	O
21.7+	O
/	O
-1.0	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
similar	O
to	O
metformin	O
treatment	O
(	O
12.8+	O
/	O
-0.9	O
mmol	O
/	O
l	O
)	O
,	O
without	O
any	O
change	O
in	O
insulin	B
concentration	O
.	O

Masoprocol	O
treatment	O
also	O
lowered	O
triglyceride	O
concentrations	O
80	O
%	O
compared	O
with	O
vehicle	O
(	O
1.0+	O
/	O
-0.1	O
vs	O
4.8+	O
/	O
-0.3	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
far	O
greater	O
than	O
following	O
metformin	O
treatment	O
(	O
3.6+	O
/	O
-0.3	O
mmol	O
/	O
l	O
)	O
.	O

Non	O
-	O
esterified	O
fatty	O
acid	O
and	O
glycerol	O
concentration	O
were	O
decreased	O
by	O
approximately	O
65	O
%	O
by	O
masoprocol	O
compared	O
with	O
vehicle	O
,	O
a	O
reduction	O
approximately	O
twice	O
as	O
great	O
as	O
seen	O
with	O
metformin	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
effect	O
of	O
masoprocol	O
on	O
in	O
vivo	O
insulin	B
-	O
mediated	O
glucose	O
disposal	O
was	O
evaluated	O
by	O
infusing	O
fat	O
-	O
fed	O
/	O
STZ	O
rats	O
with	O
glucose	O
(	O
0.22	O
mmol	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
and	O
insulin	B
(	O
30	O
pmol	O
x	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
for	O
5	O
h.	O
In	O
response	O
to	O
the	O
infusion	O
,	O
steady	O
-	O
state	O
plasma	O
glucose	O
concentrations	O
were	O
reduced	O
30	O
%	O
in	O
masoprocol	O
-	O
treated	O
animals	O
compared	O
with	O
vehicle	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
with	O
no	O
change	O
noted	O
in	O
rats	O
treated	O
with	O
metformin	O
.	O

The	O
effect	O
of	O
masoprocol	O
treatment	O
was	O
also	O
tested	O
in	O
primary	O
adipocytes	O
isolated	O
from	O
normal	O
animals	O
.	O

Adipocytes	O
treated	O
with	O
masoprocol	O
(	O
30	O
micromol	O
/	O
l	O
)	O
had	O
higher	O
basal	O
and	O
insulin	B
-	O
stimulated	O
glucose	O
clearance	O
than	O
did	O
adipocytes	O
treated	O
with	O
vehicle	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
data	O
show	O
that	O
masoprocol	O
decreases	O
both	O
plasma	O
glucose	O
and	O
triglyceride	O
concentrations	O
in	O
fat	O
-	O
fed	O
/	O
STZ	O
rats	O
,	O
presumably	O
as	O
a	O
result	O
of	O
its	O
ability	O
to	O
both	O
increase	O
glucose	O
disposal	O
and	O
decrease	O
lipolysis	O
.	O

The	O
induction	O
of	O
micronucleated	O
erythrocytes	O
by	O
diisopropylcarbodiimide	O
(	O
DIC	O
)	O
and	O
dicyclohexylcarbodiimide	O
(	O
DCC	O
)	O
was	O
investigated	O
as	O
part	O
of	O
a	O
U.S.	O
National	O
Toxicology	O
Program	O
(	O
NTP	O
)	O
evaluation	O
of	O
the	O
subchronic	O
toxicity	O
of	O
these	O
chemicals	O
.	O

Analysis	O
of	O
peripheral	O
blood	O
smears	O
from	O
male	O
and	O
female	O
B6C3F1	O
mice	O
exposed	O
to	O
17.5	O
-	O
140.0	O
mg	O
DIC	O
/	O
kg	O
/	O
day	O
by	O
skin	O
painting	O
for	O
13	O
weeks	O
revealed	O
dose	O
-	O
related	O
increases	O
in	O
the	O
frequency	O
of	O
micronucleated	O
normochromatic	O
erythrocytes	O
(	O
MN	O
-	O
NCE	O
)	O
in	O
both	O
sexes	O
.	O

Results	O
of	O
a	O
similar	O
13-week	O
peripheral	O
blood	O
micronucleus	O
(	O
MN	O
)	O
test	O
with	O
DCC	O
(	O
1.5	O
-	O
12.0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
also	O
positive	O
,	O
although	O
the	O
increases	O
in	O
MN	O
-	O
NCE	O
were	O
not	O
as	O
great	O
as	O
those	O
observed	O
with	O
DIC	O
.	O

In	O
contrast	O
to	O
the	O
positive	O
results	O
of	O
the	O
subchronic	O
skin	O
-	O
painting	O
studies	O
in	O
mice	O
,	O
acute	O
bone	O
marrow	O
MN	O
studies	O
with	O
DIC	O
and	O
DCC	O
in	O
male	O
F344	O
rats	O
,	O
using	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
,	O
yielded	O
negative	O
results	O
.	O

Both	O
the	O
acute	O
and	O
the	O
subchronic	O
exposures	O
included	O
doses	O
that	O
produced	O
clinical	O
signs	O
of	O
toxicity	O
.	O

Acute	O
mouse	O
bone	O
marrow	O
MN	O
tests	O
with	O
DIC	O
administered	O
in	O
single	O
or	O
triple	O
i.p	O
.	O

injection	O
protocols	O
were	O
subsequently	O
conducted	O
to	O
determine	O
if	O
the	O
differing	O
responses	O
between	O
mice	O
and	O
rats	O
were	O
due	O
to	O
species	O
or	O
protocol	O
differences	O
.	O

The	O
results	O
of	O
these	O
acute	O
tests	O
were	O
negative	O
or	O
equivocal	O
.	O

Because	O
the	O
subchronic	O
studies	O
produced	O
positive	O
results	O
,	O
it	O
was	O
hypothesized	O
that	O
these	O
carbodiimides	O
required	O
multiple	O
treatments	O
over	O
an	O
extended	O
period	O
of	O
time	O
to	O
produce	O
an	O
increase	O
in	O
MN	O
-	O
erythrocytes	O
.	O

To	O
confirm	O
the	O
original	O
response	O
,	O
a	O
second	O
dermal	O
subchronic	O
study	O
was	O
conducted	O
with	O
DIC	O
;	O
the	O
protocol	O
was	O
modified	O
to	O
include	O
sequential	O
blood	O
samplings	O
to	O
permit	O
monitoring	O
MN	O
frequencies	O
over	O
time	O
.	O

The	O
data	O
demonstrated	O
a	O
small	O
but	O
consistent	O
induction	O
of	O
micronucleated	O
erythrocytes	O
in	O
mice	O
treated	O
with	O
DIC	O
by	O
skin	O
painting	O
.	O

Antibacterial	O
antibiotics	O
,	O
diperamycin	O
(	O
1	O
)	O
was	O
produced	O
in	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
griseoaurantiacus	O
MK393-AF2	O
.	O

Various	O
spectroscopic	O
analyses	O
of	O
1	O
suggested	O
that	O
1	O
belonged	O
to	O
a	O
member	O
of	O
cyclic	O
hexadepsipeptide	O
antibiotic	O
.	O

Antibiotic	O
1	O
had	O
potent	O
inhibitory	O
activity	O
against	O
various	O
Gram	O
-	O
positive	O
bacteria	O
including	O
Enterococcus	O
seriolicida	O
and	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

Subcutaneous	O
tumor	O
induction	O
with	O
three	O
dose	O
levels	O
of	O
3-methylcholanthrene	O
(	O
MCA	O
)	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BP	O
)	O
,	O
and	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
in	O
two	O
vehicles	O
was	O
studied	O
in	O
C3H	O
/	O
Anf	O
Cum	O
,	O
C57BL	O
/	O
6	O
Cum	O
,	O
DBA	O
/	O
2J	O
,	O
and	O
(	O
C57BLXC3H	O
/	O
Anf	O
)	O
F1	O
(	O
BC3F1	O
/	O
Cum	O
)	O
mice	O
.	O

Median	O
tumor	O
dose	O
levels	O
were	O
significantly	O
lower	O
when	O
the	O
three	O
carcinogens	O
were	O
suspended	O
in	O
trioctanoin	O
.	O

When	O
beeswax	O
:	O
trioctanoin	O
(	O
B	O
:	O
T	O
)	O
was	O
used	O
as	O
a	O
vehicle	O
,	O
the	O
three	O
carcinogens	O
differed	O
in	O
their	O
abilities	O
to	O
be	O
absorbed	O
or	O
solubilized	O
from	O
the	O
vehicle	O
by	O
the	O
three	O
strains	O
of	O
mice	O
and	O
the	O
hybrid	O
.	O

In	O
C3H	O
/	O
Anf	O
mice	O
,	O
BP	O
in	O
B	O
:	O
T	O
failed	O
to	O
produce	O
tumors	O
.	O

In	O
BC3F1	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
MCA	O
,	O
BP	O
,	O
or	O
DMBA	O
in	O
B	O
:	O
T.	O
In	O
C57BL	O
/	O
6	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
with	O
DMBA	O
or	O
MCA	O
in	O
B	O
:	O
T.	O
In	O
DBA	O
/	O
2	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
BP	O
or	O
MCA	O
in	O
B	O
:	O
T.	O
These	O
results	O
indicated	O
that	O
the	O
interpretation	O
of	O
tumor	O
induction	O
results	O
obtained	O
with	O
B	O
:	O
T	O
vehicle	O
may	O
be	O
related	O
to	O
the	O
conditions	O
of	O
bioassay	O
rather	O
than	O
to	O
the	O
carcinogenic	O
potential	O
of	O
a	O
compound	O
.	O

DNA	B
-	I
dependent	I
protein	I
kinase	I
(	O
DNA	B
-	I
PK	I
)	O
and	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
are	O
activated	O
by	O
DNA	O
strand	O
breaks	O
and	O
participate	O
in	O
DNA	O
repair	O
.	O

We	O
investigated	O
the	O
interactive	O
effects	O
of	O
inhibitors	O
of	O
these	O
enzymes	B
[	O
wortmannin	O
(	O
WM	O
)	O
,	O
which	O
inhibits	O
DNA	B
-	I
PK	I
,	O
and	O
8-hydroxy-2-methylquinazolin-4-one	O
(	O
NU1025	O
)	O
,	O
a	O
PARP	B
inhibitor	O
]	O
on	O
cell	O
survival	O
and	O
DNA	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
and	O
single	O
-	O
strand	O
break	O
(	O
SSB	O
)	O
rejoining	O
in	O
Chinese	O
hamster	O
ovary	O
-	O
K1	O
cells	O
following	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
or	O
temozolomide	O
.	O

WM	O
(	O
20	O
microM	O
)	O
or	O
NU1025	O
(	O
300	O
microM	O
)	O
potentiated	O
the	O
cytotoxicity	O
of	O
IR	O
with	O
dose	O
enhancement	O
factors	O
at	O
10	O
%	O
survival	O
(	O
DEF10	O
)	O
values	O
of	O
4.5	O
+	O
/-	O

0.6	O
and	O
1.7	O
+	O
/-	O

0.2	O
,	O
respectively	O
.	O

When	O
used	O
in	O
combination	O
,	O
a	O
DEF10	O
of	O
7.8	O
+	O
/-	O

1.5	O
was	O
obtained	O
.	O

WM	O
or	O
NU1025	O
potentiated	O
the	O
cytotoxicity	O
of	O
temozolomide	O
,	O
and	O
an	O
additive	O
effect	O
on	O
the	O
DEF10	O
value	O
was	O
obtained	O
with	O
the	O
combined	O
inhibitors	O
.	O

Using	O
the	O
same	O
inhibitor	O
concentrations	O
,	O
their	O
single	O
and	O
combined	O
effects	O
on	O
DSB	O
and	O
SSB	O
levels	O
following	O
IR	O
were	O
assessed	O
by	O
neutral	O
and	O
alkaline	O
elution	O
.	O

Cells	O
exposed	O
to	O
IR	O
were	O
post	O
-	O
incubated	O
for	O
30	O
min	O
to	O
allow	O
repair	O
to	O
occur	O
.	O

WM	O
or	O
NU1025	O
increased	O
net	O
DSB	O
levels	O
relative	O
to	O
IR	O
alone	O
(	O
DSB	O
levels	O
of	O
1.29	O
+	O
/-	O

0.04	O
and	O
1.20	O
+	O
/-	O

0.05	O
,	O
respectively	O
,	O
compared	O
with	O
1.01	O
+	O
/-	O

0.03	O
for	O
IR	O
alone	O
)	O
and	O
the	O
combination	O
had	O
an	O
additive	O
effect	O
.	O

WM	O
had	O
no	O
effect	O
on	O
SSB	O
levels	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
NU1025	O
.	O

SSB	O
levels	O
were	O
increased	O
to	O
1.27	O
+	O
/-	O

0.05	O
with	O
NU1025	O
compared	O
with	O
IR	O
alone	O
,	O
1.02	O
+	O
/-	O

0.04	O
.	O

The	O
dose	O
-	O
dependent	O
effects	O
of	O
the	O
inhibitors	O
on	O
DSB	O
levels	O
showed	O
that	O
they	O
were	O
near	O
maximal	O
by	O
20	O
microM	O
WM	O
and	O
300	O
microM	O
NU1025	O
.	O

DSB	O
repair	O
kinetics	O
were	O
studied	O
.	O

Both	O
inhibitors	O
increased	O
net	O
DSB	O
levels	O
over	O
a	O
3	O
h	O
time	O
period	O
;	O
when	O
they	O
were	O
combined	O
,	O
net	O
DSB	O
levels	O
at	O
3	O
h	O
were	O
identical	O
to	O
DSB	O
levels	O
immediately	O
post	O
-	O
IR	O
.	O

The	O
combined	O
use	O
of	O
DNA	O
repair	O
inhibitors	O
may	O
have	O
therapeutic	O
potential	O
.	O

Chemical	O
investigation	O
of	O
the	O
sponge	O
Spongia	O
matamata	O
collected	O
in	O
Yap	O
,	O
Micronesia	O
,	O
has	O
resulted	O
in	O
the	O
isolation	O
of	O
six	O
new	O
spongian	O
diterpenoids	O
,	O
2	O
-	O
7	O
,	O
along	O
with	O
the	O
known	O
compound	O
,	O
spongia-13	O
(	O
16	O
)	O
,	O
14-dien-19-oic	O
acid	O
(	O
1	O
)	O
.	O

The	O
structures	O
were	O
determined	O
by	O
spectroscopic	O
methods	O
.	O

Meloxicam	O
[	O
4-hydroxy-2-methyl	O
-	O
N-	O
(	O
5-methyl-2-thiazolyl	O
)	O
-2H-1,2-benzothiazine	O
-3-carboxamide-1	O
,	O
1-dioxide	O
]	O
is	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
of	O
the	O
oxicam	O
class	O
which	O
shows	O
preferential	O
inhibition	O
of	O
cyclo	B
-	I
oxygenase-2	I
.	O

Meloxicam	O
has	O
a	O
plasma	O
half	O
-	O
life	O
of	O
approximately	O
20	O
hours	O
,	O
making	O
it	O
convenient	O
for	O
once	O
-	O
daily	O
administration	O
.	O

Meloxicam	O
is	O
eliminated	O
after	O
biotransformation	O
to	O
4	O
pharmacologically	O
inactive	O
metabolites	O
,	O
which	O
are	O
excreted	O
in	O
urine	O
and	O
faeces	O
.	O

Meloxicam	O
and	O
its	O
metabolites	O
bind	O
extensively	O
to	O
plasma	B
albumin	I
.	O

Substantial	O
concentrations	O
of	O
meloxicam	O
are	O
attained	O
in	O
synovial	O
fluid	O
,	O
the	O
proposed	O
site	O
of	O
action	O
in	O
chronic	O
inflammatory	O
arthropathies	O
.	O

Neither	O
moderate	O
renal	O
nor	O
hepatic	O
insufficiency	O
significantly	O
alter	O
the	O
pharmacokinetics	O
of	O
meloxicam	O
.	O

Dosage	O
adjustment	O
is	O
not	O
required	O
in	O
the	O
elderly	O
.	O

Drug	O
-	O
drug	O
interaction	O
studies	O
are	O
available	O
for	O
some	O
commonly	O
co	O
-	O
prescribed	O
medications	O
.	O

Concentration	O
-	O
dependent	O
therapeutic	O
and	O
toxicological	O
effects	O
have	O
yet	O
to	O
be	O
extensively	O
elucidated	O
for	O
this	O
NSAID	O
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
the	O
enzymes	B
we	O
hypothesize	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
bis	O
(	O
monoacylglycerol	O
)	O
phosphate	O
from	O
phosphatidylglycerol	O
.	O

Here	O
we	O
describe	O
a	O
transacylase	B
,	O
active	O
at	O
acidic	O
pH	O
values	O
,	O
isolated	O
from	O
a	O
macrophage	O
-	O
like	O
cell	O
line	O
,	O
RAW	O
264.7	O
.	O

This	O
enzyme	B
acylates	O
the	O
head	O
group	O
glycerol	O
of	O
sn-3	O
:	O
sn-1	O
'	O
lysophosphatidylglycerol	O
to	O
form	O
sn-3	O
:	O
sn-1	O
'	O
bis	O
(	O
monoacylglycerol	O
)	O
phosphate	O
.	O

Here	O
we	O
demonstrate	O
that	O
this	O
enzyme	B
uses	O
two	O
lysophosphatidylglycerol	O
molecules	O
,	O
one	O
as	O
an	O
acyl	O
donor	O
and	O
another	O
as	O
an	O
acyl	O
acceptor	O
,	O
and	O
that	O
the	O
acyl	O
contributions	O
from	O
all	O
other	O
lipids	O
tested	O
are	O
comparatively	O
minor	O
.	O

This	O
enzyme	B
prefers	O
saturated	O
acyl	O
chains	O
to	O
monounsaturates	O
,	O
16	O
and	O
18	O
carbon	O
fatty	O
acids	O
over	O
14	O
carbon	O
fatty	O
acids	O
,	O
and	O
saturated	O
acyl	O
chains	O
at	O
the	O
sn-1	O
position	O
to	O
monounsaturated	O
acyl	O
chains	O
on	O
the	O
sn-2	O
carbon	O
of	O
lysophosphatidylglycerol	O
.	O

We	O
present	O
data	O
which	O
show	O
the	O
transacylase	B
activity	O
depends	O
on	O
the	O
presence	O
of	O
a	O
lipid	O
-	O
water	O
interface	O
and	O
the	O
lipid	O
polymorphic	O
state	O
.	O

INTRODUCTION	O
We	O
have	O
recently	O
shown	O
that	O
rabbit	O
antibodies	B
to	O
the	O
p	O
-	O
azophenylphosphorylcholine	O
(	O
APPC	O
)	O
determinant	O
,	O
which	O
bears	O
2	O
charges	O
of	O
opposite	O
sign	O
,	O
have	O
both	O
positively	O
and	O
negatively	O
charged	O
groups	O
in	O
their	O
binding	O
sites	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
positive	O
charge	O
is	O
contributed	O
by	O
the	O
guanidinium	O
group	O
of	O
arginine	O
and	O
the	O
negative	O
charge	O
is	O
contributed	O
by	O
the	O
carboxylate	O
group	O
of	O
either	O
a	O
glutamyl	O
or	O
aspartyl	O
residue	O
.	O

We	O
have	O
also	O
previously	O
shown	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
that	O
the	O
phosphorylcholine	O
-	O
binding	O
mouse	B
myeloma	I
protein	I
,	O
HOPC-8	B
,	O
similarly	O
contains	O
gaunidinium	O
and	O
carboxylate	O
groups	O
in	O
its	O
binding	O
site	O
.	O

In	O
an	O
attempt	O
to	O
gain	O
further	O
insight	O
into	O
the	O
nature	O
of	O
these	O
binding	O
sites	O
we	O
have	O
measured	O
the	O
relative	O
binding	O
constants	O
of	O
several	O
structurally	O
related	O
small	O
molecules	O
with	O
anti	B
-	I
APPC	I
antibodies	I
and	O
with	O
HOPC-8	B
.	O

The	O
Krel	O
values	O
for	O
hapten	O
binding	O
to	O
the	O
rabbit	O
anti	B
-	I
APPC	I
antibodies	I
and	O
to	O
the	O
myeloma	B
protein	I
,	O
together	O
with	O
our	O
evidence	O
for	O
specific	O
functional	O
groups	O
in	O
the	O
binding	O
sites	O
,	O
have	O
allowed	O
us	O
to	O
draw	O
inferences	O
regarding	O
the	O
topography	O
of	O
the	O
binding	O
sites	O
of	O
anti	B
-	I
APPC	I
antibodies	I
and	O
HOPC-8	B
.	O

*	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
U.S.	O
Public	O
Health	O
Service	O
Research	O
Grants	O
CA-11656	O
and	O
AI-03962	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

t	O
A	O
unit	O
of	O
the	O
New	O
York	O
State	O
Department	O
of	O
Health	O
.	O

$	O
Abbreviations	O
used	O
:	O
APPC	O
,	O
p	O
-	O
azophenylphosphorylcholine	O
;	O
NPPC	O
,	O
p	O
-	O
nitrophenylphosphorylcholine	O
;	O
PC	O
,	O
phosphorylcholine	O
;	O
GPC	O
,	O
L	O
-	O
a	O
-	O
glycerophosphorylcholine	O
;	O
AcC	O
,	O
acetylcholine	O
;	O
I	O
-	O
Ap	O
,	O
p	O
-	O
iodophenyltrimethylammonium	O
;	O
PO3	O
,	O
phenylphosphate	O
;	O
03	O
,	O
phenylphosphonate	O
;	O
BBS	O
,	O
borate	O
buffered	O
saline	O
.	O

901	O
MATERIALS	O
AND	O
METHODS	O
p	O
-	O
Diazonium	O
phenylphosphorylcholine	O
chloride	O
(	O
DPPC	O
)	O
This	O
was	O
prepared	O
according	O
to	O
Chesebro	O
&	O
Metzger	O
(	O
1972	O
)	O
with	O
the	O
exception	O
that	O
in	O
the	O
diazotization	O
step	O
1.0	O
N	O
HCl	O
rather	O
than	O
0.1	O
N	O
HCl	O
was	O
used	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Haptens	O
Haptens	O
tested	O
were	O
reagent	O
grade	O
commercial	O
products	O
,	O
used	O
without	O
further	O
purification	O
.	O

Goat	O
anti	B
-	I
rabbit	I
IgG	I
This	O
serum	O
was	O
a	O
preparation	O
previously	O
described	O
(	O
Hoffman	O
et	O
al.	O
,	O
1971	O
)	O
.	O

Rabbit	O
anti	B
-	I
mouse	I
IgA	I
This	O
serum	O
was	O
obtained	O
from	O
Dr.	O
Oliver	O
A.	O
Roholt	O
of	O
our	O
Department	O
.	O

It	O
was	O
prepared	O
by	O
hyperimmunization	O
of	O
rabbits	O
with	O
MOPC-315	B
myeloma	I
protein	I
.	O

Anti	B
-	I
APPC	I
antibodies	I
The	O
preparation	O
of	O
rabbit	O
antisera	O
to	O
the	O
APPC	O
determinant	O
and	O
the	O
subsequent	O
isolation	O
and	O
purification	O
of	O
the	O
antibodies	B
from	O
individual	O
rabbits	O
by	O
specific	O
immunoadsorption	O
has	O
been	O
described	O
previously	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
present	O
work	O
preparations	O
from	O
rabbits	O
6055	O
and	O
6057	O
were	O
specifically	O
purified	O
anti	B
-	I
APPC	I
antibodies	I
and	O
the	O
preparation	O
from	O
rabbit	O
5920	O
was	O
a	O
gamma	B
globulin	I
fraction	O
of	O
anti	B
-	I
APPC	I
serum	O
.	O

HOPC-8	B
myeloma	I
protein	I
This	O
was	O
obtained	O
from	O
the	O
serum	O
of	O
tumor	O
-	O
bearing	O
mice	O
as	O
previously	O
described	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

The	O
myeloma	O
tumor	O
was	O
obtained	O
through	O
the	O
courtesy	O
of	O
Dr.	O
Michael	O
Potter	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
MD	O
.	O

L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
Rabbit	B
serum	I
albumin	I
(	O
RSA	B
)	O
This	O
was	O
Fraction	O
V	O
obtained	O
from	O
Pentex	O
,	O
Inc.	O
,	O
Kankakee	O
,	O
IL	O
.	O

RSA	B
-	O
APPC	O
This	O
was	O
prepared	O
by	O
reacting	O
160	O
mg	O
of	O
RSA	B
in	O
about	O
10	O
ml	O
of	O
pH	O
9.5	O
borate	O
buffer	O
with	O
90	O
umoles	O
of	O
DPPC	O
for	O
18	O
hr	O
.	O

The	O
solution	O
was	O
then	O
dialyzed	O
against	O
pH	O
8	O
z	O
BBS	O
,	O
stored	O
frozen	O
and	O
used	O
as	O
needed	O
.	O

The	O
entire	O
prep-	O
ae	O
aration	O
was	O
carried	O
out	O
at	O
4	O
.	O

Radioiodination	O
of	O
RSA	B
-	B
APPC	I
RSA	B
-	B
APPC	I
was	O
trace	O
labeled	O
with	O
'	O
251	O
by	O
a	O
modification	O
of	O
the	O
method	O
of	O
Greenwood	O
et	O
al.	O
(	O
1963	O
)	O
.	O

Iodination	O
was	O
carried	O
out	O
in	O
0.45	O
ml	O
of	O
pH	O
8	O
BBS	O
containing	O
200	O
Ug	O
(	O
ca	O
.	O

3	O
n	O
-	O
mole	O
)	O
RSA	B
-	B
APPC	I
,	O
1	O
n	O
-	O
mole	O
of	O
KI	O
,	O
0.4	O
mCi	O
of	O
'	O
ZSI	O
and	O
300	O
n	O
-	O
mole	O
of	O
chloromine	O
T.	O
The	O
reaction	O
was	O
allowed	O
to	O
proceed	O
for	O
30	O
min	O
,	O
stopped	O
with	O
300	O
n	O
-	O
mole	O
of	O
bisulfite	O
and	O
the	O
product	O
dialyzed	O
to	O
remove	O
free	O
""""	O
'	O
I	O
and	O
reagents	O
.	O

Measurement	O
of	O
K	O
,	O
e	O
,	O
The	O
method	O
used	O
to	O
obtain	O
the	O
relative	O
binding	O
constants	O
for	O
the	O
various	O
haptens	O
is	O
based	O
on	O
the	O
technique	O
originally	O
developed	O
by	O
Skom	O
&	O
Talmadge	O
(	O
1958	O
)	O
for	O
precipitating	O
antigen	O
-	O
antibody	B
complexes	O
with	O
antiglobulin	B
.	O

In	O
our	O
assay	O
the	O
primary	O
haptenic	O
determinant	O
,	O
p	O
-	O
azophenylphosphory1choline	O
,	O
was	O
coupled	O
to	O
rabbit	B
serum	I
albumin	I
which	O
was	O
then	O
trace	O
labeled	O
with	O
1251	O
.	O

Labeled	O
antigen	O
was	O
mixed	O
with	O
varying	O
amounts	O
of	O
antibody	B
and	O
the	O
amount	O
of	O
antigen	O
bound	O
was	O
determined	O
by	O
precipitating	O
all	O
the	O
gamma	B
globulin	I
(	O
i.e.	O
bound	O
and	O
unbound	O
antibody	B
as	O
well	O
as	O
non	O
-	O
specific	O
y	B
globulin	I
)	O
with	O
goat	O
antiglobulin	B
antibody	I
and	O
measuring	O
the	O
radioactivity	O
associated	O
with	O
the	O
precipitate	O
.	O

Relative	O
binding	O
constants	O
(	O
K	O
,	O
e	O
,	O
)	O
for	O
the	O
different	O
haptens	O
were	O
determined	O
by	O
measuring	O
their	O
ability	O
to	O
inhibit	O
the	O
reaction	O
of	O
labeled	O
antigen	O
with	O
antibody	B
.	O

The	O
amount	O
of	O
antibody	B
was	O
chosen	O
so	O
that	O
about	O
60	O
%	O
of	O
the	O
labeled	O
antigen	O
was	O
bound	O
by	O
antibody	B
in	O
the	O
absence	O
of	O
hapten	O
.	O

In	O
a	O
typical	O
determination	O
the	O
antigen	O
solution	O
was	O
made	O
to	O
contain	O
100	O
ng	O
per	O
ml	O
of	O
1251-RSA	O
-	B
APPC	I
and	O
1	O
mg	O
/	O
ml	O
of	O
RSA	B
in	O
pH	O
8	O
BBS	O
.	O

The	O
required	O
concentration	O
of	O
antibody	B
was	O
made	O
up	O
in	O
normal	O
rabbit	O
serum	O
diluted	O
1:5	O
with	O
pH	O
8	O
BBS	O
.	O

HOPC-8	B
myeloma	I
protein	I
was	O
made	O
up	O
in	O
normal	O
mouse	O
serum	O
diluted	O
1:5	O
.	O

To	O
0.1	O
ml	O
of	O
antibody	B
(	O
or	O
HOPC-8	B
)	O
solution	O
were	O
added	O
,	O
0.1	O
ml	O
'	B
251-RSA	I
-	I
APPC	I
solution	O
and	O
0.1	O
ml	O
hapten	O
solution	O
in	O
pH	O
8	O
BBS	O
.	O

Hapten	O
concentrations	O
ranged	O
from	O
10	O
'	O
to	O
10-'M.	O
In	O
one	O
sample	O
(	O
uninhibited	O
)	O
,	O
hapten	O
solution	O
was	O
replaced	O
by	O
buffer	O
to	O
determine	O
the	O
amount	O
of	O
antigen	O
precipitated	O
in	O
the	O
absence	O
of	O
hapten	O
.	O

Another	O
mixture	O
(	O
non	O
-	O
specific	O
control	O
)	O
contained	O
0.1	O
ml	O
1:5	O
diluted	O
normal	O
rabbit	O
(	O
or	O
mouse	O
)	O
serum	O
in	O
place	O
of	O
antibody	B
,	O
0.1	O
ml	O
of	O
antigen	O
and	O
0.1	O
ml	O
of	O
buffer	O
.	O

All	O
tubes	O
were	O
incubated	O
at	O
37	O
for	O
30	O
min	O
.	O

Then	O
0.2	O
ml	O
of	O
anti	B
-	I
globulin	I
antiserum	O
was	O
added	O
to	O
all	O
tubes	O
.	O

The	O
amount	O
added	O
was	O
that	O
determined	O
to	O
be	O
sufficient	O
to	O
precipitate	O
all	O
the	O
globulin	B
in	O
the	O
mixture	O
.	O

Goat	O
anti	B
-	I
rabbit	I
y	I
-	I
globulin	I
was	O
used	O
to	O
precipitate	O
the	O
rabbit	O
antibodies	B
and	O
rabbit	O
anti	B
-	I
mouse	I
IgA	I
was	O
used	O
to	O
precipitate	O
the	O
HOPC-8	B
myeloma	I
protein	I
.	O

The	O
reaction	O
mixtures	O
were	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
1	O
hr	O
,	O
and	O
then	O
stored	O
at	O
5	O
overnight	O
.	O

The	O
tubes	O
were	O
centrifuged	O
,	O
the	O
supernatants	O
discarded	O
and	O
the	O
precipitates	O
washed	O
twice	O
with	O
saline	O
.	O

Radioactivity	O
in	O
the	O
precipitates	O
was	O
determined	O
.	O

All	O
determinations	O
were	O
done	O
in	O
duplicate	O
.	O

Per	O
cent	O
inhibition	O
is	O
given	O
by	O
:	O
Inhibition	O
=	O
f	O
1	O
ANTI	B
-	I
APPC	I
#	O
6055	O
loo	O
50	O
01	O
10	O
-	O
6	O
10	O
-	O
5	O
NPPC	O
GPC	O
,	O
Pc	O
P03	O
I_AD	O
CHOLINE	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
Fig.	O
1	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	B
-	B
APPC	I
antigen	O
to	O
anti	B
-	I
APPC	I
antibody	I
from	O
rabbit	O
6055	O
.	O

Values	O
determined	O
in	O
this	O
manner	O
were	O
reproducible	O
to	O
within	O
%	O
.	O

RESULTS	O
Plots	O
of	O
effect	O
of	O
hapten	O
on	O
antigen	O
binding	O
are	O
given	O
in	O
Fig.	O
1	O
for	O
anti	B
-	I
APPC	I
from	O
rabbit	O
6055	O
and	O
in	O
Fig.	O
2	O
for	O
anti	B
-	I
APPC	I
from	O
rabbit	O
5920	O
.	O

The	O
plots	O
for	O
anti	B
-	I
APPC	I
from	O
rabbit	O
6057	O
,	O
were	O
essentially	O
identical	O
to	O
those	O
in	O
Fig.	O
1	O
.	O

From	O
these	O
data	O
,	O
K	O
,	O
el	O
values	O
were	O
calculated	O
relative	O
to	O
the	O
most	O
inhibitory	O
hapten	O
,	O
NPPC	O
,	O
according	O
to	O
the	O
formula	O
:	O
_	O
(	O
NPPC	O
)	O
at	O
50	O
%	O
inhibition	O
K	O
""""	O
'	O
(	O
HAPTEN	O
)	O
at	O
50	O
%	O
inhibition	O
The	O
values	O
of	O
K	O
,	O
e	O
,	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
only	O
effective	O
inhibitors	O
observed	O
are	O
those	O
listed	O
in	O
Table	O
1	O
,	O
having	O
K	O
,	O
e	O
,	O
values	O
>	O
0.0001	O
.	O

It	O
is	O
interesting	O
that	O
the	O
p	O
-	O
iodophenyltrimethylammonium	O
ion	O
gave	O
detectable	O
inhibition	O
in	O
2	O
instances	O
.	O

Twentyfive	O
other	O
haptens	O
were	O
tested	O
.	O

None	O
showed	O
appreciable	O
binding	O
to	O
anti	B
-	I
APPC	I
antibodies	I
.	O

Among	O
those	O
tested	O
were	O
negatively	O
and	O
positively	O
chargen	O
haptens	O
,	O
including	O
other	O
phenyltrimethylammonium	O
ions	O
and	O
ANTI	B
-	I
APPC	I
#	O
5920	O
loo	O
50	O
z	O
x	O
NPPC	O
,	O
GPC	O
I	O
-	O
AP	O
PC	O
CHOLINE	O
0	O
10	O
-	O
6	O
10	O
-	O
5	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10-I	O
INHIBITOR	O
CONC.	O
(	O
M	O
)	O
Fig.	O
2	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	B
-	O
APPC	O
antigen	O
to	O
anti	B
-	I
APPC	I
antibody	I
from	O
rabbit	O
5920	O
.	O

inhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
uninhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
x	O
100	O
.	O

Specificity	O
of	O
Anti	B
-	I
p	I
-	I
Azophenylphosphorylcholine	I
Antibodies	I
Table	O
1	O
.	O

Relative	O
binding	O
constants	O
of	O
haptens	O
for	O
anti	B
APPC	I
antibodies	I
Hapten	O
NPPC	O
t	O
.-	O
a	O
-	O
glycerophosphorylcholine	O
Phosphorylcholine	O
I	O
-	O
Ap	O
Choline	O
Phenylphosphonate	O
Phenylphosphate	O
Rabbit	O
No.	O
5920	O
6055	O
6057	O
K	O
1.0	O
0.015	O
0.0003	O
0.004	O
0.0007	O
0.0001	O
0.0001	O
1.0	O
1.0	O
0.019	O
0.016	O
0.0004	O
0.0005	O
0.0001	O
<	O
0.0001	O
0.00006	O
0.00006	O
0.0002	O
<	O
0.0001	O
0.0001	O
<	O
0.0001	O
several	O
phenylarsonates	O
and	O
sulfonates	O
.	O

A	O
representative	O
list	O
of	O
some	O
of	O
these	O
non	O
-	O
inhibitory	O
haptens	O
is	O
given	O
in	O
Table	O
2	O
.	O

The	O
results	O
of	O
inhibition	O
studies	O
with	O
the	O
mouse	B
myeloma	I
protein	I
HOPC-8	I
are	O
given	O
in	O
Fig.	O
3	O
where	O
the	O
inhibition	O
curves	O
are	O
drawn	O
only	O
for	O
those	O
haptens	O
showing	O
significant	O
ability	O
to	O
inhibit	O
.	O

K	O
,	O
e	O
,	O
values	O
were	O
calculated	O
as	O
described	O
above	O
and	O
are	O
listed	O
in	O
Table	O
3	O
.	O

For	O
comparison	O
,	O
Table	O
3	O
also	O
lists	O
values	O
of	O
K	O
,	O
el	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
TEPC-15	O
in	O
a	O
system	O
using	O
the	O
C	O
-	O
polysaccharide	O
of	O
pneumococcus	O
as	O
an	O
antigen	O
.	O

There	O
is	O
adequate	O
serological	O
and	O
chemical	O
evidence	O
showing	O
that	O
HOPC-8	B
and	O
TEPC-15	B
are	O
nearly	O
identical	O
proteins	O
(	O
Potter	O
&	O
Lieberman	O
,	O
1970	O
;	O
Hood	O
et	O
al.	O
,	O
1970	O
)	O
.	O

The	O
values	O
in	O
Table	O
3	O
show	O
the	O
close	O
correspondence	O
between	O
our	O
values	O
of	O
K	O
,	O
e	O
,	O
for	O
HOPC-8	B
and	O
those	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
for	O
TECP-15	B
.	O

The	O
K	O
,	O
e	O
,	O
values	O
for	O
anti	B
-	I
APPC	I
from	O
rabbit	O
6055	O
are	O
also	O
listed	O
in	O
Table	O
3	O
to	O
facilitate	O
comparisons	O
with	O
HOPC-8	B
.	O

In	O
order	O
to	O
assess	O
further	O
the	O
validity	O
of	O
the	O
inhibition	O
method	O
as	O
used	O
here	O
for	O
obtaining	O
Kre	O
,	O
values	O
,	O
we	O
have	O
compared	O
the	O
value	O
of	O
K	O
,	O
e	O
,	O
calculated	O
from	O
the	O
individual	O
binding	O
constants	O
of	O
HOPC-8	B
for	O
phosphory1choline	O
(	O
PC	O
)	O
and	O
p	O
-	O
nitrophenylphosphorylcholine	O
(	O
NPPC	O
)	O
as	O
determined	O
by	O
equilibrium	O
dialysis	O
,	O
to	O
the	O
Kre	O
,	O
values	O
calculated	O
from	O
the	O
inhibition	O
data	O
.	O

As	O
measured	O
by	O
equilibrium	O
dialysis	O
with	O
HOPC-8	B
the	O
binding	O
constant	O
for	O
PC	O
(	O
KPc	O
)	O
was	O
found	O
to	O
be	O
1.2	O
x	O
106	O
M-1	O
and	O
for	O
NPPC	O
the	O
KNPPC	O
was	O
0.43	O
x	O
106	O
M-1	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
ratio	O
of	O
the	O
two	O
is	O
:	O
1.20	O
x	O
106	O
_	O
KPCIKNPPC	O
-	O
0.43	O
x	O
106	O
-	O
2.8	O
.	O

Table	O
2	O
.	O

Haptens	O
unable	O
to	O
inhibit	O
binding	O
of	O
RSA	B
-	O
APPC	O
to	O
anti	B
-	I
APPC	I
antibodies	I
""""	O
Acetylcholine	O
Phenyltrimethylammonium	O
p	O
-	O
Aminophenyltrimethylammonium	O
chloride	O
Phenylarsonate	O
p	O
-	O
Nitrophenylarsonate	O
p	O
-	O
lodophenylarsonate	O
Hydroxyphenylazo	O
)	O
phenylarsonate	O
p	O
-	O
lodobenzenesulfonate	O
Naphthalene	O
-	O
l	O
-	O
sulfonate	O
5-Nitro-3-iodo-4-hydroxyphenylacetate	O
5-Nitro-4-hydroxyphenylacetate	O
Kre	O
,	O
<	O
0.0001	O
,	O
relative	O
to	O
NPPC	O
,	O
which	O
is	O
equivalent	O
to	O
<	O
50	O
%	O
inhibition	O
at	O
0.1	O
M	O
hapten	O
concentration	O
.	O

903	O
HOPC-8	O
100	O
PC	O
WPC	O
I	O
-	O
Ap	O
GPC	O
AcC	O
m	O
50	O
z	O
_	O
<	O
60P	O
Y	O
,	O
OOPO=3	O
~	O
OP	O
03	O
0	O
ITS	O
I	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
IT	O
2	O
IT	O
l	O
Fig.	O
3	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	B
-	O
APPC	O
antigen	O
to	O
mouse	B
myeloma	I
protein	I
HOPC-8	I
.	O

The	O
ratio	O
obtained	O
using	O
K	O
,	O
e	O
,	O
values	O
obtained	O
by	O
hapten	O
inhibition	O
(	O
Table	O
3	O
)	O
is	O
2.9	O
,	O
a	O
satisfactory	O
agreement	O
.	O

DISCUSSION	O
The	O
relative	O
binding	O
constants	O
(	O
K	O
,	O
,	O
,	O
)	O
for	O
haptens	O
to	O
anti	B
-	I
APPC	I
antibodies	I
were	O
determined	O
by	O
hapten	O
inhibition	O
.	O

About	O
30	O
potential	O
ligands	O
were	O
tested	O
and	O
only	O
5	O
of	O
these	O
were	O
shown	O
to	O
bind	O
significantly	O
(	O
NPPC	O
,	O
glycerophosphorylcholine	O
,	O
I	O
-	O
Ap	O
,	O
choline	O
and	O
phosphorylcholine	O
)	O
.	O

The	O
values	O
of	O
K	O
,	O
,	O
,	O
obtained	O
with	O
the	O
several	O
haptens	O
allow	O
inferences	O
as	O
to	O
the	O
relative	O
importance	O
of	O
the	O
particular	O
structural	O
features	O
of	O
each	O
hapten	O
in	O
contributing	O
to	O
the	O
binding	O
energy	O
.	O

The	O
rabbit	O
anti	B
-	I
APPC	I
antibodies	I
studied	O
here	O
were	O
raised	O
against	O
a	O
hapten	O
having	O
3	O
distinct	O
structural	O
features	O
-	O
a	O
p	O
-	O
azophenyl	O
group	O
,	O
a	O
negatively	O
charged	O
phosphoryl	O
ester	O
group	O
,	O
and	O
a	O
positively	O
charged	O
quarternary	O
ammonium	O
group	O
.	O

Of	O
these	O
,	O
the	O
one	O
apparently	O
very	O
important	O
for	O
binding	O
is	O
the	O
positively	O
charged	O
group	O
,	O
since	O
haptens	O
which	O
were	O
most	O
effective	O
in	O
inhibiting	O
the	O
binding	O
of	O
the	O
APPC	O
-	O
containing	O
antigen	O
to	O
antibody	B
contained	O
this	O
group	O
(	O
Table	O
1	O
)	O
and	O
those	O
least	O
effective	O
did	O
not	O
.	O

Thus	O
,	O
removal	O
of	O
the	O
choline	O
group	O
from	O
phenylphosphorylcholine	O
decreases	O
its	O
binding	O
strength	O
by	O
a	O
factor	O
of	O
about	O
Table	O
3	O
.	O

Comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
for	O
HOPC-8	B
,	O
TEPC-15	B
and	O
a	O
rabbit	O
anti	B
-	I
APPC	I
antibody	I
Hapten	O
HOPC-8	B
2.9	O
1.0	O
0.5	O
0.033	O
0.015	O
0.01	O
""""	O
0.001	O
<	O
0.0001	O
Rabbit	O
anti	B
APPC	I
-	O
No	O
.	O

6055	O
K	O
,	O
TEPC-15	B
Phosphorylcholine	O
NPPC	O
-a	O
-	O
glycerophosphorylchole	O
I	O
-	O
Ap	O
Acetylcholine	O
Choline	O
Phenylphosphate	O
Phenylphosphonate	O
2.9	O
0.0004	O
1.0	O
0.019	O
0.0001	O
0.0001	O
0.008	O
0.00006	O
0.005	O
0.0001	O
-	O
0.0002	O
-	O
0.27	O
Calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
c	O
-	O
polysaccharide	O
of	O
Pneumococcus	O
.	O

The	O
values	O
were	O
obtained	O
by	O
setting	O
the	O
Kre	O
,	O
value	O
for	O
phosphorylchole	O
at	O
2.9	O
and	O
calculating	O
the	O
other	O
values	O
relative	O
to	O
this	O
.	O

""""	O
Estimated	O
from	O
the	O
value	O
of	O
Kre	O
,	O
for	O
choline	O
with	O
TEPC-15	B
.	O

904	O
L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
10,000	O
since	O
K	O
,	O
e	O
,	O
for	O
phenylphosphate	O
was	O
at	O
least	O
this	O
much	O
smaller	O
than	O
the	O
K	O
,	O
e	O
,	O
for	O
NPPC	O
(	O
Table	O
1	O
)	O
.	O

Moreover	O
,	O
p	O
-	O
iodophenyltrimethylammonium	O
gave	O
detectable	O
inhibition	O
with	O
one	O
anti	B
-	I
APPC	I
preparation	O
,	O
although	O
its	O
structure	O
is	O
otherwise	O
rather	O
different	O
from	O
the	O
choline	O
inhibitors	O
.	O

The	O
p	O
-	O
nitrophenyl	O
group	O
of	O
NPPC	O
contributes	O
very	O
effectively	O
to	O
the	O
specific	O
interaction	O
,	O
since	O
replacing	O
it	O
by	O
the	O
glycerol	O
group	O
decreases	O
the	O
binding	O
by	O
a	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
removing	O
the	O
p	O
-	O
nitrophenyl	O
group	O
,	O
to	O
give	O
phosphorylcholine	O
,	O
decreases	O
the	O
binding	O
by	O
another	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
so	O
that	O
phosphorylcholine	O
binds	O
2500	O
times	O
more	O
weakly	O
than	O
NPPC	O
.	O

The	O
negatively	O
charged	O
phosphoryl	O
group	O
apparently	O
interacts	O
only	O
to	O
a	O
small	O
extent	O
with	O
the	O
antibody	B
site	O
.	O

This	O
is	O
evident	O
from	O
the	O
fact	O
that	O
K	O
,	O
,	O
,	O
for	O
phosphorylcholine	O
is	O
only	O
6	O
-	O
8	O
times	O
greater	O
than	O
Kre	O
,	O
for	O
choline	O
for	O
2	O
antibody	B
preparations	O
studied	O
and	O
is	O
actually	O
smaller	O
than	O
that	O
for	O
choline	O
for	O
the	O
third	O
antibody	B
preparation	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
phenylphosphate	O
(	O
Table	O
2	O
)	O
and	O
phenylphosphonate	O
(	O
Table	O
1	O
)	O
show	O
only	O
weak	O
binding	O
to	O
the	O
antibodies	B
.	O

Thus	O
the	O
contribution	O
of	O
the	O
negative	O
charge	O
to	O
binding	O
is	O
not	O
great	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
we	O
have	O
previously	O
shown	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
that	O
a	O
positively	O
charged	O
arginyl	O
residue	O
is	O
present	O
in	O
the	O
anti	B
-	I
APPC	I
antibody	I
site	O
,	O
providing	O
a	O
basis	O
for	O
electrostatic	O
interaction	O
with	O
the	O
phosphoryl	O
group	O
.	O

When	O
the	O
rabbit	O
anti	B
-	I
APPC	I
antibodies	I
are	O
compared	O
to	O
the	O
mouse	B
myeloma	I
protein	I
,	O
HOPC-8	B
,	O
some	O
very	O
obvious	O
differences	O
in	O
specificity	O
are	O
apparent	O
.	O

In	O
general	O
HOPC-8	B
shows	O
broader	O
cross	O
-	O
reactivity	O
than	O
the	O
induced	O
rabbit	O
antibody	B
.	O

The	O
representative	O
comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
(	O
relative	O
to	O
NPPC	O
)	O
given	O
in	O
Table	O
3	O
,	O
indicates	O
that	O
many	O
more	O
of	O
the	O
compounds	O
listed	O
show	O
appreciable	O
binding	O
(	O
K	O
,	O
e	O
,	O
>	O
0.005	O
)	O
to	O
HOPC-8	B
than	O
to	O
rabbit	O
anti	B
-	I
APPC	I
.	O

In	O
addition	O
,	O
the	O
fine	O
specificity	O
of	O
HOPC-8	B
is	O
quite	O
different	O
from	O
that	O
of	O
the	O
rabbit	O
antibody	B
,	O
since	O
the	O
relative	O
binding	O
constant	O
for	O
phosphorylcholine	O
is	O
10	O
'	O
greater	O
with	O
HOPC-8	B
than	O
with	O
rabbit	O
anti	B
-	I
APPC	I
.	O

The	O
binding	O
to	O
the	O
2	O
proteins	B
differs	O
for	O
glycerophosphorylcholine	O
by	O
a	O
factor	O
of	O
25	O
,	O
for	O
chohne	O
by	O
a	O
factor	O
of	O
100	O
and	O
for	O
acetylcholine	O
by	O
a	O
factor	O
greater	O
than	O
100	O
.	O

The	O
negatively	O
charged	O
phosphoryl	O
group	O
appears	O
to	O
be	O
much	O
more	O
important	O
for	O
binding	O
to	O
HOPC-8	B
than	O
to	O
the	O
rabbit	O
antibody	B
,	O
since	O
the	O
K-	O
,	O
value	O
for	O
phosphorylcholine	O
is	O
greater	O
than	O
that	O
for	O
choline	O
by	O
a	O
factor	O
of	O
about	O
300	O
in	O
the	O
case	O
of	O
HOPC-8	B
.	O

For	O
rabbit	O
antibody	B
this	O
factor	O
is	O
only	O
about	O
10	O
(	O
Table	O
3	O
)	O
.	O

Moreover	O
,	O
phenylphosphate	O
binds	O
more	O
than	O
10	O
times	O
more	O
strongly	O
to	O
HOPC-8	B
than	O
to	O
anti	B
-	I
APPC	I
antibody	I
.	O

This	O
is	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
addition	O
of	O
the	O
p	O
-	O
nitrophenyl	O
group	O
to	O
phosphorylcholine	O
neither	O
adds	O
to	O
nor	O
subtracts	O
from	O
the	O
binding	O
energy	O
with	O
HOPC-8	B
,	O
whereas	O
it	O
adds	O
a	O
great	O
deal	O
to	O
the	O
binding	O
energy	O
with	O
anti	B
-	I
APPC	I
antibody	I
.	O

The	O
fact	O
that	O
the	O
HOPC-8	B
site	O
is	O
large	O
enough	O
to	O
accommodate	O
the	O
p	O
-	O
nitrophenyl	O
group	O
of	O
NPPC	O
with	O
little	O
steric	O
hindrance	O
is	O
of	O
interest	O
,	O
since	O
the	O
site	O
of	O
McPC-603	B
protein	O
,	O
which	O
also	O
binds	O
phosphorylcholine	O
analogues	O
with	O
similar	O
although	O
not	O
identical	O
specificity	O
(	O
Leon	O
&	O
Young	O
,	O
1971	O
)	O
also	O
can	O
accommodate	O
a	O
large	O
substituent	O
on	O
phosphorylcholine	O
.	O

Thus	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
studies	O
of	O
the	O
Fab	O
fragment	O
of	O
McPC-603	B
as	O
summarized	O
by	O
Segal	O
et	O
al.	O
(	O
1974	O
)	O
indicate	O
that	O
there	O
is	O
a	O
large	O
region	O
of	O
the	O
cleft	O
in	O
which	O
phosphorylcholine	O
is	O
bound	O
which	O
is	O
available	O
for	O
binding	O
additional	O
structure	O
.	O

Indeed	O
,	O
one	O
of	O
the	O
compounds	O
used	O
in	O
defining	O
the	O
site	O
region	O
was	O
2-	O
(	O
5'-acetoxy	O
-	O
mercury-2'-thiemyl	O
)	O
-ethylphosphory1choline	O
(	O
Padlan	O
et	O
al.	O
,	O
1973	O
)	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
large	O
compound	O
might	O
bind	O
equally	O
as	O
well	O
to	O
the	O
HOPC-8	B
site	O
as	O
to	O
the	O
McPC-603	B
site	O
.	O

The	O
differences	O
between	O
HOPC-8	B
sites	O
and	O
rabbit	O
anti	B
-	I
APPC	I
sites	O
are	O
interesting	O
in	O
view	O
of	O
the	O
fact	O
that	O
when	O
APPC	O
conjugated	O
to	O
protein	B
is	O
used	O
as	O
an	O
immunogen	O
in	O
the	O
BALB	O
/	O
c	O
mouse	O
,	O
the	O
IgM	O
antibodies	B
elicited	O
are	O
largely	O
of	O
the	O
HOPC-8-TEPC-15	O
idiotype	O
and	O
show	O
the	O
same	O
binding	O
characteristics	O
as	O
the	O
myeloma	B
proteins	I
(	O
Lee	O
it	O
al.	O
,	O
1974	O
)	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
receptor	B
sites	I
on	O
cells	O
responding	O
to	O
APPC	O
in	O
the	O
rabbits	O
we	O
used	O
are	O
quite	O
different	O
in	O
structure	O
from	O
sites	O
on	O
cells	O
which	O
respond	O
in	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
have	O
previously	O
observed	O
that	O
the	O
rabbit	O
antibodies	B
are	O
rather	O
heterogeneous	O
,	O
as	O
evidenced	O
by	O
their	O
non	O
-	O
linear	O
binding	O
curves	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
their	O
complex	O
isoelectric	O
focusing	O
patterns	O
(	O
Nutt	O
et	O
al.	O
,	O
1976	O
)	O
.	O

Populations	O
of	O
anti	B
-	I
APPC	I
antibodies	I
produced	O
also	O
differ	O
from	O
rabbit	O
to	O
rabbit	O
as	O
evidenced	O
by	O
the	O
differences	O
in	O
binding	O
strength	O
for	O
p	O
-	O
iodophenyltrimethylammonium	O
and	O
for	O
choline	O
shown	O
by	O
antibodies	B
from	O
rabbits	O
6055	O
and	O
5920	O
(	O
Table	O
1	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
induced	O
mouse	O
antibodies	B
appear	O
to	O
be	O
essentially	O
monoclonal	O
products	O
(	O
Lee	O
et	O
al.	O
,	O
1974	O
)	O
.	O

There	O
are	O
,	O
of	O
course	O
,	O
some	O
similarities	O
between	O
the	O
rabbit	O
antibodies	B
and	O
HOPC-8	B
.	O

The	O
major	O
of	O
these	O
is	O
that	O
for	O
both	O
binding	O
sites	O
the	O
positively	O
charged	O
quarternary	O
ammonium	O
group	O
appears	O
to	O
be	O
the	O
immunodominant	O
group	O
,	O
since	O
those	O
haptens	O
not	O
containing	O
this	O
group	O
are	O
bound	O
very	O
poorly	O
in	O
both	O
cases	O
(	O
Table	O
3	O
)	O
.	O

Thus	O
a	O
negatively	O
charged	O
carboxylate	O
group	O
which	O
would	O
interact	O
with	O
this	O
group	O
,	O
and	O
which	O
we	O
have	O
shown	O
to	O
be	O
present	O
in	O
the	O
combining	O
site	O
of	O
both	O
HOPC-8	B
and	O
anti	B
-	I
APPC	I
antibodies	I
,	O
is	O
probably	O
the	O
most	O
important	O
common	O
feature	O
of	O
both	O
sites	O
.	O

The	O
above	O
considerations	O
allow	O
us	O
to	O
make	O
the	O
following	O
inferences	O
about	O
the	O
topography	O
of	O
the	O
antiAPPC	B
and	O
HOPC-8	B
binding	O
sites	O
:	O
(	O
1	O
)	O
The	O
anti	B
-	I
APPC	I
site	O
contains	O
a	O
region	O
closely	O
complementary	O
to	O
the	O
phenyl	O
group	O
of	O
APPC	O
,	O
so	O
that	O
an	O
appreciable	O
part	O
ofAhe	O
binding	O
interaction	O
occurs	O
in	O
this	O
region	O
.	O

The	O
HOPC-8	B
site	O
accommodates	O
the	O
phenyl	O
group	O
with	O
little	O
interaction	O
energy	O
.	O

(	O
2	O
)	O
An	O
arginyl	O
residue	O
in	O
the	O
HOPC-8	B
site	O
contributes	O
a	O
positive	O
charge	O
which	O
interacts	O
strongly	O
with	O
the	O
negative	O
charge	O
on	O
the	O
phosphoryl	O
group	O
.	O

In	O
the	O
anti	B
-	I
APPC	I
site	O
,	O
which	O
also	O
contains	O
an	O
arginyl	O
residue	O
,	O
the	O
interaction	O
with	O
the	O
phosphoryl	O
group	O
is	O
much	O
weaker	O
,	O
and	O
therefore	O
the	O
2	O
groups	O
are	O
probably	O
farther	O
apart	O
than	O
in	O
the	O
HOPC-8	B
site	O
.	O

(	O
3	O
)	O
Both	O
sites	O
interact	O
strongly	O
with	O
the	O
quaternary	O
ammonium	O
group	O
of	O
choline	O
and	O
thus	O
this	O
group	O
probably	O
closely	O
approaches	O
a	O
carboxylate	O
group	O
present	O
in	O
both	O
sites	O
.	O

Acknowledgements	O
-	O
We	O
thank	O
Messrs.	O
Robert	O
Hewson	O
,	O
Leonard	O
Rendina	O
and	O
Arthur	O
Trott	O
for	O
expert	O
technical	O
assistance	O
.	O

Specificity	O
of	O
Anti	B
-	I
p	I
-	I
Azophenylphosphorylcholine	I
Antibodies	I

Manganous	O
chloride	O
and	O
Congo	O
red	O
incorporated	O
into	O
blotting	O
paper	O
discs	O
have	O
been	O
used	O
to	O
differentiate	O
gonococci	O
from	O
meningococci	O
.	O

The	O
new	O
technique	O
is	O
simple	O
and	O
reliable	O
;	O
the	O
materials	O
for	O
the	O
test	O
are	O
inexpensive	O
.	O

The	O
method	O
will	O
increase	O
the	O
efficiency	O
of	O
distinguishing	O
between	O
the	O
pathogenic	O
Neisseria	O
in	O
any	O
clinical	O
bacteriology	O
laboratory	O
and	O
especially	O
in	O
those	O
in	O
the	O
tropical	O
areas	O
.	O

A	O
methodology	O
to	O
determine	O
the	O
intrinsic	O
capacities	O
of	O
a	O
microflora	O
to	O
degrade	O
gasoline	O
was	O
developed	O
,	O
in	O
particular	O
for	O
assessing	O
the	O
potential	O
of	O
autochtonous	O
populations	O
of	O
polluted	O
and	O
non	O
polluted	O
soils	O
for	O
natural	O
attenuation	O
and	O
engineered	O
bioremediation	O
.	O

A	O
model	O
mixture	O
(	O
GM23	O
)	O
constituted	O
of	O
the	O
23	O
most	O
representative	O
hydrocarbons	O
of	O
a	O
commercial	O
gasoline	O
was	O
used	O
.	O

The	O
capacities	O
of	O
the	O
microflorae	O
(	O
kinetics	O
and	O
extent	O
of	O
biodegradation	O
)	O
were	O
assessed	O
by	O
chromatographic	O
analysis	O
of	O
hydrocarbon	O
consumption	O
and	O
of	O
CO2	O
production	O
.	O

The	O
degradation	O
of	O
the	O
components	O
of	O
GM23	O
was	O
assayed	O
in	O
separate	O
incubations	O
of	O
each	O
component	O
and	O
in	O
the	O
complete	O
mixture	O
.	O

For	O
the	O
microflora	O
of	O
an	O
unpolluted	O
spruce	O
forest	O
soil	O
,	O
all	O
hydrocarbons	O
of	O
GM23	O
except	O
cyclohexane	O
,	O
2,2,4-	O
and	O
2,3,4-trimethylpentane	O
isomers	O
were	O
degraded	O
to	O
below	O
detection	O
limit	O
in	O
28	O
days	O
.	O

This	O
microflora	O
was	O
reinforced	O
with	O
two	O
mixed	O
microbial	O
communities	O
selected	O
from	O
gasoline	O
-	O
polluted	O
sites	O
and	O
shown	O
to	O
degrade	O
cyclohexane	O
and	O
2,2,4-trimethylpentane	O
.	O

With	O
the	O
reinforced	O
microflora	O
,	O
complete	O
degradation	O
of	O
GM23	O
was	O
observed	O
.	O

The	O
degradation	O
patterns	O
of	O
individual	O
components	O
of	O
GM23	O
were	O
similar	O
when	O
the	O
compounds	O
were	O
present	O
individually	O
or	O
in	O
the	O
GM23	O
mixture	O
,	O
as	O
long	O
as	O
the	O
concentrations	O
of	O
2-ethyltoluene	O
and	O
trimethylbenzene	O
isomers	O
were	O
kept	O
sufficiently	O
low	O
(	O
<	O
or	O
=	O
35	O
mg.l-1	O
)	O
to	O
remain	O
below	O
their	O
inhibitory	O
level	O
.	O

The	O
first	O
acyclonucleosides	O
based	O
on	O
the	O
benzothiadiazine	O
dioxide	O
system	O
were	O
synthesized	O
following	O
the	O
silylation	O
procedure	O
.	O

Several	O
acyclic	O
moieties	O
,	O
including	O
acetoxyethoxymethyl	O
,	O
benzyloxymethyl	O
,	O
and	O
propargyloxymethyl	O
groups	O
,	O
were	O
introduced	O
.	O

Two	O
synthetic	O
strategies	O
were	O
designed	O
to	O
selectively	O
obtain	O
the	O
N-1	O
or	O
N-3	O
derivatives	O
.	O

Lipase	B
-	O
mediated	O
deacylation	O
was	O
used	O
for	O
the	O
deprotection	O
of	O
the	O
acyclonucleosides	O
.	O

Some	O
of	O
the	O
benzothiadiazine	O
dioxide	O
acyclonucleosides	O
,	O
in	O
particular	O
16	O
,	O
proved	O
active	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
at	O
concentrations	O
slightly	O
higher	O
than	O
that	O
found	O
for	O
ganciclovir	O
[	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
=	O
3	O
.	O
5	O
-	O
3.7	O
micrograms	O
/	O
mL	O
,	O
cytotoxicity	O
(	O
CC50	O
)	O
>	O
/=	O
40	O
micrograms	O
/	O
mL	O
,	O
MCC	O
=	O
20	O
micrograms	O
/	O
mL	O
]	O
.	O

Additionally	O
,	O
compound	O
16	O
inhibited	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
in	O
CEM	O
cells	O
at	O
concentrations	O
that	O
were	O
5-fold	O
lower	O
than	O
its	O
cytotoxic	O
concentration	O
.	O

To	O
examine	O
the	O
stereospecific	O
effects	O
of	O
lipoic	O
compounds	O
on	O
pyruvate	O
metabolism	O
,	O
the	O
effects	O
of	O
R	O
-	O
lipoic	O
acid	O
(	O
R	O
-	O
LA	O
)	O
,	O
S	O
-	O
lipoic	O
acid	O
(	O
S	O
-	O
LA	O
)	O
and	O
1,2-diselenolane-3-pentanoic	O
acid	O
(	O
Se	O
-	O
LA	O
)	O
on	O
the	O
activities	O
of	O
the	O
mammalian	O
pyruvate	B
dehydrogenase	I
complex	I
(	O
PDC	B
)	O
and	O
its	O
catalytic	O
components	O
were	O
investigated	O
.	O

Both	O
S	O
-	O
LA	O
and	O
R	O
-	O
LA	O
markedly	O
inhibited	O
PDC	B
activity	O
;	O
whereas	O
Se	O
-	O
LA	O
displayed	O
inhibition	O
only	O
at	O
higher	O
concentrations	O
.	O

Examination	O
of	O
the	O
effects	O
on	O
the	O
individual	O
catalytic	O
components	O
indicated	O
that	O
Se	O
-	O
LA	O
inhibited	O
the	O
pyruvate	B
dehydrogenase	I
component	O
;	O
whereas	O
R	O
-	O
LA	O
and	O
S	O
-	O
LA	O
inhibited	O
the	O
dihydrolipoamide	B
acetyltransferase	I
component	O
.	O

The	O
three	O
lipoic	O
compounds	O
lowered	O
dihydrolipoamide	B
dehydrogrenase	I
(	O
E3	O
)	O
activity	O
in	O
the	O
forward	O
reaction	O
by	O
about	O
30	O
to	O
45	O
%	O
.	O

The	O
kinetic	O
data	O
of	O
E3	B
showed	O
that	O
both	O
R	O
-	O
LA	O
and	O
Se	O
-	O
LA	O
are	O
used	O
as	O
substrates	O
by	O
E3	B
for	O
the	O
reverse	O
reaction	O
.	O

Decarboxylation	O
of	O
[	O
1	O
-	O
14C	O
]	O
pyruvate	O
via	O
PDC	B
by	O
cultured	O
HepG2	O
cells	O
was	O
not	O
affected	O
by	O
R	O
-	O
LA	O
,	O
but	O
moderately	O
decreased	O
with	O
S	O
-	O
LA	O
and	O
Se	O
-	O
LA	O
.	O

These	O
findings	O
indicate	O
that	O
(	O
i	O
)	O
purified	O
PDC	B
and	O
its	O
catalytic	O
components	O
are	O
affected	O
by	O
lipoic	O
compounds	O
based	O
on	O
their	O
stereoselectivity	O
;	O
and	O
(	O
ii	O
)	O
the	O
oxidation	O
of	O
pyruvate	O
by	O
intact	O
HepG2	O
cells	O
is	O
not	O
inhibited	O
by	O
R	O
-	O
LA	O
.	O

The	O
later	O
finding	O
with	O
the	O
intact	O
cells	O
is	O
in	O
support	O
of	O
therapeutic	O
role	O
of	O
R	O
-	O
LA	O
as	O
an	O
antioxidant	O
.	O

A	O
highly	O
sensitive	O
pre	O
-	O
column	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
in	O
urine	O
was	O
developed	O
.	O

The	O
analytes	O
were	O
labelled	O
with	O
4-	O
(	O
5,6-dimethoxy-2-phthalimidinyl	O
)	O
-2-methoxyphenylsulfonyl	O
chloride	O
at	O
70	O
degrees	O
C	O
for	O
20	O
min	O
.	O

The	O
derivatives	O
separated	O
on	O
tandem	O
reversed	O
-	O
phase	O
columns	O
by	O
a	O
gradient	O
elution	O
and	O
were	O
monitored	O
with	O
fluorescence	O
detection	O
at	O
318	O
nm	O
(	O
excitation	O
)	O
and	O
392	O
nm	O
(	O
emission	O
)	O
.	O

The	O
detection	O
limits	O
for	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
were	O
1	O
-	O
5	O
fmol	O
/	O
injection	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

Urine	O
samples	O
were	O
treated	O
with	O
o	O
-	O
phthalaldehyde	O
,	O
followed	O
by	O
purification	O
on	O
a	O
Bond	O
Elut	O
C18	O
column	O
before	O
conducting	O
the	O
labelling	O
reaction	O
.	O

Pro	O
-	O
Hyp	O
,	O
Pro	O
-	O
Gly	O
and	O
Pro	O
-	O
Pro	O
were	O
identified	O
as	O
prolyl	O
dipeptides	O
in	O
urine	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
relative	O
standard	O
deviations	O
were	O
1.5	O
-	O
4.8	O
and	O
1.7	O
-	O
5.8	O
%	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
Pro	O
-	O
Hyp	O
,	O
Pro	O
-	O
Gly	O
,	O
Pro	O
-	O
Pro	O
,	O
Pro	O
and	O
Hyp	O
in	O
normal	O
human	O
urine	O
were	O
97.6	O
+	O
/-	O

28.2	O
,	O
2.74	O
+	O
/-	O

1.48	O
,	O
2.08	O
+	O
/-	O

1.13	O
,	O
6.71	O
+	O
/-	O

3.34	O
and	O
2.30	O
+	O
/-	O

1.59	O
nmol	O
/	O
mg	O
creatinine	O
,	O
respectively	O
.	O

An	O
enzyme	B
with	O
lipase	B
and	O
esterase	B
activity	O
was	O
purified	O
from	O
bovine	O
pancreas	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
radioactive	O
lipase	B
assay	O
was	O
developed	O
which	O
is	O
100	O
times	O
more	O
sensitive	O
than	O
the	O
conventional	O
methods	O
and	O
allowed	O
the	O
characterization	O
of	O
the	O
lipase	B
activity	O
of	O
the	O
enzyme	B
.	O

The	O
lipase	B
activity	O
increased	O
42	O
times	O
in	O
the	O
presence	O
of	O
10	O
mM	O
sodium	O
taurocholate	O
,	O
which	O
for	O
the	O
first	O
time	O
provides	O
direct	O
evidence	O
that	O
a	O
bile	B
salt	I
-	I
activated	I
lipase	I
(	O
bp	B
-	I
BAL	I
)	O
was	O
isolated	O
from	O
bovine	O
pancreas	O
.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
fact	O
that	O
the	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
this	O
lipase	B
/	O
esterase	B
is	O
88	O
%	O
homologous	O
to	O
human	O
milk	B
BAL	I
and	O
human	O
pancreatic	B
BAL	I
.	O

Staining	O
with	O
various	O
lectins	B
showed	O
that	O
bp	B
-	I
BAL	I
is	O
a	O
glycoprotein	B
which	O
contains	O
fucose	O
residues	O
.	O

Previously	O
from	O
bovine	O
pancreas	O
a	O
lysophospholipase	B
has	O
been	O
purified	O
and	O
a	O
gene	O
was	O
cloned	O
and	O
sequenced	O
encoding	O
an	O
enzyme	B
with	O
cholesterol	B
esterase	I
/	O
lysophospholipase	B
activity	O
.	O

Comparison	O
of	O
the	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
bp	B
-	I
BAL	I
with	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
latter	O
revealed	O
that	O
they	O
are	O
identical	O
.	O

Furthermore	O
,	O
the	O
molecular	O
weight	O
of	O
the	O
purified	O
bp	B
-	I
BAL	I
of	O
63,000	O
,	O
as	O
estimated	O
by	O
SDS	O
-	O
PAGE	O
,	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
purified	O
lysophospholipase	B
(	O
65,000	O
)	O
and	O
to	O
the	O
theoretical	O
molecular	O
weight	O
of	O
65,147	O
of	O
the	O
cholesterol	B
esterase	I
/	O
lysophospholipase	B
.	O

These	O
data	O
suggest	O
that	O
these	O
three	O
enzymes	B
are	O
one	O
and	O
the	O
same	O
.	O

The	O
antioxidant	O
activity	O
of	O
Eriobotrya	O
japonica	O
was	O
determined	O
by	O
measuring	O
the	O
radical	O
scavenging	O
effect	O
on	O
DPPH	O
(	O
1,1-diphenyl-2-picrylhydrazyl	O
)	O
radical	O
and	O
lipid	O
peroxidation	O
produced	O
when	O
mouse	O
liver	O
homogenate	O
was	O
exposed	O
to	O
the	O
air	O
at	O
37	O
degrees	O
C	O
,	O
using	O
2-thiobarbituric	O
acid	O
(	O
TBA	O
)	O
.	O

The	O
methanol	O
extract	O
and	O
its	O
fractions	O
of	O
Eriobotrya	O
japonica	O
leaves	O
showed	O
strong	O
antioxidant	O
activity	O
.	O

The	O
antioxidant	O
activity	O
of	O
EtOAc	O
and	O
n	O
-	O
BuOH	O
soluble	O
fractions	O
were	O
stronger	O
than	O
the	O
others	O
,	O
and	O
were	O
further	O
purified	O
by	O
repeated	O
silica	O
gel	O
,	O
MCl	O
gel	O
CHP-20P	O
,	O
and	O
Sephadex	O
LH-20	O
column	O
chromatography	O
.	O

Antioxidant	O
chlorogenic	O
acid	O
,	O
quercetin-3-sambubioside	O
from	O
n	O
-	O
BuOH	O
fraction	O
,	O
and	O
methyl	O
chlorogenate	O
,	O
kaempferol-	O
and	O
quercetin-3-rhamnosides	O
,	O
together	O
with	O
the	O
inactive	O
ursolic	O
acid	O
and	O
2	O
alpha	O
-	O
hydroxyursolic	O
acid	O
from	O
EtOAc	O
fraction	O
were	O
isolated	O
.	O

Antioxidant	O
flavonoids	O
and	O
chlorogenic	O
acid	O
also	O
showed	O
prominent	O
inhibitory	O
activity	O
against	O
free	O
radical	O
generation	O
in	O
dichlorofluorescein	O
(	O
DCF	O
)	O
method	O
.	O

The	O
synthesis	O
and	O
the	O
antimicrobial	O
properties	O
of	O
a	O
new	O
series	O
of	O
cephalosporinic	O
beta	O
-	O
lactam	O
antibiotics	O
is	O
described	O
.	O

The	O
data	O
reported	O
in	O
the	O
present	O
paper	O
show	O
the	O
potential	O
of	O
this	O
type	O
of	O
substituted	O
cephalosporins	O
as	O
new	O
anti	O
Gram	O
-	O
positive	O
antibiotic	O
drugs	O
.	O

In	O
fact	O
,	O
all	O
compounds	O
tested	O
showed	O
a	O
good	O
in	O
vitro	O
antibacterial	O
activity	O
against	O
the	O
most	O
relevant	O
Gram	O
-	O
positive	O
pathogens	O
including	O
resistant	O
species	O
that	O
currently	O
represent	O
unmet	O
medical	O
need	O
.	O

On	O
the	O
contrary	O
,	O
the	O
new	O
synthesized	O
compounds	O
were	O
found	O
to	O
be	O
completely	O
devoid	O
of	O
any	O
activity	O
on	O
Gram	O
-	O
negative	O
bacteria	O
up	O
to	O
a	O
concentration	O
of	O
the	O
single	O
agent	O
of	O
128	O
microg	O
/	O
ml	O
.	O

The	O
hydroxylation	O
at	O
C-2	O
of	O
testosterone	O
and	O
5alpha	O
-	O
dihydrotestosterone	O
is	O
measured	O
by	O
isolation	O
of	O
HTO	O
after	O
incubating	O
""""	O
metabolically	O
labile	O
""""	O
tritium	O
labeled	O
steroids	O
with	O
the	O
enzymes	B
.	O

After	O
hydroxylation	O
of	O
testosterone	O
in	O
rat	O
liver	O
2alpha	O
-	O
hydroxytestosterone	O
was	O
isolated	O
and	O
identified	O
by	O
gaschromatography	O
and	O
mass	O
spectra	O
.	O

Oxamniquine	O
(	O
1,2,3,4-tetrahydro-2-	O
[	O
(	O
isopropylamino	O
)	O
methyl	O
]	O
-7-nitro-6-quinoline	O
methanol	O
)	O
is	O
an	O
antischistosomal	O
agent	O
that	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
S.	O
mansoni	O
(	O
intestinal	O
schistosomiasis	O
)	O
infection	O
.	O

It	O
has	O
been	O
shown	O
to	O
inhibit	O
DNA	O
,	O
RNA	O
and	O
protein	B
synthesis	O
in	O
schistosomes	O
.	O

The	O
oral	O
bioavailability	O
of	O
oxamniquine	O
is	O
good	O
,	O
effective	O
plasma	O
levels	O
are	O
achieved	O
in	O
1–1.5	O
h	O
[	O
1	O
]	O
.	O

Oxamniquine	O
is	O
the	O
subject	O
of	O
a	O
monograph	O
in	O
the	O
US	O
Pharmacopoeia	O
(	O
USP	O
XXIII	O
)	O
[	O
2	O
]	O
whereby	O
a	O
spectrophotometric	O
method	O
is	O
recommended	O
for	O
its	O
determination	O
,	O
whether	O
in	O
its	O
pure	O
form	O
or	O
in	O
capsules	O
.	O

Other	O
reported	O
methods	O
include	O
spectrophotometry	O
[	O
3,4	O
]	O
,	O
non	O
-	O
aqueous	O
titration	O
[	O
5	O
]	O
,	O
gas	O
chromatography	O
[	O
6	O
]	O
,	O
high	O
-	O
performance	O
liquid	O
chromatography	O
[	O
7–11	O
]	O
,	O
polarography	O
[	O
12	O
]	O
,	O
capillary	O
electrophoresis	O
[	O
9	O
]	O
,	O
flow	O
-	O
injection	O
analysis	O
[	O
13	O
]	O
and	O
cyclic	O
voltammetry	O
[	O
14	O
]	O
.	O

The	O
above	O
-	O
mentioned	O
methods	O
are	O
either	O
not	O
sufficiently	O
sensitive	O
or	O
are	O
tedious	O
and	O
require	O
highly	O
sophisticated	O
instrumentation	O
.	O

Therefore	O
,	O
there	O
is	O
still	O
a	O
need	O
for	O
a	O
much	O
more	O
sensitive	O
and	O
simple	O
method	O
for	O
the	O
determination	O
of	O
oxamniquine	O
,	O
especially	O
in	O
biological	O
fluids	O
.	O

Fluorimetry	O
,	O
by	O
virtue	O
of	O
its	O
high	O
sensitivity	O
,	O
meets	O
this	O
requirement	O
.	O

Reviewing	O
the	O
literature	O
revealed	O
that	O
no	O
fluorimetric	O
methods	O
were	O
reported	O
for	O
oxamniquine	O
.	O

As	O
for	O
2-cyanoacetamide	O
,	O
it	O
has	O
been	O
recently	O
used	O
for	O
the	O
determination	O
of	O
aminoglycosides	O
[	O
15	O
]	O
,	O
reducing	O
carbohydrates	O
[	O
16–18	O
]	O
,	O
enzymatic	O
degradation	O
products	O
of	O
reducing	O
polysaccharides	O
[	O
19	O
]	O
and	O
catecholamines	O
[	O
20,21	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
is	O
to	O
study	O
the	O
reaction	O
of	O
the	O
reduced	O
derivative	O
(	O
nitroso	O
)	O
of	O
oxamniquine	O
with	O
2-cyanoacetamide	O
in	O
an	O
attempt	O
to	O
develop	O
a	O
sensitive	O
fluorimetric	O
method	O
to	O
be	O
used	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
.	O

2	O
Experimental	O
2.1	O
Apparatus	O
An	O
Aminco	O
-	O
Bowman	O
Model	O
J4	O
-9860	O
spectrofluorometer	O
was	O
used	O
with	O
the	O
excitation	O
and	O
emission	O
slits	O
set	O
at	O
5	O
mm	O
.	O

A	O
1-cm	O
quartz	O
cell	O
was	O
used	O
for	O
all	O
measurements	O
.	O

2.2	O
Materials	O
and	O
reagents	O
All	O
the	O
chemicals	O
used	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
while	O
the	O
solvents	O
were	O
of	O
the	O
spectroscopic	O
grade	O
.	O

A	O
pure	O
drug	O
sample	O
of	O
oxamniquine	O
was	O
kindly	O
supplied	O
by	O
Pfizer	O
(	O
Sandwich	O
,	O
UK	O
)	O
and	O
was	O
used	O
as	O
received	O
.	O

2-Cyanoacetamide	O
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
Co.	O
Plasma	O
was	O
obtained	O
from	O
Mansoura	O
University	O
Hospital	O
,	O
Mansoura	O
(	O
Egypt	O
)	O
and	O
urine	O
was	O
obtained	O
from	O
healthy	O
volunteers	O
.	O

Freshly	O
prepared	O
10	O
%	O
aqueous	O
solution	O
of	O
calcium	O
chloride	O
and	O
4	O
%	O
aqueous	O
solution	O
of	O
2-cyanoacetamide	O
were	O
prepared	O
and	O
used	O
throughout	O
the	O
study	O
.	O

2.2.1	O
Stock	O
solution	O
Dissolve	O
20	O
mg	O
of	O
oxamniquine	O
in	O
100	O
of	O
methanol	O
.	O

Make	O
serial	O
dilutions	O
with	O
water	O
to	O
obtain	O
a	O
final	O
concentration	O
of	O
20	O
μg	O
/	O
ml	O
.	O

2.3	O
Procedure	O
2.3.1	O
Preparation	O
of	O
the	O
calibration	O
curve	O
Transfer	O
aliquots	O
of	O
oxamniquine	O
final	O
stock	O
solution	O
into	O
a	O
series	O
of	O
25	O
ml	O
standard	O
flasks	O
so	O
that	O
the	O
final	O
drug	O
concentration	O
is	O
in	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
.	O

Add	O
to	O
each	O
flask	O
120±5	O
mg	O
of	O
zinc	O
dust	O
and	O
12	O
ml	O
of	O
calcium	O
chloride	O
solution	O
.	O

Shake	O
well	O
and	O
leave	O
to	O
stand	O
for	O
20	O
min	O
.	O

Filter	O
the	O
excess	O
zinc	O
powder	O
.	O

Add	O
1	O
ml	O
of	O
2-cyanoacetamide	O
solution	O
to	O
the	O
filtrate	O
,	O
then	O
heat	O
on	O
a	O
boiling	O
water	O
bath	O
for	O
1	O
h.	O
Cool	O
and	O
fill	O
to	O
the	O
mark	O
in	O
25	O
ml	O
standard	O
flask	O
with	O
water	O
.	O

Measure	O
the	O
fluorescence	O
of	O
the	O
filtrate	O
using	O
370	O
nm	O
as	O
the	O
excitation	O
wavelength	O
and	O
450	O
nm	O
as	O
the	O
emission	O
wavelength	O
.	O

A	O
blank	O
reagent	O
is	O
prepared	O
simultaneously	O
.	O

Plot	O
the	O
values	O
of	O
the	O
%	O
relative	O
intensity	O
against	O
the	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
to	O
get	O
the	O
calibration	O
graph	O
.	O

Alternatively	O
,	O
the	O
regression	O
equation	O
is	O
derived	O
.	O

2.3.2	O
Determination	O
of	O
oxamniquine	O
in	O
spiked	O
human	O
plasma	O
and	O
urine	O
A	O
standard	O
calibration	O
curve	O
was	O
prepared	O
daily	O
by	O
spiking	O
blank	O
plasma	O
or	O
urine	O
with	O
varying	O
amounts	O
of	O
oxamniquine	O
.	O

A	O
stock	O
solution	O
containing	O
10	O
μg	O
/	O
ml	O
of	O
oxamniquine	O
was	O
freshly	O
prepared	O
.	O

Control	O
samples	O
of	O
plasma	O
or	O
urine	O
were	O
spiked	O
with	O
different	O
quantities	O
of	O
oxamniquine	O
to	O
give	O
a	O
final	O
drug	O
concentration	O
of	O
0.2–0.8	O
μg	O
/	O
ml	O
.	O

Add	O
0.8	O
ml	O
of	O
1	O
M	O
NaOH	O
with	O
gentle	O
shaking	O
to	O
1.0	O
ml	O
of	O
the	O
spiked	O
urine	O
or	O
plasma	O
.	O

The	O
solution	O
was	O
then	O
vortexed	O
with	O
3	O
×	O
5	O
ml	O
of	O
ether	O
for	O
2	O
min	O
then	O
centrifuged	O
at	O
2500	O
rpm	O
for	O
5	O
min	O
.	O

The	O
resulting	O
supernatant	O
was	O
then	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	O
at	O
ambient	O
temperature	O
.	O

The	O
resulting	O
residue	O
was	O
dissolved	O
in	O
5	O
ml	O
of	O
methanol	O
and	O
then	O
made	O
up	O
to	O
10	O
ml	O
with	O
water	O
in	O
a	O
volumetric	O
flask	O
.	O

The	O
procedure	O
described	O
in	O
Section	O
2.3.1	O
was	O
then	O
applied	O
.	O

A	O
blank	O
experiment	O
using	O
plasma	O
or	O
urine	O
without	O
the	O
drug	O
was	O
carried	O
out	O
simultaneously	O
.	O

The	O
content	O
of	O
oxamniquine	O
was	O
then	O
determined	O
from	O
the	O
previously	O
plotted	O
calibration	O
graphs	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
nitro	O
group	O
is	O
reported	O
to	O
be	O
reduced	O
into	O
the	O
corresponding	O
nitroso	O
group	O
upon	O
reduction	O
with	O
Zn	O
/	O
CaCl2	O
[	O
22	O
]	O
.	O

This	O
process	O
was	O
confirmed	O
by	O
testing	O
for	O
the	O
nitroso	O
group	O
using	O
sodium	O
nitroprusside	O
[	O
23	O
]	O
.	O

The	O
nitroso	O
compounds	O
were	O
reported	O
to	O
react	O
with	O
active	O
methylene	O
containing	O
compounds	O
with	O
the	O
production	O
of	O
the	O
corresponding	O
imines	O
[	O
24	O
]	O
.	O

The	O
latter	O
is	O
proposed	O
to	O
undergo	O
a	O
ring	O
-	O
closing	O
reaction	O
with	O
the	O
elimination	O
of	O
one	O
molecule	O
of	O
ammonia	O
and	O
the	O
production	O
of	O
the	O
3-cyanooxazazepin-2-one	O
derivative	O
,	O
which	O
is	O
the	O
fluorescent	O
product	O
.	O

A	O
proposal	O
of	O
reaction	O
pathway	O
is	O
suggested	O
in	O
Scheme	O
1	O
.	O

A	O
highly	O
fluorescent	O
product	O
with	O
λmax	O
excitation	O
at	O
370	O
nm	O
and	O
λmax	O
emission	O
of	O
450	O
nm	O
was	O
obtained	O
(	O
Fig.	O
1	O
)	O
.	O

3.1	O
Study	O
of	O
the	O
experimental	O
conditions	O
The	O
factors	O
affecting	O
the	O
production	O
of	O
nitroso	O
derivative	O
were	O
first	O
studied	O
.	O

All	O
factors	O
were	O
kept	O
constant	O
except	O
one	O
,	O
which	O
was	O
changed	O
in	O
turn	O
to	O
study	O
its	O
effect	O
.	O

Any	O
amount	O
of	O
zinc	O
powder	O
in	O
the	O
range	O
100–300	O
mg	O
was	O
found	O
to	O
give	O
the	O
same	O
results	O
;	O
therefore	O
120±5	O
mg	O
were	O
used	O
throughout	O
the	O
work	O
.	O

As	O
for	O
calcium	O
chloride	O
solution	O
12±1	O
ml	O
of	O
10	O
%	O
(	O
wt.	O
/	O
vol	O
.	O
)	O

aqueous	O
solution	O
was	O
found	O
to	O
give	O
maximum	O
fluorescence	O
.	O

Larger	O
volumes	O
caused	O
slight	O
decrease	O
in	O
fluorescence	O
.	O

Increasing	O
the	O
reduction	O
time	O
(	O
at	O
room	O
temperature	O
)	O
was	O
found	O
to	O
increase	O
the	O
fluorescence	O
up	O
to	O
20	O
min	O
,	O
after	O
which	O
time	O
the	O
fluorescence	O
intensity	O
remained	O
unchanged	O
.	O

3.2	O
Factors	O
affecting	O
the	O
development	O
of	O
the	O
fluorophore	O
The	O
effect	O
of	O
the	O
concentration	O
of	O
2-cyanoacetamide	O
was	O
studied	O
by	O
using	O
increasing	O
volumes	O
of	O
4	O
%	O
aqueous	O
solution	O
.	O

It	O
was	O
found	O
that	O
1.0±0.1	O
ml	O
is	O
appropriate	O
for	O
maximum	O
fluorescence	O
intensity	O
;	O
larger	O
volumes	O
caused	O
no	O
further	O
increase	O
in	O
fluorescence	O
.	O

The	O
temperature	O
and	O
time	O
of	O
heating	O
were	O
also	O
studied	O
.	O

It	O
was	O
concluded	O
that	O
heating	O
in	O
a	O
boiling	O
water	O
-	O
bath	O
for	O
1	O
h	O
gave	O
the	O
highest	O
fluorescence	O
readings	O
.	O

Longer	O
heating	O
time	O
caused	O
a	O
decrease	O
in	O
fluorescence	O
as	O
shown	O
in	O
Fig.	O
2	O
.	O

After	O
optimizing	O
the	O
conditions	O
,	O
it	O
was	O
found	O
that	O
the	O
relation	O
between	O
the	O
%	O
relative	O
intensity	O
(	O
%	O
RI	O
)	O
and	O
final	O
concentration	O
of	O
oxamniquine	O
was	O
rectilinear	O
over	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
with	O
a	O
minimum	O
detectability	O
(	O
S	O
/N	O
=	O
2	O
)	O
of	O
8	O
ng	O
/	O
ml	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
linear	O
regression	O
analysis	O
of	O
the	O
results	O
gave	O
the	O
following	O
equation:%	O
RI	O
=	O
0.0358	O
+	O
107.4C	O
(	O
r=0.9999	O
)	O
where	O
C	O
=	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
,	O
%	O
RI	O
=	O
relative	O
fluorescence	O
intensity	O
and	O
r	O
=	O
correlation	O
coefficient	O
.	O

Statistical	O
analysis	O
of	O
the	O
results	O
of	O
analysis	O
of	O
authentic	O
sample	O
of	O
oxamniquine	O
obtained	O
by	O
both	O
the	O
proposed	O
method	O
and	O
the	O
official	O
method	O
[	O
2	O
]	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
regarding	O
the	O
accuracy	O
and	O
precision	O
,	O
as	O
indicated	O
by	O
the	O
F	O
-test	O
and	O
Student	O
's	O
t	O
-test	O
,	O
respectively	O
[	O
25	O
]	O
.	O

Oxamniquine	O
is	O
readily	O
absorbed	O
following	O
oral	O
ingestion	O
,	O
and	O
a	O
peak	O
concentration	O
in	O
plasma	O
occurs	O
within	O
about	O
3	O
h.	O
The	O
presence	O
of	O
food	O
significantly	O
delays	O
absorption	O
and	O
limits	O
the	O
concentration	O
achieved	O
in	O
plasma	O
during	O
the	O
first	O
several	O
hours	O
after	O
administration	O
.	O

Urinary	O
excretion	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
humans	O
[	O
26	O
]	O
.	O

Oxamniquine	O
is	O
given	O
orally	O
in	O
a	O
dose	O
of	O
250	O
mg	O
three	O
times	O
daily	O
;	O
this	O
leads	O
to	O
a	O
final	O
blood	O
level	O
concentration	O
of	O
about	O
5	O
μg	O
/	O
ml	O
,	O
i.e.	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
the	O
working	O
range	O
of	O
the	O
proposed	O
method	O
.	O

Thus	O
,	O
the	O
high	O
sensitivity	O
of	O
the	O
proposed	O
method	O
allowed	O
the	O
determination	O
of	O
oxamniquine	O
in	O
biological	O
fluids	O
.	O

Table	O
1	O
shows	O
the	O
results	O
for	O
the	O
fluorimetric	O
determination	O
of	O
a	O
pure	O
sample	O
of	O
oxamniquine	O
,	O
while	O
Table	O
2	O
shows	O
the	O
results	O
of	O
the	O
fluorometric	O
determination	O
of	O
oxamniquine	O
in	O
spiked	O
urine	O
and	O
plasma	O
samples	O
,	O
respectively	O
.	O

The	O
extraction	O
procedure	O
described	O
by	O
Woolhouse	O
and	O
Wood	O
[	O
6	O
]	O
was	O
adopted	O
here	O
.	O

The	O
results	O
are	O
satisfactorily	O
accurate	O
and	O
precise	O
.	O

In	O
conclusion	O
,	O
a	O
highly	O
sensitive	O
and	O
accurate	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
oxamniquine	O
in	O
urine	O
and	O
plasma	O
.	O

Although	O
the	O
previously	O
reported	O
methods	O
[	O
6,7	O
]	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
may	O
be	O
less	O
time	O
-	O
consuming	O
,	O
the	O
proposed	O
method	O
is	O
,	O
however	O
,	O
more	O
sensitive	O
and	O
does	O
not	O
need	O
complicated	O
instrumentation	O
.	O

The	O
relationship	O
between	O
taurine	O
and	O
aging	O
of	O
brain	O
neural	O
cells	O
was	O
studied	O
by	O
using	O
primary	O
human	O
fetal	O
brain	O
neural	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
results	O
indicated	O
that	O
the	O
activity	O
of	O
superoxide	B
dismutase	I
(	O
SOD	B
)	O
was	O
significantly	O
higher	O
in	O
taurine	O
added	O
group	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
,	O
9	O
and	O
15	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

With	O
different	O
taurine	O
levels	O
,	O
the	O
SOD	B
activities	O
of	O
50	O
mg	O
/	O
L	O
and	O
200	O
mg	O
/	O
L	O
taurine	O
groups	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
3-day	O
culture	O
,	O
the	O
activity	O
of	O
glutathione	B
peroxidase	I
(	O
GSH	B
-	I
Px	I
)	O
in	O
the	O
taurine	O
added	O
group	O
was	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
decreased	O
with	O
time	O
in	O
control	O
group	O
,	O
but	O
was	O
stable	O
in	O
the	O
group	O
treated	O
with	O
taurine	O
.	O

The	O
fluidity	O
was	O
more	O
stable	O
in	O
the	O
groups	O
treated	O
with	O
50	O
,	O
200	O
and	O
400	O
mg	O
/	O
L	O
groups	O
cultured	O
for	O
6	O
days	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
or	O
0.01	O
)	O
.	O

The	O
present	O
study	O
showed	O
that	O
taurine	O
is	O
necessary	O
for	O
maintaining	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
in	O
proper	O
levels	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
postponing	O
the	O
aging	O
process	O
of	O
brain	O
neural	O
cells	O
.	O

A	O
combination	O
of	O
atovaquone	O
and	O
proguanil	O
has	O
been	O
found	O
to	O
be	O
quite	O
effective	O
in	O
treating	O
malaria	O
,	O
with	O
little	O
evidence	O
of	O
the	O
emergence	O
of	O
resistance	O
when	O
atovaquone	O
was	O
used	O
as	O
a	O
single	O
agent	O
.	O

We	O
have	O
examined	O
possible	O
mechanisms	O
for	O
the	O
synergy	O
between	O
these	O
two	O
drugs	O
.	O

While	O
proguanil	O
by	O
itself	O
had	O
no	O
effect	O
on	O
electron	O
transport	O
or	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsim	O
)	O
,	O
it	O
significantly	O
enhanced	O
the	O
ability	O
of	O
atovaquone	O
to	O
collapse	O
DeltaPsim	O
when	O
used	O
in	O
combination	O
.	O

This	O
enhancement	O
was	O
observed	O
at	O
pharmacologically	O
achievable	O
doses	O
.	O

Proguanil	O
acted	O
as	O
a	O
biguanide	O
rather	O
than	O
as	O
its	O
metabolite	O
cycloguanil	O
(	O
a	O
parasite	B
dihydrofolate	I
reductase	I
[	O
DHFR	B
]	O
inhibitor	O
)	O
to	O
enhance	O
the	O
atovaquone	O
effect	O
;	O
another	O
DHFR	B
inhibitor	O
,	O
pyrimethamine	O
,	O
also	O
had	O
no	O
enhancing	O
effect	O
.	O

Proguanil	O
-	O
mediated	O
enhancement	O
was	O
specific	O
for	O
atovaquone	O
,	O
since	O
the	O
effects	O
of	O
other	O
mitochondrial	O
electron	O
transport	O
inhibitors	O
,	O
such	O
as	O
myxothiazole	O
and	O
antimycin	O
,	O
were	O
not	O
altered	O
by	O
inclusion	O
of	O
proguanil	O
.	O

Surprisingly	O
,	O
proguanil	O
did	O
not	O
enhance	O
the	O
ability	O
of	O
atovaquone	O
to	O
inhibit	O
mitochondrial	O
electron	O
transport	O
in	O
malaria	O
parasites	O
.	O

These	O
results	O
suggest	O
that	O
proguanil	O
in	O
its	O
prodrug	O
form	O
acts	O
in	O
synergy	O
with	O
atovaquone	O
by	O
lowering	O
the	O
effective	O
concentration	O
at	O
which	O
atovaquone	O
collapses	O
DeltaPsim	O
in	O
malaria	O
parasites	O
.	O

This	O
could	O
explain	O
the	O
paradoxical	O
success	O
of	O
the	O
atovaquone	O
-	O
proguanil	O
combination	O
even	O
in	O
regions	O
where	O
proguanil	O
alone	O
is	O
ineffective	O
due	O
to	O
resistance	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
atovaquone	O
-	O
proguanil	O
combination	O
may	O
act	O
as	O
a	O
site	O
-	O
specific	O
uncoupler	O
of	O
parasite	O
mitochondria	O
in	O
a	O
selective	O
manner	O
.	O

To	O
develop	O
positron	O
-	O
emitting	O
tracers	O
for	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
studies	O
,	O
ex	O
vivo	O
autoradiography	O
(	O
ARG	O
)	O
is	O
a	O
useful	O
technique	O
to	O
demonstrate	O
the	O
distribution	O
of	O
the	O
tracer	O
in	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
whole	O
body	O
.	O

A	O
recent	O
advent	O
of	O
radioluminography	O
using	O
phosphor	O
-	O
imaging	O
plates	O
(	O
12	O
,	O
14	O
)	O
has	O
enabled	O
the	O
ex	O
vivo	O
ARG	O
to	O
be	O
applied	O
to	O
ultrashort	O
-	O
lived	O
11	O
C	O
-	O
labeled	O
tracers	O
.	O

Yanai	O
et	O
al.	O
reported	O
a	O
potential	O
of	O
the	O
imaging	O
plates	O
for	O
receptor	O
ARG	O
with	O
11	O
C	O
-	O
labeled	O
ligands	O
compared	O
with	O
tritiated	O
ligands	O
(	O
25	O
)	O
.	O

Planas	O
et	O
al.	O
(	O
18	O
)	O
characterized	O
a	O
cholinesterase	B
inhibitor	O
[	O
11	O
C	O
]	O
physostigmine	O
using	O
a	O
similar	O
type	O
storage	O
phosphor	O
plates	O
.	O

We	O
also	O
used	O
imaging	O
plates	O
to	O
characterize	O
newly	O
developed	O
11	O
C	O
-	O
labeled	O
receptor	B
ligands	O
(	O
3	O
,	O
10	O
,	O
16	O
)	O
.	O

Because	O
the	O
intensity	O
of	O
photo	O
-	O
stimulated	O
-	O
luminescence	O
(	O
PSL	O
)	O
is	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
in	O
a	O
wide	O
range	O
,	O
ARG	O
images	O
expressed	O
as	O
PSL	O
is	O
considered	O
to	O
reflect	O
the	O
quantitative	O
distribution	O
of	O
radioactivity	O
.	O

Recently	O
,	O
Sihver	O
et	O
al.	O
(	O
21	O
)	O
have	O
quantitatively	O
evaluated	O
in	O
vitro	O
ARG	O
with	O
storage	O
phosphor	O
plates	O
and	O
11	O
C	O
-	O
flumazenil	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
describe	O
quantitative	O
evaluation	O
of	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
using	O
an	O
imaging	O
plate	O
and	O
a	O
11	O
C	O
-	O
labeled	O
dopamine	B
D2	I
-like	I
receptor	I
ligand	O
,	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
[	O
11	O
C	O
]	O
YM-09151	O
-	O
2	O
)	O
(	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
11	O
)	O
.	O

Its	O
tritiated	O
compound	O
has	O
been	O
used	O
widely	O
for	O
pharmacological	O
studies	O
as	O
one	O
of	O
representative	O
dopamine	B
D2	I
-like	I
receptor	I
ligands	O
.	O

We	O
report	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	O
11	O
C	O
]	O
nemonapride	O
in	O
the	O
cortex	O
beside	O
the	O
dopamine	B
D2	I
-like	I
receptors	I
in	O
the	O
striatum	O
both	O
ex	O
vivo	O
and	O
in	O
vitro	O
.	O

Materials	O
and	O
methods	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
9	O
)	O
and	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
4	O
)	O
were	O
synthesized	O
by	O
11	O
C	O
-	O
methylation	O
of	O
the	O
corresponding	O
desmethyl	O
compound	O
with	O
[	O
11	O
C	O
]	O
methyl	O
iodide	O
by	O
the	O
method	O
previously	O
described	O
.	O

The	O
specific	O
activity	O
of	O
the	O
compounds	O
was	O
measured	O
as	O
follows	O
.	O

The	O
radioactivity	O
(	O
MBq	O
)	O
of	O
an	O
appropriate	O
volume	O
of	O
tracer	O
solution	O
was	O
measured	O
by	O
a	O
radioisotope	O
calibrator	O
(	O
type	O
CRC-712	O
,	O
Capintec	O
Inc.	O
,	O
Ramsey	O
,	O
NJ	O
)	O
,	O
and	O
a	O
part	O
of	O
the	O
solution	O
was	O
applied	O
to	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
to	O
determine	O
the	O
mass	O
(	O
nmol	O
)	O
of	O
the	O
compounds	O
based	O
on	O
the	O
ultraviolet	O
(	O
UV	O
)	O
response	O
to	O
the	O
authentic	O
sample	O
.	O

Male	O
Wistar	O
rats	O
(	O
8–10	O
weeks	O
old	O
)	O
were	O
obtained	O
from	O
Tokyo	O
Laboratory	O
Animals	O
Company	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
animal	O
studies	O
were	O
approved	O
by	O
the	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Tokyo	O
Metropolitan	O
Institute	O
of	O
Gerontology	O
.	O

Calibration	O
of	O
PSL	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
A	O
solution	O
of	O
11	O
C	O
-	O
tracer	O
was	O
prepared	O
at	O
the	O
concentration	O
of	O
100	O
MBq	O
/	O
mL	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
t	O
=	O
0	O
min	O
,	O
26	O
min	O
after	O
end	O
of	O
bombardment	O
[	O
EOB	O
]	O
)	O
.	O

The	O
solution	O
was	O
diluted	O
to	O
0.03–10	O
MBq	O
/	O
mL	O
,	O
and	O
10	O
μL	O
of	O
each	O
diluted	O
solution	O
(	O
0.3–100	O
kBq	O
)	O
was	O
loaded	O
on	O
six	O
pieces	O
of	O
filter	O
paper	O
(	O
5	O
mm	O
×	O
5	O
mm	O
,	O
0.23	O
±	O
0.05	O
mm	O
thickness	O
,	O
Toyo	O
Roshi	O
Kaisha	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Three	O
pieces	O
of	O
the	O
filter	O
paper	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
of	O
type	O
IP	O
BAS	O
SR	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
until	O
the	O
decay	O
-	O
out	O
of	O
11	O
C	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
activity	O
at	O
the	O
start	O
of	O
contact	O
ranged	O
from	O
1.05	O
to	O
2990	O
Bq	O
(	O
t	O
=	O
35.5	O
min	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
other	O
three	O
pieces	O
of	O
the	O
filter	O
paper	O
was	O
measured	O
with	O
a	O
well	O
-	O
type	O
auto	O
-	O
gamma	O
counter	O
(	O
type	O
1282	O
Compugamma	O
CS	O
,	O
Wallac	O
Oy	O
,	O
Turku	O
,	O
Finland	O
)	O
for	O
15	O
s	O
,	O
and	O
the	O
cpm	O
/	O
Bq	O
was	O
computed	O
with	O
decay	O
correction	O
.	O

The	O
PSL	O
values	O
over	O
the	O
entire	O
piece	O
of	O
filter	O
paper	O
(	O
25	O
mm2	O
)	O
were	O
measured	O
with	O
a	O
bioimaging	O
analyzer	O
of	O
type	O
BAS	O
2500	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
to	O
compute	O
the	O
PSL	O
per	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
The	O
filter	O
paper	O
provided	O
with	O
the	O
11	O
C	O
-	O
radioactivity	O
as	O
described	O
above	O
and	O
the	O
autoradiographic	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
(	O
1.11–31.73	O
kBq	O
/	O
g	O
)	O
(	O
Amersham	O
International	O
plc	O
.	O
,	O
Buckinghamshire	O
,	O
England	O
)	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
of	O
the	O
same	O
type	O
for	O
4	O
h	O
to	O
examine	O
the	O
reproducibility	O
between	O
imaging	O
plates	O
;	O
the	O
PSL	O
of	O
the	O
micro	O
-	O
scales	O
were	O
measured	O
as	O
PSL	O
/	O
mm2	O
.	O

Ex	O
vivo	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
143	O
MBq	O
/	O
4.3	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
a	O
rat	O
(	O
235	O
g	O
)	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
.	O

Fifteen	O
minutes	O
later	O
,	O
the	O
rat	O
was	O
killed	O
and	O
the	O
brain	O
was	O
removed	O
.	O

The	O
brain	O
at	O
the	O
bregma	O
(	O
17	O
)	O
was	O
cut	O
into	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thick	O
coronal	O
sections	O
using	O
a	O
cryotome	O
(	O
Bright	O
Instruments	O
Co.	O
Ltd.	O
,	O
UK	O
)	O
at	O
−15	O
°	O
C	O
.	O

The	O
brain	O
sections	O
were	O
thaw	O
-	O
mounted	O
on	O
glass	O
plates	O
(	O
20	O
×	O
32	O
mm2	O
)	O
that	O
were	O
precoated	O
with	O
3	O
%	O
3-aminopropyltriethoxysilane	O
in	O
acetone	O
.	O

The	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
and	O
apposed	O
placed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
110	O
min	O
)	O
.	O

The	O
tracer	O
uptake	O
was	O
visualized	O
as	O
described	O
above	O
.	O

Regions	O
of	O
interest	O
(	O
ROIs	O
)	O
were	O
placed	O
on	O
the	O
striatum	O
(	O
6–8	O
mm2	O
)	O
and	O
on	O
the	O
cerebral	O
cortex	O
(	O
6–8	O
mm2	O
)	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
were	O
measured	O
.	O

From	O
the	O
other	O
rat	O
(	O
230	O
g	O
)	O
given	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
136	O
MBq	O
/	O
4.4	O
nmol	O
)	O
,	O
the	O
coronal	O
brain	O
sections	O
with	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
were	O
also	O
obtained	O
as	O
described	O
above	O
.	O

The	O
whole	O
section	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
for	O
15	O
s.	O

The	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
,	O
assuming	O
equal	O
radioactivity	O
concentration	O
between	O
corresponding	O
regions	O
or	O
whole	O
brains	O
in	O
neighboring	O
sections	O
at	O
the	O
bregma	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
To	O
obtain	O
coronal	O
brain	O
sections	O
having	O
a	O
wider	O
range	O
of	O
radioactivity	O
,	O
ex	O
vivo	O
ARG	O
was	O
performed	O
with	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
,	O
which	O
is	O
more	O
concentrated	O
in	O
the	O
striatum	O
than	O
[	O
11	O
C	O
]	O
nemonapride	O
.	O

[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
236	O
MBq	O
/	O
11.1	O
nmol	O
and	O
47	O
MBq	O
/	O
2.2	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
two	O
rats	O
(	O
t	O
=	O
0	O
min	O
,	O
30	O
min	O
after	O
EOB	O
)	O
.	O

The	O
rats	O
were	O
killed	O
15	O
min	O
later	O
,	O
and	O
25	O
pairs	O
of	O
the	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
prepared	O
throughout	O
the	O
brain	O
as	O
described	O
above	O
.	O

One	O
set	O
of	O
the	O
brain	O
sections	O
was	O
applied	O
to	O
an	O
imaging	O
plate	O
until	O
decay	O
-	O
out	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
,	O
and	O
the	O
other	O
set	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
(	O
t	O
=	O
102	O
min	O
)	O
.	O

Then	O
the	O
PSL	O
/	O
cpm	O
was	O
calculated	O
for	O
each	O
brain	O
section	O
.	O

Regional	O
brain	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
method	O
[	O
11	O
C	O
]	O
Nemonapride	O
(	O
82.6–96.7	O
MBq	O
/	O
2.1–5.7	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
four	O
rats	O
(	O
260–290	O
g	O
)	O
.	O

They	O
were	O
killed	O
30	O
min	O
later	O
and	O
the	O
brains	O
were	O
removed	O
.	O

From	O
a	O
half	O
brain	O
hemisphere	O
,	O
three	O
pairs	O
of	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
cut	O
near	O
bregma	O
.	O

The	O
radioactivity	O
(	O
cpm	O
)	O
of	O
one	O
set	O
of	O
section	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
and	O
converted	O
to	O
Bq	O
.	O

The	O
other	O
section	O
was	O
exposed	O
to	O
an	O
imaging	O
plate	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
as	O
described	O
above	O
,	O
and	O
the	O
PSL	O
/	O
Bq	O
was	O
calculated	O
assuming	O
that	O
the	O
pair	O
of	O
adjacent	O
brain	O
sections	O
had	O
the	O
same	O
radioactivity	O
.	O

ROIs	O
were	O
placed	O
on	O
the	O
striatum	O
and	O
on	O
the	O
cortex	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
regional	O
brain	O
section	O
volume	O
(	O
mm2	O
×	O
0.02	O
mm	O
)	O
,	O
which	O
was	O
converted	O
to	O
Bq	O
/	O
mL.	O
Then	O
,	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
the	O
striatum	O
or	O
cortex	O
was	O
assessed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
milliliter	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
mL	O
)	O
.	O

From	O
the	O
other	O
hemisphere	O
the	O
striatum	O
and	O
cortex	O
were	O
dissected	O
and	O
weighed	O
,	O
and	O
the	O
radioactivity	O
of	O
the	O
tissues	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
.	O

The	O
uptake	O
was	O
expressed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
gram	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
g	O
)	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
measure	O
the	O
receptor	B
binding	O
capacity	O
quantitatively	O
in	O
ex	O
vivo	O
ARG	O
,	O
the	O
amount	O
of	O
injected	O
carrier	O
ligand	O
must	O
be	O
sufficiently	O
small	O
to	O
avoid	O
saturation	O
effect	O
.	O

To	O
determine	O
if	O
the	O
carrier	O
amount	O
of	O
nemonapride	O
meets	O
this	O
requirement	O
under	O
the	O
specific	O
activity	O
of	O
current	O
experimental	O
condition	O
,	O
the	O
effect	O
of	O
carrier	O
dose	O
on	O
the	O
regional	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
evaluated	O
by	O
tissue	O
sampling	O
.	O

[	O
11	O
C	O
]	O
Nemonapride	O
with	O
various	O
amount	O
of	O
carrier	O
(	O
10	O
MBq	O
/	O
0.027–500	O
nmol	O
)	O
was	O
injected	O
into	O
rats	O
(	O
227	O
±	O
12	O
g	O
)	O
,	O
and	O
the	O
uptake	O
(	O
%	O
ID	O
/	O
g	O
)	O
by	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
was	O
measured	O
at	O
30	O
min	O
after	O
the	O
injection	O
by	O
the	O
tissue	O
sampling	O
method	O
as	O
described	O
above	O
.	O

In	O
vitro	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
In	O
vitro	O
ARG	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Przedborski	O
et	O
al.	O
(	O
19	O
)	O
with	O
a	O
slight	O
modification	O
.	O

Coronal	O
rat	O
brain	O
sections	O
with	O
10-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
near	O
the	O
bregma	O
(	O
17	O
)	O
were	O
prepared	O
.	O

The	O
brain	O
sections	O
were	O
pre	O
-	O
incubated	O
in	O
100	O
mL	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.4	O
,	O
containing	O
120	O
mM	O
NaCl	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
same	O
buffer	O
containing	O
100	O
kBq	O
/	O
mL	O
(	O
25	O
TBq	O
/	O
mmol	O
)	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
,	O
in	O
which	O
all	O
the	O
sections	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

After	O
being	O
washed	O
with	O
ice	O
-	O
cold	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
containing	O
120	O
mM	O
NaCl	O
,	O
the	O
brain	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
,	O
and	O
then	O
contacted	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
58	O
min	O
)	O
until	O
the	O
activity	O
decayed	O
out	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
binding	O
of	O
11	O
C	O
was	O
measured	O
as	O
the	O
PSL	O
/	O
mm2	O
over	O
the	O
ROIs	O
placed	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
.	O

The	O
other	O
set	O
of	O
the	O
brain	O
section	O
was	O
also	O
assayed	O
as	O
described	O
above	O
and	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
whole	O
section	O
was	O
measured	O
with	O
a	O
gamma	O
counter	O
.	O

Saturation	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
binding	O
The	O
buffer	O
containing	O
various	O
concentrations	O
(	O
0.156	O
,	O
0.313	O
,	O
0.625	O
,	O
1.25	O
,	O
and	O
2.50	O
nM	O
)	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
(	O
21	O
TBq	O
/	O
mmol	O
)	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
40	O
min	O
after	O
EOB	O
)	O
,	O
and	O
six	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
each	O
buffer	O
as	O
described	O
above	O
.	O

Nonspecific	O
binding	O
was	O
determined	O
by	O
incubating	O
adjacent	O
six	O
sections	O
in	O
the	O
medium	O
to	O
which	O
haloperidol	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
20	O
μM.	O
Three	O
brain	O
sections	O
in	O
each	O
assay	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
85	O
min	O
)	O
to	O
measure	O
the	O
PSL	O
values	O
,	O
and	O
the	O
adjacent	O
three	O
sections	O
were	O
measured	O
for	O
radioactivity	O
(	O
cpm	O
)	O
.	O

Then	O
,	O
the	O
PSL	O
/	O
Bq	O
calculated	O
as	O
described	O
above	O
was	O
converted	O
to	O
concentration	O
of	O
receptor	B
-	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
using	O
the	O
specific	O
activity	O
of	O
the	O
ligand	O
.	O

Scatchard	O
plot	O
,	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
versus	O
bound	O
ligand	O
/	O
free	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
/	O
nM	O
)	O
,	O
was	O
carried	O
out	O
.	O

Results	O
and	O
discussion	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
Figure	O
1	O
shows	O
the	O
PSL	O
values	O
of	O
the	O
standard	O
sample	O
on	O
filter	O
paper	O
.	O

The	O
PSL	O
values	O
were	O
linearly	O
proportional	O
to	O
the	O
11	O
C	O
radioactivity	O
(	O
Bq	O
)	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
the	O
ratio	O
was	O
10.7	O
PSL	O
/	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Because	O
each	O
sample	O
presented	O
uniform	O
activity	O
distribution	O
within	O
the	O
piece	O
of	O
filter	O
paper	O
,	O
the	O
PSL	O
of	O
the	O
standard	O
sample	O
on	O
the	O
filter	O
paper	O
was	O
expressed	O
as	O
a	O
linear	O
function	O
of	O
radioactivity	O
in	O
the	O
range	O
from	O
0.4	O
to	O
1110	O
PSL	O
/	O
mm2	O
(	O
0.04–104	O
Bq	O
/	O
mm2	O
)	O
in	O
the	O
present	O
study	O
.	O

The	O
linearity	O
between	O
the	O
radioisotope	O
calibrator	O
and	O
the	O
well	O
-	O
type	O
gamma	O
counter	O
was	O
also	O
confirmed	O
,	O
the	O
ratio	O
being	O
40.1	O
cpm	O
/	O
Bq	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
When	O
the	O
11	O
C	O
-	O
samples	O
on	O
filter	O
paper	O
and	O
standard	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
,	O
the	O
coefficient	O
variation	O
(	O
SD	O
/	O
mean	O
)	O
of	O
the	O
five	O
plates	O
for	O
11	O
C	O
-	O
sensitivity	O
and	O
14	O
C	O
-	O
sensitivity	O
was	O
2.4–3.2	O
%	O
at	O
17.4–164	O
PSL	O
/	O
mm2	O
and	O
2.6–6.9	O
%	O
at	O
5.2–36.6	O
PSL	O
/	O
mm2	O
,	O
respectively	O
.	O

The	O
variation	O
for	O
11	O
C	O
was	O
comparable	O
to	O
that	O
for	O
14	O
C	O
,	O
which	O
confirmed	O
the	O
reliability	O
of	O
our	O
homemade	O
standard	O
source	O
on	O
filter	O
paper	O
.	O

Effect	O
of	O
section	O
thickness	O
Figure	O
2	O
shows	O
representative	O
autoradiograms	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

High	O
11	O
C	O
density	O
was	O
observed	O
in	O
the	O
caudate	O
putamen	O
,	O
nucleus	O
accumbens	O
,	O
and	O
olfactory	O
tubercle	O
,	O
consistent	O
with	O
the	O
well	O
-	O
known	O
distribution	O
of	O
dopamine	B
D2	I
receptors	I
.	O

Figure	O
3	O
illustrates	O
the	O
relationship	O
between	O
brain	O
section	O
thickness	O
and	O
PSL	O
values	O
measured	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

The	O
PSL	O
/	O
mm2	O
value	O
for	O
ex	O
vivo	O
ARG	O
was	O
not	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
(	O
Fig.	O
3A	O
)	O
,	O
suggesting	O
that	O
the	O
absorption	O
of	O
radiation	O
increases	O
as	O
the	O
section	O
thickness	O
increases	O
,	O
because	O
it	O
is	O
reasonably	O
assumed	O
that	O
the	O
radioactivity	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
uniformly	O
distributed	O
throughout	O
the	O
thickness	O
in	O
the	O
striatum	O
and	O
cortex	O
near	O
the	O
bregma	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
deviation	O
from	O
the	O
linear	O
function	O
was	O
much	O
larger	O
for	O
the	O
in	O
vitro	O
ARG	O
than	O
for	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
reached	O
a	O
plateau	O
both	O
in	O
the	O
striatum	O
and	O
cortex	O
for	O
over	O
100-μm	O
thick	O
sections	O
.	O

This	O
finding	O
is	O
probably	O
because	O
diffusion	O
of	O
the	O
11	O
C	O
-	O
tracer	O
into	O
the	O
brain	O
tissue	O
was	O
not	O
completed	O
in	O
thick	O
brain	O
sections	O
during	O
the	O
incubation	O
period	O
,	O
and	O
the	O
binding	O
did	O
not	O
reach	O
an	O
equilibrium	O
state	O
.	O

The	O
explanation	O
was	O
approved	O
by	O
measurement	O
of	O
radioactivity	O
of	O
the	O
whole	O
brain	O
sections	O
with	O
a	O
gamma	O
counter	O
(	O
Fig.	O
3C	O
)	O
.	O

The	O
radioactivity	O
was	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
in	O
ex	O
vivo	O
ARG	O
,	O
but	O
not	O
in	O
in	O
vitro	O
ARG	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
Figure	O
4	O
shows	O
relationship	O
between	O
the	O
PSL	O
value	O
and	O
the	O
radioactivity	O
of	O
11	O
C	O
on	O
the	O
whole	O
section	O
with	O
20-μm	O
thickness	O
and	O
for	O
the	O
entire	O
piece	O
of	O
25-mm2	O
filter	O
paper	O
with	O
230-μm	O
thickness	O
.	O

The	O
PSL	O
was	O
found	O
to	O
be	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
within	O
the	O
brain	O
sections	O
or	O
filter	O
paper	O
,	O
although	O
the	O
coefficient	O
was	O
different	O
between	O
the	O
two	O
materials	O
because	O
of	O
different	O
thickness	O
as	O
suggested	O
from	O
Figure	O
2	O
.	O

Therefore	O
,	O
the	O
PSL	O
value	O
can	O
be	O
converted	O
to	O
the	O
radioactivity	O
expressed	O
as	O
Bq	O
unit	O
,	O
if	O
the	O
radioactivity	O
of	O
the	O
adjacent	O
brain	O
sections	O
with	O
the	O
same	O
thickness	O
is	O
measured	O
with	O
a	O
gamma	O
-	O
counter	O
.	O

Table	O
1	O
summarizes	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
by	O
the	O
striatum	O
and	O
cortex	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
by	O
the	O
tissue	O
sampling	O
.	O

Comparable	O
values	O
of	O
the	O
striatal	O
and	O
cortical	O
uptake	O
were	O
obtained	O
by	O
the	O
two	O
methods	O
,	O
nevertheless	O
the	O
technical	O
problem	O
that	O
the	O
nonstriatal	O
region	O
might	O
be	O
contaminated	O
with	O
the	O
striatal	O
sample	O
in	O
the	O
tissue	O
sampling	O
,	O
and	O
the	O
fact	O
that	O
the	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
is	O
less	O
homogeneous	O
in	O
the	O
striatum	O
than	O
in	O
the	O
cortex	O
.	O

Therefore	O
,	O
ex	O
vivo	O
ARG	O
may	O
be	O
a	O
suitable	O
method	O
to	O
quantitatively	O
evaluate	O
small	O
regions	O
such	O
as	O
nucleus	O
accumbens	O
and	O
olfactory	O
tubercles	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
evaluate	O
the	O
carrier	O
dose	O
on	O
the	O
regional	O
brain	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
,	O
the	O
uptake	O
was	O
measured	O
by	O
tissue	O
sampling	O
method	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
at	O
the	O
dose	O
of	O
22	O
nmol	O
/	O
kg	O
the	O
uptake	O
was	O
slightly	O
decreased	O
,	O
though	O
not	O
statistically	O
significant	O
.	O

In	O
the	O
regional	O
brain	O
distribution	O
study	O
with	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
(	O
Table	O
1	O
)	O
,	O
the	O
injected	O
doses	O
were	O
320–330	O
MBq	O
/	O
kg	O
as	O
radioactivity	O
and	O
8.1–20	O
nmol	O
/	O
kg	O
as	O
carrier	O
amounts	O
.	O

Therefore	O
,	O
the	O
injected	O
carrier	O
dose	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
slightly	O
exceeded	O
to	O
the	O
optimum	O
condition	O
.	O

However	O
,	O
because	O
the	O
PSL	O
/	O
mm2	O
values	O
measured	O
in	O
the	O
cortex	O
were	O
12–14	O
at	O
65–70	O
min	O
after	O
the	O
tracer	O
injection	O
(	O
at	O
35–40	O
min	O
after	O
the	O
exposing	O
time	O
)	O
in	O
the	O
study	O
described	O
in	O
Table	O
1	O
,	O
the	O
injected	O
dose	O
for	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
can	O
be	O
reasonably	O
reduced	O
to	O
approximately	O
one	O
-	O
tenth	O
within	O
the	O
linearity	O
range	O
for	O
the	O
PSL	O
/	O
mm2	O
(	O
>	O
0.4	O
in	O
Fig.	O
1	O
)	O
,	O
although	O
statistical	O
noise	O
is	O
increased	O
.	O

Therefore	O
,	O
the	O
quantitative	O
ex	O
vivo	O
ARG	O
method	O
using	O
imaging	O
plates	O
presented	O
in	O
this	O
study	O
is	O
applicable	O
to	O
quantitative	O
measurement	O
of	O
the	O
receptor	B
binding	O
capacity	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
.	O

It	O
can	O
also	O
be	O
applied	O
to	O
other	O
dopamine	B
receptor	I
ligands	O
such	O
as	O
[	O
11	O
C	O
]	O
raclopride	O
,	O
[	O
11	O
C	O
]	O
N	O
-methylspiperone	O
,	O
and	O
[	O
11	O
C	O
]	O
SCH	O
23390	O
(	O
data	O
not	O
shown	O
)	O
,	O
although	O
the	O
uptake	O
depends	O
in	O
the	O
ligand	O
.	O

Figure	O
5	O
also	O
showed	O
that	O
a	O
saturable	O
uptake	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
observed	O
in	O
the	O
cortex	O
and	O
cerebellum	O
besides	O
in	O
the	O
striatum	O
,	O
which	O
was	O
preliminarily	O
suggested	O
by	O
a	O
previous	O
report	O
(	O
5	O
)	O
.	O

In	O
vitro	O
[	O
11	O
C	O
]	O
Nemonapride	O
binding	O
to	O
the	O
striatum	O
and	O
cortex	O
In	O
previous	O
studies	O
on	O
in	O
vitro	O
binding	O
of	O
radiolabeled	O
nemonapride	O
(	O
[	O
3	O
H	O
]	O
YM-09151	O
-	O
2	O
)	O
at	O
room	O
temperature	O
,	O
the	O
tracer	O
binding	O
reached	O
equilibrium	O
after	O
90	O
min	O
(	O
2	O
,	O
15	O
,	O
24	O
)	O
.	O

In	O
our	O
preliminary	O
experiment	O
,	O
when	O
the	O
incubation	O
was	O
carried	O
out	O
at	O
37	O
°	O
C	O
to	O
accelerate	O
the	O
equilibration	O
,	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
binding	O
reached	O
a	O
maximal	O
level	O
at	O
30	O
min	O
(	O
data	O
not	O
shown	O
)	O
,	O
which	O
enabled	O
the	O
use	O
of	O
the	O
short	O
-	O
lived	O
11	O
C	O
-	O
ligand	O
.	O

The	O
specific	O
activity	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
was	O
reasonably	O
high	O
(	O
25	O
TBq	O
/	O
mmol	O
at	O
the	O
start	O
of	O
assay	O
in	O
the	O
present	O
study	O
)	O
compared	O
with	O
conventional	O
in	O
vitro	O
ARG	O
using	O
3	O
H	O
-	O
labeled	O
compounds	O
.	O

Thus	O
the	O
in	O
vitro	O
ARG	O
with	O
[	O
11	O
C	O
]	O
nemonapride	O
is	O
a	O
practicable	O
technique	O
.	O

The	O
period	O
required	O
from	O
the	O
end	O
of	O
radiosynthesis	O
to	O
the	O
exposing	O
the	O
brain	O
slice	O
to	O
imaging	O
plate	O
was	O
approximately	O
90	O
min	O
.	O

A	O
saturation	O
binding	O
experiment	O
showed	O
a	O
specific	O
binding	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
to	O
the	O
striatum	O
and	O
cortex	O
(	O
Fig.	O
6A	O
)	O
.	O

Scatchard	O
analysis	O
indicated	O
a	O
Kd	O
of	O
730	O
pM	O
and	O
an	O
apparent	O
Bmax	O
of	O
160	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
striatum	O
and	O
a	O
Kd	O
of	O
1.5	O
nM	O
and	O
a	O
Bmax	O
of	O
29	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
cortex	O
.	O

The	O
Kd	O
value	O
of	O
730	O
pM	O
for	O
the	O
striatum	O
is	O
in	O
the	O
same	O
order	O
as	O
those	O
obtained	O
with	O
in	O
vitro	O
ARG	O
by	O
Unis	O
et	O
al.	O
(	O
626	O
pM	O
)	O
(	O
24	O
)	O
and	O
Yokoyama	O
et	O
al.	O
(	O
315	O
pM	O
)	O
(	O
26	O
)	O
,	O
but	O
is	O
larger	O
than	O
those	O
(	O
21–82	O
pM	O
)	O
measured	O
by	O
the	O
membrane	O
binding	O
assay	O
(	O
1	O
,	O
13	O
,	O
15	O
,	O
23	O
)	O
or	O
with	O
in	O
vitro	O
ARG	O
(	O
2	O
)	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
the	O
assay	O
conditions	O
such	O
as	O
incubation	O
time	O
,	O
temperature	O
,	O
blockers	O
used	O
to	O
evaluate	O
the	O
nonspecific	O
binding	O
,	O
other	O
medium	O
components	O
,	O
and	O
slice	O
thickness	O
in	O
ARG	O
.	O

The	O
saturation	O
kinetics	O
may	O
also	O
be	O
different	O
between	O
the	O
membrane	O
homogenate	O
and	O
the	O
brain	O
slice	O
.	O

An	O
in	O
vivo	O
saturation	O
binding	O
experiment	O
in	O
Figure	O
6	O
revealed	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	O
11	O
C	O
]	O
nemonapride	O
in	O
the	O
cortex	O
and	O
striatum	O
.	O

This	O
finding	O
was	O
also	O
revealed	O
by	O
an	O
ex	O
vivo	O
study	O
(	O
Fig.	O
5	O
)	O
,	O
which	O
also	O
suggested	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
in	O
the	O
cerebellum	O
.	O

The	O
specific	O
binding	O
evaluated	O
with	O
a	O
haloperidol	O
-	O
blockade	O
was	O
lower	O
than	O
the	O
nonspecific	O
binding	O
in	O
the	O
cortex	O
(	O
Fig.	O
6A	O
-2	O
)	O
.	O

Kazawa	O
et	O
al.	O
(	O
13	O
)	O
demonstrated	O
that	O
[	O
3	O
H	O
]	O
nemonapride	O
binding	O
in	O
the	O
cortical	O
membrane	O
was	O
displaced	O
by	O
sulpiride	O
or	O
by	O
haloperidol	O
.	O

They	O
also	O
showed	O
that	O
these	O
binding	O
sites	O
were	O
apparently	O
different	O
from	O
serotonin-2	B
receptors	I
.	O

The	O
unknown	O
binding	O
sites	O
may	O
be	O
dopamine	B
D4	I
receptors	I
,	O
because	O
haloperidol	O
,	O
but	O
not	O
raclopride	O
,	O
displaced	O
the	O
uptake	O
(	O
20	O
)	O
.	O

Sigma	B
receptors	I
may	O
be	O
another	O
candidate	O
for	O
the	O
unknown	O
binding	O
sites	O
.	O

Helmeste	O
et	O
al.	O
(	O
7	O
)	O
suggested	O
that	O
nemonapride	O
also	O
has	O
an	O
affinity	O
for	O
sigma	B
receptors	I
,	O
which	O
was	O
evaluated	O
by	O
a	O
blocking	O
study	O
with	O
a	O
selective	O
sigma	B
receptor	I
ligand	O
,	O
R	O
(	O
−	O
)	O
-N	O
-	O
(	O
3-phenyl	O
-	O
n	O
-propyl	O
)	O
-1-phenyl-2-aminopropane	O
(	O
PPAP	O
)	O
.	O

Preliminary	O
findings	O
indicated	O
that	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
uptake	O
was	O
reduced	O
by	O
carrier	O
nemonapride	O
or	O
by	O
haloperidol	O
in	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
of	O
the	O
mouse	O
brain	O
,	O
but	O
that	O
other	O
sigma	B
receptor	I
ligands	O
such	O
as	O
PPAP	O
,	O
(	O
+	O
)	O
-SKF10047	O
,	O
R	O
(	O
+	O
)	O
-3-	O
(	O
3-hydroxyphenyl	O
)	O
-N	O
-propylpiperidine	O
hydrochloride	O
(	O
R	O
[	O
+	O
]	O
-3-PPP	O
)	O
and	O
NE-100	O
(	O
22	O
)	O
did	O
not	O
reduce	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
uptake	O
by	O
the	O
striatum	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
in	O
vivo	O
affinity	O
of	O
the	O
[	O
11	O
C	O
]	O
nemonapride	O
for	O
sigma	B
receptors	I
is	O
under	O
investigation	O
.	O

So	O
far	O
,	O
we	O
confirmed	O
in	O
ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
that	O
the	O
saturable	O
binding	O
sites	O
of	O
[	O
11	O
C	O
]	O
nemonapride	O
are	O
present	O
in	O
the	O
cortex	O
(	O
and	O
probably	O
in	O
the	O
cerebellum	O
)	O
although	O
their	O
characteristics	O
remain	O
unknown	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
No.	O
10558115	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Perillyl	O
alcohol	O
is	O
a	O
hydroxylated	O
metabolite	O
of	O
d	O
-limonene	O
[	O
1–3	O
]	O
,	O
which	O
is	O
the	O
major	O
,	O
naturally	O
occurring	O
monoterpene	O
present	O
in	O
orange	O
peel	O
oil	O
.	O

Perillyl	O
alcohol	O
is	O
also	O
found	O
in	O
lavender	O
,	O
mints	O
,	O
and	O
celery	O
seeds	O
.	O

It	O
has	O
been	O
shown	O
that	O
d	O
-limonene	O
and	O
metabolites	O
possess	O
chemopreventative	O
and	O
chemotherapeutic	O
activity	O
against	O
human	O
malignancies	O
with	O
low	O
toxicity	O
[	O
4–8	O
]	O
.	O

d	O
-Limonene	O
is	O
extensively	O
metabolized	O
(	O
Scheme	O
1	O
)	O
in	O
animals	O
[	O
1–5	O
]	O
and	O
in	O
humans	O
[	O
9,10	O
]	O
and	O
perillic	O
acid	O
and	O
dihydroperillic	O
acid	O
were	O
found	O
to	O
be	O
the	O
major	O
circulating	O
metabolites	O
[	O
1–3,5,6	O
]	O
and	O
for	O
perillyl	O
alcohol	O
[	O
11	O
]	O
.	O

Metabolites	O
of	O
limonene	O
with	O
intermediate	O
polarity	O
such	O
as	O
perillyl	O
alcohol	O
,	O
perillic	O
acid	O
methyl	O
ester	O
and	O
perillaldehyde	O
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
of	O
isoprenylation	O
of	O
the	O
p21–26	B
kDa	I
protein	I
,	O
which	O
is	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
[	O
7	O
]	O
,	O
than	O
limonene	O
itself	O
.	O

In	O
vivo	O
,	O
perillyl	O
alcohol	O
was	O
also	O
found	O
to	O
be	O
more	O
active	O
than	O
d	O
-limonene	O
[	O
4–7,12–14	O
]	O
.	O

Phillips	O
et	O
al.	O
[	O
11	O
]	O
conducted	O
a	O
pharmacokinetic	O
study	O
of	O
perillyl	O
alcohol	O
in	O
dogs	O
using	O
a	O
GC	O
–	O
MS	O
method	O
with	O
a	O
sensitivity	O
limit	O
of	O
0.25	O
μg	O
/	O
ml	O
,	O
but	O
were	O
unable	O
to	O
detect	O
the	O
parent	O
drug	O
in	O
circulation	O
.	O

In	O
order	O
to	O
understand	O
the	O
pharmacokinetic	O
and	O
disposition	O
characteristics	O
of	O
perillyl	O
alcohol	O
,	O
the	O
development	O
of	O
a	O
more	O
sensitive	O
quantitation	O
assay	O
method	O
is	O
necessary	O
.	O

The	O
present	O
report	O
describes	O
a	O
sensitive	O
GC	O
–	O
MS	O
method	O
for	O
the	O
measurement	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
plasma	O
using	O
the	O
stable	O
isotope	O
-	O
labelled	O
analogs	O
as	O
the	O
internal	O
standards	O
.	O

A	O
derivatization	O
procedure	O
is	O
also	O
used	O
to	O
facilitate	O
the	O
GC	O
separation	O
and	O
mass	O
spectrometric	O
detection	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
and	O
reagents	O
(	O
S	O
)	O
-	O
(	O
−	O
)	O
-Perillyl	O
alcohol	O
(	O
POH	O
)	O
was	O
purchased	O
from	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Perillic	O
acid	O
(	O
PA	O
)	O
,	O
cis-	O
/trans-	O
dihydroperillic	O
acid	O
(	O
cis-	O
/trans-	O
DHPA	O
,	O
cis-	O
/trans-	O
4	O
(	O
1′-methylethenyl	O
)	O
cyclohexane-1-carboxylic	O
acid	O
)	O
,	O
perillyl	O
alcohol	O
-	O
d3	O
(	O
POH	O
-	O
d3	O
)	O
and	O
perillic	O
acid	O
-	O
d2	O
-13	O
C	O
(	O
13	O
C	O
-	O
PA	O
-	O
d2	O
)	O
(	O
Fig.	O
1	O
)	O
were	O
synthesized	O
according	O
to	O
the	O
literature	O
method	O
[	O
15	O
]	O
.	O

POH	O
-	O
d3	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
POH	O
,	O
whereas	O
13	O
C	O
-	O
PA	O
-	O
d2	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
PA	O
and	O
cis-	O
/	O
trans	O
-DHPA	O
.	O

Cis-	O
and	O
trans-	O
1-carboxy-4-methylcyclohexane	O
were	O
purchased	O
from	O
Aldrich	O
.	O

The	O
chemical	O
purity	O
of	O
all	O
these	O
synthetic	O
compounds	O
as	O
well	O
as	O
the	O
isotope	O
purity	O
of	O
labeled	O
compounds	O
was	O
99	O
%	O
.	O

N	O
,-	O
O	O
-Bis-	O
(	O
trimethylsilyl	O
)	O
silyltrifluoroacetamide	O
(	O
BSTFA	O
)	O
was	O
obtained	O
from	O
Pierce	O
(	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Acetonitrile	O
(	O
HPLC	O
grade	O
)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

All	O
other	O
organic	O
solvents	O
and	O
reagents	O
purchased	O
from	O
Fisher	O
Scientific	O
were	O
of	O
reagent	O
grade	O
.	O

2.2	O
Sample	O
extraction	O
To	O
each	O
of	O
a	O
set	O
of	O
16	O
×	O
125-mm	O
disposable	O
tubes	O
was	O
added	O
appropriate	O
amounts	O
of	O
the	O
internal	O
standards	O
in	O
acetonitrile	O
followed	O
by	O
gentle	O
evaporation	O
of	O
the	O
solvent	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

A	O
plasma	O
sample	O
(	O
0.5	O
ml	O
or	O
less	O
)	O
was	O
then	O
added	O
and	O
the	O
content	O
mixed	O
.	O

The	O
sample	O
volume	O
of	O
less	O
than	O
0.5	O
ml	O
was	O
made	O
up	O
to	O
0.5	O
ml	O
by	O
addition	O
of	O
blank	O
mouse	O
or	O
human	O
plasma	O
.	O

Acetonitrile	O
(	O
1.0	O
ml	O
)	O
was	O
added	O
to	O
precipitate	O
the	O
protein	B
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
set	O
of	O
disposable	O
tubes	O
and	O
was	O
acidified	O
by	O
addition	O
of	O
10	O
μl	O
of	O
3	O
M	O
HCl	O
.	O

The	O
extraction	O
was	O
accomplished	O
with	O
3	O
×	O
2	O
ml	O
methylene	O
chloride	O
by	O
vigorously	O
mixing	O
on	O
a	O
vortex	O
-	O
mixer	O
for	O
10	O
s	O
,	O
followed	O
by	O
centrifugation	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
methylene	O
chloride	O
extracts	O
were	O
combined	O
and	O
evaporated	O
to	O
dryness	O
by	O
a	O
stream	O
of	O
N2	O
.	O

Forty	O
μl	O
of	O
60	O
%	O
BSTFA	O
in	O
acetonitrile	O
was	O
then	O
added	O
.	O

The	O
content	O
was	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
5	O
min	O
before	O
analysis	O
by	O
GC	O
–	O
MS	O
.	O

2.3	O
GC	O
–	O
MS	O
analysis	O
GC	O
–	O
MS	O
analysis	O
of	O
the	O
analytes	O
was	O
performed	O
on	O
a	O
Finnigan	O
MAT	O
ITS40	O
(	O
Finnigan	O
MAT	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
coupled	O
to	O
a	O
3300	O
/	O
3400	O
Model	O
Varian	O
gas	O
chromatograph	O
(	O
Walnut	O
Creek	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
gas	O
chromatograph	O
was	O
equipped	O
with	O
a	O
DB-5	O
fused	O
-	O
silica	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
)	O
wall	O
-	O
coated	O
with	O
0.25	O
mm	O
of	O
cross	O
-	O
linked	O
95	O
%	O
methyl-	O
and	O
5	O
%	O
phenyl	O
-	O
polysiloxane	O
(	O
J&W	O
Scientific	O
,	O
Folsom	O
,	O
CA	O
,	O
USA	O
)	O
and	O
an	O
autosampler	O
(	O
Finnigan	O
MAT	O
)	O
.	O

Ultra	O
-	O
high	O
purity	O
helium	O
was	O
used	O
as	O
the	O
carrier	O
gas	O
with	O
a	O
head	O
pressure	O
of	O
15	O
psi	O
(	O
ca	O
.	O

105	O
Pa	O
)	O
.	O

The	O
injection	O
port	O
and	O
the	O
transfer	O
line	O
were	O
set	O
at	O
270	O
°	O
C	O
.	O

The	O
oven	O
temperature	O
was	O
initiated	O
at	O
100	O
°	O
C	O
for	O
1	O
min	O
,	O
and	O
was	O
ramped	O
to	O
250	O
°	O
C	O
at	O
15	O
°	O
C	O
/	O
min	O
,	O
then	O
increased	O
to	O
280	O
°	O
C	O
at	O
30	O
°	O
C	O
/	O
min	O
.	O

The	O
column	O
was	O
held	O
at	O
250	O
°	O
C	O
for	O
1	O
min	O
.	O

Analysis	O
was	O
performed	O
using	O
chemical	O
ionization	O
mode	O
and	O
ammonia	O
was	O
used	O
as	O
the	O
reagent	O
gas	O
.	O

Quantitation	O
was	O
performed	O
in	O
the	O
selected	O
ion	O
monitor	O
mode	O
by	O
measuring	O
the	O
base	O
peak	O
of	O
either	O
MH+	O
or	O
the	O
fragment	O
ions	O
characteristic	O
of	O
the	O
trimethylsilylated	O
derivatives	O
of	O
the	O
analytes	O
and	O
their	O
respective	O
internal	O
standards	O
.	O

The	O
peak	O
area	O
ratio	O
method	O
was	O
used	O
in	O
construction	O
of	O
the	O
calibration	O
curves	O
.	O

2.4	O
13	O
C	O
-	O
NMR	O
analysis	O
13	O
C	O
-	O
NMR	O
spectra	O
were	O
recorded	O
on	O
either	O
a	O
Brucker	O
NR-250	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
62.89	O
MHz	O
or	O
a	O
Brucker	O
AM-500	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
125.77	O
MHz	O
with	O
tetramethylsilane	O
as	O
the	O
internal	O
standard	O
and	O
CDCl3	O
as	O
the	O
solvent	O
.	O

2.5	O
Separation	O
of	O
cis-	O
and	O
trans-	O
dihydroperillic	O
acid	O
A	O
mixture	O
of	O
synthetic	O
cis-	O
and	O
trans-	O
dihydroperillic	O
acids	O
was	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
.	O

The	O
mixture	O
(	O
10	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
CH2	O
Cl2	O
and	O
the	O
solution	O
was	O
applied	O
onto	O
a	O
precoated	O
silica	O
gel	O
G	O
60	O
thin	O
-	O
layer	O
plate	O
(	O
EM	O
Merck	O
,	O
thickness	O
0.2	O
mm	O
,	O
20	O
×	O
20	O
cm	O
)	O
.	O

This	O
plate	O
was	O
developed	O
ascendingly	O
with	O
50:1	O
CH2	O
Cl2	O
–MeOH	O
on	O
a	O
lined	O
tank	O
for	O
one	O
full	O
-	O
length	O
.	O

Under	O
UV	O
light	O
visualization	O
,	O
two	O
overlapping	O
spots	O
(	O
ca	O
.	O
50	O
%	O
)	O
(	O
R	O
f	O
0.55–0.76	O
)	O
were	O
seen	O
and	O
the	O
upper	O
portion	O
of	O
the	O
faster	O
-	O
running	O
spot	O
(	O
R	O
f	O
0.72–0.76	O
)	O
was	O
scrapped	O
off	O
and	O
eluted	O
with	O
CH2	O
Cl2	O
.	O

The	O
collected	O
compound	O
(	O
ca	O
.	O

2	O
mg	O
)	O
was	O
found	O
to	O
be	O
the	O
pure	O
component	O
corresponding	O
to	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
on	O
GC	O
–	O
MS	O
using	O
the	O
condition	O
as	O
described	O
above	O
.	O

The	O
lower	O
portion	O
of	O
the	O
spot	O
was	O
also	O
collected	O
and	O
GC	O
–	O
MS	O
still	O
showed	O
a	O
mixture	O
of	O
cis	O
/	O
trans	O
-DHPA	O
with	O
retention	O
times	O
of	O
6.3	O
and	O
6.7	O
min	O
.	O

Attempts	O
to	O
further	O
resolve	O
these	O
components	O
were	O
unsuccessful	O
.	O

2.6	O
Assay	O
characterization	O
and	O
validation	O
Detection	O
limit	O
was	O
measured	O
by	O
reducing	O
the	O
amount	O
of	O
each	O
analyte	O
until	O
the	O
signal	O
-	O
to	O
-	O
noise	O
equaled	O
to	O
four	O
,	O
which	O
is	O
defined	O
as	O
the	O
detection	O
limit	O
.	O

The	O
recovery	O
was	O
estimated	O
by	O
comparing	O
the	O
ratio	O
of	O
the	O
extracted	O
analytes	O
to	O
the	O
unextracted	O
internal	O
standard	O
with	O
that	O
of	O
the	O
unextracted	O
pairs	O
.	O

Within	O
-	O
run	O
precision	O
for	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
was	O
determined	O
by	O
analyzing	O
six	O
replicates	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
concentrations	O
used	O
were	O
:	O
for	O
POH	O
at	O
2	O
,	O
4	O
,	O
20	O
,	O
200	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
at	O
40	O
,	O
200	O
,	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	O
and	O
trans-	O
DHPA	O
each	O
at	O
20	O
,	O
100	O
,	O
and	O
1000	O
ng	O
/	O
ml	O
.	O

Between	O
-	O
run	O
precision	O
was	O
evaluated	O
by	O
analyzing	O
the	O
variation	O
of	O
the	O
slopes	O
of	O
six	O
standard	O
curves	O
for	O
each	O
analyte	O
obtained	O
on	O
six	O
different	O
days	O
.	O

2.7	O
Pilot	O
animal	O
study	O
The	O
femoral	O
and	O
jugular	O
veins	O
of	O
a	O
Sprague	O
-	O
Dawley	O
rat	O
weighing	O
350	O
g	O
were	O
cannulated	O
under	O
ether	O
anesthesia	O
.	O

Three	O
hours	O
after	O
recovery	O
,	O
the	O
animal	O
was	O
given	O
neat	O
perillyl	O
alcohol	O
(	O
ca	O
.	O

22	O
μl	O
)	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

via	O
the	O
femoral	O
cannula	O
over	O
30	O
s	O
followed	O
by	O
a	O
rinse	O
of	O
0.5	O
ml	O
normal	O
saline	O
.	O

At	O
the	O
time	O
schedule	O
of	O
0	O
,	O
3	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
180	O
,	O
240	O
,	O
300	O
,	O
360	O
,	O
480	O
,	O
720	O
,	O
960	O
,	O
1200	O
,	O
and	O
1440	O
min	O
following	O
dosing	O
,	O
approximately	O
0.2	O
ml	O
of	O
heparinized	O
blood	O
each	O
was	O
withdrawn	O
from	O
the	O
jugular	O
vein	O
cannula	O
.	O

Plasma	O
was	O
separated	O
by	O
centrifugation	O
.	O

An	O
aliquot	O
of	O
each	O
plasma	O
sample	O
was	O
appropriately	O
diluted	O
with	O
blank	O
rat	O
plasma	O
to	O
make	O
up	O
to	O
0.5	O
ml	O
.	O

Under	O
this	O
condition	O
,	O
the	O
measured	O
concentrations	O
were	O
in	O
the	O
range	O
of	O
the	O
calibration	O
-	O
curve	O
.	O

To	O
each	O
plasma	O
sample	O
was	O
added	O
200	O
ng	O
of	O
the	O
internal	O
standard	O
followed	O
by	O
an	O
addition	O
of	O
1.0	O
ml	O
acetonitrile	O
to	O
precipitate	O
the	O
protein	B
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
2000	O
g	O
for	O
5	O
m.	O
The	O
supernatant	O
was	O
removed	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
analysis	O
.	O

2.8	O
Preliminary	O
clinical	O
study	O
The	O
clinical	O
study	O
is	O
a	O
part	O
of	O
an	O
ongoing	O
Phase	O
I	O
evaluation	O
of	O
POH	O
as	O
a	O
chemopreventative	O
agent	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

The	O
Phase	O
I	O
protocol	O
was	O
approved	O
by	O
the	O
Institution	O
Review	O
Board	O
(	O
IRB	O
)	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

Subjects	O
with	O
a	O
personal	O
history	O
of	O
AJCC	O
Stage	O
I	O
–	O
IIIa	O
breast	O
cancer	O
who	O
have	O
undergone	O
definitive	O
resection	O
with	O
curative	O
intent	O
and	O
who	O
have	O
completed	O
all	O
adjuvant	O
radiation	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
reversible	O
hormone	O
therapy	O
are	O
eligible	O
to	O
enroll	O
in	O
this	O
study	O
.	O

All	O
subjects	O
were	O
in	O
good	O
general	O
health	O
with	O
adequate	O
major	O
organ	O
functions	O
and	O
ECOG	O
Performance	O
Status	O
of	O
0–1	O
.	O

Patients	O
were	O
treated	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
,	O
Cleveland	O
,	O
Ohio	O
.	O

The	O
current	O
study	O
was	O
limited	O
to	O
patients	O
at	O
the	O
first	O
of	O
the	O
five	O
dose	O
levels	O
.	O

Dose	O
at	O
0.5	O
g	O
/	O
m2	O
was	O
given	O
as	O
capsules	O
,	O
which	O
were	O
supplied	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Following	O
dosing	O
,	O
blood	O
samples	O
were	O
drawn	O
at	O
0	O
(	O
predose	O
)	O
,	O
0.25	O
,	O
0.5	O
,	O
0.75	O
,	O
1.0	O
,	O
1.5	O
,	O
2.0	O
,	O
3.0	O
,	O
4.0	O
,	O
6.0	O
,	O
8.0	O
,	O
10.0	O
,	O
and	O
24	O
h.	O
Plasma	O
was	O
separated	O
from	O
red	O
blood	O
cells	O
by	O
centrifugation	O
and	O
kept	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
shipment	O
.	O

All	O
frozen	O
specimens	O
were	O
then	O
shipped	O
in	O
a	O
dry	O
-	O
ice	O
container	O
(	O
overnight	O
)	O
to	O
Dr.	O
Chan	O
's	O
Laboratory	O
at	O
the	O
Ohio	O
State	O
University	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
in	O
the	O
same	O
manner	O
as	O
the	O
rat	O
plasma	O
samples	O
.	O

2.9	O
Quality	O
control	O
and	O
stability	O
Two	O
sets	O
of	O
spiked	O
plasma	O
samples	O
consisting	O
of	O
three	O
concentration	O
levels	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
ml	O
of	O
POH	O
,	O
PA	O
,	O
cis-	O
/trans-	O
DHPA	O
were	O
prepared	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
.	O

One	O
frozen	O
set	O
was	O
sent	O
to	O
the	O
Laboratory	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
by	O
overnight	O
courier	O
service	O
in	O
dry	O
-	O
ice	O
.	O

After	O
storage	O
for	O
approximately	O
one	O
week	O
at	O
−20	O
°	O
C	O
,	O
the	O
same	O
samples	O
were	O
returned	O
by	O
courier	O
service	O
to	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
.	O

Another	O
set	O
of	O
samples	O
were	O
maintained	O
frozen	O
at	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
for	O
the	O
same	O
duration	O
until	O
analysis	O
.	O

Drug	O
and	O
metabolite	O
levels	O
were	O
analyzed	O
in	O
these	O
two	O
sets	O
of	O
samples	O
at	O
the	O
same	O
time	O
and	O
the	O
results	O
were	O
compared	O
.	O

3	O
Results	O
3.1	O
Analysis	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
The	O
GC	O
–	O
MS	O
mass	O
spectra	O
of	O
POH	O
,	O
PA	O
and	O
cis-	O
/trans-	O
DHPA	O
and	O
their	O
internal	O
standards	O
,	O
POH	O
-	O
d3	O
and	O
13	O
C	O
-	O
PA	O
-	O
d2	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

As	O
shown	O
,	O
silylated	O
POH	O
and	O
its	O
internal	O
standard	O
each	O
showed	O
the	O
base	O
peak	O
at	O
m	O
/	O
z	O
135	O
and	O
138	O
corresponding	O
to	O
their	O
C	O
–	O
O	O
cleavages	O
.	O

MH+	O
ions	O
as	O
their	O
TMS	O
derivatives	O
at	O
m	O
/	O
z	O
239	O
and	O
m	O
/	O
z	O
242	O
,	O
respectively	O
,	O
were	O
detected	O
for	O
PA	O
and	O
13	O
C	O
-	O
PA	O
-	O
d2	O
as	O
the	O
base	O
peak	O
,	O
and	O
also	O
for	O
cis-	O
/trans-	O
DHPA	O
at	O
m	O
/	O
z	O
241	O
at	O
55	O
%	O
relative	O
abundance	O
.	O

These	O
ions	O
were	O
used	O
for	O
subsequent	O
quantitation	O
.	O

On	O
this	O
basis	O
,	O
a	O
typical	O
set	O
of	O
GC	O
mass	O
chromatograms	O
of	O
human	O
and	O
rat	O
plasma	O
extracts	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

As	O
shown	O
,	O
all	O
analytes	O
were	O
detected	O
as	O
symmetrical	O
peaks	O
and	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
well	O
resolved	O
.	O

The	O
retention	O
times	O
of	O
the	O
analytes	O
were	O
:	O
POH	O
/	O
POH	O
-	O
d3	O
at	O
6.2	O
min	O
,	O
PA	O
/	O
13	O
C	O
-	O
PA	O
-	O
d2	O
at	O
7.3	O
min	O
,	O
cis-	O
DHPA	O
at	O
6.3	O
min	O
,	O
and	O
trans-	O
DHPA	O
at	O
6.7	O
min	O
.	O

The	O
assignments	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
are	O
described	O
below	O
and	O
coincided	O
with	O
those	O
of	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
.	O

No	O
interference	O
peaks	O
at	O
the	O
selected	O
ion	O
regions	O
were	O
found	O
in	O
the	O
human	O
or	O
rat	O
plasma	O
blank	O
,	O
except	O
for	O
low	O
levels	O
of	O
signal	O
contributed	O
by	O
the	O
internal	O
standards	O
.	O

These	O
interference	O
contributions	O
were	O
due	O
to	O
incomplete	O
isotope	O
labeling	O
and	O
were	O
all	O
<	O
2	O
%	O
.	O

Thus	O
,	O
the	O
ions	O
monitored	O
at	O
m	O
/	O
z	O
135	O
,	O
138	O
,	O
239	O
,	O
242	O
and	O
241	O
were	O
considered	O
to	O
be	O
highly	O
specific	O
and	O
sensitive	O
for	O
detecting	O
POH	O
and	O
its	O
metabolites	O
.	O

3.2	O
Assignments	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
using	O
GC	O
–	O
MS	O
method	O
with	O
electron	O
-	O
impact	O
ionization	O
partially	O
resolved	O
the	O
underivatized	O
cis-	O
and	O
trans-	O
DHPA	O
.	O

On	O
the	O
basis	O
of	O
the	O
different	O
mass	O
spectral	O
fragmentation	O
patterns	O
of	O
these	O
two	O
isomers	O
augmented	O
by	O
a	O
quantum	O
mechanical	O
calculation	O
to	O
correlate	O
the	O
configuration	O
and	O
mass	O
fragmentation	O
preference	O
,	O
they	O
assigned	O
the	O
smaller	O
component	O
with	O
a	O
shorter	O
retention	O
time	O
as	O
the	O
cis-	O
isomer	O
and	O
the	O
larger	O
slower	O
-	O
eluting	O
component	O
as	O
the	O
trans-	O
isomer	O
.	O

Since	O
we	O
employed	O
derivatization	O
in	O
our	O
GC	O
–	O
MS	O
assay	O
,	O
direct	O
correlation	O
of	O
our	O
system	O
with	O
those	O
of	O
Philips	O
et	O
al.	O
was	O
difficult	O
.	O

Therefore	O
,	O
we	O
resorted	O
to	O
use	O
an	O
alternative	O
method	O
for	O
the	O
assignment	O
of	O
these	O
isomers	O
.	O

Using	O
thin	O
layer	O
chromatographic	O
separation	O
,	O
we	O
were	O
able	O
to	O
partially	O
resolve	O
the	O
two	O
isomers	O
.	O

The	O
faster	O
running	O
spot	O
was	O
enriched	O
and	O
accumulated	O
.	O

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
enriched	O
component	O
had	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
.	O

The	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
synthetic	O
mixture	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
showed	O
sets	O
of	O
doublets	O
at	O
180.97	O
and	O
181.65	O
ppm	O
corresponding	O
to	O
the	O
-COOH	O
signals	O
,	O
at	O
149.76	O
and	O
149.96	O
ppm	O
corresponding	O
to	O
C-1′	O
,	O
at	O
108.54	O
and	O
108.75	O
ppm	O
corresponding	O
to	O
C-2′	O
,	O
at	O
44.15	O
and	O
44.55	O
ppm	O
corresponding	O
to	O
C-4	O
,	O
at	O
39.37	O
and	O
42.98	O
ppm	O
corresponding	O
to	O
C-1	O
,	O
and	O
at	O
above	O
40	O
ppm	O
for	O
the	O
remaining	O
carbons	O
and	O
the	O
side	O
chain	O
methyl	O
.	O

The	O
carbon	O
chemical	O
shift	O
assignments	O
were	O
based	O
on	O
the	O
H	O
-	O
coupling	O
,	O
H	O
-	O
decoupling	O
data	O
,	O
and	O
comparison	O
with	O
known	O
assignments	O
of	O
several	O
monoterpenes	O
and	O
cyclohexane	O
systems	O
[	O
16–18	O
]	O
.	O

However	O
,	O
the	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
above	O
described	O
enriched	O
component	O
failed	O
to	O
show	O
signals	O
with	O
adequate	O
intensity	O
at	O
the	O
downfield	O
region	O
(	O
180	O
ppm	O
)	O
but	O
signals	O
above	O
120	O
ppm	O
were	O
clearly	O
discernible	O
with	O
unequal	O
intensity	O
,	O
consistent	O
with	O
the	O
enrichment	O
.	O

Based	O
on	O
the	O
cyclohexanol	O
system	O
,	O
chemical	O
shift	O
of	O
C-1	O
appears	O
to	O
be	O
most	O
sensitive	O
to	O
cis-	O
/trans-	O
isomerism	O
[	O
18	O
]	O
.	O

Thus	O
,	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
cis-	O
and	O
trans-	O
1,4-methyl	O
cyclohexanol	O
show	O
C-1	O
at	O
66.2	O
and	O
70.0	O
ppm	O
,	O
respectively	O
,	O
and	O
cis-	O
and	O
trans-	O
1,4-t	O
-	O
butylcyclohexanol	O
show	O
C-1	O
at	O
65.0	O
and	O
70.4	O
ppm	O
,	O
respectively	O
.	O

In	O
both	O
cases	O
C-1s	O
for	O
the	O
cis-	O
isomer	O
are	O
several	O
ppm	O
upfield	O
from	O
the	O
trans-	O
isomer	O
.	O

The	O
enriched	O
DHPA	O
isomer	O
showed	O
only	O
a	O
singlet	O
at	O
39.36	O
ppm	O
of	O
C-1	O
with	O
the	O
more	O
downfield	O
signal	O
missing	O
.	O

This	O
suggests	O
that	O
the	O
enriched	O
DHPA	O
isomer	O
may	O
be	O
the	O
cis-	O
isomer	O
.	O

This	O
possibility	O
was	O
further	O
supported	O
by	O
examination	O
of	O
the	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
synthetic	O
cis-	O
and	O
trans-	O
1-carboxyl-4-methylcyclohexanes	O
which	O
showed	O
C-1	O
chemical	O
shifts	O
at	O
31.32	O
and	O
34.21	O
ppm	O
,	O
respectively	O
.	O

Again	O
,	O
the	O
C-1	O
of	O
cis-	O
isomer	O
shows	O
nearly	O
3	O
ppm	O
upfield	O
from	O
that	O
of	O
the	O
trans-	O
isomer	O
.	O

In	O
order	O
to	O
correlate	O
the	O
GC	O
–	O
MS	O
retention	O
times	O
of	O
the	O
silyl	O
derivatives	O
of	O
these	O
cyclohexane	O
isomers	O
with	O
their	O
stereochemistry	O
,	O
cis-	O
and	O
trans-	O
1-carboxyl-4-methylcyclohexane	O
were	O
silylated	O
with	O
BSTFA	O
.	O

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
cis-	O
isomer	O
gave	O
a	O
retention	O
time	O
of	O
4.12	O
min	O
while	O
the	O
trans-	O
isomer	O
gave	O
a	O
retention	O
time	O
of	O
4.28	O
min	O
using	O
the	O
similar	O
temperature	O
programming	O
and	O
column	O
as	O
those	O
of	O
DHPA	O
.	O

On	O
this	O
basis	O
,	O
it	O
was	O
concluded	O
that	O
the	O
DHPA	O
isomer	O
with	O
the	O
shorter	O
retention	O
time	O
was	O
the	O
cis-	O
isomer	O
and	O
that	O
with	O
the	O
longer	O
retention	O
time	O
was	O
the	O
isomer	O
with	O
trans-	O
configuration	O
.	O

Interestingly	O
,	O
the	O
assignment	O
appeared	O
to	O
be	O
the	O
same	O
as	O
those	O
of	O
Philips	O
et	O
al.	O
[	O
11	O
]	O
,	O
based	O
on	O
the	O
relative	O
retention	O
times	O
of	O
the	O
underivatized	O
compounds	O
and	O
the	O
relative	O
amount	O
of	O
the	O
DHPA	O
found	O
as	O
metabolite	O
in	O
vivo	O
.	O

3.3	O
Within	O
-	O
run	O
validation	O
When	O
plotting	O
the	O
peak	O
area	O
ratios	O
between	O
the	O
analyte	O
and	O
the	O
internal	O
standard	O
against	O
the	O
added	O
concentrations	O
of	O
the	O
analytes	O
a	O
linear	O
relationship	O
was	O
obtained	O
within	O
the	O
concentration	O
ranges	O
monitored	O
for	O
all	O
analytes	O
.	O

In	O
both	O
human	O
and	O
rat	O
plasma	O
,	O
for	O
POH	O
linearity	O
was	O
demonstrated	O
from	O
2	O
to	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
and	O
trans-	O
DHPA	O
from	O
10	O
to	O
1000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	O
DHPA	O
20	O
to1000	O
ng	O
/	O
ml	O
.	O

The	O
routine	O
sensitivity	O
limit	O
was	O
found	O
to	O
be	O
2	O
ng	O
/	O
ml	O
for	O
POH	O
,	O
10	O
ng	O
/	O
ml	O
for	O
PA	O
and	O
trans-	O
DHPA	O
,	O
and	O
20	O
ng	O
/	O
ml	O
for	O
cis-	O
DHPA	O
.	O

The	O
within	O
-	O
run	O
validation	O
data	O
for	O
POH	O
and	O
metabolites	O
in	O
rat	O
and	O
human	O
plasma	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Also	O
shown	O
in	O
the	O
same	O
table	O
are	O
the	O
accuracy	O
data	O
.	O

As	O
shown	O
,	O
the	O
%	O
C.V.	O
values	O
ranged	O
from	O
0.5	O
to	O
8	O
%	O
with	O
the	O
majority	O
falling	O
below	O
5	O
%	O
and	O
a	O
mean	O
accuracy	O
value	O
of	O
98.6	O
%	O
.	O

3.4	O
Between	O
-	O
run	O
validation	O
The	O
between	O
-	O
run	O
variation	O
for	O
POH	O
in	O
human	O
plasma	O
was	O
5.5	O
%	O
and	O
6.3	O
%	O
in	O
rat	O
plasma	O
as	O
measured	O
by	O
the	O
slopes	O
of	O
six	O
calibration	O
curves	O
in	O
each	O
medium	O
at	O
six	O
different	O
occasions	O
(	O
Table	O
2	O
)	O
.	O

At	O
each	O
case	O
,	O
the	O
mean	O
intercept	O
is	O
less	O
than	O
2	O
ng	O
/	O
ml	O
equivalent	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
PA	O
by	O
similar	O
measurements	O
were	O
5.5	O
%	O
in	O
human	O
plasma	O
and	O
3.4	O
%	O
in	O
rat	O
plasma	O
,	O
all	O
n	O
=	O
6	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
cis-	O
DHPA	O
in	O
human	O
and	O
rat	O
plasma	O
were	O
6.9	O
%	O
and	O
5.1	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
trans-	O
DHPA	O
were	O
5.0	O
and	O
6.3	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
these	O
cases	O
,	O
the	O
mean	O
intercepts	O
for	O
the	O
calibration	O
curves	O
of	O
the	O
metabolites	O
were	O
less	O
than	O
5	O
ng	O
/	O
ml	O
analyte	O
equivalent	O
.	O

3.5	O
Recovery	O
and	O
quality	O
control	O
The	O
recovery	O
values	O
of	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
from	O
the	O
entire	O
procedure	O
were	O
:	O
98	O
%	O
,	O
59	O
%	O
,	O
64	O
%	O
and	O
72	O
%	O
in	O
human	O
plasma	O
and	O
90	O
%	O
,	O
77	O
%	O
,	O
69	O
%	O
and	O
76	O
%	O
in	O
rat	O
plasma	O
,	O
respectively	O
.	O

There	O
was	O
less	O
than	O
3	O
%	O
variation	O
for	O
POH	O
and	O
metabolite	O
levels	O
in	O
plasma	O
samples	O
kept	O
at	O
−20	O
°	O
C	O
over	O
the	O
course	O
of	O
four	O
weeks	O
and	O
there	O
was	O
no	O
appreciable	O
difference	O
in	O
the	O
samples	O
tested	O
through	O
mailing	O
via	O
the	O
courier	O
service	O
.	O

3.6	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
a	O
rat	O
Fig.	O
3	O
shows	O
a	O
plasma	O
concentration	O
–	O
time	O
profile	O
of	O
POH	O
and	O
metabolites	O
in	O
the	O
rat	O
given	O
POH	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

As	O
shown	O
,	O
POH	O
was	O
detected	O
in	O
circulation	O
up	O
to	O
360	O
min	O
with	O
the	O
initial	O
concentration	O
at	O
2089	O
ng	O
/	O
ml	O
.	O

The	O
concentrations	O
declined	O
biexponentially	O
with	O
a	O
terminal	O
half	O
-	O
life	O
of	O
approximately	O
135	O
min	O
.	O

PA	O
appeared	O
in	O
plasma	O
in	O
the	O
first	O
sample	O
at	O
3	O
min	O
and	O
peaked	O
at	O
10	O
at	O
8893	O
ng	O
/	O
ml	O
and	O
declined	O
approximately	O
monoexponentially	O
to	O
about	O
35	O
ng	O
/	O
ml	O
at	O
720	O
min	O
.	O

Cis	O
-	O
and	O
trans-	O
DHPA	O
appeared	O
in	O
plasma	O
at	O
about	O
10	O
min	O
and	O
peaked	O
at	O
about	O
60	O
min	O
and	O
also	O
declined	O
monoexponentially	O
.	O

The	O
plasma	O
levels	O
of	O
the	O
trans-	O
metabolite	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
cis-	O
isomer	O
.	O

An	O
unknown	O
metabolite	O
,	O
labeled	O
as	O
M2	O
,	O
was	O
also	O
detected	O
in	O
plasma	O
at	O
high	O
levels	O
and	O
this	O
metabolite	O
has	O
the	O
same	O
m	O
/	O
z	O
value	O
as	O
PA	O
but	O
with	O
a	O
retention	O
time	O
of	O
8.3	O
min	O
.	O

M2	O
appeared	O
in	O
plasma	O
at	O
3	O
min	O
at	O
2070	O
ng	O
/	O
ml	O
PA	O
equivalent	O
and	O
peaked	O
at	O
10	O
min	O
at	O
levels	O
over	O
6000	O
ng	O
/	O
ml	O
.	O

Although	O
the	O
initial	O
levels	O
of	O
this	O
metabolite	O
were	O
slightly	O
lower	O
than	O
those	O
of	O
PA	O
,	O
the	O
levels	O
after	O
2	O
h	O
exceeded	O
those	O
of	O
PA	O
after	O
and	O
were	O
detectable	O
even	O
at	O
1440	O
min	O
.	O

The	O
plasma	O
half	O
-	O
life	O
was	O
approximately	O
3	O
h.	O
3.7	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
a	O
patient	O
The	O
plasma	O
concentration	O
–	O
time	O
profiles	O
of	O
POH	O
and	O
its	O
metabolites	O
were	O
measured	O
in	O
a	O
patient	O
who	O
received	O
a	O
p.o	O
.	O

dose	O
at	O
500	O
mg	O
/	O
m2	O
and	O
the	O
results	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

As	O
shown	O
,	O
POH	O
,	O
PA	O
,	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
all	O
detectable	O
in	O
plasma	O
.	O

POH	O
was	O
detectable	O
at	O
3.5	O
ng	O
/	O
ml	O
at	O
0.75	O
h	O
and	O
peaked	O
at	O
5.0	O
ng	O
/	O
ml	O
at	O
1.5	O
h.	O
The	O
levels	O
then	O
declined	O
monoexponentially	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2.3	O
h.	O
The	O
AUC	O
value	O
was	O
22	O
ng	O
/	O
ml	O
h.	O
The	O
most	O
abundant	O
metabolite	O
in	O
circulation	O
was	O
PA	O
which	O
peaked	O
slowly	O
at	O
11400	O
ng	O
/	O
ml	O
at	O
about	O
1.5	O
h.	O
PA	O
was	O
formed	O
rapidly	O
following	O
the	O
POH	O
administration	O
,	O
and	O
remained	O
at	O
a	O
steady	O
-	O
state	O
for	O
1–2	O
h	O
before	O
declining	O
.	O

The	O
level	O
then	O
declined	O
monoexponentially	O
to	O
about	O
40	O
ng	O
/	O
ml	O
at	O
8	O
h	O
and	O
became	O
undetectable	O
thereafter	O
.	O

Similar	O
to	O
the	O
case	O
in	O
the	O
rat	O
,	O
cis-	O
DHPA	O
levels	O
were	O
lower	O
than	O
those	O
of	O
trans	O
.	O

Two	O
previously	O
undescribed	O
metabolites	O
were	O
detected	O
in	O
circulation	O
.	O

M1	O
gave	O
a	O
retention	O
time	O
of	O
7.7	O
min	O
and	O
M2	O
gave	O
a	O
retention	O
of	O
8.3	O
min	O
,	O
which	O
appears	O
identical	O
to	O
the	O
one	O
described	O
in	O
the	O
rat	O
.	O

Both	O
of	O
these	O
metabolites	O
gave	O
the	O
MH+	O
ion	O
identical	O
to	O
that	O
of	O
PA	O
.	O

Levels	O
of	O
M2	O
were	O
lower	O
than	O
those	O
of	O
PA	O
but	O
higher	O
than	O
those	O
of	O
M1	O
.	O

M2	O
peaked	O
at	O
over	O
1000	O
ng	O
/	O
ml	O
at	O
3	O
h	O
,	O
and	O
M1	O
peaked	O
at	O
76	O
ng	O
/	O
ml	O
at	O
1	O
h.	O
4	O
Discussion	O
Previous	O
GC	O
and	O
GC	O
–	O
MS	O
methods	O
failed	O
to	O
detect	O
POH	O
in	O
plasma	O
presumably	O
because	O
of	O
inadequate	O
sensitivity	O
[	O
11	O
]	O
.	O

The	O
reason	O
for	O
the	O
low	O
sensitivity	O
may	O
be	O
due	O
to	O
the	O
use	O
of	O
electron	O
impact	O
mass	O
spectrometry	O
for	O
detection	O
.	O

Excess	O
fragmentation	O
under	O
the	O
EI	O
condition	O
significantly	O
reduced	O
the	O
assay	O
sensitivity	O
.	O

Moreover	O
,	O
POH	O
and	O
its	O
metabolites	O
such	O
as	O
PA	O
are	O
still	O
rather	O
polar	O
.	O

Tailing	O
of	O
their	O
GC	O
peaks	O
may	O
also	O
reduce	O
the	O
assay	O
sensitivity	O
.	O

The	O
present	O
method	O
used	O
a	O
soft	O
ammonia	O
chemical	O
ionization	O
,	O
which	O
could	O
reduce	O
fragmentation	O
and	O
increase	O
the	O
relative	O
abundance	O
of	O
the	O
ion	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
BSTFA	O
derivatization	O
of	O
POH	O
and	O
its	O
metabolites	O
reduced	O
tailing	O
and	O
further	O
reduced	O
fragmentation	O
and	O
enhanced	O
sensitivity	O
.	O

Another	O
improvement	O
of	O
our	O
analytical	O
method	O
was	O
to	O
use	O
the	O
stable	O
isotopically	O
labeled	O
POH	O
and	O
PA	O
as	O
the	O
internal	O
standard	O
that	O
provided	O
the	O
excellent	O
C.V.s	O
obtained	O
.	O

Thus	O
,	O
the	O
current	O
assay	O
provided	O
more	O
than	O
a	O
hundred	O
-	O
fold	O
improvement	O
in	O
sensitivity	O
over	O
the	O
previous	O
GC	O
–	O
MS	O
method	O
,	O
and	O
made	O
it	O
possible	O
to	O
detect	O
circulating	O
POH	O
following	O
POH	O
administration	O
.	O

The	O
use	O
of	O
derivatization	O
and	O
a	O
capillary	O
column	O
in	O
this	O
method	O
also	O
permitted	O
the	O
complete	O
separation	O
of	O
cis-	O
and	O
trans-	O
DHPA	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
earlier	O
eluting	O
peak	O
(	O
6.3	O
min	O
)	O
was	O
assigned	O
to	O
be	O
the	O
cis-	O
isomer	O
,	O
based	O
on	O
the	O
NMR	O
method	O
and	O
this	O
assignment	O
is	O
identical	O
to	O
those	O
of	O
Philip	O
et	O
al.	O
[	O
11	O
]	O
who	O
assigned	O
their	O
earlier	O
eluting	O
component	O
in	O
the	O
partially	O
resolved	O
pair	O
as	O
the	O
cis-	O
isomer	O
.	O

Both	O
the	O
preliminary	O
rat	O
and	O
human	O
pharmacokinetic	O
data	O
show	O
that	O
POH	O
was	O
detectable	O
in	O
circulation	O
for	O
the	O
first	O
time	O
following	O
POH	O
administration	O
.	O

Metabolites	O
of	O
POH	O
were	O
detected	O
in	O
high	O
levels	O
in	O
both	O
rat	O
and	O
human	O
plasma	O
.	O

PA	O
appeared	O
very	O
rapidly	O
in	O
circulation	O
and	O
rose	O
to	O
high	O
concentrations	O
,	O
suggesting	O
that	O
POH	O
underwent	O
rapid	O
metabolism	O
.	O

Both	O
cis-	O
and	O
trans-	O
DHPA	O
were	O
unequivocally	O
detected	O
in	O
the	O
human	O
and	O
in	O
the	O
rat	O
and	O
their	O
formation	O
as	O
a	O
mixture	O
was	O
previously	O
under	O
debate	O
[	O
11	O
]	O
.	O

Two	O
previously	O
undescribed	O
metabolites	O
were	O
detected	O
in	O
significant	O
levels	O
in	O
human	O
plasma	O
and	O
one	O
also	O
in	O
the	O
rat	O
.	O

These	O
two	O
metabolites	O
as	O
their	O
silylated	O
derivatives	O
gave	O
the	O
parent	O
ion	O
(	O
MH+	O
)	O
at	O
m	O
/	O
z	O
239	O
identical	O
to	O
that	O
of	O
silylated	O
PA	O
but	O
with	O
different	O
retention	O
times	O
.	O

Characterization	O
of	O
these	O
metabolites	O
is	O
currently	O
underway	O
.	O

Thus	O
,	O
the	O
current	O
method	O
is	O
useful	O
to	O
support	O
preclinical	O
and	O
clinical	O
investigations	O
of	O
disposition	O
of	O
perillyl	O
alcohol	O
.	O

5	O
Conclusion	O
A	O
GC	O
–	O
MS	O
stable	O
isotope	O
-	O
dilution	O
method	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
perillyl	O
alcohol	O
and	O
its	O
metabolites	O
in	O
human	O
and	O
animal	O
plasma	O
and	O
the	O
method	O
has	O
been	O
validated	O
.	O

Unchanged	O
perillyl	O
alcohol	O
in	O
plasma	O
was	O
detected	O
in	O
human	O
and	O
animal	O
circulation	O
for	O
the	O
first	O
time	O
.	O

Isomers	O
of	O
a	O
reduced	O
metabolite	O
DHPA	O
have	O
been	O
total	O
resolved	O
and	O
detected	O
and	O
their	O
previous	O
cis-	O
and	O
trans-	O
assignments	O
verified	O
by	O
alternate	O
techniques	O
.	O

Two	O
new	O
metabolites	O
were	O
also	O
detected	O
.	O

This	O
GC	O
–	O
MS	O
can	O
be	O
applied	O
to	O
investigate	O
preclinical	O
and	O
clinical	O
pharmacokinetics	O
of	O
perillyl	O
alcohol	O
both	O
as	O
a	O
chemopreventative	O
and	O
chemotherapeutical	O
agent	O
.	O

Acknowledgments	O
This	O
study	O
was	O
in	O
part	O
supported	O
by	O
PHS	O
Contract	O
NCI	O
-	O
CN-55083070	O
,	O
Task	O
22	O
,	O
awarded	O
to	O
the	O
Cleveland	O
Clinic	O
Foundation	O
subcontracted	O
to	O
the	O
Ohio	O
State	O
University	O
and	O
by	O
P30	O
CA16058	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Eosinophils	O
may	O
play	O
important	O
roles	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
and	O
atopic	O
dermatitis	O
)	O
'	O
2	O
In	O
such	O
diseases	O
,	O
eosinophiis	O
migrate	O
to	O
inflammatory	O
sites	O
and	O
degranulate	O
eytotoxic	O
proteins	B
such	O
as	O
major	O
basic	O
protein	B
and	O
eosinophil	B
-	I
derived	I
neurotoxin	I
(	O
EDN	B
)	O
.	O

The	O
cytotoxic	O
proteins	B
damage	O
tissues	O
and	O
cause	O
physiologic	O
abnormalities	O
in	O
patients	O
with	O
allergic	O
diseases	O
.	O

Therefore	O
,	O
cosinophil	O
degranulation	O
inhibitors	O
may	O
be	O
anti	O
-	O
allergic	O
drugs	O
.	O

Recently	O
,	O
we	O
found	O
that	O
sulochrin	O
(	O
6	O
)	O
,	O
a	O
metabolite	O
of	O
fungi	O
,	O
was	O
a	O
specific	O
inhibitor	O
of	O
eosinophil	O
degranulation3	O
and	O
also	O
inhibited	O
eosinophll	O
activation	O
and	O
chemotaxis	O
.	O

*	O
We	O
report	O
here	O
the	O
effects	O
of	O
ortho-	O
substituent	O
groups	O
on	O
inhibitory	O
activity	O
to	O
eosinophil	O
degranulation	O
.	O

Chemistry	O
Sulochrin	O
(	O
6	O
)	O
was	O
synthesized	O
as	O
shown	O
in	O
scheme	O
1	O
.	O

Benzoic	O
acid	O
benzyl	O
ester	O
(	O
5	O
)	O
was	O
obtained	O
by	O
the	O
condensation	O
of	O
2-bromo	O
benzyl	O
alcohol	O
(	O
2	O
)	O
and	O
benzoic	O
acid	O
(	O
4	O
)	O
.	O

Anion	O
induced	O
rearrangement	O
of	O
(	O
5	O
)	O
gave	O
1-	O
benzoyl	O
benzyl	O
alcohol	O
,	O
which	O
was	O
oxidized	O
to	O
benzoyl	O
benzoic	O
acid	O
without	O
isolation.5	O
'	O
6	O
Esterification	O
of	O
the	O
benzoyl	O
benzoic	O
acid	O
followed	O
by	O
debenzylatinn	O
afforded	O
sulochrin	O
(	O
6	O
)	O
.7	O
All	O
other	O
sulochrin	O
derivatives	O
except	O
for	O
(	O
9	O
)	O
were	O
obtained	O
through	O
a	O
modified	O
methodology	O
.	O

Compound	O
9	O
was	O
prepared	O
as	O
shown	O
in	O
scheme	O
2	O
.	O

Results	O
and	O
Discussion	O
The	O
derivatives	O
of	O
sulochrin	O
(	O
6	O
)	O
were	O
examined	O
for	O
their	O
"inba""oitory"	O
activity	O
against	O
eosinophil	O
degranulation	O
as	O
descn'bed	O
previously.3	O
At	O
first	O
,	O
ester	O
derivatives	O
were	O
synthesized	O
to	O
examine	O
the	O
structure	O
-	O
activity	O
relationship	O
.	O

As	O
shown	O
in	O
Table	O
la	O
,	O
alkyl	O
esters	O
(	O
11	O
-	O
15	O
)	O
retained	O
activity	O
,	O
and	O
in	O
particular	O
,	O
n	O
-	O
butyl	O
and	O
see	O
-	O
butyl	O
esters	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

Pll	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00305	O
-	O
4	O
1946	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O

Scheme	O
I	O
OH	O
OBn	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
Br	O
Me	O
""""	O
<	O
~	O
OH	O
Me	O
""""	O
""""	O
~	O
OBn	O
COOMe	O
""""	O
~OH	O
e	O
,	O
f	O
1	O
2	O
3	O
4	O
O	O
OBn	O
7	O
~	O
-~	O
OMe	O
QH13	O
!	O

r	O
2	O
+	O
4	O
P	O
5~	O
15	O
T	O
""""	O
Br	O
BnO	O
""""	O
-	O
..	O

:	O
I	O
""""	O
Me	O
h	O
,	O
i	O
,	O
j	O
,	O
k	O
,	O
I	O
I	O
""""	O
~1	O
-	O
1	O
""""	O
g	O
OMe	O
MeOOC	O
O	O
OH	O
9	O
8	O
5	O
6	O
(	O
Sulochrln	O
)	O
(	O
a	O
)	O
BnBr	O
,	O
K	O
~	O
O~	O
/	O
CH3CN	O
/	O
reflux,33	O
%	O
;	O
(	O
b	O
)	O
Me	O
zSO4,K	O
~	O
CO3	O
/	O
CHaCN	O
/	O
reflux,96	O
%	O
;	O
(	O
c	O
)	O
UAIH4	O
/	O
I'HF,96	O
%	O
;	O
(	O
d	O
)	O
NBS	O
/	O
CCI4,43	O
%	O
;	O
(	O
e	O
)	O
BnBr	O
,	O
l	O
~	O
COa	O
/	O
DMF	O
/	O
reflux,74	O
%	O
;	O
(	O
f	O
)	O
t	O
-	O
BuOWiPr	O
=	O
O	O
/	O
reflux,93	O
%	O
;	O
(	O
g	O
)	O
DEAD	O
/	O
PPh	O
.	O

VrHF,82	O
%	O
;	O
(	O
h	O
)	O
n	O
-	O
BuLi	O
/	O
"1""HF,-78""C,45"	O
%	O
;	O
(	O
i	O
)	O
PDC	O
/	O
DMF,54	O
%	O
;	O
(	O
j	O
)	O
BudNH4	O
)	O
KMnO,~=yddlne,81	O
%	O
;	O
(	O
k	O
)	O
Mel	O
K2CO	O
~	O
JDMF	O
;	O
(	O
I	O
)	O
Pd	O
(	O
OH	O
)	O
rCarbon	O
/	O
EtOH	O
/	O
Cyclohexene	O
/	O
refiux	O
81	O
%	O
Scheme	O
2	O
Me	O
~	O
OMe	O
o~	O
OMe	O
OH	O
MeO	O
~	O
OMe	O
~	O
MeO'~OMe	O
.	O

HO	O
~	O
Me	O
""""	O
COOH	O
m	O
""""	O
~	O
""""	O
COCI	O
n	O
,	O
p	O
7	O
8	O
O	O
OH	O
(	O
m	O
)	O
SOCle	O
;	O
(	O
n	O
)	O
n	O
-	O
BuLi	O
/	O
THF	O
,	O
-4YC,15	O
%	O
;	O
(	O
P	O
)	O
BBrdCH	O
=	O
Cle,64	O
%	O
(	O
13	O
and	O
14	O
)	O
showed	O
more	O
potent	O
activity	O
than	O
sulochrin	O
(	O
6	O
)	O
.	O

On	O
thc	O
other	O
hand	O
,	O
decarboxyl	O
and	O
flee	O
carboxylic	O
acid	O
derivatives	O
(	O
9	O
and	O
10	O
)	O
did	O
not	O
show	O
any	O
activity	O
even	O
at	O
10	O
pM.	O
These	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
1947	O
Table	O
la	O
Effects	O
of	O
alkylester	O
on	O
eoslnophll	O
degranulation	O
OMe	O
OH	O
R1	O
O	O
OH	O
Compound	O
R	O
,	O
ICso	O
(	O
mlcroM	O
)	O
Sulochrin	O
(	O
6	O
)	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
COOCHa	O
H	O
COOH	O
COOCH2CHa	O
COOCH	O
=	O
CH	O
=	O
CHa	O
COOCH	O
=	O
CH2CH	O
=	O
CHa	O
COO	O
(	O
CH	O
)	O
CHaCH	O
=	O
CHa	O
COO	O
(	O
CH=	O
)	O
sCH.~	O
0.1	O
>	O
10	O
>	O
10	O
0.1	O
0.1	O
0.04	O
0.03	O
0.3	O
Table	O
lb	O
Effects	O
of	O
phenolic	O
hydroxyl	O
groups	O
on	O
eoslnophil	O
degranulation	O
Sulochdn	O
(	O
6	O
)	O
HO-,~zFtz	O
12~	O
16	O
17	O
MeOOC	O
O	O
OR	O
,	O
19	O
2O	O
Compound	O
R2	O
FL~	O
P~	O
ICs0	O
(	O
microM	O
)	O
H	O
Me	O
H	O
Me	O
H	O
H	O
Me	O
H	O
Me	O
Me	O
Me	O
H	O
(	O
CH2	O
)	O
2OH	O
H	O
H	O
Me	O
H	O
(	O
CH=	O
)	O
=OH	O
0.1	O
0.4	O
0.3	O
>	O
10	O
>	O
10	O
>	O
10	O
alkyl	O
ester	O
at	O
C-6	O
position	O
is	O
essential	O
and	O
see	O
-	O
butyl	O
ester	O
is	O
most	O
suitable	O
for	O
activity	O
.	O

Next	O
,	O
we	O
examined	O
the	O
importance	O
of	O
methoxy	O
and	O
hydroxyl	O
groups	O
at	O
C-2	O
,	O
C-12	O
and	O
C-16	O
positions	O
(	O
Table	O
lb	O
)	O
.	O

Compared	O
to	O
sulochrin	O
(	O
6	O
)	O
,	O
19	O
showed	O
much	O
less	O
activity	O
.	O

Activity	O
of	O
16	O
approached	O
that	O
of	O
sulochrin	O
(	O
6	O
)	O
after	O
methylation	O
of	O
hydroxyl	O
group	O
at	O
C-12	O
position	O
in	O
19	O
.	O

Furthermore	O
,	O
compound	O
17	O
also	O
showed	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
methoxy	O
group	O
at	O
C-2	O
or	O
(	O
2	O
-	O
12	O
position	O
is	O
required	O
for	O
activity	O
.	O

Compound	O
18	O
,	O
in	O
which	O
two	O
methoxy	O
groups	O
at	O
C-12	O
and	O
(	O
2	O
-	O
16	O
positions	O
on	O
the	O
ring	O
B	O
were	O
introduced	O
,	O
showed	O
much	O
less	O
activity	O
than	O
16	O
or	O
17	O
.	O

Furthermore	O
,	O
compound	O
20	O
also	O
lost	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
free	O
hydroxyl	O
group	O
at	O
ortho	O
-	O
position	O
on	O
the	O
ring	O
B	O
is	O
required	O
for	O
activity	O
,	O
suggesting	O
that	O
hydrogen	O
bond	O
between	O
16-OH	O
and	O
carbunyl	O
at	O
(	O
2	O
-	O
10	O
might	O
contn'bute	O
to	O
activity	O
.	O

We	O
have	O
recently	O
shown	O
that	O
substituents	O
at	O
ortho	O
-	O
positions	O
showed	O
effect	O
on	O
the	O
conformation	O
from	O
the	O
analysis	O
of	O
crystal	O
structures	O
of	O
suiochrin	O
derivatives	O
,	O
a	O
The	O
hydrogen	O
bond	O
between	O
16-OH	O
and	O
earbonyl	O
at	O
C-10	O
may	O
contribute	O
to	O
the	O
conformation	O
where	O
the	O
ring	O
B	O
and	O
the	O
central	O
carbunyl	O
planes	O
are	O
co	O
-	O
planner	O
and	O
cross	O
at	O
a	O
right	O
angle	O
to	O
the	O
1948	O
1	O
t	O
.	O

Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
ring	O
A.	O
This	O
conformation	O
would	O
be	O
inaccess	O
~	O
le	O
to	O
the	O
less	O
active	O
compounds	O
that	O
lack	O
the	O
hydrogen	O
bond	O
,	O
supporting	O
the	O
speculation	O
.	O

Compounds	O
10	O
and	O
19	O
,	O
which	O
have	O
more	O
hydrophilic	O
substitution	O
at	O
ortho	O
-	O
positions	O
,	O
lost	O
activity	O
.	O

Therefore	O
,	O
hydrophobicity	O
is	O
also	O
important	O
for	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
that	O
i	O
)	O
alkylester	O
at	O
C-6	O
position	O
is	O
required	O
;	O
ii	O
)	O
see	O
-	O
butyl	O
ester	O
at	O
C-6	O
position	O
is	O
optimal	O
for	O
activity	O
;	O
ill	O
)	O
optimal	O
hydrophobicity	O
of	O
the	O
ortho	O
-	O
substituents	O
may	O
exist	O
;	O
and	O
iv	O
)	O
the	O
conformation	O
of	O
sulochrin	O
may	O
influence	O
to	O
the	O
inlu'bitory	O
activity	O
against	O
eosinophil	O
degranulation	O
.	O

Acknowledgements	O

We	O
thank	O
to	O
Dr.	O
Masakazu	O
Sakalo'bara	O
for	O
critical	O
reading	O
of	O
this	O
manuscript	O
.	O

An	O
accurate	O
estimation	O
of	O
the	O
onset	O
of	O
oestrus	O
in	O
cows	O
is	O
vital	O
to	O
the	O
cost	O
-	O
efficient	O
application	O
of	O
artificial	O
insemination	O
(	O
AI	O
)	O
procedures	O
(	O
Ball	O
,	O
1982	O
)	O
.	O

The	O
steroid	O
hormone	O
progesterone	O
,	O
which	O
is	O
secreted	O
by	O
the	O
corpus	O
luteum	O
,	O
functions	O
to	O
prepare	O
the	O
uterus	O
for	O
pregnancy	O
and	O
to	O
maintain	O
pregnancy	O
following	O
conception	O
.	O

Fluctuations	O
in	O
the	O
level	O
of	O
secreted	O
progesterone	O
are	O
reflected	O
throughout	O
the	O
oestrus	O
cycle	O
by	O
the	O
concentration	O
of	O
the	O
hormone	O
present	O
in	O
cows	O
'	O
milk	O
.	O

It	O
follows	O
that	O
by	O
monitoring	O
milk	O
progesterone	O
concentration	O
it	O
has	O
been	O
possible	O
accurately	O
to	O
predict	O
the	O
onset	O
of	O
oestrus	O
;	O
using	O
enzyme	O
immunoassay	O
methodology	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982a	O
)	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
optimum	O
fertility	O
rates	O
can	O
be	O
achieved	O
when	O
AI	O
is	O
performed	O
on	O
the	O
third	O
day	O
of	O
sustained	O
low	O
milk	O
progesterone	O
concentration	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982b	O
;	O
Foulkes	O
and	O
Goodey	O
,	O
1988	O
)	O
.	O

The	O
search	O
for	O
a	O
rapid	O
,	O
convenient	O
and	O
inexpensive	O
means	O
of	O
frequently	O
monitoring	O
milk	O
progesterone	O
levels	O
in	O
a	O
herd	O
of	O
animals	O
has	O
led	O
into	O
research	O
toward	O
a	O
user	O
-	O
friendly	O
on	O
-	O
the	O
-	O
farm	O
device	O
.	O

One	O
such	O
approach	O
is	O
a	O
disposable	O
screen	O
-	O
printed	O
amperometric	O
biosensor	O
.	O

Previously	O
,	O
we	O
described	O
the	O
development	O
of	O
a	O
prototype	O
progesterone	O
biosensor	O
comprising	O
mAb	B
immobilised	O
on	O
the	O
working	O
surface	O
of	O
a	O
screen	O
-	O
printed	O
carbon	O
electrode	O
(	O
SPCE	O
)	O
.	O

It	O
operated	O
in	O
a	O
competitive	O
immunoassay	O
format	O
,	O
relying	O
upon	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
enzyme	O
-	O
labelled	O
progesterone	O
in	O
the	O
presence	O
of	O
endogenous	O
milk	O
progesterone	O
.	O

Initial	O
proof	O
-	O
of	O
-	O
principle	O
was	O
provided	O
from	O
experiments	O
conducted	O
in	O
aqueous	O
buffer	O
solution	O
using	O
phenyl	O
phosphate	O
as	O
substrate	O
for	O
the	O
enzyme	B
alkaline	B
phosphatase	I
,	O
with	O
a	O
chronoamperometric	O
readout	O
dependent	O
on	O
the	O
oxidation	O
of	O
phenol	O
at	O
a	O
potential	O
of	O
+	O
700	O
mV	O
versus	O
SCE	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Operating	O
at	O
this	O
relatively	O
high	O
electrode	O
potential	O
,	O
however	O
,	O
it	O
was	O
not	O
possible	O
to	O
obtain	O
a	O
calibration	O
in	O
milk	O
,	O
due	O
to	O
variable	O
adsorption	O
,	O
at	O
the	O
electrode	O
surface	O
,	O
of	O
electroactive	O
species	O
present	O
within	O
this	O
complex	O
matrix	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
;	O
even	O
washing	O
with	O
solvents	O
of	O
varying	O
polarity	O
did	O
not	O
remove	O
the	O
interferent	O
.	O

For	O
this	O
reason	O
,	O
it	O
is	O
desirable	O
to	O
reduce	O
the	O
operating	O
potential	O
to	O
below	O
that	O
required	O
to	O
oxidise	O
the	O
interferent	O
.	O

In	O
order	O
to	O
achieve	O
this	O
objective	O
,	O
two	O
potentially	O
useful	O
enzyme	B
substrates	O
,	O
1-naphthyl	O
phosphate	O
(	O
1-NP	O
)	O
and	O
4-aminophenyl	O
phosphate	O
(	O
4-APP	O
)	O
,	O
may	O
be	O
considered	O
.	O

These	O
are	O
hydrolysed	O
to	O
their	O
corresponding	O
phenols	O
,	O
1-naphthol	O
and	O
4-aminophenol	O
,	O
on	O
reaction	O
with	O
alkaline	O
phosphatase	O
.	O

Both	O
4-APP	O
(	O
Tang	O
et	O
al.	O
,	O
1988	O
;	O
Pemberton	O
et	O
al.	O
,	O
1998	O
;	O
Schreiber	O
et	O
al.	O
,	O
1997	O
)	O
and	O
1-NP	O
(	O
Athey	O
et	O
al.	O
,	O
1993	O
;	O
Fernandez	O
-	O
Sanchez	O
and	O
Costa	O
-	O
Garcia	O
,	O
1997	O
)	O
have	O
been	O
investigated	O
previously	O
in	O
immunoassay	O
systems	O
,	O
but	O
no	O
detailed	O
comparative	O
studies	O
of	O
their	O
performance	O
have	O
been	O
reported	O
at	O
SPCEs	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
electrochemical	O
behaviour	O
of	O
1-naphthol	O
and	O
4-aminophenol	O
at	O
bare	O
and	O
antibody	B
-	O
coated	O
SPCEs	O
and	O
to	O
determine	O
which	O
phenol	O
would	O
be	O
the	O
more	O
compatible	O
with	O
biosensor	O
operation	O
.	O

Their	O
phosphorylated	O
derivatives	O
were	O
then	O
evaluated	O
as	O
substrates	O
for	O
use	O
with	O
a	O
milk	O
progesterone	O
immunosensor	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
these	O
studies	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
reagents	O
Chemicals	O
used	O
were	O
of	O
AR	O
-	O
grade	O
and	O
were	O
purchased	O
from	O
Merck	O
(	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
.	O

Water	O
for	O
the	O
preparation	O
of	O
buffer	O
solutions	O
was	O
drawn	O
from	O
a	O
Milli	O
-	O
Q	O
Water	O
Purification	O
System	O
(	O
Millipore	O
UK	O
,	O
Watford	O
,	O
UK	O
)	O
.	O

Carbonate	O
coating	O
buffer	O
(	O
CB	O
)	O
comprised	O
0.015	O
mol	O
/	O
dm	O
Na2	O
CO3	O
and	O
0.035	O
mol	O
/	O
dm3	O
NaHCO3	O
at	O
a	O
pH	O
of	O
9.6	O
.	O

Diethanolamine	O
-	O
HCl	O
buffer	O
(	O
DB	O
;	O
0.1	O
mol	O
/	O
dm3	O
)	O
was	O
adjusted	O
to	O
a	O
final	O
pH	O
of	O
7.2	O
or	O
9.8	O
.	O

MgCl2	O
at	O
a	O
concentration	O
of	O
0.01	O
mol	O
/	O
dm3	O
was	O
included	O
in	O
pH9.8	O
DB	O
as	O
a	O
cofactor	O
for	O
alkaline	B
phosphatase	I
.	O

Before	O
final	O
dilution	O
in	O
DB	O
,	O
4-aminophenol	O
(	O
Sigma	O
-	O
Aldrich	O
Company	O
,	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
0.1	O
mol	O
/	O
dm3	O
NaOH	O
;	O
1-naphthol	O
(	O
Acros	O
Organics	O
,	O
Loughborough	O
,	O
Leics	O
,	O
UK	O
)	O
was	O
dissolved	O
directly	O
in	O
DB	O
.	O

A	O
polyclonal	O
rabbit	O
antibody	B
(	O
IgG	O
fraction	O
)	O
against	O
sheep	O
IgG	B
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
rIg	O
)	O
.	O

Sheep	O
monoclonal	B
antibody	I
(	O
mAb	B
)	O
against	O
progesterone	O
(	O
Groves	O
et	O
al.	O
,	O
1990	O
)	O
was	O
kindly	O
provided	O
by	O
Ridgeway	O
Science	O
Ltd.	O
in	O
the	O
form	O
of	O
culture	O
supernatant	O
.	O

A	O
solution	O
containing	O
alkaline	B
-	I
phosphatase	I
-	B
labelled	I
progesterone	I
(	O
AP	B
-	I
prog	I
)	O
was	O
obtained	O
from	O
the	O
same	O
source	O
.	O

Unlabelled	O
progesterone	O
(	O
f.wt.=314.5	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

4-APP	O
(	O
monosodium	O
salt	O
)	O
and	O
1-NP	O
were	O
purchased	O
from	O
ICN	O
Biomedicals	O
Ltd.	O
,	O
Thame	O
,	O
Oxon	O
,	O
UK	O
and	O
Acros	O
Organics	O
,	O
respectively	O
.	O

Whole	O
milk	O
test	O
samples	O
from	O
six	O
different	O
Fresian	O
Holstein	O
dairy	O
cows	O
at	O
various	O
stages	O
of	O
their	O
oestrus	O
cycles	O
were	O
obtained	O
from	O
Ridgeway	O
Science	O
Ltd.	O
These	O
samples	O
were	O
collected	O
following	O
agitation	O
of	O
the	O
complete	O
milking	O
jar	O
after	O
morning	O
milking	O
of	O
cows	O
.	O

One	O
Lactab	O
MkIII	O
tablet	O
(	O
Thompson	O
and	O
Capper	O
Ltd.	O
,	O
Runcorn	O
,	O
Cheshire	O
,	O
UK	O
)	O
containing	O
30	O
mg	O
potassium	O
dichromate	O
was	O
added	O
to	O
every	O
25	O
ml	O
milk	O
as	O
a	O
preservative	O
.	O

Samples	O
were	O
then	O
stored	O
at	O
4	O
°	O
C	O
where	O
they	O
were	O
stable	O
for	O
up	O
to	O
3	O
months	O
.	O

In	O
the	O
present	O
study	O
,	O
assays	O
were	O
performed	O
after	O
21	O
days	O
of	O
storage	O
.	O

Standards	O
containing	O
known	O
concentrations	O
of	O
progesterone	O
were	O
prepared	O
by	O
dissolving	O
progesterone	O
in	O
methanol	O
at	O
1	O
mg	O
/	O
ml	O
,	O
aliquoting	O
a	O
known	O
volume	O
into	O
a	O
glass	O
tube	O
and	O
evaporating	O
the	O
methanol	O
under	O
N2	O
before	O
adding	O
to	O
whole	O
milk	O
(	O
sampled	O
and	O
preserved	O
as	O
above	O
)	O
from	O
an	O
oestrus	O
cow	O
(	O
containing	O
<	O
1	O
ng	O
/	O
ml	O
progesterone	O
)	O
.	O

Serial	O
dilutions	O
were	O
then	O
performed	O
in	O
the	O
same	O
milk	O
over	O
the	O
desired	O
concentration	O
range	O
.	O

2.2	O
Biosensor	O
preparation	O
Carbon	O
electrodes	O
(	O
3	O
×	O
3	O
mm	O
working	O
area	O
)	O
were	O
screen	O
-	O
printed	O
using	O
code	O
D14	O
ink	O
formulation	O
onto	O
PVC	O
backing	O
card	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
Mamhilad	O
,	O
Gwent	O
,	O
UK	O
)	O
as	O
described	O
elsewhere	O
(	O
Sprules	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Individual	O
screen	O
-	O
printed	O
electrodes	O
(	O
SPCEs	O
)	O
were	O
coated	O
with	O
rIg	O
(	O
to	O
capture	O
and	O
orientate	O
the	O
mAb	B
)	O
and	O
mAb	B
as	O
described	O
previously	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

For	O
these	O
studies	O
,	O
a	O
1	O
/	O
20	O
dilution	O
of	O
mAb	B
was	O
applied	O
to	O
the	O
electrodes	O
,	O
being	O
chosen	O
empirically	O
as	O
the	O
highest	O
dilution	O
giving	O
an	O
optimum	O
sigmoidal	O
calibration	O
plot	O
for	O
progesterone	O
measured	O
colorimetrically	O
(	O
see	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

These	O
are	O
referred	O
to	O
as	O
mAb	B
-	O
SPCEs	O
.	O

2.3	O
Instrumentation	O
Electrochemical	O
procedures	O
were	O
carried	O
out	O
using	O
an	O
E612	O
VA	O
Scanner	O
and	O
an	O
E611	O
VA	O
Detector	O
(	O
Metrohm	O
,	O
Herisau	O
,	O
Switzerland	O
)	O
attached	O
to	O
a	O
Linseis	O
LY18100	O
x	O
–y	O
plotter	O
(	O
Recorder	O
Laboratory	O
Services	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK	O
)	O
.	O

A	O
Viglen	O
486	O
Sx	O
computer	O
was	O
used	O
for	O
simulation	O
of	O
cyclic	O
voltammograms	O
using	O
the	O
simulation	O
program	O
CVSIM	O
(	O
Gosser	O
,	O
1993	O
)	O
.	O

The	O
simple	O
'	O
E	O
r	O
'	O
,	O
mechanism	O
for	O
a	O
one	O
-	O
electron	O
oxidation	O
of	O
a	O
solution	O
species	O
at	O
the	O
working	O
electrode	O
was	O
used	O
to	O
estimate	O
values	O
for	O
k	O
het	O
from	O
simulations	O
of	O
the	O
oxidation	O
of	O
4-aminophenol	O
at	O
bare	O
and	O
mAb	B
-	O
coated	O
SPCEs	O
.	O

Common	O
electroactive	O
species	O
parameters	O
were	O
:	O
C	O
red	O
=	O
1	O
mM	O
,	O
C	O
ox	O
=	O
0.0	O
mM	O
,	O
D	O
=	O
5	O
×	O
10−6	O
cm2	O
/s	O
;	O
and	O
common	O
experimental	O
settings	O
were	O
:	O
number	O
of	O
half	O
cycles=2	O
,	O
A	O
=	O
0.09	O
cm2	O
,	O
E	O
i	O
=	O
−0.3	O
V	O
,	O
E	O
s	O
=	O
+	O
1.0	O
V	O
,	O
E	O
f	O
=	O
−0.3	O
V	O
,	O
v	O
=	O
0.05	O
vs−1	O
.	O

Parameters	O
specific	O
for	O
reaction	O
at	O
a	O
bare	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.050	O
V	O
,	O
α	O
=	O
0.533	O
and	O
for	O
reaction	O
at	O
a	O
mAb	B
-	O
coated	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.037	O
V	O
,	O
α	O
=	O
0.400	O
.	O

2.4	O
Cyclic	O
voltammetry	O
and	O
chronoamperometry	O
Cyclic	O
voltammetric	O
studies	O
were	O
conducted	O
using	O
10	O
ml	O
analyte	O
volumes	O
in	O
a	O
glass	O
voltammetric	O
cell	O
.	O

Individual	O
working	O
SPCEs	O
or	O
mAb	O
-	O
SPCEs	O
were	O
used	O
in	O
a	O
3-electrode	O
configuration	O
in	O
conjunction	O
with	O
a	O
saturated	O
calomel	O
reference	O
and	O
platinum	O
counter	O
electrode	O
.	O

Chronoamperometric	O
measurements	O
were	O
made	O
by	O
using	O
individual	O
working	O
mAb	B
-	O
SPCEs	O
,	O
together	O
with	O
a	O
saturated	O
calomel	O
electrode	O
functioning	O
as	O
a	O
combined	O
counter	O
/	O
reference	O
electrode	O
in	O
a	O
two	O
electrode	O
configuration	O
.	O

In	O
this	O
way	O
it	O
was	O
possible	O
to	O
perform	O
measurements	O
using	O
a	O
small	O
(	O
0.5	O
ml	O
)	O
volume	O
of	O
enzyme	B
substrate	O
solution	O
in	O
a	O
conical	O
polypropylene	O
cell	O
.	O

2.5	O
Electrochemical	O
immunoassay	O
procedure	O
Milk	O
samples	O
were	O
mixed	O
with	O
AP	B
-	I
prog	I
solution	O
in	O
the	O
ratio	O
3:5	O
(	O
this	O
combination	O
gave	O
a	O
maximum	O
signal	O
:	O
noise	O
ratio	O
)	O
.	O

Eight	O
microlitre	O
volumes	O
of	O
these	O
mixtures	O
were	O
added	O
to	O
the	O
surface	O
of	O
individual	O
mAb	B
-	O
SPCEs	O
.	O

After	O
30	O
min	O
at	O
room	O
temperature	O
(	O
18–25	O
°	O
C	O
;	O
RT	O
)	O
,	O
the	O
electrodes	O
were	O
washed	O
three	O
times	O
in	O
DB	O
,	O
pH	O
9.8	O
,	O
then	O
placed	O
in	O
0.5	O
ml	O
DB	O
,	O
pH	O
9.8	O
or	O
the	O
same	O
buffer	O
containing	O
5	O
mmol	O
/	O
dm3	O
4-APP	O
or	O
1-NP	O
.	O

After	O
5	O
min	O
(	O
a	O
compromise	O
between	O
maximum	O
enzyme	B
activity	O
and	O
speed	O
of	O
assay	O
for	O
multiple	O
samples	O
)	O
,	O
the	O
working	O
electrode	O
potential	O
was	O
stepped	O
from	O
open	O
circuit	O
to	O
+	O
200	O
or	O
+	O
300	O
mV	O
versus	O
SCE	O
,	O
respectively	O
and	O
the	O
peak	O
current	O
(	O
i	O
p	O
)	O
response	O
was	O
recorded	O
.	O

Calibration	O
graphs	O
were	O
obtained	O
by	O
plotting	O
i	O
p	O
values	O
in	O
the	O
presence	O
of	O
an	O
enzyme	B
substrate	O
minus	O
background	O
i	O
p	O
values	O
in	O
buffer	O
only	O
for	O
each	O
known	O
standard	O
progesterone	O
concentration	O
(	O
y	O
-axis	O
)	O
against	O
progesterone	O
concentration	O
(	O
x	O
-axis	O
)	O
.	O

For	O
each	O
unknown	O
cow	O
sample	O
,	O
a	O
similar	O
subtraction	O
of	O
the	O
buffer	O
blank	O
i	O
p	O
value	O
was	O
performed	O
before	O
using	O
the	O
calibration	O
plot	O
by	O
interpolation	O
to	O
obtain	O
an	O
estimate	O
of	O
progesterone	O
concentration	O
.	O

The	O
relationship	O
between	O
readings	O
obtained	O
by	O
EIA	O
and	O
electrochemical	O
assays	O
was	O
investigated	O
using	O
linear	O
regression	O
analysis	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Electrochemistry	O
of	O
4-aminophenol	O
,	O
1-naphthol	O
and	O
corresponding	O
monophosphates	O
The	O
electrochemical	O
behaviour	O
of	O
the	O
enzyme	B
substrates	O
4-APP	O
and	O
1-NP	O
,	O
and	O
their	O
hydrolysis	O
products	O
,	O
4-aminophenol	O
and	O
1-naphthol	O
,	O
was	O
examined	O
by	O
cyclic	O
voltammetry	O
at	O
unmodified	O
SPCEs	O
(	O
Fig.	O
1	O
)	O
.	O

4-Aminophenol	O
showed	O
well	O
-	O
defined	O
oxidation	O
and	O
reduction	O
peaks	O
and	O
the	O
ΔE	O
p	O
value	O
indicated	O
that	O
the	O
electrode	O
reaction	O
was	O
quasi	O
-	O
reversible	O
(	O
Fig.	O
1	O
(	O
a	O
)	O
)	O
.	O

The	O
anodic	O
potential	O
(	O
E	O
pa	O
)	O
was	O
well	O
below	O
that	O
required	O
for	O
the	O
oxidation	O
of	O
the	O
corresponding	O
monophosphate	O
,	O
4-APP	O
(	O
Fig.	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
contrast	O
,	O
1-naphthol	O
gave	O
only	O
an	O
oxidation	O
peak	O
at	O
+	O
230	O
mV	O
(	O
Fig.	O
1	O
(	O
c	O
)	O
)	O
,	O
which	O
could	O
be	O
due	O
to	O
the	O
electrode	O
reaction	O
itself	O
giving	O
an	O
electro	O
-	O
inactive	O
product	O
,	O
or	O
to	O
the	O
oxidised	O
naphthol	O
product	O
undergoing	O
an	O
irreversible	O
chemical	O
reaction	O
.	O

1-NP	O
(	O
Fig.	O
1	O
(	O
d	O
)	O
)	O
was	O
not	O
electrochemically	O
active	O
over	O
the	O
potential	O
range	O
studied	O
.	O

At	O
this	O
stage	O
,	O
it	O
appeared	O
that	O
the	O
anodic	O
signals	O
for	O
either	O
4-aminophenol	O
or	O
1-naphthol	O
could	O
be	O
used	O
as	O
the	O
basis	O
for	O
an	O
immunoassay	O
for	O
progesterone	O
.	O

Further	O
studies	O
were	O
therefore	O
performed	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
voltammetric	O
behaviour	O
of	O
these	O
two	O
phenols	O
.	O

The	O
cyclic	O
voltammetric	O
behaviour	O
of	O
4-aminophenol	O
and	O
1-naphthol	O
was	O
next	O
compared	O
at	O
naked	O
and	O
mAb	B
-	O
SPCEs	O
(	O
Fig.	O
2	O
)	O
.	O

For	O
both	O
analytes	O
,	O
the	O
presence	O
of	O
the	O
antibodies	B
increased	O
the	O
background	O
oxidation	O
signal	O
at	O
potentials	O
above	O
+	O
0.5	O
V	O
(	O
Fig.	O
2	O
(	O
b	O
,	O
d	O
)	O
)	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
overall	O
peak	O
currents	O
were	O
the	O
same	O
as	O
obtained	O
at	O
naked	O
SPCEs	O
(	O
Fig.	O
2	O
(	O
a	O
,	O
c	O
)	O
)	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
4aminophenol	O
,	O
the	O
oxidation	O
peak	O
became	O
broader	O
in	O
the	O
presence	O
of	O
the	O
antibodies	B
and	O
showed	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼30	O
mV	O
,	O
Fig.	O
2	O
(	O
a	O
,	O
b	O
)	O
)	O
.	O

In	O
the	O
case	O
of	O
1-naphthol	O
,	O
there	O
was	O
also	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼10	O
mV	O
)	O
in	O
the	O
presence	O
of	O
the	O
antibodies	B
(	O
Fig.	O
2	O
(	O
c	O
,	O
d	O
)	O
)	O
.	O

Further	O
comparison	O
of	O
the	O
electrochemistry	O
of	O
4-aminophenol	O
and	O
1-naphthol	O
,	O
at	O
naked	O
and	O
mAb	B
-	O
coated	O
SPCEs	O
,	O
was	O
obtained	O
by	O
performing	O
cyclic	O
voltammetry	O
at	O
various	O
scan	O
rates	O
.	O

The	O
relationship	O
produced	O
during	O
cyclic	O
voltammetry	O
between	O
peak	O
current	O
(	O
i	O
p	O
)	O
and	O
v	O
1	O
/	O
2	O
is	O
described	O
by	O
the	O
Randles	O
-	O
Sevcik	O
equation	O
,	O
modified	O
for	O
irreversible	O
systems	O
:	O

Cv	O
1	O
/	O
2	O
ip	O
=	O
(	O
2.99	O
×	O
10	O
5	O
)	O
·	O
n	O
(	O
αna	O
)	O
1	O
/	O
2	O
AD1	O
/	O
2	O
(	O
Heineman	O
and	O
Kissinger	O
,	O
1984	O
)	O
where	O
i	O
p	O
=	O
peak	O
current	O
(	O
μA	O
)	O
,	O
n	O
=	O
number	O
of	O
electrons	O
,	O
αn	O
a	O
=	O
electron	O
transfer	O
coefficient	O
,	O
A	O
=	O
working	O
electrode	O
area	O
(	O
cm2	O
)	O
,	O
D	O
=	O
diffusion	O
coefficient	O
(	O
cm2	O
/s	O
)	O
,	O
C=	O
bulk	O
concentration	O
of	O
analyte	O
(	O
mmoles	O
/	O
ml	O
)	O
and	O
v	O
=	O
scan	O
rate	O
(	O
mV	O
/	O
s	O
)	O
.	O

Plots	O
of	O
i	O
p	O
versus	O
v	O
1	O
/	O
2	O
for	O
both	O
analytes	O
at	O
naked	O
and	O
mAb	B
-	O
SPCEs	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
the	O
case	O
of	O
4-aminophenol	O
,	O
there	O
is	O
evidence	O
that	O
the	O
presence	O
of	O
the	O
mAb	B
results	O
in	O
lower	O
i	O
p	O
values	O
at	O
all	O
scan	O
rates	O
compared	O
with	O
naked	O
SPCEs	O
(	O
Fig.	O
3	O
(	O
a	O
)	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
mAb	B
may	O
slow	O
the	O
diffusion	O
of	O
4-AP	O
towards	O
the	O
electrode	O
surface	O
,	O
and	O
may	O
combine	O
with	O
polyphenols	O
to	O
reduce	O
the	O
working	O
area	O
available	O
for	O
the	O
oxidation	O
of	O
4-AP	O
.	O

In	O
contrast	O
,	O
ip	O
values	O
obtained	O
for	O
1-naphthol	O
at	O
naked	O
and	O
mAb	B
-	O
SPCEs	O
are	O
almost	O
superimposed	O
for	O
scan	O
rates	O
up	O
to	O
200	O
mVs−1	O
(	O
Fig.	O
3	O
(	O
b	O
)	O
)	O
.	O

This	O
suggests	O
that	O
the	O
antibody	B
coating	O
has	O
little	O
effect	O
on	O
the	O
diffusional	O
characteristics	O
of	O
1-naphthol	O
.	O

Electron	O
transfer	O
coefficients	O
(	O
αn	O
a	O
)	O
were	O
calculated	O
for	O
naked	O
and	O
mAb	B
-	O
SPCEs	O
as	O
described	O
previously	O
(	O
Galus	O
,	O
1976	O
)	O
.	O

For	O
4-aminophenol	O
,	O
these	O
values	O
were	O
0.533	O
and	O
0.400	O
,	O
respectively	O
;	O
this	O
decrease	O
indicates	O
that	O
the	O
antibody	B
layer	O
partially	O
inhibits	O
the	O
electron	O
transfer	O
step	O
,	O
possibly	O
due	O
to	O
steric	O
hindrance	O
.	O

A	O
computer	O
simulation	O
program	O
(	O
CVSIM	O
,	O
Gosser	O
,	O
1993	O
)	O
was	O
used	O
to	O
simulate	O
cyclic	O
voltammograms	O
for	O
4-aminophenol	O
in	O
order	O
to	O
obtain	O
values	O
for	O
the	O
electrochemical	O
rate	O
constant	O
.	O

Using	O
the	O
above	O
αn	O
a	O
values	O
,	O
it	O
was	O
found	O
that	O
the	O
heterogeneous	O
rate	O
constant	O
(	O
k	O
het	O
)	O
for	O
the	O
mAb	B
-	O
SPCEs	O
was	O
3.0	O
×	O
10−4	O
/cm	O
s−1	O
,	O
whereas	O
k	O
het	O
for	O
a	O
naked	O
SPCE	O
was	O
calculated	O
to	O
be	O
6.5	O
×	O
10−4	O
cm	O
s−1	O
.	O

The	O
slower	O
rate	O
constant	O
obtained	O
with	O
the	O
mAb	B
-	O
SPCEs	O
supports	O
the	O
suggestion	O
of	O
partial	O
inhibition	O
discussed	O
above	O
.	O

Finally	O
,	O
the	O
αn	O
a	O
values	O
were	O
calculated	O
for	O
1-naphthol	O
at	O
naked-	O
and	O
mAb	B
-	O
SPCEs	O
,	O
to	O
be	O
0.53	O
and	O
0.60	O
,	O
respectively	O
.	O

These	O
values	O
suggest	O
that	O
the	O
antibody	B
coating	O
does	O
not	O
inhibit	O
the	O
rate	O
of	O
electron	O
transfer	O
during	O
the	O
oxidation	O
of	O
this	O
phenol	O
.	O

Fig.	O
4	O
(	O
a	O
)	O
shows	O
the	O
effect	O
of	O
scan	O
rate	O
on	O
the	O
anodic	O
peak	O
potential	O
for	O
4-aminophenol	O
,	O
at	O
naked	O
and	O
antibody	B
-	O
coated	O
SPCEs	O
.	O

True	O
reversible	O
reactions	O
do	O
not	O
show	O
shifts	O
of	O
E	O
p	O
with	O
scan	O
rate	O
,	O
inferring	O
that	O
the	O
oxidation	O
reactions	O
at	O
both	O
types	O
of	O
SPCE	O
appear	O
to	O
be	O
quasi	O
-	O
reversible	O
over	O
the	O
range	O
studied	O
.	O

In	O
contrast	O
,	O
at	O
scan	O
rates	O
above	O
100	O
mVs−1	O
,	O
1-naphthol	O
appears	O
to	O
show	O
more	O
reversible	O
behaviour	O
at	O
both	O
SPCEs	O
than	O
4-aminophenol	O
.	O

This	O
may	O
be	O
explained	O
by	O
a	O
slow	O
chemical	O
follow	O
-	O
up	O
reaction	O
(	O
possibly	O
polymerisation	O
)	O
for	O
1-naphthol	O
after	O
the	O
initial	O
electron	O
transfer	O
step	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
peak	O
potential	O
for	O
the	O
oxidation	O
of	O
1-naphthol	O
obtained	O
at	O
the	O
mAb	B
-	O
SPCE	O
at	O
200	O
mVs−1	O
is	O
+	O
0.38	O
V	O
;	O
for	O
4-aminophenol	O
at	O
this	O
electrode	O
the	O
E	O
p	O
value	O
was	O
+	O
0.28	O
V.	O
All	O
of	O
the	O
above	O
observations	O
using	O
cyclic	O
voltammetry	O
suggested	O
that	O
1-NP	O
would	O
be	O
a	O
suitable	O
candidate	O
for	O
the	O
chronoamperometric	O
immunoassay	O
.	O

Although	O
the	O
magnitude	O
of	O
the	O
anodic	O
response	O
was	O
lower	O
than	O
that	O
seen	O
for	O
4-aminophenol	O
at	O
equivalent	O
concentration	O
,	O
the	O
hydrolysis	O
product	O
,	O
1-naphthol	O
,	O
appeared	O
capable	O
of	O
producing	O
a	O
significant	O
and	O
unimpeded	O
oxidation	O
signal	O
at	O
mAb	B
-	O
SPCEs	O
.	O

3.2	O
Establishing	O
the	O
operating	O
potential	O
for	O
chronoamperometric	O
detection	O
of	O
l	O
-	O
naphthol	O
Previous	O
cyclic	O
voltammograms	O
with	O
SPCEs	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
have	O
demonstrated	O
the	O
presence	O
,	O
in	O
milk	O
,	O
of	O
electroactive	O
species	O
capable	O
of	O
adsorbing	O
onto	O
the	O
electrode	O
surface	O
and	O
being	O
oxidised	O
to	O
produce	O
anodic	O
signals	O
capable	O
of	O
interfering	O
with	O
the	O
operation	O
of	O
the	O
immunosensor	O
by	O
chronoamperometry	O
.	O

Using	O
4-APP	O
as	O
enzyme	B
substrate	O
it	O
was	O
possible	O
to	O
select	O
an	O
operating	O
potential	O
of	O
+	O
200	O
mV	O
,	O
well	O
below	O
the	O
potential	O
required	O
to	O
oxidise	O
adsorbed	O
milk	O
species	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
order	O
to	O
confirm	O
that	O
1-naphthol	O
could	O
be	O
detected	O
amperometrically	O
and	O
to	O
establish	O
an	O
operating	O
potential	O
for	O
use	O
in	O
the	O
assay	O
,	O
chronoamperometric	O
measurement	O
of	O
a	O
1	O
mM	O
1-naphthol	O
solution	O
was	O
performed	O
over	O
a	O
range	O
of	O
operating	O
potentials	O
at	O
mAb	B
-	O
SPCEs	O
which	O
had	O
been	O
incubated	O
with	O
enzyme	B
-	O
labelled	O
progesterone	O
either	O
in	O
buffer	O
solution	O
or	O
in	O
milk	O
.	O

Fig.	O
5	O
shows	O
that	O
in	O
order	O
to	O
avoid	O
signals	O
due	O
to	O
the	O
oxidation	O
of	O
electroactive	O
species	O
within	O
milk	O
,	O
it	O
would	O
be	O
necessary	O
to	O
operate	O
below	O
+	O
400	O
mV.	O
It	O
was	O
necessary	O
to	O
operate	O
at	O
+	O
600	O
mV	O
to	O
achieve	O
the	O
maximum	O
current	O
signal	O
from	O
chronoamperometry	O
of	O
1-naphthol	O
.	O

However	O
,	O
it	O
was	O
still	O
possible	O
to	O
obtain	O
over	O
50	O
%	O
of	O
this	O
response	O
at	O
+	O
300	O
mV	O
which	O
was	O
therefore	O
chosen	O
as	O
the	O
operating	O
potential	O
for	O
the	O
biosensor	O
.	O

3.3	O
Analysis	O
of	O
cows	O
'	O
milk	O
-	O
comparison	O
of	O
enzyme	B
substrates	O
4-APP	O
and	O
1-NP	O
In	O
order	O
to	O
compare	O
the	O
performance	O
of	O
the	O
immunosensor	O
using	O
1-NP	O
as	O
an	O
enzyme	B
substrate	O
with	O
its	O
performance	O
using	O
4-APP	O
,	O
milk	O
samples	O
obtained	O
from	O
a	O
number	O
of	O
different	O
cows	O
were	O
analysed	O
for	O
progesterone	O
content	O
using	O
both	O
approaches	O
.	O

The	O
results	O
were	O
then	O
compared	O
with	O
those	O
obtained	O
using	O
a	O
commercial	O
EIA	O
(	O
Ridgeway	O
Science	O
Ltd.	O
;	O
accuracy=±8	O
%	O
inter	O
-	O
assay	O
C.V.	O
,	O
sensitivity=0.6	O
ng	O
/	O
ml	O
)	O
by	O
reference	O
to	O
a	O
standard	O
curve	O
of	O
absorbance	O
reading	O
versus	O
progesterone	O
concentration	O
(	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Fig.	O
6	O
(	O
a	O
)	O
shows	O
the	O
calibration	O
curve	O
obtained	O
using	O
4-APP	O
as	O
substrate	O
to	O
measure	O
progesterone	O
milk	O
standards	O
over	O
the	O
concentration	O
range	O
,	O
0–50	O
ng	O
/	O
ml	O
,	O
before	O
and	O
after	O
background	O
subtraction	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
ranged	O
from	O
5.3	O
to	O
18.3	O
%	O
.	O

The	O
readings	O
obtained	O
for	O
six	O
cows	O
'	O
milk	O
samples	O
,	O
together	O
with	O
those	O
obtained	O
using	O
the	O
standard	O
EIA	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
for	O
the	O
two	O
sets	O
of	O
values	O
(	O
Fig.	O
6	O
(	O
b	O
)	O
)	O
.	O

Reasonable	O
agreement	O
(	O
r	O
=	O
0.840	O
)	O
was	O
obtained	O
between	O
the	O
two	O
methods	O
.	O

One	O
calibration	O
curve	O
obtained	O
using	O
1-NP	O
is	O
shown	O
in	O
Fig.	O
7	O
(	O
a	O
)	O
,	O
before	O
and	O
after	O
adjustment	O
for	O
background	O
current	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
was	O
improved	O
compared	O
with	O
the	O
4-APP	O
assay	O
and	O
ranged	O
from	O
4.1	O
to	O
12.4	O
%	O
;	O
this	O
may	O
have	O
been	O
due	O
to	O
the	O
improved	O
solubility	O
of	O
the	O
1-naphthyl	O
phosphate	O
over	O
the	O
4-APP	O
.	O

Readings	O
obtained	O
for	O
the	O
same	O
six	O
cows	O
'	O
milk	O
samples	O
tested	O
above	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
comparing	O
these	O
values	O
with	O
those	O
obtained	O
by	O
EIA	O
(	O
Fig.	O
7	O
(	O
b	O
)	O
)	O
.	O

The	O
result	O
was	O
a	O
close	O
agreement	O
between	O
the	O
two	O
sets	O
of	O
readings	O
and	O
an	O
improved	O
correlation	O
(	O
r	O
=	O
0.946	O
)	O
over	O
the	O
4-APP	O
assay	O
.	O

4	O
Conclusion	O
In	O
summary	O
,	O
the	O
above	O
results	O
have	O
demonstrated	O
that	O
by	O
using	O
1-naphthyl	O
phosphate	O
(	O
1-NP	O
)	O
as	O
enzyme	B
substrate	O
,	O
it	O
is	O
possible	O
to	O
develop	O
an	O
amperometric	O
screen	O
-	O
printed	O
immunosensor	O
for	O
milk	O
progesterone	O
based	O
on	O
the	O
detection	O
of	O
the	O
product	O
,	O
1-naphthol	O
at	O
an	O
operating	O
potential	O
of	O
+	O
300	O
mV.	O
The	O
required	O
detection	O
limit	O
of	O
2–5	O
ng	O
/	O
ml	O
(	O
Bulman	O
,	O
1979	O
;	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
was	O
achieved	O
using	O
this	O
approach	O
.	O

Examination	O
of	O
the	O
electrochemistry	O
of	O
1-naphthol	O
itself	O
indicated	O
that	O
it	O
was	O
readily	O
oxidisable	O
at	O
the	O
surface	O
of	O
an	O
SPCE	O
in	O
the	O
presence	O
or	O
absence	O
of	O
immobilised	O
antibody	B
.	O

This	O
was	O
a	O
potential	O
advantage	O
over	O
4-aminophenol	O
which	O
appeared	O
to	O
suffer	O
from	O
a	O
diffusional	O
barrier	O
,	O
most	O
probably	O
as	O
a	O
result	O
of	O
the	O
formation	O
of	O
polyphenols	O
at	O
the	O
electrode	O
surface	O
.	O

Although	O
the	O
operating	O
potential	O
required	O
for	O
oxidation	O
of	O
1-naphthol	O
was	O
100	O
mV	O
higher	O
than	O
that	O
used	O
for	O
the	O
detection	O
of	O
4-aminophenol	O
,	O
the	O
1-naphthol	O
assay	O
operated	O
below	O
the	O
oxidation	O
potential	O
of	O
milkborne	O
interferents	O
and	O
did	O
not	O
suffer	O
from	O
a	O
loss	O
of	O
sensitivity	O
.	O

Indeed	O
,	O
a	O
closer	O
agreement	O
than	O
that	O
achieved	O
using	O
4-APP	O
was	O
obtained	O
with	O
an	O
established	O
EIA	O
method	O
for	O
milk	O
samples	O
taken	O
from	O
different	O
cows	O
having	O
varying	O
background	O
responses	O
.	O

Furthermore	O
,	O
this	O
correlation	O
was	O
also	O
better	O
than	O
that	O
obtained	O
using	O
4-APP	O
in	O
a	O
previous	O
study	O
on	O
milk	O
samples	O
taken	O
from	O
a	O
single	O
animal	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Since	O
1-NP	O
is	O
inexpensive	O
,	O
readily	O
soluble	O
and	O
easy	O
to	O
obtain	O
,	O
the	O
screenprinted	O
immunosensor	O
when	O
used	O
in	O
combination	O
with	O
this	O
substrate	O
may	O
hold	O
promise	O
for	O
future	O
development	O
into	O
a	O
device	O
for	O
large	O
-	O
scale	O
milk	O
monitoring	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
R.	O
Pittson	O
and	O
his	O
staff	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
GEM	O
)	O
,	O
Mamhilad	O
,	O
Gwent	O
for	O
supplying	O
the	O
SPCEs	O
.	O

Drs	O
D.J.	O
Groves	O
and	O
B.A.	O
Morris	O
from	O
the	O
Heterohybridoma	O
Antibody	O
Group	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Surrey	O
are	O
gratefully	O
acknowledged	O
as	O
the	O
originators	O
of	O
the	O
mAb	B
.	O

Financial	O
support	O
for	O
this	O
project	O
was	O
provided	O
by	O
the	O
HEFCE	O
.	O

Ferbam	O
[	O
iron	O
(	O
III	O
)	O
dimethyldithiocarbamate	O
]	O
is	O
a	O
well	O
known	O
dithiocarbamate	O
effective	O
fungicide	O
widely	O
used	O
against	O
a	O
variety	O
of	O
plant	O
pathogenic	O
fungi	O
.	O

Ferbam	O
is	O
generally	O
determined	O
by	O
the	O
carbon	O
disulphide	O
evolution	O
method	O
based	O
on	O
its	O
decomposition	O
by	O
hot	O
mineral	O
acids	O
to	O
amine	O
and	O
carbon	O
disulfide	O
using	O
different	O
approaches	O
[	O
1	O
]	O
.	O

Ferbam	O
is	O
also	O
determined	O
by	O
converting	O
it	O
into	O
moybdenum	O
[	O
2	O
]	O
,	O
copper	O
[	O
3	O
]	O
and	O
1,10-phenanthroline	O
[	O
4	O
]	O
complexes	O
.	O

McLeod	O
and	O
McCulley	O
[	O
5	O
]	O
determined	O
dithiocarbamate	O
fungicides	O
by	O
headspace	O
gas	O
chromatography	O
of	O
the	O
carbon	O
disulphide	O
evolved	O
in	O
controlled	O
conditions	O
from	O
foodstuffs	O
and	O
similar	O
methods	O
were	O
also	O
given	O
by	O
the	O
Committee	O
for	O
Analytical	O
Methods	O
[	O
6	O
]	O
.	O

However	O
,	O
all	O
these	O
methods	O
suffer	O
from	O
the	O
following	O
disadvantages	O
:	O
(	O
a	O
)	O
Methods	O
other	O
than	O
gas	O
chromatography	O
are	O
indirect	O
,	O
time	O
consuming	O
and	O
sensitivity	O
is	O
low	O
.	O

(	O
b	O
)	O
Gas	O
chromatographic	O
methods	O
are	O
sensitive	O
but	O
suffer	O
from	O
lack	O
of	O
the	O
selectivity	O
since	O
all	O
dithiocarbamate	O
fungicides	O
evolve	O
carbon	O
disulphide	O
on	O
acid	O
hydrolysis	O
.	O

(	O
c	O
)	O
Spectrophotometric	O
methods	O
suffer	O
the	O
interference	O
of	O
various	O
ions	O
.	O

Capillary	O
electrophoresis	O
[	O
7,8	O
]	O
,	O
is	O
a	O
microvolume	O
separation	O
technique	O
increasingly	O
achieving	O
recognition	O
for	O
its	O
use	O
in	O
the	O
separation	O
of	O
inorganic	O
and	O
organic	O
compounds	O
.	O

The	O
key	O
features	O
of	O
this	O
technique	O
are	O
its	O
very	O
short	O
analysis	O
time	O
and	O
small	O
sample	O
volumes	O
in	O
the	O
nanoliter	O
and	O
picoliter	O
range	O
.	O

Capillary	O
electrophoresis	O
has	O
been	O
used	O
for	O
the	O
determination	O
of	O
sodium	O
dimethyldithiocarbamate	O
using	O
sulphonic	O
acid	O
polymer	O
coated	O
capillary	O
columns	O
at	O
pH	O
6.5	O
using	O
sodium	O
phosphate	O
buffer	O
[	O
9	O
]	O
.	O

Liang	O
et	O
al.	O
used	O
diode	O
array	O
detection	O
and	O
factor	O
analysis	O
for	O
the	O
determination	O
of	O
dithiocarbamates	O
[	O
10	O
]	O
.	O

In	O
another	O
approach	O
,	O
solid	O
-	O
phase	O
extraction	O
was	O
used	O
to	O
separate	O
dithiocarbamates	O
with	O
other	O
pesticides	O
[	O
11	O
]	O
.	O

The	O
extensive	O
studies	O
of	O
metal	O
–	O
aminopolycarboxylate	O
complexes	O
are	O
reviewed	O
by	O
Timerbaev	O
[	O
12	O
]	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
investigation	O
of	O
the	O
potential	O
of	O
capillary	O
electrophoresis	O
in	O
the	O
determination	O
of	O
Ferbam	O
.	O

As	O
will	O
be	O
demonstrated	O
in	O
this	O
report	O
,	O
capillary	O
electrophoresis	O
with	O
its	O
precision	O
instrumentation	O
and	O
small	O
sample	O
requirements	O
is	O
well	O
suited	O
for	O
the	O
determination	O
of	O
Ferbam	O
.	O

Here	O
,	O
we	O
present	O
a	O
relatively	O
simple	O
and	O
selective	O
capillary	O
electrophoretic	O
method	O
by	O
converting	O
Fe	O
(	O
III	O
)	O
present	O
in	O
Ferbam	O
into	O
Fe	O
(	O
III	O
)	O
–EDTA−	O
complex	O
.	O

The	O
chemical	O
structure	O
of	O
Ferbam	O
is	O
as	O
follows	O
:	O
[	O
(	O
CH3	O
)	O
2	O
–NC	O
(	O
S	O
)	O
2	O
]	O
3	O
Fe	O
.	O

2	O
Experimental	O
2.1	O
Instrumentation	O
Separations	O
were	O
performed	O
on	O
a	O
Thermo	O
Separation	O
Products	O
100	O
CE	O
-	O
system	O
equipped	O
with	O
an	O
UV	O
absorbance	O
detector	O
.	O

Fused	O
silica	O
capillaries	O
of	O
75	O
cm	O
long	O
(	O
45	O
cm	O
to	O
the	O
detector	O
)	O
×	O
100	O
μm	O
I.D.	O
were	O
used	O
.	O

The	O
solutes	O
were	O
injected	O
in	O
the	O
hydrodynamic	O
mode	O
by	O
vacuum	O
injection	O
for	O
2	O
s.	O
TSP	O
1000	O
software	O
was	O
used	O
for	O
the	O
data	O
acquisition	O
.	O

Detection	O
was	O
performed	O
by	O
direct	O
UV	O
absorbance	O
at	O
254	O
nm	O
.	O

All	O
experiments	O
were	O
conducted	O
at	O
25±1	O
°	O
C	O
.	O

2.2	O
Reagents	O
and	O
solutions	O
All	O
chemicals	O
used	O
were	O
of	O
analytical	O
-	O
reagent	O
grade	O
and	O
doubly	O
distilled	O
water	O
was	O
used	O
for	O
the	O
preparation	O
of	O
solutions	O
and	O
all	O
dilutions	O
.	O

2.2.1	O
Ferbam	O
solution	O
Ferbam	O
was	O
obtained	O
from	O
Riedel	O
-	O
de	O
Haën	O
(	O
Germany	O
)	O
and	O
used	O
as	O
received	O
.	O

Ferbam	O
solution	O
was	O
prepared	O
by	O
decomposing	O
its	O
20	O
mg	O
with	O
concentrated	O
nitric	O
acid	O
(	O
5–10	O
ml	O
)	O
and	O
heated	O
till	O
all	O
the	O
fumes	O
were	O
ceased	O
(	O
almost	O
to	O
dryness	O
)	O
and	O
dissolved	O
the	O
residue	O
in	O
1–2	O
ml	O
of	O
concentrated	O
HCl	O
and	O
diluted	O
upto	O
30–40	O
ml	O
and	O
pH	O
adjusted	O
in	O
the	O
range	O
2–3	O
using	O
dilute	O
NaOH	O
and	O
finally	O
diluted	O
to	O
100	O
ml	O
in	O
a	O
calibrated	O
flask	O
.	O

The	O
recovery	O
of	O
iron	O
(	O
III	O
)	O
from	O
Ferbam	O
was	O
checked	O
by	O
titrating	O
it	O
using	O
Variamine	O
Blue	O
B	O
as	O
indicator	O
[	O
13	O
]	O
.	O

Working	O
solutions	O
of	O
lower	O
concentrations	O
were	O
prepared	O
by	O
appropriate	O
dilutions	O
with	O
distilled	O
water	O
.	O

2.2.2	O
EDTA	O
solution	O
Stock	O
solution	O
of	O
EDTA	O
(	O
0.5	O
mM	O
)	O
as	O
disodium	O
salt	O
was	O
prepared	O
in	O
distilled	O
water	O
.	O

2.2.3	O
Buffer	O
solution	O
Electrophoretic	O
buffer	O
solution	O
was	O
prepared	O
from	O
boric	O
acid	O
50	O
mM	O
and	O
adjusting	O
the	O
desired	O
pH	O
by	O
adding	O
0.1	O
M	O
NaOH	O
solution	O
.	O

2.3	O
Procedures	O
2.3.1	O
Basic	O
procedure	O
The	O
capillary	O
was	O
rinsed	O
with	O
1	O
M	O
NaOH	O
,	O
0.1	O
M	O
NaOH	O
and	O
water	O
for	O
2	O
min	O
,	O
respectively	O
,	O
then	O
equilibrated	O
with	O
the	O
carrier	O
electrolyte	O
for	O
2	O
min	O
.	O

Between	O
all	O
electrophoretic	O
separations	O
the	O
capillary	O
was	O
rinsed	O
for	O
2	O
min	O
with	O
carrier	O
electrolyte	O
.	O

All	O
electrolyte	O
solutions	O
were	O
filtered	O
through	O
a	O
0.45	O
μm	O
membrane	O
filter	O
.	O

2.3.2	O
Preparation	O
of	O
standard	O
calibration	O
graph	O
A	O
series	O
of	O
standard	O
solutions	O
of	O
Ferbam	O
were	O
mixed	O
with	O
EDTA	O
(	O
1	O
ml	O
)	O
and	O
diluted	O
to	O
2	O
ml	O
with	O
distilled	O
water	O
and	O
injected	O
into	O
the	O
capillary	O
under	O
the	O
optimised	O
conditions	O
to	O
test	O
the	O
linearity	O
of	O
the	O
calibration	O
graph	O
.	O

2.3.3	O
Determination	O
of	O
Ferbam	O
in	O
grains	O
The	O
method	O
was	O
applied	O
for	O
the	O
determination	O
of	O
Ferbam	O
from	O
wheat	O
grains	O
.	O

A	O
known	O
amount	O
of	O
Ferbam	O
in	O
acetonitrile	O
was	O
crushed	O
with	O
10	O
g	O
of	O
wheat	O
grains	O
and	O
shaken	O
mechanically	O
with	O
chloroform	O
(	O
100	O
ml	O
)	O
for	O
1	O
h.	O
The	O
mixture	O
was	O
filtered	O
and	O
the	O
residue	O
in	O
the	O
funnel	O
was	O
washed	O
with	O
chloroform	O
(	O
3	O
×	O
10	O
ml	O
)	O
.	O

The	O
extracts	O
were	O
evaporated	O
to	O
dryness	O
and	O
solution	O
was	O
prepared	O
as	O
discussed	O
above	O
and	O
determined	O
by	O
the	O
general	O
procedure	O
.	O

Untreated	O
samples	O
were	O
taken	O
as	O
reference	O
and	O
the	O
results	O
indicated	O
good	O
recoveries	O
in	O
all	O
cases	O
.	O

The	O
results	O
of	O
the	O
determinations	O
are	O
given	O
in	O
Table	O
1	O
.	O

3	O
Results	O
and	O
discussion	O
A	O
typical	O
capillary	O
electropherogram	O
of	O
Ferbam	O
at	O
pH	O
9.0	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

It	O
shows	O
a	O
sharp	O
peak	O
with	O
baseline	O
resolution	O
.	O

In	O
order	O
to	O
determine	O
the	O
best	O
experimental	O
conditions	O
(	O
peak	O
efficiency	O
,	O
analysis	O
time	O
)	O
borate	O
,	O
phosphate	O
and	O
acetate	O
buffer	O
of	O
pH	O
9.0	O
,	O
7.0	O
and	O
4.5	O
,	O
respectively	O
of	O
1.25–50	O
mM	O
were	O
investigated	O
and	O
compared	O
.	O

It	O
was	O
observed	O
that	O
below	O
pH	O
7.0	O
in	O
phosphate	O
and	O
acetate	O
buffer	O
good	O
peak	O
were	O
not	O
observed	O
.	O

A	O
well	O
defined	O
peak	O
was	O
obtained	O
in	O
between	O
25	O
and	O
50	O
mM	O
borate	O
buffer	O
of	O
pH	O
9.0	O
.	O

It	O
was	O
observed	O
that	O
the	O
migration	O
time	O
was	O
more	O
at	O
the	O
higher	O
concentrations	O
of	O
the	O
borate	O
buffer	O
.	O

Above	O
25	O
mM	O
concentration	O
of	O
borate	O
buffer	O
there	O
was	O
a	O
considerable	O
increase	O
in	O
the	O
migration	O
time	O
of	O
the	O
both	O
analytes	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
analysis	O
time	O
.	O

Therefore	O
,	O
25	O
mM	O
of	O
borate	O
buffer	O
concentration	O
was	O
preferred	O
.	O

The	O
influence	O
of	O
the	O
applied	O
voltage	O
was	O
also	O
studied	O
by	O
increasing	O
the	O
applied	O
voltage	O
.	O

The	O
retention	O
time	O
decreases	O
with	O
increasing	O
voltage	O
.	O

Therefore	O
,	O
+	O
30	O
kV	O
was	O
applied	O
to	O
get	O
the	O
shortest	O
time	O
.	O

A	O
linear	O
relationship	O
between	O
peak	O
height	O
and	O
concentrations	O
were	O
obtained	O
in	O
the	O
range	O
3.5–500	O
μg	O
/	O
ml	O
with	O
an	O
correlation	O
coefficient	O
of	O
0.9994	O
.	O

The	O
linear	O
regression	O
equation	O
for	O
the	O
calibration	O
curve	O
is	O
y	O
=	O
0.0001x	O
+	O
0.0003	O
.	O

Aliquots	O
containing	O
50	O
μg	O
/	O
ml	O
of	O
give	O
a	O
relative	O
standard	O
deviation	O
of	O
2.9	O
%	O
in	O
analysis	O
.	O

Ferbam	O
,	O
if	O
present	O
with	O
other	O
water	O
soluble	O
dithiocarbamates	O
such	O
as	O
nabam	O
,	O
metham	O
,	O
sodium	O
diethyldithiocarbamate	O
,	O
etc	O
.	O
,	O
can	O
easily	O
be	O
separated	O
by	O
extraction	O
with	O
chloroform	O
;	O
Nabam	O
and	O
others	O
will	O
remain	O
in	O
the	O
aqueous	O
phase	O
which	O
can	O
then	O
be	O
analysed	O
by	O
the	O
basic	O
procedure	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
our	O
experiments	O
have	O
shown	O
that	O
Ferbam	O
can	O
be	O
determined	O
directly	O
in	O
the	O
presence	O
of	O
metal	O
ions	O
like	O
Co	O
(	O
II	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cu	O
(	O
II	O
)	O
and	O
Ni	O
(	O
II	O
)	O
without	O
any	O
interference	O
,	O
whereas	O
,	O
these	O
metal	O
ions	O
strongly	O
interfere	O
in	O
the	O
spectrophotometric	O
methods	O
[	O
2,3	O
]	O
.	O

These	O
results	O
are	O
similar	O
to	O
as	O
reported	O
by	O
earlier	O
workers	O
[	O
12,15	O
]	O
.	O

4	O
Conclusions	O
Capillary	O
electrophoresis	O
provides	O
an	O
important	O
tool	O
in	O
the	O
hands	O
of	O
the	O
analytical	O
chemists	O
for	O
the	O
determination	O
of	O
Ferbam	O
.	O

The	O
detection	O
limit	O
(	O
S	O
/N	O
=3	O
)	O
using	O
this	O
method	O
is	O
0.7	O
μg	O
/	O
ml	O
(	O
0.7	O
mg	O
/	O
kg	O
)	O
of	O
Ferbam	O
which	O
is	O
better	O
than	O
1	O
μg	O
/	O
ml	O
of	O
Nitowski	O
et	O
al.	O
's	O
[	O
9	O
]	O
method	O
reported	O
for	O
dimethyldithiocarbamate	O
using	O
sulphonic	O
acid	O
polymer	O
-	O
coated	O
capillary	O
columns	O
.	O

As	O
most	O
of	O
the	O
cations	O
and	O
anions	O
do	O
not	O
interfere	O
in	O
the	O
determination	O
of	O
Ferbam	O
,	O
moreover	O
,	O
the	O
simplicity	O
and	O
small	O
sample	O
volume	O
requirements	O
makes	O
it	O
advantageous	O
to	O
other	O
chromatographic	O
techniques	O
.	O

Thus	O
,	O
the	O
usefulness	O
of	O
capillary	O
electrophoresis	O
as	O
a	O
tool	O
for	O
checking	O
the	O
amount	O
of	O
Ferbam	O
is	O
successfully	O
demonstrated	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
A.K.M.	O
)	O
thanks	O
the	O
AvH	O
Foundation	O
,	O
Bonn	O
,	O
Germany	O
for	O
financial	O
assistance	O
.	O

l	O
-cis	O
Diltiazem	O
,	O
the	O
enantiomer	O
of	O
diltiazem	O
(	O
d	O
-cis	O
diltiazem	O
)	O
,	O
has	O
100	O
times	O
less	O
Ca2	B
+	I
channel	I
blocking	O
activity	O
than	O
diltiazem	O
(	O
Ikeda	O
et	O
al.	O
,	O
1991	O
)	O
.	O

l	O
-cis	O
Diltiazem	O
is	O
not	O
a	O
simple	O
inactive	O
stereoisomer	O
but	O
has	O
been	O
established	O
as	O
a	O
unique	O
pharmacological	O
tool	O
(	O
Caretta	O
et	O
al.	O
,	O
1979	O
)	O
.	O

For	O
example	O
,	O
l	O
-cis	O
diltiazem	O
,	O
but	O
not	O
diltiazem	O
,	O
inhibits	O
the	O
cGMP	B
-	I
gated	I
cation	I
channel	I
in	O
rod	O
cells	O
(	O
Stern	O
et	O
al.	O
,	O
1986	O
;	O
Quandt	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Interestingly	O
,	O
there	O
have	O
been	O
several	O
reports	O
indicating	O
that	O
l	O
-cis	O
diltiazem	O
protects	O
against	O
ischemic	O
cardiac	O
injury	O
.	O

For	O
example	O
,	O
l	O
-cis	O
diltiazem	O
produces	O
a	O
high	O
recovery	O
of	O
cardiac	O
function	O
after	O
ischemia	O
/	O
reperfusion	O
and	O
inhibits	O
the	O
increase	O
of	O
non	O
-	O
esterified	O
fatty	O
acids	O
during	O
ischemia	O
in	O
isolated	O
,	O
perfused	O
working	O
rat	O
heart	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
;	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
our	O
laboratory	O
has	O
reported	O
that	O
treatment	O
with	O
l	O
-cis	O
diltiazem	O
reduced	O
infarct	O
size	O
without	O
affecting	O
any	O
hemodynamic	O
parameter	O
in	O
rabbit	O
heart	O
in	O
vivo	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Since	O
l	O
-cis	O
diltiazem	O
has	O
a	O
much	O
less	O
potent	O
Ca2	B
+	I
channel	I
blocking	O
action	O
than	O
diltiazem	O
,	O
it	O
has	O
been	O
suggested	O
that	O
l	O
-cis	O
diltiazem	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
with	O
a	O
mechanism	O
other	O
than	O
Ca2	B
+	I
channel	I
blockade	O
.	O

We	O
have	O
also	O
demonstrated	O
that	O
treatment	O
with	O
l	O
-cis	O
diltiazem	O
before	O
reperfusion	O
also	O
reduced	O
infarct	O
size	O
in	O
ischemic	O
rabbit	O
heart	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Ca2	O
+	O
overload	O
at	O
reperfusion	O
after	O
ischemia	O
(	O
Allen	O
and	O
Orchard	O
,	O
1983	O
)	O
and	O
reoxygenation	O
after	O
hypoxia	O
(	O
Poole	O
-	O
Wilson	O
et	O
al.	O
,	O
1984	O
)	O
have	O
been	O
considered	O
to	O
be	O
involved	O
in	O
the	O
final	O
stage	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
of	O
cardiac	O
myocytes	O
(	O
Nayler	O
,	O
1981	O
;	O
Farber	O
,	O
1982	O
;	O
Steenbergen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Thus	O
,	O
it	O
is	O
postulated	O
that	O
l	O
-cis	O
diltiazem	O
elicits	O
a	O
cardioprotective	O
action	O
via	O
the	O
attenuation	O
of	O
Ca2	O
+	O
overload	O
after	O
reperfusion	O
.	O

In	O
terms	O
of	O
energy	O
metabolism	O
,	O
ischemic	O
insults	O
can	O
be	O
simulated	O
,	O
in	O
part	O
,	O
by	O
controlled	O
metabolic	O
inhibition	O
.	O

Li	O
et	O
al.	O
(	O
1989	O
)	O
has	O
reported	O
that	O
the	O
myocytes	O
were	O
reversibly	O
ATP	O
-	O
depleted	O
by	O
metabolic	O
inhibitors	O
.	O

Thus	O
,	O
myocardial	O
Ca2	O
+	O
overload	O
induced	O
by	O
ischemia	O
and	O
reperfusion	O
is	O
considered	O
to	O
be	O
simply	O
mimicked	O
,	O
in	O
part	O
,	O
by	O
treatment	O
with	O
carbonyl	O
cyanide	O
m	O
-chrolophenylhydrazone	O
(	O
CCCP	O
)	O
,	O
a	O
mitochondrial	O
uncoupler	O
,	O
followed	O
by	O
washout	O
of	O
CCCP	O
.	O

In	O
order	O
to	O
assess	O
the	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
,	O
we	O
used	O
a	O
model	O
for	O
Ca2	O
+	O
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
isolated	O
guinea	O
pig	O
cardiomyocytes	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
other	O
drugs	O
,	O
Ca2	B
+	I
channel	I
blockers	O
and	O
Na+	O
/Ca2	O
+	O
exchanger	O
blockers	O
,	O
to	O
clarify	O
the	O
mechanism	O
for	O
Ca2	O
+	O
overload	O
in	O
this	O
model	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Preparation	O
of	O
single	O
cells	O
Ventricular	O
myocytes	O
were	O
isolated	O
enzymatically	O
from	O
the	O
hearts	O
of	O
male	O
Hartley	O
guinea	O
pigs	O
(	O
weight	O
250–500	O
g	O
)	O
according	O
to	O
the	O
method	O
described	O
(	O
Kurokawa	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
animals	O
were	O
anaesthetized	O
with	O
sodium	O
pentobarbital	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
the	O
ascending	O
aorta	O
was	O
cannulated	O
in	O
situ	O
under	O
artificial	O
respiration	O
.	O

The	O
heart	O
was	O
perfused	O
with	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
for	O
10	O
min	O
,	O
followed	O
by	O
the	O
same	O
solution	O
containing	O
collagenase	B
for	O
7–14	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
8–10	O
ml	O
/	O
min	O
via	O
a	O
Langendorff	O
apparatus	O
at	O
37	O
°	O
C	O
.	O

Subsequently	O
,	O
the	O
enzyme	B
solution	O
was	O
washed	O
out	O
with	O
a	O
high	O
K+	O
,	O
Ca2	O
+	O
-free	O
solution	O
(	O
Kraftbrühe	O
(	O
KB	O
)	O
solution	O
,	O
Isenberg	O
and	O
Klöckner	O
,	O
1982	O
)	O
.	O

The	O
ventricular	O
myocytes	O
were	O
dissociated	O
by	O
gentle	O
stirring	O
of	O
the	O
tissue	O
fragments	O
at	O
37	O
°	O
C	O
.	O

The	O
dissociated	O
cells	O
were	O
stored	O
in	O
KB	O
solution	O
at	O
4	O
°	O
C	O
,	O
and	O
were	O
used	O
up	O
to	O
10	O
h	O
after	O
isolation	O
.	O

Nominally	O
Ca2	O
+	O
-free	O
solution	O
had	O
the	O
following	O
composition	O
(	O
mM	O
)	O
:	O
NaCl	O
135	O
,	O
KCl	O
5.4	O
,	O
MgCl2	O
1	O
,	O
glucose	O
5.8	O
,	O
HEPES	O
5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
tris	O
)	O
.	O

Normal	O
Tyrode	O
solution	O
was	O
made	O
by	O
adding	O
1.8	O
mM	O
CaCl2	O
to	O
nominally	O
Ca2	O
+	O
-free	O
solution	O
.	O

The	O
collagenase	B
solutions	O
were	O
prepared	O
by	O
adding	O
collagenase	B
(	O
110	O
units	O
/	O
ml	O
Collagenase	B
S-1	I
,	O
Nitta	O
Gelatin	O
,	O
Osaka	O
,	O
Japan	O
;	O
200–220	O
units	O
/	O
ml	O
collagenase	B
,	O
Yakult	O
,	O
Tokyo	O
.	O

Japan	O
)	O
and	O
10.8	O
nM	O
CaCl2	O
to	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
,	O
or	O
by	O
combining	O
collagenase	B
(	O
0.145	O
U	O
/	O
ml	O
collagenase	B
A	I
,	O
Boehringer	O
Mannheim	O
,	O
Japan	O
)	O
and	O
protease	B
(	O
0.156	O
units	O
/	O
ml	O
protease	B
type	I
IX	I
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
to	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
.	O

The	O
KB	O
solution	O
contained	O
(	O
mM	O
)	O
:	O
potassium	O
glutamate	O
70	O
,	O
KCl	O
20	O
,	O
oxalic	O
acid	O
10	O
,	O
KH2	O
PO4	O
10	O
,	O
taurine	O
10	O
,	O
glucose	O
5.8	O
,	O
HEPES	O
5	O
,	O
EGTA	O
0.5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
KOH	O
)	O
.	O

2.2	O
Measurement	O
of	O
fluorescence	O
ratio	O
of	O
fura-2	O
in	O
cardiac	O
myocytes	O
For	O
measurement	O
of	O
a	O
change	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
of	O
cardiac	O
myocytes	O
,	O
a	O
Ca2	O
+	O
-sensitive	O
fluorescent	O
dye	O
,	O
fura-2	O
/	O
acetoxymethylester	O
(	O
fura-2	O
/	O
AM	O
)	O
,	O
was	O
used	O
.	O

Fura-2	O
/	O
AM	O
(	O
1	O
mM	O
,	O
dissolved	O
in	O
dimethylsulfoxide	O
,	O
DMSO	O
)	O
was	O
prepared	O
in	O
KB	O
solution	O
and	O
applied	O
to	O
isolated	O
myocytes	O
at	O
a	O
final	O
concentration	O
of	O
10	O
μM.	O
After	O
the	O
cell	O
suspension	O
had	O
been	O
incubated	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
settled	O
out	O
and	O
became	O
loosely	O
attached	O
to	O
the	O
bottom	O
of	O
the	O
chamber	O
.	O

Then	O
the	O
fura-2-loaded	O
myocytes	O
were	O
washed	O
and	O
superfused	O
(	O
4–5	O
ml	O
/	O
min	O
,	O
37	O
°	O
C	O
)	O
with	O
normal	O
Tyrode	O
solution	O
containing	O
1.8	O
mM	O
Ca2	O
+	O
for	O
30	O
min	O
.	O

The	O
myocytes	O
were	O
illuminated	O
with	O
a	O
dual	O
wavelength	O
fluorometer	O
(	O
CAM-230	O
,	O
Japan	O
Spectroscopic	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Video	O
images	O
were	O
digitized	O
,	O
using	O
an	O
Argus-50	O
/	O
Ca	O
system	O
(	O
Hamamatsu	O
Photonics	O
)	O
.	O

The	O
fluorescence	O
ratio	O
was	O
calculated	O
from	O
the	O
value	O
of	O
the	O
fluorescence	O
intensity	O
at	O
500	O
nm	O
with	O
340-	O
and	O
380-nm	O
excitation	O
.	O

The	O
digital	O
images	O
were	O
obtained	O
every	O
5	O
min	O
from	O
just	O
before	O
treatment	O
with	O
CCCP	O
till	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.3	O
Evaluation	O
of	O
morphological	O
changes	O
of	O
cardiac	O
myocytes	O
Cells	O
lightly	O
attached	O
to	O
the	O
perfusion	O
chamber	O
were	O
superfused	O
with	O
normal	O
Tyrode	O
solution	O
at	O
37	O
°	O
C	O
.	O

After	O
30	O
min	O
of	O
stabilization	O
,	O
a	O
rod	O
-	O
shaped	O
cell	O
was	O
selected	O
randomly	O
from	O
those	O
within	O
the	O
microscopic	O
field	O
of	O
the	O
chamber	O
.	O

Caffeine	O
(	O
5	O
mM	O
)	O
was	O
added	O
for	O
1	O
min	O
to	O
the	O
chamber	O
in	O
order	O
to	O
confirm	O
that	O
the	O
function	O
of	O
the	O
intracellular	O
Ca2	O
+	O
store	O
of	O
the	O
myocyte	O
was	O
maintained	O
.	O

After	O
washing	O
out	O
of	O
the	O
caffeine	O
for	O
5	O
min	O
,	O
the	O
morphology	O
of	O
the	O
myocyte	O
was	O
recorded	O
as	O
a	O
digital	O
image	O
using	O
the	O
Argus-50	O
/	O
Ca	O
system	O
.	O

To	O
examine	O
the	O
morphological	O
change	O
of	O
the	O
myocyte	O
,	O
the	O
morphology	O
of	O
the	O
same	O
cell	O
was	O
also	O
recorded	O
at	O
the	O
end	O
of	O
chemical	O
ischemia	O
and	O
also	O
at	O
the	O
end	O
of	O
30-min	O
reperfusion	O
.	O

After	O
Ca2	O
+	O
measurement	O
,	O
the	O
morphological	O
change	O
was	O
analyzed	O
by	O
measuring	O
the	O
area	O
of	O
the	O
myocyte	O
.	O

The	O
cell	O
surface	O
area	O
was	O
calculated	O
from	O
the	O
digitized	O
image	O
of	O
the	O
cell	O
and	O
the	O
post	O
-	O
ischemic	O
value	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
pre	O
-	O
ischemic	O
value	O
.	O

2.4	O
Experimental	O
protocols	O
In	O
order	O
to	O
determine	O
the	O
optimal	O
condition	O
of	O
the	O
Ca2	O
+	O
overload	O
model	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
,	O
we	O
performed	O
some	O
preliminary	O
experiments	O
.	O

We	O
first	O
followed	O
a	O
protocol	O
for	O
metabolic	O
inhibition	O
,	O
using	O
Tyrode	O
solution	O
containing	O
normal	O
Ca2	O
+	O
and	O
1	O
μM	O
of	O
CCCP	O
.	O

However	O
,	O
the	O
myocytes	O
exposed	O
to	O
CCCP	O
for	O
10–15	O
min	O
showed	O
a	O
rigor	O
contraction	O
with	O
an	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
but	O
failed	O
to	O
show	O
Ca2	O
+	O
overload	O
on	O
washout	O
of	O
CCCP	O
(	O
energy	O
repletion	O
)	O
after	O
the	O
transition	O
to	O
rigor	O
contraction	O
(	O
the	O
sign	O
of	O
ATP	O
depletion	O
)	O
.	O

These	O
cells	O
showed	O
neither	O
further	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
nor	O
morphological	O
changes	O
after	O
energy	O
repletion	O
.	O

To	O
improve	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
,	O
we	O
used	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
for	O
metabolic	O
inhibition	O
,	O
since	O
it	O
was	O
reported	O
that	O
cells	O
in	O
the	O
low	O
Ca2	O
+	O
solution	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
)	O
.	O

We	O
also	O
examined	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
CCCP	O
(	O
100	O
nM	O
,	O
1	O
and	O
3	O
μM	O
)	O
,	O
and	O
confirmed	O
that	O
1	O
μM	O
of	O
CCCP	O
was	O
the	O
most	O
stable	O
to	O
induce	O
Ca2	O
+	O
overload	O
after	O
energy	O
repletion	O
.	O

Based	O
on	O
these	O
experiments	O
,	O
we	O
established	O
the	O
standard	O
procedure	O
as	O
follows	O
.	O

After	O
confirmation	O
of	O
the	O
integrity	O
of	O
the	O
myocardial	O
store	O
functions	O
described	O
in	O
the	O
previous	O
section	O
,	O
Ca2	O
+	O
-free	O
Tyrode	O
containing	O
CCCP	O
(	O
1	O
μM	O
)	O
was	O
perfused	O
for	O
40	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
2–3	O
ml	O
/	O
min	O
.	O

Ca2	O
+	O
overload	O
was	O
induced	O
by	O
washout	O
of	O
CCCP	O
with	O
normal	O
Tyrode	O
solution	O
for	O
30	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
4–5	O
ml	O
/	O
min	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
the	O
following	O
two	O
protocols	O
:	O
(	O
A	O
)	O
before	O
metabolic	O
inhibition	O
,	O
in	O
which	O
drugs	O
were	O
included	O
throughout	O
the	O
experiment	O
,	O
and	O
(	O
B	O
)	O
before	O
energy	O
repletion	O
,	O
in	O
which	O
drugs	O
were	O
included	O
from	O
5	O
min	O
before	O
energy	O
repletion	O
to	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.5	O
Calibration	O
for	O
Ca2	O
+	O
concentration	O
The	O
maximum	O
ratio	O
(	O
R	O
max	O
)	O
unique	O
to	O
individual	O
cells	O
was	O
obtained	O
at	O
the	O
end	O
of	O
each	O
experiment	O
by	O
applying	O
ionomycin	O
(	O
2	O
μM	O
)	O
to	O
the	O
normal	O
Tyrode	O
solution	O
.	O

The	O
minimum	O
ratio	O
(	O
R	O
min	O
)	O
was	O
obtained	O
by	O
applying	O
EGTA	O
(	O
10	O
mM	O
)	O
to	O
the	O
ionomycin	O
containing	O
Tyrode	O
solution	O
.	O

Both	O
R	O
max	O
and	O
R	O
min	O
values	O
were	O
obtained	O
under	O
steady	O
state	O
conditions	O
.	O

[	O
Ca2	O
+	O
]	O
i	O
was	O
calculated	O
from	O
the	O
following	O
formula	O
:	O
[	O
Ca2	O
+	O
]	O
i	O
(	O
nM	O
)	O
=	O
(	O
R	O
−R	O
min	O
)	O
×K	O
d	O
×F	O
min	O
/	O
(	O
(	O
R	O
max	O
−R	O
)	O
×F	O
max	O
)	O
)	O
,	O
where	O
R	O
is	O
the	O
ratio	O
obtained	O
from	O
the	O
experiment	O
,	O
F	O
means	O
the	O
fluorescence	O
intensity	O
at	O
380-nm	O
excitation	O
,	O
and	O
K	O
d	O
is	O
the	O
dissociation	O
constant	O
defined	O
as	O
224	O
nM.	O
2.6	O
Chemicals	O
l	O
-cis	O
Diltiazem	O
and	O
diltiazem	O
were	O
kind	O
gifts	O
from	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

A	O
specific	O
inhibitor	O
of	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
2-	O
[	O
2-	O
[	O
4-	O
(	O
4-nitrobenzyloxy	O
)	O
phenyl	O
]	O
ethyl	O
]	O
isothiourea	O
methanesulphonate	O
(	O
KB	O
-	O
R7943	O
)	O
,	O
was	O
a	O
kind	O
gift	O
from	O
Kanebo	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

CCCP	O
was	O
purchased	O
from	O
Sigma	O
.	O

2.7	O
Statistical	O
analysis	O
All	O
data	O
were	O
expressed	O
as	O
means±S.E.M.	O
The	O
time	O
course	O
data	O
(	O
Ca2	O
+	O
measurement	O
)	O
were	O
divided	O
into	O
two	O
events	O
,	O
during	O
40	O
min	O
of	O
metabolic	O
inhibition	O
and	O
during	O
30-min	O
energy	O
repletion	O
,	O
and	O
repeated	O
measures	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
used	O
.	O

If	O
there	O
was	O
no	O
interaction	O
between	O
the	O
drug	O
factor	O
and	O
the	O
time	O
factor	O
,	O
Bonferroni	O
/	O
Dunn	O
(	O
Dunn	O
's	O
Procedure	O
for	O
Comparing	O
a	O
Control	O
to	O
All	O
other	O
Means	O
)	O
post	O
-	O
hoc	O
test	O
was	O
done	O
thereafter	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
the	O
Bonferroni	O
/	O
Dunn	O
post	O
-	O
hoc	O
test	O
was	O
used	O
for	O
the	O
cell	O
size	O
data	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Super	O
ANOVA	O
™	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
)	O
.	O

Differences	O
were	O
considered	O
to	O
be	O
statistically	O
significant	O
when	O
the	O
P	O
value	O
was	O
less	O
than	O
0.05	O
.	O

3	O
Results	O
3.1	O
Cell	O
selection	O
In	O
all	O
the	O
experiments	O
,	O
rod	O
-	O
shaped	O
myocytes	O
as	O
shown	O
in	O
Fig.	O
1A	O
were	O
selected	O
.	O

A	O
single	O
myocyte	O
was	O
further	O
selected	O
for	O
the	O
ischemia	O
experiment	O
,	O
based	O
on	O
the	O
criterion	O
that	O
it	O
showed	O
a	O
transient	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
on	O
treatment	O
with	O
5	O
mM	O
caffeine	O
(	O
Fig.	O
1B	O
)	O
.	O

The	O
cells	O
,	O
which	O
did	O
not	O
satisfy	O
these	O
criteria	O
,	O
or	O
which	O
changed	O
morphologically	O
after	O
the	O
treatment	O
with	O
caffeine	O
,	O
were	O
excluded	O
.	O

3.2	O
Changes	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
Fig.	O
2	O
represents	O
the	O
change	O
in	O
time	O
course	O
of	O
[	O
Ca2	O
+	O
]	O

i	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
.	O

Before	O
CCCP	O
treatment	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
of	O
all	O
cells	O
used	O
were	O
almost	O
identical	O
in	O
level	O
(	O
about	O
100	O
nM	O
)	O
.	O

In	O
the	O
control	O
myocytes	O
,	O
[	O
Ca2	O
+	O
]	O
i	O
did	O
not	O
change	O
during	O
40	O
min	O
of	O
CCCP	O
treatment	O
.	O

After	O
washout	O
of	O
CCCP	O
,	O
[	O
Ca2	O
+	O
]	O
i	O
increased	O
dramatically	O
within	O
5	O
min	O
and	O
continued	O
to	O
increase	O
until	O
the	O
end	O
of	O
energy	O
repletion	O
.	O

In	O
order	O
to	O
confirm	O
that	O
this	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
not	O
due	O
to	O
the	O
simple	O
entry	O
of	O
extracellular	O
Ca2	O
+	O
when	O
Ca2	O
+	O
-free	O
Tyrode	O
was	O
replaced	O
by	O
normal	O
Tyrode	O
,	O
we	O
performed	O
the	O
same	O
perfusion	O
protocol	O
without	O
CCCP	O
treatment	O
.	O

We	O
observed	O
that	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
showed	O
a	O
small	O
(	O
20–30	O
nM	O
)	O
,	O
but	O
not	O
significant	O
,	O
increase	O
at	O
5	O
min	O
after	O
energy	O
repletion	O
.	O

Therefore	O
,	O
the	O
Ca2	O
+	O
overload	O
observed	O
here	O
is	O
considered	O
to	O
be	O
induced	O
by	O
the	O
injury	O
due	O
to	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

Furthermore	O
,	O
Ni2	O
+	O
(	O
5	O
mM	O
)	O
and	O
KB	O
-	O
R7943	O
(	O
10	O
μM	O
)	O
,	O
known	O
as	O
inhibitors	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
completely	O
blocked	O
the	O
initial	O
rise	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
after	O
washout	O
of	O
CCCP	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
and	O
continued	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
30	O
min	O
of	O
energy	O
repletion	O
.	O

However	O
,	O
nitrendipine	O
(	O
10	O
μM	O
)	O
,	O
a	O
dihydropyridine	O
Ca2	B
+	I
channel	I
blocker	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
washout	O
of	O
CCCP	O
.	O

Nicardipine	O
(	O
10	O
μM	O
)	O
,	O
another	O
dihydropyridine	O
Ca2	B
+	I
channel	I
blocker	O
,	O
also	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
see	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
in	O
this	O
model	O
was	O
suggested	O
to	O
be	O
mediated	O
,	O
not	O
by	O
L	B
-	I
type	I
Ca2	I
+	I
channels	I
but	O
by	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
before	O
metabolic	O
inhibition	O
(	O
protocol	O
(	O
A	O
)	O
)	O
,	O
diltiazem	O
(	O
3	O
μM	O
)	O
and	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
but	O
not	O
l	O
-cis	O
diltiazem	O
(	O
3	O
μM	O
)	O
significantly	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
energy	O
repletion	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
(	O
protocol	O
(	O
B	O
)	O
)	O
,	O
3	O
μM	O
of	O
diltiazem	O
,	O
which	O
was	O
effective	O
in	O
protocol	O
(	O
A	O
)	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
.	O

However	O
,	O
a	O
higher	O
concentration	O
of	O
diltiazem	O
(	O
10	O
μM	O
)	O
could	O
significantly	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

l	O
-cis	O
Diltiazem	O
(	O
10	O
μM	O
)	O
also	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
.	O

3.3	O
Morphological	O
change	O
of	O
the	O
cell	O
after	O
energy	O
repletion	O
Cells	O
,	O
which	O
showed	O
a	O
rigor	O
contraction	O
during	O
CCCP	O
treatment	O
,	O
were	O
all	O
excluded	O
from	O
the	O
experiments	O
.	O

Table	O
1	O
represents	O
the	O
morphological	O
change	O
in	O
cell	O
size	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
,	O
accompanied	O
by	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Compared	O
with	O
the	O
control	O
,	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
diltiazem	O
(	O
10	O
μM	O
)	O
,	O
Ni2	O
+	O
(	O
5	O
mM	O
)	O
and	O
KB	O
-	O
R7943	O
(	O
10	O
μM	O
)	O
,	O
added	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
,	O
all	O
reduced	O
the	O
cell	O
shortening	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
these	O
effects	O
correlated	O
well	O
with	O
the	O
attenuation	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
.	O

Treatment	O
with	O
diltiazem	O
(	O
3	O
μM	O
)	O
failed	O
to	O
reduce	O
the	O
contraction	O
,	O
which	O
correlated	O
with	O
the	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Neither	O
nitrendipine	O
(	O
10	O
μM	O
)	O
nor	O
nicardipine	O
(	O
10	O
μM	O
)	O
attenuated	O
the	O
contraction	O
or	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
.	O

4	O
Discussion	O
4.1	O
Increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
isolated	O
myocytes	O
Isolated	O
cardiomyocytes	O
are	O
reversibly	O
made	O
ATP	O
-	O
depleted	O
by	O
CCCP	O
,	O
a	O
reversible	O
inhibitor	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
(	O
Li	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
myocytes	O
,	O
which	O
show	O
a	O
rigor	O
contraction	O
on	O
metabolic	O
inhibition	O
are	O
reported	O
to	O
have	O
depressed	O
Ca2	O
+	O
overload	O
,	O
because	O
the	O
activity	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
is	O
inhibited	O
by	O
energy	O
depletion	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
;	O
Collins	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Li	O
et	O
al.	O
(	O
1988	O
)	O
have	O
also	O
reported	O
that	O
cells	O
maintaining	O
a	O
low	O
[	O
Ca2	O
+	O
]	O
i	O
level	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
.	O

Since	O
our	O
aim	O
was	O
to	O
assess	O
the	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
in	O
vitro	O
,	O
we	O
followed	O
a	O
protocol	O
with	O
Ca2	O
+	O
-free	O
Tyrode	O
solution	O
,	O
which	O
improves	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
.	O

Using	O
this	O
type	O
of	O
model	O
,	O
we	O
could	O
partially	O
simulate	O
the	O
ischemia	O
/	O
reperfusion	O
-	O
induced	O
Ca2	O
+	O
overload	O
in	O
vitro	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
marked	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
observed	O
after	O
washout	O
of	O
CCCP	O
with	O
Ca2	O
+	O
-containing	O
Tyrode	O
solution	O
.	O

This	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
was	O
suppressed	O
by	O
Ni2	O
+	O
or	O
KB	O
-	O
R7943	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
but	O
was	O
not	O
suppressed	O
by	O
nitrendipine	O
or	O
nicardipine	O
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
by	O
energy	O
repletion	O
occurred	O
via	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
but	O
not	O
through	O
the	O
dihydropyridine	O
-	O
sensitive	O
Ca2	B
+	I
channel	I
in	O
this	O
model	O
.	O

4.2	O
Cardioprotective	O
effect	O
of	O
l	O
-cis	O
diltiazem	O
on	O
Ca2	O
+	O
overload	O
in	O
guinea	O
pig	O
myocytes	O
In	O
the	O
present	O
study	O
,	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuated	O
both	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
and	O
the	O
cell	O
shortening	O
induced	O
by	O
CCCP	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
demonstrated	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuated	O
veratridine	O
-	O
induced	O
Ca2	O
+	O
overload	O
and	O
hypercontracture	O
in	O
isolated	O
rat	O
hearts	O
.	O

However	O
,	O
this	O
is	O
not	O
direct	O
evidence	O
that	O
l	O
-cis	O
diltiazem	O
actually	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
by	O
inhibiting	O
Ca2	O
+	O
overload	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
mimicked	O
the	O
phenomenon	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
the	O
chamber	O
and	O
our	O
data	O
are	O
the	O
first	O
demonstration	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
protect	O
against	O
the	O
Ca2	O
+	O
overload	O
induced	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
same	O
concentration	O
range	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
observation	O
that	O
nitrendipine	O
and	O
nicardipine	O
were	O
without	O
effect	O
,	O
suggests	O
that	O
their	O
effects	O
are	O
independent	O
of	O
L	B
-	I
type	I
Ca2	I
+	I
channel	I
blocking	O
.	O

This	O
possibility	O
is	O
also	O
supported	O
by	O
the	O
results	O
of	O
a	O
previous	O
study	O
in	O
our	O
laboratory	O
showing	O
that	O
l	O
-cis	O
diltiazem	O
(	O
10	O
μM	O
)	O
as	O
well	O
as	O
diltiazem	O
(	O
3	O
μM	O
)	O
worked	O
to	O
preserve	O
high	O
-	O
energy	O
phosphates	O
in	O
the	O
ischemia	O
–	O
reperfusion	O
model	O
of	O
isolated	O
guinea	O
pig	O
hearts	O
(	O
submitted	O
for	O
publication	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
inclusion	O
of	O
diltiazem	O
(	O
3	O
μM	O
)	O
throughout	O
the	O
experiment	O
attenuated	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
during	O
reperfusion	O
(	O
Fig.	O
3A	O
)	O
.	O

However	O
,	O
the	O
addition	O
of	O
diltiazem	O
(	O
3	O
μM	O
)	O
,	O
started	O
5	O
min	O
before	O
reperfusion	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
we	O
suggest	O
that	O
some	O
events	O
during	O
chemical	O
ischemia	O
,	O
which	O
could	O
be	O
affected	O
by	O
diltiazem	O
,	O
might	O
be	O
involved	O
in	O
the	O
Ca2	O
+	O
overload	O
during	O
reperfusion	O
(	O
Watts	O
et	O
al.	O
,	O
1990	O
;	O
Sakamoto	O
et	O
al.	O
,	O
1997	O
)	O
.	O

4.3	O
Cardioprotective	O
mechanism	O
by	O
l	O
-cis	O
diltiazem	O
on	O
Ca2	O
+	O
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
In	O
the	O
present	O
model	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
was	O
inhibited	O
by	O
both	O
Ni2	O
+	O
and	O
KB	O
-	O
R7943	O
(	O
Fig.	O
2	O
)	O
.	O

Concerning	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
in	O
this	O
model	O
,	O
the	O
L	B
-	I
type	I
Ca2	I
+	I
channel	I
does	O
not	O
seem	O
to	O
be	O
involved	O
.	O

This	O
is	O
because	O
the	O
dihydropyridine	O
Ca2	B
+	I
channel	I
blockers	O
,	O
nitrendipine	O
and	O
nicardipine	O
,	O
affected	O
neither	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
nor	O
cell	O
shortening	O
(	O
Table	O
1	O
)	O
.	O

The	O
inhibition	O
of	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
may	O
afford	O
protection	O
from	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
previous	O
report	O
has	O
demonstrated	O
that	O
the	O
intracellular	O
Na+	O
concentration	O
(	O
[	O
Na+	O
]	O
i	O
)	O
is	O
increased	O
by	O
metabolic	O
inhibition	O
in	O
guinea	O
pig	O
myocytes	O
(	O
Satoh	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
indicates	O
that	O
Na+	O
overload	O
caused	O
during	O
metabolic	O
inhibition	O
is	O
important	O
in	O
this	O
model	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
previously	O
reported	O
that	O
l	O
-cis	O
diltiazem	O
inhibited	O
veratridine	O
-	O
induced	O
Na+	O
overload	O
in	O
rat	O
cardiac	O
myocytes	O
.	O

Haigney	O
et	O
al.	O
(	O
1992	O
)	O
reported	O
that	O
the	O
[	O
Na+	O
]	O
i	O
increase	O
seen	O
during	O
hypoxia	O
is	O
potentiated	O
after	O
rigor	O
contraction	O
in	O
isolated	O
rat	O
myocytes	O
.	O

They	O
also	O
suggested	O
that	O
inactivation	O
-	O
resistant	O
Na+	B
channels	I
were	O
involved	O
in	O
this	O
[	O
Na+	O
]	O
i	O
increase	O
.	O

We	O
demonstrated	O
in	O
the	O
present	O
study	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
at	O
10	O
μM	O
,	O
when	O
introduced	O
5	O
min	O
before	O
washout	O
of	O
CCCP	O
,	O
attenuated	O
cell	O
shortening	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
it	O
is	O
speculated	O
that	O
both	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
attenuate	O
Ca2	O
+	O
overload	O
by	O
inhibiting	O
the	O
[	O
Na+	O
]	O
i	O
accumulation	O
early	O
after	O
energy	O
repletion	O
.	O

In	O
conclusion	O
,	O
we	O
first	O
demonstrated	O
that	O
l	O
-cis	O
diltiazem	O
attenuated	O
the	O
Ca2	O
+	O
overload	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
myocytes	O
.	O

The	O
cardioprotective	O
action	O
of	O
l	O
-cis	O
diltiazem	O
evidenced	O
in	O
the	O
present	O
work	O
merits	O
further	O
research	O
,	O
since	O
l	O
-cis	O
diltiazem	O
could	O
become	O
a	O
lead	O
compound	O
for	O
investigating	O
protection	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
Dr.	O
Satomi	O
Adachi	O
-	O
Akahane	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
helpful	O
discussions	O
and	O
Mr.	O
Shoichi	O
Kanda	O
,	O
Ms.	O
Maki	O
Urata	O
,	O
and	O
Mr.	O
Taichiro	O
Tomida	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
kind	O
assistance	O
with	O
cell	O
preparation	O
.	O

We	O
thank	O
Tanabe	O
Seiyaku	O
for	O
the	O
kind	O
gift	O
of	O
l	O
-cis	O
diltiazem	O
and	O
diltiazem	O
.	O

We	O
thank	O
Kanebo	O
for	O
the	O
kind	O
gift	O
of	O
KB	O
-	O
R	O
7943	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Dopamine	O
(	O
DA	O
)	O
is	O
a	O
neurotransmitter	O
that	O
plays	O
a	O
fundamental	O
role	O
in	O
the	O
control	O
of	O
a	O
variety	O
of	O
physiological	O
functions	O
including	O
locomotor	O
movement	O
,	O
learning	O
,	O
reward	O
behavior	O
,	O
and	O
hormone	O
synthesis	O
and	O
release	O
[	O
40	O
]	O
.	O

However	O
,	O
overflow	O
of	O
DA	O
in	O
the	O
brain	O
has	O
been	O
suggested	O
to	O
participate	O
in	O
certain	O
neurodegenerative	O
processes	O
.	O

These	O
include	O
ischemia	O
[	O
6	O
]	O
,	O
hypoxia	O
[	O
2	O
]	O
,	O
and	O
neurotoxicities	O
induced	O
by	O
excitatory	O
amino	O
acids	O
[	O
16	O
]	O
and	O
methamphetamine	O
[	O
38	O
]	O
.	O

In	O
all	O
of	O
the	O
above	O
cases	O
,	O
striatal	O
DA	O
availability	O
in	O
the	O
brain	O
is	O
significantly	O
increased	O
.	O

For	O
example	O
,	O
the	O
striatal	O
DA	O
concentration	O
rapidly	O
reaches	O
concentrations	O
as	O
high	O
as	O
0.2	O
mM	O
after	O
ligation	O
of	O
the	O
cervical	O
artery	O
in	O
the	O
gerbil	O
ischemic	O
model	O
[	O
45	O
]	O
.	O

Depletion	O
of	O
endogenous	O
DA	O
by	O
chemical	O
lesion	O
of	O
the	O
nigrostriatal	O
dopaminergic	O
pathway	O
reduces	O
ischemic	O
insult	O
to	O
the	O
striatum	O
[	O
17	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
DA	O
result	O
in	O
apoptosis	O
and	O
neurodegeneration	O
[	O
18	O
,	O
19	O
]	O
.	O

This	O
DA	O
neurotoxicity	O
is	O
believed	O
to	O
be	O
mediated	O
through	O
a	O
DA	O
-	O
oxidation	O
-	O
associated	O
pathway	O
.	O

DA	O
oxidative	O
stress	O
is	O
also	O
assumed	O
to	O
be	O
a	O
major	O
pathological	O
factor	O
that	O
contributes	O
to	O
dopaminergic	O
neuronal	O
degeneration	O
in	O
Parkinson	O
's	O
disease	O
[	O
14	O
]	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
DA	O
induces	O
apoptosis	O
involving	O
the	O
oxidation	O
–	O
JNK	O
–	O
c	O
-	O
Jun	O
activation	O
pathway	O
in	O
in	O
vitro	O
cell	O
cultures	O
[	O
32	O
]	O
and	O
activation	O
of	O
transcription	O
factors	O
AP-1	B
and	O
NF	B
-	I
κB	I
in	O
an	O
in	O
vivo	O
rat	O
model	O
[	O
29	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
high	O
concentrations	O
of	O
DA	O
in	O
rats	O
also	O
result	O
in	O
activation	O
of	O
astrocytes	O
as	O
indicated	O
by	O
an	O
increase	O
of	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
immunocytochemical	O
staining	O
and	O
astrocyte	O
proliferation	O
determined	O
by	O
[	O
3	O
H	O
]	O
R05	O
-	O
4864	O
binding	O
to	O
peripheral	O
benzodiazepine	B
receptors	I
on	O
astrocytes	O
[	O
15	O
]	O
.	O

Astrocytes	O
are	O
the	O
intimate	O
partners	O
of	O
neurons	O
and	O
play	O
important	O
physiological	O
roles	O
in	O
the	O
maintenance	O
of	O
the	O
microenvironment	O
of	O
neurons	O
,	O
including	O
sequestration	O
and	O
metabolism	O
of	O
various	O
neurotransmitters	O
,	O
and	O
production	O
of	O
proinflammatory	O
and	O
immunomodulatory	O
cytokines	O
and	O
neuropeptides	O
[	O
50	O
]	O
.	O

In	O
the	O
rat	O
ischemic	O
model	O
,	O
activated	O
striatal	O
astrocytes	O
appear	O
to	O
play	O
a	O
protective	O
role	O
for	O
DA	O
-	O
innervated	O
neurons	O
[	O
51	O
]	O
.	O

In	O
a	O
cell	O
culture	O
system	O
,	O
striatal	O
astrocytes	O
were	O
also	O
shown	O
to	O
have	O
a	O
protective	O
effect	O
against	O
hydrogen	O
peroxide	O
toxicity	O
in	O
dopaminergic	O
neurons	O
[	O
24	O
]	O
.	O

Nevertheless	O
,	O
the	O
mechanism	O
by	O
which	O
DA	O
activates	O
astrocytes	O
is	O
unknown	O
.	O

To	O
investigate	O
potential	O
signaling	O
of	O
activation	O
of	O
astrocytes	O
by	O
DA	O
,	O
we	O
have	O
chosen	O
a	O
rat	O
C6	O
glioma	O
cell	O
line	O
stably	O
expressing	O
DA	B
D2L	I
receptors	I
based	O
on	O
the	O
following	O
reasons	O
.	O

(	O
1	O
)	O
C6	O
glioma	O
cells	O
have	O
been	O
widely	O
used	O
as	O
a	O
model	O
of	O
glial	O
phenotype	O
[	O
5	O
,	O
39	O
]	O
.	O

(	O
2	O
)	O
Recent	O
evidence	O
suggests	O
that	O
D2	B
receptors	I
are	O
expressed	O
in	O
striatal	O
astrocytes	O
.	O

Physiologically	O
,	O
DA	O
can	O
induce	O
membrane	O
hyperpolarization	O
in	O
the	O
majority	O
of	O
astrocytes	O
from	O
the	O
striatum	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
application	O
of	O
domperidone	O
,	O
a	O
D2	B
receptor	I
antagonist	O
[	O
21	O
]	O
.	O

D2	B
antagonists	O
,	O
[	O
3	O
H	O
]	O
domperidone	O
and	O
[	O
3	O
H	O
]	O
spiperone	O
,	O
can	O
specifically	O
label	O
striatal	O
astrocytes	O
[	O
20	O
]	O
.	O

D2	B
receptor	I
mRNA	O
can	O
be	O
detected	O
by	O
either	O
in	O
situ	O
hybridization	O
or	O
polymerase	B
chain	O
reaction	O
from	O
astrocytes	O
in	O
striatum	O
,	O
an	O
area	O
enriched	O
with	O
dopaminergic	O
termini	O
,	O
but	O
not	O
astrocytes	O
in	O
cerebellum	O
,	O
which	O
receives	O
little	O
dopaminergic	O
innervation	O
[	O
4	O
]	O
.	O

This	O
region	O
-	O
specific	O
expression	O
of	O
D2	B
receptors	I
suggests	O
that	O
dopaminergic	O
neurons	O
may	O
physiologically	O
influence	O
astrocyte	O
functions	O
.	O

(	O
3	O
)	O
C6-D2L	O
cells	O
stably	O
express	O
recombinant	O
D2L	B
DA	I
receptors	I
[	O
36	O
]	O
.	O

The	O
expression	O
level	O
of	O
D2	B
receptors	I
in	O
C6-D2L	O
cells	O
is	O
about	O
188	O
fmol	O
/	O
mg	O
protein	O
,	O
which	O
is	O
close	O
to	O
that	O
in	O
striatal	O
membranes	O
(	O
∼400	O
fmol	O
/	O
mg	O
protein	O
)	O
[	O
30	O
,	O
37	O
]	O
.	O

(	O
4	O
)	O
Like	O
native	O
neuronal	O
D2	B
receptors	I
,	O
the	O
binding	O
of	O
agonist	O
to	O
D2	B
receptors	I
in	O
the	O
C6-D2L	O
cells	O
is	O
functionally	O
coupled	O
to	O
pertussis	B
-	I
toxin	I
-	O
sensitive	O
G	B
proteins	I
,	O
resulting	O
in	O
inhibition	O
of	O
adenylate	B
cyclase	I
[	O
49	O
]	O
and	O
activation	O
of	O
both	O
extracellular	B
signal	I
-	I
regulated	I
kinases	I
(	O
ERKs	B
)	O
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
[	O
30	O
]	O
.	O

Given	O
the	O
fact	O
of	O
C6	O
glial	O
phenotype	O
and	O
D2	B
receptors	I
in	O
striatal	O
astrocytes	O
,	O
the	O
biological	O
functions	O
stimulated	O
by	O
D2	B
receptors	I
observed	O
in	O
C6-D2L	O
cells	O
may	O
mimic	O
those	O
produced	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
C6-D2L	O
cell	O
line	O
may	O
serve	O
as	O
a	O
good	O
in	O
vitro	O
cell	O
culture	O
model	O
for	O
studies	O
of	O
DA	O
regulation	O
of	O
glial	O
response	O
.	O

Using	O
this	O
C6-D2L	O
cell	O
line	O
,	O
we	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	O
stimulate	O
cell	O
proliferation	O
through	O
activation	O
of	O
both	O
ERKs	B
and	O
JNK	B
[	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
found	O
that	O
high	O
concentrations	O
(	O
micromolar	O
levels	O
)	O
of	O
DA	O
stimulate	O
a	O
delayed	O
mitogenesis	O
compared	O
to	O
that	O
induced	O
by	O
the	O
nanomolar	O
levels	O
of	O
DA	O
.	O

This	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
D2-receptor	B
-	O
mediated	O
intracellular	O
redox	O
–	O
tyrosine	B
kinase	I
cascade	O
,	O
but	O
does	O
not	O
need	O
ERK	B
activation	O
.	O

In	O
addition	O
,	O
micromolar	O
levels	O
of	O
DA	O
also	O
increase	O
GFAP	B
expression	O
,	O
which	O
is	O
linked	O
to	O
a	O
D2-receptor	B
-	O
independent	O
p38	B
MAPK	I
activation	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Antibodies	B
against	O
phosphorylated	O
tyrosine	O
(	O
PY99	O
)	O
and	O
ERK2	B
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Antibodies	B
against	O
phospho	B
-	I
specific	I
ERK	I
and	O
phospho	B
-	I
specific	I
p38	I
MAPK	I
were	O
from	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O

DA	O
,	O
(	O
+	O
)	O
-	O
and	O
(	O
−	O
)	O
-butaclamol	O
hydrochloride	O
,	O
and	O
(	O
−	O
)	O
-quinpirole	O
hydrochloride	O
were	O
from	O
Research	O
Biochemicals	O
International	O
(	O
Natick	O
,	O
MA	O
)	O
.	O

PD098059	O
,	O
p38	B
inhibitor	O
SB	O
203580	O
,	O
diphenyleneiodonium	O
chloride	O
(	O
DPI	O
)	O
,	O
Herbimycin	O
A	O
,	O
Wortmannin	O
,	O
H7	O
,	O
and	O
staurosporine	O
were	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Pertussis	B
toxin	I
(	O
PTX	B
)	O
and	O
N	O
-acetyl	O
-	O
l	O
-cysteine	O
(	O
NAC	O
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

[	O
3	O
H	O
]	O
Thymidine	O
was	O
purchased	O
form	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

Genistein	O
was	O
from	O
Gibco	O
BRL	O
(	O
Gaithersburg	O
,	O
MD	O
)	O
.	O

Hoechst	O
33342	O
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O

2.2	O
Cell	O
culture	O
and	O
treatments	O
Stably	O
transfected	O
C6-D2L	O
cells	O
were	O
prepared	O
as	O
described	O
[	O
46	O
]	O
and	O
maintained	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	O
serum	O
and	O
5	O
%	O
donor	O
calf	O
serum	O
with	O
penicillin	O
/	O
streptomycin	O
and	O
puromycin	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

The	O
wild	O
-	O
type	O
C6	O
cells	O
were	O
maintained	O
in	O
the	O
above	O
medium	O
without	O
puromycin	O
.	O

For	O
tyrosine	O
phosphorylation	O
and	O
GFAP	B
studies	O
,	O
the	O
cells	O
were	O
starved	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	O
acid	O
for	O
6–8	O
h	O
and	O
then	O
stimulated	O
with	O
indicated	O
reagents	O
.	O

All	O
reagents	O
were	O
prepared	O
or	O
diluted	O
with	O
DMEM	O
plus	O
0.025	O
%	O
ascorbic	O
acid	O
.	O

For	O
inhibitory	O
experiments	O
,	O
all	O
inhibitory	O
reagents	O
except	O
PTX	B
were	O
added	O
0.5	O
h	O
(	O
PTX	B
for	O
6	O
h	O
)	O
prior	O
to	O
stimulation	O
with	O
DA	O
.	O

2.3	O
Lysate	O
preparation	O
After	O
stimulation	O
,	O
the	O
cells	O
were	O
immediately	O
washed	O
twice	O
using	O
cold	O
PBS	O
and	O
then	O
solubilized	O
with	O
ice	O
-	O
cold	O
buffer	O
consisting	O
of	O
25	O
mM	O
Hepes	O
,	O
pH	O
7.5	O
,	O
300	O
mM	O
NaCl	O
,	O
1.5	O
mM	O
MgCl2	O
,	O
0.2	O
mM	O
EDTA	O
,	O
0.1	O
%	O
Triton	O
X-100	O
,	O
20	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.1	O
mM	O
sodium	O
orthovanadate	O
,	O
0.5	O
mM	O
DTT	O
,	O
100	O
μg	O
/	O
ml	O
PMSF	O
,	O
and	O
2	O
μg	O
/	O
ml	O
leupeptin	O
.	O

Cellular	O
extracts	O
were	O
cleared	O
by	O
centrifugation	O
for	O
30	O
min	O
at	O
14,000	O
rpm	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatants	O
were	O
saved	O
and	O
the	O
protein	O
concentration	O
was	O
determined	O
using	O
Bio	O
-	O
Rad	O
protein	O
reagent	O
.	O

For	O
determination	O
of	O
GFAP	B
,	O
the	O
cell	O
lysates	O
were	O
prepared	O
as	O
follows	O
.	O

Stimulated	O
cells	O
were	O
scraped	O
and	O
collected	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
3000	O
rpm	O
.	O

The	O
cell	O
pellets	O
were	O
washed	O
once	O
with	O
cold	O
PBS	O
,	O
pH	O
7.4	O
,	O
solubilized	O
with	O
hot	O
lysis	O
buffer	O
(	O
80–90	O
°	O
C	O
)	O
containing	O
10	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.6	O
,	O
150	O
mM	O
NaCl	O
,	O
0.5	O
mm	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
,	O
1	O
%	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
,	O
1	O
mM	O
sodium	O
orthovanadate	O
,	O
1	O
mM	O
PMSF	O
,	O
1	O
μg	O
/	O
ml	O
pepstatin	O
A	O
,	O
and	O
2	O
μg	O
/	O
ml	O
aprotinin	B
,	O
and	O
heated	O
for	O
20	O
min	O
at	O
90	O
°	O
C	O
.	O

The	O
protein	B
concentration	O
of	O
the	O
lysates	O
was	O
determined	O
by	O
using	O
Micro	O
BCA	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
.	O

All	O
lysates	O
were	O
used	O
immediately	O
or	O
aliquoted	O
and	O
stored	O
at	O
−70	O
°	O
C	O
for	O
further	O
use	O
.	O

2.4	O
Immunoblotting	O
Equal	O
amounts	O
of	O
lysate	O
protein	B
(	O
40	O
μg	O
/	O
lane	O
)	O
were	O
run	O
on	O
8–16	O
%	O
SDS	O
-	O
PAGE	O
and	O
electrophoretically	O
transferred	O
to	O
nitrocellulose	O
.	O

The	O
nitrocellulose	O
blot	O
was	O
blocked	O
with	O
10	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
TBST	O
buffer	O
(	O
20	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.4	O
,	O
500	O
mM	O
NaCl	O
,	O
and	O
0.01	O
%	O
Tween-20	O
)	O
and	O
then	O
incubated	O
with	O
primary	O
antibodies	O
(	O
phospho	B
-	I
specific	I
ERK	I
,	O
ERK2	B
,	O
phospho	B
-	I
specific	I
p38	I
MAPK	I
,	O
or	O
PY99	B
,	O
1:1000	O
)	O
in	O
TBST	O
containing	O
5	O
%	O
BSA	B
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
immunoreactive	O
bands	O
were	O
detected	O
by	O
sequential	O
incubation	O
with	O
horseradish	B
-	I
peroxidase	I
-	O
conjugated	O
secondary	O
antibody	B
(	O
1:5000	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
and	O
Renaissance	O
substrate	O
(	O
DuPont	O
;	O
Boston	O
,	O
MA	O
)	O
.	O

For	O
control	O
of	O
protein	B
loading	O
,	O
immunoblotting	O
with	O
ERK2	B
was	O
performed	O
using	O
either	O
a	O
sister	O
gel	O
or	O
a	O
stripped	O
blot	O
.	O

For	O
quantitative	O
studies	O
,	O
the	O
band	O
was	O
quantified	O
with	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
results	O
were	O
normalized	O
to	O
fold	O
of	O
control	O
and	O
presented	O
as	O
means±S.E.M.	O
2.5	O
Measurement	O
of	O
mitogenesis	O
The	O
procedures	O
were	O
described	O
elsewhere	O
[	O
31	O
]	O
.	O

C6-D2L	O
cells	O
(	O
1	O
×	O
105	O
/ml	O
,	O
0.2	O
ml	O
/	O
well	O
)	O
were	O
plated	O
in	O
a	O
96-well	O
plate	O
and	O
grown	O
for	O
24	O
h.	O
The	O
cells	O
were	O
rinsed	O
twice	O
with	O
serum	O
-	O
free	O
DMEM	O
and	O
starved	O
for	O
8	O
h	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	O
acid	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
incubated	O
with	O
DA	O
for	O
23	O
h	O
and	O
pulsed	O
with	O
2	O
μCi	O
[	O
3	O
H	O
]	O
thymidine	O
per	O
well	O
for	O
an	O
additional	O
6	O
h.	O
The	O
cells	O
in	O
each	O
well	O
were	O
fixed	O
with	O
ice	O
-	O
cold	O
5	O
%	O
trichloroacetic	O
acid	O
,	O
washed	O
three	O
times	O
with	O
cold	O
STE	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.2	O
,	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
solubilized	O
with	O
0.1	O
ml	O
of	O
a	O
mixture	O
of	O
0.1	O
%	O
SDS	O
and	O
0.01	O
N	O
NaOH	O
.	O

Incorporated	O
[	O
3	O
H	O
]	O
thymidine	O
was	O
counted	O
with	O
a	O
Beckman	O
liquid	O
scintillation	O
counter	O
and	O
expressed	O
as	O
counts	O
per	O
minute	O
per	O
well	O
(	O
cpm	O
/	O
well	O
)	O
.	O

2.6	O
Cell	O
cycle	O
analysis	O
by	O
flow	O
cytometry	O
Cell	O
cycle	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
method	O
by	O
Chrest	O
et	O
al.	O
[	O
9	O
]	O
.	O

Briefly	O
,	O
C6-D2L	O
cells	O
were	O
plated	O
in	O
35	O
mm	O
dishes	O
,	O
and	O
seeded	O
overnight	O
.	O

The	O
cells	O
were	O
starved	O
for	O
8	O
h	O
by	O
replacing	O
the	O
mixture	O
of	O
DMEM	O
plus	O
0.025	O
%	O
ascorbic	O
acid	O
and	O
stimulated	O
for	O
29	O
h.	O
The	O
cells	O
were	O
then	O
collected	O
and	O
suspended	O
in	O
complete	O
cell	O
culture	O
medium	O
.	O

The	O
cells	O
(	O
1	O
×	O
106	O
cells	O
/	O
ml	O
)	O
were	O
treated	O
with	O
1	O
μM	O
Hoechst	O
33342	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Cells	O
were	O
analyzed	O
for	O
DNA	O
content	O
using	O
a	O
FACStarplus	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
Immunocytometry	O
System	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
equipped	O
with	O
argon	O
and	O
krypton	O
lasers	O
.	O

Hoechst	O
33342	O
stained	O
cells	O
were	O
excited	O
with	O
350–356	O
nm	O
wavelength	O
UV	O
light	O
from	O
the	O
krypton	O
laser	O
and	O
the	O
fluorescence	O
emission	O
was	O
collected	O
with	O
a	O
424-nm	O
filter	O
.	O

DNA	O
histograms	O
were	O
acquired	O
by	O
collecting	O
a	O
total	O
of	O
10,000	O
events	O
.	O

Cell	O
compartments	O
,	O
including	O
G1	O
,	O
S	O
,	O
and	O
G2	O
/M	O
phases	O
,	O
were	O
determined	O
using	O
the	O
Multicycle	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

3	O
Results	O
3.1	O
DA	O
stimulates	O
mitogenesis	O
We	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
[	O
30	O
]	O
.	O

The	O
maximal	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
occurs	O
at	O
17	O
h	O
after	O
exposure	O
to	O
100	O
nM	O
DA	O
concentration	O
.	O

We	O
extended	O
this	O
study	O
by	O
observing	O
the	O
cell	O
response	O
at	O
high	O
DA	O
concentrations	O
and	O
longer	O
exposure	O
.	O

Interestingly	O
,	O
micromolar	O
levels	O
of	O
DA	O
also	O
stimulate	O
DNA	O
synthesis	O
but	O
with	O
a	O
slower	O
time	O
course	O
(	O
about	O
29	O
h	O
after	O
DA	O
stimulation	O
,	O
data	O
not	O
shown	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
DA	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

The	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
was	O
linearly	O
increased	O
from	O
0.1	O
to	O
500	O
μM	O
DA	O
.	O

The	O
mitogenic	O
activity	O
at	O
500	O
μM	O
DA	O
was	O
about	O
3.2±0.2	O
times	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

This	O
DA	O
-	O
induced	O
mitogenesis	O
could	O
be	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
aphidicoline	O
(	O
20	O
μg	O
/	O
ml	O
,	O
data	O
not	O
shown	O
)	O
,	O
a	O
potent	O
DNA	B
polymerase	I
a	O
inhibitor	O
.	O

To	O
confirm	O
the	O
DA	O
mitogenic	O
activation	O
,	O
we	O
also	O
determined	O
the	O
cell	O
cycle	O
distribution	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
200	O
μM	O
DA	O
increased	O
the	O
percentage	O
of	O
the	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
of	O
cells	O
in	O
G1	O
phase	O
,	O
suggesting	O
that	O
DA	O
promotes	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
this	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
activation	O
of	O
D2	B
receptors	I
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
10	O
μM	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
potent	O
D2	B
receptor	I
antagonist	O
,	O
completely	O
inhibited	O
DA	O
-	O
induced	O
DNA	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
,	O
while	O
10	O
μM	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
form	O
of	O
(	O
+	O
)	O
-butaclamol	O
,	O
had	O
no	O
effect	O
on	O
the	O
DA	O
-	O
stimulated	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

To	O
confirm	O
these	O
results	O
,	O
we	O
determined	O
the	O
effect	O
of	O
quinpirole	O
,	O
a	O
specific	O
D2	B
receptor	I
agonist	O
,	O
on	O
cell	O
cycling	O
.	O

Like	O
the	O
effect	O
of	O
micromolar	O
levels	O
of	O
DA	O
,	O
micromolar	O
levels	O
of	O
quinpirole	O
promoted	O
cell	O
proliferation	O
.	O

Quinpirole	O
increased	O
the	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
in	O
G1	O
phase	O
(	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
mitogenic	O
effect	O
within	O
a	O
DA	O
concentration	O
range	O
of	O
0–500	O
μM	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
without	O
expression	O
of	O
D2L	B
receptors	I
(	O
Fig.	O
1	O
a	O
)	O
.	O

Instead	O
,	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
of	O
wild	O
-	O
type	O
C6	O
cells	O
was	O
decreased	O
about	O
20–26	O
%	O
at	O
DA	O
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	B
,	O
a	O
G	B
protein	I
-	I
receptor	I
uncoupler	O
,	O
partially	O
blocked	O
DA	O
-	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
this	O
DA	O
-	O
stimulated	O
mitogenesis	O
requires	O
DA	O
D2	B
receptor	I
activation	O
.	O

3.2	O
Effects	O
of	O
kinase	B
inhibitors	O
on	O
DA	O
-	O
induced	O
mitogenesis	O
In	O
order	O
to	O
examine	O
the	O
signaling	O
that	O
mediates	O
the	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
we	O
first	O
tested	O
the	O
effect	O
of	O
DA	O
on	O
the	O
activity	O
of	O
ERK	B
,	O
a	O
protein	B
serine	I
kinase	I
that	O
is	O
linked	O
to	O
cell	O
proliferation	O
stimulated	O
by	O
growth	O
factors	O
,	O
cytokines	O
and	O
neurotransmitters	O
[	O
11	O
,	O
34	O
]	O
.	O

As	O
shown	O
in	O
the	O
phospho	O
-	O
specific	O
ERK	B
immunoblot	O
of	O
Fig.	O
2	O
a	O
,	O
DA	O
had	O
little	O
or	O
no	O
effect	O
on	O
ERK	B
phosphorylation	O
at	O
concentrations	O
corresponding	O
to	O
its	O
mitogenic	O
effect	O
(	O
10–500	O
μM	O
)	O
,	O
although	O
DA	O
at	O
lower	O
concentrations	O
did	O
stimulate	O
ERK	B
phosphorylation	O
and	O
activity	O
[	O
30	O
]	O
.	O

The	O
bottom	O
panel	O
in	O
Fig.	O
2	O
a	O
shows	O
ERK2	B
immunoblot	O
of	O
a	O
sister	O
gel	O
,	O
indicating	O
that	O
a	O
similar	O
amount	O
of	O
protein	B
was	O
loaded	O
.	O

To	O
confirm	O
that	O
ERK	B
was	O
not	O
involved	O
in	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
PD098059	O
,	O
a	O
selective	O
MEK1	B
inhibitor	O
[	O
3	O
]	O
,	O
on	O
DA	O
-	O
induced	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
b	O
,	O
the	O
DA	O
-	O
stimulated	O
DNA	O
synthesis	O
was	O
only	O
partially	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
PD	O
098059	O
(	O
10–50	O
μM	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

With	O
application	O
of	O
either	O
10	O
or	O
50	O
μM	O
PD	O
098059	O
,	O
bFGF	B
-	O
stimulated	O
ERK	B
activity	O
,	O
as	O
indicated	O
by	O
ERK	B
phosphorylation	O
,	O
was	O
greatly	O
or	O
completely	O
inhibited	O
,	O
respectively	O
(	O
Fig.	O
2	O
c	O
)	O
,	O
which	O
serves	O
as	O
a	O
positive	O
control	O
of	O
the	O
inhibitory	O
effect	O
of	O
PD098059	O
on	O
MEK1–ERK	B
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
mitogenesis	O
induced	O
by	O
micromolar	O
levels	O
of	O
DA	O
is	O
not	O
mediated	O
by	O
a	O
MEK	B
–	O
ERK	B
activation	O
pathway	O
.	O

We	O
have	O
also	O
tested	O
other	O
kinase	B
inhibitors	O
on	O
DA	O
-	O
stimulated	O
mitogenesis	O
.	O

These	O
inhibitors	O
included	O
Wortmannin	O
for	O
PI3	B
kinase	I
,	O
rapamycin	O
for	O
S6	B
kinase	I
,	O
and	O
SB203580	O
for	O
p38	B
MAP	I
kinase	I
.	O

Staurosporine	O
and	O
H7	O
are	O
inhibitors	O
for	O
a	O
broad	O
spectrum	O
of	O
protein	O
kinases	O
,	O
which	O
include	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
G	O
,	O
CaM	O
kinase	O
,	O
and	O
myosin	O
light	O
chain	O
kinase	O
.	O

The	O
effect	O
of	O
depletion	O
of	O
PKC	B
on	O
DA	O
-	O
stimulated	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
into	O
DNA	O
was	O
also	O
examined	O
by	O
prolonged	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
.	O

The	O
data	O
are	O
summarized	O
on	O
Table	O
2	O
.	O

All	O
these	O
treatments	O
had	O
no	O
effect	O
on	O
DA	O
-	O
induced	O
DNA	O
synthesis	O
.	O

3.3	O
DA	O
stimulates	O
mitogenesis	O
-	O
associated	O
protein	B
tyrosine	O
phosphorylation	O
DA	O
stimulated	O
protein	B
tyrosine	O
phosphorylation	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
3	O
a	O
and	O
b	O
)	O
.	O

The	O
phosphorylated	O
tyrosine	O
-	O
containing	O
proteins	B
were	O
easily	O
immunodetected	O
with	O
monoclonal	B
anti	I
-	I
phosphotyrosine	I
IgG	I
(	O
PY99	B
)	O
.	O

When	O
C6-D2L	O
cells	O
were	O
treated	O
with	O
200	O
μM	O
DA	O
,	O
protein	B
tyrosine	O
phosphorylation	O
rapidly	O
increased	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
between	O
15	O
and	O
30	O
min	O
,	O
then	O
decreased	O
by	O
1	O
h	O
(	O
Fig.	O
3	O
a	O
)	O
.	O

A	O
majority	O
of	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
were	O
located	O
within	O
the	O
molecular	O
size	O
range	O
of	O
50–200	O
kDa	O
,	O
some	O
of	O
which	O
are	O
indicated	O
by	O
arrows	O
in	O
Fig.	O
3	O
a.	O
DA	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
was	O
evident	O
within	O
DA	O
concentrations	O
ranging	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
3	O
b	O
)	O
,	O
which	O
paralleled	O
the	O
DA	O
concentrations	O
for	O
stimulation	O
of	O
mitogenesis	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

To	O
monitor	O
the	O
amounts	O
of	O
protein	B
loaded	O
,	O
all	O
blots	O
were	O
stripped	O
and	O
then	O
immunoblotted	O
with	O
anti	B
-	I
ERK2	I
.	O

The	O
lower	O
anti	B
-	I
ERK2	I
immunoblottings	O
in	O
Fig.	O
3	O
a	O
and	O
b	O
show	O
that	O
a	O
similar	O
amount	O
of	O
protein	B
was	O
loaded	O
.	O

This	O
protein	B
tyrosine	O
phosphorylation	O
,	O
mostly	O
at	O
molecular	O
sizes	O
between	O
50	O
and	O
150	O
kDa	O
,	O
required	O
D2	B
receptor	I
activation	O
.	O

Preincubation	O
of	O
C6-D2L	O
cells	O
30	O
min	O
with	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
specific	O
D2	B
receptor	I
antagonist	O
,	O
could	O
block	O
DA	O
-	O
induced	O
protein	B
tyrosine	O
phosphorylation	O
(	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
antagonistic	O
effect	O
was	O
concentration	O
-	O
dependent	O
.	O

Increasing	O
(	O
+	O
)	O
-butaclamol	O
from	O
1	O
to	O
100	O
μM	O
resulted	O
in	O
significant	O
inhibition	O
of	O
protein	B
tyrosine	O
phosphorylation	O
.	O

Especially	O
in	O
the	O
presence	O
of	O
100	O
μM	O
(	O
+	O
)	O
-butaclamol	O
,	O
the	O
cells	O
failed	O
to	O
respond	O
to	O
200	O
μM	O
DA	O
stimulation	O
(	O
upper	O
left	O
panel	O
,	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
blocking	O
effect	O
was	O
specific	O
to	O
D2	B
receptors	I
since	O
application	O
of	O
the	O
same	O
amount	O
of	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
form	O
of	O
(	O
+	O
)	O
-butaclamol	O
,	O
did	O
not	O
show	O
any	O
effect	O
on	O
DA	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
.	O

We	O
have	O
also	O
directly	O
tested	O
the	O
effect	O
of	O
quinpirole	O
,	O
a	O
D2	B
receptor	I
agonist	O
,	O
on	O
protein	B
tyrosine	O
phosphorylation	O
.	O

As	O
shown	O
in	O
the	O
right	O
panel	O
of	O
Fig.	O
3	O
c	O
,	O
increasing	O
quinpirole	O
from	O
10	O
to	O
200	O
μM	O
resulted	O
in	O
a	O
great	O
increase	O
in	O
the	O
amount	O
of	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
.	O

Furthermore	O
,	O
we	O
could	O
not	O
observe	O
significant	O
changes	O
in	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
in	O
wild	O
-	O
type	O
C6	O
cells	O
treated	O
with	O
DA	O
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
data	O
not	O
shown	O
)	O
.	O

Inactivation	O
of	O
cellular	O
PTX	B
-	B
sensitive	I
G	I
proteins	I
by	O
PTX	B
partially	O
blocked	O
DA	O
-	O
induced	O
protein	B
tyrosine	O
phosphorylation	O
.	O

We	O
have	O
quantified	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
between	O
50	O
and	O
150	O
kDa	O
by	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
500	O
ng	O
/	O
ml	O
PTX	B
inhibited	O
DA	O
(	O
200	O
μM	O
)	O
-stimulated	O
tyrosine	O
phosphorylation	O
by	O
57±15	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

PTX	B
at	O
a	O
concentration	O
of	O
100	O
ng	O
/	O
ml	O
also	O
reduced	O
the	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
by	O
24±13	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

Coincidentally	O
,	O
this	O
percentage	O
of	O
reduction	O
of	O
tyrosine	O
phosphorylation	O
by	O
100	O
ng	O
/	O
ml	O
PTX	B
is	O
close	O
to	O
its	O
inhibitory	O
ability	O
(	O
32±10	O
%	O
,	O
n	O
=3	O
,	O
Fig.	O
1	O
b	O
)	O
to	O
DA	O
-	O
stimulated	O
mitogenesis	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
D2	B
receptor	I
activation	O
is	O
associated	O
with	O
protein	B
tyrosine	I
kinase	I
activity	O
.	O

In	O
order	O
to	O
test	O
the	O
idea	O
that	O
tyrosine	B
kinase	I
is	O
involved	O
in	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
genistein	O
,	O
a	O
potent	O
tyrosine	B
kinase	I
inhibitor	O
,	O
on	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
a	O
,	O
preincubation	O
of	O
either	O
genistein	O
or	O
herbimycin	O
(	O
another	O
tyrosine	B
kinase	I
inhibitor	O
)	O
significantly	O
blocked	O
the	O
protein	B
tyrosine	O
phosphorylation	O
stimulated	O
by	O
200	O
μM	O
DA	O
.	O

Application	O
of	O
10	O
μM	O
genistein	O
completely	O
inhibited	O
the	O
DNA	O
synthesis	O
induced	O
by	O
DA	O
(	O
Fig.	O
4	O
b	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
activation	O
of	O
protein	B
tyrosine	I
kinase	I
is	O
required	O
for	O
the	O
promotion	O
of	O
mitogenesis	O
induced	O
by	O
DA	O
.	O

3.4	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
involved	O
in	O
an	O
intracellular	O
redox	O
–	O
tyrosine	O
phosphorylation	O
pathway	O
Although	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
implicated	O
in	O
pathological	O
cellular	O
processes	O
,	O
including	O
oxidative	O
stress	O
damage	O
[	O
47	O
]	O
and	O
ischemic	O
neuronal	O
injury	O
[	O
10	O
]	O
,	O
recent	O
evidence	O
suggests	O
that	O
ROS	O
are	O
involved	O
in	O
cell	O
signaling	O
that	O
regulates	O
proliferation	O
and	O
DNA	O
synthesis	O
[	O
22	O
]	O
.	O

To	O
test	O
the	O
idea	O
that	O
D2	B
receptors	I
stimulate	O
mitogenesis	O
through	O
regulation	O
of	O
an	O
intracellular	O
redox	O
–	O
tyrosine	B
kinase	I
cascade	O
,	O
we	O
examined	O
the	O
effect	O
of	O
diphenylene	O
iodonium	O
(	O
DPI	O
)	O
and	O
N	O
-acetyl	O
cysteine	O
(	O
NAC	O
)	O
on	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

DPI	O
is	O
an	O
inhibitor	O
of	O
flavonoid	O
-	O
containing	O
oxidases	B
that	O
can	O
catalyze	O
the	O
formation	O
of	O
superoxide	O
from	O
oxygen	O
with	O
NADH	O
/	O
NADPH	O
as	O
an	O
electron	O
donor	O
[	O
28	O
,	O
43	O
]	O
.	O

Some	O
flavonoid	O
-	O
containing	O
oxidases	B
,	O
such	O
as	O
NADPH	B
-	I
dependent	I
oxidase	I
,	O
have	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
membrane	O
receptors	B
,	O
such	O
as	O
intrinsic	O
tyrosine	B
-	I
kinase	I
-	B
containing	I
receptors	I
and	O
G	B
-	I
protein	I
-	B
coupled	I
receptors	I
[	O
22	O
,	O
23	O
]	O
.	O

NAC	O
is	O
an	O
antioxidant	O
that	O
can	O
scavenge	O
free	O
radicals	O
.	O

Pretreatment	O
of	O
C6-D2L	O
cells	O
with	O
either	O
1	O
μM	O
DPI	O
or	O
20	O
mM	O
NAC	O
greatly	O
reduced	O
tyrosine	O
phosphorylation	O
and	O
consequent	O
mitogenesis	O
induced	O
by	O
DA	O
(	O
Fig.	O
5	O
a	O
and	O
b	O
)	O
.	O

Either	O
DPI	O
or	O
NAC	O
itself	O
has	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
of	O
proteins	B
(	O
Fig.	O
5	O
)	O
.	O

The	O
anti	B
-	I
ERK2	I
immunoblotting	O
of	O
same	O
stripped	O
blot	O
shows	O
that	O
a	O
similar	O
amount	O
of	O
protein	B
was	O
loaded	O
in	O
each	O
lane	O
(	O
lower	O
panel	O
,	O
Fig.	O
5	O
a	O
)	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
protein	B
tyrosine	I
kinase	I
and	O
consequent	O
mitogenesis	O
may	O
be	O
regulated	O
by	O
intracellular	O
ROS	O
,	O
which	O
are	O
assumed	O
to	O
be	O
produced	O
by	O
flavonoid	O
-	O
containing	O
oxidases	B
.	O

Next	O
,	O
we	O
tested	O
the	O
roles	O
of	O
ROS	O
in	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
by	O
application	O
of	O
exogenous	O
H2	O
O2	O
.	O

We	O
assumed	O
that	O
the	O
protein	B
tyrosine	I
kinase	I
could	O
be	O
activated	O
by	O
DA	O
-	O
stimulated	O
increase	O
of	O
intracellular	O
ROS	O
.	O

If	O
this	O
is	O
the	O
case	O
,	O
exogenous	O
application	O
of	O
low	O
concentrations	O
of	O
H2	O
O2	O
may	O
enhance	O
protein	B
kinase	I
activity	O
and	O
subsequent	O
mitogenesis	O
induced	O
by	O
DA	O
.	O

As	O
shown	O
in	O
Fig.	O
6	O
a	O
,	O
increasing	O
extracellular	O
H2	O
O2	O
concentrations	O
did	O
result	O
in	O
increase	O
of	O
DA	O
-	O
induced	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
.	O

The	O
upper	O
panel	O
shows	O
anti	B
-	I
phosphotyrosine	I
immunoblotting	O
,	O
while	O
the	O
lower	O
panel	O
is	O
a	O
quantified	O
data	O
(	O
from	O
50	O
to	O
150	O
kDa	O
)	O
of	O
at	O
least	O
three	O
experiments	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
sister	O
gel	O
was	O
run	O
and	O
immunostained	O
with	O
anti	B
-	I
ERK2	I
to	O
monitor	O
protein	B
loading	O
.	O

The	O
nanomolar	O
levels	O
of	O
H2	O
O2	O
enhanced	O
by	O
about	O
2.7-fold	O
amounts	O
of	O
tyrosine	B
-	I
phosphorylated	I
proteins	I
stimulated	O
by	O
10	O
μM	O
DA	O
,	O
although	O
H2	O
O2	O
levels	O
below	O
1	O
nM	O
show	O
only	O
a	O
small	O
effect	O
(	O
Fig.	O
6	O
a	O
)	O
.	O

Furthermore	O
,	O
an	O
enhancement	O
effect	O
of	O
H2	O
O2	O
on	O
DA	O
-	O
stimulated	O
mitogenesis	O
was	O
also	O
observed	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

However	O
,	O
the	O
capability	O
of	O
increasing	O
DA	O
-	O
induced	O
mitogenesis	O
at	O
nanomolar	O
levels	O
of	O
H2	O
O2	O
was	O
reduced	O
when	O
compared	O
with	O
that	O
at	O
0.1	O
pM	O
H2	O
O2	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
a	O
dual	O
effect	O
of	O
ROS	O
in	O
cell	O
proliferation	O
:	O
a	O
stimulatory	O
effect	O
at	O
low	O
concentrations	O
and	O
a	O
toxic	O
effect	O
at	O
high	O
concentrations	O
[	O
22	O
]	O
.	O

With	O
the	O
application	O
of	O
H2	O
O2	O
alone	O
without	O
DA	O
,	O
C6-D2L	O
cells	O
did	O
exhibit	O
such	O
a	O
dual	O
mitogenic	O
effect	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.5	O
DA	O
increases	O
GFAP	B
expression	O
In	O
addition	O
to	O
stimulating	O
DNA	O
synthesis	O
,	O
DA	O
at	O
micromolar	O
levels	O
also	O
significantly	O
increased	O
the	O
expression	O
of	O
GFAP	B
,	O
a	O
sensitive	O
parameter	O
serving	O
as	O
another	O
criterion	O
of	O
reactive	O
astrocytes	O
[	O
33	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
a	O
,	O
C6-D2L	O
cells	O
responded	O
to	O
DA	O
(	O
200	O
μM	O
)	O
treatment	O
with	O
an	O
increase	O
in	O
GFAP	B
expression	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Between	O
0	O
and	O
48	O
h	O
after	O
stimulation	O
,	O
the	O
amount	O
of	O
GFAP	B
was	O
increased	O
about	O
2.1±0.1-fold	O
(	O
Fig.	O
7	O
a	O
)	O
.	O

Concentration	O
dependence	O
studies	O
carried	O
out	O
at	O
24	O
h	O
showed	O
that	O
maximal	O
stimulation	O
of	O
GFAP	B
expression	O
occurred	O
at	O
200	O
μM	O
DA	O
(	O
Fig.	O
7	O
b	O
)	O
.	O

Interestingly	O
,	O
GFAP	B
production	O
was	O
decreased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
500	O
μM	O
DA	O
for	O
24	O
h	O
(	O
Fig.	O
7	O
b	O
)	O
,	O
which	O
differs	O
from	O
the	O
dose	O
–	O
response	O
data	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
DA	O
stimulatory	O
GFAP	B
synthesis	O
may	O
be	O
regulated	O
by	O
a	O
different	O
pathway	O
from	O
mitogenesis	O
.	O

Alternatively	O
,	O
this	O
decrease	O
of	O
GFAP	B
expression	O
at	O
500	O
μM	O
DA	O
may	O
be	O
due	O
to	O
widespread	O
mitogenesis	O
since	O
immature	O
astrocytes	O
have	O
a	O
less	O
amount	O
of	O
GFAP	B
expression	O
.	O

3.6	O
DA	O
-	O
induced	O
GFAP	B
generation	O
involves	O
activation	O
of	O
p38	B
MAPK	I
It	O
became	O
important	O
to	O
determine	O
whether	O
DA	O
-	O
stimulated	O
GFAP	B
production	O
might	O
also	O
be	O
required	O
to	O
activate	O
the	O
D2	B
receptor	I
–	I
tyrosine	I
kinase	I
pathway	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
used	O
a	O
paradigm	O
similar	O
to	O
that	O
for	O
DA	O
-	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
(	O
Fig.	O
1	O
)	O
.	O

Surprisingly	O
,	O
the	O
GFAP	B
stimulation	O
did	O
not	O
appear	O
to	O
be	O
regulated	O
by	O
D2	B
receptors	I
since	O
it	O
was	O
not	O
influenced	O
by	O
the	O
D2	B
receptor	I
antagonist	O
,	O
(	O
+	O
)	O
-butaclamol	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Application	O
of	O
DA	O
to	O
wild	O
-	O
type	O
C6	O
cells	O
also	O
resulted	O
in	O
a	O
similar	O
increase	O
in	O
GFAP	B
expression	O
as	O
that	O
in	O
C6-D2L	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
direct	O
application	O
of	O
quinpirole	O
(	O
200	O
μM	O
)	O
,	O
a	O
D2	B
receptor	I
agonist	O
,	O
had	O
no	O
effect	O
on	O
GFAP	B
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
PTX	B
for	O
6	O
h	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
GFAP	B
generation	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
suggesting	O
that	O
PTX	B
-	B
sensitive	I
G	I
proteins	I
might	O
also	O
not	O
be	O
involved	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
either	O
10	O
μM	O
genistein	O
or	O
20	O
mM	O
NAC	O
also	O
had	O
no	O
effect	O
on	O
GFAP	B
expression	O
due	O
to	O
DA	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
while	O
the	O
identical	O
treatments	O
resulted	O
in	O
the	O
blocking	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
4	O
b	O
,	O
Fig.	O
5	O
b	O
)	O
.	O

PD098059	O
also	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
GFAP	B
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Thus	O
,	O
unlike	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
GFAP	B
stimulation	O
does	O
not	O
seem	O
to	O
involve	O
the	O
D2	B
receptor	I
–	I
tyrosine	I
kinase	I
pathway	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
GFAP	B
expression	O
stimulated	O
by	O
DA	O
could	O
be	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
a	O
selective	O
p38	B
MAPK	I
inhibitor	O
[	O
13	O
,	O
27	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
8	O
b	O
,	O
application	O
of	O
10	O
μM	O
SB	O
203580	O
completely	O
blocked	O
the	O
increases	O
in	O
GFAP	B
generation	O
stimulated	O
by	O
DA	O
at	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
,	O
suggesting	O
that	O
activation	O
of	O
p38	B
MAPK	I
might	O
be	O
required	O
for	O
the	O
regulation	O
of	O
GFAP	B
generation	O
.	O

By	O
using	O
anti	B
-	I
phospho	I
-	I
specific	I
p38	I
MAPK	I
immunoblotting	O
,	O
we	O
examined	O
the	O
effect	O
of	O
DA	O
on	O
p38	B
MAPK	I
phosphorylation	O
,	O
a	O
requirement	O
for	O
p38	O
MAPK	O
activity	O
[	O
42	O
]	O
.	O

With	O
the	O
application	O
of	O
100	O
μM	O
DA	O
to	O
C6-D2L	O
cells	O
,	O
p38	B
MAPK	I
was	O
rapidly	O
phosphorylated	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
at	O
15	O
min	O
,	O
then	O
gradually	O
decreased	O
to	O
basal	O
level	O
by	O
about	O
1	O
h	O
(	O
Fig.	O
9	O
a	O
)	O
.	O

The	O
p38	B
MAPK	I
phosphorylation	O
was	O
greatly	O
increased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
DA	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
for	O
15	O
min	O
(	O
Fig.	O
9	O
b	O
)	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
(	O
+	O
)	O
-butaclamol	O
had	O
no	O
effect	O
on	O
DA	O
-	O
stimulated	O
phosphorylation	O
of	O
p38	B
MAPK	I
(	O
Fig.	O
9	O
c	O
)	O
.	O

These	O
data	O
suggest	O
that	O
DA	O
-	O
activated	O
p38	B
MAPK	I
may	O
not	O
be	O
mediated	O
by	O
D2	B
receptors	I
.	O

4	O
Discussion	O
In	O
this	O
paper	O
,	O
we	O
report	O
that	O
micromolar	O
levels	O
of	O
DA	O
stimulate	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
.	O

In	O
contrast	O
with	O
our	O
previous	O
report	O
for	O
earlier	O
mitogenesis	O
(	O
peaking	O
at	O
17	O
h	O
)	O
induced	O
by	O
nanomolar	O
levels	O
of	O
DA	O
[	O
30	O
]	O
,	O
this	O
mitogenesis	O
stimulated	O
by	O
micromolar	O
levels	O
of	O
DA	O
occurs	O
at	O
about	O
29	O
h.	O
Biochemically	O
,	O
the	O
earlier	O
phase	O
of	O
mitogenesis	O
requires	O
D2	B
receptor	I
–	I
MAPK	I
signaling	O
,	O
while	O
the	O
later	O
phase	O
requires	O
the	O
D2-receptor	B
–	I
tyrosine	I
kinase	I
pathway	O
.	O

Although	O
relationship	O
of	O
the	O
two	O
phases	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
not	O
clear	O
,	O
the	O
different	O
signaling	O
mechanisms	O
suggest	O
that	O
they	O
are	O
not	O
likely	O
to	O
be	O
dependent	O
on	O
each	O
other	O
.	O

For	O
example	O
,	O
nanomolar	O
levels	O
of	O
DA	O
strongly	O
stimulate	O
MAPK	B
without	O
significant	O
protein	B
tyrosine	O
phosphorylation	O
and	O
the	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
blockers	O
of	O
MAPK	B
pathway	I
.	O

Micromolar	O
levels	O
of	O
DA	O
strongly	O
stimulate	O
protein	B
tyrosine	I
kinase	I
without	O
effect	O
on	O
MAPK	B
,	O
and	O
the	O
consequent	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
tyrosine	B
kinase	I
inhibitors	O
but	O
not	O
by	O
blockers	O
of	O
the	O
MAPK	B
pathway	I
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
striatal	O
astrocytes	O
surround	O
dopaminergic	O
neurons	O
.	O

Although	O
the	O
astrocytes	O
do	O
not	O
have	O
synaptic	O
contact	O
with	O
dopaminergic	O
neurons	O
,	O
D2	B
receptors	I
in	O
astrocytes	O
may	O
sense	O
DA	O
(	O
low	O
concentrations	O
)	O
that	O
might	O
escape	O
from	O
the	O
synapse	O
and	O
play	O
a	O
physiological	O
role	O
via	O
the	O
MAPK	B
pathway	I
.	O

In	O
pathologic	O
conditions	O
,	O
such	O
as	O
ischemia	O
,	O
hypoxia	O
and	O
excitatory	O
amino	O
acid	O
-	O
induced	O
neurotoxicity	O
,	O
the	O
extracellular	O
DA	O
concentration	O
in	O
striata	O
is	O
significantly	O
increased	O
to	O
micromolar	O
levels	O
[	O
2	O
,	O
6	O
,	O
45	O
]	O
.	O

Although	O
the	O
length	O
of	O
DA	O
exposure	O
in	O
our	O
cell	O
culture	O
was	O
relatively	O
long	O
,	O
the	O
signaling	O
responses	O
,	O
such	O
as	O
protein	B
tyrosine	O
phosphorylation	O
and	O
p38	B
MAPK	I
phosphorylation	O
,	O
were	O
rapid	O
,	O
within	O
a	O
few	O
minutes	O
(	O
Fig.	O
3	O
a	O
,	O
Fig.	O
9	O
a	O
)	O
.	O

Thus	O
,	O
the	O
micromolar	O
level	O
DA	O
-	O
induced	O
activation	O
of	O
astrocytes	O
may	O
be	O
implicated	O
in	O
these	O
pathologic	O
conditions	O
.	O

Our	O
results	O
suggest	O
that	O
micromolar	O
levels	O
of	O
DA	O
activate	O
C6-D2L	O
cells	O
through	O
an	O
interaction	O
with	O
receptors	B
.	O

This	O
is	O
evident	O
since	O
DA	O
-	O
stimulated	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
(	O
+	O
)	O
-butaclamol	O
,	O
a	O
selective	O
D2	B
DA	I
receptor	I
antagonist	O
,	O
with	O
no	O
effect	O
of	O
(	O
−	O
)	O
-butaclamol	O
,	O
an	O
inactive	O
isoform	O
of	O
(	O
+	O
)	O
-butaclamol	O
.	O

Quinpirole	O
,	O
a	O
specific	O
D2	B
receptor	I
agonist	O
,	O
also	O
promotes	O
cell	O
cycle	O
progression	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
C6	O
cells	O
,	O
lacking	O
the	O
expression	O
of	O
D2	B
receptors	I
,	I
exhibit	O
no	O
mitogenic	O
response	O
to	O
stimulation	O
by	O
DA	O
.	O

This	O
also	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
mitogenesis	O
might	O
be	O
mediated	O
by	O
ROS	O
produced	O
by	O
DA	O
autoxidation	O
.	O

However	O
,	O
considering	O
the	O
fact	O
that	O
C6	O
cells	O
contain	O
other	O
monoamine	B
receptors	I
,	O
such	O
as	O
β	B
adrenergic	I
receptors	I
[	O
35	O
]	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
micromolar	O
levels	O
of	O
DA	O
may	O
also	O
non	O
-	O
specifically	O
stimulate	O
these	O
receptors	B
and	O
may	O
cooperate	O
with	O
DA	B
receptors	I
.	O

A	O
receptor	B
-	O
mediated	O
mechanism	O
may	O
also	O
be	O
involved	O
in	O
GFAP	B
upregulation	O
stimulated	O
by	O
DA	O
since	O
GFAP	B
synthesis	O
could	O
not	O
be	O
prevented	O
by	O
preincubation	O
with	O
20	O
mM	O
NAC	O
,	O
which	O
can	O
scavenge	O
ROS	O
generated	O
either	O
by	O
DA	O
oxidation	O
or	O
through	O
a	O
D2-receptor	B
-	O
mediated	O
redox	O
system	O
.	O

Although	O
the	O
type	O
of	O
receptor	B
involved	O
in	O
DA	O
-	O
stimulated	O
GFAP	B
expression	O
is	O
currently	O
unknown	O
,	O
it	O
would	O
appear	O
not	O
to	O
be	O
D2	B
receptors	I
since	O
both	O
wild	O
-	O
type	O
C6	O
and	O
C6-D2L	O
cells	O
gave	O
a	O
similar	O
GFAP	B
regulatory	O
response	O
to	O
DA	O
stimulation	O
.	O

One	O
potential	O
candidate	O
would	O
be	O
β	B
adrenergic	I
receptors	I
,	O
shown	O
to	O
stimulate	O
GFAP	B
expression	O
through	O
cAMP	O
[	O
44	O
]	O
.	O

High	O
-	O
concentration	O
DA	O
-	O
stimulated	O
mitogenesis	O
appears	O
to	O
involve	O
the	O
intracellular	O
production	O
of	O
ROS	O
as	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

First	O
,	O
DA	O
-	O
stimulated	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
DPI	O
.	O

DPI	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
for	O
membrane	O
-	O
bound	O
NADPH	B
-	I
dependent	I
oxidase	I
through	O
a	O
binding	O
to	O
the	O
flavoprotein	B
component	O
of	O
the	O
oxidase	B
[	O
12	O
,	O
28	O
,	O
43	O
]	O
.	O

This	O
intracellular	O
NADPH	B
-	I
dependent	I
oxidase	I
can	O
directly	O
catalyze	O
substrate	O
oxygen	O
conversion	O
to	O
the	O
superoxide	O
anion	O
,	O
which	O
can	O
in	O
turn	O
generate	O
other	O
reactive	O
oxygen	O
intermediates	O
.	O

Secondly	O
,	O
DA	O
-	O
induced	O
mitogenesis	O
is	O
prevented	O
by	O
the	O
membrane	O
-	O
permeable	O
antioxidant	O
,	O
NAC	O
.	O

Finally	O
,	O
application	O
of	O
very	O
low	O
concentrations	O
of	O
H2	O
O2	O
can	O
enhance	O
both	O
DA	O
-	O
induced	O
protein	B
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
.	O

These	O
observations	O
suggest	O
that	O
ROS	O
may	O
serve	O
as	O
a	O
second	O
messenger	O
in	O
the	O
signaling	O
of	O
DA	O
-	O
stimulated	O
mitogenesis	O
,	O
adding	O
evidence	O
in	O
support	O
of	O
the	O
recent	O
notion	O
that	O
ROS	O
act	O
as	O
intracellular	O
messengers	O
of	O
cell	O
proliferation	O
[	O
22	O
]	O
.	O

Like	O
other	O
astrocyte	O
mitogens	O
,	O
such	O
as	O
endothelin	O
[	O
7	O
,	O
26	O
]	O
,	O
micromolar	O
level	O
DA	O
-	O
induced	O
mitogenesis	O
requires	O
tyrosine	O
phosphorylation	O
.	O

Application	O
of	O
DA	O
to	O
C6-D2L	O
cells	O
rapidly	O
increases	O
protein	B
tyrosine	O
phosphorylation	O
.	O

Concentration	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
studies	O
show	O
a	O
similar	O
profile	O
to	O
that	O
of	O
DA	O
-	O
induced	O
DNA	O
synthesis	O
.	O

Both	O
protein	B
tyrosine	O
phosphorylation	O
and	O
mitogenesis	O
can	O
be	O
effectively	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
genistein	O
,	O
a	O
potent	O
protein	B
tyrosine	I
kinase	I
inhibitor	O
[	O
1	O
]	O
.	O

However	O
,	O
unlike	O
for	O
the	O
mitogen	O
endothelin	O
,	O
DA	O
-	O
stimulated	O
mitogenesis	O
is	O
not	O
linked	O
to	O
the	O
tyrosine	B
kinase	I
–	O
ERK	B
pathway	O
since	O
DA	O
at	O
micromolar	O
levels	O
has	O
no	O
stimulatory	O
effect	O
on	O
ERK	B
activation	O
.	O

Furthermore	O
,	O
PD098095	O
,	O
the	O
MEK1	B
inhibitor	O
,	O
has	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
high	O
concentration	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
although	O
it	O
does	O
have	O
some	O
inhibitory	O
effects	O
on	O
basal	O
DNA	O
synthesis	O
.	O

DA	O
-	O
stimulated	O
mitogenesis	O
at	O
micromolar	O
levels	O
is	O
partially	O
mediated	O
by	O
PTX	B
-	B
sensitive	I
G	I
proteins	I
.	O

This	O
is	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

(	O
1	O
)	O
Pretreatment	O
of	O
the	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	B
only	O
inhibits	O
DA	O
-	O
stimulated	O
mitogenesis	O
by	O
about	O
24–50	O
%	O
,	O
depending	O
on	O
concentrations	O
of	O
DA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

(	O
2	O
)	O
Application	O
of	O
PTX	B
,	O
even	O
in	O
a	O
very	O
high	O
concentration	O
(	O
500	O
ng	O
/	O
ml	O
)	O
,	O
only	O
partially	O
blocks	O
DA	O
-	O
induced	O
tyrosine	O
phosphorylation	O
.	O

(	O
3	O
)	O
The	O
ability	O
of	O
PTX	B
to	O
inhibit	O
protein	B
tyrosine	O
phosphorylation	O
is	O
correlated	O
with	O
that	O
to	O
inhibit	O
DA	O
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
PTX	B
-	B
resistant	I
G	I
proteins	I
may	O
participate	O
in	O
the	O
signaling	O
of	O
high	O
concentration	O
of	O
DA	O
-	O
induced	O
mitogenesis	O
,	O
although	O
further	O
studies	O
are	O
required	O
.	O

Some	O
literature	O
reports	O
suggest	O
that	O
receptors	B
coupled	O
to	O
PTX	B
-	B
insensitive	I
G	I
proteins	I
or	O
the	O
small	O
G	B
protein	I
Ras	B
can	O
regulate	O
cell	O
proliferation	O
.	O

For	O
example	O
,	O
thrombin	B
,	O
an	O
astrocytic	O
mitogen	B
,	O
has	O
been	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
in	O
1321N1	O
astrocytoma	O
cells	O
through	O
coupling	O
with	O
G12	B
,	O
a	O
Gq	O
subtype	O
of	O
GTP	B
binding	I
proteins	I
[	O
41	O
]	O
.	O

Recently	O
,	O
D2	B
receptors	I
were	O
also	O
reported	O
to	O
stimulate	O
prolactin	B
release	O
via	O
coupling	O
of	O
a	O
PTX	B
-	B
insensitive	I
G	I
protein	I
pathway	O
[	O
8	O
]	O
.	O

Whether	O
or	O
not	O
D2	B
receptors	I
might	O
be	O
coupled	O
to	O
PTX	B
-	B
insensitive	I
G	I
proteins	I
or	O
Ras	B
small	I
G	I
proteins	I
in	O
response	O
to	O
high	O
concentrations	O
of	O
DA	O
needs	O
further	O
study	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
p38	B
MAPK	I
is	O
required	O
for	O
upregulation	O
of	O
GFAP	B
synthesis	O
following	O
high	O
concentrations	O
of	O
DA	O
stimulation	O
.	O

This	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

(	O
1	O
)	O
Micromolar	O
level	O
DA	O
-	O
stimulated	O
GFAP	B
production	O
can	O
be	O
completely	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
a	O
highly	O
selective	O
inhibitor	O
of	O
p38	B
MAPK	I
[	O
13	O
,	O
27	O
]	O
.	O

Inhibition	O
of	O
a	O
parallel	O
MAPK	B
pathway	I
by	O
PD098059	O
has	O
no	O
effect	O
on	O
DA	O
-	O
induced	O
GFAP	B
expression	O
,	O
suggesting	O
that	O
a	O
relative	O
specificity	O
of	O
p38	B
MAPK	I
may	O
play	O
a	O
role	O
in	O
GFAP	B
generation	O
.	O

(	O
2	O
)	O
DA	O
activates	O
p38	B
MAPK	I
activity	O
at	O
concentrations	O
similar	O
to	O
those	O
of	O
DA	O
-	O
induced	O
GFAP	B
expression	O
.	O

(	O
3	O
)	O
Both	O
activation	O
of	O
p38	B
MAPK	I
and	O
GFAP	B
synthesis	O
are	O
not	O
regulated	O
by	O
D2	B
receptors	I
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
the	O
regulation	O
of	O
GFAP	B
by	O
p38	B
MAPK	I
.	O

In	O
C6	O
cells	O
,	O
an	O
increase	O
in	O
intracellular	O
cAMP	O
,	O
either	O
by	O
stimulation	O
of	O
β	B
-	I
adrenergic	I
receptors	I
[	O
44	O
]	O
or	O
by	O
stimulation	O
of	O
adenylate	B
cyclase	I
by	O
forskolin	O
[	O
44	O
]	O
,	O
is	O
capable	O
of	O
stimulating	O
GFAP	B
.	O

The	O
relationship	O
of	O
cAMP	O
to	O
p38	B
MAPK	I
deserves	O
further	O
investigation	O
.	O

In	O
our	O
cell	O
culture	O
studies	O
,	O
at	O
least	O
two	O
pathways	O
have	O
been	O
demonstrated	O
to	O
activate	O
C6-D2L	O
glioma	O
cells	O
.	O

One	O
is	O
the	O
D2-receptor	B
-	O
required	O
intracellular	O
redox	B
–	I
protein	I
tyrosine	I
kinase	I
pathway	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
cell	O
mitogenesis	O
.	O

Another	O
is	O
the	O
D2	B
receptor	I
-	O
independent	O
p38	B
MAPK	I
cascade	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
GFAP	B
synthesis	O
.	O

Interestingly	O
,	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
,	O
reactive	O
astrocytes	O
in	O
the	O
brain	O
respond	O
differently	O
to	O
brain	O
injury	O
.	O

Some	O
astrocytes	O
undergo	O
proliferation	O
as	O
indicated	O
only	O
by	O
[	O
3	O
H	O
]	O
thymidine	O
incorporation	O
;	O
some	O
exhibit	O
hypertrophy	O
labeled	O
only	O
by	O
GFAP	B
;	O
some	O
are	O
labeled	O
by	O
both	O
GFAP	B
and	O
[	O
3	O
H	O
]	O
thymidine	O
[	O
25	O
,	O
48	O
]	O
.	O

This	O
observation	O
suggests	O
that	O
these	O
two	O
separate	O
pathways	O
may	O
operate	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

Taken	O
together	O
,	O
the	O
information	O
from	O
our	O
in	O
vitro	O
cell	O
culture	O
studies	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
in	O
vivo	O
striatal	O
astrocytic	O
response	O
and	O
help	O
to	O
elucidate	O
potential	O
roles	O
of	O
astrocytes	O
in	O
neurodegeneration	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
K.A.	O
Neve	O
for	O
providing	O
C6-D2L	O
cells	O
.	O

Malaria	O
is	O
still	O
the	O
most	O
important	O
parasitic	O
disease	O
in	O
the	O
world	O
,	O
causing	O
2–3	O
million	O
deaths	O
every	O
year	O
(	O
WHO	O
,	O
1997	O
)	O
.	O

The	O
rising	O
resistance	O
of	O
Plasmodium	O
spp	O
.	O
,	O
especially	O
Plasmodium	O
falciparum	O
,	O
to	O
known	O
antimalarials	O
such	O
as	O
chloroquine	O
makes	O
the	O
search	O
for	O
new	O
antimalarial	O
drugs	O
increasingly	O
important	O
.	O

Therefore	O
,	O
we	O
investigated	O
several	O
medicinal	O
plants	O
,	O
which	O
are	O
traditionally	O
used	O
as	O
antimalarial	O
or	O
antipyretic	O
remedies	O
by	O
the	O
indigenous	O
population	O
in	O
Latin	O
America	O
(	O
Duke	O
,	O
1975	O
;	O
Hirschhorn	O
,	O
1981	O
;	O
Joly	O
et	O
al.	O
,	O
1987	O
;	O
Gupta	O
et	O
al.	O
,	O
1993	O
)	O
.	O

During	O
a	O
screening	O
program	O
,	O
we	O
obtained	O
lipophilic	O
and	O
hydrophilic	O
extracts	O
of	O
these	O
plants	O
with	O
antiplasmodial	O
activity	O
and	O
we	O
selected	O
the	O
most	O
active	O
ones	O
for	O
further	O
investigation	O
(	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Andira	O
inermis	O
(	O
W.	O
Wright	O
)	O
H.B.K.	O
(	O
Fabaceae	O
)	O
is	O
a	O
tall	O
tree	O
characterised	O
by	O
a	O
thick	O
trunk	O
and	O
red	O
-	O
purple	O
flowers	O
,	O
native	O
from	O
southern	O
Mexico	O
to	O
northern	O
South	O
America	O
.	O

As	O
a	O
febrifuge	O
,	O
the	O
bark	O
is	O
boiled	O
in	O
milk	O
,	O
sweetened	O
water	O
or	O
performed	O
in	O
pills	O
.	O

It	O
is	O
also	O
used	O
as	O
a	O
purgative	O
,	O
vermifuge	O
,	O
or	O
for	O
dermal	O
irritations	O
.	O

The	O
seeds	O
have	O
similar	O
uses	O
.	O

Large	O
doses	O
of	O
the	O
stem	O
bark	O
or	O
seeds	O
caused	O
vomiting	O
and	O
violent	O
diarrhoea	O
;	O
in	O
some	O
cases	O
they	O
were	O
even	O
fatal	O
(	O
Hirschhorn	O
,	O
1981	O
;	O
Morton	O
,	O
1981	O
)	O
.	O

From	O
this	O
species	O
,	O
several	O
isoflavones	O
and	O
related	O
structures	O
have	O
been	O
reported	O
(	O
Cocker	O
et	O
al.	O
,	O
1962	O
;	O
Lock	O
de	O
Ugaz	O
et	O
al.	O
,	O
1991	O
)	O
.	O

The	O
lipophilic	O
extracts	O
of	O
stems	O
and	O
leaves	O
showed	O
moderate	O
in	O
vitro	O
activity	O
against	O
P.	O
falciparum	O
in	O
this	O
screening	O
program	O
and	O
were	O
further	O
analysed	O
by	O
bioassay	O
-	O
guided	O
fractionation	O
to	O
isolate	O
the	O
active	O
compounds	O
.	O

2	O
Material	O
and	O
methods	O
2.1	O
General	O
For	O
fractionation	O
,	O
silica	O
gel	O
60	O
(	O
70–230	O
mesh	O
)	O
was	O
utilised	O
.	O

Preparative	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
performed	O
on	O
a	O
Knauer	O
Eurochrom	O
2000	O
equipped	O
with	O
a	O
Nucleosil	O
P	O
300	O
C-18	O
(	O
10	O
μm	O
)	O
column	O
.	O

Mass	O
spectra	O
were	O
determined	O
with	O
a	O
Finnigan	O
MAT	O
CH7A	O
(	O
220	O
°	O
C	O
,	O
ionisation	O
70	O
eV	O
)	O
and	O
1	O
H	O
-	O
NMR	O
spectra	O
were	O
obtained	O
using	O
acetone	O
-	O
D6	O
as	O
a	O
solvent	O
with	O
a	O
Bruker	O
AVANCE	O
DPX	O
400	O
(	O
400	O
MHz	O
,	O
TMS	O
as	O
internal	O
standard	O
)	O
.	O

The	O
erythrocytes	O
were	O
harvested	O
with	O
an	O
Inotech	O
cell	O
harvester	O
and	O
the	O
β	O
-	O
radiation	O
of	O
the	O
incorporated	O
[	O
3	O
H	O
]	O
hypoxanthine	O
was	O
measured	O
with	O
a	O
Wallac	O
1450	O
MicroBeta	O
plus	O
liquid	O
scintillation	O
counter	O
.	O

2.2	O
Plant	O
material	O
Leaves	O
and	O
stems	O
of	O
A.	O
inermis	O
were	O
collected	O
in	O
the	O
area	O
of	O
Panama	O
City	O
(	O
at	O
the	O
road	O
El	O
Llano	O
-	O
Carti	O
)	O
,	O
Panama	O
,	O
during	O
March	O
1997	O
.	O

Voucher	O
specimens	O
(	O
FLORPAN	O
2758	O
)	O
were	O
identified	O
by	O
Professor	O
M.D.	O
Correa	O
A.	O
and	O
deposited	O
at	O
the	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
.	O

2.3	O
Extraction	O
and	O
isolation	O
In	O
the	O
screening	O
program	O
,	O
the	O
air	O
-	O
dried	O
stem	O
bark	O
and	O
leaves	O
(	O
20	O
g	O
)	O
were	O
extracted	O
three	O
times	O
for	O
2	O
h	O
with	O
150	O
ml	O
petroleum	O
ether	O
/	O
ethyl	O
acetate	O
(	O
1:1	O
)	O
at	O
room	O
temperature	O
.	O

Then	O
the	O
plant	O
material	O
was	O
air	O
dried	O
again	O
and	O
treated	O
three	O
times	O
with	O
150	O
ml	O
methanol	O
/	O
water	O
(	O
8:2	O
)	O
to	O
yield	O
the	O
hydrophilic	O
extracts	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

For	O
further	O
investigations	O
,	O
the	O
crushed	O
stems	O
(	O
600	O
g	O
)	O
were	O
air	O
dried	O
and	O
extracted	O
three	O
times	O
with	O
2	O
l	O
of	O
petroleum	O
ether	O
/	O
ethyl	O
acetate	O
(	O
1:1	O
)	O
for	O
24	O
h	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

The	O
oily	O
residue	O
(	O
3.3	O
g	O
)	O
was	O
subjected	O
to	O
column	O
chromatography	O
on	O
silica	O
gel	O
60	O
(	O
45	O
g	O
)	O
and	O
eluted	O
with	O
cyclohexane	O
,	O
cyclohexane	O
/	O
ethyl	O
acetate	O
mixtures	O
,	O
and	O
methanol	O
to	O
yield	O
seven	O
fractions	O
,	O
which	O
were	O
tested	O
against	O
P.	O
falciparum	O
.	O

Fraction	O
5	O
and	O
6	O
,	O
which	O
were	O
eluted	O
with	O
cyclohexane	O
/	O
ethyl	O
acetate	O
(	O
8:2	O
and	O
7:3	O
,	O
respectively	O
)	O
,	O
proved	O
to	O
be	O
most	O
active	O
.	O

Further	O
separation	O
of	O
fraction	O
5	O
(	O
150	O
mg	O
)	O
by	O
HPLC	O
at	O
a	O
5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
methanol	O
/	O
water	O
(	O
55:45	O
)	O
yielded	O
the	O
compounds	O
1	O
(	O
2.4	O
mg	O
)	O
,	O
2	O
(	O
6.1	O
mg	O
)	O
,	O
and	O
3	O
(	O
6.6	O
mg	O
)	O
.	O

Fraction	O
6	O
was	O
separated	O
with	O
methanol	O
/	O
water	O
(	O
45:55	O
)	O
to	O
give	O
the	O
compounds	O
4	O
(	O
8.3	O
mg	O
)	O
,	O
5	O
(	O
8.5	O
mg	O
)	O
,	O
and	O
6	O
(	O
1.6	O
mg	O
)	O
.	O

Compound	O
2	O
(	O
prunetin	O
)	O
:	O
EI	O
-	O
MS	O
:	O
m	O
/z	O
(	O
rel	O
.	O

int.	O
)	O
=284	O
(	O
M+	O
,	O
100	O
)	O
,	O
166	O
(	O
35	O
)	O
,	O
138	O
(	O
22	O
)	O
,	O
118	O
(	O
15	O
)	O
,	O
110	O
(	O
10	O
)	O
,	O
95	O
(	O
13	O
)	O
;	O
1	O
H	O
-	O
NMR	O
(	O
400	O
MHz	O
,	O
acetone	O
-	O
D6	O
):	O
δ	O
(	O
ppm	O
)	O
=3.93	O
(	O
3	O
H	O
,	O
s	O
,	O
CH3	O
O-7	O
)	O
,	O
6.36	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-6	O
)	O
,	O
6.55	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.4	O
Hz	O
,	O
H-8	O
)	O
,	O
6.91	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-3′,5′	O
)	O
,	O
7.47	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-2′,6′	O
)	O
,	O
8.22	O
(	O
1	O
H	O
,	O
s	O
,	O
H-2	O
)	O
,	O
13.4	O
(	O
1	O
H	O
,	O
s	O
,	O
OH-5	O
)	O
.	O

2.4	O
Antiplasmodial	O
bioassay	O
In	O
this	O
study	O
,	O
the	O
chloroquine	O
-	O
sensitive	O
strain	O
of	O
P.	O
falciparum	O
poW	O
(	O
IC50	O
=	O
0.015	O
μM	O
)	O
and	O
the	O
chloroquine	O
-	O
resistant	O
clone	O
Dd2	O
(	O
IC50	O
=	O
0.14	O
μM	O
)	O
were	O
used	O
.	O

They	O
were	O
maintained	O
in	O
continuous	O
culture	O
in	O
human	O
red	O
blood	O
cells	O
(	O
A+	O
)	O
diluted	O
to	O
5	O
%	O
haematocrit	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
25	O
mM	O
Hepes	O
,	O
30	O
mM	O
NaHCO3	O
,	O
and	O
10	O
%	O
human	O
A+	O
serum	O
.	O

Crude	O
extracts	O
and	O
isolated	O
compounds	O
were	O
dissolved	O
in	O
DMSO	O
(	O
1	O
mg	O
/	O
50	O
μl	O
)	O
and	O
diluted	O
in	O
RPMI	O
1640	O
medium	O
(	O
Trager	O
and	O
Jensen	O
,	O
1976	O
)	O
.	O

The	O
tests	O
were	O
performed	O
in	O
96-well	O
microtiter	O
plates	O
(	O
Desjardins	O
et	O
al.	O
,	O
1979	O
)	O
which	O
contained	O
150	O
μl	O
of	O
a	O
parasitized	O
red	O
blood	O
suspension	O
(	O
A+	O
,	O
2.5	O
%	O
haematocrit	O
,	O
0.5	O
%	O
parasitaemia	O
)	O
.	O

The	O
samples	O
were	O
added	O
to	O
give	O
final	O
concentrations	O
between	O
1.56	O
and	O
100	O
μg	O
/	O
ml	O
.	O

After	O
incubation	O
in	O
a	O
candle	O
jar	O
for	O
24	O
h	O
,	O
0.5	O
μCi	O
[	O
3	O
H	O
]	O
hypoxanthine	O
(	O
1	O
mCi	O
/	O
ml	O
,	O
ICN	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
another	O
18	O
h.	O
Incorporation	O
of	O
[	O
3	O
H	O
]	O
hypoxanthine	O
was	O
measured	O
by	O
liquid	O
scintillation	O
after	O
harvesting	O
the	O
cells	O
on	O
glass	O
fibre	O
filters	O
with	O
the	O
cell	O
harvester	O
.	O

All	O
tests	O
were	O
performed	O
in	O
triplicate	O
.	O

The	O
percentage	O
of	O
growth	O
inhibition	O
was	O
calculated	O
as	O
follows	O
:	O
(	O
1−	O
[	O
cpm	O
in	O
drug	O
treated	O
cultures	O
/	O
cpm	O
in	O
untreated	O
cultures	O
]	O
)	O
×	O
100	O
.	O

The	O
concentration	O
at	O
which	O
growth	O
was	O
inhibited	O
by	O
50	O
%	O
(	O
IC50	O
)	O
was	O
estimated	O
by	O
interpolation	O
.	O

Extracts	O
with	O
IC50	O
values	O
above	O
50	O
μg	O
/	O
ml	O
were	O
considered	O
to	O
be	O
inactive	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
)	O
.	O

3	O
Results	O
The	O
isolated	O
compounds	O
1–6	O
(	O
Fig.	O
1	O
)	O
turned	O
out	O
to	O
be	O
isoflavones	O
.	O

Compound	O
1	O
,	O
isolated	O
from	O
both	O
stems	O
and	O
leaves	O
was	O
identified	O
as	O
formononetin	O
by	O
comparison	O
with	O
an	O
authentic	O
sample	O
.	O

According	O
to	O
the	O
spectral	O
data	O
(	O
1	O
H	O
-	O
NMR	O
,	O
EI	O
-	O
MS	O
)	O
,	O
compound	O
2	O
proved	O
to	O
be	O
prunetin	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
1	O
H	O
-	O
NMR	O
values	O
for	O
prunetin	O
have	O
been	O
published	O
so	O
far	O
,	O
therefore	O
they	O
are	O
given	O
in	O
Section	O
2.3	O
.	O

The	O
isoflavones	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
identified	O
as	O
biochanin	O
A	O
,	O
calycosin	O
,	O
genistein	O
,	O
and	O
pratensein	O
,	O
respectively	O
,	O
by	O
comparison	O
of	O
1	O
H	O
-	O
NMR	O
and	O
EI	O
-	O
MS	O
with	O
published	O
data	O
(	O
Asres	O
et	O
al.	O
,	O
1985	O
;	O
Kobayashi	O
et	O
al.	O
,	O
1985	O
)	O
.	O

Prunetin	O
(	O
2	O
)	O
,	O
calycosin	O
(	O
4	O
)	O
,	O
and	O
pratensein	O
(	O
6	O
)	O
were	O
detected	O
for	O
the	O
first	O
time	O
from	O
the	O
genus	O
Andira	O
.	O

The	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
exhibited	O
IC50	O
values	O
from	O
56.0	O
μg	O
/	O
ml	O
(	O
leaves	O
)	O
to	O
108.7	O
μg	O
/	O
ml	O
(	O
stems	O
)	O
against	O
P.	O
falciparum	O
in	O
vitro	O
(	O
Table	O
1	O
)	O
.	O

The	O
hydrophilic	O
extracts	O
proved	O
to	O
be	O
inactive	O
.	O

For	O
all	O
tested	O
substances	O
the	O
antiparasitic	O
activity	O
against	O
the	O
chloroquine	O
-	O
sensitive	O
strain	O
poW	O
was	O
higher	O
(	O
factor	O
two	O
)	O
than	O
against	O
the	O
chloroquine	O
-	O
resistant	O
clone	O
Dd2	O
.	O

Calycosin	O
(	O
IC50	O
4.2	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
9.8	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
and	O
genistein	O
(	O
IC50	O
2.0	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
4.1	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
proved	O
to	O
be	O
most	O
active	O
.	O

The	O
other	O
four	O
compounds	O
were	O
considered	O
to	O
be	O
inactive	O
.	O

4	O
Discussion	O
Although	O
the	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
showed	O
only	O
moderate	O
antiplasmodial	O
activity	O
compared	O
to	O
those	O
known	O
for	O
other	O
plant	O
remedies	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
;	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
they	O
afforded	O
two	O
active	O
isoflavones	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
antiplasmodial	O
activity	O
of	O
isoflavones	O
against	O
P.	O
falciparum	O
.	O

The	O
low	O
concentration	O
of	O
calycosin	O
and	O
genistein	O
(	O
<	O
0.01	O
%	O
w	O
/	O
w	O
)	O
may	O
be	O
the	O
explanation	O
for	O
the	O
low	O
antiplasmodial	O
activity	O
of	O
the	O
crude	O
extract	O
.	O

It	O
is	O
known	O
that	O
calycosin	O
also	O
proved	O
to	O
be	O
active	O
against	O
Giardia	O
intestinalis	O
,	O
a	O
potent	O
protozoan	O
agent	O
for	O
enteric	O
diseases	O
(	O
ElSohly	O
et	O
al.	O
,	O
1999	O
)	O
.	O

During	O
the	O
preparation	O
of	O
this	O
paper	O
a	O
patent	O
application	O
was	O
published	O
(	O
Khan	O
et	O
al.	O
,	O
1999	O
)	O
,	O
which	O
claimed	O
a	O
method	O
of	O
treating	O
giardiasis	O
and/or	O
malaria	O
comprising	O
the	O
use	O
of	O
isoflavones	O
,	O
but	O
mentioning	O
no	O
data	O
,	O
proving	O
their	O
antiplasmodial	O
activity	O
against	O
P.	O
falciparum	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
focused	O
on	O
the	O
investigation	O
of	O
the	O
lipophilic	O
extract	O
.	O

The	O
indigenous	O
population	O
,	O
e.g.	O
in	O
Brazil	O
(	O
Morton	O
,	O
1981	O
)	O
,	O
prefer	O
to	O
boil	O
the	O
stem	O
bark	O
with	O
milk	O
.	O

This	O
procedure	O
covers	O
the	O
bitter	O
taste	O
and	O
probably	O
causes	O
the	O
extraction	O
of	O
lipophilic	O
constituents	O
.	O

Interestingly	O
,	O
hydrophilic	O
extracts	O
(	O
methanol	O
/	O
water	O
8:2	O
)	O
from	O
A.	O
inermis	O
did	O
not	O
show	O
antiplasmodial	O
activity	O
in	O
our	O
test	O
system	O
.	O

The	O
evaluation	O
of	O
extracts	O
obtained	O
with	O
water	O
or	O
milk	O
is	O
still	O
in	O
progress	O
and	O
might	O
be	O
interesting	O
with	O
regard	O
to	O
the	O
ethnobotanical	O
use	O
of	O
this	O
species	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
indebted	O
to	O
C.	O
Guerra	O
,	O
for	O
his	O
support	O
in	O
collecting	O
the	O
plant	O
material	O
,	O
and	O
to	O
Professor	O
M.D.	O
Correa	O
A.	O
,	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
,	O
Republic	O
of	O
Panama	O
,	O
for	O
her	O
identification	O
of	O
the	O
species	O
.	O

We	O
thank	O
Drs	O
D.S.	O
Kim	O
and	O
B.	O
Kleuser	O
,	O
Institut	O
für	O
Pharmazie	O
,	O
Freie	O
Universität	O
Berlin	O
,	O
Germany	O
,	O
for	O
their	O
advice	O
concerning	O
determination	O
of	O
radioactivity	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Deutsche	O
Pharmazeutische	O
Gesellschaft	O
to	O
K.	O
Jenett	O
-	O
Siems	O
and	O
by	O
Charité	O
Grant	O
Nr	O
.	O

98	O
-	O
700	O
.	O

CIFLORPAN	O
acknowledges	O
the	O
Fundation	O
Natura	O
and	O
the	O
Organization	O
of	O
American	O
States	O
(	O
OAS	O
)	O
for	O
financial	O
support	O
.	O

Identification	O
of	O
a	O
Wnt	B
-	O
responsive	O
signal	O
transduction	O
pathway	O
in	O
primary	O
endothelial	O
cells	O
.	O

The	O
beta	B
-	I
catenin	I
signal	O
transduction	O
pathway	O
,	O
which	O
can	O
be	O
activated	O
by	O
secreted	O
Wnt	B
proteins	O
,	O
plays	O
a	O
key	O
role	O
in	O
normal	O
embryonic	O
development	O
and	O
in	O
malignant	O
transformation	O
of	O
the	O
mammary	O
gland	O
and	O
colon	O
.	O

Here	O
we	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
Wnt	B
and	O
beta	B
-	I
catenin	I
signaling	O
also	O
function	O
in	O
cells	O
of	O
the	O
vasculature	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
primary	O
endothelial	O
and	O
smooth	O
muscle	O
cell	O
cultures	O
,	O
of	O
both	O
mouse	O
and	O
human	O
origin	O
,	O
express	O
members	O
of	O
the	O
Wnt	B
and	O
Wnt	B
receptor	O
(	O
Frizzled	O
)	O
gene	O
families	O
.	O

Transfection	O
of	O
an	O
expression	O
vector	O
for	O
Wnt-1	B
into	O
primary	O
endothelial	O
cells	O
increased	O
both	O
the	O
free	O
pool	O
of	O
beta	B
-	I
catenin	I
and	O
the	O
transcription	O
from	O
a	O
Lef	O
/	O
tcf	O
-	O
dependent	O
reporter	O
gene	O
construct	O
.	O

Expression	O
of	O
Wnt-1	B
,	O
but	O
not	O
Wnt-5a	B
,	O
also	O
stimulated	O
proliferation	O
of	O
primary	O
endothelial	O
cell	O
cultures	O
.	O

These	O
data	O
show	O
that	O
Wnt	B
and	O
Frizzled	O
proteins	O
can	O
regulate	O
signal	O
transduction	O
,	O
via	O
beta	B
-	I
catenin	I
,	O
in	O
endothelial	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
Wnt	B
signaling	O
may	O
feature	O
in	O
normal	O
differentiation	O
of	O
the	O
vasculature	O
as	O
well	O
as	O
in	O
pathological	O
settings	O
where	O
endothelial	O
and	O
smooth	O
muscle	O
proliferation	O
is	O
disturbed	O
.	O

The	O
VacA	O
toxin	O
of	O
Helicobacter	O
pylori	O
identifies	O
a	O
new	O
intermediate	O
filament	O
-	O
interacting	O
protein	O
.	O

The	O
VacA	O
toxin	O
produced	O
by	O
Helicobacter	O
pylori	O
acts	O
inside	O
cells	O
and	O
induces	O
the	O
formation	O
of	O
vacuoles	O
arising	O
from	O
late	O
endosomal	O
/	O
lysosomal	O
compartments	O
.	O

Using	O
VacA	O
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
a	O
HeLa	O
cell	O
library	O
,	O
we	O
have	O
identified	O
a	O
novel	O
protein	O
of	O
54	O
kDa	O
(	O
VIP54	B
)	O
,	O
which	O
interacts	O
specifically	O
with	O
VacA	O
,	O
as	O
indicated	O
by	O
co	O
-	O
immunoprecipitation	O
and	O
binding	O
experiments	O
.	O

VIP54	B
is	O
expressed	O
in	O
cultured	O
cells	O
and	O
many	O
tissues	O
,	O
with	O
higher	O
expression	O
in	O
the	O
brain	O
,	O
muscle	O
,	O
kidney	O
and	O
liver	O
.	O

Confocal	O
immunofluorescence	O
microscopy	O
with	O
anti	O
-	O
VIP54	B
affinity-	O
purified	O
antibodies	O
shows	O
a	O
fibrous	O
pattern	O
typical	O
of	O
intermediate	O
filaments	O
.	O

Double	O
label	O
immunofluorescence	O
performed	O
on	O
various	O
cell	O
lines	O
with	O
antibodies	O
specific	O
to	O
different	O
intermediate	O
filament	O
proteins	O
revealed	O
that	O
VIP54	B
largely	O
co	O
-	O
distributes	O
with	O
vimentin	B
.	O

In	O
contrast	O
to	O
known	O
intermediate	O
filament	O
proteins	O
,	O
VIP54	B
is	O
predicted	O
to	O
contain	O
approximately	O
50	O
%	O
of	O
helical	O
segments	O
,	O
but	O
no	O
extended	O
coiled	O
-	O
coil	O
regions	O
.	O

The	O
possible	O
involvement	O
of	O
this	O
novel	O
protein	O
in	O
interactions	O
between	O
intermediate	O
filaments	O
and	O
late	O
endosomal	O
compartments	O
is	O
discussed	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
new	O
human	O
ETS	O
-	O
family	O
transcription	O
factor	O
,	O
TEL2	B
,	O
that	O
is	O
expressed	O
in	O
hematopoietic	O
tissues	O
and	O
can	O
associate	O
with	O
TEL1	B
/	O
ETV6	B
.	O

The	O
ETS	O
family	O
of	O
proteins	O
is	O
a	O
large	O
group	O
of	O
transcription	O
factors	O
implicated	O
in	O
many	O
aspects	O
of	O
normal	O
hematopoietic	O
development	O
,	O
as	O
well	O
as	O
oncogenesis	O
.	O

For	O
example	O
,	O
the	O
TEL1	B
/	O
ETV6	B
(	O
TEL1	B
)	O
gene	O
is	O
required	O
for	O
normal	O
yolk	O
sac	O
angiogenesis	O
,	O
adult	O
bone	O
marrow	O
hematopoiesis	O
,	O
and	O
is	O
rearranged	O
or	O
deleted	O
in	O
numerous	O
leukemias	O
.	O

This	O
report	O
describes	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
ETS	O
gene	O
that	O
is	O
highly	O
related	O
to	O
TEL1	B
and	O
is	O
therefore	O
called	O
TEL2	B
.	O

The	O
TEL2	B
gene	O
consists	O
of	O
8	O
exons	O
spanning	O
approximately	O
21	O
kilobases	O
(	O
kb	O
)	O
in	O
human	O
chromosome	O
6p21	O
.	O

Unlike	O
the	O
ubiquitously	O
expressed	O
TEL1	B
gene	O
,	O
however	O
,	O
TEL2	B
appears	O
to	O
be	O
expressed	O
predominantly	O
in	O
hematopoietic	O
tissues	O
.	O

Antibodies	O
raised	O
against	O
the	O
C	O
-	O
terminus	O
of	O
the	O
TEL2	B
protein	O
were	O
used	O
to	O
show	O
that	O
TEL2	B
localizes	O
to	O
the	O
nucleus	O
.	O

All	O
ETS	O
proteins	O
can	O
bind	O
DNA	O
via	O
the	O
highly	O
conserved	O
ETS	O
domain	O
,	O
which	O
recognizes	O
a	O
purine	O
-	O
rich	O
DNA	O
sequence	O
with	O
a	O
GGAA	O
core	O
motif	O
.	O

DNA	O
binding	O
assays	O
show	O
that	O
TEL2	B
can	O
bind	O
the	O
same	O
consensus	O
DNA	O
binding	O
sequence	O
recognized	O
by	O
TEL1	B
/	O
ETV6	B
.	O

Additionally	O
,	O
the	O
TEL2	B
protein	O
is	O
capable	O
of	O
associating	O
with	O
itself	O
and	O
with	O
TEL1	B
in	O
doubly	O
transfected	O
Hela	O
cells	O
,	O
and	O
this	O
interaction	O
is	O
mediated	O
through	O
the	O
pointed	O
(	O
PNT	O
)	O
domain	O
of	O
TEL1	B
.	O

The	O
striking	O
similarities	O
of	O
TEL2	B
to	O
the	O
oncogenic	O
TEL1	B
,	O
its	O
expression	O
in	O
hematopoietic	O
tissues	O
,	O
and	O
its	O
ability	O
to	O
associate	O
with	O
TEL1	B
suggest	O
that	O
TEL2	B
may	O
be	O
an	O
important	O
hematopoietic	O
regulatory	O
protein	O
.	O

The	O
SCA8	O
transcript	O
is	O
an	O
antisense	O
RNA	O
to	O
a	O
brain	O
-	O
specific	O
transcript	O
encoding	O
a	O
novel	O
actin	O
-	O
binding	O
protein	O
(	O
KLHL1	B
)	O
.	O

Spinocerebellar	O
ataxia	O
type	O
8	O
(	O
SCA8	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
that	O
is	O
transcribed	O
as	O
part	O
of	O
an	O
untranslated	O
RNA	O
.	O

As	O
a	O
step	O
towards	O
understanding	O
the	O
molecular	O
pathology	O
of	O
SCA8	O
,	O
we	O
have	O
defined	O
the	O
genomic	O
organization	O
of	O
the	O
SCA8	O
RNA	O
transcripts	O
and	O
assembled	O
a	O
166	O
kb	O
segment	O
of	O
genomic	O
sequence	O
containing	O
the	O
repeat	O
.	O

The	O
most	O
striking	O
feature	O
of	O
the	O
SCA8	O
transcripts	O
is	O
that	O
the	O
most	O
5	O
'	O
exon	O
is	O
transcribed	O
through	O
the	O
first	O
exon	O
of	O
another	O
gene	O
that	O
is	O
transcribed	O
in	O
the	O
opposite	O
orientation	O
.	O

This	O
gene	O
arrangement	O
suggests	O
that	O
the	O
SCA8	O
transcript	O
is	O
an	O
endogenous	O
antisense	O
RNA	O
that	O
overlaps	O
the	O
transcription	O
and	O
translation	O
start	O
sites	O
as	O
well	O
as	O
the	O
first	O
splice	O
donor	O
sequence	O
of	O
the	O
sense	O
gene	O
.	O

The	O
sense	O
transcript	O
encodes	O
a	O
748	O
amino	O
acid	O
protein	O
with	O
a	O
predicted	O
domain	O
structure	O
typical	O
of	O
a	O
family	O
of	O
actin	O
-	O
organizing	O
proteins	O
related	O
to	O
the	O
Drosophila	O
Kelch	O
gene	O
,	O
and	O
so	O
has	O
been	O
given	O
the	O
name	O
Kelch	B
-	I
like	I
1	I
(	O
KLHL1	B
)	O
.	O

We	O
have	O
identified	O
the	O
full	O
-	O
length	O
cDNA	O
sequence	O
for	O
both	O
the	O
human	O
and	O
mouse	O
KLHLI	B
genes	O
,	O
and	O
have	O
elucidated	O
the	O
general	O
genomic	O
organization	O
of	O
the	O
human	O
gene	O
.	O

The	O
predicted	O
open	O
reading	O
frame	O
and	O
promoter	O
region	O
are	O
highly	O
conserved	O
,	O
and	O
both	O
genes	O
are	O
primarily	O
expressed	O
in	O
specific	O
brain	O
tissues	O
,	O
including	O
the	O
cerebellum	O
,	O
the	O
tissue	O
most	O
affected	O
by	O
SCA8	O
.	O

Transfection	O
studies	O
with	O
epitope	O
-	O
tagged	O
KLHL1	B
demonstrate	O
that	O
the	O
protein	O
localizes	O
to	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
it	O
may	O
play	O
a	O
role	O
in	O
organizing	O
the	O
actin	O
cytoskeleton	O
of	O
the	O
brain	O
cells	O
in	O
which	O
it	O
is	O
expressed	O
.	O

Identification	O
of	O
cDNAs	O
encoding	O
two	O
novel	O
nuclear	O
proteins	O
,	O
IMUP-1	B
and	O
IMUP-2	B
,	O
upregulated	O
in	O
SV40-immortalized	O
human	O
fibroblasts	O
.	O

Using	O
a	O
model	O
system	O
of	O
young	O
,	O
senescent	O
and	O
SV40-immortalized	O
WI-38	O
fibroblasts	O
,	O
we	O
identified	O
two	O
mRNAs	O
upregulated	O
in	O
immortalized	O
cells	O
(	O
imup-1	B
,	O
immortalization	B
-	I
upregulated	I
protein	I
1	I
,	O
and	O
imup-2	B
)	O
.	O

Compared	O
to	O
normal	O
tissues	O
,	O
both	O
genes	O
were	O
more	O
frequently	O
expressed	O
in	O
cancer	O
cells	O
.	O

The	O
open	O
reading	O
frame	O
of	O
imup-1	B
spans	O
321bp	O
,	O
coding	O
for	O
a	O
10.9	O
kDa	O
protein	O
of	O
106	O
amino	O
acids	O
,	O
while	O
an	O
insertion	O
of	O
59bp	O
in	O
the	O
otherwise	O
identical	O
mRNA	O
of	O
imup-2	B
leads	O
to	O
a	O
frameshift	O
,	O
resulting	O
in	O
an	O
8.5	O
kDa	O
protein	O
of	O
85	O
amino	O
acids	O
.	O

Database	O
searches	O
identified	O
these	O
genes	O
on	O
chromosome	O
19	O
,	O
which	O
could	O
account	O
for	O
the	O
cloned	O
imup-1	B
and	O
imup-2	B
transcripts	O
by	O
alternative	O
splicing	O
.	O

Southern	O
blot	O
analysis	O
of	O
digested	O
genomic	O
DNA	O
confirmed	O
that	O
both	O
transcripts	O
are	O
derived	O
from	O
a	O
single	O
locus	O
.	O

The	O
expressed	O
proteins	O
IMUP-1	B
and	O
IMUP-2	B
share	O
46	O
identical	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
whereas	O
the	O
C	O
-	O
termini	O
are	O
unrelated	O
.	O

Green	O
fluorescent	O
protein	O
-	O
fusions	O
of	O
both	O
IMUP-1	B
and	O
IMUP-2	B
accumulated	O
in	O
the	O
nucleus	O
of	O
HeLa	O
cells	O
.	O

The	O
C	O
-	O
terminus	O
of	O
IMUP-1	B
contains	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
,	O
the	O
deletion	O
of	O
which	O
impaired	O
nuclear	O
translocation	O
.	O

In	O
-	O
vitro	O
translated	O
proteins	O
bound	O
to	O
poly	O
(	O
rG	O
)	O
,	O
but	O
did	O
not	O
interact	O
with	O
single	O
-	O
stranded	O
DNA	O
or	O
double	O
-	O
stranded	O
DNA	O
.	O

The	O
nuclear	O
localization	O
of	O
IMUP-1	B
and	O
IMUP-2	B
as	O
well	O
as	O
the	O
upregulation	O
of	O
both	O
underlying	O
mRNAs	O
in	O
immortalized	O
cells	O
suggest	O
a	O
function	O
in	O
immortalization	O
.	O

Identification	O
of	O
a	O
novel	O
thioredoxin	B
-	O
related	O
transmembrane	O
protein	O
.	O

We	O
recently	O
identified	O
a	O
series	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
-	O
responsive	O
genes	O
in	O
A549	O
human	O
adenocarcinoma	O
cell	O
line	O
by	O
a	O
gene	O
trap	O
screening	O
method	O
.	O

Here	O
we	O
report	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
one	O
of	O
these	O
genes	O
,	O
designated	O
TMX	B
,	O
that	O
encodes	O
a	O
novel	O
protein	O
of	O
280	O
amino	O
acid	O
residues	O
.	O

The	O
TMX	B
protein	O
possesses	O
an	O
N	O
-	O
terminal	O
signal	O
peptide	O
followed	O
by	O
one	O
thioredoxin	B
(	O
Trx	B
)	O
-like	O
domain	O
with	O
a	O
unique	O
active	O
site	O
sequence	O
,	O
Cys	O
-	O
Pro	O
-	O
Ala	O
-	O
Cys	O
,	O
and	O
a	O
potential	O
transmembrane	O
domain	O
.	O

There	O
are	O
putative	O
TMX	B
homologs	O
with	O
identical	O
active	O
site	O
sequences	O
in	O
the	O
Caenorhabditis	O
elegans	O
and	O
Drosophila	O
genomes	O
.	O

Using	O
recombinant	O
proteins	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
we	O
demonstrated	O
the	O
activity	O
of	O
the	O
Trx	B
domain	O
of	O
TMX	B
to	O
cleave	O
the	O
interchain	O
disulfide	O
bridges	O
in	O
insulin	B
in	O
vitro	O
.	O

The	O
TMX	B
transcript	O
is	O
widely	O
expressed	O
in	O
normal	O
human	O
tissues	O
,	O
and	O
subcellular	O
fractionation	O
and	O
immunostaining	O
for	O
an	O
epitope	O
-	O
tagged	O
TMX	B
protein	O
suggest	O
that	O
TMX	B
is	O
predominantly	O
localized	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

When	O
TMX	B
was	O
expressed	O
in	O
HEK293	O
cells	O
,	O
it	O
significantly	O
suppressed	O
the	O
apoptosis	O
induced	O
by	O
brefeldin	O
A	O
,	O
an	O
inhibitor	O
of	O
ER	O
-	O
Golgi	O
transport	O
.	O

This	O
activity	O
was	O
abolished	O
when	O
two	O
Cys	O
residues	O
in	O
the	O
active	O
site	O
sequence	O
were	O
mutated	O
to	O
Ser	O
,	O
suggesting	O
that	O
the	O
Trx	B
-	O
like	O
activity	O
of	O
TMX	B
may	O
help	O
relieve	O
ER	O
stress	O
caused	O
by	O
brefeldin	O
A.	O

A	O
new	O
spectrin	B
,	I
beta	I
IV	I
,	O
has	O
a	O
major	O
truncated	O
isoform	O
that	O
associates	O
with	O
promyelocytic	B
leukemia	I
protein	I
nuclear	O
bodies	O
and	O
the	O
nuclear	O
matrix	O
.	O

We	O
isolated	O
cDNAs	O
that	O
encode	O
a	O
77-kDa	O
peptide	O
similar	O
to	O
repeats	O
10	O
-	O
16	O
of	O
beta	O
-	O
spectrins	O
.	O

Its	O
gene	O
localizes	O
to	O
human	O
chromosome	O
19q13.13-q13.2	O
and	O
mouse	O
chromosome	O
7	O
,	O
at	O
7.5	O
centimorgans	O
.	O

A	O
289-kDa	O
isoform	O
,	O
similar	O
to	O
full	O
-	O
length	O
beta	O
-	O
spectrins	O
,	O
was	O
partially	O
assembled	O
from	O
sequences	O
in	O
the	O
human	O
genomic	O
DNA	O
data	O
base	O
and	O
completely	O
cloned	O
and	O
sequenced	O
.	O

RNA	O
transcripts	O
are	O
seen	O
predominantly	O
in	O
the	O
brain	O
,	O
and	O
Western	O
analysis	O
shows	O
a	O
major	O
peptide	O
that	O
migrates	O
as	O
a	O
72-kDa	O
band	O
.	O

This	O
new	O
gene	O
,	O
spectrin	B
betaIV	I
,	O
thus	O
encodes	O
a	O
full	O
-	O
length	O
minor	O
isoform	O
(	O
SpbetaIVSigma1	B
)	O
and	O
a	O
truncated	O
major	O
isoform	O
(	O
SpbetaIVSigma5	B
)	O
.	O

Immunostaining	O
of	O
cells	O
shows	O
a	O
micropunctate	O
pattern	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
.	O

In	O
mesenchymal	O
stem	O
cells	O
,	O
the	O
staining	O
concentrates	O
at	O
nuclear	O
dots	O
that	O
stain	O
positively	O
for	O
the	O
promyelocytic	B
leukemia	I
protein	I
(	O
PML	B
)	O
.	O

Expression	O
of	O
SpbetaIVSigma5	B
fused	O
to	O
green	O
fluorescence	O
protein	O
in	O
cells	O
produces	O
nuclear	O
dots	O
that	O
include	O
all	O
PML	B
bodies	O
,	O
which	O
double	O
in	O
number	O
in	O
transfected	O
cells	O
.	O

Deletion	O
analysis	O
shows	O
that	O
partial	O
repeats	O
10	O
and	O
16	O
of	O
SpbetaIVSigma5	B
are	O
necessary	O
for	O
nuclear	O
dot	O
formation	O
.	O

Immunostaining	O
of	O
whole	O
-	O
mount	O
nuclear	O
matrices	O
reveals	O
diffuse	O
positivity	O
with	O
accentuation	O
at	O
PML	B
bodies	O
.	O

Spectrin	B
betaIV	I
is	O
the	O
first	O
beta	O
-	O
spectrin	O
associated	O
with	O
a	O
subnuclear	O
structure	O
and	O
may	O
be	O
part	O
of	O
a	O
nuclear	O
scaffold	O
to	O
which	O
gene	O
regulatory	O
machinery	O
binds	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
human	O
mitochondrial	O
homologue	O
of	O
the	O
bacterial	O
co	O
-	O
chaperone	O
GrpE.	B
We	O
have	O
identified	O
a	O
novel	O
human	O
cDNA	O
with	O
a	O
predicted	O
protein	O
sequence	O
that	O
has	O
28	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
E.	O
coli	O
Hsp70	O
co	O
-	O
chaperone	O
GrpE	B
and	O
designated	O
it	O
HMGE	B
.	O

Even	O
with	O
this	O
low	O
level	O
of	O
amino	O
acid	O
identity	O
the	O
human	O
sequence	O
could	O
be	O
efficiently	O
modelled	O
on	O
the	O
X	O
-	O
ray	O
structure	O
of	O
the	O
E.	O
coli	O
protein	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
significant	O
functional	O
conservation	O
.	O

Indeed	O
,	O
HMGE	B
expressed	O
in	O
E.	O
coli	O
as	O
a	O
GST	O
fusion	O
protein	O
co	O
-	O
purified	O
with	O
the	O
E.	O
coli	O
Hsp70	O
protein	O
DnaK	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

DnaK	O
could	O
be	O
released	O
from	O
the	O
GST	O
-	O
HMGE	B
with	O
a	O
Mg	O
-	O
ATP	O
wash	O
.	O

Subcellular	O
fractionation	O
and	O
immunocytochemistry	O
studies	O
using	O
antisera	O
raized	O
against	O
HMGE	B
show	O
that	O
it	O
is	O
a	O
mitochondrial	O
protein	O
.	O

In	O
contrast	O
to	O
studies	O
of	O
rat	O
GrpE	B
,	O
however	O
,	O
HMGE	B
also	O
appears	O
to	O
bind	O
the	O
constitutive	O
cytosolic	O
Hsp70	O
,	O
Hsc70	B
,	O
in	O
addition	O
to	O
mitochondrial	O
Hsp70	O
,	O
Mt	B
-	I
Hsp70	I
.	O

We	O
have	O
previously	O
shown	O
that	O
Hsc70	B
nucleotide	O
-	O
exchange	O
is	O
rate	O
limiting	O
in	O
the	O
presence	O
of	O
the	O
DnaJ	O
-	O
protein	O
,	O
HSJ1b	B
.	O

However	O
,	O
HMGE	B
was	O
found	O
to	O
inhibit	O
the	O
HSJ1b	B
-	O
enhanced	O
Hsc70	B
ATPase	O
activity	O
and	O
may	O
mediate	O
this	O
inhibition	O
by	O
binding	O
the	O
DnaJ	O
-	O
protein	O
,	O
HSJ1b	B
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
direct	O
interaction	O
between	O
a	O
DnaJ	O
protein	O
and	O
GrpE	B
-	O
like	O
protein	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
structure	O
of	O
GrpE	B
has	O
been	O
conserved	O
throughout	O
evolution	O
and	O
that	O
the	O
conserved	O
structure	O
can	O
interact	O
with	O
several	O
forms	O
of	O
Hsp70	O
,	O
but	O
that	O
HMGE	B
can	O
not	O
form	O
part	O
of	O
the	O
reaction	O
cycle	O
for	O
cytosolic	O
Hsc70	B
.	O

Paip1	B
interacts	O
with	O
poly	B
(	I
A	I
)	I
binding	I
protein	I
through	O
two	O
independent	O
binding	O
motifs	O
.	O

The	O
3	O
'	O
poly	O
(	O
A	O
)	O
tail	O
of	O
eukaryotic	O
mRNAs	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
translation	O
.	O

The	O
poly	B
(	I
A	I
)	I
binding	I
protein	I
(	O
PABP	B
)	O
interacts	O
with	O
eukaryotic	B
initiation	I
factor	I
4	I
G	I
(	O
eIF4	B
G	I
)	O
,	O
a	O
component	O
of	O
the	O
eIF4F	B
complex	O
,	O
which	O
binds	O
to	O
the	O
5	O
'	O
cap	O
structure	O
.	O

The	O
PABP	B
-	O
eIF4	B
G	I
interaction	O
brings	O
about	O
the	O
circularization	O
of	O
the	O
mRNA	O
by	O
joining	O
its	O
5	O
'	O
and	O
3	O
'	O
termini	O
,	O
thereby	O
stimulating	O
mRNA	O
translation	O
.	O

The	O
activity	O
of	O
PABP	B
is	O
regulated	O
by	O
two	O
interacting	O
proteins	O
,	O
Paip1	B
and	O
Paip2	B
.	O

To	O
study	O
the	O
mechanism	O
of	O
the	O
Paip1-PABP	B
interaction	O
,	O
far	O
-	O
Western	O
,	O
glutathione	O
S	O
-	O
transferase	O
pull	O
-	O
down	O
,	O
and	O
surface	O
plasmon	O
resonance	O
experiments	O
were	O
performed	O
.	O

Paip1	B
contains	O
two	O
binding	O
sites	O
for	O
PABP	B
,	O
PAM1	O
and	O
PAM2	O
(	O
for	O
PABP	B
-	O
interacting	O
motifs	O
1	O
and	O
2	O
)	O
.	O

PAM2	O
consists	O
of	O
a	O
15-amino	O
-	O
acid	O
stretch	O
residing	O
in	O
the	O
N	O
terminus	O
,	O
and	O
PAM1	O
encompasses	O
a	O
larger	O
C	O
-	O
terminal	O
acidic	O
-	O
amino	O
-	O
acid	O
-	O
rich	O
region	O
.	O

PABP	B
also	O
contains	O
two	O
Paip1	B
binding	O
sites	O
,	O
one	O
located	O
in	O
RNA	O
recognition	O
motifs	O
1	O
and	O
2	O
and	O
the	O
other	O
located	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

Paip1	B
binds	O
to	O
PABP	B
with	O
a	O
1:1	O
stoichiometry	O
and	O
an	O
apparent	O
K	O
(	O
d	O
)	O
of	O
1.9	O
nM.	O

Poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase-1	I
cleavage	O
during	O
apoptosis	O
:	O
an	O
update	O
.	O

Poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
is	O
a	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
playing	O
a	O
crucial	O
role	O
in	O
many	O
processes	O
,	O
including	O
DNA	O
repair	O
and	O
cell	O
death	O
.	O

The	O
best	O
known	O
poly	O
(	O
ADP	O
-	O
ribosylating	O
)	O
enzyme	O
,	O
PARP-1	B
,	O
is	O
a	O
DNA	O
nick	O
sensor	O
and	O
uses	O
betaNAD	O
(	O
+	O
)	O
to	O
form	O
polymers	O
of	O
ADP	O
-	O
ribose	O
which	O
are	O
further	O
bound	O
to	O
nuclear	O
protein	O
acceptors	O
.	O

To	O
strictly	O
regulate	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
turnover	O
,	O
its	O
degradation	O
is	O
assured	O
by	O
the	O
enzyme	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
glycohydrolase	I
(	O
PARG	B
)	O
.	O

During	O
apoptosis	O
,	O
PARP-1	B
plays	O
two	O
opposite	O
roles	O
:	O
its	O
stimulation	O
leads	O
to	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
synthesis	O
,	O
whereas	O
caspases	O
cause	O
PARP-1	B
cleavage	O
and	O
inactivation	O
.	O

PARP-1	B
proteolysis	O
produces	O
an	O
89	O
kDa	O
C	O
-	O
terminal	O
fragment	O
,	O
with	O
a	O
reduced	O
catalytic	O
activity	O
,	O
and	O
a	O
24	O
kDa	O
N	O
-	O
terminal	O
peptide	O
,	O
which	O
retains	O
the	O
DNA	O
binding	O
domains	O
.	O

The	O
fate	O
and	O
the	O
possible	O
role	O
of	O
these	O
fragments	O
during	O
apoptosis	O
will	O
be	O
discussed	O
.	O

Inhibition	O
of	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
activation	O
attenuates	O
beta	O
-	O
lapachone	O
-	O
induced	O
necrotic	O
cell	O
death	O
in	O
human	O
osteosarcoma	O
cells	O
.	O

beta	O
-	O
Lapachone	O
,	O
a	O
novel	O
anticancer	O
drug	O
,	O
induces	O
various	O
human	O
carcinoma	O
cells	O
to	O
undergo	O
apoptotic	O
cell	O
death	O
.	O

However	O
,	O
we	O
report	O
here	O
that	O
,	O
in	O
human	O
osteocarcinoma	O
(	O
U2-OS	O
)	O
cells	O
,	O
beta	O
-	O
lapachone	O
induces	O
necrosis	O
rather	O
than	O
apoptosis	O
.	O

beta	O
-	O
Lapachone	O
-	O
induced	O
necrotic	O
cell	O
death	O
in	O
U2-OS	O
cells	O
was	O
characterized	O
by	O
propidium	O
iodide	O
uptake	O
,	O
cytochrome	B
c	I
release	O
,	O
a	O
decreased	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
ATP	O
depletion	O
.	O

The	O
mitochondrial	O
potential	O
transition	O
(	O
MPT	O
)	O
,	O
including	O
the	O
reduction	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	B
c	I
,	O
occurred	O
in	O
beta	O
-	O
lapachone	O
-	O
treated	O
cells	O
;	O
cotreatment	O
of	O
these	O
cells	O
with	O
cyclosporin	O
A	O
,	O
an	O
inhibitor	O
of	O
MPT	O
pore	O
,	O
failed	O
to	O
prevent	O
necrotic	O
cell	O
death	O
.	O

This	O
indicates	O
that	O
the	O
MPT	O
transition	O
does	O
not	O
play	O
a	O
crucial	O
role	O
in	O
this	O
process	O
.	O

Furthermore	O
,	O
beta	O
-	O
lapachone	O
-	O
induced	O
necrosis	O
was	O
independent	O
of	O
oxidative	O
stress	O
and	O
caspase	O
activation	O
.	O

However	O
,	O
excessive	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
activation	O
and	O
subsequent	O
depletion	O
of	O
intracellular	O
NAD	O
(	O
+	O
)	O
and	O
ATP	O
were	O
seen	O
in	O
beta	O
-	O
lapachone	O
-	O
treated	O
U2-OS	O
cells	O
.	O

Cotreatment	O
with	O
a	O
PARP	B
inhibitor	O
,	O
3-aminobenzamide	O
,	O
decreased	O
beta	O
-	O
lapachone	O
-	O
induced	O
PARP	B
activation	O
and	O
provided	O
significant	O
protection	O
from	O
necrosis	O
by	O
preventing	O
depletion	O
of	O
intracellular	O
NAD	O
(	O
+	O
)	O
and	O
ATP	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
PARP	B
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	O
pathway	O
for	O
beta	O
-	O
lapachone	O
-	O
induced	O
necrosis	O
in	O
U2-OS	O
cells	O
.	O

Nociceptive	O
sensitization	O
by	O
the	O
secretory	O
protein	O
Bv8	O
.	O

1	O
The	O
small	O
protein	O
Bv8	O
,	O
isolated	O
from	O
amphibian	O
skin	O
,	O
belongs	O
to	O
a	O
novel	O
family	O
of	O
secretory	O
proteins	O
(	O
Bv8-Prokineticin	O
family	O
,	O
SWISS	O
-	O
PROT	O
:	O
Q9PW66	O
)	O
whose	O
orthologues	O
have	O
been	O
conserved	O
throughout	O
evolution	O
,	O
from	O
invertebrates	O
to	O
humans	O
.	O

2	O
When	O
injected	O
intravenously	O
or	O
subcutaneously	O
(	O
from	O
0.06	O
to	O
500	O
pmol	O
kg	O
(	O
-1	O
)	O
)	O
or	O
intrathecally	O
(	O
from	O
6	O
fmol	O
to	O
250	O
pmol	O
)	O
in	O
rats	O
,	O
Bv8	O
produced	O
an	O
intense	O
systemic	O
nociceptive	O
sensitization	O
to	O
mechanical	O
and	O
thermal	O
stimuli	O
applied	O
to	O
the	O
tail	O
and	O
paws	O
.	O

3	O
Topically	O
delivered	O
into	O
one	O
rat	O
paw	O
,	O
50	O
fmol	O
of	O
Bv8	O
decreased	O
by	O
50	O
%	O
the	O
nociceptive	O
threshold	O
to	O
pressure	O
in	O
the	O
injected	O
paw	O
without	O
affecting	O
the	O
threshold	O
in	O
the	O
contralateral	O
paw	O
.	O

4	O
The	O
two	O
G	O
-	O
protein	O
coupled	O
prokineticin	O
receptors	O
,	O
PK	B
-	I
R1	I
and	O
PK	B
-	I
R2	I
,	O
were	O
expressed	O
in	O
rat	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
and	O
in	O
dorsal	O
quadrants	O
of	O
spinal	O
cord	O
(	O
DSC	O
)	O
and	O
bound	O
Bv8	O
and	O
the	O
mammalian	O
orthologue	O
,	O
EG	B
-	I
VEGF	I
,	O
with	O
high	O
affinity	O
.	O

In	O
DSC	O
,	O
PK	B
-	I
R1	I
was	O
more	O
abundant	O
than	O
PK	B
-	I
R2	I
,	O
whereas	O
both	O
receptors	O
were	O
equally	O
expressed	O
in	O
DRG	O
.	O

IC	O
(	O
50	O
)	O
of	O
Bv8	O
and	O
EG	B
-	I
VEGF	I
to	O
inhibit	O
[	O
(	O
125	O
)	O
I	O
]	O
-Bv8	O
binding	O
to	O
rat	O
DRG	O
and	O
DSC	O
were	O
4.1+	O
/	O
-0.4	O
nM	O
Bv8	O
and	O
76.4+	O
/	O
-7.6	O
nM	O
EG	B
-	I
VEGF	I
,	O
in	O
DRG	O
;	O
7.3+	O
/	O
-0.9	O
nM	O
Bv8	O
and	O
330+	O
/	O
-41	O
nM	O
EG	B
-	I
VEGF	I
,	O
in	O
DSC	O
.	O

5	O
In	O
the	O
small	O
diameter	O
neurons	O
(	O
<	O
30	O
microm	O
)	O
of	O
rat	O
DRG	O
cultures	O
,	O
Bv8	O
concentrations	O
,	O
ranging	O
from	O
0.2	O
to	O
10	O
nM	O
,	O
raised	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

6	O
These	O
data	O
suggest	O
that	O
Bv8	O
,	O
through	O
binding	O
to	O
PK	O
receptors	O
of	O
DSC	O
and	O
primary	O
sensitive	O
neurons	O
,	O
results	O
in	O
intense	O
sensitization	O
of	O
peripheral	O
nociceptors	O
to	O
thermal	O
and	O
mechanical	O
stimuli	O
.	O

US11	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
interacts	O
with	O
HIPK2	B
and	O
antagonizes	O
HIPK2-induced	B
cell	O
growth	O
arrest	O
.	O

Homeodomain	B
-	I
interacting	I
protein	I
kinase	I
2	I
(	O
HIPK2	B
)	O
is	O
a	O
nuclear	O
serine	O
/	O
threonine	O
kinase	O
of	O
the	O
subfamily	O
of	O
dual	O
-	O
specificity	O
Yak1-related	O
kinase	O
proteins	O
.	O

HIPK2	B
was	O
first	O
described	O
as	O
a	O
homeodomain	O
-	O
interacting	O
protein	O
kinase	O
acting	O
as	O
a	O
corepressor	O
for	O
homeodomain	O
transcription	O
factors	O
.	O

More	O
recently	O
,	O
it	O
was	O
reported	O
that	O
HIPK2	B
plays	O
a	O
role	O
in	O
p53-mediated	B
cellular	O
apoptosis	O
and	O
could	O
also	O
participate	O
in	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O

US11	O
protein	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
is	O
a	O
multifunctional	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
several	O
processes	O
related	O
to	O
the	O
survival	O
of	O
cells	O
submitted	O
to	O
environmental	O
stresses	O
by	O
mechanisms	O
that	O
are	O
not	O
fully	O
elucidated	O
.	O

In	O
an	O
attempt	O
to	O
better	O
understand	O
the	O
multiple	O
functions	O
of	O
US11	O
,	O
we	O
identified	O
cellular	O
binding	O
partners	O
of	O
this	O
protein	O
by	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

We	O
report	O
that	O
US11	O
interacts	O
with	O
HIPK2	B
through	O
the	O
PEST	O
domain	O
of	O
HIPK2	B
and	O
that	O
this	O
interaction	O
occurs	O
also	O
in	O
human	O
cells	O
.	O

This	O
interaction	O
modifies	O
the	O
subcellular	O
distribution	O
of	O
HIPK2	B
and	O
protects	O
the	O
cell	O
against	O
the	O
HIPK2-induced	B
cell	O
growth	O
arrest	O
.	O

Physical	O
and	O
functional	O
interactions	O
between	O
Daxx	B
and	O
TSG101	B
.	O

Daxx	B
has	O
been	O
reported	O
to	O
mediate	O
the	O
Fas	B
/	O
JNK	B
-	O
dependent	O
signals	O
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
several	O
evidences	O
have	O
suggested	O
that	O
Daxx	B
is	O
located	O
mainly	O
in	O
the	O
nucleus	O
and	O
functions	O
as	O
a	O
transcriptional	O
regulator	O
.	O

Recently	O
,	O
we	O
identified	O
DMAP1	B
,	O
a	O
TSG101-interacting	B
protein	O
as	O
a	O
Daxx	B
binding	O
partner	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

TSG101	B
has	O
been	O
shown	O
to	O
act	O
as	O
transcriptional	O
co	O
-	O
repressor	O
of	O
nuclear	O
hormone	O
receptors	O
.	O

Here	O
we	O
examined	O
whether	O
TSG101also	O
interacts	O
with	O
Daxx	B
directly	O
.	O

The	O
association	O
of	O
Daxx	B
and	O
TSG101	B
was	O
confirmed	O
using	O
co	O
-	O
expressed	O
tagged	O
proteins	O
.	O

The	O
interaction	O
regions	O
in	O
both	O
proteins	O
were	O
also	O
mapped	O
,	O
and	O
the	O
cellular	O
localization	O
of	O
the	O
interaction	O
was	O
examined	O
.	O

TSG101	B
formed	O
a	O
complex	O
with	O
Daxx	B
through	O
its	O
coiled	O
-	O
coil	O
domain	O
and	O
co	O
-	O
localized	O
in	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
TSG101	B
enhanced	O
Daxx	B
-	O
mediated	O
repression	O
of	O
glucocorticoid	B
receptor	I
transcriptional	O
activity	O
.	O

These	O
results	O
provide	O
the	O
novel	O
molecular	O
interactions	O
between	O
Daxx	B
and	O
TSG101	B
,	O
which	O
establish	O
an	O
efficient	O
repressive	O
transcription	O
complex	O
in	O
the	O
nucleus	O
.	O

Statherin	B
:	O
a	O
major	O
boundary	O
lubricant	O
of	O
human	O
saliva	O
.	O

The	O
lubricating	O
properties	O
of	O
human	O
submandibular	O
-	O
sublingual	O
salivary	O
fractions	O
were	O
examined	O
using	O
a	O
servohydraulic	O
model	O
of	O
mandibular	O
movement	O
.	O

Fractions	O
containing	O
statherin	B
exhibited	O
a	O
strong	O
tendency	O
to	O
boundary	O
lubrication	O
.	O

The	O
lubricity	O
of	O
purified	O
statherin	B
was	O
confirmed	O
and	O
compared	O
to	O
the	O
amphipathic	O
molecules	O
gramacidin	O
S	O
and	O
sodium	O
dodecyl	O
sulfate	O
.	O

Contact	O
angle	O
measurements	O
of	O
statherin	B
paralleled	O
the	O
other	O
amphipathic	O
molecules	O
.	O

The	O
helical	O
content	O
of	O
statherin	B
increased	O
in	O
trifluoroethanol	O
indicating	O
the	O
presence	O
of	O
amphipathic	O
helical	O
regions	O
.	O

CD	O
studies	O
and	O
hydrophobic	O
moment	O
calculations	O
indicated	O
that	O
statherin	B
adopts	O
an	O
amphipathic	O
helical	O
conformation	O
at	O
the	O
N	O
-	O
terminus	O
.	O

An	O
energy	O
-	O
minimized	O
model	O
of	O
the	O
polar	O
N	O
-	O
terminal	O
residues	O
1	O
-	O
15	O
suggested	O
that	O
this	O
domain	O
could	O
be	O
positioned	O
in	O
space	O
to	O
interact	O
with	O
a	O
hydroxyapatite	O
substrate	O
.	O

These	O
data	O
imply	O
that	O
under	O
appropriate	O
conditions	O
statherin	B
may	O
display	O
an	O
amphipathic	O
nature	O
which	O
enables	O
it	O
to	O
function	O
as	O
a	O
boundary	O
lubricant	O
on	O
enamel	O
.	O

A	O
novel	O
IL-1	B
receptor	O
,	O
cloned	O
from	O
B	O
cells	O
by	O
mammalian	O
expression	O
,	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O

cDNA	O
clones	O
corresponding	O
to	O
an	O
Mr	O
approximately	O
80,000	O
receptor	O
(	B
type	I
I	I
receptor	I
)	I
for	I
interleukin-1	I
(	I
IL-1	I
)	I
have	O
been	O
isolated	O
previously	O
by	O
mammalian	O
expression	O
.	O

Here	O
,	O
we	O
report	O
the	O
use	O
of	O
an	O
improved	O
expression	O
cloning	O
method	O
to	O
isolate	O
human	O
and	O
murine	O
cDNA	O
clones	O
encoding	O
a	B
second	I
type	I
(	I
Mr	I
approximately	I
60,000	I
)	I
of	I
IL-1	I
receptor	I
(	I
type	I
II	I
receptor	I
)	I
.	O

The	O
mature	O
type	B
II	I
IL-1	I
receptor	I
consists	O
of	O
(	O
i	O
)	O
a	O
ligand	O
binding	O
portion	O
comprised	O
of	O
three	O
immunoglobulin	O
-	O
like	O
domains	O
;	O
(	O
ii	O
)	O
a	O
single	O
transmembrane	O
region	O
;	O
and	O
(	O
iii	O
)	O
a	O
short	O
cytoplasmic	O
domain	O
of	O
29	O
amino	O
acids	O
.	O

This	O
last	O
contrasts	O
with	O
the	O
approximately	O
215	O
amino	O
acid	O
cytoplasmic	O
domain	O
of	O
the	O
type	O
I	O
receptor	O
,	O
and	O
suggests	O
that	O
the	O
two	O
IL-1	B
receptors	O
may	O
interact	O
with	O
different	O
signal	O
transduction	O
pathways	O
.	O

The	O
type	O
II	O
receptor	O
is	O
expressed	O
in	O
a	O
number	O
of	O
different	O
tissues	O
,	O
including	O
both	O
B	O
and	O
T	O
lymphocytes	O
,	O
and	O
can	O
be	O
induced	O
in	O
several	O
cell	O
types	O
by	O
treatment	O
with	O
phorbol	O
ester	O
.	O

Both	O
IL-1	B
receptors	O
appear	O
to	O
be	O
well	O
conserved	O
in	O
evolution	O
,	O
and	O
map	O
to	O
the	O
same	O
chromosomal	O
location	O
.	O

Like	O
the	O
type	O
I	O
receptor	O
,	O
the	O
human	O
type	B
II	I
IL-1	I
receptor	I
can	O
bind	O
all	O
three	O
forms	O
of	O
IL-1	B
(	O
IL-1	B
alpha	I
,	O
IL-1	B
beta	I
and	O
IL-1ra	B
)	O
.	O

Vaccinia	O
virus	O
contains	O
an	O
open	O
reading	O
frame	O
bearing	O
strong	O
resemblance	O
to	O
the	O
type	B
II	I
IL-1	I
receptor	I
.	O

A	O
1.1-Mb	O
transcript	O
map	O
of	O
the	O
hereditary	O
hemochromatosis	O
locus	O
.	O

In	O
the	O
process	O
of	O
positionally	O
cloning	O
a	O
candidate	O
gene	O
responsible	O
for	O
hereditary	O
hemochromatosis	O
(	O
HH	O
)	O
,	O
we	O
constructed	O
a	O
1.1-Mb	O
transcript	O
map	O
of	O
the	O
region	O
of	O
human	O
chromosome	O
6p	O
that	O
lies	O
4.5	O
Mb	O
telomeric	O
to	O
HLA	B
-	I
A.	I
A	O
combination	O
of	O
three	O
gene	O
-	O
finding	O
techniques	O
,	O
direct	O
cDNA	O
selection	O
,	O
exon	O
trapping	O
,	O
and	O
sample	O
sequencing	O
,	O
were	O
used	O
initially	O
for	O
a	O
saturation	O
screening	O
of	O
the	O
1.1-Mb	O
region	O
for	O
expressed	O
sequence	O
fragments	O
.	O

As	O
genetic	O
analysis	O
further	O
narrowed	O
the	O
HH	O
candidate	O
locus	O
,	O
we	O
sequenced	O
completely	O
0.25	O
Mb	O
of	O
genomic	O
DNA	O
as	O
a	O
final	O
measure	O
to	O
identify	O
all	O
genes	O
.	O

Besides	O
the	O
novel	O
MHC	O
class	O
1-like	O
HH	O
candidate	O
gene	O
HLA	B
-	I
H	I
,	O
we	O
identified	O
a	O
family	O
of	O
five	O
butyrophilin	O
-	O
related	O
sequences	O
,	O
two	O
genes	O
with	O
structural	O
similarity	O
to	O
a	O
type	O
1	O
sodium	O
phosphate	O
transporter	O
,	O
12	O
novel	O
histone	O
genes	O
,	O
and	O
a	O
gene	O
we	O
named	O
RoRet	B
based	O
on	O
its	O
strong	O
similarity	O
to	O
the	O
52-kD	O
Ro	O
/	O
SSA	B
lupus	O
and	O
Sjogren	O
's	O
syndrome	O
auto	O
-	O
antigen	O
and	O
the	O
RET	B
finger	I
protein	I
.	O

Several	O
members	O
of	O
the	O
butyrophilin	O
family	O
and	O
the	O
RoRet	B
gene	O
share	O
an	O
exon	O
of	O
common	O
evolutionary	O
origin	O
called	O
B30	O
-	O
2	O
.	O

The	O
B30	O
-	O
2	O
exon	O
was	O
originally	O
isolated	O
from	O
the	O
HLA	O
class	O
1	O
region	O
,	O
yet	O
has	O
apparently	O
""""	O
shuffled	O
""""	O
into	O
several	O
genes	O
along	O
the	O
chromosome	O
telomeric	O
to	O
the	O
MHC	O
.	O

The	O
conservation	O
of	O
the	O
B30	O
-	O
2	O
exon	O
in	O
several	O
novel	O
genes	O
and	O
the	O
previously	O
described	O
amino	O
acid	O
homology	O
of	O
HLA	B
-	I
H	I
to	O
MHC	O
class	O
1	O
molecules	O
provide	O
further	O
support	O
that	O
this	O
gene	O
-	O
rich	O
region	O
of	O
6p21.3	O
is	O
related	O
to	O
the	O
MHC	O
.	O

Finally	O
,	O
we	O
performed	O
an	O
analysis	O
of	O
the	O
four	O
approaches	O
for	O
gene	O
finding	O
and	O
conclude	O
that	O
direct	O
selection	O
provides	O
the	O
most	O
effective	O
probes	O
for	O
cDNA	O
screening	O
,	O
and	O
that	O
as	O
much	O
as	O
30	O
%	O
of	O
ESTs	O
in	O
this	O
1.1-Mb	O
region	O
may	O
be	O
derived	O
from	O
noncoding	O
genomic	O
DNA	O
.	O

Mutations	O
in	O
PROP1	B
cause	O
familial	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Combined	O
pituitary	O
hormone	O
deficiency	O
(	O
CPHD	O
)	O
in	O
man	O
denotes	O
impaired	O
production	O
of	O
growth	B
hormone	I
(	O
GH	B
)	O
and	O
one	O
or	O
more	O
of	O
the	O
other	O
five	O
anterior	O
pituitary	O
hormones	O
.	O

Mutations	O
of	O
the	O
pituitary	O
transcription	O
factor	O
gene	O
POU1F1	B
(	O
the	O
human	B
homologue	I
of	I
mouse	I
Pit1	I
)	O
are	O
responsible	O
for	O
deficiencies	O
of	O
GH	B
,	O
prolactin	B
and	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
in	O
Snell	O
and	O
Jackson	O
dwarf	O
mice	O
and	O
in	O
man	O
,	O
while	O
the	O
production	O
of	O
adrenocorticotrophic	O
hormone	O
(	O
ACTH	O
)	O
,	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
and	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
is	O
preserved	O
.	O

The	O
Ames	O
dwarf	O
(	O
df	O
)	O
mouse	O
displays	O
a	O
similar	O
phenotype	O
,	O
and	O
appears	O
to	O
be	O
epistatic	O
to	O
Snell	O
and	O
Jackson	O
dwarfism	O
.	O

We	O
have	O
recently	O
positionally	O
cloned	O
the	O
putative	O
Ames	O
dwarf	O
gene	O
Prop1	B
,	O
which	O
encodes	O
a	O
paired	O
-	O
like	O
homeodomain	O
protein	O
that	O
is	O
expressed	O
specifically	O
in	O
embryonic	O
pituitary	O
and	O
is	O
necessary	O
for	O
Pit1	B
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
identified	O
four	O
CPHD	O
families	O
with	O
homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
inactivating	O
mutations	O
of	O
PROP1	B
.	O

These	O
mutations	O
in	O
the	O
human	O
PROP1	B
gene	O
result	O
in	O
a	O
gene	O
product	O
with	O
reduced	O
DNA	O
-	O
binding	O
and	O
transcriptional	O
activation	O
ability	O
in	O
comparison	O
to	O
the	O
product	O
of	O
the	O
murine	O
df	O
mutation	O
.	O

In	O
contrast	O
to	O
individuals	O
with	O
POU1F1	B
mutations	O
,	O
those	O
with	O
PROP1	B
mutations	O
can	O
not	O
produce	O
LH	O
and	O
FSH	O
at	O
a	O
sufficient	O
level	O
and	O
do	O
not	O
enter	O
puberty	O
spontaneously	O
.	O

Our	O
results	O
identify	O
a	O
major	O
cause	O
of	O
CPHD	O
in	O
humans	O
and	O
suggest	O
a	O
direct	O
or	O
indirect	O
role	O
for	O
PROP1	B
in	O
the	O
ontogenesis	O
of	O
pituitary	O
gonadotropes	O
,	O
as	O
well	O
as	O
somatotropes	O
,	O
lactotropes	O
and	O
caudomedial	O
thyrotropes	O
.	O

Discovery	O
of	O
three	O
novel	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
genes	O
.	O

We	O
report	O
here	O
the	O
molecular	O
cloning	O
,	O
tissue	O
distribution	O
,	O
and	O
chromosomal	O
localization	O
of	O
novel	O
genes	O
encoding	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
.	O

A	O
search	O
of	O
a	O
mouse	O
database	O
of	O
expressed	O
sequence	O
tags	O
revealed	O
an	O
EST	O
partially	O
encoding	O
a	O
GPCR	O
,	O
which	O
was	O
used	O
to	O
screen	O
a	O
mouse	O
genomic	O
library	O
to	O
obtain	O
the	O
translational	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
.	O

The	O
resultant	O
clone	O
,	O
GPR27	B
,	O
contained	O
an	O
intronless	O
ORF	O
,	O
encoding	O
a	O
receptor	O
of	O
379	O
amino	O
acids	O
.	O

In	O
an	O
alternate	O
strategy	O
,	O
human	O
genomic	O
DNA	O
was	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
,	O
using	O
degenerate	O
oligonucleotides	O
based	O
on	O
GPR1	B
.	O

Two	O
PCR	O
products	O
partially	O
encoding	O
GPCRs	O
were	O
isolated	O
and	O
used	O
to	O
screen	O
a	O
genomic	O
library	O
to	O
obtain	O
the	O
translational	O
ORF	O
.	O

One	O
of	O
the	O
resultant	O
clones	O
,	O
GPR30	B
,	O
contained	O
an	O
intronless	O
ORF	O
encoding	O
a	O
receptor	O
of	O
375	O
amino	O
acids	O
.	O

The	O
other	O
clone	O
,	O
GPR35	B
,	O
also	O
contained	O
an	O
intronless	O
ORF	O
encoding	O
a	O
receptor	O
of	O
309	O
amino	O
acids	O
.	O

Transcripts	O
corresponding	O
to	O
GPR27	B
and	O
GPR30	B
were	O
detected	O
in	O
several	O
areas	O
of	O
human	O
and	O
rat	O
CNS	O
,	O
While	O
GPR35	B
expression	O
was	O
detected	O
only	O
in	O
the	O
rat	O
intestine	O
.	O

Through	O
fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
the	O
gene	O
encoding	O
GPR30	B
was	O
localized	O
to	O
chromosome	O
7p22	O
and	O
GPR35	B
to	O
chromosome	O
2q37.3	O
.	O

New	O
eukaryotic	O
semaphorins	O
with	O
close	O
homology	O
to	O
semaphorins	O
of	O
DNA	O
viruses	O
.	O

Semaphorins	O
were	O
initially	O
described	O
as	O
a	O
family	O
of	O
repulsive	O
guidance	O
molecules	O
in	O
embryonal	O
development	O
.	O

Their	O
basic	O
structure	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
signal	O
sequence	O
,	O
the	O
defining	O
semaphorin	O
domain	O
ofapproximately	O
500	O
amino	O
acids	O
,	O
an	O
Ig	O
-	O
like	O
domain	O
,	O
and	O
a	O
variable	O
carboxy	O
-	O
terminus	O
.	O

We	O
recently	O
described	O
a	O
viral	O
semaphorin	O
homologue	O
encoded	O
by	O
the	O
alcelaphine	O
herpesvirus	O
type	O
1	O
.	O

Less	O
conserved	O
,	O
truncated	O
homologues	O
were	O
also	O
identified	O
in	O
poxviruses	O
.	O

Here	O
we	O
describe	O
new	O
human	O
and	O
murine	O
semaphorin	O
homologues	O
.	O

The	O
respective	O
genes	O
were	O
cloned	O
and	O
sequenced	O
,	O
and	O
they	O
were	O
termed	O
H	B
-	I
Sema	I
-	I
L	I
and	O
M	O
-	O
Sema	O
-	O
L	O
(	O
HGMW	O
-	O
approved	O
symbols	O
SEMAL	B
and	O
Semal	B
,	O
respectively	O
)	O
.	O

A	O
multiply	O
spliced	O
mRNA	O
of	O
3.2	O
kb	O
is	O
expressed	O
in	O
human	O
placenta	O
,	O
spleen	O
,	O
thymus	O
,	O
and	O
gonadal	O
tissue	O
.	O

H	B
-	I
Sema	I
-	I
L	I
maps	O
to	O
chromosome	O
15q22.3-q23	O
and	O
M	O
-	O
Sema	O
-	O
L	O
to	O
the	O
homologous	O
locus	O
9A3.3-B	O
in	O
the	O
mouse	O
genome	O
.	O

The	O
expression	O
patterns	O
and	O
the	O
presence	O
of	O
related	O
genes	O
in	O
large	O
DNA	O
viruses	O
suggest	O
that	O
this	O
new	O
semaphorin	O
has	O
a	O
relevant	O
function	O
in	O
the	O
immune	O
system	O
.	O

We	O
describe	O
an	O
experimental	O
approach	O
to	O
the	O
use	O
of	O
genetics	O
to	O
study	O
muscle	O
contraction	O
in	O
Drosophila	O
melanogaster	O
.	O

Mutations	O
induced	O
by	O
in	O
vitro	O
mutagenesis	O
are	O
inserted	O
into	O
the	O
genome	O
of	O
flies	O
using	O
P	B
-	I
element	I
mediated	O
transformation	O
,	O
permitting	O
the	O
effects	O
of	O
the	O
mutant	O
genes	O
to	O
be	O
studied	O
in	O
vivo	O
in	O
the	O
indirect	O
flight	O
muscles	O
(	O
IFMs	O
)	O
.	O

Details	O
of	O
how	O
mechanical	O
experiments	O
can	O
be	O
performed	O
on	O
skinned	O
IFMs	O
,	O
despite	O
their	O
small	O
size	O
,	O
are	O
provided	O
.	O

The	O
effects	O
of	O
two	O
in	O
vitro	O
actin	B
mutations	O
,	O
G368E	O
and	O
E316	O
K	O
,	O
are	O
described	O
.	O

The	O
problems	O
of	O
performing	O
biochemical	O
and	O
biophysical	O
experiments	O
on	O
the	O
IFMs	O
and	O
their	O
myofibrillar	O
proteins	O
are	O
described	O
,	O
together	O
with	O
indications	O
as	O
to	O
how	O
these	O
may	O
be	O
overcome	O
.	O

The	O
genetic	O
structure	O
of	O
a	O
segregation	B
distorter	I
chromosome	O
(	O
a	O
derivative	O
of	O
SD-36	B
)	O
has	O
been	O
analyzed	O
in	O
a	O
system	O
in	O
which	O
recombination	O
in	O
the	O
second	O
chromosome	O
is	O
blocked	O
by	O
inversions	O
except	O
for	O
the	O
critical	O
region	O
around	O
the	O
centromeric	O
heterochromatin	O
.	O

The	O
results	O
confirm	O
the	O
map	O
order	O
and	O
characteristics	O
of	O
four	O
loci	O
known	O
to	O
be	O
involved	O
in	O
segregation	O
distortion	O
,	O
namely	O
Sd	B
,	O
E	B
(	I
SD	I
)	I
,	O
Rspins	O
,	O
M	B
(	I
SD	I
)	I
.	O

However	O
,	O
SD-36	B
carries	O
a	O
fifth	O
major	O
locus	O
involved	O
in	O
distortion	O
.	O

This	O
locus	O
is	O
near	O
pr	O
in	O
2L	O
and	O
has	O
the	O
effect	O
of	O
enhancing	O
the	O
degree	O
of	O
distortion	O
.	O

In	O
addition	O
,	O
reciprocal	O
recombinant	O
products	O
from	O
SD-36	B
are	O
recovered	O
unequally	O
.	O

All	O
recombinants	O
carrying	O
the	O
pr	O
region	O
from	O
SD-36	B
seem	O
also	O
to	O
carry	O
Sd	B
,	O
although	O
Sd	B
has	O
previously	O
been	O
mapped	O
1.6	O
units	O
to	O
the	O
left	O
of	O
pr	O
.	O

Both	O
the	O
enhancement	O
of	O
distortion	O
and	O
the	O
unequal	O
recovery	O
of	O
reciprocal	O
products	O
can	O
be	O
explained	O
if	O
it	O
is	O
assumed	O
that	O
the	O
new	O
locus	O
near	O
pr	O
in	O
SD-36	B
is	O
actually	O
a	O
duplication	O
of	O
Sd	B
.	O

Cellularization	O
of	O
the	O
Drosophila	O
embryo	O
requires	O
the	O
establishment	O
of	O
a	O
hexagonal	O
network	O
of	O
actin	O
and	O
myosin	O
filaments	O
that	O
are	O
interconnected	O
around	O
the	O
nuclei	O
in	O
the	O
cortex	O
of	O
the	O
syncytial	O
blastoderm	O
.	O

This	O
cytoskeletal	O
network	O
provides	O
the	O
framework	O
and	O
possibly	O
the	O
contractile	O
force	O
for	O
the	O
membrane	O
invaginations	O
that	O
synchronously	O
subdivide	O
the	O
syncytial	O
embryo	O
into	O
individual	O
cells	O
.	O

Zygotic	O
expression	O
of	O
the	O
nullo	B
locus	O
is	O
essential	O
for	O
the	O
preservation	O
of	O
an	O
intact	O
actin	O
-	O
myosin	O
network	O
.	O

Embryos	O
deleted	O
for	O
the	O
nullo	B
locus	O
have	O
a	O
disrupted	O
network	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
many	O
multinucleate	O
cells	O
.	O

We	O
show	O
that	O
nullo	B
is	O
not	O
required	O
for	O
the	O
initial	O
formation	O
of	O
the	O
actin	O
-	O
myosin	O
network	O
,	O
but	O
is	O
necessary	O
for	O
the	O
maintenance	O
of	O
its	O
hexagonal	O
shape	O
during	O
cellularization	O
.	O

The	O
phenotype	O
of	O
embryonic	O
mosaics	O
is	O
nonautonomous	O
,	O
indicating	O
that	O
nullo	B
does	O
not	O
have	O
to	O
be	O
expressed	O
in	O
every	O
nucleus	O
for	O
proper	O
cellularization	O
.	O

Examination	O
of	O
nullo	B
mutant	O
clones	O
in	O
adults	O
reveals	O
that	O
nullo	B
activity	O
is	O
not	O
required	O
for	O
cell	O
division	O
in	O
imaginal	O
discs	O
.	O

Furthermore	O
,	O
germline	O
clone	O
experiments	O
suggest	O
that	O
maternal	O
expression	O
of	O
the	O
nullo	B
locus	O
is	O
not	O
essential	O
for	O
either	O
germline	O
proliferation	O
or	O
the	O
cellularization	O
of	O
progeny	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
nullo	B
functions	O
specifically	O
at	O
cellularization	O
to	O
stabilize	O
the	O
actin	O
-	O
myosin	O
network	O
during	O
contraction	O
.	O

The	O
nucleotide	O
sequence	O
of	O
a	O
segment	O
of	O
the	O
mtDNA	B
molecule	O
of	O
Drosophila	O
yakuba	O
has	O
been	O
determined	O
,	O
within	O
which	O
have	O
been	O
identified	O
the	O
3	O
'	O
end	O
of	O
the	O
large	O
rRNA	O
gene	O
and	O
the	O
entire	O
genes	O
for	O
tRNAleuCUN	O
,	O
URF1	O
,	O
tRNAserUCN	O
,	O
cytochrome	O
b	O
,	O
URF6	O
,	O
tRNApro	O
,	O
tRNAthr	O
,	O
URF4L	O
,	O
URF4	O
,	O
tRNAhis	O
and	O
URF5	O
.	O

The	O
genes	O
are	O
arranged	O
in	O
the	O
order	O
given	O
,	O
with	O
the	O
large	O
rRNA	O
gene	O
being	O
closest	O
to	O
the	O
A+T	O
-	O
rich	O
region	O
which	O
contains	O
the	O
origin	O
of	O
replication	O
.	O

Transcription	O
of	O
all	O
of	O
these	O
genes	O
except	O
those	O
for	O
cytochrome	O
b	O
,	O
URF6	O
,	O
tRNAserUCN	O
and	O
tRNAthr	O
proceeds	O
in	O
the	O
same	O
direction	O
as	O
replication	O
.	O

Differences	O
occur	O
in	O
the	O
relative	O
arrangement	O
and	O
in	O
the	O
direction	O
of	O
transcription	O
of	O
these	O
twelve	O
genes	O
between	O
D.	O
yakuba	O
and	O
mammalian	O
mtDNA	B
molecules	O
.	O

Internal	O
AGA	O
codons	O
occur	O
in	O
all	O
of	O
the	O
polypeptide	O
genes	O
except	O
URF6	O
.	O

Comparisons	O
of	O
the	O
positions	O
of	O
these	O
AGA	O
codons	O
to	O
codons	O
in	O
corresponding	O
mouse	O
genes	O
is	O
consistent	O
with	O
the	O
view	O
that	O
in	O
the	O
D.	O
yakuba	O
mitochondrial	O
genetic	O
code	O
AGA	O
specifies	O
serine	O
.	O

Genes	O
equivalent	O
to	O
all	O
of	O
the	O
polypeptide	O
,	O
tRNA	O
and	O
rRNA	O
genes	O
found	O
in	O
mammalian	O
mtDNA	B
have	O
now	O
been	O
identified	O
in	O
D.	O
yakuba	O
mtDNA	B
.	O

Arthropods	B
exhibit	O
great	O
diversity	O
in	O
the	O
position	O
,	O
number	O
,	O
morphology	O
,	O
and	O
function	O
of	O
their	O
limbs	O
.	O

The	O
evolutionary	O
relations	O
among	O
limb	O
types	O
and	O
among	O
the	O
arthropod	O
groups	O
that	O
bear	O
them	O
(	O
insects	O
,	O
crustaceans	O
,	O
myriapods	O
,	O
and	O
chelicerates	O
)	O
are	O
controversial	O
.	O

Here	O
,	O
the	O
use	O
of	O
molecular	O
probes	O
,	O
including	O
an	O
antibody	O
to	O
proteins	O
encoded	O
by	O
arthropod	O
and	O
vertebrate	O
Distal	B
-	I
less	I
(	O
Dll	B
and	O
Dlx	O
)	O
genes	O
,	O
provided	O
evidence	O
that	O
common	O
genetic	O
mechanisms	O
underlie	O
the	O
development	O
of	O
all	O
arthropod	O
limbs	O
and	O
their	O
branches	O
and	O
that	O
all	O
arthropods	O
derive	O
from	O
a	O
common	O
ancestor	O
.	O

However	O
,	O
differences	O
between	O
crustacean	O
and	O
insect	O
body	O
plans	O
were	O
found	O
to	O
correlate	O
with	O
differences	O
in	O
the	O
deployment	O
of	O
particular	O
homeotic	O
genes	O
and	O
in	O
the	O
ways	O
that	O
these	O
genes	O
regulate	O
limb	O
development	O
.	O

Dorsal	B
-	O
ventral	O
patterning	O
within	O
the	O
ectoderm	O
of	O
the	O
Drosophila	O
embryo	O
requires	O
seven	O
zygotic	O
genes	O
,	O
including	O
short	B
gastrulation	I
(	O
sog	B
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
sog	B
,	O
which	O
is	O
expressed	O
in	O
the	O
ventrolateral	O
region	O
of	O
the	O
embryo	O
that	O
gives	O
rise	O
to	O
the	O
nerve	O
cord	O
,	O
is	O
functionally	O
homologous	O
to	O
the	O
chordin	B
gene	O
of	O
Xenopus	O
,	O
which	O
is	O
expressed	O
in	O
the	O
dorsal	B
blastopore	O
lip	O
of	O
the	O
embryo	O
and	O
in	O
dorsal	B
mesoderm	O
,	O
in	O
particular	O
the	O
notochord	O
.	O

We	O
show	O
by	O
injections	O
of	O
messenger	O
RNA	O
that	O
both	O
sog	B
and	O
chordin	B
can	O
promote	O
ventral	O
development	O
in	O
Drosophila	O
,	O
and	O
that	O
sog	B
,	O
like	O
chordin	B
,	O
can	O
promote	O
dorsal	B
development	O
in	O
Xenopus	O
.	O

In	O
Drosophila	O
,	O
sog	B
antagonizes	O
the	O
dorsalizing	O
effects	O
of	O
decapentaplegic	B
(	O
dpp	B
)	O
,	O
a	O
member	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
.	O

One	O
of	O
the	O
dpp	B
homologues	O
in	O
vertebrates	O
,	O
bmp-4	O
,	O
is	O
expressed	O
ventrally	O
in	O
Xenopus	O
and	O
promotes	O
ventral	O
development	O
.	O

We	O
show	O
that	O
dpp	B
can	O
promote	O
ventral	O
fates	O
in	O
Xenopus	O
,	O
and	O
that	O
injection	O
of	O
sog	B
mRNA	O
counteracts	O
the	O
ventralizing	O
effects	O
of	O
dpp	B
.	O

These	O
results	O
suggest	O
the	O
molecular	O
conservation	O
of	O
dorsoventral	O
patterning	O
mechanisms	O
during	O
evolution	O
.	O

The	O
three	O
yolk	O
proteins	O
(	O
YP1	B
,	O
YP2	B
and	O
YP3	B
)	O
of	O
Drosophila	O
melanogaster	O
are	O
synthesized	O
in	O
two	O
tissues	O
of	O
the	O
adult	O
female	O
,	O
the	O
fat	O
body	O
and	O
ovarian	O
follicle	O
cells	O
.	O

The	O
YPs	O
are	O
selectively	O
accumulated	O
in	O
the	O
oocyte	O
to	O
provide	O
nutrients	O
for	O
embryogenesis	O
.	O

We	O
describe	O
a	O
female	O
-	O
sterile	O
mutant	O
,	O
fs	O
(	O
1	O
)	O
A1526	O
,	O
which	O
lacks	O
YP3	B
in	O
the	O
haemolymph	O
.	O

The	O
female	O
sterility	O
mutation	O
mapped	O
some	O
distance	O
away	O
from	O
the	O
yp3	B
gene	O
on	O
the	O
X	B
chromosome	O
and	O
we	O
were	O
able	O
to	O
separate	O
the	O
YP3	B
defect	O
from	O
the	O
female	O
sterility	O
by	O
recombination	O
,	O
thus	O
producing	O
a	O
fertile	O
line	O
of	O
flies	O
having	O
no	O
YP3	B
in	O
the	O
eggs	O
.	O

This	O
shows	O
that	O
YP3	B
is	O
not	O
essential	O
for	O
embryogenesis	O
.	O

The	O
mutant	O
line	O
is	O
to	O
be	O
known	O
as	O
YP3s1	O
.	O

Investigation	O
of	O
yp3	B
transcription	O
in	O
the	O
mutant	O
females	O
revealed	O
that	O
the	O
gene	O
is	O
transcribed	O
but	O
yp3s1	O
mRNA	O
levels	O
are	O
reduced	O
relative	O
to	O
wild	O
type	O
.	O

Transcription	O
of	O
the	O
mutant	O
yp3	B
gene	O
can	O
be	O
induced	O
in	O
males	O
by	O
ecdysone	O
.	O

Investigation	O
of	O
the	O
yolk	O
proteins	O
in	O
YP3s1	O
females	O
suggested	O
that	O
the	O
YP3s1	O
polypeptide	O
is	O
synthesized	O
in	O
the	O
fat	O
body	O
but	O
not	O
secreted	O
.	O

The	O
mutant	O
YP3	B
protein	O
shows	O
an	O
increase	O
in	O
apparent	O
molecular	O
weight	O
of	O
approximately	O
1	O
kDa	O
.	O

The	O
mutant	O
yp3	B
gene	O
was	O
cloned	O
and	O
the	O
DNA	O
sequence	O
determined	O
.	O

The	O
sequence	O
differences	O
between	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
genes	O
include	O
an	O
amino	O
acid	O
substitution	O
in	O
the	O
leader	O
sequence	O
.	O

We	O
suggest	O
that	O
this	O
may	O
be	O
responsible	O
for	O
the	O
failure	O
of	O
YP3	B
secretion	O
in	O
the	O
mutant	O
YP3s1	O
,	O
and	O
speculate	O
on	O
the	O
cause	O
of	O
the	O
reduction	O
seen	O
in	O
the	O
steady	O
-	O
state	O
level	O
of	O
yp3	B
mRNA	O
.	O

We	O
have	O
examined	O
the	O
RNA	O
expression	O
pattern	O
for	O
the	O
Drosophila	O
calmodulin	B
gene	O
during	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
to	O
transcripts	O
in	O
whole	O
embryos	O
.	O

Our	O
results	O
indicate	O
that	O
maternally	O
derived	O
calmodulin	B
mRNA	O
is	O
homogeneously	O
distributed	O
throughout	O
the	O
early	O
embryo	O
,	O
but	O
that	O
these	O
maternal	O
transcripts	O
are	O
lost	O
by	O
maximal	O
germ	O
band	O
extension	O
.	O

Zygotic	O
transcription	O
of	O
the	O
gene	O
in	O
mid-	O
to	O
late	O
-	O
stage	O
embryos	O
is	O
restricted	O
to	O
neural	O
cell	O
precursors	O
and	O
their	O
progeny	O
in	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O

Thus	O
,	O
activation	O
of	O
calmodulin	B
transcription	O
during	O
embryonic	O
development	O
appears	O
to	O
mark	O
a	O
commitment	O
to	O
a	O
neural	O
fate	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
the	O
two	O
transcripts	O
from	O
the	O
calmodulin	B
gene	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
.	O

Comparison	O
of	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
data	O
indicates	O
that	O
the	O
longer	O
calmodulin	B
mRNA	O
is	O
a	O
nervous	O
tissue	O
-	O
specific	O
transcript	O
.	O

This	O
suggests	O
that	O
neural	O
-	O
specific	O
regulation	O
of	O
polyadenylation	O
site	O
usage	O
occurs	O
.	O

We	O
have	O
also	O
examined	O
calmodulin	B
expression	O
in	O
embryos	O
homozygous	O
for	O
mutations	O
in	O
four	O
loci	O
which	O
are	O
known	O
to	O
affect	O
nervous	O
system	O
development	O
:	O
numb	B
,	O
the	O
achaete	B
-	I
scute	I
complex	I
,	O
daughterless	B
,	O
and	O
mastermind	B
.	O

The	O
calmodulin	B
transcription	O
pattern	O
is	O
altered	O
in	O
embryos	O
mutant	O
for	O
each	O
of	O
these	O
loci	O
,	O
suggesting	O
that	O
regulation	O
by	O
these	O
genes	O
,	O
either	O
directly	O
or	O
indirectly	O
,	O
is	O
taking	O
place	O
.	O

A	B
goal	O
of	O
modern	O
biology	O
is	O
to	O
identify	O
the	O
physical	O
interactions	O
that	O
define	O
'	O
functional	O
modules	O
'	O
of	O
proteins	O
that	O
govern	O
biological	O
processes	O
.	O

One	O
essential	O
regulatory	O
process	O
is	O
the	O
maintenance	O
of	O
master	O
regulatory	O
genes	O
,	O
such	O
as	O
homeotic	O
genes	O
,	O
in	O
an	O
appropriate	O
'	O
on	O
'	O
or	O
'	O
off	O
'	O
state	O
for	O
the	O
lifetime	O
of	O
an	O
organism	O
.	O

The	O
Polycomb	B
group	O
(	O
PcG	O
)	O
of	O
genes	O
maintain	O
a	B
repressed	O
transcriptional	O
state	O
,	O
and	O
PcG	O
proteins	O
form	O
large	O
multiprotein	O
complexes	O
,	O
but	O
these	O
complexes	O
have	O
not	O
been	O
described	O
owing	O
to	O
inherent	O
difficulties	O
in	O
purification	O
.	O

We	O
previously	O
fractionated	O
a	B
major	O
PcG	O
complex	O
,	O
PRC1	O
,	O
to	O
20	O
-	O
50	O
%	O
homogeneity	O
from	O
Drosophila	O
embryos	O
.	O

Here	O
,	O
we	O
identify	O
30	O
proteins	O
in	O
these	O
preparations	O
,	O
then	O
further	O
fractionate	O
the	O
preparation	O
and	O
use	O
western	O
analyses	O
to	O
validate	O
unanticipated	O
connections	O
.	O

We	O
show	O
that	O
the	O
known	O
PcG	O
proteins	O
Polycomb	B
,	O
Posterior	B
sex	I
combs	I
,	O
Polyhomeotic	B
and	O
dRING1	B
exist	O
in	O
robust	O
association	O
with	O
the	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
factor	O
Zeste	B
and	O
with	O
numerous	O
TBP	B
(	O
TATA	O
-	O
binding	O
-	O
protein	O
)	O
-associated	O
factors	O
that	O
are	O
components	O
of	O
general	O
transcription	O
factor	O
TFIID	B
(	O
dTAFIIs	O
)	O
.	O

Thus	O
,	O
in	O
fly	O
embryos	O
,	O
there	O
is	O
a	B
direct	O
physical	O
connection	O
between	O
proteins	O
that	O
bind	O
to	O
specific	O
regulatory	O
sequences	O
,	O
PcG	O
proteins	O
,	O
and	O
proteins	O
of	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
have	O
developed	O
an	O
in	O
vitro	O
reaction	O
system	O
for	O
Drosophila	O
P	B
element	I
transposition	O
.	O

Transposition	O
products	O
were	O
recovered	O
by	O
selection	O
in	O
E.	O
coli	O
,	O
and	O
contained	O
simple	O
P	B
element	I
insertions	O
flanked	O
by	O
8	O
bp	O
target	O
site	O
duplications	O
as	O
observed	O
in	O
vivo	O
.	O

Transposition	O
required	O
Mg+2	O
and	O
partially	O
purified	O
P	B
element	I
transposase	I
.	O

Unlike	O
other	O
DNA	O
rearrangement	O
reactions	O
,	O
P	B
element	I
transposition	O
in	O
vitro	O
used	O
GTP	O
as	O
a	O
cofactor	O
;	O
deoxyGTP	O
,	O
dideoxyGTP	O
,	O
or	O
the	O
nonhydrolyzable	O
GTP	O
analogs	O
GMP	O
-	O
PNP	O
or	O
GMP	O
-	O
PCP	O
were	O
also	O
used	O
.	O

Transposon	O
DNA	O
molecules	O
cleaved	O
at	O
the	O
P	B
element	I
termini	O
were	O
able	O
to	O
transpose	O
,	O
but	O
those	O
lacking	O
3'-hydroxyl	O
groups	O
were	O
inactive	O
.	O

These	O
biochemical	O
data	O
are	O
consistent	O
with	O
genetic	O
data	O
suggesting	O
that	O
P	B
element	I
transposition	O
occurs	O
via	O
a	O
""""	O
cut	O
-	O
and	O
-	O
paste	O
""""	O
mechanism	O
.	O

The	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERKs	O
)	O
comprise	O
a	O
class	O
of	O
protein	O
-	O
serine	O
/	O
threonine	O
kinases	O
that	O
are	O
activated	O
in	O
response	O
to	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
transduced	O
via	O
receptor	O
tyrosine	O
kinases	O
.	O

Activation	O
of	O
the	O
ERKs	O
requires	O
both	O
threonine	O
and	O
tyrosine	O
phosphorylation	O
suggestive	O
of	O
a	O
key	O
role	O
in	O
mediating	O
intracellular	O
events	O
in	O
response	O
to	O
extracellular	O
cues	O
.	O

To	O
critically	O
assess	O
the	O
role	O
of	O
ERKs	O
in	O
intracellular	O
signaling	O
,	O
a	O
genetically	O
tractable	O
receptor	O
tyrosine	O
kinase	O
system	O
would	O
be	O
invaluable	O
.	O

In	O
this	O
paper	O
we	O
report	O
the	O
identification	O
of	O
a	O
Drosophila	O
homolog	O
of	O
ERK1	B
and	O
-2	O
,	O
designated	O
DmERK	B
-	I
A.	I
DmERK	B
-	I
A	I
is	O
80	O
%	O
identical	O
to	O
rat	O
ERK1	B
and	O
-2	O
and	O
is	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
in	O
response	O
to	O
an	O
extracellular	O
signal	O
activating	O
a	O
receptor	O
tyrosine	O
kinase	O
.	O

Biochemical	O
and	O
histological	O
studies	O
reveal	O
its	O
expression	O
in	O
the	O
eye	O
imaginal	O
disc	O
.	O

These	O
studies	O
provide	O
a	O
first	O
step	O
in	O
a	O
genetic	O
analysis	O
of	O
ERK	B
function	O
.	O

We	O
have	O
expressed	O
two	O
antifreeze	O
protein	O
genes	O
from	O
the	O
Atlantic	O
wolffish	O
,	O
Anarhichas	O
lupus	O
,	O
in	O
Drosophila	O
melanogaster	O
by	O
placing	O
them	O
under	O
the	O
divergent	O
transcriptional	O
control	O
of	O
the	O
host	O
yolk	O
polypeptide	O
(	O
1	O
and	O
2	O
)	O
gene	O
promoters	O
.	O

Both	O
genes	O
were	O
joined	O
to	O
the	O
central	O
promoter	O
region	O
by	O
fusion	O
within	O
the	O
DNA	O
encoding	O
the	O
signal	O
polypeptides	O
.	O

The	O
chimeric	O
genes	O
were	O
introduced	O
into	O
flightless	O
mutant	O
Drosophila	O
through	O
P	B
-	I
element	I
transformation	O
.	O

Transformed	O
adult	O
females	O
from	O
individual	O
lines	O
accumulated	O
1.5	O
-	O
5	O
mg	O
/	O
ml	O
of	O
antifreeze	O
protein	O
in	O
their	O
hemolymph	O
.	O

The	O
protein	O
was	O
purified	O
to	O
homogeneity	O
from	O
hemolymph	O
following	O
thermal	O
denaturation	O
,	O
step	O
elution	O
from	O
SP	O
-	O
Sephadex	O
,	O
and	O
reverse	O
-	O
phase	O
HPLC	O
.	O

It	O
was	O
recovered	O
in	O
high	O
yield	O
and	O
retained	O
full	O
biological	O
activity	O
even	O
though	O
one	O
of	O
the	O
two	O
gene	O
fusions	O
gave	O
rise	O
to	O
a	O
seven	O
amino	O
acid	O
N	O
-	O
terminal	O
extension	O
on	O
its	O
antifreeze	O
protein	O
product	O
.	O

cDNA	O
clones	O
encoding	O
the	O
BALB	O
/	O
c	O
murine	O
erythrocyte	O
band	O
7	O
integral	O
membrane	O
protein	O
(	O
also	O
termed	O
protein	B
7.2b	I
,	O
or	O
'	O
stomatin	B
'	O
)	O
were	O
isolated	O
by	O
the	O
screening	O
of	O
a	O
corresponding	O
bone	O
-	O
marrow	O
lambda	O
gt11	O
cDNA	O
library	O
with	O
a	O
human	O
cDNA	O
probe	O
,	O
and	O
by	O
5'-RACE	O
PCR	O
cloning	O
.	O

Comparison	O
of	O
the	O
murine	O
,	O
human	O
and	O
Caenorhabditis	O
elegans	O
protein	B
7.2b	I
amino	O
acid	O
(	O
aa	O
)	O
sequences	O
revealed	O
overall	O
identities	O
of	O
88	O
%	O
(	O
human	O
)	O
and	O
61	O
%	O
(	O
C.	O
elegans	O
)	O
,	O
with	O
the	O
N	O
-	O
terminal	O
domains	O
showing	O
only	O
little	O
similarity	O
.	O

The	O
7.2b	O
protein	O
sequences	O
of	O
the	O
two	O
mouse	O
strains	O
,	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
,	O
showed	O
six	O
rather	O
conservative	O
aa	O
substitutions	O
,	O
three	O
of	O
them	O
in	O
the	O
hydrophobic	O
domain	O
.	O

The	O
BALB	O
/	O
c	O
murine	O
mRNA	O
,	O
about	O
3.5	O
kb	O
in	O
size	O
,	O
is	O
widely	O
expressed	O
in	O
various	O
tissues	O
,	O
most	O
notably	O
in	O
spleen	O
,	O
lung	O
and	O
testis	O
.	O

Using	O
a	O
transgenic	O
mouse	O
derived	O
GnRH	B
expressing	O
neuronal	O
cell	O
line	O
,	O
GT1	O
-	O
3	O
,	O
we	O
studied	O
the	O
effects	O
of	O
activation	O
of	O
cAMP	O
,	O
Ca2	O
+	O
and	O
protein	O
kinase	O
C	O
pathways	O
by	O
forskolin	O
,	O
ionomycin	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
respectively	O
,	O
upon	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRH	B
)	O
secretion	O
,	O
cellular	O
peptide	O
content	O
,	O
mRNA	O
and	O
RNA	O
primary	O
transcript	O
levels	O
.	O

Forskolin	O
,	O
ionomycin	O
and	O
phorbol	O
ester	O
all	O
caused	O
an	O
increase	O
in	O
GnRH	B
secretion	O
in	O
GT1	O
-	O
3	O
cells	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
during	O
a	O
short	O
-	O
term	O
(	O
1	O
h	O
)	O
static	O
incubation	O
.	O

Prolonged	O
treatment	O
with	O
forskolin	O
(	O
10	O
microM	O
)	O
,	O
ionomycin	O
(	O
1	O
microM	O
)	O
and	O
PMA	O
(	O
10	O
nM	O
)	O
for	O
12	O
or	O
24	O
h	O
resulted	O
in	O
significant	O
decreases	O
in	O
GnRH	B
mRNA	O
levels	O
.	O

Time	O
-	O
course	O
studies	O
showed	O
that	O
the	O
increases	O
in	O
GnRH	B
secretion	O
stimulated	O
by	O
forskolin	O
,	O
ionomycin	O
and	O
PMA	O
were	O
gradually	O
attenuated	O
over	O
time	O
in	O
parallel	O
with	O
the	O
decreases	O
in	O
mRNA	O
expression	O
.	O

In	O
contrast	O
,	O
there	O
were	O
only	O
small	O
and	O
variable	O
changes	O
in	O
the	O
GnRH	B
cellular	O
content	O
.	O

Studies	O
using	O
a	O
GnRH	B
antagonist	O
(	O
100	O
microM	O
)	O
suggested	O
that	O
the	O
released	O
GnRH	B
has	O
a	O
negative	O
feedback	O
effect	O
on	O
its	O
own	O
secretion	O
.	O

However	O
,	O
co	O
-	O
incubation	O
with	O
the	O
GnRH	B
antagonist	O
did	O
not	O
alter	O
the	O
inhibitory	O
effects	O
on	O
GnRH	B
mRNA	O
levels	O
by	O
the	O
secretagogues	O
.	O

Further	O
studies	O
on	O
the	O
transcriptional	O
effects	O
of	O
forskolin	O
,	O
ionomycin	O
and	O
PMA	O
on	O
GnRH	B
gene	O
expression	O
in	O
GT1	O
-	O
3	O
cells	O
revealed	O
that	O
all	O
three	O
secretagogues	O
suppressed	O
GnRH	B
RNA	O
primary	O
transcript	O
levels	O
,	O
with	O
forskolin	O
having	O
a	O
slower	O
time	O
course	O
of	O
action	O
.	O

Thus	O
,	O
the	O
inhibition	O
of	O
cytoplasmic	O
GnRH	B
mRNA	O
,	O
and	O
presumably	O
its	O
synthesis	O
,	O
after	O
12	O
-	O
24	O
h	O
of	O
secretagogue	O
treatment	O
may	O
be	O
due	O
at	O
least	O
in	O
part	O
to	O
a	O
suppression	O
of	O
GnRH	B
gene	O
transcription.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
primary	O
structures	O
of	O
interferon	O
(	O
IFN	O
)	O
-induced	O
guanylate	O
-	O
binding	O
proteins	O
(	O
GBPs	O
)	O
were	O
deduced	O
from	O
cloned	O
human	O
and	O
murine	O
cDNAs	O
.	O

These	O
proteins	O
contained	O
only	O
two	O
of	O
the	O
three	O
sequence	O
motifs	O
typically	O
found	O
in	O
GTP	O
/	O
GDP	O
-	O
binding	O
proteins	O
.	O

The	O
N	O
(	O
T	O
)	O
KXD	O
motif	O
,	O
which	O
is	O
believed	O
to	O
confer	O
guanine	O
specificity	O
in	O
other	O
nucleotide	O
-	O
binding	O
proteins	O
,	O
was	O
absent	O
.	O

Nevertheless	O
,	O
the	O
IFN	O
-	O
induced	O
GBPs	O
exhibited	O
a	O
high	O
degree	O
of	O
selectivity	O
for	O
binding	O
to	O
agarose	O
-	O
immobilized	O
guanine	O
nucleotides	O
.	O

An	O
interesting	O
feature	O
of	O
IFN	O
-	O
induced	O
GBPs	O
is	O
that	O
they	O
strongly	O
bound	O
to	O
GMP	O
agarose	O
in	O
addition	O
to	O
GDP	O
and	O
GTP	O
agaroses	O
but	O
failed	O
to	O
bind	O
to	O
ATP	O
agarose	O
and	O
all	O
other	O
nucleotide	O
agaroses	O
tested	O
.	O

Both	O
GTP	O
and	O
GMP	O
,	O
but	O
not	O
ATP	O
,	O
competed	O
for	O
binding	O
of	O
murine	O
GBP-1	B
to	O
agarose	O
-	O
immobilized	O
GMP	O
.	O

The	O
IFN	O
-	O
induced	O
GBPs	O
thus	O
define	O
a	O
distinct	O
novel	O
family	O
of	O
proteins	O
with	O
GTP	O
-	O
binding	O
activity	O
.	O

We	O
further	O
demonstrate	O
that	O
human	O
and	O
murine	O
cells	O
contain	O
at	O
least	O
two	O
genes	O
encoding	O
IFN	O
-	O
induced	O
GBPs	O
.	O

The	O
cloned	O
murine	O
cDNA	O
codes	O
for	O
GBP-1	B
,	O
an	O
IFN	O
-	O
induced	O
protein	O
previously	O
shown	O
to	O
be	O
absent	O
from	O
mice	O
of	O
Gbp-1b	O
genotype	O
.	O

Dominant	B
megacolon	I
(	O
Dom	B
)	O
is	O
one	O
of	O
four	O
mutations	O
in	O
the	O
mouse	O
that	O
can	O
produce	O
a	O
phenotype	O
similar	O
to	O
Hirschsprung	O
disease	O
in	O
human	O
.	O

The	O
Dom	B
gene	O
product	O
is	O
not	O
known	O
,	O
and	O
no	O
candidate	O
region	O
has	O
been	O
defined	O
for	O
a	O
possible	O
human	O
homolog	O
.	O

In	O
this	O
publication	O
we	O
report	O
mapping	O
the	O
Dom	B
locus	O
with	O
high	O
definition	O
,	O
using	O
several	O
intra	O
-	O
and	O
interspecific	O
crosses	O
and	O
a	O
set	O
of	O
16	O
Chr	O
15-specific	O
microsatellites	O
flanking	O
this	O
locus	O
.	O

Zp1	B
encodes	O
one	O
of	O
the	O
three	O
major	O
glycoproteins	O
of	O
the	O
zona	O
pellucida	O
,	O
an	O
extracellular	O
matrix	O
that	O
surrounds	O
growing	O
oocytes	O
,	O
ovulated	O
eggs	O
,	O
and	O
preimplantation	O
embryos	O
.	O

The	O
mouse	O
gene	O
is	O
composed	O
of	O
12	O
exons	O
ranging	O
in	O
size	O
from	O
82	O
to	O
364	O
base	O
pairs	O
and	O
spans	O
6.5	O
kilobase	O
pairs	O
on	O
chromosome	O
19	O
(	O
2.13	O
+	O
/-	O

1.5	O
centimorgans	O
distal	O
to	O
D19Bir1	B
)	O
.	O

The	O
Zp1	B
exon	O
map	O
is	O
similar	O
to	O
ZPB	O
,	O
a	O
human	O
orthologue	O
,	O
and	O
an	O
E	O
-	O
box	O
(	O
CANNTG	O
)	O
,	O
implicated	O
in	O
oocyte	O
-	O
specific	O
gene	O
expression	O
of	O
mouse	O
Zp2	O
and	O
Zp3	O
,	O
is	O
similarly	O
located	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

The	O
single	O
copy	O
Zp1	B
gene	O
encodes	O
a	O
623-amino	O
acid	O
protein	O
,	O
the	O
carboxyl	O
-	O
terminal	O
half	O
of	O
which	O
is	O
significantly	O
similar	O
to	O
a	O
corresponding	O
region	O
of	O
mouse	O
ZP2	O
.	O

The	O
conservation	O
of	O
this	O
same	O
region	O
in	O
a	O
fish	O
egg	O
envelope	O
protein	O
suggests	O
that	O
not	O
only	O
has	O
this	O
protein	O
domain	O
been	O
duplicated	O
in	O
mammals	O
but	O
that	O
it	O
has	O
been	O
conserved	O
and	O
used	O
as	O
an	O
egg	O
envelope	O
protein	O
in	O
species	O
that	O
diverged	O
650	O
million	O
years	O
ago	O
.	O

Glycogen	O
storage	O
disease	O
type	O
1a	O
(	O
GSD-1a	O
)	O
,	O
characterized	O
by	O
hypoglycemia	O
,	O
liver	O
and	O
kidney	O
enlargement	O
,	O
growth	O
retardation	O
,	O
hyperlipidemia	O
,	O
and	O
hyperuricemia	O
,	O
is	O
caused	O
by	O
a	O
deficiency	O
in	O
glucose-6-phosphatase	O
(	O
G6Pase	B
)	O
,	O
a	O
key	O
enzyme	O
in	O
glucose	O
homeostasis	O
.	O

To	O
evaluate	O
the	O
feasibility	O
of	O
gene	O
replacement	O
therapy	O
for	O
GSD-1a	O
,	O
we	O
have	O
infused	O
adenoviral	O
vector	O
containing	O
the	O
murine	O
G6Pase	B
gene	O
(	O
Ad	O
-	O
mG6Pase	O
)	O
into	O
G6Pase	B
-	O
deficient	O
(	O
G6Pase	B
(	I
-	I
/	I
-	I
)	I
)	O
mice	O
that	O
manifest	O
symptoms	O
characteristic	O
of	O
human	O
GSD-1a	O
.	O

Whereas	O
<	O
15	O
%	O
of	O
G6Pase	B
(	I
-	I
/	I
-	I
)	I
mice	O
under	O
glucose	O
therapy	O
survived	O
weaning	O
,	O
a	O
100	O
%	O
survival	O
rate	O
was	O
achieved	O
when	O
G6Pase	B
(	I
-	I
/	I
-	I
)	I
mice	O
were	O
infused	O
with	O
Ad	O
-	O
mG6Pase	O
,	O
90	O
%	O
of	O
which	O
lived	O
to	O
3	O
months	O
of	O
age	O
.	O

Hepatic	O
G6Pase	B
activity	O
in	O
Ad	O
-	O
mG6Pase	O
-	O
infused	O
mice	O
was	O
restored	O
to	O
19	O
%	O
of	O
that	O
in	O
G6Pase	B
(	I
+	I
/	I
+	I
)	I
mice	O
at	O
7	O
-	O
14	O
days	O
post	O
-	O
infusion	O
;	O
the	O
activity	O
persisted	O
for	O
at	O
least	O
70	O
days	O
.	O

Ad	O
-	O
mG6Pase	O
infusion	O
also	O
greatly	O
improved	O
growth	O
of	O
G6Pase	B
(	I
-	I
/	I
-	I
)	I
mice	O
and	O
normalized	O
plasma	O
glucose	O
,	O
cholesterol	O
,	O
triglyceride	O
,	O
and	O
uric	O
acid	O
profiles	O
.	O

Furthermore	O
,	O
liver	O
and	O
kidney	O
enlargement	O
was	O
less	O
pronounced	O
with	O
near	O
-	O
normal	O
levels	O
of	O
glycogen	O
depositions	O
in	O
both	O
organs	O
.	O

Our	O
data	O
demonstrate	O
that	O
a	O
single	O
administration	O
of	O
a	O
recombinant	O
adenoviral	O
vector	O
can	O
alleviate	O
the	O
pathological	O
manifestations	O
of	O
GSD-1a	O
in	O
mice	O
,	O
suggesting	O
that	O
this	O
disorder	O
in	O
humans	O
can	O
potentially	O
be	O
corrected	O
by	O
gene	O
therapy	O
.	O

The	O
role	O
of	O
metallothionein	O
with	O
regard	O
to	O
cadmium	O
toxicity	O
in	O
vitro	O
was	O
investigated	O
using	O
preimplantation	O
mouse	O
blastocysts	O
derived	O
from	O
a	O
transgenic	O
strain	O
that	O
constitutively	O
overexpresses	O
metallothionein	O
-	O
I	O
transgenes	O
(	O
MT	B
-	I
I	I
*	O
)	O
.	O

Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
revealed	O
high	O
levels	O
of	O
MT	B
-	I
I	I
mRNA	O
in	O
transgenic	O
blastocysts	O
when	O
compared	O
with	O
control	O
blastocysts	O
,	O
and	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
MT	B
-	I
I	I
mRNA	O
was	O
almost	O
exclusively	O
MT	B
-	I
I*.	I
Moreover	O
,	O
pulse	O
-	O
labeling	O
experiments	O
showed	O
that	O
the	O
relative	O
rate	O
of	O
synthesis	O
of	O
MT	O
was	O
9-fold	O
higher	O
in	O
transgenic	O
blastocysts	O
.	O

Cadmium	O
(	O
Cd2	O
+	O
)	O
toxicity	O
was	O
assessed	O
after	O
incubating	O
blastocysts	O
for	O
4	O
hr	O
in	O
Whitten	O
's	O
medium	O
containing	O
50	O
microM	O
Cd2	O
+	O
.	O

Embryos	O
that	O
displayed	O
abnormal	O
morphology	O
were	O
judged	O
""""	O
sensitive	O
""""	O
.	O

Transgenic	O
blastocysts	O
were	O
more	O
resistant	O
to	O
cadmium	O
-	O
induced	O
morphological	O
changes	O
than	O
were	O
control	O
blastocysts	O
.	O
""""	O

Sensitive	O
""""	O
and	O
""""	O
resistant	O
""""	O
blastocysts	O
were	O
individually	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
,	O
or	O
they	O
were	O
transferred	O
to	O
foster	O
mothers	O
,	O
and	O
embryonic	O
development	O
to	O
midterm	O
was	O
monitored	O
.	O

Of	O
the	O
blastocysts	O
derived	O
from	O
mating	O
heterozygous	O
transgenic	O
males	O
with	O
control	O
females	O
,	O
56	O
%	O
were	O
transgenic	O
before	O
incubation	O
with	O
Cd2	O
+	O
,	O
whereas	O
95	O
%	O
of	O
the	O
blastocysts	O
that	O
retained	O
normal	O
morphology	O
after	O
incubation	O
were	O
transgenic	O
.	O

Moreover	O
,	O
after	O
Cd2	O
+	O
exposure	O
,	O
transgenic	O
blastocysts	O
with	O
normal	O
morphology	O
were	O
nine	O
times	O
more	O
likely	O
to	O
develop	O
to	O
midterm	O
than	O
were	O
control	O
blastocysts	O
with	O
normal	O
morphology	O
.	O

Blastocysts	O
with	O
abnormal	O
morphology	O
failed	O
to	O
develop	O
to	O
midterm	O
.	O

These	O
studies	O
indicate	O
that	O
MT	O
plays	O
a	O
central	O
role	O
in	O
protection	O
from	O
Cd2	O
+	O
toxicity	O
within	O
the	O
physiological	O
context	O
of	O
the	O
developing	O
mouse	O
embryo	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequent	O
tumor	O
type	O
among	O
women	O
in	O
the	O
United	O
States	O
and	O
in	O
individuals	O
with	O
Li	O
-	O
Fraumeni	O
syndrome	O
.	O

The	O
p53	B
tumor	O
suppressor	O
gene	O
is	O
altered	O
in	O
a	O
large	O
proportion	O
of	O
both	O
spontaneous	O
breast	O
malignancies	O
and	O
Li	O
-	O
Fraumeni	O
breast	O
cancers	O
.	O

This	O
suggests	O
that	O
loss	O
of	O
p53	B
can	O
accelerate	O
breast	O
tumorigenesis	O
,	O
yet	O
p53-deficient	B
mice	O
rarely	O
develop	O
mammary	O
tumors	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
p53	B
loss	O
on	O
mammary	O
tumor	O
formation	O
,	O
the	O
p53	B
(	I
null	I
)	I
allele	O
was	O
back	O
-	O
crossed	O
onto	O
the	O
BALB	O
/	O
c	O
genetic	O
background	O
.	O

Median	O
survival	O
was	O
15.4	O
weeks	O
for	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
-	I
/	I
-	I
)	I
mice	O
compared	O
to	O
54	O
weeks	O
for	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
+	I
/	I
-	I
)	I
mice	O
.	O

Sarcomas	O
and	O
lymphomas	O
were	O
the	O
most	O
frequent	O
tumor	O
types	O
in	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
-	I
/	I
-	I
)	I
mice	O
,	O
whereas	O
55	O
%	O
of	O
the	O
female	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
+	I
/	I
-	I
)	I
mice	O
developed	O
mammary	O
carcinomas	O
.	O

The	O
mammary	O
tumors	O
were	O
highly	O
aneuploid	O
,	O
frequently	O
lost	O
the	O
remaining	O
wild	O
-	O
type	O
p53	B
allele	O
,	O
but	O
rarely	O
lost	O
BRCA1	O
.	O

Although	O
mammary	O
tumors	O
were	O
rarely	O
detected	O
in	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
-	I
/	I
-	I
)	I
female	O
mice	O
,	O
when	O
glands	O
from	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
-	I
/	I
-	I
)	I
mice	O
were	O
transplanted	O
into	O
wild	O
-	O
type	O
BALB	O
/	O
c	O
hosts	O
,	O
75	O
%	O
developed	O
mammary	O
tumors	O
.	O

The	O
high	O
rate	O
of	O
mammary	O
tumor	O
development	O
in	O
the	O
BALB	O
/	O
c	O
background	O
,	O
but	O
not	O
C57Bl	O
/	O
6	O
or	O
129	O
/	O
Sv	O
,	O
suggests	O
a	O
genetic	O
predisposition	O
toward	O
mammary	O
tumorigenesis	O
.	O

Therefore	O
,	O
the	O
BALB	O
/	O
c	O
-	O
p53	B
(	I
+	I
/	I
-	I
)	I
mice	O
provide	O
a	O
unique	O
model	O
for	O
the	O
study	O
of	O
breast	O
cancer	O
in	O
Li	O
-	O
Fraumeni	O
syndrome	O
.	O

These	O
results	O
demonstrate	O
the	O
critical	O
role	O
that	O
the	O
p53	B
tumor	O
suppressor	O
gene	O
plays	O
in	O
preventing	O
tumorigenesis	O
in	O
the	O
mammary	O
gland	O
.	O

Nonobese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
spontaneously	O
develop	O
diabetes	O
as	O
a	O
consequence	O
of	O
an	O
autoimmune	O
process	O
that	O
can	O
be	O
inhibited	O
by	O
immunotherapy	O
with	O
the	O
60-kDa	O
heat	O
shock	O
protein	O
(	O
hsp60	B
)	O
,	O
with	O
its	O
mycobacterial	O
counterpart	O
65-kDa	O
(	O
hsp65	O
)	O
,	O
or	O
with	O
other	O
Ags	O
such	O
as	O
insulin	O
and	O
glutamic	O
acid	O
decarboxylase	O
(	O
GAD	O
)	O
.	O

Microbial	O
infection	O
and	O
innate	O
signaling	O
via	O
LPS	O
or	O
CpG	O
motifs	O
can	O
also	O
inhibit	O
the	O
spontaneous	O
diabetogenic	O
process	O
.	O

In	O
addition	O
to	O
the	O
spontaneous	O
disease	O
,	O
however	O
,	O
NOD	O
mice	O
can	O
develop	O
a	O
more	O
robust	O
cyclophosphamide	O
-	O
accelerated	O
diabetes	O
(	O
CAD	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
effect	O
on	O
CAD	O
of	O
DNA	O
vaccination	O
with	O
constructs	O
encoding	O
the	O
Ags	O
human	O
hsp60	B
(	O
phsp60	O
)	O
or	O
mycobacterial	O
hsp65	O
(	O
phsp65	O
)	O
.	O

Vaccination	O
with	O
phsp60	O
protected	O
NOD	O
mice	O
from	O
CAD	O
.	O

In	O
contrast	O
,	O
vaccination	O
with	O
phsp65	O
,	O
with	O
an	O
empty	O
vector	O
,	O
or	O
with	O
a	O
CpG	O
-	O
positive	O
oligonucleotide	O
was	O
not	O
effective	O
,	O
suggesting	O
that	O
the	O
efficacy	O
of	O
the	O
phsp60	O
construct	O
might	O
be	O
based	O
on	O
regulatory	O
hsp60	B
epitopes	O
not	O
shared	O
with	O
its	O
mycobacterial	O
counterpart	O
,	O
hsp65	O
.	O

Vaccination	O
with	O
phsp60	O
modulated	O
the	O
T	O
cell	O
responses	O
to	O
hsp60	B
and	O
also	O
to	O
the	O
GAD	O
and	O
insulin	O
autoantigens	O
;	O
T	O
cell	O
proliferative	O
responses	O
were	O
significantly	O
reduced	O
,	O
and	O
the	O
pattern	O
of	O
cytokine	O
secretion	O
to	O
hsp60	B
,	O
GAD	O
,	O
and	O
insulin	O
showed	O
an	O
increase	O
in	O
IL-10	B
and	O
IL-5	B
secretion	O
and	O
a	O
decrease	O
in	O
IFN	B
-	I
gamma	I
secretion	O
,	O
compatible	O
with	O
a	O
shift	O
from	O
a	O
Th1-like	O
toward	O
a	O
Th2-like	O
autoimmune	O
response	O
.	O

Our	O
results	O
extend	O
the	O
role	O
of	O
specific	O
hsp60	B
immunomodulation	O
in	O
the	O
control	O
of	O
beta	O
cell	O
autoimmunity	O
and	O
demonstrate	O
that	O
immunoregulatory	O
networks	O
activated	O
by	O
specific	O
phsp60	O
vaccination	O
can	O
spread	O
to	O
other	O
Ags	O
targeted	O
during	O
the	O
progression	O
of	O
diabetes	O
,	O
like	O
insulin	O
and	O
GAD	O
.	O

Age	O
-	O
related	O
changes	O
in	O
T	O
cell	O
subsets	O
were	O
examined	O
in	O
intestinal	O
intraepithelial	O
lymphocytes	O
(	O
i	O
-	O
IEL	O
)	O
,	O
which	O
contain	O
unique	O
T	O
cells	O
differentiating	O
extrathymically	O
.	O

In	O
2-month	O
-	O
old	O
mice	O
bred	O
under	O
conventional	O
condition	O
,	O
i	O
-	O
IEL	O
consisted	O
of	O
a	O
large	O
number	O
of	O
CD4-CD8	O
alpha	O
/	O
alpha+	O
cells	O
bearing	O
either	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
alpha	O
/	O
beta	O
or	O
TcR	O
gamma	O
/	O
delta	O
and	O
only	O
a	O
few	O
CD4+CD8	O
alpha-	O
cells	O
.	O

In	O
aged	O
mice	O
(	O
6	O
months	O
old	O
and	O
24	O
months	O
old	O
)	O
,	O
unique	O
CD4+CD8	O
alpha	O
/	O
alpha+	O
i	O
-	O
IEL	O
bearing	O
TcR	B
alpha	I
/	O
beta	O
increased	O
in	O
number	O
and	O
conversely	O
the	O
proportion	O
of	O
TcR	O
gamma	O
/	O
delta+	O
i	O
-	O
IEL	O
was	O
decreased	O
.	O

Such	O
an	O
increase	O
in	O
number	O
of	O
CD4+CD8	O
alpha	O
/	O
alpha+	O
cells	O
was	O
detected	O
in	O
i	O
-	O
IEL	O
from	O
aged	O
(	O
14-months	O
old	O
)	O
nude	O
mice	O
,	O
but	O
not	O
in	O
aged	O
(	O
14	O
months	O
old	O
)	O
germ	O
-	O
free	O
mice	O
,	O
suggesting	O
that	O
a	O
significant	O
fraction	O
of	O
TcR	B
alpha	I
/	O
beta	O
T	O
cells	O
such	O
as	O
CD4+CD8	O
alpha+	O
i	O
-	O
IEL	O
can	O
develop	O
along	O
an	O
extrathymic	O
pathway	O
under	O
the	O
influence	O
of	O
intestinal	O
microflora	O
with	O
age	O
.	O

BACKGROUND	O
:	O
Tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
is	O
chronically	O
elevated	O
in	O
the	O
adipose	O
tissue	O
from	O
obese	O
humans	O
and	O
mice	O
.	O

This	O
increase	O
in	O
TNF	B
-	I
alpha	I
contributes	O
to	O
the	O
insulin	O
resistance	O
,	O
elevated	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	B
)	O
levels	O
,	O
and	O
cardiovascular	O
complications	O
associated	O
with	O
obesity	O
and	O
noninsulin	O
-	O
dependent	O
diabetes	O
(	O
NIDDM	O
)	O
.	O

PAI-1	B
gene	O
expression	O
in	O
adipose	O
tissue	O
is	O
also	O
stimulated	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
.	O

Experiments	O
were	O
performed	O
to	O
determine	O
whether	O
TGF	O
-	O
beta	O
is	O
regulated	O
by	O
TNF	B
-	I
alpha	I
and	O
elevated	O
in	O
obesity	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
concentration	O
of	O
TGF	O
-	O
beta	O
and	O
PAI-1	B
mRNA	O
in	O
murine	O
adipose	O
tissue	O
and	O
cultured	O
3T3-L1	O
adipocytes	O
was	O
determined	O
by	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
and	O
the	O
cellular	O
localization	O
of	O
these	O
molecules	O
was	O
evaluated	O
using	O
in	O
situ	O
hybridization	O
and	O
cell	O
fractionation	O
.	O

Total	O
TGF	O
-	O
beta	O
protein	O
was	O
determined	O
by	O
employing	O
an	O
ELISA	O
assay	O
.	O

RESULTS	O
:	O
TGF	O
-	O
beta	O
mRNA	O
and	O
protein	O
were	O
increased	O
in	O
the	O
adipose	O
tissue	O
from	O
two	O
different	O
strains	O
of	O
genetically	O
obese	O
mice	O
(	O
i.e.	O
,	O
ob	O
/	O
ob	O
and	O
db	O
/	O
db	O
)	O
,	O
compared	O
with	O
their	O
lean	O
counterparts	O
.	O

This	O
increase	O
in	O
TGF	O
-	O
beta	O
may	O
result	O
from	O
TNF	B
-	I
alpha	I
since	O
TNF	B
-	I
alpha	I
increased	O
TGF	O
-	O
beta	O
mRNA	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
lean	O
mice	O
and	O
stimulated	O
TGF	O
-	O
beta	O
production	O
by	O
cultured	O
adipocytes	O
.	O

Administration	O
of	O
TGF	O
-	O
beta	O
increased	O
PAI-1	B
antigen	O
in	O
the	O
plasma	O
and	O
PAI-1	B
mRNA	O
in	O
the	O
adipocytes	O
of	O
lean	O
mice	O
,	O
and	O
enhanced	O
the	O
rate	O
of	O
PAI-1	B
synthesis	O
by	O
adipocytes	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
TNF	B
-	I
alpha	I
contributes	O
to	O
the	O
elevated	O
TGF	O
-	O
beta	O
expression	O
demonstrated	O
in	O
the	O
adipose	O
tissue	O
of	O
obese	O
mice	O
.	O

A	O
potential	O
role	O
for	O
TGF	O
-	O
beta	O
in	O
the	O
increased	O
PAI-1	B
and	O
vascular	O
pathologies	O
associated	O
with	O
obesity	O
/	O
NIDDM	O
is	O
suggested	O
.	O

These	O
studies	O
examined	O
the	O
importance	O
of	O
phospholipase	O
Cbeta	O
(	O
PLCbeta	O
)	O
in	O
the	O
calcium	O
responses	O
of	O
pituitary	O
cells	O
using	O
PLCbeta3	O
knockout	O
mice	O
.	O

Pituitary	O
tissue	O
from	O
wild	O
-	O
type	O
mice	O
contained	O
PLCbeta1	O
and	O
PLCbeta3	O
but	O
not	O
PLCbeta2	O
or	O
PLCbeta4	O
.	O

Both	O
Galphaq	B
/	O
11	O
and	O
Gbetagamma	O
can	O
activate	O
PLCbeta3	O
,	O
whereas	O
only	O
Galphaq	B
/	O
11	O
activates	O
PLCss1	O
effectively	O
.	O

In	O
knockout	O
mice	O
,	O
PLCbeta3	O
was	O
absent	O
,	O
PLCbeta1	O
was	O
not	O
up	O
-	O
regulated	O
,	O
and	O
PLCbeta2	O
and	O
PLCbeta4	O
were	O
not	O
expressed	O
.	O

Since	O
somatostatin	B
inhibited	O
influx	O
of	O
extracellular	O
calcium	O
in	O
pituitary	O
cells	O
from	O
wild	O
-	O
type	O
and	O
PLCbeta3	O
knockout	O
mice	O
,	O
the	O
somatostatin	B
signal	O
pathway	O
was	O
intact	O
.	O

However	O
,	O
somatostatin	B
failed	O
to	O
increase	O
intracellular	O
calcium	O
in	O
pituitary	O
cells	O
from	O
either	O
wild	O
-	O
type	O
or	O
knockout	O
mice	O
under	O
a	O
variety	O
of	O
conditions	O
,	O
indicating	O
that	O
it	O
did	O
not	O
stimulate	O
PLCbeta3	O
.	O

In	O
contrast	O
,	O
somatostatin	B
increased	O
intracellular	O
calcium	O
in	O
aortic	O
smooth	O
muscle	O
cells	O
from	O
wild	O
-	O
type	O
mice	O
,	O
although	O
it	O
evoked	O
no	O
calcium	O
response	O
in	O
cells	O
from	O
PLCbeta3	O
knockout	O
animals	O
These	O
results	O
show	O
that	O
somatostatin	B
,	O
like	O
other	O
Gi	O
/	O
Go	O
-	O
linked	O
hormones	O
,	O
can	O
stimulate	O
a	O
calcium	O
transient	O
by	O
activating	O
PLCbeta3	O
through	O
Gbetagamma	O
,	O
but	O
this	O
response	O
does	O
not	O
normally	O
occur	O
in	O
pituitary	O
cells	O
.	O

The	O
densities	O
of	O
Gi	O
and	O
Go	O
,	O
as	O
well	O
as	O
the	O
relative	O
concentrations	O
of	O
PLCbeta1	O
and	O
PLCbeta3	O
,	O
were	O
similar	O
in	O
cells	O
that	O
responded	O
to	O
somatostatin	B
with	O
an	O
increase	O
in	O
calcium	O
and	O
pituitary	O
cells	O
.	O

Calcium	O
responses	O
to	O
1	O
nM	O
and	O
1	O
microM	O
TRH	B
and	O
GnRH	B
were	O
identical	O
in	O
pituitary	O
cells	O
from	O
wild	O
-	O
type	O
and	O
PLCbeta3	O
knockout	O
mice	O
,	O
as	O
were	O
responses	O
to	O
other	O
Gq	B
-	O
linked	O
agonists	O
.	O

These	O
results	O
show	O
that	O
in	O
pituitary	O
cells	O
,	O
PLCbeta1	O
is	O
sufficient	O
to	O
transmit	O
signals	O
from	O
Gq	B
-	O
coupled	O
hormones	O
,	O
whereas	O
PLCbeta3	O
is	O
required	O
for	O
the	O
calcium	O
-	O
mobilizing	O
actions	O
of	O
somatostatin	B
observed	O
in	O
smooth	O
muscle	O
cells	O
.	O

Mitochondrial	O
uncoupling	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
maintenance	O
of	O
metabolic	O
rate	O
and	O
adaptational	O
thermoregulation	O
.	O

We	O
recently	O
reported	O
the	O
identification	O
of	O
a	O
brain	O
-	O
specific	O
mitochondrial	O
uncoupling	O
protein	O
homologue	O
,	O
UCP4	O
.	O

Here	O
we	O
characterized	O
another	O
newly	O
described	O
member	O
of	O
the	O
uncoupling	O
protein	O
family	O
,	O
termed	O
UCP5	B
(	O
also	O
called	O
BMCP1	B
)	O
.	O

UCP5	B
transcripts	O
are	O
present	O
in	O
multiple	O
human	O
and	O
mouse	O
tissues	O
,	O
with	O
an	O
especially	O
high	O
abundance	O
in	O
the	O
brain	O
and	O
testis	O
.	O

Expression	O
of	O
UCP5	B
in	O
mammalian	O
cells	O
reduces	O
the	O
mitochondrial	O
membrane	O
potential	O
.	O

Multiple	O
isoforms	O
of	O
UCP5	B
were	O
identified	O
and	O
exhibited	O
tissue	O
-	O
specific	O
distribution	O
and	O
different	O
potency	O
in	O
reduction	O
of	O
membrane	O
potential	O
.	O

Furthermore	O
,	O
the	O
mRNA	O
abundance	O
of	O
both	O
UCP4	O
and	O
UCP5	B
is	O
modulated	O
by	O
nutritional	O
status	O
or	O
temperature	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
in	O
mice	O
.	O

Brain	O
UCP4	O
and	O
UCP5	B
mRNA	O
transcripts	O
rose	O
by	O
1.5-	O
and	O
1.7-fold	O
,	O
respectively	O
,	O
and	O
liver	O
UCP5	B
expression	O
increased	O
by	O
1.8-fold	O
in	O
response	O
to	O
acute	O
cold	O
exposure	O
.	O

A	O
high	O
-	O
fat	O
diet	O
increased	O
UCP5	B
mRNA	O
in	O
liver	O
by	O
1.6-fold	O
selectively	O
in	O
the	O
obesity	O
-	O
resistant	O
A	O
/	O
J	O
but	O
not	O
in	O
the	O
obesity	O
-	O
prone	O
C57BL	O
/	O
6J	O
mouse	O
strain	O
.	O

Liver	O
UCP5	B
expression	O
decreased	O
significantly	O
with	O
a	O
24	O
h	O
fast	O
and	O
was	O
restored	O
to	O
the	O
normal	O
level	O
after	O
refeeding	O
.	O

In	O
contrast	O
,	O
brain	O
transcripts	O
for	O
both	O
genes	O
were	O
not	O
significantly	O
altered	O
by	O
fasting	O
or	O
high	O
-	O
fat	O
diet	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
UCP4	O
and	O
UCP5	B
may	O
be	O
involved	O
in	O
tissue	O
-	O
specific	O
thermoregulation	O
and	O
metabolic	O
changes	O
associated	O
with	O
nutritional	O
status	O
.	O

In	O
this	O
study	O
we	O
investigate	O
the	O
roles	O
of	O
the	O
organizer	O
factors	O
chordin	B
and	O
noggin	B
,	O
which	O
are	O
dedicated	O
antagonists	O
of	O
the	O
bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
,	O
in	O
formation	O
of	O
the	O
mammalian	O
head	O
.	O

The	O
mouse	O
chordin	B
and	O
noggin	B
genes	O
(	O
Chrd	B
and	O
Nog	B
)	O
are	O
expressed	O
in	O
the	O
organizer	O
(	O
the	O
node	O
)	O
and	O
its	O
mesendodermal	O
derivatives	O
,	O
including	O
the	O
prechordal	O
plate	O
,	O
an	O
organizing	O
center	O
for	O
rostral	O
development	O
.	O

They	O
are	O
also	O
expressed	O
at	O
lower	O
levels	O
in	O
and	O
around	O
the	O
anterior	O
neural	O
ridge	O
,	O
another	O
rostral	O
organizing	O
center	O
.	O

To	O
elucidate	O
roles	O
of	O
Chrd	B
and	O
Nog	B
that	O
are	O
masked	O
by	O
the	O
severe	O
phenotype	O
and	O
early	O
lethality	O
of	O
the	O
double	O
null	O
,	O
we	O
have	O
characterized	O
embryos	O
of	O
the	O
genotype	O
Chrd	B
(	I
-	I
/	I
-	I
)	I
;Nog	O
(	B
+	I
/	I
-	I
)	I
.	O

These	O
animals	O
display	O
partially	O
penetrant	O
neonatal	O
lethality	O
,	O
with	O
defects	O
restricted	O
to	O
the	O
head	O
.	O

The	O
variable	O
phenotypes	O
include	O
cyclopia	O
,	O
holoprosencephaly	O
,	O
and	O
rostral	O
truncations	O
of	O
the	O
brain	O
and	O
craniofacial	O
skeleton	O
.	O

In	O
situ	O
hybridization	O
reveals	O
a	O
loss	O
of	O
SHH	B
expression	O
and	O
signaling	O
by	O
the	O
prechordal	O
plate	O
,	O
and	O
a	O
decrease	O
in	O
FGF8	B
expression	O
and	O
signaling	O
by	O
the	O
anterior	O
neural	O
ridge	O
at	O
the	O
five	O
-	O
somite	O
stage	O
.	O

Defective	O
Chrd	B
(	I
-	I
/	I
-	I
)	I
;Nog	O
(	B
+	I
/	I
-	I
)	I
embryos	O
exhibit	O
reduced	O
cell	O
proliferation	O
in	O
the	O
rostral	O
neuroepithelium	O
at	O
10	O
somites	O
,	O
followed	O
by	O
increased	O
cell	O
death	O
1	O
day	O
later	O
.	O

Because	O
these	O
phenotypes	O
result	O
from	O
reduced	O
levels	O
of	O
BMP	O
antagonists	O
,	O
we	O
hypothesized	O
that	O
they	O
are	O
due	O
to	O
increased	O
BMP	O
activity	O
.	O

Ectopic	O
application	O
of	O
BMP2	B
to	O
wild	O
-	O
type	O
cephalic	O
explants	O
results	O
in	O
decreased	O
FGF8	B
and	O
SHH	B
expression	O
in	O
rostral	O
tissue	O
,	O
suggesting	O
that	O
the	O
decreased	O
expression	O
of	O
FGF8	B
and	O
SHH	B
observed	O
in	O
vivo	O
is	O
due	O
to	O
ectopic	O
BMP	O
activity	O
.	O

Cephalic	O
explants	O
isolated	O
from	O
Chrd;Nog	B
double	O
mutant	O
embryos	O
show	O
an	O
increased	O
sensitivity	O
to	O
ectopic	O
BMP	O
protein	O
,	O
further	O
supporting	O
the	O
hypothesis	O
that	O
these	O
mutants	O
are	O
deficient	O
in	O
BMP	O
antagonism	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BMP	O
antagonists	O
chordin	B
and	O
noggin	B
promote	O
the	O
inductive	O
and	O
trophic	O
activities	O
of	O
rostral	O
organizing	O
centers	O
in	O
early	O
development	O
of	O
the	O
mammalian	O
head	O
.	O

Cyclic	O
AMP	O
is	O
hydrolyzed	O
by	O
members	O
of	O
at	O
least	O
eight	O
classes	O
of	O
cyclic	O
nucleotide	O
phosphodiesterases	O
(	O
PDEs	O
)	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
cyclic	O
AMP	O
PDE	O
activity	O
in	O
mammalian	O
tissues	O
can	O
be	O
inhibited	O
by	O
benzodiazepines	O
,	O
it	O
has	O
not	O
been	O
conclusively	O
demonstrated	O
that	O
members	O
of	O
the	O
class	O
of	O
cyclic	O
AMP	O
-	O
specific	O
,	O
rolipram	O
-	O
inhibitable	O
PDEs	O
(	O
PDE4s	O
)	O
are	O
targets	O
for	O
these	O
drugs	O
.	O

Moreover	O
,	O
no	O
PDE4s	O
expressed	O
in	O
mice	O
have	O
been	O
characterized	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
isolated	O
two	O
cDNAs	O
representing	O
homologues	O
of	O
PDE4A1	O
and	O
PDE4B3	O
from	O
a	O
mouse	O
brain	O
library	O
.	O

After	O
transient	O
transfection	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cells	O
,	O
the	O
mouse	O
PDEs	O
hydrolyzed	O
cyclic	O
AMP	O
with	O
a	O
low	O
K	O
(	O
m	O
)	O
and	O
were	O
inhibited	O
by	O
rolipram	O
;	O
both	O
are	O
properties	O
typical	O
of	O
other	O
mammalian	O
PDE4	O
enzymes	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
diazepam	O
inhibited	O
cyclic	O
AMP	O
hydrolysis	O
by	O
the	O
mouse	O
PDE4	O
subtypes	O
.	O

Interestingly	O
,	O
PDE4B	B
was	O
significantly	O
more	O
sensitive	O
to	O
inhibition	O
by	O
both	O
rolipram	O
and	O
diazepam	O
than	O
the	O
PDE4A	B
subtype	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
recombinantly	O
expressed	O
PDE4s	O
are	O
inhibited	O
by	O
diazepam	O
,	O
and	O
should	O
facilitate	O
future	O
studies	O
with	O
mouse	O
models	O
of	O
depression	O
and	O
anxiety	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
is	O
normally	O
subject	O
to	O
servo	O
control	O
mechanisms	O
that	O
suppress	O
plasma	O
renin	O
levels	O
in	O
response	O
to	O
increased	O
blood	O
pressure	O
and	O
increase	O
plasma	O
renin	O
levels	O
when	O
blood	O
pressure	O
falls	O
.	O

In	O
most	O
species	O
,	O
renin	O
is	O
rate	O
limiting	O
,	O
and	O
angiotensinogen	B
circulates	O
at	O
a	O
concentration	O
close	O
to	O
the	O
Km	O
,	O
so	O
varying	O
the	O
concentration	O
of	O
either	O
can	O
affect	O
the	O
rate	O
of	O
angiotensin	O
formation	O
.	O

However	O
,	O
only	O
the	O
plasma	O
renin	O
level	O
responds	O
to	O
changes	O
in	O
blood	O
pressure	O
and	O
sodium	O
balance	O
to	O
maintain	O
blood	O
pressure	O
homeostasis	O
.	O

Therefore	O
,	O
the	O
high	O
plasma	O
human	O
renin	O
levels	O
and	O
the	O
hypertension	O
of	O
mice	O
and	O
rats	O
containing	O
both	O
human	O
renin	O
and	O
angiotensinogen	B
transgenes	O
indicate	O
inappropriate	O
regulation	O
of	O
renin	O
and	O
blood	O
pressure	O
.	O

These	O
anomalies	O
led	O
us	O
to	O
develop	O
new	O
lines	O
of	O
transgenic	O
mice	O
with	O
a	O
longer	O
human	O
renin	O
gene	O
fragment	O
(	O
45	O
kb	O
)	O
than	O
earlier	O
lines	O
(	O
13	O
to	O
15	O
kb	O
)	O
.	O

Unlike	O
their	O
predecessors	O
,	O
the	O
45-kb	O
hREN	O
mice	O
secrete	O
human	O
renin	O
only	O
from	O
the	O
kidneys	O
,	O
and	O
both	O
the	O
human	O
and	O
mouse	O
renins	O
respond	O
appropriately	O
to	O
physiological	O
stimuli	O
.	O

To	O
determine	O
whether	O
blood	O
pressure	O
is	O
also	O
regulated	O
appropriately	O
,	O
we	O
crossed	O
these	O
new	O
45-kb	O
hREN	O
mice	O
with	O
mice	O
containing	O
the	O
human	O
angiotensinogen	B
gene	O
.	O

All	O
doubly	O
transgenic	O
mice	O
were	O
normotensive	O
like	O
their	O
singly	O
transgenic	O
and	O
nontransgenic	O
littermates	O
.	O

Moreover	O
,	O
among	O
doubly	O
transgenic	O
mice	O
,	O
both	O
human	O
and	O
mouse	O
plasma	O
renin	O
concentrations	O
were	O
suppressed	O
relative	O
to	O
the	O
singly	O
transgenic	O
45-kb	O
hREN	O
mice	O
.	O

These	O
findings	O
demonstrate	O
the	O
importance	O
of	O
appropriate	O
cell	O
and	O
tissue	O
specificity	O
of	O
gene	O
expression	O
in	O
constructing	O
transgenic	O
models	O
and	O
affirm	O
the	O
pivotal	O
role	O
played	O
by	O
renal	O
renin	O
secretion	O
in	O
blood	O
pressure	O
control	O
.	O

Endoglin	B
is	O
an	O
integral	O
membrane	O
glycoprotein	O
predominantly	O
expressed	O
on	O
human	O
endothelial	O
cells	O
and	O
recently	O
shown	O
to	O
bind	O
transforming	O
growth	O
factor	O
-	O
beta	O
1	O
(	O
TGF	O
beta	O
1	O
)	O
with	O
high	O
affinity	O
.	O

We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
a	O
full	O
-	O
length	O
murine	O
endoglin	B
complementary	O
DNA	O
of	O
2902	O
base	O
pairs	O
which	O
hybridizes	O
specifically	O
with	O
a	O
single	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
species	O
.	O

The	O
polypeptide	O
of	O
653	O
amino	O
acids	O
has	O
an	O
overall	O
identity	O
of	O
72	O
%	O
with	O
human	O
and	O
porcine	O
endoglin	B
.	O

The	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
of	O
all	O
three	O
proteins	O
differ	O
by	O
two	O
to	O
four	O
amino	O
acids	O
and	O
are	O
70	O
%	O
identical	O
to	O
the	O
corresponding	O
regions	O
of	O
the	O
TGF	O
beta	O
binding	O
protein	O
,	O
betaglycan	B
.	O

Relative	O
levels	O
of	O
murine	O
endoglin	B
mRNA	O
were	O
estimated	O
by	O
polymerase	O
chain	O
reaction	O
and	O
found	O
to	O
be	O
high	O
in	O
ovary	O
and	O
uterus	O
,	O
intermediate	O
in	O
heart	O
and	O
muscle	O
,	O
and	O
low	O
in	O
placenta	O
and	O
spleen	O
.	O

In	O
situ	O
hybridization	O
and	O
immunofluorescence	O
confirmed	O
that	O
murine	O
endoglin	B
,	O
like	O
its	O
human	O
counterpart	O
,	O
is	O
present	O
in	O
blood	O
vessels	O
and	O
capillaries	O
in	O
all	O
tissues	O
examined	O
.	O

In	O
addition	O
,	O
the	O
stromal	O
cells	O
in	O
the	O
connective	O
tissue	O
of	O
intestine	O
,	O
stomach	O
,	O
heart	O
,	O
muscle	O
,	O
uterus	O
,	O
ovary	O
,	O
and	O
testis	O
were	O
strongly	O
and	O
specifically	O
reactive	O
with	O
complementary	O
RNA	O
probes	O
and	O
with	O
a	O
polyclonal	O
antibody	O
to	O
endoglin	B
;	O
epithelial	O
cell	O
layers	O
were	O
distinctly	O
unreactive	O
.	O

This	O
distribution	O
is	O
similar	O
to	O
that	O
of	O
extracellular	O
TGF	O
beta	O
1	O
,	O
particularly	O
in	O
heart	O
and	O
uterus	O
,	O
and	O
suggests	O
that	O
endoglin	B
on	O
stromal	O
fibroblast	O
-	O
like	O
cells	O
might	O
be	O
regulating	O
access	O
of	O
TGF	O
beta	O
1	O
to	O
the	O
signaling	O
receptor	O
complex	O
.	O

NCTC-2071	O
fibroblasts	O
in	O
culture	O
were	O
shown	O
to	O
express	O
high	O
levels	O
of	O
endoglin	B
mRNA	O
by	O
polymerase	O
chain	O
reaction	O
.	O

After	O
chemical	O
cross	O
-	O
linking	O
with	O
[	O
125I	O
]	O
TGF	O
beta	O
1	O
and	O
immunoprecipitation	O
with	O
the	O
polyclonal	O
antihuman	O
endoglin	B
serum	O
,	O
a	O
radiolabeled	O
band	O
of	O
mol	O
wt	O
180,000	O
corresponding	O
to	O
dimeric	O
endoglin	B
was	O
observed	O
under	O
nonreducing	O
conditions	O
,	O
whereas	O
a	O
single	O
band	O
of	O
mol	O
wt	O
90,000	O
was	O
seen	O
under	O
reducing	O
conditions	O
.	O

Thus	O
murine	O
fibroblast	O
endoglin	B
is	O
capable	O
of	O
binding	O
TGF	O
beta	O
1	O
.	O

Future	O
studies	O
should	O
establish	O
the	O
specialized	O
role	O
of	O
endoglin	B
in	O
the	O
TGF	O
beta	O
receptor	O
complex	O
of	O
endothelial	O
and	O
stromal	O
cells	O
.	O

The	O
BCL-2	B
family	O
has	O
various	O
pairs	O
of	O
antagonist	O
and	O
agonist	O
proteins	O
that	O
regulate	O
apoptosis	O
.	O

Whether	O
their	O
function	O
is	O
interdependent	O
is	O
uncertain	O
.	O

Using	O
a	O
genetic	O
approach	O
to	O
address	O
this	O
question	O
,	O
we	O
utilized	O
gain-	O
and	O
loss	O
-	O
of	O
-	O
function	O
models	O
of	O
Bcl-2	B
and	O
Bax	B
and	O
found	O
that	O
apoptosis	O
and	O
thymic	O
hypoplasia	O
characteristic	O
of	O
Bcl-2-deficient	B
mice	O
are	O
largely	O
absent	O
in	O
mice	O
also	O
deficient	O
in	O
Bax	B
.	O

A	O
single	O
copy	O
of	O
Bax	B
promoted	O
apoptosis	O
in	O
the	O
absence	O
of	O
Bcl-2	B
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Bcl-2	B
still	O
repressed	O
apoptosis	O
in	O
the	O
absence	O
of	O
Bax	B
.	O

While	O
an	O
in	O
vivo	O
competition	O
exists	O
between	O
Bax	B
and	O
Bcl-2	B
,	O
each	O
is	O
able	O
to	O
regulate	O
apoptosis	O
independently	O
.	O

Major	O
histocompatibility	O
complex	O
class	O
II	O
positive	O
cells	O
,	O
namely	O
dendritic	O
cells	O
,	O
monocytes	O
/	O
macrophages	O
,	O
and	O
B	O
cells	O
,	O
are	O
categorized	O
as	O
antigen	O
-	O
presenting	O
cells	O
.	O

Dendritic	O
cells	O
,	O
so	O
-	O
called	O
professional	O
antigen	O
-	O
presenting	O
cells	O
,	O
use	O
distinct	O
sets	O
of	O
surface	O
receptors	O
before	O
and	O
after	O
maturation	O
:	O
those	O
to	O
capture	O
antigens	O
and	O
those	O
to	O
interact	O
with	O
T	O
cells	O
,	O
respectively	O
.	O

But	O
there	O
remain	O
many	O
surface	O
molecules	O
whose	O
functions	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
dendritic	B
cell	I
immunoreceptor	I
from	O
mouse	O
bone	O
-	O
marrow	O
-	O
derived	O
mature	O
dendritic	O
cells	O
.	O

Dendritic	B
cell	I
immunoreceptor	I
is	O
a	O
recently	O
reported	O
C	O
-	O
type	O
lectin	O
receptor	O
characteristic	O
with	O
cytoplasmic	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
.	O

Expression	O
of	O
mouse	O
dendritic	B
cell	I
immunoreceptor	I
mRNA	O
was	O
observed	O
specifically	O
in	O
spleen	O
and	O
lymph	O
node	O
,	O
slightly	O
increased	O
with	O
dendritic	O
cell	O
maturation	O
during	O
in	O
vitro	O
culture	O
of	O
bone	O
marrow	O
cells	O
,	O
and	O
was	O
not	O
detected	O
in	O
cultured	O
natural	O
killer	O
cells	O
.	O

Surface	O
expression	O
of	O
mouse	O
dendritic	B
cell	I
immunoreceptor	I
protein	O
was	O
observed	O
in	O
splenic	O
antigen	O
-	O
presenting	O
cells	O
including	O
B	O
cells	O
,	O
monocytes	O
/	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

To	O
reveal	O
the	O
downregulating	O
capacity	O
of	O
dendritic	B
cell	I
immunoreceptor	I
in	O
antigen	O
-	O
presenting	O
cells	O
,	O
the	O
change	O
of	O
B	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
signals	O
after	O
coligation	O
with	O
a	O
chimeric	O
Fcgamma	O
receptor	O
IIB	O
containing	O
the	O
cytoplasmic	O
portion	O
of	O
mouse	O
dendritic	B
cell	I
immunoreceptor	I
was	O
examined	O
.	O

As	O
a	O
result	O
,	O
we	O
detected	O
two	O
distinct	O
inhibitory	O
effects	O
of	O
cytoplasmic	O
dendritic	B
cell	I
immunoreceptor	I
minus	O
sign	O
inhibition	O
of	O
B	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
Ca2	O
+	O
mobilization	O
and	O
protein	O
tyrosine	O
phosphorylation	O
minus	O
sign	O
and	O
both	O
of	O
these	O
effects	O
required	O
the	O
tyrosine	O
residue	O
inside	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
.	O

This	O
report	O
presents	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
-	O
dependent	O
negative	O
regulatory	O
function	O
of	O
dendritic	O
cell	O
immunoreceptors	O
.	O

In	O
conclusion	O
,	O
mouse	O
dendritic	B
cell	I
immunoreceptor	I
expressed	O
on	O
antigen	O
-	O
presenting	O
cells	O
can	O
exert	O
two	O
distinct	O
inhibitory	O
signals	O
depending	O
on	O
its	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
tyrosine	O
residue	O
.	O

We	O
have	O
used	O
a	O
quantitative	O
RT	O
-	O
PCR	O
approach	O
to	O
determine	O
the	O
levels	O
of	O
Brn3a	B
and	O
Brn3b	B
POU	O
domain	O
transcription	O
factor	O
mRNAs	O
in	O
the	O
developing	O
mouse	O
trigeminal	O
ganglion	O
from	O
E10	O
to	O
E18	O
.	O

Using	O
low	O
density	O
neuronal	O
cultures	O
,	O
we	O
have	O
shown	O
that	O
NT-3	B
can	O
regulate	O
the	O
expression	O
of	O
Brn3a	B
mRNA	O
in	O
trigeminal	O
neurons	O
during	O
the	O
periods	O
that	O
they	O
are	O
differentiating	O
and	O
innervating	O
their	O
peripheral	O
and	O
central	O
targets	O
.	O

In	O
contrast	O
to	O
Brn3a	B
,	O
Brn3b	B
mRNA	O
is	O
expressed	O
at	O
extremely	O
low	O
levels	O
in	O
the	O
early	O
trigeminal	O
ganglion	O
.	O

Trigeminal	O
neurons	O
from	O
early	O
ganglia	O
express	O
low	O
levels	O
of	O
Brn3b	B
mRNA	O
in	O
culture	O
and	O
do	O
not	O
up	O
-	O
regulate	O
Brn3b	B
mRNA	O
in	O
response	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
experimental	O
conditions	O
.	O

However	O
,	O
at	O
later	O
ages	O
,	O
when	O
in	O
vivo	O
levels	O
of	O
Brn3b	B
mRNA	O
are	O
high	O
,	O
FGF2	B
,	O
TGFbeta1	O
and	O
retinoic	O
acid	O
all	O
up	O
-	O
regulate	O
Brn3b	B
mRNA	O
expression	O
in	O
cultured	O
trigeminal	O
neurons	O
.	O

Since	O
NT-3	B
regulates	O
the	O
developmental	O
expression	O
of	O
Brn3a	B
,	O
Brn3a	B
may	O
mediate	O
some	O
of	O
the	O
effects	O
that	O
NT-3	B
exerts	O
on	O
sensory	O
neurons	O
and	O
their	O
progenitors	O
.	O

Similarly	O
,	O
Brn3b	B
may	O
mediate	O
some	O
of	O
the	O
effects	O
that	O
FGF2	B
,	O
TGFbeta1	O
and	O
retinoic	O
acid	O
have	O
on	O
neurons	O
.	O

In	O
this	O
study	O
we	O
have	O
examined	O
the	O
expression	O
of	O
murine	O
Hox	O
homeobox	O
containing	O
genes	O
by	O
in	O
situ	O
hybridisation	O
in	O
the	O
branchial	O
region	O
of	O
the	O
head	O
.	O

Genes	O
from	O
the	O
Hox	O
complexes	O
display	O
segmentally	O
restricted	O
domains	O
of	O
expression	O
in	O
the	O
developing	O
hindbrain	O
,	O
which	O
are	O
correlated	O
with	O
similar	O
restricted	O
domains	O
in	O
the	O
neural	O
crest	O
and	O
surface	O
ectoderm	O
of	O
the	O
branchial	O
arches	O
.	O

Comparison	O
of	O
related	O
genes	O
from	O
the	O
different	O
clusters	O
shows	O
that	O
subfamily	O
members	O
are	O
expressed	O
in	O
identical	O
rhombomeres	O
and	O
branchial	O
arches	O
.	O

These	O
patterns	O
suggest	O
a	O
combinatorial	O
system	O
for	O
specifying	O
regional	O
variation	O
in	O
the	O
head	O
,	O
which	O
we	O
refer	O
to	O
as	O
a	O
Hox	O
code	O
.	O

The	O
Hox	O
genes	O
also	O
display	O
dynamic	O
dorso	O
-	O
ventral	O
(	O
D	O
-	O
V	O
)	O
restrictions	O
in	O
the	O
developing	O
neural	O
tube	O
which	O
mirror	O
the	O
timing	O
and	O
spatial	O
distributions	O
of	O
the	O
birth	O
of	O
major	O
classes	O
of	O
neurons	O
in	O
the	O
CNS	O
.	O

Genes	O
in	O
the	O
Hox-2	O
cluster	O
all	O
have	O
a	O
similar	O
D	O
-	O
V	O
distribution	O
that	O
differs	O
from	O
that	O
of	O
genes	O
from	O
the	O
other	O
Hox	O
clusters	O
,	O
and	O
suggests	O
that	O
members	O
of	O
a	O
subfamily	O
may	O
be	O
used	O
to	O
specify	O
positional	O
values	O
to	O
different	O
subsets	O
of	O
cells	O
at	O
the	O
same	O
axial	O
level	O
.	O

These	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
a	O
system	O
for	O
patterning	O
the	O
branchial	O
regions	O
of	O
the	O
vertebrate	O
head	O
,	O
and	O
evolution	O
of	O
head	O
structures	O
.	O

We	O
have	O
also	O
examined	O
aspects	O
of	O
the	O
transcriptional	O
regulation	O
of	O
Hox-2	O
genes	O
in	O
transgenic	O
mice	O
using	O
a	O
lacZ	O
reporter	O
gene	O
.	O

We	O
have	O
been	O
able	O
to	O
reconstruct	O
the	O
major	O
pattern	O
of	O
the	O
Hox-2.6	O
gene	O
on	O
the	O
basis	O
of	O
identical	O
expression	O
of	O
the	O
transgene	O
and	O
the	O
endogenous	O
gene	O
with	O
respect	O
to	O
timing	O
,	O
spatial	O
restrictions	O
and	O
tissue	O
-	O
specific	O
distributions	O
.	O

Deletion	O
analysis	O
has	O
enabled	O
us	O
to	O
identify	O
three	O
regions	O
involved	O
in	O
generating	O
this	O
pattern	O
.	O

Two	O
of	O
these	O
regions	O
have	O
the	O
properties	O
of	O
enhancers	O
which	O
are	O
capable	O
of	O
imposing	O
spatially	O
-	O
restricted	O
domains	O
of	O
expression	O
on	O
heterologous	O
promoters	O
.	O

We	O
have	O
generated	O
similar	O
Hox	O
-	O
lacZ	O
fusions	O
that	O
reconstruct	O
the	O
highly	O
restricted	O
patterns	O
of	O
the	O
Hox-2.1	B
and	O
Hox-2.8	B
genes	O
in	O
the	O
developing	O
nervous	O
system	O
,	O
supporting	O
our	O
in	O
situ	O
analysis	O
and	O
the	O
idea	O
of	O
a	O
Hox	O
code	O
.	O

These	O
transgenic	O
experiments	O
are	O
a	O
useful	O
step	O
in	O
examining	O
regulation	O
in	O
the	O
Hox	O
cascade	O
.	O

Tottering	B
mice	O
inherit	O
a	O
recessive	O
mutation	O
of	O
the	O
calcium	O
channel	O
alpha1A	B
subunit	O
that	O
causes	O
ataxia	O
,	O
polyspike	O
discharges	O
,	O
and	O
intermittent	O
dystonic	O
episodes	O
.	O

The	O
calcium	O
channel	O
alpha1A	B
subunit	O
gene	O
encodes	O
the	O
pore	O
-	O
forming	O
protein	O
of	O
P	O
/	O
Q	O
-	O
type	O
voltage	O
-	O
dependent	O
calcium	O
channels	O
and	O
is	O
predominantly	O
expressed	O
in	O
cerebellar	O
granule	O
and	O
Purkinje	O
neurons	O
with	O
moderate	O
expression	O
in	O
hippocampus	O
and	O
inferior	O
colliculus	O
.	O

Because	O
calcium	O
misregulation	O
likely	O
underlies	O
the	O
tottering	B
mouse	O
phenotype	O
,	O
calcium	O
channel	O
blockers	O
were	O
tested	O
for	O
their	O
ability	O
to	O
block	O
the	O
motor	O
episodes	O
.	O

Pharmacologic	O
agents	O
that	O
specifically	O
block	O
L	O
-	O
type	O
voltage	O
-	O
dependent	O
calcium	O
channels	O
,	O
but	O
not	O
P	O
/	O
Q	O
-	O
type	O
calcium	O
channels	O
,	O
prevented	O
the	O
inducible	O
dystonia	O
of	O
tottering	B
mutant	O
mice	O
.	O

Specifically	O
,	O
the	O
dihydropyridines	O
nimodipine	O
,	O
nifedipine	O
,	O
and	O
nitrendipine	O
,	O
the	O
benzothiazepine	O
diltiazem	O
,	O
and	O
the	O
phenylalkylamine	O
verapamil	O
all	O
prevented	O
restraint	O
-	O
induced	O
tottering	B
mouse	O
motor	O
episodes	O
.	O

Conversely	O
,	O
the	O
L	O
-	O
type	O
calcium	O
channel	O
agonist	O
Bay	O
K8644	O
induced	O
stereotypic	O
tottering	B
mouse	O
dystonic	O
at	O
concentrations	O
significantly	O
below	O
those	O
required	O
to	O
induce	O
seizures	O
in	O
control	O
mice	O
.	O

In	O
situ	O
hybridization	O
demonstrated	O
that	O
L	O
-	O
type	O
calcium	O
channel	O
alpha1C	O
subunit	O
mRNA	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
the	O
Purkinje	O
cells	O
of	O
tottering	B
mice	O
.	O

Radioligand	O
binding	O
with	O
[	O
3H	O
]	O
nitrendipine	O
also	O
revealed	O
a	O
significant	O
increase	O
in	O
the	O
density	O
of	O
L	O
-	O
type	O
calcium	O
channels	O
in	O
tottering	B
mouse	O
cerebellum	O
.	O

These	O
data	O
suggest	O
that	O
although	O
a	O
P	O
/	O
Q	O
-	O
type	O
calcium	O
channel	O
mutation	O
is	O
the	O
primary	O
defect	O
in	O
tottering	B
mice	O
,	O
L	O
-	O
type	O
calcium	O
channels	O
may	O
contribute	O
to	O
the	O
generation	O
of	O
the	O
intermittent	O
dystonia	O
observed	O
in	O
these	O
mice	O
.	O

The	O
susceptibility	O
of	O
L	O
-	O
type	O
calcium	O
channels	O
to	O
voltage	O
-	O
dependent	O
facilitation	O
may	O
promote	O
this	O
abnormal	O
motor	O
phenotype	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
shows	O
that	O
fission	O
yeast	O
centromeres	O
and	O
telomeres	O
make	O
up	O
specific	O
spatial	O
arrangements	O
in	O
the	O
nucleus	O
.	O

Their	O
positioning	O
and	O
clustering	O
are	O
cell	O
cycle	O
regulated	O
.	O

In	O
G2	O
,	O
centromeres	O
cluster	O
adjacent	O
to	O
the	O
spindle	O
pole	O
body	O
(	O
SPB	O
)	O
,	O
while	O
in	O
mitosis	O
,	O
their	O
association	O
with	O
each	O
other	O
and	O
with	O
the	O
SPB	O
is	O
disrupted	O
.	O

Similarly	O
,	O
telomeres	O
cluster	O
at	O
the	O
nuclear	O
periphery	O
in	O
G2	O
and	O
their	O
associations	O
are	O
disrupted	O
in	O
mitosis	O
.	O

Mitotic	O
centromeres	O
interact	O
with	O
the	O
spindle	O
.	O

They	O
remain	O
undivided	O
until	O
the	O
spindle	O
reaches	O
a	O
critical	O
length	O
,	O
then	O
separate	O
and	O
move	O
towards	O
the	O
poles	O
.	O

This	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
anaphase	O
A	O
occurs	O
in	O
fission	O
yeast	O
.	O

The	O
mode	O
of	O
anaphase	O
A	O
and	O
B	O
is	O
similar	O
to	O
that	O
of	O
higher	O
eukaryotes	O
.	O

In	O
nda3	O
and	O
cut7	O
mutants	O
defective	O
in	O
tubulin	O
of	O
a	O
kinesin	O
-	O
related	O
motor	O
,	O
cells	O
are	O
blocked	O
in	O
early	O
stages	O
of	O
mitosis	O
due	O
to	O
the	O
absence	O
of	O
the	O
spindle	O
,	O
and	O
centromeres	O
dissociate	O
but	O
remain	O
close	O
to	O
the	O
SPB	O
,	O
whereas	O
in	O
a	O
metaphase	O
-	O
arrested	O
nuc2	B
mutant	O
,	O
they	O
reside	O
at	O
the	O
middle	O
of	O
the	O
spindle	O
.	O

FISH	O
is	O
therefore	O
a	O
powerful	O
tool	O
for	O
analyzing	O
mitotic	O
chromosome	O
movement	O
and	O
disjunction	O
using	O
various	O
mutants	O
.	O

Surprisingly	O
,	O
in	O
top2	B
defective	O
in	O
DNA	O
topoisomerase	O
II	O
,	O
while	O
most	O
chromatid	O
DNAs	O
remain	O
undivided	O
,	O
sister	O
centromeres	O
are	O
separated	O
.	O

Significance	O
of	O
this	O
finding	O
is	O
discussed	O
.	O

In	O
contrast	O
,	O
most	O
chromatid	O
DNAs	O
are	O
separated	O
but	O
telomeric	O
DNAs	O
are	O
not	O
in	O
cut1	O
mutant	O
.	O

In	O
cut1	O
,	O
the	O
dependence	O
of	O
SPB	O
duplication	O
on	O
the	O
completion	O
of	O
mitosis	O
is	O
abolished	O
.	O

In	O
crm1	B
mutant	O
cells	O
defective	O
in	O
higher	O
-	O
order	O
chromosome	O
organization	O
,	O
the	O
interphase	O
arrangements	O
of	O
centromeres	O
and	O
telomeres	O
are	O
disrupted	O
.	O

We	O
have	O
continued	O
our	O
studies	O
on	O
the	O
import	O
pathway	O
of	O
the	O
precursor	O
to	O
yeast	O
cytochrome	O
c	O
oxidase	O
subunit	O
Va	O
(	O
pVa	O
)	O
,	O
a	O
mitochondrial	O
inner	O
membrane	O
protein	O
.	O

Previous	O
work	O
on	O
this	O
precursor	O
demonstrated	O
that	O
import	O
of	O
pVa	O
is	O
unusually	O
efficient	O
,	O
and	O
that	O
inner	O
membrane	O
localization	O
is	O
directed	O
by	O
a	O
membrane	O
-	O
spanning	O
domain	O
in	O
the	O
COOH	O
-	O
terminal	O
third	O
of	O
the	O
protein	O
.	O

Here	O
we	O
report	O
the	O
results	O
of	O
studies	O
aimed	O
at	O
analyzing	O
the	O
intramitochondrial	O
sorting	O
of	O
pVa	O
,	O
as	O
well	O
as	O
the	O
role	O
played	O
by	O
ancillary	O
factors	O
in	O
import	O
and	O
localization	O
of	O
the	O
precursor	O
.	O

We	O
found	O
that	O
pVa	O
was	O
efficiently	O
imported	O
and	O
correctly	O
sorted	O
in	O
mitochondria	O
prepared	O
from	O
yeast	O
strains	O
defective	O
in	O
the	O
function	O
of	O
either	O
mitochondrial	O
heat	O
shock	O
protein	O
(	O
hsp	O
)	O
60	O
or	O
hsp70	B
.	O

Under	O
identical	O
conditions	O
the	O
import	O
and	O
sorting	O
of	O
another	O
mitochondrial	O
protein	O
,	O
the	O
precursor	O
to	O
the	O
beta	O
subunit	O
of	O
the	O
F1	O
ATPase	O
,	O
was	O
completely	O
defective	O
.	O

Consistent	O
with	O
previous	O
results	O
demonstrating	O
that	O
the	O
subunit	O
Va	O
precursor	O
is	O
loosely	O
folded	O
,	O
we	O
found	O
that	O
pVa	O
could	O
be	O
efficiently	O
imported	O
into	O
mitochondria	O
after	O
translation	O
in	O
wheat	O
germ	O
extracts	O
.	O

This	O
results	O
suggests	O
that	O
normal	O
levels	O
of	O
extramitochondrial	O
hsp70	B
are	O
also	O
not	O
required	O
for	O
import	O
of	O
the	O
protein	O
.	O

The	O
results	O
of	O
this	O
study	O
enhance	O
our	O
understanding	O
of	O
the	O
mechanism	O
by	O
which	O
pVa	O
is	O
routed	O
to	O
the	O
mitochondrial	O
inner	O
membrane	O
.	O

They	O
suggest	O
that	O
while	O
the	O
NH2	O
terminus	O
of	O
pVa	O
is	O
exposed	O
to	O
the	O
matrix	O
and	O
processed	O
by	O
the	O
matrix	O
metalloprotease	O
,	O
the	O
protein	O
remains	O
anchored	O
to	O
the	O
inner	O
membrane	O
before	O
being	O
assembled	O
into	O
a	O
functional	O
holoenzyme	O
complex	O
.	O

ENP1	B
is	O
an	O
essential	O
Saccharomyces	O
cerevisiae	O
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

Enp1	B
protein	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
concentrated	O
in	O
the	O
nucleolus	O
.	O

An	O
enp1	B
-	I
1	I
temperature	O
-	O
sensitive	O
mutant	O
inhibited	O
35S	O
pre	O
-	O
rRNA	O
early	O
processing	O
at	O
sites	O
A	O
(	O
0	O
)	O
,	O
A	O
(	O
1	O
)	O
and	O
A	O
(	O
2	O
)	O
as	O
shown	O
by	O
northern	O
analysis	O
of	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
.	O

Pulse	O
-	O
chase	O
analysis	O
further	O
revealed	O
that	O
the	O
enp1	B
-	I
1	I
strain	O
was	O
defective	O
in	O
the	O
synthesis	O
of	O
20S	O
pre	O
-	O
rRNA	O
and	O
hence	O
18S	O
rRNA	O
,	O
which	O
led	O
to	O
reduced	O
formation	O
of	O
40S	O
ribosomal	O
subunits	O
.	O

Co	O
-	O
precipitation	O
analysis	O
revealed	O
that	O
Enp1	B
was	O
associated	O
with	O
Nop1	B
protein	O
,	O
as	O
well	O
as	O
with	O
U3	O
and	O
U14	O
RNAs	O
,	O
two	O
snoRNAs	O
implicated	O
in	O
early	O
pre	O
-	O
rRNA	O
processing	O
steps	O
.	O

These	O
results	O
suggest	O
a	O
direct	O
role	O
for	O
Enp1	B
in	O
the	O
early	O
steps	O
of	O
rRNA	O
processing	O
.	O

The	O
PUT1	B
gene	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
believed	O
to	O
encode	O
proline	O
oxidase	O
,	O
has	O
been	O
completely	O
sequenced	O
and	O
contains	O
an	O
open	O
reading	O
frame	O
capable	O
of	O
encoding	O
a	O
polypeptide	O
of	O
476	O
amino	O
acids	O
in	O
length	O
.	O

The	O
amino	O
terminus	O
of	O
the	O
protein	O
deduced	O
from	O
the	O
DNA	O
sequence	O
has	O
a	O
characteristic	O
mitochondrial	O
import	O
signal	O
;	O
two	O
PUT1-lacZ	B
gene	O
fusions	O
were	O
constructed	O
that	O
produced	O
mitochondrially	O
localized	O
beta	O
-	O
galactosidase	O
in	O
vivo	O
.	O

The	O
transcription	O
initiation	O
and	O
termination	O
sites	O
of	O
the	O
PUT1	B
mRNA	O
were	O
determined	O
.	O

By	O
using	O
a	O
PUT1-lacZ	B
gene	O
fusion	O
that	O
makes	O
a	O
cytoplasmic	O
beta	O
-	O
galactosidase	O
,	O
the	O
regulation	O
of	O
the	O
PUT1	B
gene	O
was	O
studied	O
.	O

PUT1	B
is	O
inducible	O
by	O
proline	O
,	O
responds	O
only	O
slightly	O
to	O
carbon	O
catabolite	O
repression	O
,	O
and	O
is	O
not	O
regulated	O
by	O
the	O
cytochrome	O
activator	O
proteins	O
HAP1	B
and	O
HAP2	B
.	O

The	O
PUT1	B
gene	O
is	O
under	O
oxygen	O
regulation	O
;	O
expression	O
in	O
anaerobically	O
grown	O
cells	O
is	O
10-fold	O
lower	O
than	O
in	O
aerobically	O
grown	O
cells	O
.	O

Oxygen	O
regulation	O
is	O
abolished	O
when	O
cells	O
are	O
respiratory	O
deficient	O
.	O

PUT1	B
expression	O
in	O
a	O
[	O
rho-	O
]	O
strain	O
grown	O
either	O
aerobically	O
or	O
anaerobically	O
is	O
as	O
high	O
as	O
that	O
seen	O
in	O
a	O
[	O
rho+	O
]	O
strain	O
grown	O
aerobically	O
.	O

Studies	O
on	O
PUT1	B
promoter	O
deletions	O
define	O
a	O
region	O
between	O
positions	O
-458	O
and	O
-293	O
from	O
the	O
translation	O
initiation	O
site	O
that	O
is	O
important	O
for	O
full	O
expression	O
of	O
the	O
PUT1	B
gene	O
and	O
required	O
for	O
oxygen	O
regulation	O
.	O

The	O
cycl-362	O
allele	O
contains	O
a	O
point	O
mutation	O
that	O
generates	O
an	O
aberrant	O
AUG	O
codon	O
upstream	O
of	O
the	O
normal	O
CYC1	B
translation	O
initiation	O
codon	O
.	O

Mutants	O
containing	O
this	O
allele	O
express	O
only	O
about	O
2	O
%	O
of	O
normal	O
iso-1-cytochrome	O
c	O
,	O
presumably	O
due	O
to	O
translation	O
initiation	O
at	O
the	O
upstream	O
AUG	O
,	O
termination	O
at	O
a	O
UAA	O
sequence	O
six	O
codons	O
downstream	O
,	O
and	O
failure	O
to	O
reinitiate	O
at	O
the	O
normal	O
AUG	O
codon	O
two	O
nucleotides	O
later	O
.	O

Both	O
intragenic	O
and	O
extragenic	O
revertants	O
of	O
cycl-362	O
,	O
expressing	O
elevated	O
levels	O
of	O
iso-1-cytochrome	O
c	O
,	O
have	O
been	O
isolated	O
simply	O
by	O
selecting	O
for	O
growth	O
on	O
lactate	O
medium	O
.	O

Here	O
we	O
describe	O
an	O
improved	O
method	O
for	O
isolating	O
and	O
readily	O
distinguishing	O
cis-	O
from	O
trans	O
-	O
acting	O
suppressors	O
of	O
the	O
upstream	O
AUG	O
.	O

Eight	O
different	O
genes	O
,	O
designated	O
sua1-sua8	B
,	O
are	O
represented	O
in	O
our	O
current	O
collection	O
of	O
extragenic	O
suppressors	O
;	O
all	O
are	O
recessive	O
and	O
enhance	O
iso-1-cytochrome	O
c	O
levels	O
to	O
10	O
-	O
60	O
%	O
of	O
normal	O
.	O

None	O
of	O
the	O
sua	O
genes	O
is	O
allelic	O
to	O
SUI2	B
or	O
sui3	B
,	O
which	O
encode	O
eIF-2	O
alpha	O
and	O
eIF-2	O
beta	O
,	O
respectively	O
,	O
or	O
to	O
SUI1	B
.	O

Many	O
of	O
the	O
suppressors	O
exhibit	O
pleiotropic	O
phenotypes	O
,	O
including	O
slow	O
growth	O
,	O
cold	O
(	O
16	O
degrees	O
C	O
)	O
and	O
heat	O
(	O
37	O
degrees	O
C	O
)	O
sensitivity	O
.	O

These	O
phenotypes	O
have	O
been	O
exploited	O
to	O
clone	O
the	O
SUA5	B
,	O
SUA7	B
and	O
SUA8	B
genes	O
,	O
which	O
are	O
presently	O
being	O
characterized	O
.	O

The	O
structure	O
of	O
cyc1	B
-	I
362	I
and	O
the	O
number	O
of	O
sua	O
genes	O
already	O
uncovered	O
suggest	O
that	O
the	O
SUA	O
genes	O
are	O
likely	O
to	O
encode	O
factors	O
affecting	O
several	O
different	O
cellular	O
processes	O
,	O
including	O
translation	O
initiation	O
,	O
mRNA	O
stability	O
and	O
possibly	O
transcription	O
start	O
site	O
selection	O
.	O

The	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
a	O
genetic	O
program	O
for	O
selecting	O
and	O
assembling	O
a	O
bud	O
site	O
on	O
the	O
cell	O
cortex	O
.	O

Yeast	O
cells	O
confine	O
their	O
growth	O
to	O
the	O
emerging	O
bud	O
,	O
a	O
process	O
directed	O
by	O
cortical	O
patches	O
of	O
actin	O
filaments	O
within	O
the	O
bud	O
.	O

We	O
have	O
investigated	O
how	O
cells	O
regulate	O
budding	O
in	O
response	O
to	O
osmotic	O
stress	O
,	O
focusing	O
on	O
the	O
role	O
of	O
the	O
high	O
osmolarity	O
glycerol	O
response	O
(	O
HOG	O
)	O
pathway	O
in	O
mediating	O
this	O
regulation	O
.	O

An	O
increase	O
in	O
external	O
osmolarity	O
induces	O
a	O
growth	O
arrest	O
in	O
which	O
actin	O
filaments	O
are	O
lost	O
from	O
the	O
bud	O
.	O

This	O
is	O
followed	O
by	O
a	O
recovery	O
phase	O
in	O
which	O
actin	O
filaments	O
return	O
to	O
their	O
original	O
locations	O
and	O
growth	O
of	O
the	O
original	O
bud	O
resumes	O
.	O

After	O
recovery	O
from	O
osmotic	O
stress	O
,	O
haploid	O
cells	O
retain	O
an	O
axial	O
pattern	O
of	O
bud	O
site	O
selection	O
while	O
diploids	O
change	O
their	O
bipolar	O
budding	O
pattern	O
to	O
an	O
increased	O
bias	O
for	O
forming	O
a	O
bud	O
on	O
the	O
opposite	O
side	O
of	O
the	O
cell	O
from	O
the	O
previous	O
bud	O
site	O
.	O

Mutants	O
lacking	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
encoded	O
by	O
HOG1	B
or	O
the	O
MAP	O
kinase	O
kinase	O
encoded	O
by	O
PBS2	B
(	O
previously	O
HOG4	B
)	O
show	O
a	O
similar	O
growth	O
arrest	O
after	O
osmotic	O
stress	O
.	O

However	O
,	O
in	O
the	O
recovery	O
phase	O
,	O
the	O
mutant	O
cells	O
(	O
a	O
)	O
do	O
not	O
restart	O
growth	O
of	O
the	O
original	O
bud	O
but	O
rather	O
start	O
a	O
new	O
bud	O
,	O
(	O
b	O
)	O
fail	O
to	O
restore	O
actin	O
filaments	O
to	O
the	O
original	O
bud	O
but	O
move	O
them	O
to	O
the	O
new	O
one	O
,	O
and	O
(	O
c	O
)	O
show	O
a	O
more	O
random	O
budding	O
pattern	O
.	O

These	O
defects	O
are	O
elicited	O
by	O
an	O
increase	O
in	O
osmolarity	O
and	O
not	O
by	O
other	O
environmental	O
stresses	O
(	O
e.g.	O
,	O
heat	O
shock	O
or	O
change	O
in	O
carbon	O
source	O
)	O
that	O
also	O
cause	O
a	O
temporary	O
growth	O
arrest	O
and	O
shift	O
in	O
actin	O
distribution	O
.	O

Thus	O
,	O
the	O
HOG	O
pathway	O
is	O
required	O
for	O
repositioning	O
of	O
the	O
actin	O
cytoskeleton	O
and	O
the	O
normal	O
spatial	O
patterns	O
of	O
cell	O
growth	O
after	O
recovery	O
from	O
osmotic	O
stress	O
.	O

A	O
cDNA	O
clone	O
encoding	O
Arabidopsis	O
thaliana	O
galactokinase	O
was	O
fortuitously	O
isolated	O
during	O
the	O
course	O
of	O
a	O
screen	O
for	O
plant	O
homologues	O
of	O
a	O
Saccharomyces	O
cerevisiae	O
peroxisome	O
assembly	O
gene	O
,	O
PAS9	B
.	O

Clones	O
were	O
sought	O
which	O
restored	O
the	O
ability	O
of	O
pas9	B
cells	O
to	O
grow	O
on	O
oleate	O
as	O
a	O
sole	O
carbon	O
source	O
,	O
as	O
oleate	O
metabolism	O
requires	O
peroxisomal	O
beta	O
-	O
oxidation	O
and	O
therefore	O
functional	O
peroxisomes	O
.	O

Subsequent	O
experiments	O
showed	O
that	O
high	O
level	O
expression	O
of	O
the	O
galactokinase	O
cDNA	O
did	O
not	O
complement	O
the	O
peroxisomal	O
assembly	O
defect	O
,	O
but	O
instead	O
permitted	O
the	O
cells	O
to	O
grow	O
on	O
agar	O
plates	O
in	O
the	O
absence	O
of	O
an	O
external	O
carbon	O
source	O
.	O

Agar	O
plates	O
were	O
shown	O
to	O
contain	O
a	O
small	O
amount	O
of	O
galactose	O
released	O
from	O
the	O
agar	O
as	O
a	O
result	O
of	O
autoclaving	O
.	O

The	O
galactokinase	O
clone	O
was	O
shown	O
to	O
be	O
functional	O
,	O
as	O
it	O
could	O
complement	O
a	O
S.	O
cerevisiae	O
galactokinase	O
mutant	O
.	O

Galactokinase	O
is	O
a	O
single	O
copy	O
gene	O
in	O
Arabidopsis	O
,	O
which	O
has	O
been	O
designated	O
AGK1	O
,	O
and	O
is	O
expressed	O
in	O
all	O
the	O
major	O
organs	O
of	O
the	O
plant	O
.	O

Human	O
cystathionine	O
beta	O
-	O
synthase	O
(	O
CBS	O
;	O
EC	O
4.2.1.22	O
)	O
deficiency	O
results	O
in	O
a	O
recessive	O
genetic	O
disorder	O
whose	O
clinical	O
and	O
biochemical	O
manifestations	O
vary	O
greatly	O
among	O
affected	O
individuals	O
.	O

In	O
an	O
effort	O
to	O
identify	O
and	O
analyze	O
mutations	O
in	O
the	O
human	O
CBS	O
gene	O
,	O
we	O
have	O
developed	O
a	O
yeast	O
expression	O
system	O
for	O
human	O
CBS	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
human	O
cDNA	O
that	O
codes	O
for	O
CBS	O
and	O
have	O
expressed	O
the	O
human	O
CBS	O
protein	O
in	O
yeast	O
cells	O
lacking	O
endogenous	O
CBS	O
.	O

The	O
human	O
enzyme	O
produced	O
in	O
yeast	O
is	O
functional	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
have	O
also	O
cloned	O
and	O
sequenced	O
the	O
yeast	O
gene	O
,	O
CYS4	B
,	O
that	O
codes	O
for	O
CBS	O
.	O

The	O
predicted	O
human	O
and	O
yeast	O
CBS	O
proteins	O
are	O
38	O
%	O
identical	O
and	O
72	O
%	O
similar	O
to	O
each	O
other	O
,	O
as	O
well	O
as	O
sharing	O
significant	O
similarity	O
with	O
bacterial	O
cysteine	O
synthase	O
.	O

These	O
results	O
demonstrate	O
the	O
evolutionary	O
conservation	O
of	O
CBS	O
and	O
establish	O
the	O
utility	O
of	O
a	O
yeast	O
expression	O
system	O
for	O
studying	O
human	O
CBS	O
.	O

It	O
is	O
thought	O
that	O
DNA	O
replication	O
and	O
mitosis	O
in	O
yeast	O
are	O
triggered	O
by	O
oscillations	O
in	O
the	O
level	O
of	O
G1-specific	O
(	O
CLN1	B
and	O
CLN2	B
)	O
and	O
G2-specific	O
(	O
CLB1-CLB4	B
)	O
cyclins	O
,	O
which	O
determine	O
the	O
substrate	O
specificity	O
of	O
the	O
CDC28	B
protein	O
kinase	O
.	O

It	O
is	O
not	O
understood	O
how	O
the	O
time	O
and	O
order	O
of	O
appearance	O
of	O
different	O
cyclin	O
types	O
are	O
determined	O
.	O

We	O
show	O
here	O
that	O
CLB2	B
proteolysis	O
,	O
which	O
is	O
important	O
for	O
transition	O
from	O
mitosis	O
to	O
G1	O
,	O
is	O
not	O
confined	O
to	O
a	O
narrow	O
window	O
at	O
the	O
end	O
of	O
mitosis	O
as	O
previously	O
thought	O
but	O
continues	O
until	O
reactivation	O
of	O
CDC28	B
by	O
CLN	O
cyclins	O
toward	O
the	O
end	O
of	O
the	O
subsequent	O
G1	O
period	O
.	O

Thus	O
,	O
cell	O
cycle	O
-	O
regulated	O
proteolysis	O
prevents	O
accumulation	O
of	O
G2-specific	O
CLB	O
cyclins	O
during	O
G1	O
and	O
thereby	O
ensures	O
that	O
the	O
CLN	O
-	O
associated	O
forms	O
of	O
the	O
CDC28	B
kinase	O
are	O
activated	O
without	O
interference	O
from	O
CLB	O
cyclins	O
.	O

Accumulation	O
of	O
CLN	O
cyclins	O
leads	O
to	O
inactivation	O
of	O
CLB	O
cyclin	O
proteolysis	O
,	O
which	O
is	O
a	O
precondition	O
for	O
subsequent	O
activation	O
of	O
G2-specific	O
B	O
-	O
type	O
cyclins	O
.	O

The	O
RES1	B
-	I
1	I
mutation	O
was	O
isolated	O
on	O
the	O
basis	O
of	O
its	O
ability	O
to	O
allow	O
MATa	O
/	O
MAT	B
alpha	O
diploid	O
Saccharomyces	O
cerevisiae	O
cells	O
to	O
express	O
a	O
late	O
sporulation	O
-	O
regulated	O
gene	O
,	O
SPR3	B
,	O
in	O
the	O
presence	O
of	O
excess	O
copies	O
of	O
RME1	B
.	O

RME1	B
is	O
a	O
repressor	O
of	O
meiosis	O
that	O
is	O
normally	O
expressed	O
in	O
cells	O
that	O
lack	O
the	O
a1	B
/	O
alpha	O
2	O
repressor	O
encoded	O
by	O
MAT	B
.	O

The	O
RES1	B
-	I
1	I
mutation	O
also	O
supports	O
sporulation	O
in	O
mat	B
-	O
insufficient	O
diploids	O
.	O

This	O
phenotype	O
does	O
not	O
result	O
from	O
a	O
failure	O
to	O
express	O
RME1	B
and	O
is	O
not	O
due	O
to	O
activation	O
of	O
the	O
silent	O
copies	O
of	O
mating	O
type	O
information	O
.	O

RES1	B
-	I
1	I
activates	O
sporulation	O
by	O
allowing	O
IME1	B
accumulation	O
in	O
all	O
cell	O
types	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
the	O
MAT	B
products	O
.	O

IME1	B
is	O
still	O
responsive	O
to	O
RME1	B
in	O
RES1	B
-	I
1	I
cells	O
,	O
since	O
double	O
mutants	O
(	O
rme1	B
RES1	B
-	I
1	I
)	O
that	O
are	O
deficient	O
at	O
MAT	B
can	O
sporulate	O
better	O
than	O
either	O
single	O
mutant	O
.	O

RES1	B
-	I
1	I
is	O
not	O
an	O
allele	O
of	O
IME1	B
.	O

The	O
Caenorhabditis	O
elegans	O
sex	O
determination	O
gene	O
mog-1	B
encodes	O
a	O
member	O
of	O
the	O
DEAH	O
-	O
Box	O
protein	O
family	O
.	O

In	O
the	O
Caenorhabditis	O
elegans	O
hermaphrodite	O
germ	O
line	O
,	O
the	O
sex	O
-	O
determining	O
gene	O
fem-3	B
is	O
repressed	O
posttranscriptionally	O
to	O
arrest	O
spermatogenesis	O
and	O
permit	O
oogenesis	O
.	O

This	O
repression	O
requires	O
a	O
cis	O
-	O
acting	O
regulatory	O
element	O
in	O
the	O
fem-3	B
3	O
'	O
untranslated	O
region	O
;	O
the	O
FBF	B
protein	O
,	O
which	O
binds	O
to	O
this	O
element	O
;	O
and	O
at	O
least	O
six	O
mog	B
genes	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
molecular	O
characterization	O
of	O
mog-1	B
as	O
well	O
as	O
additional	O
phenotypic	O
characterization	O
of	O
this	O
gene	O
.	O

The	O
mog-1	B
gene	O
encodes	O
a	O
member	O
of	O
the	O
DEAH	O
-	O
box	O
family	O
.	O

Three	O
mog-1	B
alleles	O
possess	O
premature	O
stop	O
codons	O
and	O
are	O
likely	O
to	O
be	O
null	O
alleles	O
,	O
and	O
one	O
is	O
a	O
missense	O
mutation	O
and	O
is	O
likely	O
to	O
retain	O
residual	O
activity	O
.	O

mog-1	B
mRNA	O
is	O
expressed	O
in	O
both	O
germ	O
line	O
and	O
somatic	O
tissues	O
and	O
appears	O
to	O
be	O
ubiquitous	O
.	O

The	O
MOG-1	B
DEAH	O
-	O
box	O
protein	O
is	O
most	O
closely	O
related	O
to	O
proteins	O
essential	O
for	O
splicing	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
but	O
splicing	O
appears	O
to	O
occur	O
normally	O
in	O
a	O
mog-1	B
-	O
null	O
mutant	O
.	O

In	O
addition	O
to	O
its	O
involvement	O
in	O
the	O
sperm	O
-	O
oocyte	O
switch	O
and	O
control	O
of	O
fem-3	B
,	O
zygotic	O
mog-1	B
is	O
required	O
for	O
robust	O
germ	O
line	O
proliferation	O
and	O
for	O
normal	O
growth	O
during	O
development	O
.	O

We	O
suggest	O
that	O
mog-1	B
plays	O
a	O
broader	O
role	O
in	O
RNA	O
regulation	O
than	O
previously	O
considered	O
.	O

A	O
novel	O
PDZ	O
domain	O
containing	O
guanine	B
nucleotide	I
exchange	I
factor	I
links	O
heterotrimeric	B
G	I
proteins	I
to	O
Rho	B
.	O

Small	B
GTP	I
-	I
binding	I
proteins	I
of	I
the	I
Rho	I
family	I
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

However	O
,	O
there	O
is	O
still	O
very	O
limited	O
information	O
on	O
how	O
they	O
are	O
activated	O
by	O
cell	O
surface	O
receptors	O
.	O

Here	O
,	O
we	O
used	O
a	O
consensus	O
sequence	O
for	O
Dbl	B
domains	O
of	O
Rho	B
guanine	I
nucleotide	I
exchange	I
factors	I
(	O
GEFs	B
)	O
to	O
search	O
DNA	O
data	O
bases	O
,	O
and	O
identified	O
a	O
novel	O
human	O
GEF	B
for	O
Rho	B
-	O
related	O
GTPases	B
harboring	O
structural	O
features	O
indicative	O
of	O
its	O
possible	O
regulatory	O
mechanism	O
(	O
s	O
)	O
.	O

This	O
protein	O
contained	O
a	O
tandem	O
DH	O
/	O
PH	O
domain	O
closely	O
related	O
to	O
those	O
of	O
Rho	B
-	I
specific	I
GEFs	I
,	O
a	O
PDZ	O
domain	O
,	O
a	O
proline	O
-	O
rich	O
domain	O
,	O
and	O
an	O
area	O
of	O
homology	O
to	O
Lsc	B
,	O
p115	B
-	I
RhoGEF	I
,	O
and	O
a	O
Drosophila	O
RhoGEF	B
that	O
was	O
termed	O
Lsc	B
-	O
homology	O
(	O
LH	O
)	O
domain	O
.	O

This	O
novel	O
molecule	O
,	O
designated	O
PDZ	B
-	I
RhoGEF	I
,	O
activated	O
biological	O
and	O
biochemical	O
pathways	O
specific	O
for	O
Rho	B
,	O
and	O
activation	O
of	O
these	O
pathways	O
required	O
an	O
intact	O
DH	O
and	O
PH	O
domain	O
.	O

However	O
,	O
the	O
PDZ	O
domain	O
was	O
dispensable	O
for	O
these	O
functions	O
,	O
and	O
mutants	O
lacking	O
the	O
LH	O
domain	O
were	O
more	O
active	O
,	O
suggesting	O
a	O
negative	O
regulatory	O
role	O
for	O
the	O
LH	O
domain	O
.	O

A	O
search	O
for	O
additional	O
molecules	O
exhibiting	O
an	O
LH	O
domain	O
revealed	O
a	O
limited	O
homology	O
with	O
the	O
catalytic	O
region	O
of	O
a	O
newly	O
identified	O
GTPase	B
-	I
activating	I
protein	I
for	O
heterotrimeric	B
G	I
proteins	I
,	O
RGS14	B
.	O

This	O
prompted	O
us	O
to	O
investigate	O
whether	O
PDZ	B
-	I
RhoGEF	I
could	O
interact	O
with	O
representative	O
members	O
of	O
each	O
G	B
protein	I
family	I
.	O

We	O
found	O
that	O
PDZ	B
-	I
RhoGEF	I
was	O
able	O
to	O
form	O
,	O
in	O
vivo	O
,	O
stable	O
complexes	O
with	O
two	O
members	O
of	O
the	O
Galpha12	B
family	I
,	O
Galpha12	B
and	O
Galpha13	B
,	O
and	O
that	O
this	O
interaction	O
was	O
mediated	O
by	O
the	O
LH	O
domain	O
.	O

Furthermore	O
,	O
we	O
obtained	O
evidence	O
to	O
suggest	O
that	O
PDZ	B
-	I
RhoGEF	I
mediates	O
the	O
activation	O
of	O
Rho	B
by	O
Galpha12	B
and	O
Galpha13	B
.	O

Together	O
,	O
these	O
findings	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
the	O
large	O
family	O
of	O
cell	O
surface	O
receptors	O
that	O
transmit	O
signals	O
through	O
heterotrimeric	B
G	I
proteins	I
activate	O
Rho	B
-	O
dependent	O
pathways	O
:	O
by	O
stimulating	O
the	O
activity	O
of	O
members	O
of	O
the	O
Galpha12	B
family	I
which	O
,	O
in	O
turn	O
,	O
activate	O
an	O
exchange	B
factor	I
acting	O
on	O
Rho	B
.	O

The	O
gene	O
bglH	B
present	O
in	O
the	O
bgl	B
operon	I
of	O
Escherichia	O
coli	O
,	O
responsible	O
for	O
uptake	O
and	O
fermentation	O
of	O
beta	O
-	O
glucosides	O
encodes	O
for	O
a	O
carbohydrate	O
-	O
specific	O
outer	O
membrane	O
porin	B
.	O

The	O
cryptic	O
gene	O
bglH	B
from	O
the	O
Escherichia	O
coli	O
chromosome	O
was	O
cloned	O
into	O
a	O
tacOP	O
-	O
driven	O
expression	O
vector	O
.	O

The	O
resulting	O
plasmid	O
was	O
transferred	O
into	O
the	O
porin	B
-	O
deficient	O
E.	O
coli	O
strain	O
KS26	O
and	O
the	O
protein	O
was	O
expressed	O
by	O
addition	O
of	O
IPTG	O
.	O

The	O
BglH	B
protein	O
was	O
localized	O
in	O
the	O
outer	O
membrane	O
.	O

It	O
was	O
purified	O
to	O
homogeneity	O
using	O
standard	O
methods	O
.	O

Reconstitution	O
experiments	O
with	O
lipid	O
bilayer	O
membranes	O
defined	O
BglH	B
as	O
a	O
channel	O
-	O
forming	O
component	O
,	O
i.e.	O
it	O
is	O
an	O
outer	O
membrane	O
porin	B
.	O

The	O
single	O
-	O
channel	O
conductance	O
of	O
BglH	B
(	O
560	O
pS	O
in	O
1	O
M	O
KCl	O
)	O
was	O
only	O
one	O
-	O
third	O
of	O
that	O
of	O
the	O
general	O
diffusion	O
porins	B
of	O
E.	O
coli	O
outer	O
membrane	O
.	O

The	O
presence	O
of	O
carbohydrates	O
in	O
the	O
aqueous	O
phase	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
block	O
of	O
ion	O
transport	O
through	O
the	O
channel	O
,	O
similar	O
to	O
that	O
found	O
for	O
LamB	B
(	O
maltoporin	B
)	O
of	O
E.	O
coli	O
and	O
Salmonella	O
typhimurium	O
,	O
which	O
means	O
that	O
BglH	B
is	O
a	O
porin	B
specific	O
for	O
the	O
uptake	O
of	O
carbohydrates	O
.	O

The	O
binding	O
constants	O
of	O
a	O
variety	O
of	O
different	O
carbohydrates	O
were	O
calculated	O
from	O
titration	O
experiments	O
of	O
the	O
BglH	B
-	O
induced	O
membrane	O
conductance	O
.	O

The	O
tightest	O
binding	O
was	O
observed	O
with	O
the	O
aromatic	O
beta	O
-	O
D	O
-	O
glucosides	O
arbutin	O
and	O
salicin	O
,	O
and	O
with	O
gentibiose	O
and	O
cellobiose	O
.	O

Binding	O
of	O
maltooligosaccharides	O
to	O
BglH	B
was	O
in	O
contrast	O
to	O
their	O
binding	O
to	O
LamB	B
in	O
that	O
it	O
was	O
much	O
weaker	O
,	O
indicating	O
that	O
the	O
binding	O
site	O
of	O
BglH	B
for	O
carbohydrates	O
is	O
different	O
from	O
that	O
of	O
LamB	B
(	O
maltoporin	B
)	O
.	O

The	O
kinetics	O
of	O
cellopentaose	O
binding	O
to	O
BglH	B
was	O
investigated	O
using	O
the	O
carbohydrate	O
-	O
induced	O
current	O
noise	O
and	O
was	O
compared	O
with	O
that	O
of	O
cellopentaose	O
binding	O
to	O
LamB	B
(	O
maltoporin	B
)	O
and	O
ScrY	B
(	O
sucroseporin	B
)	O
.	O

The	O
cyclic	B
AMP	I
receptor	I
protein	I
is	O
dependent	O
on	O
GcvA	B
for	O
regulation	O
of	O
the	O
gcv	B
operon	I
.	O

The	O
Escherichia	O
coli	O
gcv	B
operon	I
is	O
transcriptionally	O
regulated	O
by	O
the	O
GcvA	B
,	O
GcvR	B
,	O
Lrp	B
,	O
and	O
PurR	B
proteins	O
.	O

In	O
this	O
study	O
,	O
the	O
cyclic	B
AMP	I
(	I
cAMP	I
)	I
receptor	I
protein	I
(	O
CRP	B
)	O
is	O
shown	O
to	O
be	O
involved	O
in	O
positive	O
regulation	O
of	O
the	O
gcv	B
operon	I
.	O

A	O
crp	B
deletion	O
reduced	O
expression	O
of	O
a	O
gcvT	B
-	O
lacZ	B
fusion	O
almost	O
fourfold	O
in	O
glucose	O
minimal	O
(	O
GM	O
)	O
medium	O
.	O

The	O
phenotype	O
was	O
complemented	O
by	O
both	O
the	O
wild	O
-	O
type	O
crp	B
gene	O
and	O
four	O
crp	B
alleles	O
that	O
encode	O
proteins	O
with	O
amino	O
acid	O
substitutions	O
in	O
known	O
activating	O
regions	O
of	O
CRP	B
.	O

A	O
cyaA	B
deletion	O
also	O
resulted	O
in	O
a	O
fourfold	O
decrease	O
in	O
gcvT	B
-	O
lacZ	B
expression	O
,	O
and	O
wild	O
-	O
type	O
expression	O
was	O
restored	O
by	O
the	O
addition	O
of	O
cAMP	O
to	O
the	O
growth	O
medium	O
.	O

A	O
cyaA	B
crp	B
double	O
deletion	O
resulted	O
in	O
levels	O
of	O
gcvT	B
-	O
lacZ	B
expression	O
identical	O
to	O
those	O
observed	O
with	O
either	O
single	O
mutation	O
,	O
showing	O
that	O
CRP	B
and	O
cAMP	O
regulate	O
through	O
the	O
same	O
mechanism	O
.	O

Growth	O
in	O
GM	O
medium	O
plus	O
cAMP	O
or	O
glycerol	O
minimal	O
medium	O
did	O
not	O
result	O
in	O
a	O
significant	O
increase	O
in	O
gcvT	B
-	O
lacZ	B
expression	O
.	O

Thus	O
,	O
the	O
level	O
of	O
cAMP	O
present	O
in	O
GM	O
medium	O
appears	O
to	O
be	O
sufficient	O
for	O
regulation	O
by	O
CRP	B
.	O

DNase	B
I	I
footprint	O
analysis	O
showed	O
that	O
CRP	B
binds	O
and	O
protects	O
two	O
sites	O
centered	O
at	O
bp	O
-	O
313	O
(	O
site	O
1	O
)	O
and	O
bp	O
-	O
140	O
(	O
site	O
2	O
)	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
,	O
but	O
a	O
mutational	O
analysis	O
demonstrated	O
that	O
only	O
site	O
1	O
is	O
required	O
for	O
CRP	B
-	O
mediated	O
regulation	O
of	O
gcvT	B
-	O
lacZ	B
expression	O
.	O

Expression	O
of	O
the	O
gcvT	B
-	O
lacZ	B
fusion	O
in	O
a	O
crp	B
gcvA	B
double	O
mutant	O
suggested	O
that	O
CRP	B
's	O
role	O
is	O
dependent	O
on	O
the	O
GcvA	B
protein	O
.	O

Identification	O
of	O
a	O
new	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
family	I
and	O
its	O
receptor	O
,	O
a	O
human	O
ortholog	O
of	O
mouse	O
GITR	B
.	O

The	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
and	I
TNF	I
receptor	I
(	I
TNFR	I
)	I
gene	I
superfamilies	I
regulate	O
diverse	O
biological	O
functions	O
,	O
including	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
[	O
1	O
]	O
[	O
2	O
]	O
[	O
3	O
]	O
.	O

We	O
have	O
identified	O
a	O
new	O
TNF	B
-	O
related	O
ligand	O
,	O
designated	O
human	O
GITR	B
ligand	I
(	O
hGITRL	B
)	O
,	O
and	O
its	O
human	O
receptor	O
(	O
hGITR	B
)	O
,	O
an	O
ortholog	O
of	O
the	O
recently	O
discovered	O
murine	O
glucocorticoid	O
-	O
induced	O
TNFR	B
-	O
related	O
(	O
mGITR	B
)	O
protein	O
[	O
4	O
]	O
.	O

The	O
hGITRL	B
gene	O
mapped	O
to	O
chromosome	O
1q23	O
,	O
near	O
the	O
gene	O
for	O
the	O
TNF	B
homolog	O
Fas	B
/	I
CD95	I
ligand	I
[	O
5	O
]	O
.	O

The	O
hGITR	B
gene	O
mapped	O
to	O
chromosome	O
1p36	O
,	O
near	O
a	O
cluster	O
of	O
five	O
genes	O
encoding	O
TNFR	B
homologs	O
[	O
1	O
]	O
[	O
6	O
]	O
.	O

We	O
found	O
hGITRL	B
mRNA	O
in	O
several	O
peripheral	O
tissues	O
,	O
and	O
detected	O
hGITRL	B
protein	O
on	O
cultured	O
vascular	O
endothelial	O
cells	O
.	O

The	O
levels	O
of	O
hGITR	B
mRNA	O
in	O
tissues	O
were	O
generally	O
low	O
;	O
in	O
peripheral	O
blood	O
T	O
cells	O
,	O
however	O
,	O
antigen	O
-	O
receptor	O
stimulation	O
led	O
to	O
a	O
substantial	O
induction	O
of	O
hGITR	B
transcripts	O
.	O

Cotransfection	O
of	O
hGITRL	B
and	O
hGITR	B
in	O
embryonic	O
kidney	O
293	O
cells	O
activated	O
the	O
anti	O
-	O
apoptotic	O
transcription	O
factor	O
NF	B
-	I
kappaB	I
,	O
via	O
a	O
pathway	O
that	O
appeared	O
to	O
involve	O
TNFR	B
-	I
associated	I
factor	I
2	I
(	O
TRAF2	B
)	O
[	O
7	O
]	O
and	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
(	O
NIK	B
)	O
[	O
8	O
]	O
.	O

Cotransfection	O
of	O
hGITRL	B
and	O
hGITR	B
in	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	O
antigen	O
-	O
receptor	O
-	O
induced	O
cell	O
death	O
.	O

Thus	O
,	O
hGITRL	B
and	O
hGITR	B
may	O
modulate	O
T	O
lymphocyte	O
survival	O
in	O
peripheral	O
tissues	O
.	O

Negative	O
regulation	O
by	O
the	O
Bacillus	O
subtilis	O
GerE	B
protein	O
.	O

GerE	B
is	O
a	O
transcription	B
factor	I
produced	O
in	O
the	O
mother	O
cell	O
compartment	O
of	O
sporulating	O
Bacillus	O
subtilis	O
.	O

It	O
is	O
a	O
critical	O
regulator	O
of	O
cot	B
genes	O
encoding	O
proteins	O
that	O
form	O
the	O
spore	O
coat	O
late	O
in	O
development	O
.	O

Most	O
cot	B
genes	O
,	O
and	O
the	O
gerE	B
gene	O
,	O
are	O
transcribed	O
by	O
sigmaK	B
RNA	B
polymerase	I
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
the	O
GerE	B
protein	O
inhibits	O
transcription	O
in	O
vitro	O
of	O
the	O
sigK	B
gene	O
encoding	O
sigmaK	B
.	O

Here	O
,	O
we	O
show	O
that	O
GerE	B
binds	O
near	O
the	O
sigK	B
transcriptional	O
start	O
site	O
,	O
to	O
act	O
as	O
a	O
repressor	O
.	O

A	O
sigK	B
-	O
lacZ	B
fusion	O
containing	O
the	O
GerE	B
-	O
binding	O
site	O
in	O
the	O
promoter	O
region	O
was	O
expressed	O
at	O
a	O
2	O
-	O
fold	O
lower	O
level	O
during	O
sporulation	O
of	O
wild	O
-	O
type	O
cells	O
than	O
gerE	B
mutant	O
cells	O
.	O

Likewise	O
,	O
the	O
level	O
of	O
SigK	B
protein	O
(	O
i.	O
e.	O
pro	O
-	O
sigmaK	B
and	O
sigmaK	B
)	O
was	O
lower	O
in	O
sporulating	O
wild	O
-	O
type	O
cells	O
than	O
in	O
a	O
gerE	B
mutant	O
.	O

These	O
results	O
demonstrate	O
that	O
sigmaK	B
-	O
dependent	O
transcription	O
of	O
gerE	B
initiates	O
a	O
negative	O
feedback	O
loop	O
in	O
which	O
GerE	B
acts	O
as	O
a	O
repressor	O
to	O
limit	O
production	O
of	O
sigmaK	B
.	O

In	O
addition	O
,	O
GerE	B
directly	O
represses	O
transcription	O
of	O
particular	O
cot	B
genes	O
.	O

We	O
show	O
that	O
GerE	B
binds	O
to	O
two	O
sites	O
that	O
span	O
the	O
-	O
35	O
region	O
of	O
the	O
cotD	B
promoter	O
.	O

A	O
low	O
level	O
of	O
GerE	B
activated	O
transcription	O
of	O
cotD	B
by	O
sigmaK	B
RNA	B
polymerase	I
in	O
vitro	O
,	O
but	O
a	O
higher	O
level	O
of	O
GerE	B
repressed	O
cotD	B
transcription	O
.	O

The	O
upstream	O
GerE	B
-	O
binding	O
site	O
was	O
required	O
for	O
activation	O
but	O
not	O
for	O
repression	O
.	O

These	O
results	O
suggest	O
that	O
a	O
rising	O
level	O
of	O
GerE	B
in	O
sporulating	O
cells	O
may	O
first	O
activate	O
cotD	B
transcription	O
from	O
the	O
upstream	O
site	O
then	O
repress	O
transcription	O
as	O
the	O
downstream	O
site	O
becomes	O
occupied	O
.	O

Negative	O
regulation	O
by	O
GerE	B
,	O
in	O
addition	O
to	O
its	O
positive	O
effects	O
on	O
transcription	O
,	O
presumably	O
ensures	O
that	O
sigmaK	B
and	O
spore	O
coat	O
proteins	O
are	O
synthesized	O
at	O
optimal	O
levels	O
to	O
produce	O
a	O
germination	O
-	O
competent	O
spore	O
.	O

Role	O
of	O
bkdR	B
,	O
a	O
transcriptional	O
activator	O
of	O
the	O
sigL	B
-	O
dependent	O
isoleucine	O
and	O
valine	O
degradation	O
pathway	O
in	O
Bacillus	O
subtilis	O
.	O

A	O
new	O
gene	O
,	O
bkdR	B
(	O
formerly	O
called	O
yqiR	B
)	O
,	O
encoding	O
a	O
regulator	O
with	O
a	O
central	O
(	O
catalytic	O
)	O
domain	O
was	O
found	O
in	O
Bacillus	O
subtilis	O
.	O

This	O
gene	O
controls	O
the	O
utilization	O
of	O
isoleucine	O
and	O
valine	O
as	O
sole	O
nitrogen	O
sources	O
.	O

Seven	O
genes	O
,	O
previously	O
called	O
yqiS	B
,	O
yqiT	B
,	O
yqiU	B
,	O
yqiV	B
,	O
bfmBAA	B
,	O
bfmBAB	B
,	O
and	O
bfmBB	B
and	O
now	O
referred	O
to	O
as	O
ptb	B
,	O
bcd	B
,	O
buk	B
,	O
lpd	B
,	O
bkdA1	B
,	O
bkdA2	B
,	O
and	O
bkdB	B
,	O
are	O
located	O
downstream	O
from	O
the	O
bkdR	B
gene	O
in	O
B.	O
subtilis	O
.	O

The	O
products	O
of	O
these	O
genes	O
are	O
similar	O
to	O
phosphate	B
butyryl	I
coenzyme	I
A	I
transferase	I
,	O
leucine	B
dehydrogenase	I
,	O
butyrate	B
kinase	I
,	O
and	O
four	O
components	O
of	O
the	O
branched	B
-	I
chain	I
keto	I
acid	I
dehydrogenase	I
complex	I
:	I
E3	I
(	O
dihydrolipoamide	B
dehydrogenase	I
)	O
,	O
E1alpha	B
(	I
dehydrogenase	I
)	I
,	O
E1beta	B
(	I
decarboxylase	I
)	I
,	O
and	O
E2	B
(	I
dihydrolipoamide	I
acyltransferase	I
)	I
.	O

Isoleucine	O
and	O
valine	O
utilization	O
was	O
abolished	O
in	O
bcd	B
and	O
bkdR	B
null	O
mutants	O
of	O
B.	O
subtilis	O
.	O

The	O
seven	O
genes	O
appear	O
to	O
be	O
organized	O
as	O
an	O
operon	O
,	O
bkd	B
,	O
transcribed	O
from	O
a	O
-	O
12	O
,	O
-	O
24	O
promoter	O
.	O

The	O
expression	O
of	O
the	O
bkd	B
operon	I
was	O
induced	O
by	O
the	O
presence	O
of	O
isoleucine	O
or	O
valine	O
in	O
the	O
growth	O
medium	O
and	O
depended	O
upon	O
the	O
presence	O
of	O
the	O
sigma	B
factor	I
SigL	B
,	O
a	O
member	O
of	O
the	O
sigma	B
54	I
family	I
.	O

Transcription	O
of	O
this	O
operon	O
was	O
abolished	O
in	O
strains	O
containing	O
a	O
null	O
mutation	O
in	O
the	O
regulatory	O
gene	O
bkdR	B
.	O

Deletion	O
analysis	O
showed	O
that	O
upstream	O
activating	O
sequences	O
are	O
involved	O
in	O
the	O
expression	O
of	O
the	O
bkd	B
operon	I
and	O
are	O
probably	O
the	O
target	O
of	O
bkdR	B
.	O

Transcription	O
of	O
the	O
bkd	B
operon	I
is	O
also	O
negatively	O
controlled	O
by	O
CodY	B
,	O
a	O
global	O
regulator	O
of	O
gene	O
expression	O
in	O
response	O
to	O
nutritional	O
conditions	O
.	O

The	O
acid	O
-	O
inducible	O
asr	B
gene	O
in	O
Escherichia	O
coli	O
:	O
transcriptional	O
control	O
by	O
the	O
phoBR	B
operon	I
.	O

Escherichia	O
coli	O
responds	O
to	O
external	O
acidification	O
(	O
pH	O
4.0	O
to	O
5.0	O
)	O
by	O
synthesizing	O
a	O
newly	O
identified	O
,	O
approximately	O
450	O
-	O
nucleotide	O
RNA	O
component	O
.	O

At	O
maximal	O
levels	O
of	O
induction	O
it	O
is	O
one	O
of	O
the	O
most	O
abundant	O
small	O
RNAs	O
in	O
the	O
cell	O
and	O
is	O
relatively	O
stable	O
bacterial	O
RNA	O
.	O

The	O
acid	O
-	O
inducible	O
RNA	O
was	O
purified	O
,	O
and	O
the	O
gene	O
encoding	O
it	O
,	O
designated	O
asr	B
(	O
for	O
acid	B
shock	I
RNA	I
)	O
,	O
mapped	O
at	O
35.98	O
min	O
on	O
the	O
E.	O
coli	O
chromosome	O
.	O

Analysis	O
of	O
the	O
asr	B
DNA	O
sequence	O
revealed	O
an	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
111	O
-	O
amino	O
-	O
acid	O
polypeptide	O
with	O
a	O
deduced	O
molecular	O
mass	O
of	O
approximately	O
11.6	O
kDa	O
.	O

According	O
to	O
computer	O
-	O
assisted	O
analysis	O
,	O
the	O
predicted	O
polypeptide	O
contains	O
a	O
typical	O
signal	O
sequence	O
of	O
30	O
amino	O
acids	O
and	O
might	O
represent	O
either	O
a	O
periplasmic	O
or	O
an	O
outer	O
membrane	O
protein	O
.	O

The	O
asr	B
gene	O
cloned	O
downstream	O
from	O
a	O
T7	O
promoter	O
was	O
translated	O
in	O
vivo	O
after	O
transcription	O
using	O
a	O
T7	O
RNA	B
polymerase	I
transcription	O
system	O
.	O

Expression	O
of	O
a	O
plasmid	O
-	O
encoded	O
asr	B
:	O
:	O
lacZ	B
fusion	O
under	O
a	O
native	O
asr	O
promoter	O
was	O
reduced	O
approximately	O
15	O
-	O
fold	O
in	O
a	O
complex	O
medium	O
,	O
such	O
as	O
Luria	O
-	O
Bertani	O
medium	O
,	O
versus	O
the	O
minimal	O
medium	O
.	O

Transcription	O
of	O
the	O
chromosomal	O
asr	O
was	O
abolished	O
in	O
the	O
presence	O
of	O
a	O
phoB	B
-	O
phoR	B
(	O
a	O
two	O
-	O
component	O
regulatory	O
system	O
,	O
controlling	O
the	O
pho	B
regulon	O
inducible	O
by	O
phosphate	O
starvation	O
)	O
deletion	O
mutant	O
.	O

Acid	O
-	O
mediated	O
induction	O
of	O
the	O
asr	B
gene	O
in	O
the	O
Delta	O
(	O
phoB	B
-	O
phoR	B
)	O
mutant	O
strain	O
was	O
restored	O
by	O
introduction	O
of	O
the	O
plasmid	O
with	O
cloned	O
phoB	B
-	O
phoR	B
genes	O
.	O

Primer	O
extension	O
analysis	O
of	O
the	O
asr	B
transcript	O
revealed	O
a	O
region	O
similar	O
to	O
the	O
Pho	B
box	O
(	O
the	O
consensus	O
sequence	O
found	O
in	O
promoters	O
transcriptionally	O
activated	O
by	O
the	O
PhoB	B
protein	O
)	O
upstream	O
from	O
the	O
determined	O
transcription	O
start	O
.	O

The	O
asr	B
promoter	O
DNA	O
region	O
was	O
demonstrated	O
to	O
bind	O
PhoB	B
protein	O
in	O
vitro	O
.	O

We	O
discuss	O
our	O
results	O
in	O
terms	O
of	O
how	O
bacteria	O
might	O
employ	O
the	O
phoB	B
-	O
phoR	B
regulatory	O
system	O
to	O
sense	O
an	O
external	O
acidity	O
and	O
regulate	O
transcription	O
of	O
the	O
asr	B
gene	O
.	O

Double	O
blind	O
,	O
randomised	O
study	O
of	O
continuous	O
terbinafine	O
compared	O
with	O
intermittent	O
itraconazole	O
in	O
treatment	O
of	O
toenail	O
onychomycosis	O
.	O

The	O
LION	O
Study	O
Group	O
.	O

OBJECTIVE	O
:	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
continuous	O
terbinafine	O
with	O
intermittent	O
itraconazole	O
in	O
the	O
treatment	O
of	O
toenail	O
onychomycosis	O
.	O

DESIGN	O
:	O

Prospective	O
,	O
randomised	O
,	O
double	O
blind	O
,	O
double	O
dummy	O
,	O
multicentre	O
,	O
parallel	O
group	O
study	O
lasting	O
72	O
weeks	O
.	O

SETTING	O
:	O

35	O
centres	O
in	O
six	O
European	O
countries	O
.	O

SUBJECTS	O
:	O

496	O
patients	O
aged	O
18	O
to	O
75	O
years	O
with	O
a	O
clinical	O
and	O
mycological	O
diagnosis	O
of	O
dermatophyte	O
onychomycosis	O
of	O
the	O
toenail	O
.	O

INTERVENTIONS	O
:	O

Study	O
patients	O
were	O
randomly	O
divided	O
into	O
four	O
parallel	O
groups	O
to	O
receive	O
either	O
terbinafine	O
250	O
mg	O
a	O
day	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
T12	O
and	O
T16	O
)	O
or	O
itraconazole	O
400	O
mg	O
a	O
day	O
for	O
1	O
week	O
in	O
every	O
4	O
weeks	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
I3	O
and	O
I4	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

Assessment	O
of	O
primary	O
efficacy	O
at	O
week	O
72	O
was	O
mycological	O
cure	O
,	O
defined	O
as	O
negative	O
results	O
on	O
microscopy	O
and	O
culture	O
of	O
samples	O
from	O
the	O
target	O
toenail	O
.	O

RESULTS	O
:	O

At	O
week	O
72	O
the	O
mycological	O
cure	O
rates	O
were	O
75.7	O
%	O
(	O
81	O
/	O
107	O
)	O
in	O
the	O
T12	O
group	O
and	O
80	O
.	O
8	O
%	O
(	O
80	O
/	O
99	O
)	O
in	O
the	O
T16	O
group	O
compared	O
with	O
38.3	O
%	O
(	O
41	O
/	O
107	O
)	O
in	O
the	O
I3	O
group	O
and	O
49.1	O
%	O
(	O
53	O
/	O
108	O
)	O
in	O
the	O
I4	O
group	O
.	O

All	O
comparisons	O
(	O
T12	O
v	O
I3	O
,	O
T12	O
v	O
I4	O
,	O
T16	O
v	O
I3	O
,	O
T16	O
v	O
I4	O
)	O
showed	O
significantly	O
higher	O
cure	O
rates	O
in	O
the	O
terbinafine	O
groups	O
(	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

Also	O
,	O
all	O
secondary	O
clinical	O
outcome	O
measures	O
were	O
significantly	O
in	O
favour	O
of	O
terbinafine	O
at	O
week	O
72	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
number	O
or	O
type	O
of	O
adverse	O
events	O
recorded	O
in	O
the	O
terbinafine	O
or	O
itraconazole	O
groups	O
.	O

CONCLUSION	O
:	O

Continuous	O
terbinafine	O
is	O
significantly	O
more	O
effective	O
than	O
intermittent	O
itraconazole	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
toenail	O
onychomycosis	O
.	O

[	O
Endotracheal	O
tube	O
cuff	O
pressure	O
.	O
Monitoring	O
during	O
general	O
anesthesia	O
]	O

BACKGROUND	O
:	O

To	O
value	O
changes	O
of	O
endotracheal	O
tube	O
cuff	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
,	O
using	O
standard	O
tubes	O
or	O
Brandt	O
-	O
system	O
tubes	O
.	O

METHODS	O
:	O

Endotracheal	O
cuff	O
pressure	O
during	O
anaesthesia	O
in	O
three	O
groups	O
of	O
patients	O
has	O
been	O
monitored	O
:	O
Group	O
1	O
(	O
n.	O
41	O
)	O
:	O
endotracheal	O
tube	O
with	O
low	O
-	O
pressure	O
cuff	O
using	O
N2O	O
/	O
O2	O
(	O
2:1	O
or	O
1	O
:	O
1	O
)	O
;	O
Group	O
2	O
(	O
n.	O
55	O
)	O
:	O
Brandt	O
's	O
double	O
cuff	O
-	O
tubes	O
using	O
N2O	O
/	O
O2	O
(	O
2	O
:	O
1	O
or	O
1:1	O
)	O
;	O
Group	O
3	O
(	O
n.	O
20	O
-	O
control	O
group	O
)	O
:	O
tubes	O
with	O
low	O
-	O
pressure	O
cuff	O
using	O
O2	O
/	O
air	O
.	O

Values	O
of	O
pressure	O
(	O
M	O
+	O
/-	O
DS	O
:	O
p	O
<	O
0.05	O
)	O
have	O
been	O
compared	O
with	O
ANOVA	O
,	O
Bonferroni	O
's	O
method	O
(	O
p	O
<	O
0.017	O
)	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O

Brandt	O
's	O
double	O
cuff	O
-	O
tubes	O
(	O
G2	O
)	O
succeed	O
in	O
avoiding	O
uncontrolled	O
increase	O
of	O
cuff	O
-	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
.	O

Standard	O
low	O
-	O
pressure	O
tubes	O
(	O
G1	O
)	O
shown	O
increase	O
of	O
cuff	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
which	O
is	O
absent	O
using	O
no	O
N2O	O
(	O
G3	O
)	O
.	O

Molecular	O
characterization	O
of	O
the	O
follicle	O
defects	O
in	O
the	O
growth	B
differentiation	I
factor	I
9	I
-	O
deficient	O
ovary	O
.	O

Growth	B
differentiation	I
factor-9	I
(	O
GDF-9	B
)	O
,	O
a	O
secreted	O
member	O
of	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
superfamily	I
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
mammalian	O
oocyte	O
beginning	O
at	O
the	O
type	O
3a	O
primary	O
follicle	O
stage	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
GDF-9	B
-	O
deficient	O
female	O
mice	O
are	O
infertile	O
because	O
of	O
an	O
early	O
block	O
in	O
folliculogenesis	O
at	O
the	O
type	O
3b	O
primary	O
follicle	O
stage	O
.	O

To	O
address	O
the	O
molecular	O
defects	O
that	O
result	O
from	O
the	O
absence	O
of	O
GDF-9	B
,	O
we	O
have	O
analyzed	O
the	O
expression	O
of	O
several	O
important	O
ovarian	O
marker	O
genes	O
.	O

The	O
major	O
findings	O
of	O
our	O
studies	O
are	O
as	O
follows	O
:	O
1	O
)	O
There	O
are	O
no	O
detectable	O
signals	O
around	O
GDF-9	B
-	O
deficient	O
follicles	O
for	O
several	O
theca	O
cell	O
layer	O
markers	O
[	O
i.e.	O
17alpha	B
-	I
hydroxylase	I
,	O
LH	B
receptor	I
(	O
LHR	B
)	O
,	O
and	O
c	B
-	I
kit	I
,	O
the	O
receptor	O
for	O
kit	B
ligand	I
]	O
.	O

This	O
demonstrates	O
that	O
in	O
the	O
absence	O
of	O
GDF-9	B
,	O
the	O
follicles	O
are	O
incompetent	O
to	O
emit	O
a	O
signal	O
that	O
recruits	O
theca	O
cell	O
precursors	O
to	O
surround	O
the	O
follicle	O
;	O
2	O
)	O
The	O
primary	O
follicles	O
of	O
GDF-9	B
-	O
deficient	O
mice	O
demonstrate	O
an	O
up	O
-	O
regulation	O
of	O
kit	B
ligand	I
and	O
inhibin	B
-	I
alpha	I
.	O

This	O
suggests	O
that	O
these	O
two	O
important	O
secreted	O
growth	B
factors	I
,	O
expressed	O
in	O
the	O
granulosa	O
cells	O
,	O
may	O
be	O
directly	O
regulated	O
in	O
a	O
paracrine	O
fashion	O
by	O
GDF	B
-	I
9	I
.	O

Up	O
-	O
regulation	O
of	O
kit	B
ligand	I
,	O
via	O
signaling	O
through	O
c	B
-	I
kit	I
on	O
the	O
oocyte	O
,	O
may	O
be	O
directly	O
involved	O
in	O
the	O
increased	O
size	O
of	O
GDF-9	B
-	O
deficient	O
oocytes	O
and	O
the	O
eventual	O
demise	O
of	O
the	O
oocyte	O
;	O
3	O
)	O
After	O
loss	O
of	O
the	O
oocyte	O
,	O
the	O
cells	O
of	O
the	O
GDF-9	B
-	O
deficient	O
follicles	O
remain	O
in	O
a	O
steroidogenic	O
cluster	O
that	O
histologically	O
resembles	O
small	O
corpora	O
lutea	O
.	O

However	O
,	O
at	O
the	O
molecular	O
level	O
,	O
these	O
cells	O
are	O
positive	O
for	O
both	O
luteal	O
markers	O
(	O
e.g.	O
LHR	B
and	O
P-450	B
side	I
chain	I
cleavage	I
)	O
and	O
nonluteal	O
markers	O
(	O
e.g.	O
inhibin	B
alpha	I
and	O
P-450	B
aromatase	I
)	O
.	O

This	O
demonstrates	O
that	O
initially	O
the	O
presence	O
of	O
the	O
oocyte	O
prevents	O
the	O
expression	O
of	O
luteinized	O
markers	O
,	O
but	O
that	O
the	O
absence	O
of	O
GDF-9	B
at	O
an	O
early	O
timepoint	O
alters	O
the	O
differentiation	O
program	O
of	O
the	O
granulosa	O
cells	O
;	O
and	O
4	O
)	O
As	O
demonstrated	O
by	O
staining	O
with	O
either	O
proliferating	B
cell	I
nuclear	I
antigen	I
(	O
PCNA	B
)	O
or	O
Ki-67	O
and	O
TUNEL	O
(	O
terminal	B
deoxynucleotidyl	I
transferase	I
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
)	O
labeling	O
,	O
the	O
granulosa	O
cells	O
of	O
GDF-9	B
-	O
deficient	O
type	O
3b	O
primary	O
follicles	O
fail	O
to	O
proliferate	O
but	O
also	O
fail	O
to	O
undergo	O
cell	O
death	O
.	O

This	O
suggests	O
that	O
granulosa	O
cells	O
of	O
type	O
3b	O
follicles	O
require	O
GDF-9	B
for	O
continued	O
growth	O
and	O
also	O
to	O
become	O
competent	O
to	O
undergo	O
apoptosis	O
,	O
possibly	O
through	O
a	O
differentiation	O
event	O
Thus	O
,	O
these	O
studies	O
have	O
enlightened	O
us	O
as	O
to	O
the	O
paracrine	O
roles	O
of	O
GDF-9	B
as	O
well	O
as	O
the	O
normal	O
steps	O
of	O
granulosa	O
cell	O
and	O
theca	O
cell	O
growth	O
and	O
differentiation	O
within	O
ovarian	O
follicles	O
.	O

A	O
novel	O
mechanism	O
for	O
cytokine	B
regulation	O
:	O
screening	O
,	O
selection	O
,	O
and	O
characterization	O
of	O
anticytokine	O
monoclonal	O
and	O
polyclonal	O
autoantibodies	O
.	O

We	O
have	O
recently	O
described	O
an	O
immunoregulatory	O
mechanism	O
involving	O
release	O
of	O
neutralizing	O
autoantibodies	O
(	O
Aab	O
)	O
to	O
cytokines	B
during	O
bacterial	O
infections	O
.	O

Intraperitoneal	O
inoculation	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
Hib	O
)	O
into	O
Sprague	O
-	O
Dawley	O
rats	O
resulted	O
in	O
high	O
levels	O
of	O
inflammatory	O
mediators	O
early	O
after	O
infection	O
.	O

Increased	O
titers	O
of	O
cytokine	B
Aab	O
were	O
observed	O
,	O
with	O
a	O
peak	O
at	O
day	O
7	O
.	O

We	O
cloned	O
Aab	O
-	O
producing	O
B	O
cells	O
.	O

Screening	O
of	O
the	O
clones	O
with	O
five	O
different	O
cytokines	B
resulted	O
in	O
detection	O
of	O
Aab	O
-	O
producing	O
clones	O
reactive	O
with	O
each	O
cytokine	B
.	O

After	O
repeated	O
subcloning	O
,	O
monoclonal	O
Aab	O
(	O
mAab	O
)	O
were	O
selected	O
and	O
characterized	O
for	O
their	O
specificity	O
,	O
isotypes	O
,	O
and	O
affinities	O
.	O

To	O
elucidate	O
regulatory	O
importance	O
,	O
mAab	O
to	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
dose	O
-	O
dependently	O
inhibited	O
IFN	B
-	I
gamma	I
-	O
induced	O
MHC	B
expression	O
by	O
peritoneal	O
macrophages	O
and	O
TNF	B
-	I
alpha	I
-	O
induced	O
thymocyte	O
proliferation	O
,	O
respectively	O
.	O

Fab	O
fragments	O
exhibited	O
binding	O
and	O
neutralizing	O
effects	O
,	O
confirming	O
specificities	O
.	O

Cross	O
-	O
reactivity	O
with	O
other	O
rat	O
cytokines	B
was	O
excluded	O
.	O

Pools	O
of	O
clones	O
containing	O
several	O
mAab	O
to	O
each	O
cytokine	B
were	O
obtained	O
and	O
served	O
as	O
polyclonal	O
Aab	O
.	O

The	O
relative	O
affinity	O
of	O
the	O
Aab	O
was	O
determined	O
and	O
found	O
to	O
be	O
of	O
high	O
index	O
.	O

The	O
characterized	O
Aab	O
were	O
tested	O
in	O
methodologic	O
assays	O
for	O
cytokine	B
detection	O
,	O
revealing	O
that	O
some	O
Aab	O
were	O
useful	O
in	O
a	O
cell	O
release	O
capturing	O
(	O
CRC	O
)	O
ELISA	O
.	O

ZntR	B
is	O
an	O
autoregulatory	O
protein	O
and	O
negatively	O
regulates	O
the	O
chromosomal	O
zinc	O
resistance	O
operon	B
znt	I
of	O
Staphylococcus	O
aureus	O
.	O

A	O
chromosomally	O
encoded	O
znt	B
operon	I
of	O
Staphylococcus	O
aureus	O
consists	O
of	O
two	O
consecutive	O
putative	O
genes	O
designated	O
zntR	B
and	O
zntA	B
.	O

The	O
zntA	B
gene	O
encodes	O
a	O
transmembrane	O
protein	O
that	O
facilitates	O
extrusion	O
of	O
Zn2	O
+	O
and	O
Co2	O
+	O
,	O
whereas	O
the	O
zntR	B
gene	O
encodes	O
a	O
putative	O
regulatory	O
protein	O
that	O
controls	O
the	O
expression	O
of	O
the	O
znt	B
operon	I
.	O

The	O
zntR	B
gene	O
was	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
into	O
Escherichia	O
coli	O
for	O
overexpression	O
as	O
His	O
-	O
tagged	O
ZntR	B
and	O
purified	O
by	O
Ni2	O
+	O
-	O
affinity	O
column	O
.	O

His	O
-	O
tag	O
-	O
free	O
ZntR	B
was	O
purified	O
to	O
near	O
homogeneity	O
after	O
digestion	O
with	O
enterokinase	B
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
the	O
ZntR	B
bound	O
to	O
a	O
fragment	O
of	O
DNA	O
corresponding	O
to	O
the	O
chromosomal	O
znt	B
promoter	O
region	O
with	O
an	O
affinity	O
of	O
about	O
8.0	O
x	O
10	O
-	O
12	O
M	O
.	O

The	O
addition	O
of	O
25	O
microM	O
Zn2	O
+	O
or	O
Co2	O
+	O
in	O
the	O
binding	O
reaction	O
completely	O
or	O
significantly	O
inhibited	O
association	O
of	O
ZntR	B
with	O
the	O
znt	B
promoter	O
.	O

DNase	B
I	I
footprinting	O
assays	O
identified	O
a	O
ZntR	B
binding	O
site	O
encompassing	O
49	O
nucleotides	O
in	O
the	O
znt	B
promoter	O
region	O
that	O
contained	O
repeated	O
TGAA	O
sequences	O
.	O

These	O
sequences	O
have	O
been	O
proposed	O
to	O
be	O
the	O
binding	O
sites	O
for	O
SmtB	B
,	O
a	O
metallorepressor	O
protein	O
from	O
the	O
cyanobacterium	O
Synechococcus	O
,	O
to	O
its	O
corresponding	O
operator	O
/	O
promoter	O
.	O

In	O
vitro	O
transcription	O
assays	O
,	O
using	O
S.	O
aureus	O
RNA	B
polymerase	I
,	O
revealed	O
that	O
ZntR	B
represses	O
transcription	O
from	O
the	O
znt	B
promoter	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
.	O

The	O
EMSAs	O
,	O
DNase	B
I	I
footprinting	O
and	O
in	O
vitro	O
transcription	O
assays	O
indicate	O
that	O
ZntR	B
is	O
a	O
trans	O
-	O
acting	O
repressor	O
protein	O
that	O
binds	O
to	O
the	O
znt	B
promoter	O
region	O
and	O
regulates	O
its	O
own	O
transcription	O
together	O
with	O
that	O
of	O
zntA	B
.	O

Molecular	O
determinants	O
of	O
the	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Alzheimer	O
's	O
beta	B
-	I
amyloid	I
peptide	I
and	O
apolipoprotein	B
E	I
alpha	O
-	O
helices	O
.	O

In	O
a	O
previous	O
work	O
,	O
we	O
predicted	O
and	O
demonstrated	O
that	O
the	O
29	O
-	O
42-residue	O
fragment	O
of	O
beta	B
-	I
amyloid	I
peptide	I
(	O
Abeta	B
peptide	I
)	O
has	O
in	O
vitro	O
capacities	O
close	O
to	O
those	O
of	O
the	O
tilted	O
fragment	O
of	O
viral	O
fusion	O
proteins	O
.	O

We	O
further	O
demonstrated	O
that	O
apolipoprotein	B
E2	I
and	O
E3	O
but	O
not	O
apolipoprotein	B
E4	I
can	O
decrease	O
the	O
fusogenic	O
activity	O
of	O
Abeta	B
(	O
29	O
-	O
42	O
)	O
via	O
a	O
direct	O
interaction	O
.	O

Therefore	O
,	O
we	O
suggested	O
that	O
this	O
fragment	O
is	O
implicated	O
in	O
the	O
neurotoxicity	O
of	O
Abeta	B
and	O
in	O
the	O
protective	O
effects	O
of	O
apolipoprotein	B
E	I
in	O
Alzheimer	O
's	O
disease	O
.	O

Because	O
structurally	O
related	O
apolipoproteins	B
do	O
not	O
interact	O
with	O
the	O
Abeta	B
C	O
-	O
terminal	O
domain	O
but	O
inhibit	O
viral	O
fusion	O
,	O
we	O
suggested	O
that	O
interactions	O
existing	O
between	O
fusogenic	O
peptides	O
and	O
apolipoproteins	B
are	O
selective	O
and	O
responsible	O
for	O
the	O
inhibition	O
of	O
fusion	O
.	O

In	O
this	O
study	O
,	O
we	O
simulated	O
interactions	O
of	O
all	O
amphipathic	O
helices	O
of	O
apolipoproteins	B
E	I
and	I
A	I
-	I
I	I
with	O
Abeta	B
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
fusogenic	O
fragments	O
by	O
molecular	O
modeling	O
.	O

We	O
further	O
calculated	O
cross	O
-	O
interactions	O
that	O
do	O
not	O
inhibit	O
fusion	O
in	O
vitro	O
.	O

The	O
results	O
suggest	O
that	O
interactions	O
of	O
hydrophobic	O
residues	O
are	O
the	O
major	O
event	O
to	O
inhibit	O
the	O
fusogenic	O
capacities	O
of	O
Abeta	B
(	O
29	O
-	O
42	O
)	O
and	O
SIV	O
peptides	O
.	O

Selectivity	O
of	O
those	O
interactions	O
is	O
due	O
to	O
the	O
steric	O
complementarity	O
between	O
bulky	O
hydrophobic	O
residues	O
in	O
the	O
fusogenic	O
fragments	O
and	O
hydrophobic	O
residues	O
in	O
the	O
apolipoprotein	B
C	I
-	O
terminal	O
amphipathic	O
helices	O
.	O

Molecular	O
dissection	O
of	O
the	O
folding	O
mechanism	O
of	O
the	O
alpha	B
subunit	I
of	I
tryptophan	I
synthase	I
:	O
an	O
amino	O
-	O
terminal	O
autonomous	O
folding	O
unit	O
controls	O
several	O
rate	O
-	O
limiting	O
steps	O
in	O
the	O
folding	O
of	O
a	O
single	O
domain	O
protein	O
.	O

The	O
alpha	O
subunit	O
of	O
tryptophan	B
synthase	I
(	O
alphaTS	B
)	O
from	O
Escherichia	O
coli	O
is	O
a	O
268	O
-	O
residue	O
8-stranded	O
beta	O
/	O
alpha	O
barrel	O
protein	O
.	O

Two	O
autonomous	O
folding	O
units	O
,	O
comprising	O
the	O
first	O
six	O
strands	O
(	O
residues	O
1	O
-	O
188	O
)	O
and	O
the	O
last	O
two	O
strands	O
(	O
residues	O
189	O
-	O
268	O
)	O
,	O
have	O
been	O
previously	O
identified	O
in	O
this	O
single	O
structural	O
domain	O
protein	O
by	O
tryptic	O
digestion	O
[	O
Higgins	O
,	O
W.	O
,	O
Fairwell	O
,	O
T.	O
,	O
and	O
Miles	O
,	O
E.	O
W.	O
(	O
1979	O
)	O
Biochemistry	O
18	O
,	O
4827	O
-	O
4835	O
]	O
.	O

The	O
larger	O
,	O
amino	O
-	O
terminal	O
fragment	O
,	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
,	O
was	O
overexpressed	O
and	O
independently	O
purified	O
,	O
and	O
its	O
equilibrium	O
and	O
kinetic	O
folding	O
properties	O
were	O
studied	O
by	O
absorbance	O
,	O
fluorescence	O
,	O
and	O
near	O
-	O
and	O
far	O
-	O
UV	O
circular	O
dichroism	O
spectroscopies	O
.	O

The	O
native	O
state	O
of	O
the	O
fragment	O
unfolds	O
cooperatively	O
in	O
an	O
apparent	O
two	O
-	O
state	O
transition	O
with	O
a	O
stability	O
of	O
3.98	O
+	O
/-	O
0.19	O
kcal	O
mol	O
(	O
-1	O
)	O
in	O
the	O
absence	O
of	O
denaturant	O
and	O
a	O
corresponding	O
m	O
value	O
of	O
1.07	O
+	O
/-	O
0.05	O
kcal	O
mol	O
(	O
-1	O
)	O
M	O
(	O
-1	O
)	O
.	O

Similar	O
to	O
the	O
full	O
-	O
length	O
protein	O
,	O
the	O
unfolding	O
of	O
the	O
fragment	O
shows	O
two	O
kinetic	O
phases	O
which	O
arise	O
from	O
the	O
presence	O
of	O
two	O
discrete	O
native	O
state	O
populations	O
.	O

Additionally	O
,	O
the	O
fragment	O
exhibits	O
a	O
significant	O
burst	O
phase	O
in	O
unfolding	O
,	O
indicating	O
that	O
a	O
fraction	O
of	O
the	O
folded	O
state	O
ensemble	O
under	O
native	O
conditions	O
has	O
properties	O
similar	O
to	O
those	O
of	O
the	O
equilibrium	O
intermediate	O
populated	O
at	O
3	O
M	O
urea	O
in	O
full	O
-	O
length	O
alphaTS	B
.	O

Refolding	O
of	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
is	O
also	O
complex	O
,	O
exhibiting	O
two	O
detectable	O
kinetic	O
phases	O
and	O
a	O
burst	O
phase	O
that	O
is	O
complete	O
within	O
5	O
ms	O
.	O

The	O
two	O
slowest	O
isomerization	O
phases	O
observed	O
in	O
the	O
refolding	O
of	O
the	O
full	O
-	O
length	O
protein	O
are	O
absent	O
in	O
the	O
fragment	O
,	O
suggesting	O
that	O
these	O
phases	O
reflect	O
contributions	O
from	O
the	O
carboxy	O
-	O
terminal	O
segment	O
.	O

The	O
folding	O
mechanism	O
of	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
appears	O
to	O
be	O
a	O
simplified	O
version	O
of	O
the	O
mechanism	O
for	O
the	O
full	O
-	O
length	O
protein	O
[	O
Bilsel	O
,	O
O.	O
,	O
Zitzewitz	O
,	O
J.	O
A.	O
,	O
Bowers	O
,	O
K.E	O
,	O
and	O
Matthews	O
,	O
C.	O
R.	O
(	O
1999	O
)	O
Biochemistry	O
38	O
,	O
1018	O
-	O
1029	O
]	O
.	O

Four	O
parallel	O
channels	O
in	O
the	O
full	O
-	O
length	O
protein	O
are	O
reduced	O
to	O
a	O
pair	O
of	O
channels	O
that	O
most	O
likely	O
reflect	O
a	O
cis	O
/	O
trans	O
proline	O
isomerization	O
reaction	O
in	O
the	O
amino	O
-	O
terminal	O
fragment	O
.	O

The	O
off	O
-	O
and	O
on	O
-	O
pathway	O
intermediates	O
that	O
exist	O
for	O
both	O
full	O
-	O
length	O
alphaTS	B
and	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
may	O
reflect	O
the	O
preponderance	O
of	O
local	O
interactions	O
in	O
the	O
beta	O
/	O
alpha	O
barrel	O
motif	O
.	O

Body	O
fat	O
,	O
caloric	O
intake	O
,	O
and	O
plasma	O
leptin	B
levels	O
in	O
women	O
with	O
anorexia	O
nervosa	O
.	O

OBJECTIVE	O
:	O

To	O
measure	O
serum	O
leptin	B
concentrations	O
in	O
women	O
with	O
anorexia	O
nervosa	O
(	O
AN	O
)	O
and	O
to	O
identify	O
independent	O
predictors	O
of	O
leptin	B
levels	O
,	O
thereby	O
allowing	O
hormone	O
levels	O
to	O
be	O
modeled	O
using	O
regression	O
analysis	O
.	O

METHODS	O
:	O

A	O
cross	O
-	O
sectional	O
study	O
of	O
15	O
AN	O
inpatients	O
and	O
16	O
healthy	O
control	O
subjects	O
.	O

Age	O
,	O
height	O
,	O
weight	O
,	O
percent	O
body	O
fat	O
,	O
total	O
caloric	O
intake	O
,	O
fat	O
intake	O
,	O
and	O
fasting	O
plasma	O
leptin	B
levels	O
were	O
recorded	O
.	O

Stepwise	O
forward	O
regression	O
analysis	O
was	O
carried	O
out	O
to	O
identify	O
predictors	O
of	O
leptin	B
levels	O
.	O

RESULTS	O
:	O

Circulating	O
leptin	B
concentrations	O
in	O
AN	O
were	O
3.5	O
+	O
/-	O
0.5	O
versus	O
7.6	O
+	O
/-	O
1.2	O
ng	O
/	O
ml	O
in	O
control	O
subjects	O
.	O

Percent	O
body	O
fat	O
correlated	O
best	O
with	O
leptin	B
levels	O
in	O
anorexic	O
and	O
control	O
subjects	O
(	O
r	O
=	O
.63	O
;	O
p	O
=	O
.0002	O
)	O
,	O
with	O
caloric	O
intake	O
showing	O
only	O
a	O
moderate	O
correlation	O
(	O
r	O
=	O
.47	O
;	O
p	O
=	O
.008	O
)	O
.	O

Only	O
percent	O
body	O
fat	O
was	O
a	O
significant	O
predictor	O
of	O
plasma	O
leptin	B
levels	O
in	O
our	O
regression	O
model	O
.	O

DISCUSSION	O
:	O

Leptin	B
levels	O
are	O
proportionately	O
lower	O
in	O
AN	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

It	O
appears	O
that	O
physiological	O
regulation	O
of	O
plasma	O
levels	O
with	O
respect	O
to	O
percent	O
body	O
fat	O
is	O
maintained	O
in	O
individuals	O
with	O
little	O
body	O
fat	O
.	O

Transcription	O
of	O
genes	O
near	O
the	O
sspE	B
locus	O
of	O
the	O
Bacillus	O
subtilis	O
genome	O
.	O

The	O
yfhP	B
,	O
yfhQ	B
(	O
mutY	B
homologue	O
)	O
,	O
yfhS	B
and	O
yfhR	B
(	O
oxidoreductase	B
homologue	O
)	O
genes	O
,	O
which	O
are	O
located	O
upstream	O
of	O
the	O
sspE	B
locus	O
,	O
have	O
been	O
identified	O
in	O
the	O
Bacillus	O
subtilis	O
genome	O
.	O

Transcriptional	O
analysis	O
showed	O
that	O
yfhP	B
,	O
yfhQ	B
and	O
yfhR	B
are	O
transcribed	O
during	O
the	O
exponential	O
growth	O
phase	O
,	O
and	O
sspE	B
is	O
monocistronically	O
transcribed	O
in	O
the	O
late	O
sporulation	O
phase	O
and	O
co	O
-	O
transcribed	O
with	O
yfhQ	B
and/or	O
yfhR	B
during	O
exponential	O
growth	O
.	O

However	O
,	O
SspE	B
was	O
not	O
translated	O
during	O
this	O
period	O
.	O

Northern	O
blot	O
and	O
primer	O
extension	O
analyses	O
indicated	O
that	O
yfhS	B
is	O
transcribed	O
by	O
E	B
sigma	I
E	I
during	O
sporulation	O
.	O

No	O
significant	O
difference	O
between	O
wild	O
-	O
type	O
and	O
yfhS	B
mutant	O
strains	O
was	O
found	O
in	O
the	O
rate	O
of	O
sporulation	O
or	O
germination	O
,	O
the	O
heat	O
tolerance	O
of	O
spores	O
or	O
the	O
transcription	O
of	O
the	O
sspE	B
locus	O
during	O
sporulation	O
.	O

The	O
transcription	O
of	O
the	O
yfhP	B
and	O
yfhQ	B
-	O
yfhR	B
-	O
sspE	B
loci	O
increased	O
2.5	O
-	O
and	O
5.3	O
-	O
fold	O
in	O
a	O
yfhP	B
-	O
deficient	O
strain	O
compared	O
to	O
the	O
wild	O
-	O
type	O
strain	O
at	O
t-2	O
(	O
2	O
h	O
before	O
initiation	O
of	O
sporulation	O
)	O
.	O

In	O
addition	O
,	O
transcription	O
corresponding	O
to	O
the	O
yfhR	B
-	O
sspE	B
loci	O
increased	O
more	O
than	O
twofold	O
with	O
maximum	O
values	O
observed	O
at	O
t	O
-	O
1.5	O
.	O

These	O
results	O
suggest	O
that	O
YfhP	B
may	O
act	O
as	O
a	O
negative	O
regulator	O
for	O
the	O
transcription	O
of	O
yfhQ	B
,	O
yfhR	B
,	O
sspE	B
and	O
yfhP	B
.	O

Cytoskeletal	O
reorganization	O
leads	O
to	O
induction	O
of	O
the	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
gene	O
by	O
activating	O
FAK	B
and	O
Src	B
and	O
subsequently	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
cytoskeletal	O
reorganization	O
(	O
CSR	O
)	O
induced	O
by	O
colchicine	O
or	O
cyochalasins	O
leads	O
to	O
activation	O
of	O
the	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
(	O
uPA	B
)	O
gene	O
in	O
LLC	O
-	O
PK	O
(	O
1	O
)	O
cells	O
via	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
[	O
Irigoyen	O
et	O
al.	O
(	O
1997	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
1904	O
]	O
.	O

It	O
remained	O
to	O
be	O
seen	O
how	O
CSR	O
activates	O
Ras	B
/	O
Erk	B
signaling	O
.	O

Changes	O
in	O
cell	O
morphology	O
triggered	O
by	O
extracellular	O
signals	O
are	O
often	O
mediated	O
by	O
integrin	B
-	O
associated	O
proteins	O
,	O
such	O
as	O
focal	B
adhesion	I
kinase	I
(	O
FAK	B
)	O
and	O
Src	B
.	O

We	O
found	O
that	O
CSR	O
induced	O
the	O
activation	O
of	O
FAK	B
and	O
Src	B
and	O
the	O
association	O
of	O
FAK	B
and	O
Shc	B
,	O
a	O
signaling	O
molecule	O
linking	O
growth	B
factor	I
receptor	I
tyrosine	I
kinase	I
and	O
Grb2	B
.	O

Furthermore	O
,	O
expression	O
of	O
either	O
FRNK	B
,	O
a	O
kinase	B
-	O
minus	O
FAK	B
-	O
like	O
molecule	O
acting	O
as	O
a	O
dominant	O
negative	O
FAK	B
,	O
or	O
a	O
dominant	O
negative	O
Src	B
suppressed	O
CSR	O
-	O
induced	O
uPA	B
gene	O
promoter	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
cells	O
respond	O
to	O
a	O
morphology	O
change	O
,	O
using	O
the	O
cytoskeleton	O
as	O
a	O
sensor	O
,	O
by	O
activating	O
FAK	B
and	O
Src	B
and	O
subsequently	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
cytokines	B
and	O
soluble	O
cytokine	B
receptors	I
in	O
peripheral	O
blood	O
of	O
patients	O
with	O
juvenile	O
rheumatoid	O
arthritis	O
.	O

Plasma	O
levels	O
of	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
,	O
IL-2	B
,	O
soluble	O
IL-2	B
receptor	I
(	O
sIL-2R	B
)	O
,	O
IL-6	B
,	O
IL-8	B
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
and	O
the	O
p60	B
soluble	I
TNF	I
receptor	I
(	O
sTNFR	B
)	O
were	O
repeatedly	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
in	O
35	O
patients	O
with	O
different	O
subtypes	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
(	O
JRA	O
)	O
during	O
an	O
observation	O
period	O
of	O
up	O
to	O
36	O
months	O
.	O

The	O
data	O
were	O
related	O
to	O
conventional	O
inflammatory	O
parameters	O
and	O
disease	O
activity	O
.	O

Patients	O
with	O
systemic	O
disease	O
showed	O
the	O
most	O
pronounced	O
elevations	O
of	O
plasma	O
cytokines	B
,	O
followed	O
by	O
polyarticular	O
and	O
pauciarticular	O
JRA	O
.	O

Soluble	O
receptors	O
sIL-2R	B
and	O
sTNFR	B
were	O
consistently	O
elevated	O
in	O
patients	O
of	O
all	O
JRA	O
subtypes	O
and	O
indicated	O
disease	O
activity	O
even	O
in	O
patients	O
with	O
normal	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
.	O

In	O
contrast	O
,	O
the	O
determination	O
of	O
IL-1beta	B
,	O
IL-2	B
,	O
IL-8	B
,	O
and	O
TNF	B
-	I
alpha	I
revealed	O
strikingly	O
different	O
individual	O
profiles	O
in	O
patients	O
of	O
the	O
same	O
clinical	O
subtype	O
of	O
JRA	O
and	O
irrespective	O
of	O
disease	O
activity	O
.	O

It	O
is	O
concluded	O
that	O
the	O
determination	O
of	O
sIL-2R	B
and	O
sTNFR	B
may	O
be	O
relevant	O
for	O
monitoring	O
JRA	O
,	O
as	O
they	O
indicate	O
disease	O
activity	O
also	O
in	O
cases	O
with	O
unaltered	O
conventional	O
inflammatory	O
parameters	O
.	O

The	O
different	O
individual	O
cytokine	B
profiles	O
of	O
patients	O
within	O
identical	O
subtypes	O
of	O
disease	O
suggest	O
JRA	O
to	O
be	O
even	O
more	O
heterogeneous	O
than	O
hitherto	O
assumed	O
.	O

The	O
data	O
should	O
be	O
considered	O
in	O
attempts	O
to	O
develop	O
anticytokine	O
strategies	O
in	O
the	O
therapy	O
of	O
JRA	O
.	O

Role	O
of	O
a	O
polycyclic	O
aromatic	O
hydrocarbon	O
bay	O
region	O
ring	O
in	O
modulating	O
DNA	O
adduct	O
structure	O
:	O
the	O
non	O
-	O
bay	O
region	O
(	O
8S,9R,10S	O
,	O
11R	O
)	O
-	O
N	O
(	O
6	O
)	O
-	O
[	O
11-	O
(	O
8,9,10,11-tetrahydro-8,9	O
,	O
10-trihydroxybenz	O
[	O
a	O
]	O
anthracenyl	O
)	O
]	O
-2	O
'	O
-	O
deoxyadenosyl	O
adduct	O
in	O
codon	O
61	O
of	O
the	O
human	O
N	B
-	I
ras	I
protooncogene	O
.	O

The	O
structure	O
of	O
the	O
non	O
-	O
bay	O
region	O
(	O
8S,9R,10S,11R	O
)	O
-N	O
(	O
6	O
)	O
-	O
[	O
11-	O
(	O
8,9,10	O
,	O
11-tetrahydro-8,9,10-trihydroxybenz	O
[	O
a	O
]	O
anthracenyl	O
)	O
]	O
-2'-de	O
oxyadenosyl	O
adduct	O
at	O
X	O
(	O
6	O
)	O
of	O
5'-d	O
(	O
CGGACXAGAAG	O
)	O
-3'.5'-d	O
(	O
CTTCTTGTCCG	O
)	O
-3	O
'	O
,	O
incorporating	O
codons	O
60	O
,	O
61	O
(	O
underlined	O
)	O
,	O
and	O
62	O
of	O
the	O
human	O
N	B
-	I
ras	I
protooncogene	O
,	O
was	O
determined	O
.	O

Molecular	O
dynamics	O
simulations	O
were	O
restrained	O
by	O
475	O
NOEs	O
from	O
(	O
1	O
)	O
H	O
NMR	O
.	O

The	O
benz	O
[	O
a	O
]	O
anthracene	O
moiety	O
intercalated	O
above	O
the	O
5	O
'	O
-	O
face	O
of	O
the	O
modified	O
base	O
pair	O
and	O
from	O
the	O
major	O
groove	O
.	O

The	O
duplex	O
suffered	O
distortion	O
at	O
and	O
immediately	O
adjacent	O
to	O
the	O
adduct	O
site	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
disruption	O
of	O
the	O
Watson	O
-	O
Crick	O
base	O
pairing	O
for	O
X	O
(	O
6	O
)	O
x	O
T	O
(	O
17	O
)	O
and	O
A	O
(	O
7	O
)	O
x	O
T	O
(	O
16	O
)	O
and	O
the	O
increased	O
rise	O
of	O
7.7	O
A	O
between	O
base	O
pairs	O
C	O
(	O
5	O
)	O
x	O
G	O
(	O
18	O
)	O
and	O
X	O
(	O
6	O
)	O
x	O
T	O
(	O
17	O
)	O
.	O

Increased	O
disorder	O
was	O
observed	O
as	O
excess	O
line	O
width	O
of	O
proton	O
resonances	O
near	O
the	O
lesion	O
site	O
.	O

Comparison	O
with	O
the	O
bay	O
region	O
benzo	O
[	O
a	O
]	O
pyrene	O
[	O
Zegar	O
,	O
I.	O
S.	O
,	O
Kim	O
,	O
S.	O
J.	O
,	O
Johansen	O
,	O
T.	O
N.	O
,	O
Horton	O
,	O
P.	O
J.	O
,	O
Harris	O
,	O
C.	O
M.	O
,	O
Harris	O
,	O
T.	O
M.	O
,	O
and	O
Stone	O
,	O
M.	O
P.	O
(	O
1996	O
)	O
Biochemistry	O
35	O
,	O
6212	O
-	O
6224	O
]	O
and	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
[	O
Li	O
,	O
Z.	O
,	O
Mao	O
,	O
H.	O
,	O
Kim	O
,	O
H.	O
-	O
Y.	O
,	O
Tamura	O
,	O
P.	O
J.	O
,	O
Harris	O
,	O
C.	O
M.	O
,	O
Harris	O
,	O
T.	O
M.	O
,	O
and	O
Stone	O
,	O
M.	O
P.	O
(	O
1999	O
)	O
Biochemistry	O
38	O
,	O
2969	O
-	O
2981	O
]	O
adducts	O
with	O
the	O
corresponding	O
stereochemistry	O
and	O
at	O
the	O
same	O
site	O
shows	O
that	O
this	O
non	O
-	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
lesion	O
assumes	O
different	O
base	O
pair	O
geometry	O
,	O
in	O
addition	O
to	O
exhibiting	O
greater	O
disorder	O
.	O

These	O
differences	O
are	O
attributed	O
to	O
the	O
loss	O
of	O
the	O
bay	O
region	O
ring	O
.	O

The	O
results	O
suggest	O
the	O
bay	O
region	O
ring	O
contributes	O
to	O
base	O
stacking	O
interactions	O
at	O
the	O
lesion	O
site	O
.	O

These	O
structural	O
differences	O
between	O
the	O
non	O
-	O
bay	O
and	O
bay	O
region	O
lesions	O
are	O
correlated	O
with	O
site	O
-	O
specific	O
mutagenesis	O
data	O
.	O

The	O
bay	O
region	O
benzo	O
[	O
a	O
]	O
pyrene	O
and	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
adducts	O
were	O
poorly	O
replicated	O
in	O
vivo	O
,	O
and	O
induced	O
A	O
--	O
>	O
G	O
mutations	O
.	O

In	O
contrast	O
,	O
the	O
non	O
-	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
adduct	O
was	O
easily	O
bypassed	O
in	O
vivo	O
and	O
was	O
nonmutagenic	O
.	O

Efficacy	O
of	O
methods	O
for	O
determining	O
ovulation	O
in	O
a	O
natural	O
family	O
planning	O
program	O
.	O

This	O
methodological	O
study	O
aims	O
to	O
evaluate	O
the	O
efficacy	O
of	O
methods	O
used	O
for	O
determining	O
ovulation	O
in	O
a	O
natural	O
family	O
planning	O
in	O
comparison	O
with	O
pelvic	O
ultrasonography	O
.	O

Prospective	O
analysis	O
of	O
ovulation	O
detection	O
methods	O
was	O
conducted	O
with	O
40	O
women	O
.	O

Ovulation	O
-	O
detection	O
methods	O
employed	O
in	O
the	O
study	O
include	O
transvaginal	O
ultrasonography	O
,	O
daily	O
morning	O
urinary	O
luteinizing	B
hormone	I
(	O
LH	B
)	O
determinations	O
,	O
determination	O
of	O
salivary	O
beta	B
-	I
glucuronidase	I
activity	O
,	O
salivary	O
ferning	O
test	O
,	O
determination	O
of	O
cervical	O
mucus	O
levels	O
and	O
characteristics	O
,	O
and	O
measurement	O
of	O
rectal	O
or	O
oral	O
basal	O
body	O
temperature	O
.	O

Results	O
revealed	O
a	O
100	O
%	O
correlation	O
between	O
urinary	O
LH	B
level	O
and	O
ovulation	O
diagnosis	O
obtained	O
from	O
ultrasonographic	O
examination	O
.	O

Other	O
ovulation	O
-	O
detection	O
methods	O
contain	O
the	O
following	O
correlation	O
results	O
:	O
mucus	O
sensations	O
and	O
characteristics	O
,	O
48.3	O
%	O
;	O
alpha	B
-	I
glucuronidase	I
,	O
27.7	O
%	O
;	O
and	O
salivary	O
ferning	O
test	O
,	O
36.8	O
%	O
.	O

These	O
findings	O
draw	O
the	O
researchers	O
to	O
conclude	O
that	O
self	O
-	O
determination	O
of	O
LH	B
levels	O
could	O
be	O
an	O
excellent	O
method	O
in	O
ovulation	O
determination	O
.	O

Outcomes	O
of	O
high	O
-	O
dose	O
chemotherapy	O
and	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
in	O
stage	O
IIIB	O
inflammatory	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O

To	O
evaluate	O
the	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
prognostic	O
factors	O
,	O
and	O
treatment	O
-	O
related	O
mortality	O
of	O
women	O
with	O
stage	O
IIIB	O
inflammatory	O
breast	O
cancer	O
(	O
IBC	O
)	O
treated	O
with	O
combined	O
modality	O
therapy	O
(	O
CMT	O
)	O
and	O
high	O
-	O
dose	O
chemotherapy	O
(	O
HDCT	O
)	O
with	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O

Between	O
1989	O
and	O
1997	O
,	O
47	O
consecutive	O
patients	O
with	O
stage	O
IIIB	O
IBC	O
were	O
treated	O
with	O
CMT	O
and	O
HDCT	O
and	O
were	O
the	O
subject	O
of	O
this	O
retrospective	O
analysis	O
.	O

Chemotherapy	O
was	O
administered	O
to	O
all	O
patients	O
before	O
and/or	O
after	O
definitive	O
surgery	O
.	O

Neoadjuvant	O
and	O
adjuvant	O
chemotherapy	O
was	O
administered	O
to	O
33	O
and	O
34	O
patients	O
,	O
respectively	O
,	O
and	O
20	O
patients	O
received	O
both	O
.	O

All	O
patients	O
received	O
HDCT	O
with	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
,	O
and	O
41	O
patients	O
received	O
locoregional	O
radiation	O
therapy	O
.	O

Tamoxifen	O
was	O
prescribed	O
to	O
patients	O
with	O
estrogen	B
receptor	I
(	O
ER	B
)	O
-	O
positive	O
cancer	O
.	O

RESULTS	O
:	O

The	O
mean	O
duration	O
of	O
follow	O
-	O
up	O
from	O
diagnosis	O
was	O
30	O
months	O
(	O
range	O
,	O
6	O
to	O
91	O
months	O
)	O
and	O
from	O
HDCT	O
was	O
22	O
months	O
(	O
range	O
,	O
0.5	O
to	O
82	O
months	O
)	O
.	O

At	O
30	O
months	O
,	O
the	O
Kaplan	O
-	O
Meier	O
estimates	O
of	O
DFS	O
and	O
OS	O
from	O
diagnosis	O
were	O
57.7	O
%	O
and	O
59.1	O
%	O
,	O
respectively	O
.	O

At	O
4	O
years	O
,	O
the	O
Kaplan	O
-	O
Meier	O
estimates	O
of	O
DFS	O
and	O
OS	O
from	O
diagnosis	O
were	O
51.3	O
%	O
and	O
51.7	O
%	O
,	O
respectively	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
the	O
only	O
factors	O
associated	O
with	O
better	O
survival	O
were	O
favorable	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
(	O
P	O
=	O
.04	O
)	O
and	O
receipt	O
of	O
tamoxifen	O
(	O
P	O
=	O
.06	O
)	O
;	O
however	O
,	O
the	O
benefit	O
of	O
tamoxifen	O
was	O
only	O
demonstrated	O
in	O
patients	O
with	O
ER	B
-	O
positive	O
breast	O
cancer	O
.	O

At	O
last	O
follow	O
-	O
up	O
,	O
28	O
patients	O
(	O
59	O
.	O
6	O
%	O
)	O
were	O
alive	O
and	O
disease	O
-	O
free	O
.	O

Seventeen	O
patients	O
(	O
36.2	O
%	O
)	O
developed	O
recurrent	O
breast	O
cancer	O
.	O

Seventeen	O
patients	O
died	O
:	O
15	O
from	O
disease	O
recurrence	O
and	O
two	O
(	O
4.2	O
%	O
)	O
from	O
treatment	O
-	O
related	O
mortality	O
due	O
to	O
HDCT	O
.	O

CONCLUSION	O
:	O

In	O
this	O
analysis	O
,	O
the	O
early	O
results	O
of	O
treatment	O
with	O
CMT	O
and	O
HDCT	O
compare	O
favorably	O
with	O
other	O
series	O
of	O
patients	O
with	O
stage	O
IIIB	O
IBC	O
treated	O
with	O
CMT	O
alone	O
.	O

These	O
outcomes	O
must	O
be	O
confirmed	O
with	O
longer	O
follow	O
-	O
up	O
and	O
controlled	O
studies	O
.	O

Glycosylation	O
of	O
homologous	O
immunodominant	O
proteins	O
of	O
Ehrlichia	O
chaffeensis	O
and	O
Ehrlichia	O
canis	O
.	O

The	O
glycoprotein	O
genes	O
of	O
Ehrlichia	O
chaffeensis	O
(	O
1	O
,	O
644	O
bp	O
)	O
and	O
Ehrlichia	O
canis	O
(	O
2	O
,	O
064	O
bp	O
)	O
encode	O
proteins	O
of	O
548	O
to	O
688	O
amino	O
acids	O
with	O
predicted	O
molecular	O
masses	O
of	O
only	O
61	O
and	O
73	O
kDa	O
but	O
with	O
electrophoretic	O
mobilities	O
of	O
120	O
kDa	O
(	O
P120	O
)	O
and	O
140	O
kDa	O
(	O
P140	O
)	O
,	O
respectively	O
.	O

The	O
120	O
-	O
kDa	O
protein	O
gene	O
of	O
E.	O
chaffeensis	O
contains	O
four	O
identical	O
240	O
-	O
bp	O
tandem	O
repeat	O
units	O
,	O
and	O
the	O
140	O
-	O
kDa	O
protein	O
gene	O
of	O
E.	O
canis	O
has	O
14	O
nearly	O
identical	O
,	O
tandemly	O
arranged	O
108	O
-	O
bp	O
repeat	O
units	O
.	O

Conserved	O
serine	O
-	O
rich	O
motifs	O
identified	O
in	O
the	O
repeat	O
units	O
of	O
P120	O
and	O
P140	O
were	O
also	O
found	O
in	O
the	O
repeat	O
units	O
of	O
the	O
human	O
granulocytotropic	O
ehrlichiosis	O
agent	O
130	O
-	O
kDa	O
protein	O
and	O
of	O
the	O
fimbria	B
-	I
associated	I
adhesin	I
protein	I
Fap1	I
of	O
Streptococcus	O
parasanguis	O
.	O

Nearly	O
the	O
entire	O
(	O
99	O
%	O
)	O
E.	O
chaffeensis	O
P120	O
gene	O
(	O
1	O
,	O
616	O
bp	O
)	O
,	O
the	O
14	O
-	O
repeat	O
region	O
(	O
78	O
%	O
)	O
of	O
the	O
E.	O
canis	O
P140	O
gene	O
(	O
1	O
,	O
620	O
bp	O
)	O
,	O
and	O
a	O
2	O
-	O
repeat	O
region	O
from	O
the	O
E.	O
chaffeensis	O
P120	O
gene	O
(	O
520	O
bp	O
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
recombinant	O
proteins	O
exhibited	O
molecular	O
masses	O
ranging	O
from	O
1.6	O
to	O
2	O
times	O
larger	O
than	O
those	O
predicted	O
by	O
the	O
amino	O
acid	O
sequences	O
.	O

Antibodies	O
against	O
the	O
recombinant	O
proteins	O
reacted	O
with	O
E.	O
chaffeensis	O
P120	O
and	O
E.	O
canis	O
P140	O
,	O
respectively	O
.	O

Carbohydrate	O
was	O
detected	O
on	O
the	O
E.	O
chaffeensis	O
and	O
E.	O
canis	O
recombinant	O
proteins	O
,	O
including	O
the	O
two	O
-	O
repeat	O
polypeptide	O
region	O
of	O
E.	O
chaffeensis	O
P120	O
.	O

A	O
carbohydrate	O
compositional	O
analysis	O
identified	O
glucose	O
,	O
galactose	O
,	O
and	O
xylose	O
on	O
the	O
recombinant	O
proteins	O
.	O

The	O
presence	O
of	O
only	O
one	O
site	O
for	O
N	O
-	O
linked	O
(	O
Asn	O
-	O
Xaa	O
-	O
Ser	O
/	O
Thr	O
)	O
glycosylation	O
,	O
a	O
lack	O
of	O
effect	O
of	O
N	B
-	I
glycosidase	I
F	I
,	O
the	O
presence	O
of	O
70	O
and	O
126	O
Ser	O
/	O
Thr	O
glycosylation	O
sites	O
in	O
the	O
repeat	O
regions	O
of	O
P120	O
and	O
P140	O
,	O
respectively	O
,	O
and	O
a	O
high	O
molar	O
ratio	O
of	O
carbohydrate	O
to	O
protein	O
suggest	O
that	O
the	O
glycans	O
may	O
be	O
O	O
linked	O
.	O

Flt3	B
ligand	I
(	O
FL	B
)	O
and	O
its	O
influence	O
on	O
immune	O
reactivity	O
.	O

Flt3	B
(	I
fms	I
-	I
like	I
tyrosine	I
kinase	I
3	I
)	I
ligand	I
(	O
FL	B
)	O
is	O
a	O
potent	O
hematopoietic	O
cytokine	B
that	O
affects	O
the	O
growth	O
and	O
differentiation	O
of	O
progenitor	O
and	O
stem	O
cells	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Its	O
capacity	O
to	O
augment	O
strikingly	O
the	O
numbers	O
of	O
dendritic	O
cells	O
(	O
rare	O
antigen	O
-	O
presenting	O
cells	O
that	O
induce	O
and	O
regulate	O
immune	O
responses	O
)	O
in	O
mice	O
and	O
humans	O
has	O
stimulated	O
considerable	O
interest	O
in	O
its	O
value	O
as	O
an	O
investigational	O
tool	O
and	O
therapeutic	O
agent	O
.	O

In	O
this	O
review	O
,	O
we	O
survey	O
the	O
hematopoietic	O
properties	O
and	O
immunobiology	O
of	O
FL	B
,	O
and	O
examine	O
its	O
therapeutic	O
potential	O
.	O

The	O
impact	O
of	O
apolipoprotein	B
E	I
genotypes	O
on	O
age	O
at	O
onset	O
of	O
symptoms	O
and	O
phenotypic	O
expression	O
in	O
Wilson	O
's	O
disease	O
.	O

Wilson	O
's	O
disease	O
is	O
a	O
disorder	O
of	O
biliary	O
copper	O
excretion	O
that	O
may	O
result	O
in	O
severe	O
neurological	O
symptoms	O
and	O
advanced	O
liver	O
disease	O
.	O

The	O
wide	O
variation	O
of	O
phenotypic	O
disease	O
expression	O
can	O
not	O
be	O
fully	O
explained	O
by	O
the	O
different	O
mutations	O
of	O
the	O
Wilson	B
disease	I
gene	I
.	O

In	O
neurological	O
disorders	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
temporal	O
lobe	O
epilepsy	O
and	O
cerebral	O
trauma	O
,	O
the	O
presence	O
of	O
the	O
apolipoprotein	B
E	I
(	O
ApoE	B
)	O
allele	O
epsilon4	O
is	O
associated	O
with	O
an	O
increased	O
vulnerability	O
of	O
the	O
brain	O
to	O
the	O
effects	O
of	O
the	O
disease	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
ApoE	B
genotype	O
epsilon3	O
/	O
3	O
appears	O
to	O
provide	O
moderate	O
neuroprotection	O
.	O

We	O
examined	O
whether	O
this	O
hypothesis	O
holds	O
true	O
for	O
the	O
development	O
of	O
neurological	O
symptoms	O
in	O
patients	O
with	O
Wilson	O
's	O
disease	O
.	O

The	O
ApoE	B
genotype	O
and	O
the	O
H1069Q	O
mutation	O
(	O
the	O
most	O
common	O
in	O
Wilson	O
's	O
disease	O
)	O
status	O
were	O
determined	O
by	O
polymerase	B
chain	O
reaction	O
-	O
based	O
mutation	O
assays	O
in	O
121	O
well	O
-	O
characterized	O
,	O
symptomatic	O
index	O
patients	O
with	O
Wilson	O
's	O
disease	O
.	O

An	O
investigation	O
profile	O
was	O
established	O
in	O
which	O
the	O
patients	O
were	O
grouped	O
according	O
to	O
the	O
clinical	O
symptoms	O
at	O
presentation	O
,	O
the	O
ApoE	B
genotypes	O
and	O
the	O
status	O
of	O
the	O
H1069Q	O
mutation	O
.	O

Fifty	O
-	O
nine	O
per	O
cent	O
of	O
the	O
121	O
patients	O
had	O
the	O
allele	O
combination	O
ApoE	B
epsilon3	O
/	O
3	O
(	O
21	O
%	O
ApoE	B
epsilon3	O
/	O
4	O
,	O
19	O
%	O
ApoE	B
epsilon3	O
/	O
2	O
,	O
1	O
%	O
ApoE	B
epsilon4	O
/	O
2	O
)	O
.	O

The	O
distribution	O
of	O
ApoE	B
genotypes	O
did	O
not	O
deviate	O
from	O
known	O
distributions	O
in	O
healthy	O
European	O
subjects	O
.	O

Within	O
the	O
group	O
of	O
40	O
H1069Q	O
-	O
homozygous	O
patients	O
,	O
the	O
onset	O
of	O
symptoms	O
was	O
significantly	O
delayed	O
in	O
patients	O
with	O
the	O
ApoE	B
epsilon3	O
/	O
3	O
genotype	O
(	O
25	O
+	O
/-	O
6	O
years	O
at	O
presentation	O
)	O
compared	O
with	O
patients	O
with	O
the	O
ApoE	B
epsilon3	O
/	O
4	O
genotype	O
(	O
20	O
+	O
/-	O
3	O
years	O
at	O
presentation	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
ApoE	B
genotype	O
was	O
established	O
as	O
an	O
important	O
factor	O
delaying	O
the	O
onset	O
of	O
neurological	O
and	O
hepatic	O
symptoms	O
,	O
but	O
not	O
modifying	O
phenotypic	O
disease	O
expression	O
in	O
a	O
homogeneous	O
group	O
of	O
patients	O
with	O
Wilson	O
's	O
disease	O
(	O
all	O
H1069Q	O
-	O
homozygotes	O
,	O
similar	O
genetic	O
background	O
)	O
.	O

The	O
presence	O
of	O
ApoE	B
epsilon3	O
/	O
3	O
attenuates	O
clinical	O
manifestations	O
in	O
Wilson	O
's	O
disease	O
by	O
mechanisms	O
which	O
might	O
involve	O
the	O
antioxidant	O
and	O
membrane	O
-	O
stabilizing	O
properties	O
of	O
the	O
ApoE	B
3	O
protein	O
.	O

Expression	O
of	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
hydroxisteroid	I
oxidoreductase	I
in	O
the	O
hippocampus	O
of	O
patients	O
with	O
chronic	O
temporal	O
lobe	O
epilepsy	O
.	O

PURPOSE	O
:	O

The	O
hippocampus	O
is	O
one	O
of	O
the	O
principal	O
target	O
areas	O
for	O
neurosteroidal	O
action	O
,	O
and	O
the	O
major	O
neuroendocrine	O
conversion	O
of	O
progesterone	O
appears	O
to	O
be	O
5alpha	O
-	O
reduction	O
and	O
3alpha	O
-	O
hydroxysteroid	O
oxidoreduction	O
,	O
leading	O
to	O
the	O
potent	O
neurosteroid	O
3alpha,5alpha	O
-	O
tetrahydroxyprogesterone	O
.	O

To	O
investigate	O
whether	O
the	O
human	O
hippocampus	O
is	O
equipped	O
with	O
the	O
enzymes	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
hydroxysteroid	I
oxidoreductase	I
(	O
3alpha	B
-	I
HSOR	I
)	O
,	O
we	O
studied	O
the	O
expression	O
of	O
5alpha	B
-	I
reductase	I
types	I
1	I
and	I
2	I
and	O
3alpha	B
-	I
HSOR	I
types	I
1	I
and	I
2	I
in	O
the	O
resected	O
hippocampi	O
of	O
patients	O
with	O
medically	O
intractable	O
chronic	O
temporal	O
lobe	O
epilepsy	O
.	O

METHODS	O
:	O

We	O
studied	O
tissue	O
specimens	O
from	O
the	O
hippocampi	O
of	O
13	O
women	O
,	O
25	O
men	O
,	O
and	O
four	O
children	O
.	O

Quantification	O
of	O
different	O
mRNAs	O
was	O
achieved	O
by	O
competitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

RESULTS	O
:	O

5Alpha	B
-	I
reductase	I
1	I
mRNA	O
and	O
3alpha	B
-	I
HSOR	I
2	I
mRNA	O
were	O
expressed	O
in	O
hippocampi	O
of	O
children	O
and	O
adults	O
,	O
whereas	O
5alpha	B
-	I
reductase	I
2	I
mRNA	O
and	O
3alpha	B
-	I
HSOR	I
1	I
mRNA	O
were	O
not	O
expressed	O
.	O

Neither	O
5alpha	B
-	I
reductase	I
1	I
mRNA	O
nor	O
3alpha	B
-	I
HSOR	I
2	I
mRNA	O
concentrations	O
in	O
hippocampal	O
tissue	O
showed	O
any	O
statistically	O
significant	O
differences	O
between	O
women	O
and	O
men	O
or	O
between	O
children	O
and	O
adults	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
mRNA	O
expression	O
of	O
the	O
type	B
1	I
isozyme	I
of	I
5alpha	I
-	I
reductase	I
and	O
the	O
type	B
2	I
isozyme	I
of	I
3alpha	I
-	I
HSOR	I
in	O
the	O
human	O
hippocampus	O
.	O

The	O
finding	O
that	O
both	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
HSOR	I
are	O
present	O
in	O
the	O
hippocampus	O
leads	O
us	O
to	O
assume	O
the	O
synthesis	O
of	O
neuroactive	O
steroids	O
in	O
this	O
human	O
brain	O
area	O
.	O

Activation	O
of	O
PLC	B
and	O
PI	B
3	I
kinase	I
by	O
PDGF	B
receptor	I
alpha	I
is	O
not	O
sufficient	O
for	O
mitogenesis	O
and	O
migration	O
in	O
mesangial	O
cells	O
.	O

BACKGROUND	O
:	O

Platelet	B
-	I
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
isoforms	O
act	O
through	O
two	O
distinct	O
cell	O
surface	O
alpha	O
and	O
beta	O
receptors	O
.	O

Glomerular	O
mesangial	O
cells	O
express	O
both	O
receptors	O
.	O

PDGF	B
BB	I
and	O
AB	O
are	O
potent	O
mitogens	O
for	O
glomerular	O
mesangial	O
cells	O
,	O
and	O
PDGF	B
BB	I
stimulates	O
cell	O
migration	O
in	O
a	O
phosphatidylinositol	B
3	I
(	I
PI	I
3	I
)	I
kinase	I
-	O
dependent	O
manner	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PDGF	B
AA	I
on	O
cell	O
migration	O
,	O
PI	B
3	I
kinase	I
and	O
phospholipase	B
C	I
(	O
PLC	B
)	O
activation	O
,	O
and	O
the	O
role	O
of	O
these	O
two	O
enzymes	O
in	O
mediating	O
biological	O
responses	O
in	O
these	O
cells	O
in	O
response	O
to	O
all	O
three	O
isoforms	O
.	O

METHODS	O
:	O

3H	O
-	O
thymidine	O
incorporation	O
and	O
modified	O
Boyden	O
chamber	O
assay	O
were	O
used	O
to	O
determine	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
,	O
respectively	O
,	O
in	O
response	O
to	O
all	O
three	O
PDGF	O
isoforms	O
.	O

Differential	O
activation	O
of	O
alpha	O
and	O
beta	O
receptors	O
was	O
studied	O
by	O
immunecomplex	O
tyrosine	B
kinase	I
assay	O
of	O
corresponding	O
receptor	O
immunoprecipitates	O
.	O

PLC	B
gamma	I
1	I
activity	O
was	O
determined	O
by	O
measuring	O
total	O
inositol	O
phosphates	O
in	O
response	O
to	O
different	O
PDGF	B
isoforms	O
.	O

PI	B
3	I
kinase	I
activity	O
was	O
determined	O
in	O
antiphosphotyrosine	O
or	O
PDGF	B
receptor	I
immunoprecipitates	O
.	O

RESULTS	O
:	O

Both	O
PDGF	B
BB	I
and	O
AB	O
resulted	O
in	O
stimulation	O
of	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
of	O
mesangial	O
cells	O
.	O

AA	O
was	O
neither	O
chemotactic	O
nor	O
mitogenic	O
.	O

However	O
,	O
all	O
three	O
isoforms	O
increased	O
tyrosine	O
phosphorylation	O
of	O
a	O
180	O
kD	O
protein	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
,	O
suggesting	O
activation	O
of	O
respective	O
receptors	O
.	O

Direct	O
immunecomplex	O
tyrosine	B
kinase	I
assay	O
of	O
alpha	O
and	O
beta	O
receptors	O
demonstrated	O
significant	O
activation	O
of	O
both	O
of	O
these	O
receptors	O
when	O
cells	O
are	O
treated	O
with	O
PDGF	B
BB	I
or	O
AB	O
.	O

PDGF	B
AA	I
increased	O
tyrosine	B
kinase	I
activity	O
of	O
the	O
alpha	O
receptor	O
but	O
not	O
the	O
beta	O
receptor	O
.	O

All	O
three	O
isoforms	O
significantly	O
stimulated	O
the	O
production	O
of	O
inositol	O
phosphates	O
with	O
order	O
of	O
potency	O
being	O
BB	O
>	O
AB	O
>	O
AA	O
.	O

PDGF	B
AA	I
also	O
dose	O
dependently	O
stimulated	O
PI	B
3	I
kinase	I
activity	O
measured	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
of	O
treated	O
cells	O
.	O

A	O
comparison	O
of	O
PI	B
3	I
kinase	I
activity	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
from	O
mesangial	O
cells	O
stimulated	O
with	O
three	O
different	O
PDGF	B
isoforms	O
showed	O
significant	O
activation	O
of	O
this	O
enzyme	O
with	O
a	O
decreasing	O
order	O
of	O
activity	O
:	O
BB	O
>	O
AB	O
>	O
AA	O
.	O

CONCLUSION	O
:	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
all	O
three	O
isoforms	O
of	O
PDGF	B
significantly	O
stimulate	O
PLC	B
gamma	I
1	I
and	O
PI	B
3	I
kinase	I
,	O
two	O
enzymes	O
necessary	O
for	O
both	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
.	O

However	O
,	O
activation	O
of	O
alpha	O
receptor	O
by	O
PDGF	B
AA	I
with	O
a	O
subsequent	O
increase	O
in	O
PLC	B
and	O
PI	B
3	I
kinase	I
activities	O
is	O
not	O
sufficient	O
to	O
induce	O
these	O
biological	O
responses	O
in	O
mesangial	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
extent	O
of	O
activation	O
of	O
signal	O
transduction	O
pathways	O
may	O
be	O
a	O
major	O
determinant	O
of	O
the	O
biological	O
activity	O
of	O
different	O
PDGF	B
isoforms	O
in	O
mesangial	O
cells	O
.	O

Elucidating	O
the	O
essential	O
role	O
of	O
the	O
A14	B
phosphoprotein	O
in	O
vaccinia	O
virus	O
morphogenesis	O
:	O
construction	O
and	O
characterization	O
of	O
a	O
tetracycline	O
-	O
inducible	O
recombinant	O
.	O

We	O
have	O
previously	O
reported	O
the	O
construction	O
and	O
characterization	O
of	O
vindH1	O
,	O
an	O
inducible	O
recombinant	O
in	O
which	O
expression	O
of	O
the	O
vaccinia	O
virus	O
H1	B
phosphatase	I
is	O
regulated	O
experimentally	O
by	O
IPTG	O
(	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactopyranoside	O
)	O
(	O
35	O
)	O
.	O

In	O
the	O
absence	O
of	O
H1	B
expression	O
,	O
the	O
transcriptional	O
competence	O
and	O
infectivity	O
of	O
nascent	O
virions	O
are	O
severely	O
compromised	O
.	O

We	O
have	O
sought	O
to	O
identify	O
H1	B
substrates	O
by	O
characterizing	O
proteins	O
that	O
are	O
hyperphosphorylated	O
in	O
H1	B
-	O
deficient	O
virions	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
A14	B
protein	O
,	O
a	O
component	O
of	O
the	O
virion	O
membrane	O
,	O
is	O
indeed	O
an	O
H1	B
phosphatase	I
substrate	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

A14	B
is	O
hyperphosphorylated	O
on	O
serine	O
residues	O
in	O
the	O
absence	O
of	O
H1	B
expression	O
.	O

To	O
enable	O
a	O
genetic	O
analysis	O
of	O
A14	B
's	O
function	O
during	O
the	O
viral	O
life	O
cycle	O
,	O
we	O
have	O
adopted	O
the	O
regulatory	O
components	O
of	O
the	O
tetracycline	O
(	O
TET	O
)	O
operon	O
and	O
created	O
new	O
reagents	O
for	O
the	O
construction	O
of	O
TET	O
-	O
inducible	O
vaccinia	O
virus	O
recombinants	O
.	O

In	O
the	O
context	O
of	O
a	O
virus	O
expressing	O
the	O
TET	B
repressor	I
(	O
tetR	B
)	O
,	O
insertion	O
of	O
the	O
TET	O
operator	O
between	O
the	O
transcriptional	O
and	O
translational	O
start	O
sites	O
of	O
a	O
late	O
viral	O
gene	O
enables	O
its	O
expression	O
to	O
be	O
tightly	O
regulated	O
by	O
TET	O
.	O

We	O
constructed	O
a	O
TET	O
-	O
inducible	O
recombinant	O
for	O
the	O
A14	B
gene	O
,	O
vindA14	O
.	O

In	O
the	O
absence	O
of	O
TET	O
,	O
vindA14	O
fails	O
to	O
form	O
plaques	O
and	O
the	O
24	O
-	O
h	O
yield	O
of	O
infectious	O
progeny	O
is	O
reduced	O
by	O
3	O
orders	O
of	O
magnitude	O
.	O

The	O
infection	O
arrests	O
early	O
during	O
viral	O
morphogenesis	O
,	O
with	O
the	O
accumulation	O
of	O
large	O
numbers	O
of	O
vesicles	O
and	O
the	O
appearance	O
of	O
""""	O
empty	O
""""	O
crescents	O
that	O
appear	O
to	O
adhere	O
only	O
loosely	O
to	O
virosomes	O
.	O

This	O
phenotype	O
corresponds	O
closely	O
to	O
that	O
observed	O
for	O
an	O
IPTG	O
-	O
inducible	O
A14	B
recombinant	O
whose	O
construction	O
and	O
characterization	O
were	O
reported	O
while	O
our	O
work	O
was	O
ongoing	O
(	O
47	O
)	O
.	O

The	O
consistency	O
in	O
the	O
phenotypes	O
seen	O
for	O
the	O
IPTG	O
-	O
and	O
TET	O
-	O
inducible	O
recombinants	O
confirms	O
the	O
efficacy	O
of	O
the	O
TET	O
-	O
inducible	O
system	O
and	O
reinforces	O
the	O
value	O
of	O
having	O
a	O
second	O
,	O
independent	O
system	O
available	O
for	O
generating	O
inducible	O
recombinants	O
.	O

The	O
motif	O
for	O
peptide	O
binding	O
to	O
the	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
-	O
associated	O
class	B
II	I
MHC	I
molecule	O
I	B
-	I
Ag7	I
validated	O
by	O
phage	O
display	O
library	O
.	O

The	O
MHC	B
class	I
II	I
molecule	O
I	B
-	I
Ag7	I
is	O
essential	O
for	O
the	O
development	O
of	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
(	O
IDDM	O
)	O
in	O
the	O
non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mouse	O
but	O
the	O
requirements	O
for	O
peptide	O
binding	O
to	O
I	B
-	I
Ag7	I
are	O
still	O
controversial	O
.	O

We	O
have	O
now	O
isolated	O
I	B
-	I
Ag7	I
-	O
binding	O
phage	O
from	O
a	O
large	O
phage	O
display	O
library	O
encoding	O
random	O
nonamer	O
peptides	O
.	O

Ninety	O
peptide	O
-	O
encoding	O
regions	O
of	O
phage	O
eluted	O
from	O
I	B
-	I
Ag7	I
were	O
sequenced	O
and	O
>	O
75	O
%	O
of	O
the	O
corresponding	O
synthetic	O
peptides	O
bound	O
to	O
I	B
-	I
Ag7	I
.	O

Peptide	O
alignment	O
led	O
to	O
the	O
identification	O
of	O
position	O
-	O
specific	O
anchor	O
residues	O
.	O

Hydrophobic	O
(	O
V	O
and	O
P	O
)	O
and	O
positively	O
charged	O
(	O
K	O
)	O
residues	O
were	O
highly	O
enriched	O
at	O
P6	O
and	O
positively	O
charged	O
(	O
R	O
and	O
K	O
)	O
,	O
aromatic	O
(	O
Y	O
)	O
or	O
hydrophobic	O
(	O
L	O
)	O
residues	O
at	O
P9	O
.	O

In	O
addition	O
,	O
small	O
amino	O
acid	O
residues	O
(	O
G	O
and	O
A	O
)	O
were	O
enriched	O
at	O
P7	O
and	O
G	O
at	O
P8	O
.	O

The	O
primary	O
anchors	O
at	O
P6	O
and	O
P9	O
defining	O
the	O
phage	O
-	O
derived	O
motif	O
were	O
present	O
in	O
most	O
high	O
-	O
affinity	O
I	B
-	I
Ag7	I
-	O
binding	O
peptides	O
from	O
IDDM	O
candidate	O
antigens	O
but	O
only	O
in	O
<	O
or	O
=	O
25	O
%	O
of	O
peptides	O
that	O
were	O
low	O
-	O
affinity	O
binders	O
or	O
failed	O
to	O
bind	O
to	O
I	B
-	I
Ag7	I
.	O

A	O
comparison	O
of	O
these	O
results	O
with	O
the	O
proposed	O
motifs	O
for	O
peptide	O
binding	O
to	O
I	B
-	I
Ag7	I
validates	O
the	O
one	O
we	O
have	O
previously	O
described	O
.	O

The	O
genomic	O
organization	O
,	O
complete	O
mRNA	O
sequence	O
,	O
cloning	O
,	O
and	O
expression	O
of	O
a	O
novel	O
human	O
intracellular	B
membrane	I
-	I
associated	I
calcium	I
-	I
independent	I
phospholipase	I
A	I
(	I
2	I
)	I
.	O

During	O
the	O
sequencing	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
7	O
in	O
the	O
Human	O
Genome	O
Project	O
,	O
a	O
predicted	O
protein	O
product	O
of	O
40	O
kDa	O
was	O
identified	O
,	O
which	O
contained	O
two	O
approximately	O
10	O
-	O
amino	O
acid	O
segments	O
homologous	O
to	O
the	O
ATP	O
and	O
lipase	B
consensus	O
sequences	O
present	O
in	O
the	O
founding	O
members	O
of	O
a	O
family	B
of	I
calcium	I
-	I
independent	I
phospholipases	I
A	I
(	I
2	I
)	I
.	O

Detailed	O
inspection	O
of	O
the	O
identified	O
sequence	O
(	O
residues	O
79	O
,	O
671	O
-	O
109	O
,	O
912	O
GenBank	O
accession	O
no.	O
AC005058	O
)	O
demonstrated	O
that	O
it	O
represented	O
only	O
a	O
partial	O
sequence	O
of	O
a	O
larger	O
undefined	O
polypeptide	O
product	O
.	O

Accordingly	O
,	O
we	O
identified	O
the	O
complete	O
genomic	O
organization	O
of	O
this	O
putative	O
phospholipase	B
A	I
(	I
2	I
)	I
through	O
analyses	O
of	O
previously	O
published	O
expressed	O
sequence	O
tags	O
,	O
PCR	O
of	O
human	O
heart	O
cDNA	O
,	O
and	O
5'-rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

Polymerase	O
chain	O
reaction	O
and	O
Northern	O
blotting	O
demonstrated	O
a	O
3.4	O
-	O
kilobase	O
message	O
,	O
which	O
encoded	O
a	O
polypeptide	O
with	O
a	O
maximum	O
calculated	O
molecular	O
weight	O
of	O
88476.9	O
.	O

This	O
3.4	O
-	O
kilobase	O
message	O
was	O
present	O
in	O
multiple	O
human	O
parenchymal	O
tissues	O
including	O
heart	O
,	O
skeletal	O
muscle	O
,	O
placenta	O
,	O
brain	O
,	O
liver	O
,	O
and	O
pancreas	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
protein	O
encoded	O
by	O
this	O
message	O
in	O
Sf9	O
cells	O
resulted	O
in	O
the	O
production	O
of	O
two	O
proteins	O
of	O
apparent	O
molecular	O
masses	O
of	O
77	O
and	O
63	O
kDa	O
as	O
assessed	O
by	O
Western	O
analyses	O
utilizing	O
immunoaffinity	O
-	O
purified	O
antibody	O
.	O

Membranes	O
from	O
Sf9	O
cells	O
expressing	O
recombinant	O
protein	O
released	O
fatty	O
acid	O
from	O
sn-2-radiolabeled	O
phosphatidylcholine	O
and	O
plasmenylcholine	O
up	O
to	O
10	O
-	O
fold	O
more	O
rapidly	O
than	O
controls	O
.	O

The	O
initial	O
rate	O
of	O
fatty	O
acid	O
release	O
from	O
the	O
membrane	O
fraction	O
was	O
0	O
.	O
3	O
nmol	O
/	O
mg.min	O
.	O

The	O
recombinant	O
protein	O
was	O
entirely	O
calcium	O
-	O
independent	O
,	O
had	O
a	O
pH	O
optimum	O
of	O
8.0	O
,	O
was	O
inhibited	O
by	O
(	O
E	O
)	O
-6-	O
(	O
bromomethylene	O
)	O
-3-	O
(	O
1-naphthalenyl	O
)	O
-2H	O
-	O
tetrahydropyran-2-one	O
(	O
IC	O
(	O
50	O
)	O
=	O
3	O
microM	O
)	O
,	O
and	O
was	O
predominantly	O
present	O
in	O
the	O
membrane	O
-	O
associated	O
fraction	O
.	O

Collectively	O
,	O
these	O
results	O
describe	O
the	O
genomic	O
organization	O
,	O
complete	O
mRNA	O
sequence	O
,	O
and	O
sn-2-lipase	B
activity	O
of	O
a	O
novel	O
intracellular	B
calcium	I
-	I
independent	I
membrane	I
-	I
associated	I
phospholipase	I
A	I
(	I
2	I
)	I
.	O

Specific	O
angiotensin	B
II	I
receptor	I
blockage	O
improves	O
intestinal	O
perfusion	O
during	O
graded	O
hypovolemia	O
in	O
pigs	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
potential	O
of	O
specific	O
angiotensin	B
II	I
subtype	I
1	I
(	I
AT1	I
)	I
receptor	I
blockade	O
to	O
modify	O
the	O
mesenteric	O
hemodynamic	O
response	O
to	O
acute	O
hypovolemia	O
and	O
retransfusion	O
.	O

DESIGN	O
:	O

Prospective	O
,	O
randomized	O
,	O
controlled	O
experimental	O
study	O
.	O

SETTING	O
:	O

University	O
-	O
affiliated	O
animal	O
research	O
laboratory	O
.	O

SUBJECTS	O
:	O

Fasted	O
,	O
anesthetized	O
,	O
ventilated	O
,	O
juvenile	O
domestic	O
pigs	O
of	O
both	O
sexes	O
.	O

INTERVENTIONS	O
:	O

Acute	O
,	O
graded	O
hypovolemia	O
by	O
20	O
%	O
and	O
40	O
%	O
of	O
the	O
total	O
estimated	O
blood	O
volume	O
followed	O
by	O
retransfusion	O
in	O
control	O
animals	O
(	O
CTRL	O
;	O
n	O
=	O
10	O
)	O
and	O
animals	O
pretreated	O
with	O
the	O
AT1	B
receptor	O
blocker	O
candesartan	O
(	O
CAND	O
;	O
n	O
=	O
10	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O

Invasive	O
monitoring	O
of	O
arterial	O
and	O
central	O
venous	O
blood	O
pressures	O
,	O
cardiac	O
output	O
,	O
portal	O
venous	O
blood	O
flow	O
,	O
and	O
jejunal	O
mucosal	O
blood	O
flow	O
.	O

Blood	O
gases	O
were	O
repeatedly	O
analyzed	O
to	O
calculate	O
oxygen	O
delivery	O
and	O
consumption	O
.	O

Thirty	O
minutes	O
after	O
each	O
level	O
of	O
hypovolemia	O
at	O
20	O
%	O
and	O
40	O
%	O
,	O
cardiac	O
output	O
was	O
decreased	O
in	O
CTRL	O
animals	O
from	O
a	O
baseline	O
of	O
2.9	O
+	O
/	O
-	O
0.1	O
to	O
1.8	O
+	O
/	O
-	O
0.2	O
and	O
1.1	O
+	O
/-	O
0.2	O
L	O
/	O
min	O
,	O
with	O
no	O
differences	O
compared	O
with	O
CAND	O
animals	O
.	O

Cardiac	O
output	O
was	O
restored	O
to	O
3.0	O
+	O
/-	O
0.3	O
L	O
/	O
min	O
30	O
mins	O
after	O
retransfusion	O
in	O
CTRL	O
animals	O
,	O
with	O
no	O
significant	O
intergroup	O
differences	O
.	O

Baseline	O
portal	O
venous	O
blood	O
flow	O
(	O
Q	O
(	O
MES	O
)	O
)	O
and	O
jejunal	O
mucosal	O
perfusion	O
(	O
PU	O
(	O
JEJ	O
)	O
)	O
were	O
greater	O
in	O
CAND	O
animals	O
compared	O
with	O
CTRL	O
animals	O
.	O

During	O
graded	O
hypovolemia	O
,	O
CAND	O
animals	O
maintained	O
Q	O
(	O
MES	O
)	O
and	O
PU	O
(	O
JEJ	O
)	O
at	O
significantly	O
higher	O
levels	O
compared	O
with	O
CTRL	O
animals	O
,	O
particularly	O
after	O
40	O
%	O
hemorrhage	O
(	O
+	O
221	O
%	O
and	O
+	O
244	O
%	O
,	O
respectively	O
,	O
relative	O
to	O
the	O
mean	O
values	O
in	O
CTRL	O
animals	O
)	O
.	O

The	O
same	O
pattern	O
was	O
observed	O
after	O
retransfusion	O
.	O

Moreover	O
,	O
the	O
calculated	O
mesenteric	O
critical	O
oxygen	O
delivery	O
was	O
significantly	O
greater	O
in	O
CTRL	O
animals	O
(	O
74	O
mL	O
/	O
min	O
)	O
compared	O
with	O
CAND	O
animals	O
(	O
34	O
mL	O
/	O
min	O
)	O
.	O

No	O
animals	O
died	O
in	O
the	O
CAND	O
group	O
,	O
whereas	O
four	O
animals	O
died	O
during	O
40	O
%	O
hypovolemia	O
or	O
retransfusion	O
in	O
the	O
CTRL	O
group	O
.	O

CONCLUSIONS	O
:	O

Specific	O
AT1	B
blockade	O
before	O
acute	O
hypovolemia	O
significantly	O
ameliorated	O
mesenteric	O
and	O
,	O
in	O
particular	O
,	O
jejunal	O
mucosal	O
hypoperfusion	O
.	O

In	O
addition	O
,	O
cardiovascular	O
stability	O
was	O
improved	O
,	O
and	O
mortality	O
in	O
conjunction	O
with	O
acute	O
hypovolemia	O
and	O
retransfusion	O
could	O
be	O
completely	O
avoided	O
.	O

These	O
findings	O
support	O
a	O
fundamental	O
role	O
of	O
the	O
renin	B
-	O
angiotensin	B
system	O
in	O
the	O
mesenteric	O
response	O
to	O
acute	O
hypovolemia	O
and	O
indicate	O
a	O
substantial	O
interventional	O
potential	O
for	O
candesartan	O
in	O
conjunction	O
with	O
circulatory	O
stress	O
.	O

Monoclonal	O
antibody	O
screening	O
of	O
a	O
phage	O
-	O
displayed	O
random	O
peptide	O
library	O
reveals	O
mimotopes	O
of	O
chemokine	B
receptor	I
CCR5	B
:	O
implications	O
for	O
the	O
tertiary	O
structure	O
of	O
the	O
receptor	O
and	O
for	O
an	O
N	O
-	O
terminal	O
binding	O
site	O
for	O
HIV	O
-	O
1	O
gp120	B
.	O

The	O
chemokine	B
receptor	I
CCR5	B
contains	O
seven	O
transmembrane	O
-	O
spanning	O
domains	O
.	O

It	O
binds	O
chemokines	B
and	O
acts	O
as	O
co	O
-	O
receptor	O
for	O
macrophage	O
(	O
m	O
)	O
-	O
tropic	O
(	O
or	O
R5	O
)	O
strains	O
of	O
HIV-1	O
.	O

Monoclonal	O
antibodies	O
(	O
mAb	O
)	O
to	O
CCR5	B
,	O
3A9	O
and	O
5C7	O
,	O
were	O
used	O
for	O
biopanning	O
a	O
nonapeptide	O
cysteine	O
(	O
C	O
)	O
-	O
constrained	O
phage	O
-	O
displayed	O
random	O
peptide	O
library	O
to	O
ascertain	O
contact	O
residues	O
and	O
define	O
tertiary	O
structures	O
of	O
possible	O
epitopes	O
on	O
CCR5	B
.	O

Reactivity	O
of	O
antibodies	O
with	O
phagotopes	O
was	O
established	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

mAb	O
3A9	O
identified	O
a	O
phagotope	O
C	O
-	O
HASIYDFGS	O
-	O
C	O
(	O
3A9	O
/	O
1	O
)	O
,	O
and	O
5C7	O
most	O
frequently	O
identified	O
C	O
-	O
PHWLRDLRV	O
-	O
C	O
(	O
5C7	O
/	O
1	O
)	O
.	O

Corresponding	O
peptides	O
were	O
synthesized	O
.	O

Phagotopes	O
and	O
synthetic	O
peptides	O
reacted	O
in	O
ELISA	O
with	O
corresponding	O
antibodies	O
and	O
synthetic	O
peptides	O
inhibited	O
antibody	O
binding	O
to	O
the	O
phagotopes	O
.	O

Reactivity	O
by	O
immunofluorescence	O
of	O
3A9	O
with	O
CCR5	B
was	O
strongly	O
inhibited	O
by	O
the	O
corresponding	O
peptide	O
.	O

Both	O
mAb	O
3A9	O
and	O
5C7	O
reacted	O
similarly	O
with	O
phagotopes	O
and	O
the	O
corresponding	O
peptide	O
selected	O
by	O
the	O
alternative	O
mAb	O
.	O

The	O
sequences	O
of	O
peptide	O
inserts	O
of	O
phagotopes	O
could	O
be	O
aligned	O
as	O
mimotopes	O
of	O
the	O
sequence	O
of	O
CCR5	B
.	O

For	O
phage	O
3A9	O
/	O
1	O
,	O
the	O
motif	O
SIYD	O
aligned	O
to	O
residues	O
at	O
the	O
N	O
terminus	O
and	O
FG	O
to	O
residues	O
on	O
the	O
first	O
extracellular	O
loop	O
;	O
for	O
5C7	O
/	O
1	O
,	O
residues	O
at	O
the	O
N	O
terminus	O
,	O
first	O
extracellular	O
loop	O
,	O
and	O
possibly	O
the	O
third	O
extracellular	O
loop	O
could	O
be	O
aligned	O
and	O
so	O
would	O
contribute	O
to	O
the	O
mimotope	O
.	O

The	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
isolated	O
phagotopes	O
showed	O
a	O
CD4	B
-	O
dependent	O
reactivity	O
with	O
gp120	B
of	O
a	O
primary	O
,	O
m	O
-	O
tropic	O
HIV	O
-	O
1	O
isolate	O
.	O

Thus	O
reactivity	O
of	O
antibodies	O
raised	O
to	O
CCR5	B
against	O
phage	O
-	O
displayed	O
peptides	O
defined	O
mimotopes	O
that	O
reflect	O
binding	O
sites	O
for	O
these	O
antibodies	O
and	O
reveal	O
a	O
part	O
of	O
the	O
gp120	B
binding	O
sites	O
on	O
CCR5	B
.	O

nef	B
/	O
long	O
terminal	O
repeat	O
quasispecies	O
from	O
HIV	O
type	O
1	O
-	O
infected	O
Mexican	O
patients	O
with	O
different	O
progression	O
patterns	O
and	O
their	O
pathogenesis	O
in	O
hu	O
-	O
PBL	O
-	O
SCID	O
mice	O
.	O

To	O
examine	O
the	O
genetic	O
features	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
derived	O
from	O
six	O
HIV-1	O
-	O
infected	O
individuals	O
enrolled	O
in	O
the	O
Mexico	O
City	O
Cohort	O
,	O
we	O
cloned	O
and	O
sequenced	O
a	O
505	O
-	O
bp	O
fragment	O
of	O
the	O
proviral	O
LTR	O
from	O
their	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

All	O
patients	O
harbored	O
HIV-1	O
LTR	O
quasispecies	O
corresponding	O
to	O
the	O
B	O
subtype	O
.	O

Three	O
patients	O
with	O
high	O
CD4	B
+	O
T	O
cell	O
counts	O
(	O
>	O
500	O
/	O
mm3	O
)	O
presented	O
LTR	O
sequences	O
with	O
point	O
mutations	O
in	O
the	O
TAR	O
bulge	O
.	O

The	O
LTR	O
sequence	O
from	O
a	O
patient	O
classified	O
as	O
a	O
long	O
-	O
term	O
nonprogressor	O
(	O
LTNP	O
)	O
presented	O
the	O
most	O
frequent	O
naturally	O
occurring	O
length	O
polymorphism	O
(	O
MFNLP	O
)	O
and	O
two	O
substitutions	O
in	O
the	O
TAR	O
region	O
that	O
were	O
predicted	O
to	O
result	O
in	O
two	O
alternative	O
secondary	O
RNA	O
structures	O
.	O

A	O
novel	O
18	O
-	O
bp	O
deletion	O
,	O
which	O
eliminates	O
part	O
of	O
the	O
putative	O
binding	O
site	O
for	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT-1	B
)	O
,	O
was	O
identified	O
in	O
the	O
overlapping	O
nef	B
/	O
LTR	O
sequence	O
derived	O
from	O
a	O
patient	O
progressing	O
to	O
AIDS	O
.	O

This	O
deletion	O
coincides	O
with	O
the	O
ability	O
of	O
this	O
virus	O
to	O
consistently	O
replicate	O
at	O
low	O
levels	O
in	O
vivo	O
(	O
viral	O
load	O
<	O
500	O
RNA	O
copies	O
/	O
ml	O
)	O
and	O
in	O
vitro	O
(	O
unsuccessful	O
virus	O
isolation	O
)	O
.	O

On	O
one	O
occasion	O
,	O
when	O
virus	O
isolation	O
was	O
successful	O
,	O
the	O
18	O
-	O
bp	O
deletion	O
was	O
no	O
longer	O
evident	O
and	O
LTR	O
sequences	O
with	O
intact	O
NFAT-1	B
-	O
binding	O
sites	O
were	O
observed	O
.	O

Inoculation	O
of	O
hu	O
-	O
PBL	O
-	O
SCID	O
mice	O
with	O
viruses	O
from	O
several	O
Mexican	O
patients	O
resulted	O
in	O
differential	O
CD4	B
+	O
T	O
cell	O
depletion	O
patterns	O
15	O
days	O
postinfection	O
,	O
which	O
agree	O
with	O
the	O
in	O
vivo	O
CD4	B
+	O
T	O
cell	O
count	O
data	O
from	O
each	O
patient	O
.	O

[	O
Cloning	O
and	O
expression	O
of	O
the	O
lux	B
-	I
operon	I
of	O
Photorhabdus	O
luminescens	O
,	O
strain	O
Zm1	O
:	O
nucleotide	O
sequence	O
of	O
luxAB	B
genes	O
and	O
basic	O
properties	O
of	O
luciferase	B
]	O

A	O
chromosomal	O
fragment	O
of	O
bacteria	O
Photorhabdus	O
luminescence	O
Zm1	O
,	O
which	O
contains	O
the	O
lux	B
operon	I
,	O
was	O
cloned	O
into	O
the	O
vector	O
pUC18	O
.	O

The	O
hybrid	O
clone	O
containing	O
plasmid	O
pXen7	O
with	O
the	O
EcoRI	B
fragment	O
approximately	O
7	O
-	O
kb	O
was	O
shown	O
to	O
manifest	O
a	O
high	O
level	O
of	O
bioluminescence	O
.	O

By	O
subcloning	O
and	O
restriction	O
analysis	O
of	O
the	O
EcoRI	B
fragment	O
,	O
the	O
location	O
of	O
luxCDABE	B
genes	O
relative	O
to	O
restriction	O
sites	O
was	O
determined	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
DNA	O
fragment	O
containing	O
the	O
luxA	B
and	O
luxB	B
genes	O
encoding	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
of	O
luciferase	B
was	O
determined	O
.	O

A	O
comparison	O
with	O
the	O
nucleotide	O
sequences	O
of	O
luxAB	B
genes	O
in	O
Hm	O
and	O
Hw	O
strains	O
of	O
Ph	O
.	O
luminescence	O
revealed	O
94.5	O
and	O
89.7	O
%	O
homology	O
,	O
respectively	O
.	O

The	O
enterobacterial	O
repetitive	O
intergenic	O
sequence	O
(	O
ERIC	O
)	O
of	O
126	O
bp	O
typical	O
for	O
Hw	O
strains	O
was	O
identified	O
in	O
the	O
spacer	O
between	O
the	O
luxD	B
and	O
luxA	B
genes	O
.	O

The	O
lux	B
operon	I
of	O
Zm1	O
is	O
assumed	O
to	O
emerge	O
through	O
recombination	O
between	O
Hm	O
and	O
Hw	O
strains	O
.	O

Luciferase	B
of	O
Ph	O
.	O
luminescence	O
was	O
shown	O
to	O
possess	O
a	O
high	O
thermal	O
stability	O
:	O
its	O
activity	O
decreased	O
by	O
a	O
factor	O
of	O
10	O
at	O
44	O
degrees	O
C	O
for	O
30	O
min	O
,	O
whereas	O
luciferases	B
of	O
marine	O
bacteria	O
Vibrio	O
fischeri	O
and	O
Vibrio	O
harveyi	O
were	O
inactivated	O
by	O
one	O
order	O
of	O
magnitude	O
at	O
44	O
degrees	O
C	O
for	O
1	O
and	O
6	O
min	O
,	O
respectively	O
.	O

The	O
lux	B
genes	O
of	O
Ph	O
.	O
luminescence	O
are	O
suggested	O
for	O
use	O
in	O
gene	O
engineering	O
and	O
biotechnology	O
.	O

Characterization	O
of	O
human	O
retinal	B
fascin	I
gene	O
(	O
FSCN2	B
)	O
at	O
17q25	O
:	O
close	O
physical	O
linkage	O
of	O
fascin	B
and	O
cytoplasmic	O
actin	B
genes	O
.	O

Retinal	B
fascin	I
is	O
a	O
newly	O
identified	O
photoreceptor	B
-	O
specific	O
paralog	O
of	O
the	O
actin	B
-	O
bundling	O
protein	O
fascin	B
.	O

Fascins	B
crosslink	O
f	B
-	I
actin	I
into	O
highly	O
ordered	O
bundles	O
within	O
dynamic	O
cell	O
extensions	O
such	O
as	O
neuronal	O
growth	O
cone	O
filopodia	O
.	O

We	O
have	O
isolated	O
cDNA	O
and	O
genomic	O
clones	O
of	O
human	O
retinal	B
fascin	I
and	O
characterized	O
the	O
structure	O
of	O
the	O
human	O
retinal	B
fascin	I
gene	O
(	O
FSCN2	B
)	O
.	O

The	O
cDNA	O
predicts	O
a	O
protein	O
of	O
492	O
amino	O
acids	O
and	O
molecular	O
mass	O
55	O
,	O
057	O
that	O
shows	O
94	O
%	O
identity	O
to	O
bovine	O
retinal	B
fascin	I
and	O
56	O
%	O
identity	O
to	O
human	O
fascin	B
.	O

Promoter	O
analysis	O
reveals	O
a	O
consensus	O
retinoic	O
acid	O
response	O
element	O
and	O
several	O
potential	O
binding	O
sites	O
for	O
transcription	B
factors	I
Crx	B
and	O
Nrl	B
,	O
which	O
correlates	O
with	O
the	O
retina	O
-	O
specific	O
expression	O
of	O
FSCN2	B
mRNA	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
and	O
genomic	O
clone	O
sequencing	O
indicate	O
that	O
the	O
FSCN2	B
gene	O
lies	O
within	O
200	O
kb	O
of	O
the	O
actin	B
gene	O
ACTG1	B
at	O
17q25	O
.	O

Database	O
searches	O
revealed	O
that	O
the	O
human	O
fascin	B
gene	O
FSCN1	B
and	O
actin	B
gene	O
ACTB	B
at	O
7p22	O
also	O
coexist	O
within	O
a	O
200	O
-	O
kb	O
genomic	O
clone	O
.	O

The	O
close	O
physical	O
linkage	O
of	O
these	O
fascin	B
/	O
actin	B
gene	O
pairs	O
suggests	O
that	O
they	O
derive	O
from	O
a	O
common	O
gene	O
duplication	O
event	O
and	O
allows	O
comparison	O
of	O
fascin	B
and	O
actin	B
phylogenetic	O
analyses	O
.	O

Finally	O
,	O
a	O
possible	O
link	O
to	O
the	O
retinitis	O
pigmentosa	O
17	O
allele	O
(	O
RP17	O
)	O
at	O
distal	O
17q	O
was	O
excluded	O
by	O
demonstration	O
of	O
multiple	O
independent	O
segregation	O
events	O
in	O
two	O
RP17	O
kindreds	O
.	O

Informative	O
FSCN2	B
polymorphisms	O
were	O
identified	O
and	O
will	O
serve	O
as	O
useful	O
markers	O
in	O
future	O
linkage	O
studies	O
.	O

The	O
likely	O
function	O
of	O
retinal	O
fascin	B
,	O
in	O
light	O
of	O
known	O
fascin	B
roles	O
in	O
other	O
cell	O
types	O
,	O
is	O
to	O
assemble	O
actin	B
microfilaments	O
in	O
support	O
of	O
photoreceptor	B
disk	O
morphogenesis	O
.	O

The	O
chromosomal	O
arsenic	B
resistance	I
genes	O
of	O
Thiobacillus	O
ferrooxidans	O
have	O
an	O
unusual	O
arrangement	O
and	O
confer	O
increased	O
arsenic	O
and	O
antimony	O
resistance	O
to	O
Escherichia	O
coli	O
.	O

The	O
chromosomal	O
arsenic	B
resistance	I
genes	O
of	O
the	O
acidophilic	O
,	O
chemolithoautotrophic	O
,	O
biomining	O
bacterium	O
Thiobacillus	O
ferrooxidans	O
were	O
cloned	O
and	O
sequenced	O
.	O

Homologues	O
of	O
four	O
arsenic	B
resistance	I
genes	O
,	O
arsB	B
,	O
arsC	B
,	O
arsH	B
,	O
and	O
a	O
putative	O
arsR	B
gene	O
,	O
were	O
identified	O
.	O

The	O
T.	O
ferrooxidans	O
arsB	B
(	O
arsenite	O
export	O
)	O
and	O
arsC	B
(	O
arsenate	B
reductase	I
)	O
gene	O
products	O
were	O
functional	O
when	O
they	O
were	O
cloned	O
in	O
an	O
Escherichia	O
coli	O
ars	B
deletion	O
mutant	O
and	O
conferred	O
increased	O
resistance	O
to	O
arsenite	O
,	O
arsenate	O
,	O
and	O
antimony	O
.	O

Therefore	O
,	O
despite	O
the	O
fact	O
that	O
the	O
ars	B
genes	O
originated	O
from	O
an	O
obligately	O
acidophilic	O
bacterium	O
,	O
they	O
were	O
functional	O
in	O
E.	O
coli	O
.	O

Although	O
T.	O
ferrooxidans	O
is	O
gram	O
negative	O
,	O
its	O
ArsC	B
was	O
more	O
closely	O
related	O
to	O
the	O
ArsC	B
molecules	O
of	O
gram	O
-	O
positive	O
bacteria	O
.	O

Furthermore	O
,	O
a	O
functional	O
trxA	B
(	O
thioredoxin	B
)	O
gene	O
was	O
required	O
for	O
ArsC	B
-	O
mediated	O
arsenate	O
resistance	O
in	O
E.	O
coli	O
;	O
this	O
finding	O
confirmed	O
the	O
gram	O
-	O
positive	O
ArsC	B
-	O
like	O
status	O
of	O
this	O
resistance	O
and	O
indicated	O
that	O
the	O
division	O
of	O
ArsC	B
molecules	O
based	O
on	O
Gram	O
staining	O
results	O
is	O
artificial	O
.	O

Although	O
arsH	B
was	O
expressed	O
in	O
an	O
E.	O
coli	O
-	O
derived	O
in	O
vitro	O
transcription	O
-	O
translation	O
system	O
,	O
ArsH	B
was	O
not	O
required	O
for	O
and	O
did	O
not	O
enhance	O
arsenic	O
resistance	O
in	O
E.	O
coli	O
.	O

The	O
T.	O
ferrooxidans	O
ars	B
genes	O
were	O
arranged	O
in	O
an	O
unusual	O
manner	O
,	O
and	O
the	O
putative	O
arsR	B
and	O
arsC	B
genes	O
and	O
the	O
arsBH	B
genes	O
were	O
translated	O
in	O
opposite	O
directions	O
.	O

This	O
divergent	O
orientation	O
was	O
conserved	O
in	O
the	O
four	O
T.	O
ferrooxidans	O
strains	O
investigated	O
.	O

Transactivation	O
properties	O
of	O
parsley	O
proline	O
-	O
rich	O
bZIP	O
transcription	B
factors	I
.	O

Light	O
-	O
responsive	O
chalcone	B
synthase	I
(	O
CHS	B
)	O
gene	O
activation	O
requires	O
LRUCHS	O
,	O
a	O
light	O
regulatory	O
promoter	O
unit	O
including	O
the	O
MYB	B
recognition	O
element	O
MRECHS	O
and	O
the	O
ACGT	O
-	O
containing	O
element	O
ACECHS	O
.	O

ACECHS	O
is	O
bound	O
by	O
the	O
parsley	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
factors	O
CPRF1	B
and	I
4	I
.	O

Factors	O
containing	O
the	O
bZIP	O
domain	O
exist	O
in	O
animals	O
,	O
plants	O
and	O
yeast	O
,	O
and	O
recognize	O
DNA	O
sequence	O
-	O
specifically	O
after	O
formation	O
of	O
homo	O
-	O
or	O
heterodimers	O
.	O

To	O
determine	O
the	O
potential	O
role	O
of	O
CPRFs	B
in	O
the	O
regulation	O
of	O
CHS	B
promoter	O
activity	O
,	O
we	O
investigated	O
the	O
functions	O
of	O
distinct	O
CPRF	B
domains	O
in	O
a	O
homologous	O
co	O
-	O
transfection	O
system	O
.	O

The	O
proline	O
-	O
rich	O
domains	O
of	O
CPRF1	B
and	O
CPRF4	B
activate	O
transcription	O
,	O
indicating	O
that	O
CPRF1	B
and	O
CPRF4	B
have	O
transactivating	O
properties	O
.	O

Over	O
-	O
expression	O
of	O
the	O
CPRF1	B
bZIP	O
domain	O
caused	O
a	O
reduction	O
of	O
LRUCHS	O
-	O
mediated	O
light	O
inducibility	O
,	O
and	O
point	O
mutations	O
throughout	O
ACECHS	O
affected	O
both	O
responsiveness	O
to	O
UV	O
-	O
containing	O
white	O
light	O
and	O
transactivation	O
by	O
CPRF1	B
:	O
VP16	B
.	O

The	O
data	O
suggest	O
that	O
a	O
CPRF1	B
-	O
containing	O
bZIP	O
heterodimer	O
interacts	O
with	O
ACECHS	O
in	O
vivo	O
.	O

We	O
discuss	O
regulatory	O
steps	O
in	O
light	O
-	O
induced	O
CHS	B
transcription	O
that	O
may	O
be	O
influenced	O
by	O
CPRF1	B
and/or	O
related	O
bZIP	O
factors	O
.	O

Bivalent	O
sequential	O
binding	O
model	O
of	O
a	O
Bacillus	O
thuringiensis	O
toxin	O
to	O
gypsy	O
moth	O
aminopeptidase	B
N	I
receptor	O
.	O

Specificity	O
for	O
target	O
insects	O
of	O
Bacillus	O
thuringiensis	O
insecticidal	O
Cry	B
toxins	O
is	O
largely	O
determined	O
by	O
toxin	O
affinity	O
for	O
insect	O
midgut	O
receptors	O
.	O

The	O
mode	O
of	O
binding	O
for	O
one	O
such	O
toxin	O
-	O
receptor	O
complex	O
was	O
investigated	O
by	O
extensive	O
toxin	O
mutagenesis	O
,	O
followed	O
by	O
real	O
-	O
time	O
receptor	O
binding	O
analysis	O
using	O
an	O
optical	O
biosensor	O
(	O
BIAcore	O
)	O
.	O

Wild	O
-	O
type	O
Cry1Ac	B
,	O
a	O
three	O
-	O
domain	O
,	O
lepidopteran	O
-	O
specific	O
toxin	O
,	O
bound	O
purified	O
gypsy	O
moth	O
(	O
Lymantria	O
dispar	O
)	O
aminopeptidase	B
N	I
(	O
APN	B
)	O
biphasically	O
.	O

Site	O
1	O
displayed	O
fast	O
association	O
and	O
dissociation	O
kinetics	O
,	O
while	O
site	O
2	O
possessed	O
slower	O
kinetics	O
,	O
yet	O
tighter	O
affinity	O
.	O

We	O
empirically	O
determined	O
that	O
two	O
Cry1Ac	B
surface	O
regions	O
are	O
involved	O
in	O
in	O
vivo	O
toxicity	O
and	O
APN	B
binding	O
.	O

Mutations	O
within	O
domain	O
III	O
affected	O
binding	O
rates	O
to	O
APN	B
site	O
1	O
,	O
whereas	O
mutations	O
in	O
domain	O
II	O
affected	O
binding	O
rates	O
to	O
APN	B
site	O
2	O
.	O

Furthermore	O
,	O
domain	O
III	O
contact	O
is	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
N	O
-	O
acetylgalactosamine	O
,	O
indicating	O
loss	O
of	O
domain	O
III	O
binding	O
eliminates	O
all	O
APN	B
binding	O
.	O

Based	O
upon	O
these	O
observations	O
,	O
the	O
following	O
model	O
is	O
proposed	O
.	O

A	O
cavity	O
in	O
lectin	B
-	O
like	O
domain	O
III	O
initiates	O
docking	O
through	O
recognition	O
of	O
an	O
N	O
-	O
acetylgalactosamine	O
moiety	O
on	O
L.	O
dispar	O
APN	B
.	O

Following	O
primary	O
docking	O
,	O
a	O
higher	O
affinity	O
domain	O
II	O
binding	O
mechanism	O
occurs	O
,	O
which	O
is	O
critical	O
for	O
insecticidal	O
activity	O
.	O

L	B
-	I
aspartase	I
:	O
new	O
tricks	O
from	O
an	O
old	O
enzyme	O
.	O

The	O
enzyme	O
L	B
-	I
aspartate	I
ammonia	I
-	I
lyase	I
(	O
aspartase	B
)	O
catalyzes	O
the	O
reversible	O
deamination	O
of	O
the	O
amino	O
acid	O
L	O
-	O
aspartic	O
acid	O
,	O
using	O
a	O
carbanion	O
mechanism	O
to	O
produce	O
fumaric	O
acid	O
and	O
ammonium	O
ion	O
.	O

Aspartase	B
is	O
among	O
the	O
most	O
specific	O
enzymes	O
known	O
with	O
extensive	O
studies	O
failing	O
,	O
until	O
recently	O
,	O
to	O
identify	O
any	O
alternative	O
amino	O
acid	O
substrates	O
that	O
can	O
replace	O
L	O
-	O
aspartic	O
acid	O
.	O

Aspartases	B
from	O
different	O
organisms	O
show	O
high	O
sequence	O
homology	O
,	O
and	O
this	O
homology	O
extends	O
to	O
functionally	O
related	O
enzymes	O
such	O
as	O
the	O
class	O
II	O
fumarases	B
,	O
the	O
argininosuccinate	B
and	I
adenylosuccinate	I
lyases	I
.	O

The	O
high	O
-	O
resolution	O
structure	O
of	O
aspartase	B
reveals	O
a	O
monomer	O
that	O
is	O
composed	O
of	O
three	O
domains	O
oriented	O
in	O
an	O
elongated	O
S	O
-	O
shape	O
.	O

The	O
central	O
domain	O
,	O
comprised	O
of	O
five	O
-	O
helices	O
,	O
provides	O
the	O
subunit	O
contacts	O
in	O
the	O
functionally	O
active	O
tetramer	O
.	O

The	O
active	O
sites	O
are	O
located	O
in	O
clefts	O
between	O
the	O
subunits	O
and	O
structural	O
and	O
mutagenic	O
studies	O
have	O
identified	O
several	O
of	O
the	O
active	O
site	O
functional	O
groups	O
.	O

While	O
the	O
catalytic	O
activity	O
of	O
this	O
enzyme	O
has	O
been	O
known	O
for	O
nearly	O
100	O
years	O
,	O
a	O
number	O
of	O
recent	O
studies	O
have	O
revealed	O
some	O
interesting	O
and	O
unexpected	O
new	O
properties	O
of	O
this	O
reasonably	O
well	O
-	O
characterized	O
enzyme	O
.	O

The	O
non	O
-	O
linear	O
kinetics	O
that	O
are	O
seen	O
under	O
certain	O
conditions	O
have	O
been	O
shown	O
to	O
be	O
caused	O
by	O
the	O
presence	O
of	O
a	O
separate	O
regulatory	O
site	O
.	O

The	O
substrate	O
,	O
aspartic	O
acid	O
,	O
can	O
also	O
play	O
the	O
role	O
of	O
an	O
activator	O
,	O
binding	O
at	O
this	O
site	O
along	O
with	O
a	O
required	O
divalent	O
metal	O
ion	O
.	O

Truncation	O
of	O
the	O
carboxyl	O
terminus	O
of	O
aspartase	B
at	O
specific	O
positions	O
leads	O
to	O
an	O
enhancement	O
of	O
the	O
catalytic	O
activity	O
of	O
the	O
enzyme	O
.	O

Truncations	O
in	O
this	O
region	O
also	O
have	O
been	O
found	O
to	O
introduce	O
a	O
new	O
,	O
non	O
-	O
enzymatic	O
biological	O
activity	O
into	O
aspartase	B
,	O
the	O
ability	O
to	O
specifically	O
enhance	O
the	O
activation	O
of	O
plasminogen	B
to	O
plasmin	B
by	O
tissue	B
plasminogen	I
activator	I
.	O

Even	O
after	O
a	O
century	O
of	O
investigation	O
there	O
are	O
clearly	O
a	O
number	O
of	O
aspects	O
of	O
this	O
multifaceted	O
enzyme	O
that	O
remain	O
to	O
be	O
explored	O
.	O

The	O
major	B
head	I
protein	I
of	O
bacteriophage	O
T4	O
binds	O
specifically	O
to	O
elongation	B
factor	I
Tu	I
.	O

The	O
Lit	B
protease	B
in	O
Escherichia	O
coli	O
K-12	O
strains	O
induces	O
cell	O
death	O
in	O
response	O
to	O
bacteriophage	O
T4	O
infection	O
by	O
cleaving	O
translation	O
elongation	B
factor	I
(	I
EF	I
)	I
Tu	I
and	O
shutting	O
down	O
translation	O
.	O

Suicide	O
of	O
the	O
cell	O
is	O
timed	O
to	O
the	O
appearance	O
late	O
in	O
the	O
maturation	O
of	O
the	O
phage	O
of	O
a	O
short	O
peptide	O
sequence	O
in	O
the	O
major	B
head	I
protein	I
,	O
the	O
Gol	O
peptide	O
,	O
which	O
activates	O
proteolysis	O
.	O

In	O
the	O
present	O
work	O
we	O
demonstrate	O
that	O
the	O
Gol	O
peptide	O
binds	O
specifically	O
to	O
domains	O
II	O
and	O
III	O
of	O
EF	B
-	I
Tu	I
,	O
creating	O
the	O
unique	O
substrate	O
for	O
the	O
Lit	B
protease	B
,	O
which	O
then	O
cleaves	O
domain	O
I	O
,	O
the	O
guanine	O
nucleotide	O
binding	O
domain	O
.	O

The	O
conformation	O
of	O
EF	B
-	I
Tu	I
is	O
important	O
for	O
binding	O
and	O
Lit	B
cleavage	O
,	O
because	O
both	O
are	O
sensitive	O
to	O
the	O
identity	O
of	O
the	O
bound	O
nucleotide	O
,	O
with	O
GDP	O
being	O
preferred	O
over	O
GTP	O
.	O

We	O
propose	O
that	O
association	O
of	O
the	O
T4	O
coat	B
protein	I
with	O
EF	B
-	I
Tu	I
plays	O
a	O
role	O
in	O
phage	O
head	O
assembly	O
but	O
that	O
this	O
association	O
marks	O
infected	O
cells	O
for	O
suicide	O
when	O
Lit	B
is	O
present	O
.	O

Based	O
on	O
these	O
data	O
and	O
recent	O
observations	O
on	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
maturation	O
,	O
we	O
speculate	O
that	O
associations	O
between	O
host	O
translation	B
factors	I
and	O
coat	B
proteins	I
may	O
be	O
integral	O
to	O
viral	O
assembly	O
in	O
both	O
prokaryotes	O
and	O
eukaryotes	O
.	O

Molecular	O
cloning	O
and	O
expression	O
patterns	O
of	O
mouse	O
cartilage	B
oligomeric	I
matrix	I
protein	I
gene	O
.	O

OBJECTIVE	O
:	O

To	O
develop	O
transgenic	O
mice	O
harboring	O
mutations	O
in	O
the	O
COMP	B
gene	O
as	O
animal	O
models	O
for	O
pseudoachondroplasia	O
(	O
PSACH	O
)	O
and	O
multiple	O
epiphyseal	O
dysplasia	O
(	O
MED	O
)	O
,	O
autosomal	O
dominant	O
disorders	O
characterized	O
by	O
early	O
onset	O
osteoarthritis	O
and	O
epiphyseal	O
abnormalities	O
.	O

As	O
a	O
first	O
step	O
in	O
generating	O
a	O
mouse	O
model	O
for	O
COMP	B
mutations	O
,	O
we	O
have	O
cloned	O
the	O
cDNA	O
of	O
mouse	O
COMP	B
and	O
examined	O
its	O
tissue	O
expression	O
pattern	O
.	O

DESIGN	O
:	O

Total	O
mRNA	O
was	O
isolated	O
from	O
the	O
skeletal	O
tissues	O
of	O
newborn	O
C57BL	O
/	O
6j	O
mice	O
and	O
used	O
as	O
a	O
template	O
for	O
oligo	O
(	O
dT	O
)	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
.	O

The	O
cDNA	O
was	O
used	O
for	O
PCR	O
amplification	O
of	O
COMP	B
using	O
three	O
oligonucleotide	O
primer	O
pairs	O
designed	O
from	O
the	O
published	O
rat	O
COMP	B
cDNA	O
sequence	O
.	O

Nested	O
PCR	O
was	O
used	O
to	O
complete	O
the	O
sequence	O
between	O
the	O
amplified	O
fragments	O
.	O

The	O
entire	O
cDNA	O
was	O
sequenced	O
and	O
the	O
expression	O
pattern	O
of	O
the	O
corresponding	O
transcripts	O
examined	O
by	O
Northern	O
hybridizations	O
.	O

RESULTS	O
:	O

A	O
full	O
-	O
length	O
COMP	B
cDNA	O
was	O
isolated	O
.	O

Analysis	O
showed	O
that	O
the	O
entire	O
translated	O
region	O
of	O
the	O
mouse	O
COMP	B
gene	O
is	O
2268	O
bp	O
and	O
the	O
derived	O
amino	O
acid	O
sequence	O
shows	O
90	O
%	O
homology	O
to	O
human	O
COMP	B
.	O

Of	O
eight	O
adult	O
mouse	O
non	O
-	O
cartilage	O
tissues	O
tested	O
,	O
COMP	B
expression	O
was	O
detected	O
only	O
in	O
testis	O
.	O

Cloning	O
of	O
two	O
human	O
thyroid	O
cDNAs	O
encoding	O
new	O
members	O
of	O
the	O
NADPH	B
oxidase	I
family	I
.	O

Two	O
cDNAs	O
encoding	O
NADPH	B
oxidases	I
and	O
constituting	O
the	O
thyroid	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
generating	O
system	O
have	O
been	O
cloned	O
.	O

The	O
strategy	O
of	O
cloning	O
was	O
based	O
on	O
the	O
functional	O
similarities	O
between	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
generation	O
in	O
leukocytes	O
and	O
the	O
thyroid	O
,	O
according	O
to	O
the	O
hypothesis	O
that	O
one	O
of	O
the	O
components	O
of	O
the	O
thyroid	O
system	O
would	O
belong	O
to	O
the	O
gp91	B
(	I
Phox	I
)	I
/	I
Mox1	I
gene	I
family	I
and	O
display	O
sequence	O
similarities	O
with	O
gp91	B
(	I
Phox	I
)	I
.	O

Screening	O
at	O
low	O
stringency	O
with	O
a	O
gp91	B
(	I
Phox	I
)	I
probe	O
of	O
cDNA	O
libraries	O
from	O
thyroid	O
cells	O
in	O
primary	O
culture	O
yielded	O
two	O
distinct	O
human	O
cDNA	O
clones	O
harboring	O
open	O
reading	O
frames	O
of	O
1551	O
(	O
ThOX1	B
)	O
and	O
1548	O
amino	O
acids	O
(	O
ThOX2	B
)	O
,	O
respectively	O
.	O

The	O
encoded	O
polypeptides	O
display	O
83	O
%	O
sequence	O
similarity	O
and	O
are	O
clearly	O
related	O
to	O
gp91	B
(	I
Phox	I
)	I
(	O
53	O
and	O
47	O
%	O
similarity	O
)	O
.	O

The	O
theoretical	O
molecular	O
mass	O
of	O
177	O
kDa	O
is	O
close	O
to	O
the	O
apparent	O
molecular	O
mass	O
of	O
180	O
kDa	O
of	O
the	O
native	O
corresponding	O
porcine	O
flavoprotein	O
and	O
the	O
protein	O
(	O
s	O
)	O
detected	O
by	O
Western	O
blot	O
in	O
dog	O
and	O
human	O
thyroid	O
.	O

ThOX1	B
and	O
ThOX2	B
display	O
sequence	O
similarities	O
of	O
53	O
%	O
and	O
61	O
%	O
,	O
respectively	O
,	O
with	O
a	O
predicted	O
protein	O
of	O
Caenorhabditis	O
elegans	O
over	O
their	O
entire	O
length	O
.	O

They	O
show	O
along	O
their	O
first	O
500	O
amino	O
acids	O
a	O
similarity	O
of	O
43	O
%	O
with	O
thyroperoxidase	B
.	O

The	O
corresponding	O
genes	O
of	O
ThOX1	B
and	O
ThOX2	B
are	O
closely	O
linked	O
on	O
chromosome	O
15q15.3	O
.	O

The	O
dog	O
mRNA	O
expression	O
is	O
thyroid	O
-	O
specific	O
and	O
up	O
-	O
regulated	O
by	O
agents	O
activating	O
the	O
cAMP	O
pathway	O
as	O
is	O
the	O
synthesis	O
of	O
the	O
polypeptides	O
they	O
are	O
coding	O
for	O
.	O

In	O
human	O
thyroid	O
the	O
positive	O
regulation	O
by	O
cAMP	O
is	O
less	O
pronounced	O
.	O

The	O
proteins	O
ThOX1	B
and	O
ThOX2	B
accumulate	O
at	O
the	O
apical	O
membrane	O
of	O
thyrocytes	O
and	O
are	O
co	O
-	O
localized	O
with	O
thyroperoxidase	B
.	O

GCN5	B
and	O
ADA	B
adaptor	I
proteins	I
regulate	O
triiodothyronine	O
/	O
GRIP1	B
and	O
SRC-1	B
coactivator	O
-	O
dependent	O
gene	O
activation	O
by	O
the	O
human	O
thyroid	B
hormone	I
receptor	I
.	O

We	O
have	O
used	O
yeast	O
genetics	O
and	O
in	O
vitro	O
protein	O
-	O
protein	O
interaction	O
experiments	O
to	O
explore	O
the	O
possibility	O
that	O
GCN5	B
(	O
general	B
control	I
nonrepressed	I
protein	I
5	I
)	O
and	O
several	O
other	O
ADA	B
(	I
alteration	I
/	I
deficiency	I
in	I
activation	I
)	I
adaptor	I
proteins	I
of	O
the	O
multimeric	O
SAGA	B
complex	I
can	O
regulate	O
T3	O
/	O
GRIP1	B
(	O
glucocorticoid	B
receptor	I
interacting	I
protein	I
1	I
)	O
and	O
SRC-1	B
(	O
steroid	B
receptor	I
coactivator-1	I
)	O
coactivator	O
-	O
dependent	O
activation	O
of	O
transcription	O
by	O
the	O
human	O
T3	B
receptor	I
beta1	I
(	O
hTRbeta1	B
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
in	O
vivo	O
activation	O
of	O
a	O
T3	O
/	O
GRIP1	B
or	O
SRC	B
-	I
1	I
coactivator	O
-	O
dependent	O
T3	O
hormone	O
response	O
element	O
by	O
hTRbeta1	B
is	O
dependent	O
upon	O
the	O
presence	O
of	O
yeast	O
GCN5	B
,	O
ADA2	B
,	O
ADA1	B
,	O
or	O
ADA3	B
adaptor	B
proteins	I
and	O
that	O
the	O
histone	B
acetyltransferase	I
(	O
HAT	B
)	O
domains	O
and	O
bromodomain	O
(	O
BrD	O
)	O
of	O
yGCN5	B
must	O
be	O
intact	O
for	O
maximal	O
activation	O
of	O
transcription	O
.	O

We	O
also	O
observed	O
that	O
hTRbeta1	B
can	O
bind	O
directly	O
to	O
yeast	O
or	O
human	O
GCN5	B
as	O
well	O
as	O
hADA2	B
,	O
and	O
that	O
the	O
hGCN5	B
(	O
387	O
-	O
837	O
)	O
sequence	O
could	O
bind	O
directly	O
to	O
either	O
GRIP1	B
or	O
SRC-1	B
coactivator	O
.	O

Importantly	O
,	O
the	O
T3	O
-	O
dependent	O
binding	O
of	O
hTRbeta1	B
to	O
hGCN5	B
(	O
387	O
-	O
837	O
)	O
could	O
be	O
markedly	O
increased	O
by	O
the	O
presence	O
of	O
GRIP1	B
or	O
SRC1	B
.	O

Mutagenesis	O
of	O
GRIP1	B
nuclear	B
receptor	I
(	O
NR	B
)	O
Box	O
II	O
and	O
III	O
LXXLL	O
motifs	O
also	O
substantially	O
decreased	O
both	O
in	O
vivo	O
activation	O
of	O
transcription	O
and	O
in	O
vitro	O
T3	O
-	O
dependent	O
binding	O
of	O
hTRbeta1	B
to	O
hGCN5	B
.	O

Taken	O
together	O
,	O
these	O
experiments	O
support	O
a	O
multistep	O
model	O
of	O
transcriptional	O
initiation	O
wherein	O
the	O
binding	O
of	O
T3	O
to	O
hTRbeta1	B
initiates	O
the	O
recruitment	O
of	O
p160	O
coactivators	O
and	O
GCN5	B
to	O
form	O
a	O
trimeric	O
transcriptional	O
complex	O
that	O
activates	O
target	O
genes	O
through	O
interactions	O
with	O
ADA	B
/	I
SAGA	I
adaptor	I
proteins	I
and	O
nucleosomal	O
histones	B
.	O

Apoptotic	B
protease	I
activating	I
factor	I
1	I
(	O
Apaf-1	B
)	O
-	O
independent	O
cell	O
death	O
suppression	O
by	O
Bcl-2	B
.	O

Reportedly	O
,	O
antiapoptotic	O
Bcl-2	B
family	I
proteins	O
suppress	O
apoptosis	O
by	O
binding	O
to	O
and	O
inhibiting	O
members	O
of	O
the	O
CED-4	B
family	I
of	O
caspase	B
activators	I
.	O

To	O
explore	O
this	O
question	O
,	O
we	O
used	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
in	O
which	O
one	O
(	O
-	O
/	O
+	O
)	O
or	O
both	O
(	O
-	O
/	O
-	O
)	O
copies	O
of	O
the	O
gene	O
encoding	O
apoptotic	B
protease	I
activating	I
factor	I
1	I
(	O
Apaf-1	B
)	O
,	O
a	O
CED-4	B
homologue	O
,	O
were	O
disrupted	O
by	O
homologous	O
recombination	O
.	O

Stable	O
clones	O
of	O
heterozygous	O
(	O
-	O
/	O
+	O
)	O
and	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
that	O
overexpressed	O
Bcl-2	B
were	O
generated	O
.	O

Withdrawal	O
of	O
serum	O
growth	B
factors	I
or	O
stimulation	O
of	O
heterozygous	O
ES	O
cells	O
with	O
staurosporine	O
(	O
STS	O
)	O
,	O
ultraviolet	O
(	O
UV	O
)	O
B	O
irradiation	O
,	O
etoposide	O
(	O
VP16	O
)	O
,	O
or	O
cisplatin	O
induced	O
apoptosis	O
followed	O
by	O
cell	O
death	O
(	O
determined	O
by	O
failure	O
to	O
exclude	O
propidium	O
iodide	O
dye	O
)	O
.	O

These	O
cell	O
death	O
stimuli	O
also	O
induced	O
activation	O
of	O
several	O
types	O
of	O
caspases	B
and	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsi	O
)	O
in	O
heterozygous	O
(	O
+	O
/-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
Bcl-2	B
protected	O
against	O
these	O
events	O
in	O
Apaf-1	B
-	O
expressing	O
ES	O
cells	O
.	O

In	O
contrast	O
,	O
STS	O
,	O
UVB	O
,	O
and	O
VP16	O
induced	O
little	O
or	O
no	O
caspase	B
activation	O
and	O
apoptosis	O
in	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
.	O

Nevertheless	O
,	O
Apaf-1	B
-	O
deficient	O
ES	O
cells	O
subjected	O
to	O
these	O
cell	O
death	O
stimuli	O
or	O
deprived	O
of	O
growth	B
factors	I
did	O
eventually	O
die	O
through	O
a	O
nonapoptotic	O
mechanism	O
associated	O
with	O
loss	O
of	O
DeltaPsi	O
.	O

Moreover	O
,	O
Bcl-2	B
overprotection	O
preserved	O
DeltaPsi	O
,	O
reduced	O
the	O
percentage	O
of	O
Apaf-1	B
(	O
-	O
/	O
)	O
-	O
ES	O
cells	O
undergoing	O
cell	O
death	O
,	O
and	O
increased	O
clonigenic	O
survival	O
.	O

The	O
extent	O
of	O
Bcl-2	B
-	O
mediated	O
cytoprotection	O
was	O
not	O
significantly	O
different	O
for	O
heterozygous	O
(	O
-	O
/	O
+	O
)	O
versus	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
cells	O
.	O

Furthermore	O
,	O
although	O
Bcl-2	B
could	O
be	O
readily	O
coimmunoprecipitated	O
with	O
Bax	B
,	O
associations	O
with	O
Apaf-1	B
were	O
undetectable	O
under	O
conditions	O
where	O
Apaf-1	B
interactions	O
with	O
procaspase	B
-	I
9	I
were	O
observed	O
.	O

We	O
conclude	O
that	O
Bcl-2	B
has	O
cytoprotective	O
functions	O
independent	O
of	O
Apaf-1	B
,	O
preserving	O
mitochondrial	O
function	O
through	O
a	O
caspase	B
-	O
independent	O
mechanism	O
.	O

Molecular	O
modeling	O
of	O
the	O
catalytic	O
domain	O
of	O
serine	B
/	I
threonine	I
phosphatase-1	I
with	O
the	O
Zn2	O
+	O
and	O
Mn2	O
+	O
di	O
-	O
nuclear	O
ion	O
centers	O
in	O
the	O
active	O
site	O
.	O

Catalytic	O
domains	O
of	O
the	O
metalloenzymes	O
protein	B
phosphatases	I
(	I
PPP	I
)	I
1	I
,	I
2A	I
and	I
2B	I
(	O
PP1	B
,	O
PP2A	B
and	O
PP2B	B
,	O
respectively	O
)	O
are	O
homologous	O
to	O
approximately	O
45	O
%	O
,	O
with	O
the	O
residues	O
in	O
the	O
enzymatic	O
centers	O
strictly	O
conserved	O
.	O

PP1	B
,	O
PP2A	B
and	O
PP2B	B
are	O
abundant	O
in	O
cells	O
and	O
they	O
dephosphorylate	O
serine	O
and/or	O
threonine	O
residues	O
in	O
a	O
variety	O
of	O
proteins	O
serving	O
as	O
cellular	O
phospho	O
switches	O
.	O

The	O
active	O
enzymes	O
work	O
as	O
invariant	O
catalytic	O
subunits	O
PP1c	B
,	O
PP2Ac	B
and	O
PP2Bc	B
,	O
respectively	O
,	O
complexed	O
with	O
diverse	O
regulatory	O
subunits	O
,	O
dependent	O
on	O
the	O
enzymes	O
'	O
specific	O
location	O
and	O
biological	O
function	O
.	O

The	O
crystal	O
structures	O
of	O
PP1c	B
and	O
PP2B	B
(	O
calcineurin	B
)	O
heterotetramer	O
calcineurinA	B
x	O
calcineurinB	B
x	O
FKBP	B
x	O
FK506	O
have	O
been	O
determined	O
.	O

A	O
comparison	O
of	O
the	O
catalytic	O
subunits	O
of	O
both	O
enzymes	O
indicates	O
their	O
significant	O
structural	O
homology	O
and	O
virtual	O
identity	O
within	O
the	O
catalytic	O
centers	O
,	O
each	O
including	O
a	O
set	O
of	O
conservative	O
amino	O
acids	O
,	O
two	O
metal	O
ions	O
and	O
a	O
phosphate	O
;	O
thus	O
confirming	O
a	O
hypothesis	O
on	O
their	O
common	O
enzymatic	O
mechanisms	O
.	O

The	O
elongated	O
substrate	O
cleft	O
at	O
the	O
active	O
centre	O
is	O
kinked	O
by	O
approximately	O
120	O
degrees	O
at	O
the	O
active	O
center	O
in	O
its	O
middle	O
and	O
thus	O
divided	O
into	O
a	O
pre	O
-	O
phospho	O
-	O
Ser	O
/	O
Thr	O
(	O
ligand	O
N	O
-	O
terminal	O
)	O
and	O
a	O
post	O
-	O
phospho	O
-	O
Ser	O
/	O
Thr	O
(	O
ligand	O
C	O
-	O
terminal	O
)	O
section	O
.	O

In	O
PP1c	B
the	O
N	O
-	O
terminal	O
section	O
is	O
highly	O
acidic	O
while	O
in	O
PP2Bc	B
is	O
not	O
.	O

This	O
feature	O
is	O
likely	O
pertinent	O
but	O
not	O
sufficient	O
to	O
the	O
enzymes	O
'	O
selectivity	O
,	O
which	O
is	O
also	O
controlled	O
by	O
regulatory	O
subunits	O
,	O
diverse	O
in	O
various	O
tissues	O
.	O

The	O
metalloenzymes	O
in	O
general	O
and	O
PPP	B
in	O
particular	O
are	O
hard	O
to	O
deal	O
with	O
using	O
theoretical	O
simulations	O
due	O
to	O
parameterization	O
problems	O
for	O
the	O
metal	O
cations	O
.	O

In	O
fact	O
,	O
there	O
are	O
only	O
a	O
few	O
PP1c	B
simulations	O
reported	O
,	O
with	O
the	O
metal	O
di	O
-	O
cations	O
treated	O
quite	O
crudely	O
.	O

This	O
is	O
a	O
preliminary	O
work	O
,	O
in	O
which	O
we	O
introduce	O
and	O
test	O
against	O
some	O
experimental	O
evidence	O
a	O
concept	O
of	O
pseudomolecules	O
of	O
proper	O
geometry	O
,	O
composed	O
of	O
double	O
metal	O
(	O
2Zn2	O
+	O
or	O
2Mn2	O
+	O
)	O
cation	O
,	O
and	O
the	O
OH	O
-	O
nuclephile	O
incorporated	O
into	O
the	O
PP1c	B
catalytic	O
site	O
.	O

Both	O
models	O
are	O
associated	O
with	O
either	O
the	O
phosphate	O
(	O
a	O
free	O
enzyme	O
)	O
or	O
the	O
phosphorylated	O
dodecapeptide	O
RRRRPpTPAMLFR	O
,	O
an	O
active	O
fragment	O
(	O
residues	O
29	O
-	O
40	O
)	O
of	O
a	O
regulatory	O
subunit	O
DARPP-32	B
inhibitor	O
(	O
PP1c	B
-	O
inhibitor	O
complex	O
)	O
;	O
four	O
models	O
total	O
.	O

We	O
have	O
parameterized	O
both	O
pseudomolecules	O
within	O
the	O
AMBER	O
force	O
field	O
.	O

Subsequently	O
,	O
using	O
molecular	O
dynamic	O
in	O
water	O
,	O
we	O
have	O
found	O
the	O
free	O
PP1c	B
subunits	O
to	O
be	O
less	O
stable	O
than	O
the	O
complexed	O
ones	O
and	O
we	O
have	O
speculated	O
on	O
possible	O
reasons	O
for	O
this	O
feature	O
.	O

Genetic	O
analysis	O
of	O
insulin	B
-	I
like	I
growth	I
factor	I
II	I
and	O
HLA	B
-	I
G	I
in	O
pre	O
-	O
eclampsia	O
.	O

Pre	O
-	O
eclampsia	O
(	O
PE	O
)	O
is	O
uniquely	O
a	O
disease	O
of	O
pregnancy	O
and	O
is	O
the	O
major	O
cause	O
of	O
foetal	O
and	O
maternal	O
morbidity	O
and	O
mortality	O
.	O

Epidemiological	O
studies	O
show	O
that	O
PE	O
is	O
highly	O
heritable	O
,	O
with	O
a	O
high	O
incidence	O
in	O
all	O
populations	O
.	O

The	O
underlying	O
pathology	O
indicates	O
that	O
absent	O
or	O
shallow	O
invasion	O
of	O
foetal	O
trophoblasts	O
into	O
maternal	O
arteries	O
is	O
a	O
feature	O
of	O
true	O
PE	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
genetic	O
factors	O
influencing	O
PE	O
.	O

A	O
large	O
number	O
of	O
mother	O
-	O
father	O
-	O
baby	O
trios	O
were	O
collected	O
in	O
which	O
the	O
first	O
pregnancy	O
was	O
complicated	O
by	O
severe	O
PE	O
.	O

After	O
careful	O
examination	O
of	O
the	O
epidemiology	O
and	O
pathology	O
of	O
the	O
disease	O
,	O
two	O
plausible	O
candidate	O
genes	O
,	O
namely	O
insulin	B
-	I
like	I
growth	I
factor	I
II	I
(	O
IGF	B
-	I
II	I
)	O
and	O
HLA	B
-	I
G	I
,	O
were	O
analysed	O
for	O
association	O
with	O
PE	O
.	O

No	O
association	O
was	O
found	O
between	O
a	O
commonly	O
occurring	O
polymorphism	O
in	O
IGF	B
-	I
II	I
and	O
PE	O
.	O

Three	O
polymorphisms	O
in	O
HLA	B
-	I
G	I
were	O
analysed	O
in	O
the	O
sample	O
cohorts	O
.	O

No	O
association	O
was	O
found	O
between	O
three	O
polymorphisms	O
in	O
HLA	B
-	I
G	I
and	O
PE	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
HLA	B
-	I
G	I
insertion	O
/	O
deletion	O
polymorphism	O
in	O
exon	O
8	O
deviated	O
significantly	O
from	O
Hardy	O
-	O
Weinberg	O
expectations	O
in	O
PE	O
off	O
-	O
spring	O
,	O
reflecting	O
an	O
excess	O
of	O
heterozygotes	O
for	O
these	O
polymorphisms	O
in	O
PE	O
offspring	O
.	O

The	O
significance	O
of	O
this	O
deviation	O
is	O
not	O
clear	O
and	O
further	O
genetic	O
analysis	O
will	O
be	O
necessary	O
to	O
confirm	O
this	O
finding	O
and	O
to	O
explore	O
further	O
the	O
candidacy	O
of	O
HLA	B
-	I
G	I
in	O
PE	O
.	O

Characterization	O
of	O
the	O
pcbE	B
gene	O
encoding	O
2-hydroxypenta-2,4-dienoate	B
hydratase	I
in	O
Pseudomonas	O
sp.	O
DJ-12	O
.	O

Nucleotide	O
sequence	O
extending	O
2,3-dihydroxybiphenyl	B
1,2-dioxygenase	I
gene	O
(	O
pcbC	B
)	O
and	O
2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate	B
hydrolase	I
gene	O
(	O
pcbD	B
)	O
of	O
Pseudomonas	O
sp.	O
DJ-12	O
was	O
previously	O
analyzed	O
and	O
the	O
two	O
genes	O
were	O
present	O
in	O
the	O
order	O
of	O
pcbD	B
-	O
pcbC	B
preceded	O
by	O
a	O
promoter	O
from	O
Pseudomonas	O
sp.	O
DJ-12	O
.	O

In	O
this	O
study	O
,	O
a	O
3.8	O
-	O
kb	O
nucleotide	O
sequence	O
located	O
downstream	O
of	O
the	O
pcbC	B
gene	O
was	O
analyzed	O
to	O
have	O
three	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
that	O
are	O
designated	O
as	O
orf1	O
,	O
pcbE	B
and	O
orf2	O
genes	O
.	O

All	O
of	O
the	O
ORFs	O
were	O
preceded	O
by	O
each	O
ribosome	O
-	O
binding	O
sequence	O
of	O
5-GGAXA-3	O
(	O
X	O
=	O
G	O
or	O
A	O
)	O
.	O

However	O
,	O
no	O
promoter	O
-	O
like	O
sequence	O
and	O
transcription	O
terminator	O
sequence	O
were	O
found	O
in	O
the	O
analyzed	O
region	O
,	O
downstream	O
of	O
pcbC	B
gene	O
.	O

Therefore	O
,	O
the	O
gene	O
cluster	O
appeared	O
to	O
be	O
present	O
in	O
the	O
order	O
of	O
pcbD	B
-	O
pcbC	B
-	O
orf1	O
-	O
pcbE	B
-	O
orf2	O
as	O
an	O
operon	O
,	O
which	O
is	O
unique	O
organization	O
characterized	O
so	O
far	O
in	O
biphenyl	O
-	O
and	O
PCB	O
-	O
degrading	O
bacteria	O
.	O

The	O
orf1	O
gene	O
was	O
composed	O
of	O
1	O
,	O
224	O
base	O
pairs	O
which	O
can	O
encode	O
a	O
polypeptide	O
of	O
molecular	O
weight	O
44	O
,	O
950	O
containing	O
405	O
amino	O
acid	O
residues	O
.	O

A	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
orf1	O
gene	O
product	O
exhibited	O
21	O
-	O
33	O
%	O
identity	O
with	O
those	O
of	O
indole	B
dioxygenase	I
and	O
phenol	B
hydroxylase	I
components	O
.	O

The	O
pcbE	B
gene	O
was	O
composed	O
of	O
783	O
base	O
pairs	O
encoding	O
2-hydroxypenta-2,4-dienoate	B
hydratase	I
involved	O
in	O
the	O
4-chlorobiphenyl	O
catabolism	O
.	O

The	O
orf2	O
gene	O
was	O
composed	O
of	O
1	O
,	O
017	O
base	O
pairs	O
encoding	O
a	O
polypeptide	O
of	O
molecular	O
weight	O
37	O
,	O
378	O
containing	O
338	O
amino	O
acid	O
residues	O
.	O

A	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
orf2	O
gene	O
product	O
exhibited	O
31	O
%	O
identity	O
with	O
that	O
of	O
a	O
nitrilotriacetate	B
monooxygenase	I
component	O
.	O

Roles	O
of	O
cyclic	B
AMP	I
receptor	I
protein	I
and	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
in	O
transcription	O
activation	O
of	O
the	O
Escherichia	O
coli	O
rhaBAD	B
operon	I
.	O

The	O
Escherichia	O
coli	O
rhaBAD	B
operon	I
encodes	O
the	O
enzymes	O
for	O
catabolism	O
of	O
the	O
sugar	O
L	O
-	O
rhamnose	O
.	O

Full	O
rhaBAD	B
activation	O
requires	O
the	O
AraC	B
family	I
activator	O
RhaS	B
(	O
bound	O
to	O
a	O
site	O
that	O
overlaps	O
the	O
-	O
35	O
region	O
of	O
the	O
promoter	O
)	O
and	O
the	O
cyclic	B
AMP	I
receptor	I
protein	I
(	O
CRP	B
;	O
bound	O
immediately	O
upstream	O
of	O
RhaS	B
at	O
-	O
92.5	O
)	O
.	O

We	O
tested	O
alanine	O
substitutions	O
in	O
activating	O
regions	O
(	O
AR	O
)	O
1	O
and	O
2	O
of	O
CRP	B
for	O
their	O
effect	O
on	O
rhaBAD	B
activation	O
.	O

Some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
in	O
both	O
AR1	O
and	O
AR2	O
resulted	O
in	O
approximately	O
twofold	O
defects	O
in	O
expression	O
from	O
rhaBAD	B
promoter	O
fusions	O
.	O

We	O
also	O
expressed	O
a	O
derivative	O
of	O
the	O
alpha	B
subunit	I
of	I
RNA	I
polymerase	I
deleted	O
for	O
the	O
entire	O
C	O
-	O
terminal	O
domain	O
(	O
alpha	O
-	O
Delta235	O
)	O
and	O
assayed	O
expression	O
from	O
rhaBAD	B
promoter	O
fusions	O
.	O

The	O
greatest	O
defect	O
(	O
54	O
-	O
fold	O
)	O
occurred	O
at	O
a	O
truncated	O
promoter	O
where	O
RhaS	B
was	O
the	O
only	O
activator	O
,	O
while	O
the	O
defect	O
at	O
the	O
full	O
-	O
length	O
promoter	O
(	O
RhaS	B
plus	O
CRP	B
)	O
was	O
smaller	O
(	O
13	O
-	O
fold	O
)	O
.	O

Analysis	O
of	O
a	O
plasmid	O
library	O
expressing	O
alanine	O
substitutions	O
at	O
every	O
residue	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
(	O
alpha	O
-	O
CTD	O
)	O
identified	O
15	O
residues	O
(	O
mostly	O
in	O
the	O
DNA	O
-	O
binding	O
determinant	O
)	O
that	O
were	O
important	O
at	O
both	O
the	O
full	O
-	O
length	O
and	O
truncated	O
promoters	O
.	O

Only	O
one	O
substitution	O
was	O
defective	O
at	O
the	O
full	O
-	O
length	O
but	O
not	O
the	O
truncated	O
promoter	O
,	O
and	O
this	O
residue	O
was	O
located	O
in	O
the	O
DNA	O
-	O
binding	O
determinant	O
.	O

Six	O
substitutions	O
were	O
defective	O
only	O
at	O
the	O
promoter	O
activated	O
by	O
RhaS	B
alone	O
,	O
and	O
these	O
may	O
define	O
a	O
protein	O
-	O
contacting	O
determinant	O
on	O
alpha	O
-	O
CTD	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
CRP	B
interaction	O
with	O
alpha	O
-	O
CTD	O
may	O
not	O
be	O
required	O
for	O
rhaBAD	B
activation	O
;	O
however	O
,	O
alpha	O
-	O
CTD	O
does	O
contribute	O
to	O
full	O
activation	O
,	O
probably	O
through	O
interactions	O
with	O
DNA	O
and	O
possibly	O
RhaS	B
.	O

Norwalk	O
virus	O
open	O
reading	O
frame	O
3	O
encodes	O
a	O
minor	O
structural	B
protein	I
.	O

Norwalk	O
virus	O
(	O
NV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
acute	O
epidemic	O
nonbacterial	O
gastroenteritis	O
in	O
humans	O
.	O

The	O
inability	O
to	O
cultivate	O
NV	O
has	O
required	O
the	O
use	O
of	O
molecular	O
techniques	O
to	O
examine	O
the	O
genome	O
organization	O
and	O
functions	O
of	O
the	O
viral	O
proteins	O
.	O

The	O
function	O
of	O
the	O
NV	O
protein	O
encoded	O
by	O
open	O
reading	O
frame	O
3	O
(	O
ORF	O
3	O
)	O
has	O
been	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
characterization	O
of	O
the	O
NV	O
ORF	O
3	O
protein	O
expressed	O
in	O
a	O
cell	O
-	O
free	O
translation	O
system	O
and	O
in	O
insect	O
cells	O
and	O
show	O
its	O
association	O
with	O
recombinant	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
and	O
NV	O
virions	O
.	O

Expression	O
of	O
the	O
ORF	O
3	O
coding	O
region	O
in	O
rabbit	O
reticulocyte	O
lysates	O
resulted	O
in	O
the	O
production	O
of	O
a	O
single	O
protein	O
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
23,000	O
(	O
23	O
K	O
protein	O
)	O
,	O
which	O
is	O
not	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	O
.	O

The	O
ORF	O
3	O
protein	O
was	O
expressed	O
in	O
insect	O
cells	O
by	O
using	O
two	O
different	O
baculovirus	O
recombinants	O
;	O
one	O
recombinant	O
contained	O
the	O
entire	O
3	O
'	O
end	O
of	O
the	O
genome	O
beginning	O
with	O
the	O
ORF	O
2	O
coding	O
sequences	O
(	O
ORFs	O
2	O
+	O
3	O
)	O
,	O
and	O
the	O
second	O
recombinant	O
contained	O
ORF	O
3	O
alone	O
.	O

Expression	O
from	O
the	O
construct	O
containing	O
both	O
ORF	O
2	O
and	O
ORF	O
3	O
resulted	O
in	O
the	O
expression	O
of	O
a	O
single	O
protein	O
(	O
23	O
K	O
protein	O
)	O
detected	O
by	O
Western	O
blot	O
analysis	O
with	O
ORF	O
3	O
-	O
specific	O
peptide	O
antisera	O
.	O

However	O
,	O
expression	O
from	O
a	O
construct	O
containing	O
only	O
the	O
ORF	O
3	O
coding	O
sequences	O
resulted	O
in	O
the	O
production	O
of	O
multiple	O
forms	O
of	O
the	O
ORF	O
3	O
protein	O
ranging	O
in	O
size	O
from	O
23,000	O
to	O
35,000	O
.	O

Indirect	O
-	O
immunofluorescence	O
studies	O
using	O
an	O
ORF	O
3	O
peptide	O
antiserum	O
showed	O
that	O
the	O
ORF	O
3	O
protein	O
is	O
localized	O
to	O
the	O
cytoplasm	O
of	O
infected	O
insect	O
cells	O
.	O

The	O
23	O
K	O
ORF	O
3	O
protein	O
was	O
consistently	O
associated	O
with	O
recombinant	O
VLPs	O
purified	O
from	O
the	O
media	O
of	O
insect	O
cells	O
infected	O
with	O
a	O
baculovirus	O
recombinant	O
containing	O
the	O
entire	O
3	O
'	O
end	O
of	O
the	O
NV	O
genome	O
.	O

Western	O
blot	O
analysis	O
of	O
NV	O
purified	O
from	O
the	O
stools	O
of	O
NV	O
-	O
infected	O
volunteers	O
revealed	O
the	O
presence	O
of	O
a	O
35	O
K	O
protein	O
as	O
well	O
as	O
multiple	O
higher	O
-	O
molecular	O
-	O
weight	O
bands	O
specifically	O
recognized	O
by	O
an	O
ORF	O
3	O
peptide	O
antiserum	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ORF	O
3	O
protein	O
is	O
a	O
minor	O
structural	O
protein	O
of	O
the	O
virion	O
.	O

Dietary	O
cholic	O
acid	O
lowers	O
plasma	O
levels	O
of	O
mouse	O
and	O
human	O
apolipoprotein	B
A	I
-	I
I	I
primarily	O
via	O
a	O
transcriptional	O
mechanism	O
.	O

To	O
induce	O
dietary	O
atherosclerosis	O
in	O
mice	O
,	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
(	O
HF	O
)	O
diets	O
are	O
frequently	O
supplemented	O
with	O
cholic	O
acid	O
(	O
CA	O
)	O
.	O

This	O
diet	O
produces	O
low	O
plasma	O
levels	O
of	O
high	B
-	I
density	I
lipoprotein	I
(	O
HDL	B
)	O
and	O
high	O
levels	O
of	O
low	B
-	I
density	I
lipoprotein	I
(	O
LDL	B
)	O
.	O

However	O
,	O
HF	O
diets	O
without	O
any	O
added	O
CA	O
,	O
which	O
more	O
closely	O
resemble	O
human	O
diets	O
,	O
increase	O
levels	O
of	O
both	O
HDL	B
and	O
LDL	B
,	O
suggesting	O
that	O
CA	O
may	O
be	O
responsible	O
for	O
the	O
lowering	O
of	O
HDL	B
.	O

Our	O
aim	O
was	O
to	O
examine	O
the	O
potential	O
mechanism	O
responsible	O
for	O
the	O
lowering	O
of	O
HDL	B
.	O

Nontransgenic	O
(	O
NTg	O
)	O
C57BL	O
mice	O
and	O
apoA	B
-	I
I	I
-	O
transgenic	O
(	O
apoAI	B
-	O
Tg	O
)	O
mice	O
,	O
with	O
greatly	O
increased	O
basal	O
apoA	B
-	I
I	I
and	O
HDL	B
levels	O
,	O
were	O
used	O
.	O

Mice	O
were	O
fed	O
the	O
following	O
four	O
diets	O
:	O
control	O
(	O
C	O
)	O
,	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
(	O
HF	O
)	O
,	O
control	O
and	O
1	O
%	O
cholate	O
(	O
CA	O
)	O
and	O
HF	O
+	O
CA	O
.	O

Dietary	O
CA	O
reduced	O
plasma	O
HDL	B
levels	O
by	O
35	O
%	O
in	O
NTg	O
and	O
250	O
%	O
in	O
apoAI	B
-	O
Tg	O
mice	O
,	O
independent	O
of	O
the	O
fat	O
or	O
cholesterol	O
content	O
of	O
the	O
diet	O
.	O

Hepatic	O
apoA	B
-	I
I	I
mRNA	O
decreased	O
30	O
%	O
in	O
NTg	O
and	O
180	O
%	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Hepatic	O
apoA	B
-	I
I	I
synthesis	O
and	O
apoA	B
-	I
I	I
mRNA	O
transcription	O
rates	O
also	O
decreased	O
in	O
parallel	O
with	O
apoA	B
-	I
I	I
mRNA	O
levels	O
,	O
suggesting	O
that	O
the	O
CA	O
-	O
induced	O
decreases	O
in	O
plasma	O
apoA	B
-	I
I	I
levels	O
occurred	O
primarily	O
via	O
decreasing	O
apoA	B
-	I
I	I
mRNA	O
transcription	O
rates	O
.	O

An	O
HF	O
diet	O
increased	O
HDL	B
levels	O
1.8	O
-	O
fold	O
in	O
NTg	O
and	O
1.5	O
-	O
fold	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Addition	O
of	O
CA	O
to	O
the	O
HF	O
diet	O
lowered	O
HDL	B
levels	O
by	O
1.6	O
-	O
fold	O
in	O
NTg	O
and	O
2	O
.	O
5	O
-	O
fold	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Transfection	O
studies	O
with	O
the	O
apoA	B
-	I
I	I
promoter	O
suggested	O
the	O
presence	O
of	O
a	O
putative	O
cis	O
-	O
acting	O
element	O
responsible	O
for	O
the	O
CA	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
the	O
apoA	B
-	I
I	I
promoter	O
activity	O
.	O

Measurements	O
of	O
apoA	B
-	I
I	I
regulatory	I
protein-1	I
(	O
ARP-1	B
)	O
mRNA	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
apoA	B
-	I
I	I
gene	O
in	O
the	O
mouse	O
liver	O
showed	O
that	O
CA	O
increased	O
the	O
ARP-1	B
mRNA	O
levels	O
.	O

Because	O
apoA	B
-	I
I	I
gene	O
transcription	O
alone	O
was	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
lowering	O
of	O
plasma	O
HDL	B
levels	O
,	O
scavenger	B
receptor	I
-	I
B1	I
(	O
SR	B
-	I
B1	I
)	O
and	O
hepatic	B
lipase	I
(	O
HL	B
)	O
mRNAs	O
levels	O
were	O
quantitated	O
.	O

The	O
levels	O
of	O
SR	B
-	I
B1	I
and	O
HL	B
mRNA	O
were	O
not	O
changed	O
by	O
dietary	O
CA	O
.	O

These	O
studies	O
suggest	O
that	O
dietary	O
cholate	O
regulates	O
plasma	O
levels	O
of	O
apoA	B
-	I
I	I
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
via	O
a	O
putative	O
bile	O
acid	O
response	O
element	O
involving	O
a	O
negative	O
regulator	O
of	O
apoA	B
-	I
I	I
,	O
and	O
partly	O
by	O
an	O
unidentified	O
post	O
-	O
transcriptional	O
mechanism	O
.	O

The	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
alpha	I
(	O
PPARalpha	B
)	O
regulates	O
bile	O
acid	O
biosynthesis	O
.	O

Fibrates	O
are	O
a	O
group	O
of	O
hypolipidemic	O
agents	O
that	O
efficiently	O
lower	O
serum	O
triglyceride	O
levels	O
by	O
affecting	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
.	O

These	O
effects	O
are	O
exerted	O
via	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
alpha	I
(	O
PPARalpha	B
)	O
.	O

In	O
addition	O
,	O
fibrates	O
also	O
lower	O
serum	O
cholesterol	O
levels	O
,	O
suggesting	O
a	O
possible	O
link	O
between	O
the	O
PPARalpha	B
and	O
cholesterol	O
metabolism	O
.	O

Bile	O
acid	O
formation	O
represents	O
an	O
important	O
pathway	O
for	O
elimination	O
of	O
cholesterol	O
,	O
and	O
the	O
sterol	B
12alpha	I
-	I
hydroxylase	I
is	O
a	O
branch	O
-	O
point	O
enzyme	O
in	O
the	O
bile	O
acid	O
biosynthetic	O
pathway	O
,	O
which	O
determines	O
the	O
ratio	O
of	O
cholic	O
acid	O
to	O
chenodeoxycholic	O
acid	O
.	O

Treatment	O
of	O
mice	O
for	O
1	O
week	O
with	O
the	O
peroxisome	O
proliferator	O
WY-14,643	O
or	O
fasting	O
for	O
24	O
h	O
both	O
induced	O
the	O
sterol	O
12alpha	B
-	I
hydroxylase	I
mRNA	O
in	O
liver	O
.	O

Using	O
the	O
PPARalpha	B
knockout	O
mouse	O
model	O
,	O
we	O
show	O
that	O
the	O
induction	O
by	O
both	O
treatments	O
was	O
dependent	O
on	O
the	O
PPARalpha	B
.	O

A	O
reporter	O
plasmid	O
containing	O
a	O
putative	O
peroxisome	O
proliferator	O
-	O
response	O
element	O
(	O
PPRE	O
)	O
identified	O
in	O
the	O
rat	O
sterol	O
12alpha	B
-	I
hydroxylase	I
promoter	O
region	O
was	O
activated	O
by	O
treatment	O
with	O
WY-14,643	O
in	O
HepG2	O
cells	O
,	O
being	O
dependent	O
on	O
co	O
-	O
transfection	O
with	O
a	O
PPARalpha	B
expression	O
plasmid	O
.	O

The	O
rat	O
12alpha	B
-	I
hydroxylase	I
PPRE	O
bound	O
in	O
vitro	O
translated	O
PPARalpha	B
and	O
retinoid	B
X	I
receptor	I
alpha	I
,	O
albeit	O
weakly	O
,	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Treatment	O
of	O
wild	O
-	O
type	O
mice	O
with	O
WY-14,643	O
for	O
1	O
week	O
resulted	O
in	O
an	O
increased	O
relative	O
amount	O
of	O
cholic	O
acid	O
,	O
an	O
effect	O
that	O
was	O
abolished	O
in	O
the	O
PPARalpha	B
null	O
mice	O
,	O
verifying	O
the	O
functionality	O
of	O
the	O
PPRE	O
in	O
vivo	O
.	O

Nuclear	O
and	O
chloroplast	O
poly	B
(	I
A	I
)	I
polymerases	I
from	O
plants	O
share	O
a	O
novel	O
biochemical	O
property	O
.	O

Poly	B
(	I
A	I
)	I
polymerases	I
are	O
centrally	O
involved	O
in	O
the	O
process	O
of	O
mRNA	O
3	O
'	O
end	O
formation	O
in	O
eukaryotes	O
.	O

In	O
animals	O
and	O
yeast	O
,	O
this	O
enzyme	O
works	O
as	O
part	O
of	O
a	O
large	O
multimeric	O
complex	O
to	O
add	O
polyadenylate	O
tracts	O
to	O
the	O
3	O
'	O
ends	O
of	O
precursor	O
RNAs	O
in	O
the	O
nucleus	O
.	O

Plant	O
nuclear	O
enzymes	O
remain	O
largely	O
uncharacterized	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
an	O
initial	O
analysis	O
of	O
plant	O
nuclear	O
poly	B
(	I
A	I
)	I
polymerases	I
(	O
nPAPs	B
)	O
.	O

An	O
enzyme	O
purified	O
from	O
pea	O
nuclear	O
extracts	O
possesses	O
many	O
features	O
that	O
are	O
seen	O
with	O
the	O
enzymes	O
from	O
yeast	O
and	O
mammals	O
.	O

However	O
,	O
the	O
pea	O
enzyme	O
possesses	O
the	O
ability	O
to	O
polyadenylate	O
RNAs	O
that	O
are	O
associated	O
with	O
polynucleotide	B
phosphorylase	I
(	O
PNP	B
)	O
,	O
a	O
chloroplast	O
-	O
localized	O
enzyme	O
involved	O
in	O
RNA	O
turnover	O
.	O

Similar	O
behavior	O
is	O
not	O
seen	O
with	O
the	O
yeast	O
poly	B
(	I
A	I
)	I
polymerase	I
(	O
PAP	B
)	O
.	O

A	O
fusion	O
protein	O
consisting	O
of	O
glutathione	B
-	I
S	I
-	I
transferase	I
and	O
the	O
active	O
domain	O
of	O
an	O
Arabidopsis	O
-	O
encoded	O
nuclear	O
poly	B
(	I
A	I
)	I
polymerase	I
was	O
also	O
able	O
to	O
utilize	O
PNP	B
,	O
indicating	O
that	O
the	O
activity	O
of	O
the	O
pea	O
enzyme	O
was	O
due	O
to	O
an	O
interaction	O
between	O
the	O
pea	O
nPAP	B
and	O
PNP	B
,	O
and	O
not	O
to	O
other	O
factors	O
that	O
might	O
copurify	O
with	O
the	O
pea	O
enzyme	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
,	O
in	O
plant	O
nuclei	O
,	O
of	O
factors	O
related	O
to	O
PNP	B
,	O
and	O
an	O
interaction	O
between	O
such	O
factors	O
and	O
poly	B
(	I
A	I
)	I
polymerases	I
.	O

Deficient	O
mineralization	O
of	O
intramembranous	O
bone	O
in	O
vitamin	B
D-24-hydroxylase	I
-	O
ablated	O
mice	O
is	O
due	O
to	O
elevated	O
1,25-dihydroxyvitamin	O
D	O
and	O
not	O
to	O
the	O
absence	O
of	O
24,25-dihydroxyvitamin	O
D	O
.	O

The	O
25-hydroxyvitamin	B
D-24-hydroxylase	I
enzyme	O
(	O
24-OHase	B
)	O
is	O
responsible	O
for	O
the	O
catabolic	O
breakdown	O
of	O
1,25-dihydroxyvitamin	O
D	O
[	O
1,25	O
(	O
OH	O
)	O
2D	O
]	O
,	O
the	O
active	O
form	O
of	O
vitamin	O
D	O
.	O

The	O
24	B
-	I
OHase	I
enzyme	O
can	O
also	O
act	O
on	O
the	O
25-hydroxyvitamin	O
D	O
substrate	O
to	O
generate	O
24,25-dihydroxyvitamin	O
D	O
,	O
a	O
metabolite	O
whose	O
physiological	O
importance	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
mice	O
with	O
a	O
targeted	O
inactivating	O
mutation	O
of	O
the	O
24-OHase	B
gene	O
had	O
impaired	O
1,25	O
(	O
OH	O
)	O
2D	O
catabolism	O
.	O

Surprisingly	O
,	O
complete	O
absence	O
of	O
24	B
-	I
OHase	I
activity	O
during	O
development	O
leads	O
to	O
impaired	O
intramembranous	O
bone	O
mineralization	O
.	O

This	O
phenotype	O
was	O
rescued	O
by	O
crossing	O
the	O
24-OHase	B
mutant	O
mice	O
to	O
mice	O
harboring	O
a	O
targeted	O
mutation	O
in	O
the	O
vitamin	B
D	I
receptor	I
gene	O
,	O
confirming	O
that	O
the	O
elevated	O
1,25	O
(	O
OH	O
)	O
2D	O
levels	O
,	O
acting	O
through	O
the	O
vitamin	B
D	I
receptor	I
,	O
were	O
responsible	O
for	O
the	O
observed	O
accumulation	O
of	O
osteoid	O
.	O

Our	O
results	O
confirm	O
the	O
physiological	O
importance	O
of	O
the	O
24	B
-	I
OHase	I
enzyme	O
for	O
maintaining	O
vitamin	O
D	O
homeostasis	O
,	O
and	O
they	O
reveal	O
that	O
24,25-dihydroxyvitamin	O
D	O
is	O
a	O
dispensable	O
metabolite	O
during	O
bone	O
development	O
.	O

Crystal	O
structure	O
of	O
the	O
BMP-2	B
-	O
BRIA	B
ectodomain	O
complex	O
.	O

Bone	B
morphogenetic	I
proteins	I
(	O
BMPs	B
)	O
belong	O
to	O
the	O
large	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGF	I
-	I
beta	I
)	I
superfamily	I
of	O
multifunctional	O
cytokines	B
.	O

BMP-2	B
can	O
induce	O
ectopic	O
bone	O
and	O
cartilage	O
formation	O
in	O
adult	O
vertebrates	O
and	O
is	O
involved	O
in	O
central	O
steps	O
in	O
early	O
embryonal	O
development	O
in	O
animals	O
.	O

Signaling	O
by	O
these	O
cytokines	B
requires	O
binding	O
of	O
two	O
types	O
of	O
transmembrane	O
serine	B
/	I
threonine	I
receptor	I
kinase	I
chains	O
classified	O
as	O
type	O
I	O
and	O
type	O
II	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
human	O
dimeric	O
BMP-2	B
in	O
complex	O
with	O
two	O
high	O
affinity	O
BMP	B
receptor	I
IA	I
extracellular	O
domains	O
(	O
BRIAec	B
)	O
.	O

The	O
receptor	O
chains	O
bind	O
to	O
the	O
'	O
wrist	O
'	O
epitopes	O
of	O
the	O
BMP-2	B
dimer	O
and	O
contact	O
both	O
BMP-2	B
monomers	O
.	O

No	O
contacts	O
exist	O
between	O
the	O
receptor	O
domains	O
.	O

The	O
model	O
reveals	O
the	O
structural	O
basis	O
for	O
discrimination	O
between	O
type	O
I	O
and	O
type	O
II	O
receptors	O
and	O
the	O
variability	O
of	O
receptor	O
-	O
ligand	O
interactions	O
that	O
is	O
seen	O
in	O
BMP	B
-	O
TGF	B
-	I
beta	I
systems	O
.	O

Modulation	O
of	O
TFIIH	B
-	I
associated	I
kinase	I
activity	O
by	O
complex	O
formation	O
and	O
its	O
relationship	O
with	O
CTD	O
phosphorylation	O
of	O
RNA	B
polymerase	I
II	I
.	O

BACKGROUND	O
:	O

The	O
general	O
transcription	B
factor	I
TFIIH	B
plays	O
important	O
roles	O
in	O
initiation	O
and	O
the	O
transition	O
to	O
elongation	O
steps	O
of	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
(	O
PolII	B
)	O
.	O

Both	O
roles	O
are	O
dependent	O
on	O
the	O
protein	B
kinase	I
,	O
DNA	O
-	O
dependent	O
ATPase	B
and	O
DNA	B
helicase	I
activities	O
of	O
TFIIH	B
.	O

However	O
,	O
how	O
these	O
enzyme	O
activities	O
of	O
TFIIH	B
contribute	O
to	O
transcription	O
has	O
remained	O
elusive	O
.	O

TFIIH	B
consists	O
of	O
nine	O
subunits	O
,	O
and	O
one	O
of	O
them	O
,	O
Cdk7	B
,	O
possesses	O
kinase	B
activity	O
.	O

Here	O
the	O
substrate	O
specificities	O
of	O
TFIIH	B
and	O
two	O
forms	O
of	O
the	O
Cdk7	B
-	O
containing	O
kinase	B
complex	O
are	O
compared	O
,	O
and	O
the	O
relationship	O
between	O
transcription	O
activity	O
and	O
the	O
TFIIH	B
-	O
dependent	O
phosphorylation	O
of	O
the	O
carboxy	O
terminal	O
domain	O
of	O
the	O
largest	O
subunit	O
of	O
PolII	B
(	O
CTD	O
)	O
is	O
studied	O
.	O

RESULTS	O
:	O

We	O
prepared	O
TFIIH	B
and	O
two	O
Cdk7	B
-	O
containing	O
kinase	B
complexes	O
,	O
Cdk7	B
/	O
Cyclin	B
H	I
and	O
CAK	B
(	O
Cdk7	B
/	O
Cyclin	B
H	I
/	O
MAT1	B
)	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
CAK	B
strongly	O
phosphorylated	O
Cdk2	B
,	O
Cdk4	B
,	O
CTD	O
and	O
intact	O
PolII	B
.	O

In	O
contrast	O
,	O
Cdk7	B
/	O
Cyclin	B
H	I
,	O
which	O
lacks	O
MAT1	B
,	O
did	O
not	O
phosphorylate	O
these	O
substrates	O
,	O
except	O
for	O
weak	O
phosphorylation	O
of	O
Cdk2	B
.	O

The	O
kinase	B
activity	O
of	O
TFIIH	B
displayed	O
stronger	O
substrate	O
preference	O
for	O
Cdk4	B
than	O
did	O
CAK	B
.	O

In	O
addition	O
,	O
TFIIH	B
phosphorylation	O
of	O
PolII	B
was	O
stimulated	O
by	O
TFIIE	B
both	O
in	O
solution	O
and	O
during	O
preinitiation	O
complex	O
formation	O
,	O
whereas	O
Cdk7	B
/	O
Cyclin	B
H	I
and	O
CAK	B
phosphorylation	O
of	O
PolII	B
was	O
not	O
.	O

In	O
combination	O
with	O
other	O
general	O
transcription	B
factors	I
,	O
TFIIH	B
,	O
but	O
not	O
Cdk7	B
/	O
CycH	B
or	O
CAK	B
,	O
promoted	O
transcription	O
on	O
a	O
linear	O
DNA	O
template	O
.	O

This	O
transcription	O
was	O
well	O
correlated	O
with	O
TFIIE	B
stimulated	O
TFIIH	B
phosphorylation	O
of	O
serine	O
at	O
position	O
5	O
(	O
Ser-5	O
)	O
within	O
the	O
heptapeptide	O
repeat	O
of	O
the	O
PolII	B
CTD	O
.	O

CONCLUSION	O
:	O

These	O
results	O
provide	O
clues	O
about	O
the	O
roles	O
of	O
CTD	O
phosphorylation	O
at	O
Ser-5	O
in	O
transcription	O
.	O

Early	O
inflammatory	O
response	O
after	O
elective	O
abdominal	O
aortic	O
aneurysm	O
repair	O
:	O
a	O
comparison	O
between	O
endovascular	O
procedure	O
and	O
conventional	O
surgery	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
the	O
nature	O
of	O
and	O
to	O
compare	O
the	O
inflammatory	O
responses	O
induced	O
by	O
(	O
1	O
)	O
endovascular	O
and	O
(	O
2	O
)	O
conventional	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
repair	O
.	O
Material	O
and	O
Methods	O
:	O
Twelve	O
consecutive	O
patients	O
undergoing	O
elective	O
infrarenal	O
AAA	O
repair	O
were	O
prospectively	O
studied	O
.	O

Seven	O
patients	O
were	O
selected	O
for	O
endovascular	O
procedures	O
(	O
the	O
EAAA	O
group	O
)	O
;	O
five	O
patients	O
underwent	O
open	O
surgery	O
(	O
the	O
OAAA	O
group	O
)	O
.	O

Three	O
control	O
patients	O
undergoing	O
carotid	O
thromboendarterectomy	O
were	O
also	O
included	O
.	O

Serial	O
peripheral	O
venous	O
blood	O
samples	O
were	O
collected	O
preoperatively	O
,	O
immediately	O
after	O
declamping	O
or	O
placement	O
of	O
the	O
endograft	O
,	O
and	O
at	O
hours	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
.	O

Acute	O
phase	O
response	O
expression	O
of	O
peripheral	O
T	O
lymphocyte	O
and	O
monocyte	O
activation	O
markers	O
and	O
adhesion	B
molecules	I
(	O
flow	O
cytometry	O
)	O
,	O
soluble	O
levels	O
of	O
cell	B
adhesion	I
molecules	I
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
,	O
cytokine	B
(	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
interleukin-6	B
,	O
and	O
interleukin-8	B
)	O
release	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
,	O
and	O
liberation	O
of	O
complement	O
products	O
(	O
nephelometry	O
)	O
were	O
measured	O
.	O

RESULTS	O
:	O

Regarding	O
acute	O
phase	O
response	O
,	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
showed	O
significant	O
increases	O
in	O
C	B
-	I
reactive	I
protein	I
(	O
P	O
<	O
.001	O
and	O
P	O
=	O
.001	O
)	O
,	O
body	O
temperature	O
(	O
P	O
=	O
.035	O
and	O
P	O
=	O
.048	O
)	O
,	O
and	O
leukocyte	O
count	O
(	O
P	O
<	O
.001	O
and	O
P	O
<	O
.001	O
)	O
.	O

Similar	O
time	O
course	O
patterns	O
were	O
observed	O
with	O
respect	O
to	O
body	O
temperature	O
(	O
P	O
=	O
.372	O
)	O
.	O

Statistically	O
significant	O
different	O
patterns	O
were	O
demonstrated	O
for	O
C	B
-	I
reactive	I
protein	I
(	O
P	O
=	O
.032	O
)	O
and	O
leukocyte	O
count	O
(	O
P	O
=	O
.002	O
)	O
.	O

Regarding	O
leukocyte	O
activation	O
,	O
a	O
significant	O
upregulation	O
of	O
peripheral	O
T	O
lymphocyte	O
CD38	B
expression	O
was	O
observed	O
in	O
the	O
OAAA	O
group	O
only	O
(	O
P	O
=	O
.001	O
)	O
.	O

Analysis	O
of	O
markers	O
such	O
as	O
CD69	B
,	O
CD40L	B
,	O
CD25	B
,	O
and	O
CD54	B
revealed	O
no	O
perioperative	O
fluctuations	O
in	O
any	O
group	O
.	O

Regarding	O
circulating	O
cell	O
adhesion	O
molecules	O
,	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
displayed	O
significant	O
increases	O
in	O
soluble	O
intercellular	B
adhesion	I
molecule-1	I
(	O
P	O
=	O
.003	O
and	O
P	O
=	O
.001	O
)	O
;	O
there	O
was	O
no	O
intergroup	O
difference	O
(	O
P	O
=	O
.193	O
)	O
.	O

All	O
groups	O
demonstrated	O
high	O
soluble	O
von	B
Willebrand	I
factor	I
levels	O
(	O
P	O
=	O
.018	O
,	O
P	O
=	O
.	O
007	O
,	O
and	O
P	O
=	O
.027	O
)	O
,	O
there	O
being	O
no	O
differences	O
in	O
the	O
patterns	O
(	O
P	O
=	O
.	O
772	O
)	O
.	O

Otherwise	O
,	O
soluble	O
vascular	B
cell	I
adhesion	I
molecule	I
-	I
1	I
,	O
soluble	O
E	B
-	I
selectin	I
,	O
and	O
soluble	O
P	B
-	I
selectin	I
did	O
not	O
appear	O
to	O
vary	O
in	O
any	O
group	O
.	O

Regarding	O
cytokine	B
release	O
,	O
although	O
a	O
tendency	O
toward	O
high	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
interleukin-8	B
levels	O
was	O
noticed	O
in	O
the	O
EAAA	O
group	O
,	O
global	O
time	O
course	O
effects	O
failed	O
to	O
reach	O
statistical	O
significance	O
(	O
P	O
=	O
.543	O
and	O
P	O
=	O
.080	O
)	O
.	O

In	O
contrast	O
,	O
interleukin-6	B
showed	O
elevations	O
in	O
all	O
groups	O
(	O
P	O
=	O
.058	O
,	O
P	O
<	O
.001	O
,	O
and	O
P	O
=	O
.004	O
)	O
.	O

Time	O
course	O
patterns	O
did	O
not	O
differ	O
between	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
(	O
P	O
=	O
.840	O
)	O
.	O

Regarding	O
complement	O
activation	O
,	O
the	O
C3d	B
/	O
C3	B
ratio	O
disclosed	O
significant	O
postoperative	O
elevations	O
in	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
(	O
P	O
=	O
.013	O
and	O
P	O
=	O
.009	O
)	O
.	O

This	O
complement	O
product	O
release	O
was	O
reduced	O
in	O
the	O
EAAA	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
current	O
study	O
indicated	O
that	O
both	O
endovascular	O
and	O
coventional	O
AAA	O
repair	O
induced	O
significant	O
inflammatory	O
responses	O
.	O

Our	O
findings	O
showed	O
that	O
there	O
were	O
no	O
large	O
differences	O
between	O
the	O
procedures	O
with	O
respect	O
to	O
circulating	O
cell	O
adhesion	B
molecule	I
and	O
cytokine	B
release	O
.	O

Moreover	O
,	O
the	O
endoluminal	O
approach	O
produced	O
a	O
limited	O
response	O
in	O
terms	O
of	O
acute	O
phase	O
reaction	O
,	O
T	O
lymphocyte	O
activation	O
,	O
and	O
complement	O
product	O
liberation	O
.	O

This	O
might	O
support	O
the	O
concept	O
that	O
endovascular	O
AAA	O
repair	O
represents	O
an	O
attractive	O
alternative	O
to	O
open	O
surgery	O
.	O

Given	O
the	O
relatively	O
small	O
sample	O
size	O
,	O
further	O
larger	O
studies	O
are	O
required	O
for	O
confirmation	O
of	O
our	O
observations	O
.	O

Regulation	O
of	O
the	O
promoter	O
activity	O
of	O
interferon	B
regulatory	I
factor-7	I
gene	O
.	O

Activation	O
by	O
interferon	B
snd	O
silencing	O
by	O
hypermethylation	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
virus	O
induces	O
expression	O
of	O
the	O
early	O
inflammatory	O
genes	O
has	O
not	O
yet	O
been	O
completely	O
elucidated	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
virus	O
-	O
mediated	O
transcription	O
of	O
type	B
I	I
interferon	I
(	O
IFN	B
)	O
genes	O
required	O
activation	O
of	O
two	O
members	O
of	O
IFN	B
regulatory	I
factor	I
(	I
IRF	I
)	I
family	I
,	O
IRF-3	B
and	O
IRF-7	B
,	O
where	O
the	O
expression	O
of	O
IRF-7	B
was	O
found	O
to	O
be	O
indispensable	O
for	O
the	O
induction	O
of	O
IFNA	B
genes	O
.	O

To	O
determine	O
the	O
factors	O
that	O
regulate	O
expression	O
of	O
IRF-7	B
gene	O
,	O
as	O
well	O
as	O
its	O
inducibility	O
by	O
type	B
I	I
IFNs	I
,	O
we	O
have	O
isolated	O
and	O
characterized	O
the	O
promoter	O
and	O
first	O
intron	O
of	O
the	O
human	O
IRF-7	B
gene	O
.	O

This	O
region	O
shows	O
a	O
presence	O
of	O
two	O
potential	O
interferon	B
-	O
sensitive	O
response	O
elements	O
(	O
ISRE	O
/	O
IRF	O
-	O
E	O
)	O
.	O

However	O
,	O
only	O
the	O
ISRE	O
present	O
in	O
the	O
first	O
intron	O
was	O
functional	O
and	O
conferred	O
interferon	B
inducibility	O
in	O
a	O
transient	O
transfection	O
assay	O
.	O

Using	O
a	O
pull	O
-	O
down	O
assay	O
with	O
an	O
oligodeoxynucleotide	O
corresponding	O
to	O
this	O
ISRE	O
immobilized	O
to	O
magnetic	O
beads	O
,	O
we	O
have	O
demonstrated	O
that	O
this	O
ISRE	O
binds	O
ISGF3	B
complex	O
and	O
IRF-1	B
from	O
the	O
extract	O
of	O
IFN	B
-	O
treated	O
cells	O
but	O
not	O
from	O
the	O
untreated	O
cells	O
.	O

We	O
have	O
further	O
shown	O
that	O
the	O
previously	O
observed	O
lack	O
of	O
expression	O
of	O
IRF-7	B
in	O
2fTGH	O
fibrosarcoma	O
cell	O
line	O
,	O
correlated	O
with	O
hypermethylation	O
of	O
the	O
CpG	O
island	O
in	O
the	O
human	O
IRF-7	B
promoter	O
.	O

The	O
repression	O
of	O
the	O
promoter	O
activity	O
was	O
relieved	O
by	O
treatment	O
with	O
DNA	B
methyltransferase	I
inhibitor	O
5-aza	O
-	O
deoxycytidine	O
.	O

In	O
vitro	O
methylation	O
of	O
IRF-7	B
promoter	O
silenced	O
IRF-7	B
directed	O
expression	O
of	O
luciferase	B
gene	O
in	O
HeLa	O
cells	O
that	O
express	O
endogenous	O
IRF-7	B
gene	O
.	O

Whether	O
silencing	O
of	O
IRF-7	B
by	O
methylation	O
is	O
instrumental	O
for	O
the	O
process	O
of	O
tumorigenesis	O
remains	O
to	O
be	O
determined	O
.	O

Oxygen	O
and	O
haem	O
regulate	O
the	O
synthesis	O
of	O
peroxisomal	O
proteins	O
:	O
catalase	B
A	I
,	O
acyl	B
-	I
CoA	I
oxidase	I
and	O
Pex1p	B
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
;	O
the	O
regulation	O
of	O
these	O
proteins	O
by	O
oxygen	O
is	O
not	O
mediated	O
by	O
haem	O
.	O

Saccharomyces	O
cerevisiae	O
genes	O
related	O
to	O
respiration	O
are	O
typically	O
controlled	O
by	O
oxygen	O
and	O
haem	O
.	O

Usually	O
the	O
regulation	O
by	O
these	O
factors	O
is	O
co	O
-	O
ordinated	O
;	O
haem	O
is	O
indicated	O
as	O
the	O
oxygen	O
sensor	O
.	O

However	O
,	O
the	O
responsiveness	O
of	O
peroxisome	O
functions	O
to	O
these	O
regulatory	O
factors	O
is	O
poorly	O
understood	O
.	O

The	O
expression	O
of	O
CTA1	B
,	O
POX1	B
and	O
PEX1	B
genes	O
encoding	O
the	O
peroxisomal	O
proteins	O
catalase	B
A	I
,	O
acyl	B
-	I
CoA	I
oxidase	I
and	O
Pex1p	B
peroxin	B
respectively	O
was	O
studied	O
under	O
various	O
conditions	O
:	O
in	O
anaerobiosis	O
,	O
in	O
the	O
absence	O
of	O
haem	O
and	O
in	O
respiratory	O
incompetence	O
caused	O
by	O
the	O
lack	O
of	O
a	O
mitochondrial	O
genome	O
(	O
rho	O
(	O
0	O
)	O
)	O
.	O

The	O
influence	O
of	O
haem	O
deficiency	O
or	O
rho	O
(	O
0	O
)	O
on	O
peroxisomal	O
morphology	O
was	O
also	O
investigated	O
.	O

Respiratory	O
incompetence	O
has	O
no	O
effect	O
on	O
the	O
expression	O
of	O
CTA1	B
and	O
POX1	B
,	O
whereas	O
in	O
the	O
absence	O
of	O
haem	O
their	O
expression	O
is	O
markedly	O
decreased	O
.	O

The	O
synthesis	O
of	O
Pex1p	B
is	O
decreased	O
in	O
rho	O
(	O
0	O
)	O
cells	O
and	O
is	O
decreased	O
even	O
more	O
in	O
haem	O
-	O
deficient	O
cells	O
.	O

Nevertheless	O
,	O
peroxisomal	O
morphology	O
in	O
both	O
these	O
types	O
of	O
cell	O
does	O
not	O
differ	O
significantly	O
from	O
the	O
morphology	O
of	O
peroxisomes	O
in	O
wild	O
-	O
type	O
cells	O
.	O

The	O
down	O
-	O
regulating	O
effect	O
of	O
anoxia	O
on	O
the	O
expression	O
of	O
CTA1	B
and	O
POX1	B
is	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
haem	O
deficiency	O
and	O
is	O
not	O
reversed	O
by	O
the	O
addition	O
of	O
exogenous	O
haem	O
or	O
the	O
presence	O
of	O
endogenous	O
haem	O
.	O

Moreover	O
,	O
neither	O
of	O
these	O
genes	O
responds	O
to	O
the	O
known	O
haem	O
-	O
controlled	O
transcriptional	B
factor	I
Hap1p	B
.	O

In	O
contrast	O
with	O
the	O
other	O
two	O
genes	O
studied	O
,	O
PEX1	B
is	O
up	O
-	O
regulated	O
in	O
anaerobiosis	O
.	O

The	O
existence	O
of	O
one	O
or	O
more	O
novel	O
mechanisms	O
of	O
regulation	O
of	O
peroxisomal	O
genes	O
by	O
haem	O
and	O
oxygen	O
,	O
different	O
from	O
those	O
already	O
known	O
in	O
S.	O
cerevisiae	O
,	O
is	O
postulated	O
.	O

A	O
second	O
leukotriene	B
B	I
(	I
4	I
)	I
receptor	I
,	O
BLT2	B
.	O

A	O
new	O
therapeutic	O
target	O
in	O
inflammation	O
and	O
immunological	O
disorders	O
.	O

Leukotriene	O
B	O
(	O
4	O
)	O
(	O
LTB	O
(	O
4	O
)	O
)	O
is	O
a	O
potent	O
chemoattractant	O
and	O
activator	O
of	O
both	O
granulocytes	O
and	O
macrophages	O
.	O

The	O
actions	O
of	O
LTB	O
(	O
4	O
)	O
appear	O
to	O
be	O
mediated	O
by	O
a	O
specific	O
G	B
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
BLT1	B
,	O
originally	O
termed	O
BLT	B
(	O
Yokomizo	O
,	O
T.	O
,	O
T.	O
Izumi	O
,	O
K.	O
Chang	O
,	O
Y.	O
Takuwa	O
,	O
and	O
T.	O
Shimizu	O
.	O
1997	O
.	O
Nature	O
.	O
387	O
:	O
620	O
-	O
624	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
a	O
novel	O
GPCR	B
for	O
LTB	O
(	O
4	O
)	O
,	O
designated	O
BLT2	B
,	O
which	O
binds	O
LTB	O
(	O
4	O
)	O
with	O
a	O
Kd	O
value	O
of	O
23	O
nM	O
compared	O
with	O
1.1	O
nM	O
for	O
BLT1	B
,	O
but	O
still	O
efficiently	O
transduces	O
intracellular	O
signaling	O
.	O

BLT2	B
is	O
highly	O
homologous	O
to	O
BLT1	B
,	O
with	O
an	O
amino	O
acid	O
identity	O
of	O
45.2	O
%	O
,	O
and	O
its	O
open	O
reading	O
frame	O
is	O
located	O
in	O
the	O
promoter	O
region	O
of	O
the	O
BLT1	B
gene	O
.	O

BLT2	B
is	O
expressed	O
ubiquitously	O
,	O
in	O
contrast	O
to	O
BLT1	B
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
leukocytes	O
.	O

Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
BLT2	B
exhibit	O
LTB	O
(	O
4	O
)	O
-	O
induced	O
chemotaxis	O
,	O
calcium	O
mobilization	O
,	O
and	O
pertussis	B
toxin	I
-	O
insensitive	O
inhibition	O
of	O
adenylyl	B
cyclase	I
.	O

Several	O
BLT1	B
antagonists	O
,	O
including	O
U	O
75302	O
,	O
failed	O
to	O
inhibit	O
LTB	O
(	O
4	O
)	O
binding	O
to	O
BLT2	B
.	O

Thus	O
,	O
BLT2	B
is	O
a	O
pharmacologically	O
distinct	O
receptor	O
for	O
LTB	O
(	O
4	O
)	O
,	O
and	O
may	O
mediate	O
cellular	O
functions	O
in	O
tissues	O
other	O
than	O
leukocytes	O
.	O

BLT2	B
provides	O
a	O
novel	O
target	O
for	O
antiinflammatory	O
therapy	O
and	O
promises	O
to	O
expand	O
our	O
knowledge	O
of	O
LTB	O
(	O
4	O
)	O
function	O
.	O

The	O
location	O
of	O
the	O
gene	O
suggests	O
shared	O
transcriptional	O
regulation	O
of	O
these	O
two	O
receptors	O
.	O

Immunolocalization	O
of	O
androgen	B
receptors	I
and	O
aromatase	B
enzyme	O
in	O
the	O
adult	O
musk	O
shrew	O
brain	O
.	O

In	O
the	O
brain	O
and	O
other	O
tissues	O
,	O
estrogens	O
are	O
produced	O
by	O
aromatization	O
of	O
androgens	O
.	O

Biochemical	O
data	O
suggest	O
that	O
aromatase	B
enzyme	O
is	O
regulated	O
by	O
the	O
androgen	B
receptor	I
(	O
AR	B
)	O
.	O

Neurons	O
that	O
contain	O
either	O
AR	B
or	O
aromatase	B
(	O
AROM	B
)	O
enzyme	O
reside	O
in	O
many	O
of	O
the	O
same	O
brain	O
regions	O
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
codistribution	O
of	O
AR	B
-	O
and	O
AROM	B
-	O
enzyme	O
-	O
immunoreactive	O
(	O
-	O
ir	O
)	O
neurons	O
in	O
several	O
regions	O
of	O
the	O
adult	O
male	O
and	O
female	O
musk	O
shrew	O
brain	O
.	O

Data	O
were	O
collected	O
from	O
the	O
intermediate	O
nucleus	O
of	O
the	O
lateral	O
septum	O
(	O
LS	O
)	O
,	O
medial	O
anterior	O
(	O
BNSTMA	O
)	O
and	O
medial	O
posterointerior	O
(	O
BNSTMP	O
)	O
divisions	O
of	O
the	O
bed	O
nucleus	O
of	O
the	O
stria	O
terminalis	O
,	O
medial	O
preoptic	O
area	O
(	O
mPOA	O
)	O
,	O
ventromedial	O
nucleus	O
of	O
the	O
hypothalamus	O
(	O
VMN	O
)	O
,	O
medial	O
(	O
MeA	O
)	O
,	O
cortical	O
and	O
central	O
nuclei	O
of	O
the	O
amygdala	O
.	O

Males	O
had	O
significantly	O
more	O
AR	B
-	O
ir	O
neurons	O
in	O
the	O
BNSTMP	O
,	O
mPOA	O
,	O
VMN	O
and	O
LS	O
as	O
compared	O
to	O
females	O
.	O

With	O
the	O
exception	O
of	O
the	O
BNSTMA	O
and	O
LS	O
,	O
males	O
had	O
more	O
AROM	B
-	O
ir	O
neurons	O
in	O
each	O
region	O
than	O
females	O
.	O

Furthermore	O
,	O
males	O
had	O
significantly	O
more	O
double	O
-	O
labeled	O
neurons	O
than	O
females	O
in	O
the	O
BNSTMP	O
,	O
mPOA	O
,	O
VMN	O
,	O
LS	O
and	O
MeA	O
.	O

The	O
percentage	O
of	O
AROM	B
-	O
ir	O
neurons	O
that	O
also	O
contained	O
AR	B
immunoreactivity	O
ranged	O
from	O
13	O
to	O
82	O
%	O
depending	O
on	O
sex	O
and	O
region	O
.	O

The	O
highest	O
percentage	O
of	O
dual	O
-	O
labeled	O
neurons	O
(	O
79	O
%	O
in	O
females	O
and	O
82	O
%	O
in	O
males	O
)	O
was	O
found	O
in	O
the	O
VMN	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
there	O
is	O
extensive	O
cellular	O
colocalization	O
of	O
AR	B
and	O
AROM	B
enzyme	O
in	O
specific	O
regions	O
of	O
the	O
musk	O
shrew	O
brain	O
.	O

We	O
propose	O
that	O
in	O
both	O
sexes	O
,	O
androgen	B
receptors	I
may	O
act	O
as	O
transcription	B
factors	I
to	O
regulate	O
AROM	B
enzyme	O
.	O

Activation	O
of	O
NFkappaB	B
is	O
necessary	O
for	O
IL-1beta	B
-	O
induced	O
cyclooxygenase-2	B
(	O
COX-2	B
)	O
expression	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

The	O
immediate	O
-	O
early	O
cyclooxygenase-2	B
(	O
COX-2	B
)	O
gene	O
encodes	O
an	O
inducible	O
prostaglandin	B
synthase	I
enzyme	O
which	O
is	O
implicated	O
in	O
inflammatory	O
and	O
proliferative	O
diseases	O
.	O

COX-2	B
is	O
highly	O
induced	O
during	O
cell	O
activation	O
by	O
various	O
factors	O
,	O
including	O
mitogens	O
,	O
hormones	O
and	O
cytokines	B
.	O

Since	O
pro	O
-	O
inflammatory	O
cytokine	B
IL-1beta	B
has	O
been	O
shown	O
to	O
induce	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
release	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HGF	O
)	O
,	O
here	O
we	O
analyzed	O
the	O
effect	O
of	O
IL-1beta	B
on	O
the	O
expression	O
of	O
COX-2	B
and	O
the	O
activation	O
of	O
NFkappaB	B
in	O
HGF	O
.	O

Northern	O
hybridization	O
analysis	O
revealed	O
that	O
IL-1beta	B
(	O
200	O
pg	O
/	O
ml	O
)	O
increased	O
the	O
expression	O
of	O
COX-2	B
mRNA	O
in	O
HGF	O
.	O

The	O
effect	O
of	O
IL-1beta	B
was	O
abrogated	O
by	O
herbimycin	O
A	O
,	O
a	O
protein	B
tyrosine	I
kinase	I
inhibitor	O
,	O
and	O
enhanced	O
by	O
orthovanadate	O
,	O
a	O
protein	B
tyrosine	I
phosphatase	I
inhibitor	O
.	O

IL-1beta	B
-	O
induced	O
PGE2	O
release	O
was	O
blocked	O
by	O
the	O
tyrosine	B
kinase	I
inhibitor	O
and	O
increased	O
by	O
the	O
tyrosine	B
phosphatase	I
inhibitor	O
.	O

The	O
results	O
of	O
transient	O
transfection	O
assays	O
using	O
chimeric	O
constructs	O
of	O
the	O
human	O
COX-2	B
promoter	O
(	O
nt	O
-	O
1432	O
approximately	O
+	O
59	O
)	O
ligated	O
to	O
a	O
luciferase	B
reporter	O
gene	O
indicated	O
that	O
IL-1beta	B
stimulated	O
the	O
transcriptional	O
activity	O
approximately	O
1.5	O
-	O
fold	O
.	O

Gel	O
mobility	O
shift	O
assays	O
with	O
a	O
radiolabelled	O
COX-2	B
-	O
NFkappaB	B
oligonucleotide	O
(	O
nts	O
-	O
223	O
to	O
-	O
214	O
)	O
revealed	O
an	O
increase	O
in	O
the	O
binding	O
of	O
nuclear	O
proteins	O
from	O
IL-1beta	B
-	O
stimulated	O
HGF	O
.	O

This	O
increase	O
of	O
DNA	O
-	O
protein	O
complex	O
formation	O
induced	O
by	O
IL-1beta	B
was	O
blocked	O
by	O
herbimycin	O
A	O
and	O
another	O
tyrosine	B
kinase	I
inhibitor	O
,	O
genistein	O
.	O

These	O
results	O
suggest	O
that	O
NFkappaB	B
is	O
an	O
important	O
transcription	B
factor	I
for	O
IL-1beta	B
-	O
induced	O
COX-2	B
gene	O
expression	O
,	O
and	O
is	O
involved	O
in	O
inducing	O
COX-2	B
gene	O
transcription	O
through	O
tyrosine	O
phosphorylation	O
in	O
HGF	O
.	O

Soluble	O
IL-6R	B
alpha	I
upregulated	O
IL-6	B
,	O
MMP-1	B
and	O
MMP-2	B
secretion	O
in	O
bone	O
marrow	O
stromal	O
cells	O
.	O

IL-6	B
mediates	O
its	O
activity	O
through	O
a	O
cell	O
surface	O
receptor	O
composed	O
of	O
a	O
signal	O
transducing	O
protein	O
,	O
CD130	B
,	O
and	O
a	O
ligand	O
-	O
binding	O
protein	O
which	O
exists	O
in	O
membrane	O
-	O
bound	O
form	O
(	O
CD126	B
)	O
or	O
in	O
soluble	O
form	O
(	O
sIL-6R	B
alpha	I
)	O
.	O

Interestingly	O
,	O
sIL-6R	B
alpha	I
combined	O
with	O
IL-6	B
is	O
able	O
to	O
interact	O
with	O
CD130	B
leading	O
to	O
the	O
intracellular	O
cascade	O
of	O
activation	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
flow	O
cytometry	O
,	O
we	O
show	O
that	O
stromal	O
cells	O
from	O
human	O
bone	O
marrow	O
(	O
BMSC	O
)	O
express	O
CD130	B
but	O
not	O
CD126	B
.	O

We	O
demonstrate	O
that	O
BMSC	O
are	O
responsive	O
to	O
IL-6	B
only	O
in	O
the	O
presence	O
of	O
exogenous	O
sIL-6R	B
alpha	I
.	O

Indeed	O
,	O
exogenous	O
sIL-6R	B
alpha	I
induces	O
in	O
BMSC	O
the	O
production	O
of	O
its	O
own	O
ligand	O
,	O
IL-6	B
,	O
and	O
of	O
both	O
MMP-1	B
and	O
MMP-2	B
,	O
two	O
matrix	O
metalloproteinases	O
involved	O
in	O
bone	O
resorption	O
and	O
in	O
tumour	O
spreading	O
,	O
respectively	O
.	O

Since	O
myeloma	O
cells	O
release	O
sIL-6R	B
alpha	I
in	O
the	O
close	O
vicinity	O
of	O
BMSC	O
,	O
these	O
data	O
suggest	O
a	O
role	O
for	O
this	O
factor	O
in	O
the	O
pathophysiology	O
of	O
multiple	O
myeloma	O
,	O
a	O
B	O
-	O
cell	O
malignancy	O
dependent	O
on	O
IL-6	B
for	O
its	O
growth	O
and	O
characterized	O
by	O
bone	O
destruction	O
.	O

Secretional	O
luciferase	B
of	O
the	O
luminous	O
shrimp	O
Oplophorus	O
gracilirostris	O
:	O
cDNA	O
cloning	O
of	O
a	O
novel	O
imidazopyrazinone	O
luciferase	B
(	I
1	I
)	I
.	O

The	O
deep	O
-	O
sea	O
shrimp	O
Oplophorus	O
gracilirostris	O
secretes	O
a	O
luciferase	B
that	O
catalyzes	O
the	O
oxidation	O
of	O
coelenterazine	O
to	O
emit	O
blue	O
light	O
.	O

The	O
luciferase	B
(	O
M	O
(	O
r	O
)	O
approx	O
.	O
106000	O
)	O
was	O
found	O
to	O
be	O
a	O
complex	O
composed	O
of	O
35	O
kDa	O
and	O
19	O
kDa	O
proteins	O
,	O
and	O
the	O
cDNAs	O
encoding	O
these	O
two	O
proteins	O
were	O
cloned	O
.	O

The	O
expression	O
of	O
the	O
cDNAs	O
in	O
bacterial	O
and	O
mammalian	O
cells	O
indicated	O
that	O
the	O
19	O
kDa	O
protein	O
,	O
not	O
the	O
35	O
kDa	O
protein	O
,	O
is	O
capable	O
of	O
catalyzing	O
the	O
luminescent	O
oxidation	O
of	O
coelenterazine	O
.	O

The	O
primary	O
sequence	O
of	O
the	O
35	O
kDa	O
protein	O
revealed	O
a	O
typical	O
leucine	O
-	O
rich	O
repeat	O
sequence	O
,	O
whereas	O
the	O
catalytic	O
19	O
kDa	O
protein	O
shared	O
no	O
homology	O
with	O
any	O
known	O
luciferases	B
including	O
various	O
imidazopyrazinone	O
luciferases	B
.	O

Tor	B
-	O
mediated	O
induction	O
of	O
autophagy	O
via	O
an	O
Apg1	B
protein	B
kinase	I
complex	O
.	O

Autophagy	O
is	O
a	O
membrane	O
trafficking	O
to	O
vacuole	O
/	O
lysosome	O
induced	O
by	O
nutrient	O
starvation	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Tor	B
protein	O
,	O
a	O
phosphatidylinositol	B
kinase	I
-	O
related	O
kinase	B
,	O
is	O
involved	O
in	O
the	O
repression	O
of	O
autophagy	O
induction	O
by	O
a	O
largely	O
unknown	O
mechanism	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
protein	B
kinase	I
activity	O
of	O
Apg1	B
is	O
enhanced	O
by	O
starvation	O
or	O
rapamycin	O
treatment	O
.	O

In	O
addition	O
,	O
we	O
have	O
also	O
found	O
that	O
Apg13	B
,	O
which	O
binds	O
to	O
and	O
activates	O
Apg1	B
,	O
is	O
hyperphosphorylated	O
in	O
a	O
Tor	B
-	O
dependent	O
manner	O
,	O
reducing	O
its	O
affinity	O
to	O
Apg1	B
.	O

This	O
Apg1	B
-	O
Apg13	B
association	O
is	O
required	O
for	O
autophagy	O
,	O
but	O
not	O
for	O
the	O
cytoplasm	O
-	O
to	O
-	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
,	O
another	O
vesicular	O
transport	O
mechanism	O
in	O
which	O
factors	O
essential	O
for	O
autophagy	O
(	O
Apg	B
proteins	O
)	O
are	O
also	O
employed	O
under	O
vegetative	O
growth	O
conditions	O
.	O

Finally	O
,	O
other	O
Apg1	B
-	O
associating	O
proteins	O
,	O
such	O
as	O
Apg17	B
and	O
Cvt9	B
,	O
are	O
shown	O
to	O
function	O
specifically	O
in	O
autophagy	O
or	O
the	O
Cvt	O
pathway	O
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
Apg1	B
complex	O
plays	O
an	O
important	O
role	O
in	O
switching	O
between	O
two	O
distinct	O
vesicular	O
transport	O
systems	O
in	O
a	O
nutrient	O
-	O
dependent	O
manner	O
.	O

The	O
enoyl-	B
[	I
acyl	I
-	I
carrier	I
-	I
protein	I
]	I
reductases	I
FabI	B
and	O
FabL	B
from	O
Bacillus	O
subtilis	O
.	O

Enoyl-	B
[	I
acyl	I
-	I
carrier	I
-	I
protein	I
]	I
(	I
ACP	I
)	I
reductase	I
is	O
a	O
key	O
enzyme	O
in	O
type	B
II	I
fatty	I
-	I
acid	I
synthases	I
that	O
catalyzes	O
the	O
last	O
step	O
in	O
each	O
elongation	O
cycle	O
.	O

The	O
FabI	B
component	O
of	O
Bacillus	O
subtilis	O
(	O
bsFabI	B
)	O
was	O
identified	O
in	O
the	O
genomic	O
data	O
base	O
by	O
homology	O
to	O
the	O
Escherichia	O
coli	O
protein	O
.	O

bsFabI	B
was	O
cloned	O
and	O
purified	O
and	O
exhibited	O
properties	O
similar	O
to	O
those	O
of	O
E.	O
coli	O
FabI	B
,	O
including	O
a	O
marked	O
preference	O
for	O
NADH	O
over	O
NADPH	O
as	O
a	O
cofactor	O
.	O

Overexpression	O
of	O
the	O
B.	O
subtilis	O
fabI	B
gene	O
complemented	O
the	O
temperature	O
-	O
sensitive	O
growth	O
phenotype	O
of	O
an	O
E.	O
coli	O
fabI	B
mutant	O
.	O

Triclosan	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
bsFabI	B
and	O
formed	O
a	O
stable	O
bsFabI	B
.	O
NAD	O
(	O
+	O
)	O
.	O

triclosan	O
ternary	O
complex	O
.	O

Analysis	O
of	O
the	O
B.	O
subtilis	O
genomic	O
data	O
base	O
revealed	O
a	O
second	O
open	O
reading	O
frame	O
(	O
ygaA	B
)	O
that	O
was	O
predicted	O
to	O
encode	O
a	O
protein	O
with	O
a	O
relatively	O
low	O
overall	O
similarity	O
to	O
FabI	B
,	O
but	O
contained	O
the	O
Tyr	O
-	O
Xaa	O
(	O
6	O
)	O
-	O
Lys	O
enoyl	B
-	I
ACP	I
reductase	I
catalytic	O
architecture	O
.	O

The	O
purified	O
YgaA	B
protein	O
catalyzed	O
the	O
NADPH	O
-	O
dependent	O
reduction	O
of	O
trans-2-enoyl	O
thioesters	O
of	O
both	O
N	O
-	O
acetylcysteamine	O
and	O
ACP	O
.	O

YgaA	B
was	O
reversibly	O
inhibited	O
by	O
triclosan	O
,	O
but	O
did	O
not	O
form	O
the	O
stable	O
ternary	O
complex	O
characteristic	O
of	O
the	O
FabI	B
proteins	O
.	O

Expression	O
of	O
YgaA	B
complemented	O
the	O
fabI	B
(	O
ts	O
)	O
defect	O
in	O
E.	O
coli	O
and	O
conferred	O
complete	O
triclosan	O
resistance	O
.	O

Single	O
knockouts	O
of	O
the	O
ygaA	B
or	O
fabI	B
gene	O
in	O
B.	O
subtilis	O
were	O
viable	O
,	O
but	O
double	O
knockouts	O
were	O
not	O
obtained	O
.	O

The	O
fabI	B
knockout	O
was	O
as	O
sensitive	O
as	O
the	O
wild	O
-	O
type	O
strain	O
to	O
triclosan	O
,	O
whereas	O
the	O
ygaA	B
knockout	O
was	O
250	O
-	O
fold	O
more	O
sensitive	O
to	O
the	O
drug	O
.	O

YgaA	B
was	O
renamed	O
FabL	B
to	O
denote	O
the	O
discovery	O
of	O
a	O
new	O
family	O
of	O
proteins	O
that	O
carry	O
out	O
the	O
enoyl	B
-	I
ACP	I
reductase	I
step	O
in	O
type	B
II	I
fatty	I
-	I
acid	I
synthases	I
.	O

Apolipoprotein	B
A4	I
-	O
1	O
/	O
2	O
polymorphism	O
and	O
response	O
of	O
serum	O
lipids	O
to	O
dietary	O
cholesterol	O
in	O
humans	O
.	O

The	O
response	O
of	O
serum	O
lipids	O
to	O
dietary	O
changes	O
is	O
to	O
some	O
extent	O
an	O
innate	O
characteristic	O
.	O

One	O
candidate	O
genetic	O
factor	O
that	O
may	O
affect	O
the	O
response	O
of	O
serum	O
lipids	O
to	O
a	O
change	O
in	O
cholesterol	O
intake	O
is	O
variation	O
in	O
the	O
apolipoprotein	B
A4	I
gene	O
,	O
known	O
as	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
or	O
apoA	B
-	I
IVGln360His	I
polymorphism	O
.	O

However	O
,	O
previous	O
studies	O
showed	O
inconsistent	O
results	O
.	O

We	O
therefore	O
fed	O
10	O
men	O
and	O
23	O
women	O
with	O
the	O
APOA4	B
-	O
1	O
/	O
1	O
genotype	O
and	O
4	O
men	O
and	O
13	O
women	O
with	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
or	O
-	O
2	O
/	O
2	O
genotype	O
(	O
carriers	O
of	O
the	O
APOA4	B
-	O
2	O
allele	O
)	O
two	O
diets	O
high	O
in	O
saturated	O
fat	O
,	O
one	O
containing	O
cholesterol	O
at	O
12.4	O
mg	O
/	O
MJ	O
,	O
136.4	O
mg	O
/	O
day	O
,	O
and	O
one	O
containing	O
cholesterol	O
at	O
86.2	O
mg	O
/	O
MJ	O
,	O
948.2	O
mg	O
/	O
day	O
.	O

Each	O
diet	O
was	O
supplied	O
for	O
29	O
days	O
in	O
crossover	O
design	O
.	O

The	O
mean	O
response	O
of	O
serum	O
low	B
density	I
lipoprotein	I
cholesterol	O
was	O
0.44	O
mmol	O
/	O
l	O
(	O
17	O
mg	O
/	O
dl	O
)	O
in	O
both	O
subjects	O
with	O
the	O
APOA4	B
-	I
1	I
/	I
1	I
genotype	O
and	O
in	O
subjects	O
with	O
the	O
APOA4	B
-	O
2	O
allele	O
[	O
95	O
%	O
confidence	O
interval	O
of	O
difference	O
in	O
response	O
,	O
-	O
0.20	O
to	O
0.19	O
mmol	O
/	O
l	O
(	O
-	O
8	O
to	O
7	O
mg	O
/	O
dl	O
)	O
]	O
.	O

The	O
mean	O
response	O
of	O
high	B
density	I
lipoprotein	I
cholesterol	O
was	O
also	O
similar	O
,	O
0.10	O
mmol	O
/	O
l	O
(	O
4	O
mg	O
/	O
dl	O
)	O
,	O
in	O
the	O
two	O
APOA-4	B
genotype	O
groups	O
[	O
95	O
%	O
confidence	O
interval	O
of	O
difference	O
in	O
response	O
,	O
-	O
0.07	O
to	O
0.08	O
mmol	O
/	O
l	O
(	O
-3	O
to	O
3	O
mg	O
/	O
dl	O
)	O
]	O
.	O

Thus	O
,	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
polymorphism	O
did	O
not	O
affect	O
the	O
response	O
of	O
serum	O
lipids	O
to	O
a	O
change	O
in	O
the	O
intake	O
of	O
cholesterol	O
in	O
this	O
group	O
of	O
healthy	O
Dutch	O
subjects	O
who	O
consumed	O
a	O
background	O
diet	O
high	O
in	O
saturated	O
fat	O
.	O

Knowledge	O
of	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
polymorphism	O
is	O
probably	O
not	O
a	O
generally	O
applicable	O
tool	O
for	O
the	O
identification	O
of	O
subjects	O
who	O
respond	O
to	O
a	O
change	O
in	O
cholesterol	O
intake	O
.	O

Collectins	B
and	O
collectin	B
receptors	I
in	O
innate	O
immunity	O
.	O

This	O
thesis	O
is	O
based	O
on	O
nine	O
papers	O
and	O
a	O
review	O
on	O
the	O
collectins	B
and	O
collectin	B
receptors	I
in	O
innate	O
immunity	O
.	O

The	O
collectins	B
are	O
a	O
family	O
of	O
proteins	O
in	O
which	O
the	O
individual	O
chains	O
consist	O
of	O
a	O
C	B
-	I
type	I
lectin	I
domain	O
attached	O
to	O
a	O
collagen	B
domain	O
via	O
an	O
alpha	O
-	O
coiled	O
neck	O
region	O
.	O

The	O
chains	O
are	O
organized	O
into	O
a	O
triple	O
collagen	O
helix	O
and	O
oligomerized	O
through	O
N	O
-	O
terminally	O
located	O
cysteines	O
.	O

The	O
collectins	B
have	O
a	O
dual	O
function	O
:	O
one	O
is	O
to	O
bind	O
specifically	O
to	O
carbohydrate	O
structures	O
on	O
the	O
surface	O
of	O
a	O
pathogen	O
;	O
the	O
other	O
is	O
subsequently	O
to	O
recruit	O
other	O
cells	O
and	O
molecules	O
to	O
destroy	O
the	O
pathogen	O
.	O

The	O
C	O
-	O
type	O
lectin	O
domains	O
contain	O
110	O
-	O
130	O
amino	O
-	O
acid	O
residues	O
arranged	O
in	O
a	O
conserved	O
sequence	O
pattern	O
which	O
allows	O
the	O
domain	O
to	O
fold	O
into	O
a	O
well	O
-	O
defined	O
tertiary	O
structure	O
.	O

Five	O
collectins	B
have	O
been	O
described	O
.	O

Lung	B
surfactant	I
proteins	I
A	I
and	I
D	I
(	O
SP	B
-	I
A	I
and	O
SP	B
-	I
D	I
)	O
are	O
mainly	O
found	O
in	O
the	O
surfactant	O
coating	O
the	O
luminal	O
surface	O
of	O
the	O
pulmonary	O
epithelial	O
cells	O
,	O
but	O
are	O
also	O
produced	O
by	O
cells	O
lining	O
the	O
gastrointestinal	O
tract	O
.	O

Mannan	B
-	I
binding	I
lectin	I
(	O
MBL	B
)	O
,	O
conglutinin	B
and	O
collectin-43	B
(	O
CL-43	B
)	O
are	O
serum	O
proteins	O
produced	O
by	O
the	O
liver	O
.	O

Conglutinin	B
and	O
CL-43	B
have	O
so	O
far	O
only	O
been	O
found	O
in	O
Bovidae	O
.	O

The	O
collectins	B
are	O
involved	O
in	O
innate	O
,	O
nonadaptive	O
immune	O
defense	O
.	O

They	O
bind	O
to	O
microbial	O
surface	O
carbohydrates	O
,	O
inducing	O
aggregation	O
and	O
thereby	O
impeding	O
infectivity	O
or	O
mediating	O
phagocytosis	O
through	O
specific	O
receptors	O
on	O
the	O
phagocytes	O
.	O

After	O
binding	O
microbial	O
carbohydrate	O
,	O
MBL	B
can	O
activate	O
the	O
complement	O
system	O
through	O
a	O
newly	O
discovered	O
pathway	O
which	O
makes	O
use	O
of	O
two	O
serine	B
proteases	I
(	O
MASP-1	B
and	O
MASP-2	B
)	O
to	O
activate	O
the	O
complement	B
factors	I
C4	B
and	O
C2	B
.	O

In	O
man	O
,	O
low	O
serum	O
MBL	B
concentrations	O
resulting	O
from	O
mutations	O
in	O
the	O
collagen	O
region	O
are	O
associated	O
with	O
a	O
common	O
opsonic	O
defect	O
.	O

CL-43	B
was	O
identified	O
as	O
a	O
new	O
collectin	O
by	O
its	O
calcium	O
-	O
dependent	O
binding	O
to	O
mannan	O
and	O
by	O
its	O
M	O
(	O
r	O
)	O
of	O
43	O
kDa	O
in	O
the	O
reduced	O
state	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

The	O
lectin	B
was	O
isolated	O
by	O
affinity	O
chromatography	O
on	O
mannan	O
-	O
Sepharose	O
,	O
absorption	O
with	O
rabbit	O
anti	O
-	O
bovine	O
Ig	B
coupled	O
to	O
Sepharose-4B	O
and	O
ion	O
-	O
exchange	O
chromatography	O
.	O

CL-43	B
shows	O
an	O
apparent	O
molecular	O
mass	O
of	O
120	O
kDa	O
in	O
the	O
unreduced	O
state	O
on	O
SDS	O
-	O
PAGE	O
and	O
elutes	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
750	O
kDa	O
on	O
gel	O
chromatography	O
under	O
nondissociating	O
conditions	O
.	O

Amino	O
-	O
acid	O
analysis	O
and	O
susceptibility	O
to	O
collagenase	B
digestion	O
indicated	O
that	O
CL-43	B
was	O
a	O
collectin	B
.	O

Electron	O
microscopy	O
of	O
purified	O
CL-43	B
revealed	O
only	O
rod	O
-	O
like	O
monomer	O
subunits	O
37.4	O
nm	O
long	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
showed	O
that	O
CL-43	B
has	O
two	O
isoforms	O
of	O
pI	O
4.9	O
and	O
5.3	O
respectively	O
,	O
corresponding	O
to	O
the	O
native	O
form	O
of	O
CL-43	B
and	O
a	O
truncated	O
form	O
which	O
lacks	O
the	O
first	O
9	O
amino	O
-	O
acid	O
residues	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
-	O
acid	O
sequence	O
of	O
CL-43	B
was	O
used	O
to	O
design	O
primers	O
for	O
PCR	O
with	O
a	O
bovine	O
liver	O
cDNA	O
as	O
template	O
.	O

The	O
cDNA	O
of	O
CL-43	B
was	O
cloned	O
and	O
the	O
open	O
reading	O
frame	O
was	O
found	O
to	O
encode	O
a	O
protein	O
of	O
301	O
amino	O
-	O
acid	O
residues	O
,	O
including	O
an	O
N	O
-	O
terminal	O
region	O
of	O
28	O
residues	O
,	O
a	O
collagen	O
region	O
of	O
114	O
residues	O
and	O
a	O
neck	O
-	O
CRD	O
region	O
of	O
159	O
residues	O
.	O

The	O
amino	O
-	O
acid	O
sequence	O
of	O
CL-43	B
shows	O
74	O
%	O
identity	O
with	O
bovine	O
conglutinin	O
and	O
70	O
%	O
identity	O
with	O
bovine	O
SP	B
-	I
D	I
,	O
but	O
the	O
collagen	B
region	O
is	O
considerably	O
shorter	O
than	O
those	O
of	O
conglutinin	O
and	O
SP	B
-	I
D	I
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
CL-43	B
was	O
only	O
synthesized	O
in	O
bovine	O
liver	O
,	O
no	O
signal	O
being	O
detected	O
in	O
a	O
variety	O
of	O
other	O
bovine	O
tissues	O
,	O
including	O
lung	O
.	O

No	O
cross	O
-	O
hybridizing	O
signals	O
were	O
detected	O
in	O
mRNA	O
from	O
ovine	O
,	O
human	O
,	O
rat	O
or	O
mouse	O
liver	O
.	O

Since	O
CL-43	B
and	O
conglutinin	B
have	O
only	O
been	O
detected	O
in	O
members	O
of	O
the	O
Bovidae	O
,	O
it	O
is	O
probable	O
that	O
an	O
ancestral	O
gene	O
of	O
these	O
two	O
proteins	O
was	O
first	O
derived	O
from	O
a	O
SP	B
-	I
D	I
-	O
like	O
gene	O
and	O
that	O
this	O
ancestral	O
gene	O
underwent	O
duplication	O
during	O
evolution	O
.	O

The	O
carbohydrate	O
binding	O
profile	O
of	O
CL-43	B
was	O
analyzed	O
by	O
an	O
inhibition	O
assay	O
with	O
biotinylated	O
CL-43	B
,	O
using	O
solid	O
-	O
phase	O
mannan	O
as	O
the	O
ligand	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

Expression	O
of	O
the	O
ftsY	B
gene	O
,	O
encoding	O
a	O
homologue	O
of	O
the	O
alpha	O
subunit	O
of	O
mammalian	O
signal	B
recognition	I
particle	I
receptor	I
,	O
is	O
controlled	O
by	O
different	O
promoters	O
in	O
vegetative	O
and	O
sporulating	O
cells	O
of	O
Bacillus	O
subtilis	O
.	O

Bacillus	O
subtilis	O
FtsY	B
(	O
Srb	B
)	O
is	O
a	O
homologue	O
of	O
the	O
alpha	O
subunit	O
of	O
the	O
receptor	O
for	O
mammalian	O
signal	B
-	I
recognition	I
particle	I
(	O
SRP	B
)	O
and	O
is	O
essential	O
for	O
protein	O
secretion	O
and	O
vegetative	O
cell	O
growth	O
.	O

The	O
ftsY	B
gene	O
is	O
expressed	O
during	O
both	O
the	O
exponential	O
phase	O
and	O
sporulation	O
.	O

In	O
vegetative	O
cells	O
,	O
ftsY	B
is	O
transcribed	O
with	O
two	O
upstream	O
genes	O
,	O
rncS	B
and	O
smc	B
,	O
that	O
are	O
under	O
the	O
control	O
of	O
the	O
major	O
transcription	B
factor	I
sigma	B
(	I
A	I
)	I
.	O

During	O
sporulation	O
,	O
Northern	O
hybridization	O
detected	O
ftsY	B
mRNA	O
in	O
wild	O
-	O
type	O
cells	O
,	O
but	O
not	O
in	O
sporulating	O
cells	O
of	O
sigma	B
(	I
K	I
)	I
and	O
gerE	B
mutants	O
.	O

Therefore	O
,	O
ftsY	B
is	O
solely	O
expressed	O
during	O
sporulation	O
from	O
a	O
sigma	B
(	I
K	I
)	I
-	O
and	O
GerE	B
-	O
controlled	O
promoter	O
that	O
is	O
located	O
immediately	O
upstream	O
of	O
ftsY	B
inside	O
the	O
smc	B
gene	O
.	O

To	O
examine	O
the	O
role	O
of	O
FtsY	B
during	O
sporulation	O
,	O
the	O
B.	O
subtilis	O
strain	O
ISR39	O
was	O
constructed	O
,	O
a	O
ftsY	B
conditional	O
mutant	O
in	O
which	O
ftsY	B
expression	O
can	O
be	O
shut	O
off	O
during	O
spore	O
formation	O
but	O
not	O
during	O
the	O
vegetative	O
state	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
outer	O
coat	O
of	O
ISR39	O
spores	O
was	O
not	O
completely	O
assembled	O
and	O
immunoelectron	O
microscopy	O
localized	O
FtsY	B
to	O
the	O
inner	O
and	O
outer	O
coats	O
of	O
wild	O
-	O
type	O
spores	O
.	O

The	O
developing	O
role	O
of	O
cytokines	B
for	O
imaging	O
inflammation	O
and	O
infection	O
.	O

The	O
diagnosis	O
of	O
inflammatory	O
processes	O
is	O
an	O
important	O
goal	O
in	O
medicine	O
.	O

In	O
some	O
cases	O
the	O
diagnosis	O
is	O
easy	O
,	O
based	O
on	O
the	O
clinical	O
history	O
and	O
the	O
physical	O
examination	O
of	O
the	O
patient	O
.	O

Other	O
cases	O
are	O
more	O
difficult	O
to	O
diagnose	O
because	O
they	O
are	O
asymptomatic	O
or	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

Thus	O
,	O
several	O
imaging	O
techniques	O
have	O
been	O
developed	O
for	O
the	O
diagnosis	O
of	O
inflammatory	O
processes	O
,	O
from	O
the	O
simple	O
X	O
-	O
ray	O
to	O
the	O
more	O
sophisticated	O
computerised	O
tomography	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
nuclear	O
medicine	O
scan	O
.	O

They	O
provide	O
different	O
information	O
and	O
their	O
role	O
in	O
different	O
diseases	O
will	O
be	O
discussed	O
in	O
this	O
review	O
with	O
particular	O
emphasis	O
on	O
the	O
expanding	O
field	O
of	O
the	O
use	O
of	O
radiolabelled	O
cytokines	B
for	O
imaging	O
infection	O
/	O
inflammation	O
.	O

So	O
far	O
,	O
IL-1	B
,	O
IL-1ra	B
,	O
IL-2	B
,	O
IL-6	B
,	O
IL-8	B
,	O
IL-10	B
,	O
IL-12	B
p40	I
,	O
G	B
-	I
CSF	I
,	O
IFN	B
-	I
gamma	I
and	O
EGF	B
have	O
been	O
radiolabelled	O
for	O
in	O
vivo	O
targetting	O
of	O
different	O
leukocyte	O
subsets	O
with	O
promising	O
results	O
for	O
their	O
clinical	O
use	O
.	O

Kinetic	O
analysis	O
of	O
Sp1	B
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
human	O
DNA	B
polymerase	I
beta	I
promoter	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
Sp1	B
on	O
the	O
activation	O
of	O
the	O
human	O
DNA	B
polymerase	I
beta	I
(	O
beta	B
-	I
pol	I
)	O
,	O
a	O
TATA	O
-	O
less	O
promoter	O
.	O

A	O
HeLa	O
cell	O
nuclear	O
extract	O
(	O
NE	O
)	O
based	O
in	O
vitro	O
runoff	O
transcription	O
system	O
of	O
core	O
beta	B
-	I
pol	I
promoter	O
human	O
DNA	O
(	O
pbetaP8	O
)	O
three	O
-	O
step	O
kinetic	O
model	O
of	O
transcription	O
initiation	O
were	O
used	O
to	O
describe	O
the	O
kinetic	O
effect	O
of	O
Sp1	B
.	O

The	O
results	O
showed	O
that	O
distal	O
Sp1	B
-	O
binding	O
sites	O
in	O
the	O
core	O
beta	B
-	I
pol	I
promoter	O
are	O
important	O
for	O
transcriptional	O
activation	O
of	O
the	O
pbetaP8	O
promoter	O
.	O

A	O
detailed	O
kinetic	O
analysis	O
showed	O
that	O
Sp1	B
stimulates	O
the	O
activity	O
of	O
the	O
pbetaP8	O
promoter	O
through	O
distal	O
Sp1	B
-	O
binding	O
sites	O
by	O
increasing	O
the	O
amount	O
of	O
recruitment	O
,	O
instead	O
of	O
stimulating	O
the	O
apparent	O
rate	O
of	O
RPc	B
assembly	O
(	O
k1	O
)	O
.	O

There	O
was	O
no	O
significant	O
effect	O
of	O
Sp1	B
on	O
the	O
apparent	O
rate	O
of	O
open	O
complex	O
(	O
RPo	B
)	O
formation	O
(	O
k2	O
)	O
or	O
on	O
the	O
apparent	O
rate	O
of	O
promoter	O
clearance	O
(	O
k3	O
)	O
of	O
the	O
pbetaP8	O
promoter	O
.	O

These	O
studies	O
define	O
the	O
kinetic	O
mechanisms	O
by	O
which	O
Sp1	B
may	O
regulate	O
the	O
rate	O
of	O
transcript	O
formation	O
of	O
the	O
pbetaP8	O
promoter	O
,	O
and	O
these	O
results	O
may	O
have	O
implications	O
for	O
Sp1	B
regulation	O
of	O
TATA	O
-	O
less	O
promoters	O
.	O

The	O
transmembrane	O
domain	O
of	O
influenza	O
hemagglutinin	B
exhibits	O
a	O
stringent	O
length	O
requirement	O
to	O
support	O
the	O
hemifusion	O
to	O
fusion	O
transition	O
.	O

Glycosylphosphatidylinositol	O
-	O
anchored	O
influenza	O
hemagglutinin	B
(	O
GPI	O
-	O
HA	B
)	O
mediates	O
hemifusion	O
,	O
whereas	O
chimeras	O
with	O
foreign	O
transmembrane	O
(	O
TM	O
)	O
domains	O
mediate	O
full	O
fusion	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
observations	O
is	O
that	O
the	O
TM	O
domain	O
must	O
be	O
a	O
critical	O
length	O
in	O
order	O
for	O
HA	B
to	O
promote	O
full	O
fusion	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
analyzed	O
biochemical	O
properties	O
and	O
fusion	O
phenotypes	O
of	O
HA	B
with	O
alterations	O
in	O
its	O
27	O
-	O
amino	O
acid	O
TM	O
domain	O
.	O

Our	O
mutants	O
included	O
sequential	O
2-amino	O
acid	O
(	O
Delta2	O
-	O
Delta14	O
)	O
and	O
an	O
11	O
-	O
amino	O
acid	O
deletion	O
from	O
the	O
COOH	O
-	O
terminal	O
end	O
,	O
deletions	O
of	O
6	O
or	O
8	O
amino	O
acids	O
from	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
and	O
middle	O
regions	O
,	O
and	O
a	O
deletion	O
of	O
12	O
amino	O
acids	O
from	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
end	O
of	O
the	O
TM	O
domain	O
.	O

We	O
also	O
made	O
several	O
point	O
mutations	O
in	O
the	O
TM	O
domain	O
.	O

All	O
of	O
the	O
mutants	O
except	O
Delta14	O
were	O
expressed	O
at	O
the	O
cell	O
surface	O
and	O
displayed	O
biochemical	O
properties	O
virtually	O
identical	O
to	O
wild	O
-	O
type	O
HA	B
.	O

All	O
the	O
mutants	O
that	O
were	O
expressed	O
at	O
the	O
cell	O
surface	O
promoted	O
full	O
fusion	O
,	O
with	O
the	O
notable	O
exception	O
of	O
deletions	O
of	O
>	O
10	O
amino	O
acids	O
.	O

A	O
mutant	O
in	O
which	O
11	O
amino	O
acids	O
were	O
deleted	O
was	O
severely	O
impaired	O
in	O
promoting	O
full	O
fusion	O
.	O

Mutants	O
in	O
which	O
12	O
amino	O
acids	O
were	O
deleted	O
(	O
from	O
either	O
end	O
)	O
mediated	O
only	O
hemifusion	O
.	O

Hence	O
,	O
a	O
TM	O
domain	O
of	O
17	O
amino	O
acids	O
is	O
needed	O
to	O
efficiently	O
promote	O
full	O
fusion	O
.	O

Addition	O
of	O
either	O
the	O
hydrophilic	O
HA	B
cytoplasmic	O
tail	O
sequence	O
or	O
a	O
single	O
arginine	O
to	O
Delta12	O
HA	B
,	O
the	O
hemifusion	O
mutant	O
that	O
terminates	O
with	O
15	O
(	O
hydrophobic	O
)	O
amino	O
acids	O
of	O
the	O
HA	B
TM	O
domain	O
,	O
restored	O
full	O
fusion	O
activity	O
.	O

Our	O
data	O
support	O
a	O
model	O
in	O
which	O
the	O
TM	O
domain	O
must	O
span	O
the	O
bilayer	O
to	O
promote	O
full	O
fusion	O
.	O

Stimulatory	O
effects	O
of	O
cartilage	B
-	I
derived	I
morphogenetic	I
proteins	I
1	I
and	I
2	I
on	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
stromal	O
cells	O
.	O

Cartilage	B
-	I
derived	I
morphogenetic	I
proteins	I
1	I
and	I
2	I
(	O
CDMP-1	B
and	O
CDMP-2	B
)	O
are	O
members	O
of	O
the	B
bone	I
morphogenetic	I
protein	I
(	I
BMP	I
)	I
family	I
which	O
play	O
an	O
important	O
role	O
in	O
embryonic	O
skeletal	O
development	O
.	O

Throughout	O
adult	O
life	O
,	O
bone	O
marrow	O
-	O
derived	O
precursor	O
cells	O
maintain	O
their	O
ability	O
to	O
differentiate	O
into	O
osteoblasts	O
in	O
response	O
to	O
local	O
growth	B
factors	I
.	O

This	O
study	O
examines	O
the	O
osteogenic	O
potential	O
of	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
and	O
osteogenic	B
protein	I
1	I
(	O
OP-1	B
)	O
in	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
and	O
investigates	O
the	O
endogenous	O
expression	O
of	O
CDMPs	B
/	O
BMPs	B
and	O
their	O
respective	O
activin	B
receptor	I
-	I
like	I
kinase	I
(	I
ALK	I
)	I
receptors	I
.	O

A	O
4	O
-	O
day	O
exposure	O
of	O
BMSC	O
to	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
,	O
and	O
OP-1	B
under	O
serum	O
-	O
free	O
conditions	O
stimulated	O
the	O
progression	O
of	O
the	O
osteogenic	O
lineage	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
as	O
evaluated	O
by	O
alkaline	B
phosphatase	I
activity	O
and	O
osteocalcin	B
synthesis	O
.	O

In	O
contrast	O
to	O
the	O
BMPs	B
,	O
CDMP-1	B
and	O
especially	O
CDMP-2	B
were	O
significantly	O
less	O
osteogenic	O
,	O
as	O
confirmed	O
by	O
Northern	O
blot	O
analysis	O
.	O

Moreover	O
,	O
BMSC	O
were	O
shown	O
to	O
express	O
endogenously	O
CDMP-2	B
,	O
BMP-2	B
to	I
-	I
6	I
and	O
ALK-1	B
,	I
-	I
2	I
,	I
-	I
3	I
,	I
-	I
5	I
and	I
-	I
6	I
.	O

Phenotypic	O
characterization	O
of	O
BMSC	O
by	O
RT	O
-	O
PCR	O
showed	O
transcripts	O
of	O
the	O
fat	O
marker	O
adipsin	O
and	O
the	O
prechondrocytic	O
marker	O
procollagen	B
type	I
IIA	I
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
detect	O
the	O
mature	O
cartilage	O
markers	O
,	O
procollagen	B
type	I
IIB	I
and	O
aggrecan	B
,	O
even	O
after	O
growth	B
factor	I
treatment	O
.	O

Our	O
data	O
indicate	O
that	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
and	O
OP-1	B
enhance	O
the	O
osteogenic	O
phenotype	O
in	O
BMSC	O
,	O
with	O
CDMPs	B
being	O
clearly	O
less	O
osteogenic	O
than	O
BMPs	B
.	O

The	O
endogenous	O
expression	O
of	O
a	O
variety	O
of	O
CDMPs	B
/	O
BMPs	B
and	O
their	O
respective	O
ALK	B
receptors	I
,	O
suggests	O
a	O
possible	O
involvement	O
of	O
these	O
growth	B
factors	I
in	O
the	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
progenitor	O
cells	O
.	O

3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
/	I
delta5	I
--	I
>	I
4-isomerase	I
activity	O
associated	O
with	O
the	O
human	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
2	I
isoform	O
.	O

The	O
type	O
2	O
isoform	O
of	O
human	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
17betaHSD2	B
)	O
efficiently	O
catalyzes	O
the	O
oxidative	O
metabolism	O
of	O
androgens	O
and	O
estrogens	O
,	O
and	O
it	O
is	O
expressed	O
in	O
a	O
large	O
series	O
of	O
human	O
peripheral	O
tissues	O
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
local	O
steroid	O
biosynthesis	O
and	O
metabolism	O
in	O
human	O
tissues	O
,	O
we	O
have	O
established	O
a	O
dual	O
steroidogenic	O
activity	O
of	O
the	O
17betaHSD2	B
enzyme	O
after	O
transfection	O
of	O
human	O
17betaHSD2	B
-	O
transfected	O
human	O
embryonic	O
kidney	O
(	O
293	O
)	O
cells	O
.	O

After	O
transient	O
transfection	O
,	O
the	O
metabolism	O
of	O
testosterone	O
,	O
pregnenolone	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
in	O
intact	O
transfected	O
293	O
cells	O
was	O
evaluated	O
by	O
TLC	O
-	O
based	O
radiometric	O
assays	O
.	O

17betaHSD2	B
-	O
transfected	O
cells	O
converted	O
91	O
%	O
of	O
testosterone	O
(	O
1	O
micromol	O
/	O
L	O
)	O
into	O
androstenedione	O
in	O
a	O
2	O
-	O
h	O
incubation	O
period	O
.	O

In	O
addition	O
,	O
pregnenolone	O
(	O
1	O
micromol	O
/	O
L	O
)	O
was	O
converted	O
to	O
progesterone	O
(	O
18.5	O
%	O
)	O
,	O
whereas	O
DHEA	O
(	O
1	O
micromol	O
/	O
L	O
)	O
was	O
metabolized	O
to	O
androstenedione	O
(	O
8.3	O
%	O
conversion	O
)	O
in	O
a	O
15	O
-	O
h	O
incubation	O
period	O
.	O

The	O
kinetics	O
of	O
the	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3betaHSD	B
)	O
and	O
17betaHSD2	B
activities	O
using	O
cell	O
homogenate	O
protein	O
of	O
stably	O
transfected	O
293	O
cells	O
indicated	O
that	O
the	O
catalytic	O
efficiency	O
(	O
apparent	O
catalytic	O
efficiency	O
=	O
maximum	O
velocity	O
/	O
Km	O
)	O
of	O
this	O
3betaHSD	B
activity	O
is	O
approximately	O
2000	O
-	O
fold	O
(	O
pregnenolone	O
as	O
substrate	O
)	O
or	O
3000	O
-	O
fold	O
(	O
DHEA	O
as	O
substrate	O
)	O
weaker	O
than	O
that	O
of	O
17betaHSD2	B
activity	O
.	O

It	O
is	O
noteworthy	O
,	O
however	O
,	O
that	O
the	O
apparent	O
catalytic	O
efficiency	O
of	O
the	O
HSD3B2	B
gene	O
product	O
is	O
only	O
approximately	O
50	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
3betaHSD	B
aspect	O
of	O
the	O
17betaHSD2	B
gene	O
product	O
.	O

Pregnenolone	O
or	O
DHEA	O
effectively	O
inhibited	O
17betaHSD2	B
activity	O
in	O
a	O
noncompetitive	O
fashion	O
.	O

Furthermore	O
,	O
the	O
potent	O
5alpha	B
-	I
reductase	I
/	I
3betaHSD	I
inhibitor	O
,	O
17beta	O
-	O
N	O
,	O
N	O
-	O
diethylcarbamoyl-4-methyl-4-aza-5alpha	O
-	O
androstane-3-one	O
,	O
inhibited	O
neither	O
3betaHSD	B
nor	O
17betaHSD2	B
activities	O
.	O

We	O
conclude	O
that	O
human	O
17betaHSD2	B
enzyme	O
exhibits	O
3betaHSD	B
activity	O
.	O

Notwithstanding	O
that	O
this	O
3betaHSD	B
activity	O
is	O
reduced	O
compared	O
to	O
17betaHSD	B
oxidative	O
activity	O
,	O
it	O
may	O
account	O
for	O
at	O
least	O
some	O
of	O
the	O
reports	O
of	O
3betaHSD	B
activity	O
found	O
in	O
human	O
peripheral	O
tissues	O
that	O
express	O
notable	O
amounts	O
of	O
the	O
17betaHSD2	B
isozyme	O
as	O
well	O
as	O
in	O
individuals	O
with	O
severe	O
classic	O
3betaHSD	B
deficiency	O
.	O

Crystal	O
structure	O
of	O
fibroblast	B
growth	I
factor	I
receptor	I
ectodomain	O
bound	O
to	O
ligand	O
and	O
heparin	O
.	O

Fibroblast	B
growth	I
factors	I
(	O
FGFs	B
)	O
are	O
a	O
large	O
family	O
of	O
structurally	O
related	O
proteins	O
with	O
a	O
wide	O
range	O
of	O
physiological	O
and	O
pathological	O
activities	O
.	O

Signal	O
transduction	O
requires	O
association	O
of	O
FGF	B
with	O
its	O
receptor	B
tyrosine	I
kinase	I
(	O
FGFR	B
)	O
and	O
heparan	O
sulphate	O
proteoglycan	O
in	O
a	O
specific	O
complex	O
on	O
the	O
cell	O
surface	O
.	O

Direct	O
involvement	O
of	O
the	O
heparan	O
sulphate	O
glycosaminoglycan	O
polysaccharide	O
in	O
the	O
molecular	O
association	O
between	O
FGF	B
and	O
its	O
receptor	O
is	O
essential	O
for	O
biological	O
activity	O
.	O

Although	O
crystal	O
structures	O
of	O
binary	O
complexes	O
of	O
FGF	B
-	O
heparin	O
and	O
FGF	B
-	O
FGFR	B
have	O
been	O
described	O
,	O
the	O
molecular	O
architecture	O
of	O
the	O
FGF	B
signalling	O
complex	O
has	O
not	O
been	O
elucidated	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
FGFR2	B
ectodomain	O
in	O
a	O
dimeric	O
form	O
that	O
is	O
induced	O
by	O
simultaneous	O
binding	O
to	O
FGF1	B
and	O
a	O
heparin	O
decasaccharide	O
.	O

The	O
complex	O
is	O
assembled	O
around	O
a	O
central	O
heparin	O
molecule	O
linking	O
two	O
FGF1	B
ligands	O
into	O
a	O
dimer	O
that	O
bridges	O
between	O
two	O
receptor	O
chains	O
.	O

The	O
asymmetric	O
heparin	O
binding	O
involves	O
contacts	O
with	O
both	O
FGF1	B
molecules	O
but	O
only	O
one	O
receptor	O
chain	O
.	O

The	O
structure	O
of	O
the	O
FGF1	B
-	O
FGFR2	B
-	O
heparin	O
ternary	O
complex	O
provides	O
a	O
structural	O
basis	O
for	O
the	O
essential	O
role	O
of	O
heparan	O
sulphate	O
in	O
FGF	B
signalling	O
.	O

Gene	O
structure	O
and	O
promoter	O
variation	O
of	O
expressed	O
and	O
nonexpressed	O
variants	O
of	O
the	O
KIR2DL5	B
gene	O
.	O

Two	O
variants	O
of	O
the	O
novel	O
KIR2DL5	B
gene	O
(	O
KIR2DL5.1	B
and.2	I
)	O
were	O
identified	O
in	O
genomic	O
DNA	O
of	O
a	O
single	O
donor	O
.	O

However	O
,	O
only	O
the	O
KIR2DL5.1	B
variant	O
was	O
transcribed	O
in	O
PBMC	O
.	O

In	O
this	O
study	O
,	O
analysis	O
of	O
seven	O
additional	O
donors	O
reveals	O
two	O
new	O
variants	O
of	O
the	O
KIR2DL5	B
gene	O
and	O
indicates	O
that	O
transcription	O
,	O
or	O
its	O
lack	O
,	O
are	O
consistently	O
associated	O
with	O
particular	O
variants	O
of	O
this	O
gene	O
.	O

Comparison	O
of	O
the	O
complete	O
nucleotide	O
sequences	O
of	O
the	O
exons	O
and	O
introns	O
of	O
KIR2DL5.1	B
and	O
KIR2DL5.2	B
reveals	O
no	O
structural	O
abnormalities	O
,	O
but	O
similar	O
open	O
reading	O
frames	O
for	O
both	O
variants	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
region	O
of	O
KIR2DL5	B
shows	O
a	O
high	O
degree	O
of	O
sequence	O
polymorphism	O
that	O
is	O
likely	O
relevant	O
for	O
expression	O
.	O

Substitution	O
within	O
a	O
putative	O
binding	O
site	O
for	O
the	O
transcription	B
factor	I
acute	B
myeloid	I
leukemia	I
gene	I
1	I
could	O
determine	O
the	O
lack	O
of	O
expression	O
for	O
some	O
KIR2DL5	B
variants	O
.	O

Influence	O
of	O
vitamin	O
C	O
supplementation	O
on	O
cytokine	B
changes	O
following	O
an	O
ultramarathon	O
.	O

The	O
influence	O
of	O
vitamin	O
C	O
supplementation	O
on	O
the	O
pattern	O
of	O
change	O
in	O
plasma	O
cytokine	B
concentrations	O
was	O
measured	O
in	O
29	O
runners	O
following	O
a	O
90	O
-	O
km	O
ultramarathon	O
.	O

The	O
study	O
was	O
based	O
on	O
a	O
3	O
(	O
groups	O
)	O
by	O
4	O
(	O
blood	O
samples	O
at	O
16	O
prerace	O
,	O
postrace	O
,	O
and	O
24	O
h	O
and	O
48	O
h	O
postrace	O
)	O
repeated	O
measures	O
design	O
.	O

Groups	O
included	O
placebo	O
control	O
(	O
n	O
=	O
7	O
)	O
and	O
two	O
groups	O
supplementing	O
vitamin	O
C	O
at	O
500	O
mg	O
/	O
day	O
(	O
vit	O
C-500	O
,	O
n	O
=	O
10	O
)	O
or	O
1500	O
mg	O
/	O
day	O
(	O
vit	O
C-1500	O
,	O
n	O
=	O
12	O
)	O
for	O
7	O
days	O
before	O
the	O
race	O
,	O
on	O
race	O
day	O
,	O
and	O
for	O
2	O
days	O
after	O
the	O
race	O
.	O

All	O
measured	O
plasma	O
cytokine	B
concentrations	O
were	O
significantly	O
elevated	O
immediately	O
postrace	O
,	O
with	O
the	O
magnitude	O
of	O
increase	O
for	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
much	O
smaller	O
than	O
for	O
IL-6	B
,	O
IL-10	B
,	O
IL-8	B
,	O
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1RA	B
)	O
.	O

Cortisol	O
increased	O
in	O
all	O
groups	O
immediately	O
after	O
the	O
race	O
but	O
significantly	O
less	O
in	O
the	O
vit	O
C-1500	O
group	O
.	O

Group	O
x	O
time	O
interaction	O
statistics	O
were	O
not	O
significant	O
for	O
any	O
of	O
the	O
plasma	O
cytokines	B
.	O

However	O
,	O
when	O
the	O
placebo	O
and	O
vit	O
C-500	O
groups	O
were	O
combined	O
(	O
n	O
=	O
17	O
)	O
and	O
compared	O
with	O
the	O
vit	O
C-1500	O
group	O
(	O
n	O
=	O
12	O
)	O
,	O
immediate	O
postrace	O
plasma	O
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
vit	O
C-1500	O
group	O
for	O
IL-1RA	O
(	O
-	O
57	O
%	O
)	O
and	O
IL-10	O
(	O
-	O
57	O
%	O
)	O
,	O
with	O
a	O
trend	O
measured	O
for	O
IL-6	B
(	O
-	O
27	O
%	O
,	O
p	O
=	O
0.11	O
)	O
and	O
IL-8	O
(	O
-	O
26	O
%	O
,	O
p	O
=	O
0.14	O
)	O
.	O

In	O
summary	O
,	O
runners	O
completing	O
the	O
90	O
-	O
km	O
Comrades	O
Ultramarathon	O
experienced	O
strong	O
increases	O
in	O
concentrations	O
of	O
plasma	O
IL-6	B
,	O
IL-10	B
,	O
IL-1RA	B
,	O
and	O
IL-8	B
.	O

These	O
increases	O
were	O
attenuated	O
in	O
runners	O
ingesting	O
1500	O
mg	O
but	O
not	O
500	O
mg	O
vitamin	O
C	O
supplements	O
for	O
1	O
week	O
prior	O
to	O
the	O
race	O
and	O
on	O
race	O
day	O
.	O

A	O
ubiquitin	B
-	O
like	O
system	O
mediates	O
protein	O
lipidation	O
.	O

Autophagy	O
is	O
a	O
dynamic	O
membrane	O
phenomenon	O
for	O
bulk	O
protein	O
degradation	O
in	O
the	O
lysosome	O
/	O
vacuole	O
.	O

Apg8	B
/	O
Aut7	B
is	O
an	O
essential	O
factor	O
for	O
autophagy	O
in	O
yeast	O
.	O

We	O
previously	O
found	O
that	O
the	O
carboxy	O
-	O
terminal	O
arginine	O
of	O
nascent	O
Apg8	B
is	O
removed	O
by	O
Apg4	B
/	O
Aut2	B
protease	B
,	O
leaving	O
a	O
glycine	O
residue	O
at	O
the	O
C	O
terminus	O
.	O

Apg8	B
is	O
then	O
converted	O
to	O
a	O
form	O
(	O
Apg8-X	B
)	O
that	O
is	O
tightly	O
bound	O
to	O
the	O
membrane	O
.	O

Here	O
we	O
report	O
a	O
new	O
mode	O
of	O
protein	O
lipidation	O
.	O

Apg8	B
is	O
covalently	O
conjugated	O
to	O
phosphatidylethanolamine	O
through	O
an	O
amide	O
bond	O
between	O
the	O
C	O
-	O
terminal	O
glycine	O
and	O
the	O
amino	O
group	O
of	O
phosphatidylethanolamine	O
.	O

This	O
lipidation	O
is	O
mediated	O
by	O
a	O
ubiquitination	O
-	O
like	O
system	O
.	O

Apg8	B
is	O
a	O
ubiquitin	B
-	I
like	I
protein	I
that	O
is	O
activated	O
by	O
an	O
E1	O
protein	O
,	O
Apg7	B
(	O
refs	O
7	O
,	O
8	O
)	O
,	O
and	O
is	O
transferred	O
subsequently	O
to	O
the	O
E2	O
enzymes	O
Apg3	B
/	O
Aut1	B
(	O
ref	O
.	O
9	O
)	O
.	O

Apg7	B
activates	O
two	O
different	O
ubiquitin	B
-	I
like	I
proteins	I
,	O
Apg12	B
(	O
ref	O
.	O
10	O
)	O
and	O
Apg8	B
,	O
and	O
assigns	O
them	O
to	O
specific	O
E2	O
enzymes	O
,	O
Apg10	B
(	O
ref	O
.	O
11	O
)	O
and	O
Apg3	B
,	O
respectively	O
.	O

These	O
reactions	O
are	O
necessary	O
for	O
the	O
formation	O
of	O
Apg8	B
-	O
phosphatidylethanolamine	O
.	O

This	O
lipidation	O
has	O
an	O
essential	O
role	O
in	O
membrane	O
dynamics	O
during	O
autophagy	O
.	O

Interaction	O
of	O
the	O
retinoblastoma	B
protein	I
(	O
pRb	B
)	O
with	O
the	O
catalytic	B
subunit	I
of	I
DNA	I
polymerase	I
delta	I
(	I
p125	I
)	I
.	O

The	O
retinoblastoma	B
gene	O
product	O
(	O
pRb	B
)	O
interacts	O
with	O
many	O
cellular	O
proteins	O
to	O
function	O
in	O
the	O
control	O
of	O
cell	O
division	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
.	O

Several	O
pRb	B
binding	O
proteins	O
complex	O
with	O
pRb	B
through	O
an	O
amino	O
acid	O
sequence	O
called	O
the	O
LXCXE	O
motif	O
.	O

The	O
catalytic	B
subunit	I
of	I
DNA	I
polymerase	I
delta	I
(	I
p125	I
)	I
contains	O
a	O
LXCXE	O
motif	O
.	O

To	O
further	O
study	O
the	O
biochemical	O
function	O
of	O
this	O
polymerase	B
,	O
we	O
sought	O
to	O
determine	O
if	O
p125	B
interacts	O
with	O
pRb	B
.	O

Experiments	O
using	O
GST	B
-	O
pRb	B
fusion	O
proteins	O
showed	O
that	O
p125	B
from	O
breast	O
epithelial	O
(	O
MCF10A	O
)	O
cell	O
extracts	O
associates	O
with	O
pRb	B
.	O

In	O
addition	O
,	O
GST	B
-	O
p125	B
fusion	O
proteins	O
bound	O
pRb	B
from	O
the	O
same	O
cell	O
extracts	O
.	O

The	O
pRb	B
that	O
associated	O
with	O
GST	B
-	O
p125	B
was	O
largely	O
unphosphorylated	O
.	O

Coimmunoprecipitation	O
experiments	O
using	O
cell	O
cycle	O
synchronized	O
cells	O
revealed	O
that	O
p125	B
and	O
pRb	B
form	O
a	O
complex	O
predominantly	O
during	O
G1	O
phase	O
,	O
the	O
phase	O
during	O
which	O
pRb	B
is	O
mostly	O
unphosphorylated	O
.	O

In	O
vitro	O
phosphorylation	O
of	O
GST	B
-	O
pRb	B
by	O
the	O
cyclin	B
dependent	I
kinases	I
reduced	O
the	O
ability	O
of	O
p125	B
to	O
associate	O
with	O
GST	B
-	O
pRh	B
.	O

Addition	O
of	O
the	O
LXCXE	O
containing	O
protein	O
SV40	O
large	B
T	I
antigen	I
to	O
GST	B
-	O
pRb	B
blocks	O
the	O
ability	O
of	O
p125	B
to	O
associate	O
with	O
pRb	B
,	O
suggesting	O
that	O
it	O
may	O
be	O
through	O
a	O
LXCXE	O
sequence	O
by	O
which	O
p125	B
interacts	O
with	O
pRb	B
.	O

Finally	O
,	O
in	O
vitro	O
polymerase	B
assays	O
demonstrate	O
that	O
GST	B
-	O
pRb	B
fusion	O
protein	O
stimulates	O
DNA	B
polymerase	I
delta	I
activity	O
.	O

Adhesion	O
of	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
to	O
intraocular	O
lens	O
materials	O
in	O
pseudophakic	O
human	O
autopsy	O
eyes	O
.	O

Part	O
1	O
:	O
histological	O
sections	O
.	O

PURPOSE	O
:	O

To	O
evaluate	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
adhesion	O
to	O
poly	O
(	O
methyl	O
methacrylate	O
)	O
(	O
PMMA	O
)	O
,	O
silicone	O
,	O
hydrophobic	O
soft	O
acrylate	O
,	O
and	O
hydrogel	O
intraocular	O
lenses	O
(	O
IOLs	O
)	O
in	O
pseudophakic	O
human	O
autopsy	O
eyes	O
.	O

SETTING	O
:	O

Center	O
for	O
Research	O
on	O
Ocular	O
Therapeutics	O
and	O
Biodevices	O
,	O
Storm	O
Eye	O
Institute	O
,	O
Medical	O
University	O
of	O
South	O
Carolina	O
,	O
Charleston	O
,	O
South	O
Carolina	O
,	O
USA	O
.	O

METHODS	O
:	O

Thirty	O
-	O
eight	O
autopsy	O
eyes	O
containing	O
PMMA	O
,	O
silicone	O
,	O
hydrophobic	O
acrylate	O
,	O
or	O
hydrogel	O
IOLs	O
were	O
assessed	O
.	O

Histological	O
sections	O
were	O
prepared	O
from	O
each	O
eye	O
,	O
and	O
immunohistochemical	O
analyses	O
were	O
performed	O
for	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
.	O

One	O
hundred	O
fifty	O
-	O
two	O
specimens	O
were	O
analyzed	O
.	O

RESULTS	O
:	O

A	O
sandwich	O
-	O
like	O
structure	O
(	O
anterior	O
or	O
posterior	O
capsule	O
/	O
fibronectin	B
/	O
1	O
cell	O
layer	O
/	O
fibronectin	B
/	O
IOL	O
surface	O
)	O
was	O
seen	O
in	O
12	O
of	O
14	O
autopsy	O
eyes	O
with	O
soft	O
acrylate	O
IOLs	O
,	O
3	O
of	O
10	O
with	O
a	O
PMMA	O
IOL	O
(	O
P	O
=	O
.0094	O
)	O
,	O
1	O
of	O
10	O
with	O
a	O
silicone	O
IOL	O
(	O
P	O
=	O
.0022	O
)	O
,	O
and	O
0	O
of	O
4	O
with	O
a	O
hydrogel	O
IOL	O
(	O
P	O
=	O
.	O
0041	O
)	O
.	O

The	O
thicker	O
fibrocellular	O
tissue	O
on	O
the	O
inner	O
surface	O
of	O
the	O
anterior	O
or	O
posterior	O
capsule	O
that	O
was	O
in	O
contact	O
with	O
silicone	O
IOLs	O
was	O
lined	O
with	O
collagen	B
type	I
IV	I
.	O

Vitronectin	B
and	O
laminin	B
were	O
not	O
found	O
at	O
the	O
fibrocellular	O
tissue	O
-	O
IOL	O
interface	O
in	O
any	O
specimen	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
seems	O
to	O
confirm	O
the	O
sandwich	O
theory	O
of	O
posterior	O
capsule	O
opacification	O
in	O
eyes	O
with	O
an	O
IOL	O
and	O
suggests	O
that	O
fibronectin	B
may	O
be	O
the	O
major	O
extracellular	O
protein	O
responsible	O
for	O
the	O
attachment	O
of	O
hydrophobic	O
soft	O
acrylate	O
(	O
AcrySof	O
(	O
R	O
)	O
)	O
IOLs	O
to	O
the	O
capsular	O
bag	O
.	O

This	O
may	O
represent	O
a	O
true	O
bioactive	O
bond	O
between	O
the	O
IOL	O
and	O
lens	O
epithelial	O
cells	O
or	O
between	O
the	O
IOL	O
and	O
the	O
capsular	O
bag	O
and	O
may	O
be	O
one	O
reason	O
the	O
PCO	O
and	O
neodymium	O
:	O
YAG	O
capsulotomy	O
rates	O
are	O
lower	O
in	O
eyes	O
with	O
a	O
soft	O
acrylate	O
IOL	O
.	O

BLyS	B
BINDS	O
TO	O
B	O
CELLS	O
WITH	O
HIGH	O
AFFINITY	O
AND	O
INDUCES	O
ACTIVATION	O
OF	O
THE	O
TRANSCRIPTION	B
FACTORS	I
NF	B
-	I
kappaB	I
AND	O
ELF-1	B
.	O

B	B
lymphocyte	I
stimulator	I
(	O
BLyS	B
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
TNF	B
family	I
of	O
proteins	O
expressed	O
by	O
myeloid	O
cells	O
as	O
membrane	O
-	O
bound	O
and	O
soluble	O
forms	O
.	O

BLyS	B
was	O
shown	O
to	O
act	O
specifically	O
on	O
B	O
cells	O
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	B
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	O
BLyS	B
to	O
its	O
cognate	O
receptor	O
on	O
human	O
B	O
lymphocytes	O
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
BLyS	B
binding	O
.	O

Similar	O
to	O
other	O
TNF	B
family	I
members	O
,	O
BLyS	B
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	O
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O

BLyS	B
binding	O
to	O
B	O
cells	O
is	O
specific	O
as	O
other	O
TNF	B
family	I
members	O
tested	O
did	O
not	O
compete	O
for	O
(	O
125	O
)	O
I	O
-	O
BLyS	B
binding	O
.	O

Analysis	O
of	O
equilibrium	O
binding	O
of	O
(	O
125	O
)	O
I	O
-	O
labeled	O
BLyS	B
to	O
purified	O
human	O
tonsillar	O
B	O
cells	O
demonstrated	O
saturable	O
binding	O
.	O

Scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
on	O
human	O
B	O
cells	O
with	O
approximately	O
2600	O
binding	O
sites	O
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
D	O
)	O
)	O
of	O
about	O
0.1	O
nM	O
.	O

In	O
addition	O
we	O
report	O
that	O
BLyS	B
binding	O
to	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
the	O
Ets	B
family	I
transcription	I
factor	I
,	O
ELF-1	B
,	O
and	O
in	O
the	O
induction	O
of	O
mRNA	O
for	O
Polo	B
-	I
like	I
kinase	I
(	O
PLK	B
)	O
.	O

Characterization	O
of	O
cytokine	B
,	O
growth	B
factor	I
receptor	I
,	O
costimulatory	O
and	O
adhesion	B
molecule	I
expression	O
patterns	O
of	O
bone	O
marrow	O
blasts	O
in	O
relapsed	O
childhood	O
B	O
cell	O
precursor	O
all	O
.	O

Relapse	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
comprises	O
a	O
leading	O
challenge	O
of	O
investigation	O
.	O

Characterization	O
of	O
leukaemic	O
cells	O
regarding	O
their	O
potency	O
to	O
express	O
growth	O
factors	O
and	O
surface	O
molecules	O
can	O
provide	O
insight	O
into	O
their	O
aberrant	O
biology	O
.	O

Thus	O
,	O
we	O
analyzed	O
bone	O
marrow	O
blasts	O
from	O
10	O
children	O
with	O
relapsed	O
B	O
cell	O
precursor	O
ALL	O
.	O

The	O
gene	O
and	O
protein	O
expression	O
of	O
essential	O
haematopoietic	O
growth	B
factors	I
(	O
IL-2	B
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-10	B
,	O
IL-15	B
,	O
IFN	B
-	I
gamma	I
,	O
G	B
-	I
CSFR	I
)	O
,	O
their	O
corresponding	O
receptors	O
as	O
well	O
as	O
the	O
expression	O
pattern	O
of	O
adhesion	B
molecules	I
(	O
ICAM-1	B
,	O
CD58	B
)	O
and	O
costimulatory	O
proteins	O
(	O
CD40	B
,	O
CD40L	B
,	O
B7.1	B
,	O
B7.2	B
,	O
CD28	B
,	O
MHC	B
-	I
I	I
and	I
II	I
)	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
and	O
flow	O
cytometry	O
.	O

Constitutive	O
gene	O
expression	O
was	O
found	O
for	O
IL-7	B
,	O
IL-10	B
,	O
IL-15	B
and	O
IFN	B
-	I
gamma	I
and	O
their	O
corresponding	O
receptors	O
.	O

Flow	O
-	O
cytometric	O
analysis	O
showed	O
that	O
IL-10R	B
,	O
IL-7Ralpha	B
,	O
IL-4Ralpha	B
and	O
the	O
gamma	B
(	I
c	I
)	I
chain	O
are	O
constitutively	O
expressed	O
,	O
and	O
that	O
some	O
cells	O
bear	O
the	O
G	B
-	I
CSFR	I
.	O

IL-10	B
and	O
IL-15	B
protein	O
-	O
producing	O
leukaemic	O
cells	O
were	O
easily	O
detectable	O
.	O

The	O
neoplastic	O
cells	O
mainly	O
lack	O
B7.1	B
,	O
and	O
ICAM-1	B
is	O
mostly	O
decreased	O
.	O

Furthermore	O
,	O
high	O
CD40	B
,	O
and	O
,	O
surprisingly	O
,	O
CD40L	B
expression	O
could	O
be	O
found	O
.	O

These	O
studies	O
show	O
that	O
ALL	O
cells	O
are	O
likely	O
to	O
be	O
sensitive	O
to	O
many	O
growth	B
factors	I
and	O
some	O
factors	O
are	O
produced	O
by	O
the	O
neoplastic	O
cell	O
itself	O
.	O

The	O
secretion	O
of	O
IL-10	B
by	O
leukaemic	O
cells	O
,	O
and	O
the	O
absence	O
or	O
downregulation	O
of	O
conventional	O
adhesion	O
and	O
costimulatory	O
molecules	O
might	O
represent	O
an	O
effective	O
mechanism	O
of	O
escape	O
of	O
immune	O
surveillance	O
in	O
relapsed	O
ALL	O
.	O

Unexpected	O
presence	O
of	O
defective	O
glpR	B
alleles	O
in	O
various	O
strains	O
of	O
Escherichia	O
coli	O
.	O

Alleles	O
of	O
glpR	B
associated	O
with	O
the	O
same	O
GlpR	B
(	O
-	O
)	O
phenotype	O
produce	O
substitutions	O
in	O
different	O
conserved	O
portions	O
of	O
the	O
glycerol	B
3-phosphate	I
repressor	I
which	O
are	O
not	O
part	O
of	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
motif	O
.	O

Analysis	O
of	O
the	O
effects	O
on	O
growth	O
and	O
enzyme	O
expression	O
show	O
that	O
glucose	O
repression	O
of	O
glycerol	O
utilization	O
is	O
not	O
dependent	O
on	O
a	O
functional	O
repressor	O
.	O

Insulinotropic	O
hormone	O
glucagon	B
-	I
like	I
peptide	I
1	I
(	O
GLP-1	B
)	O
activation	O
of	O
insulin	B
gene	O
promoter	O
inhibited	O
by	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
.	O

The	O
insulin	B
gene	O
promoter	O
contains	O
many	O
transcriptional	O
response	O
elements	O
that	O
predispose	O
the	O
gene	O
to	O
a	O
wide	O
range	O
of	O
regulatory	O
signals	O
.	O

Glucagon	B
-	I
like	I
peptide	I
1	I
(	O
GLP-1	B
)	O
stimulates	O
insulin	B
gene	O
transcription	O
by	O
intracellular	O
second	O
messenger	O
cascades	O
leading	O
to	O
direct	O
transcription	B
factor	I
activation	O
or	O
to	O
the	O
up	O
-	O
regulation	O
of	O
insulin	B
promoter	O
specific	O
transcription	B
factors	I
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
a	O
novel	O
regulatory	O
signaling	O
mechanism	O
acting	O
on	O
the	O
rat	O
insulin	B
1	I
promoter	O
(	O
rINS1	B
)	O
in	O
the	O
INS	B
-	I
1	I
beta	O
-	O
cell	O
line	O
.	O

In	O
the	O
presence	O
of	O
stimulatory	O
concentrations	O
of	O
GLP-1	B
(	O
0.1	O
--	O
100	O
nM	O
)	O
on	O
rINS1	B
activity	O
,	O
inhibition	O
of	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
p38	B
MAPK	I
)	O
using	O
SB	O
203580	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
promoter	O
activity	O
(	O
maximum	O
3	O
-	O
fold	O
)	O
over	O
GLP	B
-	I
1	I
alone	O
,	O
as	O
determined	O
by	O
rINS1	B
promoter	O
-	O
luciferase	B
reporter	O
gene	O
expression	O
.	O

This	O
effect	O
was	O
revealed	O
to	O
be	O
mediated	O
via	O
the	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
of	O
rINS1	B
,	O
because	O
site	O
directed	O
mutagenesis	O
of	O
the	O
CRE	O
motif	O
in	O
rINS1	B
abolished	O
the	O
increased	O
response	O
to	O
SB	O
203580	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
p38	B
MAPK	I
uncovered	O
a	O
similar	O
,	O
more	O
pronounced	O
,	O
response	O
in	O
the	O
expression	O
of	O
a	O
generic	O
CRE	O
promoter	O
driven	O
reporter	O
gene	O
.	O

Time	O
course	O
dose	O
-	O
response	O
studies	O
indicate	O
that	O
the	O
p38	B
MAPK	I
induced	O
inhibitory	O
response	O
may	O
involve	O
expression	O
of	O
immediate	O
early	O
genes	O
(	O
IEGs	O
)	O
;	O
maximum	O
repression	O
of	O
rINS1	B
activity	O
occurred	O
after	O
4	O
h	O
of	O
treatment	O
,	O
comparable	O
with	O
regulatory	O
responses	O
by	O
IEGs	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
demonstrate	O
a	O
novel	O
signaling	O
mechanism	O
whereby	O
p38	B
MAPK	I
represses	O
rINS1	B
promoter	O
activity	O
in	O
response	O
to	O
GLP	B
-	I
1	I
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
robust	O
regulatory	O
control	O
by	O
p38	B
MAPK	I
in	O
insulin	B
gene	O
expression	O
.	O

The	O
relevance	O
of	O
this	O
mechanism	O
may	O
be	O
most	O
apparent	O
during	O
periods	O
of	O
cellular	O
stress	O
in	O
which	O
p38	B
MAPK	I
activity	O
is	O
stimulated	O
.	O

In	O
this	O
regard	O
,	O
reduced	O
insulin	O
expression	O
levels	O
caused	O
by	O
chronic	O
hyperglycemia	O
(	O
glucotoxicity	O
)	O
and	O
/	O
or	O
hyperlipidemia	O
(	O
lipotoxicity	O
)	O
may	O
be	O
a	O
direct	O
consequence	O
of	O
this	O
mechanism	O
.	O

Directly	O
linked	O
soluble	O
IL-6	B
receptor	I
-	O
IL-6	B
fusion	O
protein	O
induces	O
astrocyte	O
differentiation	O
from	O
neuroepithelial	O
cells	O
via	O
activation	O
of	O
STAT3	B
.	O

Signals	O
of	O
interleukin	B
6	I
(	O
IL-6	B
)	O
are	O
transduced	O
by	O
binding	O
of	O
IL-6	B
to	O
its	O
cell	O
surface	O
receptor	O
(	O
IL-6R	B
)	O
and	O
subsequent	O
association	O
of	O
the	O
resultant	O
IL-6	B
/	O
IL-6R	B
complex	O
with	O
gp130	B
,	O
the	O
signal	O
transducing	O
receptor	O
component	O
utilized	O
in	O
common	O
by	O
all	O
the	O
IL-6	B
family	I
of	I
cytokines	I
.	O

A	O
soluble	O
form	O
of	O
IL-6R	B
(	O
sIL-6R	B
)	O
,	O
which	O
lacks	O
transmembrane	O
and	O
cytoplasmic	O
regions	O
,	O
retains	O
the	O
ability	O
to	O
bind	O
IL-6	B
and	O
signal	O
through	O
gp130	B
.	O

We	O
show	O
here	O
that	O
a	O
fusion	O
protein	O
of	O
sIL-6R	B
and	O
IL-6	B
without	O
a	O
polypeptide	O
linker	O
,	O
termed	O
FP6	O
,	O
induces	O
differentiation	O
of	O
astrocytes	O
from	O
fetal	O
mouse	O
neuroepithelial	O
cells	O
as	O
potently	O
as	O
a	O
representative	O
IL-6	B
family	I
cytokine	I
,	O
leukaemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
.	O

FP6	O
has	O
a	O
potential	O
to	O
activate	O
a	O
transcription	B
factor	I
,	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
,	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
,	O
ERK1	B
and	O
ERK2	B
,	O
in	O
these	O
cells	O
as	O
does	O
LIF	B
.	O

FP6	O
activates	O
a	O
promoter	O
of	O
the	O
gene	O
for	O
an	O
astrocytic	O
marker	O
,	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
,	O
in	O
neuroepithelial	O
cells	O
.	O

This	O
activation	O
is	O
virtually	O
abolished	O
by	O
ectopic	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
STAT3	B
,	O
or	O
by	O
introducing	O
a	O
point	O
mutation	O
into	O
the	O
STAT3	B
response	O
element	O
located	O
in	O
the	O
GFAP	B
promoter	O
.	O

These	O
results	O
suggest	O
that	O
FP6	O
induces	O
astrocyte	O
differentiation	O
from	O
neuroepithelial	O
cells	O
through	O
STAT3	B
activation	O
and	O
that	O
FP6	O
could	O
be	O
of	O
use	O
as	O
a	O
substitute	O
for	O
natural	O
IL-6	B
family	I
cytokines	I
.	O

Stromal	O
and	O
epithelial	O
expression	O
of	O
tumor	O
markers	O
hyaluronic	O
acid	O
and	O
HYAL1	B
hyaluronidase	B
in	O
prostate	O
cancer	O
.	O

Hyaluronic	O
acid	O
(	O
HA	O
)	O
,	O
a	O
glycosaminoglycan	O
,	O
regulates	O
cell	O
adhesion	O
and	O
migration	O
.	O

Hyaluronidase	B
(	O
HAase	B
)	O
,	O
an	O
endoglycosidase	B
,	O
degrades	O
HA	O
into	O
small	O
angiogenic	O
fragments	O
.	O

Using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
like	O
assay	O
,	O
we	O
found	O
increased	O
HA	O
levels	O
(	O
3	O
-	O
8	O
-	O
fold	O
)	O
in	O
prostate	O
cancer	O
(	O
CaP	O
)	O
tissues	O
when	O
compared	O
with	O
normal	O
(	O
NAP	O
)	O
and	O
benign	O
(	O
BPH	O
)	O
tissues	O
.	O

The	O
majority	O
(	O
approximately	O
75	O
-	O
80	O
%	O
)	O
of	O
HA	O
in	O
prostate	O
tissues	O
was	O
found	O
to	O
exist	O
in	O
the	O
free	O
form	O
.	O

Primary	O
CaP	O
fibroblast	O
and	O
epithelial	O
cells	O
secreted	O
3	O
-	O
8	O
-	O
fold	O
more	O
HA	O
than	O
respective	O
NAP	O
and	O
BPH	O
cultures	O
.	O

Only	O
CaP	O
epithelial	O
cells	O
and	O
established	O
CaP	O
lines	O
secreted	O
HAase	B
and	O
the	O
secretion	O
increased	O
with	O
tumor	O
grade	O
and	O
metastasis	O
.	O

The	O
pH	O
activity	O
profile	O
and	O
optimum	O
(	O
4.2	O
;	O
range	O
4.0	O
-	O
4.3	O
)	O
of	O
CaP	O
HAase	B
was	O
identical	O
to	O
the	O
HYAL1	B
-	O
type	O
HAase	B
present	O
in	O
human	O
serum	O
and	O
urine	O
.	O

Full	O
-	O
length	O
HYAL1	B
transcript	O
and	O
splice	O
variants	O
were	O
detected	O
in	O
CaP	O
cells	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
cloning	O
,	O
and	O
sequencing	O
.	O

Immunoblotting	O
confirmed	O
secretion	O
of	O
a	O
approximately	O
60	O
-	O
kDa	O
HYAL1	B
-	O
related	O
protein	O
by	O
CaP	O
cells	O
.	O

Immunohistochemistry	O
showed	O
minimal	O
HA	O
and	O
HYAL1	B
staining	O
in	O
NAP	O
and	O
BPH	O
tissues	O
.	O

However	O
,	O
a	O
stromal	O
and	O
epithelial	O
pattern	O
of	O
HA	O
and	O
HYAL1	B
expression	O
was	O
observed	O
in	O
CaP	O
tissues	O
.	O

While	O
high	O
HA	O
staining	O
was	O
observed	O
in	O
tumor	O
-	O
associated	O
stroma	O
,	O
HYAL1	B
staining	O
in	O
tumor	O
cells	O
increased	O
with	O
tumor	O
grade	O
and	O
metastasis	O
.	O

The	O
gel	O
-	O
filtration	O
column	O
profiles	O
of	O
HA	O
species	O
in	O
NAP	O
,	O
BPH	O
,	O
and	O
CaP	O
tissues	O
were	O
different	O
.	O

While	O
the	O
higher	O
molecular	O
mass	O
and	O
intermediate	O
size	O
HA	O
was	O
found	O
in	O
all	O
tissues	O
,	O
the	O
HA	O
fragments	O
were	O
found	O
only	O
in	O
CaP	O
tissues	O
.	O

In	O
particular	O
,	O
the	O
high	O
-	O
grade	O
CaP	O
tissues	O
,	O
which	O
showed	O
both	O
elevated	O
HA	O
and	O
HYAL1	B
levels	O
,	O
contained	O
angiogenic	O
HA	O
fragments	O
.	O

The	O
stromal	O
-	O
epithelial	O
HA	O
and	O
HYAL1	B
expression	O
may	O
promote	O
angiogenesis	O
in	O
CaP	O
and	O
may	O
serve	O
as	O
prognostic	O
markers	O
for	O
CaP	O
.	O

A	O
family	O
of	O
AP-2	B
proteins	O
down	O
-	O
regulate	O
manganese	B
superoxide	I
dismutase	I
expression	O
.	O

Manganese	B
superoxide	I
dismutase	I
(	O
Mn	B
-	I
SOD	I
)	O
is	O
a	O
primary	O
antioxidant	O
enzyme	O
whose	O
expression	O
is	O
essential	O
for	O
life	O
in	O
oxygen	O
.	O

Mn	B
-	I
SOD	I
has	O
tumor	O
suppressor	O
activity	O
in	O
a	O
wide	O
variety	O
of	O
tumors	O
and	O
transformed	O
cell	O
systems	O
.	O

Our	O
initial	O
observations	O
revealed	O
that	O
Mn	B
-	I
SOD	I
expression	O
was	O
inversely	O
correlated	O
with	O
expression	O
of	O
AP-2	B
transcription	B
factors	I
in	O
normal	O
human	O
fibroblasts	O
and	O
their	O
SV-40	O
transformed	O
counterparts	O
.	O

Thus	O
we	O
hypothesized	O
that	O
AP-2	B
may	O
down	O
-	O
regulate	O
Mn	B
-	I
SOD	I
expression	O
.	O

To	O
examine	O
the	O
functional	O
role	O
of	O
AP-2	B
on	O
Mn	B
-	I
SOD	I
promoter	O
transactivation	O
we	O
cotransfected	O
AP-2	B
-	O
deficient	O
HepG2	O
cells	O
with	O
a	O
human	O
Mn	B
-	I
SOD	I
promoter	O
-	O
reporter	O
construct	O
and	O
expression	O
vectors	O
encoding	O
each	O
of	O
the	O
three	O
known	O
AP-2	B
family	I
members	O
.	O

Our	O
results	O
indicated	O
that	O
AP-2	B
could	O
significantly	O
repress	O
Mn	B
-	I
SOD	I
promoter	O
activity	O
,	O
and	O
that	O
this	O
repression	O
was	O
both	O
Mn	B
-	I
SOD	I
promoter	O
and	O
AP-2	B
-	O
specific	O
.	O

The	O
three	O
AP-2	B
proteins	O
appeared	O
to	O
play	O
distinct	O
roles	O
in	O
Mn	B
-	I
SOD	I
gene	O
regulation	O
.	O

Moreover	O
,	O
although	O
all	O
three	O
AP-2	B
proteins	O
could	O
repress	O
the	O
Mn	B
-	I
SOD	I
promoter	O
,	O
AP-2alpha	B
and	O
AP-2gamma	B
were	O
more	O
active	O
in	O
this	O
regard	O
than	O
AP-2beta	B
.	O

Transcriptional	O
repression	O
by	O
AP-2	B
was	O
not	O
a	O
general	O
effect	O
in	O
this	O
system	O
,	O
because	O
another	O
AP-2	B
-	O
responsive	O
gene	O
,	O
c	B
-	I
erbB	I
-	I
3	I
,	O
was	O
transactivated	O
by	O
AP-2	B
.	O

Repression	O
of	O
Mn	B
-	I
SOD	I
by	O
AP-2	B
was	O
dependent	O
on	O
DNA	O
binding	O
,	O
and	O
expression	O
of	O
AP-2B	B
,	O
a	O
dominant	O
negative	O
incapable	O
of	O
DNA	O
binding	O
,	O
relieved	O
the	O
repression	O
on	O
Mn	B
-	I
SOD	I
promoter	O
and	O
reactivated	O
Mn	B
-	I
SOD	I
expression	O
in	O
the	O
AP-2	B
abundant	O
SV40	O
-	O
transformed	O
fibroblast	O
cell	O
line	O
MRC-5VA	O
.	O

These	O
results	O
indicate	O
that	O
AP-2	B
-	O
mediated	O
transcriptional	O
repression	O
contributes	O
to	O
the	O
constitutively	O
low	O
expression	O
of	O
Mn	B
-	I
SOD	I
in	O
SV40	O
-	O
transformed	O
fibroblasts	O
and	O
suggest	O
a	O
mechanism	O
for	O
Mn	B
-	I
SOD	I
down	O
-	O
regulation	O
in	O
cancer	O
.	O

Visualization	O
of	O
unwinding	O
activity	O
of	O
duplex	O
RNA	O
by	O
DbpA	B
,	O
a	O
DEAD	O
box	O
helicase	B
,	O
at	O
single	O
-	O
molecule	O
resolution	O
by	O
atomic	O
force	O
microscopy	O
.	O

The	O
Escherichia	O
coli	O
protein	O
DbpA	B
is	O
unique	O
in	O
its	O
subclass	O
of	O
DEAD	O
box	O
RNA	B
helicases	I
,	O
because	O
it	O
possesses	O
ATPase	B
-	O
specific	O
activity	O
toward	O
the	O
peptidyl	B
transferase	I
center	O
in	O
23S	O
rRNA	O
.	O

Although	O
its	O
remarkable	O
ATPase	B
activity	O
had	O
been	O
well	O
defined	O
toward	O
various	O
substrates	O
,	O
its	O
RNA	B
helicase	I
activity	O
remained	O
to	O
be	O
characterized	O
.	O

Herein	O
,	O
we	O
show	O
by	O
using	O
biochemical	O
assays	O
and	O
atomic	O
force	O
microscopy	O
that	O
DbpA	B
exhibits	O
ATP	O
-	O
stimulated	O
unwinding	O
activity	O
of	O
RNA	O
duplex	O
regardless	O
of	O
its	O
primary	O
sequence	O
.	O

This	O
work	O
presents	O
an	O
attempt	O
to	O
investigate	O
the	O
action	O
of	O
DEAD	O
box	O
proteins	O
by	O
a	O
single	O
-	O
molecule	O
visualization	O
methodology	O
.	O

Our	O
atomic	O
force	O
microscopy	O
images	O
enabled	O
us	O
to	O
observe	O
directly	O
the	O
unwinding	O
reaction	O
of	O
a	O
DEAD	O
box	O
helicase	B
on	O
long	O
stretches	O
of	O
double	O
-	O
stranded	O
RNA	O
.	O

Specifically	O
,	O
we	O
could	O
differentiate	O
between	O
the	O
binding	O
of	O
DbpA	B
to	O
RNA	O
in	O
the	O
absence	O
of	O
ATP	O
and	O
the	O
formation	O
of	O
a	O
Y	O
-	O
shaped	O
intermediate	O
after	O
its	O
progression	O
through	O
double	O
-	O
stranded	O
RNA	O
in	O
the	O
presence	O
of	O
ATP	O
.	O

Recent	O
studies	O
have	O
questioned	O
the	O
designation	O
of	O
DbpA	B
,	O
in	O
particular	O
,	O
and	O
DEAD	O
box	O
proteins	O
in	O
general	O
as	O
RNA	B
helicases	I
.	O

However	O
,	O
accumulated	O
evidence	O
and	O
the	O
results	O
reported	O
herein	O
suggest	O
that	O
these	O
proteins	O
are	O
indeed	O
helicases	B
that	O
resemble	O
in	O
many	O
aspects	O
the	O
DNA	B
helicases	I
.	O

Expression	O
and	O
functional	O
analysis	O
of	O
chemokine	B
receptors	I
in	O
human	O
peripheral	O
blood	O
leukocyte	O
populations	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
chemokine	B
receptor	I
expression	O
patterns	O
are	O
critical	O
in	O
determining	O
the	O
spectrum	O
of	O
action	O
of	O
the	O
chemokines	B
.	O

We	O
have	O
analysed	O
the	O
expression	O
patterns	O
of	O
17	O
chemokine	B
receptors	I
and	O
two	O
orphan	O
chemokine	B
receptor	I
-	O
like	O
genes	O
in	O
various	O
freshly	O
prepared	O
human	O
peripheral	O
blood	O
leucocyte	O
populations	O
,	O
including	O
neutrophils	O
,	O
lymphocytes	O
,	O
and	O
naÃ?Â¯ve	O
and	O
differentiated	O
monocytes	O
using	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
TaqMan	O
)	O
.	O

This	O
is	O
the	O
first	O
comprehensive	O
study	O
of	O
chemokine	B
receptor	I
expression	O
in	O
such	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Human	O
peripheral	O
blood	O
leukocyte	O
populations	O
were	O
found	O
to	O
express	O
a	O
wide	O
range	O
of	O
chemokine	B
receptors	I
that	O
varies	O
depending	O
on	O
cell	O
type	O
and	O
differentiation	O
state	O
.	O

Novel	O
expression	O
patterns	O
of	O
certain	O
chemokine	B
receptors	I
were	O
seen	O
during	O
our	O
analysis	O
.	O

For	O
example	O
,	O
the	O
orphan	O
chemokine	B
receptor	I
HCR	B
was	O
expressed	O
at	O
very	O
high	O
levels	O
by	O
both	O
primary	O
neutrophils	O
and	O
primary	O
monocytes	O
,	O
and	O
was	O
further	O
upregulated	O
on	O
neutrophil	O
activation	O
and	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
.	O

When	O
neutrophil	O
calcium	O
transients	O
were	O
measured	O
in	O
response	O
to	O
a	O
panel	O
of	O
30	O
different	O
chemokines	B
the	O
results	O
clearly	O
correlated	O
with	O
the	O
chemokine	B
receptor	I
expression	O
profile	O
.	O

For	O
example	O
strong	O
calcium	O
responses	O
were	O
seen	O
in	O
neutrophils	O
following	O
stimulation	O
with	O
the	O
CXCR1	B
and	O
CXCR2	B
ligands	O
,	O
interleukin	B
(	I
IL-	I
)	I
8	I
,	O
GCP-2	B
and	O
Gro	B
-	I
beta	I
.	O

These	O
data	O
have	O
implications	O
for	O
the	O
study	O
of	O
the	O
functional	O
responses	O
of	O
leukocytes	O
to	O
external	O
stimuli	O
and	O
will	O
aid	O
in	O
our	O
understanding	O
of	O
general	O
leukocyte	O
biology	O
.	O

Case	O
-	O
control	O
study	O
of	O
ovarian	O
cancer	O
and	O
polymorphisms	O
in	O
genes	O
involved	O
in	O
catecholestrogen	O
formation	O
and	O
metabolism	O
.	O

Steroid	O
hormones	O
,	O
such	O
as	O
estrogens	O
,	O
appear	O
to	O
be	O
associated	O
with	O
ovarian	O
carcinogenesis	O
,	O
but	O
the	O
precise	O
biological	O
mechanisms	O
are	O
unclear	O
.	O

Polymorphisms	O
in	O
genes	O
that	O
regulate	O
the	O
concentration	O
of	O
estrogens	O
and	O
their	O
metabolites	O
may	O
contribute	O
directly	O
to	O
the	O
individual	O
variation	O
in	O
ovarian	O
cancer	O
risk	O
through	O
a	O
mechanism	O
involving	O
oxidative	O
stress	O
or	O
indirectly	O
by	O
influencing	O
ovarian	O
cancer	O
susceptibility	O
associated	O
with	O
ovulation	O
and	O
reproduction	O
.	O

We	O
conducted	O
a	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
of	O
primary	O
ovarian	O
cancer	O
between	O
1993	O
and	O
1999	O
in	O
Hawaii	O
to	O
test	O
several	O
genetic	O
and	O
related	O
hypotheses	O
.	O

A	O
personal	O
interview	O
and	O
blood	O
specimen	O
were	O
obtained	O
in	O
the	O
subjects	O
'	O
homes	O
.	O

In	O
a	O
sample	O
of	O
129	O
epithelial	O
ovarian	O
cancer	O
cases	O
and	O
144	O
controls	O
,	O
we	O
compared	O
the	O
frequencies	O
of	O
several	O
polymorphisms	O
in	O
genes	O
that	O
regulate	O
steroid	O
hormone	O
metabolism	O
and	O
catecholestrogen	O
formation	O
.	O

Multivariate	O
unconditional	O
logistic	O
regression	O
was	O
used	O
to	O
model	O
the	O
association	O
of	O
each	O
genetic	O
polymorphism	O
separately	O
after	O
adjusting	O
for	O
age	O
,	O
ethnicity	O
,	O
and	O
other	O
covariates	O
.	O

The	O
high	O
-	O
activity	O
Val432	O
allele	O
of	O
the	O
CYP1B1	B
gene	O
,	O
which	O
may	O
be	O
linked	O
to	O
oxidative	O
stress	O
through	O
elevated	O
4-hydroxylated	O
catecholestrogen	O
formation	O
,	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ovarian	O
cancer	O
.	O

The	O
Val	O
/	O
Leu	O
genotype	O
for	O
CYP1B1	B
was	O
associated	O
with	O
an	O
odds	O
ratio	O
of	O
1.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.0	O
-	O
3.3	O
)	O
and	O
the	O
Val	O
/	O
Val	O
genotype	O
with	O
an	O
odds	O
ratio	O
of	O
3.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.2	O
-	O
11.4	O
)	O
compared	O
with	O
the	O
Leu	O
/	O
Leu	O
genotype	O
(	O
P	O
=	O
0.005	O
)	O
.	O

Tobacco	O
smokers	O
with	O
at	O
least	O
one	O
CYP1A1	B
(	O
MspI	O
)	O
m2	O
allele	O
,	O
one	O
CYP1B1	B
Val	O
allele	O
,	O
one	O
COMT	B
Met	O
allele	O
,	O
or	O
two	O
CYP1A2	B
A	O
alleles	O
were	O
at	O
significantly	O
increased	O
risk	O
of	O
ovarian	O
cancer	O
compared	O
to	O
never	O
-	O
smokers	O
with	O
CYP1A1	B
(	O
MspI	O
)	O
ml	O
/	O
ml	O
,	O
CYP1B1	B
Leu	O
/	O
Leu	O
,	O
COMT	B
Val	O
/	O
Val	O
,	O
or	O
CYP1A2	B
A	O
/	O
A	O
genotypes	O
,	O
respectively	O
.	O

We	O
found	O
a	O
positive	O
statistical	O
interaction	O
(	O
P	O
=	O
0.03	O
)	O
between	O
tobacco	O
smoking	O
and	O
the	O
CYP1A1	B
(	O
MspI	O
)	O
polymorphism	O
on	O
the	O
risk	O
of	O
ovarian	O
cancer	O
.	O

None	O
of	O
the	O
other	O
gene	O
-	O
environment	O
(	O
pregnancy	O
,	O
oral	O
contraceptive	O
pill	O
use	O
)	O
or	O
gene	O
-	O
gene	O
interactions	O
were	O
statistically	O
significant	O
.	O

Although	O
not	O
significant	O
,	O
there	O
was	O
a	O
suggestion	O
that	O
the	O
effect	O
of	O
the	O
CYP1B1	B
Val	O
allele	O
was	O
reduced	O
substantially	O
in	O
the	O
presence	O
of	O
the	O
high	O
-	O
activity	O
COMT	B
Met	O
allele	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
CYP1B1	B
-	O
Val	O
allele	O
and	O
perhaps	O
other	O
genetic	O
polymorphisms	O
in	O
combination	O
with	O
environmental	O
or	O
hormonal	O
exposures	O
are	O
susceptibility	O
factors	O
for	O
ovarian	O
cancer	O
.	O

Cathepsin	B
S	I
regulates	O
the	O
expression	O
of	O
cathepsin	B
L	I
and	O
the	O
turnover	O
of	O
gamma	B
-	I
interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
in	O
B	O
lymphocytes	O
.	O

Loading	O
of	O
antigenic	O
peptide	O
fragments	O
on	O
major	B
histocompatibility	I
complex	I
class	I
II	I
molecules	O
is	O
essential	O
for	O
generation	O
of	O
CD4	B
(	O
+	O
)	O
T	O
cell	O
responses	O
and	O
occurs	O
after	O
cathepsin	B
-	O
mediated	O
degradation	O
of	O
the	O
invariant	B
chain	I
chaperone	B
molecule	O
.	O

Cathepsins	B
are	O
expressed	O
differentially	O
in	O
antigen	O
presenting	O
cells	O
,	O
and	O
mice	O
deficient	O
in	O
cathepsin	B
S	I
or	O
cathepsin	B
L	I
exhibit	O
severely	O
impaired	O
antigen	O
presentation	O
in	O
peripheral	O
lymphoid	O
organs	O
and	O
the	O
thymus	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
these	O
defects	O
are	O
due	O
solely	O
to	O
the	O
block	O
in	O
invariant	B
chain	I
cleavage	O
,	O
we	O
used	O
cathepsin	B
-	O
deficient	O
B	O
cells	O
to	O
examine	O
the	O
role	O
of	O
cathepsins	B
S	I
and	I
B	I
in	O
the	O
degradation	O
of	O
other	O
molecules	O
important	O
in	O
the	O
class	O
II	O
presentation	O
pathway	O
.	O

Our	O
data	O
indicate	O
that	O
neither	O
cathepsin	B
S	I
nor	I
B	I
is	O
critical	O
for	O
H-2	B
M	I
degradation	O
or	O
processing	O
of	O
precursor	O
gamma	B
-	I
interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
(	O
GILT	B
)	O
to	O
a	O
mature	O
thiol	B
reductase	I
,	O
but	O
suggest	O
a	O
role	O
for	O
cathepsin	B
S	I
in	O
the	O
turnover	O
of	O
mature	O
GILT	B
and	O
in	O
regulating	O
levels	O
of	O
mature	O
cathepsin	B
L	I
protein	O
in	O
B	O
cells	O
.	O

Despite	O
the	O
presence	O
of	O
mature	O
cathepsin	B
L	I
protein	O
,	O
no	O
enzyme	O
activity	O
could	O
be	O
detected	O
in	O
B	O
cells	O
or	O
dendritic	O
cells	O
.	O

These	O
experiments	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
these	O
functionally	O
important	O
enzymes	O
may	O
be	O
regulated	O
.	O

IFN	B
-	I
beta1b	I
augments	O
glucocorticoid	O
-	O
induced	O
suppression	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
production	O
by	O
increasing	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
on	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

We	O
studied	O
the	O
effect	O
of	O
recombinant	O
interferon	B
-	I
beta1b	I
(	O
IFN	B
-	I
beta1b	I
)	O
on	O
the	O
sensitivity	O
to	O
glucocorticoids	O
(	O
GC	O
)	O
and	O
on	O
the	O
number	O
of	O
GC	B
receptors	I
(	O
GCR	B
)	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O

We	O
found	O
that	O
IFN	B
-	I
beta1b	I
augments	O
the	O
suppressive	O
effect	O
that	O
dexamethasone	O
has	O
on	O
the	O
stimulated	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
most	O
likely	O
related	O
to	O
the	O
increased	O
number	O
of	O
GCR	B
observed	O
after	O
exposure	O
to	O
IFN	B
-	I
beta1b	I
.	O

This	O
provides	O
a	O
possible	O
clue	O
to	O
the	O
mechanism	O
of	O
action	O
of	O
IFN	B
-	I
beta	I
in	O
multiple	O
sclerosis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
galactose	B
3-O	I
-	I
sulfotransferase	I
that	O
transfers	O
sulfate	O
to	O
gal	O
beta	O
1	O
--	O
>	O
3galNAc	O
residue	O
in	O
O	O
-	O
glycans	O
.	O

We	O
have	O
identified	O
a	O
novel	O
galactose	B
3-O	I
-	I
sulfotransferase	I
,	O
termed	O
Gal3ST	B
-	I
4	I
,	O
by	O
analysis	O
of	O
an	O
expression	O
sequence	O
tag	O
using	O
the	O
amino	O
acid	O
sequence	O
of	O
human	O
cerebroside	B
3'-sulfotransferase	I
(	O
Gal3ST-1	B
)	O
.	O

The	O
isolated	O
cDNA	O
contains	O
a	O
single	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
protein	O
of	O
486	O
amino	O
acids	O
with	O
a	O
type	O
II	O
transmembrane	O
topology	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
Gal3ST-4	B
revealed	O
33	O
%	O
,	O
39	O
%	O
,	O
and	O
30	O
%	O
identity	O
to	O
human	O
Gal3ST-1	B
,	O
Gal	B
beta	I
1	I
--	I
>	I
3	I
/	I
4GlcNAc	I
:	I
-->3'-sulfotransferase	I
(	O
Gal3ST-2	B
)	O
and	O
Gal	B
beta	I
1	I
--	I
>	I
4GlcNAc	I
:	I
--	I
>	I
3	I
'	I
-	I
sulfotransferase	I
(	O
Gal3ST	B
-	I
3	I
)	O
,	O
respectively	O
.	O

The	O
Gal3ST-4	B
gene	O
comprised	O
at	O
least	O
four	O
exons	O
and	O
was	O
located	O
on	O
human	O
chromosome	O
7q22	O
.	O

Expression	O
of	O
Gal3ST-4	B
in	O
COS-7	O
cells	O
produced	O
a	O
sulfotransferase	B
activity	O
that	O
catalyzes	O
the	O
transfer	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfate	O
to	O
the	O
C-3	O
'	O
position	O
of	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
alpha	O
1-O	O
-	O
Bn	O
.	O

Gal3ST-4	B
recognizes	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
and	O
Gal	O
beta	O
1	O
--	O
>	O
3	O
(	O
GlcNAc	O
beta	O
1	O
--	O
>	O
6	O
)	O
GalNAc	O
as	O
good	O
substrates	O
,	O
but	O
not	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
(	O
OH	O
)	O
or	O
Gal	O
beta	O
1	O
-->3	O
/	O
4GlcNAc	O
.	O

Asialofetuin	O
is	O
also	O
a	O
good	O
substrate	O
,	O
and	O
the	O
sulfation	O
was	O
found	O
exclusively	O
in	O
O	O
-	O
linked	O
glycans	O
that	O
consist	O
of	O
the	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
moiety	O
,	O
suggesting	O
that	O
the	O
enzyme	O
is	O
specific	O
for	O
O	O
-	O
linked	O
glycans	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
2.5	O
-	O
kilobase	O
mRNA	O
for	O
the	O
enzyme	O
is	O
expressed	O
extensively	O
in	O
various	O
tissues	O
.	O

These	O
results	O
suggest	O
that	O
Gal3ST-4	B
is	O
the	O
fourth	O
member	O
of	O
a	O
Gal	B
:	I
--	I
>	I
3	I
-	I
sulfotransferase	I
family	I
and	O
that	O
the	O
four	O
members	O
,	O
Gal3ST-1	B
,	O
Gal3ST-2	B
,	O
Gal3ST-3	B
,	O
and	O
Gal3ST-4	B
,	O
are	O
responsible	O
for	O
sulfation	O
of	O
different	O
acceptor	O
substrates	O
.	O

Protein	B
tyrosine	I
kinase	I
regulates	O
FAS	B
-	O
mediated	O
apoptosis	O
in	O
human	O
BCG	O
-	O
infected	O
monocytes	O
.	O

Apoptosis	O
of	O
monocytes	O
/	O
macrophages	O
has	O
emerged	O
as	O
a	O
central	O
regulatory	O
event	O
in	O
the	O
defense	O
against	O
mycobacterial	O
infections	O
.	O

The	O
involvement	O
of	O
protein	B
tyrosine	I
kinases	I
(	O
PTK	B
)	O
in	O
Fas	B
-	O
mediated	O
apoptosis	O
in	O
T	O
cells	O
is	O
well	O
established	O
,	O
but	O
the	O
possible	O
role	O
of	O
PTK	B
in	O
Fas	B
-	O
dependent	O
death	O
of	O
human	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
-	O
infected	O
monocytes	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
first	O
examined	O
the	O
expression	O
and	O
function	O
of	O
Fas	B
on	O
BCG	O
-	O
infected	O
human	O
monocytes	O
by	O
flow	O
cytometry	O
.	O

The	O
results	O
demonstrated	O
that	O
BCG	O
-	O
infected	O
monocytes	O
expressed	O
significant	O
Fas	B
protein	O
levels	O
.	O

In	O
addition	O
,	O
engagement	O
of	O
the	O
Fas	B
antigen	O
with	O
its	O
agonistic	O
antibody	O
(	O
Ab	O
)	O
resulted	O
in	O
apoptosis	O
of	O
monocytes	O
,	O
as	O
monitored	O
by	O
DNA	O
analysis	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
(	O
FACS	O
)	O
analysis	O
.	O

The	O
apoptotic	O
action	O
of	O
Fas	B
was	O
suppressed	O
significantly	O
by	O
genistein	O
,	O
indicating	O
a	O
role	O
for	O
PTK	B
in	O
this	O
death	O
process	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
herbimycin	O
A	O
and	O
tyrphostin	O
,	O
two	O
selective	O
tyrosine	B
kinase	I
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
,	O
effectively	O
inhibited	O
Fas	B
-	O
mediated	O
apoptosis	O
of	O
BCG	O
-	O
infected	O
monocytes	O
,	O
as	O
demonstrated	O
by	O
DNA	O
content	O
analysis	O
.	O

Moreover	O
,	O
we	O
confirmed	O
the	O
effect	O
of	O
genistein	O
,	O
herbimycin	O
A	O
,	O
and	O
tyrphostin	O
by	O
examining	O
apoptosis	O
with	O
the	O
terminal	B
transferase	I
dUTP	O
nick	O
endlabeling	O
(	O
TUNEL	O
)	O
assay	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
Fas	B
-	O
induced	O
apoptosis	O
may	O
represent	O
an	O
important	O
mechanism	O
for	O
eliminating	O
BCG	O
-	O
activated	O
human	O
monocytes	O
and	O
that	O
this	O
apoptosis	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
signaling	O
via	O
a	O
PTK	B
pathway	O
.	O

Quaternary	O
structure	O
of	O
the	O
ATPase	B
complex	O
of	O
human	O
26S	O
proteasomes	O
determined	O
by	O
chemical	O
cross	O
-	O
linking	O
.	O

The	O
26S	O
proteasome	O
is	O
the	O
major	O
protease	B
responsible	O
for	O
nonlysosomal	O
protein	O
degradation	O
in	O
eukaryotic	O
cells	O
.	O

The	O
enzyme	O
is	O
composed	O
of	O
two	O
subparticles	O
:	O
the	O
20S	O
proteasome	O
,	O
and	O
a	O
19S	B
regulatory	I
particle	I
(	O
PA700	B
)	O
which	O
binds	O
to	O
the	O
ends	O
of	O
the	O
20S	O
proteasome	O
cylinder	O
and	O
accounts	O
for	O
ATP	O
dependence	O
and	O
substrate	O
specificity	O
.	O

Among	O
the	O
approximately	O
18	O
subunits	O
of	O
PA700	B
regulator	I
,	O
six	O
are	O
ATPases	B
.	O

The	O
ATPases	B
presumably	O
recognize	O
,	O
unfold	O
,	O
and	O
translocate	O
substrates	O
into	O
the	O
interior	O
of	O
the	O
26S	O
proteasome	O
.	O

It	O
is	O
generally	O
believed	O
that	O
the	O
ATPases	B
form	O
a	O
hexameric	O
ring	O
.	O

By	O
means	O
of	O
chemical	O
cross	O
-	O
linking	O
,	O
immunoprecipitation	O
,	O
and	O
blotting	O
,	O
we	O
have	O
determined	O
that	O
the	O
ATPases	B
are	O
organized	O
in	O
the	O
order	O
S6	O
-	O
S6	O
'	O
-	O
S10b	B
-	O
S8	O
-	O
S4-S7	O
.	O

Additionally	O
,	O
we	O
found	O
cross	O
-	O
links	O
between	O
the	O
ATPase	B
S10b	I
and	O
the	O
20S	B
proteasome	I
subunit	I
alpha6	I
.	O

Together	O
with	O
the	O
previously	O
known	O
interaction	O
between	O
S8	O
and	O
alpha1	O
and	O
between	O
S4	O
and	O
alpha7	O
,	O
these	O
data	O
establish	O
the	O
relative	O
orientations	O
of	O
ATPases	B
with	O
respect	O
to	O
the	O
20S	O
proteasome	O
.	O

Characterization	O
of	O
the	O
gene	O
family	O
encoding	O
alternative	B
oxidase	I
from	O
Candida	O
albicans	O
.	O

Candida	O
albicans	O
possesses	O
a	O
cyanide	O
-	O
resistant	O
respiratory	O
pathway	O
mediated	O
by	O
alternative	B
oxidase	I
(	O
AOX	B
)	O
,	O
which	O
seems	O
to	O
be	O
encoded	O
by	O
a	O
gene	O
family	O
with	O
two	O
members	O
.	O

Cloning	O
and	O
expression	O
of	O
AOX1a	B
,	O
one	O
of	O
the	O
genes	O
encoding	O
alternative	B
oxidase	I
from	O
C.	O
albicans	O
,	O
has	O
previously	O
been	O
reported	O
[	O
Huh	O
and	O
Kang	O
(	O
1999	O
)	O
J.	O
Bacteriol	O
.	O
181	O
,	O
4098	O
-	O
4102	O
]	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
the	O
isolation	O
of	O
another	O
gene	O
coding	O
for	O
alternative	B
oxidase	I
,	O
designated	O
AOX1b	B
.	O

AOX1b	B
contains	O
a	O
continuous	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
polypeptide	O
consisting	O
of	O
365	O
amino	O
acids	O
.	O

Interestingly	O
,	O
AOX1a	B
and	O
AOX1b	B
were	O
found	O
to	O
be	O
located	O
in	O
tandem	O
on	O
one	O
of	O
the	O
chromosomes	O
of	O
C.	O
albicans	O
.	O

The	O
presence	O
of	O
cyanide	O
in	O
the	O
culture	O
medium	O
remarkably	O
retarded	O
the	O
growth	O
of	O
the	O
aox1a	B
/	O
aox1a	B
mutants	O
.	O

The	O
growth	O
of	O
the	O
aox1b	B
/	O
aox1b	B
mutants	O
and	O
the	O
aox1a	B
/	O
aox1a	B
aox1b	B
/	O
aox1b	B
double	O
mutants	O
was	O
almost	O
completely	O
inhibited	O
in	O
the	O
same	O
medium	O
.	O

beta	B
-	I
Galactosidase	I
reporter	O
assays	O
indicated	O
that	O
,	O
whereas	O
AOX1a	B
was	O
expressed	O
constitutively	O
,	O
the	O
expression	O
of	O
AOX1b	B
was	O
dependent	O
on	O
growth	O
phase	O
and	O
was	O
induced	O
by	O
treatment	O
with	O
cyanide	O
,	O
antimycin	O
A	O
,	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
menadione	O
and	O
paraquat	O
.	O

Growth	O
of	O
the	O
cells	O
in	O
media	O
with	O
non	O
-	O
fermentable	O
carbon	O
sources	O
also	O
enhanced	O
the	O
expression	O
of	O
AOX1b	B
.	O

CaSLN1	B
,	O
which	O
encodes	O
a	O
histidine	B
kinase	I
,	O
seems	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
AOX	B
expression	O
in	O
C.	O
albicans	O
on	O
the	O
basis	O
of	O
the	O
observation	O
that	O
the	O
activity	O
of	O
cyanide	O
-	O
resistant	O
respiration	O
and	O
the	O
expression	O
level	O
of	O
AOX	B
in	O
the	O
casln1	B
/	O
casln1	B
mutants	O
were	O
found	O
to	O
be	O
significantly	O
low	O
under	O
normal	O
conditions	O
and	O
slightly	O
increased	O
in	O
the	O
presence	O
of	O
respiratory	O
inhibitors	O
compared	O
with	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Like	O
AOX1a	B
,	O
AOX1b	B
could	O
also	O
be	O
functionally	O
expressed	O
in	O
AOX	B
-	O
deficient	O
Saccharomyces	O
cerevisiae	O
and	O
confer	O
cyanide	O
-	O
resistant	O
respiration	O
on	O
the	O
organism	O
.	O

The	O
hemidesmosomal	O
protein	O
bullous	B
pemphigoid	I
antigen	I
1	I
and	O
the	O
integrin	B
beta	I
4	I
subunit	O
bind	O
to	O
ERBIN	B
.	O

Molecular	O
cloning	O
of	O
multiple	O
alternative	O
splice	O
variants	O
of	O
ERBIN	B
and	O
analysis	O
of	O
their	O
tissue	O
expression	O
.	O

The	O
bullous	B
pemphigoid	I
antigen	I
1	I
(	O
eBPAG1	B
)	O
is	O
a	O
constituent	O
of	O
hemidesmosomes	O
(	O
HDs	O
)	O
,	O
cell	O
-	O
substrate	O
adhesion	O
complexes	O
in	O
stratified	O
epithelia	O
.	O

Although	O
its	O
COOH	O
terminus	O
interacts	O
with	O
intermediate	O
filaments	O
,	O
its	O
NH	O
(	O
2	O
)	O
terminus	O
is	O
important	O
for	O
its	O
recruitment	O
into	O
HDs	O
.	O

To	O
identify	O
proteins	O
that	O
interact	O
with	O
the	O
NH	O
(	O
2	O
)	O
terminus	O
of	O
human	O
eBPAG1	B
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
which	O
uncovered	O
a	O
protein	O
belonging	O
to	O
the	O
LAP	B
/	I
LERP	I
(	I
for	I
LRR	I
and	I
PDZ	I
domain	I
)	I
protein	I
family	I
with	O
16	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
leucine	O
-	O
rich	O
repeats	O
and	O
a	O
COOH	O
-	O
terminal	O
PDZ	O
domain	O
.	O

The	O
gene	O
for	O
this	O
LAP	B
/	O
LERP	O
protein	O
comprises	O
at	O
least	O
26	O
exons	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

In	O
most	O
human	O
tissues	O
,	O
several	O
transcripts	O
were	O
detected	O
differing	O
in	O
the	O
coding	O
region	O
situated	O
upstream	O
of	O
or	O
within	O
the	O
PDZ	O
domain	O
.	O

One	O
of	O
the	O
encoded	O
variants	O
was	O
found	O
to	O
correspond	O
to	O
the	O
recently	O
described	O
protein	O
ERBIN	B
.	O

In	O
yeast	O
and	O
in	O
vitro	O
binding	O
experiments	O
,	O
ERBIN	B
was	O
shown	O
to	O
interact	O
not	O
only	O
with	O
eBPAG1	B
but	O
also	O
with	O
the	O
COOH	O
-	O
terminal	O
region	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
integrin	B
beta4	I
subunit	O
,	O
another	O
component	O
of	O
HDs	O
.	O

Antibodies	O
raised	O
against	O
the	O
COOH	O
terminus	O
showed	O
that	O
ERBIN	B
is	O
expressed	O
in	O
keratinocytes	O
.	O

In	O
transfected	O
epithelial	O
cells	O
the	O
protein	O
,	O
however	O
,	O
was	O
not	O
localized	O
in	O
HDs	O
but	O
was	O
either	O
diffusely	O
distributed	O
over	O
the	O
cytoplasm	O
or	O
concentrated	O
at	O
the	O
basolateral	O
plasma	O
membrane	O
.	O

Because	O
ERBIN	B
had	O
been	O
shown	O
previously	O
to	O
interact	O
with	O
the	O
transmembrane	O
tyrosine	B
kinase	I
receptor	I
Erb	B
-	I
B2	I
,	O
which	O
in	O
turn	O
associates	O
with	O
the	O
integrin	B
beta4	I
subunit	O
,	O
we	O
suggest	O
that	O
ERBIN	B
provides	O
a	O
link	O
between	O
HD	O
assembly	O
and	O
Erb	B
-	I
B2	I
receptor	O
signaling	O
.	O

MÃ?Â¼llerian	B
inhibiting	I
substance	I
signaling	O
uses	O
a	O
bone	B
morphogenetic	I
protein	I
(	O
BMP	B
)	O
-	O
like	O
pathway	O
mediated	O
by	O
ALK2	B
and	O
induces	O
SMAD6	B
expression	O
.	O

Signal	O
reception	O
of	O
MÃ?Â¼llerian	B
inhibiting	I
substance	I
(	O
MIS	B
)	O
in	O
the	O
mesenchyme	O
around	O
the	O
embryonic	O
MÃ?Â¼llerian	O
duct	O
in	O
the	O
male	O
is	O
essential	O
for	O
regression	O
of	O
the	O
duct	O
.	O

Deficiency	O
of	O
MIS	B
or	O
of	O
the	O
MIS	B
type	I
II	I
receptor	I
,	O
MISRII	B
,	O
results	O
in	O
abnormal	O
reproductive	O
development	O
in	O
the	O
male	O
due	O
to	O
the	O
maintenance	O
of	O
the	O
duct	O
.	O

MIS	B
is	O
a	O
member	O
of	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGFbeta	I
)	I
superfamily	I
of	O
secreted	O
protein	O
hormones	O
that	O
signal	O
through	O
receptor	O
complexes	O
of	O
type	B
I	I
and	I
type	I
II	I
serine	I
/	I
threonine	I
kinase	I
receptors	I
.	O

To	O
investigate	O
candidate	O
MIS	B
type	I
I	I
receptors	I
,	O
we	O
examined	O
reporter	O
construct	O
activation	O
by	O
MIS	B
.	O

The	O
bone	B
morphogenetic	I
protein	I
(	O
BMP	B
)	O
-	O
responsive	O
Tlx2	B
and	O
Xvent2	B
promoter	O
-	O
driven	O
reporter	O
constructs	O
were	O
stimulated	O
by	O
MIS	B
but	O
the	O
TGFbeta	B
/	O
activin	B
-	O
induced	O
p3TP	O
-	O
lux	B
or	O
CAGA	O
-	O
luc	B
reporter	O
constructs	O
were	O
not	O
.	O

The	O
induction	O
of	O
Tlx2	B
-	O
luc	B
was	O
dependent	O
upon	O
the	O
kinase	B
activity	O
of	O
MISRII	B
and	O
was	O
blocked	O
by	O
a	O
dominant	O
negative	O
truncated	O
ALK2	B
(	O
tALK2	B
)	O
receptor	O
but	O
not	O
by	O
truncated	O
forms	O
of	O
the	O
other	O
BMP	B
type	I
I	I
receptors	I
ALK1	B
,	O
ALK3	B
,	O
or	O
ALK6	B
.	O

MIS	B
induced	O
activation	O
of	O
a	O
Gal4DBD	O
-	O
Smad1	B
but	O
not	O
a	O
Gal4DBD	O
-	O
Smad2	B
fusion	O
protein	O
.	O

This	O
activation	O
could	O
also	O
be	O
blocked	O
by	O
tALK2	B
.	O

The	O
BMP	B
-	O
induced	O
inhibitory	O
Smad	B
,	O
Smad6	B
,	O
was	O
up	O
-	O
regulated	O
by	O
MIS	B
endogenously	O
in	O
Leydig	O
cell	O
-	O
derived	O
lines	O
and	O
is	O
expressed	O
in	O
male	O
but	O
not	O
female	O
MÃ?Â¼llerian	O
duct	O
mesenchyme	O
.	O

ALK6	B
has	O
been	O
shown	O
to	O
function	O
as	O
an	O
MIS	B
type	I
I	I
receptor	I
.	O

Investigation	O
of	O
the	O
pattern	O
of	O
ALK2	B
,	O
MISRII	B
,	O
and	O
ALK6	B
in	O
the	O
developing	O
urogenital	O
system	O
demonstrated	O
overlapping	O
expression	O
of	O
ALK2	B
and	O
MISRII	B
in	O
the	O
mesenchyme	O
surrounding	O
the	O
duct	O
while	O
ALK6	B
was	O
observed	O
only	O
in	O
the	O
epithelium	O
.	O

Examination	O
of	O
ALK6	B
-	O
/	O
-	O
male	O
animals	O
revealed	O
no	O
defect	O
in	O
duct	O
regression	O
.	O

The	O
reporter	O
construct	O
analysis	O
,	O
pattern	O
of	O
expression	O
of	O
the	O
receptors	O
,	O
and	O
analysis	O
of	O
ALK6	B
-	O
deficient	O
animals	O
suggest	O
that	O
ALK2	B
is	O
the	O
MIS	B
type	I
I	I
receptor	I
involved	O
in	O
MÃ?Â¼llerian	O
duct	O
regression	O
.	O

SET	B
-	O
related	O
cell	B
division	I
autoantigen-1	I
(	O
CDA1	B
)	O
arrests	O
cell	O
growth	O
.	O

We	O
used	O
an	O
autoimmune	O
serum	O
from	O
a	O
patient	O
with	O
discoid	O
lupus	O
erythematosus	O
to	O
clone	O
a	O
cDNA	O
of	O
2808	O
base	O
pairs	O
.	O

Its	O
open	O
reading	O
frame	O
of	O
2079	O
base	O
pairs	O
encodes	O
a	O
predicted	O
polypeptide	O
of	O
693	O
amino	O
acids	O
named	O
CDA1	B
(	O
cell	B
division	I
autoantigen-1	I
)	O
.	O

CDA1	B
has	O
a	O
predicted	O
molecular	O
mass	O
of	O
79,430	O
Daltons	O
and	O
a	O
pI	O
of	O
4.26	O
.	O

The	O
size	O
of	O
the	O
cDNA	O
is	O
consistent	O
with	O
its	O
estimated	O
mRNA	O
size	O
.	O

CDA1	B
comprises	O
an	O
N	O
-	O
terminal	O
proline	O
-	O
rich	O
domain	O
,	O
a	O
central	O
basic	O
domain	O
,	O
and	O
a	O
C	O
-	O
terminal	O
bipartite	O
acidic	O
domain	O
.	O

It	O
has	O
four	O
putative	O
nuclear	O
localization	O
signals	O
and	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
cAMP	B
and	I
cGMP	I
-	I
dependent	I
kinases	I
,	O
protein	B
kinase	I
C	I
,	O
thymidine	B
kinase	I
,	O
casein	B
kinase	I
II	I
,	O
and	O
cyclin	B
-	I
dependent	I
kinases	I
(	O
CDKs	B
)	O
.	O

CDA1	B
is	O
phosphorylated	O
in	O
HeLa	O
cells	O
and	O
by	O
cyclin	B
D1	I
/	O
CDK4	B
,	O
cyclin	B
A	I
/	O
CDK2	B
,	O
and	O
cyclin	B
B	I
/	O
CDK1	B
in	O
vitro	O
.	O

Its	O
basic	O
and	O
acidic	O
domains	O
contain	O
regions	O
homologous	O
to	O
almost	O
the	O
entire	O
human	O
leukemia	O
-	O
associated	O
SET	B
protein	O
.	O

The	O
same	O
basic	O
region	O
is	O
also	O
homologous	O
to	O
nucleosome	O
assembly	O
proteins	O
,	O
testis	O
TSPY	B
protein	O
,	O
and	O
an	O
uncharacterized	O
brain	O
protein	O
.	O

CDA1	B
is	O
present	O
in	O
the	O
nuclear	O
fraction	O
of	O
HeLa	O
cells	O
and	O
localizes	O
to	O
the	O
nucleus	O
and	O
nucleolus	O
in	O
HeLa	O
cells	O
transfected	O
with	O
CDA1	B
or	O
its	O
N	O
terminus	O
containing	O
all	O
four	O
nuclear	O
localization	O
signals	O
.	O

Its	O
acidic	O
C	O
terminus	O
localizes	O
mainly	O
to	O
the	O
cytoplasm	O
.	O

CDA1	B
levels	O
are	O
low	O
in	O
serum	O
-	O
starved	O
cells	O
,	O
increasing	O
dramatically	O
with	O
serum	O
stimulation	O
.	O

Expression	O
of	O
the	O
CDA1	B
transgene	O
,	O
but	O
not	O
its	O
N	O
terminus	O
,	O
arrests	O
HeLa	O
cell	O
growth	O
,	O
colony	O
numbers	O
,	O
cell	O
density	O
,	O
and	O
bromodeoxyuridine	O
uptake	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
ability	O
of	O
CDA1	B
to	O
arrest	O
cell	O
growth	O
is	O
abolished	O
by	O
mutation	O
of	O
the	O
two	O
CDK	B
consensus	O
phosphorylation	O
sites	O
.	O

We	O
propose	O
that	O
CDA1	B
is	O
a	O
negative	O
regulator	O
of	O
cell	O
growth	O
and	O
that	O
its	O
activity	O
is	O
regulated	O
by	O
its	O
expression	O
level	O
and	O
phosphorylation	O
.	O

Yeast	O
histone	B
deposition	O
protein	O
Asf1p	B
requires	O
Hir	B
proteins	O
and	O
PCNA	B
for	O
heterochromatic	O
silencing	O
.	O

BACKGROUND	O
:	O

Position	O
-	O
dependent	O
gene	O
silencing	O
in	O
yeast	O
involves	O
many	O
factors	O
,	O
including	O
the	O
four	O
HIR	B
genes	O
and	O
nucleosome	B
assembly	I
proteins	I
Asf1p	B
and	O
chromatin	B
assembly	I
factor	I
I	I
(	O
CAF	B
-	I
I	I
,	O
encoded	O
by	O
the	O
CAC1	B
-	I
3	I
genes	O
)	O
.	O

Both	O
cac	B
Delta	O
asfl	B
Delta	O
and	O
cac	B
Delta	O
hir	B
Delta	O
double	O
mutants	O
display	O
synergistic	O
reductions	O
in	O
heterochromatic	O
gene	O
silencing	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
contributions	O
of	O
HIR	B
genes	O
and	O
ASF1	B
to	O
silencing	O
has	O
not	O
previously	O
been	O
explored	O
.	O

RESULTS	O
:	O

Our	O
biochemical	O
and	O
genetic	O
studies	O
of	O
yeast	O
Asf1p	B
revealed	O
links	O
to	O
Hir	B
protein	O
function	O
.	O

In	O
vitro	O
,	O
an	O
active	O
histone	B
deposition	I
complex	I
was	O
formed	O
from	O
recombinant	O
yeast	O
Asf1p	B
and	O
histones	B
H3	I
and	O
H4	B
that	O
lack	O
a	O
newly	O
synthesized	O
acetylation	O
pattern	O
.	O

This	O
Asf1p	B
/	O
H3	B
/	O
H4	B
complex	O
generated	O
micrococcal	B
nuclease	I
--	O
resistant	O
DNA	O
in	O
the	O
absence	O
of	O
DNA	O
replication	O
and	O
stimulated	O
nucleosome	O
assembly	O
activity	O
by	O
recombinant	O
yeast	O
CAF	B
-	I
I	I
during	O
DNA	O
synthesis	O
.	O

Also	O
,	O
Asf1p	B
bound	O
to	O
the	O
Hir1p	B
and	O
Hir2p	B
proteins	O
in	O
vitro	O
and	O
in	O
cell	O
extracts	O
.	O

In	O
vivo	O
,	O
the	O
HIR1	B
and	O
ASF1	B
genes	O
contributed	O
to	O
silencing	O
the	O
heterochromatic	O
HML	O
locus	O
via	O
the	O
same	O
genetic	O
pathway	O
.	O

Deletion	O
of	O
either	O
HIR1	B
or	O
ASF1	B
eliminated	O
telomeric	O
gene	O
silencing	O
in	O
combination	O
with	O
pol30	B
--	O
8	O
,	O
encoding	O
an	O
altered	O
form	O
of	O
the	O
DNA	B
polymerase	I
processivity	O
factor	O
PCNA	B
that	O
prevents	O
CAF	B
-	I
I	I
from	O
contributing	O
to	O
silencing	O
.	O

Conversely	O
,	O
other	O
pol30	B
alleles	O
prevented	O
Asf1	B
/	O
Hir	B
proteins	O
from	O
contributing	O
to	O
silencing	O
.	O

CONCLUSIONS	O
:	O

Yeast	O
CAF	B
-	I
I	I
and	O
Asf1p	B
cooperate	O
to	O
form	O
nucleosomes	O
in	O
vitro	O
.	O

In	O
vivo	O
,	O
Asf1p	B
and	O
Hir	B
proteins	O
physically	O
interact	O
and	O
together	O
promote	O
heterochromatic	O
gene	O
silencing	O
in	O
a	O
manner	O
requiring	O
PCNA	B
.	O

This	O
Asf1	B
/	O
Hir	B
silencing	O
pathway	O
functionally	O
overlaps	O
with	O
CAF	B
-	I
I	I
activity	O
.	O

The	O
gene	O
for	O
alternative	B
oxidase-2	I
(	O
AOX2	B
)	O
from	O
Arabidopsis	O
thaliana	O
consists	O
of	O
five	O
exons	O
unlike	O
other	O
AOX	B
genes	O
and	O
is	O
transcribed	O
at	O
an	O
early	O
stage	O
during	O
germination	O
.	O

We	O
investigated	O
the	O
expressions	O
of	O
genes	O
for	O
alternative	B
oxidase	I
(	O
AOX1a	B
,	O
AOX1b	B
,	O
AOX1c	B
and	O
AOX2	B
)	O
and	O
genes	O
for	O
cytochrome	B
c	I
oxidase	I
(	O
COX5b	B
and	O
COX6b	B
)	O
during	O
germination	O
of	O
Arabidopsis	O
thaliana	O
,	O
and	O
examined	O
oxygen	O
uptakes	O
of	O
the	O
alternative	O
respiration	O
and	O
the	O
cytochrome	B
respiration	O
in	O
imbibed	O
Arabidopsis	O
seeds	O
.	O

A	O
Northern	O
blot	O
analysis	O
showed	O
that	O
AOX2	B
mRNA	O
has	O
already	O
accumulated	O
in	O
dry	O
seeds	O
and	O
subsequently	O
decreased	O
,	O
whereas	O
accumulation	O
ofAOX1a	B
mRNA	O
was	O
less	O
abundant	O
from	O
0	O
hours	O
to	O
48	O
hours	O
after	O
imbibition	O
and	O
then	O
increased	O
.	O

The	O
increase	O
of	O
the	O
capacity	O
of	O
the	O
alternative	O
pathway	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
expressions	O
of	O
both	O
AOX2	B
and	O
AOX1a	B
.	O

On	O
the	O
other	O
hand	O
,	O
steady	O
-	O
state	O
mRNA	O
levels	O
of	O
COX5b	B
and	O
COX6b	B
were	O
gradually	O
increased	O
during	O
germination	O
,	O
and	O
the	O
capacity	O
of	O
the	O
cytochrome	B
pathway	O
was	O
correlated	O
with	O
the	O
increase	O
of	O
expressions	O
of	O
the	O
COX	B
genes	O
.	O

Antimycin	O
A	O
,	O
the	O
respiratory	O
inhibitor	O
,	O
strongly	O
increased	O
the	O
expression	O
of	O
AOX1a	B
but	O
had	O
no	O
effect	O
on	O
the	O
expression	O
of	O
AOX2	B
.	O

A	O
5	O
'	O
RACE	O
analysis	O
showed	O
that	O
AOX2	B
consists	O
of	O
five	O
exons	O
,	O
which	O
is	O
different	O
from	O
the	O
case	O
of	O
most	O
AOX	B
genes	O
identified	O
so	O
far	O
.	O

Analysis	O
of	O
subcellular	O
localization	O
of	O
AOX2	B
using	O
green	B
fluorescent	I
protein	I
indicated	O
that	O
the	O
AOX2	B
protein	O
is	O
imported	O
into	O
the	O
mitochondria	O
.	O

Direct	O
interaction	O
of	O
the	O
Rab3	B
effector	O
RIM	B
with	O
Ca2	B
+	I
channels	I
,	O
SNAP-25	B
,	O
and	O
synaptotagmin	B
.	O

To	O
define	O
the	O
role	O
of	O
the	O
Rab3	B
-	I
interacting	I
molecule	I
RIM	B
in	O
exocytosis	O
we	O
searched	O
for	O
additional	O
binding	O
partners	O
of	O
the	O
protein	O
.	O

We	O
found	O
that	O
the	O
two	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
display	O
properties	O
analogous	O
to	O
those	O
of	O
the	O
C	O
(	O
2	O
)	O
B	O
domain	O
of	O
synaptotagmin	B
-	I
I	I
.	O

Thus	O
,	O
RIM	B
-	O
C	O
(	O
2	O
)	O
A	O
and	O
RIM	B
-	O
C	O
(	O
2	O
)	O
B	O
bind	O
in	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
manner	O
to	O
alpha1B	B
,	O
the	O
pore	O
-	O
forming	O
subunit	O
of	O
N	B
-	I
type	I
Ca	I
(	I
2	I
+	I
)	I
channels	I
(	O
EC	O
(	O
50	O
)	O
=	O
approximately	O
20	O
nm	O
)	O
.	O

They	O
also	O
weakly	O
interact	O
with	O
the	O
alpha1C	B
but	O
not	O
the	O
alpha1D	B
subunit	O
of	O
L	B
-	I
type	I
Ca	I
(	I
2	I
+	I
)	I
channels	I
.	O

In	O
addition	O
,	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	O
associate	O
with	O
SNAP-25	B
and	O
synaptotagmin	B
-	I
I	I
.	O

The	O
binding	O
affinities	O
for	O
these	O
two	O
proteins	O
are	O
203	O
and	O
24	O
nm	O
,	O
respectively	O
,	O
for	O
RIM	B
-	O
C	O
(	O
2	O
)	O
A	O
and	O
224	O
and	O
16	O
nm	O
for	O
RIM	B
-	O
C	O
(	O
2	O
)	O
B	O
.	O

The	O
interactions	O
of	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
with	O
SNAP-25	B
and	O
synaptotagmin	B
-	I
I	I
are	O
modulated	O
by	O
Ca	O
(	O
2	O
+	O
)	O
.	O

Thus	O
,	O
in	O
the	O
presence	O
of	O
Ca	O
(	O
2	O
+	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
approximately	O
75	O
microm	O
)	O
the	O
interaction	O
with	O
synaptotagmin	B
-	I
I	I
is	O
increased	O
,	O
whereas	O
SNAP-25	B
binding	O
is	O
reduced	O
.	O

Synaptotagmin	B
-	I
I	I
binding	O
is	O
abolished	O
by	O
mutations	O
in	O
two	O
positively	O
charged	O
amino	O
acids	O
in	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
and	O
by	O
the	O
addition	O
of	O
inositol	O
polyphosphates	O
.	O

We	O
propose	O
that	O
the	O
Rab3	B
effector	O
RIM	B
is	O
a	O
scaffold	O
protein	O
that	O
participates	O
through	O
its	O
multiple	O
binding	O
partners	O
in	O
the	O
docking	O
and	O
fusion	O
of	O
secretory	O
vesicles	O
at	O
the	O
release	O
sites	O
.	O

Molecular	O
analysis	O
of	O
estrogen	O
induction	O
of	O
preproenkephalin	B
gene	O
expression	O
and	O
its	O
modulation	O
by	O
thyroid	O
hormones	O
.	O

Estrogen	B
receptors	I
(	O
ER	B
)	O
and	O
thyroid	B
hormone	I
receptors	I
(	O
TR	B
)	O
are	O
ligand	O
-	O
dependent	O
nuclear	O
transcription	B
factors	I
.	O

Estrogen	O
-	O
induced	O
preproenkephalin	B
(	O
PPE	B
)	O
gene	O
expression	O
in	O
the	O
hypothalamus	O
is	O
directly	O
related	O
to	O
estrogen	O
-	O
induced	O
lordosis	O
behavior	O
in	O
the	O
rat	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
the	O
PPE	B
mRNA	O
level	O
in	O
the	O
ventromedial	O
hypothalamus	O
of	O
female	O
rats	O
was	O
significantly	O
decreased	O
by	O
ovariectomy	O
.	O

This	O
decrease	O
was	O
reversed	O
by	O
estrogen	O
replacement	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Using	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
functional	O
estrogen	O
response	O
elements	O
(	O
ERE	O
)	O
were	O
identified	O
between	O
-	O
437	O
and	O
-	O
145	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
region	O
.	O

Two	O
ERE	O
-	O
like	O
elements	O
are	O
present	O
between	O
-	O
405	O
and	O
-	O
364	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
,	O
which	O
bind	O
ERalpha	B
as	O
demonstrated	O
by	O
EMSA	O
.	O

Estrogen	O
produced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
CAT	B
activity	O
in	O
cotransfection	O
assays	O
with	O
ERalpha	B
expression	O
vector	O
and	O
a	O
437PPE	B
-	O
CAT	B
reporter	O
construct	O
containing	O
437	O
bp	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
and	O
the	O
CAT	B
reporter	O
gene	O
.	O

This	O
estrogen	O
-	O
induced	O
PPE	B
promoter	O
activity	O
was	O
inhibited	O
by	O
liganded	O
-	O
TR	B
in	O
transient	O
cotransfection	O
assays	O
.	O

Analysis	O
of	O
DNA	O
-	O
protein	O
interactions	O
by	O
EMSA	O
revealed	O
that	O
both	O
ERalpha	B
and	O
TR	B
(	I
alpha1	I
and	I
beta1	I
)	I
could	O
bind	O
to	O
the	O
EREs	O
in	O
the	O
rat	O
PPE	B
gene	O
promoter	O
.	O

Furthermore	O
,	O
estrogen	O
induction	O
of	O
PPE	B
mRNA	O
in	O
the	O
ventromedial	O
hypothalamus	O
of	O
the	O
ovariectomized	O
female	O
rat	O
was	O
significantly	O
attenuated	O
by	O
concomitant	O
administration	O
of	O
triiodothyronine	O
.	O

These	O
results	O
suggest	O
that	O
estrogen	O
regulation	O
of	O
the	O
hypothalamic	O
PPE	B
gene	O
expression	O
is	O
mediated	O
through	O
an	O
estrogen	B
-	I
receptor	I
complex	O
directly	O
interacting	O
with	O
the	O
functional	O
EREs	O
in	O
its	O
promoter	O
region	O
;	O
and	O
that	O
this	O
estrogen	O
effect	O
can	O
be	O
modified	O
by	O
thyroid	O
hormones	O
.	O

Genomic	O
organization	O
and	O
chromosomal	O
localization	O
of	O
the	O
Asna1	B
gene	O
,	O
a	O
mouse	O
homologue	O
of	O
a	O
bacterial	O
arsenic	O
-	O
translocating	O
ATPase	B
gene	O
.	O

The	O
plasmid	O
encoded	O
ArsA	B
ATPase	I
in	O
Escherichia	O
coli	O
is	O
the	O
catalytic	O
component	O
of	O
an	O
oxyanion	O
pump	O
that	O
is	O
responsible	O
for	O
resistance	O
to	O
arsenicals	O
and	O
antimonials	O
.	O

Arsenite	O
or	O
antimonite	O
allosterically	O
activates	O
the	O
ArsA	B
ATPase	I
activity	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
the	O
mouse	O
homologue	O
(	O
Asna1	B
)	O
of	O
the	O
bacterial	O
arsA	B
gene	O
.	O

The	O
Asna1	B
gene	O
encodes	O
an	O
open	O
reading	O
frame	O
of	O
348	O
amino	O
acids	O
and	O
exhibits	O
27	O
%	O
identity	O
to	O
the	O
bacterial	O
ArsA	B
protein	O
and	O
99	O
%	O
similarity	O
to	O
its	O
human	O
counterpart	O
(	O
hASNA-1	B
)	O
.	O

The	O
Asna1	B
mRNA	O
is	O
a	O
approximately	O
1.3	O
kb	O
transcript	O
and	O
is	O
present	O
at	O
high	O
levels	O
in	O
kidney	O
and	O
testis	O
,	O
moderate	O
levels	O
in	O
brain	O
,	O
liver	O
,	O
lung	O
and	O
skin	O
,	O
and	O
low	O
levels	O
in	O
heart	O
,	O
small	O
intestine	O
,	O
spleen	O
,	O
stomach	O
,	O
and	O
thymus	O
.	O

A	O
negligible	O
amount	O
of	O
Asna1	B
transcript	O
is	O
detected	O
in	O
skeletal	O
muscle	O
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	O
structure	O
of	O
the	O
Asna1	B
gene	O
.	O

The	O
gene	O
spans	O
over	O
7	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

All	O
splice	O
sites	O
conform	O
to	O
the	O
GT	O
-	O
AG	O
rule	O
,	O
except	O
for	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
4	O
that	O
is	O
GC	O
instead	O
of	O
GT	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
indicates	O
that	O
the	O
Asna1	B
gene	O
is	O
localized	O
in	O
the	O
C3	O
-	O
D1	O
region	O
of	O
mouse	O
chromosome	O
8	O
.	O

Escherichia	O
coli	O
SecA	B
helicase	B
activity	O
is	O
not	O
required	O
in	O
vivo	O
for	O
efficient	O
protein	O
translocation	O
or	O
autogenous	O
regulation	O
.	O

SecA	B
is	O
an	O
essential	O
ATP	O
-	O
driven	O
motor	O
protein	O
that	O
binds	O
to	O
preproteins	O
and	O
the	O
translocon	O
to	O
promote	O
protein	O
translocation	O
across	O
the	O
eubacterial	O
plasma	O
membrane	O
.	O

Escherichia	O
coli	O
SecA	B
contains	O
seven	O
conserved	O
motifs	O
characteristic	O
of	O
superfamily	O
II	O
of	O
DNA	B
and	I
RNA	I
helicases	I
,	O
and	O
it	O
has	O
been	O
shown	O
previously	O
to	O
possess	O
RNA	B
helicase	I
activity	O
.	O

SecA	B
has	O
also	O
been	O
shown	O
to	O
be	O
an	O
autogenous	O
repressor	O
that	O
binds	O
to	O
its	O
translation	O
initiation	O
region	O
on	O
secM	B
-	O
secA	B
mRNA	O
,	O
thereby	O
blocking	O
and	O
dissociating	O
30	O
S	O
ribosomal	O
subunits	O
.	O

Here	O
we	O
show	O
that	O
SecA	B
is	O
an	O
ATP	O
-	O
dependent	O
helicase	B
that	O
unwinds	O
a	O
mimic	O
of	O
the	O
repressor	O
helix	O
of	O
secM	B
-	O
secA	B
mRNA	O
.	O

Mutational	O
analysis	O
of	O
the	O
seven	O
conserved	O
helicase	B
motifs	O
in	O
SecA	B
allowed	O
us	O
to	O
identify	O
mutants	O
that	O
uncouple	O
SecA	B
-	O
dependent	O
protein	O
translocation	O
activity	O
from	O
its	O
helicase	B
activity	O
.	O

Helicase	B
-	O
defective	O
secA	B
mutants	O
displayed	O
normal	O
protein	O
translocation	O
activity	O
and	O
autogenous	O
repression	O
of	O
secA	B
in	O
vivo	O
.	O

Our	O
studies	O
indicate	O
that	O
SecA	B
helicase	B
activity	O
is	O
nonessential	O
and	O
does	O
not	O
appear	O
to	O
be	O
necessary	O
for	O
efficient	O
protein	O
secretion	O
and	O
secA	B
autoregulation	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
18S	O
rRNA	O
gene	O
and	O
matK	B
gene	O
sequences	O
of	O
Panax	O
vietnamensis	O
and	O
five	O
related	O
species	O
.	O

Panax	O
vietnamensis	O
was	O
discovered	O
recently	O
in	O
Vietnam	O
.	O

Its	O
bamboo	O
-	O
like	O
rhizomes	O
,	O
called	O
Vietnamese	O
Ginseng	O
,	O
have	O
attracted	O
considerable	O
attention	O
because	O
of	O
their	O
specific	O
pharmacological	O
activities	O
.	O

In	O
order	O
to	O
define	O
the	O
taxonomic	O
position	O
of	O
this	O
new	O
species	O
and	O
include	O
it	O
in	O
the	O
molecular	O
authentication	O
of	O
Ginseng	O
drugs	O
,	O
the	O
18S	O
ribosomal	O
RNA	O
gene	O
and	O
matK	B
gene	O
sequences	O
of	O
P.	O
vietnamensis	O
were	O
determined	O
and	O
compared	O
with	O
those	O
of	O
its	O
related	O
taxa	O
,	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
,	O
besides	O
previously	O
reported	O
P.	O
ginseng	O
,	O
P.	O
japonicus	O
and	O
P.	O
quinquefolius	O
.	O

The	O
18S	O
rRNA	O
gene	O
sequences	O
were	O
found	O
to	O
be	O
1809	O
bps	O
in	O
length	O
.	O

The	O
sequence	O
of	O
P.	O
vietnamensis	O
was	O
identical	O
to	O
that	O
of	O
P.	O
quinquefolius	O
,	O
and	O
presented	O
one	O
base	O
substitution	O
from	O
those	O
of	O
both	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
.	O

The	O
matK	B
gene	O
sequences	O
of	O
6	O
taxa	O
were	O
found	O
to	O
be	O
1509	O
bps	O
in	O
length	O
.	O

The	O
sequence	O
of	O
P.	O
vietnamensis	O
differed	O
from	O
those	O
of	O
P.	O
japonicus	O
var	O
.	O
major	O
,	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
,	O
P.	O
ginseng	O
,	O
P.	O
japonicus	O
and	O
P.	O
quinquefolius	O
at	O
4	O
,	O
5	O
,	O
9	O
,	O
9	O
and	O
10	O
nucleotide	O
positions	O
,	O
respectively	O
.	O

The	O
phylogenetic	O
tree	O
reconstructed	O
by	O
the	O
combined	O
18S	O
rRNA	O
-	O
matK	B
gene	O
analysis	O
using	O
the	O
maximum	O
parsimony	O
method	O
showed	O
that	O
P.	O
vietnamensis	O
was	O
sympatric	O
with	O
other	O
Panax	O
species	O
and	O
had	O
a	O
close	O
relationship	O
with	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
.	O

Characterization	O
of	O
inhibitors	O
acting	O
at	O
the	O
synthetase	B
site	O
of	O
Escherichia	O
coli	O
asparagine	B
synthetase	I
B	I
.	O

Asparagine	B
synthetase	I
catalyzes	O
the	O
ATP	O
-	O
dependent	O
formation	O
of	O
L	O
-	O
asparagine	O
from	O
L	O
-	O
aspartate	O
and	O
L	O
-	O
glutamine	O
,	O
via	O
a	O
beta	O
-	O
aspartyl	O
-	O
AMP	O
intermediate	O
.	O

Since	O
interfering	O
with	O
this	O
enzyme	O
activity	O
might	O
be	O
useful	O
for	O
treating	O
leukemia	O
and	O
solid	O
tumors	O
,	O
we	O
have	O
sought	O
small	O
-	O
molecule	O
inhibitors	O
of	O
Escherichia	O
coli	O
asparagine	B
synthetase	I
B	I
(	O
AS	B
-	I
B	I
)	O
as	O
a	O
model	O
system	O
for	O
the	O
human	O
enzyme	O
.	O

Prior	O
work	O
showed	O
that	O
L	O
-	O
cysteine	O
sulfinic	O
acid	O
competitively	O
inhibits	O
this	O
enzyme	O
by	O
interfering	O
with	O
L	O
-	O
aspartate	O
binding	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
cysteine	O
sulfinic	O
acid	O
is	O
also	O
a	O
partial	O
substrate	O
for	O
E.	O
coli	O
asparagine	B
synthetase	I
,	O
acting	O
as	O
a	O
nucleophile	O
to	O
form	O
the	O
sulfur	O
analogue	O
of	O
beta	O
-	O
aspartyl	O
-	O
AMP	O
,	O
which	O
is	O
subsequently	O
hydrolyzed	O
back	O
to	O
cysteine	O
sulfinic	O
acid	O
and	O
AMP	O
in	O
a	O
futile	O
cycle	O
.	O

While	O
cysteine	O
sulfinic	O
acid	O
did	O
not	O
itself	O
constitute	O
a	O
clinically	O
useful	O
inhibitor	O
of	O
asparagine	B
synthetase	I
B	I
,	O
these	O
results	O
suggested	O
that	O
replacing	O
this	O
linkage	O
by	O
a	O
more	O
stable	O
analogue	O
might	O
lead	O
to	O
a	O
more	O
potent	O
inhibitor	O
.	O

A	O
sulfoximine	O
reported	O
recently	O
by	O
Koizumi	O
et	O
al.	O
as	O
a	O
competitive	O
inhibitor	O
of	O
the	O
ammonia	O
-	O
dependent	O
E.	O
coli	O
asparagine	B
synthetase	I
A	I
(	O
AS	B
-	I
A	I
)	O
[	O
Koizumi	O
,	O
M.	O
,	O
Hiratake	O
,	O
J.	O
,	O
Nakatsu	O
,	O
T.	O
,	O
Kato	O
,	O
H.	O
,	O
and	O
Oda	O
,	O
J.	O
(	O
1999	O
)	O
J.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
121	O
,	O
5799	O
-	O
5800	O
]	O
can	O
be	O
regarded	O
as	O
such	O
a	O
species	O
.	O

We	O
found	O
that	O
this	O
sulfoximine	O
also	O
inhibited	O
AS	B
-	I
B	I
,	O
effectively	O
irreversibly	O
.	O

Unlike	O
either	O
the	O
cysteine	O
sulfinic	O
acid	O
interaction	O
with	O
AS	B
-	I
B	I
or	O
the	O
sulfoximine	O
interaction	O
with	O
AS	B
-	I
A	I
,	O
only	O
AS	B
-	I
B	I
productively	O
engaged	O
in	O
asparagine	O
synthesis	O
could	O
be	O
inactivated	O
by	O
the	O
sulfoximine	O
;	O
free	O
enzyme	O
was	O
unaffected	O
even	O
after	O
extended	O
incubation	O
with	O
the	O
sulfoximine	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
the	O
notion	O
that	O
sulfur	O
-	O
containing	O
analogues	O
of	O
aspartate	O
can	O
serve	O
as	O
platforms	O
for	O
developing	O
useful	O
inhibitors	O
of	O
AS	B
-	I
B	I
.	O

Human	O
B	B
cell	I
-	I
attracting	I
chemokine	I
1	I
(	O
BCA-1	B
;	O
CXCL13	B
)	O
is	O
an	O
agonist	O
for	O
the	O
human	O
CXCR3	B
receptor	O
.	O

The	O
CXC	B
chemokine	I
CXCL13	B
,	O
known	O
as	O
BCA-1	B
(	O
B	B
cell	I
-	I
attracting	I
chemokine	I
1	I
)	O
or	O
BLC	B
(	O
B	B
-	I
lymphocyte	I
chemoattractant	I
)	O
,	O
has	O
been	O
identified	O
as	O
an	O
efficacious	O
attractant	O
selective	O
for	O
B	O
lymphocytes	O
.	O

The	O
chemokine	B
receptor	I
BLR1	B
(	O
Burkitt	B
's	I
lymphoma	I
receptor	I
1	I
)	O
/	O
CXCR5	B
expressed	O
by	O
all	O
mature	O
B	O
cells	O
has	O
to	O
date	O
been	O
identified	O
as	O
the	O
only	O
known	O
receptor	O
for	O
BCA-1	B
.	O

As	O
the	O
loss	O
of	O
the	O
BLR1	B
/	O
CXCR5	B
receptor	O
is	O
sufficient	O
to	O
disrupt	O
organization	O
of	O
follicles	O
in	O
spleen	O
and	O
Peyer	O
's	O
patches	O
,	O
BCA-1	B
may	O
act	O
as	O
a	O
B	O
cell	O
homing	O
chemokine	B
.	O

Nonetheless	O
,	O
BCA-1	B
has	O
not	O
been	O
tested	O
against	O
all	O
known	O
chemokine	B
receptors	I
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
human	O
BCA-1	B
competes	O
with	O
radiolabeled	O
interferon	B
gamma	I
(	I
IFN	I
-	I
gamma	I
)	I
inducible	I
protein	I
10	I
(	O
IP-10	B
)	O
for	O
binding	O
to	O
the	O
human	O
CXCR3	B
receptor	O
expressed	O
in	O
Ba	O
/	O
F3	O
and	O
293EBNA	O
cell	O
lines	O
.	O

Furthermore	O
,	O
human	O
BCA-1	B
is	O
an	O
efficacious	O
attractant	O
for	O
human	O
CXCR3	B
transfected	O
cells	O
;	O
BCA-1	B
-	O
induced	O
chemotaxis	O
is	O
inhibited	O
by	O
a	O
monoclonal	O
antibody	O
against	O
human	O
CXCR3	B
.	O

In	O
these	O
cells	O
,	O
as	O
in	O
human	O
B	O
lymphocytes	O
expressing	O
CXCR5	B
,	O
BCA-1	B
does	O
not	O
induce	O
a	O
calcium	O
flux	O
.	O

Indeed	O
,	O
BCA-1	B
attenuates	O
the	O
calcium	O
flux	O
induced	O
by	O
IP-10	B
.	O

In	O
addition	O
,	O
human	O
BCA-1	B
is	O
an	O
agonist	O
in	O
stimulating	O
GTP	O
gamma	O
S	O
binding	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
human	O
BCA-1	B
is	O
a	O
specific	O
and	O
functional	O
G	B
-	I
protein	I
-	O
linked	O
chemotactic	O
ligand	O
for	O
the	O
human	O
CXCR3	B
receptor	O
.	O

The	O
biological	O
significance	O
of	O
this	O
new	O
finding	O
is	O
supported	O
by	O
our	O
recent	O
observation	O
that	O
human	O
BCA-1	B
induces	O
chemotaxis	O
of	O
activated	O
T	O
cells	O
and	O
the	O
BCA-1	B
-	O
induced	O
chemotaxis	O
is	O
inhibited	O
by	O
a	O
monoclonal	O
antibody	O
against	O
human	O
CXCR3	B
.	O

Luteal	O
expression	O
of	O
cytochrome	B
P450	I
side	I
-	I
chain	I
cleavage	I
,	O
steroidogenic	B
acute	I
regulatory	I
protein	I
,	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
,	O
and	O
20alpha	B
-	I
hydroxysteroid	I
dehydrogenase	I
genes	O
in	O
late	O
pregnant	O
rats	O
:	O
effect	O
of	O
luteinizing	B
hormone	I
and	O
RU486	O
.	O

A	O
decrease	O
in	O
serum	O
progesterone	O
at	O
the	O
end	O
of	O
pregnancy	O
is	O
essential	O
for	O
the	O
induction	O
of	O
parturition	O
in	O
rats	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
LH	B
participates	O
in	O
this	O
process	O
through	O
:	O
1	O
)	O
inhibiting	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3beta	B
-	I
HSD	I
)	O
activity	O
and	O
2	O
)	O
stimulating	O
progesterone	O
catabolism	O
by	O
inducing	O
20alpha	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	B
20alpha	I
-	I
HSD	I
)	O
activity	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
effect	O
of	O
LH	B
and	O
progesterone	O
on	O
the	O
luteal	O
expression	O
of	O
the	O
steroidogenic	B
acute	I
regulatory	I
protein	I
(	O
StAR	B
)	O
,	O
cytochrome	B
P450	I
side	I
-	I
chain	I
cleavage	I
(	O
P450	B
(	I
scc	I
)	I
)	O
,	O
3beta	B
-	I
HSD	I
,	O
and	O
20alpha	B
-	I
HSD	I
genes	O
.	O

Gene	O
expression	O
was	O
analyzed	O
by	O
Northern	O
blot	O
analysis	O
24	O
and	O
48	O
h	O
after	O
administration	O
of	O
LH	B
or	O
vehicle	O
on	O
Day	O
19	O
of	O
pregnancy	O
.	O

StAR	B
and	O
3beta	B
-	I
HSD	I
mRNA	O
levels	O
were	O
lower	O
in	O
LH	B
-	O
treated	O
rats	O
than	O
in	O
rats	O
administered	O
with	O
vehicle	O
at	O
both	O
time	O
points	O
studied	O
.	O

P450	B
(	I
scc	I
)	I
mRNA	O
levels	O
were	O
unaffected	O
by	O
LH	B
.	O

The	O
20alpha	B
-	I
HSD	I
mRNA	O
levels	O
were	O
not	O
different	O
between	O
LH	B
and	O
control	O
rats	O
24	O
h	O
after	O
treatment	O
;	O
however	O
,	O
greater	O
expression	O
of	O
20alpha	B
-	I
HSD	I
,	O
with	O
respect	O
to	O
controls	O
,	O
was	O
observed	O
in	O
LH	B
-	O
treated	O
rats	O
48	O
h	O
after	O
treatment	O
.	O

Luteal	O
progesterone	O
content	O
dropped	O
in	O
LH	B
-	O
treated	O
rats	O
at	O
both	O
time	O
points	O
studied	O
,	O
whereas	O
serum	O
progesterone	O
decreased	O
after	O
48	O
h	O
only	O
.	O

In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
the	O
anti	O
-	O
progesterone	O
RU486	O
was	O
injected	O
intrabursally	O
on	O
Day	O
20	O
of	O
pregnancy	O
.	O

RU486	O
had	O
no	O
effect	O
on	O
3beta	B
-	I
HSD	I
or	O
P450	B
(	I
scc	I
)	I
expression	O
but	O
increased	O
20alpha	B
-	I
HSD	I
mRNA	O
levels	O
after	O
8	O
h	O
treatment	O
.	O

In	O
conclusion	O
,	O
the	O
luteolytic	O
effect	O
of	O
LH	B
is	O
mediated	O
by	O
a	O
drop	O
in	O
StAR	B
and	O
3beta	B
-	I
HSD	I
expression	O
without	O
effect	O
on	O
P450	B
(	I
scc	I
)	I
expression	O
.	O

We	O
also	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
indicating	O
that	O
a	O
decrease	O
in	O
luteal	O
progesterone	O
content	O
may	O
be	O
an	O
essential	O
step	O
toward	O
the	O
induction	O
of	O
20alpha	B
-	I
HSD	I
expression	O
at	O
the	O
end	O
of	O
pregnancy	O
in	O
rats	O
.	O

Molecular	O
cloning	O
of	O
a	O
gene	O
encoding	O
matrix	B
metalloproteinase	I
-	I
like	I
protein	I
from	O
Gnathostoma	O
spinigerum	O
.	O

The	O
advanced	O
third	O
-	O
stage	O
larvae	O
(	O
aL3	O
)	O
of	O
Gnathostoma	O
spinigerum	O
contain	O
a	O
24	O
kDa	O
glycoprotein	O
with	O
diagnostic	O
potential	O
.	O

Immunoscreening	O
with	O
the	O
monoclonal	O
antibody	O
to	O
the	O
24	O
-	O
kDa	O
protein	O
(	O
mAb	O
GN6	O
/	O
24	O
)	O
has	O
identified	O
a	O
cDNA	O
clone	O
with	O
an	O
insert	O
of	O
932	O
base	O
pairs	O
(	O
bp	O
)	O
.	O

The	O
insert	O
contains	O
a	O
full	O
-	O
length	O
gene	O
of	O
732	O
bp	O
encoding	O
a	O
protein	O
that	O
is	O
33	O
-	O
39	O
%	O
similar	O
to	O
matrix	B
metalloproteinases	I
(	O
MMPs	B
)	O
of	O
Caenorhabditis	O
elegans	O
and	O
several	O
lower	O
and	O
higher	O
vertebrates	O
.	O

The	O
MMP	B
-	I
like	I
protein	I
of	O
G.	O
spinigerum	O
possesses	O
the	O
catalytic	O
domain	O
,	O
but	O
lacks	O
the	O
propeptide	O
and	O
hemopexin	B
-	O
like	O
domains	O
found	O
in	O
other	O
MMPs	B
.	O

A	O
signal	O
peptide	O
of	O
23	O
amino	O
acids	O
at	O
its	O
amino	O
terminus	O
indicates	O
that	O
it	O
is	O
a	O
secretory	O
protein	O
,	O
which	O
is	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
showing	O
the	O
presence	O
of	O
the	O
24	O
kDa	O
protein	O
in	O
the	O
excretory	O
-	O
secretory	O
products	O
of	O
aL3	O
.	O

International	O
collaborative	O
study	O
:	O
evaluation	O
of	O
proposed	O
International	O
Reference	O
Reagent	O
of	O
pertussis	O
antiserum	O
(	O
mouse	O
)	O
97	O
/	O
642	O
.	O

A	O
freeze	O
dried	O
preparation	O
of	O
mouse	O
serum	O
in	O
vials	O
coded	O
97	O
/	O
642	O
containing	O
antibodies	O
to	O
five	O
pertussis	O
antigens	O
[	O
pertussis	B
toxin	I
(	O
PT	B
)	O
,	O
filamentous	B
hemagglutinin	I
(	O
FHA	B
)	O
,	O
pertactin	B
(	O
PRN	B
)	O
,	O
fimbriae	B
type	I
2	I
and	I
3	I
(	O
Fim	B
2	I
and	I
3	I
)	O
]	O
has	O
been	O
assessed	O
for	O
its	O
suitability	O
as	O
an	O
international	O
reference	O
reagent	O
in	O
an	O
international	O
collaborative	O
study	O
by	O
thirteen	O
laboratories	O
in	O
nine	O
countries	O
.	O

This	O
serum	O
has	O
been	O
compared	O
with	O
U.S	O
.	O

Standard	O
Pertussis	O
Antiserum	O
(	O
mouse	O
)	O
Lot	O
No.	O
1	O
(	O
US	O
Lot	O
1	O
)	O
,	O
which	O
has	O
been	O
in	O
use	O
since	O
1995	O
,	O
for	O
antibodies	O
for	O
each	O
antigen	O
.	O

Calibration	O
of	O
the	O
proposed	O
International	O
Reference	O
Reagent	O
of	O
Pertussis	O
Antiserum	O
(	O
pIRR	O
)	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
gives	O
results	O
which	O
are	O
broadly	O
consistent	O
between	O
laboratories	O
for	O
antibodies	O
to	O
each	O
antigen	O
,	O
although	O
the	O
between	O
-	O
laboratory	O
differences	O
are	O
larger	O
than	O
those	O
seen	O
for	O
comparison	O
of	O
identical	O
sera	O
.	O

Calibration	O
of	O
two	O
positive	O
control	O
sera	O
in	O
terms	O
of	O
the	O
pIRR	O
gave	O
similar	O
between	O
laboratory	O
variability	O
of	O
estimates	O
to	O
that	O
obtained	O
when	O
the	O
same	O
sera	O
were	O
calibrated	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
.	O

Overall	O
continuity	O
of	O
estimates	O
is	O
maintained	O
if	O
units	O
are	O
assigned	O
to	O
the	O
pIRR	O
based	O
on	O
its	O
calibration	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
in	O
this	O
study	O
.	O

Data	O
presently	O
available	O
indicate	O
that	O
the	O
pIRR	O
is	O
sufficiently	O
stable	O
to	O
serve	O
as	O
a	O
reference	O
reagent	O
.	O

It	O
was	O
therefore	O
recommended	O
,	O
with	O
the	O
agreement	O
of	O
all	O
participants	O
,	O
that	O
the	O
preparation	O
in	O
vials	O
coded	O
97	O
/	O
642	O
be	O
established	O
as	O
the	O
First	O
International	O
Reference	O
Reagent	O
for	O
Pertussis	O
Antiserum	O
,	O
mouse	O
,	O
with	O
assigned	O
unitages	O
16	O
units	O
of	O
anti	O
-	O
PT	B
per	O
vial	O
,	O
143	O
units	O
of	O
anti	O
-	O
FHA	B
per	O
vial	O
and	O
30	O
units	O
of	O
anti	O
-	O
PRN	B
per	O
vial	O
based	O
on	O
its	O
calibration	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
.	O

These	O
unitages	O
are	O
also	O
consistent	O
with	O
calibration	O
of	O
97	O
/	O
642	O
in	O
terms	O
of	O
the	O
Japanese	O
preparations	O
JNIH-11	O
for	O
anti	O
-	O
FHA	B
and	O
of	O
JNIH-12	O
for	O
anti	O
-	O
PT	B
.	O

Purified	O
antigens	O
for	O
Fim	B
2	I
and	O
Fim	B
3	I
are	O
not	O
readily	O
available	O
and	O
an	O
arbitrary	O
value	O
of	O
32	O
units	O
per	O
vial	O
is	O
suggested	O
for	O
anti	O
-	O
Fim	B
2	I
and	I
3	I
mixture	O
.	O

These	O
recommendations	O
were	O
agreed	O
by	O
the	O
Expert	O
Committee	O
on	O
Biological	O
Standardization	O
of	O
the	O
World	O
Health	O
Organization	O
.	O

Histone	B
deacetylase	I
as	O
a	O
new	O
target	O
for	O
cancer	O
chemotherapy	O
.	O

Trichostatin	O
A	O
(	O
TSA	O
)	O
and	O
trapoxin	O
(	O
TPX	O
)	O
,	O
inhibitors	O
of	O
the	O
eukaryotic	O
cell	O
cycle	O
and	O
inducers	O
of	O
morphological	O
reversion	O
of	O
transformed	O
cells	O
,	O
inhibit	O
histone	B
deacetylase	I
(	O
HDAC	B
)	O
at	O
nanomolar	O
concentrations	O
.	O

Recently	O
,	O
FK228	O
(	O
also	O
known	O
as	O
FR901228	O
and	O
depsipeptide	O
)	O
and	O
MS-275	O
.	O

antitumor	O
agents	O
structurally	O
unrelated	O
to	O
TSA	O
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
HDAC	B
inhibitors	O
.	O

These	O
inhibitors	O
activate	O
the	O
expression	O
of	O
p21Waf1	B
in	O
a	O
p53	B
-	O
independent	O
manner	O
.	O

Changes	O
in	O
the	O
expression	O
of	O
regulators	O
of	O
the	O
cell	O
cycle	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
with	O
increased	O
histone	B
acetylation	O
may	O
be	O
responsible	O
for	O
the	O
cell	O
cycle	O
arrest	O
and	O
antitumor	O
activity	O
of	O
HDAC	B
inhibitors	O
.	O

TSA	O
has	O
been	O
suggested	O
to	O
block	O
the	O
catalytic	O
reaction	O
by	O
chelating	O
a	O
zinc	O
ion	O
in	O
the	O
active	O
site	O
pocket	O
through	O
its	O
hydroxamic	O
acid	O
group	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
epoxyketone	O
has	O
been	O
suggested	O
to	O
be	O
the	O
functional	O
group	O
of	O
TPX	O
capable	O
of	O
alkylating	O
the	O
enzyme	O
.	O

We	O
synthesized	O
a	O
novel	O
TPX	O
analogue	O
containing	O
a	O
hydroxamic	O
acid	O
instead	O
of	O
the	O
epoxyketone	O
.	O

The	O
hybrid	O
compound	O
,	O
called	O
cyclic	O
hydroxamic	O
-	O
acid	O
-	O
containing	O
peptide	O
1	O
(	O
CHAP1	O
)	O
inhibited	O
HDAC	B
at	O
low	O
nanomolar	O
concentrations	O
.	O

The	O
HDAC1	B
inhibition	O
by	O
CHAPI	O
was	O
reversible	O
,	O
as	O
is	O
that	O
by	O
TSA	O
,	O
in	O
contrast	O
to	O
irreversible	O
inhibition	O
by	O
TPX	O
.	O

Interestingly	O
,	O
HDAC6	B
,	O
but	O
not	O
HDAC1	B
or	O
HDAC4	B
,	O
was	O
resistant	O
to	O
TPX	O
and	O
CHAP1	O
,	O
while	O
TSA	O
inhibited	O
these	O
HDACs	B
to	O
a	O
similar	O
degree	O
.	O

CHAP31	O
,	O
the	O
strongest	O
HDAC	B
inhibitor	O
obtained	O
from	O
a	O
variety	O
of	O
CHAP	O
derivatives	O
,	O
exhibited	O
antitumor	O
activity	O
in	O
BDF1	O
mice	O
bearing	O
B16	O
/	O
BL6	O
tumor	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
CHAP31	O
is	O
promising	O
as	O
a	O
novel	O
therapeutic	O
agent	O
for	O
cancer	O
treatment	O
,	O
and	O
that	O
CHAP	O
may	O
serve	O
as	O
a	O
basis	O
for	O
new	O
HDAC	B
inhibitors	O
and	O
be	O
useful	O
for	O
combinatorial	O
synthesis	O
and	O
high	O
-	O
throughput	O
screening	O
.	O

Molecular	O
control	O
of	O
acid	B
phosphatase	I
secretion	O
into	O
the	O
rhizosphere	O
of	O
proteoid	O
roots	O
from	O
phosphorus	O
-	O
stressed	O
white	O
lupin	O
.	O

White	O
lupin	O
(	O
Lupinus	O
albus	O
)	O
grown	O
under	O
P	O
deficiency	O
displays	O
a	O
suite	O
of	O
highly	O
coordinated	O
adaptive	O
responses	O
.	O

Included	O
among	O
these	O
is	O
secretion	O
of	O
copious	O
amounts	O
of	O
acid	B
phosphatase	I
(	O
APase	B
)	O
.	O

Although	O
numerous	O
reports	O
document	O
that	O
plants	O
secrete	O
APases	B
in	O
response	O
to	O
P	O
deficiency	O
,	O
little	O
is	O
known	O
of	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
this	O
process	O
.	O

Here	O
we	O
characterize	O
the	O
secreted	O
APase	B
protein	O
,	O
cDNA	O
,	O
and	O
gene	O
from	O
white	O
lupin	O
.	O

The	O
secreted	O
APase	B
enzyme	O
is	O
a	O
glycoprotein	O
with	O
broad	O
substrate	O
specificity	O
.	O

It	O
is	O
synthesized	O
as	O
a	O
preprotein	O
with	O
a	O
deduced	O
M	O
(	O
r	O
)	O
of	O
52,000	O
containing	O
a	O
31	O
-	O
amino	O
acid	O
presequence	O
.	O

Analysis	O
of	O
the	O
presequence	O
predicts	O
that	O
the	O
protein	O
is	O
targeted	O
to	O
outside	O
the	O
cell	O
.	O

The	O
processed	O
protein	O
has	O
a	O
predicted	O
M	O
(	O
r	O
)	O
of	O
49,000	O
but	O
migrates	O
as	O
a	O
protein	O
with	O
M	O
(	O
r	O
)	O
of	O
70,000	O
on	O
sodium	O
dodecyl	O
sulfate	O
gels	O
.	O

This	O
is	O
likely	O
due	O
to	O
glycosylation	O
.	O

Enhanced	O
expression	O
is	O
fairly	O
specific	O
to	O
proteoid	O
roots	O
of	O
P	O
-	O
stressed	O
plants	O
and	O
involves	O
enhanced	O
synthesis	O
of	O
both	O
enzyme	O
protein	O
and	O
mRNA	O
.	O

Secreted	O
APase	B
appears	O
to	O
be	O
encoded	O
by	O
a	O
single	O
gene	O
containing	O
seven	O
exons	O
interrupted	O
by	O
six	O
introns	O
.	O

The	O
5	O
'	O
-	O
upstream	O
putative	O
promoter	O
of	O
the	O
white	O
lupin	O
-	O
secreted	O
APase	B
contains	O
a	O
50	O
-	O
base	O
pair	O
region	O
having	O
72	O
%	O
identity	O
to	O
an	O
Arabidopsis	O
APase	B
promoter	O
that	O
is	O
responsive	O
to	O
P	O
deficiency	O
.	O

The	O
white	O
lupin	O
-	O
secreted	O
APase	B
promoter	O
and	O
targeting	O
sequence	O
may	O
be	O
useful	O
tools	O
for	O
genetically	O
engineering	O
important	O
proteins	O
from	O
plant	O
roots	O
.	O

Organization	O
of	O
the	O
human	O
tarbp2	B
gene	O
reveals	O
two	O
promoters	O
that	O
are	O
repressed	O
in	O
an	O
astrocytic	O
cell	O
line	O
.	O

TRBP1	B
and	O
TRBP2	B
are	O
isoforms	O
of	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
that	O
differ	O
in	O
their	O
N	O
-	O
terminal	O
end	O
and	O
were	O
each	O
identified	O
by	O
binding	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
trans	O
-	O
activation	O
-	O
responsive	O
RNA	O
.	O

TRBP1	B
and	O
TRBP2	B
also	O
bind	O
and	O
modulate	O
the	O
function	O
of	O
the	O
double	B
-	I
stranded	I
RNA	I
-	I
activated	I
protein	I
kinase	I
,	O
protein	B
kinase	I
R	I
.	O

Both	O
proteins	O
increase	O
long	O
terminal	O
repeat	O
expression	O
in	O
human	O
and	O
murine	O
cells	O
,	O
and	O
their	O
gene	O
has	O
been	O
mapped	O
to	O
human	O
chromosome	O
12	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
complete	O
tarbp2	B
gene	O
(	O
5493	O
bp	O
)	O
coding	O
for	O
the	O
two	O
TRBP	B
proteins	O
.	O

Two	O
adjacent	O
promoters	O
initiate	O
transcription	O
of	O
alternative	O
first	O
exons	O
for	O
TRBP1	B
and	O
TRBP2	B
mRNAs	O
that	O
are	O
spliced	O
onto	O
common	O
downstream	O
exons	O
.	O

TRBP2	B
transcription	O
and	O
translation	O
start	O
sites	O
are	O
localized	O
within	O
the	O
first	O
intron	O
of	O
TRBP1	B
.	O

TRBP	B
promoters	O
are	O
TATA	O
-	O
less	O
but	O
have	O
CCAAT	O
boxes	O
,	O
a	O
CpG	O
island	O
,	O
and	O
several	O
potential	O
binding	O
sites	O
for	O
transcriptional	B
factors	I
.	O

Promoter	O
deletion	O
analysis	O
identified	O
two	O
regions	O
from	O
position	O
-	O
1397	O
to	O
-	O
330	O
for	O
TRBP1	B
and	O
from	O
position	O
-	O
330	O
to	O
+	O
38	O
for	O
TRBP2	B
that	O
are	O
important	O
for	O
promoter	O
function	O
.	O

TRBP2	B
promoter	O
activity	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
compared	O
with	O
TRBP1	B
promoter	O
.	O

In	O
addition	O
,	O
a	O
specific	O
down	O
-	O
regulation	O
of	O
TRBP1	B
and	O
TRBP2	B
promoter	O
activity	O
was	O
identified	O
in	O
human	O
astrocytic	O
cell	O
line	O
U251MG	O
compared	O
with	O
HeLa	O
cells	O
.	O

This	O
minimal	O
TRBP	B
promoter	O
activity	O
may	O
account	O
for	O
minimal	O
HIV-1	O
replication	O
in	O
astrocytes	O
.	O

Identification	O
of	O
the	O
cellular	O
receptor	O
for	O
anthrax	O
toxin	O
.	O

The	O
tripartite	O
toxin	O
secreted	O
by	O
Bacillus	O
anthracis	O
,	O
the	O
causative	O
agent	O
of	O
anthrax	O
,	O
helps	O
the	O
bacterium	O
evade	O
the	O
immune	O
system	O
and	O
can	O
kill	O
the	O
host	O
during	O
a	O
systemic	O
infection	O
.	O

Two	O
components	O
of	O
the	O
toxin	O
enzymatically	O
modify	O
substrates	O
within	O
the	O
cytosol	O
of	O
mammalian	O
cells	O
:	O
oedema	B
factor	I
(	O
OF	B
)	O
is	O
an	O
adenylate	B
cyclase	I
that	O
impairs	O
host	O
defences	O
through	O
a	O
variety	O
of	O
mechanisms	O
including	O
inhibiting	O
phagocytosis	O
;	O
lethal	B
factor	I
(	O
LF	B
)	O
is	O
a	O
zinc	O
-	O
dependent	O
protease	B
that	O
cleaves	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
and	O
causes	O
lysis	O
of	O
macrophages	O
.	O

Protective	B
antigen	I
(	O
PA	B
)	O
,	O
the	O
third	O
component	O
,	O
binds	O
to	O
a	O
cellular	O
receptor	O
and	O
mediates	O
delivery	O
of	O
the	O
enzymatic	O
components	O
to	O
the	O
cytosol	O
.	O

Here	O
we	O
describe	O
the	O
cloning	O
of	O
the	O
human	O
PA	O
receptor	O
using	O
a	O
genetic	O
complementation	O
approach	O
.	O

The	O
receptor	O
,	O
termed	O
ATR	B
(	O
anthrax	B
toxin	I
receptor	I
)	O
,	O
is	O
a	O
type	O
I	O
membrane	O
protein	O
with	O
an	O
extracellular	O
von	B
Willebrand	I
factor	I
A	O
domain	O
that	O
binds	O
directly	O
to	O
PA	O
.	O

In	O
addition	O
,	O
a	O
soluble	O
version	O
of	O
this	O
domain	O
can	O
protect	O
cells	O
from	O
the	O
action	O
of	O
the	O
toxin	O
.	O

A	O
Golgi	O
-	O
associated	O
PDZ	O
domain	O
protein	O
modulates	O
cystic	B
fibrosis	I
transmembrane	I
regulator	I
plasma	O
membrane	O
expression	O
.	O

We	O
identified	O
a	O
novel	O
cystic	B
fibrosis	I
transmembrane	I
conductance	I
regulator	I
(	O
CFTR	B
)	O
-	O
associating	O
,	O
PDZ	O
domain	O
-	O
containing	O
protein	O
,	O
CAL	B
(	O
CFTR	B
associated	I
ligand	I
)	O
containing	O
two	O
predicted	O
coiled	O
-	O
coiled	O
domains	O
and	O
one	O
PDZ	O
domain	O
.	O

The	O
PDZ	O
domain	O
of	O
CAL	B
binds	O
to	O
the	O
C	O
terminus	O
of	O
CFTR	B
.	O

Although	O
CAL	B
does	O
not	O
have	O
any	O
predicted	O
transmembrane	O
domains	O
,	O
CAL	B
is	O
associated	O
with	O
membranes	O
mediated	O
by	O
a	O
region	O
containing	O
the	O
coiled	O
-	O
coil	O
domains	O
.	O

CAL	B
is	O
located	O
primarily	O
at	O
the	O
Golgi	O
apparatus	O
,	O
co	O
-	O
localizing	O
with	O
trans	O
-	O
Golgi	O
markers	O
and	O
is	O
sensitive	O
to	O
Brefeldin	O
A	O
treatment	O
.	O

Immunoprecipitation	O
experiments	O
suggest	O
that	O
CAL	B
exists	O
as	O
a	O
multimer	O
.	O

Overexpression	O
of	O
CAL	B
reduces	O
CFTR	B
chloride	O
currents	O
in	O
mammalian	O
cells	O
and	O
decreases	O
expression	O
,	O
rate	O
of	O
insertion	O
and	O
half	O
-	O
life	O
of	O
CFTR	B
in	O
the	O
plasma	O
membrane	O
.	O

The	O
Na	B
(	I
+	I
)	I
/	I
H	I
(	I
+	I
)	I
exchanger	I
regulatory	I
factor	I
,	O
NHE	B
-	I
RF	I
,	O
a	O
subplasma	O
membrane	O
PDZ	O
domain	O
protein	O
,	O
restores	O
cell	O
surface	O
expression	O
of	O
CFTR	B
and	O
chloride	O
currents	O
.	O

In	O
addition	O
,	O
NHE	B
-	I
RF	I
inhibits	O
the	O
binding	O
of	O
CAL	B
to	O
CFTR	B
.	O

CAL	B
modulates	O
the	O
surface	O
expression	O
of	O
CFTR	B
.	O

CAL	B
favors	O
retention	O
of	O
CFTR	B
within	O
the	O
cell	O
,	O
whereas	O
NHE	B
-	I
RF	I
favors	O
surface	O
expression	O
by	O
competing	O
with	O
CAL	B
for	O
the	O
binding	O
of	O
CFTR	B
.	O

Thus	O
,	O
the	O
regulation	O
of	O
CFTR	B
in	O
the	O
plasma	O
membrane	O
involves	O
the	O
dynamic	O
interaction	O
between	O
at	O
least	O
two	O
PDZ	O
domain	O
proteins	O
.	O

Crystal	O
structure	O
of	O
Arp2	B
/	I
3	I
complex	I
.	O

We	O
determined	O
a	O
crystal	O
structure	O
of	O
bovine	O
Arp2	B
/	I
3	I
complex	I
,	O
an	O
assembly	O
of	O
seven	O
proteins	O
that	O
initiates	O
actin	B
polymerization	O
in	O
eukaryotic	O
cells	O
,	O
at	O
2.0	O
angstrom	O
resolution	O
.	O

Actin	B
-	I
related	I
protein	I
2	I
(	O
Arp2	B
)	O
and	O
Arp3	B
are	O
folded	O
like	O
actin	B
,	O
with	O
distinctive	O
surface	O
features	O
.	O

Subunits	O
ARPC2	B
p34	I
and	O
ARPC4	B
p20	I
in	O
the	O
core	O
of	O
the	O
complex	O
associate	O
through	O
long	O
carboxyl	O
-	O
terminal	O
alpha	O
helices	O
and	O
have	O
similarly	O
folded	O
amino	O
-	O
terminal	O
alpha	O
/	O
beta	O
domains	O
.	O

ARPC1	B
p40	I
is	O
a	O
seven	O
-	O
blade	O
beta	O
propeller	O
with	O
an	O
insertion	O
that	O
may	O
associate	O
with	O
the	O
side	O
of	O
an	O
actin	B
filament	O
.	O

ARPC3	B
p21	I
and	O
ARPC5	B
p16	I
are	O
globular	O
alpha	O
-	O
helical	O
subunits	O
.	O

We	O
predict	O
that	O
WASp	B
/	O
Scar	B
proteins	O
activate	O
Arp2	B
/	I
3	I
complex	I
by	O
bringing	O
Arp2	B
into	O
proximity	O
with	O
Arp3	B
for	O
nucleation	O
of	O
a	O
branch	O
on	O
the	O
side	O
of	O
a	O
preexisting	O
actin	B
filament	O
.	O

Thromboembolic	O
disease	O
and	O
antithrombotic	O
therapy	O
in	O
newborns	O
.	O

This	O
update	O
uses	O
an	O
evidence	O
based	O
approach	O
to	O
analyze	O
and	O
present	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
,	O
etiologies	O
,	O
currently	O
used	O
techniques	O
for	O
diagnosis	O
with	O
their	O
limitations	O
,	O
and	O
current	O
therapeutic	O
approaches	O
.	O

In	O
addition	O
,	O
the	O
approaches	O
to	O
both	O
prevention	O
and	O
optimal	O
therapies	O
are	O
discussed	O
.	O

In	O
Section	O
I	O
Dr.	O
Paul	O
Monagle	O
addresses	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
outside	O
of	O
the	O
central	O
nervous	O
system	O
in	O
both	O
arterial	O
and	O
venous	O
locations	O
,	O
and	O
those	O
that	O
occur	O
in	O
utero	O
.	O

The	O
specific	O
contributions	O
of	O
catheters	O
and	O
congenital	O
prothrombotic	O
disorders	O
are	O
delineated	O
.	O

Dr.	O
Monagle	O
also	O
describes	O
currently	O
used	O
techniques	O
for	O
the	O
diagnosis	O
of	O
thrombotic	O
events	O
as	O
well	O
as	O
their	O
limitations	O
and	O
the	O
current	O
therapeutic	O
approaches	O
.	O

In	O
Section	O
II	O
,	O
Dr.	O
Gabrielle	O
deVeber	O
reviews	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
within	O
the	O
central	O
nervous	O
system	O
,	O
in	O
both	O
arterial	O
and	O
venous	O
locations	O
and	O
those	O
that	O
occur	O
in	O
utero	O
.	O

The	O
neurological	O
presentation	O
,	O
risk	O
factors	O
including	O
congenital	O
prothrombotic	O
disorders	O
,	O
anatomical	O
distribution	O
,	O
diagnostic	O
tests	O
,	O
use	O
of	O
antithrombotic	O
therapy	O
and	O
neurologic	O
outcome	O
of	O
neonates	O
with	O
either	O
sinovenous	O
thrombosis	O
or	O
arterial	O
ischemic	O
stroke	O
are	O
discussed	O
.	O

In	O
Section	O
III	O
,	O
Dr.	O
Anthony	O
Chan	O
reviews	O
the	O
current	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
neonatal	O
thrombosis	O
.	O

Information	O
on	O
the	O
differences	O
in	O
the	O
response	O
of	O
neonates	O
compared	O
to	O
adults	O
to	O
antithrombotic	O
therapy	O
and	O
new	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
thrombosis	O
in	O
neonates	O
are	O
emphasized	O
.	O

Intergenic	O
mRNA	O
molecules	O
resulting	O
from	O
trans	O
-	O
splicing	O
.	O

Accumulated	O
recent	O
evidence	O
is	O
indicating	O
that	O
alternative	O
splicing	O
represents	O
a	O
generalized	O
process	O
that	O
increases	O
the	O
complexity	O
of	O
human	O
gene	O
expression	O
.	O

Here	O
we	O
show	O
that	O
mRNA	O
production	O
may	O
not	O
necessarily	O
be	O
limited	O
to	O
single	O
genes	O
,	O
as	O
human	O
liver	O
also	O
has	O
the	O
potential	O
to	O
produce	O
a	O
variety	O
of	O
hybrid	O
cytochrome	B
P450	I
3A	I
mRNA	O
molecules	O
.	O

The	O
four	O
known	O
cytochrome	B
P450	I
3A	I
genes	O
in	O
humans	O
,	O
CYP3A4	B
,	O
CYP3A5	B
,	O
CYP3A7	B
,	O
and	O
CYP3A43	B
,	O
share	O
a	O
high	O
degree	O
of	O
similarity	O
,	O
consist	O
of	O
13	O
exons	O
with	O
conserved	O
exon	O
-	O
intron	O
boundaries	O
,	O
and	O
form	O
a	O
cluster	O
on	O
chromosome	O
7	O
.	O

The	O
chimeric	O
CYP3A	B
mRNA	O
molecules	O
described	O
herein	O
are	O
characterized	O
by	O
CYP3A43	B
exon	O
1	O
joined	O
at	O
canonical	O
splice	O
sites	O
to	O
distinct	O
sets	O
of	O
CYP3A4	B
or	O
CYP3A5	B
exons	O
.	O

Because	O
the	O
CYP3A43	B
gene	O
is	O
in	O
a	O
head	O
-	O
to	O
-	O
head	O
orientation	O
with	O
the	O
CYP3A4	B
and	O
CYP3A5	B
genes	O
,	O
bypassing	O
transcriptional	O
termination	O
can	O
not	O
account	O
for	O
the	O
formation	O
of	O
hybrid	O
CYP3A	B
mRNAs	O
.	O

Thus	O
,	O
the	O
mechanism	O
generating	O
these	O
molecules	O
has	O
to	O
be	O
an	O
RNA	O
processing	O
event	O
that	O
joins	O
exons	O
of	O
independent	O
pre	O
-	O
mRNA	O
molecules	O
,	O
i.e.	O
trans	O
-	O
splicing	O
.	O

Using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
the	O
ratio	O
of	O
one	O
CYP3A43	B
/	I
3A4	I
intergenic	O
combination	O
was	O
estimated	O
to	O
be	O
approximately	O
0.15	O
%	O
that	O
of	O
the	O
CYP3A43	B
mRNAs	O
.	O

Moreover	O
,	O
trans	O
-	O
splicing	O
has	O
been	O
found	O
not	O
to	O
interfere	O
with	O
polyadenylation	O
.	O

Heterologous	O
expression	O
of	O
the	O
chimeric	O
species	O
composed	O
of	O
CYP3A43	B
exon	O
1	O
joined	O
to	O
exons	O
2	O
-	O
13	O
of	O
CYP3A4	B
revealed	O
catalytic	O
activity	O
toward	O
testosterone	O
.	O

Angiogenesis	O
-	O
dependent	O
diseases	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
leukemias	O
and	O
other	O
hematologic	O
diseases	O
are	O
angiogenesis	O
-	O
dependent	O
.	O

Therefore	O
,	O
angiogenesis	O
inhibitors	O
may	O
be	O
useful	O
adjuncts	O
to	O
conventional	O
therapies	O
in	O
the	O
treatment	O
of	O
these	O
diseases	O
.	O

When	O
all	O
conventional	O
therapy	O
has	O
failed	O
,	O
an	O
angiogenesis	O
inhibitor	O
may	O
be	O
successfully	O
used	O
alone	O
,	O
as	O
has	O
been	O
demonstrated	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
by	O
thalidomide	O
.	O

The	O
experimental	O
and	O
clinical	O
evidence	O
that	O
the	O
efficacy	O
of	O
thalidomide	O
against	O
multiple	O
myeloma	O
is	O
mediated	O
in	O
part	O
by	O
its	O
antiangiogenic	O
activity	O
is	O
presented	O
here	O
.	O

In	O
current	O
clinical	O
trials	O
throughout	O
the	O
United	O
States	O
,	O
angiogenesis	O
inhibitors	O
are	O
being	O
used	O
against	O
cancer	O
in	O
combination	O
with	O
conventional	O
chemotherapy	O
or	O
radiotherapy	O
.	O

Angiogenesis	O
inhibitors	O
are	O
also	O
being	O
used	O
in	O
combination	O
with	O
each	O
other	O
.	O

This	O
practice	O
may	O
increase	O
as	O
different	O
angiogenesis	O
inhibitors	O
become	O
more	O
widely	O
available	O
.	O

Transcription	B
factors	I
NF	B
-	I
Y	I
and	O
Sp1	B
are	O
important	O
determinants	O
of	O
the	O
promoter	O
activity	O
of	O
the	O
bovine	O
and	O
human	O
neuronal	O
nicotinic	B
receptor	I
beta	I
4	I
subunit	O
genes	O
.	O

The	O
beta4	O
subunit	O
is	O
a	O
component	O
of	O
the	O
neuronal	O
nicotinic	B
acetylcholine	I
receptors	I
which	O
control	O
catecholamine	O
secretion	O
in	O
bovine	O
adrenomedullary	O
chromaffin	O
cells	O
.	O

The	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
this	O
subunit	O
was	O
characterized	O
.	O

A	O
proximal	O
region	O
(	O
from	O
minus	O
sign99	O
to	O
minus	O
sign64	O
)	O
was	O
responsible	O
for	O
the	O
transcriptional	O
activity	O
observed	O
in	O
chromaffin	O
,	O
C2C12	O
,	O
and	O
COS	O
cells	O
.	O

Within	O
this	O
region	O
two	O
cis	O
-	O
acting	O
elements	O
that	O
bind	O
transcription	B
factors	I
Sp1	B
and	O
NF	B
-	I
Y	I
were	O
identified	O
.	O

Mutagenesis	O
of	O
the	O
two	O
elements	O
indicated	O
that	O
they	O
cooperate	O
for	O
the	O
basal	O
transcription	O
activity	O
of	O
the	O
promoter	O
.	O

The	O
human	O
beta4	O
promoter	O
,	O
that	O
was	O
also	O
characterized	O
,	O
shared	O
structural	O
and	O
functional	O
homologies	O
with	O
the	O
bovine	O
promoter	O
.	O

Thus	O
,	O
two	O
adjacent	O
binding	O
elements	O
for	O
Sp1	B
and	O
NF	B
-	I
Y	I
were	O
detected	O
.	O

Whereas	O
the	O
Sp1	B
site	O
was	O
an	O
important	O
determinant	O
of	O
the	O
promoter	O
activity	O
,	O
the	O
NF	B
-	I
Y	I
site	O
may	O
have	O
cell	O
-	O
specific	O
effects	O
.	O

Given	O
that	O
these	O
promoters	O
showed	O
no	O
structural	O
or	O
functional	O
homology	O
with	O
the	O
previously	O
characterized	O
rat	O
beta4	O
subunit	O
promoter	O
(	O
Bigger	O
,	O
C.	O
B.	O
,	O
Casanova	O
,	O
E.	O
A.	O
,	O
and	O
Gardner	O
,	O
P.	O
D.	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
32842	O
-	O
-	O
32848	O
)	O
except	O
for	O
the	O
involvement	O
of	O
an	O
Sp1	B
binding	O
element	O
,	O
we	O
propose	O
that	O
constitutive	O
expression	O
of	O
the	O
beta4	O
subunit	O
gene	O
in	O
these	O
three	O
close	O
species	O
may	O
be	O
controlled	O
by	O
the	O
general	O
transcription	B
factor	I
Sp1	B
.	O

Nevertheless	O
,	O
other	O
components	O
could	O
determine	O
species	O
-	O
specific	O
beta4	O
subunit	O
expression	O
.	O

Solution	O
structures	O
of	O
the	O
YAP65	B
WW	O
domain	O
and	O
the	O
variant	O
L30	O
K	O
in	O
complex	O
with	O
the	O
peptides	O
GTPPPPYTVG	O
,	O
N-	O
(	O
n	O
-	O
octyl	O
)	O
-	O
GPPPY	O
and	O
PLPPY	O
and	O
the	O
application	O
of	O
peptide	O
libraries	O
reveal	O
a	O
minimal	O
binding	O
epitope	O
.	O

The	O
single	O
mutation	O
L30	O
K	O
in	O
the	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
increased	O
the	O
stability	O
of	O
the	O
complex	O
with	O
the	O
peptide	O
GTPPPPYTVG	O
(	O
K	O
(	O
d	O
)	O
=	O
40	O
(	O
+	O
/-	O
5	O
)	O
microM	O
)	O
.	O

Here	O
we	O
report	O
the	O
refined	O
solution	O
structure	O
of	O
this	O
complex	O
by	O
NMR	O
spectroscopy	O
and	O
further	O
derived	O
structure	O
-	O
activity	O
relationships	O
by	O
using	O
ligand	O
peptide	O
libraries	O
with	O
truncated	O
sequences	O
and	O
a	O
substitution	O
analysis	O
that	O
yielded	O
acetyl	O
-	O
PPPPY	O
as	O
the	O
smallest	O
high	O
-	O
affinity	O
binding	O
peptide	O
(	O
K	O
(	O
d	O
)	O
=	O
60	O
microM	O
)	O
.	O

The	O
structures	O
of	O
two	O
new	O
complexes	O
with	O
weaker	O
binding	O
ligands	O
chosen	O
based	O
on	O
these	O
results	O
(	O
N-	O
(	O
n	O
-	O
octyl	O
)	O
-GPPPYNH	O
(	O
2	O
)	O
and	O
Ac	O
-	O
PLPPY	O
)	O
comprising	O
the	O
wild	O
-	O
type	O
WW	O
domain	O
of	O
Hu	O
-	O
Yap65	B
were	O
determined	O
.	O

Comparison	O
of	O
the	O
structures	O
of	O
the	O
three	O
complexes	O
were	O
useful	O
for	O
identifying	O
the	O
molecular	O
basis	O
of	O
high	O
-	O
affinity	O
:	O
hydrophobic	O
and	O
specific	O
interactions	O
between	O
the	O
side	O
-	O
chains	O
of	O
Y28	O
and	O
W39	O
and	O
P5	O
'	O
and	O
P4	O
'	O
,	O
respectively	O
,	O
and	O
hydrogen	O
bonds	O
between	O
T37	O
(	O
donnor	O
)	O
and	O
P5	O
'	O
(	O
acceptor	O
)	O
and	O
between	O
W39	O
(	O
donnor	O
)	O
and	O
T2	O
'	O
(	O
acceptor	O
)	O
stabilize	O
the	O
complex	O
.	O
The	O
structure	O
of	O
the	O
complex	O
L30	O
K	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
/	O
GTPPPPYTVG	O
is	O
compared	O
to	O
the	O
published	O
crystal	O
structure	O
of	O
the	O
dystrophin	B
WW	O
domain	O
bound	O
to	O
a	O
segment	O
of	O
the	O
beta	B
-	I
dystroglycan	I
protein	O
and	O
to	O
the	O
solution	O
structure	O
of	O
the	O
first	O
Nedd4	B
WW	O
domain	O
and	O
its	O
prolin	O
-	O
rich	O
ligand	O
,	O
suggesting	O
that	O
WW	O
sequences	O
bind	O
proline	O
-	O
rich	O
peptides	O
in	O
an	O
evolutionary	O
conserved	O
fashion	O
.	O

The	O
position	O
equivalent	O
to	O
T22	O
in	O
the	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
sequence	O
is	O
seen	O
as	O
responsible	O
for	O
differentiation	O
in	O
the	O
binding	O
mode	O
among	O
the	O
WW	O
domains	O
of	O
group	O
I	O
.	O

Liposome	O
-	O
encapsulated	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
enhances	O
the	O
effects	O
of	O
radiation	O
against	O
human	O
colon	O
tumor	O
xenografts	O
.	O

Recent	O
reports	O
have	O
shown	O
that	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
can	O
augment	O
the	O
effects	O
of	O
radiation	O
against	O
certain	O
tumor	O
types	O
.	O

However	O
,	O
the	O
high	O
concentrations	O
of	O
intravenous	O
infusion	O
of	O
TNF	B
-	I
alpha	I
needed	O
to	O
cause	O
tumor	O
regression	O
can	O
induce	O
many	O
systemic	O
side	O
effects	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
if	O
TNF	B
-	I
alpha	I
encapsulated	O
in	O
sterically	O
stabilized	O
(	O
Stealth	O
,	O
ALZA	O
Corporation	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
,	O
PEGylated	O
liposomes	O
(	O
SL	O
)	O
augments	O
the	O
antitumor	O
effects	O
of	O
radiation	O
and	O
to	O
compare	O
its	O
efficacy	O
and	O
possible	O
toxicity	O
with	O
free	O
TNF	B
-	I
alpha	I
in	O
the	O
LS174	O
T	O
human	O
colon	O
tumor	O
xenograft	O
model	O
.	O

Nude	O
mice	O
were	O
injected	O
subcutaneously	O
(	O
s.c	O
.	O
)	O
with	O
LS174	O
T	O
cells	O
and	O
treated	O
intravenously	O
(	O
i.v	O
.	O
)	O
with	O
Stealth	O
-	O
liposomal	O
TNF	B
-	I
alpha	I
(	O
SL	O
-	O
TNF	O
-	O
alpha	O
)	O
with	O
and	O
without	O
radiation	O
or	O
TNF	B
-	I
alpha	I
with	O
or	O
without	O
radiation	O
when	O
tumor	O
size	O
was	O
approximately	O
200	O
mm	O
(	O
3	O
)	O
.	O

In	O
phase	O
1	O
,	O
a	O
significant	O
decrease	O
(	O
p	O
=	O
0.047	O
)	O
in	O
tumor	O
growth	O
was	O
observed	O
with	O
radiation	O
at	O
day	O
21	O
but	O
not	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
or	O
free	O
TNF	B
-	I
alpha	I
alone	O
.	O

By	O
the	O
end	O
of	O
phase	O
1	O
(	O
day	O
27	O
)	O
with	O
continued	O
treatments	O
,	O
the	O
SL	O
-	O
TNF	B
-	I
alpha	I
plus	O
radiation	O
group	O
had	O
significantly	O
smaller	O
tumors	O
(	O
p	O
=	O
0.044	O
)	O
than	O
those	O
in	O
the	O
free	O
TNF	B
-	I
alpha	I
plus	O
radiation	O
group	O
.	O

In	O
phase	O
2	O
,	O
where	O
a	O
similar	O
tumor	O
growth	O
reduction	O
pattern	O
was	O
observed	O
,	O
the	O
addition	O
of	O
TNF	B
-	I
alpha	I
to	O
radiation	O
,	O
either	O
as	O
free	O
protein	O
or	O
within	O
SL	O
,	O
increased	O
lymphocyte	O
activation	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
numbers	O
in	O
both	O
blood	O
and	O
spleen	O
.	O

The	O
effect	O
was	O
generally	O
more	O
pronounced	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
.	O

Systemic	O
toxicity	O
,	O
based	O
on	O
hematologic	O
analyses	O
and	O
body	O
weight	O
,	O
was	O
absent	O
or	O
minimal	O
.	O

Collectively	O
,	O
the	O
data	O
show	O
that	O
pretreatment	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
can	O
enhance	O
more	O
effectively	O
,	O
and	O
possibly	O
more	O
safely	O
,	O
the	O
effects	O
of	O
radiation	O
against	O
human	O
colon	O
tumor	O
xenografts	O
than	O
can	O
free	O
TNF	B
-	I
alpha	I
and	O
that	O
the	O
increased	O
antitumor	O
action	O
may	O
involve	O
upregulation	O
of	O
lymphocytes	O
.	O

Identification	O
of	O
a	O
novel	O
human	O
cytokine	B
gene	O
in	O
the	O
interleukin	B
gene	O
cluster	O
on	O
chromosome	O
2q12	O
-	O
14	O
.	O

Genes	O
in	O
the	O
interleukin-1	B
(	O
IL-1	B
)	O
gene	O
cluster	O
on	O
human	O
chromosome	O
2	O
play	O
an	O
important	O
role	O
in	O
mediating	O
inflammatory	O
responses	O
and	O
are	O
associated	O
with	O
numerous	O
diseases	O
.	O

We	O
have	O
identified	O
a	O
novel	O
IL-1	B
-	O
like	O
gene	O
,	O
IL-1F10	B
,	O
on	O
human	O
chromosome	O
2q13	O
-	O
14.1	O
near	O
the	O
IL-1	B
receptor	I
antagonist	I
gene	O
(	O
IL-1RN	B
)	O
.	O

The	O
IL1F10	B
gene	O
is	O
encoded	O
by	O
5	O
exons	O
spanning	O
over	O
7.8	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
1008	O
-	O
bp	O
IL-1F10	B
cDNA	O
encodes	O
a	O
152	O
-	O
amino	O
acid	O
protein	O
that	O
shares	O
between	O
41	O
%	O
and	O
43	O
%	O
amino	O
acid	O
identity	O
with	O
human	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
and	O
FIL-1delta	B
,	O
respectively	O
.	O

IL-1F10	B
shares	O
characteristics	O
of	O
the	O
IL-1Ra	B
family	I
,	O
including	O
key	O
amino	O
acid	O
consensus	O
sequences	O
and	O
a	O
similar	O
genomic	O
structure	O
.	O

By	O
multitissue	O
first	O
-	O
strand	O
cDNA	O
PCR	O
analysis	O
,	O
IL-1F10	B
mRNA	O
is	O
expressed	O
in	O
heart	O
,	O
placenta	O
,	O
fetal	O
liver	O
,	O
spleen	O
,	O
thymus	O
,	O
and	O
tonsil	O
.	O

The	O
expression	O
in	O
a	O
variety	O
of	O
immune	O
tissues	O
and	O
similarity	O
to	O
IL-1Ra	B
suggest	O
a	O
role	O
of	O
IL-1F10	B
in	O
the	O
inflammatory	O
response	O
.	O

Identification	O
of	O
novel	O
Plasmodium	O
gallinaceum	O
zygote	O
-	O
and	O
ookinete	O
-	O
expressed	O
proteins	O
as	O
targets	O
for	O
blocking	O
malaria	O
transmission	O
.	O

The	O
development	O
of	O
transmission	O
-	O
blocking	O
vaccines	O
is	O
one	O
approach	O
to	O
malaria	O
control	O
.	O

To	O
identify	O
novel	O
Plasmodium	O
zygote	O
-	O
and	O
ookinete	O
-	O
secreted	O
proteins	O
as	O
targets	O
of	O
blocking	O
malaria	O
transmission	O
,	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
were	O
produced	O
against	O
parasite	O
-	O
secreted	O
proteins	O
found	O
in	O
Plasmodium	O
gallinaceum	O
ookinete	O
culture	O
supernatants	O
.	O

Four	O
MAbs-1A6	O
,	O
2A5	O
,	O
2B5	O
,	O
and	O
4B6	O
-	O
were	O
identified	O
that	O
bound	O
to	O
P.	O
gallinaceum	O
zygotes	O
and	O
ookinetes	O
in	O
diverse	O
patterns	O
in	O
terms	O
of	O
spatial	O
localization	O
on	O
parasites	O
,	O
time	O
course	O
of	O
antigen	O
expression	O
,	O
and	O
Western	O
immunoblot	O
patterns	O
.	O

MAbs	O
2A5	O
and	O
4B6	O
recognized	O
more	O
than	O
one	O
protein	O
band	O
as	O
detected	O
by	O
Western	O
immunoblot	O
of	O
P.	O
gallinaceum	O
ookinete	O
supernatants	O
.	O

Beginning	O
at	O
0	O
h	O
postfertilization	O
,	O
MAb	O
2A5	O
recognized	O
a	O
diverse	O
set	O
of	O
antigens	O
;	O
at	O
10	O
h	O
postfertilization	O
,	O
MAb	O
4B6	O
recognized	O
several	O
antigens	O
as	O
well	O
.	O

MAb	O
1A6	O
recognized	O
a	O
single	O
approximately	O
17	O
-	O
kDa	O
protein	O
,	O
and	O
2B5	O
recognized	O
a	O
single	O
approximately	O
32	O
-	O
kDa	O
protein	O
at	O
15	O
h	O
postfertilization	O
.	O

In	O
membrane	O
feeding	O
assays	O
to	O
assess	O
the	O
effect	O
of	O
these	O
MAbs	O
on	O
P.	O
gallinaceum	O
infectivity	O
for	O
Aedes	O
aegypti	O
mosquitoes	O
,	O
the	O
addition	O
of	O
MAbs	O
1A6	O
and	O
2B5	O
to	O
infectious	O
blood	O
meals	O
significantly	O
inhibited	O
oocyst	O
development	O
in	O
the	O
mosquito	O
midgut	O
.	O

In	O
contrast	O
,	O
MAb	O
2A5	O
seemed	O
to	O
enhance	O
infectivity	O
.	O

These	O
results	O
demonstrate	O
that	O
Plasmodium	O
ookinetes	O
secrete	O
proteins	O
(	O
in	O
addition	O
to	O
previously	O
characterized	O
chitinases	O
)	O
that	O
may	O
be	O
targets	O
for	O
blocking	O
malaria	O
transmission	O
.	O

Future	O
investigation	O
of	O
ookinete	O
-	O
secreted	O
neutralization	O
-	O
sensitive	O
molecules	O
should	O
provide	O
valuable	O
insight	O
into	O
mechanisms	O
by	O
which	O
ookinetes	O
exit	O
the	O
blood	O
meal	O
,	O
penetrate	O
and	O
transverse	O
the	O
peritrophic	O
matrix	O
,	O
and	O
invade	O
the	O
mosquito	O
midgut	O
epithelium	O
.	O

A	O
reassessment	O
of	O
the	O
International	O
Study	O
Group	O
criteria	O
for	O
the	O
diagnosis	O
(	O
classification	O
)	O
of	O
BehÃ?Â§et	O
's	O
syndrome	O
.	O

OBJECTIVE	O
:	O

Patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
and	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
were	O
not	O
represented	O
in	O
the	O
diseased	O
controls	O
group	O
that	O
had	O
been	O
utilised	O
in	O
the	O
development	O
of	O
the	O
International	O
Study	O
Group	O
(	O
ISG	O
)	O
criteria	O
for	O
the	O
diagnosis	O
of	O
BehÃ?Â§et	O
's	O
syndrome	O
(	O
BS	O
)	O
.	O

Having	O
similar	O
features	O
,	O
both	O
of	O
these	O
conditions	O
can	O
pose	O
problems	O
in	O
the	O
differential	O
diagnosis	O
of	O
BS	O
.	O

Moreover	O
,	O
there	O
has	O
been	O
a	O
recent	O
awareness	O
of	O
coexistence	O
of	O
BS	O
and	O
familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
reassess	O
the	O
performance	O
of	O
ISG	O
criteria	O
among	O
patients	O
with	O
BS	O
and	O
other	O
rheumatological	O
conditions	O
,	O
specifically	O
including	O
those	O
with	O
CD	O
,	O
UC	O
,	O
and	O
FMF	O
.	O

METHODS	O
:	O

302	O
consecutive	O
patients	O
with	O
BS	O
and	O
438	O
patients	O
with	O
other	O
rheumatological	O
conditions	O
were	O
surveyed	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
features	O
of	O
BS	O
by	O
means	O
of	O
a	O
standard	O
form	O
which	O
had	O
been	O
prepared	O
according	O
to	O
ISG	O
criteria	O
.	O

All	O
control	O
patients	O
with	O
a	O
history	O
of	O
oral	O
ulcer	O
had	O
a	O
pathergy	O
test	O
and	O
an	O
eye	O
examination	O
by	O
an	O
experienced	O
ophthalmologist	O
with	O
a	O
slit	O
lamp	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ISG	O
criteria	O
were	O
calculated	O
.	O

RESULTS	O
:	O

Seven	O
of	O
302	O
patients	O
with	O
BS	O
(	O
2	O
%	O
)	O
did	O
not	O
fulfill	O
the	O
ISG	O
criteria	O
while	O
5	O
of	O
438	O
controls	O
(	O
1	O
%	O
)	O
fulfilled	O
the	O
ISG	O
criteria	O
.	O

CONCLUSION	O
:	O

In	O
this	O
study	O
ISG	O
criteria	O
performed	O
well	O
in	O
correctly	O
classifying	O
BS	O
.	O

Further	O
specificity	O
studies	O
might	O
be	O
considered	O
in	O
CD	O
.	O

Involvement	O
of	O
BMP-2	B
signaling	O
in	O
a	O
cartilage	O
cap	O
in	O
osteochondroma	O
.	O

This	O
study	O
describes	O
the	O
distributions	O
of	O
bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
2	I
as	O
well	O
as	O
mRNAs	O
for	O
BMP	B
receptor	I
type	I
IB	I
(	O
BMPRIB	B
)	O
.	O

collagen	B
types	I
II	I
(	I
Col	I
II	I
)	I
and	I
III	I
(	I
Col	I
III	I
)	I
in	O
a	O
growing	O
""""	O
cartilage	O
cap	O
""""	O
of	O
osteochondroma	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemical	O
study	O
were	O
performed	O
using	O
histological	O
sections	O
obtained	O
during	O
surgery	O
.	O

BMP-2	B
was	O
detected	O
in	O
mesenchymal	O
cells	O
in	O
the	O
outer	O
fibrous	O
layer	O
and	O
chondrocytes	O
in	O
the	O
inner	O
cartilaginous	O
matrix	O
,	O
positive	O
for	O
Col	B
III	I
and	O
Col	B
II	I
,	O
respectively	O
.	O

BMPRIB	B
mRNA	O
was	O
distributed	O
in	O
chondrocytes	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
provide	O
observational	O
evidence	O
of	O
the	O
involvement	O
of	O
BMP-2	B
signaling	O
in	O
the	O
pathogenesis	O
of	O
cartilage	O
cap	O
of	O
osteochondroma	O
.	O

and	O
suggests	O
the	O
role	O
of	O
BMP-2	B
in	O
the	O
growth	O
of	O
cartilage	O
cap	O
in	O
osteochondroma	O
.	O

Identification	O
and	O
molecular	O
characterisation	O
of	O
hordoindolines	O
from	O
barley	O
grain	O
.	O

Grain	O
texture	O
in	O
barley	O
is	O
an	O
important	O
quality	O
character	O
as	O
soft	O
-	O
textured	O
cultivars	O
have	O
better	O
malting	O
quality	O
.	O

In	O
wheat	O
,	O
texture	O
is	O
considered	O
to	O
be	O
determined	O
by	O
the	O
puroindolines	O
,	O
a	O
group	O
of	O
basic	O
hydrophobic	O
proteins	O
present	O
on	O
the	O
surface	O
of	O
the	O
starch	O
granule	O
.	O

Hard	O
wheats	O
have	O
been	O
proposed	O
to	O
lack	O
puroindoline	B
a	I
or	O
to	O
have	O
mutant	O
forms	O
of	O
puroindoline	B
b	I
which	O
do	O
not	O
bind	O
to	O
the	O
granule	O
surface	O
.	O

Analysis	O
of	O
six	O
barley	O
cultivars	O
(	O
three	O
soft	O
-	O
textured	O
and	O
three	O
hard	O
)	O
showed	O
that	O
all	O
contained	O
proteins	O
homologous	O
to	O
wheat	O
puroindoline	B
b	I
,	O
but	O
PCR	O
analysis	O
failed	O
to	O
show	O
any	O
differences	O
in	O
amino	O
acid	O
sequences	O
similar	O
to	O
those	O
which	O
have	O
been	O
proposed	O
to	O
determine	O
textural	O
differences	O
in	O
wheat	O
.	O

Southern	O
blot	O
analysis	O
showed	O
two	O
hordoindoline	B
b	I
genes	O
which	O
were	O
isolated	O
and	O
shown	O
to	O
encode	O
proteins	O
with	O
94	O
%	O
sequence	O
identity	O
.	O

Expression	O
of	O
hordoindoline	B
b	I
mRNA	O
occurred	O
in	O
the	O
starchy	O
endosperm	O
and	O
aleurone	O
layer	O
of	O
the	O
developing	O
seed	O
,	O
but	O
not	O
in	O
the	O
embryo	O
.	O

Analysis	O
of	O
seven	O
soft	O
-	O
and	O
six	O
hard	O
-	O
textured	O
barley	O
varieties	O
showed	O
that	O
all	O
contained	O
hordoindoline	B
a	O
except	O
two	O
hard	O
varieties	O
(	O
Sundance	O
,	O
Hart	O
)	O
which	O
were	O
subsequently	O
shown	O
to	O
both	O
lack	O
hordoindoline	B
a	I
mRNA	O
.	O

It	O
was	O
therefore	O
concluded	O
that	O
there	O
is	O
not	O
a	O
clear	O
relationship	O
between	O
the	O
presence	O
of	O
hordoindoline	B
a	O
and	O
grain	O
texture	O
in	O
barley	O
.	O

Immunohistochemical	O
analysis	O
of	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
in	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

BACKGROUND	O
:	O

To	O
elucidate	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
(	O
ErbB-1	B
,	O
neu	B
/	O
ErbB-2	B
,	O
ErbB-3	B
,	O
and	O
ErbB-4	B
)	O
and	O
tumor	O
recurrence	O
.	O

METHODS	O
:	O

We	O
used	O
immunohistochemistry	O
to	O
examine	O
the	O
expression	O
of	O
four	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
in	O
73	O
patients	O
with	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

RESULTS	O
:	O

Using	O
Cox	O
univariate	O
analysis	O
,	O
we	O
determined	O
that	O
angiolymphatic	O
tumor	O
emboli	O
and	O
non	O
-	O
well	O
-	O
differentiated	O
tumor	O
cells	O
were	O
two	O
significant	O
conventional	O
pathologic	O
predictors	O
of	O
tumor	O
recurrence	O
,	O
and	O
that	O
ErbB-1	B
and	O
ErbB-3	B
were	O
also	O
significant	O
predictors	O
.	O

Co	O
-	O
expression	O
of	O
ErbB-1	B
+	I
,	I
-3	I
+	O
,	O
or	O
expression	O
of	O
three	O
or	O
more	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
had	O
a	O
significant	O
effect	O
on	O
lung	O
cancer	O
recurrence	O
.	O

A	O
stepwise	O
multivariate	O
Cox	O
proportional	O
hazards	O
regression	O
analysis	O
provided	O
a	O
predictive	O
model	O
for	O
tumor	O
recurrence	O
.	O

CONCLUSIONS	O
:	O

The	O
present	O
study	O
shows	O
that	O
in	O
patients	O
with	O
a	O
non	O
-	O
well	O
-	O
differentiated	O
tumor	O
,	O
overexpression	O
of	O
ErbB-3	B
is	O
a	O
useful	O
marker	O
for	O
predicting	O
tumor	O
recurrence	O
.	O

The	O
present	O
study	O
also	O
confirmed	O
that	O
ErbB-1	B
expression	O
increased	O
in	O
proportion	O
to	O
the	O
loss	O
of	O
tumor	O
differentiation	O
.	O

The	O
correlation	O
between	O
ErbB-3	B
and	O
distant	O
metastasis	O
was	O
good	O
.	O

CD40	B
ligation	O
induces	O
macrophage	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
production	O
:	O
differential	O
use	O
of	O
the	O
PI3	B
K	I
and	O
p42	B
/	I
44	I
MAPK	I
-	O
pathways	O
.	O

Interleukin	B
10	I
(	O
IL-10	B
)	O
is	O
an	O
anti	O
-	O
inflammatory	O
cytokine	B
produced	O
in	O
the	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
joint	O
by	O
macrophages	O
/	O
monocytes	O
and	O
infiltrating	O
peripheral	O
blood	O
derived	O
lymphocytes	O
.	O

Recent	O
data	O
suggest	O
a	O
role	O
for	O
physical	O
cell	O
-	O
to	O
-	O
cell	O
interactions	O
in	O
the	O
production	O
of	O
IL-10	B
.	O

In	O
this	O
report	O
,	O
we	O
have	O
investigated	O
the	O
signalling	O
mechanisms	O
involved	O
in	O
IL-10	B
production	O
by	O
peripheral	O
blood	O
-	O
derived	O
macrophages	O
upon	O
interaction	O
with	O
fixed	O
CD40L	B
transfectants	O
.	O

IL-10	B
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
are	O
produced	O
by	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
-	O
primed	O
monocytes	O
/	O
macrophages	O
in	O
response	O
to	O
CD40	B
ligation	O
.	O

The	O
utilization	O
of	O
the	O
inhibitors	O
,	O
wortmannin	O
and	O
LY294002	O
,	O
demonstrated	O
a	O
role	O
for	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
whereas	O
rapamycin	O
demonstrated	O
p70	B
S6	I
-	I
kinase	I
(	O
p70S6	B
K	I
)	O
involvement	O
in	O
the	O
production	O
of	O
IL-10	B
by	O
these	O
monocytes	O
.	O

The	O
production	O
of	O
TNF	B
-	I
alpha	I
was	O
enhanced	O
by	O
wortmannin	O
and	O
LY294002	O
,	O
suggesting	O
negative	O
regulation	O
by	O
PI3	B
K	I
;	O
however	O
,	O
it	O
was	O
dependent	O
on	O
p70S6	B
K	I
suggesting	O
a	O
PI3	B
K	I
-	O
independent	O
mechanism	O
of	O
p70S6	O
K	O
activation	O
.	O

One	O
alternative	O
pathway	O
that	O
activates	O
p70S6	B
K	I
independently	O
of	O
PI3	B
K	I
and	O
also	O
differentiates	O
between	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
is	O
the	O
p42	B
/	I
44	I
mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
,	O
which	O
regulates	O
TNF	B
-	I
alpha	I
production	O
in	O
a	O
PI3	B
K	I
-	O
independent	O
manner	O
.	O

These	O
observations	O
suggest	O
that	O
CD40	B
ligation	O
induces	O
macrophage	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
production	O
,	O
the	O
mechanism	O
of	O
which	O
is	O
p70S6	B
K	I
-	O
dependent	O
yet	O
bifurcates	O
at	O
the	O
level	O
of	O
PI3	B
K	I
and	O
p42	B
/	I
44	I
MAPK	I
.	O

Adeno	O
-	O
associated	O
virus	O
vector	O
-	O
mediated	O
triple	O
gene	O
transfer	O
of	O
dopamine	O
synthetic	O
enzymes	O
.	O

OBJECTIVE	O
:	O

To	O
explore	O
triple	O
gene	O
transfer	O
of	O
dopamine	O
synthetic	O
enzymes	O
with	O
separate	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
vectors	O
.	O

METHODS	O
:	O

The	O
genes	O
for	O
dopamine	O
synthetic	O
enzymes	O
,	O
tyrosine	B
hydroxylase	I
(	O
TH	B
)	O
,	O
aromatic	B
L	I
-	I
amino	I
acid	I
decarboxylase	I
(	O
AADC	B
)	O
,	O
and	O
GTP	B
cyclohydrolase	I
I	I
(	O
GCH	B
,	O
an	O
enzyme	O
critical	O
for	O
tetrahydrobiopterin	O
synthesis	O
)	O
were	O
contransduced	O
into	O
293	O
cells	O
with	O
separate	O
AAV	O
vectors	O
.	O

Expressions	O
of	O
TH	B
,	O
AADC	B
and	O
GCH	B
were	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O

Intracellular	O
dopamine	O
level	O
was	O
assayed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

RESULTS	O
:	O

TH	B
,	O
AADC	B
and	O
GCH	B
were	O
effectively	O
coexpressed	O
in	O
transduced	O
cells	O
with	O
three	O
separate	O
AAV	O
vectors	O
,	O
AAV	O
-	O
TH	B
,	O
AAV	O
-	O
AADC	B
and	O
AAV	O
-	O
GCH	B
.	O

Furthermore	O
,	O
the	O
coexpression	O
resulted	O
in	O
an	O
effectively	O
spontaneous	O
dopamine	O
production	O
in	O
cotransduced	O
cells	O
.	O

CONCLUSION	O
:	O

The	O
triple	O
transduction	O
of	O
TH	B
,	O
AADC	B
and	O
GCH	B
genes	O
with	O
separate	O
AAV	O
vectors	O
is	O
effective	O
,	O
which	O
might	O
be	O
important	O
to	O
gene	O
therapy	O
for	O
Parkinson	O
's	O
disease	O
.	O

ARL2	B
and	O
BART	B
enter	O
mitochondria	O
and	O
bind	O
the	O
adenine	B
nucleotide	I
transporter	I
.	O

The	O
ADP	B
-	I
ribosylation	I
factor	I
-	I
like	I
2	I
(	O
ARL2	B
)	O
GTPase	B
and	O
its	O
binding	O
partner	O
binder	B
of	I
ARL2	I
(	O
BART	B
)	O
are	O
ubiquitously	O
expressed	O
in	O
rodent	O
and	O
human	O
tissues	O
and	O
are	O
most	O
abundant	O
in	O
brain	O
.	O

Both	O
ARL2	B
and	O
BART	B
are	O
predominantly	O
cytosolic	O
,	O
but	O
a	O
pool	O
of	O
each	O
was	O
found	O
associated	O
with	O
mitochondria	O
in	O
a	O
protease	B
-	O
resistant	O
form	O
.	O

ARL2	B
was	O
found	O
to	O
lack	O
covalent	O
N	O
-	O
myristoylation	O
,	O
present	O
on	O
all	O
other	O
members	O
of	O
the	O
ARF	B
family	I
,	O
thereby	O
preserving	O
the	O
N	O
-	O
terminal	O
amphipathic	O
alpha	O
-	O
helix	O
as	O
a	O
potential	O
mitochondrial	O
import	O
sequence	O
.	O

An	O
overlay	O
assay	O
was	O
developed	O
to	O
identify	O
binding	O
partners	O
for	O
the	O
BART	B
.	O
ARL2	B
.	O
GTP	O
complex	O
and	O
revealed	O
a	O
specific	O
interaction	O
with	O
a	O
protein	O
in	O
bovine	O
brain	O
mitochondria	O
.	O

Purification	O
and	O
partial	O
microsequencing	O
identified	O
the	O
protein	O
as	O
an	O
adenine	B
nucleotide	I
transporter	I
(	O
ANT	B
)	O
.	O

The	O
overlay	O
assay	O
was	O
performed	O
on	O
mitochondria	O
isolated	O
from	O
five	O
different	O
tissues	O
from	O
either	O
wild	O
-	O
type	O
or	O
transgenic	O
mice	O
deleted	O
for	O
ANT1	B
.	O

Results	O
confirmed	O
that	O
ANT1	B
is	O
the	O
predominant	O
binding	O
partner	O
for	O
the	O
BART	B
.	O
ARL2	B
.	O
GTP	O
complex	O
and	O
that	O
the	O
structurally	O
homologous	O
ANT2	B
protein	O
does	O
not	O
bind	O
the	O
complex	O
.	O

Cardiac	O
and	O
skeletal	O
muscle	O
mitochondria	O
from	O
ant1	B
(	O
-	O
)	O
/	O
ant1	B
(	O
-	O
)	O
mice	O
had	O
increased	O
levels	O
of	O
ARL2	B
,	O
relative	O
to	O
that	O
seen	O
in	O
mitochondria	O
from	O
wild	O
-	O
type	O
animals	O
.	O

We	O
conclude	O
that	O
the	O
amount	O
of	O
ARL2	B
in	O
mitochondria	O
is	O
subject	O
to	O
regulation	O
via	O
an	O
ANT1	B
-	O
sensitive	O
pathway	O
in	O
muscle	O
tissues	O
.	O

A	O
major	O
marker	O
for	O
normal	O
tension	O
glaucoma	O
:	O
association	O
with	O
polymorphisms	O
in	O
the	O
OPA1	B
gene	O
.	O

Normal	O
tension	O
glaucoma	O
(	O
NTG	O
)	O
is	O
a	O
major	O
form	O
of	O
glaucoma	O
,	O
associated	O
with	O
intraocular	O
pressures	O
that	O
are	O
within	O
the	O
statistically	O
normal	O
range	O
of	O
the	O
population	O
.	O

OPA1	B
,	O
the	O
gene	O
responsible	O
for	O
autosomal	O
dominant	O
optic	O
atrophy	O
represents	O
an	O
excellent	O
candidate	O
gene	O
for	O
NTG	O
,	O
as	O
the	O
clinical	O
phenotypes	O
are	O
similar	O
and	O
OPA1	B
is	O
expressed	O
in	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

Eighty	O
-	O
three	O
well	O
-	O
characterized	O
NTG	O
patients	O
were	O
screened	O
for	O
mutations	O
in	O
OPA1	B
by	O
heteroduplex	O
analysis	O
and	O
bi	O
-	O
directional	O
sequencing	O
.	O

Sequences	O
found	O
to	O
be	O
altered	O
in	O
NTG	O
subjects	O
were	O
examined	O
for	O
variations	O
in	O
100	O
population	O
controls	O
.	O

A	O
second	O
cohort	O
of	O
80	O
NTG	O
patients	O
and	O
86	O
population	O
controls	O
was	O
subsequently	O
screened	O
to	O
determine	O
whether	O
the	O
initial	O
findings	O
could	O
be	O
replicated	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
on	O
intervening	O
sequence	O
(	O
IVS	O
)	O
8	O
(	O
IVS8	O
+	O
4	O
C	O
/	O
T	O
)	O
was	O
found	O
to	O
be	O
strongly	O
associated	O
with	O
the	O
occurrence	O
of	O
NTG	O
in	O
both	O
cohorts	O
(	O
chi	O
(	O
2	O
)	O
=	O
7.97	O
,	O
P	O
=	O
0.005	O
in	O
the	O
first	O
cohort	O
,	O
chi	O
(	O
2	O
)	O
=	O
9.93	O
,	O
P	O
=	O
0.002	O
in	O
the	O
second	O
cohort	O
;	O
odds	O
ratio	O
3.1	O
(	O
95	O
%	O
CI	O
:	O
1.8	O
-	O
5.6	O
)	O
.	O
A	O
second	O
SNP	O
(	O
IVS8	O
+	O
32	O
T	O
/	O
C	O
)	O
appeared	O
to	O
be	O
associated	O
with	O
disease	O
in	O
the	O
first	O
cohort	O
(	O
chi	O
(	O
2	O
)	O
=	O
4.71	O
,	O
P	O
=	O
0.030	O
)	O
,	O
but	O
this	O
finding	O
could	O
not	O
be	O
replicated	O
in	O
the	O
second	O
cohort	O
.	O

In	O
the	O
combined	O
cohort	O
,	O
the	O
compound	O
at	O
-	O
risk	O
genotype	O
IVS8	O
+	O
4	O
C	O
/	O
T	O
,	O
+	O
32	O
T	O
/	O
C	O
was	O
strongly	O
associated	O
with	O
the	O
occurrence	O
of	O
NTG	O
(	O
chi	O
(	O
2	O
)	O
=	O
22.04	O
,	O
P	O
=	O
0.00001	O
after	O
correcting	O
for	O
testing	O
four	O
genotypes	O
)	O
.	O

These	O
results	O
indicate	O
that	O
polymorphisms	O
in	O
the	O
OPA1	B
gene	O
are	O
associated	O
with	O
NTG	O
and	O
may	O
be	O
a	O
marker	O
for	O
the	O
disease	O
.	O

Caspase-2	B
can	O
trigger	O
cytochrome	B
C	I
release	O
and	O
apoptosis	O
from	O
the	O
nucleus	O
.	O

The	O
cysteine	B
proteases	I
specific	O
for	O
aspartic	O
residues	O
,	O
known	O
as	O
caspases	B
,	O
are	O
localized	O
in	O
different	O
subcellular	O
compartments	O
and	O
play	O
specific	O
roles	O
during	O
the	O
regulative	O
and	O
the	O
executive	O
phase	O
of	O
the	O
cell	O
death	O
process	O
.	O

Here	O
we	O
investigated	O
the	O
subcellular	O
localization	O
of	O
caspase-2	B
in	O
healthy	O
cells	O
and	O
during	O
the	O
execution	O
of	O
the	O
apoptotic	O
program	O
.	O

We	O
have	O
found	O
that	O
caspase-2	B
is	O
a	O
nuclear	O
resident	O
protein	O
and	O
that	O
its	O
import	O
into	O
the	O
nucleus	O
is	O
regulated	O
by	O
two	O
different	O
nuclear	O
localization	O
signals	O
.	O

We	O
have	O
shown	O
that	O
in	O
an	O
early	O
phase	O
of	O
apoptosis	O
caspase-2	B
can	O
trigger	O
mitochondrial	O
dysfunction	O
from	O
the	O
nucleus	O
without	O
relocalizing	O
into	O
the	O
cytoplasm	O
.	O

Release	O
of	O
cytochrome	B
c	I
occurs	O
in	O
the	O
absence	O
of	O
overt	O
alteration	O
of	O
the	O
nuclear	O
pores	O
and	O
changes	O
of	O
the	O
nuclear	O
/	O
cytoplasmic	O
barrier	O
.	O

Addition	O
of	O
leptomycin	O
B	O
,	O
an	O
inhibitor	O
of	O
nuclear	O
export	O
,	O
did	O
not	O
interfere	O
with	O
the	O
ability	O
of	O
caspase-2	B
to	O
trigger	O
cytochrome	B
c	I
release	O
.	O

Only	O
during	O
the	O
late	O
phase	O
of	O
the	O
apoptotic	O
process	O
can	O
caspase-2	B
relocalize	O
in	O
the	O
cytoplasm	O
,	O
as	O
consequence	O
of	O
an	O
increase	O
in	O
the	O
diffusion	O
limits	O
of	O
the	O
nuclear	O
pores	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
the	O
existence	O
of	O
a	O
nuclear	O
/	O
mitochondrial	O
apoptotic	O
pathway	O
elicited	O
by	O
caspase-2	B
.	O

Mrnp41	B
(	O
Rae	B
1p	I
)	O
associates	O
with	O
microtubules	O
in	O
HeLa	O
cells	O
and	O
in	O
neurons	O
.	O

Mrnp41	B
(	O
hRae1p	B
)	O
is	O
an	O
evolutionarily	O
highly	O
conserved	O
protein	O
,	O
which	O
is	O
a	O
potential	O
component	O
of	O
mRNP	O
particles	O
and	O
plays	O
a	O
role	O
in	O
nuclear	O
mRNA	O
export	O
.	O

The	O
protein	O
is	O
mainly	O
localized	O
at	O
the	O
nuclear	O
pore	O
complex	O
,	O
but	O
is	O
also	O
associated	O
with	O
distinct	O
nuclear	O
domains	O
and	O
with	O
a	O
meshwork	O
of	O
numerous	O
small	O
particles	O
in	O
the	O
cytoplasm	O
(	O
Kraemer	O
and	O
Blobel	O
(	O
1997	O
)	O
:	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
,	O
1519	O
-	O
1523	O
)	O
.	O

We	O
show	O
that	O
the	O
cytoplasmic	O
pattern	O
of	O
mrnp41	B
is	O
sensitive	O
to	O
treatment	O
with	O
the	O
microtubule	O
(	O
MT	O
)	O
-	O
depolymerizing	O
drug	O
nocodazole	O
which	O
causes	O
disappearance	O
of	O
mrnp41	B
from	O
the	O
cell	O
periphery	O
and	O
concentration	O
around	O
the	O
nucleus	O
.	O

By	O
immunofluorescence	O
we	O
demonstrate	O
that	O
mrnp41	B
colocalizes	O
with	O
MT	O
in	O
HeLa	O
cells	O
and	O
displays	O
an	O
MT	O
-	O
like	O
distribution	O
in	O
cultured	O
neurons	O
.	O

Association	O
of	O
mrnp41	B
with	O
MT	O
is	O
further	O
demonstrated	O
by	O
copurification	O
with	O
MT	O
from	O
pig	O
brain	O
throughout	O
several	O
steps	O
of	O
polymerization	O
and	O
depolymerization	O
.	O

Separation	O
of	O
MT	B
-	I
associated	I
proteins	I
(	O
MAPs	B
)	O
by	O
phosphocellulose	O
(	O
PC	O
)	O
chromatography	O
showed	O
copurification	O
of	O
mrnp41	B
with	O
MAPs	B
.	O

These	O
data	O
show	O
an	O
association	O
of	O
mrnp41	B
with	O
MT	O
and	O
,	O
moreover	O
,	O
demonstrate	O
that	O
an	O
intact	O
MT	O
system	O
is	O
necessary	O
for	O
dispersion	O
of	O
mrnp41	B
-	O
containing	O
particles	O
to	O
the	O
cellular	O
periphery	O
.	O

The	O
essential	O
role	O
of	O
mrnp41	B
in	O
spindle	O
pole	O
separation	O
and	O
cell	O
cycle	O
progression	O
may	O
also	O
be	O
related	O
to	O
its	O
ability	O
to	O
bind	O
to	O
MTs	O
.	O

Functional	O
implications	O
of	O
the	O
localization	O
and	O
activity	O
of	O
acid	B
-	I
sensitive	I
channels	I
in	O
rat	O
peripheral	O
nervous	O
system	O
.	O

Acid	B
-	I
sensitive	I
ion	I
channels	I
(	O
ASIC	B
)	O
are	O
proton	O
-	O
gated	O
ion	B
channels	I
expressed	O
in	O
neurons	O
of	O
the	O
mammalian	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O

The	O
functional	O
role	O
of	O
these	O
channels	O
is	O
still	O
uncertain	O
,	O
but	O
they	O
have	O
been	O
proposed	O
to	O
constitute	O
mechanoreceptors	B
and/or	O
nociceptors	B
.	O

We	O
have	O
raised	O
specific	O
antibodies	O
for	O
ASIC1	B
,	O
ASIC2	B
,	O
ASIC3	B
,	O
and	O
ASIC4	B
to	O
examine	O
the	O
distribution	O
of	O
these	O
proteins	O
in	O
neurons	O
from	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
and	O
to	O
determine	O
their	O
subcellular	O
localization	O
.	O

Western	O
blot	O
analysis	O
demonstrates	O
that	O
all	O
four	O
ASIC	B
proteins	O
are	O
expressed	O
in	O
DRG	O
and	O
sciatic	O
nerve	O
.	O

Immunohistochemical	O
experiments	O
and	O
functional	O
measurements	O
of	O
unitary	O
currents	O
from	O
the	O
ASICs	B
with	O
the	O
patch	O
-	O
clamp	O
technique	O
indicate	O
that	O
ASIC1	B
localizes	O
to	O
the	O
plasma	O
membrane	O
of	O
small	O
-	O
,	O
medium	O
-	O
,	O
and	O
large	O
-	O
diameter	O
cells	O
,	O
whereas	O
ASIC2	B
and	O
ASIC3	B
are	O
preferentially	O
in	O
medium	O
to	O
large	O
cells	O
.	O

Neurons	O
coexpressing	O
ASIC2	B
and	O
ASIC3	B
form	O
predominantly	O
heteromeric	O
ASIC2	B
-	I
3	I
channels	I
.	O

Two	O
spliced	O
forms	O
,	O
ASIC2a	B
and	O
ASIC2b	B
,	O
colocalize	O
in	O
the	O
same	O
population	O
of	O
DRG	O
neurons	O
.	O

Within	O
cells	O
,	O
the	O
ASICs	B
are	O
present	O
mainly	O
on	O
the	O
plasma	O
membrane	O
of	O
the	O
soma	O
and	O
cellular	O
processes	O
.	O

Functional	O
studies	O
indicate	O
that	O
the	O
pH	O
sensitivity	O
for	O
inactivation	O
of	O
ASIC1	B
is	O
much	O
higher	O
than	O
the	O
one	O
for	O
activation	O
;	O
hence	O
,	O
increases	O
in	O
proton	O
concentration	O
will	O
inactivate	O
the	O
channel	O
.	O

These	O
functional	O
properties	O
and	O
localization	O
in	O
DRG	O
have	O
profound	O
implications	O
for	O
the	O
putative	O
functional	O
roles	O
of	O
ASICs	B
in	O
the	O
nervous	O
system	O
.	O

Peritoneal	O
and	O
hemodialysis	O
:	O
I	O
.	O

Differences	O
in	O
patient	O
characteristics	O
at	O
initiation	O
.	O

BACKGROUND	O
:	O

Comparisons	O
of	O
mortality	O
outcomes	O
between	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
and	O
hemodialysis	O
(	O
HD	O
)	O
patients	O
have	O
shown	O
varying	O
results	O
,	O
which	O
may	O
be	O
caused	O
by	O
the	O
unequally	O
distributed	O
clinical	O
conditions	O
of	O
patients	O
at	O
initiation	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
evaluated	O
the	O
clinical	O
characteristics	O
of	O
105	O
,	O
954	O
patients	O
at	O
the	O
initiation	O
of	O
PD	O
and	O
HD	O
,	O
using	O
the	O
U.S.	O
national	O
incidence	O
data	O
on	O
treated	O
end	O
-	O
stage	O
renal	O
disease	O
from	O
the	O
Medical	O
Evidence	O
Form	O
,	O
1995	O
to	O
1997	O
.	O

METHODS	O
:	O

A	O
general	O
linear	O
model	O
was	O
used	O
to	O
analyze	O
differences	O
of	O
age	O
,	O
albumin	B
,	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
,	O
and	O
hematocrit	O
;	O
categorical	O
data	O
analysis	O
to	O
evaluate	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
grouped	O
into	O
four	O
categories	O
:	O
<	O
19	O
,	O
19	O
-	O
25	O
(	O
<	O
25	O
)	O
,	O
25	O
-	O
30	O
(	O
<	O
30	O
)	O
,	O
and	O
30	O
+	O
;	O
and	O
logistic	O
regression	O
to	O
assess	O
the	O
likelihood	O
of	O
initiating	O
PD	O
versus	O
HD	O
.	O

Diabetics	O
(	O
DM	O
)	O
were	O
analyzed	O
separately	O
from	O
non	O
-	O
diabetics	O
(	O
NDM	O
)	O
.	O

Explanatory	O
variables	O
in	O
the	O
logistic	O
regression	O
included	O
incidence	O
year	O
,	O
race	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
albumin	B
,	O
creatinine	O
,	O
BUN	O
,	O
and	O
hematocrit	O
.	O

Race	O
included	O
white	O
and	O
black	O
.	O

Age	O
was	O
categorized	O
into	O
four	O
groups	O
:	O
20	O
-	O
44	O
,	O
45	O
-	O
64	O
,	O
65	O
-	O
74	O
,	O
and	O
75	O
+	O
.RESULTS	O
:	O

At	O
the	O
initiation	O
of	O
dialysis	O
PD	O
patients	O
were	O
approximately	O
6	O
years	O
younger	O
(	O
P	O
<	O
0.0001	O
)	O
than	O
HD	O
patients	O
.	O

PD	O
patients	O
also	O
had	O
higher	O
(	O
P	O
<	O
0.0001	O
)	O
albumin	B
(	O
+	O
0.35	O
g	O
/	O
dL	O
for	O
DM	O
and	O
+	O
0.23	O
g	O
/	O
dL	O
for	O
NDM	O
)	O
and	O
hematocrit	O
(	O
+	O
1.64	O
%	O
for	O
DM	O
and	O
+	O
1.71	O
%	O
for	O
NDM	O
)	O
levels	O
,	O
and	O
lower	O
(	O
P	O
<	O
0.04	O
)	O
BUN	O
(	O
-	O
8.75	O
mg	O
/	O
dL	O
for	O
DM	O
and	O
-	O
5.24	O
mg	O
/	O
dL	O
for	O
NDM	O
)	O
and	O
creatinine	O
(	O
-	O
0.51	O
mg	O
/	O
dL	O
for	O
DM	O
and	O
-	O
0.23	O
mg	O
/	O
dL	O
for	O
NDM	O
)	O
levels	O
than	O
HD	O
patients	O
.	O

Whites	O
had	O
a	O
higher	O
(	O
P	O
<	O
0.0001	O
)	O
likelihood	O
of	O
starting	O
PD	O
than	O
blacks	O
,	O
and	O
patients	O
with	O
BMI	O
<	O
19	O
had	O
a	O
lower	O
(	O
P	O
<	O
0.0001	O
)	O
chance	O
of	O
beginning	O
on	O
PD	O
.	O

CONCLUSION	O
:	O

PD	O
patients	O
had	O
favorable	O
clinical	O
conditions	O
at	O
the	O
initiation	O
of	O
dialysis	O
,	O
which	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
comparing	O
dialysis	O
outcomes	O
between	O
the	O
two	O
modalities	O
.	O

Allelic	O
polymorphism	O
synergizes	O
with	O
variable	O
gene	O
content	O
to	O
individualize	O
human	O
KIR	B
genotype	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genes	O
are	O
a	O
multigene	O
family	O
on	O
human	O
chromosome	O
19	O
.	O

KIR	B
genes	O
occur	O
in	O
various	O
combinations	O
on	O
different	O
haplotypes	O
.	O

Additionally	O
,	O
KIR	B
genes	O
are	O
polymorphic	O
.	O

To	O
examine	O
how	O
allelic	O
polymorphism	O
diversifies	O
KIR	B
haplotypes	O
with	O
similar	O
or	O
identical	O
combinations	O
of	O
KIR	B
genes	O
,	O
we	O
devised	O
methods	O
for	O
discriminating	O
alleles	O
of	O
KIR2DL1	B
,	O
-	O
2DL3	B
,	O
-	O
3DL1	B
,	O
and	O
-	O
3DL2	B
.	O

These	O
methods	O
were	O
applied	O
to	O
143	O
individuals	O
from	O
34	O
families	O
to	O
define	O
98	O
independent	O
KIR	B
haplotypes	O
at	O
the	O
allele	O
level	O
.	O

Three	O
novel	O
3DL2	B
alleles	O
and	O
a	O
chimeric	O
3DL1	B
/	O
3DL2	B
sequence	O
were	O
also	O
identified	O
.	O

Among	O
the	O
A	O
group	O
haplotypes	O
were	O
22	O
different	O
combinations	O
of	O
2DL1	B
,	O
2DL3	B
,	O
3DL1	B
,	O
and	O
3DL2	B
alleles	O
.	O

Among	O
the	O
B	O
group	O
haplotypes	O
that	O
were	O
unambiguously	O
determined	O
were	O
15	O
distinct	O
haplotypes	O
involving	O
9	O
different	O
combinations	O
of	O
KIR	B
genes	O
.	O

A	O
and	O
B	O
haplotypes	O
both	O
exhibit	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
between	O
2DL1	B
and	O
2DL3	B
alleles	O
,	O
and	O
between	O
3DL1	B
and	O
3DL2	B
alleles	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
LD	O
between	O
the	O
2DL1	B
/	O
2DL3	B
and	O
3DL1	B
/	O
3DL2	B
pairs	O
that	O
define	O
the	O
two	O
halves	O
of	O
the	O
KIR	B
gene	O
complex	O
.	O

The	O
synergistic	O
combination	O
of	O
allelic	O
polymorphism	O
and	O
variable	O
gene	O
content	O
individualize	O
KIR	B
genotype	O
to	O
an	O
extent	O
where	O
unrelated	O
individuals	O
almost	O
always	O
have	O
different	O
KIR	B
types	O
.	O

This	O
level	O
of	O
diversity	O
likely	O
reflects	O
strong	O
pressure	O
from	O
pathogens	O
on	O
the	O
human	O
NK	O
cell	O
response	O
.	O

[	O
A	O
cross	O
-	O
sectional	O
study	O
on	O
the	O
effects	O
of	O
microcystin	O
in	O
drinking	O
water	O
to	O
the	O
health	O
of	O
human	O
beings	O
]	O

OBJECTIVE	O
:	O

To	O
understand	O
the	O
effects	O
of	O
microcystin	O
(	O
MC	O
)	O
in	O
drinking	O
water	O
on	O
health	O
of	O
human	O
beings	O
.	O

METHODS	O
:	O

In	O
Taixing	O
,	O
a	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
in	O
two	O
middle	O
schools	O
with	O
different	O
types	O
of	O
drinking	O
water	O
,	O
from	O
which	O
111	O
and	O
92	O
students	O
were	O
randomly	O
selected	O
and	O
investigated	O
.	O

Blood	O
samples	O
from	O
all	O
individuals	O
were	O
collected	O
and	O
tested	O
for	O
serum	O
HBsAg	B
,	O
HBeAg	B
,	O
anti	O
-	O
HBe	B
,	O
anti	O
-	O
HBs	B
,	O
anti	O
-	O
HBc	B
with	O
enzyme	O
linked	O
immunoabsorbent	O
assay	O
and	O
for	O
serum	O
alanine	B
aminotransferase	I
(	O
ALT	B
)	O
,	O
gamma	B
-	I
glutamyltransferase	I
(	O
gamma	B
-	I
GT	I
)	O
and	O
alkaline	B
phosphatase	I
(	O
ALP	B
)	O
contents	O
by	O
colorimetry	O
.	O

These	O
levels	O
of	O
enzymes	O
in	O
sera	O
were	O
compared	O
after	O
the	O
students	O
were	O
stratified	O
according	O
to	O
the	O
status	O
of	O
HBV	O
infection	O
.	O

RESULT	O
:	O

With	O
the	O
exclusion	O
of	O
the	O
effect	O
of	O
HBV	O
infection	O
,	O
three	O
enzymes	O
levels	O
in	O
sera	O
between	O
two	O
groups	O
of	O
students	O
showed	O
significant	O
differences	O
(	O
P	O
<	O
0.01	O
)	O
,	O
much	O
higher	O
in	O
exposure	O
group	O
than	O
those	O
in	O
control	O
group	O
.	O

CONCLUSION	O
:	O

MC	O
was	O
possibly	O
harmful	O
to	O
human	O
beings	O
in	O
drinking	O
water	O
and	O
induced	O
the	O
contents	O
of	O
some	O
enzymes	O
from	O
the	O
liver	O
of	O
human	O
beings	O
to	O
increase	O
in	O
sera	O
.	O

The	O
roX	B
genes	O
encode	O
redundant	O
male	O
-	O
specific	O
lethal	O
transcripts	O
required	O
for	O
targeting	O
of	O
the	O
MSL	B
complex	I
.	O

The	O
roX1	B
and	O
roX2	B
genes	O
of	O
Drosophila	O
produce	O
male	O
-	O
specific	O
non	O
-	O
coding	O
RNAs	O
that	O
co	O
-	O
localize	O
with	O
the	O
Male	B
-	I
Specific	I
Lethal	I
(	I
MSL	I
)	I
protein	I
complex	I
.	O

This	O
complex	O
mediates	O
up	O
-	O
regulation	O
of	O
the	O
male	O
X	O
chromosome	O
by	O
increasing	O
histone	B
H4	I
acetylation	O
,	O
thus	O
contributing	O
to	O
the	O
equalization	O
of	O
X	O
-	O
linked	O
gene	O
expression	O
between	O
the	O
sexes	O
.	O

Both	O
roX	B
genes	O
overlap	O
two	O
of	O
approximately	O
35	O
chromatin	O
entry	O
sites	O
,	O
DNA	O
sequences	O
proposed	O
to	O
act	O
in	O
cis	O
to	O
direct	O
the	O
MSL	B
complex	I
to	O
the	O
X	O
chromosome	O
.	O

Although	O
dosage	O
compensation	O
is	O
essential	O
in	O
males	O
,	O
an	O
intact	O
roX1	B
gene	O
is	O
not	O
required	O
by	O
either	O
sex	O
.	O

We	O
have	O
generated	O
flies	O
lacking	O
roX2	B
and	O
find	O
that	O
this	O
gene	O
is	O
also	O
non	O
-	O
essential	O
.	O

However	O
,	O
simultaneous	O
removal	O
of	O
both	O
roX	B
RNAs	O
causes	O
a	O
striking	O
male	O
-	O
specific	O
reduction	O
in	O
viability	O
accompanied	O
by	O
relocation	O
of	O
the	O
MSL	B
proteins	O
and	O
acetylated	O
histone	B
H4	I
from	O
the	O
X	O
chromosome	O
to	O
autosomal	O
sites	O
and	O
heterochromatin	O
.	O

Males	O
can	O
be	O
rescued	O
by	O
roX	B
cDNAs	O
from	O
autosomal	O
transgenes	O
,	O
demonstrating	O
the	O
genetic	O
separation	O
of	O
the	O
chromatin	O
entry	O
and	O
RNA	O
-	O
encoding	O
functions	O
.	O

Therefore	O
,	O
the	O
roX1	B
and	O
roX2	B
genes	O
produce	O
redundant	O
,	O
male	B
-	I
specific	I
lethal	I
transcripts	O
required	O
for	O
targeting	O
the	O
MSL	B
complex	I
.	O

Human	O
bronchial	O
epithelium	O
expresses	O
interleukin-9	B
receptors	I
and	O
releases	O
neutrophil	B
chemotactic	I
factor	I
.	O

Growing	O
evidence	O
obtained	O
from	O
human	O
genomic	O
analysis	O
and	O
antigen	O
-	O
challenged	O
transgenic	O
mice	O
suggests	O
that	O
interleukin-9	B
(	O
IL-9	B
)	O
is	O
a	O
candidate	O
factor	O
in	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
production	O
and	O
thus	O
is	O
thought	O
to	O
be	O
associated	O
with	O
bronchial	O
inflammation	O
and	O
bronchial	O
hyperresponsiveness	O
(	O
BHR	O
)	O
.	O

To	O
evaluate	O
the	O
expression	O
of	O
the	O
IL-9	B
receptor	I
and	O
its	O
effect	O
on	O
the	O
IL-9	B
human	O
bronchial	O
cell	O
line	O
BEAS-2B	O
cells	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
immunohistochemical	O
investigation	O
,	O
and	O
chemotaxis	O
assay	O
were	O
performed	O
.	O

The	O
components	O
of	O
the	O
IL-9	B
receptor	I
,	O
consisting	O
of	O
IL-9	B
receptor	I
alpha	I
(	O
CD129	B
)	O
and	O
IL-2	O
receptory	O
(	O
(	O
1	O
)	O
132	O
)	O
,	O
were	O
expressed	O
on	O
BEAS-2B	O
cells	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
flow	O
cytometry	O
.	O

BEAS-2B	O
cells	O
exposed	O
to	O
IL-9	B
released	O
neutrophil	O
chemotactic	O
activity	O
(	O
NCA	O
)	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
the	O
presence	O
of	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
was	O
also	O
detected	O
.	O

This	O
factor	O
is	O
primarily	O
involved	O
in	O
NCA	O
for	O
the	O
measurement	O
of	O
cytokines	B
and	O
in	O
the	O
inhibition	O
assay	O
of	O
neutrophil	O
chemotaxis	O
.	O

These	O
findings	O
suggest	O
that	O
bronchial	O
epithelial	O
cells	O
may	O
express	O
IL-9	B
receptors	I
,	O
and	O
that	O
IL-9	B
may	O
induce	O
airway	O
inflammation	O
through	O
the	O
release	O
of	O
G	B
-	I
CSF	I
from	O
bronchial	O
epithelial	O
cells	O
.	O

HIV-1	O
infection	O
in	O
rural	O
Africa	O
:	O
is	O
there	O
a	O
difference	O
in	O
median	O
time	O
to	O
AIDS	O
and	O
survival	O
compared	O
with	O
that	O
in	O
industrialized	O
countries	O
?	O

OBJECTIVES	O
:	O

To	O
describe	O
the	O
progression	O
times	O
of	O
HIV-1	O
infection	O
from	O
seroconversion	O
to	O
AIDS	O
and	O
to	O
death	O
,	O
and	O
time	O
from	O
first	O
developing	O
AIDS	O
to	O
death	O
in	O
rural	O
Uganda	O
.	O

Also	O
,	O
to	O
describe	O
the	O
proportion	O
of	O
individuals	O
within	O
the	O
cohort	O
dying	O
with	O
AIDS	O
and	O
the	O
CD4	B
lymphocyte	O
count	O
before	O
death	O
.	O

DESIGN	O
:	O

A	O
prospective	O
,	O
longitudinal	O
,	O
population	O
-	O
based	O
cohort	O
.	O

METHODS	O
:	O

Since	O
1990	O
,	O
107	O
HIV	O
-	O
prevalent	O
cases	O
,	O
168	O
incident	O
cases	O
and	O
235	O
HIV	O
-	O
seronegative	O
controls	O
have	O
been	O
recruited	O
into	O
a	O
cohort	O
in	O
rural	O
Uganda	O
.	O

Participants	O
are	O
recruited	O
from	O
the	O
general	O
population	O
and	O
they	O
are	O
reviewed	O
routinely	O
every	O
3	O
months	O
and	O
at	O
other	O
times	O
when	O
ill	O
.	O

RESULTS	O
:	O

The	O
median	O
time	O
from	O
seroconversion	O
to	O
death	O
was	O
9.8	O
years	O
.	O

Age	O
over	O
40	O
years	O
at	O
seroconversion	O
was	O
associated	O
with	O
more	O
rapid	O
progression	O
(	O
P	O
<	O
0.001	O
,	O
log	O
rank	O
test	O
)	O
.	O

For	O
the	O
first	O
4	O
years	O
of	O
the	O
study	O
,	O
HIV	O
contributed	O
little	O
to	O
the	O
death	O
rates	O
in	O
the	O
HIV	O
incident	O
cases	O
,	O
but	O
after	O
5	O
years	O
,	O
the	O
contribution	O
of	O
HIV	O
became	O
greater	O
and	O
was	O
particularly	O
marked	O
in	O
the	O
oldest	O
age	O
group	O
.	O

Survival	O
rates	O
in	O
the	O
cohort	O
were	O
similar	O
to	O
those	O
in	O
the	O
general	O
population	O
.	O

The	O
median	O
time	O
from	O
seroconversion	O
to	O
AIDS	O
was	O
9.4	O
years	O
and	O
from	O
AIDS	O
to	O
death	O
was	O
9.2	O
months	O
.	O

Of	O
those	O
infected	O
with	O
HIV-1	O
,	O
80	O
%	O
died	O
with	O
AIDS	O
and	O
20	O
%	O
had	O
a	O
CD4	B
count	O
<	O
10	O
x	O
106	O
cells	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O

Survival	O
with	O
HIV-1	O
infection	O
is	O
similar	O
in	O
Africa	O
to	O
industrialized	O
countries	O
before	O
the	O
use	O
of	O
antiretroviral	O
therapy	O
;	O
when	O
they	O
do	O
die	O
,	O
many	O
of	O
those	O
in	O
Africa	O
are	O
severely	O
immunosuppressed	O
and	O
most	O
have	O
clinical	O
features	O
of	O
AIDS	O
.	O

Neural	O
progenitor	O
cells	O
of	O
the	O
neonatal	O
rat	O
anterior	O
subventricular	O
zone	O
express	O
functional	O
GABA	B
(	I
A	I
)	I
receptors	I
.	O

The	O
interneurons	O
of	O
the	O
olfactory	O
bulb	O
arise	O
from	O
precursor	O
cells	O
in	O
the	O
anterior	O
part	O
of	O
the	O
neonatal	O
subventricular	O
zone	O
,	O
the	O
SVZa	O
,	O
and	O
are	O
distinctive	O
in	O
that	O
they	O
possess	O
a	O
neuronal	O
phenotype	O
and	O
yet	O
undergo	O
cell	O
division	O
.	O

To	O
characterize	O
the	O
differentiation	O
of	O
neonatal	O
SVZa	O
progenitor	O
cells	O
,	O
we	O
analyzed	O
the	O
complement	O
of	O
ionotropic	O
neurotransmitter	O
receptors	O
that	O
they	O
express	O
in	O
vitro	O
.	O

For	O
this	O
analysis	O
,	O
we	O
tested	O
the	O
sensitivity	O
of	O
SVZa	O
progenitor	O
cells	O
to	O
gamma	O
-	O
amino	O
-	O
n	O
-	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
,	O
kainate	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
,	O
and	O
acetylcholine	O
(	O
ACh	O
)	O
after	O
1	O
day	O
in	O
vitro	O
.	O

SVZa	O
progenitor	O
cells	O
had	O
chloride	O
currents	O
activated	O
by	O
GABA	O
and	O
muscimol	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
-	O
specific	O
agonist	O
,	O
but	O
were	O
insensitive	O
to	O
ATP	O
,	O
kainate	O
,	O
NMDA	O
,	O
and	O
ACh	O
.	O

In	O
addition	O
,	O
GABA	O
-	O
or	O
muscimol	O
-	O
activated	O
chloride	O
currents	O
were	O
blocked	O
nearly	O
completely	O
by	O
30	O
microM	O
bicuculline	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
-	O
specific	O
antagonist	O
,	O
suggesting	O
that	O
GABA	B
(	I
B	I
)	I
and	I
GABA	I
(	I
C	I
)	I
receptors	I
are	O
absent	O
.	O

Measurements	O
of	O
the	O
chloride	O
reversal	O
potential	O
by	O
gramicidin	O
-	O
perforated	O
patch	O
clamp	O
revealed	O
that	O
currents	O
generated	O
by	O
activation	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
were	O
inward	O
,	O
and	O
thus	O
,	O
depolarizing	O
.	O

A	O
set	O
of	O
complementary	O
experiments	O
was	O
undertaken	O
to	O
determine	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
whether	O
SVZa	O
progenitor	O
cells	O
express	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
coding	O
for	O
glutamic	B
acid	I
decarboxylase	I
67	I
(	O
GAD67	B
)	O
,	O
used	O
in	O
the	O
synthesis	O
of	O
GABA	O
and	O
for	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
.	O

Both	O
postnatal	O
day	O
(	O
P0	O
)	O
SVZa	O
and	O
olfactory	O
bulb	O
possessed	O
detectable	O
mRNA	O
coding	O
for	O
GAD67	B
.	O

In	O
P0	O
SVZa	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
detected	O
with	O
RT	O
-	O
PCR	O
included	O
alpha	O
2	O
-	O
4	O
,	O
beta	O
1	O
-	O
3	O
,	O
and	O
gamma	O
2S	O
(	O
short	O
form	O
)	O
.	O

By	O
comparison	O
,	O
the	O
P0	O
olfactory	O
bulb	O
expressed	O
all	O
of	O
the	O
subunits	O
detectable	O
in	O
the	O
SVZa	O
and	O
additional	O
subunit	O
mRNAs	O
:	O
alpha	O
1	O
,	O
alpha	O
5	O
,	O
gamma	O
1	O
,	O
gamma	O
2L	O
(	O
long	O
form	O
)	O
,	O
gamma	O
3	O
,	O
and	O
delta	O
subunit	O
mRNAs	O
.	O

Antibodies	O
recognizing	O
GABA	O
,	O
GAD	O
,	O
and	O
various	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
were	O
used	O
to	O
label	O
SVZa	O
cells	O
harvested	O
from	O
P0	O
-	O
1	O
rats	O
and	O
cultured	O
for	O
1	O
day	O
.	O

The	O
cells	O
were	O
immunoreactive	O
for	O
GABA	O
,	O
GAD	O
,	O
and	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
alpha	O
2	O
-	O
5	O
,	O
beta	O
1	O
-	O
3	O
,	O
and	O
gamma	O
2	O
.	O

To	O
relate	O
the	O
characteristics	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
in	O
cultured	O
SVZa	O
precursor	O
cells	O
to	O
particular	O
combinations	O
of	O
subunits	O
,	O
the	O
open	O
reading	O
frames	O
of	O
the	O
dominant	O
subunits	O
detected	O
by	O
RT	O
-	O
PCR	O
(	O
alpha	O
2	O
-	O
4	O
,	O
beta	O
3	O
,	O
and	O
gamma	O
2S	O
)	O
were	O
cloned	O
into	O
a	O
mammalian	O
cell	O
expression	O
vector	O
and	O
different	O
combinations	O
were	O
transfected	O
into	O
Chinese	O
hamster	O
ovary	O
-	O
K1	O
(	O
CHO	O
-	O
K1	O
)	O
cells	O
.	O

A	O
comparison	O
of	O
the	O
sensitivity	O
to	O
inhibition	O
by	O
zinc	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
in	O
SVZa	O
precursor	O
cells	O
and	O
in	O
CHO	O
-	O
K1	O
cells	O
expressing	O
various	O
combinations	O
of	O
recombinant	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
suggested	O
that	O
the	O
gamma	O
2S	O
subunit	O
was	O
present	O
and	O
functional	O
in	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
chloride	B
channel	I
complex	O
.	O

Thus	O
,	O
SVZa	O
precursor	O
cells	O
are	O
GABAergic	O
and	O
a	O
subset	O
of	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
detected	O
in	O
the	O
olfactory	O
bulb	O
was	O
found	O
in	O
the	O
SVZa	O
,	O
as	O
might	O
be	O
expected	O
because	O
SVZa	O
progenitor	O
cells	O
migrate	O
to	O
the	O
bulb	O
as	O
they	O
differentiate	O
.	O

Fine	O
mapping	O
of	O
the	O
chromosome	O
2p12	O
-	O
16	O
dyslexia	O
susceptibility	O
locus	O
:	O
quantitative	O
association	O
analysis	O
and	O
positional	O
candidate	O
genes	O
SEMA4F	B
and	O
OTX1	B
.	O

A	O
locus	O
on	O
chromosome	O
2p12	O
-	O
16	O
has	O
been	O
implicated	O
in	O
dyslexia	O
susceptibility	O
by	O
two	O
independent	O
linkage	O
studies	O
,	O
including	O
our	O
own	O
study	O
of	O
119	O
nuclear	O
twin	O
-	O
based	O
families	O
,	O
each	O
with	O
at	O
least	O
one	O
reading	O
-	O
disabled	O
child	O
.	O

Nonetheless	O
,	O
no	O
variant	O
of	O
any	O
gene	O
has	O
been	O
reported	O
to	O
show	O
association	O
with	O
dyslexia	O
,	O
and	O
no	O
consistent	O
clinical	O
evidence	O
exists	O
to	O
identify	O
candidate	O
genes	O
with	O
any	O
strong	O
a	O
priori	O
logic	O
.	O

We	O
used	O
21	O
microsatellite	O
markers	O
spanning	O
2p12	O
-	O
16	O
to	O
refine	O
our	O
1-LOD	O
unit	O
linkage	O
support	O
interval	O
to	O
12cM	O
between	O
D2S337	O
and	O
D2S286	O
.	O

Then	O
,	O
in	O
quantitative	O
association	O
analysis	O
,	O
two	O
microsatellites	O
yielded	O
P	O
values	O
<	O
0.05	O
across	O
a	O
range	O
of	O
reading	O
-	O
related	O
measures	O
(	O
D2S2378	O
and	O
D2S2114	O
)	O
.	O

The	O
exon	O
/	O
intron	O
borders	O
of	O
two	O
positional	O
candidate	O
genes	O
within	O
the	O
region	O
were	O
characterized	O
,	O
and	O
the	O
exons	O
were	O
screened	O
for	O
polymorphisms	O
.	O

The	O
genes	O
were	O
Semaphorin4F	B
(	O
SEMA4F	B
)	O
,	O
which	O
encodes	O
a	O
protein	O
involved	O
in	O
axonal	O
growth	O
cone	O
guidance	O
,	O
and	O
OTX1	B
,	O
encoding	O
a	O
homeodomain	O
transcription	B
factor	I
involved	O
in	O
forebrain	O
development	O
.	O

Two	O
non	O
-	O
synonymous	O
single	O
nucleotide	O
polymorphisms	O
were	O
found	O
in	O
SEMA4F	B
,	O
each	O
with	O
a	O
heterozygosity	O
of	O
0.03	O
.	O

One	O
intronic	O
single	O
nucleotide	O
polymorphism	O
between	O
exons	O
12	O
and	O
13	O
of	O
SEMA4F	B
was	O
tested	O
for	O
quantitative	O
association	O
,	O
but	O
no	O
significant	O
association	O
was	O
found	O
.	O

Only	O
one	O
single	O
nucleotide	O
polymorphism	O
was	O
found	O
in	O
OTX1	B
,	O
which	O
was	O
exonic	O
but	O
silent	O
.	O

Our	O
data	O
therefore	O
suggest	O
that	O
linkage	O
with	O
reading	O
disability	O
at	O
2p12	O
-	O
16	O
is	O
not	O
caused	O
by	O
coding	O
variants	O
of	O
SEMA4F	B
or	O
OTX1	B
.	O

Our	O
study	O
outlines	O
the	O
approach	O
necessary	O
for	O
the	O
identification	O
of	O
genetic	O
variants	O
causing	O
dyslexia	O
susceptibility	O
in	O
an	O
epidemiological	O
population	O
of	O
dyslexics	O
.	O

Association	O
of	O
dopamine	B
D	I
(	I
3	I
)	I
receptors	I
with	O
actin	B
-	I
binding	I
protein	I
280	I
(	O
ABP-280	B
)	O
.	O

Proteins	O
that	O
bind	O
to	O
G	B
protein	I
-	I
coupled	I
receptors	I
have	O
been	O
identified	O
as	O
regulators	O
of	O
receptor	O
localization	O
and	O
signaling	O
.	O

In	O
our	O
previous	O
studies	O
,	O
a	O
cytoskeletal	O
protein	O
,	O
actin	B
-	I
binding	I
protein	I
280	I
(	O
ABP-280	B
)	O
,	O
was	O
found	O
to	O
associate	O
with	O
the	O
third	O
cytoplasmic	O
loop	O
of	O
dopamine	B
D	I
(	I
2	I
)	I
receptors	I
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
ABP-280	B
also	O
interacts	O
with	O
dopamine	B
D	I
(	I
3	I
)	I
receptors	I
,	O
but	O
not	O
with	O
D	B
(	I
4	I
)	I
receptors	I
.	O

Similar	O
to	O
the	O
dopamine	B
D	I
(	I
2	I
)	I
receptor	I
,	O
the	O
D	B
(	I
3	I
)	I
/	O
ABP-280	B
association	O
is	O
of	O
signaling	O
importance	O
.	O

In	O
human	O
melanoma	O
M2	O
cells	O
lacking	O
ABP-280	B
,	O
D	B
(	I
3	I
)	I
receptors	I
were	O
unable	O
to	O
inhibit	O
forskolin	O
-	O
stimulated	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
production	O
significantly	O
.	O

D	B
(	I
4	I
)	I
receptors	I
,	O
however	O
,	O
exhibited	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
forskolin	O
-	O
stimulated	O
cAMP	O
production	O
in	O
ABP-280	B
-	O
deficient	O
M2	O
cells	O
and	O
ABP-280	B
-	O
replent	O
M2	O
subclones	O
(	O
A7	O
cells	O
)	O
.	O

Further	O
experiments	O
revealed	O
that	O
the	O
D	B
(	I
3	I
)	I
/	O
ABP-280	B
interaction	O
was	O
critically	O
dependent	O
upon	O
a	O
36	O
amino	O
acid	O
carboxyl	O
domain	O
of	O
the	O
D	B
(	I
3	I
)	I
receptor	I
third	O
loop	O
,	O
which	O
is	O
conserved	O
in	O
the	O
D	B
(	I
2	I
)	I
receptor	I
but	O
not	O
in	O
the	O
D	B
(	I
4	I
)	I
receptor	I
.	O

Our	O
results	O
demonstrate	O
a	O
subtype	O
-	O
specific	O
regulation	O
of	O
dopamine	B
D	I
(	I
2	I
)	I
-	I
family	I
receptor	I
signaling	O
by	O
the	O
cytoskeletal	O
protein	O
ABP-280	B
.	O

Fibroblast	B
growth	I
factor-10	I
is	O
a	O
mitogen	O
for	O
urothelial	O
cells	O
.	O

Fibroblast	B
growth	I
factor	I
(	I
FGF	I
)	I
-	I
10	I
plays	O
an	O
important	O
role	O
in	O
regulating	O
growth	O
,	O
differentiation	O
,	O
and	O
repair	O
of	O
the	O
urothelium	O
.	O

This	O
process	O
occurs	O
through	O
a	O
paracrine	O
cascade	O
originating	O
in	O
the	O
mesenchyme	O
(	O
lamina	O
propria	O
)	O
and	O
targeting	O
the	O
epithelium	O
(	O
urothelium	O
)	O
.	O

In	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
(	O
i	O
)	O
fibroblasts	O
of	O
the	O
human	O
lamina	O
propria	O
were	O
the	O
cell	O
type	O
that	O
synthesized	O
FGF-10	B
RNA	O
and	O
(	O
ii	O
)	O
the	O
FGF-10	B
gene	O
is	O
located	O
at	O
the	O
5p12	O
-	O
p13	O
locus	O
of	O
chromosome	O
5	O
.	O

Recombinant	O
(	O
r	O
)	O
preparations	O
of	O
human	O
FGF-10	B
were	O
found	O
to	O
induce	O
proliferation	O
of	O
human	O
urothelial	O
cells	O
in	O
vitro	O
and	O
of	O
transitional	O
epithelium	O
of	O
wild	O
-	O
type	O
and	O
FGF7	B
-	O
null	O
mice	O
in	O
vivo	O
.	O

Mechanistic	O
studies	O
with	O
human	O
cells	O
indicated	O
two	O
modes	O
of	O
FGF-10	B
action	O
:	O
(	O
i	O
)	O
translocation	O
of	O
rFGF	B
-	I
10	I
into	O
urothelial	O
cell	O
nuclei	O
and	O
(	O
ii	O
)	O
a	O
signaling	O
cascade	O
that	O
begins	O
with	O
the	O
heparin	O
-	O
dependent	O
phosphorylation	O
of	O
tyrosine	O
residues	O
of	O
surface	O
transmembrane	O
receptors	O
.	O

The	O
normal	O
urothelial	O
phenotype	O
,	O
that	O
of	O
quiescence	O
,	O
is	O
proposed	O
to	O
be	O
typified	O
by	O
negligible	O
levels	O
of	O
FGF-10	B
.	O

During	O
proliferative	O
phases	O
,	O
levels	O
of	O
FGF-10	B
rise	O
at	O
the	O
urothelial	O
cell	O
surface	O
and/or	O
within	O
urothelial	O
cell	O
nuclei	O
.	O

An	O
understanding	O
of	O
how	O
FGF-10	B
works	O
in	O
conjunction	O
with	O
these	O
other	O
processes	O
will	O
lead	O
to	O
better	O
management	O
of	O
many	O
diseases	O
of	O
the	O
bladder	O
and	O
urinary	O
tract	O
.	O

Identification	O
of	O
a	O
domain	O
conferring	O
nucleotide	O
binding	O
to	O
the	O
N	B
-	I
acetyl	I
-	I
d	I
-	I
glucosamine	I
2-epimerase	I
(	O
Renin	B
binding	I
protein	I
)	O
.	O

Renin	B
binding	I
protein	I
(	O
RnBP	B
)	O
,	O
a	O
cellular	O
renin	B
inhibitor	O
,	O
has	O
been	O
identified	O
as	O
the	O
enzyme	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
glucosamine	I
(	I
GlcNAc	I
)	I
2-epimerase	I
.	O

Our	O
recent	O
studies	O
demonstrated	O
that	O
rat	O
GlcNAc	B
2-epimerase	I
has	O
a	O
ten	O
-	O
times	O
higher	O
affinity	O
for	O
ATP	O
,	O
dATP	O
,	O
and	O
ddATP	O
than	O
the	O
human	O
enzyme	O
[	O
Takahashi	O
,	O
S.	O
et	O
al.	O
(	O
2001	O
)	O
J.	O
Biochem	O
.	O
130	O
,	O
815	O
-	O
821	O
]	O
.	O

To	O
identify	O
the	O
domain	O
conferring	O
nucleotide	O
binding	O
to	O
GlcNAc	B
2-epimerase	I
,	O
we	O
constructed	O
a	O
series	O
of	O
chimeric	O
enzymes	O
successively	O
replacing	O
the	O
three	O
domains	O
of	O
the	O
human	O
enzyme	O
(	O
N	O
-	O
terminal	O
,	O
middle	O
,	O
and	O
C	O
-	O
terminal	O
domains	O
)	O
with	O
the	O
corresponding	O
domains	O
of	O
the	O
rat	O
enzyme	O
.	O

Chimeras	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
JM109	O
cells	O
under	O
the	O
control	O
of	O
the	O
Taq	B
promoter	O
.	O

The	O
purified	O
chimeric	O
enzymes	O
had	O
GlcNAc	B
2-epimerase	I
activity	O
and	O
inhibited	O
renin	B
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
recombinant	O
human	O
and	O
rat	O
enzymes	O
required	O
catalytic	O
amounts	O
of	O
ATP	O
with	O
apparent	O
K	O
(	O
m	O
)	O
values	O
of	O
73	O
and	O
5.5	O
microM	O
,	O
respectively	O
.	O

Chimeric	O
enzymes	O
of	O
HHR	O
,	O
RHH	O
,	O
and	O
RHR	O
(	O
H	O
,	O
human	O
type	O
domain	O
;	O
R	O
,	O
rat	O
type	O
domain	O
)	O
had	O
nearly	O
the	O
same	O
nucleotide	O
specificity	O
as	O
the	O
human	O
GlcNAc	B
2-epimerase	I
.	O

On	O
the	O
other	O
hand	O
,	O
HRR	O
,	O
HRH	O
,	O
and	O
RRH	O
chimeras	O
had	O
the	O
same	O
nucleotide	O
specificity	O
as	O
the	O
rat	O
enzyme	O
.	O

These	O
results	O
indicate	O
that	O
the	O
middle	O
domain	O
of	O
the	O
GlcNAc	B
2-epimerase	I
molecule	O
participates	O
in	O
the	O
specificity	O
for	O
and	O
binding	O
of	O
nucleotides	O
,	O
and	O
that	O
nucleotides	O
are	O
essential	O
to	O
form	O
the	O
catalytic	O
domain	O
of	O
the	O
enzyme	O
.	O

Sec34	B
is	O
implicated	O
in	O
traffic	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
and	O
exists	O
in	O
a	O
complex	O
with	O
GTC-90	B
and	O
ldlBp	B
.	O

Sec34p	B
/	O
Grd20p	B
has	O
been	O
implicated	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
to	O
-	O
Golgi	O
transport	O
and/or	O
post	O
-	O
Golgi	O
trafficking	O
events	O
and	O
exists	O
in	O
a	O
protein	O
complex	O
consisting	O
of	O
at	O
least	O
eight	O
subunits	O
in	O
yeast	O
.	O

Although	O
the	O
mammalian	O
counterpart	O
(	O
Sec34	B
)	O
of	O
Sec34p	B
has	O
been	O
molecularly	O
identified	O
,	O
its	O
role	O
and	O
interacting	O
partners	O
remain	O
undefined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
prepared	O
antibodies	O
specifically	O
against	O
the	O
recombinant	O
N	O
-	O
terminal	O
fragment	O
of	O
Sec34	B
that	O
recognize	O
a	O
polypeptide	O
of	O
about	O
93	O
kDa	O
and	O
label	O
the	O
Golgi	O
apparatus	O
.	O

In	O
a	O
well	O
-	O
characterized	O
semi	O
-	O
intact	O
cell	O
assay	O
that	O
reconstitutes	O
transport	O
of	O
the	O
envelope	O
glycoprotein	O
(	O
VSVG	O
)	O
of	O
vesicular	O
stomatitis	O
virus	O
from	O
the	O
ER	O
to	O
the	O
Golgi	O
apparatus	O
,	O
anti	O
-	O
Sec34	B
antibodies	O
inhibited	O
the	O
transport	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
by	O
anti	O
-	O
Sec34	B
antibodies	O
could	O
be	O
neutralized	O
by	O
a	O
noninhibitory	O
amount	O
of	O
the	O
antigen	O
.	O

Large	O
-	O
scale	O
immunoprecipitation	O
of	O
rat	O
liver	O
cytosol	O
with	O
immobilized	O
anti	O
-	O
Sec34	B
antibodies	O
has	O
co	O
-	O
immunoprecipitated	O
GTC-90	B
and	O
ldlBp	B
,	O
two	O
peripheral	O
Golgi	O
proteins	O
previously	O
shown	O
to	O
exist	O
in	O
separate	O
protein	O
complexes	O
.	O

Two	O
mammalian	O
homologues	O
(	O
Dor1	B
and	O
Cod1	B
)	O
of	O
the	O
yeast	O
Sec34	B
complex	O
were	O
similarly	O
recovered	O
in	O
the	O
Sec34	B
immunoprecipitates	O
.	O

When	O
expressed	O
in	O
transfected	O
cells	O
,	O
epitope	O
-	O
tagged	O
ldlCp	B
and	O
Cod2	B
were	O
co	O
-	O
immunoprecipitated	O
with	O
anti	O
-	O
Sec34	B
antibodies	O
with	O
efficiencies	O
comparable	O
to	O
that	O
observed	O
for	O
tagged	O
ldlBp	B
,	O
Dor1	B
,	O
and	O
Cod1	B
.	O

Direct	O
interactions	O
of	O
Sec34	B
with	O
ldlBp	B
and	O
ldlCp	B
were	O
further	O
demonstrated	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
Sec34	B
,	O
GTC-90	B
,	O
and	O
ldlBp	B
/	O
ldlCp	B
are	O
part	O
of	O
the	O
same	O
protein	O
complex	O
(	O
es	O
)	O
that	O
regulates	O
diverse	O
aspects	O
of	O
Golgi	O
function	O
,	O
including	O
transport	O
from	O
the	O
ER	O
to	O
the	O
Golgi	O
apparatus	O
.	O

GGA	B
proteins	O
associate	O
with	O
Golgi	O
membranes	O
through	O
interaction	O
between	O
their	O
GGAH	O
domains	O
and	O
ADP	B
-	I
ribosylation	I
factors	I
.	O

ADP	B
-	I
ribosylation	I
factors	I
(	O
ARFs	B
)	O
are	O
a	O
family	O
of	O
small	B
GTPases	I
that	O
are	O
involved	O
in	O
various	O
aspects	O
of	O
membrane	O
trafficking	O
events	O
.	O

These	O
include	O
ARF1	B
-	I
ARF6	I
,	O
which	O
are	O
divided	O
into	O
three	O
classes	O
on	O
the	O
basis	O
of	O
similarity	O
in	O
the	O
primary	O
structure	O
:	O
Class	O
I	O
,	O
ARF1-ARF3	B
;	O
Class	O
II	O
,	O
ARF4	B
and	O
ARF5	B
;	O
and	O
Class	O
III	O
,	O
ARF6	B
.	O

Previous	O
studies	O
identified	O
a	O
novel	O
family	O
of	O
potential	O
ARF	B
effectors	O
,	O
termed	O
GGA1	B
-	I
GGA3	I
,	O
which	O
interact	O
specifically	O
with	O
GTP	O
-	O
bound	O
ARF1	B
and	O
ARF3	B
and	O
are	O
localized	O
to	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
or	O
its	O
related	O
compartment	O
(	O
s	O
)	O
(	O
GGA	B
is	O
an	O
abbreviation	O
for	O
Golgi	B
-	I
localizing	I
,	I
gamma	I
-	I
adaptin	I
ear	I
homology	I
domain	I
,	I
ARF	I
-	I
binding	I
protein	I
)	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
shown	O
that	O
ARF	B
proteins	O
belonging	O
to	O
the	O
three	O
classes	O
,	O
ARF1	B
,	O
ARF5	B
and	O
ARF6	B
,	O
can	O
interact	O
with	O
all	O
GGA	B
proteins	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Segmentation	O
of	O
GGA	B
proteins	O
and	O
isolation	O
of	O
GGA	B
mutants	O
defective	O
in	O
ARF	B
binding	O
have	O
revealed	O
that	O
a	O
limited	O
region	O
within	O
the	O
GGA	B
homology	O
domain	O
,	O
which	O
is	O
conserved	O
in	O
the	O
GGA	B
family	I
,	O
is	O
essential	O
for	O
ARF	B
binding	O
.	O

Expression	O
in	O
cells	O
of	O
GTPase	B
-	O
restricted	O
mutants	O
of	O
ARF1	B
and	O
ARF5	B
blocks	O
dissociation	O
of	O
GGA	B
proteins	O
from	O
membranes	O
induced	O
by	O
brefeldin	O
A	O
.	O

However	O
,	O
neither	O
of	O
the	O
ARF	B
mutants	O
recruits	O
GGA	B
mutants	O
defective	O
in	O
ARF	B
binding	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
at	O
least	O
ARF1	B
(	O
Class	O
I	O
)	O
and	O
ARF5	B
(	O
Class	O
II	O
)	O
in	O
their	O
GTP	O
-	O
bound	O
state	O
cause	O
recruitment	O
of	O
GGA	B
proteins	O
on	O
to	O
TGN	O
membranes	O
.	O

In	O
contrast	O
,	O
on	O
the	O
basis	O
of	O
similar	O
experiments	O
,	O
ARF6	B
(	O
Class	O
III	O
)	O
may	O
be	O
involved	O
in	O
recruitment	O
of	O
GGA	B
proteins	O
to	O
other	O
compartments	O
,	O
possibly	O
early	O
endosomes	O
.	O

Human	O
CAP1	B
is	O
a	O
key	O
factor	O
in	O
the	O
recycling	O
of	O
cofilin	B
and	O
actin	B
for	O
rapid	O
actin	B
turnover	O
.	O

Cofilin	B
-	O
ADF	B
(	O
actin	B
-	I
depolymerizing	I
factor	I
)	O
is	O
an	O
essential	O
driver	O
of	O
actin	B
-	O
based	O
motility	O
.	O

We	O
discovered	O
two	O
proteins	O
,	O
p65	B
and	O
p55	B
,	O
that	O
are	O
components	O
of	O
the	O
actin	B
-	O
cofilin	B
complex	O
in	O
a	O
human	O
HEK293	O
cell	O
extract	O
and	O
identified	O
p55	B
as	O
CAP1	B
/	O
ASP56	B
,	O
a	O
human	O
homologue	O
of	O
yeast	O
CAP	B
/	O
SRV2	B
(	O
cyclase	B
-	I
associated	I
protein	I
)	O
.	O

CAP	B
is	O
a	O
bifunctional	O
protein	O
with	O
an	O
N	O
-	O
terminal	O
domain	O
that	O
binds	O
to	O
Ras	B
-	O
responsive	O
adenylyl	B
cyclase	I
and	O
a	O
C	O
-	O
terminal	O
domain	O
that	O
inhibits	O
actin	B
polymerization	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
CAP1	B
,	O
but	O
not	O
the	O
C	O
-	O
terminal	O
domain	O
,	O
is	O
responsible	O
for	O
the	O
interaction	O
with	O
the	O
actin	B
-	O
cofilin	B
complex	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
CAP1	B
was	O
also	O
found	O
to	O
accelerate	O
the	O
depolymerization	O
of	O
F	B
-	I
actin	I
at	O
the	O
pointed	O
end	O
,	O
which	O
was	O
further	O
enhanced	O
in	O
the	O
presence	O
of	O
cofilin	B
and/or	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
CAP1	B
.	O

Moreover	O
,	O
CAP1	B
and	O
its	O
C	O
-	O
terminal	O
domain	O
were	O
observed	O
to	O
facilitate	O
filament	O
elongation	O
at	O
the	O
barbed	O
end	O
and	O
to	O
stimulate	O
ADP	O
-	O
ATP	O
exchange	O
on	O
G	B
-	I
actin	I
,	O
a	O
process	O
that	O
regenerates	O
easily	O
polymerizable	O
G	B
-	I
actin	I
.	O

Although	O
cofilin	B
inhibited	O
the	O
nucleotide	O
exchange	O
on	O
G	B
-	I
actin	I
even	O
in	O
the	O
presence	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
CAP1	B
,	O
its	O
N	O
-	O
terminal	O
domain	O
relieved	O
this	O
inhibition	O
.	O

Thus	O
,	O
CAP1	B
plays	O
a	O
key	O
role	O
in	O
speeding	O
up	O
the	O
turnover	O
of	O
actin	B
filaments	O
by	O
effectively	O
recycling	O
cofilin	B
and	O
actin	B
and	O
through	O
its	O
effect	O
on	O
both	O
ends	O
of	O
actin	B
filament	O
.	O

The	O
type	B
XIII	I
collagen	I
ectodomain	O
is	O
a	O
150	O
-	O
nm	O
rod	O
and	O
capable	O
of	O
binding	O
to	O
fibronectin	B
,	O
nidogen-2	B
,	O
perlecan	B
,	O
and	O
heparin	O
.	O

Type	B
XIII	I
collagen	I
consists	O
of	O
a	O
short	O
N	O
-	O
terminal	O
intracellular	O
domain	O
,	O
a	O
transmembrane	O
domain	O
,	O
and	O
a	O
collagenous	O
ectodomain	O
,	O
and	O
it	O
is	O
found	O
at	O
many	O
sites	O
of	O
cell	O
adhesion	O
.	O

We	O
report	O
on	O
the	O
characterization	O
of	O
recombinant	O
type	B
XIII	I
collagen	I
.	O

The	O
shed	O
ectodomain	O
was	O
purified	O
from	O
insect	O
cell	O
culture	O
medium	O
and	O
shown	O
to	O
form	O
240	O
-	O
kDa	O
trimers	O
with	O
a	O
T	O
(	O
m	O
)	O
of	O
42	O
degrees	O
C	O
.	O

Correct	O
chain	O
association	O
into	O
a	O
triple	O
-	O
helical	O
conformation	O
was	O
confirmed	O
by	O
limited	O
pepsin	B
digestion	O
and	O
CD	O
spectroscopy	O
.	O

Rotary	O
shadowing	O
electron	O
microscopy	O
of	O
the	O
ectodomain	O
revealed	O
it	O
to	O
be	O
a	O
150	O
-	O
nm	O
rod	O
with	O
two	O
flexible	O
hinges	O
separating	O
31	O
-	O
,	O
52	O
-	O
,	O
and	O
68	O
-	O
nm	O
portions	O
.	O

The	O
rods	O
represent	O
the	O
collagenous	O
domains	O
1	O
-	O
3	O
,	O
and	O
the	O
hinges	O
coincide	O
with	O
the	O
non	O
-	O
collagenous	O
domains	O
2	O
and	O
3	O
.	O

By	O
using	O
surface	O
plasmon	O
resonance	O
analysis	O
,	O
the	O
ectodomain	O
showed	O
interaction	O
with	O
immobilized	O
fibronectin	B
,	O
nidogen-2	B
,	O
and	O
perlecan	B
with	O
K	O
(	O
D	O
)	O
values	O
in	O
the	O
nanomolar	O
range	O
.	O

The	O
binding	O
sites	O
of	O
type	B
XIII	I
collagen	I
for	O
fibronectin	B
were	O
localized	O
to	O
the	O
collagenous	O
domains	O
,	O
whereas	O
the	O
binding	O
activities	O
for	O
nidogen-2	B
and	O
perlecan	B
resided	O
in	O
the	O
pepsin	B
-	O
sensitive	O
portions	O
of	O
the	O
ectodomain	O
.	O

Furthermore	O
,	O
the	O
ectodomain	O
bound	O
significantly	O
to	O
heparin	O
,	O
which	O
also	O
inhibited	O
shedding	O
of	O
the	O
ectodomain	O
in	O
insect	O
cell	O
cultures	O
.	O

The	O
results	O
reveal	O
that	O
type	B
XIII	I
collagen	I
is	O
notably	O
distinct	O
in	O
its	O
structure	O
compared	O
with	O
other	O
cell	O
-	O
surface	O
proteins	O
,	O
and	O
the	O
in	O
vitro	O
binding	O
with	O
fibronectin	B
,	O
heparin	O
,	O
and	O
two	O
basement	O
membrane	O
components	O
is	O
indicative	O
of	O
multiple	O
cell	O
-	O
matrix	O
interactions	O
in	O
which	O
this	O
ubiquitously	O
expressed	O
protein	O
participates	O
.	O

Mutational	O
analysis	O
of	O
K28	O
preprotoxin	O
processing	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

K28	O
killer	O
strains	O
of	O
Saccharomyces	O
cerevisiae	O
are	O
permanently	O
infected	O
with	O
a	O
cytoplasmic	O
persisting	O
dsRNA	O
virus	O
encoding	O
a	O
secreted	O
alpha	O
/	O
beta	O
heterodimeric	O
protein	O
toxin	O
that	O
kills	O
sensitive	O
cells	O
by	O
cell	O
-	O
cycle	O
arrest	O
and	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

In	O
vivo	O
processing	O
of	O
the	O
345	O
aa	O
toxin	O
precursor	O
(	O
preprotoxin	O
;	O
pptox	O
)	O
involves	O
multiple	O
internal	O
and	O
carboxy	O
-	O
terminal	O
cleavage	O
events	O
by	O
the	O
prohormone	O
convertases	O
Kex2p	B
and	O
Kex1p	B
.	O

By	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
preprotoxin	O
gene	O
and	O
phenotypic	O
analysis	O
of	O
its	O
in	O
vivo	O
effects	O
it	O
is	O
now	O
demonstrated	O
that	O
secretion	O
of	O
a	O
biological	O
active	O
virus	O
toxin	O
requires	O
signal	B
peptidase	I
cleavage	O
after	O
Gly	O
(	O
36	O
)	O
and	O
Kex2p	O
-	O
mediated	O
processing	O
at	O
the	O
alpha	O
subunit	O
N	O
terminus	O
(	O
after	O
Glu	O
-	O
Arg	O
(	O
49	O
)	O
)	O
,	O
the	O
alpha	O
subunit	O
C	O
terminus	O
(	O
after	O
Ser	O
-	O
Arg	O
(	O
149	O
)	O
)	O
and	O
at	O
the	O
beta	O
subunit	O
N	O
terminus	O
(	O
after	O
Lys	O
-	O
Arg	O
(	O
245	O
)	O
)	O
.	O

The	O
mature	O
C	O
terminus	O
of	O
the	O
beta	O
subunit	O
is	O
trimmed	O
by	O
Kex1p	B
,	O
which	O
removes	O
the	O
terminal	O
Arg	O
(	O
345	O
)	O
residue	O
,	O
thus	O
uncovering	O
the	O
toxin	O
'	O
s	O
endoplasmic	O
reticulum	O
targeting	O
signal	O
(	O
HDEL	O
)	O
which	O
-	O
-	O
in	O
a	O
sensitive	O
target	O
cell	O
--	O
is	O
essential	O
for	O
retrograde	O
toxin	O
transport	O
.	O

Interestingly	O
,	O
both	O
toxin	O
subunits	O
are	O
covalently	O
linked	O
by	O
a	O
single	O
disulfide	O
bond	O
between	O
alpha	O
-	O
Cys	O
(	O
56	O
)	O
and	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
,	O
and	O
expression	O
of	O
a	O
mutant	O
toxin	O
in	O
which	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
had	O
been	O
replaced	O
by	O
Ser	O
(	O
340	O
)	O
resulted	O
in	O
the	O
secretion	O
of	O
a	O
non	O
-	O
toxic	O
alpha	O
/	O
beta	O
heterodimer	O
that	O
is	O
blocked	O
in	O
retrograde	O
transport	O
and	O
incapable	O
of	O
entering	O
the	O
yeast	O
cell	O
cytosol	O
,	O
indicating	O
that	O
one	O
important	O
in	O
vivo	O
function	O
of	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
might	O
be	O
to	O
ensure	O
accessibility	O
of	O
the	O
toxin	O
'	O
s	O
beta	O
subunit	O
C	O
terminus	O
to	O
the	O
HDEL	O
receptor	O
of	O
the	O
target	O
cell	O
.	O

Steroidogenic	O
enzyme	O
gene	O
expression	O
in	O
the	O
human	O
brain	O
.	O

mRNA	O
,	O
protein	O
and	O
activity	O
for	O
the	O
enzymes	O
required	O
for	O
the	O
synthesis	O
of	O
adrenal	O
corticosteroids	O
have	O
been	O
demonstrated	O
in	O
rat	O
brains	O
by	O
several	O
laboratories	O
.	O

In	O
this	O
study	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
determine	O
whether	O
mRNA	O
for	O
these	O
enzymes	O
are	O
expressed	O
in	O
the	O
human	O
amygdala	O
,	O
caudate	O
nucleus	O
,	O
cerebellum	O
,	O
corpus	O
callosum	O
,	O
hippocampus	O
,	O
spinal	O
cord	O
,	O
and	O
thalamus	O
.	O

Published	O
sequences	O
for	O
the	O
human	O
adrenal	O
enzymes	O
were	O
used	O
to	O
construct	O
primers	O
.	O

Results	O
:	O
mRNAs	O
encoding	O
cholesterol	B
side	I
-	I
chain	I
cleavage	I
enzyme	I
(	O
CYP11A	B
gene	O
)	O
,	O
17beta	B
-	I
hydroxylase	I
(	O
CYP17	B
)	O
,	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3beta	B
-	I
HSD	I
)	O
,	O
21-hydroxylase	B
(	O
CYP21	B
)	O
,	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11beta	B
-	I
HSD2	I
)	O
and	O
glucocorticoid	B
and	I
mineralocorticoid	I
receptors	I
were	O
detectable	O
in	O
all	O
anatomical	O
regions	O
evaluated	O
.	O

The	O
11beta	B
-	I
hydroxylase	I
mRNA	O
was	O
detected	O
in	O
all	O
except	O
cerebellum	O
and	O
hippocampus	O
.	O

The	O
aldosterone	B
synthase	I
mRNA	O
was	O
not	O
found	O
in	O
amygdala	O
,	O
cerebellum	O
or	O
hippocampus	O
.	O

Levels	O
of	O
transcripts	O
were	O
10	O
(	O
-1	O
)	O
-10	O
(	O
-7	O
)	O
-	O
fold	O
lower	O
than	O
those	O
in	O
the	O
adrenal	O
,	O
with	O
corpus	O
callosum	O
and	O
spinal	O
cord	O
having	O
the	O
highest	O
concentrations	O
.	O

Enzyme	O
activity	O
or	O
relevance	O
is	O
yet	O
unknown	O
.	O

The	O
mitochondrial	O
12S	O
gene	O
is	O
a	O
suitable	O
marker	O
of	O
populations	O
of	O
Sarcoptes	O
scabiei	O
from	O
wombats	O
,	O
dogs	O
and	O
humans	O
in	O
Australia	O
.	O

We	O
sequenced	O
part	O
of	O
the	O
mitochondrial	O
12S	O
ribosomal	O
RNA	O
gene	O
of	O
23	O
specimens	O
of	O
Sarcoptes	O
scabiei	O
from	O
eight	O
wombats	O
,	O
one	O
dog	O
and	O
three	O
humans	O
.	O

Twelve	O
of	O
the	O
326	O
nucleotide	O
positions	O
varied	O
among	O
these	O
mites	O
and	O
there	O
were	O
nine	O
haplotypes	O
(	O
sequences	O
)	O
that	O
differed	O
by	O
1	O
-	O
8	O
nucleotides	O
.	O

Phylogenetic	O
analyses	O
indicated	O
that	O
these	O
mites	O
were	O
from	O
two	O
lineages	O
:	O
(	O
1	O
)	O
mites	O
from	O
wombats	O
from	O
Victoria	O
,	O
Australia	O
,	O
and	O
mites	O
from	O
the	O
humans	O
and	O
dog	O
from	O
the	O
Northern	O
Territory	O
,	O
Australia	O
(	O
haplotypes	O
1	O
-	O
4	O
,	O
9	O
)	O
;	O
and	O
(	O
2	O
)	O
mites	O
from	O
the	O
humans	O
and	O
dog	O
from	O
the	O
Northern	O
Territory	O
(	O
haplotypes	O
5	O
-	O
8	O
)	O
.	O

Mites	O
from	O
the	O
three	O
different	O
hosts	O
(	O
wombats	O
,	O
a	O
dog	O
and	O
humans	O
)	O
had	O
not	O
diverged	O
phylogenetically	O
;	O
rather	O
,	O
these	O
mites	O
had	O
similar	O
12S	O
sequences	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
these	O
mites	O
from	O
wombats	O
,	O
humans	O
and	O
a	O
dog	O
are	O
closely	O
related	O
,	O
and	O
that	O
they	O
diverged	O
from	O
a	O
common	O
ancestor	O
relatively	O
recently	O
.	O

This	O
conclusion	O
is	O
consistent	O
with	O
the	O
argument	O
that	O
people	O
and/or	O
their	O
dogs	O
introduced	O
to	O
Australia	O
the	O
S.	O
scabiei	O
mites	O
that	O
infect	O
wombats	O
in	O
Australia	O
.	O

So	O
,	O
S.	O
scabiei	O
,	O
which	O
has	O
been	O
blamed	O
for	O
the	O
extinction	O
of	O
populations	O
of	O
wombats	O
in	O
Australia	O
,	O
may	O
be	O
a	O
parasitic	O
mite	O
that	O
was	O
introduced	O
to	O
Australia	O
with	O
people	O
and/or	O
their	O
dogs	O
.	O

These	O
data	O
show	O
that	O
the	O
mitochondrial	O
12S	O
rRNA	O
gene	O
may	O
be	O
a	O
suitable	O
population	O
marker	O
of	O
S.	O
scabiei	O
from	O
wombats	O
,	O
dogs	O
and	O
humans	O
in	O
Australia	O
.	O

Novel	O
intercellular	O
communication	O
system	O
in	O
Escherichia	O
coli	O
that	O
confers	O
antibiotic	O
resistance	O
between	O
physically	O
separated	O
populations	O
.	O

AIMS	O
:	O

To	O
determine	O
whether	O
intercellular	O
signalling	O
can	O
occur	O
between	O
physically	O
separated	O
populations	O
of	O
Escherichia	O
coli	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Intercellular	O
signalling	O
between	O
physically	O
discrete	O
populations	O
of	O
E.	O
coli	O
BL21	O
was	O
analysed	O
in	O
bi	O
-	O
partite	O
Petri	O
dishes	O
.	O

Transfer	O
of	O
a	O
growth	O
-	O
promoting	O
signal	O
resulted	O
in	O
induction	O
of	O
resistance	O
to	O
the	O
antibiotic	O
ampicillin	O
.	O

Optimal	O
expression	O
of	O
the	O
signal	O
occurred	O
when	O
the	O
signalling	O
population	O
was	O
established	O
as	O
a	O
bacterial	O
lawn	O
for	O
24	O
h	O
.	O

This	O
represented	O
an	O
entry	O
into	O
the	O
stationary	O
phase	O
of	O
growth	O
,	O
as	O
indicated	O
by	O
the	O
expression	O
profile	O
of	O
the	O
RNA	B
polymerase	I
subunit	I
sigma38	I
(	O
sigmaS	B
;	O
sigma	B
S	I
)	O
.	O

The	O
growth	O
-	O
promoting	O
effect	O
was	O
also	O
observed	O
when	O
E.	O
coli	O
DH5alpha	O
(	O
luxS	B
-	O
)	O
was	O
used	O
as	O
the	O
signalling	O
population	O
.	O

Preventing	O
passage	O
of	O
air	O
between	O
the	O
two	O
populations	O
resulted	O
in	O
a	O
complete	O
cessation	O
of	O
the	O
growth	O
-	O
promoting	O
effect	O
.	O

CONCLUSIONS	O
:	O

A	O
growth	O
-	O
promoting	O
signal	O
occurs	O
between	O
physically	O
separated	O
cultures	O
of	O
E.	O
coli	O
.	O

The	O
exact	O
nature	O
of	O
the	O
signal	O
remains	O
to	O
be	O
determined	O
but	O
does	O
not	O
involve	O
the	O
production	O
of	O
autoinducer-2	O
from	O
the	O
luxS	B
gene	O
.	O

Signal	O
transmission	O
is	O
likely	O
to	O
involve	O
airborne	O
transfer	O
of	O
a	O
signal	O
species	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O

Intercellular	O
signalling	O
systems	O
exist	O
in	O
bacteria	O
that	O
enable	O
antibiotic	O
resistance	O
to	O
be	O
conferred	O
between	O
physically	O
separated	O
populations	O
.	O

An	O
essential	O
role	O
for	O
DNA	B
methyltransferase	I
DNMT3B	B
in	O
cancer	O
cell	O
survival	O
.	O

Abnormal	O
methylation	O
and	O
associated	O
silencing	O
of	O
tumor	O
suppressor	O
genes	O
is	O
a	O
common	O
feature	O
of	O
many	O
types	O
of	O
cancers	O
.	O

The	O
observation	O
of	O
persistent	O
methylation	O
in	O
human	O
cancer	O
cells	O
lacking	O
the	O
maintenance	O
methyltransferase	B
DNMT1	B
suggests	O
the	O
involvement	O
of	O
other	O
DNA	B
methyltransferases	I
in	O
gene	O
silencing	O
in	O
cancer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
evaluated	O
methylation	O
and	O
gene	O
expression	O
in	O
cancer	O
cells	O
specifically	O
depleted	O
of	O
DNMT3A	B
or	O
DNMT3B	B
,	O
de	O
novo	O
methyltransferases	B
that	O
are	O
expressed	O
in	O
adult	O
tissues	O
.	O

Here	O
we	O
have	O
shown	O
that	O
depletion	O
of	O
DNMT3B	B
,	O
but	O
not	O
DNMT3A	B
,	O
induced	O
apoptosis	O
of	O
human	O
cancer	O
cells	O
but	O
not	O
normal	O
cells	O
.	O

DNMT3B	B
depletion	O
reactivated	O
methylation	O
-	O
silenced	O
gene	O
expression	O
but	O
did	O
not	O
induce	O
global	O
or	O
juxtacentromeric	O
satellite	O
demethylation	O
as	O
did	O
specific	O
depletion	O
of	O
DNMT1	B
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
DNMT3B	B
depletion	O
was	O
rescued	O
by	O
exogenous	O
expression	O
of	O
either	O
of	O
the	O
splice	O
variants	O
DNMT3B2	B
or	O
DNMT3B3	B
but	O
not	O
DNMT1	B
.	O

These	O
results	O
indicate	O
that	O
DNMT3B	B
has	O
significant	O
site	O
selectivity	O
that	O
is	O
distinct	O
from	O
DNMT1	B
,	O
regulates	O
aberrant	O
gene	O
silencing	O
,	O
and	O
is	O
essential	O
for	O
cancer	O
cell	O
survival	O
.	O

Polymorphism	O
at	O
GSTM1	B
,	O
GSTM3	B
and	O
GSTT1	B
gene	O
loci	O
and	O
susceptibility	O
to	O
oral	O
cancer	O
in	O
an	O
Indian	O
population	O
.	O

This	O
study	O
evaluates	O
the	O
influence	O
of	O
genetic	O
polymorphism	O
at	O
GSTM1	B
,	O
GSTM3	B
and	O
GSTT1	B
gene	O
loci	O
on	O
oral	O
cancer	O
risk	O
among	O
Indians	O
habituated	O
to	O
the	O
use	O
of	O
,	O
smokeless	O
tobacco	O
,	O
bidi	O
or	O
cigarette	O
.	O

DNA	O
extracted	O
from	O
white	O
blood	O
cells	O
of	O
297	O
cancer	O
patients	O
and	O
450	O
healthy	O
controls	O
by	O
the	O
proteinase	B
K	I
phenol	O
-	O
chloroform	O
extraction	O
procedure	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analyses	O
.	O

Lifetime	O
tobacco	O
exposure	O
was	O
evaluated	O
as	O
a	O
risk	O
factor	O
in	O
relation	O
to	O
the	O
polymorphism	O
at	O
the	O
GST	B
gene	O
loci	O
using	O
logistic	O
regression	O
analysis	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
the	O
GSTM3	B
and	O
GSTT1	B
genotypes	O
between	O
oral	O
cancer	O
patients	O
and	O
controls	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
3	O
-	O
fold	O
increase	O
in	O
risk	O
was	O
seen	O
for	O
patients	O
with	O
the	O
GSTM1	B
null	O
genotype	O
(	O
age	O
adjusted	O
OR	O
=	O
3.2	O
,	O
95	O
%	O
CI	O
2.4	O
-	O
4.3	O
)	O
.	O

The	O
impact	O
of	O
the	O
GSTM1	B
null	O
genotype	O
on	O
oral	O
cancer	O
risk	O
was	O
also	O
analyzed	O
in	O
separate	O
groups	O
of	O
individuals	O
with	O
different	O
tobacco	O
habits	O
.	O

The	O
odds	O
ratio	O
associated	O
with	O
the	O
GSTM1	B
null	O
genotype	O
was	O
3.7	O
(	O
95	O
%	O
CI	O
2.0	O
-	O
7.1	O
)	O
in	O
tobacco	O
chewers	O
,	O
3.7	O
(	O
5	O
%	O
CI	O
1.3	O
-	O
7.9	O
)	O
in	O
bidi	O
smokers	O
and	O
5.7	O
(	O
95	O
%	O
CI	O
2.0	O
-	O
16.3	O
)	O
in	O
cigarette	O
smokers	O
.	O

Furthermore	O
,	O
increased	O
lifetime	O
exposure	O
to	O
chewing	O
tobacco	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
oral	O
cancer	O
risk	O
in	O
GSTM1	B
null	O
individuals	O
.	O

The	O
results	O
suggest	O
that	O
the	O
GSTM1	B
null	O
genotype	O
is	O
a	O
risk	O
factor	O
for	O
development	O
of	O
oral	O
cancer	O
among	O
Indian	O
tobacco	O
habitues	O
.	O

Subunit	B
H	I
of	I
the	I
V	I
-	I
ATPase	I
binds	O
to	O
the	O
medium	B
chain	I
of	I
adaptor	I
protein	I
complex	I
2	I
and	O
connects	O
Nef	B
to	O
the	O
endocytic	O
machinery	O
.	O

Nef	B
is	O
an	O
accessory	O
protein	O
of	O
human	O
and	O
simian	O
immunodeficiency	O
viruses	O
(	O
HIV	O
and	O
SIV	O
)	O
that	O
is	O
required	O
for	O
efficient	O
viral	O
infectivity	O
and	O
pathogenicity	O
.	O

It	O
decreases	O
the	O
expression	O
of	O
CD4	B
on	O
the	O
surface	O
of	O
infected	O
cells	O
.	O

V1H	B
is	O
the	O
regulatory	O
subunit	B
H	I
of	I
the	I
vacuolar	I
membrane	I
ATPase	I
(	O
V	B
-	I
ATPase	I
)	O
.	O

Previously	O
,	O
the	O
interaction	O
between	O
Nef	B
and	O
V1H	B
has	O
been	O
found	O
to	O
facilitate	O
the	O
internalization	O
of	O
CD4	B
,	O
suggesting	O
that	O
V1H	B
could	O
connect	O
Nef	B
to	O
the	O
endocytic	O
machinery	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
V1H	B
binds	O
to	O
the	O
C	O
-	O
terminal	O
flexible	O
loop	O
in	O
Nef	B
from	O
HIV-1	O
and	O
to	O
the	O
medium	B
chain	I
(	I
mu2	I
)	I
of	I
the	I
adaptor	I
protein	I
complex	I
2	I
(	O
AP-2	B
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
interaction	O
sites	O
of	O
V1H	B
and	O
mu2	B
were	O
mapped	O
to	O
a	O
central	O
region	O
in	O
V1H	B
from	O
positions	O
133	O
to	O
363	O
,	O
which	O
contains	O
4	O
armadillo	B
repeats	O
,	O
and	O
to	O
the	O
N	O
-	O
terminal	O
adaptin	B
-	O
binding	O
domain	O
in	O
mu2	B
from	O
positions	O
1	O
to	O
145	O
.	O

Fusing	O
Nef	B
to	O
V1H	B
reproduced	O
the	O
appropriate	O
trafficking	O
of	O
Nef	B
.	O

This	O
chimera	O
internalized	O
CD4	B
even	O
in	O
the	O
absence	O
of	O
the	O
C	O
-	O
terminal	O
flexible	O
loop	O
in	O
Nef	B
.	O

Finally	O
,	O
blocking	O
the	O
expression	O
of	O
V1H	B
decreased	O
the	O
enhancement	O
of	O
virion	O
infectivity	O
by	O
Nef	B
.	O

Thus	O
,	O
V1H	B
can	O
function	O
as	O
an	O
adaptor	O
for	O
interactions	O
between	O
Nef	B
and	O
AP-2	B
.	O

Mastermind	B
mediates	O
chromatin	O
-	O
specific	O
transcription	O
and	O
turnover	O
of	O
the	O
Notch	B
enhancer	O
complex	O
.	O

Signaling	O
through	O
the	O
Notch	B
pathway	O
activates	O
the	O
proteolytic	O
release	O
of	O
the	O
Notch	B
intracellular	O
domain	O
(	O
ICD	O
)	O
,	O
a	O
dedicated	O
transcriptional	O
coactivator	O
of	O
CSL	O
enhancer	O
-	O
binding	O
proteins	O
.	O

Here	O
we	O
show	O
that	O
chromatin	O
-	O
dependent	O
transactivation	O
by	O
the	O
recombinant	O
Notch	B
ICD	O
-	O
CBF1	B
enhancer	O
complex	O
in	O
vitro	O
requires	O
an	O
additional	O
coactivator	O
,	O
Mastermind	B
(	O
MAM	B
)	O
.	O

MAM	B
provides	O
two	O
activation	O
domains	O
necessary	O
for	O
Notch	B
signaling	O
in	O
mammalian	O
cells	O
and	O
in	O
Xenopus	O
embryos	O
.	O

We	O
show	O
that	O
the	O
central	O
MAM	B
activation	O
domain	O
(	O
TAD1	O
)	O
recruits	O
CBP	B
/	O
p300	B
to	O
promote	O
nucleosome	O
acetylation	O
at	O
Notch	B
enhancers	O
and	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
also	O
find	O
that	O
MAM	B
expression	O
induces	O
phosphorylation	O
and	O
relocalization	O
of	O
endogenous	O
CBP	B
/	O
p300	B
proteins	O
to	O
nuclear	O
foci	O
in	O
vivo	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
coexpression	O
with	O
MAM	B
and	O
CBF1	B
strongly	O
enhances	O
phosphorylation	O
and	O
proteolytic	O
turnover	O
of	O
the	O
Notch	B
ICD	O
in	O
vivo	O
.	O

Enhanced	O
phosphorylation	O
of	O
the	O
ICD	O
and	O
p300	B
requires	O
a	O
glutamine	O
-	O
rich	O
region	O
of	O
MAM	B
(	O
TAD2	O
)	O
that	O
is	O
essential	O
for	O
Notch	B
transcription	O
in	O
vivo	O
.	O

Thus	O
MAM	B
may	O
function	O
as	O
a	O
timer	O
to	O
couple	O
transcription	O
activation	O
with	O
disassembly	O
of	O
the	O
Notch	B
enhancer	O
complex	O
on	O
chromatin	O
.	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
and	O
hepatic	O
mallory	O
body	O
formation	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
has	O
been	O
documented	O
in	O
the	O
cerebral	O
cortex	O
of	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
and	O
Down	O
syndrome	O
.	O

This	O
novel	O
process	O
consists	O
of	O
the	O
unfaithful	O
conversion	O
of	O
genomic	O
information	O
into	O
aberrant	O
transcripts	O
and	O
its	O
subsequent	O
translation	O
into	O
+	O
1	O
proteins	O
.	O

METHODS	O
:	O

Because	O
Mallory	O
bodies	O
(	O
MBs	O
)	O
also	O
contain	O
ubiquitinated	O
proteins	O
,	O
we	O
stained	O
11	O
autopsied	O
and	O
6	O
biopsied	O
MB	O
-	O
containing	O
livers	O
from	O
patients	O
with	O
steatohepatitis	O
with	O
an	O
antibody	O
to	O
ubiquitin	B
(	O
+	O
1	O
)	O
to	O
look	O
for	O
the	O
presence	O
of	O
mutant	O
(	O
ubiquitin	B
(	O
+	O
1	O
)	O
)	O
protein	O
.	O

Antibodies	O
to	O
wild	O
-	O
type	O
ubiquitin	B
were	O
used	O
to	O
document	O
the	O
presence	O
of	O
MBs	O
in	O
all	O
cases	O
.	O

RESULTS	O
:	O

Ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
was	O
detected	O
in	O
all	O
MB	O
-	O
containing	O
livers	O
with	O
steatohepatitis	O
;	O
no	O
ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
was	O
found	O
in	O
13	O
MB	O
-	O
free	O
liver	O
controls	O
.	O

A	O
subpopulation	O
(	O
about	O
one	O
third	O
of	O
the	O
MBs	O
)	O
of	O
the	O
MB	O
-	O
containing	O
hepatocytes	O
in	O
autopsied	O
livers	O
showed	O
ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
(	O
i.e.	O
,	O
ubiquitin	B
and	O
ubiquitin	B
(	O
+	O
1	O
)	O
colocalized	O
in	O
MBs	O
)	O
.	O

MB	O
-	O
containing	O
liver	O
biopsy	O
specimens	O
showed	O
colocalization	O
of	O
ubiquitin	B
and	O
ubiquitin	B
(	O
+	O
1	O
)	O
in	O
every	O
MB	O
.	O

Western	O
blot	O
analysis	O
showed	O
an	O
ubiquitin	B
(	O
+	O
1	O
)	O
band	O
of	O
11	O
kilodaltons	O
.	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
(	O
DeltaGU	O
)	O
was	O
shown	O
in	O
one	O
of	O
the	O
livers	O
,	O
which	O
contained	O
numerous	O
MBs	O
using	O
an	O
expression	O
cloning	O
strategy	O
.	O

CONCLUSIONS	O
:	O

The	O
results	O
showed	O
that	O
molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
occurred	O
in	O
hepatocytes	O
in	O
virtually	O
all	O
of	O
the	O
MB	O
-	O
containing	O
livers	O
tested	O
.	O

Ubiquitin	B
(	O
+	O
1	O
)	O
protein	O
was	O
only	O
found	O
within	O
the	O
MBs	O
and	O
therefore	O
may	O
act	O
by	O
interfering	O
with	O
the	O
degradation	O
of	O
the	O
MBs	O
because	O
ubiquitin	B
(	O
+	O
1	O
)	O
may	O
inhibit	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
.	O

The	O
combination	O
of	O
soluble	O
IL-18Ralpha	B
and	O
IL-18Rbeta	B
chains	O
inhibits	O
IL-18	B
-	O
induced	O
IFN	B
-	I
gamma	I
.	O

Although	O
the	O
beta	B
chain	I
of	I
interleukin-18	I
receptor	I
(	B
IL-18Rbeta	I
)	O
is	O
required	O
for	O
signaling	O
,	O
the	O
soluble	O
(	O
extracellular	O
)	O
form	O
does	O
not	O
bind	O
IL-18	B
,	O
and	O
its	O
role	O
in	O
inhibiting	O
IL-18	B
is	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
both	O
the	O
soluble	O
human	O
IL-18	B
ligand	O
binding	O
alpha	O
chain	O
(	O
sIL-18Ralpha	B
)	O
and	O
the	O
sIL-18Rbeta	B
chain	O
were	O
investigated	O
for	O
inhibition	O
of	O
IL-18	B
-	O
induced	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
production	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
whole	O
blood	O
,	O
and	O
KG-1	O
macrophage	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O

Neutralization	O
of	O
IL-18	B
by	O
soluble	O
receptors	O
was	O
compared	O
with	O
that	O
of	O
the	O
IL-18	B
binding	I
protein	I
(	O
IL-18BP	B
)	O
.	O

An	O
equimolar	O
concentration	O
IL-18BP	B
inhibited	O
90	O
%	O
of	O
IL-18	B
activity	O
,	O
whereas	O
a	O
4	O
-	O
fold	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
had	O
no	O
effect	O
.	O

A	O
dimeric	O
construct	O
of	O
sIL-18Ralpha	B
linked	O
to	O
the	O
Fc	O
domain	O
of	O
IgG1	B
(	O
sIL-18Ralpha	B
:	O
Fc	O
)	O
increased	O
IL-18	B
activity	O
2.5	O
-	O
fold	O
.	O

In	O
PBMC	O
stimulated	O
with	O
lypopolysaccharide	O
(	O
LPS	O
)	O
or	O
in	O
whole	O
blood	O
stimulated	O
with	O
Staphylococcus	O
epidermidis	O
,	O
3	O
nM	O
IL-18BP	B
reduced	O
IFN	B
-	I
gamma	I
by	O
80	O
%	O
,	O
whereas	O
IL-18Ralpha	B
:	O
Fc	O
had	O
no	O
effect	O
.	O

A	O
construct	O
of	O
the	O
sIL-18Rbeta	B
linked	O
to	O
Fc	O
(	O
sIL-18Rbeta	B
:	O
Fc	O
)	O
did	O
not	O
affect	O
IL-18	B
-	O
induced	O
IFN	B
-	I
gamma	I
even	O
at	O
80	O
-	O
fold	O
molar	O
excess	O
of	O
IL-18	B
.	O

However	O
,	O
the	O
combination	O
of	O
both	O
soluble	O
receptors	O
reduced	O
IFN	B
-	I
gamma	I
by	O
80	O
%	O
.	O

In	O
KG-1	O
cells	O
,	O
a	O
50	O
%	O
reduction	O
in	O
IL-18	B
activity	O
was	O
observed	O
using	O
an	O
80	O
-	O
fold	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
:	O
Fc	O
but	O
only	O
in	O
the	O
presence	O
of	O
sIL-18Rbeta	B
:	O
Fc	O
.	O

Similarly	O
,	O
a	O
50	O
%	O
reduction	O
was	O
observed	O
using	O
sIL-18Rbeta	B
:	O
Fc	O
in	O
the	O
presence	O
of	O
a	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
:	O
Fc	O
.	O

Similar	O
inhibition	O
was	O
observed	O
in	O
NK	O
cells	O
.	O

These	O
studies	O
reveal	O
that	O
the	O
combination	O
of	O
the	O
ligand	O
-	O
binding	O
and	O
the	O
nonligand	O
-	O
binding	O
extracellular	O
domains	O
of	O
IL-18R	B
is	O
needed	O
to	O
inhibit	O
IL-18	B
,	O
whereas	O
IL-18BP	B
neutralizes	O
at	O
equimolar	O
concentration	O
.	O

Distinct	O
sets	O
of	O
adjacent	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
(	I
hnRNP	I
)	I
A1	I
/	I
A2	I
binding	O
sites	O
control	O
5	O
'	O
splice	O
site	O
selection	O
in	O
the	O
hnRNP	B
A1	I
mRNA	O
precursor	O
.	O

In	O
the	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
(	I
hnRNP	I
)	I
A1	I
pre	O
-	O
mRNA	O
,	O
different	O
regions	O
in	O
the	O
introns	O
flanking	O
alternative	O
exon	O
7B	O
have	O
been	O
implicated	O
in	O
the	O
production	O
of	O
the	O
A1	B
and	O
A1B	B
mRNA	O
splice	O
isoforms	O
.	O

Among	O
these	O
,	O
the	O
CE1a	O
and	O
CE4	O
elements	O
,	O
located	O
downstream	O
of	O
common	O
exon	O
7	O
and	O
alternative	O
exon	O
7B	O
,	O
respectively	O
,	O
are	O
bound	O
by	O
hnRNP	B
A1	I
to	O
promote	O
skipping	O
of	O
exon	O
7B	O
in	O
vivo	O
and	O
distal	O
5	O
'	O
splice	O
site	O
selection	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
report	O
that	O
CE1a	O
is	O
flanked	O
by	O
an	O
additional	O
high	O
affinity	O
A1	O
binding	O
site	O
(	O
CE1d	O
)	O
.	O

In	O
a	O
manner	O
similar	O
to	O
CE1a	O
,	O
CE1d	O
affects	O
5	O
'	O
splice	O
site	O
selection	O
in	O
vitro	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
hnRNP	B
A1	I
in	O
the	O
activity	O
of	O
CE1d	O
,	O
a	O
mutation	O
that	O
abrogates	O
A1	O
binding	O
abolishes	O
distal	O
5	O
'	O
splice	O
site	O
activation	O
.	O

Moreover	O
,	O
the	O
ability	O
of	O
CE1d	O
to	O
stimulate	O
distal	O
5	O
'	O
splice	O
site	O
usage	O
is	O
lost	O
in	O
an	O
HeLa	O
extract	O
depleted	O
of	O
hnRNP	B
A	I
/	I
B	I
proteins	O
,	O
and	O
the	O
addition	O
of	O
recombinant	O
A1	B
restores	O
the	O
activity	O
of	O
CE1d	O
.	O

Notably	O
,	O
distal	O
5	O
'	O
splice	O
site	O
selection	O
mediated	O
by	O
A1	B
binding	O
sites	O
is	O
not	O
compromised	O
in	O
an	O
extract	O
prepared	O
from	O
mouse	O
cells	O
that	O
are	O
severely	O
deficient	O
in	O
hnRNP	B
A1	I
proteins	O
.	O

In	O
this	O
case	O
,	O
we	O
show	O
that	O
hnRNP	B
A2	I
compensates	O
for	O
the	O
A1	B
deficiency	O
.	O

Further	O
studies	O
with	O
the	O
CE4	O
element	O
reveal	O
that	O
it	O
also	O
consists	O
of	O
two	O
distinct	O
portions	O
(	O
CE4	O
m	O
and	O
CE4p	O
)	O
,	O
each	O
one	O
capable	O
of	O
promoting	O
distal	O
5	O
'	O
splice	O
site	O
use	O
in	O
an	O
hnRNP	B
A1	I
-	O
dependent	O
manner	O
.	O

The	O
presence	O
of	O
multiple	O
A1	B
/	O
A2	B
binding	O
sites	O
downstream	O
of	O
common	O
exon	O
7	O
and	O
alternative	O
exon	O
7B	O
probably	O
plays	O
an	O
important	O
role	O
in	O
maximizing	O
the	O
activity	O
of	O
hnRNP	B
A1	I
/	I
A2	I
proteins	O
.	O

A	O
role	O
for	O
ASIC3	B
in	O
the	O
modulation	O
of	O
high	O
-	O
intensity	O
pain	O
stimuli	O
.	O

Acid	B
-	I
sensing	I
ion	I
channel	I
3	I
(	O
ASIC3	B
)	O
,	O
a	O
proton	B
-	I
gated	I
ion	I
channel	I
of	O
the	O
degenerins	B
/	I
epithelial	I
sodium	I
channel	I
(	I
DEG	I
/	I
ENaC	I
)	I
receptor	I
family	I
is	O
expressed	O
predominantly	O
in	O
sensory	O
neurons	O
including	O
nociceptive	O
neurons	O
responding	O
to	O
protons	O
.	O

To	O
study	O
the	O
role	O
of	O
ASIC3	B
in	O
pain	O
signaling	O
,	O
we	O
generated	O
ASIC3	B
knockout	O
mice	O
.	O

Mutant	O
animals	O
were	O
healthy	O
and	O
responded	O
normally	O
to	O
most	O
sensory	O
stimuli	O
.	O

However	O
,	O
in	O
behavioral	O
assays	O
for	O
pain	O
responses	O
,	O
ASIC3	B
null	O
mutant	O
mice	O
displayed	O
a	O
reduced	O
latency	O
to	O
the	O
onset	O
of	O
pain	O
responses	O
,	O
or	O
more	O
pain	O
-	O
related	O
behaviors	O
,	O
when	O
stimuli	O
of	O
moderate	O
to	O
high	O
intensity	O
were	O
used	O
.	O

This	O
unexpected	O
effect	O
seemed	O
independent	O
of	O
the	O
modality	O
of	O
the	O
stimulus	O
and	O
was	O
observed	O
in	O
the	O
acetic	O
acid	O
-	O
induced	O
writhing	O
test	O
(	O
0.6	O
vs.	O
0.1	O
-	O
0.5	O
%	O
)	O
,	O
in	O
the	O
hot	O
-	O
plate	O
test	O
(	O
52.5	O
and	O
55	O
vs.	O
50	O
degrees	O
C	O
)	O
,	O
and	O
in	O
tests	O
for	O
mechanically	O
induced	O
pain	O
(	O
tail	O
-	O
pinch	O
vs.	O
von	O
Frey	O
filaments	O
)	O
.	O

We	O
postulate	O
that	O
ASIC3	B
is	O
involved	O
in	O
modulating	O
moderate	O
-	O
to	O
high	O
-	O
intensity	O
pain	O
sensation	O
.	O

Connexin-43	B
interactions	O
with	O
ZO-1	B
and	O
alpha	B
-	I
and	I
beta	I
-	I
tubulin	I
.	O

Gap	O
junctions	O
are	O
composed	O
of	O
connexins	B
that	O
form	O
transmembrane	O
channels	O
between	O
adjacent	O
cells	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
of	O
connexin-43	B
(	O
Cx43	B
)	O
,	O
the	O
most	O
widely	O
expressed	O
connexin	B
member	O
,	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
Cx43	B
channel	O
gating	O
.	O

Interestingly	O
,	O
channel	O
-	O
independent	O
processes	O
regulated	O
by	O
Cx43	B
have	O
also	O
been	O
postulated	O
.	O

In	O
our	O
studies	O
to	O
elucidate	O
the	O
mechanism	O
of	O
Cx43	B
channel	O
gating	O
by	O
growth	B
factors	I
and	O
to	O
explore	O
additional	O
functions	O
of	O
gap	O
junctions	O
,	O
we	O
have	O
identified	O
three	O
interacting	O
partners	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
Cx43	B
(	O
Cx43CT	B
)	O
.	O

(	O
i	O
)	O
the	O
c	B
-	I
Src	I
tyrosine	B
kinase	I
,	O
which	O
phosphorylates	O
Cx43CT	B
and	O
is	O
involved	O
in	O
G	B
protein	I
-	O
mediated	O
inhibition	O
of	O
Cx43	B
gap	O
junctional	O
communication	O
.	O

(	O
ii	O
)	O
the	O
ZO-1	B
'	O
scaffold	O
'	O
protein	O
,	O
which	O
might	O
recruit	O
signaling	O
proteins	O
into	O
Cx43	B
-	O
based	O
gap	O
junctions	O
.	O

(	O
iii	O
)	O
microtubules	O
(	O
consisting	O
of	O
alpha	B
/	I
beta	I
-	I
tubulin	I
dimers	O
)	O
,	O
which	O
extend	O
with	O
their	O
distal	O
ends	O
to	O
Cx43	B
-	O
based	O
gap	O
junctions	O
,	O
suggesting	O
that	O
Cx43	B
gap	O
junctions	O
may	O
play	O
a	O
novel	O
role	O
in	O
regulating	O
microtubule	O
stability	O
in	O
contacted	O
cells	O
.	O

Here	O
we	O
show	O
that	O
Cx43	B
binds	O
alpha	B
-	I
tubulin	I
equally	O
well	O
as	O
beta	B
-	I
tubulin	I
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
second	O
,	O
but	O
not	O
the	O
first	O
,	O
PDZ	O
domain	O
of	O
ZO-1	B
binds	O
directly	O
to	O
Cx43	B
,	O
and	O
we	O
confirm	O
that	O
the	O
very	O
C	O
-	O
terminal	O
isoleucine	O
residue	O
of	O
Cx43	B
is	O
critical	O
for	O
ZO-1	B
binding	O
.	O

Identification	O
of	O
a	O
novel	O
human	O
eicosanoid	B
receptor	I
coupled	O
to	O
G	B
(	I
i	I
/	I
o	I
)	I
.	O

We	O
have	O
conducted	O
an	O
in	O
silico	O
data	O
base	O
search	O
for	O
and	O
cloned	O
a	O
novel	O
G	B
-	I
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
named	O
TG1019	B
.	O

Dot	O
and	O
Northern	O
blotting	O
analyses	O
showed	O
that	O
transcripts	O
of	O
the	O
novel	O
GPCR	B
were	O
expressed	O
in	O
various	O
tissues	O
except	O
brain	O
,	O
and	O
the	O
expression	O
was	O
more	O
intense	O
in	O
liver	O
,	O
kidney	O
,	O
peripheral	O
leukocyte	O
,	O
lung	O
,	O
and	O
spleen	O
than	O
in	O
other	O
tissues	O
.	O

By	O
GTP	O
gamma	O
S	O
binding	O
assay	O
using	O
the	O
TG1019	B
-	O
G	B
alpha	I
(	I
i1	I
)	I
-	O
protein	O
fusion	O
expressed	O
in	O
insect	O
cells	O
,	O
eicosanoids	O
,	O
and	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
5-oxo-6E,8Z,11Z,14Z	O
-	O
eicosatetraenoic	O
acid	O
(	O
5-oxo	O
-	O
ETE	O
)	O
,	O
5	O
(	O
S	O
)	O
-hydroperoxy-6E,8Z	O
,	O
11Z,14Z	O
-	O
eicosatetraenoic	O
acid	O
,	O
and	O
arachidonic	O
acid	O
were	O
identified	O
to	O
exhibit	O
agonistic	O
activities	O
against	O
TG1019	B
.	O

5-oxo	O
-	O
ETE	O
was	O
the	O
most	O
potent	O
to	O
enhance	O
the	O
specific	O
binding	O
by	O
6	O
-	O
fold	O
at	O
a	O
maximum	O
effect	O
dose	O
of	O
submicromolar	O
to	O
micromolar	O
order	O
with	O
an	O
ED	O
(	O
50	O
)	O
value	O
of	O
5.7	O
nM	O
.	O

Conversely	O
,	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
docosahexaenoic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
showed	O
antagonistic	O
activities	O
against	O
TG1019	B
.	O

In	O
Chinese	O
hamster	O
ovary	O
cells	O
transiently	O
expressing	O
TG1019	B
,	O
the	O
forskolin	O
-	O
stimulated	O
production	O
of	O
cAMP	O
was	O
inhibited	O
up	O
to	O
approximately	O
70	O
%	O
by	O
5-oxo	O
-	O
ETE	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
33	O
nM	O
.	O

This	O
inhibition	O
was	O
sensitive	O
to	O
pretreatment	O
of	O
the	O
cells	O
with	O
pertussis	B
toxin	I
.	O

p52	B
Mediates	O
XPB	B
function	O
within	O
the	O
transcription	O
/	O
repair	O
factor	O
TFIIH	B
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
transcription	O
/	O
DNA	O
repair	O
factor	O
TFIIH	B
,	O
we	O
investigated	O
the	O
role	O
of	O
its	O
p52	B
subunit	O
in	O
TFIIH	B
function	O
.	O

Using	O
a	O
completely	O
reconstituted	O
in	O
vitro	O
transcription	O
or	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
system	O
,	O
we	O
show	O
that	O
deletion	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
p52	B
results	O
in	O
a	O
dramatic	O
reduction	O
of	O
TFIIH	B
NER	O
and	O
transcription	O
activities	O
.	O

This	O
mutation	O
prevents	O
promoter	O
opening	O
and	O
has	O
no	O
effect	O
on	O
the	O
other	O
enzymatic	O
activities	O
of	O
TFIIH	B
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
intact	O
p52	B
is	O
needed	O
to	O
anchor	O
the	O
XPB	B
helicase	I
within	O
TFIIH	B
,	O
providing	O
an	O
explanation	O
for	O
the	O
transcription	O
and	O
NER	O
defects	O
observed	O
with	O
the	O
mutant	O
p52	B
.	O

We	O
show	O
that	O
these	O
two	O
subunits	O
physically	O
interact	O
and	O
map	O
domains	O
involved	O
in	O
the	O
interface	O
.	O

Taken	O
together	O
,	O
our	O
results	O
show	O
that	O
the	O
p52	B
/	O
Tfb2	B
subunit	O
of	O
TFIIH	B
regulates	O
the	O
function	O
of	O
XPB	B
through	O
pair	O
-	O
wise	O
interactions	O
as	O
described	O
previously	O
for	O
p44	B
and	O
XPD	B
.	O

cGMP	B
-	I
dependent	I
protein	I
kinase	I
I	I
beta	I
physically	O
and	O
functionally	O
interacts	O
with	O
the	O
transcriptional	O
regulator	O
TFII	B
-	I
I	I
.	O

Transcriptional	O
regulation	O
of	O
the	O
fos	B
promoter	O
by	O
nitric	O
oxide	O
and	O
cGMP	O
can	O
occur	O
by	O
nuclear	O
translocation	O
of	O
cGMP	B
-	I
dependent	I
protein	I
kinase	I
I	I
(	O
G	B
-	I
kinase	I
I	I
)	O
(	O
Gudi	O
,	O
T.	O
,	O
Lohmann	O
,	O
S.	O
M.	O
,	O
and	O
Pilz	O
,	O
R.	O
B.	O
(	O
1997	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
17	O
,	O
5244	O
-	O
5254	O
)	O
.	O

To	O
identify	O
nuclear	O
targets	O
of	O
G	B
-	I
kinase	I
I	I
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
G	B
-	I
kinase	I
I	I
beta	I
as	O
bait	O
.	O

We	O
found	O
that	O
G	B
-	I
kinase	I
I	I
beta	I
interacted	O
specifically	O
with	O
TFII	B
-	I
I	I
,	O
an	O
unusual	O
transcriptional	O
regulator	O
that	O
associates	O
with	O
multiple	O
proteins	O
to	O
modulate	O
both	O
basal	O
and	O
signal	O
-	O
induced	O
transcription	O
.	O

By	O
using	O
purified	O
recombinant	O
proteins	O
,	O
the	O
interaction	O
was	O
mapped	O
to	O
the	O
N	O
-	O
terminal	O
93	O
amino	O
acids	O
of	O
G	B
-	I
kinase	I
I	I
beta	I
and	O
one	O
of	O
six	O
95	O
-	O
amino	O
acid	O
repeats	O
found	O
in	O
TFII	B
-	I
I	I
.	O

In	O
baby	O
hamster	O
kidney	O
cells	O
,	O
cGMP	O
analogs	O
enhanced	O
co	O
-	O
immunoprecipitation	O
of	O
G	B
-	I
kinase	I
I	I
beta	I
and	O
TFII	B
-	I
I	I
by	O
inducing	O
co	O
-	O
localization	O
of	O
both	O
proteins	O
in	O
the	O
nucleus	O
,	O
but	O
in	O
other	O
cell	O
types	O
containing	O
cytoplasmic	O
TFII	B
-	I
I	I
the	O
G	B
-	I
kinase	I
-	O
TFII	B
-	I
I	I
interaction	O
was	O
largely	O
cGMP	O
-	O
independent	O
.	O

G	B
-	I
kinase	I
phosphorylated	O
TFII	B
-	I
I	I
in	O
vitro	O
and	O
in	O
vivo	O
on	O
Ser	O
(	O
371	O
)	O
and	O
Ser	O
(	O
743	O
)	O
outside	O
of	O
the	O
interaction	O
domain	O
.	O

G	B
-	I
kinase	I
strongly	O
enhanced	O
TFII	B
-	I
I	I
transactivation	O
of	O
a	O
serum	O
-	O
response	O
element	O
-	O
containing	O
promoter	O
in	O
COS7	O
cells	O
,	O
and	O
this	O
effect	O
was	O
lost	O
when	O
Ser	O
(	O
371	O
)	O
and	O
Ser	O
(	O
743	O
)	O
of	O
TFII	B
-	I
I	I
were	O
mutated	O
.	O

TFII	B
-	I
I	I
by	O
itself	O
had	O
little	O
effect	O
on	O
a	O
full	O
-	O
length	O
fos	O
promoter	O
in	O
baby	O
hamster	O
kidney	O
cells	O
,	O
but	O
it	O
synergistically	O
enhanced	O
transcriptional	O
activation	O
by	O
G	B
-	I
kinase	I
I	I
beta	O
.	O

Binding	O
of	O
G	B
-	I
kinase	I
to	O
TFII	B
-	I
I	I
may	O
position	O
the	O
kinase	B
to	O
phosphorylate	O
and	O
regulate	O
TFII	B
-	I
I	I
and/or	O
factors	O
that	O
interact	O
with	O
TFII	B
-	I
I	I
at	O
the	O
serum	O
-	O
response	O
element	O
.	O

Live	O
-	O
cell	O
imaging	O
reveals	O
divergent	O
intracellular	O
dynamics	O
of	O
polyglutamine	O
disease	O
proteins	O
and	O
supports	O
a	O
sequestration	O
model	O
of	O
pathogenesis	O
.	O

Protein	O
misfolding	O
and	O
aggregation	O
are	O
central	O
features	O
of	O
the	O
polyglutamine	O
neurodegenerative	O
disorders	O
,	O
but	O
the	O
dynamic	O
properties	O
of	O
expanded	O
polyglutamine	O
proteins	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
use	O
fluorescence	O
recovery	O
after	O
photobleaching	O
(	O
FRAP	O
)	O
and	O
fluorescence	O
loss	O
in	O
photobleaching	O
(	O
FLIP	O
)	O
with	O
green	B
fluorescent	I
protein	I
fusion	O
proteins	O
to	O
study	O
polyglutamine	O
protein	O
kinetics	O
in	O
living	O
cells	O
.	O

Our	O
results	O
reveal	O
markedly	O
divergent	O
mobility	O
states	O
for	O
an	O
expanded	O
polyglutamine	O
protein	O
,	O
ataxin-3	B
,	O
and	O
establish	O
that	O
nuclear	O
inclusions	O
formed	O
by	O
this	O
protein	O
are	O
aggregates	O
.	O

Additional	O
studies	O
of	O
green	B
fluorescent	I
protein	I
-	O
tagged	O
cAMP	B
response	I
element	I
binding	I
protein	I
coexpressed	O
with	O
either	O
of	O
two	O
mutant	O
polyglutamine	O
proteins	O
,	O
ataxin	B
-	I
3	I
and	O
huntingtin	B
,	O
support	O
a	O
model	O
of	O
disease	O
in	O
which	O
coaggregation	O
of	O
transcriptional	O
components	O
contributes	O
to	O
pathogenesis	O
.	O

Finally	O
,	O
studies	O
of	O
a	O
third	O
polyglutamine	O
disease	O
protein	O
,	O
ataxin-1	B
,	O
reveal	O
unexpected	O
heterogeneity	O
in	O
the	O
dynamics	O
of	O
inclusions	O
formed	O
by	O
different	O
disease	O
proteins	O
,	O
a	O
finding	O
which	O
may	O
help	O
explain	O
disease	O
-	O
specific	O
elements	O
of	O
pathogenesis	O
in	O
these	O
neurodegenerative	O
disorders	O
.	O

The	O
mRNA	O
structure	O
has	O
potent	O
regulatory	O
effects	O
on	O
type	B
2	I
iodothyronine	I
deiodinase	I
expression	O
.	O

Type	B
2	I
deiodinase	I
(	O
D2	B
)	O
is	O
a	O
selenoenzyme	O
catalyzing	O
the	O
activation	O
of	O
T	O
(	O
4	O
)	O
to	O
T	O
(	O
3	O
)	O
.	O

D2	B
activity	O
/	O
mRNA	O
ratios	O
are	O
often	O
low	O
,	O
suggesting	O
that	O
there	O
is	O
significant	O
posttranscriptional	O
regulation	O
.	O

The	O
D2	B
mRNA	O
in	O
higher	O
vertebrates	O
is	O
more	O
than	O
6	O
kb	O
,	O
containing	O
long	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
.	O

The	O
D2	B
5	O
'	O
UTRs	O
are	O
greater	O
than	O
600	O
nucleotides	O
and	O
contain	O
3	O
-	O
5	O
short	O
open	O
reading	O
frames	O
.	O

These	O
full	O
-	O
length	O
5	O
'	O
UTRs	O
reduce	O
the	O
D2	B
translation	O
efficiency	O
approximately	O
5	O
-	O
fold	O
.	O

The	O
inhibition	O
by	O
human	O
D2	B
5	O
'	O
UTR	O
is	O
localized	O
to	O
a	O
region	O
containing	O
the	O
first	O
short	O
open	O
reading	O
frame	O
encoding	O
a	O
tripeptide	O
-	O
MKG	O
.	O

This	O
inhibition	O
was	O
abolished	O
by	O
mutating	O
the	O
AUG	O
start	O
codon	O
and	O
weakened	O
by	O
modification	O
of	O
the	O
essential	O
purine	O
of	O
the	O
Kozak	O
consensus	O
.	O

Deletion	O
of	O
the	O
3.7	O
-	O
kb	O
3'UTR	O
of	O
the	O
chicken	O
D2	B
mRNA	O
increased	O
D2	B
activity	O
approximately	O
3.8	O
-	O
fold	O
due	O
to	O
an	O
increase	O
in	O
D2	B
mRNA	O
half	O
-	O
life	O
.	O

In	O
addition	O
,	O
alternatively	O
spliced	O
D2	B
mRNA	O
transcripts	O
similar	O
in	O
size	O
to	O
the	O
major	O
6	O
-	O
to	O
7	O
-	O
kb	O
D2	B
mRNAs	O
but	O
not	O
encoding	O
an	O
active	O
enzyme	O
are	O
present	O
in	O
both	O
human	O
and	O
chicken	O
tissues	O
.	O

Our	O
results	O
indicate	O
that	O
a	O
number	O
of	O
factors	O
reduce	O
the	O
D2	B
protein	O
levels	O
.	O

These	O
mechanisms	O
,	O
together	O
with	O
the	O
short	O
half	O
-	O
life	O
of	O
the	O
protein	O
,	O
ensure	O
limited	O
expression	O
of	O
this	O
key	O
regulator	O
of	O
T	O
(	O
4	O
)	O
activation	O
.	O

The	O
transcriptional	B
regulating	I
protein	I
of	I
132	I
kDa	I
(	O
TReP-132	B
)	O
enhances	O
P450scc	B
gene	O
transcription	O
through	O
interaction	O
with	O
steroidogenic	B
factor-1	I
in	O
human	O
adrenal	O
cells	O
.	O

The	O
human	O
P450scc	B
gene	O
is	O
regulated	O
by	O
the	O
tissue	O
-	O
specific	O
orphan	O
nuclear	O
receptor	O
,	O
steroidogenic	B
factor-1	I
(	O
SF-1	B
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
several	O
physiologic	O
processes	O
including	O
steroid	O
synthesis	O
,	O
adrenal	O
and	O
gonadal	O
development	O
,	O
and	O
sexual	O
differentiation	O
.	O

Several	O
studies	O
have	O
demonstrated	O
the	O
interaction	O
of	O
SF-1	B
with	O
different	O
proteins	O
.	O

However	O
,	O
it	O
is	O
clear	O
that	O
additional	O
factors	O
not	O
yet	O
identified	O
are	O
involved	O
with	O
SF-1	B
to	O
regulate	O
different	O
target	O
genes	O
.	O

Recently	O
,	O
it	O
was	O
demonstrated	O
that	O
a	O
novel	O
transcriptional	B
regulating	I
protein	I
of	I
132	I
kDa	I
(	O
TReP-132	B
)	O
regulates	O
expression	O
of	O
the	O
human	O
P450scc	B
gene	O
.	O

The	O
overexpression	O
of	O
TReP-132	B
in	O
adrenal	O
cells	O
increases	O
the	O
production	O
of	O
pregnenolone	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
P450scc	B
gene	O
expression	O
.	O

Considering	O
the	O
colocalization	O
of	O
TReP-132	B
and	O
SF-1	B
in	O
steroidogenic	O
tissues	O
such	O
as	O
the	O
adrenal	O
and	O
testis	O
,	O
and	O
the	O
presence	O
of	O
two	O
putative	O
LXXLL	O
motifs	O
in	O
TReP-132	B
that	O
can	O
potentially	O
interact	O
with	O
SF-1	B
,	O
the	O
relationship	O
between	O
these	O
two	O
factors	O
on	O
the	O
P450scc	B
gene	O
promoter	O
was	O
determined	O
.	O

The	O
coexpression	O
of	O
SF-1	B
and	O
TReP-132	B
in	O
adrenal	O
NCI	O
-	O
H295	O
cells	O
cooperates	O
to	O
increase	O
promoter	O
activity	O
.	O

Pull	O
-	O
down	O
experiments	O
demonstrated	O
the	O
interaction	O
between	O
TReP-132	B
and	O
SF-1	B
,	O
and	O
this	O
was	O
further	O
confirmed	O
in	O
intact	O
cells	O
by	O
coimmunoprecipitation	O
/	O
Western	O
blot	O
and	O
two	O
-	O
hybrid	O
analyses	O
.	O

Deletions	O
and	O
mutations	O
of	O
the	O
TReP-132	B
cDNA	O
sequence	O
demonstrate	O
that	O
SF-1	B
interaction	O
requires	O
the	O
LXXLL	O
motif	O
found	O
at	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O

Also	O
,	O
the	O
""""	O
proximal	O
activation	O
domain	O
""""	O
and	O
the	O
""""	O
AF-2	O
hexamer	O
""""	O
motif	O
of	O
SF-1	B
are	O
involved	O
in	O
interaction	O
with	O
TReP-132	B
.	O

Consistent	O
with	O
previous	O
studies	O
showing	O
interaction	O
between	O
CBP	B
/	O
p300	B
and	O
SF-1	B
or	O
TReP-132	B
,	O
the	O
coexpression	O
of	O
these	O
three	O
proteins	O
results	O
in	O
a	O
synergistic	O
effect	O
on	O
P450scc	B
gene	O
promoter	O
activity	O
.	O

Taken	O
together	O
the	O
results	O
in	O
this	O
study	O
identify	O
a	O
novel	O
function	O
of	O
TReP-132	B
as	O
a	O
partner	O
in	O
a	O
complex	O
with	O
SF-1	B
and	O
CBP	B
/	O
p300	B
to	O
regulate	O
gene	O
transcription	O
involved	O
in	O
steroidogenesis	O
.	O

Mass	O
spectrometric	O
analysis	O
of	O
GAP-43	B
/	O
neuromodulin	B
reveals	O
the	O
presence	O
of	O
a	O
variety	O
of	O
fatty	O
acylated	O
species	O
.	O

GAP-43	B
(	O
neuromodulin	B
)	O
is	O
a	O
protein	B
kinase	I
C	I
substrate	O
that	O
is	O
abundant	O
in	O
developing	O
and	O
regenerating	O
neurons	O
.	O

Thioester	O
-	O
linked	O
palmitoylation	O
at	O
two	O
cysteines	O
near	O
the	O
GAP-43	B
N	O
terminus	O
has	O
been	O
implicated	O
in	O
directing	O
membrane	O
binding	O
.	O

Here	O
,	O
we	O
use	O
mass	O
spectrometry	O
to	O
examine	O
the	O
stoichiometry	O
of	O
palmitoylation	O
and	O
the	O
molecular	O
identity	O
of	O
the	O
fatty	O
acid	O
(	O
s	O
)	O
attached	O
to	O
GAP-43	B
in	O
vivo	O
.	O

GAP-43	B
expressed	O
in	O
either	O
PC12	O
or	O
COS-1	O
cells	O
was	O
acetylated	O
at	O
the	O
N	O
-	O
terminal	O
methionine	O
.	O

Approximately	O
35	O
%	O
of	O
the	O
N	O
-	O
terminal	O
GAP	B
-	I
43	I
peptides	O
were	O
also	O
modified	O
by	O
palmitate	O
and/or	O
stearate	O
on	O
Cys	O
residues	O
.	O

Interestingly	O
,	O
a	O
variety	O
of	O
acylated	O
species	O
was	O
detected	O
,	O
in	O
which	O
one	O
of	O
the	O
Cys	O
residues	O
was	O
acylated	O
by	O
either	O
palmitate	O
or	O
stearate	O
,	O
or	O
both	O
Cys	O
residues	O
were	O
acylated	O
by	O
palmitates	O
or	O
stearates	O
or	O
a	O
combination	O
of	O
palmitate	O
and	O
stearate	O
.	O

Depalmitoylation	O
of	O
membrane	O
-	O
bound	O
GAP-43	B
did	O
not	O
release	O
the	O
protein	O
from	O
the	O
membrane	O
,	O
implying	O
that	O
additional	O
forces	O
function	O
to	O
maintain	O
membrane	O
binding	O
.	O

Indeed	O
,	O
mutation	O
of	O
four	O
basic	O
residues	O
within	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
GAP-43	B
dramatically	O
reduced	O
membrane	O
localization	O
of	O
GAP-43	B
without	O
affecting	O
palmitoylation	O
.	O

These	O
data	O
reveal	O
the	O
heterogeneous	O
nature	O
of	O
S	O
-	O
acylation	O
in	O
vivo	O
and	O
illustrate	O
the	O
power	O
of	O
mass	O
spectrometry	O
for	O
identification	O
of	O
key	O
regulatory	O
protein	O
modifications	O
.	O

Cloning	O
,	O
characterization	O
,	O
and	O
functional	O
studies	O
of	O
a	O
47	B
-	I
kDa	I
platelet	I
receptor	I
for	I
type	I
III	I
collagen	I
.	O

A	O
1.2	O
-	O
kb	O
cDNA	O
fragment	O
encoding	O
a	O
platelet	O
47	O
-	O
kDa	O
protein	O
has	O
been	O
isolated	O
from	O
a	O
human	O
bone	O
marrow	O
cDNA	O
library	O
by	O
using	O
a	O
degenerate	O
oligonucleotide	O
of	O
the	O
sequenced	O
amino	O
terminus	O
of	O
the	O
purified	O
platelet	O
protein	O
with	O
a	O
poly	O
(	O
dT	O
)	O
(	O
12	O
)	O
.	O
(	O
dG	O
)	O
by	O
polymerase	O
chain	O
reaction	O
.	O

A	O
computer	O
search	O
revealed	O
that	O
the	O
cDNA	O
represents	O
the	O
coding	O
sequence	O
of	O
a	O
protein	O
with	O
a	O
fragmentary	O
homology	O
to	O
several	O
proteins	O
.	O

Using	O
a	O
prokaryotic	O
expression	O
system	O
,	O
pBad	O
TOPO-47	O
cDNA	O
,	O
a	O
47	O
-	O
kDa	O
recombinant	O
protein	O
was	O
obtained	O
and	O
purified	O
to	O
apparent	O
homogeneity	O
by	O
nickel	O
-	O
nitrilotriacetic	O
acid	O
resin	O
and	O
collagen	O
affinity	O
column	O
.	O

The	O
recombinant	O
protein	O
binds	O
to	O
type	B
III	I
but	I
not	I
type	I
I	I
collagen	I
-	O
Sepharose	O
2B	O
affinity	O
columns	O
.	O

Anti	O
-	O
47	O
-	O
kDa	O
but	O
not	O
anti	O
-	O
65	O
-	O
kDa	O
antibody	O
inhibits	O
the	O
binding	O
of	O
the	O
recombinant	O
protein	O
to	O
the	O
type	B
III	I
collagen	I
-	O
coated	O
micro	O
titer	O
wells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Like	O
the	O
receptor	O
protein	O
purified	O
from	O
platelet	O
membranes	O
,	O
the	O
recombinant	O
protein	O
inhibits	O
type	B
III	I
collagen	I
-	O
induced	O
platelet	O
aggregation	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
defined	O
two	O
active	O
peptides	O
from	O
the	O
cloned	O
deduced	O
amino	O
acid	O
sequence	O
.	O

Both	O
peptides	O
inhibit	O
type	B
III	I
but	I
not	I
type	I
I	I
collagen	I
-	O
induced	O
platelet	O
aggregation	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

These	O
results	O
suggest	O
that	O
the	O
active	O
binding	O
site	O
of	O
the	O
platelet	B
receptor	I
to	I
type	I
III	I
collagen	I
resides	O
in	O
these	O
portions	O
of	O
the	O
protein	O
.	O

Cytological	O
grading	O
,	O
apoptosis	O
,	O
and	O
Bcl-2	B
protein	O
expression	O
in	O
breast	O
cancer	O
.	O

A	O
prospective	O
study	O
was	O
conducted	O
on	O
27	O
cases	O
of	O
infiltrating	O
duct	O
carcinoma	O
of	O
breast	O
diagnosed	O
by	O
fine	O
-	O
needle	O
aspirate	O
cytology	O
(	O
FNAC	O
)	O
,	O
subjected	O
to	O
mastectomy	O
following	O
the	O
FNA	O
diagnosis	O
.	O

Cytological	O
grading	O
,	O
Bcl-2	B
score	O
,	O
and	O
quantification	O
of	O
apoptotic	O
cell	O
count	O
were	O
done	O
on	O
FNA	O
material	O
.	O

Next	O
,	O
the	O
carcinomas	O
were	O
graded	O
on	O
the	O
corresponding	O
histopathological	O
sections	O
.	O

The	O
overall	O
concordance	O
between	O
cytological	O
and	O
histological	O
gradings	O
was	O
77.7	O
%	O
,	O
with	O
maximum	O
concordance	O
in	O
Grade	O
I	O
tumors	O
and	O
minimum	O
in	O
Grade	O
II	O
.	O

The	O
mean	O
apoptotic	O
rates	O
were	O
0.59	O
+	O
/-	O
0.722	O
,	O
2.11	O
+	O
/-	O
0.707	O
,	O
and	O
2.95	O
+	O
/-	O
0.854	O
in	O
Grades	O
I	O
,	O
II	O
,	O
and	O
III	O
,	O
respectively	O
.	O

Similarly	O
Bcl-2	B
scores	O
were	O
1.36	O
+	O
/-	O
0.82	O
,	O
0.22	O
+	O
/-	O
0.13	O
,	O
and	O
0.14	O
+	O
/-	O
0.116	O
,	O
in	O
Grades	O
I	O
,	O
II	O
,	O
and	O
III	O
lesions	O
,	O
respectively	O
.	O

When	O
the	O
cytological	O
grade	O
was	O
correlated	O
with	O
histological	O
grade	O
alone	O
,	O
and	O
subsequently	O
along	O
with	O
Bcl-2	B
scores	O
and	O
apoptotic	O
rates	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
from	O
0.662	O
-	O
0.713	O
(	O
P	O
value	O
,	O
0.001	O
)	O
.	O

Adenovirus	O
oncoproteins	O
inactivate	O
the	O
Mre11	B
-	O
Rad50	B
-	O
NBS1	B
DNA	O
repair	O
complex	O
.	O

In	O
mammalian	O
cells	O
,	O
a	O
conserved	O
multiprotein	O
complex	O
of	O
Mre11	B
,	O
Rad50	B
and	O
NBS1	B
(	O
also	O
known	O
as	O
nibrin	B
and	O
p95	B
)	O
is	O
important	O
for	O
double	O
-	O
strand	O
break	O
repair	O
,	O
meiotic	O
recombination	O
and	O
telomere	O
maintenance	O
.	O

This	O
complex	O
forms	O
nuclear	O
foci	O
and	O
may	O
be	O
a	O
sensor	O
of	O
double	O
-	O
strand	O
breaks	O
.	O

In	O
the	O
absence	O
of	O
the	O
early	O
region	O
E4	B
,	O
the	O
double	O
-	O
stranded	O
DNA	O
genome	O
of	O
adenovirus	O
is	O
joined	O
into	O
concatemers	O
too	O
large	O
to	O
be	O
packaged	O
.	O

We	O
have	O
investigated	O
the	O
cellular	O
proteins	O
involved	O
in	O
this	O
concatemer	O
formation	O
and	O
how	O
they	O
are	O
inactivated	O
by	O
E4	B
products	O
during	O
a	O
wild	O
-	O
type	O
infection	O
.	O

Here	O
we	O
show	O
that	O
concatemerization	O
requires	O
functional	O
Mre11	B
and	O
NBS1	B
,	O
and	O
that	O
these	O
proteins	O
are	O
found	O
at	O
foci	O
adjacent	O
to	O
viral	O
replication	O
centres	O
.	O

Infection	O
with	O
wild	O
-	O
type	O
virus	O
results	O
in	O
both	O
reorganization	O
and	O
degradation	O
of	O
members	O
of	O
the	O
Mre11	B
-	O
Rad50	B
-	O
NBS1	B
complex	O
.	O

These	O
activities	O
are	O
mediated	O
by	O
three	O
viral	O
oncoproteins	O
that	O
prevent	O
concatemerization	O
.	O

This	O
targeting	O
of	O
cellular	O
proteins	O
involved	O
in	O
genomic	O
stability	O
suggests	O
a	O
mechanism	O
for	O
'	O
hit	O
-	O
and	O
-	O
run	O
'	O
transformation	O
observed	O
for	O
these	O
viral	O
oncoproteins	O
.	O

A	O
bimolecular	O
mechanism	O
of	O
HIV-1	O
Tat	B
protein	O
interaction	O
with	O
RNA	B
polymerase	I
II	I
transcription	O
elongation	O
complexes	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
element	O
is	O
regulated	O
by	O
the	O
essential	O
viral	O
Tat	B
protein	O
that	O
binds	O
to	O
the	O
viral	O
TAR	O
RNA	O
target	O
and	O
recruits	O
a	O
positive	B
transcription	I
elongation	I
complex	I
(	O
P	B
-	I
TEFb	I
)	O
.	O

We	O
have	O
used	O
a	O
stepwise	O
transcription	O
approach	O
and	O
a	O
highly	O
sensitive	O
assay	O
to	O
determine	O
the	O
dynamics	O
of	O
interactions	O
between	O
HIV-1	O
Tat	B
and	O
the	O
transcription	O
complexes	O
actively	O
engaged	O
in	O
elongation	O
.	O

Our	O
results	O
demonstrate	O
that	O
Tat	B
protein	O
associates	O
with	O
RNA	B
polymerase	I
II	I
complexes	O
during	O
early	O
transcription	O
elongation	O
after	O
the	O
promoter	O
clearance	O
and	O
before	O
the	O
synthesis	O
of	O
full	O
-	O
length	O
TAR	O
RNA	O
transcript	O
.	O

This	O
interaction	O
of	O
Tat	B
with	O
RNA	B
polymerase	I
II	I
elongation	O
complexes	O
is	O
P	B
-	I
TEFb	I
-	O
independent	O
.	O

Our	O
results	O
also	O
show	O
that	O
there	O
are	O
two	O
Tat	B
binding	O
sites	O
on	O
each	O
transcription	O
elongation	O
complex	O
;	O
one	O
is	O
located	O
on	O
TAR	O
RNA	O
and	O
the	O
other	O
one	O
on	O
RNA	B
polymerase	I
II	I
near	O
the	O
exit	O
site	O
for	O
nascent	O
mRNA	O
transcripts	O
.	O

These	O
findings	O
suggest	O
that	O
two	O
Tat	B
molecules	O
are	O
involved	O
in	O
performing	O
various	O
functions	O
during	O
a	O
single	O
round	O
of	O
HIV-1	O
mRNA	O
synthesis	O
.	O

Spectrin	B
-	O
like	O
repeats	O
from	O
dystrophin	B
and	O
alpha	B
-	I
actinin-2	I
are	O
not	O
functionally	O
interchangeable	O
.	O

Mutations	O
in	O
the	O
dystrophin	B
gene	O
result	O
in	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
.	O

Dystrophin	B
is	O
a	O
multidomain	O
protein	O
that	O
functions	O
to	O
stabilize	O
the	O
sarcolemmal	O
membrane	O
during	O
muscle	O
contraction	O
.	O

The	O
central	O
rod	O
domain	O
has	O
been	O
proposed	O
to	O
act	O
as	O
a	O
shock	O
absorber	O
,	O
as	O
a	O
force	O
transducer	O
or	O
as	O
a	O
spacer	O
separating	O
important	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
that	O
interact	O
with	O
actin	B
and	O
the	O
dystrophin	B
-	O
glycoprotein	O
complex	O
(	O
DGC	O
)	O
.	O

Structure	O
/	O
function	O
studies	O
demonstrated	O
that	O
deletion	O
of	O
large	O
portions	O
of	O
the	O
rod	O
domain	O
can	O
result	O
in	O
the	O
production	O
of	O
smaller	O
,	O
yet	O
highly	O
functional	O
,	O
dystrophin	B
proteins	O
.	O

In	O
a	O
dramatic	O
example	O
,	O
a	O
'	O
micro	O
-	O
dystrophin	B
'	O
transgene	O
containing	O
only	O
four	O
dystrophin	B
spectrin	B
-	O
like	O
repeats	O
resulted	O
in	O
complete	O
correction	O
of	O
most	O
of	O
the	O
symptoms	O
associated	O
with	O
dystrophy	O
in	O
the	O
mdx	O
mouse	O
model	O
for	O
DMD	O
.	O

Dystrophin	B
shares	O
considerable	O
homology	O
with	O
the	O
multidomain	O
,	O
actin	B
-	O
crosslinking	O
protein	O
alpha	B
-	I
actinin	I
.	O

To	O
explore	O
the	O
hypothesis	O
that	O
the	O
dystrophin	B
rod	O
domain	O
acts	O
as	O
a	O
spacer	O
region	O
,	O
a	O
chimeric	O
micro	O
-	O
dystrophin	B
transgene	O
containing	O
the	O
four	O
-	O
repeat	O
rod	O
domain	O
of	O
alpha	B
-	I
actinin-2	I
was	O
expressed	O
in	O
mdx	O
mice	O
.	O

This	O
chimeric	O
transgene	O
was	O
incapable	O
of	O
correcting	O
the	O
morphological	O
pathology	O
of	O
the	O
mdx	O
mouse	O
,	O
but	O
still	O
functioned	O
to	O
assemble	O
the	O
DGC	O
at	O
the	O
membrane	O
and	O
provided	O
some	O
protection	O
from	O
contraction	O
-	O
induced	O
injury	O
.	O

These	O
data	O
demonstrated	O
that	O
different	O
spectrin	B
-	O
like	O
repeats	O
are	O
not	O
equivalent	O
,	O
and	O
reinforced	O
the	O
suggestion	O
that	O
the	O
dystrophin	B
rod	O
domain	O
is	O
not	O
merely	O
a	O
spacer	O
but	O
likely	O
contributes	O
an	O
important	O
mechanical	O
role	O
to	O
overall	O
dystrophin	B
function	O
.	O

PAX	B
genes	O
in	O
development	O
and	O
disease	O
:	O
the	O
role	O
of	O
PAX2	B
in	O
urogenital	O
tract	O
development	O
.	O

PAX	B
genes	O
play	O
an	O
important	O
role	O
in	O
fetal	O
development	O
.	O

Moreover	O
,	O
heterozygous	O
mutations	O
in	O
several	O
PAX	B
genes	O
cause	O
human	O
disease	O
.	O

Here	O
we	O
review	O
the	O
role	O
of	O
PAX2	B
in	O
kidney	O
development	O
,	O
focusing	O
on	O
the	O
morphological	O
effects	O
of	O
PAX2	B
mutations	O
.	O

We	O
discuss	O
the	O
role	O
of	O
PAX2	B
in	O
the	O
context	O
of	O
an	O
inhibitory	O
field	O
model	O
of	O
kidney	O
branching	O
morphogenesis	O
and	O
summarize	O
recent	O
progress	O
in	O
this	O
area	O
.	O

Cytoplasmic	B
serine	I
hydroxymethyltransferase	I
mediates	O
competition	O
between	O
folate	O
-	O
dependent	O
deoxyribonucleotide	O
and	O
S	O
-	O
adenosylmethionine	O
biosyntheses	O
.	O

Folate	O
-	O
dependent	O
one	O
-	O
carbon	O
metabolism	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
purines	O
and	O
thymidylate	O
and	O
for	O
the	O
remethylation	O
of	O
homocysteine	O
to	O
methionine	O
.	O

Methionine	O
is	O
subsequently	O
adenylated	O
to	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
,	O
a	O
cofactor	O
that	O
methylates	O
DNA	O
,	O
RNA	O
,	O
proteins	O
,	O
and	O
many	O
metabolites	O
.	O

Previous	O
experimental	O
and	O
theoretical	O
modeling	O
studies	O
have	O
indicated	O
that	O
folate	O
cofactors	O
are	O
limiting	O
for	O
cytoplasmic	O
folate	O
-	O
dependent	O
reactions	O
and	O
that	O
the	O
synthesis	O
of	O
DNA	O
precursors	O
competes	O
with	O
SAM	O
synthesis	O
.	O

Each	O
of	O
these	O
studies	O
concluded	O
that	O
SAM	O
synthesis	O
has	O
a	O
higher	O
metabolic	O
priority	O
than	O
dTMP	O
synthesis	O
.	O

The	O
influence	O
of	O
cytoplasmic	B
serine	I
hydroxymethyltransferase	I
(	O
cSHMT	B
)	O
on	O
this	O
competition	O
was	O
examined	O
in	O
MCF-7	O
cells	O
.	O

Increases	O
in	O
cSHMT	B
expression	O
inhibit	O
SAM	O
concentrations	O
by	O
two	O
proposed	O
mechanisms	O
:	O
(	O
1	O
)	O
cSHMT	B
-	O
catalyzed	O
serine	O
synthesis	O
competes	O
with	O
the	O
enzyme	O
methylenetetrahydrofolate	B
reductase	I
for	O
methylenetetrahydrofolate	O
in	O
a	O
glycine	O
-	O
dependent	O
manner	O
,	O
and	O
(	O
2	O
)	O
cSHMT	B
,	O
a	O
high	O
affinity	O
5	O
-	O
methyltetrahydrofolate	O
-	O
binding	O
protein	O
,	O
sequesters	O
this	O
cofactor	O
and	O
inhibits	O
methionine	O
synthesis	O
in	O
a	O
glycine	O
-	O
independent	O
manner	O
.	O

Stable	O
isotope	O
tracer	O
studies	O
indicate	O
that	O
cSHMT	B
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
flux	O
of	O
one	O
-	O
carbon	O
units	O
between	O
dTMP	O
and	O
SAM	O
syntheses	O
.	O

We	O
conclude	O
that	O
cSHMT	B
has	O
three	O
important	O
functions	O
in	O
the	O
cytoplasm	O
:	O
(	O
1	O
)	O
it	O
preferentially	O
supplies	O
one	O
-	O
carbon	O
units	O
for	O
thymidylate	O
biosynthesis	O
,	O
(	O
2	O
)	O
it	O
depletes	O
methylenetetrahydrofolate	O
pools	O
for	O
SAM	O
synthesis	O
by	O
synthesizing	O
serine	O
,	O
and	O
(	O
3	O
)	O
it	O
sequesters	O
5-methyltetrahydrofolate	O
and	O
inhibits	O
SAM	O
synthesis	O
.	O

These	O
results	O
indicate	O
that	O
cSHMT	B
is	O
a	O
metabolic	O
switch	O
that	O
,	O
when	O
activated	O
,	O
gives	O
dTMP	O
synthesis	O
higher	O
metabolic	O
priority	O
than	O
SAM	O
synthesis	O
.	O

Elucidating	O
changes	O
in	O
surface	O
marker	O
expression	O
of	O
dendritic	O
cells	O
following	O
chemical	O
allergen	O
treatment	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
highly	O
specialized	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
located	O
in	O
lymphoid	O
and	O
many	O
nonlymphoid	O
tissues	O
,	O
and	O
Langerhans	O
cells	O
(	O
LC	O
)	O
,	O
a	O
specialized	O
form	O
of	O
DC	O
,	O
are	O
found	O
in	O
the	O
skin	O
.	O

LC	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
contact	O
dermatitis	O
and	O
therefore	O
have	O
become	O
a	O
focal	O
point	O
for	O
the	O
development	O
of	O
in	O
vitro	O
cell	O
-	O
based	O
methods	O
for	O
contact	O
sensitization	O
testing	O
.	O

Because	O
of	O
the	O
low	O
abundance	O
of	O
skin	O
-	O
derived	O
LC	O
,	O
methods	O
to	O
culture	O
DC	O
from	O
peripheral	O
blood	O
are	O
being	O
used	O
by	O
investigators	O
to	O
generate	O
LC	O
surrogates	O
to	O
examine	O
the	O
effects	O
of	O
sensitizing	O
chemicals	O
on	O
APC	O
.	O

It	O
has	O
been	O
reported	O
recently	O
that	O
chemical	O
allergens	O
can	O
induce	O
changes	O
in	O
the	O
expression	O
of	O
various	O
DC	O
surface	O
markers	O
and	O
it	O
has	O
been	O
suggested	O
that	O
the	O
measure	O
of	O
these	O
changes	O
in	O
surface	O
marker	O
expression	O
following	O
allergen	O
treatment	O
could	O
provide	O
the	O
basis	O
for	O
an	O
in	O
vitro	O
test	O
method	O
to	O
predict	O
the	O
contact	O
sensitization	O
potential	O
of	O
a	O
chemical	O
.	O

For	O
the	O
work	O
presented	O
here	O
,	O
DC	O
were	O
differentiated	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
-	O
DC	O
)	O
in	O
culture	O
medium	O
containing	O
GM	B
-	I
CSF	I
and	O
interleukin	B
(	I
IL	I
)	I
-	I
4	I
to	O
ensure	O
an	O
immature	O
phenotype	O
or	O
were	O
derived	O
from	O
the	O
KG	O
-	O
1	O
cell	O
line	O
(	O
KG-1	O
DC	O
)	O
using	O
a	O
defined	O
cytokine	B
cocktail	O
consisting	O
of	O
GM	B
-	I
CSF	I
,	O
IL	B
-	I
4	I
,	O
Flt	B
-	I
3	I
/	O
Flk	B
-	I
2	I
-	O
ligand	O
,	O
thrombopoietin	B
,	O
stem	B
cell	I
factor	I
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNFalpha	B
)	O
.	O

Surface	O
marker	O
expression	O
(	O
HLA	B
-	I
DR	I
,	O
CD54	B
,	O
CD80	B
,	O
and	O
CD86	B
)	O
on	O
these	O
DC	O
was	O
measured	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
treatment	O
with	O
the	O
known	O
chemical	O
allergens	O
dinitrofluorobenzene	O
(	O
DNFB	O
)	O
and	O
methylchloroisothiazolinone	O
/	O
methylisothiazolinone	O
(	O
MCI	O
/	O
MI	O
)	O
,	O
the	O
irritant	O
sodium	O
dodecyl	O
sulfate	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
and	O
TNFalpha	B
.	O

Treatment	O
of	O
PBMC	O
-	O
DC	O
with	O
either	O
MCI	O
/	O
MI	O
or	O
DNFB	O
induced	O
a	O
slight	O
upregulation	O
of	O
class	B
II	I
major	I
histocompatibility	I
(	I
MHC	I
)	I
expression	O
(	O
HLA	B
-	I
DR	I
)	O
,	O
whereas	O
LPS	O
and	O
TNFalpha	B
significantly	O
upregulated	O
CD54	B
and	O
slightly	O
upregulated	O
CD80	B
and	O
HLA	B
-	I
DR	I
expression	O
.	O

For	O
KG-1	O
DC	O
,	O
only	O
MCI	O
/	O
MI	O
upregulated	O
CD86	B
expression	O
,	O
whereas	O
TNFalpha	B
upregulated	O
CD54	B
and	O
slightly	O
upregulated	O
CD80	B
and	O
CD86	B
expression	O
.	O

SDS	O
had	O
no	O
effect	O
on	O
surface	O
marker	O
expression	O
in	O
either	O
PBMC	O
-	O
DC	O
or	O
KG-1	O
DC	O
.	O

Changes	O
in	O
surface	O
marker	O
expression	O
in	O
PBMC	O
-	O
DC	O
treated	O
with	O
chemical	O
allergens	O
were	O
detected	O
in	O
two	O
of	O
five	O
donors	O
,	O
suggesting	O
a	O
limited	O
sensitivity	O
of	O
PBMC	O
-	O
DC	O
under	O
these	O
defined	O
isolation	O
and	O
culture	O
conditions	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
presence	O
of	O
GM	B
-	I
CSF	I
and	O
IL	B
-	I
4	I
during	O
chemical	O
allergen	O
treatment	O
masked	O
the	O
ability	O
to	O
detect	O
changes	O
in	O
surface	O
marker	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
under	O
these	O
culture	O
and	O
treatment	O
conditions	O
,	O
measurement	O
of	O
surface	O
marker	O
changes	O
in	O
vitro	O
using	O
PBMC	O
-	O
DC	O
or	O
KG-1	O
DC	O
does	O
not	O
provide	O
a	O
sensitive	O
in	O
vitro	O
method	O
with	O
sufficient	O
dynamic	O
range	O
for	O
assessing	O
the	O
contact	O
sensitization	O
potential	O
of	O
a	O
chemical	O
.	O

Pre	B
-	I
pro	I
-	I
B	I
cell	I
growth	I
-	I
stimulating	I
factor	I
(	O
PPBSF	B
)	O
upregulates	O
IL-7Ralpha	B
chain	O
expression	O
and	O
enables	O
pro	O
-	O
B	O
cells	O
to	O
respond	O
to	O
monomeric	O
IL-7	B
.	O

Although	O
pro	O
-	O
B	O
cells	O
are	O
well	O
represented	O
in	O
IL-7	B
knockout	O
(	O
KO	O
)	O
mice	O
,	O
they	O
express	O
abnormally	O
low	O
concentrations	O
of	O
the	O
interleukin-7	B
receptor	I
alpha	I
-	I
chain	I
(	O
IL-7Ralpha	B
)	O
and	O
do	O
not	O
generate	O
pre	O
-	O
B	O
cells	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
can	O
be	O
induced	O
to	O
generate	O
pre	O
-	O
B	O
cells	O
and	O
immature	O
B	O
cells	O
by	O
exposure	O
to	O
recombinant	O
IL-7	B
(	O
rIL-7	B
)	O
in	O
vivo	O
but	O
not	O
in	O
vitro	O
.	O

Experiments	O
in	O
recombinant	B
activation	I
gene-1	I
(	O
RAG-1	B
)	O
KO	O
mice	O
indicate	O
that	O
the	O
in	O
vitro	O
unresponsiveness	O
of	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
to	O
rIL-7	B
is	O
unrelated	O
to	O
the	O
absence	O
of	O
a	O
functional	O
pre	O
-	O
B	B
cell	I
receptor	I
(	O
pre	O
-	O
BCR	B
)	O
.	O

Rather	O
,	O
it	O
appears	O
to	O
be	O
due	O
to	O
the	O
suboptimal	O
expression	O
of	O
the	O
IL-7Ralpha	B
chain	O
.	O

Thus	O
,	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
readily	O
respond	O
to	O
rIL-7	B
in	O
vitro	O
if	O
IL-7Ralpha	B
chain	O
expression	O
is	O
first	O
upregulated	O
by	O
exposure	O
to	O
IL-7	B
in	O
vivo	O
or	O
to	O
IL-7	B
(	O
+	O
/+	O
)	O
bone	O
marrow	O
(	O
BM	O
)	O
stromal	O
cells	O
or	O
conditioned	O
medium	O
(	O
CM	O
)	O
therefrom	O
in	O
vitro	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
were	O
cultured	O
on	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
BM	O
stromal	O
cells	O
in	O
the	O
presence	O
of	O
rIL-7	B
.	O

This	O
suggested	O
that	O
the	O
recently	O
described	O
pre	B
-	I
pro	I
-	I
B	I
cell	I
growth	I
-	I
stimulating	I
factor	I
(	O
PPBSF	B
)	O
,	O
a	O
self	O
-	O
assembling	O
hybrid	O
cytokine	B
comprising	O
IL-7	B
and	O
the	O
stromal	O
cell	O
-	O
derived	O
hepatocyte	B
growth	I
factor	I
beta	I
-	I
chain	I
(	O
HGFbeta	B
)	O
,	O
is	O
required	O
to	O
stimulate	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
.	O

This	O
inference	O
was	O
verified	O
by	O
demonstrating	O
that	O
purified	O
PPBSF	B
upregulates	O
IL-7Ralpha	B
chain	O
expression	O
on	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
in	O
vitro	O
and	O
enables	O
them	O
to	O
respond	O
to	O
rIL-7	B
in	O
a	O
stepwise	O
manner	O
.	O

We	O
,	O
therefore	O
,	O
postulate	O
that	O
PPBSF	B
is	O
the	O
operative	O
form	O
of	O
IL-7	B
that	O
normally	O
induces	O
IL-7Ralpha	B
(	O
lo	O
)	O
pre	O
-	O
pro	O
-	O
B	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
into	O
IL-7Ralpha	B
(	O
hi	O
)	O
pro	O
-	O
B	O
cells	O
,	O
which	O
then	O
proliferate	O
and	O
differentiate	O
into	O
pre	O
-	O
B	O
cells	O
on	O
stimulation	O
with	O
monomeric	O
IL-7	B
.	O

Lon	B
protease	I
preferentially	O
degrades	O
oxidized	O
mitochondrial	B
aconitase	I
by	O
an	O
ATP	O
-	O
stimulated	O
mechanism	O
.	O

Mitochondrial	B
aconitase	I
is	O
sensitive	O
to	O
oxidative	O
inactivation	O
and	O
can	O
aggregate	O
and	O
accumulate	O
in	O
many	O
age	O
-	O
related	O
disorders	O
.	O

Here	O
we	O
report	O
that	O
Lon	B
protease	I
,	O
an	O
ATP	O
-	O
stimulated	O
mitochondrial	O
matrix	O
protein	O
,	O
selectively	O
recognizes	O
and	O
degrades	O
the	O
oxidized	O
,	O
hydrophobic	O
form	O
of	O
aconitase	B
after	O
mild	O
oxidative	O
modification	O
,	O
but	O
that	O
severe	O
oxidation	O
results	O
in	O
aconitase	B
aggregation	O
,	O
which	O
makes	O
it	O
a	O
poor	O
substrate	O
for	O
Lon	B
.	O

Similarly	O
,	O
a	O
morpholino	O
oligodeoxynucleotide	O
directed	O
against	O
the	O
lon	O
gene	O
markedly	O
decreases	O
the	O
amount	O
of	O
Lon	B
protein	O
,	O
Lon	B
activity	O
and	O
aconitase	B
degradation	O
in	O
WI-38	O
VA-13	O
human	O
lung	O
fibroblasts	O
and	O
causes	O
accumulation	O
of	O
oxidatively	O
modified	O
aconitase	B
.	O

The	O
ATP	O
-	O
stimulated	O
Lon	B
protease	I
may	O
be	O
an	O
essential	O
defence	O
against	O
the	O
stress	O
of	O
life	O
in	O
an	O
oxygen	O
environment	O
.	O

By	O
recognizing	O
minor	O
oxidative	O
changes	O
to	O
protein	O
structure	O
and	O
rapidly	O
degrading	O
the	O
mildly	O
modified	O
protein	O
,	O
Lon	B
protease	I
may	O
prevent	O
extensive	O
oxidation	O
,	O
aggregation	O
and	O
accumulation	O
of	O
aconitase	B
,	O
which	O
could	O
otherwise	O
compromise	O
mitochondrial	O
function	O
and	O
cellular	O
viability	O
.	O

Aconitase	B
is	O
probably	O
only	O
one	O
of	O
many	O
mitochondrial	O
matrix	O
proteins	O
that	O
are	O
preferentially	O
degraded	O
by	O
Lon	B
protease	I
after	O
oxidative	O
modification	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bone	B
morphogenetic	I
protein-1	I
is	O
required	O
for	O
secretion	O
and	O
stability	O
of	O
the	O
protein	O
.	O

Bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
1	I
is	O
a	O
glycosylated	O
metalloproteinase	B
that	O
is	O
fundamental	O
to	O
the	O
synthesis	O
of	O
a	O
normal	O
extracellular	O
matrix	O
because	O
it	O
cleaves	O
type	B
I	I
procollagen	I
,	O
as	O
well	O
as	O
other	O
precursor	O
proteins	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
BMP-1	B
has	O
six	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
(	O
i.e.	O
NXS	O
/	O
T	O
)	O
namely	O
:	O
Asn	O
(	O
91	O
)	O
(	O
prodomain	O
)	O
,	O
Asn	O
(	O
142	O
)	O
(	O
metalloproteinase	B
domain	O
)	O
,	O
Asn	O
(	O
332	O
)	O
and	O
Asn	O
(	O
363	O
)	O
(	O
CUB1	O
domain	O
)	O
,	O
Asn	O
(	O
599	O
)	O
(	O
CUB3	O
domain	O
)	O
,	O
and	O
Asn	O
(	O
726	O
)	O
in	O
the	O
C	O
-	O
terminal	O
-	O
specific	O
domain	O
.	O

In	O
this	O
study	O
we	O
showed	O
that	O
all	O
these	O
sites	O
are	O
N	O
-	O
glycosylated	O
with	O
complex	O
-	O
type	O
oligosaccharides	O
containing	O
sialic	O
acid	O
,	O
except	O
Asn	O
(	O
726	O
)	O
presumably	O
because	O
proline	O
occurs	O
immediately	O
C	O
-	O
terminal	O
of	O
threonine	O
in	O
the	O
consensus	O
sequence	O
.	O

Recombinant	O
BMP-1	B
molecules	O
lacking	O
all	O
glycosylation	O
sites	O
or	O
the	O
three	O
CUB	O
-	O
specific	O
sites	O
were	O
not	O
secreted	O
.	O

BMP-1	B
lacking	O
CUB	O
glycosylation	O
was	O
translocated	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

BMP-1	B
molecules	O
lacking	O
individual	O
glycosylation	O
sites	O
were	O
efficiently	O
secreted	O
and	O
exhibited	O
full	O
procollagen	B
C	I
-	I
proteinase	I
activity	O
,	O
but	O
N332Q	O
and	O
N599Q	O
exhibited	O
a	O
slower	O
rate	O
of	O
cleavage	O
.	O

BMP-1	B
molecules	O
lacking	O
any	O
one	O
of	O
the	O
CUB	O
-	O
specific	O
glycosylation	O
sites	O
were	O
sensitive	O
to	O
thermal	O
denaturation	O
.	O

The	O
study	O
showed	O
that	O
the	O
glycosylation	O
sites	O
in	O
the	O
CUB	O
domains	O
of	O
BMP-1	B
are	O
important	O
for	O
secretion	O
and	O
stability	O
of	O
the	O
molecule	O
.	O

Cutting	O
edge	O
:	O
susceptibility	O
to	O
psoriatic	O
arthritis	O
:	O
influence	O
of	O
activating	O
killer	B
Ig	I
-	I
like	I
receptor	I
genes	O
in	O
the	O
absence	O
of	O
specific	O
HLA	B
-	I
C	I
alleles	O
.	O

NK	O
cell	O
activity	O
is	O
partially	O
controlled	O
through	O
interactions	O
between	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
on	O
NK	O
cells	O
and	O
their	O
respective	O
HLA	B
class	I
I	I
ligands	O
.	O

Independent	O
segregation	O
of	O
HLA	B
and	O
KIR	B
genes	O
,	O
along	O
with	O
KIR	B
specificity	O
for	O
particular	O
HLA	B
allotypes	O
,	O
raises	O
the	O
possibility	O
that	O
any	O
given	O
individual	O
may	O
express	O
KIR	B
molecules	O
for	O
which	O
no	O
ligand	O
is	O
present	O
.	O

Inhibitory	O
receptor	O
genes	O
KIR2DL2	B
/	I
3	I
and	O
KIR2DL1	B
were	O
present	O
in	O
nearly	O
all	O
subjects	O
sampled	O
in	O
this	O
study	O
,	O
whereas	O
their	O
respective	O
activating	O
homologs	O
,	O
KIR2DS2	B
and	O
KIR2DS1	B
,	O
are	O
each	O
present	O
in	O
about	O
half	O
of	O
the	O
subjects	O
.	O

In	O
this	O
work	O
we	O
report	O
that	O
subjects	O
with	O
activating	O
KIR2DS1	B
and/or	O
KIR2DS2	B
genes	O
are	O
susceptible	O
to	O
developing	O
psoriatic	O
arthritis	O
,	O
but	O
only	O
when	O
HLA	B
ligands	O
for	O
their	O
homologous	O
inhibitory	O
receptors	O
,	O
KIR2DL1	B
and	O
KIR2DL2	B
/	I
3	I
,	O
are	O
missing	O
.	O

Absence	O
of	O
ligands	O
for	O
inhibitory	O
KIRs	B
could	O
potentially	O
lower	O
the	O
threshold	O
for	O
NK	O
(	O
and	O
/	O
or	O
T	O
)	O
cell	O
activation	O
mediated	O
through	O
activating	O
receptors	O
,	O
thereby	O
contributing	O
to	O
pathogenesis	O
of	O
psoriatic	O
arthritis	O
.	O

Drosophila	O
APC2	B
and	O
APC1	B
play	O
overlapping	O
roles	O
in	O
wingless	O
signaling	O
in	O
the	O
embryo	O
and	O
imaginal	O
discs	O
.	O

The	O
regulation	O
of	O
signal	O
transduction	O
plays	O
a	O
key	O
role	O
in	O
cell	O
fate	O
choices	O
,	O
and	O
its	O
disregulation	O
contributes	O
to	O
oncogenesis	O
.	O

This	O
duality	O
is	O
exemplified	O
by	O
the	O
tumor	O
suppressor	O
APC	B
.	O

Originally	O
identified	O
for	O
its	O
role	O
in	O
colon	O
tumors	O
,	O
APC	B
family	I
members	O
were	O
subsequently	O
shown	O
to	O
negatively	O
regulate	O
Wnt	B
signaling	O
in	O
both	O
development	O
and	O
disease	O
.	O

The	O
analysis	O
of	O
the	O
normal	O
roles	O
of	O
APC	B
proteins	O
is	O
complicated	O
by	O
the	O
presence	O
of	O
two	O
APC	B
family	I
members	O
in	O
flies	O
and	O
mice	O
.	O

Previous	O
work	O
demonstrated	O
that	O
,	O
in	O
some	O
tissues	O
,	O
single	O
mutations	O
in	O
each	O
gene	O
have	O
no	O
effect	O
,	O
raising	O
the	O
question	O
of	O
whether	O
there	O
is	O
functional	O
overlap	O
between	O
the	O
two	O
APCs	B
or	O
whether	O
APC	B
-	O
independent	O
mechanisms	O
of	O
Wnt	B
regulation	O
exist	O
.	O

We	O
addressed	O
this	O
by	O
eliminating	O
the	O
function	O
of	O
both	O
Drosophila	O
APC	B
genes	O
simultaneously	O
.	O

We	O
find	O
that	O
APC1	B
and	O
APC2	B
play	O
overlapping	O
roles	O
in	O
regulating	O
Wingless	B
signaling	O
in	O
the	O
embryonic	O
epidermis	O
and	O
the	O
imaginal	O
discs	O
.	O

Surprisingly	O
,	O
APC1	B
function	O
in	O
embryos	O
occurs	O
at	O
levels	O
of	O
expression	O
nearly	O
too	O
low	O
to	O
detect	O
.	O

Further	O
,	O
the	O
overlapping	O
functions	O
exist	O
despite	O
striking	O
differences	O
in	O
the	O
intracellular	O
localization	O
of	O
the	O
two	O
APC	B
family	I
members	O
.	O

Inhibition	O
of	O
silencing	O
and	O
accelerated	O
aging	O
by	O
nicotinamide	O
,	O
a	O
putative	O
negative	O
regulator	O
of	O
yeast	O
sir2	B
and	O
human	O
SIRT1	B
.	O

The	O
Saccharomyces	O
cerevisiae	O
Sir2	B
protein	O
is	O
an	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
histone	B
deacetylase	I
that	O
plays	O
a	O
critical	O
role	O
in	O
transcriptional	O
silencing	O
,	O
genome	O
stability	O
,	O
and	O
longevity	O
.	O

A	O
human	O
homologue	O
of	O
Sir2	B
,	O
SIRT1	B
,	O
regulates	O
the	O
activity	O
of	O
the	O
p53	B
tumor	I
suppressor	I
and	O
inhibits	O
apoptosis	O
.	O

The	O
Sir2	B
deacetylation	O
reaction	O
generates	O
two	O
products	O
:	O
O	O
-	O
acetyl	O
-	O
ADP	O
-	O
ribose	O
and	O
nicotinamide	O
,	O
a	O
precursor	O
of	O
nicotinic	O
acid	O
and	O
a	O
form	O
of	O
niacin	O
/	O
vitamin	O
B	O
(	O
3	O
)	O
.	O

We	O
show	O
here	O
that	O
nicotinamide	O
strongly	O
inhibits	O
yeast	O
silencing	O
,	O
increases	O
rDNA	O
recombination	O
,	O
and	O
shortens	O
replicative	O
life	O
span	O
to	O
that	O
of	O
a	O
sir2	B
mutant	O
.	O

Nicotinamide	O
abolishes	O
silencing	O
and	O
leads	O
to	O
an	O
eventual	O
delocalization	O
of	O
Sir2	B
even	O
in	O
G	O
(	O
1	O
)	O
-	O
arrested	O
cells	O
,	O
demonstrating	O
that	O
silent	O
heterochromatin	O
requires	O
continual	O
Sir2	B
activity	O
.	O

We	O
show	O
that	O
physiological	O
concentrations	O
of	O
nicotinamide	O
noncompetitively	O
inhibit	O
both	O
Sir2	B
and	O
SIRT1	B
in	O
vitro	O
.	O

The	O
degree	O
of	O
inhibition	O
by	O
nicotinamide	O
(	O
IC	O
(	O
50	O
)	O
<	O
50	O
microm	O
)	O
is	O
equal	O
to	O
or	O
better	O
than	O
the	O
most	O
effective	O
known	O
synthetic	O
inhibitors	O
of	O
this	O
class	O
of	O
proteins	O
.	O

We	O
propose	O
a	O
model	O
whereby	O
nicotinamide	O
inhibits	O
deacetylation	O
by	O
binding	O
to	O
a	O
conserved	O
pocket	O
adjacent	O
to	O
NAD	O
(	O
+	O
)	O
,	O
thereby	O
blocking	O
NAD	O
(	O
+	O
)	O
hydrolysis	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
nicotinamide	O
is	O
a	O
physiologically	O
relevant	O
regulator	O
of	O
Sir2	B
enzymes	O
.	O

Mot1p	B
is	O
essential	O
for	O
TBP	B
recruitment	O
to	O
selected	O
promoters	O
during	O
in	O
vivo	O
gene	O
activation	O
.	O

Recruitment	O
of	O
TATA	B
-	I
binding	I
protein	I
(	O
TBP	B
)	O
is	O
central	O
to	O
activation	O
of	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
(	O
pol	B
II	I
)	O
.	O

This	O
depends	O
upon	O
co	O
-	O
activator	O
proteins	O
including	O
TBP	B
-	I
associated	I
factors	I
(	O
TAFs	B
)	O
.	O

Yeast	O
Mot1p	B
was	O
identified	O
as	O
a	O
general	O
transcriptional	O
repressor	O
in	O
genetic	O
screens	O
and	O
is	O
also	O
found	O
associated	O
with	O
TBP	B
.	O

To	O
obtain	O
insight	O
into	O
Mot1p	B
function	O
in	O
vivo	O
,	O
we	O
determined	O
the	O
mRNA	O
expression	O
profile	O
of	O
the	O
mot1	B
-	O
1	O
temperature	O
-	O
sensitive	O
(	O
Ts	O
)	O
strain	O
.	O

Unexpectedly	O
,	O
this	O
indicated	O
that	O
Mot1p	B
mostly	O
plays	O
a	O
positive	O
role	O
for	O
transcription	O
.	O

For	O
one	O
potential	O
activation	O
target	O
,	O
HXT2	B
,	O
we	O
analyzed	O
promoter	O
recruitment	O
of	O
Mot1p	B
,	O
TBP	B
,	O
Taf1p	B
(	O
Taf130p	B
)	O
and	O
pol	B
II	I
by	O
chromatin	O
immunoprecipitation	O
assays	O
.	O

Whereas	O
TBP	B
becomes	O
stably	O
associated	O
upon	O
activation	O
of	O
the	O
HXT2	B
and	O
HXT4	B
promoters	O
,	O
Mot1p	B
showed	O
only	O
a	O
transient	O
association	O
.	O

TBP	B
recruitment	O
was	O
compromised	O
in	O
two	O
different	O
mot1	B
mutant	O
strains	O
,	O
but	O
was	O
only	O
moderately	O
affected	O
in	O
a	O
taf1	B
Ts	O
strain	O
.	O

Together	O
,	O
our	O
data	O
indicate	O
that	O
Mot1p	B
can	O
assist	O
in	O
recruitment	O
of	O
TBP	B
on	O
promoters	O
during	O
gene	O
activation	O
in	O
vivo	O
.	O

Vpr	B
-	O
and	O
Nef	B
-	O
dependent	O
induction	O
of	O
RANTES	B
/	O
CCL5	B
in	O
microglial	O
cells	O
.	O

Microglia	O
are	O
pivotal	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
,	O
as	O
they	O
serve	O
as	O
the	O
major	O
target	O
of	O
HIV	O
infection	O
in	O
the	O
CNS	O
.	O

In	O
addition	O
,	O
activation	O
of	O
microglia	O
correlates	O
best	O
with	O
clinical	O
dementia	O
.	O

Although	O
the	O
beta	B
-	I
chemokine	I
RANTES	B
/	O
CCL5	B
is	O
important	O
in	O
modulating	O
HIV	O
infection	O
as	O
well	O
as	O
cellular	O
activation	O
,	O
no	O
information	O
is	O
available	O
regarding	O
how	O
its	O
expression	O
is	O
regulated	O
in	O
microglia	O
by	O
HIV-1	O
.	O

Here	O
we	O
report	O
that	O
RANTES	B
/	O
CCL5	B
expression	O
is	O
induced	O
in	O
microglia	O
by	O
HIV-1	O
,	O
but	O
that	O
this	O
requires	O
infection	O
by	O
HIV-1	O
.	O

This	O
conclusion	O
was	O
supported	O
by	O
(	O
1	O
)	O
the	O
delayed	O
kinetics	O
coinciding	O
with	O
viral	O
replication	O
;	O
(	O
2	O
)	O
the	O
lack	O
of	O
effect	O
of	O
X4	O
viruses	O
;	O
(	O
3	O
)	O
inhibition	O
by	O
the	O
reverse	B
transcriptase	I
inhibitor	O
AZT	O
,	O
and	O
(	O
4	O
)	O
the	O
lack	O
of	O
effect	O
of	O
cytokine	B
antagonists	O
or	O
antibodies	O
.	O

Interestingly	O
,	O
RANTES	B
/	O
CCL5	B
production	O
was	O
dependent	O
on	O
the	O
viral	O
accessory	O
protein	O
Vpr	B
,	O
in	O
addition	O
to	O
Nef	B
,	O
demonstrating	O
a	O
novel	O
role	O
for	O
Vpr	B
in	O
chemokine	B
induction	O
in	O
primary	O
macrophage	O
-	O
type	O
cells	O
.	O

Furthermore	O
,	O
the	O
specific	O
p38	B
MAP	I
kinase	I
inhibitor	O
SB203580	O
augmented	O
chemokine	B
expression	O
in	O
microglia	O
,	O
indicating	O
a	O
negative	O
role	O
played	O
by	O
p38	B
.	O

These	O
data	O
suggest	O
unique	O
features	O
of	O
RANTES	B
/	O
CCL5	B
regulation	O
by	O
HIV-1	O
in	O
human	O
microglial	O
cells	O
.	O

[	O
The	O
role	O
of	O
lipid	O
metabolism	O
in	O
Alzheimer	O
's	O
disease	O
]	O

Lipid	O
metabolism	O
in	O
the	O
central	O
nervous	O
system	O
has	O
been	O
focused	O
as	O
an	O
important	O
factor	O
of	O
Alzheimer	O
's	O
disease	O
,	O
since	O
the	O
apolipoprotein	B
E	I
gene	O
was	O
discovered	O
as	O
a	O
genetic	O
risk	O
for	O
the	O
disease	O
.	O

Lipid	O
metabolism	O
in	O
the	O
brain	O
,	O
showing	O
relatively	O
closed	O
environment	O
,	O
necessitates	O
lipid	O
reutilization	O
.	O

Cerebrospinal	O
fluid	O
contains	O
only	O
high	B
-	I
density	I
lipoproteins	I
composed	O
of	O
apoE	B
and	O
apoJ	B
secreted	O
from	O
astrocytes	O
and	O
of	O
apoA	B
-	I
I	I
and	O
apoA	B
-	I
II	I
transported	O
via	O
the	O
blood	O
brain	O
barrier	O
.	O

These	O
apolipoproteins	B
can	O
bind	O
to	O
beta	O
amyloid	O
and	O
possibly	O
relate	O
to	O
its	O
clearance	O
.	O

The	O
aggregation	O
of	O
phosphorylated	O
tau	B
,	O
found	O
in	O
neurofibrillary	O
tangles	O
in	O
Alzheimer	O
's	O
brain	O
,	O
is	O
also	O
found	O
in	O
the	O
brain	O
with	O
Niemann	O
-	O
Pick	O
disease	O
,	O
suggesting	O
that	O
the	O
impairment	O
of	O
lipid	O
transport	O
in	O
neuronal	O
cells	O
participates	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Mitochondrial	O
function	O
,	O
lipid	O
production	O
,	O
and	O
acetylcholine	O
production	O
are	O
closely	O
related	O
,	O
and	O
these	O
alterations	O
could	O
be	O
involved	O
in	O
cholinergic	O
dysfunction	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
regulation	O
of	O
lipid	O
metabolism	O
in	O
and	O
outside	O
the	O
brain	O
could	O
be	O
a	O
therapeutic	O
and	O
preventive	O
target	O
for	O
Alzheimer	O
's	O
disease	O
.	O

Molecular	O
characterization	O
of	O
the	O
growth	O
phase	O
-	O
dependent	O
expression	O
of	O
the	O
lsrA	B
gene	O
,	O
encoding	O
levansucrase	B
of	O
Rahnella	O
aquatilis	O
.	O

Expression	O
of	O
the	O
lsrA	B
gene	O
from	O
Rahnella	O
aquatilis	O
,	O
encoding	O
levansucrase	B
,	O
is	O
tightly	O
regulated	O
by	O
the	O
growth	O
phase	O
of	O
the	O
host	O
cell	O
;	O
low	O
-	O
level	O
expression	O
was	O
observed	O
in	O
the	O
early	O
phase	O
of	O
cell	O
growth	O
,	O
but	O
expression	O
was	O
significantly	O
stimulated	O
in	O
the	O
late	O
phase	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
regulation	O
occurred	O
at	O
the	O
level	O
of	O
transcription	O
.	O

The	O
promoter	O
region	O
was	O
identified	O
by	O
primer	O
extension	O
analysis	O
.	O

Two	O
opposite	O
genetic	O
elements	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
lsrA	B
expression	O
were	O
identified	O
upstream	O
of	O
the	O
lsrA	B
gene	O
:	O
the	O
lsrS	B
gene	O
and	O
the	O
lsrR	B
region	O
.	O

The	O
lsrS	B
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
70	O
amino	O
acid	O
residues	O
(	O
M	O
(	O
r	O
)	O
,	O
8,075	O
)	O
,	O
which	O
positively	O
activated	O
lsrA	B
expression	O
approximately	O
20	O
-	O
fold	O
in	O
a	O
growth	O
phase	O
-	O
dependent	O
fashion	O
.	O

The	O
cis	O
-	O
acting	O
lsrR	B
region	O
,	O
which	O
repressed	O
lsrA	B
expression	O
about	O
10	O
-	O
fold	O
,	O
was	O
further	O
narrowed	O
to	O
two	O
DNA	O
regions	O
by	O
deletion	O
analysis	O
.	O

The	O
concerted	O
action	O
of	O
two	O
opposite	O
regulatory	O
functions	O
resulted	O
in	O
the	O
growth	O
phase	O
-	O
dependent	O
activation	O
of	O
gene	O
expression	O
in	O
Escherichia	O
coli	O
independent	O
of	O
the	O
stationary	O
sigma	B
factor	I
sigma	B
(	I
S	I
)	I
.	O

Structural	O
and	O
functional	O
variation	O
within	O
the	O
alanine	O
-	O
rich	O
repetitive	O
domain	O
of	O
streptococcal	O
antigen	B
I	I
/	I
II	I
.	O

Members	O
of	O
the	O
antigen	B
I	I
/	I
II	I
family	I
of	O
cell	O
surface	O
proteins	O
are	O
highly	O
conserved	O
,	O
multifunctional	O
adhesins	B
that	O
mediate	O
interactions	O
of	O
oral	O
streptococci	O
with	O
other	O
oral	O
bacteria	O
,	O
with	O
cell	O
matrix	O
proteins	O
(	O
e.g.	O
,	O
type	B
I	I
collagen	I
)	O
,	O
and	O
with	O
salivary	O
glycoproteins	O
,	O
e.g.	O
,	O
gp340	B
.	O

The	O
interaction	O
of	O
gp340	B
(	O
formerly	O
designated	O
salivary	B
agglutinin	I
)	O
with	O
Streptococcus	O
mutans	O
requires	O
an	O
alanine	O
-	O
rich	O
repetitive	O
domain	O
(	O
A	O
region	O
)	O
of	O
antigen	B
I	I
/	I
II	I
that	O
is	O
highly	O
conserved	O
in	O
all	O
members	O
of	O
this	O
family	O
of	O
proteins	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
A	O
regions	O
from	O
the	O
two	O
Streptococcus	O
gordonii	O
M5	O
antigen	B
I	I
/	I
II	I
proteins	O
(	O
SspA	B
and	O
SspB	B
)	O
interact	O
differently	O
with	O
the	O
salivary	O
gp340	B
glycoprotein	O
and	O
appear	O
to	O
be	O
structurally	O
distinct	O
.	O

Recombinant	O
polypeptides	O
encompassing	O
the	O
A	O
region	O
of	O
SspA	B
or	O
from	O
a	O
highly	O
related	O
S.	O
mutans	O
antigen	B
I	I
/	I
II	I
protein	O
(	O
SpaP	B
)	O
competitively	O
inhibited	O
the	O
interaction	O
of	O
gp340	B
with	O
intact	O
S.	O
gordonii	O
and	O
S.	O
mutans	O
cells	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
an	O
A	O
region	O
polypeptide	O
from	O
SspB	B
was	O
inactive	O
,	O
and	O
furthermore	O
,	O
it	O
did	O
not	O
bind	O
to	O
purified	O
gp340	B
in	O
vitro	O
.	O

Circular	O
dichroism	O
spectra	O
suggested	O
that	O
all	O
three	O
polypeptides	O
were	O
highly	O
alpha	O
-	O
helical	O
and	O
may	O
form	O
coiled	O
-	O
coil	O
structures	O
.	O

However	O
,	O
the	O
A	O
region	O
of	O
SspB	B
underwent	O
a	O
conformational	O
change	O
and	O
exhibited	O
reduced	O
alpha	O
-	O
helical	O
structure	O
at	O
pH	O
8.5	O
,	O
whereas	O
the	O
A	O
region	O
polypeptides	O
from	O
SspA	B
and	O
SpaP	B
were	O
relatively	O
stable	O
under	O
these	O
conditions	O
.	O

Melt	O
curves	O
also	O
indicated	O
that	O
at	O
physiological	O
pH	O
,	O
the	O
A	O
region	O
of	O
SspB	B
lost	O
alpha	O
-	O
helical	O
structure	O
more	O
rapidly	O
than	O
that	O
of	O
SspA	B
or	O
SpaP	B
when	O
the	O
temperature	O
was	O
increased	O
from	O
10	O
to	O
40	O
degrees	O
C	O
.	O

Furthermore	O
,	O
the	O
SspB	B
A	O
region	O
polypeptide	O
denatured	O
completely	O
at	O
a	O
temperature	O
that	O
was	O
7	O
to	O
9	O
degrees	O
C	O
lower	O
than	O
that	O
required	O
for	O
the	O
A	O
region	O
polypeptide	O
of	O
SspA	B
or	O
SpaP	B
.	O

The	O
full	O
-	O
length	O
SspB	B
protein	O
and	O
the	O
three	O
A	O
region	O
peptides	O
migrated	O
in	O
native	O
gel	O
electrophoresis	O
and	O
column	O
chromatography	O
with	O
apparent	O
molecular	O
masses	O
that	O
were	O
approximately	O
2	O
-	O
to	O
2.5	O
-	O
fold	O
greater	O
than	O
their	O
predicted	O
molecular	O
masses	O
.	O

However	O
,	O
sedimentation	O
equilibrium	O
ultracentrifugation	O
data	O
showed	O
that	O
the	O
A	O
region	O
peptides	O
sedimented	O
as	O
monomers	O
,	O
suggesting	O
that	O
the	O
peptides	O
may	O
form	O
nonglobular	O
intramolecular	O
coiled	O
-	O
coil	O
structures	O
under	O
the	O
experimental	O
conditions	O
used	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
A	O
region	O
of	O
SspB	B
is	O
less	O
stable	O
than	O
the	O
corresponding	O
A	O
regions	O
of	O
SspA	B
and	O
SpaP	B
and	O
that	O
this	O
structural	O
difference	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
functional	O
variation	O
observed	O
in	O
their	O
interactions	O
with	O
salivary	O
gp340	B
.	O

Mast	O
cell	O
-	O
restricted	O
p70	O
Stat6	B
isoform	O
is	O
a	O
product	O
of	O
selective	O
proteolysis	O
.	O

Signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
Stat	I
)	I
-	I
6	I
is	O
the	O
principle	O
Stat	B
protein	O
activated	O
by	O
interleukin	B
(	I
IL	I
)	I
-	I
4	I
.	O

We	O
defined	O
a	O
role	O
for	O
IL-4	B
in	O
mast	O
cell	O
homeostasis	O
through	O
inhibiting	O
expression	O
of	O
Kit	B
and	O
F	B
(	I
c	I
)	I
epsilonRI	I
,	O
and	O
by	O
inducing	O
mast	O
cell	O
apoptosis	O
.	O

These	O
effects	O
required	O
Stat6	B
expression	O
.	O

A	O
molecular	O
mechanism	O
by	O
which	O
Stat6	B
directs	O
these	O
inhibitory	O
actions	O
in	O
BMMC	O
was	O
potentially	O
elucidated	O
by	O
the	O
discovery	O
of	O
a	O
carboxyl	O
-	O
truncated	O
Stat6	B
isoform	O
.	O

Expression	O
of	O
this	O
70kDa	O
isoform	O
was	O
unique	O
to	O
cultured	O
mast	O
cells	O
and	O
mast	O
cell	O
lines	O
.	O

Furthermore	O
,	O
this	O
isoform	O
lacked	O
a	O
carboxyl	O
-	O
transactivation	O
domain	O
,	O
suggesting	O
that	O
it	O
might	O
behave	O
as	O
a	O
dominant	O
negative	O
isoform	O
.	O

To	O
better	O
understand	O
this	O
truncated	O
Stat6	B
,	O
we	O
characterized	O
its	O
origins	O
.	O

Using	O
Western	O
blotting	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
,	O
we	O
assessed	O
BMMC	O
p70	O
Stat6	B
expression	O
using	O
standard	O
and	O
enhanced	O
protease	O
inhibitor	O
cocktails	O
.	O

These	O
experiments	O
demonstrated	O
that	O
p70	O
Stat6	B
is	O
derived	O
by	O
proteolysis	O
during	O
sample	O
preparation	O
,	O
and	O
has	O
no	O
cellular	O
correlate	O
.	O

While	O
some	O
Stat	B
family	I
members	O
are	O
known	O
to	O
exist	O
as	O
naturally	O
occurring	O
truncated	O
forms	O
,	O
p70	O
Stat6	B
does	O
not	O
appear	O
to	O
be	O
such	O
a	O
case	O
.	O

Instead	O
,	O
the	O
very	O
high	O
concentrations	O
of	O
proteases	B
released	O
during	O
mast	O
cell	O
lysis	O
result	O
in	O
selective	O
proteolysis	O
of	O
the	O
full	O
-	O
length	O
Stat6	B
,	O
with	O
p70	O
being	O
the	O
major	O
degradation	O
product	O
.	O

Apocytochrome	B
c	I
blocks	O
caspase-9	B
activation	O
and	O
Bax	B
-	O
induced	O
apoptosis	O
.	O

Complex	O
networks	O
of	O
signaling	O
pathways	O
control	O
the	O
apoptotic	O
response	O
and	O
,	O
therefore	O
,	O
cell	O
survival	O
.	O

However	O
,	O
these	O
networks	O
converge	O
on	O
a	O
common	O
machinery	O
,	O
of	O
which	O
the	O
caspase	B
cysteine	I
proteases	I
are	O
key	O
components	O
.	O

Diverse	O
apoptotic	O
stimuli	O
release	O
holocytochrome	B
c	I
from	O
mitochondria	O
,	O
allowing	O
holocytochrome	B
c	I
to	O
bind	O
apoptotic	B
protease	I
activating	I
factor-1	I
(	O
Apaf-1	B
)	O
,	O
which	O
in	O
turn	O
binds	O
caspase-9	B
both	O
activating	O
this	O
caspase	B
and	O
forming	O
an	O
Apaf-1	B
/	O
caspase-9	B
holoenzyme	O
.	O

Cytochrome	B
c	I
lacking	O
heme	O
(	O
the	O
apo	O
form	O
)	O
can	O
not	O
support	O
caspase	B
activation	O
,	O
although	O
the	O
reason	O
for	O
this	O
has	O
not	O
been	O
studied	O
.	O

Here	O
we	O
show	O
that	O
apocytochrome	B
c	I
still	O
binds	O
Apaf-1	B
and	O
that	O
it	O
can	O
block	O
holo	O
-	O
dependent	O
caspase	B
activation	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

In	O
addition	O
we	O
show	O
that	O
overexpression	O
of	O
apocytochrome	B
c	I
blocks	O
Bax	B
-	O
induced	O
apoptosis	O
in	O
cells	O
.	O

Thus	O
it	O
is	O
possible	O
to	O
modulate	O
cell	O
survival	O
by	O
interfering	O
with	O
the	O
Apaf-1	B
/	O
cytochrome	B
c	I
interaction	O
.	O

Given	O
the	O
key	O
role	O
played	O
by	O
Apaf-1	B
/	O
cytochrome	B
c	I
in	O
the	O
apoptotic	O
process	O
,	O
and	O
the	O
role	O
of	O
apoptosis	O
in	O
degenerative	O
disease	O
,	O
this	O
interaction	O
may	O
serve	O
as	O
a	O
novel	O
therapeutic	O
target	O
.	O

MdmX	B
is	O
a	O
RING	B
finger	I
ubiquitin	I
ligase	I
capable	O
of	O
synergistically	O
enhancing	O
Mdm2	B
ubiquitination	O
.	O

It	O
has	O
been	O
well	O
documented	O
that	O
Mdm2	B
and	O
its	O
homologue	O
MdmX	B
not	O
only	O
are	O
critical	O
negative	O
regulators	O
of	O
the	O
tumor	B
suppressor	I
p53	I
but	O
that	O
both	O
Mdm2	B
and	O
MdmX	B
interact	O
to	O
affect	O
the	O
function	O
of	O
the	O
other	O
.	O

The	O
mechanisms	O
through	O
which	O
these	O
effects	O
are	O
manifested	O
,	O
however	O
,	O
remain	O
unclear	O
.	O

Although	O
Mdm2	B
has	O
been	O
established	O
as	O
a	O
RING	B
finger	I
ubiquitin	I
ligase	I
,	O
MdmX	B
has	O
not	O
been	O
shown	O
to	O
possess	O
this	O
activity	O
despite	O
the	O
extensive	O
sequence	O
homology	O
between	O
their	O
respective	O
RING	O
finger	O
domains	O
.	O

Here	O
we	O
demonstrate	O
that	O
MdmX	B
acts	O
as	O
a	O
ubiquitin	B
ligase	I
in	O
vitro	O
,	O
being	O
capable	O
of	O
autoubiquitination	O
,	O
as	O
well	O
as	O
mediating	O
the	O
ubiquitination	O
of	O
p53	B
.	O

The	O
addition	O
of	O
Mdm2	B
to	O
in	O
vitro	O
ubiquitination	O
assays	O
containing	O
MdmX	B
results	O
in	O
a	O
synergistic	O
increase	O
of	O
ubiquitin	B
conjugation	O
.	O

Analysis	O
of	O
the	O
resulting	O
ubiquitin	B
conjugates	O
reveals	O
that	O
this	O
observed	O
synergy	O
reflects	O
an	O
increase	O
in	O
Mdm2	B
ubiquitination	O
.	O

This	O
study	O
also	O
suggests	O
that	O
ubiquitination	O
of	O
Mdm2	B
and	O
MdmX	B
may	O
not	O
serve	O
as	O
a	O
signal	O
for	O
degradation	O
,	O
as	O
we	O
show	O
that	O
each	O
are	O
capable	O
of	O
synthesizing	O
non	O
-	O
lysine	O
48	O
polyubiquitin	O
chains	O
and	O
,	O
in	O
fact	O
,	O
utilize	O
multiple	O
lysine	O
linkages	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
more	O
active	O
role	O
for	O
MdmX	B
in	O
the	O
Mdm2	B
-	O
MdmX	B
-	O
p53	B
regulatory	O
network	O
than	O
has	O
been	O
proposed	O
previously	O
.	O

Inhibition	O
of	O
Tat	B
-	O
mediated	O
transactivation	O
and	O
HIV-1	O
replication	O
by	O
human	O
anti	O
-	O
hCyclinT1	B
intrabodies	O
.	O

Human	O
immunodeficiency	O
virus	O
,	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
requires	O
the	O
interaction	O
of	O
Tat	B
protein	O
with	O
the	O
human	O
cyclinT1	B
(	O
hCyclinT1	B
)	O
subunit	O
of	O
the	O
positive	B
transcription	I
elongation	I
factor	I
(	I
P	I
-	I
TEFb	I
)	I
complex	I
,	O
which	O
then	O
cooperatively	O
binds	O
to	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
RNA	O
to	O
transactivate	O
HIV	O
transcription	O
.	O

In	O
this	O
report	O
,	O
a	O
non	O
-	O
immune	O
human	O
single	O
-	O
chain	O
antibody	O
(	O
sFv	O
)	O
phage	O
display	O
library	O
was	O
used	O
to	O
isolate	O
anti	O
-	O
hCyclinT1	B
sFvs	O
that	O
could	O
disrupt	O
hCyclinT1	B
-	O
Tat	B
interactions	O
.	O

The	O
N	O
-	O
terminal	O
272	O
residues	O
of	O
hCyclinT1	B
,	O
including	O
the	O
entire	O
cyclin	B
domains	O
and	O
the	O
Tat	B
.	O
TAR	O
recognition	O
motif	O
(	O
TRM	O
)	O
,	O
that	O
fully	O
support	O
Tat	B
transactivation	O
was	O
used	O
for	O
panning	O
,	O
and	O
of	O
the	O
five	O
unique	O
anti	O
-	O
hCyclinT1	B
sFvs	O
that	O
were	O
obtained	O
,	O
three	O
bound	O
to	O
the	O
cyclin	B
box	O
domains	O
and	O
two	O
bound	O
to	O
TRM	O
.	O

All	O
sFvs	O
could	O
be	O
expressed	O
as	O
intrabodies	O
at	O
high	O
levels	O
in	O
transiently	O
transfected	O
293	O
T	O
and	O
in	O
stable	O
Jurkat	O
and	O
SupT1	O
transfectants	O
and	O
could	O
specifically	O
co	O
-	O
immunoprecipitate	O
co	O
-	O
expressed	O
hCyclinT1	B
in	O
293	O
T	O
cells	O
with	O
varying	O
efficacy	O
without	O
disrupting	O
hCyclinT1	B
-	O
Cdk9	B
interactions	O
.	O

In	O
addition	O
,	O
two	O
sFv	O
clones	O
(	O
3R6	O
-	O
1	O
and	O
2R6	O
-	O
21	O
)	O
that	O
mapped	O
to	O
the	O
cyclin	B
box	O
domains	O
markedly	O
inhibited	O
Tat	B
-	O
mediated	O
transactivation	O
in	O
several	O
transiently	O
transfected	O
cell	O
lines	O
without	O
inhibiting	O
basal	O
transcription	O
or	O
inducing	O
apoptosis	O
.	O

When	O
HIV-1	O
challenge	O
studies	O
were	O
performed	O
on	O
stable	O
3R6	O
-	O
1	O
-	O
expressing	O
Jurkat	O
T	O
cells	O
,	O
near	O
complete	O
inhibition	O
of	O
viral	O
replication	O
was	O
obtained	O
at	O
a	O
low	O
challenge	O
dose	O
,	O
and	O
74	O
-	O
88	O
%	O
inhibition	O
to	O
HIV-1	O
replication	O
was	O
achieved	O
at	O
a	O
high	O
infection	O
dose	O
in	O
SupT1	O
cells	O
.	O

These	O
results	O
provide	O
proof	O
-	O
in	O
-	O
principle	O
that	O
anti	O
-	O
hCyclinT1	B
intrabodies	O
can	O
be	O
designed	O
to	O
block	O
HIV-1	O
replication	O
without	O
causing	O
cellular	O
toxicity	O
,	O
and	O
as	O
a	O
result	O
,	O
they	O
may	O
be	O
useful	O
agents	O
for	O
""""	O
intracellular	O
immunization	O
""""	O
-	O
based	O
gene	O
therapy	O
strategies	O
for	O
HIV	O
-	O
1	O
infection	O
/	O
AIDS	O
.	O

Furin	B
gene	O
(	O
fur	B
)	O
regulation	O
in	O
differentiating	O
human	O
megakaryoblastic	O
Dami	O
cells	O
:	O
involvement	O
of	O
the	O
proximal	O
GATA	O
recognition	O
motif	O
in	O
the	O
P1	O
promoter	O
and	O
impact	O
on	O
the	O
maturation	O
of	O
furin	B
substrates	O
.	O

The	O
convertase	O
furin	B
is	O
involved	O
in	O
the	O
maturation	O
of	O
key	O
growth	O
/	O
aggregation	O
mediators	O
synthesized	O
by	O
the	O
platelet	O
producers	O
,	O
megakaryocytes	O
,	O
but	O
the	O
regulation	O
of	O
furin	B
in	O
these	O
cells	O
remains	O
unknown	O
.	O

Computer	O
-	O
assisted	O
search	O
of	O
the	O
furin	B
promoter	O
sequence	O
revealed	O
multiple	O
potential	O
binding	O
motifs	O
for	O
GATA-1	O
,	O
suggesting	O
that	O
furin	B
is	O
expressed	O
and	O
regulated	O
in	O
these	O
cells	O
.	O

Using	O
megakaryoblastic	O
Dami	O
cells	O
,	O
we	O
observed	O
that	O
fur	O
mRNA	O
expression	O
increased	O
gradually	O
on	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
induced	O
differentiation	O
,	O
reaching	O
maximum	O
levels	O
(	O
8.3	O
-	O
fold	O
increase	O
)	O
at	O
10	O
days	O
.	O

Transient	O
transfections	O
with	O
P1	O
,	O
P1A	O
,	O
or	O
P1B	O
fur	B
-	O
LUC	O
-	O
promoter	O
constructs	O
revealed	O
that	O
in	O
Dami	O
cells	O
,	O
the	O
P1	O
promoter	O
is	O
the	O
strongest	O
and	O
the	O
most	O
sensitive	O
to	O
forced	O
expression	O
of	O
GATA-1	B
.	O

Coexpression	O
of	O
GATA-1	B
and	O
its	O
comodulator	O
,	O
Friend	B
of	I
GATA-1	I
(	O
FOG-1	B
)	O
,	O
resulted	O
in	O
a	O
cooperative	O
increase	O
in	O
P1	O
activity	O
.	O

Deletion	O
analysis	O
indicated	O
that	O
important	O
GATA-1	B
-	O
regulated	O
sequences	O
are	O
located	O
in	O
the	O
most	O
proximal	O
region	O
of	O
the	O
P1	O
promoter	O
.	O

Further	O
analysis	O
revealed	O
2	O
potential	O
GATA	O
-	O
binding	O
motifs	O
at	O
positions	O
-	O
66	O
and	O
+	O
62	O
.	O

Point	O
mutation	O
of	O
each	O
of	O
the	O
2	O
motifs	O
indicated	O
that	O
the	O
intactness	O
of	O
the	O
first	O
GATA	O
site	O
is	O
required	O
for	O
full	O
basal	O
and	O
GATA-1	B
-	O
stimulated	O
promoter	O
activity	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
furin	B
activity	O
through	O
gene	O
transfer	O
of	O
the	O
inhibitor	O
alpha1-AT	O
-	O
PDX	O
led	O
to	O
a	O
block	O
in	O
maturation	O
of	O
the	O
furin	B
substrates	O
transforming	B
growth	I
factor	I
-	I
beta1	I
and	O
platelet	B
-	I
derived	I
growth	I
factor	I
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
most	O
proximal	O
GATA	O
element	O
in	O
the	O
P1	O
promoter	O
is	O
needed	O
for	O
fur	B
gene	O
expression	O
in	O
megakaryoblastic	O
cells	O
.	O

They	O
also	O
suggest	O
that	O
proper	O
regulation	O
of	O
the	O
fur	B
gene	O
in	O
megakaryocytes	O
has	O
an	O
impact	O
on	O
the	O
activation	O
of	O
furin	B
substrates	O
involved	O
in	O
megakaryocyte	O
maturation	O
and	O
platelet	O
functions	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
sphingosine-1-phosphate	B
phosphohydrolase	I
,	O
hSPP2	B
.	O

Sphingosine	O
1-phosphate	O
(	O
S1P	O
)	O
is	O
a	O
bioactive	O
lipid	O
molecule	O
that	O
acts	O
as	O
both	O
an	O
extracellular	O
signaling	O
mediator	O
and	O
an	O
intracellular	O
second	O
messenger	O
.	O

S1P	O
is	O
synthesized	O
from	O
sphingosine	O
by	O
sphingosine	B
kinase	I
and	O
is	O
degraded	O
either	O
by	O
S1P	B
lyase	I
or	O
by	O
S1P	B
phosphohydrolase	I
.	O

Recently	O
,	O
mammalian	O
S1P	B
phosphohydrolase	I
(	O
SPP1	B
)	O
was	O
identified	O
and	O
shown	O
to	O
constitute	O
a	O
novel	O
lipid	B
phosphohydrolase	I
family	I
,	O
the	O
SPP	B
family	I
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
a	O
second	O
human	O
S1P	B
phosphohydrolase	I
,	O
SPP2	B
,	O
based	O
on	O
sequence	O
homology	O
to	O
human	O
SPP1	B
.	O

SPP2	B
exhibited	O
high	O
phosphohydrolase	B
activity	O
against	O
S1P	O
and	O
dihydrosphingosine	O
1-phosphate	O
.	O

The	O
dihydrosphingosine-1-phosphate	B
phosphohydrolase	I
activity	O
was	O
efficiently	O
inhibited	O
by	O
excess	O
S1P	O
but	O
not	O
by	O
lysophosphatidic	O
acid	O
,	O
phosphatidic	O
acid	O
,	O
or	O
glycerol	O
3-phosphate	O
,	O
indicating	O
that	O
SPP2	B
is	O
highly	O
specific	O
to	O
sphingoid	O
base	O
1	O
-	O
phosphates	O
.	O

Immunofluorescence	O
microscopic	O
analysis	O
demonstrated	O
that	O
SPP2	B
is	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

Although	O
the	O
enzymatic	O
properties	O
and	O
localization	O
of	O
SPP2	B
were	O
similar	O
to	O
those	O
of	O
SPP1	B
,	O
the	O
tissue	O
-	O
specific	O
expression	O
pattern	O
of	O
SPP2	B
was	O
different	O
from	O
that	O
of	O
SPP1	B
.	O

Thus	O
,	O
SPP2	B
is	O
another	O
member	O
of	O
the	O
SPP	B
family	I
that	O
may	O
play	O
a	O
role	O
in	O
attenuating	O
intracellular	O
S1P	O
signaling	O
.	O

Regulation	O
of	O
the	O
hydrogenase-4	B
operon	I
of	O
Escherichia	O
coli	O
by	O
the	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
transcriptional	O
activators	O
FhlA	B
and	O
HyfR	B
.	O

The	O
hyf	B
locus	O
(	O
hyfABCDEFGHIJ	B
-	O
hyfR	B
-	O
focB	B
)	O
of	O
Escherichia	O
coli	O
encodes	O
a	O
putative	O
10	O
-	O
subunit	O
hydrogenase	B
complex	O
(	O
hydrogenase	B
-	I
4	I
[	O
Hyf	B
]	O
)	O
;	O
a	O
potential	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
transcriptional	O
activator	O
,	O
HyfR	B
(	O
related	O
to	O
FhlA	B
)	O
;	O
and	O
a	O
putative	O
formate	B
transporter	I
,	O
FocB	B
(	O
related	O
to	O
FocA	B
)	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
physiological	O
role	O
of	O
the	O
Hyf	B
system	O
,	O
we	O
investigated	O
hyf	B
expression	O
by	O
using	O
a	O
hyfA	B
-	O
lacZ	B
transcriptional	O
fusion	O
.	O

This	O
work	O
revealed	O
that	O
hyf	B
is	O
induced	O
under	O
fermentative	O
conditions	O
by	O
formate	O
at	O
a	O
low	O
pH	O
and	O
in	O
an	O
FhlA	B
-	O
dependent	O
fashion	O
.	O

Expression	O
was	O
sigma	B
(	I
54	I
)	I
dependent	O
and	O
was	O
inhibited	O
by	O
HycA	B
,	O
the	O
negative	O
transcriptional	O
regulator	O
of	O
the	O
formate	O
regulon	O
.	O

Thus	O
,	O
hyf	B
expression	O
resembles	O
that	O
of	O
the	O
hyc	B
operon	I
.	O

Primer	O
extension	O
analysis	O
identified	O
a	O
transcriptional	O
start	O
site	O
30	O
bp	O
upstream	O
of	O
the	O
hyfA	B
structural	O
gene	O
,	O
with	O
appropriately	O
located	O
-	O
24	O
and	O
-	O
12	O
boxes	O
indicative	O
of	O
a	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
promoter	O
.	O

No	O
reverse	O
transcriptase	O
PCR	O
product	O
could	O
be	O
detected	O
for	O
hyfJ	B
-	O
hyfR	B
,	O
suggesting	O
that	O
hyfR	B
-	O
focB	B
may	O
be	O
independently	O
transcribed	O
from	O
the	O
rest	O
of	O
the	O
hyf	B
operon	I
.	O

Expression	O
of	O
hyf	B
was	O
strongly	O
induced	O
(	O
approximately	O
1,000-fold	O
)	O
in	O
the	O
presence	O
of	O
a	O
multicopy	O
plasmid	O
expressing	O
hyfR	B
from	O
a	O
heterologous	O
promoter	O
.	O

This	O
induction	O
was	O
dependent	O
on	O
low	O
pH	O
,	O
anaerobiosis	O
,	O
and	O
postexponential	O
growth	O
and	O
was	O
weakly	O
enhanced	O
by	O
formate	O
.	O

The	O
hyfR	B
-	O
expressing	O
plasmid	O
increased	O
fdhF	B
-	O
lacZ	B
transcription	O
just	O
twofold	O
but	O
did	O
not	O
influence	O
the	O
expression	O
of	O
hycB	B
-	O
lacZ	B
.	O

Interestingly	O
,	O
inactivation	O
of	O
the	O
chromosomal	O
hyfR	B
gene	O
had	O
no	O
effect	O
on	O
hyfA	B
-	O
lacZ	B
expression	O
.	O

Purified	O
HyfR	B
was	O
found	O
to	O
specifically	O
interact	O
with	O
the	O
hyf	B
promoter	O
/	O
operator	O
region	O
.	O

Inactivation	O
of	O
the	O
hyf	B
operon	I
had	O
no	O
discernible	O
effect	O
on	O
growth	O
under	O
the	O
range	O
of	O
conditions	O
tested	O
.	O

No	O
Hyf	B
-	O
derived	O
hydrogenase	B
or	O
formate	B
dehydrogenase	I
activity	O
could	O
be	O
detected	O
,	O
and	O
no	O
Ni	O
-	O
containing	O
protein	O
corresponding	O
to	O
HyfG	B
was	O
observed	O
.	O

Quantitative	O
analysis	O
of	O
human	O
kallikrein	B
gene	I
14	I
expression	O
in	O
breast	O
tumours	O
indicates	O
association	O
with	O
poor	O
prognosis	O
.	O

KLK14	B
(	O
formerly	O
known	O
as	O
KLK	B
-	I
L6	I
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
human	O
kallikrein	B
gene	I
family	I
.	O

This	O
family	O
harbours	O
several	O
genes	O
aberrantly	O
expressed	O
in	O
various	O
cancers	O
as	O
well	O
as	O
established	O
(	O
PSA	B
/	O
hK3	B
,	O
hK2	B
)	O
and	O
potential	O
(	O
hK6	B
,	O
hK10	B
)	O
cancer	O
markers	O
.	O

Similar	O
to	O
other	O
kallikrein	B
genes	O
,	O
KLK14	B
was	O
found	O
to	O
be	O
regulated	O
by	O
steroid	O
hormones	O
,	O
particularly	O
androgens	O
and	O
progestins	O
,	O
in	O
breast	O
and	O
ovarian	O
cancer	O
cell	O
lines	O
.	O

Preliminary	O
studies	O
indicated	O
that	O
KLK14	B
is	O
differentially	O
expressed	O
in	O
breast	O
,	O
ovarian	O
,	O
prostatic	O
and	O
testicular	O
tumours	O
.	O

Given	O
the	O
above	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
KLK14	B
expression	O
in	O
breast	O
cancer	O
.	O

We	O
studied	O
KLK14	B
expression	O
in	O
178	O
histologically	O
confirmed	O
epithelial	O
breast	O
carcinomas	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
correlated	O
with	O
clinicopathological	O
variables	O
(	O
tumour	O
stage	O
,	O
grade	O
,	O
histotype	O
etc	O
.	O
)	O
and	O
with	O
outcome	O
(	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
)	O
,	O
monitored	O
over	O
a	O
median	O
of	O
76	O
months	O
.	O

KLK14	B
mRNA	O
levels	O
ranged	O
from	O
0	O
to	O
1	O
,	O
219	O
arbitrary	O
units	O
in	O
breast	O
cancer	O
tissues	O
,	O
with	O
a	O
mean	O
+	O
/-	O
s.e	O
.	O
of	O
136	O
+	O
/	O
-	O
22	O
.	O

An	O
optimal	O
cutoff	O
value	O
of	O
40.5	O
arbitrary	O
units	O
was	O
selected	O
,	O
to	O
categorise	O
tumours	O
as	O
KLK14	B
-	O
positive	O
or	O
negative	O
.	O

Higher	O
concentrations	O
of	O
KLK14	B
mRNA	O
were	O
more	O
frequently	O
found	O
in	O
patients	O
with	O
advanced	O
stage	O
(	O
III	O
)	O
disease	O
(	O
P	O
=	O
0.032	O
)	O
.	O

No	O
statistically	O
significant	O
association	O
was	O
found	O
between	O
KLK14	B
and	O
the	O
other	O
clinicopathological	O
variables	O
.	O

KLK14	B
overexpression	O
was	O
found	O
to	O
be	O
a	O
significant	O
predictor	O
of	O
decreased	O
disease	O
-	O
free	O
survival	O
(	O
hazard	O
ratio	O
of	O
2.31	O
,	O
P	O
=	O
0.001	O
)	O
and	O
overall	O
survival	O
(	O
hazard	O
ratio	O
of	O
2.21	O
,	O
P	O
=	O
0.005	O
)	O
.	O

Cox	O
multivariate	O
analysis	O
indicated	O
that	O
KLK14	B
was	O
an	O
independent	O
prognostic	O
indicator	O
of	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
.	O

KLK14	B
also	O
has	O
independent	O
prognostic	O
value	O
in	O
subgroups	O
of	O
patients	O
with	O
a	O
tumour	O
size	O
<	O
/	O
=	O
2	O
cm	O
and	O
positive	O
nodal	O
,	O
oestrogen	B
receptor	I
and	O
progestin	B
receptor	I
status	O
.	O

We	O
conclude	O
that	O
KLK14	B
expression	O
,	O
as	O
assessed	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
is	O
an	O
independent	O
marker	O
of	O
unfavourable	O
prognosis	O
for	O
breast	O
cancer	O
.	O

Effects	O
of	O
dehydration	O
on	O
endocrine	O
regulation	O
of	O
the	O
electrolyte	O
and	O
fluid	O
balance	O
and	O
atrial	B
natriuretic	I
peptide	I
-	O
binding	O
sites	O
in	O
perinatally	O
malnourished	O
adult	O
male	O
rats	O
.	O

OBJECTIVE	O
:	O

The	O
first	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
,	O
under	O
basal	O
conditions	O
in	O
adult	O
male	O
rats	O
,	O
the	O
long	O
-	O
term	O
consequences	O
of	O
perinatal	O
maternal	O
food	O
restriction	O
on	O
the	O
plasma	O
concentrations	O
of	O
vasopressin	B
(	O
VP	B
)	O
,	O
aldosterone	O
and	O
atrial	B
natriuretic	I
peptide	I
(	O
ANP	B
)	O
and	O
on	O
plasma	O
renin	B
activity	O
(	O
PRA	O
)	O
.	O

Furthermore	O
,	O
under	O
these	O
same	O
conditions	O
,	O
the	O
hypothalamic	O
VP	B
gene	O
expression	O
as	O
well	O
as	O
the	O
density	O
(	O
B	O
(	O
max	O
)	O
)	O
,	O
affinity	O
(	O
K	O
(	O
d	O
)	O
)	O
and	O
gene	O
expression	O
of	O
ANP	B
receptors	I
were	O
determined	O
in	O
kidneys	O
and	O
adrenals	O
.	O

The	O
second	O
aim	O
of	O
this	O
work	O
was	O
to	O
examine	O
the	O
responsiveness	O
to	O
dehydration	O
in	O
perinatally	O
malnourished	O
rats	O
.	O

Thus	O
,	O
the	O
latter	O
parameters	O
were	O
studied	O
in	O
these	O
rats	O
after	O
72	O
h	O
water	O
deprivation	O
.	O

METHODS	O
:	O

This	O
study	O
was	O
conducted	O
on	O
4	O
-	O
Month	O
-	O
old	O
male	O
rats	O
from	O
mothers	O
exposed	O
to	O
50	O
%	O
food	O
restriction	O
(	O
FR50	O
)	O
during	O
the	O
last	O
week	O
of	O
gestation	O
and	O
lactation	O
and	O
on	O
age	O
-	O
matched	O
control	O
animals	O
(	O
C	O
)	O
.	O

At	O
this	O
stage	O
,	O
both	O
C	O
and	O
FR50	O
rats	O
were	O
killed	O
by	O
decapitation	O
between	O
0900	O
h	O
and	O
1000	O
h	O
in	O
order	O
to	O
determine	O
parameters	O
under	O
basal	O
conditions	O
or	O
after	O
72	O
h	O
water	O
deprivation	O
.	O

Plasma	O
VP	B
,	O
ANP	B
and	O
aldosterone	O
levels	O
and	O
PRA	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Hypothalamic	O
VP	B
gene	O
expression	O
was	O
determined	O
in	O
the	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nucleus	O
(	O
SON	O
)	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
B	O
(	O
max	O
)	O
and	O
K	O
(	O
d	O
)	O
values	O
of	O
ANP	B
receptors	I
were	O
evaluated	O
from	O
Scatchard	O
plots	O
.	O

ANP	B
receptor	I
gene	O
expression	O
was	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O

Under	O
basal	O
conditions	O
,	O
perinatal	O
malnutrition	O
reduced	O
body	O
weight	O
,	O
absolute	O
weight	O
of	O
kidneys	O
and	O
adrenals	O
,	O
and	O
haematocrit	O
.	O

Compared	O
with	O
control	O
rats	O
,	O
FR50	O
rats	O
had	O
significantly	O
greater	O
plasma	O
VP	B
and	O
aldosterone	O
levels	O
but	O
PRA	O
,	O
plasma	O
ANP	B
levels	O
,	O
plasma	O
osmolality	O
and	O
hypothalamic	O
VP	B
gene	O
expression	O
were	O
not	O
significantly	O
different	O
.	O

Perinatal	O
malnutrition	O
did	O
not	O
significantly	O
affect	O
glomerular	O
ANP	B
receptor	I
density	O
,	O
but	O
in	O
adrenals	O
it	O
decreased	O
both	O
B	O
(	O
max	O
)	O
and	O
K	O
(	O
d	O
)	O
values	O
of	O
ANP	B
-	I
B	I
receptors	I
(	O
biological	O
receptors	O
)	O
and	O
increased	O
B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
C	I
receptors	I
(	O
clearance	O
receptors	O
)	O
.	O

ANP	B
-	I
B	I
(	I
A	I
)	I
(	I
receptor	I
subtype	I
A	I
of	I
ANP	I
-	I
B	I
receptors	I
)	I
receptor	I
gene	O
expression	O
was	O
not	O
significantly	O
affected	O
,	O
whereas	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
was	O
enhanced	O
in	O
both	O
adrenals	O
and	O
kidneys	O
in	O
FR50	O
rats	O
.	O

After	O
72	O
h	O
dehydration	O
,	O
control	O
rats	O
showed	O
a	O
significant	O
rise	O
in	O
haematocrit	O
,	O
plasma	O
osmolality	O
,	O
PRA	O
,	O
circulating	O
levels	O
of	O
VP	B
and	O
aldosterone	O
and	O
VP	B
gene	O
expression	O
in	O
both	O
PVN	O
and	O
SON	O
but	O
showed	O
a	O
decrease	O
in	O
plasma	O
ANP	B
levels	O
.	O

B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
B	I
receptors	I
was	O
decreased	O
whereas	O
B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
C	I
receptors	I
was	O
enhanced	O
in	O
both	O
adrenals	O
and	O
kidneys	O
.	O

ANP	B
-	I
B	I
(	I
A	I
)	I
receptor	I
gene	O
expression	O
was	O
not	O
significantly	O
affected	O
in	O
either	O
kidneys	O
or	O
adrenals	O
in	O
dehydrated	O
control	O
rats	O
.	O

Similarly	O
,	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
was	O
unaffected	O
in	O
kidneys	O
whereas	O
it	O
was	O
significantly	O
enhanced	O
in	O
adrenals	O
.	O

In	O
FR50	O
rats	O
,	O
the	O
effects	O
of	O
water	O
deprivation	O
were	O
qualitatively	O
similar	O
to	O
those	O
reported	O
in	O
controls	O
concerning	O
plasma	O
parameters	O
except	O
for	O
plasma	O
VP	B
levels	O
which	O
tended	O
to	O
rise	O
(	O
not	O
significant	O
)	O
but	O
this	O
increase	O
was	O
only	O
very	O
slight	O
compared	O
with	O
controls	O
.	O

Moreover	O
,	O
unlike	O
controls	O
,	O
VP	B
gene	O
expression	O
in	O
both	O
PVN	O
and	O
SON	O
was	O
not	O
enhanced	O
after	O
dehydration	O
in	O
FR50	O
rats	O
.	O

In	O
kidneys	O
,	O
dehydrated	O
FR50	O
rats	O
,	O
like	O
controls	O
,	O
upregulated	O
ANP	B
-	I
C	I
receptors	I
,	O
but	O
they	O
were	O
unable	O
to	O
downregulate	O
ANP	B
-	I
B	I
receptors	I
.	O

In	O
adrenals	O
,	O
unlike	O
controls	O
,	O
FR50	O
rats	O
enhanced	O
ANP	B
-	I
B	I
receptor	I
density	O
whereas	O
they	O
decreased	O
both	O
ANP	B
-	I
C	I
receptor	I
density	O
and	O
expression	O
after	O
72	O
h	O
dehydration	O
.	O

Similar	O
to	O
controls	O
,	O
the	O
expression	O
of	O
ANP	B
-	I
B	I
(	I
A	I
)	I
receptors	I
in	O
both	O
kidneys	O
and	O
adrenals	O
as	O
well	O
as	O
the	O
expression	O
of	O
ANP	B
-	I
C	I
receptors	I
in	O
kidneys	O
,	O
were	O
unaffected	O
in	O
dehydrated	O
FR50	O
rats	O
.	O

CONCLUSION	O
:	O

Perinatal	O
malnutrition	O
had	O
long	O
-	O
lasting	O
effects	O
on	O
regulation	O
of	O
the	O
fluid	O
and	O
electrolyte	O
balance	O
under	O
basal	O
conditions	O
.	O

The	O
main	O
effects	O
were	O
a	O
significant	O
rise	O
in	O
circulating	O
levels	O
of	O
VP	B
and	O
aldosterone	O
,	O
and	O
changes	O
in	O
density	O
of	O
adrenal	O
ANP	B
-	O
binding	O
sites	O
and	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
in	O
both	O
adrenals	O
and	O
kidneys	O
.	O

Perinatal	O
malnutrition	O
also	O
affects	O
the	O
responsiveness	O
to	O
water	O
deprivation	O
with	O
alterations	O
in	O
both	O
hypothalamic	O
VP	B
gene	O
expression	O
and	O
regulation	O
of	O
ANP	B
-	O
binding	O
sites	O
.	O

Hodgkin	O
's	O
lymphoma	O
cell	O
lines	O
are	O
characterized	O
by	O
frequent	O
aberrations	O
on	O
chromosomes	O
2p	O
and	O
9p	O
including	O
REL	B
and	O
JAK2	B
.	O

Four	O
Hodgkin	O
's	O
lymphoma	O
cell	O
lines	O
(	O
KM	O
-	O
H2	O
,	O
HDLM-2	O
,	O
L428	O
,	O
L1236	O
)	O
were	O
analyzed	O
for	O
cytogenetic	O
aberrations	O
,	O
applying	O
multiplex	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
chromosome	O
banding	O
and	O
comparative	O
genomic	O
hybridization	O
.	O

Each	O
line	O
was	O
characterized	O
by	O
a	O
highly	O
heterogeneous	O
pattern	O
of	O
karyotypic	O
changes	O
with	O
a	O
large	O
spectrum	O
of	O
different	O
translocated	O
chromosomes	O
(	O
range	O
22	O
-	O
57	O
)	O
.	O

A	O
recurrent	O
finding	O
in	O
all	O
cell	O
lines	O
was	O
the	O
presence	O
of	O
chromosomal	O
rearrangements	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
2	O
involving	O
the	O
REL	B
oncogene	O
locus	O
.	O

Furthermore	O
,	O
multiple	O
translocated	O
copies	O
of	O
telomeric	O
chromosomal	O
segments	O
were	O
frequently	O
detected	O
.	O

This	O
resulted	O
in	O
a	O
copy	O
number	O
increase	O
of	O
putative	O
oncogenes	O
,	O
e.g.	O
,	O
JAK2	B
(	O
9p24	O
)	O
in	O
3	O
cell	O
lines	O
,	O
FGFR3	B
(	O
4p16	O
)	O
and	O
CCND2	B
(	O
12p13	O
)	O
in	O
2	O
cell	O
lines	O
as	O
well	O
as	O
MYC	B
(	O
8q24	O
)	O
in	O
1	O
cell	O
line	O
.	O

Our	O
data	O
confirm	O
previous	O
cytogenetic	O
results	O
from	O
primary	O
Hodgkin	O
's	O
tumors	O
suggesting	O
an	O
important	O
pathogenic	O
role	O
of	O
REL	B
and	O
JAK2	B
in	O
this	O
disease	O
.	O

In	O
addition	O
,	O
they	O
provide	O
evidence	O
for	O
a	O
novel	O
cytogenetic	O
pathomechanism	O
leading	O
to	O
increased	O
copy	O
numbers	O
of	O
putative	O
oncogenes	O
from	O
terminal	O
chromosomal	O
regions	O
,	O
most	O
probably	O
in	O
the	O
course	O
of	O
chromosomal	O
stabilization	O
by	O
telomeric	O
capture	O
.	O

Two	O
different	O
modes	O
of	O
transcription	O
repression	O
of	O
the	O
Escherichia	O
coli	O
acetate	B
operon	I
by	O
IclR	B
.	O

IclR	B
is	O
a	O
repressor	O
for	O
the	O
Escherichia	O
coli	O
aceBAK	B
operon	I
,	O
which	O
encodes	O
isocitrate	B
lyase	I
(	O
aceB	B
)	O
,	O
malate	B
synthase	I
(	O
aceA	B
)	O
and	O
isocitrate	B
dehydroge	I
-	I
nase	I
kinase	I
/	I
phosphorylase	I
(	O
aceK	B
)	O
in	O
the	O
glyoxylate	O
bypass	O
.	O

IclR	B
also	O
represses	O
the	O
expression	O
of	O
iclR	B
in	O
an	O
autogenous	O
manner	O
.	O

DNase	B
I	I
footprinting	O
and	O
in	O
vitro	O
transcription	O
assays	O
indicated	O
that	O
IclR	B
binds	O
to	O
an	O
IclR	B
box	O
(	O
-	O
21	O
to	O
+	O
14	O
)	O
,	O
which	O
overlaps	O
the	O
iclR	B
promoter	O
and	O
thus	O
competes	O
with	O
the	O
RNA	B
polymerase	I
for	O
DNA	O
binding	O
,	O
leading	O
to	O
transcription	O
repression	O
.	O

In	O
the	O
case	O
of	O
the	O
aceBAK	B
operon	I
,	O
IclR	B
binds	O
to	O
IclR	B
box	O
II	O
between	O
-	O
52	O
and	O
-	O
19	O
of	O
the	O
aceB	B
promoter	O
and	O
interferes	O
with	O
binding	O
of	O
the	O
RNA	B
polymerase	I
to	O
this	O
promoter	O
.	O

A	O
secondary	O
IclR	B
binding	O
site	O
(	O
IclR	B
box	O
I	O
)	O
was	O
identified	O
between	O
-	O
125	O
and	O
-	O
99	O
of	O
the	O
aceB	B
promoter	O
.	O

IclR	B
binds	O
to	O
this	O
IclR	B
box	O
I	O
even	O
after	O
formation	O
of	O
the	O
aceB	B
promoter	O
open	O
complex	O
and	O
,	O
moreover	O
,	O
induces	O
disassembly	O
of	O
the	O
open	O
complex	O
,	O
leading	O
to	O
repression	O
of	O
aceB	B
transcription	O
.	O

In	O
parallel	O
,	O
the	O
location	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	I
(	O
alphaCTD	O
)	O
on	O
DNA	O
is	O
shifted	O
close	O
to	O
the	O
IclR	B
box	O
I	O
,	O
indicating	O
that	O
direct	O
interaction	O
between	O
the	O
alphaCTD	O
and	O
the	O
IclR	B
box	O
I	O
-	O
associated	O
IclR	B
caused	O
the	O
repression	O
.	O

Transcriptional	O
repressor	O
germ	B
cell	I
-	I
less	I
(	O
GCL	B
)	O
and	O
barrier	B
to	I
autointegration	I
factor	I
(	O
BAF	B
)	O
compete	O
for	O
binding	O
to	O
emerin	B
in	O
vitro	O
.	O

Emerin	B
belongs	O
to	O
the	O
""""	O
LEM	O
domain	O
""""	O
family	O
of	O
nuclear	O
proteins	O
,	O
which	O
contain	O
a	O
characteristic	O
approximately	O
40	O
-	O
residue	O
LEM	O
motif	O
.	O

The	O
LEM	O
domain	O
mediates	O
direct	O
binding	O
to	O
barrier	B
to	I
autointegration	I
factor	I
(	O
BAF	B
)	O
,	O
a	O
conserved	O
10	O
-	O
kDa	O
chromatin	O
protein	O
essential	O
for	O
embryogenesis	O
in	O
Caenorhabditis	O
elegans	O
.	O

In	O
mammalian	O
cells	O
,	O
BAF	B
recruits	O
emerin	B
to	O
chromatin	O
during	O
nuclear	O
assembly	O
.	O

BAF	B
also	O
mediates	O
chromatin	O
decondensation	O
during	O
nuclear	O
assembly	O
.	O

The	O
LEM	O
domain	O
and	O
central	O
region	O
of	O
emerin	B
are	O
essential	O
for	O
binding	O
to	O
BAF	B
and	O
lamin	B
A	I
,	O
respectively	O
.	O

However	O
,	O
two	O
other	O
conserved	O
regions	O
of	O
emerin	B
lacked	O
ascribed	O
functions	O
,	O
suggesting	O
that	O
emerin	B
could	O
have	O
additional	O
partners	O
.	O

We	O
discovered	O
that	O
these	O
""""	O
unascribed	O
""""	O
domains	O
of	O
emerin	B
mediate	O
direct	O
binding	O
to	O
a	O
transcriptional	O
repressor	O
,	O
germ	B
cell	I
-	I
less	I
(	O
GCL	B
)	O
.	O

GCL	B
co	O
-	O
immunoprecipitates	O
with	O
emerin	O
from	O
HeLa	O
cells	O
.	O

We	O
determined	O
the	O
binding	O
affinities	O
of	O
emerin	B
for	O
GCL	B
,	O
BAF	B
,	O
and	O
lamin	B
A	I
and	O
analyzed	O
their	O
oligomeric	O
interactions	O
.	O

We	O
showed	O
that	O
emerin	B
forms	O
stable	O
complexes	O
with	O
either	O
lamin	B
A	I
plus	O
GCL	B
or	O
lamin	B
A	I
plus	O
BAF	B
.	O

Importantly	O
,	O
BAF	B
competed	O
with	O
GCL	B
for	O
binding	O
to	O
emerin	B
in	O
vitro	O
,	O
predicting	O
that	O
emerin	B
can	O
form	O
at	O
least	O
two	O
distinct	O
types	O
of	O
complexes	O
in	O
vivo	O
.	O

Loss	O
of	O
emerin	B
causes	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
,	O
a	O
tissue	O
-	O
specific	O
inherited	O
disease	O
that	O
affects	O
skeletal	O
muscles	O
,	O
major	O
tendons	O
,	O
and	O
the	O
cardiac	O
conduction	O
system	O
.	O

Although	O
GCL	B
alone	O
can	O
not	O
explain	O
the	O
disease	O
mechanism	O
,	O
our	O
results	O
strongly	O
support	O
gene	O
expression	O
models	O
for	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
by	O
showing	O
that	O
emerin	B
binds	O
directly	O
to	O
a	O
transcriptional	O
repressor	O
,	O
GCL	B
,	O
and	O
by	O
suggesting	O
that	O
emerin	B
-	O
repressor	O
complexes	O
might	O
be	O
regulated	O
by	O
BAF	B
.	O

Biochemical	O
roles	O
for	O
emerin	B
in	O
gene	O
expression	O
are	O
discussed	O
.	O

[	O
Mutation	O
analysis	O
of	O
KLF6	B
gene	O
in	O
human	O
nasopharyngeal	O
carcinomas	O
]	O

BACKGROUND	O
&	O
OBJECTIVE	O
:	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
cancers	O
in	O
South	O
China	O
and	O
Southeast	O
Asia	O
.	O

The	O
etiological	O
factor	O
is	O
believed	O
to	O
be	O
the	O
interaction	O
between	O
genetic	O
susceptibility	O
,	O
EBV	O
infection	O
and	O
environmental	O
factors	O
,	O
involved	O
in	O
the	O
multi	O
-	O
step	O
process	O
of	O
carcinogenesis	O
and	O
development	O
of	O
NPC	O
.	O

However	O
,	O
the	O
molecular	O
pathology	O
of	O
NPC	O
is	O
unclear	O
yet	O
.	O

Kruppel	B
-	I
like	I
factor	I
6	I
(	O
KLF6	B
)	O
is	O
a	O
ubiquitously	O
expressed	O
nuclear	O
transcription	B
factor	I
,	O
which	O
is	O
deleted	O
and/or	O
mutated	O
with	O
high	O
frequency	O
in	O
a	O
subset	O
of	O
prostate	O
cancer	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
KLF6	B
mutation	O
in	O
NPC	O
tumors	O
and	O
NPC	O
cell	O
lines	O
.	O

METHODS	O
:	O

Genomic	O
DNAs	O
from	O
19	O
NPC	O
tumor	O
biospies	O
and	O
3	O
NPC	O
cell	O
lines	O
were	O
used	O
in	O
mutation	O
detection	O
of	O
KLF6	B
coding	O
region	O
and	O
splice	O
sites	O
by	O
PCR	O
-	O
sequencing	O
.	O

100	O
chromosomes	O
from	O
50	O
random	O
healthy	O
individuals	O
were	O
used	O
as	O
control	O
.	O

RESULTS	O
:	O

In	O
3	O
of	O
19	O
NPC	O
tissues	O
,	O
3	O
different	O
mutations	O
(	O
Glu75Val	O
,	O
Ser136Arg	O
,	O
Arg243	O
Lys	O
)	O
in	O
KLF6	B
gene	O
were	O
found	O
by	O
PCR	O
-	O
sequencing	O
.	O

None	O
of	O
the	O
3	O
mutations	O
were	O
detected	O
in	O
the	O
50	O
random	O
healthy	O
individuals	O
.	O

CONCLUSION	O
:	O

KLF6	B
gene	O
may	O
be	O
involved	O
in	O
carcinogenesis	O
of	O
sporadic	O
NPC	O
.	O

BCR	B
/	O
ABL	B
alters	O
the	O
function	O
of	O
NK	O
cells	O
and	O
the	O
acquisition	O
of	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
decrease	O
in	O
function	O
during	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
progression	O
from	O
chronic	O
phase	O
to	O
blast	O
crisis	O
,	O
and	O
they	O
can	O
become	O
BCR	B
/	O
ABL	B
(	O
+	O
)	O
late	O
in	O
the	O
disease	O
course	O
.	O

To	O
study	O
this	O
altered	O
function	O
,	O
NK92	O
cells	O
were	O
transduced	O
with	O
the	O
BCR	B
/	O
ABL	B
oncogene	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
cells	O
,	O
which	O
died	O
when	O
deprived	O
of	O
interleukin	B
2	I
(	O
IL-2	B
)	O
,	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
proliferated	O
and	O
survived	O
indefinitely	O
in	O
the	O
absence	O
of	O
IL-2	B
.	O

BCR	B
/	O
ABL	B
also	O
decreased	O
the	O
natural	O
cytotoxicity	O
of	O
NK92	O
cells	O
against	O
K562	O
targets	O
,	O
without	O
affecting	O
IL-2	B
,	O
interferon	B
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
production	O
.	O

Although	O
the	O
ABL	B
-	O
specific	O
tyrosine	B
kinase	I
inhibitor	O
imatinib	O
mesylate	O
(	O
STI-571	O
)	O
had	O
no	O
effect	O
on	O
parental	O
NK92	O
cells	O
,	O
it	O
markedly	O
decreased	O
the	O
growth	O
and	O
survival	O
of	O
IL-2	B
-	O
independent	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
cell	O
line	O
,	O
serial	O
analysis	O
of	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
detected	O
small	O
populations	O
that	O
clonally	O
expressed	O
one	O
or	O
more	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
.	O

Unlike	O
the	O
decreased	O
natural	O
cytotoxicity	O
,	O
the	O
function	O
of	O
the	O
activating	O
CD158j	B
receptor	O
remained	O
intact	O
.	O

Southern	O
blotting	O
and	O
hybridization	O
with	O
an	O
enhanced	O
green	B
fluorescence	I
protein	I
(	O
eGFP	B
)	O
probe	O
showed	O
that	O
KIR	B
(	O
-	O
)	O
and	O
KIR	B
(	O
+	O
)	O
NK92	O
cells	O
were	O
all	O
derived	O
from	O
the	O
same	O
clone	O
,	O
suggesting	O
that	O
KIR	B
acquisition	O
remains	O
dynamic	O
at	O
the	O
maturational	O
stage	O
represented	O
by	O
the	O
NK92	O
cell	O
line	O
.	O

When	O
tested	O
in	O
primary	O
CD56	B
(	O
+	O
bright	O
)	O
NK	O
cells	O
,	O
p210	O
induced	O
partial	O
IL-2	B
-	O
independent	O
growth	O
and	O
increased	O
KIR	B
expression	O
similar	O
to	O
findings	O
in	O
NK92	O
cells	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
BCR	B
/	O
ABL	B
,	O
well	O
known	O
for	O
its	O
effects	O
on	O
the	O
myeloid	O
lineage	O
,	O
can	O
alter	O
the	O
function	O
of	O
lymphoid	O
cells	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
defect	O
in	O
innate	O
immunity	O
associated	O
with	O
CML	O
progression	O
.	O

Specific	O
stimulation	O
of	O
human	O
apurinic	B
/	I
apyrimidinic	I
endonuclease	I
by	O
heat	B
shock	I
protein	I
70	I
.	O

We	O
previously	O
demonstrated	O
the	O
stimulation	O
of	O
human	O
apurinic	B
/	I
apyrimidinic	I
endonuclease	I
1	I
(	O
HAP1	B
)	O
by	O
heat	B
shock	I
protein	I
70	I
(	O
HSP70	B
)	O
.	O

In	O
this	O
work	O
,	O
we	O
further	O
defined	O
the	O
functional	O
interaction	O
between	O
these	O
proteins	O
.	O

Digestion	O
of	O
HSP70	B
by	O
trypsin	B
released	O
48	O
and	O
43	O
kDa	O
amino	O
terminal	O
fragments	O
that	O
retained	O
the	O
ability	O
to	O
stimulate	O
HAP1	B
.	O

In	O
agreement	O
with	O
this	O
result	O
,	O
an	O
HSP70	B
N	O
-	O
terminal	O
deletion	O
mutant	O
protein	O
containing	O
amino	O
acids	O
1	O
-	O
385	O
was	O
comparable	O
to	O
the	O
full	O
-	O
length	O
protein	O
in	O
its	O
ability	O
to	O
enhance	O
HAP1	B
activity	O
.	O

HSP70	B
mutants	O
containing	O
carboxy	O
terminal	O
amino	O
acids	O
386	O
-	O
640	O
stimulated	O
HAP1	B
only	O
slightly	O
,	O
as	O
did	O
unrelated	O
proteins	O
.	O

These	O
results	O
implicate	O
the	O
amino	O
terminal	O
portion	O
of	O
HSP70	B
in	O
stimulating	O
the	O
activity	O
of	O
HAP1	B
.	O

Regulation	O
of	O
arginine	O
biosynthesis	O
in	O
the	O
psychropiezophilic	O
bacterium	O
Moritella	O
profunda	O
:	O
in	O
vivo	O
repressibility	O
and	O
in	O
vitro	O
repressor	O
-	O
operator	O
contact	O
probing	O
.	O

We	O
report	O
the	O
cloning	O
of	O
the	O
arginine	B
repressor	I
gene	O
from	O
the	O
psychropiezophilic	O
Gram	O
-	O
negative	O
bacterium	O
Moritella	O
profunda	O
,	O
the	O
purification	O
of	O
its	O
product	O
(	O
ArgR	B
(	O
Mp	O
)	O
)	O
,	O
the	O
identification	O
of	O
the	O
operator	O
in	O
the	O
bipolar	O
argECBFGH	B
(	I
A	I
)	I
operon	I
,	O
in	O
vivo	O
repressibility	O
studies	O
,	O
and	O
an	O
in	O
vitro	O
analysis	O
of	O
the	O
repressor	O
-	O
operator	O
interaction	O
,	O
including	O
binding	O
to	O
mutant	O
and	O
heterologous	O
arginine	O
operators	O
.	O

The	O
ArgR	B
(	O
Mp	O
)	O
subunit	O
shows	O
about	O
70	O
%	O
amino	O
acid	O
sequence	O
identity	O
with	O
Escherichia	O
coli	O
ArgR	B
(	O
ArgR	B
(	O
Ec	O
)	O
)	O
.	O

Binding	O
of	O
purified	O
hexameric	O
ArgR	B
(	O
Mp	O
)	O
to	O
the	O
control	O
region	O
of	O
the	O
divergent	O
operon	O
proved	O
to	O
be	O
arginine	O
-	O
dependent	O
,	O
sequence	O
-	O
specific	O
,	O
and	O
significantly	O
more	O
sensitive	O
to	O
heat	O
than	O
complex	O
formation	O
with	O
ArgR	B
(	O
Ec	O
)	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
E.coli	O
arginine	O
operators	O
very	O
efficiently	O
,	O
but	O
hardly	O
recognizes	O
the	O
operator	O
from	O
Bacillus	O
stearothermophilus	O
or	O
Thermotoga	O
maritima	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
to	O
a	O
single	O
site	O
overlapping	O
the	O
-	O
35	O
element	O
of	O
argC	B
(	O
P	O
)	O
,	O
but	O
not	O
argE	B
(	O
P	O
)	O
.	O

Therefore	O
,	O
the	O
arrangement	O
of	O
promoter	O
and	O
operator	O
sites	O
in	O
the	O
bipolar	O
argECBFGH	B
(	I
A	I
)	I
operon	I
of	O
M.profunda	O
is	O
very	O
different	O
from	O
the	O
organization	O
of	O
control	O
elements	O
in	O
the	O
bipolar	O
argECBH	B
operon	I
of	O
E.coli	O
,	O
where	O
both	O
promoters	O
overlap	O
the	O
common	O
operator	O
and	O
are	O
equally	O
repressible	O
.	O

We	O
demonstrate	O
that	O
M.profunda	O
argC	B
(	O
P	O
)	O
is	O
about	O
44	O
-	O
fold	O
repressible	O
,	O
whereas	O
argE	B
(	O
P	O
)	O
is	O
fully	O
constitutive	O
.	O

A	O
high	O
-	O
resolution	O
contact	O
map	O
of	O
the	O
ArgR	B
(	O
Mp	O
)	O
-	O
operator	O
interaction	O
was	O
established	O
by	O
enzymatic	O
and	O
chemical	O
footprinting	O
,	O
missing	O
contact	O
and	O
base	O
-	O
specific	O
premodification	O
binding	O
interference	O
studies	O
.	O

The	O
results	O
indicate	O
that	O
the	O
argC	B
operator	O
consists	O
of	O
two	O
ARG	B
box	O
-	O
like	O
sequences	O
(	O
18bp	O
imperfect	O
palindromes	O
)	O
separated	O
by	O
3bp	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
to	O
one	O
face	O
of	O
the	O
DNA	O
helix	O
and	O
establishes	O
contacts	O
with	O
two	O
major	O
groove	O
segments	O
and	O
the	O
intervening	O
minor	O
groove	O
of	O
each	O
ARG	B
box	O
,	O
whereas	O
the	O
minor	O
groove	O
segment	O
facing	O
the	O
repressor	O
at	O
the	O
center	O
of	O
the	O
operator	O
remains	O
largely	O
uncontacted	O
.	O

This	O
pattern	O
is	O
reminiscent	O
of	O
complex	O
formation	O
with	O
the	O
repressors	O
of	O
E.coli	O
and	O
B.stearothermophilus	O
,	O
and	O
suggests	O
that	O
each	O
ARG	B
box	O
is	O
contacted	O
by	O
two	O
ArgR	B
subunits	O
belonging	O
to	O
opposite	O
trimers	O
.	O

Moreover	O
,	O
the	O
premodification	O
interference	O
patterns	O
and	O
mutant	O
studies	O
clearly	O
indicate	O
that	O
the	O
inner	O
,	O
center	O
proximal	O
halves	O
of	O
each	O
ARG	B
box	O
in	O
the	O
M.profunda	O
argC	B
operator	O
are	O
more	O
important	O
for	O
complex	O
formation	O
and	O
repression	O
than	O
the	O
outermost	O
halves	O
.	O

A	O
close	O
inspection	O
of	O
sequence	O
conservation	O
and	O
of	O
single	O
base	O
-	O
pair	O
O	O
(	O
c	O
)	O
-	O
type	O
mutations	O
indicate	O
that	O
the	O
same	O
conclusion	O
can	O
be	O
generalized	O
to	O
E.coli	O
operators	O
.	O

A	O
eukaryotic	O
type	O
serine	B
/	I
threonine	I
kinase	I
and	I
phosphatase	I
in	O
Streptococcus	O
agalactiae	O
reversibly	O
phosphorylate	O
an	O
inorganic	B
pyrophosphatase	I
and	O
affect	O
growth	O
,	O
cell	O
segregation	O
,	O
and	O
virulence	O
.	O

Protein	O
phosphorylation	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
growth	O
,	O
division	O
,	O
and	O
differentiation	O
in	O
both	O
prokaryotes	O
and	O
eukaryotes	O
.	O

Signal	O
transduction	O
in	O
prokaryotes	O
was	O
previously	O
thought	O
to	O
occur	O
primarily	O
by	O
histidine	B
kinases	I
,	O
involved	O
in	O
two	O
-	O
component	O
signaling	O
pathways	O
.	O

Lately	O
,	O
bacterial	O
homologues	O
of	O
eukaryotic	O
-	O
type	O
serine	B
/	I
threonine	I
kinases	I
and	I
phosphatases	I
have	O
been	O
found	O
to	O
be	O
necessary	O
for	O
cellular	O
functions	O
such	O
as	O
growth	O
,	O
differentiation	O
,	O
pathogenicity	O
,	O
and	O
secondary	O
metabolism	O
.	O

The	O
Gram	O
-	O
positive	O
bacteria	O
Streptococcus	O
agalactiae	O
(	O
group	O
B	O
streptococci	O
,	O
GBS	O
)	O
is	O
an	O
important	O
human	O
pathogen	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
eukaryotic	O
-	O
type	O
serine	B
/	I
threonine	I
protein	I
kinase	I
(	O
Stk1	B
)	O
and	O
its	O
cognate	O
phosphatase	B
(	O
Stp1	B
)	O
in	O
GBS	O
.	O

Biochemical	O
assays	O
revealed	O
that	O
Stk1	B
has	O
kinase	B
activity	O
and	O
localizes	O
to	O
the	O
membrane	O
and	O
that	O
Stp1	B
is	O
a	O
soluble	O
protein	O
with	O
manganese	O
-	O
dependent	O
phosphatase	B
activity	O
on	O
Stk1	B
.	O

Mutations	O
in	O
these	O
genes	O
exhibited	O
pleiotropic	O
effects	O
on	O
growth	O
,	O
virulence	O
,	O
and	O
cell	O
segregation	O
of	O
GBS	O
.	O

Complementation	O
of	O
these	O
mutations	O
restored	O
the	O
wild	O
type	O
phenotype	O
linking	O
these	O
genes	O
to	O
the	O
regulation	O
of	O
various	O
cellular	O
processes	O
in	O
GBS	O
.	O

In	O
vitro	O
phosphorylation	O
of	O
cell	O
extracts	O
from	O
wild	O
type	O
and	O
mutant	O
strains	O
revealed	O
that	O
Stk1	B
is	O
essential	O
for	O
phosphorylation	O
of	O
six	O
GBS	O
proteins	O
.	O

We	O
have	O
identified	O
the	O
predominant	O
endogenous	O
substrate	O
of	O
both	O
Stk1	B
and	O
Stp1	B
as	O
a	O
manganese	B
-	I
dependent	I
inorganic	I
pyrophosphatase	I
(	O
PpaC	B
)	O
by	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
.	O

These	O
results	O
suggest	O
that	O
these	O
eukaryotic	O
-	O
type	O
enzymes	O
regulate	O
pyrophosphatase	B
activity	O
and	O
other	O
cellular	O
functions	O
of	O
S.	O
agalactiae	O
.	O

Ubiquitin	B
-	O
proteasome	O
-	O
dependent	O
muscle	O
proteolysis	O
responds	O
slowly	O
to	O
insulin	B
release	O
and	O
refeeding	O
in	O
starved	O
rats	O
.	O

The	O
central	O
role	O
of	O
the	O
ubiquitin	B
-	O
proteasome	O
system	O
in	O
the	O
loss	O
of	O
skeletal	O
muscle	O
protein	O
in	O
many	O
wasting	O
conditions	O
has	O
been	O
well	O
established	O
.	O

However	O
,	O
it	O
is	O
unclear	O
what	O
factors	O
are	O
responsible	O
for	O
the	O
suppression	O
of	O
this	O
system	O
during	O
periods	O
of	O
protein	O
gain	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
these	O
studies	O
was	O
to	O
examine	O
the	O
short	O
-	O
term	O
effects	O
of	O
insulin	B
release	O
and	O
nutrients	O
on	O
skeletal	O
muscle	O
protein	O
turnover	O
in	O
young	O
rats	O
starved	O
for	O
48	O
h	O
,	O
and	O
then	O
infused	O
intravenously	O
with	O
amino	O
acids	O
(	O
AA	O
)	O
,	O
or	O
fed	O
an	O
oral	O
diet	O
.	O

Forty	O
-	O
eight	O
hours	O
of	O
starvation	O
(	O
i.e.	O
prolonged	O
starvation	O
in	O
young	O
rats	O
)	O
decreased	O
muscle	O
protein	O
synthesis	O
and	O
increased	O
proteasome	O
-	O
dependent	O
proteolysis	O
.	O

Four	O
-	O
hour	O
AA	O
infusion	O
and	O
4	O
h	O
of	O
refeeding	O
increased	O
plasma	O
insulin	B
release	O
and	O
AA	O
concentrations	O
,	O
and	O
stimulated	O
muscle	O
protein	O
synthesis	O
,	O
but	O
had	O
no	O
effect	O
on	O
either	O
total	O
or	O
proteasome	O
-	O
dependent	O
proteolysis	O
,	O
despite	O
decreased	O
plasma	O
corticosterone	O
concentrations	O
.	O

Both	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
and	O
the	O
rate	O
of	O
ubiquitination	O
of	O
muscle	O
proteins	O
were	O
not	O
suppressed	O
until	O
10	O
h	O
of	O
refeeding	O
.	O

The	O
temporal	O
response	O
of	O
these	O
two	O
measurements	O
correlated	O
with	O
the	O
normalised	O
expression	O
of	O
the	O
14	O
-	O
kDa	O
E2	O
(	O
a	O
critical	O
enzyme	O
in	O
substrate	O
ubiquitination	O
in	O
muscle	O
)	O
and	O
the	O
expression	O
of	O
the	O
MSS1	B
subunit	O
of	O
the	O
19S	B
regulatory	I
complex	I
of	O
the	O
26S	O
proteasome	O
.	O

In	O
contrast	O
,	O
the	O
starvation	O
-	O
induced	O
increase	O
in	O
mRNA	O
levels	O
for	O
20S	O
proteasome	O
subunits	O
was	O
normalised	O
by	O
refeeding	O
within	O
24	O
h	O
in	O
muscle	O
,	O
and	O
6	O
h	O
in	O
jejunum	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
unlike	O
protein	O
synthesis	O
,	O
skeletal	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
is	O
not	O
acutely	O
responsive	O
in	O
vivo	O
to	O
insulin	B
,	O
AA	O
,	O
and/or	O
nutrient	O
intake	O
in	O
refed	O
starved	O
rats	O
.	O

This	O
suggests	O
that	O
distinct	O
and	O
perhaps	O
independent	O
mechanisms	O
are	O
responsible	O
for	O
the	O
nutrient	O
-	O
dependent	O
regulation	O
of	O
protein	O
synthesis	O
and	O
ubiquitin	B
-	O
proteasome	O
-	O
dependent	O
proteolysis	O
following	O
a	O
prolonged	O
period	O
of	O
catabolism	O
.	O

Furthermore	O
,	O
factors	O
other	O
than	O
the	O
expression	O
of	O
ubiquitin	B
-	O
proteasome	O
pathway	O
components	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
suppression	O
of	O
skeletal	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
by	O
nutrition	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
a	O
mitochondrial	O
gene	O
cluster	O
encoding	O
cytochrome	B
C	I
oxidase	I
subunit	I
III	I
from	O
Trichoderma	O
pseudokoningii	O
.	O

A	O
mitochondrial	O
gene	O
cluster	O
encoding	O
cytochrome	B
c	I
oxidase	I
subunit	I
III	I
(	O
COX3	B
)	O
,	O
an	O
ORF	O
(	O
called	O
ORF250	O
)	O
similar	O
to	O
NADH	B
dehydrogenase	I
subunit	I
VI	I
(	O
ND6	B
)	O
,	O
ten	O
tRNA	O
molecules	O
,	O
partial	O
rRNA	O
small	O
subunit	O
and	O
rRNA	O
large	O
subunit	O
from	O
Trichoderma	O
pseudokoningii	O
S38	O
was	O
cloned	O
and	O
sequenced	O
.	O

These	O
genes	O
are	O
tandemly	O
clustered	O
on	O
the	O
mitochondrial	O
genome	O
of	O
Trichoderma	O
pseudokoningii	O
S38	O
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
cytochrome	B
C	I
oxidase	I
subunits	I
III	I
exhibited	O
high	O
degree	O
of	O
similarity	O
to	O
sequences	O
from	O
Hypocrea	O
jecorina	O
,	O
Verticillium	O
lecanii	O
,	O
Podospora	O
anserine	O
,	O
Neurospora	O
crassa	O
and	O
Magnaporthe	O
grisea	O
(	O
99	O
,	O
90	O
,	O
84	O
,	O
82	O
and	O
79	O
%	O
identity	O
,	O
respectively	O
)	O
.	O

Prediction	O
of	O
transmembrane	O
helices	O
revealed	O
that	O
COX3	B
was	O
a	O
transmembrane	O
protein	O
.	O

Northern	O
dot	O
blot	O
analysis	O
showed	O
that	O
the	O
cytochrome	B
c	I
oxidase	I
subunits	I
III	I
gene	O
we	O
had	O
cloned	O
is	O
actively	O
transcribed	O
in	O
the	O
T.	O
pseudokoningii	O
mitochondria	O
.	O

Targeting	O
tuberculosis	O
and	O
malaria	O
through	O
inhibition	O
of	O
Enoyl	B
reductase	I
:	O
compound	O
activity	O
and	O
structural	O
data	O
.	O

Tuberculosis	O
and	O
malaria	O
together	O
result	O
in	O
an	O
estimated	O
5	O
million	O
deaths	O
annually	O
.	O

The	O
spread	O
of	O
multidrug	O
resistance	O
in	O
the	O
most	O
pathogenic	O
causative	O
agents	O
,	O
Mycobacterium	O
tuberculosis	O
and	O
Plasmodium	O
falciparum	O
,	O
underscores	O
the	O
need	O
to	O
identify	O
active	O
compounds	O
with	O
novel	O
inhibitory	O
properties	O
.	O

Although	O
genetically	O
unrelated	O
,	O
both	O
organisms	O
use	O
a	O
type	B
II	I
fatty	I
-	I
acid	I
synthase	I
system	O
.	O

Enoyl	B
acyl	I
carrier	I
protein	I
reductase	I
(	O
ENR	B
)	O
,	O
a	O
key	O
type	O
II	O
enzyme	O
,	O
has	O
been	O
repeatedly	O
validated	O
as	O
an	O
effective	O
antimicrobial	O
target	O
.	O

Using	O
high	O
throughput	O
inhibitor	O
screens	O
with	O
a	O
combinatorial	O
library	O
,	O
we	O
have	O
identified	O
two	O
novel	O
classes	O
of	O
compounds	O
with	O
activity	O
against	O
the	O
M.	O
tuberculosis	O
and	O
P.	O
falciparum	O
enzyme	O
(	O
referred	O
to	O
as	O
InhA	O
and	O
PfENR	O
,	O
respectively	O
)	O
.	O

The	O
crystal	O
structure	O
of	O
InhA	O
complexed	O
with	O
NAD	O
+	O
and	O
one	O
of	O
the	O
inhibitors	O
was	O
determined	O
to	O
elucidate	O
the	O
mode	O
of	O
binding	O
.	O

Structural	O
analysis	O
of	O
InhA	O
with	O
the	O
broad	O
spectrum	O
antimicrobial	O
triclosan	O
revealed	O
a	O
unique	O
stoichiometry	O
where	O
the	O
enzyme	O
contained	O
either	O
a	O
single	O
triclosan	O
molecule	O
,	O
in	O
a	O
configuration	O
typical	O
of	O
other	O
bacterial	O
ENR	B
:	O
triclosan	O
structures	O
,	O
or	O
harbored	O
two	O
triclosan	O
molecules	O
bound	O
to	O
the	O
active	O
site	O
.	O

Significantly	O
,	O
these	O
compounds	O
do	O
not	O
require	O
activation	O
and	O
are	O
effective	O
against	O
wild	O
-	O
type	O
and	O
drug	O
-	O
resistant	O
strains	O
of	O
M.	O
tuberculosis	O
and	O
P.	O
falciparum	O
.	O

Moreover	O
,	O
they	O
provide	O
broader	O
chemical	O
diversity	O
and	O
elucidate	O
key	O
elements	O
of	O
inhibitor	O
binding	O
to	O
InhA	O
for	O
subsequent	O
chemical	O
optimization	O
.	O

The	O
2b	B
protein	I
of	O
cucumoviruses	O
has	O
a	O
role	O
in	O
promoting	O
the	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
pseudorecombinant	O
viruses	O
.	O

Pseudorecombinant	O
viruses	O
(	O
i.e.	O
,	O
those	O
containing	O
a	O
reassorted	O
genome	O
of	O
closely	O
related	O
multipartite	O
viruses	O
)	O
are	O
often	O
not	O
as	O
competitive	O
as	O
the	O
parental	O
viruses	O
.	O

The	O
role	O
of	O
the	O
2b	B
gene	O
in	O
hypervirulence	O
and	O
maintenance	O
of	O
a	O
progressive	O
infection	O
was	O
assessed	O
in	O
a	O
pseudorecombinant	O
virus	O
formed	O
between	O
RNAs	O
1	O
plus	O
2	O
of	O
Cucumber	O
mosaic	O
virus	O
(	O
CMV	O
)	O
and	O
RNA	O
3	O
of	O
Tomato	O
aspermy	O
virus	O
(	O
TAV	O
)	O
.	O

The	O
presence	O
of	O
RNA	O
3	O
of	O
TAV	O
was	O
found	O
to	O
affect	O
the	O
level	O
of	O
RNA	O
accumulation	O
but	O
not	O
the	O
level	O
of	O
virulence	O
.	O

By	O
contrast	O
,	O
the	O
2b	B
genes	O
of	O
both	O
TAV	O
and	O
a	O
hypervirulent	O
strain	O
of	O
CMV	O
(	O
WAII	O
-	O
CMV	O
)	O
were	O
found	O
to	O
affect	O
the	O
virulence	O
of	O
the	O
pseudorecombinant	O
viruses	O
but	O
not	O
the	O
levels	O
of	O
viral	O
RNA	O
accumulation	O
.	O

The	O
2b	B
gene	O
rather	O
than	O
the	O
overlapping	O
open	O
reading	O
frame	O
encoding	O
the	O
C	O
-	O
terminal	O
41	O
amino	O
acids	O
of	O
2a	B
protein	I
of	O
the	O
corresponding	O
virus	O
was	O
found	O
to	O
be	O
essential	O
for	O
promoting	O
infection	O
of	O
the	O
pseudorecombinant	O
viruses	O
in	O
planta	O
.	O

However	O
,	O
the	O
2b	B
gene	O
was	O
not	O
essential	O
for	O
replication	O
of	O
pseudorecombinant	O
viruses	O
containing	O
CMV	O
RNAs	O
1	O
plus	O
2	O
and	O
TAV	O
RNA	O
3	O
.	O

These	O
results	O
indicate	O
that	O
the	O
2b	B
protein	I
is	O
involved	O
in	O
promoting	O
the	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
the	O
pseudorecombinant	O
viruses	O
.	O

These	O
data	O
also	O
suggest	O
the	O
existence	O
of	O
specific	O
interaction	O
between	O
the	O
TAV	O
2b	B
protein	I
and	O
either	O
RNA	O
3	O
or	O
its	O
encoded	O
proteins	O
,	O
which	O
may	O
be	O
critical	O
for	O
promoting	O
or	O
maintaining	O
infection	O
or	O
both	O
.	O

ArhGAP15	B
,	O
a	O
novel	O
human	O
RacGAP	B
protein	O
with	O
GTPase	B
binding	O
property	O
.	O

We	O
have	O
previously	O
described	O
a	O
partial	O
cDNA	O
sequence	O
encoding	O
a	O
RhoGAP	B
protein	O
,	O
GAP25	B
that	O
is	O
homologous	O
to	O
the	O
recently	O
reported	O
ArhGAP9	B
and	O
ArhGAP12	B
.	O

We	O
now	O
describe	O
a	O
related	O
new	O
member	O
ArhGAP15	B
that	O
shares	O
a	O
number	O
of	O
domain	O
similarities	O
,	O
including	O
a	O
pleckstrin	B
homology	O
(	O
PH	O
)	O
domain	O
,	O
a	O
RhoGAP	B
domain	O
and	O
a	O
novel	O
motif	O
N	O
-	O
terminal	O
to	O
the	O
GAP	B
domain	O
.	O

This	O
novel	O
motif	O
was	O
found	O
to	O
be	O
responsible	O
for	O
nucleotide	O
-	O
independent	O
Rac1	B
binding	O
.	O

Using	O
swop	O
mutants	O
of	O
Rac	B
/	O
Cdc42	B
,	O
we	O
have	O
established	O
that	O
the	O
binding	O
is	O
through	O
the	O
C	O
-	O
terminal	O
half	O
of	O
Rac1	B
.	O

The	O
GAP	B
domain	O
of	O
ArhGAP15	B
showed	O
specificity	O
towards	O
Rac1	B
in	O
vitro	O
.	O

The	O
PH	O
domain	O
is	O
required	O
for	O
ArhGAP15	B
to	O
localize	O
to	O
cell	O
periphery	O
and	O
over	O
-	O
expression	O
of	O
the	O
full	O
-	O
length	O
ArhGAP15	B
,	O
but	O
not	O
the	O
mutant	O
with	O
a	O
partial	O
deletion	O
of	O
the	O
PH	O
domain	O
,	O
resulted	O
in	O
an	O
increase	O
in	O
actin	B
stress	O
fibers	O
and	O
cell	O
contraction	O
.	O

These	O
morphological	O
effects	O
can	O
be	O
attenuated	O
by	O
the	O
co	O
-	O
expression	O
of	O
dominant	O
negative	O
Rac1	B
(	O
N17	O
)	O
.	O

HeLa	O
cells	O
expressing	O
ArhGAP15	B
were	O
also	O
resistant	O
to	O
phorbol	O
myristatate	O
acetate	O
treatment	O
,	O
suggesting	O
that	O
ArhGAP15	B
is	O
a	O
potential	O
regulator	O
of	O
Rac1	B
.	O

Overexpression	O
of	O
the	O
tumor	O
autocrine	B
motility	I
factor	I
receptor	I
Gp78	I
,	O
a	O
ubiquitin	B
protein	I
ligase	I
,	O
results	O
in	O
increased	O
ubiquitinylation	O
and	O
decreased	O
secretion	O
of	O
apolipoprotein	B
B100	I
in	O
HepG2	O
cells	O
.	O

Apolipoprotein	B
B100	I
(	O
apoB	B
)	O
is	O
a	O
large	O
(	O
520	O
-	O
kDa	O
)	O
complex	O
secretory	O
protein	O
;	O
its	O
secretion	O
is	O
regulated	O
posttranscriptionally	O
by	O
several	O
degradation	O
pathways	O
.	O

The	O
best	O
described	O
of	O
these	O
degradative	O
processes	O
is	O
co	O
-	O
translational	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
nascent	O
apoB	B
,	O
involving	O
the	O
70	B
-	I
and	I
90	I
-	I
kDa	I
heat	I
shock	I
proteins	I
and	O
the	O
multiple	O
components	O
of	O
the	O
proteasomal	O
pathway	O
.	O

Ubiquitinylation	O
involves	O
several	O
proteins	O
,	O
including	O
ligases	B
called	O
E3s	B
,	O
that	O
coordinate	O
the	O
covalent	O
binding	O
of	O
ubiquitin	B
to	O
target	O
proteins	O
.	O

The	O
recent	O
discovery	O
that	O
tumor	O
autocrine	B
motility	I
factor	I
receptor	I
,	O
also	O
known	O
as	O
gp78	B
,	O
is	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
associated	O
E3	B
,	O
raised	O
the	O
possibility	O
that	O
this	O
E3	B
might	O
be	O
involved	O
in	O
the	O
ER	O
-	O
associated	O
degradation	O
of	O
nascent	O
apoB	B
.	O

In	O
a	O
series	O
of	O
experiments	O
in	O
HepG2	O
cells	O
,	O
we	O
demonstrated	O
that	O
overexpression	O
of	O
gp78	B
was	O
sufficient	O
for	O
increased	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
apoB	B
,	O
with	O
reduced	O
secretion	O
of	O
apoB	B
-	O
lipoproteins	O
.	O

This	O
action	O
of	O
gp78	B
was	O
specific	O
:	O
overexpression	O
of	O
the	O
protein	O
did	O
not	O
affect	O
secretion	O
of	O
either	O
albumin	B
or	O
apolipoprotein	B
AI	I
.	O

Furthermore	O
,	O
overexpression	O
of	O
a	O
cytosolic	O
E3	B
,	I
Itch	I
,	O
had	O
no	O
effect	O
on	O
apoB	B
secretion	O
.	O

Finally	O
,	O
using	O
an	O
in	O
vitro	O
translation	O
system	O
,	O
we	O
demonstrated	O
that	O
gp78	B
led	O
to	O
increased	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
apoB48	B
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
an	O
ER	O
-	O
associated	O
protein	O
,	O
gp78	B
,	O
is	O
a	O
bona	O
fide	O
E3	B
ligase	I
in	O
the	O
apoB	B
ER	O
-	O
associated	O
degradation	O
pathway	O
.	O

Clinical	O
significance	O
of	O
antiphospholipid	O
protein	O
antibodies	O
.	O

Receiver	O
operating	O
characteristics	O
plot	O
analysis	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
utility	O
of	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
in	O
determining	O
the	O
strength	O
of	O
association	O
between	O
various	O
antiphospholipid	O
and	O
anti	O
-	O
protein	O
cofactor	O
antibodies	O
(	O
aPA	O
)	O
and	O
thrombosis	O
,	O
pregnancy	O
morbidity	O
,	O
and	O
thrombocytopenia	O
.	O

METHODS	O
:	O

Clinical	O
and	O
laboratory	O
variables	O
were	O
retrospectively	O
studied	O
in	O
204	O
patients	O
:	O
160	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
22	O
with	O
lupus	O
-	O
like	O
syndrome	O
(	O
SLE	O
-	O
LS	O
)	O
,	O
and	O
22	O
with	O
primary	O
antiphospholipid	O
syndrome	O
(	O
APS	O
)	O
.	O

Laboratory	O
evaluation	O
included	O
detection	O
of	O
lupus	O
anticoagulant	O
(	O
LAC	O
)	O
and	O
measurement	O
of	O
IgG	B
and	O
IgM	B
anticardiolipin	O
(	O
aCL	O
)	O
,	O
antiphosphatidylserine	O
(	O
aPS	O
)	O
,	O
antiphosphatidylinositol	O
(	O
aPI	O
)	O
,	O
anti	O
-	O
beta	B
2	I
glycoprotein	I
I	I
(	O
a	O
beta	B
2GPI	I
)	O
,	O
and	O
antiprothrombin	O
(	O
aPT	B
)	O
antibodies	O
.	O

ROC	O
plot	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
clinical	O
accuracy	O
of	O
aPA	O
tests	O
,	O
and	O
calculate	O
cut	O
-	O
off	O
values	O
which	O
best	O
associate	O
with	O
clinical	O
symptoms	O
typical	O
for	O
APS	O
.	O

RESULTS	O
:	O

The	O
LAC	O
was	O
associated	O
with	O
a	O
history	O
of	O
thrombosis	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
:	O
3.04	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.5	O
-	O
6.2	O
]	O
and	O
even	O
more	O
strongly	O
with	O
recurrent	O
fetal	O
loss	O
(	O
OR	O
:	O
8.7	O
;	O
95	O
%	O
CI	O
:	O
2.8	O
-	O
26.7	O
)	O
.	O

ROC	O
plot	O
analysis	O
revealed	O
that	O
the	O
most	O
accurate	O
test	O
for	O
thrombosis	O
was	O
aCL	O
IgG	B
(	O
ROC	O
-	O
derived	O
cutoff	O
value	O
>	O
17.2	O
GPL	O
;	O
OR	O
:	O
3.69	O
;	O
95	O
%	O
CI	O
:	O
1.8	O
-	O
7.4	O
)	O
,	O
for	O
recurrent	O
fetal	O
loss	O
,	O
aPI	O
IgG	B
[	O
>	O
22.1	O
theoretical	O
units	O
(	O
TU	O
)	O
;	O
OR	O
:	O
6.21	O
;	O
95	O
%	O
CI	O
:	O
2.1	O
-	O
18.5	O
]	O
,	O
closely	O
followed	O
by	O
aCL	O
IgG	B
and	O
a	O
beta	B
2GPI	I
IgG	B
,	O
and	O
for	O
thrombocytopenia	O
aPS	O
IgM	B
(	O
>	O
6.7	O
TU	O
;	O
OR	O
:	O
1.9	O
;	O
95	O
%	O
CI	O
:	O
1.04	O
-	O
3.4	O
)	O
.	O

Among	O
182	O
autoimmune	O
patients	O
(	O
SLE	O
+	O
SLE	O
-	O
LS	O
)	O
,	O
6.6	O
%	O
presented	O
clinical	O
symptoms	O
of	O
APS	O
without	O
classic	O
aPA	O
(	O
LAC	O
and/or	O
aCL	O
)	O
,	O
but	O
with	O
elevated	O
levels	O
of	O
antibodies	O
against	O
other	O
phospholipids	O
,	O
mainly	O
aPI	O
IgM	B
.	O

CONCLUSION	O
:	O

A	O
laboratory	O
that	O
evaluates	O
APS	O
patients	O
should	O
establish	O
its	O
own	O
threshold	O
values	O
for	O
aPA	O
tests	O
.	O

We	O
suggest	O
that	O
ROC	O
plot	O
analysis	O
is	O
a	O
valuable	O
tool	O
in	O
establishing	O
cutoff	O
values	O
.	O

LAC	O
and	O
aCL	O
determinations	O
seem	O
sufficient	O
for	O
the	O
majority	O
of	O
laboratories	O
.	O

However	O
,	O
in	O
specialized	O
centers	O
other	O
tests	O
should	O
be	O
available	O
to	O
detect	O
those	O
patients	O
with	O
clinical	O
symptoms	O
for	O
APS	O
but	O
who	O
are	O
positive	O
for	O
antiphospholipid	O
antibodies	O
other	O
than	O
aCL	O
and	O
the	O
LAC	O
.	O

MASE1	O
and	O
MASE2	O
:	O
two	O
novel	O
integral	O
membrane	O
sensory	O
domains	O
.	O

Escherichia	O
coli	O
proteins	O
YegE	B
and	O
YaiC	B
contain	O
N	O
-	O
terminal	O
integral	O
membrane	O
regions	O
,	O
followed	O
by	O
the	O
putative	O
diguanylate	B
cyclase	I
(	O
GGDEF	O
,	O
DUF1	O
)	O
domains	O
.	O

The	O
membrane	O
domains	O
of	O
these	O
proteins	O
,	O
named	O
MASE1	O
(	O
membrane	O
-	O
associated	O
sensor	O
)	O
and	O
MASE2	O
,	O
respectively	O
,	O
were	O
found	O
in	O
other	O
bacterial	O
signaling	O
proteins	O
,	O
such	O
as	O
histidine	B
kinases	I
(	O
MASE1	O
)	O
and	O
an	O
adenylate	B
cyclase	I
(	O
MASE2	O
)	O
.	O

Although	O
the	O
nature	O
of	O
the	O
signals	O
sensed	O
by	O
MASE1	O
and	O
MASE2	O
is	O
still	O
unknown	O
,	O
MASE1	O
-	O
containing	O
receptors	O
appear	O
to	O
play	O
important	O
roles	O
in	O
bacteria	O
,	O
including	O
iron	O
and/or	O
oxygen	O
sensing	O
by	O
hemerythrine	O
-	O
containing	O
proteins	O
in	O
the	O
sulfate	O
-	O
reducing	O
bacterium	O
Desulfovibrio	O
vulgaris	O
.	O

Origin	O
of	O
lipid	O
A	O
species	O
modified	O
with	O
4-amino-4-deoxy	O
-	O
L	O
-	O
arabinose	O
in	O
polymyxin	O
-	O
resistant	O
mutants	O
of	O
Escherichia	O
coli	O
.	O

An	O
aminotransferase	B
(	O
ArnB	B
)	O
that	O
generates	O
UDP-4-deoxyl	O
-	O
L	O
-	O
arabinose	O
.	O

In	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
,	O
addition	O
of	O
the	O
4-amino-4-deoxy	O
-	O
l	O
-	O
arabinose	O
(	O
l	O
-	O
Ara4N	O
)	O
moiety	O
to	O
the	O
phosphate	O
group	O
(	O
s	O
)	O
of	O
lipid	O
A	O
is	O
required	O
for	O
resistance	O
to	O
polymyxin	O
and	O
cationic	O
antimicrobial	O
peptides	O
.	O

We	O
have	O
proposed	O
previously	O
(	O
Breazeale	O
,	O
S.	O
D.	O
,	O
Ribeiro	O
,	O
A.	O
A.	O
,	O
and	O
Raetz	O
,	O
C.	O
R.	O
H.	O
(	O
2002	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
2886	O
-	O
2896	O
)	O
a	O
pathway	O
for	O
l	O
-	O
Ara4N	O
biosynthesis	O
that	O
begins	O
with	O
the	O
ArnA	O
-	O
catalyzed	O
C-4	O
""""	O
oxidation	O
and	O
C-6	O
""""	O
decarboxylation	O
of	O
UDP	O
-	O
glucuronic	O
acid	O
,	O
followed	O
by	O
the	O
C-4	O
""""	O
transamination	O
of	O
the	O
product	O
to	O
generate	O
the	O
novel	O
sugar	O
nucleotide	O
UDP	O
-	O
l	O
-	O
Ara4N	O
.	O

We	O
now	O
show	O
that	O
ArnB	B
(	O
PmrH	B
)	O
encodes	O
the	O
relevant	O
aminotransferase	B
.	O

ArnB	B
was	O
overexpressed	O
using	O
a	O
T7lac	O
promoter	O
-	O
driven	O
construct	O
and	O
shown	O
to	O
catalyze	O
the	O
reversible	O
transfer	O
of	O
the	O
amino	O
group	O
from	O
glutamate	O
to	O
the	O
acceptor	O
,	O
uridine	O
5'-	O
(	O
beta	O
-	O
l	O
-	O
threo	O
-	O
"pentapyranosyl-4""-ulose"	O
diphosphate	O
)	O
,	O
the	O
intermediate	O
that	O
is	O
synthesized	O
by	O
ArnA	B
from	O
UDP	O
-	O
glucuronic	O
acid	O
.	O

A	O
1.7	O
-	O
mg	O
sample	O
of	O
the	O
putative	O
UDP	O
-	O
l	O
-	O
Ara4N	O
product	O
generated	O
in	O
vitro	O
was	O
purified	O
by	O
ion	O
exchange	O
chromatography	O
,	O
and	O
its	O
structure	O
was	O
confirmed	O
by	O
1H	O
and	O
13C	O
NMR	O
spectroscopy	O
.	O

ArnB	B
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
was	O
purified	O
to	O
homogeneity	O
from	O
an	O
overproducing	O
strain	O
of	O
E.	O
coli	O
and	O
shown	O
to	O
contain	O
a	O
pyridoxal	O
phosphate	O
cofactor	O
,	O
as	O
judged	O
by	O
ultraviolet	O
/	O
visible	O
spectrophotometry	O
.	O

The	O
pyridoxal	O
phosphate	O
was	O
converted	O
to	O
the	O
pyridoxamine	O
form	O
in	O
the	O
presence	O
of	O
excess	O
glutamate	O
.	O

A	O
simple	O
quantitative	O
radiochemical	O
assay	O
was	O
developed	O
for	O
ArnB	B
,	O
which	O
can	O
be	O
used	O
to	O
assay	O
the	O
enzyme	O
either	O
in	O
the	O
forward	O
or	O
the	O
reverse	O
direction	O
.	O

The	O
enzyme	O
is	O
highly	O
selective	O
for	O
glutamate	O
as	O
the	O
amine	O
donor	O
,	O
but	O
the	O
equilibrium	O
constant	O
in	O
the	O
direction	O
of	O
UDP	O
-	O
l	O
-	O
Ara4N	O
formation	O
is	O
unfavorable	O
(	O
approximately	O
0.1	O
)	O
.	O

ArnB	B
is	O
a	O
member	O
of	O
a	O
very	O
large	O
family	O
of	O
aminotransferases	B
,	O
but	O
closely	O
related	O
ArnB	B
orthologs	O
are	O
present	O
only	O
in	O
those	O
bacteria	O
capable	O
of	O
synthesizing	O
lipid	O
A	O
species	O
modified	O
with	O
the	O
l	O
-	O
Ara4N	O
moiety	O
.	O

Possible	O
cause	O
of	O
taurine	O
-	O
deficient	O
cardiomyopathy	O
:	O
potentiation	O
of	O
angiotensin	B
II	I
action	O
.	O

Taurine	O
,	O
an	O
amino	O
acid	O
that	O
exhibits	O
anti	O
-	O
angiotensin	B
II	I
and	O
osmoregulatory	O
activity	O
,	O
is	O
found	O
in	O
very	O
high	O
concentration	O
in	O
the	O
heart	O
.	O

When	O
the	O
intracellular	O
content	O
of	O
taurine	O
is	O
dramatically	O
reduced	O
,	O
the	O
heart	O
develops	O
contractile	O
defects	O
and	O
undergoes	O
an	O
eccentric	O
form	O
of	O
hypertrophy	O
.	O

The	O
development	O
of	O
myocyte	O
hypertrophy	O
has	O
been	O
largely	O
attributed	O
to	O
angiotensin	B
II	I
,	O
whose	O
growth	O
properties	O
are	O
antagonized	O
by	O
taurine	O
.	O

Overt	O
heart	O
failure	O
is	O
usually	O
associated	O
with	O
myocyte	O
death	O
,	O
including	O
death	O
due	O
to	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
.	O

However	O
,	O
the	O
effect	O
of	O
taurine	O
deficiency	O
on	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
has	O
not	O
been	O
examined	O
.	O

To	O
investigate	O
this	O
effect	O
,	O
taurine	O
-	O
deficient	O
cells	O
,	O
produced	O
by	O
incubating	O
rat	O
neonatal	O
cardiomyocytes	O
with	O
medium	O
containing	O
the	O
taurine	O
transport	O
inhibitor	O
,	O
beta	O
-	O
alanine	O
,	O
were	O
exposed	O
to	O
angiotensin	B
II	I
.	O

The	O
peptide	O
increased	O
terminal	B
deoxynucleotidyl	I
transferase	I
-	O
mediated	O
deoxyuridine	O
triphosphate	O
nick	O
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
and	O
caspase	B
9	I
activation	O
more	O
in	O
the	O
taurine	O
-	O
deficient	O
than	O
the	O
normal	O
cell	O
.	O

Angiotensin	B
II	I
also	O
promoted	O
the	O
translocation	O
of	O
protein	B
kinase	I
C	I
(	I
PKC	I
)	I
epsilon	I
and	O
PKCdelta	B
,	O
the	O
expression	O
of	O
Bax	B
,	O
and	O
the	O
activation	O
of	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
effects	O
that	O
were	O
greater	O
in	O
the	O
taurine	O
-	O
deficient	O
cell	O
.	O

However	O
,	O
the	O
data	O
ruled	O
out	O
a	O
role	O
for	O
extracellular	B
signal	I
-	I
related	I
kinase	I
(	O
ERK	B
)	O
,	O
Bad	B
,	O
and	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
in	O
the	O
beta	O
-	O
alanine	O
-	O
angiotensin	B
II	I
interaction	O
.	O

Because	O
PKC	B
and	O
JNK	B
affect	O
the	O
expression	O
and	O
phosphorylation	O
state	O
of	O
certain	O
Bcl-2	B
family	I
members	O
,	O
they	O
appear	O
to	O
contribute	O
to	O
the	O
potentiation	O
of	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
by	O
taurine	O
deficiency	O
.	O

Polypeptide	O
components	O
of	O
oligomeric	O
legumin	B
-	O
like	O
thiamin	B
-	I
binding	I
protein	I
from	O
buckwheat	O
seeds	O
characterized	O
by	O
partial	O
amino	O
acid	O
sequencing	O
and	O
photoaffinity	O
labeling	O
.	O

Among	O
thiamin	B
-	I
binding	I
proteins	I
that	O
ubiquitously	O
occur	O
in	O
plant	O
seeds	O
,	O
that	O
of	O
common	O
buckwheat	O
became	O
a	O
model	O
of	O
extensive	O
studies	O
of	O
the	O
chemical	O
mechanism	O
of	O
ligand	O
-	O
protein	O
interaction	O
.	O

In	O
this	O
work	O
,	O
the	O
polypeptide	O
components	O
of	O
buckwheat	B
seed	I
thiamin	I
-	I
binding	I
protein	I
(	O
BSTBP	B
)	O
are	O
identified	O
and	O
characterized	O
.	O

We	O
suggest	O
that	O
BSTBP	B
is	O
probably	O
a	O
fraction	O
of	O
major	O
storage	O
13	B
S	I
globulin	I
(	O
legumin	B
)	O
,	O
has	O
an	O
average	O
molecular	O
mass	O
of	O
235	O
kDa	O
and	O
comprises	O
hexamers	O
of	O
57	O
-	O
kDa	O
and	O
38	O
-	O
kDa	O
subunits	O
in	O
variable	O
combinations	O
.	O

Each	O
subunit	O
is	O
a	O
pair	O
of	O
disulfide	O
-	O
linked	O
polypeptide	O
chains	O
,	O
36	O
kDa	O
plus	O
24	O
kDa	O
and	O
two	O
-	O
times	O
22	O
kDa	O
,	O
respectively	O
.	O

The	O
N	O
-	O
terminal	O
sequences	O
of	O
22	O
-	O
kDa	O
and	O
24	O
-	O
kDa	O
components	O
show	O
strict	O
homology	O
with	O
those	O
reported	O
for	O
""""	O
basic	O
subunits	O
""""	O
of	O
buckwheat	O
legumin	B
.	O

By	O
photoaffinity	O
labeling	O
of	O
BSTBP	B
with	O
4-azido-2-nitrobenzoylthiamine	O
,	O
it	O
is	O
shown	O
that	O
the	O
36	O
-	O
kDa	O
chain	O
plays	O
the	O
major	O
role	O
in	O
thiamin	O
binding	O
,	O
but	O
the	O
other	O
chains	O
may	O
also	O
be	O
variably	O
involved	O
.	O

Putative	O
thiamin	O
-	O
binding	O
fragments	O
are	O
identified	O
and	O
sequenced	O
.	O

Different	O
and	O
divergent	O
regulation	O
of	O
the	O
KIR2DL4	B
and	O
KIR3DL1	B
promoters	O
.	O

The	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
are	O
a	O
family	O
of	O
highly	O
related	O
MHC	B
class	I
I	I
receptors	O
that	O
show	O
extreme	O
genetic	O
polymorphism	O
both	O
within	O
the	O
human	O
population	O
and	O
between	O
closely	O
related	O
primate	O
species	O
,	O
suggestive	O
of	O
rapid	O
evolutionary	O
diversification	O
.	O

Most	O
KIR	B
are	O
expressed	O
in	O
a	O
variegated	O
fashion	O
by	O
the	O
NK	O
population	O
,	O
giving	O
rise	O
to	O
an	O
NK	O
repertoire	O
of	O
specificities	O
for	O
MHC	B
class	I
I	I
.	O

We	O
compared	O
the	O
promoter	O
for	O
KIR3DL1	B
,	O
which	O
exhibits	O
variegated	O
gene	O
expression	O
,	O
with	O
that	O
for	O
KIR2DL4	B
,	O
which	O
is	O
expressed	O
by	O
all	O
NK	O
cell	O
clones	O
.	O

Maximum	O
transcriptional	O
activity	O
of	O
each	O
was	O
encoded	O
within	O
approximately	O
270	O
bp	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
.	O

The	O
KIR2DL4	B
promoter	O
drove	O
reporter	O
gene	O
expression	O
only	O
in	O
NK	O
cells	O
,	O
while	O
the	O
KIR3DL1	B
promoter	O
was	O
active	O
in	O
a	O
range	O
of	O
cell	O
types	O
,	O
suggesting	O
that	O
the	O
latter	O
requires	O
other	O
regulatory	O
elements	O
for	O
physiological	O
expression	O
.	O

In	O
NK	O
cells	O
,	O
reporter	O
gene	O
expression	O
driven	O
by	O
the	O
KIR2DL4	B
promoter	O
was	O
greater	O
than	O
that	O
driven	O
by	O
the	O
KIR3DL1	B
promoter	O
.	O

DNase	B
I	I
footprinting	O
revealed	O
that	O
transcription	B
factor	I
binding	O
sites	O
differ	O
between	O
the	O
two	O
promoters	O
.	O

The	O
data	O
indicate	O
that	O
while	O
the	O
promoters	O
of	O
these	O
two	O
KIR	B
genes	O
share	O
67	O
%	O
nucleotide	O
identity	O
,	O
they	O
have	O
evolved	O
distinct	O
properties	O
consistent	O
with	O
different	O
roles	O
in	O
regulating	O
the	O
generation	O
of	O
NK	O
repertoire	O
.	O

Restricted	O
spatial	O
expression	O
of	O
a	O
high	O
-	O
affinity	O
phosphate	B
transporter	I
in	O
potato	O
roots	O
.	O

Phosphorus	O
deficiency	O
limits	O
plant	O
growth	O
,	O
and	O
high	O
-	O
affinity	O
phosphate	B
transporters	I
,	O
of	O
the	O
Pht1	B
family	I
,	O
facilitate	O
phosphate	O
uptake	O
and	O
translocation	O
.	O

The	O
family	O
is	O
subdivided	O
into	O
root	O
specific	O
,	O
phosphate	O
deprivation	O
induced	O
members	O
and	O
those	O
also	O
expressed	O
in	O
leaves	O
.	O

An	O
antibody	O
to	O
StPT2	B
,	O
a	O
potato	O
root	O
specific	O
transporter	O
,	O
detected	O
two	O
bands	O
(	O
52	O
kDa	O
and	O
30	O
kDa	O
)	O
on	O
western	O
blots	O
of	O
root	O
plasma	O
membrane	O
extracts	O
that	O
were	O
most	O
intense	O
in	O
whole	O
extracts	O
from	O
the	O
root	O
tip	O
and	O
slightly	O
increased	O
throughout	O
the	O
root	O
in	O
response	O
to	O
phosphate	O
depletion	O
.	O

RT	O
-	O
PCR	O
,	O
using	O
StPT2	B
specific	O
primers	O
,	O
confirmed	O
these	O
findings	O
.	O

Low	O
power	O
confocal	O
immunofluorescent	O
images	O
showed	O
StPT2	B
expression	O
mainly	O
in	O
the	O
elongation	O
zone	O
at	O
the	O
root	O
tip	O
.	O

By	O
contrast	O
,	O
a	O
vacuolar	O
pyrophosphatase	B
and	O
a	O
plasma	O
membrane	O
ATPase	B
antibody	O
labelled	O
the	O
whole	O
root	O
.	O

High	O
power	O
images	O
showed	O
,	O
by	O
comparison	O
with	O
alpha	B
-	I
tubulin	I
,	O
cell	O
wall	O
and	O
plasma	O
membrane	O
ATPase	B
labelling	O
,	O
that	O
StPT2	B
was	O
in	O
the	O
epidermal	O
plasma	O
membrane	O
and	O
restricted	O
to	O
the	O
apical	O
surface	O
.	O

This	O
is	O
the	O
first	O
evidence	O
of	O
polar	O
plasma	O
membrane	O
localisation	O
of	O
a	O
plant	O
nutrient	O
transporter	O
and	O
is	O
consistent	O
with	O
a	O
role	O
for	O
StPT2	B
in	O
phosphate	O
capture	O
and	O
uptake	O
.	O

Purification	O
of	O
N	O
-	O
terminally	O
truncated	O
histone	B
H2A	I
-	O
monoubiquitin	O
conjugates	O
from	O
leukemic	O
cell	O
nuclei	O
:	O
probable	O
proteolytic	O
products	O
of	O
ubiquitinated	O
H2A	B
.	O

To	O
gain	O
insight	O
into	O
the	O
significance	O
of	O
nuclear	O
ubiquitinated	O
proteins	O
,	O
two	O
serial	O
extracts	O
prepared	O
from	O
various	O
leukemic	O
cells	O
were	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
ubiquitin	B
antibody	O
.	O

Two	O
previously	O
unidentified	O
ubiquitinated	O
proteins	O
with	O
molecular	O
masses	O
of	O
10	O
and	O
17	O
kDa	O
were	O
found	O
in	O
8	O
M	O
urea	O
-	O
soluble	O
extracts	O
,	O
obtained	O
from	O
Tris	O
-	O
buffer	O
-	O
insoluble	O
materials	O
,	O
of	O
acute	O
myeloid	O
leukemia	O
OCI	O
/	O
AML	O
1a	O
cells	O
and	O
the	O
cells	O
from	O
the	O
leukemia	O
patients	O
.	O

Both	O
proteins	O
were	O
successfully	O
purified	O
from	O
the	O
OCI	O
/	O
AML	O
1a	O
cells	O
and	O
identified	O
as	O
monoubiquitin	O
-	O
truncated	O
H2A	B
conjugates	O
,	O
the	O
10	O
kDa	O
ubiquitinated	O
H2A	B
(	O
115	O
-	O
129	O
)	O
and	O
the	O
17	O
kDa	O
ubiquitinated	O
H2A	B
(	O
54	O
-	O
129	O
)	O
,	O
suggesting	O
that	O
both	O
proteins	O
were	O
produced	O
by	O
limited	O
proteolysis	O
of	O
an	O
intact	O
form	O
(	O
23	O
kDa	O
)	O
of	O
ubiquitinated	O
H2A	B
(	O
1	O
-	O
129	O
)	O
.	O

The	O
17	O
kDa	O
protein	O
as	O
well	O
as	O
the	O
23	O
kDa	O
ubiquitinated	O
histone	B
H2A	I
were	O
localised	O
in	O
chromatin	O
fractions	O
of	O
the	O
OCI	O
/	O
AML	O
cells	O
and	O
released	O
by	O
high	O
concentrations	O
of	O
salt	O
in	O
a	O
micrococcal	O
nuclease	O
-	O
sensitive	O
manner	O
,	O
suggesting	O
their	O
association	O
with	O
chromatin	O
.	O

In	O
contrast	O
,	O
the	O
10	O
kDa	O
protein	O
remained	O
insoluble	O
even	O
when	O
the	O
nuclei	O
were	O
treated	O
with	O
nuclease	O
under	O
high	O
salt	O
concentrations	O
,	O
presumably	O
due	O
to	O
binding	O
to	O
the	O
nuclear	O
matrix	O
.	O

An	O
antibody	O
recognising	O
H2A	B
(	O
70	O
-	O
81	O
)	O
also	O
detected	O
the	O
17	O
kDa	O
protein	O
in	O
anti	O
-	O
ubiquitin	B
immunoprecipitates	O
obtained	O
from	O
the	O
OCI	O
/	O
AML	O
cell	O
nuclei	O
.	O

In	O
addition	O
,	O
the	O
17	O
kDa	O
protein	O
levels	O
in	O
THP-1	O
cells	O
were	O
transiently	O
increased	O
,	O
concomitant	O
with	O
a	O
decrease	O
in	O
the	O
23	O
kDa	O
ubiquitinated	O
H2A	B
,	O
by	O
treatment	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
or	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
,	O
both	O
of	O
which	O
induce	O
differentiation	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
probable	O
proteolytic	O
products	O
of	O
ubiquitinated	O
H2A	B
,	O
which	O
might	O
have	O
a	O
role	O
in	O
nuclear	O
functions	O
.	O

[	O
Metabolic	O
intolerance	O
to	O
exercise	O
]	O

Exercise	O
intolerance	O
(	O
EI	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
medical	O
attention	O
,	O
although	O
it	O
is	O
sometimes	O
difficult	O
to	O
come	O
to	O
a	O
final	O
diagnosis	O
.	O

However	O
,	O
there	O
is	O
a	O
group	O
of	O
patients	O
in	O
whom	O
EI	O
is	O
due	O
to	O
a	O
metabolic	O
dysfunction	O
.	O

McArdle	O
's	O
disease	O
(	O
type	O
V	O
glucogenosis	O
)	O
is	O
due	O
to	O
myophosphorylase	B
(	O
MPL	B
)	O
deficiency	O
.	O

The	O
ischemic	O
exercise	O
test	O
shows	O
a	O
flat	O
lactate	O
curve	O
.	O

The	O
most	O
frequent	O
mutations	O
in	O
the	O
PYGM	B
gene	O
(	O
MPL	B
gene	O
)	O
in	O
Spanish	O
patients	O
with	O
MPL	B
deficiency	O
are	O
R49X	O
and	O
W797R	O
.	O

Carnitine	B
palmitoyltransferase	I
(	I
CPT	I
)	I
II	I
deficiency	O
is	O
invariably	O
associated	O
to	O
repetitive	O
episodes	O
of	O
myoglobinuria	O
triggered	O
by	O
exercise	O
,	O
cold	O
,	O
fever	O
or	O
fasting	O
.	O

The	O
diagnosis	O
depends	O
on	O
the	O
demonstration	O
of	O
CPT	B
II	I
deficiency	O
in	O
muscle	O
.	O

The	O
most	O
frequent	O
mutation	O
in	O
the	O
CPT2	B
gene	O
is	O
the	O
S113L	O
.	O

Patients	O
with	O
muscle	O
adenylate	O
deaminase	O
deficiency	O
usually	O
show	O
either	O
a	O
mild	O
myopathy	O
or	O
no	O
symptom	O
.	O

The	O
diagnosis	O
is	O
based	O
on	O
the	O
absence	O
of	O
enzyme	O
activity	O
in	O
muscle	O
and	O
the	O
lack	O
of	O
rise	O
of	O
ammonia	O
in	O
the	O
forearm	O
ischemic	O
exercise	O
test	O
.	O

The	O
mutation	O
Q12X	O
in	O
the	O
AMPD1	B
gene	O
is	O
strongly	O
associated	O
with	O
the	O
disease	O
.	O

Exercise	O
intolerance	O
is	O
a	O
common	O
complaint	O
in	O
patients	O
with	O
mitochondrial	O
respiratory	O
chain	O
(	O
MRC	O
)	O
deficiencies	O
,	O
although	O
it	O
is	O
often	O
overshadowed	O
by	O
other	O
symptoms	O
and	O
signs	O
.	O

Only	O
recently	O
we	O
have	O
come	O
to	O
appreciate	O
that	O
exercise	O
intolerance	O
can	O
be	O
the	O
sole	O
presentation	O
of	O
defects	O
in	O
the	O
mtDNA	O
,	O
particularly	O
in	O
complex	O
I	O
,	O
complex	O
III	O
,	O
complex	O
IV	O
,	O
or	O
in	O
some	O
tRNAs	O
.	O

In	O
addition	O
,	O
myoglobinuria	O
can	O
be	O
observed	O
in	O
patients	O
under	O
statin	O
treatment	O
,	O
particularly	O
if	O
associated	O
with	O
fibrates	O
,	O
due	O
to	O
an	O
alteration	O
in	O
the	O
assembly	O
of	O
the	O
complex	O
IV	O
of	O
the	O
MRC	O
.	O

Protein	B
kinase	I
network	O
in	O
the	O
regulation	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
of	O
smooth	O
muscle	O
myosin	B
light	I
chain	I
.	O

The	O
contraction	O
of	O
smooth	O
muscle	O
is	O
regulated	O
primarily	O
by	O
intracellular	O
Ca2	O
+	O
signal	O
.	O

It	O
is	O
well	O
established	O
that	O
the	O
elevation	O
of	O
the	O
cytosolic	O
Ca2	O
+	O
level	O
activates	O
myosin	B
light	I
chain	I
kinase	I
,	O
which	O
phosphorylates	O
20	O
kDa	O
regulatory	O
myosin	B
light	I
chain	I
and	O
activates	O
myosin	B
ATPase	I
.	O

The	O
simultaneous	O
measurement	O
of	O
cytosolic	O
Ca2	O
+	O
concentration	O
and	O
force	O
development	O
revealed	O
that	O
the	O
alteration	O
of	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
of	O
the	O
contractile	O
apparatus	O
as	O
well	O
as	O
the	O
Ca2	O
+	O
signal	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
smooth	O
muscle	O
contraction	O
.	O

The	O
fluctuation	O
of	O
an	O
extent	O
of	O
myosin	B
phosphorylation	O
for	O
a	O
given	O
change	O
in	O
Ca2	O
+	O
concentration	O
is	O
considered	O
to	O
contribute	O
to	O
the	O
major	O
mechanisms	O
regulating	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
.	O

The	O
level	O
of	O
myosin	B
phosphorylation	O
is	O
determined	O
by	O
the	O
balance	O
between	O
phosphorylation	O
and	O
dephosphorylation	O
.	O

The	O
phosphorylation	O
level	O
for	O
a	O
given	O
Ca2	O
+	O
elevation	O
is	O
increased	O
either	O
by	O
Ca2	O
+	O
-	O
independent	O
activation	O
of	O
phosphorylation	O
process	O
or	O
inhibition	O
of	O
dephosphorylation	O
.	O

In	O
the	O
last	O
decade	O
,	O
the	O
isolation	O
and	O
cloning	O
of	O
myosin	B
phosphatase	I
facilitated	O
the	O
understanding	O
of	O
regulatory	O
mechanism	O
of	O
dephosphorylation	O
process	O
at	O
the	O
molecular	O
level	O
.	O

The	O
inhibition	O
of	O
myosin	B
phosphatase	I
can	O
be	O
achieved	O
by	O
(	O
1	O
)	O
alteration	O
of	O
hetrotrimeric	O
structure	O
,	O
(	O
2	O
)	O
phosphorylation	O
of	O
110	O
kDa	O
regulatory	O
subunit	O
MYPT1	B
at	O
the	O
specific	O
site	O
and	O
(	O
3	O
)	O
inhibitory	O
protein	O
CPI-17	B
upon	O
its	O
phosphorylation	O
.	O

Rho	B
-	I
kinase	I
was	O
first	O
identified	O
to	O
phosphorylate	O
MYPT1	B
,	O
and	O
later	O
many	O
kinases	B
were	O
found	O
to	O
phosphorylate	O
MYPT1	B
and	O
inhibit	O
dephosphorylation	O
of	O
myosin	B
.	O

Similarly	O
,	O
the	O
phosphorylation	O
of	O
CPI-17	B
can	O
be	O
catalysed	O
by	O
multiple	O
kinases	B
.	O

Moreover	O
,	O
the	O
myosin	B
light	I
chain	I
can	O
be	O
phosphorylated	O
by	O
not	O
only	O
authentic	O
myosin	B
light	I
chain	I
kinase	I
in	O
a	O
Ca2	O
+	O
-	O
dependent	O
manner	O
but	O
also	O
by	O
multiple	O
kinases	B
in	O
a	O
Ca2	O
+	O
-	O
independent	O
manner	O
,	O
thus	O
adding	O
a	O
novel	O
mechanism	O
to	O
the	O
regulation	O
of	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
by	O
regulating	O
the	O
phosphorylation	O
process	O
.	O

It	O
is	O
now	O
clarified	O
that	O
the	O
protein	B
kinase	I
network	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
myosin	B
phosphorylation	O
and	O
dephosphorylation	O
.	O

However	O
,	O
the	O
physiological	O
role	O
of	O
each	O
component	O
remains	O
to	O
be	O
determined	O
.	O

One	O
approach	O
to	O
accomplish	O
this	O
purpose	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
the	O
dominant	O
negative	O
mutants	O
of	O
the	O
signalling	O
molecule	O
on	O
the	O
smooth	O
muscle	O
contraction	O
.	O

In	O
this	O
regards	O
,	O
a	O
protein	O
transduction	O
technique	O
utilizing	O
the	O
cell	O
-	O
penetrating	O
peptides	O
would	O
provide	O
a	O
useful	O
tool	O
.	O

In	O
the	O
preliminary	O
study	O
,	O
we	O
succeeded	O
in	O
introducing	O
a	O
fragment	O
of	O
MYPT1	B
into	O
the	O
arterial	O
strips	O
,	O
and	O
found	O
enhancement	O
of	O
contraction	O
.	O

Apolipoprotein	B
D	I
levels	O
are	O
elevated	O
in	O
prefrontal	O
cortex	O
of	O
subjects	O
with	O
Alzheimer	O
's	O
disease	O
:	O
no	O
relation	O
to	O
apolipoprotein	B
E	I
expression	O
or	O
genotype	O
.	O

BACKGROUND	O
:	O

Apolipoprotein	B
E	I
(	O
apoE	B
)	O
has	O
been	O
implicated	O
in	O
the	O
pathology	O
of	O
AD	O
ever	O
since	O
inheritance	O
of	O
the	O
epsilon4	O
allele	O
was	O
shown	O
to	O
be	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
AD	O
.	O

Apolipoprotein	B
D	I
(	O
apoD	B
)	O
is	O
elevated	O
in	O
association	O
with	O
several	O
central	O
nervous	O
system	O
disorders	O
,	O
including	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
and	O
has	O
been	O
proposed	O
to	O
be	O
an	O
especially	O
robust	O
marker	O
for	O
brain	O
regions	O
specifically	O
affected	O
by	O
particular	O
neuropathologies	O
.	O

Progressive	O
cognitive	O
decline	O
is	O
the	O
core	O
clinical	O
feature	O
of	O
AD	O
and	O
is	O
associated	O
with	O
disturbances	O
in	O
the	O
prefrontal	O
cortex	O
.	O

METHODS	O
:	O

We	O
measured	O
apoD	B
levels	O
in	O
prefrontal	O
cortex	O
samples	O
obtained	O
postmortem	O
from	O
20	O
autopsy	O
-	O
confirmed	O
AD	O
subjects	O
and	O
40	O
control	O
subjects	O
.	O

RESULTS	O
:	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
analysis	O
revealed	O
a	O
significant	O
increase	O
in	O
apoD	B
expression	O
in	O
AD	O
subjects	O
compared	O
with	O
control	O
subjects	O
(	O
.218	O
+	O
/-	O
.029	O
microg	O
/	O
mg	O
protein	O
vs.117	O
+	O
/-	O
.011	O
microg	O
/	O
mg	O
protein	O
;	O
p	O
=	O
0003	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
apoD	B
expression	O
between	O
early	O
-	O
onset	O
and	O
late	O
-	O
onset	O
Alzheimer	O
's	O
subjects	O
.	O

Apolipoprotein	B
D	I
expression	O
levels	O
were	O
not	O
correlated	O
with	O
apoE	B
levels	O
,	O
nor	O
were	O
they	O
correlated	O
with	O
inheritance	O
of	O
the	O
APOE	B
epsilon4	O
allele	O
.	O

CONCLUSIONS	O
:	O

These	O
findings	O
suggest	O
that	O
apoD	B
may	O
be	O
related	O
to	O
the	O
cognitive	O
decline	O
observed	O
in	O
AD	O
patients	O
and	O
that	O
apoD	B
and	O
apoE	B
likely	O
play	O
different	O
roles	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O

New	O
members	O
of	O
the	O
Escherichia	O
coli	O
sigmaE	B
regulon	O
identified	O
by	O
a	O
two	O
-	O
plasmid	O
system	O
.	O

A	O
previously	O
established	O
method	O
,	O
based	O
on	O
a	O
two	O
-	O
plasmid	O
system	O
,	O
was	O
used	O
to	O
identify	O
promoters	O
recognized	O
by	O
RNA	B
polymerase	I
containing	O
the	O
extracytoplasmic	O
stress	O
response	O
sigma	B
factor	I
sigmaE	B
in	O
Escherichia	O
coli	O
.	O

In	O
addition	O
to	O
previously	O
identified	O
rpoE	B
-	O
dependent	O
promoters	O
,	O
11	O
new	O
promoters	O
potentially	O
directing	O
the	O
expression	O
of	O
15	O
genes	O
were	O
identified	O
that	O
were	O
active	O
only	O
after	O
over	O
-	O
expression	O
of	O
rpoE	B
.	O

The	O
promoters	O
were	O
confirmed	O
and	O
transcriptional	O
start	O
points	O
of	O
the	O
promoters	O
were	O
determined	O
by	O
primer	O
extension	O
analysis	O
and	O
S1	B
-	I
nuclease	I
mapping	O
.	O

All	O
the	O
promoters	O
contained	O
sequences	O
similar	O
to	O
the	O
consensus	O
sequence	O
of	O
rpoE	B
-	O
dependent	O
promoters	O
.	O

The	O
new	O
rpoE	B
-	O
dependent	O
promoters	O
governed	O
expression	O
of	O
genes	O
encoding	O
proteins	O
involved	O
in	O
primary	O
metabolism	O
(	O
fusA	B
,	O
tufA	B
,	O
recR	B
)	O
,	O
phospholipid	O
and	O
lipopolysaccharide	O
biosynthesis	O
(	O
psd	B
,	O
lpxP	B
)	O
,	O
signal	O
transduction	O
(	O
sixA	B
)	O
,	O
proposed	O
inner	O
or	O
outer	O
membrane	O
proteins	O
(	O
bacA	B
,	O
sbmA	B
,	O
smpA	B
,	O
yeaY	B
)	O
,	O
and	O
proteins	O
with	O
unknown	O
function	O
(	O
ybaB	B
,	O
yaiW	B
,	O
yiiS	B
,	O
yiiT	B
,	O
yfeY	B
)	O
.	O

Regulation	O
of	O
the	O
C	B
-	I
X	I
-	I
C	I
chemokine	I
,	O
mob-1	B
,	O
gene	O
expression	O
in	O
primary	O
rat	O
hepatocytes	O
.	O

The	O
chemokine	B
,	O
mob-1	B
,	O
is	O
involved	O
in	O
inflammatory	O
and	O
immune	O
responses	O
and	O
may	O
be	O
an	O
important	O
mediator	O
of	O
the	O
inflammatory	O
response	O
in	O
the	O
liver	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
upstream	O
signal	O
pathways	O
that	O
could	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
mob-1	B
expression	O
.	O

We	O
have	O
found	O
that	O
in	O
primary	O
rat	O
hepatocytes	O
the	O
isolation	O
and	O
subsequent	O
culture	O
of	O
these	O
cells	O
induced	O
mob-1	B
expression	O
.	O

A	O
similar	O
induction	O
of	O
mob-1	B
mRNA	O
was	O
observed	O
when	O
the	O
hepatocytes	O
were	O
stimulated	O
with	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O

When	O
hepatocytes	O
were	O
stimulated	O
with	O
IFN	B
-	I
gamma	I
or	O
cytokine	B
mixture	O
(	O
IFN	B
-	I
gamma	I
,	O
interleukin-1beta	B
and	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
)	O
,	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
p38	B
and	O
extracellular	B
-	I
regulated	I
kinase	I
(	O
ERK	B
)	O
were	O
phosphorylated	O
,	O
suggesting	O
an	O
involvement	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
(	O
MAPK	B
)	O
in	O
the	O
induction	O
of	O
mob-1	B
expression	O
.	O

The	O
p38	B
kinase	B
inhibitor	O
,	O
SB	O
203580	O
,	O
and	O
the	O
NF	B
-	I
kappaB	I
inhibitor	O
,	O
MG-132	O
,	O
inhibited	O
the	O
induction	O
of	O
mob-1	B
mRNA	O
and	O
the	O
effects	O
were	O
not	O
additive	O
.	O

These	O
results	O
demonstrate	O
that	O
in	O
primary	O
rat	O
hepatocytes	O
the	O
transient	O
induction	O
of	O
mob-1	B
expression	O
was	O
regulated	O
by	O
p38	B
kinase	B
and	O
NF	B
-	I
kappaB	I
through	O
a	O
common	O
regulatory	O
pathway	O
.	O

A	O
synthetic	O
peptide	O
from	O
transforming	B
growth	I
factor	I
beta	I
type	I
III	I
receptor	I
inhibits	O
liver	O
fibrogenesis	O
in	O
rats	O
with	O
carbon	O
tetrachloride	O
liver	O
injury	O
.	O

Transforming	B
growth	I
factor	I
beta1	I
(	O
TGF	B
-	I
beta1	I
)	O
is	O
a	O
pleiotropic	O
cytokine	B
,	O
which	O
displays	O
potent	O
profibrogenic	O
effects	O
and	O
is	O
highly	O
expressed	O
in	O
fibrotic	O
livers	O
.	O

For	O
this	O
reason	O
,	O
development	O
of	O
TGF	B
-	I
B1	I
inhibitors	O
might	O
be	O
of	O
great	O
importance	O
to	O
control	O
liver	O
fibrogenesis	O
as	O
well	O
as	O
other	O
undesired	O
side	O
effects	O
due	O
to	O
this	O
cytokine	B
.	O

Potential	O
peptide	O
inhibitors	O
of	O
TGF	B
-	I
beta1	I
(	O
derived	O
from	O
TGF	B
-	I
beta1	I
and	O
from	O
its	O
type	O
III	O
receptor	O
)	O
were	O
tested	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
different	O
assays	O
.	O

Peptides	O
P11	O
and	O
P12	O
,	O
derived	O
from	O
TGF	B
-	I
beta1	I
,	O
and	O
P54	O
and	O
P144	O
,	O
derived	O
from	O
its	O
type	O
III	O
receptor	O
,	O
prevented	O
TGF	B
-	I
beta1	I
-	O
dependent	O
inhibition	O
of	O
MV1Lu	O
proliferation	O
in	O
vitro	O
and	O
markedly	O
reduced	O
binding	O
of	O
TGF	B
-	I
beta1	I
to	O
its	O
receptors	O
.	O

P144	O
blocked	O
TGF	B
-	I
beta1	I
-	O
dependent	O
stimulation	O
of	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
human	O
alpha2	B
(	I
I	I
)	I
collagen	I
promoter	O
.	O

Intraperitoneal	O
administration	O
of	O
P144	O
also	O
showed	O
potent	O
antifibrogenic	O
activity	O
in	O
vivo	O
in	O
the	O
liver	O
of	O
rats	O
receiving	O
CCl4	O
.	O

These	O
rats	O
also	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
activated	O
hepatic	O
stellate	O
cells	O
as	O
compared	O
with	O
those	O
treated	O
with	O
saline	O
only	O
.	O

These	O
results	O
suggest	O
that	O
short	O
synthetic	O
peptides	O
derived	O
from	O
TGF	B
-	I
beta1	I
type	I
III	I
receptor	I
may	O
be	O
of	O
value	O
in	O
reducing	O
liver	O
fibrosis	O
in	O
chronic	O
liver	O
injury	O
.	O

Ribosomal	O
RNA	O
and	O
ribosomal	O
proteins	O
in	O
corynebacteria	O
.	O

Ribosomal	O
RNAs	O
(	O
rRNAs	O
)	O
(	O
16S	O
,	O
23S	O
,	O
5S	O
)	O
encoded	O
by	O
the	O
rrn	O
operons	O
and	O
ribosomal	O
proteins	O
play	O
a	O
very	O
important	O
role	O
in	O
the	O
formation	O
of	O
ribosomes	O
and	O
in	O
the	O
control	O
of	O
translation	O
.	O

Five	O
copies	O
of	O
the	O
rrn	O
operon	O
were	O
reported	O
by	O
hybridization	O
studies	O
in	O
Brevibacterium	O
(	O
Corynebacterium	O
)	O
lactofermentum	O
but	O
the	O
genome	O
sequence	O
of	O
Corynebacterium	O
glutamicum	O
provided	O
evidence	O
for	O
six	O
rrn	O
copies	O
.	O

All	O
six	O
copies	O
of	O
the	O
C.	O
glutamicum	O
16S	O
rRNA	O
have	O
a	O
size	O
of	O
1523	O
bp	O
and	O
each	O
of	O
the	O
six	O
copies	O
of	O
the	O
5S	O
contain	O
120	O
bp	O
whereas	O
size	O
differences	O
are	O
found	O
between	O
the	O
six	O
copies	O
of	O
the	O
23S	O
rRNA	O
.	O

The	O
anti	O
-	O
Shine	O
-	O
Dalgarno	O
sequence	O
at	O
the	O
3'-end	O
of	O
the	O
16S	O
rRNA	O
was	O
5'-CCUCCUUUC-3	O
'	O
.	O

Each	O
rrn	O
operon	O
is	O
transcribed	O
as	O
a	O
large	O
precursor	O
rRNA	O
(	O
pre	O
-	O
rRNA	O
)	O
that	O
is	O
processed	O
by	O
RNaseIII	B
and	O
other	O
RNases	B
at	O
specific	O
cleavage	O
boxes	O
that	O
have	O
been	O
identified	O
in	O
the	O
C.	O
glutamicum	O
pre	O
-	O
rRNA	O
.	O

A	O
secondary	O
structure	O
of	O
the	O
C.	O
glutamicum	O
16S	O
rRNA	O
is	O
proposed	O
.	O

The	O
16S	O
rRNA	O
sequence	O
has	O
been	O
used	O
as	O
a	O
molecular	O
evolution	O
clock	O
allowing	O
the	O
deduction	O
of	O
a	O
phylogenetic	O
tree	O
of	O
all	O
Corynebacterium	O
species	O
.	O

In	O
C.	O
glutamicum	O
,	O
there	O
are	O
11	O
ribosomal	O
protein	O
gene	O
clusters	O
encoding	O
42	O
ribosomal	O
proteins	O
.	O

The	O
organization	O
of	O
some	O
of	O
the	O
ribosomal	O
protein	O
gene	O
cluster	O
is	O
identical	O
to	O
that	O
of	O
Escherichia	O
coli	O
whereas	O
in	O
other	O
clusters	O
the	O
organization	O
of	O
the	O
genes	O
is	O
rather	O
different	O
.	O

Some	O
specific	O
ribosomal	O
protein	O
genes	O
are	O
located	O
in	O
a	O
different	O
cluster	O
in	O
C.	O
glutamicum	O
when	O
compared	O
with	O
E.	O
coli	O
,	O
indicating	O
that	O
the	O
control	O
of	O
expression	O
of	O
these	O
genes	O
is	O
different	O
in	O
E.	O
coli	O
and	O
C.	O
glutamicum	O
.	O

Vitamin	O
D	O
inhibits	O
G1	O
to	O
S	O
progression	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
through	O
p27Kip1	B
stabilization	O
and	O
Cdk2	B
mislocalization	O
to	O
the	O
cytoplasm	O
.	O

1,25-	O
(	O
OH	O
)	O
2	O
vitamin	O
D3	O
(	O
1,25-	O
(	O
OH	O
)	O
2D3	O
)	O
exerts	O
antiproliferative	O
effects	O
via	O
cell	O
cycle	O
regulation	O
in	O
a	O
variety	O
of	O
tumor	O
cells	O
,	O
including	O
prostate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
in	O
the	O
human	O
prostate	O
cancer	O
cell	O
line	O
LN	O
-	O
CaP	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
mediates	O
an	O
increase	O
in	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
p27Kip1	B
levels	O
,	O
inhibition	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
2	I
(	O
Cdk2	B
)	O
activity	O
,	O
hypophosphorylation	O
of	O
retinoblastoma	B
protein	I
,	O
and	O
accumulation	O
of	O
cells	O
in	O
G1	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
whereby	O
1,25-	O
(	O
OH	O
)	O
2D3	O
increases	O
p27	B
levels	O
.	O

1,25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
p27	B
mRNA	O
levels	O
or	O
on	O
the	O
regulation	O
of	O
a	O
3.5	O
-	O
kb	O
fragment	O
of	O
the	O
p27	B
promoter	O
.	O

The	O
rate	O
of	O
p27	B
protein	O
synthesis	O
was	O
not	O
affected	O
by	O
1,25-	O
(	O
OH	O
)	O
2D3	O
as	O
measured	O
by	O
luciferase	B
activity	O
driven	O
by	O
the	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
of	O
p27	B
that	O
regulate	O
p27	B
protein	O
synthesis	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
35S	O
-	O
labeled	O
p27	B
revealed	O
an	O
increased	O
p27	B
protein	O
half	O
-	O
life	O
with	O
1,25-	O
(	O
OH	O
)	O
2D3	O
treatment	O
.	O

Because	O
Cdk2	B
-	O
mediated	O
phosphorylation	O
of	O
p27	B
at	O
Thr187	O
targets	O
p27	B
for	O
Skp2	B
-	O
mediated	O
degradation	O
,	O
we	O
examined	O
the	O
phosphorylation	O
status	O
of	O
p27	B
in	O
1,25-	O
(	O
OH	O
)	O
2D3	O
-	O
treated	O
cells	O
.	O

1,25-	O
(	O
OH	O
)	O
2D3	O
decreased	O
levels	O
of	O
Thr187	O
phosphorylated	O
p27	B
,	O
consistent	O
with	O
inhibition	O
of	O
Thr187	O
phosphorylation	O
-	O
dependent	O
p27	B
degradation	O
.	O

In	O
addition	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
reduced	O
Skp2	B
protein	O
levels	O
in	O
LNCaP	O
cells	O
.	O

Cdk2	B
is	O
activated	O
in	O
the	O
nucleus	O
by	O
Cdk	B
-	I
activating	I
kinase	I
through	O
Thr160	O
phosphorylation	O
and	O
by	O
cdc25A	B
phosphatase	I
via	O
Thr14	O
and	O
Tyr15	O
dephosphorylation	O
.	O

Interestingly	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
decreased	O
nuclear	O
Cdk2	B
levels	O
as	O
assessed	O
by	O
subcellular	O
fractionation	O
and	O
confocal	O
microscopy	O
.	O

Inhibition	O
of	O
Cdk2	B
by	O
1,25-	O
(	O
OH	O
)	O
2D3	O
may	O
thus	O
involve	O
two	O
mechanisms	O
:	O
1	O
)	O
reduced	O
nuclear	O
Cdk2	B
available	O
for	O
cyclin	B
binding	O
and	O
activation	O
and	O
2	O
)	O
impairment	O
of	O
cyclin	B
E	I
-	O
Cdk2	B
-	O
dependent	O
p27	B
degradation	O
through	O
cytoplasmic	O
mislocalization	O
of	O
Cdk2	B
.	O

These	O
data	O
suggest	O
that	O
Cdk2	B
mislocalization	O
is	O
central	O
to	O
the	O
antiproliferative	O
effects	O
of	O
1,25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
respiratory	O
arsenate	B
reductase	I
from	O
Bacillus	O
selenitireducens	O
strain	O
MLS10	O
.	O

The	O
respiratory	O
arsenate	B
reductase	I
from	O
the	O
Gram	O
-	O
positive	O
,	O
haloalkaliphile	O
,	O
Bacillus	O
selenitireducens	O
strain	O
MLS10	O
was	O
purified	O
and	O
characterized	O
.	O

It	O
is	O
a	O
membrane	O
bound	O
heterodimer	O
(	O
150	O
kDa	O
)	O
composed	O
of	O
two	O
subunits	O
ArrA	B
(	O
110	O
kDa	O
)	O
and	O
ArrB	B
(	O
34	O
kDa	O
)	O
,	O
with	O
an	O
apparent	O
K	O
(	O
m	O
)	O
for	O
arsenate	O
of	O
34	O
microM	O
and	O
V	O
(	O
max	O
)	O
of	O
2.5	O
micromol	O
min	O
(	O
-1	O
)	O
mg	O
(	O
-1	O
)	O
.	O

Optimal	O
activity	O
occurred	O
at	O
pH	O
9.5	O
and	O
150	O
g	O
l	O
(	O
-1	O
)	O
of	O
NaCl	O
.	O

Metal	O
analysis	O
(	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
)	O
of	O
the	O
holoenzyme	O
and	O
sequence	O
analysis	O
of	O
the	O
catalytic	O
subunit	O
(	O
ArrA	B
;	O
the	O
gene	O
for	O
which	O
was	O
cloned	O
and	O
sequenced	O
)	O
indicate	O
it	O
is	O
a	O
member	O
of	O
the	O
DMSO	B
reductase	I
family	I
of	O
molybdoproteins	O
.	O

Organization	O
of	O
the	O
mouse	O
Zfhx1b	B
gene	O
encoding	O
the	O
two	O
-	O
handed	O
zinc	O
finger	O
repressor	O
Smad	B
-	I
interacting	I
protein-1	I
.	O

SIP1	B
,	O
a	O
member	O
of	O
the	O
deltaEF1	B
family	I
of	O
two	O
-	O
handed	O
zinc	O
finger	O
transcriptional	O
repressors	O
,	O
has	O
been	O
identified	O
as	O
a	O
Smad	B
-	O
binding	O
protein	O
.	O

Recently	O
,	O
mutations	O
in	O
the	O
human	O
SIP1	B
gene	O
(	O
ZFHX1B	B
)	O
have	O
been	O
implicated	O
in	O
Hirschsprung	O
disease	O
.	O

Here	O
we	O
document	O
extensively	O
the	O
structure	O
and	O
transcriptional	O
pattern	O
of	O
the	O
mouse	O
SIP1	B
gene	O
(	O
Zfhx1b	B
)	O
and	O
compare	O
it	O
to	O
homologues	O
from	O
other	O
species	O
.	O

The	O
overall	O
structure	O
of	O
Zfhx1b	B
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
deltaEF1	B
gene	O
(	O
Zfhx1a	B
)	O
,	O
confirming	O
their	O
close	O
evolutionary	O
relationship	O
.	O

In	O
contrast	O
to	O
Zfhx1a	B
,	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
SIP1	B
-	O
encoding	O
mouse	O
gene	O
is	O
very	O
complex	O
and	O
includes	O
several	O
alternative	O
exons	O
.	O

The	O
corresponding	O
5'-UTR	O
splicing	O
pattern	O
seems	O
to	O
be	O
conserved	O
between	O
species	O
and	O
suggests	O
a	O
role	O
in	O
its	O
transcriptional	O
and/or	O
translational	O
regulation	O
.	O

The	O
gene	O
also	O
codes	O
for	O
an	O
antisense	O
transcript	O
that	O
is	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

Extrinsic	O
proteins	O
of	O
photosystem	B
II	I
:	O
an	O
intermediate	O
member	O
of	O
PsbQ	B
protein	I
family	I
in	O
red	O
algal	O
PS	B
II	I
.	O

The	O
oxygen	O
-	O
evolving	O
photosystem	B
II	I
(	O
PS	B
II	I
)	O
complex	O
of	O
red	O
algae	O
contains	O
four	O
extrinsic	O
proteins	O
of	O
12	O
kDa	O
,	O
20	O
kDa	O
,	O
33	O
kDa	O
and	O
cyt	B
c-550	I
,	O
among	O
which	O
the	O
20	O
kDa	O
protein	O
is	O
unique	O
in	O
that	O
it	O
is	O
not	O
found	O
in	O
other	O
organisms	O
.	O

We	O
cloned	O
the	O
gene	O
for	O
the	O
20	O
-	O
kDa	O
protein	O
from	O
a	O
red	O
alga	O
Cyanidium	O
caldarium	O
.	O

The	O
gene	O
consists	O
of	O
a	O
leader	O
sequence	O
which	O
can	O
be	O
divided	O
into	O
two	O
parts	O
:	O
one	O
for	O
transfer	O
across	O
the	O
plastid	O
envelope	O
and	O
the	O
other	O
for	O
transfer	O
into	O
thylakoid	O
lumen	O
,	O
indicating	O
that	O
the	O
gene	O
is	O
encoded	O
by	O
the	O
nuclear	O
genome	O
.	O

The	O
sequence	O
of	O
the	O
mature	O
20	O
-	O
kDa	O
protein	O
has	O
low	O
but	O
significant	O
homology	O
with	O
the	O
extrinsic	O
17	O
-	O
kDa	O
(	O
PsbQ	B
)	O
protein	O
of	O
PS	B
II	I
from	O
green	O
algae	O
Volvox	O
Carteri	O
and	O
Chlamydomonas	O
reinhardtii	O
,	O
as	O
well	O
as	O
the	O
PsbQ	B
protein	O
of	O
higher	O
plants	O
and	O
PsbQ	B
-	O
like	O
protein	O
from	O
cyanobacteria	O
.	O

Cross	O
-	O
reconstitution	O
experiments	O
with	O
combinations	O
of	O
the	O
extrinsic	O
proteins	O
and	O
PS	B
IIs	I
from	O
the	O
red	O
alga	O
Cy	O
.	O
caldarium	O
and	O
green	O
alga	O
Ch	O
.	O
reinhardtii	O
showed	O
that	O
the	O
extrinsic	O
20	O
-	O
kDa	O
protein	O
was	O
functional	O
in	O
place	O
of	O
the	O
green	O
algal	O
17	O
-	O
kDa	O
protein	O
on	O
binding	O
to	O
the	O
green	O
algal	O
PS	B
II	I
and	O
restoration	O
of	O
oxygen	O
evolution	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
20	O
-	O
kDa	O
protein	O
is	O
the	O
ancestral	O
form	O
of	O
the	O
extrinsic	O
17	O
-	O
kDa	O
protein	O
in	O
green	O
algal	O
and	O
higher	O
plant	O
PS	B
IIs	I
.	O

This	O
provides	O
an	O
important	O
clue	O
to	O
the	O
evolution	O
of	O
the	O
oxygen	O
-	O
evolving	O
complex	O
from	O
prokaryotic	O
cyanobacteria	O
to	O
eukaryotic	O
higher	O
plants	O
.	O

The	O
gene	O
coding	O
for	O
the	O
extrinsic	O
20	O
-	O
kDa	O
protein	O
was	O
named	O
psbQ	B
'	I
(	I
prime	I
)	I
.	O

Interaction	O
with	O
Tap42	B
is	O
required	O
for	O
the	O
essential	O
function	O
of	O
Sit4	B
and	O
type	B
2A	I
phosphatases	I
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Pph21	B
and	O
Pph22	B
are	O
the	O
two	O
catalytic	B
subunits	I
of	I
type	I
2A	I
phosphatase	I
(	O
PP2Ac	B
)	O
,	O
and	O
Sit4	B
is	O
a	O
major	O
form	O
of	O
2A	O
-	O
like	O
phosphatase	B
.	O

The	O
function	O
of	O
these	O
phosphatases	B
requires	O
their	O
association	O
with	O
different	O
regulatory	O
subunits	O
.	O

In	O
addition	O
to	O
the	O
conventional	O
regulatory	O
subunits	O
,	O
namely	O
,	O
the	O
A	O
and	O
B	O
subunits	O
for	O
Pph21	B
/	I
22	I
and	O
the	O
Sap	B
proteins	O
for	O
Sit4	B
,	O
these	O
phosphatases	B
have	O
been	O
found	O
to	O
associate	O
with	O
a	O
protein	O
termed	O
Tap42	B
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
Sit4	B
and	O
PP2Ac	B
interact	O
with	O
Tap42	B
via	O
an	O
N	O
-	O
terminal	O
domain	O
that	O
is	O
conserved	O
in	O
all	O
type	O
2A	O
and	O
2A	O
-	O
like	O
phosphatases	B
.	O

We	O
found	O
that	O
the	O
Sit4	B
phosphatase	B
in	O
the	O
sit4	B
-	O
102	O
strain	O
contains	O
a	O
reverse	O
-	O
of	O
-	O
charge	O
amino	O
acid	O
substitution	O
within	O
its	O
Tap42	B
binding	O
domain	O
and	O
is	O
defective	O
for	O
formation	O
of	O
the	O
Tap42	B
-	O
Sit4	B
complex	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
interaction	O
with	O
Tap42	B
is	O
required	O
for	O
the	O
activity	O
as	O
well	O
as	O
for	O
the	O
essential	O
function	O
of	O
Sit4	B
and	O
PP2Ac	B
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
Tap42	B
is	O
able	O
to	O
interact	O
with	O
two	O
other	O
2A	O
-	O
like	O
phosphatases	B
,	O
Pph3	B
and	O
Ppg1	B
.	O

Effect	O
of	O
MG132	O
,	O
a	O
proteasome	O
inhibitor	O
,	O
on	O
the	O
expression	O
of	O
growth	B
related	I
oncogene	I
protein	I
-	I
alpha	I
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Growth	B
related	I
oncogene	I
protein	I
-	I
alpha	I
(	O
GRO	B
-	I
alpha	I
)	O
is	O
a	O
member	O
of	O
C	B
-	I
X	I
-	I
C	I
chemokine	I
and	O
plays	O
an	O
important	O
role	O
in	O
inflammatory	O
responses	O
.	O

Expression	O
of	O
GRO	B
gene	I
family	I
is	O
regulated	O
by	O
a	O
number	O
of	O
factors	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
addressed	O
the	O
possible	O
regulation	O
of	O
GRO	B
-	I
alpha	I
expression	O
by	O
ubiquitin	B
-	O
proteasome	O
system	O
.	O

Cultures	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
treated	O
with	O
a	O
proteasome	O
inhibitor	O
,	O
MG132	O
,	O
and	O
the	O
levels	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
were	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
or	O
northern	O
blotting	O
.	O

Levels	O
of	O
GRO	B
-	I
alpha	I
protein	O
in	O
the	O
cell	O
-	O
conditioned	O
medium	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

MG132	O
alone	O
increased	O
the	O
levels	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
and	O
protein	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
the	O
GRO	B
-	I
alpha	I
mRNA	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
inhibited	O
the	O
LPS	O
-	O
induced	O
decrease	O
in	O
IkappaB	B
levels	O
.	O

Other	O
proteasome	O
inhibitors	O
,	O
MG115	O
and	O
lactacystin	O
,	O
also	O
induced	O
the	O
expression	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
.	O

MG132	O
induced	O
the	O
phosphorylation	O
of	O
p38	B
MAPK	I
,	O
MEK	B
and	O
JNK	B
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
an	O
inhibitor	O
of	O
p38	B
MAPK	I
,	O
suppressed	O
the	O
MG132	O
-	O
induced	O
GRO	B
-	I
alpha	I
expression	O
,	O
but	O
pretreatment	O
of	O
the	O
cells	O
with	O
U0126	O
,	O
PD98059	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
MEK1	B
/	I
2	I
or	O
JNK	B
,	O
did	O
not	O
influence	O
the	O
effect	O
of	O
MG132	O
.	O

We	O
conclude	O
that	O
MG132	O
upregulates	O
GRO	B
-	I
alpha	I
expression	O
in	O
vascular	O
endothelial	O
cells	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
the	O
activation	O
of	O
p38	B
MAPK	I
.	O

CC	B
-	I
chemokine	I
receptor	I
2	I
required	O
for	O
bleomycin	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O

MCP-1	B
,	O
which	O
signals	O
via	O
the	O
CC	B
chemokine	I
receptor	I
2	I
(	O
CCR2	B
)	O
,	O
is	O
induced	O
in	O
lung	O
fibrosis	O
that	O
is	O
accompanied	O
by	O
mononuclear	O
cell	O
recruitment	O
and	O
activation	O
of	O
lung	O
fibroblasts	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
CCR2	B
in	O
lung	O
fibrosis	O
,	O
CCR2	B
knockout	O
(	O
ko	O
)	O
mice	O
were	O
used	O
in	O
a	O
model	O
of	O
bleomycin	O
-	O
induced	O
lung	O
fibrosis	O
.	O

Wild	O
type	O
(	O
wt	O
)	O
and	O
ko	O
mice	O
were	O
injected	O
endotracheally	O
with	O
bleomycin	O
to	O
induce	O
lung	O
injury	O
and	O
fibrosis	O
,	O
and	O
then	O
analyzed	O
for	O
degree	O
of	O
lung	O
fibrosis	O
and	O
cytokine	B
expression	O
.	O

The	O
results	O
showed	O
significantly	O
reduced	O
fibrosis	O
in	O
ko	O
mice	O
as	O
evidenced	O
by	O
decreased	O
lung	O
type	B
I	I
collagen	I
gene	O
expression	O
and	O
hydroxyproline	O
content	O
relative	O
to	O
those	O
in	O
wt	O
mice	O
.	O

Lung	O
TNF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
expression	O
was	O
significantly	O
lower	O
in	O
ko	O
vs.	O
wt	O
mice	O
,	O
while	O
MCP-1	B
expression	O
was	O
unaffected	O
.	O

Interestingly	O
,	O
lung	O
alpha	B
-	I
smooth	I
muscle	I
actin	I
(	O
alpha	B
-	I
SMA	I
)	O
expression	O
,	O
a	O
marker	O
for	O
myofibroblast	O
differentiation	O
,	O
was	O
also	O
decreased	O
in	O
ko	O
mice	O
,	O
which	O
was	O
confirmed	O
by	O
analysis	O
of	O
isolated	O
lung	O
fibroblasts	O
.	O

Fibroblasts	O
from	O
ko	O
mice	O
exhibited	O
decreased	O
responsiveness	O
to	O
TGF	B
-	I
beta1	I
induced	O
alpha	B
-	I
SMA	I
expression	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
expression	O
of	O
TGF	B
-	I
beta	I
receptor	I
II	I
(	O
TbetaRII	B
)	O
and	O
Smad3	B
.	O

These	O
findings	O
suggest	O
that	O
CCR2	B
signaling	O
plays	O
a	O
key	O
role	O
in	O
bleomycin	O
-	O
induced	O
pulmonary	O
fibrosis	O
by	O
regulating	O
fibrogenic	O
cytokine	B
expression	O
and	O
fibroblast	O
responsiveness	O
to	O
TGF	B
-	I
beta	I
.	O

ApoE	B
phenotype	O
influences	O
plasma	O
ASP	B
in	O
hyperapoB	O
subjects	O
.	O

Acylation	B
stimulating	I
protein	I
(	O
ASP	B
)	O
is	O
increased	O
in	O
cardiovascular	O
patients	O
who	O
often	O
present	O
with	O
dyslipidemias	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
apolipoprotein	B
E	I
(	O
apoE	B
)	O
phenotype	O
and	O
lipids	O
on	O
ASP	B
.	O

Plasma	O
ASP	B
,	O
lipids	O
and	O
apoE	B
phenotype	O
were	O
measured	O
in	O
407	O
subjects	O
and	O
separated	O
according	O
to	O
the	O
75th	O
percentile	O
of	O
apolipoprotein	B
B	I
(	O
apoB	B
)	O
into	O
a	O
HyperapoB	O
(	O
HB	O
)	O
group	O
(	O
apoB	O
=	O
152	O
+	O
/	O
-	O
34	O
mg	O
/	O
dl	O
,	O
117	O
men	O
,	O
80	O
women	O
)	O
and	O
a	O
normal	O
apoB	B
(	O
NB	O
)	O
group	O
(	O
apoB	O
=	O
88	O
+	O
/	O
-	O
19	O
mg	O
/	O
dl	O
,	O
126	O
men	O
,	O
84	O
women	O
)	O
.	O

Triglyceride	O
(	O
TG	O
)	O
,	O
cholesterol	O
and	O
LDL	B
cholesterol	O
were	O
significantly	O
increased	O
in	O
HB	O
versus	O
NB	O
but	O
there	O
was	O
no	O
difference	O
in	O
age	O
or	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

HB	O
had	O
increased	O
ASP	B
(	O
42	O
%	O
>	O
75th	O
percentile	O
,	O
median	O
=	O
48.4	O
nM	O
,	O
P	O
<	O
0.001	O
)	O
versus	O
NB	O
(	O
36.5	O
nM	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
ASP	B
in	O
NB	O
with	O
any	O
apoE3	B
variant	O
(	O
E3	O
/	O
3	O
=	O
41	O
nM	O
,	O
n	O
=	O
98	O
;	O
E3	O
/	O
4	O
=	O
46	O
nM	O
,	O
n	O
=	O
55	O
;	O
E3	O
/	O
2	O
=	O
50	O
nM	O
,	O
n	O
=	O
41	O
)	O
,	O
but	O
ASP	B
was	O
increased	O
in	O
E2	O
/	O
2	O
(	O
126	O
nM	O
,	O
n	O
=	O
9	O
)	O
,	O
and	O
E4	O
/	O
4	O
(	O
186	O
nM	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0.001	O
ANOVA	O
)	O
.	O

In	O
HB	O
,	O
ASP	B
was	O
increased	O
in	O
three	O
apoE	B
phenotypes	O
:	O
E2	O
/	O
4	O
(	O
209	O
nM	O
,	O
n=6	O
)	O
,	O
E2	O
/	O
2	O
(	O
135	O
nM	O
,	O
n	O
=	O
6	O
)	O
and	O
E4	O
/	O
4	O
(	O
189	O
nM	O
,	O
n	O
=	O
26	O
)	O
,	O
P	O
<	O
0.001	O
ANOVA	O
relative	O
to	O
the	O
other	O
apoE	B
phenotypes	O
(	O
E3	O
/	O
3	O
=	O
50	O
nM	O
,	O
n	O
=	O
102	O
;	O
E3	O
/	O
4	O
=	O
41	O
nM	O
,	O
n	O
=	O
40	O
;	O
E3	O
/	O
2	O
=	O
87	O
nM	O
,	O
n	O
=	O
17	O
)	O
with	O
a	O
wide	O
range	O
of	O
values	O
.	O

By	O
stepwise	O
regression	O
analysis	O
,	O
the	O
best	O
model	O
that	O
predicted	O
ASP	B
was	O
:	O
[	O
plasma	O
non	O
-	O
esterified	O
fatty	O
acid	O
(	O
NEFA	O
)	O
+	O
TG	O
+	O
cholesterol	O
]	O
,	O
where	O
r	O
=	O
0.407	O
,	O
P	O
=	O
0.001	O
.	O

These	O
data	O
suggest	O
that	O
apoE	B
phenotype	O
may	O
potentially	O
influence	O
ASP	B
,	O
although	O
primarily	O
in	O
rare	O
apoE	B
phenotypes	O
.	O

Specific	O
elevation	O
in	O
plasma	O
tissue	B
plasminogen	I
activator	I
antigen	O
concentrations	O
in	O
South	O
Asians	O
relative	O
to	O
Europeans	O
.	O

Elevated	O
levels	O
of	O
haemostatic	O
factors	O
including	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
antigen	O
are	O
associated	O
with	O
coronary	O
heart	O
disease	O
in	O
Europeans	O
but	O
data	O
in	O
South	O
Asians	O
are	O
sparse	O
.	O

We	O
performed	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
111	O
healthy	O
men	O
and	O
women	O
aged	O
40	O
-	O
55	O
years	O
(	O
56	O
European	O
and	O
55	O
Asian	O
)	O
frequency	O
matched	O
across	O
a	O
wide	O
range	O
of	O
body	O
mass	O
index	O
(	O
17	O
-	O
34	O
kg	O
/	O
m2	O
)	O
.	O

All	O
subjects	O
had	O
detailed	O
adiposity	O
and	O
metabolic	O
measurements	O
,	O
and	O
five	O
haemostatic	O
factors	O
were	O
determined	O
.	O

South	O
Asians	O
had	O
greater	O
insulin	B
resistance	O
than	O
Europeans	O
(	O
fasting	O
insulin	B
geometric	O
mean	O
,	O
7.1	O
versus	O
4.7	O
microU	O
/	O
ml	O
,	O
and	O
2	O
-	O
h	O
insulin	B
,	O
37.3	O
versus	O
14.1	O
microU	O
/	O
ml	O
,	O
respectively	O
)	O
.	O

There	O
were	O
no	O
significant	O
ethnic	O
differences	O
in	O
the	O
mean	O
concentrations	O
of	O
fibrinogen	B
,	O
factor	B
VII	I
,	O
von	B
Willebrand	I
factor	I
,	O
or	O
fibrin	B
D	O
-	O
dimer	O
(	O
P	O
>	O
0.10	O
)	O
.	O

However	O
,	O
the	O
t	B
-	I
PA	I
antigen	O
concentration	O
was	O
significantly	O
elevated	O
in	O
South	O
Asians	O
compared	O
with	O
Europeans	O
(	O
mean	O
,	O
10.6	O
versus	O
8.2	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
.	O

t	B
-	I
PA	I
correlated	O
positively	O
in	O
both	O
ethnic	O
groups	O
with	O
features	O
of	O
the	O
metabolic	O
syndrome	O
but	O
the	O
ethnic	O
difference	O
in	O
t	B
-	I
PA	I
persisted	O
after	O
adjustment	O
for	O
adiposity	O
,	O
metabolic	O
and	O
inflammatory	O
variables	O
(	O
beta	O
=	O
2.0	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
0.5	O
-	O
3.6	O
,	O
P	O
=	O
0.012	O
)	O
.	O

We	O
therefore	O
hypothesize	O
that	O
elevated	O
t	B
-	I
PA	I
antigen	O
may	O
be	O
a	O
novel	O
mechanism	O
contributing	O
to	O
increased	O
cardiovascular	O
risk	O
in	O
South	O
Asians	O
.	O

The	O
l	O
-	O
isomer	O
-	O
selective	O
transport	O
of	O
aspartic	O
acid	O
is	O
mediated	O
by	O
ASCT2	B
at	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Aspartic	O
acid	O
(	O
Asp	O
)	O
undergoes	O
l	O
-	O
isomer	O
-	O
selective	O
efflux	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

This	O
transport	O
system	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
l	O
-	O
and	O
d	O
-	O
Asp	O
levels	O
in	O
the	O
brain	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
responsible	O
transporters	O
and	O
elucidate	O
the	O
mechanism	O
for	O
l	O
-	O
isomer	O
-	O
selective	O
Asp	O
transport	O
at	O
the	O
BBB	O
.	O

The	O
l	O
-	O
isomer	O
-	O
selective	O
uptake	O
of	O
Asp	O
by	O
conditionally	O
immortalized	O
mouse	O
brain	O
capillary	O
endothelial	O
cells	O
used	O
as	O
an	O
in	O
vitro	O
model	O
of	O
the	O
BBB	O
took	O
place	O
in	O
an	O
Na+	O
-	O
and	O
pH	O
-	O
dependent	O
manner	O
.	O

This	O
process	O
was	O
inhibited	O
by	O
system	O
ASC	O
substrates	O
such	O
as	O
l	O
-	O
alanine	O
and	O
l	O
-	O
serine	O
,	O
suggesting	O
that	O
system	O
ASC	B
transporters	I
,	O
ASCT1	B
and	O
ASCT2	B
,	O
are	O
involved	O
in	O
the	O
l	O
-	O
isomer	O
selective	O
transport	O
.	O

Indeed	O
,	O
l	O
-	O
Asp	O
uptake	O
by	O
oocytes	O
injected	O
with	O
either	O
ASCT1	B
or	O
ASCT2	B
cRNA	O
took	O
place	O
in	O
a	O
similar	O
manner	O
to	O
that	O
in	O
cultured	O
BBB	O
cells	O
,	O
whereas	O
no	O
significant	O
d	O
-	O
Asp	O
uptake	O
occurred	O
.	O

Although	O
both	O
ASCT1	B
and	O
ASCT2	B
mRNA	O
were	O
expressed	O
in	O
the	O
cultured	O
BBB	O
cells	O
,	O
the	O
expression	O
of	O
ASCT2	B
mRNA	O
was	O
6.7	O
-	O
fold	O
greater	O
than	O
that	O
of	O
ASCT1	B
.	O

Moreover	O
,	O
immunohistochemical	O
analysis	O
suggests	O
that	O
ASCT2	B
is	O
localized	O
at	O
the	O
abluminal	O
side	O
of	O
the	O
mouse	O
BBB	O
.	O

These	O
results	O
suggest	O
that	O
ASCT2	B
plays	O
a	O
key	O
role	O
in	O
l	O
-	O
isomer	O
-	O
selective	O
Asp	O
efflux	O
transport	O
at	O
the	O
BBB	O
.	O

A	O
Korean	O
kindred	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
and	O
mental	O
retardation	O
.	O

BACKGROUND	O
:	O

A	O
Korean	O
family	O
had	O
distinctive	O
clinical	O
and	O
neuroimaging	O
features	O
and	O
carried	O
the	O
same	O
genetic	O
mutation	O
that	O
was	O
found	O
in	O
a	O
previously	O
described	O
Japanese	O
kindred	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

OBJECTIVE	O
:	O

To	O
describe	O
the	O
first	O
Korean	O
family	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

METHODS	O
:	O

Members	O
of	O
a	O
large	O
family	O
,	O
including	O
9	O
affected	O
individuals	O
from	O
3	O
generations	O
,	O
underwent	O
a	O
comprehensive	O
genetic	O
,	O
clinical	O
,	O
electroencephalographic	O
,	O
neuropsychological	O
,	O
and	O
neuroimaging	O
evaluation	O
.	O

Affected	O
members	O
were	O
tested	O
for	O
possible	O
mutations	O
in	O
transmembrane	O
regions	O
1	O
through	O
3	O
of	O
the	O
neuronal	B
nicotinic	I
acetylcholine	I
receptor	I
alpha4	I
subunit	O
(	O
CHRNA4	B
)	O
by	O
direct	O
sequencing	O
and	O
subsequent	O
restriction	O
analysis	O
.	O

RESULTS	O
:	O

Seizures	O
began	O
in	O
childhood	O
,	O
presenting	O
as	O
nocturnal	O
episodes	O
of	O
staring	O
,	O
confusion	O
,	O
shouting	O
,	O
perioral	O
movements	O
,	O
unintelligible	O
speech	O
,	O
and	O
hand	O
waving	O
.	O

Some	O
patients	O
had	O
ictal	O
or	O
interictal	O
epileptiform	O
activity	O
in	O
the	O
temporal	O
and/or	O
frontocentral	O
areas	O
.	O

Neurological	O
examination	O
and	O
brain	O
magnetic	O
resonance	O
imaging	O
results	O
showed	O
no	O
abnormalities	O
,	O
except	O
that	O
all	O
patients	O
available	O
for	O
testing	O
had	O
mild	O
to	O
moderate	O
mental	O
retardation	O
.	O

Fluorodeoxyglucose	O
F	O
18	O
with	O
positron	O
emission	O
tomography	O
showed	O
mild	O
decreased	O
glucose	O
uptake	O
in	O
the	O
superior	O
and	O
middle	O
frontal	O
regions	O
,	O
more	O
so	O
on	O
the	O
left	O
than	O
on	O
the	O
right	O
.	O

Patient	O
response	O
to	O
carbamazepine	O
was	O
poor	O
.	O

All	O
affected	O
members	O
were	O
heterozygous	O
for	O
the	O
CHRNA4	B
Ser252Leu	O
mutation	O
.	O

CONCLUSIONS	O
:	O

Disorders	O
associated	O
with	O
mutations	O
in	O
the	O
transmembrane	O
region	O
2	O
of	O
CHRNA4	B
are	O
genetically	O
and	O
phenotypically	O
heterogeneous	O
.	O

Distinctive	O
features	O
of	O
this	O
kindred	O
include	O
(	O
1	O
)	O
mental	O
retardation	O
in	O
all	O
affected	O
members	O
available	O
for	O
testing	O
,	O
(	O
2	O
)	O
abnormal	O
brain	O
findings	O
on	O
fluorodeoxyglucose	O
F	O
18	O
with	O
positron	O
emission	O
tomography	O
,	O
(	O
3	O
)	O
poor	O
response	O
to	O
carbamazepine	O
,	O
and	O
(	O
4	O
)	O
full	O
penetrance	O
.	O

Complete	O
sequencing	O
and	O
expression	O
of	O
three	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
of	O
the	O
classical	O
activation	O
pathway	O
of	O
the	O
complement	O
system	O
in	O
rainbow	O
trout	O
Oncorhynchus	O
mykiss	O
.	O

Three	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
of	O
the	O
classical	O
activation	O
pathway	O
have	O
been	O
fully	O
sequenced	O
and	O
their	O
expression	O
investigated	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O

Trout	O
C1r	B
cDNA	O
encodes	O
a	O
707-amino	O
-	O
acid	O
(	O
aa	O
)	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
77,200	O
.	O

The	O
trout	O
translation	O
shows	O
highest	O
homology	O
with	O
carp	O
C1r	B
/	I
s	I
,	O
and	O
lower	O
,	O
equal	O
homologies	O
to	O
mammalian	O
C1r	B
and	O
C1s	B
,	O
and	O
MASPs	B
from	O
other	O
vertebrate	O
species	O
.	O

However	O
,	O
phylogenetic	O
analysis	O
and	O
structural	O
features	O
suggest	O
that	O
the	O
trout	O
sequence	O
,	O
together	O
with	O
the	O
two	O
carp	O
sequences	O
,	O
are	O
the	O
orthologues	O
of	O
mammalian	O
C1r	B
.	O

The	O
trout	O
C4	B
cDNA	O
encodes	O
a	O
1,724-aa	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
192,600	O
.	O

The	O
trout	O
translation	O
shows	O
higher	O
homologies	O
to	O
the	O
carp	O
C4B	B
and	O
medaka	O
C4	B
,	O
but	O
lower	O
homologies	O
to	O
C4	B
from	O
other	O
species	O
and	O
the	O
carp	O
C4A	B
.	O

It	O
has	O
a	O
predicted	O
signal	O
peptide	O
of	O
22	O
aa	O
,	O
a	O
alpha	O
-	O
chain	O
of	O
773	O
aa	O
,	O
a	O
beta	O
-	O
chain	O
of	O
635	O
aa	O
and	O
a	O
lambda	O
-	O
chain	O
of	O
288	O
aa	O
.	O

Trout	O
C1	B
inhibitor	I
cDNA	O
encodes	O
a	O
611	O
-	O
aa	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
68,700	O
.	O

The	O
trout	O
translation	O
has	O
a	O
C	O
-	O
terminal	O
serpin	B
domain	O
with	O
high	O
homologies	O
with	O
mammalian	O
counterparts	O
(	O
~37	O
%	O
identities	O
)	O
,	O
and	O
a	O
longer	O
N	O
-	O
terminus	O
,	O
with	O
no	O
significant	O
homology	O
to	O
other	O
serpins	B
,	O
which	O
contains	O
two	O
Ig	B
-	O
like	O
domains	O
.	O

A	O
molecule	O
containing	O
two	O
Ig	B
-	O
like	O
domains	O
followed	O
by	O
a	O
serpin	B
domain	O
,	O
has	O
also	O
been	O
found	O
in	O
an	O
EST	O
clone	O
from	O
another	O
bony	O
fish	O
,	O
the	O
Japanese	O
flounder	O
.	O

This	O
suggests	O
a	O
unique	O
structural	O
feature	O
of	O
C1	B
inhibitor	I
in	O
fish	O
.	O

The	O
functional	O
significance	O
of	O
the	O
Ig	B
domains	O
is	O
discussed	O
.	O

The	O
liver	O
is	O
the	O
major	O
site	O
of	O
expression	O
of	O
the	O
three	O
trout	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
although	O
their	O
expression	O
is	O
also	O
detectable	O
in	O
other	O
tissues	O
.	O

The	O
extra	O
-	O
hepatic	O
expression	O
of	O
complement	O
genes	O
may	O
be	O
important	O
for	O
local	O
protection	O
and	O
inflammatory	O
responses	O
.	O

Low	O
-	O
level	O
constitutive	O
expression	O
of	O
the	O
three	O
components	O
was	O
also	O
detectable	O
in	O
a	O
trout	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
RTS-11	O
,	O
but	O
only	O
the	O
expression	O
of	O
C4	B
could	O
be	O
upregulated	O
by	O
LPS	O
.	O

Increase	O
of	O
inflammatory	O
state	O
in	O
overweight	O
adults	O
with	O
combined	O
hyperlipidemia	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O

Elevated	O
levels	O
of	O
acute	O
phase	O
reactants	O
are	O
found	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
.	O

It	O
is	O
suggested	O
that	O
adipose	O
tissue	O
is	O
a	O
determinant	O
of	O
a	O
low	O
level	O
of	O
inflammatory	O
state	O
in	O
overweight	O
persons	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
,	O
whether	O
combined	O
hyperlipidemia	O
,	O
which	O
is	O
an	O
important	O
factor	O
of	O
atherosclerosis	O
,	O
has	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
overweight	O
adults	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Levels	O
of	O
soluble	O
cell	O
adhesion	B
molecules	I
sICAM-1	B
,	O
sE	B
-	I
selectin	I
and	O
sP	B
-	I
selectin	I
,	O
PAI-1	B
Ag	O
(	O
by	O
Elisa	O
test	O
)	O
,	O
orosomucoid	B
(	O
ORM	B
)	O
and	O
transferrin	B
(	O
TRF	B
)	O
(	O
by	O
microturbidimetry	O
)	O
and	O
fibrinogen	B
(	O
FBG	B
)	O
according	O
to	O
Clauss	O
were	O
examined	O
in	O
peripheral	O
blood	O
of	O
overweight	O
adults	O
(	O
n	O
33	O
,	O
body	O
mass	O
index	O
27.1	O
+	O
/-	O
1.8	O
kg	O
/	O
m2	O
)	O
with	O
combined	O
hyperlipidemia	O
and	O
in	O
equal	O
numbers	O
of	O
age	O
,	O
sex	O
and	O
BMI	O
matched	O
non	O
-	O
hyperlipidemic	O
group	O
.	O

Overweight	O
adults	O
with	O
combined	O
hyperlipidemia	O
had	O
significantly	O
higher	O
plasma	O
levels	O
of	O
sICAM-1	B
(	O
376.5	O
+	O
/-	O
107.4	O
ng	O
/	O
mL	O
vs	O
239.3	O
+	O
/-	O
60.4	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.001	O
)	O
,	O
sE	B
-	I
selectin	I
(	O
70.4	O
+	O
/-	O
20.2	O
ng	O
/	O
mL	O
vs	O
48.5	O
+	O
/-	O
25.6	O
ng	O
/	O
mL	O
;	O
p	O
=	O
0.005	O
)	O
,	O
sP	B
-	I
selectin	I
(	O
228.2	O
+	O
/-	O
88.6	O
ng	O
/	O
mL	O
vs	O
123.1	O
+	O
/-	O
45.3	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.001	O
)	O
and	O
positive	O
acute	O
phase	O
proteins	O
ORM	B
(	O
0.82	O
+	O
/-	O
0.16	O
g	O
/	O
L	O
vs	O
0.64	O
+	O
/-	O
0.20	O
g	O
/	O
L	O
;	O
p	O
=	O
0.005	O
)	O
,	O
FBG	B
(	O
3.42	O
+	O
/-	O
0.54	O
g	O
/	O
L	O
vs	O
2.74	O
+	O
/-	O
0.57	O
g	O
/	O
L	O
;	O
p	O
=	O
0.037	O
)	O
and	O
PAI-1	B
Ag	O
(	O
97.9	O
+	O
/-	O
40.6	O
ng	O
/	O
mL	O
vs	O
56.4	O
+	O
/-	O
25.6	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.05	O
)	O
,	O
and	O
a	O
decrease	O
of	O
negative	O
acute	O
phase	O
protein	O
TRF	B
(	O
2.14	O
+	O
/-	O
0.40	O
g	O
/	O
L	O
vs	O
2.77	O
+	O
/-	O
0.45	O
g	O
/	O
L	O
;	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
the	O
results	O
in	O
overweight	O
non	O
-	O
hyperlipidemic	O
controls	O
.	O

CONCLUSIONS	O
:	O

It	O
is	O
suggested	O
that	O
overweight	O
adults	O
have	O
an	O
increase	O
of	O
inflammatory	O
response	O
dependent	O
on	O
hyperlipidemia	O
.	O

It	O
was	O
apparent	O
from	O
the	O
elevation	O
of	O
sE	B
--	I
selectin	I
,	O
sP	B
--	I
selectin	I
and	O
sICAM-1	B
and	O
from	O
an	O
increase	O
of	O
systemic	O
inflammatory	O
response	O
according	O
to	O
the	O
increase	O
of	O
""""	O
positive	O
""""	O
acute	O
phase	O
proteins	O
(	O
APRs	O
)	O
and	O
the	O
decrease	O
of	O
""""	O
negative	O
""""	O
APR	O
protein	O
levels	O
in	O
these	O
patients	O
.	O

Domain	O
shuffling	O
has	O
been	O
the	O
main	O
mechanism	O
forming	O
new	O
hominoid	O
killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
.	O

The	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
gene	I
family	I
encodes	O
MHC	B
class	I
I	I
-	O
specific	O
receptors	O
,	O
which	O
regulate	O
NK	O
cell	O
responses	O
and	O
are	O
also	O
expressed	O
on	O
subpopulations	O
of	O
T	O
cells	O
.	O

KIR	B
haplotypes	O
vary	O
in	O
gene	O
content	O
,	O
which	O
,	O
in	O
combination	O
with	O
allelic	O
polymorphism	O
,	O
extensively	O
diversifies	O
the	O
KIR	B
genotype	O
both	O
within	O
and	O
between	O
human	O
populations	O
.	O

Species	O
comparison	O
indicates	O
that	O
formation	O
of	O
new	O
KIR	B
genes	O
and	O
loss	O
of	O
old	O
ones	O
are	O
frequent	O
events	O
,	O
so	O
that	O
few	O
genes	O
are	O
conserved	O
even	O
between	O
closely	O
related	O
species	O
.	O

In	O
this	O
regard	O
,	O
the	O
hominoids	O
define	O
a	O
time	O
frame	O
that	O
is	O
particularly	O
informative	O
for	O
understanding	O
the	O
processes	O
of	O
KIR	B
evolution	O
and	O
its	O
potential	O
impact	O
on	O
killer	O
cell	O
biology	O
.	O

KIR	B
cDNA	O
were	O
characterized	O
from	O
PBMC	O
of	O
three	O
gorillas	O
,	O
and	O
genomic	O
DNA	O
were	O
characterized	O
for	O
six	O
additional	O
individuals	O
.	O

Eleven	O
gorilla	O
KIR	B
genes	O
were	O
defined	O
.	O

With	O
attainment	O
of	O
these	O
data	O
,	O
a	O
set	O
of	O
75	O
KIR	B
sequences	O
representing	O
five	O
hominoid	O
species	O
was	O
assembled	O
,	O
which	O
also	O
included	O
rhesus	O
monkey	O
,	O
cattle	O
,	O
and	O
rodent	O
KIR	B
.	O

Searching	O
this	O
data	O
set	O
for	O
recombination	O
events	O
,	O
and	O
phylogenetic	O
analysis	O
using	O
Bayesian	O
methods	O
,	O
demonstrated	O
that	O
new	O
KIR	B
were	O
usually	O
the	O
result	O
of	O
recombination	O
between	O
loci	O
in	O
which	O
complete	O
protein	O
domains	O
were	O
shuffled	O
.	O

Further	O
phylogenetic	O
analysis	O
of	O
the	O
KIR	B
sequences	O
after	O
removal	O
of	O
confounding	O
recombined	O
segments	O
showed	O
that	O
only	O
two	O
KIR	B
genes	O
,	O
KIR2DL4	B
and	O
KIR2DL5	B
,	O
have	O
been	O
preserved	O
throughout	O
hominoid	O
evolution	O
,	O
and	O
one	O
of	O
them	O
,	O
KIR2DL4	B
,	O
is	O
also	O
common	O
to	O
rhesus	O
monkey	O
and	O
hominoids	O
.	O

Other	O
KIR	B
genes	O
represent	O
recombinant	O
forms	O
present	O
in	O
a	O
minority	O
of	O
species	O
,	O
often	O
only	O
one	O
,	O
as	O
exemplified	O
by	O
8	O
of	O
the	O
11	O
gorilla	O
KIR	B
genes	O
.	O

Interleukin-4	B
inhibits	O
platelet	B
-	I
derived	I
growth	I
factor	I
-	O
induced	O
preadipocyte	O
proliferation	O
.	O

Interleukin-4	B
(	O
IL-4	B
)	O
activates	O
STAT6	B
in	O
3T3-L1	O
preadipocytes	O
but	O
its	O
functional	O
role	O
is	O
not	O
known	O
.	O

In	O
this	O
report	O
,	O
we	O
first	O
assessed	O
interleukin-4	B
receptor	I
alpha	I
(	O
IL-4Ralpha	B
)	O
expression	O
during	O
adipogenesis	O
.	O

IL-4Ralpha	B
was	O
highly	O
expressed	O
in	O
proliferating	O
3T3-L1	O
preadipocytes	O
.	O

Receptor	O
expression	O
was	O
down	O
-	O
regulated	O
in	O
post	O
-	O
confluent	O
growth	O
arrested	O
preadipocytes	O
.	O

Induction	O
of	O
differentiation	O
led	O
to	O
a	O
transient	O
36	O
-	O
h	O
increase	O
in	O
expression	O
,	O
but	O
then	O
levels	O
decreased	O
to	O
undetectable	O
amounts	O
3	O
-	O
8	O
days	O
after	O
induction	O
of	O
differentiation	O
.	O

Depending	O
on	O
the	O
cell	O
type	O
,	O
IL-4	B
either	O
increases	O
or	O
decreases	O
cell	O
proliferation	O
.	O

In	O
growth	O
arrested	O
preconfluent	O
3T3-L1	O
preadipocytes	O
,	O
IL-4	B
alone	O
had	O
no	O
effect	O
on	O
preadipocyte	O
proliferation	O
.	O

In	O
contrast	O
,	O
IL-4	B
inhibited	O
platelet	B
-	I
derived	I
growth	I
factor	I
(	O
PDGF	B
-	I
BB	I
)	O
induced	O
preadipocyte	O
proliferation	O
.	O

PDGF	B
-	I
BB	I
,	O
but	O
not	O
IL-4	B
,	O
induced	O
STAT3	B
tyrosine	O
and	O
AKT	B
serine	O
phosphorylation	O
.	O

Both	O
PDGF	B
-	I
BB	I
and	O
IL-4	B
induced	O
STAT6	B
tyrosine	O
phosphorylation	O
,	O
but	O
the	O
bands	O
showed	O
distinct	O
electrophoretic	O
migration	O
patterns	O
.	O

IL-4	B
alone	O
and	O
IL-4	B
added	O
to	O
the	O
differentiation	O
cocktail	O
had	O
no	O
effect	O
on	O
adipocyte	O
formation	O
or	O
PPARgamma	B
expression	O
.	O

Collectively	O
,	O
these	O
studies	O
demonstrate	O
that	O
IL-4	B
inhibits	O
PDGF	B
-	I
BB	I
-	O
induced	O
preadipocyte	O
proliferation	O
,	O
possibly	O
through	O
STAT6	B
activation	O
.	O

The	O
pattern	O
of	O
IL-4	B
receptor	I
expression	O
suggests	O
that	O
the	O
effects	O
of	O
IL-4	B
are	O
targeted	O
primarily	O
towards	O
preadipocytes	O
.	O

Multiple	O
stress	O
signal	O
integration	O
in	O
the	O
regulation	O
of	O
the	O
complex	O
sigma	B
S	I
-	O
dependent	O
csiD	B
-	O
ygaF	B
-	O
gabDTP	B
operon	I
in	O
Escherichia	O
coli	O
.	O

The	O
csiD	B
-	O
ygaF	B
-	O
gabDTP	B
region	O
in	O
the	O
Escherichia	O
coli	O
genome	O
represents	O
a	O
cluster	O
of	O
sigma	B
S	I
-	O
controlled	O
genes	O
.	O

Here	O
,	O
we	O
investigated	O
promoter	O
structures	O
,	O
sigma	B
factor	I
dependencies	O
,	O
potential	O
co	O
-	O
regulation	O
and	O
environmental	O
regulatory	O
patterns	O
for	O
all	O
of	O
these	O
genes	O
.	O

We	O
find	O
that	O
this	O
region	O
constitutes	O
a	O
complex	O
operon	O
with	O
expression	O
being	O
controlled	O
by	O
three	O
differentially	O
regulated	O
promoters	O
:	O
(	O
i	O
)	O
csiDp	B
,	O
which	O
affects	O
the	O
expression	O
of	O
all	O
five	O
genes	O
,	O
is	O
cAMP	O
-	O
CRP	B
/	O
sigma	B
S	I
-	O
dependent	O
and	O
activated	O
exclusively	O
upon	O
carbon	O
starvation	O
and	O
stationary	O
phase	O
;	O
(	O
ii	O
)	O
gabDp1	B
,	O
which	O
is	O
sigma	B
S	I
-	O
dependent	O
and	O
exhibits	O
multiple	O
stress	O
induction	O
like	O
sigma	B
S	I
itself	O
;	O
and	O
(	O
iii	O
)	O
gabDp2	B
[	O
previously	O
suggested	O
by	O
Schneider	O
,	O
B.L.	O
,	O
Ruback	O
,	O
S.	O
,	O
Kiupakis	O
,	O
A.K.	O
,	O
Kasbarian	O
,	O
H.	O
,	O
Pybus	O
,	O
C.	O
,	O
and	O
Reitzer	O
,	O
L.	O
(	O
2002	O
)	O
J.	O
Bacteriol	O
.	O
184	O
:	O
6976	O
-	O
6986	O
]	O
,	O
which	O
appears	O
to	O
be	O
Nac	B
/	O
sigma	B
70	I
-	O
controlled	O
and	O
to	O
respond	O
to	O
poor	O
nitrogen	O
sources	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
novel	O
repressor	O
,	O
CsiR	B
,	O
which	O
modulates	O
csiDp	B
activity	O
in	O
a	O
temporal	O
manner	O
during	O
early	O
stationary	O
phase	O
.	O

Finally	O
,	O
we	O
propose	O
a	O
physiological	O
role	O
for	O
sigma	B
S	I
-	O
controlled	O
GabT	B
/	I
D	I
-	O
mediated	O
gamma	O
-	O
aminobutyrate	O
(	O
GABA	O
)	O
catabolism	O
and	O
glutamate	O
accumulation	O
in	O
general	O
stress	O
adaptation	O
.	O

This	O
physiological	O
role	O
is	O
reflected	O
by	O
the	O
activation	O
of	O
the	O
operon	O
-	O
internal	O
gabDp1	B
promoter	O
under	O
the	O
different	O
conditions	O
that	O
also	O
induce	O
sigma	B
S	I
,	O
which	O
include	O
shifts	O
to	O
acidic	O
pH	O
or	O
high	O
osmolarity	O
as	O
well	O
as	O
starvation	O
or	O
stationary	O
phase	O
.	O

Forest	O
tent	O
caterpillars	O
(	O
Malacosoma	O
disstria	O
)	O
induce	O
local	O
and	O
systemic	O
diurnal	O
emissions	O
of	O
terpenoid	O
volatiles	O
in	O
hybrid	O
poplar	O
(	O
Populus	O
trichocarpa	O
x	O
deltoides	O
)	O
:	O
cDNA	O
cloning	O
,	O
functional	O
characterization	O
,	O
and	O
patterns	O
of	O
gene	O
expression	O
of	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
,	O
PtdTPS1	B
.	O

Feeding	O
forest	O
tent	O
caterpillars	O
(	O
FTCs	O
)	O
induced	O
local	O
and	O
systemic	O
diurnal	O
emissions	O
of	O
(	O
-	O
)	O
-germacrene	O
D	O
,	O
along	O
with	O
(	O
E	O
)	O
-beta	O
-	O
ocimene	O
,	O
linalool	O
,	O
(	O
E	O
)	O
-4,8-dimethyl-1,3,7-nonatriene	O
(	O
DMNT	O
)	O
,	O
benzene	O
cyanide	O
,	O
and	O
(	O
E	O
,	O
E	O
)	O
-alpha	O
-	O
farnesene	O
,	O
from	O
leaves	O
of	O
hybrid	O
poplar	O
.	O

FTC	O
feeding	O
induced	O
substantially	O
higher	O
levels	O
of	O
volatiles	O
in	O
local	O
and	O
systemic	O
leaves	O
than	O
did	O
mechanical	O
wounding	O
.	O

A	O
full	O
-	O
length	O
poplar	O
sesquiterpene	B
synthase	I
cDNA	O
(	O
PtdTPS1	B
)	O
was	O
isolated	O
and	O
functionally	O
identified	O
as	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
.	O

Expression	O
of	O
PtdTPS1	B
,	O
expression	O
of	O
genes	O
of	O
early	O
,	O
intermediate	O
and	O
late	O
steps	O
in	O
terpenoid	O
biosynthesis	O
,	O
and	O
expression	O
of	O
a	O
lipoxygenase	B
gene	O
(	O
PtdLOX1	B
)	O
were	O
analyzed	O
in	O
local	O
FTC	O
-	O
infested	O
and	O
systemic	O
leaves	O
.	O

Transcript	O
levels	O
of	O
PtdTPS1	B
and	O
PtdLOX1	B
were	O
strongly	O
increased	O
in	O
response	O
to	O
herbivory	O
.	O

PtdTPS1	B
was	O
also	O
induced	O
by	O
mechanical	O
wounding	O
or	O
by	O
methyl	O
jasmonate	O
(	O
MeJA	O
)	O
treatment	O
.	O

FTC	O
feeding	O
did	O
not	O
affect	O
transcript	O
levels	O
of	O
3-hydroxy-3-methylglutaryl	B
-	I
CoA	I
reductase	I
(	O
HMGR	B
)	O
,	O
1-deoxy	B
-	I
d	I
-	I
xylulose	I
5-phosphate	I
reductoisomerase	I
(	O
DXR	B
)	O
,	O
and	O
isoprene	B
synthase	I
(	O
IPS	B
)	O
.	O

Two	O
other	O
TPS	B
genes	O
,	O
PtdTPS2	B
and	O
PtTPS3	B
,	O
and	O
farnesyl	B
diphosphate	I
synthase	I
were	O
only	O
very	O
transiently	O
induced	O
.	O

These	O
results	O
illustrate	O
differential	O
expression	O
of	O
terpenoid	O
pathway	O
genes	O
in	O
response	O
to	O
insect	O
feeding	O
and	O
a	O
key	O
function	O
of	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
PtdTPS1	B
for	O
herbivore	O
-	O
induced	O
local	O
and	O
systemic	O
volatile	O
emissions	O
in	O
hybrid	O
poplar	O
.	O

FTC	O
-	O
induced	O
transcripts	O
of	O
PtdTPS1	B
followed	O
diurnal	O
rhythm	O
.	O

Spatial	O
patterns	O
of	O
FTC	O
-	O
induced	O
PtdTPS1	B
transcript	O
accumulation	O
revealed	O
acropetal	O
but	O
not	O
basipetal	O
direction	O
of	O
the	O
systemic	O
response	O
.	O

Implications	O
for	O
tritrophic	O
poplar	O
-	O
FTC	O
-	O
predator	O
/	O
parasitoid	O
interactions	O
are	O
discussed	O
.	O

The	O
linker	O
region	O
between	O
the	O
helicase	B
and	O
primase	B
domains	O
of	O
the	O
gene	O
4	O
protein	O
of	O
bacteriophage	O
T7	O
.	O

Role	O
in	O
helicase	B
conformation	O
and	O
activity	O
.	O

The	O
gene	O
4	O
protein	O
of	O
bacteriophage	O
T7	O
provides	O
both	O
helicase	B
and	O
primase	B
activities	O
.	O

The	O
C	O
-	O
terminal	O
helicase	B
domain	O
is	O
responsible	O
for	O
DNA	O
-	O
dependent	O
dTTP	O
hydrolysis	O
,	O
translocation	O
,	O
and	O
DNA	O
unwinding	O
whereas	O
the	O
N	O
-	O
terminal	O
primase	B
domain	O
is	O
responsible	O
for	O
template	O
-	O
directed	O
oligoribonucleotide	O
synthesis	O
.	O

A	O
26	O
amino	O
acid	O
linker	O
region	O
(	O
residues	O
246	O
-	O
271	O
)	O
connects	O
the	O
two	O
domains	O
and	O
is	O
essential	O
for	O
the	O
formation	O
of	O
functional	O
hexamers	O
.	O

In	O
order	O
to	O
further	O
dissect	O
the	O
role	O
of	O
the	O
linker	O
region	O
,	O
three	O
residues	O
(	O
Ala257	O
,	O
Pro259	O
,	O
and	O
Asp263	O
)	O
that	O
was	O
disordered	O
in	O
the	O
crystal	O
structure	O
of	O
the	O
hexameric	O
helicase	B
fragment	O
were	O
substituted	O
with	O
all	O
amino	O
acids	O
,	O
and	O
the	O
altered	O
proteins	O
were	O
analyzed	O
for	O
their	O
ability	O
to	O
support	O
growth	O
of	O
T7	O
phage	O
lacking	O
gene	O
4	O
.	O

The	O
in	O
vivo	O
screening	O
revealed	O
Ala257	O
and	O
Asp263	O
to	O
be	O
essential	O
whereas	O
Pro259	O
could	O
be	O
replaced	O
with	O
any	O
amino	O
acid	O
without	O
loss	O
of	O
function	O
.	O

Selected	O
gene	O
4	O
proteins	O
with	O
substitution	O
for	O
Ala257	O
or	O
Asp263	O
were	O
purified	O
and	O
examined	O
for	O
their	O
ability	O
to	O
unwind	O
DNA	O
,	O
hydrolyze	O
dTTP	O
,	O
translocate	O
on	O
ssDNA	O
,	O
and	O
oligomerize	O
.	O

In	O
the	O
presence	O
of	O
Mg2	O
+	O
,	O
all	O
of	O
the	O
altered	O
proteins	O
oligomerize	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
divalent	O
ion	O
,	O
alterations	O
at	O
position	O
257	O
increase	O
the	O
extent	O
of	O
oligomerization	O
whereas	O
those	O
at	O
position	O
263	O
reduce	O
oligomer	O
formation	O
.	O

Although	O
dTTP	O
hydrolysis	O
activity	O
is	O
reduced	O
only	O
2	O
-	O
3	O
-	O
fold	O
,	O
none	O
of	O
the	O
altered	O
gene	O
4	O
proteins	O
can	O
translocate	O
effectively	O
on	O
single	O
-	O
strand	O
DNA	O
,	O
and	O
they	O
can	O
not	O
mediate	O
the	O
unwinding	O
of	O
duplex	O
DNA	O
.	O

Primer	O
synthesis	O
catalyzed	O
by	O
the	O
altered	O
proteins	O
is	O
relatively	O
normal	O
on	O
a	O
short	O
DNA	O
template	O
but	O
it	O
is	O
severely	O
impaired	O
on	O
longer	O
templates	O
where	O
translocation	O
is	O
required	O
.	O

The	O
results	O
suggest	O
that	O
the	O
linker	O
region	O
not	O
only	O
connects	O
the	O
two	O
domains	O
of	O
the	O
gene	O
4	O
protein	O
and	O
participates	O
in	O
oligomerization	O
,	O
but	O
also	O
contributes	O
to	O
helicase	B
activity	O
by	O
mediating	O
conformations	O
within	O
the	O
functional	O
hexamer	O
.	O

Expression	O
of	O
the	O
chitobiose	B
operon	I
of	O
Escherichia	O
coli	O
is	O
regulated	O
by	O
three	O
transcription	B
factors	I
:	O
NagC	B
,	O
ChbR	B
and	O
CAP	B
.	O

The	O
chitobiose	B
operon	I
,	O
chbBCARFG	B
,	O
encodes	O
genes	O
for	O
the	O
transport	O
and	O
degradation	O
of	O
the	O
N	O
-	O
acetylglucosamine	O
disaccharide	O
,	O
chitobiose	O
.	O

Chitobiose	O
is	O
transported	O
by	O
the	O
phosphotransferase	B
system	I
(	O
PTS	B
)	O
producing	O
chitobiose-6P	O
which	O
is	O
hydrolysed	O
to	O
GlcNAc-6P	O
by	O
the	O
chbF	B
gene	O
product	O
and	O
then	O
further	O
degraded	O
by	O
the	O
nagBA	B
gene	O
products	O
.	O

Expression	O
of	O
the	O
chb	B
operon	I
is	O
repressed	O
by	O
NagC	B
,	O
which	O
regulates	O
genes	O
involved	O
in	O
amino	O
sugar	O
metabolism	O
.	O

The	O
inducer	O
for	O
NagC	B
is	O
GlcNAc-6P	O
.	O

NagC	B
binds	O
to	O
two	O
sites	O
separated	O
by	O
115	O
bp	O
and	O
the	O
transcription	O
start	O
point	O
of	O
the	O
chb	B
operon	I
lies	O
within	O
the	O
downstream	O
NagC	B
operator	O
.	O

In	O
addition	O
the	O
chb	B
operon	I
encodes	O
its	O
own	O
specific	O
regulator	O
,	O
ChbR	B
,	O
an	O
AraC	B
-	O
type	O
dual	O
repressor	O
-	O
activator	O
,	O
which	O
binds	O
to	O
two	O
direct	O
repeats	O
of	O
19	O
bp	O
located	O
between	O
the	O
two	O
NagC	B
sites	O
.	O

ChbR	B
is	O
necessary	O
for	O
transcription	O
activation	O
in	O
the	O
presence	O
of	O
chitobiose	O
in	O
vivo	O
.	O

Induction	O
of	O
the	O
operon	O
also	O
requires	O
CAP	B
,	O
which	O
binds	O
to	O
a	O
site	O
upstream	O
of	O
the	O
ChbR	B
repeats	O
.	O

In	O
the	O
absence	O
of	O
chitobiose	O
both	O
NagC	B
and	O
ChbR	B
act	O
as	O
repressors	O
.	O

Together	O
these	O
three	O
factors	O
cooperate	O
in	O
switching	O
chb	B
expression	O
from	O
the	O
repressed	O
to	O
the	O
activated	O
state	O
.	O

The	O
need	O
for	O
two	O
specific	O
inducing	O
signals	O
,	O
one	O
for	O
ChbR	B
to	O
activate	O
the	O
expression	O
of	O
the	O
operon	O
and	O
a	O
second	O
for	O
NagC	B
to	O
relieve	O
its	O
repression	O
,	O
ensure	O
that	O
the	O
chb	B
operon	I
is	O
only	O
induced	O
when	O
there	O
is	O
sufficient	O
flux	O
through	O
the	O
combined	O
chb	B
-	O
nag	B
metabolic	O
pathway	O
to	O
activate	O
expression	O
of	O
both	O
the	O
chb	B
and	I
nag	I
operons	I
.	O

La	B
protein	I
binding	O
at	O
the	O
GCAC	O
site	O
near	O
the	O
initiator	O
AUG	O
facilitates	O
the	O
ribosomal	O
assembly	O
on	O
the	O
hepatitis	O
C	O
virus	O
RNA	O
to	O
influence	O
internal	O
ribosome	O
entry	O
site	O
-	O
mediated	O
translation	O
.	O

Human	O
La	B
autoantigen	I
has	O
been	O
shown	O
to	O
influence	O
internal	O
initiation	O
of	O
translation	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
RNA	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
among	O
the	O
three	O
RRMs	O
of	O
La	B
protein	I
,	O
the	O
RRM2	O
interacts	O
with	O
HCV	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
around	O
the	O
GCAC	O
motif	O
near	O
the	O
initiator	O
AUG	O
present	O
in	O
the	O
stem	O
region	O
of	O
stem	O
-	O
loop	O
IV	O
(	O
SL	O
IV	O
)	O
(	O
Pudi	O
,	O
R.	O
,	O
Abhiman	O
,	O
S.	O
,	O
Srinivasan	O
,	O
N.	O
,	O
and	O
Das	O
S.	O
(	O
2003	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
278	O
,	O
12231	O
-	O
12240	O
)	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
mutations	O
in	O
the	O
GCAC	O
motif	O
,	O
which	O
altered	O
the	O
binding	O
to	O
RRM2	O
,	O
had	O
drastic	O
effect	O
on	O
HCV	O
IRES	O
-	O
mediated	O
translation	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
results	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
the	O
stem	O
region	O
of	O
SL	O
IV	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
internal	O
initiation	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
mutations	O
also	O
altered	O
the	O
ability	O
to	O
bind	O
to	O
ribosomal	B
protein	I
S5	I
(	O
p25	O
)	O
,	O
through	O
which	O
40	O
S	O
ribosomal	O
subunit	O
is	O
known	O
to	O
contact	O
the	O
HCV	O
IRES	O
RNA	O
.	O

Interestingly	O
,	O
binding	O
of	O
La	B
protein	I
to	O
SL	O
IV	O
region	O
induced	O
significant	O
changes	O
in	O
the	O
circular	O
dichroism	O
spectra	O
of	O
the	O
HCV	O
RNA	O
indicating	O
conformational	O
alterations	O
that	O
might	O
assist	O
correct	O
positioning	O
of	O
the	O
initiation	O
complex	O
.	O

Finally	O
,	O
the	O
ribosome	O
assembly	O
analysis	O
using	O
sucrose	O
gradient	O
centrifugation	O
implied	O
that	O
the	O
mutations	O
within	O
SL	O
IV	O
of	O
HCV	O
IRES	O
impair	O
the	O
formation	O
of	O
functional	O
ribosomal	O
complexes	O
.	O

These	O
observations	O
strongly	O
support	O
the	O
hypothesis	O
that	O
La	B
protein	I
binding	O
near	O
the	O
initiator	O
AUG	O
facilitates	O
the	O
interactions	O
with	O
ribosomal	B
protein	I
S5	I
and	O
48	O
S	O
ribosomal	O
assembly	O
and	O
influences	O
the	O
formation	O
of	O
functional	O
initiation	O
complex	O
on	O
the	O
HCV	O
IRES	O
RNA	O
to	O
mediate	O
efficient	O
internal	O
initiation	O
of	O
translation	O
.	O

Suppressors	B
of	I
cytokine	I
signaling	I
regulate	O
Fc	B
receptor	I
signaling	O
and	O
cell	O
activation	O
during	O
immune	O
renal	O
injury	O
.	O

Suppressors	B
of	I
cytokine	I
signaling	I
(	O
SOCS	B
)	O
are	O
cytokine	B
-	O
inducible	O
proteins	O
that	O
modulate	O
receptor	O
signaling	O
via	O
tyrosine	B
kinase	I
pathways	O
.	O

We	O
investigate	O
the	O
role	O
of	O
SOCS	B
in	O
renal	O
disease	O
,	O
analyzing	O
whether	O
SOCS	B
regulate	O
IgG	B
receptor	I
(	O
FcgammaR	B
)	O
signal	O
pathways	O
.	O

In	O
experimental	O
models	O
of	O
immune	O
complex	O
(	O
IC	O
)	O
glomerulonephritis	O
,	O
the	O
renal	O
expression	O
of	O
SOCS	B
family	I
genes	O
,	O
mainly	O
SOCS-3	B
,	O
significantly	O
increased	O
,	O
in	O
parallel	O
with	O
proteinuria	O
and	O
renal	O
lesions	O
,	O
and	O
the	O
proteins	O
were	O
localized	O
in	O
glomeruli	O
and	O
tubulointerstitium	O
.	O

Induction	O
of	O
nephritis	O
in	O
mice	O
with	O
a	O
deficiency	O
in	O
the	O
FcgammaR	B
gamma	O
-	O
chain	O
(	O
gamma	O
(	O
-	O
/	O
-	O
)	O
mice	O
)	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
renal	O
expression	O
of	O
SOCS-3	B
and	O
SOCS-1	B
.	O

Moreover	O
,	O
blockade	O
of	O
FcgammaR	B
by	O
Fc	O
fragment	O
administration	O
in	O
rats	O
with	O
ongoing	O
nephritis	O
selectively	O
inhibited	O
SOCS-3	B
and	O
SOCS-1	B
,	O
without	O
affecting	O
cytokine	B
-	O
inducible	O
Src	B
homology	O
2	O
-	O
containing	O
protein	O
and	O
SOCS-2	B
.	O

In	O
cultured	O
human	O
mesangial	O
cells	O
(	O
MC	O
)	O
and	O
monocytes	O
,	O
IC	O
caused	O
a	O
rapid	O
and	O
transient	O
induction	O
of	O
SOCS-3	B
expression	O
.	O

Similar	O
kinetics	O
was	O
observed	O
for	O
SOCS-1	B
,	O
whereas	O
SOCS-2	B
expression	O
was	O
very	O
low	O
.	O

MC	O
from	O
gamma	O
(	O
-	O
/	O
-	O
)	O
mice	O
failed	O
to	O
respond	O
to	O
IC	O
activation	O
,	O
confirming	O
the	O
participation	O
of	O
FcgammaR	B
.	O

Interestingly	O
,	O
IC	O
induced	O
tyrosine	O
phosphorylation	O
of	O
SOCS-3	B
and	O
Tec	B
tyrosine	I
kinase	I
,	O
and	O
both	O
proteins	O
coprecipitated	O
in	O
lysates	O
from	O
IC	O
-	O
stimulated	O
MC	O
,	O
suggesting	O
intracellular	O
association	O
.	O

IC	O
also	O
activated	O
STAT	B
pathway	O
in	O
MC	O
,	O
which	O
was	O
suppressed	O
by	O
SOCS	B
overexpression	O
,	O
mainly	O
SOCS-3	B
.	O

In	O
SOCS-3	B
knockdown	O
studies	O
,	O
specific	O
antisense	O
oligonucleotides	O
inhibited	O
mesangial	O
SOCS-3	B
expression	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
IC	O
-	O
induced	O
STAT	B
activation	O
.	O

Our	O
results	O
indicate	O
that	O
SOCS	B
may	O
play	O
a	O
regulatory	O
role	O
in	O
FcgammaR	B
signaling	O
,	O
and	O
implicate	O
SOCS	B
as	O
important	O
modulators	O
of	O
cell	O
activation	O
during	O
renal	O
inflammation	O
.	O

Sporulation	O
regulatory	O
protein	O
GerE	B
from	O
Bacillus	O
subtilis	O
binds	O
to	O
and	O
can	O
activate	O
or	O
repress	O
transcription	O
from	O
promoters	O
for	O
mother	O
-	O
cell	O
-	O
specific	O
genes	O
.	O

The	O
mother	O
-	O
cell	O
line	O
of	O
gene	O
expression	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
is	O
a	O
hierarchical	O
cascade	O
consisting	O
of	O
at	O
least	O
four	O
temporally	O
controlled	O
gene	O
sets	O
,	O
the	O
first	O
three	O
of	O
which	O
each	O
contain	O
a	O
regulatory	O
gene	O
for	O
the	O
next	O
gene	O
set	O
in	O
the	O
pathway	O
.	O

gerE	B
,	O
a	O
member	O
of	O
the	O
penultimate	O
gene	O
set	O
,	O
is	O
a	O
regulatory	O
gene	O
whose	O
products	O
is	O
required	O
for	O
the	O
transcriptional	O
activation	O
of	O
genes	O
(	O
coat	O
protein	O
genes	O
cotB	B
and	O
cotC	B
)	O
in	O
the	O
last	O
gene	O
set	O
.	O

The	O
gerE	B
product	O
also	O
influences	O
the	O
expression	O
of	O
other	O
members	O
of	O
the	O
penultimate	O
gene	O
set	O
(	O
coat	O
protein	O
genes	O
cotA	B
and	O
cotD	B
appear	O
to	O
be	O
repressed	O
and	O
activated	O
,	O
respectively	O
)	O
.	O

We	O
now	O
report	O
that	O
the	O
purified	O
product	O
of	O
gerE	B
(	O
GerE	B
)	O
is	O
a	O
DNA	O
-	O
binding	O
protein	O
that	O
adheres	O
to	O
the	O
promoters	O
for	O
cotB	B
and	O
cotC	B
.	O

We	O
also	O
show	O
that	O
GerE	B
stimulates	O
cotB	B
and	O
cotC	B
transcription	O
in	O
vitro	O
by	O
RNA	B
polymerase	I
containing	O
the	O
mother	O
-	O
cell	O
sigma	B
factor	I
sigma	B
K	I
.	O

These	O
findings	O
support	O
the	O
view	O
that	O
GerE	B
is	O
a	O
positively	O
acting	O
,	O
regulatory	O
protein	O
whose	O
appearance	O
at	O
a	O
late	O
stage	O
of	O
development	O
directly	O
activates	O
the	O
transcription	O
of	O
genes	O
in	O
the	O
last	O
known	O
temporal	O
class	O
of	O
mother	O
-	O
cell	O
-	O
expressed	O
genes	O
.	O

In	O
addition	O
,	O
GerE	B
stimulates	O
cotD	B
transcription	O
and	O
inhibits	O
cotA	B
transcription	O
in	O
vitro	O
by	O
sigma	B
K	I
RNA	B
polymerase	I
,	O
as	O
expected	O
from	O
in	O
vivo	O
studies	O
,	O
and	O
,	O
unexpectedly	O
,	O
profoundly	O
inhibits	O
in	O
vitro	O
transcription	O
of	O
the	O
gene	O
(	O
sigK	B
)	O
that	O
encodes	O
sigma	B
K	I
.	O

The	O
effects	O
of	O
GerE	B
on	O
cotD	B
and	O
sigK	B
transcription	O
are	O
just	O
the	O
opposite	O
of	O
the	O
effects	O
exerted	O
by	O
the	O
earlier	O
-	O
appearing	O
,	O
mother	O
-	O
cell	O
regulatory	O
protein	O
spoIIID	B
,	O
suggesting	O
that	O
the	O
ordered	O
appearance	O
of	O
first	O
SpoIIID	B
,	O
then	O
GerE	B
,	O
ensures	O
proper	O
flow	O
of	O
the	O
regulatory	O
cascade	O
controlling	O
gene	O
expression	O
in	O
the	O
mother	O
cell	O
.	O

Characterization	O
of	O
B	O
-	O
and	O
T	O
-	O
cell	O
responses	O
and	O
HLA	B
-	I
DR4	I
binding	O
motifs	O
of	O
the	O
latex	O
allergen	O
Hev	B
b	I
6.01	I
(	O
prohevein	B
)	O
and	O
its	O
post	O
-	O
transcriptionally	O
formed	O
proteins	O
Hev	B
b	I
6.02	I
and	O
Hev	B
b	I
6.03	I
.	O

BACKGROUND	O
:	O

Multiple	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
-	O
binding	O
proteins	O
in	O
natural	O
rubber	O
latex	O
extracts	O
have	O
been	O
identified	O
.	O

In	O
the	O
case	O
of	O
Hev	B
b	I
6	I
a	O
differentiation	O
was	O
made	O
between	O
the	O
precursor	O
protein	O
prohevein	B
(	O
Hev	B
b	I
6.01	I
)	O
and	O
its	O
two	O
post	O
-	O
transcriptionally	O
formed	O
proteins	O
,	O
the	O
N	O
-	O
terminal	O
hevein	B
(	O
Hev	B
b	I
6.02	I
)	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
Hev	B
b	I
6.03	I
)	O
.	O

All	O
three	O
components	O
act	O
as	O
independent	O
allergens	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
a	O
detailed	O
analysis	O
of	O
the	O
T	O
-	O
cell	O
responses	O
and	O
the	O
IgE	B
-	O
binding	O
capacity	O
of	O
Hev	B
b	I
6.01	I
,	O
Hev	B
b	I
6.02	I
and	O
Hev	B
b	I
6.03	I
by	O
using	O
these	O
allergens	O
as	O
recombinant	O
maltose	O
-	O
binding	O
fusion	O
(	O
MBP	B
)	O
proteins	O
and	O
the	O
usage	O
of	O
synthetic	O
modified	O
hevein	B
peptides	O
.	O

METHODS	O
:	O

Latex	O
-	O
allergic	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
suffering	O
from	O
rhinitis	O
,	O
conjunctivitis	O
,	O
contact	O
urticaria	O
and	O
/	O
or	O
asthma	O
with	O
increased	O
specific	O
IgE	B
-	O
antibodies	O
to	O
latex	O
were	O
tested	O
for	O
their	O
IgE	B
-	O
binding	O
capacity	O
and	O
T	O
-	O
cell	O
reactivity	O
(	O
by	O
proliferation	O
response	O
)	O
to	O
the	O
recombinant	O
MBP	B
-	O
rHev	B
b	I
6.01	I
,	O
MBP	B
-	O
rHev	B
b	I
6.02	I
,	O
MBP	B
-	O
rHev	B
b	I
6.03	I
,	O
to	O
native	O
Hev	B
b	I
6.02	I
,	O
to	O
modified	O
hevein	O
peptides	O
and	O
wheat	B
germ	I
agglutinin	I
(	O
WGA	B
)	O
.	O

For	O
testing	O
of	O
the	O
human	B
leucocyte	I
antigen	I
(	I
HLA	I
)	I
class	I
II	I
restriction	O
of	O
MBP	B
-	O
rHev	B
b	I
6.01	I
induced	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
,	O
monoclonal	O
antibodies	O
against	O
HLA	B
-	I
DR	I
,	O
HLA	B
-	I
DP	I
or	O
HLA	B
-	I
DQ	I
were	O
added	O
.	O

RESULTS	O
:	O

Seventeen	O
of	O
18	O
(	O
94	O
%	O
)	O
serum	O
samples	O
from	O
latex	O
-	O
allergic	O
HCWs	O
had	O
increased	O
levels	O
of	O
specific	O
IgE	B
to	O
MBP	B
-	O
rHev	B
b	I
6.01	I
,	O
16	O
(	O
89	O
%	O
)	O
to	O
MBP	B
-	O
rHev	B
b	I
6.02	I
and	O
13	O
(	O
72	O
%	O
)	O
to	O
MBP	B
-	O
rHev	B
b	I
6.03	I
.	O

A	O
significant	O
difference	O
existed	O
between	O
the	O
specific	O
IgE	B
-	O
values	O
of	O
MBP	B
-	O
rHev	B
b	I
6.02	I
and	O
MBP	B
-	O
rHev	B
b	I
6.03	I
(	O
P	O
<	O
0.01	O
)	O
.	O

Proliferation	O
responses	O
of	O
PBMC	O
of	O
the	O
same	O
18	O
latex	O
-	O
allergic	O
patients	O
were	O
positive	O
for	O
MBP	B
-	O
rHev	B
b	I
6.01	I
and	O
MBP	B
-	O
rHev	B
b	I
6.03	I
in	O
83	O
and	O
67	O
%	O
of	O
the	O
tested	O
PBMC	O
suspension	O
,	O
whereas	O
the	O
proliferation	O
responses	O
induced	O
with	O
MBP	B
-	O
rHev	B
b	I
6.02	I
or	O
native	O
Hev	B
b	I
6.02	I
were	O
very	O
low	O
(	O
5.6	O
and	O
22.2	O
%	O
)	O
.	O

Sera	O
from	O
nine	O
additional	O
latex	O
-	O
allergic	O
patients	O
showed	O
specific	O
IgE	B
binding	O
to	O
the	O
native	O
Hev	B
b	I
6.02	I
,	O
but	O
none	O
of	O
these	O
sera	O
showed	O
specific	O
IgE	B
binding	O
to	O
the	O
modified	O
Hev	B
b	I
6.02	I
-	O
peptides	O
[	O
whereby	O
all	O
eight	O
cysteine	O
residues	O
were	O
substituted	O
by	O
serine	O
(	O
C	O
--	O
>	O
S	O
)	O
or	O
by	O
alanine	O
(	O
C	O
--	O
>	O
A	O
)	O
]	O
.	O

Proliferation	O
responses	O
induced	O
by	O
the	O
modified	O
Hev	B
b	I
6.02	I
peptides	O
were	O
not	O
significantly	O
different	O
from	O
that	O
induced	O
by	O
Hev	B
b	I
6.02	I
.	O

Potential	O
HLA	B
-	I
DR4Dw4	I
(	O
DRB1	B
*	I
0401	I
)	O
-	O
restricted	O
T	O
-	O
cell	O
epitopes	O
of	O
Hev	B
b	I
6.01	I
predicted	O
by	O
two	O
computer	O
algorithms	O
were	O
only	O
found	O
in	O
the	O
Hev	B
b	I
6.03	I
-	O
part	O
of	O
Hev	B
b	I
6.01	I
.	O

CONCLUSION	O
:	O

In	O
the	O
Hev	B
b	I
6.01	I
precursor	O
the	O
regions	O
responsible	O
for	O
IgE	B
binding	O
and	O
those	O
for	O
inducing	O
the	O
T	O
-	O
cell	O
proliferation	O
responses	O
are	O
settled	O
in	O
different	O
parts	O
of	O
the	O
protein	O
.	O

The	O
Hev	B
b	I
6.02	I
domain	O
is	O
responsible	O
for	O
IgE	B
binding	O
and	O
carries	O
discontinuous	O
B	O
-	O
cell	O
epitopes	O
whereas	O
Hev	B
b	I
6.03	I
is	O
a	O
better	O
inducer	O
of	O
a	O
proliferation	O
response	O
and	O
contains	O
HLA	B
-	I
DR4	I
-	O
binding	O
motifs	O
.	O

2S	B
storage	I
protein	I
gene	O
of	O
Douglas	O
-	O
fir	O
:	O
characterization	O
and	O
activity	O
of	O
promoter	O
in	O
transgenic	O
tobacco	O
seeds	O
.	O

To	O
date	O
a	O
few	O
sequences	O
regulating	O
expression	O
of	O
conifer	O
seed	O
-	O
specific	O
genes	O
have	O
been	O
reported	O
.	O

To	O
characterize	O
Douglas	O
-	O
fir	O
(	O
Pseudotsuga	O
menziesii	O
[	O
Mirb	O
]	O
Franco	O
)	O
2S	B
albumin	I
storage	O
protein	O
genes	O
,	O
a	O
genomic	O
DNA	O
sequence	O
containing	O
upstream	O
promoter	O
sequences	O
was	O
isolated	O
by	O
screening	O
a	O
Douglas	O
-	O
fir	O
genomic	O
library	O
.	O

Sequence	O
analysis	O
of	O
the	O
Douglas	O
-	O
fir	O
gPm2S1	O
promoter	O
revealed	O
the	O
presence	O
of	O
RY	O
-	O
repeated	O
elements	O
(	O
GCATGC	O
)	O
,	O
and	O
multiple	O
E	O
-	O
box	O
motifs	O
(	O
CANNTG	O
)	O
and	O
ACGT	O
-	O
core	O
elements	O
,	O
features	O
characteristic	O
of	O
2S	B
storage	I
protein	I
genes	O
in	O
angiosperms	O
.	O

When	O
fused	O
to	O
the	O
GUS	B
reporter	O
gene	O
,	O
the	O
1.16	O
kb	O
Douglas	O
-fir	O
2S	B
promoter	O
sequence	O
was	O
sufficient	O
to	O
direct	O
transient	O
expression	O
in	O
both	O
developing	O
Douglas	O
-	O
fir	O
embryos	O
and	O
maternally	O
derived	O
haploid	O
megagametophytes	O
.	O

Analysis	O
of	O
this	O
promoter	O
construct	O
in	O
transgenic	O
tobacco	O
showed	O
that	O
expression	O
was	O
restricted	O
to	O
embryo	O
and	O
endosperm	O
in	O
developing	O
seeds	O
and	O
was	O
not	O
detected	O
in	O
vegetative	O
tissues	O
of	O
two	O
-	O
week	O
-	O
old	O
seedlings	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
both	O
structural	O
and	O
regulatory	O
elements	O
as	O
well	O
as	O
upstream	O
signaling	O
components	O
controlling	O
the	O
expression	O
of	O
2S	B
albumin	I
genes	O
are	O
highly	O
conserved	O
during	O
evolution	O
.	O

A	O
chitinase	B
indispensable	O
for	O
formation	O
of	O
protoplast	O
of	O
Schizophyllum	O
commune	O
in	O
basidiomycete	O
-	O
lytic	O
enzyme	O
preparation	O
produced	O
by	O
Bacillus	O
circulans	O
KA-304	O
.	O

KA	O
-	O
prep	O
,	O
a	O
culture	O
filtrate	O
of	O
Bacillus	O
circulans	O
KA	O
-	O
304	O
grown	O
on	O
a	O
cell	O
-	O
wall	O
preparation	O
of	O
Schizophyllum	O
commune	O
,	O
has	O
an	O
activity	O
to	O
form	O
protoplasts	O
from	O
S.	O
commune	O
mycelia	O
.	O

alpha-1,3-Glucanase	B
,	O
which	O
was	O
isolated	O
from	O
an	O
ammonium	O
sulfate	O
fraction	O
of	O
0	O
-	O
30	O
%	O
saturation	O
of	O
KA	O
-	O
prep	O
,	O
gave	O
the	O
protoplast	O
-	O
forming	O
activity	O
to	O
an	O
ammonium	O
sulfate	O
fraction	O
of	O
30	O
-	O
50	O
%	O
saturation	O
of	O
KA	O
-	O
prep	O
,	O
which	O
contained	O
chitinase	B
(	O
s	O
)	O
and	O
beta	B
-	I
glucanase	I
(	O
s	O
)	O
but	O
was	O
inactive	O
in	O
the	O
protoplast	O
formation	O
.	O

Chitinase	B
(	I
s	I
)	I
and	O
beta	B
-	I
glucanase	I
(	O
s	O
)	O
in	O
the	O
ammonium	O
sulfate	O
fraction	O
of	O
30	O
-	O
50	O
%	O
saturation	O
were	O
separated	O
by	O
DEAE	O
-	O
cellulofine	O
A	O
-	O
500	O
column	O
chromatography	O
,	O
and	O
the	O
protoplast	O
-	O
forming	O
activity	O
appeared	O
when	O
the	O
chitinase	B
preparation	O
was	O
mixed	O
with	O
the	O
alpha-1	B
,	I
3	I
-	I
glucanase	I
.	O

The	O
beta	B
-	I
glucanase	I
preparation	O
was	O
not	O
effective	O
for	O
the	O
protoplast	O
formation	O
whereas	O
its	O
addition	O
enhanced	O
the	O
protoplast	O
-	O
forming	O
activity	O
of	O
the	O
mixture	O
of	O
alpha-1,3-glucanase	B
and	O
the	O
chitinase	B
preparation	O
.	O

The	O
chitinase	B
preparation	O
contained	O
two	O
chitinases	B
(	O
chitinase	B
I	I
and	I
II	I
)	O
.	O

Chitinase	B
I	I
showed	O
the	O
protoplast	O
-	O
forming	O
activity	O
with	O
alpha-1,3-glucanase	B
,	O
but	O
chitinase	B
II	I
did	O
not	O
.	O

Chitinase	B
I	I
,	O
a	O
monomeric	O
protein	O
with	O
a	O
molecular	O
weight	O
of	O
41,000	O
,	O
was	O
active	O
toward	O
colloidal	O
chitin	O
and	O
ethylene	O
glycol	O
chitin	O
.	O

Chitinase	B
I	I
produced	O
predominantly	O
N	O
,	O
N'-diacetylchitobiose	O
and	O
N	O
,	O
N',N	O
"""-"	O
triacetylchitotriose	O
from	O
colloidal	O
chitin	O
,	O
and	O
the	O
enzyme	O
was	O
inactive	O
to	O
p	O
-	O
NP	O
-	O
beta	O
-	O
D	O
-	O
N	O
-	O
acetylglucosaminide	O
,	O
suggesting	O
that	O
it	O
was	O
an	O
endo	O
-	O
type	O
enzyme	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
chitinase	B
I	I
(	O
A	O
L	O
A	O
T	O
P	O
T	O
L	O
N	O
V	O
S	O
A	O
S	O
S	O
G	O
M	O
)	O
had	O
no	O
sequential	O
identity	O
to	O
those	O
of	O
known	O
chitinases	B
.	O

Transcription	O
activation	O
by	O
remodelling	O
of	O
a	O
nucleoprotein	O
assembly	O
:	O
the	O
role	O
of	O
NarL	B
at	O
the	O
FNR	B
-	O
dependent	O
Escherichia	O
coli	O
nir	B
promoter	O
.	O

Expression	O
from	O
the	O
Escherichia	O
coli	O
nir	B
promoter	O
is	O
co	O
-	O
dependent	O
on	O
both	O
the	O
FNR	B
protein	O
(	O
an	O
anaerobically	O
triggered	O
transcription	O
activator	O
)	O
and	O
NarL	B
or	O
NarP	B
proteins	O
(	O
transcription	O
activators	O
triggered	O
by	O
nitrite	O
and	O
nitrate	O
)	O
.	O

We	O
found	O
previously	O
that	O
FNR	B
binds	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
41.5	O
at	O
the	O
nir	B
promoter	O
,	O
but	O
that	O
FNR	B
-	O
dependent	O
activation	O
is	O
repressed	O
by	O
IHF	B
binding	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
88	O
(	O
IHF	B
I	O
)	O
and	O
Fis	B
binding	O
to	O
sites	O
centred	O
at	O
positions	O
-	O
142	O
(	O
Fis	B
I	O
)	O
and	O
+	O
23	O
(	O
Fis	B
II	O
)	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
binding	O
of	O
purified	O
IHF	B
,	O
Fis	B
and	O
FNR	B
to	O
the	O
nir	B
promoter	O
in	O
vitro	O
.	O

Our	O
results	O
show	O
that	O
the	O
nir	B
promoter	O
contains	O
a	O
second	O
IHF	B
site	O
at	O
position	O
-	O
115	O
(	O
IHF	B
II	O
)	O
and	O
a	O
third	O
Fis	B
site	O
at	O
position	O
-	O
97	O
(	O
Fis	B
III	O
)	O
,	O
and	O
that	O
IHF	B
,	O
Fis	B
and	O
FNR	B
can	O
bind	O
together	O
to	O
form	O
multiprotein	O
complexes	O
.	O

Surprisingly	O
,	O
IHF	B
binding	O
at	O
the	O
IHF	B
II	O
site	O
increases	O
FNR	B
-	O
dependent	O
activation	O
by	O
decreasing	O
the	O
repression	O
mediated	O
by	O
IHF	B
and	O
Fis	B
binding	O
at	O
the	O
other	O
sites	O
.	O

In	O
previous	O
work	O
,	O
we	O
found	O
that	O
NarL	B
or	O
NarP	B
activates	O
the	O
nir	B
promoter	O
by	O
binding	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
69.5	O
and	O
counteracting	O
the	O
repressive	O
effects	O
of	O
IHF	B
and	O
Fis	B
.	O

We	O
now	O
show	O
that	O
NarL	B
can	O
displace	O
IHF	B
bound	O
at	O
the	O
IHF	B
I	O
site	O
,	O
but	O
IHF	B
is	O
unable	O
to	O
displace	O
bound	O
NarL	B
.	O

We	O
suggest	O
that	O
NarL	B
interferes	O
with	O
IHF	B
binding	O
at	O
the	O
nir	B
promoter	O
by	O
distorting	O
the	O
minor	O
groove	O
at	O
its	O
target	O
site	O
,	O
and	O
we	O
argue	O
that	O
the	O
resulting	O
activation	O
by	O
NarL	B
results	O
from	O
remodelling	O
of	O
the	O
local	O
nucleoprotein	O
structure	O
to	O
facilitate	O
FNR	B
-	O
dependent	O
transcription	O
.	O

Population	O
genetics	O
of	O
apolipoproteins	B
A	I
-	I
IV	I
,	I
E	I
,	I
and	I
H	I
,	O
and	O
the	O
angiotensin	B
converting	I
enzyme	I
(	O
ACE	B
)	O
:	O
associations	O
with	O
lipids	O
,	O
and	O
apolipoprotein	B
levels	O
in	O
American	O
Samoans	O
.	O

Distributions	O
of	O
alleles	O
at	O
three	O
apolipoprotein	B
loci	O
(	O
APO	B
E	I
,	O
APO	B
H	I
,	O
and	O
APO	B
A	I
-	I
IV	I
)	O
and	O
an	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
at	O
the	O
angiotensin	B
converting	I
enzyme	I
(	O
ACE	B
)	O
locus	O
among	O
274	O
American	O
Samoans	O
are	O
described	O
here	O
.	O

Genotypes	O
at	O
each	O
locus	O
are	O
examined	O
for	O
associations	O
with	O
quantitative	O
lipid	O
(	O
total	O
cholesterol	O
(	O
total	O
-c	O
)	O
,	O
LDL	B
-	O
cholesterol	O
(	O
LDL	B
-	O
c	O
)	O
,	O
HDL	B
-	O
cholesterol	O
(	O
HDL	B
-	O
c	O
)	O
,	O
and	O
triglycerides	O
)	O
and	O
apolipoprotein	B
(	O
APO	B
AI	I
,	O
APO	B
AII	I
,	O
APO	B
E	I
,	O
and	O
APO	B
B	I
)	O
levels	O
.	O

Genotype	O
frequencies	O
at	O
all	O
four	O
loci	O
are	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

The	O
most	O
common	O
APO	B
A	I
-	I
IV	I
genotype	O
(	O
1	O
-	O
1	O
)	O
was	O
observed	O
in	O
252	O
American	O
Samoans	O
(	O
97	O
%	O
)	O
.	O

The	O
three	O
most	O
common	O
APO	B
E	I
genotypes	O
were	O
3	O
-	O
3	O
(	O
47	O
%	O
)	O
,	O
3	O
-	O
4	O
(	O
30	O
%	O
)	O
,	O
and	O
2	O
-	O
3	O
(	O
12	O
%	O
)	O
.	O

The	O
most	O
frequent	O
APO	B
H	I
genotype	O
was	O
2	O
-	O
2	O
(	O
86	O
%	O
)	O
.	O

The	O
most	O
common	O
ACE	B
genotype	O
(	O
I	O
/	O
I	O
)	O
was	O
observed	O
in	O
75	O
%	O
of	O
sampled	O
individuals	O
,	O
and	O
23	O
%	O
were	O
I	O
/	O
D	O
heterozygotes	O
.	O

APO	B
E	I
genotypic	O
variation	O
was	O
associated	O
with	O
total	O
-	O
c	O
,	O
HDL	B
-	O
c	O
,	O
LDL	B
-	O
c	O
,	O
and	O
all	O
four	O
quantitative	O
apolipoproteins	B
(	I
AI	I
,	I
AII	I
,	I
E	I
,	I
and	I
B	I
)	I
.	O

APO	B
A	I
-	I
IV	I
genotypes	O
were	O
associated	O
significantly	O
with	O
total	O
cholesterol	O
,	O
LDL	B
-	O
c	O
,	O
and	O
APO	B
-	I
B	I
levels	O
.	O

APO	B
H	I
showed	O
little	O
association	O
with	O
any	O
quantitative	O
lipid	O
or	O
apolipoprotein	B
.	O

ACE	B
D	O
/	O
D	O
homozygotes	O
had	O
higher	O
AII	B
levels	O
.	O

ACE	B
showed	O
a	O
consistent	O
association	O
with	O
APO	B
AII	I
levels	O
,	O
with	O
either	O
APO	B
A	I
-	I
IV	I
or	O
APO	B
E	I
as	O
a	O
covariate	O
.	O

The	O
interaction	O
term	O
between	O
ACE	B
and	O
APO	B
E	I
was	O
also	O
significantly	O
associated	O
with	O
total	O
-	O
c	O
and	O
APO	B
E	I
levels	O
,	O
and	O
the	O
ACE	B
genotype	O
showed	O
a	O
significant	O
main	O
effect	O
on	O
APO	B
AI	I
levels	O
in	O
multivariate	O
analyses	O
.	O

Identification	O
and	O
characterization	O
of	O
ARHGAP24	B
and	O
ARHGAP25	B
genes	O
in	O
silico	O
.	O

RhoGAP	B
family	I
proteins	O
,	O
encoded	O
by	O
ARHGAP	B
family	I
genes	O
,	O
are	O
negative	O
regulators	O
of	O
Rho	B
family	I
GTPases	I
,	O
which	O
are	O
implicated	O
in	O
actin	B
remodeling	O
,	O
cell	O
polarity	O
control	O
,	O
and	O
cell	O
migration	O
.	O

Based	O
on	O
the	O
homology	O
with	O
ARHGAP22	B
,	O
we	O
identified	O
and	O
characterized	O
two	O
novel	O
ARHGAP	B
family	I
genes	O
,	O
ARHGAP24	B
and	O
ARHGAP25	B
.	O

FLJ33877	B
cDNA	O
(	O
AK091196.1	O
)	O
and	O
aberrant	O
DKFZp564	B
-	I
B1162	I
cDNA	O
(	O
NM_031305.1	O
)	O
were	O
derived	O
from	O
human	O
ARHGAP24	B
gene	O
.	O

Two	O
isoforms	O
of	O
KIAA0053	B
type	O
(	O
D29642.1	O
)	O
and	O
BM927439	O
type	O
were	O
derived	O
from	O
human	O
ARHGAP25	B
gene	O
due	O
to	O
alternative	O
splicing	O
(	O
alternative	O
promoter	O
)	O
.	O

Mouse	O
0610025G21	B
(	O
NM_029270.1	O
)	O
and	O
A130039I20	O
(	O
AK037710.1	O
)	O
were	O
representative	O
cDNAs	O
derived	O
from	O
mouse	O
Arhgap24	B
and	O
Arhgap25	B
genes	O
,	O
respectively	O
.	O

Exon	O
-	O
intron	O
structure	O
of	O
ARHGAP25	B
gene	O
at	O
human	O
chromosome	O
2p13	O
was	O
slightly	O
divergent	O
from	O
that	O
of	O
ARHGAP22	B
and	O
ARHGAP24	B
genes	O
.	O

MGC35285	B
,	O
MAPK8	B
and	O
C10orf64	B
genes	O
linked	O
to	O
ARHGAP22	B
gene	O
were	O
paralogs	O
of	O
PTPN13	B
,	O
MAPK10	B
and	O
WDFY3	B
genes	O
linked	O
to	O
ARHGAP24	B
gene	O
,	O
respectively	O
.	O

MGC35285	B
-	O
ARHGAP22	B
-	O
MAPK8	B
-	O
C10orf64	B
locus	O
at	O
human	O
chromosome	O
10q11	O
and	O
the	O
WDFY3	B
-	O
ARHGAP24	B
-	O
MAPK10	B
-	O
PTPN13	B
locus	O
at	O
human	O
chromosome	O
4q21	O
were	O
paralogous	O
regions	O
(	O
paralogons	O
)	O
within	O
the	O
human	O
genome	O
.	O

Human	O
ARHGAP24	B
showed	O
91.8	O
%	O
and	O
48.6	O
%	O
total	O
-	O
amino	O
-	O
acid	O
identity	O
with	O
mouse	O
Arhgap24	B
and	O
human	O
ARHGAP22	B
,	O
respectively	O
.	O

Human	O
ARHGAP25	B
showed	O
86.1	O
%	O
and	O
40.8	O
%	O
total	O
-	O
amino	O
-	O
acid	O
identity	O
with	O
mouse	O
Arhgap25	B
and	O
human	O
ARHGAP22	B
,	O
respectively	O
.	O

ARHGAP22	B
,	O
ARHGAP24	B
and	O
ARHGAP25	B
were	O
found	O
to	O
constitute	O
the	O
RhoGAP	B
subfamily	I
featured	O
by	O
Pleckstrin	B
homology	O
(	O
PH	O
)	O
domain	O
and	O
C	O
-	O
terminal	O
Coiled	O
-	O
coil	O
domain	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
identification	O
and	O
characterization	O
of	O
the	O
ARHGAP24	B
and	O
ARHGAP25	B
genes	O
.	O

Subdivision	O
of	O
flagellar	O
region	O
III	O
of	O
the	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
chromosomes	O
and	O
identification	O
of	O
two	O
additional	O
flagellar	O
genes	O
.	O

The	O
many	O
genes	O
involved	O
in	O
flagellar	O
structure	O
and	O
function	O
in	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
are	O
located	O
in	O
three	O
major	O
clusters	O
on	O
the	O
chromosome	O
:	O
flagellar	O
regions	O
I	O
,	O
II	O
and	O
III	O
.	O

We	O
have	O
found	O
that	O
region	O
III	O
does	O
not	O
consist	O
of	O
a	O
contiguous	O
set	O
of	O
flagellar	O
genes	O
,	O
as	O
was	O
thought	O
,	O
but	O
that	O
in	O
E.	O
coli	O
there	O
is	O
almost	O
7	O
kb	O
of	O
DNA	O
between	O
the	O
filament	O
cap	O
gene	O
,	O
fliD	B
,	O
and	O
the	O
next	O
known	O
flagellar	O
gene	O
,	O
fliE	B
;	O
a	O
similar	O
situation	O
occurs	O
in	O
S.	O
typhimurium	O
.	O

Most	O
of	O
this	O
DNA	O
is	O
unrelated	O
to	O
flagellar	O
function	O
,	O
since	O
a	O
mutant	O
in	O
which	O
5.4	O
kb	O
of	O
it	O
had	O
been	O
deleted	O
remained	O
fully	O
motile	O
and	O
chemotactic	O
as	O
judged	O
by	O
swarming	O
on	O
semi	O
-	O
solid	O
agar	O
.	O

We	O
have	O
therefore	O
subdivided	O
flagellar	O
region	O
III	O
into	O
two	O
regions	O
,	O
IIIa	O
and	O
IIIb	O
.	O

The	O
known	O
genes	O
in	O
region	O
IIIa	O
are	O
fliABCD	B
,	O
all	O
of	O
which	O
are	O
involved	O
in	O
filament	O
structure	O
and	O
assembly	O
,	O
while	O
region	O
IIIb	O
contains	O
genes	O
fliEFGHIJKLMNOPQR	B
,	O
all	O
of	O
which	O
are	O
related	O
to	O
formation	O
of	O
the	O
hook	O
(	O
basal	O
-	O
body	O
)	O
-	O
complex	O
or	O
to	O
even	O
earlier	O
assembly	O
events	O
.	O

We	O
have	O
found	O
that	O
fliD	B
,	O
the	O
last	O
known	O
gene	O
in	O
region	O
IIIa	O
,	O
is	O
immediately	O
followed	O
by	O
two	O
additional	O
genes	O
,	O
both	O
necessary	O
for	O
flagellation	O
,	O
which	O
we	O
have	O
designated	O
fliS	B
and	O
fliT	B
.	O

They	O
encode	O
small	O
proteins	O
with	O
deduced	O
molecular	O
masses	O
of	O
about	O
15	O
kDa	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O

The	O
functions	O
of	O
FliS	B
and	O
FliT	B
remain	O
to	O
be	O
determined	O
,	O
but	O
they	O
do	O
not	O
appear	O
to	O
be	O
members	O
of	O
the	O
axial	O
family	O
of	O
structural	O
proteins	O
to	O
which	O
FliD	B
belongs	O
.	O

Gene	O
for	O
the	O
activating	O
natural	O
killer	O
cell	O
receptor	O
,	O
KIR2DS1	B
,	O
is	O
associated	O
with	O
susceptibility	O
to	O
psoriasis	O
vulgaris	O
.	O

Psoriasis	O
vulgaris	O
,	O
particularly	O
its	O
juvenile	O
form	O
,	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	B
-	I
Cw*06	I
allele	O
encoding	O
the	O
HLA	B
-	I
Cw6	I
molecule	O
.	O

This	O
molecule	O
is	O
recognized	O
by	O
the	O
inhibitory	O
receptor	O
KIR2DL1	B
and	O
the	O
activatory	O
receptor	O
KIR2DS1	B
,	O
which	O
are	O
expressed	O
on	O
natural	O
killer	O
cells	O
and	O
subpopulations	O
of	O
T	O
lymphocytes	O
.	O

Humans	O
differ	O
by	O
the	O
presence	O
or	O
absence	O
of	O
particular	O
KIR	B
genes	O
.	O

We	O
hypothesized	O
that	O
either	O
activatory	O
KIR2DS1	B
or	O
inhibitory	O
KIR2DL1	B
gene	O
frequencies	O
might	O
be	O
different	O
in	O
psoriatic	O
patients	O
from	O
a	O
control	O
population	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
frequencies	O
of	O
KIR2D	B
inhibitory	O
(	O
L	O
)	O
and	O
activatory	O
(	O
S	O
)	O
genes	O
in	O
116	O
psoriasis	O
vulgaris	O
patients	O
and	O
in	O
123	O
healthy	O
controls	O
.	O

Fourteen	O
novel	O
gene	O
combinations	O
were	O
found	O
.	O

KIR2DS1	B
was	O
present	O
in	O
85	O
%	O
of	O
the	O
patients	O
,	O
but	O
only	O
in	O
51	O
%	O
of	O
the	O
controls	O
(	O
corrected	O
p	O
[	O
pc	O
]	O
<	O
0.0009	O
)	O
.	O

Similarly	O
,	O
HLA	B
-	I
Cw*06	I
was	O
much	O
more	O
frequent	O
in	O
patients	O
(	O
77	O
%	O
)	O
than	O
in	O
controls	O
(	O
17	O
%	O
;	O
pc	O
<	O
0.00002	O
)	O
.	O

Statistical	O
analysis	O
suggests	O
that	O
,	O
although	O
the	O
contribution	O
of	O
these	O
two	O
factors	O
to	O
psoriasis	O
is	O
partially	O
independent	O
,	O
they	O
interact	O
nevertheless	O
.	O

This	O
result	O
strongly	O
speaks	O
for	O
a	O
role	O
of	O
KIR2DS1	B
on	O
recognition	O
of	O
HLA	B
-	I
Cw6	I
in	O
susceptibility	O
to	O
psoriasis	O
.	O

Isolation	O
of	O
a	O
novel	O
KIR2DL3	B
-	O
specific	O
mAb	O
:	O
comparative	O
analysis	O
of	O
the	O
surface	O
distribution	O
and	O
function	O
of	O
KIR2DL2	B
,	O
KIR2DL3	B
and	O
KIR2DS2	B
.	O

In	O
recent	O
years	O
an	O
increasing	O
number	O
of	O
sequences	O
coding	O
for	O
new	O
KIRs	B
have	O
been	O
described	O
.	O

However	O
,	O
the	O
limited	O
availability	O
of	O
mAbs	O
with	O
unique	O
KIR	B
specificities	O
has	O
hindered	O
an	O
exhaustive	O
assessment	O
of	O
their	O
actual	O
function	O
,	O
HLA	B
-	O
specificity	O
,	O
expression	O
at	O
the	O
cell	O
surface	O
and	O
distribution	O
in	O
different	O
cell	O
populations	O
.	O

In	O
this	O
study	O
we	O
report	O
the	O
generation	O
of	O
a	O
novel	O
mAb	O
(	O
ECM41	O
)	O
specific	O
for	O
KIR2DL3	B
molecules	O
.	O

By	O
the	O
use	O
of	O
cell	O
transfectants	O
expressing	O
one	O
or	O
other	O
KIR	B
we	O
show	O
that	O
this	O
reagent	O
allows	O
discrimination	O
of	O
KIR2DL3	B
from	O
other	O
GL183	B
mAb	O
-	O
reactive	O
molecules	O
such	O
as	O
KIR2DL2	B
and	O
KIR2DS2	B
.	O

Moreover	O
we	O
show	O
that	O
this	O
novel	O
mAb	O
can	O
be	O
used	O
to	O
assess	O
the	O
surface	O
expression	O
and	O
distribution	O
of	O
KIR2DL3	B
in	O
different	O
polyclonal	O
NK	O
populations	O
and	O
in	O
NK	O
cell	O
clones	O
.	O

Along	O
this	O
line	O
,	O
we	O
were	O
able	O
to	O
analyze	O
the	O
HLA	B
class	I
I	I
specificity	O
of	O
NK	O
clones	O
expressing	O
either	O
KIR2DL3	B
or	O
KIR2DL2	B
,	O
two	O
inhibitory	O
receptors	O
that	O
were	O
so	O
far	O
serologically	O
undistinguishable	O
.	O

Finally	O
,	O
the	O
combined	O
use	O
of	O
GL183	B
and	O
ECM41	O
mAbs	O
in	O
redirected	O
killing	O
assays	O
allowed	O
us	O
to	O
investigate	O
the	O
functional	O
outcome	O
of	O
the	O
simultaneous	O
engagement	O
of	O
KIR2DL3	B
and	O
KIR2DS2	B
in	O
NK	O
cell	O
clones	O
co	O
-	O
expressing	O
KIRs	B
that	O
display	O
opposite	O
(	O
inhibitory	O
vs	O
activating	O
)	O
function	O
.	O

Two	O
arginine	B
repressors	I
regulate	O
arginine	O
biosynthesis	O
in	O
Lactobacillus	O
plantarum	O
.	O

The	O
repression	O
of	O
the	O
carAB	B
operon	I
encoding	O
carbamoyl	B
phosphate	I
synthase	I
leads	O
to	O
Lactobacillus	O
plantarum	O
FB331	O
growth	O
inhibition	O
in	O
the	O
presence	O
of	O
arginine	O
.	O

This	O
phenotype	O
was	O
used	O
in	O
a	O
positive	O
screening	O
to	O
select	O
spontaneous	O
mutants	O
deregulated	O
in	O
the	O
arginine	O
biosynthesis	O
pathway	O
.	O

Fourteen	O
mutants	O
were	O
genetically	O
characterized	O
for	O
constitutive	O
arginine	O
production	O
.	O

Mutations	O
were	O
located	O
either	O
in	O
one	O
of	O
the	O
arginine	B
repressor	I
genes	O
(	O
argR1	B
or	O
argR2	B
)	O
present	O
in	O
L.	O
plantarum	O
or	O
in	O
a	O
putative	O
ARG	B
operator	O
in	O
the	O
intergenic	O
region	O
of	O
the	O
bipolar	O
carAB	B
-	I
argCJBDF	I
operons	I
involved	O
in	O
arginine	O
biosynthesis	O
.	O

Although	O
the	O
presence	O
of	O
two	O
ArgR	B
regulators	O
is	O
commonly	O
found	O
in	O
gram	O
-	O
positive	O
bacteria	O
,	O
only	O
single	O
arginine	B
repressors	I
have	O
so	O
far	O
been	O
well	O
studied	O
in	O
Escherichia	O
coli	O
or	O
Bacillus	O
subtilis	O
.	O

In	O
L.	O
plantarum	O
,	O
arginine	O
repression	O
was	O
abolished	O
when	O
ArgR1	B
or	O
ArgR2	B
was	O
mutated	O
in	O
the	O
DNA	O
binding	O
domain	O
,	O
or	O
in	O
the	O
oligomerization	O
domain	O
or	O
when	O
an	O
A123D	O
mutation	O
occurred	O
in	O
ArgR1	B
.	O

A123	O
,	O
equivalent	O
to	O
the	O
conserved	O
residue	O
A124	O
in	O
E.	O
coli	O
ArgR	B
involved	O
in	O
arginine	O
binding	O
,	O
was	O
different	O
in	O
the	O
wild	O
-	O
type	O
ArgR2	B
.	O

Thus	O
,	O
corepressor	O
binding	O
sites	O
may	O
be	O
different	O
in	O
ArgR1	B
and	O
ArgR2	B
,	O
which	O
have	O
only	O
35	O
%	O
identical	O
residues	O
.	O

Other	O
mutants	O
harbored	O
wild	O
-	O
type	O
argR	B
genes	O
,	O
and	O
20	O
mutants	O
have	O
lost	O
their	O
ability	O
to	O
grow	O
in	O
normal	O
air	O
without	O
carbon	O
dioxide	O
enrichment	O
;	O
this	O
revealed	O
a	O
link	O
between	O
arginine	O
biosynthesis	O
and	O
a	O
still	O
-	O
unknown	O
CO2	O
-	O
dependent	O
metabolic	O
pathway	O
.	O

In	O
many	O
gram	O
-	O
positive	O
bacteria	O
,	O
the	O
expression	O
and	O
interaction	O
of	O
different	O
ArgR	B
-	O
like	O
proteins	O
may	O
imply	O
a	O
complex	O
regulatory	O
network	O
in	O
response	O
to	O
environmental	O
stimuli	O
.	O

Muscle	O
involvement	O
in	O
juvenile	O
idiopathic	O
arthritis	O
.	O

OBJECTIVE	O
:	O

An	O
observational	O
study	O
of	O
changes	O
in	O
muscle	O
structure	O
and	O
the	O
relation	O
to	O
muscle	O
strength	O
in	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
.	O

METHODS	O
:	O

Fifteen	O
children	O
and	O
teenagers	O
(	O
eight	O
girls	O
and	O
seven	O
boys	O
)	O
with	O
JIA	O
,	O
aged	O
9	O
-	O
19	O
yr	O
(	O
mean	O
age	O
16.1	O
)	O
,	O
were	O
studied	O
.	O

Muscle	O
biopsies	O
were	O
obtained	O
from	O
the	O
anterior	O
tibial	O
muscle	O
and	O
were	O
examined	O
using	O
histopathological	O
and	O
immunohistochemical	O
methods	O
.	O

Muscle	O
fibre	O
types	O
were	O
classified	O
and	O
fibre	O
areas	O
measured	O
.	O

As	O
markers	O
of	O
inflammation	O
,	O
the	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
and	I
class	I
II	I
and	O
the	O
membrane	B
attack	I
complex	I
(	O
MAC	B
)	O
were	O
analysed	O
.	O

Results	O
were	O
compared	O
with	O
biopsies	O
from	O
the	O
gastrocnemius	O
muscle	O
in	O
33	O
young	O
(	O
19	O
-	O
23	O
yr	O
)	O
healthy	O
controls	O
.	O

Isometric	O
and	O
isokinetic	O
muscle	O
strengths	O
were	O
measured	O
in	O
ankle	O
dorsiflexion	O
.	O

Strength	O
was	O
compared	O
with	O
reference	O
values	O
for	O
healthy	O
age	O
-	O
matched	O
controls	O
.	O

Nerve	O
conduction	O
velocities	O
were	O
recorded	O
in	O
the	O
peroneal	O
and	O
sural	O
nerves	O
.	O

RESULTS	O
:	O

Four	O
of	O
the	O
15	O
muscle	O
biopsies	O
were	O
morphologically	O
normal	O
.	O

Eleven	O
biopsies	O
showed	O
minor	O
unspecific	O
changes	O
.	O

Two	O
of	O
these	O
also	O
showed	O
minor	O
signs	O
of	O
inflammation	O
.	O

MHC	B
class	I
II	I
expression	O
was	O
found	O
in	O
4	O
/	O
15	O
patients	O
,	O
which	O
was	O
significantly	O
more	O
than	O
in	O
the	O
healthy	O
controls	O
(	O
P	O
=	O
0.0143	O
)	O
.	O

The	O
expression	O
of	O
MHC	B
class	I
I	I
and	O
MAC	B
did	O
not	O
differ	O
from	O
that	O
in	O
the	O
controls	O
.	O

The	O
mean	O
area	O
of	O
type	O
I	O
fibres	O
was	O
lower	O
than	O
that	O
of	O
type	O
IIA	O
fibres	O
in	O
12	O
/	O
13	O
biopsies	O
.	O

Muscle	O
strength	O
was	O
significantly	O
reduced	O
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
muscle	O
fibre	O
area	O
and	O
muscle	O
strength	O
.	O

Nerve	O
conduction	O
studies	O
were	O
normal	O
in	O
all	O
cases	O
.	O

CONCLUSIONS	O
:	O

Changes	O
in	O
leg	O
muscle	O
biopsies	O
appear	O
to	O
be	O
common	O
in	O
children	O
and	O
teenagers	O
with	O
JIA	O
.	O

The	O
presence	O
of	O
inflammatory	O
cells	O
in	O
the	O
muscle	O
and	O
expression	O
of	O
MHC	B
class	I
II	I
on	O
muscle	O
fibres	O
may	O
be	O
a	O
sign	O
of	O
inflammatory	O
myopathy	O
.	O

There	O
are	O
no	O
findings	O
of	O
type	O
II	O
muscle	O
fibre	O
hypotrophy	O
or	O
neuropathy	O
,	O
as	O
in	O
adults	O
with	O
RA	O
.	O

Cell	O
division	O
and	O
cell	O
survival	O
in	O
the	O
absence	O
of	O
survivin	B
.	O

The	O
survivin	B
protein	O
contains	O
structural	O
features	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
family	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
survivin	B
is	O
essential	O
for	O
cell	O
survival	O
because	O
it	O
counteracts	O
an	O
otherwise	O
constitutive	O
propensity	O
to	O
apoptosis	O
during	O
mitosis	O
.	O

In	O
addition	O
,	O
survivin	B
appears	O
to	O
be	O
a	O
component	O
of	O
the	O
chromosomal	O
passenger	O
protein	O
complex	O
that	O
participates	O
in	O
multiple	O
facets	O
of	O
cell	O
division	O
.	O

Here	O
we	O
report	O
that	O
euploid	O
human	O
cells	O
do	O
not	O
die	O
in	O
the	O
absence	O
of	O
survivin	B
.	O

Instead	O
,	O
depletion	O
of	O
survivin	B
caused	O
defects	O
in	O
cell	O
division	O
,	O
followed	O
by	O
an	O
arrest	O
of	O
DNA	O
synthesis	O
due	O
to	O
activation	O
of	O
a	O
checkpoint	O
involving	O
the	O
tumor	B
suppressor	I
protein	I
p53	I
.	O

During	O
anaphase	O
mitosis	O
in	O
survivin	B
-	O
deficient	O
cells	O
,	O
sister	O
chromatids	O
disjoined	O
normally	O
,	O
but	O
one	O
or	O
more	O
of	O
the	O
sister	O
chromatids	O
frequently	O
lagged	O
behind	O
the	O
main	O
mass	O
of	O
segregating	O
chromosomes	O
,	O
probably	O
because	O
of	O
merotelic	O
kinetochore	O
attachments	O
.	O

Survivin	B
-	O
deficient	O
cells	O
initiated	O
but	O
failed	O
to	O
complete	O
cytokinesis	O
,	O
apparently	O
because	O
the	O
spindle	O
midzone	O
and	O
midbody	O
microtublues	O
were	O
absent	O
during	O
late	O
mitosis	O
.	O

The	O
abnormalities	O
of	O
both	O
chromosome	O
segregation	O
and	O
cytokinesis	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
in	O
the	O
chromosomal	O
passenger	O
protein	O
complex	O
,	O
with	O
a	O
consequent	O
mislocalization	O
of	O
the	O
kinesin	B
-	I
like	I
motor	I
protein	I
MKLP-1	I
playing	O
a	O
more	O
immediate	O
role	O
in	O
the	O
microtubule	O
abnormalities	O
.	O

Depletion	O
of	O
another	O
chromosomal	O
passenger	O
protein	O
,	O
aurora	B
-	I
B	I
,	O
recapitulated	O
the	O
survivin	B
RNA	O
interference	O
phenotypes	O
.	O

We	O
conclude	O
that	O
survivin	B
can	O
be	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	O
human	O
cells	O
by	O
virtue	O
of	O
its	O
contributions	O
to	O
accurate	O
sister	O
chromatid	O
segregation	O
and	O
assembly	O
/	O
stabilization	O
of	O
microtubules	O
in	O
late	O
mitosis	O
.	O

However	O
,	O
the	O
protein	O
is	O
not	O
inevitably	O
required	O
for	O
the	O
survival	O
of	O
normal	O
cells	O
.	O

Depletion	O
of	O
apolipoprotein	B
N	I
-	I
acyltransferase	I
causes	O
mislocalization	O
of	O
outer	O
membrane	O
lipoproteins	O
in	O
Escherichia	O
coli	O
.	O

Lipoproteins	O
in	O
Gram	O
-	O
negative	O
Enterobacteriaceae	O
carry	O
three	O
fatty	O
acids	O
on	O
the	O
N	O
-	O
terminal	O
cysteine	O
residue	O
,	O
two	O
as	O
a	O
diacylglyceride	O
and	O
one	O
through	O
an	O
N	O
-	O
linkage	O
following	O
signal	O
peptide	O
cleavage	O
.	O

Most	O
lipoproteins	O
are	O
anchored	O
in	O
the	O
outer	O
membrane	O
,	O
facing	O
the	O
periplasm	O
,	O
but	O
some	O
lipoproteins	O
remain	O
in	O
the	O
plasma	O
membrane	O
,	O
depending	O
on	O
the	O
amino	O
acid	O
at	O
position	O
+	O
2	O
,	O
immediately	O
after	O
the	O
fatty	O
-	O
acylated	O
cysteine	O
.	O

In	O
vitro	O
,	O
the	O
last	O
step	O
in	O
lipoprotein	O
maturation	O
,	O
N	O
-	O
acylation	O
of	O
apolipoproteins	B
by	O
the	O
plasma	O
membrane	O
apolipoprotein	B
N	I
-	I
acyltransferase	I
(	O
Lnt	B
)	O
,	O
is	O
necessary	O
for	O
efficient	O
recognition	O
of	O
outer	O
membrane	O
lipoproteins	O
by	O
the	O
Lol	B
system	O
,	O
which	O
transports	O
them	O
from	O
the	O
plasma	O
to	O
the	O
outer	O
membrane	O
(	O
Fukuda	O
,	O
A.	O
,	O
Matsuyama	O
,	O
S	O
.-	O
I.	O
,	O
Hara	O
,	O
T.	O
,	O
Nakayama	O
,	O
J.	O
,	O
Nagasawa	O
,	O
H.	O
,	O
and	O
Tokuda	O
,	O
H.	O
(	O
2002	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
43512	O
-	O
43518	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
Lnt	B
in	O
vivo	O
,	O
we	O
constructed	O
a	O
conditional	O
lnt	B
mutant	O
of	O
Escherichia	O
coli	O
.	O

The	O
apo	O
-	O
form	O
of	O
peptidoglycan	O
-	O
anchored	O
major	B
lipoprotein	I
(	O
Lpp	B
)	O
and	O
two	O
other	O
outer	O
membrane	O
lipoproteins	O
accumulated	O
in	O
the	O
plasma	O
membrane	O
when	O
lnt	B
expression	O
was	O
reduced	O
.	O

We	O
also	O
found	O
that	O
Lnt	B
is	O
an	O
essential	O
protein	O
in	O
E.	O
coli	O
and	O
that	O
the	O
lethality	O
is	O
partially	O
because	O
of	O
the	O
retention	O
of	O
apoLpp	B
in	O
the	O
plasma	O
membrane	O
.	O

Topology	O
mapping	O
of	O
Lnt	B
with	O
beta	B
-	I
galactosidase	I
and	O
alkaline	B
phosphatase	I
fusions	O
indicated	O
the	O
presence	O
of	O
six	O
membrane	O
-	O
spanning	O
segments	O
.	O

The	O
lnt	B
gene	O
in	O
a	O
mutant	O
of	O
Salmonella	O
enterica	O
displaying	O
thermosensitive	O
Lnt	B
activity	O
(	O
Gupta	O
,	O
S.	O
D.	O
,	O
Gan	O
,	O
K.	O
,	O
Schmid	O
,	O
M.	O
B.	O
,	O
and	O
Wu	O
,	O
H.	O
C.	O
(	O
1993	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
16551	O
-	O
16556	O
)	O
was	O
found	O
to	O
carry	O
a	O
mutation	O
causing	O
a	O
single	O
glutamate	O
to	O
lysine	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
last	O
predicted	O
periplasmic	O
loop	O
of	O
the	O
protein	O
.	O

Endogenous	O
glucocorticoids	O
modulate	O
neutrophil	O
function	O
in	O
a	O
murine	O
model	O
of	O
haemolytic	O
uraemic	O
syndrome	O
.	O

Haemolytic	O
uraemic	O
syndrome	O
(	O
HUS	O
)	O
is	O
caused	O
by	O
Shiga	B
-	I
toxin	I
-	O
producing	O
Escherichia	O
coli	O
(	O
STEC	O
)	O
.	O

Although	O
,	O
Shiga	B
toxin	I
type	I
2	I
(	O
Stx2	B
)	O
is	O
responsible	O
for	O
the	O
renal	O
pathogenesis	O
observed	O
in	O
patients	O
,	O
the	O
inflammatory	O
response	O
,	O
including	O
cytokines	B
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
HUS	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
Stx2	B
injection	O
generates	O
an	O
anti	O
-	O
inflammatory	O
reaction	O
characterized	O
by	O
endogenous	O
glucocorticoid	O
(	O
GC	O
)	O
secretion	O
,	O
which	O
attenuates	O
HUS	O
severity	O
in	O
mice	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
effects	O
of	O
Stx2	B
on	O
the	O
pathogenic	O
function	O
of	O
PMN	O
and	O
the	O
potential	O
role	O
of	O
endogenous	O
GC	O
to	O
limit	O
PMN	O
activation	O
during	O
HUS	O
development	O
in	O
a	O
murine	O
model	O
.	O

For	O
this	O
purpose	O
we	O
assessed	O
the	O
functional	O
activity	O
of	O
isolated	O
PMN	O
after	O
in	O
vivo	O
treatment	O
with	O
Stx2	B
alone	O
or	O
in	O
simultaneous	O
treatment	O
with	O
Ru486	O
(	O
GC	B
receptor	I
antagonist	O
)	O
.	O

We	O
found	O
that	O
Stx2	B
increased	O
the	O
generation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
under	O
phobol	O
-	O
myristate	O
-	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
and	O
that	O
the	O
simultaneous	O
treatment	O
with	O
Ru486	O
strengthened	O
this	O
effect	O
.	O

Conversely	O
,	O
both	O
treatments	O
significantly	O
inhibited	O
in	O
vitro	O
phagocytosis	O
.	O

Furthermore	O
,	O
Stx2	B
augmented	O
in	O
vitro	O
PMN	O
adhesion	O
to	O
fibrinogen	B
(	O
FGN	B
)	O
and	O
bovine	O
serum	B
albumin	I
(	O
BSA	B
)	O
but	O
not	O
to	O
collagen	B
type	I
I	I
(	O
CTI	B
)	O
.	O

Stx2	B
+	O
Ru486	O
caused	O
enhanced	O
adhesion	O
to	O
BSA	B
and	O
CTI	B
compared	O
to	O
Stx2	B
.	O

Whereas	O
Stx2	B
significantly	O
increased	O
migration	O
towards	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
fMLP	O
)	O
,	O
Stx2	B
+	O
Ru486	O
treatment	O
enhanced	O
and	O
accelerated	O
this	O
process	O
.	O

The	O
percentage	O
of	O
apoptotic	O
PMN	O
from	O
Stx2	B
-	O
treated	O
mice	O
was	O
higher	O
compared	O
with	O
controls	O
,	O
but	O
equal	O
to	O
Stx2	B
+	O
Ru486	O
treated	O
mice	O
.	O

We	O
conclude	O
that	O
Stx2	B
activates	O
PMN	O
and	O
that	O
the	O
absence	O
of	O
endogenous	O
GC	O
enhances	O
this	O
activation	O
suggesting	O
that	O
endogenous	O
GC	O
can	O
,	O
at	O
least	O
partially	O
,	O
counteract	O
PMN	O
inflammatory	O
functions	O
.	O

Interleukin-1beta	B
can	O
mediate	O
growth	O
arrest	O
and	O
differentiation	O
via	O
the	O
leukemia	B
inhibitory	I
factor	I
/	O
JAK	B
/	O
STAT	B
pathway	O
in	O
medullary	O
thyroid	O
carcinoma	O
cells	O
.	O

Interleukin-1beta	B
(	O
IL-1beta	B
)	O
is	O
a	O
pleiotropic	O
cytokine	B
that	O
can	O
induce	O
several	O
cellular	O
signal	O
transduction	O
pathways	O
.	O

Here	O
,	O
we	O
show	O
that	O
IL-1beta	B
can	O
induce	O
cell	O
cycle	O
arrest	O
and	O
differentiation	O
in	O
the	O
human	O
medullary	O
thyroid	O
carcinoma	O
(	O
MTC	O
)	O
cell	O
line	O
,	O
TT	O
.	O

IL-1beta	B
induces	O
cell	O
cycle	O
arrest	O
accompanied	O
by	O
morphological	O
changes	O
and	O
expression	O
of	O
the	O
neuroendocrine	O
marker	O
calcitonin	B
.	O

These	O
changes	O
are	O
blocked	O
by	O
the	O
MEK1	B
/	I
2	I
specific	O
inhibitor	O
U0126	O
,	O
indicating	O
that	O
MEK1	B
/	I
2	I
is	O
essential	O
for	O
IL-1beta	B
signaling	O
in	O
TT	O
cells	O
.	O

IL-1beta	B
induces	O
expression	O
of	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
and	O
activation	O
of	O
STAT3	B
via	O
the	O
MEK	B
/	O
ERK	B
pathway	O
.	O

This	O
activation	O
of	O
STAT3	B
could	O
be	O
abrogated	O
by	O
treatment	O
with	O
anti	O
-	O
LIF	B
neutralizing	O
antibody	O
or	O
anti	O
-	O
gp130	B
blocking	O
antibody	O
,	O
indicating	O
that	O
induction	O
of	O
LIF	B
expression	O
is	O
sufficient	O
and	O
essential	O
for	O
STAT3	B
activation	O
by	O
IL-1beta	B
.	O

In	O
addition	O
to	O
activation	O
of	O
the	O
LIF	B
/	O
JAK	B
/	O
STAT	B
pathway	O
,	O
IL-1beta	B
also	O
induced	O
an	O
MEK	B
/	O
ERK	B
-	O
mediated	O
intracellular	O
cell	O
-	O
autonomous	O
signaling	O
pathway	O
that	O
is	O
independently	O
sufficient	O
for	O
growth	O
arrest	O
and	O
differentiation	O
.	O

Thus	O
,	O
IL-1beta	B
activates	O
the	O
MEK	B
/	O
ERK	B
pathway	O
to	O
induce	O
growth	O
arrest	O
and	O
differentiation	O
in	O
MTC	O
cells	O
via	O
dual	O
independent	O
signaling	O
mechanisms	O
,	O
the	O
cell	O
-	O
extrinsic	O
LIF	B
/	O
JAK	B
/	O
STAT	B
pathway	O
,	O
and	O
the	O
cell	O
-	O
intrinsic	O
autonomous	O
signaling	O
pathway	O
.	O

Enzymes	O
involved	O
in	O
anaerobic	O
respiration	O
appear	O
to	O
play	O
a	O
role	O
in	O
Actinobacillus	O
pleuropneumoniae	O
virulence	O
.	O

Actinobacillus	O
pleuropneumoniae	O
,	O
the	O
etiological	O
agent	O
of	O
porcine	O
pleuropneumonia	O
,	O
is	O
able	O
to	O
survive	O
on	O
respiratory	O
epithelia	O
,	O
in	O
tonsils	O
,	O
and	O
in	O
the	O
anaerobic	O
environment	O
of	O
encapsulated	O
sequesters	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
a	O
deletion	O
of	O
the	O
anaerobic	O
dimethyl	B
sulfoxide	I
reductase	I
gene	O
(	O
dmsA	B
)	O
results	O
in	O
attenuation	O
in	O
acute	O
disease	O
(	O
N.	O
Baltes	O
,	O
S.	O
Kyaw	O
,	O
I.	O
Hennig	O
-	O
Pauka	O
,	O
and	O
G.	O
F.	O
Gerlach	O
,	O
Infect	O
.	O
Immun	O
.	O
71	O
:	O
6784	O
-	O
6792	O
,	O
2003	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
,	O
we	O
identified	O
an	O
aspartate	B
ammonia	I
-	I
lyase	I
(	O
AspA	B
)	O
which	O
is	O
upregulated	O
upon	O
induction	O
with	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
.	O

This	O
enzyme	O
is	O
involved	O
in	O
the	O
production	O
of	O
fumarate	O
,	O
an	O
alternative	O
electron	O
acceptor	O
under	O
anaerobic	O
conditions	O
.	O

The	O
coding	O
gene	O
(	O
aspA	B
)	O
was	O
cloned	O
and	O
shown	O
to	O
be	O
present	O
in	O
all	O
A.	O
pleuropneumoniae	O
serotype	O
reference	O
strains	O
.	O

The	O
transcriptional	O
start	O
point	O
was	O
identified	O
downstream	O
of	O
a	O
putative	O
FNR	B
binding	O
motif	O
,	O
and	O
BALF	O
-	O
dependent	O
activation	O
of	O
aspA	B
was	O
confirmed	O
by	O
construction	O
of	O
an	O
isogenic	O
A.	O
pleuropneumoniae	O
mutant	O
carrying	O
a	O
chromosomal	O
aspA	B
:	O
:	O
luxAB	B
transcriptional	O
fusion	O
.	O

Two	O
aspA	B
deletion	O
mutants	O
,	O
A.	O
pleuropneumoniae	O
DeltaaspA	O
and	O
A.	O
pleuropneumoniae	O
DeltaaspADeltadmsA	O
,	O
were	O
constructed	O
,	O
both	O
showing	O
reduced	O
growth	O
under	O
anaerobic	O
conditions	O
in	O
vitro	O
.	O

Pigs	O
challenged	O
with	O
either	O
of	O
the	O
two	O
mutants	O
in	O
an	O
aerosol	O
infection	O
model	O
showed	O
a	O
lower	O
lung	O
lesion	O
score	O
than	O
that	O
of	O
the	O
A.	O
pleuropneumoniae	O
wild	O
-	O
type	O
(	O
wt	O
)	O
controls	O
.	O

Pigs	O
challenged	O
with	O
A.	O
pleuropneumoniae	O
DeltaaspADeltadmsA	O
had	O
a	O
significantly	O
lower	O
clinical	O
score	O
,	O
and	O
this	O
mutant	O
was	O
rarely	O
reisolated	O
from	O
unaltered	O
lung	O
tissue	O
;	O
in	O
contrast	O
,	O
A.	O
pleuropneumoniae	O
DeltaaspA	O
and	O
the	O
A.	O
pleuropneumoniae	O
wt	O
were	O
consistently	O
reisolated	O
in	O
high	O
numbers	O
.	O

These	O
results	O
suggest	O
that	O
enzymes	O
involved	O
in	O
anaerobic	O
respiration	O
are	O
necessary	O
for	O
the	O
pathogen	O
's	O
ability	O
to	O
persist	O
on	O
respiratory	O
tract	O
epithelium	O
and	O
play	O
an	O
important	O
role	O
in	O
A.	O
pleuropneumoniae	O
pathogenesis	O
.	O

The	O
expression	O
of	O
intact	O
and	O
mutant	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
in	O
transgenic	O
mice	O
.	O

The	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
gene	O
cluster	O
is	O
involved	O
in	O
lipid	O
metabolism	O
and	O
has	O
a	O
complex	O
pattern	O
of	O
gene	O
expression	O
modulated	O
by	O
a	O
common	O
regulatory	O
element	O
,	O
the	O
apoCIII	B
enhancer	O
.	O

A	O
new	O
member	O
of	O
this	O
cluster	O
,	O
apolipoprotein	B
(	I
apo	I
)	I
AV	I
,	O
has	O
recently	O
been	O
discovered	O
as	O
a	O
novel	O
modifier	O
in	O
triglyceride	O
metabolism	O
.	O

To	O
determine	O
the	O
expression	O
of	O
all	O
four	O
apo	B
genes	O
in	O
combination	O
and	O
,	O
most	O
importantly	O
,	O
whether	O
the	O
transcription	O
of	O
apoAV	B
is	O
coregulated	O
by	O
the	O
apoCIII	B
enhancer	O
in	O
the	O
cluster	O
,	O
we	O
generated	O
an	O
intact	O
transgenic	O
line	O
carrying	O
the	O
116	O
-	O
kb	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
and	O
a	O
mutant	O
transgenic	O
line	O
in	O
which	O
the	O
apoCIII	B
enhancer	O
was	O
deleted	O
from	O
the	O
116	O
-	O
kb	O
structure	O
.	O

We	O
demonstrated	O
that	O
the	O
apoCIII	B
enhancer	O
regulated	O
hepatic	O
and	O
intestinal	O
apoAI	B
,	O
apoCIII	B
,	O
and	O
apoAIV	B
expression	O
;	O
however	O
,	O
it	O
did	O
not	O
direct	O
the	O
newly	O
identified	O
apoAV	B
in	O
the	O
cluster	O
.	O

Furthermore	O
,	O
human	O
apo	B
genes	O
displayed	O
integrated	O
position	O
-	O
independent	O
expression	O
and	O
a	O
closer	O
approximation	O
of	O
copy	O
number	O
-	O
dependent	O
expression	O
in	O
the	O
intact	O
transgenic	O
mice	O
.	O

Because	O
apoCIII	B
and	O
apoAV	B
play	O
opposite	O
roles	O
in	O
triglyceride	O
homeostasis	O
,	O
we	O
analyzed	O
the	O
lipid	O
profiles	O
in	O
our	O
transgenic	O
mice	O
to	O
assess	O
the	O
effects	O
of	O
human	O
apoAI	B
gene	O
cluster	O
expression	O
on	O
lipid	O
metabolism	O
.	O

The	O
triglyceride	O
level	O
was	O
elevated	O
in	O
intact	O
transgenic	O
mice	O
but	O
decreased	O
in	O
mutant	O
ones	O
compared	O
with	O
nontransgenic	O
mice	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
human	O
apoAI	B
and	O
apoAIV	B
elevated	O
high	B
density	I
lipoprotein	I
cholesterol	O
in	O
transgenic	O
mice	O
fed	O
an	O
atherogenic	O
diet	O
.	O

In	O
conclusion	O
,	O
our	O
studies	O
with	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
transgenic	O
models	O
showed	O
that	O
the	O
apoCIII	B
enhancer	O
regulated	O
expression	O
of	O
apoAI	B
,	O
apo	B
-	I
CIII	I
,	O
and	O
apoAIV	B
but	O
not	O
apoAV	B
in	O
vivo	O
and	O
showed	O
the	O
influences	O
of	O
expression	O
of	O
the	O
entire	O
cluster	O
on	O
lipid	O
metabolism	O
.	O

IL-8	B
promotes	O
cell	O
proliferation	O
and	O
migration	O
through	O
metalloproteinase	B
-	O
cleavage	O
proHB	B
-	I
EGF	I
in	O
human	O
colon	O
carcinoma	O
cells	O
.	O

Interleukin-8	B
(	O
IL-8	B
)	O
has	O
been	O
reported	O
to	O
promote	O
tumor	O
cell	O
growth	O
in	O
colon	O
cancer	O
cells	O
after	O
binding	O
to	O
its	O
receptors	O
,	O
which	O
are	O
members	O
of	O
the	O
G	B
-	I
protein	I
coupled	I
receptor	I
(	I
GPCR	I
)	I
family	I
.	O

Recent	O
studies	O
demonstrated	O
that	O
stimulation	O
of	O
GPCR	B
can	O
induce	O
shedding	O
of	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
ligands	O
via	O
activation	O
of	O
a	B
disintegrin	I
and	I
metalloprotease	I
(	O
ADAM	B
)	O
,	O
with	O
subsequent	O
transactivation	O
of	O
the	O
EGF	B
receptor	I
(	O
EGFR	B
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
mechanisms	O
of	O
cell	O
proliferation	O
and	O
migration	O
stimulated	O
by	O
IL-8	B
in	O
a	O
human	O
colon	O
carcinoma	O
cell	O
line	O
(	O
Caco2	O
)	O
.	O

IL-8	B
increased	O
DNA	O
synthesis	O
of	O
Caco2	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
this	O
was	O
inhibited	O
by	O
ADAM	B
,	O
EGFR	B
kinase	B
,	O
and	O
MEK	B
inhibitors	O
.	O

IL-8	B
transiently	O
induced	O
EGFR	B
tyrosine	O
phosphorylation	O
after	O
5	O
-	O
90	O
min	O
and	O
this	O
was	O
completely	O
inhibited	O
by	O
ADAM	B
inhibitor	O
.	O

Neutralizing	O
antibody	O
against	O
HB	B
-	I
EGF	I
as	O
a	O
key	O
ligand	O
for	O
EGFR	B
also	O
blocked	O
transactivation	O
of	O
EGFR	B
and	O
cell	O
proliferation	O
by	O
IL-8	B
.	O

Since	O
IL-8	B
-	O
induced	O
cell	O
migration	O
was	O
further	O
suppressed	O
by	O
the	O
ADAM	B
inhibitor	O
and	O
the	O
HB	B
-	I
EGF	I
neutralizing	O
antibody	O
,	O
our	O
data	O
indicate	O
that	O
IL-8	B
induces	O
cell	O
proliferation	O
and	O
migration	O
by	O
an	O
ADAM	B
-	O
dependent	O
pathway	O
,	O
and	O
that	O
HB	B
-	I
EGF	I
plays	O
an	O
important	O
role	O
as	O
the	O
major	O
ligand	O
for	O
this	O
pathway	O
.	O

Lack	O
of	O
tumor	B
necrosis	I
factor	I
receptor	I
type	I
1	I
inhibits	O
liver	O
fibrosis	O
induced	O
by	O
carbon	O
tetrachloride	O
in	O
mice	O
.	O

Chronic	O
liver	O
injury	O
causes	O
liver	O
regeneration	O
,	O
resulting	O
in	O
fibrosis	O
.	O

The	O
proinflammatory	O
cytokine	B
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
acute	O
and	O
chronic	O
liver	O
diseases	O
.	O

TNF	B
has	O
pleiotropic	O
functions	O
,	O
but	O
its	O
role	O
in	O
liver	O
fibrosis	O
has	O
not	O
been	O
clarified	O
.	O

Chronic	O
repeated	O
injection	O
of	O
CCl4	O
induces	O
liver	O
fibrosis	O
in	O
mice	O
.	O

We	O
examined	O
whether	O
signaling	O
through	O
TNF	B
receptors	I
was	O
critical	O
for	O
this	O
process	O
,	O
using	O
mice	O
lacking	O
either	O
TNF	B
receptor	I
(	I
TNFR	I
)	I
type	I
1	I
or	O
TNFR	B
type	I
2	I
to	O
define	O
the	O
pathophysiologic	O
role	O
of	O
TNFR	B
signals	O
in	O
liver	O
fibrosis	O
.	O

Liver	O
fibrosis	O
caused	O
by	O
chronic	O
CCl4	O
exposure	O
was	O
TNF	B
-	O
dependent	O
;	O
histological	O
fibrosis	O
was	O
seen	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
TNFR-2	B
knockout	O
(	O
KO	O
)	O
mice	O
,	O
but	O
not	O
in	O
TNFR-1	B
KO	O
mice	O
.	O

Furthermore	O
,	O
a	O
marked	O
reduction	O
in	O
procollagen	O
and	O
TGF	B
-	I
beta	I
synthesis	O
was	O
observed	O
in	O
TNFR-1	B
KO	O
mice	O
,	O
which	O
also	O
had	O
little	O
detectable	O
NF	B
-	I
kappa	I
B	I
,	O
STAT3	B
,	O
and	O
AP1	B
binding	O
,	O
and	O
reduced	O
levels	O
of	O
liver	O
interleukin-6	B
(	O
IL-6	B
)	O
mRNA	O
compared	O
to	O
WT	O
and	O
TNFR-2	B
KO	O
mice	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
the	O
possibility	O
that	O
NF	B
-	I
kappa	I
B	I
,	O
STAT3	B
,	O
and	O
AP1	B
binding	O
by	O
signals	O
transduced	O
through	O
TNFR-1	B
plays	O
an	O
important	O
role	O
in	O
liver	O
fibrosis	O
formation	O
.	O

11	B
{	I
beta	I
}	I
-Hydroxysteroid	I
dehydrogenase	I
2	I
in	O
rat	O
leydig	O
cells	O
:	O
its	O
role	O
in	O
blunting	O
glucocorticoid	O
action	O
at	O
physiological	O
levels	O
of	O
substrate	O
.	O

Corticosterone	O
(	O
CORT	O
)	O
suppresses	O
Leydig	O
cell	O
steroidogenesis	O
by	O
inhibiting	O
the	O
expression	O
of	O
proteins	O
involved	O
in	O
testosterone	O
biosynthesis	O
including	O
steroidogenic	O
acute	O
regulatory	O
protein	O
and	O
steroidogenic	O
enzymes	O
.	O

In	O
most	O
cells	O
,	O
intracellular	O
glucocorticoid	O
levels	O
are	O
controlled	O
by	O
either	O
or	O
both	O
of	O
the	O
two	O
known	O
isoforms	O
of	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11beta	B
HSD	I
)	O
:	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
reduced	O
-	O
dependent	O
low	O
-	O
affinity	O
type	B
I	I
11beta	I
HSD	I
(	O
11beta	B
HSD1	I
)	O
oxidoreductase	B
and	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
-	O
dependent	O
11beta	B
HSD2	I
high	O
-	O
affinity	O
unidirectional	O
oxidase	B
.	O

In	O
Leydig	O
cells	O
,	O
11beta	B
HSD1	I
alone	O
may	O
not	O
be	O
sufficient	O
to	O
prevent	O
glucocorticoid	O
-	O
mediated	O
suppression	O
due	O
to	O
its	O
low	O
affinity	O
for	O
CORT	O
at	O
basal	O
concentrations	O
.	O

The	O
high	O
-	O
affinity	O
unidirectional	O
11beta	B
HSD2	I
,	O
if	O
also	O
present	O
,	O
may	O
be	O
critical	O
for	O
lowering	O
intracellular	O
CORT	O
levels	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
11beta	B
HSD2	I
is	O
present	O
in	O
rat	O
Leydig	O
cells	O
by	O
PCR	O
amplification	O
,	O
immunohistochemical	O
staining	O
,	O
enzyme	O
histochemistry	O
,	O
immunoprecipitation	O
,	O
and	O
Western	O
blotting	O
.	O

Real	O
-	O
time	O
PCR	O
showed	O
a	O
6	O
-	O
fold	O
enrichment	O
of	O
11beta	B
HSD2	I
mRNA	O
in	O
these	O
cells	O
,	O
compared	O
with	O
whole	O
testis	O
and	O
that	O
the	O
amount	O
of	O
11beta	B
HSD2	I
message	O
was	O
about	O
1000	O
-	O
fold	O
lower	O
,	O
compared	O
with	O
11beta	B
HSD1	I
.	O

Diffuse	O
immunofluorescent	O
staining	O
of	O
11beta	B
HSD2	I
protein	O
in	O
the	O
Leydig	O
cell	O
cytoplasm	O
was	O
consistent	O
with	O
its	O
localization	O
in	O
the	O
smooth	O
endoplasm	O
reticulum	O
.	O

11beta	B
HSD1	I
or	O
11beta	B
HSD2	I
activities	O
were	O
selectively	O
inhibited	O
using	O
antisense	O
methodology	O
:	O
inhibition	O
of	O
11beta	B
HSD1	I
lowered	O
reductase	O
activity	O
by	O
60	O
%	O
and	O
oxidation	O
by	O
25	O
%	O
,	O
whereas	O
inhibition	O
of	O
11beta	B
HSD2	I
alone	O
suppressed	O
oxidase	B
activity	O
by	O
50	O
%	O
.	O

This	O
shows	O
that	O
the	O
high	O
-	O
affinity	O
,	O
low	O
-	O
capacity	O
11beta	B
HSD2	I
isoform	O
,	O
present	O
at	O
only	O
one	O
thousandth	O
the	O
level	O
of	O
the	O
low	O
-	O
affinity	O
isoform	O
may	O
significantly	O
affect	O
the	O
level	O
of	O
CORT	O
.	O

The	O
inhibition	O
of	O
either	O
11beta	B
HSD1	I
or	O
11beta	B
HSD2	I
significantly	O
lowered	O
testosterone	O
production	O
in	O
the	O
presence	O
of	O
CORT	O
.	O

These	O
data	O
suggest	O
that	O
both	O
types	B
I	I
and	I
II	I
11beta	I
HSD	I
in	O
Leydig	O
cells	O
play	O
a	O
protective	O
role	O
,	O
opposing	O
the	O
adverse	O
effects	O
of	O
excessive	O
CORT	O
on	O
testosterone	O
production	O
.	O

Angiotensin	B
II	I
increases	O
the	O
expression	O
of	O
lectin	B
-	I
like	I
oxidized	I
low	I
-	I
density	I
lipoprotein	I
receptor-1	I
in	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
via	O
a	O
lipoxygenase	B
-	O
dependent	O
pathway	O
.	O

BACKGROUND	O
:	O

Lectin	B
-	I
like	I
oxidized	I
low	I
-	I
density	I
lipoprotein	I
receptor-1	I
(	O
LOX-1	B
)	O
is	O
a	O
membrane	O
protein	O
that	O
can	O
act	O
as	O
a	O
surface	O
endocytosis	O
receptor	O
for	O
oxidized	O
LDL	B
(	O
ox	O
-	O
LDL	B
)	O
.	O

As	O
increased	O
cellular	O
uptake	O
of	O
ox	O
-	O
LDL	B
by	O
macrophages	O
and	O
activated	O
smooth	O
muscle	O
cells	O
may	O
transform	O
these	O
cells	O
into	O
foam	O
cells	O
,	O
potential	O
interactions	O
among	O
LDL	B
oxidation	O
,	O
ox	O
-	O
LDL	B
uptake	O
,	O
and	O
regulators	O
of	O
vascular	O
smooth	O
muscle	O
cell	O
function	O
are	O
of	O
obvious	O
interest	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
angiotensin	B
II	I
(	O
AII	B
)	O
on	O
the	O
expression	O
of	O
LOX-1	B
and	O
ox	O
-	O
LDL	B
degradation	O
in	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
METHODS	O
:	O

We	O
performed	O
in	O
vitro	O
experiments	O
in	O
a	O
human	O
VSMC	O
line	O
(	O
T	O
/	O
G	O
HA	O
-	O
VSMC	O
)	O
derived	O
from	O
normal	O
aortic	O
VSMC	O
,	O
using	O
standards	O
methods	O
.	O

RESULTS	O
:	O

We	O
found	O
that	O
AII	B
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
increased	O
the	O
expression	O
of	O
LOX-1	B
(	O
approximately	O
2.5	O
-	O
fold	O
,	O
P	O
<	O
.0001	O
)	O
in	O
association	O
with	O
higher	O
degradation	O
of	O
ox	O
-	O
LDL	B
by	O
HA	O
-	O
SMC	O
(	O
from	O
4019	O
+	O
/-	O
529	O
ng	O
/	O
mg	O
cell	O
protein	O
to	O
6207	O
+	O
/-	O
287	O
ng	O
/	O
mg	O
cell	O
protein	O
;	O
P	O
=	O
.0033	O
)	O
.	O

AII	O
also	O
increased	O
the	O
expression	O
of	O
12-lipoxygenase	B
(	O
12-LO	B
)	O
and	O
15-lipoxygenase	B
(	O
15-LO	B
)	O
by	O
approximately	O
2.2	O
-	O
fold	O
(	O
P	O
=	O
.03	O
)	O
and	O
approximately	O
3	O
-	O
fold	O
(	O
P	O
=	O
.006	O
)	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
AII	B
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
increased	O
the	O
release	O
of	O
12	O
-	O
and	O
15-hydroxyeicosatetraenoic	O
acid	O
from	O
VSMC	O
within	O
10	O
min	O
approximately	O
3	O
-	O
fold	O
(	O
P	O
=	O
.03	O
)	O
and	O
50	O
%	O
(	O
P	O
<	O
.05	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O

Our	O
study	O
findings	O
provide	O
evidence	O
that	O
angiotensin	B
II	I
upregulates	O
LOX-1	B
and	O
12-LO	B
and	O
15-LO	B
expression	O
in	O
human	O
VSMC	O
,	O
thereby	O
potentially	O
providing	O
mechanisms	O
for	O
both	O
accelerated	O
LDL	B
oxidation	O
within	O
the	O
cell	O
and	O
the	O
internalization	O
of	O
exogenous	O
ox	O
-	O
LDL	B
,	O
two	O
processes	O
that	O
could	O
increase	O
the	O
susceptibility	O
of	O
human	O
VSMC	O
to	O
further	O
transformation	O
into	O
foam	O
cells	O
.	O

Isolation	O
by	O
improved	O
thermal	O
asymmetric	O
interlaced	O
PCR	O
and	O
characterization	O
of	O
a	O
seed	O
-	O
specific	O
2S	B
albumin	I
gene	O
and	O
its	O
promoter	O
from	O
grape	O
(	O
Vitis	O
vinifera	O
L.	O
)	O
.	O

A	O
seed	O
-	O
specific	O
2S	B
albumin	I
gene	O
and	O
its	O
promoter	O
region	O
of	O
grape	O
(	O
Vitis	O
vinifera	O
L.	O
)	O
were	O
isolated	O
using	O
an	O
improved	O
thermal	O
asymmetric	O
interlaced	O
PCR	O
that	O
allowed	O
efficient	O
amplification	O
of	O
target	O
sequence	O
of	O
up	O
to	O
3	O
kbp	O
in	O
length	O
directly	O
from	O
genomic	O
DNA	O
.	O

The	O
2S	B
albumin	I
VvAlb1	B
(	O
for	O
V.	O
vinifera	O
2S	B
albumin	I
1	I
)	O
gene	O
from	O
different	O
grape	O
cultivars	O
encompasses	O
a	O
coding	O
region	O
of	O
504	O
-	O
540	O
nucleotides	O
corresponding	O
to	O
a	O
deduced	O
amino	O
acid	O
sequence	O
of	O
167	O
-	O
179	O
residues	O
.	O

This	O
deduced	O
protein	O
contains	O
up	O
to	O
30	O
%	O
glutamine	O
residues	O
and	O
eight	O
cysteine	O
residues	O
arranged	O
in	O
a	O
pattern	O
highly	O
conserved	O
among	O
2S	B
albumins	I
for	O
disulfide	O
bond	O
formation	O
.	O

DNA	O
sequence	O
alignment	O
revealed	O
that	O
the	O
same	O
VvAlb1	B
gene	O
among	O
different	O
grape	O
cultivars	O
varied	O
greatly	O
,	O
including	O
an	O
insertion	O
of	O
up	O
to	O
36	O
bp	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
sequence	O
isolated	O
from	O
'	O
Thompson	O
Seedless	O
'	O
.	O

DNA	O
sequence	O
analysis	O
indicated	O
that	O
several	O
conserved	O
seed	O
-	O
specific	O
regulatory	O
motifs	O
were	O
clustered	O
within	O
a	O
0.6	O
-	O
kbp	O
region	O
5	O
'	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

To	O
further	O
test	O
promoter	O
activity	O
,	O
the	O
sequence	O
of	O
this	O
region	O
was	O
used	O
to	O
drive	O
a	O
bifunctional	O
EGFP	B
/	O
NPTII	B
fusion	O
gene	O
in	O
Agrobacterium	O
-	O
mediated	O
transformation	O
of	O
grape	O
somatic	O
embryos	O
and	O
leaf	O
discs	O
of	O
grape	O
and	O
tobacco	O
(	O
Nicotiana	O
tabacum	O
L.	O
)	O
.	O

A	O
high	O
level	O
of	O
GFP	B
expression	O
,	O
comparable	O
with	O
that	O
derived	O
from	O
an	O
enhanced	O
double	O
CsVMV	O
promoter	O
,	O
was	O
observed	O
in	O
the	O
cotyledonary	O
but	O
not	O
hypocotyl	O
and	O
vegetative	O
tissues	O
of	O
grape	O
and	O
tobacco	O
.	O

These	O
results	O
suggest	O
that	O
the	O
VvAlb1	B
gene	O
promoter	O
isolated	O
is	O
capable	O
of	O
conferring	O
seed	O
-	O
specific	O
gene	O
expression	O
.	O

Immune	O
-	O
regulation	O
of	O
the	O
apolipoprotein	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
in	O
experimental	O
inflammation	O
.	O

Apolipoprotein	B
A	I
-	I
IV	I
is	O
a	O
member	O
of	O
the	O
apo	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
.	O

In	O
order	O
to	O
investigate	O
its	O
hypothetical	O
coordinated	O
regulation	O
,	O
an	O
acute	O
phase	O
was	O
induced	O
in	O
pigs	O
by	O
turpentine	O
oil	O
injection	O
.	O

The	O
hepatic	O
expression	O
of	O
the	O
gene	O
cluster	O
as	O
well	O
as	O
the	O
plasma	O
levels	O
of	O
apolipoproteins	B
were	O
monitored	O
at	O
different	O
time	O
periods	O
.	O

Furthermore	O
,	O
the	O
involvement	O
of	O
the	O
inflammatory	O
mediators	O
'	O
interleukins	B
1	I
and	I
6	I
and	O
tumor	B
necrosis	I
factor	I
in	O
the	O
regulation	O
of	O
this	O
gene	O
cluster	O
was	O
tested	O
in	O
cultured	O
pig	O
hepatocytes	O
,	O
incubated	O
with	O
those	O
mediators	O
and	O
apo	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
expression	O
at	O
the	O
mRNA	O
level	O
was	O
measured	O
.	O

In	O
response	O
to	O
turpentine	O
oil	O
-	O
induced	O
inflammation	O
,	O
a	O
decreased	O
hepatic	O
apo	B
A	I
-	I
IV	I
mRNA	O
expression	O
was	O
observed	O
(	O
independent	O
of	O
apo	B
A	I
-	I
I	I
and	O
apo	B
C	I
-	I
III	I
mRNA	O
)	O
not	O
correlating	O
with	O
the	O
plasma	O
protein	O
levels	O
.	O

The	O
distribution	O
of	O
plasma	O
apo	B
A	I
-	I
IV	I
experienced	O
a	O
shift	O
from	O
HDL	B
to	O
larger	O
particles	O
.	O

In	O
contrast	O
,	O
the	O
changes	O
in	O
apo	B
A	I
-	I
I	I
and	O
apo	B
C	I
-	I
III	I
mRNA	O
were	O
reflected	O
in	O
their	O
corresponding	O
plasma	O
levels	O
.	O

Addition	O
of	O
cytokines	B
to	O
cultured	O
pig	O
hepatocytes	O
also	O
decreased	O
apo	B
A	I
-	I
IV	I
and	O
apo	B
A	I
-	I
I	I
mRNA	O
levels	O
.	O

All	O
these	O
results	O
show	O
that	O
the	O
down	O
-	O
regulation	O
of	O
apolipoprotein	B
A	I
-	I
I	I
and	I
A	I
-	I
IV	I
messages	O
in	O
the	O
liver	O
may	O
be	O
mediated	O
by	O
interleukin	B
6	I
and	O
TNF	B
-	I
alpha	I
.	O

The	O
well	O
-	O
known	O
HDL	B
decrease	O
found	O
in	O
many	O
different	O
acute	O
-	O
phase	O
responses	O
also	O
appears	O
in	O
the	O
pig	O
due	O
to	O
the	O
decreased	O
expression	O
of	O
apolipoprotein	B
A	I
-	I
I	I
and	O
the	O
enlargement	O
of	O
the	O
apolipoprotein	B
A	I
-	I
IV	I
-	O
containing	O
HDL	B
.	O

Structure	O
and	O
function	O
of	O
RGD	O
peptides	O
derived	O
from	O
disintegrin	B
proteins	I
.	O

The	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
sequence	O
serves	O
as	O
the	O
primary	O
recognition	O
site	O
in	O
extracellular	O
matrix	O
proteins	O
,	O
and	O
peptides	O
containing	O
this	O
sequence	O
can	O
mimic	O
the	O
biological	O
activities	O
of	O
matrix	O
proteins	O
.	O

We	O
have	O
initiated	O
structure	O
-	O
function	O
studies	O
of	O
two	O
RGD	O
containing	O
peptides	O
,	O
RGD-5	O
(	O
AGGDD	O
)	O
and	O
cyclic	O
RGD-6	O
(	O
CARGDDC	O
)	O
.	O

Assays	O
have	O
shown	O
that	O
cyclic	O
RGD	O
-	O
peptides	O
inhibit	O
platelet	O
aggregation	O
more	O
efficiently	O
than	O
linear	O
ones	O
.	O

NMR	O
data	O
revealed	O
that	O
RGD-5	O
and	O
RGD-6	O
have	O
entirely	O
different	O
conformation	O
.	O

RGD-5	O
has	O
a	O
linear	O
extended	O
structure	O
and	O
RGD-6	O
has	O
a	O
stable	O
loop	O
conformation	O
.	O

In	O
RGD-5	O
the	O
guanidinium	O
group	O
of	O
Arg2	O
and	O
the	O
carboxyl	O
group	O
of	O
Asp4	O
lie	O
in	O
parallel	O
,	O
whereas	O
the	O
side	O
-	O
chains	O
of	O
Arg3	O
and	O
Asp5	O
of	O
RGD-6	O
are	O
located	O
in	O
different	O
planes	O
,	O
supporting	O
the	O
idea	O
that	O
the	O
stability	O
of	O
the	O
cyclic	O
form	O
derives	O
from	O
the	O
packing	O
of	O
the	O
side	O
chain	O
of	O
the	O
Arg	O
and	O
Asp	O
residues	O
.	O

The	O
structural	O
features	O
of	O
these	O
peptides	O
could	O
provide	O
a	O
basis	O
for	O
designing	O
new	O
drugs	O
against	O
diseases	O
related	O
to	O
platelet	O
aggregation	O
and	O
as	O
cancer	O
antagonists	O
.	O

Acclimation	O
to	O
diverse	O
environmental	O
stresses	O
caused	O
by	O
a	O
suppression	O
of	O
cytosolic	B
ascorbate	I
peroxidase	I
in	O
tobacco	O
BY-2	O
cells	O
.	O

The	O
active	O
oxygen	O
species	O
(	O
AOS	O
)	O
that	O
arise	O
from	O
normal	O
metabolic	O
processes	O
are	O
kept	O
under	O
tight	O
control	O
by	O
various	O
antioxidant	O
mechanisms	O
.	O

AOS	O
are	O
important	O
signal	O
molecules	O
that	O
regulate	O
many	O
physiological	O
processes	O
,	O
including	O
environmental	O
stress	O
responses	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
lowered	O
cytosolic	B
ascorbate	I
peroxidase	I
(	O
APX	B
)	O
activity	O
in	O
transgenic	O
tobacco	O
BY-2	O
cells	O
,	O
using	O
two	O
transformed	O
BY-2	O
cell	O
lines	O
,	O
cAPX	B
-	O
S2	O
and	O
cAPX	B
-	O
S3	O
,	O
resulting	O
from	O
co	O
-	O
suppression	O
by	O
expression	O
of	O
Arabidopsis	O
APX1	B
cDNA	O
under	O
the	O
cauliflower	O
mosaic	O
virus	O
(	O
CaMV	O
)	O
35S	O
promoter	O
.	O

cAPX	B
-	O
S2	O
and	O
cAPX	B
-	O
S3	O
possessed	O
50	O
and	O
75	O
%	O
lower	O
cytosolic	O
APX	B
activity	O
,	O
respectively	O
,	O
compared	O
with	O
that	O
in	O
the	O
untransformed	O
cells	O
.	O

Chemical	O
fluorescence	O
analysis	O
indicated	O
that	O
the	O
AOS	O
levels	O
were	O
markedly	O
higher	O
in	O
the	O
two	O
APX	B
-	O
suppressed	O
cell	O
lines	O
than	O
in	O
the	O
wild	O
-	O
type	O
cells	O
.	O

However	O
,	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
the	O
activity	O
levels	O
of	O
the	O
various	O
other	O
antioxidant	O
enzymes	O
.	O

Interestingly	O
,	O
the	O
APX	B
-	O
suppressed	O
cells	O
showed	O
different	O
responses	O
and	O
tolerances	O
to	O
environmental	O
stresses	O
,	O
such	O
as	O
heat	O
and	O
salinity	O
.	O

Suppression	O
subtractive	O
hybridization	O
revealed	O
that	O
several	O
heat	O
-	O
and	O
salt	O
stress	O
-	O
inducible	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
cAPX	B
-	O
S3	O
cells	O
.	O

HSP70	B
,	O
DnaJ	B
-	O
like	O
protein	O
and	O
purple	B
acid	I
phosphatase	I
were	O
among	O
the	O
constitutively	O
induced	O
genes	O
.	O

An	O
in	O
-	O
gel	O
kinase	B
assay	O
suggested	O
that	O
a	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
of	O
approximately	O
46	O
kDa	O
was	O
predominantly	O
active	O
in	O
the	O
APX	B
-	O
suppressed	O
cells	O
,	O
and	O
transcript	O
levels	O
of	O
both	O
nicotiana	B
protein	I
kinase	I
1	I
(	O
NPK1	B
)	O
and	O
nucleoside	B
diphosphate	I
kinase	I
2	I
(	O
NDPK2	B
)	O
were	O
up	O
-	O
regulated	O
.	O

These	O
data	O
suggest	O
the	O
possibility	O
that	O
MAP	B
kinase	I
cascades	O
are	O
activated	O
by	O
subtle	O
imbalances	O
in	O
the	O
homeostasis	O
of	O
the	O
cellular	O
redox	O
status	O
caused	O
by	O
lowered	O
cytosolic	O
APX	B
activity	O
.	O

Transcript	O
profiling	O
of	O
immediate	O
early	O
genes	O
reveals	O
a	O
unique	O
role	O
for	O
activating	B
transcription	I
factor	I
3	I
in	O
mediating	O
activation	O
of	O
the	O
glycoprotein	B
hormone	I
alpha	I
-	O
subunit	O
promoter	O
by	O
gonadotropin	B
-	I
releasing	I
hormone	I
.	O

Recent	O
studies	O
profiling	O
immediate	O
early	O
gene	O
responses	O
to	O
GnRH	B
in	O
the	O
LbetaT2	O
gonadotrope	O
cell	O
model	O
revealed	O
increased	O
expression	O
of	O
numerous	O
genes	O
including	O
activating	B
transcription	I
factor	I
(	I
ATF	I
)	I
3	I
.	O

The	O
present	O
studies	O
demonstrate	O
similar	O
results	O
with	O
GnRH	B
administration	O
in	O
vivo	O
in	O
ovariectomized	O
mice	O
.	O

In	O
this	O
model	O
,	O
ATF3	B
mRNA	O
was	O
markedly	O
up	O
-	O
regulated	O
at	O
20	O
,	O
40	O
,	O
and	O
60	O
min	O
after	O
in	O
vivo	O
administration	O
of	O
a	O
GnRH	B
analog	O
.	O

In	O
alphaT3	O
-	O
1	O
gonadotrope	O
cells	O
,	O
ATF3	B
mRNA	O
and	O
protein	O
were	O
induced	O
by	O
GnRH	B
in	O
a	O
manner	O
consistent	O
with	O
in	O
vivo	O
observations	O
.	O

Pharmacological	O
studies	O
implicated	O
a	O
combined	O
role	O
for	O
the	O
activities	O
of	O
protein	B
kinase	I
C	I
isozymes	O
,	O
ERK	B
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
in	O
modulating	O
ATF3	B
expression	O
.	O

The	O
role	O
of	O
ATF3	B
was	O
further	O
investigated	O
in	O
the	O
activation	O
of	O
the	O
human	O
glycoprotein	B
hormone	I
alpha	I
-	O
subunit	O
gene	O
promoter	O
.	O

GnRH	B
induced	O
the	O
alpha	O
-	O
subunit	O
promoter	O
-	O
luciferase	B
reporter	O
approximately	O
16	O
-	O
fold	O
,	O
and	O
this	O
induction	O
was	O
completely	O
abolished	O
with	O
mutations	O
in	O
the	O
dual	O
cAMP	O
response	O
elements	O
(	O
CREs	O
)	O
or	O
the	O
combined	O
inhibition	O
of	O
GnRH	B
-	O
induced	O
ERK	B
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
.	O

GnRH	B
induced	O
recruitment	O
of	O
ATF3	B
,	O
c	B
-	I
Jun	I
,	O
and	O
c	B
-	I
Fos	I
to	O
the	O
dual	O
CREs	O
.	O

Overexpression	O
and	O
specific	O
knockdown	O
of	O
ATF3	B
by	O
small	O
inhibitory	O
RNA	O
implicate	O
a	O
functional	O
role	O
for	O
ATF3	B
in	O
mediating	O
activation	O
of	O
the	O
alpha	O
-	O
subunit	O
gene	O
promoter	O
.	O

These	O
studies	O
provide	O
clear	O
evidence	O
that	O
ATF3	B
is	O
a	O
key	O
immediate	O
early	O
gene	O
induced	O
by	O
GnRH	B
administration	O
in	O
vivo	O
and	O
in	O
the	O
alphaT3	O
-	O
1	O
gonadotrope	O
cell	O
model	O
.	O

These	O
studies	O
support	O
the	O
conclusion	O
that	O
the	O
dual	O
CREs	O
of	O
the	O
human	O
alpha	O
-	O
subunit	O
promoter	O
are	O
the	O
target	O
of	O
GnRH	B
-	O
induced	O
MAPK	B
regulation	O
through	O
ATF3	B
.	O

Simultaneous	O
expression	O
of	O
apolipoprotein	B
B	I
mRNA	I
editing	I
enzyme	I
and	O
scavenger	B
receptor	I
BI	I
mediated	O
by	O
a	O
therapeutic	O
gene	O
expression	O
system	O
.	O

Cardiovascular	O
diseases	O
are	O
often	O
accompanied	O
by	O
elevated	O
LDL	B
particles	O
and	O
endothelial	O
dysfunction	O
.	O

We	O
have	O
examined	O
the	O
possibility	O
of	O
concurrently	O
reducing	O
LDL	B
levels	O
and	O
modulating	O
endothelial	O
function	O
using	O
a	O
single	O
helper	O
-	O
dependent	O
adenovirus	O
vector	O
system	O
to	O
simultaneously	O
express	O
the	O
apolipoprotein	B
B	I
mRNA	I
editing	I
enzyme	I
(	O
Apobec1	B
)	O
and	O
the	O
scavenger	B
receptor	I
,	I
class	I
B	I
,	I
type	I
I	I
(	O
SR	B
-	I
BI	I
)	O
genes	O
under	O
the	O
control	O
of	O
separate	O
promoters	O
(	O
designated	O
HD	O
-	O
C2	O
)	O
.	O

Apobec1	B
edits	O
apoB	B
mRNA	O
at	O
nucleotide	O
C-6666	O
to	O
produce	O
truncated	O
apoB48	B
and	O
is	O
normally	O
expressed	O
in	O
small	O
intestine	O
only	O
.	O

SR	B
-	I
BI	I
is	O
a	O
receptor	O
for	O
multiple	O
ligands	O
with	O
distinct	O
tissue	O
-	O
specific	O
functions	O
.	O

Expression	O
of	O
Apobec1	B
in	O
HepG2	O
cells	O
resulted	O
in	O
apoB	B
mRNA	O
editing	O
,	O
leading	O
to	O
decreased	O
apoB100	B
abundance	O
(	O
to	O
6	O
%	O
of	O
control	O
)	O
and	O
the	O
appearance	O
of	O
apoB48	B
.	O

Editing	O
of	O
apoB	B
mRNA	O
in	O
HepG2	O
cells	O
resulted	O
in	O
decline	O
in	O
apoB	B
mRNA	O
levels	O
of	O
50	O
%	O
.	O

This	O
was	O
probably	O
the	O
result	O
of	O
nonsense	O
-	O
mediated	O
decay	O
of	O
edited	O
message	O
,	O
since	O
over	O
-	O
expression	O
of	O
Apobec1	B
increased	O
neither	O
Apobec1	B
complementary	I
factor	I
(	O
ACF	B
)	O
mRNA	O
nor	O
protein	O
abundance	O
.	O

Over	O
-	O
expression	O
of	O
SR	B
-	I
BI	I
in	O
human	O
endothelial	O
cells	O
activated	O
endothelial	B
nitric	I
oxide	I
synthase	I
(	O
eNOS	B
)	O
activity	O
by	O
phosphorylation	O
of	O
eNOS	B
at	O
residue	O
Ser	O
-	O
1177	O
in	O
the	O
presence	O
of	O
HDL	B
,	O
leading	O
to	O
increased	O
production	O
of	O
the	O
anti	O
-	O
atherogenic	O
molecule	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrates	O
that	O
using	O
one	O
vector	O
delivery	O
system	O
to	O
express	O
two	O
genes	O
in	O
two	O
different	O
cell	O
types	O
results	O
in	O
the	O
cell	O
-	O
specific	O
beneficial	O
effects	O
of	O
decreasing	O
apoB100	B
production	O
and	O
increasing	O
eNOS	B
activities	O
.	O

This	O
combined	O
gene	O
expression	O
approach	O
may	O
provide	O
an	O
improved	O
therapeutic	O
strategy	O
by	O
targeting	O
multiple	O
sites	O
in	O
the	O
mechanism	O
of	O
cardiovascular	O
injury	O
.	O

Neuroprotective	O
potential	O
of	O
three	O
neuropeptides	O
PACAP	B
,	O
VIP	B
and	O
PHI	B
.	O

Pituitary	B
adenylate	I
cyclase	I
activating	I
polypeptide	I
(	O
PACAP	B
)	O
,	O
vasoactive	B
intestinal	I
peptide	I
(	O
VIP	B
)	O
and	O
peptide	B
histidine	I
-	I
isoleucine	I
(	O
PHI	B
)	O
,	O
are	O
structurally	O
related	O
endogenous	O
peptides	O
widely	O
expressed	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
showing	O
rich	O
profile	O
of	O
biological	O
activities	O
.	O

They	O
act	O
as	O
neurotransmitters	B
,	O
neuromodulators	O
and	O
neurotrophic	B
factors	B
.	O

Recently	O
,	O
their	O
neuroprotective	O
potential	O
has	O
been	O
revealed	O
in	O
numerous	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

Thus	O
,	O
PACAP	B
and	O
VIP	B
protected	O
the	O
cells	O
from	O
neurotoxic	O
effects	O
of	O
ethanol	O
,	O
hydrogen	O
peroxide	O
(	O
H2O2	O
,	O
beta	B
-	I
amyloid	I
and	O
glycoprotein	B
120	I
(	O
gp120	B
)	O
.	O
Moreover	O
,	O
PACAP	B
showed	O
neuroprotection	O
against	O
glutamate	O
,	O
human	O
prion	B
protein	I
fragment	O
106	O
-	O
126	O
[	O
PrP	B
(	O
106	O
-	O
126	O
)	O
]	O
and	O
C2	O
-	O
ceramide	O
.	O
Both	O
peptides	O
reduced	O
brain	O
damage	O
after	O
ischemia	O
and	O
ameliorated	O
neurological	O
deficits	O
in	O
a	O
model	O
of	O
Parkinson	O
's	O
disease	O
.	O
Neuroprotective	O
potential	O
of	O
PHI	B
has	O
not	O
been	O
thoroughly	O
investigated	O
yet	O
,	O
but	O
several	O
results	O
obtained	O
in	O
the	O
last	O
years	O
do	O
not	O
exclude	O
it	O
.	O

The	O
mechanism	O
underlying	O
neuroprotective	O
properties	O
of	O
PACAP	B
seems	O
to	O
involve	O
activation	O
of	O
adenylyl	B
cyclase	I
(	O
AC	B
)	O
--	O
>	O
cyclic	O
adenosine	O
3',5'-mono	O
-	O
phosphate	O
(	O
cAMP	O
)	O
--	O
>	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
and	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
pathways	O
,	O
and	O
inhibition	O
of	O
caspase-3	B
.	O

PACAP	B
can	O
also	O
,	O
yet	O
indirectly	O
,	O
stimulate	O
astrocytes	O
to	O
release	O
neuroprotective	O
factors	O
,	O
such	O
as	O
regulated	B
upon	I
activation	I
normal	I
T	I
cell	I
expressed	I
and	I
secreted	I
(	O
RANTES	B
)	O
and	O
macrophage	B
inflammatory	I
protein	I
1	I
(	O
MIP-1	B
)	O
chemokines	B
.	O

Neuroprotective	O
activity	O
of	O
VIP	B
seems	O
to	O
involve	O
an	O
indirect	O
mechanism	O
requiring	O
astrocytes	O
.	O

VIP	B
-	O
stimulated	O
astrocytes	O
secrete	O
neuroprotective	O
proteins	O
,	O
including	O
activity	B
-	I
dependent	I
neurotrophic	I
factor	I
(	O
ADNF	B
)	O
and	O
activity	B
-	I
dependent	I
neuroprotective	I
protein	I
(	O
ADNP	B
)	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
cytokines	B
.	O

However	O
,	O
in	O
the	O
activated	O
microglia	O
,	O
VIP	B
and	O
PACAP	B
are	O
capable	O
of	O
inhibiting	O
the	O
production	O
of	O
inflammatory	O
mediators	O
which	O
can	O
lead	O
to	O
neurodegenerative	O
processes	O
within	O
the	O
brain	O
.	O

In	O
conclusion	O
,	O
studies	O
carried	O
out	O
on	O
the	O
central	O
nervous	O
system	O
have	O
shown	O
that	O
PACAP	B
,	O
VIP	B
,	O
and	O
likely	O
PHI	B
,	O
are	O
endowed	O
with	O
a	O
neuroprotective	O
potential	O
,	O
which	O
renders	O
them	O
(	O
or	O
their	O
derivatives	O
)	O
promising	O
therapeutic	O
agents	O
in	O
several	O
psychoneurological	O
disorders	O
linked	O
to	O
neurodegeneration	O
.	O

Molecular	O
characterization	O
of	O
major	B
histocompatibility	I
complex	I
class	I
I	I
(	I
B	I
-	I
F	I
)	I
mRNA	O
variants	O
from	O
chickens	O
differing	O
in	O
resistance	O
to	O
Marek	O
's	O
disease	O
.	O

In	O
this	O
study	O
,	O
the	O
relative	O
distributions	O
of	O
two	O
alternatively	O
polyadenylated	O
chicken	O
major	B
histocompatibility	I
complex	I
(	O
MHC	B
)	O
mRNA	O
isoforms	O
of	O
approximately	O
1.5	O
and	O
1.9	O
kb	O
were	O
analysed	O
in	O
spleen	O
cells	O
from	O
chickens	O
homozygous	O
for	O
the	O
MHC	B
haplotypes	O
B21	B
and	O
B19v1	B
as	O
well	O
as	O
in	O
heterozygous	O
B19v1	B
/	O
B21	B
birds	O
.	O

Both	O
isoforms	O
are	O
likely	O
to	O
encode	O
classical	B
MHC	I
class	I
I	I
(	I
B	I
-	I
F	I
)	I
alpha	I
chains	O
.	O

The	O
B19v1	B
and	O
B21	B
MHC	I
haplotypes	O
confer	O
different	O
levels	O
of	O
protection	O
against	O
Marek	O
's	O
disease	O
(	O
MD	O
)	O
,	O
which	O
is	O
caused	O
by	O
infection	O
with	O
MD	O
virus	O
(	O
MDV	O
)	O
.	O

In	O
spleen	O
cells	O
,	O
MD	O
-	O
resistant	O
B21	B
birds	O
were	O
shown	O
to	O
have	O
the	O
highest	O
percentage	O
of	O
the	O
1.5	O
kb	O
variant	O
relative	O
to	O
the	O
total	O
MHC	B
class	I
I	I
expression	O
,	O
MD	O
-	O
susceptible	O
B19v1	B
birds	O
the	O
lowest	O
and	O
B19v1	B
/	O
B21	B
birds	O
an	O
intermediate	O
percentage	O
.	O

Infection	O
of	O
4	O
-	O
week	O
-	O
old	O
chickens	O
with	O
the	O
GA	O
strain	O
of	O
MDV	O
was	O
shown	O
to	O
cause	O
a	O
significant	O
increase	O
in	O
the	O
relative	O
amount	O
of	O
1.5	O
kb	O
transcripts	O
in	O
B21	B
birds	O
32	O
days	O
postinfection	O
(	O
dpi	O
)	O
.	O

Alternatively	O
polyadenylated	O
mRNA	O
isoforms	O
may	O
encode	O
identical	O
proteins	O
,	O
but	O
differences	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
can	O
influence	O
polyadenylation	O
,	O
mRNA	O
stability	O
,	O
intracellular	O
localization	O
and	O
translation	O
efficiency	O
.	O

It	O
was	O
shown	O
that	O
the	O
increased	O
1.5	O
kb	O
percentage	O
in	O
B21	B
birds	O
32	O
days	O
postinfection	O
may	O
be	O
a	O
result	O
of	O
a	O
change	O
in	O
the	O
choice	O
of	O
poly	O
(	O
A	O
)	O
site	O
rather	O
than	O
a	O
locus	O
-	O
specific	O
upregulated	O
transcription	O
of	O
the	O
BF1	B
gene	O
that	O
preferentially	O
expresses	O
the	O
1.5	O
kb	O
variant	O
.	O

Furthermore	O
,	O
the	O
3	O
'	O
end	O
of	O
the	O
1.5	O
kb	O
mRNA	O
variants	O
deriving	O
from	O
B19v1	B
and	O
B21	B
chickens	O
was	O
characterized	O
by	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
and	O
sequencing	O
.	O

No	O
potentially	O
functional	O
elements	O
were	O
identified	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
RACE	O
products	O
corresponding	O
to	O
this	O
short	O
isoform	O
.	O

However	O
,	O
variation	O
in	O
polyadenylation	O
site	O
was	O
observed	O
between	O
the	O
BF1	B
and	O
BF2	B
mRNA	O
transcripts	O
and	O
alternative	O
splicing	O
-	O
out	O
of	O
the	O
sequence	O
(	O
exon	O
7	O
)	O
encoding	O
the	O
second	O
segment	O
of	O
the	O
cytoplasmic	O
part	O
of	O
the	O
mature	O
BF2	B
*	I
19	I
molecules	O
.	O

This	O
alternative	O
exon	O
7	O
splice	O
variant	O
was	O
also	O
detected	O
in	O
other	O
MD	O
-	O
susceptible	O
haplotypes	O
,	O
but	O
not	O
in	O
the	O
MD	O
-	O
resistant	O
B21	B
and	O
B21	B
-	O
like	O
haplotypes	O
,	O
suggesting	O
a	O
potential	O
role	O
of	O
exon	O
7	O
in	O
MHC	B
-	O
related	O
MD	O
resistance	O
.	O

Adaptor	O
heat	B
shock	I
protein	I
complex	I
formation	O
regulates	O
trafficking	O
of	O
the	O
asialoglycoprotein	B
receptor	I
.	O

In	O
the	O
asialoglycoprotein	B
receptor	I
(	O
ASGPR	B
)	O
endocytic	O
pathway	O
,	O
internalized	O
receptors	O
pass	O
through	O
early	O
,	O
recycling	O
,	O
and	O
sorting	O
endosomal	O
compartments	O
before	O
returning	O
to	O
the	O
cell	O
surface	O
.	O

Sorting	O
motifs	O
in	O
the	O
cytoplasmic	O
domain	O
(	O
CD	O
)	O
and	O
protein	O
interactions	O
with	O
these	O
sequences	O
presumably	O
direct	O
receptor	O
trafficking	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
association	O
of	O
a	O
potential	O
sorting	O
heat	B
shock	I
protein	I
(	I
HSP	I
)	I
heterocomplex	I
with	O
the	O
ASGPR	B
-	O
CD	O
was	O
regulated	O
by	O
casein	B
kinase	I
2	I
(	O
CK2	B
)	O
-	O
mediated	O
phosphorylation	O
.	O

Mass	O
spectrometry	O
and	O
immunoblot	O
analyses	O
identified	O
five	O
of	O
these	O
ASGPR	B
-	O
CD	O
-	O
associated	O
proteins	O
as	O
the	O
molecular	O
chaperones	B
glycoprotein	B
96	I
,	O
HSP70	B
,	O
HSP90	B
,	O
cyclophilin	B
A	I
,	O
and	O
FK	B
506	I
binding	I
protein	I
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
any	O
of	O
the	O
adaptor	B
protein	I
complexes	I
(	O
AP1	B
,	O
AP2	B
,	O
or	O
AP3	B
)	O
were	O
selectivity	O
associated	O
with	O
the	O
ASGPR	B
-	O
CD	O
.	O

In	O
conjunction	O
with	O
molecular	O
chaperones	B
,	O
AP2	B
and	O
AP1	B
were	O
recovered	O
from	O
a	O
CK2	B
phosphorylated	O
agarose	O
-	O
GSH	O
-	O
GST	B
-	O
ASGPR	B
-	O
CD	O
matrix	O
.	O

Binding	O
of	O
AP3	B
was	O
independent	O
of	O
the	O
phosphorylation	O
status	O
of	O
the	O
CD	O
matrix	O
.	O

Inhibition	O
of	O
CK2	B
-	O
mediated	O
phosphorylation	O
with	O
tetrabromobenzotriazole	O
prevented	O
AP	B
recovery	O
within	O
an	O
immunoadsorbed	O
ASGPR	B
complex	O
.	O

Rapamycin	O
,	O
which	O
dissociates	O
the	O
HSP	B
heterocomplex	I
from	O
ASGPR	B
-	O
CD	O
,	O
thereby	O
altering	O
receptor	O
trafficking	O
also	O
,	O
inhibited	O
AP	B
association	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
an	O
inhibitor	O
of	O
HSP90	B
heterocomplex	I
formation	O
,	O
geldanmycin	O
.	O

The	O
data	O
presented	O
provide	O
evidence	O
that	O
recruitment	O
of	O
AP1	B
and	O
AP2	B
,	O
which	O
is	O
necessary	O
for	O
appropriate	O
receptor	O
trafficking	O
,	O
is	O
mediated	O
by	O
the	O
interaction	O
of	O
AP	B
with	O
the	O
ASGPR	B
-	O
CD	O
-	O
bound	O
HSP	B
complex	I
.	O

Unusual	O
features	O
of	O
self	O
-	O
peptide	O
/	O
MHC	B
binding	O
by	O
autoimmune	O
T	O
cell	O
receptors	O
.	O

Structural	O
studies	O
on	O
T	B
cell	I
receptors	I
(	O
TCRs	B
)	O
specific	O
for	O
foreign	O
antigens	O
demonstrated	O
a	O
remarkably	O
similar	O
topology	O
characterized	O
by	O
a	O
central	O
,	O
diagonal	O
TCR	B
binding	O
mode	O
that	O
maximizes	O
interactions	O
with	O
the	O
MHC	B
bound	O
peptide	O
.	O

However	O
,	O
three	O
recent	O
structures	O
involving	O
autoimmune	O
TCRs	B
demonstrated	O
unusual	O
interactions	O
with	O
self	O
-	O
peptide	O
/	O
MHC	B
complexes	O
.	O

Two	O
TCRs	B
from	O
multiple	O
sclerosis	O
patients	O
bind	O
with	O
unconventional	O
topologies	O
,	O
and	O
both	O
TCRs	B
are	O
shifted	O
toward	O
the	O
peptide	O
N	O
terminus	O
and	O
the	O
MHC	B
class	I
II	I
beta	I
chain	O
helix	O
.	O

A	O
TCR	B
from	O
the	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
model	O
binds	O
in	O
a	O
conventional	O
orientation	O
,	O
but	O
the	O
structure	O
is	O
unusual	O
because	O
the	O
self	O
-	O
peptide	O
only	O
partially	O
fills	O
the	O
binding	O
site	O
.	O

For	O
all	O
three	O
TCRs	B
,	O
interaction	O
with	O
the	O
MHC	B
bound	O
self	O
-	O
peptide	O
is	O
suboptimal	O
,	O
and	O
only	O
two	O
or	O
three	O
TCR	B
loops	O
contact	O
the	O
peptide	O
.	O

Optimal	O
TCR	B
binding	O
modes	O
confer	O
a	O
competitive	O
advantage	O
for	O
antimicrobial	O
T	O
cells	O
during	O
an	O
infection	O
,	O
whereas	O
altered	O
binding	O
properties	O
may	O
permit	O
survival	O
of	O
a	O
subset	O
of	O
autoreactive	O
T	O
cells	O
during	O
thymic	O
selection	O
.	O

Screening	O
of	O
novel	O
cellulose	O
-	O
degrading	O
bacterium	O
and	O
its	O
application	O
to	O
denitrification	O
of	O
groundwater	O
.	O

To	O
establish	O
an	O
environmentally	O
friendly	O
groundwater	O
bioremediation	O
process	O
using	O
a	O
cellulose	O
carrier	O
combined	O
with	O
cellulose	O
-	O
utilizing	O
,	O
denitrifying	O
microorganisms	O
,	O
a	O
novel	O
psychrophilic	O
bacterium	O
,	O
designated	O
CL-5	O
,	O
which	O
can	O
degrade	O
a	O
commercial	O
-	O
based	O
cellulose	O
carrier	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
was	O
screened	O
.	O

Since	O
the	O
denitrification	O
capability	O
of	O
CL-5	O
is	O
low	O
,	O
complex	O
microbial	O
systems	O
were	O
constructed	O
together	O
with	O
other	O
denitrifying	O
bacteria	O
designated	O
NR-1	O
and	O
NR-2	O
that	O
were	O
also	O
isolated	O
from	O
soil	O
.	O

The	O
nitrate	O
-	O
reducing	O
activities	O
of	O
mixed	O
cultures	O
were	O
much	O
higher	O
than	O
those	O
of	O
the	O
pure	O
cultures	O
of	O
CL-5	O
,	O
NR-1	O
and	O
NR-2	O
.	O

The	O
highest	O
N	O
(	O
2	O
)	O
O	O
and	O
N	O
(	O
2	O
)	O
formation	O
activities	O
were	O
observed	O
in	O
the	O
mixed	O
culture	O
of	O
CL-5+NR-2	O
.	O

A	O
splicing	O
repressor	O
domain	O
in	O
polypyrimidine	B
tract	I
-	I
binding	I
protein	I
.	O

Polypyrimidine	B
tract	I
-	I
binding	I
protein	I
(	O
PTB	B
)	O
is	O
an	O
hnRNP	O
with	O
four	O
RRM	O
type	O
domains	O
.	O

It	O
plays	O
roles	O
as	O
a	O
repressive	O
alternative	O
splicing	O
regulator	O
of	O
multilple	O
target	O
genes	O
,	O
as	O
well	O
as	O
being	O
involved	O
in	O
pre	O
-	O
mRNA	O
3	O
'	O
end	O
processing	O
,	O
mRNA	O
localization	O
,	O
stability	O
,	O
and	O
internal	O
ribosome	O
entry	O
site	O
-	O
mediated	O
translation	O
.	O

Here	O
we	O
have	O
used	O
a	O
tethered	O
function	O
assay	O
,	O
in	O
which	O
a	O
fusion	O
protein	O
of	O
PTB	B
and	O
the	O
bacteriophage	O
MS2	O
coat	B
protein	I
is	O
recruited	O
to	O
a	O
splicing	O
regulatory	O
site	O
by	O
binding	O
to	O
an	O
artificially	O
inserted	O
MS2	O
binding	O
site	O
.	O

Deletion	O
mutations	O
of	O
PTB	B
in	O
this	O
system	O
allowed	O
us	O
to	O
identify	O
RRM2	O
and	O
the	O
following	O
inter	O
-	O
RRM	O
linker	O
region	O
as	O
the	O
minimal	O
region	O
of	O
PTB	B
that	O
can	O
act	O
as	O
splicing	O
repressor	O
domain	O
when	O
recruited	O
to	O
RNA	O
.	O

Splicing	O
repression	O
by	O
the	O
minimal	O
repressor	O
domain	O
remained	O
cell	O
type	O
-	O
specific	O
and	O
dependent	O
upon	O
other	O
defined	O
regulatory	O
elements	O
in	O
the	O
alpha	B
-	I
tropomyosin	I
test	O
minigene	O
.	O

Our	O
results	O
highlight	O
the	O
fact	O
that	O
splicing	O
repression	O
by	O
PTB	B
can	O
be	O
uncoupled	O
from	O
the	O
mode	O
by	O
which	O
it	O
binds	O
to	O
RNA	O
.	O

Short	O
communication	O
:	O
impairment	O
of	O
membrane	O
markers	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
imbalance	O
of	O
cytokine	B
secretion	O
in	O
the	O
pathogenesis	O
of	O
multiple	O
sclerosis	O
active	O
phases	O
.	O

Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

In	O
active	O
disease	O
,	O
a	O
transmigration	O
of	O
autoreactive	O
T	O
cells	O
to	O
myelin	O
antigens	O
recruited	O
from	O
the	O
peripheral	O
blood	O
(	O
PBMC	O
)	O
to	O
the	O
CNS	O
occurs	O
,	O
and	O
there	O
these	O
cells	O
prolong	O
their	O
survival	O
and	O
contribute	O
to	O
the	O
perpetuation	O
of	O
the	O
inflammation	O
.	O

In	O
the	O
active	O
local	O
lesions	O
of	O
MS	O
patients	O
,	O
these	O
cells	O
display	O
activation	O
and	O
apoptosis	O
surface	O
markers	O
and	O
secrete	O
a	O
range	O
of	O
cytokines	B
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
study	O
on	O
PBMCs	O
and	O
in	O
the	O
serum	O
of	O
stable	O
and	O
active	O
MS	O
subjects	O
(	O
1	O
)	O
the	O
behavior	O
of	O
the	O
CD40	B
/	O
CD40L	B
system	O
and	O
the	O
consequent	O
balance	O
of	O
Th1	O
and	O
Th2	O
cytokines	B
and	O
(	O
2	O
)	O
the	O
apoptosis	O
marker	O
system	O
CD95	B
/	O
CD95L	B
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
-	O
binding	O
receptors	O
,	O
TNFRI	B
and	O
TNFRII	B
.	O

A	O
possible	O
excess	O
of	O
activation	O
marker	O
expression	O
affecting	O
and	O
driving	O
Th1	O
cytokine	B
production	O
or	O
a	O
parallel	O
impairment	O
of	O
apoptosis	O
may	O
contribute	O
to	O
MS	O
relapses	O
.	O

Our	O
results	O
may	O
indicate	O
that	O
a	O
dysregulation	O
of	O
early	O
activation	O
and	O
apoptosis	O
receptor	O
systems	O
and	O
a	O
profound	O
and	O
complex	O
imbalance	O
of	O
cytokine	B
production	O
occurred	O
in	O
the	O
peripheral	O
blood	O
of	O
MS	O
patients	O
.	O

This	O
impairment	O
could	O
account	O
for	O
active	O
phases	O
of	O
the	O
disease	O
.	O

ASB	O
proteins	O
interact	O
with	O
Cullin5	B
and	O
Rbx2	B
to	O
form	O
E3	B
ubiquitin	I
ligase	I
complexes	O
.	O

The	O
ankyrin	B
repeat	I
and	I
SOCS	I
box	I
(	I
ASB	I
)	I
family	I
is	O
composed	O
of	O
18	O
proteins	O
from	O
ASB1	B
to	O
ASB18	B
and	O
belongs	O
to	O
the	O
suppressor	B
of	I
cytokine	I
signaling	I
(	I
SOCS	I
)	I
box	I
protein	I
superfamily	I
.	O

ASB2	B
was	O
recently	O
shown	O
to	O
interact	O
with	O
a	O
certain	O
Cul	B
-	O
Rbx	B
module	O
to	O
form	O
an	O
E3	B
ubiquitin	I
(	I
Ub	I
)	I
ligase	I
complex	O
,	O
but	O
the	O
functional	O
composition	O
of	O
the	O
ASB	O
-	O
containing	O
E3	B
Ub	I
ligase	I
complexes	O
remains	O
to	O
be	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
ASB	O
proteins	O
interact	O
with	O
Cul5	B
-	O
Rbx2	B
but	O
neither	O
Cul2	B
nor	O
Rbx1	B
in	O
cells	O
.	O

Mutational	O
analysis	O
revealed	O
that	O
the	O
highly	O
conserved	O
amino	O
acid	O
sequences	O
of	O
the	O
BC	O
box	O
and	O
Cul5	B
box	O
in	O
the	O
SOCS	B
box	O
of	O
ASB	O
proteins	O
were	O
essential	O
for	O
the	O
interaction	O
with	O
Cul5	B
-	O
Rbx2	B
.	O

Although	O
ASB	O
proteins	O
show	O
slight	O
divergences	O
from	O
the	O
consensus	O
sequences	O
of	O
the	O
BC	O
box	O
and	O
Cul5	B
box	O
,	O
all	O
five	O
tested	O
ASB	O
proteins	O
bound	O
to	O
Cul5	B
-	O
Rbx2	B
.	O

Furthermore	O
,	O
all	O
three	O
tested	O
ASB	O
complexes	O
containing	O
Cul5	B
-	O
Rbx2	B
were	O
found	O
to	O
have	O
E3	B
Ub	I
ligase	I
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
ASB	B
family	I
proteins	O
interact	O
with	O
Cul5	B
-	O
Rbx2	B
to	O
form	O
E3	B
Ub	I
ligases	I
and	O
play	O
significant	O
roles	O
via	O
a	O
ubiquitination	O
-	O
mediated	O
pathway	O
.	O

Expression	O
of	O
TWEAK	B
and	O
its	O
receptor	O
Fn14	B
in	O
human	O
subcutaneous	O
adipose	O
tissue	O
.	O

Relationship	O
with	O
other	O
inflammatory	O
cytokines	B
in	O
obesity	O
.	O

TWEAK	B
,	O
a	O
cytokine	B
of	O
the	O
TNF	B
family	I
,	O
has	O
been	O
found	O
to	O
be	O
expressed	O
under	O
different	O
inflammatory	O
conditions	O
but	O
no	O
data	O
is	O
available	O
concerning	O
the	O
expression	O
of	O
this	O
cytokine	B
and	O
its	O
receptor	O
(	O
Fn14	B
)	O
in	O
human	O
obesity	O
.	O

In	O
the	O
present	O
work	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
many	O
pro	O
-	O
inflammatory	O
TNF	B
system	O
cytokines	B
(	O
TNF	B
-	I
alpha	I
,	O
TWEAK	B
and	O
their	O
respective	O
receptors	O
,	O
TNFR1	B
,	O
TNFR2	B
and	O
Fn14	B
)	O
in	O
human	O
adipose	O
tissue	O
of	O
84	O
subjects	O
some	O
with	O
different	O
degree	O
of	O
obesity	O
and	O
type	O
2	O
diabetes	O
,	O
and	O
its	O
relation	O
with	O
inflammation	O
by	O
also	O
measuring	O
the	O
expression	O
of	O
macrophage	O
marker	O
CD68	B
.	O

We	O
detected	O
expression	O
of	O
TWEAK	B
and	O
Fn14	B
in	O
isolated	O
mature	O
adipocytes	O
and	O
in	O
the	O
stromovascular	O
fraction	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
LPS	O
upregulates	O
the	O
expression	O
of	O
both	O
genes	O
on	O
THP-1	O
human	O
monocytic	O
cell	O
line	O
.	O

TWEAK	B
was	O
expressed	O
in	O
adipose	O
tissue	O
of	O
all	O
studied	O
subjects	O
with	O
no	O
differences	O
between	O
obesity	O
group	O
,	O
and	O
was	O
associated	O
with	O
Fn14	B
expression	O
in	O
morbid	O
obese	O
,	O
mainly	O
in	O
women	O
with	O
type	O
2	O
diabetes	O
.	O

The	O
data	O
obtained	O
here	O
also	O
showed	O
that	O
TNF	B
-	I
alpha	I
and	O
TNFR2	B
mRNAs	O
were	O
significantly	O
more	O
expressed	O
in	O
subcutaneous	O
adipose	O
tissue	O
of	O
subjects	O
with	O
morbid	O
obesity	O
compared	O
to	O
obese	O
and	O
non	O
-	O
obese	O
subjects	O
.	O

In	O
contrast	O
,	O
TNFR1	B
gene	O
expression	O
was	O
negatively	O
associated	O
with	O
BMI	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
TNF	B
-	O
derived	O
pro	O
-	O
inflammatory	O
cytokines	B
are	O
increased	O
in	O
severe	O
obesity	O
,	O
where	O
macrophage	O
infiltrate	O
could	O
modulate	O
the	O
inflammatory	O
environment	O
through	O
activation	O
of	O
its	O
receptors	O
.	O

Action	O
of	O
intracellular	O
IL-1Ra	B
(	O
Type	O
1	O
)	O
is	O
independent	O
of	O
the	O
IL-1	B
intracellular	O
signalling	O
pathway	O
.	O

The	O
balance	O
between	O
IL-1	B
and	O
its	O
naturally	O
occurring	O
inhibitor	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
is	O
critical	O
in	O
determining	O
the	O
inflammatory	O
response	O
.	O

Four	O
splice	O
variants	O
of	O
the	O
IL-1ra	B
gene	O
have	O
been	O
identified	O
;	O
one	O
secreted	O
(	O
sIL-1ra	B
)	O
and	O
three	O
intracellular	O
(	O
icIL-1ra1	B
-	I
3	I
)	O
.	O

The	O
biological	O
roles	O
of	O
the	O
intracellular	O
isoforms	O
remain	O
largely	O
unclear	O
.	O

We	O
wished	O
to	O
determine	O
whether	O
icIL	B
-	I
1ra1	I
had	O
intracellular	O
functions	O
regulating	O
IL-1	B
signalling	O
.	O

Signalling	O
was	O
determined	O
using	O
an	O
NF	B
-	I
kappaB	I
reporter	O
assay	O
measuring	O
induction	O
of	O
the	O
IL-8	B
promoter	O
in	O
transfected	O
cells	O
.	O

Over	O
-	O
expression	O
of	O
icIL-1ra1	B
in	O
HeLa	O
cells	O
had	O
no	O
effect	O
on	O
IL-1	B
stimulated	O
IL-8	B
activity	O
.	O

In	O
contrast	O
over	O
-	O
expression	O
of	O
sIL	B
-	I
ra	I
significantly	O
attenuated	O
IL-1	B
activity	O
.	O

In	O
addition	O
,	O
transfection	O
of	O
icIL-1ra1	B
in	O
HeLa	O
cells	O
did	O
not	O
cause	O
inhibition	O
of	O
IL-8	B
promoter	O
activity	O
following	O
over	O
-	O
expression	O
of	O
the	O
IL-1	B
signalling	O
components	O
MyD88	B
,	O
IRAK-1	B
,	O
TRAF-6	B
,	O
Ikappakappabeta	B
or	O
RelA	B
.	O

This	O
implies	O
that	O
icIL-1ra1	B
does	O
not	O
act	O
to	O
alter	O
IL-1	B
mediated	O
intracellular	O
signalling	O
in	O
this	O
system	O
.	O

We	O
investigated	O
whether	O
ATP	O
and/or	O
over	O
-	O
expression	O
of	O
the	O
P2X7	B
receptor	O
caused	O
icIL	B
-	I
1ra1	I
inhibition	O
of	O
IL-1beta	B
mediated	O
IL-8	B
reporter	O
activation	O
,	O
by	O
permitting	O
its	O
release	O
.	O

In	O
HeLa	O
cells	O
,	O
no	O
effect	O
of	O
icIL-1ra1	B
was	O
observed	O
in	O
ATP	O
stimulated	O
and/or	O
P2X7	B
transfected	O
cells	O
,	O
compared	O
to	O
a	O
significant	O
inhibition	O
in	O
sIL-1ra	B
transfected	O
cells	O
.	O

However	O
,	O
in	O
endothelial	O
cells	O
stimulated	O
with	O
ATP	O
,	O
the	O
released	O
fraction	O
was	O
effective	O
in	O
attenuating	O
IL-1beta	B
activation	O
of	O
the	O
IL-8	B
reporter	O
.	O

These	O
results	O
suggest	O
that	O
icIL	B
-	I
1ra1	I
does	O
not	O
act	O
at	O
an	O
intracellular	O
level	O
to	O
alter	O
IL-1	B
mediated	O
signalling	O
,	O
and	O
is	O
effective	O
in	O
inhibiting	O
IL-1	B
responses	O
only	O
when	O
released	O
in	O
an	O
ATP	O
-	O
dependent	O
and	O
cell	O
type	O
specific	O
manner	O
.	O

Aberrant	O
expression	O
of	O
cytoskeleton	O
proteins	O
in	O
hippocampus	O
from	O
patients	O
with	O
mesial	O
temporal	O
lobe	O
epilepsy	O
.	O

Mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
MTLE	O
)	O
,	O
the	O
most	O
common	O
form	O
of	O
epilepsy	O
,	O
is	O
characterised	O
by	O
cytoarchitectural	O
abnormalities	O
including	O
neuronal	O
cell	O
loss	O
and	O
reactive	O
gliosis	O
in	O
hippocampus	O
.	O

Determination	O
of	O
aberrant	O
cytoskeleton	O
protein	O
expression	O
by	O
proteomics	O
techniques	O
may	O
help	O
to	O
understand	O
pathomechanism	O
that	O
is	O
still	O
elusive	O
.	O

We	O
searched	O
for	O
differential	O
expression	O
of	O
hippocampal	O
proteins	O
by	O
an	O
analytical	O
method	O
based	O
on	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
(	O
2-DE	O
)	O
coupled	O
with	O
mass	O
spectrometry	O
unambiguously	O
identifying	O
77	O
proteins	O
analysed	O
in	O
eight	O
control	O
and	O
eight	O
MTLE	O
hippocampi	O
.	O

Proteins	O
were	O
quantified	O
and	O
we	O
observed	O
18	O
proteins	O
that	O
were	O
altered	O
in	O
MTLE	O
.	O

Cytoskeleton	O
proteins	O
tubulin	B
alpha-1	I
chain	O
,	O
beta	B
-	I
tubulin	I
,	O
profilin	B
II	I
,	O
neuronal	B
tropomodulin	I
were	O
significantly	O
reduced	O
and	O
one	O
actin	O
spot	O
was	O
missing	O
,	O
whereas	O
ezrin	B
and	O
vinculin	B
were	O
significantly	O
increased	O
in	O
MTLE	O
.	O

Proteins	O
of	O
several	O
classes	O
as	O
e.g.	O
antioxidant	O
proteins	O
(	O
peroxiredoxins	B
3	I
and	I
6	I
)	O
,	O
chaperons	B
(	O
T	B
-	I
complex	I
protein	I
1-alpha	I
,	O
stress	B
-	I
induced	I
-	I
phosphoprotein	I
1	I
)	O
,	O
signaling	O
protein	O
MAP	B
kinase	I
kinase	I
1	I
,	O
synaptosomal	O
proteins	O
(	O
synaptotagmin	B
I	I
,	O
alpha	B
-	I
synuclein	I
)	O
,	O
NAD	B
-	I
dependent	I
deacetylase	I
sirtuin-2	I
and	O
26S	B
protease	I
regulatory	I
subunit	I
7	I
protein	O
,	O
neuronal	O
-	O
specific	O
septin	B
3	I
were	O
altered	O
in	O
MTLE	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
may	O
represent	O
or	O
lead	O
to	O
cytoskeletal	O
impairment	O
;	O
aberrant	O
antioxidant	O
proteins	O
,	O
chaperons	B
,	O
MAP	B
kinase	I
kinase	I
1	I
and	O
NAD	B
-	I
dependent	I
deacetylase	I
sirtuin-2	I
may	O
have	O
been	O
involved	O
in	O
pathogenetic	O
mechanisms	O
and	O
altered	O
synaptosomal	O
protein	O
expression	O
possibly	O
reflects	O
synaptic	O
impairment	O
in	O
MTLE	O
.	O

arsRBOCT	B
arsenic	B
resistance	I
system	O
encoded	O
by	O
linear	O
plasmid	O
pHZ227	O
in	O
Streptomyces	O
sp.	O
strain	O
FR-008	O
.	O

In	O
the	O
arsenic	B
resistance	I
gene	O
cluster	O
from	O
the	O
large	O
linear	O
plasmid	O
pHZ227	O
,	O
two	O
novel	O
genes	O
,	O
arsO	B
(	O
for	O
a	O
putative	O
flavin	B
-	I
binding	I
monooxygenase	I
)	O
and	O
arsT	B
(	O
for	O
a	O
putative	O
thioredoxin	B
reductase	I
)	O
,	O
were	O
coactivated	O
and	O
cotranscribed	O
with	O
arsR1	B
-	O
arsB	B
and	O
arsC	B
,	O
respectively	O
.	O

Deletion	O
of	O
the	O
ars	B
gene	O
cluster	O
on	O
pHZ227	O
in	O
Streptomyces	O
sp.	O
strain	O
FR-008	O
resulted	O
in	O
sensitivity	O
to	O
arsenic	O
,	O
and	O
heterologous	O
expression	O
of	O
the	O
ars	B
gene	O
cluster	O
in	O
the	O
arsenic	O
-	O
sensitive	O
Streptomyces	O
strains	O
conferred	O
resistance	O
on	O
the	O
new	O
hosts	O
.	O

The	O
pHZ227	O
ArsB	B
protein	O
showed	O
homology	O
to	O
the	O
yeast	O
arsenite	O
transporter	O
Acr3p	B
.	O

The	O
pHZ227	O
ArsC	B
appears	O
to	O
be	O
a	O
bacterial	O
thioredoxin	O
-	O
dependent	O
ArsC	B
-	O
type	O
arsenate	B
reductase	I
with	O
four	O
conserved	O
cysteine	O
thioredoxin	O
-	O
requiring	O
motifs	O
.	O

Effect	O
of	O
chronic	O
tadalafil	O
administration	O
on	O
penile	O
hypoxia	O
induced	O
by	O
cavernous	O
neurotomy	O
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O

Numerous	O
men	O
develop	O
postprostatectomy	O
erectile	O
dysfunction	O
(	O
PPED	O
)	O
,	O
due	O
to	O
surgery	O
-	O
related	O
nervous	O
damage	O
.	O

PPED	O
is	O
often	O
refractory	O
to	O
phosphodiesterase	B
type	I
5	I
(	O
PDE5	B
)	O
inhibitors	O
therapy	O
.	O

AIM	O
:	O

To	O
verify	O
whether	O
chronic	O
tadalafil	O
(	O
CT	O
)	O
preserves	O
bilateral	O
cavernous	O
neurotomy	O
(	O
BCN	O
)	O
-	O
induced	O
penile	O
damage	O
and	O
hypo	O
-	O
oxygenation	O
.	O

METHODS	O
:	O

In	O
a	O
rat	O
model	O
of	O
BCN	O
we	O
evaluated	O
in	O
vitro	O
and	O
ex	O
vivo	O
effect	O
of	O
CT	O
treatment	O
(	O
2	O
mg	O
/	O
kg	O
,	O
daily	O
for	O
3	O
months	O
)	O
.	O

RESULTS	O
:	O

Bilateral	O
cavernous	O
neurotomy	O
induced	O
massive	O
hypoxia	O
and	O
decreased	O
muscle	O
/	O
fiber	O
ratio	O
,	O
completely	O
restored	O
by	O
CT	O
.	O

Hypersensitivity	O
of	O
hypoxic	O
tissues	O
to	O
the	O
relaxant	O
effect	O
of	O
the	O
endothelin	B
type	I
B	I
receptor	I
(	O
ETB	B
)	O
agonist	O
IRL-1620	O
was	O
observed	O
,	O
along	O
with	O
ETB	B
mRNA	O
and	O
protein	O
overexpression	O
.	O

CT	O
restored	O
sensitivity	O
to	O
IRL-1620	O
,	O
and	O
normalized	O
ETB	B
expression	O
.	O

Hypoxic	O
penis	O
showed	O
increased	O
sensitivity	O
to	O
the	O
relaxant	O
effect	O
of	O
the	O
nitric	O
oxide	O
donor	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
,	O
while	O
acute	O
tadalafil	O
(	O
100	O
nM	O
)	O
did	O
not	O
amplify	O
the	O
SNP	O
effect	O
.	O

Accordingly	O
,	O
PDE5	B
mRNA	O
and	O
protein	O
were	O
reduced	O
in	O
BCN	O
penile	O
tissues	O
.	O

By	O
restoring	O
PDE5	B
,	O
CT	O
decreased	O
SNP	O
-	O
induced	O
relaxation	O
and	O
rescued	O
sensitivity	O
to	O
acute	O
tadalafil	O
.	O

However	O
,	O
in	O
hypoxic	O
penis	O
,	O
CT	O
normalizes	O
neither	O
acetylcholine	O
hyporesponsiveness	O
nor	O
neuronal	B
nitric	I
oxide	I
synthase	I
-	O
endothelial	B
nitric	I
oxide	I
synthase	I
expression	O
.	O

CONCLUSION	O
:	O

Chronic	O
tadalafil	O
restores	O
some	O
of	O
the	O
investigated	O
BCN	O
-	O
induced	O
alterations	O
,	O
including	O
PDE5	B
and	O
tadalafil	O
efficacy	O
.	O

Apo2l	B
/	O
Tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
prevents	O
breast	O
cancer	O
-	O
induced	O
bone	O
destruction	O
in	O
a	O
mouse	O
model	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
common	O
carcinoma	O
that	O
metastasizes	O
to	O
bone	O
.	O

To	O
examine	O
the	O
efficacy	O
of	O
recombinant	O
soluble	O
Apo2	B
ligand	I
(	O
Apo2L	B
)	O
/	O
tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
(	O
TRAIL	B
)	O
against	O
breast	O
cancer	O
growth	O
in	O
bone	O
,	O
we	O
established	O
a	O
mouse	O
model	O
in	O
which	O
MDA	O
-	O
MB-231	O
human	O
breast	O
cancer	O
cells	O
were	O
transplanted	O
directly	O
into	O
the	O
marrow	O
cavity	O
of	O
the	O
tibiae	O
of	O
athymic	O
nude	O
mice	O
producing	O
osteolytic	O
lesions	O
in	O
the	O
area	O
of	O
injection	O
.	O

All	O
vehicle	O
-	O
treated	O
control	O
animals	O
developed	O
large	O
lesions	O
that	O
established	O
in	O
the	O
marrow	O
cavity	O
,	O
eroded	O
the	O
cortical	O
bone	O
,	O
and	O
invaded	O
the	O
surrounding	O
soft	O
tissue	O
,	O
as	O
assessed	O
by	O
radiography	O
,	O
micro	O
-	O
computed	O
tomography	O
,	O
and	O
histology	O
.	O

In	O
contrast	O
,	O
animals	O
treated	O
with	O
recombinant	O
soluble	O
Apo2L	B
/	O
TRAIL	B
showed	O
significant	O
conservation	O
of	O
the	O
tibiae	O
,	O
with	O
85	O
%	O
reduction	O
in	O
osteolysis	O
,	O
90	O
%	O
reduction	O
in	O
tumor	O
burden	O
,	O
and	O
no	O
detectable	O
soft	O
tissue	O
invasion	O
.	O

Tumor	O
cells	O
explanted	O
from	O
Apo2L	B
/	O
TRAIL	B
-	O
treated	O
animals	O
were	O
significantly	O
more	O
resistant	O
to	O
the	O
effects	O
of	O
Apo2L	B
/	O
TRAIL	B
when	O
compared	O
with	O
the	O
cells	O
explanted	O
from	O
the	O
vehicle	O
-	O
treated	O
control	O
animals	O
,	O
suggesting	O
that	O
prolonged	O
treatment	O
with	O
Apo2	B
/	O
TRAIL	B
in	O
vivo	O
selects	O
for	O
a	O
resistant	O
phenotype	O
.	O

However	O
,	O
such	O
resistance	O
was	O
readily	O
reversed	O
when	O
Apo2L	B
/	O
TRAIL	B
was	O
used	O
in	O
combination	O
with	O
clinically	O
relevant	O
chemotherapeutic	O
drugs	O
,	O
including	O
taxol	O
,	O
etoposide	O
,	O
doxorubicin	O
,	O
cisplatin	O
,	O
or	O
the	O
histone	B
deacetylase	I
inhibitor	O
suberoylanilide	O
hydroxamic	O
acid	O
.	O

These	O
studies	O
show	O
for	O
the	O
first	O
time	O
that	O
Apo2L	B
/	O
TRAIL	B
can	O
prevent	O
breast	O
cancer	O
-	O
induced	O
bone	O
destruction	O
and	O
highlight	O
the	O
potential	O
of	O
this	O
ligand	O
for	O
the	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
bone	O
.	O

Role	O
of	O
Shigella	O
flexneri	O
2a	O
34	B
kDa	I
outer	I
membrane	I
protein	I
in	O
induction	O
of	O
protective	O
immune	O
response	O
.	O

Emergence	O
of	O
Shigella	O
vaccine	O
is	O
in	O
great	O
need	O
in	O
developing	O
countries	O
.	O

In	O
this	O
paper	O
we	O
have	O
shown	O
that	O
34	O
kDa	O
Shigella	O
flexneri	O
2a	O
outer	O
membrane	O
protein	O
has	O
a	O
role	O
in	O
eliciting	O
immune	O
responses	O
.	O

When	O
injected	O
parentarally	O
this	O
protein	O
gives	O
significant	O
protection	O
against	O
challenge	O
with	O
virulent	O
Shigella	O
flexneri	O
2a	O
.	O

Macrophages	O
activated	O
with	O
the	O
34	O
kDa	O
protein	O
resulted	O
in	O
the	O
dose	O
dependent	O
production	O
of	O
nitric	O
oxide	O
,	O
the	O
highly	O
reactive	O
free	O
radical	O
responsible	O
for	O
killing	O
of	O
invading	O
bacterial	O
pathogen	O
.	O

Also	O
,	O
treatment	O
of	O
murine	O
peritoneal	O
macrophages	O
with	O
the	O
34	O
kDa	O
protein	O
showed	O
dose	O
dependent	O
increase	O
in	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-12	B
.	O

However	O
,	O
there	O
was	O
no	O
dose	O
dependent	O
increase	O
in	O
interleukin-10	B
production	O
.	O

These	O
data	O
indicated	O
that	O
the	O
34	B
kDa	I
outer	I
membrane	I
protein	I
has	O
the	O
ability	O
to	O
modulate	O
the	O
protective	O
immune	O
response	O
against	O
the	O
invading	O
bacterial	O
pathogen	O
,	O
mainly	O
through	O
TH1	O
mediated	O
pathway	O
.	O

So	O
,	O
the	O
34	B
kDa	I
outer	I
mebrane	I
protein	I
can	O
be	O
one	O
of	O
the	O
major	O
components	O
for	O
developing	O
subunit	O
vaccine	O
against	O
shigellosis	O
.	O

A	O
role	O
for	O
KIR	B
gene	O
variants	O
other	O
than	O
KIR2DS1	B
in	O
conferring	O
susceptibility	O
to	O
psoriasis	O
.	O

Recently	O
we	O
described	O
an	O
association	O
between	O
psoriasis	O
and	O
KIR2DS1	B
,	O
a	O
gene	O
for	O
a	O
stimulatory	O
natural	O
killer	O
cell	O
receptor	O
,	O
in	O
a	O
Polish	O
population	O
.	O

The	O
association	O
was	O
independently	O
reported	O
among	O
Japanese	O
and	O
confirmed	O
in	O
a	O
U.S.	O
population	O
.	O

Prompted	O
by	O
these	O
findings	O
,	O
we	O
reanalyzed	O
data	O
by	O
a	O
multivariate	O
approach	O
in	O
search	O
of	O
possible	O
effects	O
of	O
KIR	B
genes	O
other	O
than	O
KIR2DS1	B
(	O
non	O
-	O
KIR2DS1	B
)	O
.	O

The	O
methodology	O
was	O
based	O
on	O
a	O
stratified	O
analysis	O
and	O
multiple	O
logistic	O
regression	O
.	O

We	O
found	O
that	O
the	O
non	O
-	O
KIR2DS1	B
genes	O
had	O
joint	O
effects	O
comparable	O
to	O
or	O
stronger	O
than	O
the	O
effects	O
of	O
KIR2DS1	B
in	O
both	O
the	O
fraction	O
of	O
explained	O
variance	O
(	O
0.174	O
vs	O
0.204	O
,	O
respectively	O
,	O
for	O
KIR2DS1	B
and	O
non	O
-	O
KIR2DS1	B
)	O
and	O
the	O
statistical	O
significance	O
(	O
p	O
=	O
0.000008	O
vs	O
p	O
=	O
0.000001	O
,	O
respectively	O
)	O
.	O

When	O
individual	O
genes	O
were	O
considered	O
,	O
a	O
decrease	O
in	O
KIR2DS5	B
among	O
patients	O
vs	O
controls	O
(	O
OR	O
=	O
0.2	O
,	O
pcor	O
=	O
0.0005	O
)	O
and	O
a	O
decrease	O
in	O
KIR2DS3	B
restricted	O
to	O
KIR2DS1	B
-	O
positive	O
individuals	O
(	O
OR	O
=	O
0.2	O
,	O
pcor	O
=	O
0.005	O
)	O
were	O
evident	O
.	O

We	O
also	O
performed	O
a	O
multivariate	O
analysis	O
of	O
the	O
HLA	B
-	I
Cw	I
genotypes	O
but	O
failed	O
to	O
demonstrate	O
any	O
effects	O
in	O
addition	O
to	O
the	O
known	O
association	O
with	O
HLA	B
-	I
Cw*06	I
.	O

We	O
conclude	O
that	O
the	O
effect	O
of	O
the	O
KIR	B
genes	O
on	O
psoriasis	O
susceptibility	O
is	O
complex	O
,	O
extending	O
beyond	O
the	O
association	O
with	O
KIR2DS1	B
and	O
involving	O
protective	O
effects	O
and	O
interactions	O
.	O

Regulation	O
of	O
IL-8	B
by	O
Irsogladine	O
maleate	O
is	O
involved	O
in	O
abolishment	O
of	O
Actinobacillus	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
of	O
gap	O
-	O
junctional	O
intercellular	O
communication	O
.	O

Our	O
previous	O
report	O
has	O
shown	O
that	O
Irsogladine	O
maleate	O
(	O
IM	O
)	O
counters	O
and	O
obviates	O
the	O
reduction	O
in	O
gap	O
junction	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
and	O
the	O
increase	O
in	O
IL-8	B
levels	O
,	O
respectively	O
,	O
induced	O
by	O
outer	O
membrane	O
protein	O
29	O
from	O
Actinobacillus	O
actinomycetemcomitans	O
(	O
A.	O
actinomycetemcomitans	O
)	O
in	O
cultured	O
human	O
gingival	O
epithelial	O
cells	O
(	O
HGEC	O
)	O
.	O

In	O
addition	O
,	O
IM	O
suppresses	O
the	O
increase	O
in	O
the	O
secretion	O
of	O
IL-8	B
caused	O
by	O
whole	O
live	O
A.	O
actinomycetemcomitans	O
.	O

These	O
findings	O
implicate	O
the	O
modulation	O
of	O
IL-8	B
levels	O
by	O
IM	O
in	O
abolishment	O
of	O
the	O
reduction	O
of	O
GJIC	O
in	O
HGEC	O
.	O

Tight	O
junctions	O
are	O
also	O
responsible	O
for	O
cell	O
-	O
cell	O
communication	O
.	O

Zonula	B
occludens	I
protein-1	I
(	O
ZO-1	B
)	O
is	O
a	O
major	O
tight	O
junction	O
protein	O
.	O

To	O
investigate	O
the	O
regulatory	O
mechanism	O
of	O
intercellular	O
communication	O
mediated	O
by	O
IM	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
involvement	O
of	O
IL-8	B
in	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
change	O
in	O
GJIC	O
and	O
ZO-1	B
expression	O
in	O
HGEC	O
.	O

IM	O
countered	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
levels	O
of	O
Connexin	B
(	I
CX	I
)	I
43	I
,	O
suggesting	O
that	O
it	O
could	O
abolish	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
GJIC	O
in	O
HGEC	O
.	O

CXCR-1	B
is	O
a	O
receptor	B
of	I
IL-8	I
.	O

The	O
simultaneous	O
addition	O
of	O
A.	O
actinomycetemcomitans	O
and	O
anti	O
-	O
CXCR-1	B
antibody	O
also	O
abrogated	O
the	O
repression	O
of	O
GJIC	O
and	O
CX43	B
expression	O
by	O
A.	O
actinomycetemcomitans	O
in	O
HGEC	O
,	O
although	O
the	O
anti	O
-	O
CXCR-1	B
antibody	O
was	O
less	O
effective	O
than	O
IM	O
.	O

IM	O
inhibited	O
the	O
IL-8	B
-	O
induced	O
reduction	O
in	O
CX43	B
levels	O
and	O
GJIC	O
in	O
HGEC	O
.	O

IM	O
countered	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
the	O
expression	O
of	O
ZO-1	B
,	O
although	O
anti	O
-	O
CXCR-1	B
antibody	O
did	O
not	O
influence	O
the	O
decrease	O
in	O
ZO-1	B
mRNA	O
levels	O
caused	O
by	O
A.	O
actinomycetemcomitans	O
.	O

Furthermore	O
,	O
IL-8	B
had	O
little	O
effect	O
on	O
the	O
mRNA	O
levels	O
of	O
ZO-1	B
.	O

These	O
findings	O
suggest	O
that	O
IL-8	B
mediates	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
of	O
GJIC	O
and	O
CX43	B
expression	O
in	O
HGEC	O
.	O

The	O
regulation	O
of	O
IL-8	B
levels	O
by	O
IM	O
in	O
HGEC	O
is	O
partially	O
involved	O
in	O
abrogation	O
of	O
the	O
reduction	O
of	O
GJIC	O
and	O
CX43	B
expression	O
by	O
A.	O
actinomycetemcomitans	O
.	O

Furthermore	O
,	O
the	O
regulatory	O
effect	O
of	O
IM	O
on	O
the	O
expression	O
of	O
CX43	B
and	O
ZO-1	B
is	O
different	O
.	O

4	B
-	I
1BB	I
-	O
mediated	O
amelioration	O
of	O
experimental	O
autoimmune	O
uveoretinitis	O
is	O
caused	O
by	O
indoleamine	B
2,3-dioxygenase	I
-	O
dependent	O
mechanisms	O
.	O

Interphotoreceptor	B
retinoid	I
binding	I
protein	I
(	O
IRBP	B
)	O
-	O
induced	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
is	O
a	O
CD4	B
+	O
T	O
cell	O
-	O
mediated	O
autoimmune	O
disease	O
.	O

Development	O
of	O
EAU	O
is	O
inhibited	O
by	O
treatment	O
with	O
an	O
agonistic	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
.	O

Even	O
established	O
EAU	O
was	O
alleviated	O
by	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
.	O

However	O
,	O
inhibition	O
of	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BB	I
ligand	I
(	O
4	B
-	I
1BBL	I
)	O
interaction	O
does	O
not	O
suppress	O
the	O
development	O
of	O
EAU	O
.	O

It	O
appears	O
that	O
cross	O
-	O
linking	O
of	O
4	B
-	I
1BB	I
evokes	O
an	O
active	O
antigen	O
-	O
specific	O
suppression	O
mechanism	O
rather	O
than	O
merely	O
blocking	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BBL	I
interaction	O
.	O

We	O
found	O
that	O
administration	O
of	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
induced	O
massive	O
clonal	O
expansion	O
of	O
CD11c	B
+	O
CD8	B
+	O
T	O
cells	O
that	O
produced	O
IFN	B
-	I
gamma	I
,	O
resulting	O
in	O
accumulation	O
of	O
a	O
high	O
level	O
of	O
indoleamine	B
2,3-dioxygenase	I
(	O
IDO	B
)	O
in	O
CD11c	B
+	O
dendritic	O
cells	O
.	O

4	B
-	I
1BB	I
-	O
mediated	O
suppression	O
of	O
EAU	O
was	O
reversed	O
by	O
the	O
pharmacological	O
IDO	B
inhibitor	O
,	O
1-methyl	O
-	O
tryptophan	O
(	O
1-MT	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
suppression	O
of	O
EAU	O
results	O
from	O
antigen	O
-	O
driven	O
,	O
4	B
-	I
1BB	I
-	O
mediated	O
expansion	O
of	O
novel	O
CD11c	B
+	O
CD8	B
+	O
T	O
cells	O
that	O
suppress	O
antigen	O
-	O
specific	O
CD4	B
+	O
T	O
cells	O
via	O
an	O
IDO	B
-	O
dependent	O
mechanism	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genotype	O
and	O
HLA	B
ligand	O
combinations	O
in	O
ulcerative	O
colitis	O
susceptibility	O
.	O

Killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
are	O
expressed	O
on	O
natural	O
killer	O
cells	O
and	O
some	O
T	O
-	O
cell	O
subsets	O
and	O
produce	O
either	O
activation	O
or	O
inhibitory	O
signals	O
upon	O
binding	O
with	O
the	O
appropriate	O
human	B
leucocyte	I
antigen	I
(	O
HLA	B
)	O
ligand	O
on	O
target	O
cells	O
.	O

Recent	O
genetic	O
association	O
studies	O
have	O
implicated	O
KIR	B
genotype	O
in	O
the	O
development	O
of	O
several	O
inflammatory	O
conditions	O
.	O

Ulcerative	O
colitis	O
(	O
UC	O
)	O
is	O
an	O
inflammatory	O
disorder	O
of	O
the	O
colonic	O
mucosa	O
that	O
results	O
from	O
an	O
inappropriate	O
activation	O
of	O
the	O
immune	O
system	O
driven	O
by	O
host	O
bacterial	O
flora	O
.	O

We	O
developed	O
a	O
polymerase	O
chain	O
reaction	O
-	O
sequence	O
specific	O
primer	O
(	O
SSP	O
)	O
-	O
based	O
assay	O
to	O
genotype	O
194	O
UC	O
patients	O
and	O
216	O
control	O
individuals	O
for	O
14	O
KIR	B
genes	O
,	O
the	O
HLA	B
-	I
Cw	I
ligand	O
epitopes	O
of	O
the	O
KIR2D	B
receptors	O
and	O
a	O
polymorphism	O
of	O
the	O
lectin	B
-	O
like	O
-	O
activating	O
receptor	O
NKG2D	B
.	O

Initial	O
analysis	O
found	O
the	O
phenotype	O
frequency	O
of	O
KIR2DL2	B
and	O
-	O
2DS2	B
to	O
be	O
significantly	O
increased	O
in	O
the	O
UC	O
cohort	O
(	O
P	O
=	O
0.030	O
and	O
0.038	O
,	O
respectively	O
)	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
a	O
protective	O
effect	O
conferred	O
by	O
KIR2DL3	B
in	O
the	O
presence	O
of	O
its	O
ligand	O
HLA	B
-	I
Cw	I
group	O
1	O
(	O
P	O
=	O
0.019	O
)	O
.	O

These	O
results	O
suggest	O
that	O
KIR	B
genotype	O
and	O
HLA	B
ligand	O
interaction	O
may	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
of	O
UC	O
.	O

Blood	O
leukocyte	O
mRNA	O
expression	O
for	O
IL-10	B
,	O
IL-1Ra	B
,	O
and	O
IL-8	B
,	O
but	O
not	O
IL-6	B
,	O
increases	O
after	O
exercise	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
project	O
was	O
to	O
study	O
exercise	O
-	O
induced	O
leukocyte	O
cytokine	B
mRNA	O
expression	O
.	O

Changes	O
in	O
plasma	O
cytokine	B
levels	O
and	O
blood	O
leukocyte	O
mRNA	O
expression	O
for	O
interleukin-6	B
(	O
IL-6	B
)	O
,	O
IL-8	B
,	O
IL	B
-	I
10	I
,	O
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
were	O
measured	O
in	O
12	O
athletes	O
following	O
2	O
h	O
of	O
intensive	O
cycling	O
(	O
approximately	O
64	O
%	O
Watts	O
(	O
max	O
)	O
)	O
while	O
ingesting	O
a	O
carbohydrate	O
or	O
placebo	O
beverage	O
(	O
randomized	O
and	O
double	O
blinded	O
)	O
.	O

Blood	O
samples	O
were	O
collected	O
30	O
min	O
preexercise	O
and	O
immediately	O
and	O
1	O
h	O
postexercise	O
.	O

Carbohydate	O
compared	O
with	O
placebo	O
ingestion	O
attenuated	O
exercise	O
-	O
induced	O
changes	O
in	O
plasma	O
cortisol	O
(	O
8.8	O
%	O
vs.	O
62	O
%	O
,	O
respectively	O
)	O
,	O
epinephrine	O
(	O
-	O
9.2	O
%	O
vs.	O
138	O
%	O
)	O
,	O
IL-6	B
(	O
10	O
-	O
fold	O
vs.	O
40	O
-	O
fold	O
)	O
,	O
IL-10	B
(	O
8.9	O
-	O
fold	O
vs.	O
26	O
-	O
fold	O
,	O
and	O
IL-1Ra	B
(	O
2.1	O
-	O
fold	O
vs.	O
5.6	O
-	O
fold	O
)	O
.	O
Significant	O
time	O
effects	O
were	O
measured	O
for	O
blood	O
leukocyte	O
IL-8	B
(	O
2.4	O
-	O
fold	O
increase	O
1	O
h	O
postexercise	O
)	O
,	O
IL-10	B
(	O
2.7	O
-	O
fold	O
increase	O
)	O
,	O
IL-1Ra	B
(	O
2.2	O
-	O
fold	O
increase	O
)	O
,	O
and	O
IL-6	B
(	O
0.8	O
-	O
fold	O
decrease	O
)	O
mRNA	O
content	O
,	O
with	O
no	O
significant	O
differences	O
between	O
Cho	O
and	O
Pla	O
test	O
conditions	O
.	O

In	O
summary	O
,	O
gene	O
expression	O
for	O
IL-8	B
,	O
IL-10	B
,	O
and	O
IL-1Ra	B
,	O
but	O
not	O
IL-6	B
,	O
is	O
increased	O
in	O
blood	O
leukocytes	O
taken	O
from	O
athletes	O
following	O
2	O
h	O
of	O
intensive	O
cycling	O
and	O
is	O
not	O
influenced	O
by	O
carbohydrate	O
compared	O
with	O
placebo	O
ingestion	O
.	O

mRNA	O
expression	O
was	O
high	O
enough	O
to	O
indicate	O
a	O
substantial	O
contribution	O
of	O
blood	O
leukocytes	O
to	O
plasma	O
levels	O
of	O
IL-8	B
,	O
IL-10	B
,	O
and	O
IL-1Ra	B
during	O
prolonged	O
exercise	O
.	O

A	O
homologue	O
of	O
the	O
3-oxoacyl	B
-	I
(	I
acyl	I
carrier	I
protein	I
)	I
synthase	I
III	I
gene	O
located	O
in	O
the	O
glycosylation	O
island	O
of	O
Pseudomonas	O
syringae	O
pv	O
.	O
tabaci	O
regulates	O
virulence	O
factors	O
via	O
N	O
-	O
acyl	O
homoserine	O
lactone	O
and	O
fatty	O
acid	O
synthesis	O
.	O

Pseudomonas	O
syringae	O
pv	O
.	O
tabaci	O
6605	O
possesses	O
a	O
genetic	O
region	O
involved	O
in	O
flagellin	B
glycosylation	O
.	O

This	O
region	O
is	O
composed	O
of	O
three	O
open	O
reading	O
frames	O
:	O
orf1	O
,	O
orf2	O
,	O
and	O
orf3	O
.	O

Our	O
previous	O
study	O
revealed	O
that	O
orf1	O
and	O
orf2	O
encode	O
glycosyltransferases	B
;	O
on	O
the	O
other	O
hand	O
,	O
orf3	O
has	O
no	O
role	O
in	O
posttranslational	O
modification	O
of	O
flagellin	B
.	O

Although	O
the	O
function	O
of	O
Orf3	O
remained	O
unclear	O
,	O
an	O
orf3	O
deletion	O
mutant	O
(	O
Deltaorf3	O
mutant	O
)	O
had	O
reduced	O
virulence	O
on	O
tobacco	O
plants	O
.	O

Orf3	O
shows	O
significant	O
homology	O
to	O
a	O
3	B
-	I
oxoacyl	I
-	I
(	I
acyl	I
carrier	I
protein	I
)	I
synthase	I
III	I
in	O
the	O
fatty	O
acid	O
elongation	O
cycle	O
.	O

The	O
Deltaorf3	O
mutant	O
had	O
a	O
significantly	O
reduced	O
ability	O
to	O
form	O
acyl	O
homoserine	O
lactones	O
(	O
AHLs	O
)	O
,	O
which	O
are	O
quorum	O
-	O
sensing	O
molecules	O
,	O
suggesting	O
that	O
Orf3	O
is	O
required	O
for	O
AHL	O
synthesis	O
.	O

In	O
comparison	O
with	O
the	O
wild	O
-	O
type	O
strain	O
,	O
swarming	O
motility	O
,	O
biosurfactant	O
production	O
,	O
and	O
tolerance	O
to	O
H2O2	O
and	O
antibiotics	O
were	O
enhanced	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

A	O
scanning	O
electron	O
micrograph	O
of	O
inoculated	O
bacteria	O
on	O
the	O
tobacco	O
leaf	O
surface	O
revealed	O
that	O
there	O
is	O
little	O
extracellular	O
polymeric	O
substance	O
matrix	O
surrounding	O
the	O
cells	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

The	O
phenotypes	O
of	O
the	O
Deltaorf3	O
mutant	O
and	O
an	O
AHL	O
synthesis	O
(	O
DeltapsyI	O
)	O
mutant	O
were	O
similar	O
,	O
although	O
the	O
mutant	O
-	O
specific	O
characteristics	O
were	O
more	O
extreme	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

The	O
swarming	O
motility	O
of	O
the	O
Deltaorf3	O
mutant	O
was	O
greater	O
than	O
that	O
of	O
the	O
DeltapsyI	O
mutant	O
.	O

This	O
was	O
attributed	O
to	O
the	O
synergistic	O
effects	O
of	O
the	O
overproduction	O
of	O
biosurfactants	O
and/or	O
alternative	O
fatty	O
acid	O
metabolism	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

Furthermore	O
,	O
the	O
amounts	O
of	O
iron	O
and	O
biosurfactant	O
seem	O
to	O
be	O
involved	O
in	O
biofilm	O
development	O
under	O
quorum	O
-	O
sensing	O
regulation	O
in	O
P.	O
syringae	O
pv	O
.	O
tabaci	O
6605	O
.	O

Influence	O
of	O
interleukin	B
IL-2	B
and	O
IL-12	B
+	O
IL-18	B
on	O
surface	O
expression	O
of	O
immunoglobulin	B
-	I
like	I
receptors	I
KIR2DL1	B
,	O
KIR2DL2	B
,	O
and	O
KIR3DL2	B
in	O
natural	O
killer	O
cells	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
express	O
killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIRs	B
)	O
that	O
recognize	O
polymorphic	O
class	B
I	I
MHC	I
molecules	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyze	O
the	O
modulatory	O
effect	O
of	O
IL-2	B
alone	O
or	O
a	O
combination	O
of	O
IL-12	B
with	O
IL-18	B
on	O
surface	O
expression	O
of	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
KIR2DL1	B
,	O
KIR2DL2	B
,	O
and	O
KIR3DL2	B
in	O
NK	O
cells	O
.	O

Thus	O
,	O
it	O
was	O
found	O
that	O
IL-2	B
causes	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
with	O
given	O
studied	O
receptors	O
.	O

Stimulation	O
by	O
a	O
mixture	O
of	O
IL-12	B
and	O
IL-18	B
caused	O
significant	O
increase	O
in	O
the	O
fraction	O
of	O
cells	O
with	O
the	O
KIR2DL1	B
and	O
KIR2DL2	B
,	O
however	O
no	O
significant	O
change	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
KIR3DL2	B
receptor	O
on	O
their	O
surface	O
was	O
observed	O
.	O

The	O
results	O
of	O
the	O
study	O
show	O
the	O
presence	O
of	O
KIRs	B
on	O
both	O
resting	O
and	O
activated	O
NK	O
cells	O
,	O
this	O
may	O
suggest	O
that	O
KIRs	B
have	O
also	O
an	O
important	O
role	O
in	O
the	O
regulatory	O
processes	O
after	O
activation	O
of	O
this	O
subpopulation	O
of	O
cells	O
.	O

Cutting	O
edge	O
:	O
resistance	O
to	O
HIV-1	O
infection	O
among	O
African	O
female	O
sex	O
workers	O
is	O
associated	O
with	O
inhibitory	O
KIR	B
in	O
the	O
absence	O
of	O
their	O
HLA	B
ligands	O
.	O

NK	O
cells	O
are	O
regulated	O
in	O
part	O
by	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
that	O
interact	O
with	O
HLA	B
molecules	O
on	O
potential	O
target	O
cells	O
.	O

KIR	B
and	O
HLA	B
loci	O
are	O
highly	O
polymorphic	O
and	O
certain	O
KIR	B
/	O
HLA	B
combinations	O
were	O
found	O
to	O
protect	O
against	O
HIV	O
disease	O
progression	O
.	O

We	O
show	O
in	O
this	O
study	O
that	O
KIR	B
/	O
HLA	B
interactions	O
also	O
influence	O
resistance	O
to	O
HIV	O
transmission	O
.	O

HIV	O
-	O
exposed	O
but	O
seronegative	O
female	O
sex	O
workers	O
in	O
Abidjan	O
,	O
CÃ?Â´te	O
d	O
'	O
Ivoire	O
,	O
frequently	O
possessed	O
inhibitory	O
KIR	B
genes	O
in	O
the	O
absence	O
of	O
their	O
cognate	O
HLA	B
genes	O
:	O
KIR2DL2	B
/	O
KIR2DL3	B
heterozygosity	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
C1	I
and	O
KIR3DL1	B
homozygosity	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
Bw4	I
.	O

HIV	O
-	O
seropositive	O
female	O
sex	O
workers	O
were	O
characterized	O
by	O
corresponding	O
inhibitory	O
KIR	B
/	O
HLA	B
pairings	O
:	O
KIR2DL3	B
homozygosity	O
together	O
with	O
HLA	B
-	I
C1	I
and	O
a	O
trend	O
toward	O
KIR3DL1	B
/	O
HLA	B
-	I
Bw4	I
homozygosity	O
.	O

Absence	O
of	O
ligands	O
for	O
inhibitory	O
KIR	B
could	O
lower	O
the	O
threshold	O
for	O
NK	O
cell	O
activation	O
.	O

In	O
addition	O
,	O
exposed	O
seronegatives	O
more	O
frequently	O
possessed	O
AB	O
KIR	B
genotypes	O
,	O
which	O
contain	O
more	O
activating	O
KIR	B
.	O

The	O
data	O
support	O
an	O
important	O
role	O
for	O
NK	O
cells	O
and	O
KIR	B
/	O
HLA	B
interactions	O
in	O
antiviral	O
immunity	O
.	O

Predominance	O
of	O
the	O
group	O
A	O
killer	O
Ig	O
-	O
like	O
receptor	O
haplotypes	O
in	O
Korean	O
patients	O
with	O
T1D	O
.	O

Type	O
1	O
diabetes	O
(	O
T1D	O
)	O
is	O
a	O
T	O
cell	O
-	O
mediated	O
autoimmune	O
disease	O
in	O
which	O
pancreatic	O
beta	O
cells	O
are	O
selectively	O
destroyed	O
.	O

Although	O
autoimmune	O
diseases	O
are	O
driven	O
by	O
inappropriate	O
adaptive	O
immunity	O
,	O
innate	O
immunity	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
T1D	O
.	O

To	O
study	O
the	O
potential	O
involvement	O
of	O
innate	O
immunity	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
,	O
we	O
investigated	O
associations	O
of	O
the	O
genes	O
for	O
14	O
different	O
killer	O
Ig	O
-	O
like	O
receptors	O
(	O
KIRs	B
)	O
,	O
the	O
well	O
-	O
characterized	O
receptors	O
in	O
natural	O
killer	O
cells	O
,	O
with	O
Korean	O
T1D	O
patients	O
.	O

Genetic	O
association	O
analyses	O
revealed	O
that	O
some	O
of	O
the	O
KIR	B
genes	O
were	O
associated	O
with	O
T1D	O
.	O

KIR2DL5	B
and	O
2DS2	B
genes	O
were	O
present	O
at	O
significantly	O
low	O
frequency	O
in	O
Korean	O
T1D	O
patients	O
(	O
P	O
<	O
10	O
(	O
-4	O
)	O
)	O
.	O

We	O
did	O
not	O
detect	O
any	O
influence	O
of	O
ligand	O
distribution	O
on	O
KIR	B
association	O
.	O

With	O
the	O
haplotype	O
assignments	O
,	O
53	O
%	O
of	O
the	O
KIR	B
haplotypes	O
in	O
the	O
control	O
are	O
of	O
type	O
A	O
.	O

Compared	O
with	O
the	O
control	O
(	O
P	O
<	O
10	O
(	O
-3	O
)	O
)	O
and	O
autoantibody	O
-	O
negative	O
patients	O
(	O
P	O
<	O
10	O
(	O
-2	O
)	O
)	O
,	O
the	O
group	O
A	O
haplotype	O
predominates	O
in	O
Korean	O
patients	O
with	O
T1D	O
.	O

The	O
KIR	B
gene	O
is	O
associated	O
with	O
T1D	O
and	O
distribution	O
differences	O
between	O
T1D	O
and	O
controls	O
were	O
not	O
influenced	O
by	O
the	O
HLA	B
genes	I
(	I
DR	I
-	I
DQ	I
-	I
A	I
-	I
C	I
)	I
.	O

T1D	O
,	O
at	O
least	O
in	O
Koreans	O
,	O
is	O
associated	O
with	O
KIR	B
genes	O
,	O
especially	O
in	O
the	O
group	O
A	O
KIR	B
haplotypes	O
.	O

There	O
is	O
a	O
close	O
relationship	O
between	O
innate	O
and	O
adaptive	O
immunity	O
.	O

Proteomics	O
-	O
based	O
identification	O
of	O
biomarkers	O
for	O
predicting	O
sensitivity	O
to	O
a	O
PI3	B
-	I
kinase	I
inhibitor	O
in	O
cancer	O
.	O

To	O
identify	O
biomarkers	O
for	O
predicting	O
sensitivity	O
to	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
inhibitors	O
,	O
we	O
have	O
developed	O
a	O
proteomics	O
-	O
based	O
approach	O
.	O

Using	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
-	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
SELDI	O
-	O
TOF	O
MS	O
)	O
,	O
we	O
measured	O
the	O
expression	O
of	O
393	O
proteins	O
in	O
39	O
human	O
cancer	O
cell	O
lines	O
(	O
JFCR	O
-	O
39	O
)	O
,	O
and	O
combined	O
it	O
with	O
our	O
previously	O
established	O
chemosensitivity	O
database	O
to	O
select	O
for	O
proteins	O
whose	O
expressions	O
show	O
significant	O
correlations	O
to	O
drug	O
sensitivities	O
.	O

This	O
integrated	O
approach	O
allowed	O
us	O
to	O
identify	O
peaks	O
from	O
two	O
proteins	O
,	O
11.6	O
and	O
11.8	O
kDa	O
,	O
that	O
showed	O
significant	O
correlations	O
with	O
the	O
sensitivity	O
to	O
a	O
PI3	B
K	I
inhibitor	O
,	O
LY294002	O
.	O

We	O
found	O
that	O
the	O
11.8	O
kDa	O
protein	O
was	O
a	O
phosphorylated	O
form	O
of	O
the	O
11.6	O
kDa	O
protein	O
.	O

While	O
the	O
11.8	O
kDa	O
protein	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
sensitivity	O
to	O
LY294002	O
,	O
the	O
11.6	O
kDa	O
protein	O
showed	O
a	O
negative	O
correlation	O
with	O
that	O
of	O
the	O
LY294002	O
.	O

The	O
11.6	O
kDa	O
protein	O
was	O
purified	O
chromatographically	O
,	O
and	O
was	O
identified	O
by	O
SELDI	O
-	O
TOF	O
MS	O
as	O
the	O
ribosomal	B
P2	I
protein	O
,	O
which	O
possesses	O
two	O
prospective	O
phosphorylation	O
sites	O
.	O

These	O
results	O
suggested	O
that	O
the	O
phosphorylation	O
status	O
of	O
the	O
ribosomal	B
P2	I
was	O
responsible	O
for	O
determining	O
the	O
sensitivity	O
to	O
LY294002	O
,	O
and	O
that	O
the	O
ribosomal	B
P2	I
could	O
be	O
a	O
potential	O
biomarker	O
for	O
predicting	O
chemosensitivity	O
.	O

Discovery	O
and	O
characterization	O
of	O
a	O
Ca2	B
+	I
-independent	I
phosphatidylethanolamine	I
N	I
-	I
acyltransferase	I
generating	O
the	O
anandamide	O
precursor	O
and	O
its	O
congeners	O
.	O

N	O
-	O
Acylphosphatidylethanolamines	O
(	O
NAPEs	O
)	O
are	O
precursors	O
of	O
bioactive	O
N	O
-	O
acylethanolamines	O
,	O
including	O
the	O
endocannabinoid	O
anandamide	O
.	O

In	O
animal	O
tissues	O
,	O
NAPE	O
is	O
formed	O
by	O
transfer	O
of	O
a	O
fatty	O
acyl	O
chain	O
at	O
the	O
sn	O
-	O
1	O
position	O
of	O
glycerophospholipids	O
to	O
the	O
amino	O
group	O
of	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
,	O
and	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
the	O
principal	O
rate	O
-	O
limiting	O
step	O
in	O
N	O
-	O
acylethanolamine	O
synthesis	O
.	O

However	O
,	O
the	O
Ca2	O
+	O
-	O
dependent	O
,	O
membrane	O
-	O
associated	O
N	B
-	I
acyltransferase	I
(	O
NAT	B
)	O
responsible	O
for	O
this	O
reaction	O
has	O
not	O
yet	O
been	O
cloned	O
.	O

In	O
this	O
study	O
,	O
on	O
the	O
basis	O
of	O
the	O
functional	O
similarity	O
of	O
NAT	B
to	O
lecithin	B
-	I
retinol	I
acyltransferase	I
(	O
LRAT	B
)	O
,	O
we	O
examined	O
a	O
possible	O
PE	O
N	O
-	O
acylation	O
activity	O
in	O
two	O
rat	O
LRAT	B
homologous	O
proteins	O
.	O

Upon	O
overexpression	O
in	O
COS-7	O
cells	O
,	O
one	O
protein	O
,	O
named	O
rat	O
LRAT	B
-	I
like	I
protein	I
(	I
RLP	I
)	I
-	I
1	I
,	O
catalyzed	O
transfer	O
of	O
a	O
radioactive	O
acyl	O
group	O
from	O
phosphatidylcholine	O
(	O
PC	O
)	O
to	O
PE	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
radioactive	O
NAPE	O
.	O

However	O
,	O
the	O
RLP-1	B
activity	O
was	O
detected	O
mainly	O
in	O
the	O
cytosolic	O
rather	O
than	O
membrane	O
fraction	O
and	O
was	O
little	O
stimulated	O
by	O
Ca2	O
+	O
.	O

Moreover	O
,	O
RLP-1	B
did	O
not	O
show	O
selectivity	O
with	O
respect	O
to	O
the	O
sn-1	O
and	O
sn	O
-	O
2	O
positions	O
of	O
PC	O
as	O
an	O
acyl	O
donor	O
and	O
therefore	O
could	O
generate	O
N	O
-	O
arachidonoyl	O
-	O
PE	O
(	O
anandamide	O
precursor	O
)	O
from	O
2	O
-	O
arachidonoyl	O
-	O
PC	O
and	O
PE	O
.	O

In	O
contrast	O
,	O
under	O
the	O
same	O
assay	O
conditions	O
,	O
partially	O
purified	O
NAT	O
from	O
rat	O
brain	O
was	O
highly	O
Ca2	O
+	O
-	O
dependent	O
,	O
membrane	O
-	O
associated	O
,	O
and	O
specific	O
for	O
the	O
sn	O
-	O
1	O
-	O
acyl	O
group	O
of	O
PC	O
.	O

RLP-1	B
mRNA	O
was	O
expressed	O
predominantly	O
in	O
testis	O
among	O
various	O
rat	O
tissues	O
,	O
and	O
the	O
testis	O
cytosol	O
exhibited	O
an	O
RLP	B
-	I
1	I
-	O
like	O
activity	O
.	O

These	O
results	O
reveal	O
that	O
RLP-1	B
can	O
function	O
as	O
a	O
PE	O
N	B
-	I
acyltransferase	I
,	O
catalytically	O
distinguishable	O
from	O
the	O
known	O
Ca2	O
+	O
-	O
dependent	O
NAT	B
.	O

Apple	O
chlorotic	O
leaf	O
spot	O
virus	O
50	B
kDa	I
movement	I
protein	I
acts	O
as	O
a	O
suppressor	O
of	O
systemic	O
silencing	O
without	O
interfering	O
with	O
local	O
silencing	O
in	O
Nicotiana	O
benthamiana	O
.	O

Apple	O
chlorotic	O
leaf	O
spot	O
virus	O
(	O
ACLSV	O
)	O
is	O
the	O
type	O
species	O
of	O
the	O
genus	O
Trichovirus	O
and	O
its	O
single	O
-	O
stranded	O
,	O
plus	O
-	O
sense	O
RNA	O
genome	O
encodes	O
a	O
216	B
kDa	I
protein	I
(	O
P216	B
)	O
involved	O
in	O
replication	O
,	O
a	O
50	B
kDa	I
movement	I
protein	I
(	O
P50	B
)	O
and	O
a	O
21	B
kDa	I
coat	I
protein	I
(	O
CP	B
)	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
investigated	O
whether	O
these	O
proteins	O
might	O
have	O
RNA	O
silencing	O
-	O
suppressor	O
activities	O
by	O
Agrobacterium	O
-	O
mediated	O
transient	O
assay	O
in	O
the	O
green	B
fluorescent	I
protein	I
-	O
expressing	O
Nicotiana	O
benthamiana	O
line	O
16c	O
.	O

The	O
results	O
indicated	O
that	O
none	O
of	O
these	O
proteins	O
could	O
suppress	O
local	O
silencing	O
in	O
infiltrated	O
leaves	O
.	O

However	O
,	O
systemic	O
silencing	O
in	O
upper	O
leaves	O
induced	O
by	O
both	O
single	O
-	O
and	O
double	O
-	O
stranded	O
RNA	O
could	O
be	O
suppressed	O
by	O
P50	B
,	O
but	O
not	O
by	O
a	O
frame	O
-	O
shift	O
mutant	O
of	O
P50	B
,	O
P216	B
or	O
CP	B
.	O

Moreover	O
,	O
when	O
P50	B
was	O
expressed	O
separately	O
from	O
where	O
silencing	O
signals	O
were	O
generated	O
in	O
a	O
leaf	O
,	O
systemic	O
silencing	O
in	O
upper	O
leaves	O
was	O
inhibited	O
.	O

Collectively	O
,	O
our	O
data	O
indicate	O
that	O
P50	B
acts	O
as	O
a	O
suppressor	O
of	O
systemic	O
silencing	O
without	O
interfering	O
with	O
local	O
silencing	O
,	O
probably	O
by	O
inhibiting	O
the	O
movement	O
of	O
silencing	O
signals	O
.	O

Proteomic	O
comparison	O
of	O
Mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
grown	O
in	O
vitro	O
and	O
isolated	O
from	O
clinical	O
cases	O
of	O
ovine	O
paratuberculosis	O
.	O

Paratuberculosis	O
(	O
Johne	O
's	O
disease	O
)	O
poses	O
a	O
significant	O
economic	O
problem	O
to	O
beef	O
,	O
dairy	O
and	O
sheep	O
industries	O
worldwide	O
,	O
and	O
is	O
caused	O
by	O
Mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
.	O

In	O
this	O
study	O
,	O
2D	O
PAGE	O
was	O
used	O
as	O
a	O
tool	O
to	O
investigate	O
the	O
virulent	O
state	O
of	O
M.	O
avium	O
subsp	O
.	O
paratuberculosis	O
,	O
incorporating	O
the	O
technique	O
of	O
beating	O
the	O
organism	O
with	O
zirconium	O
/	O
silica	O
beads	O
to	O
provide	O
a	O
comprehensive	O
representation	O
of	O
its	O
proteome	O
.	O

A	O
direct	O
comparison	O
of	O
the	O
proteomes	O
of	O
M.	O
avium	O
subsp	O
.	O
paratuberculosis	O
scraped	O
from	O
the	O
terminal	O
ileum	O
of	O
ovine	O
paratuberculosis	O
cases	O
,	O
and	O
the	O
identical	O
strain	O
grown	O
in	O
vitro	O
,	O
is	O
presented	O
.	O

These	O
analyses	O
identified	O
a	O
set	O
of	O
10	O
proteins	O
whose	O
expression	O
is	O
upregulated	O
during	O
natural	O
infection	O
:	O
1-pyrroline-5-carboxylate	B
dehydrogenase	I
(	O
RocA	B
)	O
,	O
a	O
putative	O
acyl	B
-	I
CoA	I
dehydrogenase	I
(	O
FadE14	B
)	O
,	O
2-methylcitrate	B
dehydratase	I
(	B
2-mcd	I
)	O
,	O
arginosuccinate	B
synthase	I
(	O
ArgG	B
)	O
,	O
universal	B
stress	I
protein	I
(	O
usp	B
)	O
,	O
30S	B
ribosomal	I
protein	I
S2	I
(	O
RpsB	B
)	O
,	O
peptidyl	B
-	I
prolyl	I
cis	I
-	I
trans	I
isomerase	I
(	O
PpiA	B
)	O
,	O
luciferase	B
-	I
like	I
monooxygenase	I
(	O
(	B
lmo	I
)	I
)	O
,	O
thiosulfate	B
sulfurtransferase	I
(	O
SseA	B
)	O
and	O
ATP	O
-	O
dependent	O
Clp	B
protease	I
(	O
ClpB	B
)	O
.	O

Most	O
of	O
the	O
proteins	O
identified	O
do	O
not	O
have	O
obviously	O
related	O
functions	O
;	O
however	O
,	O
ArgG	B
and	O
RocA	B
function	O
in	O
the	O
same	O
pathway	O
,	O
and	O
may	O
have	O
a	O
concerted	O
action	O
for	O
energy	O
production	O
in	O
vivo	O
.	O

Sex	O
-	O
specific	O
,	O
independent	O
associations	O
of	O
insulin	B
resistance	O
with	O
erythrocyte	O
sedimentation	O
rate	O
in	O
apparently	O
healthy	O
subjects	O
.	O

Insulin	B
resistance	O
and	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
,	O
a	O
non	O
-	O
specific	O
marker	O
of	O
inflammation	O
)	O
are	O
known	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
.	O

Although	O
obesity	O
is	O
associated	O
with	O
increased	O
ESR	O
,	O
it	O
is	O
unclear	O
whether	O
insulin	B
resistance	O
is	O
associated	O
with	O
ESR	O
in	O
humans	O
.	O

The	O
relationship	O
between	O
insulin	B
resistance	O
and	O
ESR	O
was	O
studied	O
in	O
a	O
cross	O
-	O
sectional	O
,	O
health	O
-	O
area	O
based	O
study	O
of	O
140	O
(	O
89	O
men	O
and	O
51	O
women	O
)	O
apparently	O
healthy	O
Caucasians	O
subjects	O
.	O

ESR	O
,	O
additional	O
inflammatory	O
markers	O
[	O
soluble	O
tumor	B
necrosis	I
alpha	I
receptors	I
1	I
and	I
2	I
(	O
sTNFR1	B
and	O
sTNFR2	B
)	O
;	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
]	O
,	O
and	O
insulin	B
sensitivity	O
(	O
SI	O
,	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
with	O
minimal	O
model	O
analysis	O
)	O
were	O
assessed	O
in	O
all	O
subjects	O
.	O

An	O
interaction	O
with	O
sex	O
was	O
documented	O
in	O
the	O
relationship	O
between	O
ESR	O
and	O
both	O
insulin	B
resistance	O
and	O
obesity	O
(	O
p	O
<	O
0.05	O
)	O
,	O
as	O
log	O
ESR	O
correlated	O
with	O
log	O
SI	O
in	O
men	O
(	O
r	O
=	O
-	O
0.29	O
,	O
p	O
=	O
0.009	O
)	O
,	O
but	O
not	O
in	O
women	O
(	O
r	O
=	O
-	O
0.14	O
,	O
p	O
=	O
0.33	O
)	O
,	O
and	O
correlated	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
women	O
(	O
r	O
=	O
0.49	O
,	O
p	O
=	O
<	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
men	O
(	O
r	O
=	O
0.15	O
,	O
p	O
=	O
0.16	O
)	O
.	O

On	O
multivariate	O
analyses	O
,	O
these	O
associations	O
proved	O
to	O
be	O
independent	O
of	O
known	O
covariates	O
,	O
such	O
as	O
age	O
,	O
hematocrit	O
,	O
smoking	O
and	O
additional	O
inflammatory	O
markers	O
in	O
both	O
men	O
and	O
women	O
.	O

In	O
a	O
replication	O
study	O
,	O
variables	O
independently	O
associated	O
with	O
ESR	O
were	O
also	O
insulin	B
resistance	O
(	O
homeostasis	O
model	O
assessment	O
)	O
in	O
men	O
and	O
obesity	O
markers	O
(	O
either	O
BMI	O
or	O
fat	O
mass	O
)	O
in	O
women	O
.	O

In	O
conclusion	O
,	O
ESR	O
is	O
independently	O
associated	O
with	O
either	O
insulin	B
resistance	O
or	O
obesity	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
.	O

These	O
findings	O
contribute	O
to	O
explain	O
the	O
known	O
relationship	O
of	O
this	O
inflammatory	O
marker	O
with	O
cardiovascular	O
disease	O
.	O

Establishment	O
and	O
characterization	O
of	O
porcine	O
Sertoli	O
cell	O
line	O
for	O
the	O
study	O
of	O
xenotransplantation	O
.	O

BACKGROUND	O
:	O

An	O
understanding	O
of	O
the	O
main	O
mechanism	O
that	O
determines	O
the	O
ability	O
of	O
immune	O
privilege	O
related	O
to	O
Sertoli	O
cells	O
(	O
SC	O
)	O
will	O
provide	O
clues	O
for	O
promoting	O
a	O
local	O
tolerogenic	O
environment	O
.	O

In	O
this	O
report	O
,	O
we	O
established	O
neonatal	O
porcine	O
SC	O
line	O
and	O
evaluated	O
their	O
characteristics	O
.	O

METHODS	O
:	O

SC	O
line	O
was	O
established	O
following	O
the	O
transfection	O
of	O
primary	O
SC	O
(	O
NPSC	O
)	O
from	O
the	O
testis	O
of	O
neonatal	O
pig	O
with	O
plasmid	O
pRNS-1	O
carrying	O
genes	O
for	O
neomycin	O
resistance	O
and	O
the	O
SV40	O
large	B
T	I
antigen	I
.	O

Immunohistochemistry	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
to	O
evaluate	O
the	O
character	O
of	O
immortalized	O
SC	O
lines	O
.	O

RESULTS	O
:	O

Our	O
immortalized	O
SC	O
line	O
(	O
iPS	O
)	O
proliferated	O
stably	O
and	O
had	O
a	O
phenotype	O
similar	O
to	O
NPSC	O
,	O
as	O
indicated	O
by	O
the	O
immunoexpression	O
of	O
follicle	B
stimulating	I
hormone	I
receptor	I
(	O
FSHR	B
)	O
,	O
and	O
mRNA	O
expression	O
of	O
androgen	B
receptor	I
(	O
AR	B
)	O
,	O
and	O
Wilms	B
'	I
tumor	I
antigen	I
(	O
WT1	B
)	O
.	O

Interestingly	O
,	O
NPSC	O
and	O
iPS	O
expressed	O
mRNA	O
of	O
complement	O
regulatory	O
proteins	O
(	O
CRP	O
)	O
such	O
as	O
membrane	B
cofactor	I
protein	I
(	O
CD46	B
)	O
,	O
decay	B
accelerating	I
factor	I
(	O
DAF	B
or	O
CD55	B
)	O
,	O
and	O
protectin	B
(	O
CD59	B
)	O
,	O
but	O
CD59	B
mRNA	O
expression	O
was	O
negligible	O
in	O
iPS	O
.	O

CONCLUSION	O
:	O

These	O
results	O
suggest	O
that	O
iPS	O
,	O
immortalized	O
by	O
the	O
introduction	O
of	O
SV40	O
T	O
,	O
retain	O
their	O
original	O
characteristics	O
,	O
except	O
for	O
the	O
relatively	O
low	O
expression	O
of	O
CD59	B
,	O
and	O
that	O
they	O
may	O
be	O
useful	O
for	O
future	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
of	O
immune	O
privilege	O
mechanisms	O
related	O
to	O
SC	O
.	O

The	O
origin	O
of	O
mammalian	O
plasma	O
amine	B
oxidases	I
.	O

Mammalian	O
blood	O
plasma	O
contains	O
considerable	O
activity	O
of	O
soluble	O
copper	B
-	I
containing	I
amine	I
oxidase	I
(	O
AOC	B
)	O
referred	O
to	O
as	O
plasma	O
or	O
serum	O
amine	B
oxidase	I
(	O
SAO	O
)	O
.	O

The	O
identity	O
and	O
origin	O
of	O
SAO	O
was	O
investigated	O
based	O
on	O
the	O
recent	O
characterization	O
of	O
four	O
porcine	O
AOC	B
genes	O
with	O
AOC1	B
encoding	O
diamine	B
oxidase	I
(	O
DAO	B
)	O
,	O
AOC2	B
retina	B
-	I
specific	I
amine	I
oxidase	I
(	O
RAO	B
)	O
,	O
AOC3	B
vascular	B
adhesion	I
protein-1	I
(	O
VAP-1	B
)	O
,	O
and	O
AOC4	B
a	O
VAP-1	B
homologue	O
that	O
is	O
expressed	O
mainly	O
in	O
the	O
liver	O
and	O
has	O
a	O
signal	O
peptide	O
sequence	O
instead	O
of	O
a	O
transmembrane	O
domain	O
at	O
its	O
N	O
-	O
terminus	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
major	O
amine	B
oxidase	I
activity	O
from	O
porcine	O
serum	O
showed	O
that	O
it	O
is	O
the	O
product	O
of	O
the	O
AOC4	B
gene	O
.	O

Intriguingly	O
,	O
all	O
mammals	O
possessing	O
a	O
functional	O
AOC4	B
gene	O
exhibit	O
high	O
plasma	O
amine	B
oxidase	I
activity	O
.	O

Humans	O
and	O
rodents	O
lack	O
a	O
functional	O
AOC4	B
gene	O
and	O
have	O
comparably	O
low	O
plasma	O
amine	B
oxidase	I
activity	O
that	O
is	O
probably	O
derived	O
from	O
partial	O
proteolytic	O
release	O
of	O
the	O
membrane	O
-	O
associated	O
AOC3	B
gene	O
product	O
VAP-1	B
.	O

Apyrases	B
(	O
nucleoside	B
triphosphate	I
-	I
diphosphohydrolases	I
)	O
play	O
a	O
key	O
role	O
in	O
growth	O
control	O
in	O
Arabidopsis	O
.	O

Expression	O
of	O
two	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
apyrase	B
(	O
nucleoside	B
triphosphate	I
-	I
diphosphohydrolase	I
)	O
genes	O
with	O
high	O
similarity	O
,	O
APY1	B
and	O
APY2	B
,	O
was	O
analyzed	O
during	O
seedling	O
development	O
and	O
under	O
different	O
light	O
treatments	O
using	O
beta	B
-	I
glucuronidase	I
fusion	O
constructs	O
with	O
the	O
promoters	O
of	O
both	O
genes	O
.	O

As	O
evaluated	O
by	O
beta	B
-	I
glucuronidase	I
staining	O
and	O
independently	O
confirmed	O
by	O
other	O
methods	O
,	O
the	O
highest	O
expression	O
of	O
both	O
apyrases	B
was	O
in	O
rapidly	O
growing	O
tissues	O
and/or	O
tissues	O
that	O
accumulate	O
high	O
auxin	O
levels	O
.	O

Red	O
-	O
light	O
treatment	O
of	O
etiolated	O
seedlings	O
suppressed	O
the	O
protein	O
and	O
message	O
level	O
of	O
both	O
apyrases	O
at	O
least	O
as	O
rapidly	O
as	O
it	O
inhibited	O
hypocotyl	O
growth	O
.	O

Adult	O
apy1	B
and	O
apy2	B
single	O
mutants	O
had	O
near	O
-	O
normal	O
growth	O
,	O
but	O
apy1apy2	B
double	O
-	O
knockout	O
plants	O
were	O
dwarf	O
,	O
due	O
primarily	O
to	O
reduced	O
cell	O
elongation	O
.	O

Pollen	O
tubes	O
and	O
etiolated	O
hypocotyls	O
overexpressing	O
an	O
apyrase	B
had	O
faster	O
growth	O
rates	O
than	O
wild	O
-	O
type	O
plants	O
.	O

Growing	O
pollen	O
tubes	O
released	O
ATP	O
into	O
the	O
growth	O
medium	O
and	O
suppression	O
of	O
apyrase	B
activity	O
by	O
antiapyrase	O
antibodies	O
or	O
by	O
inhibitors	O
simultaneously	O
increased	O
medium	O
ATP	O
levels	O
and	O
inhibited	O
pollen	O
tube	O
growth	O
.	O

These	O
results	O
imply	O
that	O
APY1	B
and	O
APY2	B
,	O
like	O
their	O
homologs	O
in	O
animals	O
,	O
act	O
to	O
reduce	O
the	O
concentration	O
of	O
extracellular	O
nucleotides	O
,	O
and	O
that	O
this	O
function	O
is	O
important	O
for	O
the	O
regulation	O
of	O
growth	O
in	O
Arabidopsis	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
human	O
Mov34	B
MPN	O
domain	O
reveals	O
a	O
metal	O
-	O
free	O
dimer	O
.	O

The	O
26S	O
proteasome	O
is	O
a	O
large	O
protein	O
complex	O
involved	O
in	O
protein	O
degradation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
PSMD7	B
/	O
Mov34	B
subunit	O
of	O
the	O
human	O
proteasome	O
contains	O
a	O
proteolytically	O
resistant	O
MPN	O
domain	O
.	O

MPN	O
domain	O
family	O
members	O
comprise	O
subunits	O
of	O
the	O
proteasome	O
,	O
COP9	B
-	O
signalosome	O
and	O
translation	B
initiation	I
factor	I
3	I
complexes	I
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
two	O
C	O
-	O
terminally	O
truncated	O
proteins	O
,	O
MPN	O
1	O
-	O
186	O
and	O
MPN	O
1	O
-	O
177	O
,	O
were	O
solved	O
to	O
1.96	O
and	O
3.0	O
A	O
resolution	O
,	O
respectively	O
.	O

MPN	O
1	O
-	O
186	O
is	O
formed	O
by	O
nine	O
beta	O
-	O
strands	O
surrounded	O
by	O
three	O
alpha	O
-	O
helices	O
plus	O
a	O
fourth	O
alpha	O
-	O
helix	O
at	O
the	O
C	O
terminus	O
.	O

This	O
final	O
alpha	O
-	O
helix	O
emerges	O
from	O
the	O
domain	O
core	O
and	O
folds	O
along	O
with	O
a	O
symmetrically	O
related	O
subunit	O
,	O
typical	O
of	O
a	O
domain	O
swap	O
.	O

The	O
crystallographic	O
dimer	O
is	O
consistent	O
with	O
size	O
-	O
exclusion	O
chromatography	O
and	O
DLS	O
analysis	O
showing	O
that	O
MPN	O
1	O
-	O
186	O
is	O
a	O
dimer	O
in	O
solution	O
.	O

MPN	O
1	O
-	O
186	O
shows	O
an	O
overall	O
architecture	O
highly	O
similar	O
to	O
the	O
previously	O
reported	O
crystal	O
structure	O
of	O
the	O
Archaeal	O
MPN	O
domain	O
AfJAMM	B
of	O
Archaeoglobus	O
fulgidus	O
.	O

However	O
,	O
previous	O
structural	O
and	O
biophysical	O
analyses	O
have	O
shown	O
that	O
neither	O
MPN	O
1	O
-	O
186	O
nor	O
full	O
-	O
length	O
human	O
Mov34	B
bind	O
metal	O
,	O
in	O
opposition	O
to	O
the	O
zinc	O
-	O
binding	O
AfJAMM	B
structures	O
.	O

The	O
zinc	O
ligand	O
residues	O
observed	O
in	O
AfJAMM	B
are	O
conserved	O
in	O
the	O
yeast	O
Rpn11	B
proteasome	O
and	O
Csn5	B
COP	B
-	O
signalosome	O
subunits	O
,	O
which	O
is	O
consistent	O
with	O
the	O
isopeptidase	B
activity	O
described	O
for	O
these	O
proteins	O
.	O

The	O
results	O
presented	O
here	O
show	O
that	O
,	O
although	O
the	O
MPN	O
domain	O
of	O
Mov34	B
shows	O
a	O
typical	O
metalloprotease	B
fold	O
,	O
it	O
is	O
unable	O
to	O
coordinate	O
a	O
metal	O
ion	O
.	O

This	O
finding	O
and	O
amino	O
acid	O
sequence	O
comparisons	O
can	O
explain	O
why	O
the	O
MPN	O
-	O
containing	O
proteins	O
Mov34	B
/	O
PSMD7	B
,	O
RPN8	B
,	O
Csn6	B
,	O
Prp8p	B
and	O
the	O
translation	B
initiation	I
factor	I
3	I
subunits	I
f	I
and	I
h	I
do	O
not	O
show	O
catalytic	O
isopeptidase	B
activity	O
,	O
allowing	O
us	O
to	O
propose	O
the	O
hypothesis	O
that	O
in	O
these	O
proteins	O
the	O
MPN	O
domain	O
has	O
a	O
primarily	O
structural	O
function	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
patients	O
with	O
giant	O
axonal	O
neuropathy	O
(	O
GAN	O
)	O
.	O

Giant	O
axonal	O
neuropathy	O
(	O
GAN	O
,	O
MIM	O
:	O
256850	O
)	O
is	O
a	O
devastating	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
an	O
early	O
onset	O
severe	O
peripheral	O
neuropathy	O
,	O
varying	O
central	O
nervous	O
system	O
involvement	O
and	O
strikingly	O
frizzly	O
hair	O
.	O

Giant	O
axonal	O
neuropathy	O
is	O
usually	O
caused	O
by	O
mutations	O
in	O
the	O
gigaxonin	B
gene	O
(	O
GAN	B
)	O
but	O
genetic	O
heterogeneity	O
has	O
been	O
demonstrated	O
for	O
a	O
milder	O
variant	O
of	O
this	O
disease	O
.	O

Here	O
,	O
we	O
report	O
ten	O
patients	O
referred	O
to	O
us	O
for	O
molecular	O
genetic	O
diagnosis	O
.	O

All	O
patients	O
had	O
typical	O
clinical	O
signs	O
suggestive	O
of	O
giant	O
axonal	O
neuropathy	O
.	O

In	O
seven	O
affected	O
individuals	O
,	O
we	O
found	O
disease	O
causing	O
mutations	O
in	O
the	O
gigaxonin	B
gene	O
affecting	O
both	O
alleles	O
:	O
two	O
splice	O
-	O
site	O
and	O
four	O
missense	O
mutations	O
,	O
not	O
reported	O
previously	O
.	O

Gigaxonin	B
binds	O
N	O
-	O
terminally	O
to	O
ubiquitin	B
activating	I
enzyme	I
E1	I
and	O
C	O
-	O
terminally	O
to	O
various	O
microtubule	O
associated	O
proteins	O
causing	O
their	O
ubiquitin	B
mediated	O
degradation	O
.	O

It	O
was	O
shown	O
for	O
a	O
number	O
of	O
gigaxonin	B
mutations	O
that	O
they	O
impede	O
this	O
process	O
leading	O
to	O
accumulation	O
of	O
microtubule	O
associated	O
proteins	O
and	O
there	O
by	O
impairing	O
cellular	O
functions	O
.	O

Vibrio	O
vulnificus	O
IlpA	O
-	O
induced	O
cytokine	B
production	O
is	O
mediated	O
by	O
Toll	B
-	I
like	I
receptor	I
2	I
.	O

Vibrio	O
vulnificus	O
is	O
a	O
pathogenic	O
bacterium	O
causing	O
primary	O
septicemia	O
,	O
which	O
follows	O
a	O
classical	O
septic	O
shock	O
pathway	O
,	O
including	O
an	O
overwhelming	O
inflammatory	O
cytokine	B
response	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
putative	O
lipoprotein	O
of	O
V.	O
vulnificus	O
,	O
encoded	O
by	O
the	O
ilpA	B
gene	O
,	O
as	O
one	O
of	O
the	O
surface	O
proteins	O
that	O
specifically	O
reacted	O
with	O
the	O
antibodies	O
raised	O
against	O
outer	O
membrane	O
proteins	O
of	O
V.	O
vulnificus	O
.	O

Using	O
a	O
mutant	O
V.	O
vulnificus	O
in	O
which	O
its	O
ilpA	B
gene	O
was	O
knocked	O
out	O
,	O
we	O
found	O
that	O
IlpA	B
is	O
important	O
in	O
the	O
production	O
of	O
interferon	B
-	I
gamma	I
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-6	B
is	O
also	O
induced	O
by	O
the	O
recombinant	O
IlpA	B
(	O
rIlpA	B
)	O
in	O
human	O
monocytes	O
.	O

Lipidation	O
of	O
the	O
rIlpA	B
was	O
observed	O
by	O
in	O
vivo	O
labeling	O
in	O
Escherichia	O
coli	O
.	O

Experiments	O
using	O
the	O
mutant	O
IlpA	B
,	O
which	O
is	O
unable	O
to	O
be	O
modified	O
by	O
lipidation	O
,	O
indicate	O
that	O
the	O
lipid	O
moiety	O
of	O
this	O
protein	O
has	O
an	O
essential	O
property	O
for	O
cytokine	B
production	O
in	O
human	O
cells	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
antibodies	O
against	O
Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
inhibited	O
production	O
of	O
both	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-6	B
.	O

The	O
role	O
of	O
TLR2	B
in	O
IlpA	B
-	O
induced	O
cytokine	B
production	O
was	O
confirmed	O
by	O
an	O
in	O
vitro	O
assay	O
,	O
in	O
which	O
only	O
the	O
TLR2	B
-	O
expressing	O
cells	O
showed	O
a	O
dramatic	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
activity	O
by	O
rIlpA	B
.	O

In	O
addition	O
,	O
rIlpA	B
treatment	O
resulted	O
in	O
induction	O
of	O
TLR2	B
transcription	O
in	O
human	O
cells	O
.	O

In	O
comparison	O
with	O
the	O
wild	O
type	O
V.	O
vulnificus	O
,	O
the	O
ilpA	B
mutant	O
showed	O
a	O
reduced	O
mortality	O
in	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
IlpA	B
of	O
V.	O
vulnificus	O
functions	O
as	O
an	O
immunostimulant	O
to	O
human	O
cells	O
via	O
TLR2	B
.	O

SLC1	B
and	O
SLC4	B
encode	O
partially	O
redundant	O
acyl	O
-	O
coenzyme	O
A	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferases	I
of	O
budding	O
yeast	O
.	O

Phosphatidic	O
acid	O
is	O
the	O
intermediate	O
,	O
from	O
which	O
all	O
glycerophospholipids	O
are	O
synthesized	O
.	O

In	O
yeast	O
,	O
it	O
is	O
generated	O
from	O
lysophosphatidic	O
acid	O
,	O
which	O
is	O
acylated	O
by	O
Slc1p	B
,	O
an	O
sn-2-specific	O
,	O
acyl	O
-	O
coenzyme	O
A	O
-	O
dependent	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferase	I
.	O

Deletion	O
of	O
SLC1	B
is	O
not	O
lethal	O
and	O
does	O
not	O
eliminate	O
all	O
microsomal	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferase	I
activity	O
,	O
suggesting	O
that	O
an	O
additional	O
enzyme	O
may	O
exist	O
.	O

Here	O
we	O
show	O
that	O
SLC4	B
(	O
Yor175c	B
)	O
,	O
a	O
gene	O
of	O
hitherto	O
unknown	O
function	O
,	O
encodes	O
a	O
second	O
1-acyl	B
-	I
sn	I
-	I
glycerol-3-phosphate	I
acyltransferase	I
.	O

SLC4	B
harbors	O
a	O
membrane	O
-	O
bound	O
O	B
-	I
acyltransferase	I
motif	O
and	O
down	O
-	O
regulation	O
of	O
SLC4	B
strongly	O
reduces	O
1-acyl	B
-	I
sn	I
-	I
glycerol-3-phosphate	I
acyltransferase	I
activity	O
in	O
microsomes	O
from	O
slc1Delta	O
cells	O
.	O

The	O
simultaneous	O
deletion	O
of	O
SLC1	B
and	O
SLC4	B
is	O
lethal	O
.	O

Mass	O
spectrometric	O
analysis	O
of	O
lipids	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
demonstrates	O
that	O
in	O
vivo	O
Slc1p	B
and	O
Slc4p	B
generate	O
almost	O
the	O
same	O
glycerophospholipid	O
profile	O
.	O

Microsomes	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
incubated	O
with	O
[	O
14C	O
]	O
oleoyl	O
-	O
coenzyme	O
A	O
in	O
the	O
absence	O
of	O
lysophosphatidic	O
acid	O
and	O
without	O
CTP	O
still	O
incorporate	O
the	O
label	O
into	O
glycerophospholipids	O
,	O
indicating	O
that	O
Slc1p	B
and	O
Slc4p	B
can	O
also	O
use	O
endogenous	O
lysoglycerophospholipids	O
as	O
substrates	O
.	O

However	O
,	O
the	O
lipid	O
profiles	O
generated	O
by	O
microsomes	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
are	O
different	O
,	O
and	O
this	O
suggests	O
that	O
Slc1p	B
and	O
Slc4p	B
have	O
a	O
different	O
substrate	O
specificity	O
or	O
have	O
access	O
to	O
different	O
lyso	O
-	O
glycerophospholipid	O
substrates	O
because	O
of	O
a	O
different	O
subcellular	O
location	O
.	O

Indeed	O
,	O
affinity	O
-	O
purified	O
Slc1p	B
displays	O
Mg2	O
+	O
-	O
dependent	O
acyltransferase	B
activity	O
not	O
only	O
toward	O
lysophosphatidic	O
acid	O
but	O
also	O
lyso	O
forms	O
of	O
phosphatidylserine	O
and	O
phosphatidylinositol	O
.	O

Thus	O
,	O
Slc1p	B
and	O
Slc4p	B
may	O
not	O
only	O
be	O
active	O
as	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferases	I
but	O
also	O
be	O
involved	O
in	O
fatty	O
acid	O
exchange	O
at	O
the	O
sn-2-position	O
of	O
mature	O
glycerophospholipids	O
.	O

Use	O
of	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
method	O
for	O
mutational	O
screening	O
of	O
patients	O
with	O
familial	O
hypercholesterolaemia	O
(	O
FH	O
)	O
and	O
Familial	O
defective	O
apolipoprotein	B
B100	I
(	O
FDB	O
)	O
.	O

Familial	O
hypercholesterolaemia	O
(	O
FH	O
)	O
and	O
Familial	O
defective	O
apolipoprotein	B
B100	I
(	O
FDB	O
)	O
are	O
autosomal	O
dominant	O
inherited	O
diseases	O
of	O
lipid	O
metabolism	O
caused	O
by	O
mutations	O
in	O
the	O
low	B
density	I
lipoprotein	I
(	I
LDL	I
)	I
receptor	I
and	O
apolipoprotein	B
B	I
100	I
genes	O
.	O

FH	O
is	O
clinically	O
characterised	O
by	O
elevated	O
concentrations	O
of	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
low	B
density	I
lipoprotein	I
cholesterol	O
(	O
LDL	B
-	O
C	O
)	O
,	O
presence	O
of	O
xanthomata	O
and	O
premature	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
associated	O
with	O
coronary	O
artery	O
disease	O
but	O
may	O
be	O
clinically	O
indistinguishable	O
.	O

Seventy	O
-	O
two	O
(	O
72	O
)	O
FH	O
patients	O
were	O
diagnosed	O
based	O
on	O
the	O
Simon	O
Broome	O
's	O
criteria	O
.	O

Mutational	O
screening	O
was	O
performed	O
by	O
polymerase	B
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

Positive	O
mutations	O
were	O
subjected	O
to	O
DNA	O
sequencing	O
for	O
confirmation	O
of	O
the	O
mutation	O
.	O

We	O
successfully	O
amplified	O
all	O
exons	O
in	O
the	O
LDL	B
receptor	I
and	O
apo	B
B100	I
genes	O
.	O

DGGE	O
was	O
performed	O
in	O
all	O
exons	O
of	O
the	O
LDL	B
receptor	I
(	O
except	O
for	O
exons	O
4	O
-	O
3	O
'	O
,	O
18	O
and	O
promoter	O
region	O
)	O
and	O
apo	B
B100	I
genes	O
.	O

We	O
have	O
identified	O
four	O
different	O
mutations	O
in	O
the	O
LDL	B
receptor	I
gene	O
but	O
no	O
mutation	O
was	O
detected	O
in	O
the	O
apo	B
B	I
100	I
gene	O
.	O

The	O
apo	B
B100	I
gene	O
mutation	O
was	O
not	O
detected	O
on	O
DGGE	O
screening	O
as	O
sequencing	O
was	O
not	O
performed	O
for	O
negative	O
cases	O
on	O
DGGE	O
technique	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
C234S	O
mutation	O
(	O
exon	O
5	O
)	O
is	O
a	O
novel	O
mutation	O
worldwide	O
.	O

The	O
D69N	O
mutation	O
(	O
exon	O
3	O
)	O
has	O
been	O
reported	O
locally	O
while	O
the	O
R385W	O
(	O
exon	O
9	O
)	O
and	O
R716	O
G	O
(	O
exon	O
15	O
)	O
mutations	O
have	O
not	O
been	O
reported	O
locally	O
.	O

However	O
,	O
only	O
4	O
mutations	O
have	O
been	O
identified	O
among	O
14	O
/	O
72	O
patients	O
(	O
19.4	O
%	O
)	O
in	O
39	O
FH	O
families	O
.	O

Specificity	O
(	O
1	O
-	O
false	O
positive	O
)	O
of	O
this	O
technique	O
was	O
44.7	O
%	O
based	O
on	O
the	O
fact	O
that	O
42	O
/	O
76	O
(	O
55.3	O
%	O
)	O
samples	O
with	O
band	O
shifts	O
showed	O
normal	O
DNA	O
sequencing	O
results	O
.	O

A	O
more	O
sensitive	O
method	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
in	O
order	O
to	O
fully	O
characterise	O
the	O
LDLR	B
and	O
apo	B
B100	I
genes	O
such	O
as	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
the	O
DNA	O
analysis	O
for	O
FH	O
patients	O
using	O
PCR	O
-	O
DGGE	O
technique	O
.	O

DNA	O
analysis	O
plays	O
an	O
important	O
role	O
to	O
characterise	O
the	O
type	O
of	O
mutations	O
and	O
forms	O
an	O
adjunct	O
to	O
clinical	O
diagnosis	O
.	O

Microalbuminuria	O
is	O
a	O
negative	O
correlate	O
for	O
cognitive	O
function	O
in	O
older	O
adults	O
with	O
peripheral	O
arterial	O
disease	O
:	O
results	O
from	O
the	O
U.S.	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
1999	O
-	O
2002	O
.	O

OBJECTIVES	O
:	O

Microalbuminuria	O
(	O
MA	O
)	O
has	O
been	O
increasingly	O
identified	O
as	O
a	O
marker	O
of	O
cardiovascular	O
risk	O
.	O

Although	O
poor	O
cognitive	O
function	O
has	O
been	O
implicated	O
as	O
a	O
sequelae	O
of	O
increased	O
cardiovascular	O
burden	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
between	O
MA	O
and	O
cognitive	O
function	O
.	O

DESIGN	O
:	O

Population	O
-	O
based	O
cross	O
-	O
sectional	O
study	O
.	O

SETTINGS	O
:	O

National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
1999	O
-	O
2002	O
in	O
the	O
USA	O
.	O

SUBJECTS	O
:	O

2049	O
noninstitutionalized	O
adults	O
(	O
>	O
/	O
=	O
60	O
years	O
)	O
with	O
nonmissing	O
values	O
in	O
cognitive	O
test	O
,	O
urinary	O
albumin	B
-	O
to	O
-	O
creatinine	O
ratio	O
(	O
UACR	O
)	O
and	O
ankle	O
-	O
brachial	O
blood	O
pressure	O
index	O
(	O
ABPI	O
)	O
was	O
analysed	O
.	O

Participants	O
with	O
UACR	O
>	O
300	O
microg	O
mg	O
(	O
-1	O
)	O
were	O
excluded	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

The	O
UACR	O
,	O
in	O
the	O
unit	O
of	O
microg	O
mg	O
(	O
-1	O
)	O
,	O
was	O
calculated	O
by	O
dividing	O
the	O
urinary	O
albumin	B
value	O
by	O
the	O
urinary	O
creatinine	O
concentration	O
.	O

MA	O
was	O
defined	O
as	O
UACR	O
between	O
30	O
and	O
300	O
microg	O
mg	O
(	O
-1	O
)	O
.	O

Cognitive	O
function	O
was	O
measured	O
by	O
a	O
2-min	O
Digit	O
Symbol	O
Substitution	O
Test	O
(	O
DSST	O
)	O
.	O

Peripheral	O
artery	O
disease	O
(	O
PAD	O
)	O
was	O
defined	O
as	O
an	O
ABPI	O
<	O
0.9	O
in	O
either	O
leg	O
.	O

RESULTS	O
:	O

Overall	O
speaking	O
,	O
MA	O
was	O
inversely	O
associated	O
with	O
DSST	O
score	O
after	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
race	O
,	O
body	O
mass	O
index	O
and	O
educational	O
level	O
(	O
regression	O
coefficient	O
=	O
-	O
2.8	O
,	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
an	O
effect	O
modification	O
of	O
PAD	O
on	O
the	O
association	O
between	O
MA	O
and	O
the	O
DSST	O
score	O
.	O

Amongst	O
participants	O
with	O
PAD	O
,	O
the	O
DSST	O
score	O
for	O
those	O
with	O
MA	O
was	O
lower	O
than	O
those	O
without	O
MA	O
(	O
beta	O
=	O
-	O
6.3	O
,	O
P	O
=	O
0.003	O
)	O
after	O
multivariate	O
adjustment	O
.	O

Moreover	O
,	O
participants	O
with	O
PAD	O
in	O
the	O
highest	O
quartile	O
of	O
UACR	O
had	O
significantly	O
lower	O
DSST	O
score	O
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
beta	O
=	O
-	O
8.7	O
,	O
P	O
=	O
0.001	O
)	O
.	O

There	O
was	O
no	O
association	O
between	O
MA	O
and	O
cognitive	O
function	O
amongst	O
participants	O
without	O
PAD	O
.	O

We	O
observed	O
an	O
additive	O
effect	O
of	O
MA	O
and	O
PAD	O
on	O
DSST	O
score	O
.	O

Participants	O
with	O
both	O
MA	O
and	O
PAD	O
had	O
a	O
lower	O
mean	O
DSST	O
score	O
compared	O
to	O
those	O
without	O
both	O
conditions	O
(	O
beta	O
=	O
-	O
6.2	O
,	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
presence	O
of	O
MA	O
or	O
a	O
higher	O
level	O
of	O
urinary	O
albumin	B
excretion	O
was	O
inversely	O
associated	O
with	O
cognitive	O
function	O
in	O
participants	O
with	O
PAD	O
.	O

Regulation	O
of	O
spo0H	B
,	O
a	O
gene	O
coding	O
for	O
the	O
Bacillus	O
subtilis	O
sigma	B
H	I
factor	I
.	O

The	O
Bacillus	O
spo0H	B
gene	O
codes	O
for	O
sigma	B
H	I
,	O
which	O
,	O
as	O
part	O
of	O
the	O
RNA	B
polymerase	I
holoenzyme	O
E	B
sigma	I
H	I
,	O
is	O
responsible	O
for	O
the	O
transcription	O
of	O
several	O
genes	O
which	O
are	O
expressed	O
at	O
the	O
beginning	O
of	O
the	O
sporulation	O
process	O
.	O

In	O
this	O
communication	O
,	O
we	O
examined	O
the	O
regulation	O
of	O
the	O
spo0H	B
gene	O
of	O
Bacillus	O
subtilis	O
by	O
using	O
lacZ	B
reporter	O
gene	O
assays	O
,	O
quantitative	O
RNA	O
determinations	O
,	O
and	O
Western	O
immunoassay	O
.	O

The	O
expression	O
of	O
the	O
spo0H	B
gene	O
increases	O
as	O
the	O
culture	O
enters	O
the	O
mid	O
-	O
logarithmic	O
stage	O
of	O
growth	O
.	O

This	O
increased	O
expression	O
requires	O
the	O
genes	O
spo0A	B
,	O
spo0B	B
,	O
spo0E	B
,	O
and	O
spo0F	B
,	O
and	O
the	O
requirement	O
for	O
at	O
least	O
spo0A	B
and	O
spo0B	B
can	O
be	O
bypassed	O
when	O
the	O
abrB	B
gene	O
is	O
mutated	O
.	O

The	O
expression	O
of	O
the	O
spo0H	B
gene	O
is	O
constitutive	O
in	O
the	O
presence	O
of	O
the	O
abrB	B
mutation	O
,	O
being	O
expressed	O
at	O
higher	O
levels	O
during	O
vegetative	O
growth	O
.	O

In	O
addition	O
,	O
the	O
sof-1	B
mutation	O
,	O
in	O
the	O
spo0A	B
structural	O
gene	O
,	O
can	O
bypass	O
the	O
need	O
for	O
spo0F	B
in	O
spo0H	B
expression	O
.	O

The	O
transcriptional	O
start	O
site	O
of	O
spo0H	B
was	O
determined	O
by	O
using	O
RNA	O
made	O
in	O
vivo	O
as	O
well	O
as	O
in	O
vitro	O
.	O

These	O
studies	O
indicate	O
that	O
spo0H	B
is	O
transcribed	O
by	O
the	O
major	O
vegetative	O
RNA	B
polymerase	I
,	O
E	B
sigma	I
A	I
.	O
spo0H	B
RNA	O
and	O
sigma	B
H	I
levels	O
during	O
growth	O
are	O
not	O
identical	O
to	O
each	O
other	O
or	O
to	O
the	O
pattern	O
of	O
expression	O
of	O
spoVG	B
,	O
a	O
gene	O
transcribed	O
by	O
E	B
sigma	I
H	I
.	O

This	O
suggests	O
that	O
spo0H	B
is	O
regulated	O
posttranscriptionally	O
and	O
also	O
that	O
factors	O
in	O
addition	O
to	O
sigma	B
H	I
levels	O
are	O
involved	O
in	O
the	O
expression	O
of	O
genes	O
of	O
the	O
E	B
sigma	I
H	I
regulon	O
.	O

Deletion	O
of	O
spoIIAB	B
blocks	O
endospore	O
formation	O
in	O
Bacillus	O
subtilis	O
at	O
an	O
early	O
stage	O
.	O

During	O
an	O
early	O
stage	O
of	O
endospore	O
formation	O
in	O
Bacillus	O
subtilis	O
,	O
the	O
cell	O
divides	O
asymmetrically	O
into	O
two	O
compartments	O
that	O
follow	O
different	O
developmental	O
paths	O
.	O

The	O
differential	O
expression	O
of	O
genes	O
in	O
these	O
two	O
compartments	O
is	O
controlled	O
in	O
part	O
by	O
the	O
production	O
of	O
compartment	O
-	O
specific	O
transcription	O
factors	O
,	O
sigma	B
G	I
and	O
sigma	B
K	I
.	O

It	O
is	O
not	O
known	O
how	O
sigma	B
G	I
accumulation	O
is	O
restricted	O
to	O
one	O
of	O
the	O
two	O
compartments	O
,	O
the	O
forespore	O
.	O

However	O
,	O
the	O
observations	O
that	O
sigma	B
F	I
directs	O
transcription	O
of	O
the	O
structural	O
gene	O
for	O
sigma	B
G	I
and	O
that	O
sigma	B
F	I
activity	O
can	O
be	O
modified	O
by	O
the	O
product	O
of	O
a	O
gene	O
,	O
spoIIAB	B
,	O
has	O
led	O
us	O
to	O
investigate	O
the	O
role	O
of	O
spoIIAB	B
during	O
sporulation	O
.	O

We	O
have	O
isolated	O
mutants	O
that	O
carry	O
deletion	O
alleles	O
of	O
spoIIAB	B
.	O

Electron	O
microscopic	O
examination	O
of	O
these	O
mutants	O
revealed	O
that	O
these	O
mutations	O
blocked	O
endospore	O
formation	O
at	O
an	O
early	O
stage	O
before	O
septation	O
and	O
caused	O
extensive	O
cell	O
lysis	O
.	O

The	O
spoIIAB	B
deletion	O
alleles	O
caused	O
hyperexpression	O
of	O
genes	O
that	O
are	O
normally	O
expressed	O
exclusively	O
in	O
the	O
forespore	O
compartments	O
of	O
sporulating	O
wild	O
-	O
type	O
cells	O
,	O
whereas	O
these	O
alleles	O
reduced	O
expression	O
of	O
other	O
genes	O
,	O
including	O
spoIIE	B
,	O
which	O
is	O
expressed	O
before	O
septation	O
in	O
wild	O
-	O
type	O
cells	O
.	O

These	O
observations	O
confirm	O
that	O
spoIIAB	B
is	O
essential	O
for	O
sporulation	O
and	O
are	O
consistent	O
with	O
models	O
in	O
which	O
the	O
product	O
of	O
spoIIAB	B
plays	O
a	O
role	O
in	O
regulating	O
the	O
timing	O
and/or	O
compartment	O
specificity	O
of	O
sigma	B
F	I
-	O
and	O
sigma	B
G	I
-	O
directed	O
transcription	O
.	O

Genetic	O
evidence	O
that	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
A	I
factor	I
uses	O
a	O
sporulation	O
-	O
specific	O
promoter	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
construction	O
of	O
allele	O
-	O
specific	O
suppressor	O
mutations	O
has	O
enabled	O
us	O
to	O
demonstrate	O
that	O
a	O
sporulation	O
-	O
specific	O
transcription	O
unit	O
in	O
Bacillus	O
subtilis	O
,	O
the	O
spoIIG	B
operon	I
,	O
is	O
transcribed	O
by	O
a	O
form	O
of	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
A	I
,	O
the	O
principal	O
sigma	B
factor	I
in	O
vegetative	O
cells	O
.	O

The	O
spoIIG	B
operon	I
encodes	O
sporulation	O
-	O
specific	O
factor	O
sigma	B
E	I
,	O
and	O
its	O
transcription	O
is	O
directed	O
from	O
a	O
promoter	O
that	O
is	O
activated	O
about	O
1	O
hr	O
after	O
the	O
onset	O
of	O
endospore	O
formation	O
.	O

This	O
promoter	O
contains	O
sequences	O
that	O
are	O
similar	O
to	O
those	O
found	O
at	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
of	O
promoters	O
that	O
are	O
used	O
by	O
sigma	B
A	I
-	O
associated	O
RNA	B
polymerase	I
,	O
but	O
these	O
sigma	B
A	I
-	O
like	O
recognition	O
sequences	O
are	O
separated	O
by	O
22	O
base	O
pairs	O
rather	O
than	O
the	O
typical	O
17	O
or	O
18	O
base	O
pairs	O
.	O

We	O
have	O
found	O
that	O
substitution	O
of	O
an	O
arginyl	O
residue	O
for	O
the	O
glutamyl	O
residue	O
at	O
position	O
196	O
of	O
sigma	B
A	I
(	O
Glu-196	O
-	O
---	O
Arg	O
)	O
suppresses	O
the	O
deleterious	O
effect	O
of	O
a	O
thymidine	O
-	O
to	O
-	O
cytidine	O
base	O
substitution	O
at	O
position	O
-	O
11	O
in	O
the	O
spoIIG	B
promoter	O
.	O

This	O
suppression	O
was	O
allele	O
-	O
specific	O
,	O
since	O
it	O
did	O
not	O
suppress	O
the	O
effects	O
of	O
base	O
substitutions	O
in	O
other	O
positions	O
in	O
the	O
spoIIG	B
promoter	O
or	O
the	O
effects	O
of	O
a	O
thymidine	O
-	O
to	O
-	O
guanosine	O
change	O
at	O
-	O
11	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
a	O
form	O
of	O
RNA	B
polymerase	I
containing	O
sigma	B
A	I
is	O
utilized	O
in	O
an	O
unusual	O
manner	O
to	O
activate	O
the	O
transcription	O
of	O
the	O
spoIIG	B
operon	I
well	O
after	O
the	O
onset	O
of	O
endospore	O
formation	O
.	O

rpoD	B
operon	O
promoter	O
used	O
by	O
sigma	B
H	I
-	O
RNA	B
polymerase	I
in	O
Bacillus	O
subtilis	O
.	O

Three	O
promoters	O
direct	O
transcription	O
of	O
the	O
sigA	B
(	O
rpoD	B
)	O
operon	O
in	O
Bacillus	O
subtilis	O
.	O

Promoters	O
P1	O
and	O
P2	O
are	O
used	O
during	O
the	O
exponential	O
growth	O
phase	O
,	O
whereas	O
P3	O
is	O
used	O
only	O
during	O
the	O
stationary	O
phase	O
.	O

We	O
examined	O
the	O
use	O
of	O
these	O
promoters	O
in	O
promoter	O
-	O
probe	O
plasmids	O
and	O
found	O
that	O
expression	O
from	O
P3	O
was	O
prevented	O
by	O
a	O
mutation	O
in	O
spoOH	B
,	O
which	O
encodes	O
the	O
secondary	O
RNA	B
polymerase	I
sigma	I
factor	I
sigma	B
H	I
.	O

Moreover	O
,	O
we	O
found	O
that	O
sigma	B
H	I
-	O
containing	O
RNA	B
polymerase	I
efficiently	O
and	O
accurately	O
used	O
the	O
P3	O
promoter	O
in	O
vitro	O
.	O

Evidently	O
,	O
this	O
operon	O
,	O
which	O
is	O
essential	O
for	O
exponential	O
growth	O
,	O
is	O
transcribed	O
during	O
the	O
early	O
phase	O
of	O
sporulation	O
by	O
this	O
secondary	O
form	O
of	O
RNA	B
polymerase	I
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
of	O
the	O
P3	O
promoter	O
and	O
the	O
spoVG	B
promoter	O
,	O
which	O
also	O
is	O
used	O
by	O
sigma	B
H	I
-	O
RNA	O
polymerase	O
,	O
revealed	O
sequences	O
at	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
of	O
these	O
promoters	O
that	O
may	O
signal	O
recognition	O
of	O
promoters	O
by	O
sigma	B
H	I
-	O
RNA	B
polymerase	I
.	O

The	O
human	O
natural	O
killer	O
cell	O
receptor	O
for	O
major	B
histocompatibility	I
complex	I
class	I
I	I
molecules	O
.	O

Surface	O
modulation	O
of	O
p58	B
molecules	O
and	O
their	O
linkage	O
to	O
CD3	B
zeta	I
chain	O
,	O
Fc	B
epsilon	I
RI	I
gamma	I
chain	O
and	O
the	O
p56lck	B
kinase	B
.	O

The	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
-	O
specific	O
p58	B
surface	O
molecules	O
,	O
recognized	O
by	O
the	O
GL183	B
and	O
EB6	B
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
,	O
have	O
been	O
shown	O
to	O
represent	O
the	O
putative	O
NK	O
receptor	O
for	O
HLA	B
-	I
C	I
molecules	O
.	O

The	O
interaction	O
between	O
p58	B
receptors	O
and	O
HLA	B
-	I
C	I
results	O
in	O
inhibition	O
of	O
the	O
NK	O
-	O
mediated	O
target	O
cell	O
lysis	O
.	O

In	O
this	O
study	O
,	O
GL183	B
-	O
EB6	B
+	O
clones	O
(	O
Cw4	B
-	O
specific	O
)	O
,	O
after	O
mAb	O
-	O
induced	O
surface	O
modulation	O
of	O
EB6	B
molecules	O
,	O
acquired	O
the	O
ability	O
to	O
lyse	O
the	O
Cw4	B
+	O
C1R	O
cells	O
.	O

In	O
NK	O
clones	O
co	O
-	O
expressing	O
both	O
GL183	B
and	O
EB6	B
molecules	O
and	O
unable	O
to	O
kill	O
Cw3	B
-	O
protected	O
target	O
cells	O
,	O
the	O
mAb	O
-	O
induced	O
modulation	O
of	O
EB6	B
molecules	O
resulted	O
both	O
in	O
selective	O
co	O
-	O
modulation	O
of	O
GL183	B
molecules	O
and	O
in	O
the	O
lysis	O
of	O
Cw3	B
-	O
transfected	O
P815	O
murine	O
cells	O
.	O

In	O
line	O
with	O
the	O
co	O
-	O
modulation	O
experiments	O
we	O
also	O
show	O
that	O
the	O
GL183	B
and	O
EB6	B
molecules	O
can	O
be	O
co	O
-	O
immunoprecipitated	O
from	O
GL183	B
+	O
/	O
EB6	B
+	O
clones	O
after	O
cell	O
lysis	O
in	O
the	O
presence	O
of	O
digitonin	O
.	O

The	O
p58	B
receptor	O
also	O
revealed	O
an	O
association	O
with	O
molecules	O
belonging	O
to	O
the	O
zeta	B
family	I
(	O
i.e.	O
CD3	B
zeta	I
and	O
Fc	B
epsilon	I
RI	I
gamma	I
chains	O
)	O
.	O

Two	O
-	O
dimensional	O
diagonal	O
gel	O
analysis	O
of	O
the	O
p58	B
complex	O
immunoprecipitated	O
from	O
polyclonally	O
activated	O
p58	B
+	O
NK	O
cells	O
indicated	O
a	O
preferential	O
association	O
with	O
CD3	B
zeta	I
chains	O
either	O
in	O
the	O
form	O
of	O
covalently	O
linked	O
zeta	O
-	O
zeta	O
homodimers	O
or	O
in	O
the	O
form	O
of	O
zeta	O
-	O
gamma	O
heterodimers	O
,	O
while	O
gamma	O
-	O
gamma	O
homodimers	O
were	O
detectable	O
in	O
low	O
amounts	O
.	O

However	O
,	O
p58	B
+	O
clones	O
displaying	O
a	O
unique	O
association	O
with	O
gamma	O
-	O
gamma	O
homodimers	O
could	O
also	O
be	O
isolated	O
.	O

Probing	O
the	O
immunoprecipitated	O
p58	B
complex	O
with	O
anti	O
-	O
p56lck	B
antibody	O
also	O
revealed	O
an	O
association	O
with	O
this	O
member	O
of	O
the	O
src	B
family	I
.	O

In	O
addition	O
,	O
mAb	O
-	O
mediated	O
signaling	O
of	O
NK	O
clones	O
via	O
p58	B
molecules	O
induced	O
increments	O
of	O
p58	B
/	O
p56lck	B
association	O
.	O

However	O
,	O
under	O
the	O
same	O
experimental	O
conditions	O
that	O
induced	O
optimal	O
in	O
vivo	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD16	B
-	O
associated	O
CD3	B
zeta	I
chains	O
,	O
no	O
tyrosine	O
phosphorylation	O
was	O
detected	O
in	O
the	O
p58	B
-	O
associated	O
CD3	B
zeta	I
chains	O
.	O

In	O
these	O
in	O
vivo	O
experiments	O
neither	O
anti	O
-	O
CD16	B
nor	O
anti	O
-	O
p58	B
mAb	O
could	O
induce	O
tyrosine	O
phosphorylation	O
of	O
the	O
gamma	O
chains	O
.	O

Finally	O
,	O
the	O
anti	O
-	O
p58	B
-	O
mediated	O
inhibition	O
of	O
the	O
NK	O
cell	O
triggering	O
via	O
CD16	B
molecules	O
was	O
not	O
accompanied	O
by	O
a	O
down	O
-	O
regulation	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD16	B
-	O
associated	O
CD3	B
zeta	I
chains	O
.	O

Molecular	O
clones	O
of	O
the	O
p58	B
NK	O
cell	O
receptor	O
reveal	O
immunoglobulin	B
-	O
related	O
molecules	O
with	O
diversity	O
in	O
both	O
the	O
extra	O
-	O
and	O
intracellular	O
domains	O
.	O

Recognition	O
of	O
major	B
histocompatibility	I
class	I
I	I
molecules	O
on	O
target	O
cells	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
confers	O
selective	O
protection	O
from	O
NK	O
-	O
mediated	O
lysis	O
.	O

Cross	O
-	O
linking	O
of	O
the	O
p58	B
NK	O
receptor	O
,	O
involved	O
in	O
the	O
recognition	O
of	O
HLA	B
-	I
C	I
alleles	O
,	O
delivers	O
a	O
negative	O
signal	O
that	O
prevents	O
target	O
cell	O
lysis	O
.	O

Molecular	O
cloning	O
of	O
the	O
p58	B
NK	O
receptor	O
reported	O
here	O
revealed	O
a	O
new	O
member	O
of	O
the	O
immunoglobulin	B
superfamily	I
.	O

Five	O
distinct	O
p58	B
receptors	O
,	O
with	O
sequence	O
diversity	O
in	O
the	O
immunoglobulin	B
-	O
related	O
domains	O
,	O
were	O
identified	O
in	O
a	O
single	O
individual	O
.	O

All	O
NK	O
clones	O
tested	O
expressed	O
at	O
least	O
one	O
p58	B
member	O
.	O

Three	O
different	O
types	O
of	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
exist	O
,	O
even	O
among	O
receptors	O
with	O
closely	O
related	O
extracellular	O
domains	O
.	O

These	O
data	O
revealed	O
a	O
repertoire	O
of	O
NK	O
cells	O
with	O
clonally	O
distributed	O
p58	B
receptors	O
exhibiting	O
diversity	O
in	O
both	O
extracellular	O
and	O
intracellular	O
domains	O
.	O

Cell	O
-	O
cell	O
signaling	O
pathway	O
activating	O
a	O
developmental	O
transcription	B
factor	I
in	O
Bacillus	O
subtilis	O
.	O

Transcription	O
in	O
the	O
mother	O
cell	O
at	O
early	O
stages	O
of	O
sporulation	O
in	O
Bacillus	O
subtilis	O
is	O
controlled	O
by	O
sigma	B
E	I
,	O
a	O
sigma	B
factor	I
that	O
is	O
synthesized	O
in	O
the	O
predivisional	O
cell	O
as	O
an	O
inactive	O
larger	O
precursor	O
,	O
pro	O
-	O
sigma	B
E	I
.	O

Activation	O
of	O
sigma	B
E	I
depends	O
on	O
sigma	B
F	I
,	O
the	O
factor	O
that	O
governs	O
transcription	O
in	O
the	O
forespore	O
.	O

Genetic	O
experiments	O
have	O
indicated	O
that	O
transduction	O
of	O
the	O
activation	O
signal	O
from	O
the	O
forespore	O
to	O
the	O
mother	O
cell	O
requires	O
the	O
products	O
of	O
some	O
genes	O
belonging	O
to	O
the	O
sigma	B
F	I
-	O
controlled	O
regulon	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
sigma	B
F	I
-	O
dependent	O
gene	O
,	O
csfX	B
,	O
encoding	O
a	O
protein	O
necessary	O
and	O
sufficient	O
for	O
triggering	O
processing	O
of	O
pro	O
-	O
sigma	B
E	I
.	O

The	O
CsfX	B
protein	O
contains	O
a	O
typical	O
amino	O
-	O
terminal	O
signal	O
sequence	O
suggesting	O
that	O
,	O
although	O
synthesized	O
in	O
the	O
forespore	O
,	O
it	O
may	O
act	O
across	O
the	O
septum	O
to	O
activate	O
the	O
membrane	O
-	O
bound	O
enzyme	O
that	O
is	O
responsible	O
for	O
pro	O
-	O
sigma	B
E	I
processing	O
in	O
the	O
mother	O
cell	O
.	O

Evidence	O
that	O
the	O
spoIIM	B
gene	O
of	O
Bacillus	O
subtilis	O
is	O
transcribed	O
by	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
E	I
.	O

We	O
have	O
investigated	O
the	O
temporal	O
and	O
spatial	O
regulation	O
of	O
spoIIM	B
,	O
a	O
gene	O
of	O
Bacillus	O
subtilis	O
whose	O
product	O
is	O
required	O
for	O
complete	O
septum	O
migration	O
and	O
engulfment	O
of	O
the	O
forespore	O
compartment	O
during	O
sporulation	O
.	O

The	O
spoIIM	B
promoter	O
was	O
found	O
to	O
become	O
active	O
about	O
2	O
h	O
after	O
the	O
initiation	O
of	O
sporulation	O
.	O

The	O
effects	O
of	O
mutations	O
on	O
the	O
expression	O
of	O
a	O
spoIIM	B
-	O
lacZ	B
fusion	O
were	O
most	O
consistent	O
with	O
its	O
utilization	O
by	O
sigma	B
-	I
E	I
-	O
associated	O
RNA	B
polymerase	I
(	O
E	B
sigma	I
E	I
)	O
.	O

A	O
unique	O
5	O
'	O
end	O
of	O
the	O
in	O
vivo	O
spoIIM	B
transcript	O
was	O
detected	O
by	O
primer	O
extension	O
analysis	O
and	O
was	O
determined	O
to	O
initiate	O
at	O
the	O
appropriate	O
distance	O
from	O
a	O
sequence	O
conforming	O
very	O
closely	O
to	O
the	O
consensus	O
for	O
genes	O
transcribed	O
by	O
E	B
sigma	I
E	I
.	O

A	O
partially	O
purified	O
preparation	O
of	O
E	B
sigma	I
E	I
produced	O
a	O
transcript	O
in	O
vitro	O
that	O
initiated	O
at	O
the	O
same	O
nucleotide	O
as	O
the	O
primer	O
extension	O
product	O
generated	O
from	O
in	O
vivo	O
RNA	O
.	O

Ectopic	O
induction	O
of	O
sigma	B
E	I
synthesis	O
during	O
growth	O
resulted	O
in	O
the	O
immediate	O
and	O
strong	O
expression	O
of	O
a	O
spoIIM	B
-	O
lacZ	B
fusion	O
,	O
but	O
an	O
identical	O
fusion	O
was	O
completely	O
unresponsive	O
to	O
induced	O
synthesis	O
of	O
either	O
sigma	B
F	I
or	O
sigma	B
G	I
under	O
similar	O
conditions	O
.	O

The	O
results	O
of	O
plasmid	O
integration	O
-	O
excision	O
experiments	O
in	O
which	O
the	O
spoIIM	B
gene	O
was	O
reversibly	O
disrupted	O
by	O
a	O
temperature	O
-	O
sensitive	O
integrational	O
vector	O
suggested	O
that	O
spoIIM	B
expression	O
is	O
required	O
in	O
the	O
forespore	O
compartment	O
,	O
but	O
direct	O
examination	O
of	O
subcellular	O
fractions	O
enriched	O
for	O
mother	O
cell	O
or	O
forespore	O
material	O
indicated	O
that	O
spoIIM	B
expression	O
can	O
not	O
be	O
confined	O
to	O
the	O
forespore	O
.	O

We	O
conclude	O
that	O
spoIIM	B
is	O
a	O
member	O
of	O
the	O
sigma	B
E	I
regulon	O
and	O
that	O
it	O
may	O
be	O
transcribed	O
exclusively	O
by	O
E	B
sigma	I
E	I
.	O

We	O
discuss	O
the	O
implications	O
of	O
this	O
conclusion	O
for	O
models	O
in	O
which	O
activation	O
of	O
sigma	B
E	I
in	O
the	O
mother	O
cell	O
is	O
proposed	O
to	O
be	O
a	O
part	O
of	O
the	O
mechanism	O
responsible	O
for	O
initiating	O
separate	O
programs	O
of	O
gene	O
activity	O
in	O
the	O
two	O
sporangium	O
compartments	O
.	O

Bacillus	O
subtilis	O
SpoIIID	B
protein	O
binds	O
to	O
two	O
sites	O
in	O
the	O
spoVD	B
promoter	O
and	O
represses	O
transcription	O
by	O
sigmaE	B
RNA	B
polymerase	I
.	O

The	O
Bacillus	O
subtilis	O
spoVD	B
gene	O
encodes	O
a	O
penicillin	O
-	O
binding	O
protein	O
required	O
for	O
spore	O
morphogenesis	O
.	O

SpoIIID	B
is	O
a	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
that	O
activates	O
or	O
represses	O
the	O
transcription	O
of	O
many	O
different	O
genes	O
.	O

We	O
have	O
defined	O
the	O
spoVD	B
promoter	O
region	O
and	O
demonstrated	O
that	O
it	O
is	O
recognized	O
by	O
sigmaE	B
RNA	B
polymerase	I
in	O
vitro	O
and	O
that	O
SpoIIID	B
represses	O
spoVD	B
transcription	O
.	O

Two	O
strong	O
SpoIIID	B
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
spoVD	B
promoter	O
region	O
,	O
one	O
overlapping	O
the	O
-	O
35	O
region	O
and	O
the	O
other	O
encompassing	O
the	O
-	O
10	O
region	O
and	O
the	O
transcriptional	O
start	O
site	O
.	O

Genomic	O
organization	O
and	O
allelic	O
polymorphism	O
of	O
the	O
human	O
killer	O
cell	O
inhibitory	O
receptor	O
gene	O
KIR103	B
.	O

Killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIR	B
)	O
belong	O
to	O
the	O
immunoglobulin	B
superfamily	I
of	O
molecules	O
and	O
are	O
expressed	O
on	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

The	O
KIRs	B
of	O
the	O
p58	B
/	I
p50	I
family	I
have	O
two	O
immunoglobulin	B
domains	O
and	O
are	O
ligands	O
for	O
HLA	B
-	I
Cw	I
antigens	O
,	O
whereas	O
the	O
p70	B
/	I
p70	I
delta	I
family	I
has	O
three	O
immunoglobulin	B
domains	O
and	O
comprises	O
ligands	O
for	O
HLA	B
-	I
B	I
antigens	O
and	O
possibly	O
some	O
HLA	B
-	I
A	I
antigens	O
.	O

Members	O
of	O
a	O
third	O
KIR	B
family	I
,	O
KIR103	B
,	O
have	O
two	O
immunoglobulin	B
domains	O
but	O
have	O
highest	O
nucleotide	O
sequence	O
homology	O
to	O
the	O
p70	B
family	I
.	O

The	O
ligands	O
for	O
KIR103	B
on	O
target	O
cells	O
are	O
currently	O
unknown	O
.	O

We	O
here	O
report	O
the	O
complete	O
genomic	O
organization	O
of	O
KIR103	B
.	O

It	O
spans	O
about	O
12	O
kb	O
of	O
DNA	O
and	O
consists	O
of	O
eight	O
exons	O
of	O
which	O
exon	O
1	O
and	O
exon	O
2	O
encode	O
the	O
leader	O
sequence	O
.	O

Exon	O
3	O
encodes	O
the	O
first	O
immunoglobulin	B
domain	O
(	O
gamma	O
1	O
)	O
,	O
and	O
exon	O
4	O
encodes	O
the	O
main	O
part	O
of	O
the	O
second	O
immunoglobulin	B
domain	O
(	O
gamma	O
3	O
)	O
,	O
which	O
also	O
contains	O
sequences	O
contributed	O
by	O
exon	O
5	O
and	O
exon	O
6	O
.	O

Exon	O
6	O
encodes	O
the	O
transmembrane	O
domain	O
,	O
whereas	O
exons	O
7	O
and	O
8	O
encode	O
most	O
of	O
the	O
cytoplasmic	O
domain	O
.	O

KIR103	B
is	O
polymorphic	O
,	O
and	O
two	O
alleles	O
,	O
103AS	B
and	O
103LP	B
,	O
are	O
defined	O
in	O
this	O
study	O
.	O

Additional	O
full	O
-	O
length	O
cDNA	O
clones	O
for	O
KIR103	B
have	O
been	O
isolated	O
and	O
are	O
shown	O
to	O
be	O
formed	O
by	O
alternative	O
mRNA	O
splicing	O
with	O
exon	O
skipping	O
.	O

Some	O
of	O
these	O
truncated	O
KIR103	B
cDNA	O
could	O
encode	O
shorter	O
transmembrane	O
molecules	O
,	O
whereas	O
others	O
lack	O
the	O
transmembrane	O
domain	O
and	O
are	O
candidate	O
genes	O
for	O
secreted	O
KIR	B
products	O
.	O

KIR103	B
is	O
localized	O
to	O
the	O
KIR	B
genetic	O
region	O
on	O
chromosome	O
19q13.4	O
.	O

Identification	B
and	O
characterization	O
of	O
sporulation	O
-	O
dependent	O
promoters	O
upstream	O
of	O
the	O
enterotoxin	B
gene	O
(	O
cpe	B
)	O
of	O
Clostridium	O
perfringens	O
.	O

Three	O
promoter	O
sites	O
(	O
P1	O
,	O
P2	O
,	O
and	O
P3	O
)	O
responsible	O
for	O
the	O
sporulation	O
-	O
associated	O
synthesis	O
of	O
Clostridium	O
perfringens	O
enterotoxin	B
,	O
a	O
common	O
cause	O
of	O
food	O
poisoning	O
in	O
humans	O
and	O
animals	O
,	O
were	O
identified	O
.	O

Nested	O
and	O
internal	O
deletions	O
of	O
the	O
cpe	O
promoter	O
region	O
were	O
made	O
to	O
narrow	O
down	O
the	O
location	O
of	O
promoter	O
elements	O
.	O

To	O
measure	O
the	O
effects	O
of	O
the	O
deletions	O
on	O
the	O
expression	O
of	O
cpe	B
,	O
translational	O
fusions	O
containing	O
the	O
promoter	O
deletions	O
were	O
made	O
with	O
the	O
gusA	B
gene	O
of	O
Escherichia	O
coli	O
,	O
which	O
codes	O
for	O
beta	B
-	I
glucuronidase	I
;	O
E.	O
coli	O
-	O
C.	O
perfringens	O
shuttle	O
vectors	O
carrying	O
the	O
fusions	O
were	O
introduced	O
into	O
C.	O
perfringens	O
by	O
electroporation	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
transcription	O
assays	O
were	O
performed	O
with	O
the	O
cpe	O
promoter	O
region	O
as	O
the	O
DNA	O
template	O
for	O
extracts	O
made	O
from	O
sporulating	O
cells	O
.	O

SigE	B
and	O
SigK	B
are	O
sporulation	O
-	O
associated	O
sigma	B
factors	I
known	O
to	O
be	O
active	O
in	O
the	O
mother	O
cell	O
compartment	O
of	O
sporulating	O
cells	O
of	O
Bacillus	O
subtilis	O
,	O
the	O
same	O
compartment	O
in	O
which	O
enterotoxin	B
is	O
synthesized	O
in	O
C.	O
perfringens	O
.	O

Human	O
EZF	B
,	O
a	O
KrÃ?Â¼ppel	B
-	I
like	I
zinc	I
finger	I
protein	I
,	O
is	O
expressed	O
in	O
vascular	O
endothelial	O
cells	O
and	O
contains	O
transcriptional	O
activation	O
and	O
repression	O
domains	O
.	O

Members	O
of	O
the	O
erythroid	O
KrÃ?Â¼ppel	B
-	I
like	I
factor	I
(	I
EKLF	I
)	I
multigene	I
family	I
contain	O
three	O
C	O
-	O
terminal	O
zinc	O
fingers	O
,	O
and	O
they	O
are	O
typically	O
expressed	O
in	O
a	O
limited	O
number	O
of	O
tissues	O
.	O

EKLF	B
,	O
the	O
founding	O
member	O
,	O
transactivates	O
the	O
beta	B
-	I
globin	I
promoter	O
by	O
binding	O
to	O
the	O
CACCC	O
motif	O
.	O

EKLF	B
is	O
essential	O
for	O
expression	O
of	O
the	O
beta	B
-	I
globin	I
gene	O
as	O
demonstrated	O
by	O
gene	O
deletion	O
experiments	O
in	O
mice	O
.	O

Using	O
a	O
DNA	O
probe	O
from	O
the	O
zinc	O
finger	O
region	O
of	O
EKLF	B
,	O
we	O
cloned	O
a	O
cDNA	O
encoding	O
a	O
member	O
of	O
this	O
family	O
from	O
a	O
human	O
vascular	O
endothelial	O
cell	O
cDNA	O
library	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
our	O
clone	O
,	O
hEZF	B
,	O
is	O
the	O
human	O
homologue	O
of	O
the	O
recently	O
reported	O
mouse	O
EZF	B
and	O
GKLF	B
.	O

hEZF	B
is	O
a	O
single	O
-	O
copy	O
gene	O
that	O
maps	O
to	O
chromosome	O
9q31	O
.	O

By	O
gel	O
mobility	O
shift	O
analysis	O
,	O
purified	O
recombinant	O
hEZF	B
protein	O
bound	O
specifically	O
to	O
a	O
probe	O
containing	O
the	O
CACCC	O
core	O
sequence	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
found	O
that	O
sense	O
but	O
not	O
antisense	O
hEZF	B
decreased	O
the	O
activity	O
of	O
a	O
reporter	O
plasmid	O
containing	O
the	O
CACCC	O
sequence	O
upstream	O
of	O
the	O
thymidine	B
kinase	I
promoter	O
by	O
6	O
-	O
fold	O
.	O

In	O
contrast	O
,	O
EKLF	B
increased	O
the	O
activity	O
of	O
the	O
reporter	O
plasmid	O
by	O
3	O
-	O
fold	O
.	O

By	O
fusing	O
hEZF	B
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
GAL4	B
,	O
we	O
mapped	O
a	O
repression	O
domain	O
in	O
hEZF	B
to	O
amino	O
acids	O
181	O
-	O
388	O
.	O

We	O
also	O
found	O
that	O
amino	O
acids	O
91	O
-	O
117	O
of	O
hEZF	B
confer	O
an	O
activation	O
function	O
on	O
the	O
GAL4	B
DNA	O
-	O
binding	O
domain	O
.	O

Role	O
of	O
Pho	B
-	I
P	I
in	O
transcriptional	O
regulation	O
of	O
genes	O
involved	O
in	O
cell	O
wall	O
anionic	O
polymer	O
biosynthesis	O
in	O
Bacillus	O
subtilis	O
.	O

tagA	B
,	O
tagD	B
,	O
and	O
tuaA	B
operons	O
are	O
responsible	O
for	O
the	O
synthesis	O
of	O
cell	O
wall	O
anionic	O
polymer	O
,	O
teichoic	O
acid	O
,	O
and	O
teichuronic	O
acid	O
,	O
respectively	O
,	O
in	O
Bacillus	O
subtilis	O
.	O

Under	O
phosphate	O
starvation	O
conditions	O
,	O
teichuronic	O
acid	O
is	O
synthesized	O
while	O
teichoic	O
acid	O
synthesis	O
is	O
inhibited	O
.	O

Expression	O
of	O
these	O
genes	O
is	O
controlled	O
by	O
PhoP	B
-	O
PhoR	B
,	O
a	O
two	O
-	O
component	O
system	O
.	O

It	O
has	O
been	O
proposed	O
that	O
Pho	B
-	I
P	I
plays	O
a	O
key	O
role	O
in	O
the	O
activation	O
of	O
tuaA	B
and	O
the	O
repression	O
of	O
tagA	B
and	O
tagD	B
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
the	O
role	O
of	O
Pho	B
-	I
P	I
in	O
the	O
switch	O
process	O
from	O
teichoic	O
acid	O
synthesis	O
to	O
teichuronic	O
acid	O
synthesis	O
,	O
by	O
using	O
an	O
in	O
vitro	O
transcription	O
system	O
.	O

The	O
results	O
indicate	O
that	O
PhoP	B
approximately	O
P	O
is	O
sufficient	O
to	O
repress	O
the	O
transcription	O
of	O
the	O
tagA	B
and	O
tagD	B
promoters	O
and	O
also	O
to	O
activate	O
the	O
transcription	O
of	O
the	O
tuaA	B
promoter	O
.	O

Interaction	O
of	O
human	O
suppressor	B
of	I
cytokine	I
signaling	I
(	I
SOCS	I
)	I
-	I
2	I
with	O
the	O
insulin	B
-	I
like	I
growth	I
factor	I
-	I
I	I
receptor	I
.	O

SOCS	B
(	O
suppressor	B
of	I
cytokine	I
signaling	I
)	O
proteins	O
have	O
been	O
shown	O
to	O
be	O
negative	O
regulators	O
of	O
cytokine	B
receptor	I
signaling	O
via	O
the	O
Janus	B
kinase	I
(	O
JAK	B
)	O
/	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT	B
)	O
pathway	O
.	O

We	O
have	O
cloned	O
a	O
member	O
of	O
this	O
family	O
(	O
hSOCS-2	B
)	O
by	O
utilizing	O
the	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
receptor	I
(	O
IGF	B
-	I
IR	I
)	O
cytoplasmic	O
domain	O
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
of	O
a	O
human	O
fetal	O
brain	O
library	O
.	O

The	O
hSOCS-2	B
protein	O
interacted	O
strongly	O
with	O
the	O
activated	O
IGF	B
-	I
IR	I
and	O
not	O
with	O
a	O
kinase	B
negative	O
mutant	O
receptor	O
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

Mutation	O
of	O
receptor	O
tyrosines	O
950	O
,	O
1250	O
,	O
1251	O
,	O
and	O
1316	O
to	O
phenylalanine	O
or	O
deletion	O
of	O
the	O
COOH	O
-	O
terminal	O
93	O
amino	O
acids	O
did	O
not	O
result	O
in	O
decreased	O
interaction	O
of	O
the	O
receptor	O
with	O
hSOCS-2	B
protein	O
.	O

hSOCS-1	B
protein	O
also	O
interacted	O
strongly	O
with	O
IGF	B
-	I
IR	I
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

Glutathione	O
S	O
-	O
transferase	O
-	O
hSOCS-2	B
associated	O
with	O
activated	O
IGF	B
-	I
IR	I
in	O
lysates	O
of	O
mouse	O
fibroblasts	O
overexpressing	O
IGF	B
-	I
IR	I
.	O

Human	O
embryonic	O
kidney	O
cells	O
(	O
293	O
)	O
were	O
transiently	O
transfected	O
with	O
vectors	O
containing	O
IGF	B
-	I
IR	I
and	O
FLAG	O
epitope	O
-	O
tagged	O
hSOCS-2	B
.	O

After	O
IGF	B
-	I
I	I
stimulation	O
,	O
activated	O
IGF	B
-	I
IR	I
was	O
found	O
in	O
anti	O
-	O
FLAG	O
immunoprecipitates	O
and	O
,	O
conversely	O
,	O
FLAG	O
-	O
hSOCS-2	B
was	O
found	O
in	O
anti	O
IGF	B
-	I
IR	I
immunoprecipitates	O
.	O

Thus	O
,	O
hSOCS-2	B
interacted	O
with	O
IGF	B
-	I
IR	I
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

HSOCS-2	B
mRNA	O
was	O
expressed	O
in	O
many	O
human	O
fetal	O
and	O
adult	O
tissues	O
with	O
particularly	O
high	O
abundance	O
in	O
fetal	O
kidney	O
and	O
adult	O
heart	O
,	O
skeletal	O
muscle	O
,	O
pancreas	O
,	O
and	O
liver	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
SOCS	B
proteins	O
may	O
also	O
play	O
a	O
regulatory	O
role	O
in	O
IGF	B
-	I
I	I
receptor	I
signaling	O
.	O

The	O
yvyD	B
gene	O
of	O
Bacillus	O
subtilis	O
is	O
under	O
dual	O
control	O
of	O
sigmaB	B
and	O
sigmaH	B
.	O

During	O
a	O
search	O
by	O
computer	O
-	O
aided	O
inspection	O
of	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
protein	O
gels	O
for	O
sigmaB	B
-	O
dependent	O
general	O
stress	O
proteins	O
exhibiting	O
atypical	O
induction	O
profiles	O
,	O
a	O
protein	O
initially	O
called	O
Hst23	B
was	O
identified	O
as	O
a	O
product	O
of	O
the	O
yvyD	B
gene	O
of	O
Bacillus	O
subtilis	O
.	O

In	O
addition	O
to	O
the	O
typical	O
sigmaB	B
-	O
dependent	O
,	O
stress	O
-	O
and	O
starvation	O
-	O
inducible	O
pattern	O
,	O
yvyD	B
is	O
also	O
induced	O
in	O
response	O
to	O
amino	O
acid	O
depletion	O
.	O

By	O
primer	O
extension	O
of	O
RNA	O
isolated	O
from	O
the	O
wild	O
-	O
type	O
strain	O
and	O
appropriate	O
mutants	O
carrying	O
mutations	O
in	O
the	O
sigB	B
and/or	O
spo0H	B
gene	O
,	O
two	O
promoters	O
were	O
mapped	O
upstream	O
of	O
the	O
yvyD	B
gene	O
.	O

The	O
sigmaB	B
-	O
dependent	O
promoter	O
drives	O
expression	O
of	O
yvyD	B
under	O
stress	O
conditions	O
and	O
after	O
glucose	O
starvation	O
,	O
whereas	O
a	O
sigmaH	B
-	O
dependent	O
promoter	O
is	O
responsible	O
for	O
yvyD	B
transcription	O
following	O
amino	O
acid	O
limitation	O
.	O

Analysis	O
of	O
Northern	O
blots	O
revealed	O
that	O
yvyD	B
is	O
transcribed	O
monocistronically	O
and	O
confirmed	O
the	O
conclusions	O
drawn	O
from	O
the	O
primer	O
extension	O
experiments	O
.	O

The	O
analysis	O
of	O
the	O
protein	O
synthesis	O
pattern	O
in	O
amino	O
acid	O
-	O
starved	O
wild	O
-	O
type	O
and	O
relA	B
mutant	O
cells	O
showed	O
that	O
the	O
YvyD	B
protein	O
is	O
not	O
synthesized	O
in	O
the	O
relA	B
mutant	O
background	O
.	O

It	O
was	O
concluded	O
that	O
the	O
stringent	O
response	O
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
sigmaH	B
.	O

The	O
yvyD	B
gene	O
product	O
is	O
homologous	O
to	O
a	O
protein	O
which	O
might	O
modify	O
the	O
activity	O
of	O
sigma54	B
in	O
gram	O
-	O
negative	O
bacteria	O
.	O

The	O
expression	O
of	O
a	O
sigmaL	B
-	O
dependent	O
(	O
sigmaL	B
is	O
the	O
equivalent	O
of	O
sigma54	B
in	O
B.	O
subtilis	O
)	O
levD	B
-	O
lacZ	B
fusion	O
is	O
upregulated	O
twofold	O
in	O
a	O
yvyD	B
mutant	O
.	O

This	O
indicates	O
that	O
the	O
yvyD	B
gene	O
product	O
,	O
being	O
a	O
member	O
of	O
both	O
the	O
sigmaB	B
and	O
sigmaH	B
regulons	O
,	O
might	O
negatively	O
regulate	O
the	O
activity	O
of	O
the	O
sigmaL	B
regulon	O
.	O

We	O
conclude	O
that	O
(	O
i	O
)	O
systematic	O
,	O
computer	O
-	O
aided	O
analysis	O
of	O
2D	O
protein	O
gels	O
is	O
appropriate	O
for	O
the	O
identification	O
of	O
genes	O
regulated	O
by	O
multiple	O
transcription	B
factors	I
and	O
that	O
(	O
ii	O
)	O
YvyD	B
might	O
form	O
a	O
junction	O
between	O
the	O
sigmaB	B
and	O
sigmaH	B
regulons	O
on	O
one	O
side	O
and	O
the	O
sigmaL	B
regulon	O
on	O
the	O
other	O
.	O

Identification	O
of	O
target	O
promoters	O
for	O
the	O
Bacillus	O
subtilis	O
extracytoplasmic	O
function	O
sigma	B
factor	I
,	O
sigma	B
W	I
.	O

The	O
Bacillus	O
subtilis	O
sigW	B
gene	O
encodes	O
an	O
extracytoplasmic	B
function	I
(	I
ECF	I
)	I
sigma	I
factor	I
that	O
is	O
expressed	O
in	O
early	O
stationary	O
phase	O
from	O
a	O
sigW	B
-	O
dependent	O
autoregulatory	O
promoter	O
,	O
PW	O
.	O

Using	O
a	O
consensus	O
-	O
based	O
search	O
procedure	O
,	O
we	O
have	O
identified	O
15	O
operons	O
preceded	O
by	O
promoters	O
similar	O
in	O
sequence	O
to	O
PW	O
.	O

At	O
least	O
14	O
of	O
these	O
promoters	O
are	O
dependent	O
on	O
sigma	B
W	I
both	O
in	O
vivo	O
and	O
in	O
vitro	O
as	O
judged	O
by	O
lacZ	B
reporter	O
fusions	O
,	O
run	O
-	O
off	O
transcription	O
assays	O
and	O
nucleotide	O
resolution	O
start	O
site	O
mapping	O
.	O

We	O
conclude	O
that	O
sigma	B
W	I
controls	O
a	O
regulon	O
of	O
more	O
than	O
30	O
genes	O
,	O
many	O
of	O
which	O
encode	O
membrane	O
proteins	O
of	O
unknown	O
function	O
.	O

The	O
sigma	B
W	I
regulon	O
includes	O
a	O
penicillin	B
binding	I
protein	I
(	O
PBP4	B
*	I
)	O
and	O
a	O
co	O
-	O
transcribed	O
amino	B
acid	I
racemase	I
(	O
RacX	B
)	O
,	O
homologues	O
of	O
signal	B
peptide	I
peptidase	I
(	O
YteI	B
)	O
,	O
flotillin	B
(	O
YuaG	B
)	O
,	O
ABC	B
transporters	I
(	O
YknXYZ	B
)	O
,	O
non	B
-	I
haem	I
bromoperoxidase	I
(	O
YdjP	B
)	O
,	O
epoxide	B
hydrolase	I
(	O
YfhM	B
)	O
and	O
three	O
small	O
peptides	O
with	O
structural	O
similarities	O
to	O
bacteriocin	B
precursor	O
polypeptides	O
.	O

We	O
suggest	O
that	O
sigma	B
W	I
activates	O
a	O
large	O
stationary	O
-	O
phase	O
regulon	O
that	O
functions	O
in	O
detoxification	O
,	O
production	O
of	O
anti	O
-	O
microbial	O
compounds	O
or	O
both	O
.	O

17-spiromethylene	O
steroids	O
The	O
invention	O
relates	O
to	O
a	O
steroid	O
derivative	O
which	O
steroidal	O
skeleton	O
is	O
bound	O
at	O
carbon	O
atom	O
17	O
to	O
a	O
spiromethylene	O
ring	O
of	O
the	O
formula	O
:	O

<	O
See	O
formula	O
I	O
>	O
wherein	O
R	O
a	O
and	O
R	O
b	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
methyl	O
,	O
and	O
halogen	O
;	O
m	O
is	O
1	O
or	O
2	O
;	O
and	O
the	O
asterisk	O
denotes	O
carbon	O
atom	O
2	O
of	O
the	O
spiromethylene	O
ring	O
which	O
is	O
carbon	O
atom	O
17	O
(	O
or	O
carbon	O
atom	O
17.alpha	O
.	O

of	O
a	O
homosteroid	O
skeleton	O
)	O
of	O
the	O
steroid	O
.	O

The	O
steroids	O
have	O
progestational	O
or	O
antiprogestational	O
activity	O
.	O

Formulations	O
containing	O
coumarins	O
and	O
the	O
use	O
thereof	O
in	O
the	O
pharmaceutical	O
and	O
cosmetic	O
fields	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
coumarins	O
such	O
as	O
esculoside	O
,	O
esculetin	O
,	O
extracts	O
containing	O
them	O
and	O
mixtures	O
thereof	O
,	O
in	O
combination	O
with	O
dimeric	O
and	O
oligomeric	O
proanthocyanidins	O
,	O
in	O
topical	O
formulations	O
for	O
the	O
treatment	O
of	O
peripheral	O
vasculopathies	O
,	O
including	O
the	O
complications	O
of	O
acute	O
venous	O
stasis	O
,	O
or	O
of	O
the	O
unesthetisms	O
related	O
to	O
capillary	O
alterations	O
,	O
or	O
to	O
improve	O
the	O
cicatrization	O
processes	O
.	O

These	O
coumarins	O
,	O
alone	O
or	O
in	O
combination	O
with	O
proanthocyanidins	O
,	O
are	O
also	O
useful	O
in	O
atopical	O
dermatitis	O
and	O
in	O
the	O
treatment	O
of	O
the	O
haematomas	O
.	O

Cosmetic	O
melanins	O
Synthetic	O
melanins	O
suitable	O
for	O
cosmetic	O
uses	O
are	O
produced	O
through	O
oxidative	O
polymerization	O
of	O
monomeric	O
precursors	O
that	O
possess	O
aromatic	O
rings	O
with	O
ionizeable	O
side	O
groups	O
.	O

Agents	O
that	O
enhance	O
adherence	O
of	O
the	O
melanins	O
to	O
skin	O
and	O
hair	O
are	O
co	O
-	O
polymerized	O
with	O
the	O
precursors	O
to	O
become	O
part	O
of	O
the	O
melanin	O
molecules	O
.	O

Potential	O
new	O
precursors	O
and	O
adherence	O
-	O
enhancing	O
agents	O
are	O
screened	O
for	O
efficacy	O
by	O
subjecting	O
them	O
to	O
six	O
separate	O
synthetic	O
procedures	O
,	O
and	O
testing	O
the	O
resulting	O
melanins	O
for	O
color	O
,	O
ultraviolet	O
absorbance	O
charcteristics	O
,	O
and	O
substantivity	O
(	O
adherence	O
)	O
to	O
skin	O
and	O
hair	O
.	O

Melanins	O
of	O
different	O
colors	O
can	O
be	O
blended	O
together	O
in	O
cosmetic	O
creams	O
and	O
lotions	O
to	O
complement	O
the	O
natural	O
skin	O
,	O
eye	O
,	O
and	O
hair	O
colors	O
of	O
an	O
individual	O
.	O

The	O
synthetic	O
procedures	O
are	O
amendable	O
to	O
industrial	O
-	O
scale	O
production	O
of	O
cosmetic	O
melanins	O
.	O

The	O
materials	O
reduce	O
the	O
incidence	O
of	O
solar	O
damage	O
to	O
the	O
skin	O
.	O

Novel	O
silyl	O
compounds	O
and	O
their	O
use	O
The	O
invention	O
describes	O
a	O
process	O
for	O
the	O
epimer	O
enrichment	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
by	O
silylation	O
,	O
fractionated	O
crystallization	O
and	O
acid	O
hydrolysis	O
.	O

Arylalkyl	O
-	O
diazinones	O
Arylalkyl	O
diazinone	O
derivatives	O
of	O
the	O
formula	O

I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
B	O
,	O
Q	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
exhibit	O
phosphodiesterase	O
IV	O
inhibition	O
and	O
can	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
inflammatory	O
processes	O
and	O
also	O
of	O
allergies	O
,	O
asthma	O
and	O
autoimmune	O
disorders	O
.	O

Novel	O
pharmaceutical	O
combination	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
topical	O
administration	O
comprising	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiiflammatory	O
glucocorticoid	O
in	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
in	O
the	O
prophylactic	O
and	O
curative	O
treatment	O
of	O
herpesvirus	O
infections	O
in	O
mammals	O
including	O
man	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiinflammatory	O
glucocorticoid	O
for	O
the	O
manufacture	O
of	O
a	O
midicament	O
for	O
said	O
prophylactic	O
and	O
curative	O
treatment	O
.	O

Substituted	O
indanylidineacetylguanidines	O
,	O
process	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
medicaments	O
or	O
diagnostic	O
and	O
medicaments	O
containing	O
them	O
Indanylidineacetylguanidines	O
I	O

(	O
see	O
formula	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
,	O
are	O
effective	O
inhibitors	O
of	O
the	O
cellular	O
sodium	O
/	O
proton	O
antiport	O
(	O
Na	O
+	O
/H	O
+	O
exchanger	O
)	O
,	O
which	O
,	O
in	O
numerous	O
diseases	O
(	O
essential	O
hypertension	O
,	O
atherosclerosis	O
,	O
diabetes	O
and	O
the	O
like	O
)	O
is	O
also	O
increased	O
in	O
those	O
cells	O
which	O
are	O
readily	O
accessible	O
for	O
measurements	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
in	O
erythrocytes	O
,	O
platelets	O
or	O
leukocytes	O
.	O

They	O
are	O
also	O
advantageous	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
disorders	O
of	O
lipid	O
metabolism	O
.	O

Cis-9,10-octadecenoamidase	B
The	O
soporific	O
activity	O
of	O
cis-9,10-octadecenoamide	O
and	O
other	O
soporific	O
fatty	O
acid	O
primary	O
amides	O
is	O
neutralized	O
by	O
hydrolysis	O
in	O
the	O
presence	O
of	O
cis-9,10-octadecenoamidase	O
.	O

Hydrolysis	O
of	O
cis-9,10-octadecenoamide	O
leads	O
to	O
the	O
formation	O
of	O
oleic	O
acid	O
,	O
a	O
compound	O
without	O
soporific	O
activity	O
.	O

Inhibitors	O
of	O
cis-9,10-octadecenoamidase	B
are	O
disclosed	O
to	O
block	O
this	O
activity	O
.	O

Nitroimidazole	O
antibacterial	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O
Methods	O
,	O
compounds	O
and	O
compositions	O
are	O
provided	O
for	O
inhibiting	O
the	O
growth	O
of	O
pathogenic	O
microbes	O
in	O
vitro	O
and	O
of	O
treatment	O
of	O
pathogenic	O
bacterial	O
infections	O
,	O
such	O
as	O
mycobacterial	O
,	O
Clostridium	O
,	O
Cryptosporidium	O
and	O
Helicobacter	O
infections	O
,	O
in	O
vivo	O
using	O
bicyclic	O
nitroimidazole	O
compounds	O
of	O
the	O
formula	O
(	O
II	O
)	O
:	O
(	O
see	O
formula	O
II	O
)	O

The	O
methods	O
,	O
compounds	O
and	O
compositions	O
are	O
particularly	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
,	O
Clostridium	O
difficile	O
,	O
Cryptosporidium	O
parvum	O
,	O
and	O
Helicobacter	O
pylori	O
,	O
and	O
may	O
be	O
used	O
alone	O
,	O
or	O
in	O
combination	O
with	O
other	O
antimicrobial	O
agents	O
.	O

Administration	O
of	O
ketamine	O
to	O
manage	O
pain	O
and	O
to	O
reduce	O
drug	O
dependency	O
The	O
present	O
invention	O
relates	O
to	O
the	O
management	O
of	O
pain	O
without	O
requiring	O
or	O
allowing	O
for	O
reduction	O
in	O
the	O
level	O
of	O
administration	O
of	O
narcotics	O
,	O
and	O
to	O
self	O
-	O
management	O
of	O
pain	O
on	O
an	O
outpatient	O
basis	O
.	O

Accordingly	O
,	O
the	O
present	O
invention	O
is	O
broadly	O
directed	O
to	O
a	O
method	O
for	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
a	O
transmucosal	O
,	O
transdermal	O
,	O
or	O
oral	O
route	O
a	O
dose	O
of	O
ketamine	O
effective	O
to	O
alleviate	O
pain	O
to	O
a	O
subject	O
suffering	O
from	O
pain	O
.	O

The	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
for	O
synergistically	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
any	O
route	O
a	O
dose	O
of	O
ketamine	O
effective	O
to	O
allow	O
for	O
reduction	O
in	O
the	O
level	O
of	O
an	O
ongoing	O
pain	O
therapy	O
,	O
or	O
decrease	O
pain	O
(	O
improve	O
the	O
level	O
of	O
pain	O
relief	O
)	O
,	O
or	O
both	O
.	O

Transmucosal	O
,	O
transdermal	O
,	O
and	O
oral	O
administration	O
of	O
ketamine	O
advantageously	O
allows	O
for	O
patient	O
self	O
administration	O
of	O
the	O
drug	O
,	O
which	O
provides	O
for	O
pain	O
management	O
on	O
an	O
outpatient	O
basis	O
.	O

Moreover	O
,	O
ketamine	O
administration	O
in	O
transdermal	O
devices	O
(	O
suppositories	O
,	O
candies	O
,	O
buccal	O
patches	O
)	O
is	O
generally	O
socially	O
acceptable	O
.	O

In	O
a	O
specific	O
example	O
,	O
a	O
patient	O
suffering	O
from	O
intractable	O
bladder	O
pain	O
controlled	O
breakthrough	O
pain	O
by	O
transmucosal	O
(	O
nasal	O
)	O
administration	O
of	O
about	O
16	O
mg	O
to	O
about	O
32	O
mg	O
of	O
ketamine	O
per	O
dose	O
.	O

G	O
-	O
coupled	O
receptor	O
showing	O
selective	O
affinity	O
for	O
atp	O
The	O
present	O
invention	O
concerns	O
a	O
G	B
-	I
coupled	I
receptor	I
which	O
has	O
an	O
amino	O
acid	O
sequence	O
having	O
more	O
than	O
50	O
%	O
homology	O
with	O
the	O
amino	O
acid	O
sequence	O
shown	O
in	O
Figure	O
1	O
.	O

An	O
infectious	O
cdna	O
clone	O
of	O
north	O
american	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
prrs	O
)	O
virus	O
and	O
uses	O
thereof	O
The	O
invention	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
including	O
plasmids	O
;	O
viral	O
vectors	O
;	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
DNA	O
sequence	O
encoding	O
an	O
infectious	O
RNA	O
sequence	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
;	O
and	O
also	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
further	O
provides	O
isolated	O
infectious	O
RNA	O
molecules	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

The	O
invention	O
also	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
infectious	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
;	O
and	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
also	O
provides	O
vaccines	O
comprising	O
such	O
plasmids	O
,	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
North	O
American	O
PRRS	O
viruses	O
,	O
and	O
methods	O
of	O
using	O
these	O
vaccines	O
in	O
swine	O
and	O
in	O
other	O
animals	O
.	O

Also	O
provided	O
are	O
isolated	O
polynucleotide	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
peptide	O
of	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

These	O
viral	O
vectors	O
and	O
transfected	O
host	O
cell	O
lines	O
are	O
useful	O
in	O
providing	O
peptides	O
to	O
compensate	O
for	O
mutated	O
peptide	O
coding	O
sequences	O
of	O
DNA	O
sequences	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
so	O
that	O
functional	O
virions	O
can	O
be	O
generated	O
.	O

Pyridine	O
derivatives	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
and	O
R1	O
to	O
R5	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
are	O
useful	O
for	O
treating	O
disorders	O
mediated	O
full	O
or	O
in	O
part	O
by	O
mGluR5	B
.	O

Therapeutic	O
process	O
for	O
inhibiting	O
nf-.kappa.b	B
A	O
therapeutic	O
process	O
is	O
provided	O
for	O
the	O
inhibition	O
of	O
NF-.kappa	B
.	I

B	B
in	O
mammals	O
in	O
whose	O
cells	O
NF-.kappa	B
.	I

B	B
has	O
been	O
activated	O
by	O
an	O
agency	O
external	O
to	O
said	O
cell	O
.	O

New	O
crystalline	O
form	O
of	O
1-methyl-5-p	O
-	O
toluoylpyrrole-2-acetamidoacetic	O
acid	O
guaiacyl	O
ester	O
A	O
new	O
crystalline	O
form	O
of	O
1-methyl-5-p	O
-	O
toluoylpyrrole-2-acetamidoacetic	O
acid	O
guaiacyl	O
ester	O
,	O
a	O
process	O
for	O
its	O
preparation	O
and	O
pharmaceutical	O
compositions	O
endowed	O
of	O
antiinflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
activity	O
containing	O
same	O
are	O
disclosed	O
.	O

Treatment	O
of	O
neuropathy	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cyclic	B
guanosine	I
3	I
'	I
,	I
5'-monophosphate	I
phosphodiesterase	I
type	I
five	I
(	O
cGMP	B
PDE5	I
)	O
inhibitors	O
,	O
including	O
in	O
particular	O
the	O
compound	O
sildenafil	O
,	O
in	O
combination	O
with	O
gabapentin	O
or	O
pregabalin	O
,	O
which	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neuropathy	O
,	O
including	O
in	O
particular	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O

Improved	O
stable	O
topical	O
ascorbic	O
acid	O
compositions	O
An	O
ascorbic	O
acid	O
(	O
Vitamin	O
C	O
)	O
composition	O
in	O
a	O
nonaqueous	O
or	O
substantially	O
anhydrous	O
silicone	O
vehicle	O
has	O
superior	O
stability	O
.	O

Particulate	O
ascorbic	O
acid	O
is	O
substantially	O
insoluble	O
in	O
the	O
disclosed	O
polyorganosiloxane	O
vehicles	O
,	O
and	O
the	O
vehicle	O
substantially	O
excludes	O
environmental	O
oxygen	O
.	O

The	O
ascorbic	O
acid	O
particles	O
have	O
surprisingly	O
been	O
found	O
to	O
have	O
a	O
high	O
degree	O
of	O
bioavailability	O
and	O
effectiveness	O
,	O
for	O
example	O
in	O
topical	O
applications	O
to	O
reduce	O
wrinkles	O
and	O
increase	O
collagen	O
growth	O
and	O
elasticity	O
.	O

Inhibitors	O
of	O
proteasomal	O
activity	O
for	O
stimulating	O
bone	O
and	O
hair	O
growth	O
Compounds	O
that	O
inhibit	O
the	O
activity	O
of	O
NF	O
-	O
B	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
proteasome	O
or	O
both	O
promote	O
bone	O
formation	O
and	O
hair	O
growth	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
;	O
they	O
also	O
stimulate	O
the	O
production	O
of	O
hair	O
follicles	O
and	O
are	O
thus	O
useful	O
in	O
stimulating	O
hair	O
growth	O
,	O
including	O
hair	O
density	O
,	O
in	O
subject	O
where	O
this	O
is	O
desirable	O
.	O

Reaction	O
products	O
of	O
hyaluronic	O
acid	O
and	O
natural	O
amino	O
acids	O
and	O
their	O
use	O
in	O
cosmetic	O
and	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
high	O
molecular	O
weight	O
salts	O
of	O
hyaluronic	O
acid	O
.	O

More	O
particularly	O
,	O
these	O
salts	O
are	O
characterized	O
in	O
that	O
they	O
have	O
as	O
a	O
counterion	O
a	O
natural	O
amino	O
acid	O
.	O

The	O
products	O
of	O
the	O
invention	O
can	O
be	O
prepared	O
starting	O
from	O
high	O
molecular	O
weight	O
hyaluronic	O
acid	O
or	O
salts	O
thereof	O
.	O

These	O
new	O
high	O
molecular	O
weights	O
salts	O
of	O
hyaluronic	O
acid	O
may	O
be	O
advantageously	O
employed	O
in	O
the	O
cosmetic	O
of	O
pharmaceutical	O
field	O
.	O

Novel	O
compounds	O
for	O
the	O
management	O
of	O
aging	O
-	O
related	O
and	O
diabetic	O
vascular	O
complications	O
,	O
process	O
for	O
their	O
preparation	O
and	O
therapeutic	O
uses	O
The	O
invention	O
discloses	O
novel	O
compounds	O
of	O
the	O
pyridinium	O
series	O
useful	O
for	O
the	O
management	O
of	O
diabetes	O
and	O
aging	O
-	O
related	O
vascular	O
complications	O
,	O
including	O
kidney	O
disease	O
,	O
nerve	O
damage	O
,	O
atherosclerosis	O
,	O
retinopathy	O
,	O
dermatological	O
disorders	O
and	O
discoloration	O
of	O
teeth	O
,	O
by	O
breaking	O
preformed	O
AGE	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
,	O
method	O
for	O
preparation	O
of	O
the	O
novel	O
compounds	O
of	O
the	O
series	O
and	O
pharmaceutical	O
composition	O
comprising	O
one	O
or	O
more	O
of	O
these	O
compounds	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
method	O
of	O
treatment	O
of	O
a	O
diabetic	O
patient	O
by	O
administering	O
the	O
compounds	O
either	O
singly	O
or	O
in	O
combination	O
with	O
drugs	O
for	O
antidiabetic	O
therapy	O
.	O

Antiparasitic	O
formulations	O
comprising	O
doramectin	O
Long	O
-	O
acting	O
antiparasitic	O
formulations	O
of	O
doramectin	O
,	O
suitable	O
for	O
injection	O
,	O
are	O
described	O
herein	O
.	O

Compounds	O
for	O
the	O
modulation	O
of	O
ppar.gamma	B
.	O

activity	O
Modulators	O
of	O
PPAR.gamma	B
.	O

activity	O
are	O
provided	O
having	O
the	O
following	O
formula	O
,	O
which	O
modulators	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O

(	O
See	O
above	O
Formula	O
)	O

Arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O
The	O
invention	O
relates	O
to	O
arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
specification	O
,	O
processes	O
for	O
preparing	O
them	O
as	O
well	O
as	O
the	O
use	O
of	O
arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
as	O
pharmaceutical	O
compositions	O
,	O
particularly	O
as	O
pharmaceutical	O
compositions	O
with	O
a	O
tryptase	B
-	O
inhibiting	O
activity	O
.	O

Iron	O
chelator	O
delivery	O
system	O
An	O
iron	O
chelator	O
delivery	O
system	O
is	O
disclosed	O
.	O

The	O
system	O
comprises	O
iron	O
chelator	O
and	O
a	O
lipid	O
carrier	O
,	O
e.g.	O
,	O
a	O
liposome	O
.	O

Methods	O
for	O
preparing	O
and	O
administering	O
the	O
iron	O
chelator	O
delivery	O
system	O
are	O
also	O
provided	O
.	O

Method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
coated	O
bodies	O
and	O
their	O
usage	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
bodies	O
coated	O
this	O
way	O
and	O
their	O
usage	O
.	O

The	O
invented	O
method	O
is	O
characterized	O
in	O
that	O
in	O
the	O
microcavities	O
of	O
non	O
-	O
metallic	O
bodies	O
an	O
aqueous	O
solution	O
1	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
antibiotic	O
component	O
from	O
the	O
groups	O
of	O
the	O
aminoglycoside	O
antibiotics	O
,	O
the	O
tetracycline	O
antibiotics	O
,	O
the	O
lincosamide	O
antibiotics	O
and	O
the	O
4-quinolone	O
antibiotics	O
,	O
and	O
an	O
aqueous	O
solution	O
2	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
amphiphilic	O
component	O
from	O
the	O
groups	O
of	O
the	O
alkyl	O
sulfates	O
,	O
alkyl	O
sulfonates	O
,	O
alkylaryl	O
sulfates	O
,	O
dialkylaryl	O
sulfates	O
,	O
alkylaryl	O
sulfonates	O
,	O
dialkylaryl	O
sulfonates	O
,	O
cycloalkyl	O
sulfates	O
,	O
cycloalkyl	O
sulfonates	O
,	O
alkylcycloalkyl	O
sulfates	O
,	O
are	O
introduced	O
,	O
wherein	O
between	O
the	O
introduction	O
of	O
solutions	O
1	O
and	O
2	O
the	O
water	O
is	O
basically	O
removed	O
through	O
vaporization	O
and/or	O
evaporation	O
,	O
and	O
whereby	O
from	O
the	O
components	O
of	O
solutions	O
1	O
and	O
2	O
in	O
the	O
microcavities	O
a	O
deposit	O
is	O
formed	O
,	O
which	O
is	O
sparingly	O
soluble	O
in	O
water	O
.	O

Ethanol	O
solvate	O
of	O
(	O
-	O
)	O
-cis-2-	O
(	O
2-chlorophenyl	O
)	O
-5,7-dihydroxy-8	O
[	O
4r-	O
(	O
3s	O
-	O
hydroxy-1-methyl	O
)	O
piperidinyl	O
]	O
-4h-1-benzopyran-4-one	O
An	O
ethanol	O
solvate	O
form	O
of	O
(	O
-	O
)	O
-cis-2-	O
(	O
2-chlorophenyl	O
)	O
-5,7-dihydroxy-8	O
[	O
4R-	O
(	O
3S	O
--	O
hydroxy-1-methyl	O
)	O
piperidinyl	O
]	O
-4H-1-benzopyran-4-one	O
(	O
Form	O
II	O
)	O
,	O
a	O
method	O
of	O
making	O
Form	O
II	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
Form	O
II	O
for	O
treating	O
cancer	O
.	O

Myeloid	B
colony	I
stimulating	I
factor	I
and	O
uses	O
thereof	O
The	O
identification	O
of	O
the	O
HYAL1	B
hyaluronidase	I
enzyme	O
as	O
a	O
human	B
plasma	I
-	I
derived	I
myeloid	I
colony	I
-	I
stimulating	I
factor	I
(	O
CSF	B
)	O
,	O
herein	O
designated	O
CSF5-hyaluronidase	B
,	O
its	O
recombinant	O
production	O
and	O
methods	O
of	O
use	O
are	O
described	O
.	O

This	O
protein	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
myelosuppression	O
as	O
may	O
occur	O
after	O
irradiation	O
,	O
chemotherapy	O
or	O
other	O
diseases	O
where	O
an	O
increase	O
in	O
leukocyte	O
levels	O
may	O
be	O
beneficial	O
.	O

For	O
example	O
,	O
CSF5	B
may	O
be	O
used	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
or	O
other	O
diseases	O
associated	O
with	O
immune	O
suppression	O
.	O

Stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
forms	O
containing	O
coloring	O
matter	O
and	O
active	O
chlorine	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O
as	O
disinfectants	O
A	O
method	O
of	O
producing	O
a	O
disinfectant	O
or	O
sterilizing	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
by	O
dissolving	O
in	O
a	O
solvent	O
a	O
stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
form	O
containing	O
coloring	O
matter	O
and	O
an	O
organic	O
chloroxidizer	O
acting	O
as	O
a	O
chlorine	O
donor	O
releasing	O
active	O
chlorine	O
.	O

The	O
coloring	O
matter	O
is	O
in	O
its	O
maximal	O
level	O
of	O
oxidation	O
.	O

The	O
chloroxidizer	O
with	O
coloring	O
matter	O
has	O
a	O
pH	O
of	O
4	O
-	O
8	O
and	O
is	O
present	O
in	O
a	O
sufficient	O
quantity	O
to	O
disinfect	O
or	O
sterilize	O
the	O
surface	O
,	O
vessel	O
,	O
or	O
tissue	O
as	O
required	O
while	O
the	O
colored	O
appearance	O
of	O
the	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
is	O
stably	O
maintained	O
over	O
a	O
period	O
of	O
time	O
which	O
exceeds	O
the	O
period	O
of	O
time	O
that	O
the	O
disinfectant	O
would	O
be	O
normally	O
used	O
for	O
that	O
purpose	O
.	O

Drug	O
formulations	O
for	O
parenteral	O
use	O
This	O
invention	O
relates	O
to	O
parenteral	O
preparations	O
of	O
antiestrogens	O
such	O
as	O
toremifene	O
,	O
desmethyl	O
toremifene	O
,	O
tamoxifen	O
or	O
desmethyltamoxifen	O
.	O

The	O
preparations	O
can	O
be	O
emulsions	O
,	O
liposomes	O
or	O
aqueous	O
solutions	O
of	O
cyclodextrin	O
-	O
drug	O
complexes	O
.	O

Particularly	O
the	O
invention	O
relates	O
to	O
a	O
parenteral	O
drug	O
formulation	O
comprising	O
a	O
complex	O
having	O
a	O
2-hydroxypropyl	O
cyclodextrin	O
component	O
and	O
including	O
an	O
active	O
drug	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
toremifene	O
,	O
desmethyl	O
toremifene	O
,	O
tamoxifen	O
and	O
desmethyltamoxifen	O
or	O
a	O
pharmaceutically	O
acceptable	O
non	O
-	O
toxic	O
salt	O
thereof	O
,	O
said	O
complex	O
being	O
present	O
either	O
in	O
an	O
aqueous	O
solution	O
or	O
emulsion	O
or	O
loaded	O
into	O
a	O
liposome	O
.	O

Pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O
The	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
which	O
is	O
aminoalkyl	O
methacrylate	O
copolymer	O
E	O
as	O
an	O
effective	O
ingredient	O
,	O
and	O
an	O
agent	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
or	O
a	O
method	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
the	O
mucosa	O
,	O
by	O
administration	O
of	O
aminoalkyl	O
methacrylate	O
copolymer	O
E.	O
Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O
,	O
which	O
comprises	O
a	O
biologically	O
active	O
peptide	O
and	O
aminoalkyl	O
methacrylate	O
copolymer	O
E.	O
Excellent	O
oral	O
absorption	O
of	O
a	O
biologically	O
active	O
peptide	O
that	O
were	O
considered	O
difficult	O
to	O
absorb	O
by	O
oral	O
administration	O
in	O
the	O
past	O
,	O
can	O
be	O
realized	O
based	O
on	O
the	O
ability	O
to	O
inhibit	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
,	O
the	O
ability	O
to	O
reduce	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
,	O
and	O
the	O
ability	O
to	O
improve	O
permeability	O
of	O
a	O
biologically	O
active	O
peptide	O
in	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
of	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
.	O

Composition	O
and	O
method	O
to	O
prevent	O
or	O
reduce	O
diarrhea	O
and	O
steatorrhea	O
in	O
hiv	O
patients	O
Method	O
of	O
preventing	O
or	O
reducing	O
diarrhea	O
and	O
correcting	O
fat	O
malabsorption	O
(	O
steatorrhea	O
)	O
and	O
loss	O
of	O
body	O
mass	O
in	O
HIV	O
-	O
positive	O
patients	O
being	O
treated	O
with	O
High	O
Activity	O
Antiretroviral	O
drugs	O
(	O
HAART	O
)	O
containing	O
protease	O
inhibitors	O
,	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
or	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
and	O
by	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
a	O
buffered	O
pancrelipase	O
composition	O
.	O

The	O
method	O
includes	O
the	O
steps	O
of	O
:	O
administering	O
to	O
the	O
HIV	O
-	O
positive	O
patient	O
a	O
High	O
Activity	O
Antiretroviral	O
drug	O
containing	O
a	O
protease	O
inhibitor	O
,	O
a	O
nucleoside	O
reverse	B
transcriptase	I
inhibitor	O
or	O
a	O
non	O
-	O
nucleoside	O
reverse	B
transcriptase	I
inhibitor	O
;	O
and	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
drug	O
a	O
gastric	O
acid	O
-	O
resistant	O
polymer	O
-	O
coated	O
and	O
buffered	O
pancrelipase	O
enzyme	O
composition	O
containing	O
pancreatic	B
proteases	I
,	O
lipases	B
,	O
co	O
-	O
lipases	O
,	O
nucleases	B
,	O
amylases	B
and	O
other	O
bio	O
-	O
active	O
substances	O
produced	O
by	O
the	O
pancreatic	O
gland	O
.	O

Dimetalhydroxy	O
malates	O
Dimetalhydroxy	O
malate	O
compositions	O
as	O
well	O
as	O
methods	O
of	O
administering	O
and	O
making	O
such	O
bioavailable	O
compositions	O
are	O
provided	O
.	O

The	O
metal	O
used	O
can	O
be	O
any	O
nutritionally	O
relevant	O
divalent	O
metal	O
such	O
as	O
calcium	O
,	O
magnesium	O
,	O
zinc	O
,	O
copper	O
,	O
manganese	O
,	O
and	O
iron	O
.	O

The	O
composition	O
can	O
be	O
prepared	O
by	O
reacting	O
malic	O
acid	O
with	O
a	O
divalent	O
metal	O
oxide	O
or	O
hydroxide	O
at	O
a	O
1:2	O
molar	O
ratio	O
.	O

The	O
composition	O
can	O
be	O
administered	O
to	O
a	O
warm	O
-	O
blooded	O
animal	O
by	O
any	O
of	O
a	O
number	O
of	O
known	O
delivery	O
routes	O
,	O
including	O
oral	O
delivery	O
.	O

Improved	O
absorption	O
of	O
fat	O
-	O
soluble	O
nutrients	O
Carotenoids	O
are	O
provided	O
as	O
dietary	O
supplements	O
to	O
animal	O
feed	O
.	O

These	O
supplements	O
improve	O
the	O
bioavailability	O
of	O
carotenoids	O
by	O
providing	O
them	O
in	O
combination	O
with	O
phospholipids	O
.	O

The	O
invention	O
provides	O
animal	O
feeds	O
for	O
aquatic	O
and	O
terrestrial	O
animals	O
,	O
and	O
methods	O
for	O
making	O
the	O
feeds	O
.	O

Combinations	O
for	O
the	O
treatment	O
of	O
depression	O
It	O
is	O
intended	O
to	O
provide	O
medicinal	O
compositions	O
and	O
the	O
like	O
useful	O
in	O
treating	O
depression	O
which	O
contain	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
adenosine	B
A2A	I
receptor	I
(	O
for	O
example	O
,	O
(	O
E	O
)	O
-8-	O
(	O
3,4-dimethoxystyryl	O
)	O
-1,3-diethyl-7-methyl-3,7-dihydro-1H	O
-	O
purin-2,6-dione	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
together	O
with	O
an	O
antidepressant	O
(	O
for	O
example	O
,	O
a	O
tricyclic	O
antidepressant	O
,	O
a	O
tetracyclic	O
antidepressant	O
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
a	O
selective	O
noradrenaline	O
reuptake	O
inhibitor	O
,	O
a	O
dopamine	O
reuptake	O
inhibitor	O
,	O
a	O
serotonin	O
/	O
noradrenaline	O
reuptake	O
inhibitor	O
,	O
a	O
monoamine	B
oxidase	I
inhibitor	O
or	O
a	O
serotonin	B
2	I
antagonist	O
)	O
.	O

Compositions	O
of	O
galactomannan	O
for	O
the	O
treatment	O
of	O
bowel	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
comprising	O
galactomannan	O
and/or	O
arabinogalactan	O
;	O
a	O
liquid	O
food	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
characterized	O
in	O
that	O
the	O
liquid	O
food	O
comprises	O
a	O
protein	O
and	O
galactomannan	O
and/or	O
arabinogalactan	O
;	O
and	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
an	O
irritable	O
bowel	O
syndrome	O
,	O
comprising	O
degraded	O
galactomannan	O
.	O

Fluorinated	O
phno	O
and	O
analogs	O
thereof	O
This	O
application	O
describes	O
fluormated	O
(	O
+	O
)	O
PHNO	O
and	O
analogs	O
thereof	O
,	O
including	O
radiolabeled	O
analogs	O
,	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
C1	O
-	O
6	O
alkyl	O
in	O
which	O
one	O
hydrogen	O
atom	O
on	O
the	O
alkyl	O
chain	O
is	O
replaced	O
with	O
fluoro	O
or	O
radioactive	O
fluoro	O
.	O

The	O
application	O
further	O
describes	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
have	O
good	O
affinity	O
and	O
selectivity	O
for	O
the	O
dopamine	B
D2	I
receptors	I
and	O
are	O
therefore	O
useful	O
for	O
the	O
labelling	O
of	O
dopamine	B
D2	I
receptors	I
in	O
vivo	O
and	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
the	O
extent	O
of	O
dopamine	O
supersensitivity	O
in	O
the	O
bram	O
in	O
various	O
stages	O
of	O
a	O
dopamine	O
-	O
related	O
disease	O
.	O

Oral	O
health	O
care	O
drink	O
and	O
method	O
for	O
reducing	O
malodors	O
An	O
oral	O
care	O
composition	O
and	O
method	O
of	O
using	O
.	O

are	O
provided	O
for	O
treating	O
and	O
preventing	O
malodors	O
or	O
disease	O
conditions	O
of	O
the	O
oral	O
cavity	O
in	O
warm	O
-	O
blooded	O
animals	O
,	O
including	O
humans	O
.	O

When	O
applying	O
an	O
oral	O
care	O
effective	O
amount	O
of	O
the	O
oral	O
care	O
composition	O
of	O
the	O
present	O
invention	O
to	O
the	O
mucosal	O
tissue	O
of	O
the	O
oral	O
cavity	O
,	O
the	O
gingival	O
tissues	O
of	O
the	O
oral	O
cavity	O
,	O
and/or	O
surface	O
of	O
the	O
teeth	O
.	O

The	O
application	O
can	O
be	O
as	O
a	O
liquid	O
for	O
bathing	O
,	O
rinsing	O
or	O
gargling	O
,	O
or	O
lather	O
generated	O
by	O
brushing	O
the	O
teeth	O
for	O
a	O
sufficient	O
time	O
.	O

After	O
rinsing	O
,	O
gargling	O
or	O
brushing	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
should	O
be	O
swallowed	O
to	O
achieve	O
effective	O
reduction	O
of	O
various	O
organisms	O
,	O
diseases	O
and	O
malodors	O
.	O

An	O
oral	O
care	O
effective	O
amount	O
can	O
also	O
prevent	O
and	O
heal	O
mouth	O
sores	O
and	O
canker	O
sores	O
.	O

High	O
fructan	O
cereal	O
plants	O
The	O
invention	O
provides	O
cereal	O
plants	O
having	O
a	O
high	O
level	O
of	O
fructan	O
useful	O
for	O
the	O
production	O
of	O
a	O
range	O
of	O
food	O
,	O
beverage	O
,	O
nutraceutical	O
and	O
pharmaceutical	O
products	O
.	O

The	O
invention	O
provides	O
methods	O
of	O
producing	O
high	O
-	O
fructan	O
products	O
from	O
plants	O
modified	O
to	O
comprise	O
a	O
reduced	O
level	O
of	O
an	O
endogenous	O
polypeptide	O
with	O
starch	B
synthase	I
activity	O
,	O
and	O
products	O
so	O
produced	O
.	O

In	O
some	O
embodiments	O
,	O
plants	O
are	O
modified	O
by	O
introduction	O
of	O
an	O
agent	O
such	O
as	O
a	O
nucleic	O
acid	O
molecule	O
which	O
down	O
regulates	O
endogenous	B
starch	I
synthase	I
II	I
gene	O
expression	O
.	O

Adhesive	O
patch	O
containing	O
fentanyl	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
An	O
adhesive	O
preparation	O
comprising	O
a	O
support	O
and	O
a	O
medicine	O
-	O
containing	O
layer	O
laminated	O
on	O
the	O
support	O
,	O
wherein	O
the	O
medicine	O
-	O
containing	O
layer	O
comprises	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fentanyl	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
an	O
adhesive	O
agent	O
comprising	O
polyisobutylene	O
and	O
a	O
silicon	O
-	O
containing	O
polymer	O
,	O
and	O
wherein	O
the	O
ratio	O
of	O
the	O
polyisobutylene	O
to	O
the	O
silicon	O
-	O
containing	O
polymer	O
in	O
the	O
adhesive	O
agent	O
is	O
20:1	O
to	O
7:3	O
by	O
mass	O
.	O

Induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
cell	O
proliferation	O
through	O
modulation	O
of	O
carnitine	O
palmitoyltransferase	O
1c	O
activity	O
This	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
cancer	O
therapeutics	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
tumors	O
by	O
inhibiting	O
the	O
activity	O
of	O
CPT1C	O
.	O

The	O
methods	O
and	O
compositions	O
can	O
additionally	O
include	O
inhibition	O
of	O
glycolysis	O
.	O

Method	O
for	O
improving	O
storage	O
stability	O
of	O
glutathione	O
Provision	O
of	O
a	O
method	O
of	O
improving	O
preservation	O
stability	O
of	O
glutathione	O
in	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
or	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
which	O
shows	O
improved	O
preservation	O
stability	O
of	O
glutathione	O
.	O

In	O
the	O
production	O
of	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
glutathione	O
and	O
arginine	O
are	O
made	O
to	O
be	O
coexistent	O
with	O
an	O
organic	O
acid	O
.	O

Examples	O
of	O
the	O
organic	O
acid	O
include	O
citric	O
acid	O
,	O
tartaric	O
acid	O
,	O
ascorbic	O
acid	O
,	O
malic	O
acid	O
,	O
malonic	O
acid	O
,	O
succinic	O
acid	O
,	O
fumaric	O
acid	O
,	O
maleic	O
acid	O
and	O
the	O
like	O
.	O

The	O
amount	O
of	O
the	O
organic	O
acid	O
to	O
be	O
coexistent	O
with	O
glutathione	O
and	O
arginine	O
is	O
generally	O
0.1	O
-	O
2	O
parts	O
by	O
weight	O
relative	O
to	O
1	O
part	O
by	O
weight	O
of	O
arginine	O
.	O

Methods	O
for	O
treating	O
bowel	O
diseases	O
The	O
present	O
invention	O
provides	O
new	O
methods	O
of	O
treating	O
bowel	O
disease	O
(	O
BD	O
)	O
by	O
increasing	O
a	O
durability	O
of	O
response	O
;	O
treating	O
BD	O
in	O
males	O
;	O
treating	O
BD	O
in	O
adolescent	O
subjects	O
;	O
treating	O
bloating	O
due	O
to	O
BD	O
in	O
males	O
;	O
and	O
methods	O
of	O
maintaining	O
remission	O
of	O
BD	O
.	O

Novel	O
and	O
potent	O
tapentadol	O
dosage	O
forms	O
The	O
present	O
invention	O
provides	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	O
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	O
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
pain	O
and	O
pain	O
related	O
conditions	O
by	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	O
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	O
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	O
.	O

Compound	O
,	O
certain	O
novel	O
forms	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
for	O
preparation	O
and	O
use	O
Compound	O
of	O
Formula	O
A	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
crystalline	O
Forms	O
I	O
and	O
ll	O
of	O
Compound	O
of	O
Formula	O
A.	O
(	O
see	O
formula	O
A	O
)	O
Also	O
,	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
methods	O
for	O
their	O
uses	O
.	O

Identification	O
of	O
tumor	O
-	O
associated	O
antigens	O
for	O
diagnosis	O
and	O
therapy	O
The	O
invention	O
relates	O
to	O
genetic	O
products	O
the	O
expression	O
of	O
which	O
is	O
associated	O
with	O
cancer	O
diseases	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
therapy	O
and	O
diagnosis	O
of	O
diseases	O
in	O
which	O
the	O
genetic	O
products	O
are	O
expressed	O
or	O
aberrantly	O
expressed	O
,	O
in	O
particular	O
cancer	O
diseases	O
.	O

Novel	O
antibacterial	O
combination	O
therapy	O
An	O
antibacterial	O
composition	O
is	O
provided	O
including	O
a	O
combination	O
of	O
a	O
ß	O
-	O
lactam	O
antibiotic	O
that	O
has	O
a	O
binding	O
affinity	O
for	O
bacterial	O
penicillin	B
-	I
binding	I
protein	I
2	I
;	O
and	O
a	O
non	O
-	O
antibiotic	O
compound	O
which	O
may	O
be	O
a	O
thienopyridine	O
or	O
a	O
non	O
-	O
thienopyridine	O
compound	O
.	O

A	O
method	O
of	O
treatment	O
using	O
the	O
composition	O
is	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
hiv	O
Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
HIV	O
are	O
provided	O
.	O

Method	O
for	O
producing	O
antifungal	O
drug	O
in	O
triazole	O
class	O
This	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
compounds	O
shown	O
in	O
formula	O
I	O
,	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

Phosphates	O
of	O
secondary	O
alcohols	O
According	O
to	O
the	O
invention	O
,	O
there	O
is	O
provided	O
a	O
phosphate	O
derivative	O
of	O
a	O
compound	O
having	O
a	O
secondary	O
hydroxy	O
group	O
.	O

The	O
compound	O
having	O
a	O
secondary	O
hydroxyl	O
group	O
may	O
,	O
for	O
example	O
,	O
be	O
chosen	O
from	O
pravastatin	O
,	O
atorvastatin	O
venlafaxine	O
,	O
their	O
derivatives	O
and	O
mixtures	O
thereof	O
.	O

Salvia	O
minium	O
phenolic	O
acid	O
A	O
and	O
process	O
of	O
preparing	O
preparation	O
and	O
use	O
This	O
invention	O
concerns	O
the	O
method	O
of	O
extracting	O
salvianolic	O
acid	O
A	O
from	O
Chinese	O
crude	O
drug	O
:	O
danshen	O
root	O
,	O
and	O
the	O
quality	O
control	O
methods	O
and	O
drug	O
combinations	O
,	O
and	O
the	O
application	O
of	O
this	O
drug	O
.	O

It	O
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
the	O
prevention	O
drugs	O
for	O
cardiovascular	O
disease	O
,	O
liver	O
damage	O
,	O
liver	O
fibrosis	O
,	O
pulmonary	O
fibrosis	O
and	O
other	O
.	O

Powder	O
and	O
salve	O
for	O
hyperplasia	O
protrusion	O
rehabilitation	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
hyperplasia	O
and	O
method	O
for	O
preparation	O
,	O
wherein	O
the	O
powdery	O
form	O
medicament	O
is	O
prepared	O
from	O
batryticated	O
silkworm	O
,	O
dahurian	O
angelica	O
root	O
,	O
buthus	O
martensi	O
karsch	O
,	O
centipede	O
,	O
pangolin	O
scales	O
,	O
vomiting	O
nut	O
and	O
musk	O
,	O
and	O
the	O
ointment	O
form	O
medicament	O
is	O
prepared	O
from	O
cibot	O
rhizome	O
,	O
eucommia	O
bark	O
,	O
spatholobus	O
stem	O
,	O
safflower	O
,	O
peach	O
kernels	O
,	O
ledebouriella	O
root	O
,	O
earthworm	O
,	O
agkistrodon	O
acutus	O
,	O
siberian	O
cocklebur	O
fruit	O
,	O
Chinese	O
starjasmine	O
,	O
homalomena	O
rhizoma	O
,	O
frankincense	O
,	O
myrrh	O
,	O
dragon	O
's	O
blood	O
resin	O
and	O
boneol	O
.	O

Organic	O
amine	O
salt	O
of	O
cephalosporin	O
compound	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
the	O
organic	O
amine	O
salt	O
or	O
hydrate	O
for	O
ceph	O
compound	O
used	O
for	O
treating	O
bacteria	O
infection	O
,	O
and	O
the	O
chemical	O
formula	O
is	O
demonstrated	O
in	O
(	O
I	O
)	O
.Said	O
organic	O
amine	O
can	O
be	O
lycine	O
,	O
arginine	O
,	O
tert	O
-	O
butylamine	O
,	O
diethanolamine	O
,	O
triethanolamine	O
,	O
diethylamine	O
or	O
meglumine	O
.	O

It	O
comprises	O
cefuroxime	O
organic	O
amine	O
salt	O
,	O
ceftriaxone	O
organic	O
amine	O
salt	O
,	O
ceftezole	O
organic	O
amine	O
salt	O
,	O
cefoperazone	O
organic	O
amine	O
salt	O
,	O
cephalothin	O
organic	O
amine	O
salt	O
,	O
cefotaxime	O
organic	O
amine	O
salt	O
,	O
cefradine	O
organic	O
amine	O
salt	O
,	O
cefonicid	O
organic	O
amine	O
salt	O
,	O
cefmetazole	O
organic	O
amine	O
salt	O
,	O
cefodizime	O
organic	O
amine	O
salt	O
,	O
cefmenoxime	O
organic	O
amine	O
salt	O
,	O
ceftizoxime	O
organic	O
amine	O
salt	O
,	O
cefpiramide	O
organic	O
amine	O
salt	O
,	O
cefazolin	O
organic	O
amine	O
salt	O
,	O
cefoxitinorganic	O
amine	O
salt	O
and	O
flomoxef	O
organic	O
amine	O
salr	O
.	O

The	O
invention	O
provides	O
the	O
medical	O
compound	O
taking	O
compound	O
in	O
formula	O
(	O
I	O
)	O
as	O
active	O
element	O
and	O
its	O
application	O
to	O
preparation	O
of	O
medicine	O
for	O
treating	O
bacteria	O
infection	O
.	O

1,6-diphospho	O
-	O
D	O
-	O
fructose	O
ester	O
arginine	O
salt	O
and	O
its	O
pharmaceutical	O
uses	O
The	O
invention	O
disclose	O
the	O
arginine	O
salt	O
of	O
1	O
,	O
6-	O
diphosphoric	O
acid-	O
D-	O
fructose	O
esters	O
in	O
hydrate	O
type	O
,	O
and	O
one	O
or	O
more	O
than	O
one	O
of	O
the	O
four	O
function	O
groups	O
is	O
salinized	O
by	O
arginine	O
.	O

The	O
salt	O
precipitation	O
with	O
1	O
,	O
6-	O
diphosphoric	O
acid-	O
D-	O
fructose	O
esters	O
and	O
arginine	O
solves	O
problems	O
of	O
strong	O
side	O
effect	O
of	O
sodium	O
fructose	O
diphosphate	O
,	O
and	O
starting	O
circuit	O
,	O
high	O
natremia	O
risk	O
.	O

It	O
is	O
demonstrated	O
through	O
pharmacological	O
test	O
that	O
arginine	O
salt	O
can	O
cooperate	O
with	O
drug	O
and	O
the	O
toxcity	O
is	O
low	O
.	O

Slow	O
release	O
tablet	O
of	O
amoxicillin	O
The	O
invention	O
discloses	O
slow	O
release	O
tablets	O
of	O
Amoxicillin	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
raw	O
materials	O
of	O
the	O
preparation	O
include	O
Amoxicillin	O
of	O
a	O
predetermined	O
proportion	O
,	O
slow	O
release	O
matrix	O
material	O
and	O
medicinal	O
material	O
,	O
the	O
preparation	O
can	O
be	O
prepared	O
into	O
solid	O
dispersing	O
agent	O
,	O
wherein	O
the	O
medicament	O
can	O
be	O
released	O
slowly	O
and	O
continuously	O
after	O
being	O
administrated	O
,	O
the	O
effective	O
concentration	O
in	O
blood	O
can	O
be	O
maintained	O
,	O
and	O
long	O
action	O
can	O
be	O
achieved	O
.	O

The	O
advantages	O
of	O
the	O
invention	O
include	O
decreased	O
frequency	O
of	O
medicinal	O
administration	O
,	O
improved	O
patient	O
's	O
adaptability	O
,	O
lowered	O
blood	O
concentration	O
peak	O
-	O
valley	O
,	O
increased	O
medicinal	O
effect	O
and	O
safety	O
,	O
and	O
reduced	O
total	O
medicinal	O
dose	O
,	O
thereby	O
optimum	O
curative	O
effect	O
can	O
be	O
achieved	O
through	O
minimum	O
dose	O
,	O
thus	O
the	O
preparation	O
is	O
more	O
suitable	O
for	O
patients	O
.	O

Nucleic	O
acid	O
molecule	O
RTN4BSR62	O
and	O
application	O
in	O
preparation	O
of	O
anti	O
-	O
cancer	O
drugs	O
The	O
invention	O
discloses	O
a	O
making	O
method	O
of	O
RTN4BSR32	O
and	O
application	O
to	O
prepare	O
tumour	O
-	O
proof	O
drug	O
,	O
whose	O
sequence	O
contains	O
5'-AATGTCTCTCCAGTACAGG-3	O
'	O
or	O
5'-AAUGUCUCUCCAGUACAGG-3	O
'	O
.	O

The	O
molecular	O
can	O
inhibit	O
tumour	O
from	O
growing	O
obviously	O
,	O
which	O
provides	O
a	O
new	O
path	O
and	O
method	O
to	O
treat	O
and	O
release	O
tumour	O
.	O

Application	O
of	O
ferricitras	O
in	O
preparation	O
of	O
medicine	O
to	O
prevent	O
and	O
treat	O
angiosteosis	O
The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
ferric	O
citrate	O
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
calcification	O
of	O
blood	O
vessel	O
.	O

The	O
present	O
invention	O
has	O
determined	O
curative	O
effect	O
.	O

Experiment	O
proves	O
that	O
ferric	O
citrate	O
can	O
intervene	O
calcification	O
of	O
blood	O
vessel	O
and	O
inhibit	O
calcification	O
effectively	O
,	O
and	O
may	O
reverse	O
calcification	O
of	O
blood	O
vessel	O
.	O

Hydrophilic	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
and	O
their	O
prepn	O
process	O
The	O
present	O
invention	O
is	O
serial	O
hydrophilic	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
obtained	O
through	O
organic	O
synthesis	O
and	O
polymerization	O
to	O
grafting	O
hydrophilic	O
polyglycol	O
onto	O
cyclohydroxy	O
group	O
of	O
ursolic	O
acid	O
A.	O
The	O
structure	O
analysis	O
and	O
experiments	O
show	O
that	O
activated	O
polyglycol	O
is	O
grafted	O
successfully	O
onto	O
ursolic	O
acid	O
said	O
water	O
insoluble	O
ursolic	O
acid	O
becomes	O
water	O
soluble	O
polyglycol	O
-	O
ursolic	O
acid	O
.	O

Polyglycol	O
-	O
ursolic	O
acid	O
has	O
excellent	O
blood	O
compatibility	O
and	O
high	O
physiological	O
activity	O
,	O
so	O
that	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
may	O
be	O
prepared	O
into	O
different	O
forms	O
,	O
including	O
injection	O
,	O
oral	O
liquid	O
,	O
capsule	O
,	O
tablet	O
,	O
etc	O
.	O

The	O
polyglycol	O
has	O
average	O
molecular	O
weight	O
of	O
200	O
-	O
60,000	O
.	O

Ruthenium	O
porphyrin	O
complex	O
and	O
its	O
prepn	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
The	O
present	O
invention	O
discloses	O
ruthenium	O
porphyrin	O
complex	O
and	O
its	O
preparation	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

The	O
ruthenium	O
porphyrin	O
complex	O
with	O
the	O
structure	O
as	O
shown	O
has	O
ruthenium	O
as	O
the	O
central	O
metal	O
ion	O
,	O
pyridyl	O
radical	O
containing	O
asymmetrical	O
porphyrin	O
and	O
its	O
metal	O
derivative	O
as	O
the	O
ligand	O
,	O
and	O
coordinate	O
bond	O
jointing	O
the	O
ruthenium	O
pyridyl	O
radical	O
and	O
the	O
porphyrin	O
ring	O
.	O

The	O
ruthenium	O
porphyrin	O
complex	O
of	O
the	O
present	O
invention	O
has	O
determined	O
composition	O
,	O
less	O
toxic	O
side	O
effect	O
and	O
good	O
absorption	O
and	O
metabolism	O
in	O
organism	O
,	O
and	O
is	O
suitable	O
for	O
use	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

Use	O
of	O
dihydro	O
myricotin	O
element	O
for	O
treating	O
cardiac	O
blood	O
diseases	O
The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
dihydromyricetin	O
in	O
preparation	O
of	O
medicine	O
for	O
preventing	O
or	O
curing	O
angiocardiopathy	O
.	O

The	O
animal	O
tests	O
show	O
that	O
the	O
dihydromyricetin	O
has	O
the	O
effect	O
for	O
resisting	O
internal	O
phlebothrombosis	O
,	O
can	O
be	O
used	O
for	O
effectively	O
preventing	O
angiocardiopathy	O
due	O
to	O
thrombosis	O
,	O
for	O
example	O
cardiac	O
disease	O
and	O
apoplexy	O
.	O

Said	O
invention	O
can	O
be	O
made	O
into	O
medicine	O
or	O
health	O
-	O
care	O
product	O
.	O

Novel	O
dihydrochalcone	O
compound	O
separated	O
and	O
purified	O
from	O
drgon	O
blood	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
new	O
dihydrochalcone	O
compound	O
that	O
is	O
separated	O
and	O
purified	O
from	O
Long	O
Xuejie	O
and	O
the	O
manufacture	O
method	O
.	O

It	O
adopts	O
Long	O
Xuejie	O
as	O
raw	O
material	O
,	O
uses	O
light	O
petroleum	O
and	O
chloroform	O
solvent	O
to	O
distill	O
,	O
decreases	O
pressure	O
and	O
concentrating	O
chloroform	O
extractive	O
,	O
takes	O
silica	O
gel	O
column	O
or	O
rapid	O
silica	O
gel	O
chromatography	O
and	O
takes	O
Sephadex	O
LH-20	O
gelcolumn	O
chromatography	O
andseparating	O
,	O
purifies	O
chromatogram	O
,	O
and	O
finally	O
gains	O
dihydrochalcone	O
compound	O
.	O

The	O
chemical	O
name	O
is	O
4'-	O
hydroxyl-2	O
'	O
,	O
4-	O
dimethoxy-	O
dihydrochalcone	O
.	O

The	O
compound	O
has	O
good	O
effect	O
to	O
avoid	O
platelet	O
aggregation	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
lower	O
urinary	O
tract	O
diseases	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
compound	O
for	O
treating	O
disease	O
of	O
lower	O
urinary	O
tract	O
,	O
which	O
comprises	O
drug	O
active	O
component	O
,	O
drug	O
carrier	O
or	O
shaping	O
agent	O
,	O
wherein	O
the	O
drug	O
active	O
component	O
is	O
terraazoles	O
and	O
amiloripin	O
.	O

The	O
disease	O
of	O
lower	O
urinary	O
tract	O
relates	O
to	O
prostatitis	O
increment	O
,	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
,	O
in	O
particular	O
to	O
treat	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
induced	O
by	O
prostatitis	O
increment	O
.	O

And	O
the	O
inventive	O
drug	O
can	O
be	O
used	O
treat	O
the	O
high	O
blood	O
pressure	O
concomitant	O
with	O
lower	O
urinary	O
tract	O
,	O
to	O
effectively	O
control	O
blood	O
pressure	O
and	O
resolve	O
the	O
lower	O
urinary	O
tract	O
disease	O
,	O
compared	O
with	O
single	O
terraazoles	O
or	O
amiloripin	O
drug	O
,	O
to	O
improve	O
the	O
health	O
quality	O
of	O
patient	O
.	O

Nanometer	O
elemental	O
selenium	O
coupled	O
with	O
liquid	O
amino	O
acid	O
and	O
the	O
method	O
for	O
preparing	O
and	O
preserving	O
the	O
same	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
nanometer	O
monomer	O
selenium	O
via	O
coupling	O
liquid	O
amino	O
acid	O
,	O
comprising	O
that	O
at	O
normal	O
temperature	O
and	O
normal	O
pressure	O
,	O
adding	O
vitamin	O
C	O
solution	O
into	O
amino	O
acid	O
solution	O
,	O
mixing	O
uniformly	O
and	O
adding	O
selenious	O
anhydride	O
or	O
selenite	O
solution	O
until	O
the	O
product	O
has	O
held	O
red	O
,	O
to	O
obtain	O
the	O
liquid	O
coupled	O
product	O
of	O
amino	O
acid	O
and	O
nanometer	O
selenium	O
.	O

The	O
nanometer	O
monomer	O
selenium	O
can	O
be	O
used	O
as	O
medical	O
health	O
-	O
care	O
product	O
to	O
display	O
the	O
cooperation	O
between	O
amino	O
acid	O
and	O
nanometer	O
selenium	O
,	O
while	O
the	O
nanometer	O
selenium	O
gel	O
has	O
small	O
diameter	O
,	O
narrow	O
distribution	O
and	O
liquid	O
storage	O
,	O
to	O
develop	O
oral	O
,	O
injection	O
or	O
the	O
like	O
.	O

Anticancer	O
compound	O
including	O
neoangiogenesis	O
inhibitors	O
and	O
alkylate	O
agent	O
The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
cancer	O
compound	O
as	O
a	O
slow	O
release	O
injection	O
which	O
contains	O
vessel	O
restrainer	O
and/or	O
alkyl	O
agent	O
,	O
formed	O
by	O
slow	O
release	O
micro	O
ball	O
and	O
solvent	O
.	O

The	O
slow	O
release	O
micro	O
ball	O
comprises	O
the	O
anti	O
-	O
cancer	O
effective	O
components	O
and	O
slow	O
release	O
findings	O
,	O
the	O
solvent	O
is	O
a	O
common	O
solvent	O
or	O
a	O
special	O
solvent	O
with	O
suspending	O
agent	O
,	O
while	O
the	O
viscosity	O
of	O
suspending	O
agent	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
-	O
30Deg	O
.	O

C	O
)	O
,	O
selected	O
from	O
carboxymethyl	O
cellulose	O
,	O
the	O
anti	O
-	O
cancer	O
effective	O
component	O
is	O
the	O
combination	O
of	O
vessel	O
restrainer	O
and/or	O
the	O
alkyl	O
agent	O
selected	O
from	O
nimuxitin	O
,	O
or	O
the	O
like	O
,	O
the	O
slow	O
release	O
finding	O
is	O
selected	O
from	O
phosphate	O
polyester	O
as	O
p	O
(	O
LAEG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
DAPG	O
-	O
EOP	O
)	O
,	O
or	O
the	O
polyester	O
or	O
mixture	O
of	O
phosphate	O
and	O
polylactic	O
acid	O
,	O
polyphenyl	O
,	O
2-aliphatic	O
acid	O
,	O
sebacic	O
acid	O
polyester	O
,	O
poly	O
(	O
erucic	O
acid	O
dimmer	O
-	O
sebacic	O
acid	O
)	O
or	O
poly	O
(	O
fumaric	O
acid	O
-	O
sebacic	O
acid	O
)	O
.	O

The	O
anti	O
-	O
cancer	O
compound	O
can	O
be	O
made	O
as	O
slow	O
release	O
plant	O
agent	O
,	O
to	O
inject	O
into	O
cancer	O
or	O
around	O
cancer	O
to	O
hold	O
the	O
effective	O
drug	O
density	O
for	O
more	O
than	O
40	O
days	O
,	O
while	O
it	O
can	O
significantly	O
reduce	O
the	O
general	O
reaction	O
of	O
drug	O
and	O
selectively	O
strengthen	O
the	O
effect	O
of	O
non	O
-	O
surgery	O
treatments	O
as	O
chemotherapy	O
or	O
the	O
like	O
.	O

Medicine	O
composition	O
and	O
its	O
preparing	O
method	O
A	O
medicinal	O
composition	O
is	O
prepared	O
from	O
gentamycin	O
,	O
amitriptyline	O
,	O
honey	O
,	O
and	O
11	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
notoginseng	O
,	O
peach	O
kernel	O
,	O
fennel	O
,	O
borax	O
,	O
etc	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

An	O
improved	O
process	O
for	O
preparing	O
pure	O
ondansetron	O
hydrochloride	O
dihydrate	O
An	O
improved	O
method	O
for	O
preparing	O
dimethylamino	O
-	O
methyl	O
-	O
carbazolone	O
and	O
ondansetron	O
base	O
.	O

A	O
recrystallization	O
process	O
for	O
preparing	O
pure	O
ondansetron	O
hydrochloride	O
dihydrate	O
with	O
a	O
purity	O
of	O
at	O
least	O
99.0	O
%	O
is	O
also	O
disclosed	O
.	O

Anethol	O
trithione	O
drop	O
pills	O
,	O
and	O
preparation	O
method	O
A	O
dripping	O
pill	O
of	O
anethol	O
trithione	O
for	O
treating	O
cholecystitis	O
,	O
cholelithiasis	O
and	O
acute	O
or	O
chronic	O
hepatitis	O
is	O
prepared	O
from	O
the	O
anethol	O
trithione	O
and	O
the	O
matrix	O
of	O
dripping	O
pill	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Suppository	O
for	O
treating	O
wound	O
caused	O
by	O
cervical	O
erosion	O
treatment	O
Disclosed	O
is	O
a	O
suppository	O
for	O
processing	O
wounds	O
in	O
the	O
treatment	O
of	O
uterine	O
neck	O
erosion	O
,	O
which	O
comprises	O
biologically	O
active	O
glass	O
,	O
collagen	O
and	O
activated	O
charcoal	O
fiber	O
by	O
a	O
weight	O
ratio	O
of	O
30	O
-	O
70:70	O
-	O
30	O
.	O

The	O
preparing	O
process	O
comprises	O
steps	O
of	O
coating	O
the	O
activated	O
charcoal	O
fiber	O
into	O
a	O
circular	O
form	O
,	O
crosslinking	O
the	O
collagen	O
solution	O
or	O
dried	O
powder	O
,	O
proportioning	O
collagen	O
and	O
biologically	O
active	O
glass	O
,	O
dissolving	O
and	O
stirring	O
20	O
-	O
50	O
minutes	O
,	O
freeze	O
drying	O
,	O
pressurizing	O
to	O
obtain	O
composite	O
film	O
,	O
adhering	O
the	O
composite	O
film	O
with	O
one	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
,	O
and	O
fixing	O
the	O
other	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
with	O
soft	O
wires	O
.	O

The	O
collagen	O
can	O
be	O
replaced	O
with	O
chitosan	O
.	O

Medical	O
combination	O
of	O
teniposide	O
,	O
the	O
preparing	O
method	O
and	O
the	O
function	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicinal	O
component	O
of	O
substitute	O
nipa	O
glycosides	O
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
incorporating	O
substitute	O
nipa	O
glycosides	O
,	O
Tuwen	O
surface	O
activator	O
,	O
assisting	O
solvent	O
and	O
inorganic	O
salt	O
;	O
choosing	O
the	O
assisting	O
solvent	O
as	O
mixture	O
of	O
dimethyl	O
ethanolamine	O
and	O
carbowax	O
;	O
choosing	O
the	O
inorganic	O
salt	O
from	O
one	O
or	O
multiple	O
common	O
salt	O
,	O
potassium	O
chloride	O
,	O
sulphate	O
and	O
sulphate	O
;	O
setting	O
this	O
component	O
as	O
injection	O
or	O
freeze	O
dry	O
powder	O
needle	O
;	O
adding	O
into	O
Tuwen	O
and	O
the	O
assisting	O
dissolvent	O
;	O
adding	O
into	O
the	O
inorganic	O
salt	O
at	O
the	O
same	O
time	O
;	O
increasing	O
solubility	O
of	O
substitute	O
nipa	O
glycosides	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
preparing	O
method	O
and	O
usage	O
of	O
this	O
medicinal	O
component	O
.	O

Novel	O
medicine	O
for	O
giving	O
up	O
drug	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
medicament	O
for	O
drug	O
abstinence	O
which	O
comprises	O
the	O
following	O
constituents	O
(	O
by	O
weight	O
ratio	O
)	O
:	O
acanthopanax	O
root	O
18	O
-	O
30	O
%	O
,	O
polygala	O
root	O
6	O
-	O
12	O
%	O
,	O
dendrobium	O
9	O
-	O
16	O
%	O
,	O
notoginseng	O
3	O
-	O
10	O
%	O
,	O
ginseng	O
10	O
-	O
24	O
%	O
,	O
ginkgo	O
leaves	O
24	O
-	O
34	O
%	O
,	O
atropine	O
sulfate	O
0	O
.	O

05	O
-	O
1	O
.	O
5	O
%	O
,	O
ansiolin	O
0	O
.	O
05	O
-	O
1	O
.	O
0	O
%	O
.	O

The	O
medicament	O
can	O
be	O
prepared	O
into	O
capsules	O
,	O
granules	O
and	O
tablets	O
through	O
conventional	O
processes	O
.	O

Method	O
for	O
preparing	O
iron	O
-	O
complementing	O
agent	O
by	O
complex	O
of	O
parafobrown	O
algin	O
and	O
iron	O
The	O
invention	O
is	O
concerned	O
with	O
the	O
method	O
to	O
produce	O
supply	O
of	O
iron	O
using	O
the	O
algin	O
and	O
compound	O
of	O
iron	O
.	O

Put	O
the	O
water	O
solution	O
or	O
degeneration	O
fluid	O
of	O
algin	O
into	O
a	O
container	O
,	O
add	O
assistant	O
stabilizer	O
and	O
inorganic	O
iron	O
salt	O
,	O
and	O
the	O
concentration	O
is	O
0.1	O
to	O
0.50	O
mol	O
/	O
L	O
,	O
adjust	O
the	O
pH	O
of	O
solution	O
is	O
4	O
to	O
8	O
,	O
refluence	O
for	O
2	O
to	O
5	O
hours	O
,	O
dialyse	O
,	O
concentrate	O
,	O
divide	O
with	O
alcohol	O
and	O
taking	O
centrifugal	O
processing	O
.	O

Wash	O
and	O
dry	O
the	O
sedimentation	O
to	O
get	O
algin	O
Fe	O
(	O
III	O
)	O
compound	O
.	O

The	O
method	O
has	O
reasonable	O
prcess	O
and	O
low	O
cost	O
,	O
the	O
produced	O
supply	O
of	O
iron	O
has	O
nice	O
stability	O
with	O
high	O
biology	O
utilization	O
ratio	O
,	O
the	O
revivification	O
and	O
dissolving	O
time	O
is	O
fit	O
to	O
absorb	O
for	O
body	O
.	O

The	O
algin	O
forms	O
into	O
gel	O
with	O
stomach	O
acid	O
and	O
protecting	O
film	O
on	O
the	O
surface	O
of	O
stomach	O
in	O
order	O
to	O
reduce	O
the	O
stimulating	O
to	O
stomach	O
.	O

It	O
is	O
fit	O
for	O
pregnant	O
woman	O
,	O
children	O
and	O
gastricism	O
sufferer	O
.	O

Novel	O
use	O
of	O
medicine	O
The	O
present	O
invention	O
provides	O
new	O
use	O
of	O
arctiin	O
,	O
and	O
is	O
especially	O
the	O
application	O
of	O
arctiin	O
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
chronic	O
renal	O
failure	O
and	O
renal	O
fiberosis	O
.	O

Improved	O
process	O
of	O
preparing	O
Raltitrexed	O
The	O
improvement	O
in	O
the	O
process	O
of	O
preparing	O
Raltitrexed	O
as	O
antitumor	O
medicine	O
includes	O
the	O
reaction	O
between	O
N-	O
(	O
5-aminothienyl-2-formoxyl	O
)	O
-L	O
-	O
diethyl	O
glutarate	O
and	O
methyl	O
iodide	O
at	O
temperature	O
raised	O
to	O
100	O
deg.c	O
in	O
lucifugous	O
condition	O
with	O
yield	O
raised	O
to	O
91	O
%	O
;	O
the	O
replacement	O
of	O
sodium	O
sulfide	O
for	O
iron	O
powder	O
as	O
reductant	O
to	O
facilitate	O
post	O
-	O
treatment	O
and	O
raise	O
yield	O
;	O
the	O
replacement	O
of	O
re	O
-	O
crystallization	O
in	O
mixed	O
solvent	O
of	O
methanol	O
and	O
ether	O
for	O
column	O
separation	O
to	O
expand	O
the	O
production	O
capacity	O
;	O
and	O
oxidizing	O
5-nitrothienyl-2-formaldehyde	O
with	O
chromic	O
acid	O
,	O
rather	O
than	O
bromine	O
,	O
to	O
eliminate	O
toxicity	O
and	O
raise	O
safety	O
.	O

The	O
improved	O
preparation	O
process	O
of	O
Raltitrexed	O
has	O
high	O
yield	O
,	O
great	O
production	O
capacity	O
,	O
low	O
solvent	O
consumption	O
and	O
high	O
safety	O
.	O

Potato	O
red	O
healing	O
liquid	O
and	O
method	O
for	O
preparing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
medicine	O
and	O
its	O
production	O
method	O
,	O
especially	O
relates	O
to	O
a	O
kind	O
of	O
rehabilitation	O
liquid	O
and	O
the	O
production	O
method	O
.	O

It	O
is	O
specialized	O
for	O
fiber	O
lung	O
treatment	O
.	O

The	O
anti	O
-	O
inflammation	O
effect	O
of	O
potato	O
is	O
strong	O
,	O
and	O
the	O
disinfection	O
effect	O
of	O
chromargyre	O
is	O
good	O
,	O
the	O
invention	O
combines	O
the	O
anti	O
-	O
inflammation	O
and	O
disinfection	O
effect	O
together	O
,	O
and	O
dissolves	O
them	O
in	O
spirit	O
to	O
treat	O
lung	O
disease	O
;	O
the	O
rehabilitation	O
liquid	O
can	O
be	O
discharged	O
through	O
manure	O
and	O
urine	O
,	O
so	O
it	O
can	O
disinfect	O
and	O
eliminate	O
inflammation	O
when	O
passing	O
through	O
other	O
organs	O
with	O
disease	O
.	O

The	O
production	O
method	O
comprises	O
two	O
technique	O
programs	O
:	O
one	O
is	O
immersion	O
and	O
another	O
is	O
blending	O
.	O

Ruthenium	O
-	O
anthraquinone	O
conjugates	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
for	O
optical	O
power	O
therapeutic	O
photosensitizer	O
The	O
invention	O
discloses	O
a	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
,	O
the	O
preparation	O
process	O
thereof	O
and	O
the	O
application	O
as	O
a	O
photo	O
-	O
dynamic	O
therapy	O
photosensitizer	O
.	O

The	O
general	O
formula	O
of	O
the	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
of	O
the	O
invention	O
is	O
[	O
Ru	O
(	O
L	O
)	O
2HAIP	O
]	O
.	O
(	O
PF6	O
)	O
2	O
,	O
the	O
general	O
formula	O
of	O
the	O
HAIP	O
is	O
1,8-	O
dihydroxy	O
-9,10-	O
anthraquinoneimidazole	O
[	O
4,5-f	O
]	O
[	O
1,10	O
]	O
phenanthroline	O
,	O
the	O
general	O
of	O
the	O
L	O
is	O
bpy	O
or	O
phen	O
.	O

The	O
preparation	O
process	O
for	O
the	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
comprises	O
the	O
following	O
procedures	O
:	O
1	O
.	O
the	O
synthesis	O
of	O
the	O
HAIP	O
:	O
1,8-	O
dihydroxy	O
-9,10-	O
anthraquinone-3-aldehyde	O
is	O
reacted	O
with	O
the	O
phenanthroline5,6-diketone	O
to	O
produce	O
the	O
HAIP	O
;	O
2	O
.	O

Ru	O
(	O
L	O
)	O
2Cl2	O
is	O
reacted	O
with	O
HAIP	O
and	O
NH4PF6	O
to	O
produce	O
the	O
[	O
Ru	O
(	O
L	O
)	O
2HAIP	O
]	O
.	O
(	O
PF6	O
)	O
2	O
.	O

The	O
invention	O
takes	O
the	O
aloe	O
-	O
emodin	O
as	O
the	O
raw	O
material	O
and	O
the	O
ruthenium	O
polypyridyl	O
complex	O
has	O
single	O
chemical	O
composition	O
;	O
the	O
synthesis	O
route	O
is	O
simple	O
and	O
the	O
yields	O
are	O
higher	O
;	O
during	O
the	O
experiment	O
,	O
the	O
compound	O
shows	O
the	O
light	O
suppression	O
to	O
the	O
growth	O
of	O
cancer	O
cells	O
.	O

Pistachio	O
galls	O
pressure	O
ulcer	O
powder	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
and	O
dietary	O
composition	O
for	O
treating	O
bedsore	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
composition	O
is	O
prepared	O
mainly	O
from	O
frankincense	O
,	O
Chinese	O
angelica	O
root	O
,	O
dahurian	O
angelica	O
root	O
,	O
dried	O
rehmannia	O
root	O
,	O
goldthread	O
root	O
and	O
boneol	O
,	O
the	O
medicament	O
can	O
also	O
be	O
used	O
as	O
a	O
conventional	O
health	O
dietary	O
preparation	O
having	O
no	O
side	O
effects	O
easy	O
administering	O
.	O

Anticancer	O
diaminocyclohexane	O
metallic	O
complex	O
The	O
invention	O
discloses	O
a	O
medicinal	O
molecule	O
with	O
selective	O
anticancer	O
activity	O
with	O
structure	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
uses	O
chiral	O
cyclohexamethylene	O
diamine	O
derivative	O
and	O
metal	O
ion	O
to	O
form	O
metal	O
complex	O
after	O
coordinating	O
and	O
provides	O
the	O
making	O
method	O
of	O
the	O
typical	O
compound	O
and	O
inhibition	O
and	O
mechanism	O
of	O
the	O
growth	O
of	O
human	O
breast	O
cancer	O
and	O
lung	O
cancer	O
,	O
wherein	O
R1	O
and	O
R2	O
contains	O
random	O
one	O
meaning	O
organic	O
group	O
or	O
hydrogen	O
atom	O
;	O
A1	O
and	O
A2	O
can	O
be	O
individually	O
selected	O
from	O
random	O
organic	O
group	O
;	O
M	O
is	O
random	O
one	O
transition	O
system	O
,	O
expensive	O
metal	O
or	O
rare	O
earth	O
metal	O
ion	O
or	O
radioactive	O
isotope	O
;	O
B1,B2,C1	O
and	O
C2	O
represent	O
random	O
one	O
complex	O
ion	O
,	O
molecular	O
or	O
vacant	O
site	O
individually	O
;	O
B1	O
and	O
B2	O
can	O
represent	O
a	O
couple	O
of	O
tooth	O
complex	O
together	O
;	O
R1,R2	O
,	O
A1,A2,B1,B2,C1	O
and	O
C2	O
can	O
link	O
biological	O
molecule	O
.	O

Application	O
of	O
alkaloids	O
compounds	O
in	O
the	O
preparation	O
of	O
antineoplastic	O
medicament	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
art	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
an	O
alkaloid	O
compound	O
in	O
the	O
preparation	O
of	O
antitumor	O
drugs	O
.	O

The	O
alkaloid	O
compound	O
consists	O
of	O
a	O
Lycoris	O
lactone	O
,	O
a	O
narciprimine	O
and	O
a	O
7-dehydroxyl	O
narciprimine	O
and	O
the	O
molecular	O
formula	O
of	O
the	O
alkaloid	O
compound	O
is	O
C17H19NO5	O
,	O
C14H9NO5	O
,	O
C14H9NO4	O
.	O

Animal	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
better	O
inhibited	O
activity	O
on	O
a	O
variety	O
of	O
tumors	O
.	O

The	O
invention	O
also	O
includes	O
one	O
or	O
more	O
than	O
one	O
types	O
of	O
three	O
compounds	O
with	O
effective	O
treatment	O
,	O
or	O
includes	O
medicine	O
combinations	O
of	O
the	O
pharmaceutical	O
acceptable	O
carrier	O
.	O

2-dihydro	O
indolone	O
derivant	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
2-dihydroindolone	O
compound	O
as	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
relative	O
application	O
of	O
the	O
compound	O
or	O
the	O
medical	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Pharmacological	O
experiment	O
proves	O
that	O
the	O
compound	O
or	O
relative	O
medical	O
acceptable	O
salt	O
can	O
restrain	O
various	O
cancer	O
cell	O
proliferations	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
an	O
intermediate	O
formula	O
(	O
II	O
)	O
of	O
the	O
compound	O
.	O

Pain	O
-	O
relieving	O
plaster	O
and	O
preparing	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pain	O
ointmentl	O
,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
the	O
major	O
components	O
of	O
the	O
drug	O
comprise	O
radix	O
saposhnikoviae	O
and	O
ginseng	O
,	O
the	O
mixture	O
ratio	O
is	O
55	O
-	O
65	O
precent:35	O
-	O
45	O
percent	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
the	O
radix	O
saposhnikoviae	O
is	O
in	O
wild	O
nature	O
with	O
sweet	O
and	O
pungent	O
taste	O
,	O
which	O
has	O
the	O
efficacy	O
of	O
inducing	O
diaphoresis	O
to	O
dispel	O
wind	O
,	O
clearing	O
wind	O
-	O
damp	O
and	O
anti	O
-	O
spasticity	O
,	O
and	O
has	O
obvious	O
significant	O
efficacy	O
for	O
muscular	O
constricture	O
,	O
rheumatism	O
and	O
pruritus	O
;	O
the	O
ginseng	O
has	O
the	O
efficacy	O
of	O
expanding	O
coronary	O
artery	O
and	O
blood	O
vessels	O
;	O
the	O
product	O
has	O
no	O
additives	O
or	O
stroma	O
for	O
affecting	O
the	O
body	O
skin	O
;	O
the	O
use	O
is	O
convenient	O
and	O
the	O
effect	O
is	O
good	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
economical	O
and	O
practical	O
.	O

Telomerase	B
inhibitor	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
thiazole	O
[	O
5	O
,	O
4-b	O
]	O
pyrimidine	O
compounds	O
(	O
I	O
)	O
,	O
preparation	O
methods	O
thereof	O
and	O
also	O
to	O
pharmaceutical	O
composites	O
containing	O
the	O
compounds	O
and	O
medical	O
purposes	O
thereof	O
,	O
in	O
particular	O
to	O
telomerase	B
inhibitors	O
.	O

Skeleton	O
type	O
roxithromycin	O
sustained	O
release	O
pellet	O
capsule	O
The	O
invention	O
provides	O
a	O
matrix	O
-	O
typed	O
roxithromycin	O
sustained	O
release	O
micropill	O
capsule	O
which	O
is	O
prepared	O
by	O
60	O
-	O
75wt	O
percent	O
of	O
roxithromycin	O
,	O
2	O
-	O
5wt	O
percent	O
of	O
waxy	O
matrix	O
material	O
,	O
10	O
-	O
25wt	O
percent	O
of	O
microcrystalline	O
cellulose	O
,	O
lactose	O
,	O
cane	O
sugar	O
or	O
xylose	O
,	O
2	O
-	O
5wt	O
percent	O
of	O
hydrophilic	O
matrix	O
material	O
,	O
1	O
-	O
4wt	O
percent	O
of	O
anhydrous	O
sodium	O
carbonate	O
and	O
4	O
-	O
10wt	O
percent	O
of	O
mannite	O
according	O
to	O
the	O
normal	O
preparation	O
method	O
.	O

The	O
waxy	O
matrix	O
material	O
is	O
octodecyl	O
alcohol	O
,	O
cetyl	O
alcohol	O
,	O
octadecanoic	O
acid	O
,	O
glycerin	O
monostearate	O
or	O
hydrogenated	O
castor	O
oil	O
.	O

The	O
hydrophilic	O
matrix	O
material	O
is	O
xanthan	O
gum	O
,	O
alginic	O
acid	O
or	O
carbomer	O
974P	O
.	O

The	O
matrix	O
material	O
adopted	O
in	O
the	O
invention	O
delays	O
the	O
release	O
of	O
the	O
drug	O
,	O
reduces	O
the	O
density	O
of	O
sustained	O
release	O
micropill	O
,	O
prolongs	O
the	O
staying	O
time	O
of	O
the	O
sustained	O
release	O
micropill	O
in	O
the	O
stomach	O
and	O
intestinal	O
tract	O
and	O
improves	O
the	O
bioavailability	O
of	O
the	O
medicine	O
.	O

A	O
comparison	O
test	O
between	O
the	O
medicine	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	O
sustained	O
release	O
pill	O
is	O
carried	O
out	O
in	O
eighteen	O
testers	O
and	O
the	O
test	O
shows	O
that	O
the	O
matrix	O
-	O
typed	O
roxithromycin	O
slow	O
-	O
release	O
micropill	O
capsule	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	O
slow	O
-	O
release	O
pill	O
have	O
bioequiavailability	O
.	O

Tinidazole	O
compound	O
nano	O
silver	O
microemulsion	O
antibacterial	O
medicine	O
The	O
invention	O
discloses	O
a	O
tinidazole	O
nano	O
-	O
composite	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
,	O
0.10	O
to	O
1.50	O
units	O
of	O
tinidazole	O
and	O
0.008	O
to	O
0.020	O
units	O
of	O
nano	O
-	O
silver	O
being	O
regarded	O
as	O
medical	O
components	O
,	O
and	O
96.92	O
to	O
99.67	O
units	O
of	O
micro	O
-	O
emulsified	O
substrate	O
and	O
0.30	O
to	O
3.00	O
units	O
of	O
auxiliary	O
materials	O
are	O
evenly	O
mixed	O
together	O
with	O
a	O
certain	O
percentage	O
,	O
then	O
the	O
tinidazole	O
complex	O
nano	O
-	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
can	O
be	O
got	O
which	O
has	O
a	O
yellow	O
outlook	O
,	O
the	O
diameter	O
of	O
grains	O
is	O
1	O
nm	O
to	O
100	O
nm	O
,	O
the	O
invention	O
is	O
stable	O
,	O
which	O
can	O
not	O
only	O
disturb	O
the	O
synthesis	O
of	O
DNA	O
,	O
but	O
also	O
be	O
able	O
to	O
combine	O
with	O
oxygen	O
metabolic	O
enzyme	O
(	O
-SH	O
)	O
to	O
interrupt	O
the	O
respiration	O
metabolism	O
process	O
,	O
so	O
as	O
to	O
kill	O
the	O
aerobic	O
and	O
anaerobic	O
pathogens	O
and	O
improve	O
the	O
recovery	O
of	O
wounds	O
,	O
and	O
diseases	O
such	O
as	O
vaginitis	O
,	O
endometritis	O
can	O
be	O
quickly	O
and	O
effectively	O
cured	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
and	O
safe	O
.	O

Application	O
of	O
asiaticoside	O
in	O
pulmonary	O
fibrosis	O
resistant	O
delayed	O
period	O
The	O
invention	O
discloses	O
a	O
new	O
application	O
in	O
a	O
preparation	O
using	O
asiaticoside	O
in	O
a	O
drug	O
against	O
delayed	O
lung	O
fibrosis	O
.	O

At	O
the	O
end	O
of	O
the	O
delayed	O
lung	O
fibrosis	O
,	O
the	O
asiaticoside	O
has	O
an	O
effect	O
against	O
the	O
lung	O
fibrosis	O
under	O
an	O
action	O
of	O
a	O
promoting	O
fibrosis	O
cytokine	B
in	O
vivo	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
drug	O
composition	O
against	O
delayed	O
lung	O
fibrosis	O
,	O
which	O
active	O
component	O
comprises	O
the	O
asiaticoside	O
and	O
the	O
exogenous	O
promoting	O
fibrosis	O
cytokine	B
.	O

Iron	O
supplement	O
composition	O
,	O
its	O
preparing	O
method	O
and	O
application	O
of	O
the	O
same	O
The	O
invention	O
discloses	O
a	O
drug	O
combination	O
as	O
iron	O
supplementary	O
agent	O
which	O
is	O
characterized	O
in	O
that	O
the	O
drug	O
combination	O
has	O
carbonyl	O
iron	O
and	O
natural	O
anti	O
-	O
oxidant	O
components	O
which	O
have	O
the	O
drug	O
activity	O
;	O
the	O
drug	O
combination	O
can	O
also	O
have	O
pharmaceutical	O
carrier	O
.	O

The	O
invention	O
also	O
disclosed	O
the	O
preparation	O
,	O
comprising	O
the	O
drug	O
combination	O
,	O
the	O
preparation	O
method	O
of	O
the	O
combination	O
and	O
the	O
preparation	O
,	O
and	O
the	O
function	O
of	O
preventing	O
and	O
curing	O
iron	O
deficiency	O
of	O
the	O
drug	O
combination	O
.	O

The	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
iron	O
deficiency	O
anemia	O
is	O
treated	O
effectively	O
;	O
the	O
production	O
of	O
free	O
radical	O
in	O
human	O
body	O
is	O
inhibited	O
;	O
the	O
oxygen	O
metabolism	O
balance	O
in	O
human	O
body	O
is	O
maintained	O
;	O
the	O
physical	O
quality	O
of	O
the	O
patient	O
is	O
enhanced	O
;	O
and	O
the	O
immunity	O
of	O
body	O
is	O
improved	O
.	O

Sheep	O
insect	O
powder	O
for	O
treating	O
epilepsy	O
The	O
invention	O
relates	O
to	O
a	O
powder	O
for	O
treating	O
epilepsy	O
,	O
comprising	O
sheep	O
parasite	O
,	O
tussah	O
pupa	O
,	O
fennel	O
,	O
muscardine	O
cadaver	O
,	O
finch	O
brain	O
,	O
hawksbill	O
,	O
oryzanol	O
,	O
and	O
cow	O
-	O
bezoar	O
,	O
which	O
are	O
prepared	O
in	O
proportion	O
and	O
in	O
order	O
under	O
normal	O
temperature	O
.	O

The	O
powder	O
has	O
the	O
advantages	O
:	O
the	O
powder	O
has	O
the	O
advantages	O
of	O
easily	O
-	O
purchased	O
raw	O
materials	O
,	O
low	O
cost	O
,	O
simple	O
technology	O
,	O
easy	O
popularization	O
,	O
and	O
convenient	O
use	O
;	O
the	O
powder	O
can	O
make	O
the	O
percentage	O
of	O
epilepsy	O
-	O
treatment	O
reach	O
98.2	O
%	O
,	O
and	O
the	O
cure	O
rate	O
91.8	O
%	O
.	O

Lamb	O
stomach	O
extract	O
vitamin	O
B12	O
preparations	O
composing	O
prescription	O
The	O
present	O
invention	O
provides	O
a	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
.	O

The	O
material	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
is	O
the	O
total	O
extracts	O
from	O
the	O
forth	O
gastric	O
of	O
the	O
lambs	O
;	O
when	O
calculated	O
as	O
the	O
dried	O
material	O
,	O
the	O
rennet	O
activity	O
in	O
each	O
gram	O
is	O
not	O
less	O
than	O
800	O
units	O
,	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
not	O
less	O
than	O
230	O
units	O
;	O
the	O
ratio	O
of	O
rennet	O
activity	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
2.0	O
to	O
4.1	O
.	O

The	O
ratio	O
can	O
clinically	O
avoid	O
side	O
effects	O
caused	O
by	O
too	O
high	O
stomach	O
enzyme	O
activity	O
;	O
the	O
invention	O
can	O
be	O
used	O
for	O
patients	O
of	O
gastritis	O
with	O
erosion	O
,	O
hyperemia	O
and	O
ulcer	O
,	O
and	O
can	O
also	O
treat	O
anorexia	O
,	O
diarrhea	O
and	O
milk	O
vomiting	O
of	O
babies	O
.	O

The	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
has	O
simple	O
manufacturing	O
process	O
and	O
does	O
not	O
use	O
organic	O
solvent	O
.	O

Smell	O
concealing	O
composition	O
of	O
hydrochloric	O
selegiline	O
,	O
and	O
preparation	O
containing	O
the	O
composition	O
The	O
invention	O
provides	O
a	O
Selegiline	O
hydrochloride	O
smell	O
covering	O
compound	O
,	O
which	O
contains	O
sugar	O
alcohol	O
,	O
corrective	O
agent	O
,	O
gelatin	B
,	O
and	O
xanthan	O
gum	O
,	O
and	O
is	O
treated	O
by	O
special	O
process	O
and	O
is	O
evenly	O
dispersed	O
with	O
Selegiline	O
hydrochloride	O
.	O

The	O
compound	O
covers	O
the	O
stimulating	O
taste	O
of	O
Selegiline	O
hydrochloride	O
,	O
is	O
used	O
for	O
preparing	O
the	O
orally	O
disintegrating	O
tablet	O
,	O
and	O
is	O
used	O
for	O
treating	O
Parkinsons	O
disease	O
.	O

Antisense	O
oligonucleotide	O
for	O
tissue	O
-	O
specific	O
regulation	O
of	O
POKEMON	B
gene	O
expression	O
and	O
application	O
thereof	O
The	O
present	O
invention	O
provides	O
an	O
antisense	O
oligonucleotide	O
of	O
tissue	O
-	O
specific	O
regulation	O
POKEMON	B
gene	O
expression	O
and	O
its	O
application	O
.	O

The	O
antisense	O
oligonucleotide	O
is	O
one	O
of	O
the	O
following	O
formulas	O
:	O
CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx	O
;	O
CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx	O
;	O
GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx	O
;	O
TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx	O
;	O
TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx	O
.	O

X	O
is	O
bond	O
between	O
thiophosphate	O
nucleoside	O
.	O

The	O
antisense	O
oligonucleotide	O
of	O
the	O
invention	O
is	O
used	O
for	O
preparing	O
gene	O
therapeutic	O
drug	O
for	O
curing	O
disease	O
caused	O
by	O
POKEMON	B
high	O
expression	O
.	O

Instant	O
type	O
gel	O
preparation	O
for	O
eye	O
and	O
method	O
of	O
producing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
an	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
can	O
be	O
prepared	O
by	O
mixing	O
a	O
Gelrite	O
Gellan	O
gum	O
as	O
a	O
matrix	O
base	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
kanamycin	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
released	O
injection	O
comprising	O
kanamycin	O
,	O
which	O
comprises	O
a	O
slow	O
-	O
released	O
microsphere	O
and	O
a	O
dissolvent	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
comprises	O
a	O
slow	O
-	O
release	O
adjuvant	O
and	O
the	O
aminoglycoside	O
antibiotic	O
;	O
the	O
dissolvent	O
is	O
the	O
special	O
dissolvent	O
which	O
comprises	O
a	O
suspending	O
agent	O
such	O
as	O
sodium	O
carboxymethylcellulose	O
,	O
etc	O
.	O
,	O
and	O
the	O
viscosity	O
of	O
which	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
DEG	O
C-30	O
DEC	O
C	O
)	O
;	O
the	O
slow	O
-	O
release	O
adjuvant	O
can	O
be	O
selected	O
from	O
EVAc	O
,	O
polifeprosan	O
,	O
PLA	O
,	O
PLGA	O
,	O
sebacic	O
acid	O
copolymer	O
,	O
albumen	O
glue	O
and	O
gelatin	O
,	O
etc	O
.	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
a	O
slow	O
-	O
released	O
implant	O
and	O
an	O
ointment	O
.	O

The	O
slow	O
-	O
released	O
implant	O
and	O
the	O
slow	O
-	O
released	O
injection	O
can	O
be	O
partially	O
placed	O
or	O
injected	O
in	O
a	O
bacterial	O
focus	O
to	O
release	O
locally	O
and	O
slowly	O
for	O
more	O
than	O
5	O
-	O
30	O
days	O
,	O
thereby	O
obviously	O
reducing	O
the	O
toxicity	O
of	O
the	O
entire	O
body	O
while	O
getting	O
and	O
maintaining	O
a	O
valid	O
medicine	O
density	O
in	O
the	O
local	O
focus	O
effectively	O
.	O

The	O
slow	O
-	O
released	O
injection	O
comprising	O
the	O
kanamycin	O
of	O
the	O
invention	O
has	O
obvious	O
special	O
treatment	O
effect	O
for	O
focus	O
of	O
local	O
infection	O
such	O
as	O
chronic	O
osteomyelitis	O
,	O
severe	O
bedsore	O
,	O
refractory	O
skin	O
ulcer	O
,	O
diabetic	O
foot	O
,	O
osteonecrosis	O
of	O
femoral	O
head	O
and	O
various	O
abscesses	O
,	O
etc	O
.	O
,	O
caused	O
by	O
staphylococcus	O
,	O
streptococcus	O
,	O
peptostreptococcus	O
,	O
propionibacterium	O
acnes	O
,	O
enterobacter	O
,	O
tubercle	O
bacillus	O
,	O
gonococcus	O
and	O
meningococcus	O
,	O
etc	O
.	O

Pabala	O
selenizing	O
VE	O
health	O
products	O
The	O
invention	O
relates	O
to	O
a	O
health	O
care	O
product	O
which	O
is	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
.	O

The	O
health	O
product	O
is	O
made	O
of	O
raw	O
materials	O
,	O
including	O
90	O
to	O
100	O
parts	O
of	O
balsam	O
pear	O
extract	O
,	O
0.5	O
to	O
1.0	O
part	O
of	O
selenium	O
,	O
0.1	O
to	O
0.5	O
part	O
of	O
Vitamin	O
E	O
and	O
90	O
to	O
110	O
parts	O
of	O
starch	O
.	O

Composing	O
prescription	O
is	O
simple	O
and	O
supplementary	O
trace	O
elements	O
are	O
reasonable	O
.	O

So	O
the	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
can	O
serve	O
as	O
accessory	O
food	O
for	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

The	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
has	O
no	O
adverse	O
effect	O
and	O
is	O
suitable	O
for	O
long	O
-	O
term	O
administration	O
.	O

Oleanolic	O
acid	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
oleanolic	O
acid	O
orally	O
disintegrating	O
tablets	O
with	O
high	O
dissolution	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oleanolic	O
acid	O
orally	O
disintegrating	O
tablets	O
are	O
characterized	O
in	O
that	O
oleanolic	O
acid	O
is	O
prepared	O
into	O
solid	O
dispersion	O
via	O
hydrophilic	O
solid	O
dispersion	O
carrier	O
,	O
so	O
as	O
to	O
remarkably	O
improve	O
the	O
dissolution	O
,	O
promote	O
the	O
absorption	O
and	O
remarkably	O
improve	O
the	O
bioavailability	O
of	O
oleanolic	O
acid	O
.	O

The	O
weight	O
ratio	O
of	O
the	O
solid	O
dispersion	O
carrier	O
and	O
oleanolic	O
acid	O
is	O
0.5	O
-	O
5	O
.	O

Then	O
,	O
the	O
solid	O
dispersion	O
is	O
mixed	O
with	O
adjuvants	O
such	O
as	O
bulking	O
agent	O
,	O
corrective	O
and	O
lubricant	O
and	O
made	O
into	O
orally	O
disintegrating	O
tablets	O
by	O
using	O
conventional	O
tablet	O
production	O
equipment	O
via	O
directly	O
tabletting	O
or	O
wet	O
granulating	O
process	O
.	O

The	O
preparation	O
has	O
disintegrating	O
time	O
of	O
5	O
-	O
50s	O
,	O
and	O
dissolution	O
in	O
0.5	O
sodium	O
lauryl	O
sulfate	O
solution	O
in	O
1	O
hour	O
over	O
80	O
%	O
,	O
even	O
over	O
90	O
%	O
.	O

Benzoxazole	O
ketones	O
derivative	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
series	O
of	O
novel	O
compounds	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
particularly	O
to	O
a	O
series	O
of	O
benzoxazolone	O
derivatives	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
solves	O
the	O
problem	O
that	O
the	O
prior	O
benzoxazolone	O
compounds	O
have	O
no	O
4-substituted	O
derivatives	O
and	O
have	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
.	O

The	O
general	O
structural	O
formula	O
of	O
the	O
derivatives	O
is	O
shown	O
in	O
the	O
figure	O
,	O
wherein	O
R	O
is	O
C3-C6	O
fatty	O
acid	O
ester	O
group	O
,	O
benzoate	O
group	O
/	O
substituted	O
benzoate	O
group	O
,	O
benzene	O
sulfonate	O
group	O
/	O
substituted	O
benzene	O
sulfonate	O
group	O
,	O
amino	O
acid	O
ester	O
group	O
,	O
or	O
heterocyclic	O
acid	O
ester	O
group	O
/	O
substituted	O
heterocyclic	O
acid	O
ester	O
group	O
.	O

The	O
invention	O
obtains	O
a	O
series	O
of	O
4-substituted	O
benzoxazolone	O
derivatives	O
with	O
proven	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
,	O
opens	O
new	O
preparation	O
paths	O
of	O
the	O
above	O
three	O
drugs	O
,	O
and	O
brings	O
new	O
breakthrough	O
in	O
pharmaceutical	O
and	O
pesticide	O
fields	O
.	O

In	O
addition	O
,	O
the	O
synthetic	O
method	O
has	O
the	O
advantages	O
of	O
easy	O
operation	O
,	O
mild	O
reaction	O
conditions	O
,	O
single	O
reaction	O
product	O
,	O
and	O
applicability	O
to	O
large	O
scale	O
production	O
.	O

Chitosan	O
oral	O
scented	O
pieces	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
chitosan	O
cachou	O
.	O

The	O
chitosan	O
cachou	O
is	O
prepared	O
by	O
chitosan	O
,	O
corn	O
starch	O
,	O
xylitol	O
,	O
maltodextrin	O
,	O
acesulfame	O
potassium	O
,	O
sodium	O
cyclamate	O
,	O
menthol	O
,	O
and	O
magnesium	O
stearate	O
,	O
and	O
the	O
preparation	O
method	O
includes	O
the	O
following	O
steps	O
:	O
embedding	O
processing	O
of	O
essence	O
,	O
mixing	O
,	O
damp	O
mass	O
making	O
,	O
wet	O
granule	O
making	O
,	O
drying	O
,	O
granule	O
finishing	O
,	O
final	O
mixing	O
,	O
sheeting	O
,	O
sterilization	O
,	O
and	O
packaging	O
,	O
thus	O
obtaining	O
the	O
chitosan	O
cachou	O
.	O

Diaminopyrimidines	O
as	O
P2X3	B
and	O
P2X2	B
/	I
3	I
modulators	O
Compounds	O
and	O
methods	O
for	O
treating	O
diseases	O
mediated	O
by	O
a	O
P2X3	B
and/or	O
a	O
P2X2	B
/	I
3	I
receptor	I
antagonist	O
,	O
the	O
compounds	O
being	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
D	O
,	O
X	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
R<6	O
>	O
,	O
R<7	O
>	O
and	O
R<8	O
>	O
are	O
as	O
defined	O
herein	O
.	O

Uses	O
of	O
rutin	O
and	O
quercetin-7-rhamnose	O
in	O
preparing	O
anti	O
-	O
hepatitis	O
medicament	O
The	O
invention	O
belongs	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
rutin	O
and	O
quercetin-7-rhamnose	O
in	O
preparation	O
of	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
.	O

According	O
to	O
the	O
results	O
of	O
experiments	O
of	O
hepatitis	B
B	I
surface	I
antigen	I
(	O
HBsAg	B
)	O
and	O
hepatitis	B
B	I
e	I
antigen	I
(	O
HBeAg	B
)	O
detection	O
reagents	O
,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
suppress	O
HBsAg	B
and	O
HBeAg	B
obviously	O
and	O
can	O
prevent	O
and	O
cure	O
hepatitis	O
B	O
virus	O
.	O

Therefore	O
,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
or	O
health	O
care	O
products	O
.	O

Flavin	O
adenine	O
dinucleotide	O
disodium	O
salt	O
freeze	O
-	O
dried	O
powder	O
needle	O
preparation	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
FAD	O
-	O
Na2	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
FAD	O
-	O
Na2	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
is	O
a	O
drug	O
composition	O
made	O
by	O
mixing	O
FAD	O
-	O
Na2	O
serving	O
as	O
medicinal	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
as	O
follows	O
:	O
the	O
FAD	O
-	O
Na2	O
is	O
used	O
as	O
raw	O
material	O
and	O
added	O
with	O
certain	O
spices	O
of	O
excipients	O
according	O
to	O
certain	O
proportions	O
;	O
the	O
mixture	O
is	O
prepared	O
and	O
developed	O
by	O
a	O
technical	O
means	O
provided	O
by	O
the	O
invention	O
into	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
agent	O
which	O
can	O
be	O
used	O
for	O
subcutaneous	O
injection	O
,	O
intramuscular	O
and	O
intravenous	O
injection	O
and	O
used	O
to	O
cure	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
lacks	O
of	O
vitamin	O
B2	O
.	O

Detection	O
method	O
of	O
compound	O
preserved	O
snake	O
gall	O
orange	O
peel	O
powder	O
The	O
present	O
invention	O
provides	O
a	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
five	O
drugs	O
of	O
orange	O
peel	O
,	O
earthworm	O
,	O
stiff	O
silkworm	O
,	O
vermilion	O
and	O
amber	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
are	O
identified	O
by	O
a	O
microscope	O
;	O
(	O
2	O
)	O
the	O
orange	O
peel	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
identified	O
by	O
the	O
thin	O
layer	O
chromatography	O
;	O
(	O
3	O
)	O
the	O
content	O
of	O
hesperidin	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
the	O
high	O
performance	O
liquid	O
chromatography	O
;	O
(	O
4	O
)	O
the	O
content	O
of	O
ethiopsite	O
in	O
the	O
vermilion	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
thiocyanometry	O
.	O

The	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
provided	O
by	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
overcoming	O
a	O
defect	O
of	O
poor	O
specificity	O
existing	O
in	O
the	O
prior	O
chemical	O
identification	O
method	O
and	O
defects	O
of	O
complicated	O
operation	O
and	O
uncontrollable	O
product	O
quality	O
existing	O
in	O
the	O
prior	O
thin	O
layer	O
chromatography	O
,	O
improving	O
the	O
specificity	O
and	O
the	O
quality	O
stability	O
of	O
the	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
and	O
ensuring	O
the	O
safety	O
and	O
effectiveness	O
of	O
medication	O
.	O

Oxazole	O
substituted	O
dihydro	O
pyrazol	O
multi	O
-	O
heterocyclic	O
ring	O
derivates	O
,	O
preparation	O
method	O
and	O
uses	O
thereof	O
The	O
invention	O
discloses	O
an	O
oxazole	O
substituted	O
dihydro	O
-	O
pyrazole	O
miscellaneous	O
polycyclic	O
derivative	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
use	O
of	O
the	O
same	O
.	O

The	O
derivative	O
provided	O
by	O
the	O
invention	O
has	O
a	O
structure	O
as	O
shown	O
in	O
a	O
chemical	O
formula	O
D	O
and	O
is	O
prepared	O
through	O
the	O
following	O
method	O
that	O
:	O
substituted	O
isoquinoline	O
propiophenone	O
is	O
used	O
for	O
leading	O
,	O
expanded	O
and	O
converted	O
into	O
substituted	O
isoquinoline	O
alpha	O
and	O
beta	O
unsaturated	O
ketone	O
;	O
ring	O
closure	O
is	O
carried	O
out	O
to	O
form	O
5-substituted	O
isoquinoline	O
substituted	O
dihydro	O
-	O
pyrazole	O
ketone	O
;	O
by	O
inducing	O
an	O
oxime	O
structure	O
unit	O
and	O
adopting	O
a	O
microwave	O
auxiliary	O
synthesis	O
method	O
,	O
a	O
series	O
of	O
3-methyl	O
oxazole-5-isoquinoline	O
substituted	O
hydrogen	O
pyrazole	O
miscellaneous	O
polycyclic	O
compounds	O
is	O
designed	O
and	O
synthesized	O
.	O

Structure	O
modification	O
is	O
carried	O
out	O
according	O
to	O
the	O
principle	O
of	O
medicinal	O
chemistry	O
,	O
so	O
as	O
to	O
design	O
and	O
synthesize	O
a	O
high	O
-	O
activity	O
compound	O
with	O
the	O
effects	O
of	O
resisting	O
tumor	O
and	O
sterilizing	O
.	O

Novel	O
cephalosporin	O
compounds	O
,	O
preparation	O
method	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
use	O
The	O
invention	O
provides	O
a	O
novel	O
cephalosporin	O
compound	O
which	O
introduces	O
thioureido	O
onto	O
position	O
7	O
of	O
cephem	O
,	O
nontoxic	O
salt	O
of	O
the	O
cephalosporin	O
compound	O
acceptable	O
on	O
pharmacy	O
,	O
physiological	O
hydrolyzable	O
ester	O
of	O
the	O
cephalosporin	O
compound	O
,	O
acid	O
amide	O
of	O
the	O
cephalosporin	O
compound	O
,	O
hydrate	O
of	O
the	O
cephalosporin	O
compound	O
,	O
solvate	O
of	O
the	O
cephalosporin	O
compound	O
or	O
an	O
isomer	O
of	O
the	O
cephalosporin	O
compound	O
,	O
a	O
method	O
for	O
preparing	O
the	O
cephalosporin	O
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
cephalosporin	O
compound	O
and	O
an	O
application	O
of	O
the	O
cephalosporin	O
compound	O
.	O

Rice	O
fermented	O
with	O
red	O
yeast	O
extract	O
,	O
preparation	O
method	O
and	O
quality	O
detection	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
red	O
yeast	O
rice	O
extract	O
and	O
a	O
preparation	O
method	O
and	O
a	O
quality	O
test	O
method	O
thereof	O
.	O

The	O
main	O
active	O
ingredient	O
of	O
the	O
extract	O
is	O
lovastatin	O
,	O
the	O
content	O
of	O
which	O
is	O
more	O
than	O
3	O
percent	O
.	O

The	O
extract	O
is	O
prepared	O
by	O
subjecting	O
a	O
medical	O
material	O
of	O
red	O
yeast	O
rice	O
to	O
extraction	O
with	O
an	O
organic	O
solvent	O
,	O
water	O
decoction	O
after	O
the	O
volatilization	O
of	O
the	O
solvent	O
,	O
precipitation	O
collection	O
by	O
siphonage	O
and	O
configuration	O
,	O
mixing	O
with	O
excipients	O
and	O
drying	O
.	O

The	O
preparation	O
method	O
improves	O
the	O
content	O
of	O
lovastatin	O
.	O

The	O
invention	O
also	O
provides	O
a	O
quality	O
control	O
method	O
for	O
identifying	O
the	O
ingredients	O
and	O
measuring	O
content	O
.	O

Medicament	O
for	O
treating	O
protrusion	O
of	O
lumber	O
intervertebral	O
disc	O
The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
treating	O
prolapse	O
of	O
lumbar	O
intervertebral	O
disc	O
.	O

The	O
preparation	O
method	O
for	O
the	O
medicine	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
medicines	O
such	O
as	O
phrymaceae	O
,	O
buck	O
grass	O
,	O
slenderstyle	O
acanthopanax	O
barks	O
,	O
cortex	O
lycii	O
radicis	O
,	O
dittany	O
,	O
heracleum	O
hemsleyanum	O
,	O
common	O
monkshood	O
mother	O
root	O
,	O
kusnezoff	O
monkshood	O
,	O
safflower	O
,	O
Chinese	O
ephedra	O
,	O
dried	O
ginger	O
,	O
pollen	O
,	O
artemisia	O
leaves	O
,	O
cassia	O
barks	O
and	O
so	O
on	O
are	O
mixed	O
and	O
ground	O
into	O
powder	O
,	O
and	O
then	O
packaged	O
into	O
a	O
medicine	O
bag	O
.	O

When	O
the	O
medicine	O
is	O
used	O
,	O
the	O
medicine	O
bag	O
is	O
immersed	O
into	O
water	O
solution	O
of	O
hot	O
peppers	O
and	O
vinegar	O
,	O
placed	O
on	O
a	O
suffered	O
lumbar	O
part	O
of	O
a	O
patient	O
and	O
heated	O
,	O
and	O
then	O
absorbed	O
through	O
hot	O
application	O
.	O

The	O
medicine	O
can	O
disperse	O
stagnancy	O
and	O
dredge	O
channels	O
,	O
relieve	O
rigidity	O
of	O
muscles	O
and	O
promote	O
blood	O
circulation	O
,	O
reduce	O
swelling	O
and	O
alleviate	O
pain	O
,	O
and	O
stimulate	O
circulation	O
to	O
end	O
stasis	O
,	O
can	O
adjust	O
the	O
water	O
filling	O
level	O
of	O
nucleus	O
pulposus	O
and	O
make	O
the	O
protruded	O
nucleus	O
pulposus	O
retracted	O
,	O
eliminate	O
irritation	O
symptoms	O
of	O
edema	O
,	O
and	O
repair	O
damaged	O
anulus	O
fibrosus	O
,	O
is	O
quick	O
to	O
take	O
effect	O
,	O
has	O
no	O
side	O
effect	O
,	O
and	O
can	O
not	O
cause	O
recrudescence	O
after	O
cure	O
.	O

Preparation	O
of	O
docetaxel	O
long	O
-	O
circulating	O
liposome	O
and	O
freeze	O
-	O
dried	O
powder	O
injection	O
thereof	O
The	O
invention	O
discloses	O
a	O
preparation	O
technique	O
of	O
non	O
-	O
pegylation	O
docetaxel	O
long	O
-	O
circulating	O
liposome	O
which	O
meets	O
clinical	O
and	O
large	O
-	O
scale	O
production	O
requirements	O
and	O
a	O
freeze	O
-	O
dried	O
powder	O
-	O
injection	O
;	O
the	O
liposome	O
consists	O
of	O
docetaxel	O
,	O
neutral	O
phospholipid	O
,	O
charged	O
phospholipid	O
,	O
cholesterin	O
,	O
antioxidant	O
,	O
excipient	O
,	O
buffering	O
agent	O
and	O
water	O
for	O
injection	O
;	O
the	O
preparation	O
technique	O
includes	O
the	O
following	O
steps	O
:	O
preparing	O
multivesicular	O
liposome	O
,	O
homogenizing	O
the	O
liposome	O
,	O
fixing	O
volume	O
,	O
sterilizing	O
,	O
split	O
charging	O
,	O
freeze	O
drying	O
,	O
etc	O
.	O

The	O
liposome	O
increases	O
the	O
solubility	O
of	O
drugs	O
,	O
overcomes	O
poor	O
stability	O
of	O
docetaxel	O
injection	O
and	O
toxicity	O
caused	O
by	O
complex	O
solvent	O
and	O
prolongs	O
the	O
in	O
vivo	O
circulating	O
time	O
of	O
drugs	O
;	O
compared	O
with	O
pegylation	O
long	O
-	O
circulating	O
liposome	O
,	O
the	O
toxicity	O
is	O
decreased	O
and	O
the	O
inhibiting	O
effect	O
on	O
tumor	O
cells	O
is	O
strengthened	O
.	O

Medicine	O
composition	O
for	O
injecting	O
triamcinolone	O
acetonide	O
palmitate	O
lipid	O
microsphere	O
and	O
preparation	O
method	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
medical	O
technical	O
field	O
,	O
in	O
particular	O
to	O
a	O
lipid	O
microsphere	O
injection	O
medical	O
combination	O
containing	O
triamcinolone	O
palmitate	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

'	O
Yizhi	O
'	O
capsule	O
for	O
enhancing	O
willpower	O
The	O
invention	O
relates	O
to	O
a	O
nootropic	O
capsule	O
used	O
for	O
strengthening	O
willpower	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
the	O
nootropic	O
capsule	O
has	O
a	O
composing	O
prescription	O
which	O
comprises	O
gen	O
-	O
seng	O
,	O
glossy	O
ganoderma	O
,	O
milkwort	O
root	O
,	O
spine	O
date	O
seed	O
,	O
root	O
poria	O
,	O
grassleaf	O
sweetflag	O
rhizome	O
,	O
silktree	O
albizia	O
bark	O
,	O
the	O
tuber	O
of	O
multiflower	O
knot	O
weed	O
,	O
longan	O
aril	O
,	O
seabuckthorn	O
fruit	O
,	O
ginkgo	O
biloba	O
extract	O
,	O
wheat	O
-	O
germ	O
oil	O
,	O
pollen	O
,	O
tortoise	O
carapace	O
and	O
plastron	O
,	O
cape	O
jasmine	O
fruit	O
,	O
liquorice	O
,	O
royal	O
jelly	O
dry	O
-	O
freezing	O
powder	O
,	O
etc	O
.	O

The	O
extract	O
can	O
be	O
made	O
by	O
the	O
preparation	O
and	O
the	O
extract	O
is	O
mixed	O
with	O
the	O
powdery	O
raw	O
materials	O
and	O
the	O
nootropic	O
capsule	O
can	O
be	O
obtained	O
after	O
the	O
processes	O
of	O
drying	O
,	O
sterilizing	O
and	O
encapsulating	O
the	O
extract	O
in	O
a	O
capsule	O
.	O

Rosuvastatin	O
azelnidipine	O
composition	O
A	O
pharmaceutical	O
composition	O
is	O
an	O
organic	O
salt	O
formed	O
by	O
an	O
organic	O
acid	O
rosuvastatin	O
and	O
an	O
organic	O
base	O
azelnidipine	O
with	O
a	O
molar	O
ratio	O
of	O
1:1	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
any	O
dosage	O
forms	O
together	O
with	O
a	O
pharmaceutically	O
-	O
acceptable	O
carrier	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
,	O
reducing	O
myocardial	O
infarction	O
and	O
treating	O
cerebral	O
apoplexy	O
.	O

The	O
inventive	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
of	O
stable	O
physiochemical	O
indexes	O
,	O
controllable	O
product	O
quality	O
,	O
and	O
convenient	O
administration	O
.	O

Eye	O
in	O
-	O
situ	O
gel	O
of	O
pirenoxine	O
sodium	O
The	O
invention	O
discloses	O
a	O
pirenoxine	O
sodium	O
eye	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pirenoxine	O
sodium	O
eye	O
gel	O
contains	O
(	O
per	O
1,000	O
mL	O
)	O
pirenoxine	O
sodium	O
20	O
-	O
50	O
mg	O
,	O
antiseptic	O
0.05	O
-	O
1	O
g	O
,	O
osmotic	O
pressure	O
regulator	O
1.0	O
-	O
7.5	O
g	O
,	O
gel	O
matrix	O
30	O
-	O
150	O
g	O
,	O
and	O
acid	O
/	O
base	O
buffer	O
and	O
water	O
for	O
injection	O
in	O
balancing	O
amount	O
.	O

The	O
inventive	O
pirenoxine	O
sodium	O
eye	O
gel	O
optimizes	O
adjuvants	O
and	O
improves	O
production	O
process	O
,	O
so	O
as	O
to	O
enrich	O
the	O
compound	O
taurine	O
dosage	O
forms	O
,	O
remarkably	O
prolong	O
the	O
retention	O
time	O
of	O
the	O
compound	O
taurine	O
in	O
eyes	O
,	O
and	O
improve	O
the	O
therapeutic	O
effect	O
;	O
and	O
has	O
no	O
adverse	O
irritant	O
reactions	O
.	O

Six	O
-	O
membered	O
heterocycles	O
useful	O
as	O
serine	B
protease	I
inhibitors	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
stereoisomer	O
,	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof	O
,	O
wherein	O
the	O
variables	O
A	O
,	O
B	O
,	O
R<3	O
>	O
and	O
R<11	O
>	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
selective	O
inhibitors	O
of	O
serine	B
protease	I
enzymes	O
of	O
the	O
coagulation	O
cascade	O
and/or	O
contact	O
activation	O
system	O
;	O
for	O
example	O
thrombin	B
,	O
factor	B
Xa	I
,	O
factor	B
XIa	I
,	O
factor	B
IXa	I
,	O
factor	B
VIIa	I
and/or	O
plasma	B
kallikrein	I
.	O

In	O
particular	O
,	O
it	O
relates	O
to	O
compounds	O
that	O
are	O
selective	O
factor	B
XIa	I
inhibitors	O
or	O
dual	O
inhibitors	O
of	O
fXIa	B
and	O
plasma	B
kallikrein	I
.	O

This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
thromboembolic	O
and/or	O
inflammatory	O
disorders	O
using	O
the	O
same	O
.	O

Lxeris	O
sonchifolia	O
(	O
bunge	O
)	O
hance	O
flavone	O
extract	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
Disclosed	O
is	O
an	O
extract	O
of	O
flavonoid	O
of	O
ixeris	O
sonchifolia	O
hance	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
an	O
extract	O
of	O
flavonoid	O
of	O
ixeris	O
sonchifolia	O
hance	O
whose	O
content	O
of	O
luteolin-7-O	O
-	O
Beta	O
-	O
D	O
glucopyranose	O
aldehyde	O
acid	O
glycoside	O
is	O
25	O
percent	O
to	O
99.5	O
percent	O
,	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
a	O
reference	O
substance	O
of	O
luteolin-7-O	O
-	O
Beta	O
-	O
D	O
glucopyranose	O
aldehyde	O
acid	O
glycoside	O
and	O
an	O
application	O
thereof	O
in	O
controlling	O
the	O
quality	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
extract	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
,	O
and	O
also	O
discloses	O
an	O
application	O
of	O
the	O
extract	O
in	O
preparing	O
drugs	O
for	O
treating	O
the	O
coronary	O
heart	O
disease	O
,	O
the	O
cerebral	O
infarction	O
and	O
the	O
fracture	O
.	O

Ambroxol	O
hydrochloride	O
oral	O
solution	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ambroxol	O
hydrochloride	O
oral	O
solution	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
western	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
medical	O
production	O
formula	O
used	O
for	O
curing	O
bronchitis	O
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
sucrose	O
,	O
preservatives	O
and	O
purified	O
water	O
are	O
dissolved	O
in	O
a	O
mixing	O
mode	O
so	O
as	O
to	O
prepare	O
simple	O
syrup	O
;	O
the	O
ambroxol	O
hydrochloride	O
,	O
corrigents	O
and	O
preservatives	O
are	O
dissolved	O
by	O
the	O
purified	O
water	O
so	O
as	O
to	O
prepare	O
ambroxol	O
hydrochloride	O
solution	O
;	O
the	O
ambroxol	O
hydrochloride	O
solution	O
and	O
the	O
simple	O
syrup	O
are	O
stirred	O
and	O
mixed	O
evenly	O
,	O
the	O
corrigents	O
and	O
the	O
preservatives	O
are	O
added	O
successively	O
and	O
discontinuously	O
and	O
then	O
the	O
purified	O
water	O
is	O
added	O
to	O
adjust	O
the	O
concentration	O
.	O

The	O
invention	O
has	O
simple	O
and	O
reasonable	O
process	O
,	O
and	O
is	O
easy	O
to	O
operate	O
practically	O
and	O
the	O
produced	O
products	O
have	O
good	O
stability	O
;	O
the	O
products	O
can	O
used	O
as	O
common	O
phlegm	O
-	O
eliminating	O
drugs	O
,	O
has	O
functions	O
of	O
increasing	O
the	O
liquid	O
level	O
of	O
the	O
respiratory	O
tract	O
,	O
reducing	O
mucus	O
secretion	O
,	O
enhancing	O
the	O
secretion	O
of	O
pulmonary	O
surfactant	O
and	O
the	O
movement	O
of	O
cilium	O
and	O
preventing	O
cough	O
to	O
a	O
certain	O
extent	O
,	O
and	O
is	O
applicable	O
to	O
acute	O
respiratory	O
disease	O
and	O
chronic	O
respiratory	O
disease	O
,	O
such	O
as	O
ropy	O
sputum	O
and	O
difficult	O
cough	O
caused	O
by	O
acute	O
bronchitis	O
and	O
chronic	O
bronchitis	O
,	O
bronchial	O
asthma	O
and	O
pulmonary	O
tuberculosis	O
,	O
etc	O
.	O

Composition	O
injection	O
containing	O
tetrandrine	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composite	O
containing	O
tetrandrine	O
,	O
and	O
discloses	O
a	O
composite	O
injection	O
containing	O
the	O
tetrandrine	O
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
composite	O
injection	O
consists	O
of	O
the	O
tetrandrine	O
,	O
latent	O
solvent	O
,	O
stabilizing	O
agent	O
and	O
sodium	O
chloride	O
;	O
wherein	O
,	O
the	O
content	O
of	O
the	O
tetrandrine	O
is	O
2	O
-	O
60	O
%	O
,	O
the	O
content	O
of	O
the	O
latent	O
solvent	O
is	O
2	O
-	O
40	O
%	O
,	O
the	O
content	O
of	O
the	O
stabilizing	O
agent	O
is	O
1	O
-	O
8	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
sodium	O
chloride	O
is	O
9	O
-	O
90	O
%	O
;	O
the	O
proportion	O
among	O
the	O
tetrandrine	O
,	O
the	O
latent	O
solvent	O
and	O
the	O
stabilizing	O
agent	O
is	O
1:0.5:0.01	O
-	O
1:1:1	O
.	O

The	O
method	O
is	O
that	O
:	O
right	O
amount	O
of	O
water	O
used	O
for	O
injecting	O
is	O
added	O
with	O
2	O
-	O
60	O
%	O
of	O
latent	O
solvent	O
,	O
1	O
-	O
8	O
%	O
of	O
stabilizing	O
agent	O
and	O
9	O
-	O
90	O
%	O
of	O
sodium	O
chloride	O
for	O
dissolving	O
;	O
the	O
2	O
-	O
60	O
%	O
of	O
tetrandrine	O
is	O
added	O
to	O
be	O
stirred	O
and	O
dissolved	O
,	O
and	O
then	O
added	O
with	O
water	O
to	O
full	O
dose	O
;	O
after	O
being	O
mixed	O
,	O
the	O
content	O
and	O
pH	O
value	O
of	O
the	O
tetrandrine	O
is	O
measured	O
,	O
and	O
then	O
poured	O
into	O
a	O
bottle	O
after	O
being	O
filtered	O
;	O
after	O
sterilization	O
,	O
lamp	O
check	O
and	O
quality	O
control	O
are	O
carried	O
out	O
,	O
the	O
injection	O
is	O
prepared	O
.	O

The	O
composite	O
injection	O
is	O
easy	O
to	O
store	O
,	O
has	O
little	O
irritation	O
and	O
good	O
stability	O
,	O
can	O
overcome	O
the	O
problems	O
of	O
easy	O
precipitation	O
of	O
the	O
tetrandrine	O
and	O
clinical	O
pain	O
.	O

Benzenesulfonamides	O
Ca-4	O
analogue	O
,	O
synthesis	O
method	O
and	O
application	O
The	O
invention	O
relates	O
to	O
benzo	O
sulfonamide	O
CA-4	O
analogues	O
,	O
a	O
synthetic	O
method	O
and	O
an	O
application	O
thereof	O
,	O
pertaining	O
to	O
the	O
field	O
of	O
chemical	O
drugs	O
.	O

The	O
compound	O
has	O
the	O
structure	O
shown	O
as	O
the	O
general	O
formula	O
(	O
IV	O
)	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
an	O
N	O
-	O
tert	O
butyl	O
-	O
benzene	O
sulfonamide	O
-	O
derivative	O
is	O
taken	O
as	O
raw	O
material	O
to	O
generate	O
corresponding	O
carbanion	O
under	O
the	O
function	O
of	O
a	O
metal	O
reagent	O
,	O
and	O
then	O
respectively	O
reacts	O
with	O
benzaldehydes	O
containing	O
methoxy	O
and	O
other	O
substituted	O
functional	O
groups	O
to	O
generate	O
secondary	O
alcohol	O
;	O
the	O
secondary	O
alcohol	O
is	O
oxidized	O
by	O
an	O
oxidant	O
;	O
a	O
series	O
of	O
conformational	O
restriction	O
CA-4	O
analogues	O
are	O
synthesized	O
by	O
making	O
use	O
of	O
a	O
novel	O
cyclization	O
reaction	O
induced	O
by	O
trimethylsilyl	O
chlorine	O
/	O
NaI	O
/	O
acetonitrile	O
reagent	O
.	O

The	O
result	O
of	O
a	O
vitro	O
cell	O
growth	O
inhibition	O
activity	O
test	O
of	O
the	O
target	O
compound	O
shows	O
that	O
the	O
CA-4	O
analogues	O
can	O
be	O
applied	O
as	O
anti	O
-	O
tumor	O
drugs	O
.	O

2-	O
(	O
4-substituted	O
phenyl-1,2,3-thiadiazole-5sulfhydryl	O
)	O
-N	O
-	O
substituted	O
phenyl	O
acetamides	O
derivates	O
,	O
preparation	O
thereof	O
and	O
application	O
The	O
invention	O
provides	O
a	O
2-	O
(	O
4-substituted	O
phenyl-1	O
,	O
2	O
,	O
3-	O
thiadiazole-5-	O
mercapto	O
)	O
-N	O
-	O
substituted	O
phenyl	O
acetamide	O
derivative	O
with	O
the	O
structure	O
general	O
formula	O
shown	O
as	O
the	O
right	O
formula	O
,	O
wherein	O
,	O
R<1	O
>	O
is	O
H	O
,	O
F	O
or	O
Cl	O
;	O
R<2	O
>	O
is	O
H	O
,	O
F	O
,	O
Cl	O
or	O
OCH3	O
;	O
X	O
is	O
F	O
,	O
Cl	O
,	O
Br	O
or	O
NO2	O
;	O
and	O
Y	O
is	O
H	O
,	O
CH3	O
,	O
COOCH3	O
or	O
COOC2H5	O
.	O

The	O
derivative	O
is	O
a	O
novel	O
structure	O
framework	O
,	O
has	O
relatively	O
high	O
inhibition	O
activity	O
on	O
HIV	O
and	O
can	O
be	O
taken	O
as	O
a	O
lead	O
compound	O
to	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
anti	O
-	O
HIV	O
agents	O
.	O

Penem	O
compound	O
containing	O
sulfhydryl	O
piperidine	O
The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
compound	O
which	O
contains	O
sulfhydryl	O
piperidine	O
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
compound	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
and	O
R<6	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Carbapenem	O
derivates	O
containing	O
sulfhydryl	O
pyrrolidine	O
The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
carbon	O
penem	O
derivative	O
which	O
contains	O
sulfhydryl	O
pyrrolidine	O
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
derivative	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
and	O
R<5	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Penem	O
derivative	O
The	O
invention	O
belongs	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
derivative	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
easily	O
-	O
hydrolyzed	O
esters	O
thereof	O
,	O
isomers	O
thereof	O
,	O
hydrate	O
thereof	O
and	O
hydrates	O
of	O
esters	O
or	O
salts	O
thereof	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
defined	O
as	O
in	O
the	O
description	O
,	O
and	O
can	O
be	O
further	O
substituted	O
on	O
a	O
benzene	O
ring	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
compound	O
containing	O
the	O
same	O
,	O
and	O
the	O
application	O
thereof	O
on	O
the	O
preparation	O
of	O
pharmaceuticals	O
for	O
treating	O
and/or	O
preventing	O
infection	O
diseases	O
.	O

Pyrrolidone	O
containing	O
hydroxymethyl	O
and	O
carboxyl	O
,	O
preparation	O
method	O
and	O
medicament	O
composition	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
pyrrolidone	O
containing	O
hydroxymethyl	O
and	O
carboxyl	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
,	O
pharmaceutical	O
compositions	O
and	O
applications	O
thereof	O
,	O
in	O
particular	O
to	O
compounds	O
containing	O
sulfonyl	O
pyrrolidone	O
shown	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
,	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
as	O
well	O
as	O
pharmaceutical	O
applications	O
of	O
the	O
compounds	O
.	O

In	O
the	O
general	O
formula	O
,	O
R1	O
is	O
the	O
hydroxymethyl	O
and	O
the	O
carboxyl	O
.	O

Novel	O
nitrogen	O
-	O
containing	O
medicament	O
with	O
anti	O
-	O
inflammatory	O
activity	O
The	O
invention	O
relates	O
to	O
an	O
androstane	O
azotic	O
glucocorticoid	B
receptor	I
stimulant	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmaceutical	O
preparations	O
comprising	O
the	O
compound	O
and	O
the	O
therapeutic	O
use	O
of	O
the	O
compound	O
,	O
in	O
particular	O
to	O
inflammatory	O
disease	O
,	O
allergic	O
disease	O
or	O
anaphylactic	O
disease	O
.	O

Compound	O
alpha	O
-	O
ketoacid	O
chewing	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
used	O
for	O
curing	O
chronic	O
renal	O
failure	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
comprises	O
the	O
following	O
components	O
:	O
Alpha	O
-	O
ketophenylalanine	O
calcium	O
,	O
Alpha	O
-	O
hydroxymethionine	O
calcium	O
,	O
Alpha	O
-	O
ketoleucine	O
calcium	O
,	O
Alpha	O
-	O
ketoisoleucine	O
calcium	O
,	O
Alpha	O
-	O
ketovaline	O
calcium	O
,	O
tryptophan	O
,	O
histidine	O
,	O
tyrosine	O
,	O
threonine	O
,	O
lysine	O
,	O
acetate	O
,	O
a	O
filling	O
agent	O
,	O
a	O
bonding	O
agent	O
,	O
a	O
taste	O
-	O
masking	O
agent	O
,	O
a	O
lubricant	O
and	O
a	O
coating	O
agent	O
.	O

The	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
not	O
only	O
widens	O
the	O
dosage	O
form	O
range	O
of	O
the	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablets	O
,	O
but	O
also	O
has	O
the	O
advantages	O
of	O
having	O
good	O
dispersing	O
state	O
,	O
short	O
disintegration	O
time	O
,	O
fast	O
drug	O
dissolution	O
,	O
rapid	O
absorption	O
,	O
high	O
biological	O
availability	O
and	O
convenient	O
taking	O
,	O
being	O
capable	O
of	O
being	O
swallowed	O
,	O
chewed	O
and	O
sucked	O
and	O
being	O
especially	O
suitable	O
for	O
old	O
people	O
,	O
stroke	O
patients	O
,	O
patients	O
with	O
special	O
diseases	O
and	O
patients	O
having	O
swallowing	O
difficulty	O
.	O

Putrefaction	O
-	O
removing	O
granulation	O
-	O
promoting	O
paste	O
The	O
invention	O
relates	O
to	O
a	O
curing	O
and	O
healing	O
ointment	O
used	O
for	O
curing	O
the	O
damage	O
of	O
big	O
muscle	O
,	O
muscle	O
fracture	O
,	O
pyogenic	O
infection	O
,	O
carbuncle	O
and	O
surgery	O
cut	O
,	O
in	O
particular	O
to	O
a	O
granulation	O
-	O
promoting	O
ointment	O
which	O
can	O
ensures	O
the	O
quick	O
growth	O
of	O
fester	O
soft	O
tissues	O
without	O
leaving	O
remarkable	O
sclerosis	O
and	O
scars	O
.	O

The	O
ointment	O
consists	O
of	O
xanthium	O
worm	O
(	O
1	O
)	O
,	O
rust	O
powder	O
(	O
2	O
)	O
,	O
vermilion	O
(	O
3	O
)	O
,	O
scorpion	O
(	O
4	O
)	O
,	O
calcined	O
alum	O
(	O
5	O
)	O
(	O
dewatered	O
alum	O
)	O
and	O
beeswax	O
(	O
6	O
)	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
.	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
-	O
promoting	O
ointment	O
which	O
consists	O
of	O
20	O
fresh	O
xanthium	O
worms	O
(	O
1	O
)	O
,	O
2.4	O
g	O
of	O
the	O
rust	O
powder	O
(	O
2	O
)	O
,	O
2.4	O
g	O
of	O
the	O
vermilion	O
(	O
3	O
)	O
,	O
3	O
g	O
of	O
the	O
scorpion	O
(	O
4	O
)	O
,	O
6	O
g	O
of	O
the	O
calcined	O
alum	O
(	O
5	O
)	O
(	O
dewatered	O
alum	O
)	O
and	O
20	O
g	O
of	O
the	O
beeswax	O
(	O
6	O
)	O
.	O

In	O
the	O
method	O
,	O
the	O
xanthium	O
worms	O
are	O
dipped	O
in	O
benne	O
oil	O
for	O
7	O
days	O
and	O
the	O
scorpion	O
is	O
fried	O
.	O

The	O
rust	O
powder	O
,	O
the	O
scorpion	O
powder	O
,	O
the	O
calcined	O
alum	O
,	O
the	O
beeswax	O
and	O
the	O
vermilion	O
are	O
heated	O
and	O
mixed	O
uniformly	O
,	O
cooled	O
and	O
then	O
the	O
xanthium	O
worms	O
and	O
proper	O
amount	O
of	O
the	O
benne	O
oil	O
are	O
added	O
and	O
mashed	O
into	O
ointment	O
for	O
standby	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
,	O
and	O
has	O
stronger	O
sterilization	O
and	O
infection	O
-	O
resistance	O
capacities	O
.	O

The	O
invention	O
also	O
has	O
the	O
advantages	O
of	O
easily	O
obtained	O
materials	O
,	O
novel	O
and	O
specific	O
prescription	O
,	O
simple	O
extraction	O
technique	O
and	O
convenient	O
medication	O
.	O

External	O
-	O
use	O
medicament	O
for	O
scald	O
The	O
invention	O
provides	O
an	O
external	O
use	O
scalding	O
drug	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
scalding	O
drug	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
percentage	O
:	O
10	O
to	O
20	O
percent	O
of	O
gypsum	O
,	O
10	O
to	O
20	O
percent	O
of	O
rhubarb	O
,	O
10	O
to	O
20	O
percent	O
of	O
green	O
tea	O
,	O
10	O
to	O
20	O
percent	O
of	O
sesame	O
oil	O
,	O
10	O
to	O
20	O
percent	O
of	O
borneol	O
,	O
10	O
to	O
20	O
percent	O
of	O
soy	O
sauce	O
.	O

The	O
scalding	O
drug	O
has	O
the	O
efficacy	O
of	O
alleviating	O
the	O
pain	O
and	O
cooling	O
the	O
blood	O
,	O
and	O
effectively	O
avoids	O
blistering	O
on	O
the	O
scalded	O
part	O
,	O
thereby	O
preventing	O
the	O
wound	O
infection	O
;	O
moreover	O
,	O
the	O
scalding	O
drug	O
has	O
the	O
advantages	O
of	O
simple	O
and	O
reasonable	O
compatibility	O
of	O
medicaments	O
,	O
quick	O
onset	O
and	O
good	O
effect	O
.	O

Enterobacter	O
cloacae	O
,	O
and	O
use	O
of	O
polysaccharide	O
and	O
polysaccharide	O
thereof	O
The	O
invention	O
discloses	O
Enterobacter	O
cloacae	O
Z0206	O
,	O
which	O
has	O
been	O
preserved	O
in	O
China	O
General	O
Microbiological	O
Culture	O
Collection	O
Center	O
on	O
December	O
3	O
,	O
2007	O
,	O
wherein	O
the	O
preserving	O
number	O
is	O
CGMCC	O
NO	O
:	O
2279	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
and	O
application	O
thereof	O
.	O

The	O
method	O
has	O
the	O
advantages	O
that	O
the	O
production	O
process	O
of	O
extracting	O
the	O
polysaccharide	O
is	O
simple	O
,	O
and	O
the	O
yield	O
and	O
the	O
purity	O
of	O
products	O
are	O
higher	O
;	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
can	O
remarkably	O
improve	O
the	O
proliferation	O
capacity	O
of	O
lymph	O
cells	O
and	O
the	O
cytokine	O
level	O
of	O
a	O
small	O
mouse	O
with	O
low	O
immunity	O
and	O
has	O
remarkable	O
adjustment	O
effect	O
on	O
the	O
immunologic	O
function	O
of	O
the	O
small	O
mouse	O
with	O
low	O
immunity	O
;	O
and	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
has	O
apparent	O
antagonism	O
on	O
the	O
oxidative	O
damage	O
caused	O
by	O
cyclophosphamide	O
,	O
can	O
remarkably	O
improve	O
the	O
antioxidase	O
activity	O
of	O
an	O
organism	O
,	O
strengthen	O
the	O
function	O
of	O
an	O
antioxidant	O
defense	O
system	O
of	O
the	O
organism	O
,	O
and	O
prevent	O
harmful	O
free	O
radicals	O
from	O
damaging	O
biological	O
macromolecules	O
in	O
cells	O
.	O

Novel	O
compound	O
separated	O
from	O
immature	O
exocarp	O
of	O
Juglans	O
mandshurica	O
Maxim	O
,	O
and	O
preparation	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
separated	O
form	O
north	O
Juglans	O
regia	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
adopts	O
a	O
method	O
for	O
combining	O
alcohol	O
extraction	O
,	O
chromatographic	O
separation	O
and	O
purification	O
and	O
cytoactive	O
assay	O
to	O
separate	O
the	O
novel	O
compound	O
,	O
which	O
is	O
not	O
reported	O
before	O
and	O
has	O
anti	O
-	O
tumor	O
function	O
,	O
from	O
the	O
north	O
Juglans	O
regia	O
,	O
and	O
adopts	O
mass	O
spectrum	O
and	O
high	O
-	O
resolution	O
nuclear	O
magnetic	O
resonance	O
technique	O
to	O
determine	O
the	O
structure	O
of	O
the	O
compound	O
.	O

The	O
structural	O
formula	O
of	O
the	O
novel	O
compound	O
is	O
the	O
right	O
formula	O
(	O
I	O
)	O
.	O

The	O
novel	O
compound	O
is	O
applied	O
in	O
the	O
field	O
of	O
medicine	O
.	O

Cefixime	O
sustained	O
-	O
release	O
tablets	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
tablet	O
prepared	O
from	O
cefixime	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
characterized	O
in	O
that	O
:	O
the	O
slow	O
-	O
release	O
tablet	O
consists	O
of	O
the	O
following	O
raw	O
materials	O
and	O
auxiliary	O
materials	O
in	O
portion	O
by	O
weight	O
:	O
200	O
portions	O
of	O
cefixime	O
(	O
counted	O
as	O
an	O
anhydride	O
)	O
,	O
20	O
to	O
200	O
portions	O
of	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
slow	O
-	O
release	O
material	O
which	O
can	O
control	O
the	O
drug	O
to	O
continuously	O
and	O
completely	O
release	O
,	O
20	O
and	O
400	O
portions	O
of	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
and	O
5	O
to	O
100	O
portions	O
of	O
at	O
least	O
one	O
solubilizer	O
which	O
can	O
effectively	O
improve	O
the	O
release	O
rate	O
of	O
the	O
drug	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
easy	O
to	O
prepare	O
and	O
facilitates	O
the	O
industrialized	O
production	O
.	O

Phenyl	O
substituted	O
heteroaryl	O
-	O
derivatives	O
and	O
use	O
thereof	O
as	O
anti	O
-	O
tumor	O
agents	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
radicals	O
Rto	O
R	O
,	O
L	O
,	O
Q	O
and	O
n	O
are	O
defined	O
as	O
indicated	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
are	O
suitable	O
for	O
treating	O
diseases	O
that	O
are	O
characterised	O
by	O
excessive	O
or	O
anomal	O
cell	O
proliferation	O
.	O

The	O
invention	O
also	O
relates	O
to	O
their	O
use	O
for	O
producing	O
a	O
medicament	O
having	O
the	O
above	O
-	O
mentioned	O
properties	O
.	O

Anti	O
-	O
infective	O
medicament	O
composition	O
and	O
application	O
The	O
invention	O
discloses	O
an	O
anti	O
-	O
infective	O
drug	O
combination	O
and	O
an	O
application	O
thereof	O
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
comprises	O
a	O
dryopteris	O
fragrans	O
extract	O
with	O
the	O
weight	O
percentage	O
being	O
1	O
%	O
to	O
99	O
%	O
of	O
the	O
drug	O
combination	O
,	O
and	O
pharmaceutically	O
conventional	O
auxiliary	O
materials	O
.	O

The	O
dryopteris	O
fragrans	O
extract	O
comprises	O
the	O
following	O
components	O
:	O
dryopteris	O
fragrans	O
essence	O
,	O
aspidin	O
AB	O
,	O
aspidin	O
PB	O
,	O
aspidin	O
BB	O
,	O
aspidinol	O
and	O
albicanol	O
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
applicable	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
curing	O
bacterial	O
,	O
fungal	O
or	O
viral	O
infection	O
diseases	O
;	O
and	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
anti	O
-	O
bacterial	O
spectrum	O
is	O
wide	O
,	O
the	O
anti	O
-	O
multidrug	O
resistance	O
is	O
good	O
and	O
the	O
safety	O
is	O
high	O
because	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
derived	O
from	O
the	O
natural	O
plant	O
resources	O
.	O

Polyhydroxyalkanoate	O
(	O
PHA	O
)	O
targeted	O
carrier	O
,	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
and	O
preparation	O
methods	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
polyhydroxyalkanoate	O
(	O
PHA	O
)	O
targeted	O
carrier	O
with	O
the	O
general	O
formula	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
and	O
a	O
targeted	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
prepared	O
by	O
encapsulating	O
anti	O
-	O
tumor	O
drugs	O
on	O
the	O
basis	O
of	O
ultrasonic	O
emulsification	O
method	O
with	O
the	O
carrier	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
.	O

The	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
is	O
characterized	O
in	O
that	O
the	O
particle	O
size	O
thereof	O
is	O
in	O
narrow	O
distribution	O
within	O
the	O
general	O
range	O
of	O
300	O
to	O
500	O
nm	O
and	O
the	O
morphological	O
feature	O
thereof	O
is	O
regular	O
,	O
has	O
the	O
advantages	O
of	O
high	O
biodegradability	O
and	O
biocompatibility	O
,	O
stable	O
structure	O
and	O
less	O
serious	O
toxic	O
andside	O
effects	O
,	O
and	O
has	O
better	O
effect	O
on	O
inhibiting	O
tumor	O
cells	O
according	O
to	O
the	O
in	O
vitro	O
cell	O
experiment	O
.	O

Liquiritin	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
liquiritin	O
preparation	O
with	O
the	O
molecular	O
formula	O
of	O
C26H30O13	O
and	O
the	O
molecular	O
weight	O
of	O
550	O
.	O

The	O
liquiritin	O
is	O
singly	O
prepared	O
or	O
by	O
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
and	O
the	O
preparation	O
composition	O
is	O
counted	O
in	O
such	O
a	O
way	O
that	O
1000	O
particles	O
contain	O
40	O
g	O
of	O
liquiritin	O
.	O

The	O
liquiritin	O
preparation	O
has	O
stronger	O
effect	O
for	O
relieving	O
cough	O
and	O
eliminating	O
phlegm	O
,	O
therefore	O
,	O
the	O
preparation	O
can	O
be	O
singly	O
prepared	O
by	O
liquiritin	O
or	O
by	O
the	O
liquiritin	O
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
can	O
be	O
used	O
for	O
improving	O
symptoms	O
of	O
cough	O
and	O
profuse	O
sputum	O
,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
for	O
curing	O
acute	O
cough	O
,	O
chronic	O
cough	O
and	O
profuse	O
sputum	O
.	O

The	O
liquiritin	O
preparation	O
originates	O
from	O
natural	O
plants	O
,	O
can	O
be	O
made	O
into	O
a	O
health	O
-	O
care	O
product	O
,	O
and	O
provides	O
the	O
natural	O
cough	O
-	O
relieving	O
medicine	O
with	O
less	O
toxic	O
side	O
effect	O
and	O
obvious	O
healing	O
effect	O
for	O
clinical	O
treatment	O
.	O

Compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
provides	O
the	O
compound	O
expressed	O
as	O
the	O
formula	O
X	O
:	O
shown	O
as	O
the	O
right	O
,	O
wherein	O
R	O
is	O
-OH	O
or	O
R1COO<-	O
>	O
,	O
R1	O
is	O
C2-C20	O
carbon	O
chain	O
.	O

The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
compound	O
and	O
a	O
drug	O
compound	O
containing	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
X.	O
The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
compound	O
on	O
preparing	O
medicaments	O
for	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
.	O

Method	O
for	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
method	O
from	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
a.	O
dried	O
liquorice	O
is	O
ground	O
;	O
b.	O
the	O
ground	O
liquorice	O
is	O
put	O
into	O
an	O
extraction	O
tank	O
,	O
petroleum	O
ether	O
is	O
added	O
for	O
reflowing	O
and	O
degreasing	O
,	O
and	O
then	O
filtered	O
out	O
to	O
obtain	O
degreased	O
residue	O
;	O
c.	O
the	O
residue	O
is	O
added	O
with	O
distilled	O
water	O
for	O
extraction	O
in	O
normal	O
termperature	O
,	O
repeatedly	O
poached	O
and	O
extracted	O
for	O
three	O
times	O
,	O
and	O
triple	O
extraction	O
solutions	O
are	O
combined	O
;	O
d.	O
the	O
extraction	O
solution	O
is	O
decompressed	O
and	O
concentrated	O
to	O
cause	O
the	O
volume	O
of	O
the	O
solution	O
to	O
be	O
the	O
liquorice	O
powder	O
in	O
the	O
step	O
a	O
,	O
thus	O
obtaining	O
a	O
concentrated	O
solution	O
;	O
e.	O
a	O
concentrated	O
solution	O
is	O
added	O
into	O
the	O
concentrated	O
solution	O
in	O
the	O
step	O
d	O
,	O
and	O
then	O
the	O
concentrated	O
mixed	O
solution	O
stands	O
overnight	O
and	O
precipitates	O
;	O
f.	O
the	O
concentrated	O
mixed	O
solution	O
is	O
centrifugalized	O
to	O
obtain	O
the	O
precipitation	O
,	O
dried	O
,	O
and	O
then	O
washed	O
with	O
absolute	O
ethyl	O
alcohol	O
,	O
acetone	O
and	O
aether	O
after	O
is	O
extracted	O
by	O
a	O
Sevag	O
method	O
;	O
g.	O
semi	O
-	O
permeable	O
membrane	O
with	O
the	O
interception	O
molecular	O
weight	O
of	O
1000	O
-	O
10000	O
is	O
used	O
for	O
dialyzing	O
in	O
water	O
,	O
the	O
liquorice	O
amylase	O
is	O
obtained	O
by	O
freezing	O
and	O
drying	O
.	O

The	O
liquorice	O
amylase	O
is	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
treating	O
or	O
preventing	O
osteoarthritis	O
.	O

The	O
liquorice	O
amylase	O
has	O
definite	O
active	O
ingredient	O
,	O
definite	O
healing	O
effect	O
and	O
no	O
toxic	O
side	O
effect	O
and	O
the	O
extraction	O
method	O
is	O
easy	O
to	O
be	O
implemented	O
.	O

Method	O
for	O
preparing	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
50	O
to	O
60	O
percent	O
of	O
tea	O
seed	O
oil	O
,	O
3	O
to	O
5	O
percent	O
of	O
borneol	O
,	O
3	O
to	O
5	O
percent	O
of	O
rhubarb	O
,	O
8	O
to	O
15	O
percent	O
of	O
dandelion	O
,	O
and	O
the	O
balance	O
of	O
bamboo	O
charcoal	O
powder	O
;	O
and	O
the	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
cleaning	O
,	O
drying	O
and	O
crushing	O
the	O
borneol	O
,	O
the	O
rhubarb	O
and	O
the	O
dandelion	O
;	O
stirring	O
the	O
materials	O
evenly	O
in	O
proportion	O
;	O
pouring	O
the	O
mixture	O
into	O
the	O
tea	O
seed	O
oil	O
and	O
stirring	O
the	O
mixture	O
;	O
and	O
finally	O
adding	O
the	O
bamboo	O
charcoal	O
powder	O
to	O
the	O
mixture	O
and	O
stirring	O
the	O
mixture	O
.	O

The	O
method	O
overcomes	O
the	O
defects	O
that	O
at	O
present	O
,	O
a	O
burn	O
medicine	O
has	O
less	O
medicinal	O
resources	O
and	O
high	O
price	O
so	O
that	O
the	O
economic	O
burden	O
of	O
a	O
patient	O
is	O
increased	O
,	O
and	O
is	O
easy	O
to	O
trickle	O
and	O
contaminate	O
clothes	O
and	O
beddings	O
.	O

The	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
prepared	O
by	O
the	O
method	O
has	O
the	O
advantages	O
of	O
no	O
trickling	O
,	O
low	O
cost	O
,	O
extensive	O
medicinal	O
resources	O
,	O
remarkable	O
curative	O
effect	O
,	O
simple	O
production	O
process	O
,	O
less	O
equipment	O
investment	O
,	O
and	O
the	O
like	O
.	O

Method	O
for	O
preparing	O
andrographolide	O
derivatives	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
andrographolide	O
derivatives	O
,	O
and	O
a	O
preparation	O
thereof	O
.	O

The	O
preparation	O
is	O
a	O
salt	O
which	O
consists	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	O
and	O
has	O
the	O
effect	O
of	O
synergistic	O
interaction	O
.	O

The	O
curative	O
effect	O
of	O
the	O
preparation	O
is	O
better	O
than	O
that	O
of	O
the	O
independent	O
use	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	O
.	O

Application	O
of	O
7,3'-dimethoxy	O
hesperetin	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O
The	O
pharmaceutical	O
application	O
of	O
a	O
hesperetin	O
derivative	O
relates	O
to	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O
,	O
in	O
particular	O
to	O
the	O
application	O
in	O
treatment	O
of	O
autoimmune	O
diseases	O
such	O
as	O
rheumatic	O
,	O
rheumatoid	O
arthritis	O
and	O
osteoarthritis	O
,	O
and	O
the	O
like	O
.	O

The	O
hesperetin	O
derivative	O
is	O
the	O
derivative	O
which	O
is	O
prepared	O
by	O
a	O
non	O
-	O
carbohydrate	O
compound	O
obtained	O
by	O
hydrolyzing	O
hesperidin	O
and	O
removing	O
glycosyl	O
.	O

The	O
pharmacological	O
effect	O
of	O
the	O
hesperetin	O
derivative	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
parent	O
hesperidin	O
;	O
and	O
compared	O
with	O
traditional	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medicament	O
naproxen	O
and	O
a	O
medicament	O
tripterygium	O
treating	O
rheumatoid	O
arthritis	O
,	O
the	O
hesperetin	O
derivative	O
has	O
equivalent	O
activeness	O
,	O
is	O
safe	O
and	O
non	O
-	O
toxic	O
,	O
not	O
only	O
treats	O
the	O
symptom	O
,	O
but	O
also	O
treats	O
the	O
root	O
,	O
thus	O
having	O
very	O
good	O
medicinal	O
prospect	O
.	O

Pharmaceutical	O
composition	O
containing	O
prasugrel	O
and	O
carbazochrome	O
sodium	O
sulfonate	O
The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
active	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
prasugrel	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
invention	O
aims	O
to	O
invent	O
a	O
more	O
effective	O
and	O
low	O
adverse	O
-	O
reaction	O
method	O
for	O
curing	O
thrombotic	O
diseases	O
by	O
using	O
the	O
combined	O
medication	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
the	O
prasugrel	O
.	O

After	O
conscientious	O
trail	O
of	O
the	O
patent	O
applicant	O
for	O
many	O
times	O
,	O
the	O
effect	O
of	O
applying	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
to	O
inhibit	O
thrombosis	O
in	O
a	O
combined	O
manner	O
is	O
discovered	O
unexpected	O
in	O
the	O
process	O
of	O
applying	O
the	O
prasugrel	O
to	O
cure	O
the	O
thrombotic	O
diseases	O
,	O
the	O
anticoagulant	O
effect	O
of	O
the	O
prasugrel	O
is	O
not	O
abated	O
but	O
increased	O
,	O
and	O
the	O
very	O
good	O
synergistic	O
effects	O
are	O
achieved	O
after	O
the	O
combination	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
the	O
prasugrel	O
,	O
therefore	O
,	O
the	O
risk	O
of	O
bleeding	O
is	O
greatly	O
reduced	O
when	O
the	O
advantages	O
of	O
good	O
anticoagulant	O
activity	O
and	O
fast	O
effect	O
of	O
the	O
prasugrel	O
during	O
the	O
antiplatelet	O
aggregation	O
are	O
fully	O
exerted	O
,	O
the	O
risk	O
of	O
bleeding	O
caused	O
by	O
the	O
prasugrel	O
is	O
effectively	O
reduced	O
and	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Method	O
for	O
preparing	O
zinc	O
supplementing	O
agent	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
zinc	O
supplementing	O
agent	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
,	O
which	O
is	O
characterized	O
in	O
that	O
10	O
g	O
of	O
carboxymethyl	O
chitosan	O
is	O
taken	O
and	O
put	O
into	O
a	O
three	O
-	O
neck	O
flask	O
,	O
and	O
is	O
added	O
with	O
90ml	O
of	O
2	O
%	O
H2O2	O
in	O
batches	O
when	O
being	O
stirred	O
for	O
full	O
reaction	O
until	O
the	O
carboxymethyl	O
chitosan	O
is	O
completely	O
dissolved	O
;	O
pH	O
value	O
is	O
adjusted	O
to	O
be	O
7	O
,	O
the	O
precipitation	O
is	O
filtered	O
out	O
,	O
the	O
product	O
is	O
washed	O
,	O
and	O
filtrate	O
and	O
washing	O
liquid	O
are	O
collected	O
;	O
the	O
filtrate	O
and	O
the	O
washing	O
liquid	O
are	O
decompressed	O
and	O
concentrated	O
,	O
and	O
then	O
precipitated	O
,	O
filtered	O
and	O
washed	O
by	O
ethanol	O
;	O
finally	O
,	O
the	O
product	O
is	O
processed	O
by	O
vacuum	O
drying	O
with	O
the	O
drying	O
temperature	O
controlled	O
to	O
be	O
60	O
DEG	O
C.	O
The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
carboxymethyl	O
chitosan	O
is	O
prepared	O
after	O
chitosan	O
oligosaccharide	O
is	O
modified	O
,	O
so	O
as	O
to	O
have	O
the	O
pharmacological	O
actions	O
of	O
arrhythmia	O
resistance	O
,	O
anticoagulation	O
,	O
infection	O
resistance	O
and	O
the	O
like	O
;	O
the	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
is	O
natural	O
modified	O
product	O
and	O
has	O
better	O
safety	O
and	O
biological	O
activity	O
compared	O
with	O
other	O
zinc	O
supplementing	O
agents	O
.	O

Two	O
sterol	O
derivatives	O
,	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O
The	O
invention	O
discloses	O
two	O
sterol	O
derivatives	O
,	O
a	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
an	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O
.	O

The	O
two	O
sterol	O
derivatives	O
arecompounds	O
24-methylene	O
cholesterol	O
linoleate	O
and	O
cycloeucalenol	O
linoleate	O
shown	O
as	O
formula	O
1	O
and	O
formula	O
2	O
.	O

The	O
compounds	O
which	O
are	O
not	O
reported	O
have	O
the	O
function	O
of	O
inhibiting	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
.	O

The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
the	O
two	O
sterol	O
derivatives	O
in	O
preparing	O
preparations	O
to	O
inhibit	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
and	O
in	O
preparing	O
pharmaceutical	O
compositions	O
to	O
prevent	O
or	O
treat	O
prostatoplasia	O
diseases	O
.	O

Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O
The	O
invention	O
discloses	O
a	O
Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O
,	O
comprising	O
raw	O
medicines	O
of	O
Lamiophlomis	O
rotate	O
,	O
whin	O
,	O
curcuma	O
,	O
pricklyash	O
peel	O
,	O
comu	O
bubal	O
,	O
Myricaria	O
paniculata	O
,	O
safflower	O
,	O
camphol	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
invention	O
has	O
the	O
functions	O
of	O
activating	O
blood	O
and	O
dissolving	O
stasis	O
,	O
and	O
relieving	O
swelling	O
and	O
pain	O
.	O

The	O
aerosol	O
of	O
the	O
invention	O
is	O
characterized	O
by	O
advanced	O
dosage	O
form	O
,	O
simple	O
process	O
,	O
rapid	O
effect	O
and	O
the	O
like	O
.	O

Stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
The	O
invention	O
discloses	O
a	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
.	O

The	O
health	O
-	O
care	O
product	O
comprises	O
the	O
following	O
compositions	O
in	O
percentage	O
by	O
weight	O
:	O
10	O
to	O
30	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
70	O
to	O
90	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
byproduct	O
,	O
1	O
to	O
10	O
percent	O
of	O
glycopeptide	O
,	O
1	O
to	O
10	O
percent	O
of	O
oleanolic	O
acid	O
,	O
1	O
to	O
10	O
percent	O
of	O
ethylamine	O
sulfonic	O
acid	O
,	O
1	O
to	O
10	O
percent	O
of	O
alkaloid	O
and	O
1	O
to	O
10	O
percent	O
of	O
terpenoid	O
.	O

The	O
main	O
composition	O
of	O
the	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
the	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
can	O
be	O
stored	O
at	O
normal	O
temperature	O
,	O
improve	O
the	O
immunity	O
level	O
of	O
cells	O
,	O
promote	O
the	O
repair	O
of	O
gastrointestinal	O
mucosa	O
,	O
relieve	O
the	O
gastrointestinal	O
spasm	O
,	O
inhibit	O
the	O
tumor	O
growth	O
,	O
promote	O
the	O
digestive	O
absorption	O
,	O
improve	O
the	O
inflammation	O
of	O
a	O
digestive	O
system	O
,	O
regulate	O
the	O
disorder	O
of	O
gastrointestinal	O
flora	O
and	O
has	O
the	O
functions	O
of	O
strengthening	O
spleen	O
,	O
harmonizing	O
stomach	O
,	O
replenishing	O
spleen	O
qi	O
and	O
relieving	O
pain	O
.	O

The	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
suitable	O
for	O
the	O
conditioning	O
and	O
health	O
care	O
of	O
diseases	O
of	O
the	O
digestive	O
system	O
.	O

Medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
The	O
invention	O
discloses	O
a	O
medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
.	O

The	O
medicament	O
composition	O
is	O
prepared	O
by	O
taking	O
medroxyprogesterone	O
,	O
nadestryl	O
,	O
amino	O
acid	O
chelated	O
calcium	O
,	O
vitamin	O
A	O
,	O
vitamin	O
D	O
and	O
vitamin	O
E	O
as	O
raw	O
materials	O
and	O
processing	O
the	O
raw	O
materials	O
according	O
to	O
a	O
conventional	O
preparation	O
.	O

By	O
complementing	O
estrogen	O
,	O
progestational	O
hormone	O
,	O
calcium	O
and	O
vitamin	O
,	O
the	O
invention	O
is	O
used	O
for	O
treating	O
the	O
climacteric	O
syndrome	O
of	O
women	O
.	O

Anti	O
-	O
inflammatory	O
and	O
antimicrobial	O
uses	O
for	O
bioactive	O
glass	O
compositions	O
Compositions	O
and	O
methods	O
for	O
treating	O
wounds	O
to	O
significantly	O
reduce	O
the	O
healing	O
time	O
,	O
reduce	O
the	O
incidence	O
of	O
scar	O
formation	O
,	O
improve	O
the	O
success	O
of	O
skin	O
grafts	O
,	O
reduce	O
the	O
inflammatory	O
response	O
and	O
providing	O
anti	O
-	O
bacterial	O
treatments	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
that	O
include	O
small	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
or	O
highly	O
porous	O
bioactive	O
glass	O
,	O
are	O
disclosed	O
.	O

Anti	O
-	O
bacterial	O
solutions	O
derived	O
from	O
bioactive	O
glass	O
,	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O
,	O
are	O
also	O
disclosed	O
.	O

The	O
compositions	O
include	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
,	O
alone	O
or	O
in	O
combination	O
with	O
anti	O
-	O
bacterial	O
agents	O
and/or	O
anti	O
-	O
inflammatory	O
agents	O
.	O

The	O
compositions	O
can	O
include	O
an	O
appropriate	O
carrier	O
for	O
topical	O
administration	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
be	O
imparted	O
to	O
implanted	O
materials	O
,	O
such	O
as	O
prosthetic	O
implants	O
,	O
sutures	O
,	O
stents	O
,	O
screws	O
,	O
plates	O
,	O
tubes	O
,	O
and	O
the	O
like	O
,	O
by	O
incorporating	O
small	O
bioactive	O
glass	O
particles	O
or	O
porous	O
bioactive	O
glass	O
into	O
or	O
onto	O
the	O
implanted	O
materials	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
also	O
be	O
imparted	O
to	O
devices	O
used	O
for	O
in	O
vitro	O
and	O
ex	O
vivo	O
cell	O
culture	O
by	O
incorporating	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
into	O
the	O
devices	O
.	O

Anti	O
-	O
bacterial	O
compositions	O
derived	O
from	O
aqueous	O
extracts	O
of	O
bioactive	O
glass	O
are	O
also	O
disclosed	O
.	O

These	O
compositions	O
can	O
be	O
used	O
,	O
for	O
example	O
,	O
in	O
food	O
preparation	O
,	O
solutions	O
used	O
for	O
cell	O
culture	O
,	O
and	O
buffer	O
solutions	O
,	O
such	O
as	O
i.v	O
.	O

solutions	O
.	O

Fluticasone	O
propionate	O
lipidosome	O
cream	O
The	O
invention	O
relates	O
to	O
a	O
lipidosome	O
medical	O
composition	O
which	O
uses	O
fluticasone	O
propionate	O
as	O
an	O
active	O
component	O
,	O
and	O
a	O
cyst	O
diameter	O
of	O
lipidosome	O
is	O
smaller	O
than	O
800	O
nm	O
.	O

The	O
composition	O
comprises	O
0.025	O
percent	O
to	O
0.2	O
percent	O
of	O
fluticasone	O
propionate	O
as	O
the	O
active	O
component	O
,	O
0.5	O
percent	O
to	O
6	O
percent	O
of	O
phospholipid	O
,	O
0	O
percent	O
to	O
1	O
percent	O
of	O
lipophilic	O
additive	O
,	O
0.01	O
percent	O
to	O
1	O
percent	O
of	O
antioxidant	O
which	O
is	O
used	O
for	O
preserving	O
the	O
medical	O
composition	O
,	O
a	O
pH	O
buffering	O
agent	O
which	O
is	O
used	O
for	O
retaining	O
the	O
pH	O
value	O
from	O
5	O
to	O
7.5	O
,	O
3	O
percent	O
to	O
15	O
percent	O
of	O
humectant	O
,	O
20	O
percent	O
to	O
30	O
percent	O
of	O
oil	O
phrase	O
component	O
,	O
0.01	O
percent	O
to	O
0.1	O
percent	O
of	O
antimicrobial	O
preservative	O
and	O
the	O
balanced	O
of	O
water	O
.	O

The	O
fluticasone	O
propionate	O
lipidosome	O
cream	O
is	O
used	O
for	O
treating	O
skin	O
diseases	O
of	O
human	O
beings	O
or	O
animals	O
.	O

Solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutics	O
.	O

The	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	O
comprises	O
(	O
1	O
)	O
ambroxol	O
or	O
medicinal	O
salt	O
thereof	O
with	O
single	O
medicinal	O
dosage	O
,	O
(	O
2	O
)	O
isotonic	O
agent	O
and	O
solvent	O
,	O
(	O
3	O
)	O
buffer	O
solution	O
and	O
(	O
4	O
)	O
medicinal	O
package	O
with	O
single	O
dosage	O
;	O
and	O
in	O
terms	O
of	O
the	O
ambroxol	O
,	O
the	O
mass	O
ratio	O
of	O
the	O
medicinal	O
components	O
to	O
the	O
isotonic	O
agent	O
is	O
1:1.1	O
-	O
1:3.3.The	O
invention	O
provides	O
the	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	O
with	O
single	O
dosage	O
and	O
the	O
medicinal	O
package	O
adopting	O
blowing	O
-	O
filling	O
-	O
sealing	O
(	O
BFS	O
)	O
integrative	O
full	O
-	O
automatic	O
production	O
,	O
which	O
have	O
the	O
advantages	O
that	O
the	O
medicinal	O
package	O
is	O
designed	O
and	O
manufactured	O
for	O
patients	O
special	O
for	O
atomizing	O
and	O
inhaling	O
;	O
the	O
solution	O
preparation	O
does	O
not	O
contain	O
preservative	O
,	O
and	O
is	O
used	O
with	O
disposable	O
single	O
dosage	O
;	O
the	O
using	O
process	O
is	O
convenient	O
and	O
does	O
not	O
need	O
dilution	O
and	O
preparation	O
;	O
and	O
the	O
microbe	O
pollution	O
,	O
waste	O
and	O
the	O
like	O
during	O
using	O
can	O
be	O
greatly	O
reduced	O
.	O

The	O
medicinal	O
preparation	O
provides	O
a	O
treatment	O
medicament	O
and	O
a	O
treatment	O
proposal	O
with	O
accurate	O
medicinal	O
dosage	O
,	O
good	O
-	O
quality	O
and	O
stable	O
medicament	O
quality	O
,	O
and	O
safe	O
and	O
simple	O
clinical	O
application	O
lacking	O
in	O
the	O
prior	O
art	O
.	O

Enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
an	O
enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
enrofloxacin	O
double	O
emulsion	O
belongs	O
to	O
the	O
field	O
of	O
antibiotic	O
preparations	O
for	O
livestock	O
.	O

The	O
W	O
/	O
O	O
/	O
W	O
type	O
double	O
emulsion	O
is	O
prepared	O
by	O
using	O
enrofloxacin	O
as	O
active	O
ingredients	O
and	O
adding	O
oil	O
phase	O
,	O
emulsifier	O
,	O
stabilizer	O
and	O
the	O
like	O
.	O

The	O
enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
can	O
better	O
cover	O
the	O
bitter	O
taste	O
of	O
the	O
enrofloxacin	O
,	O
improves	O
the	O
adaptation	O
of	O
oral	O
drugs	O
for	O
livestock	O
,	O
can	O
better	O
control	O
the	O
diffusion	O
rate	O
of	O
the	O
drugs	O
to	O
play	O
a	O
role	O
of	O
slow	O
release	O
,	O
and	O
better	O
adapts	O
different	O
clinical	O
drugs	O
requirements	O
.	O

Clinical	O
tests	O
show	O
that	O
the	O
invention	O
can	O
overcome	O
phenomena	O
of	O
food	O
refusal	O
and	O
poor	O
appetite	O
of	O
taste	O
acuity	O
animals	O
of	O
pigs	O
and	O
the	O
like	O
,	O
therebyensuring	O
the	O
dosage	O
,	O
improving	O
the	O
medicine	O
effect	O
,	O
and	O
achieving	O
the	O
purpose	O
of	O
ideal	O
treatment	O
.	O

Meanwhile	O
,	O
because	O
of	O
a	O
certain	O
slow	O
release	O
function	O
,	O
the	O
frequency	O
for	O
medicine	O
administration	O
can	O
be	O
reduced	O
,	O
and	O
the	O
invention	O
provides	O
an	O
efficient	O
and	O
long	O
-	O
acting	O
enrofloxacin	O
preparation	O
for	O
clinical	O
veterinarian	O
.	O

New	O
use	O
of	O
isosorbide	O
mononitrate	O
in	O
preparing	O
medicine	O
for	O
increasing	O
endometrial	O
thickness	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
particularly	O
relates	O
to	O
a	O
new	O
use	O
of	O
isosorbide	O
5-mononitrate	O
and	O
a	O
corresponding	O
new	O
dosage	O
form	O
suitable	O
for	O
the	O
new	O
use	O
,	O
and	O
concretely	O
relates	O
to	O
a	O
use	O
of	O
isosorbide	O
5-mononitrate	O
in	O
preparing	O
drug	O
for	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
.	O

The	O
improvement	O
of	O
the	O
receptive	O
performance	O
of	O
endometrium	O
is	O
concretely	O
realized	O
through	O
repairing	O
and	O
improving	O
the	O
endometrium	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
glandular	O
organ	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
mesenchyma	O
.	O

In	O
order	O
to	O
adapt	O
to	O
the	O
four	O
new	O
uses	O
,	O
the	O
prepared	O
drug	O
is	O
vagina	O
local	O
drug	O
feeding	O
preparation	O
,	O
namely	O
,	O
preparation	O
which	O
takes	O
isosorbide	O
5-mononitrate	O
with	O
effective	O
amount	O
as	O
active	O
components	O
and	O
is	O
prepared	O
through	O
adding	O
accessories	O
which	O
are	O
allowable	O
in	O
pharmacy	O
.	O

The	O
isosorbide	O
5-mononitrate	O
not	O
only	O
can	O
exert	O
excellent	O
medical	O
effects	O
of	O
prompting	O
the	O
development	O
of	O
endometrium	O
tissues	O
and	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
,	O
but	O
also	O
can	O
effectively	O
avoid	O
the	O
side	O
effect	O
that	O
isosorbide	O
5-mononitrate	O
lowers	O
blood	O
pressure	O
after	O
giving	O
drug	O
in	O
vagina	O
,	O
and	O
provides	O
a	O
new	O
choice	O
for	O
clinical	O
application	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O
,	O
having	O
the	O
strong	O
eliminating	O
function	O
on	O
bacteria	O
,	O
epiphyte	O
and	O
viruses	O
and	O
has	O
the	O
obvious	O
effect	O
on	O
tinea	O
of	O
feet	O
and	O
hands	O
,	O
onychomycosis	O
,	O
tinea	O
cruris	O
,	O
scald	O
head	O
,	O
furuncle	O
,	O
mosquito	O
bite	O
and	O
acrohyperhidrosis	O
.	O

The	O
high	O
-	O
molecule	O
material	O
and	O
recipe	O
composition	O
of	O
the	O
pharmaceutical	O
composition	O
has	O
no	O
poison	O
and	O
little	O
stimulation	O
on	O
skin	O
,	O
has	O
long	O
action	O
time	O
and	O
presents	O
the	O
actions	O
of	O
controlled	O
release	O
and	O
stability	O
.	O

The	O
quality	O
can	O
be	O
kept	O
to	O
be	O
stable	O
when	O
the	O
composition	O
is	O
stored	O
at	O
normal	O
temperature	O
,	O
and	O
thereby	O
,	O
the	O
composition	O
is	O
safe	O
and	O
effective	O
.	O

The	O
composition	O
contains	O
the	O
main	O
constituents	O
of	O
povidone	O
iodine	O
,	O
acetylsalicylic	O
acid	O
,	O
polyethylene	O
glycol	O
,	O
potash	O
iodate	O
,	O
phenol	O
and	O
high	O
-	O
molecule	O
material	O
.	O

Transdermal	O
zinc	O
supplement	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
zinc	O
supplement	O
,	O
in	O
particular	O
to	O
a	O
transdermal	O
zinc	O
supplement	O
which	O
comprises	O
zinc	O
oxide	O
and	O
citric	O
acid	O
and	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
material	O
components	O
by	O
weight	O
percent	O
:	O
10	O
-	O
40	O
%	O
of	O
zinc	O
oxide	O
,	O
30	O
-	O
70	O
%	O
of	O
citric	O
acid	O
and	O
10	O
-	O
50	O
%	O
of	O
sodium	O
hydroxide	O
.	O

A	O
method	O
for	O
manufacturing	O
the	O
transdermal	O
zinc	O
supplement	O
comprises	O
the	O
following	O
steps	O
:	O
weighing	O
the	O
raw	O
material	O
components	O
according	O
to	O
the	O
weight	O
percent	O
,	O
and	O
mixing	O
and	O
grinding	O
the	O
raw	O
material	O
components	O
until	O
being	O
evenly	O
mixed	O
;	O
heating	O
the	O
ground	O
material	O
to	O
the	O
temperature	O
of	O
120	O
-	O
150	O
DEG	O
C	O
and	O
then	O
carrying	O
out	O
heat	O
preservation	O
for	O
1	O
-	O
2h	O
to	O
lead	O
the	O
material	O
to	O
be	O
dried	O
;	O
and	O
finally	O
,	O
crushing	O
the	O
dried	O
material	O
,	O
screening	O
the	O
material	O
by	O
a	O
No.	O
5	O
sieve	O
,	O
obtaining	O
undersized	O
material	O
which	O
is	O
the	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	O
supplement	O
,	O
and	O
then	O
split	O
packaging	O
the	O
obtained	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	O
supplement	O
.	O

The	O
transdermal	O
zinc	O
supplement	O
can	O
avoid	O
the	O
interference	O
of	O
gastrointestinal	O
tract	O
as	O
well	O
as	O
the	O
influence	O
of	O
factors	O
such	O
as	O
the	O
pH	O
value	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
food	O
,	O
digestive	O
juice	O
and	O
the	O
like	O
,	O
improves	O
the	O
bioavailability	O
of	O
the	O
zinc	O
supplement	O
,	O
has	O
wide	O
application	O
range	O
including	O
infants	O
children	O
,	O
pregnant	O
women	O
,	O
nursing	O
women	O
and	O
adults	O
,	O
and	O
improves	O
the	O
life	O
quality	O
of	O
the	O
whole	O
life	O
.	O

Cyclopentenyl	O
fatty	O
acid	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
cyclopentenyl	O
fatty	O
acid	O
and	O
ester	O
or	O
a	O
solvate	O
thereof	O
.	O

The	O
cyclopentenyl	O
fatty	O
acid	O
consists	O
of	O
a	O
cyclopentenyl	O
structural	O
unit	O
and	O
a	O
long	O
-	O
chain	O
fatty	O
acid	O
or	O
the	O
ester	O
or	O
the	O
solvate	O
thereof	O
,	O
and	O
compounds	O
with	O
structural	O
formulas	O
A	O
and	O
B	O
are	O
preferable	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
application	O
thereof	O
in	O
preparing	O
anti	O
-	O
tuberculous	O
drugs	O
.	O

Ornidazole	O
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ornidazole	O
medicinal	O
composition	O
.	O

Each	O
100	O
milliliters	O
of	O
ornidazole	O
medicinal	O
composition	O
contains	O
5	O
grams	O
of	O
ornidazole	O
,	O
35	O
to	O
60	O
milliliters	O
of	O
1,2-propylene	O
glycol	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
pH	O
value	O
of	O
the	O
ornidazole	O
medicinal	O
composition	O
is	O
2.5	O
to	O
4.5	O
.	O

The	O
composition	O
can	O
be	O
made	O
into	O
a	O
small	O
-	O
volume	O
injection	O
,	O
wherein	O
the	O
injection	O
can	O
be	O
a	O
5-milliliter	O
injection	O
containing	O
0.25	O
gram	O
of	O
the	O
composition	O
or	O
a	O
10-milliliter	O
injection	O
containing	O
0.5	O
gram	O
of	O
the	O
composition	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
ornidazole	O
medicinal	O
composition	O
,	O
which	O
comprises	O
:	O
adding	O
ornidazole	O
into	O
1,2-propylene	O
glycol	O
,	O
keeping	O
the	O
temperature	O
to	O
be	O
45	O
to	O
60	O
DEG	O
C	O
and	O
stirring	O
the	O
mixture	O
till	O
the	O
ornidazole	O
dissolves	O
completely	O
;	O
adding	O
disodium	O
ethylenediamintetraacetate	O
aqueous	O
solution	O
at	O
a	O
concentration	O
of	O
40	O
-	O
70mg	O
/	O
100ml	O
;	O
and	O
using	O
needle	O
active	O
carbon	O
for	O
absorption	O
and	O
microporous	O
filter	O
membrane	O
for	O
filtration	O
decarbonization	O
,	O
supplying	O
water	O
for	O
injection	O
and	O
adjusting	O
the	O
pH	O
value	O
to	O
2.5	O
to	O
4.5	O
to	O
obtain	O
the	O
ornidazole	O
medicinal	O
composition	O
.	O

The	O
method	O
provided	O
by	O
the	O
invention	O
has	O
simple	O
process	O
and	O
the	O
prepared	O
product	O
has	O
high	O
stability	O
.	O

Plaster	O
for	O
treating	O
facial	O
paralysis	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
facial	O
paralysis	O
,	O
which	O
comprises	O
rhizoma	O
typhonii	O
,	O
scorpio	O
,	O
stiff	O
silkworm	O
,	O
uncaria	O
,	O
rhizoma	O
gastrodiae	O
,	O
futokadsura	O
stem	O
,	O
notopterygium	O
root	O
,	O
asarum	O
,	O
herba	O
schizonepetae	O
,	O
radix	O
sileris	O
,	O
cicada	O
slough	O
,	O
angelica	O
root	O
,	O
centipede	O
,	O
zaocys	O
dhumnade	O
,	O
earthworm	O
,	O
mastic	O
,	O
myrrh	O
,	O
radix	O
salviae	O
miltiorrhizae	O
,	O
safflower	O
,	O
artemisia	O
anomala	O
,	O
cinnamon	O
,	O
rhizoma	O
ligustici	O
wallichii	O
,	O
red	O
peony	O
root	O
,	O
Chinese	O
ephedra	O
,	O
equisetum	O
,	O
tetrandra	O
root	O
,	O
rhizoma	O
atractylodis	O
,	O
pawpaw	O
,	O
pangolin	O
scales	O
,	O
speranskia	O
tuberculata	O
,	O
oyster	O
,	O
sea	O
-	O
ear	O
shell	O
,	O
strychnos	O
,	O
white	O
mustard	O
seed	O
,	O
musk	O
,	O
colophony	O
,	O
verdigris	O
,	O
draconis	O
sanguis	O
,	O
catechu	O
and	O
gleditsia	O
sinensis	O
lam	O
.	O

The	O
components	O
are	O
mutually	O
coordinated	O
to	O
achieve	O
the	O
functions	O
of	O
calming	O
the	O
endopathic	O
wind	O
,	O
relieving	O
convulsion	O
and	O
spasm	O
,	O
dispersing	O
pathogenic	O
wind	O
,	O
dispelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
,	O
relieving	O
the	O
stasis	O
of	O
blood	O
,	O
resolving	O
phlegm	O
,	O
reducing	O
the	O
stagnation	O
,	O
nourishing	O
the	O
blood	O
,	O
smoothing	O
collaterals	O
,	O
promoting	O
the	O
circulation	O
of	O
qi	O
and	O
alleviating	O
pain	O
.	O

Method	O
for	O
preparing	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
,	O
belonging	O
to	O
the	O
field	O
of	O
the	O
pharmaceutical	O
preparation	O
.	O

The	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
is	O
clear	O
and	O
transparent	O
solution	O
which	O
comprises	O
oil	O
phase	O
,	O
surfactant	O
,	O
cosurfactant	O
and	O
water	O
phase	O
by	O
appropriate	O
proportion	O
,	O
wherein	O
the	O
proportion	O
of	O
the	O
oil	O
phase	O
to	O
the	O
surfactant	O
is	O
45:1	O
-	O
1:7	O
,	O
and	O
the	O
proportion	O
of	O
the	O
surfactant	O
to	O
the	O
cosurfactant	O
is	O
4:1	O
-	O
1:4	O
.	O

The	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
can	O
improve	O
the	O
bioavailability	O
of	O
the	O
chondroitin	O
sulfate	O
,	O
reduce	O
the	O
toxic	O
and	O
side	O
effect	O
of	O
the	O
chondroitin	O
sulfate	O
and	O
fully	O
exert	O
the	O
efficacy	O
of	O
the	O
chondroitin	O
sulfate	O
.	O

Raloxifene	O
emplastrum	O
preparation	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
raloxifene	O
emplastrum	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Raloxifene	O
microemulsion	O
is	O
made	O
into	O
a	O
transdermal	O
emplastrum	O
which	O
is	O
divided	O
into	O
an	O
anti	O
-	O
adhesion	O
layer	O
,	O
a	O
viscose	O
layer	O
,	O
a	O
backlining	O
layer	O
and	O
a	O
medicine	O
storage	O
layer	O
.	O

The	O
raloxifene	O
microemulsion	O
taken	O
as	O
a	O
medical	O
ingredient	O
of	O
the	O
raloxifene	O
emplastrum	O
comprises	O
the	O
following	O
ingredients	O
:	O
raloxifene	O
taken	O
as	O
an	O
active	O
ingredient	O
,	O
polysorbate	O
taken	O
as	O
surfactant	O
,	O
propanediol	O
taken	O
as	O
cosurfactant	O
,	O
pure	O
water	O
or	O
distilled	O
water	O
,	O
and	O
the	O
like	O
.	O

Except	O
for	O
the	O
medical	O
ingredient	O
,	O
a	O
plurality	O
of	O
nonpolar	O
polymers	O
,	O
plasticizing	O
agent	O
,	O
caking	O
agent	O
,	O
transdermal	O
enhancing	O
agent	O
and	O
antioxidant	O
are	O
also	O
added	O
in	O
the	O
emplastrum	O
.	O

Compared	O
with	O
the	O
prior	O
dosage	O
forms	O
,	O
such	O
as	O
tablets	O
,	O
the	O
invention	O
has	O
the	O
remarkable	O
advantages	O
of	O
durable	O
medical	O
effect	O
,	O
safety	O
,	O
low	O
toxicity	O
,	O
simple	O
,	O
convenient	O
and	O
sanitary	O
,	O
and	O
accurate	O
medical	O
dosage	O
.	O

Pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O
,	O
which	O
comprises	O
sea	O
buckthorn	O
,	O
vitamin	O
B	O
complex	O
,	O
vitamin	O
E	O
and	O
trace	O
elements	O
of	O
zinc	O
,	O
selenium	O
,	O
chromium	O
and	O
molybdenum	O
.	O

The	O
pharmaceutical	O
composite	O
is	O
used	O
for	O
people	O
suffering	O
from	O
hyperlipaemia	O
,	O
has	O
very	O
good	O
effect	O
on	O
reducing	O
blood	O
fat	O
,	O
and	O
can	O
be	O
applied	O
to	O
a	O
long	O
time	O
or	O
in	O
course	O
of	O
treatment	O
.	O

Cancer	O
pain	O
elimination	O
pill	O
The	O
invention	O
relates	O
to	O
a	O
cancer	O
pain	O
elimination	O
pill	O
which	O
is	O
a	O
medicament	O
for	O
treating	O
esophageal	O
cancer	O
,	O
esophagus	O
cancer	O
,	O
gastric	O
cancer	O
and	O
postoperation	O
metastasis	O
cancer	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
prepared	O
from	O
trogopterus	O
dung	O
,	O
akebia	O
trifoliata	O
koidz	O
.	O
,	O
long	O
-	O
noded	O
pit	O
viper	O
,	O
honeysuckle	O
flower	O
,	O
pangolin	O
,	O
fructus	O
amomi	O
,	O
lima	O
beans	O
,	O
borneol	O
,	O
radix	O
pseudostellariae	O
,	O
paris	O
polyphylla	O
,	O
radix	O
curcumae	O
,	O
white	O
paeony	O
roots	O
,	O
angelica	O
sinensis	O
,	O
peach	O
kernels	O
,	O
rabdosia	O
rubescens	O
,	O
curcuma	O
zedoary	O
,	O
rhizoma	O
zedoariae	O
,	O
malts	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
hawthorns	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
medicated	O
leaven	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
agastache	O
rugosus	O
,	O
senecio	O
dianthus	O
franch	O
and	O
caulis	O
perllae	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
suitable	O
for	O
treating	O
the	O
esophageal	O
cancer	O
,	O
the	O
esophagus	O
cancer	O
,	O
the	O
gastric	O
cancer	O
and	O
the	O
postoperation	O
metastasis	O
cancer	O
,	O
has	O
good	O
curative	O
effect	O
and	O
quick	O
effect	O
,	O
treats	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
and	O
is	O
convenient	O
to	O
take	O
.	O

Proved	O
by	O
years	O
of	O
clinical	O
experiments	O
,	O
the	O
cancer	O
pain	O
elimination	O
pill	O
effectively	O
relieves	O
pains	O
of	O
patients	O
and	O
gets	O
the	O
praises	O
of	O
a	O
lot	O
of	O
patients	O
.	O

Preparation	O
method	O
and	O
products	O
of	O
danofloxacin	O
mesylate	O
liposome	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
and	O
products	O
of	O
danofloxacin	O
mesylate	O
liposome	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
adopting	O
the	O
ammonium	O
sulfate	O
gradient	O
method	O
to	O
prepare	O
blank	O
liposome	O
;	O
and	O
(	O
2	O
)	O
adding	O
danofloxacin	O
mesylate	O
liquor	O
in	O
the	O
blank	O
liposome	O
,	O
using	O
water	O
bath	O
for	O
incubation	O
,	O
filtrating	O
,	O
and	O
performing	O
repeated	O
freeze	O
thawing	O
to	O
the	O
filtrate	O
by	O
using	O
the	O
freeze	O
and	O
thawing	O
method	O
to	O
obtain	O
the	O
danofloxacin	O
mesylate	O
liposome	O
.	O

The	O
finished	O
liposome	O
prepared	O
by	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
milky	O
semitransparent	O
mixed	O
suspension	O
which	O
appears	O
as	O
spherical	O
or	O
nearly	O
globose	O
small	O
vesicles	O
with	O
regular	O
shape	O
,	O
good	O
dispersity	O
and	O
uniform	O
grain	O
size	O
under	O
an	O
electron	O
microscope	O
;	O
the	O
entrapment	O
rate	O
of	O
the	O
liposome	O
is	O
above	O
90	O
%	O
and	O
the	O
liposome	O
has	O
good	O
stability	O
;	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
of	O
the	O
liposome	O
are	O
better	O
than	O
that	O
of	O
conventional	O
dosage	O
forms	O
and	O
the	O
liposome	O
is	O
characterized	O
by	O
slow	O
release	O
,	O
long	O
acting	O
and	O
high	O
lung	O
-	O
targeting	O
.	O

Anti	O
-	O
drug	O
medicine	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
narcotic	O
-	O
abstaining	O
medicine	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
narcotic	O
-	O
abstaining	O
medicine	O
is	O
a	O
narcotic	O
-	O
abstaining	O
oral	O
medicine	O
prepared	O
from	O
the	O
raw	O
material	O
medicines	O
such	O
as	O
American	O
ginseng	O
,	O
astragalus	O
root	O
,	O
angelica	O
,	O
wild	O
or	O
spiny	O
jujuba	O
seed	O
,	O
schisandra	O
fruit	O
,	O
tuckahoe	O
,	O
corydalis	O
tuber	O
,	O
thymeleaf	O
sandwort	O
,	O
licorice	O
and	O
the	O
like	O
according	O
to	O
the	O
methods	O
of	O
grinding	O
,	O
decocting	O
,	O
distilling	O
,	O
concentrating	O
,	O
mixing	O
and	O
the	O
like	O
.	O

Clinical	O
observation	O
shows	O
that	O
the	O
medicine	O
has	O
good	O
functions	O
of	O
detoxication	O
and	O
addiction	O
abstaining	O
and	O
has	O
an	O
obvious	O
functionof	O
resisting	O
freak	O
-	O
out	O
recovery	O
,	O
and	O
the	O
narcotic	O
-	O
abstaining	O
rehabilitation	O
rate	O
of	O
resisting	O
freak	O
-	O
out	O
recovery	O
is	O
more	O
than	O
65	O
%	O
.	O

Compound	O
in	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
and	O
application	O
thereof	O
in	O
curing	O
treating	O
cardiovascular	O
disease	O
The	O
invention	O
discloses	O
a	O
new	O
phenolic	O
acid	O
compound	O
,	O
i.e.	O
danshinolic	O
acid	O
M	O
extracted	O
from	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
,	O
the	O
compound	O
also	O
can	O
be	O
extracted	O
from	O
a	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
,	O
and	O
the	O
invention	O
simultaneously	O
also	O
discloses	O
a	O
method	O
for	O
extracting	O
the	O
new	O
compound	O
respectively	O
from	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
and	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
.	O

Pharmacological	O
studies	O
indicate	O
that	O
the	O
danshinolic	O
acid	O
M	O
has	O
myocardial	O
preservation	O
and	O
oxidation	O
resistant	O
activity	O
,	O
thereby	O
the	O
compound	O
has	O
the	O
prospect	O
of	O
being	O
further	O
developed	O
into	O
an	O
effective	O
medicament	O
for	O
curing	O
treating	O
cardiovascular	O
diseases	O
and	O
can	O
be	O
used	O
in	O
the	O
quality	O
control	O
standard	O
of	O
the	O
salvia	O
miltiorrhiza	O
bunge	O
red	O
sage	O
root	O
injection	O
.	O

Substituted	O
pyridino-	O
[	O
2',1':2,3	O
]	O
imidazo	O
[	O
4,5-c	O
]	O
isoquinolone	O
compounds	O
,	O
method	O
for	O
synthesizing	O
same	O
,	O
use	O
of	O
same	O
and	O
medicinal	O
composition	O
having	O
same	O
The	O
invention	O
relates	O
to	O
substituted	O
pyridino-	O
[	O
2',1':2,3	O
]	O
imidazo	O
[	O
4,5-c	O
]	O
isoquinolone	O
compounds	O
,	O
a	O
method	O
for	O
synthesizing	O
the	O
same	O
,	O
use	O
of	O
the	O
same	O
and	O
a	O
medicinal	O
composition	O
having	O
the	O
same	O
,	O
in	O
particular	O
to	O
compounds	O
of	O
a	O
general	O
formula	O
(	O
I	O
)	O
or	O
stereoisomers	O
thereof	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
promedicaments	O
thereof	O
or	O
solvate	O
thereof	O
and	O
synthesis	O
method	O
thereof	O
.	O

With	O
specific	O
and	O
high	O
-	O
efficiency	O
mitosis	O
retarding	O
effect	O
,	O
the	O
compounds	O
can	O
be	O
used	O
as	O
mitosis	O
inhibitors	O
to	O
induce	O
the	O
apoptosis	O
of	O
cells	O
.	O

And	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
compounds	O
is	O
different	O
from	O
those	O
of	O
known	O
mitosis	O
inhibitors	O
and	O
can	O
be	O
used	O
in	O
treating	O
leukemia	O
,	O
stomach	O
cancer	O
,	O
cervical	O
cancer	O
,	O
melanoma	O
,	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
liver	O
cancer	O
and	O
lung	O
cancer	O
.	O

Cefixime	O
oral	O
administration	O
mixed	O
suspension	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cefixime	O
oral	O
administration	O
mixed	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
order	O
to	O
meet	O
the	O
requirement	O
of	O
special	O
medicament	O
taking	O
crowds	O
on	O
the	O
taking	O
of	O
cefixime	O
.	O

The	O
cefixime	O
oral	O
administration	O
mixed	O
suspension	O
per	O
100ml	O
comprises	O
the	O
following	O
components	O
:	O
0.5	O
-	O
4.0	O
g	O
of	O
cefixime	O
,	O
larger	O
than	O
0	O
-	O
20.0	O
g	O
of	O
thickening	O
suspension	O
assistant	O
agent	O
,	O
a	O
cosolvent	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
preservative	O
and	O
the	O
balance	O
of	O
non	O
-	O
aqueous	O
liquid	O
medium	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
preservative	O
into	O
the	O
cosolvent	O
;	O
adding	O
the	O
thickening	O
suspension	O
assistant	O
agent	O
into	O
the	O
non	O
-	O
aqueous	O
liquid	O
medium	O
,	O
stirring	O
and	O
dissolving	O
;	O
adding	O
solutions	O
of	O
the	O
flavoring	O
agent	O
,	O
the	O
preservative	O
and	O
the	O
cosolvent	O
uniformly	O
stirring	O
;	O
and	O
adding	O
cefixime	O
micropowder	O
and	O
uniformly	O
stirring	O
and	O
spreading	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
unstable	O
cefixime	O
in	O
water	O
is	O
made	O
into	O
the	O
oral	O
administration	O
mixed	O
suspension	O
by	O
using	O
non	O
-	O
aqueous	O
liquid	O
as	O
a	O
dispersing	O
medium	O
,	O
and	O
the	O
invention	O
solves	O
the	O
problem	O
of	O
stability	O
,	O
has	O
good	O
taste	O
and	O
simple	O
preparation	O
method	O
,	O
is	O
convenient	O
for	O
children	O
,	O
old	O
people	O
and	O
a	O
dysphagia	O
patient	O
to	O
accept	O
and	O
is	O
suitable	O
for	O
industrialized	O
production	O
.	O

Preparation	O
and	O
application	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O
The	O
invention	O
discloses	O
a	O
compound	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O
,	O
the	O
first	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
dissolving	O
2-	O
acetoxyl	O
group-5-lorobenzoyl	O
chloride	O
with	O
chloroform	O
,	O
adding	O
4-amino	O
group-3-chloropyridine	O
,	O
reacting	O
at	O
room	O
temperature	O
to	O
obtain	O
a	O
target	O
compound	O
,	O
wherein	O
triethylamine	O
is	O
used	O
an	O
acid	O
-	O
binding	O
agent	O
;	O
and	O
the	O
second	O
preparation	O
method	O
comprises	O
the	O
step	O
of	O
carrying	O
out	O
a	O
heating	O
reflow	O
reaction	O
on	O
2-acetoxyl	O
group-5-chlorobenzoic	O
methyl	O
formate	O
and	O
4-amino	O
group-3-chloropyridin	O
to	O
obtain	O
the	O
target	O
compound	O
.	O

The	O
compound	O
has	O
the	O
function	O
of	O
resisting	O
tubercule	O
bacillus	O
.	O

Docetaxel	O
nano	O
-	O
particle	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
docetaxel	O
nano	O
-	O
particle	O
composition	O
for	O
injection	O
administration	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
docetaxel	O
nano	O
-	O
particle	O
composition	O
contains	O
neutral	O
phospholipid	O
and	O
docetaxel	O
,	O
and	O
does	O
not	O
contain	O
negative	O
phospholipid	O
and	O
cholesterol	O
.	O

Method	O
for	O
preparing	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	O
,	O
which	O
uses	O
a	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
as	O
a	O
micelle	O
carrier	O
to	O
wrap	O
the	O
docetaxel	O
inside	O
the	O
micelle	O
and	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
carrier	O
and	O
the	O
docetaxel	O
into	O
an	O
organic	O
solvent	O
to	O
make	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
and	O
the	O
docetaxel	O
fully	O
dissolved	O
in	O
the	O
organic	O
solvent	O
,	O
and	O
then	O
preparing	O
aqueous	O
solution	O
of	O
the	O
docetaxel	O
micelle	O
by	O
using	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
as	O
the	O
carrier	O
;	O
and	O
(	O
2	O
)	O
adding	O
a	O
freeze	O
-	O
drying	O
protective	O
agent	O
into	O
the	O
aqueous	O
solution	O
of	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
carrying	O
micelle	O
,	O
and	O
filtering	O
,	O
sterilizing	O
and	O
freeze	O
-	O
drying	O
the	O
mixture	O
to	O
obtain	O
freeze	O
-	O
drying	O
preparation	O
of	O
the	O
carrier	O
micelle	O
system	O
.	O

The	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
the	O
docetaxel	O
can	O
increase	O
the	O
dissolubility	O
,	O
metabolic	O
stability	O
and	O
in	O
vivo	O
circulation	O
time	O
of	O
the	O
docetaxel	O
,	O
reduce	O
the	O
toxicity	O
and	O
improve	O
the	O
bioavailability	O
,	O
and	O
is	O
more	O
suitable	O
for	O
clinical	O
application	O
.	O

Novel	O
application	O
of	O
tetrahydrocurcumin	O
The	O
invention	O
provides	O
application	O
of	O
tetrahydrocurcumin	O
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
/	O
and	O
treating	O
a	O
set	O
of	O
clinical	O
syndromes	O
which	O
are	O
characterized	O
by	O
aggregating	O
a	O
variety	O
of	O
metabolic	O
disturbances	O
in	O
an	O
individual	O
,	O
such	O
as	O
obesity	O
,	O
hypertension	O
,	O
abnormal	O
blood	O
fat	O
,	O
abnormal	O
saccharometabolism	O
,	O
has	O
specific	O
medicinal	O
effect	O
,	O
and	O
is	O
a	O
new	O
treatment	O
medicament	O
which	O
can	O
simultaneously	O
and	O
effectively	O
correct	O
a	O
variety	O
of	O
clinical	O
disturbance	O
factors	O
of	O
MS	O
clinically	O
.	O

External	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
and	O
women	O
's	O
menorrhalgia	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
quality	O
control	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
compound	O
preparation	O
prepared	O
from	O
lesser	O
galangal	O
rhizome	O
oil	O
,	O
nutgrass	O
galingale	O
rhizome	O
oil	O
and	O
clonidine	O
hydrochloride	O
,	O
which	O
is	O
an	O
external	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
.	O

Clinical	O
tests	O
prove	O
that	O
the	O
prepared	O
emulsifiable	O
paste	O
preparation	O
has	O
good	O
treatment	O
effects	O
on	O
derangement	O
of	O
vitality	O
and	O
blood	O
,	O
and	O
irregular	O
cycles	O
,	O
abdominal	O
pain	O
during	O
menstruation	O
,	O
hypochondriac	O
pain	O
,	O
abdominal	O
distension	O
and	O
the	O
like	O
caused	O
by	O
the	O
derangement	O
of	O
vitality	O
and	O
blood	O
when	O
applied	O
to	O
abdomen	O
.	O

The	O
invention	O
also	O
carries	O
out	O
a	O
series	O
of	O
related	O
experiments	O
such	O
as	O
percutaneous	O
absorption	O
experiments	O
of	O
the	O
clonidine	O
hydrochloride	O
,	O
and	O
determination	O
tests	O
of	O
the	O
clonidine	O
hydrochloride	O
in	O
blood	O
concentration	O
,	O
which	O
further	O
affirms	O
medicinal	O
quality	O
control	O
and	O
clinical	O
effects	O
.	O

Stable	O
fat	O
emulsion	O
containing	O
prostaglandin	O
e1	O
Disclosed	O
is	O
a	O
fat	O
emulsion	O
containing	O
a	O
compound	O
having	O
prostaglandin	O
E1	O
activity	O
,	O
which	O
fat	O
emulsion	O
is	O
hermetically	O
sealed	O
in	O
a	O
glass	O
container	O
and	O
then	O
heat	O
sterilized	O
.	O

The	O
residual	O
amount	O
of	O
prostaglandin	O
E1	O
activity	O
after	O
16-month	O
storage	O
at	O
5	O
DEG	O
C	O
is	O
not	O
less	O
than	O
65	O
%	O
but	O
not	O
more	O
than	O
100	O
%	O
of	O
the	O
prostaglandin	O
E1	O
activity	O
at	O
the	O
beginning	O
of	O
storage	O
.	O

Solid	O
dispersion	O
of	O
dihydropyrimidine	O
compounds	O
and	O
preparation	O
thereof	O
for	O
medical	O
purpose	O
The	O
invention	O
provides	O
solid	O
dispersion	O
of	O
bromophenyl	O
-	O
substituted	O
thiazole	O
dihydropyrimidine	O
,	O
salts	O
thereof	O
or	O
hydrates	O
thereof	O
and	O
a	O
preparation	O
thereof	O
for	O
medical	O
purpose	O
.	O

Dissolutions	O
of	O
the	O
compound	O
of	O
bromophenyl	O
-	O
substituted	O
thiazole	O
dihydropyrimidine	O
,	O
the	O
salts	O
thereof	O
,	O
or	O
the	O
hydrates	O
thereof	O
in	O
various	O
mediums	O
are	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
preparation	O
is	O
guaranteed	O
.	O

Diaryl	O
pyrimidine	O
derivative	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
diaryl	O
pyrimidine	O
derivative	O
of	O
the	O
general	O
formula	O
I	O
,	O
medicinal	O
salts	O
thereof	O
,	O
hydrates	O
and	O
solvolytes	O
thereof	O
,	O
polycrystal	O
and	O
eutectic	O
thereof	O
,	O
and	O
precursors	O
and	O
derivatives	O
thereof	O
with	O
the	O
same	O
biological	O
functions	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
application	O
of	O
combination	O
containing	O
one	O
or	O
more	O
compounds	O
in	O
relative	O
medicines	O
for	O
treating	O
acquired	O
immune	O
deficiency	O
syndrome	O
and	O
the	O
like	O
,	O
a	O
preparation	O
method	O
and	O
use	O
of	O
the	O
combination	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
compound	O
of	O
the	O
invention	O
not	O
only	O
has	O
excellent	O
biological	O
activity	O
of	O
resisting	O
HIV-1	O
virus	O
and	O
relatively	O
small	O
cytotoxicity	O
,	O
but	O
also	O
shows	O
relatively	O
good	O
inhibitory	O
action	O
to	O
a	O
drug	O
-	O
resistant	O
virus	O
strain	O
L103N+Y181C	O
,	O
can	O
be	O
used	O
as	O
medical	O
candidate	O
resisting	O
the	O
HIV	O
and	O
can	O
be	O
further	O
developed	O
as	O
a	O
medicine	O
resisting	O
AIDS	O
.	O

5-chloro	O
-	O
salicyloyl	O
hydrazine	O
tributyltin	O
chloride	O
coordination	O
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
5-chloro	O
-	O
salicyloyl	O
hydrazine	O
tributyltin	O
chloride	O
coordination	O
compound	O
which	O
has	O
a	O
structural	O
formula	O
as	O
follows	O
.	O

A	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
sequentially	O
adding	O
1.5	O
-	O
2.0	O
mmol	O
of	O
N-1	O
,	O
8-naphthyl	O
diacyl-5-chloro	O
-	O
salicyloyl	O
hydrazine	O
,	O
3.0	O
-	O
4.0	O
mmol	O
of	O
sodium	O
methoxide	O
and	O
50	O
mL	O
of	O
absolute	O
methanol	O
,	O
stirring	O
for	O
0.5	O
hour	O
;	O
then	O
adding	O
2.0	O
-	O
3.0	O
mmol	O
of	O
tributyltin	O
chloride	O
,	O
stirring	O
for	O
6	O
-	O
8	O
hours	O
at	O
normal	O
temperature	O
;	O
filtering	O
,	O
rotationally	O
evaporating	O
filter	O
liquor	O
to	O
obtain	O
a	O
white	O
solid	O
;	O
and	O
then	O
recrystallizing	O
by	O
using	O
methylene	O
dichloride	O
-	O
absolute	O
methanol	O
to	O
obtain	O
a	O
light	O
yellow	O
crystal	O
,	O
i.e.	O
an	O
organotin	O
coordination	O
compound	O
which	O
has	O
higher	O
anticancer	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
preparing	O
drugs	O
treating	O
liver	O
cancer	O
and	O
cervical	O
cancer	O
.	O

Compared	O
with	O
the	O
traditional	O
commonly	O
-	O
used	O
platinum	O
anticancer	O
drug	O
,	O
the	O
organotin	O
coordination	O
compound	O
has	O
the	O
advantages	O
of	O
higher	O
anticancer	O
activity	O
,	O
good	O
lipid	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
,	O
and	O
the	O
like	O
.	O

Preparation	O
formulations	O
of	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
injection	O
and	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O
The	O
invention	O
relates	O
to	O
preparation	O
formulations	O
of	O
a	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
method	O
and	O
a	O
technology	O
for	O
preparing	O
pyruvate	O
and	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
made	O
of	O
the	O
pyruvate	O
.	O

The	O
raw	O
materials	O
of	O
sodium	O
pyruvate	O
(	O
containing	O
calcium	O
and	O
potassium	O
)	O
is	O
synthesized	O
by	O
the	O
following	O
steps	O
of	O
:	O
reacting	O
pyruvic	O
acid	O
and	O
sodium	O
carbonate	O
(	O
salts	O
containing	O
organic	O
acid	O
)	O
produced	O
by	O
fermentation	O
and	O
chemical	O
synthesis	O
to	O
generate	O
sodium	O
pyruvate	O
(	O
and	O
corresponding	O
salts	O
)	O
at	O
a	O
reaction	O
temperature	O
of	O
20	O
-	O
90	O
DEG	O
C	O
for	O
60	O
-	O
70	O
min	O
;	O
filtering	O
in	O
vacuum	O
;	O
washing	O
the	O
crystal	O
with	O
ethyl	O
acetate	O
and	O
ethanol	O
for	O
3	O
-	O
5	O
times	O
;	O
drying	O
in	O
vacuum	O
to	O
obtain	O
a	O
product	O
with	O
the	O
purity	O
higher	O
than	O
99	O
percent	O
;	O
and	O
preparing	O
the	O
product	O
into	O
the	O
preparation	O
formulations	O
of	O
a	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
.	O

Dendrobii	O
extract	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
substance	O
with	O
a	O
structure	O
as	O
a	O
formula	O
I	O
,	O
wherein	O
R1	O
and	O
R2	O
in	O
the	O
formula	O
I	O
are	O
one	O
material	O
respectively	O
selected	O
from	O
alpha	O
-	O
arabinose	O
(	O
alpha	O
-	O
Ara	O
)	O
,	O
beta	O
-	O
arabinose	O
(	O
beta	O
-	O
Ara	O
)	O
and	O
beta	O
-	O
xylose	O
(	O
beta	O
-	O
Xyl	O
)	O
.	O

New	O
application	O
of	O
cimetidine	O
The	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
cimetidine	O
for	O
trauma	O
hemostasis	O
and	O
for	O
treating	O
periodontitis	O
.	O

The	O
method	O
for	O
trauma	O
hemostasis	O
comprises	O
the	O
following	O
steps	O
:	O
cimetidine	O
is	O
coated	O
on	O
the	O
bleeding	O
wound	O
surface	O
twice	O
each	O
day	O
with	O
dosage	O
thereof	O
being	O
approximately	O
200	O
mg	O
and	O
the	O
wound	O
can	O
be	O
cured	O
two	O
days	O
later	O
;	O
the	O
method	O
for	O
treating	O
periodontitis	O
:	O
one	O
tablet	O
of	O
cimetidine	O
weighing	O
200	O
mg	O
is	O
put	O
into	O
the	O
mouth	O
and	O
the	O
disease	O
can	O
be	O
cured	O
by	O
taking	O
the	O
medicine	O
once	O
a	O
day	O
.	O

The	O
medicine	O
of	O
the	O
invention	O
features	O
rapid	O
treatment	O
speed	O
,	O
good	O
curative	O
effect	O
and	O
radical	O
treatment	O
,	O
thus	O
being	O
widely	O
applied	O
to	O
various	O
groups	O
of	O
people	O
for	O
treating	O
trauma	O
hemostasis	O
and	O
periodontitis	O
.	O

Propofol	O
phosphate	O
for	O
injection	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
propofol	O
phosphate	O
for	O
injection	O
,	O
pharmaceutical	O
salt	O
thereof	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
adding	O
5	O
-	O
98	O
percent	O
of	O
water	O
for	O
injection	O
into	O
a	O
preparation	O
container	O
,	O
adding	O
propofol	O
phosphate	O
and	O
pharmaceutical	O
salt	O
thereof	O
of	O
90	O
-	O
110	O
percent	O
of	O
accurate	O
prescriptions	O
,	O
slowly	O
dropping	O
a	O
pH	O
value	O
regulator	O
while	O
stirring	O
so	O
as	O
to	O
adjust	O
the	O
pH	O
to	O
be	O
6.0	O
-	O
11	O
,	O
adding	O
water	O
to	O
the	O
full	O
volume	O
,	O
then	O
adding	O
medicinal	O
carbon	O
of	O
0.01	O
-	O
1.0	O
percent	O
(	O
W	O
/	O
V	O
)	O
,	O
stirring	O
for	O
15	O
-	O
60	O
minutes	O
,	O
roughly	O
filtering	O
with	O
a	O
sand	O
filter	O
rod	O
to	O
remove	O
the	O
carbon	O
,	O
and	O
finely	O
filtering	O
with	O
a	O
0.22mum	O
microporous	O
membrane	O
until	O
the	O
clarity	O
is	O
qualified	O
;	O
and	O
measuring	O
until	O
the	O
intermediate	O
content	O
is	O
acceptable	O
,	O
fixing	O
the	O
filling	O
amount	O
,	O
sub	O
-	O
packaging	O
into	O
cillin	O
bottles	O
,	O
plugging	O
in	O
plugs	O
by	O
half	O
,	O
freezing	O
and	O
drying	O
samples	O
to	O
control	O
the	O
moisture	O
content	O
being	O
0.1	O
-	O
8	O
percent	O
,	O
pressing	O
the	O
plugs	O
,	O
and	O
capping	O
.	O

Lipoamide	O
series	O
derivates	O
,	O
preparation	O
method	O
and	O
pharmaceutical	O
application	O
thereof	O
The	O
invention	O
provides	O
lipoamide	O
series	O
derivates	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
derivates	O
are	O
characterized	O
in	O
that	O
the	O
molecular	O
structural	O
formula	O
of	O
the	O
compounds	O
are	O
represented	O
as	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
one	O
of	O
substituted	O
phenyl	O
,	O
and	O
substituted	O
pyridyl	O
,	O
naphthyl	O
and	O
biphenyl	O
;	O
and	O
R2	O
is	O
one	O
of	O
hydrogen	O
,	O
C1	O
-	O
5	O
alkanoyl	O
and	O
aroyl	O
.	O

The	O
novel	O
derivates	O
have	O
low	O
toxicity	O
and	O
anti	O
-	O
tumor	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
functional	O
foods	O
or	O
medicament	O
for	O
preventing	O
or	O
curing	O
tumor	O
diseases	O
.	O

pharmaceutical	O
compounds	O
The	O
invention	O
provides	O
a	O
compound	O
which	O
is	O
a	O
pyrimidine	O
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PI3	B
K	I
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth	O
,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B
kinase	I
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O

Tolyltriazole	O
derivatives	O
,	O
preparation	O
method	O
thereof	O
and	O
use	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
antifungal	O
medicaments	O
and	O
provides	O
tolyltriazole	O
derivatives	O
having	O
a	O
structure	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

In	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
and	O
also	O
discloses	O
medicinal	O
compositions	O
using	O
thecompounds	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
medicinal	O
compositions	O
as	O
antifungal	O
medicaments	O
.	O

Ant	O
and	O
ginseng	O
wine	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
wine	O
,	O
in	O
particular	O
to	O
ant	O
and	O
ginseng	O
wine	O
.	O

The	O
invention	O
has	O
the	O
main	O
technical	O
scheme	O
that	O
1000	O
g	O
of	O
wine	O
comprises	O
1	O
to	O
5	O
g	O
of	O
ginseng	O
,	O
1	O
to	O
5	O
g	O
of	O
lucid	O
ganoderma	O
,	O
1	O
to	O
5	O
g	O
of	O
polyrhachis	O
vicina	O
,	O
0.01	O
to	O
0.1	O
g	O
of	O
stevioside	O
and	O
0.1	O
to	O
1	O
g	O
of	O
flavouring	O
agents	O
.	O

The	O
invention	O
gives	O
full	O
play	O
to	O
the	O
medical	O
value	O
of	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
per	O
se	O
,	O
so	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
have	O
the	O
pharmacodynamic	O
effects	O
,	O
and	O
in	O
addition	O
,	O
the	O
wine	O
has	O
the	O
effects	O
of	O
clearing	O
and	O
activating	O
the	O
channels	O
and	O
collaterals	O
,	O
nourishing	O
qi	O
,	O
activating	O
blood	O
and	O
regulating	O
the	O
immunity	O
in	O
two	O
ways	O
.	O

Particularly	O
,	O
the	O
wine	O
of	O
the	O
invention	O
is	O
sweet	O
,	O
contains	O
no	O
sugar	O
,	O
does	O
not	O
have	O
medicine	O
flavor	O
,	O
and	O
is	O
applicable	O
to	O
wide	O
range	O
of	O
people	O
.	O

epothilone	O
derivatives	O
The	O
invention	O
relates	O
to	O
Epothilone	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
a	O
medicament	O
.	O

Compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	O
-	O
CB1	B
antagonism	O
and	O
serotonin	O
reuptake	O
inhibition	O
This	O
invention	O
relates	O
to	O
compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	O
-	O
CB1antagonism	B
and	O
serotonin	O
reuptake	O
inhibition	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
,	O
methods	O
for	O
preparing	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis	O
,	O
and	O
methods	O
for	O
preparing	O
compositions	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
psychosis	O
,	O
anxiety	O
,	O
depression	O
,	O
attention	O
deficits	O
,	O
cognitive	O
disorders	O
,	O
obesity	O
,	O
drug	O
dependence	O
,	O
Parkinson	O
's	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
pain	O
disorders	O
,	O
neuropathic	O
pain	O
disorders	O
and	O
sexual	O
disorders	O
.	O

In	O
particular	O
the	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O

Salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Salvianic	O
acid	O
A	O
can	O
be	O
dissolved	O
in	O
water	O
,	O
but	O
the	O
preparation	O
of	O
the	O
salvianic	O
acid	O
A	O
has	O
poor	O
stability	O
,	O
is	O
easy	O
for	O
oxidization	O
,	O
is	O
sensitive	O
to	O
light	O
and	O
heat	O
,	O
and	O
causes	O
content	O
reduction	O
and	O
impurity	O
increase	O
,	O
and	O
the	O
guarantee	O
on	O
the	O
stability	O
is	O
a	O
technical	O
problem	O
.	O

The	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
comprises	O
the	O
salvianic	O
acid	O
A	O
,	O
a	O
pharmacological	O
allowable	O
pH	O
adjusting	O
substance	O
,	O
a	O
stabilizing	O
agent	O
and	O
an	O
excipient	O
.	O

The	O
salvianic	O
acid	O
A	O
in	O
the	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
0.5	O
-	O
2,000	O
mg	O
.	O

The	O
weight	O
part	O
of	O
the	O
pH	O
adjusting	O
substance	O
is	O
the	O
adding	O
dosage	O
when	O
a	O
pH	O
value	O
is	O
adjusted	O
to	O
2.5	O
-	O
7.5	O
,	O
and	O
the	O
stabilizing	O
agent	O
in	O
the	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
1mg-0.5	O
g	O
.	O

The	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
is	O
used	O
as	O
an	O
injection	O
with	O
the	O
effects	O
of	O
protecting	O
the	O
cardiac	O
muscle	O
,	O
promoting	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
resisting	O
bacteria	O
,	O
eliminating	O
inflammation	O
,	O
strengthening	O
body	O
immunity	O
,	O
resisting	O
atherosclerosis	O
,	O
reducing	O
blood	O
fat	O
,	O
resisting	O
platelet	O
aggregation	O
,	O
resisting	O
thrombosis	O
,	O
expanding	O
the	O
coronary	O
artery	O
,	O
treating	O
liver	O
injury	O
,	O
resisting	O
cerebral	O
ischemia	O
injury	O
,	O
resisting	O
tumors	O
,	O
and	O
the	O
like	O
and	O
a	O
therapeutical	O
effect	O
on	O
pulmonary	O
heart	O
disease	O
,	O
psoriasis	O
,	O
altitude	O
disease	O
,	O
and	O
the	O
like	O
.	O

Composition	O
containing	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
The	O
invention	O
discloses	O
a	O
composition	O
containing	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
.	O

The	O
ratio	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
to	O
methylmorphine	O
in	O
the	O
mixture	O
is	O
(	O
8	O
-	O
15	O
)	O
:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
the	O
optimal	O
ratio	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
to	O
the	O
methylmorphine	O
in	O
the	O
mixture	O
is	O
12:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
and	O
the	O
ratio	O
of	O
the	O
mixture	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
and	O
the	O
methylmorphine	O
to	O
poloxamer	O
is	O
25:1	O
,	O
based	O
on	O
the	O
weight	O
.	O

By	O
combining	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
and	O
the	O
methylmorphin	O
,	O
the	O
invention	O
greatly	O
improves	O
the	O
antibacterial	O
activity	O
of	O
the	O
medicament	O
and	O
remarkably	O
reduces	O
the	O
side	O
effects	O
.	O

Flavones	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
as	O
alpha1	O
receptor	O
antagonist	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
preparation	O
method	O
of	O
new	O
flavonoids	O
compounds	O
and	O
application	O
of	O
the	O
new	O
flavonoids	O
compounds	O
as	O
an	O
alpha1	O
receptor	O
antagonist	O
,	O
wherein	O
R1	O
and	O
R2	O
are	O
defined	O
as	O
the	O
specifications	O
.	O

A	O
group	O
with	O
larger	O
polarity	O
is	O
introduced	O
in	O
a	O
flavones	O
structure	O
to	O
enable	O
the	O
polarity	O
of	O
an	O
integral	O
molecule	O
to	O
be	O
increased	O
;	O
meanwhile	O
,	O
the	O
compounds	O
have	O
a	O
certain	O
alkalinity	O
and	O
can	O
be	O
formed	O
into	O
salts	O
with	O
common	O
medicinal	O
acids	O
to	O
ensure	O
that	O
the	O
integral	O
molecule	O
has	O
a	O
certain	O
water	O
-	O
solubility	O
.	O

Preliminary	O
pharmacological	O
tests	O
indicate	O
that	O
the	O
compounds	O
have	O
an	O
alpha1	O
receptor	O
antagonizing	O
function	O
.	O

Preparation	O
method	O
of	O
gossypol	O
acetate	O
intravenous	O
injection	O
fatty	O
emulsion	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
gossypol	O
acetate	O
intravenous	O
injection	O
fatty	O
emulsion	O
.	O

In	O
the	O
method	O
,	O
gossypol	O
acetate	O
is	O
used	O
as	O
an	O
active	O
constituent	O
,	O
ethyl	O
oleate	O
or	O
middle	O
-	O
chain	O
fatty	O
acid	O
triglyceride	O
is	O
used	O
as	O
an	O
oil	O
phase	O
,	O
soya	O
bean	O
lecithin	O
is	O
used	O
as	O
a	O
surface	O
active	O
agent	O
,	O
absolute	O
ethyl	O
alcohol	O
or	O
PEG	O
(	O
Polyethylene	O
Glycol	O
)	O
400	O
is	O
used	O
as	O
a	O
cosurfactant	O
,	O
and	O
sterilized	O
water	O
for	O
injection	O
is	O
used	O
as	O
a	O
water	O
phase	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
gossypol	O
acetate	O
in	O
diethyl	O
ether	O
and	O
then	O
mixing	O
with	O
the	O
oil	O
phase	O
,	O
the	O
surface	O
active	O
agent	O
and	O
the	O
cosurfactant	O
;	O
decompressing	O
and	O
evaporating	O
to	O
remove	O
the	O
diethyl	O
ether	O
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
2	O
)	O
heating	O
the	O
sterilized	O
water	O
for	O
injection	O
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
mixing	O
liquids	O
obtained	O
in	O
the	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
at	O
a	O
constant	O
temperature	O
of	O
60	O
or	O
70	O
DEG	O
C	O
and	O
stirring	O
until	O
a	O
transparent	O
and	O
homogeneous	O
solution	O
is	O
formed	O
;	O
making	O
the	O
volume	O
constant	O
and	O
then	O
repeatedly	O
homogenizing	O
by	O
using	O
a	O
homogenizer	O
;	O
and	O
filtering	O
by	O
using	O
a	O
millipore	O
filter	O
membrane	O
.	O

Proved	O
by	O
researches	O
,	O
the	O
gossypol	O
acetate	O
intravenousinjection	O
fatty	O
emulsion	O
prepared	O
by	O
using	O
the	O
method	O
has	O
good	O
slow	O
release	O
and	O
targeting	O
effects	O
and	O
good	O
stability	O
.	O

Magnetic	O
lipid	O
nano	O
particle	O
and	O
preparation	O
method	O
The	O
invention	O
provides	O
a	O
magnetic	O
lipid	O
nano	O
particle	O
comprising	O
2.2%-5.9	O
%	O
of	O
ferroferric	O
oxide	O
nano	O
magnetic	O
powder	O
,	O
4.4%-28.6	O
%	O
of	O
oleic	O
acid	O
,	O
66.7%-93.4	O
%	O
of	O
glycerine	O
or	O
stearic	O
acid	O
and	O
0	O
-	O
28.2	O
%	O
of	O
hydrophobic	O
anti	O
-	O
tumor	O
medicaments	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
a	O
stable	O
ferroferric	O
oxide	O
nano	O
dispersing	O
solution	O
by	O
adopting	O
lipid	O
material	O
oleic	O
acid	O
in	O
a	O
liquid	O
state	O
at	O
room	O
temperature	O
as	O
a	O
surfactant	O
,	O
and	O
further	O
injecting	O
an	O
organic	O
solvent	O
dissolved	O
with	O
lipid	O
materials	O
to	O
the	O
ferroferric	O
oxide	O
nano	O
dispersing	O
solution	O
stabilized	O
by	O
the	O
oleic	O
to	O
prepare	O
the	O
magnetic	O
lipid	O
nano	O
particle	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
containing	O
the	O
medicaments	O
can	O
be	O
prepared	O
by	O
adding	O
the	O
hydrophobic	O
medicament	O
in	O
the	O
organic	O
solvent	O
dissolved	O
with	O
the	O
lipidmaterials	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
can	O
be	O
further	O
applied	O
to	O
magnetic	O
resonance	O
imaging	O
and	O
targeted	O
therapy	O
of	O
anti	O
-	O
tumor	O
medicaments	O
.	O

Application	O
of	O
baicalein	O
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
The	O
invention	O
discloses	O
application	O
of	O
baicalein	O
(	O
chemical	O
name	O
:	O
5,6,7-trihydroxyflavone	O
)	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
.	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
baicalein	O
capable	O
of	O
reducing	O
the	O
trembling	O
frequencies	O
and	O
amplitudes	O
of	O
the	O
Parkinson	O
diseases	O
and	O
improving	O
and	O
treating	O
the	O
symptoms	O
of	O
the	O
Parkinson	O
diseases	O
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
baicalein	O
capable	O
of	O
protecting	O
dopaminergic	O
neurons	O
from	O
damage	O
so	O
that	O
the	O
pathological	O
changes	O
and	O
the	O
development	O
of	O
the	O
Parkinson	O
diseases	O
can	O
be	O
effectively	O
prevented	O
and	O
treated	O
;	O
and	O
the	O
baicalein	O
exerts	O
the	O
function	O
of	O
protecting	O
the	O
dopaminergic	O
neurons	O
through	O
apoptosis	O
resistance	O
,	O
inflammatory	O
resistance	O
and	O
antioxidation	O
and	O
exerts	O
the	O
function	O
of	O
inhibiting	O
Parkinson	O
symptoms	O
through	O
the	O
function	O
on	O
nervous	O
systems	O
.	O

Anti	O
-	O
aging	O
compound	O
The	O
invention	O
discloses	O
an	O
anti	O
-	O
aging	O
compound	O
which	O
comprises	O
spirulina	O
polysaccharide	O
and	O
folium	O
ginkgo	O
extract	O
,	O
and	O
the	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
0.35	O
to	O
1.5:0.35	O
to	O
1.5	O
.	O

The	O
preferred	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
2:1	O
.	O

The	O
spirulina	O
polysaccharide	O
is	O
water	O
-	O
soluble	O
heteropolysaccharide	O
,	O
and	O
the	O
content	O
of	O
the	O
polysaccharide	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
93	O
percent	O
.	O

The	O
content	O
of	O
general	O
flavone	O
of	O
the	O
folium	O
ginkgo	O
extract	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
24	O
percent	O
,	O
and	O
the	O
content	O
of	O
terpene	O
lactones	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
6	O
percent	O
.	O

The	O
anti	O
-	O
aging	O
compound	O
comprises	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
,	O
can	O
play	O
the	O
cooperative	O
and	O
synergistic	O
roles	O
by	O
combination	O
.	O

because	O
both	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
contain	O
hydroxyl	O
or	O
phenolic	O
hydroxyl	O
structures	O
,	O
thereby	O
significantly	O
improving	O
the	O
anti	O
-	O
aging	O
effect	O
.	O

Medical	O
composition	O
and	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
medical	O
composition	O
and	O
a	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medical	O
composition	O
(	O
100	O
grams	O
)	O
comprises	O
:	O
1	O
to	O
10	O
grams	O
of	O
astragalus	O
polysaccharides	O
,	O
3	O
to	O
12	O
grams	O
of	O
taurine	O
,	O
4	O
to	O
15	O
grams	O
of	O
aminopyrine	O
,	O
2	O
to	O
10	O
grams	O
of	O
vitamin	O
C	O
,	O
0.04	O
to	O
0.2	O
gram	O
of	O
interferon	O
inducer	O
,	O
5	O
to	O
20	O
grams	O
of	O
alcohol	O
,	O
0.1	O
to	O
0.4	O
gram	O
of	O
sodium	O
benzoate	O
,	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
product	O
is	O
characterized	O
by	O
reasonable	O
formula	O
composition	O
,	O
stable	O
physical	O
and	O
chemical	O
properties	O
,	O
accurate	O
dose	O
,	O
quick	O
effect	O
,	O
long	O
-	O
lasting	O
medicament	O
effect	O
,	O
high	O
bioavailability	O
,	O
safe	O
use	O
and	O
exact	O
treatment	O
effect	O
.	O

Aryl	O
ruthenium	O
(	O
11	O
)	O
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

In	O
the	O
structural	O
formula	O
(	O
I	O
)	O
of	O
the	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
,	O
R	O
is	O
chosen	O
from	O
H	O
,	O
C1	O
to	O
C6	O
alkyl	O
or	O
alkyl	O
substituent	O
,	O
phenyl	O
or	O
phenyl	O
substituent	O
,	O
pyridyl	O
or	O
pyridyl	O
substituent	O
,	O
furyl	O
or	O
furyl	O
substituent	O
,	O
pyrrolyl	O
or	O
pyrrolyl	O
substituent	O
and	O
thiazole	O
or	O
thiazole	O
substituent	O
.	O

R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
chosen	O
from	O
H	O
,	O
C2	O
to	O
C6	O
alkenyl	O
,	O
C2	O
to	O
C6	O
alkynyl	O
,	O
oxhydryl	O
C1	O
to	O
C6	O
alkyl	O
,	O
amido	O
C1	O
to	O
C6	O
alkyl	O
,	O
halogen	O
,	O
CO2R7	O
,	O
CONR8R9	O
,	O
COR10	O
,	O
SO3H	O
,	O
SO2R11R12	O
,	O
aryloxy	O
,	O
C1	O
to	O
C6	O
alkoxy	O
,	O
C1	O
to	O
C6	O
alkylthio	O
,	O
-N	O
=	O
NR13,NR14R15	O
,	O
aryl	O
or	O
aralkyl	O
.	O

The	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
can	O
be	O
used	O
to	O
prepare	O
tumor	O
medicine	O
,	O
has	O
good	O
inhibitory	O
action	O
particularly	O
on	O
lung	O
adenocarcinoma	O
and	O
has	O
potential	O
great	O
value	O
in	O
terms	O
of	O
tumor	O
disease	O
clinical	O
treatment	O
application	O
.	O

The	O
formula	O
(	O
I	O
)	O
.	O

Open	O
loop	O
steroid	O
saponin	O
compound	O
with	O
antibacterial	O
activity	O
in	O
sinularia	O
gyrosa	O
The	O
invention	O
relates	O
to	O
two	O
open	O
loop	O
steroid	O
saponin	O
compounds	O
,	O
i.e.	O
Sinularoside	O
A	O
and	O
Sinularoside	O
B	O
with	O
antibacterial	O
activity	O
,	O
separated	O
from	O
sinularia	O
gyrosa	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
compounds	O
have	O
the	O
chemical	O
structural	O
formulas	O
as	O
the	O
specification	O
,	O
wherein	O
the	O
R	O
group	O
is	O
FORMULA	O
.	O

The	O
in	O
-	O
vitro	O
antibacterial	O
test	O
on	O
the	O
Sinularoside	O
A	O
and	O
the	O
Sinularoside	O
B	O
shows	O
that	O
the	O
compounds	O
have	O
obvious	O
effect	O
for	O
inhibiting	O
fungus	O
,	O
bacteria	O
and	O
algae	O
for	O
test	O
,	O
thereby	O
the	O
two	O
open	O
loop	O
steroid	O
saponin	O
compounds	O
can	O
be	O
used	O
for	O
preparing	O
antibacterial	O
medicaments	O
.	O

The	O
invention	O
provides	O
a	O
new	O
lead	O
compound	O
for	O
developing	O
new	O
antibacterial	O
medicaments	O
and	O
has	O
great	O
significance	O
for	O
developing	O
ocean	O
medicine	O
biological	O
resources	O
in	O
China	O
.	O

American	O
ginseng	O
saponin	O
F6	O
as	O
well	O
as	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
American	O
ginseng	O
saponin	O
F6	O
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
,	O
which	O
belong	O
to	O
a	O
new	O
compound	O
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
.	O

The	O
extraction	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
American	O
ginseng	O
fruit	O
as	O
a	O
raw	O
material	O
,	O
obtaining	O
the	O
new	O
compound	O
through	O
macroporous	O
absorbent	O
resin	O
,	O
normal	O
and	O
reversed	O
-	O
phase	O
silica	O
gel	O
column	O
chromatography	O
and	O
a	O
recrystallization	O
method	O
of	O
fruit	O
juice	O
,	O
wherein	O
the	O
new	O
compound	O
has	O
the	O
chemical	O
name	O
of	O
6-O	O
-	O
beta	O
-	O
D	O
-	O
glucopyranesyl-20-O-	O
[	O
alpha	O
-	O
L	O
-	O
arabinofuranosyl-	O
(	O
1	O
-	O
6	O
)	O
-beta	O
-	O
D	O
-	O
glucopyranosyl	O
]	O
-dammar-24-ene-3beta	O
,	O
6alpha,12beta	O
,	O
20S	O
-	O
tetraol	O
and	O
is	O
abbreviated	O
as	O
the	O
American	O
ginseng	O
saponin	O
F6	O
,	O
and	O
the	O
yield	O
reaches	O
more	O
than	O
0.01	O
%	O
.	O

The	O
American	O
ginseng	O
saponin	O
F6	O
has	O
wide	O
application	O
in	O
preparing	O
antitumor	O
medicaments	O
.	O

8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
as	O
well	O
as	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
with	O
a	O
structure	O
shown	O
as	O
the	O
following	O
general	O
formula	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
and	O
application	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
.	O

The	O
8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
has	O
the	O
effect	O
of	O
promoting	O
the	O
glucose	O
absorption	O
on	O
muscle	O
cells	O
.	O

Proved	O
by	O
in	O
-	O
vivo	O
animal	O
experiments	O
,	O
the	O
compound	O
has	O
the	O
effects	O
on	O
improving	O
the	O
carbohydrate	O
tolerance	O
and	O
the	O
insulin	B
resistance	O
,	O
reducing	O
weight	O
,	O
relieving	O
fatty	O
livers	O
,	O
and	O
the	O
like	O
,	O
has	O
high	O
bioavailability	O
,	O
enhances	O
the	O
in	O
-	O
vivo	O
pesticide	O
effect	O
,	O
and	O
has	O
stable	O
structure	O
under	O
an	O
acidic	O
condition	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
type-2	O
diabetes	O
,	O
obesity	O
,	O
fatty	O
livers	O
or	O
complications	O
thereof	O
.	O

Rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
basically	O
contains	O
5	O
to	O
10	O
mg	O
of	O
rosuvastatin	O
calcium	O
,	O
and	O
the	O
balance	O
of	O
sustained	O
-	O
release	O
framework	O
material	O
and	O
other	O
pharmaceutical	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
;	O
and	O
all	O
the	O
materials	O
are	O
proportioned	O
and	O
the	O
preparation	O
is	O
prepared	O
by	O
the	O
preparation	O
method	O
for	O
common	O
tablets	O
,	O
granules	O
or	O
capsules	O
.	O

The	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
prepared	O
by	O
the	O
method	O
avoids	O
adverse	O
reactions	O
such	O
as	O
rhabdomyolysis	O
,	O
proteinuria	O
,	O
nephrosis	O
,	O
kidney	O
failure	O
,	O
hepatotoxicity	O
and	O
the	O
like	O
caused	O
by	O
overdosage	O
of	O
medicaments	O
;	O
meanwhile	O
,	O
due	O
blood	O
concentration	O
and	O
time	O
for	O
treating	O
diseases	O
after	O
the	O
medicaments	O
are	O
taken	O
can	O
be	O
maintained	O
,	O
and	O
the	O
peak	O
valley	O
phenomenon	O
of	O
the	O
blood	O
concentration	O
is	O
effectively	O
avoided	O
.	O

Medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
.	O

The	O
medicament	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1	O
to	O
20	O
parts	O
of	O
rose	O
,	O
1	O
to	O
20	O
parts	O
of	O
Seville	O
orange	O
flower	O
,	O
1	O
to	O
20	O
parts	O
of	O
Paris	O
polyphylla	O
Sm	O
.	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
selfheal	O
fruit	O
-	O
spike	O
,	O
1	O
to	O
20	O
parts	O
of	O
barbed	O
skullcap	O
herb	O
,	O
1	O
to	O
20	O
parts	O
of	O
snakegourd	O
fruit	O
,	O
1	O
to	O
20	O
parts	O
of	O
seaweed	O
,	O
1	O
to	O
20	O
parts	O
of	O
kelp	O
,	O
1	O
to	O
20	O
parts	O
of	O
frankincense	O
,	O
1	O
to	O
20	O
parts	O
of	O
myrrh	O
,	O
1	O
to	O
20	O
parts	O
of	O
tangerine	O
leaves	O
,	O
1	O
to	O
20	O
parts	O
of	O
green	O
tangerine	O
peel	O
,	O
1	O
to	O
20	O
parts	O
of	O
thunberg	O
fritillary	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
burreed	O
rhizome	O
,	O
1	O
to	O
20	O
parts	O
of	O
zedoary	O
,	O
1	O
to	O
20	O
parts	O
of	O
Indian	O
iphigenia	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
India	O
madder	O
root	O
,	O
1	O
to	O
20	O
parts	O
of	O
edible	O
alcohol	O
of	O
which	O
the	O
content	O
is	O
over	O
95	O
percent	O
.	O

The	O
medicament	O
can	O
be	O
absorbed	O
by	O
spleen	O
and	O
stomach	O
through	O
oral	O
administration	O
or	O
absorbed	O
by	O
skin	O
through	O
external	O
application	O
and	O
also	O
can	O
be	O
absorbed	O
through	O
the	O
combination	O
of	O
oral	O
administration	O
and	O
external	O
administration	O
.	O

The	O
medicament	O
of	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
reasonable	O
formula	O
,	O
simple	O
compatibility	O
,	O
clear	O
treatment	O
effect	O
and	O
addressing	O
both	O
symptoms	O
and	O
root	O
causes	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
medicament	O
.	O

Novel	O
formulation	O
of	O
piperazine	O
ferulate	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
injection	O
of	O
piperazine	O
ferulate	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
novel	O
formulation	O
of	O
the	O
piperazine	O
ferulate	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
dissolving	O
piperazine	O
ferulate	O
as	O
a	O
medicine	O
component	O
into	O
a	O
solvent	O
and	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
5.0	O
-	O
8.0	O
with	O
a	O
pH	O
regulating	O
agent	O
so	O
that	O
the	O
piperazine	O
ferulate	O
is	O
fully	O
dissolved	O
to	O
prepare	O
an	O
injection	O
.	O

The	O
content	O
of	O
the	O
piperazine	O
ferulate	O
in	O
the	O
novel	O
formulation	O
is	O
27	O
-	O
200mg	O
/	O
ml	O
,	O
and	O
the	O
agent	O
is	O
the	O
water	O
of	O
injection	O
.	O

The	O
invention	O
broadens	O
the	O
clinical	O
application	O
range	O
of	O
the	O
piperazine	O
ferulate	O
,	O
has	O
the	O
characteristics	O
of	O
high	O
medicine	O
dissolubility	O
,	O
high	O
bioavailability	O
,	O
rapid	O
medicine	O
administration	O
,	O
more	O
quick	O
effect	O
-	O
taking	O
,	O
stronger	O
treatment	O
effect	O
,	O
and	O
the	O
like	O
,	O
is	O
especially	O
suitable	O
for	O
preventing	O
and	O
treating	O
patients	O
suffering	O
from	O
heavy	O
cerebral	O
infarction	O
,	O
nephroma	O
,	O
coronary	O
heart	O
disease	O
,	O
vascular	O
complication	O
in	O
diabetes	O
mellitus	O
and	O
dysphagia	O
,	O
overcomes	O
the	O
problem	O
of	O
low	O
dissolubility	O
of	O
the	O
piperazine	O
ferulate	O
in	O
the	O
prior	O
art	O
,	O
and	O
realizes	O
the	O
solubilization	O
of	O
the	O
piperazine	O
ferulate	O
by	O
regulating	O
the	O
pH	O
value	O
with	O
the	O
pH	O
regulating	O
agent	O
,	O
wherein	O
at	O
least	O
500	O
mg	O
of	O
piperazine	O
ferulate	O
can	O
be	O
dissolved	O
in	O
10mlof	O
water	O
solution	O
with	O
pH	O
value	O
of	O
5.5	O
.	O

High	O
-	O
release	O
erythrocin	O
enteric	O
-	O
coated	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
high	O
-	O
release	O
erythrocin	O
enteric	O
-	O
coated	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
antibiotic	O
drugs	O
.	O

The	O
enteric	O
-	O
coated	O
tablet	O
contains	O
two	O
parts	O
:	O
a	O
substrate	O
and	O
an	O
enteric	O
coating	O
,	O
wherein	O
the	O
substrate	O
contains	O
the	O
following	O
components	O
:	O
12.5	O
(	O
BOU	O
)	O
of	O
erythrocin	O
,	O
2.5	O
-	O
3.0	O
kg	O
of	O
starch	O
,	O
0.21	O
-	O
0.25	O
kg	O
of	O
Tween-80	O
,	O
1	O
-	O
1.5	O
kg	O
of	O
hydroxy	O
propyl	O
cellulose	O
,	O
0.3	O
-	O
0.5	O
kg	O
of	O
magnesium	O
stearate	O
and	O
0.8	O
-	O
1.5	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	O
enteric	O
-	O
coated	O
tablets	O
;	O
the	O
enteric	O
-	O
coated	O
tablet	O
contains	O
the	O
following	O
components	O
of	O
:	O
0.81	O
-	O
0.84	O
kg	O
of	O
polyacrylic	O
resin	O
(	O
II	O
)	O
,	O
15	O
-	O
16	O
kg	O
of	O
ethanol	O
the	O
concentration	O
of	O
more	O
than	O
90	O
percent	O
,	O
0.16	O
-	O
0.2	O
kg	O
of	O
Tween-80	O
,	O
0.16	O
-	O
0.20	O
kg	O
of	O
diethyl	O
phthalate	O
,	O
0.48	O
-	O
0.60	O
kg	O
of	O
castor	O
oil	O
and	O
0.59	O
-	O
0.70	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	O
enteric	O
-	O
coated	O
tablets	O
.	O

The	O
average	O
release	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
prepared	O
by	O
adopting	O
the	O
prescription	O
of	O
the	O
substrate	O
and	O
the	O
enteric	O
coating	O
is	O
not	O
less	O
than	O
90	O
percent	O
in	O
drug	O
effect	O
and	O
is	O
far	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
,	O
and	O
the	O
enteric	O
-	O
coated	O
tablet	O
can	O
be	O
stably	O
released	O
;	O
the	O
drug	O
action	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
in	O
the	O
period	O
of	O
validity	O
;	O
the	O
surface	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
fine	O
and	O
smooth	O
and	O
glossy	O
in	O
appearance	O
;	O
and	O
the	O
effectiveness	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
not	O
influenced	O
after	O
being	O
stored	O
for	O
a	O
long	O
time	O
.	O

Plaster	O
for	O
treating	O
bone	O
fracture	O
The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
bone	O
fracture	O
,	O
mainly	O
comprising	O
the	O
following	O
drugs	O
in	O
parts	O
by	O
weight	O
:	O
20	O
-	O
40	O
parts	O
of	O
corydalis	O
tuber	O
,	O
20	O
-	O
30	O
parts	O
of	O
safflower	O
,	O
20	O
-	O
40	O
parts	O
of	O
frankincense	O
,	O
20	O
-	O
30	O
parts	O
of	O
myrrh	O
,	O
15	O
-	O
30	O
parts	O
of	O
scaly	O
anteater	O
,	O
20	O
-	O
40	O
parts	O
of	O
scorpio	O
,	O
20	O
-	O
40	O
parts	O
of	O
panax	O
notoginseng	O
,	O
10	O
-	O
20	O
parts	O
of	O
crinis	O
ustus	O
,	O
10	O
-	O
20	O
parts	O
of	O
eupolyphaga	O
,	O
20	O
-	O
40	O
parts	O
of	O
drgonsbone	O
,	O
20	O
-	O
40	O
parts	O
of	O
earthworm	O
,	O
20	O
-	O
40	O
parts	O
of	O
pyrite	O
,	O
20	O
-	O
40	O
parts	O
of	O
sapanwood	O
,	O
20	O
-	O
40	O
parts	O
of	O
rhizoma	O
drynariae	O
,	O
10	O
-	O
30	O
parts	O
of	O
dragon	O
's	O
blood	O
,	O
20	O
-	O
40	O
parts	O
of	O
peach	O
kernel	O
and	O
20	O
-	O
40	O
parts	O
of	O
angelica	O
.	O

The	O
plaster	O
for	O
treating	O
bone	O
fracture	O
has	O
the	O
effects	O
of	O
dredging	O
the	O
channel	O
,	O
stopping	O
bleeding	O
,	O
promoting	O
the	O
circulation	O
of	O
Qi	O
,	O
relieving	O
swelling	O
,	O
stopping	O
pain	O
,	O
removing	O
heat	O
from	O
the	O
heart	O
to	O
restore	O
to	O
consciousness	O
,	O
reuniting	O
bones	O
and	O
muscles	O
,	O
circulating	O
blood	O
and	O
promoting	O
the	O
quick	O
formation	O
of	O
poroma	O
and	O
has	O
obvious	O
treatment	O
effect	O
and	O
little	O
adverse	O
reaction	O
.	O

Substituted	O
benzodihydropyran	O
derivatives	O
and	O
anti	O
-	O
tumor	O
application	O
thereof	O
The	O
invention	O
discloses	O
substituted	O
benzodihydropyran	O
derivatives	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
hydrogen	O
atom	O
or	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkane	O
,	O
methoxy	O
acyl	O
isopropyl	O
or	O
methoxy	O
acyl	O
oxy	O
isopropyl	O
,	O
methoxy	O
acyl	O
isobutyl	O
or	O
methoxy	O
acyl	O
oxy	O
isobutyl	O
,	O
methoxy	O
acyl	O
tertiary	O
butyl	O
or	O
methoxy	O
acyl	O
cyclobutyl	O
;	O
and	O
n	O
is	O
1	O
-	O
5	O
,	O
and	O
is	O
represented	O
as	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
,	O
which	O
comprises	O
a	O
step	O
of	O
applying	O
a	O
composition	O
containing	O
the	O
compounds	O
.	O

The	O
compounds	O
designed	O
by	O
the	O
pharmacokinetics	O
have	O
improved	O
therapeutic	O
index	O
,	O
are	O
strong	O
inhibitors	O
for	O
cancer	O
cell	O
growth	O
,	O
and	O
have	O
high	O
anti	O
-	O
cancer	O
activity	O
and	O
extremely	O
small	O
side	O
effect	O
.	O

Antibacterial	O
agent	O
The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
agent	O
,	O
belonging	O
to	O
the	O
field	O
of	O
hygiene	O
,	O
wherein	O
the	O
antibacterial	O
agent	O
comprises	O
the	O
following	O
active	O
components	O
:	O
tetracycline	O
and	O
bacillus	O
subtilis	O
;	O
the	O
ratio	O
of	O
the	O
tetracycline	O
to	O
the	O
bacillus	O
subtilis	O
in	O
the	O
antibacterial	O
agent	O
is	O
(	O
0.18	O
-	O
6.0	O
)	O
mu	O
g:	O
(	O
2.0	O
-	O
6.0	O
)	O
*10	O
to	O
the	O
power	O
of	O
[	O
6	O
]	O
cfu	O
;	O
and	O
the	O
antibacterial	O
agent	O
can	O
be	O
used	O
for	O
inhibiting	O
and	O
killing	O
staphylococcus	O
aurous	O
,	O
vibrio	O
,	O
escherichia	O
coli	O
,	O
salmonella	O
,	O
proteus	O
bacterial	O
and	O
fusarium	O
,	O
etc	O
.	O

The	O
antibacterial	O
agent	O
provided	O
by	O
the	O
invention	O
has	O
the	O
function	O
of	O
inhibiting	O
the	O
quorum	O
sensing	O
molecules	O
by	O
the	O
bacillus	O
subtilis	O
for	O
the	O
first	O
time	O
,	O
has	O
a	O
synergistic	O
effect	O
together	O
with	O
the	O
tetracycline	O
,	O
greatly	O
improves	O
the	O
performance	O
of	O
the	O
antibacterial	O
agent	O
for	O
killing	O
bacteria	O
,	O
obviously	O
lowers	O
the	O
threshold	O
value	O
of	O
the	O
efficient	O
dosage	O
of	O
the	O
tetracycline	O
and	O
prevents	O
the	O
tolerance	O
during	O
the	O
antibacterial	O
process	O
;	O
the	O
antibacterial	O
agent	O
also	O
has	O
effective	O
antibacterial	O
effect	O
,	O
less	O
side	O
effect	O
to	O
the	O
environment	O
and	O
less	O
toxic	O
side	O
effect	O
.	O

RGD	O
peptide	O
-	O
epimedium	O
flavone	O
combination	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
an	O
RGD	O
peptide	O
-	O
epimedium	O
flavone	O
combination	O
synthesized	O
by	O
combining	O
two	O
structural	O
units	O
of	O
RGD	O
peptides	O
and	O
epimedium	O
flavone	O
which	O
have	O
pharmacological	O
activities	O
of	O
different	O
action	O
mechanisms	O
on	O
osseous	O
metabolic	O
diseases	O
,	O
and	O
also	O
provides	O
a	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
of	O
the	O
invention	O
has	O
two	O
receptor	O
combining	O
sites	O
and	O
simultaneously	O
has	O
the	O
capability	O
of	O
combining	O
estrogen	O
receptors	O
of	O
icaritin	O
and	O
the	O
capability	O
of	O
combining	O
integrins	B
alphaVbeta3	I
of	O
RGD	O
,	O
and	O
the	O
capabilities	O
of	O
combining	O
the	O
two	O
different	O
receptors	O
can	O
produce	O
a	O
synergistic	O
effect	O
to	O
greatly	O
improve	O
the	O
curative	O
activity	O
of	O
the	O
medicament	O
on	O
osteoporosis	O
and	O
osseous	O
metabolic	O
diseases	O
.	O

The	O
synthesis	O
method	O
has	O
the	O
advantages	O
of	O
high	O
yield	O
,	O
high	O
synthesis	O
speed	O
and	O
easy	O
purification	O
of	O
products	O
.	O

Inhibitors	O
for	O
matrix	B
metalloproteinases	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
Inhibitors	O
for	O
matrix	B
metalloproteinases	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
.	O

The	O
inhibitors	O
for	O
matrix	B
metalloproteinases	I
have	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
W	O
,	O
X1	O
,	O
X2	O
,	O
R1	O
,	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

They	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
regulated	O
by	O
matrix	B
metalloproteinases	I
,	O
in	O
particular	O
corneal	O
ulceration	O
,	O
pulmonary	O
emphysema	O
or	O
dermal	O
ulceration	O
resulted	O
from	O
chemical	O
injury	O
,	O
or	O
pulmonary	O
emphysema	O
caused	O
by	O
smoking	O
or	O
drowning	O
.	O

Protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O
The	O
invention	O
relates	O
to	O
protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O
,	O
belonging	O
to	O
the	O
field	O
of	O
biomedical	O
preparation	O
and	O
comprising	O
a	O
collagenous	O
substance	O
,	O
an	O
acidifying	O
or	O
alkalizing	O
agent	O
,	O
a	O
cross	O
-	O
linking	O
agent	O
and	O
an	O
adhesive	O
based	O
on	O
the	O
weight	O
ratio	O
of	O
1:0.01	O
-	O
0.3:0.1	O
-	O
0.5	O
,	O
wherein	O
the	O
dosage	O
of	O
the	O
acidifying	O
or	O
alkalizing	O
agent	O
is	O
proper	O
when	O
the	O
pH	O
value	O
is	O
regulated	O
to	O
6.5	O
-	O
8.5	O
.	O

Under	O
the	O
action	O
of	O
gastric	O
acid	O
,	O
the	O
cross	O
-	O
linking	O
agent	O
in	O
the	O
protecting	O
colloid	O
can	O
be	O
released	O
so	O
as	O
to	O
form	O
a	O
colloid	O
membrane	O
on	O
the	O
surface	O
of	O
ulcer	O
,	O
avoid	O
the	O
gastroenteric	O
mucosa	O
from	O
being	O
digested	O
by	O
gastric	O
acid	O
and	O
pepsase	O
and	O
promote	O
healing	O
of	O
the	O
ulcer	O
.	O

Animal	O
tests	O
show	O
that	O
the	O
protecting	O
colloid	O
can	O
greatly	O
lower	O
the	O
ulcer	O
formation	O
caused	O
by	O
absolute	O
ethyl	O
alcohol	O
and	O
hydrochloric	O
acid	O
,	O
inhibit	O
ulcer	O
formation	O
and	O
have	O
a	O
protecting	O
effect	O
on	O
injury	O
of	O
the	O
mice	O
gastroenteric	O
mucosa	O
caused	O
by	O
absolute	O
ethyl	O
alcohol	O
and	O
hydrochloric	O
acid	O
.	O

Therefore	O
,	O
the	O
protecting	O
colloid	O
is	O
used	O
for	O
protecting	O
and	O
curing	O
gastroenteric	O
mucosa	O
ulcer	O
for	O
patients	O
.	O

Aloe	O
oculentum	O
and	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
aloe	O
oculentum	O
and	O
a	O
preparation	O
method	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
eyedrops	O
.	O

The	O
aloe	O
oculentum	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
medicaments	O
and	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
90	O
parts	O
of	O
aloe	O
gel	O
,	O
1	O
to	O
5	O
parts	O
of	O
aloin	O
,	O
0.1	O
to	O
1	O
part	O
of	O
alomycin	O
,	O
0.1	O
to	O
0.3	O
part	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
sodium	O
hyaluronate	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
anthraquinone	O
compounds	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
cinnamate	O
and	O
0.2	O
to	O
0.5	O
part	O
of	O
free	O
amino	O
acid	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
extracting	O
the	O
aloe	O
gel	O
from	O
aloe	O
barbadensis	O
by	O
adopting	O
a	O
freezing	O
stabilization	O
method	O
,	O
and	O
converting	O
the	O
aloe	O
gel	O
into	O
aloe	O
gel	O
powder	O
;	O
and	O
mixing	O
the	O
aloe	O
gel	O
powder	O
and	O
water	O
for	O
injection	O
under	O
the	O
acidic	O
condition	O
or	O
neutral	O
condition	O
,	O
of	O
which	O
the	O
PH	O
is	O
between	O
5.5	O
and	O
7.5	O
,	O
mixing	O
the	O
mixture	O
and	O
the	O
aloin	O
,	O
the	O
alomycin	O
,	O
the	O
carbomer	O
,	O
the	O
sodium	O
hyaluronate	O
,	O
the	O
anthraquinone	O
compounds	O
,	O
the	O
cinnamate	O
and	O
the	O
free	O
amino	O
acid	O
,	O
stirring	O
uniformly	O
,	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
neutral	O
,	O
and	O
subpackaging	O
and	O
disinfecting	O
.	O

The	O
aloe	O
oculentum	O
can	O
treat	O
eye	O
diseases	O
such	O
as	O
pterygium	O
,	O
conjunctivochalasis	O
,	O
corneal	O
nebula	O
,	O
chronic	O
dacryocystitis	O
,	O
eye	O
itching	O
,	O
xerophthalmia	O
and	O
the	O
like	O
.	O

Hydroxyl	O
whole	O
-	O
protection	O
didecyl	O
quaternary	O
ammonium	O
with	O
anti	O
-	O
tumor	O
activity	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
synthesis	O
of	O
an	O
emodin	O
derivant	O
with	O
an	O
anti	O
-	O
tumor	O
function	O
,	O
in	O
particular	O
to	O
a	O
hydroxyl	O
whole	O
-	O
protection	O
didecyl	O
quaternary	O
ammonium	O
with	O
anti	O
-	O
tumor	O
activity	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
didecyl	O
quaternary	O
ammonium	O
is	O
decyldimethylchlorosilane-	O
[	O
2-	O
(	O
4,5,7-trimethoxy-9,10-anthraquinonyl	O
)	O
methyl	O
]	O
.	O

The	O
preparation	O
method	O
is	O
characterized	O
by	O
taking	O
emodin	O
as	O
a	O
raw	O
material	O
to	O
carry	O
out	O
a	O
series	O
of	O
synthetic	O
reaction	O
.	O

The	O
emodin	O
derivant	O
of	O
the	O
invention	O
has	O
proliferation	O
inhibition	O
action	O
of	O
different	O
degrees	O
on	O
liver	O
cancer	O
HepG2	O
,	O
gastric	O
cancer	O
BGC	O
,	O
neuroma	O
SH	O
-	O
SY5Y	O
,	O
gastric	O
cancer	O
AGS	O
,	O
cervical	O
cancer	O
Hela	O
and	O
the	O
like	O
as	O
well	O
as	O
normal	O
human	O
embryonic	O
lung	O
fibroblast	O
HELP	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
treating	O
cancers	O
.	O

Irinotecan	O
nano	O
circulating	O
liposome	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
novel	O
Irinotecan	O
carrier	O
which	O
is	O
circulating	O
nano	O
liposome	O
and	O
a	O
novel	O
preparation	O
method	O
thereof	O
which	O
is	O
an	O
ethanol	O
injection	O
-	O
ammonium	O
sulfate	O
active	O
medicament	O
-	O
loading	O
method	O
.	O

The	O
preparation	O
process	O
comprises	O
:	O
a	O
,	O
dissolving	O
a	O
lipid	O
material	O
for	O
forming	O
the	O
liposome	O
in	O
ethanol	O
to	O
prepare	O
solution	O
;	O
b	O
,	O
dissolving	O
a	O
polyethylene	O
glycol	O
compound	O
in	O
solution	O
of	O
ammonium	O
sulfate	O
to	O
prepare	O
a	O
hydration	O
medium	O
;	O
c	O
,	O
injecting	O
solution	O
obtained	O
by	O
the	O
step	O
a	O
into	O
the	O
hydration	O
medium	O
obtained	O
by	O
the	O
step	O
b	O
with	O
stirring	O
in	O
a	O
water	O
bath	O
,	O
stirring	O
at	O
a	O
constant	O
temperature	O
for	O
a	O
certain	O
period	O
under	O
a	O
condition	O
of	O
introducing	O
N2	O
to	O
form	O
circulating	O
blank	O
liposome	O
;	O
d	O
,	O
dialyzing	O
the	O
blank	O
liposome	O
obtained	O
by	O
the	O
step	O
c	O
in	O
physiological	O
saline	O
;	O
and	O
e	O
,	O
adding	O
solution	O
of	O
Irinotecan	O
into	O
the	O
blank	O
liposome	O
,	O
regulating	O
the	O
pH	O
value	O
of	O
an	O
external	O
phase	O
,	O
and	O
performing	O
incubation	O
and	O
medicament	O
loading	O
at	O
a	O
certain	O
temperature	O
to	O
obtain	O
the	O
Irinotecan	O
circulating	O
nano	O
liposome	O
.	O

The	O
process	O
is	O
simple	O
,	O
the	O
particle	O
size	O
is	O
80	O
to	O
150	O
nanometers	O
,	O
the	O
coating	O
rate	O
is	O
over	O
95	O
percent	O
,	O
the	O
sterile	O
preparation	O
can	O
be	O
obtained	O
easily	O
,	O
and	O
an	O
industrialization	O
requirement	O
is	O
met	O
.	O

Intranasal	O
administration	O
encapsulated	O
based	O
on	O
polyelectrolyte	O
capsule	O
A	O
micron	O
and	O
nanometer	O
encapsulated	O
technology	O
synthesized	O
by	O
step	O
-	O
by	O
-	O
step	O
shells	O
can	O
be	O
applied	O
for	O
intranasal	O
and	O
pulmonary	O
administration	O
.	O

Liquid	O
,	O
gas	O
or	O
solid	O
encapsulation	O
can	O
form	O
an	O
aerosol	O
in	O
spray	O
treatment	O
.	O

Different	O
shell	O
compositions	O
create	O
stability	O
,	O
compatibility	O
,	O
and	O
degradation	O
and	O
releasing	O
attributes	O
.	O

A	O
plurality	O
of	O
substances	O
comprising	O
the	O
compound	O
widely	O
used	O
for	O
intranasal	O
administration	O
can	O
be	O
encapsulated	O
,	O
or	O
are	O
administrated	O
through	O
spray	O
capsules	O
.	O

Medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
a	O
preparation	O
method	O
thereof	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicaments	O
.	O

The	O
orally	O
taken	O
medicament	O
is	O
prepared	O
from	O
routine	O
auxiliary	O
materials	O
and	O
the	O
following	O
raw	O
medicinal	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
120	O
parts	O
of	O
scutellaria	O
total	O
flavonoid	O
,	O
60	O
to	O
100	O
parts	O
of	O
paeonia	O
saponins	O
,	O
60	O
to	O
120	O
parts	O
of	O
liquritin	O
and	O
proper	O
amount	O
of	O
auxiliary	O
materials	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
the	O
scutellaria	O
total	O
flavonoid	O
by	O
performing	O
water	O
extraction	O
on	O
scutellaria	O
;	O
preparing	O
the	O
paeonia	O
saponins	O
by	O
performing	O
water	O
extraction	O
on	O
paeonia	O
;	O
preparing	O
the	O
liquritin	O
by	O
performing	O
percolation	O
on	O
liquorice	O
;	O
and	O
preparing	O
the	O
general	O
formulation	O
by	O
blending	O
the	O
extracts	O
and	O
the	O
auxiliary	O
materials	O
,	O
and	O
obtaining	O
the	O
medicament	O
.	O

The	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
active	O
ingredient	O
content	O
,	O
stable	O
quality	O
,	O
safety	O
,	O
clear	O
treatment	O
effect	O
and	O
convenience	O
.	O

Compared	O
with	O
the	O
traditional	O
medicaments	O
,	O
the	O
orally	O
taken	O
medicament	O
greatly	O
reduces	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
medicaments	O
and	O
obviously	O
improves	O
the	O
treatment	O
effect	O
.	O

Method	O
for	O
establishing	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
biomedicine	O
and	O
particularly	O
relates	O
to	O
a	O
method	O
for	O
establishing	O
an	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O
.	O

In	O
the	O
method	O
of	O
the	O
invention	O
,	O
an	O
experimental	O
rat	O
liver	O
cirrhosis	O
model	O
caused	O
by	O
composite	O
factors	O
such	O
as	O
high	O
fat	O
and	O
low	O
protein	O
of	O
carbon	O
tetrachloride	O
is	O
subjected	O
to	O
learning	O
,	O
recall	O
test	O
and	O
evoked	O
potential	O
test	O
of	O
a	O
nervous	O
system	O
and	O
a	O
brain	O
function	O
and	O
the	O
learning	O
,	O
memory	O
and	O
spatial	O
cognition	O
impairment	O
and	O
nerve	O
electrophysiology	O
test	O
abnormity	O
of	O
the	O
model	O
are	O
monitored	O
,	O
so	O
that	O
the	O
method	O
achieves	O
statistical	O
significance	O
compared	O
with	O
the	O
normal	O
comparison	O
group	O
and	O
a	O
relatively	O
ideal	O
SHE	O
animal	O
model	O
is	O
established	O
.	O

An	O
established	O
experiment	O
animal	O
model	O
provides	O
a	O
platform	O
for	O
the	O
research	O
,	O
diagnosis	O
and	O
treatment	O
of	O
SHE	O
and	O
has	O
high	O
clinically	O
practical	O
meaning	O
and	O
value	O
.	O

Compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O
The	O
invention	O
discloses	O
a	O
compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O
.	O

The	O
compound	O
tincture	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1.5	O
to	O
5.5	O
parts	O
of	O
densefruit	O
pittany	O
root	O
-	O
bark	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
bark	O
of	O
Chinese	O
redbud	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
palemane	O
prunella	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
Chinese	O
honeylocust	O
spine	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
angelica	O
dahurica	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
platycodon	O
root	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
safflower	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
szechuan	O
lovage	O
rhizome	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
natural	O
indigo	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
wild	O
chrysanthemum	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
dandelion	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borax	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borneol	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
peppermint	O
oil	O
and	O
100	O
parts	O
of	O
ethanol	O
.	O

The	O
inventor	O
studies	O
assiduously	O
under	O
the	O
condition	O
that	O
the	O
prior	O
art	O
is	O
not	O
perfect	O
.	O

The	O
compound	O
tincture	O
has	O
unique	O
therapeutic	O
effects	O
of	O
dispelling	O
wind	O
and	O
removing	O
dampness	O
,	O
detoxifying	O
and	O
relieving	O
itching	O
,	O
softening	O
and	O
dilating	O
blood	O
vessels	O
,	O
promoting	O
regeneration	O
of	O
necrotic	O
nerve	O
cells	O
and	O
treating	O
external	O
acoustic	O
meatus	O
mycosis	O
,	O
relieves	O
the	O
pain	O
of	O
patients	O
and	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
.	O

Microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
additive	O
is	O
prepared	O
from	O
the	O
main	O
components	O
of	O
bacillus	O
subtilis	O
and	O
saccharomyces	O
cerevisiae	O
which	O
are	O
mixed	O
with	O
baking	O
soda	O
,	O
xylo	O
-	O
oligosaccharides	O
,	O
vitamins	O
,	O
vitamin	O
complex	O
,	O
glucose	O
and	O
the	O
like	O
according	O
to	O
certain	O
proportions	O
.	O

The	O
microbial	O
feed	O
additive	O
has	O
the	O
following	O
advantages	O
that	O
:	O
the	O
active	O
substances	O
such	O
as	O
subtilin	O
,	O
polymyxin	O
,	O
nystatin	O
,	O
gramicidin	O
and	O
the	O
like	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
bacillus	O
subtilis	O
have	O
obvious	O
inhibitionto	O
pathogens	O
or	O
conditioned	O
pathogens	O
of	O
endogenous	O
infection	O
;	O
cell	O
wall	O
polysaccharides	O
of	O
the	O
saccharomyces	O
cerevisiae	O
and	O
a	O
great	O
amount	O
of	O
nucleotides	O
and	O
bioactive	O
peptides	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
can	O
improve	O
the	O
immunity	O
of	O
animals	O
,	O
and	O
a	O
compound	O
taste	O
substance	O
is	O
also	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
to	O
promote	O
animal	O
feeding	O
;	O
the	O
baking	O
soda	O
replenishes	O
electrolyte	O
;	O
the	O
xylo	O
-	O
oligosaccharides	O
selectively	O
proliferate	O
beneficial	O
bacteria	O
such	O
as	O
bifidobacterium	O
and	O
the	O
like	O
;	O
the	O
vitamins	O
have	O
the	O
effects	O
of	O
resisting	O
stress	O
and	O
replenishing	O
nutrition	O
;	O
and	O
the	O
glucose	O
has	O
the	O
effects	O
of	O
supplying	O
energy	O
and	O
promoting	O
healing	O
.	O

Solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
The	O
invention	O
discloses	O
solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
preparation	O
and	O
application	O
of	O
health	O
care	O
products	O
.	O

One	O
liter	O
of	O
solution	O
comprises	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
and	O
50	O
g	O
of	O
brown	O
sugar	O
.	O

The	O
solution	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
of	O
:	O
1	O
,	O
preparing	O
solution	O
matrix	O
:	O
adding	O
500	O
g	O
of	O
brown	O
sugar	O
into	O
one	O
liter	O
of	O
water	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
brown	O
sugar	O
is	O
completely	O
dissolved	O
to	O
obtain	O
the	O
matrix	O
solution	O
;	O
and	O
2	O
,	O
adding	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
into	O
the	O
one	O
liter	O
of	O
matrix	O
solution	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
mixture	O
is	O
boiling	O
to	O
ensure	O
that	O
the	O
purslane	O
herb	O
extract	O
is	O
completely	O
dissolved	O
to	O
obtain	O
solution	O
A	O
or	O
solution	O
B	O
,	O
and	O
cooling	O
,	O
filming	O
and	O
packaging	O
.	O

The	O
solution	O
is	O
edible	O
,	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
,	O
has	O
the	O
effect	O
of	O
chills	O
and	O
fever	O
complementation	O
,	O
and	O
can	O
be	O
taken	O
for	O
a	O
long	O
time	O
.	O

The	O
solution	O
has	O
an	O
extremely	O
simple	O
formula	O
,	O
an	O
extremely	O
simple	O
preparation	O
method	O
,	O
low	O
cost	O
,	O
and	O
good	O
mouthfeel	O
,	O
has	O
the	O
exact	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
has	O
ideal	O
effect	O
of	O
treating	O
accompanied	O
delayed	O
muscle	O
soreness	O
and	O
wide	O
market	O
application	O
prospect	O
.	O

Method	O
for	O
preparing	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
an	O
antibacterial	O
agent	O
suspension	O
,	O
in	O
particular	O
to	O
a	O
method	O
for	O
preparing	O
a	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
.	O

Taking	O
5000ml	O
of	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
as	O
reference	O
,	O
the	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
contains	O
the	O
following	O
components	O
:	O
1	O
-	O
2.5	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Cefquinome	O
sulfate	O
micro	O
powder	O
,	O
0.15	O
-	O
0.3	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Vitamin	O
E	O
and	O
the	O
balance	O
of	O
esters	O
solvent	O
or	O
injection	O
oil	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
heating	O
the	O
esters	O
solvent	O
or	O
the	O
injection	O
oil	O
to	O
115	O
-	O
125	O
DEG	O
C	O
in	O
a	O
high	O
-	O
shear	O
homogenizer	O
;	O
carrying	O
out	O
heat	O
preservation	O
on	O
the	O
heated	O
esters	O
solvent	O
or	O
injection	O
oil	O
for	O
4	O
-	O
6	O
hours	O
;	O
cooling	O
to	O
below	O
40	O
DEG	O
C	O
;	O
adding	O
sterilized	O
Cefquinome	O
sulfate	O
raw	O
materials	O
;	O
dispersing	O
at	O
the	O
rotating	O
speed	O
of	O
5000	O
-	O
8000rpm	O
(	O
Revolutions	O
Per	O
Minute	O
)	O
;	O
homogenizing	O
by	O
using	O
a	O
high	O
-	O
pressure	O
homogenize	O
at	O
the	O
working	O
pressure	O
of	O
1200bar	O
after	O
the	O
Cefquinome	O
sulfate	O
raw	O
materials	O
are	O
evenly	O
dispersed	O
;	O
encapsuling	O
;	O
and	O
irradiating	O
with	O
cobalt60	O
for	O
sterilization	O
for	O
5	O
-	O
6	O
hours	O
.	O

The	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
prepared	O
by	O
the	O
invention	O
has	O
high	O
safety	O
,	O
good	O
curative	O
effect	O
and	O
small	O
stimulation	O
in	O
intramuscular	O
injection	O
.	O

Flake	O
and	O
pearl	O
nucleus	O
matching	O
treating	O
fluid	O
for	O
culturing	O
Pinctada	O
martensii	O
pearl	O
The	O
invention	O
relates	O
to	O
treating	O
fluid	O
for	O
culturing	O
a	O
Pinctada	O
martensii	O
seawater	O
pearl	O
and	O
a	O
method	O
for	O
culturing	O
the	O
seawater	O
pearl	O
.	O

The	O
treating	O
fluid	O
is	O
obtained	O
by	O
the	O
steps	O
of	O
weighing	O
raw	O
materials	O
including	O
aureomycin	O
,	O
polyvinylpyrrolidone	O
,	O
taurine	O
,	O
vitamin	O
C	O
and	O
the	O
like	O
and	O
then	O
dissolving	O
the	O
raw	O
materials	O
into	O
sodium	O
alga	O
acid	O
of	O
physiological	O
saline	O
solution	O
with	O
the	O
weight	O
contentof	O
0.7	O
-	O
1	O
%	O
.	O

In	O
the	O
process	O
of	O
culturing	O
the	O
seawater	O
pearls	O
,	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
sliced	O
from	O
selected	O
healthy	O
nacres	O
which	O
are	O
not	O
damaged	O
by	O
diseases	O
and	O
insects	O
and	O
are	O
soaked	O
inthe	O
treating	O
fluid	O
and	O
then	O
are	O
implanted	O
into	O
the	O
pearl	O
culturing	O
bags	O
of	O
the	O
nacres	O
.	O

The	O
nucleus	O
implanting	O
operation	O
procedure	O
is	O
carried	O
out	O
according	O
to	O
the	O
traditional	O
conventional	O
means	O
;	O
the	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
transferred	O
to	O
a	O
sea	O
area	O
for	O
hanging	O
culture	O
after	O
20	O
-	O
25	O
days	O
of	O
recreation	O
period	O
.	O

The	O
seawater	O
pearls	O
cultured	O
by	O
the	O
treating	O
fluid	O
have	O
thick	O
pearl	O
layers	O
,	O
high	O
survival	O
rate	O
and	O
high	O
high	O
-	O
quality	O
pearl	O
rate	O
.	O

The	O
invention	O
reduces	O
the	O
death	O
rate	O
and	O
the	O
nucleus	O
splitting	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
greatly	O
improves	O
the	O
yield	O
and	O
the	O
nucleus	O
reservation	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
the	O
economic	O
benefits	O
of	O
culture	O
production	O
.	O

Compound	O
apramycin	O
sulfate	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
apramycin	O
sulfate	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
apramycin	O
sulfate	O
injection	O
comprises	O
the	O
following	O
components	O
of	O
:	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	O
sulfate	O
,	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	O
,	O
10	O
-	O
400kg	O
/	O
L	O
of	O
soldium	O
salicylate	O
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	O
sulfate	O
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
adding	O
100	O
-	O
400kg	O
/	O
L	O
of	O
soldium	O
salicylate	O
into	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
then	O
adding	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	O
,	O
and	O
stirring	O
for	O
10	O
-	O
20min	O
until	O
a	O
solution	O
is	O
clarified	O
;	O
(	O
2	O
)	O
taking	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
sequentially	O
adding	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	O
sulfate	O
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	O
sulfate	O
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	O
,	O
stirring	O
and	O
dissolving	O
;	O
and	O
(	O
3	O
)	O
combining	O
the	O
solution	O
prepared	O
in	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
then	O
adding	O
the	O
water	O
for	O
injection	O
to	O
a	O
marked	O
volume	O
,	O
uniformly	O
stirring	O
,	O
keeping	O
for	O
15	O
-	O
20min	O
,	O
and	O
clarifying	O
liquid	O
medicine	O
to	O
obtain	O
the	O
compound	O
apramycin	O
sulfate	O
injection	O
.	O

In	O
the	O
invention	O
,	O
the	O
compound	O
preparation	O
consisting	O
of	O
the	O
apramycin	O
sulfate	O
and	O
the	O
mequindox	O
has	O
very	O
obvious	O
treatment	O
effect	O
on	O
pig	O
bacterial	O
diarrhea	O
and	O
can	O
effectively	O
relieve	O
stress	O
reaction	O
of	O
a	O
suffering	O
animal	O
body	O
;	O
experiments	O
show	O
that	O
the	O
combination	O
use	O
of	O
the	O
apramycin	O
sulfate	O
,	O
the	O
mequindox	O
and	O
the	O
atropine	O
sulfate	O
can	O
remarkably	O
enhance	O
a	O
curative	O
effect	O
;	O
and	O
the	O
compound	O
has	O
wide	O
clinical	O
application	O
range	O
,	O
and	O
can	O
be	O
widely	O
used	O
for	O
treating	O
bacterial	O
diarrhea	O
of	O
livestock	O
,	O
such	O
as	O
pig	O
,	O
cattle	O
,	O
sheep	O
,	O
and	O
the	O
like	O
,	O
enhance	O
the	O
survival	O
rate	O
and	O
increase	O
the	O
body	O
weights	O
of	O
the	O
pig	O
,	O
the	O
cattle	O
and	O
the	O
sheep	O
.	O

Application	O
of	O
antrodia	O
camphorata	O
cyclohexenone	O
compound	O
in	O
preparing	O
medicine	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
The	O
invention	O
relates	O
to	O
a	O
new	O
purpose	O
of	O
a	O
compound	O
.	O

In	O
the	O
invention	O
,	O
antrodia	O
camphorata	O
extract	O
is	O
separated	O
and	O
purified	O
to	O
obtain	O
4-hydroxy-2,3-dimethoxy-6-methy-5	O
(	O
3,7,11-trimethyl	O
-	O
dodeca-2,6,10-trienyl	O
)	O
-cyclohex-2-enone	O
.	O

The	O
cyclohexenone	O
compound	O
can	O
be	O
used	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
and	O
simultaneously	O
can	O
be	O
used	O
for	O
pharmaceutical	O
compositions	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
.	O

2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
,	O
and	O
discloses	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
in	O
preparing	O
anti	O
-	O
tumor	O
medicaments	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
in	O
preparing	O
anti	O
-	O
endometrial	O
cancer	O
or	O
anti	O
-	O
lung	O
cancermedicaments	O
.	O

The	O
invention	O
has	O
the	O
main	O
beneficial	O
effects	O
that	O
:	O
(	O
1	O
)	O
the	O
method	O
for	O
preparing	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
is	O
provided	O
;	O
(	O
2	O
)	O
the	O
novel	O
anti	O
-	O
tumor	O
medicament	O
with	O
remarkable	O
anti	O
-	O
tumor	O
activity	O
is	O
provided	O
,	O
a	O
research	O
foundation	O
is	O
laid	O
for	O
novel	O
medicament	O
screening	O
,	O
and	O
the	O
compound	O
has	O
great	O
application	O
prospect	O
;	O
and	O
(	O
3	O
)	O
the	O
preparation	O
process	O
is	O
simple	O
,	O
and	O
is	O
advantageous	O
to	O
industrial	O
production	O
.	O

Postoperative	O
anti	O
-	O
adhesion	O
medicament	O
The	O
invention	O
relates	O
to	O
a	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
capable	O
of	O
effectively	O
preventing	O
postoperative	O
adhesion	O
,	O
lubricating	O
tissues	O
and	O
inhibiting	O
inflammation	O
.	O

The	O
technical	O
scheme	O
is	O
that	O
:	O
the	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
consists	O
of	O
berberine	O
hydrochloride	O
,	O
dicynone	O
and	O
polyethylene	O
glycol	O
.	O

Tablet	O
capsule	O
with	O
roxithromycin	O
tablets	O
and	O
ambroxol	O
hydrochloride	O
tablets	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
hard	O
capsule	O
,	O
in	O
particular	O
to	O
a	O
tablet	O
capsule	O
with	O
roxithromycin	O
tablets	O
and	O
ambroxol	O
hydrochloride	O
tablets	O
.	O

The	O
tablet	O
capsule	O
consists	O
of	O
a	O
capsule	O
and	O
tablets	O
in	O
the	O
capsule	O
,	O
wherein	O
the	O
capsule	O
comprises	O
an	O
upper	O
capsule	O
body	O
and	O
a	O
lower	O
capsule	O
body	O
,	O
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
roxithromycin	O
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
ambroxol	O
hydrochloride	O
are	O
filled	O
in	O
the	O
capsule	O
.	O

Because	O
the	O
active	O
ingredients	O
in	O
the	O
capsule	O
do	O
not	O
contact	O
,	O
chemical	O
changes	O
can	O
not	O
be	O
generated	O
between	O
the	O
ingredients	O
,	O
side	O
products	O
can	O
not	O
be	O
generated	O
,	O
and	O
the	O
stability	O
of	O
the	O
product	O
is	O
improved	O
,	O
degradation	O
products	O
generated	O
after	O
the	O
roxithromycin	O
and	O
the	O
ambroxol	O
hydrochloride	O
contact	O
are	O
reduced	O
particularly	O
.	O

In	O
addition	O
,	O
the	O
designs	O
of	O
cylindrical	O
tablets	O
and	O
different	O
colors	O
and	O
the	O
application	O
of	O
transparent	O
capsule	O
shells	O
are	O
adopted	O
,	O
and	O
the	O
product	O
of	O
the	O
invention	O
is	O
particularly	O
suitable	O
for	O
industrial	O
production	O
,	O
thereby	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Meanwhile	O
,	O
the	O
active	O
ingredients	O
are	O
respectively	O
tabletted	O
,	O
thus	O
the	O
drug	O
assay	O
and	O
the	O
quality	O
control	O
are	O
easier	O
.	O

Chewable	O
tablet	O
of	O
calcium	O
carbonate	O
dimeticone	O
and	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
chewable	O
tablet	O
of	O
calcium	O
carbonate	O
dimeticone	O
and	O
a	O
preparation	O
process	O
,	O
belonging	O
to	O
four	O
new	O
national	O
chemical	O
medicines	O
.	O

The	O
preparation	O
of	O
the	O
invention	O
is	O
prepared	O
from	O
the	O
following	O
main	O
components	O
:	O
calcium	O
carbonate	O
,	O
simethicone	O
,	O
siliciidoxydum	O
,	O
aspartame	O
,	O
essence	O
powder	O
,	O
mannite	O
,	O
corn	O
starch	O
,	O
low	O
-	O
substituted	O
hydroxypropyl	O
cellulose	O
and	O
magnesium	O
stearate	O
,	O
wherein	O
the	O
calcium	O
carbonate	O
as	O
the	O
main	O
content	O
has	O
stronger	O
acid	O
-	O
resisting	O
action	O
and	O
rapid	O
and	O
lasting	O
effects	O
,	O
and	O
the	O
simethicone	O
is	O
a	O
foam	O
suppressor	O
for	O
eliminating	O
gastrointestinal	O
tract	O
pneumatosis	O
.	O

The	O
preparation	O
is	O
used	O
for	O
treating	O
peptic	O
ulcers	O
including	O
stomach	O
and	O
duodenal	O
ulcer	O
and	O
easing	O
various	O
uncomfortable	O
symptoms	O
caused	O
by	O
hyperacidity	O
.	O

Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O
The	O
invention	O
relates	O
to	O
a	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
,	O
in	O
particular	O
to	O
the	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O
.	O

The	O
preparation	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
10	O
mg	O
of	O
antihistaminics	O
Loratadine	O
,	O
5	O
g	O
of	O
divaricate	O
saposhnikovia	O
root	O
,	O
8	O
g	O
of	O
belvedere	O
fruit	O
,	O
10	O
g	O
of	O
astragalus	O
mongholicus	O
,	O
5	O
g	O
of	O
Chinese	O
angelica	O
,	O
10	O
g	O
of	O
cocklebur	O
fruit	O
,	O
3	O
g	O
of	O
cassia	O
twig	O
,	O
and	O
1	O
part	O
of	O
musk	O
;	O
the	O
antihistaminics	O
Loratadine	O
,	O
the	O
musk	O
,	O
the	O
divaricate	O
saposhnikovia	O
root	O
,	O
the	O
belvedere	O
fruit	O
,	O
the	O
astragalus	O
mongholicus	O
,	O
the	O
Chinese	O
angelica	O
,	O
the	O
cocklebur	O
fruit	O
and	O
the	O
cassia	O
twig	O
are	O
ground	O
into	O
powder	O
and	O
mixed	O
uniformly	O
,	O
and	O
the	O
powder	O
in	O
which	O
musk	O
is	O
added	O
is	O
then	O
regulated	O
into	O
paste	O
with	O
yellow	O
wine	O
.	O

The	O
preparation	O
for	O
treating	O
the	O
chronic	O
urticaria	O
is	O
simple	O
and	O
practicable	O
in	O
method	O
,	O
has	O
small	O
toxic	O
or	O
side	O
effect	O
,	O
and	O
has	O
good	O
auxiliary	O
treatment	O
effect	O
on	O
the	O
chronic	O
urticaria	O
.	O

Medicine	O
for	O
treating	O
rheumatic	O
fever	O
The	O
invention	O
discloses	O
a	O
Chinese	O
materia	O
medica	O
preparation	O
for	O
treating	O
intense	O
heat	O
evil	O
rheumatic	O
fever	O
,	O
comprising	O
the	O
following	O
medicines	O
by	O
fixed	O
weight	O
ratio	O
:	O
gypsum	O
,	O
rhizoma	O
anemarrhenae	O
,	O
golden	O
cypress	O
,	O
polished	O
round	O
-	O
grained	O
rice	O
,	O
Cape	O
Jasmine	O
Fruit	O
and	O
the	O
like	O
.	O

The	O
raw	O
materials	O
of	O
the	O
medicine	O
are	O
easy	O
to	O
obtain	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
medicine	O
has	O
the	O
advantages	O
of	O
short	O
course	O
of	O
treatment	O
,	O
excellent	O
curative	O
effect	O
and	O
no	O
side	O
effect	O
.	O

Nimesulide	O
temperature	O
sensitive	O
hydrogel	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
comprises	O
Nimesulide	O
,	O
a	O
temperature	O
sensitive	O
gel	O
material	O
,	O
a	O
pH	O
regulator	O
,	O
a	O
preservative	O
and	O
the	O
like	O
and	O
is	O
characterized	O
in	O
that	O
:	O
the	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
poloxamer	O
to	O
the	O
Nimesulide	O
is	O
9:1	O
;	O
and	O
the	O
optimized	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
407	O
.	O

The	O
temperature	O
sensitive	O
gel	O
is	O
sensitive	O
to	O
temperature	O
changes	O
,	O
and	O
rabbit	O
rectum	O
experimental	O
results	O
show	O
that	O
the	O
temperature	O
sensitive	O
gel	O
has	O
higher	O
medicament	O
release	O
rate	O
and	O
higher	O
bioavailability	O
which	O
are	O
obviously	O
better	O
than	O
those	O
of	O
the	O
conventional	O
Nimesulide	O
common	O
suppositories	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
reserves	O
the	O
advantages	O
of	O
the	O
conventional	O
suppositories	O
,	O
overcomes	O
the	O
defects	O
of	O
the	O
conventional	O
suppositories	O
to	O
a	O
certain	O
extent	O
and	O
has	O
a	O
wide	O
clinical	O
application	O
prospect	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
uses	O
common	O
safe	O
pharmaceutical	O
excipients	O
,	O
has	O
a	O
simple	O
production	O
process	O
,	O
stable	O
and	O
easily	O
-	O
controlled	O
quality	O
and	O
high	O
process	O
reproducibility	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Perfusate	O
and	O
preparation	O
method	O
thereof	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
The	O
invention	O
relates	O
to	O
perfusate	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
,	O
which	O
mainly	O
comprises	O
the	O
raw	O
materials	O
with	O
the	O
following	O
ratios	O
:	O
4000	O
-	O
5000	O
g	O
of	O
radix	O
astragali	O
,	O
4000	O
-	O
5000	O
g	O
of	O
herba	O
epimedii	O
,	O
300	O
-	O
500	O
g	O
of	O
levamisole	O
hydrochloride	O
,	O
300	O
-	O
400	O
g	O
of	O
antibacterial	O
pepetide	O
,	O
2000	O
-	O
3000ml	O
of	O
glycerol	O
,	O
400	O
-	O
500	O
g	O
of	O
gelatine	O
,	O
and	O
50	O
-	O
100	O
g	O
of	O
sodium	O
benzoate	O
,	O
wherein	O
pH	O
of	O
the	O
perfusate	O
is	O
5.5	O
-	O
7.5	O
.	O

The	O
perfusate	O
is	O
used	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
with	O
determine	O
curative	O
effect	O
,	O
drug	O
concentration	O
for	O
local	O
application	O
is	O
high	O
,	O
absorption	O
ratio	O
is	O
high	O
,	O
the	O
direction	O
is	O
high	O
,	O
drug	O
application	O
is	O
convenient	O
and	O
safe	O
,	O
thereby	O
the	O
goal	O
of	O
fast	O
treating	O
cow	O
recessive	O
mastitis	O
is	O
achieved	O
,	O
and	O
the	O
perfusate	O
is	O
compound	O
perfusion	O
preparation	O
combining	O
antibiosis	O
,	O
antiphlogosis	O
and	O
improving	O
immunity	O
of	O
the	O
organism	O
.	O

Nano	O
selenium	O
-	O
germanium	O
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O
The	O
invention	O
relates	O
to	O
a	O
nano	O
selenium	O
-	O
germanium	O
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drink	O
production	O
and	O
preparation	O
.	O

Snake	O
medicinal	O
material	O
has	O
rich	O
nutrients	O
.	O

The	O
snake	O
medicinal	O
material	O
not	O
only	O
contain	O
protein	O
,	O
fat	O
,	O
sugar	O
,	O
macro	O
and	O
trace	O
elements	O
and	O
vitamins	O
,	O
but	O
also	O
contains	O
eight	O
necessary	O
amino	O
acids	O
which	O
can	O
not	O
be	O
synthesized	O
in	O
human	O
bodies	O
or	O
are	O
synthesized	O
slowly	O
in	O
human	O
bodies	O
.	O

The	O
snake	O
medicinal	O
material	O
can	O
purify	O
water	O
source	O
.	O

The	O
snake	O
material	O
can	O
activate	O
,	O
purify	O
and	O
mineralize	O
65	O
percent	O
or	O
100	O
percent	O
of	O
water	O
in	O
human	O
bodies	O
and	O
therefore	O
can	O
promote	O
metabolism	O
element	O
balance	O
and	O
acid	O
-	O
base	O
balance	O
in	O
human	O
bodies	O
,	O
increase	O
oxygen	O
content	O
in	O
cells	O
of	O
human	O
bodies	O
and	O
strength	O
the	O
circulation	O
of	O
anions	O
in	O
the	O
drink	O
in	O
blood	O
;	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
anions	O
in	O
the	O
drink	O
and	O
the	O
far	O
infrared	O
electromagnetic	O
wave	O
resisting	O
materials	O
can	O
reach	O
a	O
3	O
to	O
5	O
millimeter	O
deep	O
place	O
in	O
skin	O
tissues	O
and	O
automatically	O
heats	O
to	O
improve	O
the	O
vitality	O
of	O
cells	O
,	O
promote	O
tissue	O
regeneration	O
,	O
supply	O
nutrients	O
to	O
cell	O
tissues	O
,	O
so	O
the	O
health	O
of	O
human	O
bodies	O
is	O
kept	O
and	O
life	O
is	O
prolonged	O
.	O

Cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	O
as	O
a	O
Tibetan	O
medicine	O
The	O
invention	O
relates	O
to	O
a	O
cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	O
as	O
a	O
Tibetan	O
medicine	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
collecting	O
mineral	O
south	O
calcite	O
,	O
cleaning	O
,	O
removing	O
impurities	O
,	O
scrapping	O
into	O
particles	O
with	O
the	O
granularity	O
of	O
10	O
-	O
30	O
mm	O
,	O
adding	O
auxiliaries	O
,	O
i.e.	O
,	O
Radix	O
Aconiti	O
and	O
potassium	O
nitrate	O
,	O
heating	O
and	O
continuously	O
boiling	O
for	O
2	O
-	O
16	O
h	O
to	O
obtain	O
the	O
boiled	O
south	O
calcite	O
;	O
(	O
2	O
)	O
rinsing	O
the	O
boiled	O
south	O
calcite	O
with	O
clear	O
water	O
until	O
the	O
rinsing	O
liquid	O
is	O
clear	O
as	O
crystal	O
,	O
and	O
drying	O
until	O
the	O
weight	O
is	O
consistent	O
to	O
obtain	O
the	O
dry	O
south	O
calcite	O
;	O
and	O
(	O
3	O
)	O
grinding	O
the	O
dry	O
south	O
calcite	O
,	O
sieving	O
with	O
a	O
screen	O
of	O
20	O
-	O
100	O
meshes	O
to	O
obtain	O
south	O
calcite	O
powder	O
,	O
uniformly	O
mixing	O
and	O
stirring	O
the	O
south	O
calcite	O
powder	O
with	O
fresh	O
milk	O
and	O
drying	O
in	O
shade	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
cold	O
-	O
system	O
preparation	O
method	O
is	O
simple	O
and	O
convenient	O
to	O
operate	O
and	O
easy	O
to	O
implement	O
and	O
can	O
greatly	O
increase	O
the	O
content	O
of	O
effective	O
trace	O
elements	O
in	O
the	O
south	O
calcitewithout	O
remarkably	O
influencing	O
the	O
main	O
contents	O
,	O
thereby	O
the	O
method	O
can	O
be	O
used	O
as	O
a	O
reference	O
for	O
preparing	O
high	O
south	O
calcite	O
and	O
a	O
standard	O
preparation	O
method	O
of	O
the	O
south	O
calcite	O
as	O
the	O
Tibetan	O
medicine	O
.	O

Plaster	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
,	O
which	O
is	O
prepared	O
according	O
to	O
the	O
following	O
steps	O
:	O
adding	O
raw	O
medicines	O
such	O
as	O
szechuan	O
aconite	O
,	O
wild	O
aconite	O
,	O
rhizoma	O
arisaematis	O
and	O
the	O
like	O
into	O
water	O
for	O
decocting	O
,	O
filtering	O
the	O
obtained	O
decoction	O
with	O
gauze	O
,	O
and	O
concentrating	O
the	O
decoction	O
into	O
fluid	O
extract	O
for	O
later	O
use	O
;	O
then	O
,	O
preparing	O
raw	O
medicines	O
such	O
as	O
mastic	O
,	O
myrrh	O
,	O
safflower	O
,	O
catechu	O
and	O
the	O
like	O
into	O
fine	O
powder	O
,	O
and	O
sieving	O
the	O
fine	O
powder	O
with	O
a	O
100-mesh	O
sieve	O
for	O
later	O
use	O
;	O
and	O
finally	O
,	O
mixing	O
and	O
heating	O
talcum	O
powder	O
,	O
zinc	O
oxide	O
,	O
sesame	O
oil	O
and	O
medical	O
solid	O
pressure	O
-	O
sensitive	O
hot	O
melt	O
adhesive	O
,	O
adding	O
the	O
fluid	O
extract	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
fine	O
powder	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
while	O
continuously	O
stirring	O
until	O
the	O
moisture	O
is	O
fully	O
evaporated	O
,	O
cooling	O
,	O
adding	O
certain	O
parts	O
by	O
weight	O
of	O
camphor	O
,	O
borneol	O
and	O
azone	O
,	O
stirring	O
uniformly	O
,	O
and	O
spreading	O
5	O
g	O
of	O
ointment	O
on	O
non	O
-	O
woven	O
fabric	O
to	O
obtain	O
the	O
plaster	O
disclosed	O
by	O
the	O
invention	O
.	O

Geldanamycin	O
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
The	O
invention	O
discloses	O
geldanamycin	O
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
.	O

The	O
structural	O
formula	O
as	O
shown	O
in	O
the	O
following	O
formula	O
(	O
I	O
)	O
is	O
a	O
novel	O
structural	O
formula	O
formed	O
by	O
modifying	O
the	O
geldanamycin	O
,	O
and	O
the	O
pair	O
of	O
heat	B
shock	I
protein	I
90	I
is	O
good	O
in	O
activity	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
medical	O
salt	O
of	O
the	O
compound	O
;	O
R1	O
group	O
is	O
phenyl	O
or	O
3-furyl	O
or	O
3-pyrryl	O
or	O
the	O
other	O
hexahydric	O
heteroaromatic	O
group	O
,	O
or	O
the	O
other	O
quinary	O
heteroaromatic	O
group	O
;	O
and	O
R2	O
group	O
is	O
carboxylic	O
acid	O
amide	O
or	O
acetyl	O
or	O
ethyl	O
or	O
the	O
fatty	O
hydrocarbon	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
or	O
the	O
carbonyl	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
fatty	O
hydrocarbon	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
has	O
the	O
characteristic	O
of	O
the	O
high	O
-	O
efficiency	O
combined	O
heat	B
shock	I
protein	I
90	I
,	O
so	O
that	O
the	O
geldanamycin	O
derivative	O
can	O
be	O
used	O
for	O
curing	O
or	O
preventing	O
the	O
tumor	O
of	O
the	O
mammal	O
,	O
in	O
particular	O
to	O
the	O
solid	O
tumor	O
.	O

Esculentoside	O
A	O
,	O
EsA	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
Esculentoside	O
A	O
,	O
EsA	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
general	O
formula	O
of	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R	O
is	O
amino	O
acid	O
,	O
polypeptide	O
,	O
piperazine	O
base	O
,	O
substituted	O
piperazine	O
bases	O
or	O
substituted	O
amido	O
.	O

An	O
active	O
ester	O
intermediate	O
formed	O
by	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
under	O
the	O
action	O
of	O
a	O
condensation	O
agent	O
reacts	O
with	O
amine	O
or	O
piperazine	O
or	O
substituted	O
piperazine	O
or	O
amino	O
acid	O
with	O
the	O
protected	O
carboxyl	O
or	O
polypeptide	O
;	O
and	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
is	O
obtained	O
by	O
separation	O
and	O
purification	O
.	O

The	O
Esculentoside	O
A	O
,	O
EsA	O
,	O
as	O
well	O
as	O
pharmaceutical	O
salt	O
and	O
medical	O
composite	O
thereof	O
can	O
be	O
used	O
for	O
preparing	O
inflammatory	O
medicaments	O
.	O

Imidazopyridine	O
and	O
imidazopyrazine	O
compounds	O
useful	O
as	O
kinase	B
inhibitors	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
and	O
enantiomers	O
,	O
diastereomers	O
and	O
pharmaceutically	O
-	O
acceptable	O
salts	O
thereof	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	B
kinase	I
.	O

Application	O
of	O
arachidonic	O
acid	O
as	O
xanthine	B
oxidase	I
inhibitor	O
and	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
The	O
invention	O
relates	O
to	O
application	O
of	O
arachidonic	O
acid	O
as	O
a	O
xanthine	B
oxidase	I
inhibitor	O
and	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
.	O

Xanthine	B
oxidase	I
is	O
a	O
key	O
enzyme	O
for	O
the	O
generation	O
and	O
the	O
development	O
of	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
,	O
most	O
substrates	O
of	O
the	O
xanthine	B
oxidase	I
are	O
cyclic	O
small	O
molecules	O
,	O
and	O
the	O
arachidonic	O
acid	O
is	O
long	O
chain	O
polyunsaturated	O
fatty	O
acid	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
xanthine	B
oxidase	I
is	O
downloaded	O
from	O
a	O
protein	O
data	O
bank	O
(	O
PDB	O
)	O
of	O
a	O
website	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
arachidonic	O
acid	O
is	O
downloaded	O
from	O
a	O
pubchem	O
;	O
molecular	O
docking	O
between	O
the	O
arachidonic	O
acid	O
and	O
the	O
xanthine	B
oxidase	I
is	O
performed	O
by	O
iGEMDOCK	O
software	O
and	O
docking	O
energy	O
is	O
computed	O
;	O
and	O
in	O
-	O
vitro	O
enzyme	O
activity	O
tests	O
prove	O
that	O
the	O
arachidonic	O
acid	O
has	O
an	O
inhibition	O
effect	O
on	O
the	O
xanthine	B
oxidase	I
.	O

By	O
the	O
application	O
,	O
another	O
important	O
physiological	O
function	O
of	O
the	O
arachidonic	O
acid	O
is	O
discovered	O
,	O
and	O
a	O
wider	O
way	O
is	O
provided	O
for	O
screening	O
the	O
xanthine	O
oxidase	O
inhibitor	O
from	O
a	O
natural	O
product	O
to	O
treat	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
simultaneously	O
.	O

Preparation	O
method	O
of	O
pulsatilla	O
saponin	O
matter	O
as	O
well	O
as	O
preparation	O
method	O
of	O
preparation	O
thereof	O
and	O
application	O
of	O
pulsatilla	O
saponin	O
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O
The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
pulsatilla	O
saponin	O
matter	O
as	O
well	O
as	O
a	O
preparation	O
method	O
of	O
a	O
preparation	O
thereof	O
and	O
application	O
of	O
the	O
pulsatilla	O
saponin	O
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O
.	O

The	O
invention	O
relates	O
to	O
the	O
pulsatilla	O
saponin	O
matter	O
which	O
is	O
pulsatilla	O
saponin	O
A	O
or	O
pulsatilla	O
saponin	O
A	O
produced	O
by	O
hydrolysis	O
,	O
thereby	O
together	O
having	O
the	O
structural	O
units	O
of	O
23-hydroxy	O
oleanolic	O
acid-3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
-alpha	O
-	O
L	O
-	O
pyran	O
Arabic	O
glucoside	O
,	O
and	O
the	O
like	O
,	O
and	O
because	O
the	O
matter	O
is	O
easy	O
to	O
generate	O
the	O
pulsatilla	O
saponin	O
A	O
after	O
being	O
hydrolyzed	O
,	O
the	O
pulsatilla	O
saponin	O
matter	O
has	O
a	O
similar	O
treating	O
effect	O
in	O
human	O
bodies	O
.	O

Dirithromycin	O
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
dirithromycin	O
medicinal	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

By	O
the	O
dirithromycin	O
medicinal	O
composition	O
,	O
the	O
problem	O
of	O
the	O
flowability	O
of	O
granules	O
during	O
preparation	O
is	O
mainly	O
solved	O
,	O
and	O
the	O
stability	O
,	O
bioavailability	O
and	O
the	O
like	O
of	O
medicaments	O
are	O
improved	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
dirithromycin	O
medicinal	O
composition	O
,	O
namely	O
the	O
dirithromycin	O
medicinal	O
composition	O
is	O
filled	O
by	O
a	O
direct	O
method	O
,	O
so	O
by	O
the	O
preparation	O
method	O
,	O
the	O
problem	O
that	O
soft	O
materials	O
have	O
high	O
viscosity	O
and	O
are	O
difficult	O
to	O
pelletize	O
in	O
the	O
process	O
of	O
preparing	O
dirithromycin	O
medicinal	O
capsules	O
in	O
the	O
prior	O
art	O
is	O
solved	O
.	O

Application	O
of	O
feather	O
cockscomb	O
saponins	O
compound	O
in	O
antitumor	O
or	O
anti	O
-	O
inflammatory	O
medicines	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
novel	O
application	O
of	O
a	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
Celosin	O
A	O
,	O
Celosin	O
B	O
,	O
Celosin	O
C1	O
,	O
Celosin	O
D1	O
,	O
Celosin	O
E	O
,	O
Celosin	O
F	O
,	O
Celosin	O
G	O
or	O
Cristatain	O
.	O

Proved	O
by	O
in	O
vitro	O
cell	O
experiments	O
,	O
the	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
the	O
Celosin	O
A	O
,	O
the	O
Celosin	O
B	O
,	O
the	O
Celosin	O
C1	O
,	O
the	O
Celosin	O
D1	O
,	O
the	O
Celosin	O
E	O
,	O
the	O
Celosin	O
F	O
,	O
Celosin	O
G	O
and	O
Cristatain	O
have	O
favorable	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
the	O
Celosin	O
A	O
,	O
the	O
Celosin	O
B	O
and	O
Cristatain	O
have	O
better	O
anti	O
-	O
inflammatory	O
effect	O
,	O
therefore	O
,	O
the	O
feather	O
cockscomb	O
saponins	O
compound	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
or	O
antitumor	O
medicines	O
.	O

The	O
invention	O
provides	O
a	O
new	O
medicine	O
source	O
for	O
the	O
anti	O
-	O
inflammatory	O
medicines	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
kit	O
and	O
package	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
a	O
kit	O
and	O
package	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
contain	O
a	O
treatment	O
effective	O
dose	O
of	O
lobaplatin	O
and	O
a	O
treatment	O
effective	O
dose	O
of	O
etoposide	O
as	O
a	O
combination	O
for	O
simultaneous	O
,	O
separated	O
or	O
sequential	O
use	O
.	O

When	O
used	O
for	O
treating	O
the	O
small	O
cell	O
lung	O
cancer	O
,	O
the	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
provided	O
by	O
the	O
invention	O
can	O
obtain	O
excellent	O
treatment	O
effect	O
and	O
have	O
small	O
toxic	O
side	O
effect	O
.	O

Absorption	O
-	O
promoting	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
a	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
.	O

The	O
pharmaceutical	O
composition	O
contains	O
the	O
following	O
components	O
in	O
proportion	O
by	O
weight	O
:	O
0.05	O
-	O
0.08	O
%	O
of	O
betamethasone	O
valerate	O
,	O
0.08	O
-	O
0.12	O
%	O
of	O
chlorocresol	O
and	O
0.08	O
-	O
0.12	O
%	O
of	O
gentamicin	O
sulfate	O
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
is	O
mainly	O
used	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
,	O
contact	O
dermatitis	O
,	O
seborrheic	O
dermatitis	O
,	O
photodermatitis	O
,	O
neurodermatitis	O
,	O
intertrigo	O
,	O
exfoliative	O
dermatitis	O
,	O
skin	O
itch	O
,	O
psoriasis	O
,	O
first	O
-	O
degree	O
burn	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
has	O
the	O
characteristics	O
of	O
jointly	O
applying	O
pharmaceutical	O
components	O
with	O
anti	O
-	O
inflammatory	O
,	O
antifungal	O
and	O
antibacterial	O
curative	O
effects	O
,	O
playing	O
the	O
curative	O
effects	O
in	O
multiple	O
aspects	O
,	O
overcoming	O
the	O
defect	O
that	O
an	O
individual	O
component	O
can	O
not	O
more	O
effectively	O
treat	O
skin	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
or	O
concurrence	O
of	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
and	O
relieving	O
the	O
serious	O
side	O
effects	O
caused	O
by	O
singly	O
using	O
a	O
big	O
amount	O
of	O
hormone	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
;	O
and	O
a	O
component	O
for	O
promoting	O
percutaneous	O
absorption	O
is	O
added	O
to	O
auxiliary	O
materials	O
to	O
enhance	O
the	O
pharmaceutical	O
curative	O
effect	O
and	O
promote	O
absorption	O
.	O

The	O
ointment	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
exact	O
efficacy	O
,	O
strong	O
local	O
pertinence	O
,	O
no	O
irritation	O
on	O
skin	O
,	O
and	O
the	O
like	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
ointment	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Hyperosteogeny	O
plaster	O
The	O
invention	O
discloses	O
a	O
hyperosteogeny	O
plaster	O
used	O
for	O
treating	O
hyperosteogeny	O
and	O
functional	O
disorder	O
,	O
soft	O
tissue	O
injury	O
,	O
swell	O
,	O
sore	O
,	O
numbness	O
and	O
pain	O
caused	O
thereby	O
.	O

The	O
hyperosteogeny	O
plaster	O
takes	O
cotton	O
cloth	O
as	O
a	O
mounting	O
material	O
,	O
acrylic	O
ester	O
polymer	O
as	O
a	O
pressure	O
sensitive	O
adhesive	O
,	O
glycerol	O
as	O
a	O
cosolvent	O
and	O
azone	O
as	O
an	O
accelerator	O
,	O
and	O
the	O
main	O
medicines	O
comprise	O
80	O
-	O
97	O
%	O
of	O
micalex	O
in	O
weight	O
,	O
1	O
-	O
7	O
%	O
of	O
coptis	O
in	O
weight	O
and	O
2	O
-	O
13	O
%	O
of	O
dried	O
alum	O
in	O
weight	O
.	O

The	O
plaster	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0.1	O
-	O
30	O
%	O
of	O
main	O
medicines	O
,	O
50	O
-	O
90	O
%	O
of	O
pressure	O
sensitive	O
adhesive	O
acrylic	O
ester	O
polymer	O
,	O
2	O
-	O
20	O
%	O
of	O
cosolvent	O
glycerol	O
and	O
0.5	O
-	O
10	O
%	O
of	O
accelerator	O
azone	O
.	O

Method	O
for	O
preparing	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
an	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
a	O
,	O
weighing	O
ephedra	O
,	O
gypsum	O
,	O
bitter	O
almond	O
,	O
whiteflower	O
hogfennel	O
root	O
,	O
baical	O
skullcap	O
root	O
,	O
perilla	O
fruit	O
powder	O
,	O
pepperweed	O
seed	O
and	O
bamboo	O
shavings	O
;	O
b	O
,	O
soaking	O
ephedra	O
coarse	O
powder	O
in	O
acidic	O
aqueous	O
solution	O
,	O
and	O
percolating	O
for	O
extracting	O
;	O
c	O
,	O
crushing	O
bitter	O
almond	O
,	O
inactivating	O
enzyme	O
,	O
and	O
extracting	O
by	O
low	O
-	O
degree	O
alcoholic	O
solution	O
;	O
d	O
,	O
decocting	O
gypsum	O
,	O
adding	O
other	O
components	O
,	O
extracting	O
in	O
water	O
,	O
mixing	O
with	O
ephedra	O
concentrating	O
solution	O
and	O
bitter	O
almond	O
concentrating	O
solution	O
,	O
and	O
concentrating	O
to	O
form	O
extract	O
;	O
and	O
e	O
,	O
adding	O
an	O
excipient	O
and	O
auxiliary	O
materials	O
,	O
and	O
preparing	O
by	O
the	O
conventional	O
method	O
of	O
preparations	O
to	O
obtain	O
a	O
pharmaceutically	O
-	O
acceptable	O
preparation	O
.	O

By	O
the	O
method	O
,	O
the	O
extraction	O
rate	O
of	O
ephedrine	O
and	O
amygdalin	O
can	O
be	O
improved	O
,	O
the	O
curative	O
effect	O
of	O
medicines	O
can	O
be	O
improved	O
,	O
and	O
the	O
quality	O
stability	O
ofproducts	O
can	O
be	O
improved	O
simultaneously	O
.	O

Lansoprazole	O
medicinal	O
composition	O
tablets	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
comprise	O
the	O
following	O
components	O
in	O
part	O
by	O
mass	O
:	O
20	O
to	O
30	O
parts	O
of	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
,	O
400	O
to	O
450	O
parts	O
of	O
sodium	O
bicarbonate	O
,	O
100	O
to	O
150	O
parts	O
of	O
calcium	O
hydrophosphate	O
,	O
600	O
to	O
700	O
parts	O
of	O
magnesium	O
hydroxide	O
,	O
250	O
to	O
500	O
parts	O
of	O
filler	O
,	O
40	O
to	O
50	O
parts	O
of	O
disintegrating	O
agent	O
,	O
50	O
to	O
100	O
parts	O
of	O
flavoring	O
agent	O
,	O
80	O
to	O
100	O
parts	O
of	O
bonding	O
agent	O
and	O
20	O
to	O
25	O
parts	O
of	O
lubricating	O
agent	O
.	O

In	O
the	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
disclosed	O
by	O
the	O
invention	O
,	O
sodium	O
bicarbonate	O
,	O
calcium	O
hydrophosphate	O
and	O
magnesium	O
hydroxide	O
are	O
used	O
in	O
place	O
of	O
enteric	O
coating	O
,	O
the	O
secretion	O
of	O
gastric	O
acid	O
can	O
be	O
inhibited	O
,	O
the	O
Lansoprazole	O
can	O
be	O
prevented	O
from	O
being	O
decomposed	O
by	O
gastric	O
acid	O
,	O
the	O
medicines	O
can	O
be	O
absorbed	O
quickly	O
,	O
and	O
peak	O
concentration	O
can	O
be	O
reached	O
quickly	O
.	O

Hederasaponin	O
derivative	O
,	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
provides	O
a	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1	O
-	O
4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
,	O
a	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O
.	O

The	O
structures	O
of	O
the	O
hederasaponin	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1->4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
and	O
salts	O
thereof	O
are	O
shown	O
as	O
follows	O
.	O

The	O
hederasaponin	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1->4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
and	O
the	O
salts	O
thereof	O
are	O
combined	O
with	O
a	O
pharmaceutical	O
acceptable	O
carrier	O
to	O
form	O
a	O
pharmaceutical	O
compound	O
which	O
is	O
used	O
for	O
preparing	O
tumor	O
-	O
resistant	O
medicines	O
.	O

Compared	O
with	O
the	O
prototype	O
medicine	O
,	O
a	O
medicine	O
containing	O
the	O
ingredient	O
derivative	O
and	O
the	O
salts	O
thereof	O
has	O
considerable	O
or	O
stronger	O
tumor	O
-	O
resistant	O
activity	O
;	O
and	O
meanwhile	O
,	O
the	O
activity	O
of	O
other	O
tumor	O
-	O
resistant	O
medicines	O
can	O
be	O
obviously	O
enhanced	O
and	O
the	O
side	O
effects	O
of	O
the	O
medicines	O
are	O
reduced	O
.	O

Slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	O
prepared	O
by	O
supercritical	O
fluid	O
method	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	O
prepared	O
by	O
a	O
supercritical	O
fluid	O
method	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
nanoparticle	O
comprises	O
active	O
ingredients	O
of	O
vinpocetine	O
,	O
glyceryl	O
monooleate	O
and	O
surfactant	O
.	O

The	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
of	O
the	O
invention	O
prepared	O
by	O
vinpocetine	O
has	O
an	O
obvious	O
slow	O
-	O
release	O
function	O
relative	O
to	O
a	O
vinpocetine	O
solution	O
and	O
has	O
a	O
remarkably	O
-	O
increased	O
oral	O
bioavailability	O
.	O

Meropenem	O
sodium	O
/	O
sulbactam	O
sodium	O
medicinal	O
composition	O
The	O
invention	O
provides	O
a	O
combined	O
medicament	O
,	O
in	O
particular	O
a	O
meropenem	O
sodium	O
and	O
sulbactam	O
sodium	O
combined	O
medicine	O
which	O
is	O
used	O
for	O
treating	O
infectious	O
diseases	O
caused	O
by	O
Acinetobacter	O
baumanii	O
.	O

The	O
meropenem	O
sodium	O
and	O
sulbactam	O
sodium	O
combined	O
medicine	O
has	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
the	O
infectious	O
diseases	O
caused	O
by	O
the	O
Acinetobacter	O
baumanii	O
,	O
particularly	O
has	O
good	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
,	O
and	O
can	O
be	O
used	O
for	O
curing	O
the	O
clinical	O
infection	O
caused	O
by	O
the	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
.	O

New	O
application	O
of	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
The	O
invention	O
relates	O
to	O
applications	O
of	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
in	O
preparing	O
a	O
medicament	O
for	O
inducing	O
glioma	O
cell	O
apoptosis	O
and	O
preparing	O
a	O
medicament	O
for	O
inhibiting	O
glioma	O
cell	O
proliferation	O
.	O

Shown	O
by	O
experimental	O
results	O
,	O
the	O
EGCG	O
can	O
obviously	O
inhibit	O
the	O
glioma	O
cell	O
proliferation	O
(	O
P	O
(	O
0.001	O
)	O
,	O
with	O
the	O
increase	O
of	O
dosage	O
of	O
the	O
EGCG	O
and	O
extension	O
of	O
time	O
,	O
the	O
cyto	O
-	O
inhibition	O
is	O
more	O
obvious	O
;	O
and	O
shown	O
by	O
experimental	O
results	O
of	O
cell	O
apoptosis	O
,	O
48	O
hours	O
later	O
after	O
the	O
EGCG	O
is	O
added	O
,	O
with	O
the	O
increase	O
of	O
concentration	O
,	O
the	O
number	O
of	O
cell	O
apoptosis	O
is	O
markedly	O
increased	O
.	O

Motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O
The	O
invention	O
relates	O
to	O
a	O
motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O
and	O
can	O
effectively	O
solve	O
the	O
treatment	O
problem	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

The	O
technical	O
schemes	O
are	O
as	O
follows	O
:	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
from	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
motherwort	O
extract	O
to	O
the	O
astragalus	O
extract	O
is	O
(	O
4	O
-	O
6	O
)	O
:	O
(	O
6	O
-	O
4	O
)	O
;	O
and	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
by	O
crushing	O
the	O
motherwort	O
extract	O
and	O
the	O
astragalus	O
extract	O
,	O
screening	O
with	O
a	O
100-mesh	O
sieve	O
,	O
mixing	O
uniformly	O
,	O
then	O
adding	O
starch	O
and	O
talcum	O
powder	O
,	O
uniformly	O
mixing	O
,	O
wherein	O
the	O
addition	O
amount	O
of	O
starch	O
and	O
talcum	O
powder	O
is	O
not	O
more	O
than	O
10	O
%	O
the	O
total	O
weight	O
of	O
the	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
and	O
the	O
weight	O
ratio	O
of	O
starch	O
to	O
talcum	O
powder	O
is	O
1:1	O
,	O
granulating	O
and	O
encapsulating	O
.	O

The	O
motherwort	O
and	O
astragalus	O
capsule	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
proper	O
compatibility	O
,	O
good	O
efficacy	O
,	O
no	O
toxic	O
or	O
side	O
effect	O
and	O
significant	O
treatment	O
effect	O
on	O
benign	O
prostatic	O
hyperplasia	O
,	O
is	O
innovative	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
,	O
and	O
has	O
huge	O
economic	O
and	O
social	O
benefits	O
.	O

Chondrocyte	O
-	O
like	O
cell	O
,	O
and	O
method	O
for	O
producing	O
same	O
Disclosed	O
is	O
a	O
cell	O
which	O
enables	O
the	O
reproduction	O
of	O
a	O
cartilage	O
tissue	O
and	O
has	O
a	O
proliferative	O
ability	O
.	O

Also	O
disclosed	O
is	O
a	O
technique	O
for	O
providing	O
a	O
cell	O
supply	O
source	O
which	O
can	O
be	O
used	O
in	O
a	O
definitive	O
treatment	O
of	O
osteochondrosis	O
deformans	O
.	O

A	O
chondrocyte	O
-	O
like	O
cell	O
which	O
has	O
the	O
same	O
properties	O
as	O
those	O
of	O
a	O
chondrocyte	O
and	O
can	O
proliferate	O
can	O
be	O
produced	O
by	O
selecting	O
a	O
combination	O
of	O
an	O
Myc	B
family	O
gene	O
and/or	O
a	O
Klf	B
family	O
gene	O
and	O
a	O
SOX9	B
gene	I
and	O
introducing	O
the	O
combination	O
into	O
a	O
somatic	O
cell	O
.	O

The	O
chondrocyte	O
-	O
like	O
cell	O
can	O
be	O
used	O
for	O
a	O
medical	O
purpose	O
of	O
cartilage	O
regeneration	O
.	O

Medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O
.	O

The	O
medicinal	O
composition	O
consists	O
of	O
mesna	O
,	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
or	O
a	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
derivative	O
and	O
a	O
pharmaceutically	O
acceptable	O
medicinal	O
carrier	O
.	O

The	O
combined	O
medication	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	O
has	O
an	O
unexpected	O
therapeutic	O
effect	O
on	O
preventing	O
or	O
treating	O
the	O
cystitis	O
caused	O
by	O
a	O
chemotherapeutic	O
medicament	O
.	O

The	O
medicinal	O
composition	O
contributes	O
to	O
relieving	O
the	O
pain	O
of	O
a	O
chemotherapy	O
patient	O
;	O
and	O
the	O
tolerance	O
dose	O
of	O
the	O
patient	O
to	O
the	O
chemotherapeutic	O
medicament	O
is	O
improved	O
.	O

Compared	O
with	O
the	O
conventional	O
medicamentssuch	O
as	O
the	O
mesna	O
and	O
the	O
like	O
,	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
that	O
:	O
the	O
composition	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	O
has	O
a	O
wide	O
therapeutic	O
effect	O
on	O
the	O
cystitis	O
caused	O
by	O
the	O
chemotherapeutic	O
medicament	O
and	O
has	O
a	O
limited	O
prevention	O
effect	O
.	O

Application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O
The	O
invention	O
discloses	O
application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O
.	O

The	O
application	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
filling	O
the	O
extracted	O
lycium	O
barbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
in	O
capsules	O
or	O
preparing	O
the	O
lycium	O
barbarum	O
polysaccharidesinto	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
uniformly	O
mixing	O
the	O
extracted	O
lyciumbarbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
and	O
corn	O
startch	O
;	O
and	O
filling	O
the	O
mixture	O
into	O
capsules	O
or	O
preparing	O
the	O
mixture	O
into	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
.	O

The	O
application	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
benefits	O
that	O
:	O
the	O
drugs	O
are	O
prescribed	O
preparations	O
composed	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
the	O
drugs	O
have	O
anti	O
-	O
stress	O
effect	O
and	O
are	O
capable	O
of	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and/or	O
posttraumatic	O
stress	O
disorder	O
and	O
improving	O
cognitive	O
function	O
;	O
the	O
pharmaceutical	O
effect	O
is	O
clear	O
;	O
the	O
safety	O
is	O
high	O
;	O
and	O
the	O
novel	O
drug	O
application	O
selection	O
is	O
provided	O
in	O
clinical	O
.	O

Cucoline	O
derivative	O
as	O
well	O
as	O
salts	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
cucoline	O
derivative	O
as	O
well	O
as	O
salts	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

According	O
to	O
the	O
invention	O
,	O
1	O
,	O
4	O
,	O
6	O
and	O
17	O
positions	O
in	O
a	O
cucoline	O
structure	O
are	O
modified	O
so	O
as	O
to	O
obtain	O
the	O
cucoline	O
derivative	O
the	O
structural	O
general	O
formula	O
of	O
which	O
is	O
as	O
follows	O
(	O
shown	O
in	O
the	O
specification	O
)	O
;	O
the	O
salts	O
of	O
the	O
cucoline	O
derivative	O
comprise	O
hydrochloride	O
,	O
sulfate	O
,	O
bisulfate	O
,	O
hydrobromide	O
,	O
oxalate	O
,	O
citrate	O
and	O
mesylate	O
;	O
and	O
the	O
inhibition	O
activity	O
of	O
partial	O
compounds	O
of	O
the	O
invention	O
on	O
NF	B
-	I
kappa	I
B	I
are	O
obviously	O
superior	O
to	O
that	O
of	O
cucoline	O
,	O
and	O
the	O
cucoline	O
derivative	O
and	O
salts	O
thereof	O
are	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
medicaments	O
.	O

Ambroxol	O
hydrochloride	O
oral	O
aqueous	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
an	O
oral	O
aqueous	O
composition	O
,	O
which	O
comprises	O
0.1	O
to	O
1	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
ambroxol	O
hydrochloride	O
,	O
0.05	O
to	O
0.2	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
solution	O
thickener	O
,	O
0.005	O
to	O
0.05	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
freshener	O
,	O
a	O
stabilizer	O
and	O
water	O
,	O
wherein	O
the	O
stabilizer	O
is	O
a	O
substance	O
for	O
forming	O
a	O
medicinal	O
solvent	O
system	O
by	O
combining	O
the	O
water	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
composition	O
.	O

The	O
oral	O
aqueous	O
composition	O
has	O
the	O
advantages	O
of	O
cool	O
and	O
refreshing	O
mouthfeel	O
,	O
wide	O
application	O
range	O
and	O
the	O
like	O
,	O
is	O
clear	O
and	O
stable	O
,	O
does	O
not	O
contain	O
any	O
natural	O
or	O
semi	O
-	O
synthetic	O
sweetener	O
,	O
and	O
is	O
suitable	O
for	O
patients	O
who	O
suffer	O
from	O
diabetes	O
and	O
people	O
who	O
are	O
allergic	O
to	O
the	O
semi	O
-	O
synthetic	O
sweetener	O
.	O

Drug	O
combination	O
containing	O
astragalus	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
combination	O
containing	O
astragalus	O
and	O
a	O
use	O
thereof	O
.	O

The	O
drug	O
combination	O
contains	O
astragalus	O
or	O
an	O
astragalus	O
extractive	O
or	O
a	O
derivative	O
thereof	O
capable	O
of	O
being	O
received	O
chemically	O
.	O

The	O
drug	O
combination	O
comprises	O
the	O
following	O
components	O
:	O
100	O
parts	O
of	O
astragalus	O
and	O
1	O
-	O
50	O
of	O
levamisole	O
hydrochloride	O
.	O

On	O
the	O
basis	O
,	O
the	O
following	O
one	O
or	O
more	O
components	O
can	O
be	O
increased	O
,	O
but	O
not	O
limited	O
:	O
20	O
-	O
150	O
parts	O
of	O
vitamin	O
C.	O
The	O
use	O
method	O
and	O
the	O
dosage	O
of	O
the	O
combination	O
are	O
shown	O
as	O
follows	O
:	O
a	O
solid	O
preparation	O
is	O
used	O
after	O
being	O
mixed	O
by	O
0.1	O
-	O
10.0	O
percent	O
of	O
complete	O
feeds	O
;	O
and	O
a	O
liquid	O
preparation	O
is	O
drunk	O
after	O
the	O
water	O
of	O
250	O
-	O
500	O
kg	O
is	O
added	O
in	O
the	O
liquid	O
preparation	O
of	O
100	O
ml	O
.	O

The	O
combination	O
has	O
the	O
main	O
function	O
of	O
inducing	O
a	O
human	O
body	O
to	O
generate	O
the	O
interferon	O
,	O
promoting	O
the	O
antibody	O
formation	O
and	O
adjusting	O
the	O
immunologic	O
function	O
of	O
the	O
human	O
body	O
.	O

The	O
drug	O
combination	O
is	O
used	O
for	O
simulating	O
an	O
immune	O
system	O
of	O
an	O
animal	O
body	O
,	O
adjusting	O
the	O
immunity	O
,	O
enhancing	O
the	O
disease	O
resistance	O
,	O
reducing	O
the	O
disease	O
incidence	O
and	O
assisting	O
to	O
treat	O
the	O
virus	O
infection	O
.	O

Fenticonazole	O
nitrate	O
medicinal	O
composition	O
The	O
invention	O
provides	O
a	O
fenticonazole	O
nitrate	O
-	O
containing	O
medicinal	O
composition	O
.	O

The	O
fenticonazole	O
nitrate	O
-	O
containing	O
medicinal	O
composition	O
consists	O
of	O
fenticonazole	O
nitrate	O
,	O
36-type	O
mixed	O
fatty	O
acid	O
glyceride	O
and	O
silicon	O
dioxide	O
in	O
a	O
ratio	O
of	O
2:	O
(	O
10	O
-	O
14	O
)	O
:	O
(	O
0.05	O
-	O
0.10	O
)	O
.	O

By	O
the	O
formula	O
,	O
the	O
problem	O
that	O
in	O
the	O
prior	O
art	O
,	O
active	O
ingredients	O
can	O
not	O
be	O
dispersed	O
well	O
is	O
solved	O
.	O

Medicinal	O
composition	O
of	O
amlodipine	O
and	O
atorvastatin	O
calcium	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
by	O
taking	O
amlodipine	O
and	O
atorvastatin	O
calcium	O
as	O
active	O
components	O
,	O
the	O
medicinal	O
composition	O
comprises	O
amlodipine	O
,	O
atorvastatin	O
calcium	O
,	O
a	O
filler	O
,	O
a	O
disintegrant	O
and	O
a	O
lubricant	O
;	O
the	O
active	O
components	O
are	O
composed	O
of	O
2	O
-	O
20	O
parts	O
of	O
amlodipine	O
and	O
5	O
-	O
120	O
parts	O
of	O
atorvastatin	O
calcium	O
;	O
the	O
amlodipine	O
is	O
a	O
maleic	O
acid	O
amlodipine	O
hydrate	O
crystal	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
maleic	O
acid	O
amlodipine	O
hydrate	O
crystal	O
is	O
C24H29C1N2O9.1.5H2O	O
.	O

The	O
amlodipine	O
in	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
of	O
fast	O
effectiveness	O
and	O
stability	O
,	O
and	O
is	O
capable	O
of	O
steadily	O
releasing	O
the	O
drug	O
effect	O
in	O
24	O
hours	O
,	O
the	O
medicinal	O
composition	O
has	O
strong	O
synergy	O
,	O
accumulation	O
and	O
complementary	O
effects	O
,	O
and	O
the	O
bioavailability	O
is	O
high	O
.	O

Application	O
of	O
atractylodin	O
alcohol	O
in	O
medicament	O
preparation	O
The	O
invention	O
provides	O
application	O
of	O
an	O
atractylodin	O
alcohol	O
(	O
CZSC	O
)	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
animal	O
virus	O
diseases	O
,	O
in	O
particular	O
application	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
infection	O
and	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
,	O
or	O
in	O
preparation	O
of	O
a	O
virus	O
gene	O
expression	O
inhibitor	O
and	O
an	O
anti	O
-	O
virus	O
medicament	O
and	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
inhibiting	O
blue	O
ear	O
disease	O
viruses	O
.	O

The	O
CZSC	O
has	O
remarkable	O
effects	O
of	O
regulating	O
nucleoprotein	B
gene	O
expression	O
of	O
the	O
PRRSV	O
down	O
and	O
inhibiting	O
virus	O
proliferation	O
;	O
and	O
in	O
vitro	O
cellular	O
pharmacological	O
tests	O
shows	O
that	O
the	O
CZSC	O
has	O
definite	O
anti	O
-	O
virus	O
effect	O
.	O

The	O
CZSC	O
has	O
wide	O
application	O
prospect	O
in	O
treatment	O
and	O
control	O
of	O
PRRSV	O
infection	O
.	O

Wound	O
healing	O
gel	O
and	O
preparation	O
process	O
thereof	O
The	O
invention	O
relates	O
to	O
wound	O
healing	O
gel	O
and	O
a	O
preparation	O
process	O
thereof	O
,	O
which	O
belong	O
to	O
the	O
field	O
of	O
medicine	O
preparations	O
and	O
clinic	O
applications	O
.	O

The	O
wound	O
healing	O
gel	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
2	O
to	O
3	O
percent	O
of	O
paste	O
powder	O
,	O
0.5	O
to	O
2	O
percent	O
of	O
30-percent	O
borneol	O
solution	O
,	O
8	O
to	O
12	O
percent	O
of	O
glycerol	O
,	O
0.8	O
to	O
1.2	O
percent	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
percent	O
of	O
NaHSO3	O
,	O
0.02	O
to	O
0.04	O
percent	O
of	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
disodium	O
(	O
EDTA-2Na	O
)	O
,	O
8	O
to	O
12	O
percent	O
of	O
propylene	O
glycol	O
,	O
0.5	O
to	O
2	O
percent	O
of	O
10-percent	O
methylparaben	O
solution	O
,	O
1.4	O
to	O
1.8	O
percent	O
of	O
triethanolamine	O
and	O
50	O
to	O
80	O
percent	O
of	O
distilled	O
water	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
treating	O
radiation	O
injury	O
,	O
cold	O
injury	O
and	O
burn	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
II	O
degree	O
surface	O
of	O
burns	O
and	O
can	O
accelerate	O
the	O
healing	O
of	O
the	O
surface	O
of	O
burns	O
and	O
relieve	O
swelling	O
of	O
surface	O
of	O
burns	O
and	O
dehydration	O
of	O
the	O
wound	O
tissue	O
obviously	O
.	O

And	O
the	O
gel	O
has	O
the	O
characteristics	O
that	O
:	O
the	O
treatment	O
effect	O
is	O
exact	O
;	O
the	O
use	O
is	O
safe	O
;	O
the	O
quality	O
index	O
is	O
easy	O
to	O
control	O
;	O
the	O
price	O
is	O
low	O
;	O
and	O
the	O
like	O
.	O

Mangiferin	O
penta	O
-	O
esterified	O
derivative	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
chemically	O
synthesizing	O
a	O
mangiferin	O
penta	O
-	O
esterified	O
derivative	O
and	O
a	O
pharmacological	O
effect	O
of	O
resisting	O
inflammation	O
and	O
reducing	O
blood	O
sugar	O
of	O
the	O
derivative	O
.	O

The	O
chemical	O
structural	O
formula	O
of	O
the	O
derivative	O
is	O
shown	O
in	O
the	O
specifications	O
.	O

The	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
inhibiting	O
mouse	O
auricle	O
tumefaction	O
caused	O
by	O
dimethylbenzene	O
;	O
and	O
the	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
treating	O
diabetic	O
mice	O
induced	O
by	O
alloxan	O
.	O

New	O
aromatic	O
polyketones	O
,	O
extraction	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
microbial	O
engineering	O
,	O
and	O
specifically	O
relates	O
to	O
new	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
,	O
an	O
extraction	O
method	O
and	O
an	O
application	O
thereof	O
,	O
wherein	O
the	O
aromatic	O
polyketones	O
are	O
extracted	O
from	O
a	O
liquid	O
fermented	O
material	O
of	O
the	O
intestinal	O
bacteria	O
of	O
Tenoderaaridifolia	O
,	O
and	O
the	O
intestinal	O
bacteria	O
of	O
the	O
Tenoderaaridifolia	O
is	O
the	O
daldiniaeschscholzii	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
the	O
present	O
invention	O
have	O
the	O
following	O
structural	O
formula	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	O
polyketone	O
1	O
has	O
strong	O
antioxidant	O
activity	O
,	O
and	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
2	O
-	O
5	O
have	O
strong	O
immunosuppression	O
activities	O
,	O
such	O
that	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
1	O
-	O
5	O
can	O
be	O
adopted	O
for	O
preparing	O
the	O
relevant	O
novel	O
drugs	O
,	O
wherein	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
1	O
-	O
5	O
are	O
adopted	O
as	O
the	O
compounds	O
with	O
the	O
antioxidant	O
effects	O
or	O
the	O
immunosuppression	O
effects	O
.	O

Freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	O
sodium	O
as	O
active	O
component	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	O
sodium	O
as	O
its	O
active	O
component	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
prepared	O
from	O
omeprazole	O
sodium	O
,	O
edetate	O
disodium	O
,	O
a	O
pH	O
value	O
conditioning	O
agent	O
and	O
injection	O
water	O
,	O
wherein	O
the	O
omeprazole	O
sodium	O
is	O
a	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C17H18N3NaO3S.2H2O	O
.	O

The	O
omeprazole	O
sodium	O
in	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
the	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
,	O
and	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
prepared	O
from	O
the	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
has	O
excellent	O
stability	O
.	O

Novel	O
pyrimidine	O
derivatives	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pyrimidine	O
compounds	O
and	O
preparation	O
methods	O
thereof	O
.	O

The	O
novel	O
pyrimidine	O
derivatives	O
and	O
salts	O
thereof	O
are	O
compounds	O
shown	O
in	O
the	O
formula	O
(	O
1	O
)	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
represents	O
-CH2NHR4	O
or	O
cyano	O
group	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
aryl	O
and	O
substituted	O
aryl	O
;	O
X	O
represents	O
methylene	O
,	O
carbonyl	O
or	O
hydroxymethylene	O
;	O
R4	O
represents	O
H	O
,	O
acetyl	O
or	O
tosyl	O
;	O
and	O
n	O
is	O
an	O
integer	O
of	O
0	O
-	O
5	O
.	O

A	O
series	O
of	O
new	O
compounds	O
are	O
prepared	O
by	O
the	O
inventor	O
of	O
the	O
invention	O
;	O
pharmacological	O
results	O
show	O
that	O
the	O
dipeptidyl	B
peptidase	I
IV	I
(	O
DPPIV	B
)	O
inhibition	O
rate	O
is	O
close	O
to	O
or	O
superior	O
to	O
that	O
of	O
the	O
reference	O
substance	O
R-1579	O
;	O
and	O
some	O
pyrimidine	O
compounds	O
with	O
new	O
structures	O
have	O
excellent	O
DPP	B
-	I
IV	I
inhibitory	O
activity	O
and	O
wide	O
application	O
prospects	O
.	O

Macrocyclic	O
4-amino	O
-	O
quinazoline	O
derivatives	O
and	O
their	O
use	O
as	O
MTKI	O
Disclosed	O
are	O
a	O
kinase	B
inhibitor	O
and	O
N	O
-	O
oxide	O
form	O
and	O
pharmaceutically	O
acceptable	O
isomerous	O
form	O
thereof	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z	O
is	O
NH	O
,	O
and	O
the	O
other	O
substituents	O
are	O
as	O
defined	O
herein	O
.	O

Hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
,	O
which	O
comprises	O
the	O
following	O
preparing	O
steps	O
:	O
step	O
(	O
1	O
)	O
,	O
dissolving	O
the	O
hypericin	O
albumin	O
nanoparticle	O
and	O
the	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
into	O
phosphate	O
buffer	O
solution	O
(	O
PBF	O
)	O
,	O
step	O
(	O
2	O
)	O
,	O
adding	O
glutaraldehyde	O
into	O
the	O
solution	O
obtained	O
by	O
the	O
step	O
(	O
1	O
)	O
,	O
and	O
obtaining	O
the	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
.	O

The	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
high	O
effective	O
utilization	O
;	O
simultaneously	O
,	O
the	O
preparation	O
method	O
of	O
the	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
being	O
simple	O
in	O
process	O
,	O
easy	O
to	O
operate	O
and	O
specially	O
suitable	O
for	O
industrial	O
production	O
.	O

Composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
sobering	O
function	O
The	O
invention	O
discloses	O
a	O
composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
a	O
sobering	O
function	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
composition	O
.	O

The	O
composition	O
contains	O
30	O
-	O
180	O
parts	O
by	O
weight	O
of	O
sesamin	O
,	O
1	O
-	O
6	O
parts	O
by	O
weight	O
of	O
schisandrin	O
B	O
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
semen	O
hoveniae	O
extract	O
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
pueraria	O
lobata	O
extract	O
,	O
0.0012	O
-	O
0.0072	O
parts	O
by	O
weight	O
of	O
vitamin	O
B12	O
and	O
14	O
-	O
84	O
parts	O
by	O
weight	O
of	O
vitamin	O
E.	O

Bisabolane	O
sesquiterpenoid	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
selective	O
antibacterial	O
agent	O
The	O
invention	O
discloses	O
a	O
bisabolane	O
sesquiterpenoid	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
a	O
selective	O
antibacterial	O
agent	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
strain	O
culturing	O
on	O
a	O
sponge	O
endophytic	O
fungi	O
,	O
i.e.	O
Asergillus	O
sp.	O
(	O
HM565949	O
)	O
in	O
a	O
strain	O
medium	O
;	O
cultivating	O
the	O
fungi	O
by	O
fermenting	O
in	O
a	O
fermentation	O
medium	O
;	O
filtering	O
the	O
obtained	O
fermentation	O
broth	O
to	O
remove	O
thallus	O
,	O
concentrating	O
the	O
filtrate	O
,	O
and	O
extracting	O
the	O
filtrate	O
with	O
ethyl	O
acetate	O
;	O
and	O
performing	O
chromatographic	O
separation	O
on	O
the	O
concentrate	O
and	O
respectively	O
concentrating	O
the	O
obtained	O
eluent	O
to	O
obtain	O
white	O
powder	O
,	O
i.e.	O
the	O
aspergterpeinoid	O
A	O
,	O
aspergiterpenoid	O
C	O
and	O
aspergiterpenoid	O
D.	O
The	O
bisabolane	O
sesquiterpenoid	O
obtained	O
from	O
a	O
marine	O
fungi	O
can	O
selectively	O
inhibit	O
the	O
activities	O
of	O
Staphylococcus	O
albus	O
,	O
Bacillus	O
subtilis	O
,	O
Bacillus	O
cereus	O
,	O
Sarcina	O
lutea	O
,	O
Escherichia	O
coli	O
,	O
Micrococcus	O
tetrgenus	O
,	O
marine	O
bacterial	O
Vibrio	O
parahaemolyticus	O
and	O
marine	O
bacterial	O
Vibrio	O
anguillarum	O
,	O
and	O
can	O
be	O
used	O
for	O
developing	O
the	O
selective	O
antibacterial	O
agent	O
.	O

In	O
addition	O
,	O
the	O
raw	O
materials	O
can	O
be	O
massively	O
produced	O
and	O
are	O
free	O
of	O
the	O
limitation	O
of	O
resources	O
.	O

Therefore	O
,	O
the	O
bisabolane	O
sesquiterpenoid	O
has	O
wide	O
application	O
prospect	O
.	O

Injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
is	O
a	O
powder	O
injection	O
and	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
carbazochrome	O
sodium	O
sulfonate	O
,	O
1.5	O
-	O
8.5	O
parts	O
of	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
0.1	O
-	O
1.8	O
parts	O
of	O
stabilizing	O
agent	O
and	O
2	O
-	O
5	O
parts	O
of	O
freezing	O
protective	O
agent	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
stability	O
and	O
the	O
dissolvability	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
are	O
improved	O
,	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
has	O
no	O
remarkable	O
change	O
of	O
various	O
indexes	O
through	O
detection	O
after	O
being	O
placed	O
for	O
a	O
long	O
time	O
,	O
the	O
quality	O
of	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
within	O
a	O
valid	O
period	O
is	O
ensured	O
to	O
be	O
qualified	O
;	O
and	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
can	O
be	O
slowly	O
administrated	O
for	O
a	O
long	O
time	O
,	O
thus	O
bioavailability	O
is	O
greatly	O
improved	O
.	O

The	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
i.e.	O
protein	O
,	O
is	O
degraded	O
in	O
vivo	O
without	O
toxicity	O
and	O
immunogenicity	O
;	O
and	O
meanwhile	O
,	O
medicine	O
therapeutic	O
indexes	O
can	O
be	O
effectively	O
increased	O
,	O
and	O
medicine	O
toxicity	O
is	O
lowered	O
and	O
medicine	O
side	O
effects	O
are	O
reduced	O
.	O

Adriamycin	O
lipid	O
pharmaceutical	O
composition	O
The	O
invention	O
relates	O
to	O
an	O
adriamycin	O
lipid	O
pharmaceutical	O
composition	O
comprising	O
the	O
following	O
components	O
:	O
(	O
1	O
)	O
adriamycin	O
,	O
(	O
2	O
)	O
phospholipids	O
,	O
(	O
3	O
)	O
cholesterol	O
and	O
(	O
4	O
)	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
(	O
described	O
in	O
the	O
specification	O
)	O
or	O
physiologically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
n	O
is	O
an	O
integral	O
number	O
of	O
5	O
-	O
500	O
,	O
m	O
is	O
an	O
integral	O
number	O
of	O
2	O
-	O
12	O
,	O
and	O
p	O
is	O
an	O
integral	O
number	O
of	O
1	O
-	O
8	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
and	O
application	O
of	O
the	O
lipid	O
pharmaceutical	O
composition	O
,	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound	O
.	O

The	O
lipid	O
pharmaceutical	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
pH	O
sensitivity	O
and	O
optional	O
targeting	O
property	O
,	O
and	O
can	O
be	O
used	O
for	O
increasing	O
the	O
concentration	O
of	O
an	O
antitumour	O
medicament	O
at	O
a	O
target	O
part	O
and	O
also	O
reducing	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
antitumour	O
medicament	O
at	O
a	O
non	O
-	O
target	O
part	O
when	O
being	O
taken	O
as	O
a	O
liposome	O
,	O
thus	O
improving	O
therapeutic	O
index	O
of	O
the	O
antitumour	O
medicament	O
.	O

Combined	O
treatment	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
and	O
pharmaceutical	O
composition	O
The	O
invention	O
discloses	O
a	O
new	O
pharmaceutical	O
composition	O
for	O
treating	O
osteoporosis	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
greatly	O
improve	O
the	O
efficacy	O
of	O
osteoporosis	O
treatment	O
,	O
and	O
reduce	O
the	O
health	O
risks	O
and	O
side	O
effects	O
associated	O
with	O
taking	O
of	O
commonly	O
used	O
drugs	O
(	O
parathyroid	B
hormone	I
,	O
thyroid	O
hormone	O
,	O
estrogen	O
,	O
and	O
calcium	O
supplements	O
)	O
for	O
treating	O
osteoporosis	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
combined	O
treatment	O
method	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
.	O

The	O
method	O
includes	O
a	O
step	O
of	O
applying	O
an	O
effective	O
dose	O
of	O
to	O
the	O
new	O
pharmaceutical	O
composition	O
treating	O
osteoporosis	O
to	O
an	O
object	O
so	O
as	O
to	O
treat	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
of	O
the	O
object	O
.	O

Acer	O
truncatum	O
health	O
-	O
care	O
lozenge	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
lozenge	O
prepared	O
by	O
taking	O
an	O
acer	O
truncatum	O
extract	O
as	O
a	O
major	O
raw	O
material	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
health	O
-	O
care	O
lozenge	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
20	O
-	O
40	O
percent	O
of	O
an	O
acer	O
truncatum	O
extract	O
,	O
15	O
-	O
25	O
percent	O
of	O
an	O
acer	O
truncatum	O
seed	O
extract	O
,	O
30	O
-	O
64	O
percent	O
of	O
a	O
seasoning	O
agent	O
and	O
1	O
-	O
5	O
percent	O
of	O
a	O
nutrition	O
fortifier	O
.	O

A	O
tablet	O
is	O
prepared	O
by	O
performing	O
deep	O
processing	O
on	O
terrestrial	O
plant	O
acer	O
truncatum	O
seeds	O
which	O
are	O
rich	O
in	O
nervonic	O
acid	O
and	O
terrestrial	O
plant	O
acer	O
truncatum	O
leaves	O
which	O
are	O
rich	O
in	O
flavone	O
,	O
and	O
has	O
the	O
effects	O
of	O
preventing	O
nerve	O
fiber	O
atrophy	O
,	O
promoting	O
brain	O
development	O
,	O
delaying	O
ageing	O
and	O
enhancing	O
the	O
immunity	O
and	O
digestive	O
function	O
of	O
a	O
human	O
body	O
;	O
and	O
over	O
-	O
high	O
blood	O
fat	O
concentration	O
in	O
blood	O
can	O
be	O
lowered	O
remarkably	O
,	O
and	O
the	O
occurrence	O
probability	O
of	O
diseases	O
such	O
as	O
certain	O
hypertension	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
blood	O
circulation	O
disorder	O
,	O
and	O
the	O
like	O
is	O
lowered	O
.	O

Sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
,	O
relating	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
sinomenine	O
4-OH	O
etherification	O
and	O
esterification	O
derivatives	O
.	O

An	O
ICR	O
(	O
Institute	O
of	O
Cancer	O
Research	O
)	O
mouse	O
model	O
and	O
an	O
SD	O
(	O
sprague	O
dawley	O
)	O
rat	O
model	O
are	O
applied	O
to	O
test	O
the	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
293	O
cells	O
of	O
pNF	O
-	O
kB	O
-	O
luc	O
are	O
transfected	O
to	O
test	O
the	O
inhibition	O
of	O
the	O
compounds	O
to	O
an	O
NF	O
-	O
kB	O
signaling	O
channel	O
,	O
and	O
results	O
show	O
that	O
part	O
of	O
the	O
compounds	O
have	O
significant	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
and	O
effects	O
on	O
inhibition	O
of	O
NF	O
-	O
kB.	O
The	O
derivatives	O
can	O
be	O
applied	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
and	O
immune	O
medicine	O
.	O

Active	O
bacteriostasis	O
capsule	O
The	O
invention	O
relates	O
to	O
an	O
active	O
bacteriostasis	O
capsule	O
,	O
comprising	O
the	O
following	O
ingredients	O
,	O
by	O
weight	O
,	O
lactobacillus	O
20	O
-	O
50	O
%	O
,	O
bifidobacterium	O
20	O
-	O
30	O
%	O
,	O
lactococcus	O
15	O
-	O
30	O
%	O
and	O
oliho	O
chitosan	O
15	O
-	O
30	O
%	O
.	O

The	O
Active	O
bacteriostasis	O
capsule	O
provided	O
in	O
the	O
invention	O
adopts	O
a	O
micro	O
ecological	O
theory	O
of	O
using	O
bacterium	O
to	O
kill	O
bacterium	O
and	O
inter	O
-	O
restriction	O
between	O
organisms	O
.	O

Large	O
amount	O
of	O
beneficial	O
bacterium	O
to	O
restrain	O
harmful	O
bacterium	O
is	O
supplied	O
and	O
the	O
beneficial	O
bacterium	O
is	O
planted	O
on	O
the	O
inner	O
wall	O
of	O
reproductive	O
tract	O
,	O
forming	O
a	O
beneficial	O
bacteria	O
barrier	O
.	O

The	O
capsule	O
can	O
repair	O
and	O
activate	O
a	O
self	O
clean	O
function	O
of	O
female	O
,	O
thereby	O
a	O
healthy	O
reproduction	O
tract	O
environment	O
is	O
formed	O
.	O

The	O
capsule	O
can	O
be	O
used	O
to	O
treat	O
various	O
vaginal	O
disease	O
caused	O
by	O
flora	O
disturbance	O
and	O
dysbacteriosis	O
.	O

Antipyrotic	O
powder	O
for	O
external	O
use	O
The	O
invention	O
relates	O
to	O
an	O
antipyrotic	O
powder	O
for	O
external	O
use	O
.	O

The	O
antipyrotic	O
powder	O
is	O
characterized	O
by	O
comprising	O
phellodendron	O
,	O
radix	O
sophorae	O
flavescentis	O
,	O
borneol	O
,	O
scorpio	O
,	O
alum	O
and	O
Senecio	O
scandens	O
with	O
auxiliary	O
materials	O
including	O
tea	O
oil	O
and	O
pig	O
bile	O
.	O

A	O
preparation	O
method	O
of	O
the	O
antipyrotic	O
powder	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
weighing	O
the	O
above	O
various	O
raw	O
materials	O
according	O
to	O
a	O
weight	O
ratio	O
,	O
placing	O
into	O
a	O
pulverizer	O
,	O
stirring	O
and	O
crushing	O
,	O
sieving	O
through	O
a	O
sieve	O
of	O
6	O
meshes	O
to	O
obtain	O
a	O
yellow	O
powder	O
,	O
and	O
packing	O
by	O
the	O
use	O
of	O
aluminium	O
foil	O
with	O
5	O
g	O
per	O
pack	O
.	O

The	O
invention	O
has	O
the	O
following	O
significant	O
effects	O
:	O
drug	O
properties	O
are	O
mild	O
;	O
there	O
is	O
no	O
side	O
effect	O
;	O
the	O
treatment	O
cost	O
is	O
low	O
;	O
the	O
curative	O
effect	O
is	O
fast	O
with	O
no	O
ache	O
;	O
and	O
the	O
total	O
efficiency	O
is	O
about	O
more	O
than	O
90	O
%	O
.	O

Tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
The	O
invention	O
provides	O
a	O
novel	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Ethyl	O
cellulose	O
and	O
povidone	O
are	O
used	O
as	O
membrane	O
forming	O
materials	O
of	O
a	O
semipermeable	O
membrane	O
,	O
and	O
the	O
asymmetric	O
tablet	O
form	O
is	O
preferably	O
selected	O
,	O
so	O
that	O
the	O
ageing	O
of	O
the	O
semipermeable	O
membrane	O
can	O
be	O
avoided	O
,	O
and	O
the	O
drug	O
residues	O
can	O
be	O
reduced	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
improving	O
the	O
ageing	O
resistance	O
of	O
the	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
,	O
wherein	O
the	O
method	O
is	O
characterized	O
in	O
that	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
are	O
used	O
as	O
the	O
membrane	O
forming	O
materials	O
of	O
the	O
semipermeable	O
membrane	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
provides	O
applications	O
of	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
composition	O
in	O
preparing	O
the	O
anti	O
-	O
ageing	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Ester	O
derivative	O
of	O
high	O
veratryl	O
alcohol	O
and	O
medical	O
treatment	O
application	O
The	O
invention	O
discloses	O
an	O
ester	O
derivative	O
of	O
high	O
veratryl	O
alcohol	O
and	O
medical	O
treatment	O
application	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
.	O

A	O
compound	O
with	O
biological	O
activity	O
is	O
a	O
compound	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
shown	O
in	O
the	O
specification	O
,	O
and	O
salt	O
,	O
a	O
solvate	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
,	O
wherein	O
X1	O
is	O
H	O
or	O
COR1	O
,	O
X2	O
is	O
H	O
or	O
COR2	O
,	O
X3	O
is	O
H	O
or	O
COR3	O
,	O
but	O
X1	O
,	O
X2	O
and	O
X3	O
are	O
not	O
H	O
and	O
3-pyridyl	O
simultaneously	O
;	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
C1-C6	O
alkyl	O
substituted	O
by	O
R4	O
or	O
can	O
be	O
substituted	O
by	O
R9	O
at	O
random	O
and	O
can	O
contain	O
one	O
or	O
more	O
4	O
-	O
7-membered	O
rings	O
of	O
additional	O
heteroatom	O
of	O
O	O
,	O
S	O
(	O
O	O
)	O
n	O
and	O
NR9	O
;	O
R4	O
is	O
F	O
,	O
CF3	O
,	O
OR5	O
,	O
NR6R7	O
or	O
S	O
(	O
O	O
)	O
nR8	O
;	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
H	O
or	O
C1-C6	O
alkyl	O
substituted	O
by	O
R4	O
at	O
random	O
,	O
or	O
NR6R7	O
is	O
one	O
or	O
more	O
C4-C6	O
heterocycle	O
alkyl	O
rings	O
of	O
the	O
heteroatom	O
of	O
O	O
,	O
NR9	O
and	O
S	O
(	O
O	O
)	O
n	O
;	O
each	O
n	O
is	O
0	O
to	O
2	O
;	O
R8	O
is	O
C1-C6	O
alkyl	O
;	O
R9	O
is	O
C1-C4	O
alkyl	O
which	O
is	O
defined	O
by	O
R4	O
or	O
substituted	O
by	O
R4	O
or	O
halogens	O
at	O
random	O
;	O
and	O
R9	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
.	O

The	O
ester	O
derivative	O
has	O
the	O
effect	O
of	O
treating	O
liver	O
diseases	O
,	O
T	O
-	O
cell	O
proliferation	O
related	O
diseases	O
or	O
proinflammatory	O
cytokine	O
mediated	O
diseases	O
.	O

Gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
.	O

The	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
mass	O
:	O
100	O
parts	O
of	O
gemcitabine	O
hydrochloride	O
,	O
160	O
-	O
180	O
parts	O
of	O
lactose	O
and	O
3	O
-	O
6	O
parts	O
of	O
sodium	O
citrate	O
.	O

As	O
proved	O
by	O
influencing	O
factor	O
testing	O
investigation	O
,	O
each	O
detection	O
index	O
the	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
prepared	O
by	O
adopting	O
a	O
formula	O
and	O
a	O
process	O
provided	O
by	O
the	O
invention	O
does	O
not	O
change	O
remarkably	O
in	O
a	O
high	O
-	O
temperature	O
,	O
high	O
-	O
humidity	O
and	O
strong	O
-	O
light	O
-	O
irradiation	O
environment	O
,	O
and	O
high	O
stability	O
is	O
achieved	O
.	O

New	O
application	O
of	O
alpinetin	O
The	O
invention	O
discloses	O
new	O
application	O
of	O
alpinetin	O
.	O

The	O
new	O
application	O
means	O
that	O
the	O
alpinetin	O
serving	O
as	O
an	O
active	O
ingredient	O
is	O
used	O
for	O
preparing	O
medicaments	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
ulcerative	O
colitis	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
alpinetin	O
can	O
obviously	O
improve	O
the	O
symptoms	O
such	O
as	O
weight	O
loss	O
,	O
bloody	O
stool	O
,	O
colon	O
shortening	O
,	O
inflammatory	O
cell	O
infiltration	O
and	O
pathological	O
tissue	O
damage	O
of	O
ulcerative	O
colitis	O
mice	O
,	O
and	O
can	O
inhibit	O
the	O
expression	O
of	O
proinflammatory	O
factors	O
TNF	O
-	O
alpha	O
and	O
IL-6	O
.	O

Therefore	O
,	O
the	O
alpinetin	O
serving	O
as	O
the	O
active	O
ingredient	O
is	O
expected	O
to	O
be	O
developed	O
into	O
a	O
medicament	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
the	O
ulcerative	O
colitis	O
.	O

The	O
medicinal	O
value	O
of	O
the	O
alpinetin	O
can	O
be	O
fully	O
exerted	O
,	O
and	O
the	O
invention	O
has	O
significance	O
for	O
research	O
and	O
application	O
of	O
the	O
alpinetin	O
.	O

Mecobalamin	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
mecobalamin	O
tablet	O
which	O
has	O
very	O
low	O
content	O
of	O
related	O
substances	O
and	O
can	O
simultaneously	O
realize	O
rapid	O
disintegration	O
.	O

The	O
mecobalamin	O
tablet	O
is	O
prepared	O
by	O
mixing	O
mecobalamin	O
powder	O
with	O
a	O
coating	O
filling	O
agent	O
,	O
then	O
using	O
an	O
Opadry	O
coating	O
to	O
prepare	O
mecobalamin	O
coated	O
particles	O
under	O
the	O
conditions	O
of	O
protecting	O
from	O
light	O
,	O
further	O
adding	O
pharmaceutically	O
acceptable	O
tablet	O
excipients	O
,	O
and	O
tabletting	O
.	O

According	O
to	O
the	O
mecobalamin	O
tablet	O
provided	O
by	O
the	O
invention	O
,	O
the	O
process	O
flow	O
of	O
mecobalamin	O
which	O
is	O
very	O
sensitive	O
to	O
light	O
is	O
improved	O
from	O
the	O
way	O
of	O
firstly	O
tabletting	O
and	O
then	O
coating	O
to	O
the	O
way	O
of	O
firstly	O
coating	O
and	O
then	O
tabletting	O
..	O

Through	O
an	O
advanced	O
powder	O
coating	O
technology	O
,	O
the	O
treatment	O
of	O
protecting	O
from	O
the	O
light	O
is	O
performed	O
on	O
the	O
mecobalamin	O
in	O
the	O
first	O
process	O
step	O
to	O
complete	O
the	O
protection	O
of	O
the	O
mecobalamin	O
so	O
as	O
to	O
enable	O
the	O
follow	O
-	O
up	O
process	O
steps	O
to	O
get	O
rid	O
of	O
the	O
influence	O
of	O
a	O
light	O
source	O
on	O
the	O
mecobalamin	O
,	O
the	O
means	O
of	O
controlling	O
the	O
related	O
substances	O
is	O
better	O
than	O
the	O
traditional	O
full	O
-	O
process	O
operation	O
of	O
protecting	O
from	O
the	O
light	O
,	O
the	O
coating	O
time	O
is	O
saved	O
,	O
and	O
the	O
efficiency	O
is	O
improved	O
.	O

Application	O
of	O
baicalin	O
to	O
preparation	O
of	O
medicament	O
for	O
treating	O
pneumonia	O
The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
baicalin	O
to	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
pneumonia	O
.	O

A	O
rabbit	O
erythrocyte	O
hemolysis	O
test	O
,	O
a	O
human	O
pulmonary	O
epithelial	O
cell	O
(	O
A549	O
)	O
injury	O
protection	O
test	O
and	O
a	O
mouse	O
Staphylococcus	O
aureus	O
pneumonia	O
model	O
are	O
employed	O
to	O
confirm	O
the	O
treatment	O
effect	O
of	O
the	O
baicalin	O
.	O

Compared	O
with	O
an	O
antibiotic	O
therapy	O
,	O
the	O
use	O
of	O
baicalin	O
has	O
characteristics	O
of	O
no	O
drug	O
resistance	O
and	O
high	O
cure	O
rate	O
.	O

1-substituted-1H-1,2,4-triazole	O
-	O
formamide	O
derivatives	O
,	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
1-substituted-1H-1,2,4-triazole	O
-	O
formamide	O
derivatives	O
.	O

The	O
substitution	O
position	O
of	O
formamido	O
is	O
in	O
5-	O
or	O
3-	O
position	O
of	O
1H-1,2,4-triazole	O
,	O
rufinamide	O
is	O
a	O
lead	O
compound	O
,	O
the	O
parent	O
nucleus	O
1,2,3-triazole	O
is	O
replaced	O
by	O
1,2,4-triazole	O
,	O
the	O
structure	O
of	O
the	O
side	O
chain	O
formamide	O
is	O
maintained	O
,	O
different	O
substituted	O
aromatic	O
(	O
heterocyclic	O
)	O
rings	O
replace	O
2,6-difluorobenzene	O
structure	O
,	O
the	O
type	O
,	O
number	O
or	O
position	O
of	O
the	O
substituent	O
group	O
on	O
a	O
benzene	O
ring	O
is	O
changed	O
to	O
obtain	O
a	O
series	O
of	O
1-substituted-1H-1,2,4-triazole-5-formamide	O
/	O
1-substituted-1H-1,2,4-triazole-3-formamide	O
derivatives	O
.	O

Pharmaceutical	O
activity	O
screening	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
good	O
anticonvulsant	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
anticonvulsant	O
medicaments	O
.	O

The	O
preparation	O
method	O
has	O
reasonable	O
design	O
,	O
simple	O
steps	O
and	O
practicality	O
;	O
and	O
the	O
derivatives	O
have	O
the	O
structural	O
general	O
formula	O
in	O
the	O
specification	O
.	O

Use	O
of	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
The	O
invention	O
discloses	O
a	O
use	O
of	O
a	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
.	O

The	O
compound	O
is	O
N'-	O
{	O
5-	O
[	O
acetyl	O
(	O
hydroxyl	O
)	O
amido	O
]	O
pentyl	O
}	O
-N-	O
[	O
5-	O
(	O
{	O
4-	O
[	O
(	O
5-aminopentyl	O
)	O
(	O
hydroxyl	O
)	O
amido	O
]	O
-4-keto	O
-	O
butyryl	O
}	O
amido	O
)	O
pentyl	O
]	O
-N	O
-	O
hydroxysuccinic	O
acid	O
amide	O
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
preventing	O
and	O
treating	O
senile	O
dementia	O
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
penetrate	O
a	O
blood	O
brain	O
barrier	O
and	O
then	O
bind	O
with	O
a	O
heavy	O
metal	O
to	O
form	O
a	O
chelate	O
thereby	O
inhibiting	O
production	O
of	O
amyloid	B
in	O
the	O
brain	O
,	O
preventing	O
polymerization	O
and	O
accumulation	O
of	O
amyloid	B
,	O
dissolving	O
produced	O
amyloid	B
plaques	O
and	O
promoting	O
amyloid	B
degradation	O
.	O

Novel	O
pyridine	O
alkaloids	O
,	O
preparation	O
process	O
thereof	O
,	O
and	O
the	O
uses	O
of	O
the	O
pyridine	O
alkaloids	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
pyridine	O
alkaloid	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
as	O
described	O
in	O
the	O
specification	O
,	O
the	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
the	O
composition	O
comprising	O
the	O
same	O
.	O

The	O
uses	O
of	O
a	O
pyridine	O
compound	O
for	O
increasing	O
the	O
activity	O
of	O
PPAR	B
[	I
gamma	I
]	I
,	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B
resistance	O
,	O
and	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
metabolic	O
syndrome	O
or	O
its	O
complication	O
are	O
also	O
provided	O
.	O

The	O
invention	O
also	O
provides	O
extracts	O
of	O
red	O
yeast	O
-	O
fermented	O
products	O
and	O
their	O
uses	O
for	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B
resistance	O
,	O
such	O
as	O
metabolic	O
syndrome	O
.	O

Granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
granulation	O
promoting	O
powder	O
comprises	O
the	O
following	O
components	O
:	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	O
,	O
15	O
g	O
of	O
borneol	O
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	O
-	O
salt	O
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
grinding	O
the	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	O
,	O
15	O
g	O
of	O
borneol	O
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	O
-	O
salt	O
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
into	O
powder	O
;	O
uniformly	O
mixing	O
;	O
and	O
sub	O
-	O
packing	O
the	O
mixed	O
powder	O
.	O

Through	O
the	O
invention	O
,	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
to	O
the	O
lesion	O
to	O
completely	O
exert	O
the	O
efficacy	O
,	O
the	O
local	O
symptoms	O
of	O
red	O
,	O
swelling	O
,	O
itch	O
,	O
pain	O
and	O
the	O
like	O
can	O
be	O
relieved	O
,	O
the	O
exudation	O
and	O
incrustation	O
are	O
reduced	O
,	O
and	O
infection	O
is	O
eliminated	O
to	O
prompt	O
the	O
inflammation	O
absorption	O
and	O
quick	O
healing	O
of	O
wound	O
.	O

Dual	O
component	O
oral	O
care	O
product	O
A	O
pull	O
-	O
apart	O
fragrance	O
sampler	O
laminate	O
is	O
constructed	O
by	O
dispersing	O
microcapsules	O
containing	O
fragrance	O
oil	O
into	O
a	O
quick	O
setting	O
adhesive	O
.	O

The	O
resulting	O
dispersion	O
is	O
applied	O
to	O
a	O
surface	O
of	O
a	O
substrate	O
and	O
then	O
covered	O
with	O
an	O
overlayer	O
.	O

The	O
substrate	O
and	O
overlayer	O
adhere	O
to	O
the	O
dispersion	O
until	O
they	O
are	O
pulled	O
apart	O
whereby	O
the	O
microcapsules	O
are	O
fractured	O
,	O
releasing	O
the	O
fragrance	O
.	O

The	O
substrate	O
may	O
be	O
a	O
continuous	O
web	O
of	O
two	O
-	O
layer	O
stock	O
having	O
a	O
silicone	O
coated	O
liner	O
and	O
a	O
release	O
layer	O
on	O
which	O
the	O
dispersion	O
is	O
coated	O
for	O
making	O
fragrance	O
samplers	O
in	O
the	O
form	O
of	O
die	O
cut	O
labels	O
.	O

The	O
dispersion	O
may	O
be	O
applied	O
to	O
the	O
substrate	O
by	O
a	O
relief	O
printing	O
plate	O
at	O
a	O
station	O
of	O
a	O
printing	O
press	O
through	O
which	O
the	O
substrate	O
and	O
cover	O
layer	O
are	O
transported	O
.	O

Suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
immune	O
system	O
The	O
invention	O
aims	O
to	O
provide	O
a	O
suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
an	O
immune	O
system	O
.	O

The	O
therapy	O
is	O
composed	O
of	O
curcumin	O
,	O
CNB-001	O
and	O
ornithine	O
and	O
is	O
characterized	O
by	O
the	O
utilization	O
of	O
a	O
suction	O
method	O
.	O

Active	O
ingredients	O
in	O
the	O
therapy	O
pass	O
through	O
a	O
respiratory	O
system	O
and	O
directly	O
penetrate	O
through	O
blood	O
cerebral	O
barrier	O
so	O
as	O
to	O
rapidly	O
reach	O
curative	O
effects	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
ecdysone	O
-	O
rich	O
plant	O
standardized	O
extract	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
an	O
ecdysone	O
-	O
rich	O
plant	O
standardized	O
extract	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
extracting	O
ecdysone	O
-	O
rich	O
plant	O
materials	O
using	O
ethanol	O
under	O
reflux	O
,	O
filtering	O
,	O
concentrating	O
and	O
centrifuing	O
;	O
decolorizing	O
the	O
centrifuged	O
supernatant	O
,	O
purifying	O
by	O
macroporous	O
resin	O
column	O
chromatography	O
,	O
concentrating	O
and	O
drying	O
to	O
obtain	O
the	O
standardized	O
extract	O
.	O

The	O
method	O
is	O
simple	O
and	O
feasible	O
,	O
short	O
in	O
production	O
period	O
,	O
and	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
is	O
easy	O
for	O
preparation	O
and	O
industrial	O
production	O
in	O
a	O
standardized	O
and	O
batch	O
manner	O
;	O
and	O
the	O
similarity	O
of	O
the	O
extract	O
obtained	O
by	O
the	O
method	O
is	O
more	O
than	O
99	O
%	O
by	O
HPLC	O
(	O
high	O
performance	O
liquid	O
chromatography	O
)	O
fingerprint	O
spectrum	O
detection	O
.	O

The	O
extract	O
can	O
be	O
applied	O
in	O
preparing	O
fixed	O
preparations	O
serving	O
as	O
drugs	O
for	O
reducing	O
blood	O
sugar	O
and	O
resisting	O
rheumatoid	O
arthritis	O
,	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
natural	O
cosmetics	O
and	O
can	O
be	O
applied	O
in	O
animal	O
breeding	O
industry	O
.	O

Application	O
of	O
isobavachalcone	O
in	O
treating	O
nerve	O
inflammatory	O
diseases	O
The	O
invention	O
relates	O
to	O
application	O
of	O
isobavachalcone	O
displayed	O
in	O
formula	O
I	O
in	O
treating	O
microglial	O
cell	O
mediated	O
diseases	O
,	O
in	O
particular	O
to	O
application	O
of	O
isobavachalcone	O
in	O
preparing	O
medicines	O
for	O
treating	O
and/or	O
preventing	O
microglial	O
cell	O
mediated	O
diseases	O
especially	O
microglial	O
cell	O
mediated	O
neural	O
immune	O
inflammatory	O
diseases	O
caused	O
by	O
neurotoxic	O
effect	O
.	O

The	O
isobavachalcone	O
has	O
new	O
functions	O
of	O
being	O
capable	O
of	O
obviously	O
restraining	O
microglial	O
cellsfrom	O
activating	O
or	O
inducing	O
cells	O
to	O
die	O
,	O
restraining	O
generation	O
and	O
expression	O
of	O
inflammatory	O
media	O
NO	O
of	O
activated	O
microglial	O
cells	O
and	O
obviously	O
relieving	O
cytotoxicity	O
of	O
activated	O
microglial	O
cells	O
to	O
neurons	O
.	O

Therefore	O
,	O
isobavachalcone	O
can	O
be	O
applied	O
to	O
preventive	O
treatment	O
of	O
diseases	O
related	O
to	O
brain	O
immune	O
inflammatory	O
diseases	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O
The	O
invention	O
discloses	O
application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O
.	O

The	O
NSC23766	O
is	O
used	O
for	O
treating	O
cocaine	O
induction	O
behaviouristics	O
plasticity	O
changes	O
,	O
and	O
the	O
NSC23766	O
is	O
proved	O
to	O
be	O
capable	O
of	O
effectively	O
restraining	O
behaviouristics	O
sensitization	O
action	O
and	O
conditioned	O
place	O
preference	O
induced	O
by	O
cocaine	O
,	O
the	O
NSC23766	O
is	O
basically	O
free	O
of	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
the	O
medicine	O
has	O
developing	O
prospects	O
and	O
can	O
treat	O
the	O
mental	O
excitation	O
drug	O
addiction	O
,	O
in	O
particular	O
to	O
cocaine	O
addiction	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
a	O
preparation	O
method	O
,	O
and	O
an	O
application	O
of	O
the	O
medicines	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
takes	O
a	O
mixture	O
of	O
at	O
least	O
one	O
or	O
more	O
of	O
Praeruptorin	O
A	O
,	O
Pb	O
-	O
Ia	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
Praeruptorin	O
B	O
,	O
Pb	O
-	O
Ia	O
II	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
and	O
Praeruptorin	O
C	O
according	O
to	O
certain	O
proportion	O
as	O
an	O
active	O
component	O
,	O
and	O
is	O
composed	O
of	O
the	O
mixture	O
and	O
a	O
conventional	O
drug	O
carrier	O
.	O

The	O
weight	O
percentage	O
content	O
of	O
the	O
active	O
component	O
is	O
0.1	O
-	O
99.5	O
%	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
used	O
for	O
preparing	O
and	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
that	O
the	O
source	O
of	O
the	O
raw	O
materials	O
is	O
abundant	O
,	O
the	O
pharmaceutical	O
composition	O
has	O
substantial	O
prevention	O
and	O
treatment	O
effects	O
for	O
diabetes	O
associated	O
with	O
hyperlipemia	O
,	O
the	O
usage	O
is	O
convenient	O
,	O
and	O
provides	O
a	O
novel	O
treatment	O
candidate	O
medicine	O
for	O
patients	O
.	O

Veterinary	O
compound	O
florfenicol	O
injection	O
The	O
invention	O
aims	O
to	O
provide	O
a	O
veterinary	O
compound	O
florfenicol	O
injection	O
,	O
which	O
is	O
used	O
for	O
efficiently	O
treating	O
porcine	O
respiratory	O
disease	O
complex	O
and	O
porcine	O
digestive	O
tract	O
disease	O
.	O

Each	O
100ml	O
of	O
veterinary	O
compound	O
florfenicol	O
injection	O
contains	O
10	O
-	O
30	O
g	O
of	O
florfenicol	O
,	O
1	O
-	O
5	O
g	O
of	O
andrographolide	O
,	O
1	O
-	O
3	O
g	O
of	O
TMP	O
(	O
Trimethoprim	O
)	O
,	O
0.1	O
-	O
0.2	O
g	O
of	O
antioxygen	O
,	O
0.01	O
-	O
0.02	O
g	O
of	O
ethylenediaminetetraacetic	O
acid	O
disodium	O
,	O
and	O
the	O
balance	O
of	O
solvent	O
for	O
injection	O
.	O

The	O
veterinary	O
compound	O
florfenicol	O
injection	O
is	O
a	O
composition	O
of	O
the	O
florfenicol	O
,	O
the	O
andrographolide	O
and	O
the	O
TMP	O
which	O
have	O
significant	O
effects	O
on	O
the	O
porcine	O
respiratory	O
disease	O
complex	O
,	O
and	O
is	O
administrated	O
through	O
an	O
injection	O
way	O
,	O
the	O
dosage	O
is	O
accurate	O
,	O
the	O
absorption	O
is	O
quick	O
,	O
the	O
blood	O
concentration	O
is	O
high	O
,	O
the	O
distribution	O
is	O
wide	O
,	O
the	O
half	O
-	O
life	O
period	O
is	O
long	O
,	O
the	O
effective	O
concentration	O
maintenance	O
time	O
is	O
long	O
,	O
and	O
compared	O
with	O
the	O
pesticide	O
effect	O
of	O
the	O
existing	O
florfenicol	O
injection	O
and	O
the	O
herba	O
andrographitis	O
injection	O
,	O
the	O
pesticide	O
effect	O
of	O
the	O
veterinary	O
compound	O
florfenicol	O
injection	O
is	O
obviously	O
enhanced	O
.	O

Application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
The	O
invention	O
provides	O
application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
.	O

Experiments	O
prove	O
that	O
the	O
neovascularization	O
inhibiting	O
rate	O
,	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
concentration	O
of	O
the	O
polysaccharide	O
sulphate	O
are	O
in	O
dosage	O
relying	O
relationship	O
in	O
a	O
certain	O
range	O
,	O
and	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
polysaccharide	O
sulphate	O
acting	O
time	O
are	O
in	O
dosage	O
relying	O
relationship	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
effect	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
aspects	O
of	O
tumor	O
neovascularization	O
inhibiting	O
and	O
tumor	O
blood	O
vessel	O
generation	O
disrupting	O
can	O
be	O
proved	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
can	O
be	O
used	O
for	O
tumor	O
blood	O
vessel	O
generation	O
and	O
other	O
blood	O
vessel	O
generation	O
disease	O
treatment	O
,	O
and	O
can	O
also	O
be	O
used	O
in	O
aspects	O
of	O
tumor	O
chemotherapy	O
and/or	O
auxiliary	O
chemotherapy	O
.	O

Many	O
diseases	O
of	O
people	O
are	O
relevant	O
to	O
the	O
blood	O
vessel	O
generation	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
as	O
the	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
can	O
be	O
widely	O
applied	O
to	O
the	O
treatment	O
of	O
diseases	O
of	O
tumor	O
and	O
the	O
like	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
application	O
range	O
of	O
the	O
polysaccharide	O
sulphate	O
is	O
widened	O
,	O
and	O
the	O
scientific	O
basis	O
is	O
provided	O
for	O
the	O
purpose	O
development	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
anti	O
-	O
tumor	O
aspect	O
and	O
the	O
like	O
.	O

Vinflunine	O
liposome	O
preparation	O
and	O
preparation	O
method	O
of	O
vinflunine	O
liposome	O
preparation	O
The	O
invention	O
relates	O
to	O
a	O
vinflunine	O
liposome	O
preparation	O
and	O
the	O
preparation	O
method	O
thereof	O
.	O

The	O
vinflunine	O
liposome	O
preparation	O
mainly	O
comprises	O
vinflunine	O
or	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	O
and	O
polyethylene	O
glycol	O
-	O
distearoyl	O
phosphatidyl	O
ethanolamine	O
of	O
the	O
vinflunine	O
,	O
wherein	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	O
and	O
polyethylene	O
glycol	O
-	O
distearoyl	O
phosphatidyl	O
ethanolamine	O
are	O
pharmaceutically	O
acceptable	O
,	O
and	O
the	O
vinflunine	O
liposome	O
preparation	O
can	O
be	O
prepared	O
into	O
an	O
injection	O
or	O
a	O
lyophilized	O
preparation	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
in	O
technology	O
,	O
easy	O
to	O
operate	O
and	O
suitable	O
for	O
industrial	O
production	O
,	O
and	O
long	O
-	O
circulating	O
vinflunine	O
liposomes	O
prepared	O
by	O
using	O
the	O
method	O
are	O
high	O
in	O
encapsulation	O
rate	O
and	O
good	O
in	O
stability	O
.	O

Iloperidone	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
an	O
iloperidone	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
the	O
iloperidone	O
composition	O
,	O
iloperidone	O
which	O
is	O
taken	O
as	O
an	O
active	O
ingredient	O
is	O
pretreated	O
,	O
so	O
that	O
the	O
particle	O
size	O
of	O
the	O
iloperidone	O
is	O
minimized	O
;	O
and	O
therefore	O
,	O
the	O
dissolution	O
rate	O
of	O
the	O
iloperidone	O
is	O
effectively	O
increased	O
.	O

Stable	O
Formulations	O
For	O
Lyophilizing	O
Therapeutic	O
Particles	O
The	O
present	O
disclosure	O
generally	O
relates	O
to	O
lyophilized	O
pharmaceutical	O
compositions	O
comprising	O
polymeric	O
nanoparticles	O
which	O
,	O
upon	O
reconstitution	O
,	O
have	O
low	O
levels	O
of	O
greater	O
than	O
10	O
micron	O
size	O
particles	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
include	O
methods	O
of	O
making	O
such	O
nanoparticles	O
.	O

Compound	O
neomycin	O
sulfate	O
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
preparation	O
method	O
of	O
compound	O
neomycin	O
sulfate	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
neomycin	O
sulfate	O
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
neomycin	O
sulfate	O
composition	O
.	O

The	O
composition	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
the	O
following	O
components	O
by	O
weight	O
:	O
1	O
-	O
3	O
parts	O
of	O
neomycin	O
sulfate	O
,	O
3	O
-	O
5	O
parts	O
of	O
erythromycin	O
thiocyanate	O
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	O
lactate	O
,	O
1	O
-	O
3	O
parts	O
of	O
cetrimonium	O
bromide	O
,	O
3	O
-	O
5	O
parts	O
of	O
piperitol	O
,	O
50	O
-	O
70	O
parts	O
of	O
liquid	O
paraffin	O
,	O
7	O
-	O
9	O
parts	O
of	O
glycerol	O
,	O
0.4	O
part	O
of	O
ethylparaben	O
,	O
1	O
-	O
3	O
parts	O
of	O
essence	O
,	O
80	O
-	O
113	O
parts	O
of	O
distilled	O
water	O
and	O
the	O
like	O
.	O

The	O
compound	O
neomycin	O
sulfate	O
composition	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
formula	O
is	O
reasonable	O
,	O
preparation	O
is	O
simple	O
,	O
curative	O
effects	O
are	O
very	O
remarkable	O
,	O
and	O
furthermore	O
,	O
clinical	O
application	O
show	O
that	O
the	O
compound	O
neomycin	O
sulfate	O
composition	O
has	O
special	O
effect	O
for	O
treating	O
pet	O
abscess	O
.	O

Application	O
of	O
dimethyldiguanide	O
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O
The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
dimethyldiguanide	O
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	O
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
radiotherapy	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	O
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
the	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
chemotherapeutics	O
.	O

Proved	O
by	O
the	O
invention	O
,	O
the	O
dimethyldiguanide	O
has	O
a	O
certain	O
protective	O
effect	O
on	O
hematopoietic	O
immune	O
cell	O
injury	O
caused	O
by	O
irradiation	O
and/or	O
the	O
chemotherapeutics	O
.	O

Application	O
of	O
Houttuynoid	O
B	O
in	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	O
B	O
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

Houttuynoid	O
B	O
can	O
inhibit	O
tumor	O
cell	O
mobility	O
and	O
migration	O
ability	O
.	O

The	O
application	O
of	O
Houttuynoid	O
B	O
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
migration	O
inhibitory	O
activity	O
to	O
pulmonary	O
cells	O
.	O

Application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

In	O
vitro	O
MTT	O
(	O
Methyl	O
Thiazolyl	O
Tetrazolium	O
)	O
antineoplastic	O
activity	O
evaluation	O
finds	O
that	O
Houttuynoid	O
D	O
has	O
remarkable	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
nasopharyngeal	O
carcinoma	O
cell	O
lines	O
HNE1	O
,	O
HNE1	O
,	O
HONE	O
and	O
CNE1	O
,	O
so	O
that	O
Houttuynoid	O
A	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
inhibiting	O
nasopharyngeal	O
carcinoma	O
and	O
has	O
good	O
development	O
application	O
prospect	O
.	O

The	O
application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
inhibitory	O
activity	O
to	O
breast	O
caner	O
cells	O
as	O
the	O
skeleton	O
type	O
belongs	O
to	O
a	O
completely	O
novel	O
skeleton	O
type	O
.	O

Prulifloxacin	O
oral	O
solid	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
prulifloxacin	O
oral	O
solid	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
prulifloxacin	O
oral	O
solid	O
composition	O
is	O
prepared	O
from	O
130	O
to	O
135	O
parts	O
by	O
weight	O
of	O
prulifloxacin	O
,	O
10	O
to	O
30	O
parts	O
by	O
weight	O
of	O
starch	O
,	O
30	O
to	O
50	O
parts	O
by	O
weight	O
of	O
microcrystalline	O
cellulose	O
,	O
20	O
to	O
40	O
parts	O
by	O
weight	O
of	O
lactose	O
,	O
0.05	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
binders	O
,	O
2	O
to	O
15	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
disintegrants	O
and	O
0.5	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
lubricants	O
.	O

The	O
one	O
or	O
more	O
binders	O
are	O
selected	O
from	O
polyvinylpyrrolidone	O
,	O
lauryl	O
sodium	O
sulfate	O
and	O
polyethylene	O
glycol	O
mixed	O
aqueous	O
solutions	O
or	O
alcoholic	O
solutions	O
.	O

The	O
one	O
or	O
more	O
disintegrants	O
are	O
selected	O
from	O
carboxymethyl	O
starch	O
sodium	O
,	O
polyvinylpolypyrrolidone	O
and	O
hydroxy	O
propyl	O
cellulose	O
.	O

The	O
one	O
or	O
more	O
lubricants	O
are	O
selected	O
from	O
magnesium	O
stearate	O
,	O
calcium	O
stearate	O
and	O
aerosil	O
.	O

The	O
prulifloxacin	O
oral	O
solid	O
composition	O
can	O
be	O
processed	O
into	O
tablets	O
,	O
capsules	O
or	O
granules	O
,	O
has	O
good	O
stability	O
,	O
can	O
effectively	O
improve	O
a	O
dissolution	O
rate	O
,	O
solves	O
the	O
problem	O
that	O
the	O
existing	O
prulifloxacin	O
oral	O
solid	O
preparation	O
has	O
a	O
slow	O
dissolution	O
speed	O
,	O
and	O
improves	O
bioavailability	O
.	O

Cis	O
-	O
platinum	O
complex	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cis	O
-	O
platinum	O
complex	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Cis	O
-	O
platinum	O
and	O
a	O
polymer	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
used	O
as	O
raw	O
materials	O
for	O
preparing	O
the	O
cis	O
-	O
platinum	O
complex	O
,	O
wherein	O
a	O
polymer	O
molecule	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
contains	O
a	O
poly	O
(	O
L	O
-	O
glutamic	O
acid	O
-	O
co	O
-	O
L	O
-	O
lysine	O
)	O
segment	O
,	O
so	O
that	O
the	O
prepared	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
biocompatibility	O
and	O
is	O
degradable	O
;	O
meanwhile	O
,	O
the	O
poly	O
(	O
L	O
-	O
glutamic	O
acid	O
-	O
co	O
-	O
L	O
-	O
lysine	O
)	O
segment	O
can	O
further	O
prevent	O
the	O
cis	O
-	O
platinum	O
complex	O
from	O
being	O
influenced	O
by	O
a	O
blood	O
circulation	O
system	O
in	O
an	O
aqueous	O
medium	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
stability	O
;	O
and	O
the	O
terminal	O
of	O
the	O
branched	O
chain	O
of	O
the	O
cis	O
-	O
platinum	O
complex	O
provided	O
by	O
the	O
invention	O
contains	O
an	O
amino	O
group	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
solubility	O
.	O

In	O
addition	O
,	O
the	O
prepared	O
cis	O
-	O
platinum	O
complex	O
contains	O
a	O
carboxy	O
group	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
pH	O
value	O
sensitivity	O
,	O
the	O
carboxy	O
group	O
tends	O
to	O
deprotonation	O
in	O
the	O
environment	O
with	O
a	O
lower	O
pH	O
value	O
so	O
as	O
to	O
be	O
beneficial	O
to	O
promoting	O
the	O
drug	O
release	O
and	O
improve	O
the	O
efficacy	O
of	O
drugs	O
.	O

Meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
The	O
invention	O
discloses	O
a	O
meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
.	O

The	O
meloxicam	O
injection	O
is	O
a	O
meloxicam	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
and	O
the	O
administration	O
route	O
is	O
intramuscular	O
injection	O
.	O

The	O
meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
has	O
the	O
effect	O
of	O
dispelling	O
wind	O
and	O
eliminating	O
dampness	O
,	O
tonifying	O
kidney	O
and	O
repelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
to	O
remove	O
meridian	O
obstruction	O
and	O
strengthening	O
tendons	O
and	O
bones	O
,	O
and	O
achieves	O
remarkable	O
effect	O
in	O
treating	O
chronic	O
infectious	O
arthritis	O
.	O

L	O
-	O
carnitine	O
calcium	O
citrate	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
new	O
pharmaceutically	O
acceptable	O
salt	O
of	O
L	O
-	O
carnitine	O
,	O
namely	O
L	O
-	O
carnitine	O
calcium	O
citrate	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
salt	O
.	O

L	O
-	O
carnitine	O
calcium	O
citrate	O
not	O
only	O
has	O
the	O
characteristics	O
of	O
high	O
stability	O
and	O
difficult	O
moisture	O
absorption	O
as	O
compared	O
with	O
L	O
-	O
carnitine	O
inner	O
salt	O
,	O
but	O
also	O
is	O
easier	O
to	O
accept	O
by	O
human	O
bodies	O
and	O
easier	O
to	O
participate	O
in	O
physiologic	O
metabolism	O
of	O
the	O
human	O
bodies	O
as	O
compared	O
with	O
the	O
existing	O
pharmaceutically	O
acceptable	O
salts	O
of	O
L	O
-	O
carnitine	O
,	O
and	O
has	O
stronger	O
nutrition	O
and	O
treatment	O
effects	O
.	O

The	O
invention	O
also	O
provides	O
application	O
of	O
L	O
-	O
carnitine	O
calcium	O
citrate	O
to	O
preparing	O
a	O
slimming	O
medicament	O
or	O
health	O
food	O
,	O
application	O
to	O
preparing	O
a	O
diet	O
/	O
nutritional	O
supplement	O
,	O
and	O
application	O
to	O
preparing	O
veterinarian	O
products	O
or	O
feed	O
.	O

Venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
comprises	O
a	O
blank	O
pellet	O
core	O
,	O
a	O
venlafaxine	O
hydrochloride	O
-	O
containing	O
layer	O
and	O
a	O
controlled	O
-	O
release	O
film	O
,	O
wherein	O
the	O
venlafaxine	O
hydrochloride	O
-	O
containing	O
layer	O
comprises	O
active	O
components	O
including	O
venlafaxine	O
hydrochloride	O
and	O
talcum	O
powder	O
which	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
12:1	O
-	O
8:1	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
venlafaxine	O
hydrochloride	O
to	O
the	O
blank	O
pellet	O
core	O
is	O
4:10	O
-	O
8:10	O
.	O

The	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
is	O
prepared	O
by	O
adopting	O
a	O
fluidized	O
bed	O
bottom	O
-	O
spraying	O
venlafaxine	O
hydrochloride	O
applying	O
mode	O
;	O
by	O
using	O
75	O
percent	O
alcohol	O
as	O
a	O
solvent	O
,	O
the	O
viscosity	O
of	O
the	O
venlafaxine	O
hydrochloride	O
in	O
a	O
water	O
solution	O
is	O
remarkably	O
lowered	O
,	O
the	O
venlafaxine	O
hydrochloride	O
applying	O
speed	O
is	O
increased	O
;	O
and	O
the	O
prepared	O
venlafaxine	O
hydrochloride	O
containing	O
pellet	O
adopts	O
a	O
bottom	O
-	O
spraying	O
coating	O
process	O
,	O
thus	O
the	O
problem	O
of	O
static	O
electricity	O
generated	O
because	O
of	O
the	O
adoption	O
of	O
the	O
pure	O
organic	O
solvent	O
is	O
overcome	O
;	O
the	O
application	O
process	O
and	O
the	O
wrapping	O
process	O
can	O
be	O
continuously	O
operated	O
in	O
the	O
same	O
device	O
,	O
thus	O
the	O
production	O
efficiency	O
is	O
increased	O
and	O
the	O
production	O
cost	O
is	O
lowered	O
;	O
and	O
no	O
toxic	O
organic	O
solvent	O
is	O
adopted	O
in	O
the	O
whole	O
process	O
,	O
thus	O
the	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
is	O
environmental	O
-	O
friendly	O
and	O
is	O
good	O
in	O
stability	O
,	O
and	O
almost	O
no	O
broken	O
pellets	O
or	O
dust	O
is	O
produced	O
.	O

Preparation	O
of	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
The	O
invention	O
provides	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
which	O
is	O
a	O
new	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C40H69O9	O
.	O

The	O
molecular	O
weight	O
of	O
the	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
is	O
692	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
the	O
compound	O
.	O

The	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
can	O
resist	O
to	O
physiological	O
activity	O
of	O
diabetes	O
mellitus	O
and	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
diabetes	O
mellitus	O
and	O
conducting	O
assistant	O
treating	O
the	O
diabetes	O
mellitus	O
.	O

Compound	O
elvucitabine	O
medicine	O
composition	O
as	O
well	O
as	O
preparation	O
method	O
and	O
use	O
for	O
same	O
The	O
invention	O
provides	O
a	O
compound	O
elvucitabine	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
comprises	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
,	O
entecavir	O
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
an	O
anti	O
-	O
acid	O
stabilizer	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
medicine	O
composition	O
,	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
mixing	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
the	O
anti	O
-	O
acid	O
stabilizer	O
,	O
then	O
mixing	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
one	O
or	O
more	O
adhesives	O
,	O
and	O
attaching	O
the	O
obtained	O
mixture	O
on	O
an	O
empty	O
carrier	O
to	O
prepare	O
a	O
medicated	O
carrier	O
;	O
and	O
(	O
2	O
)	O
mixing	O
the	O
medicated	O
carrier	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
with	O
entecavir	O
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
one	O
or	O
more	O
pharmaceutical	O
excipients	O
.	O

The	O
invention	O
further	O
provides	O
a	O
use	O
of	O
the	O
compound	O
elvucitabine	O
medicine	O
composition	O
for	O
preparing	O
a	O
medicine	O
for	O
treating	O
hepatitis	O
B	O
virus	O
.	O

Cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighting	O
raw	O
materials	O
;	O
(	O
2	O
)	O
adding	O
water	O
to	O
loquat	O
leaves	O
,	O
decocting	O
,	O
filtering	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
adding	O
ethanol	O
,	O
stirring	O
sufficiently	O
,	O
standing	O
and	O
taking	O
supernate	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
crushing	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
carrying	O
out	O
hot	O
reflux	O
extraction	O
on	O
the	O
crushed	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
together	O
with	O
platycodon	O
root	O
and	O
perilla	O
fruit	O
by	O
using	O
ethanol	O
,	O
filtering	O
,	O
mixing	O
the	O
obtained	O
filtrate	O
with	O
the	O
supernate	O
obtained	O
in	O
(	O
2	O
)	O
,	O
recovering	O
the	O
ethanol	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
cooling	O
to	O
room	O
temperature	O
,	O
adding	O
butanone	O
for	O
extraction	O
,	O
recovering	O
the	O
butanone	O
,	O
concentrating	O
to	O
obtain	O
thick	O
paste	O
,	O
and	O
drying	O
,	O
crushing	O
and	O
sieving	O
the	O
thick	O
paste	O
to	O
obtain	O
extractive	O
powder	O
;	O
and	O
(	O
4	O
)	O
adding	O
a	O
proper	O
amount	O
of	O
binding	O
agent	O
into	O
the	O
extractive	O
powder	O
,	O
a	O
filling	O
agent	O
,	O
hydroxypropyl	O
methylcellulose	O
and	O
a	O
release	O
rate	O
regulator	O
to	O
prepare	O
a	O
soft	O
material	O
,	O
granulating	O
,	O
drying	O
and	O
tabletting	O
.	O

The	O
sustained	O
release	O
tablet	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
effects	O
of	O
relieving	O
cough	O
,	O
eliminating	O
phlegm	O
and	O
relieving	O
asthma	O
,	O
and	O
the	O
sustained	O
release	O
tablet	O
prepared	O
from	O
the	O
raw	O
materials	O
extracted	O
by	O
using	O
an	O
extraction	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
low	O
in	O
drug	O
dose	O
,	O
high	O
in	O
content	O
,	O
convenient	O
to	O
take	O
and	O
carry	O
,	O
good	O
in	O
curative	O
effect	O
,	O
favorable	O
for	O
fixed	O
-	O
quantity	O
taking	O
,	O
and	O
beneficial	O
to	O
storage	O
and	O
transportation	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
supramolecular	O
inclusion	O
complex	O
thereof	O
with	O
adriamycin	O
The	O
invention	O
discloses	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
prepared	O
by	O
connecting	O
harmine	O
onto	O
cyclodextrin	O
with	O
ethylenediamine	O
as	O
a	O
connection	O
arm	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
supramolecular	O
inclusion	O
complex	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
adriamycin	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
further	O
discloses	O
the	O
evaluation	O
of	O
anti	O
-	O
tumor	O
activity	O
and	O
survival	O
rate	O
of	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
on	O
a	O
S180	O
mouse	O
model	O
.	O

As	O
a	O
result	O
of	O
in	O
-	O
vivo	O
experiment	O
,	O
with	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
,	O
adriamycin	O
toxicity	O
is	O
reduced	O
.	O

Especially	O
,	O
under	O
high	O
dosage	O
,	O
on	O
a	O
basis	O
that	O
anti	O
-	O
tumor	O
activity	O
equivalent	O
with	O
that	O
of	O
adriamycin	O
is	O
maintained	O
,	O
mouse	O
survival	O
rate	O
is	O
improved	O
.	O

The	O
invention	O
assists	O
in	O
providing	O
a	O
novel	O
approach	O
for	O
clinical	O
applications	O
of	O
the	O
anticancer	O
medicine	O
adriamycin	O
.	O

Health	O
-	O
care	O
foot	O
solution	O
The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
foot	O
solution	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
2	O
parts	O
of	O
ginger	O
,	O
6	O
-	O
8	O
parts	O
of	O
red	O
flower	O
,	O
2	O
-	O
5	O
parts	O
of	O
semen	O
armeniacae	O
amarae	O
,	O
3	O
-	O
8	O
parts	O
of	O
green	O
tea	O
,	O
2	O
-	O
3	O
parts	O
of	O
salt	O
and	O
the	O
balance	O
of	O
water	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
can	O
accelerate	O
leg	O
blood	O
circulation	O
,	O
so	O
that	O
venous	O
blood	O
in	O
the	O
legs	O
can	O
timely	O
flow	O
back	O
to	O
the	O
right	O
side	O
of	O
the	O
heart	O
,	O
and	O
the	O
health	O
-	O
care	O
foot	O
solution	O
contributes	O
to	O
lightening	O
venous	O
congestion	O
of	O
the	O
legs	O
and	O
preventing	O
varicose	O
vein	O
of	O
lower	O
limbs	O
and	O
contributes	O
to	O
soothing	O
the	O
nerves	O
and	O
removing	O
troubles	O
,	O
performing	O
hypnosis	O
and	O
falling	O
asleep	O
,	O
so	O
that	O
the	O
sleep	O
is	O
deep	O
and	O
sweet	O
.	O

Tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medical	O
engineering	O
and	O
provides	O
a	O
tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
mixture	O
is	O
formed	O
by	O
mixing	O
a	O
diphosphate	O
medicine	O
and	O
bone	O
cement	O
according	O
to	O
a	O
ratio	O
,	O
wherein	O
the	O
bone	O
cement	O
serves	O
as	O
a	O
controlled	O
release	O
carrier	O
of	O
the	O
diphosphate	O
medicine	O
,	O
so	O
that	O
a	O
topical	O
administration	O
system	O
is	O
formed	O
.	O

The	O
principle	O
is	O
that	O
the	O
bone	O
cement	O
serves	O
as	O
the	O
release	O
carrier	O
of	O
the	O
medicine	O
and	O
the	O
diphosphate	O
medicine	O
is	O
released	O
at	O
a	O
focus	O
,	O
so	O
that	O
the	O
aim	O
that	O
the	O
focus	O
is	O
positioned	O
in	O
a	O
long	O
-	O
term	O
high	O
-	O
concentration	O
medicine	O
environment	O
is	O
fulfilled	O
;	O
and	O
therefore	O
,	O
the	O
effects	O
of	O
suppressing	O
bone	O
destruction	O
and	O
preventing	O
bone	O
resorption	O
through	O
the	O
diphosphate	O
medicine	O
are	O
improved	O
,	O
and	O
the	O
function	O
of	O
repairing	O
the	O
bone	O
destruction	O
through	O
the	O
bone	O
cement	O
is	O
not	O
influenced	O
.	O

Bath	O
powder	O
for	O
treating	O
neurasthenia	O
The	O
invention	O
relates	O
to	O
bath	O
powder	O
for	O
treating	O
neurasthenia	O
.	O

The	O
bath	O
powder	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
mixing	O
50	O
parts	O
of	O
zizyphus	O
jujube	O
tree	O
roots	O
,	O
35	O
parts	O
of	O
salviae	O
miltiorrhizae	O
,	O
30	O
parts	O
of	O
longspur	O
epimedium	O
,	O
30	O
parts	O
of	O
lily	O
,	O
30	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
20	O
parts	O
of	O
coptidis	O
rhizome	O
,	O
30	O
parts	O
of	O
rhizoma	O
sparganii	O
,	O
30	O
parts	O
of	O
earthworm	O
,	O
50	O
parts	O
of	O
agilawood	O
,	O
25	O
parts	O
of	O
mint	O
,	O
30	O
parts	O
of	O
cortex	O
albiziae	O
,	O
20	O
parts	O
of	O
radix	O
curcumae	O
,	O
45	O
parts	O
of	O
mirabilite	O
,	O
20	O
parts	O
of	O
liquorice	O
and	O
20	O
parts	O
of	O
polygala	O
tenuifolia	O
together	O
;	O
performing	O
heating	O
drying	O
the	O
above	O
drugs	O
with	O
an	O
intake	O
air	O
temperature	O
of	O
180	O
-	O
290	O
DEG	O
C	O
and	O
outlet	O
air	O
temperature	O
of	O
80	O
-	O
90	O
DEG	O
C	O
;	O
grinding	O
the	O
above	O
drugs	O
into	O
powder	O
;	O
and	O
subpackaging	O
quantitatively	O
.	O

In	O
the	O
above	O
composition	O
,	O
the	O
composition	O
can	O
be	O
made	O
into	O
80	O
-	O
100	O
g	O
per	O
bag	O
if	O
being	O
weighed	O
in	O
grams	O
.	O

When	O
the	O
bath	O
powder	O
is	O
in	O
use	O
,	O
the	O
drug	O
formula	O
is	O
put	O
in	O
bath	O
water	O
with	O
stirring	O
.	O

The	O
water	O
consumption	O
of	O
the	O
bath	O
is	O
between	O
80	O
L	O
and	O
100	O
L	O
;	O
an	O
immersing	O
time	O
is	O
1	O
-	O
2	O
hours	O
every	O
day	O
;	O
and	O
10	O
days	O
is	O
a	O
course	O
of	O
treatment	O
.	O

Usually	O
,	O
neurasthenia	O
is	O
healed	O
after	O
three	O
to	O
five	O
courses	O
.	O

The	O
effective	O
rate	O
is	O
97	O
%	O
.	O

The	O
usage	O
amount	O
can	O
be	O
adjusted	O
according	O
to	O
conditions	O
of	O
patients	O
.	O

The	O
bath	O
powder	O
has	O
the	O
main	O
functions	O
for	O
treating	O
neurasthenia	O
,	O
intractable	O
insomnia	O
,	O
disturbed	O
consciousness	O
and	O
dysphoria	O
and	O
impatience	O
.	O

Expectorant	O
The	O
invention	O
discloses	O
an	O
expectorant	O
.	O

The	O
expectorant	O
comprises	O
the	O
following	O
active	O
pharmaceutical	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
2	O
-	O
4	O
parts	O
of	O
sapium	O
sebiferum	O
,	O
1	O
-	O
3	O
parts	O
of	O
rhizoma	O
curcumae	O
longae	O
,	O
3	O
-	O
8	O
parts	O
of	O
realgar	O
,	O
1	O
-	O
3	O
parts	O
of	O
agkistrodon	O
,	O
2	O
-	O
5	O
parts	O
of	O
bulbus	O
allii	O
macrostemonis	O
,	O
3	O
-	O
6	O
parts	O
of	O
common	O
achyranthes	O
herb	O
,	O
1	O
-	O
2	O
parts	O
of	O
squama	O
manis	O
,	O
4	O
-	O
9	O
parts	O
of	O
plantago	O
asiatica	O
L.	O
and	O
1	O
-	O
4	O
parts	O
of	O
fructus	O
rosae	O
laevigatae	O
.	O

The	O
expectorant	O
not	O
only	O
has	O
the	O
effects	O
of	O
drying	O
dampness	O
,	O
eliminating	O
phlegm	O
,	O
clearing	O
heat	O
,	O
relieving	O
exterior	O
syndrome	O
,	O
alleviating	O
water	O
retention	O
,	O
activating	O
blood	O
,	O
relieving	O
cough	O
and	O
preventing	O
asthma	O
,	O
but	O
also	O
can	O
activate	O
blood	O
to	O
remove	O
stasis	O
,	O
break	O
blood	O
to	O
promote	O
qi	O
circulation	O
,	O
induce	O
menstruation	O
to	O
relieve	O
menalgia	O
,	O
draw	O
out	O
poison	O
to	O
astringe	O
and	O
dispel	O
wind	O
and	O
dampness	O
.	O

Long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
a	O
preparation	O
process	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
comprises	O
,	O
by	O
weight	O
,	O
1.5	O
-	O
3.5	O
kg	O
of	O
ofloxacin	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
flunixin	O
meglumine	O
,	O
0.125	O
-	O
0.75	O
kg	O
of	O
metronidazole	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
leonurus	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
angelica	O
sinensis	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.25	O
-	O
1.25	O
kg	O
of	O
polyvinyl	O
pyrrolidone	O
(	O
PVP	O
)	O
-K30	O
,	O
2	O
-	O
15	O
kg	O
of	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
-400	O
,	O
0.03	O
kg	O
of	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
(	O
EDTA	O
)	O
-2Na	O
and	O
appropriate	O
water	O
for	O
injection	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
suitable	O
for	O
postpartum	O
health	O
care	O
,	O
is	O
used	O
for	O
postpartum	O
female	O
animal	O
preventive	O
perfusion	O
,	O
effectively	O
reduces	O
morbidity	O
of	O
endometritism	O
,	O
remarkably	O
shortens	O
female	O
animal	O
estrus	O
interval	O
,	O
and	O
improves	O
breeding	O
success	O
rate	O
and	O
farrowing	O
rate	O
of	O
female	O
animals	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
injected	O
in	O
uterus	O
by	O
using	O
an	O
irrigator	O
.	O

Folium	O
mori	O
tablets	O
for	O
moistening	O
dryness	O
and	O
lungs	O
The	O
invention	O
discloses	O
a	O
folium	O
mori	O
tablet	O
for	O
moistening	O
dryness	O
and	O
lungs	O
.	O

The	O
folium	O
mori	O
tablet	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
:	O
folium	O
mori	O
,	O
gypsum	O
fibrosum	O
,	O
unibract	O
fritillary	O
bulb	O
,	O
fructus	O
trichosanthis	O
,	O
liquorice	O
,	O
sang	O
,	O
linseed	O
,	O
donkey	O
-	O
hide	O
gelatin	O
,	O
radix	O
ophiopogonis	O
,	O
roasted	O
almond	O
and	O
folium	O
eriobotryae	O
.	O

Urease	B
inhibitor	O
genistein	O
hydroxamic	O
acid	O
compound	O
and	O
synthesis	O
and	O
application	O
thereof	O
A	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
the	O
following	O
structural	O
general	O
formula	O
.	O

The	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
good	O
inhibitional	O
effect	O
on	O
urease	B
and	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treating	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
lithangiuria	O
and	O
the	O
like	O
.	O

A	O
manufacturing	O
method	O
of	O
the	O
genistein	O
hydroxamic	O
acid	O
compound	O
is	O
disclosed	O
.	O

Antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O
The	O
invention	O
provides	O
an	O
antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O
,	O
and	O
especially	O
relates	O
to	O
a	O
drug	O
composed	O
of	O
dimemorfan	O
and	O
carbocisteine	O
which	O
are	O
effective	O
components	O
,	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
accessories	O
,	O
and	O
a	O
preparation	O
technology	O
.	O

The	O
dimemorfan	O
used	O
in	O
the	O
invention	O
is	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
;	O
and	O
compared	O
with	O
central	O
antitussive	O
drugs	O
present	O
on	O
the	O
market	O
,	O
the	O
dimemorfan	O
is	O
equivalent	O
in	O
antitussive	O
effects	O
but	O
low	O
in	O
adverse	O
reaction	O
.	O

Compared	O
with	O
commercially	O
available	O
compound	O
antitussive	O
and	O
expectorant	O
drugs	O
,	O
the	O
compound	O
chemical	O
drug	O
provided	O
by	O
the	O
invention	O
has	O
advantages	O
of	O
relatively	O
good	O
efficacies	O
and	O
low	O
adverse	O
reaction	O
rate	O
,	O
and	O
has	O
quite	O
good	O
social	O
and	O
economic	O
benefits	O
.	O

Compound	O
chemical	O
medicament	O
containing	O
guaiacol	O
The	O
invention	O
provides	O
a	O
compound	O
chemical	O
medicament	O
containing	O
guaiacol	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
medicament	O
consisting	O
of	O
dimemorfan	O
and	O
guaifenesin	O
serving	O
as	O
effective	O
components	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
,	O
and	O
a	O
preparation	O
process	O
of	O
the	O
medicament	O
.	O

According	O
to	O
the	O
compound	O
chemical	O
medicament	O
,	O
guaiacol	O
serving	O
as	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
has	O
equivalent	O
antitussive	O
effect	O
but	O
lower	O
adverse	O
reaction	O
compared	O
with	O
a	O
conventional	O
central	O
antitussive	O
drug	O
in	O
current	O
market	O
.	O

Compared	O
with	O
currently	O
commercial	O
compound	O
antitussive	O
expectorant	O
drug	O
,	O
the	O
composition	O
has	O
advantages	O
of	O
better	O
curative	O
effect	O
and	O
low	O
adverse	O
reaction	O
,	O
and	O
has	O
good	O
social	O
benefit	O
and	O
economic	O
benefit	O
.	O

Application	O
of	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
wind	O
pipe	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
a	O
wind	O
pipe	O
.	O

The	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
hypersecretion	O
of	O
mucoprotein	O
in	O
the	O
wind	O
pipe	O
of	O
the	O
lung	O
tissue	O
.	O

Compared	O
with	O
the	O
commonly	O
used	O
mucolytic	O
agents	O
,	O
the	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
expression	O
and	O
the	O
secretion	O
of	O
mucoprotein	O
,	O
and	O
the	O
obvious	O
side	O
and	O
toxic	O
effects	O
can	O
not	O
be	O
found	O
.	O

Application	O
of	O
doxycycline	O
in	O
preparing	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
novel	O
application	O
of	O
doxycycline	O
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Animal	O
experiments	O
and	O
in	O
-	O
vitro	O
cell	O
experiments	O
prove	O
that	O
doxycycline	O
can	O
inhibit	O
multiplication	O
and	O
invasion	O
of	O
ovarian	O
cancer	O
cells	O
,	O
can	O
prevent	O
epithelial	O
ovarian	O
cancer	O
cells	O
from	O
transferring	O
,	O
can	O
promote	O
apoptosis	O
of	O
epithelial	O
ovarian	O
cancer	O
cells	O
,	O
has	O
a	O
remarkable	O
inhibition	O
effect	O
to	O
ovarian	O
cancer	O
cells	O
,	O
in	O
particular	O
platinum	O
-	O
based	O
drug	O
-	O
resistance	O
ovarian	O
cancer	O
cells	O
,	O
and	O
can	O
inhibit	O
growth	O
of	O
ovarian	O
cancer	O
tissues	O
and	O
formation	O
of	O
ascites	O
,	O
so	O
that	O
doxycycline	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
application	O
to	O
doxycycline	O
,	O
and	O
compared	O
with	O
other	O
chemotherapeutic	O
drugs	O
,	O
doxycycline	O
has	O
the	O
advantages	O
of	O
convenient	O
administration	O
and	O
small	O
side	O
effect	O
in	O
the	O
field	O
of	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Application	O
of	O
active	O
component	O
baicalin	O
of	O
Qingkailing	O
compound	O
in	O
preparation	O
of	O
medicines	O
resisting	O
multiple	O
drug	O
-	O
resistance	O
bacteria	O
The	O
invention	O
relates	O
to	O
an	O
active	O
component	O
baicalin	O
of	O
a	O
Qingkailing	O
compound	O
,	O
which	O
has	O
an	O
inhibiting	O
effect	O
on	O
acinetobacter	O
calcoaceticus	O
,	O
acinetobacter	O
baumannii	O
,	O
A.baumannii	O
,	O
stenotrophomonas	O
maltophilia	O
and	O
escherichia	B
coli	I
containing	I
NDM-1	I
drug	O
resistance	O
gene	O
,	O
so	O
that	O
the	O
active	O
component	O
baicalin	O
can	O
be	O
used	O
for	O
inhibiting	O
these	O
bacterial	O
diseases	O
and	O
treating	O
and/or	O
preventing	O
diseases	O
caused	O
by	O
these	O
bacteria	O
.	O

Novel	O
amoxicillin	O
sodium	O
compound	O
and	O
composition	O
of	O
amoxicillin	O
sodium	O
compound	O
and	O
sulbactam	O
sodium	O
compound	O
The	O
invention	O
discloses	O
a	O
novel	O
amoxicillin	O
sodium	O
compound	O
.	O

The	O
purity	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
is	O
more	O
than	O
99	O
%	O
,	O
the	O
specific	O
rotation	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
is	O
between	O
+	O
260	O
degrees	O
and	O
+	O
280	O
degrees	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
50	O
-	O
100	O
parts	O
of	O
amoxicillin	O
sodium	O
,	O
25	O
-	O
50	O
parts	O
of	O
sulbactam	O
sodium	O
,	O
3	O
-	O
9	O
parts	O
of	O
vitamin	O
C	O
,	O
1	O
-	O
6	O
parts	O
of	O
proline	O
,	O
and	O
2	O
-	O
8	O
parts	O
of	O
nicotinamide	O
.	O

According	O
to	O
the	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
,	O
the	O
vitamin	O
C	O
,	O
the	O
proline	O
and	O
the	O
nicotinamide	O
are	O
taken	O
as	O
stabilizers	O
and	O
play	O
synergistic	O
effect	O
so	O
as	O
to	O
improve	O
the	O
stability	O
of	O
the	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
effectively	O
,	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
stable	O
injection	O
which	O
is	O
not	O
easy	O
to	O
deteriorate	O
due	O
to	O
oxygenolysis	O
after	O
being	O
laid	O
for	O
a	O
period	O
,	O
and	O
the	O
injection	O
does	O
not	O
need	O
to	O
be	O
prepared	O
when	O
being	O
used	O
,	O
thus	O
being	O
convenient	O
to	O
use	O
.	O

Resveratrol	O
nano	O
-	O
liposome	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
resveratrol	O
nano	O
-	O
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
mixing	O
and	O
dissolving	O
resveratrol	O
,	O
a	O
film	O
material	O
,	O
an	O
antioxidant	O
and	O
an	O
organic	O
solvent	O
,	O
forming	O
a	O
film	O
and	O
removing	O
the	O
organic	O
solvent	O
at	O
the	O
same	O
time	O
,	O
and	O
then	O
adding	O
a	O
buffer	O
solution	O
to	O
hydrate	O
to	O
obtain	O
a	O
coarse	O
suspension	O
liquid	O
of	O
the	O
resveratrol	O
nano	O
-	O
liposome	O
,	O
and	O
carrying	O
out	O
high	O
-	O
pressure	O
microjet	O
treatment	O
on	O
the	O
coarse	O
suspension	O
liquid	O
to	O
obtain	O
the	O
resveratrol	O
nano	O
-	O
liposome	O
.	O

The	O
resveratrol	O
nano	O
-	O
liposome	O
is	O
prepared	O
through	O
the	O
steps	O
of	O
dissolving	O
,	O
lipid	O
forming	O
,	O
sufficient	O
hydrating	O
,	O
microjet	O
dispersing	O
and	O
other	O
steps	O
by	O
adopting	O
a	O
high	O
-	O
pressure	O
microjet	O
method	O
.	O

The	O
resveratrol	O
nano	O
-	O
liposome	O
is	O
uniform	O
and	O
consistent	O
,	O
small	O
in	O
grain	O
size	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
and	O
good	O
in	O
stability	O
.	O

Pharmaceutical	O
composition	O
containing	O
granisetron	O
hydrochloride	O
compound	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
granisetron	O
hydrochloride	O
compound	O
,	O
and	O
in	O
particular	O
to	O
a	O
freeze	O
-	O
dried	O
injection	O
preparation	O
of	O
granisetron	O
hydrochloride	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

For	O
every	O
1000	O
injections	O
,	O
the	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
components	O
:	O
3	O
g	O
of	O
granisetron	O
hydrochloride	O
,	O
100	O
-	O
200	O
g	O
of	O
mannitol	O
,	O
1	O
-	O
3	O
g	O
of	O
sodium	O
hydroxide	O
,	O
1	O
-	O
2	O
g	O
of	O
vitamin	O
C	O
,	O
and	O
2000ml	O
of	O
sodium	O
hydrogencitrate	O
and	O
trisodium	O
citrate	O
buffer	O
liquor	O
with	O
molar	O
ratio	O
of	O
1:4	O
.	O

Liver	O
benefiting	O
powder	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
Chinese	O
patent	O
drug	O
for	O
treating	O
a	O
primary	O
liver	O
cancer	O
,	O
and	O
an	O
administration	O
method	O
of	O
the	O
compound	O
Chinese	O
patent	O
drug	O
.	O

The	O
primary	O
liver	O
cancer	O
is	O
one	O
of	O
the	O
common	O
malignant	O
tumors	O
in	O
China	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
13	O
medicinal	O
materials	O
for	O
compounding	O
,	O
can	O
eliminate	O
pathogens	O
,	O
strengthen	O
body	O
resistance	O
,	O
promote	O
blood	O
circulation	O
,	O
stop	O
bleeding	O
and	O
treat	O
a	O
liver	O
and	O
a	O
spleen	O
,	O
and	O
treats	O
the	O
primary	O
liver	O
cancer	O
by	O
integrating	O
external	O
treatment	O
and	O
internal	O
treatment	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
the	O
technical	O
scheme	O
that	O
the	O
following	O
medicinal	O
materials	O
and	O
matching	O
ratio	O
are	O
adopted	O
,	O
and	O
the	O
13	O
medicinal	O
materials	O
are	O
porphyrized	O
and	O
uniformly	O
mixed	O
into	O
powder	O
according	O
to	O
the	O
matching	O
ratio	O
.	O

The	O
1.5	O
-	O
2	O
g	O
liver	O
benefiting	O
powder	O
is	O
taken	O
directly	O
with	O
warm	O
water	O
at	O
each	O
time	O
for	O
2	O
-	O
3	O
times	O
per	O
day	O
.	O

External	O
application	O
treatment	O
is	O
conducted	O
as	O
follows	O
:	O
realgar	O
is	O
placed	O
in	O
an	O
abdomen	O
of	O
a	O
live	O
toad	O
(	O
with	O
viscera	O
being	O
removed	O
)	O
,	O
warm	O
water	O
is	O
added	O
to	O
prepare	O
paste	O
,	O
and	O
then	O
the	O
toad	O
is	O
externally	O
applied	O
at	O
a	O
hepatic	O
region	O
for	O
twice	O
per	O
day	O
.	O

Compound	O
solid	O
preparation	O
containing	O
tranexamic	O
acid	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
solid	O
preparation	O
containing	O
tranexamic	O
acid	O
.	O

The	O
compound	O
oral	O
solid	O
preparation	O
containing	O
the	O
tranexamic	O
acid	O
is	O
prepared	O
from	O
the	O
tranexamic	O
acid	O
serving	O
as	O
a	O
main	O
active	O
ingredient	O
,	O
other	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
by	O
a	O
preparation	O
technology	O
.	O

The	O
compound	O
solid	O
preparation	O
containing	O
the	O
tranexamic	O
acid	O
is	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
safe	O
and	O
effective	O
.	O

Bifendate	O
derivative	O
,	O
preparation	O
method	O
and	O
application	O
of	O
bifendate	O
derivative	O
for	O
treating	O
autoimmune	O
disease	O
The	O
invention	O
belongs	O
to	O
the	O
chemical	O
medicine	O
technical	O
field	O
,	O
and	O
especially	O
relates	O
to	O
a	O
bifendate	O
derivative	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
the	O
bifendate	O
derivative	O
for	O
treating	O
autoimmune	O
disease	O
.	O

A	O
structure	O
of	O
the	O
bifendate	O
derivative	O
is	O
shown	O
as	O
a	O
formula	O
I	O
,	O
and	O
has	O
good	O
effects	O
for	O
inhibiting	O
autoimmune	O
diseases	O
such	O
as	O
acute	O
hepatitis	O
,	O
chronic	O
hepatic	O
fibrosis	O
and	O
pulmonary	O
fibrosis	O
,	O
and	O
the	O
bifendate	O
derivative	O
provides	O
a	O
new	O
choice	O
for	O
medicines	O
exploitation	O
for	O
treating	O
the	O
diseases	O
.	O

Imidazole	O
[	O
4,5-c	O
]	O
pyridine-7-methanamide	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry	O
and	O
in	O
particular	O
relates	O
to	O
an	O
imidazole	O
[	O
4,5-c	O
]	O
pyridine-7-methanamide	O
derivative	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
defined	O
in	O
the	O
specification	O
.	O

Pharmacodynamic	O
tests	O
proof	O
that	O
the	O
derivative	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
serve	O
as	O
a	O
tumour	O
therapeutic	O
agent	O
and	O
especially	O
the	O
derivative	O
compound	O
has	O
extremely	O
strong	O
anti	O
-	O
tumour	O
effect	O
when	O
being	O
combined	O
with	O
cis	O
-	O
platinum	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
compound	O
.	O

Thiophene	O
derivative	O
and	O
application	O
thereof	O
to	O
medicine	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
an	O
inhibitor	O
for	O
hepatitis	O
C	O
virus	O
.	O

In	O
addition	O
,	O
the	O
invention	O
describes	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
and	O
application	O
of	O
the	O
inhibitor	O
to	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Repaglinide	O
and	O
metformin	O
hydrochloride	O
medicinal	O
composition	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
including	O
active	O
components	O
of	O
repaglinide	O
and	O
metformin	O
hydrochloride	O
,	O
and	O
its	O
preparation	O
method	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
carrying	O
out	O
hot	O
melting	O
granulation	O
of	O
metformin	O
hydrochloride	O
to	O
prepare	O
particles	O
,	O
directly	O
spraying	O
a	O
repaglinide	O
solution	O
on	O
the	O
metformin	O
hydrochloride	O
particles	O
through	O
a	O
one	O
-	O
step	O
granulation	O
technology	O
,	O
and	O
adding	O
parts	O
of	O
auxiliary	O
materials	O
to	O
prepare	O
a	O
tablet	O
.	O

Medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O
A	O
medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O
is	O
formed	O
by	O
combining	O
active	O
components	O
with	O
pharmaceutical	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
active	O
components	O
adopt	O
ecitalopram	O
(	O
salt	O
)	O
and	O
olanzapine	O
(	O
salt	O
)	O
.	O

Oral	O
preparations	O
,	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
soft	O
capsules	O
,	O
chewable	O
tablets	O
,	O
orally	O
disintegration	O
tablets	O
,	O
buccal	O
tablets	O
,	O
pill	O
and	O
the	O
like	O
,	O
can	O
be	O
produced	O
through	O
certain	O
preparation	O
techniques	O
.	O

The	O
composition	O
is	O
used	O
for	O
treating	O
the	O
mental	O
disorder	O
,	O
such	O
as	O
depression	O
,	O
insomnia	O
,	O
anxiety	O
,	O
schizophrenia	O
and	O
the	O
like	O
.	O

Anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
-	O
infection	O
compositions	O
and	O
applications	O
thereof	O
The	O
invention	O
discloses	O
compositions	O
with	O
anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
functions	O
,	O
and	O
applications	O
thereof	O
in	O
preparing	O
medicine	O
used	O
for	O
preventing	O
and/or	O
treating	O
Japanese	O
encephalitis	O
virus	O
infections	O
.	O

The	O
compositions	O
comprise	O
a	O
N-	O
(	O
2-thiazolyl	O
)	O
benzamide	O
compound	O
represented	O
by	O
the	O
formula	O
A	O
,	O
and	O
trehalose	O
or	O
Huangqi	O
Shengmai	O
Yin	O
.	O

R1	O
is	O
OH	O
,	O
OCOCH3	O
,	O
OCOC2H5	O
,	O
OCOCH2CH2CH3	O
or	O
OCOCH	O
(	O
CH3	O
)	O
2	O
;	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
independently	O
H	O
or	O
C1-C3	O
alkyl	O
;	O
R5	O
is	O
halogen	O
,	O
nitro	O
,	O
or	O
C1-C3	O
of	O
the	O
alkylsulfonyl	O
;	O
and	O
R6	O
is	O
H	O
or	O
C1-C3	O
alkylsulfonyl	O
.	O

The	O
composition	O
provided	O
by	O
the	O
invention	O
can	O
effectively	O
inhibit	O
Japanese	O
encephalitis	O
virus	O
proliferation	O
.	O

Compound	O
Caulis	O
Sinomenii	O
tablet	O
The	O
invention	O
discloses	O
a	O
compound	O
preparation	O
for	O
reducing	O
the	O
concentration	O
of	O
uric	O
acid	O
in	O
the	O
blood	O
to	O
treat	O
gout	O
,	O
and	O
concretely	O
discloses	O
a	O
compound	O
Caulis	O
Sinomenii	O
tablet	O
.	O

The	O
tablet	O
is	O
characterized	O
in	O
that	O
the	O
components	O
of	O
the	O
tablet	O
and	O
the	O
proportions	O
of	O
the	O
components	O
are	O
shown	O
in	O
the	O
specification	O
,	O
and	O
eight	O
medicines	O
which	O
are	O
the	O
components	O
are	O
mixed	O
according	O
to	O
the	O
proportions	O
to	O
prepare	O
the	O
tablet	O
or	O
a	O
pill	O
.	O

0.5	O
-	O
1.0	O
g	O
of	O
the	O
tablet	O
or	O
the	O
pill	O
is	O
orally	O
taken	O
each	O
time	O
,	O
and	O
is	O
continuously	O
taken	O
three	O
times	O
a	O
day	O
after	O
each	O
meal	O
for	O
2	O
-	O
3	O
weeks	O
.	O

Medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O
The	O
invention	O
discloses	O
a	O
medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
comprises	O
procyanidine	O
and	O
cysteine	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
procyanidine	O
to	O
the	O
cysteine	O
is	O
(	O
0.1	O
-	O
10	O
)	O
:1	O
,	O
preferably	O
(	O
1	O
-	O
3	O
)	O
:1	O
;	O
and	O
the	O
procyanidine	O
is	O
preferably	O
lotus	O
procyanidine	O
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
improve	O
the	O
oxidation	O
resistance	O
of	O
brain	O
tissue	O
,	O
avoid	O
free	O
radical	O
injury	O
to	O
the	O
brain	O
tissue	O
,	O
inhibit	O
MAO	B
-	I
B	I
and	O
AchE	B
activity	O
and	O
enhance	O
the	O
oxidation	O
resistance	O
of	O
brain	O
and	O
hippocampal	O
anti	O
-	O
oxidation	O
system	O
and	O
serum	O
so	O
as	O
to	O
improve	O
the	O
learning	O
and	O
memory	O
function	O
.	O

According	O
to	O
animal	O
tests	O
,	O
the	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
effectively	O
improve	O
mouse	O
learning	O
and	O
memory	O
injury	O
induced	O
by	O
ethanol	O
and	O
scopolamine	O
,	O
and	O
the	O
curative	O
effect	O
is	O
more	O
excellent	O
than	O
that	O
of	O
piracetam	O
and	O
procyanidine	O
.	O

Slow	O
-	O
release	O
composition	O
containing	O
L	O
-	O
milnacipran	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
composition	O
containing	O
L	O
-	O
milnacipran	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
contains	O
the	O
L	O
-	O
milnacipran	O
serving	O
as	O
an	O
active	O
ingredient	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
also	O
comprising	O
high	O
-	O
viscosity	O
hydroxypropyl	O
methylcellulose	O
serving	O
as	O
a	O
hydrophilic	O
gel	O
slow	O
-	O
release	O
skeleton	O
material	O
and	O
acrylic	O
resin	O
serving	O
as	O
a	O
pH	O
adjustor	O
,	O
wherein	O
the	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
10	O
to	O
70	O
parts	O
of	O
L	O
-	O
milnacipran	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
5	O
to	O
30	O
parts	O
of	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
3.5	O
to	O
7.5	O
parts	O
of	O
acrylic	O
resin	O
;	O
and	O
during	O
preparation	O
,	O
the	O
L	O
-	O
milnacipran	O
,	O
the	O
hydroxypropyl	O
methylcellulose	O
and	O
the	O
acrylic	O
resin	O
are	O
bound	O
to	O
be	O
mixed	O
uniformly	O
.	O

The	O
composition	O
can	O
realize	O
consistency	O
of	O
release	O
behaviors	O
in	O
artificial	O
gastric	O
juice	O
and	O
artificial	O
intestinal	O
juice	O
and	O
keep	O
12-hour	O
continuous	O
release	O
effect	O
,	O
and	O
is	O
low	O
in	O
preparation	O
loss	O
,	O
high	O
in	O
efficiency	O
,	O
high	O
in	O
stability	O
,	O
easy	O
to	O
operate	O
and	O
easy	O
to	O
popularize	O
.	O

Carboxylic	O
acid	O
derivative	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
carboxylic	O
acid	O
derivative	O
compound	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
not	O
only	O
can	O
reduce	O
the	O
level	O
of	O
triglyceride	O
in	O
high	O
fat	O
model	O
animal	O
blood	O
,	O
but	O
also	O
has	O
the	O
good	O
function	O
of	O
reducing	O
cholesterol	O
and	O
low	O
-	O
density	O
lipoprotein	O
and	O
the	O
effects	O
of	O
promoting	O
biliation	O
,	O
reducing	O
content	O
of	O
cholesterol	O
in	O
bile	O
and	O
increasing	O
the	O
content	O
of	O
bile	O
acid	O
,	O
and	O
also	O
has	O
the	O
effect	O
of	O
preventing	O
and	O
treating	O
gallstone	O
when	O
being	O
applied	O
to	O
a	O
golden	O
gopher	O
gallstone	O
model	O
.	O

The	O
particular	O
importance	O
is	O
that	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
is	O
low	O
in	O
toxicity	O
.	O

Application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
The	O
invention	O
belongs	O
to	O
the	O
fields	O
of	O
chemical	O
industry	O
and	O
medicine	O
,	O
and	O
relates	O
to	O
application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

In	O
the	O
application	O
of	O
the	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
,	O
tumor	O
cells	O
include	O
liver	O
cancer	O
cells	O
,	O
leukemia	O
cells	O
and	O
pancreatic	O
cancer	O
cells	O
.	O

The	O
isosteviol	O
lactone	O
belongs	O
to	O
a	O
natural	O
product	O
,	O
is	O
low	O
in	O
toxic	O
and	O
side	O
effect	O
,	O
high	O
in	O
bioavailability	O
and	O
stable	O
in	O
property	O
,	O
and	O
has	O
clinical	O
use	O
value	O
.	O

The	O
small	O
-	O
molecule	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
developed	O
as	O
a	O
new	O
antitumor	O
medicament	O
or	O
an	O
auxiliary	O
component	O
thereof	O
,	O
has	O
remarkable	O
tumor	O
inhibition	O
effect	O
,	O
and	O
is	O
green	O
and	O
environment	O
-	O
friendly	O
,	O
thereby	O
providing	O
a	O
new	O
way	O
and	O
means	O
for	O
treating	O
and	O
curing	O
tumors	O
.	O

Method	O
for	O
preparing	O
farrerol	O
solid	O
dispersion	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
farrerol	O
solid	O
dispersion	O
,	O
and	O
the	O
method	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
is	O
used	O
for	O
solving	O
the	O
problems	O
of	O
low	O
dissolution	O
rate	O
,	O
incomplete	O
dissolution	O
and	O
low	O
bioavailability	O
of	O
farrerol	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
farrerol	O
and	O
a	O
carrier	O
material	O
into	O
a	O
medicinal	O
organic	O
solvent	O
according	O
to	O
a	O
mass	O
ratio	O
of	O
(	O
1:1	O
)	O
-	O
(	O
1:12	O
)	O
so	O
as	O
to	O
form	O
a	O
transparent	O
solution	O
;	O
heating	O
the	O
organic	O
solvent	O
in	O
a	O
water	O
bath	O
of	O
50	O
-	O
80	O
DEG	O
C	O
,	O
vaporizing	O
the	O
organic	O
solvent	O
to	O
be	O
sticky	O
and	O
then	O
quickly	O
putting	O
the	O
organic	O
solvent	O
in	O
a	O
refrigerator	O
of	O
-20	O
DEG	O
C	O
to	O
be	O
solidified	O
for	O
3	O
-	O
5	O
hours	O
;	O
taking	O
the	O
solidified	O
organic	O
solvent	O
out	O
,	O
and	O
grinding	O
the	O
solidified	O
organic	O
solvent	O
into	O
small	O
particles	O
of	O
20	O
meshes	O
;	O
putting	O
the	O
small	O
particles	O
in	O
a	O
vacuum	O
drying	O
oven	O
for	O
12	O
-	O
24	O
hours	O
so	O
as	O
to	O
thoroughly	O
remove	O
the	O
residual	O
organic	O
solvent	O
;	O
taking	O
the	O
small	O
particles	O
out	O
,	O
finely	O
grinding	O
and	O
screening	O
the	O
small	O
particles	O
through	O
a	O
screen	O
of	O
80	O
meshes	O
and	O
putting	O
the	O
small	O
particles	O
in	O
a	O
drying	O
device	O
to	O
be	O
kept	O
in	O
dark	O
places	O
.	O

In	O
a	O
process	O
of	O
preparing	O
the	O
solid	O
dispersion	O
,	O
the	O
farrerol	O
is	O
uniformly	O
dispersed	O
into	O
the	O
water	O
-	O
soluble	O
carrier	O
,	O
so	O
that	O
the	O
water	O
solubility	O
,	O
dissolution	O
rate	O
,	O
bioavailability	O
and	O
therapeutic	O
effect	O
of	O
the	O
farrerol	O
are	O
improved	O
.	O

Application	O
of	O
Aphanamixoid	O
A	O
in	O
medicine	O
for	O
treating	O
liver	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Aphanamixoid	O
A	O
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
the	O
medicine	O
.	O

The	O
Aphanamixoid	O
A	O
has	O
outstanding	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
liver	O
cancer	O
cell	O
strains	O
HepG2	O
,	O
MHCC	O
-	O
LM3	O
,	O
Bel-7402	O
and	O
HuH-7	O
through	O
in	O
-	O
vitro	O
MTT	O
(	O
Methyl	O
Thiazolyl	O
Tetrazolium	O
)	O
antineoplastic	O
activity	O
evaluation	O
.	O

Thus	O
,	O
the	O
Aphanamixoid	O
A	O
can	O
be	O
used	O
for	O
preparing	O
the	O
medicine	O
for	O
resisting	O
the	O
liver	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospect	O
;	O
and	O
the	O
application	O
of	O
the	O
Aphanamixoid	O
A	O
in	O
preparing	O
the	O
medicine	O
for	O
treating	O
the	O
liver	O
cancer	O
is	O
firstly	O
disclosed	O
because	O
a	O
skeleton	O
type	O
belongs	O
to	O
a	O
fire	O
-	O
new	O
skeleton	O
type	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Aphanamixoid	O
A	O
on	O
liver	O
cancer	O
cells	O
is	O
inconceivably	O
high	O
.	O

Composition	O
containing	O
high	O
purity	O
bilobalide	O
B	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
high	O
purity	O
bilobalide	O
B.	O
The	O
composition	O
is	O
a	O
bilobalide	O
B	O
injection	O
which	O
comprises	O
the	O
following	O
medical	O
active	O
components	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
bilobalide	O
B	O
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	O
glycol-400	O
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	O
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	O
.	O

The	O
bilobalide	O
B	O
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
and	O
contains	O
bilobalide	O
B	O
and	O
bilobalide	O
A	O
'	O
.	O

The	O
content	O
of	O
bilobalide	O
B	O
is	O
greater	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	O
A	O
'	O
is	O
less	O
than	O
0.4	O
%	O
.	O

In	O
the	O
bilobalide	O
B	O
composition	O
provided	O
by	O
the	O
invention	O
,	O
purity	O
of	O
bilobalide	O
B	O
in	O
the	O
bilobalide	O
B	O
extract	O
as	O
a	O
raw	O
material	O
medicine	O
is	O
high	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	O
A'is	O
extremely	O
low	O
,	O
so	O
that	O
the	O
demand	O
of	O
injection	O
to	O
the	O
raw	O
material	O
medicine	O
is	O
met	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
material	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	O
B	O
as	O
active	O
ingredient	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	O
B	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
composition	O
is	O
a	O
ginkgolide	O
B	O
injection	O
.	O

The	O
ginkgolide	O
B	O
injection	O
comprises	O
the	O
following	O
pharmaceutical	O
active	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
ginkgolide	O
B	O
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	O
glycol-400	O
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	O
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	O
,	O
wherein	O
the	O
ginkgolide	O
B	O
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
,	O
and	O
comprises	O
ginkgolide	O
B	O
and	O
ginkgolide	O
K	O
,	O
the	O
content	O
of	O
the	O
ginkgolide	O
B	O
is	O
more	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	O
K	O
is	O
less	O
than	O
0.6	O
%	O
.	O

In	O
a	O
ginkgolide	O
B	O
composition	O
provided	O
by	O
the	O
invention	O
,	O
the	O
ginkgolide	O
B	O
in	O
the	O
ginkgolide	O
B	O
extract	O
as	O
a	O
raw	O
medicine	O
has	O
a	O
high	O
purity	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	O
K	O
is	O
extremely	O
low	O
,	O
so	O
that	O
requirement	O
of	O
the	O
injection	O
on	O
the	O
raw	O
medicine	O
is	O
met	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Calcitriol	O
powder	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
calcitriol	O
powder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
powder	O
is	O
prepared	O
from	O
the	O
following	O
ingredients	O
in	O
percentage	O
by	O
weight	O
:	O
0.0005	O
%	O
of	O
calcitriol	O
,	O
2.0	O
-	O
7.0	O
%	O
of	O
meglumine	O
,	O
2	O
-	O
4	O
%	O
of	O
polyethylene	O
glycol	O
400	O
,	O
20	O
-	O
30	O
%	O
of	O
polyethylene	O
glycol	O
6000	O
,	O
50.0	O
-	O
70.0	O
%	O
of	O
filler	O
and	O
an	O
appropriate	O
amount	O
of	O
lubricant	O
.	O

According	O
to	O
the	O
powder	O
,	O
the	O
content	O
of	O
calcitriol	O
is	O
remarkably	O
increased	O
,	O
so	O
that	O
the	O
drug	O
dosage	O
is	O
reduced	O
;	O
and	O
the	O
stability	O
of	O
calcitriol	O
to	O
light	O
and	O
air	O
is	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
calcitriol	O
is	O
also	O
remarkably	O
improved	O
.	O

Application	O
of	O
barbaloin	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
barbaloin	O
in	O
preparing	O
medicines	O
or	O
cosmetics	O
for	O
preventing	O
or	O
treating	O
acne	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

The	O
invention	O
discloses	O
the	O
medicines	O
or	O
cosmetics	O
which	O
contain	O
the	O
barbaloin	O
which	O
can	O
effectively	O
treat	O
the	O
acne	O
generation	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

Ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O
The	O
invention	O
discloses	O
an	O
ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O
.	O

The	O
composition	O
contains	O
cephaeline	O
and	O
emetine	O
that	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
1	O
-	O
2:1	O
.	O

The	O
preparation	O
method	O
of	O
the	O
ipecacuanha	O
effective	O
component	O
composition	O
comprises	O
:	O
taking	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
,	O
mixing	O
them	O
in	O
proportion	O
to	O
prepare	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
,	O
or	O
conducting	O
extraction	O
on	O
the	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
to	O
prepare	O
extracts	O
,	O
performing	O
mixing	O
in	O
proportion	O
,	O
and	O
then	O
making	O
the	O
mixture	O
into	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
.	O

Based	O
on	O
the	O
pharmacological	O
and	O
pharmacokinetic	O
differences	O
of	O
emetine	O
and	O
cephaeline	O
,	O
screening	O
research	O
on	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effect	O
differences	O
caused	O
by	O
different	O
proportions	O
of	O
emetine	O
and	O
cephaeline	O
is	O
carried	O
out	O
,	O
and	O
a	O
good	O
emetine	O
and	O
cephaeline	O
combination	O
region	O
for	O
ideal	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effects	O
can	O
be	O
determined	O
.	O

Bicyclic	O
heteroaryl	O
kinase	B
inhibitors	O
and	O
methods	O
of	O
use	O
Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
kinases	B
including	O
Mixed	B
Lineage	I
Kinases	I
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
preparing	O
the	O
compounds	O
,	O
synthetic	O
intermediates	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
for	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
affected	O
by	O
Mixed	B
Lineage	I
Kinase	I
inhibition	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
that	O
comprise	O
the	O
inhibition	O
of	O
Mixed	B
Lineage	I
Kinases	I
.	O

Kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
drug	O
composition	O
thereof	O
The	O
invention	O
discloses	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
a	O
drug	O
composition	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drugs	O
.	O

Kidney	O
bean	O
phytolectins	O
are	O
used	O
as	O
active	O
components	O
for	O
preparing	O
drugs	O
used	O
for	O
adding	O
lactobacillus	O
amounts	O
in	O
woman	O
vaginas	O
.	O

The	O
drug	O
composition	O
adopts	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
tremella	O
polysaccharide	O
,	O
stachyose	O
or	O
/	O
and	O
raffinose	O
and	O
bletilla	O
gum	O
,	O
or	O
added	O
scutellaria	O
,	O
Hollygreen	O
Barberry	O
and	O
matrine	O
extraction	O
as	O
the	O
active	O
components	O
.	O

The	O
drug	O
composition	O
comprises	O
relative	O
weight	O
parts	O
of	O
that	O
0.5	O
-	O
1.0	O
part	O
of	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
1.5	O
-	O
3.0	O
parts	O
of	O
the	O
tremella	O
polysaccharide	O
,	O
0.2	O
-	O
2.0	O
parts	O
of	O
the	O
stachyose	O
or	O
/	O
and	O
raffinose	O
,	O
0.2	O
-	O
0.5	O
part	O
of	O
the	O
bletilla	O
gum	O
and	O
1.0	O
-	O
3.0	O
parts	O
of	O
the	O
extraction	O
of	O
one	O
kind	O
or	O
more	O
than	O
one	O
kind	O
of	O
scutellaria	O
dry	O
powder	O
,	O
Hollygreen	O
Barberry	O
dry	O
powder	O
and	O
matrine	O
dry	O
powder	O
.	O

The	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
people	O
use	O
drugs	O
and	O
the	O
drug	O
composition	O
can	O
be	O
water	O
-	O
soluble	O
complex	O
liquid	O
and	O
is	O
best	O
to	O
be	O
gel	O
,	O
and	O
also	O
can	O
be	O
solid	O
dosage	O
forms	O
such	O
as	O
suppository	O
,	O
disintegrating	O
tablets	O
and	O
the	O
like	O
which	O
are	O
drug	O
dosage	O
forms	O
suitable	O
for	O
external	O
uses	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
obtained	O
products	O
do	O
not	O
need	O
to	O
be	O
preserved	O
in	O
a	O
low	O
temperature	O
and	O
is	O
long	O
in	O
storage	O
time	O
and	O
convenient	O
to	O
use	O
.	O

Vidarabine	O
monophosphate	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
vidarabine	O
monophosphate	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
injection	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
50	O
-	O
200	O
parts	O
of	O
vidarabine	O
monophosphate	O
,	O
0.015	O
-	O
0.05	O
part	O
of	O
a	O
pH	O
regulator	O
and	O
2000	O
parts	O
of	O
water	O
for	O
injection	O
.	O

A	O
finished	O
product	O
prepared	O
by	O
the	O
method	O
provided	O
by	O
the	O
invention	O
has	O
low	O
impurity	O
content	O
,	O
good	O
homogeneity	O
and	O
good	O
stability	O
.	O

A	O
water	O
injection	O
is	O
subjected	O
to	O
terminal	O
sterilization	O
to	O
ensure	O
the	O
safety	O
of	O
the	O
product	O
.	O

The	O
water	O
injection	O
is	O
convenient	O
to	O
use	O
,	O
and	O
does	O
not	O
need	O
to	O
be	O
prepared	O
before	O
clinical	O
application	O
,	O
so	O
as	O
to	O
reduce	O
the	O
potential	O
safety	O
hazard	O
caused	O
by	O
operation	O
and	O
provide	O
a	O
new	O
choice	O
of	O
medication	O
for	O
clinical	O
use	O
.	O

Application	O
of	O
terpenoid	O
The	O
invention	O
provides	O
an	O
application	O
of	O
a	O
terpenoid	O
to	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
.	O

The	O
terpenoid	O
has	O
a	O
structural	O
formula	O
I	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
wherein	O
R1	O
represents	O
H	O
,	O
C1-C5	O
linear	O
alkyl	O
,	O
glycosyl	O
or	O
a	O
formula	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
and	O
R2	O
is	O
selected	O
from	O
C1-C4	O
linear	O
alkyl	O
.	O

According	O
to	O
the	O
application	O
of	O
the	O
terpenoid	O
,	O
an	O
ionane	O
type	O
sesquiterpene	O
compound	O
separated	O
and	O
obtained	O
from	O
leonurus	O
for	O
the	O
first	O
time	O
can	O
obviously	O
inhibit	O
the	O
platelet	O
aggregation	O
in	O
vitro	O
and	O
has	O
extension	O
tendencies	O
to	O
prothrombin	B
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	B
time	O
(	O
APTT	O
)	O
and	O
thrombin	B
time	O
(	O
TT	O
)	O
and	O
has	O
a	O
certain	O
anticoagulation	O
activity	O
,	O
so	O
that	O
a	O
new	O
choice	O
is	O
provided	O
for	O
the	O
development	O
of	O
natural	O
anti	O
-	O
thrombus	O
drugs	O
.	O

Imatinib	O
mesylate	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
imatinib	O
mesylate	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
imatinib	O
mesylate	O
tablet	O
comprises	O
8	O
-	O
30	O
%	O
of	O
crospovidone	O
and	O
8	O
to	O
40	O
%	O
of	O
silica	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
carrying	O
out	O
granulation	O
of	O
imatinib	O
mesylate	O
and	O
a	O
waterless	O
organic	O
solvent	O
,	O
drying	O
the	O
granules	O
,	O
uniformly	O
mixing	O
the	O
granules	O
,	O
crospovidone	O
,	O
silica	O
,	O
a	O
filler	O
and	O
a	O
lubricant	O
,	O
and	O
carrying	O
out	O
tabletting	O
.	O

The	O
preparation	O
method	O
solves	O
the	O
problem	O
of	O
a	O
slow	O
dissolution	O
rate	O
of	O
a	O
preparation	O
obtained	O
by	O
the	O
prior	O
art	O
.	O

Ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
compound	O
preparation	O
and	O
preparation	O
method	O
of	O
ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
compound	O
preparation	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
preparation	O
which	O
takes	O
ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
as	O
effective	O
components	O
and	O
has	O
the	O
effects	O
of	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
.	O

The	O
compound	O
preparation	O
is	O
a	O
sustained	O
release	O
tablet	O
.	O

Aiming	O
at	O
the	O
problems	O
of	O
poor	O
water	O
solubility	O
of	O
the	O
ezetimibe	O
,	O
unstability	O
of	O
the	O
simvastatin	O
to	O
acid	O
and	O
oxygen	O
,	O
and	O
the	O
like	O
,	O
the	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
adopts	O
a	O
melt	O
extrusion	O
technology	O
for	O
improving	O
the	O
dissolution	O
rate	O
of	O
the	O
ezetimibe	O
,	O
and	O
adopts	O
a	O
cladding	O
membrane	O
technology	O
for	O
enhancing	O
the	O
stability	O
of	O
the	O
simvastatin	O
in	O
a	O
body	O
so	O
as	O
to	O
give	O
full	O
play	O
to	O
the	O
efficacy	O
of	O
all	O
components	O
of	O
the	O
compound	O
preparation	O
and	O
have	O
the	O
best	O
synergy	O
effect	O
.	O

The	O
specific	O
process	O
comprises	O
the	O
steps	O
of	O
preparing	O
the	O
nicotinic	O
acid	O
into	O
a	O
tablet	O
core	O
as	O
a	O
sustained	O
release	O
part	O
,	O
spraying	O
an	O
isolating	O
layer	O
on	O
the	O
tablet	O
core	O
,	O
then	O
spraying	O
the	O
simvastatin	O
and	O
the	O
ezetimibe	O
on	O
an	O
outer	O
layer	O
of	O
the	O
sustained	O
release	O
part	O
as	O
a	O
quick	O
release	O
layer	O
,	O
and	O
then	O
carrying	O
out	O
film	O
coating	O
on	O
the	O
quick	O
release	O
layer	O
.	O

The	O
compound	O
preparation	O
provided	O
by	O
the	O
invention	O
is	O
mainly	O
applied	O
to	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
and	O
indications	O
associated	O
with	O
heart	O
and	O
cerebral	O
vessels	O
.	O

Enrofloxacin	O
clathrate	O
compound	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
enrofloxacin	O
clathrate	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
enrofloxacin	O
clathrate	O
compound	O
is	O
prepared	O
by	O
taking	O
enrofloxacin	O
and	O
fenugreek	O
as	O
raw	O
materials	O
,	O
performing	O
clathration	O
treatment	O
on	O
auxiliary	O
materials	O
such	O
as	O
a	O
slow	O
release	O
formulation	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
plasticizer	O
,	O
a	O
curing	O
agent	O
and	O
a	O
flocculant	O
,	O
and	O
drying	O
the	O
materials	O
.	O

The	O
enrofloxacin	O
clathrate	O
compound	O
has	O
the	O
advantages	O
that	O
the	O
delay	O
medicines	O
are	O
released	O
,	O
the	O
clinical	O
administration	O
frequency	O
is	O
reduced	O
,	O
the	O
product	O
stability	O
is	O
improved	O
and	O
the	O
palatability	O
of	O
the	O
medicines	O
is	O
improved	O
.	O

2,6-diketone	O
-	O
piperazine	O
(	O
piperidine	O
)	O
type	O
derivative	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
2,6-diketone	O
-	O
piperazine	O
(	O
piperidine	O
)	O
type	O
derivative	O
and	O
an	O
application	O
thereof	O
.	O

The	O
derivative	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
medicines	O
for	O
preventing	O
or	O
treating	O
central	O
nervous	O
system	O
diseases	O
.	O

Animal	O
experiment	O
results	O
show	O
that	O
the	O
derivative	O
has	O
smaller	O
ED50	O
and	O
stronger	O
action	O
in	O
MK-801-induced	O
high	O
activity	O
and	O
apomorphine	O
-	O
induced	O
climbing	O
animal	O
models	O
as	O
well	O
as	O
has	O
larger	O
ED50	O
and	O
larger	O
therapeutic	O
indexes	O
in	O
an	O
animal	O
catalepsy	O
model	O
.	O

The	O
derivative	O
is	O
a	O
compound	O
or	O
salt	O
thereof	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
.	O

Application	O
of	O
ampelopsin	O
in	O
mutation	O
resistance	O
composition	O
preparation	O
The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
ampelopsin	O
in	O
preparation	O
of	O
mutation	O
resistance	O
health	O
food	O
or	O
drugs	O
,	O
wherein	O
purified	O
ampelopsin	O
or	O
an	O
unpurified	O
extract	O
containing	O
ampelopsin	O
can	O
be	O
adopted	O
to	O
prepare	O
into	O
a	O
pharmaceutically	O
acceptable	O
oral	O
formulation	O
,	O
a	O
pharmaceutically	O
acceptable	O
injection	O
formulation	O
or	O
a	O
pharmaceutically	O
acceptable	O
external	O
application	O
formulation	O
.	O

Application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
The	O
invention	O
relates	O
to	O
drug	O
application	O
of	O
an	O
organic	O
compound	O
and	O
in	O
particular	O
relates	O
to	O
application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

According	O
to	O
the	O
pharmacological	O
experiment	O
results	O
,	O
the	O
compound	O
has	O
better	O
inbibitional	O
effect	O
for	O
pains	O
and	O
inflammations	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
diseases	O
including	O
rheumatic	O
arthritis	O
,	O
rheumatoid	O
arthritis	O
and	O
the	O
like	O
.	O

Pleuromutilin	O
expansion	O
ring	O
derivative	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pleuromutilin	O
expansion	O
ring	O
derivative	O
shown	O
in	O
a	O
structural	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

A	O
novel	O
expansion	O
ring	O
pleuromutilin	O
compound	O
is	O
synthetized	O
by	O
rearrangement	O
reaction	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
synthesizing	O
a	O
new	O
pleuromutilin	O
derivative	O
and	O
preparing	O
an	O
antibacterial	O
agent	O
.	O

Topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
topical	O
ointment	O
is	O
characterized	O
in	O
that	O
the	O
topical	O
ointment	O
is	O
made	O
from	O
the	O
following	O
raw	O
medicines	O
,	O
by	O
weight	O
,	O
17	O
-	O
23	O
parts	O
of	O
honeysuckles	O
,	O
8	O
-	O
12	O
parts	O
of	O
chrysanthemums	O
,	O
8	O
-	O
12	O
parts	O
of	O
scutellaria	O
baicalensis	O
,	O
8	O
-	O
12	O
parts	O
of	O
rheum	O
officinale	O
,	O
8	O
-	O
12	O
parts	O
of	O
fructus	O
forsythia	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
violets	O
,	O
6	O
-	O
8	O
parts	O
of	O
moutan	O
bark	O
,	O
6	O
-	O
8	O
parts	O
of	O
golden	O
cypress	O
,	O
6	O
-	O
8	O
parts	O
of	O
coptis	O
,	O
6	O
-	O
8	O
parts	O
of	O
radix	O
rehmanniae	O
,	O
6	O
-	O
8	O
parts	O
of	O
hematoxylon	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
angelica	O
,	O
4	O
-	O
6	O
parts	O
of	O
cape	O
jasmine	O
,	O
4	O
-	O
6	O
parts	O
of	O
notopterygium	O
roots	O
,	O
4	O
-	O
6	O
parts	O
of	O
flos	O
sophorae	O
,	O
4	O
-	O
6	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
4	O
-	O
6	O
parts	O
of	O
Chinese	O
parsnip	O
roots	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plums	O
,	O
2	O
-	O
4	O
parts	O
of	O
plant	O
soot	O
and	O
0.8	O
-	O
1.2	O
parts	O
of	O
calomel	O
.	O

The	O
topical	O
ointment	O
is	O
advantaged	O
by	O
rapid	O
effects	O
,	O
significant	O
effects	O
and	O
simple	O
preparation	O
method	O
.	O

Through	O
clinical	O
verifications	O
,	O
the	O
cure	O
rate	O
of	O
the	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
is	O
100	O
%	O
.	O

[	O
0	O
]	O

High	O
-	O
permeability	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O
The	O
invention	O
relates	O
to	O
an	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O
.	O

The	O
emulsifiable	O
paste	O
comprises	O
geniposide	O
,	O
isopropyl	O
myristate	O
,	O
caprylic	O
/	O
capric	O
triglyceride	O
and	O
polyoxyethylene	O
ether	O
40	O
hydrogenated	O
castor	O
oil	O
.	O

In	O
the	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
,	O
isopropyl	O
myristate	O
is	O
used	O
as	O
a	O
novel	O
percutaneous	O
permeation	O
agent	O
for	O
geniposide	O
,	O
thus	O
greatly	O
increasing	O
the	O
permeation	O
amount	O
for	O
geniposide	O
.	O

The	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
is	O
excellent	O
in	O
performance	O
,	O
low	O
in	O
greasy	O
feeling	O
,	O
easy	O
to	O
coat	O
and	O
clean	O
,	O
and	O
good	O
in	O
heat	O
stability	O
.	O

Method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	O
injection	O
by	O
utilizing	O
carbamide	O
and	O
sodium	O
bisulfite	O
in	O
combined	O
way	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	O
injection	O
by	O
utilizing	O
carbamide	O
and	O
sodium	O
bisulfite	O
in	O
a	O
combined	O
way	O
.	O

The	O
long	O
-	O
acting	O
terramycin	O
injection	O
comprises	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
15	O
parts	O
of	O
tetramycin	O
hydrochloride	O
,	O
4	O
-	O
5	O
parts	O
of	O
magnesium	O
chloride	O
,	O
2	O
-	O
3	O
parts	O
of	O
carbamide	O
,	O
0.5	O
-	O
0.8	O
part	O
of	O
sodium	O
thiosulfate	O
,	O
4	O
-	O
6	O
parts	O
of	O
ethanolamine	O
,	O
1	O
-	O
1.5	O
parts	O
of	O
sodium	O
bisulfite	O
,	O
50	O
-	O
60	O
parts	O
of	O
alpha	O
-	O
pyrrolidone	O
,	O
0.01	O
-	O
0.03	O
part	O
of	O
disodium	O
EDTA	O
and	O
100	O
-	O
150	O
parts	O
of	O
water	O
for	O
injection	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
long	O
-	O
acting	O
terramycin	O
injection	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
curative	O
effect	O
,	O
quick	O
effect	O
,	O
definite	O
curative	O
effect	O
and	O
stability	O
in	O
quality	O
and	O
can	O
keep	O
higher	O
biological	O
activity	O
for	O
a	O
longer	O
time	O
and	O
sufficiently	O
keep	O
the	O
stability	O
of	O
a	O
product	O
;	O
the	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
easiness	O
for	O
operation	O
of	O
product	O
preparation	O
,	O
low	O
cost	O
and	O
industrialized	O
large	O
-	O
scale	O
production	O
.	O

Application	O
of	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
.	O

According	O
to	O
the	O
application	O
disclosed	O
by	O
the	O
invention	O
,	O
pharmacological	O
research	O
performed	O
on	O
Polyflavanostilbene	O
A	O
,	O
Polyflavanostilbene	O
A	O
is	O
found	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
D	O
-	O
galactosamine	O
(	O
D	O
-	O
GalN	O
)	O
,	O
of	O
mice	O
,	O
and	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
CC14	O
,	O
of	O
mice	O
.	O

Therefore	O
,	O
the	O
Polyflavanostilbene	O
A	O
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
or	O
hepatitis	O
.	O

The	O
application	O
of	O
the	O
Polyflavanostilbene	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
Polyflavanostilbene	O
A	O
has	O
a	O
new	O
framework	O
type	O
,	O
and	O
an	O
unexpectedly	O
high	O
activity	O
for	O
the	O
treatment	O
effect	O
on	O
liver	O
injury	O
,	O
so	O
that	O
the	O
possibility	O
of	O
giving	O
any	O
revelation	O
by	O
other	O
compounds	O
is	O
avoided	O
;	O
and	O
the	O
Polyflavanostilbene	O
A	O
has	O
prominent	O
substantive	O
features	O
and	O
has	O
an	O
obviously	O
remarkable	O
improvement	O
in	O
case	O
of	O
being	O
used	O
for	O
resisting	O
liver	O
injury	O
.	O

Cinnamic	O
amide	O
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
The	O
invention	O
discloses	O
cinnamic	O
amide	O
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
the	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
.	O

The	O
preparation	O
methods	O
adopting	O
hydroxycinnamic	O
acid	O
and	O
sulfanilamide	O
medicines	O
as	O
raw	O
materials	O
comprise	O
the	O
following	O
steps	O
:	O
dissolving	O
hydroxycinnamic	O
acid	O
in	O
acetic	O
anhydride	O
,	O
sequentially	O
adding	O
pyridine	O
and	O
tetrahydrofuran	O
for	O
reacting	O
with	O
the	O
sulfanilamide	O
medicines	O
to	O
obtain	O
crude	O
amide	O
compounds	O
,	O
filtering	O
,	O
washing	O
,	O
and	O
recrystallizing	O
to	O
obtain	O
the	O
novel	O
cinnamic	O
amide	O
derivatives	O
.	O

Researches	O
find	O
that	O
the	O
derivatives	O
can	O
activate	O
the	O
blood	O
coagulation	O
factor	O
in	O
an	O
endogenous	O
and	O
exogenous	O
blood	O
coagulation	O
way	O
,	O
reinforces	O
the	O
uterine	O
action	O
,	O
can	O
be	O
well	O
combined	O
with	O
the	O
human	O
serum	O
,	O
has	O
a	O
coagulation	O
promoting	O
activity	O
and	O
a	O
pain	O
easing	O
effect	O
,	O
and	O
also	O
has	O
a	O
two	O
-	O
way	O
regulation	O
effect	O
on	O
the	O
stasis	O
dissolving	O
.	O

Experiments	O
on	O
the	O
four	O
blood	O
coagulation	O
indexes	O
,	O
the	O
calcium	O
recovering	O
time	O
of	O
the	O
blood	O
plasma	O
and	O
the	O
mouse	O
in	O
-	O
vitro	O
uterus	O
confirm	O
that	O
the	O
derivatives	O
have	O
the	O
coagulation	O
promoting	O
,	O
coagulation	O
preventing	O
and	O
two	O
-	O
way	O
regulating	O
activities	O
,	O
have	O
a	O
use	O
in	O
the	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
blood	O
disease	O
medicines	O
.	O

Oxiracetam	O
medicinal	O
composition	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
oxiracetam	O
medicinal	O
composition	O
having	O
a	O
high	O
safety	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
contains	O
oxiracetam	O
and	O
below	O
0.5	O
%	O
of	O
a	O
compound	O
having	O
a	O
structure	O
represented	O
by	O
formula	O
II	O
.	O

A	O
case	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
is	O
the	O
largest	O
-	O
content	O
impurity	O
in	O
the	O
oxiracetam	O
compound	O
is	O
proved	O
for	O
the	O
first	O
time	O
,	O
purifying	O
characterization	O
and	O
relevant	O
researches	O
on	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
are	O
carried	O
out	O
,	O
and	O
the	O
researches	O
find	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
is	O
related	O
with	O
the	O
side	O
effects	O
of	O
the	O
oxiracetam	O
medicine	O
and	O
can	O
cause	O
a	O
series	O
of	O
untoward	O
effects	O
.	O

The	O
oxiracetam	O
medicinal	O
composition	O
has	O
a	O
high	O
safety	O
.	O

The	O
invention	O
further	O
provides	O
the	O
preparation	O
method	O
of	O
the	O
oxiracetam	O
medicinal	O
composition	O
.	O

Natural	O
pharmaceutical	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
composition	O
.	O

The	O
natural	O
pharmaceutical	O
composition	O
comprises	O
a	O
katsumade	O
galangal	O
seed	O
and	O
baical	O
skullcap	O
root	O
water	O
decoction	O
concentrated	O
extract	O
,	O
a	O
katsumade	O
galangal	O
seed	O
ethyl	O
acetate	O
extract	O
,	O
total	O
flavonoids	O
of	O
baical	O
skullcap	O
root	O
and	O
baicalin	O
according	O
to	O
the	O
proportion	O
of	O
(	O
2	O
-	O
4	O
)	O
:	O
(	O
3	O
-	O
8	O
)	O
:	O
(	O
3	O
-	O
9	O
)	O
:	O
(	O
1	O
-	O
4	O
)	O
,	O
and	O
the	O
composition	O
has	O
an	O
excellent	O
curative	O
effect	O
against	O
diarrhea	O
which	O
is	O
related	O
to	O
cancer	O
chemotherapy	O
and	O
can	O
simultaneously	O
realize	O
a	O
synergistic	O
action	O
against	O
the	O
cancer	O
chemotherapy	O
.	O

N-3-arylamine-5-cyclopropane	O
spirohydantoin	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
N-3-arylamine-5-cyclopropane	O
spirohydantoin	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
is	O
phenyl	O
,	O
substituted	O
phenyl	O
and	O
heterocyclic	O
arene	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
a	O
reaction	O
between	O
1-carboxyl-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
and	O
ethyl	O
chloroformate	O
to	O
generate	O
1-acyl	O
azide-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
under	O
the	O
effect	O
of	O
NaN3	O
;	O
performing	O
Curtius	O
rearrangement	O
on	O
the	O
1-acyl	O
azide-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
to	O
generate	O
corresponding	O
isocyanate	O
;	O
performing	O
a	O
reaction	O
between	O
the	O
isocyanate	O
and	O
hydrazine	O
to	O
obtain	O
N'-arylamine	O
substituent	O
ureidocyclopropane	O
;	O
and	O
generating	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
from	O
the	O
N'-arylamine	O
substituent	O
ureidocyclopropane	O
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
simple	O
,	O
has	O
higher	O
yield	O
,	O
and	O
can	O
be	O
used	O
for	O
easily	O
preparing	O
the	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
.	O

6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
,	O
which	O
has	O
a	O
chemical	O
structure	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
.	O

The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
reacting	O
phenylpiperazine	O
pyridazinone	O
and	O
1-	O
(	O
2-bromoethoxyl	O
)	O
-2-chlorobenzene	O
.	O

The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
is	O
remarkable	O
in	O
effect	O
of	O
suppressing	O
an	O
alpha	B
1-adrenergic	I
receptor	I
.	O

Feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O
The	O
invention	O
relates	O
to	O
a	O
feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O
.	O

The	O
feed	O
additive	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
10	O
parts	O
of	O
medlar	O
,	O
15	O
-	O
20	O
parts	O
of	O
Chinese	O
dates	O
,	O
5	O
-	O
8	O
parts	O
of	O
flowers	O
carthami	O
,	O
5	O
-	O
8	O
parts	O
of	O
chrysanthemum	O
,	O
2	O
-	O
4	O
parts	O
of	O
radix	O
paeoniae	O
alba	O
,	O
8	O
-	O
12	O
parts	O
of	O
polygonum	O
multiflorum	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plum	O
,	O
1	O
-	O
3	O
parts	O
of	O
yeast	O
culture	O
,	O
2	O
-	O
4	O
parts	O
of	O
medicinal	O
stones	O
and	O
3	O
-	O
5	O
parts	O
of	O
bentonite	O
.	O

The	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
for	O
preventing	O
the	O
dairy	O
cow	O
mastitis	O
effectively	O
,	O
so	O
that	O
the	O
health	O
condition	O
of	O
dairy	O
cow	O
is	O
improved	O
,	O
and	O
the	O
effects	O
on	O
the	O
milk	O
yield	O
and	O
the	O
quality	O
of	O
a	O
dairy	O
product	O
due	O
to	O
diseases	O
such	O
as	O
mastitis	O
are	O
avoided	O
.	O

By	O
virtue	O
of	O
the	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
,	O
the	O
economic	O
benefits	O
of	O
cow	O
cultivation	O
are	O
greatly	O
improved	O
,	O
and	O
the	O
adverse	O
effects	O
on	O
the	O
quality	O
of	O
the	O
dairy	O
product	O
and	O
the	O
health	O
of	O
the	O
dairy	O
cow	O
caused	O
by	O
antibiotics	O
can	O
be	O
avoided	O
.	O

Natural	O
pharmaceutical	O
extractive	O
The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
extractive	O
which	O
comprises	O
concentrated	O
extractive	O
of	O
water	O
decocted	O
shizandra	O
berry	O
-	O
long	O
pepper	O
,	O
shizandra	O
berry	O
polyose	O
,	O
long	O
pepper	O
-	O
ethanol	O
extractive	O
,	O
and	O
piperine	O
according	O
to	O
the	O
proportion	O
of	O
(	O
3	O
-	O
6	O
)	O
:	O
(	O
3	O
-	O
7	O
)	O
:	O
(	O
1	O
-	O
3	O
)	O
:	O
(	O
4	O
-	O
9	O
)	O
.	O

The	O
natural	O
pharmaceutical	O
extractive	O
has	O
an	O
excellent	O
curative	O
effect	O
on	O
diarrhea	O
related	O
to	O
cancer	O
chemo	O
-	O
treatment	O
and	O
a	O
synergistic	O
effect	O
on	O
cancer	O
chemo	O
-	O
treatment	O
.	O

Composition	O
with	O
alimentary	O
anemia	O
improving	O
function	O
and	O
preparation	O
method	O
of	O
composition	O
The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
with	O
an	O
alimentary	O
anemia	O
improving	O
function	O
and	O
a	O
preparation	O
method	O
of	O
the	O
composition	O
.	O

The	O
composition	O
is	O
prepared	O
from	O
astragalus	O
membranaceus	O
,	O
codonopsis	O
pilosula	O
,	O
angelica	O
,	O
jujube	O
and	O
prepared	O
rehmannia	O
root	O
according	O
to	O
a	O
certain	O
weight	O
percentage	O
,	O
and	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
any	O
commonly	O
used	O
preparation	O
,	O
preferably	O
an	O
oral	O
preparation	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
a	O
function	O
of	O
improving	O
alimentary	O
anemia	O
.	O

Application	O
of	O
Sarcaboside	O
B	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
alzheimer	O
disease	O
The	O
invention	O
discloses	O
a	O
new	O
application	O
of	O
Sarcaboside	O
B.	O
The	O
Sarcaboside	O
B	O
has	O
inhibitory	O
activity	O
on	O
acetylcholin	B
esterase	I
and	O
a	O
nerve	O
cell	O
protection	O
effect	O
.	O

As	O
a	O
multi	O
-	O
target	O
directed	O
compound	O
,	O
the	O
Sarcaboside	O
B	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
alzheimer	O
disease	O
.	O

The	O
application	O
of	O
the	O
Sarcaboside	O
B	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
alzheimer	O
disease	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Sarcaboside	O
B	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Sarcaboside	O
B	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
the	O
acetylcholin	B
esterase	I
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Sarcaboside	O
B	O
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
alzheimer	O
disease	O
.	O

Application	O
of	O
Chukrasone	O
A	O
in	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	O
A	O
in	O
preparing	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Chukrasone	O
A	O
can	O
effectively	O
inhibit	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
but	O
is	O
small	O
in	O
cytotoxicity	O
,	O
so	O
that	O
the	O
Chukrasone	O
A	O
can	O
be	O
further	O
developed	O
to	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
,	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
.	O

The	O
use	O
of	O
the	O
Chukrasone	O
A	O
for	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
framework	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Chukrasone	O
A	O
to	O
yellow	O
fever	O
virus	O
infection	O
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	O
A	O
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
for	O
preventing	O
and	O
treating	O
yellow	O
fever	O
virus	O
infection	O
.	O

Crystal	O
form	O
,	O
preparation	O
method	O
and	O
application	O
of	O
agomelatine	O
,	O
as	O
well	O
as	O
medicine	O
composition	O
The	O
invention	O
provides	O
a	O
crystal	O
form	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
agomelatine	O
,	O
as	O
well	O
as	O
a	O
medicine	O
composition	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
crystal	O
form	O
provided	O
by	O
the	O
invention	O
has	O
the	O
following	O
advantages	O
and	O
positive	O
effects	O
that	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	O
obtained	O
by	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
is	O
high	O
in	O
purity	O
,	O
stable	O
,	O
good	O
in	O
repeatability	O
,	O
better	O
than	O
a	O
plurality	O
of	O
existing	O
crystal	O
forms	O
in	O
purity	O
and	O
stability	O
,	O
and	O
suitable	O
for	O
preparing	O
medicament	O
preparations	O
.	O

The	O
preparation	O
method	O
of	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	O
provided	O
by	O
the	O
invention	O
is	O
simpler	O
and	O
more	O
convenient	O
than	O
the	O
existing	O
crystal	O
form	O
,	O
is	O
also	O
moderate	O
in	O
condition	O
,	O
easy	O
to	O
be	O
applied	O
in	O
actual	O
production	O
and	O
low	O
in	O
cost	O
,	O
and	O
satisfies	O
the	O
requirements	O
of	O
industrial	O
production	O
.	O

Salt	O
of	O
chelidonine	O
derivative	O
The	O
invention	O
relates	O
to	O
chelidonine	O
,	O
fumarate	O
of	O
a	O
derivative	O
of	O
the	O
chelidonine	O
or	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
of	O
the	O
chelidonine	O
and	O
applications	O
of	O
the	O
chelidonine	O
,	O
the	O
fumarate	O
and	O
the	O
solvate	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
hepatitis	O
B.	O

Ursodeoxycholic	O
acid	O
vitamin	O
composition	O
,	O
preparation	O
method	O
and	O
applications	O
thereof	O
The	O
invention	O
discloses	O
an	O
ursodeoxycholic	O
acid	O
vitamin	O
composition	O
,	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
composite	O
comprises	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
1	O
to	O
30	O
%	O
of	O
ursodesoxycholic	O
acid	O
,	O
0.1	O
to	O
5	O
%	O
of	O
thiamine	O
mononitrate	O
,	O
0.05	O
to	O
2.5	O
%	O
of	O
riboflavin	O
and	O
the	O
balance	O
of	O
dispersion	O
supporter	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
capsule	O
preparation	O
of	O
the	O
composition	O
,	O
and	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simple	O
operation	O
and	O
good	O
capsule	O
luster	O
and	O
homogeneity	O
.	O

The	O
ursodesoxycholic	O
acid	O
,	O
thiamine	O
mononitrate	O
and	O
riboflavin	O
are	O
used	O
together	O
to	O
have	O
the	O
functions	O
of	O
antagonizing	O
liver	O
hydrophobic	O
toxic	O
bile	O
acid	O
,	O
protecting	O
liver	O
cells	O
,	O
providing	O
enough	O
energy	O
to	O
liver	O
cells	O
,	O
and	O
helping	O
damaged	O
liver	O
cells	O
to	O
recover	O
,	O
the	O
ursodesoxycholic	O
acid	O
vitamin	O
composition	O
has	O
the	O
function	O
of	O
protecting	O
liver	O
and	O
gallbladder	O
,	O
and	O
is	O
capable	O
of	O
being	O
used	O
for	O
preparing	O
drugs	O
for	O
curing	O
liver	O
and	O
gallbladder	O
.	O

Application	O
of	O
ginseng	O
oligosaccharide	O
composition	O
in	O
preparation	O
of	O
anti	O
-	O
oxidation	O
medicine	O
or	O
health	O
-	O
care	O
food	O
The	O
invention	O
discloses	O
a	O
novel	O
application	O
of	O
a	O
ginseng	O
oligosaccharide	O
composition	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
oxidation	O
medicine	O
and	O
a	O
health	O
-	O
care	O
food	O
.	O

The	O
ginseng	O
oligosaccharide	O
composition	O
is	O
extracted	O
from	O
ginseng	O
.	O

According	O
to	O
an	O
in	O
-	O
vitro	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
a	O
good	O
effect	O
of	O
clearing	O
away	O
hydroxyl	O
free	O
radicals	O
and	O
DPPH	O
(	O
1,1-Diphenyl-2-picrylhydrazyl	O
radical	O
2,2-Diphenyl-1-	O
(	O
2,4,6-trinitrophenyl	O
)	O
hydrazyl	O
)	O
,	O
and	O
also	O
has	O
the	O
good	O
effect	O
of	O
chelating	O
Fe<2+>.	O
According	O
to	O
an	O
animal	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
the	O
good	O
effect	O
of	O
enhancing	O
the	O
enzyme	O
activities	O
of	O
SOD	B
(	O
Superoxide	B
Dismutase	I
)	O
,	O
CAT	B
(	O
Catalase	B
)	O
,	O
GSH	B
-	I
Px	I
(	O
Glutathione	B
Peroxidase	I
)	O
and	O
T	O
-	O
AOC	O
(	O
Total	O
Antioxidative	O
Capacity	O
)	O
in	O
the	O
serum	O
and	O
the	O
liver	O
of	O
an	O
oxidative	O
stress	O
-	O
injured	O
mice	O
induced	O
by	O
D	O
-	O
Gal	O
(	O
Galactosamine	O
)	O
,	O
and	O
can	O
be	O
used	O
for	O
obviously	O
decreasing	O
the	O
MDA	O
(	O
Methane	O
Dicarboxylic	O
Aldehyde	O
)	O
level	O
of	O
the	O
oxidative	O
stress	O
-	O
injured	O
mice	O
.	O

Medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
The	O
invention	O
provides	O
a	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
.	O

The	O
medicament	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
6	O
-	O
12	O
parts	O
of	O
spina	O
date	O
seed	O
,	O
8	O
-	O
16	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
8	O
-	O
12	O
parts	O
of	O
rhizoma	O
acori	O
graminei	O
,	O
8	O
-	O
12	O
parts	O
of	O
platycladi	O
seed	O
,	O
7	O
-	O
15	O
parts	O
of	O
polygala	O
tenuifolia	O
,	O
8	O
-	O
12	O
parts	O
of	O
nacre	O
mother	O
of	O
pearl	O
,	O
8	O
-	O
16	O
parts	O
of	O
amber	O
,	O
8	O
-	O
16	O
parts	O
of	O
magnet	O
,	O
9	O
-	O
15	O
parts	O
of	O
lily	O
,	O
7	O
-	O
14	O
parts	O
of	O
stamen	O
nelumbinis	O
,	O
and	O
8	O
-	O
15	O
parts	O
of	O
red	O
-	O
rooted	O
salvia	O
root	O
.	O

The	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
has	O
the	O
advantages	O
and	O
positive	O
effects	O
of	O
good	O
treatment	O
effect	O
,	O
no	O
independence	O
and	O
small	O
toxic	O
and	O
side	O
effects	O
.	O

Amide	O
arylpiperazine	O
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
application	O
in	O
benign	O
prostatic	O
hyperplasia	O
resistance	O
The	O
invention	O
relates	O
to	O
ten	O
amide	O
arylpiperazine	O
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
use	O
in	O
the	O
preparation	O
of	O
benign	O
prostatic	O
hyperplasia	O
treatment	O
medicines	O
.	O

The	O
preparation	O
method	O
of	O
the	O
amide	O
arylpiperazine	O
derivatives	O
comprises	O
the	O
following	O
steps	O
:	O
reacting	O
free	O
alkali	O
of	O
3-bromopropylamine	O
hydrobromide	O
with	O
di	O
-	O
tert	O
-	O
butyl	O
dicarbonate	O
to	O
obtain	O
a	O
colorless	O
oily	O
liquid	O
,	O
reacting	O
the	O
colorless	O
oily	O
liquid	O
with	O
o	O
-	O
methoxyphenylpiperazine	O
to	O
obtain	O
a	O
light	O
yellow	O
oily	O
material	O
,	O
reacting	O
the	O
light	O
yellow	O
oily	O
material	O
with	O
trifluoroacetic	O
acid	O
to	O
obtain	O
a	O
product	O
,	O
and	O
reacting	O
the	O
product	O
with	O
N	O
,	O
N	O
-	O
diisopropylethylaine	O
,	O
2-	O
(	O
7-azobenzotriazol	O
)	O
-N	O
,	O
N	O
,	O
N',N'-tetramethylformamidinium	O
hexafluorophosphate	O
,	O
and	O
5-indoleacetic	O
acid	O
or	O
3-indoleacetic	O
acid	O
or	O
3-indolepropionic	O
acid	O
or	O
3-indolebutyric	O
acid	O
or	O
5-hydroxy-2-indoleacetic	O
acid	O
or	O
5-methoxy-2-indoleacetic	O
acid	O
or	O
1-methyl-3-indoleacetic	O
acid	O
or	O
6-bromo-2-indoleacetic	O
acid	O
or	O
5-chloro-2-indoleacetic	O
acid	O
or	O
7-nitro-2-indoleacetic	O
acid	O
to	O
obtain	O
final	O
products	O
.	O

Experiments	O
prove	O
that	O
the	O
benign	O
prostatic	O
hyperplasia	O
resistance	O
activities	O
of	O
eight	O
compounds	O
in	O
the	O
amide	O
arylpiperazine	O
derivatives	O
are	O
stronger	O
than	O
a	O
contrast	O
drug	O
prazosin	O
.	O

Vagina	O
mold	O
containing	O
estriol	O
The	O
invention	O
relates	O
to	O
a	O
vagina	O
mold	O
containing	O
estriol	O
.	O

The	O
vagina	O
mold	O
is	O
composed	O
of	O
silicone	O
rubber	O
and	O
the	O
estriol	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
silicone	O
rubber	O
and	O
the	O
estriol	O
is	O
20	O
:	O
(	O
5	O
-	O
8	O
)	O
.	O

The	O
vagina	O
mold	O
containing	O
the	O
estriol	O
has	O
the	O
advantages	O
that	O
the	O
vagina	O
mold	O
containing	O
estrogen	O
greatly	O
lowers	O
the	O
contracture	O
rate	O
of	O
a	O
man	O
-	O
made	O
vagina	O
.	O

The	O
silicone	O
rubber	O
and	O
the	O
estrogen	O
are	O
combined	O
to	O
manufacture	O
the	O
vagina	O
mold	O
with	O
the	O
estrogen	O
slow	O
releasing	O
ability	O
,	O
and	O
therefore	O
vagina	O
mold	O
treatment	O
and	O
estrogen	O
treatment	O
are	O
effectively	O
combined	O
,	O
and	O
the	O
vagina	O
mold	O
with	O
the	O
slow	O
releasing	O
function	O
has	O
great	O
potential	O
in	O
future	O
clinical	O
application	O
.	O

Application	O
of	O
berberine	O
in	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
preparation	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
berberine	O
in	O
a	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

According	O
to	O
the	O
invention	O
,	O
db	O
/	O
db	O
mouse	O
with	O
diabetic	O
obesity	O
and	O
NAFLD	O
(	O
Non	O
-	O
Alcoholic	O
Fatty	O
Liver	O
Disease	O
)	O
is	O
employed	O
to	O
simulate	O
a	O
fat	O
NAFLD	O
patient	O
,	O
and	O
a	O
mouse	O
with	O
non	O
-	O
obese	O
fatty	O
liver	O
caused	O
by	O
methionine	O
-	O
choline	O
deficient	O
(	O
MCD	O
)	O
is	O
used	O
as	O
a	O
model	O
to	O
simulate	O
a	O
non	O
-	O
fat	O
NAFLD	O
patient	O
so	O
as	O
to	O
observe	O
the	O
effect	O
of	O
BBR	O
.	O

Shown	O
by	O
all	O
test	O
results	O
,	O
the	O
BBR	O
not	O
only	O
can	O
reduce	O
the	O
weight	O
of	O
the	O
obese	O
mouse	O
and	O
improve	O
the	O
glycometabolism	O
and	O
lipid	O
metabolism	O
,	O
but	O
also	O
can	O
treat	O
the	O
concurrent	O
fatty	O
liver	O
of	O
the	O
obese	O
mouse	O
,	O
and	O
also	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
fatty	O
liver	O
of	O
the	O
non	O
-	O
obese	O
mouse	O
,	O
and	O
the	O
results	O
are	O
verified	O
in	O
a	O
cell	O
model	O
simulated	O
in	O
vitro	O
,	O
so	O
that	O
the	O
BBR	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
obesity	O
and	O
the	O
non	O
-	O
obese	O
NAFLD	O
surely	O
and	O
can	O
be	O
used	O
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
the	O
NAFLD	O
.	O

Imidazolyl	O
-	O
substituted	O
thiazocyclohexane	O
compounds	O
and	O
antitumor	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
anticancer	O
related	O
drugs	O
,	O
particularly	O
imidazolyl	O
-	O
substituted	O
thiazocyclohexane	O
derivatives	O
with	O
antitumor	O
activity	O
disclosed	O
as	O
Formula	O
I	O
,	O
and	O
a	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
.	O

Substituted	O
-	O
pyrrolidinyl	O
-	O
contained	O
thiomorpholine	O
compounds	O
The	O
invention	O
discloses	O
substituted	O
-	O
pyrrolidinyl	O
-	O
contained	O
thiomorpholine	O
compounds	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
applications	O
thereof	O
.	O

In	O
concrete	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
having	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
stereoisomers	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
acceptable	O
salts	O
of	O
the	O
compounds	O
,	O
wherein	O
R	O
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
the	O
applications	O
of	O
the	O
compounds	O
in	O
preparing	O
medicines	O
used	O
for	O
treating	O
and/or	O
preventing	O
a	O
disease	O
or	O
a	O
symptom	O
which	O
are	O
related	O
to	O
over	O
-	O
high	O
activity	O
of	O
DPP	B
-	I
IV	I
or	O
over	O
-	O
expression	O
of	O
the	O
DPP	B
-	I
IV	I
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
related	O
diseases	O
.	O

The	O
compounds	O
have	O
activity	O
for	O
effectively	O
inhibiting	O
the	O
DPP	B
-	I
IV	I
.	O

Meclozine	O
oral	O
film	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
meclozine	O
oral	O
film	O
comprising	O
a	O
pharmaceutical	O
ingredient	O
meclozine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
flavoring	O
agent	O
,	O
a	O
filling	O
agent	O
,	O
a	O
wetting	O
agent	O
,	O
a	O
coloring	O
agent	O
,	O
a	O
film	O
-	O
forming	O
material	O
and	O
an	O
essence	O
.	O

The	O
meclozine	O
oral	O
film	O
is	O
uniform	O
in	O
appearance	O
,	O
pleasant	O
in	O
mouth	O
feel	O
and	O
capable	O
of	O
reducing	O
medication	O
compliance	O
of	O
children	O
,	O
is	O
directly	O
swallowed	O
after	O
dissolution	O
in	O
the	O
mouth	O
without	O
drinking	O
water	O
,	O
is	O
quick	O
in	O
drug	O
release	O
and	O
especially	O
suitable	O
for	O
children	O
,	O
old	O
people	O
and	O
critical	O
patients	O
who	O
are	O
difficult	O
in	O
swallowing	O
.	O

The	O
meclozine	O
oral	O
film	O
also	O
has	O
the	O
advantages	O
of	O
few	O
auxiliary	O
materials	O
,	O
low	O
production	O
cost	O
and	O
simple	O
preparation	O
process	O
and	O
is	O
liable	O
to	O
industrial	O
production	O
.	O

Pharmaceutical	O
composition	O
of	O
paclitaxel	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
discloses	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	O
,	O
polyoxyethylated	O
castor	O
oil	O
,	O
sodium	O
dihydrogen	O
phosphate	O
,	O
hexanedioic	O
acid	O
and	O
ethanol	O
.	O

The	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
prepared	O
into	O
an	O
injection	O
;	O
the	O
single	O
impurity	O
and	O
total	O
impurities	O
accord	O
with	O
the	O
quality	O
requirements	O
by	O
virtue	O
of	O
a	O
high	O
-	O
temperature	O
and	O
highlight	O
test	O
.	O

The	O
preparation	O
prepared	O
from	O
the	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
stability	O
and	O
low	O
impurity	O
content	O
.	O

Composition	O
containing	O
resveratrol	O
and	O
pterostilbene	O
and	O
preparation	O
containing	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
resveratrol	O
and	O
pterostilbene	O
,	O
which	O
contains	O
resveratrol	O
and	O
pterostilbene	O
.	O

As	O
shown	O
in	O
an	O
experimental	O
result	O
,	O
the	O
composition	O
containing	O
the	O
resveratrol	O
and	O
the	O
pterostilbene	O
has	O
a	O
synergistic	O
effect	O
of	O
inhibiting	O
the	O
growth	O
of	O
malignant	O
melanoma	O
grafts	O
.	O

Application	O
of	O
Incarviatone	O
A	O
in	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	O
thiazolyl	O
tetrazolium	O
(	O
MTT	O
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	O
A	O
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bladder	O
cancer	O
cell	O
strains	O
T-24	O
.	O

Therefore	O
,	O
the	O
Incarviatone	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bladder	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	O
A	O
has	O
an	O
unexpectedly	O
strong	O
bladder	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Incarviatone	O
A	O
in	O
medicaments	O
for	O
treating	O
bile	O
duct	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	O
thiazolyl	O
tetrazolium	O
(	O
MTT	O
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	O
A	O
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bile	O
duct	O
cancer	O
cell	O
strains	O
RBE	O
.	O

Therefore	O
,	O
the	O
Incarviatone	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bile	O
duct	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	O
A	O
has	O
an	O
unexpectedly	O
strong	O
human	O
bile	O
duct	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Lycojaponicumin	O
A	O
in	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
The	O
invention	O
discloses	O
application	O
of	O
Lycojaponicumin	O
A	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
drugs	O
.	O

In	O
vitro	O
MTT	O
anticancer	O
activity	O
evaluation	O
discovers	O
that	O
Lycojaponicumin	O
A	O
shows	O
remarkable	O
inhibitory	O
effects	O
on	O
growth	O
of	O
human	O
tongue	O
cancer	O
cell	O
lines	O
Tca8113	O
and	O
T6	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tongue	O
cancer	O
drugs	O
,	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

Application	O
of	O
the	O
Lycojaponicumin	O
A	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
and	O
because	O
skeleton	O
type	O
is	O
completely	O
new	O
,	O
inhibitory	O
activity	O
on	O
tongue	O
cancer	O
cells	O
is	O
extraordinary	O
strong	O
.	O

Application	O
of	O
Lycojaponicumin	O
C	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

The	O
evaluation	O
on	O
an	O
in	O
vitro	O
MTT	O
(	O
3-	O
(	O
4,5-Dimethylthiazol-2-yl	O
)	O
-2,5-diphenyltetrazolium	O
bromide	O
)	O
anti	O
-	O
tumor	O
activity	O
shows	O
that	O
the	O
Lycojaponicumin	O
C	O
also	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
ovarian	O
cancer	O
cell	O
lines	O
HO-8910	O
,	O
HOC1	O
and	O
OVAC	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	O
C	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
ovarian	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
treating	O
the	O
human	O
ovarian	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	O
C	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	O
C	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
human	O
ovarian	O
cancer	O
cells	O
.	O

Application	O
of	O
Lycojaponicumin	O
C	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Lycojaponicumin	O
C	O
can	O
be	O
used	O
for	O
effectively	O
inhibiting	O
the	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
,	O
has	O
very	O
low	O
toxicity	O
on	O
cells	O
,	O
can	O
be	O
further	O
developed	O
into	O
the	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
and	O
has	O
wide	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	O
C	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	O
C	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
yellow	O
fever	O
virus	O
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Lycojaponicumin	O
C	O
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
or	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
.	O

CBP	B
/	O
catenin	B
antagonists	O
for	O
enhancing	O
asymmetric	O
division	O
of	O
somatic	O
stem	O
cells	O
Provided	O
are	O
:	O
methods	O
for	O
treating	O
aging	O
or	O
an	O
age	O
-	O
related	O
condition	O
,	O
symptom	O
or	O
disease	O
;	O
methods	O
for	O
stimulating	O
hair	O
growth	O
,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
methods	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	O
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
methods	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof	O
,	O
including	O
cosmetic	O
treatment	O
(	O
e.g.	O
,	O
wrinkles	O
,	O
hyperpigmentation	O
,	O
redness	O
,	O
rosacea	O
,	O
dryness	O
,	O
cracking	O
,	O
loss	O
of	O
firmness	O
,	O
loss	O
of	O
elasticity	O
,	O
thinning	O
,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O

The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
a	O
CBP	B
/	O
catenin	B
(	O
e.g.	O
,	O
CBP	B
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
as	O
disclosed	O
,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to	O
,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O

In	O
particular	O
aspects	O
,	O
the	O
CBP	B
/	O
catenin	B
(	O
e.g.	O
,	O
CBP	B
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
comprises	O
an	O
alkyl	O
and/or	O
fatty	O
acid	O
ester	O
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O

Method	O
for	O
preparing	O
levofloxacin	O
hydrochloride	O
sodium	O
chloride	O
injection	O
The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
levofloxacin	O
hydrochloride	O
sodium	O
chloride	O
injection	O
.	O

By	O
researching	O
a	O
liquid	O
medicine	O
preparation	O
method	O
,	O
medicinal	O
charcoal	O
pretreatment	O
and	O
a	O
terminal	O
sterilization	O
process	O
,	O
product	O
quality	O
is	O
ensured	O
by	O
the	O
aid	O
of	O
technologies	O
of	O
a	O
concentrated	O
solution	O
and	O
diluted	O
solution	O
method	O
,	O
charcoal	O
slurry	O
preparation	O
from	O
medicinal	O
charcoal	O
,	O
water	O
bath	O
sterilization	O
and	O
the	O
like	O
,	O
production	O
is	O
facilitated	O
,	O
obtained	O
finished	O
products	O
have	O
higher	O
stability	O
,	O
so	O
that	O
the	O
storage	O
life	O
of	O
the	O
finished	O
products	O
can	O
be	O
prolonged	O
,	O
and	O
clinical	O
use	O
effects	O
are	O
better	O
.	O

Compound	O
norfloxacin	O
nicotinate	O
soluble	O
powder	O
for	O
animals	O
,	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
norfloxacin	O
nicotinate	O
soluble	O
powder	O
for	O
animals	O
.	O

A	O
formula	O
of	O
100	O
g	O
of	O
the	O
powder	O
comprises	O
5	O
-	O
10	O
g	O
of	O
norfloxacin	O
nicotinate	O
,	O
5	O
-	O
10	O
g	O
of	O
apramyein	O
sulfate	O
,	O
2	O
-	O
4	O
g	O
of	O
trimethoprim	O
lactate	O
,	O
and	O
the	O
balance	O
anhydrous	O
glucose	O
.	O

The	O
above	O
medicine	O
can	O
rapidly	O
kill	O
intestinal	O
pathogenic	O
microorganisms	O
to	O
timely	O
effectively	O
control	O
intestinal	O
bacterial	O
diseases	O
of	O
the	O
animals	O
,	O
and	O
alleviates	O
the	O
bacterial	O
drug	O
resistance	O
.	O

Burn	O
ointment	O
for	O
treating	O
burn	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
burn	O
ointment	O
for	O
treating	O
burn	O
.	O

The	O
ointment	O
comprises	O
the	O
following	O
active	O
components	O
by	O
weight	O
:	O
60	O
-	O
80	O
g	O
of	O
indigo	O
naturalis	O
,	O
40	O
-	O
60	O
g	O
of	O
mint	O
,	O
40	O
-	O
60	O
g	O
of	O
astragalus	O
,	O
20	O
-	O
30	O
g	O
of	O
talcum	O
,	O
40	O
-	O
60	O
g	O
of	O
fresh	O
sunflower	O
,	O
50	O
-	O
70	O
g	O
of	O
polygonum	O
cuspidatum	O
,	O
40	O
-	O
60	O
g	O
of	O
ligusticum	O
wallichii	O
,	O
50	O
-	O
70	O
g	O
of	O
bamboo	O
leaves	O
,	O
50	O
-	O
70	O
g	O
of	O
common	O
jujube	O
bark	O
,	O
40	O
-	O
60	O
g	O
of	O
bile	O
arisaema	O
,	O
10	O
-	O
20	O
g	O
of	O
fructus	O
evodiae	O
,	O
40	O
-	O
60	O
g	O
of	O
beewax	O
,	O
40	O
-	O
60	O
g	O
of	O
borneol	O
,	O
and	O
30	O
-	O
50	O
g	O
of	O
angelica	O
root	O
.	O

The	O
ointment	O
can	O
be	O
used	O
for	O
solving	O
the	O
problems	O
of	O
local	O
blood	O
stasis	O
and	O
obstruction	O
,	O
meridian	O
stagnation	O
and	O
toxic	O
heat	O
flourishing	O
,	O
and	O
has	O
good	O
effects	O
in	O
activating	O
blood	O
circulation	O
,	O
removing	O
stasis	O
and	O
dredging	O
collaterals	O
,	O
clearing	O
heat	O
and	O
toxicity	O
and	O
cooling	O
blood	O
,	O
and	O
treating	O
burns	O
,	O
wherein	O
the	O
effective	O
rate	O
is	O
93.6	O
percent	O
,	O
and	O
the	O
rate	O
of	O
favorable	O
curative	O
effect	O
is	O
90.7	O
percent	O
.	O

Resorcarenes	O
-	O
polysubstitution	O
pyrimidine	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
of	O
derivative	O
The	O
invention	O
relates	O
to	O
a	O
resorcarenes	O
-	O
polysubstitution	O
pyrimidine	O
derivative	O
shown	O
in	O
a	O
general	O
formula	O
I	O
and	O
a	O
salt	O
,	O
ester	O
or	O
prodrug	O
acceptable	O
in	O
pharmacy	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
and	O
an	O
application	O
of	O
a	O
composition	O
containing	O
one	O
or	O
a	O
plurality	O
of	O
such	O
type	O
of	O
compounds	O
during	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
and	O
preventing	O
infection	O
of	O
an	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
.	O

Combined	O
medicine	O
for	O
treating	O
diarrhea	O
disease	O
in	O
livestock	O
The	O
invention	O
discloses	O
a	O
combined	O
medicine	O
for	O
treating	O
the	O
diarrhea	O
disease	O
in	O
livestock	O
.	O

The	O
combined	O
medicine	O
comprises	O
the	O
following	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
8	O
-	O
12	O
parts	O
of	O
streptomycin	O
sulphate	O
or	O
derivative	O
,	O
4	O
-	O
8	O
parts	O
of	O
sulfamethoxazole	O
or	O
derivative	O
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	O
or	O
derivative	O
,	O
and	O
2	O
-	O
3	O
parts	O
of	O
Tranexamic	O
acid	O
or	O
derivative	O
.	O

The	O
combined	O
medicine	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
following	O
beneficial	O
effects	O
:	O
a	O
specific	O
antibiotic	O
,	O
a	O
specific	O
bacteriophage	O
and	O
a	O
specific	O
hemostatic	O
agent	O
are	O
used	O
in	O
combination	O
,	O
so	O
that	O
the	O
antibacterial	O
activity	O
and	O
antivirus	O
capacity	O
of	O
the	O
medicine	O
are	O
obviously	O
improved	O
and	O
the	O
curative	O
effect	O
is	O
improved	O
.	O

Composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O
.	O

The	O
composition	O
comprises	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
60	O
%	O
to	O
80	O
%	O
of	O
mushroom	O
mycelium	O
polysaccharides	O
,	O
10	O
%	O
to	O
20	O
%	O
of	O
black	O
rice	O
polypeptide	O
,	O
and	O
10	O
%	O
to	O
20	O
%	O
of	O
bird	O
cherry	O
anthocyanin	O
.	O

The	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
can	O
be	O
used	O
to	O
produce	O
anti	O
-	O
fatigue	O
drugs	O
,	O
anti	O
-	O
fatigue	O
health	O
food	O
and	O
feed	O
.	O

Vitamin	O
A	O
nano	O
-	O
emulsion	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
comprises	O
vitamin	O
A	O
and	O
tween-80	O
in	O
a	O
mass	O
ratio	O
of	O
1:	O
(	O
1.5	O
-	O
5	O
)	O
,	O
and	O
water	O
of	O
which	O
the	O
mass	O
is	O
0.5	O
-	O
3	O
times	O
of	O
the	O
total	O
mass	O
of	O
vitamin	O
A	O
and	O
tween-80	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
vitamin	O
A	O
and	O
tween-80	O
into	O
a	O
container	O
,	O
uniformly	O
mixing	O
,	O
and	O
adding	O
water	O
to	O
obtain	O
a	O
mixed	O
solution	O
;	O
performing	O
ultrasonic	O
treatment	O
on	O
the	O
mixed	O
solution	O
until	O
the	O
mixed	O
solution	O
is	O
clear	O
and	O
transparent	O
,	O
thus	O
obtaining	O
the	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
.	O

The	O
method	O
is	O
used	O
for	O
preparing	O
the	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
by	O
adopting	O
an	O
ultrasonic	O
emulsification	O
method	O
,	O
is	O
simple	O
in	O
production	O
process	O
,	O
mild	O
in	O
condition	O
,	O
short	O
in	O
preparation	O
time	O
and	O
low	O
in	O
equipment	O
requirement	O
.	O

The	O
prepared	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
is	O
of	O
an	O
oil	O
-	O
in	O
-	O
water	O
mode	O
,	O
is	O
clear	O
and	O
transparent	O
,	O
excellent	O
in	O
water	O
solution	O
and	O
good	O
in	O
stability	O
,	O
has	O
a	O
grain	O
distribution	O
range	O
of	O
23	O
-	O
62	O
nm	O
and	O
average	O
grain	O
diameter	O
of	O
38	O
nm	O
,	O
and	O
accords	O
with	O
the	O
basic	O
characteristics	O
of	O
a	O
nano	O
-	O
grade	O
material	O
.	O

Compound	O
alpha	O
-	O
ketoacid	O
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
preparation	O
process	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
alpha	O
-	O
ketoacid	O
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O

The	O
conventional	O
preparation	O
process	O
is	O
changed	O
without	O
adding	O
the	O
talcum	O
powder	O
;	O
the	O
tablet	O
prepared	O
by	O
the	O
method	O
has	O
good	O
compressibility	O
,	O
attractive	O
appearance	O
,	O
high	O
disintegrating	O
speed	O
,	O
high	O
dissolution	O
rate	O
,	O
high	O
stability	O
in	O
long	O
-	O
term	O
placement	O
and	O
high	O
medicinal	O
safety	O
.	O

Wet	O
granulation	O
is	O
performed	O
separately	O
according	O
to	O
the	O
acidic	O
and	O
alkaline	O
ingredients	O
and	O
the	O
mass	O
balance	O
ratio	O
of	O
main	O
medicines	O
,	O
i.e.	O
,	O
a	O
meta	O
-	O
alkaline	O
ingredient	O
,	O
a	O
meta	O
-	O
acidic	O
ingredient	O
and	O
a	O
nearly	O
neutral	O
ingredient	O
are	O
subjected	O
to	O
wet	O
granulation	O
separately	O
,	O
and	O
then	O
mixing	O
,	O
tabletting	O
and	O
coating	O
are	O
performed	O
,	O
so	O
that	O
the	O
direct	O
contact	O
among	O
the	O
ingredients	O
is	O
avoided	O
,	O
long	O
-	O
term	O
stable	O
placement	O
can	O
be	O
realized	O
and	O
the	O
contents	O
of	O
the	O
active	O
ingredients	O
are	O
guaranteed	O
.	O

A	O
disintegrating	O
agent	O
internal	O
and	O
external	O
addition	O
method	O
is	O
adopted	O
in	O
the	O
formula	O
,	O
the	O
content	O
of	O
polyethylene	O
glycol	O
is	O
optimized	O
,	O
and	O
no	O
talcum	O
powder	O
or	O
analogs	O
with	O
ingredients	O
similar	O
to	O
the	O
talcum	O
powder	O
are	O
included	O
in	O
the	O
formula	O
,	O
so	O
that	O
the	O
problems	O
of	O
agglomeration	O
phenomenon	O
and	O
larger	O
viscosity	O
in	O
the	O
granulation	O
process	O
are	O
solved	O
,	O
and	O
the	O
safety	O
in	O
medication	O
is	O
guaranteed	O
.	O

Application	O
of	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
antiviral	O
drug	O
The	O
invention	O
discloses	O
application	O
of	O
a	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
an	O
antiviral	O
drug	O
.	O

Experiments	O
prove	O
that	O
the	O
small	O
-	O
molecule	O
inhibitor	O
MLN4924	O
with	O
good	O
performance	O
in	O
human	O
anti	O
-	O
tumor	O
clinical	O
trials	O
is	O
strong	O
in	O
antiviral	O
activity	O
and	O
can	O
inhibit	O
virus	O
replication	O
by	O
more	O
than	O
80	O
%	O
due	O
to	O
the	O
virus	O
inhibition	O
accessory	O
protein	O
function	O
.	O

With	O
long	O
preliminary	O
experimental	O
clinical	O
experience	O
and	O
a	O
strong	O
drug	O
action	O
effect	O
,	O
the	O
drug	O
can	O
be	O
produced	O
in	O
a	O
large	O
scale	O
and	O
has	O
great	O
potential	O
of	O
becoming	O
an	O
efficient	O
antiviral	O
drug	O
.	O

Through	O
an	O
ubiquitin	B
system	O
for	O
inhibiting	O
Neddylation	O
activation	O
dominated	O
by	O
virus	O
protein	O
by	O
small	O
molecule	O
drugs	O
,	O
the	O
application	O
value	O
of	O
the	O
tumor	O
inhibitor	O
MLN4924	O
for	O
preparing	O
the	O
antiviral	O
drug	O
is	O
detected	O
.	O

Preparation	O
method	O
for	O
gel	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
a	O
gel	O
,	O
belonging	O
to	O
the	O
field	O
of	O
preparation	O
of	O
medicines	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
extracting	O
common	O
cnidium	O
fruit	O
to	O
obtain	O
an	O
extract	O
containing	O
osthole	O
and	O
carrying	O
out	O
clathration	O
on	O
the	O
extract	O
by	O
using	O
beta	O
-	O
cyclodextrin	O
or	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
;	O
treating	O
clindamycin	O
hydrochloride	O
and	O
adding	O
a	O
saturated	O
aqueous	O
solution	O
prepared	O
from	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clindamycin	O
hydrochloride	O
clathrate	O
;	O
and	O
mixing	O
the	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
with	O
the	O
clindamycin	O
hydrochloride	O
clathrate	O
,	O
adding	O
hydroxypropyl	O
methylcellulose	O
,	O
water	O
,	O
glycerin	O
,	O
chitosan	O
,	O
a	O
10	O
%	O
ethylparaben	O
ethanol	O
solution	O
,	O
a	O
10	O
%	O
aqueous	O
sodium	O
hydrosulphite	O
solution	O
and	O
Tween-80	O
and	O
carrying	O
out	O
mixing	O
with	O
stirring	O
so	O
as	O
to	O
obtain	O
the	O
gel	O
.	O

With	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
,	O
the	O
gel	O
can	O
safely	O
and	O
effectively	O
perform	O
curative	O
effects	O
and	O
has	O
reduced	O
irritation	O
,	O
improved	O
solubility	O
,	O
an	O
accelerated	O
dissolution	O
speed	O
and	O
enhanced	O
bioavailability	O
.	O

Preparation	O
method	O
for	O
Sanhuang	O
tablet	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
for	O
a	O
Sanhuang	O
tablet	O
.	O

The	O
Sanhuang	O
tablet	O
is	O
prepared	O
from	O
the	O
bulk	O
drugs	O
consisting	O
of	O
300	O
g	O
of	O
rhubarb	O
root	O
and	O
rhizome	O
,	O
5	O
g	O
of	O
berberine	O
hydrochloride	O
and	O
80	O
g	O
of	O
baical	O
skullcap	O
root	O
extract	O
through	O
supercritical	O
extraction	O
,	O
so	O
the	O
content	O
of	O
Sanhuang	O
tablet	O
is	O
greatly	O
increased	O
,	O
and	O
the	O
dose	O
of	O
the	O
Sanhuang	O
tablet	O
is	O
reduced	O
.	O

The	O
invention	O
further	O
provides	O
application	O
of	O
the	O
Sanhuang	O
tablet	O
in	O
preparation	O
of	O
drugs	O
used	O
for	O
inhibiting	O
cell	O
proliferation	O
of	O
human	O
large	O
cell	O
carcinoma	O
NCI	O
-	O
H460	O
.	O

Dextromethorphan	O
hydrobromide	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
dextromethorphan	O
hydrobromide	O
injection	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
15	O
g	O
of	O
dextromethorphan	O
hydrobromide	O
,	O
13	O
g	O
of	O
lactic	O
acid	O
,	O
7	O
g	O
of	O
sorbic	O
acid	O
,	O
42	O
g	O
of	O
polyethylene	O
glycol	O
2000	O
and	O
2000ml	O
of	O
water	O
for	O
injection	O
through	O
adjusting	O
the	O
pH	O
value	O
to	O
3.4	O
-	O
3.5	O
.	O

Proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
.	O

The	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
comprise	O
1	O
-	O
5	O
parts	O
of	O
proanthocyanidin	O
,	O
1	O
-	O
12	O
parts	O
of	O
chitosan	O
or	O
derivatives	O
thereof	O
,	O
1	O
-	O
12	O
parts	O
of	O
phospholipid	O
or	O
derivatives	O
thereof	O
and	O
1	O
-	O
10	O
parts	O
of	O
excipients	O
,	O
wherein	O
the	O
chitosan	O
and	O
the	O
derivatives	O
thereof	O
are	O
one	O
or	O
more	O
of	O
high	O
,	O
medium	O
and	O
low	O
-	O
molecular	O
weight	O
chitosan	O
,	O
chitosan	O
oligosaccharide	O
,	O
chitosan	O
quaternary	O
ammonium	O
salt	O
and	O
carboxymethyl	O
chitosan	O
.	O

The	O
particle	O
size	O
of	O
the	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
is	O
10nm-0.3	O
mu	O
m	O
;	O
the	O
proanthocyanidin	O
is	O
prepared	O
into	O
the	O
powder	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
and	O
the	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
can	O
directly	O
play	O
a	O
role	O
in	O
the	O
lung	O
as	O
a	O
pulmonary	O
inhalation	O
medicine	O
-	O
carrying	O
formulation	O
,	O
improve	O
the	O
bioavailability	O
of	O
the	O
proanthocyanidin	O
and	O
reduce	O
the	O
dosage	O
by	O
sustained	O
release	O
;	O
the	O
proanthocyanidin	O
nano	O
-	O
micro	O
spheres	O
can	O
also	O
be	O
applied	O
as	O
an	O
oral	O
sustained	O
release	O
formulation	O
;	O
the	O
proanthocyanidin	O
nano	O
-	O
micro	O
spheres	O
have	O
appropriate	O
particle	O
size	O
and	O
morphology	O
and	O
other	O
powder	O
properties	O
,	O
as	O
well	O
as	O
sustained	O
release	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simplicity	O
and	O
convenience	O
in	O
operation	O
,	O
stable	O
process	O
and	O
easiness	O
in	O
industrial	O
production	O
.	O

Application	O
of	O
fisetin	O
in	O
preparation	O
of	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
The	O
invention	O
relates	O
to	O
application	O
of	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

The	O
drug	O
can	O
reduce	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
and	O
has	O
the	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

According	O
to	O
the	O
technical	O
scheme	O
provided	O
by	O
the	O
invention	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
for	O
generating	O
anticoagulation	O
effects	O
is	O
for	O
inhibiting	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
,	O
inhibiting	O
thrombocyte	O
release	O
,	O
and	O
reducing	O
serum	O
Fg	O
and	O
vWF	B
content	O
to	O
achieve	O
anticoagulation	O
function	O
;	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
thrombosis	O
drug	O
is	O
also	O
for	O
significantly	O
prolonging	O
CT	O
,	O
PT	O
,	O
TT	O
and	O
APTT	O
to	O
indirectly	O
achieve	O
an	O
anti	O
-	O
thrombosis	O
effect	O
;	O
moreover	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
the	O
cardioprotective	O
effects	O
on	O
ischemia	O
/	O
reperfusion	O
myocardial	O
cells	O
is	O
for	O
reducing	O
the	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
decreasing	O
the	O
infarct	O
area	O
of	O
injured	O
cardiac	O
muscle	O
and	O
achieving	O
a	O
protection	O
effect	O
on	O
the	O
ischemic	O
myocardial	O
cell	O
by	O
means	O
of	O
inhibiting	O
inflammatory	O
cells	O
invasion	O
,	O
MMP-9	B
and	O
NF	B
-	I
kB	I
expression	O
and	O
NF	B
-	I
kB	I
nuclear	O
migration	O
,	O
myocardial	O
apoptosis	O
and	O
the	O
like	O
.	O

Haemorrhoid	O
treatment	O
lotion	O
The	O
invention	O
discloses	O
a	O
haemorrhoid	O
treatment	O
lotion	O
,	O
which	O
is	O
used	O
for	O
positively	O
preventing	O
,	O
treating	O
and	O
performing	O
health	O
-	O
care	O
to	O
patients	O
with	O
three	O
human	O
common	O
diseases	O
,	O
namely	O
haemorrhoid	O
,	O
acnes	O
and	O
male	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
as	O
well	O
as	O
frequently	O
-	O
occurring	O
diseases	O
radically	O
by	O
a	O
mode	O
of	O
self	O
-	O
healthcare	O
or	O
simple	O
self	O
-	O
therapy	O
in	O
daily	O
lives	O
.	O

The	O
lotion	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
15	O
elementary	O
components	O
according	O
to	O
a	O
scientific	O
proportional	O
prescription	O
and	O
compatibility	O
.	O

The	O
lotion	O
has	O
the	O
characteristics	O
of	O
wide	O
adaptability	O
,	O
high	O
popularization	O
and	O
application	O
values	O
,	O
safety	O
and	O
efficiency	O
,	O
and	O
no	O
toxic	O
or	O
side	O
effect	O
,	O
the	O
aim	O
that	O
the	O
three	O
diseases	O
severely	O
disturbing	O
human	O
beings	O
by	O
an	O
economical	O
and	O
simple	O
method	O
can	O
be	O
achieved	O
,	O
and	O
the	O
novel	O
product	O
has	O
three	O
dramatic	O
efficacies	O
and	O
applications	O
.	O

Antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
The	O
invention	O
discloses	O
an	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
according	O
to	O
percentage	O
by	O
weight	O
:	O
5	O
-	O
15	O
%	O
of	O
folium	O
ginkgo	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
dandelion	O
extract	O
,	O
8	O
-	O
10	O
%	O
of	O
borneol	O
,	O
10	O
-	O
20	O
%	O
of	O
folium	O
artemisiae	O
argyi	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
honey	O
,	O
5	O
-	O
10	O
%	O
of	O
felwort	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
seven	O
-	O
leaf	O
ginseng	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
pueraria	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
pseudo	O
-	O
ginseng	O
extract	O
and	O
15	O
-	O
30	O
%	O
of	O
medical	O
ethanol	O
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
has	O
the	O
advantages	O
that	O
the	O
prepared	O
medicament	O
has	O
a	O
quick	O
anti	O
-	O
inflammation	O
effect	O
and	O
a	O
high	O
curative	O
effect	O
,	O
generates	O
no	O
resistance	O
to	O
medicaments	O
on	O
bacteria	O
and	O
has	O
a	O
remarkable	O
effect	O
on	O
such	O
diseases	O
caused	O
by	O
fungus	O
as	O
tinea	O
pedis	O
,	O
tinea	O
manuum	O
,	O
neurodermatitis	O
,	O
contact	O
dermatitis	O
and	O
onychomycosis	O
.	O

Capsule	O
and	O
preparation	O
containing	O
rich	O
hydroxytyrosol	O
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	O
and	O
used	O
for	O
protecting	O
liver	O
The	O
invention	O
discloses	O
a	O
capsule	O
and	O
a	O
tablet	O
containing	O
rich	O
hydroxytyrosol	O
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	O
and	O
particularly	O
discloses	O
a	O
preparation	O
product	O
used	O
for	O
protecting	O
liver	O
.	O

The	O
preparation	O
product	O
,	O
namely	O
the	O
capsule	O
or	O
tablet	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0	O
-	O
60	O
%	O
of	O
hydroxytyrosol	O
,	O
0	O
-	O
30	O
%	O
of	O
lycium	O
barbarum	O
polysaccharide	O
,	O
0	O
-	O
50	O
%	O
of	O
apple	O
polyphenol	O
,	O
20	O
-	O
98	O
%	O
of	O
starch	O
,	O
0	O
-	O
20	O
%	O
of	O
xylitol	O
,	O
0	O
-	O
10	O
%	O
of	O
aspartame	O
and	O
0	O
-	O
2	O
%	O
of	O
magnesium	O
stearate	O
.	O

On	O
the	O
condition	O
of	O
satisfying	O
the	O
preparation	O
processing	O
and	O
producing	O
conditions	O
,	O
the	O
components	O
are	O
respectively	O
filtered	O
through	O
a	O
sieve	O
of	O
10	O
-	O
100	O
meshes	O
and	O
are	O
weighed	O
and	O
uniformly	O
mixed	O
according	O
to	O
prescriptions	O
,	O
the	O
mixed	O
components	O
are	O
pelletized	O
and	O
dried	O
,	O
and	O
products	O
with	O
proper	O
particle	O
sizes	O
are	O
selected	O
and	O
are	O
filled	O
to	O
capsules	O
or	O
tabletted	O
.	O

The	O
preparation	O
product	O
disclosed	O
by	O
the	O
invention	O
has	O
strong	O
oxidation	O
resistance	O
and	O
radiation	O
resistance	O
and	O
has	O
a	O
strong	O
effect	O
of	O
recovering	O
health	O
of	O
human	O
body	O
internal	O
organs	O
and	O
especially	O
protecting	O
the	O
liver	O
,	O
and	O
the	O
efficacy	O
is	O
better	O
than	O
the	O
single	O
component	O
effect	O
in	O
the	O
formulation	O
.	O

Since	O
the	O
dosage	O
of	O
a	O
single	O
component	O
in	O
the	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
relatively	O
decreased	O
,	O
adverse	O
reactions	O
caused	O
by	O
single	O
use	O
of	O
the	O
single	O
component	O
is	O
alleviated	O
or	O
reduced	O
.	O

The	O
composition	O
disclosed	O
by	O
invention	O
has	O
the	O
advantages	O
of	O
being	O
clear	O
in	O
curative	O
effect	O
,	O
free	O
of	O
toxic	O
side	O
effect	O
,	O
convenient	O
to	O
take	O
and	O
low	O
in	O
price	O
.	O

Compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
scientific	O
prescription	O
and	O
preparation	O
process	O
are	O
utilized	O
to	O
make	O
the	O
prepared	O
compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
have	O
the	O
advantages	O
of	O
high	O
stability	O
,	O
low	O
impurity	O
content	O
and	O
the	O
like	O
.	O

Damp	O
clearing	O
decoction	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
damp	O
clearing	O
decoction	O
which	O
is	O
a	O
medicament	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
7	O
parts	O
of	O
rhizoma	O
alismatis	O
,	O
8	O
-	O
12	O
parts	O
of	O
plantain	O
seed	O
,	O
8	O
-	O
12	O
parts	O
of	O
talc	O
,	O
5	O
-	O
7	O
parts	O
of	O
cortex	O
phellodendri	O
,	O
5	O
-	O
7	O
parts	O
of	O
white	O
poria	O
,	O
5	O
-	O
7	O
parts	O
of	O
caulis	O
akebiae	O
,	O
8	O
-	O
12	O
parts	O
of	O
christina	O
loosestrife	O
herb	O
,	O
8	O
-	O
12	O
parts	O
of	O
japanese	O
climbing	O
fern	O
spore	O
,	O
15	O
-	O
18	O
parts	O
of	O
herba	O
pyrrosiae	O
stephania	O
,	O
15	O
-	O
18	O
parts	O
of	O
rhizoma	O
atractylodis	O
sinensis	O
,	O
15	O
-	O
18	O
parts	O
of	O
cortex	O
eucommiae	O
,	O
15	O
-	O
18	O
parts	O
of	O
psoralea	O
corylifolia	O
,	O
5	O
-	O
7	O
parts	O
of	O
phaseolus	O
calcaratus	O
and	O
5	O
-	O
7	O
parts	O
of	O
euphorbia	O
helioscopia	O
.	O

By	O
taking	O
the	O
decoction	O
provided	O
by	O
the	O
invention	O
,	O
the	O
damp	O
in	O
a	O
body	O
can	O
be	O
effectively	O
cleared	O
,	O
and	O
the	O
immunity	O
of	O
the	O
body	O
is	O
enhanced	O
.	O

Bufalin	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
bufalin	O
derivative	O
having	O
a	O
structure	O
represented	O
as	O
a	O
general	O
formula	O
I	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
one	O
of	O
the	O
following	O
structure	O
groups	O
as	O
shown	O
in	O
the	O
specification	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
,	O
a	O
pharmaceutical	O
composition	O
and	O
application	O
of	O
the	O
derivative	O
.	O

The	O
bufalin	O
derivative	O
has	O
an	O
activity	O
on	O
inhibiting	O
tumor	O
cell	O
lines	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
treating	O
malignant	O
tumors	O
.	O

Preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O
The	O
invention	O
discloses	O
a	O
preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O
.	O

The	O
preparation	O
is	O
prepared	O
with	O
the	O
main	O
raw	O
materials	O
including	O
American	O
ginseng	O
powder	O
,	O
walnut	O
powder	O
,	O
soy	O
isoflavone	O
and	O
calcium	O
phosphate	O
.	O

The	O
product	O
is	O
prepared	O
according	O
to	O
the	O
appropriate	O
ratio	O
,	O
so	O
as	O
to	O
generate	O
synergistic	O
effects	O
,	O
and	O
is	O
in	O
particular	O
suitable	O
for	O
having	O
by	O
the	O
middle	O
aged	O
and	O
elderly	O
people	O
.	O

Medical	O
application	O
of	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
containing	O
piperazine	O
structures	O
and	O
analogues	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
medical	O
application	O
of	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
containing	O
piperazine	O
structures	O
and	O
analogues	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
,	O
X	O
is	O
independently	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
when	O
Y	O
is	O
selected	O
from	O
CH2	O
,	O
Ar	O
is	O
independently	O
selected	O
from	O
methyl	O
,	O
hydroxy	O
,	O
methoxy	O
,	O
ethoxy	O
,	O
nitryl	O
,	O
fluorine	O
,	O
chlorine	O
,	O
bromine	O
substituted	O
or	O
unsubstituted	O
phenyl	O
;	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
0	O
to	O
3	O
;	O
and	O
X	O
is	O
independently	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
when	O
Y	O
is	O
selected	O
from	O
C	O
=	O
O	O
,	O
Ar	O
is	O
independently	O
selected	O
from	O
methyl	O
,	O
hydroxy	O
,	O
methoxy	O
,	O
ethoxy	O
,	O
nitryl	O
,	O
fluorine	O
,	O
chlorine	O
,	O
bromine	O
substituted	O
or	O
unsubstituted	O
phenyl	O
;	O
and	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
1	O
to	O
3	O
.	O

The	O
novel	O
compounds	O
provided	O
by	O
the	O
invention	O
are	O
used	O
as	O
effective	O
antiplatelet	O
drugs	O
and	O
are	O
especially	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
or	O
treating	O
platelet	O
aggregation	O
caused	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
for	O
clinical	O
use	O
.	O

Pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
a	O
freeze	O
-	O
drying	O
method	O
for	O
the	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
,	O
every	O
1000	O
bottles	O
of	O
the	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
are	O
prepared	O
by	O
dissolving	O
the	O
components	O
consisting	O
of	O
pantoprazole	O
sodium	O
,	O
mannitol	O
,	O
calcium	O
edentate	O
/	O
sodium	O
edentate	O
/	O
sodium	O
calcium	O
edentate	O
and	O
citric	O
acid	O
in	O
injection	O
water	O
to	O
obtain	O
drug	O
liquid	O
and	O
freeze	O
-	O
drying	O
the	O
drug	O
liquid	O
,	O
wherein	O
before	O
freeze	O
-	O
drying	O
of	O
the	O
drug	O
liquid	O
,	O
a	O
proper	O
amount	O
of	O
sodium	O
hydroxide	O
is	O
used	O
to	O
adjust	O
a	O
pH	O
value	O
to	O
9.5	O
to	O
10.5	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
)	O
weighing	O
;	O
2	O
)	O
preparation	O
;	O
3	O
)	O
degerming	O
and	O
filtering	O
;	O
4	O
)	O
bottle	O
washing	O
,	O
drying	O
and	O
disinfection	O
;	O
5	O
)	O
rubber	O
plug	O
cleaning	O
,	O
disinfection	O
and	O
drying	O
;	O
6	O
)	O
filling	O
;	O
7	O
)	O
freeze	O
-	O
drying	O
and	O
plug	O
pressing	O
;	O
and	O
8)	O
cover	O
rolling	O
.	O

With	O
such	O
a	O
technical	O
scheme	O
,	O
the	O
preparation	O
method	O
enables	O
sublimation	O
and	O
drying	O
time	O
to	O
be	O
saved	O
,	O
energy	O
consumption	O
to	O
be	O
reduced	O
and	O
product	O
quality	O
to	O
be	O
guaranteed	O
.	O

Drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	O
lipidosome	O
for	O
injection	O
and	O
preparation	O
method	O
of	O
same	O
The	O
invention	O
provides	O
a	O
drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	O
(	O
DHP	O
)	O
lipidosome	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
.	O

The	O
drug	O
delivery	O
system	O
comprises	O
effective	O
amount	O
of	O
16-dehydropregnenolone	O
,	O
a	O
phospholipid	O
membrane	O
,	O
a	O
membrane	O
stabilization	O
material	O
and	O
pharmaceutically	O
-	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
16-dehydropregnenolone	O
to	O
the	O
phospholipid	O
membrane	O
to	O
the	O
membrane	O
stabilization	O
material	O
is	O
1:5:0.2	O
-	O
1:50:50	O
.	O

The	O
preparation	O
technology	O
comprises	O
the	O
steps	O
of	O
preparing	O
multi	O
-	O
chamber	O
lipidosome	O
,	O
homogenizing	O
the	O
lipidosome	O
,	O
metering	O
volume	O
,	O
sterilizing	O
,	O
subpackaging	O
,	O
freeze	O
-	O
drying	O
and	O
the	O
like	O
.	O

The	O
lipidosome	O
prepared	O
by	O
the	O
method	O
is	O
small	O
in	O
average	O
grain	O
diameter	O
,	O
narrow	O
in	O
distribution	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
high	O
in	O
drug	O
loading	O
capacity	O
,	O
good	O
in	O
repeatability	O
and	O
good	O
in	O
stability	O
,	O
and	O
can	O
satisfy	O
the	O
requirements	O
on	O
intravenous	O
injection	O
.	O

The	O
results	O
of	O
anti	O
-	O
tumor	O
in	O
vivo	O
experiments	O
show	O
that	O
16-DHP	O
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
remarkably	O
inhibit	O
growth	O
of	O
a	O
transplantation	O
tumor	O
of	O
a	O
nude	O
mouse	O
bearing	O
the	O
tumor	O
and	O
has	O
a	O
relatively	O
good	O
anti	O
-	O
tumor	O
effect	O
.	O

An	O
experiment	O
result	O
of	O
rat	O
pharmacokinetics	O
shows	O
that	O
the	O
16-DHP	O
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
prolong	O
the	O
time	O
that	O
a	O
medicine	O
stays	O
in	O
the	O
body	O
and	O
improve	O
the	O
amount	O
of	O
the	O
medicine	O
that	O
enters	O
systemic	O
circulation	O
of	O
a	O
rat	O
.	O

Formula	O
and	O
preparation	O
method	O
for	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O
The	O
invention	O
discloses	O
a	O
formula	O
and	O
a	O
preparation	O
method	O
for	O
an	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O
.	O

The	O
formula	O
comprises	O
,	O
by	O
mass	O
,	O
3.5	O
%	O
of	O
sorbitan	O
olivate	O
,	O
3	O
%	O
of	O
cetearyl	O
alcohol	O
,	O
2	O
%	O
of	O
squalane	O
,	O
2	O
%	O
of	O
iso	O
-	O
octyl	O
palmitate	O
,	O
2	O
%	O
of	O
caprylic	O
/	O
capric	O
triglyceride	O
,	O
0.5	O
%	O
of	O
xanthan	O
gum	O
,	O
4	O
%	O
of	O
glycerin	O
,	O
0.5	O
%	O
of	O
azelaic	O
acid	O
,	O
2	O
%	O
of	O
aloe	O
,	O
1	O
%	O
of	O
a	O
honeysuckle	O
flower	O
extract	O
,	O
1	O
%	O
of	O
a	O
chrysanthemum	O
extract	O
,	O
0.05	O
%	O
of	O
a	O
freshener	O
(	O
menthol	O
)	O
,	O
0.1	O
%	O
of	O
methyl	O
hydroxybenzoate	O
,	O
0.1	O
%	O
of	O
propyl	O
hydroxybenzoate	O
,	O
0.15	O
%	O
of	O
imidazolidinyl	O
urea	O
and	O
79.1	O
%	O
of	O
water	O
.	O

The	O
medicine	O
is	O
prepared	O
by	O
processing	O
the	O
above	O
-	O
mentioned	O
components	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
uses	O
herbaceous	O
plants	O
as	O
raw	O
materials	O
and	O
has	O
small	O
toxic	O
and	O
side	O
effects	O
;	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
on	O
the	O
surface	O
layer	O
of	O
the	O
skin	O
,	O
targetedly	O
reaches	O
a	O
desired	O
site	O
through	O
rapid	O
absorption	O
by	O
the	O
skin	O
,	O
exerts	O
good	O
anti	O
-	O
inflammation	O
and	O
sterilization	O
effects	O
and	O
has	O
fast	O
action	O
.	O

Efficient	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
for	O
livestock	O
The	O
invention	O
relates	O
to	O
veterinary	O
drugs	O
,	O
in	O
particular	O
to	O
a	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
and	O
aims	O
to	O
provide	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
which	O
has	O
small	O
side	O
effects	O
.	O

The	O
formula	O
of	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
comprises	O
the	O
following	O
components	O
:	O
60	O
g	O
of	O
plaster	O
,	O
30	O
-	O
45	O
g	O
of	O
radix	O
rehmanniae	O
,	O
60	O
g	O
of	O
cornu	O
bubali	O
,	O
20	O
g	O
of	O
coptis	O
chinensis	O
,	O
35	O
-	O
45	O
g	O
of	O
cape	O
jasmine	O
,	O
20	O
g	O
of	O
cortex	O
moutan	O
,	O
25	O
g	O
of	O
scutellaria	O
baicalensis	O
,	O
30	O
g	O
of	O
radix	O
paeoniae	O
rubra	O
,	O
30	O
g	O
of	O
rhizoma	O
anemarrhenae	O
,	O
30	O
g	O
of	O
fructus	O
forsythia	O
,	O
25	O
g	O
of	O
platycodon	O
grandiflorum	O
,	O
15	O
g	O
of	O
liquorice	O
,	O
and	O
25	O
g	O
of	O
lophatherum	O
gracile	O
,	O
and	O
the	O
raw	O
materials	O
of	O
the	O
drug	O
are	O
smashed	O
and	O
further	O
smashed	O
superfinely	O
to	O
obtain	O
superfine	O
powder	O
.	O

According	O
to	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
the	O
use	O
amount	O
of	O
plaster	O
is	O
remarkably	O
reduced	O
,	O
the	O
cold	O
property	O
of	O
the	O
drug	O
is	O
lowered	O
,	O
and	O
harm	O
and	O
side	O
effects	O
on	O
animal	O
bodies	O
are	O
alleviated	O
;	O
the	O
effects	O
of	O
an	O
original	O
drug	O
is	O
maintained	O
through	O
the	O
appropriate	O
adjustment	O
on	O
the	O
use	O
amount	O
of	O
other	O
components	O
;	O
the	O
curative	O
effect	O
is	O
exact	O
,	O
remarkable	O
,	O
and	O
the	O
drug	O
is	O
mild	O
in	O
property	O
;	O
radix	O
scrophulariae	O
is	O
eliminated	O
,	O
so	O
that	O
the	O
drug	O
formula	O
is	O
simplified	O
;	O
the	O
drug	O
raw	O
materials	O
and	O
processing	O
cost	O
are	O
reduced	O
.	O

Medicine	O
for	O
treating	O
cough	O
and	O
preparation	O
method	O
of	O
medicine	O
The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
cough	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
atractylodes	O
macrocephala	O
koidz	O
,	O
radix	O
polygonati	O
officinalis	O
,	O
herba	O
houttuyniae	O
,	O
spreading	O
hedyotis	O
herb	O
,	O
edible	O
tulip	O
,	O
honeysuckle	O
,	O
rhizoma	O
belamcandae	O
,	O
adenophora	O
tetraphylla	O
,	O
common	O
hogfenneI	O
root	O
,	O
flos	O
farfarae	O
,	O
radix	O
ophiopogonis	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
dispelling	O
cold	O
and	O
warming	O
lung	O
,	O
eliminating	O
phlegm	O
and	O
stopping	O
cough	O
,	O
clearing	O
lung	O
and	O
harmonizing	O
stomach	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
short	O
in	O
course	O
of	O
treatment	O
after	O
healing	O
when	O
used	O
for	O
treating	O
cough	O
,	O
and	O
prevents	O
relapse	O
.	O

Medicine	O
for	O
treating	O
male	O
infertility	O
and	O
preparation	O
method	O
of	O
medicine	O
The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
male	O
infertility	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
dendrobe	O
,	O
nidus	O
vespae	O
,	O
epimedium	O
,	O
tribulus	O
terrestris	O
,	O
bamboo	O
leaf	O
,	O
actinolite	O
,	O
raspberry	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
invigorating	O
the	O
kidney	O
and	O
strengthening	O
Yang	O
,	O
activating	O
the	O
channels	O
and	O
strengthening	O
spleen	O
,	O
nourishing	O
blood	O
and	O
arresting	O
emission	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
good	O
in	O
curative	O
effect	O
when	O
used	O
for	O
treating	O
male	O
infertility	O
,	O
and	O
prevents	O
relapse	O
.	O

Drug	O
for	O
treating	O
infantile	O
cough	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
infantile	O
cough	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
contains	O
5	O
-	O
15	O
parts	O
of	O
honeysuckle	O
,	O
10	O
-	O
15	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
10	O
-	O
15	O
parts	O
of	O
licorice	O
,	O
5	O
-	O
10	O
parts	O
of	O
white	O
radish	O
,	O
5	O
-	O
12	O
parts	O
of	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
2	O
-	O
8	O
parts	O
of	O
towel	O
gourd	O
and	O
15	O
-	O
25	O
parts	O
of	O
brown	O
sugar	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighing	O
honeysuckle	O
,	O
platycodon	O
grandiflorum	O
,	O
licorice	O
and	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
I	O
after	O
the	O
decocting	O
treatment	O
;	O
(	O
2	O
)	O
weighing	O
white	O
radish	O
and	O
towel	O
gourd	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
and	O
then	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
II	O
;	O
(	O
3	O
)	O
mixing	O
the	O
filtrate	O
I	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
filtrate	O
II	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
,	O
and	O
decocting	O
the	O
mixture	O
to	O
obtain	O
a	O
mixed	O
concentrated	O
solution	O
III	O
;	O
and	O
(	O
4	O
)	O
adding	O
brown	O
sugar	O
in	O
the	O
mixed	O
concentrated	O
solution	O
III	O
,	O
and	O
slightly	O
heating	O
the	O
mixture	O
to	O
obtain	O
the	O
drug	O
.	O

The	O
drug	O
is	O
good	O
in	O
curative	O
effect	O
,	O
free	O
of	O
side	O
effect	O
and	O
capable	O
of	O
both	O
treating	O
infantile	O
cough	O
fundamentally	O
and	O
reinforcing	O
body	O
and	O
enhancing	O
immunity	O
of	O
children	O
on	O
chills	O
and	O
fever	O
and	O
the	O
like	O
.	O

Antibacterial	O
finishing	O
agent	O
for	O
medical	O
dressing	O
The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
finishing	O
agent	O
for	O
a	O
medical	O
dressing	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
prepared	O
through	O
an	O
antibacterial	O
agent	O
,	O
a	O
hemostatic	O
,	O
and	O
an	O
astringent	O
capable	O
of	O
promoting	O
wound	O
healing	O
by	O
virtue	O
of	O
a	O
special	O
process	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
used	O
for	O
finishing	O
gauze	O
,	O
a	O
bandage	O
,	O
sponge	O
and	O
other	O
medical	O
dressings	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
broad	O
-	O
spectrum	O
antibacterial	O
property	O
,	O
blood	O
stopping	O
,	O
healing	O
promoting	O
,	O
safety	O
and	O
non	O
-	O
irritation	O
,	O
and	O
simple	O
preparation	O
process	O
.	O

The	O
finished	O
medical	O
dressing	O
has	O
the	O
effects	O
of	O
resisting	O
bacteria	O
,	O
stopping	O
blooding	O
,	O
diminishing	O
inflammation	O
,	O
and	O
promoting	O
wound	O
healing	O
.	O

Mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
The	O
invention	O
discloses	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
,	O
and	O
is	O
applicable	O
to	O
diagnosis	O
and	O
treatment	O
in	O
dental	O
clinic	O
.	O

A	O
formula	O
of	O
the	O
mouth	O
wash	O
consists	O
of	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
3	O
-	O
6	O
%	O
of	O
carboxymethyl	O
chitosan	O
,	O
2	O
-	O
6	O
%	O
of	O
marine	O
organism	O
lysozyme	B
and	O
reverse	O
osmosis	O
pure	O
water	O
to	O
100	O
%	O
.	O

The	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
containing	O
a	O
marine	O
organism	O
antibacterial	O
component	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
(	O
1	O
)	O
being	O
remarkable	O
in	O
antibacterial	O
effect	O
;	O
(	O
2	O
)	O
being	O
free	O
from	O
irritation	O
to	O
mucous	O
membrane	O
of	O
mouth	O
;	O
and	O
(	O
3	O
)	O
being	O
environmentally	O
friendly	O
and	O
non	O
-	O
toxic	O
due	O
to	O
the	O
marine	O
organism	O
component	O
.	O

Pharmaceutical	O
use	O
of	O
2	O
,	O
2-dimethyl	O
chromanone	O
type	O
compound	O
and	O
analogs	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
pharmaceutical	O
use	O
of	O
a	O
2	O
,	O
2-dimethyl	O
chromanone	O
type	O
compound	O
and	O
analogs	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
is	O
as	O
follows	O
,	O
wherein	O
X	O
can	O
be	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
and	O
R	O
and	O
R	O
'	O
are	O
as	O
described	O
in	O
the	O
description	O
.	O

The	O
new	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
used	O
as	O
an	O
effective	O
anti	O
-	O
platelet	O
medicament	O
,	O
can	O
be	O
particularly	O
applied	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
or	O
treating	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
caused	O
by	O
platelet	O
aggregation	O
and	O
can	O
further	O
treat	O
thrombus	O
formation	O
,	O
ischemia	O
,	O
stroke	O
,	O
restenosis	O
or	O
inflammation	O
.	O

Oxazole	O
and	O
thiazole	O
derivatives	O
as	O
selective	O
protein	B
kinase	I
inhibitors	O
(	O
c	B
-	I
kit	I
)	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
Q	O
,	O
W	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

These	O
compounds	O
selectively	O
modulate	O
,	O
regulate	O
,	O
and/or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and/or	O
mutant	O
proteine	O
kinases	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative	O
,	O
metabolic	O
,	O
allergic	O
,	O
and	O
degenerative	O
disorders	O
.	O

More	O
particularly	O
,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
native	O
and/or	O
mutant	O
c	B
-	I
kit	I
inhibitors	O
.	O

Teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
The	O
invention	O
relates	O
to	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

25	O
parts	O
of	O
teasel	O
roots	O
,	O
14	O
parts	O
of	O
sappan	O
wood	O
,	O
12	O
parts	O
of	O
peach	O
seeds	O
and	O
16	O
parts	O
of	O
borneol	O
are	O
washed	O
,	O
chopped	O
and	O
dried	O
;	O
16	O
parts	O
of	O
catechu	O
,	O
17	O
parts	O
of	O
green	O
tea	O
and	O
filiform	O
medicinal	O
material	O
are	O
uniformly	O
mixed	O
and	O
dried	O
,	O
and	O
are	O
packaged	O
into	O
packed	O
dipsacus	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

The	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
and	O
convenient	O
carriage	O
with	O
good	O
effect	O
;	O
the	O
invention	O
has	O
the	O
blood	O
circulation	O
invigorating	O
,	O
stasis	O
dispersing	O
,	O
pain	O
relieving	O
and	O
hemostasis	O
efficacies	O
,	O
and	O
the	O
product	O
can	O
help	O
people	O
to	O
invigorate	O
blood	O
circulation	O
,	O
disperse	O
stasis	O
,	O
prevent	O
and	O
control	O
stasis	O
ache	O
symptoms	O
.	O

Fluoroquinolonesilver	O
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
fluoroquinolonesilver	O
,	O
and	O
a	O
preparation	O
method	O
and	O
medical	O
application	O
of	O
the	O
fluoroquinolonesilver	O
.	O

The	O
fluoroquinolonesilver	O
has	O
a	O
structure	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
(	O
refer	O
to	O
the	O
Specification	O
)	O
.	O

Silver	O
ions	O
and	O
fluoroquinolone	O
are	O
combined	O
together	O
,	O
and	O
through	O
the	O
synergistic	O
effect	O
of	O
the	O
silver	O
ions	O
and	O
fluoroquinolone	O
,	O
the	O
antibacterial	O
effect	O
is	O
further	O
enhanced	O
,	O
and	O
the	O
problem	O
of	O
the	O
drug	O
resistance	O
of	O
the	O
existing	O
fluoroquinolone	O
drugs	O
can	O
be	O
solved	O
to	O
a	O
certain	O
degree	O
.	O

The	O
fluoroquinolonesilver	O
is	O
simple	O
in	O
preparation	O
process	O
,	O
and	O
stable	O
in	O
productivity	O
(	O
refer	O
to	O
the	O
Specification	O
for	O
the	O
formula	O
I	O
)	O
.	O

Substituted	O
imidazole-1-ethylene	O
compound	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
substituted	O
imidazole-1-ethylene	O
compound	O
as	O
well	O
as	O
a	O
preparation	O
and	O
an	O
application	O
thereof	O
.	O

The	O
substituted	O
imidazole-1-ethylene	O
compound	O
is	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
I	O
,	O
or	O
salts	O
thereof	O
formed	O
with	O
medicinal	O
acids	O
or	O
bases	O
.	O

According	O
to	O
the	O
antifungal	O
activity	O
test	O
performed	O
on	O
eight	O
clinical	O
fungi	O
by	O
the	O
compound	O
provided	O
in	O
the	O
invention	O
,	O
a	O
good	O
fungus	O
killing	O
effect	O
is	O
achieved	O
.	O

The	O
compound	O
can	O
serve	O
as	O
a	O
novel	O
broad	O
-	O
spectrum	O
antifungal	O
activity	O
compound	O
and	O
is	O
developed	O
into	O
antifungal	O
medicines	O
,	O
disinfectants	O
or	O
feed	O
additives	O
.	O

Application	O
of	O
natural	O
medicinal	O
composition	O
in	O
preparing	O
anti	O
-	O
hypoxia	O
medicines	O
and	O
health	O
-	O
care	O
products	O
The	O
invention	O
provides	O
a	O
natural	O
medicinal	O
composition	O
beneficial	O
to	O
hypoxia	O
tolerance	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
asiaticoside	O
and	O
paeoniflorin	O
with	O
effects	O
of	O
anti	O
-	O
inflammation	O
anti	O
-	O
exudation	O
,	O
and	O
ginseng	O
saponin	O
and	O
total	O
saponins	O
of	O
dried	O
tangerine	O
peel	O
with	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
effects	O
.	O

The	O
natural	O
medicinal	O
composition	O
is	O
clear	O
in	O
substances	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
sufficiently	O
utilizes	O
the	O
synergetic	O
effect	O
of	O
each	O
component	O
.	O

Besides	O
consideration	O
on	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
substances	O
,	O
the	O
prescription	O
of	O
the	O
natural	O
medicinal	O
composition	O
is	O
contributed	O
to	O
prevention	O
and	O
treatment	O
of	O
emergent	O
inflammatory	O
exudation	O
caused	O
by	O
ischemia	O
and	O
hypoxia	O
to	O
tissues	O
of	O
heart	O
and	O
cerebral	O
vessels	O
.	O

The	O
composition	O
can	O
be	O
used	O
for	O
preparing	O
oral	O
preparations	O
,	O
such	O
as	O
hard	O
capsules	O
,	O
tablets	O
,	O
granules	O
,	O
powder	O
,	O
pills	O
,	O
teabags	O
and	O
oral	O
solutions	O
,	O
and	O
can	O
be	O
used	O
in	O
Chinese	O
patent	O
medicines	O
or	O
health	O
-	O
care	O
foods	O
for	O
improving	O
hypoxia	O
tolerance	O
.	O

Ornidazole	O
paster	O
for	O
transluminal	O
administration	O
The	O
invention	O
provides	O
an	O
oidazole	O
paster	O
for	O
transluminal	O
administration	O
,	O
and	O
the	O
oidazole	O
paster	O
comprises	O
ornidazole	O
and	O
a	O
solid	O
water	O
-	O
soluble	O
matrix	O
.	O

The	O
solid	O
water	O
-	O
soluble	O
matrix	O
includes	O
carbopol	O
,	O
lactose	O
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

A	O
preparation	O
method	O
of	O
the	O
oidazole	O
patch	O
comprises	O
the	O
following	O
steps	O
:	O
respectively	O
sieving	O
secnidazole	O
,	O
lactose	O
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
in	O
the	O
prescription	O
dose	O
through	O
a	O
screen	O
of	O
80	O
mesh	O
,	O
mixing	O
well	O
,	O
adding	O
70	O
%	O
ethanol	O
for	O
granulation	O
,	O
drying	O
,	O
finishing	O
by	O
a	O
screen	O
of	O
30	O
mesh	O
,	O
adding	O
carbopol	O
,	O
magnesium	O
stearate	O
and	O
talcum	O
powder	O
,	O
which	O
are	O
sieved	O
through	O
a	O
screen	O
of	O
100	O
mesh	O
,	O
fully	O
mixing	O
and	O
tabletting	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
rapid	O
,	O
durable	O
and	O
reliable	O
effect	O
,	O
and	O
high	O
safety	O
;	O
at	O
the	O
same	O
time	O
,	O
the	O
local	O
administration	O
can	O
avoid	O
or	O
reduce	O
adverse	O
effects	O
of	O
systemic	O
administration	O
.	O

Application	O
of	O
3'-methoxy	O
benzyl-4-hydroxy-3,5-dimethoxy	O
-	O
benzoate	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
or	O
preventing	O
rheumatoid	O
arthritis	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
drugs	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
capable	O
of	O
inhibiting	O
proteasomes	O
and	O
preventing	O
and	O
treating	O
rheumatoid	O
arthritis	O
.	O

The	O
compound	O
has	O
the	O
molecular	O
structure	O
of	O
3'-methoxy	O
benzyl-4-hydroxy-3,5-dimethoxy	O
-	O
benzoate	O
.	O

The	O
compound	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
compound	O
can	O
be	O
used	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
and	O
has	O
potential	O
new	O
drug	O
development	O
value	O
.	O

Preparation	O
containing	O
methimazole	O
and	O
its	O
preparing	O
method	O
A	O
slowly	O
-	O
releasing	O
thiazmazole	O
tablet	O
for	O
treating	O
thyroidism	O
is	O
disclosed	O
.	O

It	O
is	O
prepared	O
by	O
unique	O
slow	O
-	O
releasing	O
technique	O
,	O
that	O
is	O
using	O
high	O
molecular	O
material	O
to	O
wrap	O
the	O
medicine	O
.	O

Use	O
of	O
gossypol	O
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
gossypol	O
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O
,	O
wherein	O
the	O
gossypol	O
has	O
the	O
constitutional	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
the	O
gossypol	O
derivative	O
is	O
gossypol	O
acetate	O
or	O
formic	O
acid	O
gossypol	O
.	O

Freeze	O
-	O
drying	O
fluconazole	O
injection	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
freeze	O
-	O
drying	O
fluconazole	O
injection	O
and	O
its	O
preparation	O
method	O
which	O
comprises	O
,	O
charging	O
a	O
definite	O
quantity	O
of	O
supporting	O
agent	O
into	O
reactive	O
medicinal	O
Fluconazole	O
(	O
50	O
-	O
200	O
mg	O
per	O
bottle	O
)	O
,	O
adding	O
pH	O
modifier	O
,	O
solubilizing	O
agent	O
so	O
as	O
to	O
prepare	O
solution	O
of	O
a	O
finite	O
concentration	O
,	O
and	O
loading	O
for	O
freeze	O
drying	O
.	O

Antiviral	O
activity	O
possessed	O
compound	O
The	O
invention	O
provides	O
an	O
antiviral	O
activity	O
possessed	O
compound	O
,	O
in	O
particular	O
organic	O
ionic	O
compounds	O
with	O
antiviral	O
reactivity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
,	O
and	O
the	O
external	O
antiviral	O
method	O
.	O

Dripping	O
pills	O
of	O
nefopam	O
hydrochloride	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
Nefopam	O
Hydrochloride	O
drop	O
pill	O
prepared	O
by	O
utilizing	O
ultramicro	O
disintegration	O
and	O
drop	O
pill	O
manufacturing	O
process	O
,	O
which	O
has	O
the	O
advantages	O
of	O
improving	O
collapse	O
and	O
dissolving	O
speed	O
,	O
quick	O
effect	O
,	O
increased	O
medicament	O
stability	O
,	O
reduced	O
adjuvant	O
consumption	O
,	O
lowered	O
production	O
costs	O
,	O
and	O
easiness	O
in	O
carrying	O
and	O
use	O
.	O

It	O
has	O
good	O
compliance	O
,	O
thus	O
is	O
especially	O
suitable	O
for	O
children	O
,	O
the	O
elderly	O
,	O
bedridden	O
patients	O
and	O
dysphagia	O
patients	O
.	O

Method	O
for	O
preparing	O
astragaloside	O
and	O
its	O
use	O
in	O
preparation	O
of	O
drug	O
for	O
preventing	O
and	O
treating	O
diabetic	O
nephropathy	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
astragaloside	O
and	O
its	O
use	O
in	O
pharmacy	O
,	O
wherein	O
the	O
preparing	O
process	O
comprises	O
subjecting	O
the	O
astragalus	O
root	O
powder	O
to	O
ethanol	O
backflow	O
,	O
decompression	O
concentrating	O
with	O
the	O
inverse	O
flow	O
,	O
charging	O
NaOH	O
into	O
the	O
concentration	O
liquid	O
,	O
compressionalcohol	O
liquid	O
backflow	O
,	O
steaming	O
the	O
ethyl	O
alcohol	O
to	O
obtain	O
ethanol	O
hydrolysate	O
,	O
extracting	O
with	O
acetic	O
ester	O
,	O
washing	O
to	O
neutral	O
,	O
evaporating	O
to	O
dryness	O
,	O
obtaining	O
crude	O
saponin	O
,	O
charging	O
acetic	O
ester	O
,	O
stirring	O
in	O
water	O
-	O
bath	O
,	O
cooling	O
down	O
,	O
filtering	O
,	O
deposition	O
,	O
and	O
recrystallizing	O
with	O
methanol	O
.	O

Hydroxymethyl	O
coumarine	O
soft	O
capsule	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
soft	O
hydroxymethyl	O
coumarine	O
capsule	O
and	O
its	O
preparation	O
process	O
.	O

The	O
soft	O
hydroxymethyl	O
coumarine	O
capsule	O
is	O
prepared	O
with	O
hydroxymethyl	O
coumarine	O
as	O
active	O
component	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
35	O
-	O
55	O
wt%	O
;	O
solvent	O
and	O
diluent	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
40	O
-	O
55	O
wt%	O
;	O
emulsifier	O
in	O
2	O
-	O
12	O
wt%	O
,	O
preferably	O
5	O
-	O
8	O
wt%	O
to	O
increase	O
the	O
solubility	O
of	O
hydroxymethyl	O
coumarine	O
in	O
animal	O
and	O
vegetable	O
oil	O
and	O
raise	O
its	O
stability	O
;	O
and	O
antioxidant	O
in	O
0.2	O
-	O
5	O
wt%	O
,	O
preferably	O
0.5	O
-	O
3	O
wt%	O
,	O
to	O
raise	O
the	O
antioxidant	O
performance	O
.	O

The	O
soft	O
capsule	O
shell	O
is	O
prepared	O
with	O
gelatin	O
,	O
glycerin	O
,	O
sorbic	O
alcohol	O
,	O
etc	O
.	O
and	O
contains	O
titania	O
in	O
0.2	O
-	O
1.2	O
wt%	O
,	O
preferably	O
0.5	O
-	O
0.7	O
wt%	O
,	O
as	O
light	O
screening	O
agent	O
.	O

Application	O
of	O
ursolic	O
acid	O
in	O
prepartation	O
of	O
anticancer	O
medicine	O
An	O
application	O
of	O
ursolic	O
acid	O
in	O
preparing	O
the	O
anticancer	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
breast	O
cancer	O
,	O
lymphomatosis	O
,	O
leukemia	O
,	O
etc	O
is	O
disclosed	O
.	O

Glycosyl	O
phthalic	O
imidine	O
compounds	O
with	O
anti	O
-	O
inflammatory	O
activity	O
The	O
invention	O
relates	O
to	O
N	O
-	O
glycosyl	O
(	O
substituted	O
)	O
phthalimide	O
compounds	O
having	O
the	O
structural	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
separate	O
halogen	O
,	O
hydroxy	O
,	O
substituted	O
C1-C10	O
alkyl	O
,	O
C1-C10	O
aryl	O
,	O
C2-C8	O
alkene	O
,	O
C1-C10	O
alkoxy	O
,	O
C1-C10	O
acyl	O
,	O
C1-C10	O
ester	O
,	O
C1-C10	O
carboxyl	O
,	O
nitro	O
,	O
amido	O
,	O
monoalkyl	O
amino	O
,	O
dialkyl	O
amido	O
,	O
cyano	O
,	O
sulfonyl	O
,	O
alkyl	O
sulfonyl	O
,	O
alkyl	O
,	O
sulfhydryl	O
,	O
A	O
is	O
various	O
substituted	O
or	O
nonsubstituted	O
glycosyl	O
residue	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
and	O
method	O
for	O
preparation	O
and	O
use	O
in	O
preparing	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

Application	O
of	O
dihydromyricetrin	O
An	O
application	O
of	O
dihydromyricetin	O
in	O
preparing	O
the	O
antalgic	O
and	O
apophlegmatic	O
medicine	O
or	O
health	O
-	O
care	O
food	O
is	O
disclosed	O
.	O

Usage	O
of	O
glanthidine	O
,	O
total	O
alkali	O
extract	O
and	O
preparation	O
method	O
and	O
usage	O
thereof	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
lycoramine	O
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
,	O
total	O
lycoramine	O
extract	O
containing	O
lycoramine	O
and	O
its	O
preparation	O
process	O
,	O
use	O
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
and	O
the	O
composition	O
therewith	O
.	O

Antiadhesion	O
protective	O
preparation	O
and	O
its	O
application	O
An	O
anti	O
-	O
adhesion	O
protector	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
adhesion	O
medicine	O
for	O
the	O
veterinary	O
operation	O
is	O
prepared	O
from	O
dihydrated	O
terramycin	O
,	O
acenocoumarol	O
,	O
erucic	O
acid	O
,	O
adrenine	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

Powder	O
and	O
injection	O
preparation	O
of	O
new	O
houttuynine	O
sodium	O
bisulfite	O
and	O
preparation	O
method	O
A	O
powder	O
injection	O
of	O
sodium	O
neohouttuyfonate	O
is	O
prepared	O
from	O
the	O
sodium	O
neohouttuyfnoate	O
or	O
its	O
physiologically	O
acceptable	O
salt	O
and	O
the	O
phamacological	O
acceptable	O
auxiliary	O
for	O
injection	O
.	O

Paracetamol	O
Pseudoephedrine	O
desintegration	O
piece	O
and	O
preparation	O
method	O

An	O
oral	O
disintegrating	O
tablet	O
of	O
Shuangpuweima	O
is	O
prepared	O
from	O
acetylaminophenol	O
,	O
pseudoephedrine	O
hydrochloride	O
,	O
chlorpheniramine	O
,	O
disintegrant	O
,	O
filler	O
and	O
flavouring	O
.	O

Angelica	O
polysaccharide	O
and	O
its	O
preparation	O
and	O
use	O
The	O
invention	O
relates	O
to	O
a	O
Chinese	O
angelica	O
polysaccharide	O
,	O
which	O
is	O
made	O
in	O
the	O
following	O
way	O
:	O
dissolve	O
alcohol	O
deposit	O
of	O
Chinese	O
angelica	O
into	O
distilled	O
water	O
,	O
use	O
savage	O
method	O
to	O
more	O
the	O
protein	O
away	O
until	O
there	O
is	O
no	O
protein	O
absorption	O
peak	O
of	O
280	O
nm	O
by	O
ultraviolet	O
test	O
,	O
centrifugation	O
to	O
clear	O
the	O
deposit	O
;	O
keep	O
the	O
water	O
-	O
phase	O
and	O
add	O
into	O
alcohol	O
for	O
depositing	O
polysaccharide	O
,	O
abandon	O
the	O
supernatant	O
liquid	O
,	O
wash	O
the	O
deposit	O
by	O
alcohol	O
,	O
then	O
freeze	O
and	O
dry	O
it	O
,	O
through	O
gel	O
molecular	O
chromatography	O
,	O
accumulate	O
the	O
separated	O
product	O
with	O
the	O
relative	O
molecule	O
mass	O
between	O
10,000	O
-	O
110,000	O
,	O
then	O
freeze	O
and	O
dry	O
it	O
again	O
to	O
acquire	O
the	O
Chinese	O
angelica	O
polysaccharide	O
.	O

The	O
invention	O
has	O
remarkable	O
analgesia	O
for	O
ache	O
caused	O
by	O
chemicals	O
and	O
hot	O
simulation	O
;	O
as	O
well	O
as	O
dysmenorrheal	O
caused	O
by	O
female	O
hormone	O
;	O
and	O
it	O
can	O
be	O
made	O
into	O
drug	O
for	O
analgesia	O
especially	O
that	O
for	O
curing	O
dysmenorrheal	O
.	O

Use	O
of	O
rapamycin	O
in	O
preparation	O
of	O
intraocularly	O
embedded	O
drug	O
The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
rapamycin	O
(	O
RAPA	O
)	O
and	O
medicament	O
capable	O
of	O
self	O
-	O
degrading	O
in	O
preparing	O
eye	O
implantation	O
slow	O
release	O
medicament	O
,	O
the	O
medicament	O
can	O
keep	O
certain	O
reinforcement	O
and	O
shape	O
after	O
complete	O
release	O
,	O
and	O
can	O
be	O
naturally	O
degraded	O
under	O
internal	O
physiological	O
conditions	O
,	O
thus	O
can	O
be	O
absorbed	O
and	O
discharged	O
externally	O
through	O
metabolizing	O
,	O
and	O
no	O
secondary	O
surgery	O
is	O
needed	O
to	O
be	O
taken	O
out	O
.	O

The	O
invention	O
can	O
be	O
applied	O
to	O
the	O
repulsion	O
reaction	O
in	O
cornea	O
transplantation	O
for	O
treating	O
ophthalmology	O
diseases	O
.	O

Anti	O
cancer	O
gene	O
medicinal	O
composition	O
,	O
micromolecule	O
interfere	O
RNA	O
and	O
its	O
screening	O
method	O
The	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
composition	O
includes	O
antisense	O
fup1	O
gene	O
and/or	O
small	O
molecular	O
interfering	O
RNA	O
and	O
pharmaceutically	O
acceptable	O
supplementary	O
material	O
.	O

The	O
antisense	O
fup1	B
gene	O
has	O
the	O
DNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
2	O
in	O
the	O
sequence	O
list	O
,	O
while	O
the	O
small	O
molecular	O
interfering	O
RNA	O
includes	O
the	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
screening	O
method	O
to	O
design	O
small	O
molecular	O
interfering	O
RNA	O
based	O
on	O
fup1	O
encoding	O
area	O
via	O
adopting	O
ambion	O
web	O
site	O
provided	O
RNAi	O
design	O
software	O
.	O

The	O
present	O
invention	O
further	O
provides	O
liver	O
cancer	O
resisting	O
small	O
molecule	O
include	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
adopts	O
gene	O
fup1	O
high	O
expressed	O
in	O
liver	O
cancer	O
cell	O
as	O
medicine	O
target	O
to	O
design	O
the	O
antagonistic	O
molecule	O
to	O
provide	O
powerful	O
measure	O
for	O
the	O
gene	O
treatment	O
of	O
liver	O
cancer	O
and	O
excellent	O
platform	O
for	O
further	O
screening	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
.	O

Ethylamine	O
thiourea	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ethylamine	O
thiourea	O
injection	O
and	O
preparation	O
method	O
,	O
wherein	O
the	O
main	O
medicinal	O
constituent	O
is	O
diaminoethylisothiuramium	O
hydrobromate	O
.	O

By	O
employing	O
the	O
two	O
methods	O
of	O
cushioning	O
liquid	O
and	O
anti	O
-	O
oxidant	O
,	O
the	O
problem	O
of	O
unstable	O
ethylamine	O
thiocarbamide	O
can	O
be	O
solved	O
effectively	O
.	O

The	O
injection	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
for	O
manufacturing	O
and	O
stabilized	O
product	O
quality	O
.	O

New	O
action	O
and	O
application	O
of	O
methylene	O
blue	O
in	O
preventing	O
dental	O
caries	O
The	O
present	O
invention	O
relates	O
to	O
the	O
new	O
action	O
application	O
of	O
methylene	O
blue	O
in	O
preventing	O
dental	O
caries	O
.	O

Methylene	O
blue	O
is	O
used	O
as	O
effective	O
component	O
in	O
preparing	O
dental	O
caries	O
preventing	O
preparation	O
.	O

Method	O
for	O
preparing	O
hard	O
-	O
soluble	O
gel	O
formulation	O
The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
insoluble	O
medicine	O
gel	O
preparation	O
.	O

The	O
physiological	O
active	O
substance	O
of	O
said	O
gel	O
preparation	O
is	O
insoluble	O
medicine	O
.	O

Its	O
preparation	O
method	O
is	O
characterized	O
by	O
that	O
the	O
ink	O
course	O
of	O
preparation	O
of	O
gel	O
a	O
hydrophilic	O
substance	O
is	O
added	O
so	O
as	O
to	O
raise	O
the	O
solubility	O
of	O
main	O
medicine	O
in	O
water	O
,	O
and	O
can	O
make	O
the	O
main	O
medicine	O
be	O
uniformly	O
diffused	O
in	O
the	O
gel	O
,	O
and	O
the	O
gel	O
stability	O
is	O
good	O
.	O

Use	O
of	O
chitin	O
,	O
chitinous	O
glycan	O
and	O
its	O
derivative	O
biomembrane	O
in	O
medicinal	O
preparation	O
for	O
treaing	O
colpitis	O
and	O
cervicitis	O
An	O
application	O
of	O
the	O
membrane	O
made	O
of	O
chitin	O
,	O
chitosan	O
,	O
or	O
their	O
derivatives	O
in	O
treating	O
vaginitis	O
and	O
cervicitis	O
is	O
disclosed	O
.	O

Said	O
membrane	O
may	O
be	O
replaced	O
by	O
fibrous	O
net	O
or	O
composite	O
material	O
.	O

Anti	O
-	O
cancer	O
analgetic	O
preparation	O
The	O
anticancer	O
analgetic	O
preparation	O
has	O
lappaconitine	O
and	O
vincristine	O
as	O
main	O
active	O
anticancer	O
components	O
.	O

Lappaconitine	O
has	O
the	O
effect	O
of	O
increasing	O
the	O
sensitivity	O
of	O
vincristine	O
in	O
killing	O
cancer	O
cell	O
,	O
so	O
that	O
the	O
preparation	O
of	O
the	O
present	O
invention	O
can	O
reverse	O
the	O
drug	O
resistance	O
of	O
tumor	O
.	O

The	O
present	O
invention	O
has	O
obvious	O
functions	O
of	O
resisting	O
liver	O
cancer	O
,	O
lung	O
cancer	O
,	O
cancer	O
of	O
uterus	O
and	O
breast	O
cancer	O
,	O
stopping	O
pain	O
,	O
etc	O
.	O
and	O
has	O
the	O
feature	O
of	O
less	O
recovery	O
of	O
the	O
blood	O
supply	O
to	O
embolized	O
tumor	O
artery	O
.	O

Compared	O
with	O
similar	O
medicines	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
less	O
side	O
effect	O
,	O
high	O
tumor	O
cell	O
killing	O
effect	O
,	O
high	O
stability	O
,	O
low	O
cost	O
,	O
etc	O
.	O

Use	O
of	O
pentacylic	O
triterpene	O
compounds	O
in	O
preparing	O
glycogenic	B
phosphorylase	I
inhibitor	O
The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
pentacyclic	O
triterpene	O
compounds	O
in	O
preparing	O
glycogenic	B
phosphorylase	I
inhibitor	O
,	O
and	O
includes	O
the	O
application	O
of	O
medicine	O
composition	O
of	O
crataegolic	O
acid	O
,	O
Corosolic	O
acid	O
,	O
oleanolic	O
acid	O
,	O
ursolic	O
acid	O
,	O
betulin	O
,	O
betulic	O
acid	O
,	O
lupeol	O
or	O
their	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
in	O
preparing	O
medicine	O
for	O
treating	O
diabetes	O
.	O

Oral	O
emulsion	O
combination	O
of	O
'	O
Chuanhuning	O
'	O
An	O
orally	O
-	O
taken	O
composite	O
emulsion	O
of	O
Chuanhuning	O
is	O
prepared	O
from	O
Chuanhuning	O
,	O
surfactant	O
as	O
emulsifier	O
,	O
organic	O
solvent	O
as	O
coemulsifier	O
and	O
oil	O
.	O

It	O
has	O
higher	O
biologic	O
utilization	O
rate	O
.	O

Nanometer	O
preparation	O
of	O
silybin	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
silybin	O
nano	O
medicinal	O
preparation	O
,	O
which	O
comprises	O
liposome	O
nano	O
particles	O
of	O
silybin	O
,	O
the	O
liposome	O
material	O
is	O
the	O
mixture	O
of	O
soya	O
bean	O
lecithin	O
,	O
vitamin	O
E	O
and	O
soyabean	O
oil	O
by	O
the	O
mass	O
ratio	O
of	O
1:2.5:12.5	O
-	O
1:15:24	O
,	O
the	O
mass	O
ratio	O
of	O
silybin	O
and	O
lipsome	O
material	O
is	O
1:32	O
-	O
1:400	O
,	O
the	O
grain	O
diameter	O
of	O
the	O
liposome	O
nano	O
particles	O
is	O
less	O
than	O
500	O
nanometer	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
preparing	O
process	O
of	O
the	O
preparation	O
.	O

Vaginal	O
tablet	O
with	O
clindamycin	O
and	O
metronidazole	O
The	O
invention	O
relates	O
to	O
a	O
vaginal	O
tablet	O
of	O
clindamycinum	O
and	O
metronidazole	O
,	O
which	O
uses	O
the	O
salts	O
or	O
esters	O
of	O
clindamycinum	O
and	O
metronidazole	O
as	O
the	O
active	O
constituents	O
,	O
and	O
the	O
conventional	O
tablets	O
as	O
the	O
auxiliary	O
material	O
.	O

Purple	O
bergenia	O
element	O
pentaacetylate	O
and	O
its	O
uses	O
The	O
invention	O
provides	O
a	O
Bergenini	O
penta	O
-	O
acetyl	O
,	O
whose	O
chemical	O
name	O
is	O
(	O
2R,3R,4R,4aS,10bS	O
)	O
-2-	O
(	O
acetoxymethyl	O
)	O
-9-methoxy-6-oxo-2,3,4,4a,6,10b	O
-	O
hexahydr	O
o	O
pyrano	O
[	O
3,2-c	O
]	O
isochromene-3,4,8,10-tetrayl	O
tetraacetate	O
,	O
and	O
is	O
prepared	O
from	O
Bergenini	O
as	O
lead	O
compound	O
through	O
butanoylation	O
reaction	O
,	O
the	O
hydroxyl	O
on	O
the	O
precursor	O
is	O
blocked	O
so	O
as	O
to	O
enhance	O
the	O
lipophilicity	O
.	O

The	O
Bergenini	O
penta	O
-	O
acetyl	O
can	O
be	O
used	O
for	O
preparing	O
medicine	O
for	O
relieving	O
cough	O
.	O

The	O
invention	O
further	O
provides	O
a	O
compound	O
preparation	O
containing	O
the	O
Bergenini	O
penta	O
-	O
acetyl	O
.	O

Azithromycin	O
gel	O
The	O
present	O
invention	O
relates	O
to	O
an	O
azithromycin	O
gel	O
.	O

Its	O
composition	O
includes	O
(	O
weight	O
portion	O
)	O
1	O
-	O
5	O
portions	O
of	O
azithromycin	O
,	O
0.5	O
-	O
10	O
portions	O
of	O
skeleton	O
materials	O
,	O
suchas	O
agar	O
and	O
arabic	O
gum	O
,	O
etc	O
.	O

capable	O
of	O
forming	O
gel	O
,	O
25	O
-	O
35	O
portions	O
of	O
sweetening	O
agent	O
and	O
80	O
-	O
120	O
portions	O
of	O
water	O
.	O

Ointment	O
medicine	O
for	O
treating	O
bedsore	O
The	O
present	O
invention	O
discloses	O
an	O
ointment	O
medicine	O
preparation	O
for	O
curing	O
bed	O
sore	O
with	O
obvious	O
therapeutic	O
effect	O
.	O

Its	O
raw	O
material	O
composition	O
includes	O
(	O
by	O
weight	O
portion	O
)	O
0.1	O
-	O
5	O
portions	O
of	O
berberine	O
,	O
20	O
-	O
40	O
portions	O
of	O
fluocinonide	O
ointment	O
,	O
0.1	O
-	O
5	O
portions	O
of	O
Yunnan	O
white	O
medicine	O
and	O
0.1	O
-	O
5	O
portions	O
of	O
sulfonamides	O
anti	O
-	O
inflammatory	O
powder	O
.	O

Soybean	O
isoflavone	O
soft	O
capsule	O
and	O
its	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
soybean	O
isoflavone	O
soft	O
capsule	O
and	O
the	O
preparing	O
method	O
,	O
belonging	O
to	O
medical	O
field	O
,	O
with	O
the	O
technique	O
feature	O
being	O
:	O
the	O
material	O
in	O
the	O
capsule	O
comprising	O
soybean	O
isoflavone	O
,	O
phospholipid	O
,	O
calcium	O
salt	O
,	O
vitamin	O
,	O
anti	O
-	O
oxidant	O
,	O
capsule	O
stabilizing	O
agent	O
and	O
deflocculating	O
agent	O
,	O
the	O
capsule	O
shell	O
comprising	O
gelatine	O
,	O
plasticity	O
agent	O
,	O
conservative	O
,	O
hiding	O
agent	O
,	O
coloring	O
matter	O
,	O
corrective	O
and	O
water	O
.	O

The	O
soft	O
capsule	O
prepared	O
by	O
using	O
method	O
in	O
this	O
invention	O
is	O
characterized	O
by	O
the	O
stale	O
quality	O
,	O
safety	O
,	O
convenient	O
usage	O
,	O
ease	O
for	O
body	O
adsorption	O
,	O
and	O
high	O
bioavailability	O
,	O
and	O
particularly	O
be	O
used	O
for	O
regulating	O
the	O
estrogenic	O
hormones	O
for	O
menopausal	O
woman	O
,	O
and	O
for	O
preventing	O
and	O
treating	O
disease	O
relevant	O
with	O
estrogenic	O
hormones	O
.	O

Breviscapine	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
Breviscapine	O
oral	O
disintegrating	O
tablet	O
,	O
which	O
comprises	O
21.0	O
-	O
35.0	O
wt%	O
of	O
Breviscapine	O
,	O
11.0	O
-	O
15.0.0wt%	O
of	O
sodium	O
carboxymethylstarch	O
,	O
45.0	O
-	O
60.0	O
wt%	O
of	O
crystalline	O
cellulose	O
,	O
1.0	O
-	O
2.0	O
wt%	O
of	O
magnesium	O
stearate	O
,	O
5.0	O
-	O
10.0	O
wt%	O
of	O
miropowdered	O
silica	O
gel	O
,	O
and	O
0.1	O
-	O
0.5wt%	O
of	O
Aspartame	O
.	O

the	O
relative	O
weight	O
ratio	O
of	O
Breviscapine	O
and	O
sodium	O
carboxymethylstarch	O
is	O
1:0.3	O
-	O
1:0.7	O
.	O

Non	O
-	O
metal	O
salt	O
of	O
Glicididazole	O
and	O
its	O
prepn	O
The	O
present	O
invention	O
relates	O
to	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	O
,	O
including	O
ammonium	O
salt	O
of	O
glycididazole	O
,	O
diethylamine	O
double	O
salt	O
of	O
glycididazole	O
and	O
ethylene	O
diamine	O
double	O
salt	O
of	O
glycididazole	O
,	O
and	O
their	O
preparation	O
process	O
.	O

The	O
present	O
invention	O
provides	O
new	O
glycididazole	O
compounds	O
with	O
improved	O
water	O
solubility	O
and	O
stability	O
for	O
convenient	O
medicinal	O
application	O
.	O

In	O
addition	O
,	O
the	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	O
are	O
non	O
-	O
sodium	O
ion	O
salt	O
and	O
can	O
avoid	O
sodium	O
accumulation	O
and	O
other	O
bad	O
reaction	O
causing	O
electrolyte	O
metabolism	O
disorder	O
.	O

Stepronin	O
injection	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
is	O
new	O
preparation	O
form	O
of	O
Stepronin	O
,	O
especially	O
great	O
capacity	O
Stepronin	O
injection	O
,	O
and	O
its	O
preparation	O
process	O
.	O

The	O
injection	O
consists	O
of	O
Stepronin	O
or	O
its	O
metal	O
salt	O
or	O
amino	O
salt	O
as	O
active	O
component	O
and	O
medicinal	O
carrier	O
.	O

Compared	O
with	O
available	O
orally	O
taken	O
Stepronin	O
preparation	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
medicine	O
absorption	O
,	O
fast	O
medicine	O
dispersion	O
,	O
fast	O
acting	O
,	O
etc	O
.	O

The	O
present	O
invention	O
expands	O
the	O
administration	O
range	O
of	O
Stepronin	O
and	O
raises	O
the	O
clinical	O
administration	O
level	O
of	O
Stepronin	O
.	O

(	O
3R,4R	O
)	O
-trans-3,4-diarylchroman	O
derivatives	O
with	O
estrogenic	O
activity	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
substituents	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
arranged	O
in	O
trans	O
-	O
configuration	O
,	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R<1	O
>	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
;	O
C3-C7	O
cycloalkyl	O
;	O
R<2	O
>	O
is	O
phenyl	O
,	O
optionally	O
substituted	O
with	O
1	O
to	O
5	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
OH	O
,	O
C1-C6	O
-alkyl	O
,	O
halogen	O
,	O
nitro	O
,	O
cyano	O
,	O
SH	O
,	O
SR<4	O
>	O
,	O
trihalo	O
-	O
C1-C6-alkyl	O
,	O
C1-C6	O
-alkoxy	O
and	O
phenyl	O
,	O
wherein	O
R<4	O
>	O
is	O
C1-C6	O
alkyl;R<3	O
>	O
is	O
phenyl	O
substituted	O
with	O
OR<5	O
>	O
wherein	O
R<5	O
>	O
has	O
the	O
Formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
or	O
(	O
IV	O
)	O
,	O
wherein	O
Y	O
is	O
chosen	O
from	O
NHR<4	O
>	O
,	O
NR<4>2	O
,	O
NHCOR<4	O
>	O
,	O
NHSO2R<4	O
>	O
,	O
CONHR<4	O
>	O
,	O
CONR<4	O
>	O
,	O
CONR<4>2	O
,	O
COOH	O
,	O
COOR<4	O
>	O
,	O
SO2R<4	O
>	O
,	O
SOR<4	O
>	O
,	O
SONHR<4	O
>	O
,	O
SONR<4>2	O
,	O
a	O
C3-C7	O
heterocyclic	O
ring	O
,	O
saturated	O
or	O
unsaturated	O
,	O
containing	O
one	O
or	O
two	O
heteroatoms	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
O	O
,	O
S	O
and	O
N	O
,	O
optionally	O
being	O
substituted	O
with	O
1	O
to	O
3	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
H	O
,	O
OH	O
,	O
halogen	O
,	O
nitro	O
,	O
cyano	O
,	O
SH	O
,	O
SR<4	O
>	O
,	O
trihalo	O
-	O
C1-C6-	O
alkyl	O
,	O
C1-C6-alkyl	O
and	O
C1-C6	O
-alkoxy	O
,	O
preferably	O
NHR<4	O
>	O
,	O
NR2<4	O
>	O
,	O
or	O
a	O
nitrogen	O
heterocycle	O
,	O
wherein	O
R<4	O
>	O
is	O
as	O
defined	O
above	O
,	O
and	O
the	O
esters	O
,	O
ethers	O
,	O
and	O
salts	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
optionally	O
along	O
pharmaceutically	O
acceptable	O
excipients	O
,	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
a	O
method	O
of	O
preventing	O
and/or	O
treating	O
estrogen	O
-	O
related	O
disease	O
conditions	O
in	O
a	O
subject	O
using	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
its	O
salts	O
,	O
optionally	O
along	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Tape	O
preparation	O
The	O
present	O
invention	O
provides	O
a	O
tape	O
preparation	O
including	O
a	O
support	O
and	O
an	O
adhesive	O
layer	O
directly	O
or	O
indirectly	O
formed	O
on	O
at	O
least	O
one	O
surface	O
of	O
the	O
support	O
,	O
wherein	O
the	O
adhesive	O
layer	O
contains	O
a	O
rubber	O
adhesive	O
containing	O
at	O
least	O
one	O
kind	O
of	O
rubber	O
polymer	O
and	O
capsaicin	O
as	O
an	O
active	O
ingredient	O
.	O

Since	O
the	O
adhesive	O
layer	O
shows	O
extremely	O
fine	O
adhesive	O
property	O
and	O
superior	O
capsaicin	O
releaseability	O
,	O
a	O
rapid	O
pharmacological	O
effect	O
can	O
be	O
afforded	O
with	O
a	O
small	O
capsaicin	O
content	O
.	O

Micro	O
-	O
powder	O
dom	O
peridone	O
maleate	O
medicinal	O
composition	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
with	O
domperidone	O
maleate	O
.	O

It	O
is	O
characterized	O
by	O
that	O
said	O
medicine	O
composition	O
is	O
micropowdered	O
,	O
and	O
can	O
be	O
used	O
for	O
invigorating	O
function	O
of	O
gastrointestinal	O
tract	O
and	O
curing	O
the	O
diseases	O
of	O
dyspepsia	O
and	O
nausea	O
-	O
vomiting	O
,	O
etc	O
.	O

Said	O
micropowdered	O
domperidone	O
maleate	O
preparation	O
can	O
raise	O
its	O
bioavailability	O
.	O

Besides	O
,	O
said	O
invention	O
also	O
provides	O
its	O
preparation	O
method	O
.	O

Compound	O
Silybum	O
drip	O
balls	O
and	O
preparation	O
thereof	O
A	O
dripping	O
pill	O
of	O
compound	O
silymarinum	O
is	O
prepared	O
from	O
the	O
silymarinum	O
and	O
the	O
alcohol	O
extract	O
of	O
5	O
kernels	O
through	O
proportionally	O
mixing	O
it	O
with	O
matrix	O
(	O
polyoxyvinyl	O
monostearate	O
)	O
,	O
heating	O
until	O
the	O
mixture	O
is	O
fused	O
,	O
stirring	O
,	O
and	O
dripping	O
in	O
condensing	O
liquid	O
.	O

Ganciclovir	O
ophthalmic	O
gel	O
and	O
its	O
prepn	O
.	O

method	O
An	O
eye	O
gel	O
of	O
Ganciclovir	O
for	O
treating	O
viral	O
keratitis	O
is	O
proportionally	O
prepared	O
from	O
ganciclovir	O
and	O
eye	O
gel	O
matrix	O
through	O
mixing	O
Ganciclovir	O
,	O
eye	O
gel	O
matrix	O
and	O
water	O
,	O
stirring	O
,	O
regulating	O
pH	O
value	O
,	O
adding	O
water	O
,	O
stirring	O
and	O
sterilizing	O
.	O

Soft	O
capsule	O
of	O
medication	O
composition	O
,	O
and	O
preparation	O
method	O
A	O
composite	O
medicine	O
in	O
the	O
form	O
of	O
softgel	O
is	O
prepared	O
from	O
domperidone	O
and	O
the	O
auxiliary	O
chosen	O
from	O
diluent	O
,	O
cosolvent	O
,	O
solubilizer	O
and	O
surfactant	O
.	O

It	O
has	O
high	O
stability	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Application	O
of	O
medication	O
composition	O
of	O
containing	O
acetamino	O
phenol	O
in	O
treating	O
insufficiency	O
of	O
blood	O
supply	O
for	O
brain	O
An	O
application	O
of	O
the	O
medicinal	O
composition	O
containing	O
paracetamol	O
,	O
propylphenazone	O
and	O
caffeine	O
in	O
treating	O
cerebral	O
ischemia	O
is	O
disclosed	O
.	O

Method	O
for	O
preparing	O
rhubarb	O
sulfur	O
gel	O
agent	O
The	O
invention	O
relates	O
to	O
the	O
process	O
for	O
preparing	O
gelling	O
agent	O
of	O
rhubarb	O
horsetails	O
and	O
sulfur	O
by	O
using	O
free	O
anthraquinone	O
of	O
rhubarb	O
horsetails	O
extract	O
and	O
sulfur	O
as	O
the	O
main	O
constituents	O
,	O
using	O
carbomer	O
as	O
the	O
gel	O
matrix	O
,	O
and	O
using	O
methyl	O
ethylene	O
glycol	O
and	O
urea	O
as	O
the	O
mixed	O
transdermal	O
accelerating	O
agent	O
.	O

The	O
preparation	O
can	O
be	O
used	O
for	O
treating	O
acne	O
.	O

An	O
externally	O
applied	O
medicine	O
for	O
treating	O
hicismus	O
by	O
use	O
of	O
steatite	O
Disclosed	O
is	O
an	O
externally	O
used	O
medicament	O
for	O
treating	O
tragomaschalia	O
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
talcum	O
powder	O
,	O
goldthread	O
root	O
,	O
dandelion	O
,	O
gypsum	O
,	O
camphor	O
,	O
perfume	O
compound	O
and	O
ethanol	O
.	O

Compound	O
medicine	O
composition	O
and	O
its	O
prepn	O
and	O
use	O
The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
veterinary	O
medicine	O
composition	O
for	O
eliminating	O
fever	O
,	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
and	O
its	O
preparation	O
process	O
and	O
use	O
.	O

The	O
veterinary	O
medicine	O
composition	O
consists	O
of	O
diclofenac	O
sodium	O
and	O
naproxen	O
in	O
the	O
weight	O
ratio	O
of	O
0.1	O
-	O
10	O
,	O
preferably	O
0.2	O
-	O
5	O
;	O
or	O
consists	O
of	O
diclofenac	O
sodium	O
and	O
barbitone	O
in	O
the	O
weight	O
ratio	O
of	O
0.2	O
-	O
10	O
,	O
preferably1	O
-	O
7.5	O
.	O

The	O
veterinary	O
medicine	O
composition	O
is	O
used	O
in	O
preventing	O
and	O
treating	O
feverish	O
animal	O
diseases	O
and	O
has	O
synergistic	O
fever	O
eliminating	O
effect	O
,	O
fast	O
acting	O
and	O
less	O
recurrence	O
.	O

Sobering	O
-	O
up	O
beverage	O
A	O
sobering	O
-	O
up	O
beverage	O
is	O
proportionally	O
prepared	O
from	O
8	O
raw	O
materials	O
including	O
purified	O
water	O
,	O
pear	O
juice	O
,	O
pueraria	O
root	O
(	O
or	O
flower	O
)	O
,	O
ginsenoside	O
Rg3	O
,	O
rebescensine	O
A	O
,	O
isoliquiritigenin	O
,	O
etc	O
.	O

Chlorhydric	O
acid	O
tranditerol	O
aerosol	O
The	O
invention	O
provides	O
a	O
Tranditerol	O
Hydrochloride	O
aerosol	O
,	O
which	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O

Tranditerol	O
Hydrochloride	O
0.005	O
-	O
0.01	O
part	O
,	O
double	O
solvent	O
5	O
-	O
10	O
parts	O
,	O
and	O
propellant	O
90	O
-	O
95	O
parts	O
.	O

Preparation	O
method	O
of	O
dexibuprofen	O
amino	O
acid	O
salt	O
and	O
application	O
The	O
invention	O
discloses	O
a	O
nalorphine	O
amino	O
compound	O
and	O
preparing	O
method	O
with	O
structural	O
formula	O
as	O
(	O
I	O
)	O
,	O
wherein	O
the	O
amino	O
can	O
be	O
Arg	O
,	O
Lys	O
or	O
His	O
;	O
the	O
molecular	O
rate	O
of	O
nalorphine	O
and	O
amino	O
is	O
1:1	O
-	O
1	O
:	O
5	O
or	O
5:1	O
-	O
1:1	O
.	O

Nifuratel	O
-	O
nystatin	O
vaginal	O
effervescent	O
-	O
tablets	O
The	O
invention	O
relates	O
to	O
a	O
nifungin	O
-	O
canstat	O
vagina	O
effervescent	O
tablet	O
.	O

Wherein	O
,	O
it	O
uses	O
nifungin	O
and	O
canstat	O
,	O
with	O
acid	O
-	O
alkali	O
adding	O
system	O
,	O
and	O
stuff	O
or	O
directly	O
being	O
compressed	O
into	O
tablet	O
or	O
particles	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
,	O
or	O
uses	O
macrogol	O
to	O
cover	O
the	O
alkali	O
,	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
.	O

The	O
invention	O
uses	O
the	O
acid	O
alkali	O
system	O
which	O
will	O
generate	O
carbon	O
dioxide	O
gas	O
when	O
meeting	O
water	O
as	O
slaking	O
agent	O
;	O
therefore	O
,	O
the	O
tablet	O
will	O
foam	O
and	O
slake	O
when	O
adsorbs	O
water	O
in	O
vagina	O
,	O
to	O
disperse	O
the	O
elements	O
into	O
vagina	O
completely	O
,	O
as	O
uterine	O
cervix	O
,	O
etc	O
.	O

Aromatic	O
reductive	O
derivative	O
of	O
geldanamycin	O
benzoquinone	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
geldanamycin	O
type	O
aromatic	O
reduced	O
benzoquinone	O
derivative	O
and	O
its	O
preparation	O
process	O
as	O
well	O
as	O
the	O
medicine	O
composition	O
with	O
the	O
compound	O
as	O
active	O
component	O
and	O
its	O
use	O
.	O

The	O
compound	O
is	O
prepared	O
through	O
fermentation	O
with	O
,	O
say	O
,	O
pseudostreptoverticillium	O
,	O
and	O
it	O
is	O
proved	O
experimentally	O
that	O
the	O
compound	O
may	O
be	O
used	O
in	O
preparing	O
cell	O
period	O
inhibitor	O
and	O
antitumor	O
preparation	O
.	O

Stomatocase	O
treating	O
medicine	O
The	O
stomatocase	O
treating	O
medicine	O
is	O
prepared	O
with	O
five	O
kinds	O
of	O
main	O
materials	O
,	O
including	O
gypsum	O
,	O
cape	O
jasmine	O
,	O
reed	O
rhizome	O
,	O
mint	O
and	O
anemarrhena	O
rhizome	O
,	O
and	O
six	O
kinds	O
of	O
supplementary	O
medicine	O
materials	O
,	O
including	O
rehmannia	O
root	O
,	O
skullcap	O
root	O
,	O
etc	O
.	O

The	O
present	O
invention	O
has	O
unique	O
recipe	O
,	O
obvious	O
treating	O
effect	O
and	O
fast	O
acting	O
.	O

Pediatric	O
paracetamol	O
artifical	O
low	O
-	O
bezoar	O
and	O
chlorphenzmine	O
maleategel	O
preparation	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
a	O
Xiaoer	O
anfenhuangnamin	O
gel	O
preparation	O
for	O
children	O
and	O
its	O
preparation	O
method	O
.	O

Said	O
gel	O
preparation	O
composition	O
contains	O
(	O
by	O
wt%	O
)	O
0.05	O
-	O
30	O
%	O
of	O
acetaminophen	O
,	O
0.005	O
-	O
1	O
%	O
of	O
artificial	O
cow	O
-	O
bezoare	O
,	O
0.0005	O
-	O
0.08	O
%	O
of	O
chlorpheamine	O
maleate	O
,	O
0.2	O
-	O
10	O
%	O
of	O
agar	O
,	O
1	O
-	O
20	O
%	O
of	O
cane	O
sugar	O
,	O
1	O
-	O
10	O
%	O
of	O
cyclodextrin	O
and	O
45	O
-	O
90	O
%	O
of	O
water	O
.	O

Pharmaceutical	O
use	O
of	O
ent	O
-	O
eudesmane	O
alcohol	O
type	O
sesquiterpene	O
for	O
inhibiting	O
hepatitis	O
virus	O
The	O
invention	O
relates	O
to	O
an	O
enantiomorphic	O
amine	O
alkyl	O
sesquiterpene	O
alcohol	O
and	O
glucoside	O
and	O
the	O
medicated	O
salt	O
or	O
solvent	O
thereof	O
,	O
as	O
well	O
as	O
the	O
effect	O
and	O
activity	O
of	O
the	O
composed	O
medicine	O
combination	O
,	O
mainly	O
relating	O
to	O
the	O
medical	O
use	O
in	O
reducing	O
HBV	O
-	O
DNA	O
replication	O
activity	O
.	O

And	O
it	O
has	O
considerably	O
strong	O
inhibiting	O
effect	O
on	O
HBsAG	O
screted	O
by	O
HepG2.2.15	O
and	O
HBV	O
-	O
DNA	O
replication	O
as	O
compared	O
with	O
positive	O
contrast	O
Lamivudine	O
;	O
and	O
it	O
has	O
obvious	O
inhibition	O
activity	O
to	O
HBV	O
-	O
DNA	O
replication	O
at	O
large	O
dosage	O
(	O
100	O
mug	O
/	O
mL	O
)	O
and	O
medium	O
dosage	O
(	O
20	O
mug	O
/	O
mL	O
)	O
as	O
contrasted	O
with	O
Lamivudine	O
,	O
and	O
can	O
be	O
expected	O
to	O
apply	O
to	O
preparing	O
medicines	O
for	O
curing	O
HB	O
virus	O
infection	O
disease	O
.	O

Medical	O
usage	O
of	O
milkvetch	O
-	O
root	O
methcoside	O
An	O
application	O
of	O
astragaloside	O
A	O
in	O
preventing	O
and	O
treating	O
acute	O
or	O
chronic	O
nephritis	O
and	O
acute	O
or	O
chronic	O
renal	O
failure	O
,	O
its	O
preparing	O
process	O
,	O
and	O
its	O
medical	O
composition	O
are	O
disclosed	O
.	O

Fat	O
emulsion	O
injection	O
liquid	O
containing	O
soybean	O
oil	O
,	O
medium	O
chain	O
triglyceride	O
,	O
olive	O
oil	O
and	O
fish	O
oil	O
and	O
method	O
for	O
preparing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
an	O
intralipid	O
injection	O
which	O
contains	O
soya	O
oil	O
,	O
middle	O
chain	O
triglyceride	O
,	O
olive	O
oil	O
,	O
and	O
fish	O
oil	O
,	O
wherein	O
it	O
comprises	O
48	O
-	O
72	O
g	O
.	O

L	O
soya	O
oil	O
,	O
48	O
-	O
72g	O
/	O
L	O
middle	O
chain	O
triglyceride	O
,	O
40	O
-	O
60g	O
/	O
L	O
olive	O
oil	O
,	O
and	O
24	O
-	O
36g	O
/	O
L	O
fish	O
oil	O
,	O
108	O
-	O
162	O
mg	O
/	O
L	O
dl	O
-	O
alpha	O
-	O
tocofecol	O
,	O
9.6	O
-	O
14.4g	O
/	O
L	O
lipovitellin	O
,	O
22.5	O
-	O
27.5g	O
/	O
L	O
pure	O
glycerin	O
,	O
240	O
-	O
360mg	O
/	O
L	O
sodium	O
oleate	O
,	O
18	O
-	O
22mg	O
/	O
L	O
caustic	O
soda	O
,	O
and	O
1L	O
injection	O
water	O
.	O

The	O
ratio	O
between	O
w-6	O
and	O
w-3	O
aliphatic	O
acid	O
is	O
3.0	O
-	O
2.2:1	O
.	O

The	O
invention	O
optimizes	O
and	O
balances	O
the	O
aliphatic	O
acid	O
mode	O
.	O

Medicament	O
for	O
harmonizing	O
middle	O
energizer	O
,	O
invigorating	O
spleen	O
and	O
regulating	O
stomach	O
function	O
The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
spleen	O
-	O
reinforcing	O
and	O
digestion	O
-	O
promoting	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
medicament	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O
wrinkled	O
giant	O
hyssop	O
3	O
-	O
8	O
,	O
cape	O
jasmine	O
2	O
-	O
5	O
,	O
calcium	O
sulphate	O
3	O
-	O
8	O
,	O
licorice	O
root	O
5	O
-	O
10	O
,	O
ledebouriella	O
root	O
10	O
-	O
20	O
,	O
ginseng	O
3	O
-	O
8	O
,	O
poria	O
cocos	O
wolf	O
2	O
-	O
5	O
,	O
white	O
atractylodes	O
rhizome	O
2	O
-	O
5	O
,	O
dried	O
orange	O
peel	O
2	O
-	O
5	O
,	O
cardamorn	O
0.1	O
-	O
0.2	O
,	O
clove	O
0.1	O
-	O
0.2	O
,	O
sulfur	O
flour	O
0.1	O
-	O
0.2	O
and	O
talcum	O
powder	O
0.3	O
-	O
0.8	O
.	O

Largngopharyngitis	O
treating	O
medicine	O
composition	O
and	O
its	O
preparation	O
The	O
medicine	O
composition	O
for	O
treating	O
laryngopharyngitis	O
is	O
prepared	O
with	O
rehmannia	O
root	O
5	O
-	O
100	O
weight	O
portions	O
,	O
date	O
coating	O
3	O
-	O
100	O
weight	O
portions	O
,	O
and	O
tortoise	O
plastron	O
5	O
-	O
200	O
weight	O
portions	O
.	O

The	O
preparation	O
process	O
includes	O
the	O
steps	O
of	O
decoction	O
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
to	O
obtain	O
paste	O
of	O
density	O
1.00	O
-	O
1.15	O
,	O
dissolving	O
the	O
paste	O
in	O
alcohol	O
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
toobtain	O
dense	O
paste	O
of	O
density	O
1.20	O
-	O
1.50	O
while	O
recovering	O
alcohol	O
,	O
and	O
drying	O
to	O
obtain	O
the	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
is	O
used	O
in	O
treating	O
laryngopharyngitis	O
,	O
and	O
has	O
high	O
safety	O
,	O
low	O
cost	O
,	O
high	O
effective	O
component	O
content	O
and	O
high	O
stability	O
.	O

Medicament	O
composition	O
of	O
cefpodoxime	O
proxetil	O
and	O
cyclodextrin	O
and	O
preparation	O
method	O
thereof	O
A	O
medication	O
compound	O
,	O
which	O
include	O
cyclodextrin	O
and	O
cephalosporin	O
ester	O
's	O
clathrate	O
;	O
this	O
invention	O
alao	O
related	O
to	O
the	O
method	O
to	O
produce	O
it	O
.	O

Cerumen	O
softening	O
agent	O
The	O
invention	O
relates	O
to	O
a	O
solvent	O
for	O
softening	O
ear	O
wax	O
,	O
which	O
is	O
prepared	O
from	O
compositions	O
of	O
sodium	O
hydrogen	O
carbonate	O
,	O
water	O
and	O
glycerine	O
through	O
specific	O
processes	O
.	O

The	O
medicament	O
provided	O
by	O
the	O
invention	O
has	O
good	O
effect	O
in	O
softening	O
ear	O
wax	O
,	O
and	O
easy	O
accessibility	O
of	O
raw	O
material	O
.	O

4-methyl	O
cyclopentadecanone	O
and	O
its	O
uses	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
4-methyl	O
cyclopentadecanone	O
in	O
the	O
drug	O
of	O
ischemic	O
cerebrovascular	O
disease	O
,	O
which	O
also	O
treats	O
antirheumatic	O
,	O
rheumatoid	O
disease	O
as	O
well	O
as	O
prevent	O
tumour	O
.	O

Bra	O
technical	O
structure	O
The	O
utility	O
model	O
relates	O
to	O
a	O
bra	O
technical	O
structure	O
simple	O
in	O
structure	O
and	O
convenient	O
for	O
the	O
use	O
of	O
a	O
bra	O
or	O
bra	O
pads	O
filled	O
with	O
medicine	O
,	O
wherein	O
hollow	O
protection	O
layers	O
in	O
contact	O
with	O
the	O
breasts	O
are	O
arranged	O
on	O
the	O
bra	O
or	O
the	O
bra	O
pads	O
,	O
and	O
openings	O
corresponding	O
to	O
the	O
breasts	O
are	O
formed	O
on	O
the	O
two	O
protection	O
layers	O
;	O
medicine	O
materials	O
are	O
arranged	O
in	O
the	O
protective	O
layers	O
after	O
being	O
wrapped	O
by	O
soft	O
and	O
air	O
permeable	O
cloths	O
,	O
so	O
as	O
to	O
permeate	O
through	O
the	O
breasts	O
through	O
the	O
contact	O
between	O
the	O
openings	O
on	O
the	O
protective	O
layers	O
and	O
the	O
breast	O
skins	O
;	O
by	O
wearing	O
the	O
bra	O
,	O
the	O
skin	O
-	O
permeation	O
of	O
the	O
medicine	O
can	O
stimulate	O
the	O
hormone	O
to	O
secrete	O
,	O
and	O
can	O
preserve	O
the	O
excellent	O
shapes	O
of	O
the	O
breasts	O
;	O
in	O
addition	O
,	O
as	O
the	O
medicine	O
has	O
the	O
functions	O
of	O
anti	O
-	O
inflammatory	O
detumescence	O
and	O
blood	O
circulation	O
improvement	O
,	O
the	O
translucency	O
of	O
the	O
breasts	O
can	O
be	O
enhanced	O
,	O
the	O
lump	O
shadow	O
is	O
lessened	O
,	O
and	O
the	O
vascularity	O
gradually	O
becomes	O
normal	O
,	O
and	O
therefore	O
the	O
purposes	O
of	O
health	O
care	O
,	O
breast	O
enlarging	O
and	O
breast	O
rounding	O
and	O
firming	O
are	O
achieved	O
.	O

Drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
bleeding	O
amount	O
in	O
operation	O
In	O
order	O
to	O
solve	O
the	O
technical	O
problem	O
existing	O
in	O
the	O
process	O
of	O
delivering	O
the	O
drug	O
to	O
the	O
skin	O
for	O
reduction	O
of	O
bleeding	O
amount	O
when	O
an	O
operation	O
is	O
performed	O
at	O
present	O
,	O
the	O
utility	O
model	O
relates	O
to	O
medical	O
supplies	O
,	O
and	O
provides	O
a	O
drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
the	O
bleeding	O
amount	O
in	O
an	O
operation	O
.	O

The	O
drug	O
delivery	O
plaster	O
comprises	O
a	O
plaster	O
body	O
,	O
and	O
is	O
characterized	O
in	O
that	O
the	O
plaster	O
body	O
is	O
formed	O
by	O
three	O
layers	O
,	O
wherein	O
the	O
surface	O
layer	O
is	O
a	O
bonding	O
layer	O
with	O
viscosity	O
,	O
and	O
a	O
plurality	O
of	O
drug	O
delivery	O
holes	O
are	O
formed	O
in	O
the	O
bonding	O
layer	O
,	O
the	O
intermediate	O
layer	O
is	O
a	O
drug	O
layer	O
,	O
the	O
bottom	O
layer	O
is	O
a	O
heating	O
layer	O
,	O
and	O
heater	O
strips	O
are	O
arranged	O
in	O
the	O
heating	O
layer	O
;	O
a	O
power	O
interface	O
connected	O
with	O
an	O
external	O
power	O
supply	O
is	O
arranged	O
in	O
the	O
bottom	O
surface	O
of	O
the	O
bottom	O
layer	O
.	O

The	O
drug	O
delivery	O
plaster	O
is	O
reasonable	O
in	O
structure	O
,	O
convenient	O
to	O
use	O
and	O
high	O
in	O
drug	O
delivery	O
efficiency	O
,	O
and	O
can	O
be	O
widely	O
applied	O
to	O
surgical	O
operations	O
.	O

New	O
piperazine	O
salt	O
of	O
omeprazol	O
is	O
proton	B
pump	I
inhibitor	O
useful	O
to	O
prevent	O
/	O
treat	O
e.g.	O
peptic	O
ulcer	O
,	O
gastritis	O
,	O
gastroesophageal	O
reflux	O
,	O
acute	O
stress	O
ulcer	O
or	O
dyspepsia	O
Piperazine	O
salt	O
(	O
I	O
)	O
of	O
omeprazole	O
or	O
its	O
enantiomer	O
is	O
new	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
the	O
preparation	O
of	O
(	O
I	O
)	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
.	O
;	O
Antiulcer	O
;	O
Antiinflammatory	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	O
pump	O
inhibitor	O
.	O

No	O
biological	O
data	O
given	O
.	O

Composition	O
for	O
topical	O
application	O
,	O
useful	O
as	O
a	O
cosmetic	O
or	O
dermatological	O
product	O
,	O
contains	O
finely	O
divided	O
barium	O
sulfate	O
Composition	O
for	O
topical	O
application	O
contains	O
barium	O
sulfate	O
with	O
a	O
particle	O
size	O
of	O
1	O
-	O
30	O
mu	O
m.	O
An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
preparing	O
a	O
composition	O
as	O
above	O
by	O
adding	O
barium	O
sulfate	O
to	O
known	O
ingredients	O
of	O
conventional	O
cosmetic	O
products	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	O
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
emulsifiers	O
Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	O
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
emulsifiers	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
,	O
protection	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	O
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
UV	O
light	O
absorbers	O
Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	O
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
UV	O
light	O
absorbers	O
.	O

Veterinary	O
rehydration	O
product	O
A	O
composition	O
for	O
the	O
treatment	O
of	O
livestock	O
suffering	O
from	O
disorders	O
such	O
as	O
fluid	O
depletion	O
,	O
acidosis	O
,	O
and	O
imbalances	O
or	O
loss	O
of	O
essential	O
electrolytes	O
,	O
same	O
to	O
be	O
made	O
up	O
in	O
water	O
at	O
point	O
of	O
use	O
as	O
an	O
oral	O
rehydration	O
formulation	O
,	O
comprises	O
an	O
intimate	O
mixture	O
of	O
an	O
energy	O
source	O
,	O
electrolytes	O
,	O
and	O
bicarbonate	O
precursors	O
,	O
which	O
precursors	O
are	O
provided	O
as	O
physiologically	O
acceptable	O
carboxylic	O
acid	O
anions	O
with	O
corresponding	O
physiologically	O
acceptable	O
cations	O
including	O
sodium	O
,	O
the	O
yield	O
of	O
bicarbonate	O
being	O
in	O
excess	O
of	O
30	O
millimole	O
/	O
litre	O
(	O
mmol	O
/	O
1	O
)	O
of	O
final	O
formulation	O
,	O
and	O
the	O
concentration	O
of	O
sodium	O
being	O
in	O
excess	O
of	O
80	O
mmol	O
/	O
1	O
of	O
final	O
formulation	O
.	O

[	O
a	O
]	O
-ANNELATED	O
PYRROLE	O
DERIVATIVES	O
AND	O
PHARMACEUTICAL	O
USES	O

THEREOF	O
The	O
present	O
invention	O
concerns	O
heterocyclic	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1-R7	O
,	O
B	O
,	O
a	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
.	O

These	O
compounds	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
rheumatic	O
ailments	O
and	O
for	O
the	O
prevention	O
of	O
allergic	O
illnesses	O
.	O

Method	O
for	O
inhibiting	O
adenylosuccinate	B
synthetase	I
activity	O
methylthioadenosine	B
phosphorylase	I
deficient	O
cells	O
An	O
in	O
vivo	O
method	O
for	O
depleting	O
mammalian	O
cells	O
of	O
adenosine	O
5'-monophosphate	O
(	O
AMP	O
)	O
useful	O
in	O
the	O
treatment	O
of	O
certain	O
cancers	O
is	O
provided	O
.	O

According	O
to	O
the	O
method	O
,	O
a	O
population	O
of	O
cells	O
is	O
obtained	O
from	O
a	O
host	O
and	O
assayed	O
for	O
loss	O
of	O
methylthioadenosine	B
phosphorylase	I
(	O
MTAse	B
)	O
activity	O
.	O

MTAse	B
catabolizes	O
methylthioadenosine	O
to	O
adenine	O
for	O
endogenous	O
salvage	O
incorporation	O
into	O
the	O
intracellular	O
AMP	O
pool	O
.	O

The	O
preferred	O
method	O
for	O
assaying	O
loss	O
of	O
MTAse	B
activity	O
is	O
a	O
hybridization	O
technique	O
for	O
detection	O
of	O
a	O
homozygous	O
loss	O
of	O
the	O
gene	O
which	O
encodes	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
which	O
inhibits	O
the	O
activity	O
of	O
adenylsuccinate	B
synthetase	I
,	O
which	O
converts	O
inosine	O
5'-monophosphate	O
to	O
AMP	O
,	O
thus	O
depleting	O
the	O
tumor	O
cells	O
of	O
substrates	O
for	O
de	O
novo	O
AMP	O
production	O
.	O

L	O
-	O
alanosine	O
is	O
the	O
preferred	O
ASS	B
inhibitory	O
agent	O
for	O
use	O
in	O
the	O
method	O
of	O
the	O
invention	O
.	O

The	O
figure	O
is	O
a	O
nucleotide	O
sequence	O
for	O
genomic	O
MTAse	O
(	O
SEQ	O
.	O
ID	O
.	O

No.	O
1	O
)	O
wherein	O
the	O
exons	O
are	O
underlined	O
.	O

Use	O
of	O
nk-1	B
receptor	I
antagonists	O
for	O
treating	O
major	O
depressive	O
disorders	O
with	O
anxiety	O
The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
an	O
orally	O
active	O
,	O
long	O
acting	O
,	O
CNS	O
-	O
penetrant	O
NK-1	B
receptor	I
antagonist	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
adapted	O
for	O
oral	O
administration	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
major	O
depressive	O
disorder	O
with	O
anxiety	O
without	O
concomitant	O
therapy	O
with	O
other	O
anti	O
-	O
depressant	O
or	O
anti	O
-	O
anxiety	O
agents	O
,	O
methods	O
of	O
treatment	O
using	O
such	O
a	O
NK-1	B
receptor	I
antagonist	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
.	O

Method	O
for	O
antagonizing	O
HEREGUlin	O
or	O
its	O
receptor	O
and	O
use	O
for	O
the	O
inhibition	O
of	O
cancer	O
cells	O
The	O
invention	O
provides	O
a	O
method	O
of	O
inhibiting	O
cancer	O
cell	O
growth	O
,	O
and	O
thereby	O
of	O
treating	O
cancer	O
comprising	O
administering	O
to	O
a	O
mammal	O
afflicted	O
with	O
cancer	O
an	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
R1+and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
specification	O
.	O

The	O
present	O
invention	O
also	O
provides	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
novel	O
pharmaceutical	O
compositions	O
and	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
figure	O
illustrates	O
the	O
structure	O
and	O
binding	O
activity	O
of	O
compounds	O
of	O
the	O
invention	O
and	O
some	O
of	O
the	O
rifamycin	O
analogs	O
.	O

Compositions	O
and	O
methods	O
for	O
stimulating	O
bone	O
growth	O
Compounds	O
of	O
formulas	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
X	O
,	O
Y	O
and	O
R	O
'	O
are	O
herein	O
defined	O
in	O
the	O
specification	O
,	O
promote	O
bone	O
information	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
.	O

The	O
figure	O
shows	O
the	O
structure	O
and	O
activity	O
of	O
several	O
compounds	O
of	O
the	O
invention	O
namely	O
,	O
nevastatin	O
,	O
lovastatin	O
and	O
pravastatin	O
,	O
as	O
tested	O
in	O
the	O
in	O
vitro	O
BMP	O
-	O
promoter	O
based	O
assay	O
.	O

Controlled	O
release	O
compositions	O
for	O
the	O
treatment	O
of	O
hyperlipidemia	O
Lipid	O
lowering	O
dosage	O
units	O
,	O
to	O
be	O
used	O
once	O
a	O
day	O
,	O
produce	O
minimal	O
side	O
effects	O
.	O

They	O
contain	O
a	O
combination	O
of	O
microspheres	O
formulated	O
to	O
co	O
-	O
deliver	O
a	O
HMG	B
-	I
CoA	I
reductase	I
inhibitor	O
component	O
and	O
a	O
niacin	O
component	O
.	O

Beta	B
-	I
catenin	I
,	O
tcf-4	B
,	O
and	O
apc	O
interact	O
to	O
prevent	O
cancer	O
The	O
APC	B
tumor	O
suppressor	O
protein	O
binds	O
to	O
beta	B
-catenin	I
,	O
a	O
protein	O
recently	O
shown	O
to	O
interact	O
with	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
.	O

Here	O
,	O
the	O
gene	O
encoding	O
a	O
Tcf	B
family	O
member	O
that	O
is	O
expressed	O
in	O
colonic	O
epithelium	O
(	O
hTcf-4	B
)	O
was	O
cloned	O
and	O
characterized	O
.	O

hTcf-4	B
transactivates	O
transcription	O
only	O
when	O
associated	O
with	O
beta	O
-catenin	O
.	O

Nuclei	O
of	O
APC<-	B
/	O
-	O
>	O
colon	O
carcinoma	O
cells	O
were	O
found	O
to	O
contain	O
a	O
stable	O
beta	B
-catenin	I
-	O
hTCF-4	B
complex	O
that	O
was	O
constitutively	O
active	O
,	O
as	O
measured	O
by	O
transcription	O
of	O
a	O
Tcf	B
reporter	O
gene	O
.	O

Reintroduction	O
of	O
APC	B
removed	O
beta	O
-catenin	O
from	O
hTcf4	B
and	O
abrogated	O
the	O
transcriptional	O
transactivation	O
.	O

Constitutive	O
transcription	O
of	O
TCF	B
target	O
genes	O
,	O
caused	O
by	O
loss	O
of	O
APC	B
function	O
,	O
may	O
be	O
a	O
crucial	O
event	O
in	O
the	O
early	O
transformation	O
of	O
colonic	O
epithelium	O
.	O

It	O
is	O
also	O
shown	O
here	O
that	O
the	O
products	O
of	O
mutant	O
APC	B
genes	O
found	O
in	O
colorectal	O
tumors	O
are	O
defective	O
in	O
regulating	O
beta	B
-catenin	I
/	O
Tcf-4	B
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
colorectal	O
tumors	O
with	O
intact	O
APC	B
genes	O
were	O
shown	O
to	O
contain	O
subtle	O
activating	O
mutations	O
of	O
beta	B
-catenin	I
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O

These	O
results	O
indicate	O
that	O
regulation	O
of	O
beta	B
-catenin	I
is	O
critical	O
to	O
APC	O
's	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	B
or	O
beta	B
-catenin	I
.	O

A	O
method	O
of	O
modulating	O
an	O
immune	O
response	O
in	O
an	O
infected	O
mammal	O
by	O
transmucosal	O
administration	O
of	O
modulating	O
agent	O
Methods	O
and	O
compositions	O
for	O
modulating	O
an	O
immune	O
response	O
in	O
a	O
mammal	O
infected	O
with	O
a	O
bacterium	O
,	O
a	O
virus	O
,	O
or	O
a	O
parasite	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
in	O
mammals	O
experiencing	O
an	O
acute	O
infection	O
and	O
in	O
mammals	O
experiencing	O
a	O
chronic	O
infection	O
.	O

The	O
methods	O
and	O
compositions	O
may	O
be	O
used	O
in	O
conjunction	O
with	O
a	O
known	O
treatment	O
for	O
infection	O
of	O
a	O
mammal	O
by	O
an	O
infectious	O
agent	O
.	O

Methods	O
and	O
compositions	O
for	O
transmucosal	O
delivery	O
of	O
a	O
molecule	O
comprising	O
an	O
epitope	O
located	O
in	O
close	O
proximity	O
to	O
the	O
immune	O
response	O
are	O
provided	O
.	O

C-4''-substituted	O
macrolide	O
derivatives	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
are	O
potent	O
antibacterial	O
agents	O
that	O
may	O
be	O
used	O
to	O
treat	O
various	O
bacterial	O
infections	O
and	O
disorders	O
related	O
to	O
such	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
methods	O
of	O
treating	O
bacterial	O
infections	O
by	O
administering	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
intermediates	O
useful	O
in	O
such	O
preparation	O
.	O

Crystalline	O
macrolides	O
and	O
process	O
for	O
their	O
preparation	O
33-Epichloro-33-desoxyascomycin	O
of	O
formula	O
(	O
I	O
)	O
and	O
various	O
tautomeric	O
or	O
solvated	O
forms	O
thereof	O
,	O
in	O
crystalline	O
form	O
,	O
such	O
as	O
Form	O
A	O
and	O
Form	O
B.	O
Their	O
preparation	O
involves	O
appropriately	O
converting	O
amorphous	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
A	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
B	O
,	O
respectively	O
,	O
from	O
a	O
solution	O
thereof	O
under	O
crystallization	O
-	O
inducing	O
conditions	O
or	O
conditions	O
inducing	O
preferential	O
crystallization	O
of	O
Form	O
A	O
or	O
B	O
,	O
respectively	O
.	O

Such	O
crystals	O
are	O
particularly	O
indicated	O
for	O
use	O
in	O
the	O
preparation	O
of	O
topical	O
galenical	O
forms	O
of	O
the	O
compound	O
for	O
pharmaceutical	O
use	O
,	O
e.g.	O
creams	O
,	O
emulsions	O
and	O
ointments	O
.	O

Use	O
of	O
taurolidine	O
or	O
taurultam	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
of	O
metastases	O
The	O
invention	O
provides	O
the	O
use	O
of	O
taurolidine	O
or	O
taurultam	O
solutions	O
to	O
prevent	O
or	O
reduce	O
metastatic	O
growth	O
.	O

This	O
is	O
of	O
particular	O
application	O
in	O
preventing	O
or	O
reducing	O
the	O
incidence	O
of	O
metastatic	O
growth	O
following	O
surgery	O
,	O
particularly	O
following	O
the	O
use	O
of	O
trocars	O
during	O
minimal	O
invasive	O
laparoscopic	O
surgery	O
.	O

metal	O
complexes	O
with	O
antibacterian	O
and	O
fungicidal	O
effects	O
Invented	O
are	O
zinc	O
chelated	O
G	B
-	I
CSF	I
receptor	I
ligands	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
as	O
agonist	O
of	O
the	O
G	B
-	I
CSF	I
receptor	I
.	O

Also	O
invented	O
are	O
novel	O
processes	O
used	O
in	O
preparing	O
these	O
compounds	O
.	O

Also	O
invented	O
are	O
novel	O
G	B
-	I
CSF	I
receptor	I
binding	O
moieties	O
of	O
the	O
invented	O
zinc	O
chelated	O
G	B
-	I
CSF	I
receptor	I
ligands	O
.	O

Novel	O
optically	O
active	O
aminopentane	O
derivative	O
Novel	O
compounds	O
involving	O
optically	O
pure	O
(	O
-	O
)	O
-1-	O
(	O
benzofuran-2-yl	O
)	O
-2-propylaminopentane	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
which	O
is	O
substantially	O
free	O
from	O
the	O
(	O
+	O
)	O
-isomer	O
and	O
pharmacologically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

Because	O
of	O
being	O
excellent	O
in	O
the	O
effect	O
of	O
regulatively	O
enhancing	O
neurotransmitters	O
catecholamines	O
(	O
i.e.	O
,	O
CAE	O
(	O
Catecholaminergic	O
Activity	O
Enhancer	O
)	O
effect	O
)	O
,	O
these	O
compounds	O
are	O
useful	O
as	O
psychotropic	O
drugs	O
and	O
remedies	O
for	O
Parkinson	O
's	O
disease	O
,	O
depression	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Thyroid	O
hormone	O
analogues	O
and	O
methods	O
for	O
their	O
preparation	O
Thyroid	O
hormone	O
analogues	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
such	O
analogues	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
novel	O
procedures	O
for	O
their	O
preparation	O
.	O

Use	O
of	O
citrate	O
in	O
a	O
catheter	O
lock	O
solution	O
This	O
invention	O
relates	O
to	O
an	O
infusion	O
device	O
for	O
a	O
catheter	O
lock	O
solution	O
,	O
to	O
a	O
method	O
of	O
enhancing	O
the	O
patency	O
of	O
catheters	O
in	O
animals	O
and	O
to	O
a	O
catheter	O
lock	O
solution	O
.	O

The	O
device	O
includes	O
a	O
syringe	O
(	O
34	O
)	O
containing	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	O
salt	O
.	O

The	O
method	O
for	O
enhancing	O
the	O
patency	O
of	O
catheters	O
includes	O
infusing	O
a	O
lumen	O
(	O
14	O
,	O
16	O
)	O
of	O
an	O
indwelling	O
catheter	O
(	O
10	O
)	O
with	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	O
salt	O
.	O

In	O
one	O
aspect	O
of	O
the	O
invention	O
,	O
the	O
catheter	O
lock	O
solution	O
includes	O
a	O
citrate	O
salt	O
and	O
a	O
viscosifying	O
agent	O
.	O

The	O
lock	O
solution	O
is	O
prepared	O
to	O
have	O
sufficient	O
viscosity	O
and	O
density	O
to	O
remain	O
in	O
the	O
lumen	O
for	O
a	O
desired	O
amount	O
of	O
time	O
.	O

Nucleic	O
acid	O
constructs	O
for	O
genetic	O
immunisation	O
Recombinant	O
nucleic	O
acid	O
molecules	O
are	O
described	O
.	O

The	O
molecules	O
have	O
a	O
first	O
sequence	O
encoding	O
a	O
Hepatitis	B
B	I
virus	I
core	I
antigen	I
and	O
a	O
second	O
sequence	O
encoding	O
at	O
least	O
one	O
T	O
cell	O
epitope	O
inserted	O
within	O
the	O
first	O
sequence	O
.	O

Vectors	O
and	O
compositions	O
containing	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Methods	O
of	O
eliciting	O
an	O
immune	O
response	O
using	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Chlamydia	O
antigen	O
and	O
corresponding	O
dna	O
fragments	O
and	O
uses	O
thereof	O
In	O
summary	O
of	O
this	O
disclosure	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
nucleic	O
acid	O
,	O
including	O
DNA	O
,	O
immunization	O
of	O
a	O
host	O
,	O
including	O
humans	O
,	O
against	O
disease	O
caused	O
by	O
infection	O
by	O
a	O
strain	O
of	O
Chlamydia	O
,	O
specifically	O
DOLLAR	O
I	O
(	O
C.	O
pneumoniae	O
)	O
,	O
employing	O
a	O
vector	O
,	O
containing	O
a	O
nucleotide	O
sequence	O
encoding	O
an	O
POMP91B	O
precursor	O
protein	O
of	O
a	O
strain	O
of	O
DOLLAR	O
I	O
(	O
Chlamydia	O
pneumoniae	O
)	O
and	O
a	O
promoter	O
to	O
effect	O
expression	O
of	O
the	O
POMP91B	O
precursor	O
gene	O
in	O
the	O
host	O
.	O

Modifications	O
are	O
possible	O
within	O
the	O
scope	O
of	O
this	O
invention	O
.	O

Inhibitors	O
of	O
c	B
-	I
jun	I
n	I
-	I
terminal	I
kinases	I
(	O
jnk	B
)	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
or	O
prodrug	O
thereof	O
;	O
wherein	O
Y	O
is	O
selected	O
from	O
-	O
(	O
CH2	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
NH	O
-	O
Q1	O
;	O
-	O
(	O
CO	O
)	O
-O	O
-	O
Q1	O
;	O
-	O
(	O
SO2	O
)	O
-Q1	O
or	O
-	O
(	O
SO2	O
)	O
NH	O
-	O
Q1	O
;	O
Q1	O
is	O
a	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkyl	O
or	O
alkenyl	O
group	O
;	O
a	O
5	O
-	O
7	O
membered	O
aromatic	O
or	O
non	O
-	O
aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
;	O
or	O
a	O
9	O
-	O
14	O
membered	O
bicyclic	O
or	O
tricyclic	O
aromatic	O
or	O
non	O
-	O
aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
system	O
,	O
W	O
is	O
N	O
or	O
C	O
;	O
Z	O
is	O
CH	O
or	O
N	O
,	O
which	O
are	O
inhibitors	O
of	O
JNK	B
,	O
a	O
mammalian	O
protein	O
kinase	B
involved	O
cell	O
proliferation	O
,	O
cell	O
death	O
and	O
response	O
to	O
extracellular	O
stimuli	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
producing	O
these	O
inhibitors	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Screening	O
methods	O
for	O
compounds	O
which	O
affect	O
melanogenesis	O
Methods	O
of	O
screening	O
for	O
compounds	O
that	O
affect	O
melanogenesis	O
and	O
the	O
function	O
of	O
P	B
protein	I
in	O
organisms	O
,	O
cells	O
,	O
or	O
cell	O
-	O
free	O
systems	O
are	O
provided	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmacologic	O
and	O
cosmetic	O
uses	O
of	O
such	O
compounds	O
to	O
reduce	O
or	O
increase	O
the	O
synthesis	O
of	O
melanin	O
in	O
animal	O
and	O
human	O
melanocytes	O
and	O
melanocyte	O
-	O
derived	O
cells	O
.	O

AMINO	O
SUBSTITUTED	O
PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES	O
AND	O
PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES	O
Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
,	O
where	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
¿	O
,	O
and	O
X	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
selective	O
modulators	O
of	O
NPY1	B
receptors	I
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
CNS	O
disorders	O
,	O
metabolic	O
disorders	O
,	O
and	O
peripheral	O
disorders	O
,	O
particularly	O
eating	O
disorders	O
and	O
hypertension	O
.	O

Methods	O
of	O
treatment	O
of	O
such	O
disorders	O
as	O
well	O
as	O
packaged	O
pharmaceutical	O
compositions	O
are	O
also	O
provided	O
.	O

Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
NPY1	B
receptors	I
and	O
as	O
standards	O
in	O
assays	O
for	O
NPY1	B
receptor	I
binding	O
.	O

Methods	O
of	O
using	O
the	O
compounds	O
in	O
receptor	O
localization	O
studies	O
are	O
given	O
.	O

Use	O
of	O
the	O
residues	O
from	O
wine	O
production	O
The	O
use	O
of	O
the	O
residues	O
from	O
wine	O
production	O
as	O
active	O
substance	O
preparations	O
in	O
the	O
production	O
of	O
cosmetic	O
and/or	O
pharmaceutical	O
preparations	O
is	O
disclosed	O
.	O

Pharmaceutical	O
preparation	O
containing	O
cytostatic	O
agents	O
and	O
electron	O
acceptors	O
for	O
treating	O
tumor	O
diseases	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
preparation	O
containing	O
at	O
least	O
one	O
active	O
substance	O
that	O
is	O
cytostatically	O
active	O
,	O
at	O
least	O
one	O
biological	O
electron	O
acceptor	O
,	O
and	O
the	O
customary	O
pharmaceutical	O
additives	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
preparation	O
for	O
treating	O
tumor	O
diseases	O
,	O
in	O
particular	O
,	O
for	O
treating	O
cancer	O
.	O

Novel	O
stromelysin	B
inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
which	O
an	O
increased	O
activity	O
of	O
matrix	B
-	I
degrading	I
enzymes	I
,	O
in	O
particular	O
,	O
stromelysin	B
,	O
are	O
implicated	O
.	O

New	O
gamma	O
selective	O
retinoids	O
New	O
RAR	O
selective	O
retinoid	O
agonists	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
active	O
salts	O
of	O
carboxylic	O
acids	O
of	O
formula	O
(	O
I	O
)	O
,	O
further	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
such	O
retinoic	B
acid	I
receptor	I
agonists	O
,	O
particularly	O
retinoic	B
acid	I
receptor	I
η	I
(	O
RARη	B
)	O
selective	O
agonists	O
for	O
the	O
treatment	O
of	O
emphysema	O
and	O
associated	O
pulmonary	O
diseases	O
,	O
as	O
well	O
as	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
dermatological	O
disorders	O
,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
malignant	O
and	O
premalignant	O
epithelial	O
lesions	O
,	O
tumours	O
and	O
precancerous	O
changes	O
of	O
the	O
mucous	O
membrane	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
larynx	O
,	O
oesophagus	O
,	O
bladder	O
,	O
cervix	O
and	O
colon	O
.	O

Method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	O
and	O
use	O
thereof	O
in	O
pharmaceutics	O
,	O
cosmetics	O
or	O
food	O
industry	O

The	O
invention	O
concerns	O
a	O
method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	O
,	O
characterised	O
in	O
that	O
it	O
consists	O
in	O
subjecting	O
to	O
an	O
esterification	O
reaction	O
at	O
least	O
a	O
fatty	O
substance	O
with	O
at	O
least	O
an	O
alcohol	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
sterols	O
,	O
stanols	O
,	O
4-methylsterols	O
and	O
their	O
hydrogenated	O
homologues	O
,	O
triterpene	O
alcohols	O
and	O
their	O
hydrogenated	O
homologues	O
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
the	O
presence	O
of	O
at	O
least	O
a	O
solid	O
catalyst	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
lanthanide	O
oxides	O
and	O
the	O
mixtures	O
of	O
said	O
oxides	O
.	O

Said	O
method	O
enables	O
to	O
obtain	O
products	O
particularly	O
suited	O
for	O
use	O
in	O
the	O
field	O
of	O
pharmaceutics	O
,	O
in	O
particular	O
dermatology	O
,	O
cosmetics	O
and	O
special	O
food	O
production	O
(	O
functional	O
food	O
products	O
,	O
medicinal	O
food	O
products	O
and	O
dietetic	O
food	O
products	O
)	O

Tetrazole	O
derivatives	O
The	O
present	O
invention	O
is	O
concerned	O
with	O
2H	O
-	O
tetrazole-5-yl	O
-	O
amide	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
signifies	O
hydrogen	O
,	O
lower	O
alkyl	O
,	O
-	O
(	O
CH¿2?	O
)	O
n	O
-	O
CF3	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
CHF2	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
CN	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
cycloalkyl	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
O	O
-	O
lower	O
alkyl	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
O	O
-	O
cycloalkyl	O
or	O
-	O
(	O
CH2	O
)	O
n	O
-	O
C	O
(	O
O	O
)	O
O	O
-	O
lower	O
alkyl	O
;	O
R?2	O
¿	O
signifies	O
hydrogen	O
,	O
lower	O
alkyl	O
,	O
lower	O
alkoxy	O
,	O
halogen	O
,	O
-C	O
(	O
O	O
)	O
-lower	O
alkyl	O
,	O
-C	O
(	O
O	O
)	O
OH	O
,	O
-C	O
(	O
O	O
)	O
O	O
-	O
lower	O
alkyl	O
,	O
-NR3R4	O
or	O
-C	O
(	O
O	O
)	O
-NR3R4	O
and	O
wherein	O
R?3	O
and	O
R4	O
¿	O
may	O
be	O
independently	O
from	O
each	O
other	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
signifies	O
-O-	O
,	O
-S-	O
,	O
-CH¿2	O
?	O
,	O
-OCH2-	O
or	O
two	O
hydrogen	O
atoms	O
not	O
forming	O
a	O
bridge	O
;	O
and	O
n	O
signifies	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
as	O
well	O
as	O
with	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
are	O
group	B
1	I
metabotropic	I
glutamate	I
receptor	I
agonists	O
(	O
mGluR	B
)	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
corresponding	O
CNS	O
-	O
disorders	O
.	O

Masp-2	B
,	O
a	O
complement	O
-	O
fixing	O
enzyme	O
,	O
and	O
uses	O
for	O
it	O
The	O
present	O
invention	O
relates	O
to	O
substantially	O
pure	O
mannin	B
-	I
binding	I
lectin	I
associated	I
serine	I
protease-2	I
(	O
MASP-2	B
)	O
polypeptides	O
and	O
fragments	O
thereof	O
as	O
well	O
as	O
nucleic	O
acids	O
encoding	O
such	O
polpeptides	O
.	O

Futhermone	O
,	O
the	O
present	O
invention	O
realates	O
to	O
uses	O
of	O
a	O
substantially	O
pure	O
polypeptide	O
comprising	O
amino	O
acid	O
sequences	O
derived	O
from	O
mannan	B
-	I
binding	I
lectin	I
associated	I
serine	I
protease-2	I
(	O
MASP2	B
)	O
or	O
a	O
functional	O
homologue	O
thereof	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
composition	O
as	O
well	O
as	O
pharmaceutical	O
compositons	O
comprising	O
MASP-2	B
and/or	O
MASP-2	B
fragments	O
.	O

In	O
addition	O
the	O
present	O
invetion	O
relates	O
to	O
inhibitors	O
of	O
MASP-2	B
and	O
pharmaceutical	O
compositiosn	O
compring	O
such	O
inhibitors	O
.	O

Methods	O
for	O
detecting	O
MASP-2	B
nucleic	O
acid	O
expression	O
are	O
included	O
in	O
the	O
invention	O
.	O

Antisense	O
modulation	O
of	O
clusterin	O
expression	O
Antisense	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
clusterin	O
.	O

The	O
compositions	O
comprise	O
antisense	O
compounds	O
,	O
particularly	O
antisense	O
oligonucleotides	O
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
clusterin	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
clusterin	O
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
clusterin	O
are	O
provided	O
.	O

Macrolide	O
antibiotics	O
The	O
present	O
invention	O
relates	O
to	O
11,12	O
gamma	O
lactone	O
ketolides	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
as	O
defined	O
herein	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
,	O
to	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
or	O
prophylaxis	O
of	O
systemic	O
or	O
topical	O
bacterial	O
infections	O
in	O
a	O
human	O
or	O
animal	O
body	O
.	O

Promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
with	O
non	O
-	O
metabolizable	O
sugar	O
and	O
a	O
polymeric	O
absorbent	O
The	O
invention	O
concerns	O
the	O
use	O
of	O
a	O
combination	O
comprising	O
at	O
least	O
an	O
absorbent	O
and	O
at	O
least	O
a	O
compound	O
selected	O
among	O
the	O
group	O
consisting	O
of	O
non	O
-	O
metabolizable	O
sugars	O
and	O
polyols	O
for	O
preparing	O
a	O
composition	O
,	O
in	O
particular	O
medicinal	O
,	O
for	O
promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
.	O

Use	O
of	O
er	B
-	I
beta	I
selective	O
antagonists	O
as	O
contraceptives	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
ERSS	O
-	O
selective	O
ligands	O
for	O
production	O
of	O
medicaments	O
for	O
regulating	O
fertility	O
without	O
additional	O
use	O
of	O
a	O
progestin	O
.	O

ERSS	O
-	O
agonists	O
are	O
used	O
for	O
treatment	O
of	O
infertility	O
and	O
ERSS	O
-	O
antagonists	O
for	O
contraception	O
.	O

Sapogenin	O
derivatives	O
,	O
their	O
synthesis	O
and	O
use	O
The	O
invention	O
discloses	O
certain	O
steroidal	O
sapogenins	O
and	O
derivatives	O
thereof	O
,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cognitive	O
dysfunction	O
,	O
non	O
-	O
cognitive	O
neurodegeneration	O
,	O
non	O
-	O
cognitive	O
neuromuscular	O
degeneration	O
,	O
and	O
receptor	O
loss	O
in	O
the	O
absence	O
of	O
cognitive	O
,	O
neural	O
and	O
neuromuscular	O
impairment	O
.	O

Methods	O
of	O
synthesis	O
,	O
treatment	O
and	O
pharmaceutical	O
compositions	O
are	O
also	O
disclosed	O
.	O

PHARMACEUTICAL	O
COMPOSITIONS	O
FOR	O
THE	O
COORDINATED	O
DELIVERY	O
OF	O
NSAIDs	O
The	O
present	O
invention	O
is	O
directed	O
to	O
drug	O
dosage	O
forms	O
that	O
release	O
an	O
agent	O
that	O
raises	O
the	O
pH	O
of	O
a	O
patient	O
's	O
gastrointestinal	O
tract	O
,	O
followed	O
by	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
.	O

The	O
dosage	O
form	O
is	O
designed	O
so	O
that	O
the	O
NSAID	O
is	O
not	O
released	O
until	O
the	O
intragastric	O
pH	O
has	O
been	O
raised	O
to	O
a	O
safe	O
level	O
.	O

The	O
invention	O
also	O
encompasses	O
methods	O
of	O
trating	O
patients	O
by	O
administering	O
this	O
coordinated	O
release	O
,	O
gastroprotective	O
,	O
antiarthitic	O
/	O
analgesic	O
combination	O
unit	O
dosage	O
form	O
to	O
achieve	O
pain	O
and	O
symptom	O
relief	O
with	O
a	O
reduced	O
risk	O
of	O
developing	O
gastrointestinal	O
damage	O
such	O
as	O
ulcers	O
,	O
erosions	O
and	O
hemorrhages	O
.	O

Improved	O
pharmaceutical	O
composition	O
containing	O
a	O
ppar	B
alpha	I
agent	O
and	O
a	O
process	O
for	O
preparing	O
it	O
Oral	O
semi	O
-	O
solid	O
or	O
liquid	O
composition	O
for	O
treating	O
hyperlipidemia	O
or	O
hypercholesterolemia	O
in	O
humans	O
,	O
which	O
comprises	O
at	O
least	O
an	O
effective	O
amount	O
of	O
peroxisome	B
proliferator	I
activated	I
receptor	I
alpha	I
agent	O
(	O
PPARa	B
)	O
,	O
one	O
polyglycolized	O
glyceride	O
and	O
one	O
hydrophilic	O
disintegrating	O
agent	O
.	O

Pharmaceutical	O
formulations	O
for	O
the	O
controlled	O
release	O
of	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
quinazoline	O
The	O
invention	O
provides	O
a	O
controlled	O
-	O
release	O
pharmaceutical	O
formulation	O
for	O
oral	O
administration	O
comprising	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
quinazoline	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
adjuvant	O
,	O
diluent	O
or	O
carrier	O
;	O
characterized	O
in	O
that	O
the	O
formulation	O
is	O
adapted	O
to	O
release	O
at	O
least	O
50	O
%	O
by	O
weight	O
of	O
the	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
-quinazoline	O
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
after	O
6	O
hours	O
in	O
Apparatus	O
1	O
described	O
in	O
the	O
United	O
States	O
Pharmacopoeia	O
24	O
(	O
2000	O
)	O
,	O
pp	O
1941	O
-	O
1943	O
,	O
having	O
1	O
litre	O
vessels	O
,	O
baskets	O
of	O
40	O
mesh	O
(	O
0.4	O
mm	O
apertures	O
)	O
,	O
a	O
rotation	O
speed	O
of	O
100	O
rpm	O
,	O
and	O
a	O
dissolution	O
medium	O
consisting	O
of	O
900	O
ml	O
of	O
0.01	O
M	O
hydrochloric	O
acid	O
containing	O
0.7	O
%	O
w	O
/	O
v	O
sodium	O
chloride	O
at	O
37	O
DEG	O
C.	O
Formulations	O
according	O
to	O
the	O
invention	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
BPH	O
.	O

Oxadiazoles	O
having	O
antiproliferative	O
activity	O
Oxadiazole	O
derivatives	O
of	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
X	O
,	O
Y	O
,	O
R	O
and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
disclosure	O
.	O

The	O
compounds	O
have	O
antiproliferative	O
activity	O
against	O
a	O
number	O
of	O
human	O
tumors	O
cell	O
lines	O
and	O
can	O
therefore	O
be	O
used	O
for	O
the	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

Pharmaceutical	O
composition	O
that	O
is	O
used	O
to	O
control	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
active	O
glimepiride	O
and	O
metformin	O
substances	O
or	O
the	O
salts	O
thereof	O
,	O
such	O
as	O
hydrochloride	O
,	O
succinate	O
,	O
fumarate	O
,	O
etc	O
.	O
,	O
which	O
are	O
used	O
to	O
control	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Clinical	O
studies	O
,	O
which	O
were	O
carried	O
out	O
in	O
order	O
to	O
demonstrate	O
the	O
effectiveness	O
of	O
said	O
combination	O
,	O
have	O
shown	O
that	O
the	O
effect	O
produced	O
by	O
the	O
two	O
drugs	O
is	O
not	O
only	O
additive	O
but	O
also	O
synergetic	O
in	O
comparison	O
with	O
the	O
monotherapy	O
which	O
uses	O
only	O
one	O
of	O
the	O
drugs	O
from	O
the	O
combination	O
.	O

As	O
a	O
result	O
,	O
the	O
use	O
of	O
said	O
combination	O
is	O
suggested	O
as	O
an	O
effective	O
and	O
safe	O
therapy	O
for	O
the	O
control	O
of	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

According	O
to	O
the	O
invention	O
,	O
different	O
proportions	O
of	O
the	O
active	O
substances	O
can	O
be	O
used	O
so	O
that	O
the	O
combination	O
suits	O
the	O
different	O
requirements	O
of	O
each	O
patient	O
.	O

Delivery	O
of	O
solid	O
drug	O
compositions	O
This	O
invention	O
relates	O
to	O
the	O
parenteral	O
administration	O
of	O
solid	O
drug	O
compositions	O
.	O

In	O
particular	O
,	O
this	O
invention	O
relates	O
to	O
a	O
syringe	O
-	O
like	O
device	O
for	O
delivering	O
solid	O
drug	O
cylinders	O
including	O
a	O
syringe	O
barrel	O
,	O
a	O
needle	O
,	O
and	O
a	O
microplunger	O
and	O
piston	O
assembly	O
,	O
wherein	O
said	O
microplunger	O
pushes	O
said	O
solid	O
drug	O
cylinder	O
out	O
of	O
said	O
needle	O
and	O
into	O
a	O
patient	O
and	O
said	O
piston	O
pushes	O
on	O
said	O
microplunger	O
.	O

Cascade	O
esters	O
of	O
camptothecins	O
and	O
methods	O
of	O
treating	O
cancer	O
using	O
these	O
compounds	O
Cascade	O
esters	O
of	O
camptothecin	O
are	O
described	O
.	O

Processes	O
for	O
making	O
these	O
compounds	O
and	O
for	O
using	O
them	O
in	O
cancer	O
treatment	O
are	O
also	O
described	O
.	O

Formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O
,	O
characterized	O
in	O
that	O
the	O
formulation	O
has	O
a	O
pH	O
value	O
of	O
6.0	O
-	O
pH	O
7,4	O
,	O
and/or	O
an	O
anion	O
concentration	O
of	O
5	O
-	O
100	O
mmol	O
/	O
l	O
and/or	O
a	O
concentration	O
of	O
10	O
-	O
500	O
ñmol	O
/	O
l	O
of	O
nonsteroidal	O
antiphlogistics	O
.	O

Compositions	O
for	O
altering	O
mucus	O
secretion	O
A	O
peptide	O
that	O
inhibits	O
mucus	O
secretion	O
in	O
subjects	O
is	O
described	O
,	O
for	O
use	O
in	O
inhibiting	O
mucus	O
secretion	O
by	O
a	O
mucus	O
secreting	O
cell	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
myristoylated	O
polypeptide	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
is	O
also	O
described	O
.	O

4-	O
(	O
3,5-dicyanophenoxy	O
)	O
pyrazole	O
derivatives	O
for	O
use	O
as	O
transcriptase	B
modulators	O
in	O
the	O
treatment	O
of	O
i.a	O
.	O

hiv	O
This	O
invention	O
relates	O
to	O
the	O
pyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
derivatives	O
thereof	O
,	O
to	O
their	O
use	O
in	O
medicine	O
,	O
to	O
compositions	O
containing	O
them	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
to	O
intermediates	O
used	O
in	O
such	O
processes	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
bind	O
to	O
the	O
enzyme	O
reverse	B
transcriptase	I
and	O
are	O
modulators	O
,	O
especially	O
inhibitors	O
,	O
thereof	O
.	O

Reverse	B
transcriptase	I
is	O
implicated	O
in	O
the	O
infectious	O
lifecycle	O
of	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
.	O

Compounds	O
which	O
interfere	O
with	O
the	O
function	O
of	O
this	O
enzyme	O
have	O
shown	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
caused	O
by	O
HIV	O
and	O
genetically	O
related	O
retroviruses	O
,	O
such	O
as	O
Acquired	O
Immune	O
Deficiency	O
Syndrome	O
(	O
AIDS	O
)	O
.	O

Therapeutic	O
use	O
of	O
fused	O
bicyclic	O
or	O
tricyclic	O
amino	O
acids	O
The	O
compounds	O
of	O
the	O
instant	O
invention	O
are	O
bicyclic	O
or	O
tricyclic	O
amino	O
acids	O
useful	O
in	O
the	O
treatment	O
of	O
fibromylagia	O
.	O

Pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
fibromyalgia	O
are	O
also	O
included	O
.	O

A	O
method	O
of	O
treating	O
vasomotor	O
symptoms	O
comprising	O
a	O
compound	O
having	O
norepinephrine	O
reuptake	O
inhibitor	O
activity	O
and	O
5-ht2a	B
antagonistic	O
activity	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
composition	O
of	O
compounds	O
that	O
modulate	O
norepinephrine	O
levels	O
for	O
the	O
treatment	O
of	O
vasomotor	O
symptoms	O
such	O
as	O
thermoregulatory	O
disorders	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
compositions	O
of	O
compounds	O
having	O
norepinephrine	O
reuptake	O
inhibitor	O
(	O
NRI	O
)	O
activity	O
alone	O
or	O
norepinephrine	O
reuptake	O
inhibitor	O
and	O
serotonin	O
reuptake	O
inhibitor	O
(	O
NRI	O
/	O
SRI	O
)	O
dual	O
activity	O
in	O
combination	O
with	O
5-HT2a	B
receptor	O
antagonist	O
activity	O
.	O

Method	O
for	O
counteracting	O
a	O
pathologic	O
change	O
in	O
the	O
beta	B
-	I
adrenergic	I
pathway	O
The	O
invention	O
concerns	O
methods	O
for	O
modulating	O
the	O
ß	B
-	I
adrenergic	I
pathway	O
.	O

In	O
particular	O
,	O
the	O
invention	O
concerns	O
methods	O
for	O
counteracting	O
a	O
pathologic	O
change	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
loss	O
in	O
ß	B
-	I
adrenergic	I
sensitivity	O
,	O
in	O
the	O
ß	B
-	I
adrenergic	I
signal	O
transduction	O
pathway	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
TGF	B
-	I
ß	I
signaling	O
through	O
a	O
TGF	B
-	I
ß	I
receptor	I
.	O

Compositions	O
and	O
methods	O
for	O
improving	O
the	O
condition	O
of	O
patients	O
suffering	O
from	O
copd	O
and	O
other	O
diseases	O
A	O
food	O
supplement	O
of	O
therapeutic	O
composition	O
is	O
provided	O
suitable	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
COPD	O
and	O
other	O
acute	O
or	O
chronic	O
diseases	O
in	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
being	O
,	O
comprising	O
at	O
least	O
one	O
of	O
glutamate	O
,	O
other	O
than	O
mono	O
sodium	O
glutamate	O
,	O
and	O
a	O
precursor	O
of	O
glutamate	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
leucine	O
,	O
valine	O
,	O
isoleucine	O
,	O
and	O
a	O
keto	O
acid	O
thereof	O
,	O
in	O
a	O
daily	O
dose	O
for	O
said	O
mammal	O
of	O
at	O
least	O
6	O
grams	O
,	O
preferably	O
between	O
9	O
and	O
20	O
grams	O
,	O
of	O
the	O
total	O
of	O
said	O
glutamate	O
and	O
precursor	O
forms	O
thereof	O
.	O

Human	B
CLTA-8	I
and	O
uses	O
of	O
CTLA-8-related	B
proteins	O
An	O
antibody	O
that	O
specifically	O
reacts	O
with	O
a	O
protein	O
comprising	O
an	O
amino	O
acid	O
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
(	O
a	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
;	O
(	O
b	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
11	O
to	O
163	O
;	O
(	O
c	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
29	O
to	O
163	O
;	O
(	O
d	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
31	O
to	O
163	O
;	O
and	O
(	O
e	O
)	O
a	O
fragment	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
having	O
a	O
CTLA-8	B
activity	O
chosen	O
from	O
one	O
or	O
more	O
of	O
induction	O
of	O
expression	O
or	O
secretion	O
of	O
γ	B
-	I
IFN	I
,	O
IL-6	B
,	O
or	O
IL-8	B
,	O
or	O
inhibition	O
of	O
angiogenesis	O
.	O

Inhibitors	O
of	O
hepatitis	O
c	O
virus	O
,	O
compositions	O
and	O
treatments	O
using	O
the	O
same	O
The	O
invention	O
relates	O
to	O
methods	O
of	O
inhibiting	O
HCV	O
viral	O
replication	O
activityy	O
comprising	O
contacting	O
an	O
HCV	B
polymerase	I
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
hydroxamate	O
MMP	B
inhibitor	O
,	O
and	O
composition	O
comprising	O
the	O
same	O
.	O

Fused	O
pyrido	O
[	O
3',2':4,5	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidines	O
and	O
pyrido	O
[	O
3',2':4,5	O
]	O
furo	O
[	O
3,2-d	O
]	O
pyrimidines	O
Tricyclic	O
thiophene	O
,	O
furan	O
or	O
pyrrole	O
derivatives	O
(	O
I	O
)	O
are	O
new	O
.	O

Tricyclic	O
thiophene	O
,	O
furan	O
or	O
pyrrole	O
derivatives	O
(	O
I	O
)	O
of	O
formula	O
(	O
Ia	O
)	O
-	O
(	O
Id	O
)	O
and	O
their	O
salts	O
,	O
solvates	O
,	O
metabolites	O
,	O
tautomers	O
and	O
prodrugs	O
are	O
new	O
,	O
other	O
than	O
2-dimethylamino-4,7-diethoxy-8-cyano-9-p	O
henyl	O
-	O
pyrido	O
[	O
3',2':4,5	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidine	O
,	O
1,4-dihydro-2,2-dimethyl-5-morpholino-10-propylthio-2H	O
-	O
pyrano	O
[	O
"4"",3"":4"	O
'	O
,	O
5'	O
]	O
pyrido	O
[	O
3',2':4',5'	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidin-8	O
(	O
9H	O
)	O
-one	O
,	O
1	O
-	O
-butylthio-1,4-dihydro-2,2-dimethyl-5-morpholino-2H	O
-	O
pyrano	O
[	O
"4"",3"":4"	O
'	O
,	O
5'	O
]	O
pyrido	O
[	O
3',2':4',5'	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidin-8	O
(	O
9H	O
)	O
-one	O
and	O
2-methyl-5-	O
(	O
2thienyl	O
)	O
-1,2,3,4-tetrahydro-11H-7-thia-2,6,9,11-tetraaza	O
-benzo	O
[	O
c	O
]	O
fluorene-8,10-dione	O
.	O

Y	O
'	O
:	O
S	O
,	O
O	O
or	O
N	O
;	O
R1	O
>	O
H	O
;	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkenyl	O
or	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkynyl	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkyl	O
,	O
5-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
4	O
heteroatoms	O
,	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkoxy	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkoxy	O
,	O
2	O
-	O
12C	O
alkanoyl	O
,	O
benzoyl	O
or	O
1-	O
or	O
2-naphthoyl	O
,	O
alkylthio	O
,	O
alkylsulfinyl	O
,	O
alkoxysulfonyl	O
or	O
alkylsulfonyl	O
,	O
alkoxycarbonyl	O
,	O
alkylcarbamoyl	O
or	O
dialkylcarbamoyl	O
,	O
(	O
hetero	O
)	O
arylthio	O
,	O
(	O
hetero	O
)	O
arylsulfinyl	O
or	O
(	O
hetero	O
)	O
arylsulfonyl	O
,	O
aryloxycarbonyl	O
,	O
arylcarbamoyl	O
,	O
arylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylcarbamoyl	O
,	O
aralkoxycarbonyl	O
or	O
aralkylcarbamoyl	O
with	O
1	O
-	O
5C	O
alkyl	O
or	O
6	O
-	O
10C	O
aryl	O
,	O
heterocyclylcarbonyl	O
,	O
heterocyclylcarbamoyl	O
,	O
heterocyclylamido	O
,	O
N	O
-	O
heterocyclyl	O
-	O
N	O
-	O
alkylamino	O
,	O
heterocyclylalkoxycarbonyl	O
or	O
heterocyclylalkylcarbamoyl	O
,	O
arylhydrazino	O
or	O
phenyl	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
1-	O
or	O
2-naphthyl	O
;	O
OH	O
,	O
SH	O
,	O
CHO	O
,	O
COOH	O
,	O
CONH2	O
,	O
CN	O
,	O
SCN	O
,	O
NO2	O
,	O
SO3H	O
;	O
with	O
heterocyclyl	O
as	O
above	O
and	O
1	O
-	O
5C	O
alkyl	O
;	O
halo	O
;	O
NH2	O
,	O
1	O
-	O
6C	O
alkylamino	O
or	O
di	O
(	O
1	O
-	O
5C	O
alkyl	O
)	O
amino	O
,	O
optionally	O
substituted	O
;	O
heterocyclylamino	O
;	O
or	O
La	O
-	O
A	O
-	O
Lb	O
-	O
B	O
;	O
La	O
:	O
a	O
bond	O
,	O
NR	O
'	O
,	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
;	O
A	O
:	O
phenyl	O
or	O
naphthyl	O
(	O
both	O
optionally	O
substituted	O
)	O
or	O
heterocyclyl	O
;	O
or	O
a	O
tricyclic	O
group	O
;	O
Lb	O
:	O
a	O
bond	O
,	O
NR	O
'	O
,	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
,	O
CHR	O
,	O
CH2O	O
,	O
OCH2	O
,	O
NR'CO	O
,	O
NR'CS	O
,	O
NR'CONR	O
'	O
,	O
NR'CSNR	O
'	O
,	O
NR'C	O
(	O
NH	O
)	O
,	O
NR'SO	O
,	O
NR'SO2	O
,	O
N	O
(	O
R'	O
)	O
=S	O
(	O
O	O
)	O
(	O
R	O
'	O
)	O
,	O
NR'C	O
(	O
NHOH	O
)	O
,	O
NHNR	O
'	O
,	O
N	O
(	O
NHR'	O
)	O
CO	O
,	O
NHN=	O
,	O
N	O
(	O
OH	O
)	O
CS	O
,	O
NR'COO	O
,	O
NR'C	O
(	O
S	O
)	O
O	O
,	O
N	O
(	O
OH	O
)	O
CO	O
;	O
B	O
:	O
H	O
;	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
CONH2	O
;	O
CONHQ	O
;	O
COOH	O
;	O
COOAlk	O
;	O
COQ	O
;	O
CH2CONH2	O
;	O
CH2CONHQ	O
;	O
CH2COOH	O
;	O
CH2COOAlk	O
;	O
CH2COQ	O
;	O
phenyl	O
or	O
naphthyl	O
or	O
4-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
optionally	O
substituted	O
with	O
oxo	O
)	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
Alk	O
:	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
Q	O
:	O
alkyl	O
,	O
aryl	O
or	O
heteroaryl	O
(	O
optionally	O
substituted	O
)	O
;	O
R	O
'	O
:	O
H	O
or	O
Alk	O
;	O
R2	O
>	O
H	O
,	O
1	O
-	O
12C	O
alkyl	O
,	O
2	O
-	O
12C	O
alkenyl	O
or	O
alkynyl	O
;	O
phenyl	O
(	O
1	O
-	O
6C	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
phenacyl	O
(	O
optionally	O
substituted	O
)	O
;	O
COOH	O
,	O
1	O
-	O
4C	O
alkoxycarbonyl	O
,	O
CONH2	O
or	O
mono-	O
or	O
di	O
(	O
1	O
-	O
6C	O
alkyl	O
)	O
carbamoyl	O
;	O
COR	O
'	O
;	O
CN	O
,	O
NO2	O
,	O
NH2	O
,	O
mono-	O
or	O
di	O
(	O
1	O
-	O
6C	O
alkyl	O
)	O
amino	O
,	O
N	O
=	O
N	O
-	O
Ph	O
,	O
N	O
=	O
N	O
-	O
C6H4-R	O
,	O
1,3-diphenyl-4-pyrazolyl	O
,	O
2-thiazolinyl	O
,	O
2-imidazolinyl	O
or	O
3,4,5,6-tetrahydropyrimidinyl	O
;	O
R3	O
>	O
H	O
;	O
OH	O
,	O
SH	O
,	O
CHO	O
,	O
COOH	O
,	O
CONH2	O
,	O
CN	O
,	O
SCN	O
,	O
NO2	O
,	O
halo	O
;	O
NH2	O
,	O
or	O
SO3H	O
or	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkenyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkynyl	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkyl	O
,	O
phenyl	O
,	O
1-	O
or	O
2-naphthyl	O
,	O
pyridyl	O
N	O
-	O
oxide	O
,	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkoxy	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkoxy	O
,	O
2	O
-	O
12C	O
alkanoyl	O
,	O
benzoyl	O
or	O
1-	O
or	O
2-naphthoyl	O
,	O
alkylthio	O
,	O
alkylsulfinyl	O
,	O
alkoxysulfonyl	O
or	O
alkylsulfonyl	O
,	O
(	O
hetero	O
)	O
arylthio	O
,	O
(	O
hetero	O
)	O
arylsulfinyl	O
or	O
(	O
hetero	O
)	O
arylsulfonyl	O
,	O
alkoxycarbonyl	O
,	O
alkylcarbamoyl	O
or	O
dialkylcarbamoyl	O
,	O
aryloxycarbonyl	O
,	O
arylcarbamoyl	O
,	O
arylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylcarbamoyl	O
,	O
aralkoxycarbonyl	O
or	O
aralkylcarbamoyl	O
with	O
1	O
-	O
5C	O
alkyl	O
or	O
6	O
-	O
10C	O
aryl	O
,	O
1	O
-	O
6C	O
alkylamino	O
or	O
di	O
(	O
1	O
-	O
5C	O
alkyl	O
)	O
amino	O
,	O
6	O
-	O
10C	O
arylamino	O
or	O
arylhydrazino	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
R4>2	O
-	O
14C	O
alkyl	O
,	O
3	O
-	O
14C	O
cycloalkyl	O
,	O
2	O
-	O
14C	O
alkenyl	O
,	O
3	O
-	O
14C	O
cycloalkenyl	O
,	O
2	O
-	O
14C	O
alkynyl	O
,	O
phenyl	O
or	O
1-	O
or	O
2-naphthyl	O
,	O
4-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
SQ1	O
>	O
,	O
SOQ1	O
>	O
,	O
SO2Q1	O
>	O
;	O
OR6	O
>	O
or	O
NR7	O
>	O
R8	O
>	O
;	O
Q1>1	O
-	O
8C	O
alkyl	O
,	O
2	O
-	O
8C	O
alkenyl	O
or	O
2	O
-	O
8C	O
alkynyl	O
,	O
(	O
optionally	O
substituted	O
)	O
;	O
R6>1	O
-	O
4C	O
n	O
-	O
alkyl	O
,	O
t	O
-	O
Bu	O
,	O
CH2CH2OH	O
,	O
CH2CH2SH	O
,	O
CH2CH2SMe	O
,	O
CH2CF3	O
,	O
CH2CCl3	O
,	O
CH2CHF2	O
,	O
CH2CHCl2	O
,	O
CH2CH2F	O
,	O
CH2CH2Cl	O
,	O
CH2CH2Br	O
;	O
3	O
-	O
7C	O
cycloalkyl	O
,	O
2	O
-	O
5C	O
alkenyl	O
or	O
alkynyl	O
;	O
3	O
-	O
7C	O
cycloalkenyl	O
;	O
aryl	O
or	O
heteroaryl	O
;	O
1-	O
or	O
2-naphthyl	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
pyridyl	O
,	O
isoquinolinyl	O

Medicament	O
for	O
local	O
use	O
Pharmaceutical	O
compositions	O
(	O
A	O
)	O
for	O
local	O
application	O
to	O
stop	O
bleeding	O
,	O
close	O
wounds	O
and/or	O
stimulate	O
wound	O
healing	O
,	O
contain	O
fibrinogen	B
(	O
I	B
)	O
or	O
fibrin	B
(	O
Ia	B
)	O
,	O
thrombin	B
(	O
II	B
)	O
and	O
one	O
or	O
more	O
transglutaminases	B
(	O
III	B
)	O
,	O
also	O
at	O
least	O
one	O
serpin	B
-	I
type	I
protease	I
inhibitor	O
(	O
IV	O
)	O
that	O
has	O
no	O
inhibitory	O
action	O
on	O
collagenases	B
or	O
elastases	B
,	O
are	O
new	O
.	O

All	O
active	O
ingredients	O
are	O
of	O
allogenic	O
origin	O
(	O
isolated	O
from	O
plasma	O
or	O
tissue	O
,	O
or	O
recombinant	O
)	O
and	O
have	O
been	O
subjected	O
to	O
a	O
virus	O
removal	O
and/or	O
inactivation	O
step	O
,	O
provided	O
that	O
virus	O
inactivation	O
of	O
(	O
IV	O
)	O
is	O
not	O
done	O
in	O
presence	O
of	O
other	O
active	O
ingredients	O
.	O

Independent	O
claims	O
are	O
also	O
included	O
for	O
the	O
following	O
:	O
(	O
a	O
)	O
preparation	O
of	O
a	O
(	O
I	O
)	O
-containing	O
solution	O
,	O
as	O
such	O
or	O
as	O
part	O
of	O
(	O
A	O
)	O
,	O
that	O
can	O
be	O
stored	O
at	O
refrigerator	O
or	O
room	O
temperature	O
;	O
(	O
b	O
)	O
pharmaceutical	O
compositions	O
(	O
B	O
)	O
containing	O
a	O
highly	O
purified	O
(	O
I	O
)	O
-	O
or	O
(	O
I	O
)	O
plus	O
fibronectin	O
-	O
containing	O
composition	O
that	O
has	O
activated	O
prothrombin	O
time	O
and	O
Taipan	O
viper	O
venom	O
prothrombin	O
time	O
at	O
37	O
[	O
deg	O
]	O
C	O
of	O
at	O
least	O
200	O
and	O
300	O
sec	O
,	O
respectively	O
;	O
(	O
c	O
)	O
a	O
method	O
for	O
preparing	O
pathogen	O
-	O
free	O
(	O
A	O
)	O
;	O
(	O
d	O
)	O
a	O
method	O
for	O
covalent	O
binding	O
of	O
(	O
A	O
)	O
to	O
a	O
biological	O
matrix	O
;	O
(	O
e	O
)	O
a	O
method	O
for	O
preparing	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
of	O
20	O
-	O
90	O
%	O
water	O
content	O
;	O
(	O
f	O
)	O
a	O
method	O
for	O
solidifying	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
with	O
or	O
without	O
removal	O
of	O
water	O
;	O
(	O
g	O
)	O
a	O
freeze	O
-	O
dried	O
(	O
Ia	O
)	O
-containing	O
gel	O
to	O
which	O
a	O
plasticizer	O
,	O
particularly	O
glycol	O
,	O
has	O
been	O
added	O
before	O
solidification	O
and	O
freeze	O
-	O
drying	O
;	O
(	O
h	O
)	O
a	O
method	O
for	O
producing	O
a	O
high	O
viscosity	O
(	O
I	O
)	O
-containing	O
solution	O
;	O
and	O
(	O
i	O
)	O
a	O
method	O
for	O
determining	O
the	O
adhesive	O
capacity	O
of	O
a	O
fibrin	O
clot	O
to	O
a	O
wound	O
bed	O
.	O

Use	O
of	O
4,5-dihydro-1h	O
-	O
pyrazole	O
derivatives	O
having	O
cb1-antagonistic	B
activity	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
medical	O
use	O
of	O
4,5-dihydro-1H	O
-	O
pyrazole	O
compounds	O
which	O
are	O
potent	O
antagonists	O
of	O
the	O
cannabis	O
CB1-receptor	B
.	O

Said	O
compounds	O
are	O
particularly	O
suitable	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
CB1	B
receptor	O
related	O
diseases	O
in	O
juvenile	O
patients	O
and/or	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
drug	O
induced	O
obesity	O
in	O
juvenile	O
as	O
well	O
as	O
in	O
adolescent	O
patients	O
.	O

The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
the	O
group	O
Bb	O
represents	O
sulfonyl	O
or	O
carbonyl	O
,	O
and	O
the	O
substituents	O
R	O
,	O
R1	O
,	O
R2and	O
R3	O
,	O
and	O
the	O
group	O
Aa	O
are	O
defined	O
as	O
shown	O
in	O
the	O
description	O
.	O

Benzimidazole	O
derivatives	O
and	O
use	O
thereof	O
as	O
peptide	B
deformylase	I
inhibitors	O
Benzimidazole	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
esters	O
thereof	O
are	O
peptide	B
deformylase	I
inhibitors	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
infections	O
and	O
other	O
diseases	O
in	O
which	O
peptide	B
deformylases	I
are	O
involved	O
,	O
especially	O
in	O
the	O
treatment	O
of	O
bacterial	O
and	O
parasitic	O
infections	O
,	O
for	O
example	O
infections	O
fully	O
or	O
partly	O
caused	O
by	O
microorganisms	O
belonging	O
to	O
Staphylococcus	O
,	O
Enterococcus	O
,	O
Streptococcus	O
,	O
Haemophilus	O
,	O
Moraxella	O
,	O
Escherichia	O
,	O
Mycobacterium	O
,	O
Mycoplasma	O
,	O
Pseudomonas	O
,	O
Chlamydia	O
,	O
Rickettsia	O
,	O
Klebsiella	O
,	O
Shigella	O
,	O
Salmonella	O
,	O
Bordetella	O
,	O
Clostridium	O
,	O
helicobacter	O
,	O
Campylobacter	O
,	O
Legionella	O
,	O
or	O
Neisseria	O
.	O

Oligo	O
-	O
beta-	O
(	O
1,3	O
)	O
-glucan	O
and	O
monoclonal	O
antibodies	O
against	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutical	O
method	O
comprising	O
administration	O
of	O
a	O
composition	O
comprising	O
a	O
monoclonal	O
antibody	O
with	O
an	O
oligo	O
-	O
β-	O
(	O
1,3	O
)	O
-glucan	O
and	O
.	O

a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
to	O
a	O
human	O
being	O
or	O
to	O
a	O
warm	O
-	O
blood	O
animal	O
suffering	O
from	O
cancer	O
in	O
an	O
amount	O
which	O
is	O
effective	O
to	O
treat	O
the	O
cancer	O
.	O

Treatment	O
of	O
a	O
Hemoglobinopathy	O
Disclosed	O
are	O
methods	O
for	O
treating	O
a	O
patient	O
identified	O
as	O
having	O
a	O
hemoglobinopathy	O
that	O
is	O
characterized	O
by	O
a	O
reduced	O
affinity	O
of	O
hemoglobin	B
for	O
oxygen	O
.	O

The	O
methods	O
involve	O
providing	O
gaseous	O
nitric	O
oxide	O
and/or	O
carbon	O
monoxide	O
for	O
(	O
i	O
)	O
inhalation	O
by	O
the	O
patient	O
or	O
(	O
ii	O
)	O
ex	O
vivo	O
treatment	O
of	O
the	O
patient	O
's	O
erythrocytes	O
.	O

Alternatively	O
,	O
a	O
nitric	O
-	O
oxide	O
-	O
releasing	O
compound	O
can	O
be	O
administered	O
to	O
the	O
patient	O
.	O

Method	O
of	O
examining	O
sensitivity	O
of	O
cancer	O
cell	O
to	O
anticancer	O
agent	O
In	O
the	O
case	O
where	O
the	O
sensitivity	O
of	O
a	O
cancer	O
cell	O
to	O
a	O
compound	O
can	O
be	O
understood	O
by	O
examining	O
molecules	O
expressed	O
in	O
the	O
cancer	O
cell	O
collected	O
from	O
a	O
cancer	O
patient	O
by	O
biopsy	O
or	O
the	O
like	O
,	O
it	O
is	O
possible	O
to	O
administer	O
the	O
compound	O
selectively	O
to	O
cancer	O
patients	O
on	O
whom	O
the	O
compound	O
can	O
exert	O
its	O
antitumor	O
effect	O
.	O

Thus	O
,	O
it	O
is	O
expected	O
that	O
the	O
therapeutic	O
effect	O
can	O
be	O
enhanced	O
while	O
relieving	O
unnecessary	O
side	O
effects	O
thereby	O
.	O

More	O
specifically	O
speaking	O
,	O
it	O
is	O
found	O
out	O
that	O
the	O
characteristics	O
""""	O
low	O
pRB	B
-	O
expression	O
""""	O
,	O
""""	O
positive	O
to	O
p16	B
expression	O
""""	O
and	O
""""	O
high	O
cyclin	B
E	I
-	O
expression	O
""""	O
are	O
usable	O
as	O
a	O
marker	O
for	O
the	O
high	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
this	O
compound	O
.	O

Examination	O
of	O
these	O
characteristics	O
of	O
cancer	O
cells	O
,	O
therefore	O
,	O
the	O
sensitivity	O
of	O
the	O
cancer	O
cells	O
to	O
this	O
compound	O
can	O
be	O
preliminarily	O
understood	O
.	O

Pyridylpyrimidine	O
derivatives	O
as	O
effective	O
compounds	O
against	O
prion	O
infections	O
and	O
prion	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
pyridylpyrimidine	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
hydrogen	O
or	O
methyl	O
and	O
Z	O
represents	O
nitrogen	O
containing	O
functional	O
groups	O
,	O
the	O
use	O
of	O
the	O
pyridylpyrimidine	O
derivatives	O
as	O
pharmaceutically	O
active	O
agents	O
,	O
especially	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
prion	O
infections	O
and	O
prion	O
diseases	O
,	O
as	O
well	O
as	O
compositions	O
containing	O
at	O
least	O
one	O
pyridylpyrimidine	O
derivative	O
and/or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
prion	O
diseases	O
using	O
said	O
pyridylpyrimidine	O
derivatives	O
.	O

Human	O
cellular	O
protein	O
kinases	O
,	O
phosphatases	O
and	O
cellular	O
signal	O
transduction	O
molecules	O
are	O
disclosed	O
as	O
targets	O
for	O
detecting	O
,	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
diseases	O
,	O
especially	O
BSE	O
,	O
vCJD	O
,	O
or	O
CJD	O
which	O
can	O
be	O
inhibited	O
by	O
the	O
inventive	O
pyridylpyrimidine	O
derivatives	O
.	O

2-substituted	O
and	O
4-substituted	O
aryl	O
nitrone	O
compouds	O
The	O
present	O
invention	O
provides	O
aryl	O
nitrones	O
,	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
of	O
their	O
use	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
oxidative	O
,	O
ischemic	O
,	O
ischemia	O
/	O
reperfusion	O
-	O
related	O
and	O
chemokine	O
mediated	O
conditions	O
.	O

Formulations	O
comprising	O
a	O
capsaicinoid	O
,	O
a	O
local	O
anesthetic	O
and/or	O
an	O
antipruritic	O
agent	O
for	O
the	O
treatment	O
of	O
pain	O
Formulations	O
and	O
methods	O
are	O
provided	O
for	O
the	O
treatment	O
of	O
pain	O
,	O
and	O
neuropathic	O
pain	O
in	O
particular	O
.	O

The	O
formulations	O
are	O
eutectic	O
mixtures	O
of	O
a	O
capsaicinoid	O
and	O
a	O
local	O
anesthetic	O
agent	O
and/or	O
anti	O
-	O
pruritic	O
agent	O
.	O

Alkyl	O
-	O
and	O
piperidine	O
-	O
substituted	O
benzimidazole	O
-	O
derivates	O
A	O
compound	O
of	O
general	O
formula	O
(	O
1a	O
)	O
wherein	O
R1	O
,	O
R5	O
,	O
R6	O
,	O
A	O
,	O
B	O
,	O
Y	O
,	O
i	O
,	O
j	O
and	O
m	O
are	O
defined	O
as	O
in	O
the	O
description	O
and	O
claims	O
.	O

It	O
is	O
another	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
pharmaceutical	O
compositions	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Oxazole	O
derivatives	O
as	O
histamine	B
h3	I
receptor	I
agents	O
,	O
preparation	O
and	O
therapeutic	O
uses	O
The	O
present	O
invention	O
discloses	O
novel	O
aryl	O
oxazole	O
compounds	O
of	O
Formula	O
I	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
have	O
histamine	B
-	I
H3	I
receptor	I
antagonist	O
or	O
inverse	O
agonist	O
activity	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
and	O
using	O
such	O
compounds	O
.	O

In	O
another	O
embodiment	O
,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
I	O
as	O
well	O
as	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
obesity	O
,	O
cognitive	O
deficiencies	O
,	O
narcolepsy	O
,	O
and	O
other	O
histamine	B
H3	I
receptor	I
-	O
related	O
diseases	O
.	O

Formula	O
I	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
m	O
is	O
independenlly	O
at	O
each	O
occurrence	O
1	O
,	O
2	O
,	O
or	O
3	O
,	O
Z	O
independently	O
represents	O
carbon	O
(	O
substituted	O
with	O
hydrogen	O
or	O
the	O
optional	O
substituents	O
indicated	O
herein	O
)	O
or	O
nitrogen	O
,	O
provided	O
that	O
when	O
Z	O
is	O
nitrogen	O
then	O
R6	O
is	O
not	O
attached	O
to	O
Z	O
;	O
R1	O
and	O
R2	O
are	O
independently	O
-	O
(	O
C1-C7	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
with	O
one	O
to	O
three	O
halogens	O
)	O
,	O
or	O
R1	O
and	O
R2	O
and	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
azetidinyl	O
ring	O
,	O
a	O
pyrrolidinyl	O
ring	O
,	O
or	O
a	O
piperidinyl	O
ring	O
,	O
wherein	O
further	O
the	O
azetidinyl	O
,	O
pyrrolidinyl	O
,	O
or	O
piperidinyl	O
ring	O
so	O
formed	O
may	O
be	O
optionally	O
substituted	O
one	O
to	O
three	O
times	O
with	O
R5	O
;	O
R6	O
is	O
independently	O
at	O
each	O
occurrence	O
-H	O
,	O
-halogen	O
,	O
or	O
-CH3	O
.	O

Pyrimidinylimidazoles	O
as	O
tgf	B
-	I
beta	I
inhibitors	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
possess	O
unexpectedly	O
high	O
affinity	O
for	O
Alk	B
5	I
and/or	O
Alk	B
4	I
,	O
and	O
can	O
be	O
useful	O
as	O
antagonists	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
numerous	O
diseases	O
,	O
including	O
fibrotic	O
disorders	O
.	O

The	O
invention	O
features	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
uses	O
thereof	O
.	O

Compositions	O
and	O
methods	O
comprising	O
vitamin	O
b12	O
and	O
an	O
impdh	B
inhibitor	O
for	O
treating	O
viral	O
,	O
inflammatory	O
and	O
proliferative	O
diseases	O
The	O
invention	O
relates	O
generally	O
to	O
novel	O
compositions	O
and	O
methods	O
comprising	O
at	O
least	O
one	O
Vitamin	O
B12	O
compound	O
,	O
at	O
least	O
one	O
IMPDH	B
inhibitor	O
,	O
and	O
optionally	O
an	O
interferon	O
.	O

The	O
compositions	O
and	O
methods	O
provide	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
viral	O
,	O
inflammatory	O
,	O
immunodeficiency	O
,	O
IMPDH	B
-	O
mediated	O
,	O
and	O
proliferative	O
diseases	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
yersinia	O
spp	O
infection	O
The	O
invention	O
generally	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
Yersinia	O
spp	O
.	O

infection	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
derivatives	O
and	O
analogs	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
analogs	O
,	O
methods	O
of	O
making	O
the	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
analogs	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Biphenyl	O
integrin	B
antagonists	O
The	O
following	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compounds	O
and	O
compositions	O
of	O
the	O
Formula	O
(	O
I	O
)	O
.	O

useful	O
for	O
treating	O
conditions	O
mediated	O
by	O
αVβ3	B
and/or	O
αVβ5	O
integrin	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
ibandronate	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
multi	O
step	O
synthesis	O
of	O
3-	O
(	O
N	O
-	O
methyl	O
-	O
N	O
-	O
pentyl	O
)	O
amino	O
-	O
l­hydroxypropane-1	O
,	O
1-diphosphonic	O
acid	O
,	O
monosodium	O
salt	O
,	O
monohydrate	O
,	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Cosmetic	O
composition	O
comprising	O
phytosterols	O
,	O
isoflavones	O
and	O
methylricinoleate	O
,	O
use	O
as	O
inhibitor	O
of	O
5-alpha	B
-	I
reductase	I
and	O
hair	O
growth	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cosmetic	O
mixture	O
comprising	O
phytosterols	O
in	O
quantities	O
ranging	O
from	O
1	O
to	O
20	O
%	O
by	O
weight	O
,	O
isoflavones	O
from	O
0.1	O
to	O
4	O
%	O
by	O
weight	O
and	O
methylricinoleate	O
from	O
80	O
to	O
90	O
%	O
by	O
weight	O
.	O

Said	O
cosmetic	O
mixture	O
is	O
formulated	O
with	O
excipients	O
normally	O
used	O
in	O
the	O
cosmetic	O
sector	O
,	O
to	O
give	O
a	O
cosmetic	O
formulation	O
.	O

The	O
cosmetic	O
mixture	O
and	O
formulation	O
are	O
capable	O
of	O
inhibiting	O
the	O
enzyme	O
5-alpha	B
-	I
reductase	I
,	O
and	O
thus	O
have	O
inhibitory	O
or	O
retardatory	O
activity	O
towards	O
the	O
growth	O
of	O
body	O
hair	O
.	O

Iridoid	O
glycoside	O
composition	O
The	O
present	O
invention	O
relates	O
to	O
an	O
adjuvants	O
,	O
particularly	O
to	O
the	O
use	O
of	O
a	O
well	O
-	O
characterized	O
plant	O
based	O
iridoid	O
glycoside	O
adjuvant	O
from	O
plant	O
Picrorhiza	O
kurroa	O
,	O
acting	O
as	O
an	O
adjuvant	O
against	O
T	O
-dependent	O
antigen	O
and	O
specifically	O
against	O
HBsAg	O
and	O
typhoid	O
antigens	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
producing	O
the	O
iridoid	O
glycoside	O
adjuvant	O
and	O
the	O
products	O
utilizing	O
such	O
adjuvants	O
for	O
induction	O
of	O
cellular	O
immunity	O
.	O

The	O
adjuvants	O
may	O
be	O
used	O
alone	O
or	O
with	O
specific	O
antigens	O
.	O

The	O
two	O
antigens	O
used	O
in	O
the	O
study	O
represents	O
HBsAg	O
,	O
a	O
recombinant	O
antigen	O
expressed	O
in	O
Pichia	O
pastoris	O
,	O
and	O
typhoid	O
Vi	O
polysaccharide	O
purified	O
from	O
Salmonella	O
typhi	O
broth	O
.	O

These	O
antigens	O
are	O
studied	O
for	O
their	O
immunogenicity	O
with	O
the	O
adjuvant	O
iridoid	O
glycoside	O
adjuvant	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
taxane	O
derivative	O
The	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
the	O
synthesis	O
of	O
13-	O
(	O
N	O
-	O
Boc	O
-	O
β	O
-	O
isobutylserinyl	O
)	O
-14-β	O
-	O
hydroxybaccatin	O
III-1,14-carbonate	O
(	O
I	O
)	O
,	O
wherein	O
carbonation	O
of	O
the	O
1,14-hydroxy	O
groups	O
of	O
the	O
baccatin	O
skeleton	O
is	O
carried	O
out	O
with	O
bis	O
(	O
trichloromethylcarbonate	O
and	O
the	O
7-hydroxy	O
group	O
is	O
protected	O
with	O
a	O
trichloroacetyl	O
group	O
.	O

Use	O
of	O
pyridoxal	O
phosphate	O
derivatives	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
related	O
complications	O
Use	O
of	O
a	O
3-acylated	O
pyridoxal	O
analogue	O
,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
,	O
or	O
a	O
mixture	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
,	O
related	O
conditions	O
,	O
symptoms	O
of	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
or	O
related	O
conditions	O
,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
mammal	O
.	O

Alcohol	O
resistant	O
pharmaceutical	O
formulations	O
The	O
present	O
invention	O
provides	O
alcohol	O
resistant	O
oral	O
dosage	O
pharmaceutical	O
forms	O
and	O
methods	O
of	O
using	O
such	O
oral	O
dosage	O
forms	O
to	O
avoid	O
dose	O
dumping	O
if	O
the	O
dosage	O
form	O
is	O
taken	O
together	O
with	O
alcohol	O
.	O

Guanosine	O
-	O
rich	O
oligonucleotides	O
as	O
agents	O
for	O
inducing	O
cell	O
death	O
in	O
eukaryotic	O
cells	O
The	O
present	O
invention	O
relates	O
to	O
guanosine	O
-	O
rich	O
oligonucleotides	O
having	O
the	O
capacity	O
to	O
induce	O
cell	O
death	O
,	O
having	O
characteristics	O
of	O
programmed	O
cell	O
death	O
,	O
in	O
non	O
-	O
quiescent	O
cells	O
of	O
higher	O
eukaryotic	O
organisms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
therapeutic	O
methods	O
involving	O
the	O
administration	O
of	O
these	O
nucleic	O
acid	O
molecules	O
to	O
subjects	O
suffering	O
from	O
,	O
or	O
being	O
predisposed	O
to	O
,	O
disorders	O
involving	O
abnormal	O
cell	O
proliferation	O
and	O
migration	O
.	O

The	O
invention	O
also	O
concerns	O
pharmaceutical	O
compositions	O
comprising	O
the	O
guanosine	O
-	O
rich	O
nucleic	O
acid	O
molecules	O
,	O
in	O
association	O
with	O
suitable	O
carriers	O
.	O

ASSOCIATION	O
OF	O
ß3	B
RECEPTOR	I
AGONIST	O
AND	O
MONOAMINE	O
REUPTAKE	O
INHIBITORS	O
,	O
PHARMACEUTICAL	O
COMPOSITION	O
AND	O
THERAPEUTIC	O
USE	O
THEREOF	O
The	O
invention	O
concerns	O
the	O
association	O
of	O
at	O
least	O
one	O
ß3	B
adrenergic	I
receptor	I
agonist	O
(	O
or	O
ß3	O
agonist	O
)	O
with	O
a	O
monoamine	O
reuptake	O
inhibitor	O
.	O

The	O
invention	O
also	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
inventive	O
association	O
and	O
its	O
therapeutic	O
use	O
.	O

Novel	O
memory	O
ctl	O
induction	O
potentiator	O
The	O
present	O
invention	O
relates	O
to	O
a	O
memory	O
CTL	O
induction	O
enhancer	O
comprising	O
a	O
combination	O
of	O
substance	O
(	O
b	O
)	O
with	O
substance	O
(	O
a	O
)	O
and/or	O
substance	O
(	O
c	O
)	O
,	O
wherein	O
substance	O
(	O
a	O
)	O
is	O
an	O
activator	O
of	O
antigen	O
-	O
presenting	O
cells	O
,	O
substance	O
(	O
b	O
)	O
is	O
an	O
inducer	O
of	O
homeostatic	O
proliferation	O
after	O
induction	O
of	O
lymphopenia	O
,	O
and	O
substance	O
(	O
c	O
)	O
is	O
a	O
suppressor	O
of	O
regulatory	O
T	O
cells	O
.	O

Use	O
of	O
tenatoprazole	O
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
disease	O
Use	O
of	O
tenatoprazole	O
is	O
claimed	O
in	O
medicines	O
for	O
the	O
treatment	O
of	O
atypical	O
and	O
esophageal	O
symptoms	O
of	O
gastroesophageal	O
reflux	O
,	O
digestive	O
hemorrhages	O
and	O
dyspepsias	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
;	O
Antiasthmatic	O
;	O
Antitussive	O
;	O
Respiratory	O
-	O
Gen	O
.	O
;	O
Antianginal	O
;	O
Hemostatic	O
.	O

In	O
a	O
test	O
,	O
fourteen	O
patients	O
suffering	O
from	O
gastroesophageal	O
reflux	O
were	O
given	O
a	O
daily	O
dose	O
of	O
tenatoprazole	O
(	O
20	O
mg	O
)	O
for	O
4	O
-	O
12	O
weeks	O
.	O

In	O
twelve	O
cases	O
,	O
the	O
dosage	O
was	O
tolerated	O
perfectly	O
and	O
in	O
the	O
other	O
two	O
cases	O
it	O
was	O
well	O
-	O
tolerated	O
.	O

The	O
effect	O
on	O
the	O
symptoms	O
was	O
very	O
good	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	B
pump	I
inhibitor	O
.	O

Inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
replication	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
their	O
derivatives	O
comprising	O
a	O
detectable	O
label	O
,	O
their	O
compositions	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
novel	O
inhibitors	O
of	O
HIV	O
replication	O
,	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
for	O
using	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
.	O

Modulation	O
of	O
the	O
P2Y2	B
receptor	I
pathway	O
The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
regulating	O
the	O
activity	O
of	O
the	O
purinergic	B
receptors	I
for	O
the	O
modulation	O
of	O
the	O
vascular	O
tone	O
,	O
particularly	O
for	O
the	O
purpose	O
of	O
treatment	O
of	O
haemodynamic	O
conditions	O
by	O
overriding	O
of	O
vasoconstriction	O
activity	O
,	O
such	O
as	O
increases	O
in	O
sympathic	O
vasoconstriction	O
.	O

Modulators	O
,	O
such	O
as	O
UTP	O
analogues	O
as	O
described	O
herein	O
are	O
preferably	O
specific	O
for	O
P2Y2	O
.	O

Compounds	O
capable	O
of	O
stimulating	O
the	O
P2Y2	B
receptor	I
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasoconstriction	O
activity	O
is	O
desirable	O
such	O
as	O
hypertension	O
and	O
hypertension	O
relates	O
disorders	O
or	O
diseases	O
,	O
whereas	O
compound	O
capable	O
of	O
counteracting	O
the	O
activity	O
of	O
the	O
P2Y2	B
receptor	I
are	O
suitable	O
for	O
the	O
treatment	O
of	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasodilatation	O
is	O
desirable	O
.	O

Derivatives	O
of	O
1-phenyl-2-pyridynyl	O
alkylene	O
alcohols	O
as	O
phosphodiesterase	B
inhibitors	O
The	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	O
phosphodiesterase	B
4	I
(	O
PDE4	B
)	O
enzyme	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
derivatives	O
of	O
1-phenyl-2-pyridynyl	O
alkylene	O
alcohols	O
,	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
compositions	O
containing	O
them	O
and	O
therapeutic	O
use	O
thereof	O
.	O

Binding	O
interaction	O
of	O
proanthocyanidins	O
with	O
bacteria	O
and	O
bacterial	O
components	O
A	O
composition	O
having	O
:	O
a	O
proanthocyanidin	O
:	O
and	O
a	O
macromolecule	O
,	O
an	O
assembly	O
of	O
macromolecules	O
,	O
a	O
semi	O
-	O
solid	O
,	O
or	O
a	O
solid	O
surface	O
to	O
which	O
the	O
proanthocyanidin	O
is	O
immobilized	O
.	O

A	O
composition	O
having	O
proanthocyanidin	O
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

A	O
method	O
of	O
administering	O
to	O
an	O
immunosuppressed	O
patient	O
or	O
a	O
patient	O
diagnosed	O
with	O
sepsis	O
or	O
septic	O
shock	O
a	O
composition	O
having	O
a	O
proanthocyanidin	O
.	O

A	O
method	O
of	O
administering	O
to	O
a	O
patient	O
diagnosed	O
with	O
a	O
gram	O
negative	O
bacterial	O
infection	O
a	O
composition	O
having	O
proanthocyanidin	O
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

Pharmaceutical	O
composition	O
using	O
aliskiren	O
and	O
avosentan	O
The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
and	O
method	O
of	O
achieving	O
a	O
therapeutic	O
effect	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
the	O
treatment	O
of	O
hypertension	O
,	O
kidney	O
or	O
heart	O
disease	O
in	O
an	O
animal	O
,	O
preferably	O
a	O
mammal	O
including	O
a	O
human	O
subject	O
,	O
using	O
(	O
i	O
)	O
SPP100	O
/	O
aliskiren	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
combination	O
with	O
(	O
ii	O
)	O
SPP301	O
/	O
avosentan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
iii	O
)	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

4	O
-	O
1	O
bb	O
ligand	O
in	O
inflammatory	O
diseases	O
The	O
invention	O
provides	O
4-IBBL	O
blocking	O
agents	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
blocking	O
agents	O
as	O
new	O
therapeutic	O
interventions	O
for	O
sustained	O
inflammation	O
.	O

Thus	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
reducing	O
sustained	O
production	O
of	O
tumor	O
necrosis	O
factor	O
.	O

Glucose	O
metabolism	O
ameliorating	O
agent	O
A	O
compound	O
of	O
the	O
formula	O
I	O
:	O
wherein	O
R1	O
is	O
lower	O
alkyl	O
,	O
R2	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
,	O
Z	O
is	O
optionally	O
substituted	O
lower	O
alkyl	O
,	O
optionally	O
substituted	O
lower	O
alkenyl	O
,	O
optionally	O
substituted	O
amino	O
,	O
optionally	O
substituted	O
lower	O
alkoxy	O
,	O
optionally	O
substituted	O
carbocyclyl	O
or	O
optionally	O
substituted	O
heterocyclyl	O
can	O
stimulate	O
the	O
glucose	O
metabolism	O
independent	O
of	O
change	O
in	O
body	O
weight	O
.	O

The	O
compound	O
can	O
be	O
used	O
as	O
a	O
glucose	O
metabolism	O
stimulating	O
agent	O
.	O

1-aryl-3-aminoalkoxy	O
-	O
pyrazoles	O
as	O
sigma	O
ligands	O
enhancing	O
analgesic	O
effects	O
of	O
opioids	O
and	O
attenuating	O
the	O
dependency	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
as	O
well	O
as	O
to	O
attenuation	O
of	O
the	O
addiction	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
group	O
of	O
sigma	O
receptor	O
ligands	O
of	O
formula	O
I	O
for	O
the	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
and	O
at	O
the	O
same	O
time	O
for	O
decreasing	O
of	O
the	O
dependency	O
induced	O
by	O
them	O
.	O

Oxylipins	O
from	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O
Disclosed	O
are	O
novel	O
oxylipins	O
,	O
referred	O
to	O
herein	O
as	O
docosanoids	O
and	O
eicosanoids	O
,	O
that	O
are	O
derived	O
from	O
C22	O
polyunsaturated	O
fatty	O
acids	O
and	O
from	O
C20	O
polyunsaturated	O
fatty	O
acids	O
,	O
respectively	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
such	O
oxylipins	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
docosapentaenoic	O
acid	O
(	O
C22:5n-6	O
)	O
(	O
DPAn-6	O
)	O
,	O
docosapentaenoic	O
acid	O
(	O
C22:5n-3	O
)	O
(	O
DPAn-3	O
)	O
,	O
and	O
docosatetraenoic	O
acid	O
(	O
DTAn-6	O
:	O
C22:4n-6	O
)	O
,	O
docosatrienoic	O
acid	O
(	O
C22:3n-3	O
)	O
(	O
DTrAn-3	O
)	O
,	O
docosadienoic	O
acid	O
(	O
C22:2n-6	O
)	O
(	O
DDAn-6	O
)	O
,	O
eicosatrienoic	O
acid	O
(	O
C20:3n-3	O
)	O
(	O
ETrAn-3	O
)	O
eicosapentaenoic	O
acid	O
and	O
arachidonic	O
acid	O
as	O
substrates	O
for	O
the	O
production	O
of	O
novel	O
oxylipins	O
,	O
and	O
to	O
the	O
oxylipins	O
produced	O
thereby	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
DPAn-6	O
,	O
DPAn-3	O
,	O
DTAn-6	O
,	O
and/or	O
the	O
oxylipins	O
derived	O
therefrom	O
,	O
and/or	O
novel	O
docosanoids	O
derived	O
from	O
the	O
structures	O
of	O
C22	O
fatty	O
acids	O
in	O
therapeutic	O
and	O
nutritional	O
or	O
cosmetic	O
applications	O
,	O
and	O
particularly	O
as	O
anti	O
-	O
inflammatory	O
or	O
anti	O
-	O
neurodegenerative	O
compounds	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
ways	O
of	O
producing	O
long	O
chain	O
polyunsaturated	O
acid	O
(	O
LCPUF	O
A	O
)	O
-rich	O
oils	O
and	O
compositions	O
that	O
contain	O
enhanced	O
and	O
effective	O
amounts	O
of	O
LCPUF	O
A	O
-	O
derived	O
oxylipins	O
,	O
and	O
particularly	O
,	O
docosanoids	O
.	O

Method	O
for	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
with	O
abl	B
tyrosine	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
evaluating	O
patients	O
to	O
help	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
in	O
a	O
human	O
patient	O
population	O
.	O

More	O
specifically	O
,	O
the	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
a	O
)	O
determining	O
the	O
OCT-1	B
Activity	O
in	O
pre	O
-	O
therapy	O
blood	O
of	O
a	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
,	O
and	O
(	O
b	O
)	O
administering	O
a	O
daily	O
dose	O
between	O
about	O
500	O
and	O
1200	O
mg	O
of	O
Imatinib	O
mesylate	O
to	O
the	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
showing	O
an	O
OCT-1	B
Activity	O
corresponding	O
to	O
Imatinib	O
intracellular	O
concentration	O
below	O
about	O
6.0	O
to	O
10.0	O
ng	O
/	O
200,000	O
cells	O
,	O
especially	O
about	O
8.0	O
to	O
8.5	O
ng	O
/	O
200,000	O
cells	O
.	O

Florfenicol	O
esters	O
for	O
treating	O
bacterial	O
infections	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
a	O
florfenicol	O
ester	O
and	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
wherein	O
the	O
florfenicol	O
ester	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
florfenicol	O
acetate	O
,	O
florfenicol	O
propionate	O
,	O
florfenicol	O
butyrate	O
,	O
florfenicol	O
pentanoate	O
,	O
florfenicol	O
heptanoate	O
,	O
florfenicol	O
octanoate	O
,	O
florfenicol	O
nanoate	O
,	O
florfenicol	O
decanoate	O
,	O
florfenicol	O
undecanoate	O
,	O
and	O
florfenicol	O
dodecanoate	O
;	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
a	O
bacterial	O
infection	O
that	O
is	O
susceptible	O
to	O
florfenicol	O
in	O
a	O
bovine	O
that	O
can	O
be	O
administered	O
as	O
a	O
single	O
injection	O
in	O
an	O
amount	O
sufficient	O
to	O
treat	O
the	O
infection	O
without	O
requiring	O
a	O
second	O
injection	O

Anti	O
-	O
glycation	O
properties	O
of	O
asicatic	O
acid	O
and	O
madecassic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
use	O
of	O
compounds	O
from	O
Centella	O
Asiatica	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Asiatic	O
acid	O
and	O
Madecassic	O
acid	O
,	O
and	O
plant	O
extracts	O
containing	O
both	O
acids	O
in	O
cosmetics	O
,	O
pharmaceuticals	O
and	O
food	O
supplements	O
for	O
preventing	O
the	O
glycation	O
phenomenon	O
and	O
the	O
glycation	O
consequences	O
in	O
tissues	O
,	O
more	O
paticularly	O
for	O
preventing	O
skin	O
aging	O
,	O
enhancing	O
wounds	O
treating	O
,	O
venous	O
insufficiency	O
etc	O
.	O

Poly	O
aromatic	O
sodium	B
channel	I
blockers	O
Polyaromatic	O
sodium	B
channel	I
blockers	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
are	O
provided	O
where	O
the	O
structural	O
variables	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
includes	O
a	O
variety	O
of	O
compositions	O
,	O
combinations	O
and	O
methods	O
of	O
treatment	O
using	O
these	O
inventive	O
sodium	B
channel	I
blockers	O
.	O

2-aminopyridine	O
kinase	B
inhibitors	O
2-Aminopyridine	O
compounds	O
having	O
the	O
structure	O
of	O
Formula	O
I	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
these	O
compounds	O
.	O

Compounds	O
of	O
Formula	O
I	O
inhibit	O
the	O
activity	O
of	O
tyrosine	B
kinase	I
enzymes	O
in	O
animals	O
,	O
including	O
humans	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
various	O
diseases	O
and	O
conditions	O
.	O

In	O
particular	O
,	O
compounds	O
disclosed	O
herein	O
are	O
inhibitors	O
of	O
kinases	O
,	O
in	O
particular	O
,	O
but	O
not	O
limited	O
to	O
,	O
KDR	B
,	O
Tie-2	B
,	O
F1t3	B
,	O
FGFR3	B
,	O
Ab1	B
,	O
Aurora	B
A	I
,	O
c	B
-	I
Src	I
,	O
IGF-	B
IR	I
,	O
ALK	B
,	O
c	B
-	I
MET	I
,	O
RON	B
,	O
PAK1	B
,	O
PAK2	B
,	O
and	O
TAK1	B
,	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
cancer	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
patient	O
having	O
a	O
condition	O
which	O
is	O
mediated	O
by	O
protein	B
kinase	I
activity	O
by	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
above	O
-	O
mentioned	O
pharmaceutical	O
composition	O
.	O

Stabilization	O
of	O
the	O
composition	O
of	O
a	O
mixture	O
Described	O
is	O
a	O
method	O
for	O
slowing	O
the	O
speed	O
of	O
the	O
isomerisation	O
of	O
petasin	O
and	O
neopetasin	O
to	O
isopetasin	O
,	O
and	O
the	O
isomerisation	O
of	O
S	O
-	O
petasin	O
and	O
neo	O
-	O
S	O
-	O
petasin	O
to	O
iso	O
-	O
S	O
-	O
petasin	O
,	O
especially	O
in	O
extracts	O
from	O
plants	O
of	O
the	O
genus	O
Petasites	O
,	O
preferably	O
Petasites	O
hybridus	O
,	O
by	O
the	O
addition	O
of	O
at	O
least	O
one	O
suitable	O
stabilizer	O
and/or	O
the	O
removal	O
of	O
at	O
least	O
one	O
destabilizing	O
substance	O
,	O
e.g.	O
a	O
fatty	O
acid	O
.	O

Enhanced	O
nsaid	O
formulations	O
The	O
application	O
is	O
directed	O
to	O
a	O
composition	O
and	O
its	O
use	O
for	O
treating	O
inflammation	O
comprising	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
agent	O
,	O
a	O
metasilicate	O
,	O
a	O
first	O
disintegrant	O
and	O
a	O
second	O
disintegrant	O
,	O
resulting	O
in	O
increased	O
absorption	O
of	O
said	O
active	O
in	O
mammals	O
with	O
suppressed	O
vagal	O
systems	O
The	O
preferred	O
composition	O
includes	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
,	O
sodium	O
bicarbonate	O
,	O
tartaric	O
acid	O
and	O
metasilicate	O
.	O

Tetracyclic	O
compound	O
Provided	O
are	O
a	O
tetracyclic	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
in	O
the	O
formula	O
(	O
I	O
)	O
,the	O
formula	O
(	O
A	O
)	O
represents	O
a	O
benzene	O
ring	O
or	O
the	O
like	O
,	O
X	O
represents	O
CH	O
or	O
a	O
nitrogen	O
atom	O
,	O
Q	O
represents	O
-O-	O
or	O
the	O
like	O
,	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
,	O
1	O
,	O
m	O
,	O
and	O
n	O
each	O
represent	O
an	O
integer	O
from	O
one	O
to	O
the	O
maximum	O
substitutable	O
number	O
of	O
substituents	O
,	O
and	O
R4	O
and	O
R5	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
like	O
.	O

Cosmetic	O
composition	O
for	O
sensitive	O
skins	O
Cosmetic	O
composition	O
for	O
sensitive	O
skins	O
comprising	O
hyperoxygenated	O
fatty	O
acids	O
and	O
one	O
or	O
more	O
volatile	O
silicones	O
,	O
together	O
with	O
the	O
use	O
thereof	O
for	O
the	O
prevention	O
of	O
ulcers	O
and	O
the	O
preservation	O
of	O
perilesional	O
skin	O
.	O

Combination	O
of	O
a	O
phosphatidylinositol-3-kinase	B
(	O
pi3k	B
)	O
inhibitor	O
and	O
a	O
mtor	B
inhibitor	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
phosphoinositide	B
3-kinase	I
inhibitor	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
b	O
)	O
a	O
mTOR	B
inhibitor	O
for	O
the	O
treatment	O
of	O
a	O
target	B
of	I
raparnycin	I
(	I
mTOR	I
)	I
kinase	I
dependent	O
disease	O
,	O
especially	O
a	O
cancer	O
disease	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
combination	O
;	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
;	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
such	O
a	O
combination	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
;	O
and	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
warm¬	O
blooded	O
animal	O
,	O
especially	O
a	O
human	O
.	O

Benzonaphtyridine	O
compounds	O
used	O
as	O
inhibitors	O
of	O
autotaxin	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5,D	O
,	O
Z	O
,	O
X	O
,	O
Y	O
,	O
m	O
and	O
p	O
are	O
defined	O
as	O
cited	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
tumours	O
.	O

Topical	O
cosmetic	O
or	O
pharmaceutical	O
composition	O
comprising	O
probiotic	O
lactobacillus	O
strains	O
and	O
use	O
of	O
same	O
A	O
topical	O
composition	O
which	O
is	O
suitable	O
for	O
treating	O
or	O
preventing	O
skin	O
or	O
mucosal	O
infectious	O
disorders	O
or	O
troubles	O
in	O
humans	O
,	O
in	O
particular	O
for	O
treating	O
or	O
preventing	O
urinary	O
tract	O
infections	O
and	O
lower	O
vaginal	O
tract	O
infections	O
in	O
females	O
comprises	O
an	O
oily	O
primary	O
phase	O
and	O
a	O
complementary	O
aqueous	O
phase	O
wherein	O
the	O
oily	O
primary	O
phase	O
consists	O
of	O
a	O
non	O
polar	O
mineral	O
or	O
silicone	O
comprising	O
an	O
efficient	O
amount	O
of	O
at	O
least	O
one	O
viable	O
probiotic	O
bacteria	O
strain	O
,	O
in	O
particular	O
a	O
lactobacillus	O
strain	O
.	O

The	O
composition	O
is	O
also	O
useful	O
for	O
suitable	O
for	O
balancing	O
or	O
restoring	O
skin	O
or	O
mucosal	O
indigenous	O
microflora	O
in	O
humans	O
,	O
in	O
particular	O
for	O
balancing	O
or	O
restoring	O
the	O
local	O
urinary	O
tract	O
and	O
lower	O
vaginal	O
tract	O
bacterial	O
flora	O
in	O
females	O
.	O

Pyrazole	O
-	O
amine	O
compounds	O
useful	O
as	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
provides	O
pyrazole	O
derived	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
where	O
W	O
,	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
m	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
further	O
pertains	O
to	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
compound	O
according	O
to	O
the	O
invention	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
and	O
methods	O
of	O
inhibiting	O
the	O
activity	O
of	O
p38	O
kinase	O
in	O
a	O
mammal	O
.	O

Methods	O
for	O
making	O
valerenic	O
acid	O
derivatives	O
and	O
their	O
use	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
,	O
intermediates	O
and	O
methods	O
for	O
making	O
valerenic	O
acid	O
and	O
its	O
derivatives	O
as	O
well	O
as	O
the	O
use	O
of	O
such	O
compounds	O
as	O
GABAA	O
receptor	O
ligands	O
.	O

3-	O
(	O
5-Amino-6-oxo-1,6-dihydropyridazin-3-yl	O
)	O
-biphenyl	O
derivatives	O
as	O
PDE4	B
inhibitors	O
New	O
pyridazin-3	O
(	O
2H	O
)	O
-one	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
the	O
phosphodiesterase	B
IV	I
(	O
PDE4	B
)	O
.	O

Diazeniumdiolated	O
phosphorylcholine	O
polymers	O
for	O
nitric	O
oxide	O
release	O
The	O
present	O
disclosure	O
in	O
a	O
broad	O
aspect	O
provides	O
for	O
diazeniumdiolated	O
phosphorylcholine	O
polymers	O
and	O
associated	O
methods	O
for	O
achieving	O
nitric	O
oxide	O
release	O
.	O

The	O
present	O
polymers	O
have	O
superior	O
biocompatibility	O
and	O
are	O
useful	O
for	O
coating	O
or	O
fabricating	O
medical	O
devices	O
such	O
as	O
a	O
vascular	O
stent	O
.	O

5,6,7,8-TETRAHYDRO	O
[	O
1,2,4	O
]	O
TRIAZOLO	O
[	O
4,3-a	O
]	O
PYRAZINE	O
DERIVATIVES	O
AS	O
P2X7	O
MODULATORS	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
A	O
is	O
hydrogen	O
,	O
C1	O
-	O
4alkyl	O
,	O
C3	O
-	O
6cycloalkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkoxy	O
C1	O
-	O
4alkyl	O
,	O
C1	O
-	O
2fluoroalkyl	O
,	O
halogen	O
,	O
NR6	O
R7	O
,	O
optionally	O
substituted	O
heteroaryl	O
(	O
Het	O
)	O
,	O
or	O
optionally	O
substituted	O
phenyl	O
,	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
or	O
salts	O
are	O
thought	O
to	O
modulate	O
P2X7	O
receptor	O
function	O
and	O
to	O
be	O
capable	O
of	O
antagonizing	O
the	O
effects	O
of	O
ATP	O
at	O
the	O
P2X7	O
receptor	O
.	O

The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
compound	O
or	O
salt	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
,	O
for	O
example	O
,	O
inflammatory	O
pain	O
,	O
neuropathic	O
pain	O
,	O
visceral	O
pain	O
,	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
or	O
neurodegenerative	O
disorders	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O
We	O
describe	O
methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O
associated	O
with	O
angiogenesis	O
,	O
vascular	O
leakage	O
,	O
and/or	O
damage	O
to	O
ganglia	O
.	O

Combination	O
of	O
dopamine	O
agonists	O
plus	O
first	O
phase	O
insulin	O
secretagouges	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
metabolic	O
disorder	O
or	O
key	O
elements	O
of	O
a	O
metabolic	O
disorder	O
such	O
method	O
comprising	O
the	O
use	O
of	O
an	O
agent	O
(	O
s	O
)	O
that	O
increases	O
central	O
dopaminergic	O
activity	O
plus	O
a	O
first	O
-	O
phase	O
insulin	B
secretagouge	O
.	O

2-	O
(	O
lh	O
-	O
pyrazol-4	O
-ylamino	O
)	O
-pyrimidine	O
as	O
kinase	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
:	O
wherein	O
A1	O
,	O
A2	O
,	O
A3	O
,	O
A4	O
,	O
X	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
making	O
said	O
compounds	O
,	O
and	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
aurora	B
and	O
KDR	B
.	O

The	O
use	O
of	O
lpa	O
for	O
encouraging	O
pregnancy	O
,	O
and	O
fertility	O
agent	O
The	O
objective	O
is	O
to	O
find	O
compounds	O
which	O
have	O
an	O
activity	O
to	O
improve	O
the	O
success	O
rate	O
of	O
pregnancy	O
and	O
implantation	O
in	O
blastocyst	O
transfer	O
in	O
mammals	O
,	O
to	O
provide	O
a	O
method	O
of	O
producing	O
and	O
using	O
the	O
compounds	O
,	O
and	O
to	O
provide	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
.	O

Disclosed	O
is	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
containing	O
one	O
or	O
more	O
lysophosphatidic	O
acids	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
LPA	O
-	O
C16:0	O
,	O
LPA	O
-	O
C16:1	O
,	O
LPA	O
-	O
C18:0	O
,	O
LPA	O
-	O
C18:1	O
and	O
LPA	O
-	O
C18:2	O
.	O

Medical	O
use	O
of	O
spla2	O
hydrolysable	O
liposomes	O
The	O
present	O
invention	O
relates	O
to	O
medical	O
use	O
of	O
liposomes	O
,	O
more	O
particular	O
the	O
first	O
medical	O
use	O
of	O
sPLA2	O
hydrolysable	O
liposomes	O
.	O

Such	O
liposomes	O
may	O
be	O
used	O
for	O
targeted	O
delivery	O
of	O
therapeutic	O
agents	O
to	O
cancerous	O
tissue	O
and	O
in	O
such	O
embodiments	O
;	O
the	O
therapeutic	O
agents	O
are	O
typically	O
small	O
molecule	O
antitumor	O
agents	O
.	O

Other	O
aspects	O
of	O
the	O
inventions	O
relates	O
to	O
methods	O
of	O
reducing	O
the	O
side	O
effects	O
of	O
therapeutic	O
agents	O
,	O
e.g.	O
reducing	O
nephrotoxicity	O
,	O
neurotoxicity	O
and	O
gastrointestinal	O
toxicity	O
of	O
a	O
therapeutic	O
agent	O
.	O

Yet	O
another	O
aspect	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
of	O
prolonging	O
the	O
therapeutic	O
effect	O
of	O
a	O
therapeutic	O
agent	O
.	O

Solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
The	O
present	O
invention	O
relates	O
to	O
a	O
solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
,	O
containing	O
the	O
following	O
components	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
2-	O
[	O
4-	O
[	O
2-	O
(	O
benzimidazol-2-ylthio	O
)	O
ethyl	O
]	O
piperazin-1-yl	O
]	O
-N-	O
[	O
2,4	O
-bis	O
(	O
methylthio	O
)	O
-6-methyl-3-pyridyl	O
]	O
acetamide	O
(	O
compound	O
a	O
)	O
or	O
an	O
acid	O
addition	O
salt	O
thereof	O
,	O
and	O
(	O
B	O
)	O
organic	O
acid	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tartaric	O
acid	O
,	O
malic	O
acid	O
,	O
ascorbic	O
acid	O
and	O
benzoic	O
acid	O
.	O

An	O
improvement	O
is	O
achieved	O
in	O
the	O
dissolubility	O
of	O
the	O
compound	O
a	O
,	O
which	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
hypercholesterolemia	O
,	O
arteriosclerosis	O
,	O
and	O
the	O
like	O
.	O

Inhibitors	O
of	O
long	O
and	O
very	O
long	O
chain	O
fatty	O
acid	O
metabolism	O
as	O
broad	O
spectrum	O
anti	O
-	O
virals	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compounds	O
for	O
treating	O
viral	O
infections	O
using	O
modulators	O
of	O
host	O
cell	O
enzymes	O
relating	O
to	O
long	O
chain	O
fatty	O
acid	O
and	O
lipid	O
droplet	O
metabolism	O
.	O

It	O
includes	O
a	O
method	O
of	O
treating	O
viral	O
infections	O
using	O
triacsin	O
C	O
and	O
its	O
relatives	O
,	O
analogues	O
and	O
derivatives	O
as	O
well	O
as	O
other	O
inhibitors	O
of	O
long	O
chain	O
fatty	O
acid	O
metabolism	O
and	O
lipid	O
droplet	O
metabolism	O
.	O

Inhibitors	O
of	O
glucose	O
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
birt	O
-	O
hogg	O
-	O
dubé	O
syndrome	O
A	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
glucose	O
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Birt	O
-	O
Hogg	O
-	O
Dubé	O
syndrome	O
.	O

The	O
inhibitor	O
of	O
glucose	O
metabolism	O
may	O
be	O
a	O
glycolytic	O
inhibitor	O
.	O

The	O
inhibitor	O
of	O
glucose	O
metabolism	O
may	O
be	O
an	O
inhibitor	O
of	O
pyruvate	O
metabolism	O
.	O

Suitable	O
inhibitors	O
of	O
glucose	O
metabolism	O
include	O
2-deoxy	O
-	O
D-	O
glucose	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
or	O
oxamate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
.	O

Treatment	O
of	O
excessive	O
menstrual	O
bleeding	O
associated	O
with	O
uterine	O
fibroids	O
The	O
present	O
invention	O
relates	O
generally	O
to	O
benign	O
gynecological	O
diseases	O
and	O
in	O
particular	O
to	O
a	O
method	O
for	O
reducing	O
heavy	O
menstruation	O
associated	O
with	O
said	O
gynecological	O
diseases	O
following	O
treatment	O
with	O
vascular	O
occlusion	O
methods	O
or	O
thermal	O
related	O
treatment	O
methods	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
the	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
the	O
method	O
for	O
prevention	O
or	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
using	O
the	O
same	O
The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
containing	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
,	O
including	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
a	O
mammal	O
including	O
a	O
human	O
in	O
need	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
use	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

Therapeutic	O
Agent	O
for	O
Migraine	O
Provided	O
are	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprise	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B
A2A	I
receptor	I
antagonistic	O
activity	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B
A2A	I
receptor	I
antagonistic	O
activity	O
,	O
which	O
has	O
an	O
affinity	O
for	O
the	O
adenosine	B
A2A	I
receptor	I
10	O
times	O
or	O
higher	O
than	O
that	O
for	O
the	O
adenosine	B
A1	I
receptor	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
the	O
like	O
.	O

Gaseous	O
nitric	O
oxide	O
-	O
sequestering	O
products	O
and	O
processes	O
of	O
preparing	O
same	O
A	O
process	O
of	O
preparing	O
articles	O
having	O
gaseous	O
NO	O
sequestered	O
therein	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
articles	O
prepared	O
thereby	O
.	O

Also	O
disclosed	O
are	O
articles	O
having	O
gaseous	O
NO	O
sequestered	O
therewithin	O
and	O
having	O
reduced	O
amount	O
of	O
oxygen	O
-	O
containing	O
and/or	O
nitrogen	O
-	O
containing	O
reactive	O
species	O
.	O

Also	O
disclosed	O
are	O
processes	O
of	O
preparing	O
packaged	O
articles	O
having	O
a	O
non	O
-	O
gas	O
permeable	O
package	O
that	O
comprises	O
gaseous	O
NO	O
therein	O
and	O
packaged	O
articles	O
made	O
therefrom	O
.	O

Also	O
disclosed	O
are	O
charging	O
devices	O
which	O
can	O
be	O
utilized	O
in	O
the	O
above	O
-	O
described	O
processes	O
.	O

The	O
articles	O
prepared	O
by	O
the	O
above	O
-	O
described	O
processes	O
are	O
preferably	O
medical	O
devices	O
such	O
as	O
indwelling	O
catheters	O
,	O
intubation	O
devices	O
and	O
tampons	O
.	O

Tampons	O
having	O
sequestered	O
therein	O
gaseous	O
NO	O
,	O
uses	O
thereof	O
and	O
processes	O
of	O
preparing	O
same	O
are	O
also	O
disclosed	O
.	O

Pharmaceutical	O
compound	O
for	O
treating	O
status	O
asthmaticus	O
Pharmaceutical	O
composition	O
comprises	O
enoximone	O
,	O
which	O
is	O
administered	O
intravenously	O
in	O
an	O
amount	O
of	O
not	O
>	O
300	O
mg	O
per	O
day	O
,	O
preferably	O
200	O
mg	O
per	O
day	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
kit	O
comprising	O
the	O
pharmaceutical	O
composition	O
and	O
a	O
drug	O
including	O
beta	O
-2	O
sympathomimetic	O
agent	O
,	O
catecholamines	O
,	O
aminophylline	O
,	O
corticosteroids	O
,	O
parasympatholytic	O
agent	O
,	O
magnesium	O
sulfate	O
,	O
ketamine	O
and/or	O
S	O
-	O
ketamine	O
for	O
treating	O
status	O
asthmaticus	O
.	O

ACTIVITY	O
:	O
Antiasthmatic	O
.	O

Test	O
details	O
are	O
described	O
but	O
no	O
results	O
given	O
.	O

MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

New	O
cathepsin	O
s	O
protease	O
inhibitors	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
e.g.	O
autoimmune	O
disorders	O
,	O
allergy	O
and	O
chronic	O
pain	O
conditions	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R2a	O
and	O
R2b	O
are	O
independently	O
H	O
,	O
halo	O
,	O
C1-C4alkyl	O
,	O
C1-C4haloalkyl	O
or	O
C1-C4alkoxy	O
,	O
or	O
R2a	O
and	O
R2b	O
together	O
with	O
the	O
carbon	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
C3-C6cycloalkyl	O
;	O
R3	O
is	O
a	O
C5-C10	O
alkyl	O
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
halo	O
,	O
C1-C4haloalkyl	O
,	O
C1-C4alkoxy	O
,	O
C1-C4haloalkoxy	O
;	O
or	O
R3	O
is	O
a	O
C2-C4alkyl	O
chain	O
with	O
at	O
least	O
2	O
chloro	O
or	O
3	O
fluoro	O
substituents	O
;	O
or	O
R3	O
is	O
C3-C7cycloalkylmethyl	O
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
C1-C4alkyl	O
,	O
halo	O
,	O
C1-C4haloalkyl	O
,	O
C1-C4alkoxy	O
,	O
C1-C4haloalkoxy	O
;	O
R4	O
is	O
C1-C6alkyl	O
,	O
C1-C6haloalkyl	O
,	O
C1-C6alkoxy	O
,	O
C1-C6haloalkoxy	O
,	O
C1-C6alkylamino	O
,	O
C1-	O
C6dialkylamino	O
or	O
;	O
R4	O
is	O
Het	O
or	O
Carbocyclyl	O
,	O
either	O
of	O
which	O
is	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
;	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
for	O
the	O
use	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
disorder	O
characterised	O
by	O
inappropriate	O
expression	O
or	O
activation	O
of	O
cathepsin	O
S.	O

Methods	O
of	O
treating	O
or	O
ameliorating	O
diseases	O
and	O
enhancing	O
performance	O
comprising	O
the	O
use	O
of	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O
The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
or	O
ameliorating	O
skin	O
conditions	O
,	O
diabetic	O
conditions	O
,	O
cardiovascular	O
conditions	O
,	O
cancer	O
,	O
infections	O
or	O
metal	O
poisoning	O
,	O
enhancing	O
performance	O
,	O
or	O
providing	O
nutritional	O
support	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
compositions	O
comprising	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O
(	O
MDSS	O
)	O
.	O

The	O
MDSS	O
solution	O
may	O
include	O
additional	O
components	O
and	O
can	O
be	O
provided	O
in	O
a	O
kit	O
.	O

Stable	O
solid	O
preparations	O
A	O
stable	O
solid	O
dosage	O
form	O
comprising	O
a	O
non	O
-	O
toxic	O
base	O
and	O
an	O
amorphous	O
benzimidazole	O
compound	O
having	O
a	O
proton	B
pump	I
inhibitor	O
(	O
PPI	O
)	O
activity	O
.	O

Hetero	O
ring	O
compound	O
[	O
Problem	O
]	O
A	O
novel	O
and	O
excellent	O
compound	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
preventing	O
and/or	O
treating	O
rejection	O
reactions	O
in	O
various	O
organ	O
transplantations	O
,	O
allergy	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
hematologic	O
tumor	O
,	O
and	O
based	O
on	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

The	O
present	O
inventors	O
have	O
investigated	O
a	O
compound	O
having	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
and	O
have	O
found	O
that	O
the	O
heterocyclic	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
and	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
thereby	O
completing	O
the	O
present	O
invention	O
.	O

Substituted	O
Thiazoles	O
as	O
VEGFR2	O
kinase	O
Inhibitors	O
This	O
invention	O
relates	O
to	O
substituted	O
thiazoles	O
of	O
formula	O
I	O
:	O
wherein	O
:	O
L	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-NHC	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH-	O
,	O
-NHC	O
(	O
X	O
)	O
NH-	O
,	O
-C	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH	O
-	O
alkylene-	O
and	O
-NHC	O
(	O
X	O
)	O
-alkylene-	O
,	O
where	O
X	O
is	O
oxygen	O
or	O
sulfur	O
;	O
and	O
Q	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alkyl	O
,	O
substituted	O
alkyl	O
,	O
aryl	O
,	O
substituted	O
aryl	O
,	O
heteroaryl	O
,	O
substituted	O
heteroaryl	O
,	O
cycloalkyl	O
,	O
substituted	O
cycloalkyl	O
,	O
heterocyclic	O
and	O
substituted	O
heterocyclic	O
,	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
VEGFR2	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
)	O
kinase	O
inhibitors	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
capable	O
of	O
treatment	O
by	O
a	O
VEGFR2	O
kinase	O
inhibitor	O
,	O
particularly	O
cancer	O
.	O

Compounds	O
and	O
pharmaceutical	O
compositions	O
for	O
treating	O
disorders	O
associated	O
with	O
the	O
5-ht1a	O
and	O
5-ht2a	O
receptors	O
This	O
invention	O
is	O
related	O
to	O
the	O
alkyl	O
-	O
piperazine	O
-	O
phenyl	O
4	O
(	O
3H	O
)	O
-quinazolinones	O
general	O
formula	O
(	O
I	O
)	O
compounds	O
,	O
pharmacologicaly	O
active	O
and	O
able	O
to	O
act	O
on	O
the	O
5-HT1A	O
and	O
5-HT2A	O
serotonin	O
receptors	O
in	O
a	O
manner	O
that	O
promotes	O
the	O
control	O
,	O
relief	O
or	O
cure	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

These	O
compounds	O
and	O
their	O
pharmaceutical	O
compositions	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
phobias	O
,	O
addictions	O
,	O
aggressiveness	O
,	O
impulsiveness	O
,	O
panic	O
,	O
psychotic	O
,	O
eating	O
and	O
sleep	O
disorders	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
among	O
other	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

Pyrazole	O
compounds	O
acting	O
against	O
allergic	O
,	O
immune	O
and	O
inflammatory	O
conditions	O
The	O
present	O
invention	O
relates	O
to	O
a	O
pyrazole	O
amide	O
derivative	O
,	O
pharmaceutical	O
compositions	O
containing	O
this	O
compound	O
and	O
to	O
its	O
use	O
in	O
therapy	O
.	O

Nitric	O
oxide	O
amino	O
acid	O
esters	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
Use	O
of	O
nitric	O
oxide	O
amino	O
acid	O
esters	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
,	O
such	O
as	O
peripheral	O
vascular	O
disease	O
.	O

The	O
nitric	O
oxide	O
amino	O
acid	O
esters	O
may	O
be	O
co	O
-	O
administered	O
with	O
an	O
antimicrobial	O
in	O
topical	O
or	O
transdermal	O
compositions	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
.	O

Bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalised	O
phenols	O
as	O
medicaments	O
This	O
invention	O
relates	O
to	O
bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalized	O
phenols	O
of	O
general	O
formula	O
1	O
,	O
their	O
use	O
as	O
inhibitors	O
of	O
CXCR2	B
activity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints	O
or	O
diseases	O
,	O
inflammatory	O
diseases	O
of	O
the	O
joints	O
,	O
skin	O
,	O
or	O
eyes	O
,	O
diseases	O
of	O
the	O
peripheral	O
or	O
central	O
nervous	O
system	O
or	O
cancers	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
compounds	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O
A	O
topical	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O
.	O

The	O
composition	O
comprises	O
an	O
antifungal	O
agent	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
an	O
antimicrobial	O
agent	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

The	O
anti	O
-	O
inflammatory	O
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
0.01%wt	O
of	O
the	O
composition	O
and	O
the	O
antimicrobial	O
agent	O
has	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
Formula	O
(	O
I	O
)	O
)	O
.	O

Heterocyclic	O
compounds	O
for	O
the	O
inhibition	O
of	O
pask	B
Disclosed	O
herein	O
are	O
new	O
heterocyclic	O
compounds	O
and	O
compositions	O
and	O
their	O
application	O
as	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
disease	O
.	O

Methods	O
of	O
inhibiting	O
PAS	B
Kinase	I
(	O
PASK	B
)	O
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
also	O
provided	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
diabetes	O
mellitus	O
.	O

COMPOUNDS	O
FOR	O
THE	O
REDUCTION	O
OF	O
ß	B
-	I
AMYLOID	I
PRODUCTION	O
The	O
present	O
disclosure	O
provides	O
a	O
series	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
which	O
modulate	O
&	O
bgr	O
;-	O
amyloid	B
peptide	O
(	O
&	O
bgr	O
;-	O
AP	B
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
&	O
bgr	O
;-	O
amyloid	B
peptide	O
(	O
&	O
bgr	O
;-	O
AP	B
)	O
production	O
.	O

Lin28-mediated	B
control	O
of	O
let-7	B
biogenesis	O
The	O
present	O
embodiments	O
provide	O
for	O
compositions	O
and	O
methods	O
that	O
regulate	O
microRNA	O
-	O
binding	O
protein	O
-	O
mediated	O
miRNA	O
biogenesis	O
;	O
for	O
example	O
Lin28-mediated	B
biogenesis	O
of	O
let-7	B
;	O
and	O
in	O
particular	O
Lin28A	B
-	O
recruited	O
3	B
'	I
terminal	I
uridylyl	I
transferase	I
(	O
TUTase	B
)	O
uridylation	O
of	O
pre	O
-	O
let-7	B
.	O

A	O
particular	O
embodiment	O
provides	O
compositions	O
and	O
methods	O
for	O
screening	O
for	O
agents	O
that	O
inhibit	O
TUTase	B
-	O
dependent	O
Lin28A	B
-	O
mediated	O
repression	O
of	O
let-7	B
miRNA	O
.	O

Pyridopyrazine	O
derivatives	O
and	O
their	O
use	O
The	O
present	O
invention	O
provides	O
new	O
pyridopyrazine	O
compounds	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
physiological	O
and/or	O
pathophysiological	O
states	O
mediated	O
and/or	O
modulated	O
by	O
signal	O
transduction	O
pathways	O
and/or	O
enzymes	O
in	O
mammals	O
and	O
in	O
particular	O
in	O
humans	O
.	O

Pyrrolo	O
sulfonamide	O
compounds	O
for	O
modulation	O
of	O
orphan	B
nuclear	I
receptor	I
rar	I
-	I
related	I
orphan	I
receptor	I
-	I
gamma	I
(	O
rorgamma	B
,	O
nr1f3	B
)	O
activity	O
and	O
for	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
and	O
autoimmune	O
diseases	O
The	O
invention	O
provides	O
modulators	O
for	O
the	O
orphan	O
nuclear	O
receptor	O
RORy	B
and	O
methods	O
for	O
treating	O
RORy	B
mediated	O
diseases	O
by	O
administrating	O
these	O
novel	O
RORy	B
modulators	O
to	O
a	O
human	O
or	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
provides	O
pyrrolo	O
sulfonamide	O
compounds	O
of	O
Formula	O
(	O
1	O
)	O
and	O
the	O
enantiomers	O
,	O
diastereomers	O
,	O
tautomers	O
,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

Methods	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancers	O
The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
curcuminoid	O
and	O
a	O
taxane	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

5-	O
or	O
6	O
-	O
substituted	O
3	O
-	O
hydroxy	O
-	O
2	O
(	O
1h	O
)	O
-	O
pyridinones	O
as	O
d	B
-	I
amino	I
acid	I
oxidase	I
(	O
daao	B
)	O
inhibitors	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorder	O
and	O
pain	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
R1	O
is	O
hydrogen	O
or	O
fluorine	O
,	O
one	O
of	O
A	O
and	O
B	O
is	O
R2	O
,	O
the	O
other	O
is	O
a	O
group	O
-X	O
-	O
Y	O
-	O
R3	O
.	O

R3	O
represents	O
a	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
.	O

Further	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
claimed	O
are-	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorders	O
and	O
pain	O
by	O
modulating	O
the	O
D	B
-	I
amino	I
acid	I
oxidase	I
enzyme	O
(	O
DAAO	B
)	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
menthane	O
carboxylic	O
acid	O
amide	O
Suggested	O
is	O
a	O
pharmaceutical	O
composition	O
,	O
comprising	O
menthane	O
carboxylic	O
acid	O
-	O
N-	O
(	O
4-methoxy	O
-	O
phenyl	O
)	O
-amide	O
.	O

Anti	O
-	O
obesity	O
agent	O
comprising	O
high	O
-	O
purity	O
epa	O
The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
the	O
increase	O
in	O
a	O
body	O
weight	O
(	O
or	O
for	O
decreasing	O
a	O
body	O
weight	O
)	O
or	O
an	O
anti	O
-	O
obesity	O
agent	O
each	O
comprising	O
at	O
least	O
one	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
EPA	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	O
and	O
derivatives	O
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
obesity	O
in	O
which	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
mild	O
,	O
preferably	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
not	O
observed	O
.	O

Liposome	O
comprising	O
at	O
least	O
a	O
cholesterol	O
derivative	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
galenic	O
form	O
of	O
cholesterol	O
derivative	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
comprising	O
at	O
least	O
one	O
cholesterol	O
derivative	O
and	O
to	O
compositions	O
comprising	O
said	O
liposomes	O
.	O

Cancer	O
stem	O
cell	O
isolation	O
An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
cancer	O
stem	O
cell	O
isolated	O
using	O
a	O
cell	O
marker	O
;	O
a	O
substantively	O
homogeneous	O
cancer	O
stem	O
cell	O
population	O
including	O
said	O
cancer	O
stem	O
cell	O
;	O
and	O
a	O
method	O
of	O
preparing	O
said	O
cancer	O
stem	O
cell	O
population	O
.	O

Another	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
for	O
separating	O
cancer	O
stem	O
cells	O
with	O
a	O
high	O
proliferative	O
potential	O
and	O
those	O
with	O
a	O
low	O
proliferative	O
potential	O
;	O
a	O
method	O
for	O
inducing	O
cancer	O
stem	O
cells	O
to	O
have	O
a	O
different	O
proliferative	O
potential	O
;	O
and	O
cancer	O
stem	O
cells	O
separated	O
or	O
induced	O
by	O
these	O
separation	O
or	O
induction	O
methods	O
.	O

A	O
further	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
of	O
screening	O
for	O
pharmaceuticals	O
using	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
;	O
a	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
and	O
for	O
identifying	O
or	O
quantifying	O
the	O
same	O
.	O

The	O
present	O
inventors	O
discovered	O
that	O
highly	O
pure	O
colon	O
cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
can	O
be	O
obtained	O
in	O
a	O
large	O
quantity	O
,	O
and	O
identified	O
two	O
types	O
of	O
states	O
of	O
colon	O
CSCs	O
distinguishable	O
through	O
Lgr5	B
expression	O
.	O

Compounds	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O
The	O
present	O
invention	O
relates	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O
,	O
wherein	O
the	O
compound	O
is	O
a	O
pyrimidine	O
being	O
at	O
least	O
substituted	O
in	O
two	O
positions	O
,	O
preferably	O
in	O
2	O
and	O
4	O
position	O
or	O
in	O
4	O
and	O
6	O
position	O
,	O
more	O
preferably	O
in	O
2	O
and	O
4	O
position	O
.	O

Method	O
for	O
inhibition	O
of	O
deubiquitinating	O
activity	O
A	O
compound	O
of	O
the	O
general	O
structure	O
(	O
I	O
)	O
is	O
capable	O
of	O
abrogating	O
the	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
of	O
the	O
19S	B
RP	I
DUBs	I
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
cancer	O
,	O
in	O
particular	O
of	O
cancer	O
refractory	O
to	O
treatment	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
chemotherapy	O
.	O

Also	O
disclosed	O
are	O
corresponding	O
methods	O
of	O
treatment	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
.	O

Mannosylated	O
compounds	O
useful	O
for	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
infectious	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
new	O
anti	O
-	O
infectious	O
compounds	O
consisting	O
of	O
(	O
i	O
)	O
a	O
polar	O
head	O
having	O
from	O
one	O
to	O
three	O
mannose	O
,	O
dimannose	O
or	O
trimannose	O
moieties	O
,	O
which	O
is	O
coupled	O
through	O
an	O
appropriate	O
linker	O
to	O
(	O
ii	O
)	O
a	O
single	O
lipid	O
chain	O
of	O
at	O
least	O
17	O
carbon	O
atoms	O
of	O
length	O
.	O

Pharmaceutical	O
compositions	O
and	O
therapeutic	O
uses	O
thereof	O
are	O
also	O
provided	O
.	O

Inducer	O
of	O
apoptosis	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
E2	O
polypeptide	O
to	O
induce	O
apoptosis	O
(	O
a	O
form	O
of	O
programmed	O
cell	O
death	O
)	O
in	O
cells	O
.	O

The	O
mutant	O
E2	O
derived	O
polypeptide	O
is	O
p53	B
binding	O
deficient	O
.	O

Preferably	O
it	O
is	O
unable	O
to	O
bind	O
p53	B
;	O
or	O
able	O
to	O
bind	O
p53	B
but	O
unable	O
to	O
induce	O
p53-dependent	B
apoptosis	O
.	O

Anticancer	O
agents	O
;	O
controlling	O
apoptosis	O
Use	O
of	O
endothelin	O
receptor	O
antagonists	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
tumour	O
diseases	O
.	O

Substituted	O
isoxazoles	O
and	O
their	O
use	O
as	O
antibiotics	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
O	O
,	O
S	O
,	O
NH	O
,	O
OCO	O
,	O
NH	O
—	O
CO	O
,	O
NH	O
—	O
COO	O
,	O
NH	O
—	O
CO	O
—	O
NH	O
,	O
NH	O
—	O
CS	O
or	O
NH	O
—	O
CS	O
—	O
NH	O
;	O
R4	O
is	O
H	O
,	O
(	O
C1-C3	O
)	O
-alkyl	O
optionally	O
substituted	O
by	O
halogen	O
,	O
or	O
a	O
C	O
-	O
linked	O
heterocyclic	O
radical	O
selected	O
from	O
several	O
possibilities	O
;	O
R1	O
and	O
R3	O
are	O
H	O
or	O
F	O
;	O
and	O
R2	O
is	O
an	O
N	O
-	O
linked	O
or	O
C	O
-	O
linked	O
heterocyclic	O
radical	O
,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
microbial	O
infections	O
in	O
human	O
or	O
animal	O
body	O
.	O

Such	O
as	O
4-cyclopentylamino	O
-	O
benzenesulfonic	O
acid	O
2-	O
(	O
3,4-dimethoxy	O
-	O
phenylamino	O
)	O
-1H	O
-	O
benzoimidazol-5-yl	O
ester	O
;	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
that	O
are	O
aimed	O
to	O
be	O
more	O
active	O
than	O
flavopiridol	O
The	O
present	O
invention	O
discloses	O
and	O
claims	O
benzimidazole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
A	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
R1	O
is	O
sleceted	O
from	O
optionally	O
substituted	O
alkyl	O
,	O
alkoxy	O
,	O
aryl	O
or	O
heteroaryl	O
,	O
NH	O
-	O
lower	O
alkyl	O
or	O
NH	O
-	O
cycloalkyl	O
,	O
or	O
halogen	O
,	O
NH2	O
;	O
1-imidazolyl	O
or	O
SO2Me	O
;	O
R2	O
is	O
selected	O
from	O
optionally	O
substituted	O
—CO	O
-	O
alkyl	O
,	O
—CO	O
-	O
cycloalkyl	O
,	O
—CO	O
-	O
aralkyl	O
,	O
—CO	O
-	O
aryl	O
,	O
—CO	O
-	O
alkoxy	O
,	O
aryl	O
or	O
aralkyl	O
,	O
or	O
—O	O
-	O
amino	O
,	O
CO	O
—	O
NHR3	O
or	O
CO	O
—	O
R3R4	O
wherein	O
R3	O
and	O
R4	O
are	O
selecteded	O
independently	O
from	O
hydrogen	O
,	O
alkyl	O
,	O
hydroxyalkyl	O
,	O
alkoxyalkyl	O
,	O
fluoroalkyl	O
,	O
alkynyl	O
,	O
heteroalkyl	O
,	O
alkylheteroalkyl	O
,	O
aryl	O
,	O
aralkyl	O
or	O
together	O
form	O
an	O
alkylene	O
chain	O
optionally	O
containing	O
one	O
to	O
4	O
heteroatoms	O
;	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
prodrug	O
thereof	O
;	O
the	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
adjuvants	O
or	O
diluents	O
.	O

Acat	O
inhibitors	O
;	O
cardiovascular	O
disorders	O
;	O
restenosis	O
;	O
Alzheimer	O
's	O
disease	O
Compounds	O
represented	O
by	O
the	O
general	O
formula	O
.	O

[	O
I	O
]	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
hydrogen	O
,	O
halogen	O
,	O
an	O
optionally	O
substituted	O
linear	O
hydrocarbon	O
group	O
,	O
or	O
hydroxyl	O
which	O
may	O
be	O
substituted	O
with	O
an	O
optionally	O
substituted	O
liner	O
hydrocarbon	O
group	O
,	O
or	O
R1	O
and	O
R2	O
together	O
with	O
the	O
carbon	O
atoms	O
adjacent	O
thereto	O
may	O
form	O
an	O
optionally	O
substituted	O
cyclic	O
hydrocarbon	O
or	O
a	O
dihydrofuran	O
ring	O
which	O
may	O
have	O
an	O
oxo	O
group	O
;	O
ring	O
A	O
is	O
a	O
benzene	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
an	O
aromatic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
whose	O
main	O
chain	O
has	O
1	O
to	O
6	O
atoms	O
;	O
Y	O
is	O
carboxyl	O
which	O
may	O
be	O
esterified	O
,	O
carbamoyl	O
which	O
may	O
be	O
substituted	O
,	O
cyano	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
bearing	O
a	O
hydrogen	O
atom	O
capable	O
of	O
being	O
deprotonated	O
,	O
or	O
salts	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
lipid	O
-	O
rich	O
plaque	O
regressing	O
agents	O
and/or	O
ACAT	B
inhibitors	O
.	O

administering	O
to	O
humans	O
synergystic	O
mixtures	O
of	O
aromatase	B
inhibitors	O
and	O
epidermal	B
growth	I
factor	I
receptor	I
antagonists	O
as	O
antitumor	O
agents	O
A	O
method	O
of	O
treating	O
a	O
human	O
being	O
suffering	O
from	O
a	O
hormone	O
-	O
dependent	O
disorder	O
characterized	O
by	O
the	O
overexpression	O
of	O
EGFR	B
,	O
comprising	O
administering	O
to	O
said	O
human	O
being	O
an	O
aromatase	O
inhibitor	O
and	O
an	O
EGFR	B
antagonist	O
or	O
EGFR	B
inhibitor	O
,	O
in	O
amounts	O
effective	O
to	O
produce	O
a	O
superadditive	O
or	O
synergistic	O
therapeutic	O
effect	O
.	O

Such	O
as	O
[	O
3-	O
(	O
2-Bromo	O
-	O
ethoxy	O
)	O
-phenyl	O
]	O
-	O
[	O
4-	O
(	O
3-cyclohexyl-5-methyl	O
-	O
isoxazol-4-yl	O
)	O
-pyrimidin-2-yl	O
]	O
-amine	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
wherein	O
A	O
-	O
B	O
is	O
N	O
—	O
O	O
or	O
O	O
—	O
N	O
and	O
G	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinase	B
,	O
particularly	O
inhibitors	O
of	O
Src	B
and	O
Lck	B
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Treatment	O
of	O
neovascular	O
opthalmic	O
disease	O
Inhibitors	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
are	O
used	O
in	O
the	O
treatment	O
of	O
various	O
eye	O
diseases	O
with	O
underlining	O
pathology	O
of	O
neovascularization	O
of	O
cornea	O
,	O
iris	O
,	O
retina	O
or	O
choroid	O
.	O

Condom	O
A	O
condom	O
has	O
a	O
vasodilator	O
active	O
compound	O
applied	O
to	O
its	O
external	O
surface	O
,	O
preferably	O
disposed	O
towards	O
the	O
open	O
end	O
of	O
the	O
condom	O
whereby	O
,	O
in	O
use	O
during	O
intercourse	O
,	O
the	O
compound	O
makes	O
contact	O
with	O
the	O
vaginal	O
meatus	O
or	O
proximal	O
region	O
of	O
the	O
vagina	O
,	O
such	O
that	O
the	O
vasodilator	O
is	O
absorbed	O
though	O
the	O
lining	O
of	O
the	O
vagina	O
to	O
stimulate	O
and	O
increase	O
the	O
flow	O
of	O
blood	O
in	O
the	O
labia	O
and	O
through	O
the	O
clitoris	O
to	O
promote	O
engorgement	O
thereof	O
to	O
alleviate	O
symptoms	O
associated	O
with	O
female	O
inorgasmia	O

Combination	O
of	O
an	O
adenosine	B
A2A	I
-	I
receptor	I
agonist	O
and	O
tiotropium	O
or	O
a	O
derivative	O
thereof	O
for	O
treating	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
A	O
combination	O
of	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
(	O
i	O
)	O
an	O
adenosine	B
A2A	I
receptor	I
agonist	O
;	O
and	O
(	O
ii	O
)	O
an	O
anti	O
-	O
cholinergic	O
agent	O
,	O
preferably	O
comprising	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tiotropium	O
and	O
derivatives	O
thereof	O
;	O
the	O
combination	O
being	O
therapeutically	O
effective	O
in	O
the	O
treatment	O
of	O
the	O
diseases	O
when	O
administered	O
by	O
inhalation	O
;	O
as	O
well	O
as	O
to	O
a	O
method	O
of	O
treating	O
the	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
administering	O
separately	O
,	O
simultaneously	O
or	O
sequentially	O
to	O
the	O
mammal	O
by	O
inhalation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
together	O
with	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
product	O
containing	O
the	O
compounds	O
of	O
the	O
combination	O
for	O
separate	O
,	O
simultaneous	O
or	O
sequential	O
administration	O
by	O
inhalation	O
to	O
a	O
mammal	O
for	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
.	O

It	O
is	O
preferred	O
that	O
the	O
anti	O
-	O
cholinergic	O
agent	O
component	O
be	O
tiotropium	O
bromide	O
.	O

3-	O
(	O
Morpholin-4-ylsulfonyl	O
)	O
-5-	O
(	O
1,3-thiazol-2-yl	O
)	O
-1H	O
-	O
indole-2-carboxamide	O
;	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	B
and	I
non	I
-	I
receptor	I
tyrosine	I
kinases	I
;	O
anticarcinogenic	O
,	O
-diabetic	O
,	O
-arhtritic	O
,	O
-inflammatory	O
agents	O
;	O
psoriasis	O
;	O
angiogenesisinhibitors	O
;	O
liver	O
cirrhosis	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
capable	O
of	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	B
-	I
type	I
and	I
non	I
-	I
receptor	I
type	I
tyrosine	I
kinases	I
.	O

The	O
compounds	O
of	O
the	O
instant	O
invention	O
possess	O
a	O
core	O
structure	O
that	O
comprises	O
a	O
sulfonyl	O
indole	O
moiety	O
.	O

The	O
present	O
invention	O
is	O
also	O
related	O
to	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
and	O
stereoisomers	O
of	O
these	O
compounds	O
.	O

Sprayable	O
compositions	O
comprising	O
a	O
combination	O
of	O
pharmaceutical	O
actives	O
and	O
an	O
oily	O
phase	O
Sprayable	O
,	O
anhydrous	O
and	O
physically	O
/	O
chemically	O
stable	O
dermatological	O
/	O
pharmaceutical	O
compositions	O
,	O
well	O
suited	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
dermatological	O
disorders	O
,	O
notably	O
psoriasis	O
,	O
contain	O
:	O
a	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
corticoid	O
,	O
notably	O
dissolved	O
clobetasol	O
propionate	O
;	O
b	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
vitamin	O
D	O
derivative	O
,	O
notably	O
dissolved	O
calcitriol	O
;	O
and	O
c	O
)	O
an	O
oily	O
phase	O
which	O
comprises	O
one	O
or	O
more	O
oils	O
;	O
formulated	O
into	O
d	O
)	O
,	O
a	O
sprayable	O
and	O
topically	O
applicable	O
,	O
dermatologically	O
/	O
pharmaceutically	O
acceptable	O
vehicle	O
therefor	O
.	O

Marker	O
genes	O
Methods	O
are	O
disclosed	O
for	O
fast	O
and	O
accurate	O
readout	O
of	O
kidney	O
toxicity	O
before	O
it	O
occurs	O
and	O
before	O
it	O
is	O
demonstrated	O
by	O
histopathology	O
examination	O
.	O

Ultimately	O
,	O
this	O
approach	O
shall	O
allow	O
earlier	O
compound	O
selection	O
.	O

The	O
twelve	O
genes	O
identified	O
,	O
namely	O
Calbindin	B
-	I
D28k	I
,	O
KIM-1	B
,	O
OPN	B
,	O
EGF	B
,	O
Clusterin	B
,	O
VEGF	B
,	O
OAT	B
-	I
K1	I
,	O
Aldolase	B
A	I
,	O
Aldolase	B
B	I
,	O
Podocin	B
,	O
Alpha-2u	B
and	I
C4	I
,	O
were	O
grouped	O
and	O
ultimately	O
can	O
be	O
assessed	O
in	O
the	O
form	O
of	O
a	O
kit	O
using	O
PCR	O
,	O
a	O
high	O
throughput	O
technology	O
,	O
in	O
order	O
to	O
characterize	O
and	O
rank	O
new	O
compounds	O
according	O
to	O
their	O
anticipated	O
general	O
kidney	O
toxicity	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
identifying	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
kidney	O
disease	O
,	O
methods	O
for	O
monitoring	O
the	O
efficacy	O
of	O
a	O
treatment	O
for	O
kidney	O
disease	O
and	O
kidney	O
-	O
specific	O
vectors	O
including	O
the	O
sequences	O
of	O
the	O
disclosed	O
genes	O
,	O
and	O
a	O
method	O
for	O
identifying	O
a	O
candidate	O
gene	O
associated	O
with	O
a	O
biological	O
process	O
including	O
kidney	O
function	O
.	O

Composition	O
having	O
antioxidant	O
properties	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
having	O
antioxidant	O
properties	O
comprising	O
at	O
least	O
one	O
compound	O
of	O
the	O
formula	O
I	O
or	O
a	O
cosmetically	O
,	O
dermatologically	O
or	O
pharmacologically	O
tolerated	O
salt	O
or	O
derivative	O
thereof	O
where	O
R1	O
to	O
R4	O
can	O
be	O
identical	O
or	O
different	O
and	O
are	O
selected	O
from	O
H	O
C6	O
-	O
28-alkylcarboxylic	O
acid	O
radicals	O
C6	O
-	O
28-alkenylcarboxylic	O
acid	O
radicals	O
radicals	O
of	O
the	O
formula	O
II	O
where	O
R5-R8	O
,	O
independently	O
of	O
one	O
another	O
,	O
are	O
H	O
,	O
hydroxyl	O
or	O
C1	O
-	O
6-alkoxy	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
the	O
radicals	O
R1	O
to	O
R4	O
is	O
a	O
radical	O
of	O
the	O
formula	O
II	O
.	O

Composition	O
for	O
use	O
in	O
prophylaxis	O
and	O
or	O
treatment	O
The	O
present	O
invention	O
relates	O
generally	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
pain	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
is	O
particularly	O
useful	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
such	O
as	O
,	O
for	O
example	O
,	O
fibromylagia	O
,	O
myofascial	O
pain	O
,	O
repetitive	O
strain	O
injury	O
or	O
overuse	O
syndromes	O
,	O
and	O
cytokine	O
-	O
mediated	O
cancer	O
and	O
chemotherapy	O
associated	O
pain	O
.	O

Sensitization	O
of	O
cells	O
to	O
cytotoxic	O
agents	O
using	O
oligonucleotides	O
directed	O
to	O
nucleotide	O
excision	O
repair	O
or	O
transcritpion	O
coupled	O
repair	O
genes	O
This	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
molecular	O
biology	O
and	O
oncology	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
the	O
sensitization	O
of	O
cancerous	O
cells	O
to	O
therapeutic	O
agents	O
.	O

The	O
invention	O
provides	O
methods	O
,	O
compositions	O
,	O
and	O
formulations	O
for	O
potentiating	O
or	O
enhancing	O
the	O
toxicity	O
of	O
various	O
cytotoxins	O
and	O
oxidizing	O
agents	O
,	O
and	O
of	O
reducing	O
the	O
resistance	O
and	O
proliferation	O
rate	O
of	O
cancer	O
cells	O
.	O

It	O
also	O
provides	O
various	O
compositions	O
and	O
therapeutic	O
formulations	O
useful	O
as	O
anticancer	O
agents	O
.	O

5-HT4	O
receptor	O
antagonists	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
X	O
—	O
CO	O
—	O
CH2-Z	O
wherein	O
X	O
is	O
a	O
monocyclic	O
or	O
polycyclic	O
aromatic	O
group	O
,	O
Z	O
is	O
of	O
sub	O
-	O
formula	O
(	O
h	O
)	O
,	O
(	O
j	O
)	O
or	O
(	O
k	O
)	O
:	O
wherein	O
n1	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n2	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n3is	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
;	O
q	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
R5	O
is	O
hydrogen	O
,	O
C1	O
-	O
2	O
alkyl	O
,	O
aralkyl	O
or	O
R5	O
is	O
(	O
CH2	O
)	O
z	O
-	O
R10	O
wherein	O
z	O
is	O
2	O
or	O
3	O
and	O
R10	O
is	O
selected	O
from	O
cyano	O
,	O
hydroxyl	O
,	O
C1	O
-	O
6	O
alkoxy	O
,	O
phenoxy	O
,	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
COC6H5	O
,	O
—CONR11R12	O
,	O
NR11COR12	O
,	O
SO2NR11R12	O
or	O
NR11SO2R12	O
wherein	O
R11	O
and	O
R12	O
are	O
hydrogen	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
or	O
R5	O
is	O
straight	O
or	O
branched	O
chain	O
alkylene	O
of	O
chain	O
length	O
1	O
-	O
6	O
carbon	O
atoms	O
terminally	O
substituted	O
by	O
aryl	O
,	O
3	O
to	O
8	O
membered	O
cycloalkyl	O
,	O
3	O
to	O
8	O
membered	O
heterocyclyl	O
,	O
5	O
or	O
6	O
membered	O
monocyclic	O
heteroaryl	O
or	O
9	O
or	O
10	O
membered	O
fused	O
bicyclic	O
heteroaryl	O
linked	O
through	O
carbon	O
,	O
C2	O
-	O
7	O
alkoxycarbonyl	O
,	O
or	O
secondary	O
or	O
tertiary	O
hydroxy	O
substituted	O
C1	O
-	O
6	O
alkyl	O
;	O
;	O
and	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
hydrogen	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
and	O
R9	O
is	O
hydrogen	O
or	O
C1	O
-	O
10alkyl	O
;	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
,	O
cardiovascular	O
disorders	O
and	O
CNS	O
disorders	O
.	O

Method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
A	O
method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
for	O
performing	O
a	O
deposition	O
treatment	O
for	O
causing	O
a	O
treating	O
aqueous	O
solution	O
containing	O
fluorine	O
and	O
iron	O
to	O
contact	O
nucleus	O
particles	O
,	O
to	O
deposit	O
iron	O
hydroxide	O
and	O
form	O
layers	O
around	O
the	O
nucleus	O
particles	O
,	O
and	O
an	O
after	O
-	O
treatment	O
for	O
heating	O
the	O
iron	O
hydroxide	O
layers	O
to	O
change	O
them	O
into	O
ferromagnetic	O
layers	O
,	O
thereby	O
producing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
with	O
outside	O
of	O
the	O
nucleus	O
particles	O
covered	O
by	O
the	O
ferromagnetic	O
layers	O
,	O
wherein	O
,	O
in	O
time	O
of	O
the	O
deposition	O
treatment	O
,	O
a	O
reaction	O
initiator	O
that	O
reacts	O
with	O
hydrogen	O
fluoride	O
is	O
added	O
to	O
said	O
treating	O
aqueous	O
solution	O
.	O

Aryl	O
boronate	O
functionalized	O
polymers	O
for	O
treating	O
obesity	O
Disclosed	O
are	O
polymers	O
comprising	O
one	O
or	O
more	O
phenyl	O
boronate	O
ester	O
,	O
boronamide	O
or	O
boronate	O
thioester	O
groups	O
.	O

The	O
phenyl	O
boronate	O
ester	O
,	O
boronamide	O
and	O
boronate	O
thioester	O
groups	O
are	O
represented	O
by	O
one	O
of	O
the	O
following	O
structural	O
formulas	O
:	O
Ar	O
in	O
Structural	O
Formulas	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
is	O
substituted	O
or	O
unsubstituted	O
;	O
and	O
each	O
Z	O
is	O
—O—	O
,	O
—NH—	O
or	O
—S—	O
and	O
is	O
independently	O
selected	O
.	O

Pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
polymer	O
are	O
also	O
included	O
.	O

The	O
aryl	O
boronate	O
ester	O
,	O
boronamide	O
or	O
boronate	O
thioester	O
can	O
be	O
cleaved	O
to	O
release	O
the	O
corresponding	O
aryl	O
boronic	O
acid	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
diluent	O
;	O
and	O
methods	O
of	O
treating	O
a	O
subject	O
for	O
obesity	O
with	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
.	O

2-Aminobicyclo	O
[	O
3.1.0	O
]	O
hexane-2,6-dicarboxylic	O
acid	O
derivative	O
One	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
drug	O
that	O
is	O
effective	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
psychiatric	O
disorders	O
and	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
neurological	O
diseases	O
,	O
inhibiting	O
a	O
Group	O
II	O
metabotropic	O
glutamate	O
receptor	O
.	O

The	O
object	O
is	O
solved	O
by	O
a	O
2-amino	O
-	O
bicyclo	O
[	O
3.1.0	O
]	O
hexane-2,6-dicarboxylic	O
acid	O
derivative	O
represented	O
by	O
formula	O
[	O
I	O
]	O
:	O
(	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
and	O
each	O
represents	O
a	O
hydrogen	O
atom	O
,	O
C1	O
-	O
10alkyl	O
group	O
,	O
etc	O
;	O
X	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
fluorine	O
atom	O
;	O
and	O
Y	O
represents	O
an	O
amino	O
group	O
,	O
—SR3	O
,	O
—S	O
(	O
O	O
)	O
nR7	O
,	O
—SCHR3R4	O
,	O
—S	O
(	O
O	O
)	O
nCHR3R4	O
,	O
—NHCHR3R4	O
,	O
—N	O
(	O
CHR3R4	O
)	O
(	O
CHR5R6	O
)	O
,	O
—NHCOR3	O
or	O
—OCOR7	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
hydrate	O
thereof	O
and	O
so	O
on	O
.	O

Diphosphonate	O
solutions	O
A	O
pharmaceutical	O
product	O
containing	O
pamidronate	O
and	O
other	O
diphosphonate	O
solutions	O
in	O
an	O
appropriate	O
container	O
,	O
a	O
pH	O
of	O
between	O
5	O
and	O
8	O
and	O
without	O
organic	O
acid	O
buffer	O
or	O
polyethylen	O
glycol	O
.	O

The	O
container	O
may	O
be	O
treated	O
glass	O
or	O
made	O
of	O
other	O
appropriate	O
material	O
.	O

Coated	O
elastomeric	O
stoppers	O
are	O
also	O
included	O
.	O

A	O
method	O
of	O
producing	O
a	O
pharmaceutical	O
product	O
comprising	O
steps	O
of	O
making	O
a	O
suspension	O
of	O
pamadronic	O
acid	O
,	O
adding	O
sodium	O
hydroxide	O
,	O
to	O
form	O
a	O
solution	O
adjusting	O
the	O
pH	O
to	O
between	O
5	O
and	O
8	O
and	O
transferring	O
the	O
solution	O
to	O
a	O
container	O
.	O

Method	O
of	O
controlling	O
damage	O
mediated	O
by	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
aldehydes	O
This	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
the	O
reaction	O
of	O
an	O
α	O
,	O
β	O
-	O
unsaturated	O
aldehyde	O
with	O
a	O
biological	O
molecule	O
,	O
the	O
method	O
including	O
the	O
step	O
of	O
administering	O
hydralazine	O
and/or	O
dihydralazine	O
in	O
an	O
amount	O
that	O
is	O
effective	O
to	O
reduce	O
the	O
rate	O
of	O
reaction	O
of	O
the	O
α	O
,	O
β	O
-	O
unsaturated	O
aldehyde	O
with	O
the	O
biological	O
molecule	O
.	O

Phthalazine	O
derivatives	O
as	O
phosphodiesterase	B
4	I
inhibitors	O
Compounds	O
of	O
formula	O
I	O
wherein	O
R	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
PDE	B
4	I
inhibitors	O
.	O

Peptides	O
and	O
nucleic	O
acids	O
of	O
the	O
cathelicidin	O
family	O
,	O
derived	O
from	O
fish	O
,	O
and	O
uses	O
thereof	O
The	O
invention	O
relates	O
to	O
anti	O
-	O
microbial	O
and	O
immunostimulatory	O
molecules	O
of	O
the	O
cathelicidin	O
family	O
derived	O
from	O
fish	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
cathelicidin	O
molecule	O
,	O
fragments	O
,	O
derivatives	O
and	O
uses	O
thereof	O
,	O
and	O
nucleic	O
acids	O
encoding	O
the	O
same	O
.	O

Having	O
antiinflammatory	O
,	O
anti	O
-	O
pyretic	O
and	O
anti	O
-	O
diarrheal	O
properties	O
According	O
to	O
the	O
invention	O
there	O
is	O
provided	O
a	O
compound	O
the	O
formula	O
I	O
;	O
wherein	O
A	O
,	O
X	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

2,3'-bipyridines	O
derivatives	O
as	O
selective	O
cox-2	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
2,3′-bipyridines	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
medical	O
uses	O
.	O

Inhibitors	O
of	O
cdc25	B
phosphatases	I
A	O
method	O
of	O
inhibiting	O
cdc25	B
phosphatases	I
in	O
warm	O
-	O
blooded	O
animals	O
comprising	O
administering	O
to	O
warm	O
-	O
blooded	O
animals	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
formula	O
wherein	O
the	O
substituents	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O

Therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
method	O
for	O
treatment	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
the	O
same	O
This	O
therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
comprises	O
,	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
of	O
a	O
7-aminoquinolinone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
alkyl	O
group	O
;	O
R2	O
and	O
R3	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	O
atom	O
,	O
an	O
acyl	O
group	O
,	O
an	O
alkyl	O
group	O
and	O
an	O
alkenyl	O
group	O
;	O
and	O
R4	O
and	O
R5	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	O
atom	O
,	O
an	O
acyl	O
group	O
,	O
an	O
alkyl	O
group	O
,	O
an	O
alkenyl	O
group	O
and	O
an	O
aralkyl	O
group	O
,	O
and	O
its	O
physiologically	O
acceptable	O
salt	O
.	O

Methods	O
of	O
using	O
benzothiophenone	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
Methods	O
of	O
using	O
benzothiophenone	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Use	O
of	O
chemokines	O
,	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
same	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
chemokines	O
and/or	O
nucleic	O
acids	O
encoding	O
a	O
chemokine	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
preparations	O
which	O
comprise	O
these	O
substances	O
and	O
which	O
are	O
preferably	O
intended	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
for	O
tissue	O
synthesis	O
.	O

Amorphous	O
antibiotic	O
composition	O
comprising	O
cefditoren	O
pivoxil	O
According	O
to	O
the	O
present	O
invention	O
,	O
there	O
is	O
provided	O
a	O
solid	O
dispersion	O
composition	O
which	O
can	O
maintain	O
amorphous	O
cefditoren	O
pivoxil	O
in	O
a	O
suspension	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
present	O
invention	O
is	O
a	O
solid	O
dispersion	O
composition	O
comprising	O
at	O
least	O
0.1	O
mg	O
of	O
a	O
sugar	O
ester	O
fatty	O
acid	O
on	O
the	O
basis	O
of	O
an	O
amount	O
equivalent	O
to	O
100	O
mg	O
efficacy	O
of	O
cefditoren	O
pivoxil	O
.	O

Methods	O
of	O
using	O
isothiazole	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
Methods	O
of	O
using	O
substituted	O
3,5-dithio-	O
,	O
disulfinyl	O
-	O
or	O
disulfonyl	O
-	O
isothiazole	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Sulfotransferase	B
inhibitor	O
The	O
hexuronic	O
acid	O
derivative	O
represented	O
by	O
the	O
following	O
formula	O
1	O
or	O
a	O
salt	O
thereof	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
heparin	O
/	O
heparan	O
sulfate	O
sulfotransferase	B
inhibitor	O
.	O

In	O
the	O
formula	O
,	O
each	O
of	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
independently	O
represent	O
(	O
s	O
)	O
SO3	O
−	O
or	O
H	O
which	O
may	O
have	O
a	O
substituent	O
,	O
provided	O
that	O
at	O
least	O
one	O
thereof	O
represents	O
SO3	O
−	O
;	O
X	O
represents	O
OR4	O
,	O
SR4	O
,	O
N	O
(	O
R4	O
)	O
2	O
,	O
or	O
C	O
(	O
R4	O
)	O
3	O
,	O
R4	O
independently	O
represents	O
H	O
,	O
alkyl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
acyl	O
,	O
aryl	O
,	O
or	O
aralkyl	O
group	O
;	O
one	O
of	O
R5	O
and	O
R6	O
represents	O
COOH	O
while	O
the	O
other	O
represents	O
H	O
;	O
and	O
the	O
wavy	O
line	O
represents	O
α	O
-	O
glycosidic	O
bond	O
or	O
β	O
-	O
glycosidic	O
bond	O
.	O

Angiogenesis	O
inhibitor	O
;	O
anticancer	O
agents	O
;	O
antiarthritic	O
agents	O
;	O
psoriasis	O
The	O
invention	O
concerns	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
ring	O
A	O
is	O
phenyl	O
or	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
as	O
defined	O
herein	O
;	O
Z	O
is	O
—O—	O
,	O
—NH—	O
or	O
—S—	O
;	O
m	O
is	O
an	O
integer	O
from	O
0	O
to	O
5	O
inclusive	O
;	O
R1	O
is	O
hydrogen	O
,	O
hydroxy	O
,	O
halogeno	O
,	O
nitro	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkylthio	O
,	O
or	O
—NR5R6	O
(	O
wherein	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
or	O
C1	O
-	O
3alkyl	O
)	O
;	O
R2	O
is	O
hydrogen	O
,	O
hydroxy	O
,	O
halogeno	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
trifluoromethyl	O
,	O
amino	O
or	O
nitro	O
;	O
R3	O
is	O
hydroxy	O
,	O
halogeno	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkanoyloxy	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
amino	O
or	O
nitro	O
;	O
provided	O
that	O
when	O
ring	O
A	O
is	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
,	O
at	O
least	O
one	O
R3	O
is	O
either	O
hydroxy	O
or	O
halogeno	O
;	O
X1	O
is	O
—O—	O
,	O
—CH2—	O
,	O
—S—	O
,	O
—SO—	O
,	O
—SO2—	O
,	O
—NR7—	O
,	O
—NR7CO—	O
,	O
—CONR7—	O
,	O
—SO2NR7—	O
or	O
—NR7SO2—	O
,	O
(	O
wherein	O
R7	O
is	O
hydrogen	O
,	O
C1	O
-	O
3alkyl	O
or	O
C1	O
-	O
3alkoxyC2	O
-	O
3alkyl	O
)	O
;	O
and	O
R4	O
is	O
selected	O
from	O
a	O
number	O
of	O
groups	O
defined	O
herein	O
comprising	O
an	O
C2	O
-	O
5alkylene	O
,	O
C3	O
-	O
5alkenylene	O
or	O
C3	O
-	O
5alkynylene	O
chain	O
wherein	O
each	O
methylene	O
group	O
(	O
other	O
than	O
that	O
of	O
the	O
α	O
-	O
carbon	O
)	O
is	O
optionally	O
substituted	O
by	O
1	O
substituent	O
independently	O
selected	O
from	O
hydroxy	O
,	O
halogeno	O
,	O
amino	O
and	O
C1	O
-	O
4alkanoyloxy	O
;	O
provisos	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
production	O
of	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
and	O
to	O
a	O
method	O
for	O
producing	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
in	O
need	O
of	O
such	O
treatment	O
.	O

The	O
compounds	O
are	O
useful	O
in	O
disease	O
states	O
such	O
as	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
psoriasis	O
.	O

Preemptive	O
Prophylaxis	O
of	O
Migraine	O
A	O
method	O
of	O
preventing	O
the	O
headache	O
phase	O
of	O
migraine	O
in	O
a	O
human	O
comprises	O
administration	O
of	O
a	O
5HT1	B
receptor	I
agonist	O
or	O
administration	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
to	O
said	O
human	O
exhibiting	O
prodrome	O
symptoms	O
of	O
migraine	O
.	O

Suitably	O
,	O
the	O
method	O
comprises	O
administration	O
of	O
a	O
migraine	O
headache	O
phase	O
-	O
preventing	O
effective	O
amount	O
of	O
the	O
5HT1	O
or	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
.	O

There	O
is	O
disclosed	O
a	O
preemptive	O
prophylaxis	O
migraine	O
method	O
using	O
the	O
following	O
cognitive	O
tests	O
:	O
Simple	O
Reaction	O
Time	O
;	O
Running	O
Memory	O
Continuous	O
Performance	O
Task	O
;	O
Matching	O
to	O
Sample	O
;	O
Mathematical	O
Processing	O
Task	O
;	O
and	O
interpreting	O
the	O
results	O
as	O
a	O
percent	O
of	O
baseline	O
indicator	O
of	O
need	O
for	O
prophylaxis	O
.	O

Active	O
substance	O
combination	O
comprising	O
a	O
carbinol	O
combined	O
to	O
at	O
least	O
an	O
NSAID	O
The	O
present	O
invention	O
relates	O
to	O
an	O
active	O
substance	O
combination	O
comprising	O
at	O
least	O
one	O
substituted	O
carbinol	O
compound	O
and	O
at	O
least	O
one	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
,	O
a	O
medicament	O
comprising	O
said	O
active	O
substance	O
combination	O
,	O
a	O
pharmaceutical	O
formulation	O
comprising	O
said	O
active	O
substance	O
combination	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
.	O

2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine	O
derivatives	O
as	O
inhibitors	O
of	O
glucosylceramide	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
a	O
substituted	O
benzyl	O
group	O
,	O
are	O
useful	O
as	O
inhibitors	O
of	O
glucosylceramide	B
synthase	I
.	O

Amino	O
nicotinate	O
derivatives	O
as	O
glucokinase	B
(	O
GLK	B
)	O
modulators	O
The	O
invention	O
is	O
related	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
n	O
and	O
m	O
are	O
as	O
described	O
in	O
the	O
specification	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
through	O
glucokinase	B
(	O
GLK	B
)	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
medicaments	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
glucokinase	B
.	O

Treating	O
inflammation	O
with	O
ondansetron	O
and	O
pharmaceutical	O
compositions	O
comprised	O
thereof	O
Inflammatory	O
skin	O
disorders	O
such	O
as	O
rosacea	O
,	O
including	O
a	O
variety	O
of	O
skin	O
diseases	O
,	O
whether	O
or	O
not	O
accompanied	O
by	O
dermatosis	O
,	O
are	O
treated	O
by	O
topically	O
applying	O
onto	O
the	O
affected	O
skin	O
area	O
,	O
a	O
thus	O
effective	O
amount	O
of	O
Ondansetron	O
,	O
or	O
salt	O
or	O
base	O
thereof	O
.	O

Combination	O
Comprising	O
Combretastatin	O
and	O
Anticancer	O
Agents	O
An	O
antitumor	O
combination	O
comprising	O
a	O
stilbene	O
derivative	O
and	O
an	O
anticancer	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
taxanes	O
,	O
alkylating	O
agents	O
,	O
antimetabolites	O
,	O
vinca	O
alkaloids	O
,	O
platinum	O
compounds	O
,	O
epidophylloptoxins	O
,	O
and	O
antibiotics	O
as	O
the	O
active	O
ingredients	O
is	O
provided	O
.	O

Methods	O
of	O
using	O
these	O
pharmaceutical	O
preparations	O
for	O
the	O
treatment	O
of	O
solid	O
carcinomas	O
and	O
the	O
like	O
are	O
also	O
provided	O
.	O

Novel	O
ureido	O
-	O
and	O
amido	O
-	O
pyrazolone	O
derivatives	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
wherein	O
each	O
of	O
R1	O
to	O
R4	O
is	O
independently	O
selected	O
from	O
hydrogen	O
,	O
a	O
halogen	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
cyclic	O
and	O
heterocyclic	O
moiety	O
,	O
substituted	O
or	O
unsubstituted	O
,	O
linear	O
or	O
branched	O
alkyl	O
,	O
alkyloxy	O
,	O
alkylcarbonyl	O
,	O
alkyloxycarbonyl	O
,	O
alkenyl	O
,	O
alkenyloxy	O
,	O
alkenylcarbonyl	O
,	O
alkenyloxycarbonyl	O
,	O
alkynyl	O
,	O
alkynyloxy	O
,	O
alkynylcarbonyl	O
,	O
alkynyloxycarbonyl	O
,	O
aryl	O
,	O
benzyl	O
,	O
arlyoxy	O
,	O
arylcarbonyl	O
,	O
aryloxycarbonyl	O
and	O
sulphur	O
equivalents	O
of	O
said	O
oxy	O
,	O
carbonyl	O
and	O
oxycarbonyl	O
moieties	O
,	O
and	O
A	O
is	O
NH	O
,	O
or	O
(	O
CH2	O
)	O
n	O
,	O
where	O
n	O
is	O
preferably	O
0	O
,	O
1	O
or	O
2	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
and	O
their	O
uses	O
as	O
CCK	B
receptor	I
ligands	O
and	O
CCK	B
antagonists	O
.	O

Therapy	O
for	O
disease	O
caused	O
by	O
nicotinic	B
receptors	I
;	O
cognition	O
activatrors	O
;	O
central	O
nervous	O
system	O
disorders	O
Compounds	O
complying	O
with	O
the	O
general	O
formula	O
in	O
which	O
R	O
either	O
represents	O
a	O
halogen	O
atom	O
or	O
a	O
phenyl	O
group	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
chosen	O
from	O
halogen	O
atoms	O
and	O
(	O
C1-C6	O
)	O
alkyl	O
,	O
(	O
C1-C6	O
)	O
alkoxy	O
,	O
nitro	O
,	O
amino	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
hydroxy	O
,	O
acetyl	O
or	O
methylenedioxy	O
groups	O
,	O
or	O
represents	O
a	O
pyridinyl	O
group	O
,	O
a	O
thienyl	O
group	O
,	O
an	O
indolyl	O
group	O
,	O
or	O
a	O
pyrimidinyl	O
group	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
(	O
C1-C6	O
)	O
alkoxy	O
groups	O
,	O
where	O
,	O
of	O
the	O
two	O
carbon	O
-	O
carbon	O
bonds	O
represented	O
by	O

Prodrugs	O
Of	O
Substituted	O
Amino	O
Heterobicycles	O

Which	O
Modulate	O
The	O
Function	O
Of	O
The	O
Vanilloid-1	B
Receptor	I
(	O
Vr1	B
)	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
useful	O
as	O
therapeutic	O
compounds	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
conditions	O
ameliorated	O
by	O
the	O
modulation	O
of	O
the	O
function	O
of	O
the	O
vanilloid-1	B
receptor	I
(	O
VR1	B
)	O
.	O

Treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
by	O
administering	O
an	O
agent	O
which	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	B
-	I
like	I
receptor	I
2	I
and	O
a	O
high	B
mobility	I
group	I
B	I
polypeptide	I
;	O
treating	O
Crohn	O
's	O
disease	O
,	O
sepsis	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
endotoxic	O
shock	O
,	O
allograft	O
rejection	O
The	O
invention	O
features	O
a	O
method	O
of	O
treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
,	O
comprising	O
administering	O
an	O
agent	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
and	O
a	O
high	B
mobility	I
group	I
B	I
(	O
HMGB	B
)	O
polypeptide	O
to	O
the	O
individual	O
.	O

The	O
invention	O
also	O
features	O
methods	O
for	O
identifying	O
agents	O
that	O
inhibit	O
the	O
interaction	O
between	O
TLR2	B
and	O
HMGB	B
.	O

Growth	B
hormone	I
receptor	I
antagonist	O
cancer	O
treatment	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
tumorigenic	O
cells	O
(	O
e.g.	O
,	O
mammary	O
progenitor	O
cancer	O
cells	O
)	O
,	O
with	O
growth	B
hormone	I
receptor	I
antagonists	O
(	O
e.g.	O
,	O
Pegvisomant	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
compositions	O
for	O
screening	O
growth	B
hormone	I
receptor	I
antagonists	O
for	O
their	O
ability	O
serve	O
as	O
anti	O
-	O
neoplastic	O
agents	O
capable	O
of	O
killing	O
tumorigenic	O
cells	O
.	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
identifying	O
tumorigenic	O
cells	O
,	O
methods	O
of	O
obtaining	O
enriched	O
populations	O
of	O
tumorigenic	O
cells	O
,	O
and	O
methods	O
of	O
causing	O
mammary	O
progenitor	O
cells	O
to	O
proliferate	O
and/or	O
differentiate	O
.	O

Chimeric	O
(	O
Double	O
)	O

Decoy	O
The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
,	O
ameliorative	O
or	O
therapeutic	O
medicament	O
for	O
vascular	O
restenosis	O
,	O
ischemic	O
disease	O
,	O
allergic	O
disease	O
,	O
inflammatory	O
disease	O
,	O
autoimmune	O
disease	O
,	O
or	O
cancer	O
metastasis	O
,	O
invasion	O
(	O
cancer	O
metastasis	O
/	O
invasion	O
)	O
or	O
cachexia	O
based	O
on	O
the	O
inhibitory	O
action	O
on	O
a	O
plural	O
of	O
transcriptional	O
regulatory	O
factor	O
.	O

A	O
chimera	O
(	O
double	O
)	O
decoy	O
of	O
the	O
present	O
invention	O
has	O
plural	O
transcriptional	O
regulatory	O
factor	O
binding	O
sequences	O
in	O
a	O
single	O
molecule	O
thereof	O
.	O

Thus	O
,	O
it	O
is	O
able	O
to	O
inhibit	O
the	O
activity	O
of	O
plural	O
transcriptional	O
regulatory	O
factors	O
with	O
a	O
single	O
molecule	O
.	O

For	O
example	O
,	O
stenosis	O
of	O
an	O
anastomosed	O
site	O
of	O
an	O
artificial	O
blood	O
vessel	O
is	O
caused	O
by	O
thickening	O
of	O
the	O
vascular	O
intima	O
,	O
and	O
this	O
is	O
mainly	O
caused	O
by	O
activation	O
of	O
cell	O
proliferation	O
by	O
an	O
inflammatory	O
reaction	O
occurring	O
at	O
the	O
anastomosed	O
site	O
.	O

Thus	O
,	O
thickening	O
of	O
vessel	O
walls	O
can	O
be	O
inhibited	O
by	O
simultaneously	O
inhibiting	O
two	O
transcriptional	O
regulatory	O
factors	O
involved	O
in	O
inflammation	O
and	O
cell	O
proliferation	O
by	O
using	O
the	O
chimera	O
decoy	O
of	O
the	O
present	O
invention	O
.	O

Triazole	O
Derivative	O
or	O
Salt	O
Thereof	O
[	O
Problem	O
]	O
There	O
is	O
provided	O
a	O
compound	O
which	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diseases	O
in	O
which	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
participates	O
,	O
in	O
particular	O
diabetes	O
,	O
insulin	B
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
has	O
been	O
found	O
that	O
a	O
triazole	O
derivative	O
wherein	O
the	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
in	O
the	O
2-position	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
a	O
strong	O
11β	B
-	I
HSD1	I
inhibitory	O
activity	O
.	O

Moreover	O
,	O
the	O
triazole	O
derivative	O
of	O
the	O
invention	O
exhibits	O
an	O
excellent	O
blood	O
-	O
glucose	O
level	O
-	O
lowering	O
action	O
and	O
hence	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diabetes	O
,	O
insulin	O
resistance	O
.	O

Amorphous	O
form	O
of	O
Olanzapine	O
The	O
present	O
invention	O
relates	O
to	O
an	O
amorphous	O
form	O
of	O
olanzapine	O
Formula	O
(	O
I	O
)	O
:	O
and	O
a	O
process	O
for	O
its	O
preparation	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
amorphous	O
form	O
of	O
olanzapine	O
(	O
I	O
)	O
.	O

The	O
pharmaceutical	O
composition	O
may	O
be	O
used	O
,	O
in	O
particular	O
,	O
for	O
the	O
treatment	O
of	O
psychiatric	O
,	O
psychological	O
or	O
psychotic	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
or	O
gastrointestinal	O
or	O
functional	O
bowel	O
disorders	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
said	O
disorders	O
.	O

Heterocycle	O
-	O
Substituted	O
Cyclic	O
Urea	O
Derivatives	O
,	O
Preparation	O
Thereof	O
And	O
Pharmaceutical	O
Use	O

Thereof	O
As	O
Kinase	B
Inhibitors	O
The	O
disclosure	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Y	O
,	O
Y1	O
,	O
Yo	O
,	O
R1	O
,	O
R2	O
,	O
R2′	O
,	O
p	O
,	O
R3	O
,	O
R3′	O
,	O
A	O
,	O
B	O
and	O
Y2	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
,	O
and	O
to	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
and	O
use	O
thereof	O
as	O
protein	B
kinase	I
inhibitors	O
.	O

Delivery	O
of	O
a	O
combination	O
therapy	O
for	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
A	O
method	O
of	O
delivery	O
of	O
a	O
combination	O
therapy	O
to	O
the	O
pulmonary	O
system	O
that	O
includes	O
providing	O
a	O
nebulizer	O
and	O
an	O
aqueous	O
solution	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	O
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

The	O
corticosteroid	O
is	O
budesonide	O
,	O
the	O
beta	O
-	O
agonist	O
is	O
formoterol	O
and	O
the	O
anticholinergic	O
is	O
tiotropium	O
.	O

A	O
pharmaceutical	O
composition	O
is	O
also	O
described	O
for	O
the	O
treatment	O
of	O
respiratory	O
conditions	O
and	O
diseases	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	O
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

Use	O
of	O
acylaminoalkenylene	O
-	O
amide	O
derivatives	O
in	O
functional	O
motility	O
disorders	O
of	O
the	O
viscera	O
The	O
use	O
of	O
a	O
compound	O
of	O
formula	O

I	O
in	O
free	O
form	O
or	O
in	O
the	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
functional	O
motility	O
disorder	O
of	O
the	O
viscera	O
.	O

New	O
Expression	O
Tools	O
for	O
Multiprotein	O
Applications	O

The	O
present	O
invention	O
relates	O
to	O
polynucleotides	O
for	O
multigene	O
applications	O
comprising	O
a	O
novel	O
functional	O
arrangement	O
,	O
as	O
well	O
as	O
vectors	O
,	O
host	O
cells	O
,	O
and	O
recombinant	O
animals	O
comprising	O
said	O
polynucleotides	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
generating	O
multigene	O
expression	O
cassettes	O
,	O
methods	O
for	O
producing	O
multiprotein	O
complexes	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
methods	O
for	O
producing	O
a	O
vaccine	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
encompasses	O
methods	O
for	O
screening	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
,	O
and	O
methods	O
for	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
screening	O
of	O
candidate	O
compounds	O
capable	O
of	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
or	O
capable	O
of	O
inhibiting	O
protein	O
complex	O
interactions	O
or	O
inhibiting	O
modifications	O
of	O
proteins	O
.	O

Also	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
polynucleotides	O
,	O
vectors	O
,	O
host	O
cells	O
or	O
recombinant	O
animals	O
of	O
the	O
invention	O
for	O
(	O
i	O
)	O
preparing	O
a	O
medicament	O
for	O
gene	O
therapy	O
,	O
for	O
(	O
ii	O
)	O
the	O
recombinant	O
production	O
of	O
multiprotein	O
complexes	O
,	O
(	O
iii	O
)	O
for	O
producing	O
a	O
vaccine	O
,	O
or	O
(	O
iv	O
)	O
for	O
screening	O
compounds	O
of	O
interest	O
.	O

Last	O
but	O
not	O
least	O
,	O
the	O
invention	O
is	O
directed	O
to	O
a	O
kit	O
of	O
parts	O
comprising	O
at	O
least	O
a	O
polynucleotide	O
,	O
a	O
vector	O
,	O
and/or	O
a	O
host	O
cell	O
according	O
to	O
the	O
invention	O
.	O

Boronated	O
Metal	O
-	O
Phthalocyanines	O
,	O
Process	O
For	O
Their	O
Preparation	O
,	O
Pharmaceutical	O
Compositions	O
Comprising	O
Them	O

And	O
Use	O
Thereof	O
The	O
present	O
invention	O
relates	O
to	O
metal	O
-	O
phthalocyanines	O
bearing	O
at	O
least	O
a	O
group	O
containing	O
boron	O
isotopes	O
11B	O
or	O
10B	O
,	O
covalently	O
bound	O
to	O
the	O
axial	O
positions	O
of	O
metal	O
-	O
phthalocyanine	O
nucleus	O
;	O
moreover	O
it	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation	O
,	O
the	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
neoplastic	O
and	O
dysplastic	O
pathologies	O
in	O
PDT	O
and/or	O
BNCT	O
.	O

Antimicrobial	O
photoinactivation	O
using	O
chalcogen	O
analogs	O
of	O
benzo	O
(	O
A	O
)	O
phenoxazinium	O
dyes	O
Compositions	O
and	O
methods	O
for	O
the	O
use	O
of	O
photoactivatable	O
antimicrobial	O
chalcogen	O
analogs	O
of	O
benzophenoxazinium	O
dyes	O
in	O
the	O
treatment	O
of	O
infections	O
are	O
provided	O
.	O

Combinations	O
of	O
Serotonin	O
Reuptake	O
Inhibitors	O
and	O
Imidazoline	O
I	O
2	O
Agonists	O
The	O
present	O
invention	O
relates	O
to	O
combinations	O
of	O
serotonin	O
reuptake	O
inhibitors	O
and	O
imidazoline	O
I2	O
agonists	O
as	O
separate	O
chemical	O
units	O
or	O
both	O
properties	O
combined	O
in	O
a	O
single	O
molecule	O
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
obsessive	O
-	O
compulsive	O
disorders	O
(	O
OCDs	O
)	O
,	O
obsessive	O
-	O
compulsive	O
spectrum	O
disorders	O
(	O
OCSDs	O
)	O
and	O
other	O
anxiety	O
states	O
.	O

Inhibition	O
Of	O
Superoxide	O
Dismutase	O
By	O
Tetrathiomolybdate	O
:	O
Identification	O
Of	O
New	O
Anti	O
-	O
Angiogenic	O
And	O
Antitumor	O
Agents	O
Though	O
copper	O
is	O
elevated	O
in	O
the	O
tumor	O
tissue	O
and	O
plasma	O
of	O
patients	O
with	O
various	O
malignancies	O
,	O
the	O
molecular	O
targets	O
for	O
copper	O
binding	O
agents	O
in	O
angiogenesis	O
and	O
tumor	O
progression	O
remain	O
poorly	O
understood	O
.	O

It	O
is	O
disclosed	O
that	O
one	O
anti	O
-	O
angiogenic	O
target	O
for	O
the	O
copper	O
binding	O
agent	O
tetrathiomolybdate	O
is	O
intracellular	O
CuZn	O
-	O
superoxide	O
dismutase	O
(	O
SOD1	O
)	O
.	O

A	O
second	O
generation	O
tetrathiomolybdate	O
analog	O
,	O
ATN-224	O
,	O
inhibits	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
in	O
vitro	O
,	O
binds	O
to	O
SOD1	O
and	O
inhibits	O
its	O
activity	O
without	O
displacing	O
bound	O
copper	O
ATN-224	O
can	O
accumulate	O
in	O
ECs	O
and	O
inhibit	O
CuZnSOD	O
activity	O
with	O
an	O
IC50	O
similar	O
to	O
the	O
IC50	O
for	O
EC	O
proliferation	O
,	O
resulting	O
in	O
increased	O
generation	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
.	O

Inhibition	O
of	O
EC	O
proliferation	O
by	O
ATN-224	O
in	O
vitro	O
is	O
substantially	O
reversed	O
by	O
a	O
synthetic	O
porphyrin	O
SOD	O
mimetic	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
vivo	O
,	O
where	O
inhibition	O
of	O
angiogenesis	O
by	O
ATN-224	O
in	O
a	O
Matrigel	O
plug	O
model	O
was	O
also	O
reversed	O
by	O
MnTBAP	O
.	O

Thus	O
,	O
a	O
distinct	O
molecular	O
target	O
for	O
copper	O
depletion	O
therapy	O
has	O
been	O
identified	O
and	O
SOD1	O
is	O
now	O
validated	O
as	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
.	O

Methods	O
for	O
screening	O
,	O
or	O
designing	O
,	O
such	O
SOD1	O
inhibitors	O
for	O
use	O
as	O
angiogenesis	O
inhibitors	O
and	O
anti	O
-	O
cancer	O
agents	O
are	O
disclosed	O
.	O

Combinatorial	O
therapy	O
;	O
genetic	O
engineered	O
protein	O
;	O
therapy	O
for	O
autoimmune	O
diaeses	O
;	O
anticancer	O
agents	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
apoptosis	O
.	O

The	O
invention	O
provides	O
novel	O
therapies	O
,	O
for	O
example	O
,	O
novel	O
combinatorial	O
therapies	O
or	O
novel	O
therapeutic	O
compounds	O
that	O
can	O
work	O
alone	O
,	O
sequentially	O
to	O
,	O
or	O
jointly	O
with	O
Apoptin	B
,	O
especially	O
in	O
those	O
cases	O
wherein	O
p53	B
is	O
completely	O
or	O
partially	O
non	O
-	O
functional	O
.	O

Isolated	O
polynucleotides	O
comprising	O
a	O
nucleic	O
acid	O
which	O
operably	O
encodes	O
50	O
contiguous	O
amino	O
acids	O
,	O
nucleic	O
acids	O
are	O
fragments	O
of	O
a	O
codon	O
-	O
optimized	O
coding	O
region	O
;	O
a	O
carrier	O
The	O
invention	O
is	O
related	O
to	O
polynucleotide	O
-	O
based	O
cytomegalovirus	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
invention	O
is	O
plasmids	O
operably	O
encoding	O
HCMV	O
antigens	O
,	O
in	O
which	O
the	O
naturally	O
-	O
occurring	O
coding	O
regions	O
for	O
the	O
HCMV	O
antigens	O
have	O
been	O
modified	O
for	O
improved	O
translation	O
in	O
human	O
or	O
other	O
mammalian	O
cells	O
through	O
codon	O
optimization	O
.	O

HCMV	O
antigens	O
which	O
are	O
useful	O
in	O
the	O
invention	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
pp65	O
,	O
glycoprotein	O
B	O
(	O
gB	O
)	O
,	O
IE1	O
,	O
and	O
fragments	O
,	O
variants	O
or	O
derivatives	O
of	O
either	O
of	O
these	O
antigens	O
.	O

In	O
certain	O
embodiments	O
,	O
sequences	O
have	O
been	O
deleted	O
,	O
e.g.	O
,	O
the	O
Arg435-Lys438	O
putative	O
kinase	B
in	O
pp65	O
and	O
the	O
membrane	O
anchor	O
and	O
endocellular	O
domains	O
in	O
gB.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
to	O
induce	O
an	O
immune	O
response	O
to	O
HCMV	O
in	O
a	O
mammal	O
,	O
for	O
example	O
,	O
a	O
human	O
,	O
comprising	O
delivering	O
a	O
plasmid	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
plasmids	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
,	O
and	O
further	O
comprising	O
adjuvants	O
,	O
excipients	O
,	O
or	O
immune	O
modulators	O
.	O

N	O
-	O
Hydroxy	O
(	O
2S	O
)	O
-2-hydroxy	O
phenyl	O
or	O
heteroaryl	O
sulfonamide	O
derivatives	O
;	O
for	O
example	O
,	O
N	O
-	O
Hydroxy	O
(	O
2S	O
)	O
-2-hydroxy-3-	O
{	O
N-	O
[	O
4-	O
(	O
4-	O
chlorophenoxy	O
)	O
phenyl	O
]	O
,	O
N-	O
methanesulfonylamino	O
}	O
propionamide	O
;	O
for	O
treating	O
disorders	O
related	O
to	O
matrix	B
metalloproteases	I
,	O
particularly	O
useful	O
for	O
treating	O
strokes	O
;	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
treating	O
disorders	O
related	O
to	O
matrix	B
metalloproteases	I
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
treating	O
stroke	O
.	O

Polymerizable	O
antimicrobial	O
composition	O
The	O
present	O
invention	O
provides	O
a	O
polymerizable	O
antimicrobial	O
composition	O
and	O
a	O
method	O
for	O
using	O
the	O
same	O
.	O

The	O
polymerizable	O
antimicrobial	O
composition	O
of	O
the	O
invention	O
comprises	O
an	O
antimicrobial	O
compound	O
,	O
a	O
linker	O
,	O
and	O
a	O
polymerizable	O
function	O
group	O
.	O

Topical	O
delivery	O
of	O
codrugs	O
The	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
for	O
topical	O
delivery	O
comprising	O
a	O
suitable	O
carrier	O
and	O
a	O
codrug	O
capable	O
of	O
penetrating	O
,	O
or	O
being	O
transported	O
across	O
,	O
the	O
dermis	O
.	O

The	O
codrug	O
according	O
to	O
the	O
invention	O
comprises	O
a	O
first	O
constituent	O
moiety	O
linked	O
to	O
a	O
second	O
constituent	O
moiety	O
,	O
wherein	O
the	O
second	O
constituent	O
moiety	O
is	O
the	O
same	O
as	O
,	O
or	O
different	O
from	O
,	O
the	O
first	O
constituent	O
moiety	O
.	O

The	O
first	O
and	O
second	O
constituent	O
moieties	O
are	O
so	O
linked	O
that	O
they	O
are	O
easily	O
transported	O
into	O
or	O
across	O
the	O
dermis	O
,	O
into	O
the	O
skin	O
,	O
or	O
into	O
the	O
blood	O
or	O
lymphatic	O
system	O
,	O
and	O
are	O
reconstituted	O
in	O
vivo	O
to	O
form	O
the	O
first	O
and	O
second	O
constituent	O
moieties	O
.	O

Crosslinked	O
Amine	O
Polymers	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
ion	O
imbalances	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
comprising	O
crosslinked	O
amine	O
polymers	O
.	O

Methods	O
of	O
use	O
of	O
the	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
for	O
therapeutic	O
and/or	O
prophylactic	O
benefits	O
are	O
disclosed	O
herein	O
.	O

Examples	O
of	O
these	O
methods	O
include	O
the	O
treatment	O
of	O
renal	O
diseases	O
and	O
hyperphosphatemia	O
.	O

drug	O
delivery	O
devices	O
comprising	O
capsules	O
containing	O
drugs	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
capsule	O
The	O
present	O
invention	O
relates	O
to	O
liposomes	O
for	O
drug	O
delivery	O
,	O
wherein	O
a	O
liposome	O
includes	O
molecules	O
of	O
at	O
least	O
one	O
desired	O
drug	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
liposome	O
and	O
wherein	O
the	O
liposome	O
further	O
includes	O
molecules	O
of	O
the	O
same	O
or	O
of	O
another	O
drug	O
attached	O
to	O
either	O
or	O
both	O
sides	O
of	O
the	O
liposomal	O
membrane	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
,	O
wherein	O
at	O
least	O
a	O
part	O
of	O
the	O
molecules	O
of	O
a	O
desired	O
drug	O
bear	O
a	O
functional	O
group	O
that	O
is	O
reactive	O
with	O
a	O
functional	O
group	O
present	O
in	O
at	O
least	O
one	O
lipid	O
fraction	O
,	O
and	O
wherein	O
the	O
drug	O
is	O
covalently	O
linked	O
to	O
the	O
membrane	O
lipids	O
by	O
chemical	O
bonding	O
,	O
e.g.	O
by	O
ester	O
bonding	O
of	O
a	O
hydroxyl	O
group	O
of	O
a	O
lipid	O
molecule	O
and	O
an	O
acidic	O
residue	O
of	O
the	O
drug	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
desired	O
drug	O
is	O
a	O
glycoprotein	B
such	O
as	O
erythropoietin	B
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
manufacture	O
of	O
said	O
liposomes	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Hes6	B
as	O
a	O
marker	O
of	O
pancreatic	O
endocrine	O
cells	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
identifying	O
endocrine	O
stem	O
and	O
progenitor	O
cells	O
.	O

Novel	O
Benzofurans	O
and	O
Indols	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
is	O
a	O
fluorine	O
or	O
a	O
chlorine	O
atom	O
;	O
the	O
methyl	O
groups	O
located	O
at	O
the	O
2-	O
and	O
5-position	O
of	O
the	O
piperazine	O
ring	O
are	O
in	O
trans	O
-	O
configuration	O
to	O
each	O
other	O
;	O
Y	O
is	O
NH	O
or	O
O	O
;	O
R1	O
is	O
selected	O
from	O
hydrogen	O
,	O
chloro	O
,	O
bromo	O
,	O
nitro	O
,	O
methyl	O
or	O
trifluoromethyl	O
;	O
R2	O
is	O
selected	O
from	O
hydrogen	O
,	O
halo	O
,	O
methyl	O
,	O
trifluoromethyl	O
,	O
methoxy	O
or	O
trifluoromethoxy	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
;	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Included	O
are	O
also	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
mammals	O
suffering	O
from	O
inflammatory	O
,	O
autoimmune	O
,	O
proliferative	O
or	O
hyperproliferative	O
diseases	O
by	O
administering	O
a	O
compound	O
having	O
the	O
formula	O
(	O
I	O
)	O
to	O
said	O
mammal	O
.	O

Topically	O
administrating	O
an	O
inhibitor	O
of	O
Erbb2	B
or	O
HER2	B
receptor	I
tyrosine	I
kinase	I
activity	O
because	O
of	O
a	O
novel	O
connection	O
between	O
HER2	B
and	O
a	O
DNA	O
damage	O
checkpoint	O
;	O
reducing	O
mutagenesis	O
and	O
apoptosis	O
;	O
antitumor	O
,	O
-carcinogenic	O
,	O
-proliferative	O
agents	O
and	O
-inflammatory	O
agents	O
;	O
sunburn	O
;	O
hyperplasia	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
suppression	O
of	O
ultra	O
violet	O
-	O
induced	O
skin	O
pathologies	O
and	O
skin	O
abnormalities	O
,	O
such	O
as	O
abnormal	O
proliferation	O
and	O
mutagenesis	O
,	O
and	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
having	O
Erbb2	B
or	O
HER2	B
receptors	O
.	O

The	O
method	O
involves	O
administration	O
of	O
Erbb2	B
/	O
HER2	B
inhibitors	O
,	O
either	O
before	O
or	O
after	O
exposure	O
to	O
UV	O
.	O

Endogenous	O
Peptide	O
and	O
Active	O
Subfragments	O
Thereof	O
The	O
present	O
invention	O
relates	O
to	O
a	O
substantially	O
pure	O
biologically	O
active	O
consecutive	O
anti	O
-	O
angiogenic	O
polypeptide	O
comprising	O
the	O
central	O
region	O
of	O
human	B
Histidine	I
Rich	I
Glycoprotein	I
(	O
HRGP	B
)	O
.	O

Said	O
polypeptide	O
is	O
shown	O
to	O
comprise	O
a	O
potential	O
endogenous	O
,	O
naturally	O
occurring	O
subfragment	O
of	O
human	B
HRGP	I
,	O
comprising	O
similar	O
anti	O
-	O
angiogenic	O
activities	O
as	O
the	O
mature	O
protein	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
one	O
or	O
more	O
new	O
biologically	O
active	O
subfragments	O
of	O
human	B
HRGP	I
,	O
derived	O
from	O
said	O
central	O
region	O
.	O

Said	O
subfragments	O
are	O
all	O
characterized	O
by	O
having	O
anti	O
-	O
angiogenic	O
activity	O
.	O

One	O
of	O
the	O
active	O
subfragments	O
is	O
referred	O
to	O
as	O
Pep2	B
.	O

Enscoped	O
by	O
the	O
present	O
invention	O
are	O
also	O
anti	O
-	O
angiogenic	O
subfragments	O
derived	O
from	O
Pep2	B
,	O
one	O
of	O
them	O
comprising	O
a	O
newly	O
identified	O
presently	O
minimal	O
functional	O
entity	O
.	O

Administering	O
vector	O
system	O
that	O
directs	O
regulated	O
erythropoietin	B
(	O
Epo	B
)	O
gene	O
therapy	O
in	O
a	O
manner	O
that	O
physiologically	O
corrects	O
the	O
hematocrit	O
levels	O
in	O
a	O
patient	O
in	O
need	O
of	O
anemia	O
treatment	O
Disclosed	O
is	O
a	O
viral	O
vector	O
containing	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
erythropoietin	B
(	O
Epo	B
)	O
,	O
in	O
operable	O
linkage	O
with	O
an	O
HRE	B
expression	O
control	O
sequence	O
,	O
as	O
well	O
as	O
uses	O
of	O
the	O
vector	O
;	O
for	O
instance	O
,	O
in	O
preparing	O
a	O
medicament	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
anemia	O
,	O
can	O
involve	O
administering	O
the	O
vector	O
to	O
a	O
patient	O
,	O
wherein	O
expression	O
of	O
Epo	B
is	O
physiologically	O
regulated	O
such	O
that	O
hematocrit	O
levels	O
of	O
the	O
patient	O
are	O
corrected	O
and	O
maintained	O
.	O

For	O
prophylaxis	O
or	O
treatment	O
of	O
apoptosis	O
or	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
,	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
a	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
namely	O
,	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
COPD	O
,	O
which	O
includes	O
(	O
1	O
)	O
comparing	O
the	O
activities	O
of	O
a	O
protein	O
having	O
an	O
amino	O
acid	O
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	O
acid	O
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
or	O
a	O
partial	O
peptide	O
thereof	O
or	O
a	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
,	O
or	O
(	O
2	O
)	O
comparing	O
the	O
expressions	O
of	O
a	O
protein	O
having	O
an	O
amino	O
acid	O
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	O
acid	O
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
a	O
partial	O
peptide	O
thereof	O
and	O
a	O
salt	O
thereof	O
in	O
the	O
cells	O
having	O
the	O
ability	O
to	O
produce	O
the	O
protein	O
,	O
the	O
partial	O
peptide	O
thereof	O
and	O
the	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
.	O

Screening	O
for	O
a	O
compound	O
which	O
inhibits	O
p62	B
/	O
ubiquitin	B
binding	O
;	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
;	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
The	O
application	O
discloses	O
a	O
role	O
of	O
p62	B
in	O
aging	O
-	O
related	O
disease	O
,	O
such	O
as	O
development	O
of	O
obesity	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
,	O
various	O
tumors	O
,	O
increased	O
male	O
mortality	O
,	O
intracellular	O
inclusion	O
named	O
sequestosome	O
,	O
and	O
redox	O
regulation	O
.	O

In	O
particular	O
the	O
application	O
discloses	O
a	O
method	O
of	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
.	O

Further	O
,	O
transgenic	O
mice	O
containing	O
a	O
mutation	O
in	O
the	O
p62	B
gene	O
and	O
having	O
a	O
functionally	O
disrupted	O
p62	B
gene	O
locus	O
are	O
also	O
disclosed	O
.	O

Administering	O
(	O
3R,5S	O
)	O
-N	O
-	O
propanesulfonyl-7-chloro-5-	O
(	O
2,3-dimethoxyphenyl	O
)	O
-1-	O
(	O
3-hydroxy-2,2-dimethylpropyl	O
)	O
-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide	O
;	O
cerebral	O
infarction	O
The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
functional	O
disorders	O
,	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
dysfunction	O
and	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
deuteropathy	O
thereof	O
,	O
each	O
of	O
which	O
comprises	O
a	O
compound	O
having	O
an	O
effect	O
of	O
increasing	O
ubiquinone	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
;	O
as	O
well	O
as	O
a	O
ubiquinone	O
increasing	O
agent	O
comprising	O
a	O
compound	O
having	O
a	O
squalene	B
synthase	I
inhibitory	O
effect	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

Hydrazide	O
Derivatives	O
A	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
the	O
foregoing	O
is	O
safe	O
while	O
exhibiting	O
suitable	O
physicochemical	O
stability	O
,	O
and	O
is	O
useful	O
as	O
therapeutic	O
or	O
prophylactic	O
agents	O
for	O
diseases	O
associated	O
with	O
thrombus	O
formation	O
.	O

wherein	O
R1a	O
,	O
R1b	O
,	O
R1c	O
and	O
R1d	O
each	O
independently	O
represent	O
hydrogen	O
,	O
etc	O
.	O
,	O
R2	O
represents	O
optionally	O
substituted	O
phenyl	O
,	O
etc	O
.	O
,	O
R3	O
represents	O
optionally	O
substituted	O
C6	O
-	O
10	O
aryl	O
,	O
etc	O
.	O
,	O
Z1	O
,	O
Z2	O
and	O
Z3	O
each	O
independently	O
represent	O
hydrogen	O
,	O
etc	O
.	O
,	O
Z4	O
represents	O
hydrogen	O
,	O
etc	O
.	O
and	O
X	O
represents	O
a	O
single	O
bond	O
or	O
—CO—	O
,	O
etc	O
.	O

Compositions	O
For	O
Treating	O
Flushing	O
And	O
Lipid	O
-	O
Associated	O
Disorders	O
Comprising	O
Niacin	O
Receptor	O
Partial	O
Agonists	O

The	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
and	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	O
or	O
a	O
niacin	O
analog	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
and	O
subsequently	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	O
or	O
a	O
niacin	O
analog	O
.	O

Pharmaceutical	O
Composition	O
Containing	O
Prostaglandin	O
An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
stable	O
aqueous	O
pharmaceutical	O
composition	O
which	O
suppresses	O
degradation	O
of	O
prostaglandin	O
F2α	O
in	O
a	O
preparation	O
containing	O
prostaglandin	O
F2α	O
.	O

The	O
object	O
was	O
attained	O
by	O
formulating	O
a	O
prostaglandin	O
F2α	O
derivative	O
into	O
an	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
together	O
with	O
an	O
oil	O
,	O
for	O
example	O
,	O
medium	O
chain	O
fatty	O
acid	O
triglyceride	O
,	O
a	O
water	O
-	O
soluble	O
polymer	O
and	O
water	O
.	O

Injectable	O
Preparations	O
Of	O
Diclofenac	O
And	O
Its	O
Pharmaceutically	O
Acceptable	O
Salts	O
The	O
present	O
invention	O
provides	O
injectable	O
formulations	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	O
in	O
single	O
doses	O
of	O
less	O
than	O
2	O
ml	O
,	O
which	O
cause	O
significantly	O
less	O
pain	O
at	O
the	O
site	O
of	O
injection	O
and	O
can	O
be	O
administered	O
by	O
intradeltoid	O
route	O
,	O
in	O
addition	O
to	O
intragluteal	O
and	O
slow	O
intravenous	O
route	O
.	O

More	O
specifically	O
the	O
injectable	O
preparations	O
contain	O
75	O
mg	O
to	O
100	O
mg	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	O
,	O
in	O
about	O
1	O
ml	O
injection	O
solution	O
without	O
significantly	O
raising	O
the	O
viscosity	O
of	O
the	O
injection	O
solution	O
without	O
the	O
use	O
surfactants	O
.	O

The	O
formulations	O
are	O
adjusted	O
to	O
pH	O
6	O
to	O
10	O
containing	O
up	O
to	O
100	O
mg	O
of	O
diclofenac	O
salt	O
in	O
a	O
medium	O
comprising	O
of	O
water	O
,	O
along	O
with	O
one	O
or	O
more	O
co	O
-	O
solvent	O
(	O
s	O
)	O
/	O
solubiliser	O
(	O
s	O
)	O
,	O
antioxidants	O
,	O
preservatives	O
,	O
buffers	O
,	O
alkali	O
and	O
stabilizers	O
.	O

Synergistic	O
composition	O
for	O
modulating	O
activity	O
of	O
substrate	O
analogs	O
for	O
NAD+	O
,	O
NADP+	O
,	O
NADH	O
or	O
NADPH	O
dependent	O
enzymes	O
and	O
process	O
thereof	O
The	O
present	O
disclosure	O
provides	O
a	O
composition	O
for	O
enhancing	O
effect	O
of	O
an	O
inhibitor	O
in	O
inhibiting	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
.	O

The	O
inhibition	O
of	O
the	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
such	O
as	O
Enoyl	O
-	O
ACP	O
reductase	O
(	O
ENR	O
)	O
by	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
serves	O
as	O
a	O
target	O
for	O
treating	O
malaria	O
and	O
other	O
infectious	O
diseases	O
.	O

The	O
present	O
disclosure	O
provides	O
composition	O
comprising	O
inhibitor	O
and	O
polyphenol	O
,	O
wherein	O
the	O
polyphenol	O
was	O
found	O
to	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
the	O
inhibitor	O
.	O

The	O
present	O
disclosure	O
provides	O
method	O
for	O
treating	O
an	O
infectious	O
disease	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
to	O
patients	O
in	O
need	O
thereof	O
.	O

The	O
present	O
disclosure	O
further	O
provides	O
a	O
method	O
for	O
identifying	O
a	O
compound	O
that	O
enhances	O
the	O
effect	O
of	O
the	O
inhibitor	O
,	O
a	O
method	O
of	O
determining	O
the	O
antimalarial	O
activity	O
of	O
a	O
compound	O
and	O
use	O
of	O
polyphenol	O
as	O
a	O
bioenhancer	O
that	O
enhances	O
effect	O
of	O
an	O
inhibitor	O
for	O
inhibiting	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
.	O

The	O
present	O
disclosure	O
provides	O
a	O
composition	O
comprising	O
inhibitor	O
and	O
a	O
polyphenol	O
wherein	O
the	O
polyphenol	O
enhances	O
effect	O
of	O
the	O
inhibitor	O
for	O
inhibiting	O
aldose	O
reductase	O
for	O
treating	O
complications	O
of	O
diabetes	O
that	O
include	O
diabetic	O
retinopathy	O
,	O
cataract	O
neuropathy	O
and	O
neural	O
complication	O
.	O

e.g.	O
9-Hydroxy-2-	O
(	O
2-methoxy	O
-	O
ethyl	O
)	O
-1,8-dioxo-1,8-dihydro-2H	O
-	O
pyrid	O
[	O
1,2-a	O
]	O
pyrazi	O
ne-7-carboxylic	O
acid	O
4-fluoro	O
-	O
banzylamide	O
;	O
Human	O
T	O
cell	O
leukemia	O
virus	O
,	O
Feline	O
and	O
Simian	O
immunodeficiency	O
virus	O
inhibitor	O
;	O
side	O
effects	O
reduction	O
[	O
Object	O
]	O
Is	O
to	O
provide	O
a	O
novel	O
compound	O
having	O
an	O
anti	O
-	O
viral	O
activity	O
,	O
particularly	O
a	O
HIV	B
integrase	I
inhibitory	O
activity	O
,	O
and	O
an	O
agent	O
,	O
particularly	O
an	O
anti	O
-	O
HIV	O
agent	O
.	O

[	O
Solving	O
means	O
]	O
A	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
(	O
wherein	O
Z1	O
is	O
NR4	O
(	O
R4	O
is	O
hydrogen	O
,	O
optionally	O
substituted	O
lower	O
alkyl	O
etc	O
.	O
)	O
,	O
O	O
or	O
CH2	O
;	O
Z2	O
is	O
optionally	O
substituted	O
lower	O
alkylene	O
or	O
optionally	O
substituted	O
lower	O
alkenylene	O
,	O
each	O
may	O
be	O
intervened	O
by	O
a	O
heteroatom	O
group	O
selected	O
from	O
group	O
consisting	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
,	O
NR5	O
(	O
R5	O
is	O
selected	O
independently	O
from	O
the	O
same	O
substituent	O
group	O
of	O
R4	O
)	O
—N	O
═	O
and	O
═	O
N—	O
;	O
R1	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
is	O
a	O
single	O
bond	O
,	O
a	O
heteroatom	O
group	O
selected	O
from	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
and	O
NH	O
,	O
or	O
lower	O
alkylene	O
or	O
lower	O
alkenylene	O
each	O
may	O
be	O
intervened	O
by	O
the	O
heteroatom	O
group	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	O
;	O
R3	O
is	O
hydrogen	O
,	O
halogen	O
,	O
hydroxy	O
,	O
optionally	O
substituted	O
alkyl	O
group	O
etc	O
.	O
)	O

Crystalline	O
,	O
formed	O
by	O
crystallizing	O
from	O
an	O
aqueous	O
solution	O
without	O
agitation	O
;	O
treating	O
cancer	O
Erlotinib	O
hydrochloride	O
hydrate	O
is	O
formed	O
from	O
an	O
aqueous	O
solution	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
and	O
as	O
a	O
purification	O
intermediate	O
.	O

Compositions	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
Compositions	O
are	O
provided	O
for	O
the	O
topical	O
treatment	O
of	O
cancer	O
consisting	O
of	O
lotions	O
,	O
creams	O
,	O
sprays	O
,	O
suppositories	O
or	O
slow	O
-	O
release	O
transdermal	O
patches	O
containing	O
lipid	O
-	O
soluble	O
,	O
skin	O
-	O
penetrating	O
organic	O
selenium	O
compounds	O
in	O
combination	O
with	O
inert	O
carriers	O
in	O
therapeutically	O
effective	O
amounts	O
of	O
selenium	O
compound	O
.	O

The	O
selenium	O
compounds	O
are	O
medium	O
linear	O
chain	O
dialkyl	O
diselenides	O
and	O
precursors	O
such	O
as	O
alkyl	O
selenols	O
.	O

Preferred	O
compositions	O
employ	O
R	O
—	O
Se	O
—	O
Se	O
—	O
R	O
compounds	O
where	O
R	O
is	O
from	O
6	O
to	O
8	O
carbon	O
atoms	O
,	O
and	O
most	O
specifically	O
di	O
-	O
n	O
-	O
hexyl	O
diselenide	O
.	O

Commonly	O
used	O
carriers	O
may	O
be	O
purified	O
hydrocarbon	O
fractions	O
,	O
oils	O
,	O
with	O
or	O
without	O
added	O
fat	O
-	O
soluble	O
vitamins	O
,	O
water	O
and	O
emulsifying	O
agents	O
.	O

Allele	O
-	O
specific	O
silencing	O
of	O
disease	O
genes	O
The	O
present	O
invention	O
is	O
directed	O
to	O
small	O
interfering	O
RNA	O
molecules	O
(	O
siRNA	O
)	O
targeted	O
against	O
an	O
allele	O
of	O
interest	O
,	O
and	O
methods	O
of	O
using	O
these	O
siRNA	O
molecules	O
.	O

Sirolimus	O
Formulation	O
The	O
present	O
invention	O
relates	O
to	O
a	O
stable	O
pharmaceutical	O
composition	O
comprising	O
sirolimus	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
sirolimus	O
in	O
the	O
amorphous	O
form	O
,	O
a	O
fatty	O
acid	O
ester	O
and	O
a	O
pharmaceutically	O
acceptable	O
polymer	O
wherein	O
the	O
fatty	O
acid	O
ester	O
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
10	O
%	O
w	O
/	O
w	O
compared	O
to	O
the	O
total	O
weight	O
of	O
the	O
composition	O
.	O

N-	O
{	O
2-	O
[	O
(	O
(	O
2S	O
)	O
-3-	O
{	O
[	O
1-	O
(	O
4-chlorobenzyl	O
)	O
piperidin-4-yl	O
]	O
amino	O
}	O
-2-hydroxy-2-methylpropyl	O
)	O
oxy	O
]	O
-4-hydroxyphenyl	O
}	O
acetamide	O
hemifumarate	O
;	O
chemokine	B
receptor	I
1	I
modulation	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
;	O
chemical	O
stability	O
;	O
easy	O
to	O
handle	O
;	O
inhalant	O
formulations	O
The	O
invention	O
provides	O
N-	O
{	O
2-	O
[	O
(	O
(	O
2S	O
)	O
-3-	O
{	O
[	O
1-	O
(	O
4-chlorobenzyl	O
)	O
piperidin-4-yl	O
]	O
amino	O
}	O
-2-hydroxy-2-methyl	O
-	O
propyl	O
)	O
oxy	O
]	O
-4-hydroxyphenyl	O
}	O
acetamide	O
hemi	O
-	O
fumarate	O
or	O
a	O
solvate	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
salt	O
or	O
solvate	O
and	O
use	O
of	O
the	O
salt	O
or	O
solvate	O
in	O
therapy	O
.	O

Weight	O
control	O
;	O
sexual	O
disorders	O
;	O
stomach	O
blotting	O
;	O
gastrointestinal	O
disorders	O
;	O
anticholesterol	O
agents	O
Disclosed	O
is	O
a	O
composition	O
and	O
method	O
,	O
for	O
various	O
conditions	O
,	O
including	O
body	O
weight	O
control	O
,	O
sexual	O
dysfunction	O
,	O
stomach	O
blotting	O
,	O
heartburn	O
,	O
body	O
pain	O
,	O
and	O
controlling	O
cholesterol	O
,	O
arginine	O
is	O
used	O
as	O
active	O
material	O
.	O

The	O
composition	O
is	O
in	O
the	O
form	O
of	O
lotion	O
/	O
cream	O
applicable	O
to	O
any	O
part	O
of	O
the	O
body	O
and	O
still	O
functional	O
.	O

It	O
does	O
not	O
need	O
to	O
be	O
applied	O
on	O
problematic	O
site	O
.	O

External	O
pharmaceutical	O
composition	O
containing	O
tramadol	O
An	O
analgesic	O
composition	O
for	O
external	O
application	O
for	O
increasing	O
the	O
percutaneous	O
permeability	O
of	O
tramadol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
for	O
achieving	O
a	O
quick	O
pharmacological	O
effect	O
.	O

The	O
analgesic	O
composition	O
includes	O
tramadol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
menthol	O
substance	O
and	O
a	O
pyrrolidone	O
compound	O
.	O

Methods	O
for	O
Improving	O
Drug	O
Disposition	O
The	O
invention	O
provides	O
a	O
method	O
for	O
improving	O
the	O
bioavailability	O
,	O
preferably	O
,	O
oral	O
bioavailability	O
and/or	O
drug	O
disposition	O
,	O
e.g.	O
brain	O
penetration	O
,	O
of	O
an	O
iron	O
chelator	O
,	O
which	O
method	O
comprises	O
co	O
-	O
administering	O
to	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
,	O
a	O
combination	O
of	O
an	O
iron	O
chelator	O
and	O
an	O
efflux	B
protein	I
inhibitor	O
.	O

Containing	O
phosphodiesterase	B
inhibitor	O
vardensfil	O
;	O
erectile	O
dysfunction	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
dosage	O
forms	O
with	O
controlled	O
release	O
of	O
active	O
ingredient	O
which	O
comprise	O
the	O
PDE	B
5	I
inhibitor	O
vardenafil	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
solvates	O
and/or	O
polymorphic	O
forms	O
thereof	O
as	O
active	O
ingredient	O
,	O
and	O
to	O
the	O
production	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
these	O
novel	O
pharmaceutical	O
dosage	O
forms	O
as	O
medicaments	O
,	O
and	O
to	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
disorders	O
in	O
humans	O
and	O
animals	O
.	O

Heterodimers	O
of	O
glutamic	O
acid	O
Compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
wherein	O
R	O
is	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
,	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl	O
or	O
—NR′R′	O
,	O
Q	O
is	O
C	O
(	O
O	O
)	O
,	O
O	O
,	O
NR′	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
Y	O
is	O
C	O
(	O
O	O
)	O
,	O
O	O
,	O
NR′	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
Z	O
is	O
H	O
or	O
C1-C4	O
alkyl	O
,	O
R′	O
is	O
H	O
,	O
C	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
or	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl	O
,	O
when	O
substituted	O
,	O
aryl	O
,	O
heteroaryl	O
and	O
alkyl	O
are	O
substituted	O
with	O
halogen	O
,	O
C6-C12	O
heteroaryl	O
,	O
—NR′R′	O
or	O
COOZ	O
,	O
which	O
have	O
diagnostic	O
and	O
therapeutic	O
properties	O
,	O
such	O
as	O
the	O
treatment	O
and	O
management	O
of	O
prostate	O
cancer	O
and	O
other	O
diseases	O
related	O
to	O
NAALADase	B
inhibition	O
.	O

Radiolabels	O
can	O
be	O
incorporated	O
into	O
the	O
structure	O
through	O
a	O
variety	O
of	O
prosthetic	O
groups	O
attached	O
at	O
the	O
X	O
amino	O
acid	O
side	O
chain	O
via	O
a	O
carbon	O
or	O
hetero	O
atom	O
linkage	O
.	O

E.g.	O
,	O
[	O
(	O
1-	O
(	O
2-aminoacetyl	O
)	O
-4-	O
{	O
N-	O
[	O
(	O
3-fluoro-2-methylphenyl	O
)	O
methyl	O
]	O
carbamoyl	O
}	O
(	O
4-piperidyl	O
)	O
)	O
methoxy	O
]	O
-N-	O
(	O
4-ethylphenyl	O
)	O
carboxamide	O
;	O
smooth	O
muscle	O
myosin	O
or	O
non	O
-	O
muscle	O
myosin	O
modulator	O
;	O
hypotensive	O
agent	O
;	O
asthma	O
,	O
COPD	O
,	O
bronchoconstrictive	O
disease	O
,	O
glaucoma	O
,	O
pre	O
-	O
menstrual	O
cramps	O
,	O
erectile	O
dysfunction	O
Chemical	O
entities	O
that	O
modulate	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
are	O
described	O
.	O

glutamate	B
receptors	I
agonists	O
;	O
especially	O
to	O
treat	O
psychotic	O
conditions	O
,	O
including	O
schizophrenia	O
and	O
enhancement	O
of	O
cognition	O
;	O
N-	O
{	O
-2-	O
[	O
4-	O
(	O
6-fluoro-3-pyridinyl	O
)	O
phenyl	O
]	O
cyclopropyl	O
}	O
-2-propanesulfonamide	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
are	O
disclosed	O
:	O
wherein	O
R1	O
is	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C2	O
-	O
6alkenyl	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
R2	O
and	O
R3	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
each	O
R4	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
is	O
C1	O
-	O
6alkyl	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
nitro	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
n	O
is	O
1	O
or	O
2	O
;	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
and	O
Het	O
is	O
thienyl	O
,	O
pyridyl	O
,	O
pyrimidinyl	O
,	O
pyridazinyl	O
,	O
pyrimidinyl	O
,	O
pyrazinyl	O
,	O
imidazolyl	O
,	O
pyrazolyl	O
,	O
pyrrolyl	O
,	O
quinolyl	O
,	O
thiazolyl	O
or	O
furyl	O
,	O
each	O
of	O
which	O
may	O
be	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
list	O
consisting	O
of	O
C1	O
-	O
6alkyl	O
,	O
C1	O
-	O
6alkoxy	O
,	O
acetyl	O
,	O
halogen	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
cyano	O
,	O
nitro	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
and	O
diC1	O
-	O
4alkylamino	O
.	O

Methods	O
of	O
preparation	O
of	O
the	O
compounds	O
,	O
and	O
uses	O
thereof	O
in	O
medicine	O
,	O
for	O
example	O
treatment	O
of	O
schizophrenia	O
,	O
are	O
also	O
disclosed	O
.	O

Novel	O
sustained	O
release	O
polymer	O
A	O
polymer	O
and	O
a	O
method	O
for	O
its	O
preparation	O
are	O
provided	O
.	O

The	O
polymer	O
comprises	O
poly	O
(	O
lactide	O
)	O
,	O
poly	O
(	O
lactide	O
/	O
glycolide	O
)	O
or	O
poly	O
(	O
lactic	O
acid	O
/	O
glycolic	O
acid	O
)	O
segments	O
bonded	O
by	O
ester	O
linkages	O
to	O
both	O
ends	O
of	O
an	O
alkanediol	O
core	O
unit	O
.	O

The	O
polymer	O
is	O
for	O
use	O
in	O
a	O
controlled	O
release	O
formulation	O
for	O
a	O
medicament	O
,	O
preferably	O
leuprolide	O
acetate	O
.	O

The	O
controlled	O
release	O
formulation	O
is	O
administered	O
to	O
a	O
patient	O
as	O
a	O
subcutaneous	O
depot	O
of	O
a	O
flowable	O
composition	O
comprising	O
the	O
polymer	O
,	O
a	O
biocompatible	O
solvent	O
,	O
and	O
the	O
medicament	O
.	O

Controlled	O
release	O
formulations	O
comprising	O
the	O
polymer	O
release	O
leuprolide	O
for	O
treatment	O
of	O
prostate	O
cancer	O
patients	O
over	O
periods	O
of	O
3	O
-	O
6	O
months	O
.	O

mobilizing	O
triacylglycerol	O
in	O
mammals	O
by	O
feeding	O
the	O
mammal	O
a	O
diet	O
that	O
includes	O
betaine	O
,	O
cysteine	O
and	O
choline	O
bitartrate	O
,	O
while	O
restricting	O
methionine	O
intake	O
;	O
reduction	O
of	O
liver	O
disorders	O
;	O
cirrhosis	O
Methods	O
for	O
use	O
in	O
mobilizing	O
triacylglycerol	O
(	O
TAG	O
)	O
in	O
order	O
to	O
elevate	O
apoliprotein	B
B	I
and	O
Very	O
-	O
Low	O
-	O
Density	O
Lipoprotein	O
(	O
VLDL	O
)	O
are	O
described	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
involves	O
providing	O
betaine	O
in	O
an	O
amount	O
of	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
in	O
order	O
to	O
mobilize	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
serum	O
VLDL	O
is	O
elevated	O
as	O
a	O
result	O
of	O
mobilizing	O
hepatic	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
restricting	O
methionine	O
intake	O
to	O
less	O
than	O
about	O
1	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
L	O
-	O
cysteine	O
at	O
a	O
level	O
of	O
at	O
least	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
choline	O
bitartrate	O
at	O
a	O
level	O
of	O
about	O
1.25	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

Mobilizing	O
hepatic	O
TAG	O
is	O
effective	O
to	O
reduce	O
hepatic	O
steatosis	O
.	O

Method	O
For	O
Diagnosing	O
Colorectal	O
Cancers	O
Objective	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
are	O
described	O
herein	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
diagnostic	O
method	O
involves	O
the	O
determining	O
an	O
expression	O
level	O
of	O
C10orf3	B
that	O
discriminate	O
between	O
CRC	O
and	O
normal	O
cell	O
.	O

The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
CRC	O
,	O
methods	O
of	O
treating	O
CRC	O
and	O
method	O
of	O
vaccinating	O
a	O
subject	O
against	O
CRC	O
.	O

Treatment	O
for	O
liver	O
disease	O
The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
artificial	O
induction	O
of	O
hepatic	O
stellate	O
cell	O
(	O
HSC	O
)	O
apoptosis	O
in	O
vivo	O
can	O
promote	O
the	O
resolution	O
of	O
liver	O
fibrosis	O
.	O

Thus	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
disease	O
in	O
a	O
subject	O
involving	O
administration	O
of	O
an	O
inducer	O
of	O
apoptosis	O
which	O
is	O
capable	O
of	O
selectively	O
inducing	O
hepatic	O
stellate	O
cell	O
apoptosis	O
in	O
the	O
liver	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
such	O
an	O
inducer	O
in	O
the	O
subject	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
fibrosis	O
in	O
a	O
subject	O
comprising	O
the	O
selective	O
delivery	O
of	O
an	O
inducer	O
of	O
apoptosis	O
specifically	O
to	O
the	O
hepatic	O
stellate	O
cells	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
an	O
inducer	O
of	O
hepatic	O
stellate	O
cell	O
apoptosis	O
.	O

Early	O
Detection	O
and	O
Prognosis	O
of	O
Colon	O
Cancers	O
We	O
have	O
developed	O
a	O
transcriptome	O
-	O
wide	O
approach	O
to	O
identify	O
genes	O
affected	O
by	O
promoter	O
CpG	O
island	O
hypermethylation	O
and	O
transcriptional	O
silencing	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

By	O
screening	O
cell	O
lines	O
and	O
validating	O
tumor	O
specific	O
hypermethylation	O
in	O
a	O
panel	O
of	O
primary	O
human	O
CRC	O
samples	O
,	O
we	O
estimate	O
that	O
nearly	O
5	O
%	O
of	O
all	O
known	O
genes	O
may	O
be	O
promoter	O
methylated	O
in	O
an	O
individual	O
tumor	O
.	O

When	O
directly	O
compared	O
to	O
gene	O
mutations	O
,	O
we	O
find	O
a	O
much	O
larger	O
number	O
of	O
genes	O
hypermethylated	O
in	O
individual	O
tumors	O
,	O
and	O
much	O
higher	O
frequency	O
of	O
hypermethylation	O
within	O
individual	O
genes	O
harboring	O
either	O
genetic	O
or	O
epigenetic	O
changes	O
.	O

Thus	O
,	O
to	O
enumerate	O
the	O
full	O
spectrum	O
of	O
alterations	O
in	O
the	O
human	O
cancer	O
genome	O
,	O
and	O
facilitate	O
the	O
most	O
efficacious	O
grouping	O
of	O
tumors	O
to	O
identify	O
cancer	O
biomarkers	O
and	O
tailor	O
therapeutic	O
approaches	O
,	O
both	O
genetic	O
and	O
epigenetic	O
screens	O
should	O
be	O
undertaken	O
.	O

The	O
genes	O
we	O
identified	O
can	O
be	O
used	O
inter	O
alia	O
diagnostically	O
to	O
detect	O
cancer	O
,	O
pre	O
-	O
cancer	O
,	O
and	O
likelihood	O
of	O
developing	O
cancer	O
.	O

Use	O
of	O
a	O
CB1	B
Antagonist	O
for	O
Treating	O
Side	O
Effects	O
and	O
Negative	O
Symptoms	O
of	O
Schizophrenia	O
The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
method	O
of	O
treating	O
cognition	O
deficits	O
in	O
a	O
patient	O
suffering	O
from	O
schizophrenia	O
by	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
CB1	B
receptor	I
antagonist	O
as	O
described	O
herein	O
.	O

In	O
another	O
aspect	O
,	O
this	O
invention	O
also	O
discloses	O
and	O
claims	O
a	O
combination	O
of	O
one	O
or	O
more	O
CB1	B
receptor	I
antagonists	O
and	O
of	O
one	O
or	O
more	O
antipsychotic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
disorders	O
.	O

The	O
combination	O
of	O
this	O
invention	O
provides	O
synergistic	O
results	O
in	O
that	O
the	O
combination	O
improves	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
,	O
weight	O
gain	O
and	O
catalepsy	O
.	O

1-	O
[	O
1-	O
(	O
methylsulfonyl	O
)	O
piperidin-4-yl	O
]	O
-3-	O
(	O
adamant-1-yl	O
)	O
urea	O
,	O
1-	O
[	O
1-	O
(	O
acetyl	O
)	O
piperidin-4-yl	O
]	O
-3-	O
(	O
adamant-1-yl	O
)	O
urea	O
;	O
incipient	O
diabetes	O
,	O
glucose	O
intolerance	O
,	O
obesity	O
,	O
hypertension	O
,	O
high	O
blood	O
pressure	O
,	O
elevated	O
serum	O
cholesterol	O
,	O
reduced	O
high	O
-	O
density	O
lipoproteins	O
and	O
elevated	O
triglyceride	O
levels	O
Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
inhibiting	O
the	O
onset	O
of	O
metabolic	O
syndrome	O
and	O
treating	O
related	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
therapy	O
are	O
disclosed	O
.	O

Controlled	O
Release	O
Formulations	O
The	O
present	O
invention	O
relates	O
to	O
controlled	O
release	O
transmucosal	O
formulations	O
which	O
mediate	O
absorption	O
and	O
methods	O
of	O
use	O
comprising	O
a	O
pharmaceutically	O
active	O
agent	O
,	O
preferably	O
morphine	O
,	O
and	O
a	O
water	O
soluble	O
polymer	O
,	O
chitosan	O
,	O
and	O
preferably	O
one	O
more	O
antioxidants	O
,	O
one	O
or	O
more	O
antimicrobial	O
agents	O
,	O
and	O
water	O
.	O

Method	O
of	O
Treatment	O
by	O
Administration	O
of	O
Rna	O
A	O
method	O
of	O
effecting	O
a	O
treatment	O
response	O
in	O
a	O
target	O
tissue	O
of	O
a	O
subject	O
,	O
comprising	O
:	O
administering	O
to	O
the	O
subject	O
isolated	O
RNA	O
comprising	O
an	O
RNA	O
sequence	O
extractable	O
or	O
extracted	O
from	O
a	O
source	O
tissue	O
such	O
that	O
said	O
treatment	O
response	O
is	O
effected	O
;	O
wherein	O
the	O
RNA	O
is	O
isolated	O
polyA	O
positive	O
RNA	O
in	O
substantially	O
pure	O
form	O
.	O

Two	O
-	O
coat	O
makeup	O
product	O
,	O
its	O
uses	O
,	O
and	O
makeup	O
kit	O
comprising	O
the	O
product	O
A	O
cosmetic	O
makeup	O
product	O
comprising	O
at	O
least	O
two	O
compositions	O
,	O
the	O
first	O
composition	O
comprising	O
a	O
physiologically	O
acceptable	O
medium	O
and	O
the	O
second	O
composition	O
comprising	O
a	O
mixture	O
of	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
greater	O
than	O
or	O
equal	O
to	O
200,000	O
g	O
/	O
mol	O
and	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	O
compound	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
less	O
than	O
200,000	O
g	O
/	O
mol	O
,	O
wherein	O
the	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
and	O
the	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	O
compound	O
are	O
present	O
in	O
a	O
proportion	O
such	O
that	O
the	O
dynamic	O
viscosity	O
of	O
the	O
mixture	O
at	O
25	O
°	O
C.	O
,	O
measured	O
with	O
a	O
Mettler	O
RM	O
180	O
rotational	O
viscometer	O
,	O
ranges	O
from	O
0.1	O
to	O
120	O
Pa·s	O
;	O
a	O
makeup	O
method	O
and	O
a	O
makeup	O
kit	O
comprising	O
the	O
cosmetic	O
makeup	O
product	O
.	O

The	O
cosmetic	O
makeup	O
product	O
may	O
,	O
for	O
example	O
,	O
be	O
a	O
lipstick	O
.	O

Alpha-4	B
Integrin	I
Mediated	O
Cell	O
Adhesion	O
Inhibitors	O
for	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Inflammatory	O
Diseases	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
capable	O
of	O
being	O
modulated	O
by	O
the	O
inhibition	O
of	O
cell	O
adhesion	O
.	O

End	O
-	O
Modified	O
Poly	O
(	O
beta	O
-	O
amino	O
esters	O
)	O
and	O
Uses	O
Thereof	O
Poly	O
(	O
beta	O
-	O
amino	O
esters	O
)	O
are	O
end	O
-	O
modified	O
to	O
form	O
materials	O
useful	O
in	O
the	O
medical	O
as	O
well	O
as	O
non	O
-	O
medical	O
field	O
.	O

An	O
amine	O
-	O
terminated	O
poly	O
(	O
beta	O
-	O
amino	O
ester	O
)	O
is	O
reacted	O
with	O
an	O
electrophile	O
,	O
or	O
an	O
acrylate	O
-	O
terminated	O
poly	O
(	O
beta	O
-	O
amino	O
ester	O
)	O
is	O
reacted	O
with	O
a	O
nucleophile	O
.	O

The	O
inventive	O
end	O
-	O
modified	O
polymers	O
may	O
be	O
used	O
in	O
any	O
field	O
where	O
polymers	O
have	O
been	O
found	O
useful	O
including	O
the	O
drug	O
delivery	O
arts	O
.	O

The	O
end	O
-	O
modified	O
polymers	O
are	O
particularly	O
useful	O
in	O
delivery	O
nucleic	O
acids	O
such	O
as	O
DNA	O
or	O
RNA	O
.	O

The	O
invention	O
also	O
provides	O
compositions	O
including	O
the	O
inventive	O
end	O
-	O
modified	O
polymers	O
,	O
methods	O
of	O
preparing	O
the	O
inventive	O
polymers	O
,	O
and	O
method	O
of	O
using	O
the	O
inventive	O
polymers	O
.	O

Using	O
vector	O
comprising	O
nucleotide	O
sequences	O
coding	O
neublastin	B
as	O
therapeutic	O
treatment	O
for	O
vision	O
defects	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
GFRα3	B
agonists	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
the	O
retina	O
.	O

A	O
preferred	O
GFRα3	B
agonist	O
is	O
Neublastin	B
.	O

Neublastin	B
may	O
be	O
administered	O
to	O
the	O
eye	O
using	O
protein	O
formulations	O
,	O
in	O
vivo	O
or	O
ex	O
vivo	O
gene	O
therapy	O
,	O
or	O
implantation	O
of	O
encapsulated	O
cells	O
delivering	O
Neublastin	B
locally	O
to	O
the	O
retina	O
.	O

Preventive	O
and/or	O
Therapeutic	O
Agent	O
for	O
Cancer	O
As	O
the	O
results	O
of	O
intensive	O
studies	O
aiming	O
at	O
providing	O
a	O
gene	O
targeting	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
,	O
novel	O
nucleotide	O
sequences	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
compared	O
with	O
normal	O
tissues	O
are	O
identified	O
.	O

As	O
the	O
results	O
of	O
the	O
subsequent	O
studies	O
,	O
genes	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
which	O
are	O
useful	O
as	O
a	O
drug	O
discovery	O
target	O
are	O
found	O
out	O
.	O

Has	O
acceptable	O
biodegradable	O
polymer	O
;	O
polyglycolic	O
acid	O
,	O
polylactic	O
acid	O
;	O
Parkinson	O
's	O
Disease	O
;	O
injectable	O
microspheres	O
,	O
injectable	O
gels	O
and	O
implants	O
;	O
enhanced	O
bioavailability	O
The	O
present	O
invention	O
relates	O
to	O
a	O
long	O
-	O
acting	O
sustained	O
-	O
release	O
dosage	O
form	O
for	O
treatment	O
of	O
Parkinson	O
Disease	O
,	O
comprising	O
a	O
dopamine	B
receptor	I
agonist	O
and	O
a	O
pharmaceutically	O
acceptable	O
biodegradable	O
polymer	O
accessories	O
,	O
wherein	O
the	O
content	O
of	O
the	O
dopamine	B
receptor	I
agonist	O
in	O
the	O
sustained	O
-	O
release	O
dosage	O
form	O
is	O
5	O
-	O
50	O
%	O
by	O
weight	O
,	O
and	O
the	O
content	O
of	O
the	O
pharmaceutically	O
acceptable	O
polymer	O
accessories	O
is	O
50	O
-	O
95	O
%	O
by	O
weight	O
.	O

Delivery	O
System	O
For	O
Bioactive	O
Agents	O
on	O
the	O
Basis	O
of	O
a	O
Polymeric	O
Drug	O
Carrier	O
Comprising	O
an	O
Amphiphilic	O
Block	O
Polymer	O
and	O
a	O
Polylacticacid	O
Derivative	O
Delivery	O
system	O
for	O
bioactive	O
agents	O
on	O
the	O
basis	O
of	O
a	O
polymeric	O
drug	O
carrier	O
formed	O
from	O
compositions	O
comprising	O
an	O
amphiphilic	O
block	O
copolymer	O
of	O
a	O
hydrophilic	O
block	O
and	O
a	O
hydrophobic	O
block	O
having	O
a	O
terminal	O
hydroxyl	O
group	O
substituted	O
with	O
a	O
tocopherol	O
or	O
cholesterol	O
group	O
,	O
and	O
a	O
polylactic	O
acide	O
derivative	O
wherein	O
one	O
end	O
of	O
the	O
polylactic	O
acid	O
is	O
covalently	O
bound	O
to	O
at	O
least	O
one	O
carboxyl	O
group	O
.	O

The	O
carboxyl	O
group	O
of	O
the	O
polylactic	O
acid	O
derivative	O
may	O
be	O
fixed	O
with	O
a	O
di-	O
or	O
trivalent	O
metal	O
ion	O
,	O
which	O
is	O
obtained	O
by	O
adding	O
the	O
di-	O
or	O
trivalent	O
metal	O
ion	O
to	O
the	O
polymeric	O
composition	O
.	O

Topical	O
;	O
adenosine	O
5'-monophosphates	O
and	O
salts	O
thereof	O
;	O
arbutins	O
,	O
ellagic	O
acid	O
,	O
4-alkylresorcinols	O
,	O
linolic	O
acid	O
,	O
tranexamic	O
acid	O
,	O
chamomile	O
extracts	O
,	O
ubiquinones	O
;	O
chloasma	O
,	O
freckles	O
A	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
which	O
can	O
produce	O
the	O
higher	O
effect	O
of	O
preventing	O
or	O
alleviating	O
pigmentation	O
.	O

The	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
comprises	O
a	O
combination	O
of	O
(	O
A	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
adenosine	O
5′-monophosphate	O
and	O
salts	O
thereof	O
with	O
(	O
B	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
arbutin	O
,	O
ellagic	O
acid	O
,	O
4-alkylresorcinols	O
,	O
linoleic	O
acid	O
,	O
tranexamic	O
acid	O
,	O
salts	O
of	O
these	O
,	O
Chamomilla	O
recuita	O
extract	O
,	O
and	O
Ubiquinone	O
.	O

Isolated	O
polynucleotide	O
encoding	O
a	O
Regulated	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
Kinase	O
polypeptide	O
;	O
host	O
cell	O
;	O
hybridization	O
;	O
screening	O
;	O
prediction	O
,	O
diagnosis	O
;	O
prognosis	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
diseases	O
of	O
defective	O
cell	O
signaling	O
Reagents	O
which	O
regulate	O
human	O
RC	O
Kinase	O
activity	O
and	O
reagents	O
which	O
bind	O
to	O
human	O
RC	O
Kinase	O
gene	O
products	O
can	O
be	O
used	O
to	O
regulate	O
this	O
protein	O
for	O
therapeutic	O
effects	O
.	O

Such	O
regulation	O
is	O
particularly	O
useful	O
for	O
treating	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
and	O
diseases	O
in	O
which	O
cell	O
signaling	O
is	O
defective	O
.	O

siRNA	O
blocks	O
expression	O
of	O
sphingosine	B
kinase	I
,	O
potentiates	O
effect	O
of	O
radiation	O
in	O
cancer	O
cells	O
of	O
breast	O
,	O
prostate	O
,	O
colorectal	O
,	O
lung	O
,	O
bladder	O
,	O
head	O
and	O
neck	O
,	O
intestine	O
,	O
ovarian	O
,	O
skin	O
;	O
reduces	O
amount	O
of	O
radiation	O
needed	O
to	O
decrease	O
cancer	O
cell	O
viability	O
,	O
tumor	O
size	O
in	O
vivo	O
The	O
present	O
invention	O
relates	O
to	O
Sphingosine	B
kinase	I
inhibitors	O
that	O
are	O
useful	O
for	O
treating	O
various	O
cancers	O
.	O

The	O
invention	O
further	O
relates	O
to	O
compositions	O
and	O
methods	O
of	O
SPK	B
inhibitors	O
,	O
including	O
siRNAs	O
,	O
which	O
specifically	O
block	O
gene	O
expression	O
of	O
SPK	B
and	O
potentiates	O
the	O
effect	O
of	O
radiation	O
in	O
the	O
treatment	O
of	O
various	O
cancers	O
.	O

Inhibitory	O
activity	O
against	O
Pin1	B
;	O
inhibit	O
peptidyl	B
-	I
prolyl	I
isomerase	I
activity	O
of	O
Pin1	B
;	O
inhibits	O
growth	O
of	O
cancer	O
cells	O
;	O
Ac	O
-	O
Phe	O
-	O
Tyr	O
-	O
phosphoSer-	O
pseudo	O
amide	O
-Pro	O
-	O
Arg	O
-	O
NH2	O
;	O
Fmoc	O
-	O
bis	O
(	O
POM	O
)	O
phosphoSer-	O
pseudo	O
amide	O
-Pro-2-aminoethyl-	O
(	O
3-indole	O
)	O
and	O
their	O
Phospho-	O
(	O
D	O
)	O
-serine	O
stereoisomers	O
Ac	O
-	O
Phe	O
-	O
Tyr	O
-	O
phosphoSer	O
-	O
Ψ	O
[	O
CH	O
═	O
C	O
]	O
-Pro	O
-	O
Arg	O
-	O
NH2AND	O
Fmoc	O
-	O
bis	O
(	O
pivaloylmethoxy	O
)	O
phosphoSer	O
-	O
Ψ	O
[	O
CH	O
═	O
C	O
]	O
-Pro-2-aminoethyl-	O
(	O
3-indole	O
)	O
;	O
and	O
their	O
Phospho-	O
(	O
D	O
)	O
-serine	O
stereoisomers	O
are	O
novel	O
compounds	O
.	O

Ψ	O
refers	O
to	O
a	O
pseudo	O
amide	O
.	O

Such	O
novel	O
compounds	O
advantageously	O
may	O
be	O
used	O
as	O
alkene	O
mimics	O
.	O

O	O
-	O
desmethylvenlafaxine	O
succinate	O
;	O
tablet	O
,	O
capsule	O
;	O
sustained	O
release	O
;	O
hydroxypropylmethyl	O
cellulose	O
rate	O
controlling	O
polymer	O
;	O
microcrystalline	O
cellulose	O
binder	O
;	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O
Methods	O
of	O
preparing	O
,	O
and	O
compositions	O
comprising	O
,	O
derivatives	O
of	O
venlafaxine	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
and	O
preventing	O
diseases	O
and	O
disorders	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
affective	O
disorders	O
such	O
as	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O
,	O
epilepsy	O
,	O
cerebral	O
function	O
disorders	O
,	O
obesity	O
and	O
weight	O
gain	O
,	O
incontinence	O
,	O
dementia	O
and	O
related	O
disorders	O
.	O

Method	O
for	O
Avoiding	O
Edema	O
in	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Ppary	O
-	O
Responsive	O
Diseases	O
,	O
Including	O
Cancer	O
Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
avoiding	O
edema	O
while	O
treating	O
or	O
preventing	O
PPARγ	B
-	O
mediated	O
diseases	O
,	O
including	O
cancer	O
,	O
using	O
derivatives	O
and	O
prodrugs	O
are	O
provided	O
.	O

Antiserotonine	O
agents	O
;	O
gastrointestinal	O
disorders	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
Alzheimer	O
's	O
disease	O
;	O
cognition	O
activators	O
;	O
analgesics	O
;	O
cardiovascular	O
disorders	O
;	O
antidiabetic	O
agents	O
;	O
sleep	O
disorders	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
and	O
m	O
are	O
each	O
as	O
described	O
herein	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
5-HT4	B
agonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
gastroesophageal	O
reflux	O
disease	O
,	O
gastrointestinal	O
disease	O
,	O
gastric	O
motility	O
disorder	O
,	O
non	O
-	O
ulcer	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
constipation	O
,	O
dyspepsia	O
,	O
esophagitis	O
,	O
gastroesophageral	O
disease	O
,	O
nausea	O
,	O
central	O
nervous	O
system	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
cognitive	O
disorder	O
,	O
emesis	O
,	O
migraine	O
,	O
neurological	O
disease	O
,	O
pain	O
,	O
cardiovascular	O
disorders	O
,	O
cardiac	O
failure	O
,	O
heart	O
arrhythmia	O
,	O
diabetes	O
and	O
apnea	O
syndrome	O
.	O

Analgesics	O
;	O
antidepressants	O
;	O
neurodegenerative	O
diseases	O
;	O
antiepileptic	O
agents	O
;	O
cognition	O
activators	O
;	O
antitussive	O
agents	O
;	O
incotinence	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
stroke	O
;	O
vision	O
defects	O
;	O
antiinflammatory	O
agents	O
;	O
skin	O
disorders	O
;	O
diarrhea	O
;	O
eating	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
spiro	O
compounds	O
,	O
to	O
processes	O
for	O
preparing	O
them	O
,	O
to	O
medicaments	O
comprising	O
these	O
compounds	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
producing	O
medicaments	O
.	O

Antibacterial	O
amide	O
-	O
macrocycles	O
v	O
The	O
invention	O
relates	O
to	O
antibacterial	O
amide	O
-	O
macrocycles	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R26	O
represents	O
hydrogen	O
,	O
halogen	O
,	O
amino	O
or	O
methyl	O
,	O
R7	O
represents	O
a	O
group	O
of	O
formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
or	O
(	O
V	O
)	O
,	O
whereby	O
R1	O
represents	O
hydrogen	O
or	O
hydroxy	O
and	O
*	O
is	O
the	O
linkage	O
site	O
to	O
the	O
carbon	O
atom	O
,	O
R2	O
represents	O
hydrogen	O
or	O
methyl	O
and	O
methods	O
for	O
their	O
production	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
as	O
well	O
as	O
their	O
use	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
particular	O
of	O
bacterial	O
infections	O
.	O

Pharmaceutical	O
Composition	O
for	O
Preventing	O
and	O
Treating	O
Metabolic	O
Bone	O
Diseases	O

Containing	O
Alpha	O
-	O
Arylmethoxyacrylate	O
Derivatives	O

The	O
present	O
invention	O
relates	O
to	O
a	O
use	O
of	O
a	O
specific	O
alpha	O
-	O
arylmethoxyacrylate	O
derivative	O
,	O
or	O
its	O
pharmacologically	O
acceptable	O
salt	O
or	O
solvate	O
for	O
preventing	O
and	O
treating	O
metabolic	O
bone	O
diseases	O
.	O

Plasminogen	B
Activator	I
Inhibitor-1	I
Inhibitors	O
Inhibitors	O
of	O
plasminogen	B
activator	I
inhibitor-1	I
(	O
PAI	B
-	I
I	I
)	O
are	O
provided	O
,	O
which	O
may	O
also	O
act	O
as	O
anti	O
cancer	O
agents	O
,	O
of	O
formulae	O
(	O
I	O
-	O
V	O
)	O
.	O

Method	O
for	O
developing	O
,	O
testing	O
,	O
and	O
using	O
associates	O
of	O
macromolecules	O
and	O
complex	O
aggregates	O
for	O
improved	O
payload	O
and	O
controllable	O
de	O
/	O
association	O
rates	O
This	O
invention	O
describes	O
the	O
principles	O
and	O
procedures	O
suitable	O
for	O
developing	O
,	O
testing	O
,	O
manufacturing	O
,	O
and	O
using	O
combinations	O
of	O
various	O
amphipatic	O
,	O
if	O
necessary	O
modified	O
,	O
macromolecules	O
(	O
such	O
as	O
polypeptides	O
,	O
proteins	O
,	O
etc	O
.	O
)	O
or	O
other	O
chain	O
molecules	O
(	O
such	O
as	O
suitable	O
,	O
e.g.	O
partly	O
hydrophobised	O
,	O
polynucleotides	O
or	O
polysaccharides	O
)	O
with	O
the	O
aggregates	O
which	O
comprise	O
a	O
mixture	O
of	O
polar	O
and/or	O
charged	O
amphipats	O
and	O
form	O
extended	O
surfaces	O
that	O
can	O
be	O
freely	O
suspended	O
or	O
supported	O
.	O

The	O
described	O
methods	O
can	O
be	O
utilised	O
for	O
the	O
optimisation	O
of	O
aggregates	O
that	O
,	O
after	O
association	O
with	O
chain	O
molecules	O
exerting	O
some	O
activity	O
or	O
a	O
useful	O
function	O
,	O
are	O
suitable	O
for	O
the	O
application	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
for	O
example	O
,	O
in	O
the	O
fields	O
of	O
drug	O
delivery	O
,	O
diagnostics	O
or	O
bio	O
/	O
catalysis	O
.	O

As	O
special	O
examples	O
,	O
mixtures	O
of	O
vesicular	O
droplets	O
consisting	O
of	O
lipids	O
loaded	O
(	O
associated	O
)	O
with	O
insulin	B
,	O
interferon	B
,	O
interleukin	B
,	O
nerve	B
growth	I
factor	I
,	O
calcitonin	B
,	O
and	O
an	O
immunoglobulin	B
,	O
etc	O
.	O
,	O
are	O
described	O
.	O

Broad	O
Spectrum	O
Non	O
-	O
Traditional	O
Preservative	O
System	O
Preservative	O
compositions	O
containing	O
emollient	O
solvents	O
such	O
as	O
octanediol	O
or	O
Symdiol	O
™	O
or	O
octoxyglycerine	O
monoesters	O
in	O
combination	O
with	O
organic	O
acids	O
such	O
as	O
alpha	O
hydroxyl	O
acids	O
can	O
be	O
used	O
for	O
preventing	O
microbial	O
growth	O
and	O
spoilage	O
in	O
cosmetic	O
and	O
topical	O
skin	O
formulations	O
with	O
the	O
added	O
benefit	O
of	O
providing	O
silky	O
smooth	O
texture	O
to	O
skin	O
.	O

The	O
compositions	O
may	O
optionally	O
contain	O
an	O
essential	O
oil	O
/	O
component	O
.	O

These	O
preservative	O
compositions	O
are	O
odorless	O
and	O
colorless	O
and	O
small	O
concentrations	O
can	O
be	O
added	O
to	O
cosmetic	O
/	O
topical	O
formulations	O
to	O
prevent	O
bacterial	O
,	O
yeast	O
and	O
fungal	O
growth	O
within	O
24	O
to	O
48	O
hours	O
after	O
contamination	O
.	O

Photochemotherapeutic	O
method	O
using	O
5-aminolevulinic	O
acid	O
and	O
other	O
precursors	O
of	O
endogenous	O
porphyrins	O
Methods	O
of	O
detecting	O
and	O
treating	O
rapidly	O
growing	O
exogenous	O
cells	O
,	O
such	O
as	O
Protista	O
,	O
or	O
parasites	O
,	O
that	O
preferentially	O
accumulate	O
a	O
photoactivatable	O
porphyrin	O
in	O
which	O
5-aminolevulinic	O
acid	O
or	O
precursor	O
thereof	O
is	O
administered	O
to	O
the	O
patient	O
,	O
or	O
contacted	O
to	O
the	O
exogenous	O
cells	O
,	O
in	O
an	O
amount	O
sufficient	O
to	O
induce	O
synthesis	O
fluorescence	O
and/or	O
photosensitizing	O
concentrations	O
of	O
a	O
protoporphyrin	O
IX	O
in	O
the	O
exogenous	O
cells	O
,	O
followed	O
by	O
exposure	O
of	O
the	O
exogenous	O
cells	O
to	O
light	O
of	O
photoactivating	O
wavelengths	O
.	O

Agent	O
for	O
Preventing	O
/	O
Ameliorating	O
Life	O
Style	O
-	O
Related	O
Diseases	O
Containing	O
Turmeric	O
Essential	O
Oil	O
Component	O
The	O
present	O
invention	O
has	O
its	O
object	O
to	O
provide	O
an	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
substance	O
derived	O
from	O
a	O
safe	O
food	O
material	O
having	O
a	O
long	O
history	O
of	O
being	O
eaten	O
as	O
a	O
food	O
and	O
which	O
is	O
capable	O
of	O
being	O
utilized	O
as	O
functional	O
foods	O
such	O
as	O
health	O
foods	O
or	O
functional	O
health	O
foods	O
(	O
specific	O
health	O
foods	O
,	O
functional	O
nutritive	O
foods	O
)	O
.	O

The	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
according	O
to	O
the	O
invention	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ar	O
-	O
turmerone	O
,	O
α	O
-	O
turmerone	O
,	O
β	O
-	O
turmerone	O
,	O
curlone	O
,	O
bisacumol	O
and	O
β	O
-	O
sesquiphellandrene	O
,	O
or	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
bisabolane	O
type	O
sesquiterpenoids	O
derived	O
from	O
Curcuma	O
longa	O
L.	O
,	O
and	O
therefore	O
is	O
useful	O
for	O
preventing	O
and/or	O
ameliorating	O
diabetes	O
,	O
visceral	O
fat	O
obesity	O
,	O
metabolic	O
syndrome	O
and	O
obesity	O
,	O
among	O
others	O
.	O

Use	O
of	O
Surfactant	O
Preparations	O
for	O
the	O
Treatment	O
of	O
Surgical	O
Adhesions	O
The	O
invention	O
describes	O
the	O
use	O
of	O
surfactant	O
comprising	O
phospholipids	O
and	O
pulmonary	O
surfactant	O
proteins	O
for	O
the	O
treatment	O
of	O
surgical	O
adhesions	O
.	O

Aldos	B
as	O
modifiers	O
of	O
the	O
igf	B
pathway	O
and	O
methods	O
of	O
use	O
Human	B
ALDO	I
genes	I
are	O
identified	O
as	O
modulators	O
of	O
the	O
IGF	B
pathway	O
,	O
and	O
thus	O
are	O
therapeutic	O
targets	O
for	O
disorders	O
associated	O
with	O
defective	O
IGF	B
function	O
.	O

Methods	O
for	O
identifying	O
modulators	O
of	O
IGF	B
,	O
comprising	O
screening	O
for	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ALDO	B
are	O
provided	O
.	O

Systems	O
and	O
methods	O
for	O
delivering	O
drugs	O
A	O
patch	O
pump	O
device	O
generally	O
includes	O
at	O
least	O
one	O
fluid	O
source	O
,	O
a	O
fluid	O
communicator	O
,	O
and	O
an	O
electrochemical	O
actuator	O
.	O

The	O
fluid	O
communicator	O
is	O
in	O
fluid	O
communication	O
with	O
the	O
fluid	O
source	O
.	O

The	O
electrochemical	O
actuator	O
is	O
operative	O
to	O
cause	O
fluid	O
to	O
be	O
delivered	O
from	O
the	O
fluid	O
source	O
into	O
the	O
fluid	O
communicator	O
.	O

Human	B
dnase	I
ii	I
This	O
invention	O
relates	O
to	O
a	O
novel	O
human	O
deoxyribonuclease	O
,	O
referred	O
to	O
as	O
human	B
DNase	I
II	I
.	O

The	O
invention	O
provides	O
nucleic	O
acid	O
sequences	O
encoding	O
human	B
DNase	I
II	I
,	O
thereby	O
enabling	O
the	O
production	O
of	O
human	B
DNase	I
II	I
by	O
recombinant	O
DNA	O
methods	O
in	O
quantities	O
sufficient	O
for	O
clinical	O
use	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
and	O
therapeutic	O
uses	O
of	O
human	B
DNase	I
II	I
.	O

Polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
Polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
are	O
provided	O
.	O

The	O
agents	O
are	O
effective	O
against	O
a	O
variety	O
of	O
pathogens	O
including	O
fungi	O
,	O
Gram	O
positive	O
bacteria	O
and	O
Gram	O
negative	O
bacteria	O
yet	O
are	O
expected	O
to	O
have	O
low	O
human	O
toxicity	O
due	O
in	O
part	O
to	O
their	O
polymeric	O
nature	O
.	O

Applications	O
for	O
the	O
polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
include	O
those	O
involving	O
human	O
and	O
plant	O
contact	O
,	O
such	O
as	O
cosmetics	O
,	O
hair	O
care	O
products	O
,	O
textiles	O
and	O
plant	O
protections	O
,	O
as	O
well	O
as	O
in	O
applications	O
with	O
much	O
less	O
human	O
contact	O
,	O
such	O
as	O
plastics	O
,	O
coatings	O
,	O
wood	O
,	O
paper	O
and	O
other	O
materials	O
of	O
construction	O
.	O

Substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
histamine	O
H4	O
receptor	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
using	O
any	O
of	O
these	O
derivatives	O
and	O
compositions	O
for	O
H4	O
receptor	O
activity	O
modulation	O
and	O
the	O
treatment	O
of	O
states	O
mediated	O
by	O
histamine	O
H4	O
receptor	O
activity	O
.	O

Novel	O
Spiro	O
-	O
benzo	O
[	O
c	O
]	O
chromene	O
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
estrogen	B
receptors	I
The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
spiro	O
-	O
benzo	O
[	O
C	O
]	O
chromene	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
one	O
or	O
more	O
estrogen	B
receptors	I
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
the	O
depletion	O
of	O
estrogen	O
such	O
as	O
hot	O
flashes	O
,	O
vaginal	O
dryness	O
,	O
osteopenia	O
and	O
osteoporosis	O
;	O
hormone	O
sensitive	O
cancers	O
and	O
hyperplasia	O
of	O
the	O
breast	O
,	O
endometrium	O
,	O
cervix	O
and	O
prostate	O
;	O
endometriosis	O
,	O
uterine	O
fibroids	O
,	O
osteoarthritis	O
and	O
as	O
contraceptive	O
agents	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
progestogen	O
or	O
progestogen	O
antagonist	O
.	O

Deuterium	O
-	O
enriched	O
miglustat	O
The	O
present	O
application	O
describes	O
deuterium	O
-	O
enriched	O
miglustat	O
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Substituted	O
N	O
[	O
N-	O
(	O
sulphonylphenyl	O
)	O
sulfonyl	O
-	O
prolyl	O
]	O
-phenylalanine	O
derivatives	O
are	O
antagonists	O
of	O
the	O
very	B
late	I
antigen-4	I
integrin	I
;	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
,	O
asthma	O
,	O
multiple	O
sclerosis	O
,	O
rheumatoid	O
arthritis	O
Substituted	O
N—	O
[	O
N-	O
(	O
sulphonylphenyl	O
)	O
sulfonyl	O
-	O
prolyl	O
]	O
-phenylalanine	O
derivatives	O
of	O
the	O
present	O
invention	O
are	O
antagonists	O
of	O
the	O
VLA-4	B
integrin	I
and	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
VLA-4-binding	B
and	O
cell	O
adhesion	O
and	O
activation	O
.	O

Moreover	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
demonstrate	O
significant	O
receptor	O
occupancy	O
of	O
VLA-4	B
bearing	O
cells	O
after	O
oral	O
administration	O
and	O
are	O
suitable	O
for	O
once-	O
,	O
twice-	O
,	O
or	O
thrice	O
-	O
a	O
-	O
day	O
oral	O
administration	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
such	O
compounds	O
.	O

Dipeptides	O
for	O
Prevention	O
of	O
Muscle	O
Breakdown	O
and	O
Microbial	O
Infection	O
The	O
subject	O
invention	O
provides	O
dipeptides	O
useful	O
in	O
promoting	O
healthy	O
muscle	O
tissues	O
as	O
well	O
as	O
effective	O
immune	O
responses	O
.	O

The	O
dipeptides	O
of	O
the	O
subject	O
invention	O
are	O
particularly	O
advantageous	O
because	O
they	O
are	O
stable	O
,	O
bioavailable	O
,	O
and	O
can	O
be	O
formulated	O
in	O
an	O
aqueous	O
solution	O
.	O

Targeting	O
Prodrugs	O
for	O
the	O
Treatment	O
of	O
Gastrointestinal	O
Diseases	O
Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
decreasing	O
NFκB	B
DNA	O
-	O
binding	O
activity	O
in	O
a	O
patient	O
comprising	O
administering	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
or	O
composition	O
of	O
the	O
application	O
to	O
the	O
patient	O
to	O
reduce	O
,	O
alleviate	O
or	O
treat	O
various	O
gastrointestinal	O
diseases	O
,	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Bifunctional	O
Resorcinol	O
,	O
Thioresorcinol	O
,	O
and	O
Dithioresorcinol	O
Derivative	O
Metal	O
Chelating	O
Conjugates	O
The	O
present	O
invention	O
is	O
directed	O
to	O
metal	O
chelating	O
conjugates	O
for	O
use	O
as	O
metallopharmaceutical	O
diagnostic	O
or	O
therapeutic	O
agents	O
.	O

Specifically	O
,	O
conjugates	O
of	O
the	O
present	O
invention	O
include	O
one	O
or	O
more	O
carriers	O
,	O
a	O
linker	O
,	O
and	O
metal	O
coordinating	O
moiety	O
comprising	O
a	O
resorcinol	O
,	O
thioresorcinol	O
,	O
or	O
dithioresorcinol	O
derivative	O
through	O
which	O
the	O
metal	O
coordinating	O
moiety	O
is	O
bonded	O
to	O
the	O
linker	O
.	O

Triazole	O
derivative	O
or	O
a	O
salt	O
thereof	O
[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
which	O
may	O
be	O
used	O
in	O
treating	O
diseases	O
in	O
which	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
is	O
concerned	O
,	O
especially	O
diabetes	O
and	O
insulin	B
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
was	O
found	O
that	O
a	O
triazole	O
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
which	O
the	O
3-position	O
of	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
and	O
the	O
5-position	O
is	O
substituted	O
with	O
a	O
lower	O
alkyl	O
,	O
cycloalkyl	O
or	O
the	O
like	O
,	O
has	O
a	O
strong	O
11β	B
-	I
HSD1-inhibitory	I
activity	O
.	O

In	O
addition	O
,	O
since	O
the	O
triazole	O
derivative	O
of	O
the	O
present	O
invention	O
shows	O
excellent	O
blood	O
glucose	O
-	O
lowering	O
action	O
,	O
it	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diabetes	O
and	O
insulin	B
resistance	O
.	O

Novel	O
Cyclic	O
Urea	O
Derivatives	O
,	O
Preparation	O
Thereof	O
and	O
Pharmaceutical	O
Use	O

Thereof	O
as	O
Kinase	B
Inhibitors	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Ra	O
,	O
Rb	O
,	O
R	O
,	O
X1	O
and	O
X2	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
processes	O
for	O
making	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
provided	O
.	O

Deuterium	O
-	O
enriched	O
pioglitazone	O
The	O
present	O
application	O
describes	O
deuterium	O
-	O
enriched	O
pioglitazone	O
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

withanolide	O
compounds	O
extracted	O
from	O
a	O
Solanaceae	O
plant	O
as	O
anticancer	O
agents	O
;	O
solvent	O
extraction	O
from	O
Tubocapsicum	O
anomalum	O
A	O
composition	O
for	O
treating	O
cancer	O
cells	O
and	O
a	O
preparation	O
method	O
therefore	O
is	O
provided	O
.	O

The	O
composition	O
includes	O
novel	O
withanolide	O
compounds	O
derived	O
from	O
a	O
Solanaceae	O
plant	O
,	O
which	O
the	O
novel	O
withanolide	O
compounds	O
have	O
the	O
cytotoxicity	O
to	O
the	O
cancer	O
cells	O
.	O

Ginkgolides	O
in	O
the	O
Treatment	O
and	O
Prevention	O
of	O
Ovarian	O
Cancer	O
The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
nutritional	O
supplements	O
that	O
contain	O
large	O
amount	O
of	O
ginkgolides	O
,	O
particularly	O
ginkgolide	O
A	O
or	O
B	O
,	O
and	O
for	O
which	O
,	O
the	O
other	O
components	O
normally	O
found	O
in	O
Ginkgo	O
biloba	O
extracts	O
have	O
been	O
removed	O
.	O

The	O
compositions	O
may	O
be	O
administered	O
to	O
women	O
to	O
prevent	O
or	O
treat	O
ovarian	O
cancer	O
,	O
particularly	O
non	O
-	O
mucinous	O
ovarian	O
cancer	O
.	O

Short	O
interfering	O
rna	O
as	O
an	O
antiviral	O
agent	O
for	O
hepatitis	O
c	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
is	O
a	O
major	O
cause	O
of	O
chronic	O
liver	O
disease	O
and	O
affects	O
over	O
270	O
million	O
individuals	O
worldwide	O
.	O

The	O
HCV	O
genome	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
that	O
functions	O
as	O
both	O
a	O
messenger	O
RNA	O
and	O
replication	O
template	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
the	O
study	O
of	O
RNA	O
interference	O
.	O

Double	O
-	O
stranded	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
designed	O
to	O
target	O
the	O
HCV	O
genome	O
are	O
disclosed	O
herein	O
.	O

20-Alkyl	O
,	O
Gemini	O
Vitamin	O
D3	O
Compounds	O
and	O
Methods	O
of	O
Use	O
Thereof	O
The	O
invention	O
provides	O
20-alkyl	O
Gemini	O
vitamin	O
D3	O
compounds	O
,	O
methods	O
for	O
using	O
the	O
compounds	O
to	O
treat	O
vitamin	O
D3	O
associated	O
states	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
.	O

Methods	O
of	O
Identifying	O
and	O
Treating	O
Individuals	O
Exhibiting	O
MDR-1	B
Overexpression	O
With	O
Protein	B
Tyrosine	I
Kinase	I
Inhibitors	O
and	O
Combinations	O
Thereof	O
The	O
invention	O
described	O
herein	O
relates	O
to	O
diagnostic	O
and	O
treatment	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders	O
,	O
for	O
example	O
cancers	O
,	O
involving	O
cells	O
that	O
overexpress	O
MDR-1	B
,	O
and	O
methods	O
of	O
decreasing	O
the	O
incidence	O
of	O
CNS	O
complications	O
that	O
are	O
often	O
associated	O
with	O
CML	O
patients	O
that	O
have	O
been	O
administered	O
imatinib	O
or	O
other	O
protein	B
tyrosine	I
kinase	I
inhibitors	O
.	O

Compositions	O
and	O
methods	O
of	O
using	O
capsid	B
protein	O
from	O
flaviviruses	O
and	O
pestiviruses	O
This	O
invention	O
provides	O
methods	O
of	O
inducing	O
cell	O
death	O
with	O
Flavivirus	O
or	O
Pestivirus	O
capsid	B
protein	O
,	O
such	O
as	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
capsid	B
protein	O
,	O
and	O
functional	O
fragments	O
thereof	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
patients	O
suffering	O
from	O
diseases	O
characterized	O
by	O
hyperproliferating	O
cells	O
by	O
administering	O
pharmaceutical	O
compositions	O
comprising	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
or	O
a	O
nucleic	O
acid	O
molecule	O
encoding	O
the	O
same	O
.	O

Methods	O
of	O
identifying	O
compounds	O
which	O
have	O
anti	O
-	O
viral	O
and/or	O
anti	O
-	O
WNV	O
and/or	O
anti	O
-	O
Flavivirus	O
and/or	O
anti	O
-	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
activity	O
are	O
disclosed	O
.	O

The	O
invention	O
also	O
provides	O
vaccine	O
compositions	O
comprising	O
capsid	B
or	O
other	O
proteins	O
,	O
or	O
fragments	O
thereof	O
,	O
or	O
nucleic	O
acids	O
encoding	O
same	O
,	O
from	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
invention	O
also	O
provides	O
diagnostic	O
methods	O
and	O
kits	O
for	O
identifying	O
individuals	O
exposed	O
to	O
WNV	O
or	O
other	O
viruses	O
including	O
Flavivirus	O
or	O
Pestivirus	O
.	O

Herbal	O
composition	O
for	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
herbal	O
composition	O
comprising	O
extract	O
of	O
roots	O
of	O
the	O
plant	O
Murraya	O
koenigii	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
,	O
particularly	O
tinea	O
infections	O
,	O
and	O
method	O
of	O
manufacture	O
of	O
said	O
composition	O
.	O

The	O
said	O
herbal	O
composition	O
comprises	O
2-methoxy-3-methyl-9H	O
-	O
carbazole	O
(	O
compound	O
1	O
)	O
as	O
a	O
bioactive	O
ingredient	O
.	O

Invention	O
also	O
discloses	O
methods	O
for	O
topical	O
application	O
of	O
the	O
said	O
herbal	O
composition	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
.	O

VEGF	B
Inhibition	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
VEGF	B
production	O
or	O
secretion	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
associated	O
with	O
abnormal	O
levels	O
of	O
VEGF	B
production	O
or	O
secretion	O
.	O

Medicated	O
sleeve	O
Embodiments	O
of	O
the	O
invention	O
provide	O
a	O
stretchable	O
sleeve	O
having	O
a	O
medicinal	O
section	O
that	O
can	O
be	O
loaded	O
with	O
a	O
medicinal	O
composition	O
and	O
a	O
perforated	O
section	O
comprising	O
a	O
plurality	O
of	O
openings	O
,	O
wherein	O
the	O
medicinal	O
section	O
and	O
the	O
perforated	O
section	O
overlap	O
,	O
and	O
wherein	O
the	O
sleeve	O
is	O
sized	O
so	O
that	O
the	O
interior	O
surface	O
of	O
the	O
medicinal	O
section	O
comfortably	O
fits	O
a	O
body	O
portion	O
and	O
the	O
medicinal	O
section	O
contacts	O
the	O
body	O
portion	O
at	O
the	O
site	O
of	O
pain	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
preparing	O
a	O
sleeve	O
by	O
applying	O
a	O
medicinal	O
composition	O
to	O
the	O
inner	O
surface	O
of	O
the	O
medicinal	O
section	O
through	O
the	O
openings	O
at	O
the	O
perforated	O
section	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
relieving	O
pain	O
in	O
a	O
body	O
portion	O
by	O
pulling	O
the	O
sleeve	O
in	O
an	O
outside	O
-	O
out	O
configuration	O
straight	O
up	O
a	O
body	O
portion	O
without	O
having	O
to	O
roll	O
and	O
flip	O
its	O
exterior	O
surface	O
outside	O
.	O

Non	O
-	O
peptidyl	O
agents	O
with	O
pHSP20-like	O
activity	O
,	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
modulating	O
smooth	O
muscle	O
cells	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
small	O
molecule	O
candidate	O
therapeutic	O
agents	O
for	O
modulating	O
smooth	O
muscle	O
.	O

Methods	O
of	O
treating	O
neurological	O
diseases	O
by	O
regulating	O
migration	O
of	O
neuroblasts	O
in	O
the	O
adult	O
nervous	O
system	O
with	O
tenascin	B
-	I
R	I
This	O
invention	O
provides	O
a	O
method	O
for	O
regulating	O
migration	O
of	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
nervous	O
system	O
of	O
a	O
mammal	O
.	O

The	O
method	O
comprises	O
providing	O
a	O
mammal	O
with	O
TNR	B
,	O
a	O
biologically	O
active	O
fragment	O
of	O
TNR	B
,	O
or	O
a	O
TNR	B
agonist	O
in	O
an	O
amount	O
sufficient	O
to	O
direct	O
migration	O
of	O
the	O
neuronal	O
progenitor	O
cells	O
.	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
neurological	O
diseases	O
by	O
replenishing	O
diseased	O
,	O
damaged	O
,	O
or	O
destroyed	O
neural	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
or	O
in	O
the	O
peripheral	O
nervous	O
system	O
.	O

Methods	O
for	O
Making	O
and	O
Delivering	O
Rho	B
-	O
Antagonist	O
Tissue	O
Adhesive	O
Formulations	O
to	O
the	O
Injured	O
Mammalian	O
Central	O
and	O
Peripheral	O
Nervous	O
Systems	O
and	O
uses	O
Thereof	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
making	O
,	O
delivering	O
and	O
using	O
formulations	O
that	O
combine	O
a	O
therapeutically	O
active	O
agent	O
(	O
s	O
)	O
(	O
such	O
as	O
for	O
example	O
a	O
Rho	B
antagonist	O
(	O
s	O
)	O
)	O
and	O
a	O
flowable	O
carrier	O
component	O
capable	O
of	O
forming	O
a	O
therapeutically	O
acceptable	O
matrix	O
in	O
vivo	O
(	O
such	O
as	O
for	O
example	O
tissue	O
adhesives	O
)	O
,	O
to	O
injured	O
nerves	O
to	O
promote	O
repair	O
and	O
regeneration	O
and	O
regrowth	O
of	O
injured	O
(	O
mammalian	O
)	O
neuronal	O
cells	O
,	O
e.g.	O
for	O
facilitating	O
axon	O
growth	O
at	O
a	O
desired	O
lesion	O
site	O
.	O

Preferred	O
active	O
agents	O
are	O
known	O
Rho	B
antagonists	O
such	O
as	O
for	O
example	O
C3	O
,	O
chimeric	O
C3	O
proteins	O
,	O
etc	O
.	O
or	O
substances	O
selected	O
from	O
among	O
known	O
trans-4-amino	O
(	O
alkyl	O
)	O
-1-pyridylcarbamoylcyclohexane	O
compounds	O
or	O
Rho	B
kinase	I
inhibitors	O
.	O

The	O
system	O
for	O
example	O
may	O
deliver	O
an	O
antagonist	O
(	O
s	O
)	O
in	O
a	O
tissue	O
adhesive	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
fibrin	O
glue	O
or	O
a	O
collagen	B
gel	O
to	O
create	O
a	O
delivery	O
matrix	O
in	O
situ	O
.	O

A	O
kit	O
and	O
methods	O
of	O
stimulating	O
neuronal	O
regeneration	O
are	O
also	O
included	O
.	O

Rate	O
-	O
controlled	O
particles	O
Rate	O
-	O
controlled	O
particles	O
,	O
comprising	O
compounds	O
of	O
the	O
formula	O
as	O
a	O
solid	O
dispersion	O
.	O

Substituted	O
nitrogen	O
-	O
containing	O
heterobicycles	O
,	O
the	O
preparation	O
thereof	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
substituted	O
nitrogen	O
-	O
containing	O
heterobicyclic	O
compounds	O
of	O
general	O
formula	O
wherein	O
B	O
,	O
X1	O
to	O
X3	O
and	O
R1	O
to	O
R5	O
are	O
defined	O
as	O
in	O
claim	O
1	O
,	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
which	O
have	O
valuable	O
properties	O
.	O

The	O
compounds	O
of	O
the	O
above	O
general	O
formula	O
I	O
as	O
well	O
as	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
and	O
their	O
stereoisomers	O
have	O
valuable	O
pharmacological	O
properties	O
,	O
particularly	O
an	O
antithrombotic	O
activity	O
and	O
a	O
factor	B
Xa	I
-	O
inhibiting	O
activity	O
.	O

Nebivolol	O
in	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
sexual	O
dysfunction	O
.	O

The	O
methods	O
include	O
administering	O
an	O
effective	O
amount	O
of	O
nebivolol	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
e.g.	O
a	O
PDE-5	B
inhibitor	O
,	O
such	O
as	O
sildenafil	O
citrate	O
.	O

The	O
methods	O
of	O
the	O
present	O
invention	O
are	O
particularly	O
suited	O
to	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
arousal	O
disorder	O
.	O

Nitrosation	O
-	O
Inducible	O
Inhibitors	O
Biological	O
Macromolecules	O
Biomacromolecules	O
such	O
as	O
proteins	O
are	O
inactivated	O
by	O
hydrophobic	O
ANSA	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
hydrophobic	O
or	O
affinity	O
groups	O
and	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aminoacyl	O
groups	O
and	O
peptidyl	O
groups	O
upon	O
nitrosation	O
.	O

ANSA	O
derivatives	O
can	O
be	O
designed	O
to	O
selectively	O
kill	O
tumor	O
cells	O
and	O
various	O
pathogens	O
,	O
including	O
bacteria	O
,	O
viruses	O
,	O
and	O
fungi	O
.	O

Agents	O
and	O
Methods	O
for	O
Osteogenic	O
Oxysterols	O
Inhibition	O
of	O
Oxidative	O
Stress	O
on	O
Osteogenic	O
Cellular	O
Differentiation	O
The	O
present	O
invention	O
discloses	O
oxygenic	O
oxygenic	O
oxysterols	O
.	O

Also	O
disclosed	O
,	O
agents	O
and	O
methods	O
for	O
protecting	O
,	O
blocking	O
or	O
rescuing	O
marrow	O
stromal	O
cells	O
from	O
the	O
inhibitory	O
effects	O
of	O
oxidative	O
stress	O
on	O
their	O
osteoblastic	O
cellular	O
differentiation	O
.	O

Exemplary	O
agents	O
include	O
oxysterols	O
,	O
rhBMP2	B
,	O
alone	O
or	O
in	O
combination	O
which	O
are	O
demonstrated	O
to	O
specifically	O
combat	O
oxidative	O
stress	O
caused	O
by	O
inflammatory	O
oxidized	O
lipids	O
,	O
such	O
as	O
xanthine	O
/	O
xanthine	O
oxidase	O
and	O
minimally	O
oxidized	O
LDL	O
.	O

The	O
synergistic	O
effects	O
of	O
oxysterols	O
and	O
bone	O
morphogenic	O
proteins	O
are	O
disclosed	O
.	O

Quinoxaline	O
Derivatives	O
as	O
Antitumor	O
Agents	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
screening	O
for	O
binding	O
partners	O
,	O
especially	O
binding	O
partners	O
essential	O
for	O
the	O
biological	O
activity	O
of	O
erastin	O
(	O
e.g.	O
VDACs	O
such	O
as	O
VDAC3	O
)	O
.	O

The	O
invention	O
also	O
provides	O
reagents	O
and	O
methods	O
for	O
effective	O
killing	O
of	O
cancer	O
cells	O
with	O
erastin	O
and	O
related	O
compounds	O
or	O
derivatives	O
.	O

Kinesin	B
inhibitors	O
This	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
shown	O
below	O
.	O

Each	O
variable	O
in	O
formula	O
(	O
I	O
)	O
is	O
defined	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
a	O
kinesin	B
Eg5	I
protein	I
-	O
mediated	O
disorder	O
.	O

Cancer	O
Related	O
Genes	O
(	O
PRLR	B
)	O
This	O
invention	O
is	O
in	O
the	O
field	O
of	O
cancer	O
-	O
associated	O
genes	O
.	O

Specifically	O
it	O
relates	O
to	O
methods	O
for	O
detecting	O
cancer	O
or	O
the	O
likelihood	O
of	O
developing	O
cancer	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
expression	O
of	O
a	O
PRLR	B
gene	O
or	O
protein	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
molecules	O
for	O
upregulating	O
or	O
downregulating	O
PRLR	B
gene	O
expression	O
and	O
PRLR	B
protein	O
activity	O
.	O

Cosmeceutical	O
composition	O
Topical	O
compositions	O
comprising	O
:	O
—a	O
physiologically	O
acceptable	O
alkanediol	O
,	O
ether	O
diol	O
or	O
diether	O
alcohol	O
containing	O
up	O
to	O
(	O
8)	O
carbon	O
atoms	O
;	O
—water	O
;	O
and	O
—	O
optionally	O
an	O
unsaturated	O
fatty	O
alcohol	O
;	O
and	O
optionally	O
further	O
conventional	O
excipients	O
,	O
for	O
use	O
as	O
a	O
cosmeceutical	O
,	O
in	O
particular	O
for	O
use	O
in	O
the	O
repair	O
or	O
maintenance	O
of	O
skin	O
barrier	O
function	O
.	O

They	O
are	O
indicated	O
for	O
use	O
in	O
e.g.	O
moisturizing	O
skin	O
,	O
nail	O
and	O
mucosa	O
and	O
,	O
when	O
an	O
optional	O
pharmaceutically	O
active	O
agent	O
is	O
present	O
,	O
additionally	O
in	O
the	O
treatment	O
of	O
various	O
skin	O
,	O
nail	O
and	O
mucosal	O
diseases	O
.	O

Also	O
disclosed	O
are	O
compositions	O
suitable	O
for	O
topical	O
application	O
to	O
infants	O
and	O
babies	O
for	O
treating	O
dry	O
skin	O
,	O
and	O
soothing	O
skin	O
irritated	O
from	O
diaper	O
rash	O
and	O
scrapes	O
.	O

Drug	O
screening	O
;	O
antagonizing	O
macrophage	B
migration	I
inhibitory	I
factor	I
(	O
MIF	B
)	O
using	O
ibudilast	O
;	O
neuropathic	O
pain	O
;	O
identifying	O
agents	O
useful	O
for	O
opiate	O
withdrawal	O
and	O
for	O
treating	O
other	O
addictions	O
and	O
dependence	O
Methods	O
of	O
antagonizing	O
MIF	B
activity	O
using	O
ibudilast	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
screening	O
for	O
MIF	B
antagonists	O
.	O

These	O
agents	O
can	O
be	O
used	O
for	O
treating	O
addictions	O
,	O
including	O
drug	O
and	O
behavioral	O
addictions	O
,	O
as	O
well	O
as	O
for	O
treating	O
neuropathic	O
pain	O
.	O

High	O
penetration	O
composition	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
uses	O
of	O
novel	O
high	O
penetration	O
compositions	O
or	O
high	O
penetration	O
prodrugs	O
(	O
HPP	O
)	O
,	O
in	O
particular	O
HPPs	O
for	O
4-aminophenol	O
derivatives	O
,	O
which	O
are	O
capable	O
of	O
crossing	O
biological	O
barriers	O
with	O
high	O
penetration	O
efficiency	O
.	O

The	O
HPPs	O
herein	O
are	O
capable	O
of	O
being	O
converted	O
to	O
parent	O
active	O
drugs	O
or	O
drug	O
metabolites	O
after	O
crossing	O
the	O
biological	O
barrier	O
and	O
thus	O
can	O
render	O
treatments	O
for	O
the	O
conditions	O
that	O
the	O
parent	O
drugs	O
or	O
metabolites	O
can	O
.	O

Additionally	O
,	O
due	O
to	O
the	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
,	O
the	O
HPPs	O
herein	O
are	O
capable	O
of	O
reaching	O
areas	O
that	O
parent	O
drugs	O
may	O
not	O
be	O
able	O
to	O
access	O
or	O
to	O
render	O
a	O
sufficient	O
concentration	O
at	O
the	O
target	O
areas	O
and	O
therefore	O
render	O
novel	O
treatments	O
.	O

The	O
HPPs	O
herein	O
can	O
be	O
administered	O
to	O
a	O
subject	O
through	O
various	O
administration	O
routes	O
.	O

For	O
example	O
,	O
the	O
HPPs	O
can	O
be	O
locally	O
delivered	O
to	O
an	O
action	O
site	O
of	O
a	O
condition	O
with	O
a	O
high	O
concentration	O
due	O
to	O
their	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
and	O
thus	O
obviate	O
the	O
need	O
for	O
a	O
systematic	O
administration	O
.	O

For	O
another	O
example	O
,	O
the	O
HPPs	O
herein	O
can	O
be	O
systematically	O
administer	O
to	O
a	O
biological	O
subject	O
and	O
enter	O
the	O
general	O
circulation	O
with	O
a	O
faster	O
rate	O
.	O

Delivery	O
scaffolds	O
and	O
related	O
methods	O
of	O
use	O
The	O
present	O
invention	O
relates	O
to	O
delivery	O
systems	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
microporous	O
scaffolds	O
having	O
thereon	O
agents	O
(	O
e.g.	O
,	O
extracellular	B
matrix	I
proteins	I
,	O
exendin-4	B
)	O
and	O
biological	O
material	O
(	O
e.g.	O
,	O
pancreatic	O
islet	O
cells	O
)	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
for	O
transplanting	O
biological	O
material	O
into	O
a	O
subject	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
type	O
1	O
diabetes	O
)	O
,	O
and	O
related	O
methods	O
(	O
e.g.	O
,	O
diagnostic	O
methods	O
,	O
research	O
methods	O
,	O
drug	O
screening	O
)	O
.	O

N	O
-	O
Pyrrolidin-3-YL	O
-	O
Amide	O
Derivatives	O
As	O
Serotonin	O
and	O
Noradrenalin	O
Re	O
-	O
Uptake	O
Inhibitors	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
and/or	O
veterinarily	O
acceptable	O
derivatives	O
thereof	O
,	O
wherein	O
:	O
R1	O
is	O
H	O
,	O
C1	O
-	O
6alkyl	O
,	O
—C	O
(	O
A	O
)	O
D	O
,	O
C3	O
-	O
8cycloalkyl	O
,	O
aryl	O
,	O
het	O
,	O
aryl	O
-	O
C1	O
-	O
4alkyl	O
or	O
het	O
-	O
C1	O
-	O
4alkyl	O
,	O
wherein	O
the	O
cycloalkyl	O
,	O
aryl	O
or	O
het	O
groups	O
are	O
optionally	O
substituted	O
;	O
A	O
is	O
S	O
or	O
O	O
;	O
D	O
is	O
H	O
,	O
C1	O
-	O
6alkyl	O
,	O
aryl	O
,	O
het	O
,	O
aryl	O
-	O
C1	O
-	O
4alkyl	O
or	O
het	O
-	O
C1	O
-	O
4alkyl	O
;	O
aryl	O
represents	O
phenyl	O
,	O
naphthyl	O
,	O
anthracyl	O
or	O
phenanthryl	O
;	O
het	O
represents	O
an	O
aromatic	O
or	O
non	O
-	O
aromatic	O
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	O
which	O
contains	O
at	O
least	O
one	O
N	O
,	O
O	O
or	O
S	O
heteroatom	O
,	O
optionally	O
fused	O
to	O
a	O
5-	O
or	O
6-membered	O
carbocyclic	O
group	O
or	O
a	O
second	O
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	O
which	O
contains	O
at	O
least	O
one	O
N	O
,	O
O	O
or	O
S	O
heteroatom	O
;	O
R2	O
is	O
aryl1	O
or	O
het1	O
,	O
each	O
optionally	O
substituted	O
;	O
n	O
is	O
1	O
or	O
2	O
,	O
provided	O
that	O
when	O
n	O
is	O
1	O
,	O
m	O
is	O
0	O
or	O
1	O
and	O
when	O
n	O
is	O
2	O
,	O
m	O
is	O
0	O
,	O
wherein	O
if	O
m	O
is	O
0	O
,	O
then	O
*	O
represents	O
a	O
chiral	O
centre	O
;	O
R3	O
is	O
(	O
CH2	O
)	O
aE	O
,	O
wherein	O
a	O
is	O
0	O
,	O
1	O
or	O
2	O
and	O
E	O
is	O
a	O
group	O
selected	O
from	O
:	O
Formula	O
(	O
i	O
)	O
wherein	O
:	O
X	O
is	O
O	O
,	O
S	O
,	O
NR12	O
,	O
(	O
CH2	O
)	O
v	O
or	O
a	O
bond	O
;	O
b	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
c	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
v	O
is	O
1	O
or	O
2	O
;	O
R10	O
and	O
11	O
are	O
each	O
independently	O
H	O
or	O
C1	O
-	O
4	O
alkyl	O
;	O
and	O
R12	O
is	O
H	O
,	O
1	O
-	O
6	O
alkyl	O
,	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
SO2—C1	O
-	O
6alkyl	O
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	O
atoms	O
on	O
adjacent	O
carbon	O
or	O
nitrogen	O
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	O
;	O
Formula	O
(	O
ii	O
)	O
a	O
carbocyclic	O
spiro	O
group	O
containing	O
6	O
to	O
12	O
carbon	O
atoms	O
;	O
Formula	O
(	O
iii	O
)	O
wherein	O
:	O
d	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
a	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
f	O
is	O
1	O
or	O
2	O
;	O
and	O
R30	O
is	O
H	O
or	O
C1	O
-	O
4alkyl	O
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	O
atoms	O
on	O
adjacent	O
carbon	O
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	O
;	O
Formula	O
(	O
iv	O
)	O
wherein	O
:	O
g	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
J	O
is	O
NR40	O
;	O
and	O
R40	O
is	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
S02-C1	O
-	O
6alkyl	O
;	O
Formula	O
(	O
v	O
)	O
wherein	O
:	O
h	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
and	O
R50	O
is	O
H	O
,	O
C1	O
-	O
8alkyl	O
,	O
C1	O
-	O
8alkoxy	O
,	O
OH	O
,	O
halo	O
,	O
CF3	O
,	O
OCF3	O
,	O
SCF3	O
,	O
hydroxy	O
-	O
C1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
-	O
C1	O
-	O
6alkyl	O
and	O
C1	O
-	O
4alkyl	O
-	O
S	O
—	O
C1	O
-	O
4alkyl	O
;	O
Formula	O
(	O
vi	O
)	O
—CH	O
(	O
cyclopropane	O
)	O
2	O
;	O
Formula	O
(	O
vii	O
)	O
C1	O
-	O
6alkyl	O
,	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
;	O
and	O
Formula	O
(	O
viii	O
)	O
C3	O
-	O
8cycloalkyl	O
-	O
C1	O
-	O
6alkyl	O
;	O
wherein	O
the	O
C1	O
-	O
6alkyl	O
moiety	O
is	O
substituted	O
at	O
any	O
point	O
other	O
than	O
at	O
the	O
junction	O
with	O
the	O
C3	O
-	O
8cycloalkyl	O
moiety	O
,	O
by	O
at	O
least	O
one	O
substituent	O
.	O

The	O
compounds	O
exhibit	O
activity	O
as	O
both	O
serotonin	O
and/or	O
noradrenaline	O
re	O
-	O
uptake	O
inhibitors	O
and	O
therefore	O
have	O
utility	O
in	O
a	O
variety	O
of	O
therapeutic	O
areas	O
,	O
for	O
example	O
urinary	O
incontinence	O
.	O

Method	O
for	O
treating	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
other	O
medical	O
diseases	O
by	O
utilizing	O
modified	O
virus	O
virions	O
to	O
insert	O
medications	O
into	O
targeted	O
cells	O
A	O
safer	O
,	O
more	O
effective	O
treatment	O
of	O
many	O
medical	O
diseases	O
may	O
be	O
approached	O
by	O
a	O
method	O
utilizing	O
modified	O
viruses	O
as	O
vehicles	O
to	O
transport	O
medically	O
therapeutic	O
drug	O
molecules	O
to	O
specific	O
cells	O
in	O
the	O
body	O
with	O
the	O
intent	O
to	O
have	O
the	O
drug	O
exert	O
an	O
effect	O
only	O
on	O
those	O
cells	O
to	O
which	O
the	O
modified	O
virus	O
delivers	O
the	O
drug	O
.	O

The	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structures	O
make	O
contact	O
with	O
specific	O
target	O
cells	O
by	O
means	O
of	O
the	O
modified	O
virus	O
's	O
exterior	O
probes	O
or	O
virus	O
-	O
like	O
structures	O
'	O
exterior	O
probes	O
.	O

Once	O
the	O
exterior	O
probes	O
engage	O
a	O
target	O
cell	O
's	O
receptors	O
,	O
the	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structure	O
inserts	O
into	O
the	O
target	O
cell	O
the	O
quantity	O
of	O
medically	O
therapeutic	O
drug	O
molecules	O
it	O
is	O
carrying	O
.	O

By	O
delivering	O
the	O
medically	O
therapeutic	O
drug	O
only	O
to	O
specific	O
cells	O
in	O
the	O
body	O
it	O
is	O
assured	O
the	O
drug	O
reaches	O
the	O
site	O
in	O
the	O
body	O
it	O
will	O
be	O
most	O
beneficial	O
and	O
the	O
occurrence	O
of	O
unwanted	O
side	O
effects	O
due	O
the	O
drug	O
are	O
significantly	O
minimized	O
.	O

2,4-Substituted	O
Quinazolines	O
as	O
Lipid	O
Kinase	B
Inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
which	O
are	O
appropriate	O
for	O
the	O
treatment	O
of	O
kinase	O
,	O
e.g.	O
PI3K	B
-	O
related	O
,	O
diseases	O
,	O
such	O
as	O
proliferative	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
obstructive	O
airways	O
disorders	O
and	O
transplantation	O
related	O
diseases	O
.	O

Concentrated	O
Liquid	O
Thyroid	O
Hormone	O
Composition	O
This	O
invention	O
is	O
directed	O
generally	O
to	O
a	O
liquid	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
thyroid	O
hormone	O
(	O
particularly	O
a	O
composition	O
further	O
comprising	O
at	O
least	O
one	O
cyclodextrin	O
compound	O
)	O
,	O
a	O
process	O
for	O
making	O
such	O
a	O
composition	O
and	O
a	O
method	O
of	O
using	O
such	O
a	O
composition	O
to	O
treat	O
a	O
condition	O
associated	O
with	O
impaired	O
thyroid	O
hormone	O
function	O
.	O

Facial	O
blemish	O
removing	O
device	O
A	O
device	O
and	O
method	O
for	O
removing	O
facial	O
blemishes	O
,	O
including	O
sebum	O
that	O
blocks	O
facial	O
pores	O
.	O

The	O
device	O
includes	O
a	O
substantially	O
flat	O
,	O
elongated	O
and	O
rigid	O
element	O
having	O
a	O
first	O
surface	O
and	O
a	O
second	O
surface	O
,	O
and	O
a	O
distal	O
end	O
and	O
a	O
proximal	O
end	O
.	O

The	O
device	O
also	O
includes	O
a	O
base	O
member	O
to	O
which	O
the	O
rigid	O
element	O
is	O
attached	O
such	O
that	O
a	O
collection	O
area	O
is	O
formed	O
between	O
the	O
second	O
surface	O
of	O
the	O
distal	O
end	O
of	O
the	O
rigid	O
element	O
and	O
a	O
portion	O
of	O
the	O
base	O
member	O
.	O

Use	O
of	O
a	O
lactose	O
-	O
derived	O
c	O
-	O
glycoside	O
compound	O
as	O
an	O
agent	O
for	O
activating	O
and	O
regulating	O
cutaneous	O
immunity	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
lactose	O
-	O
derived	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
to	O
their	O
use	O
as	O
agents	O
for	O
stimulating	O
the	O
immune	O
system	O
of	O
the	O
skin	O
and/or	O
as	O
immunoregulators	O
,	O
and	O
for	O
preparing	O
a	O
composition	O
containing	O
a	O
cosmetically	O
or	O
pharmaceutically	O
acceptable	O
medium	O
,	O
intended	O
in	O
particular	O
to	O
prevent	O
and/or	O
limit	O
the	O
appearance	O
of	O
cutaneous	O
immune	O
imbalances	O
,	O
in	O
particular	O
related	O
to	O
environmental	O
stresses	O
.	O

Substituted	O
heterocycles	O
and	O
their	O
use	O
as	O
chk1	B
,	O
pdk1	B
and	O
pak	B
inhibitors	O
The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
possess	O
CHK1	B
kinase	O
inhibitory	O
activity	O
,	O
PDK1	B
inhibitory	O
activity	O
and	O
Pak	B
kinase	I
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
cancer	O
.	O

M3	B
Muscarinic	I
Acetylcholine	I
Receptor	I
Antagonists	O
Muscarinic	B
Acetylcholine	I
receptor	I
antagonists	O
and	O
methods	O
of	O
using	O
them	O
are	O
provided	O
.	O

Compositions	O
and	O
Their	O
Uses	O
Directed	O
to	O
IL-4R	O
Alpha	O
Disclosed	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
IL-4R	O
alpha	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
animal	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
target	O
validation	O
.	O

Also	O
provided	O
are	O
uses	O
of	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
expression	O
of	O
IL	O
4R	O
-	O
α	O
,	O
airway	O
hyperresponsiveness	O
,	O
and/or	O
pulmonary	O
inflammation	O
.	O

33	O
Human	O
Secreted	O
Proteins	O
The	O
present	O
invention	O
relates	O
to	O
33	O
novel	O
human	O
secreted	O
proteins	O
and	O
isolated	O
nucleic	O
acids	O
containing	O
the	O
coding	O
regions	O
of	O
the	O
genes	O
encoding	O
such	O
proteins	O
.	O

Also	O
provided	O
are	O
vectors	O
,	O
host	O
cells	O
,	O
antibodies	O
,	O
and	O
recombinant	O
methods	O
for	O
producing	O
human	O
secreted	O
proteins	O
.	O

The	O
invention	O
further	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
useful	O
for	O
diagnosing	O
and	O
treating	O
diseases	O
,	O
disorders	O
,	O
and/or	O
conditions	O
related	O
to	O
these	O
novel	O
human	O
secreted	O
proteins	O
.	O

Controlled	O
Release	O
Complex	O
Formulation	O
For	O
Oral	O
Administration	O
of	O
Medicine	O
For	O
Diabetes	O
and	O
Method	O
For	O
The	O
Preparation	O
Thereof	O
A	O
controlled	O
release	O
combination	O
formulation	O
for	O
oral	O
administration	O
comprising	O
a	O
)	O
a	O
controlled	O
release	O
portion	O
containing	O
metformin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
combination	O
of	O
a	O
polyethylene	O
oxide	O
and	O
a	O
natural	O
gum	O
as	O
a	O
carrier	O
for	O
controlled	O
release	O
;	O
and	O
b	O
)	O
a	O
rapid	O
-	O
release	O
portion	O
containing	O
a	O
sulfonylurea	O
-	O
based	O
medicine	O
for	O
treating	O
diabetes	O
as	O
an	O
active	O
ingredient	O
coated	O
on	O
the	O
controlled	O
release	O
portion	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
for	O
it	O
is	O
capable	O
of	O
maintaining	O
an	O
effective	O
concentration	O
of	O
the	O
medicines	O
in	O
blood	O
at	O
a	O
constant	O
level	O
.	O

Perfluorocarbon	O
conjugate	O
as	O
a	O
blood	O
substitute	O
There	O
are	O
provided	O
disclosures	O
relating	O
to	O
a	O
conjugate	O
of	O
a	O
perfluorocarbon	O
compound	O
and	O
a	O
cationic	O
polymer	O
wherein	O
the	O
conjugate	O
is	O
a	O
blood	O
substitute	O
.	O

Hpv-18-based	O
papillomavirus	O
vaccines	O
Compositions	O
containing	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-18	O
or	O
a	O
nucleic	O
acid	O
encoding	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
HPV-18	O
are	O
useful	O
for	O
preventing	O
or	O
treating	O
an	O
infection	O
or	O
a	O
pathological	O
condition	O
caused	O
by	O
at	O
least	O
one	O
papillomavirus	O
other	O
than	O
HPV-18	O
;	O
the	O
subject	O
compositions	O
are	O
of	O
very	O
special	O
interest	O
in	O
immunotherapy	O
,	O
in	O
particular	O
for	O
preventing	O
or	O
treating	O
HPV	O
persistent	O
infections	O
that	O
might	O
promote	O
cervical	O
intraepithelial	O
neoplasia	O
(	O
CIN	O
)	O
and	O
ultimately	O
cervical	O
cancer	O
.	O

Drug	O
for	O
treating	O
gastric	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
interleukin-17	B
inhibitor	O
and/or	O
of	O
at	O
least	O
one	O
IL-17	B
receptor	I
inhibitor	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting	O
,	O
preventing	O
or	O
treating	O
gastric	O
cancer	O
.	O

Cyclodextrin	O
conjugates	O
It	O
has	O
been	O
discovered	O
that	O
the	O
uptake	O
of	O
anionic	O
charged	O
species	O
into	O
cells	O
can	O
be	O
enhanced	O
by	O
noncovalently	O
associating	O
such	O
species	O
with	O
specifically	O
modified	O
forms	O
of	O
cyclodextrin	O
.	O

The	O
invention	O
modified	O
forms	O
of	O
cyclodextrin	O
form	O
well	O
defined	O
stoichiometric	O
complexes	O
with	O
anionic	O
charged	O
molecules	O
.	O

This	O
discovery	O
enables	O
one	O
to	O
produce	O
various	O
compositions	O
containing	O
anionic	O
charged	O
molecules	O
and	O
facilitates	O
methods	O
for	O
enhancing	O
the	O
cellular	O
uptake	O
of	O
double	O
-	O
stranded	O
or	O
hairpin	O
nucleic	O
acid	O
.	O

Substituted	O
2-amino	O
-	O
fused	O
heterocyclic	O
compounds	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
Z1	O
,	O
t	O
,	O
and	O
ring	O
A	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
JNK	B
,	O
such	O
as	O
diabetes	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O

Indazoles	O
Used	O
To	O
Treat	O
Estrogen	B
Receptor	I
Beta	I
Mediated	O
Disorders	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
indazole	O
derivatives	O
having	O
pharmacological	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
estrogen	B
receptor	I
beta	I
mediated	O
diseases	O
.	O

Site	O
-	O
specific	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
n	O
-	O
termini	O
,	O
enabling	O
the	O
formation	O
of	O
homogeneous	O
adducts	O
Site	O
-	O
specific	O
modifications	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
are	O
provided	O
.	O

In	O
particular	O
,	O
a	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
via	O
a	O
transamination	O
reaction	O
to	O
form	O
homogeneous	O
adducts	O
such	O
as	O
,	O
the	O
corresponding	O
oxime	O
derivatives	O
is	O
provided	O
.	O

Methods	O
of	O
making	O
and	O
using	O
the	O
adducts	O
in	O
radio	O
-	O
labelling	O
,	O
molecular	O
imaging	O
applications	O
,	O
and	O
treatment	O
of	O
disorders	O
such	O
as	O
cancer	O
,	O
Crohn	O
's	O
disease	O
,	O
arthritis	O
,	O
atherothrombosis	O
and	O
plaque	O
rupture	O
are	O
also	O
provided	O
.	O

Early	O
intervention	O
of	O
viral	O
infection	O
with	O
immune	O
activators	O
Symptoms	O
of	O
viral	O
infection	O
are	O
mitigated	O
by	O
administering	O
to	O
a	O
subject	O
exposed	O
to	O
a	O
virus	O
a	O
protective	O
or	O
symptom	O
-	O
mitigating	O
amount	O
of	O
a	O
dsRNA	O
and	O
continuing	O
administration	O
until	O
the	O
subject	O
's	O
symptoms	O
have	O
improved	O
.	O

Antibiotic	O
synergism	O
The	O
present	O
invention	O
relates	O
to	O
antibiotic	O
synergism	O
of	O
pharmaceutical	O
compositions	O
comprising	O
a	O
defensin	O
and	O
a	O
beta	O
-	O
lactam	O
antibiotic	O
.	O

Directional	O
use	O
The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
oral	O
administration	O
of	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
to	O
a	O
subject	O
for	O
improved	O
absorption	O
into	O
the	O
subject	O
's	O
bloodstream	O
includes	O
the	O
steps	O
of	O
providing	O
a	O
delivery	O
device	O
containing	O
the	O
liquid	O
and	O
having	O
a	O
mouthpiece	O
for	O
directing	O
the	O
liquid	O
in	O
a	O
defined	O
direction	O
during	O
delivery	O
;	O
directing	O
the	O
mouthpiece	O
toward	O
a	O
localized	O
area	O
of	O
the	O
subject	O
's	O
mouth	O
being	O
especially	O
suitable	O
for	O
increased	O
uptake	O
and	O
faster	O
onset	O
of	O
action	O
of	O
the	O
active	O
substance	O
relative	O
to	O
other	O
areas	O
of	O
and/or	O
the	O
whole	O
mouth	O
;	O
and	O
delivering	O
a	O
measured	O
amount	O
of	O
the	O
liquid	O
directly	O
to	O
the	O
localized	O
area	O
using	O
the	O
delivery	O
device	O
,	O
and	O
a	O
spray	O
device	O
for	O
administering	O
an	O
active	O
substance	O
to	O
the	O
oral	O
cavity	O
of	O
a	O
subject	O
that	O
includes	O
a	O
container	O
capable	O
of	O
holding	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
,	O
and	O
a	O
mouthpiece	O
being	O
constructed	O
to	O
dispense	O
the	O
liquid	O
containing	O
the	O
substance	O
in	O
a	O
defined	O
direction	O
and	O
directly	O
to	O
a	O
localized	O
area	O
of	O
a	O
subject	O
's	O
mouth	O
,	O
the	O
localized	O
area	O
being	O
the	O
oral	O
vestibule	O
.	O

Cyclopropane	O
amides	O
and	O
analogs	O
exhibiting	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
proliferative	O
activities	O
Compounds	O
of	O
the	O
present	O
invention	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
mammalian	O
cancers	O
and	O
especially	O
human	O
cancers	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
malignant	O
melanomas	O
,	O
solid	O
tumors	O
,	O
glioblastomas	O
,	O
ovarian	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
prostate	O
cancer	O
,	O
lung	O
cancers	O
,	O
breast	O
cancers	O
,	O
kidney	O
cancers	O
,	O
hepatic	O
cancers	O
,	O
cervical	O
carcinomas	O
,	O
metastasis	O
of	O
primary	O
tumor	O
sites	O
,	O
myeloproliferative	O
diseases	O
,	O
chronic	O
myelogenous	O
leukemia	O
,	O
leukemias	O
,	O
papillary	O
thyroid	O
carcinoma	O
,	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
mesothelioma	O
,	O
hypereosinophilic	O
syndrome	O
,	O
gastrointestinal	O
stromal	O
tumors	O
,	O
colonic	O
cancers	O
,	O
ocular	O
diseases	O
characterized	O
by	O
hyperproliferation	O
leading	O
to	O
blindness	O
including	O
various	O
retinopathies	O
,	O
diabetic	O
retinopathy	O
,	O
rheumatoid	O
arthritis	O
,	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
mastocytosis	O
,	O
mast	O
cell	O
leukemia	O
,	O
and	O
diseases	O
caused	O
by	O
PDGFR	B
-	I
α	I
kinase	O
,	O
PDGFR	B
-	I
β	I
kinase	O
,	O
c	B
-	I
KIT	I
kinase	O
,	O
cFMS	B
kinase	O
,	O
c	B
-	I
MET	I
kinase	O
,	O
and	O
oncogenic	O
forms	O
,	O
aberrant	O
fusion	O
proteins	O
and	O
polymorphs	O
of	O
any	O
of	O
the	O
foregoing	O
kinases	O
.	O

Sustained	O
release	O
formulation	O
of	O
melatonin	O
The	O
present	O
invention	O
relates	O
to	O
low	O
-	O
dose	O
formulations	O
of	O
melatonin	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
which	O
provide	O
a	O
sustained	O
release	O
of	O
melatonin	O
so	O
as	O
to	O
rapidly	O
increase	O
plasma	O
levels	O
of	O
melatonin	O
,	O
maintain	O
a	O
relatively	O
high	O
level	O
(	O
which	O
mimics	O
the	O
endogenous	O
level	O
of	O
a	O
young	O
subject	O
)	O
for	O
approximately	O
5	O
-	O
6	O
hours	O
,	O
and	O
then	O
decrease	O
so	O
as	O
to	O
achieve	O
low	O
levels	O
by	O
early	O
morning	O
(	O
rapid	O
washout	O
)	O
,	O
thereby	O
avoiding	O
a	O
""""	O
hangover	O
effect	O
""""	O
.	O

The	O
sustained	O
release	O
formulations	O
of	O
the	O
invention	O
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
sleep	O
-	O
related	O
disorders	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
delayed	O
onset	O
and	O
maintenance	O
forms	O
of	O
insomnia	O
.	O

Iodo	O
-	O
Hexose	O
Compounds	O
Useful	O
to	O
Treat	O
Cancer	O
Methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
are	O
provided	O
by	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
iodo	O
-	O
hexose	O
compound	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

The	O
subject	O
disclosure	O
includes	O
methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
comprising	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
hexose	O
compound	O
including	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
mannose	O
,	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
glucose	O
,	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
galactose	O
,	O
and/or	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
talose	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Novel	O
polymorphous	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	O
-	O
n-	O
(	O
{	O
(	O
5s	O
)	O
-2-oxo-3	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
(	O
-phenyl	O
]	O
-1,3-oxazolidine-5-yl	O
}	O
-methyl	O
)	O
-2-thiophene	O
carboxamide	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
polymorphic	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	O
-	O
N-	O
(	O
{	O
(	O
5S	O
)	O
-2-oxo-3-	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
)	O
-phenyl	O
]	O
-1,3-oxazolidin-5-yl	O
}	O
-methyl	O
)	O
-2-thiophene	O
-	O
carboxamide	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
medicaments	O
comprising	O
these	O
forms	O
,	O
and	O
their	O
use	O
in	O
the	O
control	O
of	O
diseases	O
.	O

Assays	O
For	O
Detecting	O
Inhibitors	O
Of	O
Binding	O
Between	O
COX-2	B
And	O
PDZ	B
Proteins	I

The	O
invention	O
provides	O
an	O
assay	O
for	O
determining	O
whether	O
a	O
test	O
agent	O
is	O
a	O
COX	B
modulator	O
.	O

In	O
general	O
terms	O
,	O
the	O
assay	O
includes	O
:	O
determining	O
whether	O
a	O
test	O
agent	O
modulates	O
binding	O
of	O
a	O
PDZ	B
-	I
containing	I
polypeptide	I
to	O
a	O
COX	B
PL	I
-	I
containing	I
polypeptide	I
.	O

The	O
PDZ	B
-	I
containing	I
polypeptide	I
may	O
contain	O
the	O
PDZ	B
domain	I
of	O
PDZ	B
domain	I
of	O
MAGI1	B
,	O
TIP-1	B
,	O
MAST2	B
,	O
PSD95	B
,	O
or	O
SHANK	B
.	O

The	O
assays	O
may	O
be	O
done	O
in	O
a	O
cell	O
-	O
free	O
environment	O
or	O
in	O
a	O
cellular	O
environment	O
,	O
particularly	O
using	O
a	O
neuronal	O
cell	O
.	O

The	O
invention	O
finds	O
use	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
treating	O
cancer	O
,	O
pain	O
,	O
inflammation	O
and	O
neuronal	O
conditions	O
caused	O
by	O
acute	O
insult	O
,	O
e.g.	O
,	O
stroke	O
.	O

Methods	O
for	O
detecting	O
and	O
modulating	O
the	O
sensitivity	O
of	O
tumor	O
cells	O
to	O
anti	O
-	O
mitotic	O
agents	O
and	O
for	O
modulating	O
turmorgenicity	O
Provided	O
herein	O
is	O
a	O
method	O
of	O
screening	O
a	O
tumour	O
cell	O
for	O
resistance	O
to	O
a	O
tubulin	B
-	O
binding	O
agent	O
,	O
the	O
method	O
comprising	O
detecting	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B
II	I
,	I
class	I
III	I
and	I
class	I
IVb	I
β	I
-	I
tubulin	I
by	O
the	O
tumour	O
cell	O
,	O
wherein	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B
II	I
,	I
class	I
III	I
and	I
class	I
IVb	I
β	I
-	I
tubulin	I
indicates	O
that	O
the	O
tumour	O
cell	O
has	O
resistance	O
or	O
potential	O
resistance	O
to	O
the	O
tubulin	B
-	O
binding	O
agent	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
modulating	O
the	O
sensitivity	O
of	O
a	O
tumour	O
cell	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
modulating	O
the	O
tumorigenesis	O
of	O
a	O
tumour	O
cell	O
.	O

Extracellular	O
matrix	O
/	O
metastasis	O
modifier	O
genes	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
growth	O
of	O
tumor	O
and	O
for	O
characterization	O
of	O
tumor	O
Disclosed	O
are	O
methods	O
involving	O
the	O
administration	O
of	O
an	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
metastasis	O
modifier	O
gene	O
,	O
e.g.	O
,	O
Anakin	B
,	O
Necdin	B
,	O
CentaurinD3	B
(	O
CentD3	B
)	O
,	O
Csf1r	B
,	O
Brd4	B
,	O
Pi16	B
,	O
and	O
Luc7l	B
,	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
of	O
tumor	O
growth	O
.	O

Further	O
disclosed	O
are	O
methods	O
of	O
characterizing	O
a	O
tumor	O
or	O
cancer	O
in	O
a	O
subject	O
comprising	O
detecting	O
(	O
i	O
)	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	B
gene	O
of	O
the	O
subject	O
,	O
(	O
ii	O
)	O
an	O
amino	O
acid	O
substitution	O
in	O
an	O
Anakin	O
protein	O
in	O
the	O
subject	O
,	O
or	O
(	O
iii	O
)	O
a	O
level	O
of	O
expression	O
of	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	B
gene	O
in	O
the	O
subject	O
.	O

Methods	O
of	O
screening	O
a	O
compound	O
for	O
anti	O
-	O
cancer	O
activity	O
and	O
use	O
of	O
a	O
compound	O
with	O
anti	O
-	O
cancer	O
activity	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
to	O
treat	O
or	O
prevent	O
cancer	O
in	O
a	O
subject	O
are	O
also	O
disclosed	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Sipa-1	B
in	O
a	O
subject	O
.	O

Composition	O
comprising	O
egg	O
white	O
-	O
chalcanthite	O
for	O
preventing	O
or	O
treating	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
an	O
egg	O
white	O
-	O
chalcanthite	O
component	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
and	O
more	O
particularly	O
,	O
to	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
which	O
comprises	O
egg	O
white	O
-	O
chalcanthite	O
prepared	O
by	O
mixing	O
a	O
roasted	O
chalcanthite	O
with	O
egg	O
white	O
to	O
reduce	O
the	O
toxicity	O
of	O
the	O
chalcanthite	O
or	O
comprises	O
a	O
mixture	O
of	O
the	O
egg	O
white	O
-	O
chalcanthite	O
and	O
a	O
bamboo	O
salt	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
composition	O
comprising	O
the	O
egg	O
white	O
-	O
chalcanthite	O
exhibits	O
excellent	O
anti	O
-	O
cancer	O
activity	O
,	O
and	O
thus	O
is	O
usefully	O
applicable	O
to	O
pharmaceutical	O
preparations	O
for	O
preventing	O
or	O
treating	O
cancer	O
or	O
the	O
manufacture	O
of	O
health	O
functional	O
foods	O
.	O

Use	O
of	O
spiro	O
-	O
oxindole	O
compounds	O
as	O
therapeutic	O
agents	O
This	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
using	O
spiro	O
-	O
oxindole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
k	O
,	O
j	O
,	O
Q	O
,	O
R1	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R2d	O
,	O
R3a	O
,	O
R3b	O
,	O
R3c	O
,	O
and	O
R3d	O
are	O
as	O
defined	O
herein	O
,	O
as	O
a	O
stereoisomer	O
,	O
enantiomer	O
,	O
tautomer	O
thereof	O
or	O
mixtures	O
thereof	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
hypercholesterolemia	O
,	O
benign	O
prostatic	O
hyperplasia	O
,	O
pruritis	O
and	O
cancer	O
.	O

Treating	O
post	O
-	O
seizure	O
patients	O
Patients	O
are	O
subject	O
to	O
a	O
post	O
-	O
seizure	O
treatment	O
regime	O
to	O
separately	O
inhibitor	O
consecutive	O
targets	O
of	O
an	O
epileptogenic	O
cascade	O
comprising	O
neurotransmitter	B
receptor	I
signaling	O
,	O
kinase	B
/	O
phosphatase	B
activity	O
,	O
protein	O
translation	O
,	O
and	O
apoptosis	O
or	O
inflammation	O
.	O

Treatment	O
of	O
Statin	O
Side	O
Effects	O
Using	O
Uridine	O
Derivatives	O
The	O
invention	O
relates	O
generally	O
to	O
treatment	O
of	O
muscle	O
pain	O
and/or	O
fatigue	O
and	O
to	O
methods	O
of	O
treatment	O
of	O
side	O
effects	O
of	O
statin	O
therapy	O
which	O
involve	O
the	O
administration	O
of	O
uridine	O
,	O
biological	O
precursors	O
or	O
derivatives	O
or	O
uridine	O
or	O
salts	O
,	O
esters	O
,	O
tautomers	O
or	O
analogues	O
thereof	O
,	O
which	O
are	O
collectively	O
referred	O
to	O
as	O
uridine	O
related	O
compounds	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
compositions	O
,	O
uses	O
and	O
combination	O
packs	O
or	O
kits	O
related	O
to	O
the	O
treatment	O
method	O
.	O

Protein	O
Kinase	B
Inhibitors	O
and	O
Methods	O
for	O
Using	O
Thereof	O
The	O
invention	O
provides	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
protein	O
kinase	O
inhibitors	O
,	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	O
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	O
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
Alk	B
,	O
Abl	B
,	O
Aurora	B
-	I
A	I
,	O
B	B
-	I
Raf	I
,	O
C	B
-	I
Raf	I
,	O
Bcr	B
-	O
Abl	B
,	O
BRK	B
,	O
Blk	B
,	O
Bmx	B
,	O
BTK	B
,	O
C	B
-	I
Kit	I
,	O
CSK	B
,	O
C	B
-	I
Src	I
,	O
EphB1	B
,	O
EphB2	B
,	O
EphB4	B
,	O
FLT1	B
,	O
Fms	B
,	O
Flt3	B
,	O
Fyn	B
,	O
FRK3	B
,	O
JAK2	B
,	O
KDR	B
,	O
Lck	B
,	O
Lyn	B
,	O
PDGFRα	B
,	O
PDGFRβ	B
,	O
PKCα	B
,	O
SAPK2α	B
,	O
Src	B
,	O
SIK	B
,	O
Syk	B
,	O
Tie2	B
and	O
TrkB	B
kinases	O
.	O

Preservative	O
-	O
free	O
prostaglandin	O
-	O
based	O
ophthalmic	O
solution	O
The	O
present	O
invention	O
provides	O
an	O
ophthalmic	O
solution	O
without	O
an	O
antimicrobial	O
preservative	O
.	O

The	O
solution	O
includes	O
as	O
an	O
active	O
substance	O
at	O
least	O
one	O
prostaglandin	O
and	O
as	O
a	O
solubilizing	O
agent	O
,	O
a	O
surfactant	O
,	O
where	O
the	O
solubilizing	O
agent	O
is	O
polyoxyl-15-hydroxystearate	O
.	O

Methods	O
of	O
Preventing	O
the	O
Serotonin	O
Syndrome	O
and	O
Compositions	O
for	O
Use	O
Therefor	O
The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	O
syndrome	O
.	O

The	O
present	O
invention	O
is	O
directed	O
at	O
a	O
method	O
of	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	O
syndrome	O
in	O
humans	O
which	O
comprises	O
administering	O
proserotonergic	O
agents	O
and	O
serotonin	O
surge	O
protectors	O
,	O
wherein	O
said	O
concurrent	O
administration	O
reduces	O
or	O
prevents	O
serotonin	O
excess	O
,	O
which	O
is	O
the	O
cause	O
of	O
the	O
serotonin	O
syndrome	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
proserotonergic	O
agents	O
and	O
serotonin	O
surge	O
protectors	O
useful	O
for	O
carrying	O
out	O
the	O
method	O
of	O
the	O
present	O
invention	O
.	O

Small	O
molecules	O
to	O
induce	O
weight	O
loss	O
or	O
to	O
reduce	O
weight	O
gain	O
Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	O
trialkyl	O
ammonium	O
-	O
containing	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
alkaline	B
phosphatase	I
or	O
other	O
weight	O
loss	O
-	O
inducing	O
drugs	O
or	O
methods	O
to	O
reduce	O
or	O
reverse	O
excess	O
weight	O
gain	O
and	O
obesity	O
as	O
well	O
as	O
reduce	O
the	O
risk	O
of	O
development	O
and	O
help	O
treatment	O
of	O
diseases	O
and	O
unhealthy	O
conditions	O
related	O
to	O
overweight	O
and	O
obesity	O
.	O

Immunostimulatory	O
activity	O
of	O
palindromic	O
immune	O
modulatory	O
oligonucleotides	O
(	O
imo	O
)	O
containing	O
different	O
lengths	O
of	O
palindromic	O
segments	O
The	O
invention	O
provides	O
a	O
palindromic	O
immune	O
modulatory	O
nucleic	O
acid	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
generating	O
,	O
enhancing	O
and	O
modifying	O
the	O
immune	O
response	O
caused	O
by	O
palindromic	O
immune	O
modulatory	O
compounds	O
used	O
for	O
immunotherapy	O
applications	O

Method	O
for	O
treating	O
onychoschizia	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
containing	O
a	O
combination	O
of	O
a	O
herb	O
from	O
the	O
genus	O
Equisetum	O
together	O
with	O
one	O
film	O
forming	O
agent	O
and	O
its	O
use	O
as	O
a	O
nail	O
topical	O
formulation	O
,	O
like	O
nail	O
varnish	O
,	O
cream	O
,	O
gel	O
,	O
lotion	O
or	O
foam	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
the	O
use	O
of	O
a	O
water	O
soluble	O
film	O
forming	O
agent	O
as	O
an	O
additive	O
in	O
a	O
nail	O
topical	O
formulation	O
.	O

These	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
specific	O
alterations	O
of	O
the	O
ungual	O
structure	O
,	O
with	O
onychoschizia	O
which	O
is	O
a	O
specific	O
alteration	O
of	O
the	O
ungual	O
structure	O
,	O
characterized	O
by	O
lamellar	O
splitting	O
of	O
the	O
nail	O
plate	O
.	O

Warming	O
vapor	O
pad	O
A	O
warming	O
vapor	O
pad	O
to	O
treat	O
respiratory	O
syncytial	O
virus	O
infections	O
in	O
babies	O
,	O
children	O
and	O
adults	O
includes	O
a	O
fabric	O
impregnated	O
with	O
a	O
topical	O
ointment	O
providing	O
medicated	O
vapors	O
to	O
relieve	O
a	O
user	O
's	O
cough	O
,	O
with	O
the	O
fabric	O
being	O
superimposed	O
on	O
an	O
elastic	O
thermal	O
wrap	O
for	O
application	O
as	O
a	O
single	O
layer	O
on	O
the	O
user	O
's	O
chest	O
.	O

Method	O
of	O
inhibiting	O
alveolar	O
bone	O
resorption	O
and	O
periodontal	O
membrane	O
loss	O
and	O
composition	O
for	O
internal	O
use	O
to	O
be	O
used	O
therein	O
Alveolar	O
bone	O
resorption	O
,	O
periodontal	O
membrane	O
loss	O
,	O
and	O
gingival	O
recession	O
can	O
be	O
inhibited	O
by	O
administering	O
500	O
mg	O
to	O
2000	O
mg	O
per	O
day	O
of	O
calcium	O
,	O
10	O
mg	O
to	O
40	O
mg	O
per	O
day	O
of	O
soy	O
isoflavone	O
aglycone	O
,	O
and	O
vitamin	O
D3	O
to	O
persons	O
having	O
a	O
tendency	O
for	O
decreased	O
bone	O
density	O
,	O
postmenopausal	O
women	O
,	O
and	O
periodontal	O
disease	O
patients	O
in	O
a	O
maintenance	O
phase	O
;	O
and	O
even	O
an	O
extended	O
period	O
of	O
administration	O
provides	O
a	O
high	O
degree	O
of	O
safety	O
.	O

Amide	O
Compounds	O
Useful	O
in	O
Therapy	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
,	O
R1	O
and	O
R2	O
each	O
independently	O
represent	O
H	O
,	O
halogen	O
,	O
CF3	O
,	O
C1	O
-	O
3	O
alkyl	O
or	O
C1	O
-	O
3	O
alkoxy	O
;	O
R3	O
represents	O
C1	O
-	O
6	O
alkyl	O
,	O
C3	O
-	O
6	O
cycloalkyl	O
,	O
phenyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Ra	O
)	O
or	O
Het	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	O
,	O
oxo	O
,	O
or	O
C1	O
-	O
4	O
alkyl	O
)	O
;	O
R4	O
represents	O
H	O
or	O
C1	O
-	O
3	O
alkyl	O
;	O
R5	O
represents	O
C1	O
-	O
6	O
alkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rb	O
)	O
,	O
C3	O
-	O
6	O
cycloalkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
oxo	O
or	O
OH	O
)	O
,	O
or	O
Het2	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rd	O
)	O
;	O
oxygen	O
atom	O
or	O
1	O
sulphur	O
atom	O
,	O
or	O
(	O
c	O
)	O
1	O
oxygen	O
atom	O
or	O
1	O
sulphur	O
atom	O
,	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	O
,	O
oxo	O
or	O
C1	O
-	O
4	O
alkyl	O
)	O
;	O
and	O
R6	O
represents	O
C1	O
-	O
3	O
alkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rf	O
)	O
,	O
C3	O
-	O
5	O
cycloalkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
halogen	O
)	O
,	O
CN	O
or	O
halogen	O
;	O
where	O
Rf	O
represents	O
halogen	O
or	O
phenyl	O
:	O
and	O
compositions	O
,	O
processes	O
for	O
the	O
preparation	O
,	O
and	O
uses	O
thereof	O
,	O
e.g.	O
in	O
the	O
treatment	O
of	O
endometriosis	O
or	O
uterine	O
fibroids	O

Substituted	O
Heteroarylpiperidine	O
Derivatives	O
As	O
Melanocortin-4	O
Receptor	O
Modulators	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
heteroarylpiperidine	O
derivatives	O
as	O
melanocortin-4	O
receptor	O
modulators	O
.	O

Depending	O
on	O
the	O
structure	O
and	O
the	O
stereochemistry	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
either	O
selective	O
agonists	O
or	O
selective	O
antagonists	O
of	O
the	O
human	O
melanocortin-4	O
receptor	O
(	O
MC-4R	O
)	O
.	O

The	O
agonists	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
obesity	O
,	O
diabetes	O
and	O
sexual	O
dysfunction	O
,	O
whereas	O
the	O
antagonists	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
cancer	O
cachexia	O
,	O
muscle	O
wasting	O
,	O
anorexia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
anxiety	O
and	O
depression	O
.	O

Generally	O
all	O
diseases	O
and	O
disorders	O
where	O
the	O
regulation	O
of	O
the	O
MC-4R	O
is	O
involved	O
can	O
be	O
treated	O
with	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Azole	O
derivatives	O
and	O
fused	O
bicyclic	O
azole	O
derivatives	O
as	O
therapeutic	O
agents	O
This	O
invention	O
provides	O
certain	O
compounds	O
,	O
methods	O
of	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
their	O
use	O
in	O
treating	O
human	O
or	O
animal	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
as	O
modulators	O
of	O
the	O
interaction	O
between	O
the	O
receptor	O
for	O
advanced	O
glycated	O
end	O
products	O
(	O
RAGE	O
)	O
and	O
its	O
ligands	O
,	O
such	O
as	O
advanced	O
glycated	O
end	O
products	O
(	O
AGEs	O
)	O
,	O
S100	O
/	O
calgranulin	O
/	O
EN	O
-	O
RAGE	O
,	O
β	O
-	O
amyloid	O
and	O
amphoterin	O
,	O
and	O
for	O
the	O
management	O
,	O
treatment	O
,	O
control	O
,	O
or	O
as	O
an	O
adjunct	O
treatment	O
for	O
diseases	O
in	O
humans	O
caused	O
by	O
RAGE	O
.	O

Such	O
diseases	O
or	O
disease	O
states	O
include	O
acute	O
and	O
chronic	O
inflammation	O
,	O
the	O
development	O
of	O
diabetic	O
late	O
complications	O
such	O
as	O
increased	O
vascular	O
permeability	O
,	O
nephrdpathy	O
,	O
atherosclerosis	O
,	O
and	O
retinopathy	O
,	O
the	O
development	O
of	O
Alzheimer	O
's	O
disease	O
,	O
erectile	O
dysfunction	O
,	O
and	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Method	O
of	O
treatment	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
sulfonamide	O
substituted	O
diphenyl	O
urea	O
compound	O
to	O
treat	O
cystic	O
fibrosis	O
,	O
or	O
the	O
symptoms	O
associated	O
with	O
cystic	O
fibrosis	O
.	O

Methods	O
and	O
materials	O
for	O
genetic	O
analysis	O
of	O
tumors	O
This	O
invention	O
relates	O
generally	O
to	O
methods	O
and	O
materials	O
for	O
rapid	O
detection	O
of	O
mutations	O
for	O
tumor	O
genotyping	O
.	O

Indolo	O
[	O
3,2-c	O
]	O
quinoline	O
compounds	O
Disclosed	O
herein	O
are	O
indolo	O
[	O
3,2-c	O
]	O
quinoline	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R	O
and	O
m	O
are	O
given	O
the	O
definitions	O
as	O
set	O
forth	O
in	O
the	O
Specification	O
and	O
Claims	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
inhibit	O
both	O
growth	O
of	O
cancer	O
cells	O
and	O
activity	O
of	O
telomerase	B
.	O

Means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	O
(	O
4,3-b	O
)	O
indoles	O
(	O
variants	O
)	O
,	O
pharmacological	O
means	O
based	O
thereon	O
and	O
method	O
for	O
the	O
use	O
thereof	O
A	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	O
(	O
4,3-b	O
)	O
indoles	O
(	O
variants	O
)	O
,	O
a	O
pharmacological	O
means	O
based	O
thereon	O
and	O
a	O
method	O
for	O
the	O
use	O
thereof	O
relate	O
to	O
the	O
use	O
of	O
chemical	O
compounds	O
in	O
the	O
field	O
of	O
medicine	O
and	O
may	O
be	O
used	O
to	O
extend	O
the	O
arsenal	O
of	O
means	O
which	O
can	O
be	O
utilized	O
for	O
substantial	O
enhancement	O
of	O
memory	O
and	O
activation	O
of	O
the	O
learning	O
process	O
,	O
for	O
the	O
treatment	O
of	O
impaired	O
cognitive	O
functions	O
and	O
memory	O
in	O
the	O
elderly	O
and	O
in	O
mild	O
cognitive	O
impairment	O
,	O
in	O
brain	O
trauma	O
,	O
in	O
chronic	O
cerebrovascular	O
insufficiency	O
,	O
in	O
hypoxic	O
encephalopathies	O
,	O
resulting	O
from	O
chronic	O
alcoholism	O
and	O
in	O
delayed	O
development	O
in	O
children	O
.	O

Said	O
task	O
is	O
resolved	O
by	O
the	O
use	O
of	O
hydrogenated	O
pyrido	O
(	O
[	O
4	O
,	O
3-b	O
]	O
)	O
indoles	O
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
as	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
.	O

Lipophilic	O
drug	O
delivery	O
vehicle	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
delivery	O
of	O
a	O
bioactive	O
agent	O
to	O
an	O
individual	O
.	O

Delivery	O
vehicles	O
are	O
provided	O
that	O
include	O
a	O
bioactive	O
agent	O
in	O
disc	O
shaped	O
particles	O
that	O
include	O
one	O
or	O
more	O
lipid	O
binding	O
polypeptides	O
circumscribing	O
the	O
perimeter	O
of	O
a	O
lipid	O
bilayer	O
in	O
which	O
the	O
bioactive	O
agent	O
is	O
localized	O
.	O

Chimeric	O
lipid	O
binding	O
polypeptides	O
are	O
also	O
provided	O
and	O
may	O
be	O
used	O
to	O
add	O
additional	O
functional	O
properties	O
to	O
the	O
delivery	O
particles	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O
This	O
invention	O
features	O
methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O
.	O

For	O
example	O
,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
can	O
be	O
used	O
to	O
kill	O
or	O
inhibit	O
the	O
growth	O
or	O
spread	O
of	O
cancer	O
cells	O
.	O

The	O
invention	O
also	O
features	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
that	O
modulates	O
a	O
signal	O
transduction	O
or	O
metabolic	O
pathway	O
.	O

Treatment	O
of	O
Cancer	O
and	O
Inflammatory	O
Disorder	O
Disclosed	O
are	O
extracts	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
disorders	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
preparing	O
extracts	O
or	O
compounds	O
for	O
treating	O
the	O
disorders	O
.	O

Pyrazinooxazepine	O
derivatives	O
Provided	O
is	O
a	O
compound	O
having	O
a	O
serotonin	O
5-HT2C	O
receptor	O
activating	O
action	O
.	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I0	O
)	O
:	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
thereof	O
.	O

Sphingosine-1-phosphate	B
(	I
s1p	I
)	I
receptor	I
compounds	O
The	O
invention	O
relates	O
to	O
compounds	O
,	O
in	O
particular	O
2-amino-3,4,5,-trisubstituted	O
thiophenes	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
the	O
uses	O
of	O
said	O
compounds	O
and	O
compositions	O
for	O
diseases	O
related	O
to	O
sphingosine-1-phosphate	B
(	I
S1P	I
)	I
receptors	I
,	O
predominantly	O
S1P3	B
receptors	I
.	O

The	O
diseases	O
include	O
cardiovascular	O
diseases	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
pulmonary	O
oedema	O
,	O
autoimmune	O
disorders	O
and	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
.	O

RNA	O
INTERFERENCE	O
MEDIATED	O
INHIBITION	O
OF	O
PLATELET	B
DERIVED	I
GROWTH	I
FACTOR	I
(	O
PDGF	B
)	O
AND	O
PLATELET	B
DERIVED	I
GROWTH	I
FACTOR	I
RECEPTOR	I
(	O
PDGFR	B
)	O
GENE	O
EXPRESSION	O
USING	O
SHORT	O
INTERFERING	O
NUCLEIC	O
ACID	O
(	O
siNA	O
)	O
This	O
invention	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
gene	O
expression	O
using	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
molecules	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
the	O
expression	O
and	O
activity	O
of	O
other	O
genes	O
involved	O
in	O
pathways	O
of	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
gene	O
expression	O
and/or	O
activity	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
using	O
small	O
nucleic	O
acid	O
molecules	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
features	O
small	O
nucleic	O
acid	O
molecules	O
,	O
such	O
as	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
,	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
,	O
and	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
molecules	O
and	O
methods	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
genes	O
,	O
such	O
as	O
PDGF	B
and/or	O
PDGFr	B
.	O

Rosemary	O
extracts	O
,	O
dietary	O
and	O
pharmaceutical	O
compostions	O
containing	O
them	O
and	O
their	O
uses	O
The	O
present	O
invention	O
refers	O
to	O
rosemary	O
extracts	O
for	O
use	O
as	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
connected	O
to	O
reduced	O
neurotransmission	O
,	O
as	O
well	O
as	O
to	O
dietary	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
rosemary	O
extracts	O
and	O
their	O
uses	O
.	O

Hyperhidrosis	O
treatment	O
Disclosed	O
is	O
a	O
medicinal	O
composition	O
and	O
method	O
of	O
use	O
conspiring	O
topiramate	O
for	O
treating	O
drug	O
-	O
induced	O
excessive	O
sweating	O
(	O
hyperhidrosis	O
)	O
.	O

As	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	O
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
causes	O
excessive	O
sweating	O
to	O
prevent	O
such	O
excessive	O
sweating	O
.	O

As	O
still	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	O
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
treats	O
excessive	O
sweating	O
,	O
such	O
that	O
the	O
synergy	O
of	O
the	O
drugs	O
effectively	O
treats	O
the	O
sweating	O
.	O

Method	O
of	O
increasing	O
metabolism	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
and/or	O
energy	O
expenditure	O
in	O
a	O
subject	O
,	O
e.g.	O
,	O
to	O
treat	O
or	O
prevent	O
obesity	O
and/or	O
a	O
related	O
condition	O
and/or	O
to	O
reduce	O
adiposity	O
,	O
the	O
method	O
comprising	O
increasing	O
the	O
level	O
and/or	O
activity	O
of	O
Hypoxia	B
Induced	I
Factor	I
1α	I
(	O
HIF-1α	B
)	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
organ	O
of	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
in	O
a	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
an	O
iron	O
chelating	O
agent	O
to	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

Method	O
for	O
controlling	O
glucose	O
uptake	O
and	O
insulin	B
sensitivity	O
The	O
invention	O
provides	O
methods	O
for	O
treating	O
diabetes	O
and	O
related	O
disorders	O
,	O
such	O
as	O
metabolic	O
syndromes	O
(	O
which	O
includes	O
insulin	B
resistance	O
)	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
osteopontin	B
(	O
OPN	B
)	O
,	O
which	O
includes	O
an	O
antibody	O
,	O
antibody	O
fragment	O
,	O
siRNA	O
,	O
and	O
aptamer	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
increasing	O
glucose	O
uptake	O
by	O
cells	O
in	O
a	O
subject	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
OPN	B
.	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
pharmaceutical	O
use	O
of	O
2-phenyl-1,2-benzisoselenazol-3	O
(	O
2H	O
)	O
-one	O
or	O
a	O
salt	O
thereof	O
.	O

2-Phenyl-1,2-benzisoselenazol-3	O
(	O
2H	O
)	O
-one	O
or	O
a	O
salt	O
thereof	O
exhibits	O
an	O
excellent	O
suppressive	O
effect	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
a	O
pharmacological	O
test	O
using	O
rats	O
,	O
and	O
is	O
therefore	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
an	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O
.	O

Quinoline	O
compounds	O
suitable	O
for	O
treating	O
disorders	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	O
5-ht6	B
receptor	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoline	O
compounds	O
.	O

The	O
compounds	O
possess	O
valuable	O
therapeutic	O
properties	O
and	O
are	O
particularly	O
suitable	O
,	O
for	O
treating	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	O
5-HT6	B
receptor	O
.	O

wherein	O
R	O
is	O
a	O
moiety	O
of	O
the	O
formula	O
wherein	O
A	O
,	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
specification	O
,	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
Ra	O
,	O
Rb	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
,	O
CN	O
,	O
C1-C4-alkyl	O
,	O
C1-C4-haloalkyl	O
,	O
C1-C4-alkoxy	O
,	O
C1-C4-haloalkoxy	O
,	O
C	O
(	O
O	O
)	O
Raa	O
,	O
C	O
(	O
O	O
)	O
NRccRbb	O
and	O
NRccRbb	O
;	O
X	O
is	O
CH2	O
,	O
C	O
(	O
O	O
)	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
or	O
S	O
(	O
O	O
)	O
2	O
;	O
which	O
is	O
located	O
in	O
the	O
3-	O
or	O
4-position	O
of	O
the	O
quinoline	O
ring	O
;	O
Ar	O
is	O
a	O
radical	O
Ar1	O
,	O
Ar2—Ar3	O
or	O
Ar2—O	O
—	O
Ar3	O
,	O
wherein	O
Ar1	O
,	O
Ar2	O
and	O
Ar3	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aryl	O
or	O
hetaryl	O
wherein	O
aryl	O
or	O
hetaryl	O
moieties	O
may	O
be	O
unsubstituted	O
or	O
may	O
carry	O
1	O
,	O
2	O
,	O
3	O
substituents	O
Rx	O
,	O
wherein	O
and	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
and	O
the	O
N	O
-	O
oxides	O
thereof	O
.	O

Solubilized	O
thiazolopyridines	O
Provided	O
herein	O
are	O
novel	O
sirtuin	B
-	O
modulating	O
compounds	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

The	O
sirtuin	B
-	O
modulating	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell	O
,	O
and	O
treating	O
and/or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including	O
,	O
for	O
example	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress	O
,	O
diabetes	O
,	O
obesity	O
,	O
neurodegenerative	O
diseases	O
,	O
cardiovascular	O
disease	O
,	O
blood	O
clotting	O
disorders	O
,	O
inflammation	O
,	O
cancer	O
,	O
and/or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O

Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
sirtuin	B
-	O
modulating	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O

Formulations	O
and	O
Methods	O
of	O
Administration	O
of	O
Cephalotaxines	O
,	O
Including	O
Homoharringtonine	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
cephalotaxines	O
,	O
for	O
example	O
,	O
homoharringtonine	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
improvements	O
in	O
the	O
purity	O
,	O
manufacturing	O
process	O
,	O
formulation	O
and	O
administration	O
of	O
homoharringtonine	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
aberrant	O
cellular	O
diseases	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
compositions	O
for	O
antiparasitic	O
,	O
antifungal	O
,	O
antiviral	O
and	O
antibacterial	O
treatments	O
.	O

Tricyclic	O
compounds	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O
The	O
present	O
invention	O
provides	O
compounds	O
represented	O
by	O
formula	O
1	O
:	O
wherein	O
,	O
R1	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
,	O
R13	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
in	O
all	O
its	O
stereoisomeric	O
and	O
tautomeric	O
forms	O
and	O
mixtures	O
thereof	O
in	O
all	O
ratios	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutically	O
acceptable	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
polymorphs	O
and	O
prodrugs	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
treatment	O
of	O
inflammatory	O
disorders	O
including	O
those	O
caused	O
by	O
elevated	O
levels	O
of	O
proinflammatory	O
cytokines	O
such	O
as	O
Tumor	B
Necrosis	I
Factor	I
(	O
TNF	B
-	I
α	I
and/or	O
interleukins	B
(	O
IL-1β	B
,	O
IL-6	B
,	O
IL-8	B
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
compounds	O
of	O
formula	O
1	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Methods	O
of	O
treating	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O
Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
pre	O
-	O
eclampsia	O
and	O
eclampsia	O
using	O
compounds	O
that	O
increase	O
VEGF	B
or	O
PlGF	B
levels	O
or	O
compounds	O
that	O
decrease	O
sFlt-1	B
levels	O
.	O

Compounds	O
that	O
inhibit	O
the	O
binding	O
of	O
VEGF	B
or	O
PlGF	B
to	O
sFlt1—are	B
also	O
disclosed	O
herein	O
for	O
the	O
treatment	O
of	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O
.	O

Pre	O
-	O
or	O
post	O
-	O
exposure	O
treatment	O
for	O
filovirus	O
or	O
arenavirus	O
infection	O
The	O
compositions	O
and	O
methods	O
of	O
the	O
invention	O
described	O
herein	O
provide	O
pre-	O
or	O
post	O
-	O
exposure	O
treatments	O
against	O
filovirus	O
or	O
arenavirus	O
infection	O
by	O
expressing	O
one	O
or	O
more	O
genes	O
(	O
e.g.	O
,	O
two	O
ore	O
more	O
genes	O
)	O
from	O
filoviruses	O
or	O
arenaviruses	O
in	O
a	O
delivery	O
vehicle	O
(	O
e.g.	O
,	O
a	O
recombinant	O
viral	O
vector	O
or	O
a	O
liposome	O
)	O
.	O

Formulation	O
with	O
reduced	O
hygroscopicity	O
The	O
invention	O
relates	O
to	O
formulations	O
of	O
hygroscopic	O
solids	O
with	O
a	O
lipophilic	O
coating	O
layer	O
,	O
and	O
a	O
method	O
of	O
production	O
thereof	O
.	O

Pharmaceutical	O
composition	O
,	O
methods	O
for	O
treating	O
and	O
uses	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
claim	O
1	O
comprising	O
an	O
SGLT2	B
inhibitor	O
,	O
a	O
DPPIV	B
inhibitor	O
and	O
a	O
third	O
antidiabetic	O
agent	O
which	O
is	O
suitable	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
one	O
or	O
more	O
conditions	O
selected	O
from	O
type	O
1	O
diabetes	O
mellitus	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
impaired	O
glucose	O
tolerance	O
and	O
hyperglycemia	O
.	O

In	O
addition	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
of	O
metabolic	O
disorders	O
and	O
related	O
conditions	O
.	O

Methods	O
of	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O
and	O
compositions	O
for	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O
Briefly	O
described	O
,	O
embodiments	O
of	O
this	O
disclosure	O
include	O
compositions	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
treating	O
a	O
host	O
infected	O
with	O
a	O
virus	O
from	O
the	O
Flaviviridae	O
family	O
of	O
viruses	O
,	O
methods	O
of	O
treating	O
HCV	O
replication	O
in	O
a	O
host	O
,	O
methods	O
of	O
inhibiting	O
the	O
binding	O
of	O
NS4B	B
polypeptide	O
to	O
the	O
3′UTR	B
of	I
HCV	I
negative	O
strand	O
RNA	O
in	O
a	O
host	O
,	O
methods	O
of	O
treating	O
liver	O
fibrosis	O
in	O
a	O
host	O
,	O
and	O
the	O
like	O
.	O

Chiral	O
Complexes	O
of	O
Ascorbic	O
Acid	O
with	O
Natural	O
Antioxidant	O
and	O
Anti	O
-	O
Inflammatory	O
Ketones	O
Including	O
Aloe	O
,	O
Citrus	O
,	O
Ginger	O
,	O
and	O
Mango	O
for	O
Skin	O
and	O
Hair	O
Care	O

This	O
invention	O
relates	O
to	O
certain	O
complexes	O
of	O
ascorbic	O
acid	O
and	O
its	O
derivatives	O
with	O
certain	O
natural	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
ketones	O
for	O
topical	O
or	O
oral	O
application	O
;	O
said	O
complexes	O
having	O
general	O
chemical	O
formula	O
(	O
I	O
)	O
,	O
its	O
isomers	O
,	O
and	O
salts	O
thereof	O
,	O
including	O
their	O
optically	O
active	O
or	O
racemic	O
forms	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
skin	O
condition	O
,	O
including	O
dark	O
skin	O
,	O
age	O
spots	O
,	O
acne	O
,	O
inflammation	O
,	O
loss	O
of	O
cellular	O
antioxidants	O
,	O
collagen	O
loss	O
with	O
aging	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
malfunction	O
of	O
matrix	B
metalloproteases	I
,	O
malfunction	O
of	O
tyrosinases	B
,	O
damage	O
from	O
free	O
radicals	O
,	O
photo	O
-	O
damage	O
,	O
nutritional	O
deficiency	O
,	O
and	O
combinations	O
thereof	O
;	O

Stable	O
Hyaluronan	O
/	O
Steroid	O
Formulation	O
A	O
pharmaceutical	O
composition	O
comprising	O
in	O
admixture	O
a	O
hyaluronic	O
acid	O
related	O
component	O
(	O
HARC	O
)	O
and	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
triamcinolone	O
hexacetonide	O
(	O
TAH	O
)	O
.	O

The	O
composition	O
is	O
stable	O
in	O
an	O
accelerated	O
shelf	O
life	O
test	O
in	O
which	O
the	O
composition	O
is	O
heated	O
to	O
80	O
°	O
C.	O
for	O
24	O
hours	O
.	O

Novel	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
containing	O
the	O
same	O
as	O
an	O
active	O
component	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
{	O
4-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
-1-	O
(	O
1-hydroxycyclohexyl	O
)	O
ethyl	O
]	O
phenoxy	O
}	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
which	O
contains	O
the	O
same	O
as	O
an	O
active	O
component	O
.	O

The	O
novel	O
{	O
4-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
-1-	O
(	O
1-hydroxycyclohexyl	O
)	O
ethyl	O
]	O
phenoxy	O
}	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
according	O
to	O
the	O
present	O
invention	O
can	O
beneficially	O
be	O
used	O
to	O
prevent	O
and	O
treat	O
central	O
nervous	O
system	O
disorders	O
since	O
it	O
exhibits	O
an	O
equivalent	O
biological	O
and	O
pharmacological	O
activity	O
to	O
venlafaxine	O
and	O
salts	O
thereof	O
which	O
are	O
known	O
in	O
the	O
field	O
,	O
it	O
has	O
very	O
little	O
toxicity	O
,	O
and	O
,	O
in	O
particular	O
,	O
it	O
is	O
outstandingly	O
soluble	O
in	O
water	O
as	O
compared	O
with	O
prior	O
-	O
art	O
venlafaxine	O
derivatives	O
.	O

Compounds	O
and	O
compositions	O
useful	O
for	O
the	O
treatment	O
of	O
parasitic	O
diseases	O
The	O
invention	O
provides	O
a	O
class	O
of	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
malaria	O
.	O

2-Aryl	O
Glycinamide	O
Derivatives	O

The	O
disclosure	O
provides	O
compounds	O
of	O
Formula	O
I	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
their	O
uses	O
in	O
inhibiting	O
β	B
-	I
amyloid	I
peptide	I
(	O
β	B
-	I
AP	I
)	O
production	O
.	O

Xanthophyll	O
composition	O
containing	O
macular	O
pigments	O
and	O
a	O
process	O
for	O
its	O
preparation	O
A	O
xanthophyll	O
composition	O
that	O
contains	O
macular	O
pigments	O
including	O
trans	O
-	O
lutein	O
and	O
zeaxanthin	O
isomers	O
,	O
namely	O
,	O
(	O
R	O
,	O
R	O
)	O
-zeaxanthin	O
and	O
(	O
R	O
,	O
S	O
)	O
-zeaxanthin	O
,	O
derived	O
from	O
the	O
plant	O
extract	O
/	O
oleoresin	O
containing	O
xanthophylls	O
/	O
xanthophylls	O
esters	O
which	O
is	O
safe	O
for	O
human	O
consumption	O
and	O
useful	O
for	O
nutrition	O
and	O
health	O
care	O
.	O

The	O
composition	O
has	O
at	O
least	O
80	O
%	O
by	O
weight	O
that	O
is	O
total	O
xanthophylls	O
,	O
of	O
which	O
the	O
ratio	O
of	O
trans	O
-	O
lutein	O
and	O
zeaxanthin	O
isomers	O
being	O
in	O
the	O
range	O
of	O
about	O
4:1	O
to	O
about	O
6:1	O
and	O
the	O
ratio	O
of	O
the	O
isomers	O
of	O
zeaxanthin	O
being	O
in	O
the	O
range	O
of	O
about	O
80	O
to	O
20:20	O
to	O
80	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O
A	O
synergistic	O
composition	O
,	O
or	O
the	O
use	O
of	O
that	O
composition	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
,	O
or	O
a	O
method	O
of	O
treatment	O
including	O
the	O
use	O
of	O
that	O
composition	O
,	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O
,	O
for	O
combined	O
,	O
sequential	O
or	O
simultaneous	O
administration	O
,	O
in	O
any	O
form	O
,	O
via	O
any	O
biological	O
route	O
.	O

In	O
its	O
optimal	O
embodiment	O
the	O
composition	O
consists	O
,	O
in	O
the	O
form	O
of	O
a	O
lotion	O
:	O
1600	O
-	O
2400	O
IU	O
/	O
mL	O
Vitamin	O
A	O
Palmitate	O
,	O
0.64%-0.96	O
%	O
Thiamine	O
Hydrochloride	O
,	O
0.64%-0.96	O
%	O
Pyridoxine	O
Hydrochloride	O
,	O
4.8%-7.2	O
%	O
Niacinamide	O
,	O
2.85%-5.2	O
%	O
D	O
-	O
Panthenol	O
,	O
1.6%-2.4	O
%	O
L	O
-	O
Arginine	O
,	O
3.6%-4.4	O
%	O
Methyl	O
Sulphonyl	O
Methane	O
(	O
MSM	O
)	O
,	O
0.08%-0.12	O
%	O
Ginger	O
Oil	O
,	O
0.08%-0.12	O
%	O
Cinnamon	O
Oil	O
,	O
0.0996%-0.1494	O
%	O
Oleoresin	O
Capsicum	O
,	O
1.3%-1.95	O
%	O
Magnesium	O
,	O
2.4%-3.6	O
%	O
Zinc	O
,	O
0.192%-0.288	O
%	O
Manganese	O
,	O
2.6%-3.9	O
%	O
Urea	O
,	O
2.4%-3.6	O
%	O
Sodium	O
Glycerophosphate	O
,	O
4.8%-7.2	O
%	O
L	O
-	O
Lysine	O
HCl	O
,	O
plus	O
Preservatives	O
,	O
Co	O
-	O
solvent	O
(	O
Propylene	O
Glycol	O
)	O
,	O
Fragrances	O
,	O
Anti	O
-	O
Oxidant	O
,	O
Cooling	O
agent	O
(	O
Menthol	O
)	O
,	O
Emulsifier	O
,	O
and	O
Vehicle	O
(	O
Purified	O
water	O
)	O
.	O

Pharmaceutically	O
useful	O
heterocycle	O
-	O
substituted	O
lactams	O
The	O
invention	O
provides	O
compounds	O
that	O
inhibit	O
CK2	B
and/or	O
Pim	B
kinases	I
and	O
compositions	O
containing	O
such	O
compounds	O
.	O

These	O
compounds	O
and	O
compositions	O
are	O
useful	O
for	O
treating	O
proliferative	O
disorders	O
such	O
as	O
cancer	O
,	O
as	O
well	O
as	O
other	O
kinase	O
-	O
associated	O
conditions	O
including	O
inflammation	O
,	O
pain	O
,	O
infections	O
,	O
and	O
certain	O
immunological	O
disorders	O
.	O

Substituted	O
quinazolines	O
as	O
blood	O
platelet	O
lowering	O
agents	O
This	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
substituted	O
analogues	O
of	O
the	O
selective	O
platelet	O
lowering	O
agent	O
anagrelide	O
with	O
reduced	O
potential	O
for	O
cardiovascular	O
side	O
-	O
effects	O
which	O
should	O
lead	O
to	O
improved	O
patient	O
compliance	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
myeloproliferative	O
diseases	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
certain	O
imidazoquinazoline	O
derivatives	O
which	O
have	O
the	O
general	O
formula	O
shown	O
below	O
wherein	O
the	O
substituents	O
have	O
the	O
meanings	O
defined	O
in	O
claim	O
(	O
I	O
)	O
:	O
and	O
which	O
have	O
utility	O
as	O
platelet	O
lowering	O
agents	O
in	O
humans	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
function	O
by	O
inhibiting	O
megakaryocytopoeisis	O
and	O
hence	O
the	O
formation	O
of	O
blood	O
platelets	O
.	O

Thiophenyl	O
Sulfonamides	O
for	O
the	O
Treatment	O
of	O
Alzheimer	O
's	O
Disease	O
There	O
is	O
provided	O
a	O
series	O
of	O
novel	O
α-	O
(	O
N	O
-	O
sulfonamido	O
)	O
acetamide	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
and	O
n	O
are	O
defined	O
herein	O
,	O
which	O
are	O
inhibitors	O
of	O
β	B
-	I
amyloid	I
peptide	I
(	O
β	B
-	I
AP	I
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
anti	O
-	O
amyloid	O
activity	O
.	O

Molecular	O
targets	O
and	O
compounds	O
,	O
and	O
methods	O
to	O
identify	O
the	O
same	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
capable	O
of	O
inhibiting	O
the	O
mutant	O
huntingtin	O
protein	O
,	O
inhibiting	O
or	O
reducing	O
polyglutamine	O
-	O
induced	O
protein	O
aggregation	O
,	O
and/or	O
altering	O
huntingtin	B
protein	O
conformation	O
,	O
which	O
inhibition	O
is	O
useful	O
in	O
the	O
prevention	O
,	O
amelioration	O
and/or	O
treatment	O
of	O
neurodegenerative	O
diseases	O
,	O
and	O
protein	O
aggregation	O
diseases	O
more	O
generally	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
Huntington	O
's	O
disease	O
.	O

The	O
invention	O
provides	O
polypeptide	O
and	O
nucleic	O
acid	O
TARGETs	O
and	O
siRNA	O
sequences	O
based	O
on	O
these	O

Prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O
A	O
composition	O
and	O
method	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
related	O
amyloid	O
plaque	O
development	O
and	O
reduction	O
of	O
amyloid	O
plaque	O
,	O
amyloidosis	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
as	O
well	O
as	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O
,	O
includes	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phytic	O
acid	O
(	O
inositol	O
hexakisphosphate	O
)	O
,	O
a	O
phytate	O
salt	O
,	O
an	O
isomer	O
or	O
hydrolysate	O
of	O
phytic	O
acid	O
or	O
a	O
phytate	O
salt	O
,	O
or	O
a	O
mixture	O
of	O
any	O
combination	O
thereof	O
,	O
being	O
administered	O
to	O
a	O
person	O
in	O
an	O
amount	O
from	O
about	O
0.5	O
grams	O
to	O
about	O
18.75	O
grams	O
per	O
day	O
,	O
with	O
or	O
without	O
a	O
dephosphorylating	O
enzyme	O
.	O

Composite	O
material	O
The	O
invention	O
relates	O
to	O
a	O
composite	O
material	O
,	O
a	O
precursor	O
for	O
forming	O
the	O
composite	O
material	O
and	O
a	O
method	O
of	O
forming	O
the	O
composite	O
material	O
from	O
the	O
precursor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
composite	O
material	O
and	O
in	O
particular	O
to	O
its	O
use	O
as	O
an	O
antibacterial	O
or	O
antimicrobial	O
agent	O
.	O

Compositions	O
of	O
nanoparticles	O
and	O
methods	O
of	O
making	O
the	O
same	O
Disclosed	O
herein	O
are	O
compositions	O
of	O
nanoparticles	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
nanoparticles	O
are	O
Janus	O
particles	O
,	O
where	O
each	O
particle	O
includes	O
a	O
first	O
component	O
and	O
second	O
component	O
that	O
are	O
exposed	O
to	O
the	O
surface	O
of	O
the	O
particle	O
.	O

Also	O
,	O
disclosed	O
are	O
methods	O
and	O
systems	O
for	O
making	O
a	O
composition	O
of	O
nanoparticles	O
.	O

Finally	O
,	O
a	O
method	O
of	O
treating	O
a	O
mammal	O
by	O
administering	O
a	O
composition	O
of	O
nanoparticles	O
is	O
disclosed	O
.	O

Method	O
of	O
conjugating	O
therapeutic	O
compounds	O
to	O
cell	O
targeting	O
devices	O
via	O
metal	O
complexes	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
-	O
targeting	O
complex	O
comprising	O
a	O
targeting	O
moiety	O
and	O
a	O
deliverable	O
compound	O
,	O
wherein	O
said	O
targeting	O
moiety	O
and	O
said	O
deliverable	O
compound	O
are	O
joined	O
by	O
means	O
of	O
a	O
(	O
transition	O
)	O
metal	O
ion	O
complex	O
having	O
at	O
least	O
a	O
first	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
targeting	O
moiety	O
and	O
having	O
at	O
least	O
a	O
second	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
deliverable	O
compound	O
,	O
and	O
wherein	O
said	O
deliverable	O
compound	O
is	O
a	O
therapeutic	O
compound	O
.	O

Inhibition	O
of	O
degradation	O
of	O
extracellular	O
matrix	O
This	O
application	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
the	O
degradation	O
of	O
an	O
extracellular	O
matrix	O
associated	O
with	O
islet	O
beta	O
cells	O
,	O
said	O
method	O
comprising	O
contacting	O
said	O
extracellular	O
matrix	O
with	O
an	O
effective	O
amount	O
of	O
a	O
heparanase	B
inhibitor	O
.	O

Novel	O
Lapachone	O
Compounds	O
And	O
Methods	O
of	O
Use	O

Thereof	O
The	O
present	O
invention	O
provides	O
novel	O
tricyclic	O
spiro	O
-	O
oxathiine	O
naphthoquinone	O
derivatives	O
,	O
a	O
synthetic	O
method	O
for	O
making	O
the	O
derivatives	O
,	O
and	O
the	O
use	O
of	O
the	O
derivatives	O
to	O
induce	O
cell	O
death	O
and/or	O
to	O
inhibit	O
proliferation	O
of	O
cancer	O
or	O
precancerous	O
cells	O
.	O

The	O
naphthoquinone	O
derivatives	O
of	O
the	O
present	O
invention	O
are	O
related	O
to	O
the	O
compound	O
known	O
as	O
β	O
-	O
lapachone	O
(	O
3,4-dihydro-2,2-dimethyl-2H	O
-	O
naphtho	O
(	O
1,2-b	O
)	O
pyran-5,6-dione	O
)	O
.	O

2-AMINO-9-	O
[	O
4-	O
(	O
4-METHOXY	O
-	O
PHENOXY	O
)	O
-PIPERIDIN-1-YL	O
]	O
-4-PHENYL	O
-	O
INDENO	O
[	O
1,2-D	O
]	O
PYRIMIDIN-5-ONE	O
AND	O
ITS	O
USE	O
AS	O
A	O
HIGHLY	O
SELECTIVE	O
ADENOSINE	B
A2a	I
RECEPTOR	I
ANTAGONIST	O
This	O
invention	O
relates	O
to	O
a	O
novel	O
arylindenopyrimidine	O
,	O
A	O
,	O
and	O
its	O
therapeutic	O
and	O
prophylactic	O
uses	O
.	O

Disorders	O
treated	O
and/or	O
prevented	O
include	O
Parkinson	O
's	O
Disease	O
.	O

Drug	O
Delivery	O
Platforms	O
Comprising	O
Silk	O
Fibroin	O
Hydrogels	O
and	O
Uses	O
Thereof	O

The	O
present	O
specification	O
provides	O
drug	O
delivery	O
platforms	O
useful	O
for	O
the	O
controlled	O
release	O
of	O
a	O
compound	O
over	O
time	O
in	O
an	O
individual	O
.	O

Methods	O
for	O
enhancing	O
muscle	O
performance	O
and	O
tone	O
This	O
disclosure	O
concerns	O
the	O
use	O
of	O
agonists	O
of	O
AMP	B
-	I
activated	I
protein	I
kinase	I
(	O
AMPK	B
)	O
for	O
improving	O
exercise	O
and	O
modifying	O
energy	O
metabolism	O
in	O
a	O
subject	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
a	O
combination	O
of	O
AMPK	B
and	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
(	I
PPAR	I
)	I
δ	I
agonists	O
for	O
improving	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
methods	O
for	O
identifying	O
substance	O
-	O
enhanced	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
and	O
methods	O
for	O
identifying	O
compounds	O
that	O
affect	O
the	O
interaction	O
of	O
PPARδ	B
with	O
exercise	O
-	O
induced	O
kinases	B
.	O

Use	O
Of	O
Tranilast	O
And	O
Derivatives	O
Thereof	O

For	O
The	O
Therapy	O
Of	O
Neurological	O
Conditions	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
tranilast	O
and	O
derivatives	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
and/or	O
preventing	O
a	O
neuronal	O
condition	O
where	O
there	O
is	O
a	O
need	O
of	O
neuroprotection	O
and	O
neuroregeneration	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
the	O
use	O
of	O
tranilast	O
and	O
derivatives	O
thereof	O
for	O
the	O
in	O
vitro	O
differentiation	O
of	O
neuronal	O
stem	O
cells	O
and	O
the	O
use	O
of	O
such	O
pre	O
-	O
treated	O
cells	O
for	O
stem	O
cell	O
therapy	O
von	O
neurological	O
conditions	O
.	O

Preparation	O
and	O
enantiomeric	O
separation	O
of	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
and	O
novel	O
salt	O
forms	O
of	O
the	O
racemate	O
and	O
enantiomers	O
A	O
novel	O
scalable	O
synthesis	O
for	O
the	O
preparation	O
of	O
7-	O
(	O
3-pyridinyI	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
)	O
nonane	O
has	O
been	O
developed	O
,	O
and	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
salts	O
have	O
been	O
formed	O
with	O
succinic	O
acid	O
and	O
oxalic	O
acid	O
.	O

Additionally	O
,	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diaza	O
-	O
spiro	O
[	O
4.4	O
]	O
nonane	O
has	O
been	O
separated	O
into	O
its	O
stereoisomers	O
via	O
resolution	O
with	O
L	O
and	O
D	O
di	O
-	O
p	O
-	O
toluoyltartaric	O
acids	O
,	O
giving	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
of	O
high	O
enantiomeric	O
purity	O
.	O

Numerous	O
solid	O
salts	O
of	O
the	O
resulting	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
}	O
nonane	O
have	O
been	O
prepared	O
.	O

Methods	O
for	O
the	O
preparation	O
of	O
the	O
racemic	O
and	O
enantiomeric	O
salts	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
salts	O
,	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

The	O
salts	O
can	O
be	O
administered	O
to	O
patients	O
susceptible	O
to	O
or	O
suffering	O
from	O
conditions	O
and	O
disorders	O
,	O
such	O
as	O
central	O
nervous	O
system	O
disorders	O
,	O
to	O
treat	O
and/or	O
prevent	O
such	O
disorders	O
.	O

PYRAZOLO	O
[	O
1,5-a	O
]	O
PYRIMIDINES	O
USEFUL	O
AS	O
JAK2	B
INHIBITORS	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
selective	O
inhibitors	O
of	O
JAK2	B
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
acceptable	O
compositions	O
comprising	O
said	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
,	O
conditions	O
or	O
disorders	O
.	O

The	O
invention	O
also	O
provides	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Thienopyrimidine	O
compounds	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
A2B	O
receptor	O
antagonists	O
,	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
aryl	O
or	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
heteroaryl	O
ring	O
;	O
R2	O
and	O
R3	O
are	O
independently	O
selected	O
from	O
hydrogen	O
,	O
C1-C6	O
alkyl	O
,	O
C3-C8	O
cycloalkyl	O
,	O
C3-C8	O
cycloalkyl-	O
(	O
C1-C6	O
)	O
-alkyl	O
,	O
aryl-	O
(	O
C1-C6	O
)	O
-alkyl	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
a	O
5-	O
or	O
6-membered	O
monocyclic	O
heterocyclic	O
group	O
optionally	O
linked	O
via	O
a	O
C1-C6	O
alkylene	O
chain	O
and	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
benzimidazol-2-yl	O
-	O
methyl	O
,	O
pyrid-3-yl	O
-	O
carbonyl	O
,	O
or	O
(	O
1-methyl	O
-	O
piperidin-4-yl	O
)	O
-carbonyl	O
-	O
methyl	O
;	O
or	O
R2	O
and	O
R3	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
ring	O
;	O
R4	O
is	O
C1-C3	O
alkyl	O
,	O
C2-C3	O
alkenyl	O
,	O
—N	O
(	O
—R5	O
)	O
—R6	O
,	O
or	O
optionally	O
substituted	O
heteroarylmethylamino	O
;	O
and	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
hydrogen	O
or	O
C1-C3	O
alkyl	O
;	O
or	O
R5	O
and	O
R6	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
4-	O
to	O
6-membered	O
saturated	O
ring	O
.	O

6	O
-	O
1h	O
-	O
imidazo	O
-	O
quinazoline	O
and	O
quinolines	O
derivatives	O
,	O
new	O
mao	B
inhibitors	O
and	O
imidazoline	O
receptor	O
ligands	O
The	O
present	O
invention	O
is	O
directed	O
to	O
6-	O
(	O
1H	O
-	O
imidazo-1-yl	O
)	O
-2-aryl	O
and	O
2-heteroaryl	O
quinazoline	O
and	O
quinolines	O
derivatives	O
,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutical	O
acceptable	O
salts	O
and	O
solvates	O
and	O
corresponding	O
pharmaceutical	O
compositions	O
,	O
that	O
acts	O
as	O
Monoamine	B
Oxidase	I
(	O
MAO	B
)	O
inhibitors	O
and	O
Imidazoline	B
Receptor	I
ligands	O
:	O
wherein	O
:	O
X	O
is	O
independently	O
selected	O
from	O
—CH	O
group	O
or	O
a	O
nitrogen	O
atom	O
(	O
—N	O
)	O
,	O
W	O
is	O
independently	O
selected	O
from	O
an	O
aryl	O
group	O
,	O
an	O
heteroaryl	O
group	O
,	O
or	O
a	O
benzocondensed	O
heteroaryl	O
group	O
such	O
as	O
1,3-benzodioxole	O
,	O
benzofuran	O
,	O
2,3-dihydrobenzofuran	O
,	O
benzothiophene	O
,	O
2,3-dihydrobenzothiophene	O
,	O
indole	O
,	O
2,3-dihydroindole	O
,	O
benzimidazole	O
,	O
benzoxazole	O
,	O
benzothiazole	O
,	O
2H-3,4-dihydrobenzopyran	O
,	O
[	O
1,4	O
]	O
-benzodioxine	O
,	O
2,3-dihydro-	O
[	O
1,4	O
]	O
-benzodioxine	O
(	O
1,4-benzodioxan	O
)	O
.	O

R1	O
is	O
independently	O
selected	O
from	O
hydrogen	O
(	O
—H	O
)	O
,	O
C1-C4	O
alkyl	O
,	O
hydroxymethyl	O
(	O
—CH2OH	O
)	O
,	O
aminomethyl	O
(	O
—CH2NH2	O
)	O
,	O
alkylaminomethyl	O
[	O
CH2NH	O
(	O
R2	O
)	O
]	O
,	O
or	O
di	O
-	O
alkylaminomethyl	O
[	O
CH2N	O
(	O
R2	O
)	O
2	O
]	O
,	O
trifluoromethyl	O
(	O
—CF3	O
)	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
elicited	O
a	O
pharmacological	O
profile	O
suitable	O
for	O
the	O
clinical	O
treatment	O
of	O
depression	O
and	O
related	O
disorders	O
,	O
Parkinson	O
disease	O
,	O
drug	O
abuse	O
,	O
and	O
morphine	O
tolerance	O
and	O
dependence	O
.	O

Multi	O
-	O
phase	O
contraceptive	O
preparation	O
based	O
on	O
a	O
natural	O
estrogen	O
The	O
multiphase	O
preparation	O
having	O
higher	O
contraceptive	O
safety	O
and	O
reduced	O
side	O
effects	O
is	O
based	O
on	O
a	O
combination	O
of	O
a	O
natural	O
oestrogen	O
with	O
dienogest	O
or	O
drospirenon	O
.	O

The	O
multiphase	O
prepration	O
is	O
characterized	O
by	O
a	O
first	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
dose	O
units	O
of	O
3	O
mg	O
of	O
oestradiol	O
valerate	O
,	O
a	O
second	O
phase	O
consisting	O
of	O
2	O
groups	O
of	O
daily	O
dose	O
units	O
,	O
wherein	O
a	O
first	O
group	O
is	O
formed	O
by	O
5	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	O
valerate	O
and	O
at	O
least	O
two	O
or	O
three	O
times	O
an	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
and	O
a	O
second	O
group	O
is	O
formed	O
by	O
17	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	O
valerate	O
and	O
at	O
least	O
three	O
or	O
four	O
times	O
the	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
,	O
a	O
third	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
1	O
mg	O
of	O
oestradiol	O
valerate	O
,	O
and	O
a	O
further	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
pharmaceutically	O
acceptable	O
placebo	O
.	O

Substituted	O
Carbamate	O
Derivatives	O
as	O
Modulators	O
of	O
Corticotropin	O
-	O
Releasing	O
Factor	O
Receptor	O
Activity	O

The	O
disclosure	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
including	O
their	O
salts	O
,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

The	O
compounds	O
are	O
CRF	B
receptor	I
antagonists	O
and	O
may	O
be	O
useful	O
for	O
treating	O
disorders	O
associated	O
with	O
abnormal	O
CRF	B
levels	O
or	O
aberrant	O
functioning	O
of	O
CRF	B
receptors	I
.	O

Viscous	O
Terpolymers	O
as	O
Drug	O
Delivery	O
Platform	O
Disclosed	O
are	O
terpolymer	O
compositions	O
of	O
lactide	O
,	O
glycolide	O
,	O
and	O
caprolactone	O
and	O
methods	O
of	O
making	O
such	O
polymers	O
with	O
an	O
initiator	O
.	O

Methods	O
of	O
using	O
the	O
terpolymers	O
as	O
a	O
drug	O
delivery	O
platform	O
are	O
also	O
disclosed	O
.	O

Platelet	O
adhesion	O
-	O
resistant	O
material	O
A	O
platelet	O
adhesion	O
-	O
resistant	O
material	O
is	O
provided	O
,	O
which	O
includes	O
polytriuret	O
-	O
urethane	O
consisting	O
essentially	O
of	O
repeating	O
structural	O
units	O
of	O
formulae	O
(	O
I	O
)	O
to	O
(	O
III	O
)	O
in	O
a	O
random	O
order	O
,	O
in	O
which	O
when	O
the	O
total	O
number	O
of	O
the	O
three	O
repeating	O
structural	O
units	O
in	O
the	O
polytriuret	O
-	O
urethane	O
is	O
100	O
,	O
the	O
number	O
of	O
the	O
repeating	O
structural	O
units	O
(	O
I	O
)	O
is	O
about	O
5	O
to	O
about	O
50	O
:	O
in	O
which	O
each	O
R	O
independently	O
represents	O
a	O
C2-C16	O
alkylene	O
group	O
,	O
a	O
C6-C30	O
aromatic	O
group	O
,	O
a	O
C6-C30	O
alicyclic	O
group	O
;	O
n	O
is	O
an	O
integer	O
of	O
2	O
to	O
16	O
;	O
and	O
R1	O
represents	O
—	O
(	O
OCmH2m	O
)	O
p	O
,	O
in	O
which	O
m	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
,	O
and	O
p	O
is	O
an	O
integer	O
of	O
3	O
to	O
150	O
.	O

Mzb1	B
,	O
a	O
novel	O
b	O
cell	O
factor	O
,	O
and	O
uses	O
thereof	O
The	O
marginal	O
zone	O
(	O
MZ	O
)	O
and	O
B1	O
subsets	O
of	O
B	O
cells	O
,	O
which	O
differ	O
from	O
conventional	O
follicular	O
(	O
FO	O
)	O
B	O
cells	O
both	O
developmentally	O
and	O
functionally	O
,	O
are	O
involved	O
in	O
early	O
responses	O
to	O
infectious	O
pathogens	O
and	O
the	O
production	O
of	O
self	O
-	O
reactive	O
antibodies	O
.	O

A	O
novel	O
gene	O
,	O
mzb1	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
MZ	O
and	O
B1	O
B	O
cells	O
but	O
at	O
low	O
level	O
,	O
if	O
at	O
all	O
,	O
in	O
FOB	O
cells	O
.	O

MZB1	B
is	O
involved	O
in	O
the	O
regulation	O
of	O
proliferation	O
,	O
BCR	B
-	O
mediated	O
signal	O
transduction	O
,	O
and	O
antibody	O
production	O
in	O
B	O
cells	O
.	O

Inhibitors	O
,	O
activators	O
and	O
enhancers	O
of	O
MZB1	B
expression	O
or	O
activity	O
can	O
be	O
used	O
as	O
immune	O
modulators	O
for	O
research	O
and	O
therapeutic	O
purposes	O
.	O

Methods	O
and	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Chronic	O
Renal	O
Hypertension	O
Methods	O
and	O
compositions	O
for	O
the	O
treating	O
chronic	O
renal	O
hypertension	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
nitroxide	O
-	O
containing	O
composition	O
to	O
the	O
subject	O
,	O
particularly	O
4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl	O
(	O
Tempol	O
)	O
.	O

Methods	O
and	O
compositions	O
for	O
targeted	O
delivery	O
of	O
gene	O
therapeutic	O
vectors	O
Embodiments	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
and	O
compositions	O
for	O
tissue-	O
specific	O
delivery	O
of	O
a	O
gene	O
therapeutic	O
,	O
transgenic	O
nucleic	O
acid	O
in	O
mammals	O
.	O

Methods	O
and	O
compositions	O
of	O
the	O
invention	O
include	O
the	O
steps	O
of	O
providing	O
a	O
nucleic	O
acid	O
comprising	O
a	O
transgene	O
flanked	O
by	O
two	O
terminal	O
repeats	O
and	O
,	O
within	O
the	O
same	O
or	O
on	O
a	O
separate	O
nucleic	O
acid	O
,	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
transposase	O
,	O
wherein	O
the	O
transgene	O
comprises	O
a	O
biotherapeutic	O
gene	O
,	O
contacting	O
the	O
nucleic	O
acid	O
with	O
perfluorocarbon	O
gas	O
-	O
filled	O
microbubbles	O
to	O
form	O
a	O
mixture	O
,	O
introducing	O
the	O
mixture	O
into	O
the	O
bloodstream	O
of	O
a	O
mammal	O
,	O
and	O
focusing	O
ultrasound	O
pulses	O
on	O
a	O
specific	O
tissue	O
of	O
said	O
mammal	O
,	O
wherein	O
said	O
pulses	O
disrupt	O
said	O
microbubbles	O
of	O
said	O
mixture	O
and	O
release	O
said	O
nucleic	O
acid	O
into	O
the	O
bloodstream	O
within	O
the	O
target	O
tissue	O
,	O
thereby	O
enabling	O
uptake	O
of	O
the	O
transgenic	O
nucleic	O
acid	O
into	O
the	O
cells	O
of	O
said	O
target	O
tissue	O
.	O

Use	O
of	O
extracellular	O
rna	O
to	O
measure	O
disease	O
Stable	O
,	O
extracellular	O
microRNAs	O
and	O
methods	O
for	O
isolating	O
and	O
identifying	O
such	O
microRNAs	O
from	O
a	O
body	O
fluid	O
are	O
provided	O
.	O

The	O
extracellular	O
microRNAs	O
isolated	O
from	O
a	O
bodily	O
fluid	O
of	O
a	O
subject	O
can	O
be	O
used	O
to	O
measure	O
disease	O
and	O
provide	O
sensitive	O
,	O
efficient	O
,	O
and	O
non	O
invasive	O
methods	O
for	O
the	O
detection	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
extracellular	O
microRNAs	O
can	O
be	O
used	O
to	O
develop	O
new	O
therapeutics	O
for	O
the	O
treatment	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
examples	O
illustrate	O
diagnosis	O
of	O
prostate	O
and	O
ovarian	O
cancer	O
and	O
differential	O
expression	O
of	O
miR-100	B
,	O
miR-135b	B
,	O
miR-141	B
,	O
miR-148a	B
,	O
miR-200a	B
,	O
miR-200c	B
,	O
miR-210	B
,	O
miR-222	B
,	O
miR-375	B
,	O
miR-425-Sp	B
and	O
miR-429	B
.	O

Device	O
and	O
methods	O
for	O
treatment	O
and	O
prevention	O
of	O
tendon	O
injuries	O
The	O
present	O
invention	O
relates	O
to	O
treatment	O
and	O
prevention	O
devices	O
and	O
regimens	O
for	O
tendon	O
injury	O
and	O
damage	O
.	O

The	O
invention	O
further	O
provides	O
compositions	O
comprising	O
therapeutic	O
agents	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
disorders	O
,	O
injuries	O
and	O
conditions	O
beneficially	O
treated	O
by	O
these	O
agents	O
,	O
particularly	O
those	O
relating	O
to	O
the	O
management	O
of	O
tendon	O
damage	O
.	O

Cd44	B
splice	O
variants	O
in	O
neurodegenerative	O
diseases	O
There	O
is	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
of	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
encoded	O
by	O
a	O
nucleic	O
acid	O
,	O
wherein	O
the	O
nucleic	O
acid	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
nucleotide	O
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
20	O
nucleotides	O
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
1	O
,	O
SEQ	O
ID	O
NO	O
:	O
3	O
,	O
SEQ	O
ID	O
NO	O
:	O
5	O
,	O
SEQ	O
ID	O
NO	O
:	O
7	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

There	O
is	O
further	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
and/or	O
activity	O
of	O
a	O
polypeptide	O
,	O
wherein	O
the	O
sequence	O
of	O
the	O
polypeptide	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
amino	O
acid	O
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
10	O
amino	O
acid	O
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
SEQ	O
ID	O
NO	O
:	O
4	O
,	O
SEQ	O
ID	O
NO	O
:	O
6	O
,	O
SEQ	O
ID	O
NO	O
:	O
8	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

Rna	O
interference	O
for	O
the	O
treatment	O
of	O
gain	O
-	O
of	O
-	O
function	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
an	O
effective	O
treatment	O
for	O
a	O
variety	O
of	O
gain	O
-	O
of	O
-	O
function	O
diseases	O
,	O
in	O
particular	O
,	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
.	O

The	O
present	O
invention	O
utilizes	O
RNA	O
Interference	O
technology	O
(	O
RNAi	O
)	O
against	O
polymorphic	O
regions	O
in	O
the	O
genes	O
encoding	O
various	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
proteins	O
resulting	O
in	O
an	O
effective	O
treatment	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
disease	O
.	O

Compositions	O
comprising	O
cationic	O
microparticles	O
and	O
hcv	B
e1e2	I
dna	I
and	O
methods	O
of	O
use	O
thereof	O
Immunogenic	O
HCV	B
E1E2809	I
DNA	I
compositions	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
described	O
.	O

The	O
compositions	O
comprise	O
HCV	B
E1E2809	I
DNA	I
adsorbed	O
to	O
cationic	O
microparticles	O
,	O
such	O
as	O
poly	O
(	O
lactide	O
-	O
co	O
-	O
glycolide	O
)	O
(	O
PLG	O
)	O
microparticles	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
boronic	O
acid	O
compounds	O
Pharmaceutical	O
compositions	O
comprising	O
bortezomib	O
for	O
oral	O
or	O
parenteral	O
administration	O
.	O

Specific	O
aspects	O
relate	O
to	O
stable	O
,	O
sugar	O
free	O
pharmaceutical	O
compositions	O
of	O
bortezomib	O
,	O
including	O
its	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
,	O
in	O
the	O
form	O
of	O
ready	O
-	O
to	O
-	O
use	O
solutions	O
,	O
lyophilized	O
forms	O
,	O
or	O
physical	O
admixtures	O
,	O
and	O
the	O
preparation	O
thereof	O
.	O

Other	O
aspects	O
include	O
processes	O
for	O
preparing	O
compositions	O
and	O
methods	O
of	O
using	O
compositions	O
for	O
treating	O
various	O
types	O
of	O
cancers	O
in	O
mammals	O
.	O

minoxidil	O
composition	O
and	O
non	O
-	O
aerosol	O
,	O
non	O
-	O
spray	O
foam	O
method	O
of	O
delivery	O
therefor	O
A	O
foamable	O
composition	O
is	O
described	O
that	O
contains	O
one	O
or	O
more	O
of	O
:	O
minoxidil	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
an	O
aqueous	O
-	O
alcoholic	O
solvent	O
medium	O
which	O
enables	O
said	O
minoxidil	O
or	O
said	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
be	O
solubilized	O
,	O
a	O
surfactant	O
,	O
such	O
as	O
oleth-20	O
,	O
a	O
foam	O
stabilizer	O
,	O
such	O
as	O
lauryl	O
glucoside	O
,	O
and	O
a	O
sunscreen	O
.	O

The	O
foamable	O
minoxidil	O
composition	O
is	O
optionally	O
delivered	O
in	O
a	O
measured	O
dosage	O
as	O
a	O
foam	O
using	O
a	O
non	O
-	O
pressurized	O
container	O
,	O
where	O
the	O
foam	O
is	O
produced	O
within	O
the	O
container	O
without	O
use	O
of	O
a	O
propellant	O
.	O

Tricyclic	O
indole	O
derivatives	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
Tricyclic	O
Indole	O
Derivatives	O
,	O
compositions	O
comprising	O
at	O
least	O
one	O
Tricyclic	O
Indole	O
Derivatives	O
,	O
and	O
methods	O
of	O
using	O
the	O
Tricyclic	O
Indole	O
Derivatives	O
for	O
treating	O
or	O
preventing	O
a	O
viral	O
infection	O
or	O
a	O
virus	O
-	O
related	O
disorder	O
in	O
a	O
patient	O
.	O

Dispersible	O
phospholipid	O
stabilized	O
microparticles	O
Rapidly	O
dispersing	O
solid	O
dry	O
therapeutic	O
dosage	O
form	O
comprised	O
of	O
a	O
water	O
insoluble	O
compound	O
existing	O
as	O
a	O
nanometer	O
or	O
micrometer	O
particulate	O
solid	O
which	O
is	O
surface	O
stabilized	O
by	O
the	O
presence	O
of	O
at	O
least	O
one	O
phospholipid	O
,	O
the	O
particulate	O
solid	O
being	O
dispersed	O
throughout	O
a	O
bulking	O
matrix	O
.	O

When	O
the	O
dosage	O
form	O
is	O
introduced	O
into	O
an	O
aqueous	O
environment	O
the	O
bulking	O
matrix	O
is	O
substantially	O
completely	O
dissolves	O
within	O
less	O
than	O
2	O
minutes	O
thereby	O
releasing	O
the	O
water	O
insoluble	O
particulate	O
solid	O
in	O
an	O
unaggregated	O
and/or	O
unagglomerated	O
state	O
.	O

The	O
matrix	O
is	O
composed	O
of	O
a	O
water	O
insoluble	O
substance	O
or	O
therapeutically	O
useful	O
water	O
insoluble	O
or	O
poorly	O
water	O
soluble	O
compound	O
,	O
a	O
phospholipid	O
and	O
optionally	O
also	O
at	O
least	O
one	O
non	O
-	O
ionic	O
,	O
anionic	O
,	O
cationic	O
,	O
or	O
amphipathic	O
surfactant	O
,	O
together	O
with	O
a	O
matrix	O
or	O
bulking	O
agent	O
and	O
if	O
needed	O
a	O
release	O
agent	O
.	O

The	O
volume	O
weighted	O
mean	O
particle	O
size	O
of	O
the	O
water	O
insoluble	O
particle	O
is	O
5	O
micrometers	O
or	O
less	O
.	O

Screening	O
Method	O
for	O
Identifying	O
Patients	O
at	O
Risk	O
of	O
Adverse	O
Hepatologic	O
Events	O

This	O
present	O
invention	O
provides	O
methods	O
and	O
kits	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
suffering	O
from	O
a	O
drug	O
induced	O
liver	O
injury	O
,	O
particularly	O
for	O
an	O
antioxidant	O
drug	O
,	O
or	O
for	O
identifying	O
patients	O
who	O
are	O
suffering	O
from	O
early	O
stages	O
of	O
a	O
liver	O
disorder	O
by	O
assessing	O
the	O
levels	O
of	O
apolipoprotein	O
in	O
a	O
sample	O
of	O
the	O
patient	O
and	O
comparing	O
that	O
to	O
a	O
reference	O
value	O
.	O

The	O
reference	O
value	O
is	O
predetermined	O
by	O
identifying	O
a	O
population	O
sample	O
and	O
determining	O
an	O
upper	O
limit	O
of	O
normal	O
value	O
.	O

This	O
value	O
is	O
then	O
used	O
as	O
a	O
reference	O
point	O
for	O
comparison	O
of	O
apolipoprotein	O
levels	O
from	O
patient	O
samples	O
.	O

In	O
one	O
embodiment	O
,	O
apolipoprotein	O
levels	O
are	O
combined	O
with	O
ATL	O
and/or	O
total	O
bilirubin	O
levels	O
for	O
predicting	O
liver	O
damage	O
,	O
hepatotoxicity	O
or	O
hepatic	O
events	O
after	O
drug	O
administration	O
.	O

Modified	O
chloroquines	O
with	O
single	O
ring	O
moiety	O
or	O
fused	O
ring	O
moiety	O
The	O
disclosure	O
provides	O
modified	O
chloroquine	O
compounds	O
having	O
single	O
ring	O
or	O
fused	O
ring	O
moieties	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
inhibit	O
or	O
treat	O
diseases	O
or	O
conditions	O
caused	O
by	O
chloroquine	O
-	O
resistant	O
(	O
CQR	O
)	O
and	O
chloroquine	O
-	O
sensitive	O
(	O
CqS	O
)	O
malaria	O
parasites	O
and	O
other	O
CQ	O
-	O
susceptible	O
microorganisms	O
,	O
and	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O

Method	O
and	O
Kit	O
for	O
Assessing	O
a	O
Patient	O
's	O
Genetic	O
Information	O
,	O
Lifestyle	O
and	O
Environment	O
Conditions	O
,	O
and	O
Providing	O
a	O
Tailored	O
Therapeutic	O
Regime	O
A	O
method	O
of	O
determining	O
a	O
personalised	O
therapeutic	O
regime	O
,	O
comprising	O
:	O
receiving	O
genetic	O
information	O
relating	O
to	O
a	O
patient	O
;	O
determining	O
genetic	O
criteria	O
relevant	O
to	O
a	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
using	O
the	O
genetic	O
information	O
;	O
receiving	O
personal	O
information	O
relating	O
to	O
the	O
patient	O
;	O
determining	O
personal	O
criteria	O
relevant	O
to	O
the	O
personalised	O
therapeutic	O
regime	O
using	O
the	O
personal	O
information	O
;	O
and	O
combining	O
the	O
genetic	O
criteria	O
and	O
the	O
personal	O
criteria	O
to	O
determine	O
the	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
.	O

Methods	O
for	O
enhancing	O
immune	O
response	O
This	O
disclosure	O
demonstrates	O
a	O
novel	O
therapy	O
immunological	O
approach	O
using	O
polyamine	O
-	O
based	O
therapy	O
(	O
PBT	O
)	O
for	O
relieving	O
tumor	O
-	O
induced	O
suppression	O
of	O
the	O
patient	O
's	O
immune	O
system	O
.	O

The	O
demonstration	O
of	O
the	O
pharmacological	O
release	O
from	O
the	O
naturally	O
occurring	O
polyamine	O
-	O
mediated	O
immune	O
suppression	O
offers	O
profound	O
impact	O
on	O
the	O
immunotherapy	O
of	O
cancer	O
together	O
with	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
the	O
disease	O
-	O
causing	O
vector	O
's	O
ability	O
to	O
evade	O
an	O
immune	O
reaction	O
.	O

This	O
therapeutic	O
approach	O
is	O
equally	O
applicable	O
to	O
disease	O
states	O
whereby	O
immune	O
system	O
suppression	O
by	O
polyamines	O
has	O
been	O
demonstrated	O
including	O
;	O
bacterial	O
infections	O
,	O
parasitic	O
infections	O
including	O
malaria	O
and	O
typanosomiasis	O
,	O
viral	O
infections	O
,	O
peptic	O
ulcers	O
and	O
gastric	O
cancer	O
due	O
to	O
H.	O
Pylori	O
infection	O
together	O
with	O
prevention	O
of	O
pregnancy	O
.	O

With	O
a	O
small	O
molecule	O
drug	O
,	O
used	O
in	O
combination	O
with	O
DFMO	O
,	O
the	O
pharmacological	O
manipulation	O
of	O
polyamine	O
levels	O
for	O
therapeutic	O
benefit	O
in	O
various	O
disease	O
states	O
is	O
possible	O
.	O

Micronutrient	O
Supplement	O
Dispensing	O
Package	O
Provided	O
herein	O
is	O
a	O
prenatal	O
and	O
postpartum	O
multivitamin	O
and	O
mineral	O
supplement	O
package	O
provided	O
in	O
the	O
form	O
of	O
a	O
plurality	O
of	O
solid	O
oral	O
dosage	O
units	O
individually	O
contained	O
in	O
blister	O
packs	O
wherein	O
a	O
portion	O
of	O
the	O
dosage	O
forms	O
are	O
iron	O
-	O
containing	O
while	O
at	O
least	O
half	O
of	O
the	O
dosage	O
units	O
are	O
essentially	O
iron	O
-	O
free	O
and	O
wherein	O
the	O
total	O
amount	O
of	O
iron	O
in	O
the	O
package	O
as	O
sold	O
to	O
purchasers	O
is	O
less	O
than	O
about	O
1300	O
mg	O
of	O
elemental	O
iron	O
.	O

Alkaloid	O
aminoester	O
derivatives	O
and	O
medicinal	O
composition	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
alkaloid	O
aminoester	O
compounds	O
which	O
act	O
as	O
muscarinic	B
receptor	I
antagonists	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
,	O
and	O
therapeutic	O
uses	O
thereof	O
.	O

Cardenolides	O
for	O
the	O
treatment	O
of	O
ocular	O
cancer	O
The	O
instant	O
invention	O
provides	O
methods	O
of	O
using	O
a	O
class	O
of	O
compounds	O
known	O
as	O
cardenolides	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
provides	O
methods	O
of	O
treating	O
ocular	O
cancer	O
{	O
e.g.	O
,	O
retinoblastoma	O
)	O
using	O
intraarterial	O
infusion	O
to	O
administer	O
cardenolides	O
locally	O
to	O
the	O
eye	O
of	O
a	O
subject	O
with	O
an	O
ocular	O
cancer	O
.	O

Novel	O
Saponin	O
Compounds	O
,	O
Methods	O
of	O
Preparation	O
Thereof	O
,	O
Use	O
Thereof	O
and	O
Pharmaceutical	O
Compositions	O

This	O
invention	O
relates	O
to	O
novel	O
saponin	O
compounds	O
of	O
formula	O
II	O
wherein	O
MBz	O
denotes	O
p	O
-	O
methoxybenzoyl	O
,	O
and	O
R	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
C6	O
-	O
10	O
aryl	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C1	O
-	O
4	O
alkyl-	O
,	O
C1	O
-	O
18	O
alkanoyl	O
,	O
C3	O
-	O
18	O
alkenyl	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C	O
(	O
O	O
)	O
—	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C1	O
-	O
4	O
alkyl	O
-	O
C	O
(	O
O	O
)	O
—	O
,	O
wherein	O
each	O
of	O
the	O
groups	O
can	O
optionally	O
be	O
substituted	O
.	O

These	O
compounds	O
possess	O
a	O
selective	O
cytostatic	O
activity	O
,	O
useful	O
,	O
e.g.	O
,	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
preparation	O
of	O
the	O
novel	O
compounds	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
these	O
compounds	O
.	O

(	O
2-aryloxyacetylamino	O
)	O
phenylpropionic	O
acid	O
derivatives	O
,	O
processes	O
for	O
preparation	O
thereof	O
and	O
use	O
thereof	O
as	O
medicaments	O
The	O
invention	O
relates	O
to	O
substituted	O
(	O
2-aryloxyacetylamino	O
)	O
phenylpropionic	O
acid	O
derivatives	O
,	O
and	O
to	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
and	O
A	O
are	O
each	O
defined	O
as	O
specified	O
,	O
and	O
the	O
physiologically	O
compatible	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
for	O
treatment	O
of	O
diabetes	O
.	O

Succinate	O
salt	O
of	O
(	O
2r	O
)	O
-methyl-1-piperazine	O
The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
which	O
are	O
therapeutically	O
active	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
HA	O
is	O
a	O
pharmaceutically	O
acceptable	O
acid	O
and	O
R1-R4	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
halogen	O
,	O
C1-C6-alkyl	O
,	O
C1-C6-alkoxy	O
,	O
and	O
di	O
-	O
C1-C6-alkylamino	O
-	O
C2-C6-alkoxy	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compound	O
to	O
manufacture	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
serotonin	O
-	O
related	O
disorder	O
.	O

Oligomer	O
-	O
Diarylpiperazine	O
Conjugates	O
The	O
invention	O
relates	O
to	O
(	O
among	O
other	O
things	O
)	O
oligomer	O
-	O
diarylpiperazine	O
conjugates	O
and	O
related	O
compounds	O
.	O

A	O
conjugate	O
of	O
the	O
invention	O
,	O
when	O
administered	O
by	O
any	O
of	O
a	O
number	O
of	O
administration	O
routes	O
,	O
exhibits	O
advantages	O
over	O
previously	O
administered	O
un	O
-	O
conjugated	O
diarylpiperazine	O
compounds	O
.	O

Rna	O
antagonist	O
compounds	O
for	O
the	O
inhibition	O
of	O
expression	O
of	O
mitochondrial	B
glycerol-3	I
phosphate	I
acyltransferase	I
1	I
(	O
mtgpat1	B
)	O
The	O
present	O
invention	O
relates	O
to	O
oligomer	O
compounds	O
(	O
oligomers	O
)	O
,	O
which	O
target	O
mtGPAT1mRNA	B
in	O
a	O
cell	O
,	O
leading	O
to	O
reduced	O
expression	O
of	O
mtGPAT1	B
.	O

Reduction	O
of	O
mtGPAT1	B
expression	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
certain	O
medical	O
disorders	O
,	O
such	O
as	O
overweight	O
,	O
obesity	O
,	O
fatty	O
liver	O
,	O
hepatosteatosis	O
,	O
non	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
non	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
insulin	B
resistance	O
,	O
and	O
non	O
insulin	B
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O

Treatment	O
of	O
delta	B
-	I
like	I
1	I
homolog	I
(	O
dlk1	B
)	O
related	O
diseases	O
by	O
inhibition	O
of	O
natural	O
antisense	O
transcript	O
to	O
dlk1	B
The	O
present	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	O
that	O
modulate	O
the	O
expression	O
of	O
and/or	O
function	O
of	O
Delta	B
-	I
like	I
(	I
1	I
)	I
homolog	I
(	O
DLK1	B
)	O
,	O
in	O
particular	O
,	O
by	O
targeting	O
natural	O
antisense	O
polynucleotides	O
of	O
Delta	B
-	I
like	I
(	I
1	I
)	I
homolog	I
(	O
DLK1	B
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
identification	O
of	O
these	O
antisense	O
oligonucleotides	O
and	O
their	O
use	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
the	O
expression	O
of	O
(	O
DLK1	B
)	O
.	O

Methods	O
and	O
compounds	O
for	O
treatment	O
of	O
neurodegenerative	O
disorders	O
Methods	O
,	O
compounds	O
and	O
compositions	O
for	O
promoting	O
motor	O
neuron	O
survival	O
and	O
the	O
treatment	O
of	O
a	O
neurodegenerative	O
disorders	O
such	O
as	O
Spinal	O
Muscular	O
Atrophy	O
(	O
SMA	O
)	O
are	O
described	O
herein	O
.	O

Method	O
of	O
mitigating	O
adverse	O
drug	O
events	O
using	O
omega-3	O
fatty	O
acids	O
as	O
a	O
parenteral	O
therapeutic	O
drug	O
vehicle	O
A	O
method	O
of	O
parenterally	O
administering	O
a	O
composition	O
,	O
the	O
method	O
including	O
parenterally	O
administering	O
to	O
a	O
person	O
a	O
composition	O
including	O
at	O
least	O
one	O
omega-3	O
fatty	O
acid	O
and	O
at	O
least	O
one	O
drug	O
,	O
wherein	O
the	O
at	O
least	O
one	O
omega-3	O
fatty	O
acid	O
source	O
and	O
the	O
at	O
least	O
one	O
drug	O
are	O
administered	O
simultaneously	O
.	O

Crystalline	O
forms	O
of	O
oxymorphone	O
hydrochloride	O
The	O
present	O
invention	O
is	O
directed	O
to	O
crystalline	O
forms	O
of	O
oxymorphone	O
hydrochloride	O
.	O

Pectin	O
-	O
containing	O
jelly	O
formulation	O
There	O
is	O
disclosed	O
a	O
technique	O
for	O
imparting	O
an	O
appropriate	O
rupture	O
strength	O
and	O
high	O
drug	O
-	O
release	O
properties	O
to	O
a	O
jelly	O
formulation	O
comprising	O
pectin	O
.	O

The	O
jelly	O
formulation	O
of	O
the	O
present	O
invention	O
comprises	O
a	O
drug	O
,	O
pectin	O
,	O
and	O
divalent	O
metal	O
ion	O
,	O
and	O
further	O
comprises	O
a	O
component	O
selected	O
from	O
sucrose	O
,	O
maltitol	O
and	O
C3-C4	O
alditols	O
,	O
and	O
a	O
component	O
selected	O
from	O
C5-C6	O
alditols	O
in	O
combination	O
.	O

Pharmaceutical	O
depot	O
for	O
5-fluoro-2-	O
[	O
[	O
(	O
1s	O
)	O
-1-	O
(	O
5-fluoro-2-pyridyl	O
)	O
ethyl	O
]	O
amino	O
]	O
-6-	O
[	O
(	O
5-isopropoxy-1h	O
-	O
pyrazol-3-yl	O
)	O
amino	O
]	O
pyridine-3-carbonitrile	O
A	O
pharmaceutical	O
depot	O
comprising	O
(	O
i	O
)	O
5-fluoro-2-	O
[	O
[	O
(	O
1S	O
)	O
-1-	O
(	O
5-fluoro-2-pyridyl	O
)	O
ethyl	O
]	O
amino	O
]	O
-6-	O
[	O
(	O
5-isopropoxy-1H	O
-	O
pyrazol-3-yl	O
)	O
amino	O
]	O
pyridine-3-carbonitrile	O
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
,	O
as	O
a	O
pharmaceutical	O
agent	O
(	O
PA	O
)	O
and	O
(	O
ii	O
)	O
a	O
polymer	O
which	O
degrades	O
to	O
create	O
an	O
acidic	O
microclimate	O
,	O
wherein	O
the	O
PA	O
is	O
released	O
from	O
the	O
polymer	O
upon	O
polymer	O
degradation	O
.	O

Low	O
-	O
dose	O
,	O
non	O
-	O
irritating	O
nicotine	O
nasal	O
composition	O
to	O
reduce	O
the	O
desire	O
to	O
smoke	O
A	O
composition	O
for	O
administration	O
to	O
the	O
nasal	O
mucosa	O
of	O
a	O
subject	O
comprises	O
a	O
solution	O
of	O
nicotine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
.	O

The	O
composition	O
has	O
a	O
nicotine	O
concentration	O
less	O
than	O
0.08	O
mg	O
/	O
ml	O
.	O

The	O
composition	O
used	O
alone	O
assists	O
in	O
reduction	O
of	O
the	O
desire	O
of	O
a	O
subject	O
to	O
smoke	O
tobacco	O
.	O

It	O
also	O
reduces	O
the	O
nasal	O
symptoms	O
associated	O
with	O
administration	O
of	O
higher	O
concentrations	O
of	O
nicotine	O
to	O
the	O
nasal	O
mucosa	O
.	O

Inhibitor	O
for	O
elevation	O
of	O
gip	B
level	O
Provided	O
is	O
a	O
GIP	B
-	O
increase	O
inhibitor	O
,	O
which	O
is	O
customary	O
used	O
for	O
food	O
production	O
,	O
is	O
excellent	O
in	O
safety	O
,	O
and	O
is	O
useful	O
for	O
,	O
for	O
example	O
,	O
a	O
medicine	O
or	O
a	O
food	O
.	O

The	O
GIP	B
-	O
increase	O
inhibitor	O
contains	O
catechins	O
as	O
active	O
ingredient	O
.	O

Use	O
of	O
bipolar	O
trans	O
carotenoids	O
as	O
a	O
pretreatment	O
and	O
in	O
the	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O
The	O
subject	O
application	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O
(	O
PVD	O
)	O
as	O
well	O
as	O
ischemic	O
osteonecrosis	O
,	O
peritoneal	O
ischemia	O
,	O
chronic	O
ocular	O
disease	O
,	O
macular	O
degeneration	O
,	O
or	O
diabetic	O
retinopathy	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
trans	O
carotenoid	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
carotenoids	O
as	O
pretreatments	O
for	O
mammals	O
at	O
risk	O
of	O
an	O
ischemic	O
event	O
.	O

Cdk	B
inhibitor	O
salts	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
form	O
(	O
s	O
)	O
of	O
water	O
-	O
soluble	O
salts	O
and	O
of	O
free	O
base	O
of	O
a	O
cdk	B
inhibitor	O
.	O

Such	O
crystal	O
salts	O
are	O
for	O
example	O
fumarate	O
,	O
L	O
-	O
malate	O
,	O
maleate	O
,	O
succinate	O
,	O
adipate	O
,	O
malonate	O
,	O
glycolate	O
,	O
phosphate	O
,	O
mesylate	O
,	O
L	O
-	O
lactate	O
,	O
hydrochloride	O
,	O
di	O
-	O
hydrochloride	O
,	O
tri	O
-	O
hydrochloride	O
.	O

Hydrates	O
and	O
polymorphs	O
of	O
such	O
new	O
salt	O
forms	O
,	O
a	O
process	O
for	O
their	O
preparation	O
,	O
their	O
utility	O
in	O
therapy	O
and	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
claimed	O
and	O
described	O
in	O
the	O
present	O
application	O
.	O

Substituted	O
spirocyclic	O
amines	O
useful	O
as	O
antidiabetic	O
compounds	O
Substituted	O
spirocyclic	O
amines	O
of	O
structural	O
formula	O
I	O
are	O
selective	O
antagonists	O
of	O
the	O
somatostatin	B
sub	I
-	I
type	I
receptor	I
5	I
(	O
SSTR5	B
)	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
,	O
control	O
or	O
prevention	O
of	O
disorders	O
responsive	O
to	O
antagonism	O
of	O
SSTR5	B
,	O
such	O
as	O
Type	O
2	O
diabetes	O
,	O
insulin	B
resistance	O
,	O
lipid	O
disorders	O
,	O
obesity	O
,	O
atherosclerosis	O
,	O
metabolic	O
syndrome	O
,	O
depression	O
,	O
and	O
anxiety	O
.	O

Tapentadol	O
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O
The	O
use	O
of	O
tapentadol	O
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O
.	O

Formulation	O
of	O
a	O
mixture	O
of	O
free	O
-	O
b	O
-	O
ring	O
flavonoids	O
and	O
flavans	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
cognitive	O
decline	O
and	O
age	O
-	O
related	O
memory	O
impairments	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
method	O
for	O
preventing	O
and	O
treating	O
memory	O
and	O
cognitive	O
impairment	O
resulting	O
from	O
oxidative	O
stress	O
,	O
inflammation	O
and	O
the	O
process	O
of	O
aging	O
,	O
as	O
well	O
as	O
,	O
neurodegenerative	O
conditions	O
.	O

The	O
method	O
is	O
comprised	O
of	O
administering	O
a	O
composition	O
comprising	O
a	O
mixture	O
of	O
Free	O
-	O
B	O
-	O
Ring	O
flavonoids	O
and	O
flavans	O
synthesized	O
and/or	O
isolated	O
from	O
a	O
single	O
plant	O
or	O
multiple	O
plants	O
to	O
a	O
host	O
in	O
need	O
thereof	O
.	O

The	O
present	O
also	O
includes	O
a	O
novel	O
method	O
for	O
simultaneously	O
inhibiting	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
preventing	O
ROS	O
generation	O
and	O
augmenting	O
anti	O
-	O
oxidant	O
defenses	O
.	O

The	O
activity	O
of	O
this	O
composition	O
is	O
conducive	O
to	O
ultimately	O
preserving	O
cognitive	O
function	O
and	O
providing	O
a	O
level	O
of	O
neuroprotection	O
.	O

Optically	O
active	O
pyrazolylaminoquinazoline	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
Provided	O
herein	O
is	O
an	O
optically	O
active	O
pyrozolylaminoquinazaline	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Also	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
JAK	B
-	O
mediated	O
condition	O
,	O
disorder	O
,	O
or	O
disease	O
.	O

Further	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
proliferative	O
disease	O
,	O
inflammatory	O
disease	O
,	O
or	O
renal	O
disease	O
.	O

Bace	O
2	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
N-1-Benzyl-2-hydroxy-3-	O
(	O
hetero	O
)	O
arylamino	O
-	O
propyl	O
)	O
-isophthalamides	O
of	O
formula	O
I	O
having	O
BACE2	O
inhibitory	O
activity	O
and	O
their	O
use	O
as	O
therapeutically	O
active	O
substances	O
,	O
their	O
manufacture	O
and	O
pharmaceutical	O
compositions	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
therapeutic	O
and/or	O
prophylactic	O
treatment	O
of	O
e.g.	O
type	O
2	O
diabetes	O
.	O

Slow	O
-	O
degrading	O
polymers	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O
The	O
invention	O
provides	O
polymers	O
and	O
methods	O
for	O
their	O
use	O
.	O

Certain	O
embodiments	O
of	O
the	O
invention	O
provide	O
slow	O
degrading	O
microspheres	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O
.	O

Ipp	B
complex	O
as	O
marker	O
for	O
erlotinib	O
treatment	O
The	O
present	O
invention	O
provides	O
biomarkers	O
which	O
are	O
predictive	O
for	O
the	O
clinical	O
benefit	O
of	O
erlotinib	O
hydrochloride	O
treatment	O
in	O
cancer	O
patients	O
.	O

Methods	O
and	O
compositions	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
mapk	B
)	O
pathway	O
inhibitors	O
for	O
treating	O
pulmonary	O
fibrosis	O
Methods	O
and	O
compositions	O
of	O
inhibitors	O
of	O
MAPK	B
kinases	I
1	I
and	I
2	I
(	O
MEK1	B
and	O
MEK2	B
,	O
or	O
together	O
,	O
MEK1	B
/	I
2	I
)	O
,	O
such	O
as	O
ARRY142886	O
,	O
and	O
their	O
use	O
in	O
inhibiting	O
MEK1	B
/	I
2	I
kinase	B
activity	O
in	O
mammals	O
for	O
the	O
treatment	O
and/or	O
reversal	O
of	O
the	O
symptoms	O
of	O
pulmonary	O
fibrosis	O
.	O

MEK1	B
/	I
2	I
inhibitors	O
can	O
selectively	O
inhibit	O
the	O
MAPK	B
/	O
ERK	B
pathway	O
in	O
vivo	O
and	O
prevent	O
TGF	B
-	I
α	I
mediated	O
fibrosis	O
.	O

There	O
are	O
several	O
distinct	O
MAPK	B
pathways	O
that	O
are	O
important	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
development	O
,	O
inflammation	O
,	O
survival	O
,	O
and	O
migration	O
.	O

The	O
Ras	B
-	O
Raf	B
-	O
MEK	B
-	O
ERK	B
pathway	O
(	O
a	O
key	O
component	O
of	O
the	O
MAPK	B
pathway	O
)	O
via	O
inhibition	O
of	O
MEK1	B
/	I
2	I
is	O
an	O
attractive	O
strategy	O
for	O
therapeutic	O
intervention	O
in	O
idiopathic	O
pulmonary	O
fibrosis	O
,	O
because	O
inhibition	O
of	O
MEK1	B
/	I
2	I
has	O
the	O
potential	O
to	O
block	O
inappropriate	O
signal	O
transduction	O
leading	O
to	O
pulmonary	O
fibrosis	O
,	O
regardless	O
of	O
the	O
upstream	O
position	O
of	O
the	O
aberration	O
causing	O
it	O
.	O

Tricyclic	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
or	O
salt	O
thereof	O
,	O
which	O
are	O
modulators	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O

The	O
compounds	O
and	O
salts	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
glucocorticoid	B
receptor	I
activity	O
.	O

Imidazo	O
[	O
1,2	O
a	O
]	O
pyridine	O
6	O
carboxamide	O
derivatives	O
,	O
their	O
use	O
for	O
the	O
treatment	O
of	O
colon	O
cancer	O
and	O
their	O
method	O
of	O
manufacture	O
This	O
invention	O
relates	O
to	O
the	O
manufacture	O
of	O
novel	O
chemical	O
compounds	O
which	O
have	O
biological	O
activity	O
,	O
particularly	O
to	O
novel	O
chemical	O
compounds	O
that	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
and	O
colon	O
cancer	O
cell	O
lines	O
.	O

The	O
manufacturing	O
of	O
said	O
chemical	O
compounds	O
displaying	O
anti	O
-	O
cancer	O
properties	O
employs	O
the	O
use	O
of	O
multi	O
-	O
component	O
chemical	O
reactions	O
.	O

The	O
object	O
of	O
this	O
invention	O
is	O
to	O
manufacture	O
and	O
isolate	O
analogues	O
of	O
imidazo	O
[	O
1,2-a	O
]	O
pyridine	O
,	O
namely	O
compounds	O
of	O
Formula	O
1	O
,	O
which	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
,	O
while	O
concomitantly	O
being	O
relatively	O
inactive	O
against	O
white	O
blood	O
cells	O
.	O

wherein	O
,	O
R	O
is	O
bromo	O
,	O
methyl	O
,	O
phenyl	O
,	O
nitro	O
,	O
hydrogen	O
or	O
an	O
amide	O
functional	O
group	O
;	O
R1	O
is	O
benzyl	O
,	O
2,6-dimethylphenyl	O
or	O
cyclohexyl	O
;	O
and	O
R2	O
is	O
methoxy	O
,	O
benzyloxy	O
or	O
hydroxy	O
.	O

Aminotetrahydroindazoloacetic	O
Acids	O
The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
I	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
wherein	O
Q	O
,	O
W	O
,	O
X	O
,	O
R1-R5	O
and	O
n	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	B
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O

5-membered	O
heteroaryl	O
derivatives	O
used	O
as	O
sphingosine	O
1-	O
phosphate	O
receptor	O
agonists	O
5-membered	O
heteroaryl	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
salts	O
thereof	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
mediated	O
by	O
S1P1	O
receptors	O
are	O
disclosed	O
.	O

Ready	O
to	O
Use	O
Ketorolac	O
Formulations	O
Disclosed	O
in	O
certain	O
embodiments	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
parenteral	O
administration	O
comprising	O
:	O
an	O
aqueous	O
solution	O
comprising	O
ketorolac	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
an	O
amount	O
from	O
about	O
0.1	O
mg	O
/	O
mL	O
to	O
about	O
10	O
mg	O
/	O
mL	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
;	O
wherein	O
the	O
formulation	O
is	O
substantially	O
free	O
of	O
alcohol	O
.	O

Synergistic	O
treatment	O
of	O
cancer	O
using	O
immunomers	O
in	O
conjunction	O
with	O
chemotherapeutic	O
agents	O
The	O
invention	O
relates	O
to	O
the	O
therapeutic	O
use	O
of	O
immunostimulatory	O
oligonucleotides	O
and/or	O
immunomers	O
in	O
combination	O
with	O
chemotherapeutic	O
agents	O
to	O
provide	O
a	O
synergistic	O
therapeutic	O
effect	O
.	O

Gene	O
expression	O
levels	O
of	O
egfr	B
,	O
vegfr2	B
,	O
and	O
ercc1	B
associated	O
with	O
clinical	O
outcomes	O
of	O
chemotherapy	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
identifying	O
a	O
cancer	O
patient	O
suitable	O
for	O
anti	O
-	O
VEGF	B
therapy	O
.	O

After	O
determining	O
if	O
a	O
patient	O
is	O
likely	O
to	O
be	O
successfully	O
treated	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
the	O
patients	O
.	O

Product	O
for	O
the	O
preparation	O
of	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
intended	O
for	O
skin	O
treatment	O
The	O
present	O
invention	O
relates	O
to	O
a	O
product	O
obtained	O
from	O
gastropod	O
spawn	O
,	O
to	O
be	O
used	O
to	O
prepare	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
designed	O
for	O
skin	O
care	O
;	O
said	O
product	O
has	O
the	O
capacity	O
to	O
activate	O
and	O
mobilise	O
skin	O
stem	O
cells	O
,	O
as	O
well	O
as	O
prevent	O
the	O
loss	O
thereof	O
that	O
takes	O
place	O
as	O
a	O
consequence	O
of	O
chronological	O
and	O
premature	O
ageing	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
process	O
followed	O
in	O
order	O
to	O
obtain	O
said	O
product	O
.	O

Effective	O
Antitumor	O
Treatments	O
ET-743	O
is	O
used	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
an	O
effective	O
treatment	O
of	O
a	O
tumour	O
by	O
combination	O
therapy	O
employing	O
ET-743	O
with	O
another	O
drug	O
.	O

Transdermal	O
delivery	O
of	O
beneficial	O
substances	O
effected	O
by	O
a	O
hostile	O
biophysical	O
environment	O
The	O
present	O
invention	O
generally	O
relates	O
to	O
the	O
transdermal	O
delivery	O
of	O
substances	O
In	O
one	O
aspect	O
,	O
various	O
methods	O
for	O
the	O
transdermal	O
delivery	O
of	O
beneficial	O
substances	O
are	O
disclosed	O
.	O

By	O
creating	O
a	O
hostile	O
biophysical	O
environment	O
,	O
beneficial	O
substances	O
may	O
be	O
delivered	O
,	O
according	O
to	O
certain	O
embodiments	O
,	O
through	O
the	O
stratum	O
corneum	O
of	O
the	O
skin	O
into	O
the	O
body	O
.	O

Beneficial	O
substances	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
pharmaceutical	O
agents	O
,	O
drugs	O
,	O
vitamins	O
,	O
co	O
-	O
factors	O
,	O
peptides	O
,	O
dietary	O
supplements	O
,	O
and	O
others	O
.	O

The	O
beneficial	O
effects	O
disclosed	O
include	O
,	O
for	O
instance	O
,	O
relief	O
of	O
pain	O
and	O
inflammation	O
,	O
prevention	O
and	O
healing	O
of	O
ulcers	O
of	O
the	O
skin	O
,	O
relief	O
of	O
headache	O
,	O
improved	O
sexual	O
function	O
and	O
enjoyment	O
,	O
growth	O
of	O
hair	O
on	O
the	O
scalp	O
,	O
improving	O
muscle	O
size	O
and/or	O
function	O
,	O
removing	O
body	O
fat	O
and/or	O
cellulite	O
,	O
treating	O
cancer	O
,	O
treating	O
viral	O
infections	O
and	O
others	O
.	O

A	O
hostile	O
biophysical	O
environment	O
may	O
also	O
be	O
used	O
in	O
conjunction	O
with	O
systems	O
and	O
methods	O
for	O
increasing	O
local	O
blood	O
flow	O
,	O
according	O
to	O
one	O
set	O
of	O
embodiments	O
.	O

Low	O
molecular	O
weight	O
cyclin	O
e	O
(	O
lmw	O
-	O
e	O
)	O
as	O
a	O
biomarker	O
for	O
personalization	O
of	O
cancer	O
therapies	O
Methods	O
are	O
disclosed	O
for	O
predicting	O
a	O
patient	O
response	O
to	O
anti	O
-	O
Her2	O
therapy	O
or	O
anti	O
-	O
aromatase	O
therapy	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
methods	O
involve	O
the	O
identification	O
of	O
low	O
molecular	O
weight	O
cyclin	O
E	O
(	O
LMW	O
-	O
E	O
)	O
in	O
cancers	O
,	O
such	O
as	O
breast	O
cancer	O
cells	O
,	O
as	O
a	O
predictive	O
and	O
prognostic	O
marker	O
.	O

In	O
further	O
embodiments	O
,	O
LMW	O
-	O
E	O
expression	O
by	O
a	O
cancerous	O
or	O
pre	O
-	O
cancerous	O
cell	O
may	O
be	O
used	O
to	O
predict	O
response	O
to	O
an	O
aromatase	O
inhibitor	O
and/or	O
CDK2	O
inhibitor	O
,	O
and	O
determination	O
of	O
LMW	O
-	O
E	O
expression	O
may	O
be	O
used	O
in	O
the	O
personalization	O
of	O
cancer	O
therapies	O
.	O

Compound	O
inhibiting	O
in	O
vivo	O
phosphorus	O
transport	O
and	O
medicine	O
containing	O
the	O
same	O
An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
compounds	O
that	O
can	O
effectively	O
suppress	O
the	O
concentration	O
of	O
phosphorus	O
in	O
serum	O
to	O
effectively	O
prevent	O
or	O
treat	O
diseases	O
induced	O
by	O
an	O
increase	O
in	O
concentration	O
of	O
phosphate	O
in	O
serum	O
.	O

The	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
are	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
:	O
wherein	O
A	O
represents	O
an	O
optionally	O
substituted	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
carbocyclic	O
moiety	O
or	O
a	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
heterocyclic	O
moiety	O
,	O
and	O
represents	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
,	O
R5	O
represents	O
optionally	O
substituted	O
aryl	O
or	O
the	O
like	O
,	O
Z	O
represents	O
—N	O
═	O
CHR6R7	O
or	O
the	O
like	O
,	O
R6	O
and	O
R7	O
represent	O
H	O
,	O
optionally	O
substituted	O
alkyl	O
,	O
optionally	O
substituted	O
aryl	O
or	O
the	O
like	O
,	O
R101	O
and	O
R102	O
together	O
form	O
═	O
O	O
,	O
and	O
R103	O
and	O
R104	O
represent	O
H	O
,	O
or	O
R101	O
and	O
R104	O
together	O
from	O
a	O
bond	O
,	O
and	O
R102	O
and	O
R103	O
together	O
form	O
a	O
bond	O
.	O

Facially	O
Amphiphilic	O
Compounds	O
,	O
Compositions	O
,	O
And	O

Uses	O
Thereof	O

In	O
Treating	O
Cancer	O
The	O
present	O
invention	O
discloses	O
compositions	O
of	O
facially	O
amphiphilic	O
compounds	O
and	O
their	O
use	O
in	O
methods	O
for	O
treating	O
or	O
reducing	O
cancers	O
in	O
animals	O
,	O
such	O
as	O
humans	O
.	O

Quinolinone	O
PDE2	B
Inhibitors	O
The	O
present	O
invention	O
is	O
directed	O
to	O
quinolinone	O
compounds	O
which	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders	O
associated	O
with	O
phosphodiesterase	B
2	I
(	O
PDE2	B
)	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
,	O
such	O
as	O
schizophrenia	O
,	O
psychosis	O
or	O
Huntington	O
's	O
disease	O
,	O
and	O
those	O
associated	O
with	O
striatal	O
hypofunction	O
or	O
basal	O
ganglia	O
dysfunction	O
.	O

Isogenic	O
human	O
cell	O
lines	O
comprising	O
mutated	O
cancer	O
alleles	O
and	O
process	O
using	O
the	O
cell	O
lines	O
Isogenic	O
human	O
cell	O
lines	O
comprising	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
,	O
which	O
corresponds	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
are	O
disclosed	O
,	O
as	O
well	O
as	O
an	O
in	O
vitro	O
process	O
for	O
determining	O
sensitivity	O
/	O
resistance	O
of	O
a	O
patient	O
suffering	O
from	O
a	O
tumor	O
to	O
a	O
pharmacological	O
agent	O
comprising	O
the	O
following	O
steps	O
:	O
a	O
)	O
identifying	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
in	O
a	O
tissue	O
affected	O
by	O
a	O
tumor	O
of	O
said	O
patient	O
;	O
b	O
)	O
providing	O
an	O
isogenic	O
human	O
cell	O
line	O
representative	O
of	O
the	O
tissue	O
,	O
wherein	O
the	O
cell	O
line	O
comprises	O
at	O
least	O
the	O
identified	O
mutated	O
cancer	O
allele	O
,	O
which	O
is	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
corresponding	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
;	O
c	O
)	O
putting	O
in	O
contact	O
said	O
cell	O
line	O
with	O
the	O
pharmacological	O
agent	O
;	O
d	O
)	O
determining	O
a	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
or	O
cytotoxicity	O
of	O
the	O
cell	O
line	O
in	O
presence	O
of	O
the	O
pharmacological	O
agent	O
;	O
wherein	O
the	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
car	O
cytotoxicity	O
indicative	O
of	O
the	O
sensitivity	O
/	O
resistance	O
of	O
the	O
patient	O
tumor	O
to	O
the	O
pharmacological	O
agent	O
.	O

PAR-1	B
Activation	O
by	O
Metalloproteinase-1	B
(	O
MMP-1	B
)	O
Matrix	B
metalloproteases	I
(	O
MMPs	B
)	O
play	O
many	O
important	O
roles	O
in	O
normal	O
and	O
pathological	O
remodeling	O
processes	O
including	O
atherothrombotic	O
disease	O
,	O
inflammation	O
,	O
angiogenesis	O
and	O
cancer	O
.	O

This	O
invention	O
relates	O
to	O
the	O
activation	O
of	O
protease	B
-	I
activated	I
receptor-1	I
(	O
PAR-1	B
)	O
by	O
endogenous	O
platelet	O
MMP-1	B
collagenase	B
on	O
the	O
surface	O
of	O
platelets	O
.	O

Exposure	O
of	O
platelets	O
to	O
fibrillar	O
collagen	O
converts	O
the	O
surface	O
-	O
bound	O
pro	B
-	I
MMP-1	I
zymogen	O
to	O
active	O
MMP-1	B
,	O
which	O
promotes	O
aggregation	O
through	O
PAR-1	B
,	O
MMP-1	B
is	O
shown	O
to	O
cleave	O
the	O
PAR-1	B
extracellular	I
domain	I
at	O
a	O
novel	O
site	O
,	O
which	O
then	O
strongly	O
activates	O
Rho	B
-	O
GTP	O
signaling	O
pathways	O
,	O
cell	O
shape	O
change	O
and	O
motility	O
,	O
and	O
MAPK	B
signaling	O
.	O

Blockade	O
of	O
MMP	B
-	O
PAR	B
1	I
suppresses	O
thrombogenesis	O
under	O
arterial	O
flow	O
conditions	O
and	O
inhibited	O
thrombosis	O
in	O
animals	O
.	O

These	O
studies	O
provide	O
a	O
link	O
between	O
matrix	O
-	O
dependent	O
activation	O
of	O
metalloproteases	B
and	O
platelet	O
-	O
G	B
protein	I
signaling	O
and	O
identify	O
MMP-1	B
/	O
PAR-1	B
as	O
a	O
new	O
target	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
arterial	O
thrombosis	O
and	O
other	O
thrombotic	O
diseases	O
.	O

Biomarkers	O
Related	O
to	O
Insulin	B
Resistance	O
and	O
Methods	O
using	O
the	O
Same	O
Biomarkers	O
relating	O
to	O
glucose	O
disposal	O
rate	O
,	O
insulin	B
resistance	O
,	O
and/or	O
insulin	B
resistance	O
-	O
related	O
disorders	O
are	O
provided	O
.	O

Methods	O
based	O
on	O
the	O
same	O
biomarkers	O
are	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
d1-d2	B
dopamine	I
receptor	I
interaction	O
and	O
function	O
The	O
present	O
invention	O
provides	O
for	O
prevention	O
and/or	O
treatment	O
of	O
neurological	O
or	O
neuropsychiatric	O
disorders	O
involving	O
abnormal	O
D1-D2	B
dopamine	I
receptor	I
coupling	O
and/or	O
activation	O
.	O

Methods	O
and	O
agents	O
are	O
provided	O
for	O
modulating	O
dopamine	O
receptor	O
function	O
arising	O
from	O
D1-D2	B
coupling	O
and/or	O
activation	O
.	O

Agents	O
of	O
the	O
present	O
invention	O
include	O
fragments	O
of	O
D2	B
receptor	I
or	O
D1	B
receptor	I
that	O
can	O
disrupt	O
D1-D2	B
coupling	O
.	O

(	O
s	O
)	O
-n	O
-	O
methylnaltrexone	O

This	O
invention	O
relates	O
to	O
S	O
-	O
MNTX	O
,	O
methods	O
of	O
producing	O
S	O
-	O
MNTX	O
,	O
pharmaceutical	O
preparations	O
comprising	O
S	O
-	O
MNTX	O
and	O
methods	O
for	O
their	O
use	O
.	O

Small	O
Molecule	O
Antagonists	O
of	O
Phosphatidylinositol-3,4,5-Triphosphate	O
(	O
PIP3	O
)	O
and	O
Uses	O
Thereof	O
Disclosed	O
are	O
a	O
new	O
class	O
of	O
non	O
-	O
lipid	O
small	O
molecule	O
inhibitors	O
which	O
interfere	O
with	O
the	O
interaction	O
between	O
PIP3	O
and	O
pleckstrin	O
homology	O
domains	O
.	O

These	O
molecules	O
target	O
a	O
broad	O
range	O
of	O
PIP3-dependent	O
signaling	O
events	O
in	O
vitro	O
and	O
exert	O
significant	O
anti	O
-	O
tumor	O
activity	O
in	O
vivo	O
.	O

The	O
small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
can	O
be	O
used	O
alone	O
or	O
together	O
with	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
-related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
other	O
cancer	O
medicament	O
to	O
treat	O
cancer	O
.	O

Small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
act	O
synergistically	O
in	O
combination	O
with	O
TRAIL	O
in	O
treating	O
cancer	O
.	O

Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cancer	O
are	O
provided	O
.	O

Topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
use	O
of	O
tocotrienols	O
for	O
the	O
treatment	O
of	O
ophthalmic	O
diseases	O
A	O
method	O
for	O
preventing	O
,	O
reducing	O
,	O
ameliorating	O
or	O
treating	O
ophthalmic	O
disorders	O
associated	O
with	O
neurodegenerative	O
diseases	O
or	O
trauma	O
,	O
comprising	O
the	O
topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
application	O
of	O
an	O
ophthalmic	O
formulation	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
ophthalmic	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alpha	O
-	O
tocotrienol	O
,	O
beta	O
-	O
tocotrienol	O
,	O
gamma	O
-	O
tocotrienol	O
,	O
delta	O
-	O
tocotrienol	O
,	O
or	O
esters	O
or	O
mixtures	O
thereof	O
is	O
disclosed	O
.	O

Use	O
of	O
tocotrienols	O
for	O
the	O
prevention	O
,	O
reduction	O
,	O
amelioration	O
or	O
treatment	O
of	O
ophthalmic	O
disorders	O
that	O
are	O
,	O
or	O
that	O
are	O
associated	O
with	O
,	O
mitochondrial	O
diseases	O
is	O
also	O
discussed	O
.	O

Topical	O
ophthalmic	O
formulations	O
comprising	O
tocotrienols	O
are	O
also	O
discussed	O
.	O

Method	O
and	O
Pharmaceutical	O
Composition	O
for	O
Use	O
in	O
the	O
Treatment	O
of	O
Neurodegenerative	O
Disorders	O
The	O
invention	O
relates	O
to	O
compounds	O
which	O
activate	O
the	O
BASIGIN	O
signaling	O
pathway	O
,	O
preferably	O
agonists	O
of	O
BASIGIN	O
,	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

Microcapsules	O
containing	O
salts	O
for	O
food	O
products	O
A	O
composition	O
for	O
delivering	O
edible	O
salts	O
into	O
food	O
products	O
via	O
microcapsules	O
having	O
a	O
protein	O
-	O
polysaccharide	O
shell	O
matrix	O
and	O
an	O
edible	O
salt	O
-	O
containing	O
active	O
material	O
.	O

A	O
method	O
of	O
treating	O
osteoporosis	O
is	O
also	O
disclosed	O
.	O

Compositions	O
for	O
Inhibiting	O
Growth	O
of	O
Cancer	O
Stem	O
Cells	O

The	O
present	O
invention	O
is	O
a	O
biomarker	O
of	O
chemotherapeutic	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
and	O
a	O
method	O
of	O
inhibiting	O
the	O
growth	O
of	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
.	O

In	O
one	O
embodiment	O
the	O
cancer	O
stem	O
cells	O
are	O
testicular	O
cancer	O
germ	O
cells	O
.	O

In	O
another	O
embodiment	O
the	O
present	O
invention	O
is	O
a	O
method	O
of	O
overcoming	O
drug	O
resistance	O
in	O
cancer	O
treatment	O
where	O
the	O
combination	O
of	O
low	O
dose	O
decitabine	O
and	O
administration	O
of	O
a	O
chemotherapeutic	O
drug	O
to	O
which	O
cancer	O
cells	O
were	O
resistant	O
results	O
in	O
successful	O
cancer	O
treatment	O
.	O

Homeopathic	O
Formulations	O
For	O
Treatment	O
Of	O
Herpes	O
Virus	O
Symptoms	O
Compositions	O
and	O
methods	O
of	O
preparing	O
and	O
using	O
such	O
compositions	O
to	O
treat	O
the	O
symptoms	O
of	O
herpes	O
virus	O
.	O

Methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O
Compounds	O
that	O
selectively	O
inhibit	O
pathological	O
production	O
of	O
human	B
vascular	I
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Compounds	O
that	O
inhibit	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
reducing	O
VEGF	B
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

Further	O
described	O
are	O
methods	O
of	O
inhibiting	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
viral	O
infections	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

The	O
Compounds	O
may	O
be	O
administered	O
as	O
a	O
single	O
agent	O
therapy	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapies	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatments	O
.	O

Tricyclic	O
and	O
Tetracyclic	O
Systems	O
with	O
Activity	O
on	O
the	O
Central	O
Nervous	O
and	O
Vascular	O
Systems	O

The	O
present	O
invention	O
relates	O
to	O
chemistry	O
and	O
pharmacy	O
and	O
,	O
in	O
particular	O
,	O
to	O
the	O
production	O
of	O
novel	O
molecular	O
entities	O
,	O
tricyclic	O
and	O
tetracyclic	O
derivatives	O
of	O
benzodiazepine	O
,	O
pyridodiazepine	O
and	O
pyrimidodiazepine	O
type	O
fused	O
with	O
1,4-dihydropyridine	O
derivatives	O
,	O
having	O
an	O
effect	O
on	O
the	O
central	O
-	O
nervous	O
and	O
vascular	O
systems	O
.	O

Derivatives	O
containing	O
a	O
dihydropyridine	O
ring	O
are	O
used	O
,	O
by	O
means	O
of	O
reactions	O
with	O
compounds	O
of	O
the	O
ortho	O
-	O
phenylenediamine	O
,	O
ortho	O
-	O
diaminopyridine	O
and	O
ortho	O
-	O
diaminopyrimidine	O
type	O
,	O
and	O
also	O
subsequent	O
conversions	O
to	O
some	O
thereof	O
,	O
to	O
obtain	O
tricyclic	O
and	O
tetracyclic	O
derivatives	O
of	O
general	O
formula	O
I	O
-	O
XII	O
that	O
contain	O
a	O
diazepine	O
or	O
diazepinone	O
nucleus	O
fused	O
to	O
a	O
1,4-dihydropyridine	O
nucleus	O
,	O
in	O
which	O
the	O
A	O
ring	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
benzene	O
,	O
pyridine	O
or	O
pyrimidine	O
ring	O
.	O

These	O
molecular	O
entities	O
exhibit	O
GABAergica	O
and	O
modulating	O
action	O
in	O
the	O
case	O
of	O
calcium	O
channels	O
which	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
cardiovascular	O
,	O
cerebrovascular	O
,	O
neurodegenerative	O
,	O
neuropsychiatric	O
and	O
neurological	O
disorders	O
.	O

Combination	O
therapy	O
using	O
a	O
beta	B
3	I
adrenergic	I
receptor	I
agonists	O
and	O
an	O
antimuscarinic	O
agent	O
Described	O
herein	O
is	O
an	O
improved	O
method	O
of	O
treating	O
overactive	O
bladder	O
,	O
wherein	O
the	O
method	O
comprises	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
beta	B
3	I
adrenergic	I
receptor	I
agonist	O
,	O
an	O
antimuscarinic	O
agent	O
,	O
and	O
an	O
optional	O
selective	O
M2	B
antagonist	O
.	O

Such	O
combination	O
therapy	O
provides	O
improved	O
efficacy	O
and/or	O
reduced	O
side	O
effects	O
.	O

Novel	O
Tetrahydroisoquinoline	O
Compounds	O
The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
having	O
an	O
excellent	O
DGAT	B
inhibitory	O
effect	O
and	O
feeding	O
suppressant	O
effect	O
.	O

The	O
present	O
invention	O
provides	O
trans-6-	O
[	O
3-	O
(	O
2,4-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2-chloro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,3-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,5-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,6-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
or	O
the	O
like	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Selenium	O
Nanoparticles	O
with	O
Improvded	O
Biological	O
Effects	O
Novel	O
methods	O
for	O
biological	O
effective	O
,	O
stable	O
amorphous	O
and	O
monoclinic	O
selenium	O
nanoparticles	O
are	O
disclosed	O
.	O

They	O
are	O
prepared	O
by	O
reacting	O
selenium	O
source	O
with	O
a	O
reducing	O
agent	O
or	O
an	O
oxidative	O
agent	O
in	O
an	O
aqueous	O
media	O
at	O
a	O
temperature	O
between	O
0	O
-	O
100	O
°	O
C.	O
in	O
the	O
presence	O
of	O
selenium	O
binding	O
polymer	O
molecules	O
such	O
as	O
poly	O
/	O
oligopeptide	O
acids	O
or	O
peptone	O
or	O
nucleic	O
acids	O
or	O
poly	O
/	O
oligosaccharide	O
or	O
their	O
mixtures	O
.	O

Methods	O
of	O
treating	O
or	O
preventing	O
influenza	O
associated	O
illness	O
with	O
oxidative	O
reductive	O
potential	O
water	O
solutions	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
,	O
reducing	O
,	O
and/or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
oxidative	O
reductive	O
potential	O
(	O
ORP	O
)	O
water	O
solution	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
reducing	O
or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
associated	O
with	O
a	O
medical	O
device	O
comprising	O
contacting	O
the	O
medical	O
device	O
with	O
an	O
effective	O
amount	O
of	O
an	O
ORP	O
water	O
solution	O
.	O

Versatile	O
nanoparticulate	O
biomaterial	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and	O
diagnostic	O
material	O
The	O
invention	O
provides	O
compositions	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and/or	O
diagnostic	O
agents	O
comprising	O
the	O
agent	O
or	O
agents	O
encapsulated	O
by	O
a	O
matrix	O
containing	O
chitosan	O
,	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
and/or	O
polyvinyl	O
alcohol	O
(	O
PVA	O
)	O
,	O
and	O
tetra	O
-	O
methoxy	O
-	O
ortho	O
-	O
silicate	O
(	O
TMOS	O
)	O
or	O
tetra	O
-	O
ethoxy	O
-	O
ortho	O
-	O
silicate	O
(	O
TEOS	O
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
the	O
compositions	O
,	O
and	O
uses	O
of	O
the	O
compositions	O
for	O
therapy	O
and	O
imaging	O
.	O

Compositions	O
of	O
omega	O
fatty	O
acids	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O
The	O
present	O
invention	O
discloses	O
compositions	O
of	O
omega	O
polyunsaturated	O
fatty	O
acids	O
for	O
controlling	O
and	O
preventing	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O
.	O

The	O
compositions	O
of	O
fatty	O
acids	O
include	O
omega-3	O
fatty	O
acids	O
,	O
omega-6	O
fatty	O
acids	O
,	O
and	O
other	O
fatty	O
acids	O
,	O
for	O
their	O
synergistic	O
bioactivity	O
against	O
cariogenic	O
pathogens	O
.	O

The	O
application	O
of	O
this	O
composition	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
drugs	O
,	O
nutritional	O
supplements	O
,	O
food	O
and	O
daily	O
necessities	O
with	O
oral	O
health	O
care	O
and	O
therapeutic	O
effects	O
.	O

Proteostasis	O
regulators	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formulae	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
,	O
(	O
V	O
)	O
,	O
(	O
VI	O
)	O
,	O
(	O
VII	O
)	O
,	O
and	O
(	O
VIII	O
)	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
a	O
dysfunction	O
in	O
proteostasis	O
.	O

Molecular	O
Predictors	O
of	O
Therapeutic	O
Response	O
to	O
Specific	O
Anti	O
-	O
Cancer	O
Agents	O
Herein	O
is	O
described	O
the	O
use	O
of	O
a	O
collection	O
of	O
50	O
breast	O
cancer	O
cell	O
lines	O
to	O
match	O
responses	O
to	O
77	O
conventional	O
and	O
experimental	O
therapeutic	O
agents	O
with	O
transcriptional	O
,	O
proteomic	O
and	O
genomic	O
subtypes	O
found	O
in	O
primary	O
tumors	O
.	O

Almost	O
all	O
compounds	O
produced	O
strong	O
differential	O
responses	O
across	O
the	O
cell	O
lines	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
transcriptional	O
and	O
proteomic	O
subtypes	O
and	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
recurrent	O
genome	O
copy	O
number	O
abnormalities	O
.	O

These	O
associations	O
can	O
now	O
be	O
incorporated	O
into	O
clinical	O
trials	O
that	O
test	O
subtype	O
markers	O
and	O
clinical	O
responses	O
simultaneously	O
.	O

Method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
smn1	B
)	O
and	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
l1	I
(	O
uchl1	B
)	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
SMN1	B
)	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
L1	I
(	O
UCHL1	B
)	O
regulator	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
L1	I
(	O
UCHL1	B
)	O
in	O
human	O
fibroblasts	O
comprising	O
detecting	O
protein	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
SMN1	B
)	O
.	O

Anti	O
-	O
miR-1	B
Therapy	O
for	O
Wound	O
Healing	O
Methods	O
for	O
modulating	O
gene	O
expression	O
in	O
a	O
skin	O
cell	O
by	O
administering	O
to	O
the	O
cell	O
an	O
amount	O
of	O
a	O
therapeutic	O
composition	O
in	O
an	O
amount	O
sufficient	O
to	O
modulate	O
the	O
expression	O
of	O
miR-1	B
,	O
and	O
therapeutic	O
compositions	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

Stable	O
rasagiline	O
composition	O
The	O
present	O
invention	O
provides	O
a	O
stable	O
composition	O
of	O
rasagiline	O
comprising	O
an	O
effective	O
dosage	O
of	O
rasagiline	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
and	O
an	O
antioxidant	O
used	O
as	O
a	O
stabilizer	O
.	O

The	O
dosage	O
forms	O
of	O
the	O
composition	O
are	O
pharmaceutically	O
common	O
transdermal	O
-	O
drug	O
delivery	O
dosage	O
form	O
and	O
mucoadhesive	O
delivery	O
dosage	O
form	O
,	O
such	O
as	O
patch	O
,	O
gel	O
,	O
ointment	O
,	O
cream	O
,	O
cataplasm	O
,	O
film	O
,	O
spray	O
and	O
solution	O
,	O
etc	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
prevent	O
or	O
treat	O
mental	O
disorders	O
.	O

Inhibitions	O
of	O
glutaminase	O
c	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
reducing	O
the	O
production	O
of	O
glutamate	O
from	O
glutamine	O
by	O
glutaminase	O
C	O
in	O
a	O
cell	O
or	O
tissue	O
.	O

The	O
method	O
involves	O
inhibiting	O
glutaminase	O
C	O
activity	O
in	O
the	O
cell	O
or	O
tissue	O
under	O
conditions	O
effective	O
to	O
reduce	O
production	O
of	O
glutamate	O
from	O
glutamine	O
.	O

Compounds	O
for	O
carrying	O
out	O
this	O
method	O
are	O
also	O
disclosed	O
.	O

Novel	O
dental	O
appliances	O
and	O
methods	O
for	O
their	O
fabrication	O
The	O
invention	O
consists	O
of	O
a	O
rapidly	O
crosslinkable	O
,	O
two	O
-	O
component	O
silicone	O
elastomer	O
together	O
with	O
a	O
specially	O
designed	O
tray	O
that	O
serves	O
as	O
a	O
form	O
for	O
the	O
silicone	O
resin	O
and	O
forms	O
an	O
integral	O
portion	O
of	O
a	O
dental	O
appliance	O
.	O

Pegylated	O
polyplexes	O
containing	O
two	O
or	O
more	O
different	O
polymers	O
for	O
polynucleotide	O
delivery	O
The	O
present	O
invention	O
provides	O
polymers	O
,	O
compositions	O
thereof	O
,	O
and	O
polyplexes	O
comprising	O
said	O
polymers	O
.	O

In	O
particular	O
,	O
cationic	O
polymers	O
,	O
pegylated	O
versions	O
thereof	O
,	O
and	O
polynucleotide	O
containing	O
polyplexes	O
comprising	O
such	O
polymers	O
are	O
provided	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
of	O
using	O
said	O
polymers	O
and	O
polyplexes	O
.	O

Bioactive	O
Load	O
-	O
Bearing	O
Composites	O
Methods	O
of	O
preparing	O
bioactive	O
composites	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
molding	O
such	O
composites	O
.	O

Shaped	O
bodies	O
comprising	O
bioactive	O
composites	O
are	O
further	O
described	O
.	O

Method	O
of	O
treating	O
cancers	O
and	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
The	O
method	O
of	O
treating	O
a	O
person	O
having	O
a	O
cancer	O
selected	O
from	O
carcinoma	O
,	O
sarcoma	O
or	O
hematopoietic	O
cancer	O
by	O
administering	O
(	O
a	O
)	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
anti	O
-	O
cancer	O
drug	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
inhibitor	O
,	O
a	O
vascular	B
endothelial	I
growth	I
factor	I
receptor	I
(	O
VEGFR	B
)	O
inhibitor	O
and	O
a	O
Raf	B
kinase	O
inhibitor	O
and	O
(	O
b	O
)	O
an	O
effective	O
amount	O
of	O
5-	O
(	O
4-	O
(	O
6-	O
(	O
4-amino-3,5-dimethyl	O
-	O
phenoxy	O
)	O
-1-methyl-1H	O
-	O
benzimidazol-2-ylmethoxy	O
)	O
-benzyl	O
)	O
-thiazolidine-2,4-dione.dihydrochloride	O
provided	O
that	O
said	O
carcinoma	O
is	O
not	O
lung	O
cancer	O
when	O
an	O
EGFR	B
inhibitor	O
is	O
erlotinib	O
.	O

The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
.	O

Adamantane	O
analogs	O
Provided	O
are	O
compounds	O
that	O
are	O
capable	O
of	O
modulating	O
the	O
activity	O
of	O
the	O
influenza	O
A	O
virus	O
via	O
interaction	O
with	O
the	O
M2	B
transmembrane	I
protein	I
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
an	O
influenza	O
A	O
-	O
affected	O
disease	O
state	O
or	O
infection	O
comprising	O
administering	O
a	O
composition	O
comprising	O
one	O
or	O
more	O
compounds	O
that	O
have	O
been	O
identified	O
as	O
being	O
capable	O
of	O
interaction	O
with	O
the	O
M2	B
protein	I
.	O

Rapidly	O
disintegrating	O
tablet	O
in	O
oral	O
cavity	O
The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
suppressing	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
when	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
.	O

When	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
,	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
is	O
suppressed	O
by	O
utilizing	O
(	O
a	O
)	O
a	O
granule	O
which	O
contains	O
a	O
drug	O
having	O
a	O
bitter	O
taste	O
and	O
an	O
excipient	O
and	O
in	O
which	O
the	O
bitter	O
taste	O
has	O
not	O
been	O
suppressed	O
and	O
(	O
b	O
)	O
a	O
granule	O
containing	O
a	O
water	O
soluble	O
saccharide	O
.	O

Microgel	O
compositions	O
This	O
invention	O
relates	O
to	O
microgel	O
compositions	O
,	O
and	O
in	O
particular	O
,	O
to	O
gel	O
compositions	O
formed	O
by	O
binding	O
a	O
plurality	O
of	O
individual	O
microgel	O
particles	O
together	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
compositions	O
and	O
their	O
use	O
for	O
particular	O
applications	O
,	O
especially	O
medical	O
applications	O
such	O
as	O
the	O
repair	O
of	O
damaged	O
,	O
degenerated	O
or	O
inappropriately	O
formed	O
load	O
-	O
bearing	O
tissue	O
(	O
such	O
as	O
,	O
for	O
example	O
,	O
intervertebral	O
discs	O
)	O
.	O

Compositions	O
of	O
Apatite	O
and	O
Methods	O
of	O
Use	O
Compositions	O
of	O
apatite	O
derivative	O
crystals	O
are	O
disclosed	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
tooth	O
sensitivity	O
,	O
to	O
use	O
as	O
an	O
anticaries	O
treatment	O
,	O
to	O
use	O
as	O
a	O
restorative	O
material	O
,	O
to	O
use	O
as	O
a	O
tooth	O
surface	O
whitener	O
,	O
and	O
to	O
combat	O
or	O
lessen	O
the	O
side	O
effects	O
of	O
tooth	O
whitening	O
.	O

Inhibiting	O
hepatitis	O
c	O
viral	O
replication	O
with	O
sirna	O
combinations	O
Compositions	O
are	O
disclosed	O
of	O
combinations	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNA	O
)	O
that	O
can	O
inhibit	O
the	O
replication	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
in	O
liver	O
cells	O
,	O
along	O
with	O
methods	O
of	O
co	O
-	O
administering	O
the	O
siRNAs	O
to	O
subjects	O
.	O

Further	O
,	O
methods	O
are	O
disclosed	O
for	O
improving	O
the	O
delivery	O
of	O
nucleic	O
acids	O
to	O
the	O
liver	O
.	O

5-membered	O
heterocycle	O
derivatives	O
and	O
manufacturing	O
process	O
thereof	O
Disclosed	O
are	O
a	O
novel	O
5-membered	O
heterocycle	O
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
a	O
pharmaceutical	O
use	O
thereof	O
.	O

The	O
5-membered	O
heterocycle	O
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
compositions	O
containing	O
them	O
are	O
useful	O
for	O
treating	O
a	O
tumor	O
.	O

Novel	O
uses	O
of	O
adipic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
or	O
insulin	B
resistance	O
syndrome	O
,	O
comprising	O
:	O
administering	O
to	O
a	O
mammalian	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
adipic	O
acid	O
.	O

The	O
present	O
composition	O
containing	O
adipic	O
acid	O
as	O
an	O
active	O
ingredient	O
is	O
very	O
effective	O
in	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
(	O
preferably	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
)	O
or	O
insulin	B
resistance	O
syndrome	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
useful	O
as	O
pharmaceuticals	O
compositions	O
or	O
functional	O
food	O
compositions	O
has	O
therapeutic	O
efficacies	O
for	O
obesity	O
,	O
dyslipidemia	O
or	O
fatty	O
liver	O
,	O
and	O
also	O
induces	O
significant	O
decrease	O
in	O
fasting	O
glucose	O
level	O
and	O
blood	O
insulin	B
level	O
to	O
improve	O
type	O
2	O
diabetes	O
,	O
insulin	B
resistance	O
and	O
related	O
metabolic	O
diseases	O
.	O

Cutaneous	O
composition	O
comprising	O
vitamin	O
d	O
analogue	O
and	O
a	O
mixture	O
of	O
solvent	O
and	O
surfactants	O
A	O
pharmaceutical	O
composition	O
comprising	O
a	O
vitamin	O
D	O
derivative	O
or	O
analogue	O
as	O
the	O
active	O
ingredient	O
dissolved	O
in	O
a	O
three	O
-	O
component	O
surfactant	O
-	O
solvent	O
mixture	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
dermal	O
disorders	O
or	O
conditions	O
.	O

Pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
A	O
pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
is	O
disclosed	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
comprises	O
:	O
a	O
first	O
pharmaceutical	O
composition	O
comprising	O
a	O
first	O
effective	O
amount	O
of	O
a	O
Mg2	O
+	O
-containing	O
compound	O
;	O
and	O
a	O
second	O
pharmaceutical	O
composition	O
comprising	O
a	O
second	O
effective	O
amount	O
of	O
a	O
COX-2	B
inhibitor	O
.	O

Nucleic	O
acid	O
molecules	O
encoding	O
bank1	B
splice	O
variants	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
splice	O
variant	O
of	O
BANK1	B
,	O
the	O
use	O
of	O
SNPs	O
in	O
BANK1	B
for	O
diagnostics	O
and	O
the	O
use	O
of	O
antagonists	O
to	O
modulate	O
BANK1	B
and/or	O
the	O
BANK1	B
pathway	O
.	O

Hydrogel	O
materials	O
incorporating	O
eluting	O
ceragenin	O
compound	O
A	O
hydrogel	O
polymer	O
includes	O
a	O
ceragenin	O
compound	O
.	O

The	O
ceragenin	O
compound	O
has	O
a	O
hydrophobicity	O
/	O
hydrophilicity	O
that	O
produces	O
a	O
release	O
rate	O
in	O
a	O
range	O
of	O
0.1	O
-	O
100	O
μg	O
/	O
ml	O
for	O
at	O
least	O
3	O
days	O
.	O

Aqueous	O
Pharmaceutical	O
Formulation	O
of	O
Tapentadol	O
for	O
Oral	O
Administration	O
An	O
aqueous	O
pharmaceutical	O
composition	O
containing	O
tapentadol	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
thereof	O
and	O
being	O
adapted	O
for	O
oral	O
administration	O
.	O

The	O
composition	O
has	O
excellent	O
storage	O
stability	O
without	O
relying	O
on	O
the	O
presence	O
of	O
high	O
amounts	O
of	O
preservatives	O
.	O

Promyelocytic	B
leukemia	I
protein	I
as	O
a	O
redox	O
sensor	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
determining	O
the	O
redox	O
status	O
of	O
a	O
cell	O
or	O
tissue	O
comprising	O
a	O
step	O
consisting	O
of	O
determining	O
the	O
level	O
of	O
PML	B
nuclear	O
bodies	O
in	O
said	O
cell	O
or	O
tissue	O
.	O

Drug	O
-	O
delivery	O
endovascular	O
stent	O
and	O
method	O
of	O
forming	O
the	O
same	O
An	O
intravascular	O
stent	O
and	O
method	O
for	O
inhibiting	O
restenosis	O
,	O
following	O
vascular	O
injury	O
,	O
is	O
disclosed	O
.	O

The	O
stent	O
has	O
an	O
expandable	O
,	O
linked	O
-	O
filament	O
body	O
and	O
a	O
drug	O
-	O
release	O
coating	O
formed	O
on	O
the	O
stent	O
-	O
body	O
filaments	O
,	O
for	O
contacting	O
the	O
vessel	O
injury	O
site	O
when	O
the	O
stent	O
is	O
placed	O
in	O
-	O
situ	O
in	O
an	O
expanded	O
condition	O
.	O

The	O
coating	O
releases	O
,	O
for	O
a	O
period	O
of	O
at	O
least	O
4	O
weeks	O
,	O
a	O
restenosis	O
-	O
inhibiting	O
amount	O
of	O
a	O
monocyclic	O
triene	O
immunosuppressive	O
compound	O
having	O
an	O
alkyl	O
group	O
substituent	O
at	O
carbon	O
position	O
40	O
in	O
the	O
compound	O
.	O

The	O
stent	O
,	O
when	O
used	O
to	O
treat	O
a	O
vascular	O
injury	O
,	O
gives	O
good	O
protection	O
against	O
clinical	O
restenosis	O
,	O
even	O
when	O
the	O
extent	O
of	O
vascular	O
injury	O
involves	O
vessel	O
overstretching	O
by	O
more	O
than	O
30	O
%	O
diameter	O
.	O

Also	O
disclosed	O
is	O
a	O
stent	O
having	O
a	O
drug	O
-	O
release	O
coating	O
composed	O
of	O
(	O
i	O
)	O
10	O
and	O
60	O
weight	O
percent	O
poly	O
-	O
dl	O
-	O
Iactide	O
polymer	O
substrate	O
and	O
(	O
ii	O
)	O
40	O
-	O
90	O
weight	O
percent	O
of	O
an	O
anti	O
-	O
restenosis	O
compound	O
,	O
and	O
a	O
polymer	O
undercoat	O
having	O
a	O
thickness	O
of	O
between	O
1	O
-	O
5	O
microns	O
.	O

Compositions	O
and	O
Methods	O
for	O
Treating	O
Pain	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
pain	O
in	O
mammals	O
.	O

A	O
composition	O
of	O
the	O
invention	O
comprises	O
one	O
or	O
more	O
anti	O
-	O
inflammatory	O
agents	O
and	O
optionally	O
contains	O
one	O
or	O
more	O
anti	O
-	O
oxidants	O
and	O
immune	O
system	O
boosting	O
agents	O
.	O

Modified	O
release	O
dosage	O
form	O
comprising	O
desvenlafaxine	O
or	O
salts	O
thereof	O
The	O
present	O
invention	O
refers	O
to	O
a	O
modified	O
release	O
pharmaceutical	O
composition	O
comprising	O
desvenlafaxine	O
or	O
salts	O
thereof	O
,	O
a	O
release	O
rate	O
modifying	O
system	O
that	O
controls	O
the	O
release	O
of	O
active	O
agent	O
(	O
s	O
)	O
in	O
both	O
acidic	O
and	O
basic	O
environments	O
.	O

A	O
process	O
of	O
making	O
and	O
method	O
of	O
using	O
the	O
above	O
-	O
described	O
composition	O
is	O
also	O
disclosed	O
.	O

Substituted	O
Carbonyloxymethylphosphoramidate	O
Compounds	O
and	O
Pharmaceutical	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Viral	O
Infections	O
Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
liver	O
disorders	O
,	O
including	O
HCV	O
infections	O
.	O

In	O
certain	O
embodiments	O
,	O
compounds	O
and	O
compositions	O
of	O
nucleoside	O
derivatives	O
are	O
disclosed	O
,	O
which	O
can	O
be	O
administered	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
anti	O
-	O
viral	O
agents	O
.	O

COMPOUNDS	O
AS	O
RORyT	B
MODULATORS	O
AND	O
USES	O
THEREOF	O
Heterocyclic	O
compounds	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
are	O
disclosed	O
as	O
RORγt	B
modulators	O
that	O
have	O
a	O
formula	O
represented	O
by	O
the	O
following	O
:	O
and	O
wherein	O
n1	O
,	O
n2	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O

These	O
compounds	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non	O
-	O
limiting	O
example	O
,	O
inflammatory	O
conditions	O
,	O
autoimmune	O
disorders	O
,	O
cancer	O
,	O
and	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O

Method	O
of	O
Achieving	O
Improved	O
Hair	O
Feel	O
A	O
method	O
of	O
achieving	O
improved	O
hair	O
feel	O
.	O

The	O
method	O
comprises	O
applying	O
to	O
hair	O
a	O
composition	O
comprising	O
:	O
(	O
a	O
)	O
a	O
specific	O
cationic	O
guar	O
polymer	O
;	O
(	O
b	O
)	O
a	O
specific	O
cationic	O
copolymer	O
;	O
(	O
c	O
)	O
an	O
anti	O
-	O
dandruff	O
active	O
;	O
(	O
d	O
)	O
a	O
cosmetically	O
acceptable	O
carrier	O
;	O
(	O
e	O
)	O
a	O
surfactant	O
;	O
wherein	O
the	O
weight	O
ratio	O
of	O
(	O
a	O
)	O
:	O
(	O
b	O
)	O
is	O
from	O
about	O
1000:1	O
to	O
about	O
3.5:1	O
;	O
and	O
wherein	O
the	O
sum	O
of	O
(	O
a	O
)	O
+	O
(	O
b	O
)	O
is	O
an	O
amount	O
of	O
from	O
about	O
0.0001	O
%	O
to	O
about	O
0.7	O
%	O
,	O
by	O
total	O
weight	O
of	O
the	O
composition	O
.	O

The	O
composition	O
forms	O
coacervate	O
particles	O
upon	O
dilution	O
of	O
the	O
composition	O
with	O
water	O
and	O
the	O
coacervate	O
particles	O
have	O
a	O
squeeze	O
flow	O
viscosity	O
of	O
from	O
about	O
1	O
cP	O
to	O
about	O
100	O
cP.	O
The	O
percentage	O
of	O
coacervate	O
particles	O
with	O
a	O
floc	O
size	O
of	O
greater	O
than	O
about	O
20	O
micron	O
is	O
from	O
about	O
1	O
%	O
to	O
about	O
60	O
%	O
and	O
the	O
on	O
-	O
scalp	O
deposition	O
of	O
the	O
anti	O
-	O
dandruff	O
active	O
is	O
at	O
least	O
about	O
1	O
microgram	O
/	O
cm2	O
.	O

Antimicrobial	O
carboline	O
compounds	O
The	O
invention	O
provides	O
compositions	O
comprising	O
carboline	O
compounds	O
for	O
treating	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
of	O
other	O
infections	O
,	O
including	O
ocular	O
infections	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
carboline	O
compounds	O
for	O
the	O
treatment	O
of	O
ocular	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
,	O
particularly	O
those	O
caused	O
by	O
adenovirus	O

Novel	O
iso	O
-	O
ergoline	O
derivatives	O
Provided	O
herein	O
are	O
novel	O
iso	O
-	O
ergoline	O
derivatives	O
and	O
compositions	O
thereof	O
.	O

In	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
5-HT1D	O
and/or	O
the	O
5-HT1Breceptor	O
,	O
without	O
agonizing	O
the	O
5-HT2B	O
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
adrenergic	O
alpha2A	O
and/or	O
the	O
alpha2Breceptors	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

Administration	O
of	O
intravenous	O
ibuprofen	O
to	O
trauma	O
patients	O
A	O
method	O
for	O
treating	O
human	O
patients	O
who	O
require	O
hospitalization	O
for	O
a	O
trauma	O
injury	O
wherein	O
the	O
patients	O
are	O
intravenously	O
administered	O
a	O
first	O
dose	O
of	O
a	O
therapeutically	O
effective	O
dose	O
of	O
ibuprofen	O
intravenously	O
as	O
soon	O
as	O
possible	O
after	O
hospitalization	O
is	O
disclosed	O
.	O

The	O
patients	O
are	O
further	O
treated	O
with	O
intravenous	O
ibuprofen	O
at	O
suitable	O
dosing	O
intervals	O
to	O
the	O
human	O
patient	O
until	O
(	O
a	O
)	O
the	O
patient	O
no	O
longer	O
requires	O
intravenous	O
dosing	O
of	O
ibuprofen	O
.	O

Method	O
and	O
composition	O
for	O
ameliorating	O
the	O
effects	O
for	O
a	O
subject	O
exposed	O
to	O
radiation	O
or	O
other	O
sources	O
of	O
oxidative	O
stress	O
Radiation	O
-	O
oxidative	O
exposure	O
treatment	O
compositions	O
may	O
include	O
a	O
mixture	O
of	O
micronutrient	O
multivitamin	O
and	O
trace	O
elements	O
,	O
a	O
mixture	O
of	O
antioxidants	O
and	O
chemopreventative	O
agents	O
,	O
and	O
optionally	O
a	O
mixture	O
of	O
fatty	O
acids	O
.	O

Methods	O
of	O
treatment	O
of	O
a	O
subject	O
exposed	O
to	O
a	O
radiation	O
source	O
or	O
an	O
oxidative	O
stress	O
with	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
may	O
include	O
the	O
step	O
of	O
administering	O
to	O
the	O
subject	O
a	O
daily	O
dose	O
of	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
such	O
that	O
the	O
life	O
shortening	O
effects	O
induced	O
by	O
the	O
radiation	O
source	O
or	O
the	O
oxidative	O
stress	O
are	O
ameliorated	O
.	O

Nanoparticles	O
,	O
Compositions	O
Thereof	O
,	O
and	O
Methods	O
of	O
Use	O
,	O
and	O
Methods	O
of	O
Making	O
the	O
Same	O
The	O
disclosure	O
is	O
directed	O
to	O
a	O
nanoparticle	O
comprising	O
a	O
porous	O
framework	O
core	O
including	O
a	O
porous	O
framework	O
material	O
and	O
a	O
compound	O
,	O
and	O
a	O
lipid	O
layer	O
disposed	O
on	O
the	O
surface	O
of	O
the	O
porous	O
framework	O
core	O
.	O

Controlled	O
release	O
hydrocodone	O
A	O
solid	O
oral	O
controlled	O
-	O
release	O
dosage	O
form	O
of	O
hydrocodone	O
is	O
disclosed	O
,	O
the	O
dosage	O
form	O
comprising	O
an	O
analgesically	O
effective	O
amount	O
of	O
hydrocodone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
controlled	O
release	O
material	O
.	O

Fullerene	O
derivative	O
and	O
composition	O
comprising	O
the	O
same	O
A	O
fullerene	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
wherein	O
,	O
A	O
is	O
a	O
residue	O
of	O
monosaccharides	O
or	O
disaccharides	O
,	O
and	O
Alk	O
is	O
a	O
lower	O
alkylene	O
group	O
,	O
the	O
group	O
represented	O
by	O
the	O
formula	O
(	O
X	O
)	O
:	O
is	O
a	O
fullerene	O
residual	O
skeleton	O
,	O
and	O
n	O
is	O
an	O
integral	O
number	O
of	O
1	O
or	O
2	O
]	O
or	O
its	O
salt	O
produces	O
a	O
formulation	O
usable	O
for	O
PDT	O
which	O
has	O
more	O
hydrophilicity	O
and	O
lipophilicity	O
,	O
is	O
expected	O
to	O
have	O
selectivity	O
to	O
tumor	O
cells	O
by	O
cell	O
recognition	O
,	O
shows	O
no	O
toxicity	O
to	O
the	O
cells	O
in	O
a	O
dark	O
place	O
and	O
has	O
a	O
cytocidal	O
effect	O
by	O
light	O
irradiation	O
.	O

Method	O
for	O
producing	O
a	O
tablet	O
made	O
of	O
isomaltulose	O
,	O
isomalt	O
or	O
isomalt	O
variants	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
producing	O
an	O
improved	O
compressed	O
product	O
,	O
wherein	O
agglomeration	O
of	O
the	O
ingredients	O
is	O
induced	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
compressed	O
product	O
produced	O
by	O
this	O
method	O
.	O

2-Ureido	O
-	O
thiazole	O
derivatives	O
,	O
process	O
for	O
their	O
preparation	O
,	O
and	O
their	O
use	O
as	O
antitumor	O
agents	O
Compounds	O
which	O
are	O
2-ureido-1,3-thiazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
a	O
halogen	O
atom	O
,	O
a	O
nitro	O
group	O
,	O
an	O
optionally	O
substituted	O
amino	O
group	O
or	O
it	O
is	O
a	O
group	O
optionally	O
further	O
substituted	O
,	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
C3-C6	O
cycloalkyl	O
;	O
iii	O
)	O
aryl	O
or	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
3	O
to	O
6	O
membered	O
carbocycle	O
or	O
5	O
to	O
7	O
membered	O
heterocycle	O
ring	O
;	O
iii	O
)	O
aryl	O
or	O
arylcarbonyl	O
;	O
iv	O
)	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R2	O
is	O
hydrogen	O
,	O
a	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
or	O
C2-C4	O
alkenyl	O
or	O
alkynyl	O
group	O
;	O
or	O
,	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
so	O
which	O
they	O
are	O
bonded	O
,	O
R1	O
and	O
R2	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
an	O
optionally	O
benzocondensed	O
or	O
bridged	O
5	O
to	O
7	O
membered	O
heterocycle	O
;	O
or	O
ii	O
)	O
a	O
9	O
to	O
11	O
membered	O
spiro	O
-	O
heterocyclic	O
compound	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
are	O
useful	O
for	O
treating	O
cell	O
proliferative	O
disorders	O
associated	O
with	O
an	O
altered	O
cell	O
dependent	O
kinase	O
activity	O
.	O

Oxalipatinum	O
preparation	O
packaging	O
Flexible	O
impervious	O
bag	O
for	O
medical	O
use	O
containing	O
a	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	O
said	O
flexible	O
bag	O
is	O
constructed	O
from	O
plastic	O
materials	O
,	O
with	O
the	O
proviso	O
that	O
any	O
portion	O
to	O
the	O
bag	O
in	O
direct	O
contact	O
with	O
said	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	O
does	O
not	O
contain	O
polyvinylchloride	O
-	O
based	O
plastic	O
material	O
.	O

Useful	O
for	O
relieving	O
infertility	O
in	O
females	O
and	O
males	O
Certain	O
novel	O
sterol	O
derivatives	O
can	O
be	O
used	O
for	O
regulating	O
the	O
meiosis	O
in	O
oocytes	O
and	O
in	O
male	O
germ	O
cells	O
.	O

Viricides	O
;	O
human	O
immunodeficiency	O
virus	O
Compounds	O
of	O
the	O
formula	O
I	O
:	O
where	O
;	O
R1	O
is	O
O	O
,	O
S	O
;	O
R2	O
is	O
an	O
optionally	O
substituted	O
nitrogen	O
-	O
containing	O
heterocycle	O
,	O
wherein	O
the	O
nitrogen	O
is	O
located	O
at	O
the	O
2	O
position	O
relative	O
to	O
the	O
(	O
thio	O
)	O
urea	O
bond	O
;	O
R3	O
is	O
H	O
,	O
C1-C3	O
alkyl	O
,	O
R4-R7	O
are	O
independently	O
selected	O
from	O
H	O
,	O
C1-C6	O
alkyl	O
,	O
C2-C6	O
alkenyl	O
,	O
C2-C6	O
alkynyl	O
,	O
haloC1-C6	O
alkyl	O
,	O
C1-C6	O
alkanoyl	O
,	O
haloC1-C6	O
alkanoyl	O
,	O
C1-C6	O
alkoxy	O
,	O
haloC1-C6	O
alkoxy	O
,	O
C1-C6	O
alkyloxy	O
-	O
C1-C6	O
alkyl	O
,	O
haloC1-C6	O
alkyloxy	O
-	O
C1-C6	O
alkyl	O
hydroxy	O
-	O
C1-C6	O
alkyl	O
,	O
amino	O
-	O
C1-C6	O
alkyl	O
,	O
carboxy	O
-	O
C1-C6	O
alkyl	O
,	O
cyano	O
-	O
C1-C6	O
alkyl	O
,	O
amino	O
,	O
carboxy	O
,	O
carbamoyl	O
,	O
cyano	O
,	O
halo	O
,	O
hydroxy	O
,	O
keto	O
;	O
X	O
is	O
—	O
(	O
CH2	O
)	O
n−—D—	O
(	O
CH2	O
)	O
m—	O
;	O
D	O
is	O
—O—	O
,	O
—S—	O
;	O
n	O
and	O
m	O
are	O
independently	O
0	O
or	O
1	O
;	O
and	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
have	O
utility	O
as	O
inhibitors	O
of	O
HIV-1	B
reverse	I
transcriptase	I
,	O
particularly	O
drug	O
escape	O
mutants	O
.	O

Diazocine	O
derivatives	O
and	O
their	O
use	O
as	O
tryptase	B
inhibitors	O
Compounds	O
of	O
the	O
formula	O
I	O
,	O
in	O
which	O
B1	O
,	O
B2	O
,	O
R1	O
,	O
R2	O
,	O
R6	O
,	O
R7	O
,	O
K1	O
and	O
K2	O
are	O
as	O
defined	O
in	O
the	O
description	O
are	O
novel	O
effective	O
tryp	B
-	I
tase	I
inhibitors	O
.	O

Active	O
agent	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
anabasine	O
,	O
anatabine	O
,	O
nomicotine	O
,	O
Yerbamate	O
(	O
Ilex	O
paraguariensis	O
)	O
extract	O
,	O
and	O
a	O
liquid	O
extract	O
of	O
tobacco	O
;	O
especially	O
for	O
treating	O
psychological	O
disorders	O
The	O
present	O
invention	O
provides	O
a	O
group	O
of	O
tobacco	O
alkaloids	O
,	O
tobacco	O
extract	O
,	O
Yerbamaté	O
extract	O
,	O
and	O
an	O
extract	O
of	O
chewing	O
gum	O
and	O
lozenges	O
which	O
are	O
modulators	O
of	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
activity	O
(	O
i.e.	O
,	O
compounds	O
and	O
substances	O
which	O
inhibit	O
MAO	O
enzyme	O
and	O
prevent	O
its	O
biological	O
activity	O
)	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
can	O
cause	O
an	O
increase	O
in	O
the	O
level	O
of	O
norepinephrine	O
,	O
dopamine	O
,	O
and	O
serotonin	O
in	O
the	O
brain	O
and	O
other	O
tissues	O
,	O
and	O
thus	O
can	O
cause	O
a	O
wide	O
variety	O
of	O
pharmacological	O
effects	O
mediated	O
by	O
their	O
effects	O
on	O
these	O
compounds	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
such	O
as	O
the	O
treatment	O
of	O
depression	O
,	O
disorders	O
of	O
attention	O
and	O
focus	O
,	O
mood	O
and	O
emotional	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
extrapyramidal	O
disorders	O
,	O
hypertension	O
,	O
substance	O
abuse	O
,	O
smoking	O
substitution	O
,	O
anti	O
-	O
depression	O
therapy	O
,	O
eating	O
disorders	O
,	O
withdrawal	O
syndromes	O
,	O
and	O
the	O
cessation	O
of	O
smoking	O
.	O

Phosphate	O
prodrugs	O
of	O
fluoroxindoles	O
The	O
present	O
invention	O
provides	O
novel	O
phosphate	O
derivatives	O
having	O

the	O
general	O
Formula	O
I	O
wherein	O
the	O
wavy	O
bond	O
(	O
)	O
represents	O
the	O
racemate	O
,	O
the	O
(	O
R	O
)	O
-enantiomer	O
or	O
the	O
(	O
S	O
)	O
-enantiomer	O
and	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
or	O
a	O
nontoxic	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
which	O
are	O
responsive	O
to	O
the	O
opening	O
of	O
potassium	O
channels	O
.	O

Fused	O
indazoles	O
and	O
indoles	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
glaucoma	O
Novel	O
fused	O
indazoles	O
and	O
indoles	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
the	O
lowering	O
and	O
controlling	O
of	O
normal	O
or	O
elevated	O
intraocular	O
pressure	O
as	O
well	O
as	O
a	O
method	O
for	O
the	O
treatment	O
of	O
glaucoma	O
using	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
.	O

Cosmetic	O
or	O
dermatological	O
composition	O
comprising	O
of	O
a	O
combination	O
of	O
an	O
elastase	B
inhibitor	O
of	O
the	O
N	O
-	O
acylaminoamide	O
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O
Cosmetic	O
or	O
dermatological	O
composition	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
combination	O
of	O
an	O
elastase	B
inhibitor	O
of	O
the	O
N	O
-	O
acylaminoamide	O
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O
.	O

useful	O
as	O
a	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
HER2	O
(	O
Human	O
epidermal	O
growth	O
factor	O
receptor-2	O
)	O
inhibitor	O
;	O
for	O
treating	O
cancer	O
This	O
invention	O
provides	O
a	O
heterocyclic	O
compound	O
having	O
potent	O
tyrosine	O
kinase	O
-	O
inhibiting	O
activity	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
3	O
;	O
n	O
is	O
an	O
integer	O
of	O
1	O
or	O
2	O
;	O
R1	O
is	O
a	O
halogen	O
atom	O
or	O
an	O
optionally	O
halogenated	O
C1	O
-	O
2	O
alkyl	O
group	O
;	O
each	O
of	O
R2	O
and	O
R3	O
is	O
,	O
same	O
or	O
different	O
,	O
a	O
hydrogen	O
atom	O
,	O
a	O
halogen	O
atom	O
,	O
a	O
lower	O
alkyl	O
group	O
or	O
a	O
lower	O
alkoxy	O
group	O
;	O
R4	O
is	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
p	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
;	O
R5	O
is	O
a	O
C1	O
-	O
4	O
alkyl	O
group	O
substituted	O
by	O
alkoxycarbonyl	O
group	O
,	O
carbamoyl	O
group	O
,	O
carbamoyloxy	O
group	O
,	O
alkylsulfonyl	O
group	O
,	O
alkylsulfinyl	O
group	O
,	O
sulfamoyl	O
group	O
,	O
carbamoylamino	O
group	O
,	O
alkylsulfonylamino	O
group	O
,	O
acylamino	O
group	O
,	O
and	O
the	O
like	O
;	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
thereof	O
.	O

To	O
treat	O
and/or	O
prevent	O
hypertension	O
,	O
cardiac	O
hypertrophy	O
,	O
cardiac	O
insufficiency	O
,	O
coronary	O
heart	O
diseases	O
such	O
as	O
angina	O
pectoris	O
,	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
of	O
atherosclerotic	O
processes	O
or	O
diabetes	O
The	O
invention	O
relates	O
to	O
p	O
-	O
thienylbenzylamides	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R	O
(	O
1	O
)	O
,	O
R	O
(	O
2	O
)	O
,	O
R	O
(	O
3	O
)	O
,	O
R	O
(	O
4	O
)	O
,	O
R	O
(	O
5	O
)	O
,	O
R	O
(	O
6	O
)	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
potent	O
agonists	O
of	O
angiotensin-	B
(	I
1	I
-	I
7	I
)	I
receptors	I
and	O
are	O
useful	O
as	O
pharmaceutically	O
active	O
compounds	O
to	O
treat	O
and/or	O
prevent	O
hypertension	O
;	O
cardiac	O
hypertrophy	O
;	O
cardiac	O
insufficiency	O
;	O
coronary	O
heart	O
diseases	O
,	O
such	O
as	O
angina	O
pectoris	O
;	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
,	O
for	O
example	O
,	O
of	O
atherosclerotic	O
processes	O
or	O
in	O
association	O
with	O
diabetes	O
mellitus	O
.	O

Prodrug	O
of	O
an	O
estradiol	O
conjugated	O
to	O
a	O
glucuronide	O
sugar	O
;	O
6-oxo-2-methoxyestradiol	O
;	O
3-acetyl-6-oxo-2-methoxyestradiol	O
;	O
and	O
2-methoxyestradiol-6-hydrazone	O
;	O
angiogenesis	O
inhibitor	O
;	O
antiinflammatory	O
for	O
asthma	O
or	O
rheumatoid	O
arthritis	O
A	O
conjugated	O
prodrug	O
of	O
an	O
estradiol	O
compound	O
conjugated	O
to	O
a	O
biological	O
activity	O
modifying	O
agent	O
.	O

Formulation	O
for	O
controlled	O
release	O
of	O
drugs	O
by	O
combining	O
hyrophilic	O
and	O
hydrophobic	O
agents	O
Combinations	O
of	O
hydrophilic	O
and	O
hydrophobic	O
entities	O
in	O
a	O
biodegradable	O
sustained	O
release	O
implant	O
are	O
shown	O
to	O
modulate	O
each	O
other	O
's	O
rate	O
of	O
release	O
.	O

Formulations	O
of	O
a	O
therapeutically	O
active	O
agent	O
and	O
modulator	O
provide	O
controlled	O
,	O
sustained	O
release	O
for	O
an	O
extended	O
period	O
of	O
time	O
.	O

Nitrogen	O
compounds	O
such	O
as	O
1-	O
(	O
(	O
3-	O
Phenylimidazo	O
(	O
5,1-a	O
)	O
-isoquinolin-6-yl	O
)	O
carbonyl	O
)	O
piperidine	O
,	O
that	O
bind	O
preferentially	O
to	O
gamma	B
-	I
aminobutyric	I
acid	I
(	I
GABAA	I
)	I
receptors	I
;	O
prophylaxis	O
of	O
nervous	O
system	O
disorders	O
Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
W	O
,	O
Q	O
,	O
X	O
,	O
X1	O
,	O
Y	O
and	O
Z	O
are	O
as	O
defined	O
herein	O
.	O

These	O
compounds	O
bind	O
with	O
high	O
selectivity	O
and/or	O
high	O
affinity	O
to	O
the	O
benzodiazepine	O
site	O
of	O
GABAA	B
receptors	I
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
diseases	O
and	O
as	O
probes	O
for	O
the	O
localization	O
of	O
GABAA	B
receptors	I
in	O
tissue	O
samples	O
.	O

Also	O
disclosed	O
are	O
intermediates	O
useful	O
in	O
the	O
preparation	O
of	O
these	O
compounds	O
.	O

Orphan	B
opioid	I
receptor	I
(	O
orl-1	B
)	O
ligands	O
;	O
anxiety	O
,	O
depression	O
,	O
neuropathic	O
and	O
acute	O
pain	O
,	O
migraines	O
,	O
asthma	O
,	O
improved	O
cognition	O
The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
1,3,8-triazaspiro	O
[	O
4.5	O
]	O
decan-4-one	O
derivatives	O
of	O
the	O
general	O
formula	O
wherein	O
all	O
variables	O
are	O
as	O
defined	O
herein	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
mediated	O
by	O
the	O
ORL-1	B
G	B
-	I
protein	I
coupled	I
receptor	I
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
such	O
as	O
anxiety	O
,	O
depression	O
,	O
substance	O
abuse	O
,	O
neuropathic	O
pain	O
,	O
acute	O
pain	O
,	O
migraine	O
,	O
asthma	O
,	O
cough	O
and	O
for	O
improved	O
cognition	O
.	O

N	O
-	O
acylamino	O
benzyl	O
ether	O
derivatives	O
This	O
invention	O
relates	O
to	O
N	O
-	O
acylamino	O
aryl	O
derivatives	O
of	O
the	O
formula	O
where	O
R1	O
,	O
R21	O
,	O
R22	O
,	O
R23	O
,	O
R24	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
and	O
where	O
X	O
is	O
—CHRO	O
,	O
—OCHR—	O
,	O
—CH2S—	O
,	O
—SCH2—	O
,	O
—CH2CH2—	O
,	O
—CH	O
═	O
CH—	O
or	O
—C≡C—.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
selective	O
monoamine	O
oxidase	O
B	O
inhibitors	O
,	O
and	O
they	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
monoamine	O
oxidase	O
B	O
,	O
for	O
example	O
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
or	O
senile	O
dementia	O
.	O

N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O
The	O
invention	O
is	O
concerned	O
with	O
novel	O
N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
,	O
E	O
,	O
X1	O
to	O
X4	O
and	O
G1	O
and	O
G2	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
the	O
claims	O
,	O
as	O
well	O
as	O
hydrates	O
or	O
solvates	O
and	O
physiologically	O
usable	O
salts	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
inducing	O
cell	O
death	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
inducing	O
cell	O
death	O
via	O
activation	O
of	O
the	O
caspase	B
,	O
SAPK	B
,	O
and	O
apoptotic	O
signaling	O
cascades	O
in	O
a	O
cell	O
comprising	O
administering	O
to	O
a	O
cell	O
a	O
composition	O
comprising	O
tempo	O
in	O
a	O
amount	O
sufficient	O
to	O
induce	O
death	O
of	O
said	O
cell	O
.	O

Use	O
of	O
the	O
(	O
1S,2R	O
)	O
enantiomer	O
of	O
milnacipran	O
for	O
the	O
preparation	O
of	O
a	O
drug	O
A	O
method	O
for	O
treating	O
or	O
preventing	O
a	O
disorder	O
or	O
a	O
condition	O
by	O
double	O
inhibition	O
of	O
serotonin	O
(	O
5-HT	O
)	O
and	O
noradrenaline	O
(	O
NA	O
)	O
reuptake	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
while	O
limiting	O
the	O
risks	O
of	O
cardiovascular	O
disturbances	O
and/or	O
organ	O
and/or	O
tissue	O
toxicity	O
,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
subject	O
a	O
mixture	O
of	O
enantiomers	O
of	O
milnacipran	O
enriched	O
in	O
the	O
(	O
1S,2R	O
)	O
enantiomer	O
of	O
milnacipran	O
and/or	O
of	O
at	O
least	O
one	O
of	O
its	O
metabolites	O
,	O
as	O
well	O
as	O
their	O
pharmaceutically	O
-	O
acceptable	O
salts	O
.	O

Antidepressants	O
and	O
their	O
analogues	O
as	O
long	O
-	O
acting	O
local	O
anesthetics	O
and	O
analgesics	O
Methods	O
and	O
compositions	O
of	O
antidepressants	O
and	O
analogs	O
thereof	O
for	O
inducing	O
local	O
long	O
-	O
lasting	O
anesthesia	O
and	O
analgesia	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
for	O
alleviating	O
acute	O
and	O
chronic	O
pain	O
,	O
particularly	O
useful	O
for	O
treating	O
a	O
localized	O
pain	O
.	O

Uses	O
of	O
galanin	O
GALR2	B
receptors	O
This	O
invention	O
provides	O
isolated	O
nucleic	O
acids	O
encoding	O
mammalian	B
galanin	I
receptors	I
,	O
isolated	O
galanin	B
receptor	I
proteins	O
,	O
vectors	O
comprising	O
isolated	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
cells	O
comprising	O
such	O
vectors	O
,	O
antibodies	O
directed	O
to	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
nucleic	O
acid	O
probes	O
useful	O
for	O
detecting	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
antisense	O
oligonucleotides	O
complementary	O
to	O
unique	O
sequences	O
of	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
nonhuman	O
transgenic	O
animals	O
which	O
express	O
DNA	O
encoding	O
a	O
normal	O
or	O
a	O
mutant	O
mammalian	B
galanin	I
receptor	I
,	O
as	O
well	O
as	O
methods	O
of	O
determining	O
binding	O
of	O
compounds	O
to	O
mammalian	B
galanin	I
receptors	I
.	O

Preparation	O
and	O
use	O
of	O
carbohydrate	O
-	O
based	O
bicyclic	O
ring	O
structures	O
with	O
antimicrobial	O
and	O
cytostatic	O
activity	O
Novel	O
carbohydrate	O
-	O
based	O
compounds	O
with	O
an	O
attached	O
ring	O
system	O
that	O
have	O
antimicrobial	O
or	O
cytostatic	O
activity	O
.	O

The	O
compounds	O
are	O
administered	O
to	O
humans	O
and	O
animals	O
for	O
the	O
treatment	O
or	O
amelioration	O
of	O
bacterial	O
,	O
fungal	O
,	O
viral	O
or	O
protozoal	O
infections	O
or	O
tumors	O
.	O

The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
:	O

Injection	O
made	O
from	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O
The	O
invention	O
discloses	O
an	O
injection	O
made	O
from	O
Chinese	O
herb	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O
.	O

The	O
injection	O
is	O
in	O
a	O
form	O
of	O
lyophilized	O
powder	O
in	O
which	O
the	O
rate	O
of	O
flavone	O
to	O
adenosine	O
is	O
5	O
mg:15	O
μg	O
or	O
5	O
mg:30	O
μg	O
.	O

The	O
flavone	O
and	O
adenosine	O
from	O
Ixeris	O
Sonchifolia	O
Hance	O
is	O
more	O
stable	O
in	O
the	O
lyophilized	O
powder	O
form	O
than	O
in	O
liquid	O
form	O
for	O
injection	O
so	O
that	O
it	O
is	O
easy	O
to	O
control	O
the	O
quality	O
of	O
the	O
product	O
so	O
as	O
to	O
make	O
the	O
medicament	O
safe	O
and	O
effective	O
.	O

It	O
has	O
benefit	O
in	O
store	O
.	O

Reducing	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
such	O
as	O
stroke	O
,	O
myocardial	O
ischemia	O
,	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
transient	O
ischemic	O
attack	O
;	O
side	O
effect	O
reduction	O
The	O
invention	O
encompasses	O
novel	O
compounds	O
of	O
Formula	O
I	O
,	O
which	O
are	O
nitric	O
oxide	O
-	O
releasing	O
prodrugs	O
of	O
diaryl-2-	O
(	O
5H	O
)	O
furanones	O
useful	O
in	O
the	O
treatment	O
of	O
cyclooxygenase-2	B
mediated	O
diseases	O
.	O

The	O
invention	O
also	O
encompasses	O
certain	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cyclooxygenase-2	B
mediated	O
diseases	O
comprising	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
I.	O
The	O
above	O
compounds	O
may	O
be	O
used	O
as	O
a	O
combination	O
therapy	O
with	O
low	O
-	O
dose	O
aspirin	O
to	O
treat	O
chronic	O
cyclooxygenase-2	B
mediated	O
diseases	O
or	O
conditions	O
while	O
also	O
reducing	O
the	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
.	O

Composition	O
based	O
on	O
ethyl	O
ester	O
of	O
linoleic	O
acid	O
and	O
triethyl	O
ester	O
of	O
citric	O
acid	O
for	O
topical	O
use	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
topical	O
use	O
for	O
treating	O
and	O
improving	O
the	O
aesthetic	O
conditions	O
of	O
the	O
skin	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
mixture	O
of	O
ethyllinoleate	O
and	O
triethylcitrate	O
.	O

This	O
composition	O
is	O
active	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O
.	O

Compounds	O
having	O
prolyl	B
oligopeptidase	I
inhibitory	O
activity	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
their	O
use	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
symbol	O
aa	O
means	O
a	O
residue	O
of	O
an	O
α	O
-	O
amino	O
acid	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
their	O
use	O
as	O
prolyl	B
oligopeptide	I
inhibitors	O
,	O
for	O
example	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Use	O
of	O
ozone	O
for	O
the	O
treatment	O
of	O
gum	O
disease	O
A	O
method	O
of	O
treating	O
gum	O
disease	O
,	O
includes	O
directing	O
a	O
stream	O
of	O
oxidizing	O
gas	O
onto	O
a	O
diseased	O
gum	O
for	O
a	O
period	O
of	O
time	O
sufficient	O
to	O
kill	O
microorganisms	O
.	O

Melanin	B
-	I
concentrating	I
hormone	I
antagonist	O
A	O
melanin	B
-	I
concentrating	I
hormone	I
antagonist	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
:	O
wherein	O
R	O
is	O
hydrogen	O
atom	O
or	O
a	O
cyclic	O
group	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
10	O
atoms	O
;	O
Y	O
is	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
6	O
atoms	O
;	O
ring	O
A	O
is	O
benzene	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
a	O
5-	O
to	O
9-membered	O
nitrogen	O
-	O
containing	O
non	O
-	O
aromatic	O
heterocyclic	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
hydrogen	O
atom	O
,	O
a	O
hydrocarbon	O
group	O
which	O
may	O
be	O
substituted	O
or	O
a	O
heterocyclic	O
group	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R1	O
and	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	O
atom	O
,	O
may	O
form	O
a	O
nitrogen	O
-	O
containing	O
heterocyclic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	O
atom	O
and	O
Y	O
,	O
may	O
form	O
a	O
nitrogen	O
-	O
containing	O
heterocyclic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
a	O
salt	O
thereof	O
is	O
useful	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
obesity	O
,	O
etc	O
.	O

A	O
polynucleotide	O
comprising	O
a	O
RNA	B
polymerase	I
promoter	I
,	O
able	O
encoding	O
a	O
siRNA	O
;	O
treating	O
cancer	O
and	O
genetic	O
disorders	O
;	O
genetic	O
engineering	O
,	O
inhibit	O
gene	O
expression	O
of	O
a	O
target	O
gene	O
The	O
present	O
invention	O
provides	O
a	O
polynucleotide	O
comprising	O
a	O
RNA	B
polymerase	I
III	I
promoter	I
,	O
a	O
region	O
encoding	O
a	O
siRNA	O
,	O
and	O
a	O
transcriptional	O
termination	O
element	O
comprising	O
five	O
consecutive	O
thymine	O
residues	O
.	O

The	O
invention	O
also	O
provides	O
for	O
vectors	O
,	O
cells	O
and	O
non	O
-	O
human	O
transgenic	O
animal	O
comprising	O
the	O
polynucleotides	O
of	O
the	O
invention	O
as	O
well	O
as	O
their	O
use	O
in	O
medicaments	O
for	O
various	O
conditions	O
.	O

Recombinant	O
sequence	O
,	O
its	O
preparation	O
and	O
use	O
An	O
isolated	O
,	O
purified	O
or	O
recombinant	O
nucleic	O
acid	O
sequence	O
is	O
disclosed	O
,	O
comprising	O
:	O
(	O
a	O
)	O
a	O
sequence	O
that	O
encodes	O
both	O
an	O
angiogenic	O
factor	O
antagonist	O
and	O
a	O
vascular	O
endothelial	O
structure	O
regulator	O
;	O
(	O
b	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
to	O
sequence	O
(	O
a	O
)	O
under	O
stringent	O
conditions	O
;	O
or	O
(	O
c	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
under	O
stringent	O
conditions	O
to	O
the	O
sequence	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
but	O
for	O
the	O
degeneracy	O
of	O
the	O
genetic	O
code	O
;	O
or	O
(	O
g	O
)	O
an	O
oligonucleotide	O
specific	O
for	O
any	O
of	O
the	O
sequences	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
.	O

Particular	O
oligonucleotides	O
(	O
d	O
)	O
are	O
those	O
encoding	O
the	O
vascular	O
endothelial	O
structure	O
regulator	O
.	O

Also	O
described	O
are	O
methods	O
for	O
preparing	O
the	O
recombinant	O
polynucleotide	O
,	O
proteins	O
encoded	O
by	O
such	O
polynucleotides	O
and	O
their	O
use	O
in	O
gene	O
or	O
protein	O
therapy	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
cancer	O
.	O

Benzofuran	O
inhibitors	O
of	O
factor	O
VIIa	O
Compounds	O
of	O
Formula	O
I	O
are	O
useful	O
for	O
inhibiting	O
serine	O
protease	O
enzymes	O
,	O
such	O
as	O
TF	O
/	O
factor	O
VIIa	O
,	O
factor	O
Xa	O
,	O
thrombin	O
and	O
kallikrein	O
and	O
have	O
improved	O
pharmacokinetic	O
properties	O
.	O

These	O
compounds	O
may	O
be	O
used	O
in	O
methods	O
of	O
preventing	O
and/or	O
treating	O
clotting	O
disorders	O
.	O

Infections	O
caused	O
by	O
Gram	O
positive	O
and/or	O
negative	O
pathogens	O
The	O
invention	O
relates	O
to	O
novel	O
tetrahydroisoquinoline	O
derivatives	O
of	O
general	O
formula	O
I	O
and	O
theirs	O
use	O
as	O
active	O
ingredients	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
.	O

The	O
invention	O
also	O
concerns	O
related	O
aspects	O
including	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
those	O
compounds	O
and	O
their	O
use	O
as	O
anti	O
-	O
infectives	O
,	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O

Method	O
for	O
use	O
of	O
IGF	B
-	I
binding	I
protein	I
for	O
selective	O
sensitization	O
of	O
target	O
cells	O
in	O
vivo	O
New	O
methods	O
for	O
the	O
treatment	O
of	O
human	O
disease	O
are	O
provided	O
.	O

IGFBP-3	B
is	O
administered	O
together	O
with	O
a	O
co	O
-	O
administered	O
agent	O
to	O
subjects	O
having	O
disease	O
,	O
thereby	O
alleviating	O
the	O
symptoms	O
of	O
the	O
disease	O
,	O
under	O
conditions	O
where	O
administration	O
of	O
IGFBP-3	B
alone	O
at	O
the	O
maximum	O
practicable	O
dose	O
has	O
no	O
measurable	O
beneficial	O
effect	O
on	O
the	O
disease	O
condition	O
.	O

Inhibiting	O
cyclin	B
-	I
dependent	I
kinase	I
complexes	I
including	O
cdk1	B
/	O
cyclin	B
B	I
,	O
cdk2	B
/	O
cyclin	B
E	I
and	O
cdk4	B
/	O
cyclin	B
D1	I
;	O
preventing	O
apoptosis	O
The	O
present	O
invention	O
is	O
directed	O
to	O
acyl	O
and	O
sulfonyl	O
derivatives	O
of	O
6,9-disubstituted	O
2-	O
(	O
trans-1,4	O
-diaminocyclohexyl	O
)	O
-purines	O
of	O
the	O
formula	O
where	O
Z	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
—S	O
(	O
O	O
)	O
2—	O
,	O
and	O
—C	O
(	O
O	O
)	O
—.	O

Methods	O
for	O
treating	O
or	O
preventing	O
an	O
inflammatory	O
or	O
metabolic	O
condition	O
or	O
inhibiting	O
JNK	B
This	O
invention	O
generally	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
responsive	O
to	O
JNK	B
inhibition	O
,	O
such	O
as	O
a	O
metabolic	O
condition	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
an	O
Anilinopyrimidine	O
Derivative	O
having	O
the	O
following	O
structure	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
through	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Inhibition	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
vertebrates	O
by	O
dietary	O
fibers	O
The	O
use	O
of	O
a	O
dietary	O
fiber	O
or	O
a	O
mixture	O
of	O
dietary	O
fibers	O
for	O
the	O
manufacture	O
of	O
a	O
composition	O
,	O
being	O
a	O
pharmaceutical	O
composition	O
or	O
a	O
functional	O
food	O
or	O
a	O
functional	O
feed	O
,	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
is	O
disclosed	O
.	O

A	O
method	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
,	O
comprising	O
administration	O
to	O
said	O
beings	O
,	O
orally	O
,	O
through	O
tube	O
feeding	O
or	O
rectally	O
,	O
a	O
composition	O
containing	O
an	O
effective	O
amount	O
of	O
a	O
dietary	O
fiber	O
or	O
mixture	O
of	O
dietary	O
fibers	O
is	O
also	O
disclosed	O
.	O

The	O
dietary	O
fiber	O
is	O
preferably	O
a	O
fructan	O
,	O
typically	O
inulin	O
and/or	O
oligofructose	O
,	O
most	O
preferably	O
chicory	O
inulin	O
with	O
an	O
average	O
degree	O
of	O
polymerization	O
(	O
DP	O
)	O
of	O
at	O
least	O
20	O
.	O

Diazepine	O
compounds	O
as	O
ligands	O
of	O
the	O
melanocortin	B
1	I
and/or	I
4	I
receptors	I
There	O
is	O
provided	O
novel	O
diazepines	O
that	O
function	O
as	O
agonists	O
at	O
the	O
melanocortin	B
4	I
receptor	I
and	O
as	O
agonists	O
at	O
the	O
melanocortin	B
1	I
receptor	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
use	O
in	O
treatment	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

For	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
inflammatory	O
or	O
autoimmune	O
condition	O
,	O
viral	O
infection	O
,	O
cancer	O
;	O
4-	O
{	O
[	O
4-	O
(	O
4-chlorophenyl	O
)	O
pyrimidin-2-yl	O
]	O
amino	O
}	O
benzamide	O
Compounds	O
having	O
activity	O
as	O
inhibitors	O
of	O
IKK	B
are	O
disclosed	O
,	O
particularly	O
IKK-2	B
.	O

The	O
compounds	O
of	O
this	O
invention	O
are	O
anilinopyrimidine	O
derivatives	O
having	O
the	O
following	O
structure	O
:	O
wherein	O
R1	O
and	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
conditions	O
that	O
are	O
responsive	O
to	O
IKK	B
inhibition	O
.	O

Thus	O
,	O
methods	O
of	O
treating	O
such	O
conditions	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
compounds	O
of	O
the	O
above	O
compounds	O
.	O

Adust	O
fatty	O
acid	O
oxidation	O
;	O
stimulant	O
of	O
carnitine	B
plamitoyl	I
treansferrase	I
This	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
inducing	O
weight	O
loss	O
and	O
maintaining	O
optimum	O
weight	O
comprising	O
administering	O
an	O
agent	O
that	O
stimulates	O
carnitine	B
palmitoyl	I
transferase-1	I
(	O
CPT-1	B
)	O
activity	O
to	O
the	O
patient	O
in	O
need	O
,	O
including	O
human	O
patients	O
.	O

These	O
methods	O
do	O
not	O
require	O
inhibition	O
of	O
fatty	O
acid	O
synthesis	O
.	O

In	O
particular	O
,	O
this	O
invention	O
provides	O
methods	O
for	O
development	O
of	O
therapeutics	O
that	O
selectively	O
enhance	O
fatty	O
acid	O
oxidation	O
,	O
increase	O
energy	O
production	O
,	O
and	O
reduce	O
adiposity	O
while	O
preserving	O
lean	O
mass	O
,	O
through	O
the	O
pharmacological	O
stimulation	O
of	O
CPT-1	B
activity	O
.	O

In	O
a	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
fatty	O
acid	O
oxidation	O
.	O

In	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
antagonize	O
malonyl	O
CoA	O
inhibition	O
of	O
CPT-1	B
.	O

In	O
yet	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
malonyl	O
CoA	O
level	O
.	O

Identifying	O
modulators	O
for	O
prevention	O
and	O
treatment	O
of	O
infection	O
,	O
blood	O
,	O
metabolic	O
,	O
cell	O
proliferative	O
and	O
respiratory	O
system	O
disorders	O
The	O
present	O
invention	O
provides	O
a	O
purified	O
polynucleotide	O
encoding	O
a	O
novel	O
polypeptide	O
,	O
designated	O
Fhm	O
,	O
which	O
belongs	O
to	O
the	O
TNF	B
gene	O
superfamily	O
;	O
to	O
purified	O
Fhm	O
polypeptide	O
molecules	O
;	O
to	O
antibodies	O
that	O
bind	O
Fhm	O
;	O
to	O
materials	O
comprising	O
such	O
molecules	O
;	O
and	O
to	O
methods	O
of	O
using	O
such	O
molecules	O
.	O

Use	O
of	O
phosphodiesterase	O
4	O
inhibitors	O
such	O
as	O
6,7-dimethoxy-1-	O
[	O
2-	O
(	O
1,3-dioxocyclohexan-2-yl	O
)	O
pyridin-4-yl	O
]	O
-2,3-bis	O
(	O
hydroxymethyl	O
)	O
naphthalene	O
to	O
treat	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
a	O
condensed	O
polycyclic	O
compound	O
useful	O
as	O
a	O
phosphodiesterase	B
4	I
inhibitor	O
,	O
which	O
is	O
shown	O
by	O
the	O
formula	O
[	O
I	O
]	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

Heparin	O
prodrugs	O
and	O
drug	O
delivery	O
stents	O
formed	O
therefrom	O
A	O
prodrug	O
comprising	O
a	O
heparin	O
and	O
a	O
drug	O
is	O
provided	O
.	O

The	O
prodrug	O
can	O
be	O
used	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
prodrug	O
can	O
also	O
be	O
used	O
with	O
a	O
polymeric	O
material	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
polymeric	O
material	O
can	O
be	O
a	O
hydrophobic	O
polymer	O
,	O
a	O
hydrophilic	O
polymer	O
,	O
a	O
non	O
-	O
fouling	O
polymer	O
,	O
or	O
combinations	O
thereof	O
.	O

The	O
medical	O
device	O
can	O
be	O
implanted	O
in	O
a	O
human	O
being	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
such	O
as	O
atherosclerosis	O
,	O
thrombosis	O
,	O
restenosis	O
,	O
hemorrhage	O
,	O
vascular	O
dissection	O
or	O
perforation	O
,	O
vascular	O
aneurysm	O
,	O
vulnerable	O
plaque	O
,	O
chronic	O
total	O
occlusion	O
,	O
claudication	O
,	O
anastomotic	O
proliferation	O
for	O
vein	O
and	O
artificial	O
grafts	O
,	O
bile	O
duct	O
obstruction	O
,	O
ureter	O
obstruction	O
,	O
tumor	O
obstruction	O
,	O
or	O
combinations	O
thereof	O
.	O

administering	O
a	O
cholinesterase	B
inhibitor	O
(	O
a	O
dimethoxyindanone	O
derivative	O
)	O
to	O
treat	O
dementia	O
associated	O
with	O
or	O
caused	O
by	O
vascular	O
diseases	O
The	O
invention	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
dementia	O
caused	O
by	O
vascular	O
diseases	O
;	O
dementia	O
associated	O
with	O
Parkinson	O
's	O
disease	O
;	O
Lewy	O
Body	O
dementia	O
;	O
AIDS	O
dementia	O
;	O
mild	O
cognitive	O
impairments	O
;	O
age	O
-	O
associated	O
memory	O
impairments	O
;	O
cognitive	O
impairments	O
and/or	O
dementia	O
associated	O
with	O
neurologic	O
and/or	O
psychiatric	O
conditions	O
,	O
including	O
epilepsy	O
,	O
brain	O
tumors	O
,	O
brain	O
lesions	O
,	O
multiple	O
sclerosis	O
,	O
Down	O
's	O
syndrome	O
,	O
Rett	O
's	O
syndrome	O
,	O
progressive	O
supranuclear	O
palsy	O
,	O
frontal	O
lobe	O
syndrome	O
,	O
and	O
schizophrenia	O
and	O
related	O
psychiatric	O
disorders	O
;	O
cognitive	O
impairments	O
caused	O
by	O
traumatic	O
brain	O
injury	O
,	O
post	O
coronary	O
artery	O
by	O
-	O
pass	O
graft	O
surgery	O
,	O
electroconvulsive	O
shock	O
therapy	O
,	O
and	O
chemotherapy	O
,	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
delirium	O
,	O
Tourette	O
's	O
syndrome	O
,	O
myasthenia	O
gravis	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
autism	O
,	O
dyslexia	O
,	O
mania	O
,	O
depression	O
,	O
apathy	O
,	O
and	O
myopathy	O
associated	O
with	O
diabetes	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
delaying	O
the	O
onset	O
of	O
Alzheimer	O
's	O
disease	O
,	O
for	O
enhancing	O
cognitive	O
functions	O
,	O
for	O
treating	O
and	O
preventing	O
sleep	O
apnea	O
,	O
for	O
alleviating	O
tobacco	O
withdrawal	O
syndrome	O
,	O
and	O
for	O
treating	O
the	O
dysfunctions	O
of	O
Huntington	O
's	O
Disease	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

A	O
preferred	O
cholinesterase	B
inhibitor	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
invention	O
is	O
donepezil	O
hydrochloride	O
or	O
ARICEPT	O
®	O
.	O

For	O
therapy	O
of	O
oncoses	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
N	O
-	O
substituted	O
indole-3-glyoxylamides	O
of	O
the	O
general	O
formula	O
I	O
as	O
antitumor	O
agents	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
having	O
antitumor	O
action	O
,	O
characterized	O
in	O
that	O
it	O
contains	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
general	O
formula	O
1	O
,	O
if	O
appropriate	O
also	O
in	O
the	O
form	O
of	O
the	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
or	O
N	O
-	O
oxides	O
.	O

Furthermore	O
,	O
the	O
invention	O
also	O
includes	O
antitumor	O
agents	O
comprising	O
as	O
active	O
compound	O
one	O
or	O
more	O
N	O
-	O
substituted	O
indole-3-glyoxylamides	O
according	O
to	O
the	O
general	O
formula	O
1	O
and	O
,	O
if	O
appropriate	O
,	O
their	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
and	O
,	O
if	O
possible	O
,	O
N	O
-	O
oxides	O
and	O
a	O
pharmaceutically	O
utilizable	O
carrier	O
and/or	O
diluent	O
or	O
auxiliary	O
substance	O
in	O
the	O
form	O
of	O
tablets	O
,	O
coated	O
tablets	O
,	O
capsules	O
,	O
solutions	O
for	O
infusion	O
or	O
ampoules	O
,	O
suppositories	O
,	O
patches	O
,	O
powder	O
preparations	O
which	O
can	O
be	O
employed	O
by	O
inhalation	O
,	O
suspensions	O
,	O
creams	O
and	O
ointments	O
.	O

Epothilone	O
derivatives	O
and	O
their	O
synthesis	O
and	O
use	O
The	O
invention	O
relates	O
to	O
epothilone	O
analog	O
represented	O
by	O
the	O
formula	O
I	O
wherein	O
(	O
i	O
)	O
R2	O
is	O
absent	O
or	O
oxygen	O
;	O
""""	O
a	O
""""	O
can	O
be	O
either	O
a	O
single	O
or	O
double	O
bond	O
;	O
""""	O
b	O
""""	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
;	O
and	O
""""	O
c	O
""""	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
oxygen	O
then	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
both	O
a	O
single	O
bond	O
and	O
""""	O
a	O
""""	O
is	O
a	O
single	O
bond	O
;	O
if	O
R2	O
is	O
absent	O
then	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
absent	O
and	O
""""	O
a	O
""""	O
is	O
a	O
double	O
bond	O
;	O
and	O
if	O
""""	O
a	O
""""	O
is	O
a	O
double	O
bond	O
,	O
then	O
R2	O
,	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
absent	O
;	O
R3	O
is	O
a	O
radical	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
;	O
lower	O
alkyl	O
;	O
—CH	O
═	O
CH2	O
;	O
—C≡CH	O
;	O
—CH2F	O
;	O
—CH2Cl	O
;	O
—CH2—OH	O
;	O
—CH2—O—	O
(	O
C1-C6-alkyl	O
)	O
;	O
and	O
—CH2—S—	O
(	O
C1-C6-alkyl	O
)	O
;	O
R4	O
and	O
R5	O
are	O
independently	O
selected	O
from	O
hydrogen	O
,	O
methyl	O
or	O
a	O
protecting	O
group	O
;	O
and	O
R1	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
of	O
a	O
compound	O
of	O
the	O
formula	O
I	O
where	O
a	O
salt	O
-	O
forming	O
group	O
is	O
present	O
.	O

A	O
further	O
aspect	O
of	O
the	O
invention	O
is	O
related	O
to	O
the	O
synthesis	O
of	O
epothilone	O
E.	O
These	O
compounds	O
have	O
inter	O
alia	O
microtubuli	O
depolymerisation	O
inhibiting	O
activity	O
and	O
are	O
e.g.	O
useful	O
against	O
proliferative	O
diseases	O
.	O

Modulators	O
of	O
blood	O
glucose	O
levels	O
,	O
triglyceride	O
levels	O
,	O
insulin	B
levels	O
and	O
non	O
-	O
esterified	O
fatty	O
acid	O
(	O
NEFA	O
)	O
levels	O
;	O
hypoglycemia	O
Compounds	O
are	O
provided	O
which	O
have	O
the	O
structure	O
wherein	O
Q	O
is	O
C	O
or	O
N	O
,	O
A	O
is	O
O	O
or	O
S	O
,	O
Z	O
is	O
O	O
or	O
a	O
bond	O
,	O
X	O
is	O
CH	O
or	O
N	O
and	O
R1	O
,	O
R2	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R3	O
,	O
Y	O
,	O
x	O
,	O
m	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
compounds	O
are	O
useful	O
as	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
and	O
antiobesity	O
agents	O
.	O

Antidiabetic	O
agents	O
,	O
antilipemic	O
agents	O
,	O
dietetics	O
,	O
anticholesterol	O
agents	O
,	O
hypotensive	O
agents	O
,	O
cardiovascular	O
disorders	O
;	O
(	O
S	O
)	O
-Ethyl	O
2-methoxy-3-	O
[	O
4-	O
{	O
3-	O
(	O
4-methanesulfonyloxyphenyl	O
)	O
propylamino	O
}	O
phenyl	O
]	O
propionate	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
antiobesity	O
and	O
hypocholesterolemic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
analogs	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

Antiproliferative	O
agents	O
;	O
antiinflammatory	O
agents	O
;	O
anticancer	O
agents	O
;	O
diagnosis	O
,	O
therapy	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
compounds	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
proliferative	O
condition	O
,	O
wherein	O
the	O
compounds	O
have	O
the	O
following	O
formula	O
:	O
wherein	O
:	O
each	O
of	O
RB2	O
,	O
RB3	O
,	O
RB4	O
,	O
and	O
RB5	O
is	O
independently	O
—H	O
,	O
—OH	O
,	O
or	O
—OMe	O
;	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
:	O
—H	O
,	O
optionally	O
substituted	O
C1	O
-	O
4alkyl	O
,	O
or	O
optionally	O
substituted	O
C5	O
-	O
20aryl	O
;	O
RA3	O
is	O
—H	O
,	O
—OH	O
,	O
—OC	O
(	O
═	O
O	O
)	O
RE	O
,	O
—OS	O
(	O
═	O
O	O
)	O
2OH	O
,	O
or	O
—OP	O
(	O
═	O
O	O
)	O
(	O
OH	O
)	O
2	O
;	O
RE	O
is	O
:	O
—H	O
,	O
optionally	O
substituted	O
C1	O
-	O
6alkyl	O
,	O
optionally	O
substituted	O
C3	O
-	O
20	O
heterocyclyl	O
,	O
or	O
optionally	O
substituted	O
C5	O
-	O
20aryl	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
,	O
amide	O
,	O
ester	O
,	O
ether	O
,	O
chemically	O
protected	O
form	O
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
for	O
both	O
diagnosis	O
and	O
treatment	O
of	O
,	O
for	O
example	O
,	O
proliferative	O
conditions	O
,	O
such	O
as	O
cancer	O
,	O
and	O
inflammatory	O
conditions	O
.	O

Induce	O
cell	O
differentiation	O
;	O
process	O
control	O
The	O
invention	O
features	O
methods	O
for	O
increasing	O
or	O
maintaining	O
the	O
number	O
of	O
functional	O
cells	O
of	O
a	O
predetermined	O
type	O
,	O
for	O
example	O
,	O
insulin	B
producing	O
cells	O
of	O
the	O
pancreas	O
,	O
blood	O
cells	O
,	O
spleen	O
cells	O
,	O
brain	O
cells	O
,	O
heart	O
cells	O
,	O
vascular	O
tissue	O
cells	O
,	O
cells	O
of	O
the	O
bile	O
duct	O
,	O
or	O
skin	O
cells	O
,	O
in	O
a	O
mammal	O
(	O
e.g.	O
,	O
a	O
human	O
patient	O
)	O
that	O
has	O
injured	O
or	O
damaged	O
cells	O
of	O
the	O
predetermined	O
type	O
.	O

Fluidized	O
bed	O
granulation	O
,	O
compression	O
to	O
form	O
tablets	O
A	O
process	O
for	O
the	O
preparation	O
of	O
an	O
orally	O
administrable	O
calcium	O
composition	O
comprising	O
the	O
steps	O
of	O
:	O
(	O
i	O
)	O
obtaining	O
a	O
physiologically	O
tolerable	O
particulate	O
calcium	O
compound	O
having	O
a	O
mean	O
particle	O
size	O
in	O
the	O
range	O
3	O
to	O
40	O
μm	O
,	O
having	O
a	O
crystalline	O
structure	O
and	O
having	O
a	O
surface	O
area	O
of	O
0.1	O
to	O
1.2	O
m2	O
/	O
g	O
;	O
(	O
ii	O
)	O
mixing	O
the	O
calcium	O
compound	O
with	O
a	O
water	O
-	O
soluble	O
diluent	O
and	O
an	O
aqueous	O
solution	O
of	O
a	O
water	O
soluble	O
binder	O
in	O
a	O
fluid	O
bed	O
granulation	O
apparatus	O
and	O
drying	O
the	O
resulting	O
mixture	O
to	O
produce	O
a	O
first	O
granulate	O
;	O
(	O
iii	O
)	O
optionally	O
mixing	O
the	O
first	O
granulate	O
with	O
one	O
or	O
more	O
further	O
components	O
to	O
produce	O
a	O
second	O
granulate	O
;	O
and	O
(	O
iv	O
)	O
optionally	O
compressing	O
the	O
first	O
or	O
second	O
granulate	O
to	O
form	O
tablets	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O
Methods	O
and	O
compositions	O
for	O
prophylaxis	O
and/or	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O
of	O
a	O
patient	O
resulting	O
angiogenesis	O
in	O
the	O
eye	O
using	O
antagonists	O
of	O
the	O
integrin	O
receptors	O
αv	O
β3	O
and/or	O
αv	O
β5	O
.	O

The	O
compositions	O
can	O
be	O
nanoparticles	O
and	O
are	O
administered	O
to	O
the	O
eye	O
by	O
injection	O
into	O
the	O
sclera	O
of	O
the	O
eye	O
.	O

4-Deoxy-3,4-	O
[	O
2-spiro-	O
[	O
1-	O
[	O
2-	O
(	O
2-methyl-5-nitro	O
-	O
imidazol-1-yl	O
)	O
ethyl	O
]	O
-piperidin-4-yl	O
]	O
]	O
-	O
(	O
1H	O
)	O
-imidazo-	O
(	O
2,5-dihydro	O
)	O
rifamycin	O
;	O
antibiotic	O
resistance	O
;	O
synergistic	O
effects	O
of	O
covalently	O
linking	O
antibacterial	O
pharmacophores	O
together	O
;	O
pharmacokinetics	O
;	O
aerobic	O
,	O
anaerobic	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
bacteria	O
Substituted	O
rifamycin	O
derivatives	O
in	O
which	O
a	O
nitroimidazole	O
,	O
nitrothiazole	O
or	O
nitrofuran	O
pharmacophore	O
is	O
covalently	O
bonded	O
to	O
a	O
rifamycin	O
,	O
methods	O
of	O
using	O
the	O
rifamycin	O
derivatives	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
rifamycin	O
derivatives	O
are	O
disclosed	O
.	O

Methods	O
of	O
synthesizing	O
these	O
substituted	O
rifamycin	O
derivatives	O
are	O
also	O
disclosed	O
.	O

The	O
rifamycin	O
derivatives	O
possess	O
antibacterial	O
activity	O
,	O
and	O
are	O
effective	O
against	O
a	O
number	O
of	O
human	O
and	O
veterinary	O
pathogens	O
in	O
the	O
treatment	O
of	O
bacterial	O
diseases	O
.	O

3-	O
(	O
(	O
1,2,5,6-tetrahydro-2-methyl-5,6-d	O
ioxo-1,2,4-triazine-3-yl	O
)	O
thio	O
)	O
methyl	O
)	O
-7-	O
[	O
[	O
[	O
[	O
[	O
(	O
1-methyl	O
ethyl	O
)	O
amino	O
]	O
[	O
(	O
1-methylethyl	O
)	O
imino	O
]	O
methyl	O
]	O
thio	O
]	O
acetyl	O
]	O
amino	O
]	O
-8-oxo-5-thia-1-aza	O
-	O
bicyclo	O
[	O
4.2.0	O
]	O
oct-2-ene-2-carboxylic	O
acid	O
;	O
bioavailibility	O
;	O
stability	O
;	O
pharmacokinetics	O
;	O
antibiotics	O
;	O
infections	O
Disclosed	O
herein	O
are	O
a	O
cephalosporin	O
compound	O
of	O
formula	O
I	O
,	O
wherein	O
R1	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
wherein	O
R2	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
the	O
preparation	O
and	O
uses	O
thereof	O
.	O

A	O
method	O
of	O
preparing	O
the	O
cephalosporin	O
compound	O
as	O
disclosed	O
herein	O
comprises	O
reacting	O
a	O
starting	O
cephalosporin	O
comprising	O
a	O
C7	O
amino	O
group	O
and	O
a	O
C3	O
thio	O
-	O
methyl	O
moiety	O
substituted	O
with	O
an	O
N	O
-	O
containing	O
heterocyclic	O
group	O
with	O
bromoacetyl	O
bromide	O
and	O
then	O
with	O
a	O
N	O
,	O
N′-bissubstituted	O
thiourea	O
.	O

Methods	O
of	O
treating	O
an	O
infectious	O
disease	O
are	O
also	O
disclosed	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
the	O
pharmaceutical	O
composition	O
disclosed	O
herein	O
.	O

1-Substituted-	O
[	O
1H	O
-	O
indene-6,1'-cyclopropane	O
]	O
-4-one	O
derivatives	O
:	O
solid	O
tumors	O
and	O
multi	O
-	O
drug	O
resistant	O
tumors	O
;	O
-cell	O
leukemia	O
,	O
B	O
-	O
cell	O
lymphoma	O
,	O
myeloma	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
T	O
-	O
cell	O
lymphoma	O
,	O
small	O
leukemia	O
,	O
and	O
small	O
cell	O
lymphoma	O
The	O
present	O
invention	O
provides	O
illudin	O
analogs	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
where	O
R1	O
is	O
(	O
CH2	O
)	O
n	O
—	O
X	O
—	O
Y	O
or	O
H	O
;	O
n	O
is	O
0	O
to	O
4	O
;	O
X	O
is	O
O	O
or	O
S	O
or	O
N	O
or	O
absent	O
;	O
and	O
Y	O
is	O
an	O
optionally	O
substituted	O
(	O
C1-C8	O
)	O
alkyl	O
,	O
(	O
C6-C10	O
)	O
aryl	O
,	O
(	O
C6-C10	O
)	O
aryl	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
cyclo	O
(	O
C3-C6	O
)	O
alkyl	O
optionally	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
;	O
a	O
monosaccharide	O
,	O
an	O
amino	O
acid	O
residue	O
,	O
or	O
H	O
when	O
n	O
is	O
2	O
-	O
4	O
;	O
R2	O
is	O
absent	O
;	O
or	O
R1	O
and	O
R2	O
together	O
comprise	O
a	O
5	O
-	O
7	O
membered	O
cyclic	O
ring	O
;	O
R3	O
is	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
H	O
;	O
R4	O
is	O
H	O
,	O
SCH2CO2	O
(	O
C1-C4	O
)	O
alkyl	O
,	O
O—	O
(	O
C5-C12	O
)	O
aryl	O
or	O
—S—	O
(	O
C5-C12	O
)	O
aryl	O
;	O
R5	O
is	O
H	O
,	O
OH	O
or	O
absent	O
;	O
R6	O
is	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
absent	O
;	O
R7	O
is	O
OH	O
or	O
OSi	O
(	O
(	O
C1-C4	O
)	O
alkyl	O
)	O
3	O
;	O
or	O
R6	O
and	O
R7	O
together	O
are	O
ethylenedioxy	O
;	O
R8	O
is	O
optionally	O
substituted	O
(	O
C1-C4	O
)	O
alkyl	O
;	O
and	O
the	O
bonds	O
represented	O
by	O
-----	O
are	O
individually	O
present	O
or	O
absent	O
.	O

The	O
invention	O
further	O
provides	O
dimers	O
comprising	O
analogs	O
of	O
formula	O
(	O
I	O
)	O
.	O

10-	O
(	O
o	O
-	O
Hydroxyphenyl	O
)	O
--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a	O
-	O
triazacyclopenty	O
[	O
b	O
]	O
fluorene-1,3-diones	O
or	O
the	O
corresponding	O
2,10a	O
-	O
diaza-9	O
oxafluorenediones	O
or	O
1,10a	O
-	O
diaza-9-thiafluorenediones	O
;	O
antiproliferative	O
,	O
apoptosis	O
-	O
inducing	O
agents	O
;	O
treating	O
color	O
cancer	O
Compounds	O
of	O
the	O
formula	O
(	O
1	O
)	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
,	O
are	O
novel	O
effective	O
compounds	O
with	O
Eg5	B
inhibitory	O
,	O
anti	O
-	O
proliferative	O
and/or	O
apoptosis	O
inducing	O
activity	O
.	O

Fasudil	O
-	O
containing	O
preparation	O
and	O
method	O
of	O
improving	O
stability	O
thereof	O
Fasudil	O
-	O
containing	O
preparations	O
that	O
despite	O
the	O
us	O
of	O
a	O
container	O
excelling	O
in	O
the	O
visibility	O
of	O
contents	O
without	O
particularly	O
blocking	O
of	O
light	O
,	O
exhibit	O
high	O
stability	O
against	O
light	O
;	O
and	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
preparations	O
against	O
light	O
of	O
storing	O
the	O
same	O
.	O

By	O
regulating	O
the	O
pH	O
value	O
of	O
aqueous	O
solution	O
of	O
fasudil	O
charged	O
in	O
a	O
colorless	O
transparent	O
container	O
to	O
≦5.5	O
,	O
there	O
can	O
be	O
provided	O
fasudil	O
-	O
containing	O
preparations	O
excelling	O
in	O
stability	O
against	O
light	O
;	O
and	O
can	O
be	O
provided	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
aqueous	O
solution	O
of	O
fasudil	O
against	O
light	O
,	O
or	O
storing	O
the	O
same	O
.	O

Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
Flavivirus	O
;	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
(	O
MVA	O
)	O
;	O
stable	O
,	O
can	O
easily	O
be	O
produced	O
The	O
present	O
invention	O
relates	O
to	O
NS1	O
proteins	O
or	O
parts	O
thereof	O
of	O
Flaviviruses	O
,	O
in	O
particular	O
of	O
Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
said	O
Flavivirus	O
and	O
against	O
one	O
or	O
more	O
other	O
Flaviviruses	O
.	O

The	O
invention	O
further	O
concerns	O
the	O
NS1	O
protein	O
or	O
parts	O
thereof	O
of	O
one	O
Dengue	O
virus	O
serotype	O
,	O
in	O
particular	O
serotype	O
2	O
,	O
useful	O
for	O
vaccination	O
against	O
Dengue	O
viruses	O
from	O
all	O
serotypes	O
.	O

The	O
invention	O
further	O
concerns	O
DNA	O
comprising	O
an	O
expression	O
cassette	O
coding	O
for	O
a	O
Flavivirus	O
NS1	O
or	O
parts	O
thereof	O
,	O
vectors	O
comprising	O
said	O
DNA	O
and	O
vaccines	O
containing	O
or	O
expressing	O
a	O
Flavivirus	O
NS1	O
.	O

inhibition	O
of	O
heat	B
shock	I
protein	I
90	I
(	O
HSP90	B
)	O
comprising	O
administering	O
benzoyl	O
compounds	O
or	O
prodrugs	O
,	O
as	O
antitumor	O
agents	O
The	O
present	O
invention	O
provides	O
Hsp90	B
family	O
protein	O
inhibitors	O
comprising	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
benzoyl	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
10	O
;	O
R1	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxy	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxycarbonyl	O
,	O
CONR7R8	O
or	O
the	O
like	O
;	O
R2	O
represents	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
heterocyclic	O
group	O
or	O
the	O
like	O
;	O
R3	O
and	O
R5	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	O
atom	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkenyl	O
or	O
the	O
like	O
;	O
and	O
R4	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	O
atom	O
,	O
halogen	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
,	O
substituted	O
or	O
unsubstituted	O
aryl	O
or	O
the	O
like	O
)	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
said	O
benzoyl	O
compound	O
or	O
said	O
prodrug	O
.	O

Isomaltooligosaccharides	O
to	O
inhibit	O
avian	O
pathogenic	O
intestinal	O
bacteria	O
Isomaltooligosaccharides	O
(	O
IMOs	O
)	O
produced	O
by	O
Leuconostoc	O
mesenteroides	O
ATCC	O
13146	O
fermentation	O
with	O
a	O
sucrose	O
:	O
maltose	O
ratio	O
of	O
2:1	O
have	O
been	O
discovered	O
to	O
be	O
effective	O
prebiotics	O
in	O
mixed	O
cultures	O
of	O
microbial	O
populations	O
,	O
including	O
cultures	O
from	O
chicken	O
ceca	O
.	O

Surprisingly	O
in	O
mixed	O
microbial	O
cultures	O
this	O
IMO	O
composition	O
proved	O
as	O
effective	O
as	O
FOS	O
.	O

Thus	O
,	O
these	O
IMOs	O
can	O
be	O
used	O
as	O
effective	O
prebiotics	O
for	O
both	O
birds	O
and	O
mammals	O
.	O

Moreover	O
,	O
the	O
IMOs	O
were	O
discovered	O
to	O
be	O
effective	O
non	O
-	O
competitive	O
inhibitors	O
of	O
α	B
-	I
glucosidase	I
.	O

These	O
IMOs	O
also	O
will	O
be	O
useful	O
,	O
as	O
an	O
α	B
-	I
glucosidase	I
inhibitor	O
,	O
in	O
a	O
therapeutic	O
application	O
for	O
several	O
diseases	O
,	O
including	O
obesity	O
,	O
diabetes	O
mellitus	O
,	O
pre	O
-	O
diabetes	O
,	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
caries	O
,	O
cancer	O
,	O
viral	O
disease	O
such	O
as	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
and	O
AIDS	O
.	O

A	O
diet	O
with	O
5	O
-	O
20	O
%	O
IMOs	O
was	O
also	O
shown	O
to	O
reduce	O
the	O
abdominal	O
fat	O
tissue	O
in	O
mammals	O
.	O

Detecting	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
,	O
detecting	O
selective	O
hybridization	O
of	O
nucleic	O
acid	O
,	O
therapeutic	O
treatment	O
of	O
a	O
cancer	O
,	O
a	O
kit	O
contains	O
oligonucleotide	O
A	O
method	O
of	O
identifying	O
epigenetically	O
silenced	O
genes	O
,	O
e.g.	O
,	O
methylation	O
silenced	O
genes	O
,	O
in	O
cancer	O
cells	O
is	O
provided	O
.	O

In	O
addition	O
,	O
methods	O
of	O
identifying	O
a	O
cancer	O
by	O
detecting	O
epigenetic	O
silencing	O
of	O
gene	O
expression	O
are	O
provided	O
,	O
as	O
are	O
methods	O
of	O
treating	O
a	O
subject	O
having	O
such	O
a	O
cancer	O
,	O
for	O
example	O
,	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
.	O

Reagents	O
for	O
practicing	O
such	O
methods	O
also	O
are	O
provided	O
.	O

fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
;	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
,	O
treat	O
dementia	O
The	O
present	O
invention	O
relates	O
to	O
cinnamic	O
acid	O
dimers	O
,	O
their	O
preparation	O
and	O
the	O
use	O
thereof	O
for	O
treating	O
neurodegenerative	O
disease	O
,	O
which	O
have	O
excellent	O
effect	O
on	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
ability	O
in	O
vivo	O
and	O
have	O
fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
,	O
even	O
when	O
administered	O
for	O
a	O
long	O
period	O
of	O
time	O
,	O
and	O
thus	O
which	O
can	O
be	O
used	O
for	O
neurodegenerative	O
disease	O
including	O
dementia	O
.	O

Using	O
HIV	B
protease	I
inhibitors	O
(	O
indinavir	O
,	O
nelfinavir	O
,	O
ritonavir	O
,	O
or	O
saquinavir	O
)	O
alone	O
or	O
in	O
combination	O
with	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O
Liposarcomas	O
are	O
treated	O
using	O
HIV	B
protease	I
inhibitors	O
,	O
particularly	O
nelfinavir	O
.	O

The	O
protease	O
inhibitors	O
may	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
traditional	O
cancer	O
treatments	O
,	O
such	O
as	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O
.	O

combination	O
of	O
N-	O
(	O
1-methylpiperidin-4-yl	O
)	O
-N-	O
(	O
4-fluorophenylmethyl	O
)	O
-N'-	O
(	O
4-	O
(	O
2-methylpropyloxy	O
)	O
phenylmethyl	O
)	O
carbamide	O
andmonoamine	O
oxidase	B
inhibitor	O
(	O
MAO	B
-	O
I	O
)	O
selected	O
from	O
tranylcypromine	O
(	O
Parnate	O
)	O
,	O
phenelzine	O
(	O
Nardil	O
)	O
,	O
maprotiline	O
,	O
and	O
isocarboxazid	O
(	O
Marplan	O
)	O
;	O
anti	O
-	O
psychotic	O
agent	O
;	O
dosage	O
form	O
;	O
capsule	O
Disclosed	O
herein	O
are	O
pharmaceutical	O
compositions	O
comprising	O
an	O
inverse	O
serotonin	B
receptor	I
agonist	O
or	O
a	O
serotonin	B
receptor	I
antagonist	O
and	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

Disclosed	O
herein	O
are	O
also	O
methods	O
of	O
treating	O
psychotic	O
disorders	O
using	O
the	O
disclosed	O
pharmaceutical	O
compositions	O
.	O

Substituted	O
5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
m	O
,	O
Q	O
and	O
B	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
tyrosine	B
kinases	I
,	O
in	O
particular	O
Met	B
kinase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
tumours	O
.	O

Antiproliferative	O
agents	O
;	O
gene	O
overexpression	O
This	O
invention	O
relates	O
to	O
vitamin	O
-	O
mitomycin	O
conjugates	O
,	O
to	O
a	O
method	O
of	O
using	O
the	O
conjugates	O
to	O
selectively	O
eliminate	O
a	O
population	O
of	O
pathogenic	O
cells	O
in	O
a	O
host	O
animal	O
harboring	O
the	O
pathogenic	O
cells	O
,	O
and	O
to	O
a	O
method	O
of	O
preparation	O
of	O
the	O
conjugates	O
.	O

The	O
conjugate	O
is	O
of	O
the	O
general	O
formula	O
B	O
-	O
L	O
-	O
X	O
wherein	O
the	O
group	O
B	O
is	O
a	O
vitamin	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
,	O
that	O
binds	O
to	O
a	O
surface	O
accessible	O
vitamin	O
receptor	O
that	O
is	O
uniquely	O
expressed	O
,	O
overexpressed	O
,	O
or	O
preferentially	O
expressed	O
by	O
a	O
population	O
of	O
pathogenic	O
cells	O
,	O
wherein	O
the	O
group	O
L	O
comprises	O
a	O
cleavable	O
linker	O
,	O
and	O
wherein	O
the	O
group	O
X	O
comprises	O
a	O
mitomycin	O
compound	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
.	O

An	O
additional	O
therapeutic	O
agent	O
,	O
such	O
as	O
a	O
chemotherapeutic	O
agent	O
,	O
can	O
be	O
administered	O
in	O
combination	O
with	O
the	O
conjugate	O
.	O

Such	O
as	O
6-benzenesulfonyl-4-piperazin-1-yl	O
-	O
quinoline	O
hydrochloride	O
;	O
for	O
treatment	O
of	O
central	O
nervous	O
system	O
and/or	O
5-	B
HT6	I
receptor	O
related	O
disorders	O
;	O
for	O
weight	O
gain	O
/	O
loss	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
P	O
is	O
sulfone	O
or	O
sulfonamide	O
;	O
and	O
A	O
,	O
B	O
,	O
W	O
,	O
X	O
,	O
Y	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
medical	O
conditions	O
relating	O
to	O
obesity	O
,	O
type	O
II	O
diabetes	O
,	O
and/or	O
CNS	O
disorders	O
,	O
to	O
achieve	O
reduction	O
of	O
body	O
weight	O
and	O
of	O
body	O
weight	O
gain	O
.	O

Gene	O
repair	O
involving	O
in	O
vivo	O
excision	O
of	O
targeting	O
DNA	O
Methods	O
of	O
modifying	O
,	O
repairing	O
,	O
attenuating	O
and	O
inactivating	O
a	O
gene	O
or	O
other	O
chromosomal	O
DNA	O
in	O
a	O
cell	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
or	O
prophylaxis	O
of	O
a	O
genetic	O
disease	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
.	O

Sustained	O
release	O
portion	O
of	O
unit	O
dose	O
containing	O
guaifenesin	O
,	O
dextromethorphan	O
and	O
a	O
release	O
-	O
delaying	O
matrix	O
contains	O
a	O
hydrophilic	O
polymer	O
and	O
a	O
water	O
insoluble	O
polymer	O
,	O
immediate	O
release	O
portion	O
containing	O
guaifenesin	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
pharmaceutical	O
modified	O
release	O
formulation	O
of	O
guaifenesin	O
and	O
dextromethorphan	O
.	O

The	O
formulation	O
may	O
comprise	O
a	O
hydrophilic	O
polymer	O
,	O
preferably	O
a	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
a	O
water	O
-	O
insoluble	O
polymer	O
,	O
preferably	O
an	O
acrylic	O
resin	O
,	O
in	O
a	O
ratio	O
range	O
of	O
about	O
one	O
-	O
to	O
-	O
one	O
(	O
1:1	O
)	O
to	O
about	O
nine	O
-	O
to	O
-	O
one	O
(	O
9:1	O
)	O
,	O
more	O
preferably	O
a	O
range	O
of	O
about	O
three	O
-	O
to	O
-	O
two	O
(	O
3:2	O
)	O
to	O
about	O
six	O
-	O
to	O
-	O
one	O
(	O
6:1	O
)	O
,	O
and	O
most	O
preferably	O
in	O
a	O
range	O
of	O
about	O
two	O
-	O
to	O
-	O
one	O
(	O
2:1	O
)	O
to	O
about	O
four	O
-	O
to	O
-	O
one	O
(	O
4:1	O
)	O
by	O
weight	O
.	O

This	O
formulation	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	O
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
modified	O
release	O
product	O
which	O
has	O
two	O
portions	O
:	O
a	O
first	O
portion	O
having	O
an	O
immediate	O
release	O
formulation	O
of	O
guaifenesin	O
and	O
a	O
second	O
portion	O
having	O
a	O
sustained	O
release	O
formulation	O
of	O
guaifenesin	O
,	O
wherein	O
one	O
or	O
both	O
portions	O
further	O
comprises	O
dextromethorphan	O
.	O

The	O
modified	O
release	O
product	O
has	O
a	O
maximum	O
guaifenesin	O
serum	O
concentration	O
equivalent	O
to	O
that	O
of	O
an	O
immediate	O
release	O
guaifenesin	O
tablet	O
,	O
and	O
is	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	O
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

Crystalline	O
forms	O
of	O
rapamycin	O
analogs	O
Provided	O
is	O
a	O
rapamycin	O
analog	O
composition	O
including	O
a	O
crystalline	O
form	O
of	O
a	O
rapamycin	O
analog	O
.	O

The	O
crystal	O
can	O
be	O
a	O
hydrate	O
.	O

dehydrate	O
,	O
solvate	O
,	O
or	O
desolvate	O
.	O

The	O
rampamycin	O
analog	O
can	O
have	O
a	O
structure	O
of	O
Formula	O
1	O
,	O
which	O
is	O
optionally	O
a	O
prodrug	O
,	O
salt	O
,	O
derivative	O
,	O
or	O
combination	O
thereof	O
:	O

Adenine	O
compound	O
A	O
novel	O
adenine	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
:	O
[	O
wherein	O
R1	O
is	O
substituted	O
or	O
unsubstituted	O
alkyl	O
,	O
etc	O
.	O
,	O
X	O
is	O
oxygen	O
,	O
etc	O
.	O
,	O
A1	O
is	O
4-	O
to	O
8-membered	O
substituted	O
or	O
unsubstituted	O
saturated	O
nitrogen	O
-	O
containing	O
heterocycle	O
containing	O
1	O
to	O
2	O
hetero	O
atom	O
(	O
s	O
)	O
selected	O
from	O
1	O
to	O
2	O
nitrogen	O
(	O
s	O
)	O
,	O
0	O
to	O
1	O
oxygen	O
and	O
0	O
to	O
1	O
sulfur	O
,	O
etc	O
.	O
,	O
A2	O
is	O
substituted	O
or	O
unsubstituted	O
6-	O
to	O
10-membered	O
aryl	O
,	O
etc	O
.	O
,	O
L1	O
and	O
L2	O
are	O
independently	O
a	O
straight	O
chain	O
or	O
branched	O
chain	O
alkylene	O
,	O
etc	O
.	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
is	O
useful	O
as	O
a	O
medicament	O
.	O

An	O
enzyme	O
in	O
the	O
tryptophan	O
degradation	O
pathway	O
,	O
used	O
to	O
treat	O
neurodegenerative	O
disorders	O
,	O
certain	O
cancers	O
,	O
drug	O
addiction	O
;	O
arylsulfonamides	O
such	O
as	O
3,4-dimethoxy	O
-	O
N-	O
[	O
5-	O
(	O
4-chlorophenyl	O
)	O
-1,2,4-thiadiazole-3-yl	O
]	O
benzenesulfonamide	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
below	O
and	O
their	O
tautomers	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
compositions	O
and	O
methods	O
of	O
uses	O
thereof	O
:	O

Administering	O
oligosaccharides	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
prebiotic	O
(	O
prebiotic	O
adjuvant	O
)	O
for	O
decreasing	O
inflammatory	O
process	O
by	O
improving	O
the	O
homeostasis	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
and	O
of	O
lymphocyte	O
subpopulations	O
.	O

It	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
prebiotic	O
formulation	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
or	O
a	O
food	O
or	O
petfood	O
composition	O
for	O
decreasing	O
inflammatory	O
process	O
and/or	O
abnormal	O
activation	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
,	O
such	O
as	O
phagocytes	O
.	O

Selective	O
proton	B
coupled	I
folate	I
transporter	I
and	O
folate	B
receptor	I
,	O
and	O
GARFTase	B
inhibitor	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
same	O
Fused	O
cyclic	O
pyrimidine	O
compounds	O
,	O
including	O
tautomers	O
thereof	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
prodrugs	O
,	O
solvates	O
and	O
hydrates	O
thereof	O
,	O
are	O
disclosed	O
having	O
the	O
general	O
Formula	O
I	O
:	O
These	O
compounds	O
are	O
useful	O
in	O
methods	O
for	O
treating	O
cancer	O
,	O
selectively	O
targeting	O
cancerous	O
cells	O
via	O
the	O
proton	B
coupled	I
folate	I
transporter	I
,	O
folate	B
receptor	I
alpha	I
,	O
and/or	O
folate	B
receptor	I
beta	I
pathways	O
,	O
inhibiting	O
GARFTase	B
in	O
cancerous	O
cells	O
,	O
and	O
selectively	O
targeting	O
activated	O
macrophages	O
in	O
a	O
patient	O
having	O
an	O
autoimmune	O
disease	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

Method	O
for	O
restructuring	O
the	O
epidermis	O
using	O
a	O
polyol	O
-	O
glycoside	O
composition	O
A	O
method	O
for	O
restructuring	O
the	O
epidermis	O
with	O
a	O
composition	O
,	O
wherein	O
said	O
composition	O
includes	O
a	O
polyol	O
-	O
glycoside	O
and	O
said	O
polyol	O
-	O
glycoside	O
is	O
obtained	O
by	O
the	O
acetalization	O
of	O
a	O
polyol	O
with	O
a	O
reducing	O
sugar	O
.	O

Fused	O
amino	O
pyridine	O
as	O
HSP90	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
HSP90	B
inhibitors	O
containing	O
fused	O
amino	O
pyridine	O
core	O
that	O
are	O
useful	O
as	O
inhibitors	O
of	O
HSP90	B
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
HSP90	B
related	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
an	O
autoimmune	O
disease	O
,	O
or	O
a	O
neurodegenerative	O
disease	O
.	O

Compounds	O
and	O
compositions	O
for	O
treating	O
cancer	O
The	O
invention	O
relates	O
to	O
compounds	O
and	O
composition	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
.	O

The	O
invention	O
also	O
covers	O
all	O
diseases	O
that	O
may	O
be	O
treated	O
by	O
selective	O
modulation	O
of	O
levels	O
of	O
reactive	O
oxygen	O
species	O
in	O
diseased	O
cells	O
versus	O
normal	O
cells	O
.	O

Methods	O
for	O
the	O
preparation	O
and	O
administration	O
of	O
such	O
compositions	O
are	O
also	O
disclosed	O
.	O

Characterization	O
of	O
GRP94-ligand	B
interactions	O
and	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
relating	O
thereto	O
The	O
presently	O
disclosed	O
subject	O
matter	O
discloses	O
characterization	O
of	O
interactions	O
between	O
ligands	O
and	O
Hsp90	B
proteins	O
,	O
including	O
GRP94	B
,	O
wherein	O
ligand	O
binding	O
to	O
the	O
N	O
-	O
terminal	O
nucleotide	O
binding	O
domain	O
of	O
GRP94	B
elicits	O
a	O
conformational	O
change	O
that	O
converts	O
the	O
GRP94	B
from	O
an	O
inactive	O
to	O
an	O
active	O
conformation	O
,	O
and	O
wherein	O
the	O
chaperone	O
and	O
peptide	O
-	O
binding	O
activities	O
of	O
the	O
GRP94	B
are	O
markedly	O
stimulated	O
.	O

Also	O
disclosed	O
are	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
pertaining	O
to	O
the	O
biological	O
activity	O
of	O
GRP94	B
,	O
and	O
in	O
some	O
instances	O
HSP90	O
,	O
based	O
upon	O
the	O
characterization	O
of	O
ligand	O
interactions	O
of	O
Hsp90	B
peptide	O
-	O
binding	O
proteins	O
,	O
including	O
GRP94	B
.	O

Wound	O
care	O
device	O
A	O
wound	O
care	O
device	O
for	O
local	O
treatment	O
of	O
pain	O
in	O
a	O
wound	O
,	O
said	O
device	O
comprising	O
an	O
active	O
pain	O
relieving	O
composition	O
,	O
the	O
device	O
being	O
constructed	O
in	O
such	O
a	O
manner	O
that	O
the	O
pain	O
killing	O
agent	O
is	O
released	O
to	O
the	O
wound	O
in	O
such	O
a	O
way	O
that	O
substantially	O
no	O
effective	O
systemic	O
plasma	O
concentration	O
of	O
the	O
pain	O
killing	O
agent	O
can	O
be	O
found	O
and	O
wherein	O
a	O
majority	O
of	O
said	O
pain	O
killing	O
agent	O
is	O
in	O
direct	O
contact	O
with	O
the	O
wound	O
.	O

Thieno-	O
and	O
furo	O
-	O
pyrimidine	O
modulators	O
of	O
the	O
histamine	B
H4	I
receptor	I
Thieno-	O
and	O
furo	O
-	O
pyrimidine	O
compounds	O
are	O
described	O
,	O
which	O
are	O
useful	O
as	O
H4	B
receptor	I
modulators	O
.	O

Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
modulation	O
of	O
histamine	B
H4	I
receptor	I
activity	O
and	O
for	O
the	O
treatment	O
of	O
disease	O
states	O
,	O
disorders	O
,	O
and	O
conditions	O
mediated	O
by	O
H4	B
receptor	I
activity	O
,	O
such	O
as	O
inflammation	O
.	O

Polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
including	O
a	O
covalent	O
bond	O
and	O
an	O
amino	O
chain	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
synthetic	O
polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
having	O
at	O
least	O
one	O
covalent	O
bond	O
with	O
an	O
amino	O
chain	O
,	O
and	O
to	O
the	O
preparation	O
method	O
thereof	O
and	O
to	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Dietary	O
fiber	O
formulation	O
and	O
method	O
of	O
administration	O
The	O
invention	O
provides	O
dietary	O
fiber	O
formulation	O
and	O
related	O
methods	O
for	O
its	O
administration	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
invention	O
provides	O
a	O
dietary	O
fiber	O
formulation	O
comprising	O
:	O
partially	O
-	O
hydrolyzed	O
guar	O
gum	O
(	O
PHGG	O
)	O
;	O
and	O
fructooligosaccharides	O
(	O
FOS	O
)	O
,	O
wherein	O
the	O
dietary	O
fiber	O
formulation	O
exhibits	O
a	O
prebiotic	O
potential	O
greater	O
than	O
a	O
prebiotic	O
potential	O
of	O
PHGG	O
and	O
FOS	O
individually	O
.	O

Assay	O
for	O
identifying	O
a	O
modulator	O
of	O
HIF	B
hydroxylase	I
A	O
novel	O
class	O
of	O
hydroxylases	O
is	O
described	O
having	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
,	O
and	O
variants	O
and	O
fragments	O
thereof	O
having	O
HIF	O
hydroxylation	O
activity	O
.	O

The	O
polypeptides	O
of	O
the	O
invention	O
have	O
in	O
particular	O
prolyl	O
hydroxylase	O
activity	O
.	O

An	O
assay	O
method	O
monitors	O
the	O
interaction	O
of	O
the	O
HIF	B
hydroxylase	I
with	O
a	O
substrate	O
.	O

Modulators	O
of	O
HIF	B
hydroxylase	I
are	O
provided	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
increased	O
or	O
decreased	O
HIF	O
levels	O
or	O
activity	O
or	O
for	O
the	O
treatment	O
of	O
a	O
condition	O
where	O
it	O
is	O
desirable	O
to	O
modulate	O
HIF	O
levels	O
or	O
activity	O
.	O

Heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyridines	O
and	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyrimidines	O
as	O
Janus	B
kinase	I
inhibitors	O
The	O
present	O
invention	O
provides	O
heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyridines	O
and	O
heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyrimidines	O
that	O
modulate	O
the	O
activity	O
of	O
Janus	B
kinases	I
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
activity	O
of	O
Janus	B
kinases	I
including	O
,	O
for	O
example	O
,	O
immune	O
-	O
related	O
diseases	O
,	O
skin	O
disorders	O
,	O
myeloid	O
proliferative	O
disorders	O
,	O
cancer	O
,	O
and	O
other	O
diseases	O
.	O

Composition	O
for	O
treating	O
mental	O
health	O
disorders	O
A	O
composition	O
of	O
three	O
compounds	O
each	O
selected	O
from	O
a	O
selective	O
re	O
-	O
uptake	O
inhibitor	O
of	O
serotonin	O
,	O
a	O
monoamine	O
oxidase	O
inhibitor	O
,	O
and	O
a	O
phosphodiesterase	O
inhibitor	O
,	O
such	O
that	O
all	O
three	O
compounds	O
are	O
different	O
and	O
are	O
naturally	O
occurring	O
.	O

Methods	O
for	O
recommending	O
neurophysiological	O
disorder	O
therapy	O
Neurophysiologic	O
information	O
such	O
as	O
quantitative	O
electroencephalography	O
(	O
QEEG	O
)	O
is	O
used	O
in	O
a	O
method	O
for	O
classifying	O
,	O
diagnosing	O
,	O
and	O
treating	O
physiologic	O
brain	O
imbalances	O
.	O

Neurophysiologic	O
information	O
is	O
also	O
used	O
to	O
guide	O
sample	O
selection	O
in	O
clinical	O
tests	O
for	O
psychopharmacologic	O
drug	O
candidates	O
.	O

Finally	O
,	O
neurophysiologic	O
information	O
is	O
used	O
for	O
remotely	O
assessing	O
and	O
treating	O
patients	O
with	O
physiologic	O
brain	O
imbalances	O
.	O

Desensitizing	O
drug	O
product	O
Desensitizing	O
drug	O
products	O
,	O
methods	O
of	O
making	O
desensitizing	O
drug	O
products	O
,	O
and	O
methods	O
of	O
using	O
desensitizing	O
drug	O
products	O
including	O
delivery	O
of	O
desensitizing	O
drug	O
products	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
desensitizing	O
drug	O
products	O
are	O
male	O
genital	O
desensitizers	O
that	O
comprise	O
one	O
or	O
anesthetic	O
agents	O
and	O
one	O
or	O
more	O
melting	O
point	O
depressing	O
agents	O
.	O

Remedy	O
for	O
overactive	O
bladder	O
comprising	O
acetic	O
acid	O
anilide	O
derivative	O
as	O
the	O
active	O
ingredient	O
(	O
R	O
)	O
-2-	O
(	O
2-aminothiazol-4-yl	O
)	O
-4′-	O
[	O
2-	O
[	O
(	O
2-hydroxy-2-phenylethyl	O
)	O
amino	O
]	O
ethyl	O
]	O
acetic	O
acid	O
anilide	O
or	O
its	O
salt	O
shows	O
a	O
potent	O
bladder	O
relaxation	O
effect	O
in	O
""""	O
isolated	O
rat	O
bladder	O
smooth	O
muscle	O
relaxation	O
test	O
""""	O
,	O
dose	O
-	O
dependently	O
lowers	O
the	O
contraction	O
frequency	O
of	O
rhythmic	O
bladder	O
contractions	O
in	O
""""	O
rat	O
rhythmic	O
bladder	O
contraction	O
measurement	O
test	O
""""	O
and	O
,	O
moreover	O
,	O
prolongs	O
the	O
urination	O
intervals	O
in	O
""""	O
urination	O
functions	O
measurement	O
test	O
on	O
cyclophosphamide	O
-	O
induced	O
overactive	O
bladder	O
model	O
rat	O
""""	O
.	O

Owing	O
to	O
these	O
effects	O
,	O
the	O
above	O
compound	O
is	O
useful	O
as	O
a	O
remedy	O
for	O
overactive	O
bladder	O
.	O

Hepatitis	O
C	O
inhibitor	O
tri	O
-	O
peptides	O
Racemates	O
,	O
diastereoisomers	O
and	O
optical	O
isomers	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
B	O
is	O
H	O
,	O
a	O
C6	O
or	O
C10	O
aryl	O
,	O
C7	O
-	O
16	O
aralkyl	O
;	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
,	O
all	O
of	O
which	O
optionally	O
substituted	O
with	O
C1	O
-	O
6	O
alkyl	O
;	O
C1	O
-	O
6	O
alkoxy	O
;	O
C1	O
-	O
6	O
alkanoyl	O
;	O
hydroxy	O
;	O
hydroxyalkyl	O
;	O
halo	O
;	O
haloalkyl	O
;	O
nitro	O
;	O
cyano	O
;	O
cyanoalkyl	O
;	O
amino	O
optionally	O
substituted	O
with	O
C1	O
-	O
6	O
alkyl	O
;	O
amido	O
;	O
or	O
(	O
lower	O
alkyl	O
)	O
amide	O
;	O
or	O
B	O
is	O
an	O
acyl	O
derivative	O
of	O
formula	O
R4—C	O
(	O
O	O
)	O
—	O
;	O
a	O
carboxyl	O
of	O
formula	O
R4—O	O
—	O
C	O
(	O
O	O
)	O
—	O
;	O
an	O
amide	O
of	O
formula	O
R4—N	O
(	O
R5	O
)	O
—C	O
(	O
O	O
)	O
—	O
;	O
a	O
thioamide	O
of	O
formula	O
R4—N	O
(	O
R5	O
)	O
—C	O
(	O
S	O
)	O
—	O
;	O
or	O
a	O
sulfonyl	O
of	O
formula	O
R4—SO2	O
;	O
R5	O
is	O
H	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
and	O
Y	O
is	O
H	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
R3	O
is	O
C1	O
-	O
8	O
alkyl	O
,	O
C3	O
-	O
7	O
cycloalkyl	O
,	O
or	O
C4	O
-	O
10	O
alkylcycloalkyl	O
,	O
all	O
optionally	O
substituted	O
with	O
hydroxy	O
,	O
C1	O
-	O
6	O
alkoxy	O
,	O
C1	O
-	O
6	O
thioalkyl	O
,	O
amido	O
,	O
(	O
lower	O
alkyl	O
)	O
amido	O
,	O
C6	O
or	O
C10	O
aryl	O
,	O
or	O
C7	O
-	O
16	O
aralkyl	O
;	O
R2	O
is	O
CH2—R20	O
,	O
NH	O
—	O
R20	O
,	O
O	O
—	O
R20	O
or	O
S	O
—	O
R20	O
,	O
wherein	O
R20	O
is	O
a	O
saturated	O
or	O
unsaturated	O
C3	O
-	O
7	O
cycloalkyl	O
or	O
C4	O
-	O
10	O
(	O
alkylcycloalkyl	O
)	O
,	O
all	O
of	O
which	O
being	O
optionally	O
mono-	O
,	O
di-	O
or	O
tri	O
-	O
substituted	O
with	O
R21	O
,	O
or	O
R20	O
is	O
a	O
C6	O
or	O
C10	O
aryl	O
or	O
C7	O
-	O
14	O
aralkyl	O
optionally	O
substituted	O
,	O
or	O
R20	O
is	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
,	O
both	O
optionally	O
substituted	O
,	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
;	O
carboxyl	O
;	O
carboxy	O
(	O
lower	O
alkyl	O
)	O
;	O
C6	O
or	O
C10	O
aryl	O
,	O
C7	O
-	O
14	O
aralkyl	O
or	O
Het	O
,	O
said	O
aryl	O
,	O
aralkyl	O
or	O
Het	O
being	O
optionally	O
substituted	O
;	O
and	O
R1	O
is	O
H	O
;	O
C1	O
-	O
6	O
alkyl	O
,	O
C3	O
-	O
7	O
cycloalkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
or	O
C2	O
-	O
6	O
alkynyl	O
,	O
all	O
optionally	O
substituted	O
with	O
halogen	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
.	O

Use	O
of	O
medium	O
chain	O
triglycerides	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
alzheimer	O
's	O
disease	O
and	O
other	O
diseases	O
resulting	O
from	O
reduced	O
neuronal	O
metabolism	O
Methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
,	O
the	O
occurrence	O
of	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
,	O
or	O
other	O
conditions	O
arising	O
from	O
reduced	O
neuronal	O
metabolism	O
and	O
leading	O
to	O
lessened	O
cognitive	O
function	O
are	O
described	O
.	O

In	O
a	O
preferred	O
embodiment	O
the	O
administration	O
of	O
triglicerides	O
or	O
fatty	O
acids	O
with	O
chain	O
lengths	O
between	O
5	O
and	O
12	O
,	O
to	O
said	O
patient	O
at	O
a	O
level	O
produce	O
an	O
improvement	O
in	O
cognitive	O
ability	O
.	O

C6-	O
and	O
c9-substituted	O
chromeno	O
[	O
4	O
,	O
3-c	O
]	O
isoxazoline	O
derivatives	O
and	O
their	O
use	O
as	O
anti	O
-	O
depressants	O
The	O
invention	O
concerns	O
substituted	O
tricyclic	O
isoxazoline	O
derivatives	O
,	O
more	O
in	O
particular	O
tricyclic	O
dihydrobenzopyranoisoxazoline	O
,	O
dihydroquinolinoisoxazoline	O
,	O
dihydronaphthalenoisoxazoline	O
and	O
dihydrobenzothiopyranoisoxazoline	O
derivatives	O
substituted	O
on	O
at	O
least	O
one	O
of	O
the	O
C6-	O
and	O
C9-positions	O
of	O
the	O
phenylpart	O
of	O
the	O
tricyclic	O
moiety	O
with	O
a	O
selected	O
radical	O
,	O
according	O
to	O
Formula	O
(	O
I	O
)	O
wherein	O
X	O
=	O
CH2	O
,	O
N	O
-	O
R7	O
,	O
S	O
or	O
O	O
,	O
R1	O
,	O
R2	O
,	O
R14	O
and	O
R15	O
are	O
certain	O
specific	O
substituents	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
R14	O
and	O
R15	O
is	O
not	O
hydrogen	O
,	O
Pir	O
is	O
preferably	O
an	O
optionally	O
substituted	O
piperidinyl	O
or	O
piperazinyl	O
radical	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
aromatic	O
homocyclic	O
or	O
heterocyclic	O
ring	O
system	O
including	O
a	O
partially	O
or	O
completely	O
hydrogenated	O
hydrocarbon	O
chain	O
of	O
maximum	O
6	O
atoms	O
long	O
with	O
which	O
the	O
ring	O
system	O
is	O
attached	O
to	O
the	O
Pir	O
radical	O
and	O
which	O
may	O
contain	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
the	O
group	O
of	O
O	O
,	O
N	O
and	O
S	O
;	O
a	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
,	O
movement	O
disorders	O
,	O
psychosis	O
,	O
Parkinson	O
's	O
disease	O
and	O
body	O
weight	O
disorders	O
..	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
have	O
surprisingly	O
been	O
shown	O
to	O
have	O
a	O
serotonine	O
(	O
5-HT	O
)	O
reuptake	O
inhibitor	O
activity	O
in	O
combination	O
with	O
additional	O
α2-adrenoceptor	B
antagonist	O
activity	O
and	O
show	O
a	O
strong	O
anti	O
-	O
depressant	O
activity	O
without	O
being	O
sedative	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
combination	O
of	O
isoxazoline	O
derivatives	O
according	O
to	O
the	O
invention	O
with	O
one	O
or	O
more	O
other	O
compounds	O
selected	O
from	O
the	O
group	O
of	O
antidepressants	O
,	O
anxiolytics	O
,	O
anti	O
-	O
psychotics	O
and	O
anti	O
-	O
Parkinson	O
's	O
disease	O
drugs	O
to	O
improve	O
efficacy	O
and/or	O
onset	O
of	O
action	O
.	O

PREPARATION	O
FOR	O
EXTERNAL	O
PERCUTANEOUS	O
ADMINISTRATION	O
CONTAINING	O
NON	O
-	O
STEROIDAL	O
ANTI	O
-	O
INFLAMMATORY	O
DRUG	O
AND	O
INTERLEUKIN-1α	B
PRODUCTION	O
INHIBITOR	O
A	O
preparation	O
for	O
external	O
percutaneous	O
administration	O
which	O
comprises	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
an	O
alkyl	O
gallate	O
,	O
and	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
.	O

Also	O
provided	O
is	O
an	O
interleukin-1α	B
production	O
inhibitor	O
which	O
comprises	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
and/or	O
an	O
alkyl	O
gallate	O
.	O

Tlr7	B
ligands	O
for	O
the	O
treatment	O
of	O
hepatitis	O
c	O
This	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
infections	O
in	O
mammals	O
using	O
Toll	B
-	I
Like	I
Receptor	I
(	I
TLR	I
)	I
7	I
ligands	O
and	O
prodrugs	O
thereof	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
methods	O
of	O
orally	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
prodrugs	O
of	O
TLR7	B
ligands	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hepatitis	O
C	O
viral	O
infection	O
.	O

Oral	O
administration	O
of	O
these	O
TLR7	B
immunomodulating	O
ligands	O
and	O
prodrugs	O
thereof	O
to	O
a	O
mammal	O
provides	O
therapeutically	O
effective	O
amounts	O
and	O
reduced	O
undesirable	O
side	O
effects	O
.	O

Antimycotic	O
nail	O
polish	O
formulations	O
comprising	O
substituted	O
2-aminothiazoles	O
as	O
an	O
active	O
substance	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
(	O
A	O
)	O
a	O
pharmaceutically	O
effective	O
compound	O
from	O
the	O
compound	O
class	O
of	O
antimycotic	O
substituted	O
2-aminothiazoles	O
,	O
and	O
(	O
B	O
)	O
a	O
nail	O
polish	O
formulation	O
of	O
said	O
compound	O
.	O

The	O
invention	O
further	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
for	O
treating	O
onychomycoses	O
and	O
other	O
diseases	O
of	O
the	O
fingernails	O
or	O
toenails	O
caused	O
by	O
fungal	O
infections	O
.	O

The	O
invention	O
particularly	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
that	O
are	O
applied	O
to	O
nails	O
and	O
form	O
a	O
coating	O
from	O
which	O
the	O
antimycotic	O
agent	O
is	O
released	O
and	O
can	O
penetrate	O
into	O
the	O
nail	O
.	O

Said	O
method	O
allows	O
nails	O
of	O
humans	O
and	O
animals	O
to	O
be	O
treated	O
against	O
fungal	O
infections	O
or	O
fungal	O
infections	O
to	O
be	O
prevented	O
.	O

N	O
-	O
acylated-3-	O
(	O
benzoyl	O
)	O
-	O
pyrrolidines	O
as	O
11-beta	B
-	I
hsd1	I
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

The	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
variable	O
groups	O
are	O
defined	O
within	O
;	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
inhibition	O
of	O
11βHSD1	B
,	O
processes	O
for	O
making	O
them	O
,	O
certain	O
compounds	O
within	O
the	O
definition	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
described	O
.	O

Agent	O
or	O
method	O
for	O
treatment	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorder	O
An	O
agent	O
or	O
method	O
for	O
treatments	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorders	O
which	O
contains	O
or	O
employs	O
2-oxo-1-pyrrolidineacetamide	O
as	O
an	O
active	O
ingredient	O
.	O

Use	O
of	O
conjugated	O
linolenic	O
acids	O
for	O
reducing	O
body	O
fat	O
mass	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
conjugated	O
linolenic	O
acids	O
selected	O
from	O
the	O
groups	O
consisting	O
of	O
Cl	O
8:3	O
(	O
9cis	O
,	O
11	O
trans	O
,	O
15	O
cis	O
)	O
octadecatrienoic	O
acid	O
,	O
C18:3	O
(	O
9cis,13trans,15cis	O
)	O
octadecatrienoic	O
acid	O
and	O
mixtures	O
thereof	O
in	O
the	O
reduction	O
of	O
body	O
fat	O
mass	O
and	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
obesity	O
.	O

These	O
conjugated	O
linolenic	O
acids	O
may	O
be	O
provided	O
in	O
the	O
form	O
of	O
a	O
food	O
supplement	O
or	O
as	O
a	O
component	O
of	O
a	O
prepared	O
food	O
product	O
.	O

Active	O
oxygen	O
eliminator	O
originating	O
in	O
natural	O
material	O
and	O
use	O
of	O
the	O
same	O
An	O
active	O
oxygen	O
eliminator	O
originating	O
in	O
a	O
natural	O
material	O
which	O
comprises	O
water	O
,	O
an	O
organic	O
solvent	O
,	O
an	O
emulsifier	O
and	O
,	O
as	O
the	O
main	O
active	O
ingredients	O
,	O
p	O
-	O
coumalic	O
acid	O
,	O
3,4-di	O
-	O
O	O
-	O
caffeoylquinic	O
acid	O
,	O
3,5-di	O
-	O
O	O
-	O
caffeoylquinic	O
acid	O
,	O
4-hydroxy-3-prenylcinnamic	O
acid	O
and	O
3,5,7-trihydroxy-4'-methoxyflavonol	O
;	O
and	O
a	O
food	O
and	O
a	O
cosmetic	O
containing	O
this	O
active	O
oxygen	O
eliminator	O
.	O

Extracts	O
of	O
scutellaria	O
for	O
the	O
treatment	O
of	O
sars	O
The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
having	O
antiviral	O
activity	O
against	O
Coronavirus	O
,	O
and	O
more	O
particularly	O
against	O
those	O
viruses	O
responsible	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
.	O

In	O
a	O
preferred	O
embodiment	O
it	O
comprises	O
a	O
total	O
standardised	O
extract	O
of	O
a	O
Scutellariae	O
spp	O
.	O

Remedy	O
for	O
urinary	O
disorder	O
It	O
is	O
intended	O
to	O
provide	O
a	O
remedy	O
for	O
urinary	O
disorder	O
.	O

Namely	O
,	O
a	O
remedy	O
for	O
urinary	O
disorder	O
containing	O
a	O
compound	O
which	O
suppresses	O
the	O
GIRK	B
channel	I
activated	O
current	O
while	O
showing	O
no	O
suppressive	O
effect	O
on	O
the	O
glycine	B
receptor	I
activated	O
current	O
or	O
NMDA	B
receptor	I
activated	O
current	O
.	O

Method	O
of	O
treating	O
sepsis	O
Compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
sepsis	O
in	O
an	O
animal	O
are	O
disclosed	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
electrolyzed	O
saline	O
solution	O
to	O
the	O
animal	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
electrolyzed	O
saline	O
solution	O
comprises	O
ozone	O
and	O
at	O
least	O
one	O
active	O
chlorine	O
species	O
.	O

The	O
electrolyzed	O
saline	O
can	O
further	O
comprise	O
at	O
least	O
one	O
active	O
hydrogen	O
species	O
.	O

Composition	O
against	O
aids	O
virus	O
and	O
method	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
An	O
antiviral	O
composition	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
which	O
comprises	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
iodine	O
ion	O
or	O
a	O
compound	O
forming	O
iodine	O
ion	O
;	O
a	O
functional	O
food	O
containing	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
thus	O
having	O
an	O
antiviral	O
function	O
imparted	O
thereto	O
;	O
and	O
an	O
antiviral	O
drug	O
comprising	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
antiviral	O
composition	O
and	O
so	O
on	O
having	O
a	O
function	O
of	O
selectively	O
inactivating	O
AIDS	O
virus	O
-	O
infected	O
cells	O
,	O
viral	O
cancer	O
cells	O
,	O
etc	O
.	O

Imine	O
derivative	O
and	O
amide	O
derivative	O
A	O
medicine	O
having	O
prostaglandin	O
D2	O
(	O
PGD2	O
)	O
production	O
inhibitory	O
activity	O
and	O
having	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
selected	O
from	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
A	O
-	O
Y	O
-	O
B	O
{	O
wherein	O
A	O
and	O
B	O
each	O
independently	O
represents	O
an	O
optionally	O
substituted	O
,	O
cyclic	O
hydrocarbon	O
or	O
heterocyclic	O
group	O
;	O
and	O
Y	O
represents	O
-CH	O
=	O
N-	O
,	O
-N	O
=	O
CH-	O
,	O
-CONH-	O
,	O
or	O
-NHCO-	O
,	O
provided	O
that	O
the	O
compounds	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I-1	O
)	O
[	O
wherein	O
X	O
represents	O
the	O
formula	O
-N	O
=	O
C	O
(	O
R5	O
)	O
-	O
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	O
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	O
atom	O
)	O
or	O
the	O
formula	O
-NH	O
-	O
CH	O
(	O
R5	O
)	O
-	O
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	O
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	O
atom	O
)	O
;	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
each	O
independently	O
represents	O
hydrogen	O
,	O
halogeno	O
,	O
or	O
optionally	O
substituted	O
C1	O
-	O
6	O
alkyl	O
or	O
hydroxy	O
;	O
R5	O
represents	O
an	O
optionally	O
substituted	O
C1	O
-	O
6	O
alkyl	O
or	O
C6	O
-	O
10	O
aryl	O
group	O
;	O
and	O
R	O
represents	O
optionally	O
substituted	O
amino	O
]	O
are	O
excluded	O
}	O
,	O
salts	O
,	O
hydrates	O
,	O
and	O
solvates	O
.	O

Macrolide	O
compositions	O
as	O
therapeutic	O
agent	O
The	O
present	O
invention	O
provides	O
compositions	O
including	O
a	O
macrolide	O
compound	O
that	O
inhibits	O
MHC	B
class	I
II	I
expression	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
are	O
used	O
as	O
an	O
immunosuppressive	O
agent	O
in	O
the	O
treatment	O
prior	O
to	O
,	O
during	O
and/or	O
after	O
organ	O
or	O
tissue	O
transplantation	O
,	O
as	O
well	O
as	O
in	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O
.	O

Abnormal	O
cannabidiols	O
for	O
lowering	O
intraocular	O
pressure	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Abnormal	O
Cannabidiols	O
as	O
potent	O
ocular	O
hypotensives	O
,	O
and	O
are	O
particular	O
suitable	O
for	O
the	O
management	O
of	O
glaucoma	O
.	O

In	O
particular	O
said	O
compounds	O
are	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
formula	O
(	O
II	O
)	O
or	O
formula	O
(	O
III	O
)	O
.	O

These	O
compounds	O
have	O
also	O
been	O
found	O
to	O
be	O
useful	O
in	O
providing	O
neuroprotective	O
effect	O
to	O
the	O
eye	O
.	O

Amino	O
-	O
tropane	O
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O
The	O
invention	O
concerns	O
amino	O
-	O
tropane	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
Ra	O
R	O
a	O
'	O
et	O
R5	O
represent	O
hydrogen	O
atoms	O
or	O
alkyl	O
groups	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
alkyl	O
,	O
cycloalkyl	O
,	O
heterocycloalkyl	O
or	O
aryl	O
group	O
;	O
R2	O
represents	O
a	O
group	O
of	O
formula	O
-	O
(	O
CH2	O
)	O
x-	O
(	O
CO	O
)	O
y	O
-	O
Y	O
or	O
-	O
(	O
CO	O
)	O
y-	O
(	O
CH2	O
)	O
x	O
-	O
Y	O
,	O
wherein	O
Y	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
hydroxy	O
,	O
alkyl	O
,	O
cycloalkyl	O
,	O
alkoxy	O
,	O
aryl	O
,	O
heteroaryl	O
group	O
or	O
NR11R12	O
;	O
R3	O
represents	O
1	O
to	O
3	O
groups	O
selected	O
among	O
halogen	O
atoms	O
and	O
alkyl	O
,	O
cycloalkyl	O
OR	O
,	O
-NRR	O
'	O
,	O
-CO	O
-	O
NRR	O
'	O
,	O
-NR	O
-	O
CO	O
-	O
R	O
'	O
,	O
-NR	O
-	O
CO	O
-	O
NRR	O
'	O
,	O
-NR	O
-	O
COOR	O
'	O
,	O
-NO2	O
,	O
-CN	O
and	O
-COOR	O
groups	O
;	O
R4	O
is	O
selected	O
among	O
a	O
group	O
of	O
formula	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
,	O
(	O
c	O
)	O
or	O
(	O
d	O
)	O
:	O
or	O
a	O
group	O
of	O
formula	O
-A	O
-	O
R18	O
,	O
-A	O
-	O
CH	O
=	O
N	O
-	O
R19	O
,	O
-A	O
-	O
N	O
(	O
R20	O
)	O
-A'-R19	O
,	O
-A	O
-	O
CO	O
-	O
N	O
(	O
R2O	O
)	O
-A'-R19	O
,	O
-A	O
-	O
CH	O
(	O
NH2	O
)	O
-R19	O
,	O
-A	O
-	O
N	O
(	O
R20	O
)	O
-COO	O
-	O
A	O
'	O
or	O
-	O
(	O
CH2	O
)	O
r	O
-	O
heteroaryl	O
.	O

The	O
invention	O
also	O
concerns	O
a	O
method	O
for	O
preparing	O
said	O
derivatives	O
and	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Donepezyl	O
salts	O
The	O
invention	O
relates	O
to	O
crystalline	O
acid	O
addition	O
salts	O
of	O
donepezil	O
with	O
an	O
organic	O
acid	O
.	O

The	O
acid	O
addition	O
salts	O
have	O
a	O
lower	O
corrosivity	O
compared	O
to	O
the	O
previously	O
known	O
donepezil	O
hydrochloride	O
.	O

The	O
salts	O
can	O
be	O
used	O
for	O
the	O
production	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
dementia	O
.	O

Preparation	O
of	O
phenol	O
-	O
amide	O
compounds	O
with	O
antioxidant	O
properties	O
The	O
invention	O
relates	O
to	O
the	O
preparation	O
of	O
compounds	O
comprising	O
at	O
least	O
one	O
phenol	O
function	O
and	O
one	O
amide	O
function	O
derived	O
from	O
amino-2	O
alkanol-1	O
having	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
,	O
which	O
have	O
antioxidant	O
and	O
antiradical	O
properties	O
and	O
which	O
are	O
soluble	O
in	O
lipid	O
media	O
.	O

The	O
inventive	O
compounds	O
can	O
be	O
used	O
as	O
cosmetic	O
or	O
pharmaceutical	O
preparations	O
for	O
the	O
prevention	O
of	O
biological	O
degradation	O
caused	O
by	O
free	O
radicals	O
.	O

Therapeutic	O
agent	O
for	O
parkinson	O
's	O
disease	O
A	O
medicine	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

It	O
comprises	O
a	O
combination	O
of	O
(	O
2R	O
)	O
-2-propyloctanoic	O
acid	O
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
with	O
an	O
agent	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

The	O
medicine	O
is	O
highly	O
effective	O
in	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

In	O
particular	O
,	O
when	O
the	O
medicinal	O
composition	O
which	O
is	O
for	O
oral	O
administration	O
,	O
which	O
contains	O
(	O
2R	O
)	O
-2-propyloctanoic	O
acid	O
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
as	O
an	O
active	O
ingredient	O
,	O
is	O
administered	O
in	O
combination	O
with	O
a	O
levodopa	O
preparation	O
,	O
levodopa	O
/	O
benserazide	O
preparation	O
,	O
levodopa	O
/	O
carbidopa	O
preparation	O
,	O
and/or	O
bromocriptine	O
mesilate	O
in	O
the	O
manner	O
and	O
dose	O
shown	O
in	O
the	O
description	O
,	O
then	O
effects	O
unobtainable	O
with	O
conventional	O
treatments	O
can	O
be	O
produced	O
,	O
such	O
as	O
a	O
dose	O
reduction	O
,	O
alleviation	O
of	O
side	O
effects	O
,	O
and	O
therapeutic	O
-	O
effect	O
enhancement	O
.	O

(	O
(	O
1h	O
-	O
indazol-3-yl	O
)	O
methyl	O
)	O
phenols	O
and	O
(	O
hydroxyphenyl	O
)	O
(	O
1h	O
-	O
indazol-3-yl	O
)	O
methanones	O
as	O
ligands	O
of	O
the	O
estrogen	B
receptor	I
This	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
agents	O
of	O
formula	O
(	O
I	O
)	O
,	O
having	O
the	O
structure	O
:	O
formula	O
(	O
I	O
)	O
,	O
formula	O
(	O
II	O
)	O
,	O
wherein	O
A	O
and	O
R1-R10	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
N	O
-	O
oxide	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

Nitrogen	O
-	O
containing	O
fused	O
ring	O
compound	O
and	O
use	O
thereof	O
An	O
URAT1	B
activity	O
inhibitor	O
which	O
contains	O
a	O
nitrogen	O
-	O
containing	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
1	O
]	O
:	O
[	O
1	O
]	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O

This	O
URAT1	B
activity	O
inhibitor	O
is	O
useful	O
in	O
,	O
for	O
example	O
,	O
treating	O
pathological	O
conditions	O
in	O
which	O
uric	O
acid	O
participates	O
such	O
as	O
hyperuricemia	O
,	O
gouty	O
node	O
,	O
acute	O
gouty	O
arthritis	O
,	O
chronic	O
gouty	O
arthritis	O
,	O
gouty	O
kidney	O
,	O
urinary	O
calcus	O
,	O
renal	O
dysfunction	O
,	O
coronary	O
artery	O
disease	O
and	O
ischemic	O
heart	O
disease	O
.	O

Indole	O
derivatives	O
for	O
use	O
as	O
ppar	B
active	O
compounds	O
Compounds	O
are	O
described	O
that	O
are	O
active	O
on	O
at	O
least	O
one	O
of	O
PPARα	B
,	O
PPARδ	B
,	O
and	O
PPARϜ	B
,	O
which	O
are	O
useful	O
for	O
therapeutic	O
and/or	O
prophylactic	O
methods	O
involving	O
modulation	O
of	O
at	O
least	O
one	O
of	O
PPARα	B
,	O
PPARδ	B
,	O
and	O
PPARϜ.	B

Method	O
of	O
treating	O
dry	O
eye	O
disorders	O
using	O
13	O
(	O
s	O
)	O
-hode	O
and	O
its	O
analogs	O
The	O
topical	O
use	O
of	O
13	O
(	O
S	O
)	O
-HODE	O
and	O
analogs	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
disorders	O
.	O

Therapeutic	O
compositions	O
for	O
intranasal	O
administration	O
of	O
ketorolac	O
Therapeutic	O
compositions	O
,	O
particularly	O
sprayable	O
aqueous	O
compositions	O
,	O
comprise	O
ketorolac	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
in	O
combination	O
with	O
a	O
local	O
anesthetic	O
,	O
such	O
as	O
lidocaine	O
hydrochloride	O
.	O

The	O
compositions	O
are	O
nasally	O
administered	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
to	O
treat	O
pain	O
or	O
inflammation	O
and	O
have	O
the	O
benefit	O
of	O
reduced	O
stinging	O
and	O
improved	O
efficacy	O
,	O
compared	O
to	O
known	O
nasally	O
administered	O
compositions	O
.	O

A	O
tetracycline	O
metal	O
complex	O
in	O
a	O
solid	O
dosage	O
form	O
The	O
present	O
invention	O
is	O
a	O
solid	O
dosage	O
form	O
of	O
a	O
metal	O
complex	O
of	O
tetracycline	O
of	O
Formula	O
(	O
I	O
)	O
for	O
pharmaceutical	O
administration	O
,	O
(	O
I	O
)	O
wherein	O
R1	O
=	O
Cl	O
,	O
N	O
(	O
CH3	O
)	O
2	O
,	O
or	O
H	O
;	O
R2	O
=	O
CH3	O
,	O
H	O
,	O
or	O
CH2=	O
;	O
R3	O
=	O
CH3	O
,	O
H	O
,	O
OH	O
,	O
or	O
absent	O
;	O
and	O
R4	O
=	O
OH	O
or	O
H	O
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
CH3	O
and	O
R3	O
is	O
H	O
,	O
then	O
R4	O
is	O
not	O
OH	O
.	O

Bambuterol	O
and	O
integrin	B
inhibitor	O
combination	O
The	O
present	O
invention	O
provides	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
for	O
oral	O
administration	O
comprising	O
a	O
therapeutically	O
active	O
amount	O
of	O
bambuterol	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
N-	O
(	O
2-chloro-6-methylbenzoyl	O
)	O
-4-	O
[	O
(	O
2,6-dichlorobenzoyl	O
)	O
amino	O
]	O
-L	O
-	O
phenylalanine-2-	O
(	O
diethylamino	O
)	O
ethyl	O
ester	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

These	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
asthma	O
.	O

Human	O
monoclonal	O
antibody	O
specific	O
for	O
lipopolysaccharides	O
(	O
lps	O
)	O
of	O
the	O
pseudomonas	O
aeruginosa	O
iats	O
o11	O
serotype	O
The	O
present	O
invention	O
relates	O
to	O
a	O
human	O
monoclonal	O
antibody	O
specific	O
for	O
the	O
serotype	O
IATS	O
O11	O
of	O
P.	O
aeruginosa	O
,	O
a	O
hybridoma	O
producing	O
it	O
,	O
nucleic	O
acids	O
encoding	O
it	O
,	O
and	O
host	O
cells	O
transfected	O
therewith	O
.	O

Further	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
producing	O
said	O
monoclonal	O
antibody	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
antibody	O
or	O
at	O
least	O
one	O
nucleic	O
acid	O
encoding	O
said	O
antibody	O
.	O

Composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
It	O
is	O
intended	O
to	O
conveniently	O
and	O
efficiently	O
provide	O
a	O
specific	O
compound	O
originating	O
in	O
a	O
natural	O
material	O
and	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
characterized	O
by	O
containing	O
the	O
above	O
compound	O
as	O
the	O
active	O
ingredient	O
.	O

Namely	O
,	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
which	O
contains	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
,	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
and	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
5	O
)	O
or	O
a	O
salt	O
or	O
an	O
ester	O
of	O
the	O
same	O
.	O

4-hydroxy	O
pentanamides	O
,	O
the	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
provides	O
4-hydroxy	O
pentanamides	O
having	O
the	O
following	O
formula	O
(	O
1	O
)	O
,	O
preparation	O
and	O
use	O
thereof	O
.	O

The	O
said	O
compounds	O
show	O
effective	O
activity	O
of	O
inhibiting	O
BACE	O
and	O
preclude	O
the	O
formation	O
of	O
Aβ	O
.	O

Thus	O
the	O
said	O
compounds	O
are	O
useful	O
in	O
the	O
manufacture	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
's	O
Disease	O
.	O

Use	O
of	O
deuterated	O
n-	O
[	O
2-	O
(	O
5-methoxy-1h	O
-	O
indol-3-yl	O
)	O
-ethyl	O
]	O
acetamides	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
medicaments	O
containing	O
said	O
compounds	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
preventing	O
,	O
treating	O
,	O
or	O
controlling	O
a	O
disorder	O
,	O
disease	O
,	O
or	O
biological	O
function	O
that	O
is	O
related	O
to	O
a	O
relative	O
melatonin	O
deficiency	O
and/or	O
can	O
be	O
treated	O
or	O
influenced	O
by	O
administering	O
melatonin	O
provided	O
that	O
the	O
disease	O
or	O
disorder	O
is	O
not	O
a	O
disorder	O
in	O
the	O
framework	O
of	O
manic	O
depression	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
producing	O
a	O
medicament	O
.	O

Also	O
disclosed	O
is	O
a	O
medicament	O
containing	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

2-quinolone	O
compounds	O
as	O
inhibitors	O
of	O
phosphodiesterases	B
There	O
is	O
provided	O
according	O
to	O
the	O
invention	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
solvates	O
thereof	O
.	O

Novel	O
preventive	O
or	O
remedy	O
for	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
use	O
therefor	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
Focusing	O
on	O
the	O
multidrug	O
therapy	O
,	O
a	O
medicine	O
is	O
designed	O
by	O
using	O
a	O
novel	O
phenylpropionic	O
acid	O
derivative	O
serving	O
as	O
a	O
PPARα	B
activator	O
(	O
for	O
example	O
,	O
(	O
S	O
)	O
-2-ethyl-3-	O
[	O
4-methoxy-3-	O
[	O
N-	O
[	O
[	O
4-	O
(	O
4-fluorophenoxy	O
)	O
phenyl	O
]	O
methyl	O
]	O
carbamoyl	O
]	O
phenyl	O
]	O
propionic	O
acid	O
(	O
KRP-101	O
)	O
)	O
together	O
with	O
a	O
statin	O
drug	O
serving	O
as	O
an	O
antihyperlipidemic	O
or	O
blending	O
them	O
to	O
synergistically	O
or	O
additionally	O
enhance	O
the	O
lipid	O
-	O
lowering	O
effect	O
,	O
thereby	O
providing	O
a	O
novel	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

Substituted	O
oxindol	O
derivatives	O
,	O
drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
novel	O
oxindol	O
derivative	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
substituents	O
R1	O
,	O
R2	O
,	O
A	O
,	O
B	O
and	O
Y	O
are	O
such	O
as	O
defined	O
in	O
a	O
claim	O
1	O
.	O

Drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
vassopress	O
-	O
and	O
/	O
or	O
oxytocin	O
-	O
dependent	O
-	O
diseases	O
are	O
also	O
disclosed	O
.	O

Antineoplastic	O
preparation	O
The	O
inventive	O
antineoplastic	O
preparation	O
is	O
based	O
on	O
a	O
gluconic	O
acid	O
and	O
exhibits	O
an	O
apoptotic	O
and	O
anti	O
-	O
proliferative	O
effect	O
preserving	O
healthy	O
cells	O
.	O

In	O
the	O
first	O
variant	O
,	O
said	O
preparation	O
is	O
embodied	O
in	O
the	O
form	O
of	O
at	O
least	O
one	O
type	O
of	O
gluconate	O
,	O
wherein	O
a	O
salt	O
-	O
forming	O
agent	O
is	O
selected	O
from	O
a	O
group	O
comprising	O
magnesium	O
,	O
sodium	O
,	O
potassium	O
,	O
η	O
-	O
aminobutyric	O
acid	O
,	O
ethylenediamine	O
or	O
the	O
mixture	O
thereof	O
.	O

In	O
the	O
second	O
variant	O
,	O
the	O
perpetration	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
co	O
-	O
ordination	O
compound	O
which	O
is	O
based	O
on	O
a	O
magnesium	O
gluconate	O
in	O
which	O
ligands	O
are	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
η	O
-	O
aminobutyric	O
acid	O
,	O
3-hydroxy	O
-	O
η	O
-	O
aminobutyric	O
acid	O
,	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
and	O
an	O
ethylene	O
glycol	O
tetraacetic	O
acid	O
.	O

In	O
the	O
third	O
variant	O
,	O
the	O
composition	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
binary	O
salt	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
magnesium	O
butyrate	O
-	O
gluconate	O
,	O
magnesium	O
oxybutyrate	O
-	O
gluconate	O
,	O
magnesium	O
glucarate	O
-	O
gluconate	O
,	O
calcium	O
butyrate	O
-	O
gluconate	O
,	O
butyrate	O
-	O
gluconate	O
oxybutyrate	O
-	O
gluconate	O
,	O
calcium	O
glucarate	O
-	O
gluconate	O
and	O
the	O
combination	O
thereof	O
.	O

Perkinson	O
disease	O
-	O
related	O
gene	O
grk5	B
and	O
use	O
thereof	O
As	O
a	O
result	O
of	O
a	O
large	O
scale	O
SNP	O
analysis	O
on	O
a	O
group	O
of	O
Perkinson	O
disease	O
patients	O
and	O
a	O
control	O
group	O
of	O
normal	O
persons	O
,	O
it	O
has	O
succeeded	O
in	O
the	O
identification	O
of	O
a	O
gene	O
involved	O
in	O
Perkinson	O
disease	O
(	O
GRK5	B
)	O
.	O

It	O
is	O
now	O
found	O
that	O
the	O
increase	O
in	O
the	O
expression	O
of	O
the	O
GRK5	B
gene	O
induces	O
the	O
enhancement	O
of	O
the	O
phosphorylation	O
of	O
α	B
-	I
synuclein	I
,	O
which	O
in	O
turn	O
induces	O
the	O
enhancement	O
of	O
the	O
formation	O
of	O
a	O
soluble	O
α	B
-	I
synuclein	I
oligomer	O
,	O
leading	O
to	O
the	O
development	O
of	O
Perkinson	O
disease	O
.	O

It	O
becomes	O
possible	O
to	O
diagnose	O
Perkinson	O
disease	O
and	O
screen	O
a	O
therapeutic	O
agent	O
for	O
Perkinson	O
disease	O
by	O
using	O
the	O
expression	O
of	O
the	O
GRK5	B
gene	O
.	O

Pharmaceutical	O
compositions	O
of	O
antiretrovirals	O
The	O
present	O
invention	O
relates	O
to	O
the	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
combination	O
of	O
antiretroviral	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
Lamivudine	O
,	O
Zidovudine	O
and	O
Nevirapine	O
,	O
prepared	O
by	O
granulation	O
technology	O
.	O

Heterocyclic	O
n	O
-	O
oxides	O
as	O
hypoxic	O
selective	O
protein	B
kinase	I
inhibitors	O
The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
N	O
-	O
oxides	O
which	O
are	O
useful	O
as	O
hypoxic	O
selective	O
cytotoxic	O
agents	O
that	O
mediate	O
and/or	O
inhibit	O
cell	O
proliferation	O
,	O
for	O
example	O
,	O
through	O
the	O
activity	O
of	O
protein	B
kinases	I
.	O

The	O
invention	O
is	O
further	O
related	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
compositions	O
,	O
and	O
to	O
methods	O
of	O
treating	O
cancer	O
as	O
well	O
as	O
other	O
disease	O
states	O
associated	O
with	O
unwanted	O
ahgiogenesis	O
and/or	O
cellular	O
proliferation	O
by	O
administering	O
effective	O
amounts	O
of	O
such	O
compounds	O
.	O

Method	O
for	O
treatment	O
of	O
uterine	O
fibroid	O
tumors	O
Various	O
injectable	O
or	O
insertable	O
uterine	O
fibroid	O
treatment	O
formulations	O
are	O
provided	O
,	O
which	O
comprise	O
a	O
uterine	O
fibroid	O
treatment	O
agent	O
in	O
an	O
amount	O
effective	O
to	O
cause	O
shrinkage	O
or	O
elimination	O
of	O
uterine	O
fibroids	O
.	O

The	O
injectable	O
or	O
insertable	O
formulations	O
are	O
typically	O
solids	O
,	O
semi	O
-	O
solids	O
or	O
high	O
-	O
viscosity	O
fluids	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
are	O
directed	O
to	O
systems	O
and	O
methods	O
for	O
treatment	O
of	O
uterine	O
fibroids	O
.	O

Substituted	O
benzo	O
(	O
d	O
)	O
isoxazol-3-yl	O
amine	O
compounds	O
as	O
analgesics	O
Disclosed	O
are	O
substituted	O
benzo	O
[	O
d	O
]	O
isoxazol-3-yl	O
amine	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
pain	O
while	O
being	O
provided	O
with	O
an	O
excellent	O
affinity	O
to	O
the	O
KCNQ2	B
/	I
3	I
K+	I
channel	I
and	O
thus	O
being	O
suitable	O
for	O
the	O
treatment	O
of	O
disorders	O
or	O
diseases	O
that	O
are	O
transmitted	O
at	O
least	O
in	O
part	O
through	O
KCNQ2	B
/	I
3	I
K+	I
channels	I
.	O

Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
their	O
use	O
in	O
treating	O
metabolic	O
disorders	O
The	O
present	O
invention	O
provides	O
compounds	O
useful	O
,	O
for	O
example	O
,	O
for	O
modulating	O
insulin	B
levels	O
in	O
a	O
subject	O
,	O
having	O
the	O
general	O
formula	O
I	O
:	O
wherein	O
Q	O
is	O
an	O
optionally	O
substituted	O
phenyl	O
;	O
L	O
is	O
a	O
bond	O
or	O
O	O
;	O
P	O
is	O
a	O
benzene	O
or	O
an	O
optionally	O
substituted	O
thiazole	O
ring	O
;	O
and	O
R1	O
has	O
the	O
values	O
provided	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
compositions	O
,	O
uses	O
,	O
and	O
methods	O
for	O
use	O
of	O
the	O
compounds	O
,	O
for	O
instance	O
,	O
for	O
treatment	O
of	O
type	O
II	O
diabetes	O
.	O

Combinations	O
of	O
erbb2	B
inhibitors	O
with	O
other	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O
This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
cancer	O
with	O
a	O
combination	O
of	O
an	O
additional	O
therapeutic	O
agent	O
in	O
mammals	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
useful	O
in	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
in	O
mammals	O
,	O
especially	O
humans	O
.	O

Sulindac	O
derivatives	O
for	O
treatment	O
of	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
compounds	O
(	O
NSAIDs	O
)	O
derivatives	O
of	O
sulindac	O
,	O
for	O
the	O
treatment	O
/	O
prevention	O
,	O
alone	O
or	O
in	O
combination	O
,	O
of	O
cancer	O
.	O

Heterocyclic	O
containing	O
amines	O
as	O
kinase	O
b	O
inhibitors	O
The	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
,	O
tautomer	O
or	O
N	O
-	O
oxide	O
thereof	O
;	O
for	O
use	O
as	O
a	O
PKB	O
kinase	O
inhibitor	O
or	O
PKA	O
kinase	O
inhibitor	O
.	O

In	O
formula	O
(	O
I	O
)	O
,	O
A	O
is	O
a	O
saturated	O
hydrocarbon	O
linker	O
group	O
;	O
E	O
is	O
a	O
monocyclic	O
or	O
bicyclic	O
carbocyclic	O
or	O
heterocyclic	O
group	O
;	O
HET	O
is	O
a	O
monocyclic	O
heterocyclic	O
group	O
;	O
R1	O
is	O
an	O
aryl	O
or	O
heteroaryl	O
group	O
;	O
n	O
is	O
0	O
to	O
4	O
;	O
and	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
provided	O
that	O
HET	O
is	O
other	O
than	O
an	O
unsubstituted	O
or	O
substituted	O
pyrazole-4-yl	O
group	O
.	O

Fluorescent	O
sulfonamide	O
derivatives	O
having	O
carbonic	B
anhydrase	I
inhibiting	O
activity	O
and	O
their	O
use	O
as	O
theapeutic	O
and	O
diagnostic	O
agents	O
The	O
present	O
invention	O
discloses	O
sulfonamide	O
CA	B
IX	I
-	O
selective	O
inhibitors	O
,	O
which	O
selectively	O
bind	O
to	O
the	O
enzyme	O
under	O
hypoxic	O
conditions	O
and	O
are	O
able	O
to	O
reverse	O
the	O
tumor	O
acidification	O
mediated	O
by	O
the	O
enzyme	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
anticancer	O
therapies	O
based	O
on	O
tumor	O
-	O
associated	O
CA	B
isozyme	I
inhibition	O
as	O
well	O
as	O
for	O
hypoxic	O
tumor	O
imaging	O
.	O

The	O
inhibitors	O
contain	O
a	O
fluorescent	O
moiety	O
,	O
preferably	O
fluorescein	O
.	O

Tablet	O
containing	O
poorly	O
soluble	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
tablet	O
containing	O
about	O
3	O
-	O
50	O
%	O
by	O
weight	O
(	O
w	O
/	O
w	O
)	O
of	O
a	O
poorly	O
soluble	O
active	O
ingredient	O
relative	O
to	O
the	O
total	O
tablet	O
weight	O
,	O
magnesium	O
stearate	O
and	O
a	O
hydroxypropylcellulose	O
having	O
a	O
viscosity	O
of	O
about	O
1	O
-	O
4	O
mPa·s	O
.	O

This	O
tablet	O
is	O
suppressed	O
in	O
dissolution	O
variation	O
between	O
lots	O
.	O

Pharmaceutical	O
compositions	O
containing	O
clopidogrel	O
bisulfate	O
Provided	O
is	O
a	O
pharmaceutical	O
composition	O
including	O
clopidogrel	O
bisulfate	O
and	O
a	O
pregelatinized	O
starch	O
.	O

The	O
pharmaceutical	O
composition	O
in	O
which	O
the	O
stability	O
of	O
clopido	O
grel	O
bisulfate	O
is	O
significantly	O
enhanced	O
can	O
be	O
obtained	O
by	O
mixing	O
clopidogrel	O
bisulfate	O
w	O
ith	O
the	O
pregelatinized	O
starch	O
.	O

Compounds	O
and	O
their	O
salts	O
specific	O
to	O
the	O
ppar	B
receptors	O
and	O
the	O
egf	B
receptors	I
and	O
their	O
use	O
in	O
the	O
medical	O
field	O
Therefore	O
the	O
present	O
invention	O
relates	O
specifically	O
to	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
and	O
R2	O
,	O
which	O
may	O
be	O
identical	O
or	O
different	O
,	O
are	O
selected	O
from	O
the	O
group	O
comprising	O
H	O
,	O
-CnH2n-1	O
,	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
,	O
or	O
together	O
form	O
an	O
aromatic	O
or	O
aliphatic	O
ring	O
with	O
5	O
or	O
6	O
atoms	O
;	O
R3	O
is	O
selected	O
from	O
-CO	O
-	O
CH3	O
,	O
-NHOH	O
,	O
-OH	O
,	O
-OR6	O
in	O
which	O
R6	O
is	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
;	O
R4	O
is	O
selected	O
from	O
H	O
,	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
,	O
phenyl	O
,	O
benzyl	O
,	O
-CF3	O
or	O
-CF2CF3	O
,	O
vinyl	O
or	O
allyl	O
;	O
R5	O
,	O
R7	O
,	O
R8	O
are	O
hydrogen	O
atoms	O
;	O
or	O
R3	O
and	O
R4	O
,	O
R4	O
and	O
R5	O
,	O
or	O
R7	O
and	O
R8	O
together	O
form	O
a	O
ring	O
,	O
fused	O
to	O
the	O
benzene	O
,	O
aromatic	O
or	O
aliphatic	O
ring	O
with	O
5	O
or	O
6	O
atoms	O
comprising	O
from	O
1	O
to	O
2	O
heteroatoms	O
selected	O
independently	O
from	O
the	O
group	O
comprising	O
N	O
,	O
O.	O
and	O
use	O
thereof	O
in	O
the	O
medical	O
field	O
.	O

Simon	O
potato	O
extract	O
,	O
glycosphingolipid	O
derived	O
from	O
simon	O
potato	O
,	O
and	O
process	O
for	O
production	O
of	O
the	O
extract	O
or	O
glycosphingolipid	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
process	O
for	O
producing	O
a	O
glycolipid	O
-	O
containing	O
Simon	O
potato	O
extract	O
or	O
a	O
glycosphingolipid	O
from	O
a	O
Simon	O
potato	O
for	O
the	O
purpose	O
of	O
providing	O
an	O
alternative	O
to	O
a	O
livestock	O
brain	O
ganglioside	O
which	O
is	O
free	O
from	O
the	O
risk	O
of	O
BSE	O
or	O
the	O
like	O
,	O
is	O
safe	O
to	O
a	O
human	O
body	O
and	O
can	O
be	O
ingested	O
on	O
a	O
daily	O
basis	O
,	O
and	O
to	O
provide	O
a	O
nerve	O
cell	O
activator	O
comprising	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
derived	O
from	O
a	O
Simon	O
potato	O
and	O
a	O
health	O
food	O
prepared	O
by	O
using	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O

A	O
Simon	O
potato	O
extract	O
can	O
be	O
produced	O
by	O
immersing	O
a	O
Simon	O
potato	O
in	O
a	O
polar	O
solvent	O
to	O
extract	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
into	O
the	O
polar	O
solvent	O
and	O
then	O
concentrating	O
the	O
resulting	O
immersion	O
fluid	O
.	O

The	O
nerve	O
cell	O
activation	O
effect	O
of	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
is	O
confirmed	O
using	O
an	O
established	O
neuroblast	O
.	O

Hepatitis	B
c	I
serine	I
protease	I
inhibitors	O
and	O
uses	O
therefor	O
The	O
present	O
invention	O
provides	O
novel	O
compounds	O
which	O
mimic	O
peptides	O
with	O
a	O
C	O
-	O
terminal	O
penultimate	O
proline	O
,	O
such	O
compounds	O
being	O
useful	O
as	O
protease	B
inhibitors	O
,	O
particularly	O
as	O
inhibitors	O
of	O
serine	B
proteases	I
,	O
and	O
more	O
particularly	O
as	O
inhibitors	O
of	O
the	O
NS3	B
serine	I
protease	I
from	O
hepatitis	O
C.	O
The	O
compounds	O
find	O
utility	O
as	O
antiviral	O
agents	O
directed	O
at	O
hepatitis	O
C.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
employing	O
such	O
inhibitors	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
to	O
treat	O
hepatitis	O
C	O
infection	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Vaginal	O
treatment	O
composition	O
A	O
vaginal	O
treatment	O
composition	O
that	O
rapidly	O
forms	O
a	O
gel	O
when	O
placed	O
into	O
contact	O
with	O
monovalent	O
or	O
polyvalent	O
cations	O
,	O
such	O
as	O
sodium	O
(	O
Na+	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
cations	O
naturally	O
found	O
in	O
vaginal	O
mucosa	O
,	O
is	O
provided	O
.	O

The	O
gel	O
may	O
form	O
in	O
less	O
than	O
about	O
1	O
hour	O
,	O
in	O
some	O
embodiments	O
less	O
than	O
about	O
1	O
minute	O
,	O
and	O
in	O
some	O
embodiments	O
,	O
less	O
than	O
about	O
30	O
seconds	O
.	O

Among	O
other	O
things	O
,	O
such	O
rapid	O
gelation	O
reduces	O
the	O
likelihood	O
of	O
leakage	O
during	O
use	O
.	O

In	O
addition	O
,	O
because	O
the	O
gel	O
may	O
form	O
intravaginally	O
,	O
it	O
is	O
more	O
likely	O
to	O
retain	O
its	O
structure	O
and	O
shape	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O

In	O
this	O
manner	O
,	O
the	O
gel	O
may	O
provide	O
the	O
prolonged	O
release	O
of	O
a	O
therapeutic	O
agent	O
that	O
inhibits	O
and/or	O
treats	O
vaginal	O
infection	O
.	O

For	O
instance	O
,	O
the	O
gel	O
may	O
remain	O
within	O
the	O
vagina	O
for	O
about	O
2	O
to	O
about	O
48	O
hours	O
to	O
provide	O
the	O
desired	O
effect	O
.	O

Chromane	O
substituted	O
2-alkyl	O
imidazopyridine	O
derivatives	O
and	O
use	O
thereof	O
as	O
acid	O
pump	O
antagonists	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
each	O
as	O
described	O
herein	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
method	O
and	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
acid	O
pump	O
antagonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
as	O
gastrointestinal	O
disease	O
,	O
gastroesophageal	O
disease	O
,	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
,	O
peptic	O
ulcer	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
NSAID	O
-	O
induced	O
ulcers	O
,	O
gastritis	O
,	O
infection	O
of	O
Helicobacter	O
pylori	O
,	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
Zollinger	O
-	O
Ellison	O
syndrome	O
,	O
non	O
-	O
erosive	O
reflux	O
disease	O
(	O
NERD	O
)	O
,	O
visceral	O
pain	O
,	O
heartburn	O
,	O
nausea	O
,	O
esophagitis	O
,	O
dysphagia	O
,	O
hypersalivation	O
,	O
airway	O
disorders	O
or	O
asthma	O
.	O

Sunscreen	O
and	O
cosmetic	O
compositions	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
skin	O
cancers	O
There	O
are	O
provided	O
sunscreen	O
and	O
cosmetics	O
compositions	O
containing	O
non	O
-	O
steroidal	O
anti-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
in	O
the	O
form	O
of	O
metal	O
complexes	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
cancers	O
of	O
the	O
skin	O
.	O

The	O
ligand	O
(	O
s	O
)	O
of	O
the	O
complex	O
typically	O
independently	O
comprise	O
a	O
carboxylate	O
,	O
or	O
a	O
derivative	O
of	O
a	O
carboxylate	O
,	O
having	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Carboxylate	O
derivatives	O
having	O
anti	O
-	O
inflammatory	O
activity	O
that	O
may	O
be	O
used	O
include	O
hydroxamates	O
,	O
hydroximates	O
,	O
amides	O
and	O
esters	O
.	O

Copper	O
and	O
zinc	O
metal	O
complexes	O
including	O
the	O
NSAIDs	O
indomethacin	O
and	O
acematacin	O
are	O
particularly	O
preferred	O
.	O

7-	O
[	O
2-	O
[	O
4-	O
(	O
6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL	O
)	O
-1-PIPERAZINYL	O
]	O
ETHYL	O
]	O
-2-	O
(	O
1-PROPYNYL	O
)	O
-7H	O
-	O
PYRAZOLO-	O
[	O
4,3-e	O
]	O
-	O
[	O
1,2,4	O
]	O
-TRIAZOLO-	O
[	O
1,5-c	O
]	O
-PYRIMIDIN-5	O

AMINE	O
The	O
compound	O
having	O
the	O
structural	O
formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
its	O
use	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
,	O
in	O
particular	O
Parkinson	O
's	O
disease	O
,	O
Extra	O
Pyramidal	O
Syndrome	O
,	O
restless	O
legs	O
syndrome	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
pharmaceutical	O
compositions	O
comprising	O
it	O
,	O
and	O
combinations	O
with	O
other	O
agents	O
.	O

Thienopyridine-2-carboxamide	O
derivative	O
Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-C6	O
alkyl	O
group	O
,	O
and	O
R2	O
represents	O
a	O
substituted	O
cyclic	O
amino	O
.	O
)	O

PYRIDOPYRIMIDINONE	O
INHIBITORS	O
OF	O
PI3Kα	B
The	O
invention	O
is	O
directed	O
to	O
Compounds	O
of	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

The	O
oral	O
agent	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
comprising	O
hyaluronic	O
acid	O
-	O
phospholipid	O
complexes	O
An	O
oral	O
formulation	O
compring	O
hyaluronid	O
acid-	O
phospholipid	O
complexes	O
as	O
active	O
ingredient	O
and	O
the	O
application	O
of	O
hyaluronic	O
acid-	O
phosphlipid	O
complexes	O
in	O
preparation	O
of	O
the	O
product	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
.	O

Pqs	O
and	O
its	O
conjugates	O
as	O
adjuvants	O
and	O
their	O
uses	O
in	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
adjuvants	O
and	O
the	O
uses	O
in	O
pharmaceutical	O
compositions	O
,	O
like	O
in	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
new	O
compounds	O
useful	O
as	O
adjuvants	O
and/or	O
immunomodulators	O
for	O
prophylactic	O
and/or	O
therapeutic	O
vaccination	O
in	O
the	O
treatment	O
of	O
infectious	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
tumours	O
,	O
allergies	O
as	O
well	O
as	O
for	O
the	O
control	O
of	O
fertility	O
in	O
human	O
or	O
animal	O
populations	O
.	O

The	O
compounds	O
are	O
particularly	O
useful	O
not	O
only	O
as	O
systemic	O
,	O
but	O
preferably	O
as	O
mucosal	O
adjuvants	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
its	O
uses	O
as	O
active	O
ingredients	O
in	O
pharmaceutical	O
compositions	O
.	O

Macrolones	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
having	O
antimicrobial	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

N4-phenyl	O
-	O
quinaz0line-4	O
-amine	O
derivatives	O
and	O
related	O
compounds	O
as	O
erbb	B
type	I
i	I
receptor	I
tyrosine	I
kinase	I
inhibitors	O
for	O
the	O
treatment	O
of	O
hyperproliferative	O
diseases	O
This	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
B	O
,	O
G	O
,	O
A	O
,	O
E	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
are	O
useful	O
as	O
type	B
I	I
receptor	I
tyrosine	I
kinase	I
inhibitors	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
in	O
mammals	O
.	O

Novel	O
proline	O
-	O
derivative	O
based	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
necessities	O
of	O
life	O
,	O
and	O
more	O
particularly	O
to	O
the	O
field	O
of	O
cosmetology	O
and	O
dermatology	O
.	O

It	O
relates	O
more	O
particularly	O
to	O
novel	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
which	O
bring	O
about	O
a	O
very	O
significant	O
increase	O
in	O
the	O
deposition	O
of	O
collagen	B
type	I
(	I
III	I
)	I
in	O
the	O
extracellular	O
matrix	O
,	O
characterized	O
in	O
that	O
they	O
contain	O
,	O
as	O
active	O
ingredient	O
,	O
a	O
combination	O
of	O
a	O
4-hydroxyproline	O
fatty	O
acid	O
amido	O
ester	O
,	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1	O
and	O
R'1	O
are	O
identical	O
or	O
different	O
aliphatic	O
chains	O
containing	O
from	O
10	O
to	O
24	O
carbon	O
atoms	O
that	O
are	O
in	O
a	O
straight	O
line	O
or	O
branched	O
,	O
and	O
of	O
an	O
extract	O
of	O
the	O
epicarp	O
of	O
the	O
Opuntia	O
ficus	O
-	O
indica	O
(	O
Barbary	O
fig	O
)	O
fruit	O
in	O
an	O
inert	O
,	O
nontoxic	O
excipient	O
or	O
carrier	O
suitable	O
for	O
topical	O
use	O
.	O

Use	O
in	O
the	O
form	O
of	O
a	O
fatty	O
cream	O
or	O
gel	O
for	O
the	O
increased	O
production	O
of	O
collagen	B
,	O
without	O
amplifying	O
that	O
of	O
procollagen	B
(	I
III	I
)	I
or	O
of	O
enzymes	O
of	O
the	O
metalloproteinase	B
family	O
.	O

A	O
g	B
protein	I
-	I
coupled	I
receptor	I
antagonist	O
and	O
its	O
use	O
for	O
preventing	O
and	O
treating	O
alzheimer	O
's	O
disease	O
A	O
method	O
of	O
screening	O
reagents	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
:	O
(	O
a	O
)	O
stimulating	O
a	O
receptor	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
,	O
wherein	O
the	O
receptor	O
is	O
a	O
G	B
protein	I
-	I
coupled	I
receptor	I
combining	O
with	O
PS1	B
;	O
(	O
b	O
)	O
stimulating	O
the	O
receptor	O
as	O
step	O
(	O
a	O
)	O
in	O
the	O
presence	O
of	O
a	O
reagent	O
,	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
again	O
;	O
(	O
c	O
)	O
comparing	O
the	O
difference	O
between	O
the	O
internalizing	O
degrees	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
;	O
(	O
d	O
)	O
repeating	O
steps	O
(	O
a	O
)	O
-	O
(	O
c	O
)	O
if	O
the	O
difference	O
is	O
less	O
than	O
the	O
least	O
value	O
.	O

And	O
use	O
of	O
the	O
receptor	O
antagonist	O
for	O
preparing	O
a	O
drug	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
receptor	O
antagonist	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
internalization	O
of	O
the	O
G	B
protein	I
-	I
coupled	I
receptor	I
combing	O
with	O
PS1	B
.	O

Mutilin	O
derivatives	O
and	O
their	O
use	O
as	O
pharmaceutical	O
14	O
-	O
0-	O
[	O
(	O
(	O
(	O
C1.6	O
)	O
Alkoxy-	O
(	O
C1.6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
(	O
C1	O
-	O
6	O
)	O
Mono-	O
or	O
dialkylamino-	O
(	O
C1.6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Hydroxy-	O
(	O
C1	O
-	O
6	O
)	O
-alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Formyl-	O
(	O
C0.5	O
)	O
-alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Guanidino	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Ureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alky	O
)	O
-phenylsulfany	O
]	O
-acety	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Thioureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
lsothioureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Sulfonamide	O
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
sulphonamide	O
derivatives	O
corresponding	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
Ar1	O
represents	O
an	O
aryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	O
group	O
;	O
T	O
represents	O
a	O
-	O
(	O
CH2	O
)	O
n-	O
or	O
a	O
group	O
(	O
II	O
)	O
,	O
Ar2	O
represents	O
an	O
aryl	O
as	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	O
group	O
;	O
Ar3	O
represents	O
an	O
aryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
else	O
an	O
optionally	O
substituted	O
heterocyclyl	O
,	O
R1	O
represents	O
a	O
group	O
of	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
(	O
B	O
)	O
in	O
the	O
form	O
of	O
a	O
base	O
,	O
an	O
addition	O
salt	O
with	O
an	O
acid	O
,	O
a	O
hydrate	O
or	O
a	O
solvate	O
,	O
in	O
the	O
form	O
of	O
enantiomers	O
,	O
diastereoisomers	O
,	O
rotamers	O
or	O
atropoisomers	O
,	O
or	O
mixtures	O
thereof	O
.	O

It	O
also	O
relates	O
to	O
the	O
process	O
for	O
the	O
preparation	O
and	O
also	O
the	O
therapeutic	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Topical	O
preparation	O
composition	O
containing	O
a	O
thiourea	O
derivative	O
for	O
preventing	O
or	O
treating	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
topical	O
composition	O
comprising	O
a	O
thiourea	O
derivative	O
,	O
which	O
is	O
a	O
vanilloid	O
receptor	O
antagonist	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
pharmaceutical	O
use	O
of	O
the	O
same	O
.	O

The	O
topical	O
composition	O
according	O
to	O
the	O
present	O
invention	O
is	O
excellent	O
in	O
skin	O
permeation	O
and	O
stability	O
and	O
effective	O
in	O
treatment	O
of	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O
.	O

Compositions	O
and	O
methods	O
for	O
effecting	O
controlled	O
posterior	O
vitreous	O
detachment	O
A	O
composition	O
comprises	O
plasmin	O
or	O
an	O
enzymatically	O
equivalent	O
derivative	O
thereof	O
and	O
at	O
least	O
an	O
anti	O
-	O
inflammatory	O
medicament	O
,	O
such	O
as	O
triamcinolone	O
acetonide	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
effect	O
or	O
induce	O
a	O
controlled	O
posterior	O
vitreous	O
detachment	O
(	O
'	O
PVD	O
'	O
)	O
to	O
prevent	O
,	O
treat	O
,	O
or	O
ameliorate	O
a	O
potential	O
complication	O
of	O
a	O
pathological	O
ocular	O
condition	O
.	O

Such	O
a	O
composition	O
can	O
be	O
administered	O
intravitreally	O
.	O

Hair	O
grower	O
The	O
invention	O
provides	O
a	O
hair	O
grower	O
having	O
a	O
hair	O
-	O
glowing	O
effect	O
and	O
useful	O
application	O
forms	O
of	O
the	O
hair	O
grower	O
.	O

The	O
invention	O
relates	O
to	O
a	O
hair	O
grower	O
containing	O
as	O
the	O
active	O
ingredient	O
a	O
lithospermic	O
acid	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
;	O
and	O
oral	O
preparations	O
,	O
external	O
preparations	O
,	O
and	O
foods	O
,	O
containing	O
the	O
hair	O
grower	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
are	O
each	O
hydrogen	O
or	O
optionally	O
substituted	O
C1	O
-	O
4	O
alkyl	O
;	O
and	O
R3	O
is	O
hydrogen	O
,	O
optionally	O
substituted	O
C1	O
-	O
4	O
alkyl	O
,	O
or	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
(	O
II	O
)	O
.	O

Diphenylurea	O
derivatives	O
and	O
their	O
use	O
as	O
chloride	B
channel	I
blockers	O
or	O
bkca	B
channel	I
modulators	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
diphenylurea	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
chloride	O
channel	O
blockers	O
or	O
BKCa	B
channel	I
modulators	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Thiazolyldihydroindazoles	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
thiazolyldihydroindazoles	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
where	O
the	O
R1	O
,	O
R2	O
and	O
R3	O
radicals	O
are	O
each	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
description	O
,	O
to	O
their	O
tautomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
and	O
mixtures	O
thereof	O
,	O
and	O
where	O
appropriate	O
to	O
their	O
pharmacologically	O
safe	O
acid	O
addition	O
salts	O
,	O
solvates	O
and	O
hydrates	O
,	O
and	O
to	O
processes	O
for	O
preparing	O
these	O
thiazolyldihydroindazoles	O
and	O
to	O
their	O
use	O
as	O
medicaments	O
.	O

Heterocyclic	O
gaba	B
alpha	I
subtype	I
selective	I
receptor	I
modulators	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
or	O
prodrugs	O
thereof	O
,	O
wherein	O
Y	O
,	O
Ar	O
,	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
their	O
use	O
and	O
methods	O
of	O
preparing	O
the	O
compounds	O
.	O

1,4:3,6-dianhydromannitol	O
derivatives	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
,	O
amongst	O
other	O
things	O
,	O
to	O
the	O
use	O
of	O
1,4:3,6-dianhydromannitol	O
derivatives	O
of	O
formulae	O
(	O
Ia	O
)	O
-	O
(	O
I	O
d	O
)	O
as	O
therapeutic	O
agents	O
.	O

3-tetrazolyl	O
indazoles	O
,	O
3-tetrazolyl	O
pyrazolopyridines	O
,	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
novel	O
3-tetrazolyl	O
indazole	O
derivatives	O
and	O
3-tetrazolyl	O
pyrazolo	O
[	O
3,4-b	O
]	O
-pyridine	O
derivatives	O
,	O
methods	O
for	O
producing	O
the	O
same	O
,	O
the	O
exclusive	O
or	O
combined	O
use	O
thereof	O
for	O
treating	O
and/or	O
preventing	O
diseases	O
,	O
and	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
utilized	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
,	O
particularly	O
cardiovascular	O
diseases	O
.	O

Isatin	O
and	O
its	O
derivatives	O
for	O
use	O
as	O
a	O
medicament	O
The	O
present	O
invention	O
relates	O
to	O
2,3-dioxoindole	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
for	O
use	O
as	O
a	O
medicament	O
,	O
and	O
particularly	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
;	O
R1	O
is	O
hydrogen	O
,	O
or	O
(	O
C1-C10	O
)	O
linear	O
or	O
branched	O
alkyl	O
or	O
hydroxyalkyl	O
group	O
or	O
acyl	O
group	O
containing	O
(	O
C1-C10	O
)	O
linear	O
or	O
branched	O
alkyl	O
group	O
,	O
R2-R5	O
are	O
independently	O
hydrogen	O
,	O
halogen	O
,	O
amino	O
group	O
,	O
nitro	O
group	O
,	O
optionally	O
halogen	O
substituted	O
(	O
C1-C10	O
)	O
alkyl	O
group	O
,	O
(	O
C1-C10	O
)	O
alkoxy	O
group	O
or	O
hydroxyl	O
group	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
a	O
medicament	O
incorporating	O
a	O
pharmacologically	O
effective	O
dose	O
of	O
the	O
above	O
described	O
active	O
ingredient	O
is	O
administered	O
to	O
patients	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Antiperiodontitis	O
agents	O
,	O
and	O
drinks	O
,	O
foods	O
or	O
oral	O
hygiene	O
products	O
containing	O
the	O
agents	O
The	O
invention	O
provides	O
antiperiodontitis	O
agents	O
which	O
originate	O
in	O
plant	O
components	O
free	O
from	O
the	O
anxiety	O
about	O
safety	O
and	O
have	O
no	O
peculiar	O
spice	O
-	O
like	O
aroma	O
or	O
taste	O
and	O
which	O
have	O
high	O
antibacterial	O
effects	O
on	O
bacteria	O
causative	O
of	O
periodontal	O
diseases	O
and	O
can	O
prevent	O
or	O
cure	O
periodontal	O
diseases	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
.	O

Antiperiodontitis	O
agents	O
,	O
characterized	O
by	O
containing	O
one	O
or	O
more	O
isothiocyanate	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ω	O
-	O
alkenyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
1	O
]	O
,	O
ω	O
-	O
alkylthioalkyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
2	O
]	O
,	O
and	O
ω	O
-	O
phenylalkyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
3	O
]	O
and	O
mint	O
essential	O
oil	O
or	O
a	O
mint	O
essential	O
oil	O
component	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
:	O
General	O
formula	O
[	O
1	O
]	O
:	O
CH2	O
=	O
CH-	O
(	O
CH2	O
)	O
m	O
-	O
NCS	O
(	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
General	O
formula	O
[	O
2	O
]	O
:	O
R	O
-	O
S-	O
(	O
CH2	O
)	O
n	O
-	O
NCS	O
(	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
and	O
R	O
is	O
straight-	O
or	O
branched	O
-	O
chain	O
alkyl	O
of	O
1	O
to	O
4	O
carbon	O
atoms	O
)	O
,	O
and	O
General	O
formula	O
[	O
3	O
]	O
:	O
Ph-	O
(	O
CH2	O
)	O
p	O
-	O
NCS	O
(	O
wherein	O
Ph	O
is	O
phenyl	O
and	O
p	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
.	O

Compounds	O
for	O
use	O
as	O
a	O
medicament	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
for	O
use	O
as	O
a	O
medicament	O
.	O

A	O
pharmaceutical	O
composition	O
the	O
compound	O
.	O

Use	O
of	O
the	O
compound	O
for	O
preparing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
selected	O
from	O
hyperproliferative	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
heart	O
diseases	O
.	O

Methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activation	O
of	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activity	O
and	O
the	O
uPA	B
/	O
plasmin	O
pathway	O
,	O
in	O
particular	O
by	O
regulating	O
pro	O
-	O
uPA	B
activation	O
by	O
hepsin	O
.	O

4,6-dl-	O
and	O
2,4,6-trisubstituted	O
quinazoline	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
viral	O
infections	O
This	O
invention	O
provides	O
the	O
treatment	O
of	O
viral	O
infections	O
with	O
a	O
4,6-	O
disubstituted	O
or	O
2,4,6-trisubstituted	O
quinazoline	O
derivative	O
represented	O
by	O
the	O
structural	O
formula	O
[	O
(	O
I	O
)	O
]	O
wherein	O
:	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
NR'R	O
'	O
and	O
C1	O
-	O
7	O
alkyl	O
;	O
-	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
bond	O
,	O
O	O
,	O
S	O
(	O
O	O
)	O
n	O
,	O
C1	O
-	O
7	O
alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
and	O
C2	O
-	O
7	O
alkynylene	O
;	O
R4	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C1	O
-	O
7	O
alkyl	O
,	O
C2	O
-	O
7	O
alkenyl	O
,	O
C3	O
-	O
10	O
cycloalkyl	O
,	O
C3	O
-	O
10	O
cycloalkenyl	O
,	O
aryl	O
,	O
heterocyclic	O
,	O
arylalkyl	O
,	O
heterocyclic	O
-	O
substituted	O
alkyl	O
and	O
cycloalkyl	O
-	O
alkyl	O
;	O
-	O
Y	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
single	O
bond	O
,	O
C1	O
-	O
7	O
alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
,	O
and	O
C2	O
-	O
7	O
alkynylene	O
;	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
and	O
R6	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
,	O
heteroaryl	O
and	O
aryl	O
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	O
-	O
Λ	O
/	O
-oxide	O
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
.	O

4,6-dl-	O
and	O
2,4,6-trisubstituted	O
quinazoline	O
derivatives	O
useful	O
for	O
treating	O
viral	O
infections	O
This	O
invention	O
provides	O
quinazoline	O
derivatives	O
represented	O
by	O
the	O
structural	O
formula	O
:	O
(	O
I	O
)	O
;	O
wherein	O
:	O
R2	O
is	O
hydrogen	O
,	O
NR'R	O
'	O
,	O
C1	O
-	O
7	O
alkyl	O
,	O
arylC1	O
-	O
7	O
alkyl	O
or	O
C3	O
-	O
10	O
cycloalkyl	O
;	O
R4	O
is	O
amino	O
,	O
C1	O
-	O
7	O
alkyl	O
,	O
C2	O
-	O
7	O
alkenyl	O
,	O
C3	O
-	O
10	O
cycloalkyl	O
,	O
C3	O
-	O
10	O
cycloalkenyl	O
,	O
aryl	O
,	O
heterocyclic	O
,	O
arylalkyl	O
,	O
heterocyclic	O
-	O
substituted	O
C1	O
-	O
7	O
alkyl	O
or	O
C3	O
-	O
10	O
cycloalkyl	O
-	O
C1	O
-	O
7	O
alkyl	O
;	O
R5	O
is	O
hydrogen	O
or	O
C1	O
-	O
7	O
alkyl	O
,	O
or	O
R5	O
and	O
R4	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
heterocyclic	O
ring	O
;	O
Y	O
is	O
a	O
single	O
bond	O
,	O
C1	O
-	O
7alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
or	O
C2	O
-	O
7	O
alkynylene	O
;	O
R6	O
is	O
halogen	O
,	O
heteroaryl	O
or	O
aryl	O
;	O
R	O
'	O
and	O
R	O
'	O
are	O
each	O
independently	O
hydrogen	O
,	O
C1	O
-	O
7	O
alkyl	O
-	O
carbonyl	O
or	O
C1	O
-	O
7	O
alkyl	O
;	O
provided	O
that	O
R4	O
is	O
not	O
phenyl	O
substituted	O
with	O
morpholino	O
when	O
R2	O
is	O
H	O
and	O
R5	O
is	O
H	O
,	O
and	O
provided	O
that	O
when	O
NR4R5	O
is	O
piperazinyl	O
,	O
said	O
NR4R5	O
is	O
either	O
non	O
-	O
substituted	O
or	O
substituted	O
with	O
methyl	O
or	O
acetyl	O
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	O
-	O
N	O
-	O
oxide	O
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
,	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
.	O

Drug	O
combinations	O
for	O
treating	O
airway	O
diseases	O
The	O
invention	O
relates	O
to	O
novel	O
drug	O
combinations	O
,	O
comprising	O
,	O
in	O
addition	O
to	O
one	O
or	O
more	O
,	O
preferably	O
one	O
,	O
compound	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
where	O
the	O
groups	O
R1	O
,	O
R2	O
and	O
R3	O
can	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
description	O
,	O
at	O
least	O
one	O
further	O
active	O
ingredient	O
2	O
,	O
a	O
method	O
for	O
production	O
and	O
use	O
thereof	O
as	O
a	O
drug	O
.	O

Remedy	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
The	O
invention	O
relates	O
to	O
an	O
inhibitor	O
of	O
pulmonary	O
emphysematous	O
lesions	O
containing	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
having	O
an	O
action	O
of	O
promoting	O
the	O
degradation	O
of	O
CSPG	O
,	O
an	O
action	O
of	O
inhibiting	O
the	O
synthesis	O
of	O
CSPG	O
,	O
or	O
an	O
action	O
of	O
inhibiting	O
the	O
sulfation	O
of	O
CSPG	O
,	O
for	O
example	O
,	O
chondroitinase	B
ABC	O
,	O
a	O
C6ST	O
antisense	O
agent	O
,	O
a	O
GalNAc	O
antisense	O
agent	O
or	O
the	O
like	O
,	O
an	O
inhibitor	O
of	O
emphysematous	O
lesions	O
suitable	O
for	O
treating	O
or	O
preventing	O
COPD	O
,	O
a	O
therapeutic	O
or	O
preventive	O
agent	O
for	O
COPD	O
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
emphysematous	O
lesions	O
and	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
COPD	O
.	O

Morpholine	O
d3	B
dopamine	I
antagonists	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
to	O
intermediates	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
as	O
modulators	O
of	O
the	O
dopamine	B
D3	I
receptor	I
,	O
particularly	O
as	O
psychotherapeutic	O
agents	O
.	O

2-alkyl-6-	O
(	O
pyrazolopyridin-4-yl	O
)	O
pyridazinone	O
derivative	O
,	O
addition	O
salt	O
thereof	O
,	O
and	O
pde	B
inhibitor	O
comprising	O
the	O
derivative	O
or	O
the	O
salt	O
as	O
active	O
ingredient	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
2-alkyl-6-	O
(	O
pyrazolopyridin-	O
4-yl	O
)	O
pyridazinone	O
derivative	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
having	O
a	O
phosphodiesterase	B
-	O
inhibiting	O
activity	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
2-alkyl-6-	O
(	O
pyrazolopyridin-4-yl	O
)	O
pyridazinone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
(	O
a	O
specific	O
example	O
:	O
6-	O
(	O
7-methoxy-2-	O
trifluoromethylpyrazolo	O
[	O
1,5-a	O
]	O
pyridin-4-yl	O
)	O
-5-methyl-2-	O
[	O
3-	O
[	O
4-	O
(	O
4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-	O
yl	O
)	O
phenoxy	O
]	O
propyl	O
]	O
-4,5-dihydro-2H-	O
pyridazin-3-one	O
)	O
.	O

Indazole	O
derivatives	O
as	O
modulators	O
of	O
interleukin-	O
1	O
receptor	O
-	O
associated	O
kinase	O
The	O
present	O
invention	O
relates	O
to	O
modulators	O
of	O
IRAK	B
kinases	O
of	O
formula	O
(	O
I	O
)	O
and	O
provides	O
compositions	O
comprising	O
such	O
modulators	O
,	O
as	O
well	O
as	O
methods	O
therewith	O
for	O
treating	O
IRAK-	B
mediated	O
or	O
IRAK	B
-associated	O
conditions	O
or	O
diseases	O
.	O

Therapeutical	O
formulation	O
comprising	O
a	O
thiazolidinedione	O
and	O
a	O
nitric	O
oxide	O
scavenger	O
.	O

A	O
therapeutic	O
formulation	O
comprising	O
of	O
Thiazolidinediones	O
as	O
active	O
agents	O
namely	O
,	O
Pioglitazone	O
and	O
Rosiglitazone	O
,	O
characterized	O
in	O
that	O
said	O
Thiazolidinediones	O
are	O
combined	O
or	O
complexated	O
with	O
NO	O
Scavenger	O
to	O
prevent	O
Diabetic	O
Complications	O
arising	O
out	O
of	O
Nitrosative	O
stress	O
.	O

Treatment	O
of	O
fibrosis	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
fibrosis	O
.	O

In	O
one	O
aspect	O
the	O
invention	O
provides	O
the	O
use	O
of	O
an	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
conjunction	O
with	O
an	O
anti-	O
fibrotic	O
agent	O
for	O
the	O
treatment	O
of	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
supplied	O
to	O
the	O
subject	O
before	O
,	O
at	O
the	O
same	O
time	O
,	O
or	O
after	O
the	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
.	O

The	O
fibrosis	O
may	O
be	O
idiopathic	O
pulmonary	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
a	O
modulator	O
of	O
RhoA	O
,	O
RhoA	O
GTPases	O
,	O
TGF	O
-	O
βl	O
or	O
CTGF	O
,	O
or	O
any	O
other	O
member	O
of	O
the	O
RhoA	O
signalling	O
pathway	O
;	O
or	O
can	O
modulate	O
the	O
effect	O
of	O
suppressor	O
of	O
cytokine	O
signalling	O
1	O
(	O
SOCS	O
1	O
)	O
,	O
suppressor	O
of	O
cytokine	O
signalling	O
3	O
(	O
SOCS	O
3	O
)	O
or	O
TLR9	O
;	O
or	O
can	O
be	O
a	O
statin	O
compound	O
or	O
derivative	O
thereof	O
.	O

Enantiomerically	O
pure	O
phosphoindoles	O
as	O
hiv	O
inhibitors	O
3-phosphoindole	O
compounds	O
substantially	O
in	O
the	O
form	O
of	O
a	O
single	O
enantiomer	O
useful	O
for	O
the	O
treatment	O
of	O
Flaviviridae	O
virus	O
infections	O
,	O
and	O
particularly	O
for	O
HLV	O
infections	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
3-phosphoindole	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
antiviral	O
agents	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
and	O
methods	O
of	O
manufacturing	O
a	O
medicament	O
incorporating	O
these	O
compounds	O
.	O

The	O
3-phosphoindole	O
compounds	O
are	O
of	O
the	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	O
,	O
or	O
esters	O
thereof	O
.	O

In	O
the	O
formulae	O
X	O
is	O
hydrogen	O
;	O
aryl	O
or	O
heterocyclyl	O
;	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
or	O
alkyl	O
;	O
Y	O
is	O
hydrogen	O
,	O
-R	O
,	O
-O	O
-	O
R	O
,	O
-NH	O
-	O
R	O
,	O
or	O
-NRR	O
;	O
Z	O
is	O
-OR	O
,	O
-NHR	O
,	O
-NRR	O
,	O
carboxamido	O
,	O
arnido	O
,	O
carboxyl	O
,	O
carbonyl	O
,	O
or	O
an	O
amino	O
acid	O
residue	O
;	O
R1	O
is	O
hydrogen	O
,	O
acyl	O
,	O
-S	O
(	O
O	O
)	O
n	O
-	O
R	O
,	O
carboxyl	O
,	O
carbonyl	O
,	O
or	O
an	O
amino	O
acid	O
residue	O
;	O
each	O
R4	O
'	O
,	O
R5	O
'	O
,	O
R6	O
'	O
and	O
R7	O
'	O
is	O
independently	O
hydrogen	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
,	O
aryl	O
,	O
heterocyclyl	O
,	O
halogen	O
,	O
-CN	O
,	O
-CF3	O
,	O
-OR	O
,	O
-NHR	O
,	O
-NRR	O
,	O
or	O
-NO2	O
;	O
n	O
is	O
0	O
,	O
1	O
,	O
or	O
2	O
;	O
and	O
each	O
R	O
is	O
independently	O
hydrogen	O
,	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
,	O
aryl	O
,	O
or	O
heterocyclyl	O
.	O

Crystalline	O
carbapenem	O
compounds	O
The	O
invention	O
provides	O
crystalline	O
substances	O
each	O
consisting	O
of	O
the	O
carbapenem	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
.	O

The	O
crystalline	O
substances	O
are	O
excellent	O
in	O
handleability	O
and	O
storage	O
stability	O
.	O

Further	O
,	O
the	O
invention	O
also	O
provides	O
solid	O
compositions	O
each	O
containing	O
both	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
an	O
alkali	O
metal	O
halide	O
.	O

The	O
crystalline	O
substances	O
and	O
the	O
solid	O
compositions	O
exhibit	O
excellent	O
antimicrobial	O
activity	O
.	O

5-	O
[	O
(	O
2r	O
)	O
-	O
[	O
2-	O
[	O
2-	O
[	O
2-	O
(	O
2,2,2-trifluoroethoxy	O
)	O
phenoxy	O
]	O
ethyl	O
]	O
amino	O
]	O
propyl	O
]	O
-2-methoxybenzenesulfonamide	O
5-	O
[	O
(	O
2R	O
)	O
-	O
[	O
2-	O
[	O
2-	O
[	O
2-	O
(	O
2,2,2-trifluoroethoxy	O
)	O
phenoxy	O
]	O
ethyl	O
]	O
amino	O
]	O
propyl	O
]	O
-2-methoxybenzenesulfonamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
the	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
has	O
strong	O
antagonism	O
toward	O
α1-adrenoceptor	B
and	O
has	O
high	O
selectivity	O
toward	O
smooth	O
muscle	O
of	O
urethra	O
.	O

Thienyl	O
-	O
containing	O
glycopyranosyl	O
derivatives	O
as	O
antidiabetics	O
The	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
described	O
herein	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
.	O

Aminothiazole	O
macrocycles	O
,	O
their	O
use	O
as	O
antibacterial	O
compounds	O
and	O
processes	O
for	O
their	O
production	O
This	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotic	O
compounds	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
to	O
methods	O
for	O
obtaining	O
such	O
compounds	O
.	O

Use	O
of	O
glucopyranosyloxy-	O
pyrazoles	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
glucopyranosyloxy	O
-	O
pyrazole	O
as	O
defined	O
in	O
claim	O
1	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
,	O
preventing	O
or	O
slowing	O
,	O
delaying	O
or	O
reversing	O
progression	O
of	O
one	O
or	O
more	O
neurodegenerative	O
disorders	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Agent	O
for	O
activating	O
or	O
improving	O
neuronal	O
cell	O
or	O
brain	O
function	O
Disclosed	O
are	O
:	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
a	O
neuronal	O
cell	O
;	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
the	O
brain	O
function	O
;	O
and	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
each	O
of	O
which	O
comprises	O
reduced	O
coenzyme	O
A	O
as	O
an	O
active	O
ingredient	O
.	O

Specifically	O
disclosed	O
are	O
:	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
has	O
less	O
adverse	O
side	O
effects	O
and	O
is	O
highly	O
safe	O
;	O
and	O
a	O
method	O
for	O
treating	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
administering	O
the	O
agent	O
.	O

Methods	O
for	O
the	O
treatment	O
of	O
senile	O
dementia	O
of	O
the	O
alzheimer	O
's	O
type	O
The	O
present	O
invention	O
relates	O
to	O
the	O
diagnosis	O
,	O
risk	O
assessment	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
Senile	O
Dementia	O
of	O
the	O
Alzheimer	O
's	O
Type	O
(	O
SDAT	O
)	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
the	O
measurement	O
of	O
ethanolamine	O
phospholipids	O
in	O
human	O
serum	O
.	O

Subsets	O
of	O
these	O
molecules	O
are	O
significantly	O
altered	O
in	O
subjects	O
with	O
pathologically	O
confirmed	O
deposits	O
of	O
β	O
-	O
amyloid	O
versus	O
subjects	O
without	O
β	O
-	O
amyloid	O
deposits	O
and	O
in	O
subjects	O
with	O
a	O
clinical	O
manifestation	O
of	O
dementia	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SDAT	O
versus	O
non	O
-	O
demented	O
controls	O
.	O

Further	O
,	O
the	O
invention	O
relates	O
to	O
the	O
diagnosis	O
of	O
various	O
stages	O
of	O
SDAT	O
,	O
the	O
early	O
detection	O
and	O
prevention	O
of	O
SDAT	O
symptoms	O
,	O
the	O
treatment	O
of	O
SDAT	O
,	O
the	O
differential	O
diagnosis	O
of	O
non	O
-	O
SDAT	O
dementia	O
,	O
and	O
the	O
identification	O
of	O
molecular	O
targets	O
for	O
which	O
chemical	O
or	O
biological	O
treatments	O
can	O
be	O
designed	O
for	O
the	O
therapeutic	O
intervention	O
of	O
SDAT	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
a	O
molecular	O
diagnostic	O
assay	O
to	O
direct	O
and	O
select	O
the	O
appropriate	O
therapeutic	O
intervention	O
for	O
subjects	O
suffering	O
from	O
dementia	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
small	O
molecules	O
or	O
metabolites	O
that	O
are	O
found	O
to	O
have	O
significantly	O
different	O
abundances	O
between	O
persons	O
with	O
a	O
clinical	O
manifestation	O
of	O
SDAT	O
and	O
normal	O
,	O
non	O
-	O
demented	O
patients	O
.	O

6-benzyl-2,3,4,7-tetrahydro	O
-	O
indolo	O
[	O
2	O
,	O
3-c	O
]	O
quinoline	O
compounds	O
useful	O
as	O
pde5	B
inhibitors	O
The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R8	O
and	O
R11	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
,	O
the	O
salts	O
thereof	O
,	O
the	O
N	O
-	O
oxides	O
of	O
the	O
compounds	O
and	O
the	O
salts	O
thereof	O
,	O
and	O
the	O
stereoisomers	O
of	O
the	O
compounds	O
,	O
the	O
salts	O
,	O
the	O
N	O
-	O
oxides	O
of	O
the	O
compounds	O
and	O
the	O
N	O
-	O
oxides	O
of	O
the	O
salts	O
thereof	O
are	O
effective	O
inhibitors	O
of	O
the	O
type	B
5	I
phosphodiesterase	I
.	O

Compositions	O
comprising	O
mkc-733	O
(	O
pumosetrag	O
)	O
useful	O
for	O
treating	O
irritable	O
bowel	O
syndrome	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
irritable	O
bowel	O
syndrome	O
with	O
constipation	O
(	O
IBS	O
-	O
c	O
)	O
or	O
irritable	O
bowel	O
syndrome	O
with	O
alternating	O
constipation	O
and	O
diarrhea	O
(	O
IBS	O
-	O
a	O
)	O
in	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
said	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
thieno	O
[	O
3,2-b	O
]	O
pyridine	O
compound	O
of	O
Structural	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
N	O
-	O
oxide	O
derivative	O
thereof	O
.	O

Method	O
for	O
the	O
treatment	O
of	O
amyloidoses	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
an	O
amyloidosis	O
such	O
as	O
Alzheimer	O
's	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
characterized	O
in	O
that	O
it	O
comprises	O
administering	O
an	O
agonist	O
of	O
the	O
P	O
/	O
Q	O
type	O
voltage	B
-	I
gated	I
presynaptic	I
calcium	I
channel	I
to	O
said	O
subject	O
.	O

Derivatives	O
of	O
benzoxadiazole	O
suitable	O
for	O
the	O
treatment	O
of	O
cell	O
proliferative	O
diseases	O
This	O
invention	O
describes	O
compounds	O
and	O
pharmaceutical	O
compositions	O
useful	O
as	O
ubiquitin	B
agent	O
inhibitors	O
,	O
particularly	O
ubiquitin	B
ligase	I
inhibitors	O
.	O

The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
the	O
biochemical	O
pathways	O
of	O
organisms	O
in	O
which	O
ubiquitination	O
is	O
involved	O
,	O
such	O
as	O
signal	O
transduction	O
pathways	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
use	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
for	O
the	O
treatment	O
of	O
conditions	O
that	O
require	O
inhibition	O
of	O
ubiquitination	O
.	O

Furthermore	O
,	O
the	O
invention	O
comprises	O
methods	O
of	O
inhibiting	O
ubiquitination	O
in	O
a	O
cell	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
ubiquitination	O
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
invention	O
.	O

Particularly	O
,	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful	O
to	O
inhibit	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
TRAF6	B
.	O

Compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O
Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	O
trialkyl	O
ammonium	O
-	O
containing	O
compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O
from	O
endogenous	O
or	O
exogenous	O
stem	O
/	O
progenitor	O
cells	O
and	O
to	O
normalize	O
blood	O
cell	O
and	O
platelet	O
counts	O
.	O

Substituted	O
piperidines	O
for	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
The	O
present	O
invention	O
relates	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
are	O
believed	O
to	O
possess	O
antibacterial	O
activity	O
.	O

Compositions	O
containing	O
phosphatidylserine	O
in	O
treating	O
diabetes	O
associated	O
conditions	O
Provided	O
is	O
a	O
pharmaceutical	O
and	O
nutraceutical	O
composition	O
for	O
oral	O
delivery	O
which	O
contains	O
at	O
least	O
60	O
wt%	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
,	O
in	O
which	O
the	O
ratio	O
of	O
esterified	O
to	O
free	O
phosphatidic	O
acid	O
is	O
between	O
6	O
and	O
7	O
,	O
and	O
wherein	O
phosphatidylserine	O
constitutes	O
more	O
than	O
50	O
wt%	O
of	O
the	O
phosphatidic	O
esters	O
.	O

The	O
composition	O
mitigates	O
diabetes	O
-	O
like	O
conditions	O
and	O
boosts	O
mental	O
and	O
bodily	O
vigor	O
.	O

Sirna	O
against	O
thymidylate	B
synthase	I
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O
regimens	O
Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
that	O
target	O
a	O
mammalian	B
thymidylate	I
synthase	I
gene	O
(	O
TS	B
)	O
,	O
and	O
which	O
are	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
their	O
target	O
gene	O
,	O
are	O
provided	O
The	O
siRNA	O
molecules	O
are	O
also	O
capable	O
of	O
sensitizing	O
cells	O
to	O
the	O
effects	O
of	O
other	O
anti	O
-	O
cancer	O
agents	O
,	O
particularly	O
chemotherapeutic	O
agents	O
that	O
target	O
TS	O
Methods	O
of	O
treating	O
cancer	O
using	O
the	O
TS	B
siRNA	O
in	O
combination	O
with	O
another	O
anti	O
-	O
cancer	O
agent	O
are	O
also	O
provided	O
Methods	O
of	O
enhancing	O
the	O
effect	O
of	O
a	O
TS	B
siRNA	O
on	O
cancer	O
cell	O
proliferation	O
by	O
combining	O
the	O
TS	B
siRNA	O
with	O
a	O
siRNA	O
targeting	O
a	O
cell	O
survival	O
gene	O
such	O
as	O
Bcl-2	B
are	O
further	O
provided	O
.	O

5-aminopyrazol-3-yl-3h	O
-	O
imidazo	O
[	O
4,5-b	O
]	O
pyridine	O
derivatives	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

External	O
preparation	O
for	O
skin	O
and	O
external	O
preparation	O
for	O
lips	O
Disclosed	O
are	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
improving	O
wrinkles	O
and	O
sagging	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
moisture	O
retention	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
promoting	O
wound	O
healing	O
and	O
an	O
external	O
preparation	O
for	O
lips	O
,	O
each	O
of	O
which	O
contains	O
raspberry	O
ketone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
respiratory	O
disease	O
Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
involving	O
disturbances	O
in	O
glutathione	O
(	O
GSH	O
)	O
metabolism	O
and	O
oxidative	O
stress	O
,	O
especially	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
and	O
most	O
especially	O
asthma	O
.	O

In	O
particular	O
embodiments	O
,	O
methods	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
involving	O
the	O
step	O
of	O
administering	O
an	O
agent	O
that	O
inhibits	O
gamma	B
glutamyl	I
transpeptidase	I
(	O
GGT	B
)	O
activity	O
in	O
lung	O
and	O
airway	O
lining	O
fluid	O
.	O

Phosphate	O
-	O
modified	O
oligonucleotide	O
analogs	O
with	O
immunostimulatory	O
activity	O
The	O
invention	O
relates	O
to	O
oligonucleotides	O
including	O
at	O
least	O
one	O
backbone	O
modification	O
and	O
a	O
pyrimidine	O
-	O
purine	O
dinucleotide	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
making	O
therapies	O
delivered	O
by	O
viral	O
vectors	O
reversible	O
for	O
safety	O
or	O
allele	O
-	O
specificity	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
methods	O
and	O
kits	O
for	O
regulation	O
of	O
gene	O
therapies	O
,	O
including	O
,	O
without	O
limitation	O
,	O
reversible	O
gene	O
therapies	O
and	O
allele-	O
specific	O
therapies	O
.	O

Triazolyl	O
aminopyrimidine	O
compounds	O
The	O
present	O
invention	O
provides	O
triazolyl	O
aminopyrimidine	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

Potassium	B
ion	I
channel	I
modulators	O
and	O
uses	O
thereof	O
Compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmacologically	O
acceptable	O
salts	O
and	O
pro	O
-	O
drugs	O
thereof	O
:	O
wherein	O
A	O
and	O
B	O
are	O
CH2	O
or	O
CH2CH2	O
,	O
R1	O
is	O
hydrogen	O
,	O
alkyl	O
,	O
cycloalkyl	O
,	O
aryl	O
,	O
aralkyl	O
or	O
heteroaralkyl	O
,	O
D	O
,	O
E	O
and	O
G	O
are	O
CR2	O
or	O
nitrogen	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
D	O
,	O
E	O
and	O
G	O
is	O
nitrogen	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
hydrogen	O
,	O
alkyl	O
,	O
halogen	O
,	O
haloalkyl	O
,	O
alkoxy	O
,	O
alkoxycarbonyl	O
,	O
carboxyl	O
,	O
hydroxyl	O
or	O
cyano	O
,	O
X	O
is	O
R5SO2	O
,	O
R5R7NCO	O
,	O
R5R7NSO2or	O
R5SO2NR7CO	O
,	O
Y	O
is	O
R6CO	O
,	O
R6SO2	O
,	O
R6R7NCO	O
,	O
R6R7NSO2	O
,	O
R6SO2NR7CO	O
or	O
CO2R8	O
,	O
R5	O
and	O
R6	O
are	O
hydrogen	O
,	O
alkyl	O
,	O
aryl	O
,	O
aralkyl	O
,	O
heteroaryl	O
or	O
heteroaralkyl	O
,	O
R7	O
is	O
hydrogen	O
,	O
alkyl	O
,	O
aryl	O
or	O
aralkyl	O
,	O
and	O
R8	O
is	O
alkyl	O
,	O
aryl	O
,	O
aralkyl	O
,	O
alkoxyalkyl	O
,	O
heteroaryl	O
or	O
heteroarylalkyl	O
,	O
are	O
of	O
use	O
inthe	O
prophylaxis	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
in	O
which	O
Kv1.x	B
channels	I
are	O
involved	O
,	O
such	O
as	O
lower	O
urinary	O
tract	O
disorders	O
,	O
cardiovascular	O
diseases	O
,	O
inflammatory	O
and	O
immunological	O
diseases	O
and	O
pain	O
.	O

Pyrazolone	O
derivative	O
and	O
pde	B
inhibitor	O
containing	O
the	O
same	O
as	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
novel	O
pyrazolone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
below	O
,	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
having	O
phosphodiesterase	B
inhibitory	O
activity	O
.	O

(	O
1	O
)	O
R1	O
,	O
R2	O
:	O
C1	O
-	O
6	O
alkyl	O
R3	O
,	O
R4	O
:	O
H	O
,	O
X	O
,	O
C1	O
-	O
6	O
alkoxy	O
Z	O
:	O
O	O
,	O
S	O
A	O
:	O
AA	O
,	O
BB	O
(	O
R5	O
:	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
;	O
R6	O
,	O
R7	O
:	O
C1	O
-	O
6	O
alkyl	O
)	O

Quinazoline	O
derivatives	O
as	O
pi3	O
kinase	O
inhibitors	O
Invented	O
is	O
a	O
method	O
of	O
inhibiting	O
the	O
activity	O
/	O
function	O
of	O
P13	O
kinases	O
using	O
quinazoline	O
derivatives	O
.	O

Also	O
invented	O
is	O
a	O
method	O
of	O
treating	O
one	O
or	O
more	O
disease	O
states	O
selected	O
from	O
:	O
autoimmune	O
disorders	O
,	O
inflammatory	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
neurodegenerative	O
diseases	O
,	O
allergy	O
,	O
asthma	O
,	O
pancreatitis	O
,	O
multiorgan	O
failure	O
,	O
kidney	O
diseases	O
,	O
platelet	O
aggregation	O
,	O
cancer	O
,	O
sperm	O
motility	O
,	O
transplantation	O
rejection	O
,	O
graft	O
rejection	O
and	O
lung	O
injuries	O
by	O
the	O
administration	O
of	O
quinazoline	O
derivatives	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
and	O
methods	O
of	O
using	O
same	O
The	O
present	O
invention	O
provides	O
novel	O
methods	O
of	O
making	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
for	O
use	O
as	O
an	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
.	O

The	O
present	O
invention	O
further	O
provides	O
novel	O
compositions	O
and	O
methods	O
which	O
can	O
be	O
used	O
to	O
provide	O
relief	O
from	O
disorders	O
related	O
to	O
or	O
complicated	O
by	O
acidosis	O
or	O
excessive	O
free	O
radical	O
or	O
other	O
reactive	O
oxygen	O
species	O
production	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
gout	O
,	O
Lesch	O
-	O
Nyhan	O
syndrome	O
,	O
hemochromatosis	O
,	O
Alzheimer	O
's	O
,	O
amyotropic	O
lateral	O
sclerosis	O
,	O
arthritis	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
cataracts	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
cellulitis	O
,	O
coronary	O
artery	O
disease	O
,	O
heart	O
failure	O
,	O
hypertension	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
macular	O
degeneration	O
,	O
multiple	O
sclerosis	O
,	O
Parkinson	O
's	O
,	O
Reynaud	O
's	O
phenomenon	O
,	O
reperfusion	O
injury	O
,	O
pancreatic	O
impairment	O
,	O
skin	O
infections	O
,	O
Hepatitis	O
C	O
,	O
methicillin-	O
resistant	O
Staphylococcus	O
aureus	O
and	O
infection	O
.	O

The	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
additionally	O
supply	O
relief	O
from	O
microbial	O
infections	O
including	O
fungal	O
infections	O
as	O
well	O
as	O
prevent	O
secondary	O
infections	O
.	O

Additional	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
employ	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
in	O
combination	O
with	O
a	O
second	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
,	O
or	O
other	O
therapeutic	O
agent	O
to	O
yield	O
a	O
more	O
effective	O
treatment	O
tool	O
against	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
including	O
free	O
radical	O
production	O
useful	O
to	O
prevent	O
or	O
reduce	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
or	O
related	O
symptoms	O
or	O
conditions	O
associated	O
with	O
acidosis	O
and/or	O
excessive	O
free	O
radical	O
production	O
in	O
mammalian	O
subjects	O
.	O

Flavonoid	O
ppar	B
agonists	O
The	O
present	O
invention	O
relates	O
to	O
PPAR	B
agonists	O
,	O
and	O
their	O
use	O
in	O
therapy	O
including	O
the	O
treatment	O
of	O
disease	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
flavonoid	O
compounds	O
which	O
are	O
PPAR	B
-	I
gamma	I
agonists	O
and/or	O
PPAR	B
alpha	I
/	I
gamma	I
dual	O
agonists	O
.	O

2,4	O
diaminopyrimid'lnes	O
for	O
the	O
treatment	O
of	O
myeloproliferative	O
disorders	O
and	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
salts	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
use	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
.	O

These	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

Therapeutic	O
agent	O
for	O
cancer	O
with	O
resistance	O
to	O
protease	B
inhibitor	O
A	O
therapeutic	O
agent	O
for	O
cancers	O
having	O
resistance	O
to	O
protease	B
inhibitors	O
which	O
contains	O
,	O
as	O
a	O
heat	B
shock	I
protein	I
90	I
(	O
Hsp90	B
)	O
family	O
protein	O
inhibitor	O
,	O
either	O
a	O
benzoyl	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
-	O
5	O
;	O
R1	O
represents	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
CONR7R8	O
(	O
wherein	O
R7	O
and	O
R8	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
)	O
,	O
etc	O
.	O
;	O
R2	O
represents	O
(	O
un	O
)	O
substituted	O
aryl	O
,	O
etc	O
.	O
;	O
R3	O
and	O
R5	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
;	O
R4	O
represents	O
hydrogen	O
,	O
etc	O
.	O
;	O
and	O
R6	O
represents	O
hydrogen	O
,	O
halogeno	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Anti	O
-	O
bacterial	O
agents	O
The	O
invention	O
relates	O
to	O
novel	O
acylphloroglucinols	O
which	O
have	O
strong	O
growth	O
inhibitory	O
effects	O
on	O
multi	O
-	O
drug	O
resistant	O
strains	O
of	O
bacteria	O
,	O
particularly	O
MRSA	O
.	O

Typically	O
the	O
compounds	O
have	O
a	O
terpene	O
substituent	O
,	O
or	O
a	O
terpene-	O
derived	O
substituent	O
.	O

Methods	O
of	O
isolating	O
the	O
compounds	O
from	O
natural	O
sources	O
,	O
and	O
synthetic	O
methods	O
for	O
forming	O
the	O
compounds	O
are	O
also	O
provided	O
.	O

Combination	O
059	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
,	O
and	O
to	O
methods	O
for	O
the	O
production	O
of	O
an	O
anti	O
-	O
cancer	O
effect	O
in	O
a	O
patient	O
,	O
which	O
is	O
accordingly	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
kit	O
of	O
parts	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
;	O
use	O
of	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
;	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
to	O
a	O
patient	O
.	O

The	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
the	O
activity	O
of	O
MEK	B
,	O
and/or	O
mTOR	B
.	O

Modulators	O
of	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
egfr	B
)	O
pathway	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
modulators	O
of	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
pathway	O
for	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
such	O
as	O
alcohol	O
abuse	O
.	O

The	O
modulators	O
include	O
small	O
molecule	O
inhibitors	O
such	O
as	O
Erlotinib	O
(	O
TARCEVA	O
®	O
,	O
N-	O
(	O
3-ethynylphenyl	O
)	O
-6,7-bis	O
(	O
2-methoxyethoxy	O
)	O
-4-	O
quinazolineamine	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
Gefitinib	O
[	O
IRES	O
S	O
A	O
®	O
,	O
N-	O
(	O
3	O
-chloro-4-fluoro	O
-	O
phenyl	O
)	O
-7-methoxy-6-	O
(	O
3	O
-morpholin-4-	O
ylpropoxy	O
)	O
quinazolin-4-amine	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
various	O
macromolecular	O
inhibitors	O
of	O
the	O
EGFR	B
pathway	O
such	O
as	O
siRNAs	O
and	O
antibodies	O
that	O
target	O
genes	O
or	O
proteins	O
in	O
the	O
EGFR	B
/	O
ERK	B
pathway	O
such	O
as	O
one	O
of	O
the	O
EGFR	B
/	O
ErbB	B
protein	O
or	O
a	O
homolog	O
thereof	O
.	O

Inhibition	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
for	O
ocular	O
neuroprotection	O
A	O
composition	O
comprises	O
a	O
material	O
capable	O
of	O
controlling	O
a	O
level	O
of	O
cortisol	O
in	O
an	O
ocular	O
environment	O
for	O
effecting	O
ocular	O
neuroprotection	O
in	O
subjects	O
in	O
risk	O
of	O
developing	O
or	O
worsening	O
an	O
ocular	O
neurodegenerative	O
condition	O
.	O

Such	O
a	O
composition	O
is	O
injected	O
into	O
or	O
implanted	O
in	O
the	O
subject	O
's	O
posterior	O
segment	O
to	O
provide	O
such	O
neuroprotection	O
.	O

Carboxamidξ	O
compounds	O
and	O
their	O
use	O
as	O
chemokine	B
receptor	I
agonists	O
Chemokine	B
receptor	I
antagonists	O
,	O
in	O
particular	O
,	O
compounds	O
of	O
Formula	O
(	O
I-	O
A	O
)	O
that	O
act	O
as	O
antagonists	O
of	O
the	O
chemokine	B
CCR2	B
receptor	O
,	O
including	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
to	O
treat	O
or	O
prevent	O
diseases	O
associated	O
with	O
monocyte	O
accumulation	O
,	O
lymphocyte	O
accumulation	O
or	O
leukocyte	O
accumulation	O
are	O
described	O
herein	O
.	O

Trail	B
variants	O
for	O
treating	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
TRAIL	B
protein	O
to	O
treat	O
various	O
cancers	O
in	O
mammals	O
.	O

The	O
invention	O
provides	O
a	O
variant	O
TRAIL	B
protein	O
,	O
which	O
has	O
superior	O
selectivity	O
for	O
the	O
death	B
receptor	I
5	I
,	O
for	O
treating	O
a	O
mammal	O
diagnosed	O
with	O
cancer	O
.	O

Cucurbitane	O
triterpenoid	O
saponins	O
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
field	O
and	O
discloses	O
cucurbitane	O
triterpenoid	O
saponins	O
extracted	O
from	O
Momordica	O
charantia	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
preparation	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
use	O
of	O
such	O
compounds	O
in	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
and	O
hyperlipaemia	O
.	O

The	O
saponins	O
disclosed	O
in	O
the	O
invention	O
are	O
represented	O
by	O
formula	O
I.	O

Preparations	O
with	O
rosehip	O
extracts	O
,	O
and	O
method	O
of	O
producing	O
rosehip	O
extracts	O
Composition	O
comprising	O
an	O
anti	O
-	O
inflammatory	O
plant	O
extract	O
from	O
rosehips	O
together	O
with	O
a	O
cartilage	O
-	O
protective	O
substance	O
,	O
and	O
a	O
method	O
of	O
producing	O
the	O
rosehip	O
extract	O
.	O

A2b	O
adenosine	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
cancer	O
Disclosed	O
are	O
methods	O
for	O
treating	O
asthma	O
,	O
inflammatory	O
gastrointestinal	O
tract	O
disorders	O
,	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
neurological	O
disorders	O
,	O
and	O
diseases	O
related	O
to	O
undesirable	O
angiogenesis	O
using	O
A2B	O
adenosine	O
receptor	O
antagonists	O
having	O
the	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
.	O

Aryl	O
-	O
substituted	O
imidazolidine-2,4-diones	O
,	O
method	O
for	O
the	O
production	O
thereof	O
,	O
medicaments	O
containing	O
said	O
compounds	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R	O
and	O
R	O
'	O
A	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
L	O
,	O
p	O
and	O
Rl	O
to	O
R1O	O
have	O
the	O
stated	O
meanings	O
and	O
to	O
their	O
physiologically	O
compatible	O
salts	O
.	O

Said	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
as	O
anti	O
-	O
obesity	O
drugs	O
.	O

Imidazopyridine	O
compounds	O
The	O
present	O
invention	O
provides	O
imidazopyridines	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
compounds	O
show	O
inhibitory	O
activity	O
against	O
protein	O
kinase	B
,	O
especially	O
VEGFR2	B
,	O
FLT3	B
,	O
and	O
C	B
-	I
KIT	I
receptors	O
and	O
so	O
on	O
,	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicament	O
for	O
treating	O
diseases	O
associated	O
with	O
abnormal	O
high	O
level	O
of	O
kinase	B
activity	O
,	O
such	O
as	O
cancer	O
.	O

Processes	O
for	O
the	O
preparation	O
of	O
bosentan	O
and	O
related	O
compounds	O
Provided	O
herein	O
are	O
novel	O
,	O
commercially	O
viable	O
and	O
industrially	O
advantageous	O
processes	O
for	O
the	O
preparation	O
of	O
substantially	O
pure	O
ethylene	O
glycol	O
sulfonamide	O
compounds	O
such	O
as	O
bosentan	O
.	O

Pyrido	O
[	O
3	O
,	O
4-b	O
]	O
indoles	O
and	O
methods	O
of	O
use	O
This	O
disclosure	O
relates	O
to	O
new	O
heterocyclic	O
compounds	O
that	O
may	O
be	O
used	O
to	O
modulate	O
a	O
histamine	O
receptor	O
in	O
an	O
individual	O
.	O

Pyrido	O
[	O
3,4-b	O
]	O
indoles	O
are	O
described	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
the	O
treatment	O
of	O
a	O
cognitive	O
disorder	O
,	O
psychotic	O
disorder	O
,	O
neurotransmitter	O
-	O
mediated	O
disorder	O
and/or	O
a	O
neuronal	O
disorder	O
.	O

2-aryl-	O
and	O
2-heteroarylthiazolyl	O
compounds	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
discloses	O
fused	O
bicyclic	O
2-aryl-	O
or	O
2-heteroarylthiazolyl	O
compounds	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
which	O
are	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
cancerous	O
cells	O
,	O
inhibiting	O
human	O
breast	O
carcinoma	O
tumor	O
growth	O
in	O
particular	O
and	O
to	O
treat	O
diseases	O
or	O
disorders	O
associated	O
with	O
securin	O
,	O
including	O
elevated	O
securin	O
levels	O
.	O

Gem	O
-	O
disubstituted	O
and	O
spirocyclic	O
amino	O
pyridines	O
/	O
pyrimidines	O
as	O
cell	O
cycle	O
inhibitors	O
Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
are	O
provided	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
CDK4-mediated	B
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
subject	O
compounds	O
are	O
gem	O
-	O
disubstituted	O
or	O
spirocyclic	O
pyridine	O
,	O
pyrimidine	O
and	O
triazine	O
derivatives	O
.	O

Therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
Disclosed	O
are	O
:	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
]	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
others	O
.	O

Indole-	O
3	O
-glyoxylamide	O
derivatives	O
for	O
use	O
as	O
calcium	O
ion	O
channel	O
modulators	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
of	O
use	O
in	O
treating	O
a	O
range	O
of	O
conditions	O
,	O
including	O
pain	O
.	O

Method	O
of	O
treating	O
anxious	O
major	O
depressive	O
disorder	O
The	O
invention	O
is	O
directed	O
to	O
using	O
4-	O
{	O
(	O
3-aminophenyl	O
)	O
[	O
4-	O
(	O
4-fluorobenzyl	O
)	O
piperazin-1-yl	O
]	O
methyl	O
}	O
-N	O
,	O
N	O
-	O
diethylbenzamide	O
,	O
or	O
enantiomer	O
thereof	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and/or	O
mixture	O
thereof	O
to	O
treat	O
anxious	O
major	O
depressive	O
disorder	O
(	O
AMDD	O
)	O
.	O

Cancer	O
drug	O
target	O
and	O
methods	O
of	O
diagnosis	O
and	O
therapy	O
A	O
single	O
nucleotide	O
G	O
>	O
A	O
polymorphism	O
at	O
position	O
-126	O
in	O
the	O
promoter	O
of	O
the	O
human	B
myeloid	I
cell	I
leukemia-1	I
gene	I
is	O
associated	O
with	O
a	O
reduced	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

The	O
G>;A	O
polymorphism	O
is	O
in	O
an	O
ELK4	B
transcription	O
factor	O
binding	O
site	O
,	O
which	O
results	O
in	O
reduced	O
myeloid	B
cell	I
leukemia-1	I
gene	I
expression	O
.	O

Elevated	O
levels	O
of	O
ELK4	B
and	O
Mcl-1	B
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
an	O
increased	O
predisposition	O
to	O
cancer	O
and	O
an	O
decreased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Reduced	O
levels	O
of	O
ELK4	B
and	O
Mcl-1	B
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
less	O
of	O
a	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

Methods	O
of	O
cancer	O
diagnosis	O
and/or	O
therapy	O
which	O
target	O
ELK4	B
and/or	O
Mcl-1	B
protein	O
and/or	O
nucleic	O
acids	O
are	O
particularly	O
applicable	O
to	O
cancers	O
such	O
as	O
glioma	O
,	O
colon	O
cancer	O
,	O
lung	O
cancer	O
,	O
thyroid	O
cancer	O
,	O
kidney	O
cancer	O
and/or	O
melanoma	O
.	O

Such	O
methods	O
and	O
compositions	O
may	O
sensitize	O
or	O
improve	O
responsiveness	O
of	O
cancer	O
cells	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Benzo	O
[	O
1	O
,	O
4	O
]	O
diazepines	O
substituted	O
at	O
the	O
1-position	O
by	O
a	O
ring	O
,	O
for	O
use	O
as	O
antidepressants	O
It	O
is	O
intended	O
to	O
provide	O
a	O
benzodiazepine	O
compound	O
useful	O
in	O
the	O
production	O
of	O
an	O
antidepressant	O
drug	O
that	O
has	O
a	O
wider	O
therapeutic	O
spectrum	O
and	O
can	O
exert	O
sufficient	O
therapeutic	O
effects	O
in	O
a	O
short	O
period	O
.	O

The	O
benzodiazepine	O
compound	O
of	O
the	O
present	O
invention	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
and	O
R7	O
respectively	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
and	O
R6	O
represents	O
a	O
substituted	O
phenyl	O
group	O
or	O
the	O
like	O
.	O

4	O
,	O
6-diphenylpyrid-2	O
-	O
0nes	O
against	O
cancer	O
A	O
compound	O
for	O
use	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
,	O
such	O
as	O
cancer	O
,	O
having	O
the	O
following	O
formula	O
:	O
z	O
wherein	O
:	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
;	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	O
-	O
lower	O
alkyl	O
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R4	O
to	O
R8	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form-0-	O
(	O
CR14R15	O
)	O
n	O
-	O
O-	O
,	O
where	O
n	O
is	O
1	O
or	O
2	O
and	O
R14	O
and	O
R15	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
,	O
and	O
the	O
remainder	O
of	O
R4	O
to	O
R8	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
;	O
and	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
and	O
R13	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	O
-	O
lower	O
alkyl	O
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R9	O
to	O
R13	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form	O
-	O
O-	O
(	O
CR16R17	O
)	O
m	O
-	O
O-	O
,	O
where	O
m	O
is	O
1	O
or	O
2	O
and	O
R16	O
and	O
R17	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
,	O
and	O
the	O
remainder	O
of	O
R9	O
to	O
R13	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
.	O

Novel	O
pde	B
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
processes	O
for	O
their	O
preparation	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
phosphodiesterase	B
inhibitors	O
(	O
PDEs	B
)	O
,	O
in	O
particular	O
phosphodiesterase	B
type	I
4	I
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

These	O
novel	O
PDEs	B
are	O
useful	O
in	O
treating	O
allergic	O
and	O
inflammatory	O
diseases	O
(	O
such	O
as	O
asthma	O
,	O
COPD	O
,	O
allergic	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
chronic	O
bronchitis	O
,	O
nephritis	O
,	O
rheumatoid	O
spondylitis	O
,	O
osteoarthritis	O
,	O
atopic	O
dermatitis	O
,	O
eosinophilic	O
granuloma	O
,	O
psoriasis	O
,	O
rheumatoid	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O
,	O
multiple	O
sclerosis	O
,	O
chronic	O
inflammation	O
,	O
Crohn	O
's	O
syndrome	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
)	O
and	O
for	O
inhibiting	O
the	O
production	O
of	O
Tumor	B
Necrosis	I
Factor	I
(	O
TNF	B
-	I
α	I
)	O
.	O

Combination	O
product	O
of	O
receptor	B
tyrosine	I
kinase	I
inhibitor	O
and	O
fatty	B
acid	I
synthase	I
inhibitor	O
for	O
treating	O
cancer	O
A	O
pharmaceutical	O
combination	O
product	O
is	O
disclosed	O
that	O
comprises	O
a	O
receptor	B
tyrosine	I
kinase	I
inhibitor	O
and	O
a	O
fatty	B
acid	I
synthase	I
inhibitor	O
,	O
and	O
to	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cancer	O
.	O

5h	O
-	O
pyrr0l0	O
[	O
2,3-b	O
]	O
pyrazine	O
derivatives	O
for	O
kinase	O
modulation	O
,	O
and	O
indications	O
therefor	O
Compounds	O
active	O
on	O
Fms	B
and/or	O
Kit	B
protein	I
kinases	I
are	O
described	O
,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
Fms	B
and/or	O
Kit	B
protein	I
kinases	I
.	O

Thiosemicarbazone	O
compounds	O
and	O
use	O
thereof	O
A	O
method	O
of	O
treating	O
a	O
proliferative	O
disease	O
in	O
a	O
vertebrate	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
vertebrate	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
of	O
formula	O
(	O
I	O
)	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
selected	O
from	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
and	O
phenyl	O
;	O
R2	O
is	O
selected	O
from	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
and	O
phenyl	O
;	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
or	O
a	O
salt	O
,	O
hydrate	O
,	O
or	O
iron	O
complex	O
thereof	O
,	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
compound	O
,	O
salt	O
,	O
hydrate	O
or	O
iron	O
complex	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
diluent	O
or	O
excipient	O
.	O

Deuterated	O
ibudilast	O
This	O
invention	O
relates	O
to	O
novel	O
compounds	O
that	O
are	O
2-alkyl-3-acylpyrazolo	O
[	O
l,5-	O
a	O
]	O
pyridines	O
,	O
their	O
derivatives	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
2-alkyl-3-acylpyrazolo	O
[	O
l,5-a	O
]	O
pyridine	O
compounds	O
that	O
are	O
derivatives	O
of	O
ibudilast	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitor	O
,	O
a	O
leukotriene	O
CysLTl	O
(	O
LTD4	O
)	O
antagonist	O
,	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
,	O
and/or	O
a	O
glial	O
cell	O
activation	O
suppressant	O
,	O
such	O
as	O
ibudilast	O
.	O

Tricyclic	O
heterocycle	O
derivatives	O
as	O
histamine	B
h3	I
antagonists	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
Tricyclic	O
Heterocylce	O
Derivatives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
Tricyclic	O
Heterocycle	O
Derivatives	O
and	O
the	O
use	O
of	O
these	O
compounds	O
for	O
treating	O
or	O
preventing	O
allergy	O
,	O
an	O
allergy	O
-	O
induced	O
airway	O
response	O
,	O
congestion	O
,	O
a	O
cardiovascular	O
disease	O
,	O
an	O
inflammatory	O
disease	O
,	O
a	O
gastrointestinal	O
disorder	O
,	O
a	O
neurological	O
disorder	O
,	O
a	O
metabolic	O
disorder	O
,	O
obesity	O
or	O
an	O
obesity	O
-	O
related	O
disorder	O
,	O
diabetes	O
,	O
a	O
diabetic	O
complication	O
,	O
impaired	O
glucose	O
tolerance	O
or	O
impaired	O
fasting	O
glucose	O
.	O

R1	O
is	O
formula	O
(	O
Ia	O
)	O
,	O
(	O
Ib	O
)	O
or	O
(	O
Ic	O
)	O
;	O
R2	O
is	O
alkvl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
aryl	O
,	O
heteroaryl	O
,	O
cycloalkyl	O
or	O
heterocycloalkyl	O
.	O

any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
R11	O
;	O
M1	O
is	O
-CH-	O
.	O

-C	O
(	O
halo	O
)	O
-	O
or	O
-N-	O
;	O
Y	O
is	O
-C	O
(	O
O	O
)	O
-	O
,	O
-S-	O
.	O
-S	O
(	O
O	O
)	O
-	O
,	O
-S	O
(	O
O	O
)	O
2-	O
,	O
-CH2-	O
or	O
-O-	O
,	O
such	O
that	O
Y	O
is	O
not	O
-O-	O
when	O
an	O
adjacent	O
atom	O
is	O
N.	O

Polyglutamine	O
aggregation	O
inhibitor	O
Disclosed	O
is	O
a	O
polyglutamine	O
aggregation	O
inhibitor	O
including	O
a	O
chemical	O
compound	O
represented	O
by	O
any	O
of	O
the	O
following	O
general	O
formulae	O
(	O
1	O
)	O
-	O
(	O
13	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
1	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
2	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y-	O
]	O
n	O
-	O
R4	O
;	O
(	O
3	O
)	O
R3-	O
[	O
-B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
4	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
5	O
)	O
R3-	O
[	O
-B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
6	O
)	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-T	O
[	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
R4	O
]	O
2	O
;	O
(	O
7	O
)	O
R3-B	O
(	O
OH	O
)	O
2	O
;	O
(	O
8)	O
R3-B	O
(	O
ZR1	O
)	O
-X	O
-	O
B	O
(	O
ZR2	O
)	O
-R4	O
;	O
(	O
9	O
)	O
R3-B	O
(	O
R1	O
)	O
-O	O
-	O
B	O
(	O
R2	O
)	O
-R4	O
;	O
(	O
10	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
11	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
Q-	O
]	O
n	O
-	O
R4	O
;	O
(	O
12	O
)	O
R3-	O
[	O
-P	O
-	O
X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
and	O
(	O
13	O
)	O
[	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
]	O
2B	O
(	O
ZR2	O
)	O
(	O
wherein	O
the	O
symbols	O
in	O
each	O
formula	O
carry	O
the	O
same	O
definitions	O
as	O
those	O
used	O
in	O
the	O
Specification	O
)	O
.	O

Pyridine	O
derivatives	O
as	O
vegfr-2	B
receptor	O
and	O
protein	B
tyrosine	I
kinase	I
inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
W	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
J	O
,	O
L	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
Y	O
are	O
as	O
defined	O
herein	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
or	O
solvates	O
thereof	O
,	O
for	O
use	O
-alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds-	O
in	O
therapy	O
,	O
for	O
treating	O
diseases	O
associated	O
with	O
deregulated	O
angiogenesis	O
,	O
such	O
as	O
cancer	O
and	O
skin	O
and	O
eye	O
diseases	O
.	O

Hybrid	O
tripyrrole	O
-	O
octaarginine	O
compounds	O
and	O
their	O
use	O
as	O
medicament	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
microbial	O
illnesses	O
Hybrid	O
tripyrrole	O
-	O
octaarginine	O
compounds	O
.	O

Hybrids	O
formed	O
of	O
a	O
tripyrrole	O
group	O
linked	O
to	O
a	O
polyarginine	O
peptide	O
which	O
permit	O
efficient	O
cellular	O
internalisation	O
and	O
promotes	O
greater	O
affinity	O
for	O
DNA	O
.	O

The	O
method	O
of	O
obtainment	O
and	O
uses	O
thereof	O
.	O

Methods	O
for	O
increasing	O
neurogenesis	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compounds	O
useful	O
for	O
increasing	O
neurogenesis	O
.	O

Methods	O
and	O
compounds	O
for	O
increasing	O
dopaminergic	O
differentiation	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
treating	O
neurological	O
disorders	O
by	O
increasing	O
neurogenesis	O
are	O
also	O
provided	O
.	O

Macrocyclics	O
pyrimidines	O
as	O
aurora	B
kinase	I
inhibitors	O
Macrocyclic	O
derivative	O
compounds	O
that	O
inhibit	O
protein	B
kinase	I
enzymes	O
are	O
disclosed	O
along	O
with	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
for	O
synthesizing	O
the	O
same	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
resulting	O
from	O
unregulated	O
and/or	O
disturbed	O
kinase	B
activity	O
such	O
as	O
cancers	O
,	O
psoriasis	O
,	O
viral	O
and	O
bacterial	O
infections	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulations	O
containing	O
salicylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulation	O
containing	O
(	O
a	O
)	O
salicylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
and	O
(	O
b	O
)	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
derivative	O
thereof	O
:	O
formula	O
(	O
I	O
)	O
wherein	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
selected	O
from	O
methyl	O
and	O
ethyl	O
and	O
R3	O
is	O
hydrogen	O
.	O

The	O
formulation	O
is	O
particularly	O
active	O
against	O
propionibacteria	O
,	O
and	O
may	O
therefore	O
be	O
used	O
to	O
treat	O
acne	O
.	O

Naringenin	O
complexes	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
hepatitis	O
C	O
,	O
dyslipidemia	O
,	O
insulin	B
resistance	O
,	O
and	O
inflammation	O
,	O
with	O
flavonoid-	O
sugar	O
complexes	O
.	O

Akr1c3	B
as	O
a	O
biomarker	O
,	O
methods	O
of	O
selecting	O
and	O
treating	O
patients	O
based	O
upon	O
an	O
akr1c3	B
profile	O
and	O
compounds	O
for	O
use	O
therein	O
The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
enzyme	O
AKR1C3	B
is	O
capable	O
of	O
exhibiting	O
nitroreductase	B
activity	O
and	O
activating	O
nitroaromatic	O
prodrugs	O
to	O
release	O
the	O
cytotoxic	O
effector	O
.	O

AKR1C3-activated	B
nitroaromatic	O
prodrugs	O
include	O
dinitrobenzamide	O
mustards	O
such	O
as	O
2-	O
(	O
(	O
2-bromoethyl	O
)	O
-2-	O
{	O
[	O
(	O
2-hydroxyethyl	O
)	O
amino	O
]	O
carbonyl	O
}	O
-4,6-dinitroanilino	O
)	O
ethyl	O
methanesulfonate	O
(	O
PR-104A	O
)	O
,	O
and	O
the	O
corresponding	O
pre	O
-	O
prodrug	O
2-	O
[	O
(	O
2-	O
(	O
bromoethyl	O
)	O
-2,4-dinitro-6-	O
[	O
[	O
[	O
2-	O
(	O
phosphonooxy	O
)	O
ethyl	O
]	O
amino	O
]	O
carbonyl	O
]	O
anilino	O
]	O
ethyl	O
methanesulfonate	O
(	O
PR-104	O
)	O
.	O

The	O
invention	O
provides	O
methods	O
and	O
procedures	O
to	O
determine	O
drug	O
sensitivity	O
in	O
patients	O
to	O
allow	O
the	O
identification	O
of	O
individualized	O
patient	O
profiles	O
which	O
will	O
aid	O
in	O
treating	O
diseases	O
and	O
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treatment	O
which	O
are	O
based	O
upon	O
such	O
biomarker	O
-	O
related	O
profiles	O
,	O
as	O
well	O
as	O
compounds	O
suitable	O
for	O
use	O
in	O
such	O
methods	O
and	O
compositions	O
comprising	O
""""	O
such	O
compounds	O
.	O

Fused	O
heteroaryl	O
diamide	O
compounds	O
useful	O
as	O
mmp-13	B
inhibitors	O
Disclosed	O
are	O
compounds	O
and	O
compositions	O
of	O
the	O
formula	O
I	O
as	O
described	O
herein	O
which	O
are	O
inhibitors	O
of	O
MMP-13	B
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
and	O
making	O
compounds	O
of	O
the	O
formula	O
I.	O

Pyrimidine	O
derivative	O
and	O
pyridine	O
derivative	O
both	O
having	O
pi3k	B
inhibitory	O
activity	O
A	O
pyrimidine	O
derivative	O
or	O
a	O
pyridine	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
pyrimidine	O
derivative	O
or	O
the	O
pyridine	O
derivative	O
,	O
which	O
can	O
inhibit	O
the	O
activity	O
of	O
PI3	B
K	I
to	O
control	O
many	O
biological	O
processes	O
including	O
growth	O
,	O
differentiation	O
,	O
survival	O
,	O
proliferation	O
,	O
migration	O
and	O
metabolism	O
of	O
cells	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
diseases	O
including	O
inflammatory	O
diseases	O
,	O
arteriosclerosis	O
,	O
vascular	O
/	O
cardiovascular	O
diseases	O
,	O
cancer	O
/	O
tumors	O
,	O
immune	O
diseases	O
,	O
cell	O
proliferative	O
diseases	O
and	O
infectious	O
diseases	O
.	O

Use	O
of	O
sabcomeline	O
for	O
the	O
treatment	O
of	O
add	O
or	O
adhd	O
The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
attention	O
deficit	O
disorder	O
(	O
ADD	O
)	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
to	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
associated	O
with	O
ADD	O
or	O
ADHD	O
,	O
and	O
to	O
sabcomeline	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
compositions	O
comprising	O
sabcomeline	O
for	O
use	O
in	O
said	O
treatments	O
.	O

Oxidized	O
cardiolipin	O
as	O
a	O
novel	O
pro	O
-	O
inflammatory	O
factor	O
Low	O
levels	O
of	O
antibodies	O
reactive	O
with	O
oxidised	O
Cardiolipin	O
(	O
oxCL	O
)	O
in	O
mammals	O
are	O
related	O
to	O
an	O
increased	O
risk	O
of	O
developing	O
cardivacular	O
diseases	O
,	O
auto	O
-	O
immune	O
diseases	O
or	O
inflammatory	O
conditions	O
.	O

High	O
levels	O
can	O
have	O
a	O
protective	O
function	O
and	O
in	O
general	O
there	O
is	O
a	O
negative	O
association	O
between	O
manifestations	O
of	O
these	O
conditions	O
and	O
antibodies	O
against	O
oxCL	O
.	O

Thus	O
,	O
based	O
on	O
their	O
relations	O
methods	O
of	O
monitoring	O
,	O
determining	O
and	O
diagnosing	O
as	O
well	O
as	O
methods	O
of	O
immunisation	O
and	O
therapy	O
of	O
these	O
diseases	O
and	O
conditions	O
are	O
provided	O
.	O

1,3-heterocycles	O
condensed	O
with	O
monoterpene	O
skeleton	O
,	O
their	O
use	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
The	O
invention	O
relates	O
to	O
chiral	O
compounds	O
with	O
monoterpene	O
skeleton	O
of	O
general	O
formula	O
(	O
I	O
)	O
-	O
where	O
in	O
the	O
formula	O
X	O
stands	O
for	O
O	O
or	O
H2	O
;	O
W	O
stands	O
for	O
O	O
,	O
S	O
,	O
N	O
-	O
R2	O
or	O
Ph	O
-	O
R3	O
;	O
Y	O
stands	O
for	O
O	O
or	O
N	O
-	O
R4	O
;	O
R1	O
stands	O
for	O
H	O
,	O
C1	O
-	O
4Alk	O
or	O
(	O
C2	O
)	O
1	O
-	O
4-Ph	O
;	O
R2	O
stands	O
for	O
C1	O
-	O
4Alk	O
or	O
Ph	O
-	O
R3	O
;	O
R3	O
stands	O
for	O
H	O
,	O
C1	O
-	O
4Alk	O
,	O
C1	O
-	O
4Alk	O
-	O
O	O
or	O
Hlg	O
;	O
R4	O
stands	O
for	O
H	O
or	O
Ph	O
;	O
and	O
one	O
of	O
the	O
signs	O
---	O
means	O
the	O
presence	O
of	O
a	O
double	O
bond	O
and	O
the	O
other	O
means	O
the	O
absense	O
of	O
a	O
double	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
only	O
one	O
of	O
W	O
and	O
Y	O
may	O
simultaneously	O
stand	O
for	O
oxygen	O
-	O
as	O
well	O
as	O
to	O
their	O
prodrugs	O
and	O
salts	O
formed	O
with	O
pharmaceutically	O
acceptable	O
acids	O
.	O

Furthermore	O
,	O
the	O
invention	O
relates	O
to	O
cytostatic	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
usual	O
inert	O
pharmaceutical	O
carriers	O
and/or	O
auxiliary	O
agents	O
,	O
to	O
the	O
use	O
of	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
for	O
preparing	O
cytostatic	O
pharmaceutical	O
compositions	O
as	O
well	O
as	O
to	O
the	O
treatment	O
and/or	O
curing	O
of	O
cancerous	O
illnesses	O
.	O

Pyrrolotriazines	O
as	O
alk	B
and	O
jak2	B
inhibitors	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
form	O
thereof	O
,	O
wherein	O
Q1	O
,	O
Q2	O
,	O
Q3	O
,	O
and	O
Q4	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
has	O
ALK	B
and/or	O
JAK2	B
inhibitory	O
activity	O
,	O
and	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	O
salts	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	O
[	O
7-	O
[	O
4-	O
(	O
4-Fluorophenyl	O
)	O
-6-isopropyl-2-	O
(	O
methanesulphonyl	O
-	O
methyl	O
-	O
amino	O
)	O
-pyrimidin-5-yl	O
]	O
-	O
(	O
3R,51S	O
)	O
-	O
dihydroxy	O
-	O
hept-6-enoic	O
acid	O
]	O
of	O
the	O
formula	O
(	O
I	O
)	O
salts	O
formed	O
with	O
bivalent	O
cations	O
,	O
preferably	O
with	O
calcium	O
or	O
zinc	O
ions	O
,	O
characterized	O
in	O
that	O
rosuvastatin	O
tert	O
.-	O
butylammonium	O
salt	O
is	O
reacted	O
with	O
the	O
appropriate	O
bivalent	O
cation	O
,	O
preferably	O
with	O
calcium	O
or	O
zinc	O
ions	O
in	O
a	O
mixture	O
of	O
a	O
water	O
immiscible	O
or	O
slightly	O
miscible	O
organic	O
solvent	O
and	O
water	O
and	O
the	O
formed	O
salt	O
is	O
isolated	O
.	O

Novel	O
metabolic	O
disease	O
therapy	O
The	O
invention	O
relates	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
abnormalities	O
characterized	O
by	O
abnormal	O
glucose	O
metabolism	O
,	O
including	O
diabetes	O
mellitus	O
and	O
new	O
onset	O
diabetes	O
mellitus	O
through	O
the	O
use	O
of	O
fibroblast	B
activation	I
protein	I
(	O
FAP	B
)	O
selective	O
inhibitors	O
.	O

Bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
,	O
compositions	O
and	O
methods	O
of	O
use	O
The	O
present	O
invention	O
provides	O
bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
and	O
compositions	O
comprising	O
such	O
analogs	O
.	O

The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
these	O
bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
and	O
methods	O
for	O
their	O
use	O
.	O

All	O
of	O
these	O
analogs	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
conditions	O
that	O
involve	O
the	O
Na+K+Cl-	B
co	I
-	I
transporter	I
or	O
GABAA	B
receptor	I
including	O
but	O
not	O
limited	O
to	O
addictive	O
disorders	O
,	O
Alzheimer	O
's	O
Disease	O
,	O
anxiety	O
disorders	O
,	O
ascites	O
,	O
autism	O
,	O
bipolar	O
disorder	O
,	O
cancer	O
,	O
depression	O
,	O
endothelial	O
corneal	O
dystrophy	O
,	O
edema	O
,	O
epilepsy	O
,	O
glaucoma	O
,	O
Huntington	O
's	O
Disease	O
,	O
insomnia	O
,	O
ischemia	O
,	O
migraine	O
,	O
migraine	O
with	O
aura	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
neuralgia	O
,	O
nociceptive	O
pain	O
,	O
ocular	O
diseases	O
,	O
pain	O
,	O
Parkinson	O
's	O
disease	O
,	O
personality	O
disorders	O
,	O
postherpetic	O
neuralgia	O
,	O
psychosis	O
,	O
schizophrenia	O
,	O
seizure	O
disorders	O
,	O
tinnitus	O
,	O
and	O
withdrawal	O
syndromes	O
.	O

C-7	O
isoxazolinyl	O
quinolone	O
/	O
naphthyridine	O
derivatives	O
useful	O
as	O
antibacterial	O
agents	O
The	O
present	O
invention	O
relates	O
to	O
C-7	O
isoxazolyl	O
quinoline	O
/	O
naphthyridine	O
derivatives	O
useful	O
as	O
antimicrobial	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
derivatives	O
and	O
the	O
use	O
of	O
said	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
as	O
antimicrobial	O
agents	O
against	O
pathogenic	O
microorganisms	O
,	O
particularly	O
against	O
resistant	O
microbes	O
.	O

Method	O
for	O
facilitating	O
extinction	O
training	O
using	O
d	O
-	O
cycloserine	O
Methods	O
are	O
disclosed	O
for	O
improving	O
treatment	O
of	O
various	O
medical	O
conditions	O
via	O
administration	O
of	O
D	O
-	O
cycloserine	O
to	O
facilitate	O
learning	O
.	O

Specifically	O
,	O
by	O
administering	O
D-	O
cycloserine	O
to	O
a	O
patient	O
at	O
a	O
time	O
that	O
is	O
both	O
subsequent	O
to	O
extinction	O
training	O
during	O
the	O
day	O
and	O
within	O
two	O
hours	O
prior	O
to	O
the	O
patient	O
's	O
initial	O
nightly	O
sleep	O
period	O
following	O
the	O
extinction	O
training	O
,	O
the	O
known	O
ability	O
of	O
D	O
-	O
cycloserine	O
to	O
facilitate	O
extinction	O
learning	O
can	O
be	O
enhanced	O
.	O

Therapeutic	O
uses	O
of	O
mastic	O
gum	O
fractions	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
formulations	O
comprising	O
polymeric	O
myrcene	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
an	O
isolated	O
fraction	O
of	O
polymeric	O
myrcene	O
in	O
a	O
hydrophobic	O
carrier	O
and	O
formulations	O
which	O
maintain	O
the	O
biological	O
activity	O
of	O
the	O
active	O
polymer	O
.	O

2-indolyl	O
imidazo	O
[	O
4,5-d	O
]	O
phenanthroline	O
derivatives	O
and	O
their	O
use	O
to	O
inhibit	O
angiogenesis	O
2-Indolyl	O
imidazo	O
[	O
4,5-d	O
]	O
phenanthroline	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
that	O
are	O
capable	O
of	O
inhibiting	O
angiogenesis	O
are	O
provided	O
Methods	O
of	O
inhibiting	O
angiogenesis	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
uses	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
associated	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
age-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
,	O
diabetic	O
retinopathy	O
and	O
retinal	O
vein	O
occlusion	O
are	O
also	O
provided	O
.	O

2	O
,	O
5-disubstituted	O
tetrazole	O
derivatives	O
and	O
their	O
use	O
as	O
nicotinic	B
acetylcholine	I
receptor	I
modulators	O
This	O
invention	O
relates	O
to	O
novel	O
tetrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
found	O
to	O
be	O
modulators	O
of	O
the	O
nicotinic	B
acetylcholine	I
receptors	I
.	O

Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction	O
,	O
endocrine	O
diseases	O
or	O
disorders	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-	O
degeneration	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation	O
,	O
pain	O
,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O

A	O
novel	O
medical	O
use	O
of	O
kynurenic	O
acid	O
,	O
its	O
precursors	O
and	O
derivatives	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
kynurenic	O
acid	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
hydroxy	O
,	O
NHR2	O
,	O
NR2R2	O
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
hydrogen	O
atom	O
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkyl	O
group	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
hydrogen	O
atom	O
,	O
halogen	O
atom	O
,	O
C1	O
-	O
10	O
alkyl	O
,	O
C2	O
-	O
10	O
alkenyl	O
or	O
alkynyl	O
group	O
optionally	O
substituted	O
with	O
a	O
halogen	O
atom	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
or	O
amide	O
thereof	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	O
α	O
-	O
amylase	O
.	O

Prefereably	O
,	O
in	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
R1	O
is	O
a	O
hydroxy	O
,	O
NH2	O
,	O
NH-	O
(	O
C1	O
-	O
5	O
straight	O
or	O
branched	O
alkyl	O
)	O
or	O
C1	O
-	O
5	O
straight	O
or	O
branched-	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
a	O
hydrogen	O
atom	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
a	O
hydrogen	O
atom	O
,	O
halogen	O
atom	O
or	O
CF3	O
group	O
.	O

In	O
the	O
most	O
preferred	O
embodiment	O
,	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
kynurenic	O
acid	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	B
α	I
-	I
amylase	I
.	O

Benzoxazoles	O
for	O
the	O
treatment	O
of	O
duchenne	O
muscular	O
dystrophy	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
conditions	O
such	O
as	O
Duchenne	O
muscular	O
dystrophy	O
,	O
Becker	O
muscular	O
dystrophy	O
,	O
and	O
cachexia	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
1-	O
[	O
[	O
[	O
3-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
ethyl	O
]	O
-1h	O
-	O
indol-5-yl	O
]	O
methyl	O
]	O
sulfonyl	O
]	O
pyrrolidine	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
A	O
process	O
for	O
preparation	O
of	O
1-	O
[	O
[	O
[	O
3-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
ethyl	O
]	O
-1H	O
-	O
indol-5-yl	O
]	O
methyl	O
]	O
sulfonyl	O
]	O
pyrrolidine	O
of	O
Formula	O
(	O
1	O
)	O
,	O
which	O
is	O
commonly	O
known	O
as	O
Almotriptan	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
is	O
provided	O
.	O

The	O
required	O
purity	O
of	O
almotriptan	O
malate	O
free	O
of	O
impurities	O
is	O
attained	O
in	O
three	O
different	O
ways	O
,	O
including	O
by	O
preparing	O
the	O
acid	O
addition	O
salts	O
of	O
amino	O
indole	O
compound	O
,	O
by	O
proceeding	O
through	O
the	O
almotriptan	O
succinate	O
and	O
by	O
specific	O
purification	O
of	O
almotriptan	O
malate	O
from	O
a	O
suitable	O
solvent	O
.	O

Tumor	O
-	O
specific	O
promoter	O
and	O
use	O
thereof	O
As	O
a	O
tumor	O
-	O
specific	O
promoter	O
,	O
a	O
polynucleotide	O
is	O
used	O
which	O
comprises	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
or	O
a	O
nucleotide	O
sequence	O
capable	O
of	O
hybridizing	O
to	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
under	O
stringent	O
conditions	O
and	O
which	O
has	O
a	O
tumor	O
-	O
specific	O
promoter	O
activity	O
.	O

Stable	O
pharmaceutical	O
compositions	O
with	O
high	O
bioavailability	O
The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
strontium	O
compound	O
alone	O
or	O
in	O
combination	O
with	O
vitamin	O
D	O
which	O
is	O
used	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
abnormal	O
bone	O
resorption	O
and/or	O
effective	O
as	O
a	O
supplement	O
.	O

Preparation	O
for	O
external	O
use	O
Provided	O
is	O
a	O
new	O
external	O
preparation	O
of	O
a	O
tertiary	O
amine	O
compound	O
that	O
exhibits	O
a	O
CXCR4-antagonizing	O
action	O
,	O
said	O
preparation	O
being	O
a	O
nonaqueous	O
preparation	O
containing	O
a	O
tertiary	O
amine	O
compound	O
indicated	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
in	O
solution	O
in	O
a	O
fatty	O
acid	O
ionic	O
liquid	O
.	O

(	O
1	O
)	O
(	O
In	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
through	O
R6	O
each	O
independently	O
represent	O
either	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1–4	O
lower	O
alkyl	O
group	O
;	O
n	O
1	O
through	O
n	O
3	O
are	O
integers	O
from	O
1	O
to	O
4	O
,	O
inclusive	O
;	O
A1	O
and	O
A2	O
represent	O
substituted	O
or	O
unsubstituted	O
heteroaromatic	O
ring	O
groups	O
;	O
W	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
phenylene	O
group	O
;	O
X	O
represents	O
an	O
N-	O
(	O
carboxymethyl	O
)	O
methylene	O
group	O
;	O
and	O
D	O
represents	O
a	O
C1–5	O
lower	O
alkylene	O
group	O
substituted	O
with	O
a	O
secondary	O
amino	O
group	O
having	O
a	O
C1–4	O
lower	O
alkyl	O
group	O
.	O
)	O

Fused	O
pyrrolopyridine	O
derivative	O
Disclosed	O
is	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
which	O
is	O
useful	O
as	O
an	O
active	O
ingredient	O
for	O
a	O
pharmaceutical	O
composition	O
,	O
in	O
particular	O
a	O
pharmaceutical	O
composition	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

The	O
inventors	O
have	O
intensively	O
studied	O
on	O
compounds	O
having	O
JAK	B
inhibitory	O
activity	O
,	O
and	O
found	O
that	O
the	O
compound	O
of	O
the	O
present	O
invention	O
,	O
namely	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
has	O
excellent	O
JAK	B
inhibitory	O
activity	O
and	O
is	O
thus	O
useful	O
as	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

Treatment	O
of	O
non	O
-	O
localized	O
inflammation	O
with	O
pan	O
-	O
hdac	B
inhibitors	O
Described	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
non	O
-	O
localized	O
inflammatory	O
condition	O
(	O
or	O
any	O
symptoms	O
associated	O
with	O
such	O
inflammation	O
)	O
,	O
including	O
systemic	O
inflammation	O
,	O
and	O
inflammatory	O
conditions	O
affecting	O
the	O
large	O
portions	O
of	O
or	O
the	O
whole	O
body	O
,	O
or	O
sepsis	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	B
inhibitor	O
.	O

Also	O
described	O
herein	O
are	O
methods	O
for	O
decreasing	O
iNOS	B
and	O
cytokine	B
expression	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	B
inhibitor	O
.	O

Sulfonamide	O
compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
Compounds	O
are	O
provided	O
according	O
to	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
W	O
,	O
X	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
ml	O
are	O
as	O
defined	O
herein	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
,	O
pain	O
,	O
inflammation	O
,	O
cognitive	O
disorders	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
others	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
also	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
immune	O
-	O
mediated	O
disorders	O
and	O
autoimmune	O
diseases	O
,	O
including	O
multiple	O
sclerosis	O
,	O
type-1	O
diabetes	O
mellitus	O
,	O
type-2	O
diabetes	O
mellitus	O
,	O
rheumatoid	O
arthritis	O
,	O
psoriasis	O
,	O
contact	O
dermatitis	O
,	O
obesity	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
graft	O
-	O
versus	O
host	O
disease	O
,	O
transplant	O
rejection	O
,	O
and	O
others	O
.	O

Anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
material	O
containing	O
avian	O
skin	O
-	O
derived	O
sphingomyelin	O
as	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
sphingomyelin	O
-	O
containing	O
material	O
which	O
can	O
be	O
produced	O
in	O
a	O
large	O
quantity	O
at	O
low	O
cost	O
.	O

Also	O
disclosed	O
is	O
an	O
useful	O
use	O
application	O
of	O
a	O
sphingomyelin	O
-	O
containing	O
material	O
.	O

Specifically	O
disclosed	O
is	O
an	O
anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
a	O
material	O
containing	O
a	O
sphingomyelin	O
derived	O
from	O
an	O
avain	O
skin	O
as	O
an	O
active	O
ingredient	O
.	O

SUBSTITUTED	O
IMIDAZO	O
[	O
1,5-a	O
]	O
QUINOXALINES	O
AS	O
INHIBITORS	O
OF	O
PHOSPHODIESTERASE	B
10	I
The	O
invention	O
relates	O
to	O
imidazo	O
[	O
1,5-a	O
]	O
quinoxaline	O
derivatives	O
which	O
are	O
inhibitors	O
of	O
phosphodiesterase	B
10	I
(	O
PDE10	B
)	O
useful	O
in	O
treating	O
central	O
nervous	O
system	O
diseases	O
such	O
as	O
psychosis	O
and	O
also	O
in	O
treating	O
,	O
for	O
example	O
,	O
obesity	O
,	O
type	O
2	O
diabetes	O
,	O
metabolic	O
syndrome	O
,	O
glucose	O
intolerance	O
,	O
and	O
pain	O
.	O

A	O
novel	O
4-methylbenzenesulphonate	O
salt	O
and	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O
The	O
invention	O
provides	O
a	O
4-methylbenzenesulphonate	O
salt	O
of	O
the	O
muscarinic	O
antagonist	O
(	O
R	O
)	O
-	O
1-	O
(	O
4-fluorophenethyl	O
)	O
-3-	O
(	O
(	O
S	O
)	O
-2-phenyl-2-	O
(	O
piperidin-1	O
-yl	O
)	O
propanoyloxy	O
)	O
-1-	O
azoniabicyclo	O
[	O
2.2.2	O
]	O
octane	O
and	O
its	O
use	O
in	O
therapy	O
,	O
as	O
well	O
as	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O
and	O
its	O
use	O
in	O
therapy	O
.	O

Liquiritigenin	O
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
Liquiritigenin	O
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

More	O
specifically	O
,	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
isomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
,	O
enantiomer	O
enrichments	O
,	O
solvates	O
,	O
prodrugs	O
,	O
and	O
esters	O
thereof	O
are	O
disclosed	O
,	O
in	O
which	O
n	O
is	O
0	O
or	O
1	O
,	O
R1	O
is	O
C3	O
-	O
8	O
cycloalkyl	O
and	O
R2	O
is	O
H.	O
The	O
preparation	O
methods	O
for	O
the	O
compounds	O
of	O
formula	O
I	O
,	O

the	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
and/or	O
preventing	O
cerebral	O
ischemic	O
diseases	O
,	O
neurodegenerative	O
diseases	O
and	O
inflammatory	O
diseases	O
are	O
also	O
disclosed	O
.	O

Conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	O
derivatives	O
,	O
photosensitizer	O
containing	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
same	O
The	O
present	O
invention	O
relates	O
to	O
conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	O
derivatives	O
,	O
photosensitizer	O
containing	O
the	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
the	O
same	O
.	O

The	O
conjugates	O
,	O
photosensitizer	O
and	O
composition	O
suppress	O
cancer	O
cell	O
proliferation	O
and	O
enables	O
photodynamic	O
therapy	O
at	O
the	O
same	O
time	O
by	O
conjugating	O
chlorine	O
derivatives	O
with	O
photodynamic	O
activity	O
and	O
an	O
anticancer	O
chemotherapeutic	O
agent	O
with	O
activity	O
of	O
suppressing	O
cell	O
proliferation	O
,	O
as	O
well	O
as	O
being	O
useful	O
in	O
cancer	O
therapy	O
by	O
reducing	O
the	O
toxicity	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
and	O
avoiding	O
chemotherapeutic	O
agent	O
-	O
resistance	O
.	O

Luteinising	O
hormone	O
releasing	O
hormone	O
antagonist	O
with	O
hydantoin	O
structure	O
A	O
decapeptide	O
derivative	O
of	O
formula	O
(	O
I	O
)	O
possessing	O
hydantoin	O
structure	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
said	O
decapeptide	O
derivative	O
and	O
applications	O
thereof	O
in	O
preparing	O
medications	O
are	O
provided	O
.	O

The	O
decapeptide	O
derivative	O
is	O
a	O
luteinising	O
hormone	O
releasing	O
hormone	O
(	O
LHRH	O
)	O
antagonist	O
,	O
having	O
LHRH	O
receptor	O
antagonist	O
activity	O
and	O
inhibiting	O
pituitary	O
gonadotropin	O
secretion	O
and	O
steroid	O
hormone	O
secretion	O
of	O
sexual	O
glands	O
.	O

Formula	O
(	O
I	O
)	O
,	O
R	O
-	O
Xaa3-Ser	O
-	O
Xaa5-	O
Xaa6-	O
Xaa7-	O
Xaa8-Pro	O
-	O
D	O
-	O
Ala	O
-	O
B	O

CREATINE	O
β	O
-	O
ALANINATE	O
:	O
A	O
NOVEL	O
SALT	O
FOR	O
INCREASING	O
ATHLETIC	O
PERFORMANCE	O
Disclosed	O
are	O
creatine	O
β	O
-	O
alaninate	O
,	O
compositions	O
and	O
formulations	O
containing	O
same	O
,	O
and	O
methods	O
of	O
use	O
therefor	O
.	O

Aromatic	O
fused	O
heterocyclic	O
derivative	O
and	O
pharmaceutical	O
composition	O
containing	O
same	O
Disclosed	O
is	O
a	O
compound	O
having	O
an	O
activity	O
of	O
modulating	O
a	O
histamine	B
-	I
H4	I
receptor	I
.	O

Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
Ra	O
and	O
Rb	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
;	O
X	O
represents	O
-O-	O
or	O
-S	O
(	O
O	O
)	O
p-	O
;	O
p	O
represents	O
an	O
integer	O
of	O
0	O
to	O
2	O
;	O
Y	O
represents	O
=	O
O	O
or	O
=	O
S	O
;	O
R1	O
represents	O
a	O
halogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
;	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
4	O
;	O
and	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
]	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
.	O

Inhibitors	O
of	O
kshv	B
vil6	I
and	O
human	B
il6	I
The	O
invention	O
features	O
compositions	O
comprising	O
microRNAs	O
that	O
are	O
capable	O
of	O
repressing	O
vIL6	B
or	O
hIL6	B
,	O
and	O
related	O
methods	O
of	O
using	O
the	O
microRNAs	O
for	O
treating	O
Kaposi	O
's	O
sarcoma-	O
associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
infections	O
or	O
diseases	O
caused	O
by	O
KSHV	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
bi-1356	O
and	O
metformin	O
The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
uses	O
of	O
pharmaceutical	O
compositions	O
or	O
combinations	O
of	O
a	O
DPP-4	O
inhibitor	O
with	O
metformin	O
.	O

Use	O
of	O
flubendazole	O
and	O
vinca	O
alkaloids	O
for	O
treatment	O
of	O
hematological	O
diseases	O
Provided	O
are	O
methods	O
for	O
treating	O
a	O
hematological	O
malignancy	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
flubendazole	O
alone	O
or	O
in	O
combination	O
with	O
a	O
vinca	O
alkaloid	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
comprising	O
an	O
effective	O
amount	O
of	O
flubendazole	O
and/or	O
a	O
vinca	O
alkaloid	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
disclosure	O
.	O

Process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
A	O
process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
comprises	O
:	O
a	O
)	O
reacting	O
an	O
indanone	O
derivative	O
or	O
a	O
salt	O
thereof	O
with	O
propargyl	O
amine	O
or	O
a	O
salt	O
thereof	O
in	O
the	O
presence	O
of	O
a	O
Lewis	O
acid	O
;	O
b	O
)	O
subjecting	O
the	O
resultant	O
reaction	O
mixture	O
to	O
reduction	O
.	O

Thiadiazolidinedioxide	O
p2x7	B
receptor	I
antagonists	O
The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
:	O
R1	O
is	O
C1	O
-	O
3alkyl	O
or	O
C1fluoroalkyl	O
-	O
CH2	O
;	O
R2	O
is	O
hydrogen	O
,	O
C1	O
-	O
4alkyl	O
,	O
C1fluoroalkyl	O
-	O
CH2-	O
,	O
C3	O
-	O
6cycloalkyl	O
,	O
C3	O
-	O
6cycloalkyl	O
-	O
methyl-	O
,	O
optionally	O
substituted	O
benzyl	O
,	O
or	O
optionally	O
substituted	O
heteroaryl-	O
(	O
CH2	O
)	O
n-	O
,	O
wherein	O
n	O
is	O
0	O
or	O
1	O
,	O
wherein	O
in	O
R2	O
the	O
benzyl	O
is	O
optionally	O
substituted	O
on	O
the	O
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
methyl	O
,	O
methoxy	O
,	O
fluorine	O
or	O
chlorine	O
,	O
and	O
wherein	O
in	O
R2	O
the	O
heteroaryl-	O
(	O
CH2	O
)	O
n-	O
optionally	O
substituted	O
on	O
the	O
heteroaryl	O
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
C1	O
-	O
3alkyl	O
,	O
CF3	O
,	O
methoxy	O
,	O
a	O
halogen	O
atom	O
,	O
or	O
cyano	O
;	O
and	O
wherein	O
:	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
independently	O
are	O
hydrogen	O
,	O
a	O
halogen	O
atom	O
,	O
C1	O
-	O
4alkyl	O
,	O
trifluoromethyl	O
,	O
or	O
cyano	O
,	O
such	O
that	O
one	O
or	O
both	O
of	O
R3	O
and	O
R7	O
is	O
or	O
are	O
a	O
group	O
other	O
than	O
hydrogen	O
.	O

Anti	O
-	O
inflammatory	O
extract	O
The	O
present	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
extracts	O
derived	O
from	O
plants	O
of	O
the	O
Dodonaeoideae	O
subfamily	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
an	O
anti	O
-	O
inflammatory	O
extracts	O
.	O

Other	O
aspects	O
of	O
the	O
present	O
invention	O
also	O
relate	O
to	O
pharmaceutical	O
compositions	O
comprising	O
anti	O
-	O
inflammatory	O
extracts	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
inflammation	O
in	O
a	O
subject	O
.	O

Novel	O
antithrombotic	O
agents	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
use	O
of	O
these	O
compounds	O
in	O
medicine	O
and	O
the	O
intermediates	O
involved	O
in	O
their	O
preparation	O
.	O

Novel	O
inositol	O
phosphate	O
derivatives	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1,R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Preferred	O
compounds	O
are	O
inositol	O
phosphate	O
derivatives	O
wherein	O
R1	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	O
and	O
at	O
least	O
one	O
of	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
is	O
PO3	O
2-	O
Alternative	O
compounds	O
are	O
inositol	O
phosphate	O
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
fiuorophore	O
moiety	O
The	O
compounds	O
are	O
useful	O
alone	O
or	O
in	O
combination	O
with	O
known	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
diseases	O
,	O
especially	O
cancer	O
.	O

Use	O
of	O
alpha	O
2	O
adrenergic	O
receptor	O
agonists	O
for	O
treating	O
or	O
preventing	O
psoriasis	O
Methods	O
and	O
kits	O
for	O
treating	O
or	O
preventing	O
psoriasis	O
or	O
a	O
symptom	O
associated	O
with	O
psoriasis	O
in	O
a	O
subject	O
are	O
described	O
.	O

The	O
methods	O
involve	O
topical	O
applications	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
α2	O
adrenergic	O
receptor	O
agonist	O
,	O
such	O
as	O
brimonidine	O
.	O

Compositions	O
containing	O
salmeterol	O
,	O
fluticasone	O
and	O
cromoglicic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cromoglicic	O
acid	O
and/or	O
nedocromil	O
salts	O
in	O
pharmaceutically	O
effective	O
amounts	O
in	O
a	O
pharmaceutical	O
composition	O
containing	O
salmeterol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
β2-agonisti	O
combined	O
with	O
fluticasone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
corticosteroid	O
for	O
the	O
treatment	O
of	O
the	O
respiratory	O
diseases	O
.	O

Compounds	O
which	O
effecttively	O
remove	O
tumor	O
or	O
cancer	O
cell	O
Compounds	O
which	O
effectively	O
remove	O
tumor	O
or	O
cancer	O
cell	O
and	O
their	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
tumor	O
or	O
cancer	O
by	O
making	O
immune	O
system	O
find	O
tumor	O
or	O
cancer	O
cell	O
are	O
provided	O
.	O

In	O
detail	O
,	O
by	O
immune	O
identifier	O
of	O
tumor	O
or	O
cancer	O
cell	O
the	O
immune	O
system	O
of	O
organism	O
can	O
find	O
and	O
remove	O
them	O
in	O
time	O
.	O

The	O
substances	O
used	O
for	O
immune	O
identifier	O
are	O
organic	O
molecules	O
(	O
including	O
organometallic	O
compounds	O
)	O
which	O
are	O
adhered	O
to	O
on	O
the	O
surface	O
of	O
the	O
cell	O
.	O

These	O
organic	O
molecules	O
are	O
linked	O
with	O
sugar	O
molecule	O
.	O

Docosahexaenoic	O
acid	O
ethyl	O
esters	O
and/or	O
its	O
derivatives	O
for	O
prevention	O
and/or	O
treatment	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
DHA	O
ethyl	O
esters	O
with	O
over	O
80	O
%	O
by	O
weight	O
purity	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
age	O
related	O
macular	O
degeneration	O
,	O
that	O
uses	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARƴ	O
)	O
as	O
target	O
.	O

Controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
containing	O
quetiapine	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
discloses	O
a	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
and	O
preparation	O
method	O
as	O
well	O
as	O
the	O
use	O
thereof	O
.	O

Said	O
preparation	O
contains	O
quetiapine	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
5	O
-	O
50	O
%	O
of	O
polyoxyethylene	O
in	O
amount	O
of	O
total	O
weight	O
of	O
said	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
,	O
and	O
remaining	O
amount	O
of	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Method	O
of	O
accelerating	O
corneal	O
wound	O
healing	O
The	O
topical	O
ophthalmic	O
use	O
of	O
5,6,7-trihydroxyheptanoic	O
acid	O
and	O
analogs	O
for	O
the	O
acceleration	O
of	O
corneal	O
wound	O
healing	O
in	O
humans	O
,	O
is	O
disclosed	O
.	O

Pharmaceutical	O
compositions	O
containing	O
berberine	O
for	O
treatment	O
or	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
associated	O
with	O
anti	O
-	O
psychotic	O
drugs	O
The	O
compositions	O
and	O
methods	O
disclosed	O
herein	O
are	O
of	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

In	O
particular	O
,	O
the	O
compositions	O
and	O
methods	O
include	O
treatment	O
of	O
weight	O
gain	O
and	O
obesity	O
with	O
berberine	O
and/or	O
berberine	O
analogs	O
alone	O
or	O
in	O
combination	O
thereof	O
to	O
cause	O
a	O
reduction	O
in	O
an	O
individual	O
's	O
weight	O
or	O
prevent	O
weight	O
gain	O
or	O
obesity	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
weight	O
gain	O
and	O
obesity	O
are	O
associated	O
with	O
administration	O
of	O
anti	O
-	O
psychotic	O
drugs	O
.	O

In	O
an	O
alternative	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
provide	O
berberine	O
or	O
berberine	O
analogs	O
alone	O
or	O
for	O
coadministration	O
with	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

In	O
an	O
additional	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
further	O
include	O
a	O
natural	O
product	O
.	O

The	O
usefulness	O
of	O
the	O
present	O
invention	O
is	O
that	O
berberine	O
and	O
berberine	O
analogs	O
do	O
not	O
have	O
synergistic	O
effects	O
with	O
other	O
drugs	O
and	O
administration	O
results	O
in	O
few	O
side	O
effects	O
.	O

Such	O
characteristics	O
of	O
berberine	O
or	O
berberine	O
analogs	O
are	O
a	O
great	O
improvement	O
able	O
to	O
support	O
the	O
widespread	O
use	O
of	O
the	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
as	O
therapeutics	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

Macrolide	O
inhibitors	O
of	O
mtor	B
The	O
present	O
invention	O
relates	O
to	O
new	O
macrolide	O
inhibitors	O
of	O
mTOR	B
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
(	O
Formula	O
I	O
)	O
.	O

Perifosine	O
and	O
capecitabine	O
as	O
a	O
combined	O
treatment	O
for	O
cancer	O
Treatment	O
regimens	O
comprising	O
co	O
-	O
treatment	O
of	O
cancer	O
with	O
perifosine	O
and	O
capecitabine	O
are	O
disclosed	O
herein	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
unit	O
dosage	O
forms	O
thereof	O
formulated	O
to	O
be	O
suitable	O
for	O
use	O
in	O
said	O
treatment	O
regimens	O
.	O

Heterocyclic	O
compounds	O
and	O
their	O
use	O
as	O
pi3k	B
inhibitors	O
Substituted	O
bicyclic	O
heteroaryls	O
and	O
compositions	O
containing	O
them	O
,	O
for	O
the	O
treatment	O
of	O
general	O
inflammation	O
,	O
arthritis	O
,	O
rheumatic	O
diseases	O
,	O
osteoarthritis	O
,	O
inflammatory	O
bowel	O
disorders	O
,	O
inflammatory	O
eye	O
disorders	O
,	O
inflammatory	O
or	O
unstable	O
bladder	O
disorders	O
,	O
psoriasis	O
,	O
skin	O
complaints	O
with	O
inflammatory	O
components	O
,	O
chronic	O
inflammatory	O
conditions	O
,	O
including	O
but	O
not	O
restricted	O
to	O
autoimmune	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosis	O
(	O
SLE	O
)	O
,	O
myestenia	O
gravis	O
,	O
rheumatoid	O
arthritis	O
,	O
acute	O
disseminated	O
encephalomyelitis	O
,	O
idiopathic	O
thrombocytopenic	O
purpura	O
,	O
multiples	O
sclerosis	O
,	O
Sjoegren	O
's	O
syndrome	O
and	O
autoimmune	O
hemolytic	O
anemia	O
,	O
allergic	O
conditions	O
including	O
all	O
forms	O
of	O
hypersensitivity	O
,	O
The	O
present	O
invention	O
also	O
enables	O
methods	O
for	O
treating	O
cancers	O
that	O
are	O
mediated	O
,	O
dependent	O
on	O
or	O
associated	O
with	O
p110	B
activity	O
,	O
including	O
but	O
not	O
restricted	O
to	O
leukemias	O
,	O
such	O
as	O
Acute	O
Myeloid	O
leukaemia	O
(	O
AML	O
)	O
Myelo	O
-	O
dysplastic	O
syndrome	O
(	O
MDS	O
)	O
myelo	O
-	O
proliferative	O
diseases	O
(	O
MPD	O
)	O
Chronic	O
Myeloid	O
Leukemia	O
(	O
CML	O
)	O
T	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
T	O
-	O
ALL	O
)	O
B	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
B	O
-	O
ALL	O
)	O
Non	O
Hodgkins	O
Lymphoma	O
(	O
NHL	O
)	O
B	O
-	O
cell	O
lymphoma	O
and	O
solid	O
tumors	O
,	O
such	O
as	O
breast	O
cancer	O
.	O

Fully	O
openable	O
multifunction	O
drawer	O
for	O
household	O
appliances	O
The	O
present	O
invention	O
describes	O
a	O
washing	O
machine	O
(	O
1	O
)	O
comprising	O
an	O
external	O
chassis	O
(	O
11	O
)	O
,	O
on	O
the	O
front	O
panel	O
(	O
12	O
)	O
of	O
which	O
are	O
accessible	O
at	O
least	O
one	O
aperture	O
(	O
13	O
)	O
,	O
equipped	O
with	O
a	O
door	O
(	O
14	O
)	O
,	O
for	O
the	O
loading	O
and/or	O
unloading	O
of	O
garments	O
into	O
or	O
from	O
the	O
rotary	O
drum	O
inside	O
said	O
chassis	O
(	O
11	O
)	O
,	O
a	O
soap	O
dispenser	O
(	O
2	O
)	O
of	O
washing	O
agents	O
assembled	O
on	O
the	O
slidable	O
drawer	O
support	O
structure	O
(	O
21	O
)	O
able	O
to	O
additionally	O
contain	O
,	O
adjacent	O
to	O
compartments	O
(	O
22	O
;	O
221	O
,	O
222	O
,	O
223	O
,	O
224	O
)	O
,	O
one	O
or	O
more	O
receptacles	O
(	O
23	O
)	O
,	O
able	O
to	O
contain	O
and	O
house	O
various	O
types	O
of	O
useful	O
objects	O
and	O
accessories	O
,	O
and	O
a	O
control	O
panel	O
(	O
26	O
;	O
261	O
,	O
262	O
)	O
.	O

Microsomal	O
prostaglandin	B
e	I
syntase-1	I
inhibitors	O
This	O
invention	O
relates	O
to	O
piperidine	O
derivatives	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

Aromatic	O
butan-2-ol	O
compounds	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
Provided	O
are	O
compounds	O
shown	O
by	O
formula	O
I	O
,	O
optical	O
isomers	O
,	O
racemes	O
,	O
diastereoisomers	O
,	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
wherein	O
each	O
substituent	O
has	O
the	O
meaning	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
provided	O
are	O
their	O
preparation	O
methods	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
said	O
compounds	O
for	O
preparation	O
of	O
drugs	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
or	O
disorders	O
caused	O
by	O
the	O
infection	O
of	O
mycobacterium	O
tuberculosis	O
.	O

Cycloamino	O
derivatives	O
as	O
gpr119	B
agonists	O
Therapeutic	O
compounds	O
are	O
disclosed	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
,	O
including	O
type	O
II	O
diabetes	O
.	O

The	O
compounds	O
have	O
activity	O
as	O
agonists	O
of	O
GPR119	B
.	O

Compounds	O
having	O
the	O
stereochemistry	O
of	O
formula	O
(	O
la	O
)	O
may	O
also	O
demonstrate	O
DPP	B
-	I
IV	I
inhibitory	O
activity	O
.	O

SUBSTITUTED	O
THIAZOLIDINEDIONE	O
INDAZOLES	O
,	O
INDOLES	O
AND	O
BENZOTRIAZOLES	O
AS	O
ESTROGEN	O
-	O
RELATED	O
RECEPTOR	O
-	O
α	O
MODULATORS	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
compositions	O
,	O
intermediates	O
and	O
derivatives	O
thereof	O
and	O
for	O
treating	O
a	O
condition	O
including	O
but	O
not	O
limited	O
to	O
ankylosing	O
spondylitis	O
,	O
artherosclerosis	O
,	O
arthritis	O
(	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
infectious	O
arthritis	O
,	O
childhood	O
arthritis	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
)	O
,	O
bone	O
-	O
related	O
diseases	O
(	O
including	O
those	O
related	O
to	O
bone	O
formation	O
)	O
,	O
breast	O
cancer	O
(	O
including	O
those	O
unresponsive	O
to	O
anti	O
-	O
estrogen	O
therapy	O
)	O
,	O
cardiovascular	O
disorders	O
,	O
cartilage	O
-	O
related	O
disease	O
(	O
such	O
as	O
cartilage	O
injury	O
/	O
loss	O
,	O
cartilage	O
degeneration	O
,	O
and	O
those	O
related	O
to	O
cartilage	O
formation	O
)	O
,	O
chondrodysplasia	O
,	O
chondrosarcoma	O
,	O
chronic	O
back	O
injury	O
,	O
chronic	O
bronchitis	O
,	O
chronic	O
inflammatory	O
airway	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
disorders	O
of	O
energy	O
homeostasis	O
,	O
gout	O
,	O
pseudogout	O
,	O
lipid	O
disorders	O
,	O
metabolic	O
syndrome	O
,	O
multiple	O
myeloma	O
,	O
obesity	O
,	O
osteoarthritis	O
,	O
osteogenesis	O
imperfecta	O
,	O
osteolytic	O
bone	O
metastasis	O
,	O
osteomalacia	O
,	O
osteoporosis	O
,	O
Paget	O
's	O
disease	O
,	O
periodontal	O
disease	O
,	O
polymyalgia	O
rheumatica	O
,	O
Reiter	O
's	O
syndrome	O
,	O
repetitive	O
stress	O
injury	O
,	O
hyperglycemia	O
,	O
elevated	O
blood	O
glucose	O
level	O
,	O
and	O
insulin	O
resistance	O
.	O

Xenon	O
-	O
based	O
inhalable	O
drug	O
for	O
preventing	O
addiction	O
relapses	O
in	O
humans	O
The	O
invention	O
relates	O
to	O
a	O
gas	O
composition	O
containing	O
xenon	O
gas	O
for	O
use	O
in	O
preventing	O
the	O
relapse	O
of	O
a	O
patient	O
who	O
has	O
been	O
weaned	O
from	O
at	O
least	O
one	O
psychotropic	O
product	O
which	O
resulted	O
in	O
said	O
patient	O
becoming	O
habituated	O
,	O
the	O
xenon	O
being	O
administered	O
to	O
the	O
patient	O
by	O
inhalation	O
.	O

The	O
composition	O
of	O
the	O
invention	O
contains	O
an	O
effective	O
volume	O
proportion	O
of	O
xenon	O
,	O
in	O
particular	O
from	O
5	O
to	O
70	O
%	O
by	O
volume	O
of	O
xenon	O
.	O

DRAWING	O
:	O
FIG	O
.	O

5	O
:	O
Nombres	O
de	O
pression	O
sur	O
le	O
levier	O
/	O
session	O
Number	O
of	O
presses	O
on	O
the	O
lever	O
/	O
session	O
Levier	O
respectif	O
inactif	O
Respective	O
inactive	O
lever	O
rechute	O
relapse	O

A	O
role	O
for	O
somatostatin	O
to	O
modulate	O
initiation	O
of	O
follicular	O
growth	O
in	O
the	O
human	O
ovary	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
and/or	O
preventing	O
gynecological	O
diseases	O
,	O
by	O
modulating	O
a	O
receptor	O
which	O
is	O
specifically	O
and	O
highly	O
expressed	O
in	O
granulosa	O
cells	O
and	O
oocytes	O
of	O
primates	O
.	O

6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
-	O
based	O
composition	O
and	O
method	O
for	O
the	O
production	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
industry	O
,	O
and	O
specifically	O
to	O
a	O
composition	O
based	O
on	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
(	O
ubinone	O
,	O
ubiquinone	O
,	O
coenzyme	O
Q10	O
)	O
in	O
liquid	O
form	O
,	O
which	O
can	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
various	O
illnesses	O
,	O
for	O
restoring	O
fitness	O
for	O
work	O
,	O
and	O
also	O
as	O
a	O
food	O
additive	O
.	O

In	O
addition	O
to	O
the	O
active	O
substance	O
,	O
the	O
composition	O
comprises	O
a	O
nonionic	O
surface	O
-	O
active	O
substance	O
,	O
an	O
antioxidant	O
,	O
a	O
preservative	O
,	O
a	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
,	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
a	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
water	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
high	O
bioaccessibility	O
and	O
an	O
extended	O
storage	O
life	O
.	O

The	O
method	O
for	O
producing	O
the	O
composition	O
consists	O
in	O
that	O
the	O
nonionic	O
surface	O
-	O
active	O
substance	O
and	O
the	O
antioxidant	O
are	O
mixed	O
and	O
heated	O
to	O
40	O
-	O
120	O
°	O
C	O
,	O
the	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
are	O
dissolved	O
in	O
the	O
solution	O
produced	O
,	O
the	O
resultant	O
mixture	O
is	O
cooled	O
to	O
30	O
-	O
60	O
°	O
С	O
and	O
poured	O
under	O
intensive	O
stirring	O
into	O
a	O
mixed	O
solution	O
,	O
preheated	O
to	O
30	O
-	O
100	O
°	O
С	O
,	O
of	O
the	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
preservative	O
in	O
water	O
.	O

6-	O
(	O
sulfonylaryl	O
)	O
pyrido	O
[	O
2,3-d	O
]	O
pyrimidin-7	O
(	O
8h	O
)	O
-ones	O
for	O
the	O
treatment	O
of	O
cns	O
disorders	O
Provided	O
herein	O
are	O
PAK	B
inhibitors	O
and	O
methods	O
of	O
utilizing	O
PAK	B
inhibitors	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O
such	O
as	O
neuropsychiatric	O
disoders	O
.	O

Anti	O
-	O
wssv	O
and/or	O
tsv	O
nucleic	O
acid	O
drug	O
An	O
anti	O
-	O
WSSV	O
and/or	O
TSV	O
nucleic	O
acid	O
drug	O
,	O
the	O
active	O
ingredients	O
of	O
which	O
are	O
five	O
nucleic	O
acids	O
whose	O
nucleotide	O
sequences	O
are	O
respectively	O
sequence	O
1	O
,	O
sequence	O
2	O
,	O
sequence	O
3	O
,	O
sequence	O
4	O
and	O
sequence	O
5	O
in	O
the	O
sequence	O
list	O
.	O

Amids	O
substituted	O
indazole	O
derivativees	O
as	O
ploy	B
(	I
adp	I
-	I
ribose	I
)	I
polymerase	I
inhibitors	O
Amide	O
substituted	O
indazoles	O
and	O
benzotriazoles	O
as	O
inhibitors	O
of	O
the	O
enzyme	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
mono	O
-	O
therapies	O
in	O
tumors	O
with	O
specific	O
defects	O
in	O
DNA	O
-	O
repair	O
pathways	O
,	O
as	O
enhancers	O
of	O
certain	O
DNA	O
-	O
damaging	O
agents	O
such	O
as	O
anticancer	O
agents	O
and	O
radiotherapy	O
,	O
for	O
reducing	O
cell	O
necrosis	O
(	O
in	O
stroke	O
and	O
myocardial	O
infarction	O
)	O
,	O
regulating	O
inflammation	O
and	O
tissue	O
injury	O
,	O
treating	O
retroviral	O
infections	O
,	O
and	O
protecting	O
against	O
the	O
toxicity	O
of	O
chemotherapy	O
.	O

Nitrogenated	O
aromatic	O
heterocyclic	O
ring	O
derivative	O
A	O
nitrogenated	O
aromatic	O
heterocyclic	O
ring	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
W	O
represents	O
CR3	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R9	O
represents	O
a	O
pyrazolyl	O
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
or	O
the	O
like	O
;	O
and	O
R12	O
and	O
R13	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
(	O
wherein	O
N-	O
[	O
2-chloro-4-	O
(	O
6,7-dimethoxy-4-	O
quinolyloxy	O
)	O
phenyl	O
]	O
-N'-	O
(	O
5-methyl-3-isooxazolyl	O
)	O
urea	O
is	O
excluded	O
from	O
the	O
derivative	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
FGFR	B
inhibitor	O
or	O
the	O
like	O
which	O
comprises	O
the	O
derivative	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O

Polydeoxyribonucleotides	O
(	O
pdrns	O
)	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
and	O
polydeoxyribonucleotide	O
-	O
based	O
compositions	O
for	O
the	O
aforesaid	O
use	O
The	O
use	O
of	O
polydeoxyribonucleotides	O
(	O
PDRNs	O
)	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
is	O
described	O
.	O

Compositions	O
comprising	O
the	O
synergistic	O
combination	O
of	O
polydeoxyribonucleotides	O
and	O
one	O
methyl	O
amide	O
,	O
such	O
as	O
carnitine	O
,	O
are	O
also	O
described	O
,	O
which	O
are	O
particularly	O
effective	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
may	O
include	O
further	O
optional	O
active	O
ingredients	O
,	O
such	O
as	O
a	O
calcium	O
salt	O
,	O
vitamins	O
of	O
the	O
D	O
or	O
B	O
groups	O
,	O
a	O
sodium	O
salt	O
and	O
a	O
potassium	O
salt	O
,	O
preferably	O
used	O
in	O
combination	O
.	O

Novel	O
polymorph	O
of	O
bis	O
[	O
(	O
e	O
)	O
-7-	O
[	O
4-	O
(	O
4-fluorophenyl	O
)	O
-6-iso	O
-	O
propyl-2-	O
[	O
methyl	O
(	O
methylsulfonyl	O
)	O
amino	O
]	O
pyrimidin-5-yl	O
]	O
(	O
3r,5s	O
)	O
-3,5-dihydroxyhept-6-enoic	O
acid	O
]	O
calcium	O
salt	O
Disclosed	O
are	O
novel	O
polymorphic	O
forms	O
of	O
bis	O
[	O
(	O
E	O
)	O
-7-	O
[	O
4-	O
(	O
4-fluorophenyl	O
)	O
-6-iso	O
-	O
propyl-2-	O
[	O
methyl	O
(	O
methylsulfonyl	O
)	O
amino	O
]	O
pyrimidin-5-yl	O
]	O
(	O
3R,5S	O
)	O
-3,5-dihydroxyhept-6-enoic	O
acid	O
]	O
calcium	O
.	O

Composition	O
suppressing	O
matrix	B
-	I
metalloproteinase	I
activity	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
that	O
has	O
the	O
effect	O
of	O
suppressing	O
matrix	B
-	I
metalloproteinase	I
activity	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
pertains	O
to	O
a	O
composition	O
which	O
suppresses	O
matrix	B
-	I
metalloproteinase	I
activity	O
and	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
glucose	O
-	O
metabolism	O
inhibitor	O
.	O

Novel	O
antibiotically	O
active	O
compound	O
and	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotically	O
active	O
compound	O
and	O
to	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O
,	O
and	O
more	O
specifically	O
relates	O
to	O
a	O
compound	O
that	O
inhibits	O
microorganism	O
protein	O
synthesis	O
and	O
to	O
a	O
use	O
for	O
the	O
compound	O
.	O

Atorbastatin	O
-	O
containing	O
medicinal	O
tablet	O
Provided	O
is	O
a	O
medicinal	O
tablet	O
,	O
particularly	O
an	O
orally	O
disintegrating	O
tablet	O
,	O
in	O
which	O
unpleasant	O
taste	O
of	O
atorbastatin	O
in	O
the	O
oral	O
cavity	O
is	O
reduced	O
(	O
drug	O
compliance	O
)	O
,	O
and	O
which	O
can	O
be	O
dispersed	O
or	O
eluted	O
rapidly	O
in	O
the	O
digestive	O
tract	O
.	O

This	O
medicinal	O
tablet	O
comprises	O
atorbastatin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
glycyrrhetinic	O
acid	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Isoxazol-3	O
(	O
2h	O
)	O
-one	O
analogs	O
as	O
plasminogen	B
inhibitors	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
fibrinolysis	O
related	O
diseases	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
hydrogen	O
;	O
R2	O
is	O
C1-C10	O
alkyl	O
,	O
which	O
C1-C10	O
alkyl	O
comprises	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
,	O
selected	O
from	O
O	O
and	O
N	O
,	O
or	O
0	O
,	O
1	O
or	O
2	O
acid	O
,	O
ester	O
or	O
amide	O
functionalities	O
,	O
and	O
said	O
C1-C10	O
alkyl	O
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	O
,	O
halogen	O
or	O
CF3	O
,	O
or	O
-XR20	O
,	O
wherein	O
X	O
is	O
a	O
bond	O
or	O
_	O
-CH2-	O
,	O
and	O
R20	O
is	O
a	O
4	O
to	O
10	O
membered	O
,	O
monocyclic	O
or	O
bicyclic	O
heterocyclic	O
aromatic	O
or	O
non	O
-	O
aromatic	O
ring	O
containing	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
selected	O
from	O
O	O
and	O
N	O
,	O
and	O
R20	O
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	O
,	O
halogen	O
or	O
CF3	O
,	O
pharmaceutical	O
compositions	O
,	O
medical	O
uses	O
and	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
disease	O
or	O
condition	O
in	O
which	O
modulation	O
of	O
fibrinolysisis	O
is	O
beneficial	O
.	O

Phosphatidylcholine	O
in	O
the	O
treatment	O
ophosphatidylcholinef	O
tumours	O
The	O
present	O
invention	O
regards	O
the	O
use	O
of	O
phosphatidylcholine	O
in	O
the	O
treatment	O
of	O
tumoral	O
pathologies	O
.	O

In	O
particular	O
,	O
the	O
phosphatidylcholine	O
according	O
to	O
the	O
present	O
invention	O
is	O
polyunsaturated	O
phosphatidylcholine	O
.	O

The	O
phosphatidylcholine	O
suitable	O
for	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
extraction	O
from	O
egg	O
-	O
yolk	O
or	O
from	O
soybean	O
seeds	O
.	O

The	O
tumoral	O
pathologies	O
that	O
can	O
be	O
treated	O
according	O
to	O
the	O
invention	O
are	O
in	O
particular	O
hepatoma	O
and	O
mammary	O
tumour	O
.	O

Novel	O
esters	O
of	O
(	O
acyloxymethyl	O
)	O
acrylamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
thioredoxin	O
-	O
thioredoxin	B
reductase	I
system	O
The	O
subject	O
of	O
the	O
present	O
invention	O
are	O
novel	O
esters	O
of	O
(	O
acyloxymethyl	O
)	O
acrylamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
production	O
of	O
drugs	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
oncogenic	O
diseases	O
and	O
diseases	O
connected	O
with	O
increased	O
cell	O
proliferation	O
.	O

Agent	O
for	O
inducing	O
endogenous	O
interferon	O
The	O
invention	O
relates	O
to	O
medicine	O
and	O
can	O
be	O
used	O
for	O
treating	O
a	O
range	O
of	O
diseases	O
in	O
the	O
treatment	O
of	O
which	O
interferon	O
is	O
used	O
.	O

The	O
agent	O
for	O
inducing	O
endogenous	O
interferon	O
is	O
comprised	O
of	O
the	O
compound	O
6-	O
(	O
3-methoxycarbonyl	O
phenyl	O
)	O
amino-2,4	O
(	O
1Н	O
,	O
ЗН	O
)	O
-pyrimidinedione	O
C12H11N3О4	O
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
.	O

The	O
preparation	O
exhibits	O
greater	O
activity	O
both	O
when	O
injected	O
and	O
when	O
administered	O
orally	O
.	O

Intraesophageal	O
administration	O
of	O
targeted	O
nitroxide	O
agents	O
for	O
protection	O
against	O
ionizing	O
irradiation	O
-	O
induced	O
esophagatis	O
Provided	O
herein	O
are	O
compositions	O
and	O
related	O
methods	O
useful	O
for	O
prevention	O
or	O
mitigation	O
of	O
ionizing	O
radiation	O
-	O
induced	O
esophagitis	O
.	O

The	O
compositions	O
comprise	O
compounds	O
comprising	O
a	O
nitroxide	O
-	O
containing	O
group	O
attached	O
to	O
a	O
mitochondria	O
-	O
targeting	O
group	O
.	O

The	O
compounds	O
can	O
be	O
cross	O
-	O
linked	O
into	O
dimers	O
without	O
loss	O
of	O
activity	O
.	O

The	O
method	O
comprises	O
delivering	O
a	O
compound	O
,	O
as	O
described	O
herein	O
,	O
to	O
a	O
patient	O
in	O
an	O
amount	O
and	O
dosage	O
regimen	O
effective	O
to	O
prevent	O
or	O
mitigate	O
esophageal	O
damage	O
caused	O
by	O
radiation	O
.	O

Therapeutic	O
compositions	O
comprising	O
rilpivirine	O
hcl	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
The	O
invention	O
provides	O
multilayer	O
tablets	O
that	O
contain	O
rilpivirine	O
hydrochloride	O
,	O
emtricitabine	O
,	O
and	O
tenofivir	O
disoproxil	O
fumarate	O
.	O

The	O
tablets	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
.	O

Composition	O
and	O
use	O
of	O
a	O
fermented	O
olive	O
leaf	O
product	O
for	O
the	O
treatment	O
of	O
nail	O
and	O
skin	O
infections	O
.	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
the	O
treatment	O
of	O
nail	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
olive	O
leaf	O
product	O
,	O
and	O
oleuropein	O
and	O
derivatives	O
thereof	O
,	O
for	O
the	O
preparation	O
of	O
a	O
product	O
for	O
the	O
treatment	O
of	O
infections	O
,	O
in	O
particular	O
nail	O
infections	O
,	O
more	O
in	O
particular	O
bacterial	O
and/or	O
fungal	O
nail	O
infections	O
.	O

The	O
compositions	O
according	O
to	O
the	O
invention	O
are	O
based	O
on	O
natural	O
products	O
and	O
have	O
a	O
lower	O
chance	O
to	O
induce	O
allergies	O
in	O
users	O
than	O
conventional	O
products	O
.	O

Antifungal	O
composition	O
including	O
polycyclic	O
peptide	O
compound	O
and	O
method	O
for	O
producing	O
same	O
The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
including	O
as	O
an	O
active	O
ingredient	O
a	O
AN1542	O
strain	O
(	O
accession	O
number	O
:	O
KCTC	O
12113BP	O
)	O
in	O
a	O
Streptomyces	O
sp.	O
having	O
antifungal	O
activity	O
,	O
an	O
antifungal	O
composition	O
including	O
a	O
compound	O
represented	O
by	O
Formula	O
1	O
or	O
Formula	O
2	O
or	O
a	O
strain	O
producing	O
same	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
.	O

The	O
compound	O
or	O
the	O
strain	O
of	O
the	O
present	O
invention	O
exhibits	O
strong	O
antifungal	O
activity	O
to	O
pathogenic	O
microorganisms	O
and	O
antibiotics	O
-	O
tolerant	O
bacteria	O
,	O
and	O
in	O
particular	O
,	O
can	O
be	O
useful	O
in	O
treating	O
contagious	O
diseases	O
due	O
to	O
super	O
bacteria	O
by	O
exhibiting	O
strong	O
antifungal	O
activity	O
to	O
MRSA	O
,	O
QRSA	O
,	O
VRSA	O
,	O
and	O
VRE	O
.	O

Pyrazole	O
derivatives	O
as	O
erk	B
inhibitors	O
This	O
invention	O
describes	O
substituted	O
pyrazole	O
derivatives	O
of	O
Formula	O
I	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

These	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
modification	O
of	O
the	O
activity	O
of	O
ERK	B
would	O
have	O
a	O
positive	O
therapeutic	O
outcome	O
,	O
for	O
instance	O
various	O
cancers	O
,	O
psoriasis	O
and	O
actinic	O
keratosis	O
.	O

Therapeutic	O
eye	O
drop	O
comprising	O
doxycycline	O
and	O
a	O
stabilizer	O
The	O
present	O
invention	O
provides	O
stable	O
aqueous	O
doxycycline	O
aqueous	O
solutions	O
suitable	O
for	O
pharmaceutical	O
,	O
especially	O
ophthalmic	O
,	O
use	O
.	O

The	O
doxycycline	O
aqueous	O
solutions	O
have	O
a	O
pH	O
ranging	O
from	O
4.5	O
-	O
8	O
,	O
and	O
contain	O
an	O
antioxidant	O
and	O
a	O
stabilizer	O
such	O
as	O
caffeine	O
,	O
creatine	O
or	O
mixtures	O
thereof	O
.	O

The	O
solutions	O
have	O
improved	O
lifetimes	O
and	O
can	O
be	O
used	O
topically	O
.	O

Dextrin	O
inclusion	O
complex	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
formulation	O
comprising	O
said	O
inclusion	O
complex	O
A	O
dextrin	O
inclusion	O
complex	O
of	O
total	O
ginsenoside	O
and	O
total	O
flavone	O
of	O
epimedium	O
and	O
the	O
preparation	O
method	O
thereof	O
are	O
disclosed	O
.	O

A	O
pharmaceutical	O
formulation	O
comprising	O
the	O
dextrin	O
inclusion	O
complex	O
and	O
the	O
use	O
of	O
the	O
dextrin	O
inclusion	O
complex	O
in	O
preparing	O
a	O
pharmaceutical	O
formulation	O
are	O
also	O
disclosed	O
.	O

Fucoidan	O
for	O
thrombolysis	O
,	O
derived	O
from	O
seaweed	O
To	O
study	O
different	O
types	O
of	O
thrombolytic	O
agents	O
,	O
both	O
thrombolysis	O
and	O
stimulation	O
of	O
fucoidan	O
were	O
studied	O
in	O
a	O
mouse	O
model	O
of	O
ferric	O
chloride	O
-	O
induced	O
arterial	O
thrombosis	O
and	O
were	O
compared	O
with	O
those	O
of	O
a	O
heparin	O
and	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
.	O

Thrombosis	O
was	O
induced	O
by	O
applying	O
a	O
filter	O
paper	O
saturated	O
with	O
5	O
%	O
FeCl3	O
to	O
the	O
left	O
carotid	O
artery	O
.	O

20	O
minutes	O
after	O
complete	O
occlusion	O
,	O
several	O
test	O
preparations	O
including	O
a	O
fucoidan	O
source	O
from	O
Undaria	O
pinnatifida	O
sporophylls	O
were	O
intravenously	O
injected	O
to	O
each	O
mouse	O
group	O
by	O
various	O
dosages	O
of	O
10	O
-	O
200	O
mg	O
/	O
kg-1	O
.	O

To	O
study	O
the	O
stimulation	O
effect	O
of	O
fucoidan	O
with	O
respect	O
to	O
t	B
-	I
PA	I
,	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	B
-	I
PA	I
was	O
injected	O
by	O
a	O
dose	O
of	O
1	O
-	O
10	O
mg	O
/	O
kg	O
.	O

Then	O
,	O
the	O
time	O
to	O
reperfusion	O
was	O
measured	O
.	O

As	O
a	O
result	O
,	O
an	O
occluded	O
aorta	O
was	O
dose	O
-	O
dependently	O
reperfused	O
,	O
and	O
the	O
reperfusion	O
was	O
observed	O
at	O
37.5±12.4	O
minutes	O
after	O
the	O
administration	O
of	O
100	O
mg	O
/	O
kg-1	O
of	O
unfractionated	O
fucoidan	O
.	O

The	O
time	O
to	O
reperfusion	O
was	O
retarded	O
to	O
55.0±8.0	O
minutes	O
when	O
a	O
large	O
amount	O
of	O
fucoidan	O
such	O
as	O
1	O
g	O
/	O
kg-1	O
was	O
administered	O
to	O
a	O
mouse	O
provided	O
with	O
low	O
molecular	O
weight	O
fucoidan	O
(	O
LMWF	O
)	O
.	O

Reperfusion	O
occurred	O
at	O
16.67	O
minutes	O
after	O
administration	O
in	O
a	O
mouse	O
of	O
a	O
control	O
group	O
provided	O
with	O
20	O
mg	O
/	O
kg-1	O
of	O
t	B
-	I
PA	I
.	O

On	O
the	O
contrary	O
,	O
reperfusion	O
was	O
not	O
observed	O
in	O
an	O
occluded	O
mouse	O
provided	O
with	O
heparin	O
(	O
p<0.01	O
)	O
.	O

The	O
occluded	O
artery	O
was	O
recovered	O
without	O
reperfusion	O
at	O
17.2	O
minutes	O
after	O
injection	O
if	O
the	O
least	O
amount	O
of	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	B
-	I
PA	I
was	O
provided	O
.	O

All	O
the	O
data	O
show	O
that	O
fucoidan	O
can	O
serve	O
as	O
both	O
a	O
thrombolytic	O
agent	O
and	O
a	O
stimulant	O
with	O
respect	O
to	O
thrombolysis	O
activation	O
of	O
t	B
-	I
PA	I
in	O
a	O
thrombosis	O
model	O
,	O
differently	O
from	O
heparin	O
.	O

Treatment	O
of	O
severe	O
persitent	O
asthma	O
with	O
masitinib	O
The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
severe	O
persistent	O
asthma	O
,	O
and	O
in	O
particular	O
severe	O
persistent	O
corticosteroid	O
-	O
dependent	O
or	O
corticosteroid	O
-	O
resistant	O
asthma	O
,	O
comprising	O
administration	O
a	O
tyrosine	O
kinase	O
inhibitor	O
or	O
a	O
mast	O
cell	O
inhibitor	O
,	O
especially	O
masitinib	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Anti	O
-	O
angiogenic	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
A	O
)	O
having	O
an	O
anti	O
-	O
angiogenic	O
and/or	O
anti	O
-	O
tumoral	O
activity	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
same	O
,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
treating	O
cancer	O
.	O

(	O
substituted	O
)	O
N-	O
(	O
CH2	O
)	O
m	O
-	O
A	O
-	O
Rc	O
where	O
A	O
is	O
a	O
bond	O
,	O
Het-	O
(	O
CH2	O
)	O
1	O
-	O
6	O
or	O
NH-	O
(	O
CH2	O
)	O
1	O
-	O
6	O
and	O
Rc	O
is	O
O	O
-	O
substituted	O
or	O
N	O
-	O
substituted	O
.	O

4-aminoalcoholquinoline	O
derivatives	O
,	O
enantioselective	O
synthesis	O
methods	O
and	O
the	O
use	O
thereof	O
The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
new	O
antimalarial	O
compounds	O
with	O
a	O
strong	O
antimalarial	O
activity	O
as	O
well	O
as	O
antibacterial	O
activity	O
with	O
few	O
neurological	O
side	O
effects	O
and	O
a	O
new	O
enantioselective	O
pathway	O
to	O
mefloquine	O
amino	O
-	O
analogs	O
allowing	O
the	O
access	O
of	O
such	O
compounds	O
.	O

The	O
present	O
invention	O
relates	O
to	O
new	O
4	O
-aminoalcohol	O
quinoline	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
the	O
synthesis	O
methods	O
and	O
the	O
uses	O
of	O
such	O
derivatives	O
.	O

In	O
which	O
Y	O
is	O
one	O
selected	O
from	O
formulae	O
(	O
II	O
)	O
to	O
(	O
III	O
)	O
.	O

In	O
which	O
Z	O
is	O
selected	O
from	O
formulae	O
(	O
IV	O
)	O
to	O
(	O
VI	O
)	O
,	O
and	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

Cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
t	O
-	O
cells	O
as	O
active	O
ingredient	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
as	O
an	O
active	O
ingredient	O
.	O

By	O
infusing	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
,	O
which	O
are	O
the	O
cellular	O
therapeutic	O
agent	O
of	O
the	O
present	O
invention	O
,	O
into	O
bone	O
marrow	O
transplant	O
animals	O
,	O
rejection	O
to	O
the	O
host	O
is	O
suppressed	O
after	O
the	O
engraftment	O
of	O
transplanted	O
bone	O
-	O
marrow	O
to	O
thus	O
obtain	O
the	O
effect	O
of	O
reducing	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
and	O
immune	O
disease	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
such	O
GVHD	O
reduction	O
is	O
much	O
greater	O
than	O
the	O
one	O
obtained	O
when	O
only	O
mesenchymal	O
stem	O
cells	O
are	O
infused	O
.	O

Accordingly	O
,	O
the	O
cell	O
therapy	O
composition	O
of	O
the	O
present	O
invention	O
having	O
the	O
above	O
-	O
mentioned	O
effects	O
can	O
be	O
useful	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
immune	O
disease	O
.	O

Compositions	O
for	O
ameliorating	O
systemic	O
inflammation	O
and	O
methods	O
for	O
making	O
and	O
using	O
them	O
In	O
alternative	O
embodiments	O
the	O
invention	O
provides	O
compositions	O
,	O
e.g.	O
,	O
pharmaceutical	O
compositions	O
and	O
preparations	O
,	O
formulations	O
,	O
kits	O
and	O
other	O
products	O
of	O
manufacture	O
,	O
e.g.	O
,	O
exemplary	O
drug	O
combinations	O
packaged	O
together	O
or	O
separately	O
in	O
blister	O
packs	O
,	O
lidded	O
blisters	O
or	O
blister	O
cards	O
,	O
or	O
wrapped	O
in	O
paper	O
,	O
plastic	O
or	O
cellophane	O
wrappers	O
(	O
e.g.	O
,	O
a	O
shrink	O
wrap	O
)	O
,	O
comprising	O
a	O
combination	O
regimen	O
of	O
at	O
least	O
two	O
active	O
ingredients	O
designed	O
to	O
diminish	O
systemic	O
inflammation	O
by	O
targeting	O
(	O
inhibiting	O
)	O
two	O
different	O
,	O
but	O
convergent	O
,	O
signaling	O
pathways	O
,	O
i.e.	O
,	O
the	O
sympathetic	O
nervous	O
system	O
and	O
the	O
lipid-	O
derived	O
autacoid	O
system	O
;	O
and	O
methods	O
for	O
making	O
and	O
using	O
these	O
compositions	O
.	O

In	O
alternative	O
embodiments	O
,	O
the	O
compositions	O
of	O
the	O
invention	O
(	O
e.g.	O
,	O
the	O
combination	O
of	O
drugs	O
)	O
are	O
used	O
to	O
ameliorate	O
,	O
diminish	O
,	O
treat	O
,	O
block	O
or	O
prevent	O
an	O
inflammatory	O
response	O
secondary	O
to	O
an	O
infection	O
,	O
e.g.	O
,	O
a	O
viral	O
infection	O
and/or	O
a	O
reactivation	O
.	O

Use	O
of	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
and	O
pharmaceutical	O
composition	O
thereof	O
Use	O
of	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
inhibiting	O
infection	O
of	O
HIV-1	O
and	O
pharmaceutical	O
composition	O
thereof	O
.	O

Said	O
pharmaceutical	O
composition	O
comprises	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
as	O
active	O
ingredient	O
and	O
conventional	O
pharmaceutical	O
carrier	O
.	O

A	O
COMPOUND	O
FOR	O
INHIBITING	O
HUMAN	B
11-β	I
-	I
HYDROXY	I
STEROID	I
DEHYDROGENASE	I
TYPE	I
1	I
,	O
AND	O
A	O
PHARMACEUTICAL	O
COMPOSITION	O
COMPRISING	O
THE	O
SAME	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
,	O
or	O
a	O
stereoisomer	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
comprising	O
the	O
same	O
.	O

The	O
invention	O
provides	O
a	O
compound	O
,	O
which	O
has	O
excellent	O
activity	O
and	O
solubility	O
and	O
is	O
more	O
efficiently	O
formulated	O
and	O
delivered	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
comprising	O
the	O
same	O
.	O

Method	O
for	O
treatment	O
of	O
xeroderma	O
pigmentosum	O
This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
xeroderma	O
pigmentosum	O
and	O
related	O
symptoms	O
in	O
patients	O
by	O
administering	O
a	O
MC1R	O
before	O
or	O
after	O
exposing	O
them	O
to	O
visible	O
light	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
or	O
prophylaxis	O
of	O
neurogenic	O
diseases	O
The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
product	O
which	O
has	O
a	O
sufficient	O
curative	O
effect	O
on	O
multiple	O
sclerosis	O
and	O
has	O
excellent	O
autoimmune	O
inhibitory	O
activity	O
,	O
while	O
being	O
reduced	O
in	O
the	O
side	O
effects	O
which	O
steroidal	O
agents	O
and	O
interferon	O
β	O
have	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
multiple	O
sclerosis	O
,	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
4-	O
(	O
2-aminopyridin-4-yl	O
)	O
-3-	O
(	O
4-fluorophenyl	O
)	O
-1-	O
(	O
1,4,5,6-tetrahydro-6-oxopyridazin-3-yl	O
)	O
-1H	O
-	O
pyrazole	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Novel	O
cephalosporin	O
derivative	O
and	O
medical	O
composition	O
containing	O
same	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
cephalosporin	O
derivative	O
indicated	O
in	O
chemical	O
formula	O
1	O
of	O
the	O
description	O
.	O

In	O
the	O
chemical	O
formula	O
1	O
,	O
X	O
,	O
Y	O
,	O
L	O
,	O
R1	O
,	O
R2	O
are	O
identical	O
as	O
defined	O
in	O
the	O
detailed	O
explanation	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
an	O
antibiotic	O
medical	O
composition	O
containing	O
the	O
novel	O
cephalosporin	O
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
a	O
prodrug	O
thereof	O
,	O
a	O
hydrate	O
thereof	O
,	O
a	O
solvate	O
thereof	O
,	O
an	O
isomer	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
,	O
as	O
active	O
ingredients	O
.	O

The	O
novel	O
cephalosporin	O
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
the	O
prodrug	O
thereof	O
,	O
the	O
hydrate	O
thereof	O
,	O
the	O
solvate	O
thereof	O
,	O
the	O
isomer	O
thereof	O
,	O
and	O
the	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
have	O
a	O
wide	O
antibacterial	O
spectrum	O
for	O
resistant	O
bacteria	O
,	O
have	O
low	O
toxicity	O
,	O
and	O
in	O
particular	O
,	O
show	O
strong	O
antibacterial	O
effect	O
on	O
gram	O
negative	O
bacteria	O
,	O
and	O
is	O
thus	O
useful	O
as	O
an	O
antibiotic	O
.	O

Methods	O
for	O
treating	O
heartburn	O
and/or	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	O
therapy	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
heartburn	O
in	O
a	O
patient	O
receiving	O
clopidogrel	O
therapy	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	O
therapy	O
.	O

Solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
processes	O
for	O
preparation	O
and	O
pharmaceutical	O
compositions	O
thereof	O
Disclosed	O
are	O
solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

Pharmaceutical	O
compositions	O
using	O
the	O
solid	O
forms	O
are	O
also	O
disclosed	O
.	O

Acadesine	O
derivatives	O
,	O
products	O
and	O
compositions	O
including	O
same	O
,	O
therapeutic	O
uses	O
thereof	O
,	O
and	O
methods	O
for	O
synthesizing	O
same	O
The	O
invention	O
relates	O
to	O
acadesine	O
derivatives	O
as	O
a	O
drug	O
,	O
as	O
well	O
as	O
to	O
said	O
derivatives	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
particularly	O
for	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
product	O
containing	O
said	O
derivatives	O
and	O
at	O
least	O
one	O
second	O
active	O
ingredient	O
as	O
a	O
combination	O
product	O
to	O
be	O
simultaneously	O
or	O
separately	O
administered	O
,	O
or	O
administered	O
over	O
time	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
including	O
said	O
derivatives	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Finally	O
,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
in	O
vitro	O
inhibition	O
of	O
the	O
proliferation	O
of	O
cells	O
,	O
including	O
contacting	O
a	O
cell	O
with	O
said	O
derivatives	O
in	O
vitro	O
,	O
and	O
to	O
methods	O
for	O
synthesizing	O
said	O
derivatives	O
.	O

2α	O
-	O
METHYL	O
AND	O
2β	O
-	O
METHYL	O
ANALOGS	O
OF	O
19,26-DINOR-1α	O
,	O
25-DIHYDROXYVITAMIN	O
D3	O
AND	O
THEIR	O
USES	O

This	O
invention	O
discloses	O
2α	O
-	O
methyl	O
and	O
2β	O
-	O
methyl	O
analogs	O
of	O
19,26-dinor-1α,25-dihydroxyvitamin	O
D3	O
and	O
pharmaceutical	O
uses	O
therefor	O
.	O

These	O
compounds	O
exhibit	O
in	O
vitro	O
biological	O
activities	O
evidencing	O
use	O
as	O
an	O
anti	O
-	O
cancer	O
agent	O
and	O
for	O
the	O
treatment	O
of	O
skin	O
diseases	O
such	O
as	O
psoriasis	O
as	O
well	O
as	O
skin	O
conditions	O
such	O
as	O
wrinkles	O
,	O
slack	O
skin	O
,	O
dry	O
skin	O
and	O
insufficient	O
sebum	O
secretion	O
.	O

These	O
compounds	O
have	O
little	O
,	O
if	O
any	O
,	O
in	O
vivo	O
calcemic	O
activity	O
and	O
therefore	O
may	O
be	O
used	O
to	O
treat	O
autoimmune	O
disorders	O
in	O
humans	O
as	O
well	O
as	O
secondary	O
hyperparathyroidism	O
and	O
renal	O
osteodystrophy	O
.	O

Anti	O
-	O
wrinkle	O
agent	O
,	O
matrix	B
metalloproteinase	I
(	O
mmp	B
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
each	O
comprising	O
1-piperidine	O
propionate	O
The	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
and	O
effective	O
anti	O
-	O
wrinkle	O
agent	O
.	O

The	O
invention	O
relates	O
to	O
a	O
matrix	B
metalloproteinase	I
(	O
MMP	B
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
as	O
well	O
as	O
an	O
anti	O
-	O
wrinkle	O
agent	O
,	O
each	O
of	O
which	O
comprises	O
1-piperidine	O
propionate	O
and/or	O
a	O
salt	O
thereof	O
.	O

Condensed	O
2	O
-	O
carbamoylpyridazinones	O
as	O
potassium	B
channel	I
modulators	O
Disclosed	O
herein	O
are	O
KCNQ	B
potassium	B
channels	I
modulators	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
ring	O
G1	O
,	O
R1	O
,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Compositions	O
comprising	O
such	O
compounds	O
;	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
described	O
.	O

Erk	B
inhibitors	O
for	O
use	O
in	O
treating	O
spinal	O
muscular	O
atrophy	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
spinal	O
muscular	O
atrophy	O
and	O
other	O
related	O
neuromuscular	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
said	O
method	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
ERK	B
inhibitor	O
,	O
such	O
as	O
Selumetinib	O
to	O
said	O
subject	O
.	O

Skin	O
treatment	O
method	O
River	O
rocks	O
are	O
used	O
in	O
a	O
therapy	O
regime	O
whereby	O
the	O
river	O
rocks	O
are	O
used	O
to	O
absorb	O
excess	O
oils	O
from	O
the	O
skin	O
of	O
a	O
user	O
.	O

In	O
one	O
method	O
,	O
river	O
rocks	O
arc	O
collected	O
from	O
a	O
source	O
(	O
e.g	O
..	O
river	O
or	O
supplier	O
)	O
,	O
sorted	O
for	O
size	O
and	O
color	O
,	O
engraved	O
with	O
logo	O
or	O
other	O
content	O
,	O
packaged	O
and	O
shipped	O
to	O
customers	O
or	O
retailers	O
with	O
instructions	O
on	O
use	O
.	O

Use	O
comprises	O
placement	O
of	O
the	O
river	O
rocks	O
on	O
oily	O
portions	O
of	O
the	O
user	O
's	O
skin	O
for	O
an	O
appropriate	O
time	O
period	O
allowing	O
the	O
river	O
rock	O
to	O
absorb	O
the	O
excess	O
oils	O
.	O

The	O
river	O
rocks	O
are	O
reusable	O
after	O
being	O
washed	O
with	O
mild	O
soap	O
and	O
water	O
.	O

Thiocarbamate	O
and	O
sulfonamide	O
hydroxamate	O
inhibitors	O
of	O
insulin	B
-	I
degrading	I
enzyme	I
This	O
disclosure	O
relates	O
to	O
pharmaceutical	O
compositions	O
useful	O
for	O
inhibiting	O
insulin	B
-	I
degrading	I
enzyme	I
(	O
IDE	B
)	O
and	O
methods	O
of	O
treating	O
disorders	O
involving	O
the	O
same	O
or	O
peptide	O
substrates	O
of	O
the	O
same	O
.	O

For	O
example	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treating	O
diabetes	O
,	O
promotion	O
of	O
wound	O
healing	O
,	O
and	O
improvement	O
of	O
memory	O
.	O

Pharmaceutical	O
composition	O
comprising	O
a	O
trpa1	B
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
The	O
present	O
patent	O
application	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
transient	B
receptor	I
potential	I
ankyrin-1	I
receptor	I
(	O
""""	O
TRPA1	B
""""	O
)	O
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O

Antifungal	O
composition	O
comprising	O
cis	O
-	O
cyclo	O
(	O
l	O
-	O
phe	O
-	O
l	O
-	O
pro	O
)	O
having	O
genus	O
ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O
The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
comprising	O
cis	O
-	O
cyclo	O
(	O
L	O
-	O
Phe	O
-	O
L	O
-	O
Pro	O
)	O
as	O
an	O
active	O
ingredient	O
and	O
having	O
Genus	O
Ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O
,	O
an	O
insecticide	O
composition	O
,	O
and	O
a	O
method	O
for	O
producing	O
an	O
antifungal	O
agent	O
for	O
Genus	O
Ganoderma	O
fungi	O
.	O

The	O
present	O
invention	O
exhibits	O
superior	O
antifungal	O
activity	O
to	O
the	O
Genus	O
Ganoderma	O
fungi	O
(	O
especially	O
,	O
to	O
Ganoderma	O
boninense	O
fungi	O
)	O
and	O
thus	O
can	O
be	O
applied	O
to	O
various	O
industrial	O
fields	O
requiring	O
removal	O
and	O
prevention	O
of	O
Genus	O
Ganoderma	O
fungi	O
,	O
and	O
is	O
economically	O
advantageous	O
in	O
terms	O
of	O
usage	O
due	O
to	O
the	O
antifungal	O
activity	O
even	O
with	O
a	O
small	O
amount	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
provides	O
basic	O
material	O
as	O
a	O
biological	O
agent	O
regarding	O
cis	O
-	O
cyclo	O
(	O
L	O
-	O
Phe	O
-	O
L	O
-	O
Pro	O
)	O
to	O
the	O
insecticide	O
industry	O
which	O
uses	O
biological	O
agents	O
.	O

Tricyclic	O
heterocyclic	O
compounds	O
as	O
kinase	B
inhibitors	O
There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
X	O
,	O
R3	O
and	O
R4	O
have	O
meanings	O
given	O
in	O
the	O
description	O
(	O
and	O
which	O
compounds	O
are	O
optionally	O
substituted	O
as	O
indicated	O
in	O
the	O
description	O
)	O
,	O
and	O
pharmaceutically	O
-	O
acceptable	O
esters	O
,	O
amides	O
,	O
solvates	O
or	O
salts	O
thereof	O
,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	O
or	O
lipid	O
kinase	O
(	O
e.g.	O
a	O
PIM	B
family	I
kinase	O
,	O
such	O
as	O
PIM-1	B
,	O
PIM-2	B
and/or	O
PIM-3	B
)	O
is	O
desired	O
and/or	O
required	O
,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O

There	O
is	O
also	O
provided	O
combinations	O
comprising	O
the	O
compounds	O
of	O
formula	O
I.	O

Tricyclic	O
inhibitors	O
of	O
kinases	B
useful	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
B	O
,	O
and	O
n	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	B
such	O
as	O
wee-1	O
and	O
methods	O
of	O
treating	O
diseases	O
such	O
as	O
cancer	O
.	O

Spirocyclic	O
molecules	O
as	O
protein	B
kinase	I
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
spirocyclic	O
compounds	O
of	O
formula	O
I	O
,	O
namely	O
spirocyclic	O
(	O
1H	O
-	O
pyrazol-4-yl	O
)	O
-3-	O
(	O
1-	O
(	O
2,6-dichloro-3-	O
fiuorophenyl	O
)	O
ethoxy	O
)	O
pyridin-2-amines	O
having	O
protein	B
kinase	I
inhibitory	O
activity	O
,	O
and	O
methods	O
of	O
synthesizing	O
and	O
using	O
such	O
compounds	O
.	O

Preferred	O
compounds	O
are	O
c	B
-	I
Met	I
and/or	O
ALK	B
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
,	O
such	O
as	O
cancers	O
.	O

Composition	O
containing	O
5-hydroxyindole	O
compounds	O
or	O
sponge	O
scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
5-hydroxyindole	O
compounds	O
or	O
sponge	O
Scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
,	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
of	O
the	O
present	O
invention	O
exhibits	O
growth	O
inhibitory	O
activities	O
against	O
various	O
cancer	O
cell	O
lines	O
and	O
is	O
thus	O
useful	O
as	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
.	O

Pyridazine	O
derivatives	O
as	O
eaat2	B
activators	O
Pyridazine	O
derivatives	O
that	O
activate	O
the	O
excitatory	B
amino	I
acid	I
transporter	I
2	I
(	O
EAAT2	B
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
associated	O
with	O
glutamate	O
excitotoxicity	O
.	O

Novel	O
urea	O
derivatives	O
as	O
tec	O
kinase	O
inhibitors	O
and	O
uses	O
thereof	O
Provided	O
are	O
urea	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
Tec	O
kinase	O
inhibitors	O
,	O
in	O
particular	O
ITK	O
(	O
interleukin-2	O
inducible	O
tyrosine	O
kinase	O
)	O
inhibitors	O
.	O

Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein	O
,	O
intermediates	O
used	O
in	O
their	O
synthesis	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
conditions	O
and/or	O
disorders	O
mediated	O
by	O
ITK	O
.	O

Methods	O
of	O
treating	O
amyloidoses	O
with	O
vitamin	O
b12	O
and	O
test	O
for	O
detecting	O
amyloid	B
-	I
beta	I
peptides	O
Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
vitamin	O
B12	O
to	O
influence	O
amyloid	B
-	I
beta	I
peptide	O
aggregation	O
.	O

A	O
preferred	O
method	O
comprises	O
contacting	O
at	O
least	O
one	O
amyloid	B
-	I
beta	I
peptide	O
oligomer	O
formed	O
from	O
a	O
plurality	O
of	O
amyloid	B
-	I
beta	I
peptide	O
monomers	O
with	O
an	O
effective	O
amount	O
of	O
vitamin	O
B12	O
,	O
the	O
effective	O
amount	O
being	O
sufficient	O
to	O
stimulate	O
dissociation	O
of	O
the	O
amyloid	B
-	I
beta	I
peptide	O
monomers	O
from	O
the	O
amyloid	B
-	I
beta	I
peptide	O
oligomer	O
or	O
fibril	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
Alzheimer	O
's	O
disease	O
and	O
diagnostic	O
tests	O
for	O
detecting	O
the	O
presence	O
of	O
amyloid	B
-	I
beta	I
peptides	O
.	O

Nkp30	B
receptor	O
targeted	O
therapeutics	O
The	O
invention	O
is	O
directed	O
to	O
T	O
cells	O
and	O
other	O
cells	O
that	O
express	O
chimeric	O
NKp30	B
receptors	O
(	O
""""	O
chimeric	O
NKp30	O
T	O
cells	O
""""	O
)	O
,	O
methods	O
of	O
making	O
and	O
using	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
using	O
these	O
chimeric	O
NKp30	O
T	O
cells	O
to	O
address	O
diseases	O
and	O
disorders	O
.	O

In	O
one	O
aspect	O
,	O
the	O
disclosure	O
broadly	O
relates	O
to	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
isolated	O
populations	O
thereof	O
,	O
and	O
compositions	O
comprising	O
the	O
same	O
.	O

In	O
another	O
aspect	O
,	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
are	O
further	O
designed	O
to	O
express	O
a	O
functional	O
non	O
-	O
TCR	O
receptor	O
.	O

The	O
disclosure	O
also	O
pertains	O
to	O
methods	O
of	O
making	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
reducing	O
or	O
ameliorating	O
,	O
or	O
preventing	O
or	O
treating	O
,	O
diseases	O
and	O
disorders	O
using	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
populations	O
thereof	O
,	O
or	O
compositions	O
comprising	O
the	O
same	O
.	O

Combination	O
use	O
of	O
vitamin	O
d	O
and	O
hmg	B
coa	I
reductase	I
inhibitor	O
for	O
treating	O
osteoporosis	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
osteoporosis	O
by	O
co-	O
administration	O
of	O
a	O
vitamin	O
D	O
and	O
a	O
3-hydroxy-3-methyl	B
-	I
glutaryl	I
-	I
Co	I
A	I
reductase	I
(	O
HMG	B
Co	I
A	I
reductase	I
)	O
inhibitor	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
useful	O
for	O
treating	O
osteoporosis	O
comprising	O
a	O
vitamin	O
D	O
and	O
an	O
HMG	B
Co	I
A	I
reductase	I
inhibitor	O
.	O

Retinal	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
for	O
clarifying	O
skin	O
complexion	O
The	O
present	O
invention	O
discloses	O
certain	O
polyene	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
that	O
are	O
effective	O
in	O
providing	O
skin	O
clarification	O
,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
acne	O
,	O
and	O
skin	O
disfigurements	O
and	O
skin	O
darkening	O
resulting	O
from	O
acne	O
;	O
skin	O
darkening	O
from	O
cancer	O
,	O
diabetes	O
,	O
radiation	O
treatments	O
,	O
chemotherapy	O
,	O
and	O
sun	O
-	O
burn	O
;	O
mitochondrial	O
and	O
DNA	O
dysfunction	O
;	O
age	O
spots	O
;	O
loss	O
of	O
cellular	O
antioxidants	O
;	O
skin	O
changes	O
associated	O
with	O
aging	O
including	O
collagen	O
loss	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
and	O
fine	O
lines	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
damage	O
from	O
free	O
radicals	O
,	O
and	O
damage	O
from	O
UV	O
;	O
dry	O
skin	O
;	O
xerosis	O
;	O
ichthyosis	O
;	O
dandruff	O
;	O
brownish	O
spots	O
;	O
keratoses	O
;	O
melasma	O
;	O
lentigines	O
;	O
liver	O
spots	O
;	O
skin	O
pigmentation	O
including	O
pigmented	O
spots	O
,	O
dark	O
circles	O
under	O
the	O
eyes	O
,	O
darkened	O
skin	O
,	O
and	O
blemishes	O
;	O
oily	O
skin	O
;	O
warts	O
;	O
eczema	O
;	O
pruritic	O
skin	O
;	O
psoriasis	O
;	O
inflammatory	O
dermatoses	O
;	O
topical	O
inflammation	O
;	O
disturbed	O
keratinization	O
;	O
scalp	O
dryness	O
,	O
and	O
combinations	O
thereof	O
.	O

Benzoic	O
acid	O
derivatives	O
as	O
eif4e	B
inhibitors	O
Disclosed	O
are	O
compounds	O
with	O
the	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
and	O
R2	O
are	O
as	O
disclosed	O
herein	O
,	O
which	O
are	O
eIF4E	B
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
cancers	O
.	O

Also	O
disclosed	O
are	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
compounds	O
.	O

Amide	O
compounds	O
,	O
compositions	O
and	O
applications	O
thereof	O
The	O
present	O
disclosure	O
relates	O
to	O
substituted	O
amide	O
compounds	O
that	O
are	O
inhibitors	O
of	O
Fatty	B
Acid	I
Amide	I
Hydrolase	I
(	O
FAAH	B
)	O
,	O
their	O
stereoisomers	O
,	O
tautomers	O
,	O
prodrugs	O
,	O
polymorphs	O
,	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
,	O
prophylaxis	O
,	O
management	O
,	O
or	O
adjunct	O
treatment	O
of	O
all	O
medical	O
conditions	O
related	O
to	O
inhibition	O
of	O
Fatty	B
Acid	I
Amide	I
Hydrolase	I
(	O
FAAH	B
)	O
,	O
such	O
as	O
pain	O
including	O
acute	O
and	O
post	O
operative	O
pain	O
,	O
chronic	O
pain	O
,	O
cancer	O
pain	O
,	O
cancer	O
chemotherapy	O
induced	O
pain	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
pain	O
,	O
inflammatory	O
pain	O
,	O
back	O
pain	O
,	O
pain	O
due	O
to	O
disease	O
of	O
various	O
origin	O
such	O
as	O
:	O
diabetic	O
neuropathy	O
,	O
neurotropic	O
viral	O
disease	O
including	O
human	O
immunodeficient	O
virus	O
(	O
HIV	O
)	O
,	O
herpes	O
zoster	O
such	O
as	O
post	O
herpetic	O
neuralgia	O
;	O
polyneuropathy	O
,	O
neurotoxicity	O
,	O
mechanical	O
nerve	O
injury	O
,	O
carpal	O
tunnel	O
syndrome	O
,	O
immunologic	O
mechanisms	O
like	O
multiple	O
sclerosis	O
;	O
sleep	O
disorders	O
,	O
anxiety	O
and	O
depression	O
disorders	O
,	O
inflammatory	O
disorders	O
,	O
weight	O
and	O
eating	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
addiction	O
,	O
spasticity	O
,	O
hypertension	O
or	O
other	O
disorders	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
the	O
process	O
of	O
preparation	O
of	O
the	O
amide	O
compounds	O
.	O

Formula	O
(	O
1	O
)	O
.	O

The	O
present	O
disclosure	O
also	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Methods	O
of	O
treating	O
fatty	O
liver	O
disease	O
with	O
helminth	O
-	O
derived	O
glycan	O
-	O
containing	O
compounds	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
(	O
e.g.	O
,	O
a	O
compound	O
comprising	O
a	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNFPIII	O
)	O
,	O
a	O
non	O
-	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNnT	O
,	O
LDN	O
,	O
and	O
LDN	O
derivatives	O
)	O
,	O
or	O
a	O
mixture	O
of	O
Lewisx	O
and	O
non	O
-	O
Lewisx	O
antigens	O
(	O
e.g.	O
,	O
SEA	O
)	O
)	O
,	O
useful	O
as	O
a	O
therapeutic	O
compound	O
for	O
treating	O
or	O
preventing	O
diseases	O
associated	O
with	O
fat	O
accumulation	O
in	O
the	O
liver	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
the	O
development	O
of	O
a	O
fatty	O
liver	O
disease	O
in	O
a	O
subject	O
that	O
has	O
the	O
disease	O
or	O
is	O
at	O
risk	O
of	O
developing	O
the	O
disease	O
,	O
and	O
inhibiting	O
lipogenesis	O
in	O
hepatocytes	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
regulating	O
the	O
Erk	O
-	O
c	O
-	O
fos	O
/	O
AP-1-FXRα	O
signalling	O
pathway	O
by	O
administering	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
to	O
a	O
subject	O
with	O
a	O
fatty	O
liver	O
disease	O
,	O
or	O
contacting	O
a	O
hepatocyte	O
with	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
.	O

Novel	O
chalcone	O
derivative	O
and	O
anticancer	O
composition	O
comprising	O
same	O
as	O
active	O
ingredient	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
chalcone	O
derivative	O
and	O
to	O
an	O
anticancer	O
composition	O
comprising	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

Liquid	O
composition	O
of	O
anti	O
-	O
hepatitis	O
b	O
virus	O
Disclosed	O
is	O
an	O
oral	O
liquid	O
for	O
treating	O
a	O
hepatitis	O
B	O
virus	O
infection	O
,	O
and	O
composed	O
of	O
entecavir	O
,	O
sodium	O
diacetate	O
and	O
water	O
.	O

The	O
content	O
of	O
entecavir	O
is	O
0.001	O
-	O
0.2mg	O
/	O
ml	O
,	O
and	O
the	O
content	O
of	O
sodium	O
diacetate	O
is	O
0.1	O
-	O
10mg	O
/	O
ml	O
.	O

Use	O
of	O
a	O
chemical	O
compound	O
derived	O
from	O
a	O
1,2,3,5-tetrasubstituted	O
pyrole	O
in	O
the	O
preparation	O
of	O
a	O
drug	O
for	O
use	O
in	O
treating	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
derived	O
from	O
1,2,3,5-tetrasubstituted	O
pyroles	O
in	O
conjunction	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
in	O
the	O
production	O
of	O
a	O
drug	O
that	O
can	O
be	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O
,	O
preferably	O
diseases	O
arising	O
through	O
sepsis	O
caused	O
by	O
Gram‑negative	O
bacteria	O
.	O

Said	O
diseases	O
include	O
acute	O
sepsis‑induced	O
pulmonary	O
diseases	O
,	O
acute	O
sepsis‑induced	O
respiratory	O
distress	O
syndrome	O
,	O
endotoxic	O
or	O
endotoxemic	O
shock	O
,	O
septic	O
peritonitis	O
or	O
trauma	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
pharmaceutical	O
composition	O
for	O
treating	O
said	O
diseases	O
.	O

A	O
new	O
diaza	O
-	O
benzofluoranthene	O
derivative	O
as	O
drug	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
16-tetrazolyl	O
-	O
eburnamenine	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and/or	O
hydrates	O
and/or	O
solvates	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
hydrates	O
or	O
solvates	O
thereof	O
as	O
active	O
ingredient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
synthesis	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
the	O
chemical	O
and	O
pharmaceutical	O
manufacture	O
of	O
medicaments	O
containing	O
these	O
compounds	O
,	O
as	O
well	O
as	O
the	O
methods	O
of	O
treatment	O
of	O
mammals	O
-	O
including	O
human	O
-	O
with	O
these	O
compounds	O
.	O

There	O
is	O
still	O
further	O
provided	O
methods	O
for	O
the	O
treatment	O
of	O
neurological	O
,	O
neurodegenerative	O
and	O
psychiatric	O
diseases	O
or	O
conditions	O
as	O
well	O
as	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
and/or	O
prophylaxis	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
alone	O
or	O
together	O
with	O
at	O
least	O
one	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and/or	O
diluent	O
.	O

Hydroxymethylfurfural	O
derivative	O
A	O
hydroxymethylfurfural	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
A	O
)	O
.	O

In	O
the	O
formula	O
,	O
R	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
HOOCCH2COCO-	O
,	O
(	O
III	O
)	O
HOOCCH2CH2COCO-	O
,	O
and	O
(	O
IV	O
)	O
a	O
hydrogen	O
atom	O
.	O

Garcinia	O
buchananii	O
baker	O
compounds	O
,	O
compositions	O
and	O
related	O
methods	O
Embodiments	O
of	O
the	O
present	O
disclosure	O
related	O
to	O
compounds	O
and	O
compositions	O
derived	O
from	O
G.	O
buchananii	O
baker	O
and	O
methods	O
thereof	O
.	O

Formulations	O
of	O
(	O
+	O
)	O
-2-	O
[	O
1-	O
(	O
3-ethoxy-4-methoxy	O
-	O
phenyl	O
)	O
-2-methanesulfonyl	O
-	O
ethyl	O
]	O
-4-acetyl	O
aminoisoindoline-1,3-dione	O
Pharmaceutical	O
compositions	O
and	O
single	O
unit	O
dosage	O
forms	O
of	O
(	O
+	O
)	O
-2-	O
[	O
l-	O
(	O
3-ethox	O
4-mcthoxy	O
-	O
phcnyl	O
)	O
-2-mcthancsulfonyl	O
-	O
cthyl	O
]	O
-4-acctylaminoisoindolinc	O
-	O
l,3-dionc	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
stereoisomer	O
,	O
prodrug	O
,	O
salt	O
,	O
solvate	O
,	O
hydrate	O
,	O
or	O
clathrate	O
5	O
thereof	O
,	O
are	O
provided	O
herein	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
,	O
managing	O
,	O
or	O
preventing	O
various	O
diseases	O
or	O
disorders	O
.	O

The	O
compound	O
is	O
known	O
as	O
Apremilast	O
and	O
has	O
the	O
following	O
structural	O
formula	O
:	O

Formulation	O
and	O
method	O
for	O
treatment	O
of	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O
Topical	O
formulations	O
comprising	O
an	O
effective	O
amount	O
of	O
menthol	O
in	O
combination	O
with	O
an	O
acidifier	O
,	O
wherein	O
the	O
topical	O
formulation	O
has	O
a	O
pH	O
of	O
about	O
1	O
to	O
3	O
,	O
and	O
methods	O
comprising	O
administration	O
of	O
the	O
same	O
,	O
and	O
use	O
of	O
the	O
topical	O
formulations	O
to	O
treat	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O
are	O
described	O
.	O

For	O
example	O
,	O
the	O
topical	O
formulation	O
relieves	O
pain	O
,	O
redness	O
,	O
swelling	O
,	O
reduces	O
rash	O
and/or	O
itching	O
relating	O
to	O
skin	O
conditions	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
any	O
kind	O
of	O
envenomation	O
from	O
stings	O
and/or	O
bites	O
from	O
animals	O
,	O
insects	O
and	O
plants	O
in	O
addition	O
to	O
contact	O
dermatitis	O
,	O
burns	O
,	O
urticaria	O
,	O
rash	O
and	O
other	O
forms	O
of	O
dermatitis	O
.	O

Treatment	O
of	O
pain	O
and/or	O
inflammation	O
including	O
activation	O
and/or	O
stimulation	O
and/or	O
blocking	O
and/or	O
reducing	O
the	O
activity	O
of	O
one	O
or	O
more	O
pain	O
receptors	O
to	O
thereby	O
treat	O
the	O
pain	O
and/or	O
inflammation	O
is	O
described	O
.	O

Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O
A	O
Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O
,	O
consisting	O
of	O
the	O
following	O
raw	O
material	O
medicines	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
30	O
parts	O
of	O
scorpion	O
,	O
1	O
-	O
30	O
parts	O
of	O
lithargite	O
,	O
1	O
-	O
30	O
parts	O
of	O
centipede	O
,	O
1	O
-	O
20	O
parts	O
of	O
borneol	O
,	O
1	O
-	O
20	O
parts	O
of	O
cirsium	O
japonicum	O
,	O
1	O
-	O
20	O
parts	O
of	O
pangolin	O
,	O
1	O
-	O
20	O
parts	O
of	O
castor	O
beans	O
,	O
1	O
-	O
20	O
parts	O
of	O
garden	O
burnet	O
,	O
and	O
1	O
-	O
20	O
parts	O
of	O
safflower	O
.	O

The	O
composition	O
has	O
the	O
effects	O
of	O
clearing	O
heat	O
and	O
detoxicating	O
,	O
eliminating	O
necrotic	O
tissue	O
and	O
promoting	O
granulation	O
,	O
stimulating	O
blood	O
circulation	O
and	O
removing	O
blood	O
stasis	O
,	O
warming	O
and	O
activating	O
arteries	O
and	O
veins	O
,	O
and	O
reducing	O
swelling	O
and	O
stopping	O
pain	O
,	O
and	O
is	O
used	O
to	O
treat	O
nerve	O
patho	O
-	O
type	O
,	O
artery	O
ischemia	O
-	O
type	O
and	O
mixed	O
-	O
type	O
diabetic	O
foot	O
with	O
the	O
symptoms	O
of	O
foot	O
muscular	O
atrophy	O
,	O
deformity	O
,	O
skin	O
infection	O
,	O
purulence	O
,	O
rhagades	O
and	O
ulcers	O
,	O
and	O
toe	O
tip	O
ulcers	O
and	O
gangrene	O
.	O

Effervescent	O
pharmaceutical	O
formulations	O
comprising	O
pregabalin	O
and	O
vitamin	O
b12	O
The	O
present	O
invention	O
relates	O
to	O
an	O
effervescent	O
pharmaceutical	O
formulation	O
comprising	O
a	O
combination	O
of	O
pregabalin	O
and	O
vitamin	O
B12	O
and	O
use	O
of	O
this	O
formulation	O
in	O
the	O
treatment	O
of	O
epilepsy	O
,	O
central	O
nervous	O
system	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
;	O
Huntington	O
's	O
disease	O
;	O
tardive	O
dyskinesia	O
;	O
spasticity	O
;	O
cerebral	O
ischemia	O
;	O
postherpetic	O
neuralgia	O
;	O
social	O
phobia	O
;	O
fibromyalgia	O
and	O
spinal	O
cord	O
injury	O
induced	O
chronic	O
pains	O
;	O
neuropathic	O
pains	O
associated	O
with	O
diabetic	O
peripheral	O
neuropathy	O
and	O
common	O
anxiety	O
disorder	O
and	O
in	O
treatment	O
and/or	O
prevention	O
of	O
anemia	O
diseases	O
such	O
as	O
macrocytic	O
anemia	O
,	O
megaloblastic	O
anemia	O
and	O
pernicious	O
anemia	O
.	O

Fatty	O
acids	O
as	O
anti	O
-	O
inflammatory	O
agents	O
A	O
class	O
of	O
enzymatically	O
generated	O
electrophilic	O
fatty	O
acid	O
derivatives	O
(	O
EFADs	O
)	O
,	O
or	O
their	O
enzymatically	O
generated	O
metabolites	O
.	O

The	O
EFAD	O
's	O
and	O
their	O
metabolites	O
have	O
beneficial	O
effects	O
human	O
health	O
.	O

According	O
to	O
the	O
inventors	O
the	O
inventive	O
keto	O
fatty	O
acids	O
or	O
their	O
enzymatically	O
generated	O
metabolites	O
,	O
can	O
inhibit	O
inflammation	O
by	O
giving	O
rise	O
to	O
adaptive	O
signaling	O
molecules	O
in	O
vivo	O
.	O

Ionophore	O
antibiotic	O
suspension	O
An	O
alcohol	O
based	O
suspension	O
formulation	O
including	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
ionophore	O
antibiotic	O
in	O
an	O
organic	O
liquid	O
phase	O
including	O
at	O
least	O
one	O
polyol	O
and	O
benzyl	O
alcohol	O
and	O
at	O
least	O
one	O
or	O
more	O
of	O
at	O
least	O
one	O
anionic	O
and/or	O
non	O
-	O
ionic	O
surfactant	O
;	O
at	O
least	O
one	O
stabilising	O
agent	O
or	O
water	O
in	O
an	O
amount	O
of	O
less	O
than	O
or	O
equal	O
to	O
15	O
%	O
v	O
/	O
v	O
of	O
the	O
total	O
formulation	O
.	O

Methods	O
of	O
manufacture	O
of	O
the	O
formulation	O
are	O
also	O
described	O
along	O
with	O
methods	O
of	O
use	O
for	O
selected	O
treatments	O
.	O

Bicyclic	O
heterocyclic	O
derivatives	O
as	O
mnk1	B
and	O
mnk2	B
modulators	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
certain	O
compounds	O
(	O
e.g.	O
,	O
imidazopyrazine	O
,	O
imidazopyridine	O
,	O
imidazopyridazine	O
and	O
imidazpyrimidine	O
compounds	O
)	O
that	O
act	O
as	O
inhibitors	O
of	O
the	O
MAP	B
kinase	I
interacting	O
kinases	O
MNK2a	B
,	O
MNK2b	B
,	O
MNK1a	B
,	O
and	O
MNK1b	B
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancer	O
)	O
,	O
inflammatory	O
diseases	O
,	O
Alzheimer	O
's	O
disease	O
)	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
these	O
diseases	O
.	O

Treatment	O
method	O
for	O
steroid	O
responsive	O
dermatoses	O
Invented	O
is	O
a	O
method	O
of	O
treating	O
steroid	O
responsive	O
dermatoses	O
in	O
a	O
mammal	O
,	O
including	O
a	O
human	O
,	O
in	O
need	O
thereof	O
which	O
comprises	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
N-	O
{	O
(	O
1S	O
)	O
-2-Amino-1-	O
[	O
(	O
3-fluorophenyl	O
)	O
methyl	O
]	O
ethyl	O
}	O
-5-chloro-4-	O
(	O
4-chloro-1-methyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-2-thiophenecarboxamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
compound	O
N-	O
{	O
(	O
1S	O
)	O
-2-amino-1-	O
[	O
(	O
3,4-difluorophenyl	O
)	O
methyl	O
]	O
ethyl	O
}	O
-5-chloro-4-	O
(	O
4-chloro-1-methyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-2-	O
furancarboxamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
such	O
mammal	O
.	O

Pyrrolopyridinone	O
derivatives	O
as	O
ttx	O
-	O
s	O
blockers	O
The	O
present	O
invention	O
relates	O
to	O
pyrrolopyridinone	O
derivatives	O
which	O
have	O
blocking	O
activities	O
of	O
voltage	B
gated	I
sodium	I
channels	I
as	O
the	O
TTX	B
-	I
S	I
channels	I
,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
and	O
diseases	O
in	O
which	O
voltage	B
gated	I
sodium	I
channels	I
are	O
involved	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
voltage	B
gated	I
sodium	I
channels	I
are	O
involved	O
.	O

Cul4b	B
as	O
predictive	O
biomarker	O
for	O
cancer	O
treatment	O
The	O
current	O
disclosure	O
describes	O
materials	O
and	O
methods	O
for	O
identifying	O
subjects	O
that	O
would	O
benefit	O
from	O
treatment	O
with	O
a	O
DNA	B
topoisomerase	I
1	I
inhibitor	O
,	O
based	O
on	O
the	O
levels	O
of	O
cullin	B
4B	I
gene	O
,	O
RNA	O
and	O
protein	O
levels	O
in	O
the	O
subject	O
.	O

The	O
disclosure	O
identifies	O
CUL4B	B
as	O
a	O
predictive	O
biomarker	O
for	O
cancer	O
diagnosis	O
and	O
the	O
subsequent	O
treatment	O
with	O
directed	O
therapeutic	O
agents	O
.	O

The	O
current	O
disclosure	O
also	O
identifies	O
novel	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
level	O
of	O
CUL4B	B
expression	O
,	O
and	O
sensitize	O
a	O
subject	O
to	O
treatment	O
with	O
a	O
second	O
therapeutic	O
agent	O
.	O

Prophylactic	O
agent	O
and/or	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
The	O
problem	O
to	O
be	O
solved	O
by	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
excellent	O
prophylactic	O
agent	O
and/or	O
an	O
excellent	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
.	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
agent	O
and/or	O
a	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
,	O
which	O
comprises	O
an	O
effective	O
amount	O
of	O
4-piperidyldiphenylpropoxyacetate	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
carrier	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
hemoglobin	B
gene	O
family	O
expression	O
Aspects	O
of	O
the	O
invention	O
provide	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
(	O
HBB	B
,	O
HBD	B
,	O
HBEl	B
,	O
HBG1	B
or	O
HBG2	B
)	O
.	O

Further	O
aspects	O
provide	O
compositions	O
and	O
kits	O
comprising	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
.	O

Methods	O
for	O
modulating	O
expression	O
of	O
hemoglobin	B
genes	O
using	O
the	O
single	O
stranded	O
oligonucleotides	O
are	O
also	O
provided	O
.	O

Further	O
aspects	O
of	O
the	O
invention	O
provide	O
methods	O
for	O
selecting	O
a	O
candidate	O
oligonucleotide	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
peridontitis	O
and	O
rheumatoid	O
arthritis	O
Disclosed	O
are	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
useful	O
for	O
the	O
treatment	O
of	O
periodontitis	O
and	O
rheumatoid	O
arthritis	O
may	O
be	O
formulated	O
for	O
oral	O
,	O
buccal	O
,	O
rectal	O
,	O
topical	O
,	O
transdermal	O
,	O
transmucosal	O
,	O
intravenous	O
,	O
parenteral	O
administration	O
,	O
syrup	O
or	O
injection	O
.	O

Polyoxopregnane	O
compounds	O
and	O
use	O
thereof	O
Disclosed	O
are	O
polyoxopregnane	O
compounds	O
and	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
manufacture	O
of	O
medicaments	O
reversing	O
or	O
inhibiting	O
mutidrug	O
resistance	O
of	O
tumor	O
cells	O
.	O

Composition	O
for	O
restricting	O
apoptosis	O
,	O
including	O
mirna	O
of	O
epstein	O
-	O
barr	O
virus	O
,	O
or	O
promoting	O
cell	O
proliferation	O
The	O
present	O
invention	O
relates	O
to	O
uses	O
for	O
:	O
restricting	O
apoptosis	O
of	O
miRNA	O
of	O
Epstein	O
-	O
Barr	O
virus	O
,	O
especially	O
miR	B
-	I
BART3	I
-	I
5p	I
,	O
miR	B
-	I
BART3	I
-	I
3p	I
,	O
miR	B
-	I
BART21	I
-	I
5p	I
,	O
miR	B
-	I
BART21	I
-	I
3p	I
,	O
miR	B
-	I
BART18	I
-	I
5p	I
,	O
miR	B
-	I
BART18	I
-	I
3p	I
,	O
miR	B
-	I
BART7	I
-	I
5p	I
,	O
miR	B
-	I
BART7	I
-	I
3p	I
,	O
miR	B
-	I
BART8	I
-	I
5p	I
,	O
miR	B
-	I
BART8	I
-	I
3p	I
,	O
miR	B
-	I
BART9	I
-	I
5p	I
,	O
miR	B
-	I
BART22	I
-	I
5p	I
,	O
miR	B
-	I
BART22	I
-	I
3p	I
,	O
miR	B
-	I
BART19	I
-	I
5p	I
,	O
miR	B
-	I
BART19	I
-	I
3p	I
,	O
miR	B
-	I
BART13	I
-	I
5p	I
,	O
miR	B
-	I
BART13	I
-	I
3p	I
,	O
miR	B
-	I
BART14	I
-	I
5p	I
,	O
miR	B
-	I
BART2	I
-	I
3p	I
,	O
miR	B
-	I
BART1	I
-	I
3p	I
,	O
miR	B
-	I
BART9	I
-	I
3p	I
,	O
miR	B
-	I
BART10	I
-	I
5p	I
,	O
miR	B
-	I
BART10	I
-	I
3p	I
,	O
miR	B
-	I
BART14	I
-	I
3p	I
and	O
their	O
mimics	O
;	O
and	O
promoting	O
cell	O
proliferation	O
.	O

Novel	O
therapeutics	O
for	O
brain	O
cancer	O
Provided	O
herein	O
are	O
novel	O
compositions	O
and	O
methods	O
to	O
inhibit	O
Olig2	B
activity	O
.	O

The	O
Olig2	B
inhibitors	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
useful	O
,	O
inter	O
alia	O
,	O
for	O
treating	O
cancer	O
.	O

In	O
particular	O
the	O
Olig2	B
inhibitors	O
may	O
be	O
used	O
to	O
treat	O
glioblastoma	O
.	O

Further	O
,	O
provided	O
are	O
peptide	O
compositions	O
capable	O
of	O
inhibiting	O
Olig	B
2	I
.	O

Neuroendocrine	O
tumor	O
treatment	O
A	O
method	O
for	O
treating	O
a	O
neuroendocrine	O
tumor	O
,	O
particularly	O
pancreatic	O
neuroendocrine	O
tumor	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
therapeutic	O
agent	O
,	O
wherein	O
said	O
neuroendocrine	O
tumor	O
is	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B
inhibitor	O
;	O
uses	O
of	O
said	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
neuroendocrine	O
tumor	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B
inhibitor	O
;	O
uses	O
of	O
said	O
compound	O
for	O
treating	O
said	O
disease	O
;	O
and	O
related	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
package	O
thereof	O
.	O

Method	O
for	O
obtaining	O
high	O
concentrations	O
of	O
the	O
chemical	O
constituent	O
trans	O
-	O
pinocarvyl	O
acetate	O
by	O
hydrodistillation	O
of	O
the	O
aerial	O
parts	O
of	O
microlicia	O
graveolens	O
and	O
obtaining	O
nano	O
-	O
emulsified	O
formulations	O
The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
provides	O
a	O
quantitative	O
and	O
qualitative	O
production	O
method	O
for	O
the	O
chemical	O
compound	O
known	O
as	O
trans	O
-	O
pinocarvyl	O
acetate	O
.	O

This	O
compound	O
has	O
relevant	O
applications	O
in	O
the	O
chemical	O
and	O
cosmetic	O
industries	O
for	O
producing	O
perfumes	O
and	O
fragrances	O
.	O

The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
also	O
provides	O
nanoemulsions	O
containing	O
essential	O
oil	O
of	O
Microlicia	O
graveolens	O
,	O
thus	O
making	O
its	O
use	O
possible	O
.	O

Novel	O
fatty	O
acid	O
-	O
salicylate	O
conjugates	O
with	O
enhanced	O
therapeutic	O
properties	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
cancer	O
with	O
an	O
inventive	O
composition	O
.	O
'	O

The	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
biomedicine	O
,	O
pharmacology	O
,	O
and	O
molecular	O
biology	O
.	O

Novel	O
heteroaryl	O
and	O
heterocycle	O
compounds	O
,	O
composition	O
and	O
methods	O
thereof	O
Disclosed	O
are	O
novel	O
heteroaryl	O
and	O
heterocycle	O
compounds	O
of	O
formula	O
I-1	O
,	O
I-2	O
or	O
I-3	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
uses	O
and	O
methods	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
PI3	B
K	I
and	O
for	O
treating	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O

Benzisoxazole	O
modulators	O
of	O
neurogenesis	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
Ar1	O
/	O
Ar2	O
are	O
phenyl	O
or	O
a	O
5	O
or	O
6-membered	O
heteroaryl	O
;	O
R1	O
/	O
R2	O
is	O
hydrogen	O
,	O
halogen	O
,	O
lower	O
alkyl	O
,	O
CF3	O
or	O
lower	O
alkoxy	O
;	O
n	O
,	O
m	O
are	O
1	O
or	O
2	O
;	O
or	O
to	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
,	O
to	O
a	O
racemic	O
mixture	O
or	O
to	O
its	O
corresponding	O
enantiomer	O
and/or	O
optical	O
isomers	O
thereof	O
,	O
with	O
the	O
exception	O
of	O
the	O
compound	O
2,1-benzisoxazole,3-	O
(	O
4-chlorophenyl	O
)	O
-5-	O
(	O
1-phenyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-	O
.	O

The	O
compounds	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
,	O
obsessive	O
-	O
compulsive	O
personality	O
disorder	O
,	O
major	O
depression	O
,	O
bipolar	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
normal	O
aging	O
,	O
epilepsy	O
,	O
retinal	O
degeneration	O
,	O
traumatic	O
brain	O
injury	O
,	O
spinal	O
cord	O
injury	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
panic	O
disorder	O
,	O
Parkinson	O
's	O
disease	O
,	O
dementia	O
,	O
Alzheimer	O
's	O
disease	O
,	O
mild	O
cognitive	O
impairment	O
,	O
chemotherapy	O
-	O
induced	O
cognitive	O
dysfunction	O
,	O
Down	O
syndrome	O
,	O
autism	O
spectrum	O
disorders	O
,	O
hearing	O
loss	O
,	O
tinnitus	O
,	O
spinocerebellar	O
ataxia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
multiple	O
sclerosis	O
,	O
Huntington	O
's	O
disease	O
,	O
stroke	O
,	O
radiation	O
therapy	O
,	O
chronic	O
stress	O
,	O
abuse	O
of	O
neuro	O
-	O
active	O
drugs	O
,	O
such	O
as	O
alcohol	O
,	O
opiates	O
,	O
methamphetamine	O
,	O
phencyclidine	O
and	O
cocaine	O
.	O

Substituted	O
naphthyridinedione	O
derivatives	O
as	O
hiv	B
integrase	I
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
Substituted	O
Naphthyridinedione	O
Derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
one	O
Substituted	O
Naphthyridinedione	O
Derivative	O
,	O
and	O
methods	O
of	O
using	O
the	O
Substituted	O
Naphthyridinedione	O
Derivatives	O
for	O
treating	O
or	O
preventing	O
HIV	O
infection	O
in	O
a	O
subject	O
.	O

Piperazinotrizole	O
compound	O
,	O
preparation	O
method	O
therefor	O
,	O
and	O
use	O
thereof	O
in	O
drug	O
preparation	O
Provided	O
is	O
a	O
piperazinotrizole	O
compound	O
represented	O
by	O
general	O
formula	O
I	O
or	O
an	O
isomer	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
,	O
prodrug	O
or	O
hydrate	O
thereof	O
.	O

Also	O
provided	O
are	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
a	O
use	O
thereof	O
as	O
a	O
high	O
-	O
selectivity	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase-1	O
(	O
PARP1	B
)	O
inhibitor	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
PARP	B
-	O
related	O
diseases	O
.	O

Orl-1	B
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
anxiety	O
The	O
use	O
of	O
ORL-1	B
receptor	O
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
is	O
described	O
.	O

(	O
aza-	O
)	O
isoquinolinone	O
derivatives	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
X	O
,	O
Y	O
and	O
n	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
Tankyrase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
central	O
nervous	O
system	O
injury	O
and	O
different	O
forms	O
of	O
inflammation	O
.	O

Buffer	O
substance	O
for	O
the	O
treatment	O
of	O
wounds	O
The	O
invention	O
relates	O
to	O
buffer	O
substances	O
for	O
the	O
phase	O
-	O
appropriate	O
treatment	O
of	O
wounds	O
,	O
said	O
treatment	O
comprising	O
the	O
suppression	O
of	O
fibrin	B
formation	O
and/or	O
fibrin	B
cross	O
-	O
linking	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
wound	O
dressing	O
product	O
containing	O
said	O
buffer	O
substances	O
to	O
suppress	O
fibrin	B
formation	O
and/or	O
fibrin	B
cross	O
-	O
linking	O
.	O

Therapeutic	O
and	O
diagnostic	O
mirna	O
regulator	O
in	O
kidney	O
disease	O
The	O
present	O
invention	O
discloses	O
a	O
method	O
of	O
diagnosing	O
glomerular	O
kidney	O
disease	O
or	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
comprising	O
determining	O
the	O
expression	O
level	O
of	O
miRNA	O
miR-193a	O
,	O
wherein	O
said	O
glomerular	O
kidney	O
disease	O
or	O
risk	O
thereof	O
is	O
detected	O
if	O
miR-193a	O
expression	O
levels	O
are	O
increased	O
as	O
compared	O
to	O
a	O
healthy	O
control	O
,	O
method	O
of	O
prophylactically	O
treating	O
a	O
glomerular	O
kidney	O
disease	O
or	O
of	O
reducing	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
progression	O
in	O
a	O
patient	O
comprising	O
inhibiting	O
miR-193a	O
in	O
a	O
podocyte	O
cell	O
in	O
said	O
patient	O
and	O
suitable	O
means	O
for	O
said	O
methods	O
.	O

Preventive	O
products	O
against	O
pathogenic	O
germs	O
,	O
and	O
method	O
for	O
use	O
thereof	O
The	O
subject	O
of	O
the	O
invention	O
is	O
a	O
group	O
of	O
preventive	O
products	O
to	O
be	O
used	O
against	O
pathogenic	O
germs	O
,	O
and	O
the	O
method	O
for	O
using	O
these	O
products	O
,	O
each	O
product	O
is	O
being	O
a	O
special	O
combined	O
additive	O
for	O
preventive	O
purposes	O
,	O
which	O
could	O
be	O
used	O
as	O
additive	O
or	O
supplementary	O
material	O
in	O
animal	O
feed	O
to	O
produce	O
products	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
infection	O
of	O
poultry	O
,	O
which	O
selectively	O
inhibit	O
the	O
propagation	O
of	O
pathogenic	O
germs	O
that	O
generate	O
endo	O
and	O
exo	O
toxins	O
.	O

The	O
product	O
according	O
to	O
the	O
invention	O
suitable	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
contamination	O
of	O
poultry	O
.	O

It	O
is	O
charactrised	O
by	O
that	O
,	O
the	O
product	O
is	O
prepared	O
by	O
homogenizing	O
or	O
blending	O
methylglyoxal	O
or	O
its	O
diacetate	O
,	O
i.e.	O
methylglyoxal	O
diacetate	O
with	O
some	O
organic	O
acids	O
and/or	O
in	O
combination	O
with	O
Na	O
salts	O
of	O
organic	O
acids	O
.	O

During	O
the	O
method	O
according	O
to	O
the	O
invention	O
the	O
product	O
is	O
added	O
to	O
the	O
drinking	O
water	O
of	O
the	O
animals	O
and/or	O
mixed	O
in	O
the	O
feed	O
,	O
and	O
in	O
this	O
way	O
it	O
is	O
administered	O
to	O
the	O
animals	O
,	O
and/or	O
used	O
for	O
disinfecting	O
the	O
bedding	O
materials	O
.	O

1,6-	O
diazabicyclo	O
[	O
3,2,1	O
]	O
octan-	O
7-	O
one	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
Compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
their	O
preparation	O
and	O
use	O
in	O
preventing	O
or	O
treating	O
bacterial	O
infections	O
are	O
disclosed	O
.	O

Quinazolinone	O
compounds	O
and	O
derivatives	O
thereof	O
Compounds	O
of	O
Formula	O

I	O
are	O
useful	O
inhibitors	O
of	O
tankyrase	O
.	O

Compounds	O
of	O
Formula	O
I	O
have	O
the	O
following	O
structure	O
:	O
where	O
the	O
definitions	O
of	O
the	O
variables	O
are	O
provided	O
herein	O
.	O

Nootropic	O
compositions	O
for	O
improving	O
memory	O
performance	O
The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
improving	O
memory	O
and	O
related	O
functions	O
as	O
alertness	O
,	O
attention	O
,	O
concentration	O
,	O
learning	O
,	O
and	O
language	O
processing	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
two	O
drugs	O
selected	O
from	O
cinacalcet	O
,	O
baclofen	O
,	O
acamprosate	O
,	O
mexiletine	O
,	O
sulfisoxazole	O
and	O
torasemide	O
useful	O
to	O
enhance	O
memory	O
and	O
related	O
functions	O
in	O
healthy	O
subjects	O
or	O
subjects	O
suffering	O
from	O
conditions	O
or	O
disorders	O
having	O
a	O
negative	O
impact	O
on	O
their	O
memory	O
.	O

Crystal	O
having	O
crystal	O
habits	O
and	O
pharmaceutical	O
composition	O
obtained	O
by	O
processing	O
the	O
crystal	O
An	O
object	O
is	O
to	O
provide	O
means	O
for	O
improving	O
the	O
solubility	O
of	O
luliconazole	O
.	O

Disclosed	O
is	O
a	O
crystal	O
of	O
luliconazole	O
wherein	O
the	O
crystal	O
has	O
such	O
a	O
crystal	O
habit	O
that	O
(	O
021	O
)	O
plane	O
is	O
a	O
specific	O
crystal	O
growth	O
plane	O
.	O

""""	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
hydrogels	O
including	O
these	O
cross	O
-	O
linkers	O
and	O
applications	O
thereof	O
""""	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
in	O
particular	O
for	O
hyaluronan	O
hydrogels	O
,	O
corresponding	O
hydrogels	O
including	O
said	O
cross	O
-	O
linkers	O
and	O
various	O
applications	O
thereof	O
.	O

The	O
cross	O
linker	O
of	O
the	O
invention	O
is	O
a	O
bi-	O
or	O
multifunctional	O
cross	O
-	O
linker	O
comprising	O
or	O
consisting	O
of	O
an	O
aromatic	O
or	O
heteroaromatic	O
ring	O
system	O
with	O
3	O
-	O
6	O
C	O
atoms	O
which	O
is	O
coupled	O
via	O
functional	O
groups	O
on	O
at	O
least	O
2	O
ring	O
positions	O
with	O
at	O
least	O
2	O
terminal	O
groups	O
capable	O
to	O
form	O
a	O
covalent	O
bond	O
with	O
thiol	O
or	O
amino	O
groups	O
,	O
in	O
particular	O
with	O
thiol	O
groups	O
in	O
a	O
thiol	O
-	O
en	O
reaction	O
.	O

The	O
cross	O
-	O
linker	O
may	O
be	O
charged	O
or	O
uncharged	O
.	O

In	O
a	O
specific	O
embodiment	O
,	O
the	O
terminal	O
groups	O
are	O
coupled	O
to	O
carboxy	O
groups	O
of	O
the	O
aromatic	O
or	O
heteroaromatic	O
ring	O
system	O
via	O
an	O
ester	O
or	O
amide	O
bond	O
.	O

More	O
specifically	O
,	O
the	O
cross	O
-	O
linker	O
of	O
the	O
invention	O
is	O
a	O
derivative	O
of	O
pyridine-3	O
,	O
5-dicarboxylic	O
acid	O
or	O
a	O
corresponding	O
pyridinium	O
salt	O
thereof	O
wherein	O
2	O
terminal	O
groups	O
are	O
coupled	O
to	O
the	O
carboxy	O
groups	O
of	O
the	O
pyridine	O
or	O
pyridinium	O
core	O
via	O
an	O
ester	O
or	O
amide	O
bond	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
cross	O
-	O
linker	O
is	O
N3,N5-bis	O
(	O
2-acrylamidoethyl	O
)	O
pyridine-3	O
,	O
5-dicarboxamide	O
or	O
a	O
3,5-bis	O
(	O
(	O
2-acrylamidoethyl	O
)	O
carbamoyl	O
)	O
-1-methylpyridin	O
-	O
l	O
-	O
ium	O
-	O
halogenide	O
.	O

Dihydroferulic	O
acid	O
and/or	O
dihydrocaffeic	O
acid	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I	O
for	O
use	O
as	O
a	O
medicament	O
,	O
wherein	O
R1	O
is	O
methyl	O
or	O
hydrogen	O
,	O
and	O
wherein	O
R2	O
is	O
methyl	O
or	O
hydrogen	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
food	O
ingredients	O
and	O
food	O
products	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
producing	O
compounds	O
of	O
the	O
formula	O
I.	O

Na	O
-	O
acyl	O
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	B
endopeptidase	I
and	O
dipeptidyl	B
peptidase	I
-	I
iv	I
,	O
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
The	O
subject	O
of	O
the	O
present	O
invention	O
is	O
nα	O
-	O
acyl	O
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	O
endopeptidase	B
and	O
dipeptidyl	O
peptidase	B
-	I
iv	I
,	I
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
.	O

Phenyl	O
1,2-isoxazolyl	O
or	O
phenyl	O
1,2-pyrazole	O
compound	O
and	O
application	O
thereof	O
Disclosed	O
is	O
an	O
application	O
of	O
a	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
following	O
structure	O
formula	O
(	O
I	O
)	O
.	O

It	O
is	O
proved	O
through	O
a	O
biological	O
activity	O
test	O
,	O
the	O
compound	O
has	O
an	O
obvious	O
activity	O
of	O
inhibiting	O
the	O
heat	B
shock	I
protein	I
90	I
.	O

Therefore	O
,	O
the	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
the	O
heat	B
shock	I
protein	I
90	I
for	O
curing	O
cancers	O
.	O

Combination	O
of	O
a	O
6-oxo-1,6-dihydro	O
-	O
pyridazine	O
derivative	O
having	O
anti	O
-	O
cancer	O
activity	O
with	O
a	O
mek	O
inhibitor	O
A	O
pharmaceutical	O
composition	O
comprising	O
:	O
3-	O
(	O
1-	O
{	O
3-	O
[	O
5-	O
(	O
1-methyl	O
-	O
piperidin-4-ylmethoxy	O
)	O
-pyrimidin-2-yl	O
]	O
-benzyl	O
}	O
-6-oxo-1,6-dihydro	O
-	O
pyridazin-3-yl	O
)	O
-	O
benzonitrile	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
and	O
N-	O
(	O
(	O
S	O
)	O
-2,3-dihydroxy	O
-	O
propyl	O
)	O
-3-	O
(	O
2-fluoro-4-iodo	O
-	O
phenylamino	O
)	O
-isonicotinamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
.	O

5-fluoro	O
-	O
n-	O
(	O
pyridin-2-yl	O
)	O
pyridin-2-amine	O
derivatives	O
containing	O
a	O
sulfone	O
group	O
The	O
present	O
invention	O
relates	O
to	O
5-fluoro	O
-	O
N-	O
(	O
pyridin-2-yl	O
)	O
pyridin-2-amine	O
derivatives	O
containing	O
a	O
sulfone	O
group	O
of	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
and	O
defined	O
herein	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
disorders	O
,	O
in	O
particular	O
of	O
hyper	O
-	O
proliferative	O
disorders	O
and/or	O
virally	O
induced	O
infectious	O
diseases	O
and/or	O
of	O
cardiovascular	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O

Anthocyanidin	O
complex	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
The	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
complex	O
of	O
delphinidin	O
and	O
a	O
sulfoalkyl	O
ether	O
ß	O
-	O
cyclodextrin	O
for	O
use	O
as	O
a	O
medicinal	O
drug	O
,	O
in	O
particular	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O

Inhibitors	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
7	I
(	O
cdk7	B
)	O
The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	O
,	O
polymorphs	O
,	O
co	O
-	O
crystals	O
,	O
tautomers	O
,	O
stereoisomers	O
,	O
isotopically	O
labeled	O
derivatives	O
,	O
prodrugs	O
,	O
and	O
compositions	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
and	O
kits	O
involving	O
the	O
inventive	O
compounds	O
or	O
compositions	O
for	O
treating	O
or	O
preventing	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancers	O
(	O
e.g.	O
,	O
leukemia	O
,	O
lymphoma	O
,	O
melanoma	O
,	O
multiple	O
myeloma	O
,	O
breast	O
cancer	O
,	O
Ewing	O
's	O
sarcoma	O
,	O
osteosarcoma	O
,	O
brain	O
cancer	O
,	O
neuroblastoma	O
,	O
lung	O
cancer	O
)	O
,	O
benign	O
neoplasms	O
,	O
angiogenesis	O
,	O
inflammatory	O
diseases	O
,	O
autoinflammatory	O
diseases	O
,	O
and	O
autoimmune	O
diseases	O
)	O
in	O
a	O
subject	O
.	O

Treatment	O
of	O
a	O
subject	O
with	O
a	O
proliferative	O
disease	O
using	O
a	O
compound	O
or	O
composition	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
aberrant	O
activity	O
of	O
a	O
kinase	B
,	O
such	O
as	O
cyclin	B
-	I
dependent	I
kinase	I
(	O
CDK	B
)	O
(	O
e.g.	O
,	O
cyclin	B
-	I
dependent	I
kinase	I
7	I
(	O
CDK7	B
)	O
)	O
,	O
and	O
therefore	O
,	O
induce	O
cellular	O
apoptosis	O
and/or	O
inhibit	O
transcription	O
in	O
the	O
subject	O
.	O

Substituted	O
pyrimidinyl	O
and	O
pyridinyl	O
-	O
pyrrolopyridinones	O
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrimidinyl-	O
and	O
pyridinylpyrrolopyridinone	O
compounds	O
which	O
modulate	O
the	O
activity	O
of	O
protein	O
kinases	O
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
caused	O
by	O
dysregulated	O
protein	O
kinase	O
activity	O
,	O
in	O
particular	O
RET	O
family	O
kinases	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
treating	O
diseases	O
utilizing	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
.	O

Compositions	O
,	O
uses	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
dental	O
caries	O
The	O
present	O
invention	O
provides	O
compositions	O
,	O
uses	O
and	O
methods	O
thereof	O
,	O
for	O
inhibiting	O
the	O
growth	O
of	O
caries	O
-	O
causing	O
bacteria	O
.	O

The	O
composition	O
comprises	O
xylitol	O
,	O
sodium	O
citrate	O
,	O
sodium	O
bicarbonate	O
,	O
anionic	O
polymers	O
and	O
acceptable	O
carrier	O
materials	O
.	O

The	O
compositions	O
can	O
tend	O
to	O
be	O
used	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
caused	O
by	O
caries	O
-	O
causing	O
bacteria	O
The	O
compositions	O
can	O
further	O
tend	O
to	O
be	O
used	O
in	O
patients	O
such	O
as	O
children	O
,	O
adolescents	O
or	O
patients	O
suffering	O
from	O
a	O
heightened	O
susceptibility	O
to	O
toxic	O
substances	O
.	O

Use	O
of	O
pkc412	O
in	O
the	O
reactivation	O
of	O
latent	O
hiv-1	O
HIV-1	O
latency	O
is	O
a	O
major	O
obstacle	O
in	O
HIV-1	O
eradication	O
.	O

Although	O
current	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
efficiently	O
decreased	O
the	O
viral	O
load	O
in	O
patients	O
,	O
latently	O
infected	O
cells	O
are	O
permanent	O
reservoirs	O
and	O
inevitably	O
lead	O
to	O
viral	O
rebound	O
upon	O
discontinuation	O
of	O
HAART	O
.	O

Therefore	O
,	O
extensive	O
efforts	O
are	O
being	O
directed	O
toward	O
the	O
reactivation	O
of	O
latent	O
HIV	O
reservoirs	O
with	O
the	O
hope	O
that	O
latently	O
infected	O
cells	O
will	O
be	O
eliminated	O
by	O
the	O
host	O
immune	O
system	O
and/or	O
virus	O
-	O
mediated	O
cell	O
lysis	O
.	O

We	O
are	O
currently	O
working	O
on	O
developing	O
strategies	O
to	O
reactivate	O
the	O
latent	O
viral	O
reservoir	O
in	O
order	O
to	O
eliminate	O
them	O
.	O

Through	O
high	O
-	O
throughput	O
screening	O
,	O
an	O
anti-	O
cancer	O
molecule	O
PKC412	O
that	O
is	O
able	O
to	O
reactivate	O
HIV-1	O
expression	O
from	O
a	O
HIV-1	O
latently	O
infected	O
ACH2	O
cell	O
line	O
and	O
latently	O
infected	O
CD4	O
+	O
T	O
cells	O
has	O
been	O
identified	O
.	O

Medical	O
patch	O
[	O
Problem	O
]	O
To	O
provide	O
a	O
medical	O
patch	O
with	O
an	O
adhesive	O
layer	O
formed	O
thereon	O
,	O
said	O
medical	O
patch	O
containing	O
a	O
large	O
amount	O
of	O
a	O
drug	O
and	O
a	O
dissolution	O
auxiliary	O
,	O
being	O
flexible	O
without	O
losing	O
shape	O
and	O
leaving	O
behind	O
adhesive	O
residue	O
,	O
and	O
exhibiting	O
excellent	O
drug	O
release	O
from	O
the	O
adhesive	O
layer	O
.	O

[	O
Solution	O
]	O
A	O
medical	O
patch	O
comprising	O
:	O
a	O
drug	O
having	O
a	O
secondary	O
or	O
tertiary	O
amine	O
structure	O
in	O
the	O
molecules	O
thereof	O
;	O
a	O
liquid	O
auxiliary	O
for	O
the	O
drug	O
;	O
and	O
a	O
resin	O
composition	O
formed	O
by	O
cross	O
-	O
linking	O
a	O
copolymerized	O
acrylic	O
resin	O
with	O
an	O
isocyanate	O
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
that	O
has	O
been	O
blocked	O
,	O
said	O
copolymerized	O
acrylic	O
resin	O
having	O
a	O
(	O
meth	O
)	O
acrylate	O
monomer	O
as	O
a	O
main	O
monomer	O
component	O
and	O
having	O
a	O
functional	O
group	O
capable	O
of	O
reacting	O
with	O
the	O
aforementioned	O
isocyanate	O
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
to	O
thereby	O
form	O
a	O
cross	O
-	O
linked	O
structure	O
.	O

The	O
solubility	O
of	O
the	O
drug	O
in	O
a	O
phosphate	O
buffer	O
solution	O
(	O
pH6.4	O
)	O
is	O
at	O
least	O
0.5wt%	O
.	O

Inhibitor	B
of	I
apoptosis	I
protein	I
(	O
iap	B
)	O
antagonists	O
Provided	O
herein	O
are	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
inhibitor	B
of	I
apoptosis	I
proteins	I
(	O
IAPs	B
)	O
,	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
comprising	O
the	O
compounds	O
.	O

Prevention	O
or	O
treatment	O
agent	O
for	O
hepatic	O
fibrosis	O
In	O
the	O
present	O
invention	O
,	O
a	O
CBP	B
/	O
β	B
-	I
catenin	I
inhibitor	O
exhibits	O
a	O
superior	O
defibrinating	O
effect	O
with	O
respect	O
to	O
Cre	O
/	O
loxP	O
/	O
HCV	O
-	O
MxCre	O
transgenic	O
mice	O
,	O
which	O
are	O
an	O
experimental	O
animal	O
model	O
for	O
hepatic	O
fibrosis	O
,	O
and	O
is	O
useful	O
as	O
a	O
prevention	O
or	O
treatment	O
drug	O
for	O
hepatic	O
fibrosis	O
.	O

Prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
Provided	O
is	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
,	O
which	O
comprises	O
a	O
novel	O
component	O
capable	O
of	O
preventing	O
the	O
deterioration	O
of	O
a	O
tear	O
fluid	O
secretion	O
ability	O
and	O
also	O
capable	O
of	O
inhibiting	O
the	O
generation	O
of	O
active	O
oxygen	O
in	O
tear	O
gland	O
tissues	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
contains	O
a	O
maqui	O
berry	O
extract	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
delphinidin	O
glycoside	O
that	O
is	O
extracted	O
from	O
maqui	O
berry	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
at	O
least	O
one	O
component	O
selected	O
from	O
delphinidin-3-sambubioside-5-glucoside	O
,	O
delphinidin-3,5-diglucoside	O
,	O
delphinidin-3-sambubioside	O
and	O
delphinidin-3-glucoside	O
,	O
desirably	O
delphinidin-3,5-diglucoside	O
,	O
as	O
an	O
active	O
ingredient	O
.	O

Pyrazolyl	O
-	O
based	O
carboxamides	O
i	O
as	O
crac	B
channel	I
inhibitors	O
The	O
Invention	O
relates	O
to	O
pyrazolyl	O
-	O
based	O
carboxamide	O
compounds	O
of	O
formula	O
(	O
l	O
)	O
useful	O
as	O
ICRAC	B
inhibitors	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
to	O
these	O
compounds	O
for	O
the	O
use	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and/or	O
disorders	O
,	O
in	O
particular	O
inflammatory	O
diseases	O
and/or	O
inflammatory	O
disorders	O
.	O

Pyrrolotriazine	O
derivatives	O
as	O
pi3k	O
inhibitors	O
New	O
pyrrolotriazine	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
Phosphoinositide	O
3-Kinases	O
(	O
PI3Ks	O
)	O

Compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
This	O
invention	O
provides	O
compounds	O
,	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
comprising	O
the	O
timely	O
administration	O
of	O
a	O
provided	O
compound	O
,	O
which	O
has	O
a	O
structure	O
related	O
to	O
an	O
endogenously	O
formed	O
lipid	O
mediator	O
.	O

One	O
embodiment	O
of	O
the	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
selected	O
from	O
a	O
group	O
having	O
the	O
general	O
formula	O
A.	O

Substituted	O
2-aza	O
-	O
bicyclo	O
[	O
2.2.1	O
]	O
heptane-3-carboxylic	O
acid	O
(	O
cyano	O
-	O
methyl	O
)	O
-amides	O
inhibitors	O
of	O
cathepsin	O
c	O
This	O
invention	O
relates	O
to	O
2-Aza	O
-	O
bicyclo	O
[	O
2.2.1	O
]	O
heptane-3-carboxylic	O
acid	O
(	O
cyano	O
-	O
methyl	O
)	O
-amides	O
of	O
formula	O
(	O
1	O
)	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
Cathepsin	O
C	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
connected	O
with	O
dipeptidyl	O
peptidase	O
I	O
activity	O
,	O
e.g.	O
respiratory	O
diseases	O
.	O

Pyrazole	O
-	O
amide	O
compound	O
and	O
medicinal	O
uses	O
therefor	O
Provided	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
[	O
I	O
]	O
[	O
in	O
which	O
n	O
indicates	O
1	O
or	O
2	O
]	O
,	O
formula	O
[	O
II	O
]	O
or	O
[	O
IIh	O
]	O
,	O
or	O
formula	O
[	O
III	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Also	O
provided	O
are	O
medicinal	O
uses	O
for	O
the	O
compound	O
or	O
the	O
salt	O
thereof	O
.	O

Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
ischemic	O
events	O
Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
pharmaceutical	O
composition	O
comprising	O
cangrelor	O
.	O

The	O
method	O
may	O
further	O
comprise	O
administering	O
an	O
additional	O
therapeutic	O
agent	O
to	O
the	O
patient	O
,	O
the	O
additional	O
therapeutic	O
agent	O
comprising	O
a	O
P2Yi2	O
inhibitor	O
.	O

Pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
.	O

The	O
pharmaceutical	O
compositions	O
comprise	O
cangrelor	O
.	O

Methods	O
of	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
,	O
comprising	O
admixing	O
cangrelor	O
with	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

An	O
ischemic	O
event	O
may	O
include	O
stent	O
thrombosis	O
,	O
myocardial	O
infarction	O
,	O
ischemia	O
-	O
driven	O
revascularization	O
,	O
and	O
mortality	O
.	O

Compositions	O
for	O
use	O
in	O
treating	O
heavy	O
menstrual	O
bleeding	O
and	O
uterine	O
fibroids	O
The	O
present	O
invention	O
relates	O
to	O
the	O
method	O
of	O
treating	O
heavy	O
menstrual	O
bleeding	O
in	O
a	O
subject	O
with	O
or	O
without	O
uterine	O
fibroids	O
and	O
in	O
need	O
of	O
treatment	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
4-	O
(	O
(	O
R	O
)	O
-2-	O
[	O
5-	O
(	O
2-fluoro-3-methoxy	O
-	O
phenyl	O
)	O
-3-	O
(	O
2-fluoro-6-trifluoromethyl	O
-	O
benzyl	O
)	O
-4-	O
methyl-2,6-dioxo-3,6-dihydro-2H	O
-	O
pyrimidin	O
-	O
l	O
-	O
yl	O
]	O
-l	O
-	O
phenyl	O
-	O
ethylamino	O
)	O
-butyric	O
acid	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
combination	O
with	O
estrogens	O
and	O
progestogens	O
.	O

3-heteroaryl	O
substituted	O
indazoles	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
Bub1	B
kinase	I
,	O
processes	O
for	O
their	O
production	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
and	O
a	O
treatment	O
method	O
therefor	O
.	O

A	O
pharmaceutical	O
composition	O
containing	O
siRNA	O
inhibiting	O
the	O
expression	O
of	O
a	O
CD98	B
heavy	O
chain	O
was	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

As	O
a	O
result	O
,	O
a	O
novel	O
treatment	O
method	O
can	O
be	O
provided	O
that	O
uses	O
the	O
siRNA	O
for	O
inflammatory	O
bowel	O
disease	O
for	O
which	O
there	O
has	O
conventionally	O
been	O
no	O
appropriate	O
treatment	O
method	O
.	O

Therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
,	O
which	O
contains	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
Ar1	O
represents	O
an	O
aromatic	O
group	O
;	O
X	O
represents	O
a	O
single	O
bond	O
or	O
a	O
linking	O
group	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
;	O
Y	O
represents	O
CH	O
(	O
R2	O
)	O
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
carbamoyl	O
group	O
,	O
an	O
acyl	O
group	O
or	O
an	O
alkyl	O
group	O
)	O
;	O
Z	O
represents	O
a	O
carbonyl	O
group	O
or	O
CH	O
(	O
R3	O
)	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
)	O
;	O
and	O
Y	O
and	O
Z	O
may	O
combine	O
together	O
and	O
represent	O
C	O
(	O
R2	O
)	O
=C	O
(	O
R4	O
)	O
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
carbamoyl	O
group	O
,	O
an	O
acyl	O
group	O
or	O
an	O
alkyl	O
group	O
,	O
and	O
R4	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
hydroxyl	O
group	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
)	O
.	O
)	O

Instantaneous	O
intestinal	O
regulator	O
The	O
present	O
invention	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
:	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	O
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
manifests	O
intestine	O
-	O
regulating	O
effects	O
within	O
one	O
day	O
after	O
being	O
taken	O
;	O
and	O
manifests	O
more	O
pronounced	O
intestine	O
-	O
regulating	O
effects	O
within	O
two	O
days	O
after	O
being	O
taken	O
.	O

The	O
present	O
invention	O
also	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	O
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
and	O
maintains	O
the	O
intestine	O
-	O
regulating	O
effects	O
for	O
two	O
weeks	O
after	O
being	O
taken	O
.	O

Oxytocin	B
stimulates	O
IP3	B
production	O
in	O
dose	O
-	O
dependent	O
fashion	O
as	O
well	O

Signal	O
transduction	O
of	O
arginine	B
vasopressin	I
-	O
induced	O
arachidonic	O
acid	O
release	O
in	O
H9c2	O
cardiac	O
myoblasts	O
:	O
role	O
of	O
Ca2	O
+	O
and	O
the	O
protein	B
kinase	I
C	I
-	O
dependent	O
activation	O
of	O
p42	O
mitogen	O
-	O
activated	O
protein	O
kinase	O

The	O
Ca2	O
+	O
ionophore	O
,	O
A23187	O
or	O
ionomycin	O
,	O
mimicked	O
the	O
effect	O
of	O
AVP	B
,	O
whereas	O
the	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
activator	O
,	O
TPA	O
,	O
only	O
induced	O
a	O
slight	O
increase	O
in	O
AA	O
release	O

Western	O
blots	O
demonstrated	O
expression	O
of	O
PKCalpha	O
,	O
betaI	O
,	O
epsilon	O
,	O
delta	O
,	O
and	O
zeta	O
in	O
H9c2	O
cells	O
;	O
PKC	B
inhibitors	O
(	O
staurosporine	O
or	O
Ro	O
31	O
-	O
8220	O
)	O
or	O
down	O
-	O
regulation	O
of	O
PKCalpha	B
,	O
betaI	O
,	O
epsilon	O
,	O
and	O
delta	O
by	O
long	O
-	O
term	O
(	O
24	O
h	O
)	O
TPA	O
treatment	O
caused	O
a	O
partial	O
blockade	O
of	O
the	O
AVP	B
-	O
induced	O
response	O
,	O
whereas	O
the	O
A23187-induced	O
AA	O
release	O
was	O
unaffected	O
by	O
down	O
-	O
regulation	O
of	O
these	O
isoforms	O

AVP-	B
or	O
TPA	O
-	O
induced	O
activation	O
and	O
tyrosine	O
phosphorylation	O
of	O
p42	O
MAPK	O
were	O
completely	O
blocked	O
by	O
down	O
-	O
regulation	O
of	O
PKCalpha	B
,	O
betaI	O
,	O
epsilon	O
,	O
and	O
delta	O
,	O
but	O
still	O
occurred	O
,	O
together	O
with	O
the	O
cytosolic	O
PLA2	O
mobility	O
shift	O
,	O
in	O
the	O
absence	O
of	O
external	O
Ca2	O
+	O

These	O
results	O
show	O
that	O
AVP	B
-	O
induced	O
AA	O
release	O
in	O
H9c2	O
cells	O
is	O
secondary	O
to	O
activation	O
of	O
the	O
V1	O
receptor	O
/	O
Gq	O
protein	O
/	O
PLCP	O
pathway	O
,	O
leading	O
to	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
and	O
activation	O
of	O
PKCalpha	B
,	O
betaI	O
,	O
epsilon	O
,	O
and	O
delta	O

The	O
second	O
class	O
of	O
mutant	O
,	O
gse	O
(	O
GA	B
sensitivity	O
)	O
,	O
differed	O
principally	O
in	O
GA	B
sensitivity	O
,	O
requiring	O
approximately	O
100-fold	O
higher	O
[	O
GA3	B
]	O
for	O
both	O
leaf	O
elongation	O
and	O
alpha	B
-	I
amylase	I
production	O
by	O
aleurone	O

These	O
results	O
suggest	O
that	O
APP	B
-	I
S	I
secretion	O
and	O
A	B
beta	I
production	O
in	O
NT2N	O
neurons	O
are	O
regulated	O
by	O
the	O
muscarinic	O
/	O
phospholipase	B
C	I
signal	O
transduction	O
pathway	O

Effects	O
of	O
intravenously	O
infused	O
leptin	B
on	O
insulin	O
sensitivity	O
and	O
on	O
the	O
expression	O
of	O
uncoupling	B
proteins	I
in	O
brown	O
adipose	O
tissue	O

Centrally	O
administered	O
leptin	B
has	O
been	O
shown	O
to	O
increase	O
insulin	O
-	O
stimulated	O
glucose	O
utilization	O
and	O
to	O
favor	O
the	O
expression	O
of	O
uncoupling	B
proteins	I
(	O
UCPs	O
)	O

To	O
study	O
if	O
leptin	B
also	O
has	O
direct	O
peripherally	O
mediated	O
effects	O
on	O
these	O
processes	O
,	O
this	O
hormone	O
(	O
1	O
mg	O
/	O
day	O
)	O
or	O
its	O
vehicle	O
was	O
infused	O
i.v	O
.	O
for	O
4	O
days	O
to	O
lean	O
rats	O
and	O
insulin	O
-	O
stimulated	O
glucose	O
utilization	O
in	O
skeletal	O
muscle	O
and	O
adipose	O
tissue	O
as	O
well	O
as	O
the	O
expression	O
of	O
UCP	B
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
in	O
brown	O
adipose	O
tissue	O
were	O
measured	O

I.v	O
.	O
leptin	B
infusion	O
also	O
favored	O
the	O
expression	O
of	O
UCPs	B
in	O
brown	O
adipose	O
tissue	O
,	O
either	O
by	O
increasing	O
their	O
expression	O
or	O
preventing	O
the	O
fall	O
occurring	O
during	O
the	O
pair	O
-	O
feeding	O
regimen	O
.	O

Relative	O
UCP	B
expression	O
levels	O
were	O
100	O
,	O
104	O
,	O
and	O
33	O
for	O
UCP1	B
,	O
100	O
,	O
191	O
,	O
and	O
125	O
for	O
UCP2	B
and	O
100	O
,	O
107	O
,	O
and	O
29	O
for	O
UCP3	B
in	O
ad	O
libitum	O
fed	O
control	O
rats	O
,	O
in	O
leptin	B
-	O
treated	O
rats	O
and	O
in	O
pair	O
-	O
fed	O
control	O
rats	O
,	O
respectively	O

These	O
results	O
suggest	O
that	O
the	O
overall	O
effect	O
of	O
leptin	B
on	O
glucose	O
utilization	O
and	O
on	O
the	O
expression	O
of	O
UCPs	B
may	O
be	O
mediated	O
through	O
central	O
mechanism	O

Our	O
data	O
demonstrate	O
,	O
that	O
activation	O
of	O
mitogen	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
alone	O
is	O
sufficient	O
to	O
promote	O
APP	B
secretion	O
,	O
whereas	O
inhibition	O
of	O
MAP	O
kinase	O
will	O
reduce	O
APP	B
secretion	O
only	O
when	O
phospholipase	B
Cgamma	I
or	O
phosphatidylinositol	O
3-kinase	O
are	O
additionally	O
inhibited	O

The	O
beta	O
amyloid	B
protein	O
fragments	O
had	O
diverse	O
effects	O
on	O
phosphoinositide	O
-	O
specific	O
phospholipase	B
C	I
(	O
PI	O
-	O
PLC	O
)	O
as	O
assayed	O
in	O
rat	O
cortical	O
membranes	O

Possible	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
mechanisms	O
could	O
mediate	O
these	O
responses	O
in	O
that	O
leptin	O
receptors	O
are	O
located	O
on	O
hypothalamic	O
neurons	O
that	O
coexpress	O
neuropeptide	B
-	I
Y	I
(	O
NPY	O
)	O
or	O
proopiomelanocortin	O
(	O
POMC	O
)	O
and	O
both	O
peptides	O
that	O
have	O
been	O
implicated	O
as	O
mediators	O
of	O
the	O
CNS	O
action	O
of	O
leptin	B
.	O

Leptin	B
has	O
been	O
demonstrated	O
to	O
decrease	O
or	O
down	O
regulate	O
NPY	B
expression	O
and	O
increase	O
POMC	O
expression	O

We	O
have	O
studied	O
the	O
effects	O
of	O
neomycin	O
,	O
a	O
potent	O
inhibitor	O
of	O
inositol	O
phospholipid	O
-	O
specific	O
phospholipase	O
C	O
(	O
PLC	O
)	O
,	O
on	O
the	O
germination	O
of	O
rice	O
seed	O
and	O
the	O
gibberellin	B
-	O
induced	O
expression	O
of	O
alpha	B
-	I
amylase	I
in	O
the	O
aleurone	O
layer	O
and	O
the	O
scutellar	O
tissues	O

It	O
was	O
shown	O
that	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
Ca2	O
+	O
,	O
neomycin	O
markedly	O
reduced	O
the	O
germination	O
speed	O
and	O
seedling	O
growth	O
of	O
rice	O
seeds	O
and	O
inhibited	O
the	O
gibberellin	B
-	O
induced	O
expression	O
of	O
alpha	B
-	I
amylase	I
in	O
both	O
secretory	O
tissues	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
phosphoinositide	O
-	O
Ca2	O
+	O
signal	O
transduction	O
pathway	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
gibberellin	B
-	O
induced	O
expression	O
of	O
alpha	B
-	I
amylase	I
molecules	O
closely	O
related	O
to	O
the	O
germination	O
processes	O
of	O
rice	O
seed	O

In	O
the	O
fasting	O
state	O
UCP-2	B
expression	O
correlated	O
inversely	O
with	O
body	O
mass	O
index	O
(	O
r	O
=	O
-0.45	O
;	O
P	O
=	O
0.026	O
)	O
,	O
percent	O
body	O
fat	O
(	O
r	O
=	O
-0.41	O
;	O
P	O
=	O
0.05	O
)	O
,	O
plasma	O
insulin	O
(	O
r	O
=	O
-0.47	O
;	O
P	O
=	O
0.02	O
)	O
,	O
epigastric	O
venous	O
fatty	O
acids	O
(	O
r	O
=	O
-0.45	O
;	O
P	O
=	O
0.04	O
)	O
,	O
and	O
leptin	B
(	O
r	O
=	O
-0.50	O
;	O
P	O
=	O
0.018	O
)	O

UCP-2	B
expression	O
remained	O
inversely	O
related	O
with	O
plasma	O
leptin	B
after	O
controlling	O
for	O
percent	O
body	O
(	O
r	O
=	O
-0.45	O
;	O
P	O
=	O
0.038	O
)	O

In	O
conclusion	O
,	O
1	O
)	O
UCP-2	B
messenger	O
ribonucleic	O
acid	O
expression	O
in	O
sc	O
adipose	O
tissue	O
is	O
inversely	O
related	O
to	O
adiposity	O
and	O
independently	O
linked	O
to	O
local	O
plasma	O
leptin	B
levels	O
;	O
and	O
2	O
)	O
UCP-2	B
expression	O
is	O
not	O
acutely	O
regulated	O
by	O
food	O
intake	O
,	O
insulin	O
,	O
or	O
fatty	O
acids	O

Activity	O
and	O
expression	O
of	O
the	O
three	O
UCP	B
's	O
are	O
stimulated	O
by	O
several	O
neuromediators	O
and	O
hormones	O
such	O
as	O
noradrenaline	O
,	O
tri	O
-	O
iodothyronine	O
and	O
leptin	B

Insulin	B
secretion	O
,	O
inositol	O
phosphate	O
levels	O
,	O
and	O
phospholipase	B
C	I
isozymes	O
in	O
rodent	O
pancreatic	O
islets	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
the	O
underexpression	O
of	O
the	O
nutrient	O
-	O
activated	O
PLC	B
isozyme	O
may	O
account	O
for	O
the	O
minimal	O
inositol	O
phosphate	O
(	O
IP	O
)	O
and	O
second	O
-	O
phase	O
insulin	B
secretory	O
response	O
from	O
mouse	O
islets	O

We	O
also	O
determined	O
whether	O
well	O
known	O
hypothalamic	O
neuropeptide	O
targets	O
,	O
e.g.	O
neuropeptide	B
Y	I
(	O
NPY	O
)	O
,	O
proopiomelanocortin	O
(	O
POMC	O
)	O
,	O
agouti	O
-	O
related	O
peptide	O
(	O
AGRP	O
)	O
and	O
cocaine	O
and	O
amphetamine	O
-	O
regulated	O
transcript	O
(	O
CART	O
)	O
were	O
regulated	O
in	O
a	O
pattern	O
consistent	O
with	O
their	O
presumed	O
roles	O
as	O
mediators	O
of	O
leptin	B
action	O

In	O
contrast	O
,	O
leptin	B
decreased	O
body	O
weight	O
and	O
adiposity	O
,	O
increased	O
CART	O
and	O
suppressed	O
NPY	B
and	O
AGRP	O
mRNA	O
expression	O
in	O
adult	O
mice	O

This	O
action	O
of	O
beta	B
-	I
amyloid	I
25	O
-	O
35	O
is	O
not	O
altered	O
by	O
pretreatment	O
with	O
the	O
calcium	O
channel	O
blockers	O
nifedipine	O
or	O
cobalt	O
,	O
with	O
the	O
depleter	O
of	O
intracellular	O
calcium	O
stores	O
cyclopiazonic	O
acid	O
,	O
or	O
with	O
the	O
phospholipase	B
C	I
inhibitor	O
neomycin	O

After	O
protein	B
kinase	I
C	I
activity	O
was	O
functionally	O
depleted	O
by	O
treating	O
cells	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
24	O
hours	O
,	O
AVP	B
did	O
not	O
augment	O
IL-1beta	O
-	O
induced	O
NO	O
production	O

The	O
effect	O
of	O
AVP	B
was	O
also	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
protein	B
kinase	I
C	I
inhibitor	O
calphostin	O
C	O

The	O
addition	O
of	O
AVP	B
increased	O
protein	B
kinase	I
C	I
activity	O
in	O
cardiac	O
myocytes	O
,	O
and	O
its	O
effect	O
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
calphostin	O
C	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
heart	O
may	O
be	O
a	O
target	O
organ	O
for	O
AVP	B
and	O
that	O
AVP	B
modulates	O
IL-1beta	O
-	O
induced	O
iNOS	O
expression	O
in	O
myocytes	O
through	O
the	O
V1a	O
receptor	O
,	O
which	O
is	O
mediated	O
at	O
least	O
partially	O
via	O
activation	O
of	O
protein	B
kinase	I
C	I

The	O
activity	O
of	O
the	O
MAPKs	O
,	O
induced	O
by	O
AVP	B
or	O
PMA	O
was	O
inhibited	O
by	O
downregulation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	O
)	O
,	O
by	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
and	O
by	O
MAPK	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
,	O
PD98059	O

We	O
suggest	O
that	O
AVP	B
activates	O
the	O
42	O
/	O
44kDa	O
MAPKs	O
through	O
a	O
signal	O
transduction	O
pathway	O
that	O
involves	O
stimulation	O
of	O
AVP	O
-	O
V1	O
receptor	O
,	O
tyrosine	O
kinase	O
,	O
PKC	B
and	O
MEK	O

Association	O
of	O
the	O
insulin	O
receptor	O
with	O
phospholipase	B
C	I
-	I
gamma	I
(	O
PLCgamma	O
)	O
in	O
3T3-L1	O
adipocytes	O
suggests	O
a	O
role	O
for	O
PLCgamma	B
in	O
metabolic	O
signaling	O
by	O
insulin	B

To	O
determine	O
the	O
functional	O
significance	O
of	O
the	O
interaction	O
of	O
PLCgamma	B
and	O
the	O
IR	O
,	O
we	O
used	O
a	O
specific	O
inhibitor	O
of	O
PLC	B
,	O
U73122	O
,	O
or	O
microinjection	O
of	O
SH2	O
domain	O
glutathione	O
S	O
-	O
transferase	O
fusion	O
proteins	O
derived	O
from	O
PLCgamma	B
to	O
block	O
insulin	B
-	O
stimulated	O
GLUT4	O
translocation	O

During	O
wk	O
6	O
,	O
milk	O
yield	O
and	O
dry	O
matter	O
intake	O
(	O
DMI	O
)	O
were	O
recorded	O
daily	O
,	O
and	O
plasma	O
concentrations	O
of	O
glucose	O
,	O
nonesterified	O
fatty	O
acids	O
,	O
urea	O
,	O
protein	O
,	O
growth	O
hormone	O
,	O
insulin	B
,	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
,	O
oxytocin	B
,	O
and	O
prolactin	O
were	O
determined	O

Hesperidin	O
,	O
the	O
most	O
important	O
flavanone	B
of	O
Citrus	O
sp.	O
,	O
significantly	O
increases	O
HDL	O
and	O
lowers	O
cholesterol	B
,	O
LDL	O
,	O
total	O
lipid	O
and	O
triglyceride	O
plasma	O
levels	O
in	O
normolipidemic	O
rats	O
and	O
in	O
rats	O
with	O
diet-	O
and	O
triton	O
-	O
induced	O
hyperlipidemia	O

Effect	O
of	O
residual	O
endogenous	O
insulin	B
secretion	O
on	O
the	O
abnormal	O
oxytocin	B
response	O
to	O
hypoglycaemia	O
in	O
insulin	B
-	O
dependent	O
diabetics	O

Since	O
previous	O
studies	O
showed	O
that	O
AVP	O
secretion	O
is	O
influenced	O
by	O
the	O
persistence	O
of	O
residual	O
endogenous	O
insulin	B
secretion	O
,	O
we	O
wondered	O
whether	O
this	O
factor	O
also	O
regulates	O
OT	B
secretion	O

DESIGN	O
:	O
Case	O
-	O
control	O
study	O
:	O
the	O
OT	B
response	O
to	O
insulin	B
-	O
induced	O
hypoglycaemia	O
was	O
measured	O
in	O
normal	O
and	O
diabetic	O
patients	O
with	O
or	O
without	O
residual	O
endogenous	O
insulin	B
secretion	O

Blood	O
samples	O
for	O
OT	B
assay	O
were	O
taken	O
just	O
before	O
the	O
rapid	O
injection	O
of	O
insulin	B
(	O
time	O
0	O
)	O
and	O
at	O
time	O
15	O
,	O
30	O
,	O
45	O
and	O
60	O
min	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
a	O
residual	O
endogenous	O
insulin	B
secretion	O
exerts	O
a	O
partial	O
protective	O
action	O
against	O
the	O
hypothalamic	O
-	O
pituitary	O
disorder	O
affecting	O
the	O
OT	B
secretory	O
system	O
in	O
IDDM	O

Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	O
I	B
aldosterone	I
receptors	I
in	O
peripheral	O
mononuclear	O
leucocytes	O
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B
receptor	I
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	O
mononuclear	O
leucocytes	O
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I	O
-	O
II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow	O
-	O
up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate	O
/	O
marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B
receptor	I
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR	O
/	O
EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High	O
-	O
risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion	B
-	I
associated	I
regulatory	I
protein	I
.	O

The	O
vpr	B
product	I
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	O
cells	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B
protein	I
.	O

The	O
vpr	B
product	I
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	O
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

The	O
suppression	O
of	O
basophils	O
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O

The	O
37.5	O
%	O
reduction	O
in	O
dose	O
produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	O
cell	O
return	O
to	O
blood	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng	O
/	O
ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng	O
/	O
ml	O
.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
`	O
`	O
dose	O
-	O
sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
II	O
rex	O
gene	O
are	O
not	O
required	O
for	O
p24rex	B
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-	O
acting	O
regulatory	O
genes	O
,	O
tax	O
and	O
rex	O
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	B
gene	I
product	I
(	O
HTLV	B
-	I
I	I
p40tax	I
and	O
HTLV	B
-	I
II	I
p37tax	I
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	O
gene	O
encodes	O
two	O
protein	O
products	O
,	O
p27rex	B
/	I
p21rex	I
and	O
p26rex	B
/	I
p24rex	I
in	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
,	O
respectively	O
.	O

Rex	B
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	B
/	I
pol	I
and	O
singly	O
spliced	O
env	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	O
gene	O
is	O
critical	O
for	O
Rex	B
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV	O
-	O
I	O
rex	O
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B
,	O
and	O
by	O
analogy	O
HTLV	O
-	O
II	O
p24rex	B
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	O
/	O
rex	O
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	O
gene	O
on	O
Rex	B
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B
of	O
HTLV	O
-	O
II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	O
gene	O
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

[	O
Glucocorticoid	B
receptors	I
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang	O
-	O
deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang	O
-	O
deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	B
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	B
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/-	O
413	O
and	O
4433	O
+	O
/-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/-	O
962	O
and	O
5622	O
+	O
/-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

GCR	B
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/-	O
370	O
,	O
4986	O
+	O
/-	O
419	O
and	O
4524	O
+	O
/-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

Type	B
-	I
II	I
estrogen	I
binding	I
sites	I
in	O
a	O
lymphoblastoid	O
cell	O
line	O
and	O
growth	O
-	O
inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti	O
-	O
estrogen	O
and	O
bioflavonoids	O
.	O

Type	B
-	I
II	I
estrogen	I
-	I
binding	I
sites	I
(	O
type	B
-	I
II	I
EBS	I
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	O
lymphoblastoid	O
cell	O
line	O
IM-9	O
using	O
a	O
whole	O
-	O
cell	O
assay	O
with	O
(	O
6	O
,	O
7	O
-	O
3H	O
)	O
estradiol	O
(	O
3H	O
-	O
E2	O
)	O
as	O
tracer	O
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type	B
-	I
II	I
EBS	I
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose	O
-	O
dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type	B
-	I
II	I
EBS	I
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type	B
-	I
II	I
EBS	I
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell	O
-	O
cycle	O
analysis	O
showed	O
that	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti	O
-	O
estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	O
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type	B
-	I
II	I
EBS	I
.	O

Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O

Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	O
mononuclear	O
leukocytes	O
.	O

Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B
1	I
receptors	I
in	O
human	O
mononuclear	O
leukocytes	O
.	O

11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd	O
-	O
C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O

With	O
hot	O
acetic	O
+	O
p	O
-	O
toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd	O
-	O
C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Pd	O
-	O
C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	O
mononuclear	O
leukocytes	O
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B
1	I
receptor	I
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Specific	O
depletion	O
of	O
the	O
B	O
-	O
cell	O
population	O
induced	O
by	O
aberrant	O
expression	O
of	O
human	O
interferon	O
regulatory	O
factor	O
1	O
gene	O
in	O
transgenic	O
mice	O
.	O

Interferons	B
(	O
IFNs	B
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B
proteins	I
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	B
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	B
factor	I
,	O
IRF-1	B
(	O
interferon	B
regulatory	I
factor	I
1	I
)	O
,	O
which	O
binds	O
to	O
type	O
I	O
IFN	O
and	O
some	O
IFN	O
-	O
inducible	O
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	B
gene	O
is	O
both	O
virus	O
and	O
IFN	B
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	O
gene	O
is	O
functioning	O
in	O
IFN	B
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	O
IRF-1	O
gene	O
linked	O
to	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B	O
-	O
cell	O
population	O
.	O

In	O
fact	O
,	O
transgenic	O
bone	O
marrow	O
cells	O
cocultured	O
with	O
a	O
bone	O
marrow	O
-	O
derived	O
stromal	O
cell	O
line	O
revealed	O
an	O
altered	O
B	O
-	O
cell	O
maturation	O
pattern	O
.	O

Functional	O
analysis	O
of	O
cis	O
-	O
linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	B
proteins	I
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA	O
-	O
DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell	O
-	O
specific	O
transcription	O
.	O

This	O
`	O
`	O
octamer	O
`	O
`	O
in	O
the	O
context	O
of	O
DRA	B
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	B
(	O
OTF-1	B
)	O
and	O
lymphoid	B
-	I
specific	I
(	I
OTF-2	I
)	I
`	I
`	I
octamer	I
''	I
binding	I
proteins	I
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
`	B
`	I
octamer	I
''	I
complex	I
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-	O
acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II	O
-	O
negative	O
HeLa	O
cells	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
`	O
`	O
octamer	O
''	O
does	O
not	O
utilize	O
OTF-2	B
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Inhibition	O
of	O
protein	B
phosphatases	I
by	O
okadaic	O
acid	O
induces	O
AP1	B
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	B
phosphatases	I
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B
1	I
and	I
2A	I
phosphatases	I
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	B
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	B
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto	O
-	O
oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B
further	O
enhanced	O
the	O
induction	O
of	O
AP1	B
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto	O
-	O
oncogenes	O
including	O
c	O
-	O
jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c	O
-	O
fos	O
and	O
fra-1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c	O
-	O
jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c	O
-	O
jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c	O
-	O
jun	O
transcription	O
.	O

The	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B
phosphatases	I
1	I
and	I
2A	I
(	O
PP1	B
and	O
PP2A	B
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B
factor	I
AP1	B
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T	B
-	I
cell	I
-	I
specific	I
membrane	I
proteins	I
allows	O
the	O
identification	O
of	O
transcription	B
factors	I
that	O
control	O
the	O
expression	O
of	O
these	O
T	O
-	O
cell	O
genes	O
.	O

Such	O
transcription	B
factors	I
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T	O
-	O
cell	O
phenotype	O
by	O
functioning	O
as	O
'	O
master	O
regulators	O
of	O
T	O
-	O
cell	O
differentiation	O
'	O
.	O

HTLV-1	B
Tax	I
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
T	O
-	O
cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	B
proteins	I
,	O
c	B
-	I
Fos	I
,	O
Fra-1	B
,	O
c	B
-	I
Jun	I
,	O
JunB	B
,	O
and	O
JunD	B
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B
transcription	I
factor	I
,	O
Tax1	B
.	O

By	O
using	O
the	O
human	O
T	O
-	O
cell	O
line	O
(	O
JPX-9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	B
,	O
c	B
-	I
Jun	I
,	O
and	O
JunD	B
was	O
also	O
transactivated	O
by	O
Tax1	B
.	O

Moreover	O
,	O
Tax1	B
activated	O
expression	O
of	O
two	O
other	O
transcription	B
factors	I
having	O
zinc	B
finger	I
motifs	I
,	O
Egr-1	B
and	O
Egr-2	B
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	B
transcription	I
factors	I
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Lymphocyte	O
glucocorticoid	B
receptor	I
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	B
glucocorticoid	I
receptor	I
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B
receptor	I
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B
receptor	I
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand	O
-	O
induced	O
plasticity	O
of	O
glucocorticoid	B
receptor	I
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B
receptor	I
numbers	O
during	O
depression	O
.	O

Glucocorticoid	B
receptors	I
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age	O
-	O
related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	B
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	B
.	O

Eight	O
patients	O
with	O
dermatomyositis	O
/	O
polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B
in	O
MNL	O
could	O
be	O
down	O
-	O
regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	B
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B
in	O
MNL	O
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0	O
/	O
G1	O
switch	O
gene	O
containing	O
a	O
CpG	O
-	O
rich	O
island	O
encodes	O
a	O
small	B
basic	I
protein	I
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
(	O
G0S	O
genes	O
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	B
-induced	O
switch	O
of	O
lymphocytes	O
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	O
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	O
genes	O
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	O
mRNA	O
increases	O
transiently	O
within	O
1	O
-	O
2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B
or	O
cycloheximide	O
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full	O
-	O
length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino	B
-	I
acid	I
basic	I
protein	I
has	O
two	O
potential	O
alpha	B
-	I
helical	I
domains	I
separated	O
by	O
a	O
hydrophobic	B
region	I
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta	O
-	O
sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B
kinase	I
C	I
and	O
casein	B
kinase	I
II	I
.	O

The	O
gene	O
contains	O
a	O
CpG	B
-	I
rich	I
island	I
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19	O
/	O
(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	O
sites	O
for	O
CCAAT	B
-	I
box	I
binding	I
factors	I
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	O
sites	O
for	O
transcription	B
factors	I
AP1	B
,	O
AP2	B
,	O
and	O
AP3	B
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	B
receptor	I
alpha	I
chain	I
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

The	O
two	B
nuclear	I
proteins	I
NF	B
-	I
kappa	I
B	I
(	O
consisting	O
of	O
subunits	O
p50	B
an	O
dp65	B
)	O
and	O
the	O
DNA	B
-	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T	O
-	O
cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	B
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B
and	O
NF	B
-	I
kappa	I
B	I
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B
(	I
IL-2	I
)	I
receptor	I
alpha	I
chain	I
(	O
IL-2R	B
alpha	I
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O

These	O
findings	O
show	O
that	O
nuclear	B
NF	I
-	I
kappa	I
B	I
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	B
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	B
is	O
a	O
competitive	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B
and	O
IL-2	B
alpha	I
genes	O
during	O
the	O
immune	O
response	O
.	O

Binding	O
of	O
erythroid	B
and	I
non	I
-	I
erythroid	I
nuclear	I
proteins	I
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	O
-	O
encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-392	O
to	O
-177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
86	O
(	O
1989	O
)	O
5306	O
-	O
5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-	O
cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	O
to	O
-251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B
receptors	I
.	O

Interrelations	O
between	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well	O
-	O
documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T	O
-	O
cell	O
proliferation	O
,	O
pokeweed	B
mitogen	I
(	O
PWM	B
)	O
-driven	O
B	O
-	O
cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B
receptor	I
function	O
,	O
dose	O
-	O
response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B
-induced	O
T	O
-	O
cell	O
mitogenesis	O
,	O
PWM	B
-generated	O
B	O
-	O
cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B
-induced	O
B	O
-	O
cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B
receptor	I
function	O
.	O

The	O
decrease	O
in	O
PWM	B
-generated	O
B	O
-	O
cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid	O
-	O
mediated	O
induction	O
of	O
interleukin-1	B
receptor	I
synthesis	O
.	O

Leukotriene	O
B4	O
stimulates	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
transcription	O
and	O
AP-1	B
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	B
mediator	I
,	O
on	O
the	O
expression	O
of	O
the	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B
factors	I
binding	O
specifically	O
to	O
the	O
AP-1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
gene	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
c	O
-	O
jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral	O
-	O
blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c	O
-	O
fos	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	O
-	O
fos	O
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	O
-	O
jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
7-fold	O
and	O
the	O
c	O
-	O
jun	O
gene	O
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	B
factors	I
binding	O
to	O
the	O
AP-1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1	B
-binding	O
activity	O
of	O
nuclear	B
proteins	I
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	B
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	B
factors	I
such	O
as	O
AP-1	B
-binding	O
proto	B
-	I
oncogene	I
products	I
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B
D	I
receptor	I
in	O
human	O
HL60	O
leukemia	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA	O
-	O
relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	B
affinity	I
receptors	I
(	O
VDR	B
)	O
for	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B
3H	I
]	I
calcitriol	I
/	I
VDR	I
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(	O
-9	O
)	O
M	O
/	O
l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B
3H	I
]	I
calcitriol	I
/	I
VDR	I
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites	O
/	O
nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	O
cells	O
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites	O
/	O
nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B
radiolabeled	I
VDR	I
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B
by	O
24	O
h	O
.	O

Radiolabeled	B
VDR	I
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse	O
/	O
chase	O
-	O
experiments	O
)	O
.	O

No	O
difference	O
of	O
VDR	B
retention	O
in	O
pulse	O
and	O
pulse	O
/	O
chase	O
-	O
experiments	O
was	O
seen	O
in	O
PBL	O
,	O
where	O
VDR	B
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

Radiolabeled	B
hormone	I
/	I
receptor	I
complexes	I
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

The	O
activity	O
of	O
DNA	B
relaxing	I
enzymes	I
(	O
e.g	O
.	O
topoisomerases	B
I	I
and	I
II	I
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation	O
-	O
assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v	O
/	O
v	O
)	O
in	O
HL60	O
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	O
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	O
treated	O
controls	O
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B
proteins	I
after	O
hormone	O
binding	O
.	O

Translocated	B
hormone	I
/	I
receptor	I
complexes	I
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	B
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA	O
-	O
unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

Specific	O
NF	B
-	I
kappa	I
B	I
subunits	I
act	O
in	O
concert	O
with	O
Tat	B
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
a	O
protein	B
complex	I
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	B
-	I
I	I
gene	I
product	I
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
family	I
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF	B
-	I
kappa	I
B	I
subunits	I
to	O
act	O
with	O
Tat	B
-	I
I	I
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	B
(	I
100	I
)	I
DNA	I
binding	I
subunit	I
,	O
together	O
with	O
p65	B
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	B
-	I
I	I
to	O
stimulate	O
the	O
expression	O
of	O
HIV	O
-	O
CAT	O
plasmid	O
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B
forms	I
of	O
p105	B
NF	B
-	I
kappa	I
B	I
or	O
rel	B
,	O
in	O
combination	O
with	O
p65	B
or	O
full	B
-	I
length	I
c	I
-	I
rel	I
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B
(	I
100	I
)	I
and	O
p65	B
NF	B
-	I
kappa	I
B	I
can	O
act	O
in	O
concert	O
with	O
the	O
tat	B
-	I
I	I
gene	I
product	I
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer	O
/	O
promoter	O
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	O
kappa	O
enhancer	O
(	O
or	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer	O
/	O
promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility	O
/	O
cell	O
type	O
specificity	O
.	O

Oct2	B
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B	O
-	O
cell	O
-	O
restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte	B
-	I
specific	I
transcription	I
factor	I
Oct2	B
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	B
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	O
octamer	O
enhancer	O
element	O
in	O
HeLa	O
cells	O
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B
isoforms	I
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B	O
-	O
cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B
isoforms	I
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B	B
-	I
cell	I
-	I
specific	I
cofactor	I
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B
or	O
the	O
Oct2	B
protein	I
in	O
Oct2	B
-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy	B
-	I
terminal	I
domain	I
of	O
Oct2	B
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B
protein	I
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine	B
-	I
rich	I
activation	I
domain	I
present	O
in	O
the	O
amino	B
-	I
terminal	I
portion	I
of	I
Oct2	I
and	O
the	O
POU	B
domain	I
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

TAR	O
-independent	O
transactivation	O
by	O
Tat	B
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	B
protein	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	B
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	B
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS	O
-	O
derived	O
cells	O
Tat	B
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	O
-independent	O
pathway	O
.	O

A	O
Tat	O
-	O
responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial	O
-	O
derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat	O
-	O
responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV-1	O
enhancer	O
,	O
or	O
NF	O
-	O
kappa	O
B	O
domain	O
.	O

DNA	O
band	O
-	O
shift	O
analysis	O
reveals	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	O
-	O
deleted	O
mutants	O
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B
p24	I
antigen	I
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Natural	O
variants	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG	O
-	O
motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	O
-	O
motif	O
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild	O
-	O
type	O
plasmid	O
were	O
cotransfected	O
into	O
T	O
-	O
cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG	O
-	O
monomer	O
virus	O
outcompeted	O
the	O
CTG	O
-	O
dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation	O
-	O
induced	O
activation	O
of	O
the	O
protein	B
kinase	I
C	I
signaling	O
pathway	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein	B
-	I
tyrosine	I
kinase	I
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B	O
-	O
lymphocyte	O
precursors	O
,	O
irradiation	O
with	O
gamma	O
-	O
rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine	B
-	I
specific	I
protein	I
kinases	I
,	O
including	O
protein	B
kinase	I
C	I
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
.	O

All	O
of	O
the	O
radiation	O
-	O
induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein	B
-	I
tyrosine	I
kinase	I
inhibitors	I
genistein	I
and	I
herbimycin	I
A	I
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	B
kinase	I
C	I
signaling	O
cascade	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation	O
-	O
induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

The	O
zinc	B
finger	I
transcription	I
factor	I
Egr-1	B
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL-60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B
,	O
a	O
zinc	B
finger	I
transcription	I
factor	I
.	O

The	O
Egr-1	O
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	O
cells	O
,	O
but	O
active	O
in	O
U-937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	B
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL-60	O
cells	O
constitutively	O
expressing	O
an	O
Egr-1	O
transgene	O
(	O
HL-60Egr-1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	B
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	O
to	O
-130	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	B
acetyltransferase	I
reporter	O
gene	O
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	O
and	O
-130	O
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
cell	O
line	O
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65	O
:	O
2436	O
-	O
2444	O
,	O
1991	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	O
to	O
-	O
184	O
,	O
-183	O
to	O
-166	O
,	O
-165	O
to	O
-148	O
,	O
and	O
-148	O
to	O
-130	O
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	O
RD	O
cells	O
with	O
CEMx174	O
cells	O
.	O

In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	O
and	O
-76	O
and	O
between	O
-75	O
and	O
-58	O
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
-	O
and	O
Sp1-binding	O
sites	O
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Three	O
mutants	O
(	O
-201	O
/	O
-184	O
NXS	O
,	O
-165	O
/	O
-148	O
NXS	O
,	O
and	O
-147	O
/	O
-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201	O
/	O
-184	O
NXS	O
and	O
-183	O
/	O
-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type	O
-	O
specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF	B
-	I
kappa	I
B	I
and	O
SP1-binding	O
sites	O
but	O
also	O
for	O
several	O
regions	O
between	O
-201	O
and	O
-130	O
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Human	O
CD4	O
lymphocytes	O
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	B
protein	I
pml	B
/	I
RAR	I
alpha	I
present	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	O
cells	O
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B
point	I
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1	O
/	O
25	O
)	O
encompassing	O
the	O
fusion	B
region	I
of	O
the	O
hybrid	O
molecule	O
pml	B
/	I
RAR	I
alpha	I
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
recognized	O
by	O
human	O
T	O
lymphocytes	O
in	O
vitro	O
.	O

CD4	O
+	O
lymphocytes	O
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1	O
/	O
25	O
in	O
an	O
HLA	B
-	I
DR	I
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
or	O
by	O
APC	O
expressing	O
the	O
HLA	B
-	I
DR11	I
restricting	I
molecule	I
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B
and	O
RAR	B
alpha	I
proteins	I
were	O
not	O
recognized	O
.	O

One	O
clone	O
(	O
DEG5	O
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	O
cells	O
pulsed	O
with	O
BCR1	O
/	O
25	O
.	O

The	O
autologous	O
DE	O
LCL	O
containing	O
a	O
transduced	O
pml	O
/	O
RAR	O
alpha	O
fusion	O
gene	O
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml	B
/	I
RAR	I
alpha	I
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	O
anti	O
-	O
BCR1	O
/	O
25	O
T	O
cell	O
clones	O
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	B
type	I
-	I
pml	I
/	I
RAR	I
alpha	I
fusion	I
protein	I
of	O
APL	O
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	O
CD4	O
+	O
lymphocytes	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid	O
-	O
specific	O
promoter	O
.	O

Mammal	B
pyruvate	I
kinases	I
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	O
the	O
erythroid	B
(	O
R	B
-	I
PK	I
)	O
or	O
the	O
hepatic	B
(	I
L	I
-	I
PK	I
)	I
isozymes	I
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	O
and	O
trans	O
-	O
acting	O
elements	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	O
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R	O
-	O
PK	O
DNA	O
fragment	O
extending	O
from	O
-870	O
to	O
+	O
54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-62	O
to	O
+	O
54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC	B
/	I
Sp1	I
family	I
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B
factor	I
GATA-1	I
.	O

Although	O
the	O
-20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	B
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC	B
/	I
Sp1	I
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
R	B
-	I
PK	I
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R	O
-	O
PK	O
promoter	O
in	O
HeLa	O
cells	O
.	O

Cell	O
type-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
CD20	B
/	I
B1	I
antigen	I
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	O
(	O
B1	O
)	O
gene	O
encodes	O
a	O
B	B
cell	I
-	I
specific	I
protein	I
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	O
promoter	O
-	O
CAT	O
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B
in	O
pre	O
-	O
B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter	O
-	O
CAT	O
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	O
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B
proteins	I
suggesting	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
were	O
Oct-1	B
and	O
Oct-2	B
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
were	O
Oct-1	B
and	O
Oct-2	B
.	O

The	O
affinity	O
of	O
the	O
BAT	B
box	I
binding	I
proteins	I
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	B
box	I
binding	I
proteins	I
dissociated	O
from	O
the	O
BAT	O
box	O
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	O
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	O
cells	O
.	O

The	O
BAT	O
box	O
and	O
Oct-2	B
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B
in	O
the	O
pre	O
-	O
B	O
cell	O
line	O
,	O
PB-697	O
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	O
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	O
mRNA	O
and	O
a	O
BAT	O
box	O
-	O
deleted	O
CD20-CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B
and	O
perhaps	O
CD21	B
.	O

NF	B
-	I
kappa	I
B	I
controls	O
expression	O
of	O
inhibitor	O
I	B
kappa	I
B	I
alpha	I
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B
kappa	I
B	I
alpha	I
.	O

Phorbol	O
ester	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
induction	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B
kappa	I
B	I
alpha	I
and	O
the	O
activation	O
of	O
I	B
kappa	I
B	I
alpha	O
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65-kilodalton	B
transactivating	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	B
kappa	I
B	I
alpha	I
with	O
p65	B
restores	O
intracellular	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	B
-	I
kappa	I
B	I
controls	O
the	O
expression	O
of	O
I	B
kappa	I
B	I
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	O
B	O
-	O
cells	O
.	O

Lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

Two	O
stable	O
B	O
cell	O
lines	O
were	O
established	O
:	O
R59Z	O
activator	O
cells	O
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B
1	I
trans	I
-	I
activator	I
(	O
Zta	B
)	O
.	O

R7	O
-	O
57	O
reporter	O
cells	O
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	O
origin	O
of	O
EBV	O
replication	O
(	O
ori	O
Lyt	O
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans	O
-	O
activation	O
converted	O
the	O
recombinant	O
ori	O
Lyt	O
element	O
in	O
R7	O
-	O
57	O
reporter	O
cells	O
.	O

BZLF	B
1	I
,	O
transiently	O
expressed	O
in	O
R7	O
-	O
57	O
reporter	O
cells	O
,	O
was	O
the	O
only	O
EBV	B
trans	I
-	I
activator	I
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans	O
-	O
cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	O
1-expressing	O
R59Z	O
activator	O
cells	O
with	O
the	O
R7	O
-	O
57	O
reporter	O
line	O
.	O

No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	O
cells	O
nor	O
by	O
coincubation	O
of	O
BZLF	B
1	I
-containing	O
cell	O
lysates	O
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	O
to	O
reporter	O
cells	O
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	O
gene	O
BZLF	O
1	O

Immobilization	O
and	O
recovery	O
of	O
fusion	B
proteins	I
and	O
B	O
-	O
lymphocyte	O
cells	O
using	O
magnetic	O
separation	O
.	O

A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	B
proteins	I
and	O
selected	O
human	O
B	O
lymphocytes	O
has	O
been	O
developed	O
.	O

Using	O
magnetic	O
beads	O
with	O
attached	O
DNA	O
containing	O
the	O
Escherichia	O
coli	O
lac	O
operator	O
,	O
fusion	B
proteins	I
comprising	O
the	O
DNA	O
-	O
binding	O
lac	O
repressor	O
could	O
be	O
affinity	O
-	O
purified	O
and	O
recovered	O
by	O
gentle	O
elution	O
conditions	O
,	O
such	O
as	O
with	O
a	O
lactose	O
analogue	O
or	O
by	O
enzymatic	O
means	O
using	O
either	O
deoxyribonuclease	B
(	O
DNase	B
)	O
or	O
restriction	B
endonucleases	I
.	O

The	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
DNA	B
-	I
binding	I
protein	I
can	O
be	O
used	O
for	O
affinity	O
purification	O
of	O
fusion	B
proteins	I
as	O
exemplified	O
by	O
the	O
specific	O
and	O
gentle	O
recovery	O
of	O
beta	B
-	I
galactosidase	I
and	O
alkaline	B
phosphatase	I
from	O
bacterial	O
lysates	O
using	O
immunomagnetic	O
separation	O
.	O

The	O
approach	O
was	O
further	O
extended	O
to	O
cell	O
separation	O
by	O
the	O
efficient	O
recovery	O
and	O
elution	O
of	O
human	O
CD37	O
B	O
lymphocytes	O
from	O
peripheral	O
blood	O
.	O

[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	O
]	O

Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	O
biology	O
since	O
genes	O
association	O
with	O
eosinophils	O
such	O
as	O
interleukin-5	B
or	O
eosinophil	B
granule	I
proteins	I
(	O
EPO	B
,	O
ECP	B
,	O
EDN	B
,	O
MBP	B
,	O
and	O
CLC	B
)	O
,	O
were	O
isolated	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
has	O
not	O
been	O
determined	O
.	O

The	O
mechanism	O
by	O
which	O
eosinophil	O
-	O
specific	O
genes	O
encoding	O
primary	O
and	O
secondary	B
granule	I
proteins	I
(	O
e.g	O
.	O
ECP	B
,	O
EDN	B
,	O
EPO	B
,	O
MBP	B
,	O
and	O
CLC	B
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
I	O
described	O
the	O
characterization	O
of	O
genes	O
encoding	O
eosinophil	B
granule	I
proteins	I
and	O
the	O
mRNA	O
expression	O
of	O
GATA-1	B
binding	I
transcription	I
factor	I
during	O
eosinophil	O
differentiation	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	B
and	O
activation	O
of	O
c	B
-	I
Rel	I
and	O
related	O
NF	B
-	I
kappa	I
B	I
proteins	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA	O
-	O
binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
transcription	I
factor	I
family	I
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS	O
-	O
generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c	B
-	I
Rel	I
/	I
p50	I
heterodimers	I
as	O
well	O
as	O
p50	B
/	I
p65	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
kappa	O
B	O
DNA	O
-	O
binding	O
complexes	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	B
ester	I
-	I
sensitive	I
protein	I
kinase	I
C	I
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c	B
-	I
Rel	I
,	O
p105	B
,	O
and	O
p50	B
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP-1	O
cells	O
.	O

LPS	O
activation	O
of	O
THP-1	O
cells	O
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B
(	O
an	O
I	B
kappa	I
B	I
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	O
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	B
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c	B
-	I
Rel	I
/	I
p50	I
and	O
p50	B
/	I
p65	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B
.	O

Regulation	O
of	O
lymphoid	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
enhancer	O
by	O
ETS	O
-	O
domain	O
proteins	O
.	O

The	O
enhancer	O
for	O
the	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
(	O
IgH	B
)	O
activates	O
a	O
heterologous	O
gene	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
of	O
B	O
lymphocyte	O
differentiation	O
.	O

A	O
lymphoid	O
-	O
specific	O
element	O
,	O
microB	O
,	O
is	O
necessary	O
for	O
enhancer	O
function	O
in	O
pre	O
-	O
B	O
cells	O
.	O

A	O
microB	B
binding	I
protein	I
is	O
encoded	O
by	O
the	O
PU.1	O
/	O
Spi-1	O
proto	O
-	O
oncogene	O
.	O

Another	O
sequence	O
element	O
,	O
microA	O
,	O
was	O
identified	O
in	O
the	O
mu	O
enhancer	O
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	O
proto	O
-	O
oncogene	O
.	O

The	O
microA	O
motif	O
was	O
required	O
for	O
microB	O
-	O
dependent	O
enhancer	O
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	O
B	O
cell	O
-	O
specific	O
enhancer	O
is	O
composed	O
of	O
both	O
the	O
PU.1	O
and	O
Ets-1	O
binding	O
sites	O
.	O

Co	O
-	O
expression	O
of	O
both	O
PU.1	B
and	O
Ets-1	B
in	O
nonlymphoid	O
cells	O
trans	O
-	O
activated	O
reporter	O
plasmids	O
that	O
contained	O
the	O
minimal	O
mu	O
enhancer	O
.	O

These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	B
family	I
in	O
the	O
activation	O
of	O
IgH	O
gene	O
expression	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
-	O
transduction	O
pathway	O
emanating	O
from	O
the	O
T	B
-	I
cell	I
receptor	I
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second	O
-	O
messenger	O
Ca2	O
+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL-2	B
,	O
among	O
which	O
are	O
calmodulin	B
,	O
calcineurin	B
and	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
.	O

Hence	O
,	O
Ca2	O
+	O
binds	O
to	O
calmodulin	B
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	B
to	O
calcineurin	B
;	O
the	O
activated	O
calcineurin	B
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	B
subunit	I
of	I
NF	I
-	I
AT	I
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	B
transcriptional	I
activator	I
.	O

As	O
described	O
by	O
Jun	B
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	B
receptors	I
called	O
immunophilins	B
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	B
prolyl	I
cis	I
-	I
trans	I
isomerase	I
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin	B
-	I
drug	I
complexes	I
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	B
activity	O
of	O
calcineurin	B
.	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B
factors	I
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B
factors	I
(	O
MyoD	B
,	O
myogenin	B
,	O
myf5	B
,	O
and	O
myf6	B
)	O
that	O
are	O
`	B
`	I
basic	I
helix	I
-	I
loop	I
-	I
helix	I
''	I
proteins	I
that	O
bind	O
to	O
the	O
promoters	O
of	O
muscle	O
-	O
specific	O
genes	O
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B
binding	I
basic	I
domain	I
of	O
MyoD	B
confers	O
c	O
-	O
myc	O
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	B
domains	I
of	O
all	O
the	O
myogenic	B
factors	I
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B
transcription	I
factors	I
.	O

The	O
SCL	B
protein	I
displays	O
cell	O
-	O
specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	B
protein	I
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	O
cell	O
lines	O
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	B
protein	I
was	O
detected	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
mast	O
and	O
early	O
myeloid	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	O
leukemia	O
cell	O
lines	O
which	O
are	O
known	O
to	O
harbor	O
SCL	O
gene	O
rearrangements	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B
weight	I
species	I
of	I
24	I
and	I
22	I
kDa	I
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell	O
-	O
specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	O
gene	O
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	O
lines	O
(	O
GP+E-86	O
,	O
AT2.5	O
,	O
M1	O
)	O
but	O
only	O
the	O
22	B
kDa	I
form	I
in	O
the	O
myeloid	O
cell	O
line	O
,	O
WEHI-3B	O
/	O
D+	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
SCL	B
protein	I
in	O
the	O
lymphoid	O
cell	O
lines	O
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B
transcription	O
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B
protein	I
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	O
mRNA	O
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B
protein	I
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

Activation	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoter	O
in	O
T	O
cells	O
requires	O
cooperative	O
binding	O
of	O
Elf-1	B
and	O
AP-1	B
transcription	B
factors	I
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T	O
-	O
lymphocyte	O
activation	O
.	O

The	O
GM	O
-	O
CSF	O
gene	O
is	O
not	O
expressed	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	B
surface	I
T	I
-	I
cell	I
receptor	I
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
TATA	O
box	O
(	O
bp	O
-34	O
to	O
-52	O
)	O
,	O
herein	O
called	O
purine	O
box	O
1	O
(	O
PB1	O
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T	B
-	I
cell	I
nuclear	I
protein	I
complex	I
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
following	O
T	O
-	O
cell	O
activation	O
.	O

The	O
PB1	O
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	O
and	O
murine	O
GM	O
-	O
CSF	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	O
element	O
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	B
nuclear	I
protein	I
-	I
binding	I
complex	I
that	O
is	O
not	O
present	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
following	O
T	O
-	O
cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	O
is	O
composed	O
of	O
adjacent	O
binding	O
sites	O
for	O
Ets	B
and	O
AP-1	B
transcription	B
factors	I
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	O
and	O
AP-1	O
sites	O
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	B
nuclear	I
protein	I
complex	I
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
activated	O
T	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Stress	O
response	O
of	O
senescent	O
T	O
lymphocytes	O
:	O
reduced	O
hsp70	B
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	O
human	O
T	O
lymphocyte	O
cultures	O
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	O
passage	O
cells	O
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

A	O
second	O
feature	O
of	O
senescent	O
T	O
cells	O
is	O
the	O
dramatic	O
reduction	O
in	O
hsp70	B
production	O
in	O
response	O
to	O
heat	O
shock	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	O
heat	O
shock	O
element	O
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	O
T	O
cells	O
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

This	O
suggests	O
that	O
for	O
senescent	O
T	O
cells	O
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	B
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

The	O
interleukin-8	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B
cytokine	I
,	O
interleukin-8	B
(	O
IL-8	B
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	O
promoters	O
,	O
the	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	B
-	I
JunD	I
or	O
c	B
-	I
Fos	I
antibody	I
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B
B	I
-	I
like	I
site	I
binding	I
complexes	I
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B
against	O
the	O
human	B
Rel	I
family	I
proteins	I
(	O
c	B
-	I
Rel	I
,	O
p65	B
,	O
p50	B
,	O
and	O
p49	B
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	B
-	I
kappa	I
B	I
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	O
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	O
kappa	O
B	O
site	O
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B
factors	I
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	O
NF	O
-	O
AT	O
and	O
NFIL-2A	O
sites	O
and	O
Ig	O
kappa	O
B	O
site	O
,	O
but	O
also	O
the	O
IL-8	B
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O

Activation	O
of	O
a	O
novel	O
serine	B
/	I
threonine	I
kinase	I
that	O
phosphorylates	O
c	B
-	I
Fos	I
upon	O
stimulation	O
of	O
T	O
and	O
B	O
lymphocytes	O
via	O
antigen	O
and	O
cytokine	B
receptors	I
.	O

Ligation	O
of	O
Ag	B
receptors	I
in	O
T	O
and	O
B	O
lymphocytes	O
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B
tyrosine	I
and	I
serine	I
/	I
threonine	I
kinases	I
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine	B
/	I
threonine	I
kinase	I
that	O
phosphorylated	O
the	O
proto	B
-	I
oncogene	I
product	I
,	O
c	B
-	I
Fos	I
,	O
and	O
is	O
termed	O
Fos	B
kinase	I
.	O

Fos	B
kinase	I
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	B
and	I
CD2	I
receptors	I
in	O
Jurkat	O
and	O
normal	O
human	O
T	O
lymphocytes	O
and	O
in	O
response	O
to	O
IL-6	B
and	O
anti	B
-	I
IgM	I
in	O
the	O
human	O
B	O
cell	O
lines	O
AF10	O
and	O
Ramos	O
,	O
respectively	O
.	O

The	O
phorbol	O
ester	O
,	O
PMA	O
,	O
was	O
also	O
a	O
potent	O
inducer	O
of	O
Fos	B
kinase	I
activity	O
in	O
all	O
of	O
the	O
above	O
populations	O
,	O
suggesting	O
that	O
PKC	B
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
this	O
enzyme	B
.	O

Fos	B
kinase	I
phosphorylates	O
c	B
-	I
Fos	I
at	O
a	O
site	O
near	O
the	O
C	B
-	I
terminus	I
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B
359	I
-	I
370	I
,	O
RKGSSSNEPSSD	B
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c	B
-	I
Fos	I
phosphorylation	O
.	O

Fos	B
kinase	I
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine	B
/	I
threonine	I
kinases	I
,	O
including	O
protein	B
kinase	I
A	I
,	O
protein	B
kinase	I
C	I
,	O
casein	B
kinase	I
II	I
,	O
MAP	B
kinases	I
,	O
p70S6	B
K	I
and	O
p90RSK	B
.	O

Fos	B
kinase	I
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M	O
(	O
r	O
)	O
=	O
65	O
,	O
000	O
and	O
isoelectric	O
point	O
=	O
6.1	O
.	O

Fos	B
kinase	I
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c	B
-	I
Fos	I
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	O
.	O

A	O
novel	O
heterodimerization	B
partner	I
for	O
thyroid	B
hormone	I
receptor	I
.	O

Peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
.	O

Retinoid	B
-	I
like	I
receptors	I
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B
with	O
other	O
nuclear	B
hormone	I
receptors	I
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
(	O
PPAR	B
)	O
as	O
a	O
new	O
thyroid	B
hormone	I
receptor	I
(	I
THR	I
)	I
auxiliary	I
nuclear	I
protein	I
,	O
heterodimerizing	O
with	O
THR	B
in	O
solution	O
.	O

Although	O
these	O
heterodimers	B
do	O
not	O
recognize	O
a	O
classical	O
thyroid	O
hormone	O
response	O
element	O
(	O
TRE	O
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	O
)	O
,	O
PPAR	B
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH	O
-	O
dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	B
beta	I
-	I
PPAR	I
but	O
not	O
the	O
THR	B
alpha	I
-	I
PPAR	I
heterodimer	I
with	O
a	O
novel	O
TRE	O
(	O
DR+2	O
)	O
.	O

The	O
critical	O
region	O
of	O
THR	B
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B
box	I
of	O
the	O
DNA	B
binding	I
domain	I
.	O

Hence	O
,	O
PPAR	B
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	B
isotype	I
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	O
gene	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte	O
-	O
mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia	O
/	O
reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14	O
-	O
18	O
Torr	O
,	O
led	O
to	O
time	O
-	O
dependent	O
release	O
of	O
IL-8	B
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	B
.	O

Production	O
of	O
IL-8	B
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	O
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	B
transcription	O
,	O
based	O
on	O
nuclear	O
run	O
-	O
on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	O
for	O
macrophage	B
chemotactic	I
protein-1	I
,	O
another	O
member	O
of	O
the	O
chemokine	B
superfamily	I
of	O
proinflammatory	B
cytokines	I
.	O

IL-8	O
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF	O
-	O
kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	B
antigen	I
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30	O
-	O
40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	B
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	B
family	I
related	O
to	O
IL-8	B
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Patterns	O
of	O
Pan	B
expression	O
and	O
role	O
of	O
Pan	B
proteins	I
in	O
endocrine	O
cell	O
type	O
-	O
specific	O
complex	O
formation	O
.	O

The	O
Pan	O
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	B
and	O
Pan-2	B
(	O
also	O
known	O
as	O
E47	B
and	O
E12	B
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	B
proteins	I
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	O
lines	O
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B
proteins	I
have	O
suggested	O
that	O
significant	O
E2A	B
protein	I
expression	O
is	O
restricted	O
to	O
B	O
-	O
lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	B
antibody	I
,	O
Yae	B
,	O
which	O
is	O
specific	O
for	O
Pan	B
/	I
E2A	I
proteins	I
,	O
and	O
have	O
used	O
the	O
Yae	B
antibody	I
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan	O
/	O
E2A	B
protein	I
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan	O
/	O
E2A	B
proteins	I
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B
proteins	I
in	O
GH	O
/	O
PRL-	O
and	O
insulin	O
-	O
producing	O
,	O
B-	O
and	O
T	O
-	O
lymphocyte	O
cells	O
.	O

IEF-1	B
,	O
a	O
pancreatic	O
beta	O
-	O
cell	O
type	O
-	O
specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B
molecules	I
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta	O
-	O
cells	O
share	O
identical	O
Pan	B
/	I
E2A	I
complexes	I
,	O
native	O
-	O
Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta	O
-	O
cells	O
detect	O
Pan	B
proteins	I
in	O
distinct	O
cell	B
type	I
-	I
specific	I
complexes	I
.	O

Novel	O
aldosterone	B
receptors	I
:	O
specificity	O
-	O
conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra	O
-	O
renal	O
,	O
nonepithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non	O
-	O
genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium	B
/	I
proton	I
-	I
exchanger	I
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate	O
/	O
calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
-	O
related	O
rapid	O
responses	O
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	O
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
receptor	B
protein	I
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two	O
-	O
step	O
model	O
for	O
non	O
-	O
genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity	O
-	O
conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

Multiple	O
prolactin	O
-	O
responsive	O
elements	O
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	O
regulatory	O
factor-1	O
gene	O
.	O

The	O
interferon	O
regulatory	O
factor-1	O
(	O
IRF-1	O
)	O
gene	O
is	O
both	O
an	O
immediate	O
-	O
early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	O
by	O
PRL	B
in	O
rat	O
Nb2	O
T	O
lymphocytes	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B
,	O
we	O
cloned	O
the	O
rat	O
IRF-1	O
gene	O
and	O
functionally	O
characterized	O
the	O
IRF-1	O
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	O
T	O
cells	O
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	O
5'-flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	B
enzyme	I
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	O
,	O
0.6	O
,	O
and	O
0.2	O
kb	O
5'-flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	B
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	O
to	O
respond	O
to	O
PRL	B
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	O
PRL	O
response	O
elements	O
may	O
require	O
an	O
interaction	O
with	O
promoter	O
-	O
proximal	O
elements	O
.	O

By	O
assaying	O
CAT	B
enzyme	I
activity	O
across	O
a	O
24-h	O
PRL	B
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	B
responses	O
of	O
the	O
IRF-1	O
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF-1	B
5'-flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0.2-kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
induced	O
by	O
PRL	B
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-	O
CAT	B
construct	O
was	O
inducible	O
by	O
PRL	B
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	B
-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	O
gene	O
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL	O
-	O
responsive	O
elements	O
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	O
promoter	O
region	O
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

HLA	O
-	O
DR-	O
,	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16-	O
myeloid	O
/	O
natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French	O
-	O
American	O
-	O
British	O
acute	O
myeloid	O
leukemia	O
-	O
M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+	O
/	O
-	O
,	O
HLA	B
-	I
DR	I
-	O
,	O
CD16	B
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	B
(	I
CD33	I
,	I
CD13	I
,	I
CD15	I
)	I
and	I
NK	I
cell	I
-	I
associated	I
(	I
CD56	I
)	I
antigens	I
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B
(	O
neural	B
cell	I
adhesion	I
molecule	I
)	O
in	O
leukemic	O
blasts	O
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B
,	O
no	O
case	O
expressed	O
CD2	B
,	O
CD3	B
,	O
or	O
CD8	B
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
beta	I
,	I
gamma	I
,	I
delta	I
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B
variant	I
(	O
FAB	B
AML	I
-	I
M3v	I
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic	O
/	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
fusion	O
transcript	O
in	O
RT	O
-	O
PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	O
17q	O
:	O
1	O
with	O
del	O
(	O
17	O
)	O
(	O
q25	O
)	O
and	O
the	O
other	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q23	O
;	O
q21	O
)	O
and	O
the	O
promyelocytic	O
leukemia	O
zinc	O
finger	O
/	O
RAR	O
alpha	O
fusion	O
transcript	O
.	O

All	O
cases	O
tested	O
(	O
6	O
/	O
20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16	B
-acute	O
leukemias	O
and	O
normal	O
CD56	O
+	O
,	O
CD16-	O
NK	O
precursor	O
cells	O
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	O
CD56	O
+	O
,	O
CD33	O
+	O
,	O
CD16-	O
counterpart	O
cell	O
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	O
and	O
NK	O
cell	O
lineages	O
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid	O
/	O
NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA	O
-	O
nonresponsive	O
cases	O
from	O
ATRA	O
-	O
responsive	O
true	O
APL	O
.	O

Upregulation	O
of	O
bcl-2	O
by	O
the	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
membrane	I
protein	I
LMP1	B
:	O
a	O
B	O
-	O
cell	O
-	O
specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
to	O
induction	O
of	O
cell	B
surface	I
markers	I
.	O

An	O
ability	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
membrane	I
protein	I
LMP1	B
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	O
of	O
the	O
bcl-2	O
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1	O
+	O
clones	O
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107	O
-	O
1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	B
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2	O
+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
and	O
upregulation	O
of	O
the	O
cell	B
adhesion	I
molecule	I
ICAM-1	B
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B	O
-	O
cell	O
lines	O
carrying	O
an	O
LMP1	B
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	O
to	O
express	O
LMP1	B
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK	B
-	I
kappa	I
B	I
and	O
upregulation	O
of	O
ICAM-1	B
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	B
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B	O
-	O
cell	O
lines	O
tested	O
showed	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
response	O
to	O
LMP1	B
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	B
and	O
Bcl-2	B
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-	O
B	O
-	O
cell	O
lines	O
showed	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
ICAM-1	B
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl-2	B
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	B
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	B
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B
signal	O
transduction	O
,	O
other	O
cell	B
-	I
specific	I
factors	I
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B
protein	I
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
in	O
relation	O
to	O
CD4	B
cell	O
number	O
and	O
antibody	O
titres	O
to	O
EBV	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti	B
-	I
Z	I
Epstein	I
-	I
Barr	I
replicative	I
activator	I
(	O
ZEBRA	B
)	O
,	O
anti	B
-	I
early	I
antigen	I
(	O
EA	B
)	O
,	O
anti	B
-	I
viral	I
capsid	I
antigen	I
(	O
VCA	B
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	B
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

METHODS	O
:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein	O
-	O
Barr	O
early	O
region	O
(	O
EBER	O
)	O
RNA	O
-	O
positive	O
]	O
.	O

Immunohistochemistry	O
was	O
performed	O
with	O
anti	B
-	I
ZEBRA	I
,	O
anti	B
-	I
EA	I
-	I
restricted	I
,	I
anti	I
-	I
VCA	I
antibodies	I
and	O
in	O
situ	O
hybridization	O
with	O
BHLF1	O
/	O
NotI	O
oligoprobes	O
on	O
tumour	O
samples	O
.	O

Results	O
were	O
statistically	O
correlated	O
with	O
those	O
of	O
CD4	B
+	I
cell	O
counts	O
(	O
17	O
out	O
of	O
17	O
)	O
and	O
with	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
13	O
out	O
of	O
17	O
)	O
assessed	O
using	O
standard	O
immunofluorescence	O
method	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
procedure	O
using	O
recombinant	B
ZEBRA	I
protein	I
and	O
synthetic	O
peptides	O
as	O
antigens	B
.	O

RESULTS	O
:	O
BZLF1	B
(	O
ZEBRA	B
)	O
or	O
early	B
gene	I
products	I
(	O
EA	B
-	I
R	I
and	O
EA	B
-	I
D	I
/	I
BHLF1	I
/	I
NotI	I
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01	O
-	O
5	O
%	O
)	O
of	O
tumour	O
cells	O
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4	B
+	I
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Anti-	O
ZEBRA	B
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
ARNHL	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	B
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Displacement	O
of	O
an	O
E	B
-	I
box	I
-	I
binding	I
repressor	I
by	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
:	O
implications	O
for	O
B	O
-	O
cell	O
specificity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

The	O
activity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
is	O
restricted	O
to	O
B	O
cells	O
,	O
although	O
it	O
binds	O
both	O
B	B
-	I
cell	I
-	I
restricted	I
and	I
ubiquitous	I
transcription	I
factors	I
.	O

Activation	O
of	O
the	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
upon	O
overexpression	O
of	O
the	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
protein	I
E2A	B
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	B
to	O
its	O
cognate	O
E	O
box	O
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	B
from	O
that	O
same	O
site	O
.	O

We	O
have	O
identified	O
a	O
`	B
`	I
two	I
-	I
handed	I
''	I
zinc	I
finger	I
protein	I
,	O
denoted	O
ZEB	B
,	O
the	O
DNA	O
-	O
binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B
repressor	I
.	O

By	O
employing	O
a	O
derivative	O
E	O
box	O
that	O
binds	O
ZEB	B
but	O
not	O
E2A	B
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B
is	O
active	O
in	O
B	O
cells	O
and	O
the	O
IgH	O
enhancer	O
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B
proteins	I
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	O
activity	O
is	O
the	O
B	O
-	O
cell	O
-	O
specific	O
displacement	O
of	O
a	O
ZEB	B
-	I
like	I
repressor	I
by	O
bHLH	B
proteins	I
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	O
and	O
interleukin	B
2	I
-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV	O
-	O
infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	O
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	O
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free	O
-	O
radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	O
cells	O
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	O
cells	O
.	O

Both	O
antioxidants	O
inhibited	O
TNF	B
-or	O
PMA	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
U1	O
cells	O
,	O
as	O
well	O
as	O
the	O
sustained	O
NF	B
-	I
kappa	I
B	I
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV	O
-	O
infected	O
U937	O
cells	O
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	O
cells	O
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	O
infected	O
U937	O
cells	O
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK	B
-	I
kappa	I
B	I
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	O
PBMC	O
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant	O
-	O
based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

A	O
low	O
NM23.H1	O
gene	O
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis	O
-	O
suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	B
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	B
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	O
gene	O
in	O
cell	O
lines	O
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease	O
-	O
free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	O
lines	O
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	O
lines	O
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24	O
-	O
58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	O
lines	O
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6	O
-	O
15	O
months	O
)	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	B
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid	O
-	O
induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat	O
-	O
activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1-infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B
(	O
IFN	B
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV-1-infected	O
cells	O
,	O
HIV-1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
of	O
the	O
HIV-1	O
LTR	O
significantly	O
inhibited	O
Tat	B
-mediated	O
transactivation	O
in	O
T	O
-	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	O
line	O
,	O
U937	O
.	O

Replacement	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
in	O
the	O
HIV-1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5'-flanking	O
region	O
of	O
IFN	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN	O
-	O
stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat	B
-mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	O
gene	O
directed	O
high	O
levels	O
of	O
IFN	B
synthesis	O
in	O
Tat	O
-	O
expressing	O
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B
necrosis	I
factor	I
alpha	I
-mediated	O
activation	O
.	O

ISG15-LTR	O
-	O
IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	O
and	O
U937	O
cells	O
.	O

Selected	O
transfected	O
clones	O
produced	O
low	O
levels	O
of	O
IFN	B
A	I
(	O
IFNA	B
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B
and	O
interleukin-2	B
receptor	I
upon	O
stimulation	O
with	O
phytohemagglutinin	B
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA	O
-	O
producing	O
cells	O
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	O
cells	O
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	O
cells	O
transduced	O
with	O
the	O
IFNA	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	B
synthesis	O
to	O
HIV-1-infected	O
cells	O
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	B
synthesis	O
results	O
in	O
a	O
long	O
-	O
lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B
receptor	I
on	O
peripheral	O
blood	O
lymphocytes	O
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
expression	O
of	O
the	O
progesterone	B
receptor	I
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
was	O
analysed	O
,	O
using	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
Abbott	O
PgR	O
-	O
EIA	O
monoclonal	O
)	O
,	O
in	O
order	O
to	O
evaluate	O
its	O
prognostic	O
character	O
in	O
the	O
context	O
of	O
spontaneous	O
abortion	O
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non	O
-	O
pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

In	O
addition	O
,	O
a	O
human	O
breast	O
carcinoma	O
cell	O
line	O
(	O
ZR-75	O
-	O
1	O
)	O
,	O
which	O
expresses	O
the	O
progesterone	B
receptor	I
,	O
was	O
analysed	O
throughout	O
.	O

The	O
ZR-75	O
-	O
1	O
cell	O
line	O
showed	O
an	O
expression	O
of	O
642	O
fmol	O
/	O
mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol	O
/	O
mg	O
.	O

Lymphocytes	O
of	O
non	O
-	O
pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre	O
-	O
term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+	O
/-	O
1	O
,	O
3	O
+	O
/-	O
2	O
and	O
5	O
+	O
/-	O
4	O
fmol	O
/	O
mg	O
respectively	O
.	O

These	O
results	O
show	O
that	O
there	O
is	O
no	O
evidence	O
of	O
specific	O
expression	O
of	O
the	O
progesterone	B
receptor	I
in	O
pregnancy	O
and	O
exclude	O
any	O
prognostic	O
character	O
in	O
spontaneous	O
abortion	O
.	O

A	O
role	O
for	O
the	O
progesterone	B
receptor	I
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	O
blood	O
lymphocytes	O
is	O
also	O
excluded	O
.	O

Characterization	O
of	O
the	O
CD48	O
gene	O
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
and	O
contains	O
an	O
essential	O
NF	O
-	O
kappa	O
B	O
site	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	O
B	O
cells	O
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	B
,	O
characteristically	O
expressed	O
on	O
normal	O
activated	O
B	O
cells	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	O
element	O
in	O
the	O
CD48	O
gene	O
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV	O
-	O
positive	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV	O
-	O
negative	O
B	O
-	O
cell	O
lines	O
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	O
phenotype	O
.	O

An	O
NF	B
-	I
kappa	I
B	I
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	B
protein	I
complex	I
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF	B
-	I
kappa	I
B1	I
(	O
p50	B
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV	B
-	I
encoded	I
latent	I
membrane	I
protein	I
1	I
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B
NF	O
-	O
kappa	O
B	O
site	O
but	O
not	O
the	O
intact	O
element	O
,	O
suggesting	O
that	O
the	O
latent	B
membrane	I
protein	I
1	I
-driven	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	O
B	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O

Activation	O
of	O
human	O
thymocytes	O
after	O
infection	O
by	O
EBV	O
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	B
receptor	I
,	O
CR2	B
/	I
CD21	I
,	O
on	O
a	O
population	O
of	O
immature	O
thymocytes	O
,	O
T	O
lymphoblastoid	O
cell	O
lines	O
,	O
and	O
childhood	O
acute	O
T	O
lymphoblastic	O
leukemia	O
cells	O
suggested	O
that	O
EBV	O
-	O
receptor	O
interactions	O
on	O
T	O
cells	O
may	O
be	O
of	O
importance	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	O
,	O
immature	O
cells	O
expresses	O
CD21	B
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	O
thymocytes	O
in	O
vitro	O
.	O

Triggering	O
through	O
CD2	B
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	O
cells	O
.	O

However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	B
caused	O
thymocytes	O
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	B
cytokines	I
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	B
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	B
mAb	I
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95	O
-	O
8	O
.	O

Immature	O
thymocytes	O
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	O
genome	O
and	O
its	O
transcriptional	O
activity	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95	B
-	I
8	I
,	O
EBNA-2	O
transcripts	O
were	O
identified	O
within	O
infected	O
thymocyte	O
populations	O
.	O

In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	O
.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	O
,	O
an	O
early	O
gene	O
that	O
characterizes	O
EBV	O
-	O
infected	O
B	O
cells	O
after	O
disruption	O
of	O
latency	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
consequences	O
of	O
EBV	O
infection	O
of	O
T	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
may	O
lead	O
to	O
failure	O
of	O
normal	O
T	O
cell	O
repertoire	O
development	O
,	O
autoimmunity	O
,	O
or	O
malignancy	O
.	O

Protein	B
kinase	I
C	I
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	O
in	O
activated	O
T	O
cells	O
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
downstream	O
of	O
p21ras	O
,	O
in	O
activating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	B
is	O
an	O
effector	B
of	O
p21ras	O
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	B
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	B
is	O
not	O
downstream	O
of	O
p21ras	O
in	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
and	O
AP-1	B
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL-2	B
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF	B
-	I
kappa	I
B	I
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	O
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	B
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	B
during	O
T	O
cell	O
activation	O
.	O

Detection	O
of	O
the	O
chromosome	O
16	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcript	O
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	O
beta	O
and	O
MYH11	O
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	O
transcripts	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
by	O
RT	O
-	O
PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty	O
-	O
three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	O
abnormal	O
eosinophils	O
(	O
AML	O
M4	O
`	O
`	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT	O
-	O
PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	O
eosinophils	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	O
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT	O
-	O
PCR	O
positive	O
.	O

Follow	O
-	O
up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	O
16	O
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	O
beta	O
-	O
MYH11	O
transcripts	O
in	O
the	O
absence	O
of	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT	O
-	O
PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	O
transcript	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM	B
-	I
CSF	I
,	O
IL-3	B
,	O
M	B
-	I
CSF	I
receptor	I
(	O
C	B
-	I
FMS	I
)	O
,	O
early	O
growth	O
response	O
gene-1	O
(	O
EGR-1	O
)	O
and	O
M	O
-	O
CSF	O
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	O
,	O
GM	O
-	O
CSF	O
,	O
FMS	O
and	O
EGR-1	O
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	O
clones	O
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M	O
-	O
CSF	O
gene	O
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	O
and	O
the	O
EGR-1	O
genes	O
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M	O
-	O
CSF	O
and	O
FMS	O
genes	O
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	B
growth	I
factors	I
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

A	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
in	O
the	O
progesterone	O
receptor	O
gene	O
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	B
receptor	I
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	O
leucocyte	O
genomic	O
DNAs	O
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	O
progesterone	O
receptor	O
(	O
hPR	O
)	O
cDNA	O
probe	O
identified	O
a	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	O
,	O
represented	O
by	O
a	O
2.7	O
kb	O
fragment	O
;	O
and	O
T2	O
,	O
represented	O
by	O
a	O
1.9	O
kb	O
fragment	O
and	O
characterised	O
by	O
an	O
additional	O
TaqI	O
restriction	O
site	O
with	O
respect	O
to	O
T1	O
.	O

An	O
over	O
-	O
representation	O
of	O
T2	O
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish	O
/	O
German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	O
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy	O
-	O
Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	O
cDNA	O
region	O
-	O
specific	O
probes	O
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	O
G	O
of	O
the	O
hPR	O
gene	O
.	O

IL-1	B
receptor	I
and	O
TCR	B
signals	O
synergize	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	B
receptor	I
(	O
IL-1R	B
)	O
-	O
and	O
TCR	B
-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	B
I	I
IL-1R	I
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

The	O
synergistic	O
antigen	B
receptor	I
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B
kinase	I
C	I
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	B
rather	O
than	O
by	O
antigen	B
receptor	I
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF	B
-	I
kappa	I
B	I
functional	O
activity	O
is	O
independent	O
of	O
I	B
kappa	I
B	I
alpha	I
(	O
MAD3	B
)	O
-	O
NF	B
-	I
kappa	I
B	I
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B
kappa	I
B	I
nuclear	O
translocation	O
.	O

The	O
IL-1	B
-induced	O
NF	B
-	I
kappa	I
B	I
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	B
induces	O
both	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	B
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	B
-induced	O
NF	B
-	I
kappa	I
B	I
-dependent	O
gene	O
transcription	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	B
kinase	I
C	I
-	I
alpha	I
,	I
-epsilon	I
,	I
and	I
-zeta	I
in	O
T	O
cell	O
activation	O
.	O

T	O
cells	O
express	O
multiple	O
isotypes	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B
isotypes	I
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC	B
-	I
alpha	I
,	I
-epsilon	I
,	I
or	I
-zeta	I
have	O
been	O
transfected	O
into	O
T	O
cells	O
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	B
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B
active	I
PKCs	I
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B
.	O

The	O
data	O
indicate	O
that	O
PKC	B
-	I
epsilon	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC	B
-	I
alpha	I
but	O
not	O
-zeta	B
,	O
can	O
regulate	O
the	O
transcription	B
factors	I
AP-1	B
and	O
nuclear	O
factor	B
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT-1	I
)	O
.	O

The	O
ability	O
of	O
PKC	B
-	I
epsilon	I
to	O
induce	O
transactivation	O
of	O
NF	B
-	I
AT-1	I
and	O
AP-1	B
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B
activated	I
p21ras	I
.	O

PKC	B
-	I
epsilon	I
,	O
but	O
not	O
PKC	B
-	I
alpha	I
nor	O
activated	O
p21ras	B
,	O
was	O
able	O
to	O
induce	O
NF	B
-	I
KB	I
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B
whereas	O
none	O
of	O
the	O
activated	B
PKC	I
isotypes	I
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	B
and	O
p21ras	B
were	O
able	O
to	O
induce	O
CD69	B
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B
isotypes	I
in	O
T	O
cells	O
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B
Ras	I
and	O
PKC	B
mutants	I
suggest	O
that	O
PKC	B
-	I
alpha	I
,	O
p21ras	B
,	O
and	O
PKC	B
-	I
epsilon	I
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Identification	O
of	O
two	O
novel	O
regulatory	O
elements	O
within	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
A	O
gamma	O
-	O
globin	O
gene	O
.	O

Interaction	O
between	O
the	O
stage	O
selector	O
element	O
(	O
SSE	O
)	O
in	O
the	O
proximal	O
gamma	O
-	O
globin	O
promoter	O
and	O
hypersensitivity	O
site	O
2	O
in	O
the	O
locus	O
control	O
region	O
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE	O
-	O
like	O
element	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
gamma	O
-	O
gene	O
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
gene	O
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	O
erythroid	O
cell	O
line	O
,	O
K562	O
,	O
we	O
have	O
shown	O
that	O
the	O
core	O
enhancer	O
of	O
hypersensitivity	O
site	O
2	O
can	O
preferentially	O
interact	O
with	O
the	O
proximal	O
gamma	O
-	O
promoter	O
in	O
the	O
absence	O
of	O
the	O
SSE	O
,	O
completely	O
silencing	O
a	O
linked	O
beta	O
-	O
promoter	O
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma	O
-	O
gene	O
5'-untranslated	O
region	O
(	O
UTR	O
)	O
led	O
to	O
derepression	O
of	O
beta	O
-	O
promoter	O
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma	O
-	O
promoter	O
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	O
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	O
+	O
13	O
to	O
+	O
15	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B
and	I
erythroid	I
-	I
specific	I
protein	I
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	O
was	O
localized	O
to	O
tandem	O
GATA	O
-	O
like	O
sites	O
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	B
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	O
of	O
the	O
gamma	O
-	O
gene	O
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

MIP1	B
alpha	I
nuclear	I
protein	I
(	O
MNP	B
)	O
,	O
a	O
novel	O
transcription	B
factor	I
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP-1	O
alpha	O
gene	O
.	O

Murine	B
macrophage	I
inflammatory	I
protein	I
1	I
alpha	I
(	O
MIP-1	B
alpha	I
)	O
and	O
its	O
human	B
equivalent	I
(	O
GOS19	B
,	O
LD78	B
,	O
or	O
AT464	B
)	O
are	O
members	O
of	O
the	O
-C	B
-	I
C	I
family	I
of	O
low	B
-	I
molecular	I
-	I
weight	I
chemokines	I
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	B
-	I
derived	I
MIP-1	I
alpha	I
/	I
GOS19	I
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B
alpha	I
/GOS19	B
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B
factors	I
(	O
the	O
ICK-1	B
family	I
)	O
affect	O
the	O
GOS19	O
promoter	O
.	O

One	O
member	O
,	O
ICK-1A	B
,	O
behaves	O
as	O
a	O
strong	B
negative	I
regulator	I
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP-1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK-1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	B
-	I
migrating	I
protein	I
-	I
DNA	I
complexes	I
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	B
protein	I
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	B
factor	I
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

The	O
transcription	B
factor	I
,	O
Nm23H2	B
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	O
site	O
on	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	O
site	O
on	O
the	O
silent	O
normal	O
c	O
-	O
myc	O
allele	O
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
SDS	O
-	O
gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c	O
-	O
myc	O
PuF	O
site	O
.	O

Transfection	O
experiments	O
with	O
c	O
-	O
myc	O
promoter	O
constructs	O
in	O
both	O
DHL-9	O
and	O
Raji	O
cells	O
revealed	O
that	O
the	O
PuF	O
site	O
functioned	O
as	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
cells	O
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	O
silent	O
c	O
-	O
myc	O
allele	O
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

Modulation	O
of	O
transcription	B
factor	I
NF	I
kappa	I
B	I
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV	O
-	O
infected	O
individuals	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Molt-4	O
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
NF	I
kappa	I
B	I
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA	O
-	O
binding	O
and	O
transactivating	O
activity	O
of	O
NF	B
kappa	I
B	I
.	O

Because	O
inhibition	O
of	O
DNA	O
-	O
binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	B
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
directly	O
in	O
cell	O
-	O
free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	B
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	O
cells	O
also	O
.	O

NF	B
kappa	I
B	I
controls	O
many	O
immunologically	O
important	O
genes	O
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Thapsigargin	O
induces	O
IL-2	B
receptor	I
alpha	I
-	I
chain	I
in	O
human	O
peripheral	O
and	O
Jurkat	O
T	O
cells	O
via	O
a	O
protein	B
kinase	I
C	I
-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-ATPase	I
,	O
depletes	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2	O
+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	B
in	O
Jurkat	O
T	O
cells	O
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B
alpha	I
protein	I
as	O
well	O
as	O
IL-2R	O
alpha	O
mRNA	O
in	O
Jurkat	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	B
alpha	I
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	B
kappa	I
B	I
in	O
Jurkat	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B
alpha	I
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B
alpha	I
through	O
distinct	O
pathways	O
.	O

PMA	B
-but	I
not	I
TG	I
-	I
induced	I
IL-2R	I
alpha	I
is	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
H7	O
,	O
whereas	O
TG	B
-but	I
not	I
PMA	I
-	I
induced	I
IL-2R	I
alpha	I
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B
alpha	I
in	O
human	O
T	O
cells	O
through	O
a	O
PKC	B
-independent	O
pathway	O
.	O

Interleukin	B
4	I
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B
(	I
Stat	I
)	I
protein	I
which	O
interacts	O
with	O
an	O
interferon	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B
kinase	I
3	I
and	O
interleukin-4	B
Stat	I
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL-4	B
in	O
the	O
human	O
B	O
cell	O
line	O
,	O
BL-2	O
.	O

Utilizing	O
a	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	B
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	O
cells	O
.	O

This	O
factor	O
was	O
designated	O
IL-4	B
NAF	I
(	O
IL-4-induced	B
nuclear	I
-	I
activating	I
factors	I
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B
phosphoprotein	I
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
Stat	I
)	I
protein	I
,	O
we	O
determined	O
whether	O
antibodies	B
to	I
Stat	I
proteins	I
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B
to	I
IL-4	I
Stat	I
,	O
also	O
known	O
as	O
Stat6	B
,	O
but	O
not	O
antibodies	B
to	O
other	O
Stat	B
proteins	I
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B
NAF	I
complex	I
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B
protein	I
,	O
IL-4	B
induced	O
robust	O
Janus	B
kinase	I
3	I
(	O
JAK3	B
)	O
activity	O
in	O
BL-2	O
cells	O
.	O

Cotransfection	O
of	O
JAK3	B
with	O
IL-4	B
Stat	I
into	O
COS-7	O
cells	O
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
and	O
comigrated	O
with	O
IL-4	B
NAF	I
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	B
NAF	I
is	O
IL-4	B
Stat	I
,	O
which	O
is	O
activated	O
by	O
JAK3	B
in	O
response	O
to	O
IL-4	B
receptor	O
engagement	O
.	O

Interleukin	B
12	I
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B
in	O
human	O
lymphocytes	O
.	O

Interleukin	B
12	I
(	O
IL-12	B
)	O
is	O
an	O
important	O
immunoregulatory	B
cytokine	I
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B
receptor	I
superfamily	I
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL-12	B
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
family	I
tyrosine	I
kinase	I
JAK2	B
and	O
Tyk2	B
,	O
implicating	O
these	O
kinases	B
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B
.	O

Recently	O
,	O
transcription	B
factors	I
known	O
as	O
STATs	B
(	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B
that	O
bind	O
hematopoietin	B
receptors	I
and	O
activate	O
JAK	B
kinases	I
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	B
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	B
family	I
member	I
,	O
STAT4	B
,	O
and	O
show	O
that	O
STAT4	B
expression	O
is	O
regulated	O
by	O
T	O
-	O
cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B
stimulates	O
formation	O
of	O
a	O
DNA	B
-	I
binding	I
complex	I
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B
proteins	I
and	O
that	O
this	O
complex	O
contains	O
STAT4	B
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	B
phosphorylation	O
by	O
IL-12	B
,	O
identify	O
a	O
rapid	O
signal	O
-	O
transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	B
-induced	O
gene	O
expression	O
.	O

Overexpression	O
of	O
DR	B
-	I
nm23	I
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	O
gene	O
family	O
,	O
inhibits	O
granulocyte	O
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	O
myeloid	O
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	O
clone	O
,	O
DR	B
-	I
nm23	I
,	O
differentially	O
expressed	O
in	O
a	O
blast	O
-	O
crisis	O
cDNA	O
library	O
,	O
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	O
metastatic	O
suppressor	O
genes	O
,	O
nm23-H1	O
and	O
nm23-H2	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B
zipper	I
-	I
like	I
and	O
the	O
RGD	B
domain	I
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B
and	O
in	O
the	O
COOH	B
-	I
terminal	I
portion	I
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B
function	O
.	O

DR	O
-	O
nm23	O
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	O
purified	O
CD34	O
+	O
cells	O
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	O
precursor	O
32Dc13	O
cell	O
line	O
,	O
which	O
is	O
growth	O
-	O
factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR	B
-	I
nm23	I
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Transcription	B
factors	I
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	O
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time	O
-	O
frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	O
gene	O
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B
factors	I
AP-1	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
NF	B
-	I
AT	I
and	O
Oct1	B
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	O
mRNA	O
and	O
secretion	O
of	O
IL-2	B
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B
factor	I
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
extracted	O
from	O
mitogen	O
-	O
stimulated	O
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF	O
-	O
AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	B
proteins	I
,	O
such	O
as	O
transcription	B
factors	I
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	O
lymphocytes	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	B
-	I
gamma	I
production	O
induced	O
by	O
IL-2	B
and	O
IL-12	B
in	O
a	O
human	O
NK	O
cell	O
line	O
.	O

Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
is	O
an	O
important	O
immunoregulatory	B
protein	I
produced	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
(	O
LGL	O
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	B
(	O
ILs	B
)	O
,	O
IL-2	B
and	O
IL-12	B
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN	B
-	I
gamma	I
gene	O
expression	O
in	O
both	O
T	O
cells	O
and	O
LGL	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	O
cell	O
lines	O
that	O
produce	O
IFN	B
-	I
gamma	I
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
line	O
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	O
line	O
NK3.3	O
derived	O
from	O
human	O
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL-2	B
and	O
IL-12	B
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN	B
-	I
gamma	I
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B
and	O
IL-12	B
synergized	O
in	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
and	O
GM	B
-	I
CSF	I
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
mRNAs	O
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B
growth	I
factor	I
-	I
beta	I
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	B
and	O
IL-12	B
on	O
NK3.3	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B
kinase	I
C	I
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B
induction	O
of	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
cytoplasmic	O
mRNA	O
.	O

In	O
contrast	O
,	O
IL-12	B
induction	O
of	O
IFN	O
-	O
gamma	O
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B
kinase	I
C	I
.	O

Furthermore	O
,	O
both	O
transforming	B
growth	I
factor	I
-	I
beta	I
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B
and	O
IL-12	B
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	O
gene	O
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	B
but	O
not	O
IL-12	B
induced	O
nuclear	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP1	B
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B
binding	I
protein	I
complexes	I
is	O
correlated	O
with	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B
and	O
IL-12	B
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
and	O
GM	B
-	I
CSF	I
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	O
cell	O
line	O
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

Restoration	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
ZEBRA	I
protein	I
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	B
activation	I
regions	I
.	O

The	O
ZEBRA	B
protein	I
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B
proteins	I
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	B
is	O
a	O
bZIP	B
transcriptional	I
activator	I
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	O
response	O
elements	O
within	O
EBV	O
promoters	O
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	O
lytic	O
origin	O
.	O

We	O
have	O
employed	O
the	O
ZEBRA	B
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B
activation	I
domain	I
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B
domain	I
)	O
.	O

The	O
ZEBRA	B
activation	I
region	I
was	O
replaced	O
with	O
the	O
potent	O
acid	B
activation	I
region	I
from	O
the	O
herpes	B
simplex	I
virus	I
VP16	I
protein	I
or	O
with	O
the	O
activation	B
region	I
of	O
the	O
EBV	B
R	I
protein	I
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell	O
-	O
type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B
's	O
ability	O
to	O
induce	O
early	B
antigen	I
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B
domain	I
present	I
within	O
ZEBRA	B
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B
factors	I
of	O
activated	O
T	O
cells	O
,	O
NFATp	B
and	O
NFATc	B
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	B
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B
factor	I
of	O
activated	O
T	O
cells	O
(	O
NFATp	B
)	O
,	O
a	O
cyclosporin	B
A	I
(	I
CsA	I
)	I
-sensitive	I
factor	I
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B
,	O
mediates	O
CD16	B
-induced	O
activation	O
of	O
cytokine	B
genes	I
in	O
human	O
NK	O
cells	O
.	O

CD16	B
(	O
Fc	B
gamma	I
RIIIA	I
)	O
-induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	B
ligands	O
induces	O
NFAT	B
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	B
cell	I
NFAT	I
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	B
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	B
and	O
NFATc	B
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	B
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B
and	I
NFATc-	I
specific	I
antibodies	I
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	O
express	O
NFATc	B
constitutively	O
,	O
but	O
NFATc	O
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	B
recognizing	O
the	O
T	B
cell	I
NFATc	I
revealed	O
no	O
detectable	O
NFATc	B
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
cells	O
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	B
-	I
sensitive	I
transcription	I
factors	I
,	O
NFATp	B
and	O
NFATc	B
,	O
are	O
expressed	O
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	O
mRNA	O
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B
receptor	I
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	O
cells	O
(	O
U937	O
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	O
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein	O
-	O
labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double	O
-	O
labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B
receptor	I
expression	O
in	O
U937	O
cells	O
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up	O
-	O
regulation	O
of	O
GR	O
mRNA	O
while	O
no	O
enhanced	O
GR	B
expression	O
was	O
perceived	O
with	O
RA	O
/	O
VD	O
treatment	O
.	O

Up	O
-	O
regulation	O
of	O
high	O
-	O
affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	O
T	O
lymphocytes	O
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
in	O
a	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+	O
/-	O
0.53	O
nmol	O
/	O
L	O
,	O
mean	O
+	O
/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2	O
+	O
ionophore	O
A23187	O
.	O

Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B
receptor	I
,	O
but	O
also	O
suggest	O
that	O
T	O
cells	O
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal	O
-	O
induced	O
activation	O
.	O

Attenuation	O
of	O
gamma	B
interferon	I
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	B
kinases	I
and	O
Stat1	B
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B
interferon	I
is	O
impaired	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B
interferon	I
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B
protein	I
tyrosine	I
kinases	I
,	O
including	O
the	O
Janus	B
kinases	I
Jak1	B
and	O
Jak2	B
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factor	I
Stat1	I
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B
interferon	I
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B
and	O
Jak2	B
and	O
phosphorylation	O
of	O
Stat1	B
was	O
developed	O
in	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
differentiated	O
U-937	O
cells	O
.	O

Analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B
interferon	I
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	O
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon	O
-	O
treated	O
cells	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
increased	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
U-937	O
cells	O
incubated	O
with	O
gamma	B
interferon	I
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	O
cells	O
were	O
also	O
obtained	O
with	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	O
mononuclear	O
phagocytes	O
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B
interferon	I
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	B
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B
interferon	I
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Regulation	O
of	O
IkB	B
alpha	I
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	B
(	I
2	I
+	I
)	I
-dependent	I
phosphatase	I
calcineurin	B
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B
-induced	O
activation	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
in	O
T	O
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
calcineurin	B
is	O
also	O
sufficient	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
PKC	O
-	O
dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B
alpha	I
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B
alpha	I
phosphorylation	O
.	O

While	O
PKC	B
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B
alpha	I
in	O
T	O
cell	O
lines	O
,	O
co	O
-	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B
alpha	I
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B
alpha	I
in	O
Jurkat	O
T	O
or	O
in	O
U937	O
cells	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	B
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA	O
-	O
induced	O
IkB	B
alpha	I
phosphorylation	O
/	O
degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B
alpha	I
induced	O
by	O
TNF	B
-	I
alpha	I
,	O
a	O
PKC	B
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B
,	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF	B
-	I
alpha	I
not	O
at	O
the	O
level	O
of	O
IkB	B
alpha	I
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B
calcineurin	B
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B
alpha	I
phosphorylation	O
and	O
degradation	O
.	O

Cupric	O
ion	O
blocks	O
NF	B
kappa	I
B	I
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O

A	O
transcription	B
factor	I
NF	B
kappa	I
B	I
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B
protein	I
I	I
kappa	I
B	I
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
to	O
release	O
NF	B
kappa	I
B	I
.	O

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B
kappa	I
B	I
induced	O
by	O
TNF	B
-	I
alpha	I
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B
-	I
alpha	I
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B
kappa	I
B	I
from	O
I	B
kappa	I
B	I
alpha	I
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B
kappa	I
B	I
-	I
I	I
kappa	I
B	I
complex	I
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
was	O
observed	O
upon	O
TNF	B
-	I
alpha	I
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	B
kappa	I
B	I
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O

ETS1	B
transactivates	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
one	O
such	O
cytokine	B
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	B
kappa	I
B	I
,	O
AP-1	B
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	B
family	I
of	O
transcription	B
factors	I
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	B
and	O
ELF1	B
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-47	O
to	O
-40	O
upstream	O
of	O
the	O
GM	O
-	O
CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	B
,	O
but	O
not	O
ELF1	B
,	O
can	O
transactivate	O
GM	B
-	I
CSF	I
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	B
-	I
like	I
factors	I
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-GGAA-	O
to	O
-GGAT-	O
prevents	O
the	O
binding	O
of	O
ETS	B
-	I
like	I
factors	I
with	O
the	O
exception	O
of	O
ETS1	B
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	B
-	I
CSF	I
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	B
activate	O
signal	B
transducer	I
and	I
activation	I
of	I
transcription	I
(	I
STAT	I
)	I
transcription	I
factors	I
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	O
cell	O
priming	O
cultures	O
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B
production	O
and	O
STAT	B
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B
(	I
IFN	I
)	I
-gamma	I
,	O
but	O
not	O
interleukin	B
(	I
IL	I
)	I
4	I
,	O
production	O
by	O
effector	O
cells	O
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B
and	O
IL-10	B
and	O
inhibition	O
of	O
IL-12	B
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

SFs	O
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B
factor	I
Stat1	I
,	O
but	O
not	O
Stat3	B
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN	B
-	I
gamma	I
production	O
.	O

Active	O
Stat3	B
,	O
but	O
not	O
Stat1	B
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

MEK1	B
and	O
the	O
extracellular	B
signal	I
-	I
regulated	I
kinases	I
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL-2	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

TCR	B
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	B
kinase	I
Raf-1	B
.	O

Active	O
Raf-1	B
phosphorylates	O
and	O
activates	O
the	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
/	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
kinase	I
1	I
(	O
MEK1	B
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	B
kinases	I
/	I
extracellular	I
signal	I
regulated	I
kinases	I
,	O
ERK1	B
and	O
ERK2	B
.	O

Raf-1	B
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	B
and	O
ERK	B
activities	O
also	O
stimulate	O
IL-2	O
gene	O
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf-1	B
or	O
MEK1	B
in	O
Jurkat	O
T	O
cells	O
enhanced	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF	B
-	I
AT	I
activity	O
.	O

Expression	O
of	O
MEK1-interfering	B
mutants	I
inhibited	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	B
and	O
Raf-1	B
to	O
costimulate	O
NF	B
-	I
AT	I
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	B
kinase	I
-	I
specific	I
phosphatase	I
,	O
MKP-1	B
,	O
which	O
blocks	O
ERK	B
activation	O
,	O
inhibited	O
IL-2	O
promoter	O
and	O
NF	B
-	I
AT	I
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	B
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	B
kinase	I
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	B
,	O
MEK1	B
,	O
and	O
ERK1	B
and	O
ERK2	B
functions	O
in	O
the	O
stimulation	O
IL-2	O
gene	O
transcription	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
NF	B
-	I
AT	I
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	B
.	O

An	O
inhibitory	O
,	O
`	O
`	O
dominant	O
-	O
negative	O
,	O
''	O
form	O
of	O
the	O
calcineurin	B
catalytic	I
(	I
A	I
)	I
subunit	I
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	B
-	I
binding	I
domain	I
,	O
autoinhibitory	B
domain	I
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B
(	I
B	I
)	I
subunit	I
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
`	O
`	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
''	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	B
-	I
AT	I
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	B
-	I
labeled	I
BKO	I
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B
B	I
subunit	I
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B
subunit	I
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	B
-	I
AT	I
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
`	O
`	O
rescued	O
''	O
by	O
overexpression	O
of	O
transfected	O
B	B
subunit	I
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	B
active	I
dimer	I
of	O
calcineurin	B
A	I
and	I
B	I
subunits	I
.	O

Inhibition	O
of	O
vitamin	B
D	I
receptor	I
-	I
retinoid	I
X	I
receptor	I
-	I
vitamin	I
D	I
response	I
element	I
complex	I
formation	O
by	O
nuclear	O
extracts	O
of	O
vitamin	O
D	O
-	O
resistant	O
New	O
World	O
primate	O
cells	O
.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

We	O
hypothesized	O
that	O
an	O
intracellular	B
vitamin	I
D	I
binding	I
protein	I
(	O
IDBP	B
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	O
cells	O
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone	O
-	O
resistant	O
state	O
in	O
NWP	O
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	B
complex	I
binding	O
to	O
the	O
consensus	O
response	O
elements	O
present	O
in	O
the	O
enhancer	O
regions	O
of	O
steroid	O
-	O
responsive	O
genes	O
.	O

We	O
employed	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
to	O
screen	O
for	O
the	O
presence	O
of	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
vitamin	O
D	O
response	O
element	O
(	O
VDRE	O
)	O
.	O

Nuclear	O
and	O
post	O
-	O
nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
and	O
wild	O
type	O
phenotypes	O
,	O
respectively	O
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	O
of	O
the	O
human	O
osteocalcin	O
and	O
the	O
mouse	O
osteopontin	O
gene	O
promoters	O
.	O

A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR	B
-	I
RXR	I
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O

In	O
addition	O
,	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	O
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR	B
-	I
RXR	I
-	I
VDRE	I
complex	I
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	O
type	O
cell	O
line	O
or	O
with	O
the	O
post	O
-	O
nuclear	O
extract	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
cell	O
line	O
.	O

We	O
conclude	O
that	O
a	O
VDRE	B
-	I
binding	I
protein	I
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	B
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	O
vitamin	O
D	O
-	O
resistant	O
NWP	O
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR	B
-	I
RXR	I
heterodimer	O
binding	O
to	O
the	O
VDRE	O
.	O

Glucocorticoids	O
induced	O
down	O
-	O
regulation	O
of	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
in	O
asthma	O
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
the	O
AP-1	B
complex	I
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes	O
,	O
including	O
glucocorticoid	B
receptor	I
itself	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
expression	O
of	O
mRNA	O
for	O
glucocorticoid	B
receptor	I
in	O
human	O
blood	O
monocytes	O
obtained	O
from	O
seven	O
unstable	O
untreated	O
asthmatic	O
patients	O
who	O
were	O
subsequently	O
treated	O
with	O
high	O
doses	O
of	O
parenteral	O
corticosteroid	O
(	O
methyl	O
prednisolone	O
120	O
mg	O
/	O
day	O
)	O
for	O
10	O
days	O
.	O

mRNA	O
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	B
transcriptase	I
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+	O
/-	O
4.93	O
versus	O
95.57	O
+	O
/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down	O
-	O
regulation	O
for	O
the	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

Differential	O
regulation	O
of	O
IL-6	O
gene	O
transcription	O
and	O
expression	O
by	O
IL-4	B
and	O
IL-10	B
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL-4	B
and	O
IL-10	B
inhibit	O
the	O
cytokine	B
production	O
and	O
mRNA	O
expression	O
by	O
monocytes	O
/	O
macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL-6	O
gene	O
expression	O
by	O
IL-4	B
and	O
IL-10	B
,	O
we	O
studied	O
IL-6	B
production	O
,	O
expression	O
level	O
of	O
IL-6	O
mRNA	O
,	O
IL-6	B
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappaB	I
and	O
NF	B
-	I
IL-6	I
,	O
and	O
IL-6	O
mRNA	O
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP-1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	B
or	O
IL-10	B
.	O

Both	O
IL-4	B
and	O
IL-10	B
were	O
seen	O
to	O
inhibit	O
IL-6	B
production	O
and	O
the	O
expression	O
of	O
IL-6	O
mRNA	O
in	O
both	O
monocytic	O
cell	O
lines	O
studied	O
.	O

In	O
chloramphenicol	B
acetyltransferase	I
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
plasmid	O
containing	O
the	O
IL-6	O
gene	O
promoter	O
,	O
IL-4	B
,	O
but	O
not	O
IL-10	B
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	B
,	O
but	O
not	O
IL-10	B
,	O
inhibited	O
nuclear	O
NF	B
-	I
kappaB	I
activity	O
,	O
and	O
that	O
IL-4	B
and	O
IL-10	B
did	O
not	O
affect	O
NF-	O
IL-6	B
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	B
enhanced	O
the	O
degradation	O
of	O
IL-6	O
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	B
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL-6	O
gene	O
by	O
affecting	O
NF	B
-	I
kappaB	I
binding	O
activity	O
,	O
while	O
IL-10	B
may	O
inhibit	O
the	O
IL-6	O
mRNA	O
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	B
and	O
IL-10	B
inhibit	O
IL-6	B
production	O
by	O
different	O
mechanisms	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

Cyclic	O
AMP	O
-responsive	O
element	O
-dependent	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
zebra	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
-	O
positive	O
B	O
cells	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate	O
-	O
early	O
EBV	O
Zebra	O
gene	O
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768	O
-	O
6777	O
,	O
1993	O
)	O
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	O
gene	O
transcription	O
through	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
located	O
within	O
the	O
Zebra	O
promoter	O
(	O
Zp	O
)	O
.	O

Using	O
human	O
B-	O
or	O
T	O
-	O
cell	O
lines	O
transfected	O
with	O
ZpCat	O
reporter	O
gene	O
constructs	O
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	O
domain	O
of	O
Zp	O
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

Mutation	O
of	O
the	O
consensus	O
AP-1	O
/	O
CRE	O
site	O
within	O
ZII	O
abolished	O
the	O
inducibility	O
of	O
Zp	O
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	O
domain	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
minimal	O
promoter	O
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	O
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	O
but	O
not	O
by	O
AP-1	O
consensus	O
sequences	O
.	O

Antibodies	O
against	O
CRE	B
-	I
binding	I
(	I
CREB	I
)	I
protein	I
but	O
not	O
against	O
c	B
-	I
Fos	I
or	O
c	B
-	I
Jun	I
were	O
able	O
to	O
supershift	O
the	O
DNA	B
-	I
protein	I
complex	I
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B
factor	I
which	O
binds	O
to	O
ZII	O
as	O
a	O
member	O
of	O
the	O
CREB	B
family	I
of	I
proteins	I
.	O

Finally	O
,	O
transfection	O
of	O
CREB	B
protein	I
and	O
protein	O
kinase	O
A	O
expression	O
vectors	O
were	O
found	O
to	O
activate	O
Zp	O
in	O
Jurkat	O
cells	O
,	O
suggesting	O
that	O
phosphorylated	O
form	O
of	O
CREB	B
protein	I
can	O
play	O
a	O
determining	O
role	O
in	O
the	O
EBV	O
reactivation	O
process	O
.	O

Expression	O
of	O
c	B
-	I
fos	I
and	I
c	I
-	I
jun	I
proteins	I
and	O
AP-1	B
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	O
cells	O
and	O
phytohemagglutinin	O
-	O
stimulated	O
lymphocytes	O
.	O

The	O
protein	O
products	O
of	O
the	O
c	O
-	O
fos	O
(	O
p62c	B
-	I
fos	I
)	O
and	O
c	O
-	O
jun	O
(	O
p39c	B
-	I
jun	I
)	O
genes	O
are	O
members	O
of	O
the	O
AP-1	B
transcription	I
factor	I
family	I
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	O
systems	O
:	O
a	O
continuously	O
growing	O
myeloid	O
leukemic	O
cell	O
line	O
,	O
HL60	O
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto-	O
hemagglutinin	O
(	O
PHA	O
)	O
-stimulated	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP-1	B
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	B
and	I
Jun	I
family	I
proteins	I
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c	B
-	I
fos	I
,	O
p39c	B
-	I
jun	I
,	O
and	O
AP-1	B
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	O
cells	O
and	O
in	O
PHA	O
-	O
stimulated	O
PBL	O
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	B
binding	O
activity	O
from	O
p62c	B
-	I
fos	I
,	O
and	O
p39c	B
-	I
jun	I
AP-1	B
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2	O
/	O
M	O
-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S	O
-	O
phase	O
enriched	O
samples	O
of	O
HL60	O
cells	O
,	O
while	O
levels	O
of	O
nuclear	B
p62c	I
-	I
fos	I
and	I
p39c	I
-	I
jun	I
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c	B
-	I
fos	I
and	O
p39c	B
-	I
jun	I
,	O
but	O
AP-1	B
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	B
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP-1	B
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c	B
-	I
jun	I
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	B
p62c	I
-	I
fos	I
and	I
p39c	I
-	I
jun	I
were	O
present	O
in	O
HL60	O
cells	O
and	O
PHA	O
-	O
stimulated	O
PBL	O
.	O

However	O
,	O
no	O
cytoplasmic	B
p62c	I
-	I
fos	I
was	O
detected	O
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	B
p39c	I
-	I
jun	I
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	B
may	O
occur	O
under	O
certain	O
circumstances	O
.	O

Soluble	B
tumor	I
necrosis	I
factor	I
receptors	I
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine	O
-	O
induced	O
HIV-1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	B
human	I
tumor	I
necrosis	I
factor	I
(	I
TNF	I
)	I
binding	I
protein-1	I
(	O
r	B
-	I
h	I
TBP-1	I
)	O
and	O
recombinant	B
human	I
soluble	I
dimeric	I
TNF	I
receptor	I
(	O
rhu	B
TNFR	I
:	I
Fc	I
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	B
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine	O
-	O
induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1-infected	O
promonocytic	O
U1	O
cells	O
with	O
r	B
-	I
h	I
-	I
TBP-1	I
or	O
rhu	B
TNFR	I
:	I
Fc	I
reduced	O
PMA	O
-	O
induced	O
HIV-1	B
p24	I
antigen	I
production	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	B
antigen	I
production	O
in	O
T	O
-	O
lymphocytic	O
ACH-2	O
cells	O
was	O
47	O
%	O
with	O
r	B
-	I
hTBP-1	I
and	O
42	O
%	O
with	O
rhu	B
TNFR	I
:	I
Fc	I
.	O

r	B
-	I
hTBP-1	I
and	O
rhu	B
TNFR	I
:	I
Fc	I
also	O
decreased	O
p24	B
antigen	I
synthesized	O
by	O
U1	O
cells	O
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B
(	I
PHA	I
)	I
-induced	I
supernatant	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
interleukin-6	B
,	O
and	O
TNF	B
.	O

Addition	O
of	O
r	B
-	I
hTBP-1	I
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B
antigen	I
production	O
by	O
15	O
%	O
.	O

U1	O
cells	O
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng	O
/	O
ml	O
endogenous	B
TBP-1	I
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r	B
-	I
hTBP-1	I
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r	B
-	I
hTBP-1	I
and	O
rhu	B
TNFR	I
:	I
Fc	I
blocked	O
PMA	O
induction	O
of	O
nuclear	B
factor	I
(	I
NK	I
)	I
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
in	O
U1	O
cells	O
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli	O
-	O
induced	O
HIV-1	O
expression	O
and	O
NK-	B
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

Reversible	O
differentiation	O
of	O
human	O
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B
light	I
chain	I
kinase	I
.	O

Human	O
monoblastic	O
leukemia	O
U937	O
cells	O
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H	O
-	O
hexahydro-1	O
,	O
4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	B
light	I
chain	I
kinase	I
,	O
induces	O
differentiation	O
of	O
monocytoid	O
leukemia	O
cell	O
lines	O
U937	O
and	O
THP-1	O
but	O
not	O
of	O
myeloblastic	O
leukemic	O
ML-1	O
cell	O
or	O
erythroleukemia	O
K562	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML-9	O
also	O
induced	O
alpha	B
-	I
naphthyl	I
acetate	I
esterase	I
(	O
ANAE	B
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML-9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML-9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML-9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation	O
-	O
associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	O
cells	O
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	O
monoblastic	O
cells	O
,	O
THP-1	O
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	O
cells	O
but	O
increased	O
the	O
expression	O
of	O
monocyte	B
-	I
macrophage	I
lineage	I
-	I
associated	I
surface	I
antigen	I
,	O
CD14	B
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
myc	O
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
,	O
but	O
ML-9	O
did	O
not	O
affect	O
the	O
expression	O
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti	O
-	O
cancer	O
drug	O
such	O
as	O
1-beta	O
-	O
D	O
-	O
arabino	O
-	O
furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	B
growth	I
factor	I
-	I
beta	I
1	I
(	O
TGF	B
-	I
beta	I
1	I
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	O
cells	O
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML-9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

The	O
myeloid	O
-	O
cell	O
-	O
specific	O
c	O
-	O
fes	O
promoter	O
is	O
regulated	O
by	O
Sp1	B
,	O
PU.1	B
,	O
and	O
a	O
novel	O
transcription	B
factor	I
.	O

The	O
protein	O
product	O
of	O
the	O
c	O
-	O
fps	O
/	O
fes	O
(	O
c	O
-	O
fes	O
)	O
proto	O
-	O
oncogene	O
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	O
cells	O
(	O
macrophages	O
and	O
neutrophils	O
)	O
.	O

mRNA	O
for	O
c	O
-	O
fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	O
cells	O
and	O
vascular	O
endothelial	O
cells	O
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13-kilobase	O
-	O
pair	O
(	O
kb	O
)	O
human	O
c	O
-	O
fes	O
transgene	O
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
human	O
c	O
-	O
fes	O
gene	O
have	O
not	O
been	O
defined	O
.	O

Transient	O
-	O
transfection	O
experiments	O
demonstrated	O
that	O
plasmids	O
containing	O
446	O
bp	O
of	O
c	O
-	O
fes	O
5'-flanking	O
sequences	O
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	O
cells	O
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	O
human	O
c	O
-	O
fes	O
locus	O
contained	O
positive	O
cis	O
-	O
acting	O
elements	O
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	O
sequences	O
.	O

DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	B
nuclear	I
proteins	I
(	O
-408	O
to	O
-386	O
,	O
-293	O
to	O
-254	O
,	O
-76	O
to	O
-65	O
,	O
and	O
-34	O
to	O
+	O
3	O
)	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Plasmids	O
containing	O
151	O
bp	O
of	O
5'-flanking	O
sequences	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
gene	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	O
region	O
contains	O
nuclear	O
protein	O
binding	O
sites	O
for	O
Sp1	B
,	O
PU.1	B
,	O
and/or	O
Elf-1	B
,	O
and	O
a	O
novel	B
factor	I
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1	O
/	O
Elf-1	O
sites	O
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

Mutation	O
of	O
the	O
PU.1	B
/Elf-1	B
site	O
or	O
the	O
3	O
'	O
site	O
(	O
FP4	O
-	O
3	O
'	O
)	O
within	O
the	O
context	O
of	O
the	O
c	O
-	O
fes	O
promoter	O
resulted	O
in	O
substantially	O
reduced	O
activity	O
in	O
transient	O
transfections	O
.	O

Furthermore	O
,	O
transient	O
-	O
cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B
(	O
and	O
not	O
Elf-1	B
)	O
can	O
transactivate	O
the	O
c	O
-	O
fes	O
promoter	O
in	O
nonmyeloid	O
cell	O
lines	O
.	O

We	O
conclude	O
that	O
the	O
human	O
c	O
-	O
fes	O
gene	O
contains	O
a	O
strong	O
myeloid	O
-	O
cell	O
-	O
specific	O
promoter	O
that	O
is	O
regulated	O
by	O
Sp1	B
,	O
PU.1	B
,	O
and	O
a	O
novel	O
transcription	B
factor	I
.	O

Transcriptional	O
activation	O
of	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
genes	O
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
tax	I
protein	I
.	O

The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
-	I
encoded	I
tax	I
protein	I
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
genes	O
transcribed	O
by	O
RNA	B
polymerase	I
II	I
.	O

We	O
find	O
that	O
both	O
chromatin	O
and	O
cell	O
extracts	O
derived	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1-infected	O
human	O
T	O
lymphocytes	O
support	O
higher	O
levels	O
of	O
5S	O
rRNA	O
and	O
tRNA	O
gene	O
transcription	O
than	O
chromatin	O
or	O
extracts	O
from	O
uninfected	O
T	O
lymphocytes	O
.	O

The	O
viral	B
protein	I
Tax	I
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	O
II	O
gene	O
transcription	O
,	O
as	O
purified	B
Tax	I
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Both	O
limiting	O
-	O
component	O
transcription	O
assays	O
and	O
DNA	O
binding	O
assays	O
identified	O
the	O
class	B
III	I
gene	I
transcription	I
factor	I
TFIIIB	B
as	O
the	O
principle	O
target	O
of	O
Tax	B
activity	O
.	O

Surprisingly	O
,	O
we	O
find	O
that	O
Tax	B
increases	O
the	O
effective	O
concentration	O
of	O
active	B
TFIIIB	I
molecules	I
.	O

These	O
data	O
suggest	O
that	O
Tax	B
stimulates	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
gene	O
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B
initiation	I
complex	I
assembly	O
.	O

Induction	O
of	O
CIITA	B
and	O
modification	O
of	O
in	O
vivo	O
HLA	O
-	O
DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN	B
-	I
gamma	I
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA	O
-	O
DR	O
-	O
constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN	B
-	I
gamma	I
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	B
class	I
II	I
induction	O
is	O
studied	O
in	O
a	O
`	O
`	O
physiologic	O
''	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B
trans	I
-	I
activator	I
,	O
a	O
crucial	O
MHC	B
class	I
II	I
gene	I
regulatory	I
factor	I
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	B
factors	I
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	B
I	I
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN	B
-	I
gamma	I
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	B
factors	I
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II	O
-	O
constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	O
lymphoma	O
line	O
Raji	O
and	O
normal	O
tonsil-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	O
,	O
either	O
IFN	B
-	I
gamma	I
-induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	B
trans	I
-	I
activator	I
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN	B
-	I
gamma	I
-induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c	O
-	O
jun	O
and	O
suppress	O
IL-2	O
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
AP-1	B
and	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
.	O

The	O
present	O
results	O
show	O
that	O
Jurkat	O
T	O
cells	O
acutely	O
exposed	O
to	O
micromolar	O
concentrations	O
of	O
H2O2	O
exhibit	O
substantial	O
increases	O
in	O
AP-1	B
binding	O
activity	O
and	O
the	O
expression	O
of	O
c	O
-	O
jun	O
but	O
not	O
c	O
-	O
fos	O
mRNA	O
.	O

The	O
preferential	O
induction	O
of	O
c	O
-	O
jun	O
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	O
transcripts	O
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA	O
/	O
PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c	O
-	O
jun	O
promoter	O
via	O
the	O
proximal	O
jun1	O
tumor	O
promoter	O
-	O
responsive	O
element	O
(	O
TRE	O
)	O
-like	O
promoter	O
element	O
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	O
AP-1	O
TRE	O
and	O
jun	O
TRE	O
-	O
like	O
motifs	O
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA	O
/	O
PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c	B
-	I
Fos	I
,	O
c	B
-	I
Jun	I
,	O
and	O
JunD	B
.	O

However	O
,	O
PHA	O
/	O
PMA	O
but	O
not	O
oxidative	O
signals	O
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	O
constructs	O
containing	O
the	O
AP-1-TRE	O
,	O
NF	O
-	O
AT	O
,	O
and	O
IL-2	O
promoter	O
regions	O
along	O
with	O
IL-2	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF	B
-	I
AT	I
and	O
IL-2	O
reporters	O
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	O
mRNA	O
in	O
cells	O
stimulated	O
with	O
PHA	O
/	O
PMA	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF	B
-	I
AT	I
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	B
complexes	I
rather	O
than	O
the	O
binding	O
of	O
preformed	O
NF	B
-	I
AT	I
complexes	I
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	O
cell	O
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP-1	B
regulation	O
of	O
c	O
-	O
jun	O
from	O
transcriptional	O
up	O
-	O
regulation	O
of	O
IL-2	B
via	O
NF	B
-	I
AT	I
.	O

HIV-1	B
tat	I
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B
cell	I
-	I
specific	I
transcription	I
factor	I
and	O
downregulates	O
MIP-1	O
alpha	O
gene	O
expression	O
in	O
activated	O
T	O
-	O
cells	O
.	O

MIP-1	B
alpha	I
is	O
a	O
secreted	O
chemokine	B
which	O
can	O
inhibit	O
hematopoietic	O
stem	O
cells	O
and	O
modulate	O
inflammatory	O
responses	O
.	O

It	O
is	O
also	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
CD8	O
+	O
T	O
-	O
cells	O
.	O

The	O
expression	O
of	O
MIP-1	B
alpha	I
is	O
induced	O
during	O
cellular	O
activation	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
and	O
monocytes	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	O
B	O
-	O
cells	O
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	B
factor	I
family	I
(	O
the	O
MNP	B
family	I
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP-1	B
alpha	I
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	O
B	O
cells	O
.	O

Monocytes	O
and	O
transformed	O
B	O
-	O
cells	O
normally	O
express	O
MNP-1	B
strongly	O
and	O
MNP-2	B
weakly	O
,	O
while	O
T	O
-	O
cells	O
strongly	O
express	O
only	O
MNP-2	B
.	O

Recently	O
,	O
we	O
reported	O
that	O
HIV-1	B
tat	I
downregulates	O
MIP-1	B
alpha	I
expression	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	B
in	O
Jurkat	O
T	O
-	O
cells	O
expressing	O
HIV-1	B
tat	I
.	O

Expression	O
of	O
neither	O
HTLV-1	B
tax	I
in	O
Jurkat	O
T	O
-	O
cells	O
nor	O
EBV	O
in	O
B	O
-	O
cells	O
had	O
any	O
effect	O
on	O
MNP-1	B
or	O
MNP-2	B
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	B
tat	I
.	O

We	O
propose	O
that	O
HIV-1	B
tat	I
may	O
inhibit	O
MIP-1	B
alpha	I
expression	O
by	O
inducing	O
MNP-1	B
expression	O
in	O
T	O
-	O
cells	O
,	O
probably	O
by	O
either	O
competing	O
with	O
MNP-2	B
for	O
binding	O
to	O
the	O
MIP-1	O
alpha	O
promoter	O
or	O
by	O
sequestering	O
it	O
into	O
inactive	O
forms	O
.	O

Cooperation	O
between	O
core	B
binding	I
factor	I
and	O
adjacent	O
promoter	O
elements	O
contributes	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	B
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
is	O
mediated	O
via	O
cis	O
-	O
acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	O
and	O
Elf-1	O
sites	O
in	O
the	O
IL-3	O
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell	O
-	O
specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL-3	O
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act-1	O
.	O

Together	O
the	O
Act-1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	O
in	O
fibroblasts	O
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL-3	O
promoter	O
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL-3	B
is	O
not	O
specified	O
by	O
the	O
activity	O
of	O
a	O
single	O
tissue	O
-	O
specific	O
element	O
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G	B
-	I
protein	I
-	I
coupled	I
chemoattractant	I
receptors	I
.	O

Receptors	O
for	O
leukocyte	B
chemoattractants	I
,	O
including	O
chemokines	B
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G	B
-	I
protein	I
-	I
coupled	I
serpentine	I
receptors	I
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	B
factors	I
,	O
such	O
as	O
NF	B
kappa	I
B	I
and	O
AP-1	B
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G	B
-	I
protein	I
coupling	O
and	O
the	O
activation	O
of	O
protein	B
kinases	I
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF	B
-	I
alpha	I
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate	O
-	O
early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	B
cytokines	I
and	O
chemokines	B
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	B
and	O
chemokine	B
gene	O
expression	O
.	O

Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T	O
-	O
cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL	O
-	O
mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	O
adenovirus	O
type	O
5	O
E1A	O
-	O
region	O
(	O
Ad5E1A234	O
-	O
243	O
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor	O
-	O
eradicating	O
CTL	O
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A	O
-	O
expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T	O
-	O
cell	O
-	O
mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A	B
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A	O
-	O
peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	B
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B
,	O
induced	O
Ad5E1A	B
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B
-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti	O
-	O
tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide	O
-	O
based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T	O
-	O
cell	O
-	O
mediated	O
autoimmune	O
diseases	O
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	O
gene	O
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c	B
-	I
Fos	I
,	O
FosB	B
,	O
and	O
JunB	B
in	O
anergic	O
T	O
helper	O
1	O
cells	O
.	O

Anergic	O
CD4	O
+	O
Th	O
cells	O
do	O
not	O
produce	O
IL-2	B
when	O
challenged	O
with	O
Ag	O
-	O
pulsed	O
accessory	O
cells	O
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	O
T	O
cells	O
are	O
defective	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	O
DNA	O
enhancer	O
elements	O
:	O
NF	B
-	I
AT	I
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	B
NFATp	I
,	I
Fos	I
,	I
and	I
Jun	I
protein	I
complex	I
)	O
and	O
Activator	B
Protein-1	I
(	O
AP-1	B
)	O
(	O
that	O
binds	O
Fos	B
and	I
Jun	I
heterodimers	I
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA	O
-	O
protein	O
interactions	O
in	O
anergic	O
T	O
cells	O
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	B
family	O
members	O
c	B
-	I
Fos	I
,	O
FosB	B
,	O
and	O
JunB	B
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR	B
/	I
CD3	I
-signaling	O
defect	O
because	O
CD3	B
cross	O
-	O
linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular	O
-	O
free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	B
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	O
and	O
anergic	O
T	O
cells	O
.	O

Thus	O
,	O
defective	O
IL-2	O
gene	O
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	B
Fos	I
and	I
Jun	I
family	I
members	I
in	O
anergic	O
T	O
cells	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
gene	O
family	O
member	O
NFATc	B
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	B
A	I
(	I
CsA	I
)	I
/FK506-sensitive	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	B
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non	O
-	O
T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	B
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	B
proteins	I
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	B
,	O
of	O
the	O
NFAT	B
gene	I
family	I
member	I
NFATc	B
(	O
designated	O
here	O
NFATc.alpha	B
)	O
.	O

The	O
amino	B
acid	I
sequence	I
of	O
NFATc.beta	B
differs	O
from	O
that	O
of	O
NFATc	B
.	O

alpha	O
in	O
the	O
first	O
NH2-terminal	B
29	I
residues	I
and	O
contains	O
an	O
additional	O
region	O
of	O
142	B
residues	I
at	O
the	O
COOH	B
terminus	I
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2.7	O
and	O
4.5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc.beta	O
-	O
specific	O
probe	O
detected	O
only	O
the	O
4.5-kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	B
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	O
NFAT	O
-	O
driven	O
reporter	O
gene	O
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	B
neither	O
bound	O
to	O
the	O
kappa3	O
element	O
(	O
an	O
NFAT	O
-	O
binding	O
site	O
)	O
in	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
nor	O
activated	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

JNK	B
(	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	O
lymphocytes	O
.	O

AP-1	B
has	O
been	O
shown	O
to	O
behave	O
as	O
a	O
redox	B
-	I
sensitive	I
transcription	I
factor	I
that	O
can	O
be	O
activated	O
by	O
both	O
oxidant	O
and	O
antioxidant	O
stimuli	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	B
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	B
(	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
)	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B
against	O
the	O
T	B
cell	I
receptor	I
-	I
CD3	I
complex	I
and	O
to	O
CD28	B
.	O

The	O
activation	O
of	O
JNK	B
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N	O
-	O
acetylcysteine	O
)	O
was	O
sustained	O
.	O

The	O
kinetics	O
of	O
JNK	B
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c	O
-	O
jun	O
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
JNK	B
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2	O
+	O
,	O
protein	B
kinase	I
C	I
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	O
to	O
inhibit	O
the	O
activation	O
mediated	O
by	O
PDTC	O
.	O

Transfection	O
of	O
trans	O
-	O
dominant	O
negative	O
expression	O
vectors	O
of	O
ras	O
and	O
raf	O
,	O
together	O
with	O
AP-1-dependent	O
reporter	O
constructs	O
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti	B
-	I
ERK	I
(	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
)	I
antibodies	I
,	O
indicated	O
that	O
the	O
Ras	O
/	O
Raf	O
/	O
ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

However	O
,	O
the	O
combined	O
treatment	O
with	O
PDTC	O
and	O
PMA	O
,	O
two	O
agents	O
that	O
synergize	O
on	O
AP-1	B
activation	O
,	O
resulted	O
in	O
the	O
persistent	O
phosphorylation	O
of	O
ERK-2	B
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	B
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B
B	I
-	I
cell	I
specific	I
transcriptional	I
coactivator	I
Bob1	B
.	O

From	O
a	O
murine	O
B	O
-	O
cell	O
cDNA	O
-	O
library	O
we	O
have	O
cloned	O
a	O
cDNA	O
encoding	O
the	O
murine	B
B	I
-	I
cell	I
specific	I
coactivator	I
mBob1	B
.	O

The	O
protein	O
is	O
the	O
murine	O
homologue	O
to	O
the	O
recently	O
described	O
human	B
coactivator	I
Bob1	I
(	O
hBob1	B
)	O
,	O
also	O
referred	O
to	O
as	O
OBF-1	B
or	O
OCA	B
-	I
B	I
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B
mBob1	I
clone	I
.	O

Analysis	O
of	O
its	O
intron	O
-	O
exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C	B
-	I
terminal	I
splice	I
variant	I
.	O

mBob1	B
is	O
B	O
-	O
cell	O
restricted	O
,	O
and	O
is	O
found	O
in	O
all	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

mBob1	B
interacts	O
with	O
the	O
octamer	B
transcription	I
factors	I
Oct-1	B
and	O
Oct-2	B
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic	O
/	O
fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	B
growth	I
factor	I
(	O
HGF	B
)	O
requirement	O
of	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
purified	O
from	O
embryonic	O
-	O
fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	B
(	O
Epo	B
)	O
for	O
colony	O
formation	O
by	O
early	O
erythroid	O
progenitors	O
(	O
burst	O
-	O
forming	O
units	O
-	O
erythroid	O
[	O
BFU	O
-	O
E	O
]	O
)	O
has	O
been	O
confirmed	O
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	B
,	O
FL	O
monocytic	O
progenitors	O
(	O
colony	O
-	O
forming	O
unit	O
monocyte	O
[	O
CFU	O
-	O
M	O
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes	O
-	O
macrophages	O
;	O
these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

On	O
this	O
basis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

Both	O
compounds	O
modulate	O
the	O
growth	O
of	O
purified	O
FL	O
HPCs	O
,	O
which	O
show	O
a	O
dose	O
-	O
dependent	O
shift	O
from	O
mixed	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
colony	O
formation	O
.	O

Studies	O
on	O
unicellular	O
and	O
paired	O
daughter	O
cell	O
culture	O
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA	O
-	O
induced	O
down	O
-	O
modulation	O
of	O
multipotent	O
/erythroid	O
/	O
monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	O
HPCs	O
)	O
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	O
HPCs	O
(	O
high	O
-	O
proliferative	O
potential	O
colony	O
-	O
forming	O
cells	O
[	O
HPP	O
-	O
CFCs	O
]	O
)	O
and	O
putative	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
;	O
assayed	O
in	O
Dexter	O
-	O
type	O
long	O
-	O
term	O
culture	O
)	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP	O
-	O
CFC	O
colonies	O
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	O
proliferation	O
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	O
transduced	O
with	O
dominant	O
negative	O
ATRA	O
receptor	O
(	O
RAR	O
)	O
gene	O
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA	O
/	O
9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR	B
/	I
RXR	I
heterodimer	I
,	O
ie	O
,	O
inhibition	O
of	O
HSC	O
/	O
primitive	O
HPC	O
proliferation	O
and	O
induction	O
of	O
CFU	O
-	O
GEMM	O
/	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
M	O
shift	O
from	O
the	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
the	O
granulocytic	O
-	O
neutrophilic	O
differentiation	O
program	O
.	O

The	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
,	O
but	O
not	O
its	O
regulatory	B
domain	I
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B
production	O
.	O

The	O
lymphoid	B
src	I
kinase	I
pp56	B
(	I
lck	I
)	I
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	O
lymphocyte	O
responses	O
,	O
including	O
CD4	B
-mediated	O
enhancement	O
of	O
Ag	O
-	O
induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	B
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	B
(	I
lck	I
)	I
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B
regulatory	B
domain	I
is	O
sufficient	O
to	O
mediate	O
CD4	B
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	B
and	I
catalytic	I
domains	I
of	O
pp56	B
(	I
lck	I
)	I
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B
:	O
TCR	O
-	O
induced	O
IL-2	B
production	O
.	O

Two	O
pp56	B
(	I
lck	I
)	I
mutants	I
lacking	O
either	O
the	O
entire	O
catalytic	B
domain	I
or	O
the	O
entire	O
NH2	B
regulatory	B
domain	I
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR	O
-	O
regulated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
region	O
of	O
the	O
IL-2	O
promoter	O
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	B
regulatory	O
,	O
domain	O
of	O
pp56	B
(	I
lck	I
)	I
was	O
able	O
to	O
induce	O
NF	B
-	I
AT	I
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
was	O
able	O
to	O
induce	O
IL-2	B
cytokine	B
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
pp56	B
(	I
lck	I
)	I
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	B
(	I
lck	I
)	I
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	B
regulatory	B
domain	I
is	O
sufficient	O
to	O
mediate	O
CD4	B
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	B
production	O
,	O
mimicking	O
TCR	B
ligation	O
.	O

Lack	O
of	O
IL-12	B
signaling	O
in	O
human	O
allergen	O
-	O
specific	O
Th2	O
cells	O
.	O

IL-12	B
is	O
a	O
powerful	O
skewer	O
of	O
CD4	O
+	O
T	O
cell	O
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN	B
-	I
gamma	I
production	O
in	O
naive	O
Th	O
cells	O
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	B
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1	O
/	O
Th0	O
responses	O
by	O
inducing	O
IFN	B
-	I
gamma	I
production	O
in	O
memory	O
Th2	O
cells	O
.	O

To	O
this	O
aim	O
,	O
allergen	O
-	O
specific	O
CD4	O
+	O
T	O
cell	O
clones	O
(	O
TCC	O
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	O
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	B
profile	O
,	O
and	O
the	O
production	O
of	O
IFN	B
-	I
gamma	I
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	B
.	O

Only	O
those	O
TCC	O
with	O
low	O
IFN	B
-	I
gamma	I
levels	O
in	O
the	O
absence	O
of	O
IL-12	B
responded	O
to	O
IL-12	B
by	O
additional	O
enhancement	O
of	O
IFN	B
-	I
gamma	I
production	O
.	O

The	O
IL-12	B
nonresponsiveness	O
of	O
the	O
Th2	O
clones	O
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	B
-induced	O
phosphorylation	O
of	O
STAT4	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-4	I
)	O
,	O
a	O
transcription	B
factor	I
that	O
is	O
typically	O
involved	O
in	O
IL-12	B
signaling	O
.	O

Consequently	O
,	O
IL-12	B
also	O
failed	O
to	O
induce	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
STAT4-containing	B
complexes	I
in	O
the	O
nuclei	O
of	O
these	O
Th2	O
clones	O
.	O

All	O
TCC	O
expressed	O
equal	O
levels	O
of	O
the	O
low	B
-	I
affinity	I
IL-12R	I
beta1	I
subunit	I
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen	O
-	O
specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	B
profiles	O
do	O
not	O
respond	O
to	O
IL-12	B
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN	B
-	I
gamma	I
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	O
Th	O
cells	O
within	O
the	O
allergen	O
-	O
specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	B
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	O
cells	O
.	O

Activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
via	O
T	B
cell	I
receptor	I
requires	O
a	O
Raf	B
kinase	I
and	O
Ca2	O
+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	B
and	O
calcineurin	B
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B
activate	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	B
kinase	I
C	I
activator	O
PMA	O
in	O
combination	O
with	O
Ca2	O
+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	B
stimulation	O
,	O
bypassing	O
the	O
TCR	B
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	B
-	I
kappaB	I
following	O
TCR	B
stimulation	O
.	O

TCR	B
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	O
T	O
cells	O
with	O
PHA	B
or	O
anti	B
-	I
CD3	I
Abs	I
,	O
and	O
NF	B
-	I
kappaB	I
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	B
-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B
kinase	I
C	I
is	O
involved	O
in	O
TCR	B
-mediated	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
PHA	B
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B
-induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	B
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	B
kinase	I
.	O

The	O
TCR	B
-mediated	O
activation	O
of	O
NF	B
-	I
kappaB	I
was	O
also	O
dependent	O
on	O
a	O
Ca2	O
+	O
influx	O
,	O
because	O
the	O
Ca2	O
+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2	O
+	O
influx	O
,	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B
largely	O
substituted	O
for	O
the	O
Ca2	O
+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B
and	O
calcineurin	B
synergistically	O
induced	O
kappaB	B
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B
and	O
the	O
phosphatase	B
.	O

Differentiation	O
-	O
dependent	O
expression	O
of	O
a	O
human	B
carboxylesterase	I
in	O
monocytic	O
cells	O
and	O
transcription	B
factor	I
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	B
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte	O
/	O
macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	B
carboxylesterase	I
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA	O
-	O
treated	O
THP-1	O
cells	O
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-1	O
to	O
-275	O
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	B
factors	I
,	O
is	O
bound	O
by	O
nuclear	B
factors	I
Sp1	B
and	O
IRBP	B
but	O
not	O
by	O
C	B
/	I
EBPs	I
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	O
cells	O
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B
and	O
IRBP	B
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation	O
-	O
dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Identification	O
of	O
Bcd	O
,	O
a	O
novel	O
proto	O
-	O
oncogene	O
expressed	O
in	O
B	O
-	O
cells	O
.	O

A	O
novel	O
B	O
-	O
cell	O
derived	O
(	O
Bcd	O
)	O
oncogene	O
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

The	O
Bcd	O
proto	O
-	O
oncogene	O
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	O
'	O
UTR	O
.	O

It	O
predicts	O
for	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

ORF1	O
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	O
ORF2	O
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

Predicted	B
peptide	I
sequence	I
of	O
ORF2	O
contained	O
a	O
zinc	B
finger	I
domain	I
which	O
showed	O
significant	O
homology	O
to	O
GC	B
box	I
binding	I
proteins	I
BTEB2	B
and	O
SP1	B
.	O

Transfection	O
of	O
an	O
expression	O
vector	O
containing	O
ORF2	O
but	O
not	O
full	O
length	O
cDNA	O
was	O
able	O
to	O
transform	O
NIH3T3	O
cells	O
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Bcd	O
mRNA	O
transcripts	O
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	O
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

Within	O
the	O
PBL	O
,	O
Bcd	O
gene	O
expression	O
was	O
restricted	O
to	O
CD19	O
+	O
B	O
-	O
cells	O
and	O
absent	O
from	O
CD14	O
+	O
monocytes	O
and	O
T	O
-	O
cells	O
.	O

Bcd	O
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	O
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	O
human	O
B	O
-	O
cell	O
lines	O
and	O
not	O
in	O
50	O
%	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O

However	O
,	O
stimulation	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	O
cells	O
was	O
associated	O
with	O
induction	O
of	O
Bcd	O
gene	O
expression	O
.	O

The	O
Bcd	O
gene	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B	O
-	O
cell	O
growth	O
and	O
development	O
.	O

Shared	O
gamma	B
(	I
c	I
)	I
subunit	I
within	O
the	O
human	B
interleukin-7	I
receptor	I
complex	I
.	O

A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
mutations	O
in	O
the	O
gamma	B
(	I
c	I
)	I
receptor	I
subunit	I
cause	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
.	O

The	O
gamma	B
(	I
c	I
)	I
subunit	I
can	O
be	O
employed	O
in	O
receptor	B
complexes	I
for	O
IL-2	B
,	I
-4	I
,	I
-7	I
,	I
-9	I
,	I
and	I
-15	I
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B
(	I
c	I
)	I
chain	I
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X	O
-	O
SCID	O
patients	O
.	O

Interestingly	O
,	O
gene	O
disruption	O
of	O
either	O
IL-7	B
or	O
the	O
IL-7	B
receptor	I
(	I
IL-7R	I
)	I
alpha	I
subunit	I
in	O
mice	O
leads	O
to	O
immunological	O
defects	O
that	O
are	O
similar	O
to	O
human	O
X	O
-	O
SCID	O
.	O

These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	B
(	I
c	I
)	I
in	O
the	O
IL-7R	B
complex	I
.	O

In	O
the	O
present	O
study	O
,	O
structure	O
/	O
function	O
analyses	O
of	O
the	O
IL-7R	B
complex	I
using	O
a	O
chimeric	B
receptor	I
system	O
demonstrated	O
that	O
gamma	B
(	I
c	I
)	I
is	O
indeed	O
critical	O
for	O
IL-7R	B
function	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B
domain	I
of	O
gamma	B
(	I
c	I
)	I
is	O
necessary	O
for	O
IL-7R	B
signal	O
transduction	O
.	O

Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B
(	I
c	I
)	I
cytoplasmic	B
domain	I
by	O
a	O
severely	B
truncated	I
erythropoeitin	I
receptor	I
does	O
not	O
affect	O
measured	O
IL-7R	B
signaling	O
events	O
.	O

These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	B
(	I
c	I
)	I
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	B
complex	I
,	O
while	O
IL-7R	B
alpha	I
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	B
signaling	I
molecules	I
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X	O
-	O
SCID	O
is	O
due	O
primarily	O
to	O
gamma	B
(	I
c	I
)	I
-mediated	O
defects	O
in	O
the	O
IL-7	B
/IL-7R	B
system	O

Generation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
against	O
immunorecessive	B
epitopes	I
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Since	O
the	O
CTL	O
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B
epitopes	I
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B
epitopes	I
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL	O
/	O
10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB	O
/	O
FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB	O
/	O
cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B
antigen	I
(	O
s	O
)	O
,	O
and	O
the	O
CTL	O
responses	O
were	O
measured	O
.	O

In	O
C57BL	O
/	O
10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	B
antigen	I
in	O
E1A	O
.	O

When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O

or	O
intranasally	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	O
region	O
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	O
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	O
and	O
E1B	O
,	O
no	O
immunorecessive	B
epitopes	I
were	O
recognized	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB	O
/	O
c	O
mice	O
was	O
more	O
complex	O
.	O

CTLs	O
from	O
BALB	O
/	O
c	O
mice	O
inoculated	O
i.p	O
.	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
E1B	O
in	O
the	O
context	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
Dd	O
allele	O
and	O
a	O
region	O
outside	O
E1	O
associated	O
with	O
the	O
Kd	O
allele	O
.	O

When	O
BALB	O
/	O
c	O
mice	O
were	O
inoculated	O
with	O
E1	O
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B
Kd	I
-	I
restricted	I
epitope	I
was	O
recognized	O
,	O
and	O
Dd	O
-	O
restricted	O
CTLs	O
did	O
not	O
develop	O
.	O

This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	O
against	O
immunorecessive	B
epitopes	I
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	B
-diverse	O
human	O
population	O
.	O

Involvement	O
of	O
Egr-1	B
/RelA	B
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-induced	O
NF	B
-	I
kappa	I
B1	I
transcription	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
an	O
important	O
transcription	B
factor	I
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF	O
-	O
kappa	O
B1	O
gene	O
encodes	O
a	O
105-kD	B
protein	I
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	B
component	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF	B
-	I
kappa	I
B	I
regulates	O
the	O
NF	O
-	O
kappa	O
B1	O
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	O
cell	O
lines	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	B
(	O
PHA	B
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF	B
-	I
kappa	I
B1	I
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O

Characterization	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
promoter	O
identified	O
an	O
Egr-1	O
site	O
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA	O
/	O
PHA	B
-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Egr-1	B
.	O

Furthermore	O
,	O
Egr-1	B
induction	O
was	O
required	O
for	O
endogenous	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
,	O
since	O
PMA	O
/	O
PHA	O
-	O
stimulated	O
T	O
cell	O
lines	O
expressing	O
antisense	O
Egr-1	O
RNA	O
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF	O
-	O
kappa	O
B1	O
transcription	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	B
and	O
NF	B
-	I
kappa	I
B	I
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
.	O

Jak1	B
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	B
signaling	B
molecules	I
.	O

The	O
Jak1	B
,	I
Jak2	I
,	I
Jak3	I
,	I
and	I
Fes	I
tyrosine	I
kinases	I
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	B
(	I
IL	I
)	I
-4	I
stimulation	O
in	O
different	O
cell	O
systems	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
kinases	O
are	O
responsible	O
for	O
initiating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
of	O
intracellular	B
substrates	I
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	O
Jak1-deficient	O
HeLa	O
cell	O
line	O
,	O
E1C3	O
,	O
and	O
its	O
parental	O
Jak1-expressing	O
counterpart	O
,	O
1D4	O
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	B
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O

IL-4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	B
receptor	I
substrate	I
(	I
IRS	I
)	I
-1	I
and	O
IRS-2	B
in	O
1D4	O
but	O
not	O
in	O
E1C3	O
cells	O
.	O

IL-4	B
-mediated	O
tyrosine	O
phosphorylation	O
of	O
Stat6	B
was	O
pronounced	O
in	O
1D4	O
cells	O
,	O
while	O
no	O
IL-4	B
-induced	O
Stat6	B
phosphorylation	O
was	O
detected	O
in	O
E1C3	O
cells	O
.	O

IL-4	B
also	O
induced	O
Stat6	B
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	O
but	O
not	O
E1C3	O
cells	O
utilizing	O
a	O
radiolabeled	O
immunoglobulin	O
heavy	O
chain	O
germline	O
epsilon	O
promotor	O
sequence	O
(	O
Iepsilon	O
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Reconstitution	O
of	O
Jak1	B
expression	O
in	O
E1C3	O
cells	O
restored	O
the	O
ability	O
of	O
IL-4	B
to	O
induce	O
IRS	O
and	O
Stat6	B
tyrosine	O
phosphorylation	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
Jak1	B
expression	O
is	O
required	O
for	O
mediating	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
crucial	O
molecules	O
involved	O
in	O
IL-4	B
signal	O
transduction	O
.	O

Interleukin-4	B
signaling	O
in	O
B	O
lymphocytes	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Interleukin-4	B
(	O
IL-4	B
)	O
is	O
an	O
important	O
cytokine	O
for	O
B	O
and	O
T	O
lymphocyte	O
function	O
and	O
mediates	O
its	O
effects	O
via	O
a	O
receptor	O
that	O
contains	O
gammac	B
.	O

B	O
cells	O
derived	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	B
-mediated	O
signaling	O
.	O

We	O
found	O
that	O
although	O
IL-4	B
stimulation	O
of	O
X	O
-	O
SCID	O
B	O
cells	O
did	O
not	O
result	O
in	O
Janus	B
tyrosine	I
kinase-3	I
(	O
JAK3	B
)	O
phosphorylation	O
,	O
other	O
IL-4	B
substrates	I
including	O
JAK1	B
and	O
IRS-1	B
were	O
phosphorylated	O
.	O

Additionally	O
,	O
we	O
detected	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
6	I
(	O
STAT6	B
)	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
in	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
a	O
wide	O
range	O
of	O
gammac	B
mutations	O
.	O

However	O
,	O
reconstitution	O
of	O
these	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
gammac	B
enhanced	O
IL-4	B
-mediated	O
responses	O
including	O
STAT6	B
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	B
expression	O
.	O

Thus	O
,	O
gammac	B
is	O
not	O
necessary	O
to	O
trigger	O
IL-4	B
-mediated	O
responses	O
in	O
B	O
cells	O
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL-4	B
-signaling	O
.	O

These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B
signaling	O
pathways	O
exist	O
.	O

Nuclear	B
Rel	I
-	I
A	I
and	I
c	I
-	I
Rel	I
protein	I
complexes	I
are	O
differentially	O
distributed	O
within	O
human	O
thymocytes	O
.	O

Nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
)	I
/Rel	I
proteins	I
are	O
inducible	O
transcriptional	B
regulators	I
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF	B
-	I
kappa	I
B	I
proteins	I
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50	B
/	I
p65	I
and	I
p50	I
/	I
c	I
-	I
Rel	I
complexes	I
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	B
Abs	I
allowed	O
visualization	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
proteins	I
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50	B
/	I
c	I
-	I
Rel	I
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50	B
/	I
p65	I
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c	O
-	O
Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	O
and	O
CD8-positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	B
and	I
c	I
-	I
Rel	I
complexes	I
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	B
-	I
kappa	I
B	I
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Common	O
and	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
human	O
neutrophils	O
utilized	O
by	O
platelet	B
activating	I
factor	I
and	O
FMLP	B
.	O

Stimulation	O
of	O
human	O
neutrophils	O
with	O
chemoattractants	B
FMLP	B
or	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O

We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O

Stimulation	O
with	O
either	O
PAF	B
or	O
FMLP	B
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	I
MAPk	I
)	I
homologue	I
38-kD	B
murine	I
MAP	I
kinase	I
homologous	O
to	O
HOG-1	B
(	I
p38	I
)	I
MAPk	I
.	O

Neither	O
FMLP	B
nor	O
PAF	B
activated	O
c	B
-	I
jun	I
NH2-terminal	I
MAPk	I
(	O
JNKs	B
)	O
.	O

Under	O
identical	O
conditions	O
,	O
FMLP	B
but	O
not	O
PAF	B
,	O
resulted	O
in	O
significant	O
p42	B
/	I
44	I
(	I
ERK	I
)	I
MAPk	I
activation	O
.	O

Both	O
FMLP	B
and	O
PAF	B
activated	I
MAP	I
kinase	I
kinase-3	I
(	O
MKK3	B
)	O
,	O
a	O
known	O
activator	O
of	O
p38	B
MAPk	I
.	O

Both	O
MAP	B
ERK	I
kinase	I
kinase-1	I
(	O
MEKK1	B
)	O
and	O
Raf	B
are	O
activated	O
strongly	O
by	O
FMLP	B
,	O
but	O
minimally	O
by	O
PAF	B
.	O

Pertussis	B
toxin	I
blocked	O
FMLP	B
-induced	O
activation	O
of	O
the	O
p42	B
/	I
44	I
(	I
ERK	I
)	I
MAPk	I
cascade	O
,	O
but	O
not	O
that	O
of	O
p38	B
MAPk	I
.	O

A	O
specific	O
p38	B
MAPk	I
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B
or	O
FMLP	B
.	O

These	O
results	O
demonstrate	O
distinct	O
patterns	O
of	O
intracellular	O
signaling	O
for	O
two	O
chemoattractants	B
and	O
suggest	O
that	O
selective	O
activation	O
of	O
intracellular	O
signaling	O
cascades	O
may	O
underlie	O
different	O
patterns	O
of	O
functional	O
responses	O
.	O

Pivotal	O
role	O
for	O
the	O
NFIL3	B
/	I
E4BP4	I
transcription	I
factor	I
in	O
interleukin	B
3	I
-mediated	O
survival	O
of	O
pro	O
-	O
B	O
lymphocytes	O
.	O

The	O
E2A	B
-	I
HLF	I
(	I
hepatic	I
leukemia	I
factor	I
)	I
oncoprotein	I
,	O
generated	O
in	O
pro	O
-	O
B	O
lymphocytes	O
by	O
fusion	O
of	O
the	O
trans	B
-	I
activation	I
domain	I
of	O
E2A	B
to	O
the	O
basic	B
region	I
/	I
leucine	I
zipper	I
(	I
bZIP	I
)	I
domain	I
of	O
HLF	B
,	O
functions	O
as	O
an	O
anti	B
-	I
apoptotic	I
transcription	I
factor	I
in	O
leukemic	O
cell	O
transformation	O
.	O

When	O
introduced	O
into	O
interleukin	B
3	I
(	O
IL-3	B
)	O
-dependent	O
mouse	O
pro	O
-	O
B	O
lymphocytes	O
,	O
E2A	B
-	I
HLF	I
prevents	O
apoptosis	O
induced	O
by	O
growth	B
factor	I
deprivation	O
,	O
suggesting	O
that	O
IL-3	B
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	B
factor	I
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	B
oncoprotein	I
.	O

We	O
considered	O
four	O
bZIP	B
transcription	I
factors	I
as	O
candidates	O
for	O
this	O
putative	O
IL-3-regulated	B
factor	I
,	O
each	O
of	O
which	O
binds	O
avidly	O
to	O
the	O
DNA	O
consensus	O
sequence	O
recognized	O
by	O
E2A	B
-	I
HLF	I
and	O
is	O
related	O
to	O
the	O
Caenorhabditis	B
elegans	I
CES-2	I
(	O
cell	B
death	I
specification	I
protein	I
)	O
neuron	B
-	I
specific	I
mediator	I
of	I
cell	I
death	I
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B
protein	I
(	O
also	O
called	O
E4bp4	B
)	O
,	O
but	O
not	O
of	O
Hlf	B
,	O
Dbp	B
,	O
or	O
Tef	B
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	B
in	O
mouse	O
pro	O
-	O
B	O
cell	O
lines	O
(	O
Baf-3	O
and	O
FL5.12	O
)	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
Nfil3	B
/	I
E4bp4	I
is	O
regulated	O
as	O
a	O
`	O
`	O
delayed	O
-	O
early	O
''	O
IL-3-responsive	O
gene	O
,	O
requiring	O
de	O
novo	O
protein	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
IL-3	B
,	O
enforced	O
expression	O
of	O
the	O
human	O
NFIL3	O
/	O
E4BP4	O
cDNA	O
promoted	O
the	O
survival	O
but	O
not	O
the	O
growth	O
of	O
IL-3-dependent	O
pro	O
-	O
B	O
cells	O
.	O

Our	O
results	O
implicate	O
NFIL3	B
/	I
E4BP4	I
(	O
nuclear	B
factor	I
regulated	I
by	I
IL-3	I
/	I
adenovirus	I
E4	I
promoter	I
binding	I
protein	I
)	O
in	O
a	O
distinct	O
growth	O
factor	O
-	O
regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	O
B	O
-	O
cell	O
progenitors	O
,	O
and	O
whose	O
alteration	O
by	O
E2A	B
-	I
HLF	I
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O

ALY	B
,	O
a	O
context	B
-	I
dependent	I
coactivator	I
of	O
LEF-1	B
and	O
AML-1	B
,	O
is	O
required	O
for	O
TCRalpha	O
enhancer	O
function	O
.	O

LEF-1	B
is	O
a	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
alpha	O
)	O
enhancer	O
by	O
facilitating	O
the	O
assembly	O
of	O
multiple	B
proteins	I
into	O
a	O
higher	O
order	O
nucleoprotein	B
complex	I
.	O

The	O
function	O
of	O
LEF-1	B
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B
domain	I
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B
domain	I
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer	B
-	I
binding	I
proteins	I
.	O

With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context	B
-	I
dependent	I
activation	I
domains	I
,	O
we	O
cloned	O
ALY	B
,	O
a	O
novel	O
LEF-1-interacting	B
protein	I
.	O

ALY	B
is	O
a	O
ubiquitously	O
expressed	O
,	O
nuclear	O
protein	O
that	O
specifically	O
associates	O
with	O
the	O
activation	B
domains	I
of	O
LEF-1	B
and	O
AML-1	B
(	O
CBF	B
alpha2	I
,	O
PEBP2	B
alpha	I
(	O
B	O
)	O
,	O
which	O
is	O
another	O
protein	O
component	O
of	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
.	O

In	O
addition	O
,	O
ALY	B
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B
and	O
AML	B
proteins	I
.	O

Overexpression	O
of	O
ALY	B
stimulates	O
the	O
activity	O
of	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
reconstituted	O
in	O
transfected	O
nonlymphoid	O
HeLa	O
cells	O
,	O
whereas	O
down	O
-	O
regulation	O
of	O
ALY	B
by	O
anti	O
-	O
sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
T	O
cells	O
.	O

Similar	O
to	O
LEF-1	B
,	O
ALY	B
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	O
alpha	O
enhancer	O
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	B
DNA	I
-	I
binding	I
domain	I
.	O

We	O
propose	O
that	O
ALY	B
mediates	O
context	O
-	O
dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	B
proteins	I
in	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
.	O

Estrogen	B
and	O
progesterone	B
receptors	I
in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE	O
:	O
Sex	O
-	O
related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B
and	O
progesterone	B
receptors	I
by	O
using	O
monoclonal	B
antibodies	I
with	O
a	O
peroxidase	O
-	O
antiperoxidase	O
technique	O
.	O

RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B
receptors	I
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B
and	O
progesterone	B
receptors	I
with	O
eosinophil	B
cationic	I
protein	I
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	O
cells	O
were	O
eosinophils	O
.	O

CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	B
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	O
in	O
patients	O
with	O
VKC	O
.	O

Induction	O
of	O
relA	B
(	I
p65	I
)	I
and	O
I	B
kappa	I
B	I
alpha	I
subunit	I
expression	O
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
subunits	I
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	B
homodimers	I
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
heterodimers	I
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	B
(	I
p65	I
)	I
subunit	I
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
was	O
significantly	O
higher	O
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
heterodimers	I
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
complexes	I
that	O
are	O
readily	O
available	O
for	O
inducer	O
-	O
mediated	O
stimulation	O
.	O

Requirement	O
of	O
prestimulated	O
THP-1	O
monocytic	O
cells	O
for	O
endothelial	O
cell	O
activation	O
.	O

Involvement	O
of	O
TNF	O
alpha	O
.	O

Blood	O
monocytes	O
spontaneously	O
activate	O
endothelial	O
cells	O
in	O
culture	O
,	O
leading	O
to	O
adhesion	O
of	O
monocytic	O
cells	O
onto	O
the	O
endothelial	O
surface	O
and	O
overproduction	O
of	O
endothelial	O
proteins	O
such	O
as	O
von	B
Willebrand	I
factor	I
(	O
vWf	B
)	O
and	O
plasminogen	B
activator	I
inhibitor	I
type	I
1	I
(	O
PAI-1	B
)	O
.	O

To	O
overcome	O
the	O
difficulty	O
in	O
obtaining	O
quiescent	O
monocytes	O
,	O
we	O
studied	O
the	O
ability	O
of	O
promonocytic	O
THP-1	O
cells	O
to	O
activate	O
endothelial	O
cells	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
-prestimulated	O
and	O
untreated	O
THP-1	O
cells	O
were	O
cocultured	O
with	O
resting	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
for	O
3	O
and	O
24	O
h	O
in	O
the	O
presence	O
of	O
colimycin	O
to	O
neutralize	O
LPS	O
traces	O
.	O

Addition	O
of	O
untreated	O
THP-1	O
cells	O
had	O
little	O
effect	O
on	O
HUVEC	O
adhesiveness	O
.	O

Addition	O
of	O
prestimulated	O
THP-1	O
cells	O
was	O
followed	O
by	O
a	O
noticeable	O
adhesion	O
after	O
3	O
h	O
which	O
reversed	O
to	O
basal	O
values	O
within	O
24	O
h	O
.	O

Under	O
these	O
conditions	O
HUVEC	B
adhesion	I
molecules	I
,	O
E	B
-	I
selectin	I
,	O
VCAM-1	B
and	O
ICAM-1	B
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	B
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

Diffusible	B
endothelial	I
proteins	I
such	O
as	O
soluble	O
E	B
-	I
selectin	I
,	O
PAI-1	B
and	O
vWf	B
to	O
a	O
minimal	O
extent	O
,	O
increased	O
in	O
supernatants	O
from	O
HUVEC	O
cocultured	O
for	O
24	O
h	O
with	O
prestimulated	O
THP-1	O
cells	O
.	O

In	O
those	O
cocultures	O
,	O
TNF	B
alpha	I
concentrations	O
peaked	O
at	O
3	O
h	O
whereas	O
IL-1	O
beta	O
levels	O
progressively	O
rose	O
until	O
24	O
h	O
.	O

Addition	O
of	O
an	O
anti	B
-	I
TNF	I
alpha	I
antibody	I
decreased	O
by	O
40	O
%	O
E	B
-	I
selectin	I
and	O
ICAM-1	B
induction	O
and	O
suppressed	O
PAI-1	B
overproduction	O
with	O
a	O
weak	O
effect	O
on	O
vWf	B
.	O

An	O
anti	B
-	I
IL-1	I
beta	I
antibody	I
had	O
negligible	O
effects	O
on	O
HUVEC	B
adhesion	I
molecules	I
,	O
PAI-1	B
or	O
vWf	B
production	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
promonocytic	O
THP-1	O
cells	O
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	O
and	O
that	O
TNF	B
alpha	I
contributes	O
to	O
this	O
phenomenon	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	B
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	B
-	I
Jkappa	I
or	O
nuclear	B
localization	I
sequences	I
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP	B
-	I
Jkappa	I
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	B
transmembrane	I
receptor	I
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	B
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	B
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	B
domain	I
(	O
DeltaE	B
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	B
domain	I
(	O
ICN	B
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	B
-	I
Jkappa	I
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B
factor	I
RBP	I
-	I
Jkappa	I
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP	B
-	I
Jkappa	I
-	I
binding	I
site	I
within	O
the	O
NOTCH1	B
ankyrin	I
repeat	I
region	I
of	O
the	O
intracellular	B
domain	I
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	B
-	I
Jkappa	I
-	I
binding	I
site	I
,	O
which	O
lies	O
within	O
the	O
intracellular	B
domain	I
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	B
-	I
Jkappa	I
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	B
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	B
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	B
localization	I
sequences	I
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	B
-	I
bound	I
DeltaE	I
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	B
-	I
bound	I
DeltaE	I
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	B
ICN	I
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	B
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP	B
-	I
Jkappa	I
at	O
promoter	O
sites	O
.	O

Glucocorticoid	O
-	O
resistance	O
in	O
peripheral	O
-	O
blood	O
lymphocytes	O
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid	B
-	I
receptors	I
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
resistance	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
seriously	O
impairs	O
successive	O
GC	O
therapy	O
after	O
renal	O
transplantation	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
GC	O
-	O
receptor	O
(	O
GC	O
-	O
R	O
)	O
parameters	O
in	O
peripheral	O
-	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
PBMC	O
resistance	O
to	O
GC	O
in	O
21	O
CRF	O
patients	O
and	O
18	O
healthy	O
subjects	O
.	O

Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	O
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng	O
/	O
mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng	O
/	O
mL	O
)	O
groups	O
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC	B
-	I
R	I
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
2.89	O
+	O
/-	O
1.23	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+	O
/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+	O
/-	O
2.02	O
(	O
257.7	O
+	O
/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

The	O
GC	B
-	I
R	I
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.33	O
+	O
/-	O
1.37	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+	O
/-	O
1.39	O
nM	O
,	O
respectively	O
.	O

Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	B
stimulation	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase	O
-	O
ratios	O
(	O
post	O
/	O
pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
6.04	O
+	O
/-	O
2.35	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+	O
/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.13	O
+	O
/-	O
2.31	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+	O
/-	O
1.62	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	B
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC	B
-	I
R	I
parameters	O
in	O
CRF	O
.	O

We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	O
capacity	O
to	O
amplify	O
GC	B
-	I
R	I
numbers	O
in	O
response	O
to	O
mitogen	B
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC	B
-	I
R	I
parameters	O
.	O

An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC	O
-	O
resistance	O
of	O
CRF	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B	B
-	I
cell	I
-	I
specific	I
activator	I
protein	I
.	O

Germline	B
transcripts	I
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	B
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B	B
-	I
cell	I
-	I
specific	I
activator	I
protein	I
(	O
BSAP	B
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	B
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	B
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	B
plays	O
a	O
role	O
in	O
both	O
IL-4	B
-dependent	O
induction	O
and	O
CD40	B
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	B
is	O
unique	O
among	O
the	O
transcription	B
factors	I
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B
switching	O
.	O

Molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

The	O
immunoregulatory	B
properties	O
of	O
prolactin	O
,	O
a	O
pituitary	O
peptide	O
hormone	O
,	O
have	O
received	O
renewed	O
attention	O
.	O

The	O
prolactin	B
receptor	I
,	O
a	O
member	O
of	O
the	O
hematopoietin	B
/	I
cytokine	I
receptor	I
superfamily	I
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O

Certain	O
subpopulations	O
of	O
lymphocytes	O
synthesize	O
and	O
secrete	O
biologically	O
active	O
prolactin	O
,	O
which	O
suggests	O
that	O
prolactin	O
can	O
act	O
as	O
an	O
autocrine	O
and/or	O
paracrine	O
factor	O
to	O
modulate	O
the	O
activities	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B
molecules	I
and	O
prolactin	O
-	O
inducible	O
target	O
genes	O
that	O
participate	O
in	O
these	O
responses	O
.	O

In	O
particular	O
,	O
the	O
prolactin	O
-	O
inducible	O
interferon	O
regulatory	O
factor-1	O
gene	O
and	O
its	O
roles	O
in	O
mediating	O
diverse	O
immune	O
responses	O
.	O

A	O
new	O
mouse	O
gene	O
,	O
SRG3	O
,	O
related	O
to	O
the	O
SWI3	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
in	O
a	O
thymoma	O
cell	O
line	O
.	O

We	O
isolated	O
a	O
new	O
mouse	O
gene	O
that	O
is	O
highly	O
expressed	O
in	O
thymocytes	O
,	O
testis	O
,	O
and	O
brain	O
.	O

This	O
gene	O
,	O
SRG3	O
,	O
showed	O
a	O
significant	O
sequence	O
homology	O
to	O
SWI3	O
,	O
a	O
yeast	O
transcriptional	O
activator	O
,	O
and	O
its	O
human	O
homolog	O
BAF155	O
.	O

SRG3	O
encodes	O
1	O
,	O
100	O
amino	O
acids	O
and	O
has	O
33	O
-	O
47	O
%	O
identity	O
with	O
SWI3	B
protein	I
over	O
three	O
regions	O
.	O

The	O
SRG3	B
protein	I
contains	O
an	O
acidic	B
NH2	I
terminus	I
,	O
a	O
myb	B
-	I
like	I
DNA	I
binding	I
domain	I
,	O
a	O
leucine	B
-	I
zipper	I
motif	I
,	O
and	O
a	O
proline-	B
and	I
glutamine	I
-	I
rich	I
region	I
at	O
its	O
COOH	B
terminus	I
.	O

Rabbit	O
antiserum	O
raised	O
against	O
a	O
COOH	O
-	O
terminal	O
polypeptide	O
of	O
the	O
SRG3	O
recognized	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
155	O
kD	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170-kD	B
protein	I
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	B
BAF170	I
.	O

Immunoprecipitation	O
of	O
cell	O
extract	O
with	O
the	O
antiserum	O
against	O
the	O
mouse	B
SRG3	I
also	O
brought	O
down	O
a	O
195-kD	B
protein	I
that	O
could	O
be	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
human	B
SWI2	I
protein	I
.	O

The	O
results	O
suggest	O
that	O
the	O
SRG3	B
protein	I
associates	O
with	O
a	O
mouse	B
SWI2	I
.	O

The	O
SRG3	B
protein	I
is	O
expressed	O
about	O
three	O
times	O
higher	O
in	O
thymocytes	O
than	O
in	O
peripheral	O
lymphocytes	O
.	O

The	O
expression	O
of	O
anti	B
-	I
sense	I
RNA	I
to	O
SRG3	O
mRNA	O
in	O
a	O
thymoma	O
cell	O
line	O
,	O
S49.1	O
,	O
reduced	O
the	O
expression	O
level	O
of	O
the	O
SRG3	B
protein	I
,	O
and	O
decreased	O
the	O
apoptotic	O
cell	O
death	O
induced	O
by	O
glucocorticoids	O
.	O

These	O
results	O
suggest	O
that	O
the	O
SRG3	B
protein	I
is	O
involved	O
in	O
the	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
thymoma	O
cell	O
line	O
.	O

This	O
implicates	O
that	O
the	O
SRG3	O
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

The	O
IL-4	B
receptor	I
alpha	I
-	I
chain	I
cytoplasmic	I
domain	I
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	B
and	O
STAT6	B
and	O
the	O
induction	O
of	O
IL-4	B
-specific	O
gene	O
expression	O
.	O

The	O
common	B
gamma	I
-	I
chain	I
(	O
gamma	B
(	I
c	I
)	I
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	B
,	O
yet	O
cells	O
lacking	O
gamma	B
(	I
c	I
)	I
are	O
able	O
to	O
respond	O
to	O
IL-4	B
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	B
gamma'-chain	I
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	B
alpha	I
chain	I
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	B
(	I
c	I
)	I
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B
(	I
c	I
)	I
,	O
the	O
IL-4R	B
alpha	I
chain	I
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	B
receptor	I
containing	O
the	O
extracellular	B
domain	I
of	O
c	B
-	I
kit	I
(	O
the	O
stem	B
cell	I
factor	I
(	I
SCF	I
)	I
receptor	I
)	O
and	O
the	O
cytoplasmic	B
and	I
transmembrane	I
domains	I
of	O
the	O
IL-4R	B
alpha	I
chain	I
was	O
generated	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B
receptor	I
kit	B
/	I
IL-4R	I
alpha	I
with	O
SCF	B
induces	O
activation	O
of	O
the	O
IL-4R	B
alpha	I
-	I
associated	I
kinase	I
JAK-1	B
and	O
the	O
transcription	B
factor	I
STAT6	B
.	O

However	O
,	O
tyrosine	O
phosphorylation	O
of	O
JAK-3	B
,	O
which	O
associates	O
with	O
gamma	B
(	I
c	I
)	I
,	O
is	O
not	O
induced	O
by	O
SCF	B
in	O
these	O
cells	O
.	O

SCF	B
-mediated	O
ligation	O
of	O
kit	B
/	I
IL-4R	I
alpha	I
is	O
sufficient	O
to	O
elicit	O
IL-4	B
-specific	O
gene	O
expression	O
,	O
including	O
up	O
-	O
regulation	O
of	O
CD23	B
and	O
synthesis	O
of	O
germ	O
-	O
line	O
epsilon	O
transcripts	O
.	O

In	O
the	O
T	O
cell	O
line	O
CTLL2	O
,	O
ligation	O
of	O
kit	B
/	I
IL-4R	I
alpha	I
induces	O
cellular	O
proliferation	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	O
HeLa	O
cells	O
,	O
STAT6	B
activation	O
by	O
IL-4	B
is	O
completely	O
abolished	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	B
alpha	I
cytoplasmic	I
domain	I
is	O
sufficient	O
to	O
activate	O
JAK-1	B
and	O
STAT6	B
and	O
to	O
induce	O
expression	O
of	O
IL-4	O
target	O
genes	O
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	B
signaling	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
JAK-3	B
and	O
gamma	B
(	I
c	I
)	I
.	O

AP-1	B
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV	O
-	O
I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	B
factors	I
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV	O
-	O
I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	O
lines	O
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	B
factors	I
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1	O
-	O
4	O
)	O
.	O

ATF	B
/	I
CREB	I
and	O
Sp	B
family	I
members	I
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA	B
-	I
protein	I
complexes	I
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA	B
-	I
protein	I
complex	I
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	O
MG	O
glioblastoma	O
cell	O
line	O
or	O
the	O
THP-1	O
mature	O
monocytic	O
cell	O
line	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA	B
-	I
protein	I
complex	I
is	O
comprised	O
of	O
the	O
AP-1	B
components	O
,	O
Fos	B
and	O
Jun	B
.	O

Expression	O
of	O
transcription	B
factors	I
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O

During	O
15	O
days	O
of	O
treatment	O
of	O
K562	O
cells	O
with	O
sodium	O
phenylacetate	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cellular	O
hemoglobin	B
concentration	O
with	O
a	O
similar	O
increase	O
in	O
the	O
expression	O
of	O
gamma	O
-	O
globin	O
mRNA	O
.	O

Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O

At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	B
surface	I
antigenes	I
CD33	B
,	O
CD34	B
,	O
CD45	B
,	O
CD71	B
and	O
glycophorin	B
A	I
.	O

Likewise	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
erythroid	B
transcription	I
factors	I
GATA-1	B
,	O
GATA-2	B
,	O
NF	B
-	I
E2	I
,	O
SCL	B
and	O
RBTN2	B
,	O
all	O
expressed	O
in	O
untreated	O
K562	O
cells	O
,	O
did	O
not	O
increase	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
.	O

The	O
expression	O
of	O
the	O
nuclear	B
factors	I
Evi-1	B
and	O
c	B
-	I
myb	I
,	O
known	O
to	O
inhibit	O
erythroid	O
differentiation	O
,	O
did	O
not	O
decrease	O
.	O

We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	O
cells	O
increases	O
gamma	O
-	O
globin	O
mRNA	O
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	B
transcription	I
factors	I
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

c	O
-	O
Myb	O
and	O
Ets	B
proteins	I
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B
.	O

The	O
Zfh	B
family	I
of	O
zinc	B
finger	I
/	I
homeodomain	I
proteins	I
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	B
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	B
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	B
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	B
factors	I
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	B
-	I
Myb	I
and	O
Ets	B
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	B
blocks	O
the	O
activity	O
of	O
c	B
-	I
Myb	I
and	O
Ets	B
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	B
-	I
Myb	I
and	O
Ets	B
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	B
and	O
transcriptional	O
activation	O
by	O
c	B
-	I
Myb	I
/Ets	B
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B
integrin	I
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

Opposite	O
effects	O
of	O
the	O
acute	B
promyelocytic	I
leukemia	I
PML	I
-	I
retinoic	I
acid	I
receptor	I
alpha	I
(	O
RAR	B
alpha	I
)	O
and	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
proteins	I
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B
alpha	I
(	O
RAR	B
alpha	I
)	O
and	O
the	O
PML	B
or	O
PLZF	B
nuclear	I
protein	I
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML	B
-	I
RAR	I
alpha	I
or	O
the	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
protein	I
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML	B
-	I
RAR	I
alpha	I
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF	B
-	I
RAR	I
alpha	I
do	O
not	O
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML	B
-	I
RAR	I
alpha	I
expression	O
,	O
PLZF	B
-	I
RAR	I
alpha	I
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	O
and	O
HL-60	O
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML	B
-	I
RAR	I
alpha	I
,	O
but	O
not	O
PLZF	B
-	I
RAR	I
alpha	I
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	O
precursor	O
cells	O
and	O
restores	O
RA	O
sensitivity	O
of	O
RA	O
-	O
resistant	O
hematopoietic	O
cells	O
;	O
(	O
iii	O
)	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML	B
-	I
RAR	I
alpha	I
enhances	O
the	O
RA	O
response	O
of	O
RA	O
target	O
genes	O
(	O
those	O
for	O
RAR	B
beta	I
,	O
RAR	B
gamma	I
,	O
and	O
transglutaminase	B
type	I
II	I
[	O
TGase	B
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF	B
-	I
RAR	I
alpha	I
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	B
beta	I
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	B
gamma	I
and	O
type	B
II	I
TGase	I
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA	O
-	O
dependent	O
enhancers	O
or	O
inhibitors	O
of	O
RA	O
-	O
responsive	O
genes	O
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
protein	I
contains	O
an	O
approximately	O
120-amino	B
-	I
acid	I
N	I
-	I
terminal	I
motif	I
(	O
called	O
the	O
POZ	B
domain	I
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	B
proteins	I
and	O
which	O
mediates	O
protein	O
-	O
protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	B
POZ	I
domain	I
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF	B
-	I
RAR	I
alpha	I
on	O
RA	O
-	O
induced	O
differentiation	O
and	O
on	O
RA	O
-	O
mediated	O
type	B
II	I
TGase	I
up	O
-	O
regulation	O
,	O
suggesting	O
that	O
POZ	O
-	O
mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF	B
-	I
RAR	I
alpha	I
.	O

Regulation	O
of	O
B	O
-	O
cell	O
commitment	O
to	O
plasma	O
cells	O
or	O
to	O
memory	O
B	O
cells	O
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B	O
-	O
lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B	O
-	O
cell	O
pathway	O
.	O

Recent	O
studies	O
suggest	O
that	O
CD40-CD40	B
ligand	I
,	O
OX	B
-	I
OX40	I
ligand	I
,	O
a	O
group	O
of	O
cytokines	B
and	O
intracellular	O
transcriptional	O
factors	O
may	O
all	O
contribute	O
to	O
B	O
-	O
lymphocyte	O
differentiation	O
control	O
.	O

Transcription	B
factor	I
GATA-3	I
is	O
differentially	O
expressed	O
in	O
murine	O
Th1	O
and	O
Th2	O
cells	O
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	O
gene	O
.	O

Interleukin-5	B
(	O
IL-5	B
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	O
by	O
Th1	O
cells	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1-	O
and	O
Th2-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	B
factor	I
GATA-3	B
in	O
IL-5	O
promoter	O
activation	O
in	O
EL-4	O
cells	O
,	O
which	O
express	O
both	O
Th1-	B
and	I
Th2-type	I
cytokines	I
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA-3	B
is	O
critical	O
for	O
expression	O
of	O
the	O
IL-5	B
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	B
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	B
in	O
Th1	O
cells	O
or	O
in	O
a	O
non	O
-	O
lymphoid	O
,	O
non	O
-	O
IL-5-producing	O
cell	O
line	O
activated	O
the	O
IL-5	O
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	B
gene	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
Th1	O
cells	O
,	O
and	O
antigen-	O
or	O
cAMP	O
-	O
activated	O
Th2	O
cells	O
(	O
but	O
not	O
Th1	O
cells	O
)	O
expressed	O
the	O
GATA-3	B
protein	I
.	O

Thus	O
,	O
GATA-3	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA-3	B
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
ability	O
of	O
BHRF1	B
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas	O
-	O
mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus	O
-	O
infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	B
,	O
an	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
early	I
-	I
lytic	I
-	I
cycle	I
protein	I
with	O
distant	O
homology	O
to	O
Bcl-2	B
,	O
as	O
an	O
anti	B
-	I
apoptosis	I
protein	I
.	O

Expression	O
of	O
BHRF1	B
in	O
MCF	O
-	O
Fas	O
cells	O
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti	B
-	I
Fas	I
antibody	I
and	O
TNF	O
-	O
mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	B
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
ability	O
of	O
BHRF1	B
to	O
protect	O
MCF	O
-	O
Fas	O
cells	O
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B
resembled	O
that	O
of	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
as	O
it	O
inhibited	O
TNF-	O
and	O
anti	O
-	O
Fas	O
-	O
induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B
phospholipase	I
A2	I
and	O
caspase-3	B
/	I
CPP32	I
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
-	I
like	I
transcription	I
factors	I
.	O

A	O
putative	O
function	O
of	O
BHRF1	B
in	O
EBV	O
-	O
infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus	O
-	O
infected	O
cells	O
from	O
TNF-	O
and/or	O
anti	O
-	O
Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B
nor	O
Bcl-2	B
in	O
a	O
B	O
-	O
cell	O
line	O
,	O
BJAB	O
,	O
protected	O
the	O
cells	O
from	O
anti	O
-	O
Fas	O
-	O
mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum	O
-	O
starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	B
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	B
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

Expression	O
of	O
bcl-6	B
protein	I
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

Bcl-6	B
protein	I
is	O
a	O
recently	O
identified	O
novel	O
transcription	B
factor	I
whose	O
deregulated	O
expression	O
is	O
associated	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
.	O

It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	O
center	O
B	O
cells	O
and	O
their	O
neoplastic	O
counterparts	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
expression	O
of	O
bcl-6	B
protein	I
on	O
normal	O
epidermis	O
,	O
benign	O
,	O
and	O
malignant	O
tumors	O
originating	O
from	O
epidermal	O
cells	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
cell	O
lines	O
are	O
investigated	O
.	O

With	O
the	O
use	O
of	O
immunohistochemistry	O
,	O
bcl-6	B
protein	I
was	O
shown	O
to	O
stain	O
intensely	O
on	O
normal	O
prickle	O
cells	O
,	O
but	O
none	O
to	O
only	O
slightly	O
on	O
epidermal	O
basal	O
cells	O
.	O

Papillomas	O
and	O
keratoacanthomas	O
copied	O
their	O
normal	O
counterparts	O
in	O
the	O
mode	O
of	O
expression	O
.	O

Various	O
levels	O
of	O
expression	O
were	O
found	O
on	O
seborrheic	O
keratoses	O
,	O
while	O
the	O
expression	O
level	O
on	O
basal	O
cell	O
epitheliomas	O
was	O
low	O
.	O

Peculiarly	O
,	O
eccrine	O
poromas	O
and	O
undifferentiated	O
spindle	O
-	O
shaped	O
basal	O
cell	O
epitheliomas	O
were	O
totally	O
unstained	O
.	O

Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle	O
-	O
shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	O
cell	O
line	O
remained	O
unstained	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B
protein	I
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	O
epidermal	O
cells	O
.	O

HIV-1	B
Vpr	I
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
[	O
see	O
comments	O
]	O

The	O
HIV-1	B
accessory	I
gene	I
product	I
Vpr	B
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	B
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B
modulates	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	B
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	B
-mediated	O
activation	O
,	O
Vpr	B
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	B
suppression	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
via	O
the	O
induction	O
of	O
I	B
kappa	I
B	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

Further	O
,	O
Vpr	B
suppresses	O
expression	O
of	O
IL-2	B
,	O
IL-10	B
,	O
IL-12	B
,	O
TNF	B
alpha	I
and	O
IL-4	B
,	O
all	O
of	O
which	O
are	O
NF	B
-	I
kappa	I
B	I
-dependent	O
.	O

The	O
effects	O
of	O
Vpr	B
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	B
can	O
regulate	O
NF	B
-	I
kappa	I
B	I
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B
.	O

Nuclear	O
localization	O
of	O
RelB	B
is	O
associated	O
with	O
effective	O
antigen	O
-	O
presenting	O
cell	O
function	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APCs	O
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

The	O
phenotype	O
of	O
RelB	B
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	B
kappa	I
B	I
/	I
Rel	I
family	I
in	O
DC	O
differentiation	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
RelB	B
in	O
DC	O
differentiation	O
,	O
mRNA	O
,	O
intracellular	O
protein	O
expression	O
,	O
and	O
DNA	O
binding	O
activity	O
of	O
RelB	B
were	O
examined	O
in	O
immature	O
and	O
differentiated	O
human	O
DC	O
,	O
as	O
well	O
as	O
other	O
PB	O
mononuclear	O
cell	O
populations	O
.	O

RelB	B
protein	O
and	O
mRNA	O
were	O
detected	O
constitutively	O
in	O
lymphocytes	O
and	O
in	O
activated	O
monocytes	O
,	O
differentiated	O
DC	O
,	O
and	O
monocyte	O
-	O
derived	O
DC	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B
within	O
the	O
differentiated	O
lymph	O
node	O
interdigitating	O
DC	O
and	O
follicular	O
DC	O
,	O
but	O
not	O
undifferentiated	O
DC	O
in	O
normal	O
skin	O
.	O

Active	O
nuclear	O
RelB	B
was	O
detected	O
by	O
supershift	O
assay	O
only	O
in	O
differentiated	O
DC	O
derived	O
from	O
either	O
PB	O
precursors	O
or	O
monocytes	O
and	O
in	O
activated	O
B	O
cells	O
.	O

These	O
RelB+	O
APC	O
were	O
potent	O
stimulators	O
of	O
the	O
MLR	B
.	O

The	O
data	O
indicate	O
that	O
RelB	B
expression	O
is	O
regulated	O
both	O
transcriptionally	O
and	O
post	O
-	O
translationally	O
in	O
myeloid	O
cells	O
.	O

Within	O
the	O
nucleus	O
,	O
RelB	B
may	O
specifically	O
transactivate	O
genes	O
that	O
are	O
critical	O
for	O
APC	O
function	O
.	O

Expression	O
of	O
c	O
-	O
fos	O
correlates	O
with	O
IFN	B
-	I
alpha	I
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	O
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN	B
-	I
alpha	I
2c	I
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c	O
-	O
fos	O
,	O
c	O
-	O
myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr	O
/	O
abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	O
-	O
fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	B
-	I
alpha	I
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr	O
/	O
abl	O
,	O
c	O
-	O
myc	O
and	O
p53	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	B
-	I
alpha	I
is	O
accompanied	O
by	O
upregulation	O
of	O
c	O
-	O
fos	O
and	O
downregulation	O
of	O
c	O
-	O
myc	O
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	O
and	O
FHIT	O
genes	O
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Intragenic	O
deletions	O
of	O
TSG101	O
,	O
the	O
human	O
homolog	O
of	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
that	O
acts	O
to	O
suppress	O
malignant	O
cell	O
growth	O
,	O
were	O
reported	O
in	O
human	O
breast	O
tumours	O
.	O

We	O
screened	O
TSG101	O
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV	O
-	O
immortalised	O
B	O
-	O
cells	O
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	O
deletions	O
in	O
RNA	O
transcripts	O
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	O
site	O
sequences	O
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	O
tumour	O
suppressor	O
gene	O
FHIT	O
.	O

We	O
analysed	O
FHIT	O
in	O
the	O
same	O
series	O
of	O
RNA	O
samples	O
and	O
detected	O
truncated	O
FHIT	O
transcripts	O
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
transcripts	O
from	O
TSG101	O
,	O
FHIT	O
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	O
peripheral	O
blood	O
lymphocytes	O
.	O

Large	O
TSG101	O
and	O
FHIT	O
intragenic	O
transcript	O
deletions	O
were	O
detected	O
and	O
these	O
appeared	O
to	O
be	O
the	O
predominant	O
transcript	O
in	O
'	O
aged	O
'	O
lymphocytes	O
.	O

Similar	O
alterations	O
were	O
not	O
detected	O
in	O
transcripts	O
of	O
the	O
other	O
genes	O
which	O
were	O
analysed	O
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	O
TSG101	O
and	O
FHIT	O
transcripts	O
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	O
and	O
FHIT	O
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O

OCA	B
-	I
B	I
is	O
a	O
functional	O
analog	O
of	O
VP16	B
but	O
targets	O
a	O
separate	O
surface	O
of	O
the	O
Oct-1	B
POU	I
domain	I
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1998	O
Apr	O
;	O
18	O
(	O
4	O
)	O
:	O
2430	O
]	O

OCA	B
-	I
B	I
is	O
a	O
B	B
-	I
cell	I
-	I
specific	I
coregulator	I
of	O
the	O
broadly	O
expressed	O
POU	B
domain	I
transcription	I
factor	I
Oct-1	B
.	O

OCA	B
-	I
B	I
associates	O
with	O
the	O
Oct-1	B
POU	I
domain	I
,	O
a	O
bipartite	O
DNA	O
-	O
binding	O
structure	O
containing	O
a	O
POU	B
-	I
specific	I
(	I
POU	I
[	I
S	I
]	I
)	I
domain	I
joined	O
by	O
a	O
flexible	O
linker	O
to	O
a	O
POU	B
homeodomain	I
(	O
POU	B
[	I
H	I
]	I
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
OCA	B
-	I
B	I
alters	O
the	O
activity	O
of	O
Oct-1	B
in	O
two	O
ways	O
.	O

It	O
provides	O
a	O
transcriptional	O
activation	O
domain	O
which	O
,	O
unlike	O
Oct-1	B
,	O
activates	O
an	O
mRNA	O
-	O
type	O
promoter	O
effectively	O
,	O
and	O
it	O
stabilizes	O
Oct-1	B
on	O
the	O
Oct-1-responsive	O
octamer	O
sequence	O
ATGCAAAT	O
.	O

These	O
properties	O
of	O
OCA	B
-	I
B	I
parallel	O
those	O
displayed	O
by	O
the	O
herpes	B
simplex	I
virus	I
Oct-1	I
coregulator	I
VP16	B
.	O

OCA	B
-	I
B	I
,	O
however	O
,	O
interacts	O
with	O
a	O
different	O
surface	O
of	O
the	O
DNA	O
-	O
bound	O
Oct-1	B
POU	I
domain	I
,	O
interacting	O
with	O
both	O
the	O
POU	B
(	I
S	I
)	I
and	I
POU	I
(	I
H	I
)	I
domains	I
and	O
the	O
center	O
of	O
the	O
ATGCAAAT	O
octamer	O
sequence	O
.	O

The	O
OCA	O
-	O
B	O
and	O
VP16	B
interactions	O
with	O
the	O
Oct-1	B
POU	I
domain	I
are	O
sufficiently	O
different	O
to	O
permit	O
OCA	B
-	I
B	I
and	O
VP16	B
to	O
bind	O
the	O
Oct-1	B
POU	I
domain	I
simultaneously	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	B
POU	I
domain	I
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	B
factor	I
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	B
factor	I
(	O
TF	B
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	B
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	B
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	B
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes	O
/	O
macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	B
activity	O
generated	O
by	O
both	O
unstimulated	O
and	O
endotoxin	O
-	O
stimulated	O
cells	O
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	O
monocyte	O
TF	B
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	B
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	B
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	B
-	I
gamma	I
or	O
interleukin-1beta	B
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	O
mRNA	O
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	O
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	B
activation	O
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	B
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	B
expression	O
and	O
NF	B
-	I
kappaB	I
activation	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	B
polymerase	I
II	I
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	O
through	O
XPG	O
.	O

Of	O
these	O
,	O
the	O
XPB	O
and	O
XPD	O
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	B
transcription	I
factor	I
,	O
TFIIH	B
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	O
or	O
XPD	O
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper	O
-	O
sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
cells	O
contained	O
reduced	O
amounts	O
of	O
TFIIH	B
.	O

Extracts	O
prepared	O
from	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	B
for	O
the	O
clinical	O
symptoms	O
in	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
patients	O
,	O
and	O
discuss	O
a	O
'	O
conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Temporal	O
control	O
of	O
IgH	O
gene	O
expression	O
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	O
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	O
3'LCR	O
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	O
gene	O
expression	O
and	O
compare	O
it	O
with	O
the	O
5'LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	B
cytokines	I
and	O
mononuclear	O
cell	O
attracting	O
chemokines	B
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF	B
-	I
kappa	I
B	I
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	O
cytokine	O
genes	O
,	O
but	O
can	O
not	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	O
genes	O
lack	O
respective	O
binding	O
sites	O
in	O
their	O
promoter	O
regions	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	B
factors	I
of	O
possible	O
importance	O
such	O
as	O
CREB	B
,	O
CTF	B
,	O
OTF-1	B
,	O
and	O
OTF-2	B
.	O

To	O
explore	O
long	O
-	O
term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	B
factors	I
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	B
transcription	I
factor	I
proteins	I
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell	O
-	O
type	O
-	O
specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
OFT-2	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
genes	O
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	O
significant	O
changes	O
were	O
detected	O
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	B
,	O
CTF	B
,	O
and	O
OTF-2	B
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	B
factor	I
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	B
factor	I
proteins	I
is	O
required	O
.	O

Genes	O
that	O
regulate	O
interleukin-4	B
expression	O
in	O
T	O
cells	O
.	O

Interleukin-4	B
is	O
an	O
immunomodulatory	B
cytokine	I
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	O
gene	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	B
factors	I
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	O
helper	O
cell	O
cytokine	O
gene	O
expression	O
.	O

Role	O
of	O
cyclic	B
AMP	I
response	I
element	I
-	I
binding	I
protein	I
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
.	O

The	O
NF	B
-	I
kappaB	I
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
elevation	O
of	O
intracellular	O
cyclic	O
AMP	O
inhibits	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
in	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
without	O
preventing	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
complexes	I
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	B
kinase	I
A	I
signaling	O
pathway	O
may	O
inhibit	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	B
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
amino	B
-	I
terminal	I
region	I
(	O
amino	B
acids	I
1	I
-	I
450	I
)	O
of	O
CBP	B
specifically	O
interacts	O
with	O
the	O
carboxyl	B
-	I
terminal	I
region	I
(	O
amino	B
acids	I
286	I
-	I
551	I
)	O
of	O
NF	B
-	I
kappaB	I
p65	B
(	O
RelA	B
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Functional	O
studies	O
using	O
human	O
endothelial	O
cells	O
demonstrated	O
that	O
overexpression	O
of	O
CBP	B
rescued	O
cAMP	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
and	O
transcription	O
mediated	O
by	O
a	O
chimeric	B
protein	I
,	O
GAL4-p65	B
(	I
286	I
-	I
551	I
)	I
,	O
which	O
contained	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
fused	O
to	O
the	O
carboxyl	B
-	I
terminal	I
region	I
of	O
p65	B
(	O
amino	B
acids	I
286	I
-	I
551	I
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	B
inhibited	O
GAL4	B
-p65	O
(	O
286	O
-	O
551	O
)	O
-mediated	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	B
kinase	I
A	I
pathway	O
inhibits	O
NF	B
-	I
kappaB	I
transcription	O
by	O
phosphorylating	O
CREB	B
,	O
which	O
competes	O
with	O
p65	B
for	O
limiting	O
amounts	O
of	O
CBP	B
.	O

Mycobacterium	O
tuberculosis	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
can	O
induce	O
NF	B
-	I
kappaB	I
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	B
-expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR	O
-	O
dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	B
tyrosine	I
kinase	I
(	I
s	I
)	I
,	O
protein	B
kinase	I
A	I
and/or	O
protein	B
kinase	I
C	I
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
-	O
driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappaB	I
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild	O
-	O
type	O
,	O
but	O
not	O
the	O
kappaB	O
-	O
mutated	O
,	O
HIV-1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	B
TNF	I
-	I
alpha	I
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Coactivation	O
by	O
OCA	B
-	I
B	I
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	B
-	I
B	I
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	O
promoters	O
through	O
interaction	O
with	O
octamer	B
-	I
bound	I
Oct-1	I
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	B
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct-1	O
and	O
OCA	O
-	O
B	O
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	B
and	O
the	O
PC4	B
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	B
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	B
/OCA	B
-	I
B	I
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	B
-	I
derived	I
PC2	I
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	B
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	B
in	O
the	O
reconstituted	O
system	O
,	O
OCA	B
-	I
B	I
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	B
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	B
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA	B
-	I
B	I
/	O
Oct-1	B
-dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct-1	B
and	O
OCA	B
-	I
B	I
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	B
coactivators	I
.	O

Differential	O
regulation	O
of	O
the	O
Janus	B
kinase	I
-STAT	B
pathway	O
and	O
biologic	O
function	O
of	O
IL-13	B
in	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
:	O
a	O
comparative	O
study	O
with	O
IL-4	B
.	O

IL-13	B
,	O
a	O
cytokine	O
similar	O
to	O
IL-4	B
,	O
is	O
a	O
regulator	O
of	O
human	O
B	O
cell	O
and	O
monocyte	O
functions	O
.	O

Biologic	O
effects	O
of	O
IL-13	B
on	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
have	O
not	O
been	O
well	O
defined	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
primary	O
NK	O
cells	O
,	O
IL-13	B
,	O
but	O
not	O
IL-4	B
,	O
may	O
induce	O
low	O
levels	O
of	O
IFN	B
-	I
gamma	I
secretion	O
.	O

When	O
NK	O
cells	O
were	O
costimulated	O
with	O
IL-13	B
and	O
IL-2	B
,	O
IL-13	B
generally	O
resulted	O
in	O
two	O
types	O
of	O
reactivity	O
:	O
IL-13	B
synergized	O
with	O
IL-2	B
to	O
stimulate	O
IFN	B
-	I
gamma	I
production	O
or	O
it	O
modestly	O
inhibited	O
IL-2	B
-mediated	O
IFN	B
-	I
gamma	I
production	O
.	O

In	O
both	O
types	O
of	O
donors	O
,	O
the	O
effect	O
of	O
IL-13	B
on	O
IL-2	B
-induced	O
IFN	B
-	I
gamma	I
production	O
was	O
in	O
marked	O
contrast	O
to	O
the	O
strong	O
inhibition	O
seen	O
with	O
IL-4	B
in	O
NK	O
cells	O
.	O

Additionally	O
,	O
IL-13	B
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	B
.	O

In	O
T	O
cells	O
,	O
IL-13	B
inhibits	O
anti	O
-	O
CD3	O
mAb	O
/	O
IL-2-	O
or	O
PHA	O
-	O
mediated	O
IFN	O
-	O
gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	B
,	O
like	O
IL-4	B
,	O
induces	O
distinct	O
STAT6-DNA	B
binding	I
complexes	I
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	B
and	O
Janus	B
kinase	I
3	I
(	O
JAK3	B
)	O
in	O
NK	O
and	O
T	O
cells	O
.	O

We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	B
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	O
cells	O
but	O
not	O
in	O
NK	O
cells	O
,	O
suggesting	O
different	O
STAT6	B
isoforms	I
.	O

These	O
findings	O
show	O
that	O
IL-13	B
and	O
IL-4	B
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B
and	O
JAK3	B
in	O
these	O
cell	O
types	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	B
factor	I
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	B
expression	O
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA	O
-	O
binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B
factors	I
:	O
NFkappaB	B
,	O
AP-1	B
and	O
NFAT	B
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	B
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	B
activity	O
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	B
factor	I
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	O
lymphocytes	O
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	B
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	B
factor	I
DNA	O
-	O
binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Macrophages	O
in	O
human	O
atheroma	O
contain	O
PPARgamma	B
:	O
differentiation	B
-	I
dependent	I
peroxisomal	I
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	B
activity	O
through	O
PPARgamma	B
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Mononuclear	O
phagocytes	O
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B
metalloproteinases	I
(	O
MMPs	B
)	O
,	O
including	O
MMP-9	B
.	O

Peroxisomal	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
,	O
a	O
transcription	B
factor	I
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O

The	O
role	O
of	O
PPARgamma	B
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O

We	O
report	O
here	O
that	O
monocytes	O
/	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	B
PPARgamma	I
.	O

Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	B
immunoreactive	I
PPARgamma	I
.	O

Human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	O
mRNA	O
and	O
protein	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
PPARgamma	O
mRNA	O
expression	O
in	O
U937	O
cells	O
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate	O
-	O
induced	O
differentiation	O
.	O

Stimulation	O
of	O
PPARgamma	B
with	O
troglitazone	O
or	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
inhibited	O
MMP-9	B
gelatinolytic	O
activity	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O

This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	B
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O

Thus	O
,	O
PPARgamma	B
is	O
present	O
in	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	B
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O

PPARgamma	B
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte	O
/	O
macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O

Suppression	O
of	O
human	O
anti	O
-	O
porcine	O
T	O
-	O
cell	O
immune	O
responses	O
by	O
major	O
histocompatibility	O
complex	O
class	O
II	O
transactivator	O
constructs	O
lacking	O
the	O
amino	O
terminal	O
domain	O
.	O

BACKGROUND	O
:	O
The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
is	O
a	O
bi-	B
or	I
multifunctional	I
domain	I
protein	I
that	O
acts	O
as	O
a	O
transcriptional	B
activator	I
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	O
CIITA	O
gene	O
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	B
terminal	I
151	I
amino	I
acids	I
,	O
acts	O
as	O
a	O
potent	O
dominant	O
-	O
negative	O
suppressor	O
of	O
HLA	B
class	I
II	I
expression	O
.	O

Porcine	B
MHC	I
class	I
II	I
antigens	I
are	O
potent	O
stimulators	O
of	O
direct	O
T	O
-	O
cell	O
recognition	O
by	O
human	O
CD4	O
+	O
T	O
cells	O
and	O
are	O
,	O
therefore	O
,	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
rejection	O
responses	O
to	O
transgenic	O
pig	O
donors	O
in	O
clinical	O
xenotransplantation	O
.	O

We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
examining	O
mutated	O
CIITA	O
constructs	O
for	O
their	O
effect	O
on	O
porcine	O
MHC	B
class	I
II	I
expression	O
.	O

METHODS	O
:	O
Stable	O
transfectants	O
of	O
the	O
porcine	O
vascular	O
endothelial	O
cell	O
line	O
PIEC	O
with	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
induction	O
by	O
recombinant	B
porcine	I
interferon	I
-	I
gamma	I
.	O

Transient	O
transfectants	O
of	O
the	O
porcine	O
B	O
-	O
cell	O
line	O
L23	O
with	O
the	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
expression	O
.	O

T	O
-	O
cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

RESULTS	O
:	O
In	O
preliminary	O
studies	O
,	O
we	O
demonstrated	O
that	O
transfection	O
of	O
the	O
PIEC	O
line	O
with	O
full	O
-	O
length	O
human	O
CIITA	O
constructs	O
resulted	O
in	O
strong	O
expression	O
of	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
antigens	O
,	O
thus	O
establishing	O
the	O
cross	O
-	O
species	O
effectiveness	O
of	O
human	B
CIITA	I
in	O
the	O
pig	O
.	O

The	O
mutated	O
human	O
CIITA	O
constructs	O
were	O
,	O
therefore	O
,	O
tested	O
in	O
the	O
pig	O
.	O

PIEC	O
clones	O
stably	O
transfected	O
with	O
one	O
of	O
these	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
antigen	O
induction	O
and	O
marked	O
suppression	O
of	O
SLA	O
-	O
DRA	O
mRNA	O
induction	O
.	O

Moreover	O
,	O
transient	O
transfection	O
of	O
the	O
porcine	O
B	O
-	O
cell	O
line	O
L23	O
showed	O
up	O
to	O
90	O
%	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
antigen	O
expression	O
in	O
5	O
-	O
8	O
days	O
.	O

In	O
functional	O
studies	O
,	O
interferon	O
-	O
gamma	O
-	O
stimulated	O
PIEC	O
clones	O
transfected	O
with	O
this	O
mutated	B
CIITA	I
construct	O
failed	O
to	O
stimulate	O
purified	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O

CONCLUSION	O
:	O
Mutated	O
human	O
CIITA	O
constructs	O
are	O
potent	O
suppressors	O
of	O
porcine	O
MHC	B
class	I
II	I
expression	O
.	O

Redox	O
signals	O
and	O
NF	B
-	I
kappaB	I
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL-2	B
,	O
IL-6	B
,	O
IL-8	B
,	O
and	O
several	O
T	B
cell	I
surface	I
receptors	I
.	O

Diminished	O
NF	B
-	I
kappaB	I
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF	B
-	I
kappaB	I
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF	B
-	I
kappaB	I
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV-1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	O
cell	O
lines	O
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF	B
-	I
kappaB	I
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF	B
-	I
kappaB	I
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF	B
-	I
kappaB	I
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF	B
-	I
kappaB	I
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF	B
-	I
kappaB	I
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF	B
-	I
kappaB	I
activation	O
may	O
be	O
relevant	O
to	O
immune	O
-	O
related	O
diseases	O
and	O
to	O
aging	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	B
transduction	I
molecules	I
.	O

The	O
adoptive	O
transfer	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti	B
-	I
CD3	I
and	O
interleukin	B
2	I
(	O
IL-2	B
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	O
modified	O
variant	O
(	O
designated	O
D5G6	O
)	O
that	O
secretes	O
granulocyte	B
/	I
macrophage	I
-	I
colony	I
-	I
stimulating	I
factor	I
.	O

In	O
contrast	O
to	O
anti	O
-	O
CD3	O
/	O
IL-2-activated	O
LN	O
cells	O
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
has	O
no	O
therapeutic	O
activity	O
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	B
kinases	I
p56lck	B
and	O
p59fyn	B
and	O
proteins	O
of	O
the	O
NF	B
-	I
kappaB	I
family	I
were	O
analyzed	O
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	O
of	O
p56lck	B
and	O
p59fyn	B
were	O
lower	O
in	O
tumor	O
-	O
draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine	B
-	I
phosphorylated	I
substrates	I
was	O
markedly	O
depressed	O
following	O
anti	B
-	I
CD3	I
stimulation	O
.	O

After	O
5-day	O
anti	B
-	I
CD3	I
/IL-2	B
activation	O
,	O
levels	O
of	O
p56lck	B
and	O
p59fyn	B
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	B
,	O
p59fyn	B
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c	B
-	I
Rel	I
and	O
Rel	B
A	I
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	B
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	B
-	I
CD3	I
mAb	I
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B
cell	I
receptor	I
/	I
CD3	I
complex	I
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	O
gene	O
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

MyD88	B
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	B
(	O
IL-1	B
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	B
receptor	I
complex	I
and	O
IL-1	B
receptor	I
-	I
associated	I
kinase	I
(	O
IRAK	B
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	B
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	B
in	O
response	O
to	O
IL-1	B
.	O

Increases	O
in	O
interferon	B
-	I
gamma	I
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	B
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL-18	B
-induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
is	O
blocked	O
in	O
MyD88-	O
/	O
-	O
Th1-developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B
receptor	I
as	O
well	O
as	O
IL-18	B
receptor	I
.	O

Characterization	O
of	O
cytokine	B
differential	O
induction	O
of	O
STAT	B
complexes	I
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
.	O

Cytokines	B
,	O
IL-2	B
,	O
IL-4	B
,	O
IL-6	B
,	O
IL-7	B
,	O
IL-12	B
,	O
and	O
IL-15	B
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O

Recent	O
studies	O
reveal	O
that	O
a	O
family	O
of	O
transcription	B
factors	I
,	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STATs	B
)	O
directly	O
mediate	O
many	O
cytokine	B
signals	O
.	O

We	O
analyzed	O
the	O
activation	O
of	O
STATs	B
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
by	O
a	O
variety	O
of	O
specific	O
cytokines	B
.	O

We	O
demonstrate	O
that	O
IL-12	B
induces	O
STAT4	B
only	O
in	O
freshly	O
isolated	O
primary	O
NK	O
cells	O
,	O
but	O
not	O
in	O
primary	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
the	O
IL-12	B
receptor	I
in	O
resting	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
IL-4	B
induces	O
different	O
C	B
epsilon	I
GAS	I
DNA	I
-	I
protein	I
binding	I
complexes	I
in	O
both	O
T	O
and	O
NK	O
cells	O
.	O

Moreover	O
,	O
IL-4	B
costimulation	O
with	O
IL-2	B
or	O
IL-12	B
does	O
not	O
alter	O
their	O
own	O
preferential	O
GAS	O
-like	O
DNA	O
binding	O
patterns	O
when	O
C	O
epsilon-	O
,	O
Fc	O
gamma	O
RI-	O
,	O
and	O
SIE	O
GAS	O
motif	O
containing	O
oligonucleotide	O
probes	O
are	O
compared	O
,	O
suggesting	O
that	O
induction	O
of	O
GAS	B
-	I
like	I
DNA	I
-	I
protein	I
binding	I
complexes	I
by	O
IL-2	B
,	O
IL-4	B
,	O
and	O
IL-12	B
is	O
highly	O
selective	O
and	O
represents	O
one	O
important	O
factor	O
in	O
determining	O
specific	O
gene	O
activation	O
.	O

In	O
addition	O
,	O
IL-6	B
and	O
IL-2	B
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	B
alpha	I
and	O
STAT3	B
in	O
both	O
NK	O
and	O
T	O
cells	O
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	O
gene	O
expression	O
.	O

We	O
further	O
demonstrated	O
that	O
IL-2	B
,	I
-7	I
,	I
and	I
-15	I
induce	O
multiple	B
STAT	I
proteins	I
,	O
including	O
STAT5a	B
,	O
STAT5b	B
,	O
STAT1	B
alpha	I
,	O
STAT3	B
,	O
and	O
another	O
unidentified	O
Fc	B
gamma	I
RI	I
GAS	I
DNA	I
-	I
binding	I
protein	I
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B
and	O
STAT5b	B
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	O
and	O
NK	O
cells	O
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	O
and	O
T	O
cells	O
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	B
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	B
transcription	I
factors	I
.	O

Interleukin-6	B
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O

Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	B
and	O
recruitment	O
of	O
neutrophils	O
(	O
PMN	O
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	B
(	O
IL-6	B
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	B
and	O
activation	O
of	O
Stat3	B
.	O

Using	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	O
mRNA	O
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Increased	O
IL-6	B
protein	O
expression	O
was	O
localized	O
to	O
bronchial	O
and	O
alveolar	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B
activation	O
with	O
kinetics	O
similar	O
to	O
IL-6	O
mRNA	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B
activation	O
predominantly	O
within	O
alveoli	O
.	O

Intratracheal	O
instillation	O
of	O
IL-6	B
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
.	O

These	O
findings	O
indicate	O
that	O
IL-6	B
production	O
and	O
Stat3	B
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN	O
-	O
mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

Activation	O
of	O
distinct	O
transcription	B
factors	I
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon	B
-	I
gamma	I
,	O
and	O
GM	B
-	I
CSF	I
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	B
proteases	I
.	O

Human	O
neutrophils	O
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early	O
-	O
response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B
,	O
chemokines	B
,	O
and	O
the	O
high	O
-	O
affinity	O
surface	O
receptor	O
for	O
IgG	B
,	O
FcgammaRI	B
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	B
factors	I
,	O
such	O
as	O
members	O
of	O
the	O
NF	B
-	I
kappaB	I
and	O
STAT	B
families	I
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	B
factors	I
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	B
-	I
kappaB	I
/	I
Rel	I
and	O
STAT	B
proteins	I
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	B
induce	O
a	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50	B
/	I
RelA	I
dimers	I
,	O
and	O
that	O
IFNgamma	B
promotes	O
the	O
binding	O
of	O
STAT1	B
homodimers	I
to	O
the	O
IFNgamma	O
response	O
region	O
of	O
the	O
FcgammaRI	O
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM	B
-	I
CSF	I
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	B
-containing	O
DNA	O
-	O
binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	B
proteases	I
.	O

Prostaglandin	O
E2	O
Up	O
-	O
regulates	O
HIV-1	O
long	O
terminal	O
repeat	O
-driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B
and	I
host	I
cellular	I
factors	I
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	B
immunomodulatory	I
molecule	I
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	O
,	O
a	O
Jurkat	O
-	O
derived	O
T	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	O
LTR	O
-mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	B
messengers	I
involved	O
in	O
this	O
PGE2-dependent	O
up	O
-	O
regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B
kinase	I
A	I
,	O
and	O
Ca2	O
+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	O
LTR	O
-	O
based	O
vectors	O
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF	B
-	I
kappaB	I
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB	O
-	O
regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	O
LTR	O
-driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	B
receptor	I
subtype	I
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV-1	O
.	O

Differential	O
regulation	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Coproporphyrinogen	B
oxidase	I
(	O
CPO	B
)	O
catalyzes	O
the	O
sixth	O
step	O
of	O
the	O
heme	B
biosynthetic	O
pathway	O
.	O

To	O
assess	O
the	O
tissue	O
-	O
specific	O
regulation	O
of	O
the	O
CPO	O
gene	O
promoter	O
,	O
mouse	O
genomic	O
DNA	O
clones	O
for	O
CPO	B
were	O
isolated	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
mouse	O
CPO	O
gene	O
spans	O
approximately	O
11	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
,	O
just	O
like	O
its	O
human	O
counterpart	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
by	O
transient	O
transfection	O
assays	O
indicated	O
that	O
synergistic	O
action	O
between	O
an	O
SP-1-like	O
element	O
at	O
-21	O
/	O
-12	O
,	O
a	O
GATA	O
site	O
at	O
-59	O
/	O
-54	O
,	O
and	O
a	O
novel	O
regulatory	O
element	O
,	O
CPRE	O
(	O
-	O
GGACTACAG	O
-	O
)	O
at	O
-49	O
/	O
-41	O
,	O
is	O
essential	O
for	O
the	O
promoter	O
activity	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
.	O

In	O
nonerythroid	O
NIH3T3	O
cells	O
,	O
however	O
,	O
the	O
GATA	O
site	O
is	O
not	O
required	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
specific	O
DNA	B
-	I
protein	I
complexes	I
can	O
be	O
formed	O
with	O
each	O
element	O
,	O
and	O
that	O
there	O
are	O
cell	O
-	O
specific	O
differences	O
in	O
factors	O
,	O
which	O
bind	O
to	O
the	O
SP-1-like	O
element	O
between	O
MEL	O
and	O
NIH3T3	O
cells	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	B
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O

Interleukin	B
1beta	I
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	O
on	O
LNCaP	O
human	O
prostate	O
cancer	O
cells	O
.	O

Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen	O
-	O
sensitive	O
prostate	O
cancer	O
LNCaP	O
cells	O
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation	O
-	O
promoting	O
substances	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	O
blood	O
monocytes	O
that	O
exhibit	O
anti	O
-	O
tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	O
cell	O
line	O
.	O

For	O
this	O
purpose	O
,	O
LNCaP	O
cells	O
were	O
incubated	O
with	O
monocyte	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	B
receptor	I
(	O
AR	B
)	O
and	O
secretion	O
of	O
prostate	B
-	I
specific	I
antigen	I
(	O
PSA	B
)	O
were	O
assessed	O
.	O

Conditioned	O
medium	O
from	O
monocytes	O
reduced	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
40	O
%	O
MCM	O
caused	O
a	O
50	O
%	O
reduction	O
in	O
cell	O
proliferation	O
.	O

AR	B
protein	I
decreased	O
by	O
70	O
%	O
and	O
PSA	B
levels	O
in	O
supernatants	O
from	O
LNCaP	O
cells	O
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	O
,	O
prostaglandin	O
E2	O
and	O
interleukin	B
1beta	I
(	O
IL-1beta	B
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O

LNCaP	O
cells	O
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
levels	O
.	O

The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	B
protein	I
and	O
PSA	B
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti	B
-	I
IL-1beta	I
antibody	I
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	B
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
proteins	O
.	O

LNCaP	O
cells	O
were	O
shown	O
to	O
express	O
the	O
IL-1beta	B
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	B
signal	O
.	O

Our	O
findings	O
reveal	O
that	O
monocyte	B
-	I
derived	I
IL-1beta	I
inhibits	O
the	O
proliferation	O
of	O
androgen	O
-	O
responsive	O
prostate	O
tumour	O
cells	O
and	O
reduces	O
AR	B
and	O
PSA	B
levels	O
.	O

p21ras	B
initiates	O
Rac-1	B
but	O
not	O
phosphatidyl	B
inositol	I
3	I
kinase	I
/	I
PKB	I
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	B
is	O
activated	O
by	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	B
lymphocyte	I
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	B
nucleotide	I
binding	I
protein	I
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	B
/	I
threonine	I
kinase	I
Raf-1	B
and	O
the	O
Ras	B
-	I
related	I
GTPase	I
Rac-1	B
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	B
3-kinase	I
(	O
PtdIns	B
3-kinase	I
)	O
.	O

Activation	O
of	O
this	O
lipid	B
kinase	I
is	O
able	O
to	O
induce	O
critical	O
Rac-1	B
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	B
/	I
threonine	I
kinase	I
Akt	I
/	I
PKB	I
.	O

The	O
role	O
of	O
PtdIns	B
3-kinase	I
in	O
Ras	B
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	B
3-kinase	I
to	O
initiate	O
the	O
Rac-1	B
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	B
/	I
PKB	I
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	B
can	O
initiate	O
a	O
Rac-1	B
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	B
complexes	I
.	O

PtdIns	B
3-kinase	I
signals	O
can	O
not	O
mimic	O
p21ras	B
and	O
induce	O
the	O
Rac	B
mediated	O
responses	O
of	O
AP-1	B
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	B
or	O
Ras	B
activation	O
of	O
AP-1	B
is	O
dependent	O
on	O
PtdIns	B
3-kinase	I
.	O

PKB	B
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
;	O
PtdIns	B
3-kinase	I
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	B
response	O
.	O

In	O
contrast	O
,	O
p21ras	B
signals	O
are	O
unable	O
to	O
induce	O
Akt	B
/	I
PKB	I
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	B
function	O
required	O
for	O
Akt	B
/	I
PKB	I
activation	O
in	O
response	O
to	O
the	O
TCR	B
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	B
3-kinase	I
and	O
Akt	B
/	I
PKB	I
are	O
not	O
universal	O
Ras	B
effector	I
molecules	I
.	O

Ras	B
can	O
initiate	O
Rac-1	B
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	B
cell	I
antigen	I
receptor	I
function	O
independently	O
of	O
PtdIns	B
3-kinase	I
activity	O
.	O

Differential	O
effects	O
of	O
protein	B
kinase	I
C	I
inhibitors	O
on	O
fibronectin	B
-induced	O
interleukin	O
-	O
beta	O
gene	O
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
when	O
stimulated	O
with	O
the	O
extracellular	B
matrix	I
glycoprotein	I
,	O
fibronectin	B
(	O
FN	B
)	O
.	O

Protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	B
acts	O
upon	O
to	O
mediate	O
the	O
FN	B
-induced	O
IL-1beta	B
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	B
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B
-induced	O
IL-1beta	B
response	O
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	B
protein	I
into	O
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	B
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	B
protein	I
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full	O
-	O
length	O
IL-1beta	O
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
activator	I
protein-1	I
(	O
AP-1	B
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	B
induction	O
of	O
IL-1beta	B
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	B
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	B
,	O
we	O
conclude	O
that	O
PKC	B
is	O
necessary	O
for	O
FN	B
-induced	O
IL-1beta	B
protein	O
production	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL-1beta	B
by	O
unknown	O
mechanisms	O

In	O
situ	O
RT	O
-	O
PCR	O
detection	O
of	O
Epstein	O
-	O
Barr	O
virus	O
immediate	O
-	O
early	O
transcripts	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

AIDS	O
-	O
related	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O

The	O
pathway	O
whereby	O
EBV	O
infects	O
T	O
cells	O
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	O
cells	O
has	O
not	O
been	O
established	O
.	O

In	O
order	O
to	O
shed	O
light	O
on	O
the	O
early	O
events	O
of	O
the	O
EBV	O
infection	O
of	O
T	O
cells	O
,	O
we	O
have	O
used	O
in	O
situ	O
reverse	O
transcription	O
based	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
study	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
homogeneous	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
.	O

Following	O
EBV	O
infection	O
,	O
Epstein	O
-	O
Barr	O
nuclear	O
antigen	O
(	O
EBNA	B
)	O
expression	O
could	O
be	O
detected	O
in	O
T	O
rosetting	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

Only	O
a	O
few	O
cells	O
showed	O
viral	B
capsid	I
antigen	I
(	O
VCA	B
)	O
.	O

EBV	O
immediate	O
-	O
early	O
gene	O
transcripts	O
(	O
BZLF1	O
,	O
BRLF1	O
,	O
and	O
BMLF1	O
)	O
encoded	O
in	O
the	O
BamHI	O
Z	O
,	O
R	O
,	O
and	O
M	O
fragments	O
could	O
be	O
detected	O
by	O
in	O
situ	O
RT	O
-	O
PCR	O
in	O
the	O
EBV	O
producer	O
cell	O
line	O
B95.8	O
.	O

Both	O
BZLF1	O
and	O
BRLF1	O
immediate	O
-	O
early	O
transcripts	O
,	O
but	O
not	O
BMLF1	O
transcript	O
,	O
could	O
be	O
detected	O
in	O
individual	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
infected	O
with	O
EBV	O
.	O

Demonstration	O
of	O
EBV	O
mRNA	O
transcripts	O
encoding	O
immediate	B
-	I
early	I
transcriptional	I
transactivators	I
in	O
EBV	O
-	O
infected	O
T	O
cells	O
provides	O
the	O
first	O
evidence	O
for	O
a	O
possible	O
mechanism	O
whereby	O
EBV	O
could	O
contribute	O
to	O
T	O
cell	O
proliferation	O
and	O
EBV	O
-	O
associated	O
T	O
cell	O
malignancies	O
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	O
human	O
T	O
cells	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
by	O
dendritic	O
cells	O
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APC	O
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	O
DC	O
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	O
CD4	O
+	O
T	O
cells	O
to	O
epitopes	B
of	O
the	O
immediate	B
early	I
62	I
(	I
IE62	I
)	I
protein	I
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

The	O
induction	O
of	O
CD4	B
+	I
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	B
IE62	I
protein	I
was	O
assessed	O
using	O
T	O
cells	O
and	O
DC	O
from	O
VZV	O
-	O
susceptible	O
donors	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	O
T	O
cells	O
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

T	O
cell	O
proliferation	O
was	O
induced	O
by	O
three	O
peptides	O
,	O
P1	O
,	O
P4	O
,	O
and	O
P7	O
,	O
in	O
71	O
-	O
100	O
%	O
of	O
the	O
donors	O
tested	O
before	O
and	O
after	O
vaccination	O
using	O
DC	O
as	O
APC	O
.	O

Monocytes	O
were	O
effective	O
APC	O
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	O
cells	O
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	O
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	O
as	O
APC	O
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	O
as	O
APC	O
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

A	O
novel	O
growth	O
-	O
factor	O
-	O
dependent	O
myeloid	O
cell	O
line	O
derived	O
from	O
mouse	O
bone	O
marrow	O
cells	O
contains	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
.	O

Constitutive	O
expression	O
of	O
human	B
colony	I
-	I
stimulating	I
factor-1	I
receptor	I
(	O
CSF-1R	B
)	O
confers	O
long	O
-	O
lasting	O
CSF-1	B
-dependent	O
proliferation	O
to	O
mouse	O
myeloid	O
cell	O
lines	O
.	O

We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	B
because	O
mouse	O
CSF-1	B
can	O
not	O
activate	O
human	O
CSF-1R	B
.	O

Then	O
bone	O
marrow	O
cells	O
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	B
form	I
of	O
human	B
CSF-1	I
(	O
2M-1	O
cells	O
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	O
cells	O
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	B
.	O

Thus	O
,	O
we	O
were	O
able	O
to	O
derive	O
a	O
hematopoietic	O
cell	O
line	O
,	O
called	O
47.10	O
,	O
that	O
grew	O
indefinitely	O
under	O
these	O
conditions	O
,	O
whereas	O
no	O
cell	O
line	O
could	O
be	O
developed	O
from	O
nontransgenic	O
mice	O
.	O

Proliferation	O
of	O
47.10	O
cells	O
is	O
severely	O
affected	O
by	O
neutralizing	O
anti	B
-	I
CSF-1R	I
monoclonal	I
antibodies	I
.	O

Morphologic	O
and	O
cytofluorometry	O
analysis	O
established	O
that	O
most	O
47.10	O
cells	O
are	O
immature	O
myelomonocytic	O
cells	O
.	O

Consistent	O
with	O
this	O
phenotype	O
,	O
the	O
myeloid	B
transcription	I
factor	I
PU.1	I
,	O
but	O
not	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	I
,	O
is	O
expressed	O
in	O
47.10	O
cells	O
.	O

A	O
few	O
47.10	O
cells	O
(	O
3	O
-	O
5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage	O
-	O
positive	O
cells	O
after	O
replating	O
on	O
2M-1	O
cells	O
.	O

In	O
agar	O
cultures	O
,	O
47.10	O
cells	O
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
2.5	O
ng	O
/	O
mL	O
)	O
,	O
interleukin-3	B
(	O
1	O
ng	O
/	O
mL	O
)	O
,	O
and	O
mouse	O
CSF-1	B
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
about	O
0.5	O
%	O
of	O
47.10	O
cells	O
formed	O
large	O
14-day	O
colonies	O
(	O
>	O
1	O
mm	O
)	O
composed	O
of	O
mature	O
monocytes	O
and	O
granulocytes	O
,	O
reflecting	O
the	O
presence	O
of	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
(	O
HPP-47.10	O
cells	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	O
myeloid	O
cell	O
line	O
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	O
marrow	O
progenitor	O
cell	O
compartment	O
.	O

Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	O
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O

The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	B
hormone	I
receptor	I
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Significantly	O
increased	O
oestrogen	B
receptor	I
expression	O
,	O
bcl-2	B
expression	O
and	O
numbers	O
of	O
CD8	O
+	O
leukocytes	O
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56	O
+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Apoptotic	O
cells	O
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O

In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	B
hormone	I
receptor	I
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O

The	O
unusual	O
CD56	O
+	O
CD16-	O
eGLs	O
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56	O
+	O
CD16	O
+	O
natural	O
killer	O
cells	O
.	O

eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U	O
/	O
ml	O
interleukin-2	B
over	O
48-h	O
and	O
120-h	O
time	O
courses	O
.	O

eGLs	O
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD+8	O
T	O
-	O
cell	O
numbers	O
and	O
increased	O
oestrogen	B
receptor	I
and	O
bcl-2	B
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	B
or	O
protease	B
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long	O
-	O
terminal	O
repeat	O
transcription	O
in	O
HIV	O
-	O
infected	O
cells	O
and	O
increased	O
NF	B
-	I
kappaB	I
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF	B
-	I
ATc	I
in	O
effector	O
T	O
cells	O
.	O

The	O
transcription	B
factor	I
NF	B
-	I
ATc	I
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	B
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	O
'	O
polyA	O
site	O
to	O
a	O
more	O
proximal	O
polyA	O
site	O
,	O
NF	B
-	I
ATc	I
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	O
T	O
cells	O
to	O
that	O
of	O
short	O
isoform	B
A	I
in	O
T	O
effector	O
cells	O
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	B
stimulation	I
factor	I
CstF-64	B
to	O
the	O
proximal	O
polyA	O
site	O
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	O
T	O
cells	O
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF	B
-	I
ATc	I
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF	B
-	I
ATc	I
for	O
gene	O
induction	O
in	O
effector	O
T	O
cells	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
cell	O
line	O
(	O
UF-1	O
)	O
associated	O
with	O
expression	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all	O
-	O
trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	B
factors	I
:	O
RA	B
receptors	I
(	O
RARs	B
)	O
and	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
.	O

RXRs	B
heterodimerize	O
with	O
1	B
,	I
25-dihydroxyvitamin	I
D3	I
[	I
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
]	I
receptor	I
(	O
VDR	B
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin	B
-	I
dependent	I
kinase	I
(	I
cdk	I
)	I
inhibitor	I
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
has	O
a	O
vitamin	O
D3-responsive	O
element	O
(	O
VDRE	O
)	O
in	O
its	O
promoter	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	O
leukemic	O
cell	O
lines	O
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	O
cell	O
line	O
(	O
UF-1	O
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF-1	O
cells	O
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all	O
-	O
trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-10	O
)	O
to	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	B
(	I
KIP1	I
)	I
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF-1	O
cells	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B
(	I
KIP1	I
)	I
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B
(	I
KIP1	I
)	I
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B
antigen	I
in	O
myeloid	O
leukemic	O
cells	O
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF-1	O
cells	O
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
transcript	O
and	O
protein	O
expression	O
in	O
RA	O
-	O
resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	B
inhibitors	I
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA	O
-	O
resistant	O
UF-1	O
cells	O
toward	O
mature	O
granulocytes	O
.	O

IL-2	B
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	B
-	I
kappa	I
B	I
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL-2	B
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL-2	B
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and/or	O
activating	B
protein-1	I
(	O
AP-1	B
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	B
factors	I
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	B
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	B
does	O
not	O
induce	O
I	B
kappa	I
B	I
alpha	O
degradation	O
or	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL-2	B
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL-2	B
neither	O
activates	O
JNK	B
nor	O
increases	O
AP-1	B
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	B
factor	I
does	O
induce	O
the	O
activation	O
of	O
STAT3	B
and	O
STAT5	B
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	B
-	I
kappa	I
B	I
nor	O
AP-1	B
activation	O
is	O
required	O
for	O
IL-2	B
-mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitor	O
I	B
kappa	I
B	I
alpha	I
(	O
mut	B
-	I
I	I
kappa	I
B	I
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	B
-	I
I	I
kappa	I
B	I
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B
-CD25	O
+	O
,	O
CD4	B
-	O
CD8	B
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B
beta	I
-	I
chain	I
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	B
-	I
I	I
kappa	I
B	I
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	B
aldosterone	I
receptors	I
outside	O
the	O
acute	O
phase	O
.	O

Pseudo	O
-	O
hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54-year	O
-	O
old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i.e.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80	O
/	O
60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol	O
/	O
l	O
)	O
;	O
hyperkalemia	O
(	O
7.6	O
mmol	O
/	O
l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg	O
/	O
dl	O
)	O
and	O
creatininemia	O
(	O
2.5	O
mg	O
/	O
dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3-	O
:	O
16	O
mmol	O
/	O
l	O
;	O
N	O
:	O
27	O
-	O
30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg	O
/	O
100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8	O
-	O
15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg	O
/	O
ml	O
,	O
N	O
:	O
10	O
-	O
60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng	O
/	O
ml	O
/	O
h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol	O
/	O
l	O
;	O
N	O
:	O
0.5	O
-	O
2.5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol	O
/	O
l	O
(	O
N	O
supine	O
:	O
5	O
-	O
25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1.4+	O
/	O
-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2.7+	O
/	O
-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+	O
/	O
-0.36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+	O
/	O
-0.42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	B
receptors	I
in	O
mononuclear	O
leukocytes	O
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
was	O
reduced	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE	O
/	O
THF	O
and	O
alpha	O
THF	O
/	O
THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	B
mineralocorticoid	I
receptors	I
outside	O
the	O
acute	O
episode	O
.	O

SHP2-interacting	B
transmembrane	I
adaptor	I
protein	I
(	O
SIT	B
)	O
,	O
a	O
novel	O
disulfide	B
-	I
linked	I
dimer	I
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	B
molecular	I
weight	I
transmembrane	I
adaptor	I
proteins	I
that	O
recruit	O
src	B
homology	I
(	I
SH	I
)	I
2	I
domain	I
-	I
containing	I
intracellular	I
molecules	I
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	B
(	O
SHP2	B
interacting	I
transmembrane	I
adaptor	I
protein	I
)	O
.	O

SIT	B
is	O
a	O
disulfide	B
-	I
linked	I
homodimeric	I
glycoprotein	I
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	B
and	O
possibly	O
syk	B
protein	B
tyrosine	I
kinases	I
SIT	B
recruits	O
the	O
SH2	B
domain	I
-	I
containing	I
tyrosine	I
phosphatase	I
SHP2	B
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	B
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	B
C	I
.	O

However	O
,	O
binding	O
of	O
SHP2	B
to	O
SIT	B
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	B
-	I
AT	I
induction	O
,	O
suggesting	O
that	O
SIT	B
not	O
only	O
regulates	O
NF	B
-	I
AT	I
activity	O
but	O
also	O
controls	O
NF	B
-	I
AT	I
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	B
.	O

GrpL	B
,	O
a	O
Grb2	B
-related	O
adaptor	B
protein	I
,	O
interacts	O
with	O
SLP-76	B
to	O
regulate	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	B
domain	I
-	I
containing	I
protein	I
76	I
(	O
SLP-76	B
)	O
interacts	O
with	O
the	O
guanine	B
nucleotide	I
exchange	I
factor	I
Vav	B
to	O
activate	O
the	O
nuclear	B
factor	I
of	I
activated	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	B
adaptor	I
molecule	I
designated	O
as	O
Grb2-related	B
protein	I
of	I
the	I
lymphoid	I
system	I
(	O
GrpL	B
)	O
.	O

Expression	O
of	O
GrpL	B
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B
by	O
having	O
a	O
proline	B
-	I
rich	I
region	I
.	O

GrpL	B
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	B
but	O
not	O
with	O
Sos1	B
or	O
Sos2	B
from	O
Jurkat	O
cell	O
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	B
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	B
and	O
Sos2	B
but	O
not	O
with	O
SLP-76	B
.	O

Moreover	O
,	O
tyrosine	B
-	I
phosphorylated	I
LAT	I
/	I
pp36	I
/	I
38	I
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	B
but	O
not	O
GrpL	B
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	B
and	O
Grb2	B
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL	B
-	I
SLP-76	I
complex	I
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	B
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	B
to	O
augment	O
NF	B
-	I
AT	I
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Transcription	B
factors	I
Sp1	B
and	O
AP-2	B
mediate	O
induction	O
of	O
acid	B
sphingomyelinase	I
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12-myristate	O
-13-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25-dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	B
enzyme	I
acid	B
sphingomyelinase	I
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	O
cells	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	O
mononuclear	O
phagocytes	O
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	B
protection	O
assay	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell	O
-	O
type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	O
'	O
deletion	O
derivatives	O
of	O
the	O
upstream	O
regulatory	O
region	O
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	O
elements	O
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-319	O
and	O
-219	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	O
factor	O
expression	O
plasmids	O
for	O
AP-2	B
and	O
Sp1	B
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	O
sites	O
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B
and	O
AP-2	B
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP-1	O
cells	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	B
factors	I
AP-2	B
and	O
Sp1	B
is	O
essential	O
for	O
the	O
up	O
-regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

Grf40	B
,	O
A	O
novel	O
Grb2	B
family	I
member	I
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP-76	B
and	O
LAT	B
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	B
family	I
member	I
,	O
named	O
Grf40	B
,	O
containing	O
the	O
common	O
SH3-SH2-SH3	B
motif	I
.	O

Expression	O
of	O
Grf40	B
is	O
predominant	O
in	O
hematopoietic	O
cells	O
,	O
particularly	O
T	O
cells	O
.	O

Grf40	B
binds	O
to	O
the	O
SH2	B
domain	I
-	I
containing	I
leukocyte	I
protein	I
of	O
76	O
kD	O
(	O
SLP-76	B
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B
.	O

Incidentally	O
,	O
Grf40	B
binds	O
to	O
linker	B
for	I
activation	I
of	I
T	I
cells	I
(	O
LAT	B
)	O
possibly	O
via	O
its	O
SH2	B
domain	I
.	O

Overexpression	O
of	O
wild	B
-	I
type	I
Grf40	I
in	O
Jurkat	O
cells	O
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
and	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
(	O
NF	B
-	I
AT	I
)	O
activation	O
upon	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
stimulation	O
,	O
whereas	O
the	O
COOH	B
-	I
terminal	I
SH3-deleted	I
Grf40	I
mutant	I
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
the	O
SH2-deleted	B
Grf40	I
mutant	I
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2-deleted	B
Grb2	I
mutant	I
.	O

Our	O
data	O
suggest	O
that	O
Grf40	B
is	O
an	O
adaptor	B
molecule	I
involved	O
in	O
TCR	B
-mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	B
with	O
SLP-76	B
and	O
LAT	B
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	B
T	I
-	I
cell	I
mitogens	I
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	O
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	B
-	I
kappaB	I
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	B
molecules	I
.	O

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV-1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

HLA	B
class	I
I	I
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	O
E	O
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	B
class	I
I	I
Ags	I
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B
class	I
I	I
molecules	I
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	B
class	I
I	I
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B
protein	I
in	O
the	O
T	O
cell	O
line	O
Jurkat	O
as	O
well	O
as	O
human	O
aortic	O
endothelial	O
cells	O
.	O

HLA	B
class	I
I	I
-mediated	O
inactivation	O
of	O
Rb	B
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	B
Abs	I
to	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	B
receptors	I
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	B
class	I
I	I
molecules	I
induced	O
cyclin	O
E	O
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	O
endothelial	O
cells	O
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	O
-	O
negative	O
cdk2	O
construct	O
prevented	O
HLA	B
class	I
I	I
-mediated	O
inactivation	O
of	O
Rb	B
;	O
in	O
contrast	O
,	O
dominant	O
-	O
negative	O
cdk4	O
and	O
cdk6	O
constructs	O
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	B
D	I
-	I
associated	I
kinase	I
activity	O
upon	O
HLA	B
class	I
I	I
ligation	O
,	O
suggesting	O
that	O
cyclin	B
E	I
-	I
dependent	I
kinase	I
activity	O
mediates	O
Rb	B
inactivation	O
,	O
leading	O
to	O
E2F	B
activation	O
and	O
cell	O
proliferation	O
.	O

Protein	B
kinase	I
B	I
(	O
c	B
-	I
Akt	I
)	O
,	O
phosphatidylinositol	B
3-kinase	I
,	O
and	O
STAT5	B
are	O
activated	O
by	O
erythropoietin	B
(	O
EPO	B
)	O
in	O
HCD57	O
erythroid	O
cells	O
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO	O
-	O
independent	O
,	O
apoptosis	O
-	O
resistant	O
subclone	O
(	O
HCD57-SREI	O
cells	O
)	O
.	O

We	O
found	O
that	O
erythropoietin	B
(	O
EPO	B
)	O
and	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
activated	B
protein	I
kinase	I
B	I
(	O
PKB	B
/	I
Akt	I
)	O
in	O
EPO	O
-	O
dependent	O
HCD57	O
erythroid	O
cells	O
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	O
cells	O
)	O
.	O

Constitutive	O
activations	O
of	O
PKB	B
/	I
Akt	I
,	O
STAT5a	B
,	O
and	O
STAT5b	B
were	O
noted	O
in	O
these	O
EPO	O
-	O
independent	O
cells	O
.	O

PI3-kinase	B
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB	B
/	I
Akt	I
because	O
the	O
PI3-kinase	B
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB	B
/	I
Akt	I
and	O
factor	O
-	O
dependent	O
PKB	B
/	I
Akt	I
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	O
and	O
HCD57	O
cells	O
correlated	O
with	O
the	O
activity	O
of	O
PKB	B
/	I
Akt	I
;	O
however	O
,	O
PKB	B
/	I
Akt	I
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	O
cells	O
with	O
SCF	B
also	O
activated	O
PKB	B
/	I
Akt	I
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB	B
/	I
PI3-kinase	I
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Constitutive	O
STAT5	B
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B
or	O
EPOR	B
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B
/PKB	B
/	I
Akt	I
pathway	O
to	O
protect	O
the	O
EPO	O
-	O
independent	O
HCD57-SREI	O
cells	O
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta	O
-	O
globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
assumes	O
a	O
transcriptionally	O
-	O
active	O
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta	O
-	O
globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	O
-	O
specific	O
DNase	O
1	O
hypersensitive	O
site	O
-	O
forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF	B
-	I
E2	I
,	O
AP-1	B
,	O
GATA-1	B
and	O
Sp-1	B
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B
1	I
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta	O
-	O
globin	O
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta	O
-	O
globin	O
gene	O
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	O
-	O
globin	O
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis	O
-	O
acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta	O
-	O
globin	O
gene	O
expression	O
.	O

Modulation	O
of	O
CD28	B
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	B
molecule	I
CD28	B
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

Although	O
CD28	B
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down	O
-	O
regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	B
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein	O
-	O
binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	B
alpha	I
and	I
beta	I
,	O
within	O
the	O
CD28	O
minimal	O
promoter	O
.	O

Both	O
alpha-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	O
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	O
B	O
cells	O
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down	O
-	O
modulation	O
of	O
site	B
beta	I
-but	O
not	O
site	B
alpha	I
-binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta	O
-	O
binding	O
activities	O
.	O

CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
differ	O
in	O
their	O
beta	O
-	O
binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down	O
-	O
regulation	O
of	O
CD28	B
in	O
senescent	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	O
and	O
CD8+CD28null	O
T	O
cells	O
uniformly	O
lack	O
alpha-	B
and	I
beta-	I
bound	I
complexes	I
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	O
activated	O
cells	O
and	O
not	O
of	O
senescent	O
cells	O
.	O

UV	O
-	O
induced	O
CYP1A1	B
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	B
P-4501A1	I
(	O
CYP1A1	B
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah	O
-	O
receptor	O
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B
P4501A1	I
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	O
mRNA	O
by	O
UV	O
irradiation	O
of	O
cultured	O
human	O
keratinocytes	O
(	O
HaCaT	O
cell	O
line	O
)	O
,	O
primary	O
human	O
blood	O
lymphocytes	O
and	O
mouse	O
Hepa-1	O
cells	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20	O
/	O
12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	B
transcriptase	I
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	O
mRNA	O
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	O
cells	O
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	O
receptor	O
ligand	O
,	O
Hepa-1	O
wild	O
-	O
type	O
and	O
Ah	O
receptor	O
deficient	O
c12	O
cell	O
lines	O
were	O
applied	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
cells	O
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6-formylindolo	O
[	O
3	O
,	O
2-b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B
receptor	I
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV	O
-	O
induced	O
CYP1A1	B
gene	O
expression	O
in	O
mammalian	O
cells	O
is	O
mediated	O
by	O
an	O
Ah	B
receptor	I
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B
receptor	I
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell	B
-	I
surface	I
receptors	I
,	O
intracellular	B
signaling	I
molecules	I
,	O
and	O
nuclear	B
transcription	I
factors	I
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	B
cell	I
transcription	I
factors	I
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	B
,	O
LKLF	B
,	O
and	O
GATA3	B
zinc	I
-	I
finger	I
proteins	I
;	O
the	O
Ets	B
,	O
CREB	B
/	I
ATF	I
,	O
and	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
/	I
NFAT	I
transcription	I
factors	I
;	O
the	O
Stat	B
proteins	I
;	O
and	O
HMG	B
box	I
transcription	I
factors	I
such	O
as	O
LEF1	B
,	O
TCF1	B
,	O
and	O
Sox4	B
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

20-Epi	O
analogues	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	B
coactivator	I
complex	I
binding	O
to	O
the	O
vitamin	B
D3	I
receptor	I
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	O
(	O
Waf1	O
,	O
Cip1	O
)	O
,	O
a	O
key	O
VDR	O
target	O
gene	O
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B
interacting	O
proteins	O
:	O
RXR	B
,	O
GRIP-1	B
,	O
and	O
DRIP205	B
,	O
a	O
subunit	O
of	O
the	O
DRIP	B
coactivator	I
complex	I
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B
with	O
RXR	B
or	O
GRIP-1	B
,	O
the	O
differentiation	O
dose	O
-	O
response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand	O
-	O
dependent	O
recruitment	O
of	O
the	O
DRIP	B
coactivator	I
complex	I
to	O
VDR	B
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	B
binding	O
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
transcription	B
factor	I
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
--	O
although	O
still	O
difficult	O
--	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti	B
-	I
TNF	I
antibody	I
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF	B
-	I
alpha	I
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	B
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	B
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	B
inhibitors	I
.	O

The	O
biological	O
significance	O
of	O
NF	B
-	I
kappaB	I
activation	O
in	O
T.	O
parva	O
-	O
infected	O
cells	O
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite	O
-	O
mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B
negative	I
mutant	I
forms	O
of	O
components	O
of	O
the	O
NF	B
-	I
kappaB	I
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B
or	O
p65	B
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	B
-	I
kappaB	I
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	B
-	I
activated	I
toll	I
-	I
like	I
receptor	I
2	I
.	O

Human	B
Toll	I
-	I
like	I
receptor	I
2	I
(	I
TLR2	I
)	I
is	O
a	O
signaling	B
receptor	I
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	B
-	I
kappaB	I
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	B
associates	O
with	O
the	O
high	B
-	I
affinity	I
LPS	I
binding	I
protein	I
membrane	O
CD14	B
to	O
serve	O
as	O
an	O
LPS	B
receptor	I
complex	I
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R	B
-	I
associated	I
kinase	I
(	I
IRAK	I
)	I
is	O
recruited	O
to	O
the	O
TLR2	B
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	B
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	B
-	I
type	I
TLR2	I
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	B
-mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	B
differentiation	I
protein	I
,	O
IRAK	B
,	O
TNF	B
receptor	I
-	I
associated	I
factor	I
6	I
,	O
and	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
,	O
when	O
coexpressed	O
with	O
TLR2	B
,	O
abrogate	O
TLR2	B
-mediated	O
NF	B
-	I
kappaB	I
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B
and	O
IL-1Rs	B
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B
by	O
DN	O
variants	O
.	O

Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA	B
-	I
DR	I
-restricted	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B
interferon	I
-induced	O
class	B
II	I
transactivator	I
expression	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN	B
-	I
gamma	I
)	O
-induced	O
HLA	B
-	I
DR	I
expression	O
in	O
U373	O
MG	O
astrocytoma	O
cells	O
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN	B
-	I
gamma	I
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
DR	I
synthesis	O
.	O

This	O
defect	O
leads	O
to	O
the	O
absence	O
of	O
presentation	O
of	O
the	O
major	B
immediate	I
-	I
early	I
protein	I
IE1	B
to	O
specific	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
clones	O
when	O
U373	O
MG	O
cells	O
,	O
used	O
as	O
antigen	O
-	O
presenting	O
cells	O
,	O
are	O
treated	O
with	O
IFN	B
-	I
gamma	I
plus	O
HCMV	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	B
can	O
be	O
restored	O
when	O
U373	O
MG	O
cells	O
are	O
transfected	O
with	O
CIITA	O
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN	O
-	O
gamma	O
-	O
responsive	O
promoter	O
of	O
CIITA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
viral	O
inhibition	O
of	O
CIITA	O
expression	O
.	O

Bcl-2	B
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	B
factor	I
of	I
activated	I
T	I
lymphocytes	I
(	O
NFAT	B
)	O
-induced	O
Fas	B
ligand	O
transcription	O
.	O

Bcl-2	B
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	B
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	B
family	I
such	O
as	O
Bax	B
and	O
Bad	B
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B
/Fas	B
ligand	I
(	O
FasL	B
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	B
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	B
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
lymphocytes	I
,	O
a	O
transcription	B
factor	I
activated	O
by	O
microtubule	B
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium	O
-	O
dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	B
nuclear	O
translocation	O
,	O
the	O
FasL	B
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	B
.	O

Furthermore	O
,	O
Bcl-2	B
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B
activation	O
,	O
blocking	O
NFAT	B
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	B
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	B
.	O

Phosphorylated	O
Bcl-2	B
can	O
not	O
bind	O
calcineurin	B
,	O
and	O
NFAT	B
activation	O
,	O
FasL	B
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B
phosphorylation	O
.	O

TCL1	O
oncogene	O
expression	O
in	O
AIDS	O
-	O
related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
AIDS	O
NHL	O
)	O
comprises	O
a	O
diverse	O
and	O
heterogeneous	O
group	O
of	O
high	O
-	O
grade	O
B	O
cell	O
tumors	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	O
or	O
tumor	O
-	O
suppressor	O
genes	O
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O

We	O
identified	O
the	O
TCL1	O
oncogene	O
from	O
a	O
set	O
of	O
AIDS	O
IBLP	O
-	O
associated	O
cDNA	O
fragments	O
generated	O
by	O
subtractive	O
hybridization	O
with	O
non	O
-	O
AIDS	O
IBLP	O
.	O

Aberrant	O
TCL1	B
expression	O
has	O
been	O
implicated	O
in	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
development	O
,	O
and	O
its	O
expression	O
also	O
has	O
been	O
seen	O
in	O
many	O
established	O
B	O
cell	O
tumor	O
lines	O
.	O

However	O
,	O
TCL1	B
expression	O
has	O
not	O
been	O
reported	O
in	O
AIDS	O
NHL	O
.	O

We	O
find	O
that	O
TCL1	B
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

TCL1	B
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Hyperplastic	O
lymph	O
node	O
and	O
tonsil	O
also	O
exhibit	O
strong	O
TCL1	B
protein	O
expression	O
in	O
mantle	O
zone	O
B	O
cells	O
and	O
in	O
rare	O
interfollicular	O
zone	O
cells	O
,	O
whereas	O
follicle	O
-	O
center	O
B	O
cells	O
(	O
centroblasts	O
and	O
centrocytes	O
)	O
show	O
weaker	O
expression	O
.	O

These	O
results	O
establish	O
TCL1	B
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	O
associated	O
with	O
AIDS	O
IBLP	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B
expression	O
in	O
quiescent	O
mantle	O
zone	O
B	O
cells	O
is	O
down	O
-	O
regulated	O
in	O
activated	O
germinal	O
center	O
follicular	O
B	O
cells	O
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	B
.	O

High	O
-	O
level	O
expression	O
in	O
nonproliferating	O
B	O
cells	O
suggests	O
that	O
TCL1	B
may	O
function	O
in	O
protecting	O
naive	O
preactivated	O
B	O
cells	O
from	O
apoptosis	O
.	O

Induction	O
of	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
expression	O
by	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
Tax	I
through	O
NF	B
-	I
kappaB	I
in	O
apoptosis	O
-	O
resistant	O
T	O
-	O
cell	O
transfectants	O
with	O
Tax	B
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	B
protected	O
the	O
mouse	O
T	O
-	O
cell	O
line	O
CTLL-2	O
against	O
apoptosis	O
induced	O
by	O
interleukin-2	B
(	O
IL-2	B
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	B
dependent	O
to	O
being	O
IL-2	B
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl	B
-	I
xl	I
but	O
not	O
bcl-2	B
,	O
bcl	B
-	I
xs	I
,	O
bak	B
,	O
bad	B
,	O
or	O
bax	B
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	B
deprivation	O
in	O
CTLL-2	O
cells	O
that	O
expressed	O
Tax	B
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	O
-	O
x	O
promoter	O
was	O
transactivated	O
by	O
wild	B
-	I
type	I
Tax	I
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	B
retaining	O
transactivating	O
ability	O
through	O
NF	B
-	I
kappaB	I
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	B
NF	I
-	I
kappaB	I
binding	I
site	I
identified	O
in	O
the	O
bcl	O
-	O
x	O
promoter	O
significantly	O
decreased	O
Tax	B
-induced	O
transactivation	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF	B
-	I
kappaB	I
family	I
proteins	I
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	B
-induced	O
transactivation	O
of	O
the	O
bcl	O
-	O
x	O
promoter	O
was	O
also	O
diminished	O
by	O
the	O
mutant	B
IkappaBalpha	I
,	O
which	O
specifically	O
inhibits	O
NF	B
-	I
kappaB	I
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
induced	O
by	O
Tax	B
through	O
the	O
NF	B
-	I
kappaB	I
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	O
cells	O
after	O
IL-2	B
deprivation	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappaB	I
(	O
NFkappaB	B
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	B
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus	O
-	O
induced	O
degradation	O
of	O
the	O
cytoplasmic	B
factor	I
IkappaBalpha	B
.	O

Tumor	B
-	I
derived	I
soluble	I
products	I
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	B
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus	O
-	O
induced	O
IkappaBalpha	B
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	B
but	O
not	O
protease	B
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	B
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	O
expression	O
of	O
the	O
cytokines	B
IL-2	B
and	O
IFN	B
-	I
gamma	I
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor	O
-	O
derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

Yeast	O
mitochondrial	B
dehydrogenases	O
are	O
associated	O
in	O
a	O
supramolecular	O
complex	O
.	O

Separation	O
of	O
yeast	O
mitochondrial	B
complexes	O
by	O
colorless	O
native	O
polyacrylamide	O
gel	O
electrophoresis	O
led	O
to	O
the	O
identification	O
of	O
a	O
supramolecular	O
structure	O
exhibiting	O
NADH	O
-	O
dehydrogenase	O
activity	O
.	O

Components	O
of	O
this	O
complex	O
were	O
identified	O
by	O
N	O
-	O
terminal	O
Edman	O
degradation	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
.	O

The	O
complex	O
was	O
found	O
to	O
contain	O
the	O
five	O
known	O
intermembrane	B
space	O
-	O
facing	O
dehydrogenases	O
,	O
namely	O
two	O
external	O
NADH	O
-	O
dehydrogenases	O
Nde1p	B
and	O
Nde2p	B
,	O
glycerol-3-phosphate	B
dehydrogenase	I
Gut2p	B
,	O
D-	B
and	I
L	I
-	I
lactate	I
-	I
dehydrogenases	I
Dld1p	B
and	O
Cyb2p	B
,	O
the	O
matrix	B
-	I
facing	I
NADH	I
-	I
dehydrogenase	I
Ndi1p	B
,	O
two	O
probable	O
flavoproteins	O
YOR356Wp	B
and	O
YPR004Cp	B
,	O
four	O
tricarboxylic	O
acids	O
cycle	O
enzymes	O
(	O
malate	O
dehydrogenase	O
Mdh1p	B
,	O
citrate	O
synthase	O
Cit1p	B
,	O
succinate	O
dehydrogenase	O
Sdh1p	B
,	O
and	O
fumarate	O
hydratase	O
Fum1p	B
)	O
,	O
and	O
the	O
acetaldehyde	O
dehydrogenase	O
Ald4p	B
.	O

The	O
association	O
of	O
these	O
proteins	O
is	O
discussed	O
in	O
terms	O
of	O
NADH	O
-	O
channeling	O
.	O

Characterization	O
of	O
CAX4	B
,	O
an	O
Arabidopsis	O
H	O
(	O
+	O
)	O
/	O
cation	O
antiporter	O
.	O

Ion	O
compartmentalization	O
is	O
essential	O
for	O
plant	O
growth	O
and	O
development	O
.	O

The	O
Arabidopsis	O
open	O
reading	O
frames	O
for	O
CAX1	B
,	O
CAX2	B
,	O
and	O
CAX3	B
(	O
cation	B
exchangers	I
1	I
,	I
2	I
,	I
and	I
3	I
)	O
were	O
previously	O
identified	O
as	O
transporters	O
that	O
may	O
modulate	O
ion	O
fluxes	O
across	O
the	O
vacuolar	B
membrane	I
.	O

To	O
understand	O
the	O
diversity	O
and	O
role	O
of	O
H	O
(	O
+	O
)	O
/	O
cation	O
transporters	O
in	O
controlling	O
plant	O
ion	O
levels	O
,	O
another	O
homolog	O
of	O
the	O
CAX	O
genes	O
,	O
CAX4	B
,	O
was	O
cloned	O
from	O
an	O
Arabidopsis	O
cDNA	O
library	O
.	O

CAX4	B
is	O
53	O
%	O
identical	O
to	O
CAX1	B
at	O
the	O
amino	O
acid	O
level	O
,	O
42	O
%	O
identical	O
to	O
CAX2	B
,	O
and	O
54	O
%	O
identical	O
to	O
CAX3	B
.	O

CAX4	B
transcripts	O
appeared	O
to	O
be	O
expressed	O
at	O
low	O
levels	O
in	O
all	O
tissues	O
and	O
levels	O
of	O
CAX4	B
RNA	O
increased	O
after	O
Mn	O
(	O
2	O
+	O
)	O
,	O
Na	O
(	O
+	O
)	O
,	O
and	O
Ni	O
(	O
2	O
+	O
)	O
treatment	O
.	O

An	O
N	O
-	O
terminal	O
CAX4-hemagglutinin	B
fusion	O
appeared	O
to	O
localize	O
to	O
both	O
yeast	O
and	O
plant	O
vacuolar	B
membranes	I
.	O

When	O
expressed	O
in	O
yeast	O
,	O
CAX4	B
,	O
like	O
CAX3	B
,	O
failed	O
to	O
suppress	O
the	O
Ca	O
(	O
2	O
+	O
)	O
sensitivity	O
of	O
yeast	O
strains	O
deficient	O
in	O
vacuolar	B
Ca	O
(	O
2	O
+	O
)	O
transport	O
.	O

Several	O
modifications	O
to	O
CAX4	B
allowed	O
the	O
protein	O
to	O
transport	O
Ca	O
(	O
2	O
+	O
)	O
.	O

Addition	O
of	O
amino	O
acids	O
to	O
the	O
N	O
terminus	O
of	O
CAX4	B
and	O
CAX3	B
caused	O
both	O
transporters	O
to	O
suppress	O
the	O
sensitivity	O
of	O
yeast	O
strains	O
deficient	O
in	O
vacuolar	B
Ca	O
(	O
2	O
+	O
)	O
transport	O
.	O

These	O
findings	O
suggest	O
that	O
CAX	O
transporters	O
may	O
modulate	O
their	O
ion	O
transport	O
properties	O
through	O
alterations	O
at	O
the	O
N	O
terminus	O
.	O

A	O
new	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
-interacting	O
protein	O
,	O
Sab	B
(	O
SH3BP5	B
)	O
,	O
associates	O
with	O
mitochondria	B
.	O

We	O
have	O
identified	O
a	O
novel	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
-interacting	O
protein	O
,	O
Sab	B
,	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

Sab	B
binds	O
to	O
and	O
serves	O
as	O
a	O
substrate	O
for	O
JNK	O
in	O
vitro	O
,	O
and	O
was	O
previously	O
found	O
to	O
interact	O
with	O
the	O
Src	O
homology	O
3	O
(	O
SH3	O
)	O
domain	O
of	O
Bruton	B
's	I
tyrosine	I
kinase	I
(	O
Btk	B
)	O
.	O

Inspection	O
of	O
the	O
sequence	O
of	O
Sab	B
reveals	O
the	O
presence	O
of	O
two	O
putative	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
interaction	O
motifs	O
(	O
KIMs	O
)	O
similar	O
to	O
that	O
found	O
in	O
the	O
JNK	O
docking	O
domain	O
of	O
the	O
c	B
-	I
Jun	I
transcription	O
factor	O
,	O
and	O
four	O
potential	O
serine	O
-	O
proline	O
JNK	O
phosphorylation	O
sites	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
the	O
molecule	O
.	O

Using	O
deletion	O
and	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
the	O
most	O
N	O
-	O
terminal	O
KIM	O
in	O
Sab	B
is	O
essential	O
for	O
JNK	O
binding	O
,	O
and	O
that	O
,	O
as	O
with	O
c	B
-	I
Jun	I
,	O
physical	O
interaction	O
with	O
JNK	O
is	O
necessary	O
for	O
Sab	B
phosphorylation	O
.	O

Interestingly	O
,	O
confocal	O
immunocytochemistry	O
and	O
cell	O
fractionation	O
studies	O
indicate	O
that	O
Sab	B
is	O
associated	O
with	O
mitochondria	B
,	O
where	O
it	O
co	O
-	O
localizes	O
with	O
a	O
fraction	O
of	O
active	O
JNK	O
.	O

These	O
and	O
previously	O
reported	O
properties	O
of	O
Sab	B
suggest	O
a	O
possible	O
role	O
in	O
targeting	O
JNK	O
to	O
this	O
subcellular	O
compartment	O
and/or	O
mediating	O
cross	O
-	O
talk	O
between	O
the	O
Btk	B
and	O
JNK	O
signal	O
transduction	O
pathways	O
.	O

The	O
proteome	O
of	O
Saccharomyces	O
cerevisiae	O
mitochondria	B
.	O

We	O
performed	O
a	O
comprehensive	O
approach	O
to	O
determine	O
the	O
proteome	O
of	O
Saccharomyces	O
cerevisiae	O
mitochondria	B
.	O

The	O
proteins	O
of	O
highly	O
pure	O
yeast	O
mitochondria	B
were	O
separated	O
by	O
several	O
independent	O
methods	O
and	O
analyzed	O
by	O
tandem	O
MS	O
.	O

From	O
>	O
20	O
million	O
MS	O
spectra	O
,	O
750	O
different	O
proteins	O
were	O
identified	O
,	O
indicating	O
an	O
involvement	O
of	O
mitochondria	B
in	O
numerous	O
cellular	O
processes	O
.	O

All	O
known	O
components	O
of	O
the	O
oxidative	O
phosphorylation	O
machinery	O
,	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
and	O
the	O
stable	O
mitochondria	B
-	O
encoded	O
proteins	O
were	O
found	O
.	O

Based	O
on	O
the	O
mitochondrial	B
proteins	O
described	O
in	O
the	O
literature	O
so	O
far	O
,	O
we	O
calculate	O
that	O
the	O
identified	O
proteins	O
represent	O
approximately	O
90	O
%	O
of	O
all	O
mitochondrial	B
proteins	O
.	O

The	O
function	O
of	O
a	O
quarter	O
of	O
the	O
identified	O
proteins	O
is	O
unknown	O
.	O

The	O
mitochondrial	B
proteome	O
will	O
provide	O
an	O
important	O
database	O
for	O
the	O
analysis	O
of	O
new	O
mitochondrial	B
and	O
mitochondria	B
-	O
associated	O
functions	O
and	O
the	O
characterization	O
of	O
mitochondrial	B
diseases	O
.	O

Expression	O
and	O
localization	O
of	O
ecto	B
-	I
nucleotide	I
pyrophosphatase	I
/	I
phosphodiesterase	I
I-1	I
(	O
E	B
-	I
NPP1	I
/	O
PC-1	B
)	O
and	O
-3	B
(	O
E	B
-	I
NPP3	I
/	O
CD203c	B
/	O
PD	B
-	I
Ibeta	I
/	O
B10	B
/	O
gp130	B
(	I
RB13	I
-	I
6	I
)	I
)	O
in	O
inflammatory	O
and	O
neoplastic	O
bile	O
duct	O
diseases	O
.	O

Ecto	O
-	O
nucleotide	O
pyrophosphatase	O
/	O
phosphodiesterase	O
-	O
I	O
enzyme	O
(	O
E	O
-	O
NPP	O
)	O
consists	O
of	O
three	O
closely	O
related	O
molecules	O
:	O
E	B
-	I
NPP1	I
,	O
E	B
-	I
NPP2	I
and	O
E	B
-	I
NPP3	I
.	O

We	O
investigated	O
the	O
expression	O
and	O
localization	O
of	O
E	B
-	I
NPP1	I
and	I
-3	I
in	O
human	O
inflammatory	O
and	O
neoplastic	O
bile	O
duct	O
diseases	O
.	O

Immunohistochemically	O
E	B
-	I
NPP1	I
was	O
located	O
on	O
the	O
apical	O
cytoplasmic	B
side	O
of	O
cancer	O
cells	O
,	O
whereas	O
E	B
-	I
NPP3	I
was	O
located	O
in	O
the	O
apical	B
plasma	I
membrane	I
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
expression	O
of	O
E	B
-	I
NPP3	I
,	O
but	O
not	O
E	B
-	I
NPP1	I
,	O
was	O
higher	O
in	O
tumor	O
tissues	O
than	O
in	O
surrounding	O
tissues	O
and	O
the	O
specific	O
form	O
of	O
the	O
E	B
-	I
NPP3	I
protein	O
was	O
readily	O
detected	O
in	O
the	O
sera	O
of	O
bile	O
duct	O
carcinoma	O
(	O
BDC	O
)	O
patients	O
.	O

Furthermore	O
,	O
it	O
was	O
confirmed	O
that	O
E	B
-	I
NPP3	I
was	O
associated	O
with	O
migration	O
ability	O
by	O
using	O
of	O
NIH3T3	O
cells	O
that	O
stably	O
transfected	O
with	O
E	B
-	I
NPP3	I
cDNA	O
.	O

These	O
results	O
suggest	O
that	O
E	B
-	I
NPP3	I
is	O
involved	O
in	O
the	O
infiltration	O
of	O
neoplastic	O
BDC	O
and	O
is	O
possible	O
to	O
be	O
a	O
tumor	O
marker	O
.	O

NFAM1	B
,	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
-	O
bearing	O
molecule	O
that	O
regulates	O
B	O
cell	O
development	O
and	O
signaling	O
.	O

A	O
functional	O
cDNA	O
cloning	O
system	O
was	O
developed	O
by	O
using	O
a	O
retrovirus	O
library	O
encoding	O
CD8-chimeric	O
proteins	O
and	O
a	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-GFP	O
reporter	O
cell	O
line	O
to	O
identify	O
molecules	O
inducing	O
NFAT	O
activation	O
.	O

By	O
using	O
this	O
strategy	O
,	O
NFAT	B
activating	I
molecule	I
1	I
(	O
NFAM1	B
)	O
was	O
cloned	O
as	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
-bearing	O
cell	B
surface	I
molecule	O
belonging	O
to	O
the	O
Ig	O
superfamily	O
and	O
is	O
predominantly	O
expressed	O
in	O
spleen	O
B	O
and	O
T	O
cells	O
.	O

NFAM1	B
crosslinking	O
induced	O
ITAM	O
phosphorylation	O
,	O
ZAP-70	B
/	O
Syk	B
recruitment	O
,	O
NFAT	O
activation	O
,	O
and	O
cytokine	O
production	O
.	O

In	O
vivo	O
overexpression	O
of	O
NFAM1	B
in	O
bone	O
marrow	O
chimeras	O
and	O
transgenic	O
mice	O
induced	O
severe	O
impairment	O
of	O
early	O
B	O
cell	O
development	O
in	O
an	O
ITAM	O
-	O
dependent	O
manner	O
.	O

In	O
NFAM1-expressing	B
B	O
cells	O
,	O
B	O
cell	O
antigen	O
receptor	O
stimulation	O
induced	O
NFAM1	B
translocation	O
to	O
lipid	B
raft	I
,	O
and	O
NFAM1	B
co	O
-	O
crosslinking	O
augmented	O
B	O
cell	O
antigen	O
receptor	O
signaling	O
.	O

The	O
results	O
suggest	O
that	O
NFAM1	B
modulates	O
B	O
cell	O
signaling	O
through	O
its	O
ITAM	O
,	O
which	O
regulates	O
B	O
cell	O
development	O
.	O

Vasohibin	B
as	O
an	O
endothelium	O
-	O
derived	O
negative	O
feedback	O
regulator	O
of	O
angiogenesis	O
.	O

Negative	O
feedback	O
is	O
a	O
crucial	O
physiological	O
regulatory	O
mechanism	O
,	O
but	O
no	O
such	O
regulator	O
of	O
angiogenesis	O
has	O
been	O
established	O
.	O

Here	O
we	O
report	O
a	O
novel	O
angiogenesis	O
inhibitor	O
that	O
is	O
induced	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
by	O
angiogenic	O
factors	O
and	O
inhibits	O
angiogenesis	O
in	O
an	O
autocrine	O
manner	O
.	O

We	O
have	O
performed	O
cDNA	O
microarray	O
analysis	O
to	O
survey	O
VEGF	B
-	O
inducible	O
genes	O
in	O
human	O
ECs	O
.	O

We	O
characterized	O
one	O
such	O
gene	O
,	O
KIAA1036	B
,	O
whose	O
function	O
had	O
been	O
uncharacterized	O
.	O

The	O
recombinant	O
protein	O
inhibited	O
migration	O
,	O
proliferation	O
,	O
and	O
network	O
formation	O
by	O
ECs	O
as	O
well	O
as	O
angiogenesis	O
in	O
vivo	O
.	O

This	O
inhibitory	O
effect	O
was	O
selective	O
to	O
ECs	O
,	O
as	O
the	O
protein	O
did	O
not	O
affect	O
the	O
migration	O
of	O
smooth	O
muscle	O
cells	O
or	O
fibroblasts	O
.	O

Specific	O
elimination	O
of	O
the	O
expression	O
of	O
KIAA1036	B
in	O
ECs	O
restored	O
their	O
responsiveness	O
to	O
a	O
higher	O
concentration	O
of	O
VEGF	B
.	O

The	O
expression	O
of	O
KIAA1036	B
was	O
selective	O
to	O
ECs	O
,	O
and	O
hypoxia	O
or	O
TNF	B
-	I
alpha	I
abrogated	O
its	O
inducible	O
expression	O
.	O

As	O
this	O
molecule	O
is	O
preferentially	O
expressed	O
in	O
ECs	O
,	O
we	O
designated	O
it	O
""""	O
vasohibin	B
.	O
""""	O

Transfection	O
of	O
Lewis	O
lung	O
carcinoma	O
cells	O
with	O
the	O
vasohibin	B
gene	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
cancer	O
cells	O
in	O
vitro	O
,	O
but	O
did	O
inhibit	O
tumor	O
growth	O
and	O
tumor	O
angiogenesis	O
in	O
vivo	O
.	O

We	O
propose	O
vasohibin	B
to	O
be	O
an	O
endothelium	O
-	O
derived	O
negative	O
feedback	O
regulator	O
of	O
angiogenesis	O
.	O

Yeast	O
homolog	O
of	O
a	O
cancer	O
-	O
testis	O
antigen	O
defines	O
a	O
new	O
transcription	O
complex	O
.	O

We	O
have	O
isolated	O
a	O
new	O
yeast	O
gene	O
(	O
PCC1	B
)	O
that	O
codes	O
for	O
a	O
factor	O
homologous	O
to	O
human	O
cancer	O
-	O
testis	O
antigens	O
.	O

We	O
provide	O
evidence	O
that	O
Pcc1p	B
is	O
a	O
new	O
transcription	O
factor	O
and	O
that	O
its	O
mutation	O
affects	O
expression	O
of	O
several	O
genes	O
,	O
some	O
of	O
which	O
are	O
involved	O
in	O
cell	O
cycle	O
progression	O
and	O
polarized	O
growth	O
.	O

Mutation	O
of	O
Pcc1p	B
also	O
affects	O
the	O
expression	O
of	O
GAL	O
genes	O
by	O
impairing	O
the	O
recruitment	O
of	O
the	O
SAGA	O
and	O
Mediator	O
co	O
-	O
activators	O
.	O

We	O
characterize	O
a	O
new	O
complex	O
that	O
contains	O
Pcc1p	B
,	O
a	O
kinase	O
,	O
Bud32p	B
,	O
a	O
putative	O
endopeptidase	O
,	O
Kae1p	B
and	O
two	O
additional	O
proteins	O
encoded	O
by	O
ORFs	O
YJL184w	B
and	O
YMLO36w	B
.	O

Genetic	O
and	O
physical	O
interactions	O
among	O
these	O
proteins	O
strongly	O
suggest	O
that	O
this	O
complex	O
is	O
a	O
functional	O
unit	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
and	O
multiple	O
genetic	O
interactions	O
of	O
pcc1	B
mutants	O
with	O
mutants	O
of	O
the	O
transcription	O
apparatus	O
and	O
chromatin	O
modifying	O
enzymes	O
underscore	O
the	O
direct	O
role	O
of	O
the	O
complex	O
in	O
transcription	O
.	O

Functional	O
complementation	O
experiments	O
indicate	O
that	O
the	O
transcriptional	O
function	O
of	O
this	O
set	O
of	O
genes	O
is	O
conserved	O
throughout	O
evolution	O
.	O

Endoplasmic	B
reticulum	I
stress	O
-	O
activated	O
C	O
/	O
EBP	O
homologous	O
protein	O
enhances	O
nuclear	B
factor	O
-	O
kappaB	O
signals	O
via	O
repression	O
of	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
.	O

Endoplasmic	B
reticulum	I
(	O
ER	B
)	O
stress	O
is	O
a	O
causative	O
factor	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O

ER	B
stress	O
mediators	O
,	O
including	O
CCAAT	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
homologous	O
protein	O
(	O
CHOP	B
)	O
,	O
are	O
elevated	O
in	O
intestinal	O
epithelia	O
from	O
patients	O
with	O
inflammatory	O
bowel	O
diseases	O
.	O

The	O
present	O
study	O
arose	O
from	O
the	O
question	O
of	O
how	O
chemical	O
ER	B
stress	O
and	O
CHOP	B
protein	O
were	O
associated	O
with	O
nuclear	B
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
-mediated	O
epithelial	O
inflammatory	O
response	O
.	O

In	O
a	O
human	O
intestinal	O
epithelial	O
cell	O
culture	O
model	O
,	O
chemical	O
ER	B
stresses	O
induced	O
proinflammatory	O
cytokine	O
interleukin-8	B
(	O
IL-8	B
)	O
expression	O
and	O
the	O
nuclear	B
translocation	O
of	O
CHOP	B
protein	O
.	O

CHOP	B
was	O
positively	O
involved	O
in	O
ER	B
-	O
activated	O
IL-8	B
production	O
and	O
was	O
negatively	O
associated	O
with	O
expression	O
of	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
γ	I
(	O
PPARγ	B
)	O
.	O

ER	B
stress	O
-	O
induced	O
IL-8	B
production	O
was	O
enhanced	O
by	O
NF	O
-	O
κB	O
activation	O
that	O
was	O
negatively	O
regulated	O
by	O
PPARγ	B
.	O

Mechanistically	O
,	O
ER	B
stress	O
-	O
induced	O
CHOP	B
suppressed	O
PPARγ	B
transcription	O
by	O
sequestering	O
C	B
/	I
EBPβ	I
and	O
limiting	O
availability	O
of	O
C	B
/	I
EBPβ	I
binding	O
to	O
the	O
PPARγ	B
promoter	O
.	O

Due	O
to	O
the	O
CHOP	B
-	O
mediated	O
regulation	O
of	O
PPARγ	B
action	O
,	O
ER	B
stress	O
can	O
enhance	O
proinflammatory	O
NF	O
-	O
κB	O
activation	O
and	O
maintain	O
an	O
increased	O
level	O
of	O
IL-8	B
production	O
in	O
human	O
intestinal	O
epithelial	O
cells	O
.	O

In	O
contrast	O
,	O
PPARγ	B
was	O
a	O
counteracting	O
regulator	O
of	O
gut	O
inflammatory	O
response	O
through	O
attenuation	O
of	O
NF	O
-	O
κB	O
activation	O
.	O

The	O
collective	O
results	O
support	O
the	O
view	O
that	O
balances	O
between	O
CHOP	B
and	O
PPARγ	B
are	O
crucial	O
for	O
epithelial	O
homeostasis	O
,	O
and	O
disruption	O
of	O
these	O
balances	O
in	O
mucosal	O
ER	B
stress	O
can	O
etiologically	O
affect	O
the	O
progress	O
of	O
human	O
inflammatory	O
bowel	O
diseases	O
.	O

Differential	O
extraction	O
and	O
protein	O
sequencing	O
reveals	O
major	O
differences	O
in	O
patterns	O
of	O
primary	O
cell	B
wall	I
proteins	O
from	O
plants	O
.	O

The	O
proteins	O
of	O
the	O
primary	O
cell	B
walls	I
of	O
suspension	O
cultured	O
cells	O
of	O
five	O
plant	O
species	O
,	O
Arabidopsis	O
,	O
carrot	O
,	O
French	O
bean	O
,	O
tomato	O
,	O
and	O
tobacco	O
,	O
have	O
been	O
compared	O
.	O

The	O
approach	O
that	O
has	O
been	O
adopted	O
is	O
differential	O
extraction	O
followed	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
,	O
rather	O
than	O
two	O
-	O
dimensional	O
gel	O
analysis	O
,	O
to	O
facilitate	O
protein	O
sequencing	O
.	O

Whole	O
cells	O
were	O
washed	O
sequentially	O
with	O
the	O
following	O
aqueous	O
solutions	O
,	O
CaCl2	O
,	O
CDTA	O
(	O
cyclohexane	O
diaminotetraacetic	O
acid	O
,	O
DTT	O
(	O
dithiothreitol	O
)	O
,	O
NaCl	O
,	O
and	O
borate	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
showed	O
consistent	O
differences	O
between	O
species	O
.	O

From	O
the	O
233	O
proteins	O
that	O
were	O
selected	O
for	O
sequencing	O
,	O
63	O
%	O
gave	O
N	O
-	O
terminal	O
data	O
.	O

This	O
analysis	O
shows	O
that	O
(	O
i	O
)	O
patterns	O
of	O
proteins	O
revealed	O
by	O
SDS	O
-	O
PAGE	O
are	O
strikingly	O
different	O
for	O
all	O
five	O
species	O
,	O
(	O
ii	O
)	O
a	O
large	O
number	O
of	O
these	O
proteins	O
can	O
not	O
be	O
identified	O
by	O
data	O
base	O
searches	O
indicating	O
that	O
a	O
significant	O
proportion	O
of	O
wall	O
proteins	O
have	O
not	O
been	O
previously	O
described	O
,	O
(	O
iii	O
)	O
the	O
major	O
proteins	O
that	O
can	O
be	O
identified	O
belong	O
to	O
very	O
different	O
classes	O
of	O
proteins	O
,	O
(	O
iv	O
)	O
the	O
majority	O
of	O
proteins	O
found	O
in	O
the	O
extracellular	O
growth	O
media	O
are	O
absent	O
from	O
their	O
respective	O
cell	B
wall	I
extracts	O
,	O
and	O
(	O
v	O
)	O
the	O
results	O
of	O
the	O
extraction	O
process	O
are	O
indicative	O
of	O
higher	O
order	O
structure	O
.	O

It	O
appears	O
that	O
aspects	O
of	O
speciation	O
reside	O
in	O
the	O
complement	O
of	O
extracellular	O
wall	O
proteins	O
.	O

The	O
data	O
represent	O
a	O
protein	O
resource	O
for	O
cell	B
wall	I
studies	O
complementary	O
to	O
EST	O
(	O
expressed	O
sequence	O
tag	O
)	O
and	O
DNA	O
sequencing	O
strategies	O
.	O

We	O
report	O
here	O
on	O
a	O
patient	O
who	O
was	O
treated	O
for	O
an	O
atypical	O
brain	O
meningioma	O
with	O
multiple	O
surgeries	O
and	O
multiple	O
sessions	O
of	O
stereotactic	O
radiosurgery	O
with	O
good	O
control	O
of	O
his	O
brain	O
disease	O
.	O

Thirteen	O
years	O
after	O
diagnosis	O
,	O
he	O
developed	O
bilateral	O
large	O
sacroiliac	O
and	O
abdominal	O
metastases	O
.	O

Extracranial	O
metastases	O
from	O
brain	O
meningiomas	O
is	O
a	O
rare	O
,	O
but	O
well	O
-	O
documented	O
entity	O
.	O

Metastases	O
occur	O
mostly	O
in	O
the	O
lungs	O
,	O
pleura	O
and	O
liver	O
,	O
but	O
may	O
also	O
affect	O
lymph	O
nodes	O
and	O
bones	O
.	O

Extraneural	O
metastases	O
from	O
cranial	O
meningioma	O
:	O
a	O
case	O
report	O
.	O

Here	O
we	O
expand	O
the	O
role	O
of	O
GRN	B
in	O
FTLD	O
-	O
U	O
and	O
demonstrate	O
that	O
a	O
common	O
genetic	O
variant	O
(	O
rs5848	O
)	O
,	O
located	O
in	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
GRN	B
in	O
a	O
binding	O
-	O
site	O
for	O
miR-659	O
,	O
is	O
a	O
major	O
susceptibility	O
factor	O
for	O
FTLD	O
-	O
U.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
progranulin	B
(	O
GRN	B
)	O
cause	O
ubiquitin-	B
and	O
TAR	B
DNA	I
-	I
binding	I
protein	I
43	I
(	O
TDP-43	B
)	O
-positive	O
frontotemporal	O
dementia	O
(	O
FTLD	O
-	O
U	O
)	O
,	O
a	O
progressive	O
neurodegenerative	O
disease	O
affecting	O
approximately	O
10	O
%	O
of	O
early	O
-	O
onset	O
dementia	O
patients	O
.	O

Common	O
variation	O
in	O
the	O
miR-659	O
binding	O
-	O
site	O
of	O
GRN	B
is	O
a	O
major	O
risk	O
factor	O
for	O
TDP43-positive	B
frontotemporal	O
dementia	O
.	O

In	O
support	O
of	O
these	O
findings	O
,	O
the	O
neuropathology	O
of	O
homozygous	O
rs5848	O
T	O
-	O
allele	O
carriers	O
frequently	O
resembled	O
the	O
pathological	O
FTLD	O
-	O
U	O
subtype	O
of	O
GRN	B
mutation	O
carriers	O
.	O

A	O
significant	O
reduction	O
in	O
GRN	B
protein	O
was	O
observed	O
in	O
homozygous	O
T	O
-	O
allele	O
carriers	O
in	O
vivo	O
,	O
through	O
biochemical	O
and	O
immunohistochemical	O
methods	O
,	O
mimicking	O
the	O
effect	O
of	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
GRN	B
mutations	O
.	O

We	O
further	O
demonstrate	O
that	O
miR-659	O
can	O
regulate	O
GRN	B
expression	O
in	O
vitro	O
,	O
with	O
miR-659	O
binding	O
more	O
efficiently	O
to	O
the	O
high	O
risk	O
T	O
-	O
allele	O
of	O
rs5848	O
resulting	O
in	O
augmented	O
translational	O
inhibition	O
of	O
GRN	B
.	O

In	O
a	O
series	O
of	O
pathologically	O
confirmed	O
FTLD	O
-	O
U	O
patients	O
without	O
GRN	B
mutations	O
,	O
we	O
show	O
that	O
carriers	O
homozygous	O
for	O
the	O
T	O
-	O
allele	O
of	O
rs5848	O
have	O
a	O
3.2-fold	O
increased	O
risk	O
to	O
develop	O
FTLD	O
-	O
U	O
compared	O
with	O
homozygous	O
C	O
-	O
allele	O
carriers	O
(	O
95	O
%	O
CI	O
:	O
1.50	O
-	O
6.73	O
)	O
.	O

Translational	O
regulation	O
by	O
miRNAs	O
may	O
represent	O
a	O
common	O
mechanism	O
underlying	O
complex	O
neurodegenerative	O
disorders	O
.	O

We	O
suggest	O
that	O
the	O
expression	O
of	O
GRN	B
is	O
regulated	O
by	O
miRNAs	O
and	O
that	O
common	O
genetic	O
variability	O
in	O
a	O
miRNA	O
binding	O
-	O
site	O
can	O
significantly	O
increase	O
the	O
risk	O
for	O
FTLD	O
-	O
U.	O

Here	O
,	O
we	O
discuss	O
recent	O
data	O
that	O
support	O
a	O
view	O
that	O
endolysosomal	O
positioning	O
of	O
RNA	O
might	O
facilitate	O
intercellular	O
transmission	O
of	O
RNA	O
and	O
host	O
defence	O
against	O
viruses	O
and	O
retrotransposons	O
.	O

Positioning	O
of	O
RNA	O
regulatory	O
mechanisms	O
on	O
endolysosomal	O
membranes	O
might	O
permit	O
rapid	O
and	O
localized	O
control	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
regulatory	O
programs	O
and	O
mRNA	O
translation	O
in	O
response	O
to	O
environmental	O
signals	O
,	O
such	O
as	O
activated	O
plasma	O
membrane	O
receptors	O
transported	O
on	O
endosomes	O
.	O

Finally	O
,	O
we	O
suggest	O
that	O
the	O
pathology	O
of	O
several	O
conditions	O
,	O
including	O
Huntington	O
's	O
disease	O
,	O
might	O
be	O
a	O
consequence	O
of	O
the	O
disruption	O
of	O
the	O
control	O
of	O
RNA	O
via	O
endolysosomal	O
membranes	O
.	O

Control	O
of	O
RNA	O
silencing	O
and	O
localization	O
by	O
endolysosomes	O
.	O

Recent	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
RNA	O
silencing	O
have	O
unraveled	O
an	O
intriguing	O
association	O
of	O
post	O
-	O
transcriptionally	O
regulated	O
RNA	O
with	O
endolysosomal	O
membranes	O
in	O
several	O
circumstances	O
of	O
mRNA	O
localization	O
,	O
microRNA	O
activity	O
and	O
viral	O
RNA	O
transport	O
and	O
packaging	O
.	O

Endolysosomal	O
membranes	O
are	O
a	O
nexus	O
of	O
communication	O
and	O
transport	O
between	O
cells	O
and	O
their	O
exterior	O
environment	O
for	O
signaling	O
receptors	O
,	O
pathogens	O
and	O
nutrients	O
.	O

The	O
method	O
by	O
which	O
MSCs	O
could	O
be	O
applied	O
for	O
future	O
therapies	O
might	O
require	O
trans	O
-	O
disciplinary	O
approaches	O
for	O
personalized	O
treatments	O
.	O

Implantation	O
of	O
adult	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
to	O
treat	O
neural	O
disorders	O
shows	O
promise	O
.	O

Depending	O
on	O
their	O
microenvironment	O
,	O
MSCs	O
could	O
potentially	O
be	O
used	O
for	O
the	O
repair	O
and/or	O
replacement	O
of	O
neurons	O
in	O
traumatic	O
brain	O
injury	O
or	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

This	O
cross	O
-	O
disciplinary	O
review	O
incorporates	O
aspects	O
of	O
neuroscience	O
,	O
stem	O
cell	O
biology	O
,	O
cancer	O
biology	O
and	O
immunology	O
to	O
discuss	O
interactions	O
between	O
inflammatory	O
mediators	O
and	O
MSCs	O
.	O

We	O
first	O
discuss	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
neurological	O
development	O
.	O

Neurogenesis	O
:	O
role	O
for	O
microRNAs	O
and	O
mesenchymal	O
stem	O
cells	O
in	O
pathological	O
states	O
.	O

Exploring	O
the	O
predisposition	O
of	O
MSCs	O
to	O
oncogenesis	O
is	O
critical	O
for	O
translational	O
science	O
since	O
the	O
implementation	O
of	O
safeguarding	O
measures	O
prior	O
to	O
therapy	O
can	O
lead	O
to	O
the	O
successful	O
delivery	O
of	O
stem	O
cells	O
to	O
patients	O
.	O

The	O
administration	O
of	O
effective	O
and	O
safe	O
MSC	O
therapy	O
must	O
acknowledge	O
immune	O
mediators	O
that	O
may	O
predispose	O
the	O
early	O
differentiating	O
MSCs	O
to	O
oncogenic	O
insults	O
.	O

Secondly	O
,	O
we	O
discuss	O
the	O
ability	O
of	O
MSCs	O
to	O
transdifferentiate	O
into	O
functional	O
neurons	O
,	O
which	O
are	O
regulated	O
by	O
miRNAs	O
,	O
and	O
the	O
implications	O
of	O
these	O
cells	O
for	O
the	O
therapy	O
of	O
neuropathological	O
states	O
.	O

Immune	O
mediators	O
could	O
be	O
central	O
to	O
MSC	O
responses	O
within	O
a	O
region	O
of	O
tissue	O
injury	O
and	O
are	O
also	O
discussed	O
in	O
detail	O
.	O

Thus	O
,	O
we	O
discuss	O
a	O
key	O
gene	O
,	O
RE-1	B
silencing	I
transcription	I
factor	I
(	O
REST	B
)	O
,	O
based	O
on	O
its	O
dual	O
role	O
in	O
neurogenesis	O
and	O
cancer	O
development	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
analysis	O
shows	O
that	O
ADCK3	B
belongs	I
to	O
the	O
family	O
of	O
atypical	O
kinases	O
,	O
which	O
includes	O
phosphoinositide	O
and	O
choline	O
kinases	O
,	O
suggesting	O
that	O
ADCK3	B
plays	O
an	O
indirect	O
regulatory	O
role	O
in	O
ubiquinone	O
biosynthesis	O
possibly	O
as	O
part	O
of	O
a	O
feedback	O
loop	O
that	O
regulates	O
ATP	O
production	O
.	O

ADCK3	B
,	O
an	O
ancestral	O
kinase	O
,	O
is	O
mutated	O
in	O
a	O
form	O
of	O
recessive	O
ataxia	O
associated	O
with	O
coenzyme	O
Q10	O
deficiency	O
.	O

Muscle	O
coenzyme	O
Q	O
(	O
10	O
)	O
(	O
CoQ	O
(	O
10	O
)	O
or	O
ubiquinone	O
)	O
deficiency	O
has	O
been	O
identified	O
in	O
more	O
than	O
20	O
patients	O
with	O
presumed	O
autosomal	O
-	O
recessive	O
ataxia	O
.	O

However	O
,	O
mutations	O
in	O
genes	O
required	O
for	O
CoQ	O
(	O
10	O
)	O
biosynthetic	O
pathway	O
have	O
been	O
identified	O
only	O
in	O
patients	O
with	O
infantile	O
-	O
onset	O
multisystemic	O
diseases	O
or	O
isolated	O
nephropathy	O
.	O

Our	O
SNP	O
-	O
based	O
genome	O
-	O
wide	O
scan	O
in	O
a	O
large	O
consanguineous	O
family	O
revealed	O
a	O
locus	O
for	O
autosomal	O
-	O
recessive	O
ataxia	O
at	O
chromosome	O
1q41	O
.	O

The	O
causative	O
mutation	O
is	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
in	O
the	O
aarF	B
-	I
domain	I
-	I
containing	I
kinase	I
3	I
gene	I
(	O
ADCK3	B
)	O
.	O

Five	O
additional	O
mutations	O
in	O
ADCK3	B
were	O
found	O
in	O
three	O
patients	O
with	O
sporadic	O
ataxia	O
,	O
including	O
one	O
known	O
to	O
have	O
CoQ	O
(	O
10	O
)	O
deficiency	O
in	O
muscle	O
.	O

All	O
of	O
the	O
patients	O
have	O
childhood	O
-	O
onset	O
cerebellar	O
ataxia	O
with	O
slow	O
progression	O
,	O
and	O
three	O
of	O
six	O
have	O
mildly	O
elevated	O
lactate	O
levels	O
.	O

ADCK3	B
is	O
a	O
mitochondrial	O
protein	O
homologous	O
to	O
the	O
yeast	O
COQ8	B
and	O
the	O
bacterial	O
UbiB	O
proteins	O
,	O
which	O
are	O
required	O
for	O
CoQ	O
biosynthesis	O
.	O

Three	O
out	O
of	O
four	O
patients	O
tested	O
showed	O
a	O
low	O
endogenous	O
pool	O
of	O
CoQ	O
(	O
10	O
)	O
in	O
their	O
fibroblasts	O
or	O
lymphoblasts	O
,	O
and	O
two	O
out	O
of	O
three	O
patients	O
showed	O
impaired	O
ubiquinone	O
synthesis	O
,	O
strongly	O
suggesting	O
that	O
ADCK3	B
is	O
also	O
involved	O
in	O
CoQ	O
(	O
10	O
)	O
biosynthesis	O
.	O

The	O
deleterious	O
nature	O
of	O
the	O
three	O
identified	O
missense	O
changes	O
was	O
confirmed	O
by	O
the	O
introduction	O
of	O
them	O
at	O
the	O
corresponding	O
positions	O
of	O
the	O
yeast	O
COQ8	B
gene	O
.	O

Interpretation	O
and	O
applicability	O
of	O
microRNA	O
data	O
to	O
the	O
context	O
of	O
Alzheimer	O
's	O
and	O
age	O
-	O
related	O
diseases	O
.	O

Generated	O
by	O
the	O
ribonuclease	B
III	I
Dicer	I
,	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	O
,	O
suggesting	O
that	O
they	O
may	O
control	O
every	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	O
body	O
!	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
age	O
-	O
related	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

Here	O
,	O
we	O
discuss	O
some	O
of	O
the	O
limitations	O
associated	O
to	O
the	O
interpretation	O
and	O
applicability	O
of	O
miRNA	O
data	O
,	O
based	O
on	O
our	O
recent	O
study	O
on	O
the	O
etiology	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Using	O
transiently	O
transfected	O
murine	O
neuronal	O
N2a	O
cells	O
in	O
culture	O
,	O
in	O
parallel	O
to	O
a	O
mouse	O
model	O
of	O
AD	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
a	O
role	O
for	O
two	O
miRNAs	O
(	O
miR-298	O
and	O
miR-328	O
)	O
in	O
the	O
regulation	O
of	O
beta	B
-	I
amyloid	I
(	I
Abeta	I
)	I
precursor	I
protein	I
(	I
APP	I
)	I
-converting	I
enzyme	I
(	O
BACE	B
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
translation	O
,	O
thereby	O
providing	O
key	O
insights	O
into	O
the	O
molecular	O
basis	O
underlying	O
BACE	B
deregulation	O
in	O
AD	O
.	O

However	O
,	O
whether	O
miRNA	O
data	O
can	O
be	O
extrapolated	O
and	O
transposed	O
to	O
the	O
human	O
context	O
of	O
age	O
-	O
related	O
diseases	O
,	O
such	O
as	O
AD	O
,	O
not	O
only	O
requires	O
caution	O
,	O
but	O
also	O
warrants	O
several	O
considerations	O
.	O

Levels	O
of	O
protein	O
expression	O
of	O
endothelial	B
NO	I
synthase	I
(	O
eNOS	B
)	O
,	O
caveolin-1	B
,	O
and	O
calmodulin	B
were	O
assessed	O
in	O
carotid	O
arteries	O
using	O
Western	O
analysis	O
.	O

Plasma	O
NO	O
levels	O
were	O
doubled	O
by	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

NO	O
production	O
and	O
endothelium	O
-	O
dependent	O
contraction	O
in	O
response	O
to	O
the	O
NOS	O
inhibitor	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NNA	O
;	O
100	O
microM	O
)	O
was	O
enhanced	O
by	O
50	O
to	O
100	O
%	O
in	O
carotid	O
arteries	O
from	O
rats	O
treated	O
with	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

Acetylcholine	O
-	O
induced	O
relaxation	O
was	O
selectively	O
enhanced	O
in	O
carotid	O
arteries	O
from	O
rats	O
treated	O
with	O
daidzein	O
.	O

The	O
use	O
of	O
estrogen	O
for	O
protection	O
against	O
vascular	O
dysfunction	O
is	O
limited	O
due	O
to	O
its	O
effects	O
on	O
the	O
reproductive	O
system	O
,	O
particularly	O
in	O
males	O
.	O

We	O
postulated	O
that	O
daidzein	O
,	O
an	O
isoflavone	O
with	O
estrogen	O
-	O
like	O
effects	O
on	O
the	O
systemic	O
vasculature	O
but	O
not	O
the	O
reproductive	O
system	O
,	O
might	O
enhance	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
cerebral	O
vasodilatation	O
.	O

Male	O
rats	O
were	O
administered	O
vehicle	O
,	O
17beta	O
-	O
estradiol	O
(	O
0.1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
,	O
or	O
daidzein	O
(	O
0.2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
daily	O
for	O
7	O
days	O
.	O

Basal	O
and	O
acetylcholine	O
-	O
stimulated	O
NO	O
release	O
was	O
assessed	O
in	O
vitro	O
via	O
carotid	O
arterial	O
rings	O
or	O
in	O
vivo	O
by	O
measuring	O
changes	O
in	O
basilar	O
artery	O
diameter	O
.	O

Similarly	O
,	O
constrictor	O
responses	O
of	O
the	O
basilar	O
artery	O
to	O
L	O
-	O
NNA	O
in	O
vivo	O
were	O
selectively	O
augmented	O
by	O
approximately	O
100	O
%	O
by	O
17beta	O
-	O
estradiol	O
treatment	O
and	O
tended	O
to	O
be	O
approximately	O
50	O
%	O
greater	O
in	O
daidzein	O
-	O
treated	O
rats	O
.	O

Effect	O
of	O
short	O
-	O
term	O
phytoestrogen	O
treatment	O
in	O
male	O
rats	O
on	O
nitric	O
oxide	O
-	O
mediated	O
responses	O
of	O
carotid	O
and	O
cerebral	O
arteries	O
:	O
comparison	O
with	O
17beta	O
-	O
estradiol	O
.	O

These	O
data	O
suggest	O
that	O
short	O
-	O
term	O
administration	O
of	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
modulates	O
cerebral	O
artery	O
reactivity	O
in	O
males	O
by	O
enhancing	O
synthesis	O
and	O
release	O
of	O
endothelium	O
-	O
derived	O
NO	O
.	O
Isoflavone	O
therapy	O
may	O
therefore	O
be	O
a	O
feasible	O
approach	O
to	O
protect	O
against	O
cerebrovascular	O
disease	O
and	O
stroke	O
.	O

Expression	O
of	O
caveolin-1	B
was	O
decreased	O
,	O
and	O
calmodulin	B
was	O
increased	O
,	O
in	O
vessels	O
from	O
daidzein-	O
or	O
17beta	O
-	O
estradiol	O
-	O
treated	O
rats	O
.	O

eNOS	B
expression	O
was	O
unaffected	O
by	O
the	O
treatments	O
.	O

However	O
,	O
we	O
report	O
the	O
experience	O
of	O
a	O
patient	O
who	O
inadvertently	O
received	O
live	O
polio	O
vaccine	O
whilst	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
.	O

International	O
guidelines	O
state	O
that	O
live	O
vaccines	O
are	O
contraindicated	O
in	O
patients	O
on	O
anti	O
-	O
TNF	O
therapy	O
.	O

Live	O
polio	O
vaccine	O
exposure	O
while	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
for	O
reactive	O
arthritis	O
.	O

Patients	O
should	O
be	O
counseled	O
regarding	O
the	O
risks	O
of	O
live	O
vaccines	O
prior	O
to	O
treatment	O
with	O
anti	O
-	O
TNF	O
therapy	O
.	O

However	O
,	O
if	O
we	O
consider	O
adult	O
patients	O
with	O
rheumatic	O
diseases	O
to	O
have	O
altered	O
immunocompetence	O
,	O
it	O
is	O
recommended	O
that	O
they	O
receive	O
the	O
usual	O
inactivated	O
vaccines	O
according	O
to	O
standard	O
schedules	O
,	O
and	O
live	O
vaccines	O
should	O
be	O
avoided	O
in	O
those	O
who	O
are	O
treated	O
with	O
more	O
potent	O
forms	O
of	O
immune	O
suppression	O
.	O

No	O
clear	O
guidelines	O
are	O
available	O
for	O
all	O
vaccines	O
in	O
patients	O
with	O
specific	O
rheumatic	O
diseases	O
.	O

Patient	O
did	O
not	O
suffer	O
from	O
any	O
infectious	O
sequel	O
as	O
a	O
result	O
.	O

Autosomal	O
-	O
recessive	O
cerebellar	O
ataxias	O
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	O
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	O
.	O

By	O
combining	O
SNP	O
array	O
-	O
based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array	O
-	O
based	O
sequence	O
capture	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	B
mutations	O
in	O
patients	O
with	O
autosomal	O
-	O
recessive	O
cerebellar	O
ataxia	O
.	O

The	O
analysis	O
of	O
ANO10	B
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	O
[	O
p	O
.	O
Leu384fs	O
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound	O
-	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
(	O
c.1476	O
+	O
1G	O
>	O
T	O
)	O
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	O
[	O
p	O
.	O
Leu535X	O
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next	O
-	O
generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal	O
-	O
recessive	O
diseases	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine	O
-	O
to	O
-	O
arginine	O
substitution	O
in	O
the	O
DUF	O
590	O
domain	O
of	O
a	O
16	O
K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium	O
-	O
activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	B
10	I
(	O
ANO10	B
)	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium	O
-	O
dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	O
ataxia	O
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	O
ataxia	O
.	O

These	O
findings	O
further	O
support	O
the	O
idea	O
that	O
iron-	O
and	O
aluminum	O
-	O
sulfates	O
induce	O
genotoxicity	O
via	O
a	O
ROS	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
specific	O
regulatory	O
elements	O
and	O
pathogenic	O
genes	O
that	O
redirect	O
brain	O
cell	O
fate	O
towards	O
progressive	O
dysfunction	O
and	O
apoptotic	O
cell	O
death	O
.	O

Notably	O
,	O
these	O
same	O
miRNAs	O
are	O
up	O
-	O
regulated	O
in	O
AD	O
brain	O
.	O

The	O
main	O
finding	O
was	O
that	O
these	O
ROS	O
-	O
generating	O
neurotoxic	O
metal	O
sulfates	O
also	O
up	O
-	O
regulate	O
a	O
specific	O
set	O
of	O
miRNAs	O
that	O
includes	O
miR-9	O
,	O
miR-125b	O
and	O
miR-128	O
.	O

In	O
this	O
study	O
we	O
have	O
extended	O
our	O
investigations	O
to	O
analyze	O
the	O
expression	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
populations	O
in	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
treated	O
human	O
neural	O
cells	O
in	O
primary	O
culture	O
.	O

Notably	O
,	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
induce	O
genes	O
in	O
cultured	O
human	O
brain	O
cells	O
that	O
exhibit	O
expression	O
patterns	O
similar	O
to	O
those	O
observed	O
to	O
be	O
up	O
-	O
regulated	O
in	O
moderate-	O
to	O
late	O
-	O
stage	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
following	O
ROS	O
induction	O
,	O
a	O
family	O
of	O
pathogenic	O
brain	O
genes	O
that	O
promote	O
inflammatory	O
signalling	O
,	O
cellular	O
apoptosis	O
and	O
brain	O
cell	O
death	O
is	O
significantly	O
over	O
-	O
expressed	O
.	O

Iron-	O
and	O
aluminum	O
-	O
sulfate	O
together	O
,	O
at	O
nanomolar	O
concentrations	O
,	O
trigger	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
cultures	O
of	O
human	O
brain	O
cells	O
.	O

Induction	O
of	O
specific	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
by	O
ROS	O
-	O
generating	O
metal	O
sulfates	O
in	O
primary	O
human	O
brain	O
cells	O
.	O

The	O
rapid	O
and	O
exciting	O
pace	O
of	O
advances	O
in	O
glioblastoma	O
genetics	O
has	O
prompted	O
this	O
up	O
-	O
to	O
-	O
date	O
review	O
.	O

The	O
likely	O
impact	O
on	O
care	O
delivery	O
in	O
the	O
clinic	O
may	O
only	O
be	O
a	O
few	O
years	O
away	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
high	O
-	O
throughput	O
efforts	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
a	O
massive	O
sequencing	O
project	O
have	O
yielded	O
novel	O
insights	O
and	O
classifications	O
of	O
this	O
dreaded	O
cancer	O
.	O

It	O
has	O
been	O
hoped	O
that	O
dissection	O
of	O
the	O
genetics	O
of	O
this	O
cancer	O
would	O
lead	O
to	O
more	O
targeted	O
and	O
effective	O
treatments	O
,	O
and	O
new	O
advances	O
may	O
finally	O
be	O
bringing	O
this	O
closer	O
to	O
fruition	O
.	O

Glioblastoma	O
genetics	O
:	O
in	O
rapid	O
flux	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
primary	O
brain	O
tumor	O
.	O

While	O
small	O
progress	O
has	O
been	O
made	O
in	O
treating	O
this	O
cancer	O
in	O
recent	O
years	O
,	O
glioblastoma	O
remains	O
largely	O
resistant	O
to	O
all	O
existing	O
therapies	O
.	O

Novel	O
animal	O
models	O
for	O
studying	O
complex	O
brain	O
disorders	O
:	O
BAC	O
-	O
driven	O
miRNA	O
-	O
mediated	O
in	O
vivo	O
silencing	O
of	O
gene	O
expression	O
.	O

In	O
schizophrenia	O
,	O
glutamic	B
acid	I
decarboxylase	I
1	I
(	O
GAD1	B
)	O
disturbances	O
are	O
robust	O
,	O
consistently	O
observed	O
,	O
cell	O
-	O
type	O
specific	O
and	O
represent	O
a	O
core	O
feature	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
neuropeptide	B
Y	I
(	O
NPY	B
)	O
,	O
which	O
is	O
a	O
phenotypic	O
marker	O
of	O
a	O
sub	O
-	O
population	O
of	O
GAD1-containing	B
interneurons	O
,	O
has	O
shown	O
reduced	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
in	O
subjects	O
with	O
schizophrenia	O
,	O
suggesting	O
that	O
dysfunction	O
of	O
the	O
NPY+	O
cortical	O
interneuronal	O
sub	O
-	O
population	O
might	O
be	O
a	O
core	O
feature	O
of	O
this	O
devastating	O
disorder	O
.	O

However	O
,	O
modeling	O
gene	O
expression	O
disturbances	O
in	O
schizophrenia	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
has	O
been	O
extremely	O
challenging	O
.	O

To	O
more	O
closely	O
mimic	O
these	O
molecular	O
and	O
cellular	O
human	O
post	O
-	O
mortem	O
findings	O
,	O
we	O
generated	O
a	O
transgenic	O
mouse	O
in	O
which	O
we	O
downregulated	O
GAD1	B
mRNA	O
expression	O
specifically	O
in	O
NPY+	B
neurons	O
.	O

This	O
novel	O
,	O
cell	O
type	O
-	O
specific	O
in	O
vivo	O
system	O
for	O
reducing	O
gene	O
expression	O
uses	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
NPY	B
promoter	O
-	O
enhancer	O
elements	O
,	O
the	O
reporter	O
molecule	O
(	O
eGFP	O
)	O
and	O
a	O
modified	O
intron	O
containing	O
a	O
synthetic	O
microRNA	O
(	O
miRNA	O
)	O
targeted	O
to	O
GAD1	B
.	O

The	O
animals	O
of	O
isogenic	O
strains	O
are	O
generated	O
rapidly	O
,	O
providing	O
a	O
new	O
tool	O
for	O
better	O
understanding	O
the	O
molecular	O
disturbances	O
in	O
the	O
GABAergic	O
system	O
observed	O
in	O
complex	O
neuropsychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

In	O
the	O
future	O
,	O
because	O
of	O
the	O
small	O
size	O
of	O
the	O
silencing	O
miRNAs	O
combined	O
with	O
our	O
BAC	O
strategy	O
,	O
this	O
method	O
may	O
be	O
modified	O
to	O
allow	O
generation	O
of	O
mice	O
with	O
simultaneous	O
silencing	O
of	O
multiple	O
genes	O
in	O
the	O
same	O
cells	O
with	O
a	O
single	O
construct	O
,	O
and	O
production	O
of	O
splice	O
-	O
variant	O
-	O
specific	O
knockdown	O
animals	O
.	O

Biomarkers	O
associated	O
with	O
metastasis	O
of	O
lung	O
cancer	O
to	O
brain	O
predict	O
patient	O
survival	O
.	O

This	O
research	O
involves	O
comprehensive	O
miRNA	O
expression	O
profiling	O
,	O
evaluation	O
of	O
normalisation	O
techniques	O
and	O
combination	O
of	O
miRNA	O
with	O
imaging	O
features	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
CT	O
Scan	O
.	O

We	O
combine	O
validated	O
miRNA	O
expression	O
values	O
with	O
imaging	O
features	O
to	O
classify	O
NSCLC	O
brain	O
mets	O
from	O
non	O
-	O
brain	O
mets	O
and	O
identify	O
possible	O
biomarkers	O
of	O
brain	O
mets	O
.	O

Generally	O
,	O
one	O
miRNA	O
is	O
predicted	O
to	O
regulate	O
several	O
hundred	O
genes	O
,	O
and	O
as	O
a	O
result	O
,	O
miRNAs	O
could	O
serve	O
as	O
a	O
better	O
classifier	O
than	O
gene	O
expression	O
.	O

MicroRNAs	O
influence	O
cell	O
physiology	O
;	O
alteration	O
in	O
miRNA	O
regulation	O
can	O
be	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

The	O
biomarkers	O
were	O
validated	O
on	O
an	O
independent	O
data	O
set	O
to	O
predict	O
potential	O
brain	O
mets	O
.	O

Through	O
various	O
experimental	O
approaches	O
,	O
we	O
validated	O
computational	O
predictions	O
and	O
demonstrated	O
that	O
miR-298	O
and	O
miR-328	O
recognize	O
specific	O
binding	O
sites	O
in	O
the	O
3'-UTR	O
of	O
BACE1	B
mRNA	O
and	O
exert	O
regulatory	O
effects	O
on	O
BACE1	B
protein	O
expression	O
in	O
cultured	O
neuronal	O
cells	O
.	O

Here	O
we	O
also	O
observed	O
a	O
loss	O
of	O
correlation	O
between	O
BACE1	B
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
hippocampus	O
of	O
a	O
mouse	O
model	O
of	O
AD	O
.	O
Consistent	O
with	O
an	O
impairment	O
of	O
miRNA	O
-	O
mediated	O
regulation	O
of	O
BACE1	B
expression	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
regulatory	O
role	O
of	O
the	O
BACE1	B
3'-UTR	O
element	O
and	O
the	O
possible	O
involvement	O
of	O
specific	O
miRNAs	O
in	O
cultured	O
neuronal	O
(	O
N2a	O
)	O
and	O
fibroblastic	O
(	O
NIH	O
3T3	O
)	O
cells	O
.	O

Our	O
results	O
may	O
provide	O
the	O
molecular	O
basis	O
underlying	O
BACE1	B
deregulation	O
in	O
AD	O
and	O
offer	O
new	O
perspectives	O
on	O
the	O
etiology	O
of	O
this	O
neurological	O
disorder	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
key	O
regulatory	O
RNAs	O
known	O
to	O
repress	O
mRNA	O
translation	O
through	O
recognition	O
of	O
specific	O
binding	O
sites	O
located	O
mainly	O
in	O
their	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
.	O

MicroRNA-298	O
and	O
microRNA-328	O
regulate	O
expression	O
of	O
mouse	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
1	O
.	O

Intriguingly	O
,	O
previous	O
post	O
-	O
mortem	O
analyses	O
showed	O
higher	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
-	I
converting	I
enzyme	I
(	I
BACE	I
)	I
protein	I
,	O
but	O
not	O
mRNA	O
,	O
levels	O
in	O
the	O
brain	O
of	O
patients	O
that	O
suffered	O
from	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Loss	O
of	O
specific	O
miRNA	O
control	O
of	O
gene	O
expression	O
is	O
thus	O
expected	O
to	O
underlie	O
serious	O
genetic	O
diseases	O
.	O

These	O
findings	O
reveal	O
a	O
significant	O
additional	O
mechanism	O
by	O
which	O
alpha	B
-	I
synuclein	I
is	O
regulated	O
and	O
point	O
toward	O
new	O
therapeutic	O
regimes	O
for	O
lowering	O
endogenous	O
alpha	B
-	I
synuclein	I
levels	O
in	O
patients	O
with	O
familial	O
or	O
sporadic	O
Parkinson	O
disease	O
.	O

Overexpression	O
of	O
mir-7	O
and	O
mir-153	O
significantly	O
reduces	O
endogenous	O
alpha	B
-	I
synuclein	I
levels	O
,	O
whereas	O
inhibition	O
of	O
mir-7	O
and	O
mir-153	O
enhances	O
translation	O
of	O
a	O
luciferase	O
construct	O
bearing	O
the	O
alpha	B
-	I
synuclein	I
3'-untranslated	O
region	O
in	O
primary	O
neurons	O
.	O

They	O
are	O
expressed	O
predominantly	O
in	O
the	O
brain	O
with	O
a	O
pattern	O
that	O
mirrors	O
synuclein	O
expression	O
in	O
different	O
tissues	O
as	O
well	O
as	O
during	O
neuronal	O
development	O
,	O
indicating	O
that	O
they	O
play	O
a	O
tuning	O
role	O
in	O
the	O
amount	O
of	O
alpha	B
-	I
synuclein	I
produced	O
.	O

These	O
microRNAs	O
bind	O
specifically	O
to	O
the	O
3'-untranslated	O
region	O
of	O
alpha	B
-	I
synuclein	I
and	O
down	O
-	O
regulate	O
its	O
mRNA	O
and	O
protein	O
levels	O
,	O
with	O
their	O
effect	O
being	O
additive	O
.	O

Here	O
,	O
two	O
microRNAs	O
,	O
namely	O
mir-7	O
and	O
mir-153	O
,	O
have	O
been	O
identified	O
to	O
regulate	O
alpha	B
-	I
synuclein	I
levels	O
post	O
-	O
transcriptionally	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
have	O
established	O
a	O
central	O
role	O
for	O
alpha	B
-	I
synuclein	I
accumulation	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
disease	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
alpha	B
-	I
synuclein	I
expression	O
by	O
mir-7	O
and	O
mir-153	O
.	O

Learning	O
,	O
retention	O
and	O
generalization	O
of	O
a	O
mirror	O
tracing	O
skill	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
present	O
study	O
examined	O
the	O
ability	O
of	O
12	O
patients	O
with	O
probable	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
12	O
age-	O
and	O
education	O
-	O
matched	O
normal	O
control	O
(	O
NC	O
)	O
subjects	O
to	O
learn	O
and	O
retain	O
the	O
visuomotor	O
skills	O
necessary	O
to	O
efficiently	O
trace	O
a	O
pattern	O
(	O
e.g.	O
,	O
a	O
4-	O
or	O
6-pointed	O
star	O
)	O
seen	O
only	O
in	O
mirror	O
-	O
reversed	O
view	O
.	O

Those	O
AD	O
(	O
N=6	O
)	O
and	O
NC	O
(	O
N=7	O
)	O
subjects	O
who	O
were	O
able	O
to	O
initially	O
perform	O
the	O
basic	O
mirror	O
tracing	O
task	O
did	O
not	O
differ	O
significantly	O
in	O
initial	O
level	O
of	O
performance	O
,	O
learning	O
over	O
trials	O
,	O
retention	O
of	O
the	O
skill	O
over	O
a	O
30-min	O
delay	O
interval	O
,	O
and	O
generalization	O
of	O
the	O
skill	O
to	O
a	O
new	O
figure	O
or	O
to	O
the	O
opposite	O
direction	O
of	O
tracing	O
.	O

The	O
AD	O
patients	O
who	O
were	O
unable	O
to	O
initially	O
perform	O
the	O
mirror	O
tracing	O
task	O
were	O
significantly	O
worse	O
than	O
those	O
who	O
could	O
perform	O
the	O
task	O
on	O
several	O
neuropsychological	O
measures	O
sensitive	O
to	O
deficits	O
in	O
problem	O
solving	O
and	O
executive	O
functions	O
,	O
but	O
not	O
on	O
tests	O
of	O
global	O
cognitive	O
decline	O
,	O
memory	O
,	O
language	O
,	O
or	O
visuoperceptual	O
functioning	O
.	O

These	O
results	O
indicate	O
that	O
acquisition	O
and	O
retention	O
of	O
a	O
complex	O
visuomotor	O
skill	O
can	O
proceed	O
normally	O
in	O
the	O
early	O
stages	O
of	O
AD	O
in	O
those	O
individuals	O
who	O
can	O
initially	O
perform	O
the	O
basic	O
task	O
,	O
and	O
that	O
inability	O
to	O
perform	O
the	O
basic	O
task	O
may	O
be	O
related	O
to	O
the	O
frontal	O
lobe	O
dysfunction	O
that	O
is	O
often	O
prominent	O
in	O
the	O
disorder	O
.	O

Thus	O
,	O
miR-206	O
slows	O
ALS	O
progression	O
by	O
sensing	O
motor	O
neuron	O
injury	O
and	O
promoting	O
the	O
compensatory	O
regeneration	O
of	O
neuromuscular	O
synapses	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
is	O
miR-206	O
,	O
a	O
skeletal	O
muscle	O
-	O
specific	O
microRNA	O
that	O
is	O
dramatically	O
induced	O
in	O
a	O
mouse	O
model	O
of	O
ALS	O
.	O

Mice	O
that	O
are	O
genetically	O
deficient	O
in	O
miR-206	O
form	O
normal	O
neuromuscular	O
synapses	O
during	O
development	O
,	O
but	O
deficiency	O
of	O
miR-206	O
in	O
the	O
ALS	O
mouse	O
model	O
accelerates	O
disease	O
progression	O
.	O

miR-206	O
is	O
required	O
for	O
efficient	O
regeneration	O
of	O
neuromuscular	O
synapses	O
after	O
acute	O
nerve	O
injury	O
,	O
which	O
probably	O
accounts	O
for	O
its	O
salutary	O
effects	O
in	O
ALS	O
.	O

miR-206	O
mediates	O
these	O
effects	O
at	O
least	O
in	O
part	O
through	O
histone	B
deacetylase	I
4	I
and	O
fibroblast	O
growth	O
factor	O
signaling	O
pathways	O
.	O

MicroRNA-206	O
delays	O
ALS	O
progression	O
and	O
promotes	O
regeneration	O
of	O
neuromuscular	O
synapses	O
in	O
mice	O
.	O

Amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
characterized	O
by	O
loss	O
of	O
motor	O
neurons	O
,	O
denervation	O
of	O
target	O
muscles	O
,	O
muscle	O
atrophy	O
,	O
and	O
paralysis	O
.	O

Understanding	O
ALS	O
pathogenesis	O
may	O
require	O
a	O
fuller	O
understanding	O
of	O
the	O
bidirectional	O
signaling	O
between	O
motor	O
neurons	O
and	O
skeletal	O
muscle	O
fibers	O
at	O
neuromuscular	O
synapses	O
.	O

[	O
A	O
study	O
on	O
miRNA	O
alternation	O
after	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
using	O
microarray	O
technique	O
]	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
H2O2	O
for	O
12	O
hours	O
,	O
and	O
then	O
the	O
cell	O
viabilities	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
cell	O
apoptosis	O
rates	O
were	O
assessed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
the	O
differentially	O
expressed	O
microRNAs	O
(	O
miRNA	O
)	O
between	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
and	O
normal	O
PC12	O
cells	O
with	O
microarray	O
chips	O
.	O

Of	O
the	O
46	O
miRNAs	O
in	O
the	O
H2O2	O
treated	O
groups	O
,	O
39	O
were	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
6	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
may	O
provide	O
a	O
new	O
potential	O
foundation	O
for	O
further	O
study	O
of	O
pathogenesis	O
and	O
its	O
treatment	O
of	O
nerve	O
cell	O
apoptosis	O
caused	O
by	O
cerebral	O
ischemia	O
reperfusion	O
.	O

The	O
apoptosis	O
rates	O
for	O
them	O
were	O
2.6	O
%	O
,	O
5.2	O
%	O
,	O
7.2	O
%	O
,	O
10.4	O
%	O
,	O
16.6	O
%	O
,	O
and	O
72.2	O
%	O
accordingly	O
.	O

Expression	O
of	O
68	O
miRNAs	O
and	O
46	O
miRNAs	O
were	O
detected	O
in	O
both	O
control	O
group	O
and	O
the	O
H2O2	O
treated	O
groups	O
.	O

miRNAs	O
were	O
isolated	O
from	O
control	O
(	O
0	O
nmol	O
/	O
L	O
H2O2	O
)	O
and	O
H2O2	O
treated	O
(	O
at	O
concentrations	O
of	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
400	O
nmol	O
/	O
L	O
H2O2	O
,	O
respectively	O
)	O
groups	O
of	O
the	O
PC12	O
cells	O
,	O
respectively	O
,	O
and	O
were	O
then	O
detected	O
and	O
analyzed	O
by	O
microarray	O
chips	O
.	O

RESULTS	O
:	O
The	O
P12	O
cell	O
viabilities	O
in	O
control	O
and	O
H2O2	O
treated	O
group	O
were	O
(	O
92	O
+	O
/-	O
9.8	O
)	O
%	O
,	O
(	O
90	O
+	O
/-	O
14.70	O
)	O
%	O
,	O
(	O
80	O
+	O
/-	O
13.85	O
)	O
%	O
,	O
(	O
54	O
+	O
/-	O
12.23	O
)	O
%	O
,	O
and	O
(	O
22	O
+	O
/-	O
7.35	O
)	O
%	O
,	O
respectively	O
.	O

In	O
particular	O
,	O
SNP	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
was	O
linked	O
to	O
PD	O
-	O
risk	O
through	O
a	O
mechanism	O
that	O
would	O
implicate	O
a	O
differential	O
binding	O
to	O
microRNA-433	O
(	O
miR-433	O
)	O
.	O

The	O
reduction	O
of	O
the	O
affinity	O
of	O
miR-433	O
to	O
the	O
3	O
'	O
UTR	O
would	O
result	O
in	O
increased	O
FGF20	B
expression	O
and	O
upregulation	O
of	O
alpha	B
-	I
synuclein	I
,	O
which	O
could	O
in	O
turn	O
promote	O
dopaminergic	O
neurons	O
degeneration	O
.	O

FGF20	B
rs12720208	O
SNP	O
and	O
microRNA-433	O
variation	O
:	O
no	O
association	O
with	O
Parkinson	O
's	O
disease	O
in	O
Spanish	O
patients	O
.	O

DNA	O
variation	O
at	O
the	O
FGF20	B
gene	O
has	O
been	O
associated	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
work	O
did	O
not	O
confirm	O
the	O
association	O
between	O
rs12720208	O
and	O
PD	O
,	O
or	O
an	O
effect	O
of	O
miR-433	O
variants	O
on	O
this	O
disease	O
.	O

None	O
of	O
the	O
patients	O
had	O
miR-433	O
variants	O
.	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
allele	O
and	O
genotype	O
frequencies	O
between	O
patients	O
and	O
controls	O
.	O

We	O
genotyped	O
the	O
rs12720208	O
SNP	O
in	O
a	O
total	O
of	O
512	O
PD	O
patients	O
and	O
258	O
healthy	O
controls	O
from	O
Spain	O
,	O
and	O
searched	O
for	O
miR-433	O
variants	O
in	O
the	O
patients	O
.	O

The	O
results	O
suggest	O
(	O
a	O
)	O
that	O
unless	O
specifically	O
stabilized	O
,	O
certain	O
brain	O
-	O
enriched	O
miRNAs	O
represent	O
a	O
rapidly	O
executed	O
signaling	O
system	O
employing	O
highly	O
transient	O
effectors	O
of	O
CNS	O
gene	O
expression	O
,	O
and	O
(	O
b	O
)	O
that	O
in	O
AD	O
temporal	O
lobe	O
neocortex	O
specific	O
brain	O
miRNAs	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
abundance	O
and	O
strongly	O
correlate	O
with	O
the	O
presence	O
of	O
AD	O
-	O
type	O
neuropatholgical	O
change	O
.	O

In	O
short	O
PMI	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
-affected	O
temporal	O
lobe	O
neocortex	O
,	O
miRNA-9	O
,	O
miRNA-125b	O
and	O
miRNA-146a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
,	O
an	O
effect	O
that	O
was	O
not	O
seen	O
in	O
several	O
related	O
neurological	O
disorders	O
.	O

In	O
these	O
studies	O
,	O
miRNA	O
array	O
and	O
Northern	O
blot	O
based	O
tracking	O
of	O
specific	O
miRNA	O
abundances	O
and	O
decay	O
kinetics	O
in	O
human	O
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
and	O
in	O
short	O
post	O
-	O
mortem	O
interval	O
(	O
PMI	O
,	O
approximately	O
1h	O
)	O
human	O
brain	O
tissues	O
showed	O
a	O
limited	O
stability	O
and	O
relatively	O
short	O
half	O
-	O
life	O
(	O
approximately	O
1	O
-	O
3.5h	O
)	O
for	O
specific	O
brain	O
-	O
enriched	O
miRNAs	O
.	O

Micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
mediated	O
regulation	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
emerging	O
as	O
a	O
critical	O
factor	O
in	O
the	O
control	O
of	O
CNS	O
-	O
specific	O
gene	O
expression	O
during	O
development	O
,	O
plasticity	O
,	O
aging	O
and	O
disease	O
.	O

Micro	O
-	O
RNA	O
abundance	O
and	O
stability	O
in	O
human	O
brain	O
:	O
specific	O
alterations	O
in	O
Alzheimer	O
's	O
disease	O
temporal	O
lobe	O
neocortex	O
.	O

Keystone	O
symposium	O
,	O
Neurodegenerative	O
Diseases	O
:	O
New	O
Molecular	O
Mechanisms	O
17	O
-	O
22	O
February	O
2009	O
.	O

Glioma	O
angiogenesis	O
:	O
Towards	O
novel	O
RNA	O
therapeutics	O
.	O

Brain	O
tumors	O
exhibit	O
marked	O
and	O
aberrant	O
blood	O
vessel	O
formation	O
indicating	O
angiogenic	O
endothelial	O
cells	O
as	O
a	O
potential	O
target	O
for	O
brain	O
tumor	O
treatment	O
.	O

The	O
brain	O
tumor	O
blood	O
vessels	O
are	O
used	O
for	O
nutrient	O
delivery	O
,	O
and	O
possibly	O
for	O
cancer	O
cell	O
migration	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
complex	O
and	O
involves	O
multiple	O
players	O
.	O

The	O
current	O
angiogenesis	O
inhibitors	O
used	O
in	O
clinical	O
trials	O
mostly	O
target	O
single	O
angiogenic	O
proteins	O
and	O
so	O
far	O
show	O
limited	O
effects	O
on	O
tumor	O
growth	O
.	O

Besides	O
the	O
conventional	O
angiogenesis	O
inhibitors	O
,	O
RNA	O
-	O
based	O
inhibitors	O
such	O
as	O
small	O
-	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
are	O
being	O
analyzed	O
for	O
their	O
capacity	O
to	O
silence	O
the	O
message	O
of	O
proteins	O
involved	O
in	O
neovascularization	O
.	O

More	O
recently	O
,	O
a	O
new	O
family	O
of	O
non	O
-	O
coding	O
RNAs	O
,	O
named	O
angiomirs	O
[	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
angiogenesis	O
]	O
has	O
emerged	O
.	O

These	O
small	O
RNAs	O
have	O
the	O
advantage	O
over	O
siRNAs	O
in	O
that	O
they	O
have	O
the	O
potential	O
of	O
silencing	O
multiple	O
messages	O
at	O
the	O
same	O
time	O
and	O
therefore	O
they	O
might	O
become	O
therapeutically	O
relevant	O
in	O
a	O
""""	O
one	O
-	O
hit	O
multiple	O
-	O
target	O
""""	O
context	O
against	O
brain	O
tumor	O
angiogenesis	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
emerging	O
technologies	O
in	O
anti	O
-	O
angiogenesis	O
emphasizing	O
on	O
RNA	O
-	O
based	O
therapeutics	O
.	O

Diseases	O
potentially	O
mediated	O
by	O
alterations	O
in	O
RNA	O
processes	O
include	O
tauopathies	O
,	O
myotonic	O
dystrophy	O
,	O
Alzheimer	O
disease	O
,	O
brain	O
cancer	O
,	O
and	O
many	O
others	O
.	O

Some	O
noncoding	O
RNAs	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
human	O
brain	O
diseases	O
.	O

Furthermore	O
,	O
there	O
is	O
poor	O
correlation	O
between	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
mammalian	O
cells	O
,	O
due	O
partly	O
to	O
complicated	O
post	O
-	O
transcriptional	O
regulation	O
by	O
hitherto	O
unknown	O
noncoding	O
RNAs	O
.	O

For	O
example	O
,	O
neurologic	O
illnesses	O
may	O
arise	O
because	O
of	O
perturbations	O
in	O
distinct	O
but	O
interrelated	O
tiers	O
of	O
RNA	O
-	O
based	O
genetic	O
regulation	O
:	O
pre	O
-	O
mRNA	O
splicing	O
;	O
nonsplicing	O
RNA	O
modifications	O
;	O
and	O
mRNA	O
translational	O
regulation	O
.	O

A	O
variety	O
of	O
unforeseen	O
complexities	O
have	O
been	O
identified	O
,	O
many	O
with	O
relevance	O
to	O
human	O
brain	O
disease	O
.	O

RNA	O
research	O
has	O
made	O
great	O
progress	O
in	O
recent	O
years	O
.	O

RNA	O
in	O
brain	O
disease	O
:	O
no	O
longer	O
just	O
""""	O
the	O
messenger	O
in	O
the	O
middle	O
""""	O
.	O

Here	O
we	O
present	O
an	O
overview	O
of	O
new	O
research	O
highlighting	O
functions	O
for	O
RNA	O
that	O
far	O
surpass	O
the	O
""""	O
messenger	O
in	O
the	O
middle	O
""""	O
role	O
and	O
that	O
identify	O
RNA	O
molecules	O
as	O
important	O
agents	O
in	O
the	O
human	O
brain	O
in	O
health	O
and	O
in	O
disease	O
states	O
.	O

RNA	O
editing	O
by	O
adenosine	O
deamination	O
is	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
is	O
particularly	O
widespread	O
in	O
mammals	O
.	O

Gene	O
regulation	O
through	O
RNA	O
editing	O
.	O

Here	O
,	O
I	O
am	O
reviewing	O
main	O
features	O
of	O
this	O
epigenetic	O
phenomenon	O
,	O
its	O
relevance	O
for	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
potential	O
prospects	O
for	O
using	O
RNA	O
editing	O
as	O
a	O
therapeutic	O
tool	O
.	O

Widespread	O
A	O
-	O
to	O
-	O
I	O
modification	O
of	O
repeat	O
sequences	O
in	O
the	O
human	O
transcriptome	O
suggests	O
additional	O
roles	O
for	O
RNA	O
editing	O
and	O
links	O
it	O
to	O
other	O
processes	O
of	O
gene	O
regulation	O
,	O
such	O
as	O
RNA	O
splicing	O
as	O
well	O
as	O
siRNA	O
mediated	O
gene	O
silencing	O
and	O
miRNA	O
function	O
.	O

The	O
deficiency	O
or	O
misregulation	O
of	O
editing	O
has	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
neurological	O
diseases	O
,	O
such	O
as	O
epilepsy	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
depression	O
and	O
tumor	O
progression	O
.	O

Also	O
,	O
it	O
regulates	O
important	O
functional	O
properties	O
of	O
neurotransmitter	O
receptor	O
genes	O
in	O
the	O
central	O
nervous	O
system	O
by	O
changing	O
single	O
codons	O
in	O
pre	O
-	O
mRNA	O
.	O

A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
generates	O
transcriptome	O
and	O
proteome	O
diversity	O
allowing	O
organisms	O
to	O
produce	O
many	O
more	O
gene	O
products	O
and	O
functions	O
than	O
predicted	O
based	O
on	O
the	O
number	O
of	O
genes	O
within	O
their	O
genome	O
.	O

Gliomas	O
display	O
a	O
microRNA	O
expression	O
profile	O
reminiscent	O
of	O
neural	O
precursor	O
cells	O
.	O

Gliomas	O
express	O
many	O
genes	O
that	O
play	O
a	O
role	O
in	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
,	O
but	O
no	O
direct	O
comparison	O
between	O
glioma	O
and	O
stem	O
cell	O
(	O
SC	O
)	O
gene	O
expression	O
profiles	O
has	O
been	O
performed	O
.	O

To	O
investigate	O
the	O
similarities	O
and	O
differences	O
between	O
gliomas	O
and	O
SCs	O
,	O
we	O
compared	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
of	O
glial	O
tumors	O
,	O
embryonic	O
SCs	O
(	O
ESCs	O
)	O
,	O
NPCs	O
,	O
and	O
normal	O
adult	O
brains	O
from	O
both	O
human	O
and	O
mouse	O
tissues	O
.	O

We	O
demonstrated	O
that	O
both	O
human	O
gliomas	O
(	O
regardless	O
of	O
their	O
grade	O
)	O
and	O
methylcholanthrene	O
-	O
induced	O
mouse	O
glioma	O
shared	O
an	O
miRNA	O
expression	O
profile	O
that	O
is	O
reminiscent	O
of	O
NPCs	O
.	O

About	O
half	O
of	O
the	O
miRNAs	O
expressed	O
in	O
the	O
shared	O
profile	O
clustered	O
in	O
seven	O
genomic	O
regions	O
susceptible	O
to	O
genetic	O
/	O
epigenetic	O
alterations	O
in	O
various	O
cancers	O
.	O

These	O
clusters	O
comprised	O
the	O
miR17	O
family	O
,	O
mir183	O
-	O
182	O
,	O
and	O
the	O
SC	O
-	O
specific	O
clusters	O
mir367	O
-	O
302	O
and	O
mir371	O
-	O
373	O
,	O
which	O
are	O
upregulated	O
in	O
gliomas	O
,	O
ESCs	O
,	O
and	O
NPCs	O
.	O

The	O
bipartite	O
cluster	O
of	O
7	O
+	O
46	O
miRNAs	O
on	O
chromosome	O
14q32.31	O
,	O

which	O
might	O
represent	O
the	O
largest	O
tumor	O
suppressor	O
miRNA	O
cluster	O
,	O
was	O
downregulated	O
in	O
the	O
shared	O
expression	O
profile	O
.	O

This	O
study	O
provides	O
the	O
first	O
evidence	O
for	O
association	O
between	O
these	O
clusters	O
and	O
gliomas	O
.	O

Despite	O
the	O
broad	O
similarity	O
in	O
the	O
miRNA	O
expression	O
profiles	O
,	O
15	O
miRNAs	O
showed	O
disparate	O
expression	O
between	O
SC	O
and	O
gliomas	O
.	O

Ten	O
miRNAs	O
belong	O
to	O
the	O
2	O
SC	O
-	O
specific	O
clusters	O
and	O
the	O
remaining	O
(	O
mir135b	O
,	O
mir141	O
,	O
mir205	O
,	O
mir200C	O
,	O
and	O
mir301a	O
)	O
have	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
malignancies	O
.	O

Our	O
finding	O
showed	O
that	O
all	O
gliomas	O
displayed	O
NPC	O
-	O
like	O
miRNA	O
signatures	O
,	O
which	O
may	O
have	O
implications	O
for	O
studies	O
of	O
glioma	O
origins	O
.	O

Furthermore	O
,	O
careful	O
study	O
of	O
the	O
15	O
miRNAs	O
that	O
differ	O
in	O
expression	O
between	O
SCs	O
and	O
gliomas	O
,	O
particularly	O
those	O
5	O
that	O
are	O
not	O
SC	O
-	O
specific	O
,	O
may	O
enhance	O
our	O
understanding	O
of	O
gliomagenesis	O
.	O

New	O
insights	O
into	O
the	O
roles	O
of	O
microRNAs	O
in	O
drug	O
addiction	O
and	O
neuroplasticity	O
.	O

In	O
this	O
review	O
,	O
the	O
aim	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
emerging	O
role	O
of	O
miRNAs	O
in	O
addiction	O
.	O

miRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
particularly	O
abundant	O
in	O
the	O
nervous	O
system	O
,	O
that	O
play	O
key	O
roles	O
as	O
regulatory	O
molecules	O
in	O
processes	O
such	O
as	O
neurogenesis	O
,	O
synapse	O
development	O
and	O
plasticity	O
in	O
the	O
brain	O
.	O

They	O
also	O
act	O
as	O
key	O
spatiotemporal	O
regulators	O
during	O
dendritic	O
morphogenesis	O
,	O
controlling	O
the	O
expression	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
neuroplasticity	O
and	O
in	O
the	O
function	O
of	O
synapses	O
.	O

Recent	O
studies	O
have	O
identified	O
changes	O
of	O
several	O
specific	O
miRNA	O
expression	O
profiles	O
and	O
polymorphisms	O
affecting	O
the	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
in	O
various	O
brain	O
disorders	O
,	O
including	O
addiction	O
:	O
miR-16	O
causes	O
adaptive	O
changes	O
in	O
production	O
of	O
the	O
serotonin	O
transporter	O
;	O
miR-133b	O
is	O
specifically	O
expressed	O
in	O
midbrain	O
dopaminergic	O
neurons	O
,	O
and	O
regulates	O
the	O
production	O
of	O
tyrosine	B
hydroxylase	I
and	O
the	O
dopamine	O
transporter	O
;	O
miR-212	O
affects	O
production	O
of	O
striatal	O
brain	B
-	I
derived	I
neurotrophic	I
factor	I
and	O
synaptic	O
plasticity	O
upon	O
cocaine	O
.	O

Clearly	O
,	O
specific	O
miRNAs	O
have	O
emerged	O
as	O
key	O
regulators	O
leading	O
to	O
addiction	O
,	O
and	O
could	O
serve	O
as	O
valuable	O
targets	O
for	O
more	O
efficient	O
therapies	O
.	O

ABSTRACT	O
:	O
Drug	O
addiction	O
is	O
a	O
major	O
public	O
health	O
issue	O
.	O

It	O
is	O
typically	O
a	O
multigenetic	O
brain	O
disorder	O
,	O
implying	O
combined	O
changes	O
of	O
expression	O
of	O
several	O
hundred	O
genes	O
.	O

Psychostimulants	O
(	O
such	O
as	O
cocaine	O
,	O
heroin	O
and	O
amphetamines	O
)	O
induce	O
strong	O
and	O
persistent	O
neuroadaptive	O
changes	O
through	O
a	O
surfeit	O
of	O
gene	O
regulatory	O
mechanisms	O
leading	O
to	O
addiction	O
.	O

Activity	O
-	O
dependent	O
synaptic	O
plasticity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
,	O
known	O
as	O
the	O
'	O
reward	O
pathway	O
'	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
drug	O
dependence	O
.	O

Identification	O
of	O
a	O
novel	O
splice	O
site	O
mutation	O
of	O
CLCN5	B
gene	O
and	O
characterization	O
of	O
a	O
new	O
alternative	O
5	O
'	O
UTR	O
end	O
of	O
ClC-5	B
mRNA	O
in	O
human	O
renal	O
tissue	O
and	O
leukocytes	O
.	O

Mutations	O
in	O
the	O
CLCN5	B
gene	O
have	O
been	O
detected	O
in	O
Dent	O
's	O
disease	O
and	O
its	O
phenotypic	O
variants	O
(	O
X	O
-	O
linked	O
recessive	O
nephrolithiasis	O
,	O
X	O
-	O
linked	O
recessive	O
hypophosphatemic	O
rickets	O
,	O
and	O
idiopathic	O
low	O
-	O
molecular	O
-	O
weight	O
proteinuria	O
of	O
Japanese	O
children	O
)	O
.	O

Dent	O
's	O
disease	O
is	O
a	O
tubular	O
disorder	O
characterized	O
by	O
low	O
-	O
molecular	O
-	O
weight	O
proteinuria	O
,	O
and	O
nephrolithiasis	O
associated	O
with	O
nephrocalcinosis	O
and	O
hypercalciuria	O
.	O

ClC-5	B
is	O
the	O
first	O
chloride	O
channel	O
for	O
which	O
a	O
definitive	O
role	O
in	O
the	O
trafficking	O
and	O
acidification	O
-	O
dependent	O
recycling	O
of	O
apical	O
membrane	O
proteins	O
has	O
been	O
established	O
.	O

In	O
the	O
course	O
of	O
CLCN5	B
SSCP	O
analysis	O
in	O
patients	O
with	O
hypercalciuric	O
nephrolithiasis	O
,	O
we	O
detected	O
a	O
novel	O
mutation	O
at	O
intron	O
2	O
of	O
the	O
CLCN5	B
gene	O
,	O
a	O
T	O
-	O
to	O
-	O
G	O
substitution	O
,	O
located	O
17	O
bp	O
upstream	O
of	O
the	O
AG	O
acceptor	O
siteCLCN5	O
gene	O
,	O
a	O
T	O
-	O
to	O
-	O
G	O
substitution	O
,	O
located	O
17	O
bp	O
upstream	O
of	O
the	O
AG	O
acceptor	O
site	O
.	O

To	O
determine	O
the	O
effect	O
of	O
IVS2	O
-	O
17	O
T	O
>	O
G	O
mutation	O
on	O
the	O
correct	O
splicing	O
of	O
intron	O
2	O
,	O
we	O
studied	O
ClC-5	B
transcripts	O
in	O
a	O
patient	O
's	O
peripheral	O
blood	O
leukocytes	O
by	O
means	O
of	O
quantitative	O
comparative	O
RT	O
/	O
PCR	O
,	O
and	O
found	O
a	O
new	O
ClC-5	B
5	O
'	O
UTR	O
isoform	O
characterized	O
by	O
the	O
untranslated	O
exon	O
1b	O
and	O
by	O
retention	O
of	O
intron	O
1b	O
.	O

This	O
new	O
isoform	O
--	O
isoform	O
B1	O
-	O
-was	O
not	O
correlated	O
with	O
mutation	O
since	O
it	O
was	O
detected	O
also	O
in	O
control	O
leukocytes	O
and	O
in	O
renal	O
tissues	O
of	O
kidney	O
donors	O
,	O
thus	O
confirming	O
its	O
physiological	O
role	O
.	O

By	O
RACE	O
analysis	O
we	O
determined	O
the	O
putative	O
transcriptional	O
start	O
site	O
which	O
is	O
located	O
at	O
intron	O
1a	O
,	O
251	O
nt	O
upstream	O
of	O
the	O
first	O
nucleotide	O
of	O
the	O
untranslated	O
exon	O
1b	O
.	O

ORF	O
analysis	O
revealed	O
that	O
intron	O
1b	O
retention	O
in	O
isoform	O
B1	O
stabilizes	O
the	O
initiation	O
of	O
translation	O
to	O
the	O
AGT	O
at	O
position	O
297	O
of	O
the	O
ClC-5	B
cDNA	O
coding	O
region	O
.	O

TNXB	B
locus	O
may	O
be	O
a	O
candidate	O
gene	O
predisposing	O
to	O
schizophrenia	O
.	O

We	O
report	O
here	O
on	O
the	O
detection	O
of	O
nine	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
near	O
to	O
the	O
NOTCH4	B
locus	O
in	O
the	O
search	O
for	O
schizophrenia	O
susceptibility	O
genes	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
.	O

We	O
totally	O
analyzed	O
122	O
family	O
trios	O
recruited	O
in	O
the	O
UK	O
.	O

The	O
TDT	O
analysis	O
demonstrated	O
that	O
of	O
the	O
nine	O
SNPs	O
,	O
three	O
were	O
associated	O
with	O
schizophrenia	O
,	O
including	O
rs1009382	O
(	O
P	O
=	O
0.00047	O
)	O
,	O
rs204887	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
rs8283	O
(	O
P	O
=	O
0.015	O
)	O
.	O

Both	O
rs1009382	O
and	O
rs204887	O
are	O
present	O
in	O
the	O
TNXB	B
locus	O
.	O

The	O
rs1009382	O
is	O
a	O
non	O
-	O
synonymous	O
SNP	O
located	O
in	O
exon	O
23	O
of	O
the	O
gene	O
and	O
its	O
A	O
to	O
G	O
base	O
change	O
causes	O
a	O
Glu2578Gly	O
substitution	O
.	O

The	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
showed	O
that	O
genotypic	O
distribution	O
of	O
rs1009382	O
was	O
deviated	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
due	O
to	O
homozygote	O
excess	O
in	O
the	O
patient	O
group	O
(	O
P	O
=	O
0.01	O
)	O
,	O
suggesting	O
that	O
a	O
double	O
dose	O
of	O
a	O
genetic	O
risk	O
may	O
be	O
involved	O
.	O

Possibly	O
,	O
rs1009382	O
is	O
a	O
candidate	O
SNP	O
predisposing	O
to	O
a	O
schizophrenic	O
illness	O
.	O

Moreover	O
,	O
the	O
test	O
for	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
between	O
paired	O
SNPs	O
showed	O
that	O
the	O
nine	O
SNPs	O
studied	O
may	O
be	O
in	O
the	O
same	O
LD	O
block	O
with	O
an	O
unexpected	O
pattern	O
as	O
the	O
strength	O
of	O
LD	O
was	O
not	O
correlated	O
with	O
the	O
distance	O
between	O
paired	O
SNPs	O
.	O

The	O
haplotype	O
analysis	O
suggested	O
that	O
there	O
might	O
be	O
more	O
than	O
one	O
disease	O
-	O
related	O
allele	O
located	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
MHC	O
,	O
and	O
that	O
these	O
alleles	O
possibly	O
confer	O
either	O
susceptibility	O
or	O
resistance	O
to	O
schizophrenia	O
.	O

No	O
association	O
between	O
the	O
APOE	B
gene	O
and	O
autism	O
.	O

Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
stereotypic	O
and	O
repetitive	O
behavior	O
and	O
interests	O
,	O
together	O
with	O
social	O
and	O
communicative	O
deficiencies	O
.	O

The	O
results	O
of	O
several	O
genomic	O
screens	O
suggest	O
the	O
presence	O
of	O
an	O
autism	O
susceptibility	O
locus	O
on	O
chromosome	O
19p13.2-q13.4	O
.	O

The	O
apolipoprotein	B
E	I
(	O
APOE	B
)	O
gene	O
on	O
chromosome	O
19	O
encodes	O
for	O
a	O
protein	O
,	O
apoE	B
,	O
whose	O
different	O
isoforms	O
(	O
E2	O
,	O
E3	O
,	O
E4	O
)	O
influence	O
neuronal	O
growth	O
.	O

APOE	B
participates	O
in	O
lipid	O
transport	O
and	O
metabolism	O
,	O
repair	O
,	O
growth	O
,	O
and	O
maintenance	O
of	O
axons	O
and	O
myelin	O
during	O
neuronal	O
development	O
.	O

The	O
APOE	B
protein	O
competes	O
with	O
the	O
Reelin	B
protein	O
for	O
VLDL	O
/	O
APOER2	B
receptor	O
binding	O
.	O

Several	O
studies	O
have	O
reported	O
evidence	O
for	O
an	O
association	O
between	O
autism	O
and	O
the	O
Reelin	B
gene	O
.	O

Based	O
on	O
these	O
data	O
we	O
tested	O
for	O
association	O
between	O
APOE	B
and	O
autism	O
using	O
family	O
-	O
based	O
association	O
methods	O
in	O
a	O
data	O
set	O
of	O
322	O
autism	O
families	O
.	O

Three	O
promoter	O
,	O
one	O
intronic	O
,	O
and	O
one	O
3	O
'	O
UTR	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
APOE	B
gene	O
(	O
-491a	O
/	O
t	O
,	O
-427c	O
/	O
t	O
,	O
-219g	O
/	O
t	O
,	O
113c	O
/	O
g	O
,	O
and	O
5361c	O
/	O
t	O
)	O
as	O
well	O
as	O
the	O
APOE	B
functional	O
polymorphism	O
(	O
E2	O
,	O
E3	O
,	O
E4	O
)	O
were	O
examined	O
and	O
failed	O
to	O
reveal	O
significant	O
evidence	O
that	O
autism	O
is	O
associated	O
with	O
APOE	B
.	O

Polymorphisms	O
in	O
the	O
prion	B
protein	I
gene	O
and	O
in	O
the	O
doppel	B
gene	I
increase	O
susceptibility	O
for	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
.	O

The	O
prion	B
protein	I
gene	O
(	O
PRNP	B
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
origin	O
of	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
CJD	O
)	O
,	O
but	O
there	O
is	O
growing	O
interest	O
in	O
other	O
polymorphisms	O
that	O
may	O
be	O
involved	O
in	O
CJD	O
.	O

Polymorphisms	O
upstream	O
of	O
PRNP	B
that	O
may	O
modulate	O
the	O
prion	B
protein	I
production	O
as	O
well	O
as	O
polymorphisms	O
in	O
the	O
prion	B
-	I
like	I
doppel	I
gene	O
(	O
PRND	B
)	O
have	O
been	O
studied	O
,	O
with	O
inconsistent	O
findings	O
.	O

We	O
investigated	O
the	O
role	O
of	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
1368	O
)	O
located	O
upstream	O
of	O
PRNP	O
and	O
three	O
polymorphisms	O
in	O
PRND	B
(	O
T26	O
M	O
,	O
P56L	O
and	O
T174	O
M	O
)	O
in	O
CJD	O
.	O

The	O
study	O
included	O
a	O
population	O
-	O
based	O
sample	O
of	O
52	O
patients	O
with	O
sporadic	O
CJD	O
and	O
250	O
controls	O
.	O

We	O
analysed	O
our	O
data	O
as	O
single	O
markers	O
and	O
haplotypes	O
.	O

Further	O
,	O
we	O
conducted	O
a	O
meta	O
-	O
analysis	O
on	O
PRND	B
T174	O
M	O
comparing	O
the	O
data	O
of	O
the	O
four	O
studies	O
conducted	O
to	O
date	O
.	O

For	O
SNP	O
1368	O
and	O
PRNP	B
M129V	O
,	O
we	O
found	O
significant	O
evidence	O
for	O
linkage	O
disequilibrium	O
.	O

No	O
evidence	O
was	O
found	O
for	O
a	O
relation	O
of	O
SNP	O
1368	O
to	O
CJD	O
independent	O
of	O
PRNP	B
M129V	O
.	O

We	O
further	O
found	O
a	O
significant	O
increased	O
prevalence	O
of	O
M	O
homozygotes	O
at	O
PRND	B
T174	O
M	O
among	O
sporadic	O
CJD	O
patients	O
,	O
when	O
adjusting	O
the	O
analyses	O
for	O
the	O
other	O
genotypes	O
.	O

In	O
the	O
haplotype	O
analyses	O
,	O
the	O
association	O
was	O
strongest	O
for	O
persons	O
homozygous	O
for	O
PRNP	B
129	O
M	O
and	O
PRND	B
174	O
M	O
(	O
odds	O
ratio	O
4.35	O
,	O
95	O
%	O
confidence	O
interval	O
1.05	O
-	O
8.09	O
;	O
P=0.04	O
)	O
.	O

The	O
meta	O
-	O
analysis	O
on	O
the	O
PRND	B
T174	O
M	O
polymorphism	O
did	O
not	O
show	O
a	O
consistent	O
effect	O
across	O
studies	O
,	O
raising	O
the	O
question	O
as	O
to	O
whether	O
PRND	B
174	O
M	O
is	O
causally	O
related	O
to	O
CJD	O
,	O
or	O
whether	O
the	O
PRND	B
allele	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
another	O
polymorphism	O
related	O
to	O
CJD	O
.	O

Is	O
there	O
a	O
future	O
for	O
TNF	B
promoter	O
polymorphisms	O
?	O

The	O
in	O
vitro	O
study	O
of	O
TNF	B
promoter	O
polymorphism	O
(	O
SNP	O
)	O
function	O
was	O
stimulated	O
by	O
the	O
numerous	O
case	O
-	O
control	O
(	O
association	O
)	O
studies	O
of	O
the	O
polymorphisms	O
in	O
relation	O
to	O
human	O
disease	O
and	O
the	O
appearance	O
of	O
several	O
studies	O
claiming	O
to	O
show	O
a	O
functional	O
role	O
for	O
these	O
SNPs	O
provided	O
a	O
further	O
impetus	O
to	O
researchers	O
interested	O
in	O
the	O
role	O
of	O
TNF	B
in	O
their	O
disease	O
of	O
interest	O
.	O

In	O
this	O
review	O
we	O
consider	O
case	O
-	O
control	O
studies	O
,	O
concentrating	O
on	O
the	O
autoimmune	O
and	O
inflammatory	O
diseases	O
rheumatoid	O
arthritis	O
,	O
multiple	O
sclerosis	O
,	O
ankylosing	O
spondylitis	O
,	O
and	O
asthma	O
,	O
and	O
on	O
infectious	O
diseases	O
including	O
malaria	O
,	O
hepatitis	O
B	O
and	O
C	O
infection	O
,	O
leprosy	O
and	O
sepsis	O
/	O
septic	O
shock	O
.	O

We	O
also	O
review	O
the	O
available	O
evidence	O
on	O
the	O
functional	O
role	O
of	O
the	O
various	O
TNF	B
promoter	O
polymorphisms	O
.	O

In	O
general	O
,	O
case	O
-	O
control	O
studies	O
have	O
produced	O
mixed	O
results	O
,	O
with	O
little	O
consensus	O
in	O
most	O
cases	O
on	O
whether	O
any	O
TNF	B
polymorphisms	O
are	O
actually	O
associated	O
with	O
disease	O
,	O
although	O
results	O
have	O
been	O
more	O
consistent	O
in	O
the	O
case	O
of	O
infectious	O
diseases	O
,	O
particularly	O
malaria	O
.	O

Functional	O
studies	O
have	O
also	O
produced	O
mixed	O
results	O
but	O
recent	O
work	O
suggests	O
that	O
the	O
much	O
studied	O
-308G	O
/	O
A	O
polymorphism	O
is	O
not	O
functional	O
,	O
while	O
the	O
function	O
of	O
other	O
TNF	B
polymorphisms	O
remains	O
controversial	O
.	O

Studies	O
of	O
the	O
TNF	B
region	O
are	O
increasingly	O
using	O
extended	O
haplotypes	O
that	O
can	O
better	O
capture	O
the	O
variation	O
of	O
the	O
MHC	O
region	O
.	O

Association	O
of	O
the	O
homeobox	O
transcription	O
factor	O
,	O
ENGRAILED	B
2	I
,	I
3	I
,	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Mouse	O
mutants	O
of	O
the	O
homeobox	O
transcription	O
factor	O
Engrailed2	B
(	O
En2	B
)	O
and	O
autistic	O
individuals	O
display	O
similar	O
cerebellar	O
morphological	O
abnormalities	O
,	O
which	O
include	O
hypoplasia	O
and	O
a	O
decrease	O
in	O
the	O
number	O
of	O
Purkinje	O
cells	O
.	O

Human	O
EN2	B
maps	O
to	O
7q36	O
,	O
a	O
chromosomal	O
region	O
that	O
has	O
demonstrated	O
suggestive	O
linkage	O
to	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

To	O
investigate	O
EN2	B
for	O
evidence	O
of	O
association	O
with	O
ASD	O
,	O
four	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
(	O
rs3735653	O
,	O
rs1861972	O
,	O
rs1861973	O
,	O
rs2361689	O
)	O
that	O
span	O
the	O
majority	O
of	O
the	O
8.0	O
kb	O
gene	O
were	O
assessed	O
by	O
the	O
transmission	O
/	O
disequilibrium	O
test	O
.	O

Initially	O
,	O
138	O
triads	O
of	O
autistic	O
individuals	O
and	O
their	O
parents	O
were	O
tested	O
.	O

Two	O
intronic	O
SNPs	O
(	O
rs1861972	O
and	O
rs1861973	O
)	O
demonstrated	O
significant	O
association	O
with	O
autism	O
(	O
rs1861972	O
,	O
P=0.0018	O
;	O
rs1861973	O
,	O
P=0.0003	O
;	O
haplotype	O
,	O
P=0.000005	O
)	O
.	O

Flanking	O
exonic	O
SNPs	O
(	O
rs3735653	O
and	O
rs2361689	O
)	O
did	O
not	O
display	O
association	O
.	O

This	O
analysis	O
was	O
then	O
extended	O
to	O
include	O
167	O
small	O
nuclear	O
ASD	O
pedigrees	O
and	O
significant	O
association	O
was	O
again	O
only	O
observed	O
for	O
rs1861972	O
and	O
rs1861973	O
under	O
both	O
the	O
narrow	O
and	O
broad	O
diagnostic	O
criteria	O
(	O
narrow	O
:	O
rs1861972	O
P=0.0290	O
,	O
rs1861973	O
P=0.0073	O
,	O
haplotype	O
P=0.0009	O
;	O
broad	O
:	O
rs1861972	O
P=0.0175	O
,	O
rs1861973	O
P=0.0107	O
,	O
haplotype	O
P=0.0024	O
)	O
.	O

These	O
data	O
demonstrate	O
association	O
between	O
a	O
cerebellar	O
patterning	O
gene	O
and	O
ASD	O
,	O
suggesting	O
a	O
role	O
for	O
EN2	B
as	O
a	O
susceptibility	O
locus	O
and	O
supporting	O
a	O
neurodevelopmental	O
defect	O
hypothesis	O
in	O
the	O
etiology	O
of	O
autism	O
.	O

Binge	O
-	O
eating	O
episodes	O
are	O
not	O
characteristic	O
of	O
carriers	O
of	O
melanocortin-4	B
receptor	O
gene	O
mutations	O
.	O

Recently	O
,	O
Branson	O
and	O
coworkers	O
reported	O
a	O
strong	O
association	O
between	O
binge	O
-	O
eating	O
disorder	O
(	O
BED	O
)	O
and	O
variants	O
in	O
the	O
melanocortin-4	B
receptor	O
gene	O
(	O
MC4R	B
)	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
compared	O
the	O
eating	O
behavior	O
of	O
43	O
obese	O
probands	O
with	O
functionally	O
relevant	O
MC4R	B
mutations	O
and	O
of	O
35	O
polymorphism	O
carriers	O
(	O
V103I	O
or	O
I251L	O
)	O
with	O
wild	O
-	O
type	O
carriers	O
.	O

The	O
module	O
for	O
eating	O
disorders	O
of	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
was	O
used	O
to	O
identify	O
binge	O
-	O
eating	O
behavior	O
.	O

The	O
Three	O
-	O
Factor	O
Eating	O
Questionnaire	O
and	O
the	O
Leeds	O
Food	O
Frequency	O
Questionnaire	O
were	O
used	O
to	O
assess	O
restrained	O
eating	O
,	O
disinhibition	O
,	O
hunger	O
and	O
percent	O
total	O
energy	O
intake	O
as	O
fat	O
.	O

No	O
significant	O
differences	O
between	O
carriers	O
of	O
MC4R	B
variants	O
and	O
wild	O
-	O
type	O
carriers	O
were	O
detected	O
.	O

In	O
particular	O
,	O
we	O
found	O
no	O
evidence	O
for	O
an	O
increased	O
rate	O
of	O
binge	O
-	O
eating	O
behavior	O
in	O
obese	O
carriers	O
of	O
MC4R	B
variants	O
.	O

Our	O
findings	O
do	O
not	O
support	O
the	O
strong	O
association	O
between	O
BED	O
and	O
MC4R	B
carrier	O
status	O
.	O

A	O
functional	O
haplotype	O
of	O
the	O
PADI4	B
gene	O
associated	O
with	O
rheumatoid	O
arthritis	O
in	O
a	O
Japanese	O
population	O
is	O
not	O
associated	O
in	O
a	O
United	O
Kingdom	O
population	O
.	O

OBJECTIVE	O
:	O
In	O
the	O
era	O
of	O
postgenomic	O
research	O
,	O
linkage-	O
and	O
association	O
-	O
based	O
strategies	O
are	O
beginning	O
to	O
reveal	O
novel	O
complex	O
disease	O
genes	O
.	O

Using	O
such	O
an	O
approach	O
,	O
a	O
functional	O
haplotype	O
of	O
the	O
peptidylarginine	B
deiminase	I
4	I
gene	O
(	O
PADI4	B
)	O
has	O
recently	O
been	O
identified	O
as	O
a	O
gene	O
conferring	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
in	O
a	O
Japanese	O
population	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
association	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
PADI4	B
gene	O
with	O
RA	O
in	O
a	O
UK	O
population	O
.	O

METHODS	O
:	O
Association	O
with	O
4	O
exonic	O
SNPs	O
(	O
padi4_89*G	B
/	O
A	O
,	O
padi4_90*T	B
/	O
C	O
,	O
padi4_92*G	B
/	O
C	O
,	O
and	O
padi4_104*T	B
/	O
C	O
)	O
,	O
mapping	O
to	O
the	O
PADI4	B
gene	O
and	O
defining	O
a	O
haplotype	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
RA	O
,	O
was	O
investigated	O
.	O

Genotyping	O
was	O
performed	O
using	O
5	O
'	O
allelic	O
discrimination	O
assays	O
.	O

Estimated	O
haplotypes	O
were	O
generated	O
using	O
the	O
expectation	O
-	O
maximization	O
algorithm	O
,	O
and	O
frequencies	O
of	O
the	O
SNPs	O
and	O
haplotypes	O
were	O
compared	O
between	O
unrelated	O
Caucasian	O
RA	O
patients	O
from	O
the	O
UK	O
(	O
n	O
=	O
839	O
)	O
and	O
population	O
controls	O
(	O
n	O
=	O
481	O
)	O
.	O

RESULTS	O
:	O
Allele	O
frequencies	O
for	O
the	O
4	O
SNPs	O
in	O
the	O
UK	O
population	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
Japanese	O
control	O
population	O
,	O
but	O
none	O
of	O
these	O
was	O
associated	O
with	O
RA	O
.	O

As	O
in	O
the	O
Japanese	O
population	O
,	O
the	O
SNPs	O
in	O
the	O
UK	O
population	O
defined	O
2	O
major	O
haplotypes	O
,	O
but	O
neither	O
was	O
associated	O
with	O
RA	O
(	O
P	O
=	O
0.79	O
)	O
.	O

CONCLUSION	O
:	O
A	O
PADI4	B
susceptibility	O
haplotype	O
associated	O
with	O
RA	O
in	O
a	O
Japanese	O
population	O
is	O
not	O
associated	O
with	O
RA	O
in	O
a	O
UK	O
population	O
.	O

Other	O
genes	O
involved	O
in	O
the	O
citrullinating	O
pathway	O
remain	O
strong	O
candidate	O
RA	O
-	O
susceptibility	O
genes	O
and	O
require	O
further	O
investigation	O
.	O

Extended	O
linkage	O
disequilibrium	O
surrounding	O
the	O
hemoglobin	B
E	I
variant	O
due	O
to	O
malarial	O
selection	O
.	O

The	O
hemoglobin	B
E	I
variant	O
(	O
HbE	B
;	O
(	O
beta	O
)	O
26Glu-->Lys	O
)	O
is	O
concentrated	O
in	O
parts	O
of	O
Southeast	O
Asia	O
where	O
malaria	O
is	O
endemic	O
,	O
and	O
HbE	B
carrier	O
status	O
has	O
been	O
shown	O
to	O
confer	O
some	O
protection	O
against	O
Plasmodium	O
falciparum	O
malaria	O
.	O

To	O
examine	O
the	O
effect	O
of	O
natural	O
selection	O
on	O
the	O
pattern	O
of	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
to	O
infer	O
the	O
evolutionary	O
history	O
of	O
the	O
HbE	B
variant	O
,	O
we	O
analyzed	O
biallelic	O
markers	O
surrounding	O
the	O
HbE	B
variant	O
in	O
a	O
Thai	O
population	O
.	O

Pairwise	O
LD	O
analysis	O
of	O
HbE	B
and	O
43	O
surrounding	O
biallelic	O
markers	O
revealed	O
LD	O
of	O
HbE	B
extending	O
beyond	O
100	O
kb	O
,	O
whereas	O
no	O
LD	O
was	O
observed	O
between	O
non	O
-	O
HbE	B
variants	O
and	O
the	O
same	O
markers	O
.	O

The	O
inferred	O
haplotype	O
network	O
suggests	O
a	O
single	O
origin	O
of	O
the	O
HbE	B
variant	O
in	O
the	O
Thai	O
population	O
.	O

Forward	O
-	O
in	O
-	O
time	O
computer	O
simulations	O
under	O
a	O
variety	O
of	O
selection	O
models	O
indicate	O
that	O
the	O
HbE	B
variant	O
arose	O
1,240	O
-	O
4,440	O
years	O
ago	O
.	O

These	O
results	O
support	O
the	O
conjecture	O
that	O
the	O
HbE	B
mutation	O
occurred	O
recently	O
,	O
and	O
the	O
allele	O
frequency	O
has	O
increased	O
rapidly	O
.	O

Our	O
study	O
provides	O
another	O
clear	O
demonstration	O
that	O
a	O
high	O
-	O
resolution	O
LD	O
map	O
across	O
the	O
human	O
genome	O
can	O
detect	O
recent	O
variants	O
that	O
have	O
been	O
subjected	O
to	O
positive	O
selection	O
.	O

Pharmacogenetics	O
of	O
the	O
CD14	B
endotoxin	O
receptor	O
polymorphism	O
and	O
progression	O
of	O
coronary	O
atherosclerosis	O
.	O

Atherosclerosis	O
is	O
at	O
least	O
in	O
part	O
an	O
inflammatory	O
disease	O
.	O

CD14	B
is	O
an	O
endotoxin	O
receptor	O
that	O
after	O
binding	O
of	O
lipopolysaccharides	O
evokes	O
endothelial	O
activation	O
and	O
secretion	O
of	O
several	O
cytokines	O
.	O

A	O
polymorphism	O
of	O
CD14	B
has	O
been	O
associated	O
with	O
myocardial	O
infarction	O
.	O

We	O
evaluated	O
the	O
role	O
of	O
the	O
-159	O
T	O
/	O
C	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
CD14	B
gene	O
in	O
relation	O
to	O
severity	O
and	O
progression	O
of	O
coronary	O
atherosclerosis	O
and	O
response	O
to	O
the	O
HMG	B
CoA	I
reductase	I
inhibitor	O
pravastatin	O
.	O

We	O
recruited	O
patients	O
from	O
the	O
multi	O
-	O
center	O
double	O
-	O
blind	O
randomized	O
placebo	O
controlled	O
REGRESS	O
trial	O
and	O
genotyped	O
the	O
-159T	O
/	O
C	O
CD14	B
polymorphism	O
.	O

DNA	O
and	O
angiographic	O
follow	O
-	O
up	O
were	O
available	O
from	O
759	O
patients	O
with	O
objectivated	O
coronary	O
artery	O
disease	O
.	O

We	O
measured	O
changes	O
in	O
mean	O
segment	O
diameter	O
(	O
MSD	O
)	O
and	O
minimum	O
obstruction	O
diameter	O
(	O
MOD	O
)	O
with	O
quantitative	O
coronary	O
angiography	O
and	O
noted	O
the	O
occurrence	O
of	O
major	O
adverse	O
cardiac	O
events	O
.	O

The	O
genotype	O
distribution	O
was	O
28	O
%	O
TT	O
,	O
49	O
%	O
CT	O
,	O
23	O
%	O
CC	O
.	O

We	O
did	O
not	O
find	O
any	O
association	O
between	O
genotype	O
and	O
MSD	O
and	O
MOD	O
at	O
baseline	O
,	O
frequency	O
of	O
previous	O
myocardial	O
infarction	O
,	O
changes	O
in	O
MSD	O
and	O
MOD	O
or	O
major	O
clinical	O
events	O
.	O

Treatment	O
with	O
the	O
HMG	B
CoA	I
reductase	I
inhibitor	O
pravastatin	O
reduced	O
progression	O
of	O
coronary	O
atherosclerosis	O
and	O
adverse	O
events	O
equally	O
for	O
all	O
genotypes	O
.	O

We	O
conclude	O
,	O
that	O
the	O
-159T	O
/	O
C	O
polymorphism	O
in	O
the	O
CD14	B
monocyte	O
receptor	O
gene	O
was	O
not	O
associated	O
with	O
progression	O
of	O
coronary	O
atherosclerosis	O
in	O
this	O
population	O
nor	O
did	O
it	O
influence	O
the	O
efficacy	O
of	O
pravastatin	O
in	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O

Evidence	O
for	O
CTLA4	B
as	O
a	O
susceptibility	O
gene	O
for	O
systemic	O
lupus	O
erythematosus	O
.	O

Several	O
lines	O
of	O
evidence	O
implicate	O
the	O
Cytotoxic	B
T	I
Lymphocyte	I
Antigen	I
4	I
(	O
CTLA4	B
)	O
gene	O
in	O
susceptibility	O
to	O
autoimmune	O
disease	O
.	O

We	O
have	O
examined	O
the	O
association	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
with	O
polymorhisms	O
within	O
the	O
CTLA4	B
gene	O
that	O
were	O
previously	O
proposed	O
to	O
regulate	O
CTLA-4	B
function	O
:	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
position	O
+	O
49	O
of	O
exon	O
1	O
and	O
a	O
dinucleotide	O
repeat	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
.	O

The	O
3'UTR	O
repeat	O
showed	O
a	O
significant	O
association	O
with	O
SLE	O
,	O
with	O
one	O
allele	O
conferring	O
susceptibility	O
and	O
another	O
conferring	O
protection	O
to	O
the	O
disease	O
.	O

The	O
associated	O
alleles	O
do	O
not	O
support	O
previous	O
suggestions	O
of	O
an	O
allele	O
size	O
-	O
dependent	O
effect	O
of	O
the	O
3	O
'	O
UTR	O
polymorphism	O
in	O
autoimmunity	O
development	O
and	O
instead	O
suggest	O
that	O
it	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
a	O
true	O
causative	O
locus	O
.	O

No	O
association	O
of	O
the	O
exon	O
1	O
SNP	O
with	O
SLE	O
was	O
found	O
in	O
our	O
population	O
.	O

Given	O
the	O
conflicting	O
results	O
obtained	O
in	O
different	O
studies	O
on	O
the	O
association	O
of	O
SLE	O
with	O
this	O
polymorphism	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
including	O
seven	O
previously	O
published	O
studies	O
and	O
the	O
present	O
one	O
.	O

Significantly	O
increased	O
and	O
decreased	O
risks	O
for	O
SLE	O
were	O
found	O
for	O
carriers	O
of	O
the	O
G	O
allele	O
and	O
the	O
A	O
allele	O
,	O
respectively	O
.	O

The	O
functional	O
characterization	O
of	O
disease	O
-	O
associated	O
CTLA4	B
gene	O
variants	O
is	O
now	O
required	O
to	O
elucidate	O
their	O
role	O
in	O
the	O
pathogenesis	O
of	O
SLE	O
and	O
other	O
autoimmune	O
diseases	O
.	O

Statistical	O
methods	O
We	O
analyzed	O
correlations	O
between	O
categorical	O
variables	O
using	O
the	O
χ2	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

We	O
used	O
analysis	O
of	O
variance	O
to	O
study	O
correlations	O
between	O
continuous	O
and	O
categorical	O
variables	O
,	O
and	O
simple	O
regression	O
to	O
analyze	O
correlations	O
between	O
continuous	O
variables	O
.	O

p53	B
mutation	O
is	O
strongly	O
associated	O
with	O
Type	O
A	O
MSI	O
in	O
human	O
colorectal	O
cancer	O
One	O
view	O
of	O
the	O
involvement	O
of	O
MMR	B
defects	O
in	O
cancer	O
development	O
is	O
that	O
the	O
'	O
microsatellite	O
mutator	O
phenotype	O
(	O
MMP	O
)	O
'	O
(	O
29,30	O
)	O
in	O
mismatch	O
repair	O
-	O
defective	O
cells	O
offers	O
an	O
alternative	O
to	O
chromosomal	O
instability	O
as	O
a	O
mechanism	O
for	O
genetic	O
instability	O
in	O
cancer	O
(	O
31	O
)	O
.	O

On	O
this	O
model	O
,	O
MSI	O
and	O
chromosomal	O
instability	O
represent	O
mutually	O
exclusive	O
pathways	O
of	O
tumour	O
development	O
.	O

This	O
reasoning	O
is	O
based	O
partly	O
in	O
the	O
observation	O
that	O
p53	B
mutations	O
,	O
commonly	O
associated	O
with	O
chromosomal	O
instability	O
,	O
are	O
infrequent	O
among	O
MSI+	O
tumours	O
(	O
2,32–34	O
)	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
Type	O
A	O
/	O
B	O
instability	O
and	O
p53	B
mutation	O
,	O
we	O
sequenced	O
the	O
p53	B
gene	O
in	O
our	O
panel	O
of	O
79	O
colorectal	O
tumours	O
.	O

p53	B
mutations	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
were	O
detected	O
in	O
23	O
tumours	O
(	O
29.1	O
%	O
)	O
.	O

The	O
mutations	O
were	O
predominantly	O
transitions	O
in	O
acknowledged	O
hot	O
spots	O
;	O
codons	O
175	O
,	O
248	O
and	O
273	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
p53	B
mutations	O
that	O
were	O
found	O
in	O
MSI+	O
tumours	O
,	O
all	O
were	O
associated	O
with	O
Type	O
A	O
MSI	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

No	O
p53	B
mutations	O
were	O
detected	O
among	O
the	O
14	O
Type	O
B	O
tumours	O
.	O

Among	O
Type	O
A	O
tumours	O
,	O
the	O
frequency	O
of	O
p53	B
mutation	O
approached	O
50	O
%	O
(	O
12	O
/	O
25	O
)	O
.	O

These	O
findings	O
confirm	O
that	O
p53	B
mutations	O
are	O
rare	O
in	O
tumours	O
with	O
Type	O
B	O
MSI	O
.	O

More	O
importantly	O
,	O
they	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
defective	O
MMR	B
is	O
significantly	O
associated	O
with	O
p53	B
mutation	O
,	O
at	O
least	O
in	O
human	O
colorectal	O
cancer	O
.	O

Discussion	O
The	O
exact	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
.	O

With	O
simple	O
multistage	O
models	O
[	O
3	O
-	O
6,11	O
]	O
,	O
all	O
cancers	O
of	O
a	O
given	O
type	O
require	O
the	O
same	O
number	O
of	O
oncogenic	O
mutations	O
,	O
but	O
stochastic	O
differences	O
in	O
the	O
times	O
to	O
accumulate	O
these	O
mutations	O
allow	O
individual	O
cancers	O
to	O
appear	O
at	O
different	O
ages	O
.	O

Precisely	O
when	O
and	O
how	O
quickly	O
mutations	O
accumulate	O
are	O
unknown	O
,	O
but	O
a	O
basic	O
premise	O
is	O
that	O
cancer	O
types	O
requiring	O
more	O
mutations	O
will	O
tend	O
to	O
appear	O
later	O
in	O
life	O
.	O

Therefore	O
,	O
numbers	O
of	O
mutations	O
may	O
be	O
estimated	O
from	O
cancer	O
epidemiology	O
.	O

Colorectal	O
cancer	O
frequencies	O
increase	O
with	O
age	O
,	O
and	O
the	O
pattern	O
of	O
this	O
increase	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
[	O
3	O
-	O
6	O
]	O
.	O

In	O
this	O
study	O
numbers	O
of	O
mutations	O
were	O
estimated	O
for	O
well	O
-	O
defined	O
subgroups	O
of	O
colorectal	O
cancers	O
because	O
biological	O
heterogeneity	O
may	O
confound	O
this	O
type	O
of	O
quantitative	O
analysis	O
.	O

Such	O
estimates	O
should	O
be	O
considered	O
rough	O
guides	O
rather	O
than	O
absolute	O
values	O
because	O
our	O
model	O
does	O
not	O
account	O
for	O
all	O
factors	O
.	O

Cancers	O
were	O
classified	O
as	O
MSI+	O
or	O
MSI-	O
,	O
and	O
MSI+	O
cancers	O
were	O
further	O
sub	O
-	O
classified	O
as	O
either	O
hereditary	O
(	O
HNPCC	O
)	O
or	O
sporadic	O
.	O

As	O
expected	O
because	O
one	O
MMR	O
mutation	O
is	O
inherited	O
,	O
estimated	O
numbers	O
of	O
critical	O
mutations	O
were	O
less	O
for	O
MSI+	O
HNPCC	O
cancers	O
compared	O
to	O
sporadic	O
MSI+	O
cancers	O
.	O

However	O
,	O
sporadic	O
MSI+	O
cancers	O
required	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
compared	O
to	O
HNPCC	O
cancers	O
.	O

Of	O
interest	O
,	O
a	O
difference	O
of	O
more	O
than	O
a	O
single	O
mutation	O
has	O
also	O
been	O
inferred	O
between	O
sporadic	O
and	O
FAP	O
cancers	O
,	O
with	O
estimates	O
of	O
three	O
to	O
four	O
mutations	O
for	O
FAP	O
cancers	O
versus	O
six	O
for	O
sporadic	O
cancers	O
[	O
6,13	O
]	O
,	O
although	O
another	O
analysis	O
was	O
consistent	O
with	O
a	O
difference	O
of	O
only	O
a	O
single	O
mutation	O
[	O
14	O
]	O
.	O

Therefore	O
,	O
germline	O
mutations	O
(	O
APC	B
and	O
MMR	B
loci	O
)	O
in	O
both	O
common	O
colorectal	O
familial	O
cancer	O
syndromes	O
(	O
FAP	O
and	O
HNPCC	O
)	O
appear	O
to	O
advance	O
progression	O
by	O
more	O
than	O
a	O
single	O
mutation	O
relative	O
to	O
their	O
sporadic	O
counterparts	O
.	O

An	O
epigenetic	O
mechanism	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
require	O
more	O
than	O
one	O
additional	O
somatic	O
alteration	O
relative	O
to	O
HNPCC	O
cancers	O
.	O

Inactivation	O
of	O
the	O
normal	O
MMR	B
allele	O
occurs	O
through	O
mutation	O
(	O
usually	O
LOH	O
[	O
15	O
]	O
)	O
in	O
HNPCC	O
whereas	O
MMR	O
loss	O
in	O
sporadic	O
MSI+	O
cancers	O
is	O
associated	O
with	O
MLH1	B
promoter	O
methylation	O
[	O
16,17	O
]	O
.	O

CpG	O
islands	O
may	O
be	O
""""	O
protected	O
""""	O
from	O
methylation	O
because	O
most	O
are	O
unmethylated	O
at	O
birth	O
and	O
usually	O
remain	O
unmethylated	O
throughout	O
life	O
[	O
18	O
]	O
.	O

Epigenetic	O
MLH1	B
inactivation	O
may	O
require	O
at	O
least	O
two	O
cis	O
acting	O
somatic	O
alterations	O
---	O
loss	O
of	O
a	O
mechanism	O
that	O
normally	O
prevents	O
methylation	O
,	O
followed	O
by	O
the	O
accumulation	O
of	O
methylation	O
at	O
sufficient	O
numbers	O
of	O
CpG	O
sites	O
to	O
silence	O
expression	O
.	O

In	O
agreement	O
with	O
prior	O
studies	O
,	O
there	O
were	O
seven	O
mutations	O
estimated	O
for	O
sporadic	O
MSI-	O
Finnish	O
cancers	O
[	O
4	O
]	O
,	O
and	O
seven	O
or	O
eight	O
mutations	O
for	O
MSI+	O
cancers	O
.	O

A	O
requirement	O
for	O
more	O
alterations	O
before	O
tranformation	O
for	O
sporadic	O
MSI+	O
compared	O
to	O
sporadic	O
MSI-	O
cancers	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	O
cancers	O
are	O
a	O
minority	O
of	O
all	O
colorectal	O
cancers	O
and	O
occur	O
in	O
slightly	O
older	O
patients	O
[	O
19,20	O
]	O
.	O

Although	O
numbers	O
of	O
oncogenic	O
mutations	O
before	O
transformation	O
are	O
similar	O
between	O
sporadic	O
MSI+	O
and	O
MSI-	O
cancers	O
,	O
their	O
identities	O
likely	O
differ	O
[	O
7,8	O
]	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
the	O
occurrence	O
of	O
mutations	O
in	O
the	O
APC	B
,	O
CTNNB1	B
and	O
K	B
-	I
ras	I
genes	O
as	O
well	O
as	O
expression	O
of	O
the	O
hMLH1	B
protein	O
in	O
tumour	O
tissue	O
of	O
656	O
sporadic	O
colorectal	O
cancer	O
cases	O
were	O
investigated	O
.	O

The	O
occurrence	O
of	O
mutations	O
in	O
the	O
CTNNB1	B
gene	O
,	O
which	O
codes	O
for	O
β	O
-	O
catenin	O
,	O
was	O
rare	O
:	O
only	O
five	O
of	O
464	O
tumours	O
analysed	O
were	O
found	O
to	O
have	O
a	O
mutation	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
.	O

Truncating	O
mutations	O
in	O
APC	B
and	O
activating	O
mutations	O
in	O
K	B
-	I
ras	I
appeared	O
to	O
occur	O
at	O
similar	O
frequencies	O
.	O

Although	O
tumours	O
harbouring	O
both	O
mutations	O
were	O
relatively	O
rare	O
,	O
mutations	O
in	O
APC	B
and	O
K	B
-	I
ras	I
seemed	O
to	O
occur	O
co	O
-	O
dependently	O
.	O

Nine	O
percent	O
of	O
all	O
tumours	O
(	O
58	O
/	O
656	O
)	O
lacked	O
hMLH1	B
expression	O
,	O
and	O
in	O
these	O
tumours	O
almost	O
no	O
APC	B
or	O
K	B
-	I
ras	I
mutations	O
was	O
detected	O
.	O

Patients	O
harbouring	O
a	O
tumour	O
with	O
absent	O
hMLH1	B
expression	O
were	O
older	O
,	O
more	O
often	O
women	O
,	O
more	O
often	O
had	O
proximal	O
colon	O
tumours	O
that	O
showed	O
poorer	O
differentiation	O
when	O
compared	O
to	O
patients	O
who	O
harboured	O
a	O
tumour	O
with	O
an	O
APC	B
and/or	O
K	B
-	I
ras	I
mutation	O
.	O

The	O
selection	O
of	O
patients	O
included	O
in	O
this	O
study	O
was	O
based	O
on	O
the	O
completeness	O
of	O
analyses	O
of	O
both	O
APC	B
and	O
K	B
-	I
ras	I
genes	O
as	O
well	O
as	O
hMLH1	B
expression	O
and	O
this	O
led	O
to	O
a	O
considerable	O
reduction	O
in	O
the	O
number	O
of	O
cases	O
that	O
could	O
be	O
included	O
in	O
the	O
analyses	O
presented	O
in	O
this	O
study	O
.	O

The	O
largest	O
reduction	O
(	O
72	O
cases	O
)	O
was	O
due	O
to	O
incompleteness	O
of	O
the	O
analysis	O
of	O
all	O
fragments	O
comprising	O
the	O
APC	B
mutation	O
cluster	O
region	O
.	O

Tumour	O
DNA	O
was	O
derived	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumour	O
tissue	O
blocks	O
.	O

Depending	O
on	O
the	O
conditions	O
of	O
fixation	O
and	O
storage	O
,	O
the	O
extracted	O
DNA	O
is	O
more	O
or	O
less	O
fragmented	O
,	O
which	O
may	O
have	O
impaired	O
the	O
analysis	O
of	O
mutations	O
in	O
the	O
APC	B
gene	O
more	O
than	O
in	O
the	O
K	B
-	I
ras	I
gene	O
,	O
since	O
the	O
analysis	O
of	O
the	O
latter	O
is	O
based	O
on	O
the	O
amplification	O
of	O
a	O
smaller	O
gene	O
fragment	O
.	O

It	O
should	O
be	O
emphasized	O
that	O
characteristics	O
of	O
patients	O
(	O
age	O
,	O
sex	O
,	O
family	O
history	O
of	O
colorectal	O
cancer	O
)	O
and	O
tumours	O
(	O
sub	O
-	O
localisation	O
,	O
Dukes	O
'	O
stage	O
and	O
differentiation	O
)	O
of	O
the	O
group	O
under	O
study	O
are	O
similar	O
to	O
the	O
737	O
patients	O
for	O
whom	O
tumour	O
material	O
was	O
available	O
and	O
to	O
all	O
819	O
patients	O
initially	O
recognized	O
within	O
the	O
cohort	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
the	O
K	B
-	I
ras	I
and	O
hMLH1data	B
presented	O
here	O
are	O
similar	O
to	O
the	O
data	O
for	O
K	B
-	I
ras	I
and	O
hMLH1	B
based	O
on	O
the	O
complete	O
groups	O
(	O
737	O
and	O
724	O
cases	O
,	O
respectively	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutations	O
in	O
exon	O
3	O
of	O
the	O
CTNNB1	B
gene	O
leading	O
to	O
loss	O
of	O
one	O
of	O
the	O
phosphorylation	O
sites	O
were	O
rare	O
.	O

Strikingly	O
,	O
all	O
five	O
of	O
these	O
mutations	O
occurred	O
in	O
the	O
proximal	O
colon	O
and	O
three	O
of	O
these	O
also	O
had	O
absent	O
hMLH1	B
expression	O
.	O

This	O
may	O
indicate	O
that	O
these	O
proximal	O
colon	O
tumours	O
,	O
which	O
often	O
also	O
show	O
mismatch	O
repair	O
deficiency	O
,	O
are	O
more	O
likely	O
to	O
harbour	O
CTNNB1	B
mutations	O
.	O

This	O
was	O
also	O
found	O
in	O
a	O
study	O
of	O
microsatellite	O
instable	O
colorectal	O
tumours	O
[	O
26	O
]	O
.	O

The	O
WAVE	O
screening	O
technique	O
has	O
not	O
been	O
used	O
previously	O
for	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
and	O
therefore	O
it	O
seems	O
plausible	O
that	O
samples	O
harbouring	O
a	O
CTNNB1	B
mutation	O
have	O
escaped	O
detection	O
.	O

However	O
,	O
all	O
58	O
hMLH1	B
deficient	O
samples	O
were	O
analysed	O
by	O
direct	O
sequencing	O
without	O
a	O
prior	O
screening	O
step	O
,	O
and	O
only	O
three	O
of	O
these	O
samples	O
harboured	O
a	O
CTNNB1	B
mutation	O
,	O
indicating	O
the	O
low	O
frequency	O
of	O
such	O
mutations	O
.	O

Background	O
Hereditary	O
non	O
-	O
polyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
is	O
an	O
inherited	O
syndrome	O
predisposing	O
to	O
the	O
early	O
development	O
of	O
cancers	O
of	O
colon	O
,	O
rectum	O
,	O
endometrium	O
,	O
ovarium	O
,	O
small	O
bowel	O
,	O
stomach	O
and	O
urinary	O
tract	O
[	O
1,2	O
]	O
.	O

Since	O
there	O
are	O
no	O
premonitory	O
signs	O
of	O
susceptibility	O
to	O
HNPCC	O
,	O
family	O
history	O
has	O
been	O
the	O
primary	O
method	O
for	O
identifying	O
patients	O
at	O
risk	O
.	O

Defined	O
by	O
the	O
International	O
Collaborative	O
group	O
on	O
HNPCC	O
,	O
the	O
typical	O
HNPCC	O
family	O
fulfill	O
the	O
following	O
criteria	O
(	O
referred	O
to	O
as	O
the	O
Amsterdam	O
-	O
I	O
criteria	O
[	O
3	O
]	O
)	O
:	O
1	O
.	O

Three	O
or	O
more	O
relatives	O
with	O
histologically	O
verified	O
colorectal	O
cancer	O
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
.	O

Colorectal	O
cancer	O
affecting	O
at	O
least	O
2	O
successive	O
generations	O
;	O
and	O
3	O
.	O

At	O
least	O
one	O
relative	O
diagnosed	O
with	O
colorectal	O
cancer	O
under	O
the	O
age	O
of	O
50	O
.	O

The	O
fulfillment	O
of	O
these	O
criteria	O
prompted	O
further	O
genetics	O
investigations	O
.	O

More	O
recently	O
it	O
has	O
been	O
revised	O
to	O
take	O
into	O
account	O
the	O
prevalence	O
of	O
extracolonic	O
cancer	O
in	O
certain	O
HNPCC	O
families	O
[	O
4	O
]	O
.	O

This	O
autosomal	O
dominantly	O
inherited	O
disorder	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
genes	O
coding	O
proteins	O
responsible	O
for	O
the	O
repair	O
of	O
DNA	O
replication	O
errors	O
,	O
which	O
are	O
referred	O
to	O
as	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
[	O
5	O
]	O
.	O

DNA	O
mismatch	O
repair	O
machinery	O
plays	O
a	O
critical	O
role	O
in	O
genomic	O
stability	O
,	O
including	O
correction	O
of	O
mispaired	O
bases	O
associated	O
with	O
DNA	O
replication	O
and	O
recombination	O
.	O

Germline	O
mutations	O
in	O
one	O
allele	O
of	O
any	O
of	O
these	O
genes	O
followed	O
by	O
the	O
somatic	O
loss	O
or	O
inactivation	O
of	O
the	O
wild	O
-	O
type	O
allele	O
leads	O
to	O
a	O
defective	O
mismatch	O
repair	O
mechanism	O
.	O

The	O
current	O
""""	O
gold	O
standard	O
""""	O
for	O
assessing	O
tumor	O
DNA	O
MMR	B
activity	O
is	O
molecular	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
testing	O
.	O

In	O
most	O
cases	O
,	O
it	O
involves	O
extracting	O
DNA	O
from	O
both	O
tumor	O
and	O
normal	O
tissue	O
.	O

The	O
DNA	O
is	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
five	O
or	O
more	O
different	O
chromosomal	O
loci	O
that	O
compare	O
""""	O
microsatellites	O
""""	O
,	O
running	O
the	O
PCR	O
products	O
through	O
a	O
gel	O
to	O
separate	O
DNA	O
fragments	O
by	O
size	O
,	O
comparing	O
the	O
tumor	O
-	O
normal	O
pairs	O
,	O
and	O
scoring	O
for	O
differences	O
between	O
the	O
two	O
.	O

Instability	O
at	O
two	O
or	O
more	O
out	O
of	O
five	O
markers	O
defines	O
a	O
tumor	O
as	O
MSI	O
-	O
H	O
and	O
prompts	O
further	O
analysis	O
,	O
as	O
sequencing	O
of	O
DNA	O
MMR	O
genes	O
.	O

A	O
number	O
of	O
them	O
have	O
been	O
associated	O
with	O
HNPCC	O
,	O
including	O
hMSH2	B
,	O
hMLH1	B
,	O
hPMS1	B
,	O
hPMS2	B
,	O
hMSH3	B
,	O
and	O
hMSH6	B
.	O

Most	O
of	O
the	O
HNPCC	O
families	O
in	O
which	O
mutations	O
have	O
been	O
identified	O
involved	O
hMSH2	B
and	O
hMLH1	B
genes	O
[	O
6	O
]	O
.	O

A	O
much	O
less	O
labor	O
-	O
intensive	O
alternative	O
method	O
used	O
to	O
prescreen	O
high	O
-	O
risk	O
individuals	O
for	O
further	O
germline	O
mutation	O
analysis	O
is	O
immunohistochemistry	O
(	O
IHC	O
)	O
testing	O
for	O
MLH1	B
and	O
MSH2	B
expression	O
.	O

IHC	O
testing	O
may	O
identify	O
which	O
gene	O
to	O
target	O
for	O
analysis	O
.	O

We	O
describe	O
MSI	O
testing	O
in	O
the	O
absence	O
of	O
proband	O
non	O
-	O
tumor	O
tissue	O
using	O
the	O
Bethesda	O
consensus	O
panel	O
(	O
mononucleotide	O
repeats	O
BAT25	O
and	O
BAT26	O
,	O
and	O
dinucleotide	O
repeats	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
and	O
we	O
report	O
a	O
novel	O
hMSH2	B
germline	O
mutation	O
found	O
in	O
the	O
family	O
.	O

Microsatellite	O
instability	O
.	O

Three	O
of	O
five	O
microsatellite	O
markers	O
(	O
BAT-25	O
,	O
BAT-26	O
and	O
D5S346	O
)	O
presented	O
different	O
alleles	O
(	O
*	O
)	O
in	O
the	O
proband	O
's	O
primary	O
tumor	O
(	O
T	O
'	O
)	O
and	O
its	O
metastasis	O
(	O
T	O
""""	O
)	O
of	O
those	O
inherited	O
from	O
his	O
biological	O
mother	O
(	O
BM	O
)	O
and	O
father	O
(	O
BF	O
)	O
.	O

DNA	O
sequencing	O
of	O
hMSH2	B
and	O
hMLH1	B
genes	O
A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
the	O
proband	O
's	O
mother	O
and	O
forwarded	O
to	O
the	O
Department	O
of	O
Clinical	O
Cancer	O
Genetics	O
(	O
City	O
of	O
Hope	O
Cancer	O
Center	O
,	O
Duarte	O
,	O
California	O
,	O
USA	O
)	O
to	O
full	O
mutation	O
analysis	O
of	O
the	O
hMSH2	B
and	O
hMLH1	B
genes	O
.	O

The	O
sample	O
was	O
amplified	O
followed	O
by	O
direct	O
sequencing	O
to	O
screen	O
the	O
coding	O
regions	O
of	O
both	O
the	O
hMSH2	B
and	O
the	O
hMLH1	B
genes	O
for	O
germline	O
mutation	O
in	O
the	O
DNA	O
.	O

After	O
establishing	O
the	O
familial	O
mutation	O
in	O
the	O
proband	O
's	O
mother	O
,	O
located	O
in	O
the	O
exon	O
12	O
of	O
hMSH2	B
gene	O
,	O
it	O
was	O
searched	O
in	O
the	O
proband	O
's	O
sisters	O
by	O
direct	O
sequencing	O
using	O
a	O
manual	O
Sequenase	O
PCR	O
products	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Mutation	O
screening	O
was	O
done	O
in	O
both	O
sisters	O
to	O
assign	O
their	O
risk	O
to	O
develop	O
HNPCC	O
and	O
other	O
related	O
cancers	O
.	O

We	O
found	O
the	O
mutation	O
in	O
one	O
of	O
them	O
and	O
opportune	O
recommendations	O
for	O
surveillance	O
and	O
prophylaxis	O
were	O
given	O
.	O

Two	O
years	O
after	O
that	O
,	O
the	O
proband	O
's	O
mother	O
,	O
unaffected	O
during	O
this	O
study	O
,	O
developed	O
an	O
endometrial	O
adenocarcinoma	O
.	O

Methods	O
Patients	O
25	O
colorectal	O
cancer	O
patients	O
undergoing	O
elective	O
standard	O
oncological	O
resection	O
at	O
the	O
department	O
of	O
surgery	O
,	O
Charité	O
,	O
Campus	O
Benjamin	O
Franklin	O
,	O
Berlin	O
,	O
Germany	O
were	O
prospectively	O
recruited	O
for	O
this	O
study	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethical	O
committee	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O

Rectal	O
cancer	O
patients	O
receiving	O
neo	O
-	O
adjuvant	O
radiochemotherapy	O
were	O
excluded	O
from	O
this	O
study	O
.	O

Tissue	O
samples	O
and	O
UV	O
-	O
laser	O
microdissection	O
Transmural	O
cancer	O
specimens	O
were	O
snap	O
frozen	O
(	O
liquid	O
nitrogen	O
)	O
within	O
20	O
minutes	O
following	O
excision	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

All	O
tissue	O
samples	O
were	O
evaluated	O
by	O
a	O
pathologist	O
before	O
and	O
during	O
laser	O
micro	O
-	O
dissection	O
to	O
ensure	O
an	O
enrichment	O
of	O
vital	O
tumor	O
cells	O
.	O

Six	O
-	O
micron	O
serial	O
frozen	O
sections	O
were	O
cut	O
on	O
a	O
standard	O
cryostat	O
and	O
mounted	O
on	O
RNase	O
-	O
free	O
foil	O
(	O
2,5	O
μm	O
)	O
coated	O
on	O
glass	O
slides	O
followed	O
by	O
immediate	O
fixation	O
(	O
70	O
%	O
ethanol	O
for	O
30s	O
)	O
,	O
H&E	O
staining	O
,	O
and	O
ethanol	O
dehydration	O
(	O
70	O
%	O
,	O
95	O
%	O
and	O
finally	O
100	O
%	O
ethanol	O
)	O
.	O

After	O
vacuum	O
drying	O
the	O
membranes	O
carrying	O
the	O
sections	O
were	O
manually	O
turned	O
and	O
coated	O
on	O
new	O
RNase	O
free	O
glass	O
slides	O
.	O

Optically	O
transparent	O
CapSure	O
LCM	O
caps	O
(	O
ARCTURUS	O
,	O
CA	O
)	O
were	O
placed	O
on	O
the	O
foil	O
over	O
a	O
selected	O
field	O
of	O
cells	O
.	O

Vital	O
colorectal	O
epithelial	O
carcinoma	O
cells	O
(	O
>	O
90	O
%	O
proportion	O
)	O
from	O
the	O
invasion	O
front	O
were	O
isolated	O
using	O
UV	O
-	O
LCM	O
Systems	O
from	O
PALM	O
(	O
Microlaser	O
Technologie	O
,	O
Germany	O
)	O
and	O
SL	O
(	O
Microtest	O
GmbH	O
,	O
Germany	O
)	O
.	O

After	O
visual	O
control	O
of	O
completeness	O
of	O
dissection	O
the	O
captured	O
cells	O
were	O
immersed	O
in	O
denaturation	O
buffer	O
(	O
GTC	O
Extraction	O
Buffer	O
,	O
2	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
Promega	O
,	O
WI	O
)	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

mRNA	O
-	O
extraction	O
,	O
cRNA	O
-	O
preparation	O
and	O
-amplification	O
Poly	O
(	O
A	O
)	O
+	O
RNAs	O
were	O
isolated	O
using	O
PolyATtract	O
1000	O
kit	O
(	O
Promega	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

For	O
each	O
sample	O
the	O
cDNA	O
synthesis	O
and	O
repetitive	O
in	O
vitro	O
transcription	O
were	O
performed	O
three	O
times	O
,	O
as	O
described	O
previously	O
[	O
38	O
-	O
40	O
]	O
.	O

In	O
brief	O
,	O
the	O
total	O
amount	O
of	O
prepared	O
mRNA	O
from	O
one	O
sample	O
was	O
used	O
.	O

First	O
strand	O
cDNA	O
synthesis	O
was	O
initiated	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
.	O

The	O
second	O
strand	O
cDNA	O
was	O
synthesized	O
by	O
internal	O
priming	O
.	O

In	O
vitro	O
transcription	O
was	O
performed	O
using	O
Ambion	O
's	O
Megascript	O
kit	O
(	O
Ambion	O
,	O
Huntington	O
,	O
UK	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

From	O
the	O
generated	O
cRNA	O
a	O
new	O
first	O
strand	O
synthesis	O
was	O
initiated	O
using	O
0.025	O
mM	O
of	O
a	O
random	O
hexamer	O
as	O
primer	O
.	O

After	O
completion	O
,	O
the	O
second	O
strand	O
synthesis	O
was	O
primed	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
at	O
a	O
concentration	O
of	O
0.1	O
mM.	O
A	O
second	O
in	O
vitro	O
transcription	O
was	O
performed	O
and	O
then	O
the	O
procedure	O
was	O
repeated	O
one	O
additional	O
time	O
.	O

During	O
the	O
third	O
in	O
vitro	O
transcription	O
biotin	O
-	O
labeled	O
nucleotides	O
were	O
incorporated	O
into	O
the	O
cRNA	O
as	O
recommended	O
by	O
the	O
Affymetrix	O
protocol	O
.	O

Microarray	O
hybridization	O
BIO+cRNAs	O
were	O
hybridized	O
on	O
Affymetrix	O
Human	O
Genome	O
U133A	O
and	O
U133B	O
GeneChips	O
,	O
that	O
consist	O
of	O
44.928	O
probe	O
sets	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Fragmentation	O
,	O
preparation	O
of	O
hybridization	O
cocktails	O
,	O
hybridization	O
,	O
washing	O
,	O
staining	O
and	O
scanning	O
of	O
Affymetrix	O
GeneChip	O
were	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocols	O
.	O

Introduction	O

The	O
traditional	O
view	O
of	O
epithelial	O
polyps	O
of	O
the	O
colorectum	O
envisages	O
a	O
larger	O
non	O
-	O
neoplastic	O
category	O
of	O
hyperplastic	O
polyps	O
(	O
HPs	O
)	O
that	O
can	O
be	O
safely	O
ignored	O
and	O
a	O
smaller	O
category	O
of	O
neoplastic	O
polyps	O
or	O
adenomas	O
that	O
are	O
precancerous.1	O
With	O
respect	O
to	O
adenomas	O
,	O
it	O
is	O
clear	O
that	O
the	O
majority	O
will	O
not	O
progress	O
to	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.2	O
The	O
risk	O
of	O
cancer	O
developing	O
within	O
an	O
adenoma	O
increases	O
with	O
size	O
,	O
grade	O
of	O
dysplasia	O
(	O
synonymous	O
with	O
intraepithelial	O
neoplasia	O
)	O
and	O
villosity.3	O
These	O
features	O
,	O
together	O
with	O
polyp	O
numbers	O
,	O
are	O
also	O
predictive	O
of	O
metachronous	O
neoplasia	O
and	O
may	O
therefore	O
influence	O
the	O
decision	O
to	O
offer	O
follow	O
-	O
up	O
endoscopic	O
surveillance.4	O
However	O
,	O
the	O
grading	O
of	O
dysplasia	O
and	O
estimation	O
of	O
the	O
extent	O
of	O
villous	O
change	O
may	O
not	O
be	O
fully	O
reproducible	O
and	O
it	O
may	O
be	O
difficult	O
to	O
distinguish	O
new	O
from	O
recurrent	O
adenomas	O
.	O

Establishing	O
a	O
risk	O
profile	O
on	O
the	O
basis	O
of	O
the	O
traditional	O
features	O
of	O
adenoma	O
is	O
therefore	O
not	O
always	O
straightforward	O
.	O

The	O
addition	O
of	O
molecular	O
profiling	O
to	O
polyp	O
description	O
offers	O
hope	O
of	O
a	O
more	O
objective	O
and	O
therefore	O
reproducible	O
approach	O
to	O
the	O
classification	O
of	O
colorectal	O
adenomas	O
.	O

The	O
genetic	O
evolutionary	O
paradigm	O
envisages	O
a	O
linear	O
sequence	O
of	O
changes	O
beginning	O
with	O
bi	O
-	O
allelic	O
inactivation	O
of	O
APC	B
,	O
followed	O
by	O
oncogenic	O
KRAS	B
mutation	O
and	O
culminating	O
in	O
inactivation	O
of	O
TP53	B
at	O
the	O
transition	O
from	O
adenoma	O
to	O
carcinoma.5	O
While	O
there	O
is	O
good	O
evidence	O
that	O
KRAS	B
mutation	O
is	O
associated	O
with	O
advanced	O
adenoma	O
features6	O
and	O
could	O
therefore	O
be	O
used	O
as	O
objective	O
evidence	O
of	O
aggression	O
,	O
this	O
approach	O
has	O
a	O
number	O
of	O
limitations	O
.	O

First	O
,	O
KRAS	B
mutation	O
also	O
occurs	O
frequently	O
in	O
dysplastic	O
aberrant	O
crypt	O
foci	O
(	O
microadenomas	O
)	O
and	O
in	O
some	O
small	O
tubular	O
adenomas	O
,	O
suggesting	O
that	O
KRAS	B
mutation	O
may	O
initiate	O
a	O
subset	O
of	O
small	O
adenomas	O
with	O
limited	O
potential	O
for	O
progression.6,7	O
Second	O
,	O
around	O
70	O
%	O
of	O
CRCs	O
lack	O
mutation	O
of	O
KRAS.8	B
From	O
this	O
it	O
follows	O
that	O
most	O
of	O
the	O
precancerous	O
lesions	O
that	O
eventually	O
become	O
cancers	O
do	O
not	O
in	O
fact	O
have	O
KRAS	B
mutation	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
CRC	O
evolves	O
through	O
a	O
number	O
of	O
pathways	O
and	O
the	O
traditional	O
adenoma	O
–	O
carcinoma	O
sequence	O
,	O
with	O
its	O
accompanying	O
genetic	O
steps	O
,	O
provides	O
a	O
surprisingly	O
narrow	O
window	O
of	O
understanding	O
of	O
this	O
multipathway	O
reality.9	O
In	O
recent	O
years	O
,	O
the	O
fundamental	O
division	O
of	O
colorectal	O
polyps	O
into	O
precancerous	O
adenomas	O
and	O
innocent	O
HPs	O
has	O
begun	O
to	O
erode	O
and	O
the	O
concept	O
of	O
an	O
alternative	O
serrated	O
pathway	O
has	O
gained	O
support	O
.	O

This	O
revision	O
began	O
with	O
the	O
description	O
of	O
an	O
intermediate	O
lesion	O
described	O
as	O
serrated	O
adenoma	O
(	O
SA	O
)	O
.10	O
Initially	O
,	O
however	O
,	O
SA	O
was	O
not	O
conceived	O
as	O
an	O
intermediate	O
category	O
of	O
polyp	O
but	O
essentially	O
as	O
an	O
adenoma	O
with	O
a	O
superimposed	O
serrated	O
architecture	O
that	O
conferred	O
only	O
a	O
superficial	O
likeness	O
to	O
a	O
HP.10	O
Additionally	O
,	O
the	O
mixed	O
polyp	O
(	O
MP	O
)	O
was	O
perceived	O
as	O
a	O
chance	O
collision	O
between	O
a	O
HP	O
and	O
an	O
adenoma	O
,	O
giving	O
a	O
combined	O
polyp	O
.	O

These	O
preliminary	O
interpretations	O
did	O
not	O
represent	O
a	O
major	O
departure	O
from	O
the	O
traditional	O
classification	O
of	O
colorectal	O
polyps	O
but	O
preserved	O
the	O
fundamental	O
distinction	O
of	O
neoplastic	O
adenomas	O
versus	O
non	O
-	O
neoplastic	O
HPs	O
.	O

Statistics	O
Data	O
were	O
analysed	O
by	O
χ2	O
test	O
,	O
Fisher	O
's	O
exact	O
test	O
or	O
T	O
-	O
test	O
,	O
as	O
appropriate	O
,	O
using	O
SAS	O
software	O
,	O
version	O
8.2	O
(	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

P	O
-	O
values	O
<	O
0.05	O
were	O
interpreted	O
as	O
significant	O
.	O

Results	O
KRAS	B
and	O
BRAF	B
mutation	O
DNA	O
failed	O
to	O
amplify	O
in	O
the	O
KRAS	B
assay	O
for	O
one	O
SSA	O
and	O
one	O
TA	O
<	O
10	O
mm	O
.	O

Overall	O
,	O
34	O
of	O
188	O
polyps	O
(	O
18	O
%	O
)	O
had	O
mutation	O
of	O
KRAS	B
.	O

Twenty	O
-	O
eight	O
mutations	O
were	O
in	O
codon	O
12	O
(	O
20	O
G→A	O
,	O
seven	O
G→T	O
and	O
one	O
G→C	O
)	O
and	O
six	O
mutations	O
were	O
in	O
codon	O
13	O
(	O
all	O
G→A	O
)	O
.	O

One	O
serrated	O
adenoma	O
had	O
two	O
KRAS	B
mutations	O
in	O
codon	O
12	O
(	O
G→T	O
at	O
position	O
35	O
and	O
T→G	O
at	O
position	O
36	O
)	O
.	O

BRAF	B
mutation	O
at	O
V600E	O
could	O
be	O
assessed	O
in	O
all	O
polyps	O
except	O
for	O
a	O
single	O
TA	O
<	O
10	O
mm	O
.	O

BRAF	B
mutation	O
was	O
found	O
in	O
82	O
of	O
189	O
polyps	O
(	O
43	O
%	O
)	O
.	O

BRAF	B
and	O
KRAS	B
mutations	O
were	O
negatively	O
correlated	O
,	O
with	O
only	O
four	O
polyps	O
having	O
both	O
mutations	O
(	O
two	O
TAs	O
,	O
one	O
TVA	O
and	O
one	O
SSA	O
)	O
.	O

The	O
three	O
conventional	O
adenomas	O
with	O
mutations	O
of	O
both	O
BRAF	B
and	O
KRAS	B
were	O
among	O
only	O
four	O
adenomas	O
that	O
had	O
any	O
BRAF	B
mutations	O
at	O
all	O
.	O

Mutation	O
frequencies	O
for	O
both	O
KRAS	B
and	O
BRAF	B
were	O
distributed	O
differently	O
across	O
the	O
seven	O
polyp	O
groups	O
(	O
Table	O
1	O
)	O
.	O

Frequency	O
of	O
KRAS	B
and	O
BRAF	B
mutation	O
and	O
loss	O
of	O
expression	O
of	O
O-6-methylguanine	B
DNA	I
methyltransferase	I
(	O
MGMT	B
)	O
by	O
polyp	O
type	O
Mutation	O
frequencies	O
for	O
both	O
KRAS	B
(	O
P	O
<	O
0.0001	O
)	O
and	O
BRAF	B
(	O
P	O
<	O
0.0001	O
)	O
are	O
distributed	O
differently	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
see	O
Results	O
for	O
individual	O
comparisons	O
)	O
.	O

Distribution	O
of	O
MGMT	B
loss	O
differs	O
across	O
the	O
seven	O
classes	O
of	O
polyp	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Note	O
:	O
no	O
result	O
for	O
KRAS	B
in	O
one	O
sessile	O
serrated	O
adenoma	O
(	O
SSA	O
)	O
and	O
one	O
tubular	O
adenoma	O
(	O
TA	O
)	O
or	O
for	O
BRAF	B
in	O
one	O
TA	O
.	O

MGMT	B
immunstaining	O
not	O
performed	O
in	O
15	O
polyps	O
(	O
seven	O
HPs	O
,	O
one	O
SSA	O
,	O
one	O
MP	O
and	O
six	O
TAs	O
)	O
.	O

KRAS	B
mutation	O
occurred	O
in	O
26.5	O
%	O
and	O
BRAF	B
mutation	O
in	O
4.8	O
%	O
of	O
adenomas	O
(	O
all	O
types	O
)	O
(	O
Table	O
1	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

TVAs	O
/	O
VAs	O
were	O
more	O
likely	O
to	O
have	O
KRAS	B
mutation	O
(	O
50	O
%	O
)	O
than	O
TAs	O
<	O
10	O
mm	O
(	O
18	O
%	O
)	O
(	O
P	O
<	O
0.004	O
)	O
or	O
TAS	O
>	O
10	O
mm	O
in	O
diameter	O
(	O
17	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

In	O
the	O
case	O
of	O
TAs	O
there	O
was	O
a	O
trend	O
for	O
KRAS	B
mutation	O
to	O
occur	O
more	O
frequently	O
in	O
polyps	O
from	O
the	O
proximal	O
colon	O
(	O
P	O
=	O
0.08	O
)	O
and	O
in	O
females	O
(	O
P	O
=	O
0.07	O
)	O
.	O

SSAs	O
were	O
more	O
likely	O
to	O
have	O
BRAF	B
mutation	O
(	O
81	O
%	O
)	O
than	O
either	O
SAs	O
(	O
33	O
%	O
)	O
(	O
P	O
<	O
0.001	O
)	O
or	O
MPs	O
(	O
40	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

KRAS	B
mutation	O
was	O
infrequent	O
among	O
both	O
SSAs	O
(	O
3	O
%	O
)	O
and	O
HPs	O
(	O
4	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O

Patient	O
age	O
,	O
gender	O
and	O
anatomical	O
location	O
were	O
not	O
predictors	O
of	O
BRAF	B
mutation	O
in	O
either	O
SSAs	O
or	O
HPs	O
.	O

The	O
mean	O
age	O
of	O
subjects	O
with	O
SSAs	O
(	O
64	O
years	O
)	O
differed	O
from	O
that	O
of	O
subjects	O
with	O
HPs	O
(	O
55	O
years	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Background	O
Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
in	O
the	O
Western	O
world	O
.	O

Already	O
in	O
1913	O
,	O
familial	O
aggregation	O
of	O
CRC	O
was	O
described	O
by	O
Warthin	O
[	O
1	O
]	O
and	O
later	O
Lynch	O
et	O
al.	O
described	O
an	O
additional	O
family	O
with	O
clustering	O
of	O
colorectal	O
and	O
endometrial	O
cancer	O
[	O
2	O
]	O
.	O

Clinical	O
definition	O
of	O
Lynch	O
syndrome	O
,	O
or	O
HNPCC	O
,	O
in	O
1991	O
[	O
3,4	O
]	O
was	O
instrumental	O
for	O
linkage	O
analysis	O
,	O
and	O
ultimately	O
for	O
the	O
identification	O
of	O
the	O
underlying	O
gene	O
defects	O
in	O
HNPCC	O
families	O
.	O

The	O
first	O
HNPCC	O
loci	O
were	O
mapped	O
to	O
chromosomes	O
2	O
and	O
3	O
using	O
microsatellite	O
markers	O
[	O
5,6	O
]	O
.	O

This	O
eventually	O
led	O
to	O
the	O
identification	O
of	O
germ	O
line	O
mutations	O
in	O
MSH2	B
[	O
7	O
]	O
and	O
MLH1	B
[	O
8	O
]	O
,	O
respectively	O
.	O

Later	O
,	O
PMS2	B
[	O
9	O
]	O
,	O
MSH6	B
[	O
10,11	O
]	O
and	O
recently	O
MutYH	B
[	O
12	O
]	O
were	O
identified	O
as	O
CRC	O
susceptibility	O
genes	O
.	O

However	O
,	O
the	O
so	O
far	O
identified	O
CRC	O
susceptibility	O
genes	O
can	O
only	O
explain	O
up	O
to	O
5	O
%	O
of	O
all	O
cases	O
[	O
13	O
]	O
,	O
while	O
in	O
~35	O
%	O
of	O
all	O
colorectal	O
cancer	O
cases	O
familial	O
clustering	O
is	O
seen	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
that	O
first	O
degree	O
relatives	O
of	O
patients	O
with	O
colorectal	O
cancer	O
have	O
a	O
relative	O
risk	O
of	O
2.3	O
to	O
develop	O
the	O
disease	O
[	O
15	O
]	O
.	O

This	O
indicates	O
that	O
still	O
some	O
genes	O
with	O
strong	O
or	O
moderate	O
effect	O
on	O
CRC	O
development	O
remain	O
to	O
be	O
identified	O
.	O

In	O
order	O
to	O
identify	O
these	O
genes	O
,	O
linkage	O
analysis	O
in	O
families	O
could	O
point	O
to	O
the	O
loci	O
where	O
unknown	O
susceptibility	O
genes	O
may	O
reside	O
.	O

Indeed	O
,	O
different	O
linkage	O
analysis	O
studies	O
revealed	O
potentially	O
interesting	O
regions	O
on	O
chromosomes	O
3q	O
,	O
9q	O
,	O
11q	O
,	O
14q	O
,	O
15q	O
and	O
22q	O
[	O
16	O
-	O
20	O
]	O
.	O

Families	O
with	O
a	O
clustering	O
of	O
colorectal	O
cancer	O
but	O
without	O
germ	O
line	O
mutations	O
in	O
CRC	O
genes	O
have	O
been	O
under	O
surveillance	O
in	O
Leiden	O
since	O
the	O
1980s	O
.	O

Due	O
to	O
the	O
long	O
period	O
of	O
follow	O
-	O
up	O
,	O
with	O
three	O
to	O
four	O
affected	O
generations	O
,	O
these	O
Dutch	O
HNPCC	O
-	O
like	O
families	O
have	O
become	O
informative	O
for	O
linkage	O
analysis	O
.	O

Traditionally	O
,	O
linkage	O
analysis	O
is	O
performed	O
with	O
multi	O
-	O
allelic	O
microsatellite	O
markers	O
.	O

Recently	O
,	O
however	O
,	O
the	O
more	O
advanced	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
arrays	O
were	O
brought	O
into	O
use	O
for	O
linkage	O
analysis	O
.	O

It	O
was	O
shown	O
that	O
the	O
information	O
content	O
of	O
a	O
dense	O
SNP	O
map	O
is	O
significantly	O
and	O
uniformly	O
higher	O
than	O
that	O
of	O
a	O
genome	O
wide	O
microsatellite	O
marker	O
map	O
[	O
21	O
]	O
.	O

Several	O
studies	O
conducting	O
linkage	O
analysis	O
on	O
genotype	O
data	O
from	O
SNP	O
arrays	O
appeared	O
in	O
recent	O
years	O
[	O
22	O
-	O
24	O
]	O
.	O

In	O
these	O
studies	O
non	O
-	O
parametric	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
was	O
performed	O
in	O
sib	O
pairs	O
or	O
in	O
small	O
to	O
moderate	O
size	O
pedigrees	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
studies	O
have	O
been	O
published	O
on	O
linkage	O
analysis	O
using	O
SNPs	O
in	O
large	O
pedigrees	O
(	O
e.g.	O
>	O
35–40	O
bits	O
)	O
.	O

Studying	O
large	O
families	O
with	O
thousands	O
of	O
SNPs	O
results	O
in	O
a	O
computational	O
complex	O
analysis	O
that	O
is	O
challenging	O
for	O
existing	O
statistical	O
packages	O
and	O
that	O
may	O
even	O
exceed	O
their	O
capacity	O
.	O

Current	O
linkage	O
analysis	O
programs	O
can	O
handle	O
either	O
large	O
pedigrees	O
or	O
large	O
numbers	O
of	O
markers	O
,	O
depending	O
on	O
the	O
underlying	O
algorithm	O
.	O

In	O
order	O
to	O
perform	O
linkage	O
analysis	O
in	O
large	O
pedigrees	O
using	O
SNP	O
arrays	O
,	O
we	O
explored	O
the	O
possibilities	O
of	O
currently	O
available	O
linkage	O
analysis	O
software	O
.	O

Most	O
currently	O
available	O
programs	O
are	O
based	O
on	O
the	O
Lander	O
-	O
Green	O
or	O
the	O
Elston	O
-	O
Stewart	O
algorithm	O
or	O
both	O
.	O

The	O
computation	O
time	O
of	O
the	O
former	O
algorithm	O
increases	O
exponentially	O
with	O
the	O
number	O
of	O
bits	O
(	O
2n	O
-	O
f	O
,	O
where	O
'	O
n	O
'	O
is	O
the	O
number	O
of	O
non	O
-	O
founders	O
and	O
'	O
f	O
'	O
the	O
number	O
of	O
founders	O
)	O
in	O
a	O
pedigree	O
,	O
whereas	O
the	O
latter	O
scales	O
exponentially	O
with	O
the	O
number	O
of	O
markers	O
.	O

To	O
perform	O
multipoint	O
linkage	O
analysis	O
in	O
a	O
large	O
family	O
with	O
SNP	O
arrays	O
in	O
one	O
run	O
would	O
probably	O
take	O
several	O
months	O
computation	O
time	O
,	O
if	O
at	O
all	O
possible	O
.	O

Statistics	O
Significance	O
values	O
were	O
calculated	O
using	O
the	O
software	O
package	O
SPSS	O
10.0.7	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Methods	O
Colorectal	O
cancer	O
samples	O
Samples	O
of	O
colorectal	O
cancer	O
tissue	O
and	O
matched	O
normal	O
colonic	O
mucosa	O
were	O
obtained	O
from	O
fresh	O
surgical	O
specimens	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-80	O
°	O
C	O
.	O

Thirty	O
nine	O
carcinomas	O
,	O
23	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
and	O
16	O
with	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
were	O
analyzed	O
in	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
clinico	O
-	O
pathological	O
features	O
of	O
the	O
tumors	O
are	O
detailed	O
in	O
Table	O
1	O
.	O

MSI	O
status	O
was	O
determined	O
with	O
a	O
fluorescence	O
-	O
based	O
PCR	O
method	O
,	O
using	O
the	O
five	O
markers	O
of	O
the	O
panel	O
of	O
Bethesda	O
(	O
BAT25	O
,	O
BAT26	O
,	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
[	O
42	O
]	O
.	O

PCR	O
products	O
were	O
run	O
in	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
Division	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
the	O
GeneScan	O
3.1	O
version	O
software	O
(	O
Perkin	O
-	O
Elmer	O
)	O
[	O
43	O
]	O
.	O

According	O
to	O
the	O
guidelines	O
of	O
the	O
Workshop	O
of	O
Bethesda	O
[	O
42	O
]	O
,	O
tumors	O
showing	O
instability	O
at	O
two	O
or	O
more	O
loci	O
were	O
classified	O
as	O
MSI	O
-	O
H	O
and	O
tumors	O
without	O
instability	O
at	O
any	O
locus	O
as	O
MSS	O
.	O

None	O
of	O
the	O
tumors	O
included	O
in	O
this	O
study	O
exhibited	O
instability	O
at	O
a	O
single	O
locus	O
(	O
low	O
-	O
frequency	O
MSI	O
or	O
MSI	O
-	O
L	O
)	O
.	O

All	O
MSI	O
-	O
H	O
carcinomas	O
displayed	O
instability	O
at	O
mononucleotide	O
DNA	O
sequences	O
(	O
BAT25	O
and	O
BAT26	O
markers	O
)	O
.	O

Tumors	O
were	O
also	O
examined	O
for	O
expression	O
of	O
the	O
DNA	O
mismatch	O
repair	O
proteins	O
MLH1	B
and	O
MSH2	B
,	O
using	O
the	O
immunohistochemical	O
analytic	O
procedure	O
previously	O
described	O
[	O
43	O
]	O
.	O

Carcinomas	O
showing	O
complete	O
loss	O
of	O
nuclear	O
MLH1	B
or	O
MSH2	B
expression	O
were	O
classified	O
as	O
MLH1	B
or	O
MSH2	B
negative	O
,	O
whereas	O
cancers	O
with	O
normal	O
expression	O
of	O
MLH1	B
and	O
MSH2	B
gene	O
products	O
were	O
classified	O
as	O
MLH1	B
and	O
MSH2	B
positive	O
.	O

As	O
reported	O
in	O
Table	O
1	O
,	O
all	O
MSS	O
carcinomas	O
demonstrated	O
normal	O
nuclear	O
expression	O
of	O
both	O
MLH1	B
and	O
MSH2	B
proteins	O
(	O
MLH1	B
/	O
MSH2	B
positive	O
)	O
.	O

By	O
contrast	O
,	O
of	O
the	O
16	O
MSI	O
-	O
H	O
tumors	O
15	O
were	O
MLH1	B
negative	O
and	O
one	O
was	O
MSH2	B
negative	O
.	O

As	O
expected	O
,	O
MSI	O
-	O
H	O
carcinomas	O
were	O
more	O
frequently	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
P	O
<	O
0.001	O
)	O
and	O
poorly	O
differentiated	O
(	O
P	O
<	O
0.001	O
)	O
and	O
more	O
often	O
contained	O
a	O
mucinous	O
component	O
(	O
P	O
<	O
0.001	O
)	O
with	O
respect	O
to	O
MSS	O
tumors	O
(	O
Table	O
1	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
following	O
manufacturer	O
's	O
indications	O
.	O

RNA	O
integrity	O
was	O
assessed	O
on	O
a	O
2100	O
Agilent	O
Bioanalyzer	O
.	O

Only	O
samples	O
with	O
intact	O
RNA	O
were	O
used	O
for	O
the	O
gene	O
expression	O
analysis	O
.	O

RNA	O
labeling	O
and	O
microarray	O
hybridization	O
RNA	O
labeling	O
and	O
hybridization	O
on	O
microRNA	O
microarray	O
chips	O
was	O
performed	O
as	O
previously	O
described	O
.	O

[	O
21,22	O
]	O
Briefly	O
,	O
5	O
μg	O
of	O
total	O
RNA	O
from	O
each	O
sample	O
was	O
biotin	O
-	O
labeled	O
by	O
reverse	O
transcription	O
using	O
5	O
'	O
biotin	O
end	O
labeled	O
random	O
examers	O
oligo	O
primer	O
.	O

Hybridization	O
of	O
biotin	O
-	O
labeled	O
cDNA	O
was	O
carried	O
out	O
on	O
our	O
miRNA	O
microarray	O
chip	O
(	O
ArrayExpress	O
accession	O
number	O
:	O
A	O
-	O
MEXP-86	O
)	O
,	O
which	O
contains	O
230	O
human	O
microRNA	O
probes	O
,	O
in	O
triplicate	O
.	O

Hybridization	O
signals	O
were	O
detected	O
by	O
biotin	O
binding	O
of	O
a	O
Streptavidin	O
–	O
Alexa	O
647	O
conjugate	O
using	O
Axon	O
Scanner	O
4000B	O
(	O
Axon	O
Instrument	O
Inc.	O
CA	O
)	O
.	O

Introduction	O
The	O
immune	O
system	O
is	O
thought	O
to	O
have	O
an	O
important	O
function	O
in	O
controlling	O
tumor	O
growth	O
and	O
eliminating	O
metastasizing	O
tumor	O
cells	O
.	O

The	O
expression	O
of	O
human	B
leukocyte	I
antigen	I
(	I
HLA	I
)	I
class	I
I	I
,	O
presenting	O
tumor	O
-	O
associated	O
antigens	O
on	O
the	O
tumor	O
cell	O
surface	O
,	O
is	O
considered	O
as	O
a	O
prerequisite	O
for	O
an	O
effective	O
T	O
cell	O
immune	O
response	O
[	O
34	O
]	O
.	O

As	O
a	O
consequence	O
,	O
tumor	O
cells	O
with	O
down	O
-	O
regulated	O
HLA	B
class	I
I	I
expression	O
might	O
escape	O
this	O
immune	O
response	O
,	O
resulting	O
in	O
a	O
selective	O
outgrowth	O
of	O
these	O
tumor	O
cells	O
.	O

Many	O
studies	O
described	O
HLA	B
class	I
I	I
expression	O
in	O
cancer	O
[	O
10	O
,	O
17	O
,	O
22	O
,	O
33	O
]	O
.	O

Only	O
limited	O
studies	O
have	O
reported	O
on	O
the	O
clinical	O
impact	O
of	O
HLA	B
class	I
I	I
expression	O
in	O
colorectal	O
cancer	O
with	O
contrasting	O
results	O
.	O

Some	O
studies	O
found	O
no	O
significant	O
correlation	O
between	O
staining	O
intensity	O
and	O
survival	O
[	O
1	O
,	O
19	O
,	O
20	O
]	O
,	O
while	O
others	O
found	O
a	O
prognostic	O
correlation	O
between	O
HLA	B
expression	O
and	O
survival	O
[	O
18	O
,	O
35	O
]	O
.	O

The	O
latter	O
two	O
studies	O
had	O
in	O
common	O
that	O
total	O
absence	O
of	O
HLA	B
class	I
I	I
resulted	O
in	O
a	O
favorable	O
prognosis	O
as	O
compared	O
to	O
patients	O
with	O
down	O
-	O
regulated	O
expression	O
of	O
HLA	B
class	I
I	I
of	O
tumor	O
cells	O
.	O

The	O
discrepancy	O
between	O
these	O
two	O
studies	O
is	O
,	O
whereas	O
the	O
one	O
described	O
high	O
expression	O
of	O
HLA	B
class	I
I	I
in	O
tumor	O
cells	O
that	O
resulted	O
in	O
a	O
better	O
prognosis	O
as	O
compared	O
to	O
the	O
partial	O
down	O
-	O
regulation	O
of	O
HLA	B
class	I
I	I
[	O
35	O
]	O
,	O
the	O
other	O
found	O
the	O
opposite	O
[	O
18	O
]	O
.	O

These	O
studies	O
both	O
analyzed	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
.	O

For	O
rectal	O
cancer	O
patients	O
,	O
the	O
clinical	O
impact	O
of	O
HLA	B
class	I
I	I
expression	O
is	O
still	O
unknown	O
.	O

Since	O
HLA	B
class	I
I	I
expression	O
is	O
often	O
absent	O
in	O
microsatellite	O
instable	O
(	O
MSI	O
)	O
tumors	O
[	O
9	O
,	O
16	O
]	O
and	O
MSI	O
is	O
more	O
frequently	O
observed	O
in	O
right	O
-	O
sided	O
colon	O
tumors	O
than	O
in	O
rectal	O
tumors	O
[	O
30	O
]	O
,	O
therefore	O
the	O
results	O
obtained	O
from	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
might	O
not	O
hold	O
true	O
for	O
rectal	O
cancer	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
relevance	O
of	O
HLA	B
class	I
I	I
expression	O
for	O
rectal	O
cancer	O
patients	O
.	O

In	O
addition	O
to	O
determining	O
the	O
impact	O
of	O
MSI	O
on	O
HLA	B
class	I
I	I
expression	O
,	O
the	O
tumors	O
most	O
at	O
risk	O
for	O
MSI	O
i.e.	O
HLA	O
-	O
negative	O
tumors	O
were	O
examined	O
for	O
MSI	O
by	O
determining	O
the	O
expression	O
of	O
the	O
mismatch	O
repair	O
proteins	O
,	O
mismatch	B
mutL	I
homolog	I
1	I
(	O
MLH1	B
)	O
and	O
postmeiotic	B
segregation	I
increased	I
2	I
(	O
PMS2	B
)	O
,	O
that	O
are	O
most	O
absent	O
in	O
sporadic	O
MSI	O
tumors	O
[	O
7	O
,	O
36	O
]	O
.	O

Radiotherapy	O
has	O
been	O
described	O
recently	O
to	O
increase	O
cell	O
surface	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
in	O
a	O
murine	O
colon	O
adenocarcinoma	O
cell	O
line	O
[	O
26	O
]	O
.	O

Therefore	O
,	O
our	O
study	O
also	O
evaluated	O
the	O
effect	O
of	O
radiotherapy	O
on	O
HLA	B
class	I
I	I
expression	O
in	O
rectal	O
cancer	O
patients	O
.	O

For	O
these	O
purposes	O
,	O
HLA	B
class	I
I	I
expression	O
was	O
evaluated	O
in	O
a	O
set	O
of	O
1,135	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
rectal	O
cancer	O
specimens	O
.	O

The	O
tumors	O
studied	O
were	O
obtained	O
at	O
the	O
time	O
of	O
surgery	O
from	O
patients	O
of	O
a	O
prospective	O
multicenter	O
trial	O
,	O
who	O
were	O
randomized	O
between	O
standardized	O
preoperative	O
radiotherapy	O
treatment	O
followed	O
by	O
surgery	O
or	O
surgery	O
alone	O
[	O
15	O
]	O
.	O

Expression	O
of	O
HLA	B
class	I
I	I
in	O
rectal	O
cancer	O
using	O
HCA2	O
and	O
HC10	O
antibodies	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
χ2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
χ2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	B
class	I
I	I
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	O
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	O
showed	O
reduced	O
numbers	O
(	O
≤50	O
%	O
)	O
of	O
HLA	B
class	I
I	I
positive	O
tumor	O
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	B
class	I
I	I
high	O
expression	O
group	O
and	O
the	O
HLA	B
class	I
I	I
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
(	O
χ2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
HLA	B
class	I
I	I
negative	O
cells	O
and	O
microsatellite	O
instability	O
It	O
has	O
been	O
described	O
that	O
a	O
majority	O
of	O
MSI	O
colorectal	O
tumors	O
do	O
not	O
express	O
HLA	B
class	I
I	I
,	O
while	O
only	O
a	O
minority	O
of	O
MSS	O
tumors	O
do	O
not	O
express	O
HLA	B
class	I
I	I
[	O
8	O
,	O
16	O
]	O
.	O

Therefore	O
,	O
HLA	B
class	I
I	I
negative	O
rectal	O
tumors	O
are	O
the	O
most	O
at	O
risk	O
to	O
be	O
MSI	O
tumors	O
.	O

To	O
evaluate	O
the	O
numbers	O
of	O
sporadic	O
MSI	O
tumors	O
in	O
our	O
study	O
,	O
HCA2	O
or	O
HC10	O
negative	O
tumors	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
PMS2	B
and	O
MLH1	B
.	O

PMS2	B
and	O
MLH1	B
are	O
mismatch	O
repairs	O
proteins	O
that	O
are	O
most	O
frequently	O
absent	O
in	O
MSI	O
sporadic	O
tumors	O
[	O
6	O
]	O
.	O

Of	O
the	O
HLA	B
class	I
I	I
negative	O
tumors	O
only	O
1	O
out	O
of	O
11	O
tumors	O
did	O
not	O
express	O
PMS2	B
and	O
MLH1	B
.	O

In	O
the	O
tumor	O
group	O
negative	O
for	O
only	O
1	O
of	O
the	O
2	O
HLA	B
class	I
I	I
markers	O
,	O
2	O
of	O
81	O
tumors	O
displayed	O
no	O
PMS2	B
and	O
MLH1	B
staining	O
.	O

These	O
results	O
indicate	O
that	O
HLA	B
class	I
I	I
down	O
-	O
regulation	O
is	O
not	O
associated	O
with	O
MSI	O
in	O
rectal	O
cancer	O
and	O
are	O
in	O
accordance	O
with	O
the	O
previous	O
findings	O
that	O
only	O
a	O
very	O
small	O
minority	O
of	O
rectal	O
tumors	O
are	O
MSI	O
[	O
4	O
,	O
25	O
]	O
.	O

HLA	B
class	I
I	I
expression	O
and	O
clinicopathological	O
parameters	O
The	O
relationship	O
between	O
HLA	B
class	I
I	I
expression	O
and	O
patient	O
/	O
tumor	O
characteristics	O
was	O
assessed	O
(	O
Table	O
3	O
)	O
.	O

The	O
HLA	B
class	I
I	I
expression	O
levels	O
were	O
distributed	O
equally	O
in	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
with	O
regard	O
to	O
most	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Three	O
significant	O
differences	O
were	O
observed	O
.	O

For	O
the	O
non	O
-	O
irradiated	O
patients	O
,	O
significantly	O
more	O
men	O
appeared	O
in	O
the	O
HLA	B
class	I
I	I
low	O
-	O
expression	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
group	O
of	O
irradiated	O
tumors	O
with	O
HLA	B
class	I
I	I
low	O
expression	O
contained	O
significantly	O
more	O
stage	O
III	O
and	O
IV	O
tumors	O
(	O
P	O
=	O
0.01	O
)	O
and	O
also	O
more	O
patients	O
with	O
a	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margin	O
(	O
P	O
=	O
0.02	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
high	O
HLA	B
class	I
I	I
expression	O
.	O

Table	O
3Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	B
class	I
I	I
positive	O
tumor	O
cells	O
Non	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
N	O
=	O
445Low	O
N	O
=	O
87P	O
valueHigh	O
N	O
=	O
406Low	O
N	O
=	O
70P	O
valueGender	O
Male	O
(	O
%	O
)	O
63750.0365660.90Age	O
Median	O
years65680.3265650.99TNM	O
stage	O
(	O
%	O
)	O
I31240.5233240.01	O
II27303021	O
III36383240	O
IV58514Circumferential	O
margin	O
Negative	O
(	O
%	O
)	O
83770.2886740.02Distant	O
from	O
anal	O
verge	O
(	O
%	O
)	O
≥10	O
cm28330.1727320.30	O
5–10	O
cm41314636	O
<	O
5	O
cm31362732Operation	O
type	O
(	O
%	O
)	O
Low	O
anterior	O
resection66610.7765660.89	O
Abdomino	O
-	O
perineal	O
resection29332930	O
Hartmann5664Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	B
class	I
I	I
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O

*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	B
class	I
I	I
positive	O
tumor	O
cells	O
Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	B
class	I
I	I
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Expression	O
of	O
HLA	B
class	I
I	I
and	O
clinical	O
prognosis	O
Because	O
radiotherapy	O
might	O
influence	O
local	O
tumor	O
recurrences	O
[	O
15	O
]	O
,	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	O
were	O
analyzed	O
separately	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
HLA	B
class	I
I	I
expression	O
on	O
tumor	O
recurrence	O
and	O
patient	O
survival	O
.	O

The	O
HLA	B
class	I
I	I
expression	O
was	O
not	O
related	O
with	O
distant	O
or	O
local	O
recurrence	O
rates	O
.	O

The	O
patients	O
with	O
low	O
expression	O
of	O
HLA	B
class	I
I	I
had	O
a	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
with	O
HLA	B
class	I
I	I
high	O
expression	O
,	O
irrespective	O
of	O
treatment	O
(	O
Fig.	O
2	O
;	O
overall	O
survival	O
:	O
P	O
=	O
0.008	O
and	O
P	O
=	O
0.01	O
;	O
disease	O
free	O
survival	O
:	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.006	O
in	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
,	O
respectively	O
)	O
.	O

Irradiated	O
patients	O
with	O
low	O
HLA	B
class	I
I	I
expression	O
also	O
had	O
a	O
worse	O
cancer	O
-	O
specific	O
survival	O
(	O
P	O
=	O
0.003	O
)	O
.	O

For	O
non	O
-	O
irradiated	O
patients	O
,	O
HLA	B
class	I
I	I
expression	O
had	O
no	O
significant	O
effect	O
on	O
cancer	O
-	O
specific	O
survival	O
(	O
Fig.	O
2	O
)	O
.	O

All	O
results	O
of	O
univariate	O
analysis	O
are	O
shown	O
in	O
Table	O
4	O
.	O

Univariate	O
analysis	O
showed	O
a	O
better	O
outcome	O
for	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
with	O
high	O
HLA	B
class	I
I	I
expression	O
.	O

Fig.	O
2Examples	O
of	O
Kaplan	O
–	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	O
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
–	O
d	O
)	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	O
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	B
class	I
I	I
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analysesTable	O
4Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	B
class	I
I	I
have	O
a	O
better	O
overall	O
,	O
and	O
disease	O
free	O
survivalNon	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueOverall	O
survival65.558.50.01267.551.30.008Disease	O
free	O
survival62.253.50.01562.248.30.006Cancer	O
specific	O
survival74.371.40.4180.161.80.003Local	O
recurrence8.913.70.224.73.20.72Distant	O
recurrence26.728.70.8824.729.30.34Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	B
class	I
I	I
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	O
free	O
survival	O
,	O
cancer	O
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Discussion	O
We	O
showed	O
that	O
rectal	O
cancer	O
patients	O
from	O
the	O
HLA	B
class	I
I	I
low	O
expression	O
group	O
had	O
an	O
independent	O
worse	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
from	O
the	O
HLA	B
class	I
I	I
high	O
-	O
expression	O
group	O
.	O

These	O
data	O
imply	O
that	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	O
cells	O
predicts	O
survival	O
for	O
rectal	O
cancer	O
patients	O
.	O

Although	O
significant	O
better	O
cancer	O
-	O
specific	O
survival	O
for	O
irradiated	O
patients	O
with	O
high	O
HLA	B
class	I
I	I
was	O
found	O
in	O
univariate	O
analysis	O
,	O
the	O
predictive	O
value	O
was	O
lost	O
in	O
multivariate	O
analysis	O
.	O

This	O
observation	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
the	O
group	O
with	O
low	O
HLA	B
class	I
I	I
significantly	O
included	O
more	O
stage	O
III	O
/	O
IV	O
and	O
more	O
patients	O
with	O
a	O
positive	O
circumferential	O
margin	O
as	O
compared	O
to	O
the	O
group	O
of	O
patients	O
with	O
high	O
expression	O
of	O
HLA	B
class	I
I.	I
Also	O
no	O
predictive	O
value	O
of	O
HLA	B
class	I
I	I
expression	O
was	O
found	O
with	O
regard	O
to	O
recurrence	O
-	O
free	O
survival	O
of	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
have	O
no	O
indications	O
that	O
support	O
the	O
notion	O
that	O
better	O
survival	O
of	O
high	O
HLA	B
class	I
I	I
expression	O
is	O
due	O
to	O
the	O
better	O
antigen	O
presenting	O
function	O
of	O
these	O
tumor	O
cells	O
,	O
as	O
has	O
been	O
suggested	O
[	O
18	O
,	O
35	O
]	O
.	O

In	O
our	O
study	O
,	O
no	O
difference	O
was	O
found	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
for	O
HLA	B
class	I
I	I
expression	O
in	O
tumor	O
cells	O
.	O

It	O
has	O
been	O
described	O
that	O
γ	O
-	O
irradiation	O
induces	O
enhanced	O
peptide	O
production	O
and	O
surface	O
expression	O
of	O
MHC	O
class	O
I	O
in	O
a	O
colorectal	O
mouse	O
tumor	O
cell	O
line	O
[	O
26	O
]	O
.	O

The	O
fact	O
that	O
we	O
could	O
not	O
find	O
more	O
HLA	B
class	I
I	I
expression	O
in	O
irradiated	O
tumors	O
than	O
in	O
non	O
-	O
irradiated	O
tumors	O
indicates	O
that	O
radiotherapy	O
does	O
not	O
induce	O
HLA	O
class	O
I	O
expression	O
in	O
vivo	O
.	O

Immunohistochemistry	O
,	O
however	O
,	O
is	O
less	O
suitable	O
to	O
measure	O
subtle	O
expression	O
changes	O
.	O

Therefore	O
,	O
additional	O
research	O
is	O
required	O
to	O
determine	O
the	O
impact	O
of	O
radiotherapy	O
on	O
expression	O
levels	O
of	O
HLA	B
class	I
I	I
in	O
human	O
tumors	O
.	O

In	O
our	O
study	O
,	O
more	O
tumors	O
showed	O
HLA	B
class	I
I	I
down	O
-	O
regulation	O
after	O
immunohistochemical	O
staining	O
using	O
HCA2	O
than	O
using	O
HC10	O
.	O

This	O
difference	O
might	O
be	O
due	O
to	O
differences	O
in	O
reactivity	O
spectrum	O
of	O
both	O
antibodies	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
or	O
to	O
the	O
fact	O
that	O
HLA	B
alleles	O
are	O
differently	O
affected	O
in	O
colorectal	O
cancer	O
.	O

If	O
the	O
latter	O
is	O
the	O
case	O
,	O
our	O
results	O
suggest	O
that	O
HLA	B
A	I
alleles	O
preferentially	O
show	O
down	O
-	O
regulation	O
in	O
rectal	O
cancer	O
.	O

Previous	O
reports	O
evaluated	O
HLA	B
class	I
I	I
expression	O
in	O
mixed	O
patient	O
populations	O
of	O
colon	O
and	O
rectal	O
cancer	O
patients	O
[	O
18	O
,	O
35	O
]	O
.	O

Watson	O
et	O
al.	O
also	O
found	O
in	O
a	O
large	O
group	O
of	O
colorectal	O
cancer	O
patients	O
that	O
patients	O
with	O
low	O
expression	O
of	O
HLA	B
class	I
I	I
had	O
a	O
poor	O
prognosis	O
[	O
35	O
]	O
.	O

However	O
,	O
in	O
contrast	O
to	O
our	O
results	O
,	O
both	O
studies	O
described	O
a	O
substantial	O
population	O
of	O
patients	O
with	O
tumors	O
showing	O
absence	O
of	O
HLA	B
class	I
I.	I
In	O
addition	O
,	O
they	O
described	O
that	O
absence	O
of	O
HLA	B
class	I
I	I
was	O
associated	O
with	O
better	O
prognosis	O
as	O
compared	O
to	O
tumors	O
expressing	O
reduced	O
numbers	O
of	O
HLA	B
class	I
I	I
positive	O
tumor	O
cells	O
.	O

A	O
relatively	O
low	O
number	O
(	O
1.1	O
%	O
)	O
of	O
HLA	O
class	O
I	O
negative	O
tumors	O
was	O
observed	O
in	O
our	O
cohort	O
of	O
rectal	O
cancer	O
patients	O
only	O
.	O

These	O
patients	O
showed	O
no	O
survival	O
advantage	O
when	O
compared	O
to	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	B
class	I
I	I
positive	O
tumor	O
cells	O
.	O

There	O
are	O
several	O
explanations	O
for	O
the	O
discrepancy	O
in	O
the	O
number	O
of	O
HLA	B
class	I
I	I
negative	O
tumors	O
between	O
the	O
study	O
of	O
Watson	O
et	O
al.	O
and	O
ours	O
,	O
like	O
different	O
definition	O
of	O
HLA	B
class	I
I	I
expression	O
,	O
differences	O
in	O
staining	O
techniques	O
,	O
different	O
patient	O
cohort	O
and	O
number	O
of	O
MSI	O
tumors	O
.	O

Both	O
human	O
CRCs	O
and	O
mouse	O
colon	O
tumors	O
reactivate	O
an	O
embryonic	O
gene	O
signature	O
.	O

When	O
human	O
and	O
murine	O
tumors	O
are	O
compared	O
,	O
they	O
both	O
broadly	O
re	O
-	O
express	O
an	O
embryonic	O
gene	O
expression	O
pattern	O
.	O

Gene	O
expression	O
profiles	O
from	O
the	O
mouse	O
tumor	O
models	O
and	O
human	O
CRC	O
samples	O
were	O
combined	O
into	O
a	O
single	O
non	O
-	O
redundant	O
gene	O
ortholog	O
genome	O
table	O
structure	O
and	O
subjected	O
to	O
comparative	O
profile	O
analysis	O
.	O

Informative	O
probe	O
-	O
sets	O
from	O
human	O
and	O
mouse	O
platforms	O
were	O
selected	O
,	O
mapped	O
to	O
corresponding	O
ortholog	O
genes	O
,	O
and	O
used	O
to	O
populate	O
a	O
table	O
in	O
which	O
normalized	O
expression	O
for	O
each	O
gene	O
is	O
relative	O
to	O
normal	O
adult	O
colon	O
.	O

(	O
a	O
)	O
Heatmap	O
plot	O
for	O
all	O
cross	O
-	O
species	O
gene	O
orthologs	O
both	O
present	O
and	O
successfully	O
measured	O
on	O
both	O
the	O
Affymetrix	O
Hg	O
-	O
U133	O
and	O
Vanderbilt	O
Mouse	O
NIA	O
20	O
K	O
microarrays	O
(	O
n	O
=	O
8,621	O
features	O
)	O
.	O

This	O
representation	O
suggests	O
that	O
a	O
large	O
number	O
of	O
human	O
CRC	O
signatures	O
exhibit	O
similar	O
behaviors	O
in	O
the	O
mouse	O
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
(	O
sidebar	O
:	O
1,080	O
(	O
red	O
)	O
and	O
431	O
(	O
green	O
)	O
gene	O
lists	O
from	O
(	O
b	O
)	O
)	O
.	O

(	O
b	O
)	O
Based	O
on	O
results	O
in	O
(	O
a	O
)	O
,	O
four	O
separate	O
gene	O
lists	O
were	O
generated	O
with	O
criteria	O
of	O
over-	O
or	O
under	O
-	O
expression	O
in	O
development	O
or	O
over	O
-	O
expression	O
or	O
under	O
-	O
expression	O
in	O
human	O
CRCs	O
(	O
2,718	O
,	O
2,365	O
,	O
2,212	O
,	O
and	O
737	O
,	O
respectively	O
,	O
with	O
the	O
overlaps	O
shown	O
as	O
a	O
sidebar	O
in	O
(	O
a	O
)	O
;	O
red	O
,	O
1,080	O
transcripts	O
,	O
and	O
green	O
,	O
431	O
transcripts	O
)	O
.	O

Genes	O
over	O
-	O
expressed	O
and	O
under	O
-	O
expressed	O
in	O
embryonic	O
mouse	O
colon	O
and	O
human	O
CRCs	O
were	O
found	O
to	O
be	O
over	O
-	O
represented	O
as	O
determined	O
by	O
Fisher	O
's	O
exact	O
test	O
analysis	O
(	O
*	O
p	O
<	O
7	O
×	O
10	O
-	O
88	O
,	O
*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
,	O

*	O

*	O
*	O
p	O
<	O
5	O
×	O
10	O
-	O
4	O
,	O

*	O

*	O

*	O

*	O
p	O
<	O
1	O
×	O
10	O
-	O
76	O
)	O
.	O

(	O
c	O
)	O
Heatmap	O
plot	O
of	O
all	O
genes	O
co	O
-	O
regulated	O
in	O
human	O
CRCs	O
and	O
during	O
early	O
(	O
ED	O
)	O
and	O
late	O
(	O
LD	O
)	O
mouse	O
embryonic	O
colon	O
development	O
(	O
n	O
=	O
2,216	O
features	O
)	O
.	O

Six	O
predominant	O
clusters	O
(	O
C18-C23	O
)	O
characterize	O
the	O
transcriptional	O
relationship	O
between	O
human	O
CRC	O
and	O
mouse	O
colon	O
tumor	O
models	O
and	O
embryonic	O
development	O
.	O

Two	O
clusters	O
(	O
C20	O
and	O
21	O
)	O
primarily	O
distinguish	O
human	O
CRCs	O
from	O
murine	O
tumors	O
(	O
A	O
,	O
M	O
,	O
S	O
and	O
T	O
)	O
.	O

For	O
example	O
,	O
CRC	O
up	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
developmentally	O
up-	O
or	O
down	O
-	O
regulated	O
are	O
represented	O
by	O
cluster	O
C22	O
(	O
n	O
=	O
860	O
features	O
)	O
and	O
clusters	O
C21	O
/	O
C23	O
(	O
n	O
=	O
142	O
features	O
)	O
,	O
respectively	O
.	O

Conversely	O
,	O
CRC	O
down	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
down-	O
or	O
up	O
-	O
regulated	O
during	O
development	O
are	O
shown	O
in	O
clusters	O
C18	O
/	O
C19	O
(	O
n	O
=	O
258	O
features	O
)	O
and	O
cluster	O
C20	O
(	O
n	O
=	O
42	O
features	O
)	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
approximately	O
80	O
%	O
and	O
approximately	O
60	O
%	O
of	O
genes	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
both	O
human	O
CRCs	O
and	O
mouse	O
development	O
were	O
also	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
tumors	O
from	O
the	O
various	O
mouse	O
models	O
,	O
several	O
clusters	O
provide	O
very	O
interesting	O
exceptions	O
:	O
cluster	O
C20	O
comprises	O
genes	O
down	O
-	O
regulated	O
in	O
human	O
CRCs	O
that	O
are	O
routinely	O
over	O
-	O
expressed	O
in	O
mouse	O
tumors	O
and	O
development	O
;	O
cluster	O
C21	O
comprises	O
genes	O
robustly	O
expressed	O
in	O
human	O
CRC	O
that	O
are	O
rarely	O
expressed	O
in	O
embryonic	O
colon	O
or	O
murine	O
tumors	O
.	O

Sample	O
groups	O
:	O
ED	O
,	O
early	O
development	O
(	O
E13.5-E15.5	O
)	O
;	O
LD	O
,	O
late	O
development	O
(	O
E16.5-E18.5	O
)	O
;	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	B
/	O
+	O
;	O
T	O
,	O
Tgfb1-	B
/	O
-	O
;	O
Rag2-	B
/	O
-	O
;	O
S	O
,	O
Smad3-	B
/	O
-	O
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	O
,	O
human	O
CRC	O
.	O

Staging	O
:	O
nAC	O
,	O
normal	O
colon	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C18-C23	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	B
/	O
+	O
;	O
PS	O
,	O
ProbeSets	O
;	O
S	O
,	O
Smad3-	B
/	O
-	O
;	O
T	O
,	O
Tgfb1-	B
/	O
-	O
;	O
Rag2-	B
/	O
-	O
.	O

The	O
up	O
-	O
regulated	O
signature	O
in	O
tumors	O
from	O
ApcMin	B
/	O
+	O
(	O
M	O
)	O
and	O
AOM	B
(	O
A	O
)	O
models	O
(	O
cluster	O
C6	O
,	O
Figure	O
2	O
)	O
is	O
enriched	O
with	O
genes	O
associated	O
with	O
the	O
activation	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
.	O

(	O
a	O
)	O
Schematic	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
showing	O
elements	O
present	O
in	O
cluster	O
C6	O
(	O
gene	O
symbols	O
with	O
gray	O
background	O
)	O
.	O

Key	O
elements	O
of	O
this	O
pathway	O
(	O
Ctnnb1	B
,	O
Lef1	B
,	O
Tcf	B
and	O
Myc	B
)	O
are	O
outlined	O
in	O
blue	O
.	O

(	O
b	O
)	O
Relative	O
gene	O
expression	O
for	O
MYC	B
and	O
SOX4	B
is	O
plotted	O
for	O
individual	O
murine	O
and	O
human	O
tumors	O
.	O

The	O
relative	O
expression	O
level	O
of	O
MYC	B
and	O
SOX4	B
is	O
normalized	O
to	O
adult	O
colon	O
.	O

Note	O
that	O
whereas	O
Sox4	B
,	O
a	O
canonical	O
WNT	O
target	O
gene	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
all	O
human	O
CRCs	O
,	O
A	O
/	O
M	O
tumors	O
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
,	O
it	O
is	O
not	O
expressed	O
in	O
Smad3-	B
/	O
-	O
(	O
S	O
)	O
and	O
Tgfb1-	B
/	O
-	O
;	O
Rag2-	B
/	O
-	O
(	O
T	O
)	O
tumors	O
(	O
black	O
)	O
.	O

In	O
contrast	O
,	O
MYC	B
is	O
over	O
-	O
expressed	O
in	O
all	O
human	O
and	O
murine	O
tumors	O
and	O
during	O
colonic	O
embryonic	O
development	O
(	O
red	O
)	O
,	O
irrespective	O
of	O
the	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
,	O
as	O
determined	O
by	O
nuclear	O
β	O
-	O
catenin	O
positivity	O
(	O
Figure	O
2	O
)	O
.	O

Tissue	O
groups	O
:	O
as	O
above	O
and	O
:	O
nAC	O
-	O
m	O
,	O
normal	O
adult	O
mouse	O
colon	O
;	O
nAC	O
-	O
h	O
,	O
normal	O
adult	O
human	O
colon	O
;	O
Dev	O
,	O
developing	O
mouse	O
colon	O
.	O

Materials	O
and	O
methods	O
Individuals	O
and	O
study	O
samples	O
The	O
research	O
was	O
completed	O
in	O
compliance	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

The	O
Ethics	O
of	O
Human	O
Research	O
Committee	O
of	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
approved	O
the	O
study	O
(	O
approval	O
number	O
02	O
/	O
70	O
)	O
.	O

Individuals	O
used	O
in	O
the	O
study	O
were	O
enrolled	O
in	O
the	O
Kathleen	O
Cuningham	O
Consortium	O
for	O
Research	O
in	O
Familial	O
Breast	O
Cancer	O
(	O
kConFab	O
)	O
.	O

kConFab	O
identified	O
seven	O
breast	O
cancer	O
cases	O
(	O
KCF1	O
-	O
7	O
)	O
with	O
BRCA1-like	B
features	O
for	O
analysis	O
.	O

kConFab	O
provided	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
each	O
case	O
and	O
DNA	O
from	O
buccal	O
mucosa	O
of	O
patient	O
KCF3	O
.	O

Tumour	O
material	O
from	O
the	O
KCF1	O
,	O
KCF2	O
,	O
KCF3	O
,	O
KCF4	O
and	O
KCF6	O
cases	O
was	O
available	O
.	O

Four	O
unstained	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
sections	O
from	O
each	O
tumour	O
were	O
provided	O
for	O
analysis	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
paraffin	O
sections	O
using	O
the	O
DNeasy	O
tissue	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Normal	O
control	O
DNAs	O
were	O
provided	O
by	O
the	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
tissue	O
bank	O
.	O

Methylation	O
analysis	O
CpGenome	O
Universal	O
Methylated	O
DNA	O
(	O
Chemicon	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
100	O
%	O
methylated	O
control	O
and	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
normal	O
individuals	O
was	O
used	O
as	O
unmethylated	O
control	O
DNA	O
.	O

Bisulfite	O
modification	O
of	O
DNA	O
was	O
performed	O
with	O
the	O
MethylEasy	O
kit	O
(	O
Human	O
Genetic	O
Signatures	O
,	O
Sydney	O
,	O
Australia	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Methylation	O
standards	O
were	O
constructed	O
by	O
diluting	O
100	O
%	O
methylated	O
control	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
in	O
a	O
pool	O
of	O
normal	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
at	O
50	O
%	O
,	O
25	O
%	O
,	O
10	O
%	O
,	O
5	O
%	O
and	O
1	O
%	O
ratios	O
.	O

Methylation	O
of	O
the	O
BRCA1	B
promoter	O
was	O
assessed	O
using	O
real	O
-	O
time	O
methylation	O
specific	O
PCR	O
(	O
MethyLight	O
)	O
[	O
19	O
]	O
and	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
[	O
20	O
]	O
.	O

All	O
samples	O
were	O
run	O
in	O
triplicate	O
for	O
each	O
assay	O
.	O

The	O
locations	O
of	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
primers	O
and	O
probes	O
on	O
the	O
BRCA1	B
promoter	O
are	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
MethyLight	O
assay	O
assessed	O
five	O
CpG	O
sites	O
and	O
the	O
MS	O
-	O
HRM	O
assay	O
assessed	O
four	O
sites	O
.	O

Careful	O
design	O
of	O
each	O
assay	O
was	O
required	O
to	O
avoid	O
amplification	O
from	O
the	O
BRCA1	B
pseudogene	O
.	O

The	O
HMBS	O
gene	O
was	O
used	O
as	O
a	O
control	O
for	O
the	O
BRCA1	B
MethyLight	O
assay	O
.	O

Primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Map	O
of	O
the	O
BRCA1	B
promoter	O
region	O
studied	O
by	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
assays	O
.	O

The	O
numbering	O
of	O
the	O
promoter	O
is	O
according	O
to	O
that	O
used	O
by	O
Rice	O
et	O
al.	O
[	O
24	O
]	O
.	O

TSS	O
denotes	O
the	O
transcription	O
start	O
site	O
.	O

The	O
positions	O
of	O
the	O
primers	O
flanking	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
amplicons	O
are	O
indicated	O
as	O
well	O
as	O
the	O
position	O
of	O
the	O
MethyLight	O
probe	O
.	O

Experiments	O
were	O
performed	O
on	O
the	O
RotorGene	O
™	O
3000	O
(	O
MethyLight	O
assays	O
)	O
and	O
RotorGene	O
™	O
6000	O
(	O
MS	O
-	O
HRM	O
assays	O
)	O
instruments	O
(	O
Corbett	O
Research	O
,	O
Sydney	O
,	O
Australia	O
)	O
.	O

The	O
MethyLight	O
data	O
was	O
analysed	O
by	O
obtaining	O
the	O
take	O
-	O
off	O
(	O
Ct	O
)	O
and	O
amplification	O
efficiency	O
values	O
for	O
each	O
sample	O
for	O
BRCA1	B
and	O
HMBS	O
from	O
the	O
comparative	O
quantitation	O
tab	O
of	O
the	O
RotorGene	O
™	O
analysis	O
software	O
and	O
comparing	O
them	O
to	O
the	O
values	O
for	O
the	O
100	O
%	O
methylated	O
DNA	O
according	O
to	O
the	O
Pfaffl	O
method	O
of	O
relative	O
quantification	O
[	O
21	O
]	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
Ingenuity	O
Systems	O
,	O
www.ingenuity.com	O
)	O
was	O
used	O
for	O
biological	O
interpretation	O
of	O
gene	O
lists	O
.	O

Analysis	O
of	O
the	O
transcripts	O
found	O
to	O
be	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
irradiated	O
LCLs	O
as	O
identified	O
for	O
the	O
different	O
mutation	O
categories	O
identified	O
those	O
biochemical	O
networks	O
most	O
likely	O
to	O
be	O
affected	O
by	O
a	O
BRCA1	B
and	O
BRCA2	B
truncating	O
and	O
missense	O
mutation	O
,	O
relative	O
to	O
BRCAX	O
.	O

Those	O
pathways	O
with	O
multiple	O
hits	O
or	O
a	O
significance	O
score	O
≥20	O
were	O
then	O
compared	O
.	O

Methods	O
Patients	O
Between	O
1957	O
and	O
31	O
December	O
2004	O
the	O
Swedish	O
Polyposis	O
Registry	O
included	O
data	O
on	O
196	O
families	O
with	O
verified	O
FAP	O
(	O
defined	O
as	O
more	O
than	O
100	O
colorectal	O
adenomas	O
or	O
if	O
less	O
with	O
a	O
family	O
history	O
of	O
FAP	O
)	O
.	O

Sixty	O
-	O
one	O
of	O
these	O
families	O
are	O
now	O
extinct	O
but	O
135	O
families	O
with	O
at	O
least	O
one	O
living	O
disease	O
-	O
affected	O
member	O
remain	O
.	O

Presently	O
,	O
315	O
disease	O
-	O
affected	O
living	O
patients	O
are	O
included	O
in	O
the	O
registry	O
.	O

The	O
geographical	O
catchment	O
area	O
comprises	O
the	O
whole	O
of	O
Sweden	O
.	O

Details	O
of	O
how	O
patients	O
have	O
been	O
eligible	O
for	O
accession	O
into	O
the	O
registry	O
are	O
given	O
in	O
[	O
30	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
96	O
families	O
included	O
in	O
the	O
registry	O
for	O
mutations	O
in	O
the	O
APC	B
gene	O
.	O

Twenty	O
-	O
four	O
of	O
the	O
remaining	O
39	O
families	O
have	O
been	O
analyzed	O
for	O
APC	B
gene	O
mutations	O
at	O
other	O
genetic	O
laboratories	O
and	O
15	O
families	O
remain	O
to	O
be	O
tested	O
.	O

We	O
have	O
previously	O
reported	O
six	O
of	O
these	O
patients	O
who	O
carried	O
bi	O
-	O
allelic	O
MUTYH	B
mutations	O
[	O
31	O
]	O
.	O

Probands	O
were	O
defined	O
as	O
those	O
diagnosed	O
on	O
the	O
basis	O
of	O
the	O
occurrence	O
of	O
symptoms	O
and	O
irrespective	O
of	O
other	O
cases	O
in	O
the	O
family	O
and	O
call	O
-	O
up	O
patients	O
,	O
as	O
those	O
identified	O
as	O
subjects	O
at	O
risk	O
on	O
the	O
basis	O
of	O
studies	O
of	O
pedigrees	O
and	O
found	O
to	O
have	O
FAP	O
.	O

De	O
novo	O
mutations	O
were	O
defined	O
in	O
those	O
individuals	O
where	O
none	O
of	O
the	O
parents	O
carried	O
the	O
mutation	O
or	O
where	O
the	O
parents	O
had	O
a	O
negative	O
colonoscopy	O
after	O
the	O
age	O
of	O
50	O
or	O
died	O
of	O
a	O
non	O
-	O
FAP	O
related	O
cause	O
after	O
the	O
age	O
of	O
75	O
.	O

All	O
patients	O
have	O
given	O
their	O
consent	O
and	O
the	O
local	O
ethics	O
committees	O
have	O
approved	O
the	O
study	O
.	O

The	O
clinical	O
features	O
of	O
index	O
patients	O
of	O
each	O
of	O
the	O
families	O
analyzed	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
and	O
Table	O
1	O
.	O

Patients	O
without	O
any	O
detected	O
mutation	O
in	O
APC	B
or	O
MUTYH	B
Age	O
,	O
age	O
at	O
diagnosis	O
;	O
DL	O
,	O
duodenal	O
lesion	O
;	O
dom	O
,	O
dominant	O
;	O
FGP	O
,	O
fundic	O
gland	O
polyps	O
;	O
NA	O
,	O
no	O
available	O
data	O
;	O
NI	O
,	O
no	O
inheritance	O
;	O
Number	O
of	O
polyps	O
,	O
number	O
of	O
polyps	O
at	O
diagnosis	O
;	O
rec	O
,	O
recessive	O
Patient	O
C896	O
,	O
with	O
only	O
five	O
adenomas	O
,	O
was	O
included	O
because	O
of	O
a	O
family	O
history	O
of	O
FAP	O
.	O

Patient	O
C107	O
underwent	O
her	O
first	O
colonoscopy	O
due	O
to	O
intestinal	O
bleeding	O
at	O
age	O
47	O
.	O

At	O
diagnosis	O
,	O
10–20	O
small	O
(	O
less	O
than	O
10	O
mm	O
)	O
polyps	O
were	O
found	O
in	O
most	O
colorectal	O
parts	O
.	O

Tubular	O
and	O
tubulovillous	O
adenomas	O
were	O
removed	O
yearly	O
.	O

At	O
age	O
50	O
,	O
carcinoma	O
(	O
Dukes	O
A	O
)	O
was	O
diagnosed	O
4	O
cm	O
from	O
valvula	O
Bauhini	O
in	O
conjunction	O
with	O
several	O
new	O
adenomas	O
.	O

At	O
that	O
time	O
the	O
patient	O
underwent	O
total	O
colectomy	O
with	O
ileorectal	O
anastomosis	O
(	O
IRA	O
)	O
.	O

DNA	O
,	O
RNA	O
and	O
cDNA	O
preparation	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
samples	O
of	O
venous	O
blood	O
,	O
anti	O
-	O
coagulated	O
in	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
.	O

DNA	O
purification	O
was	O
performed	O
using	O
the	O
PuregeneR	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
as	O
described	O
previously	O
[	O
32	O
]	O
.	O

Histopaque	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
or	O
Lymphoprep	O
(	O
Axis	O
-	O
Shield	O
PoC	O
AS	O
,	O
Oslo	O
,	O
Norway	O
)	O
was	O
used	O
for	O
purification	O
of	O
the	O
lymphocytes	O
,	O
and	O
total	O
RNA	O
was	O
extracted	O
using	O
RNA	O
-	O
Stat	O
60	O
(	O
Tel	O
-	O
Test	O
,	O
Friendswood	O
,	O
TX	O
)	O
.	O

cDNA	O
was	O
synthesized	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

The	O
phenotype	O
of	O
the	O
patient	O
(	O
C157	O
)	O
,	O
carrying	O
the	O
c.70C	O
>	O
T	O
mutation	O
,	O
is	O
in	O
agreement	O
with	O
the	O
suggested	O
genotype	O
-	O
phenotype	O
correlation	O
where	O
a	O
milder	O
form	O
of	O
polyposis	O
is	O
proposed	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
model	O
for	O
the	O
attenuated	O
phenotype	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
of	O
APC	B
have	O
been	O
suggested	O
by	O
Heppner	O
Goss	O
et	O
al	O
[	O
42	O
]	O
,	O
in	O
which	O
the	O
internal	O
ATG	O
at	O
codon	O
184	O
could	O
be	O
used	O
as	O
an	O
alternative	O
translation	O
initiation	O
codon	O
in	O
the	O
allele	O
carrying	O
a	O
truncating	O
mutation	O
upstream	O
of	O
this	O
site	O
(	O
Figure	O
1	O
)	O
.	O

Such	O
an	O
alternative	O
start	O
of	O
translation	O
would	O
supply	O
the	O
cell	O
with	O
an	O
APC	B
protein	O
of	O
almost	O
full	O
length	O
,	O
thus	O
explaining	O
the	O
attenuated	O
phenotype	O
.	O

Patient	O
C159	O
,	O
with	O
the	O
most	O
3	O
'	O
localized	O
mutation	O
was	O
a	O
case	O
of	O
attenuated	O
FAP	O
(	O
100–1000	O
polyps	O
,	O
46	O
years	O
of	O
age	O
at	O
diagnosis	O
)	O
.	O

In	O
family	O
1	O
(	O
reduced	O
expression	O
of	O
APC	B
)	O
,	O
patient	O
C152	O
displayed	O
a	O
classical	O
FAP	O
phenotype	O
including	O
a	O
large	O
number	O
of	O
polyps	O
,	O
duodenal	O
adenomas	O
,	O
and	O
fundic	O
gland	O
polyps	O
(	O
Additional	O
file	O
1	O
)	O
.	O

The	O
APC-	B
and	O
MUTYH	B
-	O
mutation	O
negative	O
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	O
with	O
a	O
low	O
number	O
of	O
polyps	O
,	O
comparably	O
high	O
age	O
at	O
diagnosis	O
,	O
and	O
a	O
low	O
frequency	O
of	O
extracolonic	O
manifestations	O
.	O

Whether	O
these	O
patients	O
really	O
are	O
affected	O
by	O
APC	B
-	O
associated	O
FAP	O
can	O
(	O
of	O
course	O
)	O
be	O
called	O
into	O
question	O
.	O

However	O
,	O
among	O
attenuated	O
cases	O
of	O
FAP	O
in	O
these	O
study	O
we	O
have	O
found	O
very	O
subtle	O
mutations	O
such	O
as	O
the	O
mosaic	O
case	O
as	O
well	O
as	O
the	O
c.70C	O
>	O
T	O
mutation	O
and	O
splice	O
-	O
site	O
mutations	O
.	O

Considering	O
these	O
facts	O
,	O
at	O
least	O
some	O
of	O
the	O
cases	O
could	O
be	O
caused	O
by	O
mutations	O
in	O
APC	B
resulting	O
in	O
only	O
partially	O
inactivation	O
of	O
the	O
gene	O
function	O
.	O

Since	O
the	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
achieve	O
as	O
high	O
mutation	O
-	O
detection	O
rate	O
as	O
possible	O
in	O
families	O
with	O
colorectal	O
polyposis	O
syndromes	O
,	O
using	O
a	O
range	O
of	O
different	O
molecular	O
genetic	O
techniques	O
,	O
we	O
have	O
not	O
yet	O
performed	O
any	O
further	O
analyses	O
of	O
the	O
relatively	O
few	O
mutation	O
negative	O
cases	O
to	O
determine	O
if	O
they	O
belong	O
to	O
non	O
-	O
polyposis	O
CRC	O
syndromes	O
.	O

Large	O
deletions	O
of	O
the	O
APC	B
gene	O
The	O
fraction	O
of	O
large	O
deletions	O
of	O
all	O
APC	B
mutations	O
identified	O
in	O
the	O
Swedish	O
patients	O
was	O
9	O
%	O
,	O
which	O
is	O
higher	O
than	O
the	O
5	O
%	O
of	O
large	O
deletions	O
reported	O
in	O
[	O
38	O
]	O
.	O

The	O
relatively	O
large	O
number	O
of	O
gross	O
deletions	O
identified	O
could	O
be	O
a	O
result	O
of	O
the	O
thorough	O
analysis	O
applied	O
for	O
every	O
patient	O
,	O
including	O
the	O
use	O
of	O
the	O
MLPA	O
technique	O
.	O

It	O
is	O
noteworthy	O
that	O
no	O
deletion	O
of	O
APC	B
exon	O
4	O
in	O
patient	O
3765	O
was	O
detected	O
using	O
MLPA	O
although	O
it	O
had	O
been	O
identified	O
and	O
confirmed	O
by	O
other	O
methods	O
.	O

A	O
still	O
untested	O
possibility	O
is	O
that	O
exon	O
4	O
has	O
been	O
translocated	O
to	O
another	O
chromosomal	O
locus	O
and	O
thus	O
generates	O
the	O
positive	O
MLPA	O
result	O
.	O

RESULTS	O
MSH6	B
Good	O
quality	O
sequence	O
was	O
obtained	O
for	O
all	O
10	O
exons	O
of	O
MSH6	B
in	O
220	O
participants	O
,	O
115	O
from	O
HNPCC	O
cohort	O
,	O
and	O
105	O
from	O
endometrial	O
cohort	O
.	O

Results	O
with	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
are	O
shown	O
in	O
table	O
I.	O
Given	O
that	O
the	O
pathogenicity	O
of	O
the	O
missense	O
mutations	O
identified	O
has	O
yet	O
to	O
be	O
determined	O
,	O
arguably	O
the	O
proportion	O
of	O
the	O
truncating	O
mutations	O
is	O
more	O
relevant	O
.	O

All	O
sequences	O
were	O
viewed	O
with	O
reference	O
to	O
a	O
control	O
sample	O
(	O
with	O
a	O
known	O
mutation	O
in	O
MLH1	B
or	O
MSH2	B
)	O
,	O
and	O
reference	O
sequences	O
(	O
,	O
)	O
.	O

All	O
variants	O
are	O
described	O
with	O
reference	O
to	O
den	O
Dunnen	O
et	O
al26	O
.	O

All	O
truncating	O
and	O
missense	O
variants	O
identified	O
are	O
shown	O
in	O
tables	O
II	O
and	O
III	O
(	O
example	O
figure	O
1	O
)	O
with	O
their	O
corresponding	O
cohort	O
and	O
family	O
classification	O
.	O

Participants	O
from	O
the	O
endometrial	O
cohort	O
with	O
a	O
variant	O
identified	O
were	O
also	O
classified	O
according	O
to	O
Amsterdam	O
I	O
,	O
II	O
,	O
'	O
HNPCC	O
like	O
'	O
,	O
or	O
,	O
a	O
family	O
history	O
that	O
was	O
not	O
in	O
keeping	O
with	O
HNPCC	O
.	O

All	O
missense	O
variants	O
were	O
subject	O
to	O
analysis	O
by	O
PolyPhen	O
(	O
)	O
,	O
a	O
tool	O
that	O
predicts	O
the	O
potential	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
(	O
see	O
table	O
III	O
for	O
predictions	O
)	O
.	O

Further	O
population	O
,	O
family	O
and	O
functional	O
studies	O
were	O
not	O
carried	O
out	O
to	O
evaluate	O
the	O
missense	O
variants	O
but	O
further	O
work	O
is	O
planned	O
.	O

Sequencing	O
analysis	O
showing	O
a	O
truncating	O
mutation	O
c.755	O
C	O
>	O
G	O
(	O
p.	O

Ser252X	O
)	O
in	O
exon	O
4	O
of	O
MSH6	B
Truncating	O
mutations	O
identified	O
Missense	O
variants	O
identified	O
MLPA	O
All	O
samples	O
underwent	O
MLPA	O
analysis	O
.	O

Out	O
of	O
268	O
successful	O
MLPA	O
results	O
,	O
no	O
aberration	O
in	O
copy	O
number	O
was	O
identified	O
.	O

Methods	O
Cell	O
Culture	O
MCF7	O
,	O
MDA	O
-	O
MB-231	O
,	O
MDA	O
-	O
MB-468	O
,	O
T-47D	O
,	O
HT-29	O
,	O
Caco-2	O
,	O
Colo320	O
,	O
SW480	O
,	O
RKO	O
,	O
and	O
HCT116	O
cells	O
and	O
isogenic	O
DNA	O
methyltransferase	O
(	O
DNMT	O
)	O
1	O
/	O
3b	O
genetic	O
knockout	O
derivatives	O
were	O
maintained	O
in	O
culture	O
as	O
recommended	O
by	O
American	O
Type	O
Tissue	O
Culture	O
(	O
ATCC	O
)	O
.	O

All	O
HCC	O
series	O
lines	O
used	O
were	O
obtained	O
from	O
ATCC	O
.	O

For	O
drug	O
treatments	O
,	O
log	O
phase	O
cells	O
were	O
cultured	O
in	O
the	O
appropriate	O
media	O
(	O
Invitrogen	O
)	O
containing	O
10	O
%	O
FBS	O
and	O
1	O
×	O
penicillin	O
/	O
streptomycin	O
with	O
5	O
μM	O
5aza	O
-	O
deoxycytidine	O
(	O
DAC	O
)	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1	O
mM	O
in	O
PBS	O
)	O
for	O
96	O
h	O
,	O
replacing	O
media	O
and	O
DAC	O
every	O
24	O
h.	O
Cell	O
treatment	O
with	O
300	O
nM	O
Trichostatin	O
A	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1.5	O
mM	O
dissolved	O
in	O
ethanol	O
)	O
was	O
performed	O
for	O
18	O
h.	O
Control	O
cells	O
underwent	O
mock	O
treatment	O
in	O
parallel	O
with	O
addition	O
of	O
equal	O
volume	O
of	O
PBS	O
or	O
ethanol	O
without	O
drugs	O
.	O

Microarray	O
Analysis	O
Total	O
RNA	O
was	O
harvested	O
from	O
log	O
phase	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Sample	O
amplification	O
and	O
labeling	O
procedures	O
were	O
carried	O
out	O
using	O
the	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
kit	O
(	O
Agilent	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
was	O
carried	O
out	O
according	O
to	O
the	O
Agilent	O
microarray	O
protocol	O
.	O

Scanning	O
was	O
performed	O
with	O
the	O
Agilent	O
G2565BA	O
microarray	O
scanner	O
.	O

Data	O
Analysis	O
All	O
arrays	O
were	O
subject	O
to	O
quality	O
checks	O
recommended	O
by	O
the	O
manufacturer	O
.	O

All	O
calculations	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
computing	O
platform	O
[	O
16	O
]	O
and	O
packages	O
from	O
Bioconductor	O
bioinformatics	O
software	O
project	O
[	O
17	O
]	O
.	O

The	O
log	O
ratio	O
of	O
red	O
signal	O
to	O
green	O
signal	O
was	O
calculated	O
after	O
background	O
-	O
subtraction	O
and	O
LoEss	O
normalization	O
as	O
implemented	O
in	O
the	O
limma	O
package	O
from	O
Bioconductor	O
[	O
18	O
]	O
.	O

Individual	O
arrays	O
were	O
scaled	O
to	O
have	O
the	O
same	O
interquartile	O
range	O
(	O
75th	O
percentile	O
to	O
25th	O
percentile	O
)	O
.	O

Patient	O
information	O
,	O
including	O
clinical	O
data	O
and	O
gene	O
expression	O
data	O
,	O
was	O
obtained	O
from	O
and	O
analyzed	O
using	O
Oncomine	O
(	O
http://www.oncomine.org	O
)	O
.	O

Our	O
analysis	O
included	O
microarray	O
databases	O
such	O
as	O
the	O
Netherlands	O
Cancer	O
Institute	O
breast	O
cancer	O
database	O
[	O
19	O
]	O
.	O

The	O
microarray	O
meta	O
-	O
analysis	O
algorithms	O
and	O
statistical	O
analysis	O
used	O
were	O
as	O
previously	O
described	O
[	O
20,21	O
]	O
.	O

p	O
-	O
Values	O
were	O
calculated	O
using	O
adjustment	O
for	O
multiple	O
testing	O
and	O
false	O
discovery	O
as	O
described	O
at	O
http://www.oncomine.org	O
[	O
21	O
]	O
.	O

Methylation	O
and	O
Gene	O
Expression	O
Analysis	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
Reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

For	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
1	O
μg	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
by	O
using	O
Ready	O
-	O
To	O
-	O
Go	O
You	O
-	O
Prime	O
First	O
-	O
Strand	O
Beads	O
(	O
Amersham	O
Biosciences	O
)	O
with	O
addition	O
of	O
random	O
hexamers	O
(	O
0.2	O
μg	O
per	O
reaction	O
)	O
.	O

Bisulfite	O
modification	O
of	O
genomic	O
DNA	O
was	O
carried	O
out	O
using	O
the	O
EZ	O
DNA	O
methylation	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O

Selection	O
of	O
primers	O
used	O
for	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
and	O
determinants	O
for	O
CpG	O
island	O
localization	O
and	O
designation	O
was	O
accomplished	O
using	O
MSPPrimer	O
(	O
http://www.mspprimer.org	O
)	O
[	O
22	O
]	O
.	O

MSP	O
was	O
performed	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

Primer	O
sequences	O
are	O
listed	O
in	O
Table	O
S3	O
.	O

Bisulfite	O
sequencing	O
and	O
RT	O
-	O
PCR	O
was	O
preformed	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O

Gene	O
expression	O
quantitation	O
was	O
performed	O
using	O
RT	O
-	O
PCR	O
and	O
the	O
1D	O
software	O
package	O
(	O
Kodak	O
)	O
.	O

For	O
Table	O
S1	O
,	O
decreased	O
expression	O
was	O
defined	O
as	O
expression	O
that	O
was	O
not	O
detectable	O
with	O
RT	O
-	O
PCR	O
or	O
decreased	O
by	O
two	O
-	O
thirds	O
compared	O
to	O
expression	O
levels	O
in	O
normal	O
tissue	O
measured	O
using	O
the	O
1D	O
software	O
to	O
quantitate	O
bands	O
.	O

Quantitative	O
PCR	O
was	O
performed	O
using	O
the	O
Invitrogen	O
SYBR	O
Green	O
qPCR	O
kit	O
according	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Real	O
-	O
time	O
PCR	O
reactions	O
were	O
performed	O
using	O
the	O
Mastercycler	O
Realplex	O
machine	O
(	O
Eppendorf	O
)	O
.	O

Readings	O
were	O
normalized	O
using	O
GAPDH	B
.	O

Discussion	O
Overall	O
our	O
study	O
presents	O
an	O
extensive	O
search	O
for	O
the	O
presence	O
of	O
and	O
interactions	O
between	O
both	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
cancer	O
.	O

As	O
it	O
currently	O
stands	O
,	O
these	O
studies	O
do	O
have	O
several	O
limitations	O
.	O

First	O
,	O
our	O
data	O
do	O
not	O
address	O
the	O
biological	O
effects	O
of	O
the	O
individual	O
mutations	O
observed	O
in	O
the	O
CAN	B
genes	O
.	O

Second	O
,	O
the	O
data	O
draw	O
on	O
only	O
the	O
13,023	O
subset	O
of	O
CCDS	B
genes	O
that	O
were	O
previously	O
sequenced	O
,	O
and	O
additional	O
genes	O
have	O
now	O
been	O
sequenced	O
and	O
more	O
mutations	O
have	O
been	O
discovered	O
[	O
42	O
]	O
.	O

Despite	O
these	O
limitations	O
,	O
our	O
study	O
describes	O
a	O
valuable	O
approach	O
to	O
begin	O
to	O
understand	O
the	O
biological	O
significance	O
of	O
the	O
vast	O
amount	O
of	O
mutational	O
data	O
generated	O
by	O
cancer	O
resequencing	O
efforts	O
.	O

In	O
these	O
regards	O
,	O
our	O
findings	O
allow	O
several	O
important	O
conclusions	O
to	O
be	O
drawn	O
.	O

First	O
,	O
our	O
study	O
shows	O
that	O
large	O
-	O
scale	O
,	O
combined	O
genetic	O
and	O
epigenetic	O
analysis	O
is	O
feasible	O
and	O
useful	O
for	O
cancer	O
gene	O
discovery	O
.	O

Such	O
combined	O
analyses	O
can	O
markedly	O
enhance	O
links	O
made	O
between	O
gene	O
alterations	O
and	O
key	O
clinical	O
parameters	O
for	O
cancer	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
examination	O
and	O
interpretation	O
of	O
mutations	O
to	O
identify	O
cancer	O
genes	O
on	O
a	O
genome	O
-	O
wide	O
scale	O
can	O
be	O
significantly	O
complicated	O
by	O
passenger	O
mutations	O
[	O
43,44	O
]	O
.	O

Furthermore	O
,	O
as	O
we	O
mentioned	O
above	O
in	O
the	O
Results	O
,	O
it	O
is	O
very	O
unlikely	O
that	O
a	O
given	O
gene	O
that	O
in	O
breast	O
and/or	O
colon	O
cancer	O
has	O
evidence	O
for	O
mutations	O
,	O
promoter	O
hypermethylation	O
,	O
reduced	O
expression	O
,	O
and	O
is	O
localized	O
to	O
chromosome	O
regions	O
harboring	O
frequent	O
deletions	O
in	O
tumors	O
is	O
not	O
important	O
for	O
tumor	O
development	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
by	O
beginning	O
with	O
a	O
large	O
pool	O
of	O
genes	O
harboring	O
mostly	O
low	O
incidence	O
heterozygous	O
missense	O
mutations	O
and	O
then	O
characterizing	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
these	O
genes	O
,	O
our	O
approach	O
allowed	O
us	O
to	O
identify	O
genes	O
that	O
possess	O
potentially	O
prognostic	O
value	O
.	O

Our	O
results	O
also	O
confirm	O
that	O
our	O
microarray	O
strategy	O
is	O
an	O
effective	O
approach	O
to	O
identify	O
genes	O
that	O
are	O
silenced	O
by	O
hypermethylation	O
in	O
colon	O
and	O
breast	O
cancer	O
.	O

Other	O
methods	O
have	O
been	O
developed	O
to	O
identify	O
hypermethylated	O
genes	O
in	O
cancer	O
,	O
including	O
restriction	O
landmark	O
genomic	O
scanning	O
,	O
promoter	O
CpG	O
island	O
microarrays	O
,	O
and	O
methylation	O
-	O
specific	O
digital	O
karyotyping	O
[	O
28,45	O
]	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
these	O
techniques	O
is	O
restricted	O
by	O
the	O
locations	O
of	O
methylation	O
-	O
sensitive	O
restriction	O
sites	O
in	O
the	O
genome	O
.	O

Several	O
of	O
the	O
common	O
target	O
genes	O
have	O
been	O
noted	O
to	O
undergo	O
methylation	O
-	O
associated	O
silencing	O
in	O
cancers	O
by	O
other	O
investigators	O
.	O

Lund	O
et	O
al.	O
noted	O
that	O
oncogenic	O
RAS	B
can	O
lead	O
to	O
the	O
hypermethylation	O
of	O
the	O
MMP2	B
gene	O
[	O
46	O
]	O
.	O

EVL	B
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
colon	O
carcinoma	O
[	O
47	O
]	O
.	O

N	B
-	I
CAM	I
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
lung	O
cancer	O
in	O
a	O
survey	O
of	O
methylated	O
genes	O
described	O
by	O
Shames	O
et	O
al.	O
[	O
48	O
]	O
.	O

The	O
presence	O
of	O
methylation	O
of	O
the	O
common	O
target	O
genes	O
in	O
other	O
tumor	O
types	O
suggests	O
that	O
these	O
genes	O
may	O
be	O
targets	O
of	O
inactivation	O
in	O
a	O
broader	O
range	O
of	O
cancers	O
,	O
a	O
hypothesis	O
that	O
warrants	O
future	O
investigation	O
.	O

In	O
particular	O
,	O
it	O
would	O
be	O
of	O
value	O
to	O
directly	O
compare	O
our	O
results	O
with	O
those	O
derived	O
by	O
other	O
strategies	O
for	O
analyzing	O
the	O
hypermethylome	O
from	O
the	O
same	O
as	O
well	O
as	O
from	O
other	O
types	O
of	O
malignancies	O
[	O
48–51	O
]	O
.	O

Together	O
with	O
these	O
studies	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
a	O
compendium	O
of	O
epigenetic	O
changes	O
underlie	O
the	O
progression	O
of	O
human	O
cancers	O
.	O

Stabilizing	O
mutation	O
of	O
/beta	O
-	O
catenin	O
and	O
protein	O
accumulation	O
analyzed	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
tumors	O
of	O
Swedish	O
patients	O
Abstract	O
Background	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
human	O
neoplasms	O
.	O

We	O
recently	O
reported	O
accumulation	O
of	O
β	O
-	O
catenin	O
in	O
parathyroid	O
adenomas	O
from	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
pHPT	O
)	O
.	O

In	O
CTNNB1	B
exon	O
3	O
,	O
we	O
detected	O
a	O
stabilizing	O
mutation	O
(	O
S37A	O
)	O
in	O
3	O
out	O
of	O
20	O
analyzed	O
adenomas	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
zygosity	O
of	O
mutations	O
in	O
CTNNB1	B
exon	O
3	O
,	O
and	O
β	O
-	O
catenin	O
accumulation	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
adenomas	O
of	O
Swedish	O
patients	O
.	O

Results	O
The	O
mutation	O
S37A	O
(	O
TCT	O
>	O
GCT	O
)	O
was	O
detected	O
by	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
fragments	O
in	O
6	O
out	O
of	O
104	O
sporadic	O
parathyroid	O
adenomas	O
(	O
5.8	O
%	O
)	O
.	O

Taking	O
our	O
previous	O
study	O
into	O
account	O
,	O
a	O
total	O
of	O
9	O
out	O
of	O
124	O
(	O
7.3	O
%	O
)	O
adenomas	O
displayed	O
the	O
same	O
mutation	O
.	O

The	O
mutations	O
were	O
homozygous	O
by	O
DNA	O
sequencing	O
,	O
restriction	O
enzyme	O
cleavage	O
,	O
and	O
gene	O
copy	O
number	O
determination	O
using	O
the	O
GeneChip	O
500	O
K	O
Mapping	O
Array	O
Set	O
.	O

All	O
tumors	O
analyzed	O
by	O
immunohistochemistry	O
,	O
including	O
those	O
with	O
mutation	O
,	O
displayed	O
aberrant	O
β	O
-	O
catenin	O
accumulation	O
.	O

Western	O
blotting	O
revealed	O
a	O
slightly	O
higher	O
expression	O
level	O
of	O
β	O
-	O
catenin	O
and	O
nonphosphorylated	O
active	O
β	O
-	O
catenin	O
in	O
tumors	O
with	O
mutation	O
compared	O
to	O
those	O
without	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
not	O
related	O
to	O
distinct	O
clinical	O
characteristics	O
.	O

Conclusion	O
Aberrant	O
accumulation	O
of	O
β	O
-	O
catenin	O
is	O
very	O
common	O
in	O
parathyroid	O
tumors	O
,	O
and	O
is	O
caused	O
by	O
stabilizing	O
homozygous	O
mutation	O
in	O
7.3	O
%	O
of	O
Swedish	O
pHPT	O
patients	O
.	O

Hybridization	O
of	O
the	O
SBE	O
reaction	O
products	O
The	O
slides	O
printed	O
with	O
'	O
anti	O
-	O
tags	O
'	O
were	O
pre	O
-	O
heated	O
to	O
42	O
°	O
C	O
in	O
a	O
custom	O
-	O
made	O
aluminium	O
reaction	O
rack	O
with	O
a	O
re	O
-	O
usable	O
silicon	O
rubber	O
grid	O
placed	O
on	O
the	O
slides	O
to	O
form	O
75	O
separate	O
reaction	O
chambers	O
on	O
each	O
slide	O
[	O
24	O
]	O
.	O

The	O
hybridization	O
mixtures	O
,	O
containing	O
the	O
SBE	O
reaction	O
products	O
in	O
6.5	O
×	O
SSC	O
were	O
added	O
to	O
each	O
reaction	O
chamber	O
on	O
the	O
pre	O
-	O
heated	O
slide	O
.	O

The	O
hybridization	O
time	O
was	O
2.5	O
hours	O
at	O
42	O
°	O
C	O
followed	O
by	O
a	O
brief	O
rinse	O
with	O
4	O
×	O
SSC	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
the	O
slides	O
were	O
washed	O
twice	O
for	O
5	O
min	O
.	O

in	O
2	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
(	O
42	O
°	O
C	O
)	O
and	O
twice	O
for	O
1	O
min	O
.	O

in	O
0.2	O
×	O
SSC	O
(	O
room	O
temperature	O
)	O
.	O

Finally	O
,	O
the	O
slides	O
were	O
spin	O
dried	O
for	O
3	O
min	O
.	O

at	O
800	O
rpm	O
.	O

Signal	O
detection	O
The	O
signal	O
detection	O
was	O
performed	O
mainly	O
as	O
described	O
by	O
Lindroos	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescence	O
signals	O
were	O
detected	O
with	O
a	O
ScanArray	O
4000XL	O
instrument	O
and	O
the	O
ScanArray	O
Express	O
software	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

The	O
four	O
excitation	O
lasers	O
were	O
:	O
blue	O
Argon	O
,	O
488	O
nm	O
;	O
Green	O
HeNe	O
,	O
543.8	O
nm	O
;	O
Yellow	O
HeNe	O
,	O
594	O
nm	O
and	O
Red	O
HeNe	O
632.8	O
nm	O
.	O

The	O
laser	O
power	O
was	O
kept	O
constant	O
at	O
90	O
%	O
,	O
whereas	O
the	O
photo	O
-	O
multiplier	O
tube	O
(	O
PMT	O
)	O
varied	O
between	O
fluorophores	O
.	O

A	O
typical	O
setting	O
for	O
the	O
PMT	O
gain	O
was	O
65	O
,	O
75	O
,	O
65	O
and	O
70	O
%	O
for	O
the	O
fluorophores	O
Cy5-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
®	O
-5-ddATP	O
and	O
R110-ddGTP	O
,	O
respectively	O
.	O

Statistics	O
Association	O
tests	O
A	O
Bonferroni	O
corrected	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
the	O
genotypes	O
of	O
each	O
SNP	O
and	O
the	O
familiar	O
CRC	O
cohort	O
and	O
the	O
cohort	O
of	O
sporadic	O
CRC	O
,	O
respectively	O
.	O

Fifteen	O
tests	O
were	O
made	O
for	O
single	O
marker	O
associations	O
,	O
in	O
the	O
cohort	O
of	O
familiar	O
CRC	O
,	O
yielding	O
a	O
Bonferroni	O
corrected	O
significance	O
level	O
of	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Likewise	O
the	O
Bonferroni	O
corrected	O
p	O
-	O
value	O
of	O
the	O
cohort	O
of	O
sporadic	O
cases	O
was	O
0.05	O
/	O
13	O
=	O
0.0038	O
.	O

A	O
Bonferroni	O
corrected	O
Monte	O
Carlo	O
(	O
MC	O
)	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
each	O
pair	O
of	O
SNPs	O
,	O
and	O
sporadic	O
or	O
familiar	O
CRC	O
.	O

One	O
hundred	O
thousand	O
permutations	O
were	O
used	O
for	O
each	O
test	O
.	O

Missing	O
data	O
were	O
handled	O
by	O
omitting	O
persons	O
with	O
missing	O
data	O
in	O
the	O
genotype	O
counts	O
;	O
e.g.	O
all	O
individuals	O
with	O
missing	O
data	O
in	O
either	O
variant	O
i	O
d	O
26	O
or	O
variant	O
i	O
d	O
27	O
were	O
omitted	O
when	O
calculating	O
the	O
genotype	O
frequencies	O
of	O
that	O
specific	O
SNP	O
-	O
pair	O
.	O

Power	O
calculations	O

The	O
power	O
was	O
calculated	O
by	O
applying	O
the	O
Fisher	O
exact	O
test	O
to	O
10000	O
independent	O
simulated	O
cases	O
with	O
the	O
given	O
odds	O
ratio	O
and	O
frequency	O
of	O
the	O
disease	O
causing	O
genotype	O
.	O

In	O
that	O
case	O
the	O
power	O
is	O
the	O
proportion	O
of	O
the	O
simulations	O
that	O
reach	O
a	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Test	O
for	O
Hardy	O
-	O
Weinberg	O
proportions	O
Each	O
variant	O
was	O
tested	O
for	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
proportions	O
in	O
the	O
sub	O
-	O
cohort	O
,	O
using	O
the	O
exact	O
test	O
described	O
by	O
Wigginton	O
et	O
al.	O
[	O
25	O
]	O
.	O

The	O
used	O
significance	O
level	O
was	O
0.01	O
.	O

Linkage	O
disequilibrium	O
Linkage	O
disequilibrium	O
(	O
LD	O
)	O
was	O
investigated	O
using	O
HaploView	O
(	O
v.	O
3.31	O
)	O
,	O
[	O
26	O
]	O
and	O
genome	O
build	O
NCBI35	O
for	O
information	O
track	O
.	O

In	O
silico	O
analysis	O
In	O
silico	O
prediction	O
of	O
the	O
functional	O
consequence	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
SIFT	O
(	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
)	O
[	O
27	O
]	O
,	O
Polyphen	O
[	O
28	O
]	O
and	O
PMUT	O
[	O
29	O
]	O
.	O

Mis	O
-	O
splicing	O
was	O
analysed	O
using	O
SNAP	O
(	O
SNP	O
Annotation	O
Platform	O
)	O
[	O
30	O
]	O
.	O

The	O
alignments	O
of	O
MSH2	B
or	O
MLH1	B
polypeptides	O
used	O
in	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
ClustalW	O
[	O
31	O
]	O
.	O

Thirteen	O
variants	O
were	O
polymorphic	O
in	O
the	O
present	O
study	O
.	O

The	O
majority	O
of	O
the	O
polymorphic	O
variants	O
(	O
i.e.	O
9	O
/	O
13	O
)	O
were	O
silent	O
or	O
present	O
in	O
non	O
-	O
coding	O
regions	O
.	O

This	O
corresponds	O
with	O
common	O
variants	O
being	O
more	O
abundant	O
in	O
introns	O
and	O
other	O
regions	O
than	O
in	O
coding	O
regions	O
[	O
38	O
]	O
.	O

Three	O
of	O
polymorphic	O
variants	O
i.e.	O
MLH1	B
p.	O

Val219Ile	O
,	O
p.	O

Ser406Asn	O
and	O
p.	O

Lys618Ala	O
changed	O
non	O
-	O
conserved	O
amino	O
acids	O
and	O
one	O
i.e.	O
MSH2	B
pGly322Asp	O
changed	O
a	O
conserved	O
amino	O
acid	O
.	O

Furthermore	O
,	O
two	O
polymorphic	O
variants	O
i.e.hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	B
c.1668	O
-	O
19	O
A	O
>	O
G	O
demonstrated	O
borderline	O
significant	O
p	O
-	O
values	O
i.e.	O
0.0037	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
13	O
=	O
0.0038	O
)	O
and	O
0.0044	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
15	O
=	O
0.0033	O
)	O
,	O
respectively	O
.	O

It	O
has	O
been	O
stated	O
that	O
the	O
conventional	O
threshold	O
for	O
declaration	O
of	O
statistical	O
evidence	O
of	O
association	O
(	O
i.e.	O
a	O
p	O
-	O
value	O
of	O
5	O
×	O
10	O
-	O
2	O
)	O
is	O
not	O
sufficient	O
to	O
detect	O
gene	O
-	O
disease	O
interactions	O
.	O

Consequently	O
,	O
it	O
has	O
been	O
suggested	O
to	O
lower	O
the	O
threshold	O
to	O
5	O
×	O
10	O
-	O
5	O
[	O
39	O
]	O
.	O

The	O
borderline	O
significant	O
p	O
-	O
values	O
and	O
the	O
previously	O
published	O
functional	O
analysis	O
of	O
one	O
of	O
the	O
variants	O
suggest	O
that	O
hMSH2	B
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	B
c.1668	O
-	O
19	O
A	O
>	O
G	O
are	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
neither	O
sporadic	O
nor	O
familiar	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
polymorphic	O
variants	O
were	O
not	O
associated	O
with	O
CRC	O
in	O
the	O
analyzed	O
cohorts	O
,	O
neither	O
individually	O
nor	O
as	O
pairs	O
,	O
and	O
they	O
are	O
hence	O
neutral	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

Some	O
of	O
these	O
variants	O
i.e.	O
hMLH1	B
c.655	O
A	O
>	O
G	O
(	O
p	O
.	O
Val219Ile	O
)	O
,	O
c.1217G	O
>	O
A	O
(	O
p.	O

Ser406Asn	O
)	O
,	O
c.1558	O
+	O
14	O
G	O
>	O
A	O
and	O
hMSH2	B
c.1959G	O
>	O
T	O
(	O
p.	O

Leu653Leu	O
)	O
have	O
been	O
characterized	O
as	O
neutral	O
variants	O
in	O
other	O
studies	O
as	O
well	O
[	O
40	O
-	O
42	O
]	O
.	O

In	O
vitro	O
functional	O
analysis	O
have	O
also	O
demonstrated	O
that	O
the	O
variants	O
MLH1	B
p.	O

Val219Ile	O
and	O
p.	O

Ser406Asn	O
exhibit	O
wild	O
-	O
type	O
activity	O
[	O
8,11,12	O
]	O
.	O

The	O
hMSH2	B
variant	O
c.965G	O
>	O
A	O
(	O
p.	O

Gly322Asp	O
)	O
has	O
previously	O
been	O
classified	O
as	O
a	O
neutral	O
variant	O
[	O
43	O
]	O
.	O

This	O
variant	O
changes	O
a	O
conserved	O
amino	O
acid	O
and	O
functional	O
analysis	O
in	O
yeast	O
has	O
shown	O
that	O
it	O
has	O
a	O
slightly	O
reduced	O
MMR	B
activity	O
[	O
8,44	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
frequency	O
of	O
the	O
c.965	O
G	O
>	O
A	O
variant	O
was	O
higher	O
in	O
the	O
cohort	O
of	O
individuals	O
with	O
familiar	O
CRC	O
compared	O
to	O
the	O
sub	O
-	O
cohort	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
Tables	O
3	O
and	O
4	O
)	O
.	O

Results	O
regarding	O
the	O
MLH1	B
p.	O

Lys618Ala	O
variants	O
have	O
so	O
far	O
been	O
contradictory	O
.	O

Functional	O
analyses	O
have	O
identified	O
this	O
variant	O
both	O
as	O
a	O
pathogenic	O
mutation	O
and	O
as	O
a	O
neutral	O
variant	O
[	O
9,11,45	O
-	O
47	O
]	O
.	O

Raevaara	O
et	O
al.	O
used	O
four	O
different	O
assays	O
to	O
evaluate	O
the	O
pathogenic	O
status	O
[	O
9	O
]	O
.	O

In	O
all	O
four	O
assays	O
the	O
p.	O

Lys618Val	O
variant	O
functioned	O
like	O
wt	O
MLH1	B
.	O

In	O
addition	O
,	O
p.	O

Lys618Ala	O
has	O
been	O
identified	O
in	O
one	O
healthy	O
control	O
in	O
a	O
previous	O
study	O
[	O
48	O
]	O
.	O

The	O
identification	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
in	O
controls	O
in	O
the	O
present	O
study	O
further	O
support	O
,	O
that	O
this	O
variant	O
is	O
not	O
a	O
disease	O
causing	O
mutation	O
involved	O
in	O
HNPCC	O
or	O
HNPCC	O
-	O
related	O
cancers	O
.	O

In	O
addition	O
,	O
the	O
frequencies	O
of	O
the	O
variant	O
in	O
the	O
cohorts	O
analyzed	O
in	O
the	O
present	O
study	O
did	O
not	O
differ	O
significantly	O
and	O
therefore	O
p.	O

Lys618Ala	O
does	O
not	O
increase	O
susceptibility	O
to	O
sporadic	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

In	O
conclusion	O
none	O
of	O
the	O
polymorphic	O
variants	O
in	O
the	O
present	O
study	O
are	O
highly	O
associated	O
with	O
CRC	O
in	O
the	O
Danish	O
population	O
.	O

When	O
we	O
ran	O
null	O
simulations	O
in	O
the	O
presence	O
of	O
heterogeneity	O
of	O
marker	O
alleles	O
,	O
disease	O
alleles	O
,	O
or	O
both	O
,	O
we	O
observed	O
that	O
Zc	O
and	O
Zp	O
behaved	O
differently	O
depending	O
on	O
the	O
heterogeneity	O
model	O
we	O
simulated	O
.	O

Although	O
Zp	O
was	O
conservatively	O
biased	O
when	O
disease	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
marker	O
allele	O
frequencies	O
differed	O
,	O
its	O
small	O
conservative	O
bias	O
was	O
not	O
significantly	O
different	O
from	O
that	O
observed	O
in	O
the	O
homogeneous	O
population	O
of	O
Table	O
2	O
.	O

In	O
contrast	O
,	O
Zc	O
exhibited	O
an	O
anticonservative	O
bias	O
when	O
marker	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
disease	O
allele	O
frequencies	O
differed	O
.	O

Alternative	O
Model	O
Simulation	O
Results	O
A	O
subset	O
of	O
results	O
from	O
alternative	O
model	O
simulations	O
in	O
which	O
there	O
were	O
linkages	O
are	O
given	O
in	O
Table	O
4	O
,	O
based	O
on	O
20	O
replicate	O
simulations	O
for	O
each	O
combination	O
of	O
parameters	O
.	O

The	O
numbers	O
given	O
represent	O
mean	O
Z	O
statistics	O
,	O
their	O
ARE	O
values	O
,	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

The	O
results	O
displayed	O
were	O
chosen	O
to	O
highlight	O
the	O
effect	O
of	O
sampling	O
(	O
and	O
genotyping	O
)	O
varying	O
the	O
numbers	O
of	O
unaffected	O
sibs	O
and/or	O
parents	O
from	O
families	O
with	O
two	O
or	O
three	O
affected	O
sibs	O
and	O
two	O
unaffected	O
sibs	O
.	O

Full	O
results	O
are	O
available	O
online	O
[	O
64	O
]	O
.	O

On	O
average	O
,	O
the	O
concordant	O
test	O
was	O
always	O
more	O
efficient	O
on	O
a	O
per	O
-	O
genotype	O
basis	O
than	O
the	O
paired	O
test	O
,	O
although	O
the	O
power	O
of	O
the	O
paired	O
test	O
was	O
usually	O
greater	O
when	O
the	O
number	O
of	O
unaffected	O
sibs	O
tested	O
was	O
>	O
2	O
.	O

Alternative	O
Model	O
Simulation	O
Mean	O
Z	O
score	O
,	O
asymptotic	O
relative	O
efficiency	O
per	O
genotype	O
(	O
ARE	O
–	O
see	O
text	O
)	O
,	O
and	O
sample	O
size	O
required	O
to	O
attain	O
80	O
%	O
power	O
for	O
two	O
-	O
point	O
linkage	O
(	O
θ	O
=	O
0.05	O
)	O
for	O
predisposition	O
to	O
colorectal	O
cancer	O
with	O
a	O
baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
under	O
3	O
different	O
heterogeneity	O
models	O
:	O
A	O
)	O
no	O
heterogeneity	O
;	O
B	O
)	O
an	O
equally	O
penetrant	O
,	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
unlinked	O
predisposing	O
locus	O
;	O
C	O
)	O
an	O
equally	O
penetrant	O
,	O
equally	O
common	O
unlinked	O
predisposing	O
locus	O
.	O

All	O
results	O
based	O
on	O
500	O
simulated	O
families	O
and	O
20	O
replicate	O
simulations	O
per	O
parameter	O
set	O
.	O

Zc	O
mean	O
concordant	O
test	O
;	O

Zp	O
mean	O
paired	O
test	O
;	O
ARE	O
(	O
Zc	O
)	O
asymptotic	O
relative	O
efficiency	O
concordant	O
test	O
;	O
ARE	O
(	O
Zp	O
)	O
asymptotic	O
relative	O
efficiency	O
paired	O
test	O
;	O
Nc	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
concordant	O
test	O
;	O
Np	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
paired	O
test	O
.	O

Regression	O
Models	O
Table	O
5	O
shows	O
the	O
effect	O
of	O
various	O
design	O
and	O
population	O
parameters	O
on	O
the	O
noncentrality	O
parameter	O
for	O
both	O
the	O
concordant	O
-	O
only	O
test	O
(	O
Zc	O
/	O
F	O
)	O
and	O
the	O
paired	O
test	O
(	O
Zp	O
/	O
F	O
)	O
.	O

The	O
only	O
change	O
in	O
parameterization	O
of	O
the	O
model	O
for	O
the	O
paired	O
test	O
vis	O
-	O
a	O
-	O
vis	O
the	O
concordant	O
test	O
involved	O
substituting	O
the	O
number	O
of	O
typed	O
unaffected	O
sibs	O
for	O
the	O
total	O
number	O
of	O
unaffected	O
sibs	O
.	O

The	O
AR	O
for	O
the	O
linked	O
locus	O
had	O
the	O
largest	O
positive	O
effect	O
on	O
power	O
of	O
the	O
concordant	O
test	O
,	O
followed	O
closely	O
by	O
the	O
negative	O
effect	O
on	O
power	O
of	O
increasing	O
AR	O
at	O
the	O
unlinked	O
locus	O
and	O
increasing	O
recombination	O
fraction	O
between	O
the	O
marker	O
and	O
trait	O
loci	O
.	O

Increasing	O
the	O
number	O
of	O
affected	O
sibs	O
per	O
family	O
and	O
increasing	O
the	O
number	O
of	O
affected	O
sibs	O
genotyped	O
per	O
family	O
both	O
substantially	O
improved	O
power	O
.	O

The	O
number	O
of	O
unaffected	O
sibs	O
present	O
in	O
sampled	O
families	O
had	O
little	O
or	O
no	O
effect	O
on	O
power	O
.	O

Increased	O
power	O
was	O
also	O
observed	O
for	O
increasing	O
numbers	O
of	O
available	O
parents	O
,	O
the	O
size	O
of	O
the	O
effect	O
on	O
Zc	O
/	O
F	O
being	O
about	O
15	O
%	O
of	O
the	O
effect	O
of	O
increasing	O
numbers	O
of	O
affected	O
sibs	O
.	O

Substituting	O
spouse	O
and	O
offspring	O
for	O
an	O
unavailable	O
affected	O
sib	O
reduced	O
power	O
substantially	O
,	O
but	O
genotyping	O
a	O
second	O
child	O
recovered	O
much	O
of	O
that	O
lost	O
power	O
.	O

Comparison	O
of	O
two	O
-	O
point	O
vs.	O
multipoint	O
linkage	O
scores	O
under	O
various	O
non	O
-	O
null	O
simulation	O
conditions	O
.	O

All	O
simulations	O
employed	O
20	O
replicates	O
of	O
500	O
families	O
with	O
2	O
affected	O
and	O
2	O
unaffected	O
sibs	O
,	O
all	O
sibs	O
typed	O
,	O
no	O
parents	O
or	O
children	O
typed	O
.	O

a	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
no	O
genetic	O
heterogeneity	O
.	O

b	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
and	O
a	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
,	O
equally	O
penetrant	O
unlinked	O
predisposition	O
syndrome	O
.	O

c	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.00325	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.002	O
.	O

d	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	O
allele	O
0.0035	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	O
allele	O
0.001	O
.	O

Replacement	O
of	O
a	O
missing	O
affected	O
individual	O
by	O
a	O
spouse	O
and	O
offspring	O
is	O
not	O
generally	O
as	O
efficient	O
per	O
genotype	O
as	O
if	O
that	O
individual	O
had	O
been	O
available	O
,	O
although	O
the	O
efficiency	O
improves	O
with	O
each	O
additional	O
offspring	O
included	O
.	O

Figure	O
5	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
ASP	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Figure	O
6	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
affected	O
sib	O
trio	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Because	O
families	O
with	O
three	O
affected	O
sibs	O
are	O
more	O
likely	O
to	O
be	O
segregating	O
a	O
disease	O
-	O
predisposing	O
allele	O
than	O
families	O
with	O
two	O
affected	O
sibs	O
,	O
each	O
family	O
is	O
more	O
informative	O
for	O
linkage	O
,	O
even	O
if	O
DNA	O
is	O
available	O
for	O
only	O
two	O
sibs	O
.	O

Substituting	O
the	O
spouse	O
and	O
one	O
or	O
more	O
offspring	O
for	O
the	O
missing	O
sib	O
adds	O
additional	O
power	O
,	O
although	O
at	O
the	O
cost	O
of	O
additional	O
genotyping	O
.	O

Conclusion	O
We	O
have	O
shown	O
that	O
for	O
a	O
wide	O
variety	O
of	O
situations	O
relevant	O
to	O
sib	O
-	O
pair	O
studies	O
of	O
colon	O
cancer	O
and	O
similar	O
late	O
-	O
onset	O
complex	O
diseases	O
,	O
standard	O
concordant	O
-	O
pair	O
allele	O
-	O
sharing	O
statistics	O
based	O
on	O
identity	O
by	O
descent	O
probabilities	O
are	O
more	O
efficient	O
than	O
similarly	O
constructed	O
discordant	O
statistics	O
in	O
homogeneous	O
populations	O
,	O
but	O
may	O
be	O
biased	O
away	O
from	O
the	O
null	O
in	O
situations	O
where	O
subjects	O
are	O
chosen	O
from	O
multiple	O
populations	O
having	O
differing	O
marker	O
allele	O
frequencies	O
or	O
other	O
sources	O
of	O
bias	O
.	O

Where	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
is	O
anticipated	O
because	O
of	O
underlying	O
population	O
admixture	O
,	O
linkage	O
tests	O
based	O
on	O
comparison	O
of	O
concordant	O
vs.	O
discordant	O
allele	O
sharing	O
should	O
be	O
considered	O
.	O

Either	O
of	O
these	O
approaches	O
should	O
allow	O
studies	O
of	O
500–1000	O
families	O
containing	O
an	O
ASP	O
to	O
achieve	O
reasonable	O
power	O
to	O
detect	O
linkage	O
under	O
conditions	O
including	O
genetic	O
and	O
population	O
heterogeneity	O
,	O
unavailable	O
parents	O
,	O
misspecified	O
allele	O
frequencies	O
,	O
and	O
other	O
afflictions	O
of	O
the	O
sib	O
-	O
pair	O
design	O
.	O

While	O
collecting	O
DNA	O
samples	O
from	O
unaffected	O
sibs	O
can	O
be	O
useful	O
for	O
a	O
wide	O
variety	O
of	O
purposes	O
–	O
especially	O
if	O
multipoint	O
methods	O
are	O
used	O
–	O
in	O
many	O
circumstances	O
it	O
should	O
be	O
unnecessary	O
to	O
genotype	O
these	O
samples	O
for	O
purposes	O
of	O
performing	O
a	O
genome	O
scan	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
and	O
microsatellites	O
are	O
being	O
used	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
a	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	O
and	O
unaffected	O
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

For	O
dense	O
SNP	O
mapping	O
studies	O
,	O
analysis	O
using	O
individual	O
SNPs	O
will	O
not	O
be	O
sufficiently	O
informative	O
and	O
so	O
multipoint	O
analyses	O
will	O
be	O
required	O
,	O
but	O
unless	O
the	O
parents	O
are	O
all	O
available	O
,	O
analyses	O
should	O
be	O
restricted	O
to	O
markers	O
that	O
show	O
low	O
levels	O
of	O
linkage	O
disequilibrium	O
(	O
the	O
reference	O
here	O
would	O
be	O
to	O
a	O
paper	O
by	O
Bacanu	O
SA	O
.	O

Multipoint	O
linkage	O
analysis	O
for	O
a	O
very	O
dense	O
set	O
of	O
markers	O
Genet	O
Epidemiol	O
.	O

2005	O
Nov;29	O
(	O
3	O
)	O
:195–203	O
.	O
)	O
or	O
estimate	O
haplotype	O
frequencies	O
(	O
Abecasis	O
and	O
Wigginton	O
,	O
Handling	O
marker	O
-	O
marker	O
linkage	O
disequilibrium	O
:	O
pedigree	O
analysis	O
with	O
clustered	O
markers	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2005	O
Nov;77	O
(	O
5	O
)	O
:754–67	O
.	O

Epub	O
2005	O
Sep	O
20	O
.	O
)	O

If	O
the	O
parents	O
are	O
available	O
,	O
even	O
though	O
we	O
have	O
shown	O
that	O
genotyping	O
them	O
is	O
inefficient	O
,	O
an	O
argument	O
can	O
be	O
made	O
for	O
genotyping	O
them	O
because	O
their	O
inclusion	O
ameliorates	O
any	O
potential	O
effect	O
of	O
population	O
admixture	O
,	O
greatly	O
facilitates	O
the	O
identification	O
of	O
any	O
genotyping	O
errors	O
and	O
reduces	O
the	O
dependence	O
upon	O
correct	O
specification	O
of	O
haplotype	O
frequencies	O
when	O
multipoint	O
analyses	O
are	O
conducted	O
(	O
can	O
refer	O
to	O
Huang	O
et	O
al	O
,	O
2004	O
Ignoring	O
linkage	O
disequilibrium	O
among	O
tightly	O
linked	O
markers	O
induces	O
false	O
-	O
positive	O
evidence	O
of	O
linkage	O
for	O
affected	O
sib	O
pair	O
analysis	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2004	O
Dec;75	O
(	O
6	O
)	O
:1106	O
-	O
12	O
.	O

Epub	O
2004	O
Oct	O
18	O
.	O
)	O
.	O

The	O
choice	O
of	O
whether	O
or	O
not	O
to	O
genotype	O
unaffected	O
individuals	O
also	O
would	O
depend	O
upon	O
the	O
feasibility	O
and	O
cost	O
of	O
cherry	O
-	O
picking	O
for	O
regional	O
genotyping	O
of	O
regions	O
showing	O
evidence	O
for	O
linkage	O
,	O
but	O
we	O
have	O
not	O
studied	O
either	O
of	O
these	O
issues	O
in	O
this	O
paper	O
.	O

Admixture	O
is	O
more	O
likely	O
to	O
be	O
of	O
concern	O
when	O
studying	O
populations	O
that	O
are	O
known	O
to	O
have	O
been	O
founded	O
by	O
different	O
ethnic	O
groups	O
or	O
races	O
such	O
as	O
Hispanics	O
and	O
African	O
-	O
Americans	O
.	O

INTRODUCTION	O
Colorectal	O
cancer	O
arises	O
from	O
a	O
series	O
of	O
somatically	O
inherited	O
changes	O
,	O
including	O
mutations	O
and	O
transmissible	O
epigenetic	O
events	O
such	O
as	O
methylation	O
of	O
CpG	O
islands	O
(	O
1	O
)	O
,	O
some	O
or	O
all	O
of	O
which	O
produce	O
a	O
growth	O
advantage	O
relative	O
to	O
surrounding	O
cells	O
(	O
2	O
,	O
3	O
)	O
.	O

Among	O
the	O
epigenetic	O
events	O
involved	O
in	O
tumorigenesis	O
are	O
DNA	O
methylation	O
,	O
genomic	O
imprinting	O
,	O
and	O
histone	O
modification	O
(	O
4	O
)	O
.	O

Global	O
decreases	O
in	O
5-methylcytosine	O
content	O
have	O
been	O
associated	O
with	O
tumor	O
formation	O
,	O
including	O
that	O
of	O
colorectal	O
cancers	O
.	O

Another	O
molecular	O
defect	O
commonly	O
occurring	O
during	O
neoplasia	O
is	O
de	O
novo	O
CpG	O
island	O
methylation	O
(	O
4	O
-	O
6	O
)	O
.	O

Recently	O
,	O
a	O
distinct	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
was	O
described	O
,	O
termed	O
the	O
CpG	O
island	O
methylation	O
phenotype	O
(	O
CIMP	O
)	O
(	O
7	O
)	O
.	O

This	O
pathway	O
was	O
uncovered	O
through	O
a	O
series	O
of	O
observations	O
that	O
included	O
association	O
between	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
hypermethylation	O
of	O
multiple	O
genes	O
,	O
from	O
the	O
concordance	O
between	O
the	O
methylation	O
status	O
of	O
different	O
genes	O
unrelated	O
to	O
the	O
gene	O
function	O
or	O
chromosomal	O
location	O
,	O
and	O
from	O
the	O
bimodal	O
distribution	O
of	O
methylation	O
in	O
a	O
selected	O
subset	O
of	O
genes	O
.	O

Colorectal	O
cancer	O
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	O
-	O
related	O
deaths	O
worldwide	O
(	O
8)	O
.	O

Almost	O
70	O
%	O
of	O
all	O
colorectal	O
cancers	O
are	O
sporadic	O
.	O

Of	O
the	O
remaining	O
30	O
%	O
,	O
a	O
small	O
number	O
belong	O
to	O
the	O
familial	O
syndromes	O
of	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
and	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
,	O
whereas	O
the	O
vast	O
majority	O
show	O
non	O
-	O
syndromatic	O
familial	O
susceptibility	O
(	O
9	O
)	O
.	O

The	O
proportion	O
of	O
all	O
cases	O
considered	O
familial	O
depends	O
in	O
the	O
definition	O
.	O

Of	O
all	O
patients	O
with	O
colorectal	O
cancer	O
,	O
11	O
-	O
16	O
%	O
have	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
with	O
colorectal	O
cancer	O
(	O
10	O
,	O
11	O
)	O
,	O
but	O
the	O
proportion	O
is	O
much	O
higher	O
if	O
second-	O
or	O
third	O
-	O
degree	O
relatives	O
are	O
considered	O
.	O

In	O
one	O
study	O
,	O
53	O
%	O
of	O
colorectal	O
cancer	O
probands	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
cancer	O
(	O
11	O
)	O
.	O

In	O
fact	O
,	O
first	O
-	O
degree	O
relatives	O
of	O
patients	O
affected	O
by	O
colorectal	O
cancer	O
,	O
but	O
who	O
do	O
not	O
fulfill	O
the	O
criteria	O
for	O
FAP	O
and	O
HNPCC	O
,	O
have	O
a	O
more	O
than	O
2-fold	O
increased	O
risk	O
of	O
developing	O
tumors	O
of	O
the	O
large	O
intestine	O
(	O
12	O
)	O
.	O

HNPCC	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
the	O
mismatch	B
repair	I
(	O
MMR	B
)	O
genes	O
hMLH1	B
,	O
hMSH2	B
,	O
hMSH6	B
,	O
and	O
hPMS2	B
,	O
with	O
a	O
penetrance	O
of	O
approximately	O
80	O
%	O
for	O
colorectal	O
cancer	O
,	O
60	O
%	O
for	O
endometrial	O
cancer	O
,	O
and	O
below	O
20	O
%	O
for	O
other	O
cancers	O
(	O
13	O
)	O
.	O

HNPCC	O
is	O
characterized	O
by	O
early	O
onset	O
,	O
the	O
development	O
of	O
neoplastic	O
lesions	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
and	O
MSI	O
.	O

The	O
Amsterdam	O
criteria	O
for	O
HNPCC	O
are	O
strictly	O
defined	O
and	O
exclude	O
most	O
tumors	O
suspected	O
of	O
being	O
hereditary	O
.	O

In	O
contrast	O
,	O
the	O
Bethesda	O
guidelines	O
broaden	O
the	O
disease	O
spectrum	O
by	O
including	O
colorectal	O
cancer	O
families	O
with	O
specific	O
accompanying	O
cancers	O
and	O
clinicopathologic	O
characteristics	O
(	O
13	O
,	O
14	O
)	O
.	O

These	O
latter	O
criteria	O
provide	O
important	O
clues	O
for	O
identifying	O
genetic	O
pathways	O
associated	O
with	O
atypical	O
phenotypes	O
of	O
hereditary	O
colorectal	O
cancer	O
.	O

Although	O
the	O
strict	O
Amsterdam	O
criteria	O
could	O
be	O
used	O
to	O
detect	O
underlying	O
molecular	O
events	O
in	O
hereditary	O
colorectal	O
cancers	O
,	O
only	O
50	O
%	O
(	O
range	O
,	O
30	O
-	O
80	O
%	O
)	O
of	O
cases	O
involve	O
a	O
detectable	O
germline	O
mutation	O
in	O
an	O
MMR	B
gene	O
(	O
15	O
)	O
.	O

Therefore	O
,	O
by	O
restricting	O
the	O
definition	O
of	O
HNPCC	O
to	O
tumors	O
containing	O
an	O
MMR	B
germline	O
mutation	O
,	O
only	O
about	O
2.5	O
%	O
of	O
colorectal	O
cancers	O
are	O
thought	O
to	O
be	O
caused	O
by	O
HNPCC	O
.	O

Thus	O
,	O
the	O
carcinogenesis	O
pathways	O
and	O
molecular	O
events	O
in	O
familial	O
cancers	O
with	O
no	O
detectable	O
germline	O
mutations	O
and/or	O
not	O
fulfilling	O
HNPCC	O
criteria	O
,	O
remain	O
to	O
be	O
determined	O
.	O

Grouping	O
of	O
adenomas	O
and	O
carcinomas	O
by	O
promoter	O
methylation	O
status	O
Tumors	O
were	O
classified	O
as	O
methylation	O
-	O
resistant	O
(	O
MR	O
)	O
if	O
fewer	O
than	O
two	O
loci	O
were	O
methylated	O
or	O
methylation	O
-	O
prone	O
(	O
MP	O
)	O
if	O
two	O
or	O
more	O
loci	O
were	O
methylated	O
.	O

Each	O
tumor	O
and	O
group	O
were	O
represented	O
by	O
a	O
methylation	O
index	O
(	O
number	O
of	O
loci	O
methylated	O
/	O
number	O
of	O
loci	O
evaluated	O
)	O
.	O

MSI	O
MSI	O
status	O
was	O
determined	O
by	O
PCR	O
using	O
primers	O
to	O
amplify	O
the	O
five	O
microsatellite	O
markers	O
recommended	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
Bethesda	O
,	O
MD	O
.	O
,	O
U.S.A.	O
)	O
,	O
i.e.	O
,	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
,	O
and	O
D2S123	O
(	O
13	O
)	O
.	O

Denaturation	O
of	O
the	O
PCR	O
products	O
,	O
gel	O
electrophoresis	O
,	O
and	O
silver	O
staining	O
were	O
performed	O
as	O
described	O
.	O

MSI	O
was	O
scored	O
as	O
positive	O
when	O
there	O
was	O
a	O
definite	O
shift	O
of	O
PCR	O
product	O
in	O
tumor	O
DNA	O
compared	O
with	O
normal	O
mucosal	O
DNA	O
.	O

All	O
MSI	O
-	O
positive	O
loci	O
were	O
confirmed	O
on	O
duplicate	O
examinations	O
.	O

Tumors	O
with	O
MSI	O
in	O
at	O
least	O
two	O
loci	O
were	O
classified	O
as	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
,	O
tumors	O
with	O
MSI	O
at	O
one	O
locus	O
were	O
classified	O
as	O
low	O
frequency	O
MSI	O
(	O
MSI	O
-	O
L	O
)	O
,	O
and	O
tumors	O
with	O
MSI	O
at	O
no	O
locus	O
were	O
classified	O
as	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
.	O

Statistical	O
analysis	O
The	O
interactions	O
between	O
methylation	O
and	O
clinicopathologic	O
parameters	O
in	O
two	O
groups	O
were	O
evaluated	O
with	O
chi	O
-	O
square	O
tests	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O

All	O
p	O
values	O
were	O
two	O
-	O
sided	O
,	O
and	O
a	O
p	O
value	O
less	O
than	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
SPSS	O
program	O
(	O
Version	O
12.0	O
,	O
Chicago	O
,	O
IL	O
,	O
U.S.A.	O
)	O
.	O

The	O
majority	O
of	O
tumors	O
were	O
found	O
to	O
be	O
moderately	O
differentiated	O
in	O
African	O
Americans	O
(	O
79	O
%	O
)	O
and	O
Omanis	O
(	O
82	O
%	O
;	O
Table	O
1	O
,	O
2	O
)	O
.	O

Iranian	O
tumors	O
were	O
mostly	O
well	O
differentiated	O
(	O
54	O
%	O
)	O
.	O

The	O
percentage	O
of	O
moderately	O
differentiated	O
tumors	O
was	O
86	O
%	O
in	O
the	O
MSI	O
-	O
H	O
Omani	O
group	O
compared	O
with	O
72	O
%	O
in	O
African	O
Americans	O
and	O
64	O
%	O
in	O
Iranians	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
seven	O
and	O
one	O
MSI	O
-	O
H	O
tumors	O
showed	O
poor	O
differentiation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
.	O

While	O
in	O
African	O
Americans	O
,	O
one	O
MSI	O
-	O
H	O
was	O
well	O
differentiated	O
,	O
no	O
patient	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
cases	O
was	O
poorly	O
differentiated	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

The	O
difference	O
was	O
insignificant	O
trend	O
in	O
African	O
Americans	O
and	O
Omanis	O
but	O
in	O
Iranian	O
patients	O
differentiation	O
was	O
significantly	O
correlated	O
with	O
MSI	O
-	O
H	O
occurrence	O
.	O

This	O
finding	O
was	O
not	O
sustained	O
in	O
multivariate	O
analysis	O
.	O

Most	O
of	O
the	O
patients	O
in	O
the	O
series	O
were	O
stage	O
II	O
or	O
higher	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
,	O
with	O
45	O
%	O
[	O
13	O
]	O
of	O
African	O
American	O
,	O
62	O
%	O
[	O
5	O
]	O
of	O
Omani	O
,	O
and	O
14	O
%	O
[	O
2	O
]	O
of	O
Iranian	O
MSI	O
-	O
H	O
lesions	O
at	O
stage	O
II	O
.	O

Thirty	O
-	O
eight	O
percent	O
[	O
24	O
]	O
of	O
African	O
American	O
,	O
28	O
%	O
[	O
15	O
]	O
of	O
Omani	O
,	O
and	O
23	O
%	O
[	O
12	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
II	O
(	O
Table	O
3	O
)	O
.	O

Forty	O
-	O
one	O
percent	O
[	O
12	O
]	O
of	O
African	O
American	O
,	O
25	O
%	O
[	O
2	O
]	O
of	O
Omani	O
,	O
and	O
79	O
%	O
[	O
11	O
]	O
of	O
Iranian	O
of	O
the	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

Thirty	O
-	O
seven	O
percent	O
[	O
23	O
]	O
of	O
African	O
American	O
,	O
55	O
%	O
[	O
29	O
]	O
of	O
Omani	O
,	O
and	O
67	O
%	O
[	O
26	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
III	O
.	O

Fourteen	O
percent	O
[	O
9	O
]	O
of	O
African	O
American	O
,	O
15	O
%	O
[	O
8	O
]	O
of	O
Omani	O
,	O
and	O
7	O
%	O
[	O
3	O
]	O
of	O
Iranian	O
of	O
the	O
non	O
-	O
MSI	O
-	O
H	O
lesions	O
were	O
at	O
stage	O
IV	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

There	O
was	O
insignificant	O
trend	O
in	O
the	O
stage	O
of	O
the	O
lesions	O
between	O
the	O
MSI	O
and	O
non	O
-	O
MSI	O
-	O
H	O
groups	O
.	O

Correlation	O
between	O
methylation	O
pattern	O
of	O
the	O
hMLH1	B
promoter	O
and	O
MSI	O
status	O
Among	O
MSI	O
-	O
H	O
samples	O
,	O
hMLH1	B
promoter	O
methylation	O
was	O
found	O
in	O
90	O
%	O
[	O
18	O
]	O
of	O
African	O
American	O
,	O
75	O
%	O
[	O
6	O
]	O
of	O
Omani	O
and	O
71	O
%	O
[	O
10	O
]	O
of	O
Iranian	O
tumors	O
,	O
confirming	O
a	O
previous	O
finding	O
of	O
predominant	O
methylation	O
of	O
these	O
genes	O
of	O
the	O
promoter	O
in	O
Africans	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
[	O
3,4	O
]	O
.	O

Non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
both	O
African	O
Americans	O
and	O
Omani	O
tumors	O
showed	O
methylation	O
of	O
the	O
hMLH1	B
promoter	O
as	O
well	O
(	O
>	O
80	O
%	O
)	O
.	O

In	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
patients	O
,	O
the	O
frequency	O
of	O
hMLH1	B
methylation	O
was	O
3	O
%	O
[	O
1	O
]	O
.	O

The	O
methylation	O
status	O
of	O
hMLH1	B
does	O
not	O
seem	O
to	O
be	O
gender-	O
or	O
stage	O
-	O
specific	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	B
methylation	O
has	O
a	O
significant	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
13.84	O
(	O
1.05–182.72	O
)	O
;	O
p	O
=	O
0.046	O
)	O
(	O
Table	O
4	O
)	O
.	O

In	O
MSI	O
-	O
H	O
tumors	O
,	O
p16	B
methylation	O
occurred	O
in	O
33	O
%	O
[	O
7	O
]	O
of	O
African	O
American	O
,	O
12	O
%	O
[	O
1	O
]	O
of	O
Omani	O
and	O
50	O
%	O
[	O
7	O
]	O
of	O
Iranian	O
tumors	O
.	O

While	O
it	O
was	O
more	O
than	O
40	O
%	O
in	O
non	O
-	O
MSI	O
-	O
H	O
tumors	O
in	O
African	O
Americans	O
and	O
Omani	O
patient	O
populations	O
,	O
this	O
figure	O
was	O
3	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
non	O
-	O
MSI	O
-	O
H	O
CRC	O
patients	O
.	O

Methods	O
We	O
analyzed	O
40	O
HNPCC	O
patients	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
with	O
histological	O
verified	O
colorectal	O
carcinoma	O
and	O
a	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	O
patients	O
with	O
no	O
familial	O
predisposition	O
,	O
observed	O
and	O
treated	O
at	O
the	O
Regina	O
Elena	O
Cancer	O
Institute	O
of	O
Rome	O
during	O
the	O
period	O
1970–1993	O
[	O
23	O
]	O
.	O

HNPCC	O
patients	O
were	O
selected	O
by	O
both	O
personal	O
and	O
familial	O
history	O
(	O
performing	O
complete	O
pedigree	O
including	O
first	O
and	O
second	O
-	O
degree	O
relatives	O
)	O
according	O
to	O
Amsterdam	O
I	O
criteria	O
.	O

In	O
15	O
patients	O
of	O
the	O
HNPCC	O
group	O
,	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	O
instability	O
,	O
investigating	O
mutations	O
in	O
mismatch	B
repair	I
genes	I
as	O
hMLH1	B
and	O
hMSH2	B
correlated	O
with	O
disease	O
.	O

We	O
analyzed	O
seven	O
microsatellite	O
loci	O
:	O
D2S123	O
,	O
D3S1611	O
,	O
and	O
BAT-26	O
,	O
D9S145	O
,	O
D1S158	O
,	O
SCZD1	O
,	O
and	O
D11S905	O
[	O
5,14,24,25	O
]	O
.	O

All	O
cases	O
were	O
pathologically	O
staged	O
taking	O
into	O
account	O
a	O
total	O
number	O
of	O
lymphonodes	O
exceeding	O
7	O
(	O
range	O
7	O
to	O
31	O
,	O
mean	O
13.0	O
,	O
mode	O
11.9	O
,	O
standard	O
deviation	O
6.2	O
)	O
,	O
as	O
recommended	O
by	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
/	O
International	O
Union	O
Against	O
Cancer	O
[	O
26	O
]	O
.	O

Histological	O
examination	O
was	O
performed	O
according	O
to	O
WHO	O
criteria	O
and	O
carcinomas	O
were	O
classified	O
according	O
to	O
the	O
Dukes	O
'	O
stage	O
.	O

Furthermore	O
,	O
we	O
defined	O
the	O
right	O
colon	O
as	O
the	O
tract	O
from	O
the	O
cecum	O
to	O
the	O
splenic	O
flexure	O
.	O

The	O
left	O
colon	O
included	O
the	O
descending	O
and	O
sigmoid	O
colon	O
.	O

The	O
rectum	O
was	O
defined	O
as	O
the	O
rectosigmoid	O
junction	O
and	O
rectum	O
.	O

From	O
1990	O
,	O
the	O
rectal	O
cancer	O
patients	O
clinically	O
staged	O
Dukes	O
'	O
B	O
and	O
C	O
were	O
addressed	O
to	O
high	O
-	O
dose	O
pelvic	O
radiotherapy	O
,	O
all	O
the	O
rectal	O
cancer	O
patients	O
underwent	O
a	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
surgery	O
.	O

Adjuvant	O
i.v	O
.	O

chemotherapy	O
was	O
administered	O
in	O
all	O
the	O
eligible	O
Dukes	O
'	O
C	O
colorectal	O
cancer	O
patients	O
,	O
those	O
staged	O
Dukes	O
'	O
D	O
underwent	O
chemotherapy	O
.	O

Patients	O
with	O
sporadic	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
for	O
the	O
first	O
5	O
years	O
and	O
every	O
2	O
years	O
thereafter	O
[	O
23	O
]	O
,	O
HNPCC	O
patients	O
with	O
CRC	O
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
.	O

Considering	O
the	O
increased	O
risk	O
of	O
extracolonic	O
manifestations	O
,	O
hereditary	O
colorectal	O
cancer	O
patients	O
were	O
also	O
submitted	O
to	O
periodical	O
instrumental	O
examinations	O
tailored	O
to	O
the	O
different	O
spectrum	O
of	O
the	O
disease	O
[	O
4,27	O
]	O
.	O

The	O
index	O
date	O
for	O
survival	O
calculation	O
was	O
defined	O
as	O
the	O
date	O
of	O
treatment	O
for	O
the	O
first	O
colorectal	O
cancer	O
.	O

Clinical	O
follow	O
-	O
up	O
procedures	O
provided	O
information	O
on	O
the	O
subject	O
's	O
status	O
.	O

Statistical	O
analysis	O
Survival	O
curves	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
stratified	O
according	O
to	O
various	O
clinical	O
and	O
pathological	O
variables	O
.	O

Differences	O
were	O
tested	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
regression	O
analysis	O
.	O

The	O
multivariate	O
analysis	O
of	O
the	O
HNPCC	O
versus	O
CRC	O
groups	O
,	O
Dukes	O
'	O
stage	O
,	O
tumor	O
site	O
showed	O
that	O
all	O
these	O
parameters	O
independently	O
affected	O
disease	O
-	O
specific	O
survival	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
<	O
0.0001	O
and	O
p	O
=	O
0.03	O
respectively	O
)	O
.	O

Out	O
of	O
40	O
HNPCC	O
patients	O
,	O
15	O
were	O
investigated	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
;	O
all	O
resulting	O
positive	O
.	O

Furthermore	O
,	O
the	O
HNPCC	O
patients	O
with	O
MSI	O
(	O
15	O
/	O
40	O
)	O
had	O
a	O
survival	O
of	O
100	O
%	O
.	O

Statistical	O
analysis	O
Mutation	O
rates	O
of	O
cell	O
lines	O
were	O
compared	O
by	O
T	O
-	O
test	O
or	O
one	O
-	O
way	O
ANOVA	O
.	O

